FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Santini, D
   Cinieri, S
   Gasparro, D
   Bordonaro, R
   Guglielmini, PF
   Chiuri, VE
   D'Angelillo, RM
   Ceresoli, GL
   Fagnani, D
   Acquati, M
   Mencoboni, M
   Lanzetta, G
   Sartori, D
   Carlini, P
   Panebianco, F
   Beccaglia, P
   Procopio, G
AF Santini, Daniele
   Cinieri, Saverio
   Gasparro, Donatello
   Bordonaro, Roberto
   Guglielmini, Pamela Francesca
   Chiuri, Vincenzo Emanuele
   D'Angelillo, Rolando M.
   Ceresoli, Giovanni Luca
   Fagnani, Daniele
   Acquati, Mirko
   Mencoboni, Manlio
   Lanzetta, Gaetano
   Sartori, Donata
   Carlini, Paolo
   Panebianco, Fabiana
   Beccaglia, Patrizia
   Procopio, Giuseppe
TI Effects of abiraterone acetate plus prednisone on bone turnover markers
   in chemotherapy naive mCRPC patients after ADT failure: A prospective
   analysis of the italian real world study ABITUDE
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Abiraterone acetate; Bone alkaline phosphatase; Bone targeting therapy;
   Bone turnover biomarkers; C terminal telopeptide; mCRPC
AB Background: Bone remodeling is disrupted in metastatic disease, which affects > 70% of metastatic castration resistant prostate cancer (mCRPC) patients. As a result, abnormal levels of specific bone turnover biomarkers (BTMs) are released. In this prospective ancillary analysis of the Italian real world study ABITUDE, four markers were measured during abiraterone acetate plus prednisone (AAP) treatment in chemotherapy naive mCRPC men failing androgen deprivation therapy.
   Methods: Patients were enrolled if a blood sample was obtained before the first administration of abiraterone (baseline); ad hoc blood samples were withdrawn during routine tests after 3, 6, and 12 months. A centralized lab measured bone alkaline phosphatase (BALP, osteoblast activity marker), type I collagenC telopeptide (CTX 1, bone resorption marker), parathyroid hormone (PTH) and vitamin D (vitD). At each time point, intra patient variations vs baseline were compared by the signed rank test (statistical significance: P value < 0.05).
   Results: Of 481 patients enrolled in ABITUDE, 186 (median age: 76 [range: 53 93] years) met the sub study criteria: 74.7% had bone metastases, 11.8% were on bone targeted therapies (BTT) and 14.0% on vitD supplementation. BALP decreased significantly at month 6 (P = 0.0010) and 12 (P < 0.0001) and CTX 1 at month 6 (P = 0.0028); PTH increased at month 3 (P < 0.0001); no significant difference in vitD levels was observed. Similar findings were observed in BTT untreated patients. The reduction in BALP and CTX 1 levels was more pronounced in patients with than without bone metastases; in the latter group, no significant variation in BALP and CTX 1 levels was observed.
   Conclusions: AAP seems to exert an effect on the microenvironment of metastatic but not of normal bone, which likely contributes to its antitumoral activity.
   (c) 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Santini, Daniele] Campus Biomed Univ, Dept Oncol, Via Alvaro del Portillo 200, I 00128 Rome, Italy.
   [Cinieri, Saverio] Antonio Perrino Hosp, Med Oncol Unit, Brindisi, Italy.
   [Gasparro, Donatello] Univ Hosp Parma, Dept Gen & Specialist Med, Med Oncol Unit, Parma, Italy.
   [Bordonaro, Roberto] MD ARNAS Garibaldi, Catania, Italy.
   [Guglielmini, Pamela Francesca] Osped SS Antonio & Biagio & Cesare Arrigo, Med Oncol Dept, Alessandria, Italy.
   [Chiuri, Vincenzo Emanuele] Osped Vito Fazzi, Med Oncol Dept, Lecce, Italy.
   [D'Angelillo, Rolando M.] Tor Vergata Univ, Dept Biomed & Prevent, Rome, Italy.
   [Ceresoli, Giovanni Luca] Clin Humanitas Gavazzeni, Dept Oncol, Bergamo, Italy.
   [Fagnani, Daniele] Med Oncol Div ASST, Vimercate, Italy.
   [Acquati, Mirko] Azienda Osped San Gerardo, Unit Med Oncol, Monza, Italy.
   [Mencoboni, Manlio] Villa Scassi Hosp, Oncol Unit, I 16149 Genoa, Italy.
   [Lanzetta, Gaetano] INI Grottaferrata, Dept Oncol & Palliat Care, Rome, Italy.
   [Sartori, Donata] AULSS 3, Oncol Unit, Mirano, Italy.
   [Carlini, Paolo] IRCCS Regina Elena Natl Canc Inst, Div Med Oncol 1, Rome, Italy.
   [Panebianco, Fabiana; Beccaglia, Patrizia] Janssen Cilag SpA, Med Affairs Dept, Oncol, Milan, Italy.
   [Procopio, Giuseppe] Ist Nazl Tumori, Dept Med Oncol, Fdn IRCCS, Milan, Italy.
C3 University Campus Bio Medico   Rome Italy; Ospedale Antonio Perrino;
   University of Parma; University Hospital of Parma; Azienda Ospedaliera
   SS Antonio Biagio Cesare Arrigo; Azienda Ospedaliera Vito Fazzi;
   University of Rome Tor Vergata; Istituto Clinico Humanitas Gavazzeni;
   ULSS 3 Serenissima; Johnson & Johnson; Johnson & Johnson Italy; Janssen
   Pharmaceuticals; Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Santini, D (通讯作者)，Campus Biomed Univ, Dept Oncol, Via Alvaro del Portillo 200, I 00128 Rome, Italy.
EM d.santini@unicampus.it
RI Bordonaro, Roberto/AAA 8138 2022; Ceresoli, Giovanni Luca/AAW 4443 2020;
   Chiodini, Paolo/E 7290 2014; Procopio, Giuseppe/K 2072 2016
OI Ceresoli, Giovanni Luca/0000 0001 8599 0629; Bordonaro,
   Roberto/0000 0001 5005 0880; 
FU Janssen Cilag SpA   Janssen Cilag SpA
FX This study was funded by Janssen Cilag SpA. Janssen Cilag had a role in
   the study design; it had no role in the interpretation of data, in the
   writing of the report and in the decision to submit the article for
   publication. Medical writing support and editorial assistance was
   provided by Dr Clara Ricci, PhD (Edra S.p.A., Milan, Italy) and
   unconditionally funded by Janssen Cilag SpA.
CR [Anonymous], 2018 TMJA ABSTRACTAI
   Baek YH, 2019, CANCER EPIDEMIOL, V61, P104, DOI 10.1016/j.canep.2019.05.013
   Berruti A, 1999, CLIN CHEM, V45, P1240
   Body JJ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100212
   Boegemann M, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5280 6
   Boivin G, 2002, CONNECT TISSUE RES, V43, P535, DOI 10.1080/03008200290000934
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Buchs N, 1998, J CLIN ENDOCR METAB, V83, P1535, DOI 10.1210/jc.83.5.1535
   Cindolo L, 2017, BMC CANCER, V17, DOI 10.1186/s12885 017 3755 x
   Coates P, 2013, AUST FAM PHYSICIAN, V42, P285
   D'Oronzo S, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12725
   D'Oronzo S, 2017, J BONE ONCOL, V9, P1, DOI 10.1016/j.jbo.2017.09.001
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   El Amm J, 2013, PROSTATE CANCER, V2013, DOI 10.1155/2013/210686
   Fizazi K, 2015, EUR UROL, V68, P42, DOI 10.1016/j.eururo.2014.10.001
   Gartrell BA, 2015, EUR UROL, V68, P850, DOI 10.1016/j.eururo.2015.06.039
   Gdowski AS, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046 017 0578 1
   Halabi S, 2016, J CLIN ONCOL, V34, P1652, DOI 10.1200/JCO.2015.65.7270
   Heinrich D, 2018, FUTURE ONCOL, V14, P2543, DOI 10.2217/fon 2018 0087
   Higano CS, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.7_suppl.256
   Iuliani M, 2015, ONCOTARGET, V6, P12520, DOI 10.18632/oncotarget.3724
   Jenkins N, 2013, BONE, V55, P271, DOI 10.1016/j.bone.2013.04.003
   Kawai AT, 2019, PROSTATE CANCER US, V2019, DOI 10.1155/2019/5971615
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Lara P N Jr, 2018, Cancer Treat Res Commun, V16, P18, DOI 10.1016/j.ctarc.2018.04.005
   Lara PN, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju013
   Mikah P, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2260 y
   Mosekilde L, 2005, CLIN ENDOCRINOL, V62, P265, DOI 10.1111/j.1365 2265.2005.02226.x
   Murray RML, 2001, J CLIN ENDOCR METAB, V86, P4133, DOI 10.1210/jc.86.9.4133
   Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028
   Qian Y, 2017, SUPPORT CARE CANCER, V25, P1845, DOI 10.1007/s00520 017 3583 1
   Rathkopf DE, 2014, EUR UROL, V66, P815, DOI 10.1016/j.eururo.2014.02.056
   Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470 2045(14)71205 7
   S. O. Professionals, EAU GUIDELINES PROST
   Saad F, 2015, EUR UROL, V68, P570, DOI 10.1016/j.eururo.2015.04.032
   Scher HI, 2016, J CLIN ONCOL, V34, P1402, DOI 10.1200/JCO.2015.64.2702
   Schwartz GG, 2008, CANCER EPIDEM BIOMAR, V17, P478, DOI 10.1158/1055 9965.EPI 07 2747
   Sciarra A, 2018, EUR UROL S, V17, P277
   Smith M, 2019, LANCET ONCOL, V20, P408, DOI 10.1016/S1470 2045(18)30860 X
   Tombal BF, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.5007
   Westerhuis LWJJM, 1997, EUR J CLIN CHEM CLIN, V35, P89
NR 42
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD FEB
PY 2021
VL 26
AR 100341
DI 10.1016/j.jbo.2020.100341
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QR2HP
UT WOS:000625035900015
PM 33425672
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Jo, S
   Yoon, S
   Lee, SY
   Kim, SY
   Park, H
   Han, J
   Choi, SH
   Han, JS
   Yang, JH
   Kim, TH
AF Jo, Sungsin
   Yoon, Subin
   Lee, So Young
   Kim, So Yeon
   Park, Hyosun
   Han, Jinil
   Choi, Sung Hoon
   Han, Joong Soo
   Yang, Jae Hyuk
   Kim, Tae Hwan
TI DKK1 Induced by 1,25D3 Is Required for the Mineralization of Osteoblasts
SO CELLS
LA English
DT Article
DE 1,25D3; C/EBP beta; DKK1; osteoblasts; differentiation; mineralization
ID VITAMIN D SUPPLEMENTATION; C/EBP BETA; GENOMIC DETERMINANTS;
   ASCORBIC ACID; BONE MASS; GENE; PROTEIN; DIFFERENTIATION; POLYMORPHISMS;
   EXPRESSION
AB 1 alpha,25 dihydroxyvitamin D3 (1,25D3), the most popular drug for osteoporosis treatment, drives osteoblast differentiation and bone mineralization. Wnt/beta catenin signaling is involved in commitment and differentiation of osteoblasts, but the role of the Dickkopf related protein 1 (DKK1), a Wnt antagonist, in osteoblasts remains unknown. Here, we demonstrate the molecular mechanism of DKK1 induction by 1,25D3 and its physiological role during osteoblast differentiation. 1,25D3 markedly promoted the expression of both CCAAT/enhancer binding protein beta (C/EBP beta) and DKK1 at day 7 during osteoblast differentiation. Interestingly, mRNA and protein levels of C/EBP beta and DKK1 in osteoblasts were elevated by 1,25D3. We also found that C/EBP beta, in response to 1,25D3, directly binds to the human DKK1 promoter. Knockdown of C/EBP beta downregulated the expression of DKK1 in osteoblasts, which was partially reversed by 1,25D3. In contrast, overexpression of C/EBP beta upregulated DKK1 expression in osteoblasts, which was enhanced by 1,25D3. Furthermore, 1,25D3 treatment in osteoblasts stimulated secretion of DKK1 protein within the endoplasmic reticulum to extracellular. Intriguingly, blocking DKK1 attenuated calcified nodule formation in mineralized osteoblasts, but not ALP activity or collagen synthesis. Taken together, these observations suggest that 1,25D3 promotes the mineralization of osteoblasts through activation of DKK1 followed by an increase of C/EBP beta.
C1 [Jo, Sungsin; Yoon, Subin; Kim, So Yeon; Park, Hyosun; Kim, Tae Hwan] Hanyang Univ, Inst Rheumatol Res, Seoul 04763, South Korea.
   [Yoon, Subin; Kim, Tae Hwan] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Translat Med, Seoul 04763, South Korea.
   [Lee, So Young; Han, Joong Soo] Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Biomed Sci, Seoul 04763, South Korea.
   [Han, Jinil] Gencurix Inc, Seoul 08394, South Korea.
   [Choi, Sung Hoon] Hanyang Univ, Seoul Hosp, Dept Orthopaed Surg, Seoul 04763, South Korea.
   [Han, Joong Soo] Hanyang Univ, Coll Med, Biomed Res Inst, Seoul 04763, South Korea.
   [Han, Joong Soo] Hanyang Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 04763, South Korea.
   [Yang, Jae Hyuk] Hanyang Univ, Guri Hosp, Dept Orthopaed Surg, Gyeonggi Do 11923, South Korea.
   [Kim, Tae Hwan] Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 04763, South Korea.
C3 Hanyang University; Hanyang University; Hanyang University; Hanyang
   University; Hanyang University; Hanyang University; Hanyang University;
   Hanyang University
RP Kim, TH (通讯作者)，Hanyang Univ, Inst Rheumatol Res, Seoul 04763, South Korea.; Kim, TH (通讯作者)，Hanyang Univ, Grad Sch Biomed Sci & Engn, Dept Translat Med, Seoul 04763, South Korea.; Kim, TH (通讯作者)，Hanyang Univ, Hosp Rheumat Dis, Dept Rheumatol, Seoul 04763, South Korea.
EM joejo0517@gmail.com; ysbin148@naver.com; soyoung130@hanyang.ac.kr;
   rlath109@naver.com; hyosun1988@naver.com; jinil@gencurix.com;
   spineshchoi@gmail.com; jshan@hanyang.ac.kr; jaekorea@hotmail.com;
   thkim@hanyang.ac.kr
RI ; Jo, Sungsin/AAL 3659 2021; Kim, Tae Hwan/M 3962 2017; Han,
   Joong Soo/P 2072 2015
OI Jo, Sungsin/0000 0003 3034 5029; Yang, Jae Hyuk/0000 0001 8853 1997; 
FU National Research Foundation of Korea (NRF)   Ministry of Science, ICT,
   and Future [NRF 2016R1A2B4008606, 2019R1A2C2004214]; Ministry of
   Education [2017R1A6A3A11034394]; Rheumatology Research Foundation
   [RRF 2018 01]; Korea Health Technology R&D grant through the Korea
   Health Industry Development Institute (KHIDI)   Ministry of Health and
   Welfare, Republic of Korea [HI17C0888]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Science, ICT, and Future (NRF 2016R1A2B4008606 and 2019R1A2C2004214)
   and the Ministry of Education (2017R1A6A3A11034394). This work was
   supported by the research fund of Rheumatology Research Foundation
   (RRF 2018 01). The study was also supported by a Korea Health Technology
   R&D grant through the Korea Health Industry Development Institute
   (KHIDI), which is funded by the Ministry of Health and Welfare, Republic
   of Korea (HI17C0888).
CR Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Arabi A, 2017, OSTEOPOROSIS INT, V28, P279, DOI 10.1007/s00198 016 3713 5
   Arensman MD, 2015, MOL CANCER RES, V13, P1509, DOI 10.1158/1541 7786.MCR 15 0204
   Bischoff Ferrari HA, 2005, JAMA J AM MED ASSOC, V293, P2257, DOI 10.1001/jama.293.18.2257
   Björk A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209268
   CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305
   D'Amico L, 2016, J EXP MED, V213, P827, DOI 10.1084/jem.20150950
   de Peppel JV, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00137
   FRANCESCHI RT, 1994, J BONE MINER RES, V9, P843
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Gaffney Stomberg E, 2017, J BONE MINER RES, V32, P498, DOI 10.1002/jbmr.3008
   Gallagher J A, 1996, Methods Mol Med, V2, P233, DOI 10.1385/0 89603 335 X:233
   GRONOWICZ G, 1986, J BONE MINER RES, V1, P441
   Gutierrez S, 2002, J BIOL CHEM, V277, P1316, DOI 10.1074/jbc.M106611200
   Ha YJ, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.47
   HARADA S, 1991, J BONE MINER RES, V6, P903
   Hata K, 2005, MOL CELL BIOL, V25, P1971, DOI 10.1128/MCB.25.5.1971 1979.2005
   Hirata M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004543
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Jin HT, 2015, BONE, V71, P63, DOI 10.1016/j.bone.2014.07.039
   Jo S, 2019, BMB REP, V52, P391, DOI 10.5483/BMBRep.2019.52.6.166
   Jo S, 2018, ARTHRITIS RES THER, V20, DOI 10.1186/s13075 018 1582 3
   Jo S, 2018, BIOCHEM BIOPH RES CO, V495, P1257, DOI 10.1016/j.bbrc.2017.11.155
   Jolliffe DA, 2016, J STEROID BIOCHEM, V164, P18, DOI 10.1016/j.jsbmb.2015.12.007
   Kim HY, 2015, FASEB J, V29, P300, DOI 10.1096/fj.14 253997
   Koontz L, 2014, METHOD ENZYMOL, V541, P3, DOI 10.1016/B978 0 12 420119 4.00001 X
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Lee Chae Jin, 2019, J Bone Metab, V26, P193, DOI 10.11005/jbm.2019.26.3.193
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Li XF, 2005, NAT GENET, V37, P945, DOI 10.1038/ng1614
   Li X, 2018, ARTHRITIS RHEUMATOL, V70, P1056, DOI 10.1002/art.40468
   Ma YY, 2017, ONCOTARGET, V8, P60080, DOI 10.18632/oncotarget.19629
   Marchwicka A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071918
   Meyer MB, 2014, J BIOL CHEM, V289, P19539, DOI 10.1074/jbc.M114.578104
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nakamichi Y, 2017, J BONE MINER RES, V32, P1297, DOI 10.1002/jbmr.3096
   Ormsby RT, 2014, J STEROID BIOCHEM, V144, P110, DOI 10.1016/j.jsbmb.2013.09.016
   Pike JW, 2016, VITAM HORM, V100, P21, DOI 10.1016/bs.vh.2015.10.011
   Plate L, 2017, TRENDS CELL BIOL, V27, P722, DOI 10.1016/j.tcb.2017.05.006
   Ryan JW, 2013, CURR DRUG TARGETS, V14, P1683, DOI 10.2174/138945011131400212
   Shirakawa K, 2006, MOL CELL BIOL, V26, P6105, DOI 10.1128/MCB.02429 05
   Takahashi N, 2013, J STEROID BIOCHEM, V136, P171, DOI 10.1016/j.jsbmb.2012.11.010
   Tominaga H, 2008, MOL BIOL CELL, V19, P5373, DOI 10.1091/mbc.E08 03 0329
   Wrobel E, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0027 8
   Yao GQ, 2011, J BONE MINER METAB, V29, P141, DOI 10.1007/s00774 010 0202 3
NR 47
TC 23
Z9 23
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD JAN
PY 2020
VL 9
IS 1
AR 236
DI 10.3390/cells9010236
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA KO2RZ
UT WOS:000515398200236
PM 31963554
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ficarra, G
   Beninati, F
   Rubino, I
   Vannucchi, A
   Longo, G
   Tonelli, P
   Pini Prato, G
AF Ficarra, G
   Beninati, F
   Rubino, I
   Vannucchi, A
   Longo, G
   Tonelli, P
   Pini Prato, G
TI Osteonecrosis of the jaws in periodontal patients with a history of
   bisphosphonates treatment
SO JOURNAL OF CLINICAL PERIODONTOLOGY
LA English
DT Article
DE bisphosphonates; jaw osteonecrosis; osteomyelitis; periodontal patients
ID AVASCULAR NECROSIS; AMERICAN SOCIETY; BONE; CANCER; PAMIDRONATE;
   MECHANISMS
AB Background/Aim: Osteonecrosis of the jaws is being increasingly reported in patients with bone metastasis from a variety of solid tumours and disseminated multiple myeloma receiving intra venous bisphosphonates. The signs and symptoms that may occur before the appearance of clinical evident osteonecrosis include changes in the health of periodontal tissues, non healing mucosal ulcers, loose teeth and unexplained soft tissue infection. A series of nine periodontally involving patients showing osteonecrosis of the jaws that appeared following the intra venous use of bisphosphonates is reported.
   Material and Methods: Nine consecutive patients with osteonecrosis of the jaws were prospectically studied. Patients' past medical histories and the drugs that they had received for their malignant disease were systematically documented. Clinical, histopathological and radiographic features and proposal for treatment modalities of osteonecrosis are also reported.
   Results: Of the nine patients (six women and three men) observed, all had osteonecrosis in the mandible; two had maxillary involvement as well. All nine patients had a history of extraction of periodontally hopeless teeth preceding the onset of osteonecrosis. In two patients, the lesions also appeared in edentulous areas spontaneously. All the patients had received intra venous bisphosphonates as treatment for their disseminated haematological neoplasms or metastatic bone disease. The duration of bisphosphonate therapy at presentation ranged from 10 to 70 months (median: 33 months).
   Conclusions: Jaw osteonecrosis appears to be associated with the intra venous use of bisphosphonates. Dental professionals should be aware of this potentially serious complication in periodontal patients receiving long term treatment with bisphosphonates.
C1 Univ Florence, Inst OdontoStomatol, Reference Ctr Study Oral Dis, I 50134 Florence, Italy.
   Univ Florence, Dept Hematol, I 50134 Florence, Italy.
   Univ Florence, Dept Oral Surg, I 50134 Florence, Italy.
   Univ Florence, Dept Periodontol, I 50134 Florence, Italy.
   Azienda Osped Univ Careggi, Florence, Italy.
C3 University of Florence; University of Florence; University of Florence;
   University of Florence; University of Florence; Azienda Ospedaliero
   Universitaria Careggi
RP Ficarra, G (通讯作者)，Univ Florence, Inst OdontoStomatol, Reference Ctr Study Oral Dis, Viale Morgagni 85, I 50134 Florence, Italy.
EM gificarr@tin.it
RI ; Vannucchi, Alessandro/K 7499 2016
OI TONELLI, PAOLO/0000 0002 6534 8345; 
CR Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Berenson JR, 2002, J CLIN ONCOL, V20, P3719, DOI 10.1200/JCO.2002.06.037
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Brumsen C, 1997, MEDICINE, V76, P266, DOI 10.1097/00005792 199707000 00005
   Devogelaer JP, 2000, CURR OPIN RHEUMATOL, V12, P331, DOI 10.1097/00002281 200007000 00017
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Fournier P, 2002, CANCER RES, V62, P6538
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Greenberg MS, 2004, ORAL SURG ORAL MED O, V98, P259, DOI 10.1016/j.tripleo.2004.08.001
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hillner BE, 2003, J CLIN ONCOL, V21, P4042, DOI 10.1200/JCO.2003.08.017
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140 6736(04)16727 5
   Lugassy G, 2004, AM J MED, V117, P440, DOI 10.1016/j.amjmed.2004.04.015
   Maerevoet M, 2005, NEW ENGL J MED, V353, P100
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Melo Maico D, 2005, J Can Dent Assoc, V71, P111
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   MILES AEW, 1972, BRIT DENT J, V133, P203, DOI 10.1038/sj.bdj.4802906
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rosenberg TJ., 2003, J. Oral Maxillofac. Surg, V61, P60, DOI [10.1016/S0278 2391(03)00566 4, DOI 10.1016/S0278 2391(03)00566 4]
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Tarassoff P, 2003, J ORAL MAXIL SURG, V61, P1238, DOI 10.1016/j.joms.2003.09.001
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Vannucchi Alessandro M, 2005, Br J Haematol, V128, P738, DOI 10.1111/j.1365 2141.2005.05382.x
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Woo SB, 2005, NEW ENGL J MED, V353, P100
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 30
TC 147
Z9 185
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0303 6979
EI 1600 051X
J9 J CLIN PERIODONTOL
JI J. Clin. Periodontol.
PD NOV
PY 2005
VL 32
IS 11
BP 1123
EP 1128
DI 10.1111/j.1600 051X.2005.00842.x
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 971NM
UT WOS:000232391100001
PM 16212571
DA 2025 08 17
ER

PT J
AU Pitari, MR
   Rossi, M
   Amodio, N
   Botta, C
   Morelli, E
   Federico, C
   Gullà, A
   Caracciolo, D
   Di Martino, MT
   Arbitrio, M
   Giordano, A
   Tagliaferri, P
   Tassone, P
AF Pitari, Maria Rita
   Rossi, Marco
   Amodio, Nicola
   Botta, Cirino
   Morelli, Eugenio
   Federico, Cinzia
   Gulla, Annamaria
   Caracciolo, Daniele
   Di Martino, Maria Teresa
   Arbitrio, Mariamena
   Giordano, Antonio
   Tagliaferri, Pierosandro
   Tassone, Pierfrancesco
TI Inhibition of miR 21 restores RANKL/OPG ratio in multiple
   myeloma derived bone marrow stromal cells and impairs the resorbing
   activity of mature osteoclasts
SO ONCOTARGET
LA English
DT Article
DE miR 21; miRNAs; multiple myeloma bone disease; OPG; RANKL
ID VIVO ANTITUMOR ACTIVITY; IN VITRO; ZOLEDRONIC ACID; DRUG RESISTANCE;
   TARGET THERAPY; MICRORNAS; EXPRESSION; GROWTH; PIAS3; DEXAMETHASONE
AB miR 21 is an oncogenic microRNA (miRNA) with an emerging role as therapeutic target in human malignancies, including multiple myeloma (MM). Here we investigated whether miR 21 is involved in MM related bone disease (BD). We found that miR 21 expression is dramatically enhanced, while osteoprotegerin (OPG) is strongly reduced, in bone marrow stromal cells (BMSCs) adherent to MM cells. On this basis, we validated the 3'UTR of OPG mRNA as miR 21 target. Constitutive miR 21 inhibition in lentiviral transduced BMSCs adherent to MM cells restored OPG expression and secretion. Interestingly, miR 21 inhibition reduced RANKL production by BMSCs. Overexpression of protein inhibitor of activated STAT3 (PIAS3), which is a direct and validated target of miR 21, antagonized STAT3 mediated RANKL gene activation. Finally, we demonstrate that constitutive expression of miR 21 inhibitors in BMSCs restores RANKL/OPG balance and dramatically impairs the resorbing activity of mature osteoclasts. Taken together, our data provide proof of concept that miR 21 overexpression within MM microenviroment plays a crucial role in bone resorption/apposition balance, supporting the design of innovative miR 21 inhibition based strategies for MM related BD.
C1 [Pitari, Maria Rita; Rossi, Marco; Amodio, Nicola; Botta, Cirino; Morelli, Eugenio; Federico, Cinzia; Gulla, Annamaria; Caracciolo, Daniele; Di Martino, Maria Teresa; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy.
   [Pitari, Maria Rita; Rossi, Marco; Amodio, Nicola; Botta, Cirino; Morelli, Eugenio; Federico, Cinzia; Gulla, Annamaria; Caracciolo, Daniele; Di Martino, Maria Teresa; Tagliaferri, Pierosandro; Tassone, Pierfrancesco] Magna Graecia Univ Catanzaro, T Campanella Canc Ctr, Catanzaro, Italy.
   [Arbitrio, Mariamena] CNR, ISN, Catanzaro, Italy.
   [Giordano, Antonio] Univ Siena, Dept Human Pathol & Oncol, I 53100 Siena, Italy.
   [Giordano, Antonio; Tassone, Pierfrancesco] Temple Univ, Sbarro Inst Canc Res & Mol Med, Ctr Biotechnol, Coll Sci & Technol, Philadelphia, PA 19122 USA.
C3 Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze
   Neurologiche (ISN CNR); University of Siena; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Temple University
RP Tassone, P (通讯作者)，Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, S Venuta Univ Campus, Catanzaro, Italy.
EM tassone@unicz.it
RI ; Morelli, Eugenio/KHD 2846 2024; Giordano, Antonio/F 1927 2010;
   Tassone, Pierfrancesco/AIA 5373 2022; Amodio, Nicola/K 7335 2016;
   Tagliaferri, Pierosandro/K 9546 2016; Arbitrio, Mariamena/ACZ 5455 2022;
   Gulla, Annamaria/ABF 4307 2021; Rossi, Marco/AAF 6413 2020; Botta,
   Cirino/K 8154 2017
OI ROSSI, Marco/0000 0002 7258 475X; Morelli, Eugenio/0000 0002 8850 0442;
   Giordano, Antonio/0000 0002 5959 016X; Amodio,
   Nicola/0000 0002 1345 4410; Gulla, Annamaria/0000 0003 4569 0095;
   Tassone, Pierfrancesco/0000 0002 8298 6787; arbitrio,
   mariamena/0000 0001 8387 3664; Botta, Cirino/0000 0002 1522 4504
FU Italian Association for Cancer Research (AIRC) PI: PT. "Special Program
   Molecular Clinical Oncology   5 per mille" [9980]; "Fondazione Umberto
   Veronesi" Fellowship
FX This work has been supported by the Italian Association for Cancer
   Research (AIRC), PI: PT. "Special Program Molecular Clinical Oncology  
   5 per mille" n. 9980, 2010/15. Nicola Amodio was supported by a
   "Fondazione Umberto Veronesi" Fellowship.
CR Abdi J, 2013, ONCOTARGET, V4, P2186, DOI 10.18632/oncotarget.1497
   Amodio N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.175
   Amodio N, 2015, ONCOTARGET, V6, P12837, DOI 10.18632/oncotarget.3805
   Amodio N, 2013, EXPERT OPIN BIOL TH, V13, pS125, DOI 10.1517/14712598.2013.796356
   Amodio N, 2012, ONCOTARGET, V3, P1246
   Amodio N, 2010, AM J PATHOL, V177, P2622, DOI 10.2353/ajpath.2010.091075
   Anderson KC, 2011, J NATL COMPR CANC NE, V9, P1146, DOI 10.6004/jnccn.2011.0095
   Anderson KC, 2011, ANNU REV PATHOL MECH, V6, P249, DOI 10.1146/annurev pathol 011110 130249
   Brocke Heidrich K, 2004, BLOOD, V103, P242, DOI 10.1182/blood 2003 04 1048
   Burger R, 2009, MOL CANCER THER, V8, P26, DOI 10.1158/1535 7163.MCT 08 0149
   Calimeri T, 2011, LEUKEMIA, V25, P707, DOI 10.1038/leu.2010.300
   Calin GA, 2007, J CLIN INVEST, V117, P2059, DOI 10.1172/JCI32577
   Cao Q, 2013, PHYSIOL GENOMICS, V45, P1206, DOI 10.1152/physiolgenomics.00122.2013
   Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803
   Croucher PI, 2001, BLOOD, V98, P3534, DOI 10.1182/blood.V98.13.3534
   Di Martino MT, 2012, CLIN CANCER RES, V18, P6260, DOI 10.1158/1078 0432.CCR 12 1708
   Di Martino MT, 2011, BRIT J HAEMATOL, V154, P529, DOI 10.1111/j.1365 2141.2011.08622.x
   Di Martino MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090005
   Di Martino MT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089659
   Di Martino MT, 2013, ONCOTARGET, V4, P242, DOI 10.18632/oncotarget.820
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Hamasaki M, 2005, BLOOD, V105, P4470, DOI 10.1182/blood 2004 09 3794
   Hikata T, 2009, BLOOD, V113, P2202, DOI 10.1182/blood 2008 06 162594
   Holien T, 2012, ONCOTARGET, V3, P739
   Hope C, 2014, BLOOD, V123, P3305, DOI 10.1182/blood 2014 02 554071
   JERNBERGWIKLUND H, 1992, LEUKEMIA, V6, P310
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Leone E, 2013, CLIN CANCER RES, V19, P2096, DOI 10.1158/1078 0432.CCR 12 3325
   Leotta M, 2014, J CELLULAR PHYSL
   Li QB, 2009, LEUKEMIA RES, V33, P1266, DOI 10.1016/j.leukres.2008.12.004
   Lionetti M, 2012, CURR CANCER DRUG TAR, V12, P823, DOI 10.2174/156800912802429274
   Liu T, 2014, BONE, V67, P156, DOI 10.1016/j.bone.2014.07.004
   Löffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood 2007 03 081133
   Longo V, 2012, CANCER TREAT REV, V38, P787, DOI 10.1016/j.ctrv.2012.03.004
   Maes K, 2014, ONCOTARGET, V5, P3115, DOI 10.18632/oncotarget.1821
   Marra M, 2009, CURR CANCER DRUG TAR, V9, P791, DOI 10.2174/156800909789760285
   Marra M, 2011, NANOMED NANOTECHNOL, V7, P955, DOI 10.1016/j.nano.2011.03.004
   Misso G, 2014, MOL THER NUCL ACIDS, V3, DOI 10.1038/mtna.2014.47
   Misso G, 2013, EXPERT OPIN BIOL TH, V13, pS95, DOI 10.1517/14712598.2013.807338
   Morelli E, 2015, LEUKEMIA, V29, P2173, DOI 10.1038/leu.2015.124
   Neri P, 2008, BRIT J HAEMATOL, V143, P520, DOI 10.1111/j.1365 2141.2008.07387.x
   Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood 2011 06 363911
   O'Brien CA, 2000, J CELL BIOCHEM, V79, P532, DOI 10.1002/1097 4644(20001215)79:4<532::AID JCB20>3.0.CO;2 U
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pichiorri F, 2008, P NATL ACAD SCI USA, V105, P12885, DOI 10.1073/pnas.0806202105
   Raimondi L, 2014, ONCOTARGET, V5, P3039, DOI 10.18632/oncotarget.1747
   Roccaro AM, 2009, BLOOD, V113, P6669, DOI 10.1182/blood 2009 01 198408
   Rolfo C, 2014, EXPERT OPIN BIOL TH, V14, P15, DOI 10.1517/14712598.2013.843667
   Rossi M, 2014, CURR PHARM BIOTECHNO, V15, P459, DOI 10.2174/1389201015666140519104743
   Rossi M, 2013, CURR DRUG TARGETS, V14, P1144, DOI 10.2174/13894501113149990186
   Rossi M, 2013, J CELL PHYSIOL, V228, P1506, DOI 10.1002/jcp.24306
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Tagliaferri P, 2012, CURR CANCER DRUG TAR, V12, P838, DOI 10.2174/156800912802429355
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   Tassone P, 2012, CURR CANCER DRUG TAR, V12, P814, DOI 10.2174/156800912802429292
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Tassone P, 2002, INT J ONCOL, V21, P867
   Tassone P, 2009, CURR CANCER DRUG TAR, V9, P854, DOI 10.2174/156800909789760393
   Wang XD, 2011, LEUKEMIA LYMPHOMA, V52, P1991, DOI 10.3109/10428194.2011.591004
   Wang ZY, 2013, BIOCHEM BIOPH RES CO, V439, P384, DOI 10.1016/j.bbrc.2013.08.072
   Xiong Q, 2012, J PROTEOME RES, V11, P2078, DOI 10.1021/pr201079y
   Yasui H, 2005, BLOOD, V106, P706, DOI 10.1182/blood 2005 02 0838
   Zhang Teng Long, 2012, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V20, P616
   Zhao JJ, 2014, CANCER RES, V74, P5351, DOI 10.1158/0008 5472.CAN 14 0994
NR 66
TC 87
Z9 100
U1 1
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 29
PY 2015
VL 6
IS 29
BP 27343
EP 27358
DI 10.18632/oncotarget.4398
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA CT9UE
UT WOS:000363161300069
PM 26160841
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, KX
   Jia, YW
   Peng, JX
   Pang, C
   Zhang, T
   Han, WQ
   Jiang, JW
   Lu, XY
   Zhu, JL
   Qian, Y
AF Zhao, Kangxian
   Jia, Yewei
   Peng, Jiaxuan
   Pang, Cong
   Zhang, Tan
   Han, Weiqi
   Jiang, Jiawei
   Lu, Xuanyuan
   Zhu, Jiling
   Qian, Yu
TI Anacardic acid inhibits RANKL induced osteoclastogenesis in vitro
   and prevents ovariectomy induced bone loss in vivo
SO FASEB JOURNAL
LA English
DT Article
DE osteoclast; TAK1; NF kappa B; MAPK; AKT
ID NF KAPPA B; HISTONE ACETYLTRANSFERASE; RECEPTOR ACTIVATOR;
   PHOSPHATIDYLINOSITOL 3 KINASE; SIGNALING COMPLEX; LIGAND RANKL; KINASE
   TAK1; C FOS; DIFFERENTIATION; CELLS
AB Postmenopausal osteoporosis is the most common form of primary osteoporosis, and the incidence of the condition is rapidly increasing. In consideration of the limitations of current therapeutic options for the treatment of postmenopausal osteoporosis, there is an urgent need to develop safer alternatives. Anacardic acid, a natural phenolic acid compound extracted from cashew nut shell, possesses potent antitumor and anti inflammatory effects and inhibits NF kappa B signaling. However, its effect on osteoclasts remains unknown. This study reports the first evidence for the antiosteoclastogenic and antiresorptive effects of anacardic acid on bone marrow derived macrophage derived osteoclasts. Mechanistically, anacardic acid disrupts the phosphorylation of TGF beta activated kinase 1 and subsequently suppresses multiple receptor activator of NF kappa B ligand induced signaling cascades, ultimately inhibiting the induction and activation of the crucial osteoclast transcriptional factor nuclear factor of activated T cell cytoplasmic 1. Consistent with cellular results in vitro, anacardic acid treatment improves bone density in the murine model of ovariectomy induced bone loss. Taken together, our study provides promising evidence for the therapeutic application of anacardic acid as a new potential pharmacological treatment for osteoporosis. Zhao, K., Jia, Y., Peng, J., Pang, C., Zhang, T., Han, W., Jiang, J., Lu, X., Zhu, J., Qian, Y. Anacardic acid inhibits RANKL induced osteoclastogenesis in vitro and prevents ovariectomy induced bone loss in vivo.
C1 [Zhao, Kangxian; Zhang, Tan; Han, Weiqi; Jiang, Jiawei; Lu, Xuanyuan; Qian, Yu] Zhejiang Univ, Sch Med, Shaoxing Peoples Hosp, Dept Orthoped, Shaoxing, Peoples R China.
   [Jia, Yewei; Jiang, Jiawei; Qian, Yu] Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthoped, Shaoxing, Peoples R China.
   [Zhao, Kangxian; Qian, Yu] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China.
   [Zhao, Kangxian; Qian, Yu] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Peng, Jiaxuan; Pang, Cong; Qian, Yu] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Peoples R China.
   [Zhu, Jiling] Shaoxing Univ, Coll Med, Dept Clin Med, Shaoxing, Peoples R China.
C3 Zhejiang University; Zhejiang University; Wenzhou Medical University;
   Wenzhou Medical University; Guangxi Medical University; Shaoxing
   University
RP Qian, Y (通讯作者)，Zhejiang Univ, Sch Med, Shaoxing Hosp, Dept Orthoped,Shaoxing Peoples Hosp, 568 Zhongxing North Rd, Shaoxing 312000, Zhejiang, Peoples R China.
EM doctor120@hotmail.com
OI Jia, Yewei/0000 0001 5447 973X
FU National Natural Science Foundation of China [81572126, 81871801];
   Natural Science Foundation of Zhejiang Province [LQ16H160013]; Zhejiang
   Basic Public Welfare Research Project [LGF18H060010]
FX The authors thank Zeng Linghui from Zhejiang University for help with
   operating the confocal laser scanning microscope and Wang Linxia from
   Shaoxing University for molecular technical assistance. This study was
   funded by the National Natural Science Foundation of China (Grant
   81572126, 81871801), the Natural Science Foundation of Zhejiang Province
   (Grant LY15H060005), Natural Science Foundation of Zhejiang Province
   (LQ16H160013), and Zhejiang Basic Public Welfare Research Project
   (LGF18H060010). K.Z. and Y.J. are co first authors. The authors declare
   no conflicts of interest.
CR Arai A, 2012, J CELL SCI, V125, P2910, DOI 10.1242/jcs.099986
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao JT, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00062
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Del Puente A, 2015, J BIOL REG HOMEOS AG, V29, P527
   Deliloglu Gurhan SI, 2006, ACTA HISTOCHEM, V108, P49, DOI 10.1016/j.acthis.2005.11.001
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Ghizzoni M, 2010, BIOORGAN MED CHEM, V18, P5826, DOI 10.1016/j.bmc.2010.06.089
   Gibney ER, 2010, HEREDITY, V105, P4, DOI 10.1038/hdy.2010.54
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   He YZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024780
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Inoue K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06446 0
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Jakob F, 2015, UNFALLCHIRURG, V118, P925, DOI 10.1007/s00113 015 0085 9
   Jang HD, 2011, J BIOL CHEM, V286, P39043, DOI 10.1074/jbc.M111.256768
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Rafael PM, 2018, NEFROLOGIA, V38, P97, DOI 10.1016/j.nefro.2017.01.004
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nakashima T, 2011, ANN NY ACAD SCI, V1240, pE13, DOI 10.1111/j.1749 6632.2011.06373.x
   Nich Christophe, 2011, Arthritis Res Ther, V13, pR100, DOI 10.1186/ar3381
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Pangrazio A, 2010, HUM MUTAT, V31, pE1071, DOI 10.1002/humu.21167
   Peserico A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/371832
   Reginster JY, 2006, BONE, V38, pS2, DOI 10.1016/j.bone.2006.01.150
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Sato S, 2005, NAT IMMUNOL, V6, P1087, DOI 10.1038/ni1255
   Shen YQ, 2012, INT J MOL SCI, V13, P2877, DOI 10.3390/ijms13032877
   Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200
   Shim JH, 2005, GENE DEV, V19, P2668, DOI 10.1101/gad.1360605
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Sunagawa Y, 2011, CIRC J, V75, P2151, DOI 10.1253/circj.CJ 10 1072
   Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood 2007 10 117994
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tan EM, 2017, J BONE MINER RES, V32, P846, DOI 10.1002/jbmr.3031
   Tan J, 2012, CHINESE J CANCER RES, V24, P275, DOI [10.1007/s11670 012 0264 y, 10.3978/j.issn.1000 9604.2012.10.07]
   Tsai YJ, 2015, FREE RADICAL BIO MED, V86, P118, DOI 10.1016/j.freeradbiomed.2015.05.009
   Wagner EF, 2010, ANN RHEUM DIS, V69, P86, DOI 10.1136/ard.2009.119396
   Wang C, 2003, J BONE MINER RES, V18, P2159, DOI 10.1359/jbmr.2003.18.12.2159
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
   Wu YY, 2011, J PHARMACOL EXP THER, V339, P403, DOI 10.1124/jpet.111.181891
   Xie H, 2012, OSTEOPOROSIS INT, V23, P1425, DOI 10.1007/s00198 011 1697 8
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yarom N, 2018, OR SURG OR MED OR PA, V125, P27, DOI 10.1016/j.oooo.2017.09.014
   Zhang T, 2019, J CELL PHYSIOL, V234, P2719, DOI 10.1002/jcp.27087
   Zhao QH, 2013, FEBS J, V280, P5801, DOI 10.1111/febs.12500
NR 62
TC 18
Z9 21
U1 0
U2 17
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
EI 1530 6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2019
VL 33
IS 8
BP 9100
EP 9115
DI 10.1096/fj.201802575RR
PG 16
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA IN7AA
UT WOS:000478832900033
PM 31050917
DA 2025 08 17
ER

PT J
AU Papadopoulos, I
   Bountouvi, E
   Attilakos, A
   Gole, E
   Dinopoulos, A
   Peppa, M
   Nikolaidou, P
   Papadopoulou, A
AF Papadopoulos, Iordanis
   Bountouvi, Evangelia
   Attilakos, Achilleas
   Gole, Evangelia
   Dinopoulos, Argirios
   Peppa, Melpomeni
   Nikolaidou, Polyxeni
   Papadopoulou, Anna
TI Osteoporosis pseudoglioma syndrome: clinical, genetic, and
   treatment response study of 10 new cases in Greece
SO EUROPEAN JOURNAL OF PEDIATRICS
LA English
DT Article
DE Bisphosphonates; Blindness; LRP5 mutation; OPPG; Osteoporosis
ID FAMILIAL EXUDATIVE VITREORETINOPATHY; BONE MINERAL DENSITY; LRP5
   MUTATIONS; EXPRESSION; THERAPY; PATHWAY
AB Osteoporosis pseudoglioma syndrome (OPPG) is a rare autosomal recessive disorder, characterized by severe osteoporosis and early onset blindness. Loss of function mutations in the gene encoding low density lipoprotein receptor related protein 5 (LRP5) have been established as the genetic defect of the disease. We report the clinical and genetic evaluation of ten OPPG cases in eight related nuclear families and their close relatives. Bone mineral density (BMD) in OPPG patients was assessed by dual energy X ray absorptiometry (DXA). Genotyping of LRP5 gene and targeted detection of index mutation were performed by DNA direct sequencing. Four patients were introduced to bisphosphonates. Mutational screening of LRP5 gene revealed the c.2409_2503+79del deletion in homozygous state, expected to result in a truncated protein. Among 44 members of the pedigree, 10 (22%) were identified homozygous and 34 (59%) heterozygous for this mutation. All patients had congenital blindness and7 of them had also impaired bone mineral density. Four of them received bisphosphonates and responded with decreased bone pain and improvement in BMD; however, 3 patients presented with one fracture during treatment.Conclusion: The current study presents the molecular and clinical profiles of 10 new OPPG cases, being part of an extended pedigree. Patients who received bisphosphonate treatment responded well with increase in their BMD, though fractures occurred during therapy.
C1 [Papadopoulos, Iordanis; Bountouvi, Evangelia; Attilakos, Achilleas; Gole, Evangelia; Dinopoulos, Argirios; Nikolaidou, Polyxeni; Papadopoulou, Anna] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Dept Pediat 3, Athens, Greece.
   [Peppa, Melpomeni] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Res Inst, Dept Internal Med 2, Athens, Greece.
   [Peppa, Melpomeni] Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Diabet Ctr, Athens, Greece.
C3 National & Kapodistrian University of Athens; University Hospital
   Attikon; National & Kapodistrian University of Athens; University
   Hospital Attikon; University Hospital Attikon; National & Kapodistrian
   University of Athens
RP Attilakos, A (通讯作者)，Natl & Kapodistrian Univ Athens, Attikon Univ Gen Hosp, Dept Pediat 3, Athens, Greece.
EM iordanispapado@hotmail.com; boudouvi@yahoo.gr; attilakos@hotmail.com;
   evi.gole@gmail.com; argidino@yahoo.com; moly6592@yahoo.com;
   pnikolaidou@med.uoa.gr; anpapado@med.uoa.gr
RI Papadopoulou, Anna/AAJ 1552 2020
OI Papadopoulou, Anna/0000 0001 8806 6255; Attilakos,
   Achilleas/0000 0002 8032 9994
CR Ai MR, 2005, AM J HUM GENET, V77, P741, DOI 10.1086/497706
   Arantes HP, 2011, J BONE MINER RES, V26, P2823, DOI 10.1002/jbmr.530
   Barros ER, 2008, J PEDIATR ENDOCR MET, V21, P811
   Bayram F, 2006, J PEDIATR ENDOCR MET, V19, P275
   Cheung WMW, 2006, BONE, V39, P470, DOI 10.1016/j.bone.2006.02.069
   Chung BD, 2009, HUM MUTAT, V30, P641, DOI 10.1002/humu.20916
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   Ferrari SL, 2005, CURR OPIN LIPIDOL, V16, P207, DOI 10.1097/01.mol.0000162326.62419.e4
   Fretz JA, 2007, J STEROID BIOCHEM, V103, P440, DOI 10.1016/j.jsbmb.2006.11.018
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Hartikka H, 2005, J BONE MINER RES, V20, P783, DOI 10.1359/JBMR.050101
   Jacobsen CM, 2017, BONE, V96, P18, DOI 10.1016/j.bone.2016.10.018
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Koay MA, 2005, TRENDS MOL MED, V11, P129, DOI 10.1016/j.molmed.2005.01.004
   Laine CM, 2011, EUR J HUM GENET, V19, P875, DOI 10.1038/ejhg.2011.42
   Lara Castillo N, 2015, REV ENDOCR METAB DIS, V16, P141, DOI 10.1007/s11154 015 9315 2
   Levasseur R, 2005, JOINT BONE SPINE, V72, P207, DOI 10.1016/j.jbspin.2004.10.008
   Levasseur Regis, 2008, Expert Rev Endocrinol Metab, V3, P337, DOI 10.1586/17446651.3.3.337
   Mosekilde L, 2011, CURR DRUG SAF, V6, P62, DOI 10.2174/157488611795684712
   Papadopoulou A, 2013, ENDOCR METAB IMMUNE, V13, P324
   Qin MH, 2005, HUM MUTAT, V26, P104, DOI 10.1002/humu.20191
   Saarinen A, 2010, CLIN ENDOCRINOL, V72, P481, DOI 10.1111/j.1365 2265.2009.03680.x
   Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097 2765(00)80327 5
   Streeten EA, 2008, BONE, V43, P584, DOI 10.1016/j.bone.2008.04.020
   Streeten EA, 2015, BONE, V77, P17, DOI 10.1016/j.bone.2015.04.007
   Tüysüz B, 2012, HORM RES PAEDIAT, V77, P115, DOI 10.1159/000336193
   Xia CH, 2008, HUM MOL GENET, V17, P1605, DOI 10.1093/hmg/ddn047
   Zacharin M, 2000, J PEDIATR US, V137, P410, DOI 10.1067/mpd.2000.107838
NR 28
TC 17
Z9 21
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340 6199
EI 1432 1076
J9 EUR J PEDIATR
JI Eur. J. Pediatr.
PD MAR
PY 2019
VL 178
IS 3
BP 323
EP 329
DI 10.1007/s00431 018 3299 3
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA HR1XX
UT WOS:000462930700006
PM 30499050
DA 2025 08 17
ER

PT J
AU Katkat, E
   Demirci, Y
   Heger, G
   Karagulle, D
   Papatheodorou, I
   Brazma, A
   Ozhan, G
AF Katkat, Esra
   Demirci, Yeliz
   Heger, Guillaume
   Karagulle, Doga
   Papatheodorou, Irene
   Brazma, Alvis
   Ozhan, Gunes
TI Canonical Wnt and TGF β/BMP signaling enhance melanocyte regeneration
   but suppress invasiveness, migration, and proliferation of melanoma
   cells
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE wound healing; melanoma; proliferation; differentiation; migration;
   epithelial to mesenchymal transition; nevus; zebrafish
ID TRANSCRIPTION FACTOR; STEM CELLS; CANCER; EXPRESSION; DIFFERENTIATION;
   REGULATOR; TARGET; SKIN; PROGRESSION; INHIBITION
AB Melanoma is the deadliest form of skin cancer and develops from the melanocytes that are responsible for the pigmentation of the skin. The skin is also a highly regenerative organ, harboring a pool of undifferentiated melanocyte stem cells that proliferate and differentiate into mature melanocytes during regenerative processes in the adult. Melanoma and melanocyte regeneration share remarkable cellular features, including activation of cell proliferation and migration. Yet, melanoma considerably differs from the regenerating melanocytes with respect to abnormal proliferation, invasive growth, and metastasis. Thus, it is likely that at the cellular level, melanoma resembles early stages of melanocyte regeneration with increased proliferation but separates from the later melanocyte regeneration stages due to reduced proliferation and enhanced differentiation. Here, by exploiting the zebrafish melanocytes that can efficiently regenerate and be induced to undergo malignant melanoma, we unravel the transcriptome profiles of the regenerating melanocytes during early and late regeneration and the melanocytic nevi and malignant melanoma. Our global comparison of the gene expression profiles of melanocyte regeneration and nevi/melanoma uncovers the opposite regulation of a substantial number of genes related to Wnt signaling and transforming growth factor beta (TGF beta)/(bone morphogenetic protein) BMP signaling pathways between regeneration and cancer. Functional activation of canonical Wnt or TGF beta/BMP pathways during melanocyte regeneration promoted melanocyte regeneration but potently suppressed the invasiveness, migration, and proliferation of human melanoma cells in vitro and in vivo. Therefore, the opposite regulation of signaling mechanisms between melanocyte regeneration and melanoma can be exploited to stop tumor growth and develop new anti cancer therapies.
C1 [Katkat, Esra; Demirci, Yeliz; Karagulle, Doga; Ozhan, Gunes] Dokuz Eylul Univ Hlth Campus, Izmir Biomed & Genome Ctr IBG, Izmir, Turkiye.
   [Katkat, Esra; Demirci, Yeliz] Dokuz Eylul Univ, Izmir Int Biomed & Genome Inst IBG Izmir, Izmir, Turkiye.
   [Heger, Guillaume] Ecole Cent Nantes, Nantes, France.
   [Karagulle, Doga; Ozhan, Gunes] Izmir Inst Technol, Dept Mol Biol & Genet, Izmir, Turkiye.
   [Papatheodorou, Irene; Brazma, Alvis] European Bioinformat Inst EMBL EBI, European Mol Biol Lab, Cambridge, England.
C3 Dokuz Eylul University; Izmir Biomedicine & Genome Center; Dokuz Eylul
   University; Nantes Universite; Ecole Centrale de Nantes; Izmir Institute
   of Technology; European Molecular Biology Laboratory (EMBL); European
   Bioinformatics Institute
RP Ozhan, G (通讯作者)，Dokuz Eylul Univ Hlth Campus, Izmir Biomed & Genome Ctr IBG, Izmir, Turkiye.; Ozhan, G (通讯作者)，Izmir Inst Technol, Dept Mol Biol & Genet, Izmir, Turkiye.
EM gunes.ozhan@ibg.edu.tr
RI ; Ozhan, Gunes/AAS 1681 2021; Brazma, Alvis/ADW 4786 2022
OI Katkat, Esra/0000 0001 7034 9652; Papatheodorou,
   Irene/0000 0001 7270 5470
FU European Molecular Biology Organization10.13039/100004410; Zebrafish
   Facility of the Center for Regenerative Therapies Dresden (CRTD)
FX We would like to thank Adam Hurlstone for the zebrafish lines mitfa / 
   (nacre) and Tg(mitfa:Hsa.HRAS G12V ,mitfa:GFP) and the Zebrafish
   Facility of the Center for Regenerative Therapies Dresden (CRTD) for the
   Casper (roy  / ; nacre / ) line. We thank Izmir Biomedicine and Genome
   Center Vivarium Zebrafish Core Facility, Optical Imaging Core Facility,
   and Histopathology Core Facility for providing zebrafish care,
   microscope facility support, and histopathology service support,
   respectively. We also thank the Genomics Core Facility (GeneCore) of
   EMBL, Heidelberg.
CR Al Zouabi L, 2020, CSH PERSPECT BIOL, V12, DOI 10.1101/cshperspect.a036210
   Andrews S, 2010, FASTQC QUALITY CONTR
   Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23
   Atkinson JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125028
   Bai X, 2019, NAT REV CLIN ONCOL, V16, P549, DOI 10.1038/s41571 019 0204 6
   Belote RL, 2021, NAT CELL BIOL, V23, P1035, DOI 10.1038/s41556 021 00740 8
   Bevona C, 2003, ARCH DERMATOL, V139, P1620, DOI 10.1001/archderm.139.12.1620
   Buac K, 2009, PIGM CELL MELANOMA R, V22, P773, DOI 10.1111/j.1755 148X.2009.00616.x
   Budi EH, 2017, TRENDS CELL BIOL, V27, P658, DOI 10.1016/j.tcb.2017.04.005
   Cangkrama M, 2020, TRENDS MOL MED, V26, P1107, DOI 10.1016/j.molmed.2020.07.009
   Ceol CJ, 2008, ZEBRAFISH, V5, P247, DOI 10.1089/zeb.2008.0544
   Cheli Y, 2010, PIGM CELL MELANOMA R, V23, P27, DOI 10.1111/j.1755 148X.2009.00653.x
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347
   Cichorek M, 2013, POSTEP DERM ALERGOL, V30, P30, DOI 10.5114/pdia.2013.33376
   Croce Laura, 2019, Oncotarget, V10, P6623, DOI 10.18632/oncotarget.27304
   Curran K, 2010, DEV BIOL, V344, P107, DOI 10.1016/j.ydbio.2010.04.023
   del Ama LF, 2016, ONCOTARGET, V7, P40348, DOI 10.18632/oncotarget.9613
   Demirci Y, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.813314
   Demirci Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.584604
   Diener J, 2021, STEM CELL TRANSL MED, V10, P522, DOI 10.1002/sctm.20 0351
   Dituri F, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101130
   Dvorak HF, 2015, CANCER IMMUNOL RES, V3, P1, DOI 10.1158/2326 6066.CIR 14 0209
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Fang CB, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00160
   Foletta VC, 2003, J CELL BIOL, V162, P1089, DOI 10.1083/jcb.200212060
   Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121
   Foster DS, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99911
   Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664
   Gelmi MC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116001
   Goding CR, 2019, GENE DEV, V33, P983, DOI 10.1101/gad.324657.119
   González Ruiz L, 2020, PIGM CELL MELANOMA R, V33, P788, DOI 10.1111/pcmr.12874
   Gramann AK, 2021, J INVEST DERMATOL, V141, P2067, DOI 10.1016/j.jid.2021.01.021
   Gruber F, 2008, COLLEGIUM ANTROPOL, V32, P147
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Harbst K, 2014, J PATHOL, V233, P39, DOI 10.1002/path.4318
   Higdon CW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067801
   Holtzhausen A, 2014, FASEB J, V28, P1248, DOI 10.1096/fj.13 239178
   Holzer Geissler JCJ, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10040856
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iismaa SE, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536 018 0044 5
   Infarinato NR, 2020, GENE DEV, V34, P1713, DOI 10.1101/gad.340281.120
   Iyengar S, 2015, DEV CELL, V33, P631, DOI 10.1016/j.devcel.2015.04.025
   Jain F, 2020, PIGM CELL MELANOMA R, V33, P834, DOI 10.1111/pcmr.12900
   Jakovija A, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1060258
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   John JK, 2012, J INVEST DERMATOL, V132, P2818, DOI 10.1038/jid.2012.237
   JOHNSON SL, 1995, DEV BIOL, V167, P27, DOI 10.1006/dbio.1995.1004
   Kang JS, 2015, DEV CELL, V33, P623, DOI 10.1016/j.devcel.2015.06.001
   Kaufman CK, 2016, SCIENCE, V351, DOI 10.1126/science.aad2197
   Kawakami A, 2017, LAB INVEST, V97, P649, DOI 10.1038/labinvest.2017.9
   Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008 5472.CAN 14 1174
   Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]
   Kolde R., 2019, pheatmap: Pretty Heatmaps
   Korotkevich G, 2019, bioRxiv, DOI [10.1101/060012, 10.1101/060012, DOI 10.1101/060012]
   Kumano K, 2008, PIGM CELL MELANOMA R, V21, P70, DOI 10.1111/j.1755 148X.2007.00423.x
   Lang D, 2013, CLIN DERMATOL, V31, P166, DOI 10.1016/j.clindermatol.2012.08.014
   Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lin SJ, 2017, BBA MOL CELL RES, V1864, P463, DOI 10.1016/j.bbamcr.2016.12.013
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   MacCarthy Morrogh L, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8690
   Martinez Lopez M, 2021, JOVE J VIS EXP, DOI 10.3791/62373
   McConnell AM, 2019, DEV BIOL, V449, P107, DOI 10.1016/j.ydbio.2018.05.026
   Michailidou C, 2009, DIS MODEL MECH, V2, P399, DOI 10.1242/dmm.001149
   Michl J, 2016, EMBO J, V35, P909, DOI 10.15252/embj.201693860
   Mikheil D, 2023, CANCERS, V15, DOI 10.3390/cancers15020519
   Militaru IV, 2023, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1061832
   Morikawa M, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021873
   Müller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712
   O'Reilly Pol T, 2013, DEVELOPMENT, V140, P996, DOI 10.1242/dev.088112
   O'Reilly Pol T, 2008, ZEBRAFISH, V5, P257, DOI 10.1089/zeb.2008.0540
   Özhan G, 2013, DEV CELL, V26, P331, DOI 10.1016/j.devcel.2013.07.020
   Oikonomou E, 2014, ONCOTARGET, V5, P11752, DOI 10.18632/oncotarget.2555
   Pages Herve, 2017, Bioconductor
   Qiu WM, 2019, EXP DERMATOL, V28, P395, DOI 10.1111/exd.13856
   Ratajczak MZ, 2018, LEUKEMIA, V32, P2519, DOI 10.1038/s41375 018 0294 7
   Rawls JF, 2001, DEVELOPMENT, V128, P1943
   Rodrigues M, 2019, PHYSIOL REV, V99, P665, DOI 10.1152/physrev.00067.2017
   Santoriello C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015170
   Sarig R, 2017, CARCINOGENESIS, V38, P359, DOI 10.1093/carcin/bgw103
   Sato Jin K, 2008, FASEB J, V22, P1155, DOI 10.1096/fj.07 9080com
   Seberg HE, 2017, PIGM CELL MELANOMA R, V30, P454, DOI 10.1111/pcmr.12611
   Sharma SS, 2016, CELL CYCLE, V15, P1189, DOI 10.1080/15384101.2016.1157238
   Steeb T, 2021, EUR J CANCER, V157, P348, DOI 10.1016/j.ejca.2021.08.015
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun Q, 2018, J INVEST DERMATOL, V138, P1591, DOI 10.1016/j.jid.2018.01.030
   Sundaram GM, 2018, FEBS J, V285, P4516, DOI 10.1111/febs.14586
   Takeda K, 2007, TOHOKU J EXP MED, V211, P201, DOI 10.1620/tjem.211.201
   Takeo M, 2016, CELL REP, V15, P1291, DOI 10.1016/j.celrep.2016.04.006
   Tanimura S, 2011, CELL STEM CELL, V8, P177, DOI 10.1016/j.stem.2010.11.029
   Taylor A, 2018, CANCER RES, V78, P706, DOI 10.1158/0008 5472.CAN 17 0491
   Tenenbaum Dan, 2017, Bioconductor
   Travnickova J, 2019, CANCER RES, V79, P5769, DOI 10.1158/0008 5472.CAN 19 0037
   Uka R, 2020, ONCOGENE, V39, P4132, DOI 10.1038/s41388 020 1267 7
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wang KL, 2021, CANCERS, V13, DOI 10.3390/cancers13010115
   Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370
   White RM, 2008, CELL STEM CELL, V3, P242, DOI 10.1016/j.stem.2008.08.005
   Wickham H., 2016, ggplot2: Elegant graphics for data analysis, DOI [10.1007/978 3 319 24277 4, DOI 10.1007/978 3 319 24277 4]
   Wilkinson HN, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200223
   Wnuk D, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 73473 7
   Wu SJ, 2023, J VENOM ANIM TOXINS, V29, DOI [10.1590/1678 9199 jvatitd 2022 0019, 10.1590/1678 9199 JVATITD 2022 0019]
   Xiang SJ, 2021, LIFE SCI, V264, DOI 10.1016/j.lfs.2020.118598
   Xiang SJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046 018 0844 x
   Yang CT, 2006, DEVELOPMENT, V133, P3563, DOI 10.1242/dev.02533
   Zhang J, 2021, GERONTOLOGY, V67, P708, DOI 10.1159/000515525
   Zhang ZD, 2019, MOL MED REP, V19, P3505, DOI 10.3892/mmr.2019.10051
NR 109
TC 6
Z9 6
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD NOV 13
PY 2023
VL 11
AR 1297910
DI 10.3389/fcell.2023.1297910
PG 20
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA Y7XA2
UT WOS:001107339900001
PM 38020918
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Hochdörffer, K
   Abu Ajaj, K
   Schäfer Obodozie, C
   Kratz, F
AF Hochdoerffer, Katrin
   Abu Ajaj, Khalid
   Schaefer Obodozie, Cynthia
   Kratz, Felix
TI Development of Novel Bisphosphonate Prodrugs of Doxorubicin for
   Targeting Bone Metastases That Are Cleaved pH Dependently or by
   Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to
   Hydroxyapatite As Well As Bone Matrix
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ENDOGENOUS SERUM ALBUMIN; PROSTATE CANCER; ANTITUMOR ACTIVITY;
   PLASMINOGEN ACTIVATOR; LINKED PHOSPHONATES; ANTICANCER ACTIVITY;
   PLASMA MEMBRANE; RUFFLED BORDER; DRUG CARRIER; CONJUGATE
AB Bone metastases are a frequent cause of morbidity in cancer patients. The present palliative therapeutic options are chemotherapy, hormone therapy, and the administration of bisphosphonates. The affinity between bisphosphonates and the apatite structure of bone metastases is strong. Thus, we designed two low molecular weight and water soluble prodrugs which incorporate a bisphosphonate group as a bone targeting ligand, doxorubicin as the anticancer agent, and either an acid sensitive bond (1) or a cathepsin B cleavable bond (3) for ensuring an effective release of doxorubicin at the site of action. Cleavage studies of both prodrugs showed a fast release of doxorubicin but sufficient stability over several hours in human plasma. Effective binding of prodrug 1 and 3 was demonstrated with hydroxyapatite and with native bone. In orientating toxicity studies in nude mice, the MTD of 1 was 3 fold higher compared to conventional doxorubicin, whereas 3 showed essentially the same MTD as doxorubicin.
C1 [Hochdoerffer, Katrin; Abu Ajaj, Khalid; Kratz, Felix] Tumor Biol Ctr, Div Macromol Prodrugs, D 79106 Freiburg, Germany.
   [Schaefer Obodozie, Cynthia] ProQinase GmbH, D 79106 Freiburg, Germany.
C3 ProQinase
RP Kratz, F (通讯作者)，Tumor Biol Ctr, Div Macromol Prodrugs, Breisacher Str 117, D 79106 Freiburg, Germany.
EM kratz@tumorbio.uni freiburg.de
FU Deutsche Forschungsgemeinschaft
FX The financial support of the Deutsche Forschungsgemeinschaft is
   gratefully acknowledged.
CR Abu Ajaj K, 2009, CANCER CHEMOTH PHARM, V64, P413, DOI 10.1007/s00280 009 0942 8
   Abu Ajaj K, 2009, BIOCONJUGATE CHEM, V20, P390, DOI 10.1021/bc800429q
   [Anonymous], [No title captured]
   Arkona C, 1996, BIOL CHEM, V377, P695, DOI 10.1515/bchm3.1996.377.11.695
   Arnett T, 2003, P NUTR SOC, V62, P511, DOI 10.1079/PNS2003268
   Bansal G, 2005, J BIOMED MATER RES A, V74A, P618, DOI 10.1002/jbm.a.30334
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535
   Bartl R., 2006, Bisphosphonat Manual
   BAYOUTH JE, 1994, J NUCL MED, V35, P63
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Brubaker KD, 2003, J BONE MINER RES, V18, P222, DOI 10.1359/jbmr.2003.18.2.222
   Cher ML, 2003, P NATL ACAD SCI USA, V100, P7847, DOI 10.1073/pnas.1331360100
   Chung DE, 2006, BIOORG MED CHEM LETT, V16, P5157, DOI 10.1016/j.bmcl.2006.07.023
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Dubowchik GM, 2002, BIOCONJUGATE CHEM, V13, P855, DOI 10.1021/bc025536j
   El Mabhouh AA, 2011, ONCOL RES, V19, P287, DOI 10.3727/096504011X13021877989874
   El Mabhouh AA, 2008, EUR J NUCL MED MOL I, V35, P1240, DOI 10.1007/s00259 008 0728 y
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003 9861(59)90090 6
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Fabulet O, 1995, PHOSPHORUS SULFUR, V101, P225, DOI 10.1080/10426509508042521
   FLEISCH H, 1991, DRUGS, V42, P919, DOI 10.2165/00003495 199142060 00003
   Gianni Luca, 2002, Cancer Chemother Biol Response Modif, V20, P59
   GOECKELER WF, 1987, J NUCL MED, V28, P495
   Hirabayashi H, 2001, PHARM RES DORDR, V18, P646, DOI 10.1023/A:1011033326980
   Hong W.K., 2010, Holland Frei cancer medicine 8
   Hosain F, 1996, J NUCL MED, V37, P105
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   KLENNER T, 1990, J CANCER RES CLIN, V116, P341, DOI 10.1007/BF01612916
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Kratz F, 2006, CURR MED CHEM, V13, P477, DOI 10.2174/092986706776055751
   Kratz F, 2005, ARCH PHARM, V338, P462, DOI 10.1002/ardp.200500130
   Kratz F, 2002, J MED CHEM, V45, P5523, DOI 10.1021/jm020276c
   Kratz F, 2000, J MED CHEM, V43, P1253, DOI 10.1021/jm9905864
   Kratz F, 2007, EXPERT OPIN INV DRUG, V16, P855, DOI 10.1517/13543784.16.6.855
   Kratz F, 2008, J CONTROL RELEASE, V132, P171, DOI 10.1016/j.jconrel.2008.05.010
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LittlewoodEvans AJ, 1997, CANCER RES, V57, P5386
   Miller K, 2011, MOL PHARMACEUT, V8, P1052, DOI 10.1021/mp200083n
   Miller K, 2009, ANGEW CHEM INT EDIT, V48, P2949, DOI 10.1002/anie.200805133
   Miyake H, 1999, INT J ONCOL, V14, P535
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Pan HZ, 2008, MOL PHARMACEUT, V5, P548, DOI 10.1021/mp800003u
   Peterson JJ, 1998, BIOCONJUGATE CHEM, V9, P618, DOI 10.1021/bc980059j
   Podgorski I, 2005, NEOPLASIA, V7, P207, DOI 10.1593/neo.04349
   POOL BL, 1988, INVEST NEW DRUG, V6, P67
   Rubens RD, 1998, EUR J CANCER, V34, P210, DOI 10.1016/S0959 8049(97)10128 9
   Rubens Robert D., 1995, Current Opinion in Oncology, V7, P523, DOI 10.1097/00001622 199511000 00008
   Schmid B, 2007, BIOCONJUGATE CHEM, V18, P702, DOI 10.1021/bc0602735
   Segal E, 2011, BIOMATERIALS, V32, P4450, DOI 10.1016/j.biomaterials.2011.02.059
   STURTZ G, 1993, EUR J MED CHEM, V28, P899, DOI 10.1016/0223 5234(93)90043 E
   STURTZ G, 1992, EUR J MED CHEM, V27, P825, DOI 10.1016/0223 5234(92)90117 J
   SWANSON AA, 1974, BIOCHEM J, V137, P223, DOI 10.1042/bj1370223
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Webb SD, 1999, CLIN EXP METASTAS, V17, P397, DOI 10.1023/A:1006667303583
   WINGEN F, 1986, J CANCER RES CLIN, V111, P209, DOI 10.1007/BF00389236
   WINGEN F, 1986, J CANCER RES CLIN, V111, P35, DOI 10.1007/BF00402773
   WINGEN F, 1988, INVEST NEW DRUG, V6, P155
   Woodward JKL, 2007, BONE, V41, P912, DOI 10.1016/j.bone.2007.07.024
NR 60
TC 92
Z9 105
U1 0
U2 98
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD SEP 13
PY 2012
VL 55
IS 17
BP 7502
EP 7515
DI 10.1021/jm300493m
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 004IT
UT WOS:000308675800015
PM 22882004
DA 2025 08 17
ER

PT J
AU Toussirot, E
AF Toussirot, Eric
TI The Use of Janus Kinase Inhibitors in Axial Spondyloarthritis: Current
   Insights
SO PHARMACEUTICALS
LA English
DT Article
DE axial spondyloarthritis; JAK/STAT; JAK inhibitors; Janus kinase
ID ANKYLOSING SPONDYLITIS; BONE FORMATION; TOFACITINIB; RATIONALE; CRITERIA
AB Current pharmacological treatments of axial spondyloarthritis (axSpA) are limited to non steroidal anti inflammatory drugs (NSAIDs) and biological agents, including TNF alpha inhibitors and IL 17 inhibitors. Despite the availability of these agents, many patients either fail to respond adequately, lose their initial therapeutic response over time, or develop undesirable side effects, thus highlighting the need for new treatment options. Janus kinase (JAK) and signal transducers and activators of transcription (STAT) are a group of intracellular kinases that play a role in the signaling pathway induced by cytokines and certain growth factors associated with the inflammatory process of axSpA. There are several lines of evidence implicating the JAK STAT pathway in the pathophysiological process of axSpA, including genetic data, the use of certain JAK in the intracellular signal of specific cytokines involved in axSpA (IL 23, IL 22, and IL 6), and data from experimental models of SpA. This provides a rationale for the assessment of JAK inhibitors (JAKi) in clinical trials with patients with axSpA. In this review, we examine the role of JAK STAT signaling in the pathogenesis of axSpA and summarize the results from recent clinical trials of JAKi (tofacitinib, upadacitinib, and filgotinib) in patients with axSpA.
C1 [Toussirot, Eric] CHU Besancon, Ctr Invest Clin, Pole Rech, INSERM CIC 1431, F 25000 Besancon, France.
   [Toussirot, Eric] CHU Besancon, Pole PACTE Pathol Aigues Chron Transplantat Educ, Rhumatol, F 25000 Besancon, France.
   [Toussirot, Eric] Univ Bourgogne Franche Comte, Dept Univ Therapeut, F 25000 Besancon, France.
   [Toussirot, Eric] Univ Bourgogne Franche Comte, Ingn Cellulaire & Gen, INSERM UMR1098 Right Relat Hote Greffon Tumeurs, F 25000 Besancon, France.
C3 Universite Marie et Louis Pasteur; CHU Besancon; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite Marie et Louis
   Pasteur; CHU Besancon; Universite Marie et Louis Pasteur; Universite
   Marie et Louis Pasteur
RP Toussirot, E (通讯作者)，CHU Besancon, Ctr Invest Clin, Pole Rech, INSERM CIC 1431, F 25000 Besancon, France.; Toussirot, E (通讯作者)，CHU Besancon, Pole PACTE Pathol Aigues Chron Transplantat Educ, Rhumatol, F 25000 Besancon, France.; Toussirot, E (通讯作者)，Univ Bourgogne Franche Comte, Dept Univ Therapeut, F 25000 Besancon, France.; Toussirot, E (通讯作者)，Univ Bourgogne Franche Comte, Ingn Cellulaire & Gen, INSERM UMR1098 Right Relat Hote Greffon Tumeurs, F 25000 Besancon, France.
EM etoussirot@chu besancon.fr
OI Toussirot, Eric/0000 0002 6228 1464
CR Benjamin M, 2007, ARTHRITIS RHEUM, V56, P224, DOI 10.1002/art.22290
   Chen C, 2010, CLIN IMMUNOL, V136, P442, DOI 10.1016/j.clim.2010.05.003
   de Koning A, 2018, EUR J CLIN INVEST, V48, DOI 10.1111/eci.12913
   De Wilde K, 2017, ANN RHEUM DIS, V76, P585, DOI 10.1136/annrheumdis 2016 209454
   Dendrou CA, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1974
   Deodhar A, 2022, ARTHRITIS RHEUMATOL, V74, P70, DOI 10.1002/art.41911
   Deodhar A, 2021, ANN RHEUM DIS, V80, P1004, DOI 10.1136/annrheumdis 2020 219601
   Dhillon S, 2020, DRUGS, V80, P1987, DOI 10.1007/s40265 020 01439 0
   Duggan S, 2019, DRUGS, V79, P1819, DOI 10.1007/s40265 019 01211 z
   Ellinghaus D, 2012, AM J HUM GENET, V90, P636, DOI 10.1016/j.ajhg.2012.02.020
   Food and Drug Administration, FDA REQWARN INCR RIS
   Gracey E, 2020, J CLIN INVEST, V130, P1863, DOI 10.1172/JCI126567
   Hammitzsch A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591176
   Hammitzsch A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34026 1
   Hromadová D, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.685280
   Jacques P, 2014, ANN RHEUM DIS, V73, P437, DOI 10.1136/annrheumdis 2013 203643
   Kuo CM, 2018, J EUR ACAD DERMATOL, V32, P355, DOI 10.1111/jdv.14695
   Lories RJU, 2012, RHEUM DIS CLIN N AM, V38, P555, DOI 10.1016/j.rdc.2012.08.003
   Maeda Y., 2018, ARTHRITIS RHEUMATOL, V10, P2065
   Maksymowych WP, 2022, RHEUMATOLOGY, V61, P2388, DOI 10.1093/rheumatology/keab758
   Maksymowych WP, 2022, RHEUMATOLOGY, V61, P2063, DOI 10.1093/rheumatology/keab543
   Maksymowych WP, 2018, RHEUMATOLOGY, V57, P1390, DOI 10.1093/rheumatology/key104
   McInnes IB, 2022, RHEUMATOLOGY, V61, P1783, DOI 10.1093/rheumatology/keab740
   Mease P, 2021, ARTHRITIS RHEUMATOL, V73, P3798
   Miceli Richard C, 2017, ANN RHEUM DIS, V76, P1325, DOI 10.1136/annrheumdis 2016 210886
   Navarro Compán V, 2021, ANN RHEUM DIS, V80, P1511, DOI 10.1136/annrheumdis 2021 221035
   O'Shea JJ, 2013, ANN RHEUM DIS, V72, P111, DOI 10.1136/annrheumdis 2012 202576
   O'Shea JJ, 2013, NAT REV RHEUMATOL, V9, P173, DOI 10.1038/nrrheum.2013.7
   Papp K, 2018, NEW ENGL J MED, V379, P1313, DOI 10.1056/NEJMoa1806382
   Perrotta FM, 2021, RMD OPEN, V7, DOI 10.1136/rmdopen 2020 001480
   Poddubnyy D, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0844 7
   Raychaudhuri S, 2021, CURR OPIN RHEUMATOL, V33, P348, DOI 10.1097/BOR.0000000000000810
   Reveille JD, 2005, AM J MED, V118, P592, DOI 10.1016/j.amjmed.2005.01.001
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P770, DOI 10.1136/ard.2009.108217
   Sandborn WJ, 2020, GASTROENTEROLOGY, V158, P2123, DOI 10.1053/j.gastro.2020.01.047
   Schett G, 2011, ARTHRITIS RES THER, V13, DOI [10.1186/1478 6354 13 S1 S4, 10.1186/ar3095]
   Schwartz DM, 2017, NAT REV DRUG DISCOV, V16, P843, DOI 10.1038/nrd.2017.201
   Scott LJ, 2013, DRUGS, V73, P857, DOI 10.1007/s40265 013 0065 8
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   Sieper J, 2019, NAT REV RHEUMATOL, V15, P747, DOI 10.1038/s41584 019 0294 7
   Sieper J, 2017, LANCET, V390, P73, DOI 10.1016/S0140 6736(16)31591 4
   Sieper J, 2016, NAT REV RHEUMATOL, V12, P282, DOI 10.1038/nrrheum.2016.42
   Smolen JS, 2018, ANN RHEUM DIS, V77, P3, DOI 10.1136/annrheumdis 2017 211734
   Toussirot E, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.782150
   Toussirot E, 2019, EXPERT OPIN PHARMACO, V20, P1483, DOI 10.1080/14656566.2019.1617853
   van der Heijde D, 2019, LANCET, V394, P2108, DOI 10.1016/S0140 6736(19)32534 6
   van der Heijde D, 2018, LANCET, V392, P2378, DOI 10.1016/S0140 6736(18)32463 2
   van der Heijde D, 2017, ANN RHEUM DIS, V76, P1340, DOI 10.1136/annrheumdis 2016 210322
   VANDERLINDEN S, 1984, ARTHRITIS RHEUM, V27, P361
   Veale DJ, 2019, RHEUMATOLOGY, V58, P197, DOI 10.1093/rheumatology/key070
   Ytterberg SR, 2022, NEW ENGL J MED, V386, P316, DOI [10.1056/NEJMoa2109927, 10.1056/NEJMc2202778]
NR 51
TC 17
Z9 18
U1 0
U2 3
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 1424 8247
J9 PHARMACEUTICALS BASE
JI Pharmaceuticals
PD MAR
PY 2022
VL 15
IS 3
AR 270
DI 10.3390/ph15030270
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 0B3AD
UT WOS:000774510700001
PM 35337068
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, JX
   Huang, JF
   Liu, LJ
AF Yang, Jinxing
   Huang, Junfeng
   Liu, Lijun
TI Infection can promotes NFκB and c Src expression during differentiation
   of osteoclasts and leads to infected nonunion
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Infected nonunion; osteoclast; differentiation; maturation; NF kappa B;
   c Src
ID ACTIVATION
AB Infected nonunions pose many challenges to the treating surgeon and the patient. Its researches focus on treatment, the basis studies are less. This study aims to investigate the effect of infection on nonunion and its possible mechanism. In our study, infected nonunion animal model were established, and osteoclasts were isolated and cultured successfully. The results show that the number of osteoclast cells, the degree of differentiation and maturation, the bone resorption activities and the expression of NF kappa B and c Src protein in infected nonunion animal model were significantly higher than those in the control model group (P < 0.05). Therefore, we concluded that infection can significantly promote the differentiation and maturation of osteoclasts, and leads to infected nonunion. Its mechanism may be related to promoting the expression of NF kappa B and c Src protein. In brief, NF kappa B and c Src may become a new early diagnosis mark and therapy target in infected nonunion.
C1 [Yang, Jinxing; Huang, Junfeng; Liu, Lijun] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Orthopaed Trauma, Sungang Rd, Shenzhen 518035, Guangdong, Peoples R China.
C3 Shenzhen University
RP Liu, LJ (通讯作者)，Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Orthopaed Trauma, Sungang Rd, Shenzhen 518035, Guangdong, Peoples R China.
EM liuli junsz123@126.com
FU Key specialty promotion project Shenzhen Health Bureau [201506017]
FX This work was supported by Key specialty promotion project Shenzhen
   Health Bureau (NO. 201506017).
CR Abuomira IEA, 2016, STRATEG TRAUMA LIMB, V11, P153, DOI 10.1007/s11751 016 0264 4
   Amoui M, 2007, ARCH BIOCHEM BIOPHYS, V463, P47, DOI 10.1016/j.abb.2007.02.025
   Baek JE, 2010, KIDNEY BLOOD PRESS R, V33, P72, DOI 10.1159/000289576
   Bhatia C, 2017, MALAYS ORTHOP J, V11, P6, DOI 10.5704/MOJ.1703.019
   Brinker MR, 2017, J ORTHOP TRAUMA, V31, pE37, DOI 10.1097/BOT.0000000000000736
   Chaudhary MM, 2017, INDIAN J ORTHOP, V51, P256, DOI 10.4103/ortho.IJOrtho_199_16
   Cheng XL, 2015, BIOCHEM BIOPH RES CO, V461, P275, DOI 10.1016/j.bbrc.2015.04.015
   Chowdhury K, 2017, CANCER INVEST, V35, P403, DOI 10.1080/07357907.2017.1309548
   Deb Roy Abhijit, 2017, Nat Commun, V8, P15831, DOI 10.1038/ncomms15831
   Feng B, 2017, INT J CLIN EXP PATHO, V10, P4107
   Hernigou P, 2016, INT ORTHOP, V40, P2331, DOI 10.1007/s00264 016 3147 x
   Lorenzo J, 2017, J CLIN INVEST, V127, P2530, DOI 10.1172/JCI94606
   Rohilla R, 2016, BONE JOINT J, V98B, P1399, DOI 10.1302/0301 620X.98B10.37946
   Roscher Anne, 2016, Bone Rep, V5, P214, DOI 10.1016/j.bonr.2016.07.002
   Shi Y, 2017, MOL MED REP, V15, P3775, DOI 10.3892/mmr.2017.6483
   Sucur A, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1337 6
   Taverna S, 2017, J TRANSL MED, V15, P128
   Taverna S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03460 y
   van Niekerk AH, 2017, J ORTHOP SURG HONG K, V25, DOI 10.1177/2309499017716242
   Xu LA, 2017, INT J CLIN EXP PATHO, V10, P2784
NR 20
TC 0
Z9 0
U1 0
U2 2
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2018
VL 11
IS 9
BP 9144
EP 9151
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GY8AL
UT WOS:000448839700030
DA 2025 08 17
ER

PT J
AU Schipani, E
   Maes, C
   Carmeliet, G
   Semenza, GL
AF Schipani, Ernestina
   Maes, Christa
   Carmeliet, Geert
   Semenza, Gregg L.
TI Regulation of Osteogenesis Angiogenesis Coupling by HIFs and VEGF
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE hypoxia inducible factor; vascular endothelial growth factor;
   osteoblast; angiogenesis
ID HYPOXIA INDUCIBLE FACTOR; ENDOTHELIAL GROWTH FACTOR; VHL
   TUMOR SUPPRESSOR; GENE EXPRESSION; FACTOR 1 ALPHA; BONE FORMATION;
   FACTOR I; DISTRACTION OSTEOGENESIS; DIFFERENTIAL ROLES;
   CELL PROLIFERATION
AB Bone is a highly vascularized tissue, but the function of angiogenesis in bone modeling and remodeling is still poorly defined, and the molecular mechanisms that regulate angiogenesis in bone are only partially elucidated. Genetic manipulations in mice have recently highlighted the critical role of the hypoxia inducible factor/vascular endothelial growth factor pathway in coupling angiogenesis and osteogenesis. In this brief perspective, we review the current understanding of the mechanisms responsible for this coupling. Elucidation of such mechanisms will expand our knowledge of bone development and homeostasis, and it may aid in the design of new therapies for accelerating bone regeneration and repair. J Bone Miner Res 2009;24:1347 1353. Published online on June 29, 2009; doi: 10.1359/JBMR.090602
C1 [Schipani, Ernestina] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Schipani, Ernestina] Harvard Univ, Sch Med, Boston, MA USA.
   [Maes, Christa; Carmeliet, Geert] Katholieke Univ Leuven, Lab Expt Med & Endocrinol, Leuven, Belgium.
   [Semenza, Gregg L.] McKusick Nathans Inst Genet Med, Inst Cell Engn, Vasc Program, Baltimore, MD USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; KU Leuven
RP Schipani, E (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Wellman 5,Fruit St, Boston, MA 02114 USA.
EM schipani@helix.mgh.harvard.edu
RI Semenza, Gregg/ABW 5102 2022
OI Maes, Christa/0000 0003 4243 5486
FU NIAMS NIH HHS [R01 AR048191] Funding Source: Medline
CR Akeno N, 2002, ENDOCRINOLOGY, V143, P420, DOI 10.1210/en.143.2.420
   Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Bishop T, 2004, PLOS BIOL, V2, P1549, DOI 10.1371/journal.pbio.0020289
   Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839
   Carano RAD, 2003, DRUG DISCOV TODAY, V8, P980, DOI 10.1016/S1359 6446(03)02866 6
   Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415 6426.2005
   Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200
   Chan DA, 2007, METHOD ENZYMOL, V435, P323, DOI 10.1016/S0076 6879(07)35016 7
   Chen EY, 1999, TERATOLOGY, V60, P215
   Choi IH, 2000, J ORTHOP RES, V18, P698, DOI 10.1002/jor.1100180504
   Compernolle V, 2003, CARDIOVASC RES, V60, P569, DOI 10.1016/j.cardiores.2003.07.003
   Compernolle V, 2002, NAT MED, V8, P702, DOI 10.1038/nm721
   Danis A, 2001, Bull Mem Acad R Med Belg, V156, P107
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199
   Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304
   Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006
   Greijer AE, 2005, J PATHOL, V206, P291, DOI 10.1002/path.1778
   Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519
   Haase VH, 2005, SEMIN CELL DEV BIOL, V16, P564, DOI 10.1016/j.semcdb.2005.03.006
   Harper J, 2001, J CELL BIOCHEM, V81, P82, DOI 10.1002/1097 4644(20010401)81:1<82::AID JCB1025>3.0.CO;2 P
   Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361 9374.2003
   ILIZAROV GA, 1990, CLIN ORTHOP RELAT R, P8
   Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817
   Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Kaelin WG, 2002, GENE DEV, V16, P1441, DOI 10.1101/gad.1003602
   Kaelin WG Jr, 1998, TRENDS GENET, V14, P423, DOI 10.1016/S0168 9525(98)01558 3
   Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573
   Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519
   Karsenty G, 2003, NATURE, V423, P316, DOI 10.1038/nature01654
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402
   Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995 4004.2001
   Lee Ji Won, 2004, Experimental & Molecular Medicine, V36, P1
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   Leo C, 2004, SEMIN RADIAT ONCOL, V14, P207, DOI 10.1016/j.semradonc.2004.04.007
   Liu LP, 2004, CANCER BIOL THER, V3, P492, DOI 10.4161/cbt.3.6.1010
   Liu Xiao Dong, 2007, Zhonghua Yi Xue Za Zhi, V87, P3357
   Maes C, 2002, MECH DEVELOP, V111, P61, DOI 10.1016/S0925 4773(01)00601 3
   Maes C, 2006, J CLIN INVEST, V116, P1230, DOI 10.1172/JCI26772
   Maes C, 2004, J CLIN INVEST, V113, P188, DOI 10.1172/JCI200419383
   Maes C, 2007, ANN NY ACAD SCI, V1116, P149, DOI 10.1196/annals.1402.060
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200
   Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440
   MITCHELL JA, 1968, ENDOCRINOLOGY, V83, P701, DOI 10.1210/endo 83 4 701
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959 4971.2003
   Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397
   Pfander D, 2004, DEVELOPMENT, V131, P2497, DOI 10.1242/dev.01138
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068
   Provot S, 2007, ANN NY ACAD SCI, V1117, P26, DOI 10.1196/annals.1402.076
   Provot S, 2007, J CELL BIOL, V177, P451, DOI 10.1083/jcb.200612023
   Ratcliffe PJ, 2000, NAT MED, V6, P1315, DOI 10.1038/82113
   Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675 5686.2005
   RODESCH F, 1992, OBSTET GYNECOL, V80, P283
   Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005
   Sacchetti B, 2007, CELL, V131, P324, DOI 10.1016/j.cell.2007.08.025
   Salim A, 2004, J BIOL CHEM, V279, P40007, DOI 10.1074/jbc.M403715200
   Schipani E, 2005, SEMIN CELL DEV BIOL, V16, P539, DOI 10.1016/j.semcdb.2005.03.003
   Schipani E, 2001, GENE DEV, V15, P2865
   Scortegagna M, 2003, NAT GENET, V35, P331, DOI 10.1038/ng1266
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2009, SEMIN CANCER BIOL, V19, P12, DOI 10.1016/j.semcancer.2008.11.009
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354
   Steinbrech DS, 1999, PLAST RECONSTR SURG, V104, P738, DOI 10.1097/00006534 199909030 00019
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang V, 2005, CANCER RES, V65, P3299, DOI 10.1158/0008 5472.CAN 04 4130
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12
   Wenger RH, 1997, EUR J BIOCHEM, V246, P155, DOI 10.1111/j.1432 1033.1997.t01 1 00155.x
   Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02 0445fje
   Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012
   Zelzer E, 2005, CURR TOP DEV BIOL, V65, P169
   Zelzer E, 2003, NATURE, V423, P343, DOI 10.1038/nature01659
   Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085
   Zelzer E, 2002, DEVELOPMENT, V129, P1893
   Zelzer E, 2004, DEVELOPMENT, V131, P2161, DOI 10.1242/dev.01053
   Zhong H, 2000, CANCER RES, V60, P1541
NR 95
TC 312
Z9 356
U1 5
U2 63
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD AUG
PY 2009
VL 24
IS 8
BP 1347
EP 1353
DI 10.1359/JBMR.090602
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 482CK
UT WOS:000268861300001
PM 19558314
OA Green Published
DA 2025 08 17
ER

PT J
AU Yamashita, S
   Katsumi, H
   Sakane, T
   Yamamoto, A
AF Yamashita, Shugo
   Katsumi, Hidemasa
   Sakane, Toshiyasu
   Yamamoto, Akira
TI Phosphorylated Serine Modified Polyamidoamine Dendrimer as an Osteoid
   Surface Targeting Drug Carrier
SO MOLECULAR PHARMACEUTICS
LA English
DT Article; Early Access
DE drug delivery; osteoid surface targeting system; phosphorylated serine;
   polyamidoamine (PAMAM) dendrimer
ID DENTIN MATRIX PROTEIN 1; I COLLAGEN; OSTEOPONTIN; OSTEOCALCIN;
   ADSORPTION; DESIGN
AB The aim of this study was to develop a polyethylene glycol (PEG) conjugated third generation polyamidoamine dendrimer (PAMAM) with phosphorylated serine as an osteoid surface targeting drug carrier for the treatment of bone diseases. We conjugated PAMAM backbones to L serine and obtained Ser PAMAM. Then, phosphoric acid and PEG were covalently bound to the Ser PAMAM to generate PEGylated phosphorylated Ser PAMAM (PEG phosSer PAMAM). Using osteoblast like cells (MC3T3 E1 cells) cultured in 3D collagen gels, we showed that phosSer PAMAM adsorbed both the hydroxyapatite and type I collagen components of the bone matrix. Fourier transform infrared spectroscopy analysis indicated that the phosphoryl side chains of phosSer PAMAM formed electrostatic interactions and hydrogen bonds with the anionic amino acid residues of type I collagen. Mice were intravenously injected with the foregoing molecules, and a tissue distribution study disclosed that the lower limb bone took up about twice as much In 111 labeled PEG phosSer PAMAM as In 111 labeled nonphosphorylated PEG Ser PAMAM or unmodified PAMAM. An intrabone distribution experiment showed that fluorescein isothiocyanate (FITC) labeled PEG phosSer PAMAM accumulated on the osteoid surfaces, which is associated with bone pathogenesis such as skeletal dysplasias and osteoporosis to a far greater extent than nonphosphorylated PEG Ser PAMAM. Our findings indicated that PEG phosSer PAMAM is a promising carrier for efficient drug targeting to osteoid surfaces.
C1 [Yamashita, Shugo; Katsumi, Hidemasa; Yamamoto, Akira] Kyoto Pharmaceut Univ, Dept Biopharmaceut, Kyoto 6078414, Japan.
   [Yamashita, Shugo; Sakane, Toshiyasu] Kobe Pharmaceut Univ, Dept Pharmaceut Technol, Kobe, Hyogo 6588558, Japan.
C3 Kyoto Pharmaceutical University; Kobe Pharmaceutical University
RP Katsumi, H (通讯作者)，Kyoto Pharmaceut Univ, Dept Biopharmaceut, Kyoto 6078414, Japan.
EM hkatsumi@mb.kyoto phu.ac.jp
FU Promotion and Mutual Aid Corporation for Private Schools of Japan;
   Grants in Aid for Scientific Research [21K15324] Funding Source: KAKEN
FX The authors thank Drs. Reiko Teraoka (Himeji Dokkyo University) and
   Reiko Yutani (Mukogawa Women's University) for their assistance with the
   FTIR analyses. This work was supported in part by the Promotion and
   Mutual Aid Corporation for Private Schools of Japan.
CR Ames B.N, 1966, Meth. Enzymol, P115, DOI DOI 10.1016/0076 6879(66)08014 5
   Barth A, 2000, PROG BIOPHYS MOL BIO, V74, P141, DOI 10.1016/S0079 6107(00)00021 3
   Bellows CG, 1999, CELL TISSUE RES, V297, P249, DOI 10.1007/s004410051353
   CALIS S, 1995, PHARM RES DORDR, V12, P1072, DOI 10.1023/A:1016278902839
   HASHIDA M, 1994, J CONTROL RELEASE, V31, P163, DOI 10.1016/0168 3659(94)00025 5
   He G, 2005, BIOCHEMISTRY US, V44, P16140, DOI 10.1021/bi051045l
   He G, 2004, J BIOL CHEM, V279, P11649, DOI 10.1074/jbc.M309296200
   Hirose M, 2003, KEY ENG MAT, V240 2, P715, DOI 10.4028/www.scientific.net/KEM.240 242.715
   HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020 708X(82)90144 2
   JOFFE P, 1994, KIDNEY INT, V46, P838, DOI 10.1038/ki.1994.340
   Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123
   Khrimian L, 2017, J EXP MED, V214, P2859, DOI 10.1084/jem.20171320
   Kitchens KM, 2006, PHARM RES DORDR, V23, P2818, DOI 10.1007/s11095 006 9122 2
   Lipik V, 2014, POLYM CHEM UK, V5, P1351, DOI 10.1039/c3py01118f
   Mammen M, 1998, ANGEW CHEM INT EDIT, V37, P2755
   Matsuura S, 2018, P NATL ACAD SCI USA, V115, P10511, DOI 10.1073/pnas.1808168115
   Matthews Brya G, 2014, Bonekey Rep, V3, P560, DOI 10.1038/bonekey.2014.55
   Mosialou I, 2017, NATURE, V543, P385, DOI 10.1038/nature21697
   Ooya T, 2002, J CONTROL RELEASE, V80, P219, DOI 10.1016/S0168 3659(02)00030 5
   Oya K, 2017, HISTOCHEM CELL BIOL, V147, P341, DOI 10.1007/s00418 016 1490 z
   Paschalis EP, 2003, J BONE MINER RES, V18, P1942, DOI 10.1359/jbmr.2003.18.11.1942
   Shen JW, 2008, BIOMATERIALS, V29, P513, DOI 10.1016/j.biomaterials.2007.10.016
   Tagliabracci VS, 2012, SCIENCE, V336, P1150, DOI 10.1126/science.1217817
   TAKAKURA Y, 1987, PHARM RES DORDR, V4, P293, DOI 10.1023/A:1016489002393
   Takamura Y, 2002, INT J CANCER, V98, P450, DOI 10.1002/ijc.10208
   Toyosawa S, 2001, J BONE MINER RES, V16, P2017, DOI 10.1359/jbmr.2001.16.11.2017
   Wang LJ, 2008, J PHYS CHEM B, V112, P9151, DOI 10.1021/jp804282u
   Warman ML, 2011, AM J MED GENET A, V155A, P943, DOI 10.1002/ajmg.a.33909
   YAMAOKA K, 1981, J PHARMACOBIO DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879
   Yamashita S, 2017, J CONTROL RELEASE, V262, P10, DOI 10.1016/j.jconrel.2017.07.018
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
NR 31
TC 2
Z9 2
U1 2
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543 8384
EI 1543 8392
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD 2022 JUN 6
PY 2022
DI 10.1021/acs.molpharmaceut.2c00271
EA JUN 2022
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 2R3UU
UT WOS:000821038900001
PM 35666687
DA 2025 08 17
ER

PT J
AU Zhang, Y
   Dang, Y
   Huang, MD
   Ma, YP
   Zhang, DM
   Wang, X
AF Zhang, Yi
   Dang, Yi
   Huang, Maodi
   Ma, Yaping
   Zhang, Dingmei
   Wang, Xin
TI Development of bioactive and ultrasound responsive microdroplets for
   preventing ovariectomy (OVX) induced osteoporosis
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; SIRNA; BONE; EPIDEMIOLOGY; INFLAMMATION;
   THERAPY
AB As a common bone disease in the elderly population, osteoporosis related bone loss and bone structure deterioration represent a major public health problem. Therapeutic strategies targeting excessive osteoclast formation are frequently used for osteoporosis treatment; however, potential side effects have been recorded. Here, we have developed a novel therapeutic strategy using microdroplets (MDs) encapsulated with NFATc1 siRNA and investigated the role of bioactive MDs NFATc1 biocompatibility in RAW 264.7 macrophages and human mesenchymal stem cells (hBMSCs), respectively. Its role in regulating osteoclast differentiation and formation was also investigated in vitro. We first fabricated MDs with spherical morphology along with a well defined core shell structure. The ultrasound responsive study demonstrated time dependent responsive structural changes following ultrasound stimulation. The internalization study into unstimulated macrophages, inflammatory macrophages, and hBMSCs indicated good delivery efficiency. Furthermore, the results from the MTT assay, the live/dead assay, and the cellular morphological analysis further indicated good biocompatibility of our bioactive MDs NFATc1. Following MDs NFATc1 treatment, the number of osteoclasts was greatly reduced, indicating their inhibitory effect on osteoclastogenesis and osteoclast formation. Subsequently, osteoporotic rats that underwent ovariectomy (OVX) were used for the in vivo studies. The rats treated with MDs NFATc1 exhibited significant resistance to bone loss induced by OVX. In conclusion, our results demonstrate that MDs NFATc1 could become an important regulator in osteoclast differentiation and functions, thus having potential applications in osteoclast related bone diseases.
   Illustration presenting the targeted osteoclastogenesis of bioactive MDs NFATc1 in a schematic diagram.
C1 [Zhang, Yi] Zunyi Med Univ, Dept Immunol, Zunyi 563000, Guizhou, Peoples R China.
   [Dang, Yi; Huang, Maodi; Ma, Yaping; Zhang, Dingmei; Wang, Xin] Zunyi Med Univ, Dept Orthopaed Surg, Affiliated Hosp, Zunyi 563003, Guizhou, Peoples R China.
   [Zhang, Yi] Zunyi Med Univ, Key Lab Maternal & Child Hlth, Zunyi 563000, Guizhou, Peoples R China.
   [Zhang, Yi] Zunyi Med Univ, Exposure Sci Guizhou Higher Educ Inst, Zunyi 563000, Guizhou, Peoples R China.
   [Wang, Xin] Zunyi Med Univ, Guizhou Prov Key Lab Med Biotechnol Coll & Univ, Zunyi 563000, Guizhou, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University; Zunyi Medical
   University; Zunyi Medical University; Zunyi Medical University
RP Wang, X (通讯作者)，Zunyi Med Univ, Dept Orthopaed Surg, Affiliated Hosp, Zunyi 563003, Guizhou, Peoples R China.; Wang, X (通讯作者)，Zunyi Med Univ, Guizhou Prov Key Lab Med Biotechnol Coll & Univ, Zunyi 563000, Guizhou, Peoples R China.
EM xin.wang@zmu.edu.cn
RI 马, 亚萍/ABB 3049 2021; Wang, Xin/GMW 8059 2022; wang, xin/A 6413 2017;
   Zhang, Dingmei/ABC 7476 2020
OI wang, xin/0000 0001 5015 3396; 
FU National Natural Science Foundation of China [82060620, 31960209,
   82260440]; National Natural Science Foundation of China [YQK[2023] 039];
   Outstanding Youth Scientific Fund of Guizhou Province [[2020]1Y093];
   Guizhou Science and Technology Fund Project; Guizhou Science and
   Technology Program Project [ZK[2023]]; Qiankehe Foundation   [gzwkj
   2022 108]; Science and Technology Fund Project of Guizhou Provincial
   Health Commission [283 [2022]]; Guizhou Province Colleges and
   Universities Youth Science and Technology Talent development project
   [Zunyi Kehe HZ Zi [2021]40]; Zunyi Science and Technology Fund Project
   [2022 02]; Future Eminent Clinician Plan of Zunyi Medical University
   [2022 5]; Affiliated Hospital of Zunyi Medical University Doctoral
   Research Start up Fund Project
FX This work was financially supported by the National Natural Science
   Foundation of China (grant no. 82060620, 31960209, and 82260440), the
   Outstanding Youth Scientific Fund of Guizhou Province (grant no. Qian Ke
   He Platform Talents YQK[2023] 039), the Guizhou Science and Technology
   Fund Project (grant no. [2020]1Y093), the Guizhou Science and Technology
   Program Project (grant no. Qiankehe Foundation   ZK[2023] General 502),
   the Science and Technology Fund Project of Guizhou Provincial Health
   Commission (grant no. gzwkj 2022 108), the Guizhou Province Colleges and
   Universities Youth Science and Technology Talent development project
   (grant no. Qian Jiao He KY Zi 283 [2022]), the Zunyi Science and
   Technology Fund Project (grant no. Zunyi Kehe HZ Zi [2021]40), the
   Future Eminent Clinician Plan of Zunyi Medical University (grant no.
   2022 02), and Affiliated Hospital of Zunyi Medical University Doctoral
   Research Start up Fund Project (grant no. 2022 5).
CR Aaron N, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.853765
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Al Bari AA, 2020, FASEB BIOADV, V2, P668, DOI 10.1096/fba.2020 00058
   Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Alvarez Fernández JA, 2011, MED INTENSIVA, V35, P134, DOI 10.1016/j.medin.2010.12.013
   Anderson CF, 2002, J LEUKOCYTE BIOL, V72, P101
   Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801
   Berebichez Fridman Roberto, 2018, Sultan Qaboos Univ Med J, V18, pe264, DOI 10.18295/squmj.2018.18.03.002
   Blume SW, 2011, OSTEOPOROSIS INT, V22, P1835, DOI 10.1007/s00198 010 1419 7
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   Brunner JS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 14285 1
   Cai XW, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01650
   Cavalli R, 2012, INT J NANOMED, V7, P3309, DOI 10.2147/IJN.S30912
   Chen KX, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.598263
   Chen XX, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 20361 w
   Chubb SAP, 2012, CLIN BIOCHEM, V45, P928, DOI 10.1016/j.clinbiochem.2012.03.035
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cui YZ, 2022, ACS NANO, V16, P11076, DOI 10.1021/acsnano.2c03781
   Cui YZ, 2022, BIOACT MATER, V10, P207, DOI 10.1016/j.bioactmat.2021.09.015
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Dong YM, 2022, PHARMACOL RES, V185, DOI 10.1016/j.phrs.2022.106513
   Ghasemi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312827
   Ginaldi Lia, 2005, Immun Ageing, V2, P14, DOI 10.1186/1742 4933 2 14
   Greenhill C, 2021, NAT REV ENDOCRINOL, V17, P577, DOI 10.1038/s41574 021 00548 4
   Guo YY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00976 4
   Hamdy NAT, 2008, DRUG TODAY, V44, P7, DOI 10.1358/dot.2008.44.1.1178467
   Harada K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078612
   Harvey N, 2010, NAT REV RHEUMATOL, V6, P99, DOI 10.1038/nrrheum.2009.260
   Hu B, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0207 x
   Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19
   Kim H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 018 1130 8
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim TH, 2016, ACTA BIOMATER, V29, P352, DOI 10.1016/j.actbio.2015.09.035
   Klibanov AL, 2010, J CONTROL RELEASE, V148, P13, DOI 10.1016/j.jconrel.2010.07.115
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   이나경, 2017, [Biomedical Science Letters, 대한의생명과학회지], V23, P295, DOI 10.15616/BSL.2017.23.4.295
   Li JY, 2011, P NATL ACAD SCI USA, V108, P768, DOI 10.1073/pnas.1013492108
   Li JP, 2020, CANCER LETT, V475, P92, DOI 10.1016/j.canlet.2020.01.028
   Li YJ, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00069
   Lin CY, 2016, J CONTROL RELEASE, V235, P72, DOI 10.1016/j.jconrel.2016.05.052
   Ma N, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201801139
   Marxer EEJ, 2011, EUR J PHARM BIOPHARM, V77, P430, DOI 10.1016/j.ejpb.2010.12.007
   Matsubara T, 2017, BIOCHEM BIOPH RES CO, V489, P472, DOI 10.1016/j.bbrc.2017.05.174
   Muñoz J, 2020, NUTRIENTS, V12, DOI 10.3390/nu12102999
   Murray IR, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0212 7
   Musial Wysocka A, 2019, CELL TRANSPLANT, V28, P801, DOI 10.1177/0963689719837897
   Nagy V., 2006, Nature Methods, V3, DOI [10.1038/nmeth879, DOI 10.1038/NMETH879]
   Nittayacharn P, 2019, J PHARM SCI US, V108, P3091, DOI 10.1016/j.xphs.2019.05.004
   Noh JY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207623
   O'Neill BE, 2011, THER DELIV, V2, P1165, DOI [10.4155/tde.11.81, 10.4155/TDE.11.81]
   Okla M, 2021, BONE, V143, DOI 10.1016/j.bone.2020.115658
   Park Chae Woon, 2009, Int J Stem Cells, V2, P59
   Park JH, 2017, MOL CELLS, V40, P706
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Roszer T, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/816460
   Sajid MI, 2020, PHARMACEUTICALS BASE, V13, DOI 10.3390/ph13100294
   Smith NC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02292
   Su CH, 2021, RSC ADV, V11, P12915, DOI 10.1039/d0ra08727k
   Tan BH, 2020, PHYS REV LETT, V124, DOI 10.1103/PhysRevLett.124.134503
   Tasset A, 2022, NANOSCALE, V14, P3698, DOI 10.1039/d1nr06939j
   Wang J, 2010, AAPS J, V12, P492, DOI 10.1208/s12248 010 9210 4
   Wang T, 2018, MOLECULES, V23, DOI 10.3390/molecules23102564
   Wang YW, 2010, PHARM RES DORDR, V27, P1273, DOI 10.1007/s11095 010 0099 5
   Wei F, 2018, BIOMATER SCI UK, V6, P2156, DOI 10.1039/c8bm00287h
   Wu HP, 2019, ULTRASOUND MED BIOL, V45, P2502, DOI 10.1016/j.ultrasmedbio.2019.05.025
   Xiao L, 2022, MATER TODAY, V54, P202, DOI 10.1016/j.mattod.2022.02.010
   Yan CG, 2015, INT J CLIN EXP MED, V8, P5746
   Yang DH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092093
   Yang J, 2019, FASEB J, V33, P7261, DOI 10.1096/fj.201802172R
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang Y, 2023, INT J NANOMED, V18, P2019, DOI 10.2147/IJN.S397359
NR 71
TC 4
Z9 4
U1 2
U2 4
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PD DEC 6
PY 2023
VL 11
IS 47
BP 11344
EP 11356
DI 10.1039/d3tb01726e
EA NOV 2023
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA Z6ZD0
UT WOS:001108094600001
PM 37990947
OA hybrid
DA 2025 08 17
ER

PT J
AU Nishioku, T
   Anzai, R
   Hiramatsu, S
   Terazono, A
   Nakao, M
   Moriyama, M
AF Nishioku, Tsuyoshi
   Anzai, Rumi
   Hiramatsu, Sami
   Terazono, Ayaka
   Nakao, Mamiko
   Moriyama, Miyu
TI Lactate dehydrogenase A inhibition prevents RANKL induced
   osteoclastogenesis by reducing enhanced glycolysis
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Osteoclast; Lactate dehydrogenase A; Monocarboxylate transporter 4;
   Lactate; Glycolysis
ID TUMOR PROGRESSION; TRANSPORTER MCT4; LACTIC ACID; EXPRESSION;
   DIFFERENTIATION; METABOLISM; PROMOTES; GROWTH; CANCER
AB Osteoclasts are multinucleated, specializes bone resorbing cells that are derived from the monocyte/ macrophage lineage. Excessive resorbing activities of osteoclasts are involved in destructive bone dis eases. The detailed mechanism of acidification at the bone adhesion surface during the bone resorption process of osteoclasts remains to be defined. During glycolysis, pyruvate proceeds to the tricarboxylic cycle under aerobic conditions and pyruvate is converted to lactate via lactate dehydrogenase A (LDHA) under anaerobic conditions. However, tumor cells produce ATP during aerobic glycolysis and large amounts of pyruvate are converted to lactate and H thorn by LDHA. Lactate and H thorn are excreted outside the cell, whereby they are involved in invasion of tumor cells due to the pH drop around the cell. In this study, we focused on aerobic glycolysis and investigated the production of lactate by LDHA in osteoclasts. Expression of LDHA and monocarboxylate transporter 4 (MCT4) was upregulated during osteoclast differentiation. Intracellular and extracellular lactate levels increased with upregulation of LDHA and MCT4, respectively. FX11 (an LDHA inhibitor) inhibited osteoclast differentiation and suppressed the bone resorbing activity of osteoclasts. We propose that inhibition of LDHA may represent a novel therapeutic strategy for controlling excessive bone resorption in osteoporosis and rheumatoid arthritis. (c) 2023 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/ 4.0/).
C1 [Nishioku, Tsuyoshi; Anzai, Rumi; Hiramatsu, Sami; Terazono, Ayaka; Nakao, Mamiko; Moriyama, Miyu] Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Pharmacol, 2825 7 Huis Ten Bosch, Sasebo, Nagasaki 8593298, Japan.
C3 Nagasaki International University
RP Nishioku, T (通讯作者)，Nagasaki Int Univ, Fac Pharmaceut Sci, Dept Pharmacol, 2825 7 Huis Ten Bosch, Sasebo, Nagasaki 8593298, Japan.
EM nishiokut@niu.ac.jp
FU Japan Society for the Promotion of Science [16K08567]; Association for
   Health Economics Research and Social Insurance and Welfare
FX This work was supported in part by Grants  in  Aid for Scientific
   Research from the Japan Society for the Promotion of Science [ (C)
   16K08567] and funds from the Association for Health Economics Research
   and Social Insurance and Welfare. We thank Edanz (https://jp.edanz.com
   /ac) for editing a draft of this manuscript.
CR Ahn H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0153886
   Bonen A, 2001, EUR J APPL PHYSIOL, V86, P6, DOI 10.1007/s004210100516
   Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   De Saedeleer CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046571
   Dhup S, 2012, CURR PHARM DESIGN, V18, P1319, DOI 10.2174/138161212799504902
   Dimmer KS, 2000, BIOCHEM J, V350, P219, DOI 10.1042/0264 6021:3500219
   Doi K, 2022, ARTHRITIS RHEUMATOL, V74, P948, DOI 10.1002/art.42074
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Felmlee MA, 2020, PHARMACOL REV, V72, P466, DOI 10.1124/pr.119.018762
   Fox JEM, 2000, J PHYSIOL LONDON, V529, P285, DOI 10.1111/j.1469 7793.2000.00285.x
   Gatenby RA, 2003, CANCER RES, V63, P3847
   Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264 6021:3430281
   Indo Y, 2013, J BONE MINER RES, V28, P2392, DOI 10.1002/jbmr.1976
   Jin JM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1351 4
   Kaushik DK, 2019, J CLIN INVEST, V129, P3277, DOI 10.1172/JCI124012
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kornberg MD, 2018, SCIENCE, V360, P449, DOI 10.1126/science.aan4665
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   Luo F, 2017, CARCINOGENESIS, V38, P615, DOI 10.1093/carcin/bgx034
   Narazaki A, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 07521 9
   Nishikawa K, 2021, EMBO REP, V22, DOI 10.15252/embr.202153035
   Nishioku T, 2020, BIOMED RES TOKYO, V41, P269, DOI 10.2220/biomedres.41.269
   Nishioku T, 2020, BIOCHEM BIOPH RES CO, V530, P455, DOI 10.1016/j.bbrc.2020.05.088
   Nishioku T, 2016, BIOCHEM BIOPH RES CO, V473, P620, DOI 10.1016/j.bbrc.2016.03.147
   Pathria G, 2018, EMBO J, V37, DOI 10.15252/embj.201899735
   RIPPLE MO, 1995, CANCER RES, V55, P4234
   Sheng SL, 2012, FEBS J, V279, P3898, DOI 10.1111/j.1742 4658.2012.08748.x
   Shestov AA, 2014, ELIFE, V3, DOI 10.7554/eLife.03342
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Todenhöfer T, 2018, MOL CANCER THER, V17, P2746, DOI 10.1158/1535 7163.MCT 18 0107
   TOKUNAGA K, 1987, CANCER RES, V47, P5616
   Ullah MS, 2006, J BIOL CHEM, V281, P9030, DOI 10.1074/jbc.M511397200
   Väänänen HK, 2008, ARCH BIOCHEM BIOPHYS, V473, P132, DOI 10.1016/j.abb.2008.03.037
   Wei HX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.942862
   Xian ZY, 2015, TUMOR BIOL, V36, P8093, DOI 10.1007/s13277 015 3540 x
   Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003
NR 39
TC 11
Z9 12
U1 4
U2 24
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI EBISUGAWA NAKAGYO KU, KYOTO, 604,
   JAPAN
SN 1347 8613
EI 1347 8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD DEC
PY 2023
VL 153
IS 4
BP 197
EP 207
DI 10.1016/j.jphs.2023.09.005
EA OCT 2023
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA W1IQ0
UT WOS:001089237500001
PM 37973217
OA gold
DA 2025 08 17
ER

PT J
AU Lin, HN
   O'Connor, JP
AF Lin, Hsuan Ni
   O'Connor, J. Patrick
TI Immunohistochemical Localization of Key Arachidonic Acid Metabolism
   Enzymes during Fracture Healing in Mice
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN G/H SYNTHASE 2;
   GROWTH FACTOR BETA; BONE FORMATION; IN VITRO; MOUSE MODEL;
   OSTEOARTHRITIC CHONDROCYTES; TRANSCRIPTIONAL INDUCTION; ENDOCHONDRAL
   OSSIFICATION; OSTEOCLAST PRECURSORS
AB This study investigated the localization of critical enzymes involved in arachidonic acid metabolism during the initial and regenerative phases of mouse femur fracture healing. Previous studies found that loss of cyclooxygenase 2 activity impairs fracture healing while loss of 5 lipoxygenase activity accelerates healing. These diametric results show that arachidonic acid metabolism has an essential function during fracture healing. To better understand the function of arachidonic acid metabolism during fracture healing, expression of cyclooxygenase 1 (COX 1), cyclooxygenase  2 (COX 2), 5 lipoxygenase (5 LO), and leukotriene A(4) hydrolase (LTA4H) was localized by immunohistochemistry in time staged fracture callus specimens. All four enzymes were detected in leukocytes present in the bone marrow and attending inflammatory response that accompanied the fracture. In the tissues surrounding the fracture site, the proportion of leukocytes expressing COX 1, COX 2, or LTA4H decreased while those expressing 5 LO remained high at 4 and 7 days after fracture. This may indicate an inflammation resolution function for 5 LO during fracture healing. Only COX 1 was consistently detected in fracture callus osteoblasts during the later stages of healing (day 14 after fracture). In contrast, callus chondrocytes expressed all four enzymes, though 5 LO appeared to be preferentially expressed in newly differentiated chondrocytes. Most interestingly, osteoclasts consistently and strongly expressed COX 2. In addition to bone surfaces and the growth plate, COX 2 expressing osteoclasts were localized at the chondro osseous junction of the fracture callus. These observations suggest that arachidonic acid mediated signaling from callus chondrocytes or from callus osteoclasts at the chondro osseous junction regulate fracture healing.
C1 [Lin, Hsuan Ni; O'Connor, J. Patrick] Rutgers State Univ, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07102 USA.
   [O'Connor, J. Patrick] Rutgers State Univ, Dept Biochem & Mol Biol, New Jersey Med Sch, Newark, NJ 07102 USA.
C3 Rutgers University System; Rutgers University Newark; Rutgers University
   New Brunswick; Rutgers University System; Rutgers University New
   Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers
   University Newark
RP O'Connor, JP (通讯作者)，Rutgers State Univ, Grad Sch Biomed Sci, Dept Biochem & Mol Biol, Newark, NJ 07102 USA.
EM oconnojp@njms.rutgers.edu
FU National Institute of Dental & Craniofacial Research of the National
   Institutes of Health [R01DE019926]; Department of Defense
   [W81XWH 10 1 0944]
FX This research was supported by the National Institute of Dental &
   Craniofacial Research of the National Institutes of Health under award
   number R01DE019926 and by the Department of Defense Peer Reviewed
   Orthopaedic Research Program under award number W81XWH 10 1 0944 to
   JPOC. The content is solely the responsibility of the authors and does
   not necessarily represent the official views of the National Institutes
   of Health, the United States Army, or the Department of Defense. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Amat M, 1998, ARTHRITIS RHEUM, V41, P1645, DOI 10.1002/1529 0131(199809)41:9<1645::AID ART16>3.0.CO;2 Z
   Beam HA, 2002, J ORTHOPAED RES, V20, P1210, DOI 10.1016/S0736 0266(02)00066 9
   Brochhausen C, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1948
   Brown HA, 2011, CHEM REV, V111, P5817, DOI 10.1021/cr200363s
   CENTRELLA M, 1994, ENDOCRINOLOGY, V135, P1611, DOI 10.1210/en.135.4.1611
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0
   Chikazu D, 2002, J BONE MINER RES, V17, P1430, DOI 10.1359/jbmr.2002.17.8.1430
   CHYUN YS, 1984, PROSTAG OTH LIPID M, V27, P97, DOI 10.1016/0090 6980(84)90223 5
   Cottrell J, 2010, PHARMACEUTICALS, V3, P1668, DOI 10.3390/ph3051668
   Cottrell JA, 2009, J BONE JOINT SURG AM, V91A, P2653, DOI 10.2106/JBJS.H.01844
   Cuetara BLV, 2006, IN VITRO CELL DEV AN, V42, P182, DOI 10.1290/0510075.1
   DOMINGUEZ JH, 1980, CALCIFIED TISSUE INT, V31, P29, DOI 10.1007/BF02407164
   FEYEN JHM, 1985, PROSTAG OTH LIPID M, V30, P827, DOI 10.1016/0090 6980(85)90011 5
   Finkensieper A, 2010, CARDIOVASC RES, V86, P37, DOI 10.1093/cvr/cvp385
   Forwood MR, 1998, ANAT REC, V252, P580, DOI 10.1002/(SICI)1097 0185(199812)252:4<580::AID AR8>3.0.CO;2 S
   Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871
   GENG Y, 1995, J IMMUNOL, V155, P796
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gubitosi Klug RA, 2008, DIABETES, V57, P1387, DOI 10.2337/db07 1217
   Haeggström JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d
   Han SY, 2005, BLOOD, V106, P1240, DOI 10.1182/blood 2004 12 4975
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   HULTH A, 1990, CLIN ORTHOP RELAT R, P289
   Igarashi K, 2002, BIOCHEM PHARMACOL, V63, P523, DOI 10.1016/S0006 2952(01)00861 9
   Iwaki A, 1997, J BONE MINER RES, V12, P96, DOI 10.1359/jbmr.1997.12.1.96
   Janckila AJ, 2005, J LEUKOCYTE BIOL, V77, P209, DOI 10.1189/jlb.0504287
   Janckila AJ, 2007, AM J CLIN PATHOL, V127, P556, DOI 10.1309/DGEA9BE2VE5VCFYH
   Kajii T, 1999, ARCH ORAL BIOL, V44, P233, DOI 10.1016/S0003 9969(98)00120 4
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45
   Koide M, 1999, BIOCHEM BIOPH RES CO, V259, P97, DOI 10.1006/bbrc.1999.0715
   Kosaki N, 2007, BIOCHEM BIOPH RES CO, V354, P846, DOI 10.1016/j.bbrc.2006.12.234
   LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092 8674(95)90126 4
   LEE SH, 1992, J BIOL CHEM, V267, P25934
   Li L, 2006, CYTOKINE GROWTH F R, V17, P203, DOI 10.1016/j.cytogfr.2006.01.005
   Li M, 2005, BONE, V37, P46, DOI 10.1016/j.bone.2005.03.016
   Li M, 2003, J BONE MINER RES, V18, P2033, DOI 10.1359/jbmr.2003.18.11.2033
   Li TF, 2004, EXP CELL RES, V300, P159, DOI 10.1016/j.yexcr.2004.06.019
   Maciel FMB, 1997, J RHEUMATOL, V24, P2429
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Manigrasso MB, 2004, J ORTHOP TRAUMA, V18, P687, DOI 10.1097/00005131 200411000 00006
   Manigrasso MB, 2008, CALCIFIED TISSUE INT, V82, P465, DOI 10.1007/s00223 008 9144 3
   Manigrasso MB, 2010, ACTA ORTHOP, V81, P748, DOI 10.3109/17453674.2010.533931
   Martel Pelletier J, 2004, ARTHRITIS RHEUM US, V50, P3925, DOI 10.1002/art.20632
   MILLER SC, 1993, BONE, V14, P143, DOI 10.1016/8756 3282(93)90241 2
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Nishida T, 2011, J BONE MINER RES, V26, P351, DOI 10.1002/jbmr.222
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Onoe Y, 1996, J IMMUNOL, V156, P758
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Pavalko FM, 1998, AM J PHYSIOL CELL PH, V275, pC1591
   Pilbeam C, 1997, ENDOCRINOLOGY, V138, P4672, DOI 10.1210/en.138.11.4672
   QUARLES LD, 1993, ENDOCRINOLOGY, V132, P1505, DOI 10.1210/en.132.4.1505
   REN W, 1991, CALCIFIED TISSUE INT, V49, P197, DOI 10.1007/BF02556118
   Sato T, 2011, ANN RHEUM DIS, V70, P221, DOI 10.1136/ard.2009.118620
   SAVOSTINASLING I, 1975, ANAT RECORD, V183, P373, DOI 10.1002/ar.1091830303
   Serhan CN, 2011, CHEM REV, V111, P5922, DOI 10.1021/cr100396c
   Shimizu T, 2009, ANNU REV PHARMACOL, V49, P123, DOI 10.1146/annurev.pharmtox.011008.145616
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   Smith WL, 2011, CHEM REV, V111, P5821, DOI 10.1021/cr2002992
   Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534
   Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372
   Talahalli R, 2010, INVEST OPHTH VIS SCI, V51, P1699, DOI 10.1167/iovs.09 3557
   TAWARA T, 1991, INFLAMMATION, V15, P145, DOI 10.1007/BF00917509
   Tay BKB, 1998, J ORTHOP RES, V16, P636, DOI 10.1002/jor.1100160518
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   UEDA K, 1980, J PEDIATR US, V97, P834, DOI 10.1016/S0022 3476(80)80282 4
   Uusitalo H, 2000, CALCIFIED TISSUE INT, V67, P382, DOI 10.1007/s002230001152
   Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Welting T J M, 2011, Eur Cell Mater, V22, P420
   Welting TJ, 2011, EUR CELLS MATER, V22, P436
   Xie C, 2008, BONE, V43, P1075, DOI 10.1016/j.bone.2008.08.109
   Xu JQ, 1997, J CELL BIOCHEM, V64, P618, DOI 10.1002/(SICI)1097 4644(19970315)64:4<618::AID JCB10>3.0.CO;2 8
   Yoshida K, 2002, P NATL ACAD SCI USA, V99, P4580, DOI 10.1073/pnas.062053399
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 79
TC 19
Z9 20
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2014
VL 9
IS 2
AR e88423
DI 10.1371/journal.pone.0088423
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AA1CR
UT WOS:000330834400070
PM 24516658
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, YC
   Li, WK
   Liu, CX
   Yan, JY
   Yuan, XF
   Wang, W
   Wang, HX
   Wu, H
   Yang, Y
AF Zhang, Yingchi
   Li, Wenkai
   Liu, Chaoxu
   Yan, Jiyuan
   Yuan, Xuefeng
   Wang, Wei
   Wang, Huaixi
   Wu, Hua
   Yang, Yong
TI Electromagnetic field treatment increases purinergic receptor P2X7
   expression and activates its downstream Akt/GSK3β/β catenin axis in
   mesenchymal stem cells under osteogenic induction
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Electromagnetic fields (EMFs); Human bone marrow mesenchymal stem cells
   (h MSCs); Osteogenic differentiation; Akt; GSK3 beta; beta catenin
   signaling pathway
ID MARROW STROMAL CELLS; ATP RELEASE; OSTEOBLAST DIFFERENTIATION;
   FLUID FLOW; BONE; PROLIFERATION; OSTEOPOROSIS; STIMULATION; REVEALS;
   REPAIR
AB Background Imbalance in bone formation and resorption is a crucial component of the pathological process leading to osteoporosis. Electromagnetic fields (EMFs) have been reported to be beneficial to osteogenesis, although the exact mechanism has not been fully clarified. Purinergic receptor P2X7 is expressed in osteoblasts and is reported to participate in the regulation of bone metabolism. Objectives To elucidate the link between EMFs and P2X7 expression and investigate its potential as a novel therapeutic target in osteoporosis. Method We investigated the effect of EMFs on P2X7 expression and downstream signaling in human bone marrow mesenchymal stem cells (h MSCs). We also established an ovariectomized (OVX) osteoporosis rat model to evaluate the therapeutic efficacy of combining EMFs with P2X7 agonists. Results EMF treatment increased P2X7 expression in h MSCs under conditions of osteogenic induction but not under regular culture conditions. P2X7 or PI3K/Akt inhibition partially inhibited the pro osteogenic effect of EMF and lowered the EMF stimulated activity of the Akt/GSK3 beta/beta catenin axis. No additive effect of this suppression was observed following simultaneous inhibition of P2X7 and PI3K/Akt. EMF treatment in the presence of a P2X7 agonist had a greater effect in increasing osteogenic marker expression than that of EMF treatment alone. In the OVX osteoporosis model, the therapeutic efficacy of combining EMFs with P2X7 agonists was superior to that of EMF treatment alone. Conclusions EMF treatment increases P2X7 expression by h MSCs during osteogenic differentiation, leading to activation of the Akt/GSK3 beta/beta catenin axis, which promotes the osteogenesis. Our findings also indicate that combined EMF and P2X7 agonist treatment may be an effective novel strategy for osteoporosis therapy.
C1 [Zhang, Yingchi; Li, Wenkai; Liu, Chaoxu; Yan, Jiyuan; Wang, Wei; Wu, Hua; Yang, Yong] Huazhong Univ Sci & Technol, Dept Orthoped, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Yuan, Xuefeng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Traumat Surg, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
   [Wang, Huaixi] Zhengzhou Univ, Dept Spine & Spinal Cord Surg, Peoples Hosp, Henan Prov Peoples Hosp, 7 Weiwu Rd, Zhengzhou 450003, Henan, Peoples R China.
C3 Huazhong University of Science & Technology; Huazhong University of
   Science & Technology; Zhengzhou University
RP Wu, H; Yang, Y (通讯作者)，Huazhong Univ Sci & Technol, Dept Orthoped, Tongji Hosp, Tongji Med Coll, 1095 Jiefang Ave, Wuhan 430030, Hubei, Peoples R China.
EM wuhua360@aliyun.com; yangyong0127@hotmail.com
RI Zhang, Yuanyuan/GYE 1266 2022
FU National Natural Science Foundation of China [81301552, 51807078,
   51537004]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81301552, 51807078, and 51537004).
CR Agrawal A, 2015, J MOL ENDOCRINOL, V54, pR75, DOI 10.1530/JME 14 0226
   An J, 2016, INT IMMUNOPHARMACOL, V36, P118, DOI 10.1016/j.intimp.2016.04.024
   Barry FP, 2004, INT J BIOCHEM CELL B, V36, P568, DOI 10.1016/j.biocel.2003.11.001
   Bernabei R, 2014, CLIN CASES MINER BON, V11, P201, DOI 10.11138/ccmbm/2014.11.3.201
   Bloise N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199046
   Burnstock G, 2009, BRAZ J MED BIOL RES, V42, P3, DOI 10.1590/S0100 879X2008005000037
   Carbonare LD, 2009, ARTHRITIS RHEUM US, V60, P3356, DOI 10.1002/art.24884
   Ceccarelli G, 2013, BIORESEARCH OPEN ACC, V2, P397, DOI 10.1089/biores.2013.0016.cxn
   Chen JC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt318
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   Egermann M, 2010, J ORTHOP RES, V28, P798, DOI 10.1002/jor.21041
   Esposito M, 2012, IN VIVO, V26, P299
   Ferrari D, 2011, EXP HEMATOL, V39, P360, DOI 10.1016/j.exphem.2010.12.001
   Grol MW, 2012, AM J PHYSIOL ENDOC M, V302, pE561, DOI 10.1152/ajpendo.00209.2011
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Gupta AK, 2009, INDIAN J ORTHOP, V43, P156, DOI 10.4103/0019 5413.50850
   Hannemann PFW, 2014, ARCH ORTHOP TRAUM SU, V134, P1093, DOI 10.1007/s00402 014 2014 8
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Jorgensen NR, 2018, CURR OPIN IMMUNOL, V52, P32, DOI 10.1016/j.coi.2018.03.016
   Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Li WK, 2015, EXP CELL RES, V339, P367, DOI 10.1016/j.yexcr.2015.10.011
   Li YP, 2019, EXP THER MED, V18, P1899, DOI 10.3892/etm.2019.7741
   Li Y, 2018, CURR STEM CELL RES T, V13, P185, DOI 10.2174/1574888X12666171012141908
   Liu CX, 2017, BIOELECTROMAGNETICS, V38, P137, DOI 10.1002/bem.22022
   Lu JM, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1345 3
   Ma YG, 2019, EXP CELL RES, V383, DOI 10.1016/j.yexcr.2019.111555
   Matzkin EG, 2019, J AM ACAD ORTHOP SUR, V27, pE902, DOI 10.5435/JAAOS D 18 00600
   Meskens M W, 1990, Acta Orthop Belg, V56, P483
   Noronha Matos JB, 2012, J CELL PHYSIOL, V227, P2694, DOI 10.1002/jcp.23014
   Noronha Matos JB, 2014, FASEB J, V28, P5208, DOI 10.1096/fj.14 257923
   Okumura H, 2008, BIOCHEM BIOPH RES CO, V372, P486, DOI 10.1016/j.bbrc.2008.05.066
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Riddle RC, 2007, J BONE MINER RES, V22, P589, DOI 10.1359/JBMR.070113
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Rumney RMH, 2012, J BIOMECH, V45, P549, DOI 10.1016/j.jbiomech.2011.11.036
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Song MY, 2014, BIOELECTROMAGNETICS, V35, P479, DOI 10.1002/bem.21867
   Sun DH, 2013, STEM CELLS, V31, P1170, DOI 10.1002/stem.1356
   Sun MY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0798 0
   TROCK DH, 1994, J RHEUMATOL, V21, P1903
   Wang YK, 2012, STEM CELLS DEV, V21, P1176, DOI 10.1089/scd.2011.0293
   Willson T, 2015, CLIN EPIDEMIOL, V7, P65, DOI 10.2147/CLEP.S40966
   Yang Y, 2010, BIOELECTROMAGNETICS, V31, P277, DOI 10.1002/bem.20560
   Zhang Q, 2016, BIOCHEM BIOPH RES CO, V476, P438, DOI 10.1016/j.bbrc.2016.05.141
   Zhang YC, 2019, INT J CANCER, V145, P1068, DOI 10.1002/ijc.32207
   Zhang YC, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0883 4
   Zhou J, 2013, RHEUMATOL INT, V33, P1135, DOI 10.1007/s00296 012 2499 9
NR 50
TC 22
Z9 22
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 21
PY 2019
VL 10
IS 1
AR 407
DI 10.1186/s13287 019 1497 1
PG 13
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JY2YV
UT WOS:000504287000003
PM 31864409
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Marsík, F
   Klika, V
   Chlup, H
AF Marsik, Frantisek
   Klika, Vaclav
   Chlup, Hynek
TI Remodelling of living bone induced by dynamic loading and drug
   delivery Numerical modelling and clinical treatment
SO MATHEMATICS AND COMPUTERS IN SIMULATION
LA English
DT Article; Proceedings Paper
CT 1st IMACS International Conference on Computational Biomechanics and
   Biology (ICCBB 2007)
CY SEP 10 14, 2007
CL Univ W Bohemia, Pilsen, CZECH REPUBLIC
SP IMACS
HO Univ W Bohemia
DE Bone remodelling; Chemical kinetics; Biochemical model; Numerical
   simulation
ID CELL
AB Remodelling is a dynamic process occurring during growth and it includes sensing of environmental changes, tissue resorbance. e the removal of existing old bone, and formation of new tissue The biomechanical remodelling process is relatively well formulated for bones and can he divided into three stages (1) bone resorption based on the osteoclast activity, (2) hone deposition based on the osteoblast activity and (3) hone growth control established on RANK/RANKL/OPG pathway RANKL/OPG balance The main driving force of remodelling process is a dynamic loading (cyclic compression and expansion. e g walking or running). which strongly influences the rate of chemical reactions The evolution from the homogeneous density distribution to the cortical's and cancellous bone formation is shown An inevitable influence of a dynamic mechanical loading and osteoprotegerin (OPG) concentration is demonstrated Deformations were calculated by commercial code ANSYS The clinical experience indicates that the dynamic loading (above the threshold level 1500 2500 microstains/s). especially walking with a characteristic time approximately 1 s, influences the whole process of bone remodelling after a time period of approximately 3 months The numerical simulation shows that the concentration of the new bone and the bone elastic constants substantially depend on history and intensity of the loading, drug delivery and nutrition (C) 2009 IMACS Published by Elsevier B V All rights reserved
C1 [Marsik, Frantisek; Klika, Vaclav; Chlup, Hynek] Acad Sci Czech Republ, Inst Thermomech, Vvi, Prague 18200, Czech Republic.
   [Klika, Vaclav] Czech Tech Univ, FNSPE, Dept Math, CR 16635 Prague, Czech Republic.
   [Chlup, Hynek] Czech Tech Univ, FME, CR 16635 Prague, Czech Republic.
C3 Czech Academy of Sciences; Institute of Thermomechanics of the Czech
   Academy of Sciences; Czech Technical University Prague; Czech Technical
   University Prague
RP Marsík, F (通讯作者)，Acad Sci Czech Republ, Inst Thermomech, Vvi, Dolejskova 5, Prague 18200, Czech Republic.
RI Marsik, Frantisek/G 8395 2014; Klika, Vaclav/AET 3996 2022
CR CHUONG CJ, 1983, J BIOMECH ENG T ASME, V105, P268, DOI 10.1115/1.3138417
   Doblaré M, 2004, ENG FRACT MECH, V71, P1809, DOI 10.1016/j.engfracmech.2003.08.003
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   FROST HM, 1987, BONE MINER, V2, P73
   Frost HM, 2004, UTAH PARADIGM SKELET, V2
   FROST HM, 1987, CLIN ORTHOP RELAT R, V216, P280
   Hayashi S, 1998, J BIOMECH ENG T ASME, V120, P468, DOI 10.1115/1.2798016
   Helgason B, 2008, CLIN BIOMECH, V23, P135, DOI 10.1016/j.clinbiomech.2007.08.024
   HERT J, 1972, ACTA ANAT, V82, P218
   HOLTZAPFEL GA, 1998, COMPUT BIOL MED, V28, P377
   Holzapfel GA, 2000, J ELASTICITY, V61, P1, DOI 10.1023/A:1010835316564
   HUISKES R, 1993, J BIOMECH ENG T ASME, V115, P520, DOI 10.1115/1.2895534
   JAWORSKI ZFG, 1986, BONE, V7, P431, DOI 10.1016/8756 3282(86)90003 7
   KLIKA V, 2008, 22 INT C THEOR APPL
   KLIKA V, 2007, LOCOMOTOR SYST S, V14, P112
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   MARIK I, 2001, LOCOMOTOR SYST, V8, P104, DOI DOI 10.1016/J.JTBI.2004.03.023
   MARSIK F, 2007, ICMOSPS P CD SCH MEC
   Nicolis G, 1977, DISSIPATIVE STRUCTUR
   Petrtyl M, 1996, J BIOMECH, V29, P161, DOI 10.1016/0021 9290(94)00035 2
   Prigogine I., 1947, Etude thermodynamique des phenomenes irreversibles
   Rajagopal KR, 2004, P ROY SOC A MATH PHY, V460, P631, DOI 10.1098/rspa.2002.1111
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Ruimerman R, 2005, J BIOMECH, V38, P931, DOI 10.1016/j.jbiomech.2004.03.037
   Wolff J., 1986, GESETZ TRANSFORMATIO
   ZHU X, 2005, J BIOMECH, P1612, DOI DOI 10.1016/J.JBIOMECH.2004.06029
NR 26
TC 5
Z9 5
U1 0
U2 8
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378 4754
EI 1872 7166
J9 MATH COMPUT SIMULAT
JI Math. Comput. Simul.
PD FEB
PY 2010
VL 80
IS 6
SI SI
BP 1278
EP 1288
DI 10.1016/j.matcom.2009.02.014
PG 11
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Software Engineering; Mathematics, Applied
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Computer Science; Mathematics
GA 579OE
UT WOS:000276380400024
DA 2025 08 17
ER

PT J
AU Xia, W
   Xie, J
   Cai, ZQ
   Liu, XH
   Wen, J
   Cui, ZK
   Zhao, R
   Zhou, XM
   Chen, JH
   Mao, XR
   Gu, ZT
   Zou, ZM
   Zou, ZP
   Zhang, Y
   Zhao, M
   Mac, M
   Song, QC
   Bai, XC
AF Xia, Wei
   Xie, Jing
   Cai, Zhiqing
   Liu, Xuhua
   Wen, Jing
   Cui, Zhong Kai
   Zhao, Run
   Zhou, Xiaomei
   Chen, Jiahui
   Mao, Xinru
   Gu, Zhengtao
   Zou, Zhimin
   Zou, Zhipeng
   Zhang, Yue
   Zhao, Ming
   Mac, Maegele
   Song, Qiancheng
   Bai, Xiaochun
TI Damaged brain accelerates bone healing by releasing small extracellular
   vesicles that target osteoprogenitors
SO NATURE COMMUNICATIONS
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; INJURY; FRACTURE; MODEL; POLARIZATION;
   EXPRESSION; EXOSOMES; RECEPTOR; BIOLOGY; CELLS
AB Clinical evidence has established that concomitant traumatic brain injury (TBI) accelerates bone healing, but the underlying mechanism is unclear. This study shows that after TBI, injured neurons, mainly those in the hippocampus, release osteogenic microRNA (miRNA) enriched small extracellular vesicles (sEVs), which targeted osteoprogenitors in bone to stimulate bone formation. We show that miR 328a 3p and miR 150 5p, enriched in the sEVs after TBI, promote osteogenesis by directly targeting the 3 ' UTR of FOXO4 or CBL, respectively, and hydrogel carrying miR 328a 3p containing sEVs efficiently repaires bone defects in rats. Importantly, increased fibronectin expression on sEVs surface contributes to targeting of osteoprogenitors in bone by TBI sEVs, thereby implying that modification of the sEVs surface fibronectin could be used in bone targeted drug delivery. Together, our work unveils a role of central regulation in bone formation and a clear link between injured neurons and osteogenitors, both in animals and clinical settings.
   Concomitant traumatic brain injury accelerates bone healing, but the mechanism is unclear. Here, the authors show that injured neurons, mainly those in the hippocampus, release osteogenic miRNA enriched small extracellular vesicles, which targete osteoprogenitors to stimulate bone formation.
C1 [Xia, Wei; Xie, Jing; Cai, Zhiqing; Cui, Zhong Kai; Zhao, Run; Zhou, Xiaomei; Zou, Zhipeng; Zhang, Yue; Song, Qiancheng; Bai, Xiaochun] Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510515, Peoples R China.
   [Liu, Xuhua; Chen, Jiahui] Southern Med Univ, Acad Orthoped, State Key Lab Organ Failure Res, Affiliated Hosp 3, Guangzhou 510630, Guangdong, Peoples R China.
   [Wen, Jing] Southern Med Univ, Nanfang Hosp, Dept Radiol, Guangzhou 510515, Guangdong, Peoples R China.
   [Mao, Xinru] Southern Med Univ, Nanfang Hosp, Dept Clin Lab, Guangzhou 510515, Guangdong, Peoples R China.
   [Gu, Zhengtao; Zou, Zhimin; Zhao, Ming] Southern Med Univ, Dept Pathophysiol, Guangdong Prov Key Lab Shock & Microcirculat Res, Guangzhou 510515, Guangdong, Peoples R China.
   [Mac, Maegele] Private Univ Witten Herdecke, Cologne Merheim Med Ctr, Inst Res Operat Med, Ostmerheimerstr 200, D 51109 Cologne, Germany.
C3 Southern Medical University   China; Southern Medical University  
   China; Southern Medical University   China; Southern Medical University
     China; Southern Medical University   China; Witten Herdecke University
RP Song, QC; Bai, XC (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Cell Biol, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, Guangzhou 510515, Peoples R China.
EM songqc@smu.edu.cn; baixc15@smu.edu.cn
RI ; Cui, Zhong Kai/K 2051 2019; wen, jing/HDM 2205 2022; Song,
   Qiancheng/U 3407 2019; zhang, yue/HZI 8553 2023
OI Xia, Wei/0000 0003 2127 1486; Cui, Zhong Kai/0000 0003 3112 9379; Chen,
   Jiahui/0000 0002 1458 1761; Bai, Xiaochun/0000 0001 9631 4781; Mao,
   Xinru/0000 0001 7961 4686; Liu, Xuhua/0000 0002 6919 8292; Song,
   Qiancheng/0000 0002 9335 5147; Cai, zhiqing/0000 0002 7935 2345; Xie,
   Jing/0000 0001 5624 458X; 
FU National Natural Science Foundation of China [81991510, 81991511,
   81625015]; Key Research & Development Program of Guangzhou Regenerative
   Medicine and Health Guangdong Laboratory [2018GZR110104002]; Natural
   Science Foundation of Guangdong Province, China [2018A030310434,
   2017A030313696]; China Postdoctoral Science Foundation [2016M602487];
   Medical Research Foundation of Guangdong Province, China [A2017117]
FX We thank Central Laboratory, Southern Medical University for providing
   facilities and technical support. This work was supported by grants from
   the National Natural Science Foundation of China (Grant No. 81991510,
   81991511, 81625015), Key Research & Development Program of Guangzhou
   Regenerative Medicine and Health Guangdong Laboratory
   (2018GZR110104002), Natural Science Foundation of Guangdong Province,
   China (2018A030310434, 2017A030313696), China Postdoctoral Science
   Foundation funded project (2016M602487), Medical Research Foundation of
   Guangdong Province, China (A2017117).
CR Ambrogini E, 2010, CELL METAB, V11, P136, DOI 10.1016/j.cmet.2009.12.009
   Beeton CA, 2004, J BONE JOINT SURG BR, V86B, P912, DOI 10.1302/0301 620x.86b6.14176
   Berger JM, 2019, CELL METAB, V30, P890, DOI 10.1016/j.cmet.2019.08.012
   Bhomia M, 2016, SCI REP UK, V6, DOI 10.1038/srep28148
   Böhm M, 2012, ENDOCR REV, V33, P623, DOI 10.1210/er.2011 1016
   Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648
   Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04
   Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613
   Coumans FAW, 2017, CIRC RES, V120, P1632, DOI 10.1161/CIRCRESAHA.117.309417
   Dieudonne FX, 2013, STEM CELLS, V31, P1340, DOI 10.1002/stem.1380
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101
   Gao MH, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0039 2
   Hadjiargyrou M, 2019, J BONE MINER RES, V34, P797, DOI 10.1002/jbmr.3708
   Hill AF, 2019, J NEUROSCI, V39, P9269, DOI 10.1523/JNEUROSCI.0147 18.2019
   Hofman M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/204842
   Hu JL, 2012, ACTA BIOMATER, V8, P1730, DOI 10.1016/j.actbio.2012.01.029
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Idelevich A, 2018, BONE, V115, P31, DOI 10.1016/j.bone.2018.05.018
   Iyer S, 2013, J CLIN INVEST, V123, P3409, DOI 10.1172/JCI68049
   Karsenty G, 2012, ANNU REV PHYSIOL, V74, P87, DOI 10.1146/annurev physiol 020911 153233
   Kim JB, 2007, J BONE MINER RES, V22, P1913, DOI 10.1359/JBMR.070802
   Kostenuik P, 2017, J ORTHOP RES, V35, P213, DOI 10.1002/jor.23460
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li Q, 2018, J BONE MINER METAB, V36, P1, DOI 10.1007/s00774 017 0860 5
   Luo ZW, 2019, NANOSCALE, V11, P20884, DOI 10.1039/c9nr02791b
   Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474 4422(17)30371 X
   Martin PJ, 2015, BMC CELL BIOL, V16, DOI 10.1186/s12860 015 0057 5
   MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306 4522(89)90247 9
   Miszczuk D, 2016, MOL NEUROBIOL, V53, P7010, DOI 10.1007/s12035 015 9578 3
   Obri A, 2018, NAT REV ENDOCRINOL, V14, P174, DOI 10.1038/nrendo.2017.181
   Ono T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10928
   Prokopi M, 2009, BLOOD, V114, P723, DOI 10.1182/blood 2009 02 205930
   Purushothaman A, 2016, J BIOL CHEM, V291, P1652, DOI 10.1074/jbc.M115.686295
   Qin YW, 2017, J BIOL CHEM, V292, P11021, DOI 10.1074/jbc.M116.770941
   Rubin C, 2005, CELL RES, V15, P66, DOI 10.1038/sj.cr.7290268
   Salvador E, 2018, METHODS MOL BIOL, V1717, P219, DOI 10.1007/978 1 4939 7526 6_17
   Schall N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.135355
   Sluijter JPG, 2018, CARDIOVASC RES, V114, P19, DOI 10.1093/cvr/cvx211
   Sun WJ, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.15
   van den Broek M, 2017, ORTHOP TRAUMATOL SUR, V103, P1127, DOI 10.1016/j.otsr.2017.07.004
   Varma VR, 2017, MOL PSYCHIATR, V22, P13, DOI 10.1038/mp.2016.206
   Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146
   Wang RS, 2015, J BIOL CHEM, V290, P30684, DOI 10.1074/jbc.M115.671735
   Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013
   Weilner S, 2015, BONE, V79, P43, DOI 10.1016/j.bone.2015.05.027
   Wildburger R, 2001, WIEN KLIN WOCHENSCHR, V113, P119
   Xie Y, 2017, J CELL MOL MED, V21, P1033, DOI 10.1111/jcmm.13039
   Yadav VK, 2008, CELL, V135, P825, DOI 10.1016/j.cell.2008.09.059
   Zhao SJ, 2020, J BONE MINER RES, V35, P2015, DOI 10.1002/jbmr.4099
   Zhao SJ, 2020, THERANOSTICS, V10, P17, DOI 10.7150/thno.36930
NR 51
TC 87
Z9 101
U1 13
U2 160
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 15
PY 2021
VL 12
IS 1
AR 6043
DI 10.1038/s41467 021 26302 y
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA WH4PG
UT WOS:000707661200021
PM 34654817
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Merrell, MA
   Wakchoure, S
   Ilvesaro, JM
   Zinn, K
   Gehrs, B
   Lehenkari, PP
   Harris, KW
   Selander, KS
AF Merrell, Melinda A.
   Wakchoure, Savita
   Ilvesaro, Joanna M.
   Zinn, Kurt
   Gehrs, Bradley
   Lehenkari, Petri P.
   Harris, Kevin W.
   Selander, Katri S.
TI Differential effects of Ca<SUP>2+</SUP> on bisphosphonate induced growth
   inhibition in breast cancer and mesothelioma cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE bisphosphonate; breast cancer; prenylation; p38; mesothelioma
ID NITROGEN CONTAINING BISPHOSPHONATES; ADJUVANT CLODRONATE TREATMENT;
   IN VITRO; ZOLEDRONIC ACID; 3RD GENERATION BISPHOSPHONATE; PLEURAL
   MESOTHELIOMA; MEVALONATE PATHWAY; OVARIAN CARCINOMA; CONTROLLED TRIAL;
   APOPTOSIS
AB Bisphosphonates are widely clinically used inhibitors of bone resorption. Pre clinical studies indicate that bisphosphonates also inhibit the growth of various cancer cells in vitro, but their in vivo anti cancer activity varies greatly, depending on the tumor type. We compared the various cellular effects of bisphosphonates in breast cancer and mesothelioma cells, with differences in growth inhibition responses to bisphosphonate treatment in vivo. We show that the growth inhibitory effects of nitrogen containing bisphosphonates are significantly affected by excess Ca2+ in a cell  and bisphosphonate specific fashion. Furthermore, excess pyrophosphate resembling bisphosphonates prevent nitrogen containing bisphosphonate induced accumulation of unprenylated Rap1A, p38 phosphorylation and growth inhibition in human MDA MB 231 breast cancer and mouse AB 12 mesothelioma cells. For some, but not all tested, pyrophosphate resembling bisphosphonate: nitrogen containing bisphosphonate combinations these results may be partially explained by the ability of the excess pyrophosphate resembling bisphosphonates to chelate Ca2+. In mice, subcutaneous AB 12 and MDA MB 231 tumors exhibit positive staining for Ca2+ minerals, as revealed with Von Kossa stainings. We further show that the AB 12 tumors accumulate significantly more of the bone scanning bisphosphonate, Tc99m medronate, as compared with MDA MB 231 tumors. In conclusion, our results suggest that Ca2+ regulates the growth inhibitory effects of bisphosphonates in a target cell and drug specific fashion. These findings may be of physiological relevance since many tumor types are calcified. They further suggest that bisphosphonates can accumulate in tumors that are growing at the visceral sites and that differences in tumor accumulation of bisphosphonates may regulate their in vivo sensitivity to these drugs. (c) 2006 Elsevier B.V. All rights reserved.
C1 Univ Alabama, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA.
   Univ Alabama, Lab Multimodal Imaging, Birmingham, AL 35294 USA.
   Vet Affairs Med Ctr, Birmingham, AL USA.
   Univ Oulu, Dept Surg, Clin Res Ctr, Oulu, Finland.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham; US
   Department of Veterans Affairs; Veterans Health Administration (VHA);
   University of Oulu
RP Selander, KS (通讯作者)，Univ Alabama, Dept Med, Div Hematol Oncol, WTI T558,1824 6th Ave S, Birmingham, AL 35294 USA.
EM Katri.Selander@ccc.uab.edu
RI Merrell, Melinda/IUO 5528 2023; Lehenkari, Petri/O 3009 2016; Selander,
   Katri/GWM 8685 2022
OI Lehenkari, Petri/0000 0002 0055 5183; Zinn, Kurt/0000 0001 7463 4741; 
CR Alakangas A, 2002, CALCIFIED TISSUE INT, V70, P40, DOI 10.1007/s002230010047
   Barai S, 2004, CLIN NUCL MED, V29, P167, DOI 10.1097/01.rlu.0000113854.98190.a9
   BERES RA, 1991, CLIN NUCL MED, V16, P550, DOI 10.1097/00003072 199108000 00003
   Chuah C, 2005, LEUKEMIA, V19, P1896, DOI 10.1038/sj.leu.2403949
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   FOGELMAN I, 1978, J NUCL MED, V19, P270
   Frith JC, 2003, J BONE MINER RES, V18, P204, DOI 10.1359/jbmr.2003.18.2.204
   Hashimoto K, 2005, CANCER RES, V65, P540
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hosfield DJ, 2004, J BIOL CHEM, V279, P8526, DOI 10.1074/jbc.C300511200
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Merrell M, 2003, BREAST CANCER RES TR, V81, P231, DOI 10.1023/A:1026126430905
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   MONKKONEN J, 1994, J DRUG TARGET, V2, P299, DOI 10.3109/10611869409015910
   Morgan MP, 2005, J MAMMARY GLAND BIOL, V10, P181, DOI 10.1007/s10911 005 5400 6
   NICHOLS DM, 1983, J CAN ASSOC RADIOL, V34, P311
   Ory B, 2005, CANCER AM CANCER SOC, V104, P2522, DOI 10.1002/cncr.21530
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Plotkin LI, 2001, CELL COMMUN ADHES, V8, P377, DOI 10.3109/15419060109080757
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Plotkin LI, 2002, J BIOL CHEM, V277, P8648, DOI 10.1074/jbc.M108625200
   Powles T, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1384
   Powles T, 2002, J CLIN ONCOL, V20, P3219, DOI 10.1200/JCO.2002.11.080
   Raizon A, 1996, J COMPUT ASSIST TOMO, V20, P42, DOI 10.1097/00004728 199601000 00009
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Riebeling C, 2002, BRIT J CANCER, V87, P366, DOI 10.1038/sj.bjc.6600476
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rogers MJ, 2004, CALCIFIED TISSUE INT, V75, P451, DOI 10.1007/s00223 004 0024 1
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   SASAKI A, 1995, CANCER RES, V55, P3551
   Sato K, 2005, INT J CANCER, V116, P94, DOI 10.1002/ijc.20987
   Sawada K, 2002, CANCER RES, V62, P6015
   Selander KS, 1996, MOL PHARMACOL, V50, P1127
   Senaratne SG, 2002, BREAST CANCER RES, V4, P18, DOI 10.1186/bcr412
   Shao Q, 2005, CANCER RES, V65, P2705, DOI 10.1158/0008 5472.CAN 04 2367
   Skerjanec A, 2003, J CLIN PHARMACOL, V43, P154, DOI 10.1177/0091270002239824
   SWAYNE LC, 1992, CLIN NUCL MED, V17, P965, DOI 10.1097/00003072 199212000 00013
   Tanabe M, 1979, Radioisotopes, V28, P177
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   Thompson K, 2006, BLOOD, V107, P651, DOI 10.1182/blood 2005 03 1025
   Thompson K, 2004, J BONE MINER RES, V19, P278, DOI 10.1359/JBMR.0301230
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   VORNE M, 1984, EUR J NUCL MED, V9, P180
   Wakchoure S, 2006, CLIN CANCER RES, V12, P2862, DOI 10.1158/1078 0432.CCR 05 2766
NR 48
TC 11
Z9 11
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD MAR 15
PY 2007
VL 559
IS 1
BP 21
EP 31
DI 10.1016/j.ejphar.2006.11.064
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 146XR
UT WOS:000244968500003
PM 17214981
DA 2025 08 17
ER

PT J
AU Shams, R
   Banik, NL
   Haque, A
AF Shams, Ramsha
   Banik, Naren L.
   Haque, Azizul
TI Implications of enolase in the RANKL mediated osteoclast activity
   following spinal cord injury
SO BIOCELL
LA English
DT Article
DE Enolase; RANK; RANKL; Osteoporosis; Neuronal death; Spinal cord injury
ID FACTOR KAPPA B; MARROW CULTURES; OSTEOPOROSIS; ALPHA; BONE;
   PATHOPHYSIOLOGY; ACTIVATION; EXPRESSION; DISEASE; LIGAND
AB Spinal Cord Injury (SCI) is a debilitating condition characterized by damage to the spinal cord, resulting in loss of function, mobility, and sensation. Although increasingly prevalent in the US, no FDA approved therapy exists due to the unfortunate complexity of the condition, and the difficulties of SCI may be furthered by the development of SCI related complications, such as osteoporosis. SCI demonstrates two crucial stages for consideration: the primary stage and the secondary stage. While the primary stage is suggested to be immediate and irreversible, the secondary stage is proposed as a promising window of opportunity for therapeutic intervention. Enolase, a metabolic enzyme upregulated after SCI, performs non glycolytic functions, promoting inflammatory events via extracellular degradative actions and increased production of inflammatory cytokines and chemokines. Neuron specific enolase (NSE) serves as a biomarker of functional damage to neurons following SCI, and the inhibition of NSE has been demonstrated to reduce signs of secondary injury of SCI and to ameliorate dysfunction. This Viewpoint article involves enolase activation in the regulation of RANK RANKL pathway and summarizes succinctly the mechanisms influencing osteoclast mediated resorption of bone in SCI. Our laboratory proposes that inhibition of enolase activation may reduce SCI induced inflammatory response and decrease osteoclast activity, limiting the chances of skeletal tissue loss in SCI.
C1 [Shams, Ramsha; Banik, Naren L.; Haque, Azizul] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
   [Shams, Ramsha; Banik, Naren L.] Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.
   [Banik, Naren L.] Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA.
C3 Medical University of South Carolina; Medical University of South
   Carolina; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Ralph H Johnson VA Medical Center
RP Banik, NL; Haque, A (通讯作者)，Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.; Banik, NL (通讯作者)，Med Univ South Carolina, Dept Neurosurg, Charleston, SC 29425 USA.; Banik, NL (通讯作者)，Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29401 USA.
EM baniknl@musc.edu; haque@musc.edu
FU Veterans Administration [1IOBX001262, 1I01 BX004269]; South Carolina
   State Spinal Cord Injury Research Fund (SCIRF) [2018 I 01]; National
   Institutes of Health [1R21NS118393 01]
FX Funding Statement: This work was supported in part by funding from the
   Veterans Administration (1IOBX001262, 1I01 BX004269) and South Carolina
   State Spinal Cord Injury Research Fund (SCIRF #2018 I 01) . Contents do
   not necessarily represent the policy of the SCIRF and do not imply
   endorsement by the funding agency. This work was also supported in part
   by funding from the National Institutes of Health (1R21NS118393 01) .
CR Alabama UO, 2019, SPIN CORD INJ FACTS
   Alizadeh A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00282
   Anand N, 2005, CEREBROVASC DIS, V20, P213, DOI 10.1159/000087701
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Avilan Luisana, 2011, Enzyme Res, V2011, P932549, DOI 10.4061/2011/932549
   Bae S, 2012, J IMMUNOL, V189, P365, DOI 10.4049/jimmunol.1102073
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bonewald LF, 2008, BONE, V42, P606, DOI 10.1016/j.bone.2007.12.224
   Chen HW, 2020, J CELL MOL MED, V24, P9067, DOI 10.1111/jcmm.15543
   Cox A, 2015, METAB BRAIN DIS, V30, P473, DOI 10.1007/s11011 014 9547 y
   DAY INM, 1993, J MOL EVOL, V36, P599, DOI 10.1007/BF00556365
   Demulder A, 1998, CALCIFIED TISSUE INT, V63, P396, DOI 10.1007/s002239900547
   Francois RJ, 2006, ANN RHEUM DIS, V65, P713, DOI 10.1136/ard.2005.037465
   Guilcher SJT, 2019, J SPINAL CORD MED, V42, pS215, DOI 10.1080/10790268.2019.1637644
   Guillou C, 2016, SCI REP UK, V6, DOI 10.1038/srep23796
   Hachem LD, 2017, J SPINAL CORD MED, V40, P665, DOI 10.1080/10790268.2017.1329076
   Hafner A, 2012, BIOCHEM J, V443, P439, DOI 10.1042/BJ20111351
   Haider IT, 2018, OSTEOPOROSIS INT, V29, P2703, DOI 10.1007/s00198 018 4733 0
   Haque A, 2018, BRAIN SCI, V8, DOI 10.3390/brainsci8020033
   Haque A, 2017, NEUROCHEM RES, V42, P2777, DOI 10.1007/s11064 017 2291 z
   Invernizzi M, 2020, CURR OSTEOPOROS REP, V18, P422, DOI 10.1007/s11914 020 00601 7
   Invernizzi M, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00204
   Jiang SD, 2006, OSTEOPOROSIS INT, V17, P180, DOI 10.1007/s00198 005 2028 8
   Jiang YN, 2014, J TRANSL MED, V12, DOI 10.1186/s12967 014 0334 7
   Keller A, 2007, BBA GEN SUBJECTS, V1770, P919, DOI 10.1016/j.bbagen.2007.01.015
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kovács B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184653
   KURIHARA N, 1990, J IMMUNOL, V144, P4226
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Li M, 2014, NEUROSCI RES, V79, P76, DOI 10.1016/j.neures.2013.12.001
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Liu YH, 2020, J CELL MOL MED, V24, P12308, DOI 10.1111/jcmm.15647
   Lung J, 2010, FEBS J, V277, P4308, DOI 10.1111/j.1742 4658.2010.07819.x
   MARANGOS PJ, 1978, BRAIN RES, V150, P117, DOI 10.1016/0006 8993(78)90657 1
   Orr MB, 2018, NEUROTHERAPEUTICS, V15, P541, DOI 10.1007/s13311 018 0631 6
   Polcyn R, 2020, NEUROCHEM INT, V139, DOI 10.1016/j.neuint.2020.104788
   Polcyn Rachel, 2017, J Clin Cell Immunol, V8, DOI 10.4172/2155 9899.1000536
   Qian Z, 2020, J CELL MOL MED, V24, P10112, DOI 10.1111/jcmm.15622
   Qin WP, 2010, ANN NY ACAD SCI, V1211, P66, DOI 10.1111/j.1749 6632.2010.05806.x
   Samantaray S, 2016, J NEUROCHEM, V137, P604, DOI 10.1111/jnc.13610
   Sedoris KC, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 157
   Shams R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22063057
   SHIMIZU A, 1983, BIOCHIM BIOPHYS ACTA, V748, P278, DOI 10.1016/0167 4838(83)90305 9
   Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756 3282(99)00210 0
   Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhao W, 2018, CALCIFIED TISSUE INT, V103, P443, DOI 10.1007/s00223 018 0439 8
NR 48
TC 1
Z9 2
U1 1
U2 2
PU TECH SCIENCE PRESS
PI HENDERSON
PA 871 CORONADO CENTER DR, SUTE 200, HENDERSON, NV 89052 USA
SN 0327 9545
EI 1667 5746
J9 BIOCELL
JI Biocell
PY 2021
VL 45
IS 6
BP 1453
EP 1457
DI 10.32604/biocell.2021.017659
PG 5
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA UL3BJ
UT WOS:000692530400003
PM 34539043
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Myers, KA
   Rattner, JB
   Shrive, NG
   Hart, DA
AF Myers, Kenneth A.
   Rattner, Jerome B.
   Shrive, Nigel G.
   Hart, David A.
TI Osteoblast like cells and fluid flow: Cytoskeleton dependent shear
   sensitivity
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE osteoblast; mechanotransduction; shear stress; primary cilium; fluid
   flow; actin; microtubule; bone adaptation; cytoskeleton; matrix
   metalloproteinase
ID MESSENGER RNA LEVELS; PRIMARY CILIUM; IN VITRO; BONE; OSTEOCYTES;
   MATRIX; MG 63; MECHANOTRANSDUCTION; COLLAGENASE; EXPRESSION
AB The cytoskeleton is thought to play a central role in cellular mechanotransduction. However, the specific mechanisms operative in bone cells have not yet been clearly elucidated. Isolating the roles of the specific cytoskeletal elements could ultimately aid in development of treatments for conditions related to the mechanoresponsiveness of bone (e.g. osteoporosis, space flight). Using an osteoblast like cell line, the minimum doses of nocodazole (microtubules) and cytochalasin D (actin filaments) that would partially disrupt the cytoskeleton while leaving some elements intact were determined. Cultures were exposed to fluid flow shear, and loaded in the presence or absence of inhibitory drugs at the previously established doses. In untreated cultures, shear stress was associated with significant increases in mRNA levels for collagen I and matrix metalloproteinases I and 3. These increases were maintained in cytochalasin D treated cultures, but were almost completely abrogated by nocodazole treatment. These results suggest that some mechanotransduction pathways related to bone matrix metabolism are primarily dependent on the microtubule network. (C) 2007 Elsevier Inc. All rights reserved.
C1 Univ Calgary, McCaig Inst Bone & Joint Hlth, Calgary, AB T2N 4N1, Canada.
C3 University of Calgary
RP Hart, DA (通讯作者)，Univ Calgary, McCaig Inst Bone & Joint Hlth, Rm 431 Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM hartd@ucalgary.ca
OI Myers, Kenneth/0000 0001 7831 4593
CR BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11
   Bonewald Lynda F, 2006, Bonekey Osteovision, V3, P7
   CAWSTON TE, 1986, PROTEINASE INHIBITOR, P59
   COWIN SC, 1995, J BIOMECH, V28, P1281, DOI 10.1016/0021 9290(95)00058 P
   CUNNINGHAM JL, 2001, BONE MECHANICS HDB
   Di Palma F, 2004, BIOMATERIALS, V25, P2565, DOI 10.1016/j.biomaterials.2003.09.026
   Giambernardi TA, 1998, MATRIX BIOL, V16, P483, DOI 10.1016/S0945 053X(98)90019 1
   Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101
   Ingber DE, 1997, ANNU REV PHYSIOL, V59, P575, DOI 10.1146/annurev.physiol.59.1.575
   Kapur S, 2005, J BIOL CHEM, V280, P20163, DOI 10.1074/jbc.M501460200
   KRANE SM, 1995, CLIN ORTHOP RELAT R, P47
   Majima T, 2000, J ORTHOPAED RES, V18, P524, DOI 10.1002/jor.1100180403
   Malone AMD, 2006, J BONE MINER RES, V21, pS39
   McGarry JG, 2005, BIOCHEM BIOPH RES CO, V330, P341, DOI 10.1016/j.bbrc.2005.02.175
   Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076
   Norvell SM, 2004, J APPL PHYSIOL, V96, P957, DOI 10.1152/japplphysiol.00869.2003
   Parreno J, 2006, MATRIX BIOL, V25, pS15, DOI 10.1016/j.matbio.2006.08.043
   POOLE CA, 1985, CELL MOTIL CYTOSKEL, V5, P175, DOI 10.1002/cm.970050302
   Rubin C., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P264
   SUN YQ, 1995, CALCIFIED TISSUE INT, V57, P456, DOI 10.1007/BF00301950
   Tasevski V, 2005, BIOCHEM CELL BIOL, V83, P96, DOI 10.1139/O04 124
   TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485
   Vasquez RJ, 1997, MOL BIOL CELL, V8, P973, DOI 10.1091/mbc.8.6.973
   Waggett AD, 1998, MATRIX BIOL, V16, P457, DOI 10.1016/S0945 053X(98)90017 8
   Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260
   Whitfield JF, 2003, J CELL BIOCHEM, V89, P233, DOI 10.1002/jcb.10509
NR 26
TC 57
Z9 77
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 14
PY 2007
VL 364
IS 2
BP 214
EP 219
DI 10.1016/j.bbrc.2007.09.109
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 232LL
UT WOS:000251021100004
PM 17942076
DA 2025 08 17
ER

PT J
AU Lee, JK
   Kim, D
   Park, SY
   Baek, SW
   Jung, JW
   Kim, TH
   Han, DK
AF Lee, Jun Kyu
   Kim, Da Seul
   Park, So Yeon
   Baek, Seung Woon
   Jung, Ji Won
   Kim, Tae Hyung
   Han, Dong Keun
TI Nitric Oxide Releasing Bioinspired Scaffold for Exquisite Regeneration
   of Osteoporotic Bone via Regulation of Homeostasis
SO ADVANCED SCIENCE
LA English
DT Article
DE alendronate; bioinspired scaffold; bone homeostasis; bone morphogenetic
   protein 2; bone regeneration; osteoporosis; zinc oxide
ID STRATEGIES; PLGA; BISPHOSPHONATES; THERAPEUTICS; DEGRADATION; PARTICLES;
   TCP
AB Osteoporotic bone regeneration is a challenging process which involves the occurrence of sophisticated interactions. Although various polymeric scaffolds have been proposed for bone repair, research on osteoporotic bone regeneration remains practically limited. In particular, achieving satisfactory bone regeneration when using osteoporotic drugs is challenging including bisphosphonates. Here, a novel nitric oxide releasing bioinspired scaffold with bioactive agents for the exquisite regeneration of osteoporotic bone is proposed. The bone like biomimetic poly(lactic co glycolic acid) scaffold is first prepared in combination with organic/inorganic ECM and magnesium hydroxide as the base implant material. Nanoparticles containing bioactive agents of zinc oxide (ZO), alendronate, and BMP2 are incorporated to the biomimetic scaffold to impart multifunctionality such as anti inflammation, angiogenesis, anti osteoclastogenesis, and bone regeneration. Especially, nitric oxide (NO) generated from ZO stimulates the activity of cGMP and protein kinase G; in addition, ZO downregulates the RANKL/osteoprotegerin ratio by suppressing the Wnt/beta catenin signaling pathway. The new bone is formed much better in the osteoporotic rat model than in the normal model through the regulation of bone homeostasis via the scaffold. These synergistic effects suggest that such a bioinspired scaffold could be a comprehensive way to regenerate exceptionally osteoporotic bones.
C1 [Lee, Jun Kyu; Kim, Da Seul; Park, So Yeon; Baek, Seung Woon; Jung, Ji Won; Han, Dong Keun] CHA Univ, Dept Biomed Sci, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea.
   [Kim, Da Seul; Kim, Tae Hyung] Chung Ang Univ, Sch Integrat Engn, 84 Heukseok Ro, Seoul 06974, South Korea.
   [Park, So Yeon] Korea Univ, Coll Life Sci & Biotechnol, Div Biotechnol, Seoul 02841, South Korea.
   [Baek, Seung Woon] Sungkyunkwan Univ SKKU, Dept Biomed Engn, 2066 Seobu Ro, Suwon 16419, Gyeonggi Do, South Korea.
   [Baek, Seung Woon] Sungkyunkwan Univ SKKU, SKKU Inst Convergence, Dept Intelligent Precis Healthcare Convergence, 2066 Seobu Ro, Suwon 16419, Gyeonggi Do, South Korea.
C3 Pochon Cha University; Chung Ang University; Korea University;
   Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)
RP Han, DK (通讯作者)，CHA Univ, Dept Biomed Sci, 335 Pangyo Ro, Seongnam Si 13488, Gyeonggi Do, South Korea.
EM dkhan@cha.ac.kr
RI ; Jung, JiWon/AAF 6236 2020; Kim, Da Seul/JGD 5215 2023; Baek,
   Seung Woon/IWD 8881 2023
OI Seung Woon, Baek/0000 0002 1816 0649; Kim, Da Seul/0000 0002 6281 0434; 
FU Basic Science Research Program through the National Research Foundation
   of Korea   Ministry of Science and ICT (MSIT) [2020R1A2B5B03002344]; Bio
   & Medical Technology Development Program through the National Research
   Foundation of Korea   Ministry of Science and ICT (MSIT)
   [2018M3A9E2024579]; Korea Medical Device Development Fund   Korea
   government (the Ministry of Science and ICT), Republic of Korea
   [RS 2020 KD000005]; Korea Medical Device Development Fund   Korea
   government (Ministry of Trade, Industry and Energy), Republic of Korea
   [RS 2020 KD000005]; Korea Medical Device Development Fund   Korea
   government (Ministry of Health & Welfare), Republic of Korea
   [RS 2020 KD000005]; Korea Medical Device Development Fund   Korea
   government (Ministry of Food and Drug Safety), Republic of Korea
   [RS 2020 KD000005]
FX J. K.L. and D. S.K. contributed equally to this work. This work was
   supported by Basic Science Research Program (2020R1A2B5B03002344) and
   Bio & Medical Technology Development Program (2018M3A9E2024579) through
   the National Research Foundation of Korea funded by the Ministry of
   Science and ICT (MSIT) and the Korea Medical Device Development Fund
   grant funded by the Korea government (the Ministry of Science and ICT,
   the Ministry of Trade, Industry and Energy, the Ministry of Health &
   Welfare, the Ministry of Food and Drug Safety) (RS 2020 KD000005),
   Republic of Korea.
CR Acevedo C, 2018, NAT BIOMED ENG, V2, P62, DOI 10.1038/s41551 017 0183 9
   Ahn GY, 2021, BIOMATER RES, V25, DOI 10.1186/s40824 021 00231 9
   Batool F, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211041428
   Bedair TM, 2021, BIOMATER SCI UK, V9, P1903, DOI 10.1039/d0bm01934h
   Bedair TM, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420967591
   Bedingfield SK, 2021, NAT BIOMED ENG, V5, P1069, DOI 10.1038/s41551 021 00780 3
   Bernhardt A, 2017, EUR CELLS MATER, V33, P28, DOI 10.22203/eCM.v033a03
   Bootz A, 2004, EUR J PHARM BIOPHARM, V57, P369, DOI 10.1016/S0939 6411(03)00193 0
   Brown GC, 2010, NITRIC OXIDE BIOL CH, V23, P153, DOI 10.1016/j.niox.2010.06.001
   Burdusel AC, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14040770
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Carrillo López N, 2021, CALCIFIED TISSUE INT, V108, P439, DOI 10.1007/s00223 020 00803 2
   Chang C, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001689
   Chang JYH, 2015, AM J PHYSIOL CELL PH, V309, pC205, DOI 10.1152/ajpcell.00347.2014
   Chaudhuri O, 2020, NATURE, V584, P535, DOI 10.1038/s41586 020 2612 2
   Chen BD, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002621
   Damanik FFR, 2020, BIOMATER SCI UK, V8, P174, DOI 10.1039/c9bm00979e
   Dong R, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420926918
   Drake MT, 2010, MOL INTERV, V10, P141, DOI 10.1124/mi.10.3.5
   Eiken P, 2016, OSTEOPOROSIS INT, V27, P1, DOI 10.1007/s00198 015 3334 4
   Ford PC, 2002, CHEM REV, V102, P993, DOI 10.1021/cr0000271
   Go EJ, 2020, BIOMATER SCI UK, V8, P937, DOI 10.1039/c9bm01864f
   Hayashida S, 2017, J BONE MINER RES, V32, P2022, DOI 10.1002/jbmr.3191
   Huang TB, 2019, BIOMATER SCI UK, V7, P1101, DOI 10.1039/c8bm01411f
   Ji Meng Xia, 2015, Chronic Dis Transl Med, V1, P9, DOI 10.1016/j.cdtm.2015.02.006
   Jiang SJ, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10206
   Kawai S, 2019, NAT BIOMED ENG, V3, P558, DOI 10.1038/s41551 019 0410 7
   Kennel KA, 2009, MAYO CLIN PROC, V84, P632, DOI 10.1016/S0025 6196(11)60752 0
   Kim DS, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abj1083
   Kim D, 2021, MATERIALS, V14, DOI 10.3390/ma14154149
   Ko KW, 2021, BIOMATER SCI UK, V9, P892, DOI 10.1039/d0bm01656j
   Kraehling JR, 2017, CIRC RES, V120, P1174, DOI 10.1161/CIRCRESAHA.117.303776
   Kramer I, 2010, MOL CELL BIOL, V30, P3071, DOI 10.1128/MCB.01428 09
   Kumar SS, 2013, INT NANO LETT, V3, DOI 10.1186/2228 5326 3 30
   Lee SK, 2019, MAT SCI ENG C MATER, V94, P65, DOI 10.1016/j.msec.2018.09.011
   Li BH, 1997, J BONE MINER RES, V12, P641, DOI 10.1359/jbmr.1997.12.4.641
   Lih E, 2018, ACS NANO, V12, P6917, DOI 10.1021/acsnano.8b02365
   Lundberg JO, 2015, NAT REV DRUG DISCOV, V14, P623, DOI 10.1038/nrd4623
   Ma SF, 2021, ENG LIFE SCI, V21, P709, DOI 10.1002/elsc.202100040
   Makadia HK, 2011, POLYMERS BASEL, V3, P1377, DOI 10.3390/polym3031377
   Martino MM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11051
   Martins C, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701035
   McCarthy CW, 2016, ACS APPL MATER INTER, V8, P10128, DOI 10.1021/acsami.6b00145
   Napoli C, 2013, J AM COLL CARDIOL, V62, P89, DOI 10.1016/j.jacc.2013.03.070
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Raja IS, 2021, BIOMATER RES, V25, DOI 10.1186/s40824 021 00229 3
   Santo VE, 2013, TISSUE ENG PART B RE, V19, P308, DOI [10.1089/ten.TEB.2012.0138, 10.1089/ten.teb.2012.0138]
   Shin EY, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02479 3
   Thomas DD, 2004, P NATL ACAD SCI USA, V101, P8894, DOI 10.1073/pnas.0400453101
   Thomas DD, 2006, J BIOL CHEM, V281, P25984, DOI 10.1074/jbc.M602242200
   Wang YW, 2012, ADV DRUG DELIVER REV, V64, P1341, DOI 10.1016/j.addr.2011.09.002
   Yang G, 2021, TISSUE ENG REGEN MED, V18, P975, DOI 10.1007/s13770 021 00372 x
   Yang T, 2020, SMALL, V16, DOI 10.1002/smll.201906744
   Yang T, 2018, ADV SCI, V5, DOI 10.1002/advs.201701043
   Yang YF, 2008, POLYM DEGRAD STABIL, V93, P1838, DOI 10.1016/j.polymdegradstab.2008.07.007
   Yin JQ, 2019, NAT BIOMED ENG, V3, P90, DOI 10.1038/s41551 018 0325 8
   Zhang PJ, 2020, ACS APPL MATER INTER, V12, P18319, DOI 10.1021/acsami.0c01792
NR 57
TC 26
Z9 27
U1 13
U2 98
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD FEB
PY 2023
VL 10
IS 6
DI 10.1002/advs.202205336
EA DEC 2022
PG 15
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 9G9KI
UT WOS:000905618400001
PM 36581472
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhao, KX
   Chen, YQ
   Yu, F
   Jian, W
   Zheng, M
   Zeng, H
AF Zhao, Kexin
   Chen, Yingqi
   Yu, Fei
   Jian, Weng
   Zheng, Ming
   Zeng, Hui
TI A biodegradable magnesium alloy sample induced rat osteochondral defect
   repair through Wnt/β catenin signaling pathway
SO ADVANCES IN NANO RESEARCH
LA English
DT Article
DE biodegradable magnesium alloy; western blot semi quantitative analysis;
   Wnt/beta catenin signaling pathway
ID FREE VIBRATION ANALYSIS; ZN ZR ALLOY; FUNCTIONALLY GRADED TIMOSHENKO;
   THERMAL BUCKLING ANALYSIS; IN VITRO DEGRADATION; COUPLE STRESS THEORY;
   NONLINEAR VIBRATION; MECHANICAL PROPERTIES; SHEAR DEFORMATION; NONLOCAL
   ELASTICITY
AB Many studies have shown that Mg Nd Zn Zr (abbreviated as JDBM) alloy has good biocompatibility and biodegradability as well as promotion of cell adhesion, proliferation and differentiation, and Wnt/beta catenin signaling pathway may play a unique role in joint tissue by controlling the function of chondrocytes, osteoblasts and synoviocytes. However, it is not clear whether the JDBM alloy induces osteochondral repair through Wnt/beta catenin signaling pathway. This study aims to verify that JDBM alloy can repair osteochondral defects in rats, which is realized by Wnt/beta catenin signaling pathway. In this study, the osteochondral defect model of the right femoral condyle non weight bearing area in rats was established and randomly divided into three groups: Control group, JDBM alloy implantation group and JDBM alloy implantation combined with signaling pathway inhibitor drug ICRT3 injection. It was found that after JDBM alloy implantation, the bone volume fraction (BVF) became larger, the bone trabeculae were increased, the relative expression of osteogenesis gene Runx2, Bmp2, Opn, Ocn and chondrogenesis gene Collagen II, Aggrecan were increased, and the tissue repair was obvious by HE and Masson staining, which could be inhibited by ICRT3.
C1 [Zhao, Kexin] Peking Univ Shenzhen Hosp, Shenzhen Peking Univ Hong Kong Univ Sci & Technol, Dept Bone & Joint Surg, Shenzhen, Guangdong, Peoples R China.
   [Zhao, Kexin; Chen, Yingqi; Yu, Fei; Jian, Weng; Zeng, Hui] Peking Univ Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen 518036, Peoples R China.
   [Zhao, Kexin; Chen, Yingqi; Yu, Fei; Jian, Weng; Zeng, Hui] Peking Univ Shenzhen Hosp, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen 518036, Peoples R China.
   [Zheng, Ming] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Physiol & Pathophysiol, Beijing 100191, Peoples R China.
   [Zheng, Ming] Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China.
C3 Hong Kong University of Science & Technology; Peking University; Peking
   University; Peking University; Peking University
RP Zeng, H (通讯作者)，Peking Univ Shenzhen Hosp, Dept Bone & Joint Surg, Shenzhen 518036, Peoples R China.; Zeng, H (通讯作者)，Peking Univ Shenzhen Hosp, Natl & Local Joint Engn Res Ctr Orthopaed Biomat, Shenzhen 518036, Peoples R China.
EM zenghui_36@163.com
RI Chen, Yingqi/NOF 6550 2025; Yu, Fei/AAA 4487 2020
OI Yu, Fei/0000 0002 5941 6452
FU National Natural Science Foundation of China [82172432, 82102568,
   82001319]; National & Local Joint Engineering Research Center of
   Orthopaedic Biomaterials [XMHT20190204007]; Shenzhen High level Hospital
   Construction Fund; Shenzhen Key Medical Discipline Construction Fund
   [SZXK023]; Shenzhen "San Ming" Project of Medicine [SZSM201612092];
   Guangdong Basic and Applied Basic Research Foundation [2021A1515012586,
   2019A1515011290]; Bethune Charitable Foundation; CSPC Osteoporosis
   Research Foundation Project [G X 2020 1107 21]; Shenzhen Research and
   Development Projects [JCYJ20210318153832004]; Sustainable development
   project of Science and Technology in Shenzhen [KCXFZ20201221173411031];
   Scientific Research Foundation of PEKING UNIVERSITY SHENZHEN HOSPITAL
   [KYQD2021099]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 82172432, 82102568 and 82001319) , National &
   Local Joint Engineering Research Center of Orthopaedic Biomaterials (No.
   XMHT20190204007) , Shenzhen High level Hospital Construction Fund,
   Shenzhen Key Medical Discipline Construction Fund (No. SZXK023) ,
   Shenzhen "San Ming" Project of Medicine (No. SZSM201612092) , Guangdong
   Basic and Applied Basic Research Foundation (No. 2021A1515012586 and
   2019A1515011290) , Bethune Charitable Foundation and CSPC Osteoporosis
   Research Foundation Project (No. G X 2020 1107 21) , Shenzhen Research
   and Development Projects (No. JCYJ20210318153832004) , Sustainable
   development project of Science and Technology in Shenzhen (No.
   KCXFZ20201221173411031) , and Scientific Research Foundation of PEKING
   UNIVERSITY SHENZHEN HOSPITAL (No. KYQD2021099) .
CR Akbas SD, 2018, ADV NANO RES, V6, P39, DOI 10.12989/anr.2018.6.1.039
   Akbas SD, 2018, ADV NANO RES, V6, P219, DOI 10.12989/anr.2018.6.3.219
   Alipour M, 2020, MECH BASED DES STRUC, V48, P525, DOI 10.1080/15397734.2019.1633343
   Allahkarami F, 2017, STEEL COMPOS STRUCT, V25, P141, DOI 10.12989/scs.2017.25.2.141
   [Anonymous], 2016, LANCET, V388, P2323, DOI 10.1016/S0140 6736(16)32170 5
   Arefi M, 2018, STEEL COMPOS STRUCT, V26, P421, DOI 10.12989/scs.2018.26.4.421
   Aydogdu M, 2018, ADV NANO RES, V6, P257, DOI 10.12989/anr.2018.6.3.257
   Azimi M, 2018, MECH ADV MATER STRUC, V25, P467, DOI 10.1080/15376494.2017.1285455
   Azimi M, 2017, APPL PHYS A MATER, V123, DOI 10.1007/s00339 016 0712 5
   Baumann C., 2019, Joint Preservation of the Knee
   Belluci MM, 2013, J NUTR BIOCHEM, V24, P1488, DOI 10.1016/j.jnutbio.2012.12.008
   Bensaid I, 2018, ADV NANO RES, V6, P279, DOI 10.12989/anr.2018.6.3.279
   Besseghier A, 2015, ADV NANO RES, V3, P29, DOI 10.12989/anr.2015.3.1.029
   Bouadi A, 2018, ADV NANO RES, V6, P147, DOI 10.12989/anr.2018.6.2.147
   Boutaleb S, 2019, ADV NANO RES, V7, P189, DOI 10.12989/anr.2019.7.3.189
   Chen M, 2008, J CELL SCI, V121, P1455, DOI 10.1242/jcs.020362
   Chen SM, 2020, AM J TRANSL RES, V12, P19
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Cheshmeh E, 2022, MECH BASED DES STRUC, V50, P1137, DOI 10.1080/15397734.2020.1744005
   Dai ZC, 2021, ADV NANO RES, V10, P175, DOI 10.12989/anr.2021.10.2.175
   Dai ZC, 2021, COMPOS STRUCT, V263, DOI 10.1016/j.compstruct.2021.113599
   Dou YN, 2014, J BIOMED MATER RES A, V102, P4455, DOI 10.1002/jbm.a.35113
   Ebrahimi F, 2020, ADV NANO RES, V8, P169, DOI 10.12989/anr.2020.8.2.169
   Ebrahimi F, 2021, WAVE RANDOM COMPLEX, V31, P1655, DOI 10.1080/17455030.2019.1694729
   Ebrahimi F, 2017, MECH ADV MATER STRUC, V24, P1257, DOI 10.1080/15376494.2016.1227499
   Ebrahimi F, 2017, MECH ADV MATER STRUC, V24, P761, DOI 10.1080/15376494.2016.1196781
   Ebrahimi F, 2016, SMART STRUCT SYST, V17, P837, DOI 10.12989/sss.2016.17.5.837
   Ehyaei J, 2017, ADV NANO RES, V5, P141, DOI 10.12989/anr.2017.5.2.141
   Fazaeli A., 2016, Metall. Eng., V19, P84, DOI [DOI 10.22076/ME.2017.41458.1064, 10.22076/me.2017.41458.1064]
   Felson DT, 2000, ANN INTERN MED, V133, P635, DOI 10.7326/0003 4819 133 8 200010170 00016
   Gafour Y, 2020, ADV NANO RES, V8, P37, DOI 10.12989/anr.2020.8.1.037
   Ghabussi A, 2021, J VIB CONTROL, V27, P101, DOI 10.1177/1077546320923930
   Ghadiri M, 2016, MECH ADV MATER STRUC, V23, P1414, DOI 10.1080/15376494.2015.1091527
   Ghadiri M., 2017, J SOLID MECH, V9, P319
   Ghadiri M, 2017, STEEL COMPOS STRUCT, V25, P197, DOI 10.12989/scs.2017.25.2.197
   Ghadiri M, 2017, MICROSYST TECHNOL, V23, P4989, DOI 10.1007/s00542 017 3308 x
   Ghadiri M, 2017, MECH ADV MATER STRUC, V24, P636, DOI 10.1080/15376494.2016.1196770
   Ghadiri M, 2016, APPL PHYS A MATER, V122, DOI 10.1007/s00339 016 0364 5
   Ghadiri M, 2016, APPL PHYS A MATER, V122, DOI 10.1007/s00339 016 0196 3
   Ghadiri M, 2017, MICROSYST TECHNOL, V23, P1045, DOI 10.1007/s00542 016 2822 6
   Ghadiri M, 2017, J VIB CONTROL, V23, P3247, DOI 10.1177/1077546315627723
   Ghadiri M, 2016, MICROSYST TECHNOL, V22, P2853, DOI 10.1007/s00542 015 2662 9
   Ghadiri M, 2016, J BRAZ SOC MECH SCI, V38, P335, DOI 10.1007/s40430 015 0472 8
   Ghadiri M, 2016, ACTA ASTRONAUT, V121, P221, DOI 10.1016/j.actaastro.2016.01.003
   Ghazanfari A., 2016, Modares Mech. Eng, V16, P137, DOI 10.12989/sss.2020.26.4.403
   Ghazanfari A, 2020, MECH BASED DES STRUC, V48, P755, DOI 10.1080/15397734.2019.1662310
   Goldring MB, 2010, ANN NY ACAD SCI, V1192, P230, DOI 10.1111/j.1749 6632.2009.05240.x
   Guo JL, 2022, ENG COMPUT GERMANY, V38, P4217, DOI 10.1007/s00366 021 01433 4
   Habibi M, 2018, J MANUF PROCESS, V31, P310, DOI 10.1016/j.jmapro.2017.11.009
   Habibi M., 2018, Modares Mechanical Engineering, V18, P174
   Habibi M, 2018, P I MECH ENG L J MAT, V232, P625, DOI 10.1177/1464420716642258
   Hadji L, 2021, ADV NANO RES, V10, P281, DOI 10.12989/anr.2021.10.3.281
   Hamidi A, 2015, STEEL COMPOS STRUCT, V18, P235, DOI 10.12989/scs.2015.18.1.235
   Hashemi HR, 2021, WAVE RANDOM COMPLEX, V31, P1340, DOI 10.1080/17455030.2019.1662968
   He X, 2021, THIN WALL STRUCT, V166, DOI 10.1016/j.tws.2021.108019
   Hou FX, 2022, ENG COMPUT GERMANY, V38, P3217, DOI 10.1007/s00366 021 01456 x
   Hsu YH, 2012, J CLIN ENDOCR METAB, V97, pE1958, DOI 10.1210/jc.2012 1890
   Hu JW, 2021, ASIAN J CONTROL, V23, P2766, DOI 10.1002/asjc.2415
   Huang XP, 2022, ENG COMPUT GERMANY, V38, P3137, DOI 10.1007/s00366 021 01320 y
   Huang XP, 2022, ENG COMPUT GERMANY, V38, P2481, DOI 10.1007/s00366 021 01395 7
   Huang XP, 2022, ENG COMPUT GERMANY, V38, P4163, DOI 10.1007/s00366 021 01399 3
   HuangHuang K., 2020, J COASTAL RES, V103, DOI [org/10.2112/2112/SI103SI103 151151, DOI 10.2112/2112/SI103SI103 151151]
   Hung CC, 2019, ACTA BIOMATER, V98, P246, DOI 10.1016/j.actbio.2019.06.001
   Huo JF, 2021, COMPOS STRUCT, V276, DOI 10.1016/j.compstruct.2021.114438
   Hussain M, 2020, ADV NANO RES, V8, P215, DOI 10.12989/anr.2020.8.3.215
   Hussain M, 2019, ADV NANO RES, V7, P431, DOI 10.12989/anr.2019.7.6.431
   Jacobs JJ, 2003, CLIN ORTHOP RELAT R, P139, DOI 10.1097/01.blo.0000096810.78689.62
   Jiao J, 2022, ENG COMPUT GERMANY, V38, P2499, DOI 10.1007/s00366 021 01391 x
   Kannan MB, 2008, BIOMATERIALS, V29, P2306, DOI 10.1016/j.biomaterials.2008.02.003
   Kassahun G. B., 2019, Adv. NanoBiomed Res, V2, P1
   Kong XD, 2018, MAT SCI ENG C MATER, V86, P42, DOI 10.1016/j.msec.2017.12.014
   Kosy JD, 2011, ARTHROSCOPY, V27, P695, DOI 10.1016/j.arthro.2010.11.058
   Kreuz PC, 2006, OSTEOARTHR CARTILAGE, V14, P1119, DOI 10.1016/j.joca.2006.05.003
   Kwon H, 2019, NAT REV RHEUMATOL, V15, P550, DOI 10.1038/s41584 019 0255 1
   Li GY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4405
   Li J, 2022, ENG COMPUT GERMANY, V38, P1559, DOI 10.1007/s00366 020 01110 y
   Li M, 2018, ARTIF CELL NANOMED B, V46, pS336, DOI 10.1080/21691401.2017.1423498
   Li TJ, 2016, SCI REP UK, V6, DOI 10.1038/srep19049
   Li XW, 2023, J MAGNES ALLOY, V11, P1213, DOI 10.1016/j.jma.2021.07.018
   Li YS, 2022, ENG COMPUT GERMANY, V38, P703, DOI 10.1007/s00366 020 01166 w
   Liao Y, 2015, INT J MOL MED, V36, P73, DOI 10.3892/ijmm.2015.2211
   Liu HW, 2022, ENG COMPUT GERMANY, V38, P3977, DOI 10.1007/s00366 021 01316 8
   Liu H, 2022, ENG COMPUT GERMANY, V38, P4181, DOI 10.1007/s00366 021 01419 2
   Liu LH, 2021, LIGHT SCI APPL, V10, DOI 10.1038/s41377 021 00618 2
   Liu Y, 2022, ENG COMPUT GERMANY, V38, P3631, DOI 10.1007/s00366 021 01454 z
   Liu ZF, 2022, MECH BASED DES STRUC, V50, P3722, DOI 10.1080/15397734.2020.1815544
   Liu Z, 2022, MECH BASED DES STRUC, V50, P2688, DOI 10.1080/15397734.2020.1784201
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv BJ, 2021, J MAGNES ALLOY, V9, P840, DOI 10.1016/j.jma.2020.06.018
   Ma LH, 2022, ENG COMPUT GERMANY, V38, P2583, DOI 10.1007/s00366 020 01210 9
   Mao L, 2013, MAT SCI ENG C MATER, V33, P242, DOI 10.1016/j.msec.2012.08.036
   Marcacci M, 2013, INJURY, V44, pS11, DOI 10.1016/S0020 1383(13)70004 4
   Lozano RM, 2013, J BIOMED MATER RES A, V101, P2753, DOI 10.1002/jbm.a.34579
   Matouk H, 2020, ADV NANO RES, V8, P293, DOI 10.12989/anr.2020.8.4.293
   Mehar K, 2019, ADV NANO RES, V7, P179, DOI 10.12989/anr.2019.7.3.179
   Mirjavadi SS, 2018, J VIB CONTROL, V24, P4211, DOI 10.1177/1077546317721871
   Mirjavadi SS, 2017, STEEL COMPOS STRUCT, V25, P415, DOI 10.12989/scs.2017.25.4.415
   Mirjavadi SS, 2017, J THERM STRESSES, V40, P1201, DOI 10.1080/01495739.2017.1332962
   Mirjavadi SS, 2017, APPL PHYS A MATER, V123, DOI 10.1007/s00339 017 0918 1
   Moayedi H, 2020, INT J APPL MECH, V12, DOI 10.1142/S1758825120500106
   Moayedi H, 2021, ENG COMPUT GERMANY, V37, P3359, DOI 10.1007/s00366 020 01002 1
   Moayedi H, 2020, THIN WALL STRUCT, V149, DOI 10.1016/j.tws.2020.106669
   Molla M.A.I., 2018, Water Conserv. Manag, V2, P1, DOI [10.26480/wcm.02.2018.01.05, DOI 10.26480/WCM.02.2018.01.05]
   Moradi Z, 2021, WAVE RANDOM COMPLEX, DOI 10.1080/17455030.2021.1926572
   Najaafi N, 2021, J BIOMOL STRUCT DYN, V39, P2543, DOI 10.1080/07391102.2020.1751297
   Navi BR, 2019, STEEL COMPOS STRUCT, V32, P753, DOI 10.12989/scs.2019.32.6.753
   Oyarhossein MA, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 61855 w
   Park KS, 2018, ACTA BIOMATER, V73, P204, DOI 10.1016/j.actbio.2018.04.022
   Pei YX, 2012, DEVELOPMENT, V139, P1724, DOI 10.1242/dev.050104
   Peng DP, 2021, ARCH CIV MECH ENG, V21, DOI 10.1007/s43452 021 00227 1
   PULEO DA, 1995, J APPL BIOMATER, V6, P109, DOI 10.1002/jab.770060205
   Samsa WE, 2016, BONE, V84, P194, DOI 10.1016/j.bone.2016.01.006
   Semmah A, 2019, ADV NANO RES, V7, P89, DOI 10.12989/anr.2019.7.2.089
   Shafiei N., 2020, J. Solid Mech., V12, P16, DOI [10.22034/JSM.2019.563759.12, DOI 10.22034/JSM.2019.563759.1273]
   Shafiei N, 2018, INT J ENG SCI, V133, P84, DOI 10.1016/j.ijengsci.2018.08.004
   Shafiei N, 2019, MECH ADV MATER STRUC, V26, P139, DOI 10.1080/15376494.2017.1365982
   Shafiei N, 2017, COMPOS STRUCT, V178, P483, DOI 10.1016/j.compstruct.2017.07.045
   Shafiei N, 2017, COMPUT METHOD APPL M, V322, P615, DOI 10.1016/j.cma.2017.05.007
   Shafiei N, 2017, AEROSP SCI TECHNOL, V66, P1, DOI 10.1016/j.ast.2017.02.019
   Shafiei N, 2017, COMPOS STRUCT, V168, P428, DOI 10.1016/j.compstruct.2017.02.048
   Shafiei N, 2017, APPL MATH MODEL, V43, P191, DOI 10.1016/j.apm.2016.10.061
   Shafiei N, 2016, INT J ENG SCI, V106, P77, DOI 10.1016/j.ijengsci.2016.05.009
   Shafiei N, 2016, INT J ENG SCI, V106, P42, DOI 10.1016/j.ijengsci.2016.05.007
   Shafiei N, 2016, PHYSICA E, V83, P74, DOI 10.1016/j.physe.2016.04.011
   Shafiei N, 2016, APPL PHYS A MATER, V122, DOI 10.1007/s00339 016 0245 y
   Shafiei N, 2016, COMPOS STRUCT, V149, P157, DOI 10.1016/j.compstruct.2016.04.024
   Shafiei N, 2016, INT J ENG SCI, V102, P12, DOI 10.1016/j.ijengsci.2016.02.007
   Shafiei N, 2017, MECH ADV MATER STRUC, V24, P240, DOI 10.1080/15376494.2015.1128025
   Shafiei N, 2016, INT J ENG SCI, V101, P29, DOI 10.1016/j.ijengsci.2015.12.008
   Shao YH, 2021, ARCH CIV MECH ENG, V21, DOI 10.1007/s43452 021 00279 3
   Shariati A., 2020, ENG COMPUT GERMANY, V37, P3629, DOI [10.1007/s00366 020 01024 9, DOI 10.1007/s00366 020 01024 9]
   Shariati A, 2020, SYMMETRY BASEL, V12, DOI 10.3390/sym12040586
   Shariati A, 2020, MATERIALS, V13, DOI 10.3390/ma13071707
   Shi XF, 2022, MECH BASED DES STRUC, V50, P2147, DOI 10.1080/15397734.2020.1772088
   Shivanian E, 2017, APPL PHYS A MATER, V123, DOI 10.1007/s00339 017 0955 9
   Tounsi A, 2013, ADV NANO RES, V1, P1, DOI 10.12989/anr.2013.1.1.001
   Wang W, 2020, MATER DESIGN, V189, DOI 10.1016/j.matdes.2020.108514
   Wang Y, 2012, INT J IMMUNOPATH PH, V25, P597, DOI 10.1177/039463201202500306
   Wang ZY, 2022, MECH ADV MATER STRUC, V29, P1475, DOI 10.1080/15376494.2020.1824284
   Witte F, 2005, BIOMATERIALS, V26, P3557, DOI 10.1016/j.biomaterials.2004.09.049
   Wu JH, 2022, ENG COMPUT GERMANY, V38, P4127, DOI 10.1007/s00366 021 01396 6
   Xu JK, 2022, BIOACT MATER, V8, P95, DOI 10.1016/j.bioactmat.2021.06.034
   Xu WT, 2021, COMPOS STRUCT, V275, DOI 10.1016/j.compstruct.2021.114395
   Yan YZ, 2020, FOOD CHEM, V306, DOI 10.1016/j.foodchem.2019.125589
   Yang JB, 2020, J COASTAL RES, P896, DOI 10.2112/SI103 186.1
   Yang Y, 2021, SCI TOTAL ENVIRON, V758, DOI 10.1016/j.scitotenv.2020.143631
   Yu XM, 2022, MECH SYST SIGNAL PR, V165, DOI 10.1016/j.ymssp.2021.108373
   Zhang J, 2016, J BIOMED MATER RES A, V104, P2476, DOI 10.1002/jbm.a.35788
   Zhang L, 2021, COMPOS STRUCT, V269, DOI 10.1016/j.compstruct.2021.114000
   Zhang XW, 2021, J BIOMOL STRUCT DYN, V39, P3128, DOI 10.1080/07391102.2020.1760939
   Zhang XB, 2012, J MECH BEHAV BIOMED, V9, P153, DOI 10.1016/j.jmbbm.2012.02.002
   Zhang XB, 2012, J MECH BEHAV BIOMED, V7, P77, DOI 10.1016/j.jmbbm.2011.05.026
   Zhao YN, 2022, ENG COMPUT GERMANY, V38, P939, DOI 10.1007/s00366 020 01242 1
   Zhou CL, 2020, ADV NANO RES, V9, P295, DOI 10.12989/anr.2020.9.4.295
   Zhu M, 2008, ARTHRITIS RHEUM US, V58, P2053, DOI 10.1002/art.23614
   Zilberman M, 2006, ANNU REV BIOMED ENG, V8, P153, DOI 10.1146/annurev.bioeng.8.013106.151418
NR 156
TC 14
Z9 14
U1 3
U2 52
PU TECHNO PRESS
PI DAEJEON
PA PO BOX 33, YUSEONG, DAEJEON 305 600, SOUTH KOREA
SN 2287 237X
EI 2287 2388
J9 ADV NANO RES
JI Adv. Nano Res.
PD MAR
PY 2022
VL 12
IS 3
BP 301
EP 317
DI 10.12989/anr.2022.12.3.301
PG 17
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA 0F4VM
UT WOS:000777359100006
DA 2025 08 17
ER

PT J
AU Fan, LL
   Li, ZQ
   Gao, LL
   Zhang, N
   Chang, WX
AF Fan, Lili
   Li, Zhenqiang
   Gao, Linlin
   Zhang, Nan
   Chang, Wenxiao
TI Isoimperatorin alleviates lipopolysaccharide induced periodontitis by
   downregulating ERK1/2 and NF κB pathways
SO OPEN LIFE SCIENCES
LA English
DT Article
DE chronic periodontitis; isoimperatorin; oxidative stress; inflammatory;
   ERK1; 2 and NF kappa B pathways
ID VITAMIN E; PARAMETERS
AB Chronic periodontitis is an inflammatory disease characterized by inflammation of the soft tissues of the gums. To combat this disease, more effective drugs are still needed to identify and develop. Isoimperatorin is a kind of a natural compound, which has anti inflammatory, analgesic, antitumor, antivirus, and other pharmacological effects. However, its possible effects on the progression of chronic periodontitis are still unclear. In this study, we used human periodontal membrane fibroblasts (hPDLCs), human bone marrow derived macrophages, and found that isoimperatorin reduced hPDLCs viability. In addition, isoimperatorin alleviated the oxidative stress of periodontal membrane cells. Isoimperatorin reduced proinflammatory factor secretion and receptor activator for nuclear factor kappa B ligand induced osteoclast differentiation in periodontal membrane cells. Further, isoimperatorin inhibited the activation of ERK1/2 and nuclear factor kappa B pathways. We, therefore, thought isoimperatorin could serve as a promising drug for the treatment of this disease.
C1 [Fan, Lili; Li, Zhenqiang; Gao, Linlin; Zhang, Nan; Chang, Wenxiao] Shanxi Med Univ, Shanxi Bethune Hosp, Shanxi Acad Med Sci, Dept Stomatol,Hosp 3, 99, Longcheng St, Taiyuan 030032, Shanxi, Peoples R China.
C3 Shanxi Medical University
RP Zhang, N; Chang, WX (通讯作者)，Shanxi Med Univ, Shanxi Bethune Hosp, Shanxi Acad Med Sci, Dept Stomatol,Hosp 3, 99, Longcheng St, Taiyuan 030032, Shanxi, Peoples R China.
EM zhangnan19770718@sina.com; wx_chang0531@163.com
RI Zhang, Nan/KMX 2755 2024; Gao, Lin/JNF 0375 2023
FU Basic Scientific Research Funding of Science and technology Commission
   of Shanxi Province [202103021224359]
FX This work was supported by Basic Scientific Research Funding of Science
   and technology Commission of Shanxi Province (Grant No.
   202103021224359).
CR Abdel latif R, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.850066
   Al Shamsi M, 2006, ANN NY ACAD SCI, V1084, P411, DOI 10.1196/annals.1372.033
   Al Shamsi M, 2006, ANN NY ACAD SCI, V1084, P371, DOI 10.1196/annals.1372.031
   Al Shamsi MS, 2004, MOL CELL BIOCHEM, V261, P35, DOI 10.1023/B:MCBI.0000028735.79172.9b
   Alawaji YN, 2022, SAUDI DENT J, V34, P142, DOI 10.1016/j.sdentj.2021.12.005
   Albuquerque Souza E, 2022, PERIODONTOL 2000, V89, P125, DOI 10.1111/prd.12427
   Amin A, 2021, MOLECULES, V26, DOI 10.3390/molecules26133855
   Camilloni A, 2021, SIGNA VITAE, V17, P54, DOI 10.22514/sv.2020.16.0111
   Cao JJ, 2015, CHEM BIOL INTERACT, V226, P23, DOI 10.1016/j.cbi.2014.12.009
   El Awady AR, 2022, PERIODONTOL 2000, V89, P41, DOI 10.1111/prd.12428
   Hajishengallis G, 2022, PERIODONTOL 2000, V89, P215, DOI 10.1111/prd.12421
   Hamza AA, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9121173
   Jakovljevic A, 2022, J EVID BASED DENT PR, V22, DOI 10.1016/j.jebdp.2021.101667
   Jalilian F, 2022, RES PHARM SCI, V17, P12, DOI 10.4103/1735 5362.329922
   Jiang TT, 2019, EXP THER MED, V18, P2160, DOI 10.3892/etm.2019.7820
   Kiyonga AN, 2021, MOLECULES, V26, DOI 10.3390/molecules26216555
   Lai YN, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.657826
   Li Q, 2022, MEDIAT INFLAMM, V2022, DOI 10.1155/2022/6447056
   Liu J, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/2138186
   Luan Y, 2021, FRONT CARDIOVASC MED, V8, DOI 10.3389/fcvm.2021.770574
   Moon L, 2011, J ETHNOPHARMACOL, V133, P336, DOI 10.1016/j.jep.2010.10.004
   Ouyang JY, 2017, MOL MED REP, V16, P9636, DOI 10.3892/mmr.2017.7777
   Pussinen PJ, 2022, PERIODONTOL 2000, V89, P19, DOI 10.1111/prd.12433
   Starzynska A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052473
   Tanaka A, 2022, IDCASES, V27, DOI 10.1016/j.idcr.2022.e01458
   Wijerathne CUB, 2017, INT IMMUNOPHARMACOL, V49, P67, DOI 10.1016/j.intimp.2017.05.012
   Yang HB, 2018, ONCOL LETT, V15, P7993, DOI 10.3892/ol.2018.8303
   Yang HX, 2020, AUTOPHAGY, V16, P271, DOI 10.1080/15548627.2019.1606647
NR 28
TC 9
Z9 10
U1 7
U2 15
PU DE GRUYTER POLAND SP Z O O
PI WARSAW
PA BOGUMILA ZUGA 32A STR, 01 811 WARSAW, MAZOVIA, POLAND
SN 2391 5412
J9 OPEN LIFE SCI
JI Open Life Sci.
PD JAN 24
PY 2023
VL 18
IS 1
AR 20220541
DI 10.1515/biol 2022 0541
PG 8
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA 8F6JT
UT WOS:000919768100001
PM 36742455
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, CN
   Kok, SH
   Wang, HW
   Chang, JZC
   Lai, EHH
   Shun, CT
   Yang, H
   Chen, MH
   Hong, CY
   Lin, SK
AF Yang, C.  N.
   Kok, S.  H.
   Wang, H.  W.
   Chang, J. Z.  C.
   Lai, E. H.  H.
   Shun, C.  T.
   Yang, H.
   Chen, M.  H.
   Hong, C.  Y.
   Lin, S.  K.
TI Simvastatin alleviates bone resorption in apical periodontitis possibly
   by inhibition of mitophagy related osteoblast apoptosis
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Article
DE apical periodontitis; apoptosis; hypoxia; mitophagy; osteoblasts;
   simvastatin
ID MITOCHONDRIAL DYSFUNCTION; PERIAPICAL LESION; AUTOPHAGY; HYPOXIA;
   MECHANISMS; EXPRESSION; PROGRESSION; STATINS; PARKIN; INFLAMMATION
AB Aim To assess the connection between mitophagy and hypoxia induced apoptosis in osteoblasts and whether simvastatin alleviates bone resorption in apical periodontitis through modulation of mitophagy related apoptosis. Methodology Hypoxia induced generation of reactive oxygen species in mitochondria and changes in mitochondrial membrane potential were evaluated, respectively, by MitoSOX and JC 1 fluorescence dye signalling. Accumulation of mitophagy markers PTEN induced putative kinase 1 (PINK1) and Parkin in mitochondria was examined by Western blotting and immunofluorescence microscopy. Osteoblast apoptosis was assessed by Western analysis of cleaved poly (adenosine diphosphate ribose) polymerase (PARP). In a rat model of induced apical periodontitis, the therapeutic effect of simvastatin and its action on osteoblast mitophagy and apoptosis were examined. anova, Fisher's and Student's t test were used for data analysis. Results Hypoxia induced mitochondrial dysfunction and stimulated mitophagy in osteoblasts. Hypoxia also provoked apoptosis in osteoblasts and inhibition of mitophagy decreased hypoxia augmented apoptotic activity. Simvastatin alleviated hypoxia induced mitochondrial dysfunction, mitophagy and apoptosis. The protective action of simvastatin against apoptosis was related to its antimitophagy activity. Experiments in the rat model of induced apical periodontitis supported the laboratory findings. Simvastatin treatment mitigated periapical bone loss and reduced the activities of apoptosis and mitophagy in regional osteoblasts. Conclusions The results suggest that modulation of osteoblast mitophagy may help diminish bone loss associated with inflammation and has potential as an auxiliary therapy for apical periodontitis.
C1 [Yang, C.  N.; Kok, S.  H.; Chang, J. Z.  C.; Lai, E. H.  H.; Hong, C.  Y.; Lin, S.  K.] Natl Taiwan Univ, Sch Dent, Dept Dent, Taipei, Taiwan.
   [Kok, S.  H.; Wang, H.  W.; Chang, J. Z.  C.; Lai, E. H.  H.; Yang, H.; Chen, M.  H.; Hong, C.  Y.; Lin, S.  K.] Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei 10048, Taiwan.
   [Shun, C.  T.] Natl Taiwan Univ Hosp, Dept Forens Med & Pathol, Taipei, Taiwan.
   [Hong, C.  Y.] China Med Univ, Sch Dent, Dept Prosthodont, Taichung, Taiwan.
   [Hong, C.  Y.] Natl Taiwan Univ, Coll Bioresources & Agr, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University Hospital; National Taiwan University; National Taiwan
   University Hospital; China Medical University Taiwan; National Taiwan
   University
RP Lin, SK (通讯作者)，Natl Taiwan Univ Hosp, Dept Dent, 1 Chang Te St, Taipei 10048, Taiwan.
EM sklin7400@gmail.com
RI ; KOK, SANG HENG/AAJ 5497 2020; Shun, Chia Tung/M 1400 2019
OI SHUN, CHIA TUNG/0000 0002 0468 4468; 
FU Ministry of Science and Technology of Taiwan
   [MOST103 2314 B 002 094 MY2, MOST 105 2314 B 002 076, MOST
   106 2314 B 002 026 MY3, MOST104 2314 B 002 154 MY3]; National Taiwan
   University Hospital [NTUH106 S3489, NTUH 105 S3076, NTUH105 S3016,
   NTUH106 S3422]
FX The project was supported by grants to SHK from Ministry of Science and
   Technology of Taiwan (MOST103 2314 B 002 094 MY2; MOST
   105 2314 B 002 076; MOST 106 2314 B 002 026 MY3) and National Taiwan
   University Hospital (NTUH105 S3016; NTUH106 S3422), SKL from Ministry of
   Science and Technology of Taiwan (MOST104 2314 B 002 154 MY3) and
   National Taiwan University Hospital (NTUH106 S3489; NTUH 105 S3076).
CR Aggarwal S, 2016, AM J PHYSIOL LUNG C, V311, pL433, DOI 10.1152/ajplung.00128.2016
   Ahmed LA, 2016, MOL NEUROBIOL, V53, P3927, DOI 10.1007/s12035 015 9303 2
   Andres AM, 2014, ANTIOXID REDOX SIGN, V21, P1960, DOI 10.1089/ars.2013.5416
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Ayukawa Y, 2009, ORAL SURG ORAL MED O, V107, P336, DOI 10.1016/j.tripleo.2008.07.013
   Bonifacio A, 2016, ARCH TOXICOL, V90, P203, DOI 10.1007/s00204 014 1378 4
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Bravo San Pedro JM, 2017, CIRC RES, V120, P1812, DOI 10.1161/CIRCRESAHA.117.311082
   Bu DX, 2011, CURR OPIN LIPIDOL, V22, P165, DOI 10.1097/MOL.0b013e3283453e41
   Carroll RG, 2014, CELL REP, V9, P1538, DOI 10.1016/j.celrep.2014.10.046
   Chuang SC, 2013, EUR J PHARMACOL, V714, P74, DOI 10.1016/j.ejphar.2013.05.044
   Cotti E, 2014, J ENDODONT, V40, P1902, DOI 10.1016/j.joen.2014.08.013
   Das DN, 2017, FREE RADICAL BIO MED, V112, P452, DOI 10.1016/j.freeradbiomed.2017.08.020
   Deretic V, 2013, NAT REV IMMUNOL, V13, P722, DOI 10.1038/nri3532
   Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283
   Galluzzi L, 2014, NAT CELL BIOL, V16, P728, DOI 10.1038/ncb3005
   GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Hamacher Brady A, 2016, CELL MOL LIFE SCI, V73, P775, DOI 10.1007/s00018 015 2087 8
   Hernandez Mijares A, 2016, ATHEROSCLEROSIS, V247, P40, DOI 10.1016/j.atherosclerosis.2016.01.044
   Huang HY, 2018, INT ENDOD J, V51, pe125, DOI 10.1111/iej.12782
   Imtiyaz HZ, 2010, CURR TOP MICROBIOL, V345, P105, DOI 10.1007/82_2010_74
   Ito Y, 2018, FEBS OPEN BIO, V8, P799, DOI 10.1002/2211 5463.12416
   Jain MK, 2005, NAT REV DRUG DISCOV, V4, P977, DOI 10.1038/nrd1901
   Kaufmann P, 2006, CELL MOL LIFE SCI, V63, P2415, DOI 10.1007/s00018 006 6235 z
   Khalighinejad N, 2016, J ENDODONT, V42, P1427, DOI 10.1016/j.joen.2016.07.007
   Kok SH, 2015, J ENDODONT, V41, P1631, DOI 10.1016/j.joen.2015.05.008
   Lai EHH, 2012, J ENDODONT, V38, P757, DOI 10.1016/j.joen.2012.02.023
   Lee YL, 2018, INT ENDOD J, V51, pe74, DOI 10.1111/iej.12742
   Leermakers PA, 2016, CURR OPIN CLIN NUTR, V19, P427, DOI 10.1097/MCO.0000000000000319
   Lin LD, 2013, J ENDODONT, V39, P619, DOI 10.1016/j.joen.2012.12.014
   Lin SK, 2007, ORAL MICROBIOL IMMUN, V22, P24, DOI 10.1111/j.1399 302X.2007.00316.x
   Lin SK, 2008, ARTHRITIS RHEUM, V58, P3145, DOI 10.1002/art.23937
   Lin SK, 2009, J ENDODONT, V35, P657, DOI 10.1016/j.joen.2009.02.004
   Marriott I, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00101
   Márton IJ, 2014, J ENDODONT, V40, P155, DOI 10.1016/j.joen.2013.10.036
   MATSUMOTO T, 1987, J ENDODONT, V13, P239, DOI 10.1016/S0099 2399(87)80098 5
   Morel J, 2017, CLIN SCI, V131, P747, DOI 10.1042/CS20160802
   Ng YL, 2008, INT ENDOD J, V41, P6, DOI 10.1111/j.1365 2591.2007.01323.x
   Park HS, 2016, DIABETES METAB J, V40, P376, DOI 10.4093/dmj.2016.40.5.376
   Prieto Domínguez N, 2016, J PINEAL RES, V61, P396, DOI 10.1111/jpi.12358
   Redmann M, 2014, INT J BIOCHEM CELL B, V53, P127, DOI 10.1016/j.biocel.2014.05.010
   Ren YH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03319 2
   Segura Egea JJ, 2015, INT ENDOD J, V48, P933, DOI 10.1111/iej.12507
   Shadmehr E, 2013, INT ENDOD J, V46, P1077, DOI 10.1111/iej.12101
   SWARTZ DB, 1983, J ENDODONT, V9, P198, DOI 10.1016/S0099 2399(83)80092 2
   Thomas RE, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004279
   Thylin MR, 2002, J PERIODONTOL, V73, P1141, DOI 10.1902/jop.2002.73.10.1141
   TORABINEJAD M, 1985, J ENDODONT, V11, P479, DOI 10.1016/S0099 2399(85)80221 1
   Vives Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wang HT, 2017, ONCOTARGET, V8, P70406, DOI 10.18632/oncotarget.19710
   Zhang CG, 2014, CURR BIOL, V24, P1854, DOI 10.1016/j.cub.2014.07.014
   Zhu LX, 2013, J ENDODONT, V39, P1379, DOI 10.1016/j.joen.2013.07.013
NR 53
TC 34
Z9 42
U1 4
U2 80
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0143 2885
EI 1365 2591
J9 INT ENDOD J
JI Int. Endod. J.
PD MAY
PY 2019
VL 52
IS 5
BP 676
EP 688
DI 10.1111/iej.13055
PG 13
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA HW0YG
UT WOS:000466408100011
PM 30537112
DA 2025 08 17
ER

PT J
AU Lee, JW
   Hoshino, A
   Inoue, K
   Saitou, T
   Uehara, S
   Kobayashi, Y
   Ueha, S
   Matsushima, K
   Yamaguchi, A
   Imai, Y
   Iimura, T
AF Lee, Ji Won
   Hoshino, Akiyoshi
   Inoue, Kazuki
   Saitou, Takashi
   Uehara, Shunsuke
   Kobayashi, Yasuhiro
   Ueha, Satoshi
   Matsushima, Kouji
   Yamaguchi, Akira
   Imai, Yuuki
   Iimura, Tadahiro
TI The HIV co receptor CCR5 regulates osteoclast function
SO NATURE COMMUNICATIONS
LA English
DT Article
ID BONE MINERAL DENSITY; ORTHODONTIC TOOTH MOVEMENT; T CELL RECOVERY;
   RHEUMATOID ARTHRITIS; CHEMOKINE RECEPTOR; ANTIRETROVIRAL THERAPY; SRC
   KINASE; TYROSINE KINASE 2; MULTIPLE MYELOMA; RANDOMIZED TRIAL
AB C C chemokine receptor 5 (CCR5) is a co receptor of HIV. Epidemiological findings suggest that the functional loss of CCR5 is correlated with a lower incidence of bone destructive diseases as well as of HIV transmission. However, it is not clear whether CCR5 is involved in regulation of the function of bone cells, in addition to that of immune cells. Here we show that blockade of CCR5 using specific antibodies impairs human osteoclast function in vitro. Ccr5 deficient (Ccr5( / )) mice presented with dysfunctional osteoclasts and were resistant to osteoporosis induced by receptor activator of nuclear factor kappa B ligand (RANKL), which triggers osteoporosis independently of inflammatory and immunomodulatory pathways. Furthermore, Ccr5 deficiency impairs the cellular locomotion and bone resorption activity of osteoclasts, which is associated with the disarrangement of podosomes and adhesion complex molecules including Pyk2. Overall, the data provides evidence that CCR5 has an essential role in bone destructive conditions through the functional regulation of osteoclasts.
C1 [Lee, Ji Won; Iimura, Tadahiro] Ehime Univ, Div Bioimaging, Proteosci Ctr PROS, Matsuyama, Ehime 7910295, Japan.
   [Hoshino, Akiyoshi] Tokyo Metropolitan Police Hosp, Tokyo 1648541, Japan.
   [Inoue, Kazuki; Imai, Yuuki; Iimura, Tadahiro] Ehime Univ, Adv Res Support Ctr ADRES, Matsuyama, Ehime 7910295, Japan.
   [Saitou, Takashi] Ehime Univ, Grad Sch Med, Dept Mol Med Pathogenesis, Matsuyama, Ehime 7910295, Japan.
   [Saitou, Takashi] Ehime Univ Hosp, Translat Res Ctr, Matsuyama, Ehime 7910295, Japan.
   [Uehara, Shunsuke] Matsumoto Dent Univ, Dept Biochem, Nagano 3990781, Japan.
   [Kobayashi, Yasuhiro] Matsumoto Dent Univ, Inst Oral Sci, Nagano 3990781, Japan.
   [Ueha, Satoshi; Matsushima, Kouji] Univ Tokyo, Dept Mol Prevent Med, Grad Sch Med, Tokyo 1330033, Japan.
   [Yamaguchi, Akira] Tokyo Dent Coll, Oral Hlth Sci Ctr, Tokyo 1010061, Japan.
   [Imai, Yuuki; Iimura, Tadahiro] Ehime Univ Hosp, Artificial Joint Integrated Ctr, Toon, Ehime 7910295, Japan.
   [Imai, Yuuki] Ehime Univ, Div Integrat Pathophysiol, Proteosci Ctr, Grad Sch Med, Matsuyama, Ehime 7910295, Japan.
C3 Ehime University; Ehime University; Ehime University; Ehime University;
   Matsumoto Dental University; Matsumoto Dental University; University of
   Tokyo; Tokyo Dental College; Ehime University; Ehime University
RP Lee, JW; Iimura, T (通讯作者)，Ehime Univ, Div Bioimaging, Proteosci Ctr PROS, Matsuyama, Ehime 7910295, Japan.; Iimura, T (通讯作者)，Ehime Univ, Adv Res Support Ctr ADRES, Matsuyama, Ehime 7910295, Japan.; Iimura, T (通讯作者)，Ehime Univ Hosp, Artificial Joint Integrated Ctr, Toon, Ehime 7910295, Japan.
EM jwlee@m.ehime u.ac.jp; iimura@m.ehime u.ac.jp
RI Imai, Yuuki/ABC 4687 2020; Yamaguchi, Akira/AAX 9286 2020; Iimura,
   Tadahiro/P 3550 2018; Saitou, Takshi/AAF 2355 2019; KOBAYASHI,
   YASUHIRO/AAU 4931 2021; Lee, Jeeyun/I 7171 2015; Inoue,
   Kazuki/GRY 3245 2022
OI Kobayashi, Yasuhiro/0000 0002 0903 3226; Ueha,
   Satoshi/0000 0002 3871 9921; Saitou, Takashi/0000 0003 0532 8112;
   Iimura, Tadahiro/0000 0002 1431 0689; LEE, JI WON/0000 0003 4578 2168;
   Imai, Yuuki/0000 0002 6119 0034; 
FU Japan Society for the Promotion of Science [JP16K20412, JP26293392];
   IMSUT Joint Research Project; Grants in Aid for Scientific Research
   [16K20412, 16K18578, 16K15791, 26293392, 16H02691, 17K19728] Funding
   Source: KAKEN
FX We express sincere thanks to Kazuaki Tokunaga at Nikon Instech for his
   microscopy expertise, to the members of ADRES in Ehime University for
   their experimental support, to Naohito Tokunaga for his technical
   assistance in performing the RNA sequencing analysis, and to Noriko
   Tokai and Miwako Iwai at The Institute of Medical Science, The
   University of Tokyo (IMSUT) for their expertise on microscopy. This work
   was supported by Grant in Aids for Scientific Research from the Japan
   Society for the Promotion of Science (JP16K20412 and JP26293392), which
   were awarded to J.W.L and T.I., respectively. This work was also partly
   supported by IMSUT Joint Research Project (2016 2019).
CR Amoui M, 2004, AM J PHYSIOL CELL PH, V287, pC874, DOI 10.1152/ajpcell.00294.2003
   Amsellem V, 2014, CIRCULATION, V130, P880, DOI 10.1161/CIRCULATIONAHA.114.010757
   Andrade I, 2009, J DENT RES, V88, P1037, DOI 10.1177/0022034509346230
   Arberas H, 2013, J ANTIMICROB CHEMOTH, V68, P577, DOI 10.1093/jac/dks432
   Ban Y, 2017, CANCER RES, V77, P2857, DOI 10.1158/0008 5472.CAN 16 2913
   Binder NB, 2009, NAT MED, V15, P417, DOI 10.1038/nm.1945
   Bonjoch A, 2010, AIDS, V24, P2827, DOI 10.1097/QAD.0b013e328340a28d
   Brown TT, 2006, AIDS, V20, P2165, DOI 10.1097/QAD.0b013e32801022eb
   Bruzzaniti A, 2005, MOL BIOL CELL, V16, P3301, DOI 10.1091/mbc.E04 12 1117
   Bruzzaniti A, 2009, MOL CELL BIOL, V29, P3644, DOI 10.1128/MCB.00851 08
   Chellaiah MA, 2006, EUR J CELL BIOL, V85, P311, DOI 10.1016/j.ejcb.2006.01.008
   Chellaiah MA, 2005, J BIOL CHEM, V280, P32930, DOI 10.1074/jbc.M500154200
   Choi SJ, 2000, BLOOD, V96, P671
   Clay PG, 2008, ANN PHARMACOTHER, V42, P670, DOI 10.1345/aph.1K465
   Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Di Marzio P, 2005, BIOCHEM BIOPH RES CO, V331, P909, DOI 10.1016/j.bbrc.2005.04.015
   Duong LT, 2001, J BIOL CHEM, V276, P7484, DOI 10.1074/jbc.M008368200
   Funderburg N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013188
   Garred P, 1998, J RHEUMATOL, V25, P1462
   Gil Henn H, 2007, J CELL BIOL, V178, P1053, DOI 10.1083/jcb.200701148
   Gómez Reino JJ, 1999, ARTHRITIS RHEUM US, V42, P989, DOI 10.1002/1529 0131(199905)42:5<989::AID ANR18>3.0.CO;2 U
   Grant PM, 2013, CLIN INFECT DIS, V57, P1483, DOI 10.1093/cid/cit538
   Grant PM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011416
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hansen AB, 2011, HIV MED, V12, P157, DOI 10.1111/j.1468 1293.2010.00864.x
   Haringman JJ, 2006, ANN RHEUM DIS, V65, P294, DOI 10.1136/ard.2005.037176
   Horne WC, 2005, IMMUNOL REV, V208, P106, DOI 10.1111/j.0105 2896.2005.00335.x
   Hoshino A, 2013, J CELL SCI, V126, P1032, DOI 10.1242/jcs.113910
   Hoshino A, 2010, J BIOL CHEM, V285, P28826, DOI 10.1074/jbc.M109.099424
   Howe EA, 2011, BIOINFORMATICS, V27, P3209, DOI 10.1093/bioinformatics/btr490
   Huang CY, 2009, BIOCHEM PHARMACOL, V77, P794, DOI 10.1016/j.bcp.2008.11.014
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hunt PW, 2013, BLOOD, V121, P4635, DOI 10.1182/blood 2012 06 436345
   Irannejad R, 2014, CURR OPIN CELL BIOL, V27, P109, DOI 10.1016/j.ceb.2013.10.003
   Ito M, 2005, J BONE MINER RES, V20, P1828, DOI 10.1359/JBMR.050610
   Kohem C, 2007, SCAND J RHEUMATOL, V36, P359, DOI 10.1080/03009740701393999
   Lakkakorpi PT, 2003, J BIOL CHEM, V278, P11502, DOI 10.1074/jbc.M206579200
   Lindner E, 2007, BMC MED GENET, V8, DOI 10.1186/1471 2350 8 33
   Pozo Balado MM, 2014, J INFECT DIS, V210, P890, DOI 10.1093/infdis/jiu180
   Matsumoto T, 2013, J DENT RES, V92, P340, DOI 10.1177/0022034513476037
   Menu E, 2006, CLIN EXP METASTAS, V23, P291, DOI 10.1007/s10585 006 9038 6
   Miyazaki T, 2004, J BIOL CHEM, V279, P17660, DOI 10.1074/jbc.M311032200
   Murai M, 2003, NAT IMMUNOL, V4, P154, DOI 10.1038/ni879
   Murphy PM, 2000, PHARMACOL REV, V52, P145
   Nishiyama Y, 2015, ARCH ORAL BIOL, V60, P45, DOI 10.1016/j.archoralbio.2014.08.013
   Oba Y, 2005, EXP HEMATOL, V33, P272, DOI 10.1016/j.exphem.2004.11.015
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Ofotokun I, 2010, CURR OPIN ENDOCRINOL, V17, P523, DOI 10.1097/MED.0b013e32833f48d6
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pokorny V, 2005, ANN RHEUM DIS, V64, P487, DOI 10.1136/ard.2004.023333
   Prahalad S, 2006, GENES IMMUN, V7, P468, DOI 10.1038/sj.gene.6364317
   Repik A, 2007, CURR OPIN INVEST DR, V8, P130
   Sharma A, 2010, AIDS, V24, P2337, DOI 10.1097/QAD.0b013e32833d7da7
   Taiwo BO, 2015, CLIN INFECT DIS, V61, P1179, DOI 10.1093/cid/civ455
   Takeuchi T, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3775
   Teitelbaum SL, 2011, ANN NY ACAD SCI, V1240, P14, DOI 10.1111/j.1749 6632.2011.06283.x
   Thomas J, 2003, JAIDS J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334 200307010 00001
   Thudium CS, 2014, CALCIFIED TISSUE INT, V95, P83, DOI 10.1007/s00223 014 9865 4
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Wang Q, 2003, J CELL BIOL, V160, P565, DOI 10.1083/jcb.200207036
   Wang SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035101
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Wilkin TJ, 2012, J INFECT DIS, V206, P534, DOI 10.1093/infdis/jis376
   Wintges K, 2013, J BONE MINER RES, V28, P2070, DOI 10.1002/jbmr.1937
   Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200
   Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044 5323(02)00123 9
   Yano S, 2005, ENDOCRINOLOGY, V146, P2324, DOI 10.1210/en.2005 0065
   Zapico I, 2000, GENES IMMUN, V1, P288, DOI 10.1038/sj.gene.6363673
   Zhang Z, 2002, BONE, V31, P359, DOI 10.1016/S8756 3282(02)00834 7
NR 70
TC 40
Z9 43
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD DEC 20
PY 2017
VL 8
AR 2226
DI 10.1038/s41467 017 02368 5
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FQ7TY
UT WOS:000418566800022
PM 29263385
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Nagai, T
   Sakamoto, K
   Ishikawa, K
   Saito, E
   Inagaki, K
AF Nagai, Takashi
   Sakamoto, Keizo
   Ishikawa, Koji
   Saito, Emi
   Inagaki, Katsunori
TI Case of femoral diaphyseal stress fracture after long term risedronate
   administration diagnosed by iliac bone biopsy
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Article
DE bisphosphonate; severely suppressed bone turnover; risedronate
ID ALENDRONATE THERAPY; COMPLICATION
AB Bisphosphonate excessively inhibits bone resorption and results in pathological fracture of the femur or ilium. The subject of this study was administered risedronate for 7 years; we suspected an easy fracture of the femoral diaphysis. In this study, we report the results of this patient's bone biopsy and bone morphometric analysis. A 76 year old female patient presented with right femoral pain. Bone mineral density of the anteroposterior surface of the 2nd to 4th lumbar vertebrae (L2 L4) was decreased and levels of bone turnover markers were high. Therefore, we initiated treatment with risedronate. As she continued the medication, urinary levels of cross linked N terminal telopeptides of type I collagen and alkaline phosphatase (bone type isozyme) were found to be within the normal ranges. After 7 years of administration, the patient experienced pain when she put weight on the right femur and right femoral pain while walking. Plain radiographic examination revealed polypoid stress fracture like lesions on the right femoral diaphysis and on the slightly distal lateral cortical bone. Similar lesions were observed on magnetic resonance imaging and bone scintigraphy. We suspected severely suppressed bone turnover. Bone biopsy was obtained after labeling with tetracycline, and bone morphometric analysis was performed. On microscopic examination, slight double tetracycline labeling was observed. The trabeculae were narrow, and the numbers of osteoblasts and osteoclasts were decreased. Further, rates of bone calcification and bone formation were slow. Hence, we diagnosed fracture as a result of low turnover osteopathy. Risedronate was withdrawn, and Vitamin D 3 was administered to improve the bone turnover. At 6 months, abnormal signals on magnetic resonance imaging had decreased and her pain while walking or undergoing the stress test disappeared as well. Thus, long term administration of bisphosphonates may lead to easy fracture, although bone turnover markers were observed to be within the normal range. During bisphosphonate administration, physicians need to monitor closely and treat their patients for any pain experienced in the femoral region while walking or undergoing a stress test.
C1 [Nagai, Takashi; Sakamoto, Keizo; Ishikawa, Koji; Saito, Emi; Inagaki, Katsunori] Showa Univ, Sch Med, Dept Orthopaed Surg, Shinagawa Ku, Tokyo 1428666, Japan.
C3 Showa University
RP Nagai, T (通讯作者)，Showa Univ, Sch Med, Dept Orthopaed Surg, Shinagawa Ku, 1 5 8 Hatanodai, Tokyo 1428666, Japan.
EM nagai.babby@gmail.com
RI ; Ishikawa, Koji/ABC 4850 2020
OI Ishikawa, Koji/0000 0003 3689 5662; Nagai, Takashi/0000 0002 8815 1182
CR Giusti A, 2010, BONE, V47, P169, DOI 10.1016/j.bone.2010.05.019
   Kwek EBK, 2008, INJURY, V39, P224, DOI 10.1016/j.injury.2007.08.036
   Nieves Jeri W, 2010, Curr Osteoporos Rep, V8, P34, DOI 10.1007/s11914 010 0007 2
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Watts NB, 2010, J CLIN ENDOCR METAB, V95, P1555, DOI 10.1210/jc.2009 1947
NR 7
TC 3
Z9 3
U1 3
U2 9
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1176 6336
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2013
VL 9
BP 191
EP 195
DI 10.2147/TCRM.S40734
PG 5
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 134QU
UT WOS:000318230100001
PM 23662061
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Schett, G
   Stolina, M
   Bolon, B
   Middleton, S
   Adlam, M
   Brown, H
   Zhu, L
   Feige, U
   Zack, DJ
AF Schett, G
   Stolina, M
   Bolon, B
   Middleton, S
   Adlam, M
   Brown, H
   Zhu, L
   Feige, U
   Zack, DJ
TI Analysis of the kinetics of osteoclastogenesis in arthritic rats
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID TUMOR NECROSIS FACTOR; SYSTEMIC BONE LOSS; RHEUMATOID ARTHRITIS;
   TARGETING OSTEOCLASTS; ADJUVANT ARTHRITIS; JOINT DESTRUCTION; LEWIS
   RATS; OSTEOPROTEGERIN; EROSION; INFLAMMATION
AB Objective. To analyze the kinetics of osteoclastogenesis in 2 models of chronic immune mediated arthritis and I model of acute arthritis.
   Methods. Adjuvant induced arthritis (AIA) and collagen induced arthritis (CIA) in Lewis rats were used as models of chronic arthritis. Acute arthritis was induced in Lewis rats by injecting carrageenan into the hind paw. Osteoclasts were identified by cathepsin K immunohistochemistry at various time points after the onset of arthritis. The location, size, and nucleation of osteoclasts were also analyzed.
   Results. In both AIA and CIA, multinucleated and cathepsin K positive osteoclasts first were observed on the day of disease onset. Initially, osteoclasts were localized at the periosteum next to the synovial membrane and in subchondral bone channels. The number, size, and nucleation of osteoclasts rapidly increased, leading to severe bone loss within days after disease onset. In addition, numerous mononucleated cathepsin K positive osteoclast precursor cells emerged in the synovial membrane. All osteoclasts (cathepsin K positive, multinucleated, attached to bone) and osteoclast precursors (cathepsin K positive, mononucleated or multinucleated, within synovial tissue) were also positive for a macrophage specific marker. Upon induction of acute arthritis with carrageenan, osteoclasts formed transiently in subchondral bone, but regressed 7 days after disease onset.
   Conclusion. Functional osteoclasts are generated at the earliest stage of arthritis, and new precursors are continuously formed in the synovial membrane to replenish the osteoclast pool. These data indicate that antiresorptive therapies may provide the most effective bone protection, when treatment is started soon after the onset of arthritis.
C1 Amgen Inc, Thousand Oaks, CA 91320 USA.
   Med Univ Vienna, Vienna, Austria.
   GEMpath Inc, Cedar City, UT USA.
C3 Amgen; Medical University of Vienna
RP Zack, DJ (通讯作者)，Amgen Inc, 1 Amgen Ctr Dr,B 38 2 B, Thousand Oaks, CA 91320 USA.
EM dzack@amgen.com
OI Adlam, Matthew/0000 0002 1471 4632
CR Bolon B, 2004, VET PATHOL, V41, P30, DOI 10.1354/vp.41 1 30
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Feige U, 2000, CELL MOL LIFE SCI, V57, P1457, DOI 10.1007/PL00000629
   GOLDRING S, 2003, PRIMER METABOLIC BON, P379
   Goldring SR, 2004, ARTHRITIS RHEUM US, V50, P2044, DOI 10.1002/art.20383
   Goldring SR, 2002, CURR OPIN RHEUMATOL, V14, P406, DOI 10.1097/00002281 200207000 00013
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Herrak P, 2004, ARTHRITIS RHEUM US, V50, P2327, DOI 10.1002/art.20384
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Lubberts E, 2002, ARTHRITIS RHEUM, V46, P3055, DOI 10.1002/art.10607
   Lubberts E, 2000, J CLIN INVEST, V105, P1697, DOI 10.1172/JCI7739
   Marinova Mutafchieva L, 2002, ARTHRITIS RHEUM, V46, P507, DOI 10.1002/art.10126
   McQueen F, 2003, J RHEUMATOL, V30, P1387
   Pap T, 2001, ARTHRITIS RHEUM, V44, P676, DOI 10.1002/1529 0131(200103)44:3<676::AID ANR117>3.3.CO;2 Y
   Peterfy CG, 2003, CURR OPIN RHEUMATOL, V15, P288, DOI 10.1097/00002281 200305000 00017
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895 4356(88)90072 8
   Redlich K, 2004, AM J PATHOL, V164, P543, DOI 10.1016/S0002 9440(10)63144 6
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Redlich K, 2002, ARTHRITIS RHEUM, V46, P785, DOI 10.1002/art.10097
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Schett G, 2003, ARTHRITIS RES THER, V5, P239, DOI 10.1186/ar990
   Scott DL, 2000, RHEUMATOLOGY, V39, P122, DOI 10.1093/rheumatology/39.2.122
   Shigeyama Y, 2000, ARTHRITIS RHEUM, V43, P2523, DOI 10.1002/1529 0131(200011)43:11<2523::AID ANR20>3.0.CO;2 Z
   Sims NA, 2004, ARTHRITIS RHEUM US, V50, P2338, DOI 10.1002/art.20382
   VanderHeijde DMFM, 1995, BRIT J RHEUMATOL, V34, P74
   Willoughby D.A., 2003, METH MOL B, P109
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 30
TC 52
Z9 56
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD OCT
PY 2005
VL 52
IS 10
BP 3192
EP 3201
DI 10.1002/art.21343
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 973UT
UT WOS:000232548800030
PM 16200623
DA 2025 08 17
ER

PT J
AU Fang, HW
   Kao, WY
   Lin, PI
   Chang, GW
   Hung, YJ
   Chen, RM
AF Fang, Hsu Wei
   Kao, Wei Yu
   Lin, Pei I
   Chang, Guang Wei
   Hung, Ya Jung
   Chen, Ruei Ming
TI Effects of Polypropylene Carbonate/Poly(D,L lactic) Acid/Tricalcium
   Phosphate Elastic Composites on Improving Osteoblast Maturation
SO ANNALS OF BIOMEDICAL ENGINEERING
LA English
DT Article
DE PPC/PLA/TCP elastic composites; Bone regeneration; Osteoblasts; Cell
   proliferation and maturation; Osteopontin
ID INDUCED APOPTOTIC INSULTS; BONE; CELLS; DIFFERENTIATION; OSTEOPONTIN;
   ACTIVATION; EXPRESSION; MATRICES; HORMONE; PROTEIN
AB Bone tissue engineering utilizing biomaterials to improve osteoblast growth has provided de novo consideration for therapy of bone diseases. Polypropylene carbonate (PPC) is a polymer with a low glass transition temperature but high elasticity. In this study, we developed a new PPC derived composite by mixing poly lactic acid (PLA) and tricalcium phosphate (TCP), called PPC/PLA/TCP elastic (PPTE) scaffolds. We also evaluated the beneficial effects of PPTE composites on osteoblast growth and maturation and the possible mechanisms. Compared to PPC polymers, PPTE composites had similar pore sizes and porosities but possessed better hydrophilic surface structures. Biological evaluations further revealed that PPTE composites attracted adhesion of mouse osteoblasts, and these bone cells extended along the porous scaffolds to produce accurate fibroblast like morphologies. In parallel, seeding mouse osteoblasts onto PPTE composites time dependently increased cell growth. Sequentially, PPTE composites augmented DNA replication and cell proliferation. Consequently, PPTE composites significantly improved osteoblast mineralization. As to the mechanism, treatment with PPTE composites induced osteopontin (OPN) mRNA and protein expression and alkaline phosphatase activity. Taken together, this study showed that PPTE composites with porous and hydrophilic surfaces can stimulate osteoblast adhesion, proliferation, and maturation through an OPN dependent mechanism. Therefore, the de novo PPTE scaffolds may have biomaterial potential for bone regeneration.
C1 [Fang, Hsu Wei; Chang, Guang Wei; Hung, Ya Jung] Natl Taipei Univ Technol, Dept Chem Engn & Biotechnol, Taipei 106, Taiwan.
   [Fang, Hsu Wei; Chen, Ruei Ming] Taipei Med Univ, Wan Fang Hosp, Cell Physiol & Mol Image Res Ctr, Taipei 110, Taiwan.
   [Kao, Wei Yu; Lin, Pei I; Chen, Ruei Ming] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei 110, Taiwan.
   [Chen, Ruei Ming] Taipei Med Univ Hosp, Anesthet & Toxicol Res Ctr, Taipei, Taiwan.
C3 National Taipei University of Technology; Taipei Municipal WanFang
   Hospital; Taipei Medical University; Taipei Medical University; Taipei
   Medical University Hospital; Taipei Medical University
RP Chen, RM (通讯作者)，Taipei Med Univ, Coll Med, Grad Inst Med Sci, 250 Wu Xing St, Taipei 110, Taiwan.
EM rmchen@tmu.edu.tw
FU Taipei Medical University; National Taipei University of Technology
   [NTUT TMU 100 06, NTUT TMU 101 15]; Wan Fang Hospital [102 wf eva 20];
   National Science Council, Taipei, Taiwan [NSC101 2314 B 038 008 MY3,
   NSC101 2314 B 038 003 MY3]
FX This study was supported by Taipei Medical University and National
   Taipei University of Technology (NTUT TMU 100 06 and NTUT TMU 101 15),
   Wan Fang Hospital (102 wf eva 20), and National Science Council
   (NSC101 2314 B 038 008 MY3; NSC101 2314 B 038 003 MY3), Taipei, Taiwan.
   We wish to confirm that there are no known conflicts of interest
   associated with this publication and there has been no significant
   financial support for this work that could have influenced its outcome.
CR Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097 4644(1998)72:30/31+<73::AID JCB11>3.0.CO;2 L
   AUBIN JE, 1995, BONE, V17, pS77, DOI 10.1016/8756 3282(95)00183 E
   Borden M, 2002, BIOMATERIALS, V23, P551, DOI 10.1016/S0142 9612(01)00137 5
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chen RM, 2013, SURGERY, V154, P58, DOI 10.1016/j.surg.2013.02.003
   Chen RM, 2010, J BONE MINER RES, V25, P2193, DOI 10.1002/jbmr.121
   Cheng YX, 2014, J BIOMED NANOTECHNOL, V10, P287, DOI 10.1166/jbn.2014.1753
   Cho HJ, 2009, CURR ATHEROSCLER REP, V11, P206, DOI 10.1007/s11883 009 0032 8
   COLLINOSDOBY P, 1995, J CELL BIOCHEM, V57, P399, DOI 10.1002/jcb.240570305
   Du LC, 2004, J APPL POLYM SCI, V92, P1840, DOI 10.1002/app.20165
   Feng JQ, 2013, BONE, V54, P213, DOI 10.1016/j.bone.2013.01.046
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gorter EA, 2014, BONE, V64, P288, DOI 10.1016/j.bone.2014.04.026
   Hamlekhan A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096213
   Haylock DN, 2006, BRIT J HAEMATOL, V134, P467, DOI 10.1111/j.1365 2141.2006.06218.x
   Ho WP, 2009, J CELL BIOCHEM, V108, P1084, DOI 10.1002/jcb.22338
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Huang Z, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/5/055005
   KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003 2697(89)90710 0
   Liao MH, 2014, BRIT J NUTR, V111, P55, DOI 10.1017/S0007114513002043
   Lin PL, 2007, MATER LETT, V61, P3009, DOI 10.1016/j.matlet.2006.10.064
   Lu PF, 2008, SCIENCE, V322, P1506, DOI 10.1126/science.1162783
   Mogi M, 2003, J BIOL CHEM, V278, P47477, DOI 10.1074/jbc.M307055200
   Nam D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040044
   Olivier V, 2004, DRUG DISCOV TODAY, V9, P803, DOI 10.1016/S1359 6446(04)03222 2
   Patntirapong S, 2015, J BIOMED MATER RES A, V103, P658, DOI 10.1002/jbm.a.35214
   Rani VVD, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957 4484/20/19/195101
   Raouf A, 2000, ONCOGENE, V19, P6455, DOI 10.1038/sj.onc.1204037
   RUNGBY J, 1993, HISTOCHEM J, V25, P446, DOI 10.1007/BF00157809
   Samavedi S, 2013, ACTA BIOMATER, V9, P8037, DOI 10.1016/j.actbio.2013.06.014
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Sheng Matilda H C, 2014, J Bone Metab, V21, P41, DOI 10.11005/jbm.2014.21.1.41
   Shrivats AR, 2014, DRUG DISCOV TODAY, V19, P781, DOI 10.1016/j.drudis.2014.04.010
   Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593
   VERT M, 1994, BIOMATERIALS, V15, P1209, DOI 10.1016/0142 9612(94)90271 2
   Wei JD, 2012, J ORTHOP RES, V30, P1058, DOI 10.1002/jor.22046
   Wu TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072404
   Yan D, 2013, J BIOMED MATER RES A, V101, P963, DOI 10.1002/jbm.a.34398
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
NR 39
TC 11
Z9 11
U1 0
U2 26
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0090 6964
EI 1573 9686
J9 ANN BIOMED ENG
JI Ann. Biomed. Eng.
PD AUG
PY 2015
VL 43
IS 8
BP 1999
EP 2009
DI 10.1007/s10439 014 1236 9
PG 11
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA CN2KM
UT WOS:000358249800025
PM 25549776
DA 2025 08 17
ER

PT J
AU Cotter, EJ
   Ip, HSM
   Powderly, WG
   Doran, PP
AF Cotter, Eoin J.
   Ip, Herbert Shi Ming
   Powderly, William G.
   Doran, Peter P.
TI Mechanism of HIV protein induced modulation of mesenchymal stem cell
   osteogenic differentiation
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
ID BONE MARROW; OSTEOBLAST DIFFERENTIATION; OSTEOPOROSIS; THERAPY; TISSUE;
   OSTEOCLASTOGENESIS; EXPRESSION; SECRETION; EXPANSION; CATENIN
AB Background: A high incidence of decreased bone mineral density (BMD) has been associated with HIV infection. Normal skeletal homeostasis is controlled, at least in part, by the maturation and activity of mature osteoblasts. Previous studies by our group have demonstrated the ability of HIV proteins to perturb osteoblast function, and the degree of osteogenesis in differentiating mesenchymal stem cells (MSCs). This study attempts to further dissect the dynamics of this effect.
   Methods: MSCs were cultured under both osteogenic (cultured in commercially available differentiation media) and quiescent (cultured in basal medium) conditions. Both cell populations were exposed to HIV p55 gag and HIV rev (100 ng/ml). Time points were taken at 3, 6, 9, and 15 days for osteogenic conditions, while quiescent cells were treated for 1 week. Cell function (alkaline phosphatase [ALP] activity, calcium deposition, and lipid levels) and the activity of the key MSC transcription factors, RUNX 2 and PPARgamma were determined post exposure. Also, in cells cultured in differentiating conditions, cellular levels of connective tissue growth factor (CTGF) were analysed using whole cell ELISA, while BMP 2 secretion was also examined. Results: In differentiating MSCs, exposure to HIV proteins caused significant changes in both the timing and magnitude of key osteogenic events and signals. Treatment with REV increased the overall rate of mineralization, and induced earlier increases in CTGF levels, RUNX 2 activity and BMP 2 secretion, than those observed in the normal course of differntiation. In contrast, p55 gag reduced the overall level of osteogenesis, and reduced BMP 2 secretion, RUNX 2 activity, CTGF levels and ALP activity at many of the timepoints examined. Finally, in cells cultured in basal conditions, treatment with HIV proteins did not in and of itself induce a significant degree of differentiation over the time period examined.
   Conclusion: These data demonstrate that the effect of HIV proteins on bone is dependent on the differentiation status of the cells that they are in contact with. The effect on bone cell signalling provides insights into the mechanism of HIV induced decreases in bone mineral density.
C1 [Cotter, Eoin J.; Powderly, William G.; Doran, Peter P.] Univ Coll Dublin, Catherine Mcauley Ctr, Sch Med & Med Sci, Clin Res Ctr, Dublin 7, Ireland.
   [Ip, Herbert Shi Ming] Univ Coll Dublin, Sch Med & Med Sci, Dublin 4, Ireland.
C3 University College Dublin; University College Dublin
RP Doran, PP (通讯作者)，Univ Coll Dublin, Catherine Mcauley Ctr, Sch Med & Med Sci, Clin Res Ctr, Nelson St, Dublin 7, Ireland.
EM ecotter.genome@mater.ie; herbert.ip@ucdconnect.ie; bill.powderly@ucd.ie;
   peter.doran@ucd.ie
OI cotter, eoin/0000 0001 6506 3254; Powderly, William/0000 0001 7808 3086;
   Doran, Peter/0000 0003 2064 5335
CR Allison GT, 2003, AIDS, V17, P1, DOI 10.1097/00002030 200301030 00003
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Cotter EJ, 2007, AIDS RES HUM RETROV, V23, P1521, DOI 10.1089/aid.2007.0112
   Dammeier J, 1998, J BIOL CHEM, V273, P18185, DOI 10.1074/jbc.273.29.18185
   Fakruddin JM, 2003, J BIOL CHEM, V278, P48251, DOI 10.1074/jbc.M304676200
   Gallant JE, 2004, JAMA J AM MED ASSOC, V292, P191, DOI 10.1001/jama.292.2.191
   Geoffroy V, 2002, MOL CELL BIOL, V22, P6222, DOI 10.1128/MCB.22.17.6222 6233.2002
   Gregory CA, 2005, EXP CELL RES, V306, P330, DOI 10.1016/j.yexcr.2005.03.018
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   Kulterer B, 2007, BMC GENOMICS, V8, DOI 10.1186/1471 2164 8 70
   Li YL, 2007, MED HYPOTHESES, V68, P169, DOI 10.1016/j.mehy.2006.06.006
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Mbalaviele G, 2005, J CELL BIOCHEM, V94, P403, DOI 10.1002/jcb.20253
   McDermott AY, 2001, AM J CLIN NUTR, V74, P679
   MEUNIER P, 1971, CLIN ORTHOP RELAT R, P147, DOI 10.1097/00003086 197110000 00021
   Mondy K, 2003, CLIN INFECT DIS, V36, P482, DOI 10.1086/367569
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Okada Y, 2004, HISTOL HISTOPATHOL, V19, P863, DOI 10.14670/HH 19.863
   OVERTON E, 2007, 14 C RETR OPP INF AB
   Pagani F, 2005, J Endocrinol Invest, V28, P8
   Powderly WG, 2002, J ACQ IMMUN DEF SYND, V29, pS28, DOI 10.1097/00126334 200202011 00005
   Scadden DT, 2003, BLOOD REV, V17, P227, DOI 10.1016/S0268 960X(03)00021 3
   SCHWARTZ GN, 1995, J LEUKOCYTE BIOL, V57, P948, DOI 10.1002/jlb.57.6.948
   SERRANO S, 1995, BONE, V16, P185, DOI 10.1016/8756 3282(94)00028 X
   Singh N, 2008, PHYTOMEDICINE, V15, P284, DOI 10.1016/j.phymed.2007.06.007
   Tebas P, 2000, AIDS, V14, pF63, DOI 10.1097/00002030 200003100 00005
   Thomas J, 2003, JAIDS J ACQ IMM DEF, V33, P281, DOI 10.1097/00126334 200307010 00001
   Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303 7207(03)00151 5
   Wang LX, 2002, AIDS RES HUM RETROV, V18, P917, DOI 10.1089/088922202760265597
   Wang MWH, 2004, J CLIN INVEST, V114, P206, DOI 10.1172/JCI200415797
   Wickert Lucia, 2007, Comp Hepatol, V6, P5
NR 33
TC 38
Z9 43
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAR 13
PY 2008
VL 9
AR 33
DI 10.1186/1471 2474 9 33
PG 12
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 296SJ
UT WOS:000255565800001
PM 18366626
OA Green Accepted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, M
   Wang, WD
   Zhu, Y
   Lu, Y
   Wan, P
   Yang, K
   Zhang, Y
   Mao, CB
AF Li, Mei
   Wang, Weidan
   Zhu, Ye
   Lu, Yao
   Wan, Peng
   Yang, Ke
   Zhang, Yu
   Mao, Chuanbin
TI Molecular and cellular mechanisms for zoledronic acid loaded
   magnesium strontium alloys to inhibit giant cell tumors of bone
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Magnesium strontium alloys; CaP coating; Zoledronic acid; Giant cell
   tumors of bone; Mechanisms
ID NF KAPPA B; IN VIVO; MULTIPLE MYELOMA; CANCER THERAPY; ROS; DEGRADATION;
   ACTIVATION; CARCINOMA; PATHWAY; CEMENT
AB Giant Cell Tumors of Bone (GCTB) are benign but aggressive and metastatic tumors. Surgical removal cannot eradicate GCTB due to the subsequent recurrence and osteolysis. Here we developed Zoledronic acid (ZA) loaded magnesium strontium (Mg Sr) alloys that can inhibit GCTB and studied the molecular and cellular mechanisms of such inhibition. We first formed a calcium phosphate (CaP) coating on the Mg 1.5 wt%Sr implants by coprecipitation and then loaded ZA on the CaP coating. We examined the response of GCTB cells to the ZA loaded alloys. At the cellular level, the alloys not only induced apoptosis and oxidative stress of GCTB cells, and suppressed their resultant pre osteoclast recruitment, but also inhibited their migration. At the molecular level, the alloys could significantly activate the mitochondrial pathway and inhibit the NF KB pathway in the GCTB cells. These collectively enable the ZA loaded alloys to suppress GCTB cell growth and osteolysis, and thus improve our understanding of the materials induced tumor inhibition. Our study shows that ZA loaded alloys could be a potential implant in repairing the bone defects after tumor removal in GCTB therapy.
   Statement of significance
   In clinics, giant cell tumors of bone (GCTB) are removed by surgery. However, the resultant defects in bone still contain aggressive and metastatic GCTB cells that can recruit osteoclasts to damage bone, leading to new GCTB tumor growth and bone damage after tumor surgery. Hence, it is of high demand in developing a material that can not only fill the bone defects as an implant but also inhibit GCTB in the defect area as a therapeutic agent. More importantly, the molecular and cellular mechanism by which such a material inhibits GCTB growth has never been explored. To solve these two problems, we prepared a new biomaterial, the Mg Sr alloys that were first coated with calcium phosphate and then loaded with a tumor inhibiting molecule (Zoledronic acid, ZA). Then, by using a variety of molecular and cellular biological assays, we studied how the ZA loaded alloys induced the death of GCTB cells (derived from patients) and inhibited their growth at the molecular and cellular level. At the cellular level, our results showed that ZA loaded Mg Sr alloys not only induced apoptosis and oxidative stress of GCTB cells, and suppressed their induced pre osteoclast recruitment, but also inhibited their migration. At the molecular level, our data showed that ZA released from the ZA loaded Mg Sr alloys could significantly activate the mitochondrial pathway and inhibit the NF kappa B pathway in the GCTB cells. Both mechanisms collectively induced GCTB cell death and inhibited GCTB cell growth. This work showed how a biomaterial inhibit tumor growth at the molecular and cellular level, increasing our understanding in the fundamental principle of materials induced cancer therapy. This work will be interesting to readers in the fields of metallic materials, inorganic materials, biomaterials and cancer therapy. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Li, Mei; Zhang, Yu] Guangdong Acad Med Sci, Guangdong Gen Hosp, Dept Orthoped, Guangzhou 510080, Guangdong, Peoples R China.
   [Wang, Weidan; Yang, Ke] Chinese Acad Sci, Inst Met Res, Shenyang 110016, Liaoning, Peoples R China.
   [Wang, Weidan] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
   [Zhu, Ye; Mao, Chuanbin] Univ Oklahoma, Inst Biomed Engn Sci & Technol, Stephenson Life Sci Res Ctr, Dept Chem & Biochem, Norman, OK 73019 USA.
   [Lu, Yao] Guangzhou Mil Command, Guangzhou Gen Hosp, Guangdong Key Lab Orthopaed Technol & Implant Mat, Dept Orthoped, Guangzhou 510010, Guangdong, Peoples R China.
   [Wan, Peng] Dongguan Univ Technol, Sch Mech Engn, Dongguan 523808, Peoples R China.
   [Mao, Chuanbin] Zhejiang Univ, Sch Mat Sci & Engn, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Southern Medical University   China; Guangdong Academy of Medical
   Sciences & Guangdong General Hospital; Chinese Academy of Sciences;
   Institute of Metal Research, CAS; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS; University of Oklahoma
   System; University of Oklahoma   Norman; Southern Theater Command
   General Hospital; Dongguan University of Technology; Zhejiang University
RP Wan, P; Zhang, Y; Mao, CB (通讯作者)，Univ Oklahoma, Inst Biomed Engn Sci & Technol, Stephenson Life Sci Res Ctr, Dept Chem & Biochem, Norman, OK 73019 USA.
EM pwan@imr.ac.cn; luck_2001@126.com; cbmao@ou.edu
RI ; Mao, Chuanbin/KIG 2918 2024; Lu, Yao/AAH 1975 2020; Li,
   Mei/KRQ 7982 2024
OI Lu, Yao/0000 0001 7650 4828; Mao, Chuanbin/0000 0002 8142 3659; Wang,
   Weidan/0000 0001 6051 4888; Li, Mei/0000 0002 9265 8541; 
FU National Natural Science Foundation of China [81501859, 31771038,
   81601884, 51673168]; National Key Research and Development Program of
   China [2017YFB0702604, 2016YFB0700800, 2016YFA0100900]; Natural Science
   Foundation of Guangdong Province, China [2015A030313607,
   2015A030312004]; National Institutes of Health [CA195607]
FX We appreciate the financial support from the National Natural Science
   Foundation of China (81501859, 31771038, 81601884, and 51673168), The
   National Key Research and Development Program of China (2017YFB0702604,
   2016YFB0700800, 2016YFA0100900). Natural Science Foundation of Guangdong
   Province, China (2015A030313607 and 2015A030312004). Y. Zhu and C.M.
   would like to thank the financial support from National Institutes of
   Health (CA195607).
CR Annunziata CM, 2010, CANCER AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190
   Bian D, 2017, ACTA BIOMATER, V64, P421, DOI 10.1016/j.actbio.2017.10.004
   Boissier S, 2000, CANCER RES, V60, P2949
   Cao BR, 2014, ADV MATER, V26, P4627, DOI 10.1002/adma.201401550
   Casey JR, 2010, NAT REV MOL CELL BIO, V11, P50, DOI 10.1038/nrm2820
   Chai YC, 2012, ACTA BIOMATER, V8, P3876, DOI 10.1016/j.actbio.2012.07.002
   Chen WQ, 2016, REDOX BIOL, V10, P78, DOI 10.1016/j.redox.2016.09.006
   Cowan RW, 2013, BONE, V52, P238, DOI 10.1016/j.bone.2012.10.002
   Fellenberg J, 2016, CANCER LETT, V371, P134, DOI 10.1016/j.canlet.2015.10.039
   Fu J, 2016, J CLIN INVEST, V126, P1759, DOI 10.1172/JCI80276
   Gaston CL, 2011, J BONE JOINT SURG BR, V93B, P1665, DOI 10.1302/0301 620X.93B12.27663
   Gouin F, 2014, EUR J CANCER, V50, P2425, DOI 10.1016/j.ejca.2014.06.003
   Gurunathan S, 2015, INT J NANOMED, V10, P4203, DOI 10.2147/IJN.S83953
   Hakimi O, 2016, MAT SCI ENG C MATER, V61, P516, DOI 10.1016/j.msec.2015.12.043
   Haus U., 2011, J CLIN ONCOL, V29
   Herr I, 2017, CANCER LETT, V409, P49, DOI 10.1016/j.canlet.2017.08.029
   Ho PWM, 2015, ONCOGENE, V34, P2922, DOI 10.1038/onc.2014.217
   Hu ZL, 2016, BIOMATERIALS, V108, P187, DOI 10.1016/j.biomaterials.2016.08.047
   Im GI, 2004, BIOMATERIALS, V25, P4105, DOI 10.1016/j.biomaterials.2003.11.024
   Josse S, 2004, ADV MATER, V16, P1423, DOI 10.1002/adma.200306340
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Kraut JA, 2015, NEW ENGL J MED, V372, P1078, DOI 10.1056/NEJMc1500327
   Lacey DL, 2012, NAT REV DRUG DISCOV, V11, P401, DOI 10.1038/nrd3705
   Lee JW, 2016, P NATL ACAD SCI USA, V113, P716, DOI 10.1073/pnas.1518238113
   Li B, 2014, ACS APPL MATER INTER, V6, P18258, DOI 10.1021/am505437e
   Li GY, 2018, ACTA BIOMATER, V65, P486, DOI 10.1016/j.actbio.2017.10.033
   Li M, 2017, MAT SCI ENG C MATER, V73, P347, DOI 10.1016/j.msec.2016.12.028
   Li M, 2016, SCI REP UK, V6, DOI 10.1038/srep32323
   Li M, 2016, ADV HEALTHC MATER, V5, P557, DOI 10.1002/adhm.201500712
   Li M, 2014, J MATER SCI TECHNOL, V30, P888, DOI 10.1016/j.jmst.2014.04.010
   Lieben L, 2016, NAT REV RHEUMATOL, V12, P263
   Liu L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.440
   Mroz RM, 2008, EUR RESPIR J, V31, P241, DOI 10.1183/09031936.00006707
   Nayak D, 2016, ACS APPL MATER INTER, V8, P28538, DOI 10.1021/acsami.6b11391
   Niu JL, 2013, MAT SCI ENG C MATER, V33, P4833, DOI 10.1016/j.msec.2013.08.008
   Niu XH, 2012, J BONE JOINT SURG AM, V94A, P461, DOI 10.2106/JBJS.J.01922
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268
   Seo CH, 2013, BIOMATERIALS, V34, P1764, DOI 10.1016/j.biomaterials.2012.11.031
   Seyfert UT, 2002, BIOMOL ENG, V19, P91, DOI 10.1016/S1389 0344(02)00015 1
   Song ZB, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.61
   Tarasenko TN, 2017, CELL METAB, V25, P1254, DOI 10.1016/j.cmet.2017.05.007
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   van der Heijden L, 2014, ONCOLOGIST, V19, P550, DOI 10.1634/theoncologist.2013 0432
   Van der Stok J, 2011, ACTA BIOMATER, V7, P739, DOI 10.1016/j.actbio.2010.07.035
   Wang Y. Z., 2016, ELIFE, V5
   Weinberg SE, 2015, NAT CHEM BIOL, V11, P9, DOI 10.1038/nchembio.1712
   Windhagen H, 2013, BIOMED ENG ONLINE, V12, DOI 10.1186/1475 925X 12 62
   Wu X, 2012, J BONE MINER RES, V27, P1298, DOI 10.1002/jbmr.1576
   Xu LQ, 2016, MOL CANCER THER, V15, P854, DOI 10.1158/1535 7163.MCT 15 0669
   Yang L, 2016, FREE RADICAL BIO MED, V95, P155, DOI 10.1016/j.freeradbiomed.2016.03.007
   Zhang J, 2015, BIOMATERIALS, V53, P251, DOI 10.1016/j.biomaterials.2015.02.097
   Zhang Q, 2015, ACS APPL MATER INTER, V7, P23336, DOI 10.1021/acsami.5b07976
   Zhang W, 2016, J AM CHEM SOC, V138, P5860, DOI 10.1021/jacs.5b12070
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zwolak P, 2010, J BONE JOINT SURG AM, V92A, P162, DOI 10.2106/JBJS.H.01679
NR 57
TC 37
Z9 39
U1 4
U2 128
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD SEP 1
PY 2018
VL 77
BP 365
EP 379
DI 10.1016/j.actbio.2018.07.028
PG 15
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GS5AL
UT WOS:000443668900032
PM 30030174
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Muñoz, AI
   Tello, JI
AF Isabel Munoz, Ana
   Ignacio Tello, J.
TI ON A MATHEMATICAL MODEL OF BONE MARROW METASTATIC NICHE
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article; Proceedings Paper
CT International Conference on Micro and Macro Systems in Life Sciences
CY JUN 08 12, 2015
CL Bedlewo, POLAND
DE Mathematical modeling of cancer; hematopoietic niche; osteoblast;
   CXCL 12; PTHrP; FEM
ID EXPRESSION
AB We propose a mathematical model to describe tumor cells movement towards a metastasis location into the bone marrow considering the influence of chemotaxis inhibition due to the action of a drug. The model considers the evolution of the signaling molecules CXCL 12 secreted by osteoblasts (bone cells responsible of the mineralization of the bone) and PTHrP (secreted by tumor cells) which activates osteoblast growth. The model consists of a coupled system of second order PDEs describing the evolution of CXCL 12 and PTHrP, an ODE of logistic type to model the Osteoblasts density and an extra equation for each cancer cell. We also simulate the system to illustrate the qualitative behavior of the solutions. The numerical method of resolution is also presented in detail.
C1 [Isabel Munoz, Ana] Univ Rey Juan Carlos, Dept Matemat Aplicada Ciencia & Ingn Mat & Tecnol, ESCET, E 28933 Madrid, Spain.
   [Ignacio Tello, J.] Univ Politecn Madrid, Dept Matemat Aplicada TIC ETSI Sistemas Informat, Madrid 28031, Spain.
   [Ignacio Tello, J.] Univ Politecn Madrid, Ctr Simulac Computac, E 28660 Madrid, Spain.
C3 Universidad Rey Juan Carlos; Universidad Politecnica de Madrid;
   Universidad Politecnica de Madrid
RP Tello, JI (通讯作者)，Univ Politecn Madrid, Dept Matemat Aplicada TIC ETSI Sistemas Informat, Madrid 28031, Spain.; Tello, JI (通讯作者)，Univ Politecn Madrid, Ctr Simulac Computac, E 28660 Madrid, Spain.
EM anaisabel.munoz@urjc.es; j.tello@upm.es
RI Tello, J./F 1957 2016; Tello, J. Ignacio/F 1957 2016; Muñoz,
   Ana/JCN 6031 2023
OI Tello, J. Ignacio/0000 0003 2671 7803; Munoz Montalvo, Ana
   Isabel/0000 0001 5741 8289; 
CR Adams R.A., 1975, Sobolev Spaces. Pure and Applied Mathematics
   Bryden AAG, 2002, PROSTATE CANCER P D, V5, P59, DOI 10.1038/sj/pcan/450553
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chang SL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123450
   Coggins NL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098328
   Golan K, 2013, PHARMACEUTICALS, V6, P1145, DOI 10.3390/ph6091145
   Tello JI, 2013, MATH BIOSCI ENG, V10, P263, DOI 10.3934/mbe.2013.10.263
   Innamorati G, 2011, PHARMACEUTICALS, V4, P567, DOI 10.3390/ph4040567
   Komarova SV, 2003, BONE, V33, P206, DOI 10.1016/S8756 3282(03)00157 1
   Lilly AJ, 2011, STEM CELLS INT, V2011, DOI 10.4061/2011/274564
   Muñoz AI, 2016, MATH MED BIOL, V33, P57, DOI 10.1093/imammb/dqv004
   O'Boyle G, 2013, BRIT J CANCER, V108, P1634, DOI 10.1038/bjc.2013.124
   Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002
   Rose AAN, 2010, FUTURE ONCOL, V6, P55, DOI [10.2217/fon.09.138, 10.2217/FON.09.138]
   Ryser MD, 2009, J BONE MINER RES, V24, P860, DOI 10.1359/JBMR.081229
   Sceneay J, 2013, CANCER METAST REV, V32, P449, DOI 10.1007/s10555 013 9420 1
   Sun YX, 2003, J CELL BIOCHEM, V89, P462, DOI 10.1002/jcb.10522
   Taichman RS, 2002, CANCER RES, V62, P1832
NR 18
TC 3
Z9 4
U1 0
U2 12
PU AMER INST MATHEMATICAL SCIENCES AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801 2604 USA
SN 1547 1063
EI 1551 0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PD FEB
PY 2017
VL 14
IS 1
BP 289
EP 304
DI 10.3934/mbe.2017019
PG 16
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Mathematical & Computational Biology
GA EB0AJ
UT WOS:000387005500020
PM 27879134
OA gold
DA 2025 08 17
ER

PT J
AU Li, JJ
   Zeng, ZB
   Zhao, YT
   Jing, D
   Tang, CH
   Ding, Y
   Feng, X
AF Li, Jianjun
   Zeng, Zhaobin
   Zhao, Yantao
   Jing, Da
   Tang, Chuhua
   Ding, Yin
   Feng, Xue
TI Effects of low intensity pulsed electromagnetic fields on bone
   microarchitecture, mechanical strength and bone turnover in type 2
   diabetic db/db mice
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OVARIECTOMY INDUCED OSTEOPOROSIS; AFFECTS OSTEOCLAST FORMATION; HORMONE
   REPLACEMENT THERAPY; KNEE OSTEOARTHRITIS; LEPTIN; TRANSCRIPTION;
   OSTEOGENESIS; STIMULATION; MODEL; GENE
AB Type 2 diabetic patients have impaired bone quality, leading to increased fracture risk. Substantial evidence demonstrates that pulsed electromagnetic fields (PEMF) could resist osteopenia/osteoporosis induced by estrogen deficiency and disuse. However, the effects of PEMF on osteopenia/osteoporosis associated with diabetes, especially for more prevalent type 2 diabetes, remain poorly understood. We herein investigated the skeletal effects and mechanisms of PEMF (15 Hz, 20 Gs) on leptin receptor deficient db/db mice with typical type 2 diabetic symptoms. Our mu CT results showed that 12 week PEMF exposure significantly improved both cancellous and cortical bone microarchitecture in db/db mice. Three point bending and biomechanical indentation testing demonstrated that PEMF improved whole bone structural properties and tissue level material properties in db/db mice. PEMF significantly promoted bone formation in db/db mice evidenced by increased serum osteocalcin and bone mineral apposition rate, whereas PEMF exerted no observable alteration in bone resorption. Real time PCR showed that PEMF upregulated tibial gene expression of osteoblastogenesis related of canonical Wnt/beta catenin signaling but not osteoclastogenesis related RANKL RANK signaling in db/db mice. Our findings demonstrate that PEMF improved bone quantity and quality with obvious anabolic activities in db/db mice, and imply that PEMF might become a clinically applicable treatment modality for improving bone quality in type 2 diabetic patients.
C1 [Li, Jianjun; Ding, Yin; Feng, Xue] Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
   [Li, Jianjun; Tang, Chuhua] 306th Hosp PLA, Dept Stomatol, Beijing 100037, Peoples R China.
   [Zeng, Zhaobin] Gen Hosp Shenyang Mil Area Command, Dept Stomatol, Shenyang 110015, Liaoning, Peoples R China.
   [Zhao, Yantao] Peoples Liberat Army Gen Hosp, Affiliated Hosp 1, Beijing Engn Res Ctr Orthoped Implants, Beijing 100048, Peoples R China.
   [Jing, Da] Fourth Mil Med Univ, Dept Biomed Engn, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Chinese People's Liberation Army General
   Hospital; Air Force Medical University
RP Ding, Y; Feng, X (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Orthodont, State Key Lab Mil Stomatol, Xian 710032, Shaanxi, Peoples R China.
EM dingyin@fmmu.edu.cn; prof.fengxue@outlook.com
RI zhu, xiaoping/A 3979 2013; Jianjun, Li/AAE 5449 2019
FU National Natural Science Foundation of China [31670953, 31500760]
FX The authors acknowledge the support from The National Natural Science
   Foundation of China (No. 31670953 and 31500760).
CR Abdelrahim A, 2011, J ORAL MAXIL SURG, V69, P1708, DOI 10.1016/j.joms.2010.10.013
   Assiotis A, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749 799X 7 24
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   BASSETT CAL, 1982, JAMA J AM MED ASSOC, V247, P623, DOI 10.1001/jama.247.5.623
   Bodamyali T, 1998, BIOCHEM BIOPH RES CO, V250, P458, DOI 10.1006/bbrc.1998.9243
   Botolin S, 2007, ENDOCRINOLOGY, V148, P198, DOI 10.1210/en.2006 1006
   BROWN JP, 1984, LANCET, V1, P1091
   Burguera B, 2001, ENDOCRINOLOGY, V142, P3546, DOI 10.1210/en.142.8.3546
   Chang K, 2005, J ORTHOP RES, V23, P1308, DOI 10.1016/j.orthres.2005.03.012
   Chang K, 2004, BIOELECTROMAGNETICS, V25, P134, DOI 10.1002/bem.10168
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P189, DOI 10.1002/bem.10078
   Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092 8674(00)81294 5
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140 6736(11)60679 X
   Diniz P, 2002, BIOELECTROMAGNETICS, V23, P398, DOI 10.1002/bem.10032
   Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Eyres KS, 1996, BONE, V18, P505, DOI 10.1016/8756 3282(96)00070 1
   Garland D E, 1999, J Spinal Cord Med, V22, P239
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Halleen JM, 2000, J BONE MINER RES, V15, P1337, DOI 10.1359/jbmr.2000.15.7.1337
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   He HB, 2004, ENDOCRINOLOGY, V145, P447, DOI 10.1210/en.2003 1239
   HEATH H, 1980, NEW ENGL J MED, V303, P567, DOI 10.1056/NEJM198009043031008
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Holloway WR, 2002, J BONE MINER RES, V17, P200, DOI 10.1359/jbmr.2002.17.2.200
   Jing D, 2011, OSTEOPOROSIS INT, V22, P1885, DOI 10.1007/s00198 010 1447 3
   Jing D., 2014, J BONE MINER RES
   Jing D, 2016, SCI REP UK, V6, DOI 10.1038/srep32045
   Jing D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079377
   Jing D, 2010, BONE, V46, P487, DOI 10.1016/j.bone.2009.09.021
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Leslie WD, 2012, J BONE MINER RES, V27, P2231, DOI 10.1002/jbmr.1759
   Li KR, 2012, HEART, V98, P920, DOI 10.1136/heartjnl 2011 301345
   Liu HF, 2013, BIOELECTROMAGNETICS, V34, P323, DOI 10.1002/bem.21770
   Lu HF, 2003, ENDOCRINOLOGY, V144, P346, DOI 10.1210/en.2002 220072
   Mahavni V, 2001, CURR OPIN ONCOL, V13, P384, DOI 10.1097/00001622 200109000 00012
   Martin A, 2005, ENDOCRINOLOGY, V146, P3652, DOI 10.1210/en.2004 1509
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   PATERSON CR, 1980, LANCET, V1, P1164
   Raaz U, 2015, CIRC RES, V117, P513, DOI 10.1161/CIRCRESAHA.115.306341
   Räkel A, 2008, DIABETES METAB, V34, P193, DOI 10.1016/j.diabet.2007.10.008
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   RUBIN CT, 1989, J BONE JOINT SURG AM, V71A, P411, DOI 10.2106/00004623 198971030 00016
   Sert C, 2002, J BONE MINER METAB, V20, P345, DOI 10.1007/s007740200050
   Silva MJ, 2009, J BONE MINER RES, V24, P1618, DOI [10.1359/JBMR.090316, 10.1359/jbmr.090316]
   TABRAH F, 1990, J BONE MINER RES, V5, P437, DOI 10.1002/jbmr.5650050504
   Tesch GH, 2011, AM J PHYSIOL RENAL, V300, pF301, DOI 10.1152/ajprenal.00607.2010
   Thamsborg G, 2005, OSTEOARTHR CARTILAGE, V13, P575, DOI 10.1016/j.joca.2005.02.012
   Thrailkill KM, 2005, DIABETES, V54, P2875, DOI 10.2337/diabetes.54.10.2875
   Tomida T, 2003, EMBO J, V22, P3825, DOI 10.1093/emboj/cdg381
   Turner RT, 2013, J BONE MINER RES, V28, P22, DOI 10.1002/jbmr.1734
   Verhaeghe J, 1997, ENDOCRINE, V7, P165, DOI 10.1007/BF02778138
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang BX, 2014, CURR DIABETES REV, V10, P131, DOI 10.2174/1573399810666140508121012
   We SR, 2013, RHEUMATOLOGY, V52, P815, DOI 10.1093/rheumatology/kes063
   Williams GA, 2011, J BONE MINER RES, V26, P1698, DOI 10.1002/jbmr.367
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang XJ, 2007, ELECTROMAGN BIOL MED, V26, P167, DOI 10.1080/15368370701580756
   Zhang X, 2010, BIOCHEM BIOPH RES CO, V396, P662, DOI 10.1016/j.bbrc.2010.04.154
   Zhou J, 2017, BIOELECTROMAGNETICS, V38, P31, DOI 10.1002/bem.22012
NR 63
TC 26
Z9 29
U1 0
U2 31
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 7
PY 2017
VL 7
AR 10834
DI 10.1038/s41598 017 11090 7
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FG1NC
UT WOS:000409561800085
PM 28883516
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nagasaki, A
   Nagasaki, K
   Chu, EY
   Kear, BD
   Tadesse, WD
   Ferebee, SE
   Li, L
   Foster, BL
   Somerman, MJ
AF Nagasaki, A.
   Nagasaki, K.
   Chu, E. Y.
   Kear, B. D.
   Tadesse, W. D.
   Ferebee, S. E.
   Li, L.
   Foster, B. L.
   Somerman, M. J.
TI Ablation of Pyrophosphate Regulators Promotes Periodontal Regeneration
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE biomineralization; cementogenesis; bone regeneration; periodontium;
   extracellular matrix; osteoclast
ID OSTEOCLAST DIFFERENTIATION; OSTEOPONTIN; BONE; MINERALIZATION;
   PHOSPHATE; MODULATION; CEMENTUM; MODEL; GENE; ANK
AB Biomineralization is regulated by inorganic pyrophosphate (PPi), a potent physiological inhibitor of hydroxyapatite crystal growth. Progressive ankylosis protein (ANK) and ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) act to increase local extracellular levels of PPi, inhibiting mineralization. The periodontal complex includes 2 mineralized tissues, cementum and alveolar bone (AB), both essential for tooth attachment. Previous studies demonstrated that loss of function of ANK or ENPP1 (reducing PPi) resulted in increased cementum formation, suggesting PPi metabolism may be a target for periodontal regenerative therapies. To compare the effects of genetic ablation of Ank, Enpp1, and both factors concurrently on cementum and AB regeneration, mandibular fenestration defects were created in Ank knockout (Ank KO), Enpp1 mutant (Enpp1(asj/asj)), and double KO (dKO) mice. Genetic ablation of Ank, Enpp1, or both factors increased cementum regeneration compared to controls at postoperative days (PODs) 15 and 30 (Ank KO: 8 fold, 3 fold; Enpp1(asj/asj): 7 fold, 3 fold; dKO: 11 fold, 4 fold, respectively) associated with increased fluorochrome labeling and expression of mineralized tissue markers, dentin matrix protein 1 (Dmp1/DMP1), osteopontin (Spp1/OPN), and bone sialoprotein (Ibsp/BSP). Furthermore, dKO mice featured increased cementum thickness compared to single KOs at POD15 and Ank KO at POD30. No differences were noted in AB volume between genotypes, but osteoblast/osteocyte markers were increased in all KOs, partially mineralized osteoid volume was increased in dKO versus controls at POD15 (3 fold), and mineral density was decreased in Enpp1(asj/asj) and dKOs at POD30 (6% and 9%, respectively). Increased numbers of osteoclasts were present in regenerated AB of all KOs versus controls. These preclinical studies suggest PPi modulation as a potential and novel approach for cementum regeneration, particularly targeting ENPP1 and/or ANK. Differences in cementum and AB regeneration in response to reduced PPi conditions highlight the need to consider tissue specific responses in strategies targeting regeneration of the entire periodontal complex.
C1 [Nagasaki, A.; Nagasaki, K.; Chu, E. Y.; Kear, B. D.; Tadesse, W. D.; Ferebee, S. E.; Somerman, M. J.] Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, Lab Oral Connect Tissue Biol, NIH, 9000 Rockville Pike,Bldg 50,Room 4120, Bethesda, MD 20892 USA.
   [Li, L.] Natl Inst Dent & Craniofacial Res NIDCR, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
   [Foster, B. L.] Ohio State Univ, Coll Dent, Biosci Div, Columbus, OH 43210 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes
   of Health (NIH)   USA; NIH National Institute of Dental & Craniofacial
   Research (NIDCR); University System of Ohio; Ohio State University
RP Nagasaki, A (通讯作者)，Natl Inst Arthrit & Musculoskeletal & Skin Dis NI, Lab Oral Connect Tissue Biol, NIH, 9000 Rockville Pike,Bldg 50,Room 4120, Bethesda, MD 20892 USA.
EM atsuhiro.nagasaki@nih.gov
RI ; Foster, Brian/H 8375 2015
OI Nagasaki, Karin/0000 0003 0528 4025; Foster, Brian/0000 0003 3444 0576
FU NIAMS Intramural Research Program, Japan Society for the Promotion of
   Science (JSPS); National Institute of Dental and Craniofacial
   Research/NIH [R03DE028411, R01DE027639];  [AR073926]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   funded by NIAMS Intramural Research Program, Japan Society for the
   Promotion of Science (JSPS) to A. Nagasaki (JSPS NIH Research Fellow,
   JSPS Research Fellowship for Japanese Biomedical and Behavioral
   Researchers at NIH), K99/R00 grant AR073926 to E.Y. Chu, and R03DE028411
   and R01DE027639 from National Institute of Dental and Craniofacial
   Research/NIH to B.L. Foster.
CR Addison WN, 2007, J BIOL CHEM, V282, P15872, DOI 10.1074/jbc.M701116200
   Albright RA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10006
   Ao M, 2017, BONE, V105, P134, DOI 10.1016/j.bone.2017.08.027
   Barros NMT, 2013, J BONE MINER RES, V28, P688, DOI 10.1002/jbmr.1766
   Beck GR Jr, 2000, P NATL ACAD SCI USA, V97, P8352, DOI 10.1073/pnas.140021997
   Boskey AL, 2002, CALCIFIED TISSUE INT, V71, P145, DOI 10.1007/s00223 001 1121 z
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   Chande S, 2018, NAT REV ENDOCRINOL, V14, P637, DOI 10.1038/s41574 018 0076 3
   Chavez MB, 2020, J STRUCT BIOL, V212, DOI 10.1016/j.jsb.2020.107597
   Chu EY, 2020, BONE, V136, DOI 10.1016/j.bone.2020.115329
   Cundy T, 2015, J BONE MINER RES, V30, P1726, DOI 10.1002/jbmr.2495
   Eke PI, 2016, J DENT RES, V95, P515, DOI 10.1177/0022034516629112
   Foster BL, 2011, CELLS TISSUES ORGANS, V194, P382, DOI 10.1159/000323457
   Foster BL, 2007, CURR TOP DEV BIOL, V78, P47, DOI 10.1016/S0070 2153(06)78003 6
   Foster BL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038393
   Harmey D, 2004, AM J PATHOL, V164, P1199, DOI 10.1016/S0002 9440(10)63208 7
   Harmey D, 2006, J BONE MINER RES, V21, P1377, DOI 10.1359/JBMR.060619
   Hayashibara T, 2007, J BONE MINER RES, V22, P1743, DOI 10.1359/JBMR.070709
   Ho AM, 2000, SCIENCE, V289, P265, DOI 10.1126/science.289.5477.265
   HUNTER GK, 1994, BIOCHEM J, V300, P723, DOI 10.1042/bj3000723
   Kamiya N, 2017, J BONE MINER RES, V32, P1716, DOI 10.1002/jbmr.3155
   Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491
   Kenkre JS, 2018, ANN CLIN BIOCHEM, V55, P308, DOI 10.1177/0004563218759371
   Kim HJ, 2010, J BONE MINER RES, V25, P1771, DOI 10.1002/jbmr.60
   King GN, 1997, J DENT RES, V76, P1460, DOI 10.1177/00220345970760080801
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Mackenzie NCW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032177
   Millan Jose Luis, 2006, Purinergic Signal, V2, P335, DOI 10.1007/s11302 005 5435 6
   Narisawa S, 2013, J BONE MINER RES, V28, P1587, DOI 10.1002/jbmr.1901
   Nishino J, 2017, J CELL BIOCHEM, V118, P1151, DOI 10.1002/jcb.25742
   Nociti FH, 2002, J DENT RES, V81, P817, DOI 10.1177/154405910208101204
   Orriss IR, 2016, CURR OPIN PHARMACOL, V28, P57, DOI 10.1016/j.coph.2016.03.003
   Rodrigues TL, 2011, J PERIODONTOL, V82, P1757, DOI 10.1902/jop.2011.110103
   Rutsch F, 2003, NAT GENET, V34, P379, DOI 10.1038/ng1221
   Szeri F, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008884
   Thumbigere Math V, 2018, J DENT RES, V97, P432, DOI 10.1177/0022034517744773
   Wolf M, 2018, J DENT RES, V97, P937, DOI 10.1177/0022034518759295
   Yamamoto T, 2010, ODONTOLOGY, V98, P102, DOI 10.1007/s10266 010 0134 3
   Zhao QX, 2007, FRONT BIOSCI LANDMRK, V12, P2519, DOI 10.2741/2252
   Zweifler LE, 2015, INT J ORAL SCI, V7, P27, DOI 10.1038/ijos.2014.62
NR 40
TC 12
Z9 13
U1 1
U2 12
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD JUN
PY 2021
VL 100
IS 6
BP 639
EP 647
DI 10.1177/0022034520981854
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SF2WJ
UT WOS:000652621200011
PM 33356859
OA Green Published
DA 2025 08 17
ER

PT J
AU Ceccarelli, S
   Gerini, G
   Megiorni, F
   Pontecorvi, P
   Messina, E
   Camero, S
   Anastasiadou, E
   Romano, E
   Onesti, MG
   Napoli, C
   Marchese, C
AF Ceccarelli, S.
   Gerini, G.
   Megiorni, F.
   Pontecorvi, P.
   Messina, E.
   Camero, S.
   Anastasiadou, E.
   Romano, E.
   Onesti, M. G.
   Napoli, C.
   Marchese, C.
TI Inhibiting DNA methylation as a strategy to enhance adipose derived stem
   cells differentiation: Focus on the role of Akt/mTOR and Wnt/β catenin
   pathways on adipogenesis
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE adipose derived adult stem cells (ASCs); epigenetic regulation;
   5 azacytidine; adipogenesis; AKT/mTOR; Wnt/beta catenin pathway
ID ACTIN STRESS FIBERS; HUMAN BONE MARROW; STROMAL CELLS; ADIPOCYTE
   DIFFERENTIATION; CANCER CELLS; TISSUE; SENESCENCE; MIGRATION;
   EXPRESSION; 5 AZA 2' DEOXYCYTIDINE
AB Adipose derived mesenchymal stem cells (ASCs) represent a valid therapeutic option for clinical application in several diseases, due to their ability to repair damaged tissues and to mitigate the inflammatory/immune response. A better understanding of the underlying mechanisms regulating ASC biology might represent the chance to modulate their in vitro characteristics and differentiation potential for regenerative medicine purposes. Herein, we investigated the effects of the demethylating agent 5 azacytidine (5 aza) on proliferation, clonogenicity, migration, adipogenic differentiation and senescence of ASCs, to identify the molecular pathways involved. Through functional assays, we observed a detrimental effect of 5 aza on ASC self renewal capacity and migration, accompanied by actin cytoskeleton reorganization, with decreased stress fibers. Conversely, 5 aza treatment enhanced ASC adipogenic differentiation, as assessed by lipid accumulation and expression of lineage specific markers. We analyzed the involvement of the Akt/mTOR, MAPK and Wnt/beta catenin pathways in these processes. Our results indicated impairment of Akt and ERK phosphorylation, potentially explaining the reduced cell proliferation and migration. We observed a 5 aza mediated inhibition of the Wnt signaling pathway, this potentially explaining the pro adipogenic effect of the drug. Finally, 5 aza treatment significantly induced ASC senescence, through upregulation of the p53/p21 axis. Our data may have important translational implications, by helping in clarifying the potential risks and advantages of using epigenetic treatment to improve ASC characteristics for cell based clinical approaches.
C1 [Ceccarelli, S.; Gerini, G.; Megiorni, F.; Pontecorvi, P.; Messina, E.; Anastasiadou, E.; Marchese, C.] Sapienza Univ Rome, Dept Expt Med, Rome, Italy.
   [Camero, S.] Sapienza Univ Rome, Dept Maternal Infantile & Urol Sci, Rome, Italy.
   [Romano, E.] Sapienza Univ Rome, Dept Sense Organs, Rome, Italy.
   [Onesti, M. G.] Sapienza Univ Rome, Dept Surg P Valdoni, Unit Plast Surg P Valdoni, Rome, Italy.
   [Napoli, C.] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci DAMSS, Naples, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome; Sapienza University Rome; Universita della Campania Vanvitelli
RP Ceccarelli, S (通讯作者)，Sapienza Univ Rome, Dept Expt Med, Rome, Italy.
EM simona.ceccarelli@uniroma1.it
RI ; Pontecorvi, Paola/HCG 8957 2022; Megiorni, Francesca/AAC 1597 2019;
   Messina, Elena/HGB 1187 2022; ANASTASIADOU, ELENI/AAU 6080 2021; Romano,
   Enrico/LOS 6881 2024; Marchese, Cinzia/J 1323 2018; Camero,
   Simona/AAT 5285 2021
OI MEGIORNI, Francesca/0000 0003 3705 3248; Messina,
   Elena/0000 0002 7182 2883; Romano, Enrico/0000 0001 9514 6472; 
FU PRIN 2017 [F8ZB89]; PRIN 2020 [XMLP45]; Progetti di Ricerca di Ateneo
   2021 by Sapienza University of Rome, Rome, Italy [RM12117A43E6555B]
FX This research was conducted with the help of the PRIN 2017 supporting
   grant no. F8ZB89, the PRIN 2020 supporting grant no. XMLP45 and a
   "Progetti di Ricerca di Ateneo 2021" grant no. RM12117A43E6555B by
   Sapienza University of Rome, Rome, Italy.
CR Ambele MA, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124283
   Anastasiadou E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257070
   Beane OS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115963
   Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200
   Berdasco M, 2012, AM J PATHOL, V181, P2079, DOI 10.1016/j.ajpath.2012.08.016
   Berdasco M, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt83
   Bost F, 2005, BIOCHIMIE, V87, P51, DOI 10.1016/j.biochi.2004.10.018
   Buchan AMJ, 2002, J BIOL CHEM, V277, P28431, DOI 10.1074/jbc.M201261200
   Ceccarelli S, 2007, EXP CELL RES, V313, P1758, DOI 10.1016/j.yexcr.2007.03.013
   Ceccarelli S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00236
   Ceccarelli S, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/1075156
   Ceccarelli S, 2014, J CELL MOL MED, V18, P1895, DOI 10.1111/jcmm.12334
   Charitos IA, 2021, STEM CELLS INT, V2021, DOI 10.1155/2021/9978837
   Chen J, 2013, TISSUE ENG PART B RE, V19, P516, DOI [10.1089/ten.teb.2012.0672, 10.1089/ten.TEB.2012.0672]
   Chen L, 2018, STEM CELL RES, V29, P76, DOI 10.1016/j.scr.2018.03.010
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Coppé JP, 2010, ANNU REV PATHOL MECH, V5, P99, DOI 10.1146/annurev pathol 121808 102144
   Dai R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/6737345
   De Miguel MP, 2012, CURR MOL MED, V12, P574
   de Winter TJJ, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.627429
   El Serafi AT, 2011, DIFFERENTIATION, V81, P35, DOI 10.1016/j.diff.2010.09.183
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Fitter S, 2012, J MOL ENDOCRINOL, V48, P229, DOI 10.1530/JME 12 0003
   Grandjenette C, 2014, NEOPLASIA, V16, P511, DOI 10.1016/j.neo.2014.05.009
   Habisch HJ, 2007, J NEURAL TRANSM, V114, P1395, DOI 10.1007/s00702 007 0748 y
   Hernandez Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100
   Hupkes M, 2011, FASEB J, V25, P3861, DOI 10.1096/fj.11 186122
   Jain AK, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001268
   Jiang CS, 2017, AGING CELL, V16, P1114, DOI 10.1111/acel.12643
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kakinuma N, 2008, J CELL BIOL, V181, P537, DOI 10.1083/jcb.200707022
   Kang S, 2007, J BIOL CHEM, V282, P14515, DOI 10.1074/jbc.M700030200
   KAUFMANN SH, 1993, CANCER RES, V53, P3976
   Kim K, 2011, NAT BIOTECHNOL, V29, P1117, DOI 10.1038/nbt.2052
   Kim KA, 2007, MOL CELL BIOL, V27, P2294, DOI 10.1128/MCB.02207 06
   Komashko VM, 2010, EPIGENETICS US, V5
   Kornicka K, 2017, J CELL MOL MED, V21, P387, DOI 10.1111/jcmm.12972
   Lehtimaki JI, 2021, ELIFE, V10, DOI 10.7554/eLife.60710
   Liao YM, 2020, CANCER GENE THER, V27, P256, DOI 10.1038/s41417 019 0135 5
   Liu MC, 2017, CELL TRANSPLANT, V26, P1505, DOI 10.1177/0963689717721221
   Liu TM, 2007, STEM CELLS, V25, P750, DOI 10.1634/stemcells.2006 0394
   Luo SM, 2013, BIOMED PHARMACOTHER, V67, P819, DOI 10.1016/j.biopha.2013.03.008
   Luo WJ, 2008, EXP CELL RES, V314, P3382, DOI 10.1016/j.yexcr.2008.07.003
   Mathieu PS, 2012, TISSUE ENG PART B RE, V18, P436, DOI [10.1089/ten.teb.2012.0014, 10.1089/ten.TEB.2012.0014]
   Melief SM, 2013, STEM CELL TRANSL MED, V2, P455, DOI 10.5966/sctm.2012 0184
   Meshorer E, 2006, NAT REV MOL CELL BIO, V7, P540, DOI 10.1038/nrm1938
   Muñoz Najar U, 2011, ANTIOXID REDOX SIGN, V14, P241, DOI 10.1089/ars.2010.3250
   Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446
   Nicolazzo C, 2017, INT J BIOL MARKER, V32, pE415, DOI 10.5301/ijbm.5000284
   Nodale C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091010
   Onesti MG, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2561461
   Pepin ME, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00346
   Porada CD, 2010, ADV DRUG DELIVER REV, V62, P1156, DOI 10.1016/j.addr.2010.08.010
   Purcell M, 2014, CELL CYCLE, V13, P3927, DOI 10.4161/15384101.2014.973327
   Putri JF, 2017, COMPUT BIOL CHEM, V70, P49, DOI 10.1016/j.compbiolchem.2017.08.003
   Ren S, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1152 x
   Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006 291X(02)02454 3
   Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950
   Rubin JP, 2013, LANCET, V382, P1077, DOI 10.1016/S0140 6736(13)61744 4
   Scioli MG, 2014, INT J MOL SCI, V15, P6517, DOI 10.3390/ijms15046517
   Scuderi N, 2013, CELL TRANSPLANT, V22, P779, DOI 10.3727/096368912X639017
   Shin S, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194076
   Shingyochi Y, 2015, EXPERT OPIN BIOL TH, V15, P1285, DOI 10.1517/14712598.2015.1053867
   Takada H, 2014, EPIGENETICS US, V9, P1195, DOI 10.4161/epi.29856
   Teklemariam T, 2014, BIOCHEM BIOPH RES CO, V452, P753, DOI 10.1016/j.bbrc.2014.08.152
   Valencia J, 2016, CYTOTHERAPY, V18, P1297, DOI 10.1016/j.jcyt.2016.07.006
   Wang CG, 2003, MOL CELL BIOL, V23, P6159, DOI 10.1128/MCB.23.17.6159 6173.2003
   Wu H, 2006, PEDIATR RES, V59, p21R, DOI 10.1203/01.pdr.0000203565.76028.2a
   Wu I, 2012, PLAST RECONSTR SURG, V129, P1247, DOI 10.1097/PRS.0b013e31824ec3dc
   Xie YY, 2018, DIABETES, V67, P2569, DOI 10.2337/db18 0311
   Yan XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090846
   Yu WH, 2008, MOL CELL BIOCHEM, V310, P11, DOI 10.1007/s11010 007 9661 9
   Zhang H, 2014, GENET MOL RES, V13, P5064, DOI 10.4238/2014.July.4.22
   Zhou GS, 2009, CYTOTECHNOLOGY, V60, P11, DOI 10.1007/s10616 009 9203 2
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zych J, 2013, BRAZ J MED BIOL RES, V46, P405, DOI 10.1590/1414 431X20132893
NR 77
TC 12
Z9 13
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD SEP 2
PY 2022
VL 10
AR 926180
DI 10.3389/fcell.2022.926180
PG 20
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA 5R9KV
UT WOS:000874823200001
PM 36120582
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Chang, JK
   Li, CJ
   Wu, SC
   Yeh, CH
   Chen, CH
   Fu, YC
   Wang, GJ
   Ho, ML
AF Chang, Je Ken
   Li, Ching Ju
   Wu, Shun Cheng
   Yeh, Ching Hua
   Chen, Chung Hwan
   Fu, Yin Chih
   Wang, Gwo Jaw
   Ho, Mei Ling
TI Effects of anti inflammatory drugs on proliferation, cytotoxicity and
   osteogenesis in bone marrow mesenchymal stem cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE anti inflammatory drugs; mesenchymal stem cells; proliferation; cell
   cycle regulators; cytotoxicity; osteogenesis
ID STEROID INDUCED ADIPOGENESIS; PHARMACOKINETIC PROPERTIES;
   RHEUMATOID ARTHRITIS; OSTEOBLASTIC CELLS; SULINDAC SULFIDE; CLONE
   MC3T3 E1; UP REGULATION; INDOMETHACIN; APOPTOSIS; PROSTAGLANDINS
AB Nonsteroidal anti inflammatory drugs (NSAIDs) were found to suppress proliferation and induce cell death in cultured osteoblasts, and steroids were found to decrease the osteogenesis potential of mesenchymal stem cells. In this study, we further tested the effects of anti inflammatory drugs (AIDs) on the functions of bone marrow mesenchymal stem cells (BMSCs). The BMSCs from mice (D1 cells) and humans (hBMSCs) were treated with dexamethasone (10( 7) to 10( 6) M), cyclooxygenase 2 (COX 2) selective NSAIDs (10( 6) to 10( 1) M) and non selective NSAIDs (10( 5) to 10( 4) M). Drug effects on proliferation, cell cycle kinetics, cytotoxicity and mRNA and protein expressions of cell cycle regulators were tested. The osteogenesis potential of D1 cells were evaluated by testing mRNA expressions of type I alpha collagen and osteocalcin 2 8 days after treatments, and testing mineralization 1 3 weeks after treatments. The results showed that all the tested drugs suppressed proliferation and arrested cell cycle of D1 cells, but no significant cytotoxic effects was found. Prostaglandin E1, E2 and F2 alpha couldn't rescue the effects of AIDs on proliferation. The p27(kip1) expression was up regulated by indomethacin, celecoxib and dexamethasone in both D1 cells and hBMSCs. Higher concentrations of indomethacin and dexamethasone also up regulated p21(Cip1/Waf1) expression in hBMSCs, and so did celecoxib on D1 cells. Expressions of cyclin El and E2 were down regulated by these AIDs in D cells, while only cyclin E2 was down regulated by dexamethasone in hBMSCs. All the tested NSAIDs revealed no obvious detrimental effects on osteogenic differentiation of D1 cells. These results suggest that the proliferation suppression of AIDs on BMSCs may act via affecting expressions of cell cycle regulators, but not prostaglandin related mechanisms. (C) 2007 Elsevier Inc. All rights reserved.
C1 Kaohsiung Med Univ, Fac Med, Dept Orthopaed, Kaohsiung, Taiwan.
   Kaohsiung Med Univ, Coll Med, Grad Inst Physiol & Mol Med, Kaohsiung, Taiwan.
   Kaohsiung Med Univ, Coll Med, Grad Inst Med, Kaohsiung, Taiwan.
   Kaohsiung Med Univ, Orthopaed Res Ctr, Kaohsiung, Taiwan.
   Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthopaed, Kaohsiung, Taiwan.
   Kaohsiung Med Univ, Fac Med, Dept Physiol, Kaohsiung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University
RP Ho, ML (通讯作者)，Kaohsiung Med Univ, Coll Med, Dept Physiol, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM homelin@cc.kmu.edu.tw
RI ; Chen, Chung Hwan/D 4036 2009; Fu, Yin Chih/D 5035 2009; Ho,
   Mei Ling/D 5515 2009; Wu, Shun Cheng/E 2989 2010; Chang,
   Je Ken/A 1315 2010
OI Ho, Mei Ling/0000 0001 8064 8488; Chen, Chung Hwan/0000 0001 8941 4792;
   Wu, Shun Cheng/0000 0003 4219 3413; 
CR Amati B., 1998, Front Biosci, V3, pd250, DOI DOI 10.2741/A239
   Arellano M, 1997, INT J BIOCHEM CELL B, V29, P559, DOI 10.1016/S1357 2725(96)00178 1
   BLOCKA KLN, 1988, J RHEUMATOL, V15, P757
   Boonstra J, 2003, J CELL BIOCHEM, V90, P244, DOI 10.1002/jcb.10617
   BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495 199039010 00008
   Centrella M, 1997, J CELL BIOCHEM, V67, P528, DOI 10.1002/(SICI)1097 4644(19971215)67:4<528::AID JCB10>3.0.CO;2 5
   Chang DJ, 1998, J BIOL CHEM, V273, P4892, DOI 10.1074/jbc.273.9.4892
   Chang JK, 2006, CLIN ORTHOP RELAT R, P286, DOI 10.1097/01.blo.0000238869.99980.b2
   Chang JK, 2005, CONNECT TISSUE RES, V46, P200, DOI 10.1080/03008200500344025
   Chen CH, 2005, OSTEOPOROSIS INT, V16, P2039, DOI 10.1007/s00198 005 1995 0
   Chua CC, 2003, BBA MOL CELL RES, V1642, P79, DOI 10.1016/S0167 4889(03)00100 9
   Clemett D, 2000, DRUGS, V59, P957, DOI 10.2165/00003495 200059040 00017
   Crowston JG, 1998, INVEST OPHTH VIS SCI, V39, P449
   Cui Q, 1997, J BONE JOINT SURG AM, V79A, P1054, DOI 10.2106/00004623 199707000 00012
   Cui QJ, 1997, CLIN ORTHOP RELAT R, P8
   Daluiski A, 2006, ORTHOPEDICS, V29, P259, DOI 10.3928/01477447 20060301 02
   Depré M, 2000, EUR J CLIN PHARMACOL, V56, P167, DOI 10.1007/s002280050736
   DICESARE PE, 1991, J ORTHOP RES, V9, P855, DOI 10.1002/jor.1100090611
   DIDUCH DR, 1993, J BONE JOINT SURG AM, V75A, P92, DOI 10.2106/00004623 199301000 00012
   Goodman S, 2002, J ORTHOP RES, V20, P1164, DOI 10.1016/S0736 0266(02)00079 7
   Grösch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01 0299fje
   HAKEDA Y, 1985, J BIOCHEM, V97, P97, DOI 10.1093/oxfordjournals.jbchem.a135072
   HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204
   Ho ML, 1999, BIOCHEM PHARMACOL, V58, P983, DOI 10.1016/S0006 2952(99)00186 0
   Ho ML, 1998, PHARMACOLOGY, V57, P148, DOI 10.1159/000028236
   HO ML, 1995, CLIN ORTHOP RELAT R, V313, P270
   Ho ML, 2001, J MUSCULOSKELETAL RE, V5, P279
   Ikui AE, 2001, ANTICANCER RES, V21, P2297
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   KELLER J, 1989, ACTA ORTHOP SCAND, V60, P119, DOI 10.3109/17453678909150109
   Kovarik JM, 1998, PHARMACOTHERAPY, V18, P1230
   Koyama A, 2000, EUR J PHARMACOL, V391, P225, DOI 10.1016/S0014 2999(00)00100 X
   Lian J B, 1993, J Oral Implantol, V19, P95
   Lin TM, 2005, STEM CELLS DEV, V14, P92, DOI 10.1089/scd.2005.14.92
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Marra DE, 2000, CIRCULATION, V102, P2124, DOI 10.1161/01.CIR.102.17.2124
   Mesner P W Jr, 1997, Adv Pharmacol, V41, P57, DOI 10.1016/S1054 3589(08)61054 6
   Morrison TB, 1998, BIOTECHNIQUES, V24, P954
   NILSSON OS, 1986, CLIN ORTHOP RELAT R, P239
   OBERBAUER R, 1993, CLIN PHARMACOKINET, V24, P428, DOI 10.2165/00003088 199324050 00007
   PARFITT AM, 1992, OSTEOBLAST OSTEOCYTE, P351
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   Seidenberg AB, 2004, PHARMACOL RES, V50, P151, DOI 10.1016/j.phrs.2003.12.017
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   SHI XM, 1998, J BONE MINER RES, V12, pS454
   SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127
   TODD PA, 1988, DRUGS, V35, P244, DOI 10.2165/00003495 198835030 00004
   TORNKVIST H, 1985, CLIN ORTHOP RELAT R, P264
   TORNKVIST H, 1980, SCAND J RHEUMATOL, V9, P167
   TRANCIK T, 1989, CLIN ORTHOP RELAT R, P113
   Tsai WC, 2004, J ORTHOP RES, V22, P586, DOI 10.1016/j.orthres.2003.10.014
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   Wang GJ, 2000, CLIN ORTHOP RELAT R, P295, DOI 10.1097/00003086 200001000 00030
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   YAMAGUCHI DT, 1989, AM J PHYSIOL, V257, pF755, DOI 10.1152/ajprenal.1989.257.5.F755
NR 57
TC 83
Z9 89
U1 0
U2 21
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD NOV 1
PY 2007
VL 74
IS 9
BP 1371
EP 1382
DI 10.1016/j.bcp.2007.06.047
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 227NR
UT WOS:000250663900006
PM 17714695
DA 2025 08 17
ER

PT J
AU Brent, MB
   Thomsen, JS
   Brüel, A
AF Brent, Mikkel Bo
   Thomsen, Jesper Skovhus
   Bruel, Annemarie
TI The Efficacy of PTH and Abaloparatide to Counteract
   Immobilization Induced Osteopenia Is in General Similar
SO FRONTIERS IN ENDOCRINOLOGY
LA English
DT Article
DE &#956; CT; bone formation; immobilization; PTH; abaloparatide
ID HUMAN PARATHYROID HORMONE; BONE MINERAL DENSITY; POSTMENOPAUSAL WOMEN;
   DISUSE OSTEOPENIA; BOTULINUM TOXIN; TRABECULAR BONE; OSTEOPOROSIS;
   STRENGTH; CONFORMATIONS; SELECTIVITY
AB Immobilization results in a substantial bone loss and increased fracture risk. Powerful bone anabolic therapies are necessary to counteract the bone loss and reduce fracture risk during periods with immobilization. Intermittent parathyroid hormone 1 34 (PTH) (teriparatide) and PTH related peptide analog abaloparatide (ABL) are potent bone anabolic therapies acting through the same receptor, but induce different durations of signaling response. We investigated the efficacy of PTH or ABL in preventing immobilization induced bone loss in rats in a direct mole to mole comparison. Immobilization was achieved by injecting botulinum toxin type A (BTX) into the right hindlimb musculature. Sixty 14 week old female Wistar rats were allocated to the following groups: Baseline, Control, BTX, BTX + PTH (80 mu g/kg/day), and BTX + ABL (77 mu g/kg/day). Immobilization resulted in a substantial and significant reduction in bone mineral density (aBMD), metaphyseal and epiphyseal trabecular bone volume fraction (BV/TV) and trabecular thickness (Tb.Th), metaphyseal trabecular number (Tb.N), and femoral neck bone strength. Both PTH and ABL prevented the immobilization induced decrease in aBMD, metaphyseal and epiphyseal Tb.Th, and metaphyseal Tb.N. In addition, PTH rescued the reduction in metaphyseal BV/TV and femoral neck strength, while ABL did not. However, the effect of PTH and ABL did not differ significantly for serum calcium, aBMD, metaphyseal, and epiphyseal BV/TV, Tb.Th, or Tb.N. In conclusion, in a mole to mole comparison the efficacy of PTH and ABL is similar in counteracting immobilization induced reduction in bone mineral density, deterioration in trabecular microarchitecture, and decrease in bone strength.
C1 [Brent, Mikkel Bo; Thomsen, Jesper Skovhus; Bruel, Annemarie] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
C3 Aarhus University
RP Brent, MB (通讯作者)，Aarhus Univ, Dept Biomed, Aarhus, Denmark.
EM mbb@biomed.au.dk
RI ; Bruel, Annemarie/AAT 2310 2020; Brent, Mikkel/Q 2703 2019; Brent,
   Mikkel Bo/Q 2703 2019; Thomsen, Jesper/HKN 2794 2023
OI Bruel, Annemarie/0000 0003 4833 0888; Thomsen, Jesper
   Skovhus/0000 0001 9386 6679; Brent, Mikkel Bo/0000 0002 3475 4295; 
FU Health Aarhus University; A.P. MOller Foundation for the Advancement of
   Medical Science; Helga and Peter Korning's Foundation; Frimodt Heineke
   Foundation; Oda and Hans Svenningsen's Foundation; DirektOr Emil C.
   Hertz and spouse Inger Hertz' Foundation; Frode Nygaard and Spouse's
   Foundation; Dagmar Marshall's Foundation; Torben and Alice Frimodt's
   Foundation; Aase and Ejnar Danielsen's Foundation
FX The authors are thankful for the excellent technical assistance of Jytte
   Utoft. We thank Visiopharm for the contribution to the newCAST
   stereology software system. The mu CT system as donated by the VELUX
   Foundation. The study was kindly supported by Health Aarhus University,
   The A.P. MOller Foundation for the Advancement of Medical Science, Helga
   and Peter Korning's Foundation, The Frimodt Heineke Foundation, Oda and
   Hans Svenningsen's Foundation, DirektOr Emil C. Hertz and spouse Inger
   Hertz' Foundation, Frode Nygaard and Spouse's Foundation, Dagmar
   Marshall's Foundation, Torben and Alice Frimodt's Foundation, and Aase
   and Ejnar Danielsen's Foundation.
CR Arlt H, 2020, BONE REP, V13, DOI 10.1016/j.bonr.2020.100291
   Bain SD, 2019, J MUSCULOSKEL NEURON, V19, P79
   Bernhardsson M, 2018, ACTA ORTHOP, V89, P674, DOI 10.1080/17453674.2018.1523771
   Besschetnova T, 2019, BONE, V124, P148, DOI 10.1016/j.bone.2019.04.025
   Bogazzi F, 2011, J ENDOCRINOL INVEST, V34, pE200, DOI 10.3275/7228
   Bouvard B, 2012, BONE, V50, P858, DOI 10.1016/j.bone.2011.12.023
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brent MB, 2018, BONE, V110, P244, DOI 10.1016/j.bone.2018.02.017
   Brüel A, 2013, BONE, V53, P51, DOI 10.1016/j.bone.2012.11.037
   Chandler H, 2019, OSTEOPOROSIS INT, V30, P1607, DOI 10.1007/s00198 019 04999 4
   Chandler H, 2019, BONE, V120, P148, DOI 10.1016/j.bone.2018.10.012
   Chappard D, 2001, BONE, V28, P72, DOI 10.1016/S8756 3282(00)00438 5
   Cusano NE, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/463675
   Datta NS, 2009, CELL SIGNAL, V21, P1245, DOI 10.1016/j.cellsig.2009.02.012
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   FROST HM, 1983, CLIN ORTHOP RELAT R, P286
   Giangregorio L, 2006, J SPINAL CORD MED, V29, P489, DOI 10.1080/10790268.2006.11753898
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kilkenny C, 2010, J GENE MED, V12, P561, DOI [10.1002/jgm.1473, 10.1113/jphysiol.2010.192278, 10.1111/j.1476 5381.2010.00872.x]
   Kroll MH, 2000, B MATH BIOL, V62, P163, DOI 10.1006/bulm.1999.0146
   Lanske B, 2019, J ORTHOP RES, V37, P812, DOI 10.1002/jor.24254
   Le Henaff C, 2020, J BONE MINER RES, V35, P714, DOI 10.1002/jbmr.3930
   LEBLANC AD, 1990, J BONE MINER RES, V5, P843
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Ma YFL, 2011, ENDOCRINOLOGY, V152, P1767, DOI 10.1210/en.2010 1112
   Maeda A, 2013, P NATL ACAD SCI USA, V110, P5864, DOI 10.1073/pnas.1301674110
   Martin TJ, 2017, J BONE MINER RES, V32, P11, DOI 10.1002/jbmr.3042
   Miller PD, 2019, BONE, V120, P137, DOI 10.1016/j.bone.2018.10.015
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Minisola S, 2019, THER ADV MUSCULOSKEL, V11, DOI 10.1177/1759720X19877994
   Moriyama Ichiro, 2002, J Orthop Sci, V7, P379, DOI 10.1007/s007760200063
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   REEVE J, 1976, LANCET, V1, P1035
   ROSENQVIST M, 1992, CLIN ENDOCRINOL, V37, P29, DOI 10.1111/j.1365 2265.1992.tb02279.x
   Ross PD, 1996, ARCH INTERN MED, V156, P1399, DOI 10.1001/archinte.156.13.1399
   Sahbani K, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14225
   SAIKAWA T, 1988, CLIN CARDIOL, V11, P75, DOI 10.1002/clc.4960110205
   Silva BC, 2015, CURR OPIN PHARMACOL, V22, P41, DOI 10.1016/j.coph.2015.03.005
   Sorensen TG, 2020, BONE, V131, DOI 10.1016/j.bone.2019.115183
   Stanislaus D, 2000, BONE, V27, P209, DOI 10.1016/S8756 3282(00)00309 4
   Tella SH, 2017, CUREUS J MED SCIENCE, V9, DOI 10.7759/cureus.1300
   Thomsen JS, 2012, CALCIFIED TISSUE INT, V90, P294, DOI 10.1007/s00223 012 9576 7
   Varela A, 2017, BONE, V95, P143, DOI 10.1016/j.bone.2016.11.027
   Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003
   Vegger JB, 2017, J MUSCULOSKEL NEURON, V17, P162
   Vegger JB, 2018, J BONE MINER METAB, V36, P170, DOI 10.1007/s00774 017 0830 y
   Vegger JB, 2015, CALCIFIED TISSUE INT, V97, P516, DOI 10.1007/s00223 015 0035 0
   Vegger JB, 2014, BONE, V66, P287, DOI 10.1016/j.bone.2014.06.020
   Vilardaga JP, 2011, CELL MOL LIFE SCI, V68, P1, DOI 10.1007/s00018 010 0465 9
   Warner SE, 2006, BONE, V38, P257, DOI 10.1016/j.bone.2005.08.009
NR 56
TC 13
Z9 14
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 2392
J9 FRONT ENDOCRINOL
JI Front. Endocrinol.
PD OCT 9
PY 2020
VL 11
AR 588773
DI 10.3389/fendo.2020.588773
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OH2CT
UT WOS:000582378100001
PM 33162940
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dondossola, E
   Alexander, S
   Holzapfel, BM
   Filippini, S
   Starbuck, MW
   Hoffman, RM
   Navone, N
   De Juan Pardo, EM
   Logothetis, CJ
   Hutmacher, DW
   Friedl, P
AF Dondossola, Eleonora
   Alexander, Stephanie
   Holzapfel, Boris M.
   Filippini, Stefano
   Starbuck, Michael W.
   Hoffman, Robert M.
   Navone, Nora
   De Juan Pardo, Elena M.
   Logothetis, Christopher J.
   Hutmacher, Dietmar W.
   Friedl, Peter
TI Intravital microscopy of osteolytic progression and therapy response of
   cancer lesions in the bone
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID IN VIVO MODEL; HEMATOPOIETIC STEM; PROSTATE CANCER; PROGENITOR CELLS;
   CONTROLLED TRIAL; IMAGING REVEALS; ZOLEDRONIC ACID; MARROW; METASTASIS;
   OSTEOCLASTS
AB Intravital multiphoton microscopy (iMPM) in mice provides access to cellular and molecular mechanisms of metastatic progression of cancers and the underlying interactions with the tumor stroma. Whereas iMPM of malignant disease has been performed for soft tissues, noninvasive iMPM of solid tumor in the bone is lacking. We combined miniaturized tissue engineered bone constructs in nude mice with a skin window to noninvasively and repetitively monitor prostate cancer lesions by three dimensional iMPM. In vivo ossicles developed large central cavities containing mature bone marrow surrounded by a thin cortex and enabled tumor implantation and longitudinal iMPM over weeks. Tumors grew inside the bone cavity and along the cortical bone interface and induced niches of osteoclast activation (focal osteolysis). Interventional bisphosphonate therapy reduced osteoclast kinetics and osteolysis without perturbing tumor growth, indicating dissociation of the tumor stroma axis. The ossicle window, with its high cavity to cortex ratio and long term functionality, thus allows for the mechanistic dissection of reciprocal epithelial tumor bone interactions and therapy response.
C1 [Dondossola, Eleonora; Alexander, Stephanie; Filippini, Stefano; Starbuck, Michael W.; Navone, Nora; Logothetis, Christopher J.; Friedl, Peter] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Holzapfel, Boris M.; De Juan Pardo, Elena M.; Hutmacher, Dietmar W.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Ctr Regenerat Med, 60 Musk Ave, Brisbane, Qld 4059, Australia.
   [Holzapfel, Boris M.] Univ Wurzburg, Orthopaed Ctr Musculoskeletal Res, Brettreichstr 11, D 97074 Wurzburg, Germany.
   [Hoffman, Robert M.] Univ Calif San Diego, Dept Surg, 7917 Ostrow St, San Diego, CA 92111 USA.
   [Hoffman, Robert M.] AntiCancer Inc, 7917 Ostrow St, San Diego, CA 92111 USA.
   [Hutmacher, Dietmar W.] QUT, ARC Ctr Addit Biomfg, 60 Musk Ave, Brisbane, Qld 4059, Australia.
   [Friedl, Peter] Radboud Univ Nijmegen, Nijmegen, Netherlands.
   [Friedl, Peter] Canc Genom Ctr CGC Nl, NL 3584 Utrecht, Netherlands.
C3 University of Texas System; UTMD Anderson Cancer Center; Queensland
   University of Technology (QUT); University of Wurzburg; University of
   California System; University of California San Diego; AntiCancer, Inc.;
   Queensland University of Technology (QUT); Radboud University Nijmegen
RP Friedl, P (通讯作者)，Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Friedl, P (通讯作者)，Radboud Univ Nijmegen, Nijmegen, Netherlands.; Friedl, P (通讯作者)，Canc Genom Ctr CGC Nl, NL 3584 Utrecht, Netherlands.
EM pfriedl@mdanderson.org
RI Filippini, Stefano/HKO 6780 2023; De Juan Pardo, Elena/I 5871 2016;
   Hutmacher, Dietmar/AEO 9578 2022; Alexander, Stephanie/B 7150 2012;
   Holzapfel, Boris/LCE 4882 2024; Friedl, Peter/A 8961 2010
OI De Juan Pardo, Elena/0000 0001 9005 7497; Logothetis, Christopher
   J./0000 0002 6365 1711; Alexander, Stephanie/0000 0002 8308 3977;
   Hutmacher, Dietmar Werner/0000 0001 5678 2134; Dondossola,
   Eleonora/0000 0001 6916 5418; 
FU Cancer Prevention and Research Institute of Texas [RP140482]; Prostate
   Cancer Foundation [16YOUN24]; Rolanette and Berdon Lawrence Bone Disease
   Program of Texas; Netherlands Science Organization (NWO VICI)
   [918.11.626]; European Research Council (ERC CoG DEEPINSIGHT) [617430];
   NIH [U54 CA210184 01]; Cancer Genomics Center; Australian Research
   Council Training Centre in Additive Biomanufacturing; National Health
   and Medical Research Council of Australia; National Breast Cancer
   Foundation [IN 15 047]; World Cancer Foundation; NIH/National Cancer
   Institute [P30 CA016672]; University of Texas MD Anderson Moon Shots
   Program
FX E.D. is supported by the Cancer Prevention and Research Institute of
   Texas (RP140482), the Prostate Cancer Foundation (16YOUN24), and The
   Rolanette and Berdon Lawrence Bone Disease Program of Texas. P.F. is
   supported by Netherlands Science Organization (NWO VICI 918.11.626), the
   European Research Council (ERC CoG DEEPINSIGHT, project no. 617430), the
   NIH (U54 CA210184 01), and the Cancer Genomics Center. D.W.H. is
   supported by the Australian Research Council Training Centre in Additive
   Biomanufacturing, the National Health and Medical Research Council of
   Australia, National Breast Cancer Foundation (IN 15 047), and World
   Cancer Foundation. The Genitourinary Cancers Program of the Cancer
   Center Support Grant (CCSG) shared resources at MD Anderson Cancer
   Center was supported by NIH/National Cancer Institute award number P30
   CA016672. N.N. is supported by the University of Texas MD Anderson Moon
   Shots Program.
CR Acar M, 2015, NATURE, V526, P126, DOI 10.1038/nature15250
   Alexander S, 2008, HISTOCHEM CELL BIOL, V130, P1147, DOI 10.1007/s00418 008 0529 1
   Anderegg F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028583
   Andresen V, 2009, CURR OPIN BIOTECH, V20, P54, DOI 10.1016/j.copbio.2009.02.008
   Antonelli A, 2016, BLOOD, V128, P2949, DOI 10.1182/blood 2016 05 719021
   Chen Y, 2012, BLOOD, V119, P4971, DOI 10.1182/blood 2011 11 389957
   Croucher PI, 2016, NAT REV CANCER, V16, P373, DOI 10.1038/nrc.2016.44
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Destaing O, 2003, MOL BIOL CELL, V14, P407, DOI 10.1091/mbc.E02 07 0389
   Dondossola E, 2017, NAT BIOMED ENG, V1, DOI 10.1038/s41551 016 0007
   Ell B, 2012, CELL, V151, DOI 10.1016/j.cell.2012.10.005
   Ellenbroek SIJ, 2014, NAT REV CANCER, V14, P406, DOI 10.1038/nrc3742
   Fossey S, 2016, J TOXICOL PATHOL, V29, p49S, DOI [10.1293/tox.29.3S 2, 10.1293/tox.2016 I002]
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202 128
   Hawkins ED, 2016, NATURE, V538, P518, DOI 10.1038/nature19801
   Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717
   Holzapfel BM, 2015, BIOMATERIALS, V61, P103, DOI 10.1016/j.biomaterials.2015.04.057
   Holzapfel BM, 2014, BIOMATERIALS, V35, P4108, DOI 10.1016/j.biomaterials.2014.01.062
   Hubin F, 2004, CELL TRANSPLANT, V13, P823, DOI 10.3727/000000004783983387
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kedrin D, 2008, NAT METHODS, V5, P1019, DOI 10.1038/nmeth.1269
   Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kim S, 2017, LEUKEMIA, V31, P1582, DOI 10.1038/leu.2016.354
   Köhler A, 2009, BLOOD, V114, P290, DOI 10.1182/blood 2008 12 195644
   Kozloff KM, 2009, BONE, V44, P190, DOI 10.1016/j.bone.2008.10.036
   Kunisaki Y, 2013, NATURE, V502, P637, DOI 10.1038/nature12612
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lassailly F, 2013, BLOOD, V122, P1730, DOI 10.1182/blood 2012 11 467498
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Lee J, 2012, P NATL ACAD SCI USA, V109, P19638, DOI 10.1073/pnas.1208384109
   Lipton A, 2010, SEMIN ONCOL, V37, pS1, DOI 10.1053/j.seminoncol.2010.06.005
   Lo Celso C, 2011, NAT PROTOC, V6, P1, DOI 10.1038/nprot.2010.168
   Lo Celso C, 2009, NATURE, V457, P92, DOI 10.1038/nature07434
   Martine LC, 2017, NAT PROTOC, V12, P639, DOI 10.1038/nprot.2017.002
   Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003
   Ritsma L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004394
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rogers TL, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 177
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Sakai H, 2006, BONE, V39, P1290, DOI 10.1016/j.bone.2006.06.012
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seib FP, 2015, BIOMATERIALS, V51, P313, DOI 10.1016/j.biomaterials.2015.01.076
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Singh AS, 2005, J UROLOGY, V174, P820, DOI 10.1097/01.ju.0000169133.82167.aa
   Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   Smith MR, 2014, J CLIN ONCOL, V32, P1143, DOI 10.1200/JCO.2013.51.6500
   Tassone P, 2005, BLOOD, V106, P1341, DOI 10.1182/blood 2004 11 4477
   Thibaudeau L, 2014, DIS MODEL MECH, V7, P299, DOI 10.1242/dmm.014076
   Turk V, 2012, BBA PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   VAANANEN HK, 1988, ANN CHIR GYNAECOL FE, V77, P193
   Weigelin B, 2016, J CELL SCI, V129, P245, DOI 10.1242/jcs.152272
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weinstein RS, 2009, NEW ENGL J MED, V360, P53, DOI 10.1056/NEJMoa0802633
   Wirth M, 2015, EUR UROL, V67, P482, DOI 10.1016/j.eururo.2014.02.014
NR 59
TC 42
Z9 48
U1 2
U2 27
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 1
PY 2018
VL 10
IS 452
AR eaao5726
DI 10.1126/scitranslmed.aao5726
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GP0JH
UT WOS:000440494900003
PM 30068572
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, YH
   Hu, CF
   Hu, B
   Tian, J
   Zhao, G
   Cai, CD
   Li, YG
   Sun, ZY
   Wang, S
   Pang, S
   Bao, R
   Tao, ZJ
   Chen, HJ
   Wu, JL
   Liu, S
AF Li, Yanhao
   Hu, Chengfang
   Hu, Bo
   Tian, Jian
   Zhao, Gang
   Cai, Chuandong
   Li, Yuange
   Sun, Zhenyu
   Wang, Shuo
   Pang, Sa
   Bao, Rong
   Tao, Zaijing
   Chen, Huajiang
   Wu, Jinglei
   Liu, Shen
TI Sustained Release of Dicumarol via Novel Grafted Polymer in Electrospun
   Nanofiber Membrane for Treatment of Peritendinous Adhesion
SO ADVANCED HEALTHCARE MATERIALS
LA English
DT Article
DE connexin43; drug grafted polymer; electrospun nanofiber membranes;
   peritendinous adhesion
ID FLEXOR TENDON REPAIR; PREVENTION; BARRIER; DESIGN
AB The prevention and treatment of post traumatic peritendinous adhesion (PA) have always been a great difficulty for orthopedic surgeons. Current treatments include resecting surgery, non steroidal anti inflammatory drugs (NSAIDs) usage and implantable membranes, often target single disease pathogenic processes, resulting in unfavorable therapeutic outcomes. Here a polylactic acid (PLA) dicumarol conjugates electrospun nanofiber membrane (ENM) (PCD) is generated, which can achieve spatial accuracy and temporal sustainability in drug release. It is further demonstrated that PCD possesses a significantly higher and more sustainable drug release profile than traditional drug loading ENM. By providing a physical barrier and continuous releasing of dicumarol, PCD implantation significantly reduces tissue adhesion by 25%, decreases fibroblasts activity and inhibits key fibrogenic cytokine transforming growth factor beta (TGF beta) production by 30%, and improves the biomechanical tendon property by 14.69%. Mechanistically, PCD potently inhibits the connexin43 (Cx43) and thereby tunes down the fibroblastic TGF beta/Smad3 signaling pathway. Thus, this approach leverages the anti adhesion effect of dicumarol and drug release properties of grafted copolymer ENM by esters to provide a promising therapeutic strategy for patients who suffer from PA.
C1 [Li, Yanhao; Hu, Chengfang; Cai, Chuandong; Li, Yuange; Sun, Zhenyu; Wang, Shuo; Pang, Sa; Bao, Rong; Tao, Zaijing; Liu, Shen] Shanghai Peoples Hosp Shanghai Jiao Tong Univ 6, Dept Orthopaed, Sch Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.
   [Hu, Bo; Chen, Huajiang] Naval Med Univ, Changzheng Hosp, Dept Orthopaed, Sect Spine Surg, Shanghai 200003, Peoples R China.
   [Tian, Jian; Zhao, Gang] Soochow Univ, Dept Orthoped, Affiliated Wuxi Peoples Hosp 9, Wuxi 214061, Peoples R China.
   [Wu, Jinglei] Donghua Univ, Coll Biol Sci & Med Engn, Shanghai Engn Res Ctr Nanobiomat & Regenerat Med, Shanghai 201620, Peoples R China.
C3 Naval Medical University; Soochow University   China; Donghua University
RP Liu, S (通讯作者)，Shanghai Peoples Hosp Shanghai Jiao Tong Univ 6, Dept Orthopaed, Sch Med, 600 Yishan Rd, Shanghai 200233, Peoples R China.; Chen, HJ (通讯作者)，Naval Med Univ, Changzheng Hosp, Dept Orthopaed, Sect Spine Surg, Shanghai 200003, Peoples R China.; Wu, JL (通讯作者)，Donghua Univ, Coll Biol Sci & Med Engn, Shanghai Engn Res Ctr Nanobiomat & Regenerat Med, Shanghai 201620, Peoples R China.
EM spine_czchenhj@163.com; jw@dhu.edu.cn; liushensjtu@126.com
RI Yanhao, Li/JUF 8684 2023; Sun, Zhenyu/ABX 2064 2022; Tian,
   Jianwu/MGU 5793 2025; Wu, Jinglei/AFW 1414 2022
OI Wu, Jinglei/0000 0001 9549 3992
FU National Natural Science Foundation of China [81902234, 82172408,
   81772314]; Shanghai Institute of Nutrition and Health, Shanghai Jiao
   Tong University Medical College "Two hundred Talent" Program [20191829,
   SHDC2020CR4032]; Shanghai Engineering Research Center for Orthopaedic
   Material Innovation and Tissue Regeneration [20DZ2254100, 22ZR1480300];
   Outstanding Academic Leaders (Youth) project of Shanghai Science and
   Technology Innovation Action Plan [21XD1422900]
FX Y.L., C.H., B.H., and J.T. contributed equally to this study. This work
   was supported by the National Natural Science Foundation of China (no.
   81902234, 82172408, and 81772314); Principle Investigator Innovation
   Team of Both Shanghai Sixth People's Hospital and Shanghai Institute of
   Nutrition and Health, Shanghai Jiao Tong University Medical College
   "Two hundred Talent" Program (no. 20191829); The Second Three Year
   Action Plan for Promoting Clinical Skills and Clinical Innovation in
   Municipal Hospitals of Shanghai Shenkang (no. SHDC2020CR4032); Shanghai
   Engineering Research Center for Orthopaedic Material Innovation and
   Tissue Regeneration (no. 20DZ2254100); Original Exploration project
   (22ZR1480300) and Outstanding Academic Leaders (Youth) project
   (21XD1422900) of Shanghai Science and Technology Innovation Action Plan.
   The authors are also grateful to Jun Qin (Shanghai Institute of
   Nutrition and Health, Chinese Academy of Sciences) for his technical
   assistance.
CR Abdelmohsen K, 2005, ARCH BIOCHEM BIOPHYS, V434, P241, DOI 10.1016/j.abb.2004.11.002
   Ang BFH, 2021, AM J SPORT MED, V49, P1854, DOI 10.1177/03635465211010158
   Asazuma Nakamura Y, 2009, EXP CELL RES, V315, P1190, DOI 10.1016/j.yexcr.2008.12.021
   Balusamy B, 2020, J CONTROL RELEASE, V326, P482, DOI 10.1016/j.jconrel.2020.07.038
   Brebels J, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14050867
   Chen CH, 2008, J HAND SURG AM, V33A, P1834, DOI 10.1016/j.jhsa.2008.07.003
   Chen S, 2014, INT J MOL SCI, V15, P14014, DOI 10.3390/ijms150814014
   de Putter CE, 2012, J BONE JOINT SURG AM, V94A, DOI 10.2106/JBJS.K.00561
   Dy CJ, 2012, J HAND SURG AM, V37A, P543, DOI 10.1016/j.jhsa.2011.11.006
   Elliot D, 2002, J HAND SURG BRIT EUR, V27B, P507, DOI 10.1054/jhsb.2002.0800
   Ewald A, 2011, AM FAM PHYSICIAN, V83, P417
   Fernandez JW, 2011, J ORTHOP RES, V29, P1168, DOI 10.1002/jor.21345
   Hata A, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022061
   Jiang SC, 2015, INT J MOL SCI, V16, P6932, DOI 10.3390/ijms16046932
   Jiang SC, 2014, BIOMATERIALS, V35, P9920, DOI 10.1016/j.biomaterials.2014.08.028
   Kao CW, 2017, INT J NANOMED, V12, P5893, DOI 10.2147/IJN.S140825
   Kramer EA, 2018, ANNU REV BIOMED ENG, V20, P1, DOI 10.1146/annurev bioeng 071516 044702
   Li J, 2017, MAT SCI ENG C MATER, V78, P988, DOI 10.1016/j.msec.2017.04.017
   Li JN, 2017, ACTA BIOMATER, V61, P21, DOI 10.1016/j.actbio.2017.08.002
   Li LF, 2016, MAT SCI ENG C MATER, V61, P220, DOI 10.1016/j.msec.2015.12.028
   Li LY, 2022, ADV FIBER MATER, V4, P475, DOI 10.1007/s42765 021 00121 8
   Li Y, 2021, ADV FIBER MATER, V3, P26, DOI 10.1007/s42765 020 00059 3
   Liu CJ, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/2354325
   Liu S, 2017, J CONTROL RELEASE, V264, P1, DOI 10.1016/j.jconrel.2017.08.011
   Liu S, 2013, TISSUE ENG PT A, V19, P529, DOI [10.1089/ten.tea.2012.0208, 10.1089/ten.TEA.2012.0208]
   Liu WY, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13060916
   Luo SH, 2017, POLYM CHEM UK, V8, P7009, DOI 10.1039/c7py01213f
   Mosher CZ, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/ac0964
   Neelakantan H, 2018, BIOCHEM PHARMACOL, V147, P141, DOI 10.1016/j.bcp.2017.11.007
   Nolte M, 2020, TRENDS CELL BIOL, V30, P49, DOI 10.1016/j.tcb.2019.10.002
   Pelipenko J, 2015, EUR J PHARM SCI, V66, P29, DOI 10.1016/j.ejps.2014.09.022
   Qin ZY, 2020, CARBOHYD POLYM, V247, DOI 10.1016/j.carbpol.2020.116734
   Stauber T, 2020, MATRIX BIOL, V85 86, P68, DOI 10.1016/j.matbio.2019.07.008
   Sultana T, 2020, CARBOHYD POLYM, V229, DOI 10.1016/j.carbpol.2019.115552
   Sun C, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105193
   Tan V, 2010, J HAND SURG AM, V35A, P941, DOI 10.1016/j.jhsa.2010.02.033
   Titan AL, 2019, PLAST RECONSTR SURG, V144, p639E, DOI 10.1097/PRS.0000000000006048
   Wen X, 2022, ADV FIBER MATER, V4, P145, DOI 10.1007/s42765 021 00113 8
   Wu GB, 2021, ACS BIOMATER SCI ENG, V7, P5739, DOI 10.1021/acsbiomaterials.1c00747
   Xu TT, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900123
   Yang XP, 2020, ADV FIBER MATER, V2, P105, DOI 10.1007/s42765 020 00027 x
   Yao ZX, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00906 4
   Yin J, 2022, ADV FIBER MATER, V4, P832, DOI 10.1007/s42765 022 00141 y
   Zhang Q, 2021, ACTA BIOMATER, V124, P15, DOI 10.1016/j.actbio.2021.01.027
   Zhu JX, 2015, COLLOID SURFACE B, V135, P416, DOI 10.1016/j.colsurfb.2015.06.049
NR 45
TC 11
Z9 12
U1 4
U2 89
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2192 2640
EI 2192 2659
J9 ADV HEALTHC MATER
JI Adv. Healthc. Mater.
PD JUN
PY 2023
VL 12
IS 15
DI 10.1002/adhm.202203078
EA MAR 2023
PG 12
WC Engineering, Biomedical; Nanoscience & Nanotechnology; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Science & Technology   Other Topics; Materials Science
GA J4FH9
UT WOS:000947037600001
PM 36864645
DA 2025 08 17
ER

PT J
AU Chang, YC
   Stoyanova, R
   Danilova, S
   Pretell Mazzini, JA
   Kerr, DA
   Wilky, BA
   Subhawong, T
AF Chang, Yu Cherng
   Stoyanova, Radka
   Danilova, Sofia
   Pretell Mazzini, Juan A.
   Kerr, Darcy A.
   Wilky, Breelyn A.
   Subhawong, Ty
TI Radiomics on radiography predicts giant cell tumor histologic response
   to denosumab
SO SKELETAL RADIOLOGY
LA English
DT Article
DE Giant cell tumor; Denosumab; Treatment response; Radiomics; Radiograph
AB Objective Denosumab is an established targeted systemic therapy for treatment of giant cell tumor of bone (GCTB). We sought to determine whether treatment response could be quantified from radiomics analysis of radiographs taken longitudinally during treatment. Materials and methods Pre  and post treatment radiographs of 10 GCTB tumors from 10 patients demonstrating histologic response after treatment with denosumab were analyzed. Intensity  and texture based radiomics features for each manually segmented tumor were calculated. Radiomics features were compared pre  and post treatment in tumors. Results Mean intensity (p = 0.033) significantly increased while skewness (p = 0.028) significantly decreased after treatment. Post treatment increases in fractal dimensions (p = 0.057) and abundance (p = 0.065) approached significance. A potential linear correlation in mean (p = 0.005; Delta Mean = 0.022 * duration   0.026) with treatment duration was observed. Conclusion Radiomics analysis of plain radiographs quantifies time dependent matrix mineralization and trabecular reconstitution that mark positive response of giant cell tumors of bone to denosumab.
C1 [Chang, Yu Cherng] Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
   [Stoyanova, Radka] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.
   [Stoyanova, Radka; Pretell Mazzini, Juan A.; Subhawong, Ty] Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
   [Danilova, Sofia; Subhawong, Ty] Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.
   [Pretell Mazzini, Juan A.] Univ Miami, Miller Sch Med, Dept Orthoped, Miami, FL 33136 USA.
   [Kerr, Darcy A.] Dartmouth Hitchcock Med Ctr, Dept Pathol & Lab Med, Lebanon, NH USA.
   [Kerr, Darcy A.] Geisel Sch Med Dartmouth, Hanover, NH USA.
   [Wilky, Breelyn A.] Univ Colorado Hosp, Dept Med Med Oncol, Aurora, CO USA.
C3 University of Miami; University of Miami; University of Miami;
   University of Miami; Dartmouth College; Dartmouth College; University of
   Colorado System; University of Colorado Hospital
RP Subhawong, T (通讯作者)，Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.; Subhawong, T (通讯作者)，Univ Miami, Miller Sch Med, Dept Radiol, Miami, FL 33136 USA.
EM tsubhawong@med.miami.edu
RI Subhawong, Ty/AFH 7771 2022; Pretell, Juan/AAD 9085 2022
FU NEI fellowship [1F30EY027162]
FX Y.C. is funded by NEI fellowship 1F30EY027162.
CR BINI SA, 1995, CLIN ORTHOP RELAT R, P245
   Branstetter DG, 2012, CLIN CANCER RES, V18, P4415, DOI 10.1158/1078 0432.CCR 12 0578
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Demirsoy U, 2014, J PEDIAT HEMATOL ONC, V36, P156, DOI 10.1097/MPH.0000000000000034
   Garcia RA, 2011, SEMIN DIAGN PATHOL, V28, P73, DOI 10.1053/j.semdp.2011.02.013
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   Karras NA, 2013, J CLIN ONCOL, V31, pE200, DOI 10.1200/JCO.2012.46.4255
   Klenke FM, 2011, CLIN ORTHOP RELAT R, V469, P591, DOI 10.1007/s11999 010 1501 7
   Mendenhall WM, 2006, AM J CLIN ONCOL CANC, V29, P96, DOI 10.1097/01.coc.0000195089.11620.b7
   Oguro S, 2018, MAGN RESON MED SCI, V17, P325, DOI 10.2463/mrms.mp.2017 0072
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tolle CR, 2008, PHYSICA D, V237, P306, DOI 10.1016/j.physd.2007.09.017
   Treffel M, 2020, AM J SURG PATHOL, V44, P1, DOI 10.1097/PAS.0000000000001388
   Trieb K, 2001, EUR J SURG ONCOL, V27, P200, DOI 10.1053/ejso.2000.1086
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Van Der Heijden L, 2015, ACTA ORTHOP, V86, P393, DOI 10.3109/17453674.2014.1002345
   Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506
   Yamagishi T, 2016, ONCOL LETT, V11, P243, DOI 10.3892/ol.2015.3858
   Yi J, 2018, J ORTHOP SCI, V23, P570, DOI 10.1016/j.jos.2018.01.006
NR 19
TC 4
Z9 4
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0364 2348
EI 1432 2161
J9 SKELETAL RADIOL
JI Skeletal Radiol.
PD SEP
PY 2021
VL 50
IS 9
BP 1881
EP 1887
DI 10.1007/s00256 021 03752 5
EA MAR 2021
PG 7
WC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Radiology, Nuclear Medicine & Medical Imaging
GA TK3SG
UT WOS:000629929300002
PM 33733693
DA 2025 08 17
ER

PT J
AU Sato, R
   Maruyama, K
   Nemoto, E
   Sakisaka, Y
   Suzuki, S
   Li, JJ
   Numazaki, K
   Tada, H
   Yamada, S
AF Sato, Rei
   Maruyama, Kentaro
   Nemoto, Eiji
   Sakisaka, Yukihiko
   Suzuki, Shigeki
   Li, Jiajun
   Numazaki, Kento
   Tada, Hiroyuki
   Yamada, Satoru
TI Extracellular Vesicles Derived From Murine Cementoblasts Possess the
   Potential to Increase Receptor Activator of Nuclear Factor κB
   Ligand Induced Osteoclastogenesis
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Article
DE extracellular vesicles; cementoblasts; RANKL; osteoclastogenesis;
   cementum resorption
ID GENE EXPRESSION; EXOSOMES; DIFFERENTIATION; OSTEOBLASTS; PROLIFERATION;
   MODULATION; REGULATOR; MECHANISM; PROTEIN; RANKL
AB Cementum resorption, unlike bone resorption, is clinically known to occur only with limited pathological stimuli, such as trauma, orthodontic forces, and large apical periodontitis; however, the molecular mechanisms that control osteoclast formation on the cementum surface remain unclear. In this study, we focused on extracellular vesicles (EVs) secreted by cementoblasts and analyzed their effects on osteoclast differentiation. EVs were extracted from the conditioned medium (CM) of the mouse cementoblast cell line OCCM 30. Transmission electron microscopy (TEM) analysis confirmed the presence of EVs with a diameter of approximately 50 200 nm. The effect of the EVs on osteoclast differentiation was examined using the mouse osteoclast progenitor cell line RAW 264.7 with recombinant receptor activator of nuclear factor (NF) kappa B ligand (rRANKL) stimulation. EVs enhanced the formation of tartrate resistant acid phosphatase (TRAP) activity positive cells upon rRANKL stimulation. EVs also enhanced the induction of osteoclast associated gene and protein expression in this condition, as determined by real time PCR and Western blotting, respectively. On the other hand, no enhancing effect of EVs was observed without rRANKL stimulation. A Western blot analysis revealed no expression of receptor activator of NF kappa B ligand (RANKL) in EVs themselves. The effect on rRANKL induced osteoclast differentiation was examined using the CM of cementoblasts in terms of TRAP activity positive cell formation and osteoclast associated gene expression. The conditioned medium partly inhibited rRANKL induced osteoclast differentiation and almost completely suppressed its enhancing effect by EVs. These results indicate that cementoblasts secreted EVs, which enhanced RANKL induced osteoclast differentiation, and simultaneously produced soluble factors that neutralized this enhancing effect of EVs, implicating this balance in the regulation of cementum absorption. A more detailed understanding of this crosstalk between cementoblasts and osteoclasts will contribute to the development of new therapies for pathological root resorption.
C1 [Sato, Rei; Maruyama, Kentaro; Nemoto, Eiji; Sakisaka, Yukihiko; Suzuki, Shigeki; Li, Jiajun; Yamada, Satoru] Tohoku Univ, Grad Sch Dent, Div Periodontol & Endodontol, Sendai, Miyagi, Japan.
   [Numazaki, Kento] Tohoku Univ, Grad Sch Dent, Div Orthodont & Dentofacial Orthoped, Sendai, Miyagi, Japan.
   [Tada, Hiroyuki] Tohoku Univ, Grad Sch Dent, Div Oral Immunol, Sendai, Miyagi, Japan.
C3 Tohoku University; Tohoku University; Tohoku University
RP Nemoto, E (通讯作者)，Tohoku Univ, Grad Sch Dent, Div Periodontol & Endodontol, Sendai, Miyagi, Japan.
EM e nemoto@dent.tohoku.ac.jp
RI Numazaki, Kento/IQT 8276 2023
OI Numazaki, Kento/0009 0003 3563 2403; Suzuki, Shigeki/0000 0003 0888 4050
FU Grants in Aid for Scientific Research [20J21391, 21K16983, 20K09933]
   Funding Source: KAKEN
CR Anderson JD, 2016, STEM CELLS, V34, P601, DOI 10.1002/stem.2298
   Bao XF, 2013, INT J MOL SCI, V14, P21140, DOI 10.3390/ijms141021140
   Barile L, 2017, EUR HEART J, V38, P1372, DOI 10.1093/eurheartj/ehw304
   Berry JE, 2008, ORAL DIS, V14, P713, DOI 10.1111/j.1601 0825.2008.01489.x
   Boabaid F, 2004, J PERIODONTOL, V75, P1247, DOI 10.1902/jop.2004.75.9.1247
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Cappariello A, 2018, J BONE MINER RES, V33, P517, DOI 10.1002/jbmr.3332
   Chen B, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/731039
   Cheng P, 2013, J BONE MINER RES, V28, P1180, DOI 10.1002/jbmr.1845
   Cui YZ, 2016, FEBS LETT, V590, P185, DOI 10.1002/1873 3468.12024
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   Deng LL, 2015, BONE, V79, P37, DOI 10.1016/j.bone.2015.05.022
   Feller L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4864195
   Feng W, 2019, J ORAL BIOSCI, V61, P16, DOI 10.1016/j.job.2019.01.001
   Ferguson SW, 2016, J CONTROL RELEASE, V228, P179, DOI 10.1016/j.jconrel.2016.02.037
   Franceschetti T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107262
   김미리, 2008, International Journal of Oral Biology, V33, P113
   Haj Salem I, 2018, ALLERGY, V73, P178, DOI 10.1111/all.13234
   Holliday LS, 2021, EXTRACELL VESICLES C, V2, P18, DOI 10.20517/evcna.2020.02
   Huynh NCN, 2017, INT J ORAL SCI, V9, DOI 10.1038/ijos.2017.45
   Jiang LR, 2019, BIOCHEM BIOPH RES CO, V508, P735, DOI 10.1016/j.bbrc.2018.11.189
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kim K, 2005, J BIOL CHEM, V280, P35209, DOI 10.1074/jbc.M505815200
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Kitaura H, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145169
   Kojima M, 2018, FASEB J, V32, P97, DOI 10.1096/fj.201700488R
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kulshreshtha A, 2013, J ALLERGY CLIN IMMUN, V131, P1194, DOI 10.1016/j.jaci.2012.12.1565
   Lamichhane TN, 2015, TISSUE ENG PART B RE, V21, P45, DOI [10.1089/ten.teb.2014.0300, 10.1089/ten.TEB.2014.0300]
   Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552
   Liu D, 2003, INT J MOL MED, V11, P17
   Lv PY, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01815 3
   Maeda K, 2012, NAT MED, V18, P405, DOI 10.1038/nm.2653
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641
   Muller L, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1261243
   Nakao Y, 2021, ACTA BIOMATER, V122, P306, DOI 10.1016/j.actbio.2020.12.046
   Nemoto E, 2008, J PERIODONTAL RES, V43, P585, DOI 10.1111/j.1600 0765.2008.01096.x
   Nemoto E, 2006, J DENT RES, V85, P733, DOI 10.1177/154405910608500809
   Ni HQ, 2019, FRONT NEUROSCI SWITZ, V13, DOI 10.3389/fnins.2019.00014
   Oka H, 2007, J DENT RES, V86, P974, DOI 10.1177/154405910708601011
   Oshiro T, 2002, ANAT REC, V266, P218, DOI 10.1002/ar.10061
   Rosenberger L, 2019, SCI REP UK, V9, DOI 10.1038/s41598 018 36855 6
   Sakisaka Y, 2015, EXP CELL RES, V336, P85, DOI 10.1016/j.yexcr.2015.06.013
   Saygin NE, 2000, PERIODONTOL 2000, V24, P73, DOI 10.1034/j.1600 0757.2000.2240105.x
   Sinha S, 2016, J CELL BIOL, V214, P197, DOI 10.1083/jcb.201601025
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood 2010 10 311415
   Wang R, 2020, INT IMMUNOPHARMACOL, V81, DOI 10.1016/j.intimp.2019.106030
   Wang XQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193059
   Wang ZY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01310
   Zhang YH, 2017, J PROTEOME RES, V16, P170, DOI 10.1021/acs.jproteome.6b00599
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
NR 54
TC 4
Z9 4
U1 1
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 1664 042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD FEB 14
PY 2022
VL 13
AR 825596
DI 10.3389/fphys.2022.825596
PG 14
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA ZI5XZ
UT WOS:000761695300001
PM 35237179
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jiang, L
   Zhao, XY
   Pei, JJ
   Mei, LJ
   Cui, YL
   Wang, S
   Shao, Y
   Zhang, XL
   Tao, YD
AF Jiang, Lei
   Zhao, Xiaoying
   Pei, Jinjin
   Mei, Lijuan
   Cui, Yulei
   Wang, Shuo
   Shao, Yun
   Zhang, Xiaoling
   Tao, Yanduo
TI Daily chemical evodiamine from Chinese prickly ash attenuates osteoclast
   differentiation through RANKL induced NFAT pathways
SO JOURNAL OF FUNCTIONAL FOODS
LA English
DT Article
DE Evodiamine; Zanthoxylum bungeanum; RANKL; Osteoclast differentiation;
   ERK; NFATc1
ID BONE LOSS; CANCER; PROLIFERATION; APOPTOSIS; OSTEOPOROSIS; RESORPTION;
   CALCIUM; CELLS
AB Osteoclasts (OCs) play an important role in a variety of lytic bone diseases. New bone protective therapies exploration has been focused on the suppression of OC formation. In this study, we report that daily chemical evodiamine from Chinese prickly ash, a very common sauce used for stewing meats, attenuates RANKL induced OC formation, the expression level of OC specific marker genes and OC marker protein in vitro. Mechanistically, evodiamine dose  and time dependently blocked the RANKL induced activation of ERK and c Fos as well as the induction of NFATc1, which is essential for OC formation. These data suggest that evodiamine might be a useful alternative therapy in preventing or treating osteolytic diseases. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Jiang, Lei; Pei, Jinjin; Mei, Lijuan; Cui, Yulei; Wang, Shuo; Shao, Yun; Tao, Yanduo] Chinese Acad Sci, Northwest Plateau Inst Biol, Key Lab Tibetan Med Res, Xining 810001, Qinghai, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Univ Chinese Acad Sci, Shanghai 200031, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Shanghai Jiao Tong Univ, Sch Med SJTUSM, Shanghai 200031, Peoples R China.
   [Zhao, Xiaoying; Zhang, Xiaoling] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200031, Peoples R China.
   [Pei, Jinjin] Shaanxi Univ Technol, Shaanxi Key Lab Bioresources & Biol, Hanzhong 723001, Peoples R China.
   [Cui, Yulei; Wang, Shuo] Univ Chinese Acad Sci, Beijing 100039, Peoples R China.
C3 Chinese Academy of Sciences; Northwest Institute of Plateau Biology,
   CAS; Chinese Academy of Sciences; University of Chinese Academy of
   Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of
   Sciences; Shaanxi University of Technology; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS
RP Zhang, XL; Tao, YD (通讯作者)，23 Xinning Rd, Xining, Qinghai, Peoples R China.
EM Chrisjiang27@163.com
RI cui, yulei/ACM 6486 2022; Zhang, Xiaoling/J 1666 2016; shao,
   yun/KLC 3238 2024
OI Zhang, Xiaoling/0000 0002 0134 1347; Cui, Yulei/0000 0002 9777 2431; 
FU Natural Science Foundation of Qinghai [2016 ZJ 942Q]; West Light
   Foundation of the Chinese Academy of Sciences [Y629071211]; Important
   Qinghai Science & Technology Specific Projects [2014 GX A3A 01];
   National Natural Science Foundation of China [81190133, 81301548];
   Shanghai Municipal Natural Science Foundation [16ZR1441700, 13ZR1424100]
FX This work was supported by grants from Natural Science Foundation of
   Qinghai (Grant No. 2016 ZJ 942Q), West Light Foundation of the Chinese
   Academy of Sciences (Grant No. Y629071211), Important Qinghai Science &
   Technology Specific Projects (Grant No. 2014 GX A3A 01), National
   Natural Science Foundation of China (Grant No. 81190133, 81301548) and
   Shanghai Municipal Natural Science Foundation (Grant No. 16ZR1441700,
   13ZR1424100).
CR Akiyama T, 2008, MOL CANCER THER, V7, P3461, DOI 10.1158/1535 7163.MCT 08 0530
   Breuksch I, 2016, J BONE ONCOL, V5, P143, DOI 10.1016/j.jbo.2016.06.004
   Chawalitpong S, 2016, EUR J PHARMACOL, V788, P351, DOI 10.1016/j.ejphar.2016.08.012
   Cheon YH, 2016, J BONE MINER RES, V31, P403, DOI 10.1002/jbmr.2612
   Choi J, 2013, CELL SIGNAL, V25, P1222, DOI 10.1016/j.cellsig.2013.02.015
   Ge X, 2016, MOL MED REP, V14, P4551, DOI 10.3892/mmr.2016.5798
   Goessl C, 2012, ANN NY ACAD SCI, V1263, P29, DOI 10.1111/j.1749 6632.2012.06674.x
   Hiraga T, 2016, EXPERT OPIN INV DRUG, V25, P319, DOI 10.1517/13543784.2016.1142972
   Hu YY, 2016, MICROB PATHOGENESIS, V99, P51, DOI 10.1016/j.micpath.2016.08.006
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Jonasson G, 2016, CLIN COSMET INV DENT, V8, P95, DOI 10.2147/CCIDE.S92774
   Kanagawa H, 2016, J BONE MINER METAB, V34, P526, DOI 10.1007/s00774 015 0702 2
   Kim HJ, 2017, CELL SIGNAL, V29, P226, DOI 10.1016/j.cellsig.2016.11.007
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Lin L, 2016, MOL MED REP, V14, P2832, DOI 10.3892/mmr.2016.5575
   Liu H, 2016, ONCOTARGETS THER, V9, P4121, DOI 10.2147/OTT.S104729
   McDonald M. M., 2016, ADIPOSE BONE MYELOMA
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Nakashima T, 2012, TRENDS ENDOCRIN MET, V23, P582, DOI 10.1016/j.tem.2012.05.005
   Nevius E, 2016, CLIN REV ALLERG IMMU, V51, P59, DOI 10.1007/s12016 015 8520 9
   Panagopoulos V, 2017, MOL CELL ENDOCRINOL, V440, P8, DOI 10.1016/j.mce.2016.11.007
   QIAO H, 2016, CELL DEATH DIS, V7
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Shi L, 2016, TUMOR BIOL, V37, P12791, DOI 10.1007/s13277 016 5251 3
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Wang X, 2016, EUR J PHARMACOL, V774, P34, DOI 10.1016/j.ejphar.2016.01.008
   Xu F, 2015, STUDY ANTIOSTEOPOROS
   Zhang Y, 2016, BIOL PHARM BULL, V39, P2028, DOI 10.1248/bpb.b16 00522
NR 30
TC 7
Z9 8
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1756 4646
J9 J FUNCT FOODS
JI J. Funct. Food.
PD OCT
PY 2017
VL 37
BP 594
EP 602
DI 10.1016/j.jff.2017.07.042
PG 9
WC Food Science & Technology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology; Nutrition & Dietetics
GA FJ6JF
UT WOS:000412863400060
DA 2025 08 17
ER

PT J
AU Duque, G
   Vidal, C
   Li, W
   Al Saedi, A
   Khalil, M
   Lim, CK
   Myers, DE
   Guillemin, GJ
AF Duque, Gustavo
   Vidal, Christopher
   Li, Wei
   Al Saedi, Ahmed
   Khalil, Mamdouh
   Lim, Chai K.
   Myers, Damian E.
   Guillemin, Gilles J.
TI Picolinic Acid, a Catabolite of Tryptophan, Has an Anabolic Effect on
   Bone In Vivo
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE KYNURENINE; OSTEOANABOLICS; OSTEOBLASTS; OSTEOPOROSIS; PICOLINIC ACID;
   WNT
ID KYNURENINE PATHWAY METABOLISM; OSTEOPOROSIS; SEROTONIN; MASS
AB Fractures attributable to osteoporosis have a severe impact on our older population. Reports of side effects with commonly prescribed osteoporosis drugs have led to the investigation of new and safer treatments with novel mechanisms of action. Picolinic acid (PIC), a catabolite of tryptophan, induces in vitro osteogenic differentiation of mesenchymal stem cells. Here we demonstrate that PIC has an anabolic effect on bone in vivo by increasing bone formation, bone mass, and bone strength in normal and ovariectomized C57BL/6 mice. Activation of the osteogenic pathways triggered this osteoanabolic response without any cross related effects on mineral absorption or calciotropic hormones. Because PIC was also well tolerated and absorbed with no side effects, it is an ideal potential candidate for the treatment of osteoporosis. (c) 2020 American Society for Bone and Mineral Research.
C1 [Duque, Gustavo; Al Saedi, Ahmed; Myers, Damian E.] Univ Melbourne, Australian Inst Musculoskeletal Sci AIMSS, 176 Furlong Rd, St Albans, Vic 3021, Australia.
   [Duque, Gustavo; Al Saedi, Ahmed; Myers, Damian E.] Western Hlth, 176 Furlong Rd, St Albans, Vic 3021, Australia.
   [Duque, Gustavo; Al Saedi, Ahmed; Myers, Damian E.] Univ Melbourne, Melbourne Med Sch, Dept Med Western Hlth, St Albans, Australia.
   [Vidal, Christopher; Li, Wei] Univ Sydney, Sydney Med Sch Nepean, Penrith, NSW, Australia.
   [Khalil, Mamdouh] Univ Sydney, Sydney Med Sch Concord, ANZAC Res Inst, Concord, Australia.
   [Lim, Chai K.; Guillemin, Gilles J.] Macquarie Univ, Fac Med & Hlth Sci, Neuroinflammat Grp, Sydney, NSW, Australia.
C3 Australian Institute for Musculoskeletal Science; University of
   Melbourne; University of Melbourne; University of Sydney; University of
   Sydney; ANZAC Research Institute; Macquarie University
RP Duque, G (通讯作者)，Univ Melbourne, Australian Inst Musculoskeletal Sci AIMSS, 176 Furlong Rd, St Albans, Vic 3021, Australia.; Duque, G (通讯作者)，Western Hlth, 176 Furlong Rd, St Albans, Vic 3021, Australia.
EM gustavo.duque@unimelb.edu.au
RI ; Duque, Gustavo/G 6656 2015; Myers, Damian/L 5302 2013; GUILLEMIN,
   Gilles/C 3878 2015; Lim, Edwin/R 5001 2019; Duque, Gustavo/HDO 1243 2022
OI Guillemin, Gilles/0000 0001 8105 4470; Duque,
   Gustavo/0000 0001 8126 0637; Myers, Damian/0000 0002 7569 9907; Al
   Saedi, Ahmed/0000 0002 2479 5317; Lim, Edwin/0000 0003 3526 8405
FU Commercial Development & Industry Partnerships (CDIP) grant from
   Sydnovate (The University of Sydney); Nepean Medical Research
   Foundation; Australian Institute for Musculoskeletal Science (AIMSS);
   Rebecca L. Cooper Foundation; Australian National Health and Medical
   Research Council (NHMRC); Australian Research Council (ARC); Macquarie
   University
FX This study was supported by a Commercial Development & Industry
   Partnerships (CDIP) grant from Sydnovate (The University of Sydney) and
   seed grants from the Nepean Medical Research Foundation and the
   Australian Institute for Musculoskeletal Science (AIMSS) to CV, AAS, and
   GD. CV was funded by a grant from the Rebecca L. Cooper Foundation. GJG
   is funded by grants from the Australian National Health and Medical
   Research Council (NHMRC), Australian Research Council (ARC), and
   Macquarie University. The authors thank Prof Nicholas Hunt from the
   Kolling Institute (Sydney, Australia) for his scientific advice and Dr
   Sara Vogrin for her assistance with the statistical analyses.
CR [Anonymous], 2017, RHEUMATOLOGY, V56, pe22
   Apalset EM, 2014, CLIN EXP IMMUNOL, V176, P452, DOI 10.1111/cei.12288
   Bliuc D, 2016, CURR OPIN RHEUMATOL, V28, P413, DOI 10.1097/BOR.0000000000000300
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Braidy N, 2017, NEURAL REGEN RES, V12, P39, DOI 10.4103/1673 5374.198971
   Braidy N, 2011, FEBS J, V278, P4425, DOI 10.1111/j.1742 4658.2011.08366.x
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   de Bie J, 2016, NEUROTOX RES, V30, P285, DOI 10.1007/s12640 016 9641 5
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Ducy P, 2011, CURR OPIN PHARMACOL, V11, P34, DOI 10.1016/j.coph.2011.01.007
   Ducy P, 2010, J CELL BIOL, V191, P7, DOI 10.1083/jcb.201006123
   Duque G, 2013, J BONE MINER RES, V28, P639, DOI 10.1002/jbmr.1782
   Duque G, 2011, J BONE MINER RES, V26, P1472, DOI 10.1002/jbmr.350
   El Refaey M, 2017, J BONE MINER RES, V32, P2182, DOI 10.1002/jbmr.3224
   Forrest CM, 2006, CLIN EXP PHARMACOL P, V33, P1078, DOI 10.1111/j.1440 1681.2006.04490.x
   Goltzman D, 2011, J BONE MINER RES, V26, P1997, DOI 10.1002/jbmr.462
   Grant RS, 2009, INT J TRYPTOPHAN RES, V2, P71
   Guillemin GJ, 2007, J NEUROSCI, V27, P12884, DOI 10.1523/JNEUROSCI.4101 07.2007
   Guillemin GJ, 2012, FEBS J, V279, P1356, DOI 10.1111/j.1742 4658.2012.08485.x
   Harslof T, 2016, CURR OPIN PHARMACOL, V28, P38, DOI 10.1016/j.coph.2016.02.012
   Jones SP, 2013, INT J TRYPTOPHAN RES, V6, P57, DOI 10.4137/IJTR.S12626
   Karsenty G, 2011, ANNU REV MED, V62, P323, DOI 10.1146/annurev med 090710 133426
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim BJ, 2019, J CLIN ENDOCR METAB, V104, P2334, DOI 10.1210/jc.2018 02481
   LAPIN IP, 1983, J NEURAL TRANSM, V56, P177, DOI 10.1007/BF01243276
   Li GW, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1403 x
   Li JF, 2017, J ORTHOP RES, V35, P812, DOI 10.1002/jor.23339
   Michalowska M, 2015, J PHYSIOL PHARMACOL, V66, P779
   Power M, 2011, CURR DIABETES REP, V11, P173, DOI 10.1007/s11892 011 0184 0
   Russow G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010083
   Saito T, 2017, OSTEOPOROSIS INT, V28, P3289, DOI 10.1007/s00198 017 4175 0
   SEAL CJ, 1985, J NUTR, V115, P986, DOI 10.1093/jn/115.8.986
   Singh L, 2018, CURR OSTEOPOROS REP, V16, P130, DOI 10.1007/s11914 018 0427 y
   SUZUKI K, 1957, J PHYS CHEM US, V61, P229, DOI 10.1021/j150548a017
   Vécsei L, 2013, NAT REV DRUG DISCOV, V12, P64, DOI 10.1038/nrd3793
   Vidal C, 2015, STEM CELLS, V33, P111, DOI 10.1002/stem.1836
   Vidal C, 2012, STEM CELLS, V30, P1042, DOI 10.1002/stem.1063
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
NR 39
TC 23
Z9 23
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2020
VL 35
IS 11
BP 2275
EP 2288
DI 10.1002/jbmr.4125
EA AUG 2020
PG 14
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OP6IX
UT WOS:000559832500001
PM 32629550
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, DJ
   Liu, J
   Yang, CF
   Tian, Y
   Yin, C
   Hu, LF
   Chen, ZH
   Zhao, F
   Zhang, R
   Lu, AP
   Zhang, G
   Qian, AR
AF Li, Dijie
   Liu, Jin
   Yang, Chaofei
   Tian, Ye
   Yin, Chong
   Hu, Lifang
   Chen, Zhihao
   Zhao, Fan
   Zhang, Ru
   Lu, Aiping
   Zhang, Ge
   Qian, Airong
TI Targeting long noncoding RNA PMIF facilitates osteo progenitor cells
   migrating to bone formation surface to promote bone formation during
   aging
SO THERANOSTICS
LA English
DT Article
DE long non coding RNA; osteoprogenitor cells; cell migration; bone
   formation; aging
ID MESENCHYMAL STEM CELLS; AGE RELATED CHANGES; BETA ACTIN; ADHESION
   DYNAMICS; DIFFERENTIATION; INVASION; PROLIFERATION; MECHANISMS;
   RESORPTION; ACF7
AB Rationale: The migration of mesenchymal osteoprogenitor cells (OPCs) to bone formation surface is the initial step of osteoblastogenesis before they undergo osteoblast differentiation and maturation for governing bone formation. However, whether the migration capacity of OPCs is compromised during aging and how it contributes to the aging related bone formation reduction remain unexplored. In the present study, we identified a migration inhibitory factor (i.e., long noncoding RNA PMIF) and examined whether targeting Inc PMIF could facilitate osteoprogenitor cells migrating to bone formation surface to promote bone formation during aging.
   Methods: Primary OPCs from young (6 momth old) and aged (18 momth old) C57BL/6 mice and stable lnc PMIF knockdown/overexpression cell lines were used for in vitro and in vivo cell migration assay (i.e., wound healing assay, transwell assay and cell intratibial injection assay). RNA pulldown MS/WB and RIP qPCR were performed to identify the RNA binding proteins (RBPs) of lnc PMIF. Truncations of lnc PMIF and the identified RBP were engaged to determine the interaction motif between them by RNA pulldown WB and EMSA. By cell based therapy approach and by pharmacological approach, small interfering RNA (siRNA) mediated lnc PMIF knockdown were used in aged mice. The cell migration ability was evaluated by transwell assay and cell intratibial injection assay. The bone formation was evaluated by microCT analysis and bone morphometry analysis.
   Results: We reported that the decreased bone formation was accompanied by the reduced migration capacity of the bone marrow mesenchymal stem cells (BMSCs, the unique source of OPCs in bone marrow) in aged mice. We further identified that the long non coding RNA PMIF (postulated migration inhibitory factor) (i.e., lnc PMIF) was highly expressed in BMSCs from aged mice and responsible for the reduced migration capacity of aged OPCs to bone formation surface. Mechanistically, we found that lnc PMIF could bind to human antigen R (HuR) for interrupting the HuR beta actin mRNA interaction, therefore inhibit the expression of beta actin for suppressing the migration of aged OPCs. We also authenticated a functionally conserved human lncRNA ortholog of the murine lnc PMIF. By cell based therapy approach, we demonstrated that replenishing the aged BMSCs with small interfering RNA (siRNA) mediated lnc PMIF knockdown could promote bone formation in aged mice. By pharmacological approach, we showed that targeted delivery of lnc PMIF siRNA approaching the OPCs around the bone formation surface could also promote bone formation in aged mice.
   Conclusion: Toward translational medicine, this study hints that targeting lnc PMIF to facilitate aged OPCs migrating to bone formation surface could be a brand new anabolic strategy for aging related osteoporosis.
C1 [Li, Dijie; Yang, Chaofei; Tian, Ye; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Zhang, Ru; Qian, Airong] Northwestern Polytech Univ, Xian Key Lab Special Med & Hlth Engn, Key Lab Space Biosci & Biotechnol, Lab Bone Metab,Sch Life Sci, Xian, Peoples R China.
   [Li, Dijie; Liu, Jin; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinses Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China.
   [Liu, Jin; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Shenzhen Inst Res & Continuing Educ IRACE, Shenzhen, Peoples R China.
   [Li, Dijie; Yang, Chaofei; Tian, Ye; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Zhang, Ru; Qian, Airong] Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci, Xian, Peoples R China.
   [Li, Dijie; Yang, Chaofei; Tian, Ye; Yin, Chong; Hu, Lifang; Chen, Zhihao; Zhao, Fan; Zhang, Ru; Qian, Airong] Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian, Peoples R China.
C3 Northwestern Polytechnical University; Hong Kong Baptist University;
   Hong Kong Baptist University; Northwestern Polytechnical University;
   Northwestern Polytechnical University
RP Qian, AR (通讯作者)，Northwestern Polytech Univ, Xian Key Lab Special Med & Hlth Engn, Key Lab Space Biosci & Biotechnol, Lab Bone Metab,Sch Life Sci, Xian, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinses Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Shenzhen Inst Res & Continuing Educ IRACE, Shenzhen, Peoples R China.; Qian, AR (通讯作者)，Northwestern Polytech Univ, Res Ctr Special Med & Hlth Syst Engn, Sch Life Sci, Xian, Peoples R China.; Qian, AR (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, NPU UAB Joint Lab Bone Metab, Xian, Peoples R China.
EM aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk; qianair@nwpu.edu.cn
RI chen, zhihao/GXM 3816 2022; Zhang, Ge/N 4150 2013; Hu,
   Lifang/W 8020 2019; LU, Aiping/JDX 0577 2023; Li, Dijie/KVB 3667 2024;
   Chen, Zhihao/ACK 3514 2022
OI Qian, Airong/0000 0002 0740 9218; Chen, Zhihao/0000 0003 0128 1409
FU National Key R&D Program of China [2018YFA0800804]; National Natural
   Science Foundation Council of China [82072106, 31570940, 81702189];
   Shaanxi Province [2018KWZ 10, 2018SF263]; Fundamental Research Funds for
   the Central Universities of China [3102019ghxm012]; Hong Kong General
   Research Fund [HKBU12102914, HKBU12101117, HKBU12100918, HKBU12136616,
   HKBU12103519]; Interdisciplinary Research Clusters Matching Scheme of
   Hong Kong Baptist University [RC IRCs/17 18/02]; China Postdoctoral
   Science Foundation [2020M683573]; Guangdong Basic and Applied Basic
   Research Foundation [2020A1515110630]
FX This work was supported by the National Key R&D Program of China
   (2018YFA0800804 to G.Z.), the National Natural Science Foundation
   Council of China (82072106 and 31570940 to A.Q., 81702189 to J.L.), the
   Shaanxi Province (2018KWZ 10 and 2018SF263 to A.Q.), the Fundamental
   Research Funds for the Central Universities of China (3102019ghxm012 to
   A.Q.), the Hong Kong General Research Fund (HKBU12102914, HKBU12101117
   and HKBU12100918 to G.Z., HKBU12136616 and HKBU12103519 to J.L.), the
   Interdisciplinary Research Clusters Matching Scheme of Hong Kong Baptist
   University (RC IRCs/17 18/02 to G.Z.), the China Postdoctoral Science
   Foundation (2020M683573), the Guangdong Basic and Applied Basic Research
   Foundation (2020A1515110630).
CR Almeida Maria, 2012, Bonekey Rep, V1
   Artman L, 2014, SEMIN CELL DEV BIOL, V34, P33, DOI 10.1016/j.semcdb.2014.05.012
   Bellantuono I, 2009, BBA MOL BASIS DIS, V1792, P364, DOI 10.1016/j.bbadis.2009.01.008
   Berger JM, 2019, CELL METAB, V30, P890, DOI 10.1016/j.cmet.2019.08.012
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   Bunnell TM, 2011, MOL BIOL CELL, V22, P4047, DOI 10.1091/mbc.E11 06 0582
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Dirckx N, 2013, BIRTH DEFECTS RES C, V99, P170, DOI 10.1002/bdrc.21047
   Dormoy Raclet V, 2007, MOL CELL BIOL, V27, P5365, DOI 10.1128/MCB.00113 07
   Gardel ML, 2010, ANNU REV CELL DEV BI, V26, P315, DOI 10.1146/annurev.cellbio.011209.122036
   Hayashi M, 2019, CELL METAB, V29, P627, DOI 10.1016/j.cmet.2018.12.021
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Joseph R, 2014, MOL VIS, V20, P593
   Katayama H, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12191 z
   Kodama A, 2003, CELL, V115, P343, DOI 10.1016/S0092 8674(03)00813 4
   Li CJ, 2018, J CLIN INVEST, V128, P5251, DOI 10.1172/JCI99044
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li PC, 2018, INT J MED SCI, V15, P1227, DOI 10.7150/ijms.25662
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep41295
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Liu K, 2018, ONCOTARGETS THER, V11, P8729, DOI 10.2147/OTT.S182993
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Peng SP, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/8273648
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Prall WC, 2018, INJURY, V49, P1504, DOI 10.1016/j.injury.2018.06.024
   Rendina Ruedy E, 2020, CELL METAB, V31, P219, DOI 10.1016/j.cmet.2019.09.015
   Reumann MK, 2018, INT J MOL SCI, P19
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Soleimani M, 2009, NAT PROTOC, V4, P102, DOI 10.1038/nprot.2008.221
   Stenderup K, 2004, BIOGERONTOLOGY, V5, P107, DOI 10.1023/B:BGEN.0000025074.88476.e2
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   Thiel A, 2018, BIOL REV, V93, P350, DOI 10.1111/brv.12345
   van Helvert S, 2018, NAT CELL BIOL, V20, P8, DOI 10.1038/s41556 017 0012 0
   Wang ZH, 2016, NAT MED, V22, P1131, DOI 10.1038/nm.4179
   Wu XY, 2008, CELL, V135, P137, DOI 10.1016/j.cell.2008.07.045
   Wu XY, 2011, CELL, V144, P341, DOI 10.1016/j.cell.2010.12.033
   Xiao YZ, 2020, CELL METAB, V31, P534, DOI 10.1016/j.cmet.2020.01.002
   Yu JM, 2011, AGING CELL, V10, P66, DOI 10.1111/j.1474 9726.2010.00646.x
   Yu YL, 2019, CELL METAB, V29, P966, DOI 10.1016/j.cmet.2019.01.016
   Yue JP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11692
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang W, 2008, J BONE MINER RES, V23, P1118, DOI [10.1359/jbmr.080304, 10.1359/JBMR.080304]
   Zhao F, 2020, CELLS BASEL, V9, DOI 10.3390/cells9030616
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
   Zhuo ZJ, 2020, ADV SCI, V7, DOI 10.1002/advs.201903451
NR 48
TC 16
Z9 16
U1 6
U2 36
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2021
VL 11
IS 11
BP 5585
EP 5604
DI 10.7150/thno.54477
PG 20
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 2T7NZ
UT WOS:000822657900004
PM 33859765
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Domazetovic, V
   Marcucci, G
   Pierucci, F
   Bruno, G
   Mannelli, LD
   Ghelardini, C
   Brandi, ML
   Iantomasi, T
   Meacci, E
   Vincenzini, MT
AF Domazetovic, Vladana
   Marcucci, Gemma
   Pierucci, Federica
   Bruno, Gennaro
   Mannelli, Lorenzo Di Cesare
   Ghelardini, Carla
   Brandi, Maria Luisa
   Iantomasi, Teresa
   Meacci, Elisabetta
   Vincenzini, Maria Teresa
TI Blueberry juice protects osteocytes and bone precursor cells against
   oxidative stress partly through SIRT1
SO FEBS OPEN BIO
LA English
DT Article
DE antiosteoclastogenic factors; antioxidant activity; apoptosis;
   blueberry; osteocyte; SIRT1
ID STARVATION INDUCED APOPTOSIS; PHENOLIC ACIDS; IN VITRO; STEM CELLS;
   POLYPHENOLS; OSTEOBLAST; DIFFERENTIATION; BIOAVAILABILITY; ANTHOCYANINS;
   OSTEOPOROSIS
AB Oxidative stress and abnormal osteocyte apoptosis are often related to dysregulation of bone turnover and chronic bone loss, and so fruit and vegetables with high antioxidant potential may play an important role in the prevention and/or management of osteoporosis. Osteocytes are the main regulators of bone remodelling. For the first time, we demonstrate here that blueberry juice (BJ), obtained from Vaccinium myrtillus, rich in polyphenols, shows antioxidant and antiosteoclastogenic properties in MLO Y4 osteocytes. We report that BJ prevents oxidative stress induced apoptosis and reverses the increase in receptor activator of nuclear factor kappa B ligand and sclerostin expression, crucial factors for osteoclast activation and bone resorption. BJ is also able to prevent oxidative stress induced cell cytotoxicity in bone marrow mesenchymal stromal cells (MSCs), which are considered to be an important tool for cell therapy in bone disorders. No significant difference in preventing these events was observed between BJ and blueberry dry extract containing equal amounts of total soluble polyphenols. We have also shown that blueberry acts as both an antioxidant and an activator of sirtuin type 1, a class III histone deacetylase involved in cell death regulation and considered a molecular target for blocking bone resorption without affecting osteoclast survival. Overall, these novel data obtained in osteocytes and MSCs may help us clarify the mechanisms by which blueberry counteracts oxidative stress induced damage in bone remodelling and osteogenesis at the cellular and molecular level. Our findings are consistent with the reported beneficial effects of blueberry on bone tissue reported in animal studies, which suggest that blueberry may be a useful supplement for the prevention and/or management of osteoporosis and osteogenic process.
C1 [Domazetovic, Vladana; Marcucci, Gemma; Pierucci, Federica; Brandi, Maria Luisa; Iantomasi, Teresa; Meacci, Elisabetta; Vincenzini, Maria Teresa] Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Viale Morgagni 50, I 50134 Florence, Italy.
   [Bruno, Gennaro] Univ Florence, Dept Hlth Sci, Florence, Italy.
   [Mannelli, Lorenzo Di Cesare; Ghelardini, Carla] Univ Florence, Pharmacol & Toxicol Sect, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Florence, Italy.
C3 University of Florence; University of Florence; University of Florence
RP Vincenzini, MT (通讯作者)，Univ Florence, Dept Biomed Expt & Clin Sci Mario Serio, Viale Morgagni 50, I 50134 Florence, Italy.
EM vincenzini@unifi.it
RI Di Cesare Mannelli, Lorenzo/A 1641 2015; Mannelli, Lorenzo/A 7165 2012;
   Marcucci, Gemma/K 5205 2016; Bruno, Gennaro/AAL 6465 2020
OI Di Cesare Mannelli, Lorenzo/0000 0001 8374 4432; brandi, maria
   luisa/0000 0002 8741 0592; 
FU Fondazione Cassa di Risparmio di Pistoia e Pescia [IANTCRPP15];
   Ministero dell'Istruzione, dell'Universita e della Ricerca [RICATEN15]
FX The authors acknowledge Dr Lynda Bonewald (School of dentistry,
   University of Missouri, Kansas City) who generously provided the MLO 4Y
   cells and Fondazione Cassa di Risparmio di Pistoia e Pescia. This study
   was supported by grants from Fondazione Cassa di Risparmio di Pistoia e
   Pescia (IANTCRPP15) and Ministero dell'Istruzione, dell'Universita e
   della Ricerca (RICATEN15).
CR Al Dujaili SA, 2011, J CELL BIOCHEM, V112, P2412, DOI 10.1002/jcb.23164
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Almeida M, 2010, J BONE MINER RES, V25, P769, DOI 10.1359/jbmr.091017
   Ancillotti C, 2016, FOOD CHEM, V204, P176, DOI 10.1016/j.foodchem.2016.02.106
   Aravilli RK, 2017, 3 BIOTECH, V7, DOI 10.1007/s13205 017 0888 1
   Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Bellido T, 2014, CALCIFIED TISSUE INT, V94, P25, DOI 10.1007/s00223 013 9774 y
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Bu SY, 2009, J NUTR BIOCHEM, V20, P35, DOI 10.1016/j.jnutbio.2007.11.012
   Cao GH, 2001, AM J CLIN NUTR, V73, P920
   Chen JR, 2014, J BONE MINER RES, V29, P1043, DOI 10.1002/jbmr.2034
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Ciuffi M, 1998, PHARMACOL RES, V38, P279, DOI 10.1006/phrs.1998.0369
   Devareddy L, 2008, J NUTR BIOCHEM, V19, P694, DOI 10.1016/j.jnutbio.2007.09.004
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Domazetovic V, 2017, FEBS OPEN BIO, V7, P705, DOI 10.1002/2211 5463.12216
   Doshi Sejal B, 2013, J Midlife Health, V4, P140, DOI 10.4103/0976 7800.118990
   El Haj M, 2016, OSTEOPOROSIS INT, V27, P2373, DOI 10.1007/s00198 016 3536 4
   Fontani F, 2015, CALCIFIED TISSUE INT, V96, P335, DOI 10.1007/s00223 015 9961 0
   Graham RM, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2015.116
   Gurt I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134391
   Higgs J, 2017, EFORT OPEN REV, V2, P300, DOI 10.1302/2058 5241.2.160079
   Horcajada Marie Noelle, 2012, Curr Mol Pharmacol, V5, P205
   Hubert PA, 2014, ANTIOXIDANTS BASEL, V3, P144, DOI 10.3390/antiox3010144
   Islam MA, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5137431
   Kalajzic I, 2013, BONE, V54, P296, DOI 10.1016/j.bone.2012.09.040
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kennedy OD, 2014, BONE, V64, P132, DOI 10.1016/j.bone.2014.03.049
   Koli R, 2010, J AGR FOOD CHEM, V58, P3927, DOI 10.1021/jf9024823
   Kuntz S, 2015, BRIT J NUTR, V113, P1044, DOI 10.1017/S0007114515000161
   Li AN, 2014, NUTRIENTS, V6, P6020, DOI 10.3390/nu6126020
   Li T, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/s13018 014 0056 9
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Liu JP, 2016, MOL MED REP, V14, P1643, DOI 10.3892/mmr.2016.5417
   Matsumoto H, 2001, J AGR FOOD CHEM, V49, P1546, DOI 10.1021/jf001246q
   McGhie TK, 2007, MOL NUTR FOOD RES, V51, P702, DOI 10.1002/mnfr.200700092
   Michalska A, 2015, INT J MOL SCI, V16, P18642, DOI 10.3390/ijms160818642
   Ohyama Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191192
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Oryan A, 2017, CELLS TISSUES ORGANS, V204, P59, DOI 10.1159/000469704
   Pierucci F, 2017, ARCH TOXICOL, V91, P749, DOI 10.1007/s00204 016 1750 7
   Prencipe FP, 2014, J PHARMACEUT BIOMED, V89, P257, DOI 10.1016/j.jpba.2013.11.016
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Ren TT, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/469059
   Rodriguez Mateos A, 2016, J BERRY RES, V6, P137, DOI 10.3233/JBR 160123
   Romagnoli C, 2013, FEBS J, V280, P867, DOI 10.1111/febs.12075
   Sassoli C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108662
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shen CL, 2013, AM J CLIN NUTR, V98, p1694S, DOI 10.3945/ajcn.113.058255
   SINGLETON V. L., 1965, AMER J ENOL VITICULT, V16, P144
   Tou JC, 2015, BBA MOL BASIS DIS, V1852, P1186, DOI 10.1016/j.bbadis.2014.10.003
   Trzeciakiewicz A, 2009, NUTR RES REV, V22, P68, DOI 10.1017/S095442240926402X
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Weaver Connie M., 2012, Journal of Nutrition in Gerontology and Geriatrics, V31, P239, DOI 10.1080/21551197.2012.698220
   Yagi H, 2013, J CELL BIOCHEM, V114, P1163, DOI 10.1002/jcb.24459
   Yao HL, 2018, MOL MED REP, V17, P6681, DOI 10.3892/mmr.2018.8657
   Zhang J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070438
   Zhang J, 2013, AGE, V35, P807, DOI 10.1007/s11357 012 9412 z
   Zhang XS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.292
   Zhong SQ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700405
   Zhou L, 2017, MOL MED REP, V16, P2969, DOI 10.3892/mmr.2017.6917
NR 61
TC 25
Z9 28
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2211 5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PD JUN
PY 2019
VL 9
IS 6
BP 1082
EP 1096
DI 10.1002/2211 5463.12634
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA IP9TU
UT WOS:000480394000002
PM 31006177
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Li, Y
   Shen, GS
   Yu, C
   Li, GF
   Shen, JK
   Gong, JP
   Xu, YJ
AF Li, Yong
   Shen, Guangsi
   Yu, Chen
   Li, Guangfei
   Shen, Junkang
   Gong, Jianping
   Xu, Youjia
TI Angiotensin II induces mitochondrial oxidative stress and mtDNA damage
   in osteoblasts by inhibiting SIRT1 FoxO3a MnSOD pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Angiotensin II; Osteoblasts; Mitochondrial oxidative stress; mtDNA
   damage; MnSOD; SIRT1
ID HYDROGEN PEROXIDE; BONE; OSTEOPOROSIS; CELLS; DYSFUNCTION; EXPRESSION;
   APOPTOSIS; AUTOPHAGY; ACTIVATOR; LIGAND
AB Previous report showed that angiotensin II accelerates osteoporosis, and recent clinical studies suggest that several antihypertensive drugs, especially angiotensin converting enzyme inhibitors, reduced bone fractures. However, the underling mechanism by which angiotensin II induces bone dysfunction is largely unknown. Here in this study, we show that angiotensin II induces mitochondrial oxidative stress and mitochondrial DNA (mtDNA) damage. We find that the protein and RNA levels of mitochondrial catalase and manganese superoxide dismutase (MnSOD) are decreased in osteoblasts in the presence of angiotensin II. Further, we show that angiotensin II inhibits the protein level of SIRT1, but not SIRT3, which results in the hyperacetylation of the forkhead box O3a (FoxO3a) and inhibition of the expression of catalase and MnSOD. Finally, we show that SRT3025 (Sirt1 activator) and Mn (III) tetrakis (4 benzoic acid) porphyrin (MnTBAP, a MnSOD mimetics) can markedly reduce mitochondrial oxidative stress and mtDNA damage. In summary, we identify a novel SIRT1 FoxO3a MnSOD axis in angiotensin II induced mitochondrial oxidative stress and mtDNA damage in osteoblasts. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Li, Yong; Shen, Junkang; Gong, Jianping] Soochow Univ, Affiliated Hosp 2, Dept Radiol, Suzhou 215004, Peoples R China.
   [Shen, Guangsi; Yu, Chen; Li, Guangfei; Xu, Youjia] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou 215004, Peoples R China.
C3 Soochow University   China; Soochow University   China
RP Xu, YJ (通讯作者)，1055 Sanxiang Rd, Suzhou 215004, Peoples R China.
EM unionlab@yeah.net
RI ; Li, Guangfei/AAA 2948 2020
OI Shen, Guangsi/0000 0002 2408 5921; 
FU National Natural Science Foundation of China [81273090, 81302438];
   Natural Science Foundation of Jiangsu Province [BK2012608]; Research and
   Innovation Project for College Graduates of Jiangsu Province
   [CX10B_053Z]; Foundation Program of Suzhou Key Laboratory of High
   Technology [SZS201208]
FX This work was supported by Grants from the National Natural Science
   Foundation of China (81273090, 81302438), the Natural Science Foundation
   of Jiangsu Province (BK2012608), Research and Innovation Project for
   College Graduates of Jiangsu Province (CX10B_053Z), and the Foundation
   Program of Suzhou Key Laboratory of High Technology (SZS201208).
CR Artsi H, 2014, ENDOCRINOLOGY, V155, P3508, DOI 10.1210/en.2014 1334
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Bartolomé A, 2013, BIOCHEM J, V455, P329, DOI 10.1042/BJ20130562
   Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Choi EM, 2014, PHYTOTHER RES, V28, P880, DOI 10.1002/ptr.5071
   Dai DF, 2011, CIRC RES, V108, P837, DOI 10.1161/CIRCRESAHA.110.232306
   Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101
   Garcia P, 2010, BRIT J PHARMACOL, V159, P1672, DOI 10.1111/j.1476 5381.2010.00651.x
   Guo L, 2011, ARCH ORAL BIOL, V56, P205, DOI 10.1016/j.archoralbio.2010.09.016
   Huang CY, 2014, CELL DEATH DIFFER, V21, P1262, DOI 10.1038/cdd.2014.46
   Kim SJ, 2014, J BIOL CHEM, V289, P6165, DOI 10.1074/jbc.M113.515130
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lai L, 2013, CIRCULATION, V127, P1692, DOI 10.1161/CIRCULATIONAHA.112.001212
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Garcia PJM, 2014, WORLD J CARDIOL, V6, P968, DOI 10.4330/wjc.v6.i9.968
   Miranda MX, 2014, EUR HEART J
   Paul M, 2006, PHYSIOL REV, V86, P747, DOI 10.1152/physrev.00036.2005
   Rudic M, 2013, FREE RADICAL BIO MED, V57, P22, DOI 10.1016/j.freeradbiomed.2012.11.023
   She F, 2014, MOL MED REP, V9, P493, DOI 10.3892/mmr.2013.1832
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Santos SHS, 2014, PEPTIDES, V59, P34, DOI 10.1016/j.peptides.2014.07.002
   Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162
   Tan WQ, 2008, J BIOL CHEM, V283, P29730, DOI 10.1074/jbc.M805514200
   Tang XQ, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00175
   Tazaki Masakazu, 2013, Bull Tokyo Dent Coll, V54, P275
   Wei W, 2011, MOL CELL BIOL, V31, P4692, DOI 10.1128/MCB.05979 11
   Wei W, 2011, MOL CELL BIOL, V31, P4706, DOI 10.1128/MCB.05980 11
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Zhang YQ, 2014, MOL CELL BIOCHEM, V396, P249, DOI 10.1007/s11010 014 2160 x
NR 30
TC 32
Z9 40
U1 0
U2 31
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD DEC 5
PY 2014
VL 455
IS 1 2
BP 113
EP 118
DI 10.1016/j.bbrc.2014.10.123
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AX4GX
UT WOS:000346892600014
PM 25450701
DA 2025 08 17
ER

PT J
AU Zhu, YL
   Qiao, SW
   Pang, YX
   Wang, HM
   Zhou, YM
AF Zhu, Yanlin
   Qiao, Shuwei
   Pang, Yuxuan
   Wang, Huimin
   Zhou, Yanmin
TI Deferoxamine Treatment Effectively Prevents Periodontitis Progression by
   Reducing Inflammation and Osteoclastogenesis in Experimental
   Periodontitis Rats
SO JOURNAL OF INFLAMMATION RESEARCH
LA English
DT Article
DE deferoxamine; periodontitis; inflammation; osteoclast differentiation
ID HIF; DESFERRIOXAMINE; PATHOGENESIS; HIF 1 ALPHA; IMMUNITY
AB Purpose: Although the anti inflammatory properties of the hypoxia mimetic drug deferoxamine (DFO) have been reported, its potential as a treatment for periodontitis remains unknown. This study investigated the therapeutic benefits of DFO on osteoclastogenesis and inflammation in periodontitis progression. Methods: RAW264.7 cells were pretreated with DFO before stimulation with lipopolysaccharides from Porphyromonas gingivalis (P. g LPS). Hypoxia inducible factor 1 alpha (HIF 1 alpha) and inflammatory factors were measured, followed by analysis of relevant inflammatory pathways. Immunofluorescence and molecular biology methods were employed to assess osteoclast differentiation in RAW264.7 cells after nuclear factor kappa B ligand (RANKL) induction. A rat model of periodontitis was es\lished using ligature wires, and alveolar bone loss was assessed via micro computed tomography. Osteoclastogenesis and periodontal inflammation were assessed through immunohistochemistry as well as hematoxylin and eosin staining. Results: DFO reduced the P.g LPS induced inflammatory factor expression (P < 0.0001) and upregulated HIF 1 alpha (P = 0.0278) in RAW264.7 cells. DFO suppressed NF kappa B signaling by inhibiting NF kappa B p65 nuclear translocation and phosphorylation. DFO pretreatment inhibited osteoclast development by decreasing F actin rings synthesis, reducing the number of mature osteoclasts (P < 0.0001) and downregulating osteoclast specific markers (P < 0.05). In rat periodontitis models, DFO treatment reduced tissue inflammation, osteoclastogenesis, and alveolar bone loss (P < 0.05). Conclusion: DFO effectively prevented osteoclast development, alveolar bone loss, and inflammation associated with periodontitis.
C1 [Zhu, Yanlin] Jilin Univ, Hosp Stomatol, Dept Dent Implantol, Changchun, Peoples R China.
   [Zhu, Yanlin; Qiao, Shuwei; Pang, Yuxuan; Wang, Huimin; Zhou, Yanmin] Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
   [Qiao, Shuwei; Pang, Yuxuan; Wang, Huimin] Jilin Univ, Hosp Stomatol, Dept Prosthodont, Changchun, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Zhou, YM (通讯作者)，Jilin Univ, Hosp Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, 1500 Qinghua Rd, Changchun 130021, Jilin, Peoples R China.
EM zhouym@jlu.edu.cn
RI Zhu, Yanlin/KEH 0907 2024
FU National Key R&D Program of China [2021YFC2400405]
FX Acknowledgments The National Key R&D Program of China (2021YFC2400405)
   provided the funding to support this work. We acknowl edge TopEdit LLC
   for the linguistic editing and proofreading during the preparation of
   this manuscript.
CR Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   Chen MH, 2021, INT IMMUNOPHARMACOL, V99, DOI 10.1016/j.intimp.2021.107901
   Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092 8674(03)00154 5
   Cummins EP, 2008, GASTROENTEROLOGY, V134, P156, DOI 10.1053/j.gastro.2007.10.012
   Cummins EP, 2016, MOL ASPECTS MED, V47 48, P24, DOI 10.1016/j.mam.2015.12.004
   Cummins EP, 2013, LAB INVEST, V93, P378, DOI 10.1038/labinvest.2013.9
   Dong XZ, 2022, BIOMATERIALS, V280, DOI 10.1016/j.biomaterials.2021.121288
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Hajishengallis G, 2014, TRENDS IMMUNOL, V35, P3, DOI 10.1016/j.it.2013.09.001
   Halligan DN, 2016, SEMIN IMMUNOL, V28, P469, DOI 10.1016/j.smim.2016.09.004
   He DW, 2023, J NEUROINFLAMM, V20, DOI 10.1186/s12974 023 02762 5
   KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Kirstein B, 2006, J CELL BIOCHEM, V98, P1085, DOI 10.1002/jcb.20835
   Lee KE, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158225
   Li J, 2021, INT IMMUNOPHARMACOL, V91, DOI 10.1016/j.intimp.2020.107275
   Lombardo M, 2020, DARU, V28, P635, DOI 10.1007/s40199 020 00370 9
   Malkov MI, 2021, CELLS BASEL, V10, DOI 10.3390/cells10092340
   Manresa MC, 2019, ALLERGY, V74, P753, DOI 10.1111/all.13655
   Nedzi Góra M, 2017, ARCH IMMUNOL THER EX, V65, P421, DOI 10.1007/s00005 017 0472 8
   Ozes ON, 1999, NATURE, V401, P82
   Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008
   Palomäki S, 2013, STEM CELLS, V31, P1902, DOI 10.1002/stem.1435
   Phelan JJ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00836
   Qiao SW, 2023, ORAL DIS, V29, P3571, DOI 10.1111/odi.14292
   Semenza GL, 2019, ANNU REV PHARMACOL, V59, P379, DOI 10.1146/annurev pharmtox 010818 021637
   Shang LL, 2019, CLIN ORAL INVEST, V23, P3123, DOI 10.1007/s00784 018 2733 2
   Sun SQ, 2024, ORAL DIS, V30, P2580, DOI 10.1111/odi.14623
   Tchanque Fossuo CN, 2017, BRIT J DERMATOL, V176, P1056, DOI 10.1111/bjd.14956
   Touil Y, 2022, J CELL BIOCHEM, V123, P543, DOI 10.1002/jcb.30198
   Velasquez J., 2022, STATPEARLS
   Watts ER, 2019, TRENDS MOL MED, V25, P33, DOI 10.1016/j.molmed.2018.10.006
   Wu Y, 2022, J IMMUNOL, V209, P2012, DOI 10.4049/jimmunol.2200346
   Xie J, 2019, BIOCHEM BIOPH RES CO, V513, P820, DOI 10.1016/j.bbrc.2019.03.206
   Zhang J, 2019, TOXICOL LETT, V313, P50, DOI 10.1016/j.toxlet.2019.06.007
   Zhang J, 2022, ADV MATER, V34, DOI 10.1002/adma.202202044
   Zhang WJ, 2010, EXP BIOL MED, V235, P633, DOI 10.1258/ebm.2009.009229
NR 37
TC 2
Z9 2
U1 15
U2 23
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178 7031
J9 J INFLAMM RES
JI J. Inflamm. Res.
PY 2024
VL 17
BP 9637
EP 9650
DI 10.2147/JIR.S490823
PG 14
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA S4Q7S
UT WOS:001398094400001
PM 39618936
OA gold
DA 2025 08 17
ER

PT J
AU Zhou, YQ
   Yu, YJ
   Shi, YQ
   Li, MY
   Yang, C
   Wang, SY
AF Zhou, Yuqiong
   Yu, Yejia
   Shi, Yueqi
   Li, Mengyu
   Yang, Chi
   Wang, Shaoyi
TI Combined Administration of Bisphosphonates, Chemotherapeutic Agents,
   and/or Targeted Drugs Increases the Risk for Stage 3 Medication Related
   Osteonecrosis of the Jaw: A 4 Year Retrospective Study
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID ASSOCIATION; MULTICENTER; MECHANISM; SURGERY; DISEASE
AB Objectives. Patients with stage 3 medication related osteonecrosis of the jaw (MRONJ) suffer from severe complications. Chemotherapeutic agents and targeted drugs are considered to be associated with the development of MRONJ. However, little is known regarding the association of those agents with stage 3 MRONJ. The purpose of this study is to analyze the comprehensive medication history of patients with advanced stage MRONJ (stage 2 and stage 3) and evaluate the possible risk factors for stage 3 MRONJ. Patients and Methods. Sixty patients with advanced stage MRONJ were involved in this retrospective study. Patients with developmental maxillofacial anomalies, previous radiation in the head and neck areas, and jaw bone tumors were excluded from the study. All patients were divided into two groups by their MRONJ stage (stage 2 or stage 3). Demographic and clinical characteristics, comprehensive medication data (bisphosphonates, chemotherapeutic agents, targeted drugs, and immunosuppressive agents), and results of serological biomarkers were recorded and compared between two groups. Univariate and multivariate logistic regressions were performed by SPSS 25.0 for evaluating risk factors of stage 3 MRONJ. Results. Our results indicate that chemotherapy (adjusted OR=3.43; 95% CI: 1.03 to 11.38), targeted drugs (adjusted OR=3.69; 95% CI: 1.06 to 12.80), and maxillary lesions (adjusted OR=4.26; 95% CI: 1.19 to 15.23) increase the risk of stage 3 MRONJ. Conclusion. The outcome of this study justifies that chemotherapeutic agents and targeted drugs are probably risk factors for stage 3 MRONJ. In addition, the osteonecrosis in maxilla is more easily to develop into stage 3 MRONJ. Intense clinical observation is recommended in MRONJ patients with maxillary osteonecrosis and in those who concurrently administered bisphosphonates, chemotherapeutic agents, and/or targeted drugs. This trial is registered with ChiCTR2000032428.
C1 [Zhou, Yuqiong; Yu, Yejia; Shi, Yueqi; Li, Mengyu; Yang, Chi; Wang, Shaoyi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9,Coll Stomatol, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.
   [Zhou, Yuqiong; Yu, Yejia; Shi, Yueqi; Li, Mengyu; Yang, Chi; Wang, Shaoyi] Shanghai Jiao Tong Univ, Sch Med, Shanghai Res Inst Stomatol, Shanghai Peoples Hosp 9,Dept Oral Surg, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Yang, C; Wang, SY (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9,Coll Stomatol, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.
EM zyqjyhospital@outlook.com; yuyejia0208@163.com; 1344097578@qq.com;
   mengyuli0463@163.com; yangchi63@hotmail.com; wangshaoyi163@163.com
OI Wang, Shaoyi/0000 0002 0871 9584
FU National Natural Science Foundation of China [81271114]; Science and
   Technology Commission of Shanghai Municipality [19411962000,
   18441903000]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81271114) and the Science and Technology Commission of
   Shanghai Municipality (19411962000 and 18441903000).
CR Aljohani S, 2018, J CRANIO MAXILL SURG, V46, P1515, DOI 10.1016/j.jcms.2018.05.046
   Banfi A, 2001, CANCER, V92, P2419, DOI 10.1002/1097 0142(20011101)92:9<2419::AID CNCR1591>3.0.CO;2 K
   Bermúdez Bejarano EB, 2017, MED ORAL PATOL ORAL, V22, pE43, DOI 10.4317/medoral.21477
   Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592
   de Oliveira CC, 2016, MED ORAL PATOL ORAL, V21, pE431, DOI 10.4317/medoral.21044
   DeSesa CR, 2016, J ORAL MAXIL SURG, V74, P292, DOI 10.1016/j.joms.2015.07.019
   Dodson TB, 2015, ORAL MAXIL SURG CLIN, V27, P509, DOI 10.1016/j.coms.2015.06.003
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Favia G, 2017, AM J CASE REP, V18, DOI 10.12659/AJCR.905355
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   Fusco V, 2016, EXPERT OPIN DRUG SAF, V15, P925, DOI 10.1080/14740338.2016.1177021
   Fusco V, 2015, CLIN GENITOURIN CANC, V13, P287, DOI 10.1016/j.clgc.2014.12.002
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Holzinger D, 2013, ORAL ONCOL, V49, P66, DOI 10.1016/j.oraloncology.2012.07.008
   Javelot MJ, 2020, J STOMATOL ORAL MAXI, V121, P300, DOI 10.1016/j.jormas.2019.06.009
   Kim JW, 2013, BONE, V57, P201, DOI 10.1016/j.bone.2013.08.005
   Kwon YD, 2009, J ORAL MAXIL SURG, V67, P2644, DOI 10.1016/j.joms.2009.04.067
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Lee CYS, 2010, IMPLANT DENT, V19, P29, DOI 10.1097/ID.0b013e3181cec8bc
   Li MY, 2020, STEM CELLS DEV, V29, P156, DOI 10.1089/scd.2019.0151
   Mergoni G, 2019, MED ORAL PATOL ORAL, V24, pE339, DOI 10.4317/medoral.22883
   Miksad RA, 2011, ONCOLOGIST, V16, P121, DOI 10.1634/theoncologist.2010 0183
   Mohamed HAM, 2018, OR SURG OR MED OR PA, V125, P157, DOI 10.1016/j.oooo.2017.10.010
   Moraschini V, 2019, OR SURG OR MED OR PA, V127, P504, DOI 10.1016/j.oooo.2019.02.014
   Nicolatou Galitis O, 2019, SUPPORT CARE CANCER, V27, P383, DOI 10.1007/s00520 018 4501 x
   Oteri G, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/4021952
   Palaska PK, 2009, ONCOLOGIST, V14, P1154, DOI 10.1634/theoncologist.2009 0115
   Pimolbutr K, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8071579
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Shim K, 2008, DRUG SAFETY, V31, P359, DOI 10.2165/00002018 200831050 00001
   Sivolella S, 2013, ANTICANCER RES, V33, P1793
   Thumbigere Math V, 2012, AM J CLIN ONCOL CANC, V35, P386, DOI 10.1097/COC.0b013e3182155fcb
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Zirk M, 2017, J CRANIO MAXILL SURG, V45, P1183, DOI 10.1016/j.jcms.2017.05.027
NR 36
TC 11
Z9 12
U1 1
U2 13
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD OCT 15
PY 2020
VL 2020
AR 5847429
DI 10.1155/2020/5847429
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA OP8EJ
UT WOS:000588322200008
PM 33123580
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU He, JC
   Zhou, QF
   Jia, XC
   Zhou, P
   Chen, L
AF He, Juncheng
   Zhou, Qifeng
   Jia, Xianchao
   Zhou, Peng
   Chen, Lin
TI Immune related expression profiles of bisphosphonates related
   osteonecrosis of the jaw in multiple myeloma
SO PHARMAZIE
LA English
DT Article
ID CONNECTIVITY MAP; IN VIVO; TOOL
AB Objective: To investigate the immune cellular and genomic profiles of bisphosphonates related osteonecrosis (BRONJ) of the jaw and excavate potential small molecule drugs. Methods and materials: The genomic profile of a multiple myeloma (MM) patient with BRONJ was downloaded from Gene Expression Omnibus (GEO). The 22 immune cell subsets infiltration in the patient were predicted by cell type identification by estimating relative subsets of RNA transcripts. In addition, the differently expressed immune related genes (DEMGs) of BRONJ were identified, followed by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses for functional annotation. Then, potential drugs for BRONJ treatment were predicted by Connectivity Map (CMAP) based on DEGs. Results: High proportions of native CD4+T cells and MO macrophages were observed while resting mast cells, NK cells, and eosinophils were downregulated in the BRONJ patient (P<0.05). Resting dendritic cells and gamma delta T cells were positively correlated (r=0.93). Additionally, 36 DEMGs were screened from 336 DEGs in BRONJ expression profiles. GO enrichment analysis revealed that DEMGs were most associated with peptidyl tyrosine modification, myeloid leukocyte migration, leukocyte chemotaxis and regulation of chemokine production(P<0.05). KEGG analysis indicated that DEMGs were mainly related to cytokine cytokine receptor interaction, IL 17 signaling pathway and NF Kappa B signaling pathway(P<0.05). Besides, 12 small molecule drugs were screened in MM patient with ONJ. Conclusion: The discovery of different composition of immune cell types and immune related transcriptomes in BRONJ helps to explain the onset and development of MRONJ, which provides a novel target for BRONJ therapy.
C1 [He, Juncheng; Zhou, Peng] Guangdong Women & Children Hosp, Dept Stomatol, Guanghzou, Peoples R China.
   [Chen, Lin] Southern Med Univ, Stomatol Hosp, Dept Endodont, Guanghzou 521533, Peoples R China.
   [Zhou, Qifeng; Jia, Xianchao] Shenzhen Matern & Child Healthcare Hosp, Dept Stomatol, Shenzhen, Peoples R China.
C3 Southern Medical University   China; Shenzhen Maternity & Child
   Healthcare Hospital
RP Chen, L (通讯作者)，Southern Med Univ, Stomatol Hosp, Dept Endodont, Guanghzou 521533, Peoples R China.
EM clstudy0830@126.com
RI Zhou, Qifeng/HPD 7023 2023
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bansal P., 2020, BISPHOSPHONATE TOXIC
   Bhattacharya S, 2014, IMMUNOL RES, V58, P234, DOI 10.1007/s12026 014 8516 1
   Brigger D, 2020, NAT METAB, V2, P688, DOI 10.1038/s42255 020 0228 3
   Chapman MA, 2018, BLOOD, V132, P2154, DOI 10.1182/blood 2018 05 849893
   Criscitiello C, 2015, CANCER TREAT REV, V41, P61, DOI 10.1016/j.ctrv.2014.12.001
   Silva PGD, 2016, ORAL DIS, V22, P649, DOI 10.1111/odi.12513
   Elsayed R, 2020, FASEB J, V34, P2595, DOI 10.1096/fj.201901819RR
   Gralow JR, 2020, JNCI J NATL CANCER I, V112, P698, DOI 10.1093/jnci/djz215
   Hayashi M, 2018, TOHOKU J EXP MED, V246, P257, DOI 10.1620/tjem.246.257
   Huang XL, 2019, INT J MOL MED, V44, P582, DOI 10.3892/ijmm.2019.4207
   Kalyan S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967 015 0568 z
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mhaskar R, 2017, COCHRANE DB SYST REV, V12
   Mhaskar R, 2018, JAMA J AM MED ASSOC, V320, P1483, DOI 10.1001/jama.2018.13773
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Nicolatou Galitis O, 2019, SUPPORT CARE CANCER, V27, P383, DOI 10.1007/s00520 018 4501 x
   Oryan A, 2020, LIFE SCI, V257, DOI 10.1016/j.lfs.2020.118038
   Paschalidi P, 2021, CLIN ORAL INVEST, V25, P2845, DOI 10.1007/s00784 020 03602 z
   Pozzi S, 2011, ONCOLOGIST, V16, P651, DOI 10.1634/theoncologist.2010 0225
   Pundole X, 2020, IMMUNOTHERAPY UK, V12, P1213, DOI 10.2217/imt 2020 0108
   Rosini S, 2015, EUR REV MED PHARMACO, V19, P3309
   Santini D, 2009, CANCER IMMUNOL IMMUN, V58, P31, DOI 10.1007/s00262 008 0521 6
   Schölkopf B, 2000, NEURAL COMPUT, V12, P1207, DOI 10.1162/089976600300015565
   Takimoto R, 2021, IMMUNOLOGY, V162, P306, DOI 10.1111/imm.13283
   Tseng HC, 2015, ONCOTARGET, V6, P20002, DOI 10.18632/oncotarget.4755
   Yang XJ, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420 020 0273 4
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang QZ, 2013, CLIN CANCER RES, V19, P3176, DOI 10.1158/1078 0432.CCR 13 0042
   Zhu WW, 2019, FASEB J, V33, P5208, DOI 10.1096/fj.201801791RR
NR 32
TC 7
Z9 7
U1 3
U2 14
PU AVOXA MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH
PI ESCHBORN
PA CARL MANNICH STR 26, ESCHBORN, GERMANY
SN 0031 7144
J9 PHARMAZIE
JI Pharmazie
PD APR
PY 2021
VL 76
IS 4
BP 159
EP 164
DI 10.1691/ph.2021.01013
PG 6
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy; Chemistry
GA RN2MN
UT WOS:000640186200007
PM 33849701
DA 2025 08 17
ER

PT J
AU Armstrong, AJ
   Febbo, PG
AF Armstrong, Andrew J.
   Febbo, Phillip G.
TI Using Surrogate Biomarkers to Predict Clinical Benefit in Men with
   Castration Resistant Prostate Cancer: An Update and Review of the
   Literature
SO ONCOLOGIST
LA English
DT Article
DE Prostate cancer; Surrogate markers; Prostate specific antigen; src
   family kinases
ID CIRCULATING TUMOR CELLS; PROGRESSION FREE SURVIVAL; KINASE INHIBITOR;
   BONE METASTASES; END POINTS; ANTITUMOR ACTIVITY; CONTROLLED TRIAL;
   TYROSINE KINASE; WORKING GROUP; SOLID TUMORS
AB Recurrent prostate cancer has a complex molecular etiology and a prolonged disease course. Although initially responsive to androgen ablation, many men eventually become castration resistant, develop skeletal metastases, and are palliatively treated with docetaxel based chemotherapy, radiation therapy, bisphosphonates, and best supportive care. Given the modest success rates of the current standard of care, clinical trial enrollment is encouraged. Castration resistant prostate cancer (CRPC) is a heterogeneous disease, both in clinical manifestations and outcomes, requiring an individualized approach to both patient care and trial design. Herein, we review surrogate markers of disease progression and treatment efficacy in advanced prostate cancer in light of recently published guidelines that have redefined eligibility, response criteria, and suitable endpoints in prostate cancer drug development. The guidelines have refined outcome measures to potentially better capture clinical benefit and the ability of novel targeted molecular and biologic agents to impact favorably on this disease. We consider prostate specific antigen changes, circulating tumor cells, bone scan alterations, markers of bone metabolism ( urinary N telopeptide and bone specific alkaline phosphatase), pain improvements, and progression free survival. To illustrate the role and challenges of these potential biomarkers and endpoints in drug development, we discuss a class of novel molecularly targeted agents, the src kinase inhibitors. Given that there are currently no validated surrogate markers of overall survival for assessing early clinical benefit from systemic therapy in metastatic CRPC, incorporation of relevant biomarkers into all phases of clinical development is essential to accelerate drug development in this field. The Oncologist 2009; 14: 816 827
C1 [Armstrong, Andrew J.; Febbo, Phillip G.] Duke Comprehens Canc Ctr, Dept Med, Durham, NC 27710 USA.
   [Armstrong, Andrew J.] Duke Comprehens Canc Ctr, Dept Surg, Div Med Oncol, Durham, NC 27710 USA.
   [Armstrong, Andrew J.] Duke Comprehens Canc Ctr, Div Urol, Durham, NC 27710 USA.
   [Armstrong, Andrew J.; Febbo, Phillip G.] Duke Prostate Ctr, Durham, NC USA.
   [Febbo, Phillip G.] Duke Comprehens Canc Ctr, Dept Mol Genet, Durham, NC 27710 USA.
   [Febbo, Phillip G.] Duke Comprehens Canc Ctr, Dept Microbiol, Durham, NC 27710 USA.
   [Febbo, Phillip G.] Duke Inst Genome Sci & Policy, Durham, NC USA.
C3 Duke University; Duke University; Duke University; Duke University; Duke
   University; Duke University
RP Armstrong, AJ (通讯作者)，Duke Comprehens Canc Ctr, Dept Med, DUMC Box 102002, Durham, NC 27710 USA.
EM andrew.armstrong@duke.edu
CR ARAUJO J, 2009, J CLIN ONCOL S, V27
   Armstrong A J, 2007, Minerva Urol Nefrol, V59, P11
   Armstrong AJ, 2007, CLIN CANCER RES, V13, P6396, DOI 10.1158/1078 0432.CCR 07 1036
   Armstrong AJ, 2007, J CLIN ONCOL, V25, P3965, DOI 10.1200/JCO.2007.11.4769
   Attard G, 2009, CANCER RES, V69, P4937, DOI 10.1158/0008 5472.CAN 08 4531
   Berthold DR, 2008, CLIN CANCER RES, V14, P2763, DOI 10.1158/1078 0432.CCR 07 0944
   Berthold DR, 2008, J CLIN ONCOL, V26, P242, DOI 10.1200/JCO.2007.12.4008
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Brown MW, 2006, CLIN GENITOURIN CANC, V4, P293, DOI 10.3816/CGC.2006.n.010
   Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461
   Carducci MA, 2003, J CLIN ONCOL, V21, P679, DOI 10.1200/JCO.2003.04.176
   Carducci MA, 2007, CANCER AM CANCER SOC, V110, P1959, DOI 10.1002/cncr.22996
   Chen L, 2004, NEW ASTRON, V10, P39, DOI 10.1016/j.newast.2004.04.008
   Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Danila DC, 2007, CLIN CANCER RES, V13, P7053, DOI 10.1158/1078 0432.CCR 07 1506
   de Bono JS, 2008, CLIN CANCER RES, V14, P6302, DOI 10.1158/1078 0432.CCR 08 0872
   Demers Laurence M., 2000, Cancer, V88, P2919, DOI 10.1002/1097 0142(20000615)88:12+<2919::AID CNCR7>3.0.CO;2 Z
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Febbo PG, 2009, J CLIN ONCOL, V27, P3088, DOI 10.1200/JCO.2008.20.9783
   Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086
   Fleming TR, 2009, J CLIN ONCOL, V27, P2874, DOI 10.1200/JCO.2008.20.4107
   Goldenberg Furmanov M, 2004, CANCER RES, V64, P1058, DOI 10.1158/0008 5472.CAN 03 2420
   Goodman OB, 2009, CANCER EPIDEM BIOMAR, V18, P1904, DOI 10.1158/1055 9965.EPI 08 1173
   Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100
   Halabi S, 2008, J CLIN ONCOL, V26, P2544, DOI 10.1200/JCO.2007.15.0367
   Halabi S, 2009, J CLIN ONCOL, V27, P2766, DOI 10.1200/JCO.2008.18.9159
   Higano C, 2009, J CLIN ONCOL
   Hricak H, 2007, RADIOLOGY, V243, P28, DOI 10.1148/radiol.2431030580
   Hussain M, 2009, J CLIN ONCOL, V27, P2450, DOI 10.1200/JCO.2008.19.9810
   Kopetz S, 2007, CLIN CANCER RES, V13, P7232, DOI 10.1158/1078 0432.CCR 07 1902
   Lecouvet FE, 2007, J CLIN ONCOL, V25, P3281, DOI 10.1200/JCO.2006.09.2940
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   Luo F, 2008, CANCER CHEMOTH PHARM, V62, P1065, DOI 10.1007/s00280 008 0699 5
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Mendiratta P, 2007, MOL DIAGN THER, V11, P345, DOI 10.1007/BF03256258
   Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882
   Miles AK, 2008, CURR CANCER THER REV, V4, P86, DOI 10.2174/157339408784310034
   MORENO J, 2007, J CLIN ONCOL, V25, pS239
   Msaouel P, 2008, BEST PRACT RES CL EN, V22, P341, DOI 10.1016/j.beem.2008.01.011
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008 5472.CAN 05 1731
   Park SI, 2008, CANCER RES, V68, P3323, DOI 10.1158/0008 5472.CAN 07 2997
   PETRYLAK D, 2007, J CLIN ONCOL
   Petrylak DP, 2006, J NATL CANCER I, V98, P516, DOI 10.1093/jnci/djj129
   RAJPAR S, 2008, J CLIN ONCOL S, V26, pS283
   Ramiah V, 2008, CURR OPIN UROL, V18, P303, DOI 10.1097/MOU.0b013e3282fb7807
   Recchi I, 2003, EUR J CANCER, V39, P1927, DOI 10.1016/S0959 8049(03)00394 0
   SARTOR AO, 2008, J CLIN ONCOL S, V26, pS250
   SCHELLHAMMER PF, 2009, AM UR ASS ANN M APR
   Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777
   Scher HI, 2005, CLIN CANCER RES, V11, P5223, DOI 10.1158/1078 0432.CCR 05 0109
   Scher HI, 2000, UROLOGY, V55, P323, DOI 10.1016/S0090 4295(99)00471 9
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Scher HI, 2007, CLIN CANCER RES, V13, P1488, DOI 10.1158/1078 0432.CCR 06 1885
   Scher HI, 2009, LANCET ONCOL, V10, P233, DOI 10.1016/S1470 2045(08)70340 1
   Schwartz GG, 2009, ANN EPIDEMIOL, V19, P96, DOI 10.1016/j.annepidem.2008.03.007
   Sella A, 2000, EUR UROL, V38, P250, DOI 10.1159/000020289
   Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078 0432.CCR 06 2701
   Slack JK, 2001, ONCOGENE, V20, P1152, DOI 10.1038/sj.onc.1204208
   Slovin SF, 2007, NAT CLIN PRACT ONCOL, V4, P551, DOI 10.1038/ncponc0910
   Smaletz O, 2002, J CLIN ONCOL, V20, P3972, DOI 10.1200/JCO.2002.11.021
   Small EJ, 2009, J CLIN ONCOL
   Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008 5472.CAN 04 4330
   Smith MR, 2007, UROLOGY, V70, P315, DOI 10.1016/j.urology.2007.03.071
   Smith MR, 2004, CANCER, V101, P1569, DOI 10.1002/cncr.20493
   Soerdjbalie Maikoe V, 2004, EUR J NUCL MED MOL I, V31, P958, DOI 10.1007/s00259 004 1479 z
   Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008 5472.CAN 05 4000
   Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078 0432.CCR 05 2692
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Vessella RL, 2006, CLIN CANCER RES, V12, p6285S, DOI 10.1158/1078 0432.CCR 06 0813
   Walker Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097 0045(19991201)41:4<275::AID PROS8>3.0.CO;2 T
   Wang XD, 2007, GENOME BIOL, V8, DOI 10.1186/gb 2007 8 11 r255
   Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563
   Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366
   YU EY, 2008, J CLIN ONCOL, V26, pS288
   Zeng GY, 2003, AM J PATHOL, V163, P2271, DOI 10.1016/S0002 9440(10)63584 5
NR 78
TC 44
Z9 46
U1 1
U2 6
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701 2884 USA
SN 1083 7159
J9 ONCOLOGIST
JI Oncologist
PY 2009
VL 14
IS 8
BP 816
EP 827
DI 10.1634/theoncologist.2009 0043
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 489HD
UT WOS:000269409900008
PM 19684076
DA 2025 08 17
ER

PT J
AU Zhao, XF
   Deng, P
   Iglesias Bartolome, R
   Amornphimoltham, P
   Steffen, DJ
   Jin, YY
   Molinolo, AA
   de Castro, LF
   Ovejero, D
   Yuan, Q
   Chen, QM
   Han, XL
   Bai, D
   Taylor, SS
   Yang, YZ
   Collins, MT
   Gutkind, JS
AF Zhao, Xuefeng
   Deng, Peng
   Iglesias Bartolome, Ramiro
   Amornphimoltham, Panomwat
   Steffen, Dana J.
   Jin, Yunyun
   Molinolo, Alfredo A.
   de Castro, Luis Fernandez
   Ovejero, Diana
   Yuan, Quan
   Chen, Qianming
   Han, Xianglong
   Bai, Ding
   Taylor, Susan S.
   Yang, Yingzi
   Collins, Michael T.
   Gutkind, J. Silvio
TI Expression of an active Gαs mutant in skeletal stem cells is
   sufficient and necessary for fibrous dysplasia initiation and
   maintenance
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GNAS; skeletal stem cell; fibrous dysplasia; mouse models; PKA
ID MCCUNE ALBRIGHT SYNDROME; STIMULATORY G PROTEIN; ACTIVATING MUTATIONS;
   PROGENITOR CELLS; NATURAL HISTORY; BONE; GNAS; MICE; DIFFERENTIATION;
   CONTRIBUTES
AB Fibrous dysplasia (FD) is a disease caused by postzygotic activating mutations of GNAS (R201C and R201H) that encode the alpha subunit of the Gs stimulatory protein. FD is characterized by the development of areas of abnormal fibroosseous tissue in the bones, resulting in skeletal deformities, fractures, and pain. Despite the well defined genetic alterations underlying FD, whether GNAS activation is sufficient for FD initiation and the molecular and cellular consequences of GNAS mutations remains largely unresolved, and there are no currently available targeted therapeutic options for FD. Here, we have developed a conditional tetracycline (Tet) inducible animal model expressing the G alpha(R201C)(s) in the skeletal stem cell (SSC) lineage (Tet G alpha(R201C)(s)/Prrx1 Cre/LSL rtTA IRES GFP mice), which develops typical FD bone lesions in both embryos and adult mice in less than 2 weeks following doxycycline (Dox) administration. Conditional G alpha(R201C)(s) expression promoted PKA activation and proliferation of SSCs along the osteogenic lineage but halted their differentiation to mature osteoblasts. Rather, as is seen clinically, areas of woven bone admixed with fibrous tissue were formed. G alpha(R201C)(s) caused the concomitant expression of receptor activator of nuclear factor kappa B ligand (Rankl) that led to marked osteoclastogenesis and bone resorption. G alpha(R201C)(s) expression ablation by Dox withdrawal resulted in FD like lesion regression, supporting the rationale for G alpha(s) targeted drugs to attempt FD cure. This model, which develops FD like lesions that can form rapidly and revert on cessation of mutant G alpha(s) expression, provides an opportunity to identify the molecular mechanism underlying FD initiation and progression and accelerate the development of new treatment options.
C1 [Zhao, Xuefeng; Deng, Peng; Yuan, Quan; Chen, Qianming; Han, Xianglong; Bai, Ding] Sichuan Univ, West China Hosp Stomatol, Natl Clin Res Ctr Oral Dis, State Key Lab Oral Dis, Chengdu 610041, Sichuan, Peoples R China.
   [Zhao, Xuefeng; Amornphimoltham, Panomwat; Steffen, Dana J.; Molinolo, Alfredo A.; Gutkind, J. Silvio] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA.
   [Iglesias Bartolome, Ramiro] NCI, NIH, Bethesda, MD 20892 USA.
   [Amornphimoltham, Panomwat] Walailak Univ, Int Coll Dent, Nakhon Si Thammarat 80161, Thailand.
   [Steffen, Dana J.; Taylor, Susan S.; Gutkind, J. Silvio] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Jin, Yunyun; Yang, Yingzi] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA.
   [Jin, Yunyun] East China Normal Univ, Inst Biomed Sci, Shanghai 200241, Peoples R China.
   [Jin, Yunyun] East China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [de Castro, Luis Fernandez; Ovejero, Diana; Collins, Michael T.] Natl Inst Dent & Craniofacial Res, Sect Skeletal Disorders & Mineral Homeostasis, NIH, Bethesda, MD 20892 USA.
   [Taylor, Susan S.] Univ Calif San Diego, Dept Chem & Biochem, San Diego, CA 92093 USA.
C3 Sichuan University; University of California System; University of
   California San Diego; National Institutes of Health (NIH)   USA; NIH
   National Cancer Institute (NCI); Walailak University; University of
   California System; University of California San Diego; Harvard
   University; Harvard School of Dental Medicine; East China Normal
   University; East China Normal University; National Institutes of Health
   (NIH)   USA; NIH National Institute of Dental & Craniofacial Research
   (NIDCR); University of California System; University of California San
   Diego
RP Gutkind, JS (通讯作者)，Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92093 USA.; Gutkind, JS (通讯作者)，Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
EM sgutkind@ucsd.edu
RI ; Gutkind, J. Silvio/J 1201 2016; Wu, Fanglong/AAT 7998 2021;
   Amornphimoltham, Walt/AAP 9654 2020; Gutkind, J Silvio/J 1201 2016; de
   Castro, Luis/AAV 1858 2021; jin, yun/GQZ 6618 2022; Iglesias Bartolome,
   Ramiro/H 4460 2014; yuan, quan/GZM 5597 2022; Zhao,
   Xuefeng/ACK 5669 2022; Yang, Yingzi/J 3501 2012
OI Zhao, Xuefeng/0000 0001 6860 7739; Yuan, Quan/0000 0002 2836 1081;
   Ramms, Dana/0000 0002 7700 1728; Chen, Qianming/0000 0002 5371 4432;
   Bai, Ding/0000 0002 5058 4329; Gutkind, J Silvio/0000 0002 5150 4482;
   Iglesias Bartolome, Ramiro/0000 0002 0792 1254; Ovejero,
   Diana/0000 0003 1312 4750; 
FU 111 Project from the Ministry of Education of China [B14038]; National
   Natural Science Foundation of China [81520108009, 81621062, 81722014,
   81671024, 81371171, 81571009]; University of Pennsylvania Orphan Disease
   Center; Fibrous Dysplasia Foundation; University of California, San
   Diego (UCSD) Department of Pharmacology and Moores Cancer Center;
   Division of Intramural Research, National Institute of Dental and
   Craniofacial Research, National Institutes of Health; UCSD Graduate
   Training Program in Cellular and Molecular Pharmacology through National
   Institute of General Medical Sciences Institutional Training Grant [T32
   GM007752]
FX We thank Dr. Zbigniew Mikulski for the whole tissue fluorescent imaging.
   This project was supported by 111 Project Grant B14038 from the Ministry
   of Education of China; National Natural Science Foundation of China
   Grants 81520108009, 81621062, 81722014, 81671024, 81371171, and
   81571009; University of Pennsylvania Orphan Disease Center, with support
   from the Fibrous Dysplasia Foundation; funding from the University of
   California, San Diego (UCSD) Department of Pharmacology and Moores
   Cancer Center; and the Division of Intramural Research, National
   Institute of Dental and Craniofacial Research, National Institutes of
   Health. D.J.S. was supported in part by the UCSD Graduate Training
   Program in Cellular and Molecular Pharmacology through National
   Institute of General Medical Sciences Institutional Training Grant T32
   GM007752.
CR Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051
   Bhattacharyya N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090766
   Bianco P, 1998, J CLIN INVEST, V101, P1737, DOI 10.1172/JCI2361
   Bianco P, 1999, J BONE MINER RES, V14, P336, DOI 10.1359/jbmr.1999.14.3.336
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Carter JM, 2014, AM J SURG PATHOL, V38, P402, DOI 10.1097/PAS.0000000000000144
   Chapurlat R, 2012, IBMS BONEKEY, P9
   Chapurlat RD, 2006, J BONE MINER RES, V21, pP114, DOI 10.1359/JBMR.06S222
   Collins MT, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750 1172 7 S1 S4
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DiCaprio MR, 2005, J BONE JOINT SURG AM, V87A, P1848, DOI 10.2106/JBJS.D.02942
   Gorham L W, 1941, Trans Am Clin Climatol Assoc, V57, P179
   Iglesias Bartolome R, 2015, NAT CELL BIOL, V17, P793, DOI 10.1038/ncb3164
   Ippolito E, 2003, J PEDIATR ORTHOP B, V12, P155, DOI 10.1097/00009957 200305000 00001
   Kawanami A, 2009, BIOCHEM BIOPH RES CO, V386, P477, DOI 10.1016/j.bbrc.2009.06.059
   Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667
   Leet AI, 2007, J CHILD ORTHOP, V1, P3, DOI 10.1007/s11832 007 0006 8
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Mansoori LS, 2010, ENDOCR PRACT, V16, P851, DOI 10.4158/EP10136.CR
   Mead TJ, 2014, METHODS MOL BIOL, V1130, P233, DOI 10.1007/978 1 62703 989 5_17
   Nemeth K., 2013, Curr Protoc Immunol, V102
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   O'Hayre M, 2013, NAT REV CANCER, V13, P412, DOI 10.1038/nrc3521
   Pattabiraman DR, 2016, SCIENCE, V351, P1042, DOI 10.1126/science.aad3680
   Piersanti S, 2010, J BONE MINER RES, V25, P1103, DOI 10.1359/jbmr.091036
   Pivonello R, 2015, FRONT NEUROSCI SWITZ, V9, DOI 10.3389/fnins.2015.00129
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Regard JB, 2011, P NATL ACAD SCI USA, V108, P20101, DOI 10.1073/pnas.1114656108
   Riminucci M, 1997, AM J PATHOL, V151, P1587
   Riminucci M, 2003, J CLIN INVEST, V112, P683, DOI 10.1172/JC120031899
   Riminucci M, 2006, J BONE MINER RES, V21, pP125, DOI 10.1359/JBMR.06S224
   Riminucci M, 2010, J MOL ENDOCRINOL, V45, P355, DOI 10.1677/JME 10 0097
   Saggio I, 2014, J BONE MINER RES, V29, P2357, DOI 10.1002/jbmr.2267
   SHENKER A, 1993, J PEDIATR US, V123, P509, DOI 10.1016/S0022 3476(05)80943 6
   SHENKER A, 1994, J CLIN ENDOCR METAB, V79, P750, DOI 10.1210/jc.79.3.750
   Toyosawa S, 2007, MODERN PATHOL, V20, P389, DOI 10.1038/modpathol.3800753
   Turan S, 2015, CURR OSTEOPOROS REP, V13, P146, DOI 10.1007/s11914 015 0268 x
   WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403
   Weinstein LS, 2004, ENDOCRINOLOGY, V145, P5459, DOI 10.1210/en.2004 0865
   Wilk K, 2017, STEM CELL REP, V8, P933, DOI 10.1016/j.stemcr.2017.03.002
   Wu JY, 2011, J CLIN INVEST, V121, P3492, DOI 10.1172/JCI46406
   Yamamizu K, 2012, CELL STEM CELL, V10, P759, DOI 10.1016/j.stem.2012.02.022
   Yuan Q, 2014, J BONE MINER RES, V29, P693, DOI 10.1002/jbmr.2079
   Zhao X, 2016, ADV HEALTHC MATER, V5, P108, DOI 10.1002/adhm.201500005
NR 45
TC 56
Z9 69
U1 0
U2 19
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JAN 16
PY 2018
VL 115
IS 3
BP E428
EP E437
DI 10.1073/pnas.1713710115
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FT3ZS
UT WOS:000423091400013
PM 29282319
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Marcuzzi, A
   Crovella, S
   Pontillo, A
AF Marcuzzi, Annalisa
   Crovella, Sergio
   Pontillo, Alessandra
TI Geraniol Rescues Inflammation in Cellular and Animal Models of
   Mevalonate Kinase Deficiency
SO IN VIVO
LA English
DT Article
DE Pamidronate; geraniol; inflammation; mevalonate kinase deficiency
ID NITROGEN CONTAINING BISPHOSPHONATES; CELLS IN VITRO; INTERLEUKIN 1 BETA
   SECRETION; CYTOKINE PROFILES; BONE RESORPTION; MECHANISMS; VIVO;
   PAMIDRONATE; ALENDRONATE; INHIBITION
AB Background/Aim: The inhibition of the mevalonate pathway through genetic defects such as mevalonate kinase deficiency (MKD) or pharmacological drugs such as aminobisphosphonates causes a shortage of intermediate compounds, in particular geranylgeranyl pyrophosphate (GGPP), which is associated with the consequent augmented IL 1 beta release in monocytes. Considering that, due to its biochemical structure, isoprenoid geraniol enters the mevalonate pathway and may revert the genetic or pharmacological inhibition, the present study tested isoprenoid geraniol in cellular and animal MKD models obtained through the use of aminobisphosphonate pamidronate. Materials and Methods: The effect of natural isoprenoid geraniol on bacterial induced inflammation was evaluated in a monocytic cell line (Raw 264.7) and in Balb/c mice treated with pamidronate. Results: Geraniol diminished the levels of inflammatory markers induced by pamidronate stimuli in vitro and in vivo. Conclusion: Geraniol may be proposed as a novel therapeutic approach for the orphan disease MKD, and may also be considered for the evaluation of possible inflammatory side effects of aminobisphosphonates.
C1 [Marcuzzi, Annalisa; Crovella, Sergio; Pontillo, Alessandra] Inst Maternal & Child Hlth IRCCS Burlo Garofolo T, Med Genet Serv, I 34134 Trieste, Italy.
   [Crovella, Sergio] Univ Fed Pernambuco, Dept Genet, Recife, PE, Brazil.
C3 IRCCS Burlo Garofolo; Universidade Federal de Pernambuco
RP Marcuzzi, A (通讯作者)，Inst Maternal & Child Hlth IRCCS Burlo Garofolo T, Med Genet Serv, Via Istria 65 1, I 34134 Trieste, Italy.
EM marcuzzi@burlo.trieste.it
RI Crovella, Sergio/K 5050 2016; Pontillo, Alessandra/D 4352 2012;
   Pontillo, Alessandra/ABC 6266 2020; Marcuzzi, Annalisa/AAA 6038 2020
OI Marcuzzi, Annalisa/0000 0003 3427 618X; Pontillo,
   Alessandra/0000 0002 7883 0640; Crovella, Sergio/0000 0001 8493 1168
FU Institute for Maternal and Child Health IRCCS 'Burlo Garofolo' [RC
   13/08]
FX This work was supported by a grant from the Institute for Maternal and
   Child Health IRCCS 'Burlo Garofolo' (RC 13/08).
CR Carbone LD, 2006, CLIN EXP IMMUNOL, V146, P371, DOI 10.1111/j.1365 2249.2006.03216.x
   CECCHINI MG, 1990, J BONE MINER RES, V5, P1019
   De Leo L, 2010, PHARMACOL RES, V61, P506, DOI 10.1016/j.phrs.2010.02.012
   Deng X, 2006, TOXICOL APPL PHARM, V213, P64, DOI 10.1016/j.taap.2005.09.005
   Diaz Borjon A, 2006, JCR J CLIN RHEUMATOL, V12, P131, DOI 10.1097/01.rhu.0000221796.06383.4e
   Dombrecht EJ, 2007, CLIN EXP RHEUMATOL, V25, P817
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Frenkel J, 2002, ARTHRITIS RHEUM, V46, P2794, DOI 10.1002/art.10550
   Halasy Nagy JM, 2001, BONE, V29, P553, DOI 10.1016/S8756 3282(01)00615 9
   Houten SM, 2000, BBA MOL CELL BIOL L, V1529, P19, DOI 10.1016/S1388 1981(00)00135 9
   Kuijk LM, 2008, MOL IMMUNOL, V45, P2158, DOI 10.1016/j.molimm.2007.12.008
   Mandey SHL, 2006, ARTHRITIS RHEUM US, V54, P3690, DOI 10.1002/art.22194
   MARCUZZI A, 2010, INT IMMUNOPHARMACOL, V61, P506
   Marcuzzi A, 2008, PEDIATR RES, V64, P177, DOI 10.1203/PDR.0b013e3181761870
   Marcuzzi A, 2010, INFLAMM RES, V59, P335, DOI 10.1007/s00011 010 0168 6
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   PENNANEN N, 1995, PHARMACEUT RES, V12, P916, DOI 10.1023/A:1016281608773
   Reinholz GG, 2002, BREAST CANCER RES TR, V71, P257, DOI 10.1023/A:1014418017382
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Slobodin G, 2009, CLIN RHEUMATOL, V28, P1359, DOI 10.1007/s10067 009 1256 2
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Thiebaud D, 1997, CALCIFIED TISSUE INT, V61, P386, DOI 10.1007/s002239900353
   van Beek ER, 2003, BONE, V33, P805, DOI 10.1016/j.bone.2003.07.007
   Van Offel JF, 2001, CLIN EXP RHEUMATOL, V19, P13
NR 24
TC 32
Z9 33
U1 0
U2 5
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
J9 IN VIVO
JI In Vivo
PD JAN FEB
PY 2011
VL 25
IS 1
BP 87
EP 92
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 720RC
UT WOS:000287296800012
PM 21282739
DA 2025 08 17
ER

PT J
AU Huang, L
   Mackenzie, GG
   Ouyang, N
   Sun, Y
   Xie, G
   Johnson, F
   Komninou, D
   Rigas, B
AF Huang, L.
   Mackenzie, G. G.
   Ouyang, N.
   Sun, Y.
   Xie, G.
   Johnson, F.
   Komninou, D.
   Rigas, B.
TI The novel phospho non steroidal anti inflammatory drugs, OXT 328, MDC 22
   and MDC 917, inhibit adjuvant induced arthritis in rats
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE arthritis; NSAIDs; anti inflammation; phospho aspirin;
   phospho ibuprofen; phospho sulindac; rheumatoid arthritis
ID RHEUMATOID ARTHRITIS; TNF ALPHA; NSAIDS; CELLS; EPIDEMIOLOGY;
   PATHOGENESIS; INFLAMMATION; NOCICEPTION; METABOLISM; RECEPTORS
AB BACKGROUND AND PURPOSE
   The use of non steroidal anti inflammatory drugs (NSAIDs) in the treatment of rheumatoid arthritis (RA) is limited by their toxicity. We evaluated the anti inflammatory efficacy and safety of three novel modified NSAIDs, phospho aspirin, phospho ibuprofen and phospho sulindac.
   EXPERIMENTAL APPROACH
   We determined the anti inflammatory effects and gastrointestinal safety of the phospho NSAIDs in the rat adjuvant arthritis model and studied their mechanism of action in cultured cells, Cytokines were measured with elisa and activation of nuclear factor kappa B (NF kappa B) by immunohistochemistry.
   KEY RESULTS
   All three phospho NSAIDs showed less gastrointestinal toxicity than their parent compounds and demonstrated strong anti inflammatory effects, essentially reversing joint inflammation and oedema. They have a broad but not uniform effect on the expression of relevant cytokines, in general decreasing IL 6 and IL 1 beta and increasing IL 10 levels in rat plasma and cultured cells. Phospho sulindac and phospho ibuprofen but not phospho aspirin suppressed PGE(2) production in vitro, whereas phospho aspirin (in contrast to aspirin) showed the same effect in vivo. In joint tissues, phospho aspirin inhibited NF kappa B activation, and suppressed inflammation and bone resorption. Phospho aspirin also inhibited Jurkat T cell proliferation. In general, phospho aspirin had greater efficacy but different effects upon inflammatory mediators compared with aspirin. The chemical modification of the parent NSAIDs seems crucial for their safety and efficacy.
   CONCLUSIONS AND IMPLICATIONS
   Phospho aspirin, phospho ibuprofen and phospho sulindac were safer than their parent NSAIDs, were highly effective in rat adjuvant arthritis and inhibited many key mediators in the pathophysiology of RA. These novel compounds are promising candidate drugs for the treatment of RA and merit further evaluation.
C1 [Rigas, B.] SUNY Stony Brook, Canc Prevent Div, HSC, Dept Med, Stony Brook, NY 11794 USA.
   [Johnson, F.] Chem Master Int Inc, Stony Brook, NY USA.
   [Komninou, D.] Medicon Inc, Stony Brook, NY USA.
C3 State University of New York (SUNY) System; Stony Brook University
RP Rigas, B (通讯作者)，SUNY Stony Brook, Canc Prevent Div, HSC, Dept Med, T17 080, Stony Brook, NY 11794 USA.
EM basil.rigas@stonybrook.edu
RI Mackenzie, Gerardo/AAW 5114 2020
OI Mackenzie, Gerardo/0000 0002 6460 7165
FU NIH [R01 CA139453, NIH RCA153662A, R01CA13945402]
FX Grant support: NIH grants, R01 CA139453, NIH RCA153662A and
   R01CA13945402.
CR Adeyeye CM, 1996, PHARMACEUT RES, V13, P784, DOI 10.1023/A:1016068104462
   Akaogi Jun, 2006, Endocrine Metabolic & Immune Disorders Drug Targets, V6, P383
   Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002
   [Anonymous], 2002, Nonparametric Analysis of Longitudinal Data in Factorial Experiments
   Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P377
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Cicala C, 2000, BRIT J PHARMACOL, V130, P1399, DOI 10.1038/sj.bjp.0703449
   Conway JG, 2001, J PHARMACOL EXP THER, V298, P900
   Dayer JM, 2003, RHEUMATOLOGY, V42, P3, DOI 10.1093/rheumatology/keg326
   Eurenius E, 2005, ARTHRIT RHEUM ARTHR, V53, P48, DOI 10.1002/art.20924
   Fahmi H, 2004, CURR OPIN RHEUMATOL, V16, P623, DOI 10.1097/01.bor.0000129664.81052.8e
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   HAMBERG M, 1971, J BIOL CHEM, V246, P6713
   Hayashida K, 2004, J VET MED SCI, V66, P149, DOI 10.1292/jvms.66.149
   Hikiji H, 2008, PROG LIPID RES, V47, P107, DOI 10.1016/j.plipres.2007.12.003
   HYMAN BT, 1982, BIOCHIM BIOPHYS ACTA, V713, P375, DOI 10.1016/0005 2760(82)90256 9
   Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141
   Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806
   Kunz M, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/979258
   Lichtman SN, 1998, AM J PHYSIOL GASTR L, V275, pG39, DOI 10.1152/ajpgi.1998.275.1.G39
   Mackenzie GG, 2010, GASTROENTEROLOGY, V139, P1320, DOI 10.1053/j.gastro.2010.06.044
   McCoy JM, 2002, J CLIN INVEST, V110, P651, DOI 10.1172/JCI200215528
   Monaco Claudia, 2004, Current Drug Targets   Inflammation and Allergy, V3, P35, DOI 10.2174/1568010043483881
   Nemmani KVS, 2009, BIOORG MED CHEM LETT, V19, P5297, DOI 10.1016/j.bmcl.2009.07.142
   PEARSON CM, 1961, J EXP MED, V113, P485, DOI 10.1084/jem.113.3.485
   Philippe L, 1997, AM J PHYSIOL REG I, V273, pR1550, DOI 10.1152/ajpregu.1997.273.4.R1550
   Piazza GA, 2009, CANCER PREV RES, V2, P572, DOI 10.1158/1940 6207.CAPR 09 0001
   Rahme E, 2010, LANCET, V376, P146, DOI 10.1016/S0140 6736(10)60839 2
   Rigas B, 2007, CURR OPIN GASTROEN, V23, P55, DOI 10.1097/MOG.0b013e32801145b0
   Roberts L.J.I.M., 2001, PHARM BASIS THERAPEU, P687
   Silverstein FE, 2000, JAMA J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247
   Singh G, 1999, J RHEUMATOL, V26, P18
   Sostres C, 2010, BEST PRACT RES CL GA, V24, P121, DOI 10.1016/j.bpg.2009.11.005
   Sun Y, 2008, CANCER RES, V68, P8269, DOI 10.1158/0008 5472.CAN 08 2010
   THEISENPOPP P, 1994, AGENTS ACTIONS, V42, P50, DOI 10.1007/BF02014300
   WHITELEY PE, 1998, CURRENT PROTOCOLS PH, V3
   WHITELEY PE, 2001, CURRENT PROTOCOLS PH, V2
   Zhao WP, 2009, CARCINOGENESIS, V30, P512, DOI 10.1093/carcin/bgp015
NR 40
TC 48
Z9 53
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD APR
PY 2011
VL 162
IS 7
BP 1521
EP 1533
DI 10.1111/j.1476 5381.2010.01162.x
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 730FE
UT WOS:000288018100006
PM 21175575
OA Green Published
DA 2025 08 17
ER

PT J
AU Zeng, YY
   Zhou, MR
   Chen, LF
   Fang, HM
   Liu, SK
   Zhou, CC
   Sun, JM
   Wang, ZX
AF Zeng, Yuyang
   Zhou, Muran
   Chen, Lifeng
   Fang, Huimin
   Liu, Shaokai
   Zhou, Chuchao
   Sun, Jiaming
   Wang, Zhenxing
TI Alendronate loaded graphene oxide functionalized collagen sponge for the
   dual effects of osteogenesis and anti osteoclastogenesis in osteoporotic
   rats
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Osteoporosis; Osteoporotic bone defect; Graphene oxide; Osteoclast;
   Alendronate
ID SIGNALING PATHWAY; BONE REGENERATION; IN VITRO; DIFFERENTIATION;
   NANOMATERIALS; DELIVERY; DENSITY; ENHANCE; REPAIR
AB Graphene Oxide (GO) related hydrogels have been extensively studied in hard tissue repair, because GO can not only enhance the mechanical properties of polymers but also promote osteogenic differentiation of mesenchymal stem cells. However, simple GO related hydrogels are not ideal for the repair of osteoporotic bone defects as the overactive osteoclasts in osteoporosis. Alendronate (Aln) is known to inhibit osteoclasts and may bind to GO through covalent connection. Therefore, delivering Aln in GO related hydrogels may be effective to repair osteoporotic bone defects. Here, we developed a control released system which is constructed by collagen (Col) GO sponges loaded with Aln (Col GO Aln) for osteoporotic bone defect repair. In vitro, Col GO Aln sponges prolonged the release period of Aln, and the sponge containing 0.05% (w/v) GO released Aln faster than sponge with 0.2% GO. Furthermore, tartrate resistant acid phosphatase (TRAP) and F actin staining demonstrated that Col GO Aln sponges effectively inhibited osteoclastogenesis of monocyte macrophages. In vivo, micro CT scan showed that the volume of newborn bone in defect site by 0.05% GO sponge was nearly three times larger than that of other groups. Moreover, the CT and histological examinations of rat femur proved that Col GO Aln sponges decreased the number of osteoclasts and suppressed the systemic bone loss in osteoporotic rats. These findings reveal that the application of GO as carriers of anti osteoporosis drugs is a viable treatment for osteoporosis. The results also underscore the potential of GO related hydrogels with Aln releasing capacity for bone regeneration in osteoporosis.
C1 [Zeng, Yuyang; Zhou, Muran; Chen, Lifeng; Fang, Huimin; Liu, Shaokai; Zhou, Chuchao; Sun, Jiaming; Wang, Zhenxing] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Plast Surg, Wuhan 430022, Peoples R China.
   [Zeng, Yuyang; Zhou, Muran; Chen, Lifeng; Fang, Huimin; Liu, Shaokai; Zhou, Chuchao; Sun, Jiaming; Wang, Zhenxing] Wuhan Clin Res Ctr Superficial Organ Reconstruct, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Sun, JM; Wang, ZX (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Plast Surg, Wuhan 430022, Peoples R China.
EM sunjm1592@sina.com; benjamin.wzx@163.com
RI ; Chen, Lifeng/JJE 7359 2023; Liu, Shaokai/ABG 8387 2021; Zhou,
   Muran/GXF 9250 2022
OI Zeng, Yu yang/0000 0003 4048 5199; Liu, Shaokai/0000 0002 2948 1798; 
FU National Key R&D Program of China [2019YFA0110500]; National Natural
   Science Foundation of China [81701922, 81873941]
FX This work was supported by the National Key R&D Program of China
   (2019YFA0110500) and the National Natural Science Foundation of China
   (81701922, 81873941).
CR Arjmandi BH, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050496
   Cao L, 2012, BIOMATERIALS, V33, P5076, DOI 10.1016/j.biomaterials.2012.03.069
   Chen K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01046
   Chen YH, 2019, ACS APPL MATER INTER, V11, P15986, DOI 10.1021/acsami.8b22606
   Choe G, 2019, NANOSCALE, V11, P23275, DOI 10.1039/c9nr07643c
   Cui X, 2020, BIOACT MATER, V5, P334, DOI 10.1016/j.bioactmat.2020.02.016
   Deepachitra R, 2014, RSC ADV, V4, P62717, DOI 10.1039/c4ra10150b
   Deng Y, 2020, CHEM MATER, V32, P2180, DOI 10.1021/acs.chemmater.0c00290
   Dong TS, 2020, ACS APPL MATER INTER, V12, P14971, DOI 10.1021/acsami.0c02304
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Gao HC, 2015, BIOSENS BIOELECTRON, V65, P404, DOI 10.1016/j.bios.2014.10.067
   Hasegawa T, 2018, HISTOCHEM CELL BIOL, V149, P289, DOI 10.1007/s00418 018 1646 0
   Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523
   Hodgins NO, 2016, J CONTROL RELEASE, V241, P229, DOI 10.1016/j.jconrel.2016.09.023
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Jaha Haytham, 2016, Biochem Biophys Rep, V6, P190
   Jiang PF, 2015, ACTA BIOMATER, V19, P76, DOI 10.1016/j.actbio.2015.03.018
   Kim SE, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/320713
   Lecka Czernik B, 2015, J BONE MINER RES, V30, P1356, DOI 10.1002/jbmr.2574
   Li J, 2019, NAT COMMUN, V10, P1, DOI DOI 10.1038/S41467 019 10348 0
   Li JL, 2019, THERANOSTICS, V9, P5839, DOI 10.7150/thno.34480
   Li M, 2018, ACTA BIOMATER, V71, P118, DOI 10.1016/j.actbio.2018.03.003
   Liu JZ, 2018, J CONTROL RELEASE, V286, P64, DOI 10.1016/j.jconrel.2018.07.034
   Liu SK, 2018, ACS APPL MATER INTER, V10, P42948, DOI 10.1021/acsami.8b11071
   Lu CJ, 2017, CHEMOSPHERE, V184, P795, DOI 10.1016/j.chemosphere.2017.06.049
   Maria S, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12465
   Mei QS, 2019, ADV SCI, V6, DOI 10.1002/advs.201900855
   Mekhail GM, 2016, NANOMEDICINE UK, V11, P2251, DOI 10.2217/nnm 2016 0151
   Nicolin V, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00494
   Ouyang L, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201800036
   Patil R, 2019, INT J BIOL MACROMOL, V141, P232, DOI 10.1016/j.ijbiomac.2019.08.243
   Quan HY, 2018, ACS APPL MATER INTER, V10, P25547, DOI 10.1021/acsami.8b09879
   Roche B, 2014, J BONE MINER RES, V29, P1608, DOI 10.1002/jbmr.2191
   Ruan J, 2016, ADV FUNCT MATER, V26, P1085, DOI 10.1002/adfm.201504141
   Sakata M, 2018, TISSUE ENG PT A, V24, P1001, DOI [10.1089/ten.tea.2017.0358, 10.1089/ten.TEA.2017.0358]
   Schlundt C, 2018, CURR OSTEOPOROS REP, V16, P155, DOI 10.1007/s11914 018 0432 1
   Shin SR, 2016, ADV DRUG DELIVER REV, V105, P255, DOI 10.1016/j.addr.2016.03.007
   Song HS, 2017, BIOSENS BIOELECTRON, V89, P187, DOI 10.1016/j.bios.2016.03.045
   Spangenberg A, 2016, CALCIFIED TISSUE INT, V99, P608, DOI 10.1007/s00223 016 0186 7
   Sui BD, 2016, J DENT RES, V95, P1333, DOI 10.1177/0022034516653589
   Tan J, 2017, CURR STEM CELL RES T, V12, P388, DOI 10.2174/1574888X10666151001114527
   Tang AM, 2016, NANOSCALE, V8, P10570, DOI 10.1039/c6nr00843g
   Tang Q, 2019, THERANOSTICS, V9, P1125, DOI 10.7150/thno.29566
   Tonelli FMP, 2015, NANOMEDICINE UK, V10, P2423, DOI [10.2217/NNM.15.65, 10.2217/nnm.15.65]
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Pham TT, 2019, J IND ENG CHEM, V76, P310, DOI 10.1016/j.jiec.2019.03.055
   Venkatesan J, 2014, J BIOMED NANOTECHNOL, V10, P3105, DOI 10.1166/jbn.2014.1969
   Walash MI, 2012, CHEM CENT J, V6, DOI 10.1186/1752 153X 6 25
   Wang X, 2018, ARTIF CELL NANOMED B, V46, P171, DOI 10.1080/21691401.2018.1453825
   Wang ZX, 2017, J MATER CHEM B, V5, P62, DOI 10.1039/c6tb02414a
   Wu T, 2020, BIOACT MATER, V5, P348, DOI 10.1016/j.bioactmat.2020.03.004
   Yang XL, 2019, ENVIRON TOXICOL, V34, P415, DOI 10.1002/tox.22695
   Yu XH, 2015, ADV HEALTHC MATER, V4, P1268, DOI 10.1002/adhm.201400760
   Zheng CX, 2020, TRENDS MOL MED, V26, P89, DOI 10.1016/j.molmed.2019.04.008
   Zheng D, 2017, J COLLOID INTERF SCI, V487, P1, DOI 10.1016/j.jcis.2016.10.014
   Zhou CX, 2018, BIOMATERIALS, V176, P50, DOI 10.1016/j.biomaterials.2018.05.039
   Zhou CH, 2018, BRIT J PHARMACOL, V175, P859, DOI 10.1111/bph.14092
   Zhou CC, 2018, ACS APPL MATER INTER, V10, P44080, DOI 10.1021/acsami.8b17636
NR 58
TC 56
Z9 59
U1 8
U2 158
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING, DONGHENG DISTRICT 100717,
   PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD DEC
PY 2020
VL 5
IS 4
BP 859
EP 870
DI 10.1016/j.bioactmat.2020.06.010
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA NE3DP
UT WOS:000562478100011
PM 32637749
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhuo, ZJ
   Wan, YY
   Guan, DG
   Ni, SJ
   Wang, LY
   Zhang, ZK
   Liu, J
   Liang, C
   Yu, YY
   Lu, AP
   Zhang, G
   Zhang, BT
AF Zhuo, Zhenjian
   Wan, Youyang
   Guan, Daogang
   Ni, Shuaijian
   Wang, Luyao
   Zhang, Zongkang
   Liu, Jin
   Liang, Chao
   Yu, Yuanyuan
   Lu, Aiping
   Zhang, Ge
   Zhang, Bao Ting
TI A Loop Based and AGO Incorporated Virtual Screening Model Targeting
   AGO Mediated miRNA mRNA Interactions for Drug Discovery to Rescue Bone
   Phenotype in Genetically Modified Mice
SO ADVANCED SCIENCE
LA English
DT Article
DE bone rescue; drug discovery; miRNA mRNA interactions; small molecule
   screening; virtual screening models
ID MESENCHYMAL STEM CELLS; SEQUENCE BASED DESIGN; SMALL MOLECULES;
   OSTEOGENIC DIFFERENTIATION; CARCINOMA CELLS; MICRORNAS; PROMOTES;
   RECOGNITION; EXPRESSION; INVASION
AB Several virtual screening models are proposed to screen small molecules only targeting primary miRNAs without selectivity. Few attempts have been made to develop virtual screening strategies for discovering small molecules targeting mature miRNAs. Mature miRNAs and their specific target mRNA can form unique functional loops during argonaute (AGO) mediated miRNA mRNA interactions, which may serve as potential targets for small molecule drug discovery. Thus, a loop based and AGO incorporated virtual screening model is constructed for targeting the loops. The previously published studies have found that miR 214 can target ATF4 to inhibit osteoblastic bone formation, whereas miR 214 can target TRAF3 to promote osteoclast activity. By using the virtual model, the top ten candidate small molecules targeting miR 214 ATF4 mRNA interactions and top ten candidate small molecules targeting miR 214 TRAF3 mRNA interactions are selected, respectively. Based on both in vitro and in vivo data, one small molecule can target miR 214 ATF4 mRNA to promote ATF4 protein expression and enhance osteogenic potential, whereas one small molecule can target miR 214 TRAF3 mRNA to promote TRAF3 protein expression and inhibit osteoclast activity. These data indicate that the loop based and AGO incorporated virtual screening model can help to obtain small molecules specifically targeting miRNA mRNA interactions to rescue bone phenotype in genetically modified mice.
C1 [Zhuo, Zhenjian; Zhang, Zongkang; Zhang, Bao Ting] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.
   [Zhuo, Zhenjian] Aptacure Therapeut Ltd, Kowloon, Hong Kong, Peoples R China.
   [Wan, Youyang; Guan, Daogang; Ni, Shuaijian; Wang, Luyao; Liu, Jin; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong, Peoples R China.
   [Wan, Youyang; Guan, Daogang; Ni, Shuaijian; Wang, Luyao; Liu, Jin; Liang, Chao; Yu, Yuanyuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Inst Integrated Bioinformed & Translat Sci, Sch Chinese Med, Hong Kong, Peoples R China.
   [Ni, Shuaijian; Wang, Luyao; Yu, Yuanyuan; Lu, Aiping] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou 510515, Peoples R China.
   [Guan, Daogang] Guangdong Hong Kong Macao Greater Bay Area Int Re, Hong Kong 999077, Peoples R China.
C3 Chinese University of Hong Kong; Hong Kong Baptist University; Hong Kong
   Baptist University; Southern Medical University   China
RP Zhang, BT (通讯作者)，Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Sch Chinese Med, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Inst Integrated Bioinformed & Translat Sci, Sch Chinese Med, Hong Kong, Peoples R China.; Lu, AP (通讯作者)，Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangdong Prov Key Lab Single Cell Technol & Appl, Guangzhou 510515, Peoples R China.
EM aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk; zhangbaoting@cuhk.edu.hk
RI Liang, Chao/AAS 6999 2021; Li, YiXue/JRW 6306 2023; Zhang,
   Ge/N 4150 2013; Zhuo, Zhenjian/V 8198 2017; Zhang, Baoting/B 6273 2015;
   Yu, YY/ADO 6482 2022; LU, Aiping/JDX 0577 2023; Zhang,
   Zongkang/AAB 2564 2020
OI Guan, Daogang/0000 0003 1414 0189; Liang, Chao/0000 0002 5617 3483; Yu,
   Yuanyuan/0000 0003 1276 5695; Zhuo, Zhenjian/0000 0003 0142 4086; 
FU National Key R&D Program of China [2018YFA0800804]; National Natural
   Science Foundation Council of China [81702189, 81703049, 81803374];
   Interdisciplinary Research Clusters Matching Scheme of Hong Kong Baptist
   University [RC IRCs/17 18/02, RC/IRCs/1718/04, RC IRMS/15 16/01]; Hong
   Kong General Research Fund [14112915, 14100218, 14108816, 12101018,
   12102518, HKBU12102914, HKBU12101117, HKBU12136616, HKBU12103519]; Hong
   Kong Baptist University Strategic Development Fund [SDF13 1209 P01,
   SDF150324 P02, SDF19 0402 P02]; Science and Technology Innovation
   Commission of Shenzhen Municipality Funds [JCYJ20160229210357960];
   Chinese University ofHong Kong [4054220, 4054138]
FX Z.Z., Y.W., D.G., S.N., and L.W. contributed equally to this work. This
   was a joint project which involved three academic units, including The
   Chinese University of Hong Kong (CUHK) and Institute of Integrated
   Bioinformedicine and Translational Science, Hong Kong Baptist University
   (HKBU IBTS), and Law Sau Fai Institute for Advancing Translational
   Medicine in Bone and Joint Diseases, Hong Kong Baptist University
   (HKBU TMBJ). This study was supported by the funds from the National Key
   R&D Program of China (2018YFA0800804), the National Natural Science
   Foundation Council of China (81702189, 81703049, and 81803374), the
   Interdisciplinary Research Clusters Matching Scheme of Hong Kong Baptist
   University (RC IRCs/17 18/02, RC/IRCs/1718/04, and RC IRMS/15 16/01),
   Hong Kong General Research Fund (14112915, 14100218, 14108816, 12101018,
   12102518, HKBU12102914, HKBU12101117, HKBU12136616, and HKBU12103519),
   Hong Kong Baptist University Strategic Development Fund (SDF13 1209 P01,
   SDF150324 P02(b), and SDF19 0402 P02), Science and Technology Innovation
   Commission of Shenzhen Municipality Funds (JCYJ20160229210357960), and
   the direct grant of The Chinese University ofHong Kong (4054220 and
   4054138). The authors thank Prof. Matthew D. Disney from Department of
   Chemistry, The Scripps Research Institute, United States, for his help
   in providing the assess to Inforna and miRNA motif database servers,
   which is the basis of the current model. The authors thank
   Bioinformedicine Service (San Diego, CA, USA) for their help in
   statistic calculation.
CR Abeydeera ND, 2016, NUCLEIC ACIDS RES, V44, P8052, DOI 10.1093/nar/gkw725
   Aghaeepour N, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 139
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Antczak M, 2016, ACTA BIOCHIM POL, V63, P737, DOI 10.18388/abp.2016_1329
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Bellissimo T, 2017, METHODS MOL BIOL, V1517, P211, DOI 10.1007/978 1 4939 6563 2_15
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   CARUTHERS MH, 1987, METHOD ENZYMOL, V154, P287
   Chiva Blanch G, 2011, J CHROMATOGR A, V1218, P698, DOI 10.1016/j.chroma.2010.12.012
   Desvignes T, 2014, RNA BIOL, V11, P281, DOI 10.4161/rna.28141
   Disney MD, 2016, ACS CHEM BIOL, V11, P1720, DOI 10.1021/acschembio.6b00001
   Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200
   Helwak A, 2013, CELL, V153, P654, DOI 10.1016/j.cell.2013.03.043
   Hofacker IL, 2006, BIOINFORMATICS, V22, P1172, DOI 10.1093/bioinformatics/btl023
   Jiang FZ, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 425
   Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284
   Kheirolomoom A, 2007, BIOMATERIALS, V28, P4311, DOI 10.1016/j.biomaterials.2007.06.008
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Kumar P, 2018, INT CONF MANIP MANU, P181, DOI 10.1109/3M NANO.2018.8552166
   Li JP, 2017, EUR REV MED PHARMACO, V21, P4777
   Lian N, 2012, J BIOL CHEM, V287, P35975, DOI 10.1074/jbc.M112.372458
   Lima WF, 2009, J BIOL CHEM, V284, P26017, DOI 10.1074/jbc.M109.010835
   Lin K, 2019, METHODS MOL BIOL, V1893, P257, DOI 10.1007/978 1 4939 8910 2_19
   Lingel A, 2005, CURR OPIN STRUC BIOL, V15, P107, DOI 10.1016/j.sbi.2005.01.010
   Liu J, 2017, SCI REP UK, V7, DOI 10.1038/srep40487
   Liu J, 2015, BIOMATERIALS, V52, P148, DOI 10.1016/j.biomaterials.2015.02.007
   Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748 7188 6 26
   Louppe Gilles, 2013, Adv Neural Inf Process Syst., V26
   Meier J, 2013, RNA BIOL, V10, P1018, DOI 10.4161/rna.24553
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Negishi Koga T, 2011, NAT MED, V17, P1473, DOI 10.1038/nm.2489
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Phatak P, 2016, ONCOGENE, V35, P2087, DOI 10.1038/onc.2015.271
   Pierson J, 2008, J NEURO ONCOL, V90, P1, DOI 10.1007/s11060 008 9624 3
   Popenda M, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks339
   Pulikkan JA, 2010, BLOOD, V116, P5638, DOI 10.1182/blood 2010 04 281600
   Rehei AL, 2018, EUR REV MED PHARMACO, V22, P5156, DOI 10.26355/eurrev_201808_15711
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Song N, 2017, MOL CELL PROBE, V35, P27, DOI 10.1016/j.mcp.2017.06.002
   Strobl C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471 2105 8 25
   Suryawanshi H, 2010, J PHYS CHEM B, V114, P11155, DOI 10.1021/jp1000545
   Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819
   Velagapudi SP, 2016, P NATL ACAD SCI USA, V113, P5898, DOI 10.1073/pnas.1523975113
   Velagapudi SP, 2014, NAT CHEM BIOL, V10, P291, DOI [10.1038/NCHEMBIO.1452, 10.1038/nchembio.1452]
   Velagapudi SP, 2010, ANGEW CHEM INT EDIT, V49, P3816, DOI 10.1002/anie.200907257
   Wang JM, 2017, AM J TRANSL RES, V9, P3541
   Wang JF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118086
   Wang M, 2017, BIOMED PHARMACOTHER, V95, P1678, DOI 10.1016/j.biopha.2017.09.048
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang XJ, 2012, BIOCHEM BIOPH RES CO, V428, P525, DOI 10.1016/j.bbrc.2012.10.039
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Yang K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13599
   Yang L, 2016, CELL PHYSIOL BIOCHEM, V38, P809, DOI 10.1159/000443036
   Yang WY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11647
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang YK, 2011, BIOCHEM BIOPH RES CO, V414, P233, DOI 10.1016/j.bbrc.2011.09.063
   Zhang YF, 2016, NAT MED, V22, P1160, DOI 10.1038/nm.4162
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133
NR 63
TC 126
Z9 128
U1 3
U2 66
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD JUL
PY 2020
VL 7
IS 13
AR 1903451
DI 10.1002/advs.201903451
EA MAY 2020
PG 22
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA MN2HR
UT WOS:000535795400001
PM 32670749
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Alhasan, H
   Terkawi, MA
   Matsumae, G
   Ebata, T
   Tian, Y
   Shimizu, T
   Nishida, Y
   Yokota, S
   Garcia Martin, F
   Abd Elwakil, MM
   Takahashi, D
   Younis, MA
   Harashima, H
   Kadoya, K
   Iwasaki, N
AF Alhasan, Hend
   Terkawi, Mohamad Alaa
   Matsumae, Gen
   Ebata, Taku
   Tian, Yuan
   Shimizu, Tomohiro
   Nishida, Yoshio
   Yokota, Shunichi
   Garcia Martin, Fayna
   Abd Elwakil, Mahmoud M.
   Takahashi, Daisuke
   Younis, Mahmoud A.
   Harashima, Hideyoshi
   Kadoya, Ken
   Iwasaki, Norimasa
TI Inhibitory role of Annexin A1 in pathological bone resorption and
   therapeutic implications in periprosthetic osteolysis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PRORESOLVING LIPID MEDIATORS; NF KAPPA B; OSTEOCLAST FORMATION;
   INFLAMMATION; RESOLUTION; PEPTIDE; MACROPHAGES; INVOLVEMENT; ACTIVATION;
   MONOCYTES
AB Periprosthetic osteolysis is a cause of arthroplasty failure without available therapies. Here the authors show that Annexin A1 (AnxA1) is involved in in periprosthetic osteolysis and exerts potential therapeutic effects through suppressing NF kappa B signaling and promoting the PPAR gamma pathway resulting in inhibition of inflammation and osteoclasts differentiation induced by wear debris.
   There is currently no therapy available for periprosthetic osteolysis, the most common cause of arthroplasty failure. Here, the role of AnxA1 in periprosthetic osteolysis and potential therapeutics were investigated. Reducing the expression of AnxA1 in calvarial tissue was found to be associated with increased osteolytic lesions and the osteolytic lesions induced by debris implantation were more severe in AnxA1 defecient mice than in wild type mice. AnxA1 inhibits the differentiation of osteoclasts through suppressing NF kappa B signaling and promoting the PPAR gamma pathway. Administration of N terminal AnxA1 (Ac2 26 peptide) onto calvariae significantly reduced osteolytic lesions triggered by wear debris. These therapeutic effects were abrogated in mice that had received the PPAR gamma antagonist, suggesting that the AnxA1/PPAR gamma axis has an inhibitory role in osteolysis. The administration of Ac2 26 suppressed osteolysis induced by TNF alpha and RANKL injections in mice. These findings indicate that AnxA1 is a potential therapeutic agent for the treatment of periprosthetic osteolysis.
C1 [Alhasan, Hend; Terkawi, Mohamad Alaa; Matsumae, Gen; Ebata, Taku; Tian, Yuan; Shimizu, Tomohiro; Nishida, Yoshio; Yokota, Shunichi; Takahashi, Daisuke; Kadoya, Ken; Iwasaki, Norimasa] Hokkaido Univ, Dept Orthoped Surg, Fac Med, Kita Ku, Kita 15,Nish 7, Sapporo, Hokkaido 0608638, Japan.
   [Alhasan, Hend; Terkawi, Mohamad Alaa; Matsumae, Gen; Ebata, Taku; Tian, Yuan; Shimizu, Tomohiro; Nishida, Yoshio; Yokota, Shunichi; Takahashi, Daisuke; Kadoya, Ken; Iwasaki, Norimasa] Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15,Nish 7, Sapporo, Hokkaido 0608638, Japan.
   [Garcia Martin, Fayna] Hokkaido Univ, Grad Sch, Kita Ku, N21 W11,Kita 21,Nish 11, Sapporo, Hokkaido 0010021, Japan.
   [Garcia Martin, Fayna] Hokkaido Univ, Fac Adv Life Sci, Lab Adv Chem Biol, Kita Ku, N21 W11,Kita 21,Nish 11, Sapporo, Hokkaido 0010021, Japan.
   [Garcia Martin, Fayna] Univ La Rioja, Dept Chem, Fac Sci & Technol, E 26006 Logrono, Spain.
   [Abd Elwakil, Mahmoud M.; Younis, Mahmoud A.; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharm & Pharmaceut Sci, Lab Innovat Nanomed, Kita Ku, Kita 12 Nishi 6, Sapporo, Hokkaido 0600812, Japan.
C3 Hokkaido University; Hokkaido University; Hokkaido University; Hokkaido
   University; Universidad de La Rioja; Hokkaido University
RP Terkawi, MA; Shimizu, T (通讯作者)，Hokkaido Univ, Dept Orthoped Surg, Fac Med, Kita Ku, Kita 15,Nish 7, Sapporo, Hokkaido 0608638, Japan.; Terkawi, MA; Shimizu, T (通讯作者)，Hokkaido Univ, Grad Sch Med, Kita Ku, Kita 15,Nish 7, Sapporo, Hokkaido 0608638, Japan.
EM materkawi@med.hokudai.ac.jp; simitom@wg8.so net.ne.jp
RI Garcia Martin, Fayna/AAG 6586 2019; Younis, Mahmoud/AAE 7888 2019;
   Harashima, Hideyoshi/D 8390 2012; Terkawi, M/NDT 1351 2025; Kadoya,
   Ken/LPP 9136 2024; Takahashi, Daisuke/F 7647 2014
OI Garcia Martin, Fayna/0000 0001 9118 3874; Younis,
   Mahmoud/0000 0001 9722 3267; Terkawi, Alaa/0000 0002 5481 8516; Kadoya,
   Ken/0000 0001 5432 3866; 
FU Japan Society for the Promotion of Science [17K10993]; Akiyama Life
   Science Foundation; Kobayashi Foundation; Uehara Memorial Foundation;
   Japan Agency for Medical Research and Development [JP20gm6210004]
FX This work was supported by research grants from Japan Society for the
   Promotion of Science (Grant in Aid for Scientific Research C; 17K10993),
   Akiyama Life Science Foundation, Kobayashi Foundation, Uehara Memorial
   Foundation, and the Japan Agency for Medical Research and Development
   (JP20gm6210004). We thank Dr. Keita Uetsuki and Mrs. Tomoyo Yutani from
   Teijin Nakashima Medical Co., Ltd. (Japan) for providing UHMWPE
   particulate debris from the hip implant materials. We also thank the
   technical assistance of Chowdhury Arpan in the synthesis and
   characterization of the peptide Ac2 26. Knockout mice (AnxA1 KO mice)
   were generated at the Laboratory Animal Resource Center, University of
   Tsukuba.
CR Bendixen AC, 2001, P NATL ACAD SCI USA, V98, P2443, DOI 10.1073/pnas.041493198
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Buckley CD, 2014, IMMUNITY, V40, P315, DOI 10.1016/j.immuni.2014.02.009
   Chan BY, 2007, BONE, V40, P149, DOI 10.1016/j.bone.2006.07.029
   Cobelli N, 2011, NAT REV RHEUMATOL, V7, P600, DOI 10.1038/nrrheum.2011.128
   Cooray SN, 2013, P NATL ACAD SCI USA, V110, P18232, DOI 10.1073/pnas.1308253110
   de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107
   Del Gaudio P, 2015, CARBOHYD POLYM, V115, P629, DOI 10.1016/j.carbpol.2014.09.040
   Dufton N, 2010, J IMMUNOL, V184, P2611, DOI 10.4049/jimmunol.0903526
   Fredman G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1065
   Fullerton JN, 2016, NAT REV DRUG DISCOV, V15, P551, DOI 10.1038/nrd.2016.39
   Gavins FNE, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00354
   Gilmore TD, 2011, CURR TOP MICROBIOL, V349, P245, DOI 10.1007/82_2010_105
   Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270
   Hounoki H, 2008, BONE, V42, P765, DOI 10.1016/j.bone.2007.11.016
   Ito S, 2004, J ORTHOP SCI, V9, P478, DOI 10.1007/s00776 004 0808 1
   Kamaly N, 2013, P NATL ACAD SCI USA, V110, P6506, DOI 10.1073/pnas.1303377110
   Kandahari AM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.14
   Kao W, 2014, BRIT J PHARMACOL, V171, P4087, DOI 10.1111/bph.12768
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Matsumae G, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10232
   McArthur S, 2020, J CLIN INVEST, V130, P1156, DOI 10.1172/JCI124635
   Mirsaeidi M, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0843 7
   Moynihan KD, 2016, NAT MED, V22, P1402, DOI 10.1038/nm.4200
   PAPATHEOFANIS FJ, 1991, J BIOMED MATER RES, V25, P761, DOI 10.1002/jbm.820250606
   Perretti M, 2009, BRIT J PHARMACOL, V158, P936, DOI 10.1111/j.1476 5381.2009.00483.x
   Perucci LO, 2017, EXPERT OPIN THER TAR, V21, P879, DOI 10.1080/14728222.2017.1364363
   RITGER P L, 1987, Journal of Controlled Release, V5, P37, DOI 10.1016/0168 3659(87)90035 6
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Schneider JG, 2011, BONE, V48, P54, DOI 10.1016/j.bone.2010.09.016
   Senchenkova EY, 2019, CIRCULATION, V140, P319, DOI 10.1161/CIRCULATIONAHA.118.039345
   Shen Z, 2010, AM J PHYSIOL GASTR L, V298, pG364, DOI 10.1152/ajpgi.00456.2009
   Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573
   Sun SC, 2013, TRENDS IMMUNOL, V34, P282, DOI 10.1016/j.it.2013.01.004
   Terkawi MA, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031786
   Terkawi MA, 2019, ACTA BIOMATER, V89, P242, DOI 10.1016/j.actbio.2019.03.028
   Terkawi MA, 2018, ACTA BIOMATER, V65, P417, DOI 10.1016/j.actbio.2017.11.001
   Tian Y, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01720
   Wozniak W, 2004, ACTA ORTHOP SCAND, V75, P549, DOI 10.1080/00016470410001402
   Xia HF, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6254587
   Yang YH, 2009, J IMMUNOL, V183, P1435, DOI 10.4049/jimmunol.0804000
NR 41
TC 29
Z9 30
U1 1
U2 11
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL 7
PY 2022
VL 13
IS 1
AR 3919
DI 10.1038/s41467 022 31646 0
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 2Y3NJ
UT WOS:000825808100020
PM 35798730
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Feigenson, M
   Shull, LC
   Taylor, EL
   Camilleri, ET
   Riester, SM
   van Wijnen, AJ
   Bradley, EW
   Westendorf, JJ
AF Feigenson, Marina
   Shull, Lomeli Carpio
   Taylor, Earnest L.
   Camilleri, Emily T.
   Riester, Scott M.
   van Wijnen, Andre J.
   Bradley, Elizabeth W.
   Westendorf, Jennifer J.
TI Histone Deacetylase 3 Deletion in Mesenchymal Progenitor Cells Hinders
   Long Bone Development
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HDAC3; FGF21; LIMB DEVELOPMENT; CHONDROGENESIS; MMP3; MMP10; VORINOSTAT;
   RGFP966
ID GROWTH FACTOR 21; SKELETAL DEVELOPMENT; CHROMATIN STRUCTURE; EXPRESSION;
   DISEASE; ACETYLATION; MAINTENANCE; INHIBITION; PHYSIOLOGY; ROLES
AB Long bone formation is a complex process that requires precise transcriptional control of gene expression programs in mesenchymal progenitor cells. Histone deacetylases (Hdacs) coordinate chromatin structure and gene expression by enzymatically removing acetyl groups from histones and other proteins. Hdac inhibitors are used clinically to manage mood disorders, cancers, and other conditions but are teratogenic to the developing skeleton and increase fracture risk in adults. In this study, the functions of Hdac3, one of the enzymes blocked by current Hdac inhibitor therapies, in skeletal mesenchymal progenitor cells were determined. Homozygous deletion of Hdac3 in Prrx1 expressing cells prevented limb lengthening, altered pathways associated with endochondral and intramembranous bone development, caused perinatal lethality, and slowed chondrocyte and osteoblast differentiation in vitro. Transcriptomic analysis revealed that Hdac3 regulates vastly different pathways in mesenchymal cells expressing the Prxx1 Cre driver than those expressing the Col2 CreERT driver. Notably, Fgf21 was elevated in Hdac3 CKOPrrx1 limbs as well as in chondrogenic cells exposed to Hdac3 inhibitors. Elevated expression of Mmp3 and Mmp10 transcripts was also observed. In conclusion, Hdac3 regulates distinct pathways in mesenchymal cell populations and is required for mesenchymal progenitor cell differentiation and long bone development. (c) 2017 American Society for Bone and Mineral Research.
C1 [Feigenson, Marina; Taylor, Earnest L.; Camilleri, Emily T.; Riester, Scott M.; van Wijnen, Andre J.; Bradley, Elizabeth W.; Westendorf, Jennifer J.] Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA.
   [Shull, Lomeli Carpio; van Wijnen, Andre J.; Westendorf, Jennifer J.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic
RP Westendorf, JJ (通讯作者)，Mayo Clin, 200 First St SW, Rochester, MN 55905 USA.
EM westendorf.jennifer@mayo.edu
RI Riester, Scott/K 7032 2015; van Wijnen, Andre/AAG 3578 2019
OI Shull, Lomeli/0000 0001 7537 8516; Camilleri, Emily/0000 0001 8982 6770;
   van Wijnen, Andre J./0000 0002 4458 0946; Bradley,
   Elizabeth/0000 0002 8814 5524
FU National Institutes of Health [AR65397]
FX The authors thank Xiaodong Li and David Razidlo for technical expertise.
   We thank the molecular biology core at Mayo Clinic and Chanana Pritha
   for the help with RNA seq data analysis. This work was supported in part
   by grants from the National Institutes of Health (AR65397 to EWB).
CR [Anonymous], FGF21 TAKES A FAT BI
   Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022
   Bradley EW, 2016, OSTEOARTHR CARTILAGE, V24, P1021, DOI 10.1016/j.joca.2015.12.014
   Bradley EW, 2015, PHYSIOL REV, V95, P1359, DOI 10.1152/physrev.00004.2015
   Bradley EW, 2013, J BIOL CHEM, V288, P9572, DOI 10.1074/jbc.M112.423723
   Carpio LR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3273
   Carpio LR, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926 016 0602 z
   Chang SR, 2004, MOL CELL BIOL, V24, P8467, DOI 10.1128/MCB.24.19.8467 8476.2004
   Dao DY, 2012, J BONE MINER RES, V27, P1680, DOI 10.1002/jbmr.1639
   Dinarello CA, 2011, MOL MED, V17, P333, DOI 10.2119/molmed.2011.00116
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Dudakovic A, 2014, J CELL BIOCHEM, V115, P1816, DOI 10.1002/jcb.24852
   Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062
   Fathe K, 2014, BIRTH DEFECTS RES A, V100, P592, DOI 10.1002/bdra.23277
   Fischle W, 2002, MOL CELL, V9, P45, DOI 10.1016/S1097 2765(01)00429 4
   Fisher FM, 2016, ANNU REV PHYSIOL, V78, P223, DOI 10.1146/annurev physiol 021115 105339
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Jia HQ, 2012, HUM MOL GENET, V21, P5280, DOI 10.1093/hmg/dds379
   Kalari KR, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471 2105 15 224
   Kawaguchi J, 2002, BIOTECHNIQUES, V32, P66, DOI 10.2144/02321st02
   Kremer KN, 2014, J CELL BIOCHEM, V115, P1128, DOI 10.1002/jcb.24755
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Lakshmaiah KC, 2014, J CANCER RES THER, V10, P469, DOI 10.4103/0973 1482.137937
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   Leng Y, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyw035
   Li HT, 2012, DIABETES, V61, P797, DOI 10.2337/db11 0846
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Longworth MS, 2006, ONCOGENE, V25, P4495, DOI 10.1038/sj.onc.1209473
   McGee Lawrence ME, 2016, J BONE MINER RES, V31, P116, DOI 10.1002/jbmr.2602
   McGee Lawrence ME, 2014, BONE, V66, P277, DOI 10.1016/j.bone.2014.06.022
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   McGee Lawrence ME, 2011, GENE, V474, P1, DOI 10.1016/j.gene.2010.12.003
   Minami J, 2014, LEUKEMIA, V28, P680, DOI 10.1038/leu.2013.231
   Oliveros JC, 2007, VENNY INTERACTIVE TO
   Paradis FH, 2015, TOXICOL SCI, V148, P220, DOI 10.1093/toxsci/kfv174
   Rakitin A, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00188
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Rivadeneira F, 2009, NAT GENET, V41, P1199, DOI 10.1038/ng.446
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schatz O, 2005, BIOTECHNIQUES, V39, P650, DOI 10.2144/000112034
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   Wein Marc N, 2015, J Bone Miner Res, V30, P400, DOI 10.1002/jbmr.2381
   Wu SF, 2012, J BIOL CHEM, V287, P26060, DOI 10.1074/jbc.M112.343707
NR 50
TC 26
Z9 30
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD DEC
PY 2017
VL 32
IS 12
BP 2453
EP 2465
DI 10.1002/jbmr.3236
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA FQ3DL
UT WOS:000418236900016
PM 28782836
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Shen, SD
   Si, MJ
   Zeng, CJ
   Liu, EK
   Chen, Y
   Vacher, J
   Zhao, HB
   Mohan, S
   Xing, WR
AF Shen, Sandi
   Si, Mingjue
   Zeng, Canjun
   Liu, Elaine K.
   Chen, Yian
   Vacher, Jean
   Zhao, Haibo
   Mohan, Subburaman
   Xing, Weirong
TI Leucine Repeat Rich Kinase 1 Controls Osteoclast Activity by Managing
   Lysosomal Trafficking and Secretion
SO BIOLOGY BASEL
LA English
DT Article
DE Lrrk1; osteoclast; osteopetrosis; bone formation; bone resorption;
   lysosome; knockout; bone mineral density; acidification; cathepsin K;
   OSTM1
ID ATYPICAL FRACTURES; BONE RESORPTION; PROTEIN; PHOSPHORYLATION; DELETION;
   MUTATION; COMPLEX; OSTM1; DIFFERENTIATION; IDENTIFICATION
AB Simple Summary Osteoporosis, an age related disease, develops in part because the rate of new bone formation does not catch up with the increased bone destruction caused by osteoclasts. A full understanding of how osteoclasts function is essential to identify novel drug targets for osteoporosis treatment. Previously, we demonstrated that mice lacking leucine rich repeat kinase 1 (LRRK1) had high bone mass due to defective resorption caused by dysfunctional osteoclasts. Little is known about how LRRK1 regulates osteoclast activity. Here, we found that LRRK1 deficient osteoclasts had an altered distribution of the acidic vacuoles/lysosomes, unlike the wild type osteoclast. The lysosomes remained in the cytoplasm away from the extracellular lacunae of the bone. The apparent F actin ring was large, but the sealing zone was weak. Albeit CTSK and v ATPase were comparably expressed in LRRK1 deficient osteoclasts, CTSK and v ATPase, two lysosome associated proteins, were not stationed on the ruffled border. Our data indicate the LRRK1 positively controls osteoclast activity via regulating lysosomal distribution, acid secretion, and protease exocytosis. We previously demonstrated that mice with targeted deletion of the leucine repeat rich kinase 1 (Lrrk1) gene were osteopetrotic due to the failure of osteoclasts to resorb bone. To determine how LRRK1 regulates osteoclast activity, we examined the intracellular and extracellular acidification with an acidotropic probe, acridine orange, in live osteoclasts on bone slices. We examined lysosome distribution in osteoclasts by localization of LAMP 2, cathepsin K, and v ATPase by immunofluorescent staining with specific antibodies. We found that both vertical and horizontal cross sectional images of the wild type (WT) osteoclasts showed orange staining of the intracellular acidic vacuoles/lysosomes dispersed to the ruffled border. By contrast, the LRRK1 deficient osteoclasts exhibited fluorescent orange staining in the cytoplasm away from the extracellular lacunae because of an altered distribution of the acidic vacuoles/lysosomes. In addition, WT osteoclasts displayed a peripheral distribution of LAMP 2 positive lysosomes with a typical actin ring. The clustered F actin constitutes a peripheral sealing zone and a ruffled border which was stretched out into a resorption pit. The LAMP 2 positive lysosomes were also distributed to the sealing zone, and the cell was associated with a resorption pit. By contrast, LRRK1 deficient osteoclasts showed diffused F actin throughout the cytoplasm. The sealing zone was weak and not associated with a resorption pit. LAMP 2 positive lysosomes were also diffuse in the cytoplasm and were not distributed to the ruffled border. Although the LRRK1 deficient osteoclast expressed normal levels of cathepsin K and v ATPase, the lysosomal associated cathepsin K and v ATPase were not accumulated at the ruffled border in Lrrk1 KO osteoclasts. Our data indicate that LRRK1 controls osteoclast activity by regulating lysosomal distribution, acid secretion, and protease exocytosis.
C1 [Shen, Sandi; Si, Mingjue; Zeng, Canjun; Liu, Elaine K.; Chen, Yian; Mohan, Subburaman; Xing, Weirong] Jerry L Pettis VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.
   [Shen, Sandi; Si, Mingjue; Zeng, Canjun; Mohan, Subburaman; Xing, Weirong] Loma Linda Univ, Dept Med, Loma Linda, CA 92354 USA.
   [Vacher, Jean] Inst Rech Clin Montreal, Montreal, PQ H2W 1R7, Canada.
   [Vacher, Jean] Univ Montreal, Dept Med, Montreal, PQ H2W 1R7, Canada.
   [Zhao, Haibo] Southern Calif Inst Res & Educ, Long Beach, CA 90822 USA.
C3 Loma Linda University; Universite de Montreal; Institut de Recherche
   Clinique de Montreal (IRCM); Universite de Montreal
RP Xing, WR (通讯作者)，Jerry L Pettis VA Med Ctr, Musculoskeletal Dis Ctr, Loma Linda, CA 92357 USA.; Xing, WR (通讯作者)，Loma Linda Univ, Dept Med, Loma Linda, CA 92354 USA.
EM weirong.xing@va.gov
RI ; Zeng, CanJun/AHC 5294 2022; Zhao, Haibo/ABG 9729 2021
OI ZHAO, HAIBO/0000 0003 0836 7555; Mohan, Subburaman/0000 0003 0063 986X; 
CR BARKER JE, 1983, BLOOD, V61, P765
   BARON R, 1985, J CELL BIOL, V101, P2210, DOI 10.1083/jcb.101.6.2210
   Brommage R, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.34
   Brown JP, 2011, J BONE MINER RES, V26, P2737, DOI 10.1002/jbmr.448
   Chalhoub N, 2003, NAT MED, V9, P399, DOI 10.1038/nm842
   Civiero L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043472
   Croke M, 2011, J CELL SCI, V124, P3811, DOI 10.1242/jcs.086280
   Das BK, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010013
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fujiwara T, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86330
   Hanafusa H, 2019, J CELL SCI, V132, DOI 10.1242/jcs.228809
   Hanafusa H, 2015, NAT CELL BIOL, V17, P1024, DOI 10.1038/ncb3204
   Hanafusa H, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1161
   Iida A, 2016, J MED GENET, V53, P568, DOI 10.1136/jmedgenet 2016 103756
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Izawa T, 2012, MOL CELL BIOL, V32, P2943, DOI 10.1128/MCB.00077 12
   Jensen PR, 2021, BONE, V145, DOI 10.1016/j.bone.2021.115850
   Kedashiro S, 2015, J CELL SCI, V128, P385, DOI 10.1242/jcs.161547
   Kidd LJ, 2011, J ORTHOP RES, V29, P1827, DOI 10.1002/jor.21464
   Korr D, 2006, CELL SIGNAL, V18, P910, DOI 10.1016/j.cellsig.2005.08.015
   Lange PF, 2006, NATURE, V440, P220, DOI 10.1038/nature04535
   Lewiecki EM, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10192
   Lizarraga SB, 2010, DEVELOPMENT, V137, P1907, DOI 10.1242/dev.040410
   Malik AU, 2021, BIOCHEM J, V478, P553, DOI 10.1042/BCJ20200937
   Marín I, 2006, MOL BIOL EVOL, V23, P2423, DOI 10.1093/molbev/msl114
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Nase JB, 2006, J AM DENT ASSOC, V137, P1115, DOI 10.14219/jada.archive.2006.0350
   Nishi H, 2011, STRUCTURE, V19, P1807, DOI 10.1016/j.str.2011.09.021
   Orwig DL, 2011, RHEUM DIS CLIN N AM, V37, P401, DOI 10.1016/j.rdc.2011.08.004
   Ott SM, 2005, J CLIN ENDOCR METAB, V90, P1897, DOI 10.1210/jc.2005 0057
   Pandruvada SNM, 2016, MOL CELL BIOL, V36, P507, DOI 10.1128/MCB.00656 15
   Pata M, 2018, J BONE MINER RES, V33, P888, DOI 10.1002/jbmr.3378
   Rajapurohitam V, 2001, BONE, V28, P513, DOI 10.1016/S8756 3282(01)00416 1
   Ramírez A, 2004, HUM MUTAT, V23, P471, DOI 10.1002/humu.20028
   Roy SG, 2013, AUTOPHAGY, V9, P1009, DOI 10.4161/auto.24468
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Sellmeyer DE, 2010, JAMA J AM MED ASSOC, V304, P1480, DOI 10.1001/jama.2010.1360
   Si MJ, 2019, AGING US, V11, P3250, DOI 10.18632/aging.101977
   Si MJ, 2018, J CELL BIOCHEM, V119, P10351, DOI 10.1002/jcb.27377
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Taylor KH, 2010, BRIT J ORAL MAX SURG, V48, P221, DOI 10.1016/j.bjoms.2009.08.030
   Verhoeven K, 2003, AM J HUM GENET, V72, P722, DOI 10.1086/367847
   Wang G, 2018, ISCIENCE, V4, P127, DOI 10.1016/j.isci.2018.05.016
   Xing WR, 2007, J BIOL CHEM, V282, P22052, DOI 10.1074/jbc.M702614200
   Xing WR, 2013, J BONE MINER RES, V28, P1962, DOI 10.1002/jbmr.1935
   Xing WR, 2010, MOL CELL BIOL, V30, P711, DOI 10.1128/MCB.00610 09
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Zeng CJ, 2016, AM J PHYSIOL ENDOC M, V311, pE772, DOI 10.1152/ajpendo.00189.2016
   Zhang XR, 2011, J BONE MINER RES, V26, P1022, DOI 10.1002/jbmr.295
   Zhao HB, 2001, J BIOL CHEM, V276, P39295, DOI 10.1074/jbc.M010999200
   Zhu ML, 2016, J BONE MINER RES, V31, P864, DOI 10.1002/jbmr.2733
NR 53
TC 3
Z9 4
U1 2
U2 8
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 7737
J9 BIOLOGY BASEL
JI Biology Basel
PD APR
PY 2023
VL 12
IS 4
AR 511
DI 10.3390/biology12040511
PG 16
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA E7OL9
UT WOS:000977393600001
PM 37106712
OA gold
DA 2025 08 17
ER

PT J
AU Migliorati, CA
   Schubert, MM
   Peterson, DE
   Seneda, LM
AF Migliorati, CA
   Schubert, MM
   Peterson, DE
   Seneda, LM
TI Bisphosphonate associated osteonecrosis of mandibular and maxillary bone
     An emerging oral complication of supportive cancer therapy
SO CANCER
LA English
DT Article
DE osteonecrosis; bisphosphonates; jaws; cancer metastasis; skeletal
   metastasis; oral complication; osteoporosis
ID ZOLEDRONIC ACID; DOSE RESPONSE; ALENDRONATE; JAWS; METASTASES; NECROSIS;
   DISEASE; RAT; ULCERATIONS; PAMIDRONATE
AB BACKGROUND. The current report presented 17 patients with cancer with bone metastases and 1 patient with osteopenia who received treatment with bisphos phonates and who subsecluently developed osteonecrosis of the mandible and/or maxilla.
   METHODS. The authors reviewed information on 18 patients who were referred to oral medicine or oral surgery specialists for evaluation and treatment of mandibular and/or maxitlary bone necrosis from June 2002 to September 2004. To be included in the current review, patients must have been treated with either pamidronate or zoledronic acid to control or prevent metastatic disease, or with alendronate for osteoporosis. All patients with cancer had received chemotherapy while receiving bisphosphonate management.
   RESULTS. The 17 patients with cancer were receiving active medical care for a malignancy. Cancer treatment included a variety of chemotherapeutic agents. They presented with metastatic disease to bone and were treated intravenously with the bisphosphonates pamidronate or zoledronic acid for a mean time of 25 months (range, 4 41 mos). There were 14 females and 4 males with a mean age of 62 years (range, 37 74 yrs). Malignancies included breast carcinoma (n = 10), multiple myeloma (n = 3), prostate carcinoma (n = 1), ovarian carcinoma (n = 1), prostate carcinoma/ lymphoma (n = 1), and breast/ovarian carcinoma (n = 1). One female patient with osteopenia received alendronate. The most common clinical osteonecrosis presentations included infection and necrotic bone in the mandible. Associated events included dental extractions, infection, and trauma. Two patients appeared to develop disease spontaneously, without any clinical or radiographic evidence of local pathology. Despite surgical intervention, antibiotic therapy, hyperbaric oxygen therapy, and topical use of chemotherapeutic mouth rinses, most of the lesions did not respond well to therapy. Discontinuation of bisphosphonate therapy did not assure heating. However, I patient with cancer healed after discontinuation of bisphosphonate therapy for 4 months.
   CONCLUSIONS. The findings in the patient population combined with recent literature reports suggested that bisphosphonates may contribute to the pathogenesis of the oral lesions. The risk factors and precise mechanism involved in the formation of the osteonecrosis are not known. This condition represents a new oral complication in patients with cancer and can be termed bisphosphonate associated osteonecrosis. Lesions in patients with osteoporosis are worrisome and need to be further evaluated. (c) 2005 American Cancer Society.
C1 Nova SE Univ, Coll Dent Med, Dept Diagnost Sci, Ft Lauderdale, FL 33328 USA.
   Univ Washington, Dept Oral Med, Sch Dent, Seattle, WA 98195 USA.
   Seattle Canc Care Alliance, Oral Med Serv, Seattle, WA USA.
   Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   Univ Connecticut, Ctr Hlth, Dept Oral Hlth & Diagnost Sci, Sch Dent Med, Farmington, CT USA.
   Univ Connecticut, Ctr Hlth, Ctr Canc, Farmington, CT USA.
   Hosp Sirio Libanes, Ctr Oncol, Oral Med Clin, Sao Paulo, Brazil.
C3 Nova Southeastern University; University of Washington; University of
   Washington Seattle; Seattle Cancer Care Alliance; Fred Hutchinson Cancer
   Center; University of Connecticut; University of Connecticut; Hospital
   Sirio Libanes
RP Migliorati, CA (通讯作者)，Nova SE Univ, Coll Dent Med, Dept Diagnost Sci, 3200 S Univ Dr, Ft Lauderdale, FL 33328 USA.
EM migliora@nova.edu
RI Peterson, Dean/AAO 3325 2021
OI Migliorati, Cesar/0000 0002 2535 2606
CR [Anonymous], BISPHOSPHONATES BONE
   [Anonymous], P AN M AM SOC CLIN
   Ashcroft AJ, 2003, LANCET ONCOL, V4, P284, DOI 10.1016/S1470 2045(03)01076 3
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Bouquot JE, 1999, J PROSTHET DENT, V81, P148, DOI 10.1016/S0022 3913(99)70242 8
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS32, DOI 10.1097/00000421 200212001 00006
   Coleman RE, 2002, AM J CLIN ONCOL CANC, V25, pS1, DOI 10.1097/00000421 200212001 00001
   Demerjian N, 1999, CLIN RHEUMATOL, V18, P349, DOI 10.1007/s100670050116
   Fournier P, 2002, CANCER RES, V62, P6538
   Gonzalez Moles MA, 2000, J ORAL PATHOL MED, V29, P514, DOI 10.1034/j.1600 0714.2000.291006.x
   Green JR, 1997, PHARMACOL TOXICOL, V80, P225, DOI 10.1111/j.1600 0773.1997.tb01964.x
   Gutteridge DH, 2003, BONE, V32, P56, DOI 10.1016/S8756 3282(02)00925 0
   Hauge EM, 2001, J BONE MINER RES, V16, P1575, DOI 10.1359/jbmr.2001.16.9.1575
   Hiller BE., 2003, J CLIN ONCOL, V21, P1
   Horner A, 2001, BONE, V28, P65, DOI 10.1016/S8756 3282(00)00422 1
   Laroche M, 2002, JOINT BONE SPINE, V69, P262, DOI 10.1016/S1297 319X(02)00391 3
   Marini JC, 2003, NEW ENGL J MED, V349, P423, DOI 10.1056/NEJMp038103
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   MARX RE., 2003, Oral and Maxillofacial Patholgy A. rationale for diagnosis and treatment. Quintessence Publishing Co Inc Chicago, P36
   Masarachia P, 1996, BONE, V19, P281, DOI 10.1016/8756 3282(96)00182 2
   McMahon RE, 2004, J ORAL MAXIL SURG, V62, P904, DOI 10.1016/j.joms.2004.04.007
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   *NOVARTIS, 2004, EXP PAN REC PREV DIA
   Pogrel MA, 2004, J ORAL MAXIL SURG, V62, P391, DOI 10.1016/j.joms.2003.11.003
   Reuther T, 2003, INT J ORAL MAX SURG, V32, P289, DOI 10.1054/ijom.2002.0332
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SIETSEMA WK, 1989, DRUG EXP CLIN RES, V15, P389
   Wang J, 2003, J ORAL MAXIL SURG, V61, P1104, DOI 10.1016/S0278 2391(03)00328 8
   Wellington K, 2003, DRUGS, V63, P417, DOI 10.2165/00003495 200363040 00009
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 33
TC 365
Z9 409
U1 0
U2 18
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0008 543X
J9 CANCER
JI Cancer
PD JUL 1
PY 2005
VL 104
IS 1
BP 83
EP 93
DI 10.1002/cncr.21130
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 936KB
UT WOS:000229852800010
PM 15929121
DA 2025 08 17
ER

PT J
AU Bargman, R
   Huang, A
   Boskey, AL
   Raggio, C
   Pleshko, N
AF Bargman, Renee
   Huang, Alice
   Boskey, Adele L.
   Raggio, Cathleen
   Pleshko, Nancy
TI RANKL Inhibition Improves Bone Properties in a Mouse Model of
   Osteogenesis Imperfecta
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Bone; Osteogenesis Imperfecta; Oim/oim; Mouse; RANK/RANKL
ID ALENDRONATE TREATMENT; PAMIDRONATE TREATMENT; POSTMENOPAUSAL
   OSTEOPOROSIS; RECEPTOR ACTIVATOR; MINERAL DENSITY; CHILDREN; SKELETAL;
   BISPHOSPHONATES; FRACTURE; MICE
AB Recently, a new class of agents targeting the receptor activator of nuclear factor kappa B ligand (RANKL) pathway has been developed for the treatment of osteoporosis and other bone diseases. In the current study, inhibition of the RANKL pathway was evaluated to assess effects on "bone quality" and fracture incidence in an animal model of osteogenesis imperfect (OI), the oim/oim mouse. Juvenile oim/oim (similar to 6 weeks old) and wildtype (+/+) mice were treated with either a RANKL inhibitor (RANK Fc) or saline. After treatment, bone density increased significantly in the femurs of both genotypes. Femoral length decreased with RANK Fc in +/+ mice. Geometric measurements at mid diaphysis in the oim/oim groups showed increases in the ML periosteal and endosteal diameters and AP cortical thickness in the treated groups. Within +/+ groups, ML cortical thickness and ML femoral periosteal diameter were significantly increased with RANK Fc. Biomechanical testing revealed increased stiffness in oim/oim and +/+ mice. Total strain was increased with treatment in the +/+ mice. Histologically, RANKL inhibition resulted in retained growth plate cartilage in both genotypes. The average number of fractures sustained by RANK Fc treated oim/oim mice was not significantly decreased compared to saline treated oim/oim mice. This preclinical study demonstrated that RANKL inhibition at the current dose improved density and some geometric and biomechanical properties of oim/oim bone, but it did not decrease fracture incidence. Further studies that address commencement of therapy at earlier time points are needed to determine whether this mode of therapy will be clinically useful in OI.
C1 [Bargman, Renee] NYPH Weill Cornell Med Ctr, New York, NY USA.
   [Huang, Alice; Boskey, Adele L.; Raggio, Cathleen; Pleshko, Nancy] Hosp Special Surg, New York, NY 10021 USA.
C3 Cornell University; Weill Cornell Medicine; Weill Cornell Medical Center
RP Pleshko, N (通讯作者)，Temple Univ, Dept Mech Engn, 1947 N 12th St, Philadelphia, PA 19122 USA.
EM npleshko@temple.edu
RI ; Huang, Alice/L 2256 2015; Bargman, Renee/HHN 1397 2022
OI Boskey, Adele/0000 0002 6181 2219; Huang, Alice/0000 0002 5037 6829; 
FU NIH [AR046121, AR48337]
FX The authors thank Ram Posham for help with analysis and statistics. This
   study utilized the facilities of the NIH sponsored Musculoskeletal
   Repair and Regeneration Core Center, AR046121. Dr. Pleshko received
   support from NIH AR48337. The first two authors contributed equally to
   the work on this project.
CR ALBRIGHT JA, 1971, J BONE JOINT SURG AM, VA 53, P1415, DOI 10.2106/00004623 197153070 00020
   BONADIO J, 1993, J CLIN INVEST, V92, P1697, DOI 10.1172/JCI116756
   Bone HG, 2008, J CLIN ENDOCR METAB, V93, P2149, DOI 10.1210/jc.2007 2814
   Bonnick S, 2006, J CLIN ENDOCR METAB, V91, P2631, DOI 10.1210/jc.2005 2602
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Camacho NP, 2001, CALCIFIED TISSUE INT, V69, P94, DOI 10.1007/s002230010045
   Chan B, 2006, J CLIN ENDOCR METAB, V91, P2017, DOI 10.1210/jc.2005 2548
   CHIPMAN SD, 1993, P NATL ACAD SCI USA, V90, P1701, DOI 10.1073/pnas.90.5.1701
   Cho TJ, 2005, J PEDIATR ORTHOPED, V25, P607, DOI 10.1097/01.bpo.0000164871.36098.4c
   de Vernejoul MC, 2008, BEST PRACT RES CL RH, V22, P71, DOI 10.1016/j.berh.2007.12.011
   Delmas PD, 2004, BONE, V34, P599, DOI 10.1016/j.bone.2003.12.022
   Delos D, 2008, J ORTHOP RES, V26, P153, DOI 10.1002/jor.20469
   Evans KD, 2003, BONE, V32, P268, DOI 10.1016/S8756 3282(02)00974 2
   Faden MA, 2009, AM J MED GENET A, V149A, P1334, DOI 10.1002/ajmg.a.32253
   Fisher S, 2003, DEV BIOL, V264, P64, DOI 10.1016/S0012 1606(03)00399 3
   Flick LM, 2003, J ORTHOP RES, V21, P676, DOI 10.1016/S0736 0266(03)00011 1
   Gatti D, 2005, J BONE MINER RES, V20, P758, DOI 10.1359/JBMR.041232
   Glorieux FH, 1998, NEW ENGL J MED, V339, P947, DOI 10.1056/NEJM199810013391402
   Glorieux FH, 2007, PEDIATRICS, V119, pS163, DOI 10.1542/peds.2006 2023I
   HUANG A, 2005, 51 ANN M ORTH RES SO
   Kamoun Goldrat AS, 2007, J BONE MINER METAB, V25, P211, DOI 10.1007/s00774 007 0750 3
   King D, 2005, J BONE MINER RES, V20, P987, DOI 10.1359/JBMR.050108
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Kozloff KM, 2004, J BONE MINER RES, V19, P614, DOI 10.1359/JBMR.040111
   Land C, 2006, J BONE MINER RES, V21, P374, DOI 10.1359/JBMR.051207
   Letocha AD, 2005, J BONE MINER RES, V20, P977, DOI 10.1359/JBMR.050109
   Madenci E, 2006, JCR J CLIN RHEUMATOL, V12, P53, DOI 10.1097/01.rhu.0000208490.22492.09
   McCarthy EA, 2002, PEDIATR RES, V52, P660, DOI 10.1203/01.PDR.0000032068.76811.0D
   Miller RE, 2007, J IMMUNOL, V179, P266, DOI 10.4049/jimmunol.179.1.266
   Misof BM, 2005, BONE, V36, P150, DOI 10.1016/j.bone.2004.10.006
   Munns CF, 2004, BONE, V35, P231, DOI 10.1016/j.bone.2004.03.008
   Pizones J, 2005, J PEDIATR ORTHOPED, V25, P332, DOI 10.1097/01.bpo.0000152940.10487.c9
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Rauch F, 2006, J CLIN ENDOCR METAB, V91, P1268, DOI 10.1210/jc.2005 2413
   Rauch F, 2004, LANCET, V363, P1377, DOI 10.1016/S0140 6736(04)16051 0
   Rauch F, 2007, BONE, V40, P821, DOI 10.1016/j.bone.2006.11.020
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Sakkers R, 2004, LANCET, V363, P1427, DOI 10.1016/S0140 6736(04)16101 1
   Samadfam R, 2007, J BONE MINER RES, V22, P55, DOI 10.1359/JBMR.060915
   SILLENCE DO, 1993, AM J MED GENET, V45, P276, DOI 10.1002/ajmg.1320450227
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Teitelbaum SL, 2007, AM J PATHOL, V170, P427, DOI 10.2353/ajpath.2007.060834
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Uveges TE, 2009, J BONE MINER RES, V24, P849, DOI [10.1359/jbmr.081238, 10.1359/JBMR.081238]
   Vallo A, 2006, ACTA PAEDIATR, V95, P332, DOI 10.1080/08035250500434785
   van der Meulen MCH, 2001, BONE, V29, P101, DOI 10.1016/S8756 3282(01)00491 4
   VANSLYKE MA, 1987, BONE, V8, P39, DOI 10.1016/8756 3282(87)90130 X
NR 48
TC 35
Z9 42
U1 1
U2 9
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD APR
PY 2010
VL 51
IS 2
BP 123
EP 131
DI 10.3109/03008200903108472
PG 9
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 563EG
UT WOS:000275110000005
PM 20053133
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Sowerwine, KJ
   Shaw, PA
   Gu, W
   Ling, JC
   Collins, MT
   Darnell, DN
   Anderson, VL
   Davis, J
   Hsu, A
   Welch, P
   Puck, JM
   Holland, SM
   Freeman, AF
AF Sowerwine, Kathryn J.
   Shaw, Pamela A.
   Gu, Wenjuan
   Ling, Jennifer C.
   Collins, Michael T.
   Darnell, Dirk N.
   Anderson, Victoria L.
   Davis, Joie
   Hsu, Amy
   Welch, Pamela
   Puck, Jennifer M.
   Holland, Steven M.
   Freeman, Alexandra F.
TI Bone Density and Fractures in Autosomal Dominant Hyper IgE Syndrome
SO JOURNAL OF CLINICAL IMMUNOLOGY
LA English
DT Article
DE Autosomal dominant hyper IgE syndrome (AD HIES); job's syndrome; signal
   transducer and activator of transcription 3 (STAT3); osteoporosis;
   retained primary teeth
ID MUTATIONS
AB Purpose Autosomal Dominant Hyper IgE Recurrent Infection Syndrome (AD HIES) is caused by mutations in STAT3 and characterized by eczema, recurrent bacterial infections, and skeletal and connective tissue abnormalities. To further understand the minimal trauma fractures of AD HIES, we examined bone mineral density (BMD) and laboratory markers of bone turnover.
   Methods Patients with AD HIES enrolled in a prospective natural history study were examined with dual x ray absorptiometry (DEXA) scans and laboratory studies of bone metabolism. The number of fractures was recorded as well as clinical features of AD HIES including scoliosis and retained primary teeth. Patients on medications with skeletal effects, including bisphosphonates, were examined separately.
   Results Twenty three AD HIES children (6 18 years) and 33 AD HIES adults (21 50 years) not receiving bone active drugs were studied. Fourteen of the 23 children (61 %) had histories of minimal trauma fractures, as did 26 of the 33 adults (79 %). Osteopenia or osteoporosis was found in 79% of children and adults. Only radial BMD correlated with the qualitative occurrence of fractures but it did not correlate with the numbers of fractures. Markers of bone metabolism did not correlate with minimal trauma fractures or BMD. Patients on bone active medications had improved BMD, but still sustained fractures.
   Conclusions Minimal trauma fractures and decreased BMD are common in AD HIES. Low radial BMD is associated with fractures, but hip and spine BMD are not. Treatment with bisphosphonates increased BMD but its role in fracture prevention remains undefined.
C1 [Sowerwine, Kathryn J.; Darnell, Dirk N.; Anderson, Victoria L.; Davis, Joie; Hsu, Amy; Holland, Steven M.; Freeman, Alexandra F.] NIAID, Labs Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
   [Shaw, Pamela A.] NIAID, Biostat Res Branch, Bethesda, MD 20892 USA.
   [Gu, Wenjuan; Welch, Pamela] Clin Res Directorate CMRP SAIC Frederick, Biostat Res Branch, Natl Lab Canc Res, Frederick, MD 21703 USA.
   [Ling, Jennifer C.] Univ Washington, Dept Allergy & Infect Dis, Seattle, WA USA.
   [Collins, Michael T.] NIDCR, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD USA.
   [Puck, Jennifer M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Allergy & Infectious Diseases (NIAID); National Institutes of Health
   (NIH)   USA; NIH National Institute of Allergy & Infectious Diseases
   (NIAID); Science Applications International Corporation (SAIC);
   SAIC Frederick; University of Washington; University of Washington
   Seattle; National Institutes of Health (NIH)   USA; NIH National
   Institute of Dental & Craniofacial Research (NIDCR); University of
   California System; University of California San Francisco
RP Freeman, AF (通讯作者)，NIAID, Labs Clin Infect Dis, NIH, Bethesda, MD 20892 USA.
EM freemaal@mail.nih.gov
RI Anderson, Victoria/KQU 7954 2024; Holland, Steven/HRB 7512 2023
OI Holland, Steven/0000 0003 3207 5464
FU Division of Intramural Research; NIAID; NIH; National Cancer Institute;
   National Institutes of Health [HHSN261200800001E]; National Institute of
   Allergy and Infectious Diseases
FX This research was supported by the Division of Intramural Research,
   NIAID, NIH. The views expressed in this article are those of the authors
   and do not reflect the official policy of the U. S. Government. This
   project has been funded in part with federal funds from the National
   Cancer Institute, National Institutes of Health, under Contract No.
   HHSN261200800001E. The content of this publication does not necessarily
   reflect the views or policies of the Department of Health and Human
   Services, nor does mention of trade names, commercial products, or
   organizations imply endorsement by the U.S. government. This research
   was supported [in part] by the Division of Intramural Research, National
   Institute of Allergy and Infectious Diseases, National Institutes of
   Health.
CR BUCKLEY RH, 1972, PEDIATRICS, V49, P59
   COHENSOLAL M, 1995, CLIN IMMUNOL IMMUNOP, V76, P75, DOI 10.1006/clin.1995.1090
   Grimbacher B, 1999, NEW ENGL J MED, V340, P692, DOI 10.1056/NEJM199903043400904
   Holland SM, 2007, NEW ENGL J MED, V357, P1608, DOI 10.1056/NEJMoa073687
   Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096
   Zhang ZY, 2005, BIOCHEM BIOPH RES CO, V328, P800, DOI 10.1016/j.bbrc.2005.01.019
NR 6
TC 28
Z9 30
U1 0
U2 2
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0271 9142
EI 1573 2592
J9 J CLIN IMMUNOL
JI J. Clin. Immunol.
PD FEB
PY 2014
VL 34
IS 2
BP 260
EP 264
DI 10.1007/s10875 013 9982 2
PG 5
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA AH3SK
UT WOS:000336045400019
PM 24402620
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Han, DD
   Chen, W
   Gu, XL
   Shan, RX
   Zou, JQ
   Liu, G
   Shahid, M
   Gao, J
   Han, B
AF Han, Dandan
   Chen, Wei
   Gu, Xiaolong
   Shan, Ruixue
   Zou, Jiaqi
   Liu, Gang
   Shahid, Muhammad
   Gao, Jian
   Han, Bo
TI Cytoprotective effect of chlorogenic acid against hydrogen
   peroxide induced oxidative stress in MC3T3 E1 cells through
   PI3K/Akt mediated Nrf2/HO 1 signaling pathway
SO ONCOTARGET
LA English
DT Article
DE chlorogenic acid; MC3T3 E1 cells; oxidative stress; Nrf2/HO 1 pathway;
   cytoprotection
ID HEME OXYGENASE 1 EXPRESSION; NF KAPPA B; INDUCED APOPTOSIS; ACTIVATION;
   PI3K/AKT; MECHANISM; SYSTEM; INJURY; INFLAMMATION; OSTEOPOROSIS
AB Osteoporosis is a disorder of bone and its development is closely associated with oxidative stress and reactive oxygen species (ROS). Chlorogenic acid (CGA) has potential antioxidant effects and its pharmacological action in osteoblasts is not clearly understood. The present study aimed to clarify the protective effects and mechanisms of CGA on hydrogen peroxide (H2O2) induced oxidative stress in osteoblast cells. MC3T3 E1 cells were treated with H2O2 to induce oxidative stress model in vitro. Cells were treated with CGA prior to H2O2 exposure, the intracellular ROS production, malondialdehyde content, nitric oxide release and glutathione level were measured. We also investigated the protein levels of heme oxygenase 1 (HO 1), the nuclear translocation of transcription factor NF erythroid 2 related factor (Nrf2) and the phosphorylation levels of Akt in CGA treated cells. The results showed that pretreatment of CGA could reverse the inhibition of cell viability and suppress the induced apoptosis and caspase 3 activity. Additionally, it significantly reduced H2O2 induced oxidative damage in a dose dependent manner. Furthermore, it induced the protein expression of HO 1 together with its upstream mediator Nrf2, and activated the phosphorylation of Akt in MC3T3 E1 cells. LY294002, a PI3K/Akt inhibitor, significantly suppressed the CGA induced Nrf2 nuclear translocation and HO 1 expression. Reduction of cell death mediated by CGA in presence of H2O2 was significantly inhibited by Zinc protoporphyrin IX (a HO 1 inhibitor) and LY294002. These data demonstrated that CGA protected MC3T3 E1 cells against oxidative damage via PI3K/Akt mediated activation of Nrf2/HO 1 pathway, which may be an effective drug in treatment of osteoporosis.
C1 [Han, Dandan; Chen, Wei; Gu, Xiaolong; Shan, Ruixue; Zou, Jiaqi; Liu, Gang; Shahid, Muhammad; Gao, Jian; Han, Bo] China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
C3 China Agricultural University
RP Han, B (通讯作者)，China Agr Univ, Coll Vet Med, Beijing 100193, Peoples R China.
EM hanbo@cau.edu.cn
RI Shahid, Muhammad/Y 6565 2018; Han, Bo/AAF 4329 2020; jiaqi,
   zou/GQB 0341 2022; Han, Dandan/JVN 3712 2024
OI Xiaolong, Gu/0000 0001 7111 2681; 
FU National Natural Science Foundation of China [30571362, 30972230,
   31272623]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NO. 30571362, NO. 30972230 and NO. 31272623).
CR Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188
   Ardura JA, 2017, J CELL PHYSIOL, V232, P785, DOI 10.1002/jcp.25473
   Baek KH, 2010, CALCIFIED TISSUE INT, V87, P226, DOI 10.1007/s00223 010 9393 9
   Cervellati C, 2016, CLIN CHEM LAB MED, V54, P739, DOI 10.1515/cclm 2015 0807
   Chen YC, 2006, TOXICOL APPL PHARM, V216, P263, DOI 10.1016/j.taap.2006.05.008
   Choi EM, 2016, J AGR FOOD CHEM, V64, P226, DOI 10.1021/acs.jafc.5b05157
   Fu C, 2015, J CELL PHYSIOL, V230, P2184, DOI 10.1002/jcp.24947
   Gul Z, 2016, NEUROCHEM RES, V41, P2075, DOI 10.1007/s11064 016 1919 8
   Guo C, 2016, INT IMMUNOPHARMACOL, V38, P349, DOI 10.1016/j.intimp.2016.06.021
   Hwang YP, 2010, TOXICOL APPL PHARM, V242, P18, DOI 10.1016/j.taap.2009.09.009
   Hwang YP, 2008, TOXICOL APPL PHARM, V233, P371, DOI 10.1016/j.taap.2008.09.006
   Jang HJ, 2016, ONCOTARGET, V7, P46219, DOI 10.18632/oncotarget.10078
   Lee D, 2015, BMB REP, V48, P636, DOI 10.5483/BMBRep.2015.48.11.112
   Lee YJ, 2012, FOOD CHEM TOXICOL, V50, P116, DOI 10.1016/j.fct.2011.10.035
   Li H, 2016, SCI REP UK, V6, DOI 10.1038/srep23693
   Lidia I, 2014, OXID MED CELL LONGEV, V2014, P390
   Liu YJ, 2013, MOL MED REP, V8, P1106, DOI 10.3892/mmr.2013.1652
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lv HM, 2016, INT J BIOL SCI, V12, P72, DOI 10.7150/ijbs.13188
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Marone R, 2008, BBA PROTEINS PROTEOM, V1784, P159, DOI 10.1016/j.bbapap.2007.10.003
   Mikulec CD, 2013, CANCER PREV RES, V6, P675, DOI 10.1158/1940 6207.CAPR 13 0064
   Min KJ, 2011, CELL SIGNAL, V23, P1505, DOI 10.1016/j.cellsig.2011.05.013
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Pae HO, 2006, WORLD J GASTROENTERO, V12, P214, DOI 10.3748/wjg.v12.i2.214
   Pisoschi AM, 2015, EUR J MED CHEM, V97, P55, DOI 10.1016/j.ejmech.2015.04.040
   Reddy PH, 2016, AM J PHYSIOL RENAL, DOI [10.1152/ajprenal.00362, DOI 10.1152/AJPRENAL.00362]
   Ryter SW, 2006, PHYSIOL REV, V86, P583, DOI 10.1152/physrev.00011.2005
   Sun Y, 2015, INT J NEUROSCI, V22, P1
   Tsang MSM, 2016, MOLECULES, V21, DOI 10.3390/molecules21040519
   Upadhyay R, 2013, CRIT REV FOOD SCI, V53, P968, DOI 10.1080/10408398.2011.576319
   Vitaglione P, 2004, CRIT REV FOOD SCI, V44, P575, DOI 10.1080/10408690490911701
   Wang P, 2015, BBA GEN SUBJECTS, V1850, P1751, DOI 10.1016/j.bbagen.2015.04.010
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Xu X, 2015, MEDIAT INFLAMM, V2015, DOI [10.1155/2015/380218, 10.1155/2015/810798]
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yang YH, 2014, FREE RADICAL BIO MED, V77, P10, DOI 10.1016/j.freeradbiomed.2014.08.028
   Ye HY, 2016, ARCH PHARM RES, V39, P989, DOI 10.1007/s12272 016 0771 3
   Zhang L, 2014, ADV MECH ENG, DOI 10.1155/2014/371673
   Zhang MJ, 2016, BIOMED REP, V5, P57, DOI 10.3892/br.2016.679
   Zhou Y, 2016, BIOSCI BIOTECH BIOCH, V80, P962, DOI 10.1080/09168451.2015.1127130
NR 41
TC 122
Z9 137
U1 2
U2 54
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2017
VL 8
IS 9
BP 14680
EP 14692
DI 10.18632/oncotarget.14747
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA EN4YV
UT WOS:000396013700038
PM 28122344
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Wang, X
   Pei, ZW
   Hao, T
   Ariben, J
   Li, SQ
   He, WX
   Kong, XY
   Chang, JL
   Zhao, ZQ
   Zhang, BX
AF Wang, Xing
   Pei, Zhiwei
   Hao, Ting
   Ariben, Jirigala
   Li, Siqin
   He, Wanxiong
   Kong, Xiangyu
   Chang, Jiale
   Zhao, Zhenqun
   Zhang, Baoxin
TI Prognostic analysis and validation of diagnostic marker genes in
   patients with osteoporosis
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE osteoporosis; geo; wgcna; immune cells; bioinformatics analysis
ID BONE LOSS; OSTEOBLASTS; DATABASE
AB BackgroundsAs a systemic skeletal dysfunction, osteoporosis (OP) is characterized by low bone mass and bone microarchitectural damage. The global incidences of OP are high. MethodsData were retrieved from databases like Gene Expression Omnibus (GEO), GeneCards, Search Tool for the Retrieval of Interacting Genes/Proteins (STRING), Gene Expression Profiling Interactive Analysis (GEPIA2), and other databases. R software (version 4.1.1) was used to identify differentially expressed genes (DEGs) and perform functional analysis. The Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression and random forest algorithm were combined and used for screening diagnostic markers for OP. The diagnostic value was assessed by the receiver operating characteristic (ROC) curve. Molecular signature subtypes were identified using a consensus clustering approach, and prognostic analysis was performed. The level of immune cell infiltration was assessed by the Cell type Identification by Estimating Relative Subsets of RNA Transcripts (CIBERSORT) algorithm. The hub gene was identified using the CytoHubba algorithm. Real time fluorescence quantitative PCR (RT qPCR) was performed on the plasma of osteoporosis patients and control samples. The interaction network was constructed between the hub genes and miRNAs, transcription factors, RNA binding proteins, and drugs. ResultsA total of 40 DEGs, eight OP related differential genes, six OP diagnostic marker genes, four OP key diagnostic marker genes, and ten hub genes (TNF, RARRES2, FLNA, STXBP2, EGR2, MAP4K2, NFKBIA, JUNB, SPI1, CTSD) were identified. RT qPCR results revealed a total of eight genes had significant differential expression between osteoporosis patients and control samples. Enrichment analysis showed these genes were mainly related to MAPK signaling pathways, TNF signaling pathway, apoptosis, and Salmonella infection. RT qPCR also revealed that the MAPK signaling pathway (p38, TRAF6) and NF kappa B signaling pathway (c FLIP, MIP1 beta) were significantly different between osteoporosis patients and control samples. The analysis of immune cell infiltration revealed that monocytes, activated CD4 memory T cells, and memory and naive B cells may be related to the occurrence and development of OP. ConclusionsWe identified six novel OP diagnostic marker genes and ten OP hub genes. These genes can be used to improve the prognostic of OP and to identify potential relationships between the immune microenvironment and OP. Our research will provide insights into the potential therapeutic targets and pathogenesis of osteoporosis.
C1 [Wang, Xing; Ariben, Jirigala; Li, Siqin] Bayannur Hosp, Bayannur City, Peoples R China.
   [Pei, Zhiwei; He, Wanxiong; Kong, Xiangyu; Chang, Jiale] Inner Mongolia Med Univ, Hohhot, Peoples R China.
   [Hao, Ting; Zhao, Zhenqun; Zhang, Baoxin] Inner Mongolia Med Univ, Affiliated Hosp 2, Hohhot, Peoples R China.
C3 Inner Mongolia Medical University; Inner Mongolia Medical University
RP Zhao, ZQ; Zhang, BX (通讯作者)，Inner Mongolia Med Univ, Affiliated Hosp 2, Hohhot, Peoples R China.
EM doctorqun@126.com; z197218275@yeah.net
RI zhang, baoxin/KPB 1358 2024; Pei, Zhiwei/KPB 2480 2024; Kong,
   Xiang Yu/A 1990 2011
FU Science and Technology Planning Project of Inner Mongolia Science and
   Technology Department [2020GG0195]; Inner Mongolia Education Department
   Project [NJZZ22665]; Inner Mongolia Autonomous Region "14th Five Year"
   social welfare field key research and development and achievement
   transformation plan project [2022YFSH0021]
FX Science and Technology Planning Project of Inner Mongolia Science and
   Technology Department (2021GG0174; Inner Mongolia Education Department
   Project (NJZZ22665); Inner Mongolia Autonomous Region "14th Five Year"
   social welfare field key research and development and achievement
   transformation plan project (2022YFSH0022); Science and Technology
   Planning Project of Inner Mongolia Science and Technology Department
   (2020GG0195); Inner Mongolia Autonomous Region "14th Five Year" social
   welfare field key research and development and achievement
   transformation plan project (2022YFSH0021).
CR Caudron Herger M, 2021, NUCLEIC ACIDS RES, V49, pD425, DOI 10.1093/nar/gkaa1040
   Chandra A, 2013, J BIOL CHEM, V288, P20488, DOI 10.1074/jbc.M112.447250
   Chang IC, 2015, AM J CHINESE MED, V43, P1031, DOI 10.1142/S0192415X15500597
   Chang L., 2020, Nucleic Acids Res, V48, pW244, DOI [DOI 10.1093/NAR/GKAA467, 10.1093/nar/gkaa467]
   Changani H, 2022, J AYURVEDA INTEGR ME, V13, DOI 10.1016/j.jaim.2021.07.017
   Chen J, 2014, MOL BIOL REP, V41, P5971, DOI 10.1007/s11033 014 3474 1
   Chin CH, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752 0509 8 S4 S11
   Cunningham F, 2019, NUCLEIC ACIDS RES, V47, pD745, DOI 10.1093/nar/gky1113
   Deng YX, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.815245
   Dong Q, 2020, BRIEF BIOINFORM, V21, P2167, DOI 10.1093/bib/bbz142
   Engebretsen S, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148 019 0730 1
   Fang Y, 2021, CANCER MANAG RES, V13, P5599, DOI 10.2147/CMAR.S318704
   G. O. Consortium, 2004, NUCLEIC ACIDS RES, V32, P258, DOI DOI 10.1093/NAR/GKH036
   Gazzola L, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 51
   Goldberg S, 2015, CALCIFIED TISSUE INT, V97, P113, DOI 10.1007/s00223 015 9994 4
   Guo Y, 2020, INT J MOL MED, V46, P751, DOI 10.3892/ijmm.2020.4606
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 7
   Han L, 2021, MOL METAB, V53, DOI 10.1016/j.molmet.2021.101322
   Han XF, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14639
   He Q, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.899776
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kazezian Z, 2015, SCI REP UK, V5, DOI 10.1038/srep15662
   Kim H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22565 7
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471 2105 9 559
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Lin CC, 2014, AM J CHINESE MED, V42, P743, DOI 10.1142/S0192415X14500487
   Lin DPL, 2017, J PHARM PHARMACOL, V69, P1661, DOI 10.1111/jphp.12790
   Lin S, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.844218
   Liu P, 2022, EXP MOL MED, V54, P765, DOI 10.1038/s12276 022 00764 6
   Liu TT, 2021, FRONT CELL DEV BIOL, V9, DOI [10.3389/fcell.2021.682002, 10.3389/fcell.2021.708066]
   Liu TT, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113140
   Marycz K, 2022, MATERIALS, V15, DOI 10.3390/ma15113990
   Newman AM, 2019, NAT BIOTECHNOL, V37, P773, DOI 10.1038/s41587 019 0114 2
   Raehtz S, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00384
   Robin X, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 77
   Safran M, 2010, DATABASE OXFORD, DOI 10.1093/database/baq020
   Sapra L, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.875788
   Schillemans M, 2019, J PROTEOMICS, V205, DOI 10.1016/j.jprot.2019.103417
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shukla P, 2017, J BIOL CHEM, V292, P4686, DOI 10.1074/jbc.M116.764779
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430
   Tao HQ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.875611
   Tian X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.628512
   Titanji K, 2020, AIDS, V34, P1475, DOI 10.1097/QAD.0000000000002563
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005
   Wang J, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.743012
   Wang XJ, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/5210870
   Whitehead MJ, 2019, BIOINFORMATICS, V35, P4528, DOI 10.1093/bioinformatics/btz403
   Wu CL, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01291
   Wu SY, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.816035
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Wu XX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.554759
   Xu F, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000011659, 10.1097/md.0000000000011659]
   Xue JY, 2022, J BONE MINER RES, V37, P226, DOI 10.1002/jbmr.4462
   Yang CS, 2022, CELL SIGNAL, V90, DOI 10.1016/j.cellsig.2021.110191
   Yang C, 2022, AUTOPHAGY, V18, P2817, DOI 10.1080/15548627.2022.2048432
   Yang CG, 2019, MOL MED REP, V19, P1065, DOI 10.3892/mmr.2018.9752
   Yang LL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20122974
   Yu GC, 2015, BIOINFORMATICS, V31, P608, DOI 10.1093/bioinformatics/btu684
   Yu T, 2020, AGING US, V12, P8191, DOI 10.18632/aging.103133
   Zhang HH, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00798
   Zhang HE, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471 2105 14 244
   Zhang W, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.779264
   Zhang X, 2018, BIOCHEM BIOPH RES CO, V504, P771, DOI 10.1016/j.bbrc.2018.08.094
   Zhang YL, 2022, WORLD J GASTROENTERO, V28, P1315, DOI 10.3748/wjg.v28.i13.1315
   Zheng LM, 2022, BIOACT MATER, V14, P250, DOI 10.1016/j.bioactmat.2021.11.012
   Zhou Y, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19196 2
NR 69
TC 24
Z9 27
U1 1
U2 37
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 13
PY 2022
VL 13
AR 987937
DI 10.3389/fimmu.2022.987937
PG 16
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 5V2HQ
UT WOS:000877056100001
PM 36311708
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhu, LX
   Wang, ZJ
   Sun, XY
   Yu, JJ
   Li, T
   Zhao, H
   Ji, YT
   Peng, B
   Du, MQ
AF Zhu, Lingxin
   Wang, Zijun
   Sun, Xiaoyue
   Yu, Jingjing
   Li, Ting
   Zhao, Huan
   Ji, Yaoting
   Peng, Bin
   Du, Minquan
TI STAT3/Mitophagy Axis Coordinates Macrophage NLRP3 Inflammasome
   Activation and Inflammatory Bone Loss
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE STAT3; INFLAMMATORY OSTEOLYSIS; NLRP3 INFLAMMASOME; MITOPHAGY
ID IMMUNE RESPONSES; STAT3; DIFFERENTIATION; OSTEOLYSIS; EXPRESSION;
   DISEASE; OSTEOIMMUNOLOGY; PATHOGENESIS; OSTEOCLASTS; HOMEOSTASIS
AB Signal transducer and activator of transcription 3 (STAT3), a cytokine responsive transcription factor, is known to play a role in immunity and bone remodeling. However, whether and how STAT3 impacts macrophage NLR family pyrin domain containing 3 (NLRP3) inflammasome activation associated with inflammatory bone loss remains unknown. Here, STAT3 signaling is hyperactivated in macrophages in the context of both non sterile and sterile inflammatory osteolysis, and this was highly correlated with the cleaved interleukin 1 beta (IL 1 beta) expression pattern. Strikingly, pharmacological inhibition of STAT3 markedly blocks macrophage NLRP3 inflammasome activation in vitro, thereby relieving inflammatory macrophage amplified osteoclast formation and bone resorptive activity. Mechanistically, STAT3 inhibition in macrophages triggers PTEN induced kinase 1 (PINK1) dependent mitophagy that eliminates dysfunctional mitochondria, reverses mitochondrial membrane potential collapse, and inhibits mitochondrial reactive oxygen species release, thus inactivating the NLRP3 inflammasome. In vivo, STAT3 inhibition effectively protects mice from both infection induced periapical lesions and aseptic titanium particle mediated calvarial bone erosion with potent induction of PINK1 and downregulation of inflammasome activation, macrophage infiltration, and osteoclast formation. This study reveals the regulatory role of the STAT3/mitophagy axis at the osteo immune interface and highlights a potential therapeutic intervention to prevent inflammatory bone loss. (c) 2022 American Society for Bone and Mineral Research (ASBMR).
C1 [Peng, Bin; Du, Minquan] Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
   [Peng, Bin; Du, Minquan] Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
C3 Wuhan University; Wuhan University
RP Peng, B; Du, MQ (通讯作者)，Wuhan Univ, State Key Lab Breeding Base Basic Sci Stomatol Hu, Minist Educ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Peoples R China.; Peng, B; Du, MQ (通讯作者)，Wuhan Univ, Key Lab Oral Biomed, Minist Educ, Sch & Hosp Stomatol, 237 Luoyu Rd, Wuhan 430079, Peoples R China.
EM phs301@whu.edu.cn; duminquan@whu.edu.cn
RI Du, Min/V 7359 2018; Wang, zijun/JNS 5435 2023; Ji, Yaoting/D 2646 2019;
   Zhu, Lingxin/AAM 6153 2020
FU NSFC [81771084, 81970919, 81970935, 81901000]; Fundamental Research
   Funds for the Central Universities [2042022kf1207]
FX This work was supported by the NSFC 81970919, the Fundamental Research
   Funds for the Central Universities 2042022kf1207 (LZ), the NSFC 81901000
   (JY), the NSFC 81970935 (BP), and the NSFC 81771084 (MD). We thank Prof
   Di Wang and Zhexu Chi from Zhejiang University for kindly providing poly
   (da:dt) for the experiment and insightful suggestions for our study. We
   thank Prof Maohua Zhong from Wuhan University of Science and Technology
   for kindly providing flagellin for our study. All animal studies in our
   experiments were approved by the Ethics Committee for Animal Research,
   School and Hospital of Stomatology, Wuhan University, China.
CR Adler J, 2010, CYTOM PART A, V77A, P733, DOI 10.1002/cyto.a.20896
   Ahuja A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207675
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Alippe Y, 2019, SEMIN IMMUNOPATHOL, V41, P607, DOI 10.1007/s00281 019 00753 4
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Bostanci N, 2009, CLIN EXP IMMUNOL, V157, P415, DOI 10.1111/j.1365 2249.2009.03972.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Cassel SL, 2014, P NATL ACAD SCI USA, V111, P1072, DOI 10.1073/pnas.1318685111
   Cavalla F, 2021, J DENT RES, V100, P29, DOI 10.1177/0022034520952341
   Chakraborty D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01236 6
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097 2765(01)00320 3
   Chung YH, 2014, INT J BIOCHEM CELL B, V54, P198, DOI 10.1016/j.biocel.2014.07.018
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Durant L, 2010, IMMUNITY, V32, P605, DOI 10.1016/j.immuni.2010.05.003
   Elliott EI, 2015, IMMUNOL REV, V265, P35, DOI 10.1111/imr.12286
   Franchi L, 2009, NAT IMMUNOL, V10, P241, DOI 10.1038/ni.1703
   Gao W, 2015, ANN RHEUM DIS, V74, P1275, DOI 10.1136/annrheumdis 2013 204105
   Gkouveris I, 2022, J BONE MINER RES, V37, P1775, DOI 10.1002/jbmr.4637
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Hoffman HM, 2016, J ALLERGY CLIN IMMUN, V138, P3, DOI 10.1016/j.jaci.2016.05.001
   Ito Y, 2010, J CLIN INVEST, V120, P1981, DOI 10.1172/JCI39650
   Jesus AA, 2014, ANNU REV MED, V65, P223, DOI 10.1146/annurev med 061512 150641
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577 018 0066 7
   Ju JH, 2012, ARTHRITIS RHEUM US, V64, P3543, DOI 10.1002/art.34601
   Kepp O, 2011, NAT IMMUNOL, V12, P199, DOI 10.1038/ni0311 199
   Khosla S, 2017, LANCET DIABETES ENDO, V5, P898, DOI 10.1016/S2213 8587(17)30188 2
   Kim MJ, 2016, BMB REP, V49, P529, DOI 10.5483/BMBRep.2016.49.10.115
   Kirkin V, 2009, MOL CELL, V33, P505, DOI 10.1016/j.molcel.2009.01.020
   Ko MS, 2021, AUTOPHAGY, V17, P1205, DOI 10.1080/15548627.2020.1753002
   Lang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04581 2
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lazarou M, 2015, NATURE, V524, P309, DOI 10.1038/nature14893
   Lee YM, 2010, INT IMMUNOL, V22, P805, DOI 10.1093/intimm/dxq431
   Li SX, 2019, BIOMATER SCI UK, V7, P2702, DOI 10.1039/c9bm00306a
   Li W, 2016, CELL MOL IMMUNOL, V13, P514, DOI 10.1038/cmi.2015.33
   Liu XB, 2008, J IMMUNOL, V180, P6070, DOI 10.4049/jimmunol.180.9.6070
   Lu HC, 2020, P NATL ACAD SCI USA, V117, P5430, DOI 10.1073/pnas.1913997117
   Lukens JR, 2014, P NATL ACAD SCI USA, V111, P1066, DOI 10.1073/pnas.1318688111
   Mangan MSJ, 2018, NAT REV DRUG DISCOV, V17, P588, DOI [10.1038/nrd.2018.97, 10.1038/nrd.2018.149]
   Manzano GW, 2018, CLIN ORTHOP RELAT R, V476, P2442, DOI 10.1097/CORR.0000000000000548
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097 2765(02)00599 3
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Mediero A, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003393
   Mizumura K, 2014, J CLIN INVEST, V124, P3987, DOI 10.1172/JCI74985
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Novack DV., 2016, MICROBIOL SPECTR, V4, P235
   Nowell MA, 2009, J IMMUNOL, V182, P613, DOI 10.4049/jimmunol.182.1.613
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Panopoulos AD, 2006, BLOOD, V108, P3682, DOI 10.1182/blood 2006 02 003012
   Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Ran SJ, 2017, ARCH ORAL BIOL, V78, P39, DOI 10.1016/j.archoralbio.2017.02.006
   Rauner M, 2007, INT ARCH ALLERGY IMM, V143, P31, DOI 10.1159/000098223
   Rubbert Roth A, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2666
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018
   Sethi G, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 66
   Shiratori T, 2018, J IMMUNOL, V200, P218, DOI 10.4049/jimmunol.1602035
   Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104
   Sinder BP, 2015, J BONE MINER RES, V30, P2140, DOI 10.1002/jbmr.2735
   Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013
   Sun XY, 2019, THERANOSTICS, V9, P5183, DOI 10.7150/thno.33376
   Taira TM, 2019, J DENT RES, V98, P476, DOI 10.1177/0022034518820289
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Weinberg SE, 2015, IMMUNITY, V42, P406, DOI 10.1016/j.immuni.2015.02.002
   Welte T, 2003, P NATL ACAD SCI USA, V100, P1879, DOI 10.1073/PNAS.0237137100
   Xu Y, 2020, AUTOPHAGY, V16, P3, DOI 10.1080/15548627.2019.1603547
   Yadav PS, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2020100118
   Yahara Y, 2020, NAT CELL BIOL, V22, P49, DOI 10.1038/s41556 019 0437 8
   Yang DH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092093
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Yao N, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1470 z
   Yokota T, 2018, NEPHROL DIAL TRANSPL, V33, P214, DOI 10.1093/ndt/gfx246
   Yu JJ, 2014, P NATL ACAD SCI USA, V111, P15514, DOI 10.1073/pnas.1414859111
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
   Zhou M, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133715
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhou SR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 27273 w
   Zhu LX, 2015, J MATER CHEM B, V3, P6820, DOI 10.1039/c5tb00894h
   Ziegler PK, 2018, CELL, V174, P88, DOI 10.1016/j.cell.2018.05.028
   Zou SL, 2020, MOL CANCER, V19, DOI 10.1186/s12943 020 01258 7
NR 88
TC 47
Z9 51
U1 3
U2 64
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD FEB
PY 2023
VL 38
IS 2
BP 335
EP 353
DI 10.1002/jbmr.4756
EA DEC 2022
PG 19
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA D4OB1
UT WOS:000906004700001
PM 36502520
DA 2025 08 17
ER

PT J
AU Zou, SE
   Zhang, SF
   Long, QQ
   Cao, YK
   Zhang, W
AF Zou, Shien
   Zhang, Shaofen
   Long, Qiqi
   Cao, Yuankui
   Zhang, Wei
TI Marker Gene Screening for Human Mesenchymal Stem Cells in Early
   Osteogenic Response to Bone Morphogenetic Protein 6 with DNA Microarray
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
ID CONNECTIVITY MAP; DIFFERENTIATION; EXPRESSION; NOGGIN; INHIBITION;
   MUTATION; GROWTH
AB Aims: Microarray data were analyzed using bioinformatic tools to screen marker genes of human mesenchymal stem cells (hMSC) in response to bone morphogenetic protein 6 (BMP6). Results: A total of 190 differentially expressed genes were identified. The interaction network was divided into three functional modules. These genes were connected with BMP signaling pathways and regulation of cell processes, while NOG and BMPR2 participated in the transforming growth factor beta signal pathway. Besides, several related small molecules were acquired. Conclusion: Marker genes in osteogenic responses to BMP6 treatment for hMSC were screened with microarray data along with elaborate function analysis by bioinformatics. NOG and BMPR2 showed potential to become indicators to monitor the directed differentiation of hMSC into osteoblasts, which can be used for bone disease treatment. Moreover, small molecules such as W 13 were retrieved and provided directions for future drug design.
C1 [Zou, Shien; Zhang, Shaofen; Long, Qiqi; Cao, Yuankui] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, Shanghai 200011, Peoples R China.
   [Zhang, Wei] Fudan Univ, Sch Publ Hlth, Dept Biostat, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University
RP Zhang, W (通讯作者)，Fudan Univ, Sch Publ Hlth, Dept Biostat, 130 Dongan Rd, Shanghai 200032, Peoples R China.
EM zhangshaofen@163.com; weizhang@shmu.edu.cn
RI Li, Haoyuan/N 3212 2015
FU National Natural Science Foundation of China [81200415]; PhD Programs
   Foundation of the Minstry of Education of China [20090071120020]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81200415) and a grant from the PhD Programs
   Foundation of the Minstry of Education of China (No. 20090071120020).
CR Arbustini Eloisa, 2008, Hum Genet, V123, P112
   Bae S, 2011, STEM CELLS DEV, V20, P197, DOI 10.1089/scd.2010.0127
   Berriz GF, 2009, BIOINFORMATICS, V25, P3043, DOI 10.1093/bioinformatics/btp498
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JL, 1997, STEM CELLS, V15, P368, DOI 10.1002/stem.150368
   Chiellini C, 2008, BIOCHEM BIOPH RES CO, V374, P64, DOI 10.1016/j.bbrc.2008.06.121
   Duncan S, 2010, BMC BIOINFORMATICS, V11, DOI [10.1186/1471 2105 11 100, 10.1186/1471 2105 11 S4 P10]
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365 2184.1987.tb01309.x
   Fu LJ, 2008, CHINESE MED J PEKING, V121, P399, DOI 10.1097/00029330 200803010 00004
   Fujita Andre, 2006, BMC Bioinformatics, V7, P469
   Gazzerro E, 1998, J CLIN INVEST, V102, P2106, DOI 10.1172/JCI3459
   Gerhart J, 2011, DEV BIOL, V359, P12, DOI 10.1016/j.ydbio.2011.08.007
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Gonzalez R, 2007, BIOCHEM BIOPH RES CO, V362, P491, DOI 10.1016/j.bbrc.2007.08.033
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Kassem M, 2004, BASIC CLIN PHARMACOL, V95, P209, DOI 10.1111/j.1742 7843.2004.pto950502.x
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lories RJU, 2006, ARTHRITIS RHEUM, V54, P1736, DOI 10.1002/art.21897
   Luo WJ, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471 2105 10 161
   Marie P, 1997, REV RHUM, V64, P44
   Masuda H, 2012, CELL TRANSPLANT, V21, P2201, DOI 10.3727/096368911X637362
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Origuchi N, 1998, IN VIVO, V12, P473
   Patil A, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471 2105 6 100
   Patil A, 2011, NUCLEIC ACIDS RES, V39, pD744, DOI 10.1093/nar/gkq897
   Riekstina U, 2009, STEM CELL REV REP, V5, P378, DOI 10.1007/s12015 009 9094 9
   Rubin LJ, 2008, AM J RESP CRIT CARE, V177, P1300, DOI 10.1164/rccm.200804 495ED
   Sawant A, 2012, J BIOL CHEM, V287, P12241, DOI 10.1074/jbc.M111.293613
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0 387 29362 0_23
   STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186
   Troyanskaya O, 2001, BIOINFORMATICS, V17, P520, DOI 10.1093/bioinformatics/17.6.520
   WEI JW, 1983, CANCER CHEMOTH PHARM, V11, P86
   Wen ZN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018278
   Yoon BS, 2005, P NATL ACAD SCI USA, V102, P5062, DOI 10.1073/pnas.0500031102
   Zeng Y, 2012, FEBS LETT, V586, P2375, DOI 10.1016/j.febslet.2012.05.049
NR 37
TC 3
Z9 3
U1 1
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945 0265
EI 1945 0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD AUG
PY 2013
VL 17
IS 8
BP 641
EP 645
DI 10.1089/gtmb.2012.0449
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 194IH
UT WOS:000322624500012
PM 23799295
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, D
   Jiang, YC
   He, P
   Li, YM
   Wu, Y
   Lei, W
   Liu, NX
   de Bruin, JD
   Zhang, H
   Zhang, HM
   Ji, P
   Yuan, HP
   Li, MZ
AF Li, Dan
   Jiang, Yucan
   He, Ping
   Li, Yeming
   Wu, Yan
   Lei, Wei
   Liu, Nanxin
   de Bruin, Joost D.
   Zhang, Hua
   Zhang, Hongmei
   Ji, Ping
   Yuan, Huipin
   Li, Mingzheng
TI Hypoxia Drives Material Induced Heterotopic Bone Formation by Enhancing
   Osteoclastogenesis via M2/Lipid Loaded Macrophage Axis
SO ADVANCED SCIENCE
LA English
DT Article
DE heterotopic ossification; hypoxia; macrophage polarization; osteoclast;
   osteoinductive materials
ID BIPHASIC CALCIUM PHOSPHATE; BETA TRICALCIUM PHOSPHATE; OSTEOINDUCTION;
   OSSIFICATION; CELLS; POLARIZATION; INFLAMMATION; REPAIR; DOGS
AB Heterotopic ossification (HO) is a double edged sword. Pathological HO presents as an undesired clinical complication, whereas controlled heterotopic bone formation by synthetic osteoinductive materials shows promising therapeutic potentials for bone regeneration. However, the mechanism of material induced heterotopic bone formation remains largely unknown. Early acquired HO being usually accompanied by severe tissue hypoxia prompts the hypothesis that hypoxia caused by the implantation coordinates serial cellular events and ultimately induces heterotopic bone formation in osteoinductive materials. The data presented herein shows a link between hypoxia, macrophage polarization to M2, osteoclastogenesis, and material induced bone formation. Hypoxia inducible factor 1 alpha (HIF 1 alpha), a crucial mediator of cellular responses to hypoxia, is highly expressed in an osteoinductive calcium phosphate ceramic (CaP) during the early phase of implantation, while pharmacological inhibition of HIF 1 alpha significantly inhibits M2 macrophage, subsequent osteoclast, and material induced bone formation. Similarly, in vitro, hypoxia enhances M2 macrophage and osteoclast formation. Osteoclast conditioned medium enhances osteogenic differentiation of mesenchymal stem cells, such enhancement disappears with the presence of HIF 1 alpha inhibitor. Furthermore, metabolomics analysis reveals that hypoxia enhances osteoclastogenesis via the axis of M2/lipid loaded macrophages. The current findings shed new light on the mechanism of HO and favor the design of more potent osteoinductive materials for bone regeneration.
C1 [Li, Dan; Jiang, Yucan; He, Ping; Li, Yeming; Wu, Yan; Lei, Wei; Liu, Nanxin; Zhang, Hua; Ji, Ping; Li, Mingzheng] Stomatol Hosp Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing 401120, Peoples R China.
   [de Bruin, Joost D.] Queen Mary Univ London, Sch Engn & Mat Sci, London E1 4NS, England.
   [de Bruin, Joost D.; Yuan, Huipin] Kuros Biosci BV, Prof Bronkhorstlaan 10, NL 3723 MB Bilthoven, Netherlands.
   [Zhang, Hongmei] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400015, Peoples R China.
   [Yuan, Huipin] Huipin Yuans Lab, Chengdu 610000, Peoples R China.
C3 Chongqing Medical University; University of London; Queen Mary
   University London; Chongqing Medical University
RP Ji, P; Li, MZ (通讯作者)，Stomatol Hosp Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing 401120, Peoples R China.; Yuan, HP (通讯作者)，Kuros Biosci BV, Prof Bronkhorstlaan 10, NL 3723 MB Bilthoven, Netherlands.
EM jiping@hospital.cqmu.edu.cn; huipin.yuan@kurosbio.com;
   mingzhengli369@hospital.cqmu.edu.cn
RI He, Ping/H 5712 2013
FU China Postdoctoral Science Foundation [2021MD703929]; Postdoctoral
   Science Foundation of Chongqing Natural Science Foundation
   [cstc2021jcy bsh0049]; Basic Research and Frontier Exploration Project
   of Chongqing [20210131]; National Natural Science Foundation of China
   [82071115, 31871464, 82220108019]; CQMU Program for Youth Innovation in
   Future Medicine [W0095]
FX Acknowledgements D.L. and Y.J. contributed equally to this work. The
   authors thank Luuk van Dijk and Florence de Groot for their invaluable
   help in editing the manuscript. Illustrations were made using BioRender.
   This study was supported by grants from the China Postdoctoral Science
   Foundation (No. 2021MD703929), Postdoctoral Science Foundation of
   Chongqing Natural Science Foundation (No. cstc2021jcy bsh0049), Basic
   Research and Frontier Exploration Project of Chongqing (No. 20210131),
   National Natural Science Foundation of China (No. 82071115, 31871464 and
   82220108019), and CQMU Program for Youth Innovation in Future Medicine
   (No. W0095).
CR Aarup A, 2016, ARTERIOSCL THROM VAS, V36, P1782, DOI 10.1161/ATVBAHA.116.307830
   Agarwal S, 2016, P NATL ACAD SCI USA, V113, pE338, DOI 10.1073/pnas.1515397113
   Aggarwal P., 2018, J ASTRONAUT SCI, V12, pED13
   Akiyama N, 2011, J BIOMED MATER RES A, V96A, P402, DOI 10.1002/jbm.a.32995
   Archer A, 2013, J LIPID RES, V54, P1300, DOI 10.1194/jlr.M033977
   Baldwin P, 2019, J ORTHOP TRAUMA, V33, P203, DOI 10.1097/BOT.0000000000001420
   Barba A, 2017, ACS APPL MATER INTER, V9, P41722, DOI 10.1021/acsami.7b14175
   Barradas AM, 2011, EUR CELLS MATER, V21, P29
   Bonetti A, 2019, J THORAC DIS, V11, P2126, DOI 10.21037/jtd.2019.04.78
   Boström P, 2006, ARTERIOSCL THROM VAS, V26, P1871, DOI 10.1161/01.ATV.0000229665.78997.0b
   Braga TT, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00602
   Brekken RA, 2014, Bio Protoc, V4, pe1254, DOI [10.21769/bioprotoc.1254, DOI 10.21769/BIOPROTOC.1254]
   Canet Soulas E, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.622736
   Cappato S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120611
   Carnero A, 2016, BIOESSAYS, V38, pS65, DOI 10.1002/bies.201670911
   Chen MH, 2021, INT IMMUNOPHARMACOL, V99, DOI 10.1016/j.intimp.2021.107901
   Chen XN, 2020, ACTA BIOMATER, V103, P318, DOI 10.1016/j.actbio.2019.12.019
   Chen Z, 2013, J CLIN INVEST, V123, P1057, DOI 10.1172/JCI65344
   Crucet M, 2013, ATHEROSCLEROSIS, V229, P110, DOI 10.1016/j.atherosclerosis.2013.04.034
   Davis EL, 2018, BONE, V109, P22, DOI 10.1016/j.bone.2017.07.016
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   Dey D, 2017, TRANSL RES, V186, P95, DOI 10.1016/j.trsl.2017.06.004
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Duan R, 2019, EUR CELLS MATER, V37, P60, DOI 10.22203/eCM.v037a05
   Egners A, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/2053646
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   García Gareta E, 2015, BONE, V81, P112, DOI 10.1016/j.bone.2015.07.007
   Gerri C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15492
   Griffett K, 2016, BIOCHEM BIOPH RES CO, V479, P424, DOI 10.1016/j.bbrc.2016.09.036
   Guo XD, 2021, ACTA BIOMATER, V134, P730, DOI 10.1016/j.actbio.2021.07.037
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Helming L, 2009, J CELL SCI, V122, P453, DOI 10.1242/jcs.037200
   Horwood NJ, 2016, CLIN REV ALLERG IMMU, V51, P79, DOI 10.1007/s12016 015 8519 2
   Huang YF, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00178 4
   Huang YF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0509 1
   Humbert P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00663
   Hwang CD, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.158996
   Irie A, 2017, SCI REP UK, V7, DOI 10.1038/srep46715
   Jacoby JJ, 2010, J THORAC ONCOL, V5, P940, DOI 10.1097/JTO.0b013e3181dc211f
   Kondo N, 2006, BIOMATERIALS, V27, P4419, DOI 10.1016/j.biomaterials.2006.04.016
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Lampiasi N, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/9089610
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Leblond MM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1056442
   Lehr AM, 2020, SPINE, V45, P944, DOI 10.1097/BRS.0000000000003440
   Li MZ, 2020, J MATER CHEM B, V8, P1863, DOI 10.1039/c9tb02932j
   Liang MM, 2021, MOL THER NUCL ACIDS, V23, P1191, DOI 10.1016/j.omtn.2021.01.031
   MacIntyre NR, 2014, RESP CARE, V59, P1590, DOI 10.4187/respcare.03357
   Manzini BM, 2021, J BIOSCIENCES, V46, DOI 10.1007/s12038 020 00122 6
   Matsuo K, 2019, CURR OSTEOPOROS REP, V17, P387, DOI 10.1007/s11914 019 00541 x
   Meyers C, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10172
   Moore EM, 2019, ANN BIOMED ENG, V47, P354, DOI 10.1007/s10439 018 02170 4
   Nauth A, 2011, J ORTHOP TRAUMA, V25, P462, DOI 10.1097/BOT.0b013e318224caf0
   Nie ZL, 2023, ACTA BIOMATER, V157, P625, DOI 10.1016/j.actbio.2022.11.005
   Oh J., 2012, J BIOL CHEM, V287
   Oryan A, 2014, BIOFACTORS, V40, P459, DOI 10.1002/biof.1177
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Palazon A, 2014, IMMUNITY, V41, P518, DOI 10.1016/j.immuni.2014.09.008
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Ripamonti U, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01084
   Schemitsch EH, 2017, J ORTHOP TRAUMA, V31, pS20, DOI 10.1097/BOT.0000000000000978
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Taylor CT, 2016, J CLIN INVEST, V126, P3716, DOI 10.1172/JCI84433
   Tsukanaka M, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 015 5469 4
   Vestergaard M, 2019, ACS OMEGA, V4, P18889, DOI 10.1021/acsomega.9b02949
   Wang HT, 2016, J BONE MINER RES, V31, P1652, DOI 10.1002/jbmr.2848
   Woo KJ, 2006, BIOCHEM BIOPH RES CO, V343, P8, DOI 10.1016/j.bbrc.2006.02.116
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965
   Yao QY, 2018, J BIOL CHEM, V293, P16572, DOI 10.1074/jbc.RA118.003161
   Yuan H, 2006, J BIOMED MATER RES A, V78A, P139, DOI 10.1002/jbm.a.30707
   Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142 9612(99)00075 7
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zakel JC, 2020, CURR PHYS MED REHAB, V8, P172, DOI 10.1007/s40141 020 00271 7
   Zhang JL, 2021, J LEUKOCYTE BIOL, V110, P485, DOI 10.1002/JLB.3MA0321 739R
NR 78
TC 13
Z9 13
U1 7
U2 71
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
EI 2198 3844
J9 ADV SCI
JI Adv. Sci.
PD MAY
PY 2023
VL 10
IS 15
DI 10.1002/advs.202207224
EA MAR 2023
PG 21
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA H4EG3
UT WOS:000952607200001
PM 36970815
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wei, HW
   Zhao, T
   Liu, XL
   Ding, QT
   Zhang, S
   Yang, JL
   Wang, N
   Zhang, LF
   Chai, GD
   Xia, GF
   Li, AN
   Ding, CB
   Liu, WC
AF Wei, Hewei
   Zhao, Ting
   Liu, Xinglong
   Ding, Qiteng
   Zhang, Shuai
   Yang, Jiali
   Wang, Ning
   Zhang, Lifeng
   Chai, Guodong
   Xia, Guofeng
   Li, Anning
   Ding, Chuanbo
   Liu, Wencong
TI An intelligent controlled release hydrogel with photothermal effect for
   the treatment of bone defects
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Hydrogel; Synergistic regulatory; Photothermal effect; Bone defects
ID OSTEOBLAST DIFFERENTIATION; IN VITRO; CURCUMIN; DELIVERY; OSTEOPONTIN;
   EXPRESSION; SYSTEM; OSTEOPOROSIS; SCAFFOLDS; STRATEGY
AB To solve the difficulty of natural healing in patients with severe bone defects, and the challenges of insufficient autologous bone graft material and large incisions in conventional surgery, we were designed an intelligent coregulated hydrogel system with NIR response. The goal is to be able to prevent inflammation and bacterial adhesion, thereby promoting repair and development of the bone defect area. The hydrogel system consisted of hyaluronic acid, carboxymethyl chitosan and Pht loaded PDA encapsulated ZIF 8 NPs (Pht@ZIF 8@PDA) by Schiff base reaction. Compared to high temperature photothermal therapy (PTT), which destroyed surrounding healthy cells, the present study was based on a new strategy of mild photothermal therapy (42.5 +/  1.2 degrees C) and leaded to a better promotion of osteogenesis. NIR activated the photothermal properties of PDA in scaffolds, intelligently released Pht and Zn 2+ , inhibited Escherichia coli and Staphylococcus aureus (inhibition rate >= 96 %), and promoted bone regeneration in the rat model. Meanwhile, it could promote bone regeneration by upregulating osteogenic factors and stimulating the expression of proteins related to BMP/SMAD signaling pathway. The research highlights the potential applications of synergistically modulated hydrogels, which opens up a new application path for this material in bone tissue engineering, regenerative medicine, and other related fields.
C1 [Wei, Hewei; Ding, Qiteng; Zhang, Shuai; Yang, Jiali; Wang, Ning; Zhang, Lifeng; Chai, Guodong; Ding, Chuanbo] Jilin Agr Univ, Changchun 130118, Peoples R China.
   [Zhao, Ting; Liu, Xinglong; Ding, Chuanbo] Jilin Agr Sci & Technol Coll, Coll Tradit Chinese Med, Jilin 132101, Peoples R China.
   [Liu, Wencong] Wuzhou Univ, Sch Food & Pharmaceut Engn, Wuzhou 543002, Peoples R China.
   [Xia, Guofeng; Li, Anning] Jilin Aodong Yanbian Pharmaceut Co Ltd, Yanbian 133000, Peoples R China.
C3 Jilin Agricultural University; Jilin Agricultural Science & Technology
   University; Wuzhou University
RP Ding, CB (通讯作者)，Jilin Agr Univ, Changchun 130118, Peoples R China.; Ding, CB (通讯作者)，Jilin Agr Sci & Technol Coll, Coll Tradit Chinese Med, Jilin 132101, Peoples R China.; Liu, WC (通讯作者)，Wuzhou Univ, Sch Food & Pharmaceut Engn, Wuzhou 543002, Peoples R China.
EM chuanboding0506@163.com; jwlw6803@126.com
RI Wang, Ning/MVZ 6316 2025; liu, wencong/KAM 2858 2024; xia,
   guofeng/HSG 1442 2023; Yang, Jiali/ACP 3268 2022; Ding,
   Qiteng/KFS 8790 2024; Li, Anning/MBH 3446 2025
CR Abedin E, 2018, TISSUE CELL, V55, P46, DOI 10.1016/j.tice.2018.09.003
   Agarwal Y, 2021, INT J BIOL MACROMOL, V176, P376, DOI 10.1016/j.ijbiomac.2021.02.025
   Aldana PR, 2009, J NEUROS PEDIATR, V3, P420, DOI 10.3171/2009.2.PEDS08230
   Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Amin MM, 2018, ENVIRON SCI POLLUT R, V25, P34046, DOI 10.1007/s11356 018 3354 7
   An HD, 2019, COORDIN CHEM REV, V384, P90, DOI 10.1016/j.ccr.2019.01.001
   An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Arnaud E, 2009, J CRANIOFAC SURG, V20, P2081, DOI 10.1097/SCS.0b013e3181be8854
   Bai L, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15051334
   Baldwin P, 2019, J ORTHOP TRAUMA, V33, P203, DOI 10.1097/BOT.0000000000001420
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Brighente IMC, 2007, PHARM BIOL, V45, P156, DOI 10.1080/13880200601113131
   Cai HT, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2020.11764
   Cardemil C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084932
   Chang GR, 2015, CARBOHYD POLYM, V122, P336, DOI 10.1016/j.carbpol.2014.12.077
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Chen Y, 2020, INT J NANOMED, V15, P3099, DOI 10.2147/IJN.S210320
   Chen Y, 2018, ACTA BIOMATER, V67, P341, DOI 10.1016/j.actbio.2017.12.004
   Cheng W, 2017, ACS APPL MATER INTER, V9, P18462, DOI 10.1021/acsami.7b02457
   Cheon D, 2019, MOLECULES, V24, DOI 10.3390/molecules24071319
   Costa BA, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15010259
   Deshpande RD, 2023, INT J PHARMACEUT, V645, DOI 10.1016/j.ijpharm.2023.123386
   Devi GVY, 2022, MAR DRUGS, V20, DOI 10.3390/md20100589
   Dibazar ZE, 2023, MATERIALS, V16, DOI 10.3390/ma16072799
   Du ZJ, 2021, ACS APPL MATER INTER, V13, P35518, DOI 10.1021/acsami.1c09610
   Fan CH, 2022, EXP MOL PATHOL, V127, DOI 10.1016/j.yexmp.2022.104814
   Fan Q, 2021, BIOACT MATER, V6, P4014, DOI 10.1016/j.bioactmat.2021.04.008
   Gholamali I, 2019, STARCH STARKE, V71, DOI 10.1002/star.201800118
   Giachelli CM, 2000, MATRIX BIOL, V19, P615, DOI 10.1016/S0945 053X(00)00108 6
   Gonzalez Pujana A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14122843
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Guo DY, 2020, J LIPOSOME RES, V30, P366, DOI 10.1080/08982104.2019.1651334
   Habtemariam S, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11010143
   He TH, 2023, J MATER SCI TECHNOL, V163, P168, DOI 10.1016/j.jmst.2023.04.032
   Hu DN, 2021, SUSMAT, V1, P266, DOI 10.1002/sus2.17
   Hytti M, 2023, MOL CELL BIOCHEM, V478, P215, DOI 10.1007/s11010 022 04504 2
   Ibrahim N, 2013, DENTOMAXILLOFAC RAD, V42, DOI 10.1259/dmfr.20120075
   Jiang X, 2023, Colloids and Surfaces B Biointerfaces, P222
   Kim JL, 2012, MOL NUTR FOOD RES, V56, P1223, DOI 10.1002/mnfr.201100831
   Lee EJ, 2014, PHYTOMEDICINE, V21, P1208, DOI 10.1016/j.phymed.2014.04.002
   Li CX, 2023, BIOACT MATER, V24, P361, DOI 10.1016/j.bioactmat.2022.12.015
   Li DH, 2021, J MATER CHEM B, V9, P479, DOI 10.1039/d0tb01924k
   Li DH, 2017, J ORTHOP SCI, V22, P1060, DOI 10.1016/j.jos.2017.05.002
   Li FY, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01347 3
   Li P, 2024, MATER TODAY BIO, V25, DOI 10.1016/j.mtbio.2023.100932
   Liang X, 2017, OR SURG OR MED OR PA, V124, P315, DOI 10.1016/j.oooo.2017.05.514
   Liebscher J, 2019, EUR J ORG CHEM, V2019, P4976, DOI 10.1002/ejoc.201900445
   Liu C, 2023, NANO TODAY, V50, DOI 10.1016/j.nantod.2023.101823
   Liu J, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1050954
   Matsumoto A, 2019, J BIOMED MATER RES B, V107, P122, DOI 10.1002/jbm.b.34102
   MERRY K, 1993, J CELL SCI, V104, P1013
   Mirpoor SF, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241411628
   Moussawi RN, 2016, RSC ADV, V6, P17256, DOI 10.1039/c5ra20221c
   Nakamura A, 2009, TISSUE ENG PART C ME, V15, P169, DOI 10.1089/ten.tec.2007.0334
   Ongay KK, 2023, MOLECULES, V28, DOI 10.3390/molecules28030919
   Oumghar IA, 2022, BIOMECH MODEL MECHAN, V21, P1841, DOI 10.1007/s10237 022 01623 z
   Park KM, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9051713
   Pooresmaeil M, 2020, INT J BIOL MACROMOL, V162, P501, DOI 10.1016/j.ijbiomac.2020.06.183
   Qi XY, 2022, J MATER SCI TECHNOL, V123, P78, DOI 10.1016/j.jmst.2021.12.076
   Rudin L, 2023, J ORAL MICROBIOL, V15, DOI 10.1080/20002297.2023.2230711
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Schejn A, 2014, CRYSTENGCOMM, V16, P4493, DOI 10.1039/c3ce42485e
   Shaabani A, 2021, CARBOHYD POLYM, V264, DOI 10.1016/j.carbpol.2021.118045
   Sheehy EJ, 2019, MATER TODAY BIO, V3, DOI 10.1016/j.mtbio.2019.100009
   Sheehy E.J., 2016, Mater. Today Bio., V3
   Shen F, 2021, CARBOHYD POLYM, V261, DOI 10.1016/j.carbpol.2021.117886
   Shi LX, 2020, ACS BIOMATER SCI ENG, V6, P4595, DOI 10.1021/acsbiomaterials.0c00935
   Soares PIP, 2021, PROG MATER SCI, V116, DOI 10.1016/j.pmatsci.2020.100742
   Sun CY, 2012, DALTON T, V41, P6906, DOI 10.1039/c2dt30357d
   Sun DD, 2022, PART PART SYST CHAR, V39, DOI 10.1002/ppsc.202100221
   Sun XY, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100546
   Sun Y, 2020, INT J ENDOCRINOL, V2020, DOI 10.1155/2020/8821077
   Symons MCR, 1996, FREE RADICAL BIO MED, V20, P831, DOI 10.1016/0891 5849(95)02174 4
   Tan BW, 2021, ACS APPL MATER INTER, V13, P31542, DOI 10.1021/acsami.1c08775
   Tian Q, 2022, APPL SURF SCI, V578, DOI 10.1016/j.apsusc.2021.152120
   Tokatlian T, 2015, ADV HEALTHC MATER, V4, P1084, DOI 10.1002/adhm.201400783
   Tong LP, 2019, BIOMATERIALS, V193, P1, DOI 10.1016/j.biomaterials.2018.12.008
   Dung TH, 2018, J NANOSCI NANOTECHNO, V18, P829, DOI 10.1166/jnn.2018.14880
   Tuli HS, 2022, MOLECULES, V27, DOI 10.3390/molecules27248819
   Vieira AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128021
   Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028
   Wu CW, 2023, NANOSCALE, V15, P5379, DOI 10.1039/d2nr05889h
   Xi DM, 2020, ADV MATER, V32, DOI 10.1002/adma.201907855
   Xu C, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202000177
   Xu ML, 2017, J BIOL CHEM, V292, P12667, DOI 10.1074/jbc.M117.777581
   Xu X, 2012, SOFT MATTER, V8, P3280, DOI 10.1039/c2sm06463d
   Xu XQ, 2020, J CELL BIOCHEM, V121, P4819, DOI 10.1002/jcb.29709
   Yang J, 2020, SMALL, V16, DOI 10.1002/smll.201906846
   Yang L, 2021, BIOFABRICATION, V13, DOI 10.1088/1758 5090/abcf8d
   Yao DC, 2005, FREE RADICAL BIO MED, V39, P1385, DOI 10.1016/j.freeradbiomed.2005.07.015
   Yao S, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100056
   Yin JX, 2021, INT J ORAL SCI, V13, DOI 10.1038/s41368 020 00105 1
   Zamboni F, 2021, CARBOHYD POLYM, V260, DOI 10.1016/j.carbpol.2021.117803
   Zhang YT, 2023, INT J POLYM MATER PO, V72, P1397, DOI 10.1080/00914037.2022.2099392
   Zhou JC, 2023, ADV SCI, V10, DOI 10.1002/advs.202302702
   Zou ML, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.593310
NR 96
TC 1
Z9 2
U1 28
U2 82
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD SEP 1
PY 2024
VL 495
AR 153597
DI 10.1016/j.cej.2024.153597
EA JUL 2024
PG 18
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA XX3F8
UT WOS:001264929700001
DA 2025 08 17
ER

PT J
AU Lee, SC
   Shin, MK
   Jang, BY
   Lee, SH
   Kim, M
   Sung, JS
AF Lee, Seung Cheol
   Shin, Min Kyoung
   Jang, Bo Young
   Lee, Seung Ho
   Kim, Min
   Sung, Jung Suk
TI Immunomodulatory Effect and Bone Homeostasis Regulation in Osteoblasts
   Differentiated from hADMSCs via the PD 1/PD L1 Axis
SO CELLS
LA English
DT Article
DE PD 1; PD L1 axis; osteoblasts; bone regeneration; bone homeostasis;
   hADMSCs
ID CYTOKINES; CELLS; INFLAMMATION
AB Human mesenchymal stem cells (hMSCs) are promising candidates for stem cell therapy and are known to secrete programmed death 1 (PD 1) ligand 1 (PD L1) regulating T cell mediated immunosuppression. Given the limitations of current stem cell therapy approaches, improvements in immunomodulatory capacity and stem cell differentiation efficacy are needed. In this study, we propose novel strategies to overcome the challenges that remain in hMSC mediated bone regeneration. We found that PD 1 is highly expressed in osteoblasts, and the PD 1/PD L1 axis mediated the decreased proinflammatory cytokine expressions in differentiated osteoblasts cocultured with human adipose derived mesenchymal stem cells (hADMSCs). Moreover, the decrease was attenuated by PD 1/PD L1 pathway inhibition. Osteogenic properties including osteogenic gene expression and calcium deposits were increased in osteoblasts cocultured with hADMSCs compared with those that were monocultured. Osteoblasts treated with PD L1 and exosomes from hADMSCs also exhibited enhanced osteogenic properties, including calcium deposits and osteogenic gene expression. In our cocultured system that mimics the physiological conditions of the bone matrix, the PD 1/PD L1 axis mediated the increased expression of osteogenic genes, thereby enhancing the osteogenic properties, while the calcium deposits of osteoblasts were maintained. Our results provide the therapeutic potentials and novel roles of the PD 1/PD L1 axis in bone matrix for modulating the bone properties and immunosuppressive potentials that can aid in the prevention of bone diseases via maintaining bone homeostasis.
C1 [Lee, Seung Cheol; Shin, Min Kyoung; Jang, Bo Young; Lee, Seung Ho; Kim, Min; Sung, Jung Suk] Dongguk Univ Seoul, Dept Life Sci, Goyang 10326, South Korea.
C3 Dongguk University
RP Sung, JS (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Goyang 10326, South Korea.
EM sungjs@dongguk.edu
OI Shin, Min Kyoung/0000 0003 0459 4937; Sung,
   Jung Suk/0000 0002 3145 8458; Lee, Seung Cheol/0000 0003 4310 5112; Kim,
   Min/0000 0001 7287 7002
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education [2022R1A6A1A03053343]
FX This research was supported by Basic Science Research Program through
   the National Research Foundation of Korea (NRF), funded by the Ministry
   of Education (2022R1A6A1A03053343).
CR Akinleye A, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0779 5
   Alonso Goulart V, 2018, Biotechnol Res Innov, V2, P74, DOI DOI 10.1016/J.BIORI.2017.10.005
   Amarasekara DS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062851
   Ayoub S, 2020, J MOL NEUROSCI, V70, P790, DOI 10.1007/s12031 020 01491 1
   Bae SJ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08190 9
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Borciani G, 2020, ACTA BIOMATER, V108, P22, DOI 10.1016/j.actbio.2020.03.043
   Bourne LE, 2021, J ENDOCRINOL, V248, pR51, DOI 10.1530/JOE 20 0428
   Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586 018 0392 8
   Davies LC, 2017, STEM CELLS, V35, P766, DOI 10.1002/stem.2509
   Delgado Calle Jesus, 2012, Biology (Basel), V1, P698, DOI 10.3390/biology1030698
   Di Tinco R, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02664 4
   Fu XR, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080784
   Han YY, 2020, AM J CANCER RES, V10, P727
   Han YY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00932 0
   Jimi E, 2012, INT J DENT, V2012, DOI 10.1155/2012/148261
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Lacey DC, 2009, OSTEOARTHR CARTILAGE, V17, P735, DOI 10.1016/j.joca.2008.11.011
   Lee BC, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01920 3
   Lee SC, 2021, CELLS BASEL, V10, DOI 10.3390/cells10123410
   Lee SC, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8870133
   Lehti MS, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19204 5
   Li MZ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12067
   Lindroos B, 2011, STEM CELL REV REP, V7, P269, DOI 10.1007/s12015 010 9193 7
   Liu SH, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738418820760
   Liu SY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01076
   Lodder EM, 2014, CIRC CARDIOVASC GENE, V7, P790, DOI 10.1161/CIRCGENETICS.114.000537
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Metzger CE, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00285
   Moll G, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00243
   Owen R, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00134
   Remmers SJA, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0257724
   Salhotra A, 2020, NAT REV MOL CELL BIO, V21, P696, DOI 10.1038/s41580 020 00279 w
   Salmaninejad A, 2018, IMMUNOGENETICS, V70, P73, DOI 10.1007/s00251 017 1015 5
   Schröder HC, 2012, J CELL BIOCHEM, V113, P3197, DOI 10.1002/jcb.24196
   Sohni A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/130763
   Storti G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3673857
   Umare V, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/385297
   Wang DF, 2019, J CELL MOL MED, V23, P7054, DOI 10.1111/jcmm.14607
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Wang XD, 2020, P NATL ACAD SCI USA, V117, P6640, DOI 10.1073/pnas.1921445117
   Watkins LR, 1995, PAIN, V63, P289, DOI 10.1016/0304 3959(95)00186 7
   Wen MR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25416 7
   Wu XM, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01855 9
   Ye LX, 2021, CELLS BASEL, V10, DOI 10.3390/cells10113247
   Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e
   Zhou KJ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.569219
   Zuo H, 2022, CANCER GENE THER, V29, P1342, DOI 10.1038/s41417 022 00446 5
NR 49
TC 5
Z9 5
U1 4
U2 14
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4409
J9 CELLS BASEL
JI Cells
PD OCT
PY 2022
VL 11
IS 19
AR 3152
DI 10.3390/cells11193152
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 5G0MG
UT WOS:000866701700001
PM 36231113
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, KR
   Yun, HM
   Yeo, IJ
   Cho, S
   Hong, JT
   Jeong, YS
AF Park, Kyung Ran
   Yun, Hyung Mun
   Yeo, In Jun
   Cho, Sehyung
   Hong, Jin Tae
   Jeong, Yong Seok
TI Peroxiredoxin 6 Inhibits Osteogenic Differentiation and Bone Formation
   Through Human Dental Pulp Stem Cells and Induces Delayed Bone
   Development
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
DE stem cell; DPSCs; PRDX6; iPLA2; GPx; osteogenesis; bone regeneration
ID TGF BETA; OSTEOBLAST DIFFERENTIATION; 1 CYS PEROXIREDOXIN; PHOSPHOLIPASE
   A(2); SKELETAL TISSUE; IN VITRO; EXPRESSION; GENE; MARROW; CANCER
AB Aims: Peroxiredoxins (PRDXs) are thiol specific antioxidant enzymes that regulate redox balance that are critical for maintaining the cellular potential for self renewal and stemness. Stem cell based regenerative medicine is a promising approach in tissue reconstruction. However, to obtain functional cells for use in clinical applications, stem cell technology still requires improvements.
   Results: In this study, we found that PRDX6 levels were decreased during osteogenic differentiation in human dental pulp stem cells (hDPSCs). hDPSCs stably expressing Myc PRDX6 (hDPSC/myc PRDX6) inhibited cell growth in hDPSCs during osteogenic differentiation and impaired osteogenic phenotypes such as alkaline phosphatase (ALP) activity, mineralized nodule formation, and osteogenic marker genes [ALP and osteocalcin (OCN)]. hDPSC cell lines stably expressing mutant glutathione peroxidase (PRDX6(C47S)) and independent phospholipase A2 (PRDX6(S32A)) were also generated. Each mutant form of PRDX6 abolished the impaired osteogenic phenotypes, the transforming growth factor beta mediated Smad2 and p38 pathways, and RUNX2 expression. Furthermore, in vivo experiments revealed that hDPSC/myc PRDX6 suppressed hDPSC based bone regeneration in calvarial defect mice, and newborn PRDX6 transgenic mice exhibited delayed bone development and reduced RUNX2 expression.
   Innovation and Conclusion: These findings illuminate the effects of PRDX6 during osteogenic differentiation of hDPSCs, and also suggest that regulating PRDX6 may improve the clinical utility of stem cell based regenerative medicine for the treatment of bone diseases. Antioxid. Redox Signal. 00, 000 000.
C1 [Park, Kyung Ran] Kyung Hee Univ, Dept Oral & Maxillofacial Regenerat, Seoul, South Korea.
   [Park, Kyung Ran; Yeo, In Jun; Hong, Jin Tae] Chungbuk Natl Univ, Coll Pharm, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
   [Park, Kyung Ran; Yeo, In Jun; Hong, Jin Tae] Chungbuk Natl Univ, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.
   [Yun, Hyung Mun] Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 02453, South Korea.
   [Cho, Sehyung] Kyung Hee Univ, Sch Med, Dept Physiol, Seoul, South Korea.
   [Jeong, Yong Seok] Kyung Hee Univ, Coll Sci, Dept Biol, 1 Hoegi Dong, Seoul 130701, South Korea.
   [Jeong, Yong Seok] Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, 1 Hoegi Dong, Seoul 130701, South Korea.
C3 Kyung Hee University; Chungbuk National University; Chungbuk National
   University; Kyung Hee University; Kyung Hee University; Kyung Hee
   University; Kyung Hee University
RP Hong, JT (通讯作者)，Chungbuk Natl Univ, Coll Pharm, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.; Hong, JT (通讯作者)，Chungbuk Natl Univ, Med Res Ctr, Osongsaengmyeong 1 Ro 194 31, Cheongju 28160, Chungbuk, South Korea.; Yun, HM (通讯作者)，Kyung Hee Univ, Sch Dent, Dept Oral & Maxillofacial Pathol, 1 Heogi Dong, Seoul 02453, South Korea.; Jeong, YS (通讯作者)，Kyung Hee Univ, Coll Sci, Dept Biol, 1 Hoegi Dong, Seoul 130701, South Korea.; Jeong, YS (通讯作者)，Kyung Hee Univ, Coll Sci, Res Inst Basic Sci, 1 Hoegi Dong, Seoul 130701, South Korea.
EM yunhm@khu.ac.kr; jinthong@chungbuk.ac.kr; ysjeong@khu.ac.k
RI Jeong, Yong/AAK 4353 2020
FU Health Fellowship Foundation; National Research Foundation of Korea
   (NRF)   Korean Government (MSIP) [MRC, 2017R1A5A2015541,
   2015R1D1A1A01059240]
FX This work was supported by the Health Fellowship Foundation and the
   National Research Foundation of Korea (NRF) grant funded by the Korean
   Government (MSIP) (Grant Nos. MRC, 2017R1A5A2015541 and
   2015R1D1A1A01059240). We extend our appreciation to Dr. Kim EC for
   providing several experimental resources.
CR Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Brooke G, 2009, BRIT J HAEMATOL, V144, P571, DOI 10.1111/j.1365 2141.2008.07492.x
   CENTRELLA M, 1988, FASEB J, V2, P3066, DOI 10.1096/fasebj.2.15.2903838
   CHAE HZ, 1994, J BIOL CHEM, V269, P27670
   Chan CKF, 2015, CELL, V160, P285, DOI 10.1016/j.cell.2014.12.002
   Chatterjee S, 2011, J BIOL CHEM, V286, P11696, DOI 10.1074/jbc.M110.206623
   Chaudhari P, 2014, ANTIOXID REDOX SIGN, V20, P1881, DOI 10.1089/ars.2012.4963
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200
   Chowdhury I, 2009, FREE RADICAL BIO MED, V46, P146, DOI 10.1016/j.freeradbiomed.2008.09.027
   Chung MT, 2013, TISSUE ENG PT A, V19, P989, DOI [10.1089/ten.tea.2012.0370, 10.1089/ten.TEA.2012.0370]
   Cox AG, 2008, FREE RADICAL BIO MED, V44, P1001, DOI 10.1016/j.freeradbiomed.2007.11.017
   Crane JL, 2014, J CLIN INVEST, V124, P466, DOI 10.1172/JCI70050
   d'Aquino R, 2009, J EXP ZOOL PART B, V312B, P408, DOI 10.1002/jez.b.21263
   Deckelbaum RA, 2006, DEVELOPMENT, V133, P63, DOI 10.1242/dev.02171
   Dennis EA, 2015, J LIPID RES, V56, P1245, DOI 10.1194/jlr.E061101
   Derynck R, 2007, NAT CELL BIOL, V9, P1000, DOI 10.1038/ncb434
   Fatma N, 2005, CELL DEATH DIFFER, V12, P734, DOI 10.1038/sj.cdd.4401597
   Fatma N, 2009, FREE RADICAL RES, V43, P783, DOI 10.1080/10715760903062887
   Fisher AB, 2017, ARCH BIOCHEM BIOPHYS, V617, P68, DOI 10.1016/j.abb.2016.12.003
   Fredericks DC, 2004, ORTHOPEDICS, V27, pS167
   FRIEDENSTEIN AJ, 1970, CELL TISSUE KINET, V3, P393, DOI 10.1111/j.1365 2184.1970.tb00347.x
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hata M, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0156 4
   Hooks SB, 2008, BIOCHEM PHARMACOL, V76, P1059, DOI 10.1016/j.bcp.2008.07.044
   Ikeda D, 2013, BIOMARKERS, V18, P565, DOI 10.3109/1354750X.2013.810667
   Jones RJ, 2007, BIOL BLOOD MARROW TR, V13, P47, DOI 10.1016/j.bbmt.2006.10.010
   Kabir Ramchandra, 2014, Niger J Surg, V20, P1, DOI 10.4103/1117 6806.127092
   Kim HS, 2002, AM J RESP CELL MOL, V27, P227, DOI 10.1165/ajrcmb.27.2.20010009oc
   Kim MB, 2014, FITOTERAPIA, V98, P59, DOI 10.1016/j.fitote.2014.07.013
   Kitagawa M, 2007, ARCH ORAL BIOL, V52, P727, DOI 10.1016/j.archoralbio.2007.02.006
   Kwan MD, 2008, HUM MOL GENET, V17, pR93, DOI 10.1093/hmg/ddn071
   Lee HS, 2011, PHYTOTHER RES, V25, P716, DOI 10.1002/ptr.3328
   Lee MH, 2003, J BIOL CHEM, V278, P34387, DOI 10.1074/jbc.M211386200
   Lee SY, 2012, CELLS TISSUES ORGANS, V196, P23, DOI 10.1159/000331247
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542
   Manevich Y, 2007, J LIPID RES, V48, P2306, DOI 10.1194/jlr.M700299 JLR200
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Moraleda JM, 2006, TRANSPL IMMUNOL, V17, P74, DOI 10.1016/j.trim.2006.09.030
   Omi M, 2016, J DIABETES INVEST, V7, P485, DOI 10.1111/jdi.12452
   Opperman LA, 2000, DEV DYNAM, V219, P472, DOI 10.1002/1097 0177(2000)9999:9999<::AID DVDY1073>3.0.CO;2 F
   Oshimori N, 2012, CELL STEM CELL, V11, P751, DOI 10.1016/j.stem.2012.11.001
   Panetta NJ, 2009, PANMINERVA MED, V51, P25
   Papageorgis P, 2015, INT J ONCOL, V46, P933, DOI 10.3892/ijo.2015.2816
   Park MH, 2016, PHARMACOL THERAPEUT, V163, P1, DOI 10.1016/j.pharmthera.2016.03.018
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Rahaman H, 2012, BIOCHEMISTRY US, V51, P5521, DOI 10.1021/bi300380h
   Rhee SG, 2001, IUBMB LIFE, V52, P35, DOI 10.1080/15216540252774748
   Ringe J, 2002, NATURWISSENSCHAFTEN, V89, P338, DOI 10.1007/s00114 002 0344 9
   Sapkota GP, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.130067
   Seong JM, 2010, BIOMED MATER, V5, DOI 10.1088/1748 6041/5/6/062001
   Shilpa P S, 2013, Dent Res J (Isfahan), V10, P149
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Ueda M, 2005, INT J PERIODONT REST, V25, P129
   Undale AH, 2009, MAYO CLIN PROC, V84, P893, DOI 10.4065/84.10.893
   Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500
   Wang JR, 2013, EUR J CANCER PREV, V22, P523, DOI 10.1097/CEJ.0b013e3283656346
   Wang Y, 2008, J CELL BIOCHEM, V104, P1274, DOI 10.1002/jcb.21703
   Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299
   Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968 0004(02)00003 8
   Yun HM, 2014, ONCOGENE, V33, P5193, DOI 10.1038/onc.2014.128
   Yun HM, 2016, MOL NEUROBIOL, V53, P2409, DOI 10.1007/s12035 015 9208 0
   Yun HM, 2015, ONCOTARGET, V6, P20875, DOI 10.18632/oncotarget.5205
   Yun HM, 2015, MOL NEUROBIOL, V52, P422, DOI 10.1007/s12035 014 8885 4
   Yun HM, 2015, FREE RADICAL BIO MED, V80, P136, DOI 10.1016/j.freeradbiomed.2014.12.022
   Yun HM, 2013, MOL NEUROBIOL, V48, P941, DOI 10.1007/s12035 013 8479 6
   Zhang H, 2003, BIOMATERIALS, V24, P2013, DOI 10.1016/S0142 9612(02)00616 6
NR 70
TC 12
Z9 12
U1 1
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523 0864
EI 1557 7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUN
PY 2019
VL 30
IS 17
BP 1969
EP 1982
DI 10.1089/ars.2018.7530
EA JUN 2018
PG 14
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA HW0DL
UT WOS:000437228400001
PM 29792351
DA 2025 08 17
ER

PT J
AU Nik, AB
   Ng, HH
   Russo, MG
   Iacoviello, F
   Shearing, PR
   Bertazzo, S
   Hutcheson, JD
AF Nik, Amirala Bakhshian
   Ng, Hooi Hooi
   Russo, Manuel Garcia
   Iacoviello, Francesco
   Shearing, Paul R.
   Bertazzo, Sergio
   Hutcheson, Joshua D.
TI The Time Dependent Role of Bisphosphonates on Atherosclerotic Plaque
   Calcification
SO JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE
LA English
DT Article
DE atherosclerotic plaque calcification; calcification paradox;
   bisphosphonates
ID SERUM ALKALINE PHOSPHATASE; VASCULAR CALCIFICATION; BONE METABOLISM; CAP
   RUPTURE; RISK; MICROCALCIFICATION; MECHANISMS; ARTERY; MINERALIZATION;
   ACCUMULATION
AB Atherosclerotic plaque calcification directly contributes to the leading cause of morbidity and mortality by affecting plaque vulnerability and rupture risk. Small microcalcifications can increase plaque stress and promote rupture, whereas large calcifications can stabilize plaques. Drugs that target bone mineralization may lead to unintended consequences on ectopic plaque calcification and cardiovascular outcomes. Bisphosphonates, common anti osteoporotic agents, have elicited unexpected cardiovascular events in clinical trials. Here, we investigated the role of bisphosphonate treatment and timing on the disruption or promotion of vascular calcification and bone minerals in a mouse model of atherosclerosis. We started the bisphosphonate treatment either before plaque formation, at early plaque formation times associated with the onset of calcification, or at late stages of plaque development. Our data indicated that long term bisphosphonate treatment (beginning prior to plaque development) leads to higher levels of plaque calcification, with a narrower mineral size distribution. When given later in plaque development, we measured a wider distribution of mineral size. These morphological alterations might be associated with a higher risk of plaque rupture by creating stress foci. Yet, bone mineral density positively correlated with the duration of the bisphosphonate treatment.
C1 [Nik, Amirala Bakhshian; Ng, Hooi Hooi; Russo, Manuel Garcia; Hutcheson, Joshua D.] Florida Int Univ, Dept Biomed Engn, Miami, FL 33174 USA.
   [Ng, Hooi Hooi] Florida Int Univ, Herbert Wertheim Coll Med, Dept Human & Mol Genet, Miami, FL 33199 USA.
   [Iacoviello, Francesco; Shearing, Paul R.] UCL, Dept Chem Engn, London WC1E 7JE, England.
   [Bertazzo, Sergio] UCL, Dept Med Phys & Biomed Engn, London WC1E 6BT, England.
   [Hutcheson, Joshua D.] Florida Int Univ, Biomol Sci Inst, Miami, FL 33199 USA.
C3 State University System of Florida; Florida International University;
   State University System of Florida; Florida International University;
   University of London; University College London; University of London;
   University College London; State University System of Florida; Florida
   International University
RP Hutcheson, JD (通讯作者)，Florida Int Univ, Dept Biomed Engn, Miami, FL 33174 USA.; Hutcheson, JD (通讯作者)，Florida Int Univ, Biomol Sci Inst, Miami, FL 33199 USA.
EM abakh002@fiu.edu; hoong@fiu.edu; manuel.garcia1405@gmail.com;
   f.iacoviello@ucl.ac.uk; p.shearing@ucl.ac.uk; s.bertazzo@ucl.ac.uk;
   jhutches@fiu.edu
RI ; Iacoviello, Francesco/D 5492 2014; Bertazzo, Sergio/J 7357 2016;
   Shearing, Paul/K 3114 2013; Iacoviello, Francesco/AAW 9047 2020
OI Bakhshian Nik, Amirala/0000 0002 1176 1628; Iacoviello,
   Francesco/0000 0003 3564 2380; Hutcheson, Joshua/0000 0002 8383 4435;
   Bertazzo, Sergio/0000 0003 4889 8190; Shearing,
   Paul/0000 0002 1387 9531; 
FU American Heart Association [17SDG633670259]; Florida International
   University Graduate School Dissertation Year Fellowship; American Heart
   Association Postdoctoral Fellowship [19POST34380255]; Florida Heart
   Research Foundation; American Heart Association (AHA) [19POST34380255]
   Funding Source: American Heart Association (AHA)
FX This research was funded by the American Heart Association, grant number
   17SDG633670259, awarded to J.D.H. Author A.B.N. was supported by the
   Florida International University Graduate School Dissertation Year
   Fellowship. H.H.N was supported by the American Heart Association
   Postdoctoral Fellowship (19POST34380255) and the 2021 "Stop Heart
   Disease" Researcher of the Year Award from Florida Heart Research
   Foundation.
CR Adami S, 2000, J BONE MINER RES, V15, P599, DOI 10.1359/jbmr.2000.15.3.599
   Aikawa E, 2007, CIRCULATION, V116, P2841, DOI 10.1161/CIRCULATIONAHA.107.732867
   Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721
   Casula M, 2020, ATHEROSCLEROSIS, V301, P1, DOI 10.1016/j.atherosclerosis.2020.03.021
   Criqui MH, 2014, JAMA J AM MED ASSOC, V311, P271, DOI 10.1001/jama.2013.282535
   Domander Richard, 2021, Wellcome Open Res, V6, P37, DOI 10.12688/wellcomeopenres.16619.1
   Geng Z, 2000, CLIN NEPHROL, V54, P45
   Goettsch C, 2014, ARTERIOSCL THROM VAS, V34, P1333, DOI 10.1161/ATVBAHA.114.303637
   Guney E, 2008, NEUROENDOCRINOL LETT, V29, P252
   Hutcheson JD, 2016, NAT MATER, V15, P335, DOI 10.1038/nmat4519
   Jin HY, 2021, JACC CARDIOVASC IMAG, V14, P233, DOI 10.1016/j.jcmg.2020.08.036
   Kelly Arnold A, 2013, P NATL ACAD SCI USA, V110, P10741, DOI 10.1073/pnas.1308814110
   Kirchmayer U, 2019, THER ADV DRUG SAF, V10, DOI 10.1177/2042098619838138
   Klein BY, 1998, J CELL BIOCHEM, V68, P186, DOI 10.1002/(SICI)1097 4644(19980201)68:2<186::AID JCB5>3.0.CO;2 R
   Kovesdy CP, 2010, NEPHROL DIAL TRANSPL, V25, P3003, DOI 10.1093/ndt/gfq144
   Lampropoulos CE, 2012, NAT REV RHEUMATOL, V8, P587, DOI 10.1038/nrrheum.2012.120
   Libby P, 2013, J CLIN INVEST, V123, P3201, DOI 10.1172/JCI67526
   Linder CH, 2013, BONE, V53, P399, DOI 10.1016/j.bone.2012.12.048
   Liu CC, 2013, NAT REV NEUROL, V9, P106, DOI 10.1038/nrneurol.2012.263
   Lo Sasso G, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0901 1
   Lomashvili KA, 2009, KIDNEY INT, V75, P617, DOI 10.1038/ki.2008.646
   MacAskill MG, 2020, IJC HEART VASC, V31, DOI 10.1016/j.ijcha.2020.100672
   Maldonado N, 2013, J BIOMECH, V46, P396, DOI 10.1016/j.jbiomech.2012.10.040
   Maldonado N, 2012, AM J PHYSIOL HEART C, V303, pH619, DOI 10.1152/ajpheart.00036.2012
   Mukaiyama K, 2015, AGING CLIN EXP RES, V27, P413, DOI 10.1007/s40520 014 0296 x
   Neven EG, 2009, KIDNEY INT, V75, P580, DOI 10.1038/ki.2008.663
   New SEP, 2013, CIRC RES, V113, P72, DOI 10.1161/CIRCRESAHA.113.301036
   Nik AB, 2017, FRONT CARDIOVASC MED, V4, DOI 10.3389/fcvm.2017.00078
   Peng AW, 2020, JACC CARDIOVASC IMAG, V13, P83, DOI 10.1016/j.jcmg.2019.02.005
   Perkins RM, 2014, CLIN J AM SOC NEPHRO, V9, P874, DOI 10.2215/CJN.07790713
   Pirmohamed M, 2000, POSTGRAD MED J, V76, P418, DOI 10.1136/pmj.76.897.418
   Ploumis A, 2015, J SPINAL CORD MED, V38, P193, DOI 10.1179/2045772314Y.0000000213
   Rattazzi M, 2005, ARTERIOSCL THROM VAS, V25, P1420, DOI 10.1161/01.ATV.0000166600.58468.1b
   Recker RR, 2009, AM J MED, V122, P22, DOI 10.1016/j.amjmed.2008.12.004
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Rogers MA, 2017, CIRC RES, V121, P5, DOI 10.1161/CIRCRESAHA.117.311219
   Ruiz JL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.1811725118
   Ruiz JL, 2015, CARDIOVASC PATHOL, V24, P207, DOI 10.1016/j.carpath.2015.03.002
   Steiner L, 2020, BONE REP, V12, DOI 10.1016/j.bonr.2020.100261
   Tacey A, 2018, NUTRIENTS, V10, DOI 10.3390/nu10101426
   Veseli BE, 2017, EUR J PHARMACOL, V816, P3, DOI 10.1016/j.ejphar.2017.05.010
   Virani SS, 2021, CIRCULATION, V143, pe254, DOI 10.1161/CIR.0000000000000950
   Wang Y, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.008564
   Whitman Stewart C, 2004, Clin Biochem Rev, V25, P81
   Whyte MP, 2010, J BONE MINER RES, V25, P2515, DOI 10.1002/jbmr.130
   Wu ST, 2021, J FORMOS MED ASSOC, V120, P1957, DOI 10.1016/j.jfma.2020.12.014
   Ylitalo R, 1996, J LAB CLIN MED, V127, P200, DOI 10.1016/S0022 2143(96)90079 7
   Ylitalo R, 1998, PHARMACOL TOXICOL, V83, P125, DOI 10.1111/j.1600 0773.1998.tb01455.x
NR 48
TC 7
Z9 7
U1 0
U2 6
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2308 3425
J9 J CARDIOVASC DEV DIS
JI J. Cardiovasc. Dev. Dis.
PD JUN
PY 2022
VL 9
IS 6
AR 168
DI 10.3390/jcdd9060168
PG 16
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cardiovascular System & Cardiology
GA 2K5VY
UT WOS:000816404400001
PM 35735797
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Niu, HQ
   Zhao, WP
   Zhao, XC
   Luo, J
   Chen, KL
   Li, XF
AF Niu, Hong Qing
   Zhao, Wen Peng
   Zhao, Xiang Cong
   Luo, Jing
   Chen, Kai Lin
   Li, Xiao Feng
TI Combination of 4 hydroperoxy cyclophosphamide and methotrexate inhibits
   IL 6/sIL 6R induced RANKL expression in fibroblast like synoviocytes
   via suppression of the JAK2/STAT3 and p38MAPK signaling pathway
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Fibroblast like synoviocytes; Cyclophosphamide;
   Methotrexate; RANKL; STAT3; p38MAPK
ID COLLAGEN INDUCED ARTHRITIS; RHEUMATOID ARTHRITIS; OSTEOCLAST
   DIFFERENTIATION; BONE EROSION; KINASE; CELLS; INDUCTION; RATS; MICE
AB Although conventional combination therapy is effective for most patients with rheumatoid arthritis (RA), many still do not respond to current therapies. Therefore, novel combination regimens that better target cellular processes involved in RA pathogenesis are required. Preliminary studies have demonstrated the beneficial effects of a combination of cyclophosphamide (CTX) and methotrexate (MTX) in models of RA. Using western blotting, real time polymerase chain reaction, enzyme linked immunosorbent assays, and immunofluorescent staining, we demonstrated that the combination of 4 hydroperoxy CTX (4 H CTX) and MTX inhibited the expression of receptor activator of nuclear factor kappa B ligand (RANKL) in fibroblast like synoviocytes (FLS) treated with the interleukin (IL) 6/soluble IL 6 receptor (sIL 6R) complex. To elucidate the mechanisms underlying this effect, we treated RA FLS with the JAK2/STAT3 inhibitor AG490 or p38MAPK inhibitor SB203580. The results showed that IL 6/sIL 6R induced RANKL upregulation required phosphorylation mediated activation of STAT3 and p38 signaling, and that 4 H CTX and/or MTX inhibited RANKL expression in IL 6/sIL 6R stimulated FLS by suppressing JAK2/STAT3 and p38MAPK signaling. This study demonstrated for the first time the inhibitory effects of 4 H CTX and MTX on RANKL expression in IL 6/sIL 6R stimulated FLS via suppression of STAT3 and p38MAPK phosphorylation. These results identify promising therapeutic agents that might have clinical applications in patients with RA who are at high risk of bone erosion or do not respond well to conventional therapy.
C1 [Niu, Hong Qing; Zhao, Wen Peng; Zhao, Xiang Cong; Luo, Jing; Chen, Kai Lin; Li, Xiao Feng] Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan 030001, Shanxi, Peoples R China.
C3 Shanxi Medical University
RP Li, XF (通讯作者)，Shanxi Med Univ, Hosp 2, Dept Rheumatol, Taiyuan 030001, Shanxi, Peoples R China.
EM lxf_9859@sxmu.edu.cn
RI li, xiaofeng/GXF 9442 2022
FU National Natural Science Foundation of China [81201376]; Scientific
   Research Foundation of Health and Family Planning Commission of Shanxi
   Province, China [201601136]; Postgraduate Education and Innovation
   Program of Education Department of Shanxi Province, China [2016BY085]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81201376), Scientific Research Foundation of Health and
   Family Planning Commission of Shanxi Province, China (No. 201601136),
   and Postgraduate Education and Innovation Program of Education
   Department of Shanxi Province, China (No. 2016BY085).
CR Aletaha D, 2010, ARTHRITIS RHEUM US, V62, P2569, DOI 10.1002/art.27584
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bottini N, 2013, NAT REV RHEUMATOL, V9, P24, DOI 10.1038/nrrheum.2012.190
   Chang SK, 2010, IMMUNOL REV, V233, P256, DOI 10.1111/j.0105 2896.2009.00854.x
   Choe JY, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4162
   Fan JN, 2017, MOL IMMUNOL, V90, P106, DOI 10.1016/j.molimm.2017.07.001
   Fu YX, 2015, MOL MED REP, V12, P6939, DOI 10.3892/mmr.2015.4284
   Gao HY, 2015, INT J CLIN EXP PATHO, V8, P15573
   Goswami RP, 2016, ANN RHEUM DIS, V75, pE35, DOI 10.1136/annrheumdis 2015 209094
   Han ZN, 2001, J CLIN INVEST, V108, P73, DOI 10.1172/JCI200112466
   Hashizume M, 2008, RHEUMATOLOGY, V47, P1635, DOI 10.1093/rheumatology/ken363
   Kanagawa H, 2016, J BONE MINER METAB, V34, P526, DOI 10.1007/s00774 015 0702 2
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Li CH, 2016, INFLAMM RES, V65, P193, DOI 10.1007/s00011 015 0905 y
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Mori T, 2011, INT IMMUNOL, V23, P701, DOI 10.1093/intimm/dxr077
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Qu B, 2015, EXP CELL RES, V338, P89, DOI 10.1016/j.yexcr.2015.07.023
   Schett G, 2008, ANN RHEUM DIS, V67, P909, DOI 10.1136/ard.2007.074278
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Sun Y, 2014, INT IMMUNOPHARMACOL, V18, P135, DOI 10.1016/j.intimp.2013.11.014
   Tunyogi Csapo M, 2008, ARTHRITIS RHEUM US, V58, P2397, DOI 10.1002/art.23653
   UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461
   Wei Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/214683
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Yao Y, 2013, RHEUMATOL INT, V33, P1845, DOI 10.1007/s00296 013 2674 7
   Yu XY, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/238035
   Zhao DF, 2017, ONCOTARGET, V8, P98163, DOI 10.18632/oncotarget.21000
NR 28
TC 3
Z9 4
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD AUG
PY 2018
VL 61
BP 45
EP 53
DI 10.1016/j.intimp.2018.05.014
PG 9
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA GQ2MG
UT WOS:000441488500006
PM 29803913
DA 2025 08 17
ER

PT J
AU Nanke, Y
   Kobashigawa, T
   Yago, T
   Kawamoto, M
   Yamanaka, H
   Kotake, S
AF Nanke, Yuki
   Kobashigawa, Tsuyoshi
   Yago, Toru
   Kawamoto, Manabu
   Yamanaka, Hisashi
   Kotake, Shigeru
TI Rebamipide, an Amino Acid Analog of 2(1H) Quinolinone, Inhibits the
   Formation of Human Osteoclasts
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID RHEUMATOID ARTHRITIS; ANTIULCER AGENT; CELL; EXPRESSION;
   GERANYLGERANYLACETONE; STIMULATION; INJURY
AB Objectives. Drug repositioning or drug reprofiling (DR) has recently been growing in importance. DR has a significant advantage over traditional drug development because the repositioned drug has already passed toxicity tests; its safety is known, and the risk of adverse toxicology is reduced. In the current study, we investigated the role of rebamipide, a mucosa protecting agent, with recently reported anti inflammatory function, in human osteoclastogenesis. Methods. Peripheral blood mononuclear cells (PBMCs) were cultured in the presence of M CSF and sRANKL. Osteoclast formation was evaluated by immunohistological staining for CD51/61 (vitronectin receptors). Osteoclast formation, in the presence or absence of rebamipide (0, 1, and 3mM), was observed by time lapse photography and actin ring formation. The number of absorption sites and area of absorption were calculated using Osteologic (TM) plates. Pit formation was studied by 3D SEM. Results. Rebamipide inhibited human osteoclast formation at 3 mM, a pharmacological concentration, and inhibited resorbing activity dose dependently. Rebamipide induced the degradation of actin rings inmature osteoclasts. This mechanismmay involve inhibiting the osteoclast fusion pathway through reducing the expression of DC specific transmembrane protein (DC STAMP). Conclusions. The present study suggests that rebamipide would be useful as a novel agent for osteoporosis and rheumatoid arthritis.
C1 [Nanke, Yuki; Kobashigawa, Tsuyoshi; Yago, Toru; Kawamoto, Manabu; Yamanaka, Hisashi; Kotake, Shigeru] Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10 22 Kawada Cho, Tokyo 1620054, Japan.
C3 Tokyo Women's Medical University
RP Nanke, Y (通讯作者)，Tokyo Womens Med Univ, Inst Rheumatol, Shinjuku Ku, 10 22 Kawada Cho, Tokyo 1620054, Japan.
EM ynn@twmu.ac.jp
OI Yamanaka, Hisashi/0000 0001 8453 6731
CR Aihara M, 1998, DIGEST DIS SCI, V43, p174S
   Bamba H, 2003, ALIMENT PHARM THER, V18, P113, DOI 10.1046/j.1365 2036.18.s1.13.x
   Byun JK, 2014, CLIN EXP IMMUNOL, V178, P9, DOI 10.1111/cei.12355
   Choe JY, 2010, INFLAMM RES, V59, P1019, DOI 10.1007/s00011 010 0221 5
   ISHIHARA K, 1992, ARZNEIMITTEL FORSCH, V42 2, P1462
   Kim CD, 2000, J PHARMACOL EXP THER, V294, P864
   Kinjo N, 2008, AM J PHYSIOL GASTR L, V295, pG1016, DOI 10.1152/ajpgi.90329.2008
   KLEINE A, 1993, DIGEST DIS SCI, V38, P1441, DOI 10.1007/BF01308601
   Kohashi M, 2008, ARTHRITIS RHEUM, V58, P389, DOI 10.1002/art.23163
   Kotake S, 2005, EUR J IMMUNOL, V35, P3353, DOI 10.1002/eji.200526141
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Moon SJ, 2014, ARTHRITIS RHEUMATOL, V66, P874, DOI 10.1002/art.38310
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Naito Y, 1996, ARZNEIMITTEL FORSCH, V46, P698
   NAITO Y, 1995, FREE RADICAL BIO MED, V18, P117, DOI 10.1016/0891 5849(94)00110 6
   Naito Y, 2007, J CLIN BIOCHEM NUTR, V41, P202, DOI 10.3164/jcbn.2007029
   Naito Y, 2010, EXPERT REV GASTROENT, V4, P261, DOI 10.1586/EGH.10.25
   Nanke Y, 2005, CALCIFIED TISSUE INT, V77, P376, DOI 10.1007/s00223 005 0123 7
   Nanke Y, 2002, CLIN RHEUMATOL, V21, P198, DOI 10.1007/s10067 002 8285 4
   Nanke Y, 2009, MOD RHEUMATOL, V19, P379, DOI 10.1007/s10165 009 0183 z
   Nishizawa T, 2009, DIGESTION, V79, P259, DOI 10.1159/000213241
   Schubert C, 2010, NAT MED, V16, P7, DOI 10.1038/nm0110 7b
   Shioya Y., 1989, Iyakuhin Kenkyu, V20, P522
   SUZUKI M, 1994, GUT, V35, P1375, DOI 10.1136/gut.35.10.1375
   YAMASAKI K, 1987, EUR J PHARMACOL, V142, P23
   Yoshida N, 1996, DIGEST DIS SCI, V41, P1139, DOI 10.1007/BF02088229
   YOSHIKAWA T, 1993, ARZNEIMITTEL FORSCH, V43 1, P363
NR 28
TC 3
Z9 4
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2016
VL 2016
AR 6824719
DI 10.1155/2016/6824719
PG 7
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA ED4UV
UT WOS:000388848200001
PM 27965978
OA Green Submitted, hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Spiegel, DM
   McPhatter, L
   Allison, A
   Drumheller, JC
   Lockridge, R
AF Spiegel, David M.
   McPhatter, Lesley
   Allison, Ann
   Drumheller, Joanne C.
   Lockridge, Robert
TI A Computerized Treatment Algorithm Trial to Optimize Mineral Metabolism
   in ESRD
SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
LA English
DT Article
ID CINACALCET; THERAPY
AB Background and objectives Achievement of mineral targets in patients receiving dialysis remains challenging. This study sought to evaluate outcomes for phosphorus, calcium, and parathyroid hormone when a dialysis population was switched from a predominantly active vitamin D analogue treatment regimen to a computerized algorithm incorporating both cinacalcet and active vitamin D as potential first line therapies.
   Design, setting, participants, & measurements This longitudinal prospective trial enrolled 92 patients undergoing maintenance hemodialysis. Baseline measures (the average of the 3 months before computerized algorithm implementation) were compared with the proportion of patients achieving the prespecified targets at 6 and 12 months.
   Results After 6 months there was a statistically significant improvement in the percentage of patients achieving the primary and secondary phosphorus targets (primary: phosphorus <= 5.5 mg/dl, increase from 41% to 75%, P<0.001; secondary: phosphorus 3.0 4.6 mg/dl, increase from 16% to 38%; P=0.005). These improvements were sustained at 12 months. There was a statistically significant improvement in the percentage of patients achieving all three prespecified secondary endpoints (an increase from 12.8% to 25.6% at 12 months; P=0.04); however, this was mainly driven by improved phosphorus control. The proportion of patients achieving the primary or secondary parathyroid hormone targets did not improve.
   Conclusions A greater proportion of dialysis patients achieved improved phosphorus but not parathyroid hormone control by switching from a predominantly active vitamin D analogue based treatment regimen for mineral and bone disorder to a computer driven algorithm that incorporated cinacalcet and low dose active vitamin D analogues as first line therapy. Clin J Am Soc Nephrol 7: 632 639, 2012. doi: 10.2215/CJN.08170811
C1 [Spiegel, David M.] Univ Colorado, Dept Med, Div Renal Dis & Hypertens, Denver, CO 80220 USA.
   [McPhatter, Lesley; Allison, Ann; Drumheller, Joanne C.] Univ Virginia, Morrison Healthcare UVA Renal Serv, Lynchburg, VA USA.
   [Lockridge, Robert] Lynchburg Nephrol Associates, Lynchburg, VA USA.
C3 University of Colorado System; University of Colorado Denver; University
   of Colorado Anschutz Medical Campus; University of Virginia
RP Spiegel, DM (通讯作者)，Univ Colorado, Dept Med, Div Renal Dis & Hypertens, 4545 E 9th Ave,Suite 160, Denver, CO 80220 USA.
EM david.spiegel@ucdenver.edu
FU Amgen, Inc.
FX This research was supported by an investigator initiated grant from
   Amgen, Inc.
CR Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   Block GA, 2008, NEPHROL DIAL TRANSPL, V23, P2311, DOI 10.1093/ndt/gfn026
   Chertow GM, 2007, CLIN J AM SOC NEPHRO, V2, P898, DOI 10.2215/CJN.04381206
   Chertow GM, 2006, CLIN J AM SOC NEPHRO, V1, P305, DOI 10.2215/CJN.00870805
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   Kidney Disease: Improving Global Outcomes (KDIGO) CKD MBD Work Group, 2009, Kidney Int Suppl, pS1, DOI 10.1038/ki.2009.188
   Malberti Fabio, 2011, G Ital Nefrol, V28, P201
   Messa P, 2008, CLIN J AM SOC NEPHRO, V3, P36, DOI 10.2215/CJN.03591006
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Zitt E, 2011, WIEN KLIN WOCHENSCHR, V123, P45, DOI 10.1007/s00508 010 1515 x
NR 10
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC NEPHROLOGY
PI WASHINGTON
PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA
SN 1555 9041
EI 1555 905X
J9 CLIN J AM SOC NEPHRO
JI Clin. J. Am. Soc. Nephrol.
PD APR
PY 2012
VL 7
IS 4
BP 632
EP 639
DI 10.2215/CJN.08170811
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 918WK
UT WOS:000302281900017
PM 22300740
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Carnovali, M
   Banfi, G
   Mariotti, M
AF Carnovali, Marta
   Banfi, Giuseppe
   Mariotti, Massimo
TI Age dependent modulation of bone metabolism in zebrafish scales as new
   model of male osteoporosis in lower vertebrates
SO GEROSCIENCE
LA English
DT Article
DE Zebrafish; Scale; Bone; Aging; Osteoporosis
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; PARATHYROID HORMONE; MECHANISMS;
   EXPRESSION; RESORPTION; FRACTURE; DIFFERENTIATION; PREDNISOLONE;
   OSTEOCLASTS; PHENOTYPE
AB After middle age, in human bone, the resorption usually exceeds formation resulting in bone loss and increased risk of fractures in the aged population. Only few in vivo models in higher vertebrates are available for pathogenic and therapeutic studies about bone aging. Among these, maleDanio rerio(zebrafish) can be successfully used as low vertebrate model to study degenerative alterations that affect the skeleton during aging, reducing the role of sex hormones. In this paper, we investigated the early bone aging mechanisms in male zebrafish (3, 6, 9 months old) scales evaluating the physiological changes and the effects of prednisolone, a pro osteoporotic drug. The results evidentiated an age dependent reduction of the mineralization rate in the fish scales, as highlighted by growing circle measurements. Indeed, the osteoblastic ALP activity at the matrix deposition site was found progressively downregulated. The higher TRAP activity was found in 63% of 9 month old fish scales associated with resorption lacunae along the scale border. Gene expression analysis evidentiated that an increase of thetnfrsf1b(homolog of humanrank) in aging scales may be responsible for resorption stimulation. Interestingly, prednisolone inhibited the physiological growth of the scale and induced in aged scales a more significant bone resorption compared with untreated fish (3.8% vs 1.02%). Bone markers analysis shown a significant reduction of ALP/TRAP ratio due to a prednisolone dependent stimulation oftnfsf11(homolog of humanrankl)in scales of older fish. The results evidentiated for the first time the presence of a senile male osteoporosis in lower vertebrate. This new model could be helpful to identify the early mechanisms of bone aging and new therapeutic strategies to prevent age related bone alterations in humans.
C1 [Carnovali, Marta; Banfi, Giuseppe; Mariotti, Massimo] IRCCS Ist Ortoped Galeazzi, Milan, Italy.
   [Banfi, Giuseppe] Univ Vita Salute San Raffaele, Milan, Italy.
   [Mariotti, Massimo] Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
C3 IRCCS Istituto Ortopedico Galeazzi; Vita Salute San Raffaele University;
   University of Milan
RP Mariotti, M (通讯作者)，Univ Milan, Dept Biomed Surg & Dent Sci, Milan, Italy.
EM massimo.mariotti@unimi.it
RI ; Carnovali, Marta/AAA 6215 2021; Banfi, Giuseppe/K 6585 2015
OI MARIOTTI, MASSIMO/0000 0002 9559 3632; Carnovali,
   Marta/0000 0002 2292 5288; Banfi, Giuseppe/0000 0001 9578 5338
FU Universita degli Studi di Milano within the CRUI CARE Agreement
FX Open access funding provided by Universita degli Studi di Milano within
   the CRUI CARE Agreement.
CR Amiche MA, 2016, OSTEOPOROSIS INT, V27, P1709, DOI 10.1007/s00198 015 3455 9
   Boskey AL, 2017, ANN NY ACAD SCI, V1410, P93, DOI 10.1111/nyas.13572
   Busse B, 2020, J ORTHOP RES, V38, P925, DOI 10.1002/jor.24539
   Cao J, 2003, J BONE MINER RES, V18, P270, DOI 10.1359/jbmr.2003.18.2.270
   Carnovali M, 2016, J BIOL REG HOMEOS AG, V30, P213
   Chang Z, 2018, J MECH BEHAV BIOMED, V84, P54, DOI 10.1016/j.jmbbm.2018.05.004
   Cheng M, 2015, CLIN LAB, V61, P899, DOI 10.7754/Clin.Lab.2015.150131
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   D'Amelio P, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/907689
   de Vrieze E, 2014, OSTEOPOROSIS INT, V25, P567, DOI 10.1007/s00198 013 2441 3
   Duque G, 2008, J AM GERIATR SOC, V56, P935, DOI 10.1111/j.1532 5415.2008.01764.x
   Dutta S, 2016, LIFE SCI, V152, P244, DOI 10.1016/j.lfs.2015.10.025
   Fatayerji D, 1999, J BONE MINER RES, V14, P1203, DOI 10.1359/jbmr.1999.14.7.1203
   Fiedler IAK, 2018, J BONE MINER RES, V33, P1489, DOI 10.1002/jbmr.3445
   Geurtzen K, 2017, J BONE MINER RES, V32, P2476, DOI 10.1002/jbmr.3231
   Gibon E, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0300 9
   Goltzman D, 2019, ADV EXP MED BIOL, V1164, P153, DOI 10.1007/978 3 030 22254 3_12
   Guggenbuhl P, 2009, JOINT BONE SPINE, V76, P595, DOI 10.1016/j.jbspin.2009.10.001
   Halloran BP, 2002, J BONE MINER RES, V17, P1044, DOI 10.1359/jbmr.2002.17.6.1044
   Hayes AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075787
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P751, DOI 10.1007/s00198 006 0298 4
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Kennel KA, 2003, OSTEOPOROSIS INT, V14, P631, DOI 10.1007/s00198 003 1417 0
   Kitamura K, 2013, COMP BIOCHEM PHYS A, V166, P74, DOI 10.1016/j.cbpa.2013.04.023
   Komori T, 2016, HORM METAB RES, V48, P755, DOI 10.1055/s 0042 110571
   Leib ES, 2016, OSTEOPOROSIS INT, V27, P39, DOI 10.1007/s00198 015 3211 1
   Levis S, 1998, ARTHRITIS RHEUM US, V41, P577, DOI 10.1002/1529 0131(199804)41:4<577::AID ART4>3.0.CO;2 7
   Li W, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891 018 2231 3
   Liu HJ, 2015, EXP BIOL MED, V240, P1099, DOI 10.1177/1535370215591828
   Liu SX, 2016, INT J MOL MED, V37, P284, DOI 10.3892/ijmm.2015.2423
   Liu Y, 2018, OSTEOPOROSIS INT, V29, P2121, DOI 10.1007/s00198 018 4591 9
   Lu SY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03187 w
   Mank JE, 2007, AM NAT, V169, P142, DOI 10.1086/510103
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Monma Y, 2019, BONE REP, V11, DOI 10.1016/j.bonr.2019.100215
   Pasqualetti S, 2015, INT J EXP PATHOL, V96, P11, DOI 10.1111/iep.12106
   Pasqualetti S, 2012, CELL TISSUE RES, V350, P69, DOI 10.1007/s00441 012 1436 2
   PERSSON P, 1995, FISH PHYSIOL BIOCHEM, V14, P329, DOI 10.1007/BF00004071
   Porcelli T, 2020, EUR J ENDOCRINOL, V183, pR75, DOI 10.1530/EJE 20 0034
   Roy B, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00439
   Sengupta P, 2013, INT J PREVENTIVE MED, V4, P624
   Shanthanagouda AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088165
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Sire JY, 2004, INT J DEV BIOL, V48, P233, DOI 10.1387/ijdb.15272389
   Suzuki N, 2011, BONE, V48, P1186, DOI 10.1016/j.bone.2011.02.004
   Tatsuno I, 2009, J CLIN ENDOCR METAB, V94, P1671, DOI 10.1210/jc.2008 1578
   Tomecka MJ, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037630
   Wang L, 2001, BONE, V29, P141, DOI 10.1016/S8756 3282(01)00483 5
   Wei Y, 2018, ADV EXP MED BIOL, V1086, P189, DOI 10.1007/978 981 13 1117 8_12
   WESTERFIELD M, 1993, ZEBRAFISH BOOK GUIDE
   Witten PE, 2009, BIOL REV, V84, P315, DOI 10.1111/j.1469 185X.2009.00077.x
   Zanatta M, 2012, J BONE MINER METAB, V30, P706, DOI 10.1007/s00774 012 0373 1
   Zhou S, 2008, AGING CELL, V7, P335, DOI 10.1111/j.1474 9726.2008.00377.x
NR 55
TC 7
Z9 8
U1 0
U2 20
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2509 2715
EI 2509 2723
J9 GEROSCIENCE
JI GeroScience
PD APR
PY 2021
VL 43
IS 2
BP 927
EP 940
DI 10.1007/s11357 020 00267 0
EA SEP 2020
PG 14
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Geriatrics & Gerontology
GA SA1JR
UT WOS:000574058900001
PM 32997256
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Lu, DG
   Lu, MJ
   Yao, SH
   Lin, JJ
   Luo, S
   Wei, JH
   Tang, YJ
AF Lu, Ding Gui
   Lu, Mei Jiao
   Yao, Shun Han
   Lin, Jia Jie
   Luo, Su
   Wei, Ji Hua
   Tang, Yu Jin
TI Long non coding RNA TUG1 promotes the osteogenic differentiation of bone
   marrow mesenchymal stem cells by regulating the AMPK/mTOR/autophagy
   pathway
SO BIOMEDICAL RESEARCH TOKYO
LA English
DT Article
ID AUTOPHAGY; METABOLISM; OSTEOPOROSIS; GROWTH; MTOR; AMPK; EAT
AB Promoting the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts is an effective strategy against osteoporosis. Long non coding RNAs are closely implicated in BMSC osteogenic differentiation. The present study explored the expression pattern and biological role of taurine upregulated gene 1 (TUG1) in osteogenic differentiation. The expressions of TUG1 and osteogenic markers following the osteogenic induction of BMSCs were detected. The functional relevance of TUG1 was evaluated by performing gain  and loss of function tests. Inhibitors of AMP activated protein kinase (AMPK) autophagy were applied to ascertain the effects of TUG1 on the osteogenic differentiation of BMSCs. TUG1 expression increased during the osteogenic differentiation of BMSCs. The overexpression of TUG1 was promoted, whereas the knockdown of TUG1 was suppressed, by BMSC osteogenic differentiation. Mechanically, TUG1 promoted the osteogenesis of BMSCs via the AMPK mammalian target of rapamycin (mTOR) autophagy signaling pathway. Blocking AMPK and autophagy could abrogate the osteogenic role of TUG1 in BMSCs. These results demonstrated that TUG1 promoted the osteogenic differentiation of BMSCs by regulating the AMPK/mTOR/autophagy axis, suggesting that targeting TUG1 may be a potential therapy for osteoporosis.
C1 [Lu, Ding Gui; Lu, Mei Jiao; Yao, Shun Han; Lin, Jia Jie; Luo, Su; Wei, Ji Hua; Tang, Yu Jin] Youjiang Med Univ Nationalities, Dept Orthoped, Affiliated Hosp, Baise 533000, Guangxi, Peoples R China.
C3 Youjiang Medical University for Nationalities
RP Wei, JH; Tang, YJ (通讯作者)，Youjiang Med Univ Nationalities, Dept Orthoped, Affiliated Hosp, Baise 533000, Guangxi, Peoples R China.
EM 1261290953@qq.com; tyj196609@163.com
RI ; Lin, Jiajie/MVW 5726 2025
OI yao, shunhan/0000 0001 8821 633X; 
FU Basic Ability Improvement Project of Young and Middle aged Teachers in
   Guangxi Universities [2018KY0449]; Self funded Scientific Research
   Projects of Health and the Family Planning Commission of the Guangxi
   Zhuang Autonomous Region [Z20170243]; Baise Scientific Research and
   Technology Development Project [20170512]; Key R&D Projects in Guangxi
   [GK A18050008]
FX This study is supported by the Basic Ability Improvement Project of
   Young and Middle aged Teachers in Guangxi Universities (2018KY0449) to
   Dinggui Lu; Self funded Scientific Research Projects of Health and the
   Family Planning Commission of the Guangxi Zhuang Autonomous Region
   (Z20170243) to Ding gui Lu; Baise Scientific Research and Technology
   Development Project (20170512) to Dinggui Lu; and Key R&D Projects in
   Guangxi (GK A18050008) to Yu jin Tang.
CR Abdrakhmanov A, 2020, TRENDS BIOCHEM SCI, V45, P347, DOI 10.1016/j.tibs.2019.11.006
   Armas LAG, 2012, ENDOCRIN METAB CLIN, V41, P475, DOI 10.1016/j.ecl.2012.04.006
   Chen S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0935 9
   Compston JE, 2019, LANCET, V393, P364, DOI 10.1016/S0140 6736(18)32112 3
   Coughlan T, 2014, CLIN MED, V14, P187, DOI 10.7861/clinmedicine.14 2 187
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580 018 0003 4
   He Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0484 2
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Jin ZX, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2851 2
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Lahiri V, 2019, CELL METAB, V29, P803, DOI 10.1016/j.cmet.2019.03.003
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Li Z, 2016, CELL PROLIFERAT, V49, P471, DOI 10.1111/cpr.12269
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028
   Pierce JL, 2019, BONE, V118, P2, DOI 10.1016/j.bone.2018.05.019
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676
   Vrahnas C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11373 9
   Wang X, 2019, MOL CELL ENDOCRINOL, V496, DOI 10.1016/j.mce.2019.110534
   Xie CH, 2016, TUMOR BIOL, V37, P15031, DOI 10.1007/s13277 016 5391 5
   Yang YH, 2020, FASEB J, V34, P8876, DOI 10.1096/fj.201903216RR
   Yu C, 2018, CARDIOVASC RES, V114, P168, DOI 10.1093/cvr/cvx180
   Yu L, 2018, AUTOPHAGY, V14, P207, DOI 10.1080/15548627.2017.1378838
   Yu L, 2010, NATURE, V465, P942, DOI 10.1038/nature09076
   Zhang EB, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.201
   Zhong X, 2011, ACTA PHARMACOL SIN, V32, P591, DOI 10.1038/aps.2011.15
NR 30
TC 6
Z9 9
U1 0
U2 9
PU BIOMEDICAL RESEARCH PRESS LTD
PI SAPPORO
PA HOKKAIDO UNIV, LAB HISTOLOGY & CYTOLOGY, C/O TOSHIHIKO IWANAGA, KITA
   15 NISHI 7, SAPPORO, 060 8638, JAPAN
SN 0388 6107
EI 1880 313X
J9 BIOMED RES TOKYO
JI Biomed. Res.
PY 2021
VL 42
IS 6
BP 239
EP 246
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA XV1IY
UT WOS:000734705700002
PM 34937823
OA gold
DA 2025 08 17
ER

PT J
AU Shim, KS
   Ma, CJ
   Cho, CW
   Ma, JY
AF Shim, Ki Shuk
   Ma, Choong Je
   Cho, Chang Won
   Ma, Jin Yeul
TI Samul tang suppresses RANKL induced osteoclast differentiation in
   RAW264.7 cells
SO BIOTECHNOLOGY AND BIOPROCESS ENGINEERING
LA English
DT Article
DE osteoclast differentiation; RAW264.7 cells; receptor activator for
   nuclear factor kappa B ligand; samul tang
ID NECROSIS FACTOR RECEPTOR; JUZEN TAIHO TO; BONE RESORPTION;
   GENE EXPRESSION; CATHEPSIN K; ENDOMETRIAL CARCINOGENESIS; WATER EXTRACT;
   SHIMOTSU TO; NFATC1; OSTEOPETROSIS
AB Samul tang (SMT) is a traditional herbal medicine used for the treatment of ischemic brain and heart diseases. In this study, we investigated the molecular mechanism underlying the inhibitory effects of SMT on osteoclast differentiation induced by the receptor activator for nuclear factor kappa B ligand (RANKL) in RAW264.7 cells. SMT dose dependently and significantly inhibited the RANKL induced tartrate resistant acid phosphatase (TRAP) activity and the formation of multi nucleated osteoclasts. In addition, SMT significantly reduced the RANKL induced mRNA expression of osteoclast differentiation related genes that encode TRAP, c src, matrix metalloproteinase (MMP) 9, cathepsin K, and the d2 isoform of vacuolar ATPase V(0) domain (ATPv0d2). SMT also inhibited the RANKL induced activation of MAP kinases and NF kappa B p65, and mRNA expression of transcription factors (Fra 2 and NFATc1). In conclusion, these results suggested that SMT suppresses the RANKL induced activation of signaling molecules and transcription factors, which consequently inhibits osteoclast differentiation.
C1 [Shim, Ki Shuk; Ma, Jin Yeul] Korea Inst Oriental Med, Ctr Herbal Med Improvement Res, Taejon 305811, South Korea.
   [Ma, Choong Je] Kangwon Natl Univ, Dept Biomat Engn, Sch Biotechnol & Bioengn, Chunchon 200701, South Korea.
   [Cho, Chang Won] Korea Food Res Inst, Reg Food Ind Res Grp, Songnam 463746, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Kangwon National
   University; Korea Food Research Institute (KFRI)
RP Shim, KS (通讯作者)，Korea Inst Oriental Med, Ctr Herbal Med Improvement Res, Taejon 305811, South Korea.
EM jyma@kiom.re.kr
RI Cho, Chang Won/GPF 4456 2022; Ma, Choong Je/H 9986 2013; Je,
   Choong/H 9986 2013
OI Ma, Choong Je/0000 0001 8818 6396; 
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology (MEST), Republic of Korea [K10050]
FX We thank Yoon Hee Lee (Korea Institute of Oriental Medicine) for
   technical support and Sung Up Choi (Korea Institute of Oriental
   Medicine) for critical reading of the manuscript. This work was
   supported by a grant (K10050) from the Korea Institute of Oriental
   Medicine, Ministry of Education, Science and Technology (MEST), Republic
   of Korea.
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ishibashi O, 2006, LIFE SCI, V79, P1657, DOI 10.1016/j.lfs.2006.05.024
   KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369
   Kil JS, 2008, PHYTOTHER RES, V22, P472, DOI 10.1002/ptr.2342
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Lee GW, 2009, KOREAN J PHYSIOL PHA, V13, P139, DOI 10.4196/kjpp.2009.13.3.139
   Lian ZL, 2006, ONCOL REP, V15, P1133
   Lian ZL, 2002, CANCER LETT, V182, P19, DOI 10.1016/S0304 3835(02)00059 9
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Pang M, 2007, GENE, V403, P151, DOI 10.1016/j.gene.2007.08.007
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   So HS, 2000, GEN PHARMACOL VASC S, V34, P303, DOI 10.1016/S0306 3623(00)00073 2
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Srivastava S, 1999, J CLIN INVEST, V104, P503, DOI 10.1172/JCI7094
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sundaram K, 2007, EXP CELL RES, V313, P168, DOI 10.1016/j.yexcr.2006.10.001
   Tagami K, 2004, BIOL PHARM BULL, V27, P156, DOI 10.1248/bpb.27.156
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tsai HY, 2008, EUR J PHARMACOL, V588, P124, DOI 10.1016/j.ejphar.2008.04.024
   Vaira S, 2008, J CLIN INVEST, V118, P2088, DOI 10.1172/JCI33392
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Watanabe H, 1991, Yakubutsu Seishin Kodo, V11, P215
   WON JB, 2009, KOR J PHARMACOGN, V40, P298
   Wu HP, 2009, J BONE MINER RES, V24, P871, DOI [10.1359/JBMR.081239, 10.1359/jbmr.081239]
NR 42
TC 3
Z9 3
U1 0
U2 6
PU KOREAN SOC BIOTECHNOLOGY & BIOENGINEERING
PI SEOUL
PA KOREAN SCIENCE TECHNOLOGY CENTER, #704 YEOGSAM DONG, KANGNAM KU, SEOUL
   135 703, SOUTH KOREA
SN 1226 8372
EI 1976 3816
J9 BIOTECHNOL BIOPROC E
JI Biotechnol. Bioprocess Eng.
PD JUN
PY 2011
VL 16
IS 3
BP 603
EP 610
DI 10.1007/s12257 010 0431 2
PG 8
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 785CJ
UT WOS:000292204700021
DA 2025 08 17
ER

PT J
AU Capo, V
   Abinun, M
   Villa, A
AF Capo, Valentina
   Abinun, Mario
   Villa, Anna
TI Osteoclast rich osteopetrosis due to defects in the TCIRG1 gene
SO BONE
LA English
DT Article
DE Osteopetrosis; Osteoclast function; Vacuolar type proton  pumping
   ATPase; Haematopoietic stem cell transplantation; Gene therapy
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; STEM CELL TRANSPLANTATION;
   BONE MARROW TRANSPLANTATION; VACUOLAR H+ ATPASE; INFANTILE
   OSTEOPETROSIS; ALLOGRAFT REJECTION; PROTON PUMP; A3 ISOFORM; MUTATIONS;
   SUBUNIT
AB Discovery that mutations in TCIRG1 (also known as Atp6i) gene are responsible for most instances of autosomal recessive osteopetrosis (ARO) heralded a new era for comprehension and treatment of this phenotypically het erogeneous rare bone disease. TCIRG1 encodes the a3 subunit, an essential isoform of the vacuolar ATPase proton pump involved in acidification of the osteoclast resorption lacuna and in secretory lysosome trafficking. TCIRG1 defects lead to inefficient bone resorption by nonfunctional osteoclasts seen in abundance on bone marrow biopsy, delineating this ARO as 'osteoclast rich'. Presentation is usually in early childhood and features of extramedullary haematopoiesis (hepatosplenomegaly, anaemia, thrombocytopenia) due to bone marrow fibrosis, and cranial nerve impingement (blindness in particular). Impaired dietary calcium uptake due to high pH causes the co occurrence of rickets, described as "osteopetrorickets". Osteoclast dysfunction leads to early death if untreated, and allogeneic haematopoietic stem cell transplantation is currently the treatment of choice. Studies of patients as well as of mouse models carrying spontaneous (the oc/oc mouse) or targeted disruption of Atp6i (TCIRG1) gene have been instrumental providing insight into disease pathogenesis and development of novel cellular therapies that exploit gene correction.
C1 [Capo, Valentina; Villa, Anna] IRCCS San Raffaele Sci Inst, San Raffaele Telethon Inst Gene Therapy SR Tiget, Milan, Italy.
   [Capo, Valentina; Villa, Anna] CNR, Inst Genet & Biomed Res, Milan Unit, Milan, Italy.
   [Abinun, Mario] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Childrens Haematopoiet Stem Cell Transplantat Unit, Newcastle Upon Tyne, England.
   [Abinun, Mario] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, England.
   [Villa, Anna] SR Tiget IRCCS San Raffaele Sci Inst, Via Olgettina 58, I 2013 Milan, Italy.
C3 Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy
   (Sr Tiget); Vita Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Ricerca
   Genetica e Biomedica (IRGB CNR); Newcastle Upon Tyne Hospitals NHS
   Foundation Trust; Newcastle University   UK
RP Villa, A (通讯作者)，SR Tiget IRCCS San Raffaele Sci Inst, Via Olgettina 58, I 2013 Milan, Italy.
EM villa.anna@hsr.it
RI Capo, Valentina/ABG 3418 2020
CR Anderson SL, 2015, CLIN GENET, V88, P74, DOI 10.1111/cge.12448
   Bhargava A, 2012, J BIOL CHEM, V287, P26829, DOI 10.1074/jbc.M112.345702
   BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207
   Blin Wakkach C, 2004, LEUKEMIA, V18, P1505, DOI 10.1038/sj.leu.2403449
   Blin Wakkach C, 2004, J BONE MINER RES, V19, P1137, DOI 10.1359/JBMR.040318
   Bliznetz EA, 2009, EUR J HUM GENET, V17, P664, DOI 10.1038/ejhg.2008.234
   Borthwick KJ, 2003, J MED GENET, V40, P115, DOI 10.1136/jmg.40.2.115
   Capo V, 2021, HAEMATOLOGICA, V106, P74, DOI 10.3324/haematol.2019.238261
   Chu A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136934
   COCCIA PF, 1980, NEW ENGL J MED, V302, P701, DOI 10.1056/NEJM198003273021301
   Cohen S, 2020, LANCET HAEMATOL, V7, pE134, DOI 10.1016/S2352 3026(19)30202 9
   Even Or E, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116229
   Even Or E, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28841
   Even Or E, 2021, BONE MARROW TRANSPL, V56, P434, DOI 10.1038/s41409 020 01040 9
   Flores C, 2013, HAEMATOLOGICA, V98, P1848, DOI 10.3324/haematol.2013.089466
   Flores C, 2010, J BONE MINER RES, V25, P2069, DOI 10.1002/jbmr.90
   Forgac M, 2007, NAT REV MOL CELL BIO, V8, P917, DOI 10.1038/nrm2272
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Futai M, 2012, BBA BIOENERGETICS, V1817, P1711, DOI 10.1016/j.bbabio.2012.03.015
   GERRITSEN EJA, 1994, PEDIATRICS, V93, P247
   GERRITSEN EJA, 1994, J PEDIATR US, V125, P896, DOI 10.1016/S0022 3476(05)82004 9
   Gonen KA, 2013, PEDIATR RADIOL, V43, P189, DOI 10.1007/s00247 012 2511 2
   Heaney C, 1998, HUM MOL GENET, V7, P1407, DOI 10.1093/hmg/7.9.1407
   Howaldt A, 2019, BONE, V120, P495, DOI 10.1016/j.bone.2018.12.002
   Koehne T, 2013, BONE, V53, P25, DOI 10.1016/j.bone.2012.11.009
   Kohn D.B.R., 2021, ESGCT M
   Kornak U, 2000, HUM MOL GENET, V9, P2059, DOI 10.1093/hmg/9.13.2059
   Krause N, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.790775
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   Liu CY, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920 021 01117 4
   Löfvall H, 2019, HUM GENE THER, V30, P1395, DOI 10.1089/hum.2019.047
   LORIACORTES R, 1977, J PEDIATR US, V91, P43, DOI 10.1016/S0022 3476(77)80441 1
   Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015
   Matsumoto N, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 24918 7
   Moscatelli I, 2021, MOL THER METH CLIN D, V20, P389, DOI 10.1016/j.omtm.2020.12.009
   Moscatelli I, 2018, HUM GENE THER, V29, P938, DOI 10.1089/hum.2017.053
   Moscatelli I, 2013, BONE, V57, P1, DOI 10.1016/j.bone.2013.07.026
   Nguyen A, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10597
   Ochotny N, 2006, J BIOL CHEM, V281, P26102, DOI 10.1074/jbc.M601118200
   Ochotny N, 2011, J BONE MINER RES, V26, P1484, DOI 10.1002/jbmr.355
   Orchard PJ, 2015, BLOOD, V126, P270, DOI 10.1182/blood 2015 01 625541
   Palagano E, 2017, J BONE MINER RES, V32, P99, DOI 10.1002/jbmr.2929
   Palagano E, 2015, J BONE MINER RES, V30, P1814, DOI 10.1002/jbmr.2517
   Pangrazio A, 2012, OSTEOPOROSIS INT, V23, P2713, DOI 10.1007/s00198 011 1878 5
   Penna S, 2021, DIS MODEL MECH, V14, DOI 10.1242/dmm.048940
   Penna S, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00085
   Rosenthal EA, 2016, GENET EPIDEMIOL, V40, P470, DOI 10.1002/gepi.21976
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Schulz A.S., 2015, ESID EBMT WP INB ERR
   Schulz AS, 2002, BLOOD, V99, P3458, DOI 10.1182/blood.V99.9.3458
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Shimada Sugawara M, 2015, SCI REP UK, V5, DOI 10.1038/srep09620
   Shinwari K, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.879875
   Simanovsky N, 2016, PEDIATR BLOOD CANCER, V63, P1222, DOI 10.1002/pbc.25952
   Sobacchi C, 2001, HUM MOL GENET, V10, P1767, DOI 10.1093/hmg/10.17.1767
   Sobacchi C, 2014, J BONE MINER RES, V29, P1646, DOI 10.1002/jbmr.2203
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Stepensky P, 2019, BLOOD ADV, V3, P862, DOI 10.1182/bloodadvances.2018025890
   Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779
   Steward CG, 2005, BIOL BLOOD MARROW TR, V11, P115, DOI 10.1016/j.bbmt.2004.11.001
   Steward CG, 2003, NEUROPATH APPL NEURO, V29, P87, DOI 10.1046/j.1365 2990.2003.00474.x
   Sun Wada GH, 2006, J CELL SCI, V119, P4531, DOI 10.1242/jcs.03234
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thudium CS, 2014, CALCIFIED TISSUE INT, V95, P83, DOI 10.1007/s00223 014 9865 4
   Thudium CS, 2016, CALCIFIED TISSUE INT, V99, P638, DOI 10.1007/s00223 016 0187 6
   Toei M, 2010, BIOCHEMISTRY US, V49, P4715, DOI 10.1021/bi100397s
   Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760
   UDAGAWA N, 1992, BIOCHEM BIOPH RES CO, V184, P67, DOI 10.1016/0006 291X(92)91158 M
   Utku N, 1998, IMMUNITY, V9, P509, DOI 10.1016/S1074 7613(00)80634 2
   Utku N, 2007, CURR OPIN INVEST DR, V8, P401
   Villa A, 2009, CALCIFIED TISSUE INT, V84, P1, DOI 10.1007/s00223 008 9196 4
   Wada K, 2013, J PEDIATR ENDOCR MET, V26, P575, DOI 10.1515/jpem 2013 0007
   Wu CC, 2017, J CLIN ENDOCR METAB, V102, P3111, DOI 10.1210/jc.2017 01127
   Zhang XY, 2017, ACTA PHARMACOL SIN, V38, P1456, DOI 10.1038/aps.2017.108
   Zirngibl RA, 2019, J CELL BIOCHEM, V120, P17180, DOI 10.1002/jcb.28979
NR 77
TC 14
Z9 16
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD DEC
PY 2022
VL 165
AR 116519
DI 10.1016/j.bone.2022.116519
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 5D1FI
UT WOS:000864695400003
PM 35981697
DA 2025 08 17
ER

PT J
AU Heo, SK
   Choi, Y
   Jeong, YK
   Ju, LJ
   Yu, HM
   Kim, DK
   Seo, HJ
   Lee, YJ
   Cheon, J
   Koh, S
   Min, YJ
   Noh, EK
   Jo, JC
AF Heo, Sook Kyoung
   Choi, Yunsuk
   Jeong, Yoo Kyung
   Ju, Lan Jeong
   Yu, Ho Min
   Kim, Do Kyoung
   Seo, Hye Jin
   Lee, Yoo Jin
   Cheon, Jaekyung
   Koh, SuJin
   Min, Young Joo
   Noh, Eui Kyu
   Jo, Jae Cheol
TI LIGHT (TNFSF14) enhances osteogenesis of human bone marrow derived
   mesenchymal stem cells
SO PLOS ONE
LA English
DT Article
AB Osteoporosis is a progressive systemic skeletal disease associated with decreased bone mineral density and deterioration of bone quality, and it affects millions of people worldwide. Currently, it is treated mainly using antiresorptive and osteoanabolic agents. However, these drugs have severe adverse effects. Cell replacement therapy using mesenchymal stem cells (MSCs) could serve as a treatment strategy for osteoporosis in the future. LIGHT (HVEM L, TNFSF14, or CD258) is a member of the tumor necrosis factor superfamily. However, the effect of recombinant LIGHT (rhLIGHT) on osteogenesis in human bone marrow derived MSCs (hBM MSCs) is unknown. Therefore, we monitored the effects of LIGHT on osteogenesis of hBM MSCs. Lymphotoxin beta receptor (LT beta R), which is a LIGHT receptor, was constitutively expressed on the surface of hBM MSCs. After rhLIGHT treatment, calcium and phosphate deposition in hBM MSCs, stained by Alizarin red and von Kossa, respectively, significantly increased. We performed quantitative real time polymerase chain reaction to examine the expressions of osteoprogenitor markers (RUNX2/CBFA1 and collagen I alpha 1) and osteoblast markers (alkaline phosphatase, osterix/Sp7, and osteocalcin) and immunoblotting to assess the underlying biological mechanisms following rhLIGHT treatment. We found that rhLIGHT treatment enhanced von Kossa  and Alizarin red positive hBM MSCs and induced the expression of diverse differentiation markers of osteogenesis in a dose dependent manner. WNT/beta catenin pathway activation strongly mediated rhLIGHT induced osteogenesis of hBM MSCs, accelerating the differentiation of hBM MSCs into osteocytes. In conclusion, the interaction between LIGHT and LT beta R enhances osteogenesis of hBM MSCs. Therefore, LIGHT might play an important role in stem cell therapy.
C1 [Heo, Sook Kyoung; Jeong, Yoo Kyung; Ju, Lan Jeong; Yu, Ho Min; Kim, Do Kyoung; Seo, Hye Jin; Jo, Jae Cheol] Univ Ulsan, Ulsan Univ Hosp, Biomed Res Ctr, Coll Med, Ulsan, South Korea.
   [Choi, Yunsuk; Lee, Yoo Jin; Cheon, Jaekyung; Koh, SuJin; Min, Young Joo; Noh, Eui Kyu; Jo, Jae Cheol] Univ Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea.
C3 University of Ulsan; Ulsan University Hospital; University of Ulsan;
   Ulsan University Hospital
RP Jo, JC (通讯作者)，Univ Ulsan, Ulsan Univ Hosp, Biomed Res Ctr, Coll Med, Ulsan, South Korea.; Noh, EK; Jo, JC (通讯作者)，Univ Ulsan, Ulsan Univ Hosp, Dept Hematol & Oncol, Coll Med, Ulsan, South Korea.
EM jcjo97@hanmail.net; noheuikyu@gmail.com
RI Seo, Hye/C 6900 2015; Lee, Kee Joon/AAA 4090 2022; Jo,
   Jae Cheol/CAE 9453 2022
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF)   Ministry of Education, Science and Technology
   [NRF 2018R1D1A1B07051343, NRF 2017R1A1A3A04069314]; Basic Science
   Research Program through the Biomedical Research Center   Ulsan
   University Hospital [UUHBRC 2016 001]
FX This work was supported by the Basic Science Research Program through
   the National Research Foundation of Korea (NRF) funded by the Ministry
   of Education, Science and Technology (NRF 2018R1D1A1B07051343,
   NRF 2017R1A1A3A04069314). The research was also supported by the Basic
   Science Research Program through the Biomedical Research Center, funded
   by the Ulsan University Hospital (UUHBRC 2016 001). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Cao L, 2012, BIOMATERIALS, V33, P5076, DOI 10.1016/j.biomaterials.2012.03.069
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   de Girolamo L, 2013, CURR PHARM DESIGN, V19, P2459, DOI 10.2174/1381612811319130015
   De Miguel MP, 2012, CURR MOL MED, V12, P574
   Fütterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074 7613(00)80588 9
   Gnecchi Massimiliano, 2009, V482, P281, DOI 10.1007/978 1 59745 060 7_18
   Han Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080886
   Harrop JA, 1998, J IMMUNOL, V161, P1786
   Hartmann C, 2006, TRENDS CELL BIOL, V16, P151, DOI 10.1016/j.tcb.2006.01.001
   Hehlgans T, 2005, IMMUNOLOGY, V115, P1, DOI 10.1111/j.1365 2567.2005.02143.x
   Heo SK, 2008, IMMUNOL LETT, V120, P57, DOI 10.1016/j.imlet.2008.07.002
   Heo SK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15492 5
   Heo SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166589
   Heo SK, 2016, EUR J PHARMACOL, V789, P280, DOI 10.1016/j.ejphar.2016.07.049
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Ju C, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108912
   Kwon BS, 1997, J BIOL CHEM, V272, P14272, DOI 10.1074/jbc.272.22.14272
   Le Blanc K, 2007, J INTERN MED, V262, P509, DOI 10.1111/j.1365 2796.2007.01844.x
   Lin H, 2019, BIOMATERIALS, V203, P96, DOI 10.1016/j.biomaterials.2018.06.026
   Lin S, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0672 5
   Meng YC, 2020, MOL THER NUCL ACIDS, V20, P345, DOI 10.1016/j.omtn.2019.11.038
   Murphy KM, 2006, NAT REV IMMUNOL, V6, P671, DOI 10.1038/nri1917
   Ocarino ND, 2010, CONNECT TISSUE RES, V51, P426, DOI 10.3109/03008201003597049
   Paino F, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.308
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Piters E, 2008, ARCH BIOCHEM BIOPHYS, V473, P112, DOI 10.1016/j.abb.2008.03.006
   Shi X, 2020, STEM CELL TRANSL MED, V9, P445, DOI 10.1002/sctm.19 0398
   Spahn TW, 2004, GUT, V53, P456, DOI 10.1136/gut.2003.023671
   Tu Kristie N, 2018, P T, V43, P92
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   van der Garde M, 2015, STEM CELLS DEV, V24, P2649, DOI 10.1089/scd.2015.0138
   Wang J, 2004, IMMUNOL RES, V30, P201, DOI 10.1385/IR:30:2:201
   Wang Y, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00353
   Wang Z, 2006, TISSUE ENG, V12, P1753, DOI 10.1089/ten.2006.12.1753
   Zhu XB, 2018, J CELL BIOCHEM, V119, P8346, DOI 10.1002/jcb.26910
NR 35
TC 5
Z9 5
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD FEB 19
PY 2021
VL 16
IS 2
AR e0247368
DI 10.1371/journal.pone.0247368
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA QK8KQ
UT WOS:000620629200145
PM 33606781
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Shan, HJ
   Zhou, XF
   Tian, B
   Zhou, CY
   Gao, X
   Bai, CW
   Shan, BC
   Zhang, YZ
   Sun, SX
   Sun, DD
   Fan, Q
   Zhou, XZ
   Wang, C
   Bai, JY
AF Shan, Huajian
   Zhou, Xuanfang
   Tian, Bo
   Zhou, Chenyu
   Gao, Xiang
   Bai, Chaowen
   Shan, Bingchen
   Zhang, Yingzi
   Sun, Shengxuan
   Sun, Dongdong
   Fan, Qin
   Zhou, Xiaozhong
   Wang, Chao
   Bai, Jinyu
TI Gold nanorods modified by endogenous protein with light irradiation
   enhance bone repair via multiple osteogenic signal pathways
SO BIOMATERIALS
LA English
DT Article
DE Photothermal therapy; Endogenous proteins; Immune response; Osteogenesis
ID FRACTURE; NANOPARTICLES; REGENERATION; HOMEOSTASIS; OSTEOBLAST;
   DEPOSITION; THERAPY; OSTERIX; TUMOR; BETA
AB Fracture is one of the most common clinical diseases that reduce the quality of patients' lives significantly. In this study, we prepared gold nanorods modified by endogenous proteins which collected from the autologous blood of individual mice for enhanced photothermal therapy (PTT) to treat fracture. Due to the outermost layer being endogenous proteins, we find that GNRs neither activate the immune cells in vitro nor cause any rejection immune responses after entering the body as compared with PEG modification. In addition, the internal bleeding and edema of the fracture site result in a rapid enrichment of GNRs after intravenous injection. Under near infrared (NIR) light irradiation, the mild photothermal effect of the accumulated GNRs can effectively promote healing of fracture in mice. The molecular mechanism of osteogenic capability is revealed by transcriptome sequencing and subsequent confirmatory experiments, indicating enhanced two key osteogenic signal transduction (MAPK, PI3K Akt) and multiple key osteogenesis related factors expression following the treatment. Our strategy offers an alternative way to promote bone regeneration following a fracture.
C1 [Shan, Huajian; Tian, Bo; Gao, Xiang; Bai, Chaowen; Shan, Bingchen; Zhang, Yingzi; Sun, Shengxuan; Zhou, Xiaozhong; Bai, Jinyu] Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.
   [Zhou, Xuanfang; Fan, Qin; Wang, Chao] Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Jiangsu Key Lab Carbon based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.
   [Zhou, Chenyu] Xuzhou Med Univ, Fac Clin Med, Xuzhou, Jiangsu, Peoples R China.
   [Sun, Dongdong] Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, Nanjing 210023, Peoples R China.
C3 Soochow University   China; Soochow University   China; Xuzhou Medical
   University; Nanjing University of Chinese Medicine
RP Zhou, XZ; Bai, JY (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 2, Suzhou 215004, Jiangsu, Peoples R China.; Wang, C (通讯作者)，Soochow Univ, Inst Funct Nano & Soft Mat FUNSOM, Jiangsu Key Lab Carbon based Funct Mat & Devices, Suzhou 215123, Jiangsu, Peoples R China.; Sun, DD (通讯作者)，Nanjing Univ Chinese Med, Sch Integrated Chinese & Western Med, Nanjing 210023, Peoples R China.
EM sundd@njucm.edu.cn; zhouxz@suda.edu.cn; cwang@suda.edu.cn;
   baijy@suda.edu.cn
RI Wang, Chao/G 5951 2012; GAO, XIANG/KCK 6653 2024; Sun,
   Dongdong/JLR 8876 2023; BAI, JINYU/MIP 5486 2025; Zhang,
   Yingzi/LGY 3932 2024
OI Wang, Chao/0000 0002 8054 3472; 
FU National Natural Science Foundation of China [82172425, 82102611];
   Natural Science Foundation of Jiangsu Province [21KJB320007]; Suzhou
   Special Foundation of Clinical Key Diseases Diagnosis and Therapy
   [LCZX201904, LCZX201708]; project of Advanced PhD research project of
   Second Affiliated Hospital of Soochow University [SDFEYJBS2011,
   SDFEYJBS2103]; Gusu health talent plan special talents [C (2021) 021];
   Gusu health talent plan research project [GSWS2021015]; Doctor of
   entrepreneurship and innovation in Jiangsu Province [JSSCBS20211554];
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions, Qinglan Project of Jiangsu Province
FX This work was supported by National Natural Science Foundation of China
   (No. 82172425, 82102611) , the Natural Science Foundation of Jiangsu
   Province (No. 21KJB320007) , Suzhou Special Foundation of Clinical Key
   Diseases Diagnosis and Therapy (LCZX201904, LCZX201708) . This study was
   also supported by the project of Advanced PhD research project of the
   Second Affiliated Hospital of Soochow University (SDFEYJBS2011,
   SDFEYJBS2103) , Gusu health talent plan special talents C (2021) 021,
   Gusu health talent plan research project (GSWS2021015) , Doctor of
   entrepreneurship and innovation in Jiangsu Province (JSSCBS20211554) ,
   the Priority Academic Program Develop ment of Jiangsu Higher Education
   Institutions, Qinglan Project of Jiangsu Province.
CR Ali MRK, 2017, P NATL ACAD SCI USA, V114, pE5655, DOI 10.1073/pnas.1703151114
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bochenek MA, 2018, NAT BIOMED ENG, V2, P810, DOI 10.1038/s41551 018 0275 1
   Chang CJ, 2017, NAT COMMUN, V8, DOI [10.1038/s41467 017 00622 4, 10.1038/s41467 017 00715 0]
   Dare AJ, 2017, LANCET GLOB HEALTH, V5, pE736, DOI 10.1016/S2214 109X(17)30254 1
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ekegren CL, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15122845
   Fan Q, 2021, BIOACT MATER, V6, P4014, DOI 10.1016/j.bioactmat.2021.04.008
   Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198 011 1611 4
   Feng L, 2020, MOL THER NUCL ACIDS, V21, P1017, DOI 10.1016/j.omtn.2020.07.018
   Foulke BA, 2016, MATURITAS, V92, P49, DOI 10.1016/j.maturitas.2016.07.014
   Gan RP, 2019, NANOMATERIALS BASEL, V9, DOI 10.3390/nano9050711
   Gould NR, 2021, BONE, V149, DOI 10.1016/j.bone.2021.115971
   Hak DJ, 2014, INJURY, V45, pS3, DOI 10.1016/j.injury.2014.04.002
   Hang K, 2018, CELL STRESS CHAPERON, V23, P1153, DOI 10.1007/s12192 018 0932 z
   Holmes D, 2017, NATURE, V550, pS193, DOI 10.1038/550S193a
   Kajiya H, 2015, INT J HYPERTHER, V31, P635, DOI 10.3109/02656736.2015.1041430
   Keren L, 2018, CELL, V174, P1373, DOI 10.1016/j.cell.2018.08.039
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lazarovits J, 2019, NANO LETT, V19, P116, DOI 10.1021/acs.nanolett.8b03434
   Li DJ, 2018, J BIOMED NANOTECHNOL, V14, P2003, DOI 10.1166/jbn.2018.2646
   Liu YJ, 2020, NANO RES, V13, P564, DOI 10.1007/s12274 020 2655 6
   Long FX, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008334
   Luo SY, 2019, MACROMOL BIOSCI, V19, DOI 10.1002/mabi.201900047
   Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022 1759(98)00204 X
   Majidinia M, 2018, J CELL PHYSIOL, V233, P2937, DOI 10.1002/jcp.26042
   Marie PJ, 2014, TRENDS ENDOCRIN MET, V25, P567, DOI 10.1016/j.tem.2014.06.009
   Masago Y, 2012, J CELL SCI, V125, P1118, DOI 10.1242/jcs.089748
   Molino NM, 2014, CURR OPIN BIOTECH, V28, P75, DOI 10.1016/j.copbio.2013.12.007
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Okike K, 2006, J BONE JOINT SURG AM, V88A, P2739, DOI 10.2106/JBJS.F.00146
   Shan HJ, 2021, MOL THER NUCL ACIDS, V24, P385, DOI 10.1016/j.omtn.2021.03.006
   Shan HJ, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211031378
   Si JY, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919159
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Tong LP, 2019, BIOMATERIALS, V193, P1, DOI 10.1016/j.biomaterials.2018.12.008
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wan ZQ, 2020, THERANOSTICS, V10, P11837, DOI 10.7150/thno.49784
   Wang PY, 2015, SCI TECHNOL ADV MAT, V16, DOI 10.1088/1468 6996/16/3/034610
   Wu HY, 2005, CHEM MATER, V17, P6447, DOI 10.1021/cm051455w
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xia YN, 2011, ACCOUNTS CHEM RES, V44, P914, DOI 10.1021/ar200061q
   Xu J, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0392 2
   Yanagi T, 2015, J BIOMATER APPL, V29, P1109, DOI 10.1177/0885328214556913
   Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015
   Zhang WX, 2019, MAT SCI ENG C MATER, V102, P458, DOI 10.1016/j.msec.2019.04.025
   Zhang XG, 2019, J PHYS CHEM LETT, V10, P4185, DOI 10.1021/acs.jpclett.9b01735
   Zhang X, 2021, POLYMERS BASEL, V13, DOI 10.3390/polym13132100
NR 50
TC 51
Z9 52
U1 10
U2 130
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2022
VL 284
AR 121482
DI 10.1016/j.biomaterials.2022.121482
EA MAR 2022
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 1B1NX
UT WOS:000792210800002
PM 35358870
DA 2025 08 17
ER

PT J
AU Ates, GB
   Ak, A
   Garipcan, B
   Gülsoy, M
AF Ates, Gamze Bolukbasi
   Ak, Ayse
   Garipcan, Bora
   Gulsoy, Murat
TI Indocyanine green mediated photobiomodulation on human osteoblast cells
SO LASERS IN MEDICAL SCIENCE
LA English
DT Article
DE Photobiomodulation (PBM); Photodynamic therapy (PDT); Osteoblast;
   Indocyanine green (ICG); Low level laser therapy (LLLT); 809 nm
ID LOW LEVEL LASER; PHOTOSENSITIZER DRUGS; PHOTODYNAMIC THERAPY; ALAMAR
   BLUE; STEM CELLS; DIFFERENTIATION; PROLIFERATION; IRRADIATION; LIGHT;
   ASSAY
AB Photobiomodulation (PBM) and photodynamic therapy (PDT) share similar mechanisms but have opposite aims. Increased levels of reactive oxygen species (ROS) in the target tissue in response to light combined photosensitizer (PS) application may lead to cell proliferation or oxidative damage depending on the ROS amount. The purpose of the present study is to investigate the effect of indocyanine green (ICG) mediated PBM on osteoblast cells by measuring cell viability, proliferation, alkaline phosphatase (ALP) activity, mineralization, and gene expressions of three phenotypic osteoblast markers. A diode laser irradiating at 809 nm (10 W output power, 50 mW/cm(2) power density) was used at 0.5, 1, and 2 J/cm(2 )energy densities (10, 20, and 40 s respectively) was applied following ICG incubation. No inhibitory effect was observed in cell viability and proliferation according to the (4,5 dimethylthiazol 2 yl) 2,5 diphenyl tetrazolium bromide (MTT) and Alamar Blue assays. ICG mediated PBM did not alter cell viability but increased ALP activity and enhanced mineralization of existing osteoblasts. These results were also confirmed by real time polymerase chain reaction (RT PCR) analysis of osteoblastic markers. PS can be combined to PBM not only to damage the malignant cells as aimed in PDT studies, but also to promote cellular activity. The findings of this in vitro study may contribute to in vivo studies and ICG mediated PBM can have promising outcomes in bone healing and regeneration therapies in future.
C1 [Ates, Gamze Bolukbasi; Garipcan, Bora; Gulsoy, Murat] Bogazici Univ, Inst Biomed Engn, TR 34684 Istanbul, Turkey.
   [Ak, Ayse] Erzincan Univ, Engn Fac, Biomed Engn, TR 24100 Erzincan, Turkey.
C3 Bogazici University; Erzincan Binali Yildirim University
RP Ates, GB (通讯作者)，Bogazici Univ, Inst Biomed Engn, TR 34684 Istanbul, Turkey.
EM gbolukbasi@boun.edu.tr
RI AK, Ayşe/AAR 1485 2020; Garipcan, Bora/AAM 1061 2020; Gülsoy,
   Murat/L 1345 2018
OI Ak, Ayse/0000 0002 1385 5847; Gulsoy, Murat/0000 0002 0773 9567; 
FU Scientific and Research Council of Turkey (TUBITAK) [113Z059]; Bogazici
   University [6701]
FX This study was supported by grant (113Z059) of the Scientific and
   Research Council of Turkey (TUBITAK). The cell culture experiments were
   performed at Bogazici University Biomedical Engineering Institute
   Biomaterials laboratory, which was supported by Bogazici University
   Research Fund with the grant number 6701.
CR Abels C, 2000, ARCH DERMATOL RES, V292, P404, DOI 10.1007/s004030000147
   AlGhamdi KM, 2012, LASER MED SCI, V27, P237, DOI 10.1007/s10103 011 0885 2
   Amid R, 2014, J LASERS MED SCI, V5, P163
   Arany PR, 2011, LASER PHOTOBIOMODULA
   Arisu HD, 2006, LASER MED SCI, V21, P175, DOI 10.1007/s10103 006 0398 6
   Ates GB, 2017, LASER MED SCI, V32, P1847, DOI 10.1007/s10103 017 2286 7
   Ates GB, 2017, LASER MED SCI, V32, P591, DOI 10.1007/s10103 017 2153 6
   Bäumler W, 1999, BRIT J CANCER, V80, P360, DOI 10.1038/sj.bjc.6690363
   Borzabadi Farahani A, 2016, J PHOTOCH PHOTOBIO B, V162, P577, DOI 10.1016/j.jphotobiol.2016.07.022
   Chen AC H, 2009, ROLE REACTIVE OXYGEN, DOI [10.1117/12.814890, DOI 10.1117/12.814890]
   Coombe A R, 2001, Clin Orthod Res, V4, P3, DOI 10.1034/j.1600 0544.2001.040102.x
   DeRosa MC, 2002, COORDIN CHEM REV, V233, P351, DOI 10.1016/S0010 8545(02)00034 6
   Desmettre T, 2000, MAJOR REV FLUORESCEN, P45
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Ebrahimi T, 2012, J Dent (Tehran), V9, P238
   FOX IJ, 1960, P STAFF M MAYO CLIN, V35, P732
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Halliwell B, 2004, BRIT J PHARMACOL, V142, P231, DOI 10.1038/sj.bjp.0705776
   Hawkins D, 2006, PHOTOMED LASER SURG, V24, P705, DOI 10.1089/pho.2006.24.705
   Hu WP, 2007, J INVEST DERMATOL, V127, P2048, DOI 10.1038/sj.jid.5700826
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Huang YY, 2009, DOSE RESPONSE, V7, P358, DOI 10.2203/dose response.09 027.Hamblin
   Jawad MM, 2013, J BIOMED OPT, V18, DOI 10.1117/1.JBO.18.12.128001
   Jayasree RS, 2001, J BIOMATER APPL, V15, P176, DOI 10.1106/9335 Q0NC 5XCQ KBYK
   Khadra M, 2005, BIOMATERIALS, V26, P3503, DOI 10.1016/j.biomaterials.2004.09.033
   Kim Won Serk, 2011, Laser Therapy, V20, P205
   Kushibiki T, 2010, J PHOTOCH PHOTOBIO B, V98, P211, DOI 10.1016/j.jphotobiol.2010.01.008
   Medina Huertas R, 2014, LASER MED SCI, V29, P1479, DOI 10.1007/s10103 014 1557 9
   Montoro LA, 2014, INT ENDOD J, V47, P747, DOI 10.1111/iej.12211
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Neupane J, 2010, PHOTODIAGN PHOTODYN, V7, P44, DOI 10.1016/j.pdpdt.2009.12.006
   Pagin MT, 2014, LASER MED SCI, V29, P55, DOI 10.1007/s10103 012 1238 5
   Petri Alice Dias, 2010, Braz. Dent. J., V21, P491, DOI 10.1590/S0103 64402010000600003
   Pettit RK, 2005, ANTIMICROB AGENTS CH, V49, P2612, DOI 10.1128/AAC.49.7.2612 2617.2005
   Rampersad SN, 2012, SENSORS BASEL, V12, P12347, DOI 10.3390/s120912347
   Rezai KA, 2004, AM J OPHTHALMOL, V137, P931, DOI 10.1016/j.ajo.2003.11.016
   RODAN G A, 1991, Critical Reviews in Eukaryotic Gene Expression, V1, P85
   Schwartz HO, 2011, LASER MED SCI, V26, P539, DOI 10.1007/s10103 011 0902 5
   Setzer B, 2009, BIOMATERIALS, V30, P979, DOI 10.1016/j.biomaterials.2008.10.054
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Silva JCE, 2004, LASER SURG MED, V34, P451, DOI 10.1002/lsm.20062
   Stein E, 2008, WIEN KLIN WOCHENSCHR, V120, P112, DOI 10.1007/s00508 008 0932 6
   Cavalcanti MFXB, 2015, PHOTOMED LASER SURG, V33, P610, DOI 10.1089/pho.2014.3864
   Yamada T, 2002, STEM CELLS, V20, P146, DOI 10.1634/stemcells.20 2 146
   Yusa K, 2016, ARCH ORAL BIOL, V71, P162, DOI 10.1016/j.archoralbio.2016.07.010
   Zachari MA, 2014, DOSE RESPONSE, V12, P246, DOI 10.2203/dose response.13 024.Koukourakis
   Zancanela DC, 2011, PHOTOMED LASER SURG, V29, P699, DOI 10.1089/pho.2010.2929
   Zhang XP, 2005, LASER MED SCI, V20, P74, DOI 10.1007/s10103 005 0348 8
NR 48
TC 20
Z9 21
U1 0
U2 16
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0268 8921
EI 1435 604X
J9 LASER MED SCI
JI Lasers Med. Sci.
PD SEP
PY 2018
VL 33
IS 7
BP 1591
EP 1599
DI 10.1007/s10103 018 2530 9
PG 9
WC Engineering, Biomedical; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Surgery
GA GR6EC
UT WOS:000442737100022
PM 29744752
DA 2025 08 17
ER

PT J
AU Murthy, PSN
   Sengupta, S
   Sharma, S
   Shingh, MM
AF Murthy, P. S. Narayana
   Sengupta, S.
   Sharma, S.
   Shingh, M. M.
TI Effect of ormeloxifene on ovariectomy induced bone resorption,
   osteoclast differentiation and apoptosis and TGF beta 3 expression
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE ormeloxifene; raloxifene; SERM; ethynylestradiol; antiresorptive; bone
   mineral density; bone mineral content; osteoclastogenesis; osteoclast
   apoptosis; TGF beta 3; retired breeder rats
ID ESTROGEN RECEPTOR MODULATOR; GROWTH FACTOR BETA; POSTMENOPAUSAL
   OSTEOPOROSIS; FEMALE RATS; IN VITRO; RALOXIFENE; CENTCHROMAN; WOMEN;
   THERAPY; CANCER
AB Effect of ormeloxifene, a multifunctional selective estrogen receptor modulator, on prevention of ovariectomy induced bone resorption in retired breeder female rats, osteoclastogenesis using bone marrow cells from adult Balb/c mice cultured in presence of M CSF and RANKL, osteoclast apoptosis using terminal deoxynucleotidyl transferase fragment end labeling and TGF beta 3 expression were investigated. Raloxifene, a benzothiophene reported to mimic effects of estrogen in bone, and estradiol were used for comparison. Ormeloxifene (10( 6) and 10( 8) M) significantly inhibited osteoclastogenesis (P < 0.001 versus vehicle control) as evidenced by lower number of TRAP positive osteoclasts in bone marrow cultures and caused apoptosis of osteoclasts. The effect was almost equivalent to that observed in presence of estradiol 17 beta, except that significant number of cells undergoing apoptosis was evident even at 10( 9) M concentration of estradiol 17 beta (P < 0.001). Raloxifene, though inhibited osteoclastogenesis at much lower concentrations (10( 8) to 10( 12) M; P < 0.001), failed to cause apoptosis of osteoclasts at any of the concentrations used. While ormeloxifene, raloxifene and ethynylestradiol significantly prevented ovariectomy induced bone loss in vivo in retired breeder female rats, prevention of ovariectomy induced decrease in BMD and trabecular network of proximal tibia, calcium and phosphorus levels in femur and tibia and prevention of ovariectomy induced down regulation of TGF beta 3 expression in lumbar vertebrae was of lower order in raloxifene  than ormeloxifene  or ethynylestradiol supplemented females. Both the SERMs, however, produced considerable estrogenic effects at the uterine level as evidenced by increase in weight, total and endometrial area and luminal epithelial cell height; the effect being generally greater in raloxifene  than ormeloxifene treated rats. Findings demonstrate that inhibition of estrogen deficiency osteoporosis by ormeloxifene, as in case of estradiol, was mediated via inhibition of osteoclastogenesis, apoptosis of osteoclasts and up regulation of TGF beta 3 expression. Raloxifene, though effective in inhibiting osteoclastogenesis in vitro at much lower concentrations, was not only less potent in preventing ovariectomy induced bone loss in retired breeder female rats in vivo but also appeared to have a different mechanism of action than ormeloxifene and estradiol. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Cent Drug Res Inst, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI)
RP Shingh, MM (通讯作者)，Cent Drug Res Inst, Div Endocrinol, Lucknow 226001, Uttar Pradesh, India.
EM singhmm@rediffmail.com
RI ; Pandruvada, Subramanya/E 4373 2012
OI Sengupta, Surojeet/0000 0002 3498 9668; Pandruvada,
   Subramanya/0000 0001 9568 7666
CR Arshad A, 2004, J STEROID BIOCHEM, V91, P67, DOI 10.1016/j.jsbmb.2004.02.010
   Ashby J, 1997, REGUL TOXICOL PHARM, V25, P226, DOI 10.1006/rtph.1997.1108
   BAIN SD, 1997, J BONE MINER RES S1, V12
   BAIN SD, 1995, CALCIFIED TISSUE INT, V54, P338
   BJARNASON K, 1997, P 19 ANN M AM SOC S1, V12
   Boss SM, 1997, AM J OBSTET GYNECOL, V177, P1458, DOI 10.1016/S0002 9378(97)70091 7
   Clemett D, 2000, DRUGS, V60, P379, DOI 10.2165/00003495 200060020 00013
   COOPER SR, 1998, EVALUATION BONE MINE, P25
   Cummings SR, 1998, NEW ENGL J MED, V339, P733, DOI 10.1056/NEJM199809103391104
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   DHAR J D, 1986, Acta Europaea Fertilitatis, V17, P285
   DHAR JD, 1983, ANDROLOGIA, V15, P463
   Draper MW, 1996, J BONE MINER RES, V11, P835
   FINKELMAN RD, 1992, P NATL ACAD SCI USA, V89, P12190, DOI 10.1073/pnas.89.24.12190
   GALLAGHER A, 1993, ENDOCRINOLOGY, V133, P2787, DOI 10.1210/en.133.6.2787
   GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029 7844(94)00383 O
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V216, P662, DOI 10.1006/bbrc.1995.2673
   Hughes DE, 1996, NAT MED, V2, P1132, DOI 10.1038/nm1096 1132
   JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195
   Labroo V. M., 1994, US Patent, Patent No. [5280040, 5407955]
   LABROO VM, 1995, Patent No. 5464862
   MISRA NC, 1989, INT J CANCER, V43, P781, DOI 10.1002/ijc.2910430506
   MISRA NC, 1998, P 8 INT C ANT CANC T
   Pinilla L, 2001, REPRODUCTION, V121, P915, DOI 10.1530/reprod/121.6.915
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   SAEED A, 1984, BIOCHEM BIOPH RES CO, V125, P346, DOI 10.1016/S0006 291X(84)80374 5
   Scott JA, 1999, AM FAM PHYSICIAN, V60, P1131
   Singh MM, 2001, MED RES REV, V21, P302, DOI 10.1002/med.1011
   SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003 2697(85)90442 7
   SUBRAMANIUM U, 1999, P 43 ALL IND C OBST, P28
   Sumner JB, 1944, SCIENCE, V100, P413, DOI 10.1126/science.100.2601.413
   TURNER CH, 1994, ENDOCRINOLOGY, V135, P2001, DOI 10.1210/en.135.5.2001
   Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927
   Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075
   1998, SCRIP, V2365, P16
   1998, SCRIP, V2374, P18
   1998, SCRIP, V2347, P19
NR 38
TC 20
Z9 22
U1 0
U2 2
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD AUG
PY 2006
VL 100
IS 4 5
BP 117
EP 128
DI 10.1016/j.jsbmb.2006.03.009
PG 12
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA 079FV
UT WOS:000240161800002
PM 16797179
DA 2025 08 17
ER

PT J
AU Kim, BG
   Lee, JH
   Ahn, JM
   Park, SK
   Cho, JH
   Hwang, D
   Yoo, JS
   Yates, JR
   Ryoo, HM
   Cho, JY
AF Kim, Byung Gyu
   Lee, Ji Hyun
   Ahn, Jung Mo
   Park, Sung Kyu
   Cho, Ji Hoon
   Hwang, Daehee
   Yoo, Jong Shin
   Yates, John R., III
   Ryoo, Hyun Mo
   Cho, Je Yoel
TI 'Two Stage Double Technique Hybrid (TSDTH)' Identification Strategy for
   the Analysis of BMP2 Induced Transdifferentiation of Premyoblast C2C12
   Cells to Osteoblast
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE Proteomics; transdifferentiation; BMP2; osteoblast; phosphoproteins;
   SILAC; premyoblast
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; GROWTH FACTOR I;
   TANDEM MASS SPECTROMETRY; TGF BETA SUPERFAMILY; FUNCTIONAL PROTEOMICS;
   SIGNALING PATHWAY; STATISTICAL MODEL; STROMAL CELLS; BMP PATHWAY
AB Transdifferentiation offers new opportunities in the area of cell replacement therapy; however, the molecular mechanism by which transdifferentiation occurs is not fully understood. Our understanding about the sophisticated regulations of transdifferentiation is limited yet since their comprehensive proteome regulations have not been fully elucidated. Studies on bone morphogenic protein 2 (BMP2) induced transdifferentiation of murine C2C12 cells, a myogenic lineage committed premyoblast, to osteogenic cells can provide a full picture of the dynamic events that occur at the level of protein activity and/or expression. Here, we investigated the overall dynamic regulatory proteome associated with BMP2 induced osteoblast transdifferentiation in premyoblast C2C12 cells using a novel Two Stage Double Technique Hybrid (TSDTH) strategy for proteomic analysis. Here, we took the approach of a TSDTH involving phosphoproteornic analysis after a short term treatment (stage one, 30 min) and a long term treatment (stage two, 3 days); SILAC (Stable isotope labeling with amino acids in cell culture) proteomics was used to map the proteins. In these experiments, a total of 1321 potential phosphoproteins were identified in stage one analysis and 433 proteins were quantified in stage two analysis. Among them, 374 BMP2 specific phosphoproteins and 54 up  or down regulated proteins were selected. In first stage analysis, several deubiquitination enzymes including Uch 13 as well as ubiquitination related proteins were newly identified, and its inhibitor reduced the stability of phosphorylated Smad1, and the BMP2 induced ALP levels of C2C12 cells were detected. In second stage analysis, Thrombosponclin'! was identified as the highest up regulated protein by BMP2 long time stimulation and this was confirmed with immunoblot analysis. Furthermore, pathway enrichment and network analyses revealed that insulin like growth factor (IGF) and calcium signaling pathways as well as TGF beta/BMP signaling proteins are found to be potentially involved in the early and long term actions of BMP2. Collectively, our TSDTH is a useful simple strategy to obtain comprehensive molecular mechanism of cellular processes such as transdifferntiation.
C1 [Kim, Byung Gyu; Lee, Ji Hyun; Ahn, Jung Mo; Cho, Je Yoel] Kyungpook Natl Univ, Dept Biochem, Sch Dent, Taegu 700422, South Korea.
   [Park, Sung Kyu; Yates, John R., III] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92014 USA.
   [Cho, Ji Hoon; Hwang, Daehee] POSTECH, Dept Chem Engn, Sch Interdisciplinary Biosci & Bioengn, Pohang 790784, South Korea.
   [Yoo, Jong Shin] Korea Basic Sci Inst, Mass Spectrometer Dev Team, Taejon, South Korea.
   [Ryoo, Hyun Mo] Seoul Natl Univ, Dept Cell & Dev Biol, Sch Dent, Seoul 110749, South Korea.
C3 Kyungpook National University (KNU); Scripps Research Institute; Pohang
   University of Science & Technology (POSTECH); Korea Basic Science
   Institute (KBSI); Seoul National University (SNU)
RP Cho, JY (通讯作者)，Kyungpook Natl Univ, Dept Biochem, Sch Dent, 101 Dong In Dong, Taegu 700422, South Korea.
EM jeycho@knu.ac.kr
RI Ryoo, Hyun Mo/D 5839 2012; Kim, Min/ACN 6827 2022; Yates,
   John/HRC 4735 2023
OI Ryoo, Hyun Mo/0000 0001 6769 8341
FU Korea Science and Engineering Foundation (KOSEF); Korea Government
   (MOST) [M10641000106 07N4100 10610, R13 2008 009 01002]; Korea Research
   Foundation; Korean Government (MOEFIRD) [KRF 2007 313 E00493]
FX This work was supported by the Korea Science and Engineering Foundation
   (KOSEF) grant funded by the Korea Government (MOST) (Grant No.
   M10641000106 07N4100 10610 and R13 2008 009 01002), and by the Korea
   Research Foundation Grant funded by the Korean Government (MOEFIRD)
   (KRF 2007 313 E00493).
CR Asano Y, 2004, J CLIN INVEST, V113, P253, DOI 10.1172/JCI200416269
   Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809
   Batts SA, 2007, HEARING RES, V227, P41, DOI 10.1016/j.heares.2006.08.015
   Butterworth MB, 2007, J BIOL CHEM, V282, P37885, DOI 10.1074/jbc.M707989200
   CANALIS E, 1994, J BONE MINER RES, V9, P1999
   Celil AB, 2005, J BIOL CHEM, V280, P31353, DOI 10.1074/jbc.M503845200
   Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537
   Chen C, 2007, CANCER METAST REV, V26, P587, DOI 10.1007/s10555 007 9091 x
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen Gai ping, 2006, Zhongguo Shuidao Kexue, V20, P53
   Chen YH, 2007, MOL CELL PROTEOMICS, V6, P2072, DOI 10.1074/mcp.M700395 MCP200
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805 758
   Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104
   Datto M, 2005, CELL, V121, P2, DOI 10.1016/j.cell.2005.03.017
   Dezawa Mari, 2007, Brain and Nerve (Tokyo), V59, P503
   Dinchuk JE, 2000, J BIOL CHEM, V275, P39543, DOI 10.1074/jbc.M006753200
   Domon B, 2006, SCIENCE, V312, P212, DOI 10.1126/science.1124619
   Fotia AB, 2004, J BIOL CHEM, V279, P28930, DOI 10.1074/jbc.M402820200
   Gao M, 2005, MOL CELL, V19, P581, DOI 10.1016/j.molcel.2005.08.017
   Gingras AC, 2007, NAT REV MOL CELL BIO, V8, P645, DOI 10.1038/nrm2208
   Günther T, 2007, NAT CELL BIOL, V9, P1229, DOI 10.1038/ncb1107 1229
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Higashi K, 2003, J BIOL CHEM, V278, P43470, DOI 10.1074/jbc.M302339200
   Imamura Takeshi, 2006, Clin Calcium, V16, P738
   Jeon EJ, 2006, J BIOL CHEM, V281, P16502, DOI 10.1074/jbc.M512494200
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim BG, 2006, PROTEOMICS, V6, P1166, DOI 10.1002/pmic.200500289
   Kim YJ, 2004, J BIOL CHEM, V279, P50773, DOI 10.1074/jbc.M404145200
   Kitisin K., 2007, SCI STKE, DOI DOI 10.1126/STKE.3992007CM1
   Knockaert M, 2006, P NATL ACAD SCI USA, V103, P11940, DOI 10.1073/pnas.0605133103
   Kocher T, 2007, NAT METHODS, V4, P807, DOI 10.1038/NMETH1093
   Kratchmarova I, 2005, SCIENCE, V308, P1472, DOI 10.1126/science.1107627
   Krüger M, 2008, P NATL ACAD SCI USA, V105, P2451, DOI 10.1073/pnas.0711713105
   Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044
   Lindner HA, 2007, VIROLOGY, V362, P245, DOI 10.1016/j.virol.2006.12.035
   Massagué J, 2000, CELL, V103, P295, DOI 10.1016/S0092 8674(00)00121 5
   McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398
   Miyazaki H, 2004, ONCOGENE, V23, P9326, DOI 10.1038/sj.onc.1208127
   Miyazawa K, 2002, GENES CELLS, V7, P1191, DOI 10.1046/j.1365 2443.2002.00599.x
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nishimura R, 2003, FRONT BIOSCI, V8, pS275, DOI 10.2741/1049
   Oestergaard VH, 2007, MOL CELL, V28, P798, DOI 10.1016/j.molcel.2007.09.020
   Ogunjimi AA, 2005, MOL CELL, V19, P297, DOI 10.1016/j.molcel.2005.06.028
   Ohta Y, 2008, J BONE MINER METAB, V26, P478, DOI 10.1007/s00774 008 0850 8
   Orkin SH, 2002, NAT IMMUNOL, V3, P323, DOI 10.1038/ni0402 323
   Park HW, 2007, PROTEOMICS, V7, P2881, DOI 10.1002/pmic.200700089
   Park HJ, 2008, J PROTEOME RES, V7, P1138, DOI 10.1021/pr7007237
   Park SK, 2008, NAT METHODS, V5, P319, DOI [10.1038/NMETH.1195, 10.1038/nmeth.1195]
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Roussa E, 2006, STEM CELLS, V24, P2120, DOI 10.1634/stemcells.2005 0514
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   SHERBINA NV, 1992, BONE, V13, P197, DOI 10.1016/8756 3282(92)90012 L
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Silani V, 2004, CURR NEUROVASC RES, V1, P283, DOI 10.2174/1567202043362243
   Slack JMW, 2007, NAT REV MOL CELL BIO, V8, P369, DOI 10.1038/nrm2146
   Smolka MB, 2007, P NATL ACAD SCI USA, V104, P10364, DOI 10.1073/pnas.0701622104
   Sridhar VV, 2007, NATURE, V447, P735, DOI 10.1038/nature05864
   Ueno A, 2006, J CELL PHYSIOL, V209, P322, DOI 10.1002/jcp.20735
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   van Bentem SD, 2007, TRENDS PLANT SCI, V12, P404, DOI 10.1016/j.tplants.2007.08.007
   Vecchione A, 2003, MOL CELL BIOL, V23, P3363, DOI 10.1128/MCB.23.9.3363 3372.2003
   Venable JD, 2007, ANAL CHEM, V79, P3056, DOI 10.1021/ac062054i
   Waanders LF, 2007, J AM SOC MASS SPECTR, V18, P2058, DOI 10.1016/j.jasms.2007.09.001
   Wang H, 2005, J BIOL CHEM, V280, P5154, DOI 10.1074/jbc.M411575200
   Wang XR, 2008, MOL CELL PROTEOMICS, V7, P46, DOI 10.1074/mcp.M700261 MCP200
   Wissing J, 2007, MOL CELL PROTEOMICS, V6, P537, DOI 10.1074/mcp.T600062 MCP200
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Zachos T, 2007, MOL THER, V15, P1543, DOI 10.1038/sj.mt.6300192
   Zayzafoon M, 2006, J CELL BIOCHEM, V97, P56, DOI 10.1002/jcb.20675
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
NR 73
TC 18
Z9 19
U1 0
U2 4
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535 3893
J9 J PROTEOME RES
JI J. Proteome Res.
PD OCT
PY 2009
VL 8
IS 10
BP 4441
EP 4454
DI 10.1021/pr900231a
PG 14
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 501BM
UT WOS:000270353900005
PM 19655815
DA 2025 08 17
ER

PT J
AU Chen, LJ
   Hu, BB
   Shi, XL
   Ren, MM
   Yu, WB
   Cen, SD
   Hu, RD
   Deng, H
AF Chen, Li Jiao
   Hu, Bi Bo
   Shi, Xin Lian
   Ren, Man Man
   Yu, Wen Bin
   Cen, Sheng Dan
   Hu, Rong Dang
   Deng, Hui
TI Baicalein enhances the osteogenic differentiation of human periodontal
   ligament cells by activating the Wnt/Iβ catenin signaling pathway
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Baicalein; Osteogenic differentiation; Wnt/I beta catenin signaling;
   Periodontal ligament cells
ID OSTEOBLAST DIFFERENTIATION; STEM CELLS; IN VITRO;
   SCUTELLARIA BAICALENSIS; TRANSCRIPTION FACTORS; GENE EXPRESSION;
   BONE FORMATION; DISEASE; INHIBITION; RUNX2
AB Objective: Periodontium regeneration is one of the most important processes for periodontitis therapy. Human periodontal ligament cells (hPDLCs) play a vital role in the repair and regeneration of periodontal tissues. Our study aimed to investigated the mechanisms underlying the promotion of hPLDCs osteogenic differentiation by baicalein.
   Design: hPDLCs were obtained from periodontal ligament (PDL) tissues by primary culture. The MIT assay was used to determine the growth curves of hPDLCs treated with different concentrations of baicalein (1.25, 2.5, 5, or 10 M). Alkaline phosphatase (ALP) staining and Alizarin red S staining were performed to assess osteogenic differentiation of hPDLCs administered baicalein. Osteogenic differentiation related gene and protein expression levels and Wnt/beta catenin pathway signal changes were assessed by qRT PCR and Western blotting analysis.
   Results: The results showed that baicalein decreased the growth of hPDLCs slightly and increased ALP activity and calcium deposition in a dose dependent manner. The expression of runt related transcription factor 2 (RUNX2), bone morphogenetic protein 2 (BMP2), Osterix (OSX) and osteocalcin (OCN) were elevated after baicalein administration. Moreover, baicalein strongly activated the Wnti beta catenin pathway and up regulated the expression of beta catenin, lymphoid enhancer factor 1 (LEFI) and Cyclin Dl. Dickkopf related protein 1 (DKK 1) significantly reversed the effects of baicalein on hPDLCs.
   Conclusions: Our findings indicated that baicalein enhanced the osteogenic differentiation of hPDLCs via the activation of the Wnt beta catenin signaling pathway, which may represent a potential candidate for periodontitis therapy. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Chen, Li Jiao; Hu, Bi Bo; Yu, Wen Bin; Hu, Rong Dang] Wenzhou Med Univ, Sch Stomatol, Dept Orthodont, 373 West Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.
   [Shi, Xin Lian; Ren, Man Man; Cen, Sheng Dan; Deng, Hui] Wenzhou Med Univ, Sch Stomatol, Dept Periodont, 373 West Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.
   [Deng, Hui] Univ Queensland, Sch Dent, Dept Orthodont, Brisbane, Qld, Australia.
C3 Wenzhou Medical University; Wenzhou Medical University; University of
   Queensland
RP Hu, RD (通讯作者)，Wenzhou Med Univ, Sch Stomatol, Dept Orthodont, 373 West Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.; Deng, H (通讯作者)，Wenzhou Med Univ, Sch Stomatol, Dept Periodont, 373 West Xueyuan Rd, Wenzhou, Zhejiang, Peoples R China.
EM hurongdang@hotmail.com; dh0726@gmail.com
FU Zhejiang Provincial Natural Science Foundation of China [LY17H140009];
   Zhejiang Provincial Traditional Chinese Medicine Science and Technology
   Plan [2015ZA122, 2017ZB068]; Public Welfare Science and Technology Plan
   of Wenzhou City [Y20150073, Y20160140]
FX This study was supported by the Zhejiang Provincial Natural Science
   Foundation of China (Grant no. LY17H140009), the Zhejiang Provincial
   Traditional Chinese Medicine Science and Technology Plan (Grant nos.
   2015ZA122 and 2017ZB068) and Public Welfare Science and Technology Plan
   of Wenzhou City (Grant nos. Y20150073 and Y20160140).
CR Ai M, 2005, MOL CELL BIOL, V25, P4946, DOI 10.1128/MCB.25.12.4946 4955.2005
   Alvarez R, 2015, INT J ORAL SCI, V7, P213, DOI 10.1038/ijos.2015.42
   Bauman WA, 2015, PM&R, V7, P201
   Bauman WA, 2015, PM&R, V7, P188, DOI 10.1016/j.pmrj.2014.08.948
   BELLOWS CG, 1991, BONE MINER, V14, P27, DOI 10.1016/0169 6009(91)90100 E
   Cai X, 2008, J PERIODONTAL RES, V43, P14, DOI 10.1111/j.1600 0765.2007.00989.x
   Cao ZG, 2010, EUR J PHARMACOL, V641, P1, DOI 10.1016/j.ejphar.2010.04.042
   CHUNG CP, 1995, PLANTA MED, V61, P150, DOI 10.1055/s 2006 958036
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fan GW, 2013, INFLAMMATION, V36, P1584, DOI 10.1007/s10753 013 9703 2
   Fu Y, 2014, INT J ENDOCRINOL, V2014, DOI 10.1155/2014/846742
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Greenstein G, 2000, J AM DENT ASSOC, V131, P1580, DOI 10.14219/jada.archive.2000.0087
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Hamidouche Z, 2008, FASEB J, V22, P3813, DOI 10.1096/fj.08 106302
   Heo JS, 2011, J CELL BIOCHEM, V112, P1880, DOI 10.1002/jcb.23108
   Heo JS, 2010, MOL CELLS, V30, P449, DOI 10.1007/s10059 010 0139 3
   Isaka J, 2001, J PERIODONTOL, V72, P314, DOI 10.1902/jop.2001.72.3.314
   Kim JM, 2008, J CELL BIOCHEM, V104, P1906, DOI 10.1002/jcb.21760
   Kim MH, 2008, FOOD CHEM TOXICOL, V46, P3375, DOI 10.1016/j.fct.2008.08.016
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Kook S. H., 2015, MOL CELLULAR BIOCH
   Lai CH, 2014, EVID BASED COMPL ALT, V2014, DOI 10.1155/2014/924560
   Lekic P, 2001, J PERIODONTAL RES, V36, P71, DOI 10.1034/j.1600 0765.2001.360202.x
   Li L, 2013, DNA CELL BIOL, V32, P488, DOI 10.1089/dna.2013.2070
   Li Weber M, 2009, CANCER TREAT REV, V35, P57, DOI 10.1016/j.ctrv.2008.09.005
   Lin HY, 2007, BBA MOL CELL RES, V1773, P1073, DOI 10.1016/j.bbamcr.2007.04.008
   Liu J, 2014, FITOTERAPIA, V93, P105, DOI 10.1016/j.fitote.2013.12.020
   Liu M., 2014, J TISSUE ENG REGENER
   Lowery JW, 2011, CRIT REV EUKAR GENE, V21, P177, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.60
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Nokhbehsaim M, 2011, J CLIN PERIODONTOL, V38, P479, DOI 10.1111/j.1600 051X.2010.01696.x
   Qiang YW, 2008, BONE, V42, P669, DOI 10.1016/j.bone.2007.12.006
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Saidak Z, 2015, J BIOL CHEM, V290, P6903, DOI 10.1074/jbc.M114.621219
   Schulze Späte U, 2015, J CLIN ENDOCR METAB, V100, P2425, DOI 10.1210/jc.2014 4180
   Serigano K, 2010, J ORTHOP RES, V28, P1267, DOI 10.1002/jor.21147
   Shimono M, 2003, MICROSC RES TECHNIQ, V60, P491, DOI 10.1002/jemt.10290
   Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522
   Sun S, 2008, INT J ORAL MAX SURG, V37, P350, DOI 10.1016/j.ijom.2007.11.024
   Tang Y, 2014, J DENT RES, V93, P175, DOI 10.1177/0022034513512507
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   Tsalikis L, 2014, J CLIN PERIODONTOL, V41, P972, DOI 10.1111/jcpe.12287
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Watanabe T, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003132
   Wolf M, 2013, J OROFAC ORTHOP, V74, P494, DOI 10.1007/s00056 013 0155 y
   Xia Y, 2016, J PERIODONTOL, V87, pE53, DOI 10.1902/jop.2015.150462
   Ying XZ, 2014, EUR J PHARMACOL, V738, P22, DOI 10.1016/j.ejphar.2014.04.049
   Yorgan Timur A, 2014, Mol Cell Ther, V2, P22
   Zhang XL, 2011, J BONE MINER RES, V26, P777, DOI 10.1002/jbmr.267
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
NR 54
TC 54
Z9 59
U1 0
U2 34
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD JUN
PY 2017
VL 78
BP 100
EP 108
DI 10.1016/j.archoralbio.2017.01.019
PG 9
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA EU0RM
UT WOS:000400719000014
PM 28222387
DA 2025 08 17
ER

PT J
AU Alvarez García, O
   García López, E
   Loredo, V
   Gil Peña, H
   Rodríguez Suárez, J
   Ordóñez, FA
   Carbajo Pérez, E
   Santos, F
AF Alvarez Garcia, Oscar
   Garcia Lopez, Enrique
   Loredo, Vanessa
   Gil Pena, Helena
   Rodriguez Suarez, Julian
   Ordonez, Flor A.
   Carbajo Perez, Eduardo
   Santos, Fernando
TI Rapamycin induces growth retardation by disrupting angiogenesis in the
   growth plate
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE children; pediatric kidney transplantation; transplantation; vascular
   endothelial growth factor
ID RENAL TRANSPLANT RECIPIENTS; DISTINCT SIGNALING PATHWAYS; MAMMALIAN
   TARGET; BONE GROWTH; YOUNG RATS; SIROLIMUS; CHONDROCYTES; INHIBITOR;
   THERAPY; CYCLOSPORINE
AB Rapamycin, a potent immunosuppressant used in renal transplantation, has been reported to impair longitudinal growth in experimental studies. Rapamycin is both antiproliferative and antiangiogenic; therefore, it has the potential to disrupt vascular endothelial growth factor (VEGF) action in the growth plate and to interfere with insulin like growth factor I (IGF I) signaling. To further investigate the mechanisms of rapamycin action on longitudinal growth, we gave the 4 week old rats rapamycin daily for two weeks. Compared with a vehicle treated group, rapamycin treated animals were severely growth retarded and had marked alterations in the growth plate. Vascular invasion was disturbed in the rapamycin group, there was a significant reduction in osteoclast cells near the chondro osseus junction, and there was lower VEGF protein and mRNA expression in the terminal chondrocytes of the growth cartilage. Compared with the control group, the rapamycin group had higher levels of circulating IGF I as well as the mRNAs for IGF I and of the receptors of IGF I and growth hormone in the liver but not in the growth cartilage. Thus our findings explain the adverse effect of rapamycin on growth plate dynamics. This should be taken into account when the drug is administered to children. Kidney International (2010) 78, 561 568; doi:10.1038/ki.2010.173; published online 16 June 2010
C1 [Santos, Fernando] Hosp Univ Cent Asturias, Fac Med, Dept Pediat, Oviedo 33006, Spain.
   [Garcia Lopez, Enrique] Hosp Alvarez Buylla, Dept Pediat, Oviedo, Spain.
   [Carbajo Perez, Eduardo; Santos, Fernando] Univ Oviedo, Dept Med, Oviedo, Spain.
C3 Central University Hospital Asturias; University of Oviedo
RP Santos, F (通讯作者)，Hosp Univ Cent Asturias, Fac Med, Dept Pediat, C Julian Claveria 6, Oviedo 33006, Spain.
EM fsantos@uniovi.es
RI ; Rodríguez, Julián/F 5900 2019
OI Rodriguez, Julian/0000 0003 4621 8905; 
FU FIS [PI08 1723]; FICYT [PC07 004]; Fundacion Nutricion y Crecimiento
FX This study was supported by FIS (PI08 1723), FICYT (PC07 004), and
   Fundacion Nutricion y Crecimiento. The results of this study were
   partially presented at the 8th symposium of the International Pediatric
   Nephrology Association on growth and nutrition in children with chronic
   renal disease, Oviedo, Spain, 2009, and at the 43rd annual scientific
   meeting of the European Society for Paedriatric Nephrology, Birmingham,
   UK. The authors gratefully thank the technical assistance of Lucia
   Mallada and Teresa Usin. We also thank Lourdes Tricas for her help in
   measuring rapamycin levels and Verdad Curto Reyes for western blot
   technical support.
CR Alvarez Garcia O, 2007, PEDIATR NEPHROL, V22, P954, DOI 10.1007/s00467 007 0456 8
   Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564
   Bohensky J, 2009, ARTHRITIS RHEUM US, V60, P1406, DOI 10.1002/art.24444
   Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83
   Chueh SCJ, 2005, TRANSPL INT, V18, P261, DOI 10.1111/j.1432 2277.2004.00039.x
   Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653
   Cravedi P, 2009, LANCET, V373, P1235, DOI 10.1016/S0140 6736(09)60709 1
   Del Bufalo D, 2006, CANCER RES, V66, P5549, DOI 10.1158/0008 5472.CAN 05 2825
   Diekmann F, 2007, J AM SOC NEPHROL, V18, P2653, DOI 10.1681/ASN.2007010087
   El Hashemite N, 2003, CANCER RES, V63, P5173
   Flechner SM, 2002, TRANSPLANTATION, V74, P1070, DOI 10.1097/00007890 200210270 00002
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Gil Peña H, 2009, AM J PHYSIOL RENAL, V297, pF639, DOI 10.1152/ajprenal.00188.2009
   Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202 128
   Hall M N, 2008, Transplant Proc, V40, pS5, DOI 10.1016/j.transproceed.2008.10.009
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Ibáñez JP, 2005, TRANSPLANT P, V37, P682, DOI 10.1016/j.transproceed.2004.12.242
   Kahan BD, 2003, TRANSPLANT P, V35, p25S, DOI 10.1016/S0041 1345(03)00351 8
   Kiepe D, 2005, ENDOCRINOLOGY, V146, P3096, DOI 10.1210/en.2005 0324
   Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53
   Luan FL, 2003, KIDNEY INT, V63, P917, DOI 10.1046/j.1523 1755.2003.00805.x
   Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964
   Mathew T, 2004, CLIN TRANSPLANT, V18, P446, DOI 10.1111/j.1399 0012.2004.00188.x
   Molinos I, 2006, KIDNEY INT, V70, P1955, DOI 10.1038/sj.ki.5001949
   Morales JM, 2005, TRANSPLANT P, V37, P693, DOI 10.1016/j.transproceed.2005.01.045
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140 6736(08)61039 9
   Phornphutkul C, 2009, J ORTHOP RES, V27, P1157, DOI 10.1002/jor.20894
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603 677
   Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101 1009
   Sanchez CP, 2009, BMC PEDIATR, V9, DOI 10.1186/1471 2431 9 3
   Srinivas V, 2006, AUTOPHAGY, V2, P215, DOI 10.4161/auto.2649
   Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831
   Starkman BG, 2005, BIOCHEM J, V389, P723, DOI 10.1042/BJ20041636
   van der Eerden BCJ, 2003, ENDOCR REV, V24, P782, DOI 10.1210/er.2002 0033
NR 34
TC 39
Z9 43
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0085 2538
EI 1523 1755
J9 KIDNEY INT
JI Kidney Int.
PD SEP
PY 2010
VL 78
IS 6
BP 561
EP 568
DI 10.1038/ki.2010.173
PG 8
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 645NH
UT WOS:000281467100008
PM 20555322
OA Bronze
DA 2025 08 17
ER

PT J
AU Ruocco, MG
   Karin, M
AF Ruocco, MG
   Karin, M
TI IKKβ as a target for treatment of inflammation induced bone loss
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article; Proceedings Paper
CT 7th International Symposium on Advances in Targeted Therapies
CY APR 06 10, 2005
CL Venice, ITALY
ID NF KAPPA B; TUMOR NECROSIS FACTOR; ALPHA MONOCLONAL ANTIBODY;
   RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; MICE LACKING; C SRC;
   CONCOMITANT METHOTREXATE; T CELLS; OSTEOPROTEGERIN
AB The transcription factor nuclear factor (NF) kappa B is well recognised as a pivotal player in osteoclastogenesis and inflammation induced bone loss. Here, the authors discuss their recent results, obtained using a genetic approach in mice, that indicate the importance of IKK beta, and not IKK alpha, as a transducer of signals from receptor activator of NF kappa B (RANK) to NF kappa B. Ablation of IKK beta results in lack of osteoclastogenesis and unresponsiveness of IKK beta deficient mice to inflammation induced bone loss. in the need of a more effective therapy for the treatment of inflammatory diseases causing bone resorption, specific inhibition of IKK beta represents a logical alternative strategy to the current therapies.
C1 Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
C3 University of California System; University of California San Diego
RP Karin, M (通讯作者)，Univ Calif San Diego, Sch Med, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA.
EM karinoffice@ucsd.edu
CR Abu Amer Y, 2000, J BIOL CHEM, V275, P27307
   Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506
   Bathon JM, 2000, NEW ENGL J MED, V343, P1586, DOI 10.1056/NEJM200011303432201
   Bolon B, 2002, CELL MOL LIFE SCI, V59, P1569, DOI 10.1007/s00018 002 8530 7
   Bonizzi G, 2004, TRENDS IMMUNOL, V25, P280, DOI 10.1016/j.it.2004.03.008
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Breedveld FC, 2004, ANN RHEUM DIS, V63, P149, DOI 10.1136/ard.2003.013961
   Campagnuolo G, 2002, ARTHRITIS RHEUM US, V46, P1926, DOI 10.1002/art.10369
   Campbell IK, 2001, J CLIN INVEST, V107, P1519, DOI 10.1172/JCI12724
   Campbell IK, 2000, J CLIN INVEST, V105, P1799, DOI 10.1172/JCI8298
   Chellaiah M, 1998, J BIOL CHEM, V273, P11908, DOI 10.1074/jbc.273.19.11908
   Danning CL, 2000, ARTHRITIS RHEUM US, V43, P1244, DOI 10.1002/1529 0131(200006)43:6<1244::AID ANR7>3.0.CO;2 2
   den Broeder A, 2002, J RHEUMATOL, V29, P2288
   den Broeder AA, 2002, ANN RHEUM DIS, V61, P311, DOI 10.1136/ard.61.4.311
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212
   ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140 6736(94)90628 9
   Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218
   Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Genovese MC, 2002, ARTHRITIS RHEUM, V46, P1443, DOI 10.1002/art.10308
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092 8674(00)80984 8
   Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605
   Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ji H, 2002, J EXP MED, V196, P77, DOI 10.1084/jem.20020439
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302 221
   Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kobayashi K, 2000, J EXP MED, V191, P275, DOI 10.1084/jem.191.2.275
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kremer JM, 2003, ARTHRITIS RHEUM, V48, P1493, DOI 10.1002/art.11142
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   LEISEN JCC, 1988, J RHEUMATOL, V15, P17
   Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321
   Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839
   Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202
   Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092 8674(00)81375 6
   MACNAUL KL, 1990, J IMMUNOL, V145, P4154
   Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074 7613(03)00301 7
   Maini R, 1999, LANCET, V354, P1932, DOI 10.1016/S0140 6736(99)05246 0
   Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529 0131(199809)41:9<1552::AID ART5>3.0.CO;2 W
   Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860
   Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859
   Moreland LW, 1999, ANN INTERN MED, V130, P478, DOI 10.7326/0003 4819 130 6 199903160 00004
   Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301
   Mostov K, 1997, SCIENCE, V276, P219, DOI 10.1126/science.276.5310.219
   Nakashima T, 2003, CURR OPIN RHEUMATOL, V15, P280, DOI 10.1097/00002281 200305000 00016
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Reddi AH, 1997, CELL, V89, P159, DOI 10.1016/S0092 8674(00)80193 2
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2002, AM J PATHOL, V161, P1419, DOI 10.1016/S0002 9440(10)64417 3
   Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301 472X(99)00061 2
   Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Sato T, 1997, BRIT J HAEMATOL, V97, P356, DOI 10.1046/j.1365 2141.1997.562704.x
   Schett G, 2003, ARTHRITIS RHEUM, V48, P2042, DOI 10.1002/art.11150
   Seetharaman R, 1999, J IMMUNOL, V163, P1577
   Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677
   Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074 7613(01)00104 2
   Shealy DJ, 2002, ARTHRITIS RES, V4, DOI 10.1186/ar430
   Shinkura R, 1999, NAT GENET, V22, P74, DOI 10.1038/8780
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Suzuki Y, 1998, J RHEUMATOL, V25, P1154
   Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830
   Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Weinblatt ME, 2003, ARTHRITIS RHEUM US, V48, P35, DOI 10.1002/art.10697
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097 2765(00)80232 4
   Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092 8674(00)80406 7
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zou J, 2001, ELEC SOC S, V2001, P70
   Zwerina J, 2004, ARTHRITIS RHEUM, V50, P277, DOI 10.1002/art.11487
NR 82
TC 27
Z9 30
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD NOV
PY 2005
VL 64
SU 4
BP 81
EP 85
DI 10.1136/ard.2005.042721
PG 5
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Rheumatology
GA 980KJ
UT WOS:000233017100019
OA Green Published
DA 2025 08 17
ER

PT J
AU Kiralj, A
   Loncarevic, S
   Mijatov, I
AF Kiralj, Aleksandar
   Loncarevic, Slobodan
   Mijatov, Ivana
TI Bisphosphonate related osteonecrosis of the maxilla   A case report
SO VOJNOSANITETSKI PREGLED
LA English
DT Article
DE bisphosphonate associated osteonecrosis of the jaws; diagnosis; drug
   therapy; oral surgical procedures; treatment outcome
ID JAWS
AB Introduction. Bisphosphonates are a group of medications which have an important role in the treatment of some bone diseases. Bisphosphonate related osteonecrosis of the jaw (BRONJ) is a side effect of intravenous bisphosphonate therapy. The mechanism of action by which they may cause osteonecrosis is questionable. BRONJ is defined by the American Association of Oral and Maxillofacial Surgeons (AAOMS) and classified into four stages (0 3). Treatment of BRONJ depends on the stage of disease and includes conservative treatment (stage 0 and 1) and surgical treatment (surgical debridement in stage 2 and sequestrectomy in stage 3). Case report. We presented a patient who had breast cancer, with stage 3 of bisphosphonate related osteonecrosis of the upper jaw after zoledronic acid therapy for diffuse metastasis of the vertebrae. Before the treatment with zoledronic acid the patient was treated by a dentist. The osteonecrosis of the upper jaw started a year and a half after the start of zoledronic acid therapy and after tooth 24 extraction. She was treated by an oral surgeon at the beginning according to the protocol of AAOMS. The patient was sent to a maxillofacial surgeon due to the disease progression, and after computed tomography (CT) examination resection of the upper jaw was done. Conclusion. BRONJ is a condition with the specific clinical presentation, and it can be very serious for the patient, therefore it is necessary to emphasize the importance of screening. The doctors in different specialties (oncologist, dentist, oral surgeon and maxillofacial surgeon) must cooperate and control the patients under treatment with bisphosphonates before the therapy starts, as well as during and after it, in order to prevent, recognize on time and treat properly this complication.
C1 [Kiralj, Aleksandar; Mijatov, Ivana] Clin Ctr Vojvodina, Clin Maxillofacial & Oral Surg, Novi Sad 21000, Serbia.
   [Kiralj, Aleksandar; Mijatov, Ivana] Univ Novi Sad, Fac Med, Novi Sad, Serbia.
   [Loncarevic, Slobodan] Mil Med Acad, Clin Maxillofacial Oral Surg & Implantol, Belgrade, Serbia.
   [Loncarevic, Slobodan] Univ Kragujevac, Fac Med Sci, Kragujevac, Serbia.
C3 University of Novi Sad; University of Kragujevac
RP Kiralj, A (通讯作者)，Clin Ctr Vojvodina, Clin Maxillofacial & Oral Surg, Novi Sad 21000, Serbia.
EM aleksandar.kiralj@kcv.rs
RI Mijatov, Ivana/JRW 8438 2023
OI Loncarevic, Slobodan/0000 0002 5297 7775
CR Agrillo A, 2012, EUR REV MED PHARMACO, V16, P1741
   Bagan J, 2009, ORAL ONCOL, V45, P551, DOI 10.1016/j.oraloncology.2009.01.002
   Borgioli Alberto, 2009, Ther Clin Risk Manag, V5, P217
   Bucur A, 2011, ACTA ENDOCRINOL BUCH, V7, P483, DOI 10.4183/aeb.2011.483
   Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006
   Filleul O, 2010, J CANCER RES CLIN, V136, P1117, DOI 10.1007/s00432 010 0907 7
   Loncarevic S, 2015, ORAL RADIOL, P1
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Mücke T, 2009, J CRANIO MAXILL SURG, V37, P291, DOI 10.1016/j.jcms.2008.12.004
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Pautke C, 2011, ORAL ONCOL, V47, P425, DOI 10.1016/j.oraloncology.2011.03.022
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Ruggiero S. L., 2009, J ORAL MAXILLOFAC SU, V67, P2, DOI DOI 10.1016/JJ0MS.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Tardast A, 2015, J APPL ORAL SCI, V23, P310, DOI 10.1590/1678 775720140506
   Wutzl A, 2012, HEAD NECK J SCI SPEC, V34, P194, DOI 10.1002/hed.21708
NR 16
TC 0
Z9 0
U1 1
U2 1
PU MILITARY MEDICAL ACAD INI
PI BELGRADE
PA CRNOTRAVSKA 17, PO BOX 33 35, BELGRADE, 11040, SERBIA
SN 0042 8450
EI 2406 0720
J9 VOJNOSANIT PREGL
JI Vojnosanit. Pregl.
PY 2017
VL 74
IS 11
BP 1084
EP 1088
DI 10.2298/VSP151228199K
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA FO2IT
UT WOS:000416600500013
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Shu, M
   Wang, JG
   Xu, ZY
   Lu, TL
   He, Y
   Li, RS
   Zhong, GQ
   Yan, YB
   Zhang, Y
   Chu, X
   Ke, J
AF Shu, Man
   Wang, Jingguang
   Xu, Ziyang
   Lu, Teliang
   He, Yue
   Li, Renshan
   Zhong, Guoqing
   Yan, Yunbo
   Zhang, Yu
   Chu, Xiao
   Ke, Jin
TI Targeting nanoplatform synergistic glutathione depletion enhanced
   chemodynamic, microwave dynamic, and selective microwave thermal to
   treat lung cancer bone metastasis
SO BIOACTIVE MATERIALS
LA English
DT Article
DE Targeting; Chemodynamic therapy; Microwave dynamic therapy; Microwave
   thermal therapy
ID FE3O4 NANOPARTICLES; ZOLEDRONATE; THERAPY; TUMOR; MECHANISMS; ABLATION;
   RADIOFREQUENCY; HYPERTHERMIA; CHEMOTHERAPY; CRYOTHERAPY
AB Once bone metastasis occurs in lung cancer, the efficiency of treatment can be greatly reduced. Current mainstream treatments are focused on inhibiting cancer cell growth and preventing bone destruction. Microwave ablation (MWA) has been used to treat bone tumors. However, MWA may damage the surrounding normal tissues. Therefore, it could be beneficial to develop a nanocarrier combined with microwave to treat bone metastasis. Herein, a microwave  responsive nanoplatform (MgFe 2 O 4 @ZOL) was constructed. MgFe 2 O 4 @ZOL NPs release the cargos of Fe 3 + , Mg 2 + and zoledronic acid (ZOL) in the acidic tumor microenvironment (TME). Fe 3 + can deplete intracellular glutathione (GSH) and catalyze H 2 O 2 to generate center dot OH, resulting in chemodynamic therapy (CDT). In addition, the microwave can significantly enhance the production of reactive oxygen species (ROS), thereby enabling the effective implementation of microwave dynamic therapy (MDT). Moreover, Mg 2 + and ZOL promote osteoblast differentiation. In addition, MgFe 2 O 4 @ZOL NPs could target and selectively heat tumor tissue and enhance the effect of microwave thermal therapy (MTT). Both in vitro and in vivo experiments revealed that synergistic targeting, GSH depletion  enhanced CDT, MDT, and selective MTT exhibited significant antitumor efficacy and bone repair. This multimodal combination therapy provides a promising strategy for the treatment of bone metastasis in lung cancer patients.
C1 [Shu, Man; Li, Renshan; Ke, Jin] Southern Med Univ, Zhujiang Hosp, Orthoped Ctr, Dept Joint & Orthoped, Guangzhou 510282, Guangdong, Peoples R China.
   [Shu, Man] Gen Hosp Southern Theater Command PLA, Dept Orthopaed, Guangzhou 510010, Peoples R China.
   [Wang, Jingguang] South China Univ Technol, Sch Mat Sci & Engn, Dept Biomed Engn, Guangzhou 510640, Peoples R China.
   [Xu, Ziyang; Lu, Teliang; He, Yue; Zhong, Guoqing; Zhang, Yu; Chu, Xiao] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, Guangzhou, Peoples R China.
   [Chu, Xiao] Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Med Res Ctr, Guangzhou 510080, Peoples R China.
   [Yan, Yunbo] Xiamen Univ, Xiangan Hosp, Sch Med, Dept Internal Med, Xiamen 361102, Peoples R China.
   [Shu, Man; Xu, Ziyang; Lu, Teliang; He, Yue; Li, Renshan; Zhong, Guoqing; Zhang, Yu; Chu, Xiao; Ke, Jin] Guangdong Engn Technol Res Ctr Funct Repair Bone D, Guangdong 510080, Peoples R China.
C3 Southern Medical University   China; Southern Theater Command General
   Hospital; South China University of Technology; Guangdong Academy of
   Medical Sciences & Guangdong General Hospital; Southern Medical
   University   China; Southern Medical University   China; Guangdong
   Academy of Medical Sciences & Guangdong General Hospital; Xiamen
   University
RP Ke, J (通讯作者)，Southern Med Univ, Zhujiang Hosp, Orthoped Ctr, Dept Joint & Orthoped, Guangzhou 510282, Guangdong, Peoples R China.; Zhang, Y; Chu, X (通讯作者)，Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Dept Thorac Surg, Guangzhou, Peoples R China.; Chu, X (通讯作者)，Southern Med Univ, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Med Res Ctr, Guangzhou 510080, Peoples R China.
EM zhangyu@gdph.org.cn; chuxiao@gdph.org.cn; kejin332500@163.com
RI Zhang, Ziyue/KSL 8395 2024; Wang, Jinguang/LXA 9330 2024; Zhong,
   Guoqing/GRJ 6541 2022
FU National Natural Science Foundation of China [SYDW2023007]; National Key
   Research and Development Program of China [U21A2084];  [2021YFC2400704]
FX <BOLD> The Animal Ethics Committee of the General Hospital of Southern
   Theatre Command authorized all animal experimental procedures (ethical
   code SYDW2023007) . </BOLD> We are grateful for the support from
   National Natural Science Foundation of China (U21A2084) and National Key
   Research and Development Program of China (2021YFC2400704) .
CR Adjei IM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10040205
   Ahmed MB, 2023, MINI REV MED CHEM, V23, P514, DOI 10.2174/1389557522666220826141837
   Al Gethami W, 2023, NANOMATERIALS BASEL, V13, DOI 10.3390/nano13010097
   Bai SB, 2020, NANOMEDICINE UK, V15, P833, DOI 10.2217/nnm 2020 0024
   Bhardwaj N, 2009, PATHOLOGY, V41, P168, DOI 10.1080/00313020802579292
   Boanini E, 2012, BIOMATERIALS, V33, P722, DOI 10.1016/j.biomaterials.2011.09.092
   Boedtkjer E, 2020, ANNU REV PHYSIOL, V82, P103, DOI 10.1146/annurev physiol 021119 034627
   Brody H, 2020, NATURE, V587, pS7, DOI 10.1038/d41586 020 03152 0
   Cadenas S, 2018, BBA BIOENERGETICS, V1859, P940, DOI 10.1016/j.bbabio.2018.05.019
   Cardoso BD, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081248
   Carrafiello Gianpaolo, 2008, Int J Surg, V6 Suppl 1, pS65, DOI 10.1016/j.ijsu.2008.12.028
   Cazzato RL, 2021, EUR RADIOL, V31, P3530, DOI 10.1007/s00330 020 07382 8
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Cheng MH, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6342104
   Cheng XT, 2021, ACS NANO, V15, P8039, DOI 10.1021/acsnano.1c00498
   Chu X, 2023, SMALL, V19, DOI 10.1002/smll.202205414
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman R, 2011, CANCER AM CANCER SOC, V117, P11, DOI 10.1002/cncr.25529
   Diao YF, 2018, J HAZARD MATER, V344, P829, DOI 10.1016/j.jhazmat.2017.11.029
   Du QJ, 2015, ACS APPL MATER INTER, V7, P13612, DOI 10.1021/acsami.5b03230
   Feng YF, 2023, J CONTROL RELEASE, V361, P102, DOI 10.1016/j.jconrel.2023.07.046
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gao HY, 2023, THERANOSTICS, V13, P1974, DOI 10.7150/thno.80887
   Gao X, 2021, BIOMATERIALS, V265, DOI 10.1016/j.biomaterials.2020.120404
   Hatami E, 2019, ACS BIOMATER SCI ENG, V5, P2343, DOI 10.1021/acsbiomaterials.9b00362
   He YF, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI157917
   Hoyos Sifuentes DHD, 2022, J MATER RES TECHNOL, V18, P3130, DOI 10.1016/j.jmrt.2022.03.117
   Hsu CC, 2016, EXP BIOL MED, V241, P1281, DOI 10.1177/1535370216641787
   Huang YJ, 2020, ACTA PHARMACOL SIN B, V10, P2384, DOI 10.1016/j.apsb.2020.06.006
   Jia CY, 2022, SMALL, V18, DOI 10.1002/smll.202103868
   Jiao DC, 2022, ACAD RADIOL, V29, P42, DOI 10.1016/j.acra.2020.09.026
   Jin YS, 2016, BIOCONJUGATE CHEM, V27, P2931, DOI 10.1021/acs.bioconjchem.6b00603
   John L, 2017, MAT SCI ENG C MATER, V78, P901, DOI 10.1016/j.msec.2017.04.133
   Jung SM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00796
   Kara M, 2022, J BIOCHEM MOL TOXIC, V36, DOI 10.1002/jbt.23083
   Kennedy L, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10101429
   Khot VM, 2013, DALTON T, V42, P1249, DOI 10.1039/c2dt31114c
   Lan Z, 2019, HUM EXP TOXICOL, V38, P598, DOI 10.1177/0960327119829527
   Li HN, 2023, THERANOSTICS, V13, P5386, DOI 10.7150/thno.87854
   Li HN, 2021, WIRES NANOMED NANOBI, V13, DOI 10.1002/wnan.1670
   Li S, 2021, INT J NANOMED, V16, P6129, DOI 10.2147/IJN.S312823
   Li XL, 2023, ADV MATER, V35, DOI 10.1002/adma.202300548
   Li YF, 2023, MICROMACHINES BASEL, V14, DOI 10.3390/mi14010177
   Li ZX, 2016, SPECTROCHIM ACTA A, V159, P249, DOI 10.1016/j.saa.2016.02.001
   Liu F, 2019, ADV MATER, V31, DOI 10.1002/adma.201902885
   Liu L, 2020, COLLOID SURFACE B, V185, DOI 10.1016/j.colsurfb.2019.110590
   Long D, 2016, ACS NANO, V10, P9516, DOI 10.1021/acsnano.6b04749
   López Lázaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029
   Lopez Olivo MA, 2012, SUPPORT CARE CANCER, V20, P2985, DOI 10.1007/s00520 012 1563 z
   Lou H, 2022, J MATER CHEM B, V10, P7955, DOI 10.1039/d2tb01015a
   Ma XY, 2019, BIOMATERIALS, V214, DOI 10.1016/j.biomaterials.2019.119223
   Manohar A, 2017, J PHOTOCH PHOTOBIO B, V173, P456, DOI 10.1016/j.jphotobiol.2017.06.025
   Manohar A, 2021, J ALLOY COMPD, V879, DOI 10.1016/j.jallcom.2021.160515
   MUNDY GR, 1991, BONE, V12, pS1, DOI 10.1016/8756 3282(91)90057 P
   Niu BY, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121110
   Peng HX, 2020, INT J NANOMED, V15, P8783, DOI 10.2147/IJN.S267614
   Qiao H, 2017, ACS NANO, V11, P7259, DOI 10.1021/acsnano.7b03197
   Qu XZ, 2021, PEERJ, V9, DOI 10.7717/peerj.12510
   Ramnandan D, 2021, MOLECULES, V26, DOI 10.3390/molecules26133893
   Ran ZY, 2023, INT J BIOPRINTING, V9, P401, DOI 10.18063/ijb.769
   Ravi R, 2022, ACS APPL BIO MATER, V5, P5365, DOI 10.1021/acsabm.2c00729
   Salih SJ, 2023, HELIYON, V9, DOI 10.1016/j.heliyon.2023.e16601
   Seror O, 2015, DIAGN INTERV IMAG, V96, P617, DOI 10.1016/j.diii.2015.04.007
   Shu M, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.935640
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Tang FQ, 2012, ADV MATER, V24, P1504, DOI 10.1002/adma.201104763
   Tang SS, 2017, BIOMATERIALS, V133, P144, DOI 10.1016/j.biomaterials.2017.04.027
   Tang ZM, 2019, ANGEW CHEM INT EDIT, V58, P946, DOI 10.1002/anie.201805664
   Tang ZM, 2017, ADV MATER, V29, DOI 10.1002/adma.201701683
   Thomas N, 2021, J HAZARD MATER, V404, DOI 10.1016/j.jhazmat.2020.124082
   Ting G, 2022, BIOMATER SCI UK, V10, P1831, DOI 10.1039/d1bm01717a
   Valkenburg KC, 2013, CHIN J CANCER, V32, P380, DOI 10.5732/cjc.012.10218
   Wang WQ, 2020, WIRES NANOMED NANOBI, V12, DOI 10.1002/wnan.1614
   Wang XM, 2023, J NANOBIOTECHNOL, V21, DOI 10.1186/s12951 023 02036 5
   Wang YD, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01278 z
   Wang YX, 2023, SMALL, V19, DOI 10.1002/smll.202304440
   Wang ZQ, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15020487
   Wei XH, 2023, BIOACT MATER, V20, P16, DOI 10.1016/j.bioactmat.2022.05.011
   Wu B, 2019, NANO LETT, V19, P5277, DOI 10.1021/acs.nanolett.9b01735
   Wu HS, 2020, NANOSCALE, V12, P17319, DOI 10.1039/d0nr03135f
   Xiong YX, 2021, CHEM SOC REV, V50, P6013, DOI 10.1039/d0cs00718h
   Xu XM, 2023, ACS APPL MATER INTER, V15, P42182, DOI 10.1021/acsami.3c05728
   Yang ZF, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110256
   Yukumi S, 2009, INT J HYPERTHER, V25, P416, DOI 10.1080/02656730902991459
   Zhang C, 2016, ANGEW CHEM INT EDIT, V55, P2101, DOI 10.1002/anie.201510031
   Zhao ZY, 2021, ACS NANO, V15, P13041, DOI 10.1021/acsnano.1c02147
   Zhou H, 2023, BIOACT MATER, V24, P322, DOI 10.1016/j.bioactmat.2022.12.023
   Zhu YJ, 2023, CHEM REV, V123, P7326, DOI 10.1021/acs.chemrev.2c00822
NR 90
TC 6
Z9 6
U1 18
U2 59
PU KEAI PUBLISHING LTD
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, Building 5, Room 411, BEIJING, DONGCHENG
   DISTRICT 100009, PEOPLES R CHINA
EI 2452 199X
J9 BIOACT MATER
JI Bioact. Mater.
PD SEP
PY 2024
VL 39
BP 544
EP 561
DI 10.1016/j.bioactmat.2024.04.016
PG 18
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA UP9R5
UT WOS:001249385500001
PM 38883314
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, JJ
   Chen, XF
   Chen, BB
   Tong, LJ
   Zhang, Y
AF Zhang, Jingjing
   Chen, Xiangfan
   Chen, Bingbing
   Tong, Lijuan
   Zhang, Yan
TI Tetrahydroxy stilbene glucoside protected against diabetes induced
   osteoporosis in mice with streptozotocin induced hyperglycemia
SO PHYTOTHERAPY RESEARCH
LA English
DT Article
DE bone; diabetes induced osteoporosis; renin angiotensin system;
   tetrahydroxy stilbene glucoside
ID RENIN ANGIOTENSIN SYSTEM; KALLIKREIN KININ SYSTEM; BONE; NEPHROPATHY;
   RECEPTOR; PROLIFERATION; INVOLVEMENT; BLOCKADE; FIBROSIS; PATHWAY
AB Tetrahydroxy stilbene glucoside (TSG), an active component from medicinal herb Polygonum multiflorum Thunb, could block the activity of the tissue renin angiotensin system (RAS), which plays a critical role in development of diabetic osteoporosis. This study aimed to determine if TSG therapy could alleviate bone deteriorations in diabetic mouse model induced by streptozotocin. The diabetic mice showed the loss of trabecular bone mass and the changes of trabecular bone microarchitectural parameters as well as the increase in amount of tartrate resistant acid phosphatase (TRAP) positive osteoclasts at the distal metaphysis of femur when compared with those of nondiabetic mice. Treatment with TSG significantly elevated calcium content in serum and bone and improved biological parameters of trabecular bone, accompanied by increasing messenger RNA (mRNA) expression of RUNX 2, COL I, and OCN and protein expression of beta catenin as well as down regulating protein expression of RAS components including renin and AT1R. In addition, TSG repressed diabetes induced decrease in ratio of OPG/RANKL expression and increase in sclerostin expression in bone. The similar effects of TSG on osteoblasts specific genes were found in MC3T3 E1 cells. Taken together, the present study demonstrated the osteopreserve effects of TSG in diabetic mice, and the underlying mechanism might be attributed to its regulation on osteogenesis and osteoclastogenesis.
C1 [Zhang, Jingjing; Chen, Xiangfan; Tong, Lijuan; Zhang, Yan] Nantong Univ, Sch Pharm, Qixiu Rd 19, Nantong 226001, Jiangsu, Peoples R China.
   [Chen, Bingbing] Univ Shanghai Sci & Technol, Sch Med Instrument & Food Engn, Shanghai, Peoples R China.
C3 Nantong University; University of Shanghai for Science & Technology
RP Zhang, Y (通讯作者)，Nantong Univ, Sch Pharm, Qixiu Rd 19, Nantong 226001, Jiangsu, Peoples R China.
EM riceandtiger@163.com
RI Chen, Xiangfan/M 3719 2016
FU specially invited professor program of Jiangsu Province (China)
FX This work was supported in part by specially invited professor program
   of Jiangsu Province (China).
CR Adil C, 2015, J PHYS THER SCI, V27, P179, DOI 10.1589/jpts.27.179
   [Anonymous], EVIDENCE BASED COMPL
   Chang MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050291
   Chen GT, 2016, FOOD FUNCT, V7, P4628, DOI [10.1039/c6fo01319h, 10.1039/C6FO01319H]
   Chen H, 2018, PHYTOMEDICINE, V42, P207, DOI 10.1016/j.phymed.2018.03.034
   Chen L, 2017, CHEM BIOL INTERACT, V273, P56, DOI 10.1016/j.cbi.2017.05.025
   Chen XF, 2018, EUR J PHARMACOL, V819, P281, DOI 10.1016/j.ejphar.2017.12.025
   Guan XX, 2011, INT J MOL SCI, V12, P4206, DOI 10.3390/ijms12074206
   Li CR, 2010, EUR J PHARMACOL, V649, P382, DOI 10.1016/j.ejphar.2010.09.004
   Li Y, 2015, INT J CLIN EXP PATHO, V8, P1604
   Liang W, 2014, AM J CHINESE MED, V42, P587, DOI 10.1142/S0192415X14500384
   Nakai K, 2013, BIOCHIMIE, V95, P922, DOI 10.1016/j.biochi.2012.12.016
   Piscitelli P, 2015, CURR OPIN ENDOCRINOL, V22, P439, DOI 10.1097/MED.0000000000000203
   Sha NN, 2017, FOOD FUNCT, V8, P4703, DOI 10.1039/c7fo01259d
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Siddapur Priyanka R, 2015, J Lab Physicians, V7, P43, DOI 10.4103/0974 2727.151681
   Skov J, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00023
   Starup Linde J, 2015, EUR J ENDOCRINOL, V173, pR93, DOI 10.1530/EJE 15 0155
   Wang M, 2018, J AGR FOOD CHEM, V66, P1828, DOI 10.1021/acs.jafc.8b00099
   Xu XL, 2015, CHIN J INTEGR MED, V21, P204, DOI 10.1007/s11655 014 1821 7
   Xu XL, 2013, EUR J PHARMACOL, V698, P370, DOI 10.1016/j.ejphar.2012.11.019
   Yamamoto S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122691
   Zhang JK, 2012, EUR J PHARMACOL, V689, P31, DOI 10.1016/j.ejphar.2012.05.045
   Zhang W, 2012, CLIN EXP PHARMACOL P, V39, P429, DOI 10.1111/j.1440 1681.2012.05692.x
   Zhang Y, 2016, OSTEOPOROSIS INT, V27, P1083, DOI 10.1007/s00198 015 3348 y
   Zhang Y, 2016, J DIABETES COMPLICAT, V30, P1419, DOI 10.1016/j.jdiacomp.2016.08.016
   Zhang Y, 2014, J RENIN ANGIO ALDO S, V15, P218, DOI 10.1177/1470320312471229
   Zhang YongJie Zhang YongJie, 2012, Mycology   An International Journal on Fungal Biology, V3, P2
   Zhang Z, 2008, P NATL ACAD SCI USA, V105, P15896, DOI 10.1073/pnas.0803751105
   Zheng YY, 2017, EXP THER MED, V14, P2845, DOI 10.3892/etm.2017.4915
   Zhou MR, 2017, EXP THER MED, V14, P2445, DOI 10.3892/etm.2017.4802
   Zhukouskaya VV, 2015, J ENDOCRINOL INVEST, V38, P941, DOI 10.1007/s40618 015 0284 9
NR 32
TC 15
Z9 17
U1 1
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0951 418X
EI 1099 1573
J9 PHYTOTHER RES
JI Phytother. Res.
PD FEB
PY 2019
VL 33
IS 2
BP 442
EP 451
DI 10.1002/ptr.6240
PG 10
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA HK2MK
UT WOS:000457745900021
PM 30456807
DA 2025 08 17
ER

PT J
AU Feng, CJ
   Liu, XK
   Li, XY
   Guo, FC
   Huang, CY
   Qin, Q
   Wang, YS
AF Feng, Chengjun
   Liu, Xiaoke
   Li, Xiaoyu
   Guo, Fuchun
   Huang, Chuying
   Qin, Qing
   Wang, Yongsheng
TI Zoledronic acid increases the antitumor effect of gefitinib treatment
   for non small cell lung cancer with EGFR mutations
SO ONCOLOGY REPORTS
LA English
DT Article
DE zoledronic acid; gefitinib; non small cell lung cancer; epithelial
   growth factor receptor mutation; signal transducer and activator of
   transcription 3
ID INDUCED APOPTOSIS; TYROSINE KINASE; INDUCE APOPTOSIS; BONE RESORPTION;
   BISPHOSPHONATES; RESISTANCE; GROWTH; STAT3; PHOSPHORYLATION;
   TRANSCRIPTION
AB Non small cell lung cancer (NSCLC) patients with epithelial growth factor receptor (EGFR) mutations and bone metastases are often concurrently administered tyrosine kinase inhibitors (TKIs) and bisphosphonates. Yet, the effects and mechanisms of these agents are unclear. In the present study, we aimed to ascertain whether zoledronic acid (ZA) increases the antitumor effects of gefitinib treatment on NSCLC with EGFR mutations and the related mechanisms of action. The effects of ZA and gefitinib on NSCLC tumor cells with EGFR mutations (HCC827, HCC827 GR and H1975) in regards to proliferation, apoptosis, cell cycle and signaling pathways were detected. ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance in vitro. Gefitinib caused cell cycle arrest in the G0/G1 phase, ZA induced S phase accumulation and the effect of the combined treatment was neutralization. Combined treatment obviously inhibited STAT3 and/or p STAT3 protein expression compared with treatment with each single drug in vitro and in vivo, and it also significantly inhibited TKI resistance NSCLC tumor growth in vivo. In conclusion, ZA increased the antitumor effects of gefitinib on NSCLC with EGFR activating mutations and TKI resistance by regulating the cell cycle, inducing caspase 3 expression and inhibiting STAT3 expression.
C1 [Feng, Chengjun; Liu, Xiaoke; Li, Xiaoyu; Guo, Fuchun; Huang, Chuying; Qin, Qing; Wang, Yongsheng] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Thorac Oncol,Canc Ctr, 37 Guoxue Xiang Rd, Chengdu 610041, Sichuan, Peoples R China.
   [Feng, Chengjun] Taizhou Peoples Hosp, Dept Oncol, Taizhou 225300, Jiangsu, Peoples R China.
   [Huang, Chuying] Enshi Tujia & Miao Autonomous Prefecture Cent Hos, Dept Med Oncol, Enshi 445000, Hubei, Peoples R China.
C3 Sichuan University
RP Wang, YS (通讯作者)，Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Dept Thorac Oncol,Canc Ctr, 37 Guoxue Xiang Rd, Chengdu 610041, Sichuan, Peoples R China.
EM wangys@scu.edu.cn
RI Huang, Chuying/LNQ 8431 2024; qin, qin/GXG 6164 2022; Li,
   Xiaoyu/HSE 9827 2023
FU National Natural Science Foundation of China [81472197]
FX We thank Novartis Pharma Stein AG who kindly provided the zoledronic
   acid for this research. The present study was supported by the National
   Natural Science Foundation of China (no. 81472197).
CR Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Chang JWC, 2009, CANCER LETT, V278, P17, DOI 10.1016/j.canlet.2008.12.019
   Chen W, 2012, LIVER INT, V32, P70, DOI 10.1111/j.1478 3231.2011.02631.x
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Fukai J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104538
   Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198
   Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294
   Huang CY, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e19073
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615
   Kiper HD, 2013, BIOMED PHARMACOTHER, V67, P527, DOI 10.1016/j.biopha.2013.04.006
   Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078 0432.CCR 06 0714
   Koto K, 2013, INT J ONCOL, V42, P525, DOI 10.3892/ijo.2012.1735
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Li TH, 2007, CLIN CANCER RES, V13, P3413, DOI 10.1158/1078 0432.CCR 06 2923
   Li YY, 2008, LUNG CANCER, V59, P180, DOI 10.1016/j.lungcan.2007.08.026
   Li YY, 2011, ANTI CANCER DRUG, V22, P89, DOI 10.1097/CAD.0b013e3283400a05
   Lin YX, 2014, AM J CANCER RES, V4, P411
   Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   Mantha AJ, 2005, CLIN CANCER RES, V11, P2398, DOI 10.1158/1078 0432.CCR 04 1951
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Morgan G, 2010, SEMIN ONCOL, V37, pS30, DOI 10.1053/j.seminoncol.2010.10.005
   Mu XD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/726375
   Okamoto K, 2010, CANCER RES, V70, P10402, DOI 10.1158/0008 5472.CAN 10 2438
   Previdi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079101
   Reuben JS, 2011, ORAL SURG ORAL MED O, V111, P196, DOI 10.1016/j.tripleo.2010.09.068
   Ringerike T, 2002, J CELL SCI, V115, P1331
   Robinson KW, 2013, ONCOLOGIST, V18, P115, DOI 10.1634/theoncologist.2012 0262
   Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Torre LA, 2015, CA CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang M, 2011, EXP THER MED, V2, P517, DOI 10.3892/etm.2011.235
   WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092 8674(95)90311 9
   Wui M, 2014, MOL MED REP, V9, P2417, DOI 10.3892/mmr.2014.2082
   Yang JJ, 2007, J THORAC ONCOL, V2, pS398, DOI 10.1097/01.JTO.0000283268.73047.26
   Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105
   Zhang W, 2010, CLIN CANCER RES, V16, P3420, DOI 10.1158/1078 0432.CCR 09 2904
NR 44
TC 10
Z9 11
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2016
VL 35
IS 6
BP 3460
EP 3470
DI 10.3892/or.2016.4741
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA DM7OT
UT WOS:000376550600038
PM 27109760
OA Bronze
DA 2025 08 17
ER

PT J
AU Liu, S
   Yu, Z
   Daley, EJ
   Bingman, CA
   Bruchs, AT
   Gardella, TJ
   Gellman, SH
AF Liu, Shi
   Yu, Zhen
   Daley, Eileen J.
   Bingman, Craig A.
   Bruchs, Austin T.
   Gardella, Thomas J.
   Gellman, Samuel H.
TI Altered signaling at the PTH receptor via modified agonist contacts with
   the extracellular domain provides a path to prolonged agonism in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GPCR pharmacology; peptides; extracellular domain; prolonged signaling;
   beta amino acids
ID PARATHYROID HORMONE RECEPTOR; CRYO EM STRUCTURE; AMINO; BACKBONE;
   COMPLEX; BINDING; ABALOPARATIDE; CONFORMATIONS; RECOGNITION; SELECTIVITY
AB The parathyroid hormone type 1 receptor (PTHR1), a Class B GPCR, is activated by long polypeptides, including drugs for osteoporosis and hypoparathyroidism. The PTHR1 engages peptide agonists via a two step mechanism. Initial contact involves the extracellular domain (ECD), which has been thought to contribute primarily to receptor peptide binding, and then the N terminus of the peptide engages the receptor transmembrane domain (TMD), which is thought to control the message conveyed to intracellular partners. This mechanism has been suggested to apply to other Class B GPCRs as well. Here, we show that modification of a PTHR1 agonist at ECD contact sites can alter the signaling profile, an outcome that is not accommodated by the current two step binding model. Our data support a modified two step binding model in which agonist orientation on the ECD surface can influence the geometry of agonist TMD engagement. This expanded binding model offers a mechanism by which altering ECD contact residues can affect signaling profile. Our discoveries provide a rationale for exploring agonist modifications distal from the TMD contact region in future efforts to optimize therapeutic performance of peptide hormone analogs.
C1 [Liu, Shi; Yu, Zhen; Bruchs, Austin T.; Gellman, Samuel H.] Univ Wisconsin, Dept Chem, Madison, WI 53706 USA.
   [Daley, Eileen J.; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Daley, Eileen J.; Gardella, Thomas J.] Harvard Med Sch, Boston, MA 02114 USA.
   [Bingman, Craig A.] Univ Wisconsin Madison, Dept Biochem, Madison, WI 53706 USA.
C3 University of Wisconsin System; University of Wisconsin Madison; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard University; Harvard Medical School; University of
   Wisconsin System; University of Wisconsin Madison
RP Gellman, SH (通讯作者)，Univ Wisconsin, Dept Chem, Madison, WI 53706 USA.; Gardella, TJ (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.; Gardella, TJ (通讯作者)，Harvard Med Sch, Boston, MA 02114 USA.
EM gardella@helix.mgh.harvard.edu; gellman@chem.wisc.edu
RI Bingman, Craig/HLG 8162 2023; Bingman, Craig/F 1711 2019; Yu,
   Zhen/S 8325 2016
OI Gellman, Samuel/0000 0001 5617 0058; Bruchs, Austin/0000 0003 0819 3639;
   Bingman, Craig/0000 0002 3073 5089; Yu, Zhen/0000 0003 2092 9960; Liu,
   Shi/0000 0002 9113 6207
FU National Institute of Diabetes and Digestive and Kidney Diseases
   [R01DK113039] Funding Source: NIH RePORTER
CR Banerjee R, 2002, J PEPT RES, V60, P88, DOI 10.1034/j.1399 3011.2002.201005.x
   Berg C, 2003, NAT REV DRUG DISCOV, V2, P257, DOI 10.1038/nrd1068
   Carter PH, 2015, MOL ENDOCRINOL, V29, P307, DOI 10.1210/me.2014 1129
   Carter PH, 1999, ENDOCRINOLOGY, V140, P4972, DOI 10.1210/en.140.11.4972
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Cheloha RW, 2017, J MED CHEM, V60, P8816, DOI 10.1021/acs.jmedchem.7b00876
   Cheloha RW, 2014, NAT BIOTECHNOL, V32, P653, DOI 10.1038/nbt.2920
   Chi YG, 2007, J AM CHEM SOC, V129, P6050, DOI 10.1021/ja070063i
   Clark LJ, 2020, NAT CHEM BIOL, V16, P1096, DOI 10.1038/s41589 020 0567 0
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Fisher BF, 2018, J AM CHEM SOC, V140, P9396, DOI 10.1021/jacs.8b05162
   GARDELLA TJ, 1995, J BIOL CHEM, V270, P6584, DOI 10.1074/jbc.270.12.6584
   GOLDMAN ME, 1988, ENDOCRINOLOGY, V123, P2597, DOI 10.1210/endo 123 5 2597
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Hollenstein K, 2014, TRENDS PHARMACOL SCI, V35, P12, DOI 10.1016/j.tips.2013.11.001
   Horne WS, 2008, P NATL ACAD SCI USA, V105, P9151, DOI 10.1073/pnas.0801135105
   Horne WS, 2009, P NATL ACAD SCI USA, V106, P14751, DOI 10.1073/pnas.0902663106
   KARLE IL, 1990, BIOCHEMISTRY US, V29, P6747, DOI 10.1021/bi00481a001
   Kim ES, 2015, DRUGS, V75, P1293, DOI 10.1007/s40265 015 0438 2
   Kobayashi K, 2022, MOL CELL, V82, P3468, DOI 10.1016/j.molcel.2022.07.003
   Liang YL, 2020, MOL CELL, V77, P656, DOI 10.1016/j.molcel.2020.01.012
   Liang YL, 2017, NATURE, V546, P118, DOI 10.1038/nature22327
   Liu S, 2019, J AM CHEM SOC, V141, P14486, DOI 10.1021/jacs.9b04179
   Liu S, 2018, P NATL ACAD SCI USA, V115, P12383, DOI 10.1073/pnas.1815294115
   Luck MD, 1999, MOL ENDOCRINOL, V13, P670, DOI 10.1210/me.13.5.670
   Ma SS, 2020, MOL CELL, V77, P669, DOI 10.1016/j.molcel.2020.01.013
   McGarvey JC, 2016, J BIOL CHEM, V291, P10986, DOI 10.1074/jbc.M115.697045
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Price JL, 2010, J AM CHEM SOC, V132, P12378, DOI 10.1021/ja103543s
   Sadowsky JD, 2007, CHEMBIOCHEM, V8, P903, DOI 10.1002/cbic.200600546
   Sankaranarayanan S, 2000, BIOPHYS J, V79, P2199, DOI 10.1016/S0006 3495(00)76468 X
   Sarkar K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51016 z
   Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   Shirley M, 2017, DRUGS, V77, P1363, DOI 10.1007/s40265 017 0780 7
   Takasu H, 1999, BIOCHEMISTRY US, V38, P13453, DOI 10.1021/bi990437n
   Thomsen ARB, 2016, CELL, V166, P907, DOI 10.1016/j.cell.2016.07.004
   Vilardaga JP, 2014, NAT CHEM BIOL, V10, P700, DOI [10.1038/NCHEMBIO.1611, 10.1038/nchembio.1611]
   Vilardaga JP, 2012, TRENDS PHARMACOL SCI, V33, P423, DOI 10.1016/j.tips.2012.05.004
   Wang X, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2101279118
   White AD, 2021, SCI SIGNAL, V14, DOI 10.1126/scisignal.abc5944
   Zhang Y, 2017, NATURE, V546, P248, DOI 10.1038/nature22394
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
   Zhou QT, 2019, ELIFE, V8, DOI 10.7554/eLife.50279
NR 47
TC 5
Z9 5
U1 1
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 21
PY 2022
VL 119
IS 48
AR e2212736119
DI 10.1073/pnas.2212736119
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA D8NI6
UT WOS:000971235800001
PM 36409914
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Tamma, R
   Dell'Endice, S
   Notarnicola, A
   Moretti, L
   Patella, S
   Patella, V
   Zallone, A
   Moretti, B
AF Tamma, Roberto
   dell'Endice, Stefania
   Notarnicola, Angela
   Moretti, Lorenzo
   Patella, Silvio
   Patella, Vittorio
   Zallone, Alberta
   Moretti, Biagio
TI EXTRACORPOREAL SHOCK WAVES STIMULATE OSTEOBLAST ACTIVITIES
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Osteoblasts; Shockwaves; Osteogenesis
ID BONE; CELLS; ERK; DIFFERENTIATION; EXPRESSION; BAX; INVOLVEMENT;
   DYSFUNCTION; ACTIVATE; GROWTH
AB The extracorporeal shock wave therapy (ESWT) is an extensively applied treatment for musculoskeletal disorders because it promotes bone repair. The aim of this study was to evaluate the direct effect of ESWT on murine osteoblasts to clarify the cellular mechanism that leads to the induction of osteogenesis. Osteoblasts in culture flasks were treated with ESWT pulses (500 impulses of 0.05 mJ/mm(2)) generated by an electromagnetic device. Using western blot analysis 3 h after ESWT, an increased expression of Bax was found, indicating a fast pro apoptotic effect of treatment on some of the osteoblasts. Activation of the cyclin E2/CDK2 is the complex that regulates the G1 S transition and is essential for cell proliferation. It was evident 24 to 72 h after treatment, indicating a proliferative stimulus. A decreased expression of osteoprotegerin (OPG) and receptor activator NF kappa B ligand (RANKL) 24 and 48 h after ESW, followed by a later increase of OPG, paired with a much smaller increase of RANKL, was evident by real time polymerase chain reaction (PCR). The decreased RANKL/OPG ratio suggests inhibition of osteoclastogenesis. We can conclude that ESWT induces bone repair through the proliferation and differentiation of osteoblasts and the reduction of their secretion of pro osteoclastogenic factors. (E mail: angelanotarnicola@yahoo.it) (C) 2009 World Federation for Ultrasound in Medicine & Biology.
C1 [Notarnicola, Angela; Moretti, Lorenzo; Patella, Silvio; Patella, Vittorio; Moretti, Biagio] Univ Bari, Dept Clin Methodol & Surg Tech, Orthopaed Sect, I 70124 Bari, Italy.
   [Tamma, Roberto; dell'Endice, Stefania; Zallone, Alberta] Univ Bari, Dept Human Anat & Histol, I 70124 Bari, Italy.
   [Moretti, Biagio] Univ Bari, Course Motor & Sports Sci, I 70124 Bari, Italy.
   [Moretti, Biagio] Italian Soc Shock Waves Therapy, SITOD, Naples, Italy.
C3 Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari
   Aldo Moro; Universita degli Studi di Bari Aldo Moro
RP Notarnicola, A (通讯作者)，Univ Bari, Dept Clin Methodol & Surg Tech, Orthopaed Sect, Piazza Giulio Cesare 11, I 70124 Bari, Italy.
EM angelanotarnicola@yahoo.it
RI tamma, roberto/C 3679 2016; Notarnicola, Angela/T 5403 2019
OI Notarnicola, Angela/0000 0002 8941 8336; TAMMA,
   Roberto/0000 0003 4623 5406; Moretti, Biagio/0000 0002 1234 8616;
   MORETTI, Lorenzo/0000 0003 4215 7615
CR Gebken J, 1999, J BIOCHEM, V126, P676, DOI 10.1093/oxfordjournals.jbchem.a022502
   GRAFF J, 1988, J UROLOGY, V139, P513, DOI 10.1016/S0022 5347(17)42507 9
   HAUPT G, 1990, J SURG RES, V49, P45, DOI 10.1016/0022 4804(90)90109 F
   Hofmann A, 2008, J TRAUMA, V65, P1402, DOI 10.1097/TA.0b013e318173e7c2
   Ikeda K, 1999, J TRAUMA, V47, P946, DOI 10.1097/00005373 199911000 00024
   Jessop HL, 2002, BONE, V31, P186, DOI 10.1016/S8756 3282(02)00797 4
   JOHANNES EJ, 1994, J SURG RES, V57, P677, DOI 10.1006/jsre.1994.1200
   Karsenty G, 2001, ENDOCRINOLOGY, V142, P2731, DOI 10.1210/en.142.7.2731
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210
   Maier M, 2002, J BONE JOINT SURG BR, V84B, P592, DOI 10.1302/0301 620X.84B4.11621
   Martini L, 2003, ARTIF CELL BLOOD SUB, V31, P449, DOI 10.1081/BIO 120025415
   Martini L, 2003, CLIN ORTHOP RELAT R, P269, DOI 10.1097/01.blo.0000073344.50837.cd
   Martini L, 2006, J TRAUMA, V61, P1198, DOI 10.1097/01.ta.0000203575.96896.34
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Meirer R, 2007, J RECONSTR MICROSURG, V23, P231, DOI 10.1055/s 2007 981506
   Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414
   Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681
   Nishida T, 2004, CIRCULATION, V110, P3055, DOI 10.1161/01.CIR.0000148849.51177.97
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Rogers A, 2005, J CLIN ENDOCR METAB, V90, P6323, DOI 10.1210/jc.2005 0794
   Rompe JD, 2001, CLIN ORTHOP RELAT R, P72
   Tischer T, 2008, EUR SURG RES, V41, P44, DOI 10.1159/000128279
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Ching Jen, 2003, Chang Gung Med J, V26, P220
   Wang FS, 2002, J BONE JOINT SURG BR, V84B, P457, DOI 10.1302/0301 620X.84B3.11609
   Wang FS, 2001, BIOCHEM BIOPH RES CO, V287, P648, DOI 10.1006/bbrc.2001.5654
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   YAO CZ, 1994, SURG ONCOL, V3, P229, DOI 10.1016/0960 7404(94)90038 8
NR 32
TC 45
Z9 52
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD DEC
PY 2009
VL 35
IS 12
BP 2093
EP 2100
DI 10.1016/j.ultrasmedbio.2009.05.022
PG 8
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 600TP
UT WOS:000278012100016
PM 19679388
DA 2025 08 17
ER

PT J
AU Sundaram, K
   Nishimura, R
   Senn, J
   Youssef, RF
   London, SD
   Reddy, SV
AF Sundaram, Kumaran
   Nishimura, Riko
   Senn, Joseph
   Youssef, Rimon F.
   London, Steven D.
   Reddy, Sakamuri V.
TI RANK ligand signaling modulates the matrix metalloproteinase 9 gene
   expression during osteoclast differentiation
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE RANK ligand (RANKL); osteoclast; matrix metalloproteinase 9 (MMP 9);
   NFAT; TRAF6
ID ACTIVATED PROTEIN KINASE; KAPPA B LIGAND; ALPHA INDUCED
   OSTEOCLASTOGENESIS; COLLAGENASE GELATINASE B; NECROSIS FACTOR RECEPTOR;
   NUCLEAR FACTOR; NFAT FAMILY; P38 MAPK; CELLS; PATHWAY
AB Osteoclast differentiation is tightly regulated by receptor activator of NF kappa B ligand (RANKL) signaling. Matrix metalloproteinase 9 (MMP 9), a type IV collagenase is highly expressed in osteoclast cells and plays an important role in degradation of extracellular matrix; however, the molecular mechanisms that regulate MMP 9 gene expression are unknown. In this study, we demonstrate that RANKL signaling induces MMP 9 gene expression in osteoclast precursor cells. We further show that RANKL regulates MMP 9 gene expression through TRAF6 but not TRAF2. Interestingly, blockade of p38 MAPK activity by pharmacological inhibitor, SB203580 increases MMP 9 activity whereas ERK1/2 inhibitor, PD98059 decreases RANKL induced MMP 9 activity in RAW264.7 cells. These data suggest that RANKL differentially regulates MMP 9 expression through p38 and ERK signaling pathways during osteoclast differentiation. Transient expression of MMP 9 gene (+ 1 to   1174 bp relative to ATG start codon) promoter luciferase reporter plasmids in RAW264.7 cells and RANKL stimulation showed significant increase (20 fold) of MMP 9 gene promoter activity; however, there is no significant change with respect to +1 bp to  446 bp promoter region and empty vector transfected cells. These results indicated that MMP 9 promoter sequence from  446 bp to  1174 bp relative to start codon is responsive to RANKL stimulation. Sequence analysis of the mouse MMP 9 gene promoter region further identified the presence of binding motif(  1123 bp to  1153 bp) for the nuclear factor of activated T cells 1 (NFATc1) transcription factor. Inhibition of NFATc1 using siRNA and VIVIT peptide inhibitor significantly decreased RANKL stimulation of MMP 9 activity. We further confirm by oligonucleotide pull down assay that RANKL stimuli enhanced NFATc1 binding to MMP 9 gene promoter element. In addition, over expression of constitutively active NFAT in RAW264.7 cells markedly increased (5 fold) MMP 9 gene promoter activity in the absence of RANKL. Taken together, our results suggest that RANKL signals through TRAF6 and that NFATc1 is a downstream effector of RANKL signaling to modulate MMP 9 gene expression during osteoclast differentiation. (c) 2006 Elsevier Inc. All rights reserved.
C1 Charles P Darby Childrens Res Inst, Charleston, SC 29425 USA.
   Osaka Univ, Grad Sch Dent, Dept Biochem, Osaka, Japan.
   Med Univ S Carolina, Coll Dent Med, Charleston, SC 29425 USA.
C3 University of Osaka; Medical University of South Carolina
RP Reddy, SV (通讯作者)，Charles P Darby Childrens Res Inst, 173 Ashley Ave, Charleston, SC 29425 USA.
EM reddysv@musc.edu
RI Reddy, Sakamuri/H 6419 2019
OI Nishimura, Riko/0000 0001 7279 8363
FU NCRR NIH HHS [C06 RR015455] Funding Source: Medline; NIDCR NIH HHS [DE
   12603] Funding Source: Medline
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559
   Crotti TN, 2006, GENE, V372, P92, DOI 10.1016/j.gene.2005.12.012
   Delaissé JM, 2003, MICROSC RES TECHNIQ, V61, P504, DOI 10.1002/jemt.10374
   Hirotani H, 2004, J BIOL CHEM, V279, P13984, DOI 10.1074/jbc.M213067200
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hong S, 2005, J BIOL CHEM, V280, P25202, DOI 10.1074/jbc.M413985200
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kanazawa K, 2005, J BONE MINER RES, V20, P840, DOI 10.1359/JBMR.041225
   Kanazawa K, 2003, J BONE MINER RES, V18, P443, DOI 10.1359/jbmr.2003.18.3.443
   Kato Y, 2005, J BIOL CHEM, V280, P10938, DOI 10.1074/jbc.M411313200
   Koide M, 2003, J BONE MINER RES, V18, P458, DOI 10.1359/jbmr.2003.18.3.458
   Komarova SV, 2005, P NATL ACAD SCI USA, V102, P2643, DOI 10.1073/pnas.0406874102
   Kusano K, 1998, ENDOCRINOLOGY, V139, P1338, DOI 10.1210/en.139.3.1338
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li XT, 2002, ENDOCRINOLOGY, V143, P3105, DOI 10.1210/en.143.8.3105
   Li XT, 2003, ENDOCRINOLOGY, V144, P4999, DOI 10.1210/en.2003 0166
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Mukhopadhyay S, 2004, J BIOL CHEM, V279, P33139, DOI 10.1074/jbc.M405194200
   Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588
   Ortega N, 2005, MOL BIOL CELL, V16, P3028, DOI 10.1091/mbc.e04 12 1119
   Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543
   Quesada AR, 1997, CLIN EXP METASTAS, V15, P26
   Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707
   REPONEN P, 1994, J CELL BIOL, V124, P1091, DOI 10.1083/jcb.124.6.1091
   Roach J, 1998, GENE, V208, P117, DOI 10.1016/S0378 1119(97)00609 4
   Spessotto P, 2002, J CELL BIOL, V158, P1133, DOI 10.1083/jcb.200202120
   Srinivasan S, 2006, GENE, V371, P16, DOI 10.1016/j.gene.2005.11.001
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Theoleyre S, 2004, BBA MOL CELL RES, V1644, P1, DOI 10.1016/j.bbamcr.2003.10.005
   Tsai CH, 2005, J ENDODONT, V31, P860, DOI 10.1097/01.don.0000164851.55389.4e
   Vignery A, 2000, INT J EXP PATHOL, V81, P291, DOI 10.1046/j.1365 2613.2000.00164.x
   Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092 8674(00)81169 1
   Wittrant Y, 2003, BIOCHEM BIOPH RES CO, V310, P774, DOI 10.1016/j.bbrc.2003.09.084
   WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549
   Yang CR, 2004, CELL DEATH DIFFER, V11, pS97, DOI 10.1038/sj.cdd.4401403
   Yu XF, 2003, J BONE MINER RES, V18, P1404, DOI 10.1359/jbmr.2003.18.8.1404
   Zhou M, 2003, J BIOL CHEM, V278, P45406, DOI 10.1074/jbc.M309075200
NR 45
TC 178
Z9 203
U1 0
U2 12
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
J9 EXP CELL RES
JI Exp. Cell Res.
PD JAN 1
PY 2007
VL 313
IS 1
BP 168
EP 178
DI 10.1016/j.yexcr.2006.10.001
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 123NS
UT WOS:000243303200015
PM 17084841
DA 2025 08 17
ER

PT J
AU Shan, ZS
   Zhao, YY
   Qiu, ZX
   Angxiu, SN
   Gu, Y
   Luo, JN
   Bi, HT
   Luo, W
   Xiong, R
   Ma, SQ
   He, Z
   Chen, L
AF Shan, Zhongshu
   Zhao, Yanyan
   Qiu, Zhixue
   Angxiu, Suonan
   Gu, Yong
   Luo, Junning
   Bi, Hongtao
   Luo, Wei
   Xiong, Rui
   Ma, Siqing
   He, Zhao
   Chen, Liang
TI Conjugated linoleic acid prompts bone formation in ovariectomized
   osteoporotic rats and weakens osteoclast formation after treatment with
   ultraviolet B
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Ultraviolet light B (UVB); conjugated linoleic acid (CLA); osteogenic
   inhibition; osteoclast promotion; ovariectomized model rats
ID HORMONE REPLACEMENT THERAPY; PREVENTION
AB Background: Ultraviolet B (UVB) has been reported to prevent bone loss by promoting the synthesis of vitamin D. However, UVB can also enhance osteoclastic differentiation, inhibit osteogenic differentiation, and cause oxidative damage. The present study aimed to analyze the osteoprotective effects of UVB and conjugated linoleic acid (CLA) in rats with ovariectomy induced osteoporosis, and to determine the interactions between UVB and CLA and their effects on bone mesenchymal stem cells (BMSCs) and bone marrow mononuclear cells (BMMCs).
   Methods: In vitro, the distance of UVB irradiation and the dose of CLA were selected by immunofluorescence assays and Cytotoxicity assay. BMSCs and BMMCs were detected by immunohistochemical and immunofluorescence assays. In vivo, three month old female Sprague Dawley rats that had undergone ovariectomy were treated with UVB and CLA. After 8 weeks of therapy, the femurs of the rats were examined by micro computed tomography (CT) and immunohistochemical detection to assess the therapeutic efficacy.
   Results: The least inhibitive UVB distance and dosage of CLA were selected for the in vivo experiments. CLA effectively weakened the osteogenic inhibitory effect of UVB (72 cm), significantly improved the activity of alkaline phosphatase (ALP), promoted the formation of mineralized nodules, and alleviated the oxidative damage induced by UVB. CLA also effectively weakened the osteoclast promoting effect of UVB (72 cm), inhibited osteoclast formation, and inhibited the inflammatory damage to BMMCs caused by UVB (72 cm) irradiation. Micro CT results showed that UVB irradiation could promote bone formation in ovariectomized Sprague Dawley rats, while CLA could significantly promote bone regeneration. Immunofluorescence assays results showed that CLA alleviated UVB induced oxidative damage to osteoblasts. The ROS detection results demonstrated that CLA effectively alleviated UVB induced oxidative damage to BMSCs. Furthermore, Immunohistochemical assays showed that UVB and CLA treatment increased bone density, inhibited osteolytic osteolysis, and enhanced osteogenic activity.
   Conclusions: CLA can effectively weaken osteoclast promotion, osteogenic inhibition, and oxidative damage caused by UVB. Combination treatment of UVB and CLA exerts an osteoprotective effect on ovariectomized osteoporotic rats and stimulates osteogenesis. The molecular mechanism of this interaction requires further investigation.
C1 [Shan, Zhongshu; Gu, Yong; Chen, Liang] Soochow Univ, Affiliated Hosp 1, Dept Orthoped Surg, 188 Shizi St, Suzhou 215006, Peoples R China.
   [Shan, Zhongshu; Zhao, Yanyan; Qiu, Zhixue; Angxiu, Suonan; He, Zhao] Peoples Hosp Qinghai Prov, Dept Orthoped Surg, Xining, Peoples R China.
   [Luo, Junning] Peoples Hosp Qinghai Prov, Dept Pathol, Xining, Peoples R China.
   [Bi, Hongtao] Chinese Acad Sci, Northwest Inst Plateau Biol, Qinghai Prov Key Lab Tibetan Med Pharmacol & Safe, Xining, Peoples R China.
   [Luo, Wei] Peoples Hosp Qinghai Prov, Dept Endocrinol, Xining, Peoples R China.
   [Xiong, Rui] Peoples Hosp Qinghai Prov, Nutr Dept, Xining, Peoples R China.
   [Ma, Siqing] Peoples Hosp Qinghai Prov, Dept Crit Care Med, Xining, Peoples R China.
C3 Soochow University   China; Chinese Academy of Sciences
RP Chen, L (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthoped Surg, 188 Shizi St, Suzhou 215006, Peoples R China.
EM chenliangspine@163.com
RI ; Chen, Liang/JYQ 1606 2024; Luo, wei/JDV 6350 2023; Bi,
   Hongtao/AAJ 3106 2020; Gu, Yong/KDN 9278 2024
OI Chen, Liang/0000 0001 8016 7596; gu, yong/0000 0002 0482 1610; 
FU Natural Science Foundation of China [81760396]; Natural Science
   Foundation of Qinghai Province [2018 ZJ 715]; Science and Technology
   Foundation Platform of Qinghai Province [2020 ZJ T08]
FX This work was supported by the Natural Science Foundation of China
   (grant No. 81760396), the Natural Science Foundation of Qinghai Province
   (grant No. 2018 ZJ 715), and the Science and Technology Foundation
   Platform of Qinghai Province (grant No. 2020 ZJ T08).
CR Anastasilakis AD, 2018, EUR J ENDOCRINOL, V179, pR31, DOI 10.1530/EJE 18 0056
   Arab K, 2006, BRIT J NUTR, V96, P811, DOI 10.1017/BJN20061910
   Bacon CJ, 2009, OSTEOPOROSIS INT, V20, P1407, DOI 10.1007/s00198 008 0814 9
   Blankson H, 2000, J NUTR, V130, P2943, DOI 10.1093/jn/130.12.2943
   Brownbill RA, 2005, J AM COLL NUTR, V24, P177, DOI 10.1080/07315724.2005.10719463
   Castelo Branco C, 1999, EUR J OBSTET GYN R B, V83, P207, DOI 10.1016/S0301 2115(98)00313 3
   Chan WH, 2003, J CELL BIOCHEM, V90, P327, DOI 10.1002/jcb.10638
   Chandra P, 2007, PHOTODERMATOL PHOTO, V23, P179, DOI 10.1111/j.1600 0781.2007.00302.x
   Doyle L, 2005, EUR J CLIN NUTR, V59, P432, DOI 10.1038/sj.ejcn.1602093
   Eastell R, 2009, J CLIN ENDOCR METAB, V94, P3215, DOI 10.1210/jc.2008 2765
   Erkal MZ, 2006, OSTEOPOROSIS INT, V17, P1133, DOI 10.1007/s00198 006 0069 2
   Ferguson G. W., 2009, Journal of Herpetological Medicine and Surgery, V19, P81
   Gambacciani M, 2019, CLIMACTERIC, V22, P303, DOI 10.1080/13697137.2018.1551347
   Gaullier JM, 2005, J NUTR, V135, P778
   Gavilanez EL, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0644 8
   Glowacki J, 2003, J BONE JOINT SURG AM, V85A, P2371, DOI 10.2106/00004623 200312000 00015
   Halliday GM, 2010, J INVEST DERMATOL, V130, P1209, DOI 10.1038/jid.2009.374
   HEYBURN PJ, 1983, EUR J CLIN INVEST, V13, P41, DOI 10.1111/j.1365 2362.1983.tb00062.x
   Hirakawa S, 2005, BLOOD, V105, P2392, DOI 10.1182/blood 2004 06 2435
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   Holick MF, 2007, J BONE MINER RES, V22, pV28, DOI 10.1359/JBMR.07S211
   Jackson S, 2000, GENE DEV, V14, P3065, DOI 10.1101/gad.182100
   Jin YM, 2018, VACCINE, V36, P5235, DOI 10.1016/j.vaccine.2018.07.038
   Karppinen T, 2017, INT J CIRCUMPOL HEAL, V76, DOI 10.1080/22423982.2016.1272790
   Katiyar SK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021410
   Kelly O, 2003, BRIT J NUTR, V90, P743, DOI 10.1079/BJN2003951
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Kim JH, 2016, ANNU REV FOOD SCI T, V7, P221, DOI 10.1146/annurev food 041715 033028
   Kragballe K, 2002, CUTIS, V70, P9
   Lee J, 2011, N AM J MED SCI, V3, P13, DOI 10.4297/najms.2011.313
   Lucatto JN, 2014, J CANDIDO TOSTES DAI, V69, P199, DOI 10.14295/2238 6416.v69i3.282
   Ma DWL, 1999, J AGR FOOD CHEM, V47, P1956, DOI 10.1021/jf981002u
   Narayanan DL, 2010, INT J DERMATOL, V49, P978, DOI 10.1111/j.1365 4632.2010.04474.x
   Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711
   Platt I, 2007, EXP BIOL MED, V232, P246
   Platt ID, 2009, J NUTR BIOCHEM, V20, P956, DOI 10.1016/j.jnutbio.2008.08.008
   Rahman MM, 2014, LIPIDS, V49, P211, DOI 10.1007/s11745 013 3872 5
   Roberts DCK., 1995, FOOD AUSTR OFFICIAL
   Rozenberg S, 1998, DRUG AGING, V13, P33, DOI 10.2165/00002512 199813010 00004
   Salucci S, 2013, INT J MOL SCI, V14, P532, DOI 10.3390/ijms14010532
   Teede HJ, 2011, AUST FAM PHYSICIAN, V40, P280
   Trummer C, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13101028
   Wakatsuki A, 1998, MATURITAS, V28, P229, DOI 10.1016/S0378 5122(97)00072 8
   Watts NB, 2018, J WOMENS HEALTH, V27, P1093, DOI 10.1089/jwh.2017.6706
   Wölfle U, 2011, FREE RADICAL BIO MED, V50, P1081, DOI 10.1016/j.freeradbiomed.2011.01.027
   Yoshitomi Y, 2019, BIOL OPEN, V8, DOI 10.1242/bio.035691
   Zhang HJ, 2005, BRIT J NUTR, V94, P746, DOI 10.1079/BJN20051482
NR 47
TC 3
Z9 3
U1 2
U2 12
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305 5839
EI 2305 5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD MAR
PY 2021
VL 9
IS 6
AR 503
DI 10.21037/atm 21 934
PG 18
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA RF8LL
UT WOS:000635089700016
PM 33850900
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Karosas, AO
AF Karosas, Ann O.
TI Ewing's sarcoma
SO AMERICAN JOURNAL OF HEALTH SYSTEM PHARMACY
LA English
DT Article
DE Antineoplastic agents; Cyclophosphamide; Epidemiology; Irinotecan;
   Mechanism of action; Mortality; Pediatrics; Radiation; Sarcoma; Site of
   action; Surgery; Temozolomide; Topotecan; Vincristine
ID CHILDRENS ONCOLOGY GROUP; PRIMITIVE NEUROECTODERMAL TUMOR; STEM CELL
   TRANSPLANTATION; TOTAL BODY IRRADIATION; SOLID TUMORS; MULTIMODAL
   THERAPY; IMATINIB MESYLATE; PHASE II; BONE; ETOPOSIDE
AB Purpose. The current treatments of and new therapeutic options for the management of Ewing's sarcoma (ES) are reviewed.
   Summary. ES is the second most common primary bone malignancy in pediatric patients and is numbered among the cancers that result in the greatest risk of mortality and morbidity in children and young adults. Much progress has been made in the treatment of ES since the disease was first described in the 1920s. With current multimodality treatment including chemotherapy, radiation, and surgery, patients with localized disease have a long term survival rate of approximately 50%. Survival rates for patients with metastatic disease or those with early relapse remain poor. New combinations of cytotoxic agents such as cyclophosphamide, topotecan, irinotecan, and temozolomide have shown efficacy and tolerability in patients with relapsed or refractory disease. To date, the role of high dose chemotherapy supported by stem cell rescue as a consolidation therapy for high risk ES tumors has yet to be conclusively determined. Much effort is being invested in treating cancer with targeted therapies, and the EWS ETS fusion gene would likely provide an important tumor specific target. Tyrosine kinases (TKs) are overexpressed in human sarcoma tumors, and cell lines may serve as potential targets for new therapies. One TK receptor that is a promising therapeutic target is insulinlike growth factor 1 receptor.
   Conclusion. Treatments for ES include surgery, radiation, and cytotoxic regimens, many of which include vincristine. Treatment for recurrent ES has included topotecan, cyclophosphamide, temozolomide, and irinotecan. Angiogenesis inhibitors, TK inhibitors, and bisphosphonates have also been studied.
C1 Geisinger Med Ctr, Danville, PA 17822 USA.
C3 Geisinger Medical Center
RP Karosas, AO (通讯作者)，Geisinger Med Ctr, 100 N Acad Ave, Danville, PA 17822 USA.
EM akarosas@geisinger.edu
CR Åhlén J, 2005, CLIN CANCER RES, V11, P206
   Al Faris N, 2007, PEDIATR BLOOD CANCER, V49, P190, DOI 10.1002/pbc.21140
   Anderson P, 2008, EXPERT OPIN INV DRUG, V17, P1703, DOI [10.1517/13543784.17.11.1703, 10.1517/13543784.17.11.1703 ]
   Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145
   Ashford Robert U., 2002, Sarcoma, V6, P131, DOI 10.1080/1357714021000022140
   Atra A, 1997, BONE MARROW TRANSPL, V20, P843, DOI 10.1038/sj.bmt.1700992
   Barker LM, 2005, J CLIN ONCOL, V23, P4354, DOI 10.1200/JCO.2005.05.105
   Bernstein M, 2005, PRINCIPLES PRACTICE, P1002
   Bond M, 2008, PEDIATR BLOOD CANCER, V50, P254, DOI 10.1002/pbc.21132
   Carvajal R, 2005, HEMATOL ONCOL CLIN N, V19, P501, DOI 10.1016/j.hoc.2005.03.004
   Champagne MA, 2004, BLOOD, V104, P2655, DOI 10.1182/blood 2003 09 3032
   Cheung CC, 2001, ARCH PATHOL LAB MED, V125, P1358
   *CHILDR ONC GROUP, PHAS 2 STUD IMC A12
   Clézardin P, 2000, JOINT BONE SPINE, V67, P22
   *CLINICALTRIALS, VINCR TOP CYCL BEV T
   *CLINICALTRIALS, TRIAL DAS ADV SARC
   COTTERILL S, 1866, J EWING
   DeLaney TF, CLIN PRESENTATION ST
   EVANS RG, 1991, J CLIN ONCOL, V9, P1173, DOI 10.1200/JCO.1991.9.7.1173
   Fraser CJ, 2006, BONE MARROW TRANSPL, V37, P175, DOI 10.1038/sj.bmt.1705224
   Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890
   HOROWITZ ME, 1993, J CLIN ONCOL, V11, P1911, DOI 10.1200/JCO.1993.11.10.1911
   Hunold A, 2006, PEDIATR BLOOD CANCER, V47, P795, DOI 10.1002/pbc.20719
   HUSTU HO, 1972, CANCER, V30, P1522, DOI 10.1002/1097 0142(197212)30:6<1522::AID CNCR2820300617>3.0.CO;2 J
   Iwamoto Y, 2007, JPN J CLIN ONCOL, V37, P79, DOI 10.1093/jjco/hyl142
   JURGENS H, 1988, CANCER, V61, P23, DOI 10.1002/1097 0142(19880101)61:1<23::AID CNCR2820610106>3.0.CO;2 M
   KRETSCHMAR CS, 1994, NEW ENGL J MED, V331, P325, DOI 10.1056/NEJM199408043310512
   KUNG FH, 1993, CANCER AM CANCER SOC, V71, P1898, DOI 10.1002/1097 0142(19930301)71:5<1898::AID CNCR2820710529>3.0.CO;2 Q
   Maki RG, 2008, J SURG ONCOL, V97, P360, DOI 10.1002/jso.20969
   MARIANI S, TARGETING CANC CELLS
   Mehta P, 1999, NEW ENGL J MED, V341, P1701
   Meyers PA, 2001, J CLIN ONCOL, V19, P2812, DOI 10.1200/JCO.2001.19.11.2812
   Miser JS, 2004, J CLIN ONCOL, V22, P2873, DOI 10.1200/JCO.2004.01.041
   MISER JS, 1987, J CLIN ONCOL, V5, P1191, DOI 10.1200/JCO.1987.5.8.1191
   Navid F, 2006, CANCER AM CANCER SOC, V106, P1846, DOI 10.1002/cncr.21810
   NESBIT ME, 1990, J CLIN ONCOL, V8, P1664, DOI 10.1200/JCO.1990.8.10.1664
   Oberlin O, 2006, J CLIN ONCOL, V24, P3997, DOI 10.1200/JCO.2006.05.7059
   Paulussen M, 2001, J CLIN ONCOL, V19, P1818, DOI 10.1200/JCO.2001.19.6.1818
   PINKEL D, 1962, CANCER AM CANCER SOC, V15, P42, DOI 10.1002/1097 0142(196201/02)15:1<42::AID CNCR2820150107>3.0.CO;2 D
   Ricchetti ET, 2005, CLIN ORTHOP RELAT R, P248, DOI 10.1097/01.blo.0000128641.53637.c9
   ROSEN G, 1974, CANCER AM CANCER SOC, V33, P384, DOI 10.1002/1097 0142(197402)33:2<384::AID CNCR2820330213>3.0.CO;2 T
   Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008 5472.CAN 04 3192
   Shor Audrey C, 2008, Cancer Control, V15, P47
   Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008 5472.CAN 06 3469
   Snyder KM, 2007, PEDIATR BLOOD CANCER, V49, P115, DOI 10.1002/pbc.21238
   SUTOW WW, 1962, CANCER CHEMOTH REP, P55
   Wagner LM, 2007, PEDIATR BLOOD CANCER, V48, P132, DOI 10.1002/pbc.20697
   Womer RB, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.10504
   Yamada K, 2007, BONE MARROW TRANSPL, V39, P471, DOI 10.1038/sj.bmt.1705625
   Yock, 2006, J CLIN ONCOL, V24, P4947, DOI 10.1200/JCO.2006.09.001
   Yock TI, 2006, J CLIN ONCOL, V24, P3838, DOI 10.1200/JCO.2006.05.9188
NR 51
TC 29
Z9 36
U1 0
U2 3
PU AMER SOC HEALTH SYSTEM PHARMACISTS
PI BETHESDA
PA 7272 WISCONSIN AVE, BETHESDA, MD 20814 USA
SN 1079 2082
EI 1535 2900
J9 AM J HEALTH SYST PH
JI Am. J. Health Syst. Pharm.
PD OCT 1
PY 2010
VL 67
IS 19
BP 1599
EP 1605
DI 10.2146/ajhp090526
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 858BT
UT WOS:000297771600010
PM 20852160
DA 2025 08 17
ER

PT J
AU Piao, HY
   Kim, MH
   Cui, ML
   Choi, G
   Choy, JH
AF Piao, Huiyan
   Kim, Myung Hun
   Cui, Meiling
   Choi, Goeun
   Choy, Jin Ho
TI Alendronate Anionic Clay Nanohybrid for Enhanced Osteogenic
   Proliferation and Differentiation
SO JOURNAL OF KOREAN MEDICAL SCIENCE
LA English
DT Article
DE Drug Delivery System; Inorganic Delivery Vehicle; Layered Double
   Hydroxide; Alendronate; Osteogenic Proliferation and Differentiation;
   Drug Clay Nanohybrid
ID LAYERED DOUBLE HYDROXIDE; DRUG DELIVERY; UPTAKE MECHANISM; CELLULAR
   UPTAKE; BISPHOSPHONATES; NANOPARTICLES; SYSTEM
AB Background: Alendronate (AL), a drug for inhibiting osteoclast mediated bone  resorption, was intercalated into an inorganic drug delivery nanovehicle, layered double hydroxide (LDH), to form a new nanohybrid, AL LDH, with 1:1 heterostructure along the crystallographic C axis. Based on the intercalation reaction strategy, the present AL LDH drug delivery system (DDS) was realized with an enhanced drug efficacy of AL, which was confirmed by the improved proliferation and osteogenic differentiation of osteoblast like cells (MG63).
   Methods: The AL LDH nanohybrid was synthesized by conventional ion exchange reaction and characterized by powder X ray diffraction (PXRD), high resolution transmission electron microscopy (HR TEM), and Fourier transform infrared (FT IR) spectroscopy. Additionally, in vitro efficacy tests, such as cell proliferation and alkaline phosphatase (ALP) activity, were analyzed.
   Results: The AL was successfully intercalated into LDH via ion exchange reaction, and thus prepared AL LDH DDS was X ray single phasic and chemically well defined. The accumulated AL content in MG63 cells treated with the AL LDH DDS nanoparticles was determined to be 10.6 fold higher than that within those treated with the intact AL after incubation for 1 hour, suggesting that intercellular permeation of AL was facilitated thanks to the hybridization with drug delivery vehicle, LDH. Furthermore, both in vitro proliferation level and ALP activity of MG63 treated with the present hybrid drug, AL LDH, were found to be much more enhanced than those treated with the intact AL. This is surely due to the fact that LDH could deliver AL drug very efficiently, although LDH itself does not show any effect on proliferation and osteogenic differentiation of MG63 cells.
   Conclusion: The present AL LDH could be considered as a promising DDS for improving efficacy of AL.
C1 [Piao, Huiyan; Kim, Myung Hun; Cui, Meiling; Choi, Goeun; Choy, Jin Ho] Ewha Womans Univ, Ctr Intelligent Nanobio Mat, Dept Chem & Nanosci, Seoul 03760, South Korea.
   [Choi, Goeun] Dankook Univ, Inst Tissue Regenerat Engn, Cheonan, South Korea.
C3 Ewha Womans University; Dankook University
RP Choy, JH (通讯作者)，Ewha Womans Univ, Ctr Intelligent Nanobio Mat, Dept Chem & Nanosci, Seoul 03760, South Korea.
EM jhchoy@ewha.ac.kr
RI ; Myung Hun, Kim/R 9249 2019; Choi, Goeun/AHC 8745 2022
OI Choi, Goeun/0000 0002 5424 8322; Choy, Jin Ho/0000 0002 4149 7100; 
FU  [2017K2A9A2A10013104]
FX This work was supported under the framework of international cooperation
   program managed by National Research Foundation of Korea (No.
   2017K2A9A2A10013104).
CR Benyettou F, 2011, J MATER CHEM, V21, P4813, DOI [10.1039/c1jm00060h, 10.1039/cljm00060h]
   Bukowski JF, 2005, BIOCHEM BIOPH RES CO, V328, P746, DOI 10.1016/j.bbrc.2004.11.075
   Chakraborti M, 2011, INT J PHARMACEUT, V416, P305, DOI 10.1016/j.ijpharm.2011.06.016
   Choi G, 2018, CHEM REC, V18, P1033, DOI 10.1002/tcr.201700091
   Choi G, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201704470
   Choi G, 2018, COORDIN CHEM REV, V359, P32, DOI 10.1016/j.ccr.2018.01.007
   Choi G, 2016, INT J NANOMED, V11, P337, DOI 10.2147/IJN.S95611
   Choi G, 2010, INT J PHARMACEUT, V402, P117, DOI 10.1016/j.ijpharm.2010.09.039
   Choi SJ, 2011, NANOMEDICINE UK, V6, P803, DOI [10.2217/NNM.11.86, 10.2217/nnm.11.86]
   Choi SJ, 2011, J MATER CHEM, V21, P5547, DOI 10.1039/c1jm10167f
   Choi SJ, 2009, J CERAM SOC JPN, V117, P543, DOI 10.2109/jcersj2.117.543
   Choy JH, 2000, ANGEW CHEM INT EDIT, V39, P4042
   Errassifi F, 2014, J COLLOID INTERF SCI, V420, P101, DOI 10.1016/j.jcis.2014.01.017
   Fazil M, 2015, DRUG DELIV, V22, P1, DOI 10.3109/10717544.2013.870259
   Gu Z, 2015, J MATER CHEM B, V3, P3331, DOI 10.1039/c5tb00248f
   Indrigo E, 2017, CHEM COMMUN, V53, P6712, DOI 10.1039/c7cc02988h
   Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kim MH, 2016, ADV HEALTHC MATER, V5, P2765, DOI 10.1002/adhm.201600761
   Kuljanin J, 2002, J PHARMACEUT BIOMED, V28, P1215, DOI 10.1016/S0731 7085(02)00021 3
   Lee SS, 2017, ACS APPL MATER INTER, V9, P42668, DOI 10.1021/acsami.7b17173
   Li SD, 2013, J MATER CHEM B, V1, P61, DOI 10.1039/c2tb00081d
   Liu XM, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/6/065008
   Lv FZ, 2015, ACS APPL MATER INTER, V7, P19104, DOI 10.1021/acsami.5b04569
   Oh JM, 2006, BIOCONJUGATE CHEM, V17, P1411, DOI 10.1021/bc0601323
   Oh JM, 2012, RECENT PAT NANOTECH, V6, P200, DOI 10.2174/187221012803531538
   Park DH, 2016, ARAB J CHEM, V9, P190, DOI 10.1016/j.arabjc.2015.07.007
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Stewart MP, 2018, CHEM REV, V118, P7409, DOI 10.1021/acs.chemrev.7b00678
   Tan CL, 2017, CHEM REV, V117, P6225, DOI 10.1021/acs.chemrev.6b00558
   Tan YF, 2018, J CONTROL RELEASE, V284, P39, DOI 10.1016/j.jconrel.2018.06.014
   von Knoch F, 2005, BIOMATERIALS, V26, P6941, DOI 10.1016/j.biomaterials.2005.04.059
   Xiong Y, 2009, J INT MED RES, V37, P407, DOI 10.1177/147323000903700216
   Yang JH, 2007, CHEM MATER, V19, P2679, DOI 10.1021/cm070259h
   Zhai YH, 2018, ADV MATER, V30, DOI 10.1002/adma.201802378
NR 36
TC 20
Z9 20
U1 1
U2 11
PU KOREAN ACAD MEDICAL SCIENCES
PI SEOUL
PA 302 75 DONG DU ICHON, DONG YONGSAN KU, SEOUL 140 031, SOUTH KOREA
SN 1011 8934
EI 1598 6357
J9 J KOREAN MED SCI
JI J. Korean Med. Sci.
PD FEB 4
PY 2019
VL 34
IS 5
AR e37
DI 10.3346/jkms.2019.34.e37
PG 17
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA HL9ZG
UT WOS:000459102800002
PM 30718990
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, S
   De Becker, A
   De Raeve, H
   Van Camp, B
   Vanderkerken, K
   Van Riet, I
AF Xu, Song
   De Becker, Ann
   De Raeve, Hendrik
   Van Camp, Ben
   Vanderkerken, Karin
   Van Riet, Ivan
TI In vitro expanded bone marrow derived murine (C57B1/KaLwRij)
   mesenchymal stem cells can acquire CD34 expression and induce sarcoma
   formation in vivo
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mesenchymal stem cells; Malignant transformation; Sarcoma
ID HUMAN ADIPOSE TISSUE; PROTEASOME INHIBITION; STEM/PROGENITOR CELLS;
   TRANSFORMATION; APOPTOSIS; GROWTH; TUMOR; RHABDOMYOSARCOMA;
   IDENTIFICATION; SUPPRESSES
AB Mesenchymal stem cells (MSCs) have currently generated numerous interests in pre clinical and clinical applications due to their multiple lineages differentiation potential and immunomodulary effects. However, accumulating evidence indicates that MSCs, especially murine MSCs (mMSCs), can undergo spontaneous transformation after long term in vitro culturing, which might reduce the therapeutic application possibilities of these stem cells. In the present study, we observed that in vitro expanded bone marrow (BM) derived mMSCs from the C57BI/KaLwRij mouse strain can lose their specific stem cells markers (CD90 and CD105) and acquire CD34 expression, accompanied with an altered morphology and an impaired tri lineages differentiation capacity. Compared to normal mMSCs, these transformed mMSCs exhibited an increased proliferation rate, an enhanced colony formation and migration ability as well as a higher sensitivity to anti tumor drugs. Transformed mMSCs were highly tumorigenic in vivo, resulting in aggressive sarcoma formation when transplanted in non immunocompromised mice. Furthermore, we found that Notch signaling downstream genes (hey1, hey2 and heyL) were significantly upregulated in transformed mMSCs, while Hedgehog signaling downstream genes Gli1 and Ptch1 and the Wnt signaling downstream gene beta catenin were all decreased. Taken together, we observed that murine in vitro expanded BM MSCs can transform into CD34 expressing cells that induce sarcoma formation in vivo. We assume that dysregulation of the Notch(+)/Hh( )/Wnt( ) signaling pathway is associated with the malignant phenotype of the transformed mMSCs. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Xu, Song; De Becker, Ann; Van Riet, Ivan] Univ Ziekenhuis Brussel UZ Brussel, Stem Cell Lab, Div Clin Hematol, B 1090 Brussels, Belgium.
   [Xu, Song] Tianjin Med Univ, Gen Hosp, Lung Canc Inst, Dept Lung Canc Surg, Tianjin 300052, Peoples R China.
   [Xu, Song; Van Camp, Ben; Vanderkerken, Karin; Van Riet, Ivan] Vrije Univ Brussel, Myeloma Ctr, Dept Hematol & Immunol, B 1090 Brussels, Belgium.
   [De Raeve, Hendrik] Univ Ziekenhuis Brussel UZ Brussel, Dept Anatomopathol, B 1090 Brussels, Belgium.
C3 University Hospital Brussels; Vrije Universiteit Brussel; Tianjin
   Medical University; Vrije Universiteit Brussel; Vrije Universiteit
   Brussel; University Hospital Brussels
RP Van Riet, I (通讯作者)，Univ Ziekenhuis Brussel UZ Brussel, Stem Cell Lab, Div Clin Hematol, Laarbeeklaan 101, B 1090 Brussels, Belgium.
EM ivan.vanriet@uzbrussel.be
RI ; Vanderkerken, Karin/I 3513 2013
OI De Becker, Ann/0000 0003 0947 8708; Vanderkerken,
   Karin/0000 0002 2137 7179
FU CSC VUB scholarship; FWO Vlaanderen; Vlaamse Liga tegen Kanker
   (Stichting Emmanuel Van der Schueren); Vrije Universiteit Brussel (HOA);
   Scientific Foundation Willy Gepts (WFWG) UZ Brussel
FX We would like to thank Nicole Arras, Wim Renmans, Angelo Willems, Carine
   Seynaeve, for their expert technical assistance, and Prof. Zhou Qinghua
   for his administrative support. We thank Merck & Co for providing
   Vorinostat. Our research work is supported by Grants from the
   FWO Vlaanderen, Vlaamse Liga tegen Kanker (Stichting Emmanuel Van der
   Schueren), the Vrije Universiteit Brussel (HOA) and the Scientific
   Foundation Willy Gepts (WFWG) UZ Brussel. Xu S is supported by CSC VUB
   scholarship.
CR Al Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008 5472.CAN 06 4690
   Bersani F, 2008, EUR J CANCER, V44, P876, DOI 10.1016/j.ejca.2008.02.022
   Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628
   Campagnoli C, 2001, BLOOD, V98, P2396, DOI 10.1182/blood.V98.8.2396
   Chiba H, 2008, STEM CELLS, V26, P2523, DOI 10.1634/stemcells.2008 0037
   Choijamts B, 2011, STEM CELLS, V29, P1485, DOI 10.1002/stem.711
   De Becker A, 2007, HAEMATOLOGICA, V92, P440, DOI 10.3324/haematol.10475
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Gursel Demirkan B, 2011, Cancers (Basel), V3, P2655, DOI 10.3390/cancers3022655
   Hrzenjak A, 2008, J PATHOL, V216, P495, DOI 10.1002/path.2434
   Hrzenjak A, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 49
   in't Anker PS, 2004, STEM CELLS, V22, P1338, DOI 10.1634/stemcells.2004 0058
   in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood 2003 04 1291
   Jeong JO, 2011, CIRC RES, V108, P1340, DOI 10.1161/CIRCRESAHA.110.239848
   JONES RR, 1995, J CLIN PATHOL, V48, P1011, DOI 10.1136/jcp.48.11.1011
   Josse C, 2010, STEM CELLS DEV, V19, P1167, DOI 10.1089/scd.2009.0264
   Kassem M, 2008, CELL TISSUE RES, V331, P157, DOI 10.1007/s00441 007 0509 0
   Kawabata N, 2011, INT J ONCOL, V39, P899, DOI 10.3892/ijo.2011.1076
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lu GR, 2008, CANCER BIOL THER, V7, P603, DOI 10.4161/cbt.7.4.5564
   Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377
   Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005 0403
   Nakamizo A, 2005, CANCER RES, V65, P3307, DOI 10.1158/0008 5472.CAN 04 1874
   Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078 0432.CCR 10 0166
   Rubio D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001398
   Shapovalov Y, 2010, INT J CANCER, V127, P67, DOI 10.1002/ijc.25024
   Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137
   Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432 007 0227 8
   Suvà ML, 2009, CANCER RES, V69, P1776, DOI 10.1158/0008 5472.CAN 08 2242
   Tang DG, 2007, MOL CARCINOGEN, V46, P1, DOI 10.1002/mc.20255
   Tang YL, 2005, METH MOLEC MED, V112, P183
   Tasso R, 2009, CARCINOGENESIS, V30, P150, DOI 10.1093/carcin/bgn234
   Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008 5472.CAN 10 3418
   Tirode F, 2007, CANCER CELL, V11, P421, DOI 10.1016/j.ccr.2007.02.027
   Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005 0620
   Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449
   Vilalta M, 2008, STEM CELLS DEV, V17, P993, DOI 10.1089/scd.2007.0201
   Yamamoto S, 2008, ANTICANCER RES, V28, P1585
   Yamanaka H, 2011, J PEDIATR SURG, V46, P320, DOI 10.1016/j.jpedsurg.2010.11.010
   Zhang PY, 2008, CLIN CANCER RES, V14, P2962, DOI 10.1158/1078 0432.CCR 07 1992
   Zhang SJ, 2010, CHEM BIOL INTERACT, V188, P119, DOI 10.1016/j.cbi.2010.06.008
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 45
TC 13
Z9 14
U1 0
U2 9
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD AUG 3
PY 2012
VL 424
IS 3
BP 391
EP 397
DI 10.1016/j.bbrc.2012.06.118
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 990GK
UT WOS:000307618800005
PM 22771324
DA 2025 08 17
ER

PT J
AU Karga, H
   Papaioannou, G
   Polymeris, A
   Papamichael, K
   Karpouza, A
   Samouilidou, E
   Papaioannou, P
AF Karga, Helen
   Papaioannou, Garyphallia
   Polymeris, Antonis
   Papamichael, Konstantinos
   Karpouza, Angeliki
   Samouilidou, Elizabeth
   Papaioannou, Panayotis
TI The effects of recombinant human TSH on bone turnover in patients after
   thyroidectomy
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Thyrotropin; PTH; Bone; Recombinant human TSH
ID THYROTROPIN RECEPTOR; ALKALINE PHOSPHATASE; STIMULATING HORMONE; MINERAL
   METABOLISM; SERUM CYTOKINES; OSTEOPROTEGERIN; EXPRESSION; MARKERS;
   CELLS; HYPERTHYROIDISM
AB Thyrotropin receptors are expressed in several extrathyroidal tissues including bone. We investigated whether the increase of thyroid stimulating hormone (TSH) levels, under stable thyroid hormone levels, affects the bone markers. Thirty two postmenopausal women, with papillary thyroid carcinoma, previously treated with near total thyroidectomy and I 131 remnant ablation underwent routine evaluation for residual disease by using injections of recombinant human TSH (rhTSH) without withdrawal from thyroxine therapy. Changes in TSH levels and various serum and urine markers of bone metabolism were followed before and 1, 2, 5, and 7 days after the rhTSH injections. A transient, significant decrease in serum calcium and urinary excretion of C  and N terminal telopeptides of type I collagen was observed after the injections of rhTSH. Serum parathyroid hormone (PTH) started to rise along with TSH, but a significant increase of PTH was only reached on Day 5 when the TSH concentration had fallen more than 80% of the peak value. Bone alkaline phosphatase and osteocalcin did not show any significant change over time. There was no significant correlation between TSH concentration and the various parameters we measured. The study provides evidence that rhTSH produces a transient inhibition of bone resorption, as well as an attenuation of osteoblast response in spite of the PTH activation. Additional studies are needed to resolve the mechanisms by which TSH alters the response of the bone cells.
C1 [Karga, Helen; Papaioannou, Garyphallia; Polymeris, Antonis; Papamichael, Konstantinos; Karpouza, Angeliki; Samouilidou, Elizabeth; Papaioannou, Panayotis] Alexandra Hosp, Div Endocrinol & Metab 2, Athens 11528, Greece.
C3 Alexandra Hospital
RP Karga, H (通讯作者)，Alexandra Hosp, Div Endocrinol & Metab 2, Athens 11528, Greece.
EM hkarga@yahoo.gr
OI Samouilidou, Elisabeth/0000 0001 8992 0564
CR Abe E, 2003, CELL, V115, P151, DOI 10.1016/S0092 8674(03)00771 2
   Akalin A, 2002, CLIN ENDOCRINOL, V57, P125, DOI 10.1046/j.1365 2265.2002.01578.x
   Bassett JHD, 2003, TRENDS ENDOCRIN MET, V14, P356, DOI 10.1016/S1043 2760(03)00144 90
   Bauer DC, 1997, J CLIN ENDOCR METAB, V82, P2931, DOI 10.1210/jc.82.9.2931
   COINDRE JM, 1986, ARCH INTERN MED, V146, P48, DOI 10.1001/archinte.146.1.48
   COOPER DS, 1979, ANN INTERN MED, V90, P164, DOI 10.7326/0003 4819 90 2 164
   Davies T, 2002, J CLIN INVEST, V110, P161, DOI 10.1172/JCI200216234
   Dutton CM, 1997, THYROID, V7, P879, DOI 10.1089/thy.1997.7.879
   Giusti Massimo, 2007, Hormones (Athens), V6, P304
   Hase H, 2006, P NATL ACAD SCI USA, V103, P12849, DOI 10.1073/pnas.0600427103
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Inoue M, 1998, THYROID, V8, P1059, DOI 10.1089/thy.1998.8.1059
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   KROLNER B, 1983, CLIN ENDOCRINOL, V18, P439, DOI 10.1111/j.1365 2265.1983.tb02873.x
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Martini G, 2008, THYROID, V18, P455, DOI 10.1089/thy.2007.0166
   Mazziotti G, 2005, J BONE MINER RES, V20, P480, DOI 10.1359/JBMR.041126
   MOSEKILDE L, 1990, ENDOCRIN METAB CLIN, V19, P35, DOI 10.1016/S0889 8529(18)30338 4
   MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497
   Pantazi H, 2000, J CLIN ENDOCR METAB, V85, P1099, DOI 10.1210/jc.85.3.1099
   Rosselli Loreta, 1994, Bird Conservation International, V4, P143
   Sampath KT, 2005, J BONE MINER RES, V20, pS415
   Sellitti DF, 2000, EXP NEPHROL, V8, P235
   Siddiqi A, 1999, J CLIN ENDOCR METAB, V84, P435, DOI 10.1210/jc.84.2.435
   Siddiqi A, 1997, J CLIN ENDOCR METAB, V82, P753, DOI 10.1210/jc.82.3.753
   Tsai JA, 2004, CALCIFIED TISSUE INT, V74, P486, DOI 10.1007/s00223 003 0108 3
NR 26
TC 24
Z9 29
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3 8 1 NISHI KANDA, CHIYODA KU, TOKYO, 101 0065,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD JAN
PY 2010
VL 28
IS 1
BP 35
EP 41
DI 10.1007/s00774 009 0098 y
PG 7
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 536GN
UT WOS:000273033000005
PM 19548061
DA 2025 08 17
ER

PT J
AU Chen, XZ
   Li, C
   Cao, XK
   Jia, XL
   Chen, XW
   Wang, ZQ
   Xu, WF
   Dai, FR
   Zhang, SY
AF Chen, Xuzhuo
   Li, Chang
   Cao, Xiankun
   Jia, Xinlin
   Chen, Xinwei
   Wang, Zhenqiang
   Xu, Weifeng
   Dai, Fengrong
   Zhang, Shanyong
TI Mitochondria targeted supramolecular coordination container encapsulated
   with exogenous itaconate for synergistic therapy of joint inflammation
SO THERANOSTICS
LA English
DT Article
DE Coordination containers; Supermolecule; ROS scavenging; Joint
   inflammation; Exogenous itaconate
ID SUCCINATE DEHYDROGENASE; RHEUMATOID ARTHRITIS; INHIBITION; ACTIVATION;
   RATS
AB Rationale: Inflammatory macrophages and osteoclasts (OCs) play critical roles in joint inflammation, which feature the excessive production of reactive oxygen species (ROS), resulting in synovial inflammation and bone erosion. Scavenging ROS, especially by modulating mitochondrial metabolic activity, could be a desirable strategy for the management of inflammatory joints. This study aimed to develop a mitochondria targeted supramolecular drug delivery system with exogenous and endogenous ROS scavenging activities for the treatment of joint inflammation.
   Methods: In this study, we utilized a zinc based metal organic supercontainer (MOSC) as a proton sponge and electron reservoir with outstanding proton binding capacity, extracellular ROS scavenging ability, and biocompatibility to establish an efficient supramolecular nanocarrier for endo/lysosomal escape and mitochondrial targeting. 4 Octyl itaconate (4 OI), an itaconate derivative, served as the loaded guest for the construction of a synergistic therapeutic system for inflammatory macrophages and OCs.
   Results: After the effective encapsulation of 4 01, 4 OI@Zn NH pyr not only exhibited potent ROS scavenging capacity, but also reduced ROS production by mediating mitochondrial respiration in inflammatory macrophages. Regarding its anti inflammatory efficacy, 4 OI@Zn NH pyr ameliorated the inflammatory reaction by activating nuclear factor erythroid 2 related factor 2 (Nrf2), thus increasing the production of antioxidants, apart from the inhibition of NF KB pathways. Additionally, receptor activator of nuclear factor KB ligand (RANKL) induced osteoclast differentiation and function was remarkably suppressed by 4 OI@Zn NH pyr. Consistent with in vitro observations, 4 OI@Zn NH pyr efficiently inhibited synovial inflammation and subchondral bone destruction in an acute arthritis model.
   Conclusion: By using MOSCs that are highly reactive to ROS as drug loaded matrices for the first time, this study provides an avenue for the management of severe joint inflammation by designing synergistic supramolecular drug delivery systems with subcellular targeting and ROS scavenging capacity.
C1 [Chen, Xuzhuo; Chen, Xinwei; Xu, Weifeng; Zhang, Shanyong] Shanghai Jiao Tong Univ, Coll Stomatol, Sch Med, Shanghai Peoples Hosp 9,Dept Oral Surg,Shanghai K, Shanghai 200011, Peoples R China.
   [Chen, Xuzhuo; Chen, Xinwei; Xu, Weifeng; Zhang, Shanyong] Shanghai Jiao Tong Univ, Coll Stomatol, Sch Med,Natl Clin Res Ctr Oral Dis, Shanghai Peoples Hosp 9,Shanghai Res Inst Stomato, Shanghai 200011, Peoples R China.
   [Li, Chang; Dai, Fengrong] Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Fujian, Peoples R China.
   [Cao, Xiankun; Jia, Xinlin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Orthoped, Shanghai Key Lab Orthoped Implant,Sch Med, Shanghai 200011, Peoples R China.
   [Wang, Zhenqiang] Univ South Dakota, Dept Chem, Vermillion, SD 57069 USA.
   [Wang, Zhenqiang] Univ South Dakota, Ctr Fluorinated Funct Mat, Vermillion, SD 57069 USA.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Fujian Institute of Research on the Structure of
   Matter, CAS; Shanghai Jiao Tong University; University of South Dakota;
   University of South Dakota
RP Xu, WF; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Sch Med, Shanghai Peoples Hosp 9,Dept Oral Surg,Shanghai K, Shanghai 200011, Peoples R China.; Xu, WF; Zhang, SY (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Sch Med,Natl Clin Res Ctr Oral Dis, Shanghai Peoples Hosp 9,Shanghai Res Inst Stomato, Shanghai 200011, Peoples R China.; Dai, FR (通讯作者)，Chinese Acad Sci, Fujian Inst Res Struct Matter, State Key Lab Struct Chem, Fuzhou 350002, Fujian, Peoples R China.
EM xwf19891215@163.com; dfr@fjirsm.ac.cn; zhangshanyong@126.com
RI ; Dai, Feng Rong/A 5963 2012; Wang, Zhenqiang/LKL 5144 2024; Chen,
   Xuzhuo/ACC 3813 2022
OI chen, xuzhuo/0000 0002 1276 1662; 
FU National Natural Science Foundation of China [82071135, 21673239];
   Shanghai Municipal Education Commission Two hundred Talent [20152226];
   Research Fund of Medicine and Engineering of Shanghai Jiao Tong
   University [ZH2018ZDA13]; Shanghai Sailing Program [21YF1423600]
FX The authors would like to thank the Bioimaging facility of Shanghai
   Institute of Precision Medicine for providing BD LSR Fortessa for flow
   cytometry, and IVIS Lumina In Vivo Imaging System for IVIS imaging. The
   authors would like to thank Editage (www.editage.com) for English
   language editing. This work was financially supported by the National
   Natural Science Foundation of China (Grant No. 82071135, 21673239),
   Shanghai Municipal Education Commission Two hundred Talent (20152226),
   Research Fund of Medicine and Engineering of Shanghai Jiao Tong
   University (ZH2018ZDA13) and Shanghai Sailing Program (21YF1423600).
CR Aletaha D, 2018, JAMA J AM MED ASSOC, V320, P1360, DOI 10.1001/jama.2018.13103
   Arora Pallak, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr 2013 009386
   Bhuvaneswari N, 2018, CHEM EUR J, V24, P6580, DOI 10.1002/chem.201705210
   Bhuvaneswari N, 2017, J MATER CHEM A, V5, P23559, DOI 10.1039/c7ta05797k
   Buch MH, 2018, ANN RHEUM DIS, V77, P966, DOI 10.1136/annrheumdis 2017 212862
   Burmester GR, 2017, LANCET, V389, P2338, DOI 10.1016/S0140 6736(17)31491 5
   Chen X, 2021, CHEM ENG J, P415
   Chen Z, 2019, NAT REV RHEUMATOL, V15, P9, DOI 10.1038/s41584 018 0109 2
   Covert L, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11030409
   Dai FR, 2016, INORG CHEM FRONT, V3, P243, DOI 10.1039/c5qi00212e
   Dai FR, 2014, J AM CHEM SOC, V136, P7480, DOI 10.1021/ja502839b
   Dai FR, 2012, J AM CHEM SOC, V134, P8002, DOI 10.1021/ja300095j
   Deng CF, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 22454 z
   Fan XX, 2020, NANO MICRO LETT, V12, DOI 10.1007/s40820 020 0410 x
   Fearon U, 2016, NAT REV RHEUMATOL, V12, P385, DOI 10.1038/nrrheum.2016.69
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Hill AV, 1910, J PHYSIOL LONDON, V40, P190
   Indekeu A, 2021, CATAL TODAY, V379, P272, DOI 10.1016/j.cattod.2020.07.017
   Kameoka S, 2010, DENTOMAXILLOFAC RAD, V39, P441, DOI 10.1259/dmfr/37174063
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Krenn V, 2006, HISTOPATHOLOGY, V49, P358, DOI 10.1111/j.1365 2559.2006.02508.x
   Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004
   Li JJ, 2020, ADV MATER, V32, DOI 10.1002/adma.202000964
   Liew SS, 2021, ANGEW CHEM INT EDIT, V60, P2232, DOI 10.1002/anie.201915826
   Liu CS, 2021, J ORG CHEM, V86, P7895, DOI 10.1021/acs.joc.0c02995
   Liu H, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964 018 0294 2
   Liu M, 2012, ANGEW CHEM INT EDIT, V51, P1585, DOI 10.1002/anie.201106732
   Liu TF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 16544 7
   Ma C, 2021, ADV MATER, V33, DOI 10.1002/adma.202100098
   Mills EL, 2018, NATURE, V556, P113, DOI 10.1038/nature25986
   Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Qiao YP, 2016, ANGEW CHEM INT EDIT, V55, P12778, DOI 10.1002/anie.201606847
   Sepehrpour H, 2019, J AM CHEM SOC, V141, P14005, DOI 10.1021/jacs.9b06222
   Sheng TP, 2022, CCS CHEM, V4, P1098, DOI 10.31635/ccschem.021.202100987
   Sheng TP, 2020, MOLECULES, V25, DOI 10.3390/molecules25112656
   Shi J, 2017, J DENT RES, V96, P888, DOI 10.1177/0022034517707515
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Sun CZ, 2019, CRYST GROWTH DES, V19, P1144, DOI 10.1021/acs.cgd.8b01633
   Sun CZ, 2018, DALTON T, V47, P10256, DOI 10.1039/c8dt01900b
   Sun KA, 2020, ELIFE, V9, DOI 10.7554/eLife.54877
   Sun XW, 2019, FASEB J, V33, P12929, DOI 10.1096/fj.201900887RR
   Volkov M, 2020, IMMUNOL REV, V294, P148, DOI 10.1111/imr.12829
   Wang DH, 2017, J DENT SCI, V12, P83, DOI 10.1016/j.jds.2016.12.001
   Wang SD, 2021, ANGEW CHEM INT EDIT, V60, P11252, DOI 10.1002/anie.202101938
   Weiss JN, 1997, FASEB J, V11, P835, DOI 10.1096/fasebj.11.11.9285481
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Xian HX, 2021, IMMUNITY, V54, P1463, DOI 10.1016/j.immuni.2021.05.004
   Zhong ZY, 2016, CELL, V164, P896, DOI 10.1016/j.cell.2015.12.057
   Zielonka J, 2017, CHEM REV, V117, P10043, DOI 10.1021/acs.chemrev.7b00042
NR 51
TC 32
Z9 33
U1 2
U2 72
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2022
VL 12
IS 7
BP 3251
EP 3272
DI 10.7150/thno.70623
PG 22
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 0S9HB
UT WOS:000786579800014
PM 35547753
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, HW
   Xing, LP
AF Zhang, Hengwei
   Xing, Lianping
TI Ubiquitin E3 Ligase Itch Negatively Regulates Osteoblast Differentiation
   from Mesenchymal Progenitor Cells
SO STEM CELLS
LA English
DT Article
DE Itch; E3 ligase; Mesenchymal progenitor cells; Osteoblasts; Bone
   formation
ID STEM CELLS; UP REGULATION; SMURF1; DEGRADATION; PROLIFERATION
AB Itch, a HECT family E3 ligase, affects numerous cell functions by regulating ubiquitination and proteasomal degradation of target proteins. However, the role of Itch in osteoblasts has not been investigated. We report that Itch( / ) mice have significantly increased bone volume, osteoblast numbers, and bone formation rate. Using bone marrow stromal cells from Itch( / ) mice and wild type (WT) littermates as bone marrow mesenchymal precursor cells (BM MPCs), we found that BM MPCs from Itch( / ) mice have compatible numbers of cells expressing mesenchymal stem cell markers. However, Itch( / ) BM MPCs grew faster in an in vitro culture, formed more CFU F mesenchymal colonies, and exhibited increased osteoblast differentiation and decreased adipogenesis. Importantly, Itch( / ) mesenchymal colony cells formed significantly more new bone in a tibial defect of recipient mice compared with WT cells. The expression levels of JunB, an AP 1 transcription factor that positively regulate osteoblast differentiation, were significantly increased in Itch( / ) BM MPCs when proteasome function is intact. In contrast, the amount of ubiquitinated JunB protein was markedly decreased in Itch( / ) cells when proteasome function was blocked. Overexpression of WT Itch, but not an Itch ligase inactive mutant, rescued differentiation defects of Itch( / ) BM MPCs. Itch( / ) BM MPCs had a similar role in immune modulation as WT cells. Thus, Itch negatively controls osteoblast differentiation from BM MPCs through the regulation of proteasomal degradation of positive osteoblast regulator JunB protein. Itch is a potential new target for bone anabolic drug development to treat patients with bone loss. STEM Cells 2013;31:1574 1583
C1 [Zhang, Hengwei; Xing, Lianping] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA.
C3 University of Rochester
RP Xing, LP (通讯作者)，Univ Rochester, Med Ctr, Dept Pathol & Lab Med, 601 Elmwood Ave,Box 626, Rochester, NY 14642 USA.
EM lianping_xing@urmc.rochester.edu
OI ZHANG, HENGWEI/0000 0001 5355 7257
FU National Institute of Health PHS [AR48697];  [P30AR0613007]
FX We thank Dr. Lydia E. Matesic (University of South Carolina) for
   providing Itch<SUP> / </SUP> mice, Dr. Abbott DW (Case Western Reserve
   University School of Medicine) for Flag Itch and Itch C830A mutant
   expression vectors, and Dr. Igor Kuzin (University of Rochester) for
   helping T cell proliferation assay. This work was supported by research
   grants from National Institute of Health PHS awards (AR48697 to L.
   Xing). MicroCT was supported by P30AR0613007 to Edward M. Schwarz.
CR Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301 472X(01)00769 X
   Darzynkiewick R., 2004, CYTOMETRY, P75
   Durrington HJ, 2010, J BIOL CHEM, V285, P37641, DOI 10.1074/jbc.M110.132415
   Fang DY, 2002, NAT IMMUNOL, V3, P281, DOI 10.1038/ni763
   Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414
   Guo R, 2008, J BIOL CHEM, V283, P23084, DOI 10.1074/jbc.M709848200
   Heissmeyer V, 2008, NAT IMMUNOL, V9, P227, DOI 10.1038/ni0308 227
   Jones DC, 2006, SCIENCE, V312, P1223, DOI 10.1126/science.1126313
   Kaneki H, 2006, J BIOL CHEM, V281, P4326, DOI 10.1074/jbc.M509430200
   Lohr NJ, 2010, AM J HUM GENET, V86, P447, DOI 10.1016/j.ajhg.2010.01.028
   Perry WL, 1998, NAT GENET, V18, P143, DOI 10.1038/ng0298 143
   Shembade N, 2008, NAT IMMUNOL, V9, P254, DOI 10.1038/ni1563
   Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285
   Tao MF, 2009, CURR BIOL, V19, P1255, DOI 10.1016/j.cub.2009.06.038
   Wei W, 2012, MOL CELL BIOL, V32, P3903, DOI 10.1128/MCB.00251 12
   Wu QQ, 2008, J BONE MINER RES, V23, P552, DOI 10.1359/JBMR.071115
   Wullaert A, 2006, TRENDS IMMUNOL, V27, P533, DOI 10.1016/j.it.2006.09.003
   Xing LP, 2010, J CELL BIOCHEM, V110, P554, DOI 10.1002/jcb.22586
   Xu J, 2008, J PATHOL, V214, P472, DOI 10.1002/path.2302
   Yamamoto N, 2007, J DERMATOL SCI, V48, P43, DOI 10.1016/j.jdermsci.2007.05.015
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood 2005 04 1496
   Zhang H, 2010, ASBMR ANN M TOR CAN
   Zhang HW, 2010, J BONE MINER RES, V25, P640, DOI 10.1359/jbmr.090812
   Zhao L, 2011, STEM CELLS, V29, P1601, DOI 10.1002/stem.703
   Zhao L, 2010, J BONE MINER RES, V25, P1246, DOI 10.1002/jbmr.28
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
   Zou WG, 2011, NAT CELL BIOL, V13, P59, DOI 10.1038/ncb2134
NR 30
TC 28
Z9 33
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD AUG
PY 2013
VL 31
IS 8
BP 1574
EP 1583
DI 10.1002/stem.1395
PG 10
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 205CM
UT WOS:000323418700012
PM 23606569
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Ling, S
   Liu, Y
   Fu, JQ
   Colletta, A
   Gilon, C
   Holoshitz, J
AF Ling, Song
   Liu, Ying
   Fu, Jiaqi
   Colletta, Alessandro
   Gilon, Chaim
   Holoshitz, Joseph
TI Shared Epitope Antagonistic Ligands: A New Therapeutic Strategy in Mice
   With Erosive Arthritis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; CELL SURFACE CALRETICULIN;
   RHEUMATOID ARTHRITIS; BONE DESTRUCTION; T CELLS; JOINT DESTRUCTION;
   ACTIVATION; DISEASE; ADIPONECTIN; ASSOCIATION
AB Objective. The mechanisms underlying bone damage in rheumatoid arthritis (RA) are incompletely understood. We recently identified the shared epitope (SE), an HLA DRB1 coded 5 amino acid sequence motif carried by the majority of RA patients as a signal transduction ligand that interacts with cell surface calreticulin and accelerates osteoclast (OC) mediated bone damage in collagen induced arthritis (CIA). Given the role of the SE/calreticulin pathway in arthritis associated bone damage, we sought to determine the therapeutic targetability of calreticulin.
   Methods. A library of backbone cyclized peptidomimetic compounds, all carrying an identical core DKCLA sequence, was synthesized. The ability of these compounds to inhibit SE activated signaling and OC differentiation was tested in vitro. The effect on disease severity and OC mediated bone damage was studied by weekly intraperitoneal administration of the compounds to DBA/1 mice with CIA.
   Results. Two members of the peptidomimetics library were found to have SE antagonistic effects and antiosteoclast differentiation effects at picomolar concentrations in vitro. The lead mimetic compound, designated HS(4 4)c Trp, potently ameliorated arthritis and bone damage in vivo when administered in picogram doses to mice with CIA. Another mimetic analog, designated HS(3 4)c Trp, was found to lack activity, both in vitro and in vivo. The differential activity of the 2 analogs depended on minor differences in their respective ring sizes and correlated with distinctive geometry when computationally docked to the SE binding site on calreticulin.
   Conclusion. These findings identify calreticulin as a novel therapeutic target in erosive arthritis and provide sound rationale and early structure/activity relationships for future drug design.
C1 [Ling, Song; Liu, Ying; Fu, Jiaqi; Colletta, Alessandro; Holoshitz, Joseph] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA.
   [Gilon, Chaim] Hebrew Univ Jerusalem, Jerusalem, Israel.
C3 University of Michigan System; University of Michigan; Hebrew University
   of Jerusalem
RP Holoshitz, J (通讯作者)，Univ Michigan, Div Rheumatol, 5520D MSRB1,1150 West Med Ctr Dr, Ann Arbor, MI 48109 USA.
EM jholo@umich.edu
RI ; Colletta, Alessandro/JED 6854 2023; Liu, Yingshuo/ABE 5299 2020
OI Colletta, Alessandro/0000 0002 3865 1015; 
FU NIH (National Institute of General Medical Sciences) [5R01 GM 088560];
   NIH (National Center for Research Resources) [UL 1 RR 024986]; NIH
   (National Institute of Arthritis and Musculoskeletal and Skin Diseases)
   [5R01 AR 059085, 3R01 AR 059085 03S1, T32 AR 07080]; National Institute
   of Arthritis and Musculoskeletal and Skin Diseases [T32AR007080] Funding
   Source: NIH RePORTER
FX Supported by the NIH (National Institute of General Medical Sciences
   grant 5R01 GM 088560, National Center for Research Resources grant UL
   1 RR 024986, and National Institute of Arthritis and Musculoskeletal and
   Skin Diseases grants 5R01 AR 059085, 3R01 AR 059085 03S1, and
   T32 AR 07080).
CR Abreu JRF, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2900
   Backhaus M, 2002, ANN RHEUM DIS, V61, P895, DOI 10.1136/ard.61.10.895
   Binder NB, 2013, ARTHRITIS RHEUM US, V65, P608, DOI 10.1002/art.37797
   Brühl H, 2009, ARTHRITIS RHEUM US, V60, P1352, DOI 10.1002/art.24441
   CARRON JA, 1995, BIOCHEM BIOPH RES CO, V213, P1017, DOI 10.1006/bbrc.1995.2230
   Chan MT, 2008, J RHEUMATOL, V35, P77
   DesAlmeida DE, 2011, SELF NONSELF, V2, P43
   DesAlmeida DE, 2010, J IMMUNOL, V185, P1927
   DesPunder YM, 2011, NAT REV RHEUMATOL, V7, P260
   Fridman JS, 2010, J IMMUNOL, V184, P5298, DOI 10.4049/jimmunol.0902819
   Fu JQ, 2013, J IMMUNOL, V191, P2096, DOI 10.4049/jimmunol.1203231
   Furst DE, 2010, SEMIN ARTHRITIS RHEU, V39, P327, DOI 10.1016/j.semarthrit.2008.10.002
   Giles JT, 2011, ANN RHEUM DIS, V70, P1562, DOI 10.1136/ard.2011.150813
   Goicoechea S, 2000, J BIOL CHEM, V275, P36358, DOI 10.1074/jbc.M005951200
   Gonzalez Gay MA, 2002, SEMIN ARTHRITIS RHEU, V31, P355, DOI 10.1053/sarh.2002.32552
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   Holoshitz J, 2013, DISCOV MED, V16, P93
   Holoshitz J, 2013, J IMMUNOL, V190, P48, DOI 10.4049/jimmunol.1202150
   Hurevich M, 2010, J PEPT SCI, V16, P178, DOI 10.1002/psc.1218
   JAWAHEER D, 1994, ARTHRITIS RHEUM, V37, P681, DOI 10.1002/art.1780370511
   Joosten LAB, 1999, J IMMUNOL, V163, P5049
   Jung MY, 2012, J IMMUNOL, V188, P2592, DOI 10.4049/jimmunol.1102588
   Kanazawa I, 2012, CURR MED CHEM, V19, P5481, DOI 10.2174/092986712803833146
   Kim HR, 2014, ARTHRITIS RHEUMATOL, V66, P538, DOI 10.1002/art.38286
   Korendowych E, 2003, J RHEUMATOL, V30, P96
   Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703
   Le Goff B, 2013, JOINT BONE SPINE, V80, P586, DOI 10.1016/j.jbspin.2013.04.002
   Ling S, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2111
   Ling S, 2007, J IMMUNOL, V179, P6359, DOI 10.4049/jimmunol.179.9.6359
   Ling S, 2006, ARTHRITIS RHEUM US, V54, P3423, DOI 10.1002/art.22178
   Ling S, 2013, ARTHRITIS RHEUM US, V65, P618, DOI 10.1002/art.37814
   Ling S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011703
   Marotte H, 2006, ANN RHEUM DIS, V65, P905, DOI 10.1136/ard.2005.036913
   Mattey DL, 2001, ARTHRITIS RHEUM, V44, P1529, DOI 10.1002/1529 0131(200107)44:7<1529::AID ART275>3.0.CO;2 P
   Merky P, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3108
   Miellot Gafsou A, 2010, IMMUNOLOGY, V130, P296, DOI 10.1111/j.1365 2567.2009.03235.x
   Naveh S, 2012, BIOORG MED CHEM LETT, V22, P493, DOI 10.1016/j.bmcl.2011.10.098
   Plant MJ, 1998, J RHEUMATOL, V25, P417
   Rico MC, 2010, CURR VASC PHARMACOL, V8, P338
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Stump KL, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3329
   Svendsen P, 2004, J IMMUNOL, V173, P7037, DOI 10.4049/jimmunol.173.11.7037
   Takemura Y, 2007, J CLIN INVEST, V117, P375, DOI 10.1172/JCI29709
   Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947
   WEYAND CM, 1994, J LAB CLIN MED, V124, P335
   William AD, 2012, J MED CHEM, V55, P2623, DOI 10.1021/jm201454n
   Yang KY, 2009, J AUTOIMMUN, V32, P94, DOI 10.1016/j.jaut.2008.12.004
NR 49
TC 8
Z9 10
U1 0
U2 4
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2326 5191
EI 2326 5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD AUG
PY 2015
VL 67
IS 8
BP 2061
EP 2070
DI 10.1002/art.39158
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA CN7JA
UT WOS:000358609300011
PM 25892196
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU Kim, JM
   Erkhembaatar, M
   Lee, GS
   Lee, JH
   Noh, EM
   Lee, M
   Song, HK
   Lee, CH
   Kwon, KB
   Kim, MS
   Lee, YR
AF Kim, Jeong Mi
   Erkhembaatar, Munkhsoyol
   Lee, Guem San
   Lee, Jin Hyun
   Noh, Eun Mi
   Lee, Minok
   Song, Hyun Kyung
   Lee, Choong Hun
   Kwon, Kang Beom
   Kim, Min Seuk
   Lee, Young Rae
TI Peucedanum japonicum Thunb. ethanol extract suppresses
   RANKL mediated osteoclastogenesis
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE Peucedanum japonicum Thunb; receptor activator of nuclear factor kappa B
   ligand; osteoclastogenesis; intracellular Ca2+ mobilization; nuclear
   factor of activated T cells cytoplasmic 1
ID GENE EXPRESSION; DIFFERENTIATION; NFATC1; FUSION; KINASE
AB The constituents of Peucedanum japonicum Thunb. (PJ) exhibit biological and pharmacological activities, including anti obesity, anti oxidant and anti allergic activities. The aim of the present study was to examine in vitro effects of PJ in RANKL induced signaling pathways, which determine osteoclast differentiation. PJ ethanol extract (PEE) exhibited anti osteoporotic activity by disrupting the phospholipase C (PLC) Ca2+ c Fos/cAMP response element binding protein (CREB) nuclear factor of activated T cells, cytoplasmic 1 (NFATc1) signaling pathway during osteoclastogenesis. Murine bone marrow derived macrophages (BMMs) were cultured and used to determine the effects of PJ in the receptor activator of nuclear factor kappa B ligand (RANKL) mediated osteoclastogenesis. The effects of PEE in the RANKL mediated signaling cascade were evaluated using a standard in vitro osteoclastogenesis system. PEE treatment of BMMs significantly reduced the number of RANKL mediated tartrate resistant acid phosphatase (TRAP) positive multinucleated cells (P < 0.05 for 5 and 10 mu g/ml PEE, P < 0.01 for 25 and 50 mu g/ml PEE), without cytotoxic effects. Furthermore, the expression of differentiation related marker genes, including TRAP, Oscar, Cathepsin K, dendrocyte expressed seven transmembrane protein, ATPase H+ Transporting V0 Subunit D2 and NFATcl, were markedly suppressed. PEE induced a transient increase in free cytoplasmic Ca2+ ([Ca2+](i)) mobilization via voltage gated Ca2+ channels and PLC sensitive pathways. Transient [Ca2+], increase consequently resulted in the suppression of c Fos, CREB and NFATcl activities. These findings highlight the potential use of PJ in treating bone disorders caused by osteoclast overgrowth.
C1 [Kim, Jeong Mi; Noh, Eun Mi; Lee, Minok; Song, Hyun Kyung; Kwon, Kang Beom; Lee, Young Rae] Wonkwang Univ, Ctr Metab Funct Regulat, Sch Med, Dept Microbiol, Iksan 54538, North Jeolla, South Korea.
   [Erkhembaatar, Munkhsoyol] Mongolian Natl Univ Med Sci, Sch Pharmacol & Biomed, Dept Physiol, Ulaanbaatar 14210, Mongolia.
   [Erkhembaatar, Munkhsoyol; Kim, Min Seuk] Wonkwang Univ, Coll Dent, Inst Biomat Implant, Dept Oral Physiol, 460 Iksan Daero, Iksan 54538, North Jeolla, South Korea.
   [Lee, Guem San] Wonkwang Univ, Sch Med, Dept Herbol, Iksan, South Korea.
   [Lee, Jin Hyun; Kwon, Kang Beom] Wonkwang Univ, Sch Med, Dept Korean Physiol, Iksan, South Korea.
   [Lee, Choong Hun] Ctr PV Human Resource Dev, Next Generat Ind Radiat Technol RIC, Microelect & Display, Iksan 54538, North Jeolla, South Korea.
   [Lee, Young Rae] Coll Dent, Inst Biomat Implant, Dept Oral Biochem, 460 Iksan Daero, Iksan 54538, North Jeolla, South Korea.
   [Lee, Young Rae] Wonkwang Univ, Integrated Omics Inst, Iksan 54538, North Jeolla, South Korea.
C3 Wonkwang University; Mongolian National University of Medical Sciences;
   Wonkwang University; Wonkwang University; Wonkwang University; Wonkwang
   University
RP Kim, MS (通讯作者)，Wonkwang Univ, Coll Dent, Inst Biomat Implant, Dept Oral Physiol, 460 Iksan Daero, Iksan 54538, North Jeolla, South Korea.; Lee, YR (通讯作者)，Wonkwang Univ, Coll Dent, Inst Biomat Implant, Dept Oral Biochem, 460 Iksan Daero, Iksan 54538, North Jeolla, South Korea.
EM happy1487@wku.ac.kr; mindy@wku.ac.kr
RI ; Lee, Jun Hyuk/KOC 2534 2024; Kim, Jae Hong/B 2530 2009
OI Lee, Jin Hyun/0000 0001 8387 2485; Erkhembaatar,
   Munkhsoyol/0009 0006 0855 9636; 
FU National Research Foundation of Korea   Ministry of Education, Science
   and Technology [2011 0030130, NRF 2015R1D1A1A01058272]
FX The present study was supported by the Basic Science Research Program
   through the National Research Foundation of Korea, funded by the
   Ministry of Education, Science and Technology (grant no. 2011 0030130,
   NRF 2015R1D1A1A01058272).
CR Aida Y, 1998, METHOD FIND EXP CLIN, V20, P343, DOI 10.1358/mf.1998.20.4.485689
   Barrow AD, 2011, J CLIN INVEST, V121, P3505, DOI 10.1172/JCI45913
   Joray MB, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/912484
   Hisamoto M, 2003, J AGR FOOD CHEM, V51, P5255, DOI 10.1021/jf0262458
   Hwang JK, 2014, J DENT RES, V93, P685, DOI 10.1177/0022034514536579
   Kim HJ, 2012, J CELL BIOL, V199, P1145, DOI 10.1083/jcb.201204067
   Kim H, 2013, CELL METAB, V17, P249, DOI 10.1016/j.cmet.2013.01.002
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Koga T, 2004, NATURE, V428, P758, DOI 10.1038/nature02444
   Lee JW, 2002, PLANTA MED, V68, P891, DOI 10.1055/s 2002 34934
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsumoto M, 2004, J BIOL CHEM, V279, P45969, DOI 10.1074/jbc.M408795200
   McChesney James D, 2002, P R Health Sci J, V21, P91
   Nguta JM, 2016, J ETHNOPHARMACOL, V182, P10, DOI 10.1016/j.jep.2016.02.010
   Nukitrangsan N, 2012, J OLEO SCI, V61, P89, DOI 10.5650/jos.61.89
   Sato K, 2006, NAT MED, V12, P1410, DOI 10.1038/nm1515
   Shen JH, 2003, CURR MED CHEM, V10, P2327, DOI 10.2174/0929867033456729
   Son A, 2012, KOREAN J PHYSIOL PHA, V16, P31, DOI 10.4196/kjpp.2012.16.1.31
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102
   Yang YM, 2013, KOREAN J PHYSIOL PHA, V17, P65, DOI 10.4196/kjpp.2013.17.1.65
   Yang YM, 2009, J BONE MINER RES, V24, P1763, DOI [10.1359/JBMR.090420, 10.1359/jbmr.090420]
   Yu MJ, 2009, J BIOL CHEM, V284, P32968, DOI 10.1074/jbc.M109.001016
NR 26
TC 12
Z9 13
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JUL
PY 2017
VL 14
IS 1
BP 410
EP 416
DI 10.3892/etm.2017.4480
PN A
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FA7RU
UT WOS:000405645400062
PM 28672947
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tong, L
   Zhu, GY
   Wang, JP
   Sun, RL
   He, FL
   Zhai, JL
AF Tong, Ling
   Zhu, Guoying
   Wang, Jianping
   Sun, Ruilian
   He, Feilong
   Zhai, Jianglong
TI Suppressing angiogenesis regulates the irradiation induced stimulation
   on osteoclastogenesis in vitro
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE angiogenesis; bone marrow derived endothelial progenitor cells
   (BM EPCs); irradiation; osteoclastogenesis; RAW 264; 7 cells
ID ENDOTHELIAL PROGENITOR CELLS; MESENCHYMAL STEM CELLS; PELVIC BONE
   COMPLICATIONS; RADIATION THERAPY; BODY IRRADIATION; DIFFERENTIATION;
   RADIOTHERAPY; NUMBER; MICE; RECRUITMENT
AB Ionizing radiation induced bone loss is a potential health concern in radiotherapy, occupational exposure, and astronauts. Although impaired bone vasculature and reduced proliferation of bone forming osteoblasts has been implicated in this process, it has not been clearly characterized that whether radiation affects the growth of bone resorbing osteoclasts. The molecular crosstalk between different cell populations in the skeletal system has not yet been elucidated in detail, especially between the increased bone resorption at early stage of post irradiation and bone marrow derived endothelial progenitor cells (BM EPCs). In order to further understand the mechanisms involved in radiation induced bone loss at the cellular level, we assessed the effects of irradiation on angiogenesis of BM EPCs and osteoclastogenesis of receptor activator for nuclear factor B ligand (RANKL) stimulated RAW 264.7 cells and crosstalk between these cell populations. We herein found significantly dysfunction of BM EPCs in response to irradiation at a dose of 2Gy, including inhibited proliferation, migration, tube forming abilities, and downregulated expression of pro angiogenesis vascular endothelial growth factors A (VEGF A). Meanwhile, we observed that irradiation promoted osteoclastogenesis of RANKL stimulated RAW 264.7 cells directly or indirectly. These results provide quantitative evidences of irradiation induced osteoclastogenesis at a cellular level, and strongly suggest the involvement of osteoclastogenesis, angiogenesis and crosstalk between bone marrow cells in the radiation induced bone loss. This study may provide new insights for the early diagnosis and intervention of bone loss post irradiation.
C1 [Tong, Ling; Zhu, Guoying; Wang, Jianping; Sun, Ruilian; He, Feilong; Zhai, Jianglong] Fudan Univ, Inst Radiat Med, 2094 Xietu Rd, Shanghai 200032, Peoples R China.
C3 Fudan University
RP Zhu, GY (通讯作者)，Fudan Univ, Inst Radiat Med, 2094 Xietu Rd, Shanghai 200032, Peoples R China.
EM zhugy@shmu.edu.cn
RI Sun, Ruilian/G 5632 2012
FU Research Project of Shanghai Municipal Commission of Health and Family
   Planning [2013ZYJB0801, 20154Y0202]; Shanghai Natural Science
   [14ZR1401600]
FX Research Project of Shanghai Municipal Commission of Health and Family
   Planning, Grant numbers: 2013ZYJB0801, 20154Y0202; Shanghai Natural
   Science, Grant number: 14ZR1401600
CR Aksnes LH, 2007, ACTA ONCOL, V46, P490, DOI 10.1080/02841860701218642
   Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Bosetti M, 2013, GROWTH FACTORS, V31, P57, DOI 10.3109/08977194.2013.770392
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao X, 2011, P NATL ACAD SCI USA, V108, P1609, DOI 10.1073/pnas.1015350108
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Chen JZ, 2004, CLIN SCI, V107, P273, DOI 10.1042/CS20030389
   D'Oronzo S, 2015, CANCER TREAT REV, V41, P798, DOI 10.1016/j.ctrv.2015.09.003
   Dernbach E, 2004, BLOOD, V104, P3591, DOI 10.1182/blood 2003 12 4103
   Dome B, 2008, CYTOM PART A, V73A, P186, DOI 10.1002/cyto.a.20480
   Erguen S, 2008, STEM CELL REV, V4, P169, DOI 10.1007/s12015 008 9028 y
   Fadini GP, 2006, ARTERIOSCL THROM VAS, V26, P2140, DOI 10.1161/01.ATV.0000237750.44469.88
   Fedorovich NE, 2010, TISSUE ENG PT A, V16, P2355, DOI [10.1089/ten.tea.2009.0603, 10.1089/ten.TEA.2009.0603]
   Fu SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091217
   Gronthos S, 2007, TRENDS ENDOCRIN MET, V18, P108, DOI 10.1016/j.tem.2007.02.002
   Güven H, 2006, J AM COLL CARDIOL, V48, P1579, DOI 10.1016/j.jacc.2006.04.101
   Hamilton SA, 2006, J APPL PHYSIOL, V101, P789, DOI 10.1152/japplphysiol.01078.2005
   Han KH, 2014, BONE, V61, P91, DOI 10.1016/j.bone.2013.12.032
   He TR, 2004, ARTERIOSCL THROM VAS, V24, P2021, DOI 10.1161/01.ATV.0000142810.27849.8f
   Hirbe AC, 2007, P NATL ACAD SCI USA, V104, P14062, DOI 10.1073/pnas.0705203104
   Igdem S, 2010, INT J RADIAT ONCOL, V77, P818, DOI 10.1016/j.ijrobp.2009.05.059
   Ikushima H, 2006, GYNECOL ONCOL, V103, P1100, DOI 10.1016/j.ygyno.2006.06.038
   Jia D, 2011, RADIAT RES, V176, P624, DOI 10.1667/RR2505.1
   Keramaris NC, 2012, CURR STEM CELL RES T, V7, P293
   Kondo T, 2003, J CLIN INVEST, V111, P1835, DOI 10.1172/JCI200317455
   Kwon JW, 2008, AM J ROENTGENOL, V191, P987, DOI 10.2214/AJR.07.3634
   Li BY, 2015, J INTERF CYTOK RES, V35, P23, DOI 10.1089/jir.2014.0004
   Li W.W., 2005, ADV SKIN WOUND CARE, V18, P501
   Ma J, 2007, HAEMATOLOGICA, V92, P889, DOI 10.3324/haematol.11106
   Matsumura S, 1996, CALCIFIED TISSUE INT, V59, P307, DOI 10.1007/s002239900129
   Nambu A, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 68
   Pang H, 2013, BIOCHEM BIOPH RES CO, V430, P729, DOI 10.1016/j.bbrc.2012.11.081
   Przybylski M, 2009, J Wound Care, V18, P516
   Rafii DC, 2008, ARTERIOSCL THROM VAS, V28, P217, DOI 10.1161/ATVBAHA.107.151159
   Sakurai T, 2007, J RADIAT RES, V48, P515, DOI 10.1269/jrr.07012
   Sasi SP, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/496512
   Shigematsu Satoshi, 1999, Endocrine Journal, V46, pS59, DOI 10.1507/endocrj.46.Suppl_S59
   Usami K, 2009, J BIOMED MATER RES A, V90A, P730, DOI 10.1002/jbm.a.32142
   Van der Meeren A, 2005, RADIAT RES, V163, P144, DOI 10.1667/RR3293
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
   Williams HJ, 2006, EUR RADIOL, V16, P619, DOI 10.1007/s00330 005 0010 7
   Wissing MD, 2015, CURR OSTEOPOROS REP, V13, P140, DOI 10.1007/s11914 015 0266 z
   Yang G, 2007, RADIAT RES, V167, P298, DOI 10.1667/RR0710.1
   Zhang HW, 2014, MOL CELL BIOCHEM, V397, P235, DOI 10.1007/s11010 014 2191 3
NR 46
TC 7
Z9 8
U1 0
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD APR
PY 2018
VL 233
IS 4
BP 3429
EP 3438
DI 10.1002/jcp.26196
PG 10
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FR0AL
UT WOS:000418723200069
PM 28941279
DA 2025 08 17
ER

PT J
AU Nakabayashi, H
   Aoyama, S
   Kawahara, M
   Nagamune, T
AF Nakabayashi, Hideto
   Aoyama, Saeko
   Kawahara, Masahiro
   Nagamune, Teruyuki
TI Differentiation signalobody: Demonstration of antigen dependent
   osteoclast differentiation from a progenitor cell line
SO JOURNAL OF BIOSCIENCE AND BIOENGINEERING
LA English
DT Article
DE Cell differentiation; Osteoclast; Signalobody; Chimeric protein; Signal
   transduction
ID MESENCHYMAL STEM CELLS; NF KAPPA B; GENETICALLY MODIFIED CELLS; RECEPTOR
   ACTIVATOR; CRYSTAL STRUCTURE; SMALL MOLECULE; LIGAND; GROWTH; RANK;
   INDUCTION
AB A "cytoldne less" in vitro differentiation method would be promising for cost effective mass production of cells used for regenerative medicine. In this study, we developed a differentiation signalobody S RANK, in which the extracellular domain of receptor activator of nuclear factor kappa B (RANK) is replaced with a single chain variable fragment (scFv) to attain signaling in response to an inexpensive antigen. A murine macrophage cell line RAW264, which is known to differentiate into an osteoclast by RANK ligand (RANKL), was lentivirally transduced with S RANK. When the resultant cells were cultured with a specific antigen, the cells differentiated into multinucleated tartrate resistant acid phosphatase positive osteoclasts. The differentiation efficiency was almost comparable to those induced by RANKL. In addition, the signaling analysis demonstrated that nuclear factor kappa B and mitogen activated protein kinase signaling pathways, which are the major signaling pathways downstream of wild type RANK, were also activated by S RANK. These results demonstrate that S RANK sufficiently mimics signal transduction of wild type RANK. Differentiation signalobodies may be applied for controlling differentiation of other cell types by using appropriate signaling domains. (C) 2016, The Society for Biotechnology, Japan. All rights reserved.
C1 [Nakabayashi, Hideto; Aoyama, Saeko; Kawahara, Masahiro; Nagamune, Teruyuki] Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138656, Japan.
C3 University of Tokyo
RP Kawahara, M (通讯作者)，Univ Tokyo, Grad Sch Engn, Dept Chem & Biotechnol, Bunkyo Ku, 7 3 1 Hongo, Tokyo 1138656, Japan.
EM kawahara@bio.t.u tokyo.ac.jp
RI ; Nagamune, Teruyuki/R 7708 2017
OI Kawahara, Masahiro/0000 0003 2301 6171; Nagamune,
   Teruyuki/0000 0002 2435 0270; Aoyama Ishiwatari,
   Saeko/0009 0001 6439 8922
FU JSPS [26.11124, 15H04190]; Science and Technology Research Promotion
   Program for Agriculture, Forestry, Fisheries and Food Industry;
   Grants in Aid for Scientific Research [14J11124, 15H04190] Funding
   Source: KAKEN
FX We are grateful to Dr. James Ellis for the plasmid pL SIN EF1
   alpha EGFP. This work was supported by JSPS KAKENHI Grant Numbers
   26.11124 (to H.N.) and 15H04190 (to M.K.) and by the Science and
   Technology Research Promotion Program for Agriculture, Forestry,
   Fisheries and Food Industry (to M.K.).
CR Abdel Latif A, 2007, ARCH INTERN MED, V167, P989, DOI 10.1001/archinte.167.10.989
   Banas A, 2008, STEM CELLS, V26, P2705, DOI 10.1634/stemcells.2008 0034
   Bolwell B, 2004, BONE MARROW TRANSPL, V33, P419, DOI 10.1038/sj.bmt.1704330
   Borowiak M, 2009, CELL STEM CELL, V4, P348, DOI 10.1016/j.stem.2009.01.014
   Chalamalasetty RB, 2014, DEVELOPMENT, V141, P4285, DOI 10.1242/dev.110908
   Chen S, 2009, NAT CHEM BIOL, V5, P258, DOI 10.1038/nchembio.154
   Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437
   Copelan EA, 2006, NEW ENGL J MED, V354, P1813, DOI 10.1056/NEJMra052638
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Healy L, 2005, ADV DRUG DELIVER REV, V57, P1981, DOI 10.1016/j.addr.2005.07.019
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Hotta A, 2009, NAT METHODS, V6, P370, DOI [10.1038/nmeth.1325, 10.1038/NMETH.1325]
   Ito S, 2002, J BIOL CHEM, V277, P6631, DOI 10.1074/jbc.M106525200
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Kadono Y, 2005, EMBO REP, V6, P171, DOI 10.1038/sj.embor.7400345
   Kaneko E, 2012, J BIOSCI BIOENG, V113, P641, DOI 10.1016/j.jbiosc.2011.12.005
   Kavitha CV, 2014, MOL CARCINOGEN, V53, P169, DOI 10.1002/mc.21959
   Kawahara M, 2014, BIOTECHNOL J, V9, P954, DOI 10.1002/biot.201300346
   Kawahara M, 2014, BIOTECHNOL PROGR, V30, P411, DOI 10.1002/btpr.1861
   Kawahara M, 2011, CYTOKINE, V55, P402, DOI 10.1016/j.cyto.2011.05.024
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Li J, 2000, P NATL ACAD SCI USA, V97, P1566, DOI 10.1073/pnas.97.4.1566
   Liu W, 2008, BIOTECHNOL BIOENG, V101, P975, DOI 10.1002/bit.21961
   Liu WH, 2009, J BIOCHEM, V145, P575, DOI 10.1093/jb/mvp013
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Miller CP, 2008, GENE THER, V15, P759, DOI 10.1038/gt.2008.43
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Nakabayashi H, 2013, CYTOTECHNOLOGY, V65, P945, DOI 10.1007/s10616 013 9571 5
   Nakagawa M, 2014, SCI REP UK, V4, DOI 10.1038/srep03594
   Neff T, 2001, BLOOD, V97, P2535, DOI 10.1182/blood.V97.9.2535
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Ren YM, 2011, J MOL CELL CARDIOL, V51, P280, DOI 10.1016/j.yjmcc.2011.04.012
   Sagal J, 2014, STEM CELL TRANSL MED, V3, P888, DOI 10.5966/sctm.2013 0213
   Sato Y, 2005, BLOOD, V106, P756, DOI 10.1182/blood 2005 02 0572
   Sogo T, 2009, CYTOKINE, V46, P127, DOI 10.1016/j.cyto.2008.12.020
   Sturgeon CM, 2014, NAT BIOTECHNOL, V32, P554, DOI 10.1038/nbt.2915
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tanaka K, 2009, BIOTECHNOL PROGR, V25, P1138, DOI 10.1002/btpr.185
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442
   Tone Y, 2013, HUM GENE THER METHOD, V24, P141, DOI 10.1089/hgtb.2012.147
   Yoshida R, 2014, BIOTECHNOL BIOENG, V111, P1170, DOI 10.1002/bit.25173
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 51
TC 6
Z9 6
U1 0
U2 3
PU SOC BIOSCIENCE BIOENGINEERING JAPAN
PI OSAKA
PA OSAKA UNIV, FACULTY ENGINEERING, 2 1 YAMADAOKA, SUITA, OSAKA, 565 0871,
   JAPAN
SN 1389 1723
EI 1347 4421
J9 J BIOSCI BIOENG
JI J. Biosci. Bioeng.
PD SEP
PY 2016
VL 122
IS 3
BP 357
EP 363
DI 10.1016/j.jbiosc.2016.02.010
PG 7
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA DW7GJ
UT WOS:000383818900017
PM 26979343
DA 2025 08 17
ER

PT J
AU Schumacher, M
   Wagner, AS
   Kokesch Himmelreich, J
   Bernhardt, A
   Rohnke, M
   Wenisch, S
   Gelinsky, M
AF Schumacher, M.
   Wagner, A. S.
   Kokesch Himmelreich, J.
   Bernhardt, A.
   Rohnke, M.
   Wenisch, S.
   Gelinsky, M.
TI Strontium substitution in apatitic CaP cements effectively attenuates
   osteoclastic resorption but does not inhibit osteoclastogenesis
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Osteoclast; Strontium; Calcium phosphate; Bone cement; Resorption;
   Osteoporosis
ID RESISTANT ACID PHOSPHATASE; CALCIUM SENSING RECEPTOR; DIFFERENTIATION
   IN VITRO; MASS SPECTROMETRY SIMS; BONE METABOLISM; RANELATE; CELLS;
   PROLIFERATION; STIMULATION; OSTEOBLASTS
AB Strontium ions were discovered to exert a dual effect on bone turnover, namely an inhibition of cell driven bone resorption and a simultaneous stimulation of new bone tissue formation. A variety of strontium containing calcium phosphate bone cements (SrCPC) have been developed to benefit from both effects to locally support the healing of osteoporotic bone defects. While the stimulating effect of strontium modification on bone forming cells has been demonstrated in a number of studies, this study focuses on the inhibition and/or reduction of osteoclastogenesis and osteoclastic resorption by a strontium substituted calcium phosphate bone cement (SrCPC). Human peripheral blood mononuclear cells (PBMC) were differentiated into osteoclasts in the presence of different Sr2+ concentrations as well as on the surface of SrCPC disks. Osteoclastogenesis of PBMC was shown to be merely unaffected by medium Sr2+ concentrations comparable to those released from SrCPC in vitro (0.05 0.15 mM). However, an altering effect of 0.1 mM strontium on the cytoskeleton of osteoclast like cells was shown. In direct contact to SrCPC disks, these cells exhibited typical morphological features and osteoclast markers on both RNA and protein level were formed. However, calcium phosphate resorption was significantly decreased on strontium containing cements in comparison to a strontium free control. This was accompanied by an intracellular accumulation of strontium that increased with substrate strontium content as demonstrated by Time of Flight Secondary Ion Mass Spectrometry (ToF SIMS). This study illustrates that SrCPC do not inhibit osteoclastogenesis but significantly attenuate osteoclastic substrate resorption in vitro.
   Statement of Significance
   Strontium ions have been shown to promote bone formation and inhibit bone resorption. Therefore strontium is successfully used in the treatment of osteoporosis and also inspired the development of strontium containing strontium/calcium phosphate bone cements (SrCPC). Studies have shown the positive effects of SrCPC on bone formation, however, the inhibiting effect of strontium on bone resorption in the context of such cements has not been shown so far. We found that the formation of bone resorbing osteoclasts is not inhibited, but that their resorption activity is decreased in contact to SrCPC. The former is important since those cells play an important role in the bone cell signaling. The latter is a key requirement in osteoporosis therapy, which addresses excess bone resorption. (c) 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Schumacher, M.; Bernhardt, A.; Gelinsky, M.] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Fac Med, Fetscherstr 74, D 01307 Dresden, Germany.
   [Schumacher, M.; Bernhardt, A.; Gelinsky, M.] Tech Univ Dresden, Univ Hosp, D 01062 Dresden, Germany.
   [Wagner, A. S.; Wenisch, S.] Univ Giessen, Dept Vet Clin Sci, Small Anim Clin, Inst Vet Anat Histol & Embryol, D 35390 Giessen, Germany.
   [Kokesch Himmelreich, J.; Rohnke, M.] Univ Giessen, Inst Phys Chem, Heinrich Buff Ring 58, Giessen, Germany.
C3 Technische Universitat Dresden; Technische Universitat Dresden; Carl
   Gustav Carus University Hospital; Justus Liebig University Giessen;
   Justus Liebig University Giessen
RP Schumacher, M (通讯作者)，Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Fac Med, Fetscherstr 74, D 01307 Dresden, Germany.
EM matthias.schumacher@tu dresden.de
RI Schumacher, Matthias/I 1530 2013; Gelinsky, Michael/A 9680 2012;
   Bernhardt, Anne/O 1242 2015; Rohnke, Marcus/I 2815 2013
OI Schumacher, Matthias/0000 0001 7207 7355; Gelinsky,
   Michael/0000 0001 9075 5121; Bernhardt, Anne/0000 0002 1903 1929;
   Rohnke, Marcus/0000 0002 8867 950X
FU German Research Society (DFG) within the Collaborative Research
   Centre/Transregio 79 [SFB/TR 79]
FX We acknowledge the German Research Society (DFG) for funding within the
   Collaborative Research Centre/Transregio 79 (SFB/TR 79), sub projects
   B5, M2 and M5. We are grateful to Dr. C. Vater for her help during
   microscopy as well as the "Core Facility Cellular Imaging (CFCI)",
   Faculty of Medicine of TU Dresden and A. Hild, Justus Liebig University
   Giessen, for excellent technical support.
CR Alatalo SL, 2000, CLIN CHEM, V46, P1751
   [Anonymous], 2003, ANORGANISCHE CHEM PR
   Bakker AD, 2013, BONE, V53, P112, DOI 10.1016/j.bone.2012.11.044
   Baron R, 2002, EUR J PHARMACOL, V450, P11, DOI 10.1016/S0014 2999(02)02040 X
   BENNINGHOVEN A, 1994, SURF SCI, V299, P246, DOI 10.1016/0039 6028(94)90658 0
   Bernhardt A, 2015, TISSUE ENG PART C ME, V21, P160, DOI [10.1089/ten.tec.2014.0187, 10.1089/ten.TEC.2014.0187]
   Bohner M, 2000, INJURY, V31, pS37
   Bonnelye E, 2008, BONE, V42, P129, DOI 10.1016/j.bone.2007.08.043
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Canalis E, 1996, BONE, V18, P517, DOI 10.1016/8756 3282(96)00080 4
   Caudrillier A., 2012, MOL PHARM, V78, P569
   Chattopadhyay N, 2007, BIOCHEM PHARMACOL, V74, P438, DOI 10.1016/j.bcp.2007.04.020
   Choudhary S, 2007, J BONE MINER RES, V22, P1002, DOI 10.1359/JBMR.070321
   Cianferotti L, 2015, OSTEOPOROSIS INT, V26, P2055, DOI 10.1007/s00198 015 3203 1
   De Souza RA, 2007, PHYS STATUS SOLIDI C, V4, P1785, DOI 10.1002/pssc.200675227
   de Vries TJ, 2005, J CELL BIOCHEM, V94, P954, DOI 10.1002/jcb.20326
   Detsch R, 2015, J TISSUE ENG REGEN M, V9, P1133, DOI 10.1002/term.1851
   Dorozhkin SV, 2010, J FUNCT BIOMATER, V1, P22, DOI 10.3390/jfb1010022
   Fuller K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012837
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Giannoudis PV, 2005, INJURY, V36, P20, DOI 10.1016/j.injury.2005.07.029
   Glenske K, 2014, BIOMATERIALS, V35, P1487, DOI 10.1016/j.biomaterials.2013.11.002
   Hayman AR, 2008, AUTOIMMUNITY, V41, P218, DOI 10.1080/08916930701694667
   Hurtel Lemaire AS, 2009, J BIOL CHEM, V284, P575, DOI 10.1074/jbc.M801668200
   Igarashi Y, 2002, J CHROMATOGR B, V781, P345, DOI 10.1016/S1570 0232(02)00431 2
   Ito A, 2015, ACTA BIOMATER, V25, P347, DOI 10.1016/j.actbio.2015.07.040
   Koblinski JE, 2000, CLIN CHIM ACTA, V291, P113, DOI 10.1016/S0009 8981(99)00224 7
   Kokesch Himmelreich J, 2013, BIOINTERPHASES, V8, DOI 10.1186/1559 4106 8 17
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Lamp EC, 2000, LEUKEMIA LYMPHOMA, V39, P477, DOI 10.3109/10428190009113378
   Llopis Hernández V, 2013, BIORESEARCH OPEN ACC, V2, P364, DOI 10.1089/biores.2013.0017
   Fernández JM, 2014, BIOMETALS, V27, P601, DOI 10.1007/s10534 014 9733 8
   Marie PJ, 2007, BONE, V40, pS5, DOI 10.1016/j.bone.2007.02.003
   Marie PJ, 2010, BONE, V46, P571, DOI 10.1016/j.bone.2009.07.082
   Marie PJ, 2005, CURR OPIN PHARMACOL, V5, P633, DOI 10.1016/j.coph.2005.05.005
   Mohamed MM, 2006, NAT REV CANCER, V6, P764, DOI 10.1038/nrc1949
   Nyman JS, 2011, J BONE MINER RES, V26, P1252, DOI 10.1002/jbmr.326
   Park JW, 2013, J BIOMED MATER RES A, V101, P298, DOI 10.1002/jbm.a.34433
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Rezwan K, 2006, BIOMATERIALS, V27, P3413, DOI 10.1016/j.biomaterials.2006.01.039
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Schumacher M, 2013, ACTA BIOMATER, V9, P9547, DOI 10.1016/j.actbio.2013.07.027
   Schumacher M, 2013, ACTA BIOMATER, V9, P7536, DOI 10.1016/j.actbio.2013.03.014
   Schumacher M, 2015, J MATER CHEM B, V3, P4626, DOI 10.1039/c5tb00654f
   Takahashi N, 2003, J BONE MINER RES, V18, P1082, DOI 10.1359/jbmr.2003.18.6.1082
   Tang L, 2014, NATURE, V505, P56, DOI 10.1038/nature12775
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Vickerman JC, 2011, ANALYST, V136, P2199, DOI 10.1039/c1an00008j
   Will J, 2012, ADV BIOCHEM ENG BIOT, V126, P195, DOI 10.1007/10_2011_106
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yang L, 2010, BIOMATERIALS, V31, P2976, DOI 10.1016/j.biomaterials.2010.01.002
NR 53
TC 77
Z9 79
U1 1
U2 69
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUN
PY 2016
VL 37
BP 184
EP 194
DI 10.1016/j.actbio.2016.04.016
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA DN8FM
UT WOS:000377314600019
PM 27084107
DA 2025 08 17
ER

PT J
AU Brubaker, KD
   Brown, LG
   Vessella, RL
   Corey, E
AF Brubaker, KD
   Brown, LG
   Vessella, RL
   Corey, E
TI Administration of zoledronic acid enhances the effects of docetaxel on
   growth of prostate cancer in the bone environment
SO BMC CANCER
LA English
DT Article
ID BISPHOSPHONATES INDUCE APOPTOSIS; BREAST CANCER; SKELETAL COMPLICATIONS;
   CELL LINES; PHASE II; METASTASES; CARCINOMA; MICROENVIRONMENT;
   ESTRAMUSTINE; INHIBITION
AB Background: After development of hormone refractory metastatic disease, prostate cancer is incurable. The recent history of chemotherapy has shown that with difficult disease targets, combinatorial therapy frequently offers the best chance of a cure. In this study we have examined the effects of a combination of zoledronic acid (ZOL), a new generation bisphosphonate, and docetaxel on LuCaP 23.1, a prostate cancer xenograft that stimulates the osteoblastic reaction when grown in the bone environment.
   Methods: Intra tibial injections of LuCaP 23.1 cells were used to generate tumors in the bone environment, and animals were treated with ZOL, docetaxel, or a combination of these. Effects on bone and tumor were evaluated by measurements of bone mineral density and histomorphometrical analysis.
   Results: ZOL decreased proliferation of LuCaP 23.1 in the bone environment, while docetaxel at a dose that effectively inhibited growth of subcutaneous tumors did not show any effects in the bone environment. The combination of the drugs significantly inhibited the growth of LuCaP 23.1 tumors in the bone.
   Conclusion: In conclusion, the use of the osteolysis inhibitory agent ZOL in combination with docetaxel inhibits growth of prostate tumors in bone and represents a potential treatment option.
C1 Univ Washington, Dept Urol, Seattle, WA 98195 USA.
   Bloomsburg Univ Penn, Dept Biol & Allied Hlth Sci, Bloomsburg, PA 17815 USA.
C3 University of Washington; University of Washington Seattle; Pennsylvania
   State System of Higher Education (PASSHE); Bloomsburg University of
   Pennsylvania
RP Corey, E (通讯作者)，Univ Washington, Dept Urol, Seattle, WA 98195 USA.
EM kbrubake@bloomu.edu; brown@u.washington.edu; vessella@u.washington.edu;
   ecorey@u.washington.edu
CR Altundag K, 2004, CANCER AM CANCER SOC, V101, P1101, DOI 10.1002/cncr.20459
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Bertolini Gerard., 2005, Economie des dechets, P1
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon JP, 2004, BJU INT, V94, P164, DOI 10.1111/j.1464 4096.2004.04831.x
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Efstathiou E, 2005, UROLOGY, V65, P126, DOI 10.1016/j.urology.2004.08.041
   Ellis WJ, 1996, CLIN CANCER RES, V2, P1039
   Ferrero JM, 2004, ONCOLOGY BASEL, V66, P281, DOI 10.1159/000078328
   Fizazi K, 2004, ANTICANCER RES, V24, P2897
   FLANAGAN AM, 1991, CALCIFIED TISSUE INT, V49, P407, DOI 10.1007/BF02555852
   Fleisch H, 2001, SEMIN ONCOL, V28, P45, DOI 10.1053/sonc.2001.24159
   Green JR, 2005, ACTA ONCOL, V44, P282, DOI 10.1080/02841860510029644
   Green JR, 2001, SEMIN ONCOL, V28, P4, DOI 10.1053/sonc.2001.24154
   Hellerstedt BA, 2002, CA CANCER J CLIN, V52, P154, DOI 10.3322/canjclin.52.3.154
   Higano Celestia S, 2005, Can J Urol, V12 Suppl 2, P38
   Higano CS, 2004, UROL CLIN N AM, V31, P331, DOI 10.1016/j.ucl.2004.01.001
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kim SJ, 2005, CANCER RES, V65, P3707, DOI 10.1158/0008 5472.CAN 04 3601
   Lee MV, 2001, CANCER RES, V61, P2602
   Lee YP, 2002, CANCER RES, V62, P5564
   Lipton Allan, 2000, Cancer, V88, P3033, DOI 10.1002/1097 0142(20000615)88:12+<3033::AID CNCR20>3.3.CO;2 3
   Mackle PS, 2001, BRIT J CANCER, V84, P951, DOI 10.1054/bjoc.2000.1679
   Magnetto S, 1999, INT J CANCER, V83, P263, DOI 10.1002/(SICI)1097 0215(19991008)83:2<263::AID IJC19>3.0.CO;2 T
   Major P, 2001, J CLIN ONCOL, V19, P558, DOI 10.1200/JCO.2001.19.2.558
   Montague R, 2004, EUR UROL, V46, P389, DOI 10.1016/j.eururo.2004.04.022
   MORTON AR, 1988, BRIT MED J, V297, P772, DOI 10.1136/bmj.297.6651.772
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Oudard S, 2003, J NEURO ONCOL, V63, P81, DOI 10.1023/A:1023756707900
   Parker CC, 2005, BJU INT, V95, P935, DOI 10.1111/j.1464 410X.2005.05441.x
   Parker CC, 2004, J NATL CANCER I, V96, P1480, DOI 10.1093/jnci/djh294
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Price Nancy, 2004, Clin Prostate Cancer, V3, P77
   Quinn JE, 2005, PROSTATE CANCER P D, V8, P253, DOI 10.1038/sj.pcan.4500815
   Saad Fred, 2002, Clin Prostate Cancer, V1, P145, DOI 10.3816/CGC.2002.n.016
   Saad Fred, 2005, Clin Prostate Cancer, V4, P31, DOI 10.3816/CGC.2005.n.009
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Stearns ME, 1996, INVAS METAST, V16, P116
   Tenta R, 2004, PROSTATE, V59, P120, DOI 10.1002/pros.10363
   Tiersten AD, 2003, CANCER, V97, P537, DOI 10.1002/cncr.11082
   Tiffany NM, 2004, UROLOGY, V63, P934, DOI 10.1016/j.urology.2003.12.022
   Vogel CL, 2004, ONCOLOGIST, V9, P687, DOI 10.1634/theoncologist.9 6 687
   Vordos D, 2004, BJU INT, V94, P524, DOI 10.1111/j.1464 4096.2004.04919.x
   Winquist E, 2004, JNCI J NATL CANCER I, V96, P1183, DOI 10.1093/jnci/djh234
NR 47
TC 68
Z9 71
U1 0
U2 1
PU BIOMED CENTRAL LTD
PI LONDON
PA MIDDLESEX HOUSE, 34 42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND
SN 1471 2407
J9 BMC CANCER
JI BMC Cancer
PD JAN 17
PY 2006
VL 6
AR 15
DI 10.1186/1471 2407 6 15
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 008KC
UT WOS:000235038300001
PM 16417633
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sun, H
   Li, LJ
   Zhang, AH
   Zhang, N
   Lv, HT
   Sun, WJ
   Wang, XJ
AF Sun, Hui
   Li, Lijing
   Zhang, Aihua
   Zhang, Ning
   Lv, Haitao
   Sun, Wenjun
   Wang, Xijun
TI Protective effects of sweroside on human MG 63 cells and rat osteoblasts
SO FITOTERAPIA
LA English
DT Article
DE Sweroside; Osteoporosis; MG 63 cells; Rat osteoblasts; Natural products
ID INDUCED BONE LOSS; FRUCTUS CORNI; INDUCED OSTEOPOROSIS; CHINESE
   MEDICINE; MORRONISIDE; CHROMATOGRAPHY; METABOLOMICS; COMPONENTS;
   EXTRACT; NETWORK
AB Herbal Fructus Corni is a folk medicine with a long history of safe use for treating osteoporosis in postmenopausal women or elderly men in Asia. Sweroside is a bioactive herbal ingredient isolated from Fructus Corni, which has been widely used for the treatment of osteoporosis in traditional Chinese medicine (TCM). Unfortunately, the working mechanisms of this compound are difficult to determine and thus remain unclear. The aim of the study was performed to determine the potential molecular mechanism of the anti osteoporotic effect of sweroside on the human MG 63 cells and rat osteoblasts. 3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide (MTT) test was used to observe the effect of sweroside on cell proliferation. The activity of alkaline phosphatase (ALP) and the amount of osteocalcin were also assayed the cell differentiation. Sweroside significantly increased the proliferation of human MG 63 cells and rat osteoblasts (P<0.01). It increased the activity of ALP, and osteocalcin was also elevated in response to sweroside (P<0.05). Of note, flowcytometer assay showed that sweroside can attenuate and inhibit apoptosis. Sweroside has a direct osteogenic effect on the proliferation and differentiation of cultured human MG 63 cells and rat osteoblasts in vitro. These data will help in understanding the molecular mechanisms of therapeutic efficacy of sweroside, and highlight insights into drug discovery. In the current study, sweroside has been suggested to be a promising osteoporosis therapeutic natural product. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Sun, Hui; Wang, Xijun] Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Harbin 150040, Peoples R China.
   [Sun, Hui; Wang, Xijun] Key Pharmacometabol Platform Chinese Med, Harbin 150040, Peoples R China.
C3 Heilongjiang University of Chinese Medicine
RP Sun, H (通讯作者)，Heilongjiang Univ Chinese Med, Natl TCM Key Lab Serum Pharmacochem, Heping Rd 24, Harbin 150040, Peoples R China.
EM metabonomics@126.com; xijunwangls@126.com
RI li, lijing/LMQ 3111 2024; Lyu, Haitao/K 9940 2016; Wang,
   Xijun/C 4477 2014
OI Wang, Xijun/0000 0002 0949 3492
FU National Key Subject of Drug Innovation [2009ZX09502 005]; Key Program
   of Natural Science Foundation of State [90709019]; National Specific
   Program on the Subject of Public Welfare [200807014]
FX This work was supported by grants from the National Key Subject of Drug
   Innovation (Grant No. 2009ZX09502 005), Key Program of Natural Science
   Foundation of State (grant no. 90709019), and the National Specific
   Program on the Subject of Public Welfare (grant no. 200807014).
CR Buckbinder L, 2007, P NATL ACAD SCI USA, V104, P10619, DOI 10.1073/pnas.0701421104
   Cao G, 2011, PHARM BIOL, V49, P989, DOI 10.3109/13880209.2010.551780
   Du WF, 2008, J PHARMACEUT BIOMED, V48, P194, DOI 10.1016/j.jpba.2008.04.021
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Ishii M, 2009, NATURE, V458, P524, DOI 10.1038/nature07713
   Ishijima M, 2006, EXP CELL RES, V312, P3075, DOI 10.1016/j.yexcr.2006.06.003
   Jun AY, 2012, FITOTERAPIA
   Kim DY, 2012, FITOTERAPIA, V83, P215, DOI 10.1016/j.fitote.2011.10.017
   Krawetz R, 2009, EXP CELL RES, V315, P2333, DOI 10.1016/j.yexcr.2009.04.026
   Li MY, 2010, MOLECULES, V15, P7403, DOI 10.3390/molecules15107403
   Li XN, 2007, J PHARMACEUT BIOMED, V45, P268, DOI 10.1016/j.jpba.2007.07.009
   Liu LP, 2009, J CHROMATOGR SCI, V47, P333
   Liu MJ, 2011, J TRADIT CHIN MED, V31, P98, DOI 10.1016/S0254 6272(11)60020 4
   Miura Y, 2005, P NATL ACAD SCI USA, V102, P14022, DOI 10.1073/pnas.0409397102
   Park CH, 2010, J PHARM PHARMACOL, V62, P374, DOI 10.1211/jpp.62.03.0013
   Sun H, 2012, PHYTOTHER RES, V26, P1466, DOI 10.1002/ptr.4613
   Wang SF, 2003, BIOMED CHROMATOGR, V17, P306, DOI 10.1002/bmc.247
   Wang XJ, 2012, MOL CELL PROTEOMICS, V11, P370, DOI 10.1074/mcp.M111.016006
   Wang XJ, 2012, OMICS, V16, P414, DOI 10.1089/omi.2011.0138
   Yokozawa T, 2008, BIOL PHARM BULL, V31, P1422, DOI 10.1248/bpb.31.1422
   Yokozawa T, 2010, DRUG DISCOV THER, V4, P223
   Zhang AH, 2012, PHARMAZIE, V67, P667, DOI 10.1691/ph.2012.2511
   Zhang AH, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752 0509 6 20
   Zhang R, 2012, J ETHNOPHARMACOL, V139, P12, DOI 10.1016/j.jep.2011.05.034
   Zhao X, 2011, J ETHNOPHARMACOL, V137, P1083, DOI 10.1016/j.jep.2011.07.017
NR 25
TC 43
Z9 53
U1 3
U2 67
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0367 326X
J9 FITOTERAPIA
JI Fitoterapia
PD JAN
PY 2013
VL 84
BP 174
EP 179
DI 10.1016/j.fitote.2012.11.010
PG 6
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 111OU
UT WOS:000316531400026
PM 23201331
DA 2025 08 17
ER

PT J
AU Su, Y
   Han, Y
   Choi, HS
   Lee, GY
   Cho, HW
   Choi, H
   Choi, JH
   Jang, YS
   Seo, JW
AF Su, Yan
   Han, Yunjon
   Choi, Hack Sun
   Lee, Gil Yong
   Cho, Hee Won
   Choi, Heonsik
   Choi, Jong Hyun
   Jang, Yong Suk
   Seo, Jeong Woo
TI Lipid mediators obtained from docosahexaenoic acid by soybean
   lipoxygenase attenuate RANKL induced osteoclast differentiation and
   rheumatoid arthritis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Rheumatoid arthritis; Lipid mediators; Inflammation
ID COLLAGEN INDUCED ARTHRITIS; MATRIX METALLOPROTEINASES; CURCUMIN;
   EFFICACY; PATHWAY; BIOLOGY; PAIN
AB Rheumatoid arthritis (RA) is a chronic immune  mediated inflammatory disease characterized by persistent inflammation and joint destruction. A lipid mediator (LM, namely, 17S monohydroxy docosahexaenoic acid, resolvin D5, and protectin DX in a ratio of 3:47:50) produced by soybean lipoxygenase from DHA, exhibits antiinflammatory activity. In this study, we determined the effect of LM on collagen antibody  induced arthritis (CAIA) in mice and receptor activator of nuclear factor kappa B ligand (RANKL) induced osteoclast formation in RAW264.7 cells. LM effectively downregulated the expression of tartrate  resistant acid phosphatase (TRAP) and cathepsin K, inhibited osteoclast formation, and suppressed the NF kappa B signaling pathway in vitro. In vivo, LM at 10 mu g/kg/day significantly decreased paw swelling and inhibited progression of arthritis in CAIA mice. Moreover, proinflammatory cytokine (tumor necrosis factor alpha, interleukin (IL)  6, IL 1 beta, IL  17, and interferon gamma) levels in serum were decreased, whereas IL  10 levels were increased following LM treatment. Furthermore, LM alleviated joint inflammation, cartilage erosion, and bone destruction in the ankles, which may be related to matrix metalloproteinase and Janus kinase (JAK) signal transducer and activators of transcription (STAT) signaling pathway. Our findings suggest that LM attenuates arthritis severity, restores serum imbalances, and modifies joint damage. Thus, LM represents a promising therapy for relieving RA symptoms.
C1 [Su, Yan; Han, Yunjon; Choi, Jong Hyun; Seo, Jeong Woo] Korea Res Inst Biosci & Biotechnol KRIBB, Microbial Biotechnol Res Ctr, Jeongeup Si 56212, South Korea.
   [Choi, Hack Sun] Yonsei Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 03722, South Korea.
   [Lee, Gil Yong; Cho, Hee Won; Choi, Heonsik] Kolon Adv Res Ctr, Healthcare Technol Inst, 110 Magokdong ro, Seoul 07793, South Korea.
   [Su, Yan; Jang, Yong Suk] Jeonbuk Natl Univ, Dept Bioact Mat Sci, Jeonju 54896, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Yonsei
   University; Yonsei University Health System; Jeonbuk National University
RP Seo, JW (通讯作者)，Korea Res Inst Biosci & Biotechnol KRIBB, Microbial Biotechnol Res Ctr, Jeongeup Si 56212, South Korea.; Jang, YS (通讯作者)，Jeonbuk Natl Univ, Dept Bioact Mat Sci, Jeonju 54896, South Korea.
EM yongsuk@jbnu.ac.kr; jwseo@kribb.re.kr
OI Choi, Heonsik/0000 0002 0489 2662
FU Microbial Biotechnology Research Center, Korea Research Institute of
   Bioscience and Biotechnology (KRIBB) from the Ministry of Science and
   ICT [KGM5482322, KGS1192322]
FX This research was funded by the Microbial Biotechnology Research Center,
   Korea Research Institute of Bioscience and Biotechnology (KRIBB) from
   the Ministry of Science and ICT (KGM5482322 and KGS1192322) .
CR Andreakos ET, 2002, CYTOKINE GROWTH F R, V13, P299, DOI 10.1016/S1359 6101(02)00018 7
   Ben Mrid R, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113126
   Benabdoun HA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1852 8
   Blair HC, 2005, BIOCHEM BIOPH RES CO, V328, P728, DOI 10.1016/j.bbrc.2004.11.077
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brown KD, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2457
   Burrage PS, 2006, FRONT BIOSCI LANDMRK, V11, P529, DOI 10.2741/1817
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choy EHS, 2018, RHEUMATOLOGY, V57, P1885, DOI 10.1093/rheumatology/kex391
   Conigliaro P, 2019, AUTOIMMUN REV, V18, P706, DOI 10.1016/j.autrev.2019.05.007
   Daily JW, 2016, J MED FOOD, V19, P717, DOI 10.1089/jmf.2016.3705
   Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007
   Endale M, 2013, INT IMMUNOPHARMACOL, V16, P232, DOI 10.1016/j.intimp.2013.04.012
   Feng ZT, 2019, BIOMED PHARMACOTHER, V113, DOI 10.1016/j.biopha.2019.108759
   Fuchs S, 2004, OSTEOARTHR CARTILAGE, V12, P409, DOI 10.1016/j.joca.2004.02.005
   Gagestein B, 2022, J AM CHEM SOC, V144, P18938, DOI 10.1021/jacs.2c06827
   Giannelli G, 2004, CLIN EXP RHEUMATOL, V22, P335
   Gomez EA, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 19176 z
   Harrington R, 2020, J INFLAMM RES, V13, P519, DOI 10.2147/JIR.S219586
   Heard BJ, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471 2474 13 126
   Heo Y, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114067
   Kiadaliri AA, 2017, ARTHRITIS RHEUMATOL, V69, P1560, DOI 10.1002/art.40091
   Kiu H, 2012, GROWTH FACTORS, V30, P88, DOI 10.3109/08977194.2012.660936
   Kondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010922
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Lau CS, 2019, INT J RHEUM DIS, V22, P357, DOI 10.1111/1756 185X.13513
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lee MS, 2009, J IMMUNOL, V183, P3390, DOI 10.4049/jimmunol.0804314
   Li YJ, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13291
   Lotz B, 2021, INT J BIOMATER, V2021, DOI 10.1155/2021/5583815
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Moon DO, 2010, INT IMMUNOPHARMACOL, V10, P605, DOI 10.1016/j.intimp.2010.02.011
   O'Shea JJ, 2015, ANNU REV MED, V66, P311, DOI 10.1146/annurev med 051113 024537
   Özdemir RBÖ, 2020, IMMUNOL LETT, V227, P34, DOI 10.1016/j.imlet.2020.08.006
   Park JH, 2017, MOL CELLS, V40, P706
   Pulik L, 2023, REUMATOLOGIA, V61, P191, DOI 10.5114/reum/168503
   Raoof R, 2018, RHEUMATOLOGY, V57, P429, DOI 10.1093/rheumatology/kex308
   Ritchlin C, 2000, ARTHRITIS RES, V2, P356, DOI 10.1186/ar112
   Shi Q, 2018, INT J NANOMED, V13, P387, DOI 10.2147/IJN.S146942
   Simon LS, 2021, SEMIN ARTHRITIS RHEU, V51, P278, DOI 10.1016/j.semarthrit.2020.10.008
   Souza PR, 2016, EUR J PHARMACOL, V785, P165, DOI 10.1016/j.ejphar.2015.05.072
   Su JS, 2021, J ETHNOPHARMACOL, V267, DOI 10.1016/j.jep.2020.113514
   Su Y, 2023, INT IMMUNOPHARMACOL, V124, DOI 10.1016/j.intimp.2023.110900
   Sun WW, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 2133 2
   Suokas AK, 2014, OSTEOARTHR CARTILAGE, V22, P1207, DOI 10.1016/j.joca.2014.06.015
   Taams LS, 2020, J EXP MED, V217, DOI 10.1084/jem.20192048
   Taylor P, 2010, J INT MED RES, V38, P1213, DOI 10.1177/147323001003800402
   Taylor PC, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060831
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang QR, 2019, INT IMMUNOPHARMACOL, V72, P292, DOI 10.1016/j.intimp.2019.04.027
   Weyand CM, 2021, NAT IMMUNOL, V22, P10, DOI 10.1038/s41590 020 00816 x
   Yamada H, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 96530 1
   Yarilina A, 2012, ARTHRITIS RHEUM US, V64, P3856, DOI 10.1002/art.37691
   Zhang SC, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 36468 2
   Zhang XR, 2023, INFLAMMOPHARMACOLOGY, V31, P2995, DOI 10.1007/s10787 023 01343 5
NR 56
TC 2
Z9 3
U1 1
U2 12
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD FEB
PY 2024
VL 171
AR 116153
DI 10.1016/j.biopha.2024.116153
EA JAN 2024
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA IB3R9
UT WOS:001163828000001
PM 38232664
OA gold
DA 2025 08 17
ER

PT J
AU Loaiza, S
   Ferreira, SA
   Chinn, TM
   Kirby, A
   Tsolaki, E
   Dondi, C
   Parzych, K
   Strange, AP
   Bozec, L
   Bertazzo, S
   Hedegaard, MAB
   Gentleman, E
   Auner, HW
AF Loaiza, Sandra
   Ferreira, Silvia A.
   Chinn, Tamara M.
   Kirby, Alex
   Tsolaki, Elena
   Dondi, Camilla
   Parzych, Katarzyna
   Strange, Adam P.
   Bozec, Laurent
   Bertazzo, Sergio
   Hedegaard, Martin A. B.
   Gentleman, Eileen
   Auner, Holger W.
TI An engineered, quantifiable in vitro model for analysing the
   effect of proteostasis targeting drugs on tissue physical properties
SO BIOMATERIALS
LA English
DT Article
DE Proteostasis; VCP/p97; Raman spectroscopy; Cancer diagnosis and therapy;
   Atomic force microscopy; Proteasome
ID PROTEASOME INHIBITOR BORTEZOMIB; VALOSIN CONTAINING PROTEIN;
   ENDOPLASMIC RETICULUM STRESS; MULTIPLE MYELOMA PATIENTS; ATOMIC FORCE
   MICROSCOPE; MESENCHYMAL STEM CELLS; CORTICAL BONE; OSTEOBLAST
   DIFFERENTIATION; MECHANICAL PROPERTIES; AAA ATPASE
AB Cellular function depends on the maintenance of protein homeostasis (proteostasis) by regulated protein degradation. Chronic dysregulation of proteostasis is associated with neurodegenerative and age related diseases, and drugs targeting components of the protein degradation apparatus are increasingly used in cancer therapies. However, as chronic imbalances rather than loss of function mediate their pathogenesis, research models that allow for the study of the complex effects of drugs on tissue properties in proteostasis associated diseases are almost completely lacking. Here, to determine the functional effects of impaired proteostatic fine tuning, we applied a combination of materials science characterisation techniques to a cell derived, in vitro model of bone like tissue formation in which we pharmacologically perturbed protein degradation. We show that low level inhibition of VCP/p97 and the proteasome, two major components of the degradation machinery, have remarkably different effects on the bone like material that human bone marrow derived mesenchymal stromal cells (hMSC) form in vitro. Specifically, whilst proteasome inhibition mildly enhances tissue formation, Raman spectroscopic, atomic force microscopy based indentation, and electron microscopy imaging reveal that VCP/p97 inhibition induces the formation of bone like tissue that is softer, contains less protein, appears to have more crystalline mineral, and may involve aberrant micro  and ultra structural tissue organisation. These observations contrast with findings from conventional osteogenic assays that failed to identify any effect on mineralisation. Taken together, these data suggest that mild proteostatic impairment in hMSC alters the bone like material they form in ways that could explain some pathologies associated with VCP/p97 related diseases. They also demonstrate the utility of quantitative materials science approaches for tackling long standing questions in biology and medicine, and could form the basis for preclinical drug testing platforms to develop therapies for diseases stemming from perturbed proteostasis or for cancer therapies targeting protein degradation. Our findings may also have important implications for the field of tissue engineering, as the manufacture of cell derived biomaterial scaffolds may need to consider proteostasis to effectively replicate native tissues.
C1 [Loaiza, Sandra; Chinn, Tamara M.; Parzych, Katarzyna; Auner, Holger W.] Imperial Coll London, Dept Med, Canc Cell Prot Metab Grp, London W12 0NN, England.
   [Ferreira, Silvia A.; Chinn, Tamara M.; Dondi, Camilla; Gentleman, Eileen] Kings Coll London, Ctr Craniofacial & Regenerat Biol, London SE1 9RT, England.
   [Kirby, Alex; Tsolaki, Elena; Bertazzo, Sergio] UCL, Dept Med Phys & Biomed Engn, London WC1E 6BT, England.
   [Strange, Adam P.; Bozec, Laurent] UCL, Biomat & Tissue Engn, Eastman Dent Inst, London WC1X 8LD, England.
   [Hedegaard, Martin A. B.] Univ Southern Denmark, Dept Chem Engn Biotechnol & Environm Technol, DK 5230 Odense M, Denmark.
   [Bozec, Laurent] Univ Toronto, Fac Dent, 124 Edward St, Toronto, ON M5G 1G6, Canada.
C3 Imperial College London; University of London; King's College London;
   University of London; University College London; University of London;
   University College London; University of Southern Denmark; University of
   Toronto
RP Auner, HW (通讯作者)，Imperial Coll London, Dept Med, Canc Cell Prot Metab Grp, London W12 0NN, England.; Gentleman, E (通讯作者)，Kings Coll London, Ctr Craniofacial & Regenerat Biol, London SE1 9RT, England.
EM eileen.gentleman@kcl.ac.uk; holger.auner04@imperial.ac.uk
RI Auner, Holger/LMO 0071 2024; Bozec, Laurent/AAY 7832 2020; Ferreira,
   Silvia/Q 2864 2018; Hedegaard, Martin A.B./X 9953 2018; Hedegaard,
   Martin/X 9953 2018; Rodrigues Mendes Ferreira, Silvia
   Alexandra/Q 2864 2018; Bertazzo, Sergio/J 7357 2016
OI Hedegaard, Martin A.B./0000 0003 2972 0899; Gentleman,
   Eileen/0000 0003 0447 5137; Rodrigues Mendes Ferreira, Silvia
   Alexandra/0000 0001 7837 3040; Bozec, Laurent/0000 0001 6322 7817;
   Auner, Holger/0000 0003 4040 0642; Tsolaki, Elena/0000 0003 1436 7834; 
FU Imperial College London NIHR BRC; Cancer Research UK Imperial Centre;
   Imperial Experimental Cancer Medicine Centre; Imperial College
   Healthcare Tissue Biobank; Cancer Research UK Clinician Scientist
   Fellowship; Research Career Development Fellowship from the Wellcome
   Trust; Leverhulme Trust; STSM Grant from the COST Action [BM1401];
   Whitaker International Program Fellowship; Cancer Research UK [15448]
   Funding Source: researchfish
FX HWA and SL acknowledge the support of the Imperial College London NIHR
   BRC, the Cancer Research UK Imperial Centre, the Imperial Experimental
   Cancer Medicine Centre, and the Imperial College Healthcare Tissue
   Biobank. HWA was supported by a Cancer Research UK Clinician Scientist
   Fellowship. EG was supported by a Research Career Development Fellowship
   from the Wellcome Trust and a Philip Leverhulme Prize from the
   Leverhulme Trust. MABH was supported by a STSM Grant from the COST
   Action BM1401. TMC was supported by a Whitaker International Program
   Fellowship.
CR Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   Almanza A., 2018, FEES J
   Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002
   Balchin D, 2016, SCIENCE, V353, DOI 10.1126/science.aac4354
   Bastola P, 2016, MOL ONCOL, V10, P1559, DOI 10.1016/j.molonc.2016.09.005
   Bertazzo S, 2013, NAT MATER, V12, P576, DOI [10.1038/NMAT3627, 10.1038/nmat3627]
   Bonewald LF, 2003, CALCIFIED TISSUE INT, V72, P537, DOI 10.1007/s00223 002 1057 y
   Butt HJ, 2005, SURF SCI REP, V59, P1, DOI 10.1016/j.surfrep.2005.08.003
   Carden A, 2000, J BIOMED OPT, V5, P259, DOI 10.1117/1.429994
   Cenci S, 2006, EMBO J, V25, P1104, DOI 10.1038/sj.emboj.7601009
   Choi S., 2018, BIOMATERIALS
   Chou TF, 2011, AUTOPHAGY, V7, P1091, DOI 10.4161/auto.7.9.16489
   Chou TF, 2011, P NATL ACAD SCI USA, V108, P4834, DOI 10.1073/pnas.1015312108
   Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015
   Clemen CS, 2010, BRAIN, V133, P2920, DOI 10.1093/brain/awq222
   de la Puente F, 2015, BIOMATERIALS, V73, P70, DOI 10.1016/j.biomaterials.2015.09.017
   Deleu S, 2009, CANCER RES, V69, P5307, DOI 10.1158/0008 5472.CAN 08 4472
   Deshaies RJ, 2014, BMC BIOL, V12, DOI 10.1186/s12915 014 0094 0
   Evans ND, 2012, EUR CELLS MATER, V24, P211, DOI 10.22203/eCM.v024a15
   Evans ND, 2010, BIOMATERIALS, V31, P3244, DOI 10.1016/j.biomaterials.2010.01.039
   Garrett IR, 2003, J CLIN INVEST, V111, P1771, DOI 10.1172/JCI200316198
   Gebrehiwet T, 2014, APPL GEOCHEM, V46, P43, DOI 10.1016/j.apgeochem.2014.04.005
   Gentleman E, 2009, NAT MATER, V8, P763, DOI [10.1038/NMAT2505, 10.1038/nmat2505]
   Gioia R, 2012, STEM CELLS, V30, P1465, DOI 10.1002/stem.1107
   Giuliani N, 2007, BLOOD, V110, P334, DOI 10.1182/blood 2006 11 059188
   Gonzalez MA, 2014, BRAIN, V137, P2897, DOI 10.1093/brain/awu224
   Gourion Arsiquaud S, 2009, J BONE MINER RES, V24, P1565, DOI [10.1359/jbmr.090414, 10.1359/JBMR.090414]
   Guo FJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.194
   Han DY, 2015, J BIOL CHEM, V290, P325, DOI 10.1074/jbc.M114.580324
   Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425
   Hetz C, 2015, NAT CELL BIOL, V17, P829, DOI 10.1038/ncb3184
   Hetz C, 2014, NAT REV NEUROSCI, V15, P233, DOI 10.1038/nrn3689
   HUTTER JL, 1993, REV SCI INSTRUM, V64, P1868, DOI 10.1063/1.1143970
   Janiesch PC, 2007, NAT CELL BIOL, V9, P379, DOI 10.1038/ncb1554
   Ju J. S., 2010, HUM MOL GENET, V19, pR38
   Jung YG, 2004, J MATER RES, V19, P3076, DOI 10.1557/JMR.2004.0380
   Kaushik S., 2015, ANNU REV BIOCHEM, V21, P1406
   Lefèvre E, 2013, COMPUT METHOD BIOMEC, V16, P337, DOI 10.1080/10255842.2013.815974
   Li BH, 1997, J BONE MINER RES, V12, P641, DOI 10.1359/jbmr.1997.12.4.641
   Lieber CA, 2003, APPL SPECTROSC, V57, P1363, DOI 10.1366/000370203322554518
   Liewluck T, 2014, MUSCLE NERVE, V50, P295, DOI 10.1002/mus.24290
   Lund T, 2010, EUR J HAEMATOL, V85, P290, DOI 10.1111/j.1600 0609.2010.01485.x
   Lv FJ, 2014, STEM CELLS, V32, P1408, DOI 10.1002/stem.1681
   Meyer H, 2014, J CELL SCI, V127, P3877, DOI 10.1242/jcs.093831
   Meyer H, 2012, BMC BIOL, V10, DOI 10.1186/1741 7007 10 48
   Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181
   Moran Crusio K, 2012, TRENDS IMMUNOL, V33, P357, DOI 10.1016/j.it.2012.01.009
   Morris MD, 2011, CLIN ORTHOP RELAT R, V469, P2160, DOI 10.1007/s11999 010 1692 y
   Müller JMM, 2007, BIOCHEM BIOPH RES CO, V354, P459, DOI 10.1016/j.bbrc.2006.12.206
   Mukherjee A, 2015, TRENDS MOL MED, V21, P439, DOI 10.1016/j.molmed.2015.04.005
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Notingher I, 2004, J CELL BIOCHEM, V92, P1180, DOI 10.1002/jcb.20136
   Nudelman F, 2010, NAT MATER, V9, P1004, DOI 10.1038/NMAT2875
   Parzych K, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.373
   Pérez VI, 2009, P NATL ACAD SCI USA, V106, P3059, DOI 10.1073/pnas.0809620106
   Qiang YW, 2009, BLOOD, V113, P4319, DOI 10.1182/blood 2008 08 174300
   Querido W, 2011, CALCIFIED TISSUE INT, V89, P358, DOI 10.1007/s00223 011 9526 9
   Reznikov N, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.41
   Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Schneider K, 2015, J CELL SCI, V128, P3861, DOI 10.1242/jcs.173047
   Sirghi L, 2008, EUR BIOPHYS J BIOPHY, V37, P935, DOI 10.1007/s00249 008 0311 2
   Skrott Z, 2017, NATURE, V552, P194, DOI 10.1038/nature25016
   Sui B.D., 2017, Biomaterials
   Tarnowski CP, 2004, J BONE MINER RES, V19, P64, DOI 10.1359/JBMR.0301201
   Tohmonda T, 2011, EMBO REP, V12, P451, DOI 10.1038/embor.2011.34
   Toscani D, 2016, J BONE MINER RES, V31, P815, DOI 10.1002/jbmr.2741
   Tresse E, 2010, AUTOPHAGY, V6, P217, DOI 10.4161/auto.6.2.11014
   Uyama M, 2012, GENES CELLS, V17, P548, DOI 10.1111/j.1365 2443.2012.01611.x
   Verma R, 2011, MOL CELL, V41, P82, DOI 10.1016/j.molcel.2010.12.017
   Volponi AA, 2015, J DENT RES, V94, P1568, DOI 10.1177/0022034515599765
   Wallace JM, 2009, J BONE MINER RES, V24, P1002, DOI [10.1359/JBMR.081259, 10.1359/jbmr.081259]
   Wang T, 2016, J BIOL CHEM, V291, P14373, DOI 10.1074/jbc.M116.729343
   Watts GDJ, 2004, NAT GENET, V36, P377, DOI 10.1038/ng1332
   Widjaja CE, 2017, J CLIN INVEST, V127, P3609, DOI 10.1172/JCI90895
   Yan YW, 2015, BIOMATERIALS, V73, P231, DOI 10.1016/j.biomaterials.2015.09.020
   Ye YH, 2003, J CELL BIOL, V162, P71, DOI 10.1083/jcb.200302169
   Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a
   Yerramshetty JS, 2008, BONE, V42, P476, DOI 10.1016/j.bone.2007.12.001
   Zimmermann EA, 2015, J BONE MINER RES, V30, P264, DOI 10.1002/jbmr.2340
NR 80
TC 9
Z9 9
U1 1
U2 35
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2018
VL 183
BP 102
EP 113
DI 10.1016/j.biomaterials.2018.08.041
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA GW7AQ
UT WOS:000447116600010
PM 30153561
OA Green Accepted, Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Kün Darbois, JD
   Quenel, L
   Badja, S
   Chappard, D
AF Kuen Darbois, Jean Daniel
   Quenel, Leonie
   Badja, Smail
   Chappard, Daniel
TI Tooth Extraction Locally Stimulates Proliferation of Multiple Myeloma in
   a Patient with Mandibular Localizations
SO ACTA HAEMATOLOGICA
LA English
DT Article
DE Bisphosphonate; Multiple myeloma; Osteonecrosis; Tooth extraction; Tumor
   growth
ID BONE DESTRUCTION; EMERGING ENTITY; VICIOUS CYCLE; MOUSE MODEL;
   BISPHOSPHONATE; MANAGEMENT; TRAUMA; OSTEOCLASTS; MECHANISMS; PREVENTION
AB Objectives: Multiple myeloma (MM) is characterized by the occurrence of osteolytic lesions. MM treatment usually involves antiresorptive drugs (mainly bisphosphonates). Case Report: A patient with an MM presented osteolytic lesions of the mandible. Extraction of teeth 45 and 46 was performed 5 years after the diagnosis of periodontitis. Four months later, osteonecrosis of the jaw (ONJ) was diagnosed at the extraction site. X ray showed an extension of osteolytic lesions on the right side, close to the extraction site, without modification of the lesions on the left side. Two months later, a curettage was performed because of a painful bone sequestration. X ray showed an extension of the osteolytic lesions on the right side. Results: Histological analysis found a vascularized plasmacytoma of the soft tissues around the ONJ. Analysis of the bone showed mixed lesions with osteonecrotic areas and living bone resorbed by active osteoclasts surrounding a plasmacytoma. The surface area of the osteolytic foci has considerably increased only close to the extraction site. Conclusions: Tooth extraction triggered an ONJ associated with bisphosphonate treatment. However, it also seemed to induce a considerable proliferation of plasma cells at the extraction site; we hypothesize that it is due to the increase in bone remodeling related to the surgical trauma. (C) 2017 S. Karger AG, Basel
C1 [Kuen Darbois, Jean Daniel; Quenel, Leonie; Badja, Smail] CHU Angers, Dept Maxillofacial Surg, Angers, France.
   [Kuen Darbois, Jean Daniel; Chappard, Daniel] Univ Angers, CHU Angers, IRIS,IBS Inst Biol Sante, GEROM Res Grp Bone Remodeling & Biomat,Grp Etud, Angers, France.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite
   d'Angers; Centre Hospitalier Universitaire d'Angers
RP Chappard, D (通讯作者)，CHU Angers, IBS, IRIS, GEROM,LHEA, 4 Rue Larrey, FR 49933 Angers, France.
EM daniel.chappard@univ angers.fr
RI ; Kün Darbois, Jean Daniel/AAD 6194 2019
OI KUN DARBOIS, Jean Daniel/0000 0002 0818 7856; 
FU French Ministry of Research
FX This work was made possible by grants from the French Ministry of
   Research.
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2009, J BONE MINER METAB, V27, P16, DOI 10.1007/s00774 008 0012 z
   AMLER MH, 1969, ORAL SURG ORAL MED O, V27, P309, DOI 10.1016/0030 4220(69)90357 0
   [Anonymous], 2014, BONE CANC PROGR THER
   Bataille R., 2015, Morphologie, V99, P31, DOI 10.1016/j.morpho.2015.03.002
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Bodic F, 2005, JOINT BONE SPINE, V72, P215, DOI 10.1016/j.jbspin.2004.03.007
   Cavo M, 2017, LANCET ONCOL, V18, pE206, DOI 10.1016/S1470 2045(17)30189 4
   Chappard D., 2011, Morphologie, V95, P65, DOI 10.1016/j.morpho.2011.02.004
   CHAPPARD D, 1991, J BONE MINER RES, V6, P673
   COHEN HJ, 1972, CANCER, V29, P466, DOI 10.1002/1097 0142(197202)29:2<466::AID CNCR2820290234>3.0.CO;2 M
   Fregnani Eduardo Rodrigues, 2016, J Clin Exp Dent, V8, pe465
   Goetze E, 2015, J MAXILLOFAC ORAL SU, V14, pS469, DOI 10.1007/s12663 014 0688 7
   HUEBSCH RF, 1952, ORAL SURG ORAL MED O, V5, P864, DOI 10.1016/0030 4220(52)90316 2
   Kim Y H, 1986, Orthop Rev, V15, P534
   KINJO T, 1985, Neurological Surgery, V13, P1191
   Krstevska Svetlana, 2015, Med Arch, V69, P367, DOI 10.5455/medarh.2015.69.367 370
   LEE JY, 1994, J SURG ONCOL, V56, P178, DOI 10.1002/jso.2930560311
   Libouban H., 2015, Morphologie, V99, P63, DOI 10.1016/j.morpho.2015.01.003
   Libouban H, 2004, BIOCHEM BIOPH RES CO, V316, P859, DOI 10.1016/j.bbrc.2004.02.131
   Libouban H, 2003, BONE, V33, P283, DOI 10.1016/S8756 3282(03)00196 0
   Libouban H, 2017, MICRON, V96, P77, DOI 10.1016/j.micron.2017.01.009
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Moura LB, 2016, J CRANIOFAC SURG, V27, pE138, DOI 10.1097/SCS.0000000000002386
   Muchtar E, 2014, ACTA HAEMATOL BASEL, V132, P39, DOI 10.1159/000354830
   Paraguassu Gardenia Matos, 2013, General Dentistry, V61, P69
   Parent E, 2016, J NUCL MED, V57
   PIETROKOVSKI J, 1971, ISRAEL J MED SCI, V7, P433
   Roodman GD, 2009, LEUKEMIA, V23, P435, DOI 10.1038/leu.2008.336
   Rosenblum MD, 2003, AM J HEMATOL, V72, P274, DOI 10.1002/ajh.10296
   Rosiñol L, 2014, ACTA HAEMATOL BASEL, V132, P36, DOI 10.1159/000354833
   Ruggiero SL, 2009, ANNU REV MED, V60, P85, DOI 10.1146/annurev.med.60.063007.134350
   Stein M E, 2003, J BUON, V8, P163
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Vermeer JAF, 2013, BONE, V57, P242, DOI 10.1016/j.bone.2013.08.007
   VIGNERY A, 1980, ANAT RECORD, V196, P191, DOI 10.1002/ar.1091960210
NR 36
TC 4
Z9 4
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 0001 5792
EI 1421 9662
J9 ACTA HAEMATOL BASEL
JI Acta Haematol.
PY 2017
VL 138
IS 4
BP 201
EP 207
DI 10.1159/000481425
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA FU3QM
UT WOS:000423766800004
PM 29207391
DA 2025 08 17
ER

PT J
AU Lee, SJ
   Yang, H
   Kim, SC
   Gu, DR
   Ryuk, JA
   Jang, SA
   Ha, H
AF Lee, Sung Ju
   Yang, Hyun
   Kim, Seong Cheol
   Gu, Dong Ryun
   Ryuk, Jin Ah
   Jang, Seon A
   Ha, Hyunil
TI Ethanol Extract of Radix Asteris Suppresses Osteoclast Differentiation
   and Alleviates Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Radix Asteris; osteoporosis; ovariectomy; osteoclast
ID C FOS; BONE HOMEOSTASIS; RANKL; INDUCTION; TATARICUS; NFATC1; FUSION;
   OSTEOGENESIS; REGULATORS; MICE
AB Radix Asteris, the root of Aster tataricus L. f., is historically significant in East Asian medicine for treating respiratory conditions. Yet, its implications on bone health remain uncharted. This research investigated the impact of an aqueous ethanol extract of Radix Asteris (EERA) on osteoclast differentiation and its prospective contribution to osteoporosis management. We discerned that EERA retards osteoclast differentiation by inhibiting receptor activator of nuclear factor kappa B ligand (RANKL) expression and obstructing RANKL induced osteoclastogenesis. EERA markedly suppressed RANKL induced expression of NFATc1, a pivotal osteoclastogenic factor, via modulating early RANK signaling. EERA's therapeutic potential was underscored by its defense against trabecular bone degradation and its counteraction to increased body and perigonadal fat in ovariectomized mice, mirroring postmenopausal physiological changes. In the phytochemical analysis of EERA, we identified several constituents recognized for their roles in regulating bone and fat metabolism. Collectively, our findings emphasize the potential of EERA in osteoclast differentiation modulation and in the management of osteoporosis and associated metabolic changes following estrogen depletion, suggesting its suitability as an alternative therapeutic strategy for postmenopausal osteoporosis intertwined with metabolic imbalances.
C1 [Lee, Sung Ju; Yang, Hyun; Kim, Seong Cheol; Gu, Dong Ryun; Ryuk, Jin Ah; Ha, Hyunil] Korea Inst Oriental Med KIOM, KM Convergence Res Div, 1672 Yuseong Daero, Daejeon 34054, South Korea.
   [Jang, Seon A] KT&G Corp, Future Technol Res Ctr, 30 Gajeong Ro, Daejeon 34128, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ha, H (通讯作者)，Korea Inst Oriental Med KIOM, KM Convergence Res Div, 1672 Yuseong Daero, Daejeon 34054, South Korea.
EM sungjulee@kiom.re.kr; hyunyang@kiom.re.kr; iron0907@kiom.re.kr;
   mrwonsin@kiom.re.kr; yukjinah@kiom.re.kr; jsa85@ktng.com;
   hyunil74@kiom.re.kr
RI Yang, Hyun/P 4126 2014
OI Yang, Hyun/0000 0001 6483 2373
FU Korea Institute of Oriental Medicine, Ministry of Education, Science,
   and Technology
FX No Statement Available
CR Bartella L, 2023, SEPARATIONS, V10, DOI 10.3390/separations10010026
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen YJ, 2020, BIOMED PHARMACOTHER, V130, DOI 10.1016/j.biopha.2020.110616
   Chen YJ, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030543
   Cho AS, 2010, FOOD CHEM TOXICOL, V48, P937, DOI 10.1016/j.fct.2010.01.003
   Choi EB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113512
   Du H, 2017, BIOMED PHARMACOTHER, V89, P617, DOI 10.1016/j.biopha.2017.01.179
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   Gu DR, 2022, NUTRIENTS, V14, DOI 10.3390/nu14173667
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Jang SA, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.719602
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 2015, EUR J PHARMACOL, V759, P287, DOI 10.1016/j.ejphar.2015.03.028
   Lee SH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020322
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Li KJ, 2022, MOLECULES, V27, DOI 10.3390/molecules27175388
   Liu XD, 2012, J PHARMACEUT BIOMED, V67 68, P51, DOI 10.1016/j.jpba.2012.04.034
   Lotinun S, 2013, J CLIN INVEST, V123, P666, DOI 10.1172/JCI64840
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Nowak B, 2017, PHARMACOL REP, V69, P1113, DOI 10.1016/j.pharep.2017.05.002
   Ono T, 2018, HISTOCHEM CELL BIOL, V149, P325, DOI 10.1007/s00418 018 1636 2
   Pacifici R, 2010, BONE, V47, P461, DOI 10.1016/j.bone.2010.04.611
   Peng SG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/8594767
   Peng WJ, 2016, AFR J TRADIT COMPLEM, V13, P38, DOI 10.21010/ajtcam.v13i6.8
   Polyzos SA, 2021, MATURITAS, V147, P19, DOI 10.1016/j.maturitas.2021.02.007
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   Rho J, 2020, J ETHNOPHARMACOL, V255, DOI 10.1016/j.jep.2020.112779
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008 1405
   Sun YP, 2018, J PHARMACEUT BIOMED, V154, P216, DOI 10.1016/j.jpba.2018.03.022
   Sung YY, 2015, J ETHNOPHARMACOL, V168, P17, DOI 10.1016/j.jep.2015.03.051
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Tori M, 2001, SPECTROSC INT J, V15, P119, DOI 10.1155/2001/719878
   Tyagi AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021216
   Wang L, 2014, CHEM BIOL INTERACT, V223, P1, DOI 10.1016/j.cbi.2014.09.003
   Wu H, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.111005
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Yang YJ, 2023, PHYTOMEDICINE, V116, DOI 10.1016/j.phymed.2023.154875
   Yu P, 2015, J ETHNOPHARMACOL, V164, P328, DOI 10.1016/j.jep.2015.02.036
   Yuan Z, 2018, AM J TRANSL RES, V10, P4313
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao DX, 2015, J SEP SCI, V38, P571, DOI 10.1002/jssc.201401008
   Zhao J, 2019, MOL MED REP, V20, P5197, DOI 10.3892/mmr.2019.10747
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
   Zhou YN, 2017, J MATER CHEM B, V5, P612, DOI 10.1039/c6tb02312f
NR 57
TC 3
Z9 3
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2023
VL 24
IS 22
AR 16526
DI 10.3390/ijms242216526
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA Z9RG6
UT WOS:001115373400001
PM 38003715
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Schurman, L
   McCarthy, AD
   Sedlinsky, C
   Gangoiti, MV
   Arnol, V
   Bruzzone, L
   Cortizo, AM
AF Schurman, L.
   McCarthy, A. D.
   Sedlinsky, C.
   Gangoiti, M. V.
   Arnol, V.
   Bruzzone, L.
   Cortizo, A. M.
TI Metformin reverts deleterious effects of advanced glycation end products
   (AGEs) on osteoblastic cells
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE metformin; advanced glycation end product; osteoblasts; oxidative
   stress; RAGE
ID DIABETES MELLITUS; ENDOTHELIAL CELLS; FRACTURE RISK; KAPPA B;
   EXPRESSION; BONE; RECEPTOR; DIFFERENTIATION; CULTURE; GLUCOSE
AB Advanced glycation endproducts (AGEs) are implicated in the complications of diabetes and ageing, affecting several tissues, including bone. Metformin, an insulin sensitizer drug, reduces the risk of life threatening macrovascular complications. We have evaluated the hypothesis that metformin can abrogate AGE induced deleterious effects in osteoblastic cells in culture. In two osteoblast like cell lines (UMR106 and MC3T3E1), AGE modified albumin induced cell death, caspase 3 activity, altered intracellular oxidative stress and inhibited alkaline phosphatase activity. Metformin treatment of osteoblastic cells prevented these AGE induced alterations. We also assessed the expression of AGE receptors as a possible mechanism by which metformin could modulate the action of AGES. AGEs treatment of osteoblast like cells enhanced RAGE protein expression, and this up regulation was prevented in the presence of metformin. Although the precise mechanisms involved in metformin signaling are still elusive, our data implicate the AGE RAGE interaction in the modulation of growth and differentiation of osteoblastic cells.
C1 [McCarthy, A. D.; Gangoiti, M. V.; Arnol, V.; Cortizo, A. M.] Natl Univ La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, RA 1900 La Plata, Argentina.
   [Schurman, L.; Sedlinsky, C.] Hosp Frances Riosa, Ctr Endocrinol & Metab, Buenos Aires, DF, Argentina.
   [Bruzzone, L.] Natl Univ La Plata, Fac Ciencias Exactas, Div Quim Analilt, RA 1900 La Plata, Argentina.
C3 National University of La Plata; National University of La Plata
RP Cortizo, AM (通讯作者)，Natl Univ La Plata, Fac Ciencias Exactas, Catedra Bioquim Patol, 47 & 115, RA 1900 La Plata, Argentina.
EM cortizo@biol.unlp.edu.ar
RI ; McCarthy, Antonio/AAN 2596 2020
OI McCarthy, Antonio Desmond/0000 0002 9175 6596; Sedlinsky,
   Claudia/0009 0006 1825 9397; Bruzzone, Liliana/0000 0001 7960 0145; 
CR Al Mashat HA, 2006, DIABETES, V55, P487, DOI 10.2337/diabetes.55.02.06.db05 1201
   Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011
   Bellin C, 2006, HORM METAB RES, V38, P732, DOI 10.1055/s 2006 955084
   Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109 005 0688 7
   Bierhaus A, 2006, CURR OPIN INVEST DR, V7, P985
   BOUILLON R, 1991, CALCIFIED TISSUE INT, V49, P155, DOI 10.1007/BF02556109
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Carnevale V, 2004, DIABETES METAB RES, V20, P196, DOI 10.1002/dmrr.449
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Cortizo AM, 2003, MOL CELL BIOCHEM, V250, P1, DOI 10.1023/A:1024934008982
   CORTIZO AM, 1995, MOL CELL BIOCHEM, V145, P97, DOI 10.1007/BF00935481
   Forbes JM, 2007, EXP CLIN ENDOCR DIAB, V115, P69, DOI 10.1055/s 2007 949721
   Haslbeck KM, 2005, EXP CLIN ENDOCR DIAB, V113, P288, DOI 10.1055/s 2005 865600
   Hein G, 2006, ANN RHEUM DIS, V65, P101, DOI 10.1136/ard.2004.034348
   Hein G, 2003, RHEUMATOLOGY, V42, P1242, DOI 10.1093/rheumatology/keg324
   Kaji Y, 2003, INVEST OPHTH VIS SCI, V44, P521, DOI 10.1167/iovs.02 0268
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   Kume S, 2005, J BONE MINER RES, V20, P1647, DOI 10.1359/JBMR.050514
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Marx N, 2004, DIABETES, V53, P2662, DOI 10.2337/diabetes.53.10.2662
   McCarthy AD, 1997, MOL CELL BIOCHEM, V170, P43, DOI 10.1023/A:1006816223292
   McCarthy AD, 1999, ACTA DIABETOL, V36, P45, DOI 10.1007/s005920050144
   McCarthy AD, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471 2121 2 16
   Mercer N, 2004, MOL CELL BIOCHEM, V266, P17, DOI 10.1023/B:MCBI.0000049128.71095.ac
   Mercer N, 2007, MOL CELL BIOCHEM, V306, P87, DOI 10.1007/s11010 007 9557 8
   Molinuevo MS, 2004, CANCER CHEMOTH PHARM, V53, P163, DOI 10.1007/s00280 003 0708 7
   Mukherjee TK, 2005, BBA MOL CELL RES, V1744, P213, DOI 10.1016/j.bbamcr.2005.03.007
   Odetti P, 2006, HORM METAB RES, V38, P817, DOI 10.1055/s 2006 956501
   Ouslimani N, 2007, METABOLISM, V56, P308, DOI 10.1016/j.metabol.2006.10.010
   PARTRIDGE NC, 1983, CANCER RES, V43, P4308
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Scharnagl H, 2007, EXP CLIN ENDOCR DIAB, V115, P372, DOI 10.1055/s 2007 973830
   Schwartz AV, 2003, CALCIFIED TISSUE INT, V73, P515, DOI 10.1007/s00223 003 0023 7
   Schwartz AV, 2001, J CLIN ENDOCR METAB, V86, P32, DOI 10.1210/jc.86.1.32
   Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612
   Tanaka N, 2000, J BIOL CHEM, V275, P25781, DOI 10.1074/jbc.M001235200
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140 6736(98)07037 8
   Ulrich P, 2001, RECENT PROG HORM RES, V56, P1, DOI 10.1210/rp.56.1.1
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
NR 43
TC 76
Z9 90
U1 0
U2 7
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D 70469 STUTTGART, GERMANY
SN 0947 7349
EI 1439 3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD JUN
PY 2008
VL 116
IS 6
BP 333
EP 340
DI 10.1055/s 2007 992786
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 320PA
UT WOS:000257245900005
PM 18273753
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Lewiecki, EM
   Anderson, PA
   Bilezikian, JP
   Binkley, N
   Cheung, AM
   Imel, EA
   Krueger, D
   McClung, MR
   Miller, PD
   Rothman, MS
AF Lewiecki, E. Michael
   Anderson, Paul A.
   Bilezikian, John P.
   Binkley, Neil
   Cheung, Angela M.
   Imel, Erik A.
   Krueger, Diane
   McClung, Michael R.
   Miller, Paul D.
   Rothman, Micol S.
TI Proceedings of the 2021 Santa Fe Bone Symposium: Advances in the
   Management of Osteoporosis and Metabolic Bone Diseases
SO JOURNAL OF CLINICAL DENSITOMETRY
LA English
DT Article; Proceedings Paper
CT Virtual Santa Fe Bone Symposium
CY AUG 05 08, 2021
CL ELECTR NETWORK
DE Osteoporosis; transgender; periprosthetic fracture; atypical femur
   fracture; anabolic; hypophosphatasia; ECHO
ID VITAMIN D STATUS; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; FRACTURE RISK;
   VERTEBRAL FRACTURES; HEALTH; DENOSUMAB; UPDATE; TERIPARATIDE; GUIDELINES
AB The 2021 Virtual Santa Fe Bone Symposium was held August 5 8, with over 300 registered attendees from throughout the USA, and at least 18 other countries. This annual meeting focuses on applying advances in basic science and clinical research to the care of patients with osteoporosis and those with inherited and acquired disorders of bone metabolism. Participants represented a broad range of medical disciplines with an interest in skeletal diseases. These included physicians of many specialties and practice settings, fellows, advanced practice providers, fracture liaison service (FLS) coordinators, clinical researchers, and bone density technologists. There were lectures, case presentations, and panel discussions, all followed by interactive discussions. Breakout sessions included an FLS workshop, Bone Health TeleECHO workshop, special interest groups, meet and greet the faculty, and satellite symposia. The agenda covered topics of interest such as strategies for the use of osteoanabolic therapy, prevention of periprosthetic fractures, management of atypical femur fractures, what we know and don't know about vitamin D, advances in the use of dual energy X ray absorptiometry in the assessment of skeletal health, controversies and conundrums in osteoporosis care, skeletal health in transgender patients, management of patients with hypophosphatasia and hypophosphatemia, and treat to target approaches for managing patients with osteoporosis. The Proceedings of the 2021 Virtual Santa Fe Bone Symposium consists of highlights of each presentation with current strategies for optimizing the care of patients with skeletal disorders.
C1 [Lewiecki, E. Michael] New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
   [Anderson, Paul A.; Binkley, Neil; Krueger, Diane] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
   [Bilezikian, John P.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA.
   [Cheung, Angela M.] Univ Toronto, Toronto, ON, Canada.
   [Imel, Erik A.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
   [McClung, Michael R.] Oregon Osteoporosis Ctr, Portland, OR USA.
   [McClung, Michael R.] Australian Catholic Univ, Mary MacKillop Ctr Hlth Res, Melbourne, Vic, Australia.
   [Miller, Paul D.] Colorado Ctr Bone Hlth, Denver, CO USA.
   [Rothman, Micol S.] Univ Colorado, Hlth Sch Med, Aurora, CO USA.
C3 New Mexico Clinical Research & Osteoporosis Center; University of
   Wisconsin System; University of Wisconsin Madison; Columbia University;
   University of Toronto; Indiana University System; Indiana University
   Bloomington; Oregon Osteoporosis Center; Australian Catholic University;
   University of Colorado System; University of Colorado Anschutz Medical
   Campus
RP Lewiecki, EM (通讯作者)，New Mexico Clin Res & Osteoporosis Ctr, 300 Oak St NE, Albuquerque, NM 87106 USA.
EM mlewiecki@gmail.com
RI Lewiecki, E./B 3706 2018; McClung, Michael/ABA 4100 2021; Imel,
   Erik/J 3837 2013
OI Lewiecki, E. Michael/0000 0003 2026 9587; Rothman,
   Micol/0000 0002 4577 6801
FU Osteoporosis Foundation of New Mexico, Albuquerque, New Mexico, USA
FX Manuscript preparation and editing was supported by the Osteoporosis
   Foundation of New Mexico, Albuquerque, New Mexico, USA.
CR Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Amgen Inc, 2021 EV PRESCR INF
   Anderson PA, 2020, NEUROSURG FOCUS, V49, DOI 10.3171/2020.5.FOCUS20255
   Anderson PA, 2019, J CLIN DENSITOM, V22, P517, DOI 10.1016/j.jocd.2019.07.013
   Anderson PA, 2019, J BONE JOINT SURG AM, V101, P1413, DOI 10.2106/JBJS.18.01229
   Arora S, 2011, NEW ENGL J MED, V364, P2199, DOI 10.1056/NEJMoa1009370
   Austin M, 2012, J BONE MINER RES, V27, P687, DOI 10.1002/jbmr.1472
   Bernatz JT, 2019, J ARTHROPLASTY, V34, P1347, DOI 10.1016/j.arth.2019.03.044
   Bhattacharyya T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 1191 8
   Bilezikian JP, 2019, OSTEOPOROSIS INT, V30, P1855, DOI 10.1007/s00198 019 05020 8
   Bilezikian JP, 2019, CURR MED RES OPIN, V35, P2097, DOI 10.1080/03007995.2019.1656955
   Bilezikian JP, 2018, J CLIN ENDOCR METAB, V103, P3993, DOI 10.1210/jc.2018 01225
   Bilezikian JP, 2018, LANCET, V391, P168, DOI 10.1016/S0140 6736(17)31430 7
   Binkley N, 2007, J CLIN ENDOCR METAB, V92, P2130, DOI 10.1210/jc.2006 2250
   Binkley NC, 2018, ENDOCR PRACT, V24, P1099, DOI 10.4158/EP 2018 0415
   Bishop A, 2020, J ADOLESCENT HEALTH, V66, P484, DOI 10.1016/j.jadohealth.2019.10.026
   Black DM, 2020, NEW ENGL J MED, V383, P743, DOI 10.1056/NEJMoa1916525
   Black DM, 2020, LANCET DIABETES ENDO, V8, P672, DOI 10.1016/S2213 8587(20)30159 5
   Bottle A, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen 2020 042371
   Bouillon R, 2017, NAT REV ENDOCRINOL, V13, P466, DOI 10.1038/nrendo.2017.31
   Camacho PM, 2020, ENDOCR PRACT, V26, P1, DOI 10.4158/GL 2020 0524SUPPL
   Carter GD, 2018, J STEROID BIOCHEM, V177, P30, DOI 10.1016/j.jsbmb.2017.07.018
   Cheung AM, 2019, J CLIN DENSITOM, V22, P506, DOI 10.1016/j.jocd.2019.07.003
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Cosman F, 2020, J BONE MINER RES, V35, P1333, DOI 10.1002/jbmr.3996
   Cummings SR, 2020, OSTEOPOROSIS INT, V31, P1019, DOI 10.1007/s00198 020 05379 z
   Cummings SR, 2018, J BONE MINER RES, V33, P190, DOI 10.1002/jbmr.3337
   Cummings SR, 2017, J BONE MINER RES, V32, P3, DOI 10.1002/jbmr.3039
   Della Rocca GJ, 2011, J ORTHOP TRAUMA, V25, pS66, DOI 10.1097/BOT.0b013e31821b8c28
   Dobnig H, 1997, ENDOCRINOLOGY, V138, P4607, DOI 10.1210/en.138.11.4607
   Eastell R, 2019, J CLIN ENDOCR METAB, V104, P1595, DOI 10.1210/jc.2019 00221
   Eli Lilly and Company, 2021 FORT PRESCR INF
   Ferrari S, 2019, J BONE MINER RES, V34, P1033, DOI 10.1002/jbmr.3722
   Gilsenan A, 2021, J BONE MINER RES, V36, P244, DOI 10.1002/jbmr.4188
   Githens M, 2018, J AM ACAD ORTHOP SUR, V26, P864, DOI 10.5435/JAAOS D 16 00717
   Greenspan SL, 2018, OSTEOPOROSIS INT, V29, P501, DOI 10.1007/s00198 017 4286 7
   Haffner D, 2019, NAT REV NEPHROL, V15, P435, DOI 10.1038/s41581 019 0152 5
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Heaney RP, 2014, NUTR REV, V72, P48, DOI 10.1111/nure.12090
   Hembree WC, 2018, J CLIN ENDOCR METAB, V103, P699, DOI [10.1210/jc.2017 02548, 10.1210/jc.2017 01658]
   Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154 017 9424 1
   Hollis BW, 2013, J CLIN ENDOCR METAB, V98, P4619, DOI 10.1210/jc.2013 2653
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   Imel EA, 2019, LANCET, V393, P2416, DOI 10.1016/S0140 6736(19)30654 3
   Iwamoto SJ, 2021, J GEN INTERN MED, V36, P1380, DOI 10.1007/s11606 021 06634 7
   Kanis JA, 2020, OSTEOPOROSIS INT, V31, P1, DOI 10.1007/s00198 019 05176 3
   Kates SL, 2016, INJURY, V47, pS65, DOI 10.1016/S0020 1383(16)30015 8
   Kiebzak GM, 2007, J CLIN DENSITOM, V10, P132, DOI 10.1016/j.jocd.2007.02.003
   Krueger D, 2017, J CLIN DENSITOM, V20, P128, DOI 10.1016/j.jocd.2016.08.068
   Kuchnia AJ, 2018, ARCH OSTEOPOROS, V13, DOI 10.1007/s11657 018 0508 7
   Lems WF, 2021, OSTEOPOROSIS INT, V32, P399, DOI 10.1007/s00198 020 05804 3
   Leslie WD, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 020 00735 2
   Lewiecki EM, 2017, OSTEOPOROSIS INT, V28, P407, DOI 10.1007/s00198 016 3708 2
   Lewiecki EM, 2020, J CLIN DENSITOM, V23, P338, DOI 10.1016/j.jocd.2020.04.003
   Lewiecki EM, 2019, CURR OSTEOPOROS REP, V17, P474, DOI 10.1007/s11914 019 00543 9
   Lewiecki EM, 2019, AM J MED, V132, pE771, DOI 10.1016/j.amjmed.2019.04.044
   Lewiecki EM, 2019, RHEUM DIS CLIN N AM, V45, P303, DOI 10.1016/j.rdc.2019.01.003
   Lewiecki EM, 2019, J BONE MINER RES, V34, P605, DOI 10.1002/jbmr.3671
   Lewiecki EM, 2019, J BONE MINER RES, V34, P419, DOI 10.1002/jbmr.3622
   Lewiecki EM, 2019, J CLIN DENSITOM, V22, P1, DOI 10.1016/j.jocd.2018.09.010
   Lewiecki EM, 2018, J CLIN DENSITOM, V21, P3, DOI 10.1016/j.jocd.2017.10.041
   Lewiecki EM, 2017, J CLIN DENSITOM, V20, P134, DOI 10.1016/j.jocd.2017.01.001
   Lewiecki EM, 2016, J CLIN DENSITOM, V19, P102, DOI 10.1016/j.jocd.2015.11.003
   Lewiecki EM, 2015, ENDOCR RES, V40, P106, DOI 10.3109/07435800.2015.1005746
   Lewiecki EM, 2014, J CLIN DENSITOM, V17, P330, DOI 10.1016/j.jocd.2013.11.006
   Lewiecki EM, 2013, J CLIN DENSITOM, V16, P584, DOI 10.1016/j.jocd.2013.01.001
   Lewiecki EM, 2012, J CLIN DENSITOM, V15, P1, DOI 10.1016/j.jocd.2011.11.004
   Lewiecki EM, 2010, J CLIN DENSITOM, V13, P1, DOI 10.1016/j.jocd.2009.12.003
   Lewiecki E Michael, 2006, Womens Health (Lond), V2, P825, DOI 10.2217/17455057.2.6.825
   Lewiecki EM, 2009, J CLIN DENSITOM, V12, P135, DOI 10.1016/j.jocd.2009.02.002
   Lewiecki EM, 2010 FE BON S OST FD
   Lewiecki EM, 2009, J CLIN DENSITOM, V13, P1
   Lewiecki EM, 2013 FE BON S HIGHL
   Lewiecki EM, 2011 FE BON S HIGHL
   Lewiecki EM, 2009 HIGHL 2009 FE B
   Lewiecki EM, 2014 FE BON S HIGHL
   Lewiecki EM, 2010, 2010 HIGHL 2010 FE B
   Lewiecki EM, 2011 HIGHL 2011 FE B
   Lewiecki EM, 2009 FE BON S OST FD
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Maier GS, 2016, ADV ORTHOP, V2016, DOI 10.1155/2016/8079354
   McCloskey EV, 2016, J BONE MINER RES, V31, P940, DOI 10.1002/jbmr.2734
   McCloskey EV, 2015, CALCIFIED TISSUE INT, V96, P500, DOI 10.1007/s00223 015 9980 x
   McClung MR, 2016, OSTEOPOROSIS INT, V27, P1677, DOI 10.1007/s00198 016 3553 3
   McClung MR, 2006, NEW ENGL J MED, V354, P821, DOI 10.1056/NEJMoa044459
   McClung MR, CLIMACTERIC, P1
   Lewiecki EM, 2017, J ENDOCR SOC, V1, P1428, DOI 10.1210/js.2017 00361
   Middleton ET, 2008, OSTEOPOROSIS INT, V19, P1167, DOI 10.1007/s00198 007 0548 0
   Miller PD, 2021, CLEV CLIN J MED, V88, P489, DOI 10.3949/ccjm.88a.21011
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   MORISHIMA A, 1995, J CLIN ENDOCR METAB, V80, P3689, DOI 10.1210/jc.80.12.3689
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Portale AA, 2019, CALCIFIED TISSUE INT, V105, P271, DOI 10.1007/s00223 019 00568 3
   Prince JM, 2019, ARCH OSTEOPOROS, V14, DOI 10.1007/s11657 019 0572 7
   Project ECHO at University of New Mexico School of Medicine, ECHO PROGR
   Rosen HN, 2019, J CLIN DENSITOM, V22, P544, DOI 10.1016/j.jocd.2019.07.004
   Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010 2704
   Rothman MS, 2019, OSTEOPOROSIS INT, V30, P2401, DOI 10.1007/s00198 019 05147 8
   Rothman MS, 2019, CLIN REV BONE MINER, V17, P77, DOI 10.1007/s12018 019 09261 3
   Rush B, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10527
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Schagen SEE, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgaa604
   Schleicher RL, 2016, AM J CLIN NUTR, V104, P454, DOI 10.3945/ajcn.115.127985
   Seefried L, 2021, OSTEOPOROSIS INT, V32, P2505, DOI 10.1007/s00198 021 06025 y
   Seefried L, 2020, J BONE MINER RES, V35, P2171, DOI 10.1002/jbmr.4130
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shi ZJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168691
   Shires DA, 2018, ANN FAM MED, V16, P555, DOI 10.1370/afm.2298
   Shuhart CR, 2019, J CLIN DENSITOM, V22, P453, DOI 10.1016/j.jocd.2019.07.001
   Sidler Maier CC, 2015, INT ORTHOP, V39, P1673, DOI 10.1007/s00264 015 2721 y
   Silva MC, 2015, NUTR RES, V35, P91, DOI 10.1016/j.nutres.2014.12.008
   Singh JA, 2019, J RHEUMATOL, V46, P1134, DOI 10.3899/jrheum.170990
   Singh Ospina N, 2017, J CLIN ENDOCR METAB, V102, P3904, DOI 10.1210/jc.2017 01642
   Siris E, 2014, OSTEOPOROSIS INT, V25, P1439, DOI 10.1007/s00198 014 2655 z
   SMITH EP, 1994, NEW ENGL J MED, V331, P1056, DOI 10.1056/NEJM199410203311604
   Tile L, 2020, THER ADV MUSCULOSKEL, V12, DOI 10.1177/1759720X20916983
   Tosi LL, 2020, CURR OSTEOPOROS REP, V18, P344, DOI 10.1007/s11914 020 00595 2
   Tsourdi E., 2020, J Clin Endocrinol Metab, pdgaa756
   U.S. 2021 Department of Health and Human Services, REP C CURR STAT TECH
   UCLA School of Law WI, 2021 MAN AD ID TRANS
   University of New Mexico School of Medicine, BON HLTH
   van de Laarschot DM, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz295
   van Vollenhoven R, 2019, NAT REV RHEUMATOL, V15, P180, DOI 10.1038/s41584 019 0170 5
   Veldurthy V, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.41
   Watts NB, 2017, J BONE MINER RES, V32, P1027, DOI 10.1002/jbmr.3081
   Whyte MP, 2020, BONE, V134, DOI 10.1016/j.bone.2020.115300
   Whyte MP, 2017, BONE, V102, P15, DOI 10.1016/j.bone.2017.02.011
   Whyte MP, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85971
   Whyte MP, 2016, J CLIN ENDOCR METAB, V101, P333, DOI 10.1210/jc.2015 3462
   Wiepjes CM, 2020, J BONE MINER RES, V35, P64, DOI 10.1002/jbmr.3862
   Wiepjes CM, 2019, J BONE MINER RES, V34, P447, DOI 10.1002/jbmr.3612
   Yamada Y, 2010, J GERONTOL A BIOL, V65, P510, DOI 10.1093/gerona/glq001
NR 132
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1094 6950
EI 1559 0747
J9 J CLIN DENSITOM
JI J. Clin. Densitom.
PD JAN MAR
PY 2022
VL 25
IS 1
BP 3
EP 19
DI 10.1016/j.jocd.2021.10.001
EA JAN 2022
PG 17
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 1N3FQ
UT WOS:000800545400002
PM 34785102
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Zhang, C
   Zhang, W
   Zhu, DS
   Li, ZH
   Wang, ZZ
   Li, JL
   Mei, X
   Xu, W
   Cheng, K
   Zhong, BA
AF Zhang, Chi
   Zhang, Wei
   Zhu, Dashuai
   Li, Zhenhua
   Wang, Zhenzhen
   Li, Junlang
   Mei, Xuan
   Xu, Wei
   Cheng, Ke
   Zhong, Biao
TI Nanoparticles functionalized with stem cell secretome and
   CXCR4 overexpressing endothelial membrane for targeted osteoporosis
   therapy
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Osteoporosis; CXCR4; Secretome; Mesenchymal stem cells; Bone targeting;
   Nanoparticles
ID CXCR4
AB Background: Osteoporosis is a chronic condition affecting patients' morbidity and mortality and represents a big socioeconomic burden. Because stem cells can proliferate and differentiate into bone forming cells, stem cell therapy for osteoporosis has been widely studied. However, cells as a live drug face multiple challenges because of their instability during preservation and transportation. In addition, cell therapy has potential adverse effects such as embolism, tumorigenicity, and immunogenicity.
   Results: Herein, we sought to use cell mimicking and targeted therapeutic nanoparticles to replace stem cells. We fabricated nanoparticles (NPs) using polylactic co glycolic acid (PLGA) loaded with the secretome (Sec) from mesenchymal stem cells (MSCs) to form MSC Sec NPs. Furthermore, we cloaked the nanoparticles with the membranes from C X C chemokine receptor type 4 (CXCR4) expressing human microvascular endothelial cells (HMECs) to generate MSC Sec/CXCR4 NP. CXCR4 can target the nanoparticles to the bone microenvironment under osteoporosis based on the CXCR4/SDF 1 axis.
   Conclusions: In a rat model of osteoporosis, MSC Sec/CXCR4 NP were found to accumulate in bone, and such treatment inhibited osteoclast differentiation while promoting osteogenic proliferation. In addition, our results showed that MSC Sec/CXCR4 NPs reduce OVX induced bone mass attenuation in OVX rats.
C1 [Zhang, Chi; Zhang, Wei; Zhong, Biao] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, 600 Yishan Rd, Shanghai 200233, Peoples R China.
   [Zhang, Chi; Zhu, Dashuai; Li, Zhenhua; Wang, Zhenzhen; Li, Junlang; Mei, Xuan; Cheng, Ke] Univ North Carolina Chapel Hill & North Carolina, Joint Dept Biomed Engn, Chapel Hill, NC 27514 USA.
   [Xu, Wei] Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Orthoped, 1111 XianXia Rd, Shanghai 200336, Peoples R China.
C3 Shanghai Jiao Tong University; North Carolina State University; Shanghai
   Jiao Tong University
RP Zhong, BA (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, 600 Yishan Rd, Shanghai 200233, Peoples R China.; Cheng, K (通讯作者)，Univ North Carolina Chapel Hill & North Carolina, Joint Dept Biomed Engn, Chapel Hill, NC 27514 USA.; Xu, W (通讯作者)，Shanghai Jiao Tong Univ, Tongren Hosp, Sch Med, Dept Orthoped, 1111 XianXia Rd, Shanghai 200336, Peoples R China.
EM weixu@shsmu.edu.cn; kcheng3@ncsu.edu; biao.zhong@sjtu.edu.cn
RI xu, wei/HHD 2891 2022; zhang, chi/GRX 3610 2022; Li,
   Zhenhua/S 9926 2019; Li, Junlang/GSO 0056 2022; Mei, Xuan/GLS 1577 2022;
   Cheng, Ke/HCH 8846 2022; Zhu, Dashuai/AHB 8198 2022; Mei,
   Xuan/GPX 2865 2022
OI Wang, Zhenzhen/0000 0002 5245 6726; Mei, Xuan/0000 0002 1190 0800; ZHU,
   DASHUAI/0000 0002 4645 5786
FU NC State University College of Veterinary Medicine; National Natural
   Science Foundation of China [81772426, 81974330, 81501897]; Shanghai
   Committee of Science and Technology [20ZR1451800]
FX B. Zhong, K. Cheng, W. Xu, C. Zhang, and W. Zhang designed the overall
   experiments. C. Zhang, W. Zhang, D. Zhu, Z. Li, Z. Wang, J. Li, X. Mei
   W. Xu, and B. Zhong performed the experiments and analyzed the data. K.
   Cheng, C. Zhang, and D. Zhu wrote the article. All authors read and
   approved the final article. All authors have provided the corresponding
   author with written permission to be named in the article. This work was
   supported by NC State University College of Veterinary Medicine. Project
   is also sponsored by National Natural Science Foundation of China (No.
   81772426 to B. Zhong, 81974330 to C. Zhang, 81501897 to W. Xu) and
   Shanghai Committee of Science and Technology (No. 20ZR1451800 to W. Xu).
CR Aghebati Maleki L, 2019, J CELL PHYSIOL, V234, P8570, DOI 10.1002/jcp.27833
   Biggin A, 2017, CURR OSTEOPOROS REP, V15, P412, DOI 10.1007/s11914 017 0401 0
   Cao X, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0040 9
   Catalano A, 2018, BONE, V116, P42, DOI 10.1016/j.bone.2018.07.010
   Chen QC, 2018, ACS APPL MATER INTER, V10, P23700, DOI 10.1021/acsami.8b08606
   Gnecchi M, 2008, CIRC RES, V103, P1204, DOI 10.1161/CIRCRESAHA.108.176826
   He Y, 2019, ACTA BIOMATER, V93, P180, DOI 10.1016/j.actbio.2019.03.050
   Hoggatt J, 2009, BLOOD, V113, P5444, DOI 10.1182/blood 2009 01 201335
   Huang K, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801011
   Huang TB, 2019, BIOMATER SCI UK, V7, P1101, DOI 10.1039/c8bm01411f
   Kang YQ, 2013, ACTA BIOMATER, V9, P4906, DOI 10.1016/j.actbio.2012.08.008
   Lapidot T, 2002, LEUKEMIA, V16, P1992, DOI 10.1038/sj.leu.2402684
   Lee Seoung Hoon, 2018, Osteoporos Sarcopenia, V4, P150, DOI 10.1016/j.afos.2018.11.083
   Li ZH, 2021, NAT NANOTECHNOL, V16, P942, DOI 10.1038/s41565 021 00923 2
   Li ZH, 2018, J MATER CHEM B, V6, P7354, DOI [10.1039/c8tb02301h, 10.1039/C8TB02301H]
   Liang HX, 2018, ACS NANO, V12, P6536, DOI 10.1021/acsnano.8b00553
   Liu FR, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900411
   Luo L, 2017, CIRC RES, V120, P1768, DOI 10.1161/CIRCRESAHA.116.310374
   Luo L, 2021, THERANOSTICS, V11, P8043, DOI 10.7150/thno.60785
   Ma CY, 2018, P NATL ACAD SCI USA, V115, pE11741, DOI 10.1073/pnas.1813000115
   Ma JN, 2019, SMALL, V15, DOI 10.1002/smll.201902011
   Mihalko E, 2018, ACS NANO, V12, P7826, DOI 10.1021/acsnano.8b01977
   Nayak S, 2019, OSTEOPOROSIS INT, V30, P705, DOI 10.1007/s00198 018 4791 3
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Schlosser S, 2012, MICROVASC RES, V83, P267, DOI 10.1016/j.mvr.2012.02.011
   Shang FQ, 2021, BIOACT MATER, V6, P666, DOI 10.1016/j.bioactmat.2020.08.014
   Shen MD, 2018, J CELL MOL MED, V22, P3751, DOI 10.1111/jcmm.13618
   Su T, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201803567
   Su T, 2018, ACS APPL MATER INTER, V10, P33088, DOI 10.1021/acsami.8b13571
   Sun WT, 2019, ACS NANO, V13, P7556, DOI 10.1021/acsnano.9b00097
   Tachibana A, 2017, CIRC RES, V121, pE22, DOI 10.1161/CIRCRESAHA.117.310803
   Tang J, 2017, TISSUE ENG PART C ME, V23, P146, DOI [10.1089/ten.tec.2016.0492, 10.1089/ten.TEC.2016.0492]
   Tang JA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms13724
   Vargas Franco JW, 2018, J CELL PHYSIOL, V233, P5696, DOI 10.1002/jcp.26465
   Wynn RF, 2004, BLOOD, V104, P2643, DOI 10.1182/blood 2004 02 0526
   Xu C, 2020, NANO RES, V13, P2323, DOI 10.1007/s12274 020 2783 z
   Yang G, 2019, ACS NANO, V13, P4354, DOI 10.1021/acsnano.8b09573
   Yang TL, 2020, NAT REV ENDOCRINOL, V16, P91, DOI 10.1038/s41574 019 0282 7
   Zheng CX, 2019, INT J ORAL SCI, V11, DOI 10.1038/s41368 019 0060 3
NR 39
TC 42
Z9 49
U1 6
U2 80
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD JAN 15
PY 2022
VL 20
IS 1
AR 35
DI 10.1186/s12951 021 01231 6
PG 11
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA YH1IO
UT WOS:000742928400002
PM 35033095
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jönsson, B
   Ström, O
   Eisman, JA
   Papaioannou, A
   Siris, ES
   Tosteson, A
   Kanis, JA
AF Jonsson, B.
   Strom, O.
   Eisman, J. A.
   Papaioannou, A.
   Siris, E. S.
   Tosteson, A.
   Kanis, J. A.
TI Cost effectiveness of Denosumab for the treatment of postmenopausal
   osteoporosis
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Adherence; Compliance; Fracture; Model; Persistence; Sweden
ID FRACTURE INTERVENTION TRIAL; QUALITY OF LIFE; HORMONE REPLACEMENT
   THERAPY; RANDOMIZED CONTROLLED TRIAL; HIP FRACTURE; ECONOMIC EVALUATION;
   BONE MASS; VERTEBRAL FRACTURES; EXCESS MORTALITY; WOMEN
AB Denosumab is an injectable drug that reduces the risk of fractures. The objective was to estimate the cost effectiveness of denosumab in a Swedish setting, also accounting for poor adherence to treatment. Denosumab is cost effective, particularly for patients at high risk of fracture and low adherence to oral treatments.
   Denosumab is a novel biologic agent developed for the treatment of osteoporosis and osteoporotic fractures that has been shown to reduce the risk of fractures in a phase III trial. The objective of this study was to estimate the cost effectiveness of denosumab from a societal perspective compared with generic alendronate, branded risedronate, strontium ranelate, and no treatment in a Swedish setting.
   A Markov cohort model was used to estimate the cost effectiveness of denosumab given for up to 5 years to a typical Swedish patient population (women aged 71 years, T score a parts per thousand currency signaEuro parts per thousand a'2.5 SD and a prevalence of morphometric vertebral fractures of 34%). The model included treatment persistence and residual effect after discontinuation assumed to be equal to the time on treatment. Persistence with the comparator treatments and with denosumab was derived from prescription data and a persistence study, respectively.
   The base case incremental cost effectiveness ratios were estimated at a,not sign27,000, a,not sign12,000, a,not sign5,000, and a,not sign14,000, for denosumab compared with generic alendronate, risedronate, strontium ranelate, and no treatment, respectively. Sub optimal persistence had the greatest impact in the comparison with generic alendronate, where the difference in drug cost was large.
   Improving persistence with osteoporosis treatment impacts positively on cost effectiveness with a larger number of fractures avoided in the population targeted for treatment. Denosumab is a cost effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture and low expected adherence to oral treatments.
C1 [Jonsson, B.] Stockholm Sch Econ, SE 11383 Stockholm, Sweden.
   [Strom, O.] i3 Innovus, Stockholm, Sweden.
   [Strom, O.] Karolinska Inst, Dept Learning Informat Management & Eth, Med Management Ctr, Stockholm, Sweden.
   [Eisman, J. A.] St Vincents Hosp, Garvan Inst Med Res, UNSW, Sydney, NSW 2010, Australia.
   [Papaioannou, A.] McMaster Univ, Hamilton, ON, Canada.
   [Siris, E. S.] Columbia Univ, New York, NY USA.
   [Tosteson, A.] Dartmouth Med Sch, Lebanon, NH USA.
   [Kanis, J. A.] Univ Sheffield, WHO Collaborating Ctr, Sheffield, S Yorkshire, England.
C3 Stockholm School of Economics; i3 Innovus; Karolinska Institutet; NSW
   Health; St Vincents Hospital Sydney; Garvan Institute of Medical
   Research; University of New South Wales Sydney; McMaster University;
   Columbia University; Dartmouth College; World Health Organization;
   University of Sheffield
RP Jönsson, B (通讯作者)，Stockholm Sch Econ, Box 6501, SE 11383 Stockholm, Sweden.
EM Bengt.Jonsson@hhs.se; oskar.strom@i3innovus.com
RI Eisman, John/C 2886 2014
FU Amgen Inc. Thousand Oaks, CA, USA; Amgen
FX The authors would like to acknowledge Amgen Inc. Thousand Oaks, CA, USA
   for funding model development and Steering Committee meetings. The
   authors are also grateful to Enkhe Badamgarav and David Macarios of
   Amgen Inc. and Deborah Marshall of the University of Calgary for their
   assistance in framing the research questions, aid in model development,
   and participation in the Steering Committee. The authors also sincerely
   appreciate the tremendous logistical and planning support provided by
   Dominika Dabrowski of i3 Innovus. Sponsored by Amgen.
CR [Anonymous], WHO 1998
   [Anonymous], 2003, GEN GUID EC EV PHARM
   [Anonymous], ADVERSE EFFECTS PERS
   [Anonymous], AVERAGE EXCHANGE RAT
   Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021
   Banks E, 2004, JAMA J AM MED ASSOC, V291, P2212, DOI 10.1001/jama.291.18.2212
   Barrett JA, 2003, OSTEOPOROSIS INT, V14, P889, DOI 10.1007/s00198 003 1494 0
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Bliuc D, 2009, JAMA J AM MED ASSOC, V301, P513, DOI 10.1001/jama.2009.50
   Borgström F, 2006, OSTEOPOROSIS INT, V17, P1781, DOI 10.1007/s00198 006 0193 z
   Borgström F, 2006, OSTEOPOROSIS INT, V17, P637, DOI 10.1007/s00198 005 0015 8
   Borgström F, 2004, PHARMACOECONOMICS, V22, P1153, DOI 10.2165/00019053 200422170 00005
   Burström K, 2001, QUAL LIFE RES, V10, P621, DOI 10.1023/A:1013171831202
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   CHRISTIANSEN C, 1981, LANCET, V1, P459
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Curtis JR, 2008, OSTEOPOROSIS INT, V19, P1613, DOI 10.1007/s00198 008 0604 4
   DeLaet CEDH, 1997, BRIT MED J, V315, P221, DOI 10.1136/bmj.315.7102.221
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650 199711000 00002
   EKMAN M, 2002, CONSUMPTION PRODUCTI
   Felsenberg D, 2002, J BONE MINER RES, V17, P716
   Gallagher AM, 2008, J BONE MINER RES, V23, P1569, DOI 10.1359/JBMR.080510
   Greendale GA, 2002, ARCH INTERN MED, V162, P665, DOI 10.1001/archinte.162.6.665
   Hasserius R, 2003, OSTEOPOROSIS INT, V14, P61, DOI 10.1007/s00198 002 1316 9
   Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022
   Ioannidis G, 2009, CAN MED ASSOC J, V181, P265, DOI 10.1503/cmaj.081720
   Johanesson M, 2009, 51 OHE
   Johnell O, 2005, J BONE MINER RES, V20, P1185, DOI 10.1359/JBMR.050304
   Johnell O, 2004, OSTEOPOROSIS INT, V15, P38, DOI 10.1007/s00198 003 1490 4
   JONSSON B, 1995, OSTEOPOROSIS INT, V5, P136, DOI 10.1007/BF01623315
   Jonsson B, 1999, OSTEOPOROSIS INT, V10, P193, DOI 10.1007/s001980050215
   Kanis J, 2008, P61 WHO U SHEFF COLL, P61
   Kanis JA, 2007, HEALTH TECHNOL ASSES, V11, P1
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, pS97
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P862, DOI 10.1007/s00198 004 1643 0
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P15, DOI 10.1007/s00198 004 1688 0
   Kanis JA, 2004, OSTEOPOROSIS INT, V15, P108, DOI 10.1007/s00198 003 1516 y
   Kanis JA, 2003, BONE, V32, P468, DOI 10.1016/S8756 3282(03)00061 9
   Kanis JA, 2002, OSTEOPOROSIS INT, V13, P765, DOI 10.1007/s001980200106
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P120, DOI 10.1007/PL00004173
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P417, DOI 10.1007/s001980170112
   Kanis JA, 2008, BONE, V42, P4, DOI 10.1016/j.bone.2007.10.019
   Kanis JA, 2009, BONE, V44, P1049, DOI 10.1016/j.bone.2009.02.014
   Klotzbuecher CM, 2000, J BONE MINER RES, V15, P721, DOI 10.1359/jbmr.2000.15.4.721
   Kothawala P, 2007, MAYO CLIN PROC, V82, P1493, DOI 10.4065/82.12.1493
   Landfeldt E, 2009, ISPOR PAR
   Lekander I, 2008, BONE, V42, P294, DOI 10.1016/j.bone.2007.09.059
   McCloskey E, 2005, J BONE MINER RES, V20, pS282
   McCloskey EV, 2009, OSTEOPOROSIS INT, V20, P811, DOI 10.1007/s00198 008 0786 9
   McClung MR, 2010, OSTEOPOROSIS INT, V21, P386
   McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503
   Medical products agency, 2007, BEH OST
   Murthy RK, 2009, ONCOLOGY NY, V23, P9
   National Institute for Clinical Excellence (NICE), 2008, SYST REV CLIN EFF PR
   NICE, 2008, OST SEC PREV INCL ST
   Papaioannou A, 2003, OSTEOPOROSIS INT, V14, P808, DOI 10.1007/s00198 003 1431 2
   Prince R, 2005, J BONE MINER RES, V20, P1507, DOI 10.1359/JBMR.050501
   Reginster JY, 2009, BONE, V45, P1059, DOI 10.1016/j.bone.2009.08.004
   Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013
   STEVENSON M, 2006, DSU EC EVALUATION PO
   Ström O, 2007, OSTEOPOROSIS INT, V18, P1047, DOI 10.1007/s00198 007 0349 5
   Ström O, 2009, OSTEOPOROSIS INT, V20, P23, DOI 10.1007/s00198 008 0644 9
   Strom O, 2010, ECCEO IOF FLOR
   Ström O, 2008, ACTA ORTHOP, V79, P269, DOI 10.1080/17453670710015094
   Tosteson AN, 2010, OSTEOPOROS INT
   Tosteson ANA, 2008, AM J MANAG CARE, V14, P605
   Zethraeus N, 2005, INT J TECHNOL ASSESS, V21, P433, DOI 10.1017/S0266462305050609
NR 72
TC 97
Z9 102
U1 0
U2 11
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD MAR
PY 2011
VL 22
IS 3
BP 967
EP 982
DI 10.1007/s00198 010 1424 x
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 718DV
UT WOS:000287101600023
PM 20936401
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Holten Andersen, L
   Pihl, S
   Rasmussen, CE
   Zettler, J
   Maitro, G
   Baron, J
   Heinig, S
   Hoffmann, E
   Wegge, T
   Krusch, M
   Faltinger, F
   Killian, S
   Sprogoe, K
   Karpf, DB
   Breinholt, VM
   Cleemann, F
AF Holten Andersen, Lars
   Pihl, Susanne
   Rasmussen, Caroline E.
   Zettler, Joachim
   Maitro, Guillaume
   Baron, Julia
   Heinig, Stefan
   Hoffmann, Eric
   Wegge, Thomas
   Krusch, Mathias
   Faltinger, Frank
   Killian, Steffen
   Sprogoe, Kennett
   Karpf, David B.
   Breinholt, Vibeke Miller
   Cleemann, Felix
TI Design and Preclinical Development of TransCon PTH, an Investigational
   Sustained Release PTH Replacement Therapy for Hypoparathyroidism
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TRANSCON PTH; PRODRUGS; HYPOPARATHYROIDISM; PTH(1 34)
ID PARATHYROID HORMONE 1 34; CALCIUM; PARATHYROID HORMONE 1 34; PTH(1 84);
   CHILDREN; ANALOG; TRIAL; PUMP
AB Hypoparathyroidism (HP) is a condition of parathyroid hormone (PTH) deficiency leading to abnormal calcium and phosphate metabolism. The mainstay of therapy consists of vitamin D and calcium supplements, as well as adjunct Natpara (PTH(1 84)). However, neither therapy optimally controls urinary calcium (uCa) or significantly reduces the incidence of hypercalcemia and hypocalcemia. TransCon PTH, a sustained release prodrug of PTH(1 34) in development for the treatment of HP, was designed to overcome these limitations. To determine the pharmacokinetics and pharmacodynamics of TransCon PTH, single and repeat s.c. dose studies were performed in rats and monkeys. TransCon PTH demonstrated a half life of 28 and 34 hours in rats and monkeys, respectively. After repeated dosing, an infusion like profile of the released PTH, characterized by low peak to trough levels, was obtained in both species. In intact rats and monkeys, daily subcutaneous administration of TransCon PTH was associated with increases in serum calcium (sCa) levels and decreases in serum phosphate levels (sP). In monkeys, at a single dose of TransCon PTH that increased sCa levels within the normal range, a concurrent decrease in uCa excretion was observed. In 4 week repeat dose studies in intact rats and monkeys, uCa excretion was comparable to controls across all dose levels despite increases in sCa levels. Further, in a rat model of HP, TransCon PTH normalized sCa and sP levels 24 hours per day. This was in contrast to only transient trends toward normalization of sCa and sP levels with an up to 6 fold higher molar dose of PTH(1 84). After repeated dosing to HP rats, uCa excretion transiently increased, corresponding to increases in sCa above normal range, but at the end of the treatment period, uCa excretion was generally comparable to sham controls. TransCon PTH was well tolerated and the observed pharmacokinetics and pharmacodynamics were in line with the expected action of physiological replacement of PTH. (c) 2019 American Society for Bone and Mineral Research.
C1 [Holten Andersen, Lars; Pihl, Susanne; Rasmussen, Caroline E.; Sprogoe, Kennett; Breinholt, Vibeke Miller] Ascendis Pharma AS, Tuborg Blvd 12, DK 2900 Hellerup, Denmark.
   [Zettler, Joachim; Maitro, Guillaume; Baron, Julia; Heinig, Stefan; Hoffmann, Eric; Wegge, Thomas; Krusch, Mathias; Faltinger, Frank; Killian, Steffen; Cleemann, Felix] Ascendis Pharma GmbH, Heidelberg, Germany.
   [Karpf, David B.] Ascendis Pharma Inc, Palo Alto, CA USA.
RP Rasmussen, CE (通讯作者)，Ascendis Pharma AS, Tuborg Blvd 12, DK 2900 Hellerup, Denmark.
EM cer@ascendi spharma.com
OI Rasmussen, Caroline/0000 0001 5407 3588
FU Ascendis Pharma A/S; Ascendis Pharma GmbH
FX This work was supported by Ascendis Pharma A/S and Ascendis Pharma GmbH.
   The authors thank the staff at Bioassay   Labor fur Biologische Analytik
   GmbH, Heidelberg; PRA Health Science, Assen; and Charles River
   Laboratories, Montreal and Edinburgh, for technical assistance during
   the in vitro and in vivo studies.
CR Abate EG, 2017, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00172
   [Anonymous], 2016, LAB NATP LAB BLA 125
   [Anonymous], 2002, 21318 NDA FDA CDER E
   [Anonymous], 2015, 125511 BLA FDA CDER
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   Díaz Soto G, 2016, INT REV CEL MOL BIO, V327, P321, DOI 10.1016/bs.ircmb.2016.05.004
   FDA, 2014, SEPT 12 2014 M END M
   Guo J, 2017, J BONE MINER RES, V32, P86, DOI 10.1002/jbmr.2917
   Hohenstein A, 2014, J PHARMACEUT BIOMED, V98, P345, DOI 10.1016/j.jpba.2014.06.004
   Krishnan V, 2018, BRIT J PHARMACOL, V175, P262, DOI 10.1111/bph.14028
   Lanske B, 2014, KIDNEY INT, V86, P1071, DOI 10.1038/ki.2014.316
   Masood T, 2015, DRUG DISCOV THER, V9, P70, DOI 10.5582/ddt.2015.01002
   Rubin MR, 2018, ENDOCRIN METAB CLIN, V47, P825, DOI 10.1016/j.ecl.2018.07.008
   Rubin MR, 2010, ARQ BRAS ENDOCRINOL, V54, P220, DOI 10.1590/S0004 27302010000200019
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2016, J BONE MINER RES, V31, P1440, DOI 10.1002/jbmr.2812
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Silva BC, 2017, OSTEOPOROSIS INT, V28, P463, DOI 10.1007/s00198 016 3750 0
   Stidl R, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11030075
   Tamura T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13384
   Webster R, 2009, MILESTONES DRUG THER, P127, DOI 10.1007/978 3 7643 8679 5_8
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
NR 29
TC 32
Z9 36
U1 1
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2019
VL 34
IS 11
BP 2075
EP 2086
DI 10.1002/jbmr.3824
EA OCT 2019
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA JM2FN
UT WOS:000489189600001
PM 31291476
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, CQ
   Wang, XG
   Cheng, H
   Fang, JH
AF Wang, Chunqiu
   Wang, Xinguo
   Cheng, Hui
   Fang, Jiahu
TI MiR 22 3p facilitates bone marrow mesenchymal stem cell osteogenesis and
   fracture healing through the SOSTDC1 PI3K/AKT pathway
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE fracture healing; miR 22 3p; PI3K/AKT; sclerostin domain containing 1
ID DIFFERENTIATION; OSTEOPOROSIS; PI3K/AKT; IMPROVES; THERAPY
AB Bone fractures are the most common form of musculoskeletal trauma worldwide. Numerous microRNAs (miRNAs) have been suggested to be participants in regulating bone related diseases. Recent studies revealed the regulatory role of miR 22 3p in osteogenic differentiation, but its role in fracture healing has not been investigated previously. Here, a rat femoral fracture model was established, Bone marrow mesenchymal stem cells (BMSCs) were isolated to detect the specific function and underlying mechanisms of miR 22 3p. MiR 22 3p and sclerostin domain containing 1 (SOSTDC1) expression was determined by RT qPCR and immunohistochemistry staining. The levels of proteins associated with osteogenic differentiation were assessed by western blotting. Flow cytometry was conducted to identify the isolated rat BMSCs. Alizarin red staining, alkaline phosphatase staining and Oil Red O staining were used to evaluate the osteogenic and adipogenic differentiation of rat BMSCs. The interaction between miR 22 3p and SOSTDC1 was verified using a luciferase reporter assay. Haematoxylin and Eosin (H&E) staining of the bone tissues was performed to analyse the effect of miR 22 3p on histopathological changes in vivo. MiR 22 3p was downregulated in the callus tissues of rat femoral fracture, while the expression of SOSTDC1 was upregulated. The isolated rat BMSCs had the capacity for both osteogenic and adipogenic differentiation. The differentiation capacity of BMSCs into osteoblasts was increased by miR 22 3p overexpression. MiR 22 3p activated the PI3K/AKT pathway by targeting SOSTDC1. SOSTDC1 overexpression and PI3K/AKT signalling inhibitor LY294002 abolished the enhancing effect of miR 22 3p overexpression on the osteogenesis of BMSCs. Thus MiR 22 3p facilitated the femoral fracture healing in rats. MiR 22 3p overexpression promoted fracture healing via the activation of PI3K/AKT pathway by targeting SOSTDC1.
C1 [Wang, Chunqiu; Fang, Jiahu] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing, Peoples R China.
   [Wang, Xinguo; Cheng, Hui] Zhenjiang 359 Hosp, Dept Orthoped, Zhenjiang, Peoples R China.
   [Fang, Jiahu] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Fang, JH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM fjh4508@163.com
CR Axelrad TW, 2007, INJURY, V38, pS49, DOI 10.1016/j.injury.2007.02.010
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Bolamperti S, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8169614
   Chiu LH, 2014, BIOMATERIALS, V35, P2680, DOI 10.1016/j.biomaterials.2013.12.005
   Collette NM, 2016, BONE, V88, P20, DOI 10.1016/j.bone.2016.04.005
   Dong J, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112137
   Fu Q, 2015, CELLS TISSUES ORGANS, V201, P412, DOI 10.1159/000445855
   Ge DW, 2017, EUR REV MED PHARMACO, V21, P4784
   Giannoudis PV, 2007, INJURY, V38, pS3, DOI 10.1016/S0020 1383(08)70003 2
   Gómez Barrena E, 2015, BONE, V70, P93, DOI 10.1016/j.bone.2014.07.033
   Goulet JA, 1997, CLIN ORTHOP RELAT R, P76
   Hernigou P, 2014, INT ORTHOP, V38, P1913, DOI 10.1007/s00264 014 2285 2
   Huang Y, 2021, EXP MOL MED, V53, P973, DOI 10.1038/s12276 021 00631 w
   Jia B, 2018, EXP THER MED, V16, P1111, DOI 10.3892/etm.2018.6303
   Jia XL, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10124
   Kassem M, 2004, CLONING STEM CELLS, V6, P369, DOI 10.1089/clo.2004.6.369
   Kocijan R, 2016, J CLIN ENDOCR METAB, V101, P4125, DOI 10.1210/jc.2016 2365
   Lang Y, 2019, EUR REV MED PHARMACO, V23, P7200, DOI 10.26355/eurrev_201909_18821
   Liu Y, 2019, EUR REV MED PHARMACO, V23, P2727, DOI 10.26355/eurrev_201904_17544
   Liu Y, 2018, MUTAGENESIS, V33, P203, DOI 10.1093/mutage/gey010
   Lozano D, 2012, ACTA BIOMATER, V8, P2770, DOI 10.1016/j.actbio.2012.04.002
   Nadri S, 2007, INT J DEV BIOL, V51, P723, DOI 10.1387/ijdb.072352ns
   Okolicsanyi RK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137255
   Poole KES, 2017, BONE, V94, P124, DOI 10.1016/j.bone.2016.10.020
   Prockop DJ, 2003, P NATL ACAD SCI USA, V100, P11917, DOI 10.1073/pnas.1834138100
   Reid IR, 2010, J BONE MINER RES, V25, P2256, DOI 10.1002/jbmr.149
   Sun L, 2019, MOL CELL BIOCHEM, V460, P165, DOI 10.1007/s11010 019 03578 9
   Waki T, 2016, BMC MUSCULOSKEL DIS, V17, DOI 10.1186/s12891 016 0931 0
   Wang WZ, 2018, BIOCHEM BIOPH RES CO, V503, P2186, DOI 10.1016/j.bbrc.2018.08.011
   Weilner S, 2015, BONE, V79, P43, DOI 10.1016/j.bone.2015.05.027
   Xie H, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01685 8
   Xu LL, 2012, INT J BIOCHEM CELL B, V44, P612, DOI 10.1016/j.biocel.2011.12.018
   Zhang XL, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01707 6
   Zheng K, 2021, MOL BIOTECHNOL, V63, P605, DOI 10.1007/s12033 021 00322 x
   Zhou LG, 2019, EUR REV MED PHARMACO, V23, P449, DOI 10.26355/eurrev_201901_16854
   Zhou QY, 2017, MOL CELL BIOCHEM, V435, P87, DOI 10.1007/s11010 017 3059 0
NR 36
TC 3
Z9 3
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0959 9673
EI 1365 2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD APR
PY 2024
VL 105
IS 2
BP 52
EP 63
DI 10.1111/iep.12500
EA DEC 2023
PG 12
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA LJ7A8
UT WOS:001132160100001
PM 38152045
DA 2025 08 17
ER

PT J
AU Zhao, DF
   Wang, Q
   Zhao, YJ
   Zhang, H
   Sha, NN
   Tang, DZ
   Liu, SF
   Lu, S
   Shi, Q
   Zhang, Y
   Dung, YL
   Wang, YJ
   Shu, B
AF Zhao, Dongfeng
   Wang, Qiang
   Zhao, Yongjian
   Zhang, Hao
   Sha, Nannan
   Tang, Dezhi
   Liu, Shufen
   Lu, Sheng
   Shi, Qi
   Zhang, Yan
   Dung, Yuleng
   Wang, Yongjun
   Shu, Bing
TI The naturally derived small compound Osthole inhibits osteoclastogenesis
   to prevent ovariectomy induced bone loss in mice
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Osteoclastogenesis; Osthole; Ovariectomy; Postmenopausal osteoporosis;
   Receptor activator of nuclear factor kappa B ligand
ID COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR; POSTMENOPAUSAL
   OSTEOPOROSIS; OSTEOBLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; ESTROGEN;
   RATS; MINERALIZATION; SUPPRESSION; CYTOKINES
AB Objective: This study was to determine the bone protective effects and underlying mechanisms of Osthole (OT) in ovariectomized (OVX) mice. We found that the inhibitory effects of OT on receptor activator of nuclear factor kappa B ligand (RANKL) activated osteoclastogenesis are responsible for its bone protective effects in OVX mice.
   Methods: Eight week old mice were ovariectomized and OT (10 mg/kg/d) was intraperitoneally administrated to OVX mice 7 days after the surgery and were sacrificed at the end of the 3 months. Osteoclasts were generated from primary hone marrow macrophages (BMMs) to investigate the inhibitory effects of OT. The activity of RANKL activated signaling was simultaneously analyzed in vitro and in vivo using immunohistochemistry, Western blot, and PCR assays.
   Results: OT dose dependently inhibited RANKL mediated osteoclastogenesis in BMM cultures, OT administration attenuated bone loss (mg Ha/cm: 894.68 +/  33.56 vs 748.08 +/  19.51, P < 0.05) in OVX mice. OT inhibits osteoclastogenesis (Oc.N/per view area: 72 +/  4.3 vs 0.8 +/  0.4, P < 0.05) and bone resorption activity (bone resorbed percentages %, 48.56 +/  7.25 vs 3.25 +/ 1.37, P < 0.05) from BMMs. Mechanistically, OT inhibited the expressions of nuclear factor of activated T cells cl (NFATc1) and c Fos. Moreover, OT suppressed the expression of RANKL induced osteoclast marker genes, including matrix metalloproteinase 9 (MMP9), Cathepsin K (Ctsk), tartrate resistant acid phosphatase (TRAP), and carbonic anhydrase 11 (Car2),
   Conclusions: OT inhibits RANKL mediated osteoclastogenesis and prevents bone loss in OVX mice. Our findings revealed that OT is a potential new drug for treating postmenopausal osteoporosis.
C1 [Zhao, Dongfeng; Wang, Qiang; Zhao, Yongjian; Zhang, Hao; Sha, Nannan; Tang, Dezhi; Liu, Shufen; Lu, Sheng; Shi, Qi; Zhang, Yan; Wang, Yongjun; Shu, Bing] Shanghai Univ Tradit Chinese Med TCM, Longhua Hosp, Shanghai, Peoples R China.
   [Zhao, Dongfeng; Wang, Qiang; Zhao, Yongjian; Zhang, Hao; Sha, Nannan; Tang, Dezhi; Liu, Shufen; Lu, Sheng; Shi, Qi; Zhang, Yan; Wang, Yongjun; Shu, Bing] Shanghai Univ TCM, Spine Res Inst, Shanghai, Peoples R China.
   [Zhao, Dongfeng; Wang, Qiang; Zhao, Yongjian; Zhang, Hao; Sha, Nannan; Tang, Dezhi; Liu, Shufen; Lu, Sheng; Shi, Qi; Zhang, Yan; Wang, Yongjun; Shu, Bing] Shanghai Univ TCM, Minist Educ, Key Lab Theory & Therapy Muscles & Bones, Shanghai, Peoples R China.
   [Wang, Yongjun] Shanghai Univ TCM, Sch Rehabil Sci, Shanghai, Peoples R China.
   [Dung, Yuleng] Louisiana State Univ, Hlth Sci Ctr, Dept Orthopaed Surg, Shreveport, LA 71105 USA.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine; Louisiana State University System; Louisiana State
   University Health Sciences Center at Shreveport
RP Shu, B (通讯作者)，Shanghai Univ Tradit Chinese Med, Longhua Hosp, Room 809,Bldg 12,725 South Wanping Rd, Shanghai 200032, Peoples R China.
EM siren17721101@163.com
RI Wang, Qianghu/HJI 9741 2023; wang, ying/L 2593 2018
OI Shu, Bing/0000 0002 6009 5377
FU program for the National Natural Science foundation of China [81673991,
   81603643, 81774329, 81528022, 81473701, 81730107]; Ministry of Science
   and Technology of China [2015RA4002]; Ministry of Education of China
   [IRT1270]
FX This work was supported by the program for the National Natural Science
   foundation of China (81673991, 81603643, 81774329, 81528022, 81473701,
   and 81730107), Ministry of Science and Technology of China (Grant No.
   2015RA4002), and Ministry of Education of China (IRT1270).
CR Albers J, 2013, J CELL BIOL, V200, P537, DOI 10.1083/jcb.201207142
   Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cabarvdic Amra, 2006, Med Arh, V60, P96
   Canalis E, 2010, ENDOCR PRACT, V16, P855, DOI 10.4158/EP10048.RA
   Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200
   Chen KM, 2007, PHARMAZIE, V62, P388, DOI 10.1691/ph.2007.5.6682
   Curtis JR, 2008, J BONE MINER RES, V23, P1435, DOI 10.1359/JBMR.080418
   Darnay BG, 2007, ADV EXP MED BIOL, V597, P152
   Feng X, 2005, GENE, V350, P1, DOI 10.1016/j.gene.2005.01.014
   Grese TA, 1998, J MED CHEM, V41, P1272, DOI 10.1021/jm970688z
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gruber HE, 2000, CALCIFIED TISSUE INT, V66, P29, DOI 10.1007/s002230010007
   Hsieh TP, 2011, PHYTOMEDICINE, V18, P176, DOI 10.1016/j.phymed.2010.04.003
   Jules J, 2010, EXPERT OPIN THER TAR, V14, P923, DOI 10.1517/14728222.2010.511179
   Kim JY, 2014, BONE, V60, P104, DOI 10.1016/j.bone.2013.12.013
   KIMBLE RB, 1995, ENDOCRINOLOGY, V136, P3054, DOI 10.1210/en.136.7.3054
   King TJ, 2012, AM J PATHOL, V181, P121, DOI 10.1016/j.ajpath.2012.03.037
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Li FM, 2017, EXP THER MED, V14, P2385, DOI 10.3892/etm.2017.4771
   Li XF, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/652317
   Li XF, 2016, MOL MED REP, V14, P3769, DOI 10.3892/mmr.2016.5687
   Li XX, 2002, BIOL PHARM BULL, V25, P738, DOI 10.1248/bpb.25.738
   Lufkin EG, 2004, CURR MED RES OPIN, V20, P351, DOI 10.1185/030079904125003071
   Luo J, 2009, DEVELOPMENT, V136, P2747, DOI 10.1242/dev.033571
   Ma XN, 2013, PLANTA MED, V79, P1501, DOI 10.1055/s 0033 1350802
   Miller Paul D, 2009, Curr Osteoporos Rep, V7, P18
   Pacifici R, 1996, J BONE MINER RES, V11, P1043
   Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756 3282(01)00642 1
   RAISZ LG, 1988, CIBA F SYMP, V136, P226
   Rho J, 2002, DNA CELL BIOL, V21, P541, DOI 10.1089/104454902320308915
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   SHU B, 2017, SCI REP UK, V7
   Shu B, 2015, CHIN J INTEGR MED, V21, P656, DOI 10.1007/s11655 015 2306 z
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Sun L, 2008, P NATL ACAD SCI USA, V105, P4289, DOI 10.1073/pnas.0712395105
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tang DZ, 2011, BIOCHEM BIOPH RES CO, V405, P256, DOI 10.1016/j.bbrc.2011.01.021
   Tang DZ, 2010, J BONE MINER RES, V25, P1234, DOI 10.1002/jbmr.21
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Wang Q, 2018, J PHARMACOL SCI, V136, P155, DOI 10.1016/j.jphs.2018.01.007
   Xu DR, 2006, J BIOL CHEM, V281, P4678, DOI 10.1074/jbc.M510383200
   Zhang ZR, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/919616
   Zhao DF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102706
   Zhao Y, 2011, MENOPAUSE, V18, P690, DOI 10.1097/gme.0b013e3181fd7f4b
NR 48
TC 20
Z9 22
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072 3714
EI 1530 0374
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD DEC
PY 2018
VL 25
IS 12
BP 1459
EP 1469
DI 10.1097/GME.0000000000001150
PG 11
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA HK3CW
UT WOS:000457791300010
PM 29944638
DA 2025 08 17
ER

PT J
AU Cicek, M
   Iwaniec, UT
   Goblirsch, MJ
   Vrabel, A
   Ruan, M
   Clohisy, DR
   Turner, RR
   Oursler, MJ
AF Cicek, Muzaffer
   Iwaniec, Urszula T.
   Goblirsch, Michael J.
   Vrabel, Anne
   Ruan, Ming
   Clohisy, Denis R.
   Turner, Russell R.
   Oursler, Merry Jo
TI 2 methoxyestradiol suppresses osteolytic breast cancer tumor progression
   in vivo
SO CANCER RESEARCH
LA English
DT Article
ID MCF 7 CELLS; GROWTH; DIFFERENTIATION; ANGIOGENESIS; OSTEOCLASTS;
   EXPRESSION; INCREASES; RAT
AB 2 Methoxyestradiol (2ME(2)), a physiologic metabolite of 17 beta estradiol (estrogen), has emerged as a promising cancer therapy because of its potent growth inhibitory and proapoptotic effects on both endothelial and tumor cells. 2ME(2) also suppresses osteoclast differentiation and induces apoptosis of mature osteoclasts, and has been shown to effectively repress bone loss in an animal model of postmenopausal osteoporosis. Given these observations, we have examined whether 2ME(2) could effectively target metastasis to bone, osteolytic tumors, and soft tissue tumors. A 4T1 murine metastatic breast cancer cell line was generated that stably expressed Far Red fluorescence protein (4T1/Red) to visualize tumor development and metastasis to bone. In an intervention study, 4T1/ Red cells were injected into bone marrow of the left femur and the mammary pad. In the latter study, 2ME(2) (10, 25, and 50 mg/kg/d) treatment began on the same day as surgery and was continued for the 16 day duration of study. Tumor cell growth and metastasis to bone were monitored and bone volume was determined by micro computed tomography. 2ME(2) inhibited tumor growth in soft tissue, metastasis to bone, osteolysis, and tumor growth in bone, with maximum effects at 50 mg/kg/d. Furthermore, tumor induced osteolysis was significantly reduced in mice receiving 2ME(2)  In vitro, 2ME(2) repressed osteoclast number by inducing apoptosis of osteoclast precursors as well as mature osteoclasts. Our data support the conclusion that 2ME(2) could be an important new therapy in the arsenal to fight metastatic breast cancer.
C1 Mayo Clin, Coll Med, Endocrine Res Unit, Rochester, MN 55905 USA.
   Oregon State Univ, Coll Hlth & Human Sci, Corvallis, OR 97331 USA.
   Univ Minnesota, Dept Orthoped Surg, Minneapolis, MN USA.
C3 Mayo Clinic; Oregon State University; University of Minnesota System;
   University of Minnesota Twin Cities
RP Cicek, M (通讯作者)，Mayo Clin, Coll Med, Endocrine Res Unit, 200 1st St SW, Rochester, MN 55905 USA.
EM Muzaffer.Cicek@Mayo.edu
FU NIDCR NIH HHS [R01 DE14680] Funding Source: Medline
CR Brueggemeier RW, 2001, J STEROID BIOCHEM, V78, P145, DOI 10.1016/S0960 0760(01)00090 5
   Clohisy DR, 1996, J ORTHOPAED RES, V14, P396
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Hiraga T, 2001, CANCER RES, V61, P4418
   Kang SH, 2006, CANCER RES, V66, P11991, DOI 10.1158/0008 5472.CAN 06 1320
   Karst M, 2004, J CELL PHYSIOL, V200, P99, DOI 10.1002/jcp.20036
   Kataoka M, 1998, CANCER RES, V58, P4761
   Klauber N, 1997, CANCER RES, V57, P81
   LIU CC, 1987, J HISTOCHEM CYTOCHEM, V35, P1355, DOI 10.1177/35.12.3680930
   LOTTERING ML, 1992, CANCER RES, V52, P5926
   Maran A, 2006, J CELL BIOCHEM, V99, P425, DOI 10.1002/jcb.20924
   Martin TJ, 2000, ENDOCR RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271
   Pederson L, 1999, CANCER RES, V59, P5849
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Rodan GA, 1998, J CELL BIOCHEM, P55
   SEEGERS JC, 1989, J STEROID BIOCHEM, V32, P797, DOI 10.1016/0022 4731(89)90455 X
   Sibonga JD, 2003, ENDOCRINOLOGY, V144, P785, DOI 10.1210/en.2002 220632
   Turner RT, 2000, CALCIFIED TISSUE INT, V66, P465, DOI 10.1007/s002230010093
   Zoubine MN, 1999, INT J ONCOL, V15, P639
NR 20
TC 34
Z9 42
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD NOV 1
PY 2007
VL 67
IS 21
BP 10106
EP 10111
DI 10.1158/0008 5472.CAN 07 1362
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 228AV
UT WOS:000250700200003
PM 17974950
DA 2025 08 17
ER

PT J
AU Santos, F
   Carbajo Pérez, E
   Rodríguez, J
   Fernández Fuente, M
   Molinos, I
   Amil, B
   García, E
AF Santos, F
   Carbajo Pérez, E
   Rodríguez, J
   Fernández Fuente, M
   Molinos, I
   Amil, B
   García, E
TI Alterations of the growth plate in chronic renal failure
SO PEDIATRIC NEPHROLOGY
LA English
DT Article; Proceedings Paper
CT 7th Symposium on Growth and Development in Children with Chronic Kidney
   Disease
CY APR 01 03, 2004
CL Heidelberg, GERMANY
SP IPNA
DE growth plate; chondrocytes; uremia; parathyroid hormone; renal
   osteodystrophy; angiogenesis; growth hormone
ID UREMIC RATS; HORMONE TREATMENT; CARTILAGE; CALCITRIOL; THERAPY; CALCIUM;
   EXPRESSION; CHILDREN; HEIGHT
AB Chronic renal failure modifies the morphology and dynamics of the growth plate (GP) of long bones. In young uremic rats, the height of cartilage columns of GP may vary markedly. The reasons for this variation are unknown, although the severity and duration of renal failure and the type of renal osteodystrophy have been shown to influence the height of GP cartilage. Expansion of GP cartilage is associated with that of the hypertrophic stratum. The interference of uremia with the process of chondrocyte differentiation is suggested by some morphological features. However, analysis by immunohistochemistry and/or in situ hybridization of markers of chondrocyte maturation in the GP of uremic rats has yielded conflicting results. Thus, there have been reported normal and reduced mRNA levels for collagen X, parathyroid hormone/parathyroid hormone related peptide receptor, and matrix metalloproteinase 9, as well as normal mRNA and protein expression for vascular endothelial growth factor and chondromodulin I, peptides related to the control of angiogenesis. In addition, a decreased immunohistochemical signal for growth hormone receptor and low insulin like growth factor I mRNA in the proliferative zone of uremic GP are supportive of reduced chondrocyte proliferation. Growth hormone treatment improves chondrocyte maturation and activates bone metabolism in the primary spongiosa.
C1 Univ Oviedo, Fac Med, E 33006 Oviedo, Asturias, Spain.
   Univ Oviedo, Hosp Univ Cent Asturias, SESPA, Oviedo, Asturiad, Spain.
   Univ Oviedo, Hosp Univ Cent Asturias, Sch Med, Oviedo, Asturiad, Spain.
C3 University of Oviedo; University of Oviedo; Central University Hospital
   Asturias; Central University Hospital Asturias; University of Oviedo
RP Santos, F (通讯作者)，Univ Oviedo, Fac Med, C Julian Claveria 6, E 33006 Oviedo, Asturias, Spain.
EM fsantos@uniovi.es
RI ; Fernandez Fuente, Marta/A 1761 2014; Rodríguez, Julián/F 5900 2019
OI Rodriguez, Julian/0000 0003 4621 8905; Fernandez Fuente,
   Marta/0009 0008 1186 9656; 
CR Alvarez J, 2001, J BONE MINER RES, V16, P511, DOI 10.1359/jbmr.2001.16.3.511
   Amil B, 2004, KIDNEY INT, V66, P51, DOI 10.1111/j.1523 1755.2004.00708.x
   Amil B, 2003, NEFROLOGIA, V23, P23
   BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306
   Carbajo E, 2001, J AM SOC NEPHROL, V12, P1228, DOI 10.1681/ASN.V1261228
   Cobo A, 1996, MINER ELECTROL METAB, V22, P192
   Cobo A, 1999, J AM SOC NEPHROL, V10, P971
   DEAN DD, 1985, J CLIN INVEST, V76, P716, DOI 10.1172/JCI112026
   Edmondson SR, 2000, KIDNEY INT, V58, P62, DOI 10.1046/j.1523 1755.2000.00141.x
   Fernaández Fuente M, 2004, PEDIATR NEPHROL, V19, P187, DOI 10.1007/s00467 003 1326 7
   Haffner D, 2000, NEW ENGL J MED, V343, P923, DOI 10.1056/NEJM200009283431304
   HANNA JD, 1995, KIDNEY INT, V47, P1374, DOI 10.1038/ki.1995.193
   KOCH VH, 1989, J PEDIATR US, V115, P365, DOI 10.1016/S0022 3476(89)80833 9
   KOVACS G, 1991, KIDNEY INT, V40, P1032, DOI 10.1038/ki.1991.311
   Kovacs GT, 1996, KIDNEY INT, V49, P1413, DOI 10.1038/ki.1996.199
   MEHLS O, 1988, KIDNEY INT, V33, P45, DOI 10.1038/ki.1988.7
   MEHLS O, 1977, NEPHRON, V18, P288, DOI 10.1159/000180845
   RITZ E, 1973, NEPHRON, V10, P195, DOI 10.1159/000180187
   Sanchez CP, 2000, ENDOCRINOLOGY, V141, P1536, DOI 10.1210/en.141.4.1536
   Sanchez CP, 1998, KIDNEY INT, V54, P1879, DOI 10.1046/j.1523 1755.1998.00199.x
   Sanchez CP, 2004, ENDOCRINOLOGY, V145, P3375, DOI 10.1210/en.2003 1306
   Sanchez CP, 2003, J AM SOC NEPHROL, V14, P148, DOI 10.1097/01.ASN.0000039565.56011.BE
   Sanchez CP, 2002, BONE, V30, P692, DOI 10.1016/S8756 3282(02)00696 8
   Santos F, 1996, MINER ELECTROL METAB, V22, P83
   SANTOS F, 1992, PEDIATR NEPHROL, V6, P262, DOI 10.1007/BF00878363
   Urena P, 1996, NEPHROL DIAL TRANSPL, V11, P2008, DOI 10.1093/oxfordjournals.ndt.a027089
NR 26
TC 22
Z9 26
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0931 041X
J9 PEDIATR NEPHROL
JI Pediatr. Nephrol.
PD MAR
PY 2005
VL 20
IS 3
BP 330
EP 334
DI 10.1007/s00467 004 1652 4
PG 5
WC Pediatrics; Urology & Nephrology
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics; Urology & Nephrology
GA 907JS
UT WOS:000227713600014
PM 15549411
DA 2025 08 17
ER

PT J
AU Chen, X
   Gu, S
   Chen, BF
   Shen, WL
   Yin, Z
   Xu, GW
   Hu, JJ
   Zhu, T
   Li, G
   Wan, C
   Ouyang, HW
   Lee, TL
   Chan, WY
AF Chen, Xiao
   Gu, Shen
   Chen, Bi Feng
   Shen, Wei Liang
   Yin, Zi
   Xu, Guo Wei
   Hu, Jia Jie
   Zhu, Ting
   Li, Gang
   Wan, Chao
   Ouyang, Hong Wei
   Lee, Tin Lap
   Chan, Wai Yee
TI Nanoparticle delivery of stable miR 199a 5p agomir improves the
   osteogenesis of human mesenchymal stem cells via the HIF1a pathway
SO BIOMATERIALS
LA English
DT Article
DE Human mesenchymal stem cells; hsa mir 199a; Drug delivery; Bone
   differentiation; Maturation; Regeneration
ID HYPOXIA INDUCIBLE FACTOR 1 ALPHA; BONE MARROW; CHITOSAN NANOPARTICLES;
   MEDIATED DELIVERY; DOWN REGULATION; DIFFERENTIATION; MICRORNAS; SIRNA;
   RNA; CHONDROGENESIS
AB Elucidating the regulatory mechanisms of osteogenesis of human mesenchymal stem cell (hMSC) is important for the development of cell therapies for bone loss and regeneration. Here we showed that hsa miR 199a 5p modulated osteogenic differentiation of hMSCs at both early and late stages through HIF1a pathway. hsa miR 199a expression was up regulated during osteogenesis for both of two mature forms, miR 199a 5p and  3p. Over expression of miR 199a 5p but not  3p enhanced differentiation of hMSCs in vitro, whereas inhibition of miR 199a 5p reduced the expression of osteoblast specific genes, alkaline phosphatase (ALP) activity, and mineralization. Furthermore, over expression of miR 199a enhanced ectopic bone formation in vivo. Chitosan nanoparticles were used for delivery of stable modified hsa miR 199a 5p (agomir) both in vitro and in vivo, as a proof of concept for stable agomir delivery on bone regeneration. The hsa mir199a 5p agomir were mixed with Chitosan nanoparticles to form nanoparticle/hsa mir199a 5p agomir plasmid (nanoparticle/agomir) complexes, and nanoparticle/agomir complexes could improve the in vivo regeneration of bone. Further mechanism studies revealed that hypoxia enhanced osteogenesis at early stage and inhibited osteogenesis maturation at late stage through HIF1a Twistl pathway. At early stage of differentiation, hypoxia induced HIF1a Twistl pathway to enhance osteogenesis by up regulating miR 199a 5p, while at late stage of differentiation, miR 199a 5p enhanced osteogenesis maturation by inhibiting HIF1 alpha Twist1 pathway. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Chen, Xiao; Shen, Wei Liang; Yin, Zi; Xu, Guo Wei; Hu, Jia Jie; Zhu, Ting; Ouyang, Hong Wei] Zhejiang Univ, Zhejiang Prov Key Lab Tissue Engn & Regenerat Med, Hangzhou 310003, Zhejiang, Peoples R China.
   [Chen, Xiao; Gu, Shen; Chen, Bi Feng; Li, Gang; Wan, Chao; Lee, Tin Lap; Chan, Wai Yee] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
   [Chen, Bi Feng] Wuhan Univ Technol, Sch Chem Engn & Life Sci, Dept Biosci & Biotechnol, Wuhan 430070, Peoples R China.
C3 Zhejiang University; Chinese University of Hong Kong; Wuhan University
   of Technology
RP Chan, WY (通讯作者)，Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China.
EM leetl@cuhk.edu.hk; chanwy@cuhk.edu.hk
RI ; Chan, Wai Yee/R 7442 2018; Ouyang, hong wei/ISS 2757 2023; Yin,
   Zi/C 3371 2017; Chan, Wai/R 7442 2018; Lee, Tin Lap/A 7853 2009; Li,
   Gang/J 7830 2018; Chen, Xiao/JAC 8548 2023; Chen, Xiao/A 4384 2009; Gu,
   Shen/AAE 2641 2020; Wan, Chao/J 9277 2013
OI Gu, Shen/0000 0003 3107 1218; Chan, Wai Yee/0000 0002 9714 0936; SHEN,
   WEI LIANG/0000 0001 8131 325X; Lee, Tin Lap/0000 0002 6654 0988; Li,
   Gang/0000 0002 3981 2239; Chen, Xiao/0000 0002 4438 5286; Wan,
   Chao/0000 0001 6780 2006
FU NSFC [81330041, 81125014, 31271041]; RGC GRF [475910]; Zhejiang
   Provincial Natural Science Foundation of China [LR14H060001]
FX This work was supported by NSFC grants (81330041, 81125014, 31271041),
   RGC GRF #475910, and Zhejiang Provincial Natural Science Foundation of
   China (LR14H060001).
CR Almalik A, 2013, MACROMOL BIOSCI, V13, P1671, DOI 10.1002/mabi.201300302
   Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534 5807(04)00058 9
   Boyette LB, 2014, STEM CELL TRANSL MED, V3, P241, DOI 10.5966/sctm.2013 0079
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Campard D, 2008, GASTROENTEROLOGY, V134, P833, DOI 10.1053/j.gastro.2007.12.024
   Colnot C, 2011, TISSUE ENG PART B RE, V17, P449, DOI [10.1089/ten.teb.2011.0243, 10.1089/ten.TEB.2011.0243]
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Furtado MB, 2014, CIRC RES, V114, P1422, DOI 10.1161/CIRCRESAHA.114.302530
   Ghosh R, 2013, BIOMATERIALS, V34, P807, DOI 10.1016/j.biomaterials.2012.10.023
   Gonsalves CS, 2010, J IMMUNOL, V184, P3878, DOI 10.4049/jimmunol.0902594
   Goodnough LH, 2012, DEVELOPMENT, V139, P4428, DOI 10.1242/dev.081679
   Gradus B, 2010, TOP BONE BIOL, V6, P81, DOI 10.1007/978 1 84882 822 3_5
   Gu S, 2012, INT J MOL SCI, V13, P8449, DOI 10.3390/ijms13078449
   Huang PI, 2012, CURR GENE THER, V12, P275, DOI 10.2174/156652312802083576
   Kang SG, 2012, CARCINOGENESIS, V33, P661, DOI 10.1093/carcin/bgr320
   Katas H, 2006, J CONTROL RELEASE, V115, P216, DOI 10.1016/j.jconrel.2006.07.021
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Laine SK, 2012, J CELL BIOCHEM, V113, P2687, DOI 10.1002/jcb.24144
   Lee YB, 2009, NUCLEIC ACIDS RES, V37, P123, DOI 10.1093/nar/gkn920
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   Lewandowska Szumiel M, 2011, CURR PHARM BIOTECHNO, V12, P1850, DOI 10.2174/138920111798376941
   Li Y, 2011, Adv Dent Res, V23, P280, DOI 10.1177/0022034511405387
   Lin EA, 2009, J BIOL CHEM, V284, P11326, DOI 10.1074/jbc.M807709200
   Liu J, 2006, BIOCHEM BIOPH RES CO, V348, P1167, DOI 10.1016/j.bbrc.2006.07.175
   Maeno T, 2011, BONE, V49, P673, DOI 10.1016/j.bone.2011.07.023
   Marie PJ, 2006, REGEN MED, V1, P539, DOI 10.2217/17460751.1.4.539
   Meijer GJ, 2007, PLOS MED, V4, P260, DOI 10.1371/journal.pmed.0040009
   Mizuno S, 2012, CHEST, V142, P663, DOI 10.1378/chest.11 2746
   Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108
   Nelson CE, 2014, ADV MATER, V26, P607, DOI 10.1002/adma.201303520
   Oskowitz AZ, 2008, P NATL ACAD SCI USA, V105, P18372, DOI 10.1073/pnas.0809807105
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Preda MB, 2014, STEM CELLS, V32, P2123, DOI 10.1002/stem.1687
   Ragelle H, 2013, J CONTROL RELEASE, V172, P207, DOI 10.1016/j.jconrel.2013.08.005
   Rane S, 2009, CIRC RES, V104, P879, DOI 10.1161/CIRCRESAHA.108.193102
   Sohn YD, 2013, BIOMATERIALS, V34, P4235, DOI 10.1016/j.biomaterials.2013.02.005
   Sun NF, 2014, CRIT REV ONCOL HEMAT, V89, P352, DOI 10.1016/j.critrevonc.2013.10.006
   Suomi S, 2008, GENE REGUL SYST BIO, V2, P177
   Tsai CC, 2011, BLOOD, V117, P459, DOI 10.1182/blood 2010 05 287508
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Watanabe T, 2008, DEV DYNAM, V237, P3738, DOI 10.1002/dvdy.21787
   Yang DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023965
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Zhang ZY, 2012, BIOMATERIALS, V33, P2656, DOI 10.1016/j.biomaterials.2011.12.025
   Zhou YL, 2013, BIOMATERIALS, V34, P8269, DOI 10.1016/j.biomaterials.2013.07.072
NR 45
TC 113
Z9 121
U1 0
U2 119
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD JUN
PY 2015
VL 53
BP 239
EP 250
DI 10.1016/j.biomaterials.2015.02.071
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA CH3KO
UT WOS:000353929800023
PM 25890723
DA 2025 08 17
ER

PT J
AU Wang, D
   Li, Y
   Liu, Y
   Shi, G
AF Wang, D.
   Li, Y.
   Liu, Y.
   Shi, G.
TI The role of autoreactive T cell in the pathogenesis of rheumatoid
   arthritis and implications for T cell targeted vaccine therapy
SO MINERVA MEDICA
LA English
DT Article
DE Arthritis, rheumatoid; Vaccines; Therapeutics
ID COLLAGEN INDUCED ARTHRITIS; HUMAN CARTILAGE GLYCOPROTEIN 39;
   EPITOPE SPECIFIC IMMUNOTHERAPY; II COLLAGEN; DOUBLE BLIND; AUTOIMMUNE
   ARTHRITIS; DENDRITIC CELLS; CITRULLINATED PROTEINS; SIGNAL TRANSDUCTION;
   IMMUNE DEVIATION
AB Rheumatoid arthritis (RA) is a systemic autoimmune disease characterised by chronic inflammation of joint synovial tissue and subsequent destruction of associated bone, cartilage and soft tissues. RA is commonly treated with non steroidal anti inflammatory drugs (NSAIDs), traditional disease modifying antirheumatic drugs (DMARDs), glucocorticoids and biologic inhibitors of TNF, IL 1 IL 6, T cells and B cells. The use of these drugs especially biological agents has greatly improved the treatment of RA. Although the pathogenesis of RA remains unclear, T cell mediated immune response is considered as a critical contributor in RA initiation and progression. It has been hypothesized that arthritogenic T cells (autoreactive T cells) escaping negative selection can recognize arthritogenic antigens and lead to autoimmunity and tissue destruction. Due to the important role of autoreactive T cells in the mechanisms of RA, they might be a novel therapeutic target. Many vaccines targeting autoreactive T cells which can establish immunological self tolerance have been developed. The efficacy of these vaccines has been justified in experimental models of RA and clinical trials. Inhibition of autoreactive T cell response by vaccination might provide a new treatment opinion in RA.
C1 [Wang, D.] Shandong Med Coll, Mol Biol Res Ctr, Linyi, Shandong, Peoples R China.
   [Li, Y.; Liu, Y.; Shi, G.] Xiamen Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, Xiamen 361003, Fujian, Peoples R China.
C3 Xiamen University
RP Shi, G (通讯作者)，Xiamen Univ, Affiliated Hosp 1, Dept Rheumatol & Clin Immunol, 55 Zhenhai Rd, Xiamen 361003, Fujian, Peoples R China.
EM gshi@xmu.edu.cn
OI shi, guixiu/0000 0003 4044 3394
FU NSFC (Natural Science Foundation of China) [81302588, 81302565]
FX Funding. The work was supported by NSFC (Natural Science Foundation of
   China) grant 81302588 to Dashan Wang; NSFC grant 81302565 to Yan Li.
CR Aarvak T, 2001, ARTHRITIS RES, V3, P13, DOI 10.1186/ar135
   Aggarwal A, 2013, RHEUMATOL INT, V33, P2359, DOI 10.1007/s00296 013 2731 2
   Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002
   Albani S, 2011, NAT REV RHEUMATOL, V7, P273, DOI 10.1038/nrrheum.2011.36
   Anthony DD, 1999, CLIN EXP RHEUMATOL, V17, P240
   Auger I, 2005, ARTHRITIS RHEUM US, V52, P3424, DOI 10.1002/ART.21391
   Barnett ML, 1998, ARTHRITIS RHEUM, V41, P290, DOI 10.1002/1529 0131(199802)41:2<290::AID ART13>3.3.CO;2 I
   Billadeau DD, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3121pe16
   Boots AMH, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2269
   Bouneaud C, 2000, IMMUNITY, V13, P829, DOI 10.1016/S1074 7613(00)00080 7
   Carpino N, 2004, IMMUNITY, V20, P37, DOI 10.1016/S1074 7613(03)00351 0
   Catchpole B, 2002, J AUTOIMMUN, V18, P271, DOI 10.1006/jaut.2002.0585
   Cavanagh LL, 2005, ARTHRITIS RES THER, V7, pR230, DOI 10.1186/ar1467
   Chen GJ, 2007, ARTHRITIS RHEUM US, V56, P453, DOI 10.1002/art.22316
   Chen LJ, 2012, PHARMACEUTICALS, V5, P339, DOI 10.3390/ph5040339
   Cho YG, 2007, AUTOIMMUN REV, V7, P65, DOI 10.1016/j.autrev.2007.08.001
   Choy EHS, 2001, ARTHRITIS RHEUM US, V44, P1993, DOI 10.1002/1529 0131(200109)44:9<1993::AID ART347>3.0.CO;2 A
   Cohen S, 2002, ARTHRITIS RHEUM, V46, P614, DOI 10.1002/art.10141
   Cope AP, 2004, ARTHRITIS RES THER, V6, P112, DOI 10.1186/ar1185
   Daikh DI, 2012, ARTHRIT CARE RES, V64, P648, DOI 10.1002/acr.21659
   De Rosa MC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011550
   Dejaco C, 2010, RHEUMATOL INT, V30, P297, DOI 10.1007/s00296 009 0949 9
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Fox DA, 2010, RHEUM DIS CLIN N AM, V36, P311, DOI 10.1016/j.rdc.2010.02.004
   Gatzka M, 2007, AUTOIMMUNITY, V40, P442, DOI 10.1080/08916930701464962
   Ge PL, 2009, CHINESE MED J PEKING, V122, P1039, DOI 10.3760/cma.j.issn.0366 6999.2009.09.007
   Gonzalez Gay MA, 2002, SEMIN ARTHRITIS RHEU, V31, P355, DOI 10.1053/sarh.2002.32552
   GREGERSEN PK, 1987, ARTHRITIS RHEUM, V30, P1205, DOI 10.1002/art.1780301102
   Hawse WF, 2014, J IMMUNOL, V192, P2885, DOI 10.4049/jimmunol.1302953
   Honda A, 2004, INT IMMUNOL, V16, P737, DOI 10.1093/intimm/dxh075
   ILONEN J, 1990, ANN RHEUM DIS, V49, P494, DOI 10.1136/ard.49.7.494
   Ivanova IP, 2007, B EXP BIOL MED+, V144, P630, DOI 10.1007/s10517 007 0391 5
   Ivanova I, 2014, HUM VACC IMMUNOTHER, V10, P1221, DOI 10.4161/hv.28299
   JENKINS RN, 1993, J CLIN INVEST, V92, P2688, DOI 10.1172/JCI116886
   Kakkar V, 2012, CURR TOP MED CHEM, V12, P2479
   KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092 8674(87)90568 X
   Kavanaugh A, 2003, J RHEUMATOL, V30, P449
   Kinne RW, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4123
   Klareskog L, 2014, CURR OPIN RHEUMATOL, V26, P72, DOI 10.1097/BOR.0000000000000016
   Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203
   Koffeman EC, 2009, ARTHRITIS RHEUM US, V60, P3207, DOI 10.1002/art.24916
   Kotlarz A, 2013, CELL STRESS CHAPERON, V18, P653, DOI 10.1007/s12192 013 0407 1
   Kremer JM, 2005, ARTHRITIS RHEUM, V52, P2263, DOI 10.1002/art.21201
   Kurkó J, 2013, CLIN REV ALLERG IMMU, V45, P170, DOI 10.1007/s12016 012 8346 7
   Landewé RBM, 2010, ANN RHEUM DIS, V69, P1655, DOI 10.1136/ard.2009.117234
   Law SC, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3848
   Leung BP, 2002, J IMMUNOL, V169, P7071, DOI 10.4049/jimmunol.169.12.7071
   Li S, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/967301
   Liu BY, 2014, CELL, V157, P357, DOI 10.1016/j.cell.2014.02.053
   Lu S, 2008, EXPERT REV VACCINES, V7, P175, DOI 10.1586/14760584.7.2.175
   Lubberts E, 2015, CURR PHARM DESIGN, V21, P142
   Ma XX, 2013, BIOMED REP, V1, P177, DOI 10.3892/br.2012.42
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Min SY, 2006, ARTHRITIS RHEUM US, V54, P887, DOI 10.1002/art.21647
   Min SY, 2004, ARTHRITIS RES THER, V6, pR213, DOI 10.1186/ar1169
   Miossec P, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2413
   Moreland LW, 1998, ARTHRITIS RHEUM, V41, P1919, DOI 10.1002/1529 0131(199811)41:11<1919::AID ART5>3.0.CO;2 1
   Mouterde G, 2010, JOINT BONE SPINE, V77, P597, DOI 10.1016/j.jbspin.2009.12.011
   ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002
   Park KS, 2009, MOD RHEUMATOL, V19, P581, DOI 10.1007/s10165 009 0210 0
   Pawlowska J, 2014, POL ARCH MED WEWN, V124, P43
   Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101
   RAMANUJAM T, 1995, PATHOBIOLOGY, V63, P100, DOI 10.1159/000163940
   Rosloniec EF, 2004, AM J MED SCI, V327, P169, DOI 10.1097/00000441 200404000 00002
   Rubbert Roth A, 2012, RHEUMATOLOGY, V51, pV38, DOI 10.1093/rheumatology/kes114
   Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119
   Sakaguchi S, 2006, SEMIN IMMUNOL, V18, P199, DOI 10.1016/j.smim.2006.03.007
   Scott DL, 2012, CLIN PHARMACOL THER, V91, P30, DOI 10.1038/clpt.2011.278
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Singh JA, 2013, CAN MED ASSOC J, V185, P793, DOI 10.1503/cmaj.121607
   Smolen JS, 2008, LANCET, V371, P987, DOI 10.1016/S0140 6736(08)60453 5
   Snir O, 2012, ARTHRITIS RHEUM US, V64, P2482, DOI 10.1002/art.34459
   Song XQ, 2009, VACCINE, V27, P690, DOI 10.1016/j.vaccine.2008.11.090
   St Clair EW, 2000, J RHEUMATOL, V27, P1855
   Strasser A, 2008, IMMUNOL CELL BIOL, V86, P57, DOI 10.1038/sj.icb.7100141
   THOMAS R, 1994, J IMMUNOL, V152, P2613
   Thomas R, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2446
   Trouw LA, 2013, ANN RHEUM DIS, V72, P132, DOI 10.1136/annrheumdis 2012 202349
   Tsark EC, 2002, J IMMUNOL, V169, P6625, DOI 10.4049/jimmunol.169.11.6625
   van Bilsen JHM, 2004, P NATL ACAD SCI USA, V101, P17180, DOI 10.1073/pnas.0407704101
   van den Boorn JG, 2006, INT REV IMMUNOL, V25, P235, DOI 10.1080/08830180600743081
   van Heemst J, 2014, ANN MED, V46, P304, DOI 10.3109/07853890.2014.907097
   van Lierop MJC, 2007, ARTHRITIS RHEUM, V56, P2150, DOI 10.1002/art.22651
   Venanzi ES, 2004, CURR OPIN IMMUNOL, V16, P197, DOI 10.1016/j.coi.2004.01.008
   von Landenberg P, 2000, CLIN REV ALLERG IMMU, V18, P59, DOI 10.1385/CRIAI:18:1:59
   Vossenaar ER, 2004, ARTHRITIS RES THER, V6, P107, DOI 10.1186/ar1184
   Wegner N, 2010, IMMUNOL REV, V233, P34, DOI 10.1111/j.0105 2896.2009.00850.x
   Wehrens EJ, 2013, NAT REV RHEUMATOL, V9, P34, DOI 10.1038/nrrheum.2012.149
   Wei W, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2870
   Woodrick RS, 2011, NAT REV RHEUMATOL, V7, P639, DOI 10.1038/nrrheum.2011.145
   Xue H, 2011, HUM GENE THER, V22, P65, DOI 10.1089/hum.2010.110
   Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20041758
   Zandbelt MM, 2006, J RHEUMATOL, V33, P1726
   Zanelli E, 2000, HUM IMMUNOL, V61, P1254, DOI 10.1016/S0198 8859(00)00185 3
   Zhang LL, 2008, ARTHRIT RHEUM ARTHR, V59, P905, DOI 10.1002/art.23824
   Zhao SZ, 2004, PHARMACOEPIDEM DR S, V13, P277, DOI 10.1002/pds.909
   Zimmerman DH, 2010, INT IMMUNOPHARMACOL, V10, P412, DOI 10.1016/j.intimp.2009.12.016
NR 97
TC 13
Z9 15
U1 0
U2 18
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83 85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026 4806
EI 1827 1669
J9 MINERVA MED
JI Minerva Med.
PD JUN
PY 2015
VL 106
IS 3
BP 157
EP 167
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA CP9AT
UT WOS:000360186800005
PM 26057192
DA 2025 08 17
ER

PT J
AU Shore, N
   Mason, M
   de Reijke, TM
AF Shore, N.
   Mason, M.
   de Reijke, Th. M.
TI New developments in castrate resistant prostate cancer
SO BJU INTERNATIONAL
LA English
DT Article
DE anti androgens; CRPC; cytotoxic therapy; immunotherapy; secondary
   hormone therapy; targeted therapy
ID PHASE II TRIAL; CIRCULATING TUMOR CELLS; IMMUNE SYSTEM; THERAPY;
   DOCETAXEL; SURVIVAL; DIETHYLSTILBESTROL; IMMUNOTHERAPY; MITOXANTRONE;
   COMBINATION
AB Castrate resistant prostate cancer (CRPC) occurs when disease progresses in the presence of castrate levels of androgens and remains sensitive to further hormonal manipulation. For many years the treatment of CRPC was limited to the use of docetaxel for metastatic disease. However, this has recently changed with the approval of several new agents. Sipuleucel T, an immunotherapeutic vaccine, is now available in the US for patients with non metastatic CRPC and abiraterone, an oral enzyme inhibitor of androgen biosynthesis, as well as cabazitaxel, a cytotoxic chemotherapeutic, have been approved for the treatment of metastatic CRPC. Also, denosumab, a subcutaneous antibody, is now an option for the treatment of patients with CRPC with bone metastases, in addition to zoledronic acid, an intravenous bisphosphonate. Further treatment advances for metastatic CRPC therapeutics are in late stage phase III development. These include therapies affecting the androgen receptor (MDV3100) as well as additional immune based therapeutics, PROSTVAC and ipilimumab. A broad range of agents is also emerging under the term targeted therapies. The endothelin A receptor antagonist zibotentan, the tyrosine kinase inhibitors dasatinib, sorafenib and cabozantinib, the anti angiogenic agent aflibercept, and the clusterin inhibitor custirsen, are all currently being tested for efficacy in metastatic CRPC. The mechanism of action of these and other promising agents are discussed alongside current therapeutic options and their potential place in the treatment landscape for CRPC is considered.
C1 [Shore, N.] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC 29572 USA.
   [Mason, M.] Cardiff Univ, Inst Canc & Genet, Velindre Hosp, Cardiff, S Glam, Wales.
   [de Reijke, Th. M.] Univ Amsterdam, Dept Urol, Amsterdam, Netherlands.
C3 Carolina Urologic Research Center; Cardiff University; Velindre Cancer
   Centre; University of Amsterdam
RP Shore, N (通讯作者)，Atlantic Urol Clin, Carolina Urol Res Ctr, 823 82nd Pkwy, Myrtle Beach, SC 29572 USA.
EM nshore@gsuro.com
RI Shore, Neal/ABM 5607 2022; Mason, Malcolm/H 6979 2013
FU Ferring Pharmaceuticals
FX Medical writing assistance (funded by Ferring Pharmaceuticals) was
   provided by Matthew deSchoolmeester of Bioscript Stirling Ltd.
CR Andersen MH, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/237623
   [Anonymous], J CLIN ONCOL S
   [Anonymous], CANCER
   [Anonymous], J UROL S
   [Anonymous], STUD EV SAF EFF LEN
   [Anonymous], EUR J CANC S2
   [Anonymous], SAF EFF STUD OR MDV3
   [Anonymous], CONCURRENT VERSUS SE
   [Anonymous], RAND STUD COMP DOC P
   [Anonymous], P 101 ANN M AM ASS C
   [Anonymous], ASTRAZENECA HALTS PH
   [Anonymous], CP675 U WISC
   [Anonymous], AFL COMB DOC MET AND
   [Anonymous], STUD COMP ORT PLUS P
   [Anonymous], EUR UROL S
   [Anonymous], CLIN GENITOURIN CANC
   [Anonymous], STUD EV PAIN PALL BE
   [Anonymous], J UROL S
   [Anonymous], PHAS 3 EFF STUD REC
   [Anonymous], J CLIN ONCOL S5
   [Anonymous], INVEST NEW DRUGS
   [Anonymous], PHAS 3 TRIAL ZD4054
   [Anonymous], COCHRANE DATABASE SY
   [Anonymous], COMP DOC PREDN DOC P
   [Anonymous], PROSTATE
   [Anonymous], J UROL S
   [Anonymous], ASCO GU 2010
   [Anonymous], DOC PRED ATR TREAT
   [Anonymous], J UROL S
   [Anonymous], SAF PHARM PROOF CONC
   [Anonymous], PHAS 3 STUD IMM TREA
   [Anonymous], DOC PREDN BEV TREAT
   [Anonymous], STUD IMM TREAT ADV P
   Aragon Ching JB, 2007, FRONT BIOSCI LANDMRK, V12, P4957, DOI 10.2741/2441
   Araujo JC, 2012, CANCER AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204
   Armstrong AJ, 2010, EUR J CANCER, V46, P517, DOI 10.1016/j.ejca.2009.11.007
   Ascierto PA, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 196
   Attard G, 2009, J CLIN ONCOL, V27, P3742, DOI 10.1200/JCO.2008.20.0642
   Beer TM, 2004, BRIT J CANCER, V91, P1425, DOI 10.1038/sj.bjc.6602198
   Bjartell A, 2011, EUR UROL, V60, P905, DOI 10.1016/j.eururo.2011.08.024
   Boasberg P, 2010, SEMIN ONCOL, V37, P440, DOI 10.1053/j.seminoncol.2010.09.004
   Bousquet G, 2011, BRIT J CANCER, V105, P1640, DOI 10.1038/bjc.2011.440
   Chiacchio S, 2011, Q J NUCL MED MOL IM, V55, P431
   ClinicalTrials.gov, ARMOR1: Study of TOK 001 to Treat Castration Resistant Prostate Cancer (ARMOR1)
   De Bono JS, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.4508
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   de Souza AP, 2009, EXPERT REV ANTICANC, V9, P1317, DOI 10.1586/ERA.09.88
   Dorff TB, 2011, ONCOLOGIST, V16, P1349, DOI 10.1634/theoncologist.2010 0014
   Dy SM, 2008, J CLIN ONCOL, V26, P3879, DOI 10.1200/JCO.2007.15.9517
   FERRO MA, 1989, UROLOGY, V34, P134, DOI 10.1016/0090 4295(89)90248 3
   Fizazi K, 2007, ANN ONCOL, V18, P1765, DOI 10.1093/annonc/mdm086
   Fizazi K, 2009, BJU INT, V104, P1423, DOI 10.1111/j.1464 410X.2009.08740.x
   Goodman OB, 2009, CANCER EPIDEM BIOMAR, V18, P1904, DOI 10.1158/1055 9965.EPI 08 1173
   Halabi S, 2003, J CLIN ONCOL, V21, P1232, DOI 10.1200/JCO.2003.06.100
   Heidenreich A., 2012, Guidelines on Prostate Cancer
   Helo P, 2009, CLIN CHEM, V55, P765, DOI 10.1373/clinchem.2008.117952
   Henriksen G, 2003, J NUCL MED, V44, P252
   Joseph JD, 2009, P NATL ACAD SCI USA, V106, P12178, DOI 10.1073/pnas.0900185106
   Kälin M, 2011, EUR UROL, V60, P1235, DOI 10.1016/j.eururo.2011.06.038
   Kaku T, 2011, BIOORGAN MED CHEM, V19, P6383, DOI 10.1016/j.bmc.2011.08.066
   Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Klotz L, 1999, J UROLOGY, V161, P169, DOI 10.1016/S0022 5347(01)62089 5
   Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008 5472.CAN 07 5997
   Longo DL, 2010, NEW ENGL J MED, V363, P479, DOI 10.1056/NEJMe1006300
   Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078 0432.CCR 10 2815
   Mathew P, 2010, CANCER CHEMOTH PHARM, V65, P811, DOI 10.1007/s00280 009 1237 9
   Matsumoto H, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.4502
   Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882
   Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008 5472.CAN 08 0249
   Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163
   National Comprehensive Cancer Network, 2012, CLIN PRACT GUID ONC
   Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990
   Nelson JB, 2008, CANCER AM CANCER SOC, V113, P2478, DOI 10.1002/cncr.23864
   Oh WK, 2011, CANCER AM CANCER SOC, V117, P517, DOI 10.1002/cncr.25394
   Oh WK, 2004, J CLIN ONCOL, V22, P3705, DOI 10.1200/JCO.2004.10.195
   Okamoto R, 2012, INT J CANCER, V130, P2464, DOI 10.1002/ijc.26279
   Peggs KS, 2006, CURR OPIN IMMUNOL, V18, P206, DOI 10.1016/j.coi.2006.01.011
   Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318
   Picus J, 2011, CANCER AM CANCER SOC, V117, P526, DOI 10.1002/cncr.25421
   Rao BQ, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 17
   Robertson CN, 1996, J NATL CANCER I, V88, P908, DOI 10.1093/jnci/88.13.908
   Saad F, 2011, CLIN CANCER RES, V17, P5765, DOI 10.1158/1078 0432.CCR 11 0859
   Scher HI, 2008, J CLIN ONCOL, V26, P1148, DOI 10.1200/JCO.2007.12.4487
   Small EJ, 1997, J CLIN ONCOL, V15, P382, DOI 10.1200/JCO.1997.15.1.382
   Small EJ, 2004, J CLIN ONCOL, V22, P1025, DOI 10.1200/JCO.2004.06.037
   Smith DC, 1998, UROLOGY, V52, P257, DOI 10.1016/S0090 4295(98)00173 3
   Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008 5472.CAN 05 4000
   Suzuki H, 2008, J UROLOGY, V180, P921, DOI 10.1016/j.juro.2008.05.045
   Sweeney C, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.e15000
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078 0432.CCR 09 1722
   Taplin ME, 1999, CANCER RES, V59, P2511
   Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078 0432.CCR 09 1691
   Zeldis JB, 2011, ANN NY ACAD SCI, V1222, P76, DOI 10.1111/j.1749 6632.2011.05974.x
   Zoubeidi A, 2010, CLIN CANCER RES, V16, P1088, DOI 10.1158/1078 0432.CCR 09 2917
NR 96
TC 33
Z9 36
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1464 4096
EI 1464 410X
J9 BJU INT
JI BJU Int.
PD JUN
PY 2012
VL 109
SU 6
SI SI
BP 22
EP 32
DI 10.1111/j.1464 410X.2012.11217.x
PG 11
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 952TR
UT WOS:000304815800003
PM 22672122
DA 2025 08 17
ER

PT J
AU Magal, I
   Lebel, E
   Altarescu, G
   Itzchaki, M
   Rudensky, B
   Foldes, AJ
   Zimran, A
   Elstein, D
AF Magal, I
   Lebel, E
   Altarescu, G
   Itzchaki, M
   Rudensky, B
   Foldes, AJ
   Zimran, A
   Elstein, D
TI Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in
   Gaucher disease
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE osteoprotegerin; Gaucher disease; bone mineral density; enzyme
   replacement therapy; osteoclasts; osteoprotegerin polymorphisms
ID MACROPHAGE TARGETED GLUCOCEREBROSIDASE; ENZYME REPLACEMENT THERAPY;
   SKELETAL INVOLVEMENT; PROMOTER REGION; HUMAN GENE; OSTEOPOROSIS;
   PATHOGENESIS; ACTIVATION; CYTOKINE; FRACTURE
AB Bone involvement in Gaucher disease causes disability and reduced quality of life; loss of function and pain are important indications for enzyme replacement therapy. The purpose of this study was to ascertain whether osteoprotegerin (OPG), which decreases osteoclast activity, is indicative of incipient bone involvement by comparing OPG serum levels to Gaucher disease severity (SSI) and bone mineral density (BMD), and to correlate bone and disease markers to OPG polymorphisms: OPG1 2(A163G), OPG3 4(T129C) and OPG5 6(C1217T). Of 554 patients, 173 Ashkenazi Jewish patients with non neuronopathic Gaucher disease were enrolled and 32 healthy Ashkenazi Jews served as controls. Serum OPG levels were detected by enzyme linked immunosorbent assay and BMD was obtained by dual X ray absorptiometry. OPG polymorphisms were determined in 63 randomly chosen patients. Serum OPG values for patients were not greater than in controls, but showed a statistically significant trend to increase with age (P = 0.057). No correlation existed between OPG levels and BMD or with genotype or other disease markers. A significant correlation was noted between OPG5 6 genotype and SSI. A significant difference was found between the allele distributions of each OPG polymorphism when compared with Caucasians and Ashkenazi Jews. OPG levels probably do not predict BMD in Gaucher disease and hence are not indicative of osteoporosis in Gaucher disease.
C1 Shaare Zedek Med Ctr, Gaucher Clin, IL 91031 Jerusalem, Israel.
   Shaare Zedek Med Ctr, Dept Orthopaed, IL 91031 Jerusalem, Israel.
   Shaare Zedek Med Ctr, Genet Unit, IL 91031 Jerusalem, Israel.
   Shaare Zedek Med Ctr, Lab Microbiol & Immunol, IL 91031 Jerusalem, Israel.
   Hebrew Univ Jerusalem, Hadassah Med Ctr, Osteoporosis Ctr, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center; Hebrew
   University of Jerusalem; Shaare Zedek Medical Center; Hebrew University
   of Jerusalem; Shaare Zedek Medical Center; Hebrew University of
   Jerusalem; Shaare Zedek Medical Center; Hebrew University of Jerusalem;
   Hadassah University Medical Center; Hadassah University Hospital
RP Shaare Zedek Med Ctr, Gaucher Clin, POB 3235, IL 91031 Jerusalem, Israel.
EM gaucher@szmc.org.il
CR Allen MJ, 1997, QJM MON J ASSOC PHYS, V90, P19
   BARTON NW, 1991, NEW ENGL J MED, V324, P1464, DOI 10.1056/NEJM199105233242104
   Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
   Brändström H, 2004, CALCIFIED TISSUE INT, V74, P18, DOI 10.1007/s00223 002 2136 9
   Brändström H, 2002, BIOCHEM BIOPH RES CO, V293, P13, DOI 10.1016/S0006 291X(02)00137 7
   Elstein D, 1996, BLOOD CELL MOL DIS, V22, P104, DOI 10.1006/bcmd.1996.0016
   Elstein D, 1997, BAILLIERE CLIN HAEM, V10, P793, DOI 10.1016/S0950 3536(97)80041 8
   Jorgensen HL, 2004, J BONE MINER METAB, V22, P132, DOI 10.1007/s00774 003 0461 3
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Langdahl BL, 2002, J BONE MINER RES, V17, P1245, DOI 10.1359/jbmr.2002.17.7.1245
   Lichtenstein M, 1997, BLOOD CELL MOL DIS, V23, P395, DOI 10.1006/bcmd.1997.0156
   Merkel KD, 1999, AM J PATHOL, V154, P203, DOI 10.1016/S0002 9440(10)65266 2
   PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616
   RAISZ LG, 1988, NEW ENGL J MED, V318, P818
   Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562
   ROSENTHAL DI, 1995, PEDIATRICS, V96, P629
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   ZIMRAN A, 1989, LANCET, V2, P349
NR 18
TC 13
Z9 14
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1048
EI 1365 2141
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD APR
PY 2006
VL 133
IS 1
BP 93
EP 97
DI 10.1111/j.1365 2141.2006.05978.x
PG 5
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 017YY
UT WOS:000235730600011
PM 16512834
DA 2025 08 17
ER

PT J
AU Shirazi, S
   Ravindran, S
   Cooper, LF
AF Shirazi, Sajjad
   Ravindran, Sriram
   Cooper, Lyndon F.
TI Topography mediated immunomodulation in osseointegration; Ally or Enemy
SO BIOMATERIALS
LA English
DT Article
DE Immunoengineering; Implant surface topography; Roughness; Nano;
   Oncostatin M; BMP 2; Macrophage
ID BONE MORPHOGENETIC PROTEIN 2; TITANIUM SURFACE TOPOGRAPHY; MESENCHYMAL
   STEM CELLS; CD4(+) T CELLS; ENGINEERED EXTRACELLULAR VESICLES;
   MULTIVARIATE REGRESSION ANALYSIS; MULTINUCLEATED GIANT CELLS; OSTEOBLAST
   LINEAGE CELLS; LASER MELTING TITANIUM; FOREIGN BODY REACTION
AB Osteoimmunology is at full display during endosseous implant osseointegration. Bone formation, maintenance and resorption at the implant surface is a result of bidirectional and dynamic reciprocal communication between the bone and immune cells that extends beyond the well defined osteoblast osteoclast signaling. Implant surface topography informs adherent progenitor and immune cell function and their cross talk to modulate the process of bone accrual. Integrating titanium surface engineering with the principles of immunology is utilized to harness the power of immune system to improve osseointegration in healthy and diseased microenvironments. This review summarizes current information regarding immune cell???titanium implant surface interactions and places these events in the context of surface mediated immunomodulation and bone regeneration. A mechanistic approach is directed in demonstrating the central role of osteoimmunology in the process of osseointegration and exploring how regulation of immune cell function at the implant bone interface may be used in future control of clinical therapies. The process of peri implant bone loss is also informed by immunomodulation at the implant surface. How surface topography is exploited to prevent osteoclastogenesis is considered herein with respect to peri implant inflammation, osteoclastic precursor surface interactions, and the upstream/downstream effects of surface topography on immune and progenitor cell function.
C1 [Shirazi, Sajjad; Ravindran, Sriram] Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60607 USA.
   [Cooper, Lyndon F.] Virginia Commonwealth Univ, Sch Dent, Richmond, VA 23284 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital; Virginia Commonwealth
   University
RP Shirazi, S (通讯作者)，Univ Illinois, Coll Dent, Dept Oral Biol, Chicago, IL 60607 USA.; Cooper, LF (通讯作者)，Virginia Commonwealth Univ, Sch Dent, Richmond, VA 23284 USA.
EM s.shirazi.tbzmed88@gmail.com; cooperlf@vcu.edu
RI ; Shirazi, Sajjad/L 7133 2017
OI Cooper, Lyndon/0000 0002 6577 781X; Shirazi, Sajjad/0000 0002 3996 6772
FU National Institute of Dental and Craniofacial Research [R01DE027404]
   Funding Source: NIH RePORTER
CR Abaricia JO, 2021, ACTA BIOMATER, V133, P58, DOI 10.1016/j.actbio.2021.04.021
   Abaricia JO, 2021, CLIN ORAL IMPLAN RES, V32, P487, DOI 10.1111/clr.13717
   Abaricia JO, 2020, BIOMATER SCI UK, V8, P2289, DOI 10.1039/c9bm01474h
   Abaricia JO, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119920
   Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Adams S, 2019, ANN BIOMED ENG, V47, P2213, DOI 10.1007/s10439 019 02302 4
   Akintoye SO, 2006, BONE, V38, P758, DOI 10.1016/j.bone.2005.10.027
   Alassy H, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040214
   Albrektsson T, 2008, AUST DENT J, V53, pS34, DOI 10.1111/j.1834 7819.2008.00039.x
   ALBREKTSSON T, 1987, ACTA ORTHOP SCAND, V58, P567, DOI 10.3109/17453678709146401
   Albrektsson T, 2004, INT J PROSTHODONT, V17, P536
   Albrektsson T, 2018, EUR J ORAL IMPLANTOL, V11, pS37
   Albrektsson T, 2014, CLIN IMPLANT DENT R, V16, P155, DOI 10.1111/cid.12142
   Alexander KA, 2011, J BONE MINER RES, V26, P1517, DOI 10.1002/jbmr.354
   Alfarsi MA, 2014, J BIOMED MATER RES A, V102, P60, DOI 10.1002/jbm.a.34666
   Alnaeeli M, 2006, J IMMUNOL, V177, P3314, DOI 10.4049/jimmunol.177.5.3314
   Alyaseer AAA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00883
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Antmen E, 2021, BIOMATER SCI UK, V9, P8090, DOI 10.1039/d1bm00840d
   AQuist Mats G., 2005, ANCIENT MED, V49, P371, DOI [10.1136/oem.2004.014332, DOI 10.4324/9780203490914, 10.1016/j.femsec.2004.04.006]
   Ariganello MB, 2018, INT J NANOMED, V13, P8297, DOI 10.2147/IJN.S185436
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Arzate Mejía RG, 2011, IUBMB LIFE, V63, P881, DOI 10.1002/iub.557
   Asa'ad F, 2019, EUR J ORAL SCI, V127, P477, DOI 10.1111/eos.12657
   Atcha H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 23482 5
   Awad F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175336
   Axmann R, 2009, ARTHRITIS RHEUM US, V60, P2747, DOI 10.1002/art.24781
   Barbeck M, 2017, J BIOMED MATER RES A, V105, P1105, DOI 10.1002/jbm.a.36006
   Barberi J, 2021, MATERIALS, V14, DOI 10.3390/ma14071590
   Barcelona Estaje E, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202002048
   Barth KA, 2013, J BIOMED MATER RES A, V101, P2679, DOI 10.1002/jbm.a.34562
   Baseri M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/7279509
   Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446
   Bastian OW, 2016, CLIN IMMUNOL, V164, P78, DOI 10.1016/j.clim.2016.02.001
   Batool F, 2021, J TISSUE ENG, V12, DOI 10.1177/20417314211041428
   Bauernfeind FG, 2009, J IMMUNOL, V183, P787, DOI 10.4049/jimmunol.0901363
   Belibasakis GN, 2014, ARCH ORAL BIOL, V59, P66, DOI 10.1016/j.archoralbio.2013.09.013
   Bergdolt S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179512
   Berger MB, 2022, BIOMIMETICS BASEL, V7, DOI 10.3390/biomimetics7020046
   Berglundh T, 2004, J CLIN PERIODONTOL, V31, P341, DOI 10.1111/j.1600 051X.2004.00486.x
   Bielemann AM, 2018, ARCH ORAL BIOL, V89, P107, DOI 10.1016/j.archoralbio.2018.02.013
   Biggs MJP, 2010, P I MECH ENG H, V224, P1441, DOI 10.1243/09544119JEIM775
   Bighetti Trevisan RL, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2021.112548
   Biguetti CC, 2018, J APPL ORAL SCI, V26
   Bosshardt DD, 2011, CLIN ORAL IMPLAN RES, V22, P357, DOI 10.1111/j.1600 0501.2010.02107.x
   Boyan B D, 2016, Adv Dent Res, V28, P10, DOI 10.1177/0022034515624444
   Boyan BD, 2022, J AM ACAD ORTHOP SUR, V30, pE894, DOI 10.5435/JAAOS D 21 00523
   Boyan BD, 2017, TISSUE ENG PT A, V23, P1479, DOI [10.1089/ten.tea.2017.0048, 10.1089/ten.TEA.2017.0048]
   Boyan BD, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26901 8
   Boyan BD, 2003, J ORTHOP RES, V21, P638, DOI 10.1016/S0736 0266(02)00261 9
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Boyce BF, 2015, ENDOCRINOL METAB, V30, P35, DOI 10.3803/EnM.2015.30.1.35
   BRANEMARK PI, 1983, J PROSTHET DENT, V50, P399, DOI 10.1016/S0022 3913(83)80101 2
   Brown BN, 2012, ACTA BIOMATER, V8, P978, DOI 10.1016/j.actbio.2011.11.031
   Brown BN, 2009, BIOMATERIALS, V30, P1482, DOI 10.1016/j.biomaterials.2008.11.040
   Bryington M, 2014, CLIN ORAL IMPLAN RES, V25, P52, DOI 10.1111/clr.12054
   Bu WH, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac009
   Burger D, 2016, SCI REP UK, V6, DOI 10.1038/srep29834
   Busslinger M, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019307
   Campos V, 2014, B MATER SCI, V37, P157, DOI 10.1007/s12034 014 0611 3
   Candel Martí ME, 2011, MED ORAL PATOL ORAL, V16, pE518, DOI 10.4317/medoral.16.e518
   Carcuac O, 2014, J DENT RES, V93, P1083, DOI 10.1177/0022034514551754
   Champagne CM, 2002, BONE, V30, P26, DOI 10.1016/S8756 3282(01)00638 X
   Chan AH, 2020, J EXP MED, V217, DOI 10.1084/jem.20190314
   Chan T, 2011, CELL IMMUNOL, V266, P180, DOI 10.1016/j.cellimm.2010.10.002
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang MK, 2008, J IMMUNOL, V181, P1232, DOI 10.4049/jimmunol.181.2.1232
   Che CY, 2018, CLIN IMPLANT DENT R, V20, P384, DOI 10.1111/cid.12592
   Chen CZ, 2021, BBA MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166217
   Chen Junhan, 2020, INT J ENV RES PUB HE, V12, P3150, DOI [10.3390/rs12193150, DOI 10.3390/IJERPH17239083]
   Chen SC, 2018, COLLOID SURFACE B, V164, P58, DOI 10.1016/j.colsurfb.2018.01.022
   Chen SY, 2020, CELL MOL IMMUNOL, V17, P36, DOI 10.1038/s41423 019 0315 0
   Chen Y. R., 2004, J BIOMED MATER RES A, V22, P2081, DOI [10.1002/bit.260221008, DOI 10.1002/JBM.A.35927, 10.1016/j]
   Chen Y, 2022, THERANOSTICS, V12, P1074, DOI 10.7150/thno.65694
   Chen ZT, 2016, MATER TODAY, V19, P304, DOI 10.1016/j.mattod.2015.11.004
   Cheng A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017889118
   Cheng XQ, 2021, FRONT CELL INFECT MI, V11, DOI 10.3389/fcimb.2021.751503
   Cho YD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052406
   Collie AMB, 2011, J BIOMED MATER RES A, V96A, P162, DOI 10.1002/jbm.a.32963
   Cooper LF, 2022, FRONT ORAL MAXIL MED, V4, DOI 10.21037/fomm 21 77
   Correa MG, 2019, BRAZ ORAL RES, V33, DOI 10.1590/1807 3107bor 2019.vol33.0066
   Costa Lucas Carneiro, 2018, Braz. Dent. J., V29, P14, DOI 10.1590/0103 6440201801241
   Coyac BR, 2020, CLIN ORAL IMPLAN RES, V31, P1125, DOI 10.1111/clr.13659
   Coyac BR, 2021, J PERIODONTOL, V92, P716, DOI 10.1002/JPER.20 0099
   Croes M, 2016, BONE, V84, P262, DOI 10.1016/j.bone.2016.01.010
   Crotti T, 2003, J PERIODONTAL RES, V38, P380, DOI 10.1034/j.1600 0765.2003.00615.x
   Cui JJ, 2021, J MATER CHEM B, V9, P9505, DOI 10.1039/d1tb01917a
   D'Amico Lucia, 2012, Bonekey Rep, V1, P82, DOI 10.1038/bonekey.2012.82
   da Silva RA, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3026893
   Dai XH, 2022, J MATER CHEM B, V10, P1875, DOI 10.1039/d1tb02871e
   Dalby MJ, 2014, NAT MATER, V13, P558, DOI [10.1038/NMAT3980, 10.1038/nmat3980]
   Faloni APD, 2011, CALCIFIED TISSUE INT, V88, P63, DOI 10.1007/s00223 010 9418 4
   Delgado Calle J, 2012, EPIGENETICS US, V7, P83, DOI 10.4161/epi.7.1.18753
   Deng S, 2020, J PERIODONTOL, V91, P671, DOI 10.1002/JPER.18 0748
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Donnelly H, 2018, NANOMED NANOTECHNOL, V14, P2455, DOI 10.1016/j.nano.2017.03.020
   Donos N, 2011, CLIN ORAL IMPLAN RES, V22, P365, DOI 10.1111/j.1600 0501.2010.02113.x
   Doornewaard R, 2017, CLIN IMPLANT DENT R, V19, P372, DOI 10.1111/cid.12457
   El Kholy K, 2020, MATERIALS, V13, DOI 10.3390/ma13153421
   Elangovan G, 2022, CLIN EXP DENT RES, V8, P950, DOI 10.1002/cre2.582
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Feller L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/171945
   Fernandes Maria Helena, 2016, J Oral Maxillofac Res, V7, pe6
   Ferreira JA, 2021, INT J ORAL MAX IMPL, V36, P650, DOI 10.11607/jomi.8748
   Fetz AE, 2022, TISSUE ENG PART B RE, V28, P437, DOI [10.1089/ten.TEB.2021.0013, 10.1089/ten.teb.2021.0013]
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Fourmousis I, 2019, IMPLANT DENT, V28, P103, DOI 10.1097/ID.0000000000000874
   Fragkioudakis Ioannis, 2021, Eur J Dent, V15, P379, DOI 10.1055/s 0040 1721903
   Franquinho F, 2010, FEBS J, V277, P3664, DOI 10.1111/j.1742 4658.2010.07774.x
   Fretwurst T, 2018, J DENT RES, V97, P259, DOI 10.1177/0022034517740560
   Fretwurst T, 2020, CLIN ORAL IMPLAN RES, V31, P274, DOI 10.1111/clr.13568
   Frontiers, RES INFL WHAT CONTR, DOI [10.3389/fimmu.2016.00160/full, DOI 10.3389/FIMMU.2016.00160/FULL]
   Galarraga Vinueza ME, 2021, CLIN ORAL INVEST, V25, P2335, DOI 10.1007/s00784 020 03556 2
   Gavazzo P, 2021, CELL BIOL TOXICOL, V37, P915, DOI 10.1007/s10565 020 09569 7
   Gavazzo Paola, 2021, CELL BIOL TOXICOL, V37, P915, DOI [10.1007/s10565 020 09569 7, DOI 10.1007/S10565 020 09569 7]
   Geblinger D, 2012, J R SOC INTERFACE, V9, P1599, DOI 10.1098/rsif.2011.0659
   Geblinger D, 2010, J CELL SCI, V123, P1503, DOI 10.1242/jcs.060954
   Giri Subhasis, 2016, BMC CANCER, V30, P5087, DOI [10.1007/s11269 016 1470 z, DOI 10.1186/S12885 019 5951 3]
   Giro G, 2021, CLIN ORAL INVEST, V25, P1291, DOI 10.1007/s00784 020 03435 w
   González Sánchez Z, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084285
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gotfredsen K, 1992, Clin Oral Implants Res, V3, P77, DOI 10.1034/j.1600 0501.1992.030205.x
   Gravallese EM, 2018, NAT REV RHEUMATOL, V14, P631, DOI 10.1038/s41584 018 0091 8
   Greenblatt Matthew B, 2013, Immune Netw, V13, P111, DOI 10.4110/in.2013.13.4.111
   GROSS UM, 1977, STAIN TECHNOL, V52, P217, DOI 10.3109/10520297709116778
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Guder C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00058
   Guihard P, 2015, AM J PATHOL, V185, P765, DOI 10.1016/j.ajpath.2014.11.008
   Guihard P, 2012, STEM CELLS, V30, P762, DOI 10.1002/stem.1040
   Guo J, 2007, BIOMATERIALS, V28, P5418, DOI 10.1016/j.biomaterials.2007.08.032
   Hajishengallis G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00406
   Hamlet S, 2012, CLIN ORAL IMPLAN RES, V23, P584, DOI 10.1111/j.1600 0501.2011.02325.x
   Hamlet SM, 2019, CLIN ORAL IMPLAN RES, V30, P1085, DOI 10.1111/clr.13522
   Han P, 2023, ACTA BIOMATER, V163, P259, DOI 10.1016/j.actbio.2022.01.020
   Han YK, 2019, J PERIODONTAL RES, V54, P73, DOI 10.1111/jre.12606
   Hara Toshihiro, 2012, Bull Tokyo Dent Coll, V53, P45
   Harmankaya N, 2012, ACTA BIOMATER, V8, P3532, DOI 10.1016/j.actbio.2012.05.017
   Hasani Sadrabadi MM, 2018, ADV MATER, V30, DOI 10.1002/adma.201706780
   Hashim D., Curr Oral Health Rep, V7, P262, DOI DOI 10.1007/S40496 020 00274 2
   Haynes DR, 2004, BIOMATERIALS, V25, P4877, DOI 10.1016/j.biomaterials.2004.01.003
   Haynes DR, 2001, J BONE JOINT SURG BR, V83B, P902, DOI 10.1302/0301 620X.83B6.10905
   He DW, 2022, J PERIODONTAL IMPLAN, V52, P28
   He YD, 2022, BIOACT MATER, V8, P109, DOI 10.1016/j.bioactmat.2021.06.033
   He YD, 2020, MAT SCI ENG C MATER, V106, DOI 10.1016/j.msec.2019.110221
   Heyman O, 2020, J DENT RES, V99, P1092, DOI 10.1177/0022034520920577
   Hidalgo A, 2019, TRENDS IMMUNOL, V40, P584, DOI 10.1016/j.it.2019.04.013
   Hotchkiss KM, 2019, DENT MATER, V35, P176, DOI 10.1016/j.dental.2018.11.011
   Hotchkiss KM, 2018, BIOMATERIALS, V182, P202, DOI 10.1016/j.biomaterials.2018.08.029
   Hotchkiss KM, 2017, CLIN ORAL IMPLAN RES, V28, P414, DOI 10.1111/clr.12814
   Hotchkiss KM, 2016, ACTA BIOMATER, V31, P425, DOI 10.1016/j.actbio.2015.12.003
   Hu K, 2017, DEV DYNAM, V246, P227, DOI 10.1002/dvdy.24463
   Huang CC, 2021, ACTA BIOMATER, V126, P199, DOI 10.1016/j.actbio.2021.03.030
   Huang CC, 2020, ACTA BIOMATER, V109, P182, DOI 10.1016/j.actbio.2020.04.017
   Huyer LD, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909331
   Hyzy SL, 2013, ACTA BIOMATER, V9, P5821, DOI 10.1016/j.actbio.2012.10.030
   Ibáñez L, 2016, J BONE MINER RES, V31, P1899, DOI 10.1002/jbmr.2868
   Ichikawa Y, 2015, J PERIODONTAL RES, V50, P468, DOI 10.1111/jre.12229
   Ichioka Y, 2021, J BIOMED MATER RES A, V109, P170, DOI 10.1002/jbm.a.37014
   Ida Yonemochi H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169201
   Ikebuchi Y, 2018, NATURE, V561, P195, DOI 10.1038/s41586 018 0482 7
   Insua A, 2017, J BIOMED MATER RES A, V105, P2075, DOI 10.1002/jbm.a.36060
   Ivanoff CJ, 2003, INT J ORAL MAX IMPL, V18, P341
   Ivanoff CJ, 2001, CLIN ORAL IMPLAN RES, V12, P128, DOI 10.1034/j.1600 0501.2001.012002128.x
   Ivanovski S, 2011, CLIN ORAL IMPLAN RES, V22, P373, DOI 10.1111/j.1600 0501.2010.02112.x
   Jäger M, 2022, J FUNCT BIOMATER, V13, DOI 10.3390/jfb13020044
   Jain N, 2019, ANNU REV BIOMED ENG, V21, P267, DOI 10.1146/annurev bioeng 062117 121224
   Jain N, 2018, NAT MATER, V17, P1134, DOI 10.1038/s41563 018 0190 6
   Jämsen E, 2020, ACTA BIOMATER, V108, P347, DOI 10.1016/j.actbio.2020.03.017
   Jann J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207597
   Javed F, 2011, CYTOKINE, V53, P8, DOI 10.1016/j.cyto.2010.08.013
   Jemt T, 2018, INT J PROSTHODONT, V31, P531, DOI 10.11607/ijp.5883
   Jemt T, 2018, INT J PROSTHODONT, V31, P425, DOI 10.11607/ijp.5875
   Jennissen Herbert P., 2016, Current Directions in Biomedical Engineering, V2, P53, DOI 10.1515/cdbme 2016 0015
   Ji G, 2019, BONE JOINT J, V101B, P108, DOI 10.1302/0301 620X.101B7.BJJ 2018 1473.R1
   Jiang MY, 2022, J PERIODONTAL RES, V57, P448, DOI 10.1111/jre.12974
   Jiang N, 2016, SCI REP UK, V6, DOI 10.1038/srep36411
   Jin QC, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258138
   Jurdzinski KT, 2020, CLIN EPIGENETICS, V12, DOI 10.1186/s13148 020 00982 7
   Kämmerer PW, 2012, CLIN ORAL IMPLAN RES, V23, P504, DOI 10.1111/j.1600 0501.2011.02153.x
   Kanazawa M., 2018, J Dent Res
   Kanczler JM, 2008, EUR CELLS MATER, V15, P100, DOI 10.22203/eCM.v015a08
   Kang MY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.878194
   Kang MY, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.596622
   Kang MY, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115627
   Kapasa ER, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8040042
   Karazisis D, 2021, ACS BIOMATER SCI ENG, V7, P5878, DOI 10.1021/acsbiomaterials.1c00861
   Karazisis D, 2017, ACTA BIOMATER, V53, P559, DOI 10.1016/j.actbio.2017.02.026
   Karazisis D, 2016, INT J NANOMED, V11, P1367, DOI 10.2147/IJN.S101294
   Kartikasari N, 2022, ACTA BIOMATER, V137, P316, DOI 10.1016/j.actbio.2021.10.019
   Kasagi S, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 4
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kelder C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145072
   Kensara A, 2021, J PROSTHODONT, V30, P210, DOI 10.1111/jopr.13270
   Khosravi N, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0074 y
   Kilian KA, 2010, P NATL ACAD SCI USA, V107, P4872, DOI 10.1073/pnas.0903269107
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim MS, 2006, J BIOL CHEM, V281, P1274, DOI 10.1074/jbc.M510156200
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Kligman S, 2021, J CLIN MED, V10, DOI 10.3390/jcm10081641
   Könnecke I, 2014, BONE, V64, P155, DOI 10.1016/j.bone.2014.03.052
   Kojima N, 2008, CLIN ORAL IMPLAN RES, V19, P173, DOI 10.1111/j.1600 0501.2007.01432.x
   Kotsakis GA, 2021, PERIODONTOL 2000, V86, P231, DOI 10.1111/prd.12372
   Kou PM, 2011, ACTA BIOMATER, V7, P1354, DOI 10.1016/j.actbio.2010.10.020
   Kumar KP, 2018, CELL TISSUE RES, V371, P551, DOI 10.1007/s00441 017 2753 2
   Kumar N Sasi, TRENDS PARASITOL, V124, P109743, DOI [10.1016/j.rser.2020.109743, DOI 10.1016/J.PT.2020.09.004, 10.1016/j.jhazmat.2020.122547, DOI 10.1016/J.JHAZMAT.2020.122547]
   Kuo I Ming, 2020, NAT CLIM CHANGE, V20, DOI [10.1186/s12885 020 07072 0, DOI 10.1038/S41558 020 0797 X]
   Kurotaki D, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115471
   Kwack KH, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.731549
   KYDD WL, 1976, J PROSTHET DENT, V35, P567, DOI 10.1016/0022 3913(76)90052 4
   De Mendoza ILI, 2022, INT J IMPLANT DENT, V8, DOI 10.1186/s40729 022 00400 y
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Larsson L, 2018, J BIOMED MATER RES B, V106, P2065, DOI 10.1002/jbm.b.33953
   Lazzara RJ, 1999, INT J PERIODONT REST, V19, P117
   Lee J, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801106
   Lee RSB, 2021, BIOMATERIALS, V267, DOI 10.1016/j.biomaterials.2020.120464
   Lee S, 2011, ACTA BIOMATER, V7, P2337, DOI 10.1016/j.actbio.2011.01.006
   Leung KS, 2022, CELLS BASEL, V11, DOI 10.3390/cells11182851
   Li H, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1387 3
   Li JY, 2019, J BONE MINER RES, V34, P349, DOI 10.1002/jbmr.3600
   Li JY, 2014, IMPLANT DENT, V23, P607, DOI 10.1097/ID.0000000000000129
   Li JH, 2021, ADV MATER, V33, DOI 10.1002/adma.202004172
   Li LJ, 2019, ACTA BIOMATER, V96, P674, DOI 10.1016/j.actbio.2019.07.007
   Li X, 2020, INFLAMMATION, V43, P1269, DOI 10.1007/s10753 020 01206 z
   Li X, 2007, J BIOL CHEM, V282, P33098, DOI 10.1074/jbc.M611781200
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liang BL, 2021, J LEUKOCYTE BIOL, V110, P433, DOI 10.1002/JLB.1MA0121 001R
   Limmer A, 2017, Z ORTHOP UNFALLCHIR, V155, P273, DOI 10.1055/s 0043 100100
   Lin SP, 2022, ACTA BIOMATER, V142, P345, DOI 10.1016/j.actbio.2022.02.007
   Lin WM, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00141 5
   Lin Z, 2011, J PERIODONTOL, V82, P1007, DOI 10.1902/jop.2010.100577
   Linderbäck P, 2010, BIOMATERIALS, V31, P4795, DOI 10.1016/j.biomaterials.2010.02.060
   Liu J, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01833 4
   Liu L, 2020, J MATER CHEM B, V8, P2754, DOI 10.1039/c9tb02882j
   Liu Q, 2014, BIOMATERIALS, V35, P6206, DOI 10.1016/j.biomaterials.2014.04.068
   Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23
   Liu WT, 2021, COLLOID SURFACE B, V205, DOI 10.1016/j.colsurfb.2021.111848
   Liu XH, 2021, MAT SCI ENG C MATER, V122, DOI 10.1016/j.msec.2021.111932
   Liu YW, 2006, CELL SIGNAL, V18, P1492, DOI 10.1016/j.cellsig.2005.12.001
   Lopes HB, 2020, J APPL ORAL SCI, V28, DOI 10.1590/1678 7757 2019 0156
   Lopes HB, 2019, J CELL BIOCHEM, V120, P16723, DOI 10.1002/jcb.28930
   Lossdörfer S, 2004, J BIOMED MATER RES A, V70A, P361, DOI 10.1002/jbm.a.30025
   Lotz EM, 2018, ACTA BIOMATER, V68, P296, DOI 10.1016/j.actbio.2017.12.039
   Lou HY, 2018, ACCOUNTS CHEM RES, V51, P1046, DOI 10.1021/acs.accounts.7b00594
   Lozano C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00375
   Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135
   Luo JJ, 2022, BIOACT MATER, V15, P145, DOI 10.1016/j.bioactmat.2021.11.024
   Lv L, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800675
   Ma QL, 2018, BIOMATERIALS, V154, P234, DOI 10.1016/j.biomaterials.2017.11.003
   Ma QL, 2014, BIOMATERIALS, V35, P9853, DOI 10.1016/j.biomaterials.2014.08.025
   Madel MB, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01408
   Makihira S, 2007, DENT MATER J, V26, P739, DOI 10.4012/dmj.26.739
   Manivasagam VK, 2021, MATER ADV, V2, P5824, DOI 10.1039/d1ma00367d
   Mao JY, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202111003
   Martin TJ, 2009, CRIT REV EUKAR GENE, V19, P73, DOI 10.1615/CritRevEukarGeneExpr.v19.i1.40
   Marusic A, 2000, LAB INVEST, V80, P1761, DOI 10.1038/labinvest.3780186
   Masaki C, 2005, CLIN ORAL IMPLAN RES, V16, P650, DOI 10.1111/j.1600 0501.2005.01170.x
   Mattheos N, 2021, CLIN ORAL IMPLAN RES, V32, P181, DOI 10.1111/clr.13823
   Mavrogenis A.F., Biology of implant osseointegration, P11
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097 0029(19960201)33:2<141::AID JEMT5>3.0.CO;2 W
   McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489
   McWhorter FY, 2015, CELL MOL LIFE SCI, V72, P1303, DOI 10.1007/s00018 014 1796 8
   McWhorter FY, 2013, P NATL ACAD SCI USA, V110, P17253, DOI 10.1073/pnas.1308887110
   Mendonça G, 2008, BIOMATERIALS, V29, P3822, DOI 10.1016/j.biomaterials.2008.05.012
   Menini M, 2017, CLIN ORAL IMPLAN RES, V28, pE121, DOI 10.1111/clr.12943
   Menini M, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060888
   Messous R, 2021, CLIN ORAL INVEST, V25, P1627, DOI 10.1007/s00784 021 03785 z
   Milinkovic I, 2021, CLIN ORAL IMPLAN RES, V32, P1496, DOI 10.1111/clr.13850
   Milleret V, 2011, EUR CELLS MATER, V21, P430, DOI 10.22203/eCM.v021a32
   Minkin C, 1999, Adv Dent Res, V13, P49
   Miron RJ, 2018, TISSUE ENG PART B RE, V24, P53, DOI [10.1089/ten.teb.2017.0242, 10.1089/ten.TEB.2017.0242]
   Miron RJ, 2016, ACTA BIOMATER, V46, P15, DOI 10.1016/j.actbio.2016.09.029
   Miron RJ, 2016, BIOMATERIALS, V82, P1, DOI 10.1016/j.biomaterials.2015.12.017
   Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331
   Mödinger Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113367
   Monje A, 2018, INT J PERIODONT REST, V38, P476, DOI 10.11607/prd.2018.4.e
   Monjo M, 2012, INT J BIOMATER, V2012, DOI 10.1155/2012/181024
   Rodrigues LM, 2022, J BIOMED MATER RES A, V110, P696, DOI 10.1002/jbm.a.37323
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Mould KJ, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126556
   Mun SH, 2020, EXP MOL MED, V52, P1239
   Murakami T, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105365
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Mussano F, 2020, APPL SURF SCI, V507, DOI 10.1016/j.apsusc.2019.145112
   Nagasawa M, 2016, J DENT RES, V95, P319, DOI 10.1177/0022034515616760
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Neacsu P, 2015, INT J NANOMED, V10, P6455, DOI 10.2147/IJN.S92019
   Neale SD, 1999, J ORTHOP RES, V17, P686, DOI 10.1002/jor.1100170510
   Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871
   Nobles KP, 2021, J BIOMED MATER RES B, V109, P1909, DOI 10.1002/jbm.b.34835
   Noris M, 2013, SEMIN NEPHROL, V33, P479, DOI 10.1016/j.semnephrol.2013.08.001
   Nunes AF, 2010, FEBS J, V277, P263, DOI 10.1111/j.1742 4658.2009.07482.x
   Ogawa T, 2006, J DENT RES, V85, P566, DOI 10.1177/154405910608500617
   Ogawa Takahiro, 2002, J Prosthodont, V11, P241, DOI 10.1053/jpro.2002.129772
   Olivares Navarrete R, 2008, P NATL ACAD SCI USA, V105, P15767, DOI 10.1073/pnas.0805420105
   Olivares Navarrete R, 2014, ANN BIOMED ENG, V42, P2551, DOI 10.1007/s10439 014 1108 3
   Olivares Navarrete R, 2011, BIOMATERIALS, V32, P6399, DOI 10.1016/j.biomaterials.2011.05.036
   Olivares Navarrete R, 2010, BIOMATERIALS, V31, P2728, DOI 10.1016/j.biomaterials.2009.12.029
   Omar O, 2010, J MATER SCI MATER M, V21, P969, DOI 10.1007/s10856 009 3915 x
   Omar OM, 2011, BIOMATERIALS, V32, P374, DOI 10.1016/j.biomaterials.2010.09.011
   Ouyang L, 2021, REGEN THER, V18, P24, DOI 10.1016/j.reth.2021.03.003
   Pacios S, 2015, SCI REP UK, V5, DOI 10.1038/srep16694
   Page G, 2005, ARTHRITIS RHEUM US, V52, P2307, DOI 10.1002/art.21211
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Pal N, 2011, ACTA BIOMATER, V7, P2926, DOI 10.1016/j.actbio.2011.04.011
   Pan HH, 2017, BIOMED MATER, V12, DOI 10.1088/1748 605X/aa6b7c
   Pan KQ, 2020, INT J IMPLANT DENT, V6, DOI 10.1186/s40729 020 00210 0
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Park JW, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1362958
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   Persson E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01164
   Pettersson M, 2017, J PERIODONTAL RES, V52, P21, DOI 10.1111/jre.12364
   Pettersson M, 2018, J BIOMED MATER RES A, V106, P2518, DOI 10.1002/jbm.a.36447
   Pham MH, 2020, MATERIALS, V13, DOI 10.3390/ma13030684
   Pinhal Enfield G, 2003, AM J PATHOL, V163, P711, DOI 10.1016/S0002 9440(10)63698 X
   Pirraco RP, 2013, J TISSUE ENG REGEN M, V7, P392, DOI 10.1002/term.535
   Ponzetti M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136651
   Porta C, 2015, SEMIN IMMUNOL, V27, P237, DOI 10.1016/j.smim.2015.10.003
   Qi XY, 2018, J NANOSCI NANOTECHNO, V18, P8016, DOI 10.1166/jnn.2018.16381
   Qu C, 2015, FASEB J, V29, P1269, DOI 10.1096/fj.14 264804
   Rafail S, 2015, J IMMUNOL, V194, P1285, DOI 10.4049/jimmunol.1402354
   Rahal MD, 2000, INT J ORAL MAX IMPL, V15, P175
   Raines AL, 2019, ACTA BIOMATER, V97, P578, DOI 10.1016/j.actbio.2019.07.036
   Raines AL, 2010, BIOMATERIALS, V31, P4909, DOI 10.1016/j.biomaterials.2010.02.071
   Refai AK, 2004, J BIOMED MATER RES A, V70A, P194, DOI 10.1002/jbm.a.30075
   Reinke S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004754
   Rocha FRG, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 64685 y
   Romero Gavilán F, 2021, J BIOL INORG CHEM, V26, P715, DOI 10.1007/s00775 021 01886 4
   Romero Gavilán F, 2017, BIOFOULING, V33, P98, DOI 10.1080/08927014.2016.1259414
   Sabokbar A, 2003, J ORTHOP RES, V21, P73, DOI 10.1016/S0736 0266(02)00106 7
   Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748
   Salvi GE, 2015, PERIODONTOL 2000, V68, P135, DOI 10.1111/prd.12054
   Sanz Martín I, 2021, CLIN ORAL IMPLAN RES, V32, P230, DOI 10.1111/clr.13840
   Sartoretto S, 2019, J CELL PHYSIOL, V234, P4140, DOI 10.1002/jcp.27226
   Sartori EM, 2019, INT J ORAL MAX IMPL, V34, P397, DOI 10.11607/jomi.6581
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Schluessel S, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.820843
   Schlundt C, 2021, ACTA BIOMATER, V133, P46, DOI 10.1016/j.actbio.2021.04.052
   Schlundt C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01954
   Schmidt Bleek K, 2014, J TISSUE ENG REGEN M, V8, P120, DOI 10.1002/term.1505
   Schminke B, 2015, J DENT RES, V94, P354, DOI 10.1177/0022034514559128
   SCHROEDER A, 1981, J MAXILLOFAC SURG, V9, P15, DOI 10.1016/S0301 0503(81)80007 0
   Schwartz Z, 1997, J PERIODONTAL RES, V32, P166, DOI 10.1111/j.1600 0765.1997.tb01399.x
   Schwartz Z, 2001, BIOMATERIALS, V22, P731, DOI 10.1016/S0142 9612(00)00241 6
   Schwartz Z, 2009, BIOMATERIALS, V30, P3390, DOI 10.1016/j.biomaterials.2009.03.047
   Schwarz F, 2021, CLIN ORAL IMPLAN RES, V32, P245, DOI 10.1111/clr.13827
   SENNERBY L, 1993, BIOMATERIALS, V14, P413, DOI 10.1016/0142 9612(93)90143 P
   Shanley LC, 2021, ACTA BIOMATER, V133, P208, DOI 10.1016/j.actbio.2021.02.023
   Sheikh Z, 2015, MATERIALS, V8, P5671, DOI 10.3390/ma8095269
   Shen FY, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.809918
   Shibli JA, 2007, IMPLANT DENT, V16, P252, DOI 10.1097/ID.0b013e3180de4d64
   Shibli JA, 2007, J BIOMED MATER RES B, V80B, P377, DOI 10.1002/jbm.b.30608
   Shirazi S, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85306 2
   Silverwood RK, 2016, ADV HEALTHC MATER, V5, P947, DOI 10.1002/adhm.201500664
   Sima C, 2019, J LEUKOCYTE BIOL, V105, P473, DOI 10.1002/JLB.1RU0818 310R
   Simoes FC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14263 2
   Sims Natalie A, 2014, Bonekey Rep, V3, P527, DOI 10.1038/bonekey.2014.22
   Singhatanadgit W, 2019, J BIOMATER APPL, V33, P997, DOI 10.1177/0885328218816565
   Sordi MB, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010372
   Souza JCM, 2019, ACTA BIOMATER, V94, P112, DOI 10.1016/j.actbio.2019.05.045
   Souza PPC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01663
   Speziani C, 2007, EUR J IMMUNOL, V37, P747, DOI 10.1002/eji.200636534
   Spiller KL, 2015, BIOMATERIALS, V37, P194, DOI 10.1016/j.biomaterials.2014.10.017
   Spiller KL, 2014, BIOMATERIALS, V35, P4477, DOI 10.1016/j.biomaterials.2014.02.012
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   Stanford CM, 2010, INT J MOL SCI, V11, P354, DOI 10.3390/ijms11010354
   Stavropoulos A, 2021, CLIN ORAL IMPLAN RES, V32, P203, DOI 10.1111/clr.13859
   Stefanowski J, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02588
   Sun SJ, 2013, CELL PROLIFERAT, V46, P685, DOI 10.1111/cpr.12072
   Sun XY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.763334
   Takayanagi H, 2005, J PERIODONTAL RES, V40, P287, DOI 10.1111/j.1600 0765.2005.00814.x
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Takebe J, 2007, J BIOMED MATER RES A, V80A, P711, DOI 10.1002/jbm.a.30988
   Takebe J, 2003, J BIOMED MATER RES A, V64A, P207, DOI 10.1002/jbm.a.10275
   Tang MJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01508
   Tang Z, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.750948
   Tarapore RS, 2016, J BONE MINER RES, V31, P52, DOI 10.1002/jbmr.2592
   ten Harkel B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139564
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Thalji Ghadeer, 2014, Int J Oral Maxillofac Implants, V29, pe171, DOI 10.11607/jomi.te55
   Thalji G, 2013, INT J ORAL MAX IMPL, V28, pE521, DOI 10.11607/jomi.te33
   Thalji G, 2013, BONE, V52, P444, DOI 10.1016/j.bone.2012.07.026
   Thalji GN, 2014, CLIN ORAL IMPLAN RES, V25, P1273, DOI 10.1111/clr.12266
   Tian Y, 2020, CLIN ORAL IMPLAN RES, V31, P1159, DOI 10.1111/clr.13662
   Trento GD, 2020, INT J IMPLANT DENT, V6, DOI 10.1186/s40729 020 00279 7
   Trindade R, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120526
   Trindade R, 2018, CLIN IMPLANT DENT R, V20, P82, DOI 10.1111/cid.12578
   Trindade R, 2016, CLIN IMPLANT DENT R, V18, P192, DOI 10.1111/cid.12274
   Tsukasaki M, 2021, J BONE MINER METAB, V39, P82, DOI 10.1007/s00774 020 01165 3
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Tu Z, 2010, BLOOD, V116, P4456, DOI 10.1182/blood 2010 01 263590
   Turajane K, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10535
   Vasse M, 1999, ARTERIOSCL THROM VAS, V19, P1835, DOI 10.1161/01.ATV.19.8.1835
   Vassey MJ, 2020, ADV SCI, V7, DOI 10.1002/advs.201903392
   Veiseh O, 2019, ADV DRUG DELIVER REV, V144, P148, DOI 10.1016/j.addr.2019.08.010
   Villar C., 2011, Endodontic Topics, V25, P44, DOI DOI 10.1111/ETP.12018
   Vitkov L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121359
   Vlacic Zischke J, 2011, BIOMATERIALS, V32, P665, DOI 10.1016/j.biomaterials.2010.09.025
   Wada S, 2001, CLIN ORAL IMPLAN RES, V12, P219, DOI 10.1034/j.1600 0501.2001.012003219.x
   Wada Shin, 2002, CLIN ORAL IMPLAN RES, V12, P219, DOI [10.1034/j.1600 0501.2001.012003219.x, DOI 10.1034/J.1600 0501.2001.012003219.X]
   Wang C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.58
   Wang HL, 2016, CLIN ORAL IMPLAN RES, V27, P1129, DOI 10.1111/clr.12708
   Wang JJ, 2018, INT J NANOMED, V13, P4029, DOI 10.2147/IJN.S163956
   Wang N, 2011, BIOMATERIALS, V32, P6900, DOI 10.1016/j.biomaterials.2011.06.023
   Wang N, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00614
   Wang T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27816 1
   Wang WZ, 2021, EXP THER MED, V22, DOI 10.3892/etm.2021.10144
   Wang X, 2020, J BIOMED MATER RES A, V108, P2206, DOI 10.1002/jbm.a.36978
   Wang Y, 2018, RSC ADV, V8, P22853, DOI 10.1039/c8ra03116a
   Wang ZZ, 2023, ORAL DIS, V29, P1927, DOI 10.1111/odi.14258
   Waterfield JD, 2010, J BIOMED MATER RES A, V95A, P837, DOI 10.1002/jbm.a.32857
   Wazen RM, 2013, NANOMEDICINE UK, V8, P1385, DOI [10.2217/NNM.12.167, 10.2217/nnm.12.167]
   Wei N, 2014, AM J DENT, V27, P171
   Wennerberg A, 1993, Int J Oral Maxillofac Implants, V8, P622
   Wennerberg A, 2010, INT J ORAL MAX IMPL, V25, P63
   Wennerberg A, 2009, CLIN ORAL IMPLAN RES, V20, P172, DOI 10.1111/j.1600 0501.2009.01775.x
   Wheelis SE, 2021, ACS BIOMATER SCI ENG, V7, P2392, DOI 10.1021/acsbiomaterials.0c01420
   Widlak P, 1997, J BIOL CHEM, V272, P17654, DOI 10.1074/jbc.272.28.17654
   Wisitpongpun P, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.856296
   Wright HL, 2009, CURR REV MUSCULOSKE, V2, P56, DOI 10.1007/s12178 009 9046 7
   Wu Andy C, 2013, Bonekey Rep, V2, P373, DOI 10.1038/bonekey.2013.107
   Wu BF, 2022, INT J NANOMED, V17, P1865, DOI 10.2147/IJN.S362720
   Wu Q, 2017, CELL PHYSIOL BIOCHEM, V41, P1360, DOI 10.1159/000465455
   Wu XB, 2021, ACTA BIOMATER, V134, P325, DOI 10.1016/j.actbio.2021.07.017
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Xu JJ, 2022, SCI ADV, V8, DOI 10.1126/sciadv.abl5716
   Xu YZ, 2022, J BIOMED MATER RES A, V110, P964, DOI 10.1002/jbm.a.37345
   Yamaguchi Y, 2017, INFLAMM RES, V66, P59, DOI 10.1007/s00011 016 0992 4
   Yang JM, 2020, J BIOMATER APPL, V35, P169, DOI 10.1177/0885328220920457
   Yang N, 2021, INT J MED SCI, V18, P3697, DOI 10.7150/ijms.61080
   Yang Y, 2021, BIOMATER SCI UK, V9, P3334, DOI 10.1039/d1bm00116g
   Yang Y, 2019, CLIN ORAL INVEST, V23, P4133, DOI 10.1007/s00784 019 02852 w
   Yang Y, 2021, J BIOMED MATER RES A, V109, P1429, DOI 10.1002/jbm.a.37134
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yi Y, 2022, J DENT RES, V101, P73, DOI 10.1177/00220345211013722
   Yin X, 2016, J CLIN PERIODONTOL, V43, P180, DOI 10.1111/jcpe.12503
   Yu Fangtang, 2017, Bone Rep, V6, P109, DOI 10.1016/j.bonr.2017.04.001
   Yu X, 2018, J PERIODONTAL RES, V53, P98, DOI 10.1111/jre.12492
   Yu XR, 2021, INT J NANOMED, V16, P3329, DOI 10.2147/IJN.S303770
   Zaiss MM, 2007, ARTHRITIS RHEUM, V56, P4104, DOI 10.1002/art.23138
   Zdziennicka J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221810060
   Zhang J, 2020, J CLIN PERIODONTOL, V47, P451, DOI 10.1111/jcpe.13258
   Zhang Q, 2020, CURR PHARM BIOTECHNO, V21, P862, DOI 10.2174/1389201021666200221121139
   Zhang Q, 2020, J PERIODONTAL RES, V55, P199, DOI 10.1111/jre.12702
   Zhang Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/284836
   Zhang T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 98007 7
   Zhang T, 2021, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.682384
   Zhang XX, 2020, CURR OPIN BIOTECH, V66, P236, DOI 10.1016/j.copbio.2020.09.004
   Zhang Y, 2019, MAT SCI ENG C MATER, V95, P143, DOI 10.1016/j.msec.2018.10.065
   Zhang Y, 2018, ACS APPL MATER INTER, V10, P36652, DOI 10.1021/acsami.8b10992
   Zhang Y, 2017, CELL TISSUE RES, V369, P273, DOI 10.1007/s00441 017 2598 8
   Zhang YF, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11102489
   Zhang Z., 2022, ACTA BIOMATER, pS1742, DOI [10.1016/j.actbio.2022.09.023,00585 2, DOI 10.1016/J.ACTBIO.2022.09.023,00585 2]
   Zhang ZC, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00826 3
   Zhao ED, 2012, CELL MOL IMMUNOL, V9, P11, DOI 10.1038/cmi.2011.47
   Zheng GY, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12460
   Zheng HM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00463
   Zheng XF, 2017, SCI REP UK, V7, DOI 10.1038/srep41945
   Zhou LQ, 2022, BIOMATER ADV, V134, DOI 10.1016/j.msec.2021.112562
   Zhou Y, 2021, BIOCHEM BIOPH RES CO, V581, P53, DOI 10.1016/j.bbrc.2021.09.021
   Zhou YH, 2018, J TISSUE ENG REGEN M, V12, pE566, DOI 10.1002/term.2327
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 461
TC 74
Z9 78
U1 17
U2 140
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2022
VL 291
AR 121903
DI 10.1016/j.biomaterials.2022.121903
EA NOV 2022
PG 30
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 6R5TJ
UT WOS:000892365100001
PM 36410109
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Kaur, K
   Das, S
   Ghosh, S
AF Kaur, Kulwinder
   Das, Sanskrita
   Ghosh, Sourabh
TI Regulation of Human Osteoblast to Osteocyte Differentiation by
   Direct Write 3D Microperiodic Hydroxyapatite Scaffolds
SO ACS OMEGA
LA English
DT Article
ID OCTACALCIUM PHOSPHATE; BONE FORMATION; IN VITRO; TITANIUM; CELLS; MODEL;
   BIOMATERIALS; OSTEOSARCOMA; TRANSITION; CONVERSION
AB Culturing osteocytes on planer surfaces on Petri dish in vitro fails to recapitulate their natural orientation as well as biological functionality in human bone. Ability to recapitulate spatial arrangement of osteoblasts can govern signaling cascades for osteoblast to osteocyte differentiation and osteogenesis. Therefore, in this study, we explored how direct write microperiodic hydroxyapatite (HAP) three dimensional (3D) scaffolds can modulate osteocyte differentiation as compared to two dimensional (2D) HAP scaffolds. Increased level of osteocalcin expression and relatively early mineralization on 2D HAP were indicative of osteoblast maturation. On the other hand, unique features of 3D HAP direct write scaffolds, in terms of the architecture and subtle difference in chemical composition, surface roughness, and stiffness, play a pivotal role in governing the complex mechanism of differentiation of osteoblast to osteocyte like phenotype. This was characterized by sequential events involving modulation in proliferation rate, time dependent downregulation in the expression of osteoblast markers, collagen type I and alkaline phosphatase, followed by the unregulated expression of matrix metalloproteinase, osteocytic terminal differentiation markers (podoplanin, sclerostin), and dendritic extension formation. Thus, establishment of a simple in vitro model to study osteoblast differentiation with respect to specific cues would offer potential as an investigative platform and versatile tool for developing a 3D in vitro model for regenerative medicine.
C1 [Kaur, Kulwinder; Das, Sanskrita; Ghosh, Sourabh] Indian Inst Technol Delhi, Regenerat Engn Lab, Dept Text Technol, New Delhi 110016, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Delhi
RP Ghosh, S (通讯作者)，Indian Inst Technol Delhi, Regenerat Engn Lab, Dept Text Technol, New Delhi 110016, India.
EM sghosh08@textile.iitd.ac.in
RI ; Kaur, Kulwinder/AAY 8138 2021
OI Kaur, Kulwinder/0000 0001 5352 0542; 
FU Department of Biotechnology, Government of India
   [BT/PR8038/MED/32/303/2013, BT/PR15451/MED/32/539/2016]
FX This study was supported by funding from the Department of
   Biotechnology, Government of India (BT/PR8038/MED/32/303/2013 and
   BT/PR15451/MED/32/539/2016).
CR Anand V, 2016, CERAM INT, V42, P3638, DOI 10.1016/j.ceramint.2015.11.029
   Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517
   Berman B, 2012, BUS HORIZONS, V55, P155, DOI 10.1016/j.bushor.2011.11.003
   Bonewald LF, 2011, J BONE MINER RES, V26, P229, DOI 10.1002/jbmr.320
   Boukhechba F, 2009, J BONE MINER RES, V24, P1927, DOI [10.1359/JBMR.090517, 10.1359/jbmr.090517]
   Brounais B, 2009, BONE, V44, P830, DOI 10.1016/j.bone.2008.12.021
   BROWN WE, 1981, PROG CRYST GROWTH CH, V4, P59, DOI 10.1016/0146 3535(81)90048 4
   Chawla S, 2018, ACS BIOMATER SCI ENG, V4, P3545, DOI 10.1021/acsbiomaterials.8b00757
   Chawla S, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201701204
   Chawla Shikha, 2017, Bioprinting, V7, P1, DOI 10.1016/j.bprint.2017.05.001
   Cohen Tanugi A, 1998, DIFFERENTIATION, V63, P115, DOI 10.1046/j.1432 0436.1998.6330115.x
   Correia C, 2012, ACTA BIOMATER, V8, P2483, DOI 10.1016/j.actbio.2012.03.019
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   Das S, 2015, ACTA BIOMATER, V11, P233, DOI 10.1016/j.actbio.2014.09.023
   Das S, 2013, BIOMACROMOLECULES, V14, P311, DOI 10.1021/bm301193t
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Fujita K, 2014, J CELL BIOCHEM, V115, P2039, DOI 10.1002/jcb.24880
   Glimcher, 1996, PHOSPHORUS RES B, V6, P67, DOI [10.3363/prb1992.6.067, DOI 10.3363/PRB1992.6.067]
   Hasegawa T, 2017, JPN DENT SCI REV, V53, P34, DOI 10.1016/j.jdsr.2016.09.002
   Hulsart Billstrom G, 2016, EUR CELLS MATER, V31, P312, DOI 10.22203/eCM.v031a20
   Iconaru S L, 2013, J. Spectrosc, V2013, P1
   Kaneko H, 2011, ANAL BIOCHEM, V418, P276, DOI 10.1016/j.ab.2011.07.022
   Karsdal MA, 2002, J BIOL CHEM, V277, P44061, DOI 10.1074/jbc.M207205200
   Kaur K, 2016, CERAM INT, V42, P12651, DOI 10.1016/j.ceramint.2016.05.001
   Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200
   Kerschnitzki M, 2011, J STRUCT BIOL, V173, P303, DOI 10.1016/j.jsb.2010.11.014
   Klein Nulend J, 2012, EUR CELLS MATER, V24, P278, DOI 10.22203/eCM.v024a20
   Kumar A, 2013, J BIOMED MATER RES A, V101, P2925, DOI 10.1002/jbm.a.34603
   Le Guehennec L, 2008, ACTA BIOMATER, V4, P535, DOI 10.1016/j.actbio.2007.12.002
   Li MQ, 2004, MICROSC RES TECHNIQ, V64, P330, DOI 10.1002/jemt.20088
   Liu XY, 2004, SURF COAT TECH, V186, P227, DOI 10.1016/j.surfcoat.2004.02.045
   Lorsch JR, 2014, SCIENCE, V346, P1452, DOI 10.1126/science.1259110
   Mattinzoli D, 2012, EUR CELLS MATER, V24, P403, DOI 10.22203/eCM.v024a29
   Michna S, 2005, BIOMATERIALS, V26, P5632, DOI 10.1016/j.biomaterials.2005.02.040
   Midha S, 2018, BIOMED MATER, V13, DOI 10.1088/1748 605X/aad2a9
   Midha S, 2016, BIOMATERIALS, V97, P133, DOI 10.1016/j.biomaterials.2016.04.020
   Moutzouri AG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/740726
   Mullen CA, 2013, J MECH BEHAV BIOMED, V28, P183, DOI 10.1016/j.jmbbm.2013.06.013
   Nara S, 2014, MATER TECHNOL, V29, pB10, DOI 10.1179/1753555713Y.0000000112
   Olivares Navarrete R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170312
   Prideaux M, 2014, CALCIFIED TISSUE INT, V95, P183, DOI 10.1007/s00223 014 9879 y
   Rausch fan XH, 2008, DENT MATER, V24, P102, DOI 10.1016/j.dental.2007.03.001
   REY C, 1989, CALCIFIED TISSUE INT, V45, P157, DOI 10.1007/BF02556059
   Sai Y, 2018, ACTA BIOMATER, V69, P362, DOI 10.1016/j.actbio.2018.01.026
   Simon JL, 2007, J BIOMED MATER RES A, V83A, P747, DOI 10.1002/jbm.a.31329
   Sims NA, 2014, ARCH BIOCHEM BIOPHYS, V561, P22, DOI 10.1016/j.abb.2014.05.015
   Smith CM, 2004, TISSUE ENG, V10, P1566, DOI 10.1089/ten.2004.10.1566
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242
   Suzuki O, 2006, BIOMATERIALS, V27, P2671, DOI 10.1016/j.biomaterials.2005.12.004
   Suzuki O, 2006, J BIOMED MATER RES B, V77B, P201, DOI 10.1002/jbm.b.30407
   Suzuki O., 2017, CELLS MAT, V5, P45
   Tamai N, 2002, J BIOMED MATER RES, V59, P110, DOI 10.1002/jbm.1222
   Tanaka Kamioka K, 1998, J BONE MINER RES, V13, P1555, DOI 10.1359/jbmr.1998.13.10.1555
   Tsuruga E, 1997, J BIOCHEM TOKYO, V121, P317
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Vandecandelaere N, 2012, J MATER SCI MATER M, V23, P2593, DOI 10.1007/s10856 012 4719 y
   Wei M, 2002, MAT SCI ENG C BIO S, V20, P125, DOI 10.1016/S0928 4931(02)00022 X
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
   Ye JH, 2011, BIOMATERIALS, V32, P5065, DOI 10.1016/j.biomaterials.2011.03.053
   Zareidoost A, 2012, J MATER SCI MATER M, V23, P1479, DOI 10.1007/s10856 012 4611 9
NR 64
TC 22
Z9 23
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD JAN
PY 2019
VL 4
IS 1
BP 1504
EP 1515
DI 10.1021/acsomega.8b03272
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA HN5HN
UT WOS:000460214700163
OA gold
DA 2025 08 17
ER

PT J
AU Liang, C
   Peng, SL
   Li, J
   Lu, J
   Guan, DG
   Jiang, F
   Lu, C
   Li, FF
   He, XJ
   Zhu, HL
   Au, DWT
   Yang, DZ
   Zhang, BT
   Lu, AP
   Zhang, G
AF Liang, Chao
   Peng, Songlin
   Li, Jie
   Lu, Jun
   Guan, Daogang
   Jiang, Feng
   Lu, Cheng
   Li, Fangfei
   He, Xiaojuan
   Zhu, Hailong
   Au, D. W. T.
   Yang, Dazhi
   Zhang, Bao Ting
   Lu, Aiping
   Zhang, Ge
TI Inhibition of osteoblastic Smurf1 promotes bone formation in mouse
   models of distinctive age related osteoporosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID UBIQUITIN LIGASE SMURF1; TARGET STABILITY DARTS; MORPHOGENETIC PROTEINS;
   TGF BETA; CLINICAL APPLICATIONS; DEGRADATION; DIFFERENTIATION;
   HOMEOSTASIS; GROWTH; IDENTIFICATION
AB Bone morphogenetic protein (BMP) signaling is essential for osteogenesis. However, recombinant human BMPs (rhBMPs) exhibit large inter individual variations in local bone formation during clinical spinal fusion. Smurf1 ubiquitinates BMP downstream molecules for degradation. Here, we classify age related osteoporosis based on distinct intraosseous BMP2 levels and Smurf1 activity. One major subgroup with a normal BMP 2 level and elevated Smurf1 activity (BMP 2(n)/Smurf1(e)) shows poor response to rhBMP 2 during spinal fusion, when compared to another major subgroup with a decreased BMP 2 level and normal Smurf1 activity (BMP 2(d)/Smurf1(n)). We screen a chalcone derivative, i.e., 2 (4 cinnamoylphenoxy) acetic acid, which effectively inhibits Smurf1 activity and increases BMP signaling. For BMP 2(n)/Smurf1(e) mice, the chalcone derivative enhances local bone formation during spinal fusion. After conjugating to an osteoblast targeting and penetrating oligopeptide (DSS)(6), the chalcone derivative promotes systemic bone formation in BMP 2(n)/Smurf1(e) mice. This study demonstrates a precision medicine based bone anabolic strategy for age related osteoporosis.
C1 [Liang, Chao; Peng, Songlin; Lu, Jun; Guan, Daogang; Jiang, Feng; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Hong Kong, Peoples R China.
   [Liang, Chao; Lu, Jun; Guan, Daogang; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Zhu, Hailong; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong 999077, Hong Kong, Peoples R China.
   [Liang, Chao; Lu, Jun; Guan, Daogang; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen 518000, Peoples R China.
   [Peng, Songlin; Yang, Dazhi] Ji Nan Univ, Shenzhen Peoples Hosp, Coll Med 2, Dept Spine Surg, Shenzhen 518020, Peoples R China.
   [Li, Jie; Zhang, Bao Ting] Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong 999077, Hong Kong, Peoples R China.
   [Li, Jie] Peking Univ, Shenzhen Hosp, Clin Med Lab, Shenzhen 518036, Peoples R China.
   [Jiang, Feng] Zhejiang Pharmaceut Coll, Ningbo 315100, Zhejiang, Peoples R China.
   [Lu, Cheng; He, Xiaojuan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Au, D. W. T.] City Univ Hong Kong, Dept Biol & Chem, Hong Kong 999077, Hong Kong, Peoples R China.
   [Lu, Aiping] Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 200032, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; HKBU
   Institute for Research & Continuing Education; Jinan University; Chinese
   University of Hong Kong; Peking University; China Academy of Chinese
   Medical Sciences; Institute of Basic Research In Clinical Medicine,
   CACMS; City University of Hong Kong
RP Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen 518000, Peoples R China.; Zhang, BT (通讯作者)，Chinese Univ Hong Kong, Fac Med, Sch Chinese Med, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP (通讯作者)，Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 200032, Peoples R China.
EM zhangbaoting@cuhk.edu.hk; aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI Liang, Chao/AAF 7703 2019; peng, sl/ISA 1370 2023; Zhang,
   Baoting/B 6273 2015; JIANG, Feng/HTP 2862 2023; LU,
   Aiping/JDX 0577 2023; Dong, Xinlong/KRO 6089 2024; Zhang, Ge/N 4150 2013
FU Ministry of Science and Technology of China [2013ZX09301307]; Hong Kong
   General Research Fund [HKBU12100918, HKBU479111, HKBU478312, HKBU262913,
   HKBU12102914, HKBU261113, CUHK14112915, CUHK489213]; Natural Science
   Foundation Council of China [81700780, 81371989, 81272045, 81401833,
   81470072, N_HKBU435/12]; Research Grants Council [N_HKBU435/12];
   Croucher Foundation [CAS14BU/CAS14201]; Interdisciplinary Research
   Matching Scheme (IRMS) of Hong Kong Baptist University
   [RC IRMS/12 13/02, RC IRMS/13 14/02]; Hong Kong Baptist University
   Strategic Development Fund [SDF13 1209 P01, SDF15 0324 P02(b)]; Hong
   Kong Research Grants Council Early Career Scheme [489213];
   Inter institutional Collaborative Research Scheme of Hong Kong Baptist
   University [RC ICRS/14 15/01, RC ICRS/16 17/01]; Faculty Research Grant
   of Hong Kong Baptist University [FRG1/13 14/024, FRG2/13 14/006,
   FRG2/14 15/010]; China Academy of Chinese Medical Sciences [Z0252,
   Z0293]
FX We thank technical staffs (Ms. Yeuk Siu Cheung and Mr. Chi Leung Chan)
   from Law Sau Fai Institute for Advancing Translational Medicine in Bone
   and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist
   University for providing technical support. This work was supported by
   the Ministry of Science and Technology of China (2013ZX09301307 to
   A.L.), the Hong Kong General Research Fund (HKBU12100918 to G.Z.,
   HKBU479111 to G.Z., HKBU478312 to G.Z., HKBU262913 to G.Z., HKBU12102914
   to G.Z., HKBU261113 to A.L., CUHK14112915 to B. T.Z., and CUHK489213 to
   B. T.Z.), the Natural Science Foundation Council of China (81272045 to
   G.Z., 81700780 to C.L., 81371989 to S.P., 81272045 to B.G., 81401833 to
   B.G., and 81470072 to X.H.), the Research Grants Council and Natural
   Science Foundation Council of China (N_HKBU435/12 to G.Z.), the Croucher
   Foundation (Gnt#CAS14BU/CAS14201 to A.L.), the Interdisciplinary
   Research Matching Scheme (IRMS) of Hong Kong Baptist University
   (RC IRMS/12 13/02 to A.L. and RC IRMS/13 14/02 to G.Z.), the Hong Kong
   Baptist University Strategic Development Fund (SDF13 1209 P01 to A.L.
   and SDF15 0324 P02(b) to A.L.), the Hong Kong Research Grants Council
   Early Career Scheme (489213 to G.Z.), the Inter institutional
   Collaborative Research Scheme of Hong Kong Baptist University
   (RC ICRS/14 15/01 to G.Z. and RC ICRS/16 17/01 to A.L.), the Faculty
   Research Grant of Hong Kong Baptist University (FRG1/13 14/024 to G.Z.,
   FRG2/13 14/006 to G.Z., and FRG2/14 15/010 to G.Z.), the China Academy
   of Chinese Medical Sciences (Z0252 and Z0293 to A.L.).
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Amin S, 2007, J BONE MINER RES, V22, P799, DOI 10.1359/JBMR.070306
   Aragón E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Bobyn J, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749 799X 8 2
   Cao Y, 2014, SCI REP UK, V4, DOI 10.1038/srep04965
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112
   Chiva Blanch G, 2011, J CHROMATOGR A, V1218, P698, DOI 10.1016/j.chroma.2010.12.012
   Chong PA, 2010, P NATL ACAD SCI USA, V107, P18404, DOI 10.1073/pnas.1003023107
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Erdogan CS, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060353
   Farr JN, 2015, NAT REV ENDOCRINOL, V11, P513, DOI 10.1038/nrendo.2015.89
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Ghodadra N, 2008, BIOL TARGETS THER, V2, P345
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Hollingsworth Scott A, 2010, Biomol Concepts, V1, P271, DOI 10.1515/BMC.2010.022
   Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291 010 0074 2
   Johnson JS, 2011, J CELL BIOCHEM, V112, P1673, DOI 10.1002/jcb.23082
   Kato S, 2011, MOL CELL BIOCHEM, V349, P97, DOI 10.1007/s11010 010 0664 6
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li J. Jenny, 2017, International Journal of Information Privacy, Security and Integrity, V3, P1
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Montgomery SR, 2014, J BONE MINER RES, V29, P1872, DOI 10.1002/jbmr.2213
   Morimoto T, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01097
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Murakami K, 2010, EXP BIOL MED, V235, P805, DOI 10.1258/ebm.2010.009383
   Pai MY, 2015, METHODS MOL BIOL, V1263, P287, DOI 10.1007/978 1 4939 2269 7_22
   Rao RD, 2007, SPINE J, V7, P61, DOI 10.1016/j.spinee.2006.03.004
   Ravindran S, 2013, J BIOL CHEM, V288, P16098, DOI 10.1074/jbc.M113.450585
   SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357 4310(95)91170 7
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Smith AL, 2012, CLIN CANCER RES, V18, P4514, DOI 10.1158/1078 0432.CCR 11 3224
   Spassov VZ, 2008, PROTEIN ENG DES SEL, V21, P91, DOI 10.1093/protein/gzm083
   Starman JS, 2012, J TRAUMA ACUTE CARE, V72, P676, DOI 10.1097/TA.0b013e318232cf5a
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang B, 2012, MOL MED REP, V5, P955, DOI 10.3892/mmr.2012.765
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Yue R, 2016, ELIFE, V5, DOI 10.7554/eLife.18782
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
NR 59
TC 0
Z9 0
U1 1
U2 49
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 27
PY 2018
VL 9
AR 3428
DI 10.1038/s41467 018 05974
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GR4QT
UT WOS:000442601100001
DA 2025 08 17
ER

PT J
AU Pellegatti, P
   Falzoni, S
   Donvito, G
   Lemaire, I
   Di Virgilio, F
AF Pellegatti, Patrizia
   Falzoni, Simonetta
   Donvito, Giovanna
   Lemaire, Irma
   Di Virgilio, Francesco
TI P2X7 receptor drives osteoclast fusion by increasing the extracellular
   adenosine concentration
SO FASEB JOURNAL
LA English
DT Article
DE purinergic receptors; cell fusion; giant cells; bone metabolism;
   inflammation
ID GIANT CELL FORMATION; P2X(7) RECEPTOR; MACROPHAGE FUSION;
   PLASMA MEMBRANE; IN VITRO; BONE; ATP; DIFFERENTIATION; ACTIVATION;
   EXPRESSION
AB Defects in bone homeostasis are a major health problem. Osteoclast differentiation and activation have a crucial role in bone remodeling in health and disease. Osteoclasts are bone resorbing cells derived from mononuclear phagocyte progenitors. The key event in osteoclast formation is fusion of mononucleate precursors to form mature multinucleated osteclasts. Here we provide evidence of an absolute requirement for the P2X7 receptor, ATP release, and adenosine signaling in human osteoclast formation, as shown by the following findings: macrophage colony stimulating factor/receptor activator for nuclear factor kappa B ligand (M CSF/RANKL) stimulated fusion of human monocytes is fully prevented by an anti P2X7 mAb, by specific P2X7 pharmacological antagonists, or by inhibition of CD39/NTPDase; fusion competent monocytes release ATP via the P2X7 receptor; accelerated degradation of released ATP by addition of either apyrase or hexokinase strongly increases fusion; removal of extracellular adenosine by adenosine deaminase blocks, while addition of exogenous adenosine strongly potentiates, fusion; and pharmacologic stimulation of the adenosine A2A receptor increases, while selective A2A blockade inhibits, fusion. These results show that the purinergic axis plays a crucial and as yet undescribed role in osteoclast formation and reconcile previous evidence advocating a key role for either ATP or adenosine receptors in multinucleated giant cell formation. Pellegatti, P., Falzoni, S., Donvito, G., Lemaire, I., Di Virgilio, F. P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration. FASEB J. 25, 1264 1274 (2011). www.fasebj.org
C1 [Pellegatti, Patrizia; Falzoni, Simonetta; Donvito, Giovanna; Di Virgilio, Francesco] Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Dept Expt & Diagnost Med, Sect Gen Pathol, I 44100 Ferrara, Italy.
   [Lemaire, Irma] Univ Ottawa, Fac Med, Dept Cellular & Mol Med, Ottawa, ON, Canada.
C3 University of Ferrara; University of Ottawa
RP Di Virgilio, F (通讯作者)，Univ Ferrara, Interdisciplinary Ctr Study Inflammat, Dept Expt & Diagnost Med, Sect Gen Pathol, Via Borsari 46, I 44100 Ferrara, Italy.
EM fdv@unife.it
RI ; Di Virgilio, Francesco/J 3754 2018; DI VIRGILIO,
   Francesco/O 4634 2019; Pellegatti, Patrizia/A 1891 2011
OI Falzoni, Simonetta/0000 0002 6594 0357; Di Virgilio,
   Francesco/0000 0003 3566 1362; 
FU Italian Association for Cancer Research [IG 5354]; Telethon of Italy
   [GGP06070]; Italian Space Agency (ASI OSMA); Commission of European
   Communities [HEALTH F2 2007 202231]; Regione Emilia Romagna; University
   of Ferrara
FX This research was supported by grants from the Italian Association for
   Cancer Research (IG 5354), Telethon of Italy (GGP06070), the Italian
   Space Agency (ASI OSMA), the Commission of European Communities (7th
   Framework Program HEALTH F2 2007 202231), the Regione Emilia Romagna
   (Innovative Approaches to the Diagnosis of Inflammatory Diseases and
   Moniter research programs), and institutional funds from the University
   of Ferrara. F. D. V. acts as a consultant of Cordex Pharma and Affectis
   Pharma, biotech companies involved in the development of ATP based
   drugs.
CR Adinolfi E, 2009, J BIOL CHEM, V284, P10120, DOI 10.1074/jbc.M805805200
   Bar Shavit Z, 2007, J CELL BIOCHEM, V102, P1130, DOI 10.1002/jcb.21553
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5
   Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697
   Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587
   Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002
   Donnelly Roberts DL, 2007, BRIT J PHARMACOL, V151, P571, DOI 10.1038/sj.bjp.0707265
   FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770
   Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169
   Ferrari D, 1997, J IMMUNOL, V159, P1451
   Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132
   Gartland A, 2003, CRIT REV EUKAR GENE, V13, P243, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.160
   Gartland A, 2003, CALCIFIED TISSUE INT, V73, P361, DOI 10.1007/s00223 002 2098 y
   Grol MW, 2009, PURINERG SIGNAL, V5, P205, DOI 10.1007/s11302 009 9139 1
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Helming L, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1159665
   Helming L, 2009, J CELL SCI, V122, P453, DOI 10.1242/jcs.037200
   Hiken JF, 2004, AM J PHYSIOL CELL PH, V287, pC403, DOI 10.1152/ajpcell.00361.2003
   Hoebertz A, 2003, TRENDS PHARMACOL SCI, V24, P290, DOI 10.1016/S0165 6147(03)00123 8
   Inui M, 2009, P NATL ACAD SCI USA, V106, P4816, DOI 10.1073/pnas.0900463106
   Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09 147447
   Ke HZ, 2003, MOL ENDOCRINOL, V17, P1356, DOI 10.1210/me.2003 0021
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lemaire I, 2006, J IMMUNOL, V177, P7257, DOI 10.4049/jimmunol.177.10.7257
   Li JL, 2005, J BIOL CHEM, V280, P42952, DOI 10.1074/jbc.M506415200
   MacLauchlan S, 2009, J LEUKOCYTE BIOL, V85, P617, DOI 10.1189/jlb.1008588
   MARKS SC, 1988, AM J ANAT, V183, P1, DOI 10.1002/aja.1001830102
   Matsuzaki K, 1998, BIOCHEM BIOPH RES CO, V246, P199, DOI 10.1006/bbrc.1998.8586
   Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529 0131(199707)40:7<1308::AID ART16>3.0.CO;2 M
   Panupinthu N, 2008, J CELL BIOL, V181, P859, DOI 10.1083/jcb.200708037
   Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378
   Pellegatti P, 2005, MOL BIOL CELL, V16, P3659, DOI 10.1091/mbc.E05 03 0222
   Schwarz N, 2009, PURINERG SIGNAL, V5, P139, DOI 10.1007/s11302 009 9135 5
   STEINBERG TH, 1987, J BIOL CHEM, V262, P8884
   Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630
   Vignery A, 2005, J EXP MED, V202, P337, DOI 10.1084/jem.20051123
   Vignery A, 2005, TRENDS CELL BIOL, V15, P188, DOI 10.1016/j.tcb.2005.02.008
   Westfall TD, 1997, EUR J PHARMACOL, V329, P169, DOI 10.1016/S0014 2999(97)89178 9
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yegutkin GG, 2008, BBA MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Zimmermann H, 2000, N S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309
NR 43
TC 82
Z9 88
U1 2
U2 9
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3998 USA
SN 0892 6638
J9 FASEB J
JI Faseb J.
PD APR
PY 2011
VL 25
IS 4
BP 1264
EP 1274
DI 10.1096/fj.10 169854
PG 11
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics; Cell Biology
GA 742ZA
UT WOS:000288982800015
PM 21233486
DA 2025 08 17
ER

PT J
AU Kaushal, N
   Vohora, D
   Jalali, RK
   Jha, S
AF Kaushal, Neelam
   Vohora, Divya
   Jalali, Rajinder K.
   Jha, Sujeet
TI Raised serum uric acid is associated with higher bone mineral density in
   a cross sectional study of a healthy Indian population
SO THERAPEUTICS AND CLINICAL RISK MANAGEMENT
LA English
DT Article
DE oxidative stress; antioxidant effect; bone mineral density; uric acid;
   osteoporosis; T scores
ID INCIDENT OSTEOPOROTIC FRACTURES; GENERAL POPULATION; OXIDATIVE STRESS;
   RISK; HYPERTENSION; ANTIOXIDANTS; PHENOTYPES; TURNOVER; MALES; WOMEN
AB Purpose: Oxidative stress has been implicated as a fundamental mechanism in the decline of bone mass. Reactive oxygen species are reported to suppress osteoblast generation and differentiation and enhance osteoclast development and activity. Increasing evidence suggests favorable effect of serum uric acid (UA) on bone metabolism due to its antioxidant properties. Therefore, we investigated the association between serum UA levels and bone mineral density (BMD) in healthy adult Indian subjects.
   Materials and methods: We reviewed the medical records of 524 subjects who had undergone preventive health check ups in a tertiary care hospital that included UA and BMD measurements at femur neck, total femur, and lumbar spine. Subjects concomitantly taking drugs or having a medical condition that would affect the bone metabolism or UA levels were excluded.
   Results: The final analysis included 310 subjects (mean age: 47.2 +/  12.2 years; females: 43.5%; males: 56.5%). Study population was categorized into two groups based on the group median value for UA (ie, 5.4 mg/dL). BMD was significantly higher at all skeletal sites in subjects with UA > 5.4 mg/dL compared to subjects with UA <= 5.4 mg/dL (p<0.001). On correlation analysis, UA was positively associated with BMD at all skeletal sites (r=0.211 0.277; p<0.05). The correlation remained significant after controlling for age (p<0.05) and lifestyle factors (smoking, alcohol use, physical activity, and diet; p<0.05) independently. UA significantly (p<0.001) accounted for 4.5% 7.7% of the variance in BMD (r(2)=0.045 0.077) in unadjusted model and 1.6% 3.2% of the variance (p<0.05) when adjusted for age and body mass index combined at lumbar spine and right femur neck, respectively.
   Conclusion: We conclude that raised UA levels are associated with higher BMD at all skeletal sites and UA may have a protective role in bone metabolism owing to its antioxidant effect.
C1 [Kaushal, Neelam; Vohora, Divya] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi, India.
   [Jalali, Rajinder K.] Sun Pharmaceut Ind Ltd, Med Affairs & Clin Res, Gurgaon, India.
   [Jha, Sujeet] Max Healthcare Inst Ltd, Inst Endocrinol Diabet & Metab, New Delhi, India.
C3 Jamia Hamdard University
RP Vohora, D; Jha, S (通讯作者)，Jamia Hamdard, Sch Pharmaceut Educ & Res, Pharmaceut Med, Mehrauli Badarpur Rd, New Delhi 110062, India.
EM divyavohora@hotmail.com; sujeet.jha@maxhealthcare.com
RI Jha, Dr.Sujeet/ABD 4884 2021; Vohora, Divya/H 4245 2019
OI Vohora, Divya/0000 0003 1852 9191
CR Ahn SH, 2013, OSTEOPOROSIS INT, V24, P2961, DOI 10.1007/s00198 013 2377 7
   ANDERSON JJB, 1994, ADV NUTR RES, V9, P129
   Andreadou E, 2009, CLIN NEUROL NEUROSUR, V111, P724, DOI 10.1016/j.clineuro.2009.06.012
   Dehghan A, 2008, DIABETES CARE, V31, P361, DOI 10.2337/dc07 1276
   Dong XW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154692
   Euser SM, 2009, BRAIN, V132, P377, DOI 10.1093/brain/awn316
   Glantzounis GK, 2005, CURR PHARM DESIGN, V11, P4145, DOI 10.2174/138161205774913255
   Ishii S, 2014, OSTEOPOROSIS INT, V25, P1099, DOI 10.1007/s00198 013 2571 7
   Johnson RJ, 2003, HYPERTENSION, V41, P1183, DOI 10.1161/01.HYP.0000069700.62727.C5
   Karasik D, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00303
   Keizman D, 2009, J NEUROL SCI, V285, P95, DOI 10.1016/j.jns.2009.06.002
   Kim BJ, 2014, OSTEOPOROSIS INT, V25, P1837, DOI 10.1007/s00198 014 2697 2
   Kim S, 2015, B KOREAN CHEM SOC, V36, P9, DOI 10.1002/bkcs.10064
   Kousteni Stavroula, 2011, Curr Osteoporos Rep, V9, P60, DOI 10.1007/s11914 011 0054 3
   Kuyumcu ME, 2012, ARCH GERONTOL GERIAT, V55, P739, DOI 10.1016/j.archger.2012.05.004
   Lai JH, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02640 0
   Lane NE, 2014, J BONE MINER RES, V29, P1701, DOI 10.1002/jbmr.2164
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Lei S. F., 2006, Journal of Musculoskeletal & Neuronal Interactions, V6, P36
   Leslie WD, 2012, J CLIN ENDOCR METAB, V97, P4329, DOI 10.1210/jc.2012 2863
   Lin XF, 2015, ONCOTARGET, V6, P35395, DOI 10.18632/oncotarget.6173
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Mainini G, 2012, CLIN EXP OBSTET GYN, V39, P489
   Makovey J, 2013, BONE, V52, P400, DOI 10.1016/j.bone.2012.10.025
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   Massa J, 2009, J NEUROL, V256, P1643, DOI 10.1007/s00415 009 5170 y
   Mehta T, 2015, METABOLISM, V64, P438, DOI 10.1016/j.metabol.2014.11.006
   Meng SJ, 2010, INT J MOL SCI, V11, P1509, DOI 10.3390/ijms11041509
   Mithal Ambrish, 2014, Indian J Endocrinol Metab, V18, P449, DOI 10.4103/2230 8210.137485
   Mlakar SJ, 2010, DIS MARKERS, V29, P71, DOI [10.1155/2010/354189, 10.3233/DMA 2010 0728]
   Muka T, 2016, J CLIN ENDOCR METAB, V101, P1113, DOI 10.1210/jc.2015 2446
   Musumeci M, 2009, J BONE MINER METAB, V27, P424, DOI 10.1007/s00774 009 0041 2
   Nabipour I, 2011, J BONE MINER RES, V26, P955, DOI 10.1002/jbmr.286
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Sautin YY, 2008, NUCLEOS NUCLEOT NUCL, V27, P608, DOI 10.1080/15257770802138558
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Sritara C, 2013, J CLIN DENSITOM, V16, P336, DOI 10.1016/j.jocd.2012.05.008
   Taghizadeh N, 2014, CANCER CAUSE CONTROL, V25, P1075, DOI 10.1007/s10552 014 0408 0
   Verdecchia P, 2000, HYPERTENSION, V36, P1072, DOI 10.1161/01.HYP.36.6.1072
   Veronese N, 2016, EUR J CLIN INVEST, V46, P920, DOI 10.1111/eci.12677
   Veronese N, 2015, BONE, V79, P183, DOI 10.1016/j.bone.2015.06.005
   Waring WS, 2003, CLIN SCI, V105, P425, DOI 10.1042/CS20030149
   Wilson Carol, 2014, Nat Rev Endocrinol, V10, P3, DOI 10.1038/nrendo.2013.225
   Xiao J, 2017, CLIN INTERV AGING, V12, P445, DOI 10.2147/CIA.S130690
   Zengin A, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00024
   Zhang DH, 2015, J BONE MINER RES, V30, P992, DOI 10.1002/jbmr.2430
NR 46
TC 18
Z9 20
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300 008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178 203X
J9 THER CLIN RISK MANAG
JI Therap. Clin. Risk Manag.
PY 2018
VL 14
BP 75
EP 82
DI 10.2147/TCRM.S147696
PG 8
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA FS8FD
UT WOS:000422644900001
PM 29379298
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Kitamura, H
   Takahashi, A
   Takei, F
   Hotta, H
   Miyao, N
   Shindo, T
   Igarashi, M
   Tachiki, H
   Kunishima, Y
   Muranaka, T
   Shigyo, M
   Ikehata, Y
   Masumori, N
AF Kitamura, Hiroshi
   Takahashi, Atsushi
   Takei, Fumiyasu
   Hotta, Hiroshi
   Miyao, Noriomi
   Shindo, Tetsuya
   Igarashi, Manabu
   Tachiki, Hitoshi
   Kunishima, Yasuharu
   Muranaka, Takashi
   Shigyo, Masanori
   Ikehata, Yoshinori
   Masumori, Naoya
CA Sapporo Med Univ
TI Molecular targeted Therapy and Surgery May Prolong Survival of Renal
   Cell Carcinoma Patients with Bone Metastasis: A Multi institutional
   Retrospective Study in Japan
SO ANTICANCER RESEARCH
LA English
DT Article
DE Kidney neoplasms; neoplasm metastasis; bone; molecular targeted therapy;
   surgery
ID POPULATION BASED ANALYSIS; PHASE III TRIAL; CYTOREDUCTIVE NEPHRECTOMY;
   PROGNOSTIC FACTORS; INTERFERON ALPHA; SUNITINIB; ERA; BISPHOSPHONATES;
   EVEROLIMUS; CANCER
AB Aim: To determine prognostic factors for overall survival (OS) in renal cell carcinoma (RCC) patients with bone metastasis in the targeted therapy era. Patients and Methods: We conducted a retrospective multi institutional review of the medical records of 149 RCC patients with bone metastasis. Survival was estimated using the Kaplan Meier method and compared with the log rank test. Univariate and multivariate Cox proportional hazard regression analyses were performed to identify independent factors associated with OS. Results: The median OS was 13.4 months. In multivariate analysis, molecular targeted therapy, nephrectomy and surgery for bone metastasis were independent prognostic factors. Bone modifying agents (BMAs) were not associated with OS. The median OS of patients receiving molecular targeted therapy after diagnosis of bone metastasis was significantly better than that of those who did not receive targeted therapy. Conclusion: Molecular targeted therapy, nephrectomy and surgery for bone metastasis should be considered for RCC patients with metastasis in the bones.
C1 [Kitamura, Hiroshi] Toyama Univ, Toyama, Japan.
   [Takahashi, Atsushi] Hakodate Goryoukaku Hosp, Hakodate, Hokkaido, Japan.
   [Takei, Fumiyasu] Sunagawa City Med Ctr, Sunagawa, Japan.
   [Hotta, Hiroshi] Japanese Red Cross Asahikawa Hosp, Asahikawa, Hokkaido, Japan.
   [Miyao, Noriomi] Muroran City Gen Hosp, Muroran, Hokkaido, Japan.
   [Shindo, Tetsuya] NTT East Japan Sapporo Hosp, Sapporo, Hokkaido, Japan.
   [Igarashi, Manabu] Takikawa Municipal Hosp, Takikawa, Hokkaido, Japan.
   [Tachiki, Hitoshi] Steel Mem Muroran Hosp, Muroran, Hokkaido, Japan.
   [Kunishima, Yasuharu] Obihiro Kyokai Hosp, Obihiro, Hokkaido, Japan.
   [Muranaka, Takashi] JCHO Hokkaido Hosp, Sapporo, Hokkaido, Japan.
   [Shigyo, Masanori] Kushiro Red Cross Hosp, Kushiro, Hokkaido, Japan.
   [Ikehata, Yoshinori] Oji Gen Hosp, Tomakomai, Japan.
   [Masumori, Naoya] Sapporo Med Univ, Sch Med, Sapporo, Hokkaido, Japan.
C3 University of Toyama; Sapporo Medical University
RP Kitamura, H (通讯作者)，Toyama Univ, Dept Urol, Grad Sch Med & Pharmaceut Sci Res, 2630 Sugitani, Toyama 9300194, Japan.
EM hkitamur@med.u toyama.ac.jp
RI Igarashi, Manabu/F 6871 2012
FU Pfizer
FX HK received lecture fees from Pfizer. The other Authors declare that
   there are no financial or personal conflicts of interest associated with
   this study.
CR Beuselinck B, 2012, BRIT J CANCER, V107, P1665, DOI 10.1038/bjc.2012.385
   Bianchi M, 2012, ANN ONCOL, V23, P973, DOI 10.1093/annonc/mdr362
   Conti SL, 2014, INT J CANCER, V134, P2245, DOI 10.1002/ijc.28553
   Culp SH, 2014, UROL ONCOL SEMIN ORI, V32, P561, DOI 10.1016/j.urolonc.2013.12.003
   Dabestani S, 2014, LANCET ONCOL, V15, pE549, DOI 10.1016/S1470 2045(14)70235 9
   Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013
   Flanigan RC, 2004, J UROLOGY, V171, P1071, DOI 10.1097/01.ju.0000110610.61545.ae
   Fuchs B, 2005, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000149820.65137.b4
   Heng DYC, 2014, EUR UROL, V66, P704, DOI 10.1016/j.eururo.2014.05.034
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Kume H, 2011, J UROLOGY, V185, P1611, DOI 10.1016/j.juro.2010.12.037
   Lipton A, 2004, CLIN CANCER RES, V10, p6397S, DOI 10.1158/1078 0432.CCR 040030
   Ljungberg B, 2015, EUR UROL, V67, P913, DOI 10.1016/j.eururo.2015.01.005
   Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140 6736(01)06103 7
   Motzer RJ, 2013, BRIT J CANCER, V108, P2470, DOI 10.1038/bjc.2013.236
   Motzer RJ, 2002, J CLIN ONCOL, V20, P289, DOI 10.1200/JCO.2002.20.1.289
   Motzer RJ, 2004, J CLIN ONCOL, V22, P454, DOI 10.1200/JCO.2004.06.132
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140 6736(08)61039 9
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2010, CANCER AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Rini BI, 2008, J CLIN ONCOL, V26, P5422, DOI 10.1200/JCO.2008.16.9847
   Saylor PJ, 2013, EUR UROL, V63, P309, DOI 10.1016/j.eururo.2012.10.007
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Tatsugami K, 2015, INT J UROL, V22, P736, DOI 10.1111/iju.12803
   Toyoda Y, 2007, EUR UROL, V52, P163, DOI 10.1016/j.eururo.2006.10.060
NR 25
TC 11
Z9 13
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250 7005
EI 1791 7530
J9 ANTICANCER RES
JI Anticancer Res.
PD OCT
PY 2016
VL 36
IS 10
BP 5531
EP 5536
DI 10.21873/anticanres.11136
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA EC9SA
UT WOS:000388483300070
PM 27798926
OA Bronze
DA 2025 08 17
ER

PT J
AU Gafni, RI
   Guthrie, LC
   Kelly, MH
   Brillante, BA
   Christie, CM
   Reynolds, JC
   Yovetich, NA
   James, R
   Collins, MT
AF Gafni, Rachel I.
   Guthrie, Lori C.
   Kelly, Marilyn H.
   Brillante, Beth A.
   Christie, C. Michele
   Reynolds, James C.
   Yovetich, Nancy A.
   James, Robert
   Collins, Michael T.
TI Transient Increased Calcium and Calcitriol Requirements After
   Discontinuation of Human Synthetic Parathyroid Hormone 1 34 (hPTH 1 34)
   Replacement Therapy in Hypoparathyroidism
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE PARATHYROID RELATED DISORDERS; PTH; BIOCHEMICAL MARKERS OF BONE
   TURNOVER; DXA; HORMONE REPLACEMENT
ID BONE MINERAL DENSITY; LONG TERM TREATMENT; PRIMARY HYPERPARATHYROIDISM;
   POSTMENOPAUSAL WOMEN; VITAMIN D; OSTEOPOROSIS; TURNOVER; SKELETON;
   DIFFERENTIATION; PTH(1 84)
AB Synthetic human PTH 1 34 (hPTH 1 34) replacement therapy in hypoparathyroidism maintains eucalcemia and converts quiescent bone to high turnover bone. However, the skeletal and metabolic effects of drug discontinuation have not been reported. Nine subjects with hypoparathyroidism received subcutaneous injections of hPTH 1 34 two to three times daily for 19.8 to 61.3 months and then transitioned back to calcium and calcitriol. Biochemistries and bone mineral density (BMD) by dual energy X ray absorptiometry (DXA) were assessed at baseline, while on treatment, and at follow up 3 to 12 months after drug discontinuation. Two subjects developed hypocalcemia when hPTH 1 34 was abruptly discontinued. Thus, to avoid hypocalcemia, subjects were slowly weaned from hPTH 1 34 over several weeks. When hPTH 1 34 was stopped, subjects were requiring two to three times pretreatment doses of calcitriol and calcium to maintain blood calcium levels. Doses were gradually reduced over many weeks until calcium levels were stable on doses similar to baseline. Bone specific alkaline phosphatase (BSAP), N telopeptide (NTX), and osteocalcin (OC) increased significantly with hPTH 1 34; at follow up, BSAP and NTX had returned to baseline while OC was still slightly elevated. During treatment, BMD was unchanged at the hip and lateral spine but declined at the anterior posterior (AP) spine, radius, and total body. During weaning, BMD increased, with the hip and lateral spine exceeding pre hPTH 1 34 values and the whole body returning to baseline. AP spine was increased non significantly compared to baseline at follow up. hPTH 1 34 must be gradually weaned in hypoparathyroid patients with high doses of oral medications given to avoid hypocalcemia. The transient increased requirements accompanied by increased BMD after long term hPTH 1 34 therapy suggest a reversal of the expanded remodeling space favoring bone formation as the skeleton returns to a low turnover state, reminiscent of the hungry bone syndrome. Further study and close monitoring is required to ensure safe transition to conventional therapy and to elucidate the physiological mechanism of this phenomenon. (c) 2015 American Society for Bone and Mineral Research.
C1 [Gafni, Rachel I.; Guthrie, Lori C.; Kelly, Marilyn H.; Brillante, Beth A.; Collins, Michael T.] Natl Inst Dent & Craniofacial Res, Skeletal Clin Studies Unit, Craniofacial & Skeletal Dis Branch, NIH, Bethesda, MD 20892 USA.
   [Christie, C. Michele] Kaiser Permanente, Dept Pediat, Springfield, VA USA.
   [Reynolds, James C.] NIH, Ctr Clin, Dept Nucl Med, Bethesda, MD 20892 USA.
   [Yovetich, Nancy A.; James, Robert] Rho Inc, Chapel Hill, NC USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Dental & Craniofacial Research (NIDCR); Kaiser Permanente; National
   Institutes of Health (NIH)   USA; NIH Clinical Center (CC); Rho
RP Gafni, RI (通讯作者)，NIDCR, NIH, Bldg 30,Room 228,30 Convent Dr MSC 4320, Bethesda, MD 20892 USA.
EM gafnir@mail.nih.gov
OI Gafni, Rachel/0000 0002 7970 3491
FU DIR, NIDCR, a part of the Intramural Research Program of the NIH, DHHS
FX This research was supported, in part, by the DIR, NIDCR, a part of the
   Intramural Research Program of the NIH, DHHS.
CR ABUGASSA S, 1993, J CLIN ENDOCR METAB, V76, P1617, DOI 10.1210/jc.76.6.1617
   BRASIER AR, 1988, AM J MED, V84, P654, DOI 10.1016/0002 9343(88)90100 3
   Chen QX, 2003, J CLIN ENDOCR METAB, V88, P4655, DOI 10.1210/jc.2003 030470
   Gafni RI, 2012, J BONE MINER RES, V27, P1811, DOI 10.1002/jbmr.1627
   HEATH DA, 1979, BMJ BRIT MED J, V1, P450, DOI 10.1136/bmj.1.6161.450
   Jilka RL, 2009, BONE, V44, P275, DOI 10.1016/j.bone.2008.10.037
   Kalkwarf HJ, 2007, J CLIN ENDOCR METAB, V92, P2087, DOI 10.1210/jc.2006 2553
   KRUSE K, 1989, EUR J PEDIATR, V148, P535, DOI 10.1007/BF00441552
   Langdahl BL, 1996, BONE, V18, P103, DOI 10.1016/8756 3282(95)00443 2
   Leder BZ, 2009, J CLIN ENDOCR METAB, V94, P2915, DOI 10.1210/jc.2008 2630
   Lee IT, 2006, J BONE MINER METAB, V24, P255, DOI 10.1007/s00774 005 0680 x
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Misof BM, 2003, J CLIN ENDOCR METAB, V88, P1150, DOI 10.1210/jc.2002 021988
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Mosekilde L, 2008, CLIN ENDOCRINOL, V69, P1, DOI 10.1111/j.1365 2265.2007.03162.x
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Ogita M, 2008, ENDOCRINOLOGY, V149, P5713, DOI 10.1210/en.2008 0369
   Roschger P, 2007, J BONE MINER RES, V22, P717, DOI 10.1359/JBMR.070120
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Rubin MR, 2008, J BONE MINER RES, V23, pS128
   Rubin MR, 2008, J BONE MINER RES, V23, pS12
   Rubin MR, 2010, BONE, V46, P190, DOI 10.1016/j.bone.2009.09.020
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   SHUKLA S, 1990, J AM GERIATR SOC, V38, P884, DOI 10.1111/j.1532 5415.1990.tb05704.x
   Sikjaer T, 2012, J BONE MINER RES, V27, P781, DOI 10.1002/jbmr.1493
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   SPIEGEL AM, 1981, CLIN ENDOCRINOL, V15, P65, DOI 10.1111/j.1365 2265.1981.tb02749.x
   Theman TA, 2009, J BONE MINER RES, V24, P964, DOI 10.1359/JBMR.081233
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
   Witteveen JE, 2013, EUR J ENDOCRINOL, V168, pR45, DOI 10.1530/EJE 12 0528
   Yu B, 2012, J BONE MINER RES, V27, P2001, DOI 10.1002/jbmr.1663
NR 33
TC 24
Z9 24
U1 3
U2 6
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2015
VL 30
IS 11
BP 2112
EP 2118
DI 10.1002/jbmr.2555
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CU1MV
UT WOS:000363286900018
PM 25990370
OA Bronze
DA 2025 08 17
ER

PT J
AU Danks, L
   Komatsu, N
   Guerrini, MM
   Sawa, S
   Armaka, M
   Kollias, G
   Nakashima, T
   Takayanagi, H
AF Danks, Lynett
   Komatsu, Noriko
   Guerrini, Matteo M.
   Sawa, Shinichiro
   Armaka, Marietta
   Kollias, George
   Nakashima, Tomoki
   Takayanagi, Hiroshi
TI RANKL expressed on synovial fibroblasts is primarily responsible for
   bone erosions during joint inflammation
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION FACTOR; COLLAGEN INDUCED ARTHRITIS;
   DENDRITIC CELL FUNCTION; FACTOR FAMILY MEMBER; FORMATION IN VITRO;
   RECEPTOR ACTIVATOR; T CELLS; OSTEOPROTEGERIN LIGAND;
   RHEUMATOID ARTHRITIS; EPITHELIAL CELLS
AB Objective RANKL is mainly expressed by synovial fibroblasts and T cells within the joints of rheumatoid arthritis patients. The relative importance of RANKL expression by these cell types for the formation of bone erosions is unclear. We therefore aimed to quantify the contribution of RANKL by each cell type to osteoclast differentiation and bone destruction during inflammatory arthritis.
   Methods RANKL was specifically deleted in T cells (Tnfsf11(flox/Delta)Lck Cre), in collagen VI expressing cells including synovial fibroblasts (Tnfsf(11flox/Delta) Col6a1 Cre) and in collagen II expressing cells including articular chondrocytes (Tnfsf(11flox/Delta)Col2a1 Cre). Erosive disease was induced using the collagen antibody induced arthritis (CAIA) and collagen induced arthritis (CIA) models. Osteoclasts and cartilage degradation were assessed by histology and bone erosions were assessed by micro CT.
   Results The inflammatory joint score during CAIA was equivalent in all mice regardless of cell targeted deletion of RANKL. Significant increases in osteoclast numbers and bone erosions were observed in both the Tnfsf(11flox/Delta) and the Tnfsf11(flox/Delta)Lck Cre groups during CAIA; however, the Tnfsf11(flox/Delta)Col6a1 Cre mice showed significant protection against osteoclast formation and bone erosions. Similar results on osteoclast formation and bone erosions were obtained in CIA mice. The deletion of RANKL on any cell type did not prevent articular cartilage loss in either model of arthritis used.
   Conclusions The expression of RANKL on synovial fibroblasts rather than T cells is predominantly responsible for the formation of osteoclasts and erosions during inflammatory arthritis. Synovial fibroblasts would be the best direct target in RANKL inhibition therapies.
C1 [Danks, Lynett; Komatsu, Noriko; Guerrini, Matteo M.; Sawa, Shinichiro; Takayanagi, Hiroshi] Univ Tokyo, Grad Sch Med, Dept Immunol, Tokyo 1130033, Japan.
   [Danks, Lynett; Komatsu, Noriko; Guerrini, Matteo M.; Sawa, Shinichiro; Takayanagi, Hiroshi] Univ Tokyo, Fac Med, Tokyo 1130033, Japan.
   [Danks, Lynett; Guerrini, Matteo M.; Sawa, Shinichiro; Takayanagi, Hiroshi] Japan Sci & Technol Agcy JST, Explorat Res Adv Technol ERATO Program, Takayanagi Osteonetwork Project, Tokyo, Japan.
   [Armaka, Marietta; Kollias, George] Biomed Sci Res Ctr Alexander Fleming, Inst Immunol, Vari, Greece.
   [Nakashima, Tomoki] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Tokyo, Japan.
   [Nakashima, Tomoki] Precursory Res Embryon Sci & Technol PRESTO, Japan Sci & Technol Agcy JST, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Japan Science & Technology
   Agency (JST); Alexander Fleming Biomedical Sciences Research Center;
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Japan Science & Technology Agency (JST)
RP Takayanagi, H (通讯作者)，Univ Tokyo, Dept Immunol, Grad Sch Med, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.; Takayanagi, H (通讯作者)，Univ Tokyo, Fac Med, Bunkyo Ku, Hongo 7 3 1, Tokyo 1130033, Japan.
EM takayana@m.u tokyo.ac.jp
RI Armaka, Marietta (Maria)/Q 6139 2017; Kollias, George/A 7079 2012;
   Armaka, Marietta/Q 6139 2017
OI Kollias, George/0000 0003 1867 3150; Armaka,
   Marietta/0000 0003 0985 9076
FU JST; Japan Society for the Promotion of Science (JSPS) [25670636]; JSPS
   [15H05703, 2200131, 2301114, 224341, 26713015]; IMI [115142 2]; GSRT
   national project INNATE FIBROBLAST [ERC06]; ESF; NSRF; ERDF;
   Grants in Aid for Scientific Research [15H05703, 15K15149, 15F15414,
   26713015, 25670636] Funding Source: KAKEN
FX This work was funded in part by a grant for the ERATO Takayanagi
   Osteonetwork Project from JST; a Grant in Aid for Challenging
   Exploratory Research from the Japan Society for the Promotion of Science
   (JSPS) (25670636); a Grant in Aid for Specially Promoted Research from
   the JSPS (15H05703). MMG and LD were supported in part by JSPS
   Postdoctoral Fellowships for Overseas Researchers (2200131 and 2301114
   respectively). NK was supported in part by JSPS Research Fellowships for
   Young Scientists (224341) and a Grant in Aid for JSPS Fellows and a
   Grant in Aid for Young Scientists A from the JSPS (26713015). GK and MA
   were supported in part by IMI funded project BeTheCure (115142 2) and
   GSRT national project INNATE FIBROBLAST (ERC06, co financed by ESF and
   NSRF 2007 2013). The authors thank the Infrafrontier GR infrastructure
   (co financed by ERDF) for animal housing.
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Armaka M, 2008, J EXP MED, V205, P331, DOI 10.1084/jem.20070906
   Bachmann MF, 1999, J EXP MED, V189, P1025, DOI 10.1084/jem.189.7.1025
   Banda NK, 2006, J IMMUNOL, V177, P1904, DOI 10.4049/jimmunol.177.3.1904
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Chabaud M, 1999, ARTHRITIS RHEUM US, V42, P963, DOI 10.1002/1529 0131(199905)42:5<963::AID ANR15>3.0.CO;2 E
   Cremer I, 2002, BLOOD, V100, P3646, DOI 10.1182/blood 2002 01 0312
   Desanti GE, 2012, J IMMUNOL, V189, P5519, DOI 10.4049/jimmunol.1201815
   Firestein GS, 2002, ARTHRITIS RHEUM, V46, P298, DOI 10.1002/art.502
   Fumoto T, 2014, J BONE MINER RES, V29, P830, DOI 10.1002/jbmr.2096
   Gravallese EM, 2000, ARTHRITIS RHEUM, V43, P250, DOI 10.1002/1529 0131(200002)43:2<250::AID ANR3>3.0.CO;2 P
   Hikosaka Y, 2008, IMMUNITY, V29, P438, DOI 10.1016/j.immuni.2008.06.018
   Horwood NJ, 1999, BIOCHEM BIOPH RES CO, V265, P144, DOI 10.1006/bbrc.1999.1623
   Josien R, 2000, J EXP MED, V191, P495, DOI 10.1084/jem.191.3.495
   Josien R, 1999, J IMMUNOL, V162, P2562
   Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098
   Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014 5793(00)01338 7
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Komatsu N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00077
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518
   Lubberts E, 2003, J IMMUNOL, V170, P2655, DOI 10.4049/jimmunol.170.5.2655
   Martínez Calatrava MJ, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3884
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nandakumar KS, 2004, ARTHRITIS RES THER, V6, pR544, DOI 10.1186/ar1217
   Nandakumar Kutty Selva, 2007, V136, P215
   Onal M, 2012, J BIOL CHEM, V287, P29851, DOI 10.1074/jbc.M112.377945
   Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526 968X(200002)26:2<145::AID GENE14>3.3.CO;2 3
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Roberts NA, 2012, IMMUNITY, V36, P427, DOI 10.1016/j.immuni.2012.01.016
   Rossi SW, 2007, J EXP MED, V204, P1267, DOI 10.1084/jem.20062497
   Sato K, 2006, J EXP MED, V203, P2673, DOI 10.1084/jem.20061775
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Stolina M, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2879
   Takayanagi H, 2000, ARTHRITIS RHEUM US, V43, P259, DOI 10.1002/1529 0131(200002)43:2<259::AID ANR4>3.0.CO;2 W
   Williamson E, 2002, J IMMUNOL, V169, P3606, DOI 10.4049/jimmunol.169.7.3606
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 42
TC 183
Z9 202
U1 2
U2 30
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003 4967
EI 1468 2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2016
VL 75
IS 6
BP 1187
EP 1195
DI 10.1136/annrheumdis 2014 207137
PG 9
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA DM6DP
UT WOS:000376440900039
PM 26025971
DA 2025 08 17
ER

PT J
AU Bernardor, J
   Flammier, S
   Ranchin, B
   Gaillard, S
   Platel, D
   Peyruchaud, O
   Machuca Gayet, I
   Bacchetta, J
AF Bernardor, Julie
   Flammier, Sacha
   Ranchin, Bruno
   Gaillard, Segolene
   Platel, Diane
   Peyruchaud, Olivier
   Machuca Gayet, Irma
   Bacchetta, Justine
TI Inhibition of Osteoclast Differentiation by 1.25 Dand the
   CalcimimeticKP2326Reveals 1.25 DResistance in AdvancedCKD
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE CHRONIC KIDNEY DISEASE; SECONDARY HYPERPARATHYROIDISM; OSTEOCLAST;
   ETELCALCETIDE; VITAMIN D
ID CALCIUM SENSING RECEPTOR; CHRONIC KIDNEY DISEASE; VITAMIN D; AMG 416;
   SECONDARY HYPERPARATHYROIDISM; PEPTIDE AGONIST; BONE METABOLISM;
   ACTIVATION; ETELCALCETIDE; CHILDREN
AB Active vitamin D analogs and calcimimetics are the main therapies used for treating secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD). Peripheral blood mononuclear cells of 19 pediatric patients with CKD1 5D and 6 healthy donors (HD) were differentiated into mature osteoclasts with receptor activator of NF kappa B ligand (RANKL) and macrophage colony stimulating factor (M CSF). The effects of single or combined treatment with active vitamin D (1.25 D) and/or calcimimetic KP2326 were evaluated on osteoclastic differentiation and osteoclastic mediated bone resorption. Although 1.25 D inhibited osteoclastic differentiation, a significant resistance to 1.25 D was observed when glomerular filtration rate decreased. A significant albeit less important inhibitory effect of KP2326 on osteoclastic differentiation was also found both in cells derived from HD and CKD patients, through a putative activation of the Erk pathway. This inhibitory effect was not modified by CKD stage. Combinatorial treatment with 1.25 D and KP2326 did not result in synergistic effects. Last, KP2326 significantly inhibited osteoclast mediated bone resorption. Both 1.25 D and KP2326 inhibit osteoclastic differentiation, however, to a different extent. There is a progressive resistance to 1.25 D in advanced CKD that is not found with KP2326. KP2326 also inhibits bone resorption. Given that 1.25 D has no effect on osteoclastic resorption activity and that calcimimetics also have direct anabolic effects on osteoblasts, there is an experimental rationale that could favor the use of decreased doses of 1.25 D with low doses of calcimimetics in SHPT in dialysis to improve the underlying osteodystrophy. However, this last point deserves confirmatory clinical studies. (c) 2020 American Society for Bone and Mineral Research.
C1 [Bernardor, Julie; Flammier, Sacha; Platel, Diane; Peyruchaud, Olivier; Machuca Gayet, Irma; Bacchetta, Justine] Univ Claude Bernard Lyon 1, INSERM, UMR 1033, Fac Med Lyon Est, Lyon, France.
   [Bernardor, Julie; Flammier, Sacha; Ranchin, Bruno; Bacchetta, Justine] Hosp Civils Lyon, Hop Femme Mere Enfant, Ctr Reference Malad Renales Rares, Bron, France.
   [Bernardor, Julie] Univ Nice Sophia Antipolis, Fac Med, Nice, France.
   [Gaillard, Segolene] Hosp Civils Lyon, INSERM CIC 1407, CNRS UMR 5558, Bron, France.
   [Gaillard, Segolene] Hosp Civils Lyon, Serv Pharmacotoxicol Clin, Bron, France.
   [Bacchetta, Justine] Hosp Civils Lyon, Ctr Reference Malad Rares Calcium & Phosphate, Hop Femme Mere Enfant, Bron, France.
   [Bacchetta, Justine] Univ Claude Bernard Lyon 1, Fac Med Lyon Est, Lyon, France.
C3 Universite Claude Bernard Lyon 1; Institut National de la Sante et de la
   Recherche Medicale (Inserm); CHU Lyon; Universite Cote d'Azur; Centre
   National de la Recherche Scientifique (CNRS); CNRS   Institute of
   Ecology & Environment (INEE); Institut National de la Sante et de la
   Recherche Medicale (Inserm); CHU Lyon; CHU Lyon; CHU Lyon; Universite
   Claude Bernard Lyon 1
RP Bacchetta, J (通讯作者)，Hop Femme Mere Enfant, 59 Blvd Pinel, F 69677 Bron, France.
EM justine.bacchetta@chu lyon.fr
RI ; Gaillard, Segolene/GXV 6498 2022; Bacchetta, Justine/B 3842 2016;
   Bernardor, Julie/HTR 2345 2023
OI Peyruchaud, Olivier/0000 0002 5393 4945; Bernardor,
   Julie/0000 0002 1356 1507; 
FU Amgen; INSERM; Universite Claude Bernard Lyon 1; ANR grant LYSBONE
   [ANR 15 CE14 0010 01]; personal grant "Annee Recherche Universite de
   Nice Sophia Antipolis"; Agence Nationale de la Recherche (ANR)
   [ANR 15 CE14 0010] Funding Source: Agence Nationale de la Recherche
   (ANR)
FX The study was sponsored by a research grant from Amgen, but Amgen was
   not involved in either the design and conduct of the study or in data
   analysis. KP2326 was provided by Amgen. SF, OP, and IM received fundings
   from the INSERM, Universite Claude Bernard Lyon 1, and the ANR grant
   LYSBONE (grant no. ANR 15 CE14 0010 01). J Bernardor received a personal
   grant "Annee Recherche Universite de Nice Sophia Antipolis" for her MSc
   project.
CR Alexander ST, 2015, MOL PHARMACOL, V88, P853, DOI 10.1124/mol.115.098392
   Allard L, 2015, CALCIFIED TISSUE INT, V97, P69, DOI 10.1007/s00223 015 0013 6
   [Anonymous], 2020, NEPHROL DIAL TRANSPL, DOI DOI 10.1093/NDT/GFZ159
   Aref MW, 2019, OSTEOPOROSIS INT, V30, P1693, DOI 10.1007/s00198 019 04974 z
   Bacchetta J, 2020, METABOLISM, V103, DOI 10.1016/j.metabol.2019.01.006
   Bacchetta J, 2012, NEPHROL DIAL TRANSPL, V27, P3063, DOI 10.1093/ndt/gfs299
   Chen P, 2018, CLIN PHARMACOKINET, V57, P71, DOI 10.1007/s40262 017 0550 4
   Cianferotti L, 2015, OSTEOPOROSIS INT, V26, P2055, DOI 10.1007/s00198 015 3203 1
   Claramunt Taberner D, 2018, NEPHROL DIAL TRANSPL, V33, P1525, DOI 10.1093/ndt/gfx362
   Díaz Tocados JM, 2019, KIDNEY INT, V95, P1064, DOI 10.1016/j.kint.2018.12.015
   Diepenhorst NA, 2018, BRIT J PHARMACOL, V175, P4095, DOI 10.1111/bph.14344
   Dvorak MM, 2007, ENDOCRINOLOGY, V148, P3156, DOI 10.1210/en.2007 0147
   Fielden MR, 2016, INT J TOXICOL, V35, P294, DOI 10.1177/1091581816633407
   Fromigué O, 2009, J CELL MOL MED, V13, P2189, DOI 10.1111/j.1582 4934.2009.00673.x
   Gerbino A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19040999
   Godwin SL, 2002, BONE, V30, P559, DOI 10.1016/S8756 3282(01)00700 1
   Goltzman D, 2015, NAT REV ENDOCRINOL, V11, P298, DOI 10.1038/nrendo.2015.30
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   Ketteler M, 2017, KIDNEY INT, V92, P26, DOI 10.1016/j.kint.2017.04.006
   Khairallah P, 2018, CLIN J AM SOC NEPHRO, V13, P962, DOI 10.2215/CJN.11031017
   Klaus G, 2006, PEDIATR NEPHROL, V21, P151, DOI 10.1007/s00467 005 2082 7
   Ko YA, 2013, GENOME BIOL, V14, DOI 10.1186/gb 2013 14 10 r108
   Leach K, 2017, PHARMACOL RES, V116, P105, DOI 10.1016/j.phrs.2016.12.006
   Li XD, 2017, BONE, V105, P163, DOI 10.1016/j.bone.2017.08.026
   Lutter AH, 2016, PROSTAG LEUKOTR ESS, V111, P1, DOI 10.1016/j.plefa.2016.03.017
   Mentaverri R, 2006, FASEB J, V20, P2562, DOI 10.1096/fj.06 6304fje
   Moe SM, 2008, CLIN J AM SOC NEPHRO, V3, pS127, DOI 10.2215/CJN.04331206
   Nemeth EF, 2016, CALCIFIED TISSUE INT, V98, P341, DOI 10.1007/s00223 015 0052 z
   Nguyen Yamamoto L, 2010, J AM SOC NEPHROL, V21, P1713, DOI 10.1681/ASN.2009050531
   Pereira RC, 2015, C AM SOC NEPHR DG SC
   Shroff R, 2017, NEPHROL DIAL TRANSPL, V32, P1114, DOI 10.1093/ndt/gfx080
   Walter S, 2013, J PHARMACOL EXP THER, V346, P229, DOI 10.1124/jpet.113.204834
   Wesseling Perry K, 2011, KIDNEY INT, V79, P112, DOI 10.1038/ki.2010.352
NR 33
TC 9
Z9 9
U1 1
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2020
VL 35
IS 11
BP 2265
EP 2274
DI 10.1002/jbmr.4122
EA AUG 2020
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OP6IX
UT WOS:000563894200001
PM 32598518
OA Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Stan, IAA
   Petrovan, C
   Cerghizan, D
   Albu, DE
   Craciun, AE
   Copotoiu, C
AF Stan, Ioana Aurita Albu
   Petrovan, Cecilia
   Cerghizan, Diana
   Albu, Daniel Emil
   Craciun, Adriana Elena
   Copotoiu, Constantin
TI Chemical Features of Bisphosphonates and Histopathological Outcomes in
   Rat Jaw Treated with Zoledronic Acid Combined with Dexamethasone
SO REVISTA DE CHIMIE
LA English
DT Article
DE bisphosphonates; dexamethasone; osteonecrosis; jaw; zoledronic acid
ID SURGEONS POSITION PAPER; AMERICAN ASSOCIATION; BONE RESORPTION;
   CANCER PATIENTS; RISK FACTORS; OSTEONECROSIS; MECHANISMS; EXTRACTION;
   BINDING; UPDATE
AB Bisphosphonate related osteonecrosis of the jaws (BRONJ) is a pathological entity described for the first time in 2003; three criteria are mandatory: no radiotion therapy, exposed bone in oral cavities for at least eight weeks with no signs of healing, bisphosphonate therapy in present or in the past, in patients with bisphosphonate therapy in present or in the past. Bisphosphonates (BPs) are stable analogues of natural inorganic pyrophosphate, which inhibit bone resorption. In literature, most patients diagnosed with BRONJ were suffering from multiple myeloma and they had a treatment with nitrogen containing BPs and steroids such as dexamethasone intravenously. With this study we have aimed to achieve a rat model of BRONJ and to evaluate histopathological findings how concurrent use of BPs and steroids can affect emergence of BRONJ in this study.
C1 [Stan, Ioana Aurita Albu; Cerghizan, Diana; Craciun, Adriana Elena] Univ Med & Pharm, Dept Fixed Prosthodont, 38 Gheorghe Marinescu Str, Targu Mures 540139, Romania.
   [Petrovan, Cecilia] Univ Med & Pharm, Dept Oral & Maxillofacial Surg, 38 Gheorghe Marinescu Str, Targu Mures 540139, Romania.
   [Albu, Daniel Emil] County Emergency Clin Hosp, Dept Orthoped Surg & Traumatol 1, 50 Gheorghe Marinescu Str, Targu Mures 540136, Romania.
   [Copotoiu, Constantin] Cty Emergency Clin Hosp, Dept Surg Clin 1, 50 Gheorghe Marinescu Str, Targu Mures 540136, Romania.
C3 George Emil Palade University of Medicine, Pharmacy, Science, &
   Technology of Targu Mures; George Emil Palade University of Medicine,
   Pharmacy, Science, & Technology of Targu Mures
RP Petrovan, C (通讯作者)，Univ Med & Pharm, Dept Oral & Maxillofacial Surg, 38 Gheorghe Marinescu Str, Targu Mures 540139, Romania.
EM ceci.petrovan@yahoo.com
RI Cerghizan, Diana/P 5912 2019
OI Cerghizan, Diana/0000 0002 7396 4877
CR Antohe ME, 2017, ROM J ORAL REHABIL, V9, P94
   Benedict J J., 1982, Symposium CEMO (Centre dEtude des Maladies Osteoarticulaires de Geneve) IV. Diphosphonates and bone, P1
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Buhaceanu R, 2013, REV CHIM BUCHAREST, V64, P803
   Buhaceanu R, 2013, REV CHIM BUCHAREST, V64, P960
   Carmen BA, 2014, KEY ENG MATER, V587, P303, DOI 10.4028/www.scientific.net/KEM.587.303
   COSTAN A., 2011, OPTOELECTRONICS ADV, V5, P92
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Earar K, 2015, MATER PLAST, V52, P487
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Ebetino FH, 1998, REV CONTEMP PHARMACO, V9, P233
   Ebetino FH., 1995, Bisphosphonate on Bones, P139
   Ebrahimpour Arman, 1995, P125
   GRAHAM R., 2007, PEDIATRICS, V119, P150
   Graziani F, 2006, INT J ORAL MAX SURG, V35, P241, DOI 10.1016/j.ijom.2005.07.010
   Green JR, 2002, DRUG DEVELOP RES, V55, P210, DOI 10.1002/ddr.10071
   Istrate B, 2016, ENVIRON ENG MANAG J, V15, P955
   JOHANSEN JR, 1970, ACTA ODONTOL SCAND, V28, P441, DOI 10.3109/00016357009028237
   Jumanca D, 2014, REV CHIM BUCHAREST, V65, P1473
   Klingenstein G, 2005, ALIMENT PHARM THER, V21, P243, DOI 10.1111/j.1365 2036.2005.02231.x
   Kozloff KM, 2010, J BONE MINER RES, V25, P1748, DOI 10.1002/jbmr.66
   Kyrgidis A, 2008, J CLIN ONCOL, V26, P4634, DOI 10.1200/JCO.2008.16.2768
   Landesberg R, 2011, ANN NY ACAD SCI, V1218, P62, DOI 10.1111/j.1749 6632.2010.05835.x
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   PIETROKOVSKI J, 1967, J DENT RES, V46, P222, DOI 10.1177/00220345670460011501
   Popescu E, 2017, MATER PLAST, V54, P390
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Reid IR, 2011, J BONE MINER RES, V26, P2261, DOI 10.1002/jbmr.438
   ROBERT S., 2012, ENDOCRINE, V41, P183
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Sambrook Philip, 2006, Aust Fam Physician, V35, P801
   Sonis ST, 2009, ORAL ONCOL, V45, P164, DOI 10.1016/j.oraloncology.2008.04.013
   Stoian A, 2016, REV CHIM BUCHAREST, V67, P2355
   vanBeek E, 1996, J BONE MINER RES, V11, P1492
   ZHANG P., 1930, PHARM RES, V30, P1525
NR 41
TC 1
Z9 1
U1 0
U2 4
PU CHIMINFORM DATA S A
PI BUCHAREST
PA CALEA PLEVNEI NR 139, SECTOR 6, BUCHAREST R 77131, ROMANIA
SN 0034 7752
J9 REV CHIM BUCHAREST
JI Rev. Chim.
PD JUL
PY 2018
VL 69
IS 7
BP 1802
EP 1807
PG 6
WC Chemistry, Multidisciplinary; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering
GA GT6BP
UT WOS:000444595700041
DA 2025 08 17
ER

PT J
AU Li, R
   Huang, C
   Ho, JCH
   Leung, CCT
   Kong, RYC
   Li, Y
   Liang, X
   Lai, KP
   Tse, WKF
AF Li, Rong
   Huang, Chen
   Ho, Jeff Cheuk Hin
   Leung, Cherry Chi Tim
   Kong, Richard Yuen Chong
   Li, Yu
   Liang, Xiao
   Lai, Keng Po
   Tse, William Ka Fai
TI The use of glutathione to reduce oxidative stress status and its
   potential for modifying the extracellular matrix organization in cleft
   lip
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Antioxidant; Craniofacial development; Redox
ID OSTEOBLAST DIFFERENTIATION; METALLOPROTEINASES; ACTIVATION; INDUCTION;
   ERK
AB Objective: Cleft lip (CL) is a common congenital anomaly that can be syndromic or non syndromic. It can be triggered by the mutation of gene or environmental factors. The incidence of CL is about 1 out of 700 live births. Facial development is a complex process, and there is no existing therapy to prevent the disease development. One of the characteristics in this facial malformation is the increased presence of reactive oxygen species (ROS). In this study, we hypothesize that the antioxidant glutathione (GSH) could help to attenuate the oxidative stress in this disease.
   Methods: Bioinformatics network pharmacology was applied to determine pharmacological targets and molecular mechanisms of GSH treatment for CL. Moreover, RNA sequencing of the POLR1C knockdown osteoblast CL model was applied to validate the in silico data of using GSH in CL.
   Results: Twenty two core targets of GSH and CL were identified via various bioinformatics tools. The GO and KEGG analysis indicated that GSH could modulate two major families (matrix metalloproteinase and integrins), which are related to extracellular matrix modification and composition for facial development in CL. The findings from POLR1C knockdown model further supported the rescue response of GSH in CL.
   Conclusions: The study uncovered the possible pharmacological mechanism of GSH for treating CL. The data helps research group to focus on the specific pathways for understanding the biological action of GSH for treating the CL in the future.
C1 [Li, Rong; Li, Yu; Liang, Xiao; Lai, Keng Po] Guilin Med Univ, Lab Environm Pollut & Integrat Om, Huan Cheng North 2nd Rd 109, Guilin 541004, Peoples R China.
   [Li, Rong; Li, Yu; Liang, Xiao; Lai, Keng Po] Guilin Med Univ, Guangxi Key Lab Tumor Immunol & Microenvironm Reg, Guilin, Peoples R China.
   [Huang, Chen] Qingdao Univ, Business Sch, Ctr Data Sci Hlth & Med, Qingdao, Shandong, Peoples R China.
   [Ho, Jeff Cheuk Hin; Leung, Cherry Chi Tim; Kong, Richard Yuen Chong; Lai, Keng Po] City Univ Hong Kong, Dept Chem, Hong Kong, Peoples R China.
   [Tse, William Ka Fai] Kyushu Univ, Ctr Promot Int Educ & Res, Fac Agr, Fukuoka, Japan.
C3 Guilin Medical University; Guilin Medical University; Qingdao
   University; City University of Hong Kong; Kyushu University
RP Lai, KP (通讯作者)，Guilin Med Univ, Lab Environm Pollut & Integrat Om, Huan Cheng North 2nd Rd 109, Guilin 541004, Peoples R China.; Tse, WKF (通讯作者)，Kyushu Univ, Ctr Promot Int Educ & Res, Fac Agr, Fukuoka, Japan.
EM kengplai@cityu.edu.hk; kftse@agr.kyushu u.ac.jp
RI TSE, KA FAI WILLIAM/C 9384 2012; Lai, Keng/F 2045 2013
OI TSE, KA FAI WILLIAM/0000 0002 3738 0460; LAI, Keng
   Po/0000 0001 8135 6030
FU National Natural Science Foundation of China [81560134]; National
   Natural Science Foundation of Guangxi [2019GXNSFBA185015]; Japan Society
   for the Promotion of Science [AJ179064]; Institute for Molecular and
   Cellular Regulation, Gunma University, Japan [18003]; National Institute
   of Basic Biology Collaborative Research Program, Japan [19 307]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81560134) and the National Natural Science Foundation of
   Guangxi (No. 2019GXNSFBA185015). The pathology works in WKF Tse
   Laboratory were partially supported by the Japan Society for the
   Promotion of Science Bilateral Open Partnership Joint Research Project
   AJ179064; the joint research program of the Institute for Molecular and
   Cellular Regulation, Gunma University, Japan (18003); and the National
   Institute of Basic Biology Collaborative Research Program, Japan
   (19 307).
CR Ahmad N, 2012, MOL CELL ENDOCRINOL, V363, P46, DOI 10.1016/j.mce.2012.07.006
   Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564
   Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]
   Ball C, 2008, THROMB HAEMOSTASIS, V100, P857, DOI 10.1160/TH08 02 0095
   Barczyk M, 2010, CELL TISSUE RES, V339, P269, DOI 10.1007/s00441 009 0834 6
   Bogani P, 2007, BIOCHEM BIOPH RES CO, V363, P651, DOI 10.1016/j.bbrc.2007.09.018
   Brown NL, 2002, J DENT RES, V81, P826, DOI 10.1177/154405910208101206
   Clouthier DE, 2000, DEV BIOL, V217, P10, DOI 10.1006/dbio.1999.9527
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Eble JA, 2014, ANTIOXID REDOX SIGN, V20, P1977, DOI 10.1089/ars.2013.5294
   Gordon CT, 2013, AM J HUM GENET, V93, P1118, DOI 10.1016/j.ajhg.2013.10.023
   Hansen JM, 2015, BBA GEN SUBJECTS, V1850, P1527, DOI 10.1016/j.bbagen.2014.12.001
   Horejs CM, 2016, EUR J CELL BIOL, V95, P427, DOI 10.1016/j.ejcb.2016.06.002
   Hozyasz Kamil K, 2005, Przegl Lek, V62, P1019
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092 8674(02)00971 6
   Jankowski R, 2016, SURG RADIOL ANAT, V38, P1161, DOI 10.1007/s00276 016 1677 y
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Jiang RL, 2006, DEV DYNAM, V235, P1152, DOI 10.1002/dvdy.20646
   Kantar RS, 2019, PLAST RECONSTR SURG, V143, P1165, DOI 10.1097/PRS.0000000000005416
   Kapila S, 2009, ANN NY ACAD SCI, V1160, P322, DOI 10.1111/j.1749 6632.2009.03830.x
   Kar S, 2010, RESP PHYSIOL NEUROBI, V174, P299, DOI 10.1016/j.resp.2010.08.019
   Kelly D, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X652328
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Lammer EJ, 2005, EPIDEMIOLOGY, V16, P698, DOI 10.1097/01.ede.0000172136.26733.4b
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Löffek S, 2011, EUR RESPIR J, V38, P191, DOI 10.1183/09031936.00146510
   Massenburg BB, 2016, J CRANIOFAC SURG, V27, P1741, DOI 10.1097/SCS.0000000000003038
   MUSHAYANDEBVU TI, 1995, BIOL REPROD, V53, P1030, DOI 10.1095/biolreprod53.5.1030
   Orbe J, 2003, ATHEROSCLEROSIS, V167, P45, DOI 10.1016/S0021 9150(02)00392 1
   Piñero J, 2020, NUCLEIC ACIDS RES, V48, pD845, DOI 10.1093/nar/gkz1021
   Rutkovskiy A, 2016, MED SCI MONIT BASIC, V22, P95, DOI 10.12659/MSMBR.901142
   Sakai D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10328
   Sandell LL, 2006, ADV EXP MED BIOL, V589, P78
   Sanderson RD, 2019, MATRIX BIOL, V75 76, P160, DOI 10.1016/j.matbio.2017.10.007
   Schilling Thomas F, 2009, J Biol, V8, P101, DOI 10.1186/jbiol205
   Paiva KBS, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00340
   Song XY, 2013, CYTOKINE, V62, P175, DOI 10.1016/j.cyto.2013.03.014
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun HL, 2013, STEM CELLS, V31, P2183, DOI 10.1002/stem.1455
   Szabo Rogers HL, 2010, DEV BIOL, V341, P84, DOI 10.1016/j.ydbio.2009.11.021
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Thompson J, 2019, DEV DYNAM, V248, P221, DOI 10.1002/dvdy.13
   Trainor P.A., 2016, FACE ROS TCOF1TREACL
   Twigg SRF, 2015, HUM MOL GENET, V24, pR50, DOI 10.1093/hmg/ddv228
   Viccica G, 2010, J Endocrinol Invest, V33, P9
   Wang TT, 2018, CYTOKINE GROWTH F R, V44, P38, DOI 10.1016/j.cytogfr.2018.10.002
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Yu GC, 2016, MOL BIOSYST, V12, P477, DOI 10.1039/c5mb00663e
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang HQ, 2012, SEMIN CELL DEV BIOL, V23, P722, DOI 10.1016/j.semcdb.2012.03.017
   Zhao XY, 2020, J MOL CELL BIOL, V12, P55, DOI 10.1093/jmcb/mjz028
NR 51
TC 29
Z9 31
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891 5849
EI 1873 4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD FEB 20
PY 2021
VL 164
BP 130
EP 138
DI 10.1016/j.freeradbiomed.2020.12.455
EA JAN 2021
PG 9
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA QL8NZ
UT WOS:000621338900006
PM 33422675
DA 2025 08 17
ER

PT J
AU Chu, EYW
   Tsang, SWY
   Kung, AWC
AF Chu, Eva Yuet wah
   Tsang, Shirley Wan yin
   Kung, Annie Wai chee
TI Treatment options for postmenopausal osteoporosis in Asia
SO INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES
LA English
DT Article
DE bone mineral density; fracture; osteoporosis; postmenopausal; treatment
ID BONE MINERAL DENSITY; ESTROGEN PLUS PROGESTIN; SALMON CALCITONIN;
   FRACTURE RISK; WOMEN; RALOXIFENE; EFFICACY; METAANALYSIS; THERAPY;
   TOLERABILITY
AB Treatment of osteoporosis has advanced dramatically during the past decade, with more therapeutic options than ever now available. Large scale randomized placebo controlled trials have documented the efficacy of a number of agents in reducing vertebral and non vertebral fractures. Anti resorptive agents (hormone replacement therapy, selective estrogen   receptor modulators, calcitonin and bisphosphonates) and bone forming anabolic agents (parathyroid horomone and strontium ranelate) act via different mechanisms to reduce fractures and improve bone strength. In view of the high prevalence of calcium and vitamin D insufficiency in Asia, calcium and vitamin D supplementation remains a fundamental part of any treatment regimen, especially among the elderly. Given the high cost of these agents, a global assessment of the fracture risk of the patient is essential to determine the need for pharmacological treatment versus life style modification and dietary supplementation in the management of postmenopausal osteoporosis in Asia.
C1 [Chu, Eva Yuet wah; Tsang, Shirley Wan yin; Kung, Annie Wai chee] Univ Hong Kong, Dept Med, Kong Kong, Peoples R China.
C3 University of Hong Kong
RP Kung, AWC (通讯作者)，Univ Hong Kong, Dept Med, Queen Mary Hosp, 4 F Professorial Block, Pokfulam, Hong Kong, Peoples R China.
EM awckung@hkucc.hku.hk
RI Kung, Annie/C 4294 2009
CR Barrett Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462
   BISCHOFFFERRARI HA, 2004, JAMA J AM MED ASSOC, V294, P1999
   Black DM, 2007, NEW ENGL J MED, V356, P1809, DOI 10.1056/NEJMoa067312
   Brown JP, 2002, CALCIFIED TISSUE INT, V71, P103, DOI 10.1007/s00223 002 2011 8
   Cauley JA, 2003, JAMA J AM MED ASSOC, V290, P1729, DOI 10.1001/jama.290.13.1729
   Chen PQ, 2007, J BONE MINER RES, V22, P1173, DOI 10.1359/JBMR.070413
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Chesnut CH III, 2000, AM J MED, V109, P267, DOI 10.1016/S0002 9343(00)00490 3
   Cranney A, 2002, ENDOCR REV, V23, P508, DOI 10.1210/er.2001 2002
   Cranney A, 2002, ENDOCR REV, V23, P517, DOI 10.1210/er.2001 3002
   Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301
   Delmas PD, 2006, ARTHRITIS RHEUM US, V54, P1838, DOI 10.1002/art.21918
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Glazier MG, 2001, ARCH INTERN MED, V161, P1161, DOI 10.1001/archinte.161.9.1161
   Iwamoto Jun, 2003, J Orthop Sci, V8, P532, DOI 10.1007/s00776 003 0655 5
   Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281
   Kung AWC, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471 2458 6 226
   Kung AWC, 2003, J CLIN ENDOCR METAB, V88, P3130, DOI 10.1210/jc.2002 021855
   Kung AWC, 2000, CALCIFIED TISSUE INT, V67, P286, DOI 10.1007/s002230001142
   MCCLUNG MR, 2001, HIP INTERVENTION PRO, V344, P333
   Mei J, 2001, J CLIN ENDOCR METAB, V86, P5217, DOI 10.1210/jc.86.11.5217
   Meunier PJ, 2003, OSTEOPOROSIS INT, V14, pS66, DOI 10.1007/s00198 002 1341 8
   Miller PD, 2005, J BONE MINER RES, V20, P1315, DOI 10.1359/JBMR.050313
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   PUN KK, 1989, CLIN THER, V11, P205
   Rivera Woll LM, 2004, INTERN MED J, V34, P109, DOI 10.1111/j.1444 0903.2004.00555.x
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Sakuma M, 2007, J BONE MINER METAB, V25, P147, DOI 10.1007/s00774 007 0749 9
   Shea BJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004526.pub3
   Silverman SL, 2007, SOUTH MED J, V100, P1214, DOI 10.1097/SMJ.0b013e31815a9685
   van Alken WG, 2004, WHO TECH REP SER, V926, P1
   Verberckmoes SC, 2003, KIDNEY INT, V64, P534, DOI 10.1046/j.1523 1755.2003.00123.x
   Wells G, 2002, ENDOCR REV, V23, P529, DOI 10.1210/er.2001 5002
NR 34
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1756 1841
EI 1756 185X
J9 INT J RHEUM DIS
JI Int. J. Rheum. Dis.
PY 2008
VL 11
IS 4
BP 386
EP 392
DI 10.1111/j.1756 185X.2008.00389.x
PG 7
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 450HO
UT WOS:000266391800011
OA Bronze
DA 2025 08 17
ER

PT J
AU Banerjee, D
   Bose, S
AF Banerjee, D.
   Bose, S.
TI Comparative effects of controlled release of sodium bicarbonate and
   doxorubicin on osteoblast and osteosarcoma cell viability
SO MATERIALS TODAY CHEMISTRY
LA English
DT Article
DE HA Polymer composite; Anticancer drug; Sustained release; Local drug
   delivery; In vitro; Bone tissue engineering
ID NANO HYDROXYAPATITE COATINGS; METASTATIC BREAST CANCER; TUMOR PH; BONE;
   POLYCAPROLACTONE; DELIVERY; CHEMOTHERAPY; PACLITAXEL; BEHAVIOR; TRIAL
AB This study intends to analyze the effects of doxorubicin and sodium bicarbonate release with polycaprolactone (PCL) coating from a calcium phosphate system on the osteoblast and osteosarcoma cell viability and proliferation. Increased systematic pH concentrations locally by the release of sodium bicarbonate diminished acidosis and alleviated malignancy. In our study, we have shown that the same dosage of doxorubicin inhibited both osteoblast and osteosarcoma cell attachment and viability, whereas sodium bicarbonate abated osteosarcoma cell proliferation. Sodium bicarbonate also inhibited osteoblast cell proliferation in the early time points; however, the cell viability increased after the initial burst release of the molecule. Polymer coating on calcium phosphate based implants, as carriers of drug, can minimize chances of toxic effects of higher oral drug dosage in the body and also help in delivering effective doses of drugs, locally to the target tissues, compared with the oral drug delivery approach. A coating of PCL was, thus, incorporated to control the initial burst release of bicarbonate, which enhanced the osteoblast cell viability, and was capable of diminishing osteosarcoma cell proliferation. The novelty and clinical significance of this study lies in the understanding of unique delivery system using encapsulated naturally occurring and more benign sodium bicarbonate, for usage after excision of the cancerous bone, without any adverse effects on normal bone cells. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Banerjee, D.; Bose, S.] Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
C3 Washington State University
RP Bose, S (通讯作者)，Washington State Univ, Sch Mech & Mat Engn, WM Keck Biomed Mat Res Lab, Pullman, WA 99164 USA.
EM sbose@wsu.edu
FU National Institutes of Health [R01 AR066361]
FX The authors would like to acknowledge financial support from the
   National Institutes of Health under grant numbers R01 AR066361. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR Bandyopadhyay A, 2017, ANN BIOMED ENG, V45, P249, DOI 10.1007/s10439 016 1673 8
   Bigi A, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010006
   Bigi A, 2017, J APPL BIOMATER FUNC, V15, pE313, DOI 10.5301/jabfm.5000367
   Bose S, 2018, MAT SCI ENG C MATER, V88, P166, DOI 10.1016/j.msec.2018.02.019
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Gatenby R A, 2001, Novartis Found Symp, V240, P85
   Gillies RJ, 2002, J MAGN RESON IMAGING, V16, P430, DOI 10.1002/jmri.10181
   Glunde K, 2003, NEOPLASIA, V5, P533, DOI 10.1016/S1476 5586(03)80037 4
   GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326
   Hayashi K, 2009, CELL CYCLE, V8, P870, DOI 10.4161/cc.8.6.7891
   Jeong YI, 2010, COLLOID SURFACE B, V79, P149, DOI 10.1016/j.colsurfb.2010.03.037
   Kamba SA, 2013, MOLECULES, V18, P10580, DOI 10.3390/molecules180910580
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Katti KS, 2004, COLLOID SURFACE B, V39, P133, DOI 10.1016/j.colsurfb.2003.12.002
   MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214
   Paridaens R, 2000, J CLIN ONCOL, V18, P724, DOI 10.1200/JCO.2000.18.4.724
   PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59
   Robey IF, 2009, CANCER RES, V69, P2260, DOI 10.1158/0008 5472.CAN 07 5575
   Rofstad EK, 2006, CANCER RES, V66, P6699, DOI 10.1158/0008 5472.CAN 06 0983
   Roy M, 2011, J BIOMED MATER RES B, V99B, P258, DOI 10.1002/jbm.b.31893
   Roy M, 2011, SURF COAT TECH, V205, P2785, DOI 10.1016/j.surfcoat.2010.10.042
   Sledge GW, 2003, J CLIN ONCOL, V21, P588, DOI 10.1200/JCO.2003.08.013
   Tarafder S, 2014, ACS APPL MATER INTER, V6, P9955, DOI 10.1021/am501048n
   Tarafder S, 2013, MAT SCI ENG C MATER, V33, P3121, DOI 10.1016/j.msec.2013.02.049
   VAUPEL P, 1989, CANCER RES, V49, P6449
   WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167 8140(84)80077 8
NR 27
TC 13
Z9 15
U1 0
U2 26
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2468 5194
J9 MATER TODAY CHEM
JI Mater. Today Chem.
PD JUN
PY 2019
VL 12
BP 200
EP 208
DI 10.1016/j.mtchem.2018.11.008
PG 9
WC Chemistry, Multidisciplinary; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Materials Science
GA IC3ZI
UT WOS:000470901900017
PM 31938758
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Chai, Y
   Su, JW
   Hong, WS
   Zhu, RJ
   Cheng, CY
   Wang, L
   Zhang, XR
   Yu, B
AF Chai, Yu
   Su, Jianwen
   Hong, Weisheng
   Zhu, Runjiu
   Cheng, Caiyu
   Wang, Lei
   Zhang, Xianrong
   Yu, Bin
TI Antenatal Corticosteroid Therapy Attenuates Angiogenesis Through
   Inhibiting Osteoclastogenesis in Young Mice
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE ACT; angiogenesis; osteoclastogenesis; EZH2; pre osteoclasts
ID CONGENITAL ADRENAL HYPERPLASIA; RESPIRATORY DISTRESS; BONE LOSS;
   DEXAMETHASONE; GROWTH; CELLS; OSTEOGENESIS; PREVENTION; PIGLETS
AB Antenatal corticosteroid therapy (ACT) has been shown to reduce morbidity and mortality rates in preterm delivery, but the fetus is more likely to face the risk of low bone mineralization and low fetal linear growth. However, the mechanism of ACT inducing low bone mineralization remains largely unknown. Pre osteoclasts, which play an important role in angiogenesis and osteogenesis, are specifically regulating type H vessels (CD31(hi)Emcn(hi)) and vessel formation by secreting platelet derived growth factor BB (PDGF BB). We find that the number of pre osteoclasts and POC secreted PDGF BB is dramatically decreased in ACT mice, contributing to the reduction in type H vessels and bone mineralization during the mouse offspring. Quantitative analyses of micro computed tomography show that the ACT mice have a significant reduction in the mass of trabecular bone relative to the control group. Mononuclear pre osteoclasts in trabecular bone decreased in ACT mice, which leads to the amount of PDGF BB reduced and attenuates type H vessel formation. After sorting the Rank+ osteoclast precursors using flow cytometry, we show that the enhancer of zeste homolog 2 (Ezh2) expression is decreased in Rank+ osteoclast precursors in ACT mice. Consistent with the flow data, by using small molecule Ezh2 inhibitor GSK126, we prove that Ezh2 is required for osteoclast differentiation. Downregulating the expression of Ezh2 in osteoclast precursors would reduce PDGF BB production. Conditioned medium from osteoclast precursor cultures treated with GSK126 inhibited endothelial tube formation, whereas conditioned medium from vehicle group stimulated endothelial tube formation. These results indicate Ezh2 expression of osteoclast precursors is suppressed after ACT, which reduced the pre osteoclast number and PDGF BB secretion, thus inhibiting type H vessel formation and ACT associated low bone mineralization.
C1 [Chai, Yu; Su, Jianwen; Hong, Weisheng; Zhu, Runjiu; Cheng, Caiyu; Wang, Lei; Zhang, Xianrong; Yu, Bin] Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Orthopaed Surg, Guangzhou, Peoples R China.
   [Chai, Yu; Su, Jianwen; Hong, Weisheng; Zhu, Runjiu; Cheng, Caiyu; Wang, Lei; Zhang, Xianrong; Yu, Bin] Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Bone & Cartilage Regenerat, Guangzhou, Peoples R China.
C3 Southern Medical University   China; Southern Medical University   China
RP Zhang, XR; Yu, B (通讯作者)，Southern Med Univ, Nanfang Hosp, Dept Orthopaed, Div Orthopaed Surg, Guangzhou, Peoples R China.; Zhang, XR; Yu, B (通讯作者)，Southern Med Univ, Nanfang Hosp, Guangdong Prov Key Lab Bone & Cartilage Regenerat, Guangzhou, Peoples R China.
EM xianrongzh@smu.edu.cn; yubin@smu.edu.cn
RI Yu, Bin/KIJ 7006 2024
FU National Natural Science Foundation of China [81573515]; Major Program
   of National Natural Science Foundation of China [81830079]; China
   Postdoctoral Science Foundation [2020M672720]; Natural Science
   Foundation of Guangdong [2019A1515011778]; President Foundation of
   Nanfang Hospital, Southern Medical University [2019Z011]; Outstanding
   Youths Development Scheme of Nanfang Hospital, Southern Medical
   University [2018J012]
FX This study was supported by grants from the National Natural Science
   Foundation of China (No. 81573515 to XZ), The Major Program of National
   Natural Science Foundation of China (No. 81830079 to BY), China
   Postdoctoral Science Foundation (Grant number: 2020M672720), Natural
   Science Foundation of Guangdong (Grant number: 2019A1515011778),
   President Foundation of Nanfang Hospital, Southern Medical University
   (Grant number: 2019Z011), and Outstanding Youths Development Scheme of
   Nanfang Hospital, Southern Medical University 2018J012.
CR Adamik J, 2020, J BONE MINER RES, V35, DOI 10.1002/jbmr.3863
   Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708
   Bloom SL, 2001, OBSTET GYNECOL, V97, P485, DOI 10.1016/S0029 7844(00)01206 0
   Brandi ML, 2006, J BONE MINER RES, V21, P183, DOI 10.1359/JBMR.050917
   Bronckaers A, 2014, PHARMACOL THERAPEUT, V143, P181, DOI 10.1016/j.pharmthera.2014.02.013
   Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214
   Chen Z, 2018, TOXICOL APPL PHARM, V351, P12, DOI 10.1016/j.taap.2018.05.005
   Cheng X, 2014, CURR PHARM DESIGN, V20, P5430, DOI 10.2174/1381612820666140205144534
   Choi IH, 2002, J KOREAN MED SCI, V17, P435, DOI 10.3346/jkms.2002.17.4.435
   de Vries A, 2007, J CLIN INVEST, V117, P1058, DOI 10.1172/JCI30982
   Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302
   Dudakovic A, 2016, J BIOL CHEM, V291, P24594, DOI 10.1074/jbc.M116.740571
   Dudakovic A, 2015, J BIOL CHEM, V290, P27604, DOI 10.1074/jbc.M115.672345
   Fang C, 2016, J IMMUNOL, V196, P4452, DOI 10.4049/jimmunol.1501466
   Fiedler J, 2004, J CELL BIOCHEM, V93, P990, DOI 10.1002/jcb.20219
   Godfrey KM, 2011, SEMIN REPROD MED, V29, P257, DOI 10.1055/s 0031 1275518
   Hemming S, 2017, FASEB J, V31, P1011, DOI 10.1096/fj.201600748R
   Jia D, 2006, ENDOCRINOLOGY, V147, P5592, DOI 10.1210/en.2006 0459
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Li CJ, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 01509 0
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Maryniak A, 2014, CHILD NEUROPSYCHOL, V20, P60, DOI 10.1080/09297049.2012.745495
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Meyer Bahlburg HFL, 2004, J CLIN ENDOCR METAB, V89, P610, DOI 10.1210/jc.2002 021129
   MORALES WJ, 1986, AM J OBSTET GYNECOL, V154, P591, DOI 10.1016/0002 9378(86)90607 1
   Murphy KE, 2008, LANCET, V372, P2143, DOI 10.1016/S0140 6736(08)61929 7
   Nakamura S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175632
   Nassiri SM, 2014, STEM CELLS DEV, V23, P319, DOI 10.1089/scd.2013.0419
   Peaceman AM, 2005, AM J OBSTET GYNECOL, V193, P1165, DOI 10.1016/j.ajog.2005.06.050
   Percival CJ, 2013, DEV DYNAM, V242, P909, DOI 10.1002/dvdy.23992
   Portal Núñez S, 2012, HISTOL HISTOPATHOL, V27, P559, DOI 10.14670/HH 27.559
   Pufe T, 2003, BONE, V33, P869, DOI 10.1016/j.bone.2003.08.002
   Ramasamy SK, 2014, NATURE, V507, P376, DOI 10.1038/nature13146
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Seeman E, 2009, CRIT REV EUKAR GENE, V19, P219, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.40
   Sliwa E, 2010, J ANIM PHYSIOL AN N, V94, P293, DOI 10.1111/j.1439 0396.2008.00909.x
   Su JW, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01790 9
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Tomaszewska E, 2013, J ANIM PHYSIOL AN N, V97, P785, DOI 10.1111/j.1439 0396.2012.01319.x
   Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030503
   Weinstein RS, 2010, BONE, V46, P564, DOI 10.1016/j.bone.2009.06.030
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu D, 2011, ENVIRON TOXICOL PHAR, V32, P356, DOI 10.1016/j.etap.2011.08.003
   Yang P, 2018, BONE, V114, P1, DOI 10.1016/j.bone.2018.05.025
   Yasui T, 2011, J BONE MINER RES, V26, P2665, DOI 10.1002/jbmr.464
   YOUNG BK, 1980, AM J OBSTET GYNECOL, V138, P203, DOI 10.1016/0002 9378(80)90036 8
   Zhang XR, 2016, BRIT J PHARMACOL, V173, P2250, DOI 10.1111/bph.13506
NR 47
TC 3
Z9 7
U1 1
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD DEC 15
PY 2020
VL 8
AR 601188
DI 10.3389/fcell.2020.601188
PG 11
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA PM0DF
UT WOS:000603480300001
PM 33384997
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Diskin, CJ
   Stokes, TJ
   Dansby, LM
   Radcliff, L
   Carter, TB
AF Diskin, Charles J.
   Stokes, Thomas J.
   Dansby, Linda M.
   Radcliff, Lautrec
   Carter, Thomas B.
TI Can the combination of calcium and parathormone levels above k/doqi
   guidelines be used as a marker of adynamic bone disease in African
   Americans?
SO INTERNATIONAL UROLOGY AND NEPHROLOGY
LA English
DT Article
DE Renal failure; Hemodialysis; Osteodystrophy; Racial differences;
   Parathormone; hypercalcemia; vitamin D; Bone resorption
ID CHRONIC KIDNEY DISEASE; STAGE RENAL DISEASE; C PTH FRAGMENTS;
   PARATHYROID HORMONE; SECONDARY HYPERPARATHYROIDISM;
   HEMODIALYSIS PATIENTS; TURNOVER; FIBROBLAST GROWTH FACTOR 23;
   HOMEOSTASIS; PTH (1 84)
AB Patients of African American descent are at risk for the development of adynamic bone disease at parathyroid hormone levels 50% above the K/DOQI guidelines. Since a low bone formation rate is associated with hypercalcemia, attempts to reach one K/DOQI guideline may result in serum calcium levels above another K/DOQI guideline. Calcium levels above K/DOQI guidelines therefore may signal a need to stop parathyroid suppression.
   Bone biopsies were performed at the East Alabama Medical Center, in Opelika AL, USA on eight patients (four Caucasians, four African Americans) whose parathormone levels and serum calcium levels both exceeded K/DOQI guideline recommendations.
   All patients had mild to severe hyperparathyroid bone disease. No variable studied was predictive of the finding.
   Small sample size and the unavailability of the original Nichols Diagnostic Institute radioimmunoassay for parathormone.
   We did not find hypercalcemia predictive of adynamic bone in patients of African American descent at levels of parathormone where low bone formation rates have been documented to occur. Since no parameter predicted bone histology, perhaps bone biopsies will be necessary to distinguish hyperparathyroidism from adynamic bone disease in African Americans with ESRD, hypercalcemia, and moderately elevated levels of PTH. Further studies are needed to determine appropriate therapy.
C1 [Diskin, Charles J.; Stokes, Thomas J.; Dansby, Linda M.; Radcliff, Lautrec; Carter, Thomas B.] Auburn Univ, Hypertens Nephrol Dialysis & Transplantat Clin, Opelika, AL 36801 USA.
C3 Auburn University System; Auburn University
RP Diskin, CJ (通讯作者)，Auburn Univ, Hypertens Nephrol Dialysis & Transplantat Clin, BLDG 21,121 N 20th St, Opelika, AL 36801 USA.
EM hndt512@bellsouth.net
RI Diskin, Charles/JLL 4802 2023
CR Akhter N, 2009, OSTEOPOROSIS INT, V20, P745, DOI 10.1007/s00198 008 0746 4
   Aloia John F, 2006, Endocr Pract, V12, P137
   [Anonymous], NKF K DOQI GUID K DO
   Arenas MD, 2007, J NEPHROL, V20, P453
   Ashman N, 2001, CLIN NEPHROL, V55, P327
   Bielesz B, 2006, EUR J CLIN INVEST, V36, P34, DOI 10.1111/j.1365 2362.2006.01659.x
   Brancaccio D, 2007, DRUGS, V67, P1981, DOI 10.2165/00003495 200767140 00002
   Buargub MA, 2006, SAUDI J KIDNEY DIS T, V17, P401
   Cantor T, 2006, CLIN CHEM, V52, P1771, DOI 10.1373/clinchem.2006.071589
   Coen G, 2002, AM J KIDNEY DIS, V40, P348, DOI 10.1053/ajkd.2002.34519
   d'Almeida Filho  E J, 2000, Sao Paulo Med J, V118, P179
   DENTON J, 1984, J CLIN PATHOL, V37, P136, DOI 10.1136/jcp.37.2.136
   Donadio C, 2007, CLIN NEPHROL, V67, P131
   Friedman PA, 2006, AM J PHYSIOL RENAL, V290, pF975, DOI 10.1152/ajprenal.00336.2005
   GOLDNER JACQUES, 1938, AMER JOUR PATH, V14, P237
   Gupta A, 2001, NEPHROL DIAL TRANSPL, V16, P1518, DOI 10.1093/ndt/16.7.1518
   Gutiérrez OM, 2008, KIDNEY INT, V73, P956, DOI 10.1038/ki.2008.4
   Haris A, 2006, KIDNEY INT, V70, P931, DOI 10.1038/sj.ki.5001666
   Herberth J, 2006, CLIN NEPHROL, V65, P328
   Herberth J, 2010, AM J KIDNEY DIS, V55, P897, DOI 10.1053/j.ajkd.2009.12.041
   Lazarus JM, 2006, COMMUNICATION
   Lillie PD, 1976, HISTOPATHOLOGIC TECH, P534
   MALLUCHE HH, 1992, KIDNEY INT, V42, pS62
   MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P439, DOI 10.1007/BF02411282
   MALLUCHE HH, 1982, CALCIFIED TISSUE INT, V34, P449, DOI 10.1007/BF02411283
   Malluche HH., 1986, ATLAS MINERALIZED BO
   Mathew S, 2007, J AM SOC NEPHROL, V18, P122, DOI 10.1681/ASN.2006050490
   Monier Faugere MC, 2001, KIDNEY INT, V60, P1460, DOI 10.1046/j.1523 1755.2001.00949.x
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Qunibi WY, 2004, KIDNEY INT, V65, P1914, DOI 10.1111/j.1523 1755.2004.00590.x
   Resic H, 2010, INT UROL NEPHROL
   Rocha LA, 2006, AM J KIDNEY DIS, V48, P430, DOI 10.1053/j.ajkd.2006.05.028
   SANCHEZ CP, 1995, KIDNEY INT, V48, P838, DOI 10.1038/ki.1995.359
   Sato T, 2004, AM J KIDNEY DIS, V44, P481, DOI 10.1053/j.ajkd.2004.05.026
   Sawaya BP, 2003, KIDNEY INT, V64, P737, DOI 10.1046/j.1523 1755.2003.00129.x
   Toussaint Nigel, 2006, Hemodial Int, V10, P326, DOI 10.1111/j.1542 4758.2006.00125.x
   White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1210/er.2005 0019
NR 37
TC 2
Z9 2
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 1623
EI 1573 2584
J9 INT UROL NEPHROL
JI Int. Urol. Nephrol.
PD DEC
PY 2011
VL 43
IS 4
BP 1127
EP 1132
DI 10.1007/s11255 010 9785 9
PG 6
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 854EI
UT WOS:000297477300027
PM 20544281
DA 2025 08 17
ER

PT J
AU Kumar, VM
   Sobha, K
AF Kumar, Verma Mahendra
   Sobha, Kota
TI An in silico approach to resolve synovial inflammation by
   inhibiting Wnt signalling via post translational modifications:
   phosphorylation and S nitrosylation
SO RESEARCH JOURNAL OF BIOTECHNOLOGY
LA English
DT Article
DE Rheumatoid arthritis; Fibroblast like synoviocytes (FLS); Wnt
   signalling; Frizzled proteins; Phosphorylation and S nitrosylation
ID RHEUMATOID ARTHRITIS; NEGATIVE REGULATOR; DISEASE ACTIVITY;
   RISK FACTORS; THROMBOCYTOSIS; AUTOIMMUNITY; PATHWAY
AB Rheumatoid arthritis (RA) is a chronic progressive autoimmune disorder with complex etiology which is not explored completely. RA affects primarily long bone joints, but recent findings have suggested it is spread to other joints too. The immune system centrally involves in the initiation and progression of the disease. The immune activity results in the production of various inflammatory mediators that start acute inflammation of synovial joints, a defensive mechanism to encounter the causes. The problem arises only when acute inflammation fails to resolve and leads to chronic. At this stage, inflammatory mediators stimulate other metabolic pathways resulting in tissue damage. The drugs available for clinical applications in RA offer only a symptomatic relief and fail to resolve inflammation. It may be because of a complex RA etiology and involvement of several metabolic players in the initiation and progression of the disease.
   Fibroblast like synoviocytes (FLS) were reported an important player in the progression of RA and are under control of Wnt signalling pathway. Here, we propose inhibition of Wnt signalling pathway and blocking the activity of Fibroblast like synoviocytes (FLS) to resolve synovial inflammation. A control over Fibroblast like synoviocytes (FLS) also provides substantial relief in the production of other inflammatory mediators in the synovial cavity in the course of RA. We aimed an in silico approach to block Wnt signaling using two post translational modifications   phosphorylation and S nitrosylation of Frizzled proteins (Fz), a family of G protein coupled receptor proteins which in turn will take control over Fibroblast like Synoviocytes (FLS) mediated inflammation of synovial joints.
C1 [Kumar, Verma Mahendra] Acharya Nagarjuna Univ, Ctr Biotechnol, Guntur 522510, Andhra Pradesh, India.
   [Sobha, Kota] RVR & JC Coll Engn A, Dept Math & Humanities, Guntur 522019, Andhra Pradesh, India.
C3 Acharya Nagarjuna University; RVR & JC College of Engineering
RP Sobha, K (通讯作者)，RVR & JC Coll Engn A, Dept Math & Humanities, Guntur 522019, Andhra Pradesh, India.
EM sobhakota2005@gmail.com
RI Verma, Mahendra/JFA 5921 2023; Kota, Sobha/AAS 6086 2020
OI Sobha, Kota/0000 0001 9140 6396; 
CR Abasolo L, 2013, REUMATOL CLIN, V9, P226, DOI 10.1016/j.reuma.2012.09.006
   Aletaha D, 2006, CLIN EXP RHEUMAT S43, V24, pS
   Beydoun HA, 2013, MENOPAUSE, V20, P930, DOI [10.1097/gme.0b013e3182a14372, 10.1097/GME.0b013e3182a14372]
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   Bunescu A, 2004, J RHEUMATOL, V31, P2347
   Ernestam S., 2015, ANN RHEUM DIS, V74, P1094
   FARR M, 1983, ANN RHEUM DIS, V42, P545, DOI 10.1136/ard.42.5.545
   Felson DT, 2011, ANN RHEUM DIS, V70, P404, DOI [10.1136/ard.2011.149765, 10.1002/art.30129]
   Hoovestol RA, 2011, CURR RHEUMATOL REP, V13, P431, DOI 10.1007/s11926 011 0203 9
   HUTCHINSON RM, 1976, ANN RHEUM DIS, V35, P138, DOI 10.1136/ard.35.2.138
   Kabouridis PS, 2008, FEBS LETT, V582, P3711, DOI 10.1016/j.febslet.2008.10.006
   Kinloch AJ, 2011, ARTHRITIS RHEUM US, V63, P3818, DOI 10.1002/art.30639
   Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823
   Kuusalo L., 2015, EULAR 2015 C ROM
   Lee TY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021849
   Liao KP, 2009, CURR OPIN RHEUMATOL, V21, P279, DOI 10.1097/BOR.0b013e32832a2e16
   Maradit Kremers H, 2007, ANN RHEUM DIS, V66, P76, DOI 10.1136/ard.2006.053710
   Niida A, 2004, ONCOGENE, V23, P8520, DOI 10.1038/sj.onc.1207892
   Oliver JE, 2006, SCAND J RHEUMATOL, V35, P169, DOI 10.1080/03009740600718080
   Panda P. K., 2015, RES REV J BIOINFORMA, V2, P15
   Sen M, 2005, RHEUMATOLOGY, V44, P708, DOI 10.1093/rheumatology/keh553
   Smith HS, 2011, PAIN PHYSICIAN, V14, pE427
   Smolen J., 2011, ANN RHEUM DIS, V70, P1519
   Smolen JS, 2010, ANN RHEUM DIS, V69, P631, DOI 10.1136/ard.2009.123919
   Studenic P, 2012, ARTHRITIS RHEUM US, V64, P2814, DOI 10.1002/art.34543
   Taubert D, 2006, J RHEUMATOL, V33, P2139
   Verma MK, 2015, INFLAMM RES, V64, P647, DOI 10.1007/s00011 015 0843 8
   Vijayakumar D, 2005, INDIAN J CLIN BIOCHE, V20, P52, DOI 10.1007/BF02893042
   Weyand CM, 1998, SPRINGER SEMIN IMMUN, V20, P5, DOI 10.1007/BF00831996
   Weyand CM, 1997, J MOL MED JMM, V75, P772, DOI 10.1007/s001090050167
   Xu J, 2010, HAMOSTASEOLOGIE, V30, P5
   Yazici S, 2010, PLATELETS, V21, P122, DOI 10.3109/09537100903474373
   Zhao S, 2015, ONCOGENE, V34, P5069, DOI 10.1038/onc.2014.429
NR 33
TC 0
Z9 0
U1 0
U2 1
PU RESEARCH JOURNAL BIOTECHNOLOGY
PI INDORE
PA SECTOR A 80, SCHEME NO 54, VIJAY NAGAR, A B ROAD, INDORE, 452 010 MP,
   INDIA
SN 2278 4535
J9 RES J BIOTECHNOL
JI Res. J. Biotechnol.
PD AUG
PY 2016
VL 11
IS 8
BP 20
EP 26
PG 7
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA DV6LG
UT WOS:000383046400003
DA 2025 08 17
ER

PT J
AU Xiang, MX
   Su, HW
   Hu, JY
   Yan, YJ
AF Xiang, Mei Xian
   Su, Han Wen
   Hu, Jinyue
   Yan, Yun Jun
TI Stimulative effects of Polygonum amplexicaule var. sinense on
   osteoblastic MC3T3 E1 cells
SO PHARMACEUTICAL BIOLOGY
LA English
DT Article
DE PAF; proliferation; differentiation; osteoblasts; pharmacology
ID BONE MORPHOGENETIC PROTEIN 2; ALKALINE PHOSPHATASE; I COLLAGEN;
   MINERALIZATION; DIFFERENTIATION; PROLIFERATION; INCREASES; APOPTOSIS;
   EXTRACT
AB Context: Polygonum amplexicaule D. Don var. sinense Forb. (Polygonaceae) (PAF) is a well known traditional herb used to treat some diseases, such as fractures, rheumatoid arthritis, muscle injury, and pain. However, its pharmacological mechanism of promoting the healing of fractures is still unknown.
   Objective: The present study was designed to investigate the effects of PAF ethanol extracts on the proliferation and differentiation of osteoblastic MC3T3 E1 cell in vitro, thereby to illuminate the pharmacological mechanism to promote the healing of fractures.
   Materials and methods: The effects of PAF ethanol extracts on MC3T3 E1 cell proliferation and differentiation were detected by using CCK 8, cell cycle, alkaline phosphatase (ALP), and prostaglandin E 2 (PGE(2)) assays in vitro.
   Results: The results showed that PAF ethanol extracts significantly stimulated cell proliferation at 0.1 100 mu g/mL and the proportion of cells in S phase increased from 16.33 to 27.29% in osteoblastic MC3T3 E1 cells. Moreover, PAF ethanol extracts increased ALP expression in MC3T3 E1 cells at the concentration from 0.1 to 100 mu g/mL and inhibited PGE(2) production induced by TNF alpha in osteoblasts at the concentrations ranging from 10 to 100 mu g/mL in MC3T3 E1 osteoblasts.
   Discussion and conclusion: These results indicated that PAF directly stimulates cell proliferation and differentiation of osteoblasts; therefore, this study preliminarily explored the pharmacological mechanism of PAF to promote the healing of bone rheumatism and various fractures.
C1 [Xiang, Mei Xian; Yan, Yun Jun] Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430061, Peoples R China.
   [Xiang, Mei Xian] S Cent Univ Nationalities, Coll Pharm, Wuhan, Peoples R China.
   [Su, Han Wen; Hu, Jinyue] Wuhan Univ, Renmin Hosp, Wuhan 430072, Peoples R China.
C3 Huazhong University of Science & Technology; South Central Minzu
   University; Wuhan University
RP Yan, YJ (通讯作者)，Huazhong Univ Sci & Technol, Coll Life Sci & Technol, Wuhan 430061, Peoples R China.
EM yanyunjun@tom.com
RI Su, Hanwen/LGY 9195 2024
FU Natural Science Foundation of Wuhan City [SZY09005]; Ministry of
   Education, P.R. China [NCET 07 0336]; SCUEC [CZY10015]
FX This work was supported by the Fund of the Natural Science Foundation of
   Wuhan City (SZY09005) and Fund for New Century Excellent Talents from
   Ministry of Education, P.R. China (NCET 07 0336) and Fund for the
   Natural Science Foundation of SCUEC (CZY10015). The authors are thankful
   to Professor Dingrong Wan in the Pharmacognosy, the College of Pharmacy,
   South Central University for Nationalities to authenticate the herb PAF.
   The authors are thankful to Dr. Guangzhong Yang for instructing
   isolation and identification of chemicals.
CR AMOS AF, 2008, EUR J PHARMACOL, V587, P35
   Brixen KT, 2004, BASIC CLIN PHARMACOL, V94, P260
   Chan BY, 2008, BONE, V43, P567, DOI 10.1016/j.bone.2008.04.018
   Choi EM, 2005, BIOCHEM PHARMACOL, V70, P363, DOI 10.1016/j.bcp.2005.04.019
   Choi EM, 2001, PHYTOCHEMISTRY, V56, P733, DOI 10.1016/S0031 9422(00)00484 2
   Hu YM, 2008, PHYTOCHEMISTRY, V69, P2367, DOI 10.1016/j.phytochem.2008.05.023
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2004, TOXICOL IN VITRO, V18, P829, DOI 10.1016/j.tiv.2004.05.002
   Kajii T, 1999, ARCH ORAL BIOL, V44, P233, DOI 10.1016/S0003 9969(98)00120 4
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kang SK, 2006, IN VITRO CELL DEV AN, V42, P225, DOI 10.1290/0510068.1
   Kim H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011608
   Kim KW, 2008, J ETHNOPHARMACOL, V115, P42, DOI 10.1016/j.jep.2007.09.003
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870
   Pozharski E, 2010, METHODS MOL BIOL, V606, P385, DOI 10.1007/978 1 60761 447 0_26
   QUARLERS JD, 1999, J BONE MINER RES, V27, P683
   REN HC, 2009, CHIN J CHIN MAT MED, V35, P183
   Son YO, 2006, EUR J PHARMACOL, V529, P24, DOI 10.1016/j.ejphar.2005.10.041
   Suh KS, 2003, PHYTOCHEMISTRY, V63, P209, DOI 10.1016/S0031 9422(03)00101 8
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tsutsumi R, 2009, J BONE MINER RES, V24, P1753, DOI [10.1359/JBMR.090412, 10.1359/jbmr.090412]
   Yamaguchi M, 1998, BIOCHEM PHARMACOL, V55, P71, DOI 10.1016/S0006 2952(97)00402 4
   Yang Zhan Jun, 2007, Xibei Zhiwu Xuebao, V27, P1261
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
NR 26
TC 10
Z9 12
U1 0
U2 8
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1388 0209
EI 1744 5116
J9 PHARM BIOL
JI Pharm. Biol.
PD OCT
PY 2011
VL 49
IS 10
BP 1091
EP 1096
DI 10.3109/13880209.2011.568507
PG 6
WC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Medical Laboratory Technology; Pharmacology & Pharmacy
GA 822XR
UT WOS:000295084400014
PM 21595574
DA 2025 08 17
ER

PT J
AU Zuo, H
   Wan, YH
AF Zuo, Hao
   Wan, Yihong
TI Inhibition of myeloid PD L1 suppresses osteoclastogenesis and cancer
   bone metastasis
SO CANCER GENE THERAPY
LA English
DT Article
ID GRANZYME B; MACROPHAGES; EXPRESSION; DISEASE; CELLS; MECHANISMS;
   NIVOLUMAB; MELANOMA
AB Programmed death ligand 1 (PD L1) is predominantly expressed in the antigen presenting cells (APCs) that are originated and are abundant in the bone marrow. The roles of PD L1 in bone cell differentiation and cancer bone metastasis remain unclear. Here we show that PD L1 antibody or PD L1 conditional knockout in the hematopoietic or myeloid lineage suppresses osteoclast differentiation in vitro and in vivo. Bone metastases of breast cancer and melanoma are diminished by PD L1 antibody or PD L1 deletion in the myeloid lineage. Transcriptional profiling of bone marrow cells reveals that PD L1 deletion in the myeloid cells upregulates immune stimulatory genes, leading to increased macrophage M1 polarization, decreased M2 polarization, enhanced IFN gamma signaling, and elevated T cell recruitment and activation. All these alterations result in heightened anti tumor immunity in the cancer microenvironment. Our findings support PD L1 antibody as a potent therapy for bone metastasis of breast cancer and melanoma by simultaneously suppressing osteoclast and enhancing immunity.
C1 [Zuo, Hao; Wan, Yihong] Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center
RP Wan, YH (通讯作者)，Univ Texas Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.
EM yihong.wan@gmail.com
RI ; Zuo, Hao/KCL 0405 2024; Wan, Yihong/J 8681 2012
OI Zuo, Hao/0000 0002 8812 7385; Wan, Yihong/0000 0003 0556 7017; 
FU UTSW Endowed Scholar Startup Fund
FX We thank Drs. Yang Xin Fu and Haidong Tang for providing the PD L1 flox
   mice; Dr. Sarah Huen for sharing cryostat; and Dr. Orson Moe for sharing
   Bioquant software. This work was supported by UTSW Endowed Scholar
   Startup Fund (Y.W.).
CR An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Biswas T, 2014, CANCER LETT, V346, P129, DOI 10.1016/j.canlet.2013.12.018
   Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91
   Cannon John G D, 2018, JAAD Case Rep, V4, P248, DOI 10.1016/j.jdcr.2018.01.015
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Diskin B, 2020, NAT IMMUNOL, V21, P442, DOI 10.1038/s41590 020 0620 x
   Dockrell DH, 1998, J CLIN INVEST, V101, P2394, DOI 10.1172/JCI1171
   Dong PX, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00386
   Gato Cañas M, 2017, CELL REP, V20, P1818, DOI 10.1016/j.celrep.2017.07.075
   Gibby K, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3174
   Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Kageyama SI, 2016, INT CANCER CONF J, V5, P192, DOI 10.1007/s13691 016 0256 8
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kim WJ, 2007, IMMUNOL LETT, V111, P57, DOI 10.1016/j.imlet.2007.05.004
   Krzeszinski JY, 2015, TRENDS PHARMACOL SCI, V36, P360, DOI [10.1016/J.tips.2015.04.006, 10.1016/j.tips.2015.04.006]
   Lin H, 2018, J CLIN INVEST, V128, P805, DOI 10.1172/JCI96113
   Liu X, 2016, SCI REP UK, V6, DOI 10.1038/srep36722
   Mina LA, 2019, BREAST CANCER TARGET, V11, P321, DOI 10.2147/BCTT.S184710
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Moseley KF, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0417 8
   Novack DV, 2008, ANNU REV PATHOL MECH, V3, P457, DOI 10.1146/annurev.pathmechdis.3.121806.151431
   Oades GM, 2002, PROSTATE CANCER P D, V5, P264, DOI 10.1038/sj.pcan.4500607
   Ogilvy S, 1999, BLOOD, V94, P1855
   Peng Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 18570 x
   Pulko V, 2011, J IMMUNOL, V187, P5606, DOI 10.4049/jimmunol.1003976
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615
   Sidhu G, 2019, JPN J CLIN ONCOL, V49, P691, DOI 10.1093/jjco/hyz077
   Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061
   Tokuhara K, 2017, INT J SURG CASE REP, V31, P188, DOI 10.1016/j.ijscr.2017.01.028
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Trapani JA, 2002, NAT REV IMMUNOL, V2, P735, DOI 10.1038/nri911
   Uluçkan Ö, 2008, J CELL BIOCHEM, V104, P1311, DOI 10.1002/jcb.21709
   Wan YH, 2007, NAT MED, V13, P1496, DOI 10.1038/nm1672
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Wei W, 2010, CELL METAB, V11, P503, DOI 10.1016/j.cmet.2010.04.015
   Zekri J, 2017, J BONE ONCOL, V8, P13, DOI 10.1016/j.jbo.2017.08.003
   Zuo H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15429 z
NR 40
TC 16
Z9 16
U1 4
U2 7
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0929 1903
EI 1476 5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD OCT
PY 2022
VL 29
IS 10
BP 1342
EP 1354
DI 10.1038/s41417 022 00446 5
EA MAR 2022
PG 13
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA 5J9QF
UT WOS:000765707300001
PM 35256753
DA 2025 08 17
ER

PT J
AU Im, NK
   Lee, DS
   Lee, SR
   Jeong, GS
AF Im, Nam Kyung
   Lee, Dong Sung
   Lee, Seong Ryong
   Jeong, Gil Saeng
TI Lupeol Isolated from Sorbus commixta Suppresses
   1α,25 (OH)2D3 Mediated Osteoclast Differentiation
   and Bone Loss in Vitro and in Vivo
SO JOURNAL OF NATURAL PRODUCTS
LA English
DT Article
ID KAPPA B LIGAND; RECEPTOR ACTIVATOR; METHANOL EXTRACT; CELL BIOLOGY;
   VITAMIN D; CORTEX; RANKL; RATS; OSTEOPOROSIS; PREVENTION
AB Lupeol is a lupane type triterpene isolated from Sorbus commixta, an oriental medicine used to treat arthritis and inflammatory diseases. However, the antiosteoporotic effects of S. commixta or any of its constituents have not been studied yet. In the present study, we have examined the effect of lupeol (a major active triterpenoid isolated from S. commixta) on osteoclastogenesis and sought to elucidate its underlying molecular mechanisms. We evaluated whether lupeol antagonized osteoclast differentiation and bone resorption. Lupeol markedly inhibited osteoclast differentiation and bone resorption activity through its effects on MAP kinases and transcription factors (NF kappa B, NFATc1, and c Fos) downstream of the osteoclast differentiation factor receptor RANK. Furthermore, in vivo efficacy of lupeol was confirmed by using an animal model of hypercalcemic mediated bone loss. Taken together, lupeol showed strong inhibitory effects on osteoclastogenesis. Supplementation with S. commixta and lupeol could be beneficial for bone health or osteoclast related diseases such as osteoporosis,Paget's disease, osteolysis associated with periodontal disease, and multiple myeloma.
C1 [Im, Nam Kyung; Jeong, Gil Saeng] Keimyung Univ, Coll Pharm, Daegu 704701, South Korea.
   [Lee, Dong Sung] Chosun Univ, Coll Pharm, Gwangju 61452, South Korea.
   [Lee, Seong Ryong] Keimyung Univ, Dept Pharmacol, Sch Med, Daegu 704701, South Korea.
   [Lee, Seong Ryong] Keimyung Univ, Brain Res Inst, Daegu 704701, South Korea.
C3 Keimyung University; Chosun University; Keimyung University; Keimyung
   University
RP Jeong, GS (通讯作者)，Keimyung Univ, Coll Pharm, Daegu 704701, South Korea.; Lee, SR (通讯作者)，Keimyung Univ, Dept Pharmacol, Sch Med, Daegu 704701, South Korea.; Lee, SR (通讯作者)，Keimyung Univ, Brain Res Inst, Daegu 704701, South Korea.
EM srlee@kmu.ac.kr; gsjeong@kmu.ac.kr
FU National Research Foundation of Korea (NRF)   Korean Government (MSIP)
   [2014R1A5A2010008, NRF 2015M3A9A5031091]
FX This work was supported by the National Research Foundation of Korea
   (NRF) Grant funded by the Korean Government (MSIP) (No. 2014R1A5A2010008
   and No. NRF 2015M3A9A5031091).
CR Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Bae JT, 2007, ARCH PHARM RES, V30, P1116, DOI 10.1007/BF02980246
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Branca F, 2003, P NUTR SOC, V62, P877, DOI 10.1079/PNS2003309
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Hasegawa S, 2010, BIOL PHARM BULL, V33, P487, DOI 10.1248/bpb.33.487
   Hofbauer LC, 2001, J MOL MED, V79, P243, DOI 10.1007/s001090100226
   Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338
   Holick MF, 2004, AM J CLIN NUTR, V79, P362
   Kang DG, 2007, AM J CHINESE MED, V35, P265, DOI 10.1142/S0192415X07004801
   Kang DG, 2005, BIOL PHARM BULL, V28, P860, DOI 10.1248/bpb.28.860
   Kobayashi T, 2005, ENDOCRINOLOGY, V146, P1012, DOI 10.1210/en.2004 1343
   Kumari A, 2012, LIFE SCI, V90, P561, DOI 10.1016/j.lfs.2012.01.012
   Kwak HB, 2010, BONE, V46, P724, DOI 10.1016/j.bone.2009.10.042
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lee SO, 2006, J PHARM PHARMACOL, V58, P685, DOI 10.1211/jpp.58.5.0014
   Leibbrandt A, 2009, ADV EXP MED BIOL, V649, P100
   Na M, 2009, J ENZYM INHIB MED CH, V24, P1056, DOI 10.1080/14756360802693312
   Nakagawa H, 2002, BIOCHEM BIOPH RES CO, V292, P94, DOI 10.1006/bbrc.2002.6622
   Oh S, 2008, MOL CELLS, V26, P486
   Omeje EO, 2014, J ETHNOPHARMACOL, V151, P643, DOI 10.1016/j.jep.2013.11.029
   Preetha SP, 2006, COMP BIOCHEM PHYS C, V143, P333, DOI 10.1016/j.cbpc.2006.03.008
   Scalbert A, 2005, CRIT REV FOOD SCI, V45, P287, DOI 10.1080/1040869059096
   Sethi G, 2007, CHEM BIOL, V14, P738, DOI 10.1016/j.chembiol.2007.07.002
   Suda T, 1997, J BONE MINER RES, V12, P869, DOI 10.1359/jbmr.1997.12.6.869
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Ullmann U, 2005, PLANTA MED, V71, P891, DOI 10.1055/s 2005 864186
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wattel A, 2003, BIOCHEM PHARMACOL, V65, P35, DOI 10.1016/S0006 2952(02)01445 4
   Woo JT, 2004, BIOL PHARM BULL, V27, P504, DOI 10.1248/bpb.27.504
   Wu J, 2006, METABOLISM, V55, P423, DOI 10.1016/j.metabol.2005.10.002
   Yi T, 2008, J CELL PHYSIOL, V217, P409, DOI 10.1002/jcp.21511
   Yu T, 2011, J ETHNOPHARMACOL, V134, P493, DOI 10.1016/j.jep.2010.12.032
NR 35
TC 17
Z9 20
U1 0
U2 10
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0163 3864
EI 1520 6025
J9 J NAT PROD
JI J. Nat. Prod.
PD FEB
PY 2016
VL 79
IS 2
BP 412
EP 420
DI 10.1021/acs.jnatprod.5b01088
PG 9
WC Plant Sciences; Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy
GA DF3XP
UT WOS:000371282000019
PM 26878936
DA 2025 08 17
ER

PT J
AU Nakata, E
   Kawai, H
   Fujiwara, T
   Kunisada, T
   Inoue, H
   Futagawa, M
   Katayama, H
   Itano, T
   Ozaki, T
AF Nakata, Eiji
   Kawai, Hotaka
   Fujiwara, Tomohiro
   Kunisada, Toshiyuki
   Inoue, Hirofumi
   Futagawa, Mashu
   Katayama, Haruyoshi
   Itano, Takuto
   Ozaki, Toshifumi
TI Clinicopathological and histological analysis of secondary malignant
   giant cell tumors of bone without radiotherapy
SO ONCOLOGY LETTERS
LA English
DT Article
DE giant cell tumor of bone; malignant transformation; p53; denosumab;
   molecular targeted therapy
ID RECEIVING TREATMENT; P53 MUTATIONS; OPEN LABEL; TRANSFORMATION; SARCOMA;
   OSTEOSARCOMA; DENOSUMAB; PATIENT; CURETTAGE; H3F3A
AB Giant cell tumor of bone (GCTB) is an intermediate bone tumor that rarely undergoes malignant transformation. Secondary malignant GCTB (SMGCTB) is defined as a lesion in which high grade sarcoma occurs at the site of previously treated GCTB. The present study retrospectively reviewed the medical records of patients with GCTB treated at Okayama University Hospital between April 1986 and April 2020. The clinicopathological and histological features of patients with SMGCTB without prior radiotherapy were investigated. A total of three patients (4%) with SMGCTB were detected, and the tumor sites were the distal ulna, distal femur and sacrum. Two of the patients had been treated with curettage and bone graft, and one had been treated with denosumab. In all cases, the lesions were made up of two components, the conventional GCTB component and the malignant component. The Ki67 labeling index was higher in the malignant components of SMGCTB and metastatic lesions compared with that in primary and recurrent conventional GCTB, or the conventional GCTB component of SMGCTB. Moreover, p53 expression was higher in these same components in patients who underwent curettage and bone grafting; however, there was no difference in the patient that received denosumab treatment. In this patient, clinical cancer genomic profiling revealed loss of CDKN2A, CDKN2B and MTAP expression. All three patients developed distant metastasis. The patients with SMGCTB in the ulna and femur died 13 and 54 months after detection of malignant transformation, respectively. The patient with SMGCTB in the sacrum received carbon ion radiotherapy to the sacrum and pazopanib; the treatment was effective and the patient was alive at the last follow up 3 years later. In conclusion, p53 may be associated with malignant transformation in GCTB. Future studies should investigate the association of between denosumab treatment and malignant transformation, as well as molecular targeted therapy to improve the clinical outcomes of SMGCTB.
C1 [Nakata, Eiji; Fujiwara, Tomohiro; Kunisada, Toshiyuki; Katayama, Haruyoshi; Itano, Takuto; Ozaki, Toshifumi] Okayama Univ Hosp, Dept Orthoped Surg, Okayama 7008558, Japan.
   [Kawai, Hotaka] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Oral Pathol & Med, Okayama 7008558, Japan.
   [Inoue, Hirofumi] Okayama Univ Hosp, Dept Pathol, Okayama 7008558, Japan.
   [Futagawa, Mashu] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Clin Genom Med, Okayama 7008558, Japan.
   [Nakata, Eiji] Okayama Univ Hosp, Dept Orthoped Surg, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
C3 Okayama University; Okayama University; Okayama University; Okayama
   University; Okayama University
RP Nakata, E (通讯作者)，Okayama Univ Hosp, Dept Orthoped Surg, 2 5 1 Shikata Cho, Okayama 7008558, Japan.
EM eijinakata8522@yahoo.co.jp
OI FUTAGAWA, MASHU/0009 0009 5951 5694; Itano, Takuto/0009 0005 0885 7193
CR Alaqaili SI, 2018, CUREUS J MED SCIENCE, V10, DOI 10.7759/cureus.3792
   Anract P, 1998, INT ORTHOP, V22, P19, DOI 10.1007/s002640050201
   Aponte Tinao LA, 2015, CLIN ORTHOP RELAT R, V473, P3050, DOI 10.1007/s11999 015 4249 2
   Mallick AB, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912 021 01047 5
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bertoni F, 2003, CANCER, V97, P2520, DOI 10.1002/cncr.11359
   Bieg Bourne CC, 2017, CANCER RES, V77, P6313, DOI 10.1158/0008 5472.CAN 17 1569
   Broehm CJ, 2015, CASE REP MED, V2015, DOI 10.1155/2015/767198
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   DAHLIN DC, 1970, CANCER, V25, P1061, DOI 10.1002/1097 0142(197005)25:5<1061::AID CNCR2820250509>3.0.CO;2 E
   Errani Costantino, 2019, J Clin Orthop Trauma, V10, P1015, DOI 10.1016/j.jcot.2019.09.017
   GITELIS S, 1989, J BONE JOINT SURG AM, V71A, P757, DOI 10.2106/00004623 198971050 00019
   Gong LH, 2021, HISTOL HISTOPATHOL, V36, P61, DOI 10.14670/HH 18 264
   Gong LH, 2012, VIRCHOWS ARCH, V460, P327, DOI 10.1007/s00428 012 1198 y
   González Gil C, 2021, GENES BASEL, V12, DOI 10.3390/genes12010079
   Gupta A, 2021, CURR ONCOL, V28, P1302, DOI 10.3390/curroncol28020124
   Hasenfratz M, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 85319 x
   Hashimoto K, 2006, TOHOKU J EXP MED, V208, P157, DOI 10.1620/tjem.208.157
   HEFTI FL, 1992, J BONE JOINT SURG AM, V74A, P930, DOI 10.2106/00004623 199274060 00015
   Imai R, 2016, INT J RADIAT ONCOL, V95, P322, DOI 10.1016/j.ijrobp.2016.02.012
   Ishihara S, 2022, MODERN PATHOL, V35, P640, DOI 10.1038/s41379 021 00972 x
   Li HY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.580605
   Li JM, 2014, ORTHOPEDICS, V37, pE512, DOI 10.3928/01477447 20140430 66
   Li LT, 2015, MOL MED REP, V11, P1566, DOI 10.3892/mmr.2014.2914
   Liu WF, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100334
   Machinami R, 2008, PATHOL RES PRACT, V204, P583, DOI 10.1016/j.prp.2008.02.002
   Marui T, 2001, SKELETAL RADIOL, V30, P104, DOI 10.1007/s002560000305
   Miller IJ, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746 1596 5 62
   Alcalde BM, 2021, ARCH ARGENT PEDIATR, V119, pE11, DOI 10.5546/aap.2021.eng.e11
   MNAYMNEH WA, 1964, J BONE JOINT SURG AM, V46, P63, DOI 10.2106/00004623 196446010 00006
   Mori Y, 2000, CLIN ORTHOP RELAT R, P185
   Movahedinia Sajjadeh, 2019, Iran J Pathol, V14, P165, DOI 10.30699/IJP.14.2.165
   Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641
   Muramatsu K, 2012, ACTA ORTHOP BELG, V78, P279
   Oda Y, 2001, HISTOPATHOLOGY, V39, P629, DOI 10.1046/j.1365 2559.2001.01275.x
   Okubo T, 2013, VIRCHOWS ARCH, V463, P67, DOI 10.1007/s00428 013 1435 z
   Palmerini E, 2021, BMC CANCER, V21, DOI 10.1186/s12885 020 07739 8
   Palmerini E, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819840000
   Park Andrew, 2016, JBJS Case Connect, V6, pe78, DOI 10.2106/JBJS.CC.16.00024
   Picci P, 2011, EUR J RADIOL, V77, P19, DOI 10.1016/j.ejrad.2010.06.053
   ROCK MG, 1986, J BONE JOINT SURG AM, V68A, P1073, DOI 10.2106/00004623 198668070 00016
   Rutkowski P, 2015, ANN SURG ONCOL, V22, P2860, DOI 10.1245/s10434 015 4634 9
   SUNDARAM M, 1982, SKELETAL RADIOL, V7, P282, DOI 10.1007/BF00361988
   Takesako Hisataka, 2016, J Med Case Rep, V10, P47, DOI 10.1186/s13256 016 0833 7
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Tsukamoto S, 2021, CANCERS, V13, DOI 10.3390/cancers13153647
   Tsukamoto S, 2021, CANCERS, V13, DOI 10.3390/cancers13143644
   Tsukamoto S, 2017, JPN J CLIN ONCOL, V47, P1090, DOI 10.1093/jjco/hyx112
   Yin HB, 2015, J NEURO ONCOL, V124, P275, DOI 10.1007/s11060 015 1835 9
   Yoshida K, 2019, MODERN PATHOL, V32, P1751, DOI 10.1038/s41379 019 0318 5
   Yung DV, 2023, J ORTHOP SCI, V28, P1492, DOI 10.1016/j.jos.2021.07.004
NR 51
TC 1
Z9 1
U1 0
U2 0
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 1074
EI 1792 1082
J9 ONCOL LETT
JI Oncol. Lett.
PD SEP
PY 2022
VL 24
IS 3
AR 319
DI 10.3892/ol.2022.13439
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 3T8ID
UT WOS:000840512400001
PM 35949597
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yang, Z
   Huang, JH
   Liu, SF
   Zhao, YJ
   Shen, ZY
   Wang, YJ
   Bian, Q
AF Yang, Zhu
   Huang, Jian hua
   Liu, Shu fen
   Zhao, Yong jian
   Shen, Zi yin
   Wang, Yong jun
   Bian, Qin
TI The osteoprotective effect of psoralen in ovariectomy induced
   osteoporotic rats via stimulating the osteoblastic differentiation from
   bone mesenchymal stem cells
SO MENOPAUSE THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY
LA English
DT Article
DE Psoralen; Ovariectomy; Stem cell microarray; Bone mesenchymal stem cell;
   Osteoporosis
ID MARROW STROMAL CELLS; VERSUS HOST DISEASE; BAND ULTRAVIOLET B; A
   IRRADIATION PUVA; POSTMENOPAUSAL WOMEN; PLUS ULTRAVIOLET; IN VIVO;
   EXPRESSION; THERAPY; NUMB
AB Objective: Psoralea corylifolia extract has been reported to promote bone formation in osteoporotic animals. Psoralen (PSO), a flavonoid glycoside, as the active component of P corylifolia L, is effective in increasing new bone forming osteoblasts in parietal bone defects. However, the effect and molecular mechanisms of PSO on bone mesenchymal stem cells (bMSCs) in the osteoporotic state are widely unknown. This study was designed to evaluate the osteoprotective effect of PSO in ovariectomy (OVX) induced rats and to seek possible molecular mechanisms of PSO in bMSCs.
   Methods: We observed the osteogenic effect of PSO (3 month treatment) on osteoporotic rat models induced by OVX via testing bone densitometry, histomorphometries, and immunohistochemistry in vivo. Alkaline phosphatase staining and colony forming unit fibroblast and colony forming unit adipocyte assays were performed to evaluate the differentiation potential of bMSCs ex vivo. In addition, the molecular targets of PSO in bMSCs were detected by stem cell microarray analysis of 256 genes and confirmed by real time reverse transcription polymerase chain reaction.
   Results: Micro CT morphometry analysis showed that PSO significantly improved bone mass indicators including increased trabecular thickness and decreased trabecular space. Meanwhile, PSO elevated the well known osteogenic marker osteocalcin level in OVX induced osteoporotic rats. Next, in ex vivo studies, we revealed that PSO facilitated alkaline phosphatase staining and increased the colony forming unit fibroblasts. Based on gene expression profile analysis, we screened a set of genes dysregulated in OVX but reversed by PSO treatment. These genes were highly enriched in the Notch signaling pathway, which was documented to play a role in bMSC differentiation.
   Conclusions: Our findings show that PSO promotes bone mass in OVX induced osteoporotic rats. This effect of PSO is highly related to the stimulation of differentiation of bMSCs to osteoblasts.
C1 [Yang, Zhu; Liu, Shu fen; Zhao, Yong jian; Wang, Yong jun; Bian, Qin] Shanghai Univ Tradit Chinese Med, Dept Orthopaed & Traumatol, Longhua Hosp, Shanghai 200032, Peoples R China.
   [Huang, Jian hua; Shen, Zi yin; Bian, Qin] Fudan Univ, Huashan Hosp, Inst Integrated Tradit Chinese Med & Western Med, Shanghai 200433, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Fudan University
RP Bian, Q (通讯作者)，Shanghai Univ Tradit Chinese Med, Dept Orthopaed & Traumatol, Longhua Hosp, 725 S Wan Ping Rd, Shanghai 200032, Peoples R China.
EM bianqin213@126.com
RI ; Huang, Chien Hao/AGG 4501 2022; Bian, Qin/C 8831 2014
OI Bian, Qin/0000 0003 4190 0913; 
FU National Basic Research Program in China (973 Plan) [2010CB530402,
   2010CB530404]; National Natural Science Foundation of China
   [30710103904, 81001526]; National Natural Foundation Committee of China
   [30930111]; Shanghai Science and Technology Development Funds
   [11QA1406600]; Theories and Therapies Bones Province Key Laboratory of
   Ministry of Education, Shanghai University; Shanghai Education
   Commission Innovation Team Program; Ministry of Education senior
   personnel items: Professor Changjiang Scholar Program
FX Funding/support: This work was supported by the National Basic Research
   Program in China (973 Plan, 2010CB530402, 2010CB530404), the
   International Cooperation Programs of National Natural Science
   Foundation of China (30710103904), a National Natural Foundation
   Committee of China key grant (30930111), the Project of National Natural
   Science Foundation of China (81001526), Shanghai Science and Technology
   Development Funds (11QA1406600), Theories and Therapies Bones Province
   Key Laboratory of Ministry of Education, Shanghai University, Shanghai
   Education Commission Innovation Team Program Section 6 (2009), and
   Ministry of Education senior personnel items: Professor Changjiang
   Scholar Program (teaching people, 2009, 17).
CR Ahdjoudj S, 2001, J CELL BIOCHEM, V81, P23, DOI 10.1002/1097 4644(20010401)81:1<23::AID JCB1021>3.0.CO;2 H
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bhatnagar A, 2007, J EUR ACAD DERMATOL, V21, P1381, DOI 10.1111/j.1468 3083.2007.02283.x
   Bian Q, 2011, PHARMAZIE, V66, P63, DOI 10.1691/ph.2011.0219
   Canalis E, 2005, NEW ENGL J MED, V352, P2014, DOI 10.1056/NEJMe058080
   CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429
   Chan GK, 2002, GERONTOLOGY, V48, P62, DOI 10.1159/000048929
   Chauhan PS, 2011, CLIN EXP DERMATOL, V36, P169, DOI 10.1111/j.1365 2230.2010.03874.x
   David V, 2007, ENDOCRINOLOGY, V148, P2553, DOI 10.1210/en.2006 1704
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Dunwoodie SL, 2009, BBA MOL BASIS DIS, V1792, P862
   Figueroa JD, 2004, EXP CELL RES, V296, P163, DOI 10.1016/j.yexer.2004.01.025
   Furlong T, 2002, BIOL BLOOD MARROW TR, V8, P206, DOI 10.1053/bbmt.2002.v8.pm12014809
   Givogri MI, 2003, DEV NEUROSCI BASEL, V25, P50, DOI 10.1159/000071468
   Gong HY, 1998, EFFECTS MECH RES PSO
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Komori T, 2010, ADV EXP MED BIOL, V658, P43, DOI 10.1007/978 1 4419 1050 9_5
   Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349
   Krebsbach PH, 1999, CRIT REV ORAL BIOL M, V10, P165, DOI 10.1177/10454411990100020401
   Kubu CJ, 2002, DEV BIOL, V244, P199, DOI 10.1006/dbio.2002.0568
   Li XD, 2003, BONE, V33, P652, DOI 10.1016/S8756 3282(03)00239 4
   Liu HD, 2010, GENE DEV, V24, P2395, DOI 10.1101/gad.1975210
   Liu M, 2009, PHARMAZIE, V64, P43, DOI 10.1691/ph.2008.8671
   Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410
   Menillo SA, 2001, BONE MARROW TRANSPL, V28, P807, DOI 10.1038/sj.bmt.1703231
   Ming Leiguo, 2011, Zhongguo Zhong Yao Za Zhi, V36, P2124
   Miura H, 1996, PLANTA MED, V62, P150, DOI 10.1055/s 2006 957839
   Nuttall ME, 2000, BONE, V27, P177, DOI 10.1016/S8756 3282(00)00317 3
   Park JJ, 2010, EUR SPINE J, V19, P1942, DOI 10.1007/s00586 010 1559 7
   Petersen PH, 2004, NAT NEUROSCI, V7, P803, DOI 10.1038/nn1289
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Raphael BA, 2011, J AM ACAD DERMATOL, V65, P212, DOI 10.1016/j.jaad.2010.06.056
   Ruiz C, 2009, CLIMACTERIC, V12, P286, DOI 10.1080/13697130902736939
   Saag KG, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2815
   Sacco SM, 2010, J OSTEOPOROS, V2010, DOI 10.4061/2010/708931
   Stern RS, 2007, NEW ENGL J MED, V357, P682, DOI 10.1056/NEJMct072317
   Tsai MH, 2007, AM J CHINESE MED, V35, P669, DOI 10.1142/S0192415X07005168
   van Coevorden AM, 2004, ARCH DERMATOL, V140, P1463, DOI 10.1001/archderm.140.12.1463
   Vercauteren SM, 2004, BLOOD, V104, P2315, DOI 10.1182/blood 2004 01 0204
   Wang DW, 2001, PLANTA MED, V67, P748, DOI 10.1055/s 2001 18343
   Wong RWK, 2011, J ORTHOP RES, V29, P158, DOI 10.1002/jor.21124
   Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015
   ZHOU H, 1994, J BONE MINER RES, V9, P1489
   Zimmer SN, 2011, BLOOD, V118, P69, DOI 10.1182/blood 2010 09 307942
NR 45
TC 49
Z9 61
U1 1
U2 47
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1072 3714
EI 1530 0374
J9 MENOPAUSE
JI Menopause J. N. Am. Menopause Soc.
PD OCT
PY 2012
VL 19
IS 10
BP 1156
EP 1164
DI 10.1097/gme.0b013e3182507e18
PG 9
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Obstetrics & Gynecology
GA 016ZQ
UT WOS:000309558800002
PM 22781784
DA 2025 08 17
ER

PT J
AU Jin, X
   Sun, J
   Yu, B
   Wang, Y
   Sun, WJ
   Yang, J
   Huang, SH
   Xie, WL
AF Jin, Xin
   Sun, Jing
   Yu, Bo
   Wang, Yue
   Sun, Wei Jia
   Yang, Jing
   Huang, Su Hui
   Xie, Wen Li
TI Daidzein stimulates osteogenesis facilitating proliferation,
   differentiation, and antiapoptosis in human osteoblast like MG 63 cells
   via estrogen receptor dependent MEK/ERK and PI3K/Akt activation
SO NUTRITION RESEARCH
LA English
DT Article
DE Daidzein; Osteoblast; Proliferation; Differentiation; Apoptosis;
   Estrogen receptor
ID SOY ISOFLAVONES; BONE LOSS; OVARIECTOMIZED MICE; TRANSCRIPTIONAL
   ACTIVITY; HORMONE THERAPY; OSTEOPENIC RATS; MC3T3 E1 CELLS; IN VITRO;
   BETA; RALOXIFENE
AB Daidzein, a natural soy isoflavone, has a structure similar to estradiol and exhibiting bone sparing effects against osteoporosis. However, the molecular mechanisms of osteogenesis remain unclear. We hypothesized that daidzein stimulates osteogenesis through estrogen receptor (ER) dependent signal pathways. To test this hypothesis, we investigated the effects of daidzein compared with 17 beta estadiol on proliferation, differentiation, and cisplatin induced apoptosis in human osteoblast like MG 63 cells containing 2 ER isoforms. The results showed that daidzein stimulated cell proliferation by altering cell cycle distribution, promoted cell differentiation by increasing the alkaline phosphatase activity and collagen content, and reduced cell apoptosis associated by up regulating the expression of Bcl xL. The above actions of daidzein were prevented by cotreatment with the ER antagonist ICI 182780. Using small interfering RNA technology, we further demonstrated that the effects of daidzein on alkaline phosphatase activity, collagen content, and cell apoptosis are mediated by both ER alpha and ER beta, whereas the effects on cell proliferation are primarily mediated by ER alpha. However, the effects of 17 beta estradiol on osteoblastic proliferation and survival are mediated by both ER isotypes, and the effects on osteoblastic differentiation are primarily mediated by ER alpha. The use of specific inhibitors indicated that activation of the mitogenactivated protein kinase kinase/extracellular regulated kinase (MEK/ERK) and phosphoinositide 3 kinase/protein kinase B or PKB (PI3K/Akt) signaling pathway at least partially accounts for these effects of daidzein. Taken together, the results indicate that daidzein stimulates osteogenesis through facilitating proliferation, differentiation, and antiapoptosis in human osteoblast like MG 63 cells via activation of MEK/ERK and PI3K/Akt in an ER dependent manner. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Jin, Xin; Wang, Yue] Tianjin Key Lab Prevent & Control Occupat & Envir, Tianjin 300309, Peoples R China.
   [Jin, Xin; Sun, Jing; Xie, Wen Li] Logist Univ Chinese Peoples Armed Police Force, Dept Pharmacol, Tianjin 300309, Peoples R China.
   [Yu, Bo; Wang, Yue; Yang, Jing; Huang, Su Hui] Logist Univ Chinese Peoples Armed Police Force, Dept Pathogen Biol & Immunol, Tianjin 300309, Peoples R China.
   [Sun, Wei Jia] Gen Hosp Chinese Peoples Armed Police Force, Dept Med Adm, Beijing 100039, Peoples R China.
RP Xie, WL (通讯作者)，Logist Univ Chinese Peoples Armed Police Force, Dept Pharmacol, Tianjin 300309, Peoples R China.
EM jinxin1227@126.com; sunjingsj2001@sina.com; 2457274460@qq.com;
   wangyue6808@126.com; niuniu19842006@163.com; yangjingdj@hotmail.com;
   sufi1209@126.com; 2236021259@qq.com
FU National Natural Science Foundation of China [81273520, 81572852];
   Program for Science and Technology of Logistics University of Chinese
   People's Armed Police Force [WHTD201303, WHJ201509, WHB201505]; Open
   Fund of Scientific Research Platform of Affiliated Hospital of Logistics
   University of Chinese People's Armed Police Force [WYKFM201609]
FX This research was supported by grants from the National Natural Science
   Foundation of China (81273520, 81572852) and the Program for Science and
   Technology of Logistics University of Chinese People's Armed Police
   Force (WHTD201303, WHJ201509, WHB201505), and the Open Fund of
   Scientific Research Platform of Affiliated Hospital of Logistics
   University of Chinese People's Armed Police Force (WYKFM201609). The
   authors declare no conflicts of interest.
CR An JP, 2001, J BIOL CHEM, V276, P17808, DOI 10.1074/jbc.M100953200
   Atmaca A, 2008, MENOPAUSE, V15, P748, DOI 10.1097/gme.0b013e31815c1e7f
   Aubin JE, 1998, BIOCHEM CELL BIOL, V76, P899, DOI 10.1139/bcb 76 6 899
   Beral V, 2011, JNCI J NATL CANCER I, V103, P296, DOI 10.1093/jnci/djq527
   Chen XW, 2002, BIOCHEM BIOPH RES CO, V295, P417, DOI 10.1016/S0006 291X(02)00667 8
   DAVIS VL, 1994, J BONE MINER RES, V9, P983
   De Wilde A, 2004, J CELL PHYSIOL, V200, P253, DOI 10.1002/jcp.20008
   FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601
   Feng J, 2008, BIOL PHARM BULL, V31, P1067, DOI 10.1248/bpb.31.1067
   Fujii S, 2016, BIOSCI BIOTECH BIOCH, V80, P1632, DOI 10.1080/09168451.2016.1184559
   Fujioka M, 2004, J NUTR, V134, P2623, DOI 10.1093/jn/134.10.2623
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Jilka RL, 2007, J BONE MINER RES, V22, P1492, DOI 10.1359/JBMR.070518
   Kang SH, 2009, ENVIRON TOXICOL PHAR, V28, P430, DOI 10.1016/j.etap.2009.07.007
   Kim H, 2015, J BONE MINER METAB, V33, P30, DOI 10.1007/s00774 014 0567 9
   Komrakova M, 2011, J ENDOCRINOL, V211, P157, DOI 10.1530/JOE 11 0096
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kousteni S, 2003, J CLIN INVEST, V111, P1651, DOI 10.1172/JCI200317261
   Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863
   Luo XH, 2003, ENDOCR RES, V29, P343, DOI 10.1081/ERC 120025041
   Manson JE, 2013, JAMA J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040
   Miki Y, 2009, J STEROID BIOCHEM, V113, P281, DOI 10.1016/j.jsbmb.2009.01.010
   Nishide Y, 2015, INT J ENV RES PUB HE, V12, P13750, DOI 10.3390/ijerph121113750
   Noda Seino H, 2013, J ENDOCRINOL INVEST, V36, P21, DOI 10.3275/8301
   Picherit C, 2000, J NUTR, V130, P1675, DOI 10.1093/jn/130.7.1675
   Qu Q, 1999, J CELL BIOCHEM, V73, P500, DOI 10.1002/(SICI)1097 4644(19990615)73:4<500::AID JCB8>3.3.CO;2 5
   Rickard DJ, 2003, J CELL BIOCHEM, V89, P633, DOI 10.1002/jcb.10539
   Setchell KD, 2001, J AM COLL NUTR, V20, p381S, DOI DOI 10.1080/07315724.2001.107
   Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168
   Srivastava K, 2013, PHYTOMEDICINE, V20, P470, DOI 10.1016/j.phymed.2012.12.021
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Sugimoto E, 2000, BIOCHEM PHARMACOL, V59, P471, DOI 10.1016/S0006 2952(99)00351 2
   Sun J, 2016, INT IMMUNOPHARMACOL, V40, P32, DOI 10.1016/j.intimp.2016.08.014
   Taku K, 2011, MATURITAS, V70, P333, DOI 10.1016/j.maturitas.2011.09.001
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tousen Y, 2016, BRIT J NUTR, V116, P247, DOI 10.1017/S0007114516001537
   Wang J, 2014, GENET MOL RES, V13, P5055, DOI 10.4238/2014.July.4.21
   Wang Y, 2013, PHYTOMEDICINE, V20, P787, DOI 10.1016/j.phymed.2013.03.005
   Wang Y, 2011, MOL CELL ENDOCRINOL, V344, P59, DOI 10.1016/j.mce.2011.06.027
   Wang Y, 2011, MOL CELL ENDOCRINOL, V337, P43, DOI 10.1016/j.mce.2011.01.018
   Watson CS, 2005, STEROIDS, V70, P364, DOI 10.1016/j.steroids.2005.03.002
   Watson CS, 2003, EXP BIOL MED, V228, P1272, DOI 10.1177/153537020322801106
   Zallone A, 2006, ANN NY ACAD SCI, V1068, P173, DOI 10.1196/annals.1346.019
NR 44
TC 49
Z9 55
U1 0
U2 38
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271 5317
J9 NUTR RES
JI Nutr. Res.
PD JUN
PY 2017
VL 42
BP 20
EP 30
DI 10.1016/j.nutres.2017.04.009
PG 11
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Nutrition & Dietetics
GA EZ6CZ
UT WOS:000404807300003
PM 28633868
DA 2025 08 17
ER

PT J
AU Rossi, F
   Bellini, G
   Luongo, L
   Torella, M
   Mancusi, S
   De Petrocellis, L
   Petrosino, S
   Siniscalco, D
   Orlando, P
   Scafuro, M
   Colacurci, N
   Perrotta, S
   Nobili, B
   Di Marzo, V
   Maione, S
AF Rossi, Francesca
   Bellini, Giulia
   Luongo, Livio
   Torella, Marco
   Mancusi, Silvia
   De Petrocellis, Luciano
   Petrosino, Stefania
   Siniscalco, Dario
   Orlando, Pierangelo
   Scafuro, Mariantonietta
   Colacurci, Nicola
   Perrotta, Silverio
   Nobili, Bruno
   Di Marzo, Vincenzo
   Maione, Sabatino
CA ERG
TI The endovanilloid/endocannabinoid system: A new potential target for
   osteoporosis therapy
SO BONE
LA English
DT Article
DE Menopause; Human bone; Osteoclasts; Vanilloid and cannabinoid receptors;
   Bone turnover markers
ID BONE MASS; CANNABINOID RECEPTOR; POSTMENOPAUSAL WOMEN; OSTEOCLAST
   FUNCTION; VANILLOID RECEPTOR; CB1 RECEPTOR; IN VITRO; ANANDAMIDE; TRPV1;
   IDENTIFICATION
AB Human osteoclasts express functional TRPV1 channels, CB1/CB2 cannabinoid receptors and endocannabinoid/endovanilloid synthetic/catabolic enzymes. Pharmacologic manipulation of this system can modulate osteoclast activity. Here, through multidisciplinary approaches, we demonstrate that enzymes and receptors of the endocannabinoid/endovanilloid system are differently expressed in osteoclasts from menopausal women without or with osteoporosis. We report that in osteoclasts from osteoporotic patients, TRPV1 channels are upregulated and, if persistently stimulated with resiniferatoxin, become clustered to the plasma membrane while inducing a massive over expression of CB2 receptors. By providing new evidence for a critical functional cross talk between CB2 and TRPV1 receptors in osteoporosis, we speculate that TRPV1 desensitization, or its enhanced trafficking, together with TRPV1 agonist induced CB2 receptor overexpression, might be critical to minimize calcium entry in osteoclasts, which could be in turn responsible of cell over activation and higher bone resorption. Our data pave the way to the use of TRPV1 agonist together with CB2 agonists or CB1 antagonists in osteoporosis. (C) 2011 Published by Elsevier Inc.
C1 [Bellini, Giulia; Luongo, Livio; Mancusi, Silvia; Siniscalco, Dario; Scafuro, Mariantonietta; Maione, Sabatino] Univ Naples 2, Dept Expt Med, I 80138 Naples, Italy.
   [Rossi, Francesca; Perrotta, Silverio; Nobili, Bruno] Univ Naples 2, Dept Pediat, I 80138 Naples, Italy.
   [Torella, Marco; Colacurci, Nicola] Univ Naples 2, Dept Gynecol Obstet & Reprod Sci, I 80138 Naples, Italy.
   [De Petrocellis, Luciano; Petrosino, Stefania; Orlando, Pierangelo; Di Marzo, Vincenzo] CNR, Inst Cybernet, Inst Biomol Chem, I 80078 Naples, Italy.
   [De Petrocellis, Luciano; Petrosino, Stefania; Orlando, Pierangelo; Di Marzo, Vincenzo; ERG] CNR, Inst Prot Biochem, I 80078 Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; Universita della Campania Vanvitelli; Consiglio Nazionale
   delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello"
   (ICIB CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Biochimica delle Proteine (IBP CNR)
RP Maione, S (通讯作者)，Univ Naples 2, Dept Expt Med, Via Costantinopoli 16, I 80138 Naples, Italy.
EM fra.rossi76@libero.it; giuliabellini@hotmail.com; livioluongo@inwind.it;
   marco.torella@unina2.it; silviamancusi@libero.it;
   l.depetrocellis@cib.na.cnr.it; spetrosino@icmib.na.cnr.it;
   dariosin@uab.edu; p.orlando@ibp.cnr.it;
   mariantonietta.scafuro@unina2.it; nicola.colacurci@unina2.it;
   silverio.perrotta@unina2.it; bruno.nobili@unina2.it;
   vdimarzo@icmib.na.cnr.it; sabatino.maione@unina2.it
RI ; torella, marco/I 7608 2012; maione, sabatino/HTM 5113 2023;
   Siniscalco, Dario/H 4657 2019; Rossi, Francesca/HTP 5870 2023; Luongo,
   Livio/GXV 1993 2022; Di Marzo, Vincenzo/AAD 7742 2019
OI Siniscalco, Dario/0000 0002 3779 2596; Perrotta,
   Silverio/0000 0001 6149 6845; Luongo, Livio/0000 0002 1949 2039; Rossi,
   Francesca/0000 0003 2879 6277; Maione, Sabatino/0000 0003 3850 6704;
   Torella, Marco/0000 0001 8853 5760; Di Marzo,
   Vincenzo/0000 0002 1490 3070
CR Abed E, 2009, MOL MEMBR BIOL, V26, P146, DOI 10.1080/09687680802612721
   Ahluwalia J, 2003, EUR J NEUROSCI, V17, P2611, DOI 10.1046/j.1460 9568.2003.02703.x
   Bab I, 2008, J NEUROENDOCRINOL, V20, P69, DOI 10.1111/j.1365 2826.2008.01675.x
   Bab I, 2009, ANN MED, V41, P560, DOI 10.1080/07853890903121025
   Brown AJ, 2007, BRIT J PHARMACOL, V152, P567, DOI 10.1038/sj.bjp.0707481
   CHRISTIANSEN C, 1981, LANCET, V1, P459
   Compston J, 2009, EUR J RADIOL, V71, P388, DOI 10.1016/j.ejrad.2008.04.063
   Curtis JR, 2009, J GEN INTERN MED, V24, P956, DOI 10.1007/s11606 009 1031 8
   Datta HK, 2008, J CLIN PATHOL, V61, P577, DOI 10.1136/jcp.2007.048868
   De Petrocellis L, 2005, LIFE SCI, V77, P1651, DOI 10.1016/j.lfs.2005.05.021
   Engeli S, 2005, DIABETES, V54, P2838, DOI 10.2337/diabetes.54.10.2838
   García Sanz N, 2004, J NEUROSCI, V24, P5307, DOI 10.1523/JNEUROSCI.0202 04.2004
   Guggenbuhl P, 2009, JOINT BONE SPINE, V76, P595, DOI 10.1016/j.jbspin.2009.10.001
   Hermann H, 2003, CELL MOL LIFE SCI, V60, P607, DOI 10.1007/s000180300052
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Idris AI, 2008, ENDOCRINOLOGY, V149, P5619, DOI 10.1210/en.2008 0150
   Idris AI, 2010, BONE, V46, P1089, DOI 10.1016/j.bone.2010.01.368
   Idris AI, 2009, CELL METAB, V10, P139, DOI 10.1016/j.cmet.2009.07.006
   Karsak M, 2005, HUM MOL GENET, V14, P3389, DOI 10.1093/hmg/ddi370
   Maccarrone M, 2008, NAT NEUROSCI, V11, P152, DOI 10.1038/nn2042
   Mackie K, 2006, AAPS J, V8, pE298, DOI 10.1007/BF02854900
   Maione S, 2007, BRIT J PHARMACOL, V150, P766, DOI 10.1038/sj.bjp.0707145
   Ofek O, 2006, P NATL ACAD SCI USA, V103, P696, DOI 10.1073/pnas.0504187103
   Palazzo E, 2010, VANILLOID RECEPTOR T
   Petrosino S, 2007, NEUROPHARMACOLOGY, V52, P415, DOI 10.1016/j.neuropharm.2006.08.011
   Pines A, 2009, CLIMACTERIC, V12, P62, DOI 10.1080/13697130902785449
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Premkumar LS, 2010, AAPS J
   Rossi F, 2009, BONE, V44, P476, DOI 10.1016/j.bone.2008.10.056
   Ryberg E, 2005, FEBS LETT, V579, P259, DOI 10.1016/j.febslet.2004.11.085
   Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050
   STEVENSON JC, 1982, BRIT MED J, V285, P585, DOI 10.1136/bmj.285.6342.585
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tominaga M, 2005, PFLUG ARCH EUR J PHY, V451, P143, DOI 10.1007/s00424 005 1457 8
   Wasnich Richard D, 2004, Menopause, V11, P622
   Whyte LS, 2009, P NATL ACAD SCI USA, V106, P16511, DOI 10.1073/pnas.0902743106
   Zethraeus N, 2007, OSTEOPOROSIS INT, V18, P9, DOI 10.1007/s00198 006 0257 0
NR 37
TC 46
Z9 53
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY 1
PY 2011
VL 48
IS 5
BP 997
EP 1007
DI 10.1016/j.bone.2011.01.001
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 754TK
UT WOS:000289879900006
PM 21237298
DA 2025 08 17
ER

PT J
AU Wang, JW
   Tao, S
   Jin, XY
   Song, YQ
   Zhou, WT
   Lou, HY
   Zhao, R
   Wang, C
   Hu, FQ
   Yuan, H
AF Wang, Jianwei
   Tao, Shan
   Jin, Xiangyu
   Song, Yanqing
   Zhou, Wentao
   Lou, Haiya
   Zhao, Rui
   Wang, Cheng
   Hu, Fuqiang
   Yuan, Hong
TI Calcium Supplement by Tetracycline guided amorphous Calcium Carbonate
   potentiates Osteoblast promotion for Synergetic Osteoporosis Therapy
SO THERANOSTICS
LA English
DT Article
DE calcium supplement; osteoporosis; amorphous calcium carbonate;
   osteoblast promotion
ID MESENCHYMAL STEM CELLS; BONE MINERAL DENSITY; IN VITRO; DIFFERENTIATION;
   NANOPARTICLES; FRACTURES; DELIVERY; PLGA; IMPROVEMENT; IMPLANTS
AB Background: The calcium supplement is a clinically approved approach for osteoporosis therapy but usually requires a large dosage without targetability and with poor outcome. This modality is not fully explored in current osteoporosis therapy due to the lack of proper calcium supplement carrier.
   Methods: In this study, we constructed a tetracycline (Tc) modified and simvastatin (Sim) loaded phospholipid amorphous calcium carbonate ( ACC) hybrid nanoparticle (Tc/ACC/Sim).
   Results: The resulted Tc/ACC/Sim was able to enhance its accumulation at the osteoporosis site. Most importantly, the combination of calcium supplement and Sim offered synergetic osteoblast promotion therapy of osteoporosis with advanced performance than non targeted system or mono therapy.
   Conclusion: This platform provides an alternative approach to stimulate bone formation by synergetic promotion of osteoblast differentiation using calcium supplement and Sim.
C1 [Tao, Shan; Jin, Xiangyu; Song, Yanqing; Zhou, Wentao; Wang, Cheng; Hu, Fuqiang; Yuan, Hong] Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.
   [Wang, Jianwei] Zhejiang Univ, Affiliated Hosp 2, Sch Med, 88 Jiefang Rd, Hangzhou 310009, Peoples R China.
   [Lou, Haiya; Zhao, Rui] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, 3 Qingchun East Rd, Hangzhou 310016, Peoples R China.
   [Wang, Cheng] Changzhou Univ, Sch Pharmaceut Engn & Life Sci, Changzhou 213164, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Changzhou
   University
RP Wang, C; Yuan, H (通讯作者)，Zhejiang Univ, Coll Pharmaceut Sci, 866 Yuhangtang Rd, Hangzhou 310058, Peoples R China.; Wang, C (通讯作者)，Changzhou Univ, Sch Pharmaceut Engn & Life Sci, Changzhou 213164, Peoples R China.
EM 11519016@zju.edu.cn; yuanhong70@zju.edu.cn
RI Jin, Xiangyu/JZE 4112 2024; Zhao, Rui/AEY 6449 2022
FU National Natural Science Foundation of China [81773644]; Natural Science
   Foundation of Zhejiang Province [LY18H060002, LY16H180003]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81773644) and Natural Science Foundation of Zhejiang Province
   (No. LY18H060002, LY16H180003).
CR Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cai MX, 2017, INT J NANOMED, V12, P7469, DOI 10.2147/IJN.S139775
   Chen PY, 2010, NUTR RES, V30, P191, DOI 10.1016/j.nutres.2010.03.004
   Duan XH, 2018, THERANOSTICS, V8, P5379, DOI 10.7150/thno.28391
   FARLEY JR, 1983, SCIENCE, V222, P330
   Fromigué O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873
   Fu YC, 2014, ACTA BIOMATER, V10, P4583, DOI 10.1016/j.actbio.2014.07.015
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Ho ML, 2008, J CONTROL RELEASE, V128, P142, DOI 10.1016/j.jconrel.2008.02.012
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kwak YD, 2014, BIOCHEM BIOPH RES CO, V447, P394, DOI 10.1016/j.bbrc.2014.03.139
   Legrand E, 2000, J BONE MINER RES, V15, P13, DOI 10.1359/jbmr.2000.15.1.13
   Li CJ, 2016, ORTHOP SURG, V8, P105, DOI 10.1111/os.12238
   Lieberman JR, 2002, J BONE JOINT SURG AM, V84A, P1032, DOI 10.2106/00004623 200206000 00022
   Lin CJ, 2019, THERANOSTICS, V9, P3780, DOI 10.7150/thno.34493
   Liu DD, 2014, J BIOL INORG CHEM, V19, P879, DOI 10.1007/s00775 014 1119 4
   Liu W, 2016, OSTEOPOROSIS INT, V27, P93, DOI 10.1007/s00198 015 3217 8
   Low SA, 2012, ADV DRUG DELIVER REV, V64, P1189, DOI 10.1016/j.addr.2012.01.012
   Lv YJ, 2018, THERANOSTICS, V8, P2387, DOI 10.7150/thno.23620
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Metavarayuth K, 2019, NANO LETT, V19, P8372, DOI 10.1021/acs.nanolett.9b02001
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Narayanan D, 2013, MOL PHARMACEUT, V10, P4159, DOI 10.1021/mp400184v
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Park JB, 2012, J SURG RES, V174, P278, DOI 10.1016/j.jss.2010.12.029
   Pauly S, 2009, BONE, V45, P505, DOI 10.1016/j.bone.2009.05.010
   PERRIN DD, 1965, NATURE, V208, P787, DOI 10.1038/208787a0
   Quan HY, 2018, ACS APPL MATER INTER, V10, P25547, DOI 10.1021/acsami.8b09879
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Sahana H, 2013, J BIOMED NANOTECHNOL, V9, P193, DOI 10.1166/jbn.2013.1482
   Tang Q, 2019, THERANOSTICS, V9, P1125, DOI 10.7150/thno.29566
   Teitelbaum SL, 2010, CELL STEM CELL, V7, P553, DOI 10.1016/j.stem.2010.10.004
   Wang C, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201900501
   Wang C, 2019, INT J NANOMED, V14, P1503, DOI 10.2147/IJN.S193976
   Wang C, 2018, CHEM COMMUN, V54, P13080, DOI 10.1039/c8cc07694d
   Wang C, 2018, ADV MATER, V30, DOI 10.1002/adma.201706407
   Wang D, 2005, ADV DRUG DELIVER REV, V57, P1049, DOI 10.1016/j.addr.2004.12.011
   Wang H, 2015, INT J NANOMED, V10, P5671, DOI 10.2147/IJN.S88798
   Yamashita M, 2008, J ENDOCRINOL, V196, P601, DOI 10.1677/JOE 07 0532
   Yang F, 2011, ORAL SURG ORAL MED O, V111, P551, DOI 10.1016/j.tripleo.2010.06.018
   Yuan H, 2007, COLLOID SURFACE B, V58, P157, DOI 10.1016/j.colsurfb.2007.03.002
   Zhao Y, 2015, ANGEW CHEM INT EDIT, V54, P919, DOI 10.1002/anie.201408510
   Zumbrennen Bullough KB, 2014, J BIOL CHEM, V289, P23796, DOI 10.1074/jbc.M114.577387
NR 45
TC 36
Z9 38
U1 2
U2 100
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2020
VL 10
IS 19
BP 8591
EP 8605
DI 10.7150/thno.45142
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA MK1RN
UT WOS:000548563800009
PM 32754265
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Anderson, G
   Gries, M
   Kurihara, N
   Honjo, T
   Anderson, J
   Donnenberg, V
   Donnenberg, A
   Ghobrial, I
   Mapara, MY
   Stirling, D
   Roodman, D
   Lentzsch, S
AF Anderson, G
   Gries, M
   Kurihara, N
   Honjo, T
   Anderson, J
   Donnenberg, V
   Donnenberg, A
   Ghobrial, I
   Mapara, MY
   Stirling, D
   Roodman, D
   Lentzsch, S
TI Thalidomide derivative CC 4047 inhibits osteoclast formation by
   down regulation of PU.1
SO BLOOD
LA English
DT Article
ID COLONY STIMULATING FACTOR; TRANSCRIPTION FACTOR PU.1; REFRACTORY
   MULTIPLE MYELOMA; HUMAN MARROW CULTURES; TUMOR NECROSIS FACTOR;
   HUMAN BONE MARROW; LINEAGE COMMITMENT; STEM CELLS; IN VITRO; C FOS
AB CC 4047, an immunomodulatory analog of thalidomide, inhibits multiple myeloma with unknown effects on the human osteoclast lineage. Early osteoclast progenitors are of hematopoietic origin and differentiate into mature bone resorbing multinucleated osteoclasts. We investigated the effects of CC 4047 and thalidomide on human osteoclastogenesis, using in vitro receptor activator of NF kappa B ligand/macrophage colony stimulating factor stimulated bone marrow cell cultures. Treating bone marrow cultures with CC 4047 for 3 weeks decreased osteoclast formation accompanied by complete inhibition of bone resorption. The inhibitory effect was similar when cultures were treated for 3 weeks or for only the first week (90% inhibition), indicating that CC 4047 inhibits early stages of osteoclast formation. Inhibition of osteoclastogenesis by CC 4047 was mediated by a shift of lineage commitment to granulocyte colony forming units at the expense of granulocyte macrophage colony forming units. Further studies revealed that this shift in lineage commitment was mediated through down regulation of PU.1. Treatment with thalidomide resulted in significantly less potent inhibition of osteoclast formation and bone resorption. These results provide evidence that CC 4047 blocks osteoclast differentiation during early phases of osteoclastogenesis. Therefore, CC 4047 might be a valuable drug for targeting both tumors and osteoclastic activity in patients with multiple myeloma and other diseases associated with osteolytic lesions.
C1 Univ Pittsburgh, Ctr Canc, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15232 USA.
   Humboldt Univ, Med Ctr Charite, Robert Rossle Klin, Dept Hematol Oncol & Tumorimmunol, Berlin, Germany.
   Celgene Corp, Warren, NJ USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; Bristol Myers Squibb; Celgene
   Corporation
RP Univ Pittsburgh, Ctr Canc, Dept Med, Div Hematol Oncol, UPMC Canc Pavil,5th Floor,5150 Ctr Ave, Pittsburgh, PA 15232 USA.
EM lentzschs@upmc.edu
RI mapara, markus/A 2134 2013
CR Akagawa KS, 1996, BLOOD, V88, P4029, DOI 10.1182/blood.V88.10.4029.bloodjournal88104029
   Anderson KL, 1998, BLOOD, V92, P1576, DOI 10.1182/blood.V92.5.1576.417k29_1576_1585
   Anderson KL, 2001, J BIOL CHEM, V276, P7637, DOI 10.1074/jbc.M009133200
   ASH P, 1980, NATURE, V283, P669, DOI 10.1038/283669a0
   BANILENION S, 2003, HEMATOLOGY, P248
   Cantor AB, 2001, CURR OPIN GENET DEV, V11, P513, DOI 10.1016/S0959 437X(00)00226 4
   CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0
   CHENU C, 1990, J BONE MINER RES, V5, P677
   Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973
   Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075
   DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456
   DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439
   DEMULDER A, 1993, ENDOCRINOLOGY, V133, P1978, DOI 10.1210/en.133.5.1978
   Enver T, 1998, BLOOD, V92, P348, DOI 10.1182/blood.V92.2.348.Con3_348_351
   Fox SW, 2003, J IMMUNOL, V170, P3679, DOI 10.4049/jimmunol.170.7.3679
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   KERBY JA, 1992, J BONE MINER RES, V7, P353
   KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092 8674(90)90219 5
   Koh KR, 2005, BLOOD, V105, P3833, DOI 10.1182/blood 2004 03 0828
   KURIHARA N, 1990, ENDOCRINOLOGY, V126, P2733, DOI 10.1210/endo 126 5 2733
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Lentzsch S, 2003, LEUKEMIA, V17, P41, DOI 10.1038/sj.leu.2402745
   Lentzsch S, 2002, CANCER RES, V62, P2300
   MACDONALD BR, 1987, ENDOCRINOLOGY, V120, P2326, DOI 10.1210/endo 120 6 2326
   Mapara MY, 1999, EXP HEMATOL, V27, P169, DOI 10.1016/S0301 472X(98)00067 8
   MCBRIDE WG, 1981, LANCET, V2, P368
   McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460 2075.1996.tb00949.x
   Menaa C, 2000, BIOCHEM BIOPH RES CO, V267, P943, DOI 10.1006/bbrc.1999.2042
   Metcalf D, 1998, BLOOD, V92, P345, DOI 10.1182/blood.V92.2.345b.Con2_345_347
   Miyamoto Takeshi, 2003, Keio J Med, V52, P1
   PAHL HL, 1993, J BIOL CHEM, V268, P5014
   PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116
   Quinn JMW, 2005, BIOCHEM BIOPH RES CO, V328, P739, DOI 10.1016/j.bbrc.2004.11.076
   REID CDL, 1992, J IMMUNOL, V149, P2681
   Richardson PG, 2002, BLOOD, V100, P3063, DOI 10.1182/blood 2002 03 0996
   ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801
   SCHEVEN BAA, 1986, NATURE, V321, P79, DOI 10.1038/321079a0
   Schey SA, 2004, J CLIN ONCOL, V22, P3269, DOI 10.1200/JCO.2004.10.052
   SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170
   Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102
   Suzuki S, 1998, P NATL ACAD SCI USA, V95, P6085, DOI 10.1073/pnas.95.11.6085
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2005, J MOL MED, V83, P170, DOI 10.1007/s00109 004 0612 6
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   WEBER D, 2005, 10 INT MY WORKSH APR
   ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085
NR 48
TC 125
Z9 136
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD APR 15
PY 2006
VL 107
IS 8
BP 3098
EP 3105
DI 10.1182/blood 2005 08 3450
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 033FY
UT WOS:000236833500023
PM 16373662
DA 2025 08 17
ER

PT J
AU Regan, JN
   Lim, J
   Shi, Y
   Joeng, KS
   Arbeit, JM
   Shohet, RV
   Long, FX
AF Regan, Jenna N.
   Lim, Joohyun
   Shi, Yu
   Joeng, Kyu Sang
   Arbeit, Jeffrey M.
   Shohet, Ralph V.
   Long, Fanxin
TI Up regulation of glycolytic metabolism is required for HIF1α driven bone
   formation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HYPOXIA INDUCIBLE FACTOR; BINDING SITES; FACTOR I; ACTIVATION;
   OSTEOBLAST; VEGF; DEHYDROGENASE; CARTILAGE; DISTINCT; 1 ALPHA
AB The bone marrow environment is among the most hypoxic in the body, but how hypoxia affects bone formation is not known. Because low oxygen tension stabilizes hypoxia inducible factor alpha (HIF alpha) proteins, we have investigated the effect of expressing a stabilized form of HIF1 alpha in osteoblast precursors. Brief stabilization of HIF1 alpha in SP7 positive cells in postnatal mice dramatically stimulated cancellous bone formation via marked expansion of the osteoblast population. Remarkably, concomitant deletion of vascular endothelial growth factor A (VEGFA) in the mouse did not diminish bone accrual caused by HIF1 alpha stabilization. Thus, HIF1 alpha driven bone formation is independent of VEGFA up regulation and increased angiogenesis. On the other hand, HIF1 alpha stabilization stimulated glycolysis in bone through up regulation of key glycolytic enzymes including pyruvate dehydrogenase kinase 1 (PDK1). Pharmacological inhibition of PDK1 completely reversed HIF1 alpha driven bone formation in vivo. Thus, HIF1 alpha stimulates osteoblast formation through direct activation of glycolysis, and alterations in cellular metabolism may be a broadly applicable mechanism for regulating cell differentiation.
C1 [Regan, Jenna N.; Lim, Joohyun; Shi, Yu; Long, Fanxin] Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.
   [Joeng, Kyu Sang; Long, Fanxin] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.
   [Arbeit, Jeffrey M.] Washington Univ, Sch Med, Dept Surg, St Louis, MO 63110 USA.
   [Long, Fanxin] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO 63110 USA.
   [Shohet, Ralph V.] Univ Hawaii, Dept Med, Honolulu, HI 96813 USA.
C3 Washington University (WUSTL); Washington University (WUSTL); Washington
   University (WUSTL); Washington University (WUSTL); University of Hawaii
   System
RP Long, FX (通讯作者)，Washington Univ, Sch Med, Dept Orthopaed Surg, St Louis, MO 63110 USA.
EM longf@wudosis.wustl.edu
RI Lim, Joohyun/HIR 7445 2022; Arbeit, Jeffrey/K 6920 2019; Shi,
   Yu/J 5370 2018
OI Lim, Joohyun/0000 0001 9670 806X; Regan, Jenna/0000 0002 6698 3340
FU National Institutes of Health [R01 DK065789, R01 AR055923, T32 HL007873,
   P30 AR057235]
FX The work is supported by National Institutes of Health Grants R01
   DK065789 and R01 AR055923 (to F. L.), T32 HL007873 (to J.N.R.), and P30
   AR057235 (Washington University Center for Musculoskeletal Research).
CR ARTEEL GE, 1995, BRIT J CANCER, V72, P889, DOI 10.1038/bjc.1995.429
   Bekeredjian R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011693
   Benita Y, 2009, NUCLEIC ACIDS RES, V37, P4587, DOI 10.1093/nar/gkp425
   Chow DC, 2001, BIOPHYS J, V81, P685, DOI 10.1016/S0006 3495(01)75733 5
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
   Gerber HP, 1999, DEVELOPMENT, V126, P1149
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hilton MJ, 2005, DEVELOPMENT, V132, P4339, DOI 10.1242/dev.02025
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Imai S, 2000, COLD SPRING HARB SYM, V65, P297, DOI 10.1101/sqb.2000.65.297
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Lendahl U, 2009, NAT REV GENET, V10, P821, DOI 10.1038/nrg2665
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467
   Maes C, 2012, J BONE MINER RES, V27, P596, DOI 10.1002/jbmr.1487
   Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schödel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood 2010 10 314427
   Semenza GL, 2011, COLD SH Q B, V76, P347, DOI 10.1101/sqb.2011.76.010678
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Shomento SH, 2010, J CELL BIOCHEM, V109, P196, DOI 10.1002/jcb.22396
   Simon MC, 2008, NAT REV MOL CELL BIO, V9, P285, DOI 10.1038/nrm2354
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang Y, 2007, J CLIN INVEST, V117, P1616, DOI 10.1172/JCI31581
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   WHITEHOUSE S, 1974, BIOCHEM J, V141, P761, DOI 10.1042/bj1410761
NR 33
TC 136
Z9 149
U1 1
U2 22
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 10
PY 2014
VL 111
IS 23
BP 8673
EP 8678
DI 10.1073/pnas.1324290111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AI6IJ
UT WOS:000336976000085
PM 24912186
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Fang, C
   Guo, JW
   Wang, YJ
   Li, XQ
   Zhang, H
   Cui, J
   Hu, Y
   Jing, YY
   Chen, X
   Su, JC
AF Fang, Chao
   Guo, Jia wei
   Wang, Ya jun
   Li, Xiao qun
   Zhang, Hao
   Cui, Jin
   Hu, Yan
   Jing, Ying ying
   Chen, Xiao
   Su, Jia can
TI Diterbutyl phthalate attenuates osteoarthritis in ACLT mice via
   suppressing ERK/c fos/NFATc1 pathway, and subsequently inhibiting
   subchondral osteoclast fusion
SO ACTA PHARMACOLOGICA SINICA
LA English
DT Article
DE osteoarthritis; Panax notoginseng; diterbutyl phthalate;
   osteoclastogenesis; subchondral bone; ERK; c fos; NFATc1 pathway;
   two dimensional cell membrane chromatography (2D; CMC); ACLT mice
ID MESENCHYMAL STEM CELLS; ARTICULAR CARTILAGE; KNEE OSTEOARTHRITIS;
   CROSS TALK; BONE; ANGIOGENESIS; ALENDRONATE; PAIN; COMPONENTS; EXHIBIT
AB Osteoarthritis (OA) is the most common arthritis with a rapidly increasing prevalence. Disease progression is irreversible, and there is no curative therapy available. During OA onset, abnormal mechanical loading leads to excessive osteoclastogenesis and bone resorption in subchondral bone, causing a rapid subchondral bone turnover, cyst formation, sclerosis, and finally, articular cartilage degeneration. Moreover, osteoclast mediated angiogenesis and sensory innervation in subchondral bone result in abnormal vascularization and OA pain. The traditional Chinese medicine Panax notoginseng (PN; Sanqi) has long been used in treatment of bone diseases including osteoporosis, bone fracture, and OA. In this study we established two dimensional/bone marrow mononuclear cell/cell membrane chromatography/time of flight mass spectrometry (2D/BMMC/CMC/TOFMS) technique and discovered that diterbutyl phthalate (DP) was the active constituent in PN inhibiting osteoclastogenesis. Then we explored the therapeutic effect of DP in an OA mouse model with anterior cruciate ligament transaction (ACLT). After ACLT was conducted, the mice received DP (5 mg center dot kg( 1)center dot d( 1), ip) for 8 weeks. Whole knee joint tissues of the right limb were harvested at weeks 2, 4, and 8 for analysis. We showed that DP administration impeded overactivated osteoclastogenesis in subchondral bone and ameliorated articular cartilage deterioration. DP administration blunted aberrant H type vessel formation in subchondral bone marrow and alleviated OA pain assessed in Von Frey test and thermal plantar test. In RANKL induced RAW264.7 cells in vitro, DP (20 mu M) retarded osteoclastogenesis by suppressing osteoclast fusion through inhibition of the ERK/c fos/NFATc1 pathway. DP treatment also downregulated the expression of dendritic cell specific transmembrane protein (DC STAMP) and d2 isoform of the vacuolar (H+) ATPase V0 domain (Atp6v0d2) in the cells. In conclusion, we demonstrate that DP prevents OA progression by inhibiting abnormal osteoclastogenesis and associated angiogenesis and neurogenesis in subchondral bone.
C1 [Fang, Chao; Guo, Jia wei; Wang, Ya jun; Li, Xiao qun; Zhang, Hao; Cui, Jin; Hu, Yan; Chen, Xiao; Su, Jia can] Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai 200433, Peoples R China.
   [Jing, Ying ying; Su, Jia can] Shanghai Univ, Inst Translat Med, Shanghai 201901, Peoples R China.
   [Chen, Xiao] Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.
   [Su, Jia can] Shanghai Clin Res Ctr Aging & Med, Shanghai 200040, Peoples R China.
C3 Naval Medical University; Shanghai University; Fudan University
RP Chen, X; Su, JC (通讯作者)，Naval Med Univ, Shanghai Changhai Hosp, Dept Orthoped Trauma, Shanghai 200433, Peoples R China.; Jing, YY; Su, JC (通讯作者)，Shanghai Univ, Inst Translat Med, Shanghai 201901, Peoples R China.; Chen, X (通讯作者)，Fudan Univ, Dept Chem, Shanghai 200433, Peoples R China.; Su, JC (通讯作者)，Shanghai Clin Res Ctr Aging & Med, Shanghai 200040, Peoples R China.
EM jingy4172@shu.edu.cn; sirchenxiao@126.com; drsujiacan@163.com
RI ; Chen, Xiao/G 2310 2018; Su, Jiacan/N 7068 2019; Guo,
   Jiawei/JMH 1084 2023
OI Guo, Jiawei/0000 0002 7613 932X; Su, Jiacan/0000 0001 7080 263X; 
FU National Key Research and Development Plan [2018YFC2001500]; National
   Natural Science Foundation of China (NSFC) Key Research Program in Aging
   [91749204]; National Natural Science Foundation of China [81771491,
   81871099, 81972254]; Shanghai Rising Star Program [21QA1412000]; School
   of Pharmacy of Naval Medical University
FX This work was supported by the National Key Research and Development
   Plan (2018YFC2001500); National Natural Science Foundation of China
   (NSFC) Key Research Program in Aging (91749204); National Natural
   Science Foundation of China (81771491, 81871099, 81972254); and Shanghai
   Rising Star Program (21QA1412000). We thank the Experimental Center of
   Changhai Hospital for providing experimental instruments and reagents.
   The technique of 2D/BMMC/CMC/TOFMS is supported by the School of
   Pharmacy of Naval Medical University. We appreciate the work of Dr
   Yan qiu Gu for screening DP from PN.
CR Aso K, 2020, OSTEOARTHR CARTILAGE, V28, P1245, DOI 10.1016/j.joca.2020.05.010
   Austin PJ, 2012, JOVE J VIS EXP, DOI 10.3791/3393
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bultink IEM, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0328 0
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chang SH, 2005, INT IMMUNOPHARMACOL, V5, P1365, DOI 10.1016/j.intimp.2005.02.019
   Chen D, 2017, BONE RES, V5, DOI 10.1038/boneres.2016.44
   Chen XF, 2014, ANAL CHEM, V86, P4748, DOI 10.1021/ac500287e
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Cui Z, 2015, BONE, V74, P37, DOI 10.1016/j.bone.2014.12.065
   Dar AA, 2020, J SEP SCI, V43, P105, DOI 10.1002/jssc.201900656
   Deveza LA, 2018, RHEUMATOLOGY, V57, P34, DOI 10.1093/rheumatology/kex417
   Ding M, 2008, CALCIFIED TISSUE INT, V82, P77, DOI 10.1007/s00223 007 9093 2
   DIXON WJ, 1980, ANNU REV PHARMACOL, V20, P441, DOI 10.1146/annurev.pa.20.040180.002301
   Donell S, 2019, EFORT OPEN REV, V4, P221, DOI 10.1302/2058 5241.4.180102
   Du WX, 2015, PHYTOMEDICINE, V22, P813, DOI 10.1016/j.phymed.2015.05.056
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Goldring SR, 2012, THER ADV MUSCULOSKEL, V4, P249, DOI 10.1177/1759720X12437353
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Gu YQ, 2020, ACTA PHARM SIN B, V10, P1856, DOI 10.1016/j.apsb.2020.01.019
   Gu YQ, 2019, J PHARMACEUT BIOMED, V164, P550, DOI 10.1016/j.jpba.2018.10.028
   Guiducci S, 2011, ANN RHEUM DIS, V70, P2011, DOI 10.1136/ard.2011.150607
   HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304 3959(88)90026 7
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Helming L, 2009, TRENDS CELL BIOL, V19, P514, DOI 10.1016/j.tcb.2009.07.005
   Hu WH, 2021, ANN RHEUM DIS, V80, P413, DOI 10.1136/annrheumdis 2020 218089
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Karsdal MA, 2014, ANN RHEUM DIS, V73, P336, DOI 10.1136/annrheumdis 2013 204111
   Khorasani MS, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0546 0
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kleiner G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/434010
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Lee MS., 1950, J IMMUNOL, V2009, P3390
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   LI B, 2018, SCI REP UK, V8
   Li XQ, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abb7135
   Li YC, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00685
   Lories RJ, 2011, NAT REV RHEUMATOL, V7, P43, DOI 10.1038/nrrheum.2010.197
   Mapp PI, 2012, NAT REV RHEUMATOL, V8, P390, DOI 10.1038/nrrheum.2012.80
   Meng LQ, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/8873261
   Müller G, 1998, EMBO J, V17, P732, DOI 10.1093/emboj/17.3.732
   Nakamura I, 2012, MOD RHEUMATOL, V22, P167, DOI 10.1007/s10165 011 0530 8
   Ni SF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 13476 9
   Park SH, 2009, KOREAN J PHYSIOL PHA, V13, P33, DOI 10.4196/kjpp.2009.13.1.33
   Peng LH, 2010, J ETHNOPHARMACOL, V131, P282, DOI 10.1016/j.jep.2010.06.039
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Sharma AR, 2013, INT J MOL SCI, V14, P19805, DOI 10.3390/ijms141019805
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Strassle BW, 2010, OSTEOARTHR CARTILAGE, V18, P1319, DOI 10.1016/j.joca.2010.06.007
   Sun MMG, 2018, CURR OPIN PHARMACOL, V40, P81, DOI 10.1016/j.coph.2018.03.008
   Suri S, 2007, ANN RHEUM DIS, V66, P1423, DOI 10.1136/ard.2006.063354
   Takayanagi H, 2007, ANN NY ACAD SCI, V1116, P227, DOI 10.1196/annals.1402.071
   Tang X, 2016, ARTHRITIS RHEUMATOL, V68, P648, DOI 10.1002/art.39465
   Tateiwa D, 2019, CELLS BASEL, V8, DOI 10.3390/cells8080818
   Walsh DA, 2015, BRIT J CLIN PHARMACO, V80, P965, DOI 10.1111/bcp.12669
   Wang YY, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.129
   Wei JL, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1485 8
   Weinstein SL, 2006, NEW ENGL J MED, V354, P2508
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xiong JH, 2011, NAT MED, V17, P1235, DOI 10.1038/nm.2448
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
   Yan J, 2020, NEUROTHERAPEUTICS, V17, P1170, DOI 10.1007/s13311 019 00821 5
   Yang A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 32216 5
   Yeon JT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088974
   Zhang ZY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 4665
   Zhen GH, 2014, TRENDS PHARMACOL SCI, V35, P227, DOI 10.1016/j.tips.2014.03.005
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou X, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/5758195
   Zhu SA, 2019, J CLIN INVEST, V129, P1076, DOI 10.1172/JCI121561
   Zhu SS, 2013, BONE, V53, P340, DOI 10.1016/j.bone.2012.12.044
NR 74
TC 50
Z9 53
U1 3
U2 49
PU NATURE PUBL GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1671 4083
EI 1745 7254
J9 ACTA PHARMACOL SIN
JI Acta Pharmacol. Sin.
PD MAY
PY 2022
VL 43
IS 5
BP 1299
EP 1310
DI 10.1038/s41401 021 00747 9
EA AUG 2021
PG 12
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 0X7AM
UT WOS:000684074700001
PM 34381182
OA Bronze, Green Published
DA 2025 08 17
ER

PT J
AU Goettsch, C
   Babelova, A
   Trummer, O
   Erben, RG
   Rauner, M
   Rammelt, S
   Weissmann, N
   Weinberger, V
   Benkhoff, S
   Kampschulte, M
   Obermayer Pietsch, B
   Hofbauer, LC
   Brandes, RR
   Schröder, K
AF Goettsch, Claudia
   Babelova, Andrea
   Trummer, Olivia
   Erben, Reinhold G.
   Rauner, Martina
   Rammelt, Stefan
   Weissmann, Norbert
   Weinberger, Valeska
   Benkhoff, Sebastian
   Kampschulte, Marian
   Obermayer Pietsch, Barbara
   Hofbauer, Lorenz C.
   Brandes, Ralf R.
   Schroeder, Katrin
TI NADPH oxidase 4 limits bone mass by promoting osteoclastogenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SMOOTH MUSCLE; FREE RADICALS; IN VITRO; NOX4; EXPRESSION;
   DIFFERENTIATION; STRESS; LIGAND; INVOLVEMENT; RESORPTION
AB ROS are implicated in bone diseases. NADPH oxid.ase 4 (NOX4), a constitutively active enzymatic source of ROS, may contribute to the development of such disorders. Therefore, we studied the role of NOX4 in bone homeostasis. Nox4( / ) mice displayed higher bone density and reduced numbers and markers of osteoclasts. Ex vivo, differentiation of monocytes into osteoclasts with RANKL and M CSF induced Nox4 expression. Loss of NOX4 activity attenuated osteoclastogenesis, which was accompanied by impaired activation of RANKL induced NFATcl and c JUN. In an in vivo model of murine ovariectomy induced osteoporosis, pharmacological inhibition or acute genetic knockdown of Nox4 mitigated loss of trabecular bone. Human bone obtained from patients with increased osteodast activity exhibited increased NOX4 expression. Moreover, a SNP of NOX4 was associated with elevated circulating markers of bone turnover and reduced bone density in women. Thus, NOX4 is involved in bone loss and represents a potential therapeutic target for the treatment of osteoporosis.
C1 [Goettsch, Claudia; Rauner, Martina; Hofbauer, Lorenz C.] Tech Univ Dresden, Dept Med 3, Div Endocrinol Diabet & Bone Dis, D 01062 Dresden, Germany.
   [Goettsch, Claudia] Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Interdisciplinary Cardiovasc Sci,Dept Med, Boston, MA 02115 USA.
   [Babelova, Andrea; Weinberger, Valeska; Benkhoff, Sebastian; Brandes, Ralf R.; Schroeder, Katrin] Goethe Univ Frankfurt, Inst Physiol 1, D 60590 Frankfurt, Germany.
   [Trummer, Olivia; Obermayer Pietsch, Barbara] Med Univ Graz, Div Endocrinol & Metab, Dept Internal Med, Graz, Austria.
   [Erben, Reinhold G.] Univ Vet Med, Vienna, Austria.
   [Rammelt, Stefan] Tech Univ Dresden, Dept Trauma & Reconstruct Surg, D 01062 Dresden, Germany.
   [Rammelt, Stefan] Ctr Regenerat Therapies Dresden, Dresden, Germany.
   [Weissmann, Norbert] Univ Giessen, Lung Ctr, D 35390 Giessen, Germany.
   [Kampschulte, Marian] Univ Klinikum Giessen & Marburg GmbH Standort Gie, Zentrum Radiol, Abt Radiol, Marburg, Germany.
C3 Technische Universitat Dresden; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Brigham & Women's
   Hospital; Goethe University Frankfurt; Medical University of Graz;
   University of Veterinary Medicine Vienna; Technische Universitat
   Dresden; Technische Universitat Dresden; Justus Liebig University
   Giessen; University Hospital of Giessen & Marburg
RP Schröder, K (通讯作者)，Goethe Univ Frankfurt, Inst Physiol 1, OG Fachbereich Med 2, Haus 75,Theodor Stern Kai 7, D 60590 Frankfurt, Germany.
EM schroeder@vrc.uni frankfurt.de
RI ; Babelova, Andrea/E 7768 2018; Schroder, Katrin/E 6874 2013; Hofbauer,
   Lorenz C./G 2490 2010; Rauner, Martina/A 1665 2015; Goettsch,
   Claudia/AAD 9658 2019; Erben, Reinhold/AAG 8007 2020; Hofbauer,
   Lorenz/G 2490 2010; Brandes, Ralf/L 3058 2017; Schröder,
   Katrin/E 6874 2013; Rammelt, Stefan/AAE 5863 2019
OI Erben, Reinhold/0000 0003 0801 6958; Weissmann,
   Norbert/0000 0003 2675 3871; Babelova, Andrea/0000 0001 9548 6602;
   Schroder, Katrin/0000 0002 3099 526X; Hofbauer, Lorenz
   C./0000 0002 8691 8423; Goettsch, Claudia/0000 0002 7973 1329; Brandes,
   Ralf/0000 0002 8035 0048; Rauner, Martina/0000 0002 4067 6799; Rammelt,
   Stefan/0000 0003 1141 6493
FU MeDDrive33 program of the Medical Faculty of the Technical University of
   Dresden; Deutsche Forschungsgemeinschaft [SFB815/TP1, SFB834/TP2,
   GO1801/4 1, FOR1586 HO 1875/12 1, FOR1586 HO 1875/13 1];
   Hugelschaffner Stiftung; DFG excellence cluster ECCPS; BioPersMed
   [825329]; Austrian Federal Ministry of Transport, Innovation and
   Technology (BMVIT); Austrian Federal Ministry of Economics and
   Labour/Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ);
   Styrian Business Promotion Agency (SFG); Genkyotex Innovation SAS
FX We thank Ramona Famulla, Jasmin Kohout, Isabella Schloffel, Nicole
   Pacyna, Cindy Hope; and Sina Batz for excellent technical support;
   Gabriele Lehmann, Voahanginirina Randriamboavonjy, Johann Isaack,
   Caroline Seebach, and Dirk Henrich for helpful discussion; and Genkyotex
   SA for providing GKT137831 and GKT137928. This work was supported by the
   MeDDrive33 program of the Medical Faculty of the Technical University of
   Dresden (to C. Goettsch); by Deutsche Forschungsgemeinschaft grants
   SFB815/TP1 (to K. Schroder), SFB834/TP2 (to R.P. Brandes), GO1801/4 1
   (to C. Goettsch and L.C. Hofbauer), and FOR1586 HO 1875/12 1 and FOR1586
   HO 1875/13 1 (to L.C. Hofbauer); by the Hugelschaffner Stiftung (to K.
   Schroder); by DFG excellence cluster ECCPS (to RP. Brandes and N.
   Weissmann); and by Goethe University (to K. Schroder). This work was
   partly supported by BioPersMed (COMET K project 825329), which is funded
   by the Austrian Federal Ministry of Transport, Innovation and Technology
   (BMVIT) and the Austrian Federal Ministry of Economics and
   Labour/Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ); by
   the Styrian Business Promotion Agency (SFG); and by Genkyotex Innovation
   SAS.
CR Aoyama T, 2012, HEPATOLOGY, V56, P2316, DOI 10.1002/hep.25938
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Burgess TL, 1999, J CELL BIOL, V145, P527, DOI 10.1083/jcb.145.3.527
   Carlson J, 2009, AM J PATHOL, V175, P1564, DOI 10.2353/ajpath.2009.090035
   Chamoux E, 2010, J BIOL CHEM, V285, P25354, DOI 10.1074/jbc.M109.075234
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Gooch JL, 2004, J BIOL CHEM, V279, P15561, DOI 10.1074/jbc.M308759200
   Gugatschka M, 2005, QJM INT J MED, V98, P857, DOI 10.1093/qjmed/hci140
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Hwang SY, 2011, BBA MOL CELL RES, V1813, P979, DOI 10.1016/j.bbamcr.2010.11.002
   Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324
   Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980
   Kajiya H, 2010, CELL CALCIUM, V48, P260, DOI 10.1016/j.ceca.2010.09.010
   Kim MS, 2010, J BIOL CHEM, V285, P6913, DOI 10.1074/jbc.M109.051557
   Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002 9440(10)64556 7
   Laleu B, 2010, J MED CHEM, V53, P7715, DOI 10.1021/jm100773e
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Liu RM, 2010, J BIOL CHEM, V285, P16239, DOI 10.1074/jbc.M110.111732
   Loeser RF, 2011, CURR OPIN RHEUMATOL, V23, P492, DOI 10.1097/BOR.0b013e3283494005
   Manolagas SC, 2013, J CLIN INVEST, V123, P1919, DOI 10.1172/JCI68062
   Mentaverri R, 2003, CELL CALCIUM, V34, P169, DOI 10.1016/S0143 4160(03)00080 0
   Miller BA, 2011, ADV EXP MED BIOL, V704, P531, DOI 10.1007/978 94 007 0265 3_29
   Obermayer Pietsch BM, 2004, J BONE MINER RES, V19, P42, DOI 10.1359/JBMR.0301207
   Paré G, 2009, CIRC CARDIOVASC GENE, V2, P142, DOI 10.1161/CIRCGENETICS.108.829804
   Sasaki H, 2009, J MED INVESTIG, V56, P33, DOI 10.2152/jmi.56.33
   Schroeder K, 2009, ARTERIOSCL THROM VAS, V29, P239, DOI 10.1161/ATVBAHA.108.174219
   Sturrock A, 2006, AM J PHYSIOL LUNG C, V290, pL661, DOI 10.1152/ajplung.00269.2005
   Takac I, 2011, J BIOL CHEM, V286, P13304, DOI 10.1074/jbc.M110.192138
   Tong XY, 2010, CIRC RES, V107, P975, DOI 10.1161/CIRCRESAHA.110.221242
   Woo KM, 2002, EXP MOL MED, V34, P340, DOI 10.1038/emm.2002.48
   Yan T, 2001, J CELL BIOCHEM, V83, P320, DOI 10.1002/jcb.1200
   Yang S, 2004, J CELL BIOCHEM, V92, P238, DOI 10.1002/jcb.20048
   Zhang M, 2010, P NATL ACAD SCI USA, V107, P18121, DOI 10.1073/pnas.1009700107
   Zhou SG, 2010, CYTOKINE, V52, P210, DOI 10.1016/j.cyto.2010.07.003
NR 40
TC 138
Z9 156
U1 0
U2 17
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD NOV
PY 2013
VL 123
IS 11
BP 4731
EP 4738
DI 10.1172/JCI67603
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 247IU
UT WOS:000326611900021
PM 24216508
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Pasqualetti, S
   Banfi, G
   Mariotti, M
AF Pasqualetti, Sara
   Banfi, Giuseppe
   Mariotti, Massimo
TI The zebrafish scale as model to study the bone mineralization process
SO JOURNAL OF MOLECULAR HISTOLOGY
LA English
DT Article
DE Zebrafish; Scale; Osteoblast; Mineralization; Bone
ID DANIO RERIO; ELASMOID SCALES; FISH; ORGANIZATION
AB Danio rerio (zebrafish) shows high similarity with humans in terms of bone architecture, bone cells, matrix proteins and molecular signalling. The fish body is covered by elasmoid scales which are part of the dermal skeleton. Since few data have been published about the function of the fish scale cells, we investigated the mineralization pattern of the scale and the role of the episquamal osteoblasts in the neodeposition of the bone tissue. First, we described a specific mineralization pattern and distribution of the bone forming cells in different areas of the scale. We observed along the external circuli that, during the scale growth, the marginal cells migrate and organize in a cord like structure just before the mineralization process takes place generating a new circulus. These cells exhibit alkaline phosphatase activity, a well known mammalian osteoblastic differentiation marker. The internal circuli are also characterized by new matrix deposition. Thus, zebrafish scale represents a useful model for analyzing the osteoblast behaviour during bone formation and mineralization and it could be useful in physiological studies and pharmacological tests.
C1 [Mariotti, Massimo] Univ Milan, Dept Clin Sci L Sacco, I 20157 Milan, Italy.
   [Pasqualetti, Sara] Grp San Donato Fdn, Milan, Italy.
   [Banfi, Giuseppe] IRCCS Ist Ortoped Galeazzi, Zebrafish Lab, Milan, Italy.
   [Banfi, Giuseppe] Univ Milan, Dip Sci & Tecnol Salute, I 20157 Milan, Italy.
C3 University of Milan; IRCCS Istituto Ortopedico Galeazzi; University of
   Milan
RP Mariotti, M (通讯作者)，Univ Milan, Dept Clin Sci L Sacco, Via GB Grassi 74, I 20157 Milan, Italy.
EM massimo.mariotti@unimi.it
RI Banfi, Giuseppe/K 6585 2015
OI Banfi, Giuseppe/0000 0001 9578 5338
FU Ministero della Salute (Italy) funds
FX This work was supported by Ministero della Salute (Italy) funds.
CR Bird NC, 2003, DEV DYNAM, V228, P337, DOI 10.1002/dvdy.10387
   de Vrieze E, 2010, J APPL ICHTHYOL, V26, P210, DOI 10.1111/j.1439 0426.2010.01407.x
   de Vrieze E, 2011, BONE, V48, P704, DOI 10.1016/j.bone.2010.12.017
   Hartmann C, 2009, CURR OPIN GENET DEV, V19, P437, DOI 10.1016/j.gde.2009.09.001
   Hoemann CD, 2009, PATHOL BIOL, V57, P318, DOI 10.1016/j.patbio.2008.06.004
   Kawasaki K, 2009, ANNU REV GENET, V43, P119, DOI 10.1146/annurev genet 102108 134242
   Kimmel CB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009475
   MEUNIER FJ, 1984, AM ZOOL, V24, P953
   Orimo Hideo, 2010, Journal of Nippon Medical School, V77, P4
   Pazzaglia UE, 2011, FETAL PEDIAT PATHOL
   Sire JY, 2004, INT J DEV BIOL, V48, P233, DOI 10.1387/ijdb.15272389
   Sire JY, 1997, J ANAT, V190, P545, DOI 10.1046/j.1469 7580.1997.19040545.x
   Suzuki N, 2011, BONE, V48, P1186, DOI 10.1016/j.bone.2011.02.004
   Suzuki N, 2009, LIFE SCI, V84, P482, DOI 10.1016/j.lfs.2009.01.008
   Takagi Y, 1989, COMP BIOCH PHYSL A, V92A, P60
   Witten PE, 1997, CELL TISSUE RES, V287, P591, DOI 10.1007/s004410050782
   ZYLBERBERG L, 1988, CELL TISSUE RES, V253, P597
NR 17
TC 51
Z9 54
U1 0
U2 28
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1567 2379
J9 J MOL HISTOL
JI J. Mol. Histol.
PD OCT
PY 2012
VL 43
IS 5
BP 589
EP 595
DI 10.1007/s10735 012 9425 z
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA 014FH
UT WOS:000309360100014
PM 22661010
DA 2025 08 17
ER

PT J
AU Liu, SY
   Wang, YN
   Yu, L
   Li, JH
   Ge, SH
AF Liu, Shiyue
   Wang, Ya nan
   Yu, Lu
   Li, Jianhua
   Ge, Shaohua
TI Development of a thermosensitive hydrogel loaded with DTT and SDF 1
   facilitating in situ periodontal bone regeneration
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Periodontitis; Thermosensitive hydrogel; Reactive oxygen species;
   Osteoblasts; Co therapy; Tissue regeneration
ID OXIDATIVE STRESS; MATRIX
AB Periodontitis is characterized by local inflammatory response and alveolar bone resorption induced by pathogenic microorganisms colonization. The increase in reactive oxygen species (ROS) levels not only aggravates the local inflammation, but also inhibits the process of osteogenesis. The coupled process of reducing ROS level and reshaping the activity of osteoblasts is prerequisite to facilitate in situ periodontal tissue regeneration. In this study, we developed a thermosensitive hydrogel loaded with dithiothreitol (DTT) and stromal cell derived factor 1 (SDF 1) and explored its effect on reshaping osteoblasts activity and facilitating periodontal bone regeneration. In vitro, the hydrogel PEGD@SDF 1 significantly reduced cellular ROS levels, reactivated the Wnt/beta catenin pathway of osteoblasts and restored their osteogenic ability in an inflammatory state. In vivo, the hydrogel PEGD@SDF 1 was applied in rat periodontitis models and showed satisfactory effects on reducing the level of ROS damage, reactivating the Wnt/beta catenin pathway, alleviating the inflammation level, and promoting the periodontal bone regeneration, simultaneously. Taken together, these results suggest that the combined application of DTT and SDF 1 facilitates in situ periodontal tissue regeneration and the thermosensitive hydrogel PEGD@SDF 1 is a promising candidate for periodontal therapy.
C1 [Liu, Shiyue; Yu, Lu; Li, Jianhua; Ge, Shaohua] Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Periodontol, Jinan 250012, Shandong, Peoples R China.
   [Liu, Shiyue; Wang, Ya nan; Yu, Lu; Li, Jianhua; Ge, Shaohua] Shandong Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   [Liu, Shiyue; Wang, Ya nan; Yu, Lu; Li, Jianhua; Ge, Shaohua] Shandong Engn Lab Dent Mat & Oral Tissue Regenera, Jinan 250012, Shandong, Peoples R China.
   [Wang, Ya nan] Shandong Univ, Cheeloo Coll Med, Sch & Hosp Stomatol, Dept Implantol, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Ge, SH (通讯作者)，44 1 Wenhua Rd West, Jinan 250012, Shandong, Peoples R China.
EM shaohuage@sdu.edu.cn
RI Li, Jianhua/P 3137 2019
OI Li, Jianhua/0000 0001 5227 8627
FU National Natural Science Foundation of China [82001055, 82170964,
   81901009]; Construction Engineering Special Fund of "Taishan Scholars"
   of Shandong Province [ts20190975]; Rongxiang Regenerative Medicine
   Foundation of Shandong University [2019SDRX 14]; Collaborative
   Innovation Center of Technology and Equipment for Biological Diagnosis
   and Therapy in Universities of Shandong; National Key Research and
   Development Program of China [2017YFA0104604]; Shandong Provincial
   Natural Science Foundation [ZR2020QH158]; Youth scientific research
   funds of School of Stomatology, Shandong University [2019QNJJ03]
FX This work was funded by the National Natural Science Foundation of China
   (No. 82001055, 82170964, and 81901009); Construction Engineering Special
   Fund of "Taishan Scholars" of Shandong Province (No. ts20190975);
   Rongxiang Regenerative Medicine Foundation of Shandong University (No.
   2019SDRX 14); Collaborative Innovation Center of Technology and
   Equipment for Biological Diagnosis and Therapy in Universities of
   Shandong, The National Key Research and Development Program of China
   (No. 2017YFA0104604); Shandong Provincial Natural Science Foundation
   (ZR2020QH158), and the Youth scientific research funds of School of
   Stomatology, Shandong University (2019QNJJ03).
CR Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Chin YT, 2017, ANN NY ACAD SCI, V1403, P101, DOI 10.1111/nyas.13433
   Deng HZ, 2019, J CONTROL RELEASE, V297, P60, DOI 10.1016/j.jconrel.2019.01.026
   Du LQ, 2016, CELL PROLIFERAT, V49, P599, DOI 10.1111/cpr.12286
   Groeger S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00208
   Hao YT, 2014, J BIOMED MATER RES A, V102, P3813, DOI 10.1002/jbm.a.35044
   Hauck AK, 2019, J BIOL CHEM, V294, P1083, DOI 10.1074/jbc.R118.003214
   He XT, 2019, ACTA BIOMATER, V88, P162, DOI 10.1016/j.actbio.2019.02.004
   Hudalla GA, 2008, BIOMACROMOLECULES, V9, P842, DOI 10.1021/bm701179s
   Jia T., 2021, PHARMIC ACTIVATION P, V2021, DOI [10.1155/2021/5552530, DOI 10.1155/2021/5552530]
   Kang WY, 2018, J PERIODONTOL, V89, P883, DOI 10.1002/JPER.17 0571
   Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38
   Lennicke C, 2021, MOL CELL, V81, P3691, DOI 10.1016/j.molcel.2021.08.018
   Li K, 2019, INT IMMUNOPHARMACOL, V76, DOI 10.1016/j.intimp.2019.105913
   Li N, 2020, FREE RADICAL BIO MED, V160, P303, DOI 10.1016/j.freeradbiomed.2020.08.009
   Li R, 2021, FREE RADICAL BIO MED, V164, P130, DOI 10.1016/j.freeradbiomed.2020.12.455
   Liang QY, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12997
   Liu HR, 2015, MAT SCI ENG C MATER, V53, P83, DOI 10.1016/j.msec.2015.04.002
   Liu SY, 2021, ACS APPL MATER INTER, V13, P36880, DOI 10.1021/acsami.1c08855
   Ma WX, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/5136957
   Miao YM, 2021, THERANOSTICS, V11, P4531, DOI 10.7150/thno.54803
   NaveenKumar SK, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12676
   Nishi H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071664
   Olsen I, 2018, J ORAL MICROBIOL, V10, DOI 10.1080/20002297.2018.1440128
   Olsen I, 2016, J ORAL MICROBIOL, V8, DOI 10.3402/jom.v8.33029
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Schenkein HA, 2020, PERIODONTOL 2000, V83, P90, DOI 10.1111/prd.12304
   Shang LL, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12516
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Shi JY, 2021, ACTA BIOMATER, V128, P42, DOI 10.1016/j.actbio.2021.04.009
   Nguyen TT, 2019, ODONTOLOGY, V107, P133, DOI 10.1007/s10266 018 0374 1
   URIST MR, 1975, CALC TISS RES, V19, P73, DOI 10.1007/BF02563992
   Wang YN, 2021, J DENT RES, V100, P658, DOI 10.1177/0022034520983245
   Wang YN, 2019, EXP BIOL MED, V244, P1493, DOI 10.1177/1535370219883419
   Xu XW, 2019, ACTA BIOMATER, V86, P235, DOI 10.1016/j.actbio.2019.01.001
   Xu XY, 2019, STEM CELL TRANSL MED, V8, P392, DOI 10.1002/sctm.18 0181
   Yang JH, 2020, INT J NANOMED, V15, P3523, DOI 10.2147/IJN.S237008
   Zheng XP, 2020, AUTOPHAGY, V16, P1838, DOI 10.1080/15548627.2019.1709763
   Zheng Y, 2017, ANTIOXID REDOX SIGN, V27, P742, DOI 10.1089/ars.2016.6826
NR 39
TC 27
Z9 30
U1 11
U2 199
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD MAR 15
PY 2022
VL 432
AR 134308
DI 10.1016/j.cej.2021.134308
PG 13
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA ZZ1YS
UT WOS:000773072700004
DA 2025 08 17
ER

PT J
AU Quarles, LD
AF Quarles, LD
TI Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in
   stage 5 chronic kidney disease
SO KIDNEY INTERNATIONAL
LA English
DT Article
DE calcimimetics; renal osteodystrophy; parathyroid hormone; vitamin D;
   hyperphosphatemia
ID HEMODIALYSIS PATIENTS; BONE METABOLISM; VITAMIN D; RECEPTOR;
   CALCIFICATION; PATHOGENESIS
AB Background. Chronic kidney disease (CKD) alters the regulation of calcium and phosphate homeostasis, leading to secondary hyperparathyroidism, metabolic bone disease, soft tissue calcifications, and other metabolic derangements that have a significant impact on morbidity and mortality. The parathyroid gland is the central organ responsible for regulating these adaptive responses. Suppression of parathyroid hormone (PTH) secretion, hypertrophy, and hyperplasia are a major goal of treatment of CKD.
   Methods. Current literature was reviewed and combined with the author's experience to address a number of issues regarding the optimal treatment of secondary hyperparathyroidism in hemodialysis patients.
   Results. The calcium sensing receptor (CASR) is the most important factor regulating parathyroid gland function, and allosteric modulators of CASR, called calcimimetics, provide a novel drug therapy to suppress PTH secretion. The current use of active vitamin D analogues to suppress PTH is often limited by hypercalcemia and hyperphosphatemia. Clinical trials of cinacalcet HCl, the first calcimimetic to be approved for treatment of secondary hyperparathyroidism in CKD, have demonstrated suppression of circulating PTH levels without increments in the calcium phosphorus (Ca x P) product, making it easier to achieve the stringent management guidelines proposed for subjects with CKD by the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI (TM)).
   Conclusion. The management of disordered calcium and phosphate homeostasis in CKD patients is evolving based on our knowledge of the major importance of the calcium sensing receptor (CASR) in controlling parathyroid gland function and the potent actions of calcimimetics to target CASR.
   The purpose of this presentation is to provide an overview of the role of the CASR in regulation of parathyroid gland function, to examine the mechanisms whereby calcimimetics target the CASR, and to review the clinical trials that support the use of cinacalcet HCl for the treatment of secondary hyperparathyroidism in stage 5 chronic kidney disease (CKD).
C1 Kidney Inst, Vice Chair Res, Dept Internal Med, Kansas City, KS 66160 USA.
   Div Nephrol, Kansas City, KS 66160 USA.
RP Quarles, LD (通讯作者)，Kidney Inst, Vice Chair Res, Dept Internal Med, Ms 3018,3901 Rainbow Blvd,6018 Wahl Hall, Kansas City, KS 66160 USA.
EM dquarles@kumc.edu
OI Quarles, L. Darryl/0000 0002 5082 7896
FU NIAMS NIH HHS [R56 AR045955] Funding Source: Medline
CR Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982
   Block GA, 2004, NEW ENGL J MED, V350, P1516, DOI 10.1056/NEJMoa031633
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   Chertow GM, 2002, KIDNEY INT, V62, P245, DOI 10.1046/j.1523 1755.2002.00434.x
   Colloton M, 2005, KIDNEY INT, V67, P467, DOI 10.1111/j.1523 1755.2005.67103.x
   Indridason OS, 2000, KIDNEY INT, V57, P282, DOI 10.1046/j.1523 1755.2000.00819.x
   Indridason OS, 1996, KIDNEY INT, V50, P1663, DOI 10.1038/ki.1996.483
   Malberti F, 2001, J AM SOC NEPHROL, V12, P1242, DOI 10.1681/ASN.V1261242
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040
   Price PA, 2000, ARTERIOSCL THROM VAS, V20, P317, DOI 10.1161/01.ATV.20.2.317
   Quarles LD, 2003, J AM SOC NEPHROL, V14, P575, DOI 10.1097/01.ASN.0000050224.03126.AD
   Quarles LD, 2002, ADV RENAL REPLACE TH, V9, P153, DOI 10.1053/jarr.2002.34839
   Slatopolsky E, 2001, AM J KIDNEY DIS, V37, pS54, DOI 10.1053/ajkd.2001.20740
   Uribarri J, 2004, SEMIN DIALYSIS, V17, P349, DOI 10.1111/j.0894 0959.2004.17354.x
NR 15
TC 16
Z9 18
U1 0
U2 2
PU BLACKWELL PUBLISHING INC
PI MALDEN
PA 350 MAIN ST, MALDEN, MA 02148 USA
SN 0085 2538
J9 KIDNEY INT
JI Kidney Int.
PD JUL
PY 2005
VL 68
SU 96
BP S24
EP S28
DI 10.1016/S0085 2538(15)51229 5
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 934BG
UT WOS:000229681000005
PM 15954947
OA Bronze
DA 2025 08 17
ER

PT J
AU Gallelli, L
   Galasso, O
   Falcone, D
   Southworth, S
   Greco, M
   Ventura, V
   Romualdi, P
   Corigliano, A
   Terracciano, R
   Savino, R
   Gulletta, E
   Gasparini, G
   De Sarro, G
AF Gallelli, L.
   Galasso, O.
   Falcone, D.
   Southworth, S.
   Greco, M.
   Ventura, V.
   Romualdi, P.
   Corigliano, A.
   Terracciano, R.
   Savino, R.
   Gulletta, E.
   Gasparini, G.
   De Sarro, G.
TI The effects of nonsteroidal anti inflammatory drugs on clinical
   outcomes, synovial fluid cytokine concentration and signal transduction
   pathways in knee osteoarthritis. A randomized open label trial
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Knee osteoarthritis; NSAID; WOMAC score; Synovial fluid cytokines;
   Signal transduction pathways
ID FACTOR KAPPA B; PROSTAGLANDIN E 2; TNF ALPHA; INTERLEUKIN 6; CELECOXIB;
   CARTILAGE; INFLAMMATION; CHONDROCYTES; SENSITIVITY; ACTIVATION
AB Objective: We investigated the effects of celecoxib, diclofenac, and ibuprofen on the disease specific quality of life, synovial fluid cytokines and signal transduction pathways in symptomatic knee osteoarthritis (OA).
   Design: Ninety patients scheduled for a total knee arthroplasty (TKA) were randomized to six groups that were treated with low and high dosages of celecoxib, diclofenac or ibuprofen. At the time of the first admission (T0) and at surgery (T1 = 14 days after beginning of the nonsteroidal anti inflammatory drugs (NSAIDs)), samples of knee synovial fluid were obtained from each patient for analysis. During the surgery the synovial tissue was harvested from the knee of patients. The Western Ontario and McMaster universities (WOMAC) score was used to evaluate the patient disease specific quality of life at T0 and T1. Microarray tests performed at T0 and T1 were used to evaluate the effects of NSAIDs on Tumor necrosis factor (TNE) alpha, Interleukin 6 (IL 6), IL8 and Vascular endothelial growth factor (VEGF) concentration in the synovial fluid. Western blot assays evaluated the effects of NSAIDs on MAP kinase (MAPK) signal transduction pathway in the synovial membrane.
   Results: NSAID treatment induced a statistically significant improvement in the WOMAC score and a statistically significant decrease in the IL 6, VEGF and TNF alpha concentration in the synovial fluid. Higher dosages of NSAIDs provided a greater improvement in the disease specific quality of life of patients and lower concentrations of pro inflammatory cytokines in the synovial fluid. Inhibition of MAPKs was noted after NSAID treatment.
   Conclusion: Short term NSAID treatment improves the patient disease specific quality of life with a parallel decrease in pro inflammatory synovial fluid cytokine levels in knee OA. Signal transduction pathways may be involved in regulating the anti inflammatory effects of NSAIDs. ClinicalTrial.gov: NCT01860833. (C) 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Gallelli, L.; Falcone, D.; Greco, M.; Ventura, V.; Terracciano, R.; Savino, R.; Gulletta, E.; De Sarro, G.] Magna Graecia Univ Catanzaro, Sch Med, Dept Hlth Sci, I 88100 Catanzaro, Italy.
   [Galasso, O.; Corigliano, A.; Gasparini, G.] Magna Graecia Univ Catanzaro, Sch Med, Dept Orthoped & Trauma Surg, I 88100 Catanzaro, Italy.
   [Southworth, S.] PLLC, North Mississippi Sports Med & Orthoped Clin, Tupelo, MS USA.
   [Romualdi, P.] Univ Bologna, Dept Pharmacol & Biotechnol, Bologna, Italy.
C3 Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro; University of Bologna
RP Galasso, O (通讯作者)，Magna Graecia Univ Catanzaro, Sch Med, Dept Orthoped & Trauma Surg, Viale Europa, I 88100 Catanzaro, Italy.
EM galasso@unicz.it
RI Galasso, Olimpio/D 4309 2012; De Sarro, Giovambattista/G 5256 2010;
   Terracciano, Rosa/AAO 8649 2020; Gasparini, Giorgio/AFU 8409 2022;
   Romualdi, Patrizia/AAR 7403 2021; Greco, Marta/K 8227 2016; Gallelli,
   Luca/LSI 9352 2024
OI De Sarro, Giovambattista/0000 0002 7629 6579; Greco,
   Marta/0000 0003 4192 3891; Savino, Rocco/0000 0002 4046 1472; VENTURA,
   Valeria/0000 0001 6378 9916; Romualdi, Patrizia/0000 0002 3610 2928;
   Gasparini, Giorgio/0000 0002 8256 7697; Terracciano,
   Rosa/0000 0002 5175 1758; Galasso, Olimpio/0000 0002 4915 046X
FU PhD Programme in Molecular Oncology, Experimental Immunology and
   Development of Innovative Therapies
FX Daniela Falcone was supported by a fellowship from the PhD Programme in
   Molecular Oncology, Experimental Immunology and Development of
   Innovative Therapies. We are grateful to Curto Lucia Stella for skilled
   experimental support and to Marco De God., M.D., for his statistical
   advice.
CR Abramson SB, 2004, J RHEUMATOL, V31, P70, DOI 10.1097/BOR.0b013e328349c2b1
   ALTMAN R, 1986, ARTHRITIS RHEUM US, V29, P1039, DOI 10.1002/art.1780290816
   Alvarez Soria MA, 2006, ANN RHEUM DIS, V65, P998, DOI 10.1136/ard.2005.046920
   Bianchi M, 2007, INT J CLIN PRACT, V61, P1270, DOI 10.1111/j.1742 1241.2007.01453.x
   Boileau C, 2006, ANN RHEUM DIS, V65, P573, DOI 10.1136/ard.2005.041855
   Boyer KA, 2012, J ORTHOP RES, V30, P1118, DOI 10.1002/jor.22037
   Brenner SS, 2004, OSTEOARTHR CARTILAGE, V12, P469, DOI 10.1016/j.joca.2004.02.011
   Cameron M L, 1994, Knee Surg Sports Traumatol Arthrosc, V2, P38, DOI 10.1007/BF01552652
   Dingle JT, 1999, OSTEOARTHR CARTILAGE, V7, P313, DOI 10.1053/joca.1998.0176
   Galasso O, 2012, ADV ORTHOP, V2012, DOI 10.1155/2012/834208
   Gallelli L, 2008, CELL PROLIFERAT, V41, P393, DOI 10.1111/j.1365 2184.2008.00538.x
   Gallelli L, 2012, CLIN DRUG INVEST, V32, P827, DOI 10.1007/s40261 012 0011 7
   Gallelli L, 2010, INT J IMMUNOPATH PH, V23, P471, DOI 10.1177/039463201002300209
   Gasparini G, 2006, INT ORTHOP, V30, P253, DOI 10.1007/s00264 005 0050 2
   Goldring MB, 2004, CLIN ORTHOP RELAT R, pS37, DOI 10.1097/01.blo.0000144484.69656.e4
   Goldring MB, 1999, CONNECT TISSUE RES, V40, P1, DOI 10.3109/03008209909005273
   Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f
   Görtz B, 2005, ARTHRITIS RES THER, V7, pR1140, DOI 10.1186/ar1797
   HARTWIG SC, 1992, AM J HOSP PHARM, V49, P2229, DOI 10.1093/ajhp/49.9.2229
   Haseeb A, 2013, CLIN IMMUNOL, V146, P185, DOI 10.1016/j.clim.2012.12.011
   Haywood L, 2003, ARTHRITIS RHEUM, V48, P2173, DOI 10.1002/art.11094
   Kaneko S, 2000, CYTOKINES CELL MOL T, V6, P71, DOI 10.1080/13684730050515796
   KELLGREN JH, 1957, ANN RHEUM DIS, V16, P494, DOI 10.1136/ard.16.4.494
   Kraus VB, 2002, ARTHRITIS RHEUM US, V46, P420, DOI 10.1002/art.10124
   Larussa T, 2010, HELICOBACTER, V15, P449, DOI 10.1111/j.1523 5378.2010.00796.x
   Lovell DJ, 2005, ARTHRITIS RHEUM US, V52, P1283, DOI 10.1002/art.20953
   Malara N, 2008, CELL CYCLE, V7, P3235, DOI 10.4161/cc.7.20.6832
   Mariconda M, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 222
   Mengshol JA, 2000, ARTHRITIS RHEUM, V43, P801, DOI 10.1002/1529 0131(200004)43:4<801::AID ANR10>3.0.CO;2 4
   NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239, DOI 10.1038/clpt.1981.154
   Ohtori S, 2004, SPINE, V29, P1082, DOI 10.1097/00007632 200405150 00006
   Oliva F, 2010, FUNCT NEUROL, V23, P1
   Orita S, 2011, BMC MUSCULOSKEL DIS, V12, DOI 10.1186/1471 2474 12 144
   Pearle AD, 2007, OSTEOARTHR CARTILAGE, V15, P516, DOI 10.1016/j.joca.2006.10.010
   Pelletier J. P., 2004, Osteoarthr. Cartil, V12, P63, DOI [10.1016/j.joca.2003.09.014, DOI 10.1016/J.JOCA.2003.09.014]
   Rainsford KD, 1997, J PHARM PHARMACOL, V49, P991, DOI 10.1111/j.2042 7158.1997.tb06030.x
   Reijman M, 2005, ARTHRITIS RHEUM US, V52, P3137, DOI 10.1002/art.21357
   Rogus J, 2008, HUM GENET, V123, P387, DOI 10.1007/s00439 008 0488 6
   Rudolphi K, 2003, OSTEOARTHR CARTILAGE, V11, P738, DOI 10.1016/S1063 4584(03)00153 5
   Salaffi F, 2003, OSTEOARTHR CARTILAGE, V11, P551, DOI 10.1016/S1063 4584(03)00089 X
   Schmidt M, 2011, BMJ BRIT MED J, V343, DOI 10.1136/bmj.d3450
   Schmidt N, 2010, BIOCHEM PHARMACOL, V79, P722, DOI 10.1016/j.bcp.2009.10.012
   Schumacher HR, 1996, J RHEUMATOL, V23, P1774
   Sellam J, 2010, NAT REV RHEUMATOL, V6, P625, DOI 10.1038/nrrheum.2010.159
   Shibakawa A, 2003, OSTEOARTHR CARTILAGE, V11, P133, DOI 10.1053/joca.2002.0871
   Takaoka Y, 1999, J BIOCHEM TOKYO, V126, P553, DOI 10.1093/oxfordjournals.jbchem.a022485
   Tibesku CO, 2001, OPEN ORTHOP J, V5, P177
   Tsutsumi R, 2008, RHEUMATOL INT, V28, P727, DOI 10.1007/s00296 007 0511 6
   Vignon E, 1993, Osteoarthritis Cartilage, V1, P115, DOI 10.1016/S1063 4584(05)80026 3
   von Banchet GS, 2005, J NEUROCHEM, V94, P238, DOI 10.1111/j.1471 4159.2005.03185.x
   White DK, 2010, J RHEUMATOL, V37, P1244, DOI 10.3899/jrheum.090989
   Zhang W, 2008, OSTEOARTHR CARTILAGE, V16, P137, DOI 10.1016/j.joca.2007.12.013
   Zweers MC, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3437
NR 53
TC 112
Z9 123
U1 2
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063 4584
EI 1522 9653
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD SEP
PY 2013
VL 21
IS 9
SI SI
BP 1400
EP 1408
DI 10.1016/j.joca.2013.06.026
PG 9
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA 225KQ
UT WOS:000324962200033
PM 23973155
OA Bronze
DA 2025 08 17
ER

PT J
AU Li, M
   Zhang, C
   Li, XH
   Lv, ZH
   Chen, Y
   Zhao, JY
AF Li, Mei
   Zhang, Chi
   Li, Xinhan
   Lv, Zeheng
   Chen, Yao
   Zhao, Jiyuan
TI Isoquercitrin promotes the osteogenic differentiation of osteoblasts and
   BMSCs via the RUNX2 or BMP pathway
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE Isoquercitrin; natural phytoestrogen; osteoblast proliferation;
   osteogenic differentiation; osteoporosis
ID IN VITRO; COLON CANCER; QUERCETIN; EXPRESSION; TISSUE; CELLS;
   QUERCITRIN; APOPTOSIS; ICARIIN; MINERALIZATION
AB AIM: Isoquercitrin is widely present in fruits, vegetables and medicinal herbs. As a natural phytoestrogen, isoquercitrin has been considered a possible osteoporosis prevention option to avoid the risk of hormone therapy. MATERIALS AND METHODS: The cell proliferation of osteoblasts and bone mesenchymal stem cells (BMSCs) was examined by cell counting kit 8 (CCK 8). The osteogenic differentiation was evaluated by real time qPCR, ALP staining and Alizarin Red S staining. Small interfering RNA (siRNA) was used to knockdown the expression of runt related transcription factor 2 (RUNX2). RESULTS: The cell proliferation of osteoblasts and BMSCs was promoted by isoquercitrin at low concentrations. High concentrations of isoquercitrin promoted the osteogenic differentiation via RUNX2 expression in osteoblasts and via the bone morphogenetic protein (BMP) pathway in BMSCs. Inhibition of RUNX2 expression in osteoblasts by siRNA or addition of noggin to the culture medium of BMSCs reduced the effects of osteogenic differentiation induced by isoquercitrin. CONCLUSIONS: These data suggest that isoquercitrin is a natural potential osteoinductive compound and might be valuable for the prevention/treatment of bone disorders.
C1 [Li, Mei; Zhang, Chi; Li, Xinhan; Lv, Zeheng; Chen, Yao; Zhao, Jiyuan] Ningbo Univ, Sch Med, Zhejiang Key Lab Pathophysiol, Ningbo, Zhejiang, Peoples R China.
   [Li, Mei] Ningbo Inst Med Sci, Ningbo, Zhejiang, Peoples R China.
C3 Ningbo University
RP Zhao, JY (通讯作者)，Ningbo Univ, Sch Med, 818 Fenghua Rd, Ningbo 315211, Zhejiang, Peoples R China.
EM zhaojiyuan@nbu.edu.cn
RI Li, Mei/JDD 8859 2023
OI Zhao, Jiyuan/0000 0002 1327 7119
FU Applied Research Project on Nonprofit Technology of Zhejiang Province
   [2017C33135]; Creative Open Experiment Project of Ningbo University
   [Cxxkf 201617]; K.C. Wong Magna Fund in Ningbo University
FX This work was supported by the Applied Research Project on Nonprofit
   Technology of Zhejiang Province (No. 2017C33135), Creative Open
   Experiment Project of Ningbo University (Cxxkf 201617), and the K.C.
   Wong Magna Fund in Ningbo University.
CR Amado NG, 2014, J BIOL CHEM, V289, P35456, DOI 10.1074/jbc.M114.621599
   Arumugam S, 2017, APPL BIOCHEM BIOTECH, V182, P697, DOI 10.1007/s12010 016 2355 6
   Bartolozzi E, 2015, CLIN CASES MINER BON, V12, P111, DOI 10.11138/ccmbm/2015.12.2.111
   Branca F, 2003, P NUTR SOC, V62, P877, DOI 10.1079/PNS2003309
   Brennan MA, 2014, HORM METAB RES, V46, P537, DOI 10.1055/s 0033 1363265
   Carbonare LD, 2012, STEM CELL REV REP, V8, P891, DOI 10.1007/s12015 011 9337 4
   Casado Díaz A, 2016, J NUTR BIOCHEM, V32, P151, DOI 10.1016/j.jnutbio.2016.03.005
   Chen F, 2016, ONCOL REP, V36, P165, DOI 10.3892/or.2016.4794
   Chen Q, 2015, ONCOL REP, V33, P840, DOI 10.3892/or.2014.3626
   Cincin ZB, 2014, ARCH MED RES, V45, P445, DOI 10.1016/j.arcmed.2014.08.002
   Clifford MN, 2004, PLANTA MED, V70, P1103, DOI 10.1055/s 2004 835835
   DUNNICK JK, 1992, FUND APPL TOXICOL, V19, P423, DOI 10.1016/0272 0590(92)90181 G
   Eb H, 2012, BONE, V51, P98, DOI [10.1016/j.bone.2012.04.004, DOI 10.1016/J.BONE.2012.04.004]
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Forte L, 2016, ACTA BIOMATER, V32, P298, DOI 10.1016/j.actbio.2015.12.013
   Ganeshpurkar A, 2017, SAUDI PHARM J, V25, P149, DOI 10.1016/j.jsps.2016.04.025
   Guo C, 2012, CELL PHYSIOL BIOCHEM, V30, P123, DOI 10.1159/000339052
   Gupta SK, 2017, MAT SCI ENG C MATER, V71, P919, DOI 10.1016/j.msec.2016.10.085
   Hazra M, 2015, SAUDI PHARM J, V23, P429, DOI 10.1016/j.jsps.2015.01.007
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Kalinova J, 2009, J AGR FOOD CHEM, V57, P2719, DOI 10.1021/jf803633f
   Kangawa Y, 2017, FOOD CHEM TOXICOL, V100, P103, DOI 10.1016/j.fct.2016.12.018
   Kugimiya F, 2005, J BIOL CHEM, V280, P35704, DOI 10.1074/jbc.M505166200
   Li L, 2016, CHIN J NAT MEDICINES, V14, P407, DOI 10.1016/S1875 5364(16)30036 X
   Li L, 2017, SAUDI PHARM J, V25, P513, DOI 10.1016/j.jsps.2017.04.016
   Li M, 2017, MAT SCI ENG C MATER, V71, P260, DOI 10.1016/j.msec.2016.10.016
   Li XC, 2016, MOLECULES, V21, DOI 10.3390/molecules21091246
   Matsumoto Y, 2013, STEROIDS, V78, P513, DOI 10.1016/j.steroids.2013.02.011
   Nie QX, 2017, CRIT REV FOOD SCI, V57, P2432, DOI 10.1080/10408398.2015.1077194
   Oliveira T, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/704781
   Paulke A, 2012, PHARMAZIE, V67, P991, DOI 10.1691/ph.2012.2050
   Prouillet C, 2004, BIOCHEM PHARMACOL, V67, P1307, DOI 10.1016/j.bcp.2003.11.009
   Ring M, 2017, PRIMARY CARE, V44, P377, DOI 10.1016/j.pop.2017.02.012
   Satue M, 2013, BIOCHEM PHARMACOL, V86, P1476, DOI 10.1016/j.bcp.2013.09.009
   Tang W, 2016, ACTA BIOMATER, V32, P309, DOI 10.1016/j.actbio.2015.12.006
   Valentová K, 2014, FOOD CHEM TOXICOL, V68, P267, DOI 10.1016/j.fct.2014.03.018
   Wang XH, 2014, BIOCHEM PHARMACOL, V89, P413, DOI 10.1016/j.bcp.2014.03.020
   Wang XC, 2014, MOL MED REP, V10, P3320, DOI 10.3892/mmr.2014.2633
   Wong RWK, 2008, J ORTHOP RES, V26, P1061, DOI 10.1002/jor.20638
   Yang J, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070650
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
   Zhao JY, 2010, TISSUE ENG PT A, V16, P233, DOI [10.1089/ten.tea.2009.0165, 10.1089/ten.TEA.2009.0165]
   Zhi KK, 2016, ANGIOGENESIS, V19, P311, DOI 10.1007/s10456 016 9504 y
   Zhu MX, 2016, MOLECULES, V21, DOI 10.3390/molecules21030356
NR 45
TC 36
Z9 41
U1 0
U2 36
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD MAR 4
PY 2019
VL 60
IS 2
BP 189
EP 199
DI 10.1080/03008207.2018.1483358
PG 11
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA HP4LE
UT WOS:000461646700012
PM 29852784
DA 2025 08 17
ER

PT J
AU Eda, H
   Santo, L
   Wein, MN
   Hu, DZ
   Cirstea, DD
   Nemani, N
   Tai, YT
   Raines, SE
   Kuhstoss, SA
   Munshi, NC
   Kronenberg, HM
   Raje, NS
AF Eda, Homare
   Santo, Loredana
   Wein, Marc N.
   Hu, Dorothy Z.
   Cirstea, Diana D.
   Nemani, Neeharika
   Tai, Yu Tzu
   Raines, Sarah E.
   Kuhstoss, Stuart Allen
   Munshi, Nikhil C.
   Kronenberg, Henry M.
   Raje, Noopur S.
TI Regulation of Sclerostin Expression in Multiple Myeloma by Dkk 1: A
   Potential Therapeutic Strategy for Myeloma Bone Disease
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE TUMOR INDUCED BONE DISEASE; CYTOKINES; OSTEOBLASTS; STROMAL; STEM CELLS;
   THERAPEUTICS
ID SINGLE AGENT CARFILZOMIB; POSTMENOPAUSAL OSTEOPOROSIS; NEUTRALIZING
   ANTIBODY; PRECLINICAL ACTIVITY; KINASE INHIBITOR; BMP ANTAGONIST;
   STEM CELLS; IN VIVO; COMBINATION; TARGET
AB Sclerostin is a potent inhibitor of osteoblastogenesis. Interestingly, newly diagnosed multiple myeloma (MM) patients have high levels of circulating sclerostin that correlate with disease stage and fractures. However, the source and impact of sclerostin in MM remains to be defined. Our goal was to determine the role of sclerostin in the biology of MM and its bone microenvironment as well as investigate the effect of targeting sclerostin with a neutralizing antibody (scl Ab) in MM bone disease. Here we confirm increased sclerostin levels in MM compared with precursor disease states like monoclonal gammopathy of undetermined significance (MGUS) and smoldering MM. Furthermore, we found that a humanized MM xenograft mouse model bearing human MM cells (NOD SCID.CB17 male mice injected intravenously with 2.5 million of MM1.S Luc GFP cells) demonstrated significantly higher concentrations of mouse derived sclerostin, suggesting a microenvironmental source of sclerostin. Associated with the increased sclerostin levels, activated  catenin expression levels were lower than normal in MM mouse bone marrow. Importantly, a high affinity grade scl Ab reversed osteolytic bone disease in this animal model. Because scl Ab did not demonstrate significant in vitro anti MM activity, we combined it with the proteasome inhibitor carfilzomib. Our data demonstrated that this combination therapy significantly inhibited tumor burden and improved bone disease in our in vivo MM mouse model. In agreement with our in vivo data, sclerostin expression was noted in marrow stromal cells and osteoblasts of MM patient bone marrow samples. Moreover, MM cells stimulated sclerostin expression in immature osteoblasts while inhibiting osteoblast differentiation in vitro. This was in part regulated by Dkk 1 secreted by MM cells and is a potential mechanism contributing to the osteoblast dysfunction noted in MM. Our data confirm the role of sclerostin as a potential therapeutic target in MM bone disease and provides the rationale for studying scl Ab combined with proteasome inhibitors in MM. (c) 2016 American Society for Bone and Mineral Research.
C1 [Eda, Homare; Santo, Loredana; Cirstea, Diana D.; Nemani, Neeharika; Raje, Noopur S.] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
   [Wein, Marc N.; Hu, Dorothy Z.; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Tai, Yu Tzu; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, 44 Binney St, Boston, MA 02115 USA.
   [Tai, Yu Tzu; Munshi, Nikhil C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, 44 Binney St, Boston, MA 02115 USA.
   [Raines, Sarah E.; Kuhstoss, Stuart Allen] Lilly Res Labs, Regenerat Biol, Indianapolis, IN USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Harvard Medical School; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   University; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Harvard Medical School; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Dana Farber Cancer
   Institute; Eli Lilly; Lilly Research Laboratories
RP Raje, NS (通讯作者)，Massachusetts Gen Hosp, MGH Canc Ctr, POB 216,55 Fruit St, Boston, MA 02114 USA.
EM nraje@partners.org
RI Munshi, Nikhil/ABE 2338 2021; KRONENBERG, HENRY/MXK 0923 2025
FU LLS Clinical Scholar Award; NIH NRSA [DK100215]; NIH [P01 DK011794]
FX We thank the Center for Skeletal Research Histology Core (NIH P30 AR
   066261) for performing IHC on MM patients and mouse samples. This work
   was supported by a LLS Clinical Scholar Award (to NSR), NIH NRSA
   DK100215 (to MNW), and NIH P01 DK011794 (to HMK).
CR Badros AZ, 2013, LEUKEMIA, V27, P1707, DOI 10.1038/leu.2013.29
   BATAILLE R, 1989, J CLIN ONCOL, V7, P1909, DOI 10.1200/JCO.1989.7.12.1909
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brunetti G, 2011, ANN NY ACAD SCI, V1237, P19, DOI 10.1111/j.1749 6632.2011.06196.x
   Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1588::AID CNCR9>3.0.CO;2 G
   Colucci S, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.22
   Eda H, 2014, LEUKEMIA, V28, P1892, DOI 10.1038/leu.2014.69
   Edwards CM, 2008, BONE, V42, P1007, DOI 10.1016/j.bone.2008.01.027
   Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood 2008 11 191577
   Giuliani N, 2012, LEUKEMIA, V26, P1391, DOI 10.1038/leu.2011.381
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Habibi H, 2013, CELL J, V15, P266
   Heiland GR, 2010, ANN RHEUM DIS, V69, P2152, DOI 10.1136/ard.2010.132852
   Hoeppner LH, 2009, EXPERT OPIN THER TAR, V13, P485, DOI [10.1517/14728220902841961 , 10.1517/14728220902841961]
   Hurchla MA, 2013, LEUKEMIA, V27, P430, DOI 10.1038/leu.2012.183
   Jagannath S, 2012, CL LYMPH MYELOM LEUK, V12, P310, DOI 10.1016/j.clml.2012.08.003
   Jakubowiak AJ, 2013, LEUKEMIA, V27, P2351, DOI 10.1038/leu.2013.152
   Kuhn DJ, 2007, BLOOD, V110, P3281, DOI 10.1182/blood 2007 01 065888
   Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood 2007 10 078022
   Lewiecki EM, 2014, THER ADV MUSCULOSKEL, V6, P48, DOI 10.1177/1759720X13510479
   Lewiecki EM, 2011, NAT REV RHEUMATOL, V7, P631, DOI 10.1038/nrrheum.2011.130
   Li XF, 2005, J BIOL CHEM, V280, P19883, DOI 10.1074/jbc.M413274200
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Mukherjee S, 2008, J CLIN INVEST, V118, P491, DOI [10.1172/JCI33102, 10.1172/JC133102]
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012
   Raje N, 2009, LEUKEMIA, V23, P961, DOI 10.1038/leu.2008.378
   Raje N, 2011, CLIN CANCER RES, V17, P1278, DOI 10.1158/1078 0432.CCR 10 1804
   Raje N, 2010, CURR OPIN MOL THER, V12, P586
   Raje NS, 2014, J NATL COMPR CANC NE, V12, P502, DOI 10.6004/jnccn.2014.0055
   Robinson MK, 2013, DRUG DISCOV TODAY, V18, P637, DOI 10.1016/j.drudis.2013.04.001
   Roodman GD, 2010, J CELL BIOCHEM, V109, P283, DOI 10.1002/jcb.22403
   Saad F, 2007, CANCER AM CANCER SOC, V110, P1860, DOI 10.1002/cncr.22991
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood 2011 10 387365
   Scullen T, 2013, LEUKEMIA, V27, P1715, DOI 10.1038/leu.2013.50
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi S, 2003, J BONE MINER RES, V18, P696, DOI 10.1359/jbmr.2003.18.4.696
   Siegel DS, 2012, BLOOD, V120, P2817, DOI 10.1182/blood 2012 05 425934
   Terpos E, 2012, INT J CANCER, V131, P1466, DOI 10.1002/ijc.27342
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   VALENTINOPRAN A, 1982, BRIT J HAEMATOL, V52, P601, DOI 10.1111/j.1365 2141.1982.tb03936.x
   Vallet S, 2011, CANCER MICROENVIRON, V4, P339, DOI 10.1007/s12307 011 0090 7
   Vallet S, 2010, P NATL ACAD SCI USA, V107, P5124, DOI 10.1073/pnas.0911929107
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   Winkler DG, 2003, EMBO J, V22, P6267, DOI 10.1093/emboj/cdg599
NR 47
TC 79
Z9 82
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2016
VL 31
IS 6
BP 1225
EP 1234
DI 10.1002/jbmr.2789
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DN7PL
UT WOS:000377269200013
PM 26763740
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Wang, XY
   Jiao, LY
   He, JL
   Fu, ZA
   Guo, RJ
AF Wang, Xiao Ying
   Jiao, Li Yan
   He, Jing Lan
   Fu, Zhi An
   Guo, Ru Jun
TI Parathyroid hormone 1 34 inhibits senescence in rat nucleus pulposus
   cells by activating autophagy via the m TOR pathway
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE intervertebral disc degeneration; osteoporosis; nucleus pulposus cells;
   parathyroid hormone 1 34; senescence
ID INTERVERTEBRAL DISC DEGENERATION; DEXAMETHASONE; APOPTOSIS; PROGRESSION;
   PROTECTS
AB Osteoporosis is closely associated with intervertebral disc degeneration. While parathyroid hormone (PTH) 1 34, which is an established drug used to treatosteoporosis, is thought to inhibit the disc degeneration associated with osteoporosis, the precise mechanism involved remains unclear. In the present study, primary Sprague Dawley rat nucleus pulposus cells (NPCs) were cultured, phenotyped and then treated with dexamethasone (DXM) for 48 h. Cell area analysis and beta galactosidase staining were used to investigate the effect of DXM on the senescence of NPCs. In addition, the protein levels of LC3 II, Beclin 1, P62, p mTOR and p p70S6k were determined by western blotting and analyzing the regulatory effect of PTH upon autophagy and the mTOR signaling pathway in cells treated with DXM. Following autophagic inhibition induced by ATGS siRNA transfection, the regulatory effect of PTH on senescence in NPCs were investigated in addition to the potential role of autophagy. As the concentration of DXM increased, the size of the NPCs was significantly enlarged and the proportion of cells with positive beta galactosidase staining increased significantly (P<0.05). In terms of protein expression, PTH treatment led to an increase in LC3 II and Beclin 1 proteins, a reduction in P62 protein, and inhibited p mTOR and p p70S6k protein expression in DXM treated NPCs (P<0.05). PTH attenuated the effect of DXM according to the cell size and percentage of beta galactosidase positive cells. However, the inhibition of autophagy via ATG5 siRNA transfection reversed the protective effect of PTH on cell senescence (P<0.05). Collectively, the present findings suggest that PTH may inhibit the senescence of NPCs induced by DXM by activating autophagy via the mTOR pathway.
C1 [Wang, Xiao Ying; He, Jing Lan; Fu, Zhi An] Hebei Univ Engn, Affiliated Hosp, Dept Orthoped Surg, Handan 056002, Hebei, Peoples R China.
   [Jiao, Li Yan] Hebei Univ Engn, Affiliated Hosp, Dept Dermatol, Handan 056002, Hebei, Peoples R China.
   [Guo, Ru Jun] Wuan First Peoples Hosp, Dept Orthoped Surg 2, 500 Meters West KuangJian Rd & XiHuan Rd, Handan 056300, Hebei, Peoples R China.
C3 Hebei University of Engineering; Hebei University of Engineering
RP Guo, RJ (通讯作者)，Wuan First Peoples Hosp, Dept Orthoped Surg 2, 500 Meters West KuangJian Rd & XiHuan Rd, Handan 056300, Hebei, Peoples R China.
EM wasyygrj@163.com
RI Yang, Juhong/GNM 8846 2022
FU project of Handan Municipal Science and Technology Bureau [1723208067 2]
FX This work was supported by the project of Handan Municipal Science and
   Technology Bureau (grant no. 1723208067 2).
CR Alayev A, 2013, J CELL PHYSIOL, V228, P1658, DOI 10.1002/jcp.24351
   Chen CH, 2018, J APPL PHYSIOL, V124, P1177, DOI 10.1152/japplphysiol.00871.2017
   Chen J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0085 5
   Chen K, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/4041768
   Gao CH, 2018, AGING US, V10, P131, DOI 10.18632/aging.101364
   He JP, 2017, FEBS J, V284, P1324, DOI 10.1111/febs.14055
   He JL, 2018, MOL MED REP, V17, P4406, DOI 10.3892/mmr.2018.8412
   Hong D, 2011, OSTEOPOROSIS INT, V22, P2175, DOI 10.1007/s00198 010 1434 8
   Hoy D, 2012, ARTHRITIS RHEUM US, V64, P2028, DOI 10.1002/art.34347
   Ito M, 2017, OSTEOARTHR CARTILAGE, V25, P2134, DOI 10.1016/j.joca.2017.08.019
   Jia HB, 2016, SCI REP UK, V6, DOI 10.1038/srep27521
   Jiang LB, 2015, CELL CYCLE, V14, P867, DOI 10.1080/15384101.2015.1004946
   Jiang LB, 2014, J ORTHOP RES, V32, P1532, DOI 10.1002/jor.22699
   Jiang LB, 2013, J ORTHOP RES, V31, P692, DOI 10.1002/jor.22289
   Luo Y, 2013, BONE, V55, P439, DOI 10.1016/j.bone.2013.03.002
   Madiraju P, 2013, EUR CELLS MATER, V25, P268, DOI 10.22203/eCM.v025a19
   MIZRAHI J, 1993, SPINE, V18, P2088, DOI 10.1097/00007632 199310001 00028
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Neidlinger Wilke C, 2014, EUR SPINE J, V23, pS333, DOI 10.1007/s00586 013 2855 9
   Quan Meiling, 2015, Eur J Orthop Surg Traumatol, V25 Suppl 1, pS43, DOI 10.1007/s00590 014 1499 8
   Rampersaud YR, 2017, SPINE, V42, pE1318, DOI 10.1097/BRS.0000000000002237
   Xue EX, 2016, MOL MED REP, V14, P3037, DOI 10.3892/mmr.2016.5662
   Yin H, 2018, BIOMED PHARMACOTHER, V97, P995, DOI 10.1016/j.biopha.2017.11.029
   Zaman F, 2014, TOXICOL LETT, V224, P196, DOI 10.1016/j.toxlet.2013.10.020
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 25
TC 22
Z9 23
U1 1
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD SEP
PY 2018
VL 18
IS 3
BP 2681
EP 2688
DI 10.3892/mmr.2018.9229
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GR7RK
UT WOS:000442890400017
PM 29956812
OA Green Published, hybrid, Green Submitted
DA 2025 08 17
ER

PT J
AU Yan, XF
   Wu, HX
   Wu, ZY
   Hua, F
   Liang, D
   Sun, H
   Yang, Y
   Huang, DJ
   Bian, JS
AF Yan, Xiaofei
   Wu, Haixia
   Wu, Zhiyuan
   Hua, Fei
   Liang, Dong
   Sun, Hong
   Yang, Yong
   Huang, Dejian
   Bian, Jin Song
TI The New Synthetic H2S Releasing SDSS Protects MC3T3 E1
   Osteoblasts against H2O2 Induced Apoptosis by
   Suppressing Oxidative Stress, Inhibiting MAPKs, and Activating the
   PI3K/Akt Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE reactive oxygen species; hydrogen sulfide donating drugs; osteoblast;
   MAPK signaling; PI3K/AKT
ID NF KAPPA B; HYDROGEN SULFIDE; SIGNALING PATHWAY; MITOCHONDRIAL
   DYSFUNCTION; SH SY5Y CELLS; TREATED RATS; INJURY; CARDIOPROTECTION;
   DIFFERENTIATION; CONTRIBUTES
AB Reactive oxygen species (ROS) are important in osteoporosis development. Oxidative stress induces apoptosis of osteoblasts and arrest of their differentiation. Both Danshensu (DSS) and hydrogen sulfide (H2S) produce significant antioxidant effect in various systems. In this study, we synthesized SDSS, a novel H2S releasing compound derived from DSS, and studied its antioxidant effect in an H2O2 induced MC3T3 E1 osteoblastic cell injury model. We first characterized the H2S releasing property of SDSS in both in vivo and in vitro models. HPLC chromatogram showed that intravenous injection of SDSS in adult rats released ADT OH, a well proved H2S sustained release moiety, within several minutes in the rat plasma. Using an H2S selective fluorescent probe, we further confirmed that SDSS released H2S in MC3T3 E1 osteoblastic cells. Biological studies revealed that SUSS had no significant toxic effect but produced protective effects against H2O2 induced MC3T3 E1 cell apoptosis. SDSS also reversed the arrest of cell differentiation caused by H2O2 treatment. This was caused by the stimulatory effect of SDSS on bone sialoprotein, runt related transcription factor 2, collagen expression, alkaline phosphatase activity, and bone nodule formation. Further studies revealed that SDSS reversed the reduced superoxide dismutase activity and glutathione content, and the increased ROS production in H2O2 treated cells. In addition, SDSS significantly attenuated H2O2 induced activation of p38 , ERK1/2 , and JNK MAPKs. SDSS also stimulated phosphatidylinositol 3 kinase/Akt signaling pathway. Blockade of this pathway attenuated the cytoprotective effect of SDSS. In conclusion, SDSS protects MC3T3 E1 cells against H2O2 induced apoptosis by suppressing oxidative stress, inhibiting MAPKs, and activating the phosphatidylinositol 3 kinase/Akt pathway.
C1 [Yan, Xiaofei] Xi An Jiao Tong Univ, Coll Med, Dept Biochem & Mol Biol, Xian, Peoples R China.
   [Yan, Xiaofei; Wu, Haixia; Wu, Zhiyuan; Hua, Fei; Bian, Jin Song] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
   [Wu, Haixia; Liang, Dong; Huang, Dejian] Natl Univ Singapore, Fac Sci, Dept Food Sci, Singapore, Singapore.
   [Sun, Hong] Xuzhou Med Univ, Dept Physiol, Xuzhou, Peoples R China.
   [Yang, Yong] China Pharmaceut Univ, Ctr New Drug Safety Evaluat & Res, Jiangsu Key Lab Drug Discovery Metab Dis, State Key Lab Nat Med, Nanjing, Jiangsu, Peoples R China.
C3 Xi'an Jiaotong University; National University of Singapore; National
   University of Singapore; Xuzhou Medical University; China Pharmaceutical
   University
RP Bian, JS (通讯作者)，Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
EM phcbjs@nus.edu.sg
RI ; Huang, Dejian/A 7439 2010; Liang, Dong/AAC 7495 2019; Hua,
   Fei/AAT 2677 2020
OI Huang, Dejian/0000 0002 2305 3960; Wu, Haixia/0000 0003 4919 788X; Bian,
   Jinsong/0000 0001 8000 3356; Liang, Dong/0000 0002 8281 5152; Bian,
   Jinsong/0000 0002 7741 598X
FU NUSHS bench to bedside grant [NUHSRO/2011/012/STB/B2B 08]; Singapore
   National Medical Research Council grant [CIRG1363/2013]; Singapore
   Ministry of Education Grant [MOE2014 T2 1 134]; National Natural Science
   Foundation of China [81400232]
FX This work was supported by NUSHS bench to bedside grant
   (NUHSRO/2011/012/STB/B2B 08), Singapore National Medical Research
   Council grant (CIRG1363/2013), Singapore Ministry of Education Grant
   (MOE2014 T2 1 134) and National Natural Science Foundation of China.
   (no.81400232).
CR Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Cooper C, 1999, Osteoporos Int, V9 Suppl 2, pS2, DOI 10.1007/PL00004156
   Cui GZ, 2013, INT J CARDIOL, V168, P1349, DOI 10.1016/j.ijcard.2012.12.012
   Cui L, 2009, ACTA PHARMACOL SIN, V30, P321, DOI 10.1038/aps.2009.9
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264 6021:3510095
   Deng XB, 2013, CELL BIOL TOXICOL, V29, P143, DOI 10.1007/s10565 013 9242 5
   Fatokun AA, 2006, BONE, V39, P542, DOI 10.1016/j.bone.2006.02.062
   Feng J, 2015, INT J BIOCHEM CELL B, V66, P59, DOI 10.1016/j.biocel.2015.07.002
   Giustarini D, 2010, FREE RADICAL BIO MED, V48, P1263, DOI 10.1016/j.freeradbiomed.2010.02.014
   Giustarini D, 2010, J CHROMATOGR B, V878, P340, DOI 10.1016/j.jchromb.2009.11.047
   Guo C, 2014, EUR J PHARMACOL, V725, P70, DOI 10.1016/j.ejphar.2014.01.009
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Hu LF, 2011, ANTIOXID REDOX SIGN, V15, P405, DOI 10.1089/ars.2010.3517
   Isomura H, 2004, TOXICOLOGY, V197, P93, DOI 10.1016/j.tox.2003.12.006
   Jiang XQ, 2015, J ETHNOPHARMACOL, V174, P270, DOI 10.1016/j.jep.2015.08.026
   Kim JL, 2012, J CELL BIOCHEM, V113, P247, DOI 10.1002/jcb.23351
   Lane RK, 2015, BBA BIOENERGETICS, V1847, P1387, DOI 10.1016/j.bbabio.2015.05.021
   Li H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048872
   Li J, 2015, SCI REP UK, V5, DOI 10.1038/srep12724
   Li L, 2007, FREE RADICAL BIO MED, V42, P706, DOI 10.1016/j.freeradbiomed.2006.12.011
   Li ZR, 2013, MOL VIS, V19, P1656
   Liu HM, 2012, BIOL TRACE ELEM RES, V150, P441, DOI 10.1007/s12011 012 9488 4
   Liu YH, 2014, ANTIOXID REDOX SIGN, V20, P759, DOI 10.1089/ars.2012.4888
   Lu HY, 2014, BIOL PHARM BULL, V37, P961, DOI 10.1248/bpb.b13 00921
   Lu M, 2012, ANTIOXID REDOX SIGN, V17, P849, DOI 10.1089/ars.2011.4507
   Maggio D, 2003, J CLIN ENDOCR METAB, V88, P1523, DOI 10.1210/jc.2002 021496
   Manolagas SC, 2010, ENDOCR REV, V31, P266, DOI 10.1210/er.2009 0024
   MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092 8674(95)90401 8
   Mustafi SB, 2009, CELL STRESS CHAPERON, V14, P579, DOI 10.1007/s12192 009 0109 x
   Muthusami S, 2005, CLIN CHIM ACTA, V360, P81, DOI 10.1016/j.cccn.2005.04.014
   Pan TT, 2008, AM J PHYSIOL CELL PH, V294, pC169, DOI 10.1152/ajpcell.00282.2007
   Pan TT, 2006, J MOL CELL CARDIOL, V40, P119, DOI 10.1016/j.yjmcc.2005.10.003
   Park BG, 2005, TOXICOLOGY, V215, P115, DOI 10.1016/j.tox.2005.07.003
   Satoh T, 2013, FREE RADICAL BIO MED, V65, P645, DOI 10.1016/j.freeradbiomed.2013.07.022
   Sikka Suresh C., 1996, Frontiers in Bioscience (online), V1, pE78
   Sivarajah A, 2006, SHOCK, V26, P154, DOI 10.1097/01.shk.0000225722.56681.64
   Sparatore A, 2009, FREE RADICAL BIO MED, V46, P586, DOI 10.1016/j.freeradbiomed.2008.11.013
   Tay AS, 2010, NEUROSCIENCE, V167, P277, DOI 10.1016/j.neuroscience.2010.02.006
   Tiong CX, 2010, BRIT J PHARMACOL, V161, P467, DOI 10.1111/j.1476 5381.2010.00887.x
   Wu HX, 2014, CHEM ASIAN J, V9, P3604, DOI 10.1002/asia.201402860
   Xi JC, 2015, J RECEPT SIG TRANSD, V35, P640, DOI 10.3109/10799893.2015.1041647
   Xie L, 2012, AM J PHYSIOL CELL PH, V303, pC81, DOI 10.1152/ajpcell.00281.2011
   Xu ZS, 2011, FREE RADICAL BIO MED, V50, P1314, DOI 10.1016/j.freeradbiomed.2011.02.016
   Yang YJ, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/351895
   Yong QC, 2008, AM J PHYSIOL HEART C, V295, pH1330, DOI 10.1152/ajpheart.00244.2008
   Yong QC, 2008, J MOL CELL CARDIOL, V44, P701, DOI 10.1016/j.yjmcc.2008.01.007
   Yu C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110124
   Yu FBA, 2012, CHEM COMMUN, V48, P2852, DOI 10.1039/c2cc17658k
   Zhang ZF, 2014, J TOXICOL SCI, V39, P803, DOI 10.2131/jts.39.803
   Zhu SK, 2014, ABSTR APPL ANAL, DOI 10.1155/2014/630547
NR 51
TC 47
Z9 50
U1 4
U2 49
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JAN 20
PY 2017
VL 8
AR 7
DI 10.3389/fphar.2017.00007
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA EI2PP
UT WOS:000392330200001
PM 28163684
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Yang, YR
   Kabir, MH
   Park, JH
   Park, JI
   Kang, JS
   Ju, S
   Shin, YJ
   Lee, SM
   Lee, J
   Kim, S
   Lee, KP
   Lee, SY
   Lee, C
   Kwon, KS
AF Yang, Yong Ryoul
   Kabir, Mohammad Humayun
   Park, Jin Hee
   Park, Jae Il
   Kang, Jae Sook
   Ju, Shinyeong
   Shin, Yeo Jin
   Lee, Seung Min
   Lee, Jaemin
   Kim, Seokho
   Lee, Kwang Pyo
   Lee, Soo Young
   Lee, Cheolju
   Kwon, Ki Sun
TI Plasma proteomic profiling of young and old mice reveals cadherin 13
   prevents age related bone loss
SO AGING US
LA English
DT Article
DE aging; bone; plasma proteins; proteomics; osteoclast differentiation
ID T CADHERIN; COGNITIVE FUNCTION; ASSOCIATION; GROWTH; CDH13;
   DIFFERENTIATION; PROGRESSION; EXPRESSION; CLEAVAGE; CELLS
AB The blood exhibits a dynamic flux of proteins that are secreted by the tissues and cells of the body. To identify novel aging related circulating proteins, we compared the plasma proteomic profiles of young and old mice using tandem mass spectrometry. The expression of 134 proteins differed between young and old mice. We selected seven proteins that were expressed at higher levels in young mice, and confirmed their plasma expression in immunoassays. The plasma levels of anthrax toxin receptor 2 (ANTXR2), cadherin 13 (CDH 13), scavenger receptor cysteine rich type 1 protein M130 (CD163), cartilage oligomeric matrix protein (COMP), Dickkopf related protein 3 (DKK3), periostin, and secretogranin 1 were all confirmed to decrease with age. We then investigated whether any of the secreted proteins influenced bone metabolism and found that CDH 13 inhibited osteoclast differentiation. CDH 13 treatment suppressed the receptor activator of NF kappa B ligand (RANKL) signaling pathway in bone marrow derived macrophages, and intraperitoneal administration of CDH 13 delayed age related bone loss in the femurs of aged mice. These findings suggest that low plasma CDH 13 expression in aged mice promotes aging associated osteopenia by facilitating excessive osteoclast formation. Thus, CDH 13 could have therapeutic potential as a protein drug for the prevention of osteopenia.
C1 [Yang, Yong Ryoul; Kang, Jae Sook; Shin, Yeo Jin; Lee, Seung Min; Lee, Jaemin; Lee, Kwang Pyo; Kwon, Ki Sun] Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Daejeon, South Korea.
   [Kabir, Mohammad Humayun; Ju, Shinyeong; Lee, Cheolju] Korea Inst Sci & Technol, Ctr Theragnosis, Seoul, South Korea.
   [Park, Jin Hee; Lee, Soo Young] Ewha Womans Univ, Dept Life Sci, Res Ctr Cellular Homeostasis, Seoul, South Korea.
   [Park, Jae Il] Chonnam Natl Univ, Gwangju Ctr, Korea Basic Sci Inst, Gwangju, South Korea.
   [Kang, Jae Sook; Kwon, Ki Sun] Korea Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Funct Genom, Daejeon, South Korea.
   [Ju, Shinyeong] Hanyang Univ, Dept Life Sci, Seoul, South Korea.
   [Ju, Shinyeong] Hanyang Univ, Res Inst Nat Sci, Seoul, South Korea.
   [Kim, Seokho] Dong A Univ, Coll Hlth Sci, Dept Med Biotechnol, Busan, South Korea.
   [Lee, Cheolju] Kyung Hee Univ, KHU KIST Dept Converging Sci & Technol, Seoul, South Korea.
   [Lee, Cheolju] Korea Univ Sci & Technol, KIST Sch, Div Biomed Sci & Technol, Seoul, South Korea.
   [Kabir, Mohammad Humayun] Incepta Vaccine Ltd, Dhamrai, Kalampur Dhaka, Bangladesh.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea
   Institute of Science & Technology (KIST); Ewha Womans University; Korea
   Basic Science Institute (KBSI); Chonnam National University; University
   of Science & Technology (UST); Hanyang University; Hanyang University;
   Dong A University; Kyung Hee University; Korea Institute of Science &
   Technology (KIST)
RP Kwon, KS (通讯作者)，Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Daejeon, South Korea.; Lee, SY (通讯作者)，Ewha Womans Univ, Dept Life Sci, Res Ctr Cellular Homeostasis, Seoul, South Korea.; Kwon, KS (通讯作者)，Korea Univ Sci & Technol UST, KRIBB Sch Biosci, Dept Funct Genom, Daejeon, South Korea.; Lee, C (通讯作者)，Kyung Hee Univ, KHU KIST Dept Converging Sci & Technol, Seoul, South Korea.; Lee, C (通讯作者)，Korea Univ Sci & Technol, KIST Sch, Div Biomed Sci & Technol, Seoul, South Korea.
EM leesy3770@gmail.com; clee270@kist.re.kr; kwonks@kribb.re.kr
RI ; Shin, Yeo Jin/JXY 2600 2024; lee, kwang pyo/LZE 8213 2025
OI Ju, Shinyeong/0000 0001 5483 4690; Lee, Kwang Pyo/0000 0003 0067 6898
FU National Research Foundation of Korea   Korean government
   [2013M3A9B6076415, 2017M3A9D8048709, 2017M3A9F9030559,
   2019R1A5A6099645]; KRIBB initiative program
FX This work was supported by grants from the National Research Foundation
   of Korea funded by the Korean government (2013M3A9B6076415 and
   2017M3A9D8048709 to KSK, 2017M3A9F9030559 to CL, 2019R1A5A6099645 to
   SYL), and by the KRIBB initiative program.
CR Abbruzzese G, 2016, DEV BIOL, V415, P383, DOI 10.1016/j.ydbio.2015.07.018
   Anderson NL, 2002, MOL CELL PROTEOMICS, V1, P845, DOI 10.1074/mcp.R200007 MCP200
   Baht GS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8131
   Bjelosevic S, 2017, MOL CELL PROTEOMICS, V16, P924, DOI 10.1074/mcp.M116.066720
   Borglum AD, 2014, MOL PSYCHIATR, V19, P325, DOI 10.1038/mp.2013.2
   Conboy IM, 2005, NATURE, V433, P760, DOI 10.1038/nature03260
   Denzel MS, 2010, J CLIN INVEST, V120, P4342, DOI 10.1172/JCI43464
   Ding J, 2011, AGE, V33, P291, DOI 10.1007/s11357 010 9179 z
   Elabd C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5082
   Fontana L, 2010, SCIENCE, V328, P321, DOI 10.1126/science.1172539
   FREDETTE BJ, 1994, J NEUROSCI, V14, P7331
   Fredette BJ, 1996, DEVELOPMENT, V122, P3163
   Gan KJ, 2019, P NATL ACAD SCI USA, V116, P12524, DOI 10.1073/pnas.1902672116
   Geyer PE, 2016, CELL SYST, V2, P185, DOI 10.1016/j.cels.2016.02.015
   Grieve AG, 2014, J CELL SCI, V127, P3331, DOI 10.1242/jcs.147926
   Hayano Y, 2014, DEVELOPMENT, V141, P4784, DOI 10.1242/dev.108290
   Hebbard LW, 2008, CANCER RES, V68, P1407, DOI 10.1158/0008 5472.CAN 07 2953
   Hoehenwarter W, 2010, RAPID COMMUN MASS SP, V24, P3609, DOI 10.1002/rcm.4818
   Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101
   Hwang CY, 2014, PROTEOMICS, V14, P121, DOI 10.1002/pmic.201200497
   Ignjatovic V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017213
   Ivanov D, 2004, CARDIOVASC RES, V64, P132, DOI 10.1016/j.cardiores.2004.06.010
   Jeong E, 2018, CELL DEATH DIFFER, V25, P1364, DOI 10.1038/s41418 017 0048 5
   Kuefer R, 2003, CLIN CANCER RES, V9, P6447
   Kwak JY, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26617 9
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lehallier B, 2019, NAT MED, V25, P1843, DOI 10.1038/s41591 019 0673 2
   Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015
   Pfaff D, 2015, EUR HEART J ACUTE CA, V4, P410, DOI 10.1177/2048872614557229
   Philippova M, 2011, EUR HEART J, V32, P760, DOI 10.1093/eurheartj/ehq206
   Philippova M, 2009, CELL SIGNAL, V21, P1035, DOI 10.1016/j.cellsig.2009.01.035
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896 6273(91)90291 7
   Resink TJ, 1999, FEBS LETT, V463, P29, DOI 10.1016/S0014 5793(99)01594 X
   Rifai N, 2006, NAT BIOTECHNOL, V24, P971, DOI 10.1038/nbt1235
   Rivero O, 2015, TRANSL PSYCHIAT, V5, DOI 10.1038/tp.2015.152
   Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898
   Suzuki ST, 1996, J CELL BIOCHEM, V61, P531, DOI 10.1002/(SICI)1097 4644(19960616)61:4<531::AID JCB6>3.0.CO;2 P
   Takeuchi T, 2000, J NEUROCHEM, V74, P1489, DOI 10.1046/j.1471 4159.2000.0741489.x
   Tanaka T, 2018, AGING CELL, V17, DOI 10.1111/acel.12799
   Tang MKS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04695 7
   Terracciano A, 2010, BIOL PSYCHIAT, V68, P811, DOI 10.1016/j.biopsych.2010.06.030
   Tirumalai RS, 2003, MOL CELL PROTEOMICS, V2, P1096, DOI 10.1074/mcp.M300031 MCP200
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Tyrberg B, 2011, ISLETS, V3, P327, DOI 10.4161/isl.3.6.17705
   Vargas Alarcon G, 2017, IMMUNOBIOLOGY, V222, P973, DOI 10.1016/j.imbio.2016.09.004
   Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569
   Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357
   Vinel C, 2018, NAT MED, V24, P1360, DOI 10.1038/s41591 018 0131 6
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Ye Y, 2013, ONCOGENE, V32, P1702, DOI 10.1038/onc.2012.180
   Yeom J, 2015, RAPID COMMUN MASS SP, V29, P128, DOI 10.1002/rcm.7081
NR 52
TC 20
Z9 21
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD MAY 15
PY 2020
VL 12
IS 9
BP 8652
EP 8668
DI 10.18632/aging.103184
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LN7ZB
UT WOS:000533150800064
PM 32396872
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Janockova, J
   Matejova, J
   Moravek, M
   Homolova, L
   Slovinska, L
   Nagyova, A
   Rak, D
   Sedlak, M
   Harvanova, D
   Spakova, T
   Rosocha, J
AF Janockova, Jana
   Matejova, Jana
   Moravek, Marko
   Homolova, Lucia
   Slovinska, Lucia
   Nagyova, Alena
   Rak, Dmytro
   Sedlak, Marian
   Harvanova, Denisa
   Spakova, Timea
   Rosocha, Jan
TI Small Extracellular Vesicles Derived from Human Chorionic MSCs as Modern
   Perspective towards Cell Free Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE extracellular vesicles; small EVs; chorion; mesenchymal stem cells;
   cell free therapy
ID MESENCHYMAL STEM CELLS; STROMAL CELLS; BONE MARROW; ENHANCE
   ANGIOGENESIS; TISSUE REGENERATION; PROGENITOR CELLS; EXOSOMES; PLACENTA;
   DIFFERENTIATION; OSTEOARTHRITIS
AB Mesenchymal stem cells (MSCs) are of great interest to scientists due to their application in cell therapy of many diseases, as well as regenerative medicine and tissue engineering. Recently, there has been growing evidence surrounding the research based on extracellular vesicles (EVs), especially small EVs (sEVs)/exosomes derived from MSCs. EVs/exosomes can be secreted by almost all cell types and various types of EVs show multiple functions. In addition, MSCs derived exosomes have similar characteristics and biological activities to MSCs and their therapeutic applications are considered as a safe strategy in cell free therapy. The aim of this study was the characterization of MSCs isolated from the chorion (CHo MSCs) of human full term placenta, as well as the isolation and analysis of small EVs obtained from these cells. Accordingly, in this study, the ability of small EVs' uptake is indicated by synovial fibroblasts, osteoblasts and periosteum derived MSCs. Improvement in the understanding of the structure, characteristics, mechanism of action and potential application of MSCs derived small EVs can provide new insight into improved therapeutic strategies.
C1 [Janockova, Jana; Matejova, Jana; Moravek, Marko; Homolova, Lucia; Slovinska, Lucia; Harvanova, Denisa; Spakova, Timea; Rosocha, Jan] Safarik Univ, Assoc Tissue Bank, Fac Med, Tr SNP 1, Kosice 04011, Slovakia.
   [Janockova, Jana; Matejova, Jana; Moravek, Marko; Homolova, Lucia; Slovinska, Lucia; Nagyova, Alena; Harvanova, Denisa; Spakova, Timea; Rosocha, Jan] L Pasteur Univ Hosp Kosice, Tr SNP 1, Kosice 04011, Slovakia.
   [Nagyova, Alena] Safarik Univ, Fac Med, Dept Obstet & Gynaecol, Tr SNP 1, Kosice 04011, Slovakia.
   [Rak, Dmytro; Sedlak, Marian] Slovak Acad Sci, Inst Expt Phys, Watsonova 47, Kosice 04001, Slovakia.
C3 University of Pavol Jozef Safarik Kosice; University of Pavol Jozef
   Safarik Kosice; Slovak Academy of Sciences
RP Janockova, J (通讯作者)，Safarik Univ, Assoc Tissue Bank, Fac Med, Tr SNP 1, Kosice 04011, Slovakia.; Janockova, J (通讯作者)，L Pasteur Univ Hosp Kosice, Tr SNP 1, Kosice 04011, Slovakia.
EM jana.janockova@gmail.com; jana.matejova@upjs.sk;
   marko.moravek@student.upjs.sk; lucia.homolova@upjs.sk;
   lucia.slovinska@upjs.sk; alena.nagyova@upjs.sk; rak@saske.sk;
   marsed@saske.sk; denisa.harvanova@upjs.sk; timea.spakova@upjs.sk;
   jan.rosocha@upjs.sk
RI , Jana/AIC 4806 2022; Sedlak, Marian/AAE 5995 2022; Morávek,
   Marko/HTN 7324 2023; Bzdilova Janockova, Jana/ACC 2379 2022; Bzdilova,
   Jana/ACC 2379 2022; Rak, Dmytro/AAD 5798 2019; Slovinská,
   Lucia/ITU 2485 2023; Spakova, Timea/GXG 4900 2022
OI Moravek, Marko/0000 0002 9795 0170; Matejova, Jana/0000 0002 9086 3621;
   Rosocha, Jan/0000 0002 1844 2048; Sedlak, Marian/0000 0003 2951 2846;
   Bzdilova Janockova, Jana/0000 0002 2034 1860; Slovinska,
   Lucia/0000 0002 9945 0655; Rak, Dmytro/0000 0001 7531 7772; Spakova,
   Timea/0000 0001 6787 1925
FU Operational Programme Integrated Infrastructure   ERDF [ITMS2014+:
   313011V455]; Slovak Research and Development Agency [APVV 17 0118];
   Scientific Grant Agency of the Ministry of Education, Science, Research
   and Sport of the Slovak Republic; Slovak Academy of Sciences (VEGA)
   [1/0229/20]
FX This publication is the result of the project implementation: "Open
   scientific community for modern interdisciplinary research in medicine
   (OPENMED)", ITMS2014+: 313011V455 supported by the Operational Programme
   Integrated Infrastructure, funded by the ERDF. This research was also
   supported by the Slovak Research and Development Agency under the
   contract No. APVV 17 0118 and the Scientific Grant Agency of the
   Ministry of Education, Science, Research and Sport of the Slovak
   Republic and Slovak Academy of Sciences (VEGA, No. 1/0229/20).
CR Akyurekli C, 2015, STEM CELL REV REP, V11, P150, DOI 10.1007/s12015 014 9545 9
   Amrichová J, 2014, CENT EUR J BIOL, V9, P139, DOI 10.2478/s11535 013 0255 0
   Andreu Z, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00442
   Bacenková D, 2020, APPL SCI BASEL, V10, DOI 10.3390/app10249040
   Bacenková D, 2011, CYTOTHERAPY, V13, P1047, DOI 10.3109/14653249.2011.592522
   Bachurski D, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1596016
   Choi YS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172642
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Coughlan Christina, 2020, Curr Protoc Cell Biol, V88, pe110, DOI 10.1002/cpcb.110
   Cui GH, 2018, FASEB J, V32, P654, DOI 10.1096/fj.201700600R
   Damania A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 017 0752 6
   De Jong OG, 2014, FRONT IMMUNOL, V5, P1, DOI 10.3389/fimmu.2014.00608
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Doyle LM, 2019, CELLS BASEL, V8, DOI 10.3390/cells8070727
   Garcia Contreras M, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05787 y
   González PL, 2015, STEM CELL TRANSL MED, V4, P1109, DOI 10.5966/sctm.2015 0022
   Gould SJ, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20389
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Harvanová D, 2011, FOLIA BIOL PRAGUE, V57, P119
   Harvanová D, 2014, VET RES COMMUN, V38, P221, DOI 10.1007/s11259 014 9607 0
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Haynesworth SE, 1996, J CELL PHYSIOL, V166, P585, DOI 10.1002/(SICI)1097 4652(199603)166:3<585::AID JCP13>3.0.CO;2 6
   Heeger PS, 2004, TRANSPLANTATION, V78, P1411, DOI 10.1097/01.TP.0000144056.92919.54
   Heidari M, 2018, J CELL PHYSIOL, V233, P8754, DOI 10.1002/jcp.26765
   Helwa I, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170628
   Hernández R, 2020, BIOMOL THER, V28, P34, DOI 10.4062/biomolther.2019.065
   Hunakova K, 2020, RES VET SCI, V132, P513, DOI 10.1016/j.rvsc.2020.08.004
   Jakob F, 2008, CURR RHEUMATOL REV, V4, P148, DOI 10.2174/157339708785133497
   Janockova J, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929 021 00736 4
   Jie Z, 2019, INT J STEM CELLS, V12, P440, DOI 10.15283/ijsc18139
   JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412
   Koo BK, 2012, J KOREAN MED SCI, V27, P857, DOI 10.3346/jkms.2012.27.8.857
   LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557
   Lee JM, 2012, INT IMMUNOPHARMACOL, V13, P219, DOI 10.1016/j.intimp.2012.03.024
   Lener T, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.30087
   Lin JJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26164987
   Liu YB, 2018, BIOCHEM J, V475, P3629, DOI 10.1042/BCJ20180675
   Lötvall J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.26913
   Murphy MB, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.94
   Najimi M, 2007, CELL TRANSPLANT, V16, P717, DOI 10.3727/000000007783465154
   Nazarov I, 2012, STEM CELL TRANSL MED, V1, P359, DOI 10.5966/sctm.2011 0021
   Nederveen JP, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.604274
   Ni ZH, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0100 9
   Parolini O, 2008, STEM CELLS, V26, P300, DOI 10.1634/stemcells.2007 0594
   Parolini O, 2010, STEM CELLS DEV, V19, P143, DOI 10.1089/scd.2009.0404
   Pfützner A, 2017, INT J STEM CELLS, V10, P154, DOI 10.15283/ijsc17033
   Pittenger MF, 2019, NPJ REGEN MED, V4, DOI 10.1038/s41536 019 0083 6
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pountos I, 2005, INJURY, V36, P8, DOI 10.1016/j.injury.2005.07.028
   Qin YH, 2016, SCI REP UK, V6, DOI 10.1038/srep21961
   Raposo G, 2013, J CELL BIOL, V200, P373, DOI 10.1083/jcb.201211138
   Raynaud CM, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/658356
   Reza Zaldivar EE, 2019, NEURAL REGEN RES, V14, P1626, DOI 10.4103/1673 5374.255978
   Rong XL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1204 2
   Savkovic V, 2014, CURR STEM CELL RES T, V9, P469, DOI 10.2174/1574888X09666140709111444
   Serrano Pertierra E, 2019, BIOENGINEERING BASEL, V6, DOI 10.3390/bioengineering6010008
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   Spakova T, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189701
   Spakova T, 2018, MOLECULES, V23, DOI 10.3390/molecules23010181
   Stranska R, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 017 1374 6
   Tang YT, 2017, INT J MOL MED, V40, P834, DOI 10.3892/ijmm.2017.3080
   Tao SC, 2017, THERANOSTICS, V7, P180, DOI 10.7150/thno.17133
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Thery Clotilde, 2011, F1000 Biol Rep, V3, P15, DOI 10.3410/B3 15
   Urbanelli L, 2013, GENES BASEL, V4, P152, DOI 10.3390/genes4020152
   Wang LB, 2012, MOL MED REP, V6, P760, DOI 10.3892/mmr.2012.1000
   Wendler F, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.22390
   Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360
   Woo CH, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1735249
   Xie XJ, 2006, ACTA PHARMACOL SIN, V27, P1153, DOI 10.1111/j.1745 7254.2006.00436.x
   Yamahara K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088319
   Yu LL, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3634563
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
   Zhang B, 2015, STEM CELL TRANSL MED, V4, P513, DOI 10.5966/sctm.2014 0267
   Zhang S, 2016, OSTEOARTHR CARTILAGE, V24, P2135, DOI 10.1016/j.joca.2016.06.022
   Zhang YL, 2017, NEUROCHEM INT, V111, P69, DOI 10.1016/j.neuint.2016.08.003
   Zhou M, 2020, EXOSOMES: A CLINICAL COMPENDIUM, P23, DOI 10.1016/B978 0 12 816053 4.00002 X
   Zou LY, 2019, EXP THER MED, V18, P2574, DOI 10.3892/etm.2019.7874
   Zou XY, 2016, AM J TRANSL RES, V8, P4289
NR 79
TC 13
Z9 13
U1 5
U2 22
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2021
VL 22
IS 24
AR 13581
DI 10.3390/ijms222413581
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA YA8XB
UT WOS:000738608200001
PM 34948379
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Huang, YM
   Fu, YS
   Chen, WL
   Lu, HC
AF Huang, Yi Ming
   Fu, You Sheng
   Chen, Woan Ling
   Lu, Hsi Chi
TI In Vitro Assessment of 4 Acetyl Antroquinonol B and Erinacine A
   in Suppressing Breast Cancer Induced Osteoclastogenesis
SO INTERNATIONAL JOURNAL OF MEDICINAL MUSHROOMS
LA English
DT Article
DE 4 acetyl antroquinonol B; erinacine A; breast cancer bone metastasis;
   MMP 9; TGF beta; MAPK signaling; Hericium erinaceus; medicinal mushrooms
ID NF KAPPA B; ANTRODIA CAMPHORATA; MESENCHYMAL TRANSITION; BONE; CELL;
   METASTASIS; INHIBITION; PROLIFERATION; ANTROQUINONOL; EXPRESSION
AB Bone metastasis in metastatic breast cancer commonly results in osteolytic lesions due to osteoclast activity, promoting bone destruction and tumor progression. The bioactive fungal isolates, 4 acetyl antroquinonol B (4 AAQB) and erinacine A, have diverse pharmacological and biological activities. However, their effects on breast cancer bone metastasis treatment remain unclear. Our study aimed to examine the impact of 4 AAQB or erinacine A on breast cancer metastases in bone. The effects of 4 AAQB and erinacine A on breast cancer induced osteoclastogenesis, breast cancer migration, production of prometastatic cytokine (TGF beta) and marker (MMP 9), as well as potential MAPK signaling transductions were assessed. The results revealed that 4 AAQB and erinacine A effectively suppressed breast cancer induced osteoclastogenesis and migration, and reduced TGF beta and MMP 9 production via Erk or JNK signaling transductions, specifically in breast cancer cells or in breast cancer cells induced osteoclasts. Based on these findings, either 4 AAQB or erinacine A showed promise in preventing breast cancer metastases in bone.
C1 [Huang, Yi Ming] Natl Chin Yi Univ Technol, Dept Chem & Mat Engn, Taichung 411030, Taiwan.
   [Fu, You Sheng; Chen, Woan Ling; Lu, Hsi Chi] Tunghai Univ, Dept Food Sci, Taichung 407224, Taiwan.
   [Chen, Woan Ling] Tunghai Univ, Dept Chem & Mat Engn, Taichung 407224, Taiwan.
C3 National Chin Yi University of Technology; Tunghai University; Tunghai
   University
RP Lu, HC (通讯作者)，1727 Taiwan Blvd,Sec 4, Taichung 407224, Taiwan.
EM hclu@thu.edu.tw
RI Lu, Hsi Chi/B 8782 2014; Lu, Hsi Chi/LFU 5869 2024
OI Lu, Hsi Chi/0000 0002 2523 591X; 
FX We thank New Bellus Enterprise Co. Ltd., for providing the valuable test
   samples of NB EA and NB AB
CR Agathocleous M, 2013, TRENDS CELL BIOL, V23, P484, DOI 10.1016/j.tcb.2013.05.004
   Bocca C, 2014, EXPERT OPIN THER TAR, V18, P121, DOI 10.1517/14728222.2014.860447
   Brockton NT, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1528 y
   Chan Hui PY, 1998, BIOCHEM J, V336, P599, DOI 10.1042/bj3360599
   Chang CH, 2015, J AGR FOOD CHEM, V63, P208, DOI 10.1021/jf504434v
   Chang TC, 2015, TOXICOL APPL PHARM, V288, P258, DOI 10.1016/j.taap.2015.07.025
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   Dillekås H, 2019, CANCER MED US, V8, P5574, DOI 10.1002/cam4.2474
   Dong HD, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12633
   Gebäck T, 2009, BIOTECHNIQUES, V46, P265, DOI 10.2144/000113083
   Geethangili M, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nep108
   Hankins ML, 2021, J BONE ONCOL, V29, DOI 10.1016/j.jbo.2021.100363
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Kimachi K, 2011, N S ARCH PHARMACOL, V383, P297, DOI 10.1007/s00210 010 0596 4
   Kong LB, 2019, J CELL MOL MED, V23, P3077, DOI 10.1111/jcmm.14277
   Kuo HC, 2016, J TRANSL MED, V14, DOI 10.1186/s12967 016 0831 y
   Lee KF, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9020137
   Lee KF, 2014, INT J MOL SCI, V15, P15073, DOI 10.3390/ijms150915073
   Lee KC, 2017, J CELL MOL MED, V21, P588, DOI 10.1111/jcmm.13004
   Lee WT, 2015, FOOD CHEM TOXICOL, V78, P33, DOI 10.1016/j.fct.2015.01.012
   Lin YW, 2011, J AGR FOOD CHEM, V59, P8625, DOI 10.1021/jf2011326
   Luegmayr E, 2004, CELL DEATH DIFFER, V11, pS108, DOI 10.1038/sj.cdd.4401399
   Mendoza Villanueva D, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 171
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nutter F, 2014, ENDOCR RELAT CANCER, V21, P327, DOI 10.1530/ERC 13 0158
   Owen S, 2013, ANTICANCER RES, V33, P199
   Prasher P, 2023, BIOMED PHARMACOTHER, V160, DOI 10.1016/j.biopha.2023.114332
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Satriyo PB, 2021, TOXICOL APPL PHARM, V422, DOI 10.1016/j.taap.2021.115493
   Shao HM, 2022, CELLS BASEL, V11, DOI 10.3390/cells11030388
   Sterling JA, 2011, BONE, V48, P6, DOI 10.1016/j.bone.2010.07.015
   Wang SC, 2014, J AGR FOOD CHEM, V62, P5625, DOI 10.1021/jf4056924
   Wei S, 2002, J BIOL CHEM, V277, P6622, DOI 10.1074/jbc.M104957200
   Wu CZ, 2022, PHYTOMEDICINE, V100, DOI 10.1016/j.phymed.2022.154062
   Xia Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124007
   Yang HL, 2011, FOOD CHEM TOXICOL, V49, P290, DOI 10.1016/j.fct.2010.10.031
NR 37
TC 0
Z9 0
U1 4
U2 8
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 1521 9437
EI 1940 4344
J9 INT J MED MUSHROOMS
JI Int. J. Med. Mushrooms
PY 2024
VL 26
IS 8
BP 41
EP 57
DI 10.1615/IntJMedMushrooms.2024053977
PG 17
WC Biochemistry & Molecular Biology; Plant Sciences; Mycology; Pharmacology
   & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Plant Sciences; Mycology; Pharmacology
   & Pharmacy
GA E4M7T
UT WOS:001302768900004
PM 38967210
DA 2025 08 17
ER

PT J
AU Liang, C
   Peng, SL
   Li, J
   Lu, J
   Guan, DG
   Jiang, F
   Lu, C
   Li, FF
   He, XJ
   Zhu, HL
   Au, DWT
   Yang, DZ
   Zhang, BT
   Lu, AP
   Zhang, G
AF Liang, Chao
   Peng, Songlin
   Li, Jie
   Lu, Jun
   Guan, Daogang
   Jiang, Feng
   Lu, Cheng
   Li, Fangfei
   He, Xiaojuan
   Zhu, Hailong
   Au, D. W. T.
   Yang, Dazhi
   Zhang, Bao Ting
   Lu, Aiping
   Zhang, Ge
TI Inhibition of osteoblastic Smurf1 promotes bone formation in mouse
   models of distinctive age related osteoporosis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID UBIQUITIN LIGASE SMURF1; TARGET STABILITY DARTS; MORPHOGENETIC PROTEINS;
   TGF BETA; CLINICAL APPLICATIONS; DEGRADATION; DIFFERENTIATION;
   HOMEOSTASIS; GROWTH; IDENTIFICATION
AB Bone morphogenetic protein (BMP) signaling is essential for osteogenesis. However, recombinant human BMPs (rhBMPs) exhibit large inter individual variations in local bone formation during clinical spinal fusion. Smurf1 ubiquitinates BMP downstream molecules for degradation. Here, we classify age related osteoporosis based on distinct intraosseous BMP 2 levels and Smurf1 activity. One major subgroup with a normal BMP 2 level and elevated Smurf1 activity (BMP 2(n)/Smurf1(e)) shows poor response to rhBMP 2 during spinal fusion, when compared to another major subgroup with a decreased BMP 2 level and normal Smurf1 activity (BMP 2(d)/Smurf1(n)). We screen a chalcone derivative, i.e., 2 (4 cinnamoylphenoxy) acetic acid, which effectively inhibits Smurf1 activity and increases BMP signaling. For BMP 2(n)/Smurf1(e) mice, the chalcone derivative enhances local bone formation during spinal fusion. After conjugating to an osteoblast targeting and penetrating oligopeptide (DSS)(6), the chalcone derivative promotes systemic bone formation in BMP 2(n)/Smurf1(e) mice. This study demonstrates a precision medicine based bone anabolic strategy for age related osteoporosis.
C1 [Liang, Chao; Peng, Songlin; Lu, Jun; Guan, Daogang; Jiang, Feng; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Hong Kong, Peoples R China.
   [Liang, Chao; Lu, Jun; Guan, Daogang; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Zhu, Hailong; Lu, Aiping; Zhang, Ge] Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong 999077, Hong Kong, Peoples R China.
   [Liang, Chao; Lu, Jun; Guan, Daogang; Lu, Cheng; Li, Fangfei; He, Xiaojuan; Lu, Aiping; Zhang, Ge] HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen 518000, Peoples R China.
   [Peng, Songlin; Yang, Dazhi] Ji Nan Univ, Shenzhen Peoples Hosp, Dept Spine Surg, Coll Med 2, Shenzhen 518020, Peoples R China.
   [Li, Jie; Zhang, Bao Ting] Chinese Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong 999077, Hong Kong, Peoples R China.
   [Li, Jie] Peking Univ, Shenzhen Hosp, Clin Med Lab, Shenzhen 518036, Peoples R China.
   [Jiang, Feng] Zhejiang Pharmaceut Coll, Ningbo 315100, Zhejiang, Peoples R China.
   [Lu, Cheng; He, Xiaojuan] China Acad Chinese Med Sci, Inst Basic Res Clin Med, Beijing 100700, Peoples R China.
   [Au, D. W. T.] City Univ Hong Kong, Dept Biol & Chem, Hong Kong 999077, Hong Kong, Peoples R China.
   [Lu, Aiping] Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 200032, Peoples R China.
C3 Hong Kong Baptist University; Hong Kong Baptist University; HKBU
   Institute for Research & Continuing Education; Jinan University; Chinese
   University of Hong Kong; Peking University; China Academy of Chinese
   Medical Sciences; Institute of Basic Research In Clinical Medicine,
   CACMS; City University of Hong Kong
RP Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Law Sau Fai Inst Adv Translat Med Bone & Joint Di, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，Hong Kong Baptist Univ, Sch Chinese Med, Inst Integrated Bioinfomed & Translat Sci, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP; Zhang, G (通讯作者)，HKBU Inst Res & Continuing Educ, Inst Precis Med & Innovat Drug Discovery, Shenzhen 518000, Peoples R China.; Zhang, BT (通讯作者)，Chinese Univ Hong Kong, Sch Chinese Med, Fac Med, Hong Kong 999077, Hong Kong, Peoples R China.; Lu, AP (通讯作者)，Shanghai Acad Chinese Med Sci, Inst Arthrit Res, Shanghai 200032, Peoples R China.
EM zhangbaoting@cuhk.edu.hk; aipinglu@hkbu.edu.hk; zhangge@hkbu.edu.hk
RI peng, sl/ISA 1370 2023; Zhang, Ge/N 4150 2013; Lu, Jun/JBJ 8742 2023;
   JIANG, Feng/HTP 2862 2023; Liang, Chao/AAF 7703 2019; LU,
   Aiping/JDX 0577 2023; Zhang, Baoting/B 6273 2015; Dong,
   Xinlong/KRO 6089 2024
OI Peng, Songlin/0000 0002 4042 7071; Zhang, Bao Ting/0000 0003 1421 0212;
   Guan, Daogang/0000 0003 1414 0189; Guan, Daogang/0000 0002 3289 1448;
   Liang, Chao/0000 0002 5617 3483; Lu, Jun/0000 0003 1625 8682; 
FU Ministry of Science and Technology of China [2013ZX09301307]; Hong Kong
   General Research Fund [HKBU12100918, HKBU479111, HKBU478312, HKBU262913,
   HKBU12102914, HKBU261113, CUHK14112915, CUHK489213]; Research Grants
   Council; Natural Science Foundation Council of China [N_HKBU435/12,
   81272045, 81700780, 81371989, 81401833, 81470072]; Croucher Foundation
   [CAS14BU/CAS14201]; Interdisciplinary Research Matching Scheme (IRMS) of
   Hong Kong Baptist University [RC IRMS/12 13/02, RC IRMS/13 14/02]; Hong
   Kong Baptist University Strategic Development Fund [SDF13 1209 P01,
   SDF15 0324 P02(b)]; Hong Kong Research Grants Council Early Career
   Scheme [489213]; Inter institutional Collaborative Research Scheme of
   Hong Kong Baptist University [RC ICRS/14 15/01, RC ICRS/16 17/01];
   Faculty Research Grant of Hong Kong Baptist University [FRG1/13 14/024,
   FRG2/13 14/006, FRG2/14 15/010]; China Academy of Chinese Medical
   Sciences [Z0252, Z0293]
FX We thank technical staffs (Ms. Yeuk Siu Cheung and Mr. Chi Leung Chan)
   from Law Sau Fai Institute for Advancing Translational Medicine in Bone
   and Joint Diseases, School of Chinese Medicine, Hong Kong Baptist
   University for providing technical support. This work was supported by
   the Ministry of Science and Technology of China (2013ZX09301307 to
   A.L.), the Hong Kong General Research Fund (HKBU12100918 to G.Z.,
   HKBU479111 to G.Z., HKBU478312 to G.Z., HKBU262913 to G.Z., HKBU12102914
   to G.Z., HKBU261113 to A.L., CUHK14112915 to B. T.Z., and CUHK489213 to
   B. T.Z.), the Natural Science Foundation Council of China (81272045 to
   G.Z., 81700780 to C.L., 81371989 to S.P., 81272045 to B.G., 81401833 to
   B.G., and 81470072 to X.H.), the lResearch Grants Council and Natural
   Science Foundation Council of China (N_HKBU435/12 to G.Z.), the Croucher
   Foundation (Gnt#CAS14BU/CAS14201 to A.L.), the Interdisciplinary
   Research Matching Scheme (IRMS) of Hong Kong Baptist University
   (RC IRMS/12 13/02 to A.L. and RC IRMS/13 14/02 to G.Z.), the Hong Kong
   Baptist University Strategic Development Fund (SDF13 1209 P01 to A.L.
   and SDF15 0324 P02(b) to A.L.), the Hong Kong Research Grants Council
   Early Career Scheme (489213 to G.Z.), the Inter institutional
   Collaborative Research Scheme of Hong Kong Baptist University
   (RC ICRS/14 15/01 to G.Z. and RC ICRS/16 17/01 to A.L.), the Faculty
   Research Grant of Hong Kong Baptist University (FRG1/13 14/024 to G.Z.,
   FRG2/13 14/006 to G.Z., and FRG2/14 15/010 to G.Z.), the China Academy
   of Chinese Medical Sciences (Z0252 and Z0293 to A.L.).
CR Alexander JM, 2001, J BONE MINER RES, V16, P1665, DOI 10.1359/jbmr.2001.16.9.1665
   Amin S, 2007, J BONE MINER RES, V22, P799, DOI 10.1359/JBMR.070306
   Aragón E, 2011, GENE DEV, V25, P1275, DOI 10.1101/gad.2060811
   Bakker AD, 2012, METHODS MOL BIOL, V816, P19, DOI 10.1007/978 1 61779 415 5_2
   Beederman M., 2013, J BIOMEDICAL SCI ENG, V6, P32, DOI DOI 10.4236/JBISE.2013.68A1004
   Bessa PC, 2008, J TISSUE ENG REGEN M, V2, P1, DOI 10.1002/term.63
   Bishop GB, 2007, INT ORTHOP, V31, P721, DOI 10.1007/s00264 007 0424 8
   Bobyn J, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749 799X 8 2
   Cao Y, 2014, SCI REP UK, V4, DOI 10.1038/srep04965
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen WJ, 2016, NAT REV IMMUNOL, V16, P723, DOI 10.1038/nri.2016.112
   Chiva Blanch G, 2011, J CHROMATOGR A, V1218, P698, DOI 10.1016/j.chroma.2010.12.012
   Chong PA, 2010, P NATL ACAD SCI USA, V107, P18404, DOI 10.1073/pnas.1003023107
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   Demontiero O, 2012, THER ADV MUSCULOSKEL, V4, P61, DOI 10.1177/1759720X11430858
   Erdogan CS, 2016, NUTRIENTS, V8, DOI 10.3390/nu8060353
   Farr JN, 2015, NAT REV ENDOCRINOL, V11, P513, DOI 10.1038/nrendo.2015.89
   Gautschi OP, 2007, ANZ J SURG, V77, P626, DOI 10.1111/j.1445 2197.2007.04175.x
   Ghodadra N, 2008, BIOL TARGETS THER, V2, P345
   Guo BS, 2014, BONE, V59, P76, DOI 10.1016/j.bone.2013.11.007
   Hollingsworth Scott A, 2010, Biomol Concepts, V1, P271, DOI 10.1515/BMC.2010.022
   Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291 010 0074 2
   Johnson JS, 2011, J CELL BIOCHEM, V112, P1673, DOI 10.1002/jcb.23082
   Kato S, 2011, MOL CELL BIOCHEM, V349, P97, DOI 10.1007/s11010 010 0664 6
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li J. Jenny, 2017, International Journal of Information Privacy, Security and Integrity, V3, P1
   Liang C, 2015, NAT MED, V21, P288, DOI 10.1038/nm.3791
   Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200
   Lissenberg Thunnissen SN, 2011, INT ORTHOP, V35, P1271, DOI 10.1007/s00264 011 1301 z
   Lomenick B, 2009, P NATL ACAD SCI USA, V106, P21984, DOI 10.1073/pnas.0910040106
   Lu KF, 2008, NAT CELL BIOL, V10, P994, DOI 10.1038/ncb1760
   Lu SS, 2007, SPINE J, V7, P50, DOI 10.1016/j.spinee.2006.04.020
   Montgomery SR, 2014, J BONE MINER RES, V29, P1872, DOI 10.1002/jbmr.2213
   Morimoto T, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01097
   Motyl KJ, 2012, J CELL PHYSIOL, V227, P1326, DOI 10.1002/jcp.22844
   Murakami K, 2010, EXP BIOL MED, V235, P805, DOI 10.1258/ebm.2010.009383
   Pai MY, 2015, METHODS MOL BIOL, V1263, P287, DOI 10.1007/978 1 4939 2269 7_22
   Rao RD, 2007, SPINE J, V7, P61, DOI 10.1016/j.spinee.2006.03.004
   Ravindran S, 2013, J BIOL CHEM, V288, P16098, DOI 10.1074/jbc.M113.450585
   SALI A, 1995, MOL MED TODAY, V1, P270, DOI 10.1016/s1357 4310(95)91170 7
   Sapkota G, 2007, MOL CELL, V25, P441, DOI 10.1016/j.molcel.2007.01.006
   Shen R, 2006, J BIOL CHEM, V281, P3569, DOI 10.1074/jbc.M506761200
   Shimazu J, 2016, CELL REP, V15, P27, DOI 10.1016/j.celrep.2016.03.003
   Smith AL, 2012, CLIN CANCER RES, V18, P4514, DOI 10.1158/1078 0432.CCR 11 3224
   Spassov VZ, 2008, PROTEIN ENG DES SEL, V21, P91, DOI 10.1093/protein/gzm083
   Starman JS, 2012, J TRAUMA ACUTE CARE, V72, P676, DOI 10.1097/TA.0b013e318232cf5a
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035
   Yang B, 2012, MOL MED REP, V5, P955, DOI 10.3892/mmr.2012.765
   Yarbrough DK, 2010, CALCIFIED TISSUE INT, V86, P58, DOI 10.1007/s00223 009 9312 0
   Yue R, 2016, ELIFE, V5, DOI 10.7554/eLife.18782
   Zhang G, 2012, NAT MED, V18, P307, DOI 10.1038/nm.2617
   Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974
   Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200
   Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293
NR 59
TC 45
Z9 51
U1 4
U2 46
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD AUG 24
PY 2018
VL 9
AR 3428
DI 10.1038/s41467 018 05974 z
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GR4PA
UT WOS:000442594800030
PM 30143635
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Nemec, K
   Schihada, H
   Kleinau, G
   Zabel, U
   Grushevskyi, EO
   Scheerer, P
   Lohse, MJ
   Maiellaro, I
AF Nemec, Katarina
   Schihada, Hannes
   Kleinau, Gunnar
   Zabel, Ulrike
   Grushevskyi, Eugene O.
   Scheerer, Patrick
   Lohse, Martin J.
   Maiellaro, Isabella
TI Functional modulation of PTH1R activation and signaling by RAMP2
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE GPCR; RAMP; BRET; FRET
ID PROTEIN COUPLED RECEPTOR; PARATHYROID HORMONE RECEPTOR; ARRESTIN;
   TRAFFICKING; INHIBITION; DYNAMICS; BINDING; PHOSPHORYLATION;
   PHARMACOLOGY; PEPTIDE
AB Receptor activity modifying proteins (RAMPs) are ubiquitously expressed membrane proteins that associate with different G protein coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R), a class B GPCR and an important modulator of mineral ion homeostasis and bone metabolism. However, it is unknown whether and how RAMP proteins may affect PTH1R function. Using different optical biosensors to measure the activation of PTH1R and its downstream signaling, we describe here that RAMP2 acts as a specific allosteric modulator of PTH1R, shifting PTH1R to a unique preactivated state that permits faster activation in a ligand specific manner. Moreover, RAMP2 modulates PTH1R downstream signaling in an agonist dependent manner, most notably increasing the PTH mediated Gi3 signaling sensitivity. Additionally, RAMP2 increases both PTH  and PTHrP triggered beta arrestin2 recruitment to PTH1R. Employing homology modeling, we describe the putative structural molecular basis underlying our functional findings. These data uncover a critical role of RAMPs in the activation and signaling of a GPCR that may provide a new venue for highly specific modulation of GPCR function and advanced drug design.
C1 [Nemec, Katarina; Grushevskyi, Eugene O.; Lohse, Martin J.] Helmholtz Assoc, Max Delbruck Ctr Mol Med, D 13125 Berlin, Germany.
   [Nemec, Katarina; Schihada, Hannes; Zabel, Ulrike; Grushevskyi, Eugene O.; Lohse, Martin J.; Maiellaro, Isabella] Univ Wurzburg, Inst Pharmacol & Toxicol, D 97078 Wurzburg, Germany.
   [Schihada, Hannes] Karolinska Inst, Dept Physiol & Amp Pharmacol, Sect Receptor Biol & Signalling, S 17177 Stockholm, Sweden.
   [Kleinau, Gunnar; Scheerer, Patrick] Charite Univ Med Berlin, Inst Med Phys & Biophys, Grp Prot Xray Crystallog & Signal Transduct, D 10117 Berlin, Germany.
   [Scheerer, Patrick] Deutsch Zentrum Herz Kreislauf Forsch, D 10785 Berlin, Germany.
   [Lohse, Martin J.] ISAR Biosci Inst, D 82152 Planegg Munich, Germany.
   [Maiellaro, Isabella] Univ Nottingham, Queens Med Ctr, Sch Life Sci, Nottingham NG7 2UH, England.
C3 Helmholtz Association; Max Delbruck Center for Molecular Medicine;
   University of Wurzburg; Karolinska Institutet; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; German Centre for Cardiovascular Research; University of
   Nottingham
RP Lohse, MJ (通讯作者)，Helmholtz Assoc, Max Delbruck Ctr Mol Med, D 13125 Berlin, Germany.; Lohse, MJ; Maiellaro, I (通讯作者)，Univ Wurzburg, Inst Pharmacol & Toxicol, D 97078 Wurzburg, Germany.; Lohse, MJ (通讯作者)，ISAR Biosci Inst, D 82152 Planegg Munich, Germany.; Maiellaro, I (通讯作者)，Univ Nottingham, Queens Med Ctr, Sch Life Sci, Nottingham NG7 2UH, England.
EM m.lohse@mdc berlin.de; Isabella.Maiellaro@nottingham.ac.uk
RI Schihada, Hannes/AAB 6440 2022; Lohse, Martin/A 7160 2012
OI Grushevskyi, Eugene/0000 0003 1779 8306; Lohse,
   Martin/0000 0002 0599 3510; Nemec, Katarina/0000 0002 3555 5853;
   Maiellaro, Isabella/0000 0001 5595 8011; Scheerer,
   Patrick/0000 0001 5028 2075
FU DFG  German Research Foundation [CRC 1423, 421152132, A01/A05/Z03, CRC
   1365, 394046635, EXC2008/1, 390540038]; European Union [956314]; German
   Research Foundation [SFB688 B08, 427840891]; Elitenetzwerk Bayern,
   Receptor Dynamics program; Federal Ministry of Research (BMBF)
   [03V0830]; University of Nottingham Anne McLaren Research Fellowship;
   Marie Curie Actions (MSCA) [956314] Funding Source: Marie Curie Actions
   (MSCA)
FX We thank all members of the M.J.L. laboratory, especially Ali Isbilir
   and Jan M_oller, for valuable discussions on the manuscript. G.K. and
   P.S. were supported by the DFG  German Research Foundation through CRC
   1423, project number 421152132, subprojects A01/A05/Z03; through CRC
   1365, project number 394046635, subproject A03; through Germany's
   Excellence Strategies ~ EXC2008/1 (UniSysCat)  390540038, and the
   European Union's Horizon 2020 MSCA Program under grant agreement 956314
   [ALLODD]. This work was supported by the German Research Foundation
   (SFB688 B08 and 427840891) and Elitenetzwerk Bayern, Receptor Dynamics
   program and Federal Ministry of Research (BMBF; 03V0830) to M.J.L. and
   University of Nottingham Anne McLaren Research Fellowship to I.M.
CR ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732
   Bailey S, 2019, BBA BIOMEMBRANES, V1861, P997, DOI 10.1016/j.bbamem.2019.02.008
   Barbash S, 2019, ISCIENCE, V11, P366, DOI 10.1016/j.isci.2018.12.024
   Barbash S, 2017, P NATL ACAD SCI USA, V114, P12015, DOI 10.1073/pnas.1713074114
   Carpenter B, 2017, CURR OPIN STRUC BIOL, V45, P124, DOI 10.1016/j.sbi.2017.04.010
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Cegla J, 2017, ENDOCRINOLOGY, V158, P2680, DOI 10.1210/en.2016 1755
   Chen TW, 2013, NATURE, V499, P295, DOI 10.1038/nature12354
   Christopoulos A, 2003, J BIOL CHEM, V278, P3293, DOI 10.1074/jbc.C200629200
   Clark LJ, 2020, NAT CHEM BIOL, V16, P1096, DOI 10.1038/s41589 020 0567 0
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476
   Dolgin E, 2018, NAT REV DRUG DISCOV, V17, P457, DOI 10.1038/nrd.2018.103
   Ehrenmann J, 2018, NAT STRUCT MOL BIOL, V25, P1086, DOI 10.1038/s41594 018 0151 4
   Feng XY, 2008, ENDOCRINOLOGY, V149, P1705, DOI 10.1210/en.2007 1341
   Gesty Palmer D, 2006, J BIOL CHEM, V281, P10856, DOI 10.1074/jbc.M513380200
   Gesty Palmer D, 2011, BRIT J PHARMACOL, V164, P59, DOI 10.1111/j.1476 5381.2011.01450.x
   Goedhart J, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1738
   Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200
   Grushevskyi EO, 2019, P NATL ACAD SCI USA, V116, P10150, DOI 10.1073/pnas.1900261116
   Harris M, 2021, bioRxiv, DOI [10.1101/2021.04.08.436756, 10.1101/2021.04.08.436756, DOI 10.1101/2021.04.08.436756]
   Harvey CD, 2008, P NATL ACAD SCI USA, V105, P19264, DOI 10.1073/pnas.0804598105
   Hauser AS, 2017, NAT REV DRUG DISCOV, V16, P829, DOI 10.1038/nrd.2017.178
   Hilger D, 2020, SCIENCE, V369, P523, DOI 10.1126/science.aba3373
   Hlavackova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002720
   Isbilir A, 2020, P NATL ACAD SCI USA, V117, P29144, DOI 10.1073/pnas.2013319117
   Kadmiel M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181597
   Keppler A, 2003, NAT BIOTECHNOL, V21, P86, DOI 10.1038/nbt765
   Klarenbeek J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122513
   Krasel C, 2005, J BIOL CHEM, V280, P9528, DOI 10.1074/jbc.M413078200
   Lee MH, 2016, NATURE, V531, P665, DOI 10.1038/nature17154
   Liang YL, 2020, ACS PHARMACOL TRANSL, V3, P263, DOI 10.1021/acsptsci.9b00080
   Liang YL, 2018, NATURE, V561, P492, DOI 10.1038/s41586 018 0535 y
   Lohse MJ, 2012, PHARMACOL REV, V64, P299, DOI 10.1124/pr.110.004309
   Lorenzen E, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw2778
   Mackie DI, 2019, P NATL ACAD SCI USA, V116, P24093, DOI 10.1073/pnas.1905561116
   Mao CY, 2020, CELL RES, V30, P564, DOI 10.1038/s41422 020 0350 5
   McGlone ER, 2021, MOL METAB, V53, DOI 10.1016/j.molmet.2021.101296
   MIYAUCHI A, 1990, AM J PHYSIOL, V259, pF485, DOI 10.1152/ajprenal.1990.259.3.F485
   Nuber S, 2016, NATURE, V531, P661, DOI 10.1038/nature17198
   Patriarchi T, 2018, SCIENCE, V360, P1420, DOI 10.1126/science.aat4422
   Sarkar K, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 51016 z
   Sato T, 2021, JBMR PLUS, V5, DOI 10.1002/jbm4.10441
   Schihada Hannes, 2021, Sci Signal, V14, peabf1653, DOI 10.1126/scisignal.abf1653
   Schihada H, 2021, METHODS MOL BIOL, V2268, P137, DOI 10.1007/978 1 0716 1221 7_9
   Schihada H, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0072 0
   Schöneberg T, 2016, PHARMACOL RES, V108, P9, DOI 10.1016/j.phrs.2016.03.027
   Serafin DS, 2020, TRENDS PHARMACOL SCI, V41, P249, DOI 10.1016/j.tips.2020.01.009
   Singh ATK, 2005, ENDOCRINOLOGY, V146, P2171, DOI 10.1210/en.2004 1283
   Syme CA, 2005, J BIOL CHEM, V280, P11281, DOI 10.1074/jbc.M413393200
   Velazhahan V, 2021, NATURE, V589, P148, DOI 10.1038/s41586 020 2994 1
   Vilardaga JP, 2008, NAT CHEM BIOL, V4, P126, DOI 10.1038/nchembio.64
   Vilardaga JP, 2013, METHOD ENZYMOL, V522, P337, DOI 10.1016/B978 0 12 407865 9.00016 9
   Vilardaga JP, 2003, NAT BIOTECHNOL, V21, P807, DOI 10.1038/nbt838
   Vilardaga JP, 2001, J BIOL CHEM, V276, P33435, DOI 10.1074/jbc.M011495200
   Wacker D, 2017, CELL, V170, P414, DOI 10.1016/j.cell.2017.07.009
   Weis WI, 2018, ANNU REV BIOCHEM, V87, P897, DOI 10.1146/annurev biochem 060614 033910
   Wesslowski J, 2020, J BIOL CHEM, V295, P8759, DOI 10.1074/jbc.RA120.012892
   Weston C, 2015, J BIOL CHEM, V290, P23009, DOI 10.1074/jbc.M114.624601
   Wolters V, 2015, MOL PHARMACOL, V87, P9, DOI 10.1124/mol.114.094722
   Wootten D, 2018, NAT REV MOL CELL BIO, V19, P638, DOI 10.1038/s41580 018 0049 3
   Yang LK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207611
   Yao ZP, 2005, ANAL BIOCHEM, V343, P344, DOI 10.1016/j.ab.2005.05.002
   Zhao LH, 2019, SCIENCE, V364, P148, DOI 10.1126/science.aav7942
NR 65
TC 18
Z9 20
U1 0
U2 4
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 9
PY 2022
VL 119
IS 32
AR e2122037119
DI 10.1073/pnas.2122037119
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 8O8TP
UT WOS:000926104800012
PM 35914163
OA Green Published, Green Accepted, hybrid
DA 2025 08 17
ER

PT J
AU Xu, X
   Zheng, LW
   Bian, Q
   Xie, L
   Liu, WL
   Zhen, GH
   Crane, JL
   Zhou, XD
   Cao, X
AF Xu, Xin
   Zheng, Liwei
   Bian, Qin
   Xie, Liang
   Liu, Wenlong
   Zhen, Gehua
   Crane, Janet L.
   Zhou, Xuedong
   Cao, Xu
TI Aberrant Activation of TGF  in Subchondral Bone at the Onset of
   Rheumatoid Arthritis Joint Destruction
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE RHEUMATOID ARTHRITIS; TGF ; SUBCHONDRAL BONE; CARTILAGE DEGENERATION;
   MESENCHYMAL STEM CELLS
ID GROWTH FACTOR BETA; MESENCHYMAL STEM CELLS; MARROW EDEMA; INFLAMMATORY
   ARTHRITIS; OSTEOARTHRITIS; PATHOGENESIS; OSTEOBLAST; DISEASE;
   MECHANISMS; RESORPTION
AB Rheumatoid arthritis (RA) is an autoimmune disease that often leads to joint destruction. A myriad of drugs targeting the immune abnormalities and downstream inflammatory cascades have been developed, but the joint destruction is not effectively halted. Here we report that aberrant activation of TGF  in the subchondral bone marrow by immune response increases osteoprogenitors and uncoupled bone resorption and formation in RA mouse/rat models. Importantly, either systemic or local blockade of TGF  activity in the subchondral bone attenuated articular cartilage degeneration in RA. Moreover, conditional deletion of TGF  receptor II (Tgfbr2) in nestin positive cells also effectively halted progression of RA joint destruction. Our data demonstrate that aberrant activation of TGF  in the subchondral bone is involved at the onset of RA joint cartilage degeneration. Thus, modulation of subchondral bone TGF  activity could be a potential therapy for RA joint destruction. (c) 2015 American Society for Bone and Mineral Research
C1 [Xu, Xin; Zheng, Liwei; Xie, Liang; Zhou, Xuedong] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China.
   [Xu, Xin; Zheng, Liwei; Bian, Qin; Xie, Liang; Liu, Wenlong; Zhen, Gehua; Crane, Janet L.; Cao, Xu] Johns Hopkins Univ, Dept Orthopaed Surg, Sch Med, Baltimore, MD 21205 USA.
   [Bian, Qin] Shanghai Univ Tradit Chinese Med, Inst Spine, Longhua Hosp, Shanghai, Peoples R China.
   [Liu, Wenlong] Univ Hong Kong, Dept Orthopaed & Traumatol, Fac Med, Hong Kong, Hong Kong, Peoples R China.
   [Crane, Janet L.] Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA.
C3 Sichuan University; Johns Hopkins University; Shanghai University of
   Traditional Chinese Medicine; University of Hong Kong; Johns Hopkins
   University
RP Xu, X (通讯作者)，Johns Hopkins Univ, Dept Orthopaed Surg, Sch Med, 720 Rutland Ave,Ross Bldg 231, Baltimore, MD 21205 USA.
EM xcao11@jhmi.edu
RI ; Liu, Wenlong/AAG 2722 2021; Zheng, Liwei/D 4835 2014; Xie,
   Liang/AAR 7725 2021; Bian, Qin/C 8831 2014; Crane, Janet/LNP 7603 2024;
   xu, xin/HNQ 6671 2023; Zhou, Xuedong/LSL 0410 2024
OI Zhou, Xuedong/0000 0002 9319 7302; Crane, Janet/0000 0001 7713 0936;
   Liu, Wenlong/0000 0003 2988 7963; Bian, Qin/0000 0003 4190 0913; Xu,
   Xin/0000 0003 4608 4556; 
FU NIH [AR063943, DK057501]; West China Hospital of Stomatology, Sichuan
   University
FX This work was supported by NIH grants AR063943 and DK057501 (to XC). XX
   and LZ were supported by the visiting scholar fellowship from West China
   Hospital of Stomatology, Sichuan University. We thank Dr. VP Chacko
   (Johns Hopkins School of Medicine) for technical support in mMRI.
CR Alonso Ruiz A, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 52
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   BORDER WA, 1994, NEW ENGL J MED, V331, P1286
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brand DD, 2007, NAT PROTOC, V2, P1269, DOI 10.1038/nprot.2007.173
   Brenet F, 2013, J EXP MED, V210, P623, DOI 10.1084/jem.20121610
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Bush JR, 2013, NAT MED, V19, P667, DOI 10.1038/nm.3228
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Elliott RL, 2005, J CLIN ONCOL, V23, P2078, DOI 10.1200/JCO.2005.02.047
   Gao PS, 2014, J IMMUNOL, V192, P4560, DOI 10.4049/jimmunol.1303461
   Grafel I, 2014, NAT MED, V20, P670, DOI 10.1038/nm.3544
   Haavardsholm EA, 2008, ANN RHEUM DIS, V67, P794, DOI 10.1136/ard.2007.071977
   Hetland ML, 2009, ANN RHEUM DIS, V68, P384, DOI 10.1136/ard.2008.088245
   Imhof H, 2000, INVEST RADIOL, V35, P581, DOI 10.1097/00004424 200010000 00004
   Jimenez Boj E, 2007, ARTHRITIS RHEUM US, V56, P1118, DOI 10.1002/art.22496
   Kristensen LE, 2007, SCAND J RHEUMATOL, V36, P411, DOI 10.1080/03009740701607067
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Li G, 2014, OSTEOARTHR CARTILAGE, V22, P2083, DOI 10.1016/j.joca.2014.08.015
   Loeuille D, 2012, OSTEOPOROSIS INT, V23, pS867, DOI 10.1007/s00198 012 2166 8
   Maxwell LJ, 2010, J RHEUMATOL, V37, P234, DOI 10.3899/jrheum.091066
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   McQueen FM, 2003, ARTHRITIS RHEUM, V48, P1814, DOI 10.1002/art.11162
   Mizoguchi T, 2014, DEV CELL, V29, P340, DOI 10.1016/j.devcel.2014.03.013
   Olech E, 2010, J RHEUMATOL, V37, P265, DOI 10.3899/jrheum.090062
   Ono N, 2014, DEV CELL, V29, P330, DOI 10.1016/j.devcel.2014.03.014
   Proulx ST, 2008, ARTHRITIS RHEUM US, V58, P2019, DOI 10.1002/art.23546
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Roemer FW, 2009, ANN RHEUM DIS, V68, P1461, DOI 10.1136/ard.2008.096834
   Sakuma M, 2007, INT IMMUNOL, V19, P117, DOI 10.1093/intimm/dxl128
   Schett G, 2010, ANN RHEUM DIS, V69, P787, DOI 10.1136/ard.2009.121657
   Schuerwegh AJ, 2003, OSTEOARTHR CARTILAGE, V11, P681, DOI 10.1016/S1063 4584(03)00156 0
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Sharkey Peter F, 2012, Am J Orthop (Belle Mead NJ), V41, P413
   Shen J, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.2
   Singh JA, 2009, CAN MED ASSOC J, V181, P787, DOI 10.1503/cmaj.091391
   Singh JA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007848.pub2
   Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979
   van den Berg WB, 2013, SEMIN ARTHRITIS RHEU, V43, P158, DOI 10.1016/j.semarthrit.2013.04.006
   Verstappen SMM, 2013, BEST PRACT RES CL RH, V27, P555, DOI 10.1016/j.berh.2013.09.004
   Vivar Nancy, 2014, F1000Prime Rep, V6, P31, DOI 10.12703/P6 31
   Wagner Stephanie, 2008, Curr Protoc Pharmacol, VChapter 5, DOI 10.1002/0471141755.ph0551s43
   WAHL SM, 1993, J EXP MED, V177, P225, DOI 10.1084/jem.177.1.225
   Walsh NC, 2010, IMMUNOL REV, V233, P301, DOI 10.1111/j.0105 2896.2009.00857.x
   Walsh NC, 2009, J BONE MINER RES, V24, P1572, DOI [10.1359/JBMR.090320, 10.1359/jbmr.090320]
   Wu XW, 2010, CELL STEM CELL, V7, P571, DOI 10.1016/j.stem.2010.09.012
   Zhang HW, 2014, J CLIN INVEST, V124, P3200, DOI 10.1172/JCI68901
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
NR 49
TC 32
Z9 46
U1 0
U2 31
PU WILEY BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD NOV
PY 2015
VL 30
IS 11
BP 2033
EP 2043
DI 10.1002/jbmr.2550
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CU1MV
UT WOS:000363286900010
PM 25967237
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Liu, ZW
   Xi, XL
   Wu, TR
   Lu, YY
   Zhong, PC
   Hu, YJ
   Shen, XL
AF Liu, Zhi Wen
   Xi, Xiu Li
   Wu, Tao Rui
   Lu, Yuan Yuan
   Zhong, Peng Cheng
   Hu, Ying Jie
   Shen, Xiao Ling
TI Aikeqing, a kidney  and spleen tonifying compound Chinese medicine
   granule, prevented ovariectomy induced bone loss in rats via the
   suppression of osteoclastogenesis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Aikeqing; Postmenopausal osteoporosis; Osteoclastogenesis; TRAF6; MAPKs
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; OSTEOPOROSIS
AB Postmenopausal women are prone to osteoporosis due to increased osteoclast activation and bone resorption caused by oestrogen deficiency. In Traditional Chinese Medicine theory, medicines with spleen and kidney nourishing effects are commonly used in postmenopausal osteoporosis (PMOP) treatment. Aikeqing (AKQ) is a compound Chinese medicinal granule with spleen and kidney nourishing effects. Herein, we investigate the in vitro and in vivo anti osteoporotic effects of AKQ, its underlying mechanisms and pharmacodynamic basis. In vitro antiosteoporotic effects of AKQ were assessed by its ability to promote osteoblastogenesis in MC3T3 E1 and/ or inhibit RANKL induced osteoclastogenesis in murine bone marrow monocytes (BMMs). The protective effect of AKQ on bone loss induced by oestrogen deficiency was evaluated in ovariectomized rats. The underlying mechanisms were studied in BMMs by detecting the effects of AKQ on the RANKL induced expression of genes and proteins involved in the regulation of osteoclastogenesis. The main chemical constituents of AKQ in the granule were analyzed by UPLC QTOF MS. Our findings show that AKQ did not affect osteoblastogenesis, but it inhibited RANKL induced osteoclastogenesis. In the ovariectomized rats, oral administration of AKQ (4 g/kg/d) for 90 d effectively prevented oestrogen deficiency induced bone loss. Mechanistic studies in BMMs revealed that AKQ inhibited RNAKL induced activation of NF & kappa;B (p65) and MAPKs (p38 and JNK) via blocking the RANKTRAF6 interaction, subsequently suppressing the translocation and expression of NFATc1 and c Fos. UPLCQTOF MS analysis quantified the 123 main components of AKQ. Taken together, AKQ was demonstrated for the first time as a novel alternative therapy for osteoclast associated bone diseases.
C1 [Liu, Zhi Wen; Xi, Xiu Li; Wu, Tao Rui; Lu, Yuan Yuan; Zhong, Peng Cheng; Hu, Ying Jie; Shen, Xiao Ling] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, Guangzhou, Guangdong, Peoples R China.
   [Hu, Ying Jie; Shen, Xiao Ling] Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, 12 Jichang Rd, Guangzhou 510405, Guangdong, Peoples R China.
C3 Guangzhou University of Chinese Medicine; Guangzhou University of
   Chinese Medicine
RP Hu, YJ; Shen, XL (通讯作者)，Guangzhou Univ Chinese Med, Sci & Technol Innovat Ctr, 12 Jichang Rd, Guangzhou 510405, Guangdong, Peoples R China.
EM yingjiehu@gzucm.edu.cn; xshen2@gzucm.edu.cn
RI Lu, Yuanyuan/IYI 9202 2023; Zhong, Pengcheng/JMR 2835 2023; Shen,
   Xiao Ling/JFB 2361 2023
OI XIULI, XI/0000 0003 4876 0781; 
FU Guangzhou University of Chinese Medicine [A1 2606 22 415 027]; Guangdong
   Shengtian Medical Technology Group Co. Ltd. [E4 6401 221 453 004]; China
   National Major Projects of Science and Technology [2019YFE0109800]
FX The study was funded by a team project of Guangzhou University of
   Chinese Medicine (No. A1 2606 22 415 027), a joint research project with
   Guangdong Shengtian Medical Technology Group Co. Ltd. (No.
   E4 6401 221 453 004) and the China National Major Projects of Science
   and Technology (No. 2019YFE0109800).
CR Bai B.H., 2018, Liaoning Zhongyiyao Daxue Xuebao, V30, P813, DOI [10.16448/j.cjtcm.2018.0243, DOI 10.13194/J.ISSN.1673 842X.2019.01.034]
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Curtis EM, 2016, BONE, V87, P19, DOI 10.1016/j.bone.2016.03.006
   Dai QG, 2018, JOVE J VIS EXP, DOI 10.3791/56468
   [邓昶 Deng Chang], 2017, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V23, P1105
   Eastell R, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.69, 10.1038/nrdp.2016.70]
   Ensrud KE, 2017, ANN INTERN MED, V167, pITC17, DOI 10.7326/AITC201708010
   Han SY, 2019, AM J CHINESE MED, V47, P439, DOI [10.1142/S0192415X19500228, 10.1142/s0192415x19500228]
   He L.J., 2020, Clinical Journal of Chinese Medicine, V12, P17, DOI 10.3969/j.issn.1674 7860.2020.02.006
   He XF, 2017, BOSNIAN J BASIC MED, V17, P295, DOI 10.17305/bjbms.2017.2596
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Ke X.M., 2015, World J Integr Tradit Chin West Med, V10, P1684, DOI 10.13935/j.cnki.sjzx.151217
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   Kim B, 2018, PHYTOMEDICINE, V51, P181, DOI 10.1016/j.phymed.2018.06.020
   Kim I, 2021, BMB REP, V54, P482, DOI 10.5483/BMBRep.2021.54.9.070
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   [李建国 Li Jiangguo], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P389
   Lin Z, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.730362
   Lu XY, 2018, J CELL MOL MED, V22, P5029, DOI 10.1111/jcmm.13785
   Martiniakova M, 2020, J PHYSIOL PHARMACOL, V71, P307, DOI 10.26402/jpp.2020.3.01
   Napetschnig J, 2013, ANNU REV BIOPHYS, V42, P443, DOI 10.1146/annurev biophys 083012 130338
   Negishi Koga T, 2009, IMMUNOL REV, V231, P241, DOI 10.1111/j.1600 065X.2009.00821.x
   [裴河欢 Pei Hehuan], 2015, [中国中医基础医学杂志, Chinese Journal of Basic Medicine in Traditional Chinese Medicine], V21, P278
   Rodríguez Carballo E, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00040
   Shen YS, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01705 8
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Tu Y., 2017, Acta Chin. Med, V32, P1981, DOI [10.16368/j.issn.1674 8999.2017.10.520, DOI 10.16368/J.ISSN.1674 8999.2017.10.520]
   Uehara IA, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.117921
   Wagner EF, 2005, IMMUNOL REV, V208, P126, DOI 10.1111/j.0105 2896.2005.00332.x
   Wu YQ, 2015, CELL PROLIFERAT, V48, P375, DOI 10.1111/cpr.12185
   Xing J, 2005, Chin J Tradit Med, V2, P1, DOI [10.4103/2225 4110.110407, DOI 10.4103/2225 4110.110407]
   Xu Q, 2019, BIOCHEM BIOPH RES CO, V508, P902, DOI 10.1016/j.bbrc.2018.11.201
   Yin ZQ, 2019, EUR J PHARMACOL, V859, DOI 10.1016/j.ejphar.2019.172550
   Yousefzadeh N, 2020, EXCLI J, V19, P89, DOI 10.17179/excli2019 1990
   Zhang GH, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0105 x
   Zhang M.M., 2008, Chin. Arch. Tradit. Chin. Med, V26, P2233, DOI [10.13193/j.archtcm.2008.10.154.zhangmm, DOI 10.13193/J.ARCHTCM.2008.10.154.ZHANGMM]
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 41
TC 2
Z9 2
U1 5
U2 14
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2023
VL 166
AR 115339
DI 10.1016/j.biopha.2023.115339
EA AUG 2023
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA R3HE0
UT WOS:001063287100001
PM 37595429
OA gold
DA 2025 08 17
ER

PT J
AU Kabir, A
   Mukilarasi, B
   Natarajan, A
   Selvaraj, V
   Sudhakar, S
AF Kabir, Anisha
   Mukilarasi, B.
   Natarajan, A.
   Selvaraj, Vimalraj
   Sudhakar, Swathi
TI Protein Nano Coop Complexes Promote Fracture Healing and Bone
   Regeneration in a Zebrafish Osteoporosis Model
SO BIOMACROMOLECULES
LA English
DT Article
ID OXIDATIVE STRESS; DIFFERENTIATION; MINERALIZATION; NANOPARTICLES;
   MECHANISMS; EXPRESSION; APOPTOSIS; ESTROGENS; CBFA1
AB Nanotherapeutic techniques are becoming increasingly important in the treatment of bone disorders owing to their targeted drug delivery. This study formulates zein nano coop composites containing chimeric antioxidants (ascorbic acid, luteolin, resveratrol, and coenzyme Q) (AZN) and evaluates its application in bone regeneration using osteoblasts and a Zebrafish osteoporosis model. In vitro experiments with human osteoblast like MG63 cells showed enhancement of bone mineralization and regeneration. It further exhibited high biocompatibility in Zebrafish larvae, with increased calcium/phosphorus deposition and upregulation of osteogenic genes. The study has unequivocally demonstrated the potential of AZN in bone regeneration and fracture healing in both normal and osteoporosis models, underscoring the significance of this research. Further investigations using higher animal models are warranted to expand on these findings. The impact of this research seems far reaching, with the possible development of new, effective, and safe treatment options for osteoporosis, addressing the limitations of the currently available treatments.
C1 [Kabir, Anisha; Mukilarasi, B.; Natarajan, A.; Selvaraj, Vimalraj; Sudhakar, Swathi] Indian Inst Technol Madras, Dept Appl Mech & Biomed Engn, Chennai 600036, Tamil Nadu, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Madras
RP Selvaraj, V; Sudhakar, S (通讯作者)，Indian Inst Technol Madras, Dept Appl Mech & Biomed Engn, Chennai 600036, Tamil Nadu, India.
EM vimalraj@iitm.ac.in; swathi.s@iitm.ac.in
RI Natarajan, Anandakumar/AAS 7358 2020; Kabir, Anisha/LIG 1226 2024;
   selvaraj, vimalraj/KDO 0834 2024
OI Kabir, Anisha/0009 0003 0591 8486; 
FU Indian Space Research Organisation [SP22231133AMISRO009000]; ISRO IIT(M)
   Space Technology Cell, Indian Institute of Technology Madras (IITM);
   Department of Applied Mechanics and Biomedical Engineering, IITM
FX The authors duly acknowledge the funding support by the ISRO IIT(M)
   Space Technology Cell, Indian Institute of Technology Madras (IITM)
   [Project Number: SP22231133AMISRO009000] and the Department of Applied
   Mechanics and Biomedical Engineering, IITM.
CR [Anonymous], 2021, Osteoporosis or Low Bone Mass in Older Adults: United States, 2017 2018
   Babunagappan KV, 2024, NANOSCALE ADV, V6, DOI 10.1039/d3na00953j
   Bai XC, 2004, BIOCHEM BIOPH RES CO, V314, P197, DOI 10.1016/j.bbrc.2003.12.073
   Ball AN, 2018, J ORTHOP RES, V36, P1559, DOI 10.1002/jor.23845
   Cada Dennis J, 2014, Hosp Pharm, V49, P273, DOI 10.1310/hpj4903 273
   Calvo E, 2007, OSTEOARTHR CARTILAGE, V15, P69, DOI 10.1016/j.joca.2006.06.006
   Cayami FK, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 18512 1
   Chaichit S, 2021, PHARMACEUTICALS BASE, V14, DOI 10.3390/ph14060536
   Choi HK, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030506
   de Vrieze E, 2012, J APPL ICHTHYOL, V28, P388, DOI 10.1111/j.1439 0426.2012.01989.x
   Delaisse Jean Marie, 2014, Bonekey Rep, V3, P561, DOI 10.1038/bonekey.2014.56
   DEMERTZIS MA, 1988, ANAL CHIM ACTA, V209, P303, DOI 10.1016/S0003 2670(00)84577 8
   Dietrich K, 2021, J BONE MINER RES, V36, P436, DOI 10.1002/jbmr.4256
   Domazetovic V, 2017, CLIN CASES MINER BON, V14, P209, DOI 10.11138/ccmbm/2017.14.1.209
   Du BJ, 2017, NAT NANOTECHNOL, V12, P1096, DOI [10.1038/nnano.2017.170, 10.1038/NNANO.2017.170]
   Fontani F, 2015, CALCIFIED TISSUE INT, V96, P335, DOI 10.1007/s00223 015 9961 0
   Fujino H, 2010, METHOD ENZYMOL, V484, P95, DOI [10.1016/S0076 6879(10)84005 4, 10.1016/B978 0 12 381298 8.00005 8]
   Gera S, 2017, CURR DRUG DELIV, V14, P904, DOI 10.2174/1567201813666161230142123
   Gilbert S. F., 2000, OSTEOGENESIS THEDEVE
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hino H, 2024, BONE REP, V20, DOI 10.1016/j.bonr.2024.101748
   Huang XL, 2019, FOOD HYDROCOLLOID, V93, P261, DOI 10.1016/j.foodhyd.2019.02.039
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Komori T, 2020, J ORAL BIOSCI, V62, P223, DOI 10.1016/j.job.2020.05.004
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Liu XW, 2021, EUR J HISTOCHEM, V65, DOI 10.4081/ejh.2021.3195
   Lobo V, 2010, Pharmacogn Rev, V4, P118, DOI 10.4103/0973 7847.70902
   Marcucci G, 2023, ANTIOXIDANTS BASEL, V12, DOI 10.3390/antiox12020373
   Michigami T, 2019, ANN PEDIATR ENDOCRIN, V24, P213, DOI 10.6065/apem.2019.24.4.213
   Chahardehi AM, 2020, PLANTS BASEL, V9, DOI 10.3390/plants9101345
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Parra Torres A. Y., 2013, TOPICS OSTEOPOROSIS
   Plotkin LI, 2005, J BIOL CHEM, V280, P7317, DOI 10.1074/jbc.M412817200
   Qureshi AT, 2014, METHOD ENZYMOL, V538, P67, DOI 10.1016/B978 0 12 800280 3.00005 0
   Rio DC., 2010, COLD SPRING HARB PRO, DOI [10.1101/pdb.prot5439, DOI 10.1101/PDB.PROT5439]
   Sakata Haga H, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25836 4
   Saleh SR, 2024, ANTIOXIDANTS BASEL, V13, DOI 10.3390/antiox13010066
   Schneider MR, 2021, HISTOCHEM CELL BIOL, V156, P523, DOI 10.1007/s00418 021 02051 3
   Scott JA, 1999, AM FAM PHYSICIAN, V60, P1131
   Sendur OF, 2009, JOINT BONE SPINE, V76, P514, DOI 10.1016/j.jbspin.2009.02.005
   Sheppard AJ, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.836764
   Takeda S, 2001, GENE DEV, V15, P467, DOI 10.1101/gad.845101
   Tomecka MJ, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.037630
   Uemoto T, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 57533 6
   van der Meulen T, 2005, BBA GENE STRUCT EXPR, V1729, P105, DOI 10.1016/j.bbaexp.2005.03.008
   Varacallo MA, 2014, MED CLIN N AM, V98, P817, DOI 10.1016/j.mcna.2014.03.007
   Vimalraj S, 2024, INT J BIOL MACROMOL, V259, DOI 10.1016/j.ijbiomac.2024.129250
   Vimalraj S, 2021, CHEM BIOL INTERACT, V349, DOI 10.1016/j.cbi.2021.109674
   Vimalraj S, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144855
   Wang XH, 2021, CRYSTALS, V11, DOI 10.3390/cryst11070728
   Watts NB, 1999, CLIN CHEM, V45, P1359
   Yusuf A, 2023, POLYMERS BASEL, V15, DOI 10.3390/polym15071596
   Zhai SF, 2023, PEPTIDES, V163, DOI 10.1016/j.peptides.2023.170974
   Zhang Y, 2020, INT J IMMUNOPATH PH, V34, DOI 10.1177/2058738420941762
   Zheng DL, 2018, MOL MED REP, V17, P400, DOI 10.3892/mmr.2017.7907
   Zhu YS, 2020, J CELL PHYSIOL, V235, P2220, DOI 10.1002/jcp.29131
NR 56
TC 1
Z9 1
U1 4
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1525 7797
EI 1526 4602
J9 BIOMACROMOLECULES
JI Biomacromolecules
PD OCT 25
PY 2024
VL 25
IS 11
BP 7237
EP 7248
DI 10.1021/acs.biomac.4c00931
EA OCT 2024
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA L7F7C
UT WOS:001343798500001
PM 39449233
DA 2025 08 17
ER

PT J
AU Serra, MPM
   Llorca, CS
   Donat, FJS
AF Minguez Serra, Maria Paz
   Salort Llorca, Cesar
   Silvestre Donat, Francisco Javier
TI Oral implants in patients receiving bisphosphonates: A review and update
SO MEDICINA ORAL PATOLOGIA ORAL Y CIRUGIA BUCAL
LA English
DT Article
DE Osteonecrosis; bisphosphonates; implants; oral surgery; osteoporosis
ID EXPERIMENTAL PERIODONTITIS; ALENDRONATE; OSTEONECROSIS; OSTEOPOROSIS;
   RESORPTION; DISEASE; WOMEN; JAWS
AB This rewiew was mad to establish the convenience of dental implant treatment in patients receiving bisphosphonates or programmed to receive such drugs, with a description of their mechanisms of action and the way in which they can affect the mandibular or maxillary bone of dental implant candidates. In turn, a description is provided of the key elements for evaluating the benefit risk ratio in patients treated with bisphosphonates who require oral surgery. Clinicians must be aware of the potential risk of osteonecrosis in patients treated with bisphosphonates via the oral or intravenous route.
   When bisphosphonates are administered via the intravenous route, all invasive oral procedures ( including implant surgery) are contraindicated, and should be avoided unless absolutely necessary. The indications are more controversial in the case of bisphosphonates administered via the oral route. There is little literature on the influence of oral bisphosphonates upon bone repair, and there are not many published cases of mandibular or maxillary osteonecrosis among patients that receive such medication.
   The use of bisphosphonates is becoming increasingly widespread, and the duration of such treatment is increasing. It would be of interest to design studies to evaluate the risk factors of maxillary osteonecrosis among dental implant patients receiving treatment with oral bisphosphonates, and to define biomarkers capable of indicating the level of risk in the event of oral surgery in patients receiving such drugs.
C1 [Minguez Serra, Maria Paz] Doctor Peset Univ Hosp, Stomatol Unit, Valencia, Spain.
   [Salort Llorca, Cesar] Mutua Terrassa Hosp, Serv Pharm, Barcelona, Spain.
   [Silvestre Donat, Francisco Javier] Valencia Univ Med & Dent School, Dept Stomatol, Valencia, Spain.
   [Silvestre Donat, Francisco Javier] Doctor Peset Univ Hosp, Stomatol Unit, Valencia, Spain.
C3 Hospital Universitario Mutua Terrassa
RP Donat, FJS (通讯作者)，Hosp Dr Peset Consultas Externas, Unidad Estomatol, C Juan Garay S N, Valencia 46017, Spain.
EM francisco.silvestre@uv.es
RI ; Garcia Suarez, Patricia/AAK 7746 2020; Silvestre, Francisco
   Javier/AEX 9672 2022
OI Silvestre, Francisco Javier/0000 0001 7858 7735; 
CR Altundal H, 2004, INT J ORAL MAX SURG, V33, P286, DOI 10.1006/ijom.2002.0472
   August M, 2001, J ORAL MAXIL SURG, V59, P1285, DOI 10.1053/joms.2001.27515
   Bagan J, 2007, MED ORAL PATOL ORAL, V12, P336
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Berardi D, 2007, INT J IMMUNOPATH PH, V20, P455, DOI 10.1177/039463200702000304
   BRUNSVOLD MA, 1992, J PERIODONTOL, V63, P825, DOI 10.1902/jop.1992.63.10.825
   Chacon GE, 2006, J ORAL MAXIL SURG, V64, P1005, DOI 10.1016/j.joms.2006.01.007
   Cosman F, 2007, CLIN THER, V29, P1116, DOI 10.1016/j.clinthera.2007.06.009
   Denissen H, 2000, J PERIODONTOL, V71, P279, DOI 10.1902/jop.2000.71.2.279
   Dimopoulos MA, 2006, HAEMATOL HEMATOL J, V91, P968
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   El Shinnawi Una M, 2003, J Int Acad Periodontol, V5, P5
   ESTEFANIAFRESCO R, 2005, MED ORAL PATOL ORAL, V11, P456
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Friberg B, 2001, Clin Implant Dent Relat Res, V3, P50, DOI 10.1111/j.1708 8208.2001.tb00128.x
   Grant BT, 2008, J ORAL MAXIL SURG, V66, P223, DOI 10.1016/j.joms.2007.09.019
   Greenspan SL, 2002, J BONE MINER RES, V17, P1988
   Hwang Debby, 2006, Implant Dent, V15, P353, DOI 10.1097/01.id.0000247855.75691.03
   Jeffcoat M, 2005, J PERIODONTOL, V76, P2125, DOI 10.1902/jop.2005.76.11 S.2125
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Minsk L, 1998, Compend Contin Educ Dent, V19, P859
   Ponte Fernandez Nerea, 2006, Med Oral Patol Oral Cir Bucal, V11, pE396
   Rocha ML, 2004, J PERIODONTOL, V75, P1579, DOI 10.1902/jop.2004.75.12.1579
   Rosen CJ, 2005, J BONE MINER RES, V20, P141, DOI 10.1359/jbmr.2005.20.1.141
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Scully Crispian, 2006, Implant Dent, V15, P212, DOI 10.1097/01.id.0000236120.22719.02
   Takaishi Y, 2003, J INT MED RES, V31, P575, DOI 10.1177/147323000303100614
   Takaishi Yoshitomo, 2003, Clin Calcium, V13, P173
   WANG HL, 2007, J PERIODONTOL, V78, P373
   WEINREB M, 1994, J PERIODONTAL RES, V29, P35, DOI 10.1111/j.1600 0765.1994.tb01088.x
NR 33
TC 20
Z9 25
U1 0
U2 5
PU MEDICINA ORAL S L
PI VALENCIA
PA CALLE DANIEL BALACIART N 4 PTA 17, VALENCIA, 46020, SPAIN
SN 1698 6946
J9 MED ORAL PATOL ORAL
JI Med. Oral Patol. Oral Cir. Bucal
PD DEC
PY 2008
VL 13
IS 12
BP E755
EP E760
AR 1111111709
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 423WJ
UT WOS:000264526400002
PM 19047961
DA 2025 08 17
ER

PT J
AU Deng, JJ
   Wang, X
   Zhang, WH
   Sun, LY
   Han, XX
   Tong, XQ
   Yu, LM
   Ding, JD
   Yu, L
   Liu, YH
AF Deng, Jiajia
   Wang, Xin
   Zhang, Weihua
   Sun, Liangyan
   Han, Xinxin
   Tong, Xianqin
   Yu, Liming
   Ding, Jiandong
   Yu, Lin
   Liu, Yuehua
TI Versatile Hypoxic Extracellular Vesicles Laden in an Injectable and
   Bioactive Hydrogel for Accelerated Bone Regeneration
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone regeneration; extracellular vesicles (EVs); hypoxia stimulation;
   injectable hydrogels; mesenchymal stem cells (MSCs)
ID STEM CELLS; CONTROLLED RELEASE; TISSUE REPAIR; EXOSOMES;
   INTERNALIZATION; TRIBLOCK; BEHAVIOR; GELATION
AB Extracellular vesicles (EVs) derived from mesenchymal stem cells (MSCs) have emerged as an appealing alternative to cell therapy in regenerative medicine. Unlike bone marrow MSCs (BMSCs) cultured in vitro with normoxia, bone marrow in vivo is exposed to a hypoxic environment. To date, it remains unclear whether hypoxia preconditioning can improve the function of BMSC derived EVs and be more conducive to bone repair. Herein, it is found that hypoxia preconditioned BMSCs secrete more biglycan (Bgn) rich EVs via proteomics analysis, and these hypoxic EVs (Hypo EVs) significantly promote osteoblast proliferation, migration, differentiation, and mineralization by activating the phosphatidylinositide 3 kinase/protein kinase B pathway. Subsequently, an injectable bioactive hydrogel composed of poly(ethylene glycol)/polypeptide copolymers is developed to improve the stability and retention of Hypo EVs in vivo. The Hypo EVs laden hydrogel shows continuous liberation of Hypo EVs for 3 weeks and substantially accelerates bone regeneration in 5 mm rat cranial defects. Finally, it is confirmed that Bgn in EVs is a pivotal protein regulating osteoblast differentiation and mineralization and exerts its effects through paracrine mechanisms. Therefore, this study shows that hypoxia stimulation is an effective approach to optimize the therapeutic effects of BMSC derived EVs and that injectable hydrogel based EVs delivery is a promising strategy for tissue regeneration.
C1 [Deng, Jiajia; Zhang, Weihua; Sun, Liangyan; Tong, Xianqin; Yu, Liming; Liu, Yuehua] Fudan Univ, Shanghai Stomatol Hosp, Dept Orthodont, Shanghai 200001, Peoples R China.
   [Deng, Jiajia; Zhang, Weihua; Sun, Liangyan; Tong, Xianqin; Yu, Liming; Liu, Yuehua] Fudan Univ, Sch Stomatol, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200001, Peoples R China.
   [Wang, Xin; Ding, Jiandong; Yu, Lin] Fudan Univ, Dept Macromol Sci, State Key Lab Mol Engn Polymers, Shanghai 200438, Peoples R China.
   [Han, Xinxin] Fudan Univ, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200001, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Fudan University
RP Yu, LM; Liu, YH (通讯作者)，Fudan Univ, Shanghai Stomatol Hosp, Dept Orthodont, Shanghai 200001, Peoples R China.; Yu, LM; Liu, YH (通讯作者)，Fudan Univ, Sch Stomatol, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200001, Peoples R China.; Yu, L (通讯作者)，Fudan Univ, Dept Macromol Sci, State Key Lab Mol Engn Polymers, Shanghai 200438, Peoples R China.
EM ylmphoebe@fudan.edu.cn; yu_lin@fudan.edu.cn; liuyuehua@fudan.edu.cn
RI ; smith, hydra/IUO 0392 2023
OI Liu, Yuehua/0000 0003 3033 8873; Han, Xinxin/0000 0002 7870 250X
FU National Natural Science Foundation of China [82071153]; Natural Science
   Foundation of Shanghai [22ZR1454300]; National Key R&D Program of China
   [2020YFC1107102, 2021YFC2701404]; Shanghai Stomatological Hospital
   Science and Technology Talents Project [SSH 2022 KJCX B03]
FX Acknowledgements J.D. and X.W. contributed equally to this work. This
   work was supported by the National Natural Science Foundation of China
   (No. 82071153), Natural Science Foundation of Shanghai (No.
   22ZR1454300), National Key R&D Program of China (Nos. 2020YFC1107102 and
   2021YFC2701404), and Shanghai Stomatological Hospital Science and
   Technology Talents Project (SSH 2022 KJCX B03).
CR Amir MS, 2022, J CELL PHYSIOL, V237, P2183, DOI 10.1002/jcp.30752
   Ansari S, 2021, CURR OSTEOPOROS REP, V19, P88, DOI 10.1007/s11914 020 00648 6
   Bae SJ, 2006, MACROMOLECULES, V39, P4873, DOI 10.1021/ma060153s
   Bannunah AM, 2014, MOL PHARMACEUT, V11, P4363, DOI 10.1021/mp500439c
   Bei HP, 2021, SMALL, V17, DOI 10.1002/smll.202101741
   Brennan MA, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201909125
   Bruick RK, 2003, GENE DEV, V17, P2614, DOI 10.1101/gad.1145503
   Cao B, 2015, BIOMATERIALS, V64, P21, DOI 10.1016/j.biomaterials.2015.06.018
   Chen LF, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbaa038
   Chen XB, 2020, SMALL METHODS, V4, DOI 10.1002/smtd.202000310
   Chen Y, 2022, ACTA HISTOCHEM, V124, DOI 10.1016/j.acthis.2022.151858
   Chen YP, 2016, SCI REP UK, V6, DOI 10.1038/srep31593
   Cheng L, 2020, SMALL, V16, DOI 10.1002/smll.202005433
   Correa S, 2021, CHEM REV, V121, P11385, DOI 10.1021/acs.chemrev.0c01177
   Cui LG, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119617
   Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600 0854.2010.01041.x
   Gan Q, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac008
   Gao YK, 2022, BIOACT MATER, V14, P377, DOI 10.1016/j.bioactmat.2022.01.041
   Gong LZ, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1800971
   Hernandez JM, 2012, SCIENCE, V336, P1581, DOI 10.1126/science.1221976
   Herrmann IK, 2021, NAT NANOTECHNOL, V16, P748, DOI 10.1038/s41565 021 00931 2
   Hertel FC, 2022, BIOLOGY BASEL, V11, DOI 10.3390/biology11050733
   Hoang DM, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 01134 4
   Huang ZJ, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/6614762
   Jeong Y, 2009, J CONTROL RELEASE, V137, P25, DOI 10.1016/j.jconrel.2009.03.008
   Jing X, 2022, ACS APPL MATER INTER, V14, P16082, DOI 10.1021/acsami.2c02278
   Kimbrel EA, 2020, NAT REV DRUG DISCOV, V19, P463, DOI 10.1038/s41573 020 0064 x
   Komori T, 2018, HISTOCHEM CELL BIOL, V149, P313, DOI 10.1007/s00418 018 1640 6
   Lan YH, 2022, BIOACT MATER, V17, P457, DOI 10.1016/j.bioactmat.2022.01.019
   Li DZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202108430
   Li ZH, 2022, CARBOHYD POLYM, V290, DOI 10.1016/j.carbpol.2022.119469
   Li ZL, 2019, KIDNEY INT, V95, P388, DOI 10.1016/j.kint.2018.09.013
   Liao ZW, 2021, ACS NANO, V15, P14709, DOI 10.1021/acsnano.1c04514
   Liu AQ, 2021, BIOMATERIALS, V272, DOI 10.1016/j.biomaterials.2021.120718
   Liu W, 2020, ACTA BIOMATER, V103, P196, DOI 10.1016/j.actbio.2019.12.020
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556 018 0250 9
   Mehta N, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202103955
   Mei QJ, 2021, INT J BIOPRINTING, V7, P37, DOI 10.18063/ijb.v7i3.367
   Mi BB, 2022, ACS NANO, V16, P771, DOI 10.1021/acsnano.1c08284
   Miao S, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100342
   Miguez PA, 2011, BIOCHEM BIOPH RES CO, V405, P262, DOI 10.1016/j.bbrc.2011.01.022
   Moncal KK, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010858
   Moon Y, 2022, J CONTROL RELEASE, V343, P118, DOI 10.1016/j.jconrel.2022.01.018
   Moreno Manzano V, 2020, REGEN BIOMATER, V7, P161, DOI 10.1093/rb/rbz049
   Nagano M, 2019, COMMUN BIOL, V2, DOI 10.1038/s42003 019 0670 5
   Orriss IR, 2009, J CELL PHYSIOL, V220, P155, DOI 10.1002/jcp.21745
   Ouyang ZH, 2017, ONCOTARGET, V8, P57870, DOI 10.18632/oncotarget.18628
   Park MH, 2020, BIOMATER RES, V24, DOI 10.1186/s40824 020 00200 8
   Phan J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1522236
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007 0637
   Ruan SB, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12194
   Seeherman HJ, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aar4953
   Shen K, 2022, ACTA BIOMATER, V143, P173, DOI 10.1016/j.actbio.2022.02.026
   Shen Y, 2022, CELL SIGNAL, V99, DOI 10.1016/j.cellsig.2022.110404
   Su YQ, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120477
   Swanson WB, 2020, ACTA BIOMATER, V118, P215, DOI 10.1016/j.actbio.2020.09.052
   Tao SC, 2018, ADV SCI, V5, DOI 10.1002/advs.201700449
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Varderidou Minasian S, 2020, THERANOSTICS, V10, P5979, DOI 10.7150/thno.40122
   Verdera HC, 2017, J CONTROL RELEASE, V266, P100, DOI 10.1016/j.jconrel.2017.09.019
   Wan XY, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010626
   Wan Z, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202113280
   Wang CC, 2016, J CLIN INVEST, V126, P1471, DOI 10.1172/JCI80672
   Wang G, 2022, REGEN BIOMATER, V9, DOI 10.1093/rb/rbac049
   Wang YB, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202206554
   Wang Y, 2019, ACS APPL MATER INTER, V11, P8725, DOI 10.1021/acsami.9b01872
   Wei Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14041
   Woo Y, 2022, ACS APPL MATER INTER, V14, P3773, DOI 10.1021/acsami.1c20585
   Wu B, 2013, J MOL HISTOL, V44, P423, DOI 10.1007/s10735 013 9497 4
   Wu D, 2022, FRONT BIOENG BIOTECH, V9, DOI 10.3389/fbioe.2021.829136
   Wu KT, 2021, MACROMOLECULES, V54, P7421, DOI 10.1021/acs.macromol.1c00959
   Xia YC, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 020 20724 w
   Xu X, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab038
   Xue H, 2022, BIOACT MATER, V18, P552, DOI 10.1016/j.bioactmat.2022.05.023
   Yang L, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab023
   Yang RH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abg3816
   Yang XW, 2020, CHEM ENG J, V396, DOI 10.1016/j.cej.2020.125320
   Ye CY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1904 7
   Yin JX, 2021, THERANOSTICS, V11, P1763, DOI 10.7150/thno.47057
   Young MF, 2002, GLYCOCONJUGATE J, V19, P257, DOI 10.1023/A:1025336114352
   Yu XG, 2022, CHEM ENG J, V433, DOI 10.1016/j.cej.2021.132799
   Zarember KA, 2005, J CLIN INVEST, V115, P1702, DOI 10.1172/JCI25740
   Zhang L, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbaa057
   Zhang W, 2017, AM J PHYSIOL RENAL, V313, pF906, DOI 10.1152/ajprenal.00178.2017
   Zhang YC, 2022, BIOACT MATER, V16, P218, DOI 10.1016/j.bioactmat.2021.12.032
   Zhao QY, 2021, REGEN BIOMATER, V8, DOI 10.1093/rb/rbab010
   Zhao Y, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201901474
   Zhou XC, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14051012
   Zhu TT, 2022, BIOACT MATER, V9, P446, DOI 10.1016/j.bioactmat.2021.08.005
NR 90
TC 41
Z9 43
U1 14
U2 255
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD MAY
PY 2023
VL 33
IS 21
DI 10.1002/adfm.202211664
EA JAN 2023
PG 22
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA G6ZI6
UT WOS:000913025800001
DA 2025 08 17
ER

PT J
AU Ren, SC
   Tang, XD
   Liu, LJ
   Meng, FR
   Yang, XD
   Li, N
   Zhang, ZY
   Aimaijiang, M
   Liu, MX
   Liu, XC
   Wang, HC
   Huangfu, HM
   Wang, H
   Zhang, JH
   Li, DW
   Zhou, YM
AF Ren, Sicong
   Tang, Xiaoduo
   Liu, Lijun
   Meng, Fanrong
   Yang, Xudong
   Li, Nuo
   Zhang, Zhiying
   Aimaijiang, Maierhaba
   Liu, Manxuan
   Liu, Xinchen
   Wang, Hanchi
   Huangfu, Huimin
   Wang, Huan
   Zhang, Junhu
   Li, Daowei
   Zhou, Yanmin
TI Reinforced Blood Derived Protein Hydrogels Enable Dual Level Regulation
   of Bio Physiochemical Microenvironments for Personalized Bone
   Regeneration with Remarkable Enhanced Efficacy
SO NANO LETTERS
LA English
DT Article
DE reinforced blood derived protein hydrogels; bone regeneration;
   dual level regulation; biophysiochemical microenvironments; personalized
   medicine
ID GROWTH FACTORS; HIPPO PATHWAY; YAP/TAZ; FIBRIN; MEMBRANES; STIFFNESS
AB Physiological microenvironment engineering has shown great promise incombating a variety of diseases. Herein, we present the rational design of reinforced andinjectable blood derived protein hydrogels (PDA@SiO2 PRF) composed of platelet richfibrin (PRF), polydopamine (PDA), and SiO2nanofibers that can act as dual levelregulators to engineer the microenvironment for personalized bone regeneration with highefficacy. From the biophysical level, PDA@SiO2 PRF with high stiffness can withstand theexternal loading and maintaining the space for bone regeneration in bone defects.Particularly, the reinforced structure of PDA@SiO2 PRF provides bone extracellular matrix(ECM) like functions to stimulate osteoblast differentiation via Yes associated protein(YAP) signaling pathway. From the biochemical level, the PDA component in PDA@SiO2 PRF hinders the fast degradation of PRF to release autologous growth factors in a sustainedmanner, providing sustained osteogenesis capacity. Overall, the present study offers a dual level strategy for personalized bone regeneration by engineering the biophysiochemicalmicroenvironment to realize enhanced osteogenesis efficacy
C1 [Ren, Sicong; Liu, Lijun; Aimaijiang, Maierhaba; Liu, Xinchen; Wang, Hanchi; Huangfu, Huimin; Li, Daowei; Zhou, Yanmin] Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Hosp Stomatol, Changchun 130021, Peoples R China.
   [Tang, Xiaoduo; Zhang, Junhu] Jilin Univ, Joint Lab Optofunct Theranost Med & Chem, Hosp 1, Changchun 130021, Peoples R China.
   [Tang, Xiaoduo; Zhang, Junhu] Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.
   [Meng, Fanrong] Aviat Gen Hosp, Dept Stomatol, Beijing 100000, Peoples R China.
   [Yang, Xudong] Changchun Univ Technol, Sch Chem Engn, Adv Inst Mat Sci, Changchun 130012, Peoples R China.
   [Li, Nuo; Zhang, Zhiying; Liu, Manxuan] Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling Ho, Changchun 130021, Peoples R China.
   [Wang, Huan] Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resources Utilizat & Lab, Changchun 130022, Peoples R China.
C3 Jilin University; Jilin University; Jilin University; Changchun
   University of Technology; Jilin University; Chinese Academy of Sciences;
   Changchun Institute of Applied Chemistry, CAS
RP Li, DW; Zhou, YM (通讯作者)，Jilin Univ, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Hosp Stomatol, Changchun 130021, Peoples R China.; Zhang, JH (通讯作者)，Jilin Univ, Joint Lab Optofunct Theranost Med & Chem, Hosp 1, Changchun 130021, Peoples R China.; Zhang, JH (通讯作者)，Jilin Univ, Coll Chem, State Key Lab Supramol Struct & Mat, Changchun 130012, Peoples R China.; Wang, H (通讯作者)，Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Rare Earth Resources Utilizat & Lab, Changchun 130022, Peoples R China.
EM huanwang@ciac.ac.cn; zju@jlu.edu.cn; jluldw@jlu.edu.cn;
   zhouym@jlu.edu.cn
RI Wang, Huan/LOR 6602 2024; Liu, Xinchen/AAA 3951 2021; Zhang,
   Junhu/O 4850 2017; Li, Daowei/X 7203 2019
OI wang, huan/0000 0001 9464 2474; 
FU National Natural Science Foundation of China [82071152, 81600823,
   21975098, 21774043, 22105197]; Interdisciplinary Integration and
   Innovation Project of Jilin University [JLUXKJC2021ZZ07]; China
   Postdoctoral Science Foundation [2017M611332]; Bethune Project of Jilin
   University [2018A06]; Science and Technology Development Project of
   Jilin Province [20180623051TC]; Science and Technology Project of Jilin
   Provincial Department of Finance [JLSZ2019378028]
FX This study was supported by National Natural Science Foundation of China
   (82071152, 81600823, 21975098, 21774043, 22105197), Interdisciplinary
   Integration and Innovation Project of Jilin University
   (JLUXKJC2021ZZ07), China Postdoctoral Science Foundation (2017M611332),
   Bethune Project of Jilin University (2018A06), Science and Technology
   Development Project of Jilin Province (20180623051TC), Science and
   Technology Project of Jilin Provincial Department of Finance,
   JLSZ2019378028.
CR Anitua E, 2019, BIOMATERIALS, V192, P440, DOI 10.1016/j.biomaterials.2018.11.029
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Cockerill I, 2020, NANO LETT, V20, P4594, DOI 10.1021/acs.nanolett.0c01448
   Coleman RE, 2013, NAT REV RHEUMATOL, V9, P365, DOI 10.1038/nrrheum.2013.36
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Fang DD, 2020, J ORAL MAXIL SURG, V78, P882, DOI 10.1016/j.joms.2020.01.037
   Gao SY, 2021, BONE, V144, DOI 10.1016/j.bone.2019.115117
   Hasani Sadrabadi MM, 2019, ACS NANO, V13, P3830, DOI 10.1021/acsnano.8b09623
   Hou Y, 2020, NANO LETT, V20, P748, DOI 10.1021/acs.nanolett.9b04761
   Kobayashi E, 2016, CLIN ORAL INVEST, V20, P2353, DOI 10.1007/s00784 016 1719 1
   LANYON LE, 1992, J BONE MINER RES, V7, pS369, DOI 10.1002/jbmr.5650071403
   Li DW, 2018, INT J NANOMED, V13, P7167, DOI 10.2147/IJN.S174553
   Lu ZH, 2020, MAT SCI ENG C MATER, V117, DOI 10.1016/j.msec.2020.111359
   Meng ZP, 2018, NATURE, V560, P655, DOI 10.1038/s41586 018 0444 0
   Miron RJ, 2021, INT J ORAL IMPL, V14, P181
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580 018 0086 y
   Mu ZX, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901469
   Patel A, 2020, ACTA BIOMATER, V112, P262, DOI 10.1016/j.actbio.2020.05.034
   Pilipchuk SP, 2015, DENT MATER, V31, P317, DOI 10.1016/j.dental.2015.01.006
   Rakhmatia YD, 2013, J PROSTHODONT RES, V57, P3, DOI 10.1016/j.jpor.2012.12.001
   Rausch V, 2020, TRENDS CELL BIOL, V30, P32, DOI 10.1016/j.tcb.2019.10.005
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rico Llanos GA, 2017, J BIOMED MATER RES A, V105, P1867, DOI 10.1002/jbm.a.36051
   Schett G, 2010, NAT REV ENDOCRINOL, V6, P698, DOI 10.1038/nrendo.2010.190
   Scognamiglio F, 2016, ACTA BIOMATER, V44, P232, DOI 10.1016/j.actbio.2016.08.017
   Stevenson S, 1998, CLIN ORTHOP RELAT R, pS239
   van den Bergh JP, 2012, NAT REV RHEUMATOL, V8, P163, DOI 10.1038/nrrheum.2011.217
   Wallace S, 2010, IMPLANT DENT, V19, P272, DOI 10.1097/ID.0b013e3181e5d2a1
   Wang DY, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202101586
   Wang LH, 2019, NANO LETT, V19, P9112, DOI 10.1021/acs.nanolett.9b04313
   Wang LH, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201901407
   Wang SJ, 2021, WOUND REPAIR REGEN, V29, P370, DOI 10.1111/wrr.12896
   Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323
   Wei Q, 2020, ADV SCI, V7, DOI 10.1002/advs.201902931
   Wen JH, 2014, NAT MATER, V13, P979, DOI [10.1038/NMAT4051, 10.1038/nmat4051]
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xu T, 2019, BONE, V122, P218, DOI 10.1016/j.bone.2019.03.006
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044
   Zhao N, 2019, ACS APPL MATER INTER, V11, P18123, DOI 10.1021/acsami.9b02462
NR 41
TC 31
Z9 32
U1 7
U2 156
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1530 6984
EI 1530 6992
J9 NANO LETT
JI Nano Lett.
PD MAY 25
PY 2022
VL 22
IS 10
BP 3904
EP 3913
DI 10.1021/acs.nanolett.2c00057
PG 10
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 1V6ZZ
UT WOS:000806236600009
PM 35522592
DA 2025 08 17
ER

PT J
AU Pham, L
   Purcell, P
   Morse, L
   Stashenko, P
   Battaglino, RA
AF Pham, L.
   Purcell, P.
   Morse, L.
   Stashenko, P.
   Battaglino, R. A.
TI Expression analysis of nha oc/NHA2:: A novel gene
   selectively expressed in
SO GENE EXPRESSION PATTERNS
LA English
DT Article
DE osteoclast specific; cation proton exchanger; bone resorption
ID OSTEOCLAST DIFFERENTIATION
AB Bone resorption by osteoclasts is required for normal bone remodeling and reshaping of growing bones. Excessive resorption is an important pathologic, feature of many diseases, including osteoporosis, arthritis, and periodontitis [Abu Amer, Y. (2005). Advances in osteoclast differentiation and function. Curr. Drug Targets. Immune. Endocr. Metabol. Disord. 5, 347 355]. On the other hand, deficient resorption leads to osteopetrosis which is characterized by increased bone mass and may lead to bone deformities or in severe cases to death [Blair, H.C., Athanasou, N.A. 2004. Recent advances in osteoclast biology and pathological bone ddresorption. Histol. Histo pathol. 19, 189 199; Del Fattore, A., Peruzzi, B., Rucci, N., Recchia, L, Cappariello, A., Longo, M., Fortunati, D., Ballanti, P., lacobini, M., Luciani, M., Devito, R., Pinto, R., Caniglia, M., Lanino, E., Messina, C., Cesaro, S., Letizia, C., Bianchini, G., Fryssira, H., Grabowski, P., Shaw, N., Bishop, N., Hughes, D., Kapur, R.P., Datta, H.K., Taranta, A., Fornari, R., Migliaccio, S., and Teti, A. 2006. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J. Med. Genet. 43, 315 325]. Recently, we identified a gene, nha oc/NHA2, which is strongly up regulated during RANKL induced osteoclast differentiation in vitro and in vivo. nha oc/NHA2 encodes a novel cation/proton exchanger that is strongly expressed in osteoclasts. The purpose of this work was to further validate the restricted expression of nha oc/NHA2 in osteoclasts by in situ hybridization. Our results showed that nha oc is expressed predominantly in bone. In the head, expression was found in the supraoccipitale bone, calvarium, mandible, and maxilla. Furthermore, nha oc positive cells co express the osteoclast markers TRAP and cathepsin k, confirming nha oc/NHA2 osteoclast localization. However, only a subset of cathepsin k expressing cells is positive for nha oc/NHA2, suggesting that nha oc is expressed by terminally differentiated osteoclasts. (c) 2007 Elsevier B.V. All rights reserved.
C1 Forsyth Inst, Dept Cytokine Biol, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
   Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA.
   Spaulding Rehabil Hosp, Boston, MA USA.
C3 Harvard University; Harvard University Medical Affiliates; Forsyth
   Institute; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Harvard University Medical Affiliates; Spaulding Rehabilitation
   Hospital
RP Battaglino, RA (通讯作者)，Forsyth Inst, Dept Cytokine Biol, 140 Fenway, Boston, MA 02115 USA.
EM rbattaglino@forsyth.org
RI Morse, Leslie/AAU 5608 2020; battaglino, ricardo/D 2892 2015
FU NIDCR NIH HHS [DE 007378 18, R01 DE007378] Funding Source: Medline
CR Abu Amer Yousef, 2005, Current Drug Targets   Immune Endocrine and Metabolic Disorders, V5, P347, DOI 10.2174/1568008054863808
   Battaglino R, 2004, J BONE MINER RES, V19, P1420, DOI 10.1359/JBMR.040606
   Battaglino R, 2002, J BONE MINER RES, V17, P763, DOI 10.1359/jbmr.2002.17.5.763
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Brett CL, 2005, AM J PHYSIOL CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004
   Burckhardt G, 2002, J NEPHROL, V15, pS3
   Del Fattore A, 2006, J MED GENET, V43, P315, DOI 10.1136/jmg.2005.036673
   DEMAUREX N, 1994, J EXP BIOL, V196, P389
   Okamatsu Y, 2004, J IMMUNOL, V173, P2084, DOI 10.4049/jimmunol.173.3.2084
   Ritter M, 2001, CELL PHYSIOL BIOCHEM, V11, P1, DOI 10.1159/000047787
NR 10
TC 18
Z9 20
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 133X
J9 GENE EXPR PATTERNS
JI Gene Expr. Patterns
PD OCT
PY 2007
VL 7
IS 8
BP 846
EP 851
DI 10.1016/j.modgep.2007.07.002
PG 6
WC Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Developmental Biology; Genetics & Heredity
GA 234VP
UT WOS:000251192600003
PM 17698421
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Premnath, P
   Lun, T
   Siddiqui, H
   Stahl, AR
   Ardebili, AA
   Olsen, A
   Krawetz, R
AF Premnath, Priyatha
   Lun, Theodore
   Siddiqui, Humza
   Stahl, Alana Ruth
   Ardebili, Aria Ahadzadeh
   Olsen, Alexandra
   Krawetz, Roman
TI Absence of E2f1 Negates Pro osteogenic Impacts of p21
   Absence
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Bone healing; Cell cycle regulation; p21; E2f1; Osteogenesis
ID LIVER REGENERATION; GENE THERAPY; BONE; HEPATOCARCINOGENESIS;
   DIFFERENTIATION; EXPRESSION; INJURY
AB Loss of p21 leads to increased bone formation post injury; however, the mechanism(s) by which this occurs remains undetermined. E2f1 is downstream of p21 and as a transcription factor can act directly on gene expression; yet it is unknown if E2f1 plays a role in the osteogenic effects observed when p21 is differentially regulated. In this study we aimed to investigate the interplay between p21 and E2f1 and determine if the pro regenerative osteogenic effects observed with the loss of p21 are E2f1 dependent. To accomplish this, we employed knockout p21 and E2f1 mice and additionally generated a p21/E2f1 double knockout. These mice underwent burr hole injuries to their proximal tibiae and healing was assessed over 7 days via microCT imaging. We found that p21 and E2f1 play distinct roles in bone regeneration where the loss of p21 increased trabecular bone formation and loss of E2f1 increased cortical bone formation, yet loss of E2f1 led to poorer bone repair overall. Furthermore, when E2f1 was absent, either individually or simultaneously with p21, there was a dramatic decrease of the number of osteoblasts, osteoclasts, and chondrocytes at the site of injury compared to p21( / ) and C57BL/6 mice. Together, these results suggest that E2f1 regulates the cell populations required for bone repair and has a distinct role in bone formation/repair compared to p21( / )E2f1( / ). These results highlight the possibility of cell cycle and/or p21/E2f1 being potential druggable targets that could be leveraged in clinical therapies to improve bone healing in pathologies such as osteoporosis.
C1 [Premnath, Priyatha] Univ Wisconsin Milwaukee, Dept Biomed Engn, Milwaukee, WI 53212 USA.
   [Lun, Theodore; Stahl, Alana Ruth; Ardebili, Aria Ahadzadeh; Olsen, Alexandra; Krawetz, Roman] Univ Calgary, McCaig Inst Bone & Joint Hlth, Cumming Sch Med, Calgary, AB, Canada.
   [Siddiqui, Humza] Univ Wisconsin Milwaukee, Dept Biol Sci, Milwaukee, WI USA.
   [Ardebili, Aria Ahadzadeh; Olsen, Alexandra] Univ Calgary, Dept Biomed Engn, Calgary, AB, Canada.
   [Krawetz, Roman] Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada.
   [Krawetz, Roman] Univ Calgary, Cumming Sch Med, Dept Surg, Calgary, AB, Canada.
C3 University of Wisconsin System; University of Wisconsin Milwaukee;
   University of Calgary; University of Wisconsin System; University of
   Wisconsin Milwaukee; University of Calgary; University of Calgary;
   University of Calgary
RP Premnath, P (通讯作者)，Univ Wisconsin Milwaukee, Dept Biomed Engn, Milwaukee, WI 53212 USA.
EM premnath@uwm.edu
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Baroli B, 2009, J PHARM SCI US, V98, P1317, DOI 10.1002/jps.21528
   Bedelbaeva K, 2010, P NATL ACAD SCI USA, V107, P5845, DOI 10.1073/pnas.1000830107
   Buitrago Molina LE, 2013, HEPATOLOGY, V58, P1143, DOI 10.1002/hep.26412
   Carofino BC, 2008, J BONE JOINT SURG AM, V90A, P99, DOI 10.2106/JBJS.G.01546
   de la Vega R, 2021, TRANSL RES, V236, P1, DOI 10.1016/j.trsl.2021.04.009
   Felder AA, 2021, ROY SOC OPEN SCI, V8, DOI 10.1098/rsos.201401
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Jablonski CL, 2021, CARTILAGE, V13, p1608S, DOI 10.1177/1947603519876348
   Klamut HJ, 2004, CRIT REV EUKAR GENE, V14, P89, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i12.60
   Kodama J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165685
   Lefebvre V, 2017, CONNECT TISSUE RES, V58, P2, DOI 10.1080/03008207.2016.1183667
   Lowery JW, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a022327
   Marhenke S, 2014, GUT, V63, P1501, DOI 10.1136/gutjnl 2013 304829
   Mistry AS, 2005, ADV BIOCHEM ENG BIOT, V94, P1, DOI 10.1007/b99997
   Premnath P, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1790 z
   Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656 3668.2003
   Stepniak E, 2006, GENE DEV, V20, P2306, DOI 10.1101/gad.390506
   Taiani JT, 2010, STEM CELLS DEV, V19, P989, DOI 10.1089/scd.2009.0297
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Watson Levings RS, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.901317
   Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593
   Wu M, 2014, CARDIOVASC RES, V104, P412, DOI 10.1093/cvr/cvu222
   Yang YQ, 2012, INT J ORAL SCI, V4, P64, DOI 10.1038/ijos.2012.33
   Yu SB, 2013, BONE, V56, P234, DOI 10.1016/j.bone.2013.06.019
   Zara JN, 2011, TISSUE ENG PT A, V17, P1389, DOI [10.1089/ten.TEA.2010.0555, 10.1089/ten.tea.2010.0555]
   Zhou HX, 2022, J CELL MOL MED, V26, P2981, DOI 10.1111/jcmm.17311
   Zu G, 2017, J MOL MED, V95, P83, DOI 10.1007/s00109 016 1464 6
NR 31
TC 2
Z9 2
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD JUN
PY 2024
VL 114
IS 6
BP 625
EP 637
DI 10.1007/s00223 024 01210 7
EA APR 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA QO2H3
UT WOS:001206221300001
PM 38643416
DA 2025 08 17
ER

PT J
AU Matsuo, T
   Dat, LT
   Komatsu, M
   Yoshimaru, T
   Daizumoto, K
   Sone, S
   Nishioka, Y
   Katagiri, T
AF Matsuo, Taisuke
   Dat, Le Tan
   Komatsu, Masato
   Yoshimaru, Tetsuro
   Daizumoto, Kei
   Sone, Saburo
   Nishioka, Yasuhiko
   Katagiri, Toyomasa
TI Early Growth Response 4 Is Involved in Cell Proliferation of Small Cell
   Lung Cancer through Transcriptional Activation of Its Downstream Genes
SO PLOS ONE
LA English
DT Article
ID HORMONE RELATED PROTEIN; BONE METASTASIS; BINDING SITE; ENCODES;
   MECHANISMS; EXPRESSION; DIFFERENTIATION; PROMOTER; ELEMENT; MEMBER
AB Small cell lung cancer (SCLC) is aggressive, with rapid growth and frequent bone metastasis; however, its detailed molecular mechanism remains poorly understood. Here, we report the critical role of early growth factor 4 (EGR4), a DNA binding, zinc finger transcription factor, in cell proliferation of SCLC. EGR4 overexpression in HEK293T cells conferred significant upregulation of specific splice variants of the parathyroid hormone related protein (PTHrP) gene, resulting in enhancement of the secretion of PTHrP protein, a known mediator of osteolytic bone metastasis. More importantly, depletion of EGR4 expression by siRNA significantly suppressed growth of the SCLC cell lines, SBC 5, SBC 3 and NCI H1048. On the other hand, introduction of EGR4 into NIH3T3 cells significantly enhanced cell growth. We identified four EGR4 target genes, SAMD5, RAB15, SYNPO and DLX5, which were the most significantly downregulated genes upon depletion of EGR4 expression in all of the SCLC cells examined, and demonstrated the direct recruitment of EGR4 to their promoters by ChIP and luciferase reporter analysis. Notably, knockdown of the expression of these genes by siRNA remarkably suppressed the growth of all the SCLC cells. Taken together, our findings suggest that EGR4 likely regulates the bone metastasis and proliferation of SCLC cells via transcriptional regulation of several target genes, and may therefore be a promising target for the development of anticancer drugs for SCLC patients.
C1 [Matsuo, Taisuke; Dat, Le Tan; Komatsu, Masato; Yoshimaru, Tetsuro; Daizumoto, Kei; Katagiri, Toyomasa] Univ Tokushima, Div Genome Med, Inst Genome Res, Tokushima 770, Japan.
   [Dat, Le Tan; Sone, Saburo; Nishioka, Yasuhiko] Univ Tokushima, Inst Hlth Biosci, Dept Med Oncol, Tokushima 770, Japan.
C3 Tokushima University; Tokushima University
RP Katagiri, T (通讯作者)，Univ Tokushima, Div Genome Med, Inst Genome Res, Tokushima 770, Japan.
EM tkatagi@genome.tokushima u.ac.jp
RI ; Yoshimaru, Tetsuro/AAE 5335 2020
OI Komatsu, Masato/0000 0003 2007 0252; Yoshimaru,
   Tetsuro/0000 0001 8582 3011; 
FU University of Tokushima; Grants in Aid for Scientific Research
   [25293079, 26461948] Funding Source: KAKEN
FX This study was supported by future advanced research from the University
   of Tokushima. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Al Husaini H, 2009, J THORAC ONCOL, V4, P251, DOI 10.1097/JTO.0b013e31819518fc
   Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400
   BURTIS WJ, 1990, NEW ENGL J MED, V322, P1106, DOI 10.1056/NEJM199004193221603
   CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460 2075.1990.tb08228.x
   Chen YC, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2781
   CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737
   CROSBY SD, 1992, P NATL ACAD SCI USA, V89, P4739, DOI 10.1073/pnas.89.10.4739
   CROSBY SD, 1991, MOL CELL BIOL, V11, P3835, DOI 10.1128/MCB.11.8.3835
   Dat L, 2012, INT J ONCOL, V40, P1455, DOI 10.3892/ijo.2012.1348
   Decker EL, 2003, NUCLEIC ACIDS RES, V31, P911, DOI 10.1093/nar/gkg186
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Kakiuchi S, 2003, MOL CANCER RES, V1, P485
   Kato T, 2008, CLIN CANCER RES, V14, P2363, DOI 10.1158/1078 0432.CCR 07 1523
   KIURA K, 1993, ANTI CANCER DRUG DES, V8, P417
   Kozlow W, 2005, J MAMMARY GLAND BIOL, V10, P169, DOI 10.1007/s10911 005 5399 8
   Kuo PL, 2013, BBA GEN SUBJECTS, V1830, P3756, DOI 10.1016/j.bbagen.2013.02.022
   LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456
   Liu Y, 2012, INT J NONLIN SCI NUM, V13, P1
   Ludwig A, 2011, J NEUROSCI, V31, P644, DOI 10.1523/JNEUROSCI.2006 10.2011
   Matsuo T, 2014, INT J ONCOL, V44, P427, DOI 10.3892/ijo.2013.2187
   Miki T, 2004, INT J CANCER, V108, P511, DOI 10.1002/ijc.11586
   MOSELEY JM, 1987, P NATL ACAD SCI USA, V84, P5048, DOI 10.1073/pnas.84.14.5048
   MULLER HJ, 1991, P NATL ACAD SCI USA, V88, P10079, DOI 10.1073/pnas.88.22.10079
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nakazawa K, 2012, ONCOL LETT, V4, P617, DOI 10.3892/ol.2012.792
   Nishimura N, 2011, ONCOL REP, V26, P145, DOI 10.3892/or.2011.1255
   Otsuka S, 2009, ONCOL RES, V17, P581, DOI 10.3727/096504009789745511
   Papachristou DJ, 2012, MED RES REV, V32, P611, DOI 10.1002/med.20224
   Poirier R, 2008, FRONT NEUROSCI SWITZ, V2, P47, DOI 10.3389/neuro.01.002.2008
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500
   Sone S, 2007, CANCER METAST REV, V26, P685, DOI 10.1007/s10555 007 9081 z
   SWIRNOFF AH, 1995, MOL CELL BIOL, V15, P2275
   Tourtellotte WG, 2000, MOL CELL BIOL, V20, P5261, DOI 10.1128/MCB.20.14.5261 5268.2000
   Tourtellotte WG, 1999, DEVELOPMENT, V126, P5061
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Watanabe T, 2014, DIS COLON RECTUM, V57, P23, DOI 10.1097/01.dcr.0000437688.33795.9d
   Wieland GD, 2005, J CELL SCI, V118, P3203, DOI 10.1242/jcs.02445
   Wong JS, 2012, EMBO J, V31, P1028, DOI 10.1038/emboj.2011.464
   Yamada T, 2009, MOL CANCER THER, V8, P119, DOI 10.1158/1535 7163.MCT 08 0874
   Yano S, 1997, ONCOL RES, V9, P573
   Yoshimaru T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3443
   Zuk PA, 2000, J BIOL CHEM, V275, P26754
NR 44
TC 26
Z9 28
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD NOV 20
PY 2014
VL 9
IS 11
AR e113606
DI 10.1371/journal.pone.0113606
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AT9ND
UT WOS:000345253000065
PM 25411851
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Monis, EL
   Mannstadt, M
AF Monis, Elizabeth L.
   Mannstadt, Michael
TI Hypoparathyroidism   disease update and emerging treatments
SO ANNALES D ENDOCRINOLOGIE
LA English
DT Article
DE Hypoparathyroidism; Complications of therapy; rhPTH(1 84)
ID PARATHYROID HORMONE 1 34; RANDOMIZED CONTROLLED TRIAL; CALCIUM SENSING
   RECEPTOR; LONG TERM TREATMENT; QUALITY OF LIFE; REPLACEMENT THERAPY;
   CROSSOVER TRIAL; PTH(1 84); CALCITRIOL; MUTATIONS
AB Parathyroid hormone (PTH) is the primary regulator of blood calcium levels and bone metabolism. Insufficient levels of PTH lead to hypoparathyroidism, characterized by low serum calcium and elevated serum phosphate levels. It is most commonly caused by the inadvertent damage to the parathyroid glands during thyroid surgery. Patients with hypoparathyroidism are currently being treated with oral calcium and active vitamin D, and to avoid worsening hypercalciuria, target serum calcium levels are within the lower end of normal. With current treatment, patients may suffer from large swings in serum calcium and are at a substantial risk of chronic renal failure, nephrocalcinosis, and kidney stones. The recent FDA approval of recombinant human (rh) PTH(1 84) for the treatment of hypoparathyroidism adds PTH replacement therapy to the endocrinologist's armamentarium to treat this chronic disease. (C) 2015 Published by Elsevier Masson SAS.
C1 [Monis, Elizabeth L.; Mannstadt, Michael] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital
RP Mannstadt, M (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Thier 1051,50 Blossom St, Boston, MA 02114 USA.
EM mannstadt@mgh.harvard.edu
RI Mannstadt, Michael/AAO 1124 2020
CR Arlt W, 2002, EUR J ENDOCRINOL, V146, P215, DOI 10.1530/eje.0.1460215
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P2356, DOI 10.1210/jc.2013 1239
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   FONSECA OA, 1967, ARCH INTERN MED, V120, P202, DOI 10.1001/archinte.120.2.202
   Goswami R, 2012, CLIN ENDOCRINOL, V77, P200, DOI 10.1111/j.1365 2265.2012.04353.x
   Grigorieva IV, 2011, ANN NY ACAD SCI, V1237, P24, DOI 10.1111/j.1749 6632.2011.06221.x
   Hadker N, 2014, ENDOCR PRACT, V20, P671, DOI 10.4158/EP13328.OR
   Hauch A, 2014, ANN SURG ONCOL, V21, P3844, DOI 10.1245/s10434 014 3846 8
   HOFFMAN E, 1958, AM J SURG, V96, P33, DOI 10.1016/0002 9610(58)90868 7
   Kifor O, 2004, J CLIN ENDOCR METAB, V89, P548, DOI 10.1210/jc.2003 031054
   Kobrynski LJ, 2007, LANCET, V370, P1443, DOI 10.1016/S0140 6736(07)61601 8
   Kronenberg HM, 2004, J CLIN ENDOCR METAB, V89, P6, DOI 10.1210/jc.2003 031943
   Li D, 2014, J CLIN ENDOCR METAB, V99, pE1774, DOI 10.1210/jc.2014 1029
   Linglart A, 2011, J CLIN ENDOCR METAB, V96, P3308, DOI 10.1210/jc.2011 1359
   Mannstadt M, 2015, PARATHYROID HORMONE, V3rd
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Mannstadt M, 2013, NEW ENGL J MED, V368, P2532, DOI 10.1056/NEJMc1300278
   Mannstadt M, 2011, J ENDOCRINOL, V210, P165, DOI 10.1530/JOE 10 0247
   Minisola S, 2002, OSTEOPOROSIS INT, V13, P171, DOI 10.1007/s001980200009
   Mitchell DM, 2012, J CLIN ENDOCR METAB, V97, P4507, DOI 10.1210/jc.2012 1808
   Nesbit MA, 2013, NEW ENGL J MED, V368, P2476, DOI 10.1056/NEJMoa1300253
   Nesbit MA, 2004, J BIOL CHEM, V279, P22624, DOI 10.1074/jbc.M401797200
   NIKIFORUK G, 1981, ORAL SURG ORAL MED O, V51, P317, DOI 10.1016/0030 4220(81)90061 X
   Parvari R, 2002, NAT GENET, V32, P448, DOI 10.1038/ng1012
   Powers J, 2013, J BONE MINER RES, V28, P2570, DOI 10.1002/jbmr.2004
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   SCHAAF M, 1966, NEW ENGL J MED, V274, P1228, DOI 10.1056/NEJM196606022742203
   Shoback D, 2008, NEW ENGL J MED, V359, P391, DOI 10.1056/NEJMcp0803050
   Sikjaer T, 2014, OSTEOPOROSIS INT, V25, P1717, DOI 10.1007/s00198 014 2677 6
   Sikjaer T, 2013, J BONE MINER RES, V28, P2232, DOI 10.1002/jbmr.1964
   Sikjaer T, 2012, J BONE MINER RES, V27, P781, DOI 10.1002/jbmr.1493
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Thakker RV, 2004, CELL CALCIUM, V35, P275, DOI 10.1016/j.ceca.2003.10.010
   Thakker RV, 2001, LANCET, V357, P974, DOI 10.1016/S0140 6736(00)04254 9
   Thaldcer RV, 2006, GENETIC DISORDERS CA
   Underbjerg L, 2014, J BONE MINER RES, V29, P2504, DOI 10.1002/jbmr.2273
   VERED I, 1989, AM J MED, V86, P413, DOI 10.1016/0002 9343(89)90338 0
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
NR 45
TC 4
Z9 6
U1 0
U2 1
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0003 4266
EI 2213 3941
J9 ANN ENDOCRINOL PARIS
JI Ann Endocrinol.
PD MAY
PY 2015
VL 76
IS 2
BP 84
EP 88
DI 10.1016/j.ando.2015.03.009
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA CJ6YM
UT WOS:000355641100003
PM 25882889
DA 2025 08 17
ER

PT J
AU Deng, L
   Ding, YD
   Peng, Y
   Wu, Y
   Fan, J
   Li, WX
   Yang, RL
   Yang, ML
   Fu, Q
AF Deng, Lili
   Ding, Yuedi
   Peng, Ying
   Wu, Yu
   Fan, Jun
   Li, Wenxin
   Yang, Runlin
   Yang, Meiling
   Fu, Qiang
TI γ Tocotrienol protects against ovariectomy induced bone loss via
   mevalonate pathway as HMG CoA reductase inhibitor
SO BONE
LA English
DT Article
DE Bone loss; HMG CoA reductase inhibitor; Mevalonate pathway;
   gamma Tocotrienol
ID KAPPA B LIGAND; VITAMIN E; OSTEOCLAST FORMATION; MALE RATS; IN VITRO;
   CHOLESTEROL BIOSYNTHESIS; ANTIOXIDANT ACTIVITIES; RECEPTOR ACTIVATOR;
   MINERAL DENSITY; GENE EXPRESSION
AB gamma Tocotrienol (GT3), an analogue of vitamin E, has gained increasing scientific interest recently as it provides significant health benefits. GT3 exerts its biological effects not only by virtue of antioxidant properties but also by inhibiting hydroxy methyl glutaryl coenzyme A (HMG CoA) reductase. Studies have reported that the mevalonate pathway is relevant for bone metabolism and HMG CoA reductase inhibitors can increase bone mass and are useful in osteoporosis therapy. However, whether it is involved in the bone anabolic activity of GT3 is not clear. This study was conducted to investigate the ability of GT3 to protect against ovariectomy induced bone loss, as well as the correlation between the protections and mevalonate pathway. Results showed that mice supplemented with 100 mg/kg emulsified GT3 via subcutaneous injection once per month for three months were significantly protected from ovariectomy induced bone loss as evaluated by various bone structural parameters, bone metabolic gene expression levels and serum levels of biochemical markers for bone resorption and bone formation. Importantly, the effect of GT3 on preventing against ovariectomy induced bone loss could be reversed by daily supplementation with mevalonate, indicating that GT3 may via an HMG CoA reductase dependent mechanism to protect against ovariectomy induced bone loss. Our results suggest that GT3 is suitable as dietary supplement and has potential as an alternative drug to treat or prevent osteoporosis. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Deng, Lili; Ding, Yuedi; Peng, Ying; Wu, Yu; Fan, Jun; Li, Wenxin; Yang, Runlin; Fu, Qiang] Jiangsu Inst Nucl Med, Key Lab Nucl Med, Minist Hlth, Jiangsu Key Lab Mol Nucl Med, Wuxi 214063, Jiangsu, Peoples R China.
   [Yang, Meiling] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Deng, L (通讯作者)，Jiangsu Inst Nucl Med, QianRong Rd 20, Wuxi 214063, Jiangsu, Peoples R China.
EM denglili@jsinm.org; fuqiang@jsinm.org
FU Jiangsu Institute of Nuclear Medicine [QN201104]; Natural Science
   Foundation of Jiangsu Province [BK2011165, BK2012104]; National Natural
   Science Foundation of China [81200645]
FX This work was supported by the Jiangsu Institute of Nuclear Medicine
   grant QN201104 to Lili Deng; by Natural Science Foundation of Jiangsu
   Province BK2011165 to Ying Peng and BK2012104 to Yuedi Ding; by National
   Natural Science Foundation of China 81200645 to Yu Wu. We thank
   Professor Charles A. O'Brien for critical reading of the manuscript.
CR Ahmad NS, 2005, CLIN EXP PHARMACOL P, V32, P761, DOI 10.1111/j.1440 1681.2005.04264.x
   Ahn KS, 2008, INT J CANCER, V123, P1733, DOI 10.1002/ijc.23745
   Bauer DC, 2003, OSTEOPOROSIS INT, V14, P273, DOI 10.1007/s00198 002 1323 x
   Berbée M, 2009, RADIAT RES, V171, P596, DOI 10.1667/RR1632.1
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brooks R, 2011, INT J VITAM NUTR RES, V81, P358, DOI 10.1024/0300 9831/a000087
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Duque G, BR J PHARM, V162, P1109
   Feresin RG, 2013, J OSTEOPOROS, V2013, DOI 10.1155/2013/825985
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Fu Q, 2006, MOL CELL BIOL, V26, P6453, DOI 10.1128/MCB.00356 06
   Fujita K, 2012, NAT MED, V18, P589, DOI 10.1038/nm.2659
   Funkhouser HL, 2002, J CLIN DENSITOM, V5, P151, DOI 10.1385/JCD:5:2:151
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Hatzigeorgiou C, 2005, OSTEOPOROSIS INT, V16, P990, DOI 10.1007/s00198 004 1793 0
   Hermizi H, 2009, CALCIFIED TISSUE INT, V84, P65, DOI 10.1007/s00223 008 9190 x
   Ima Nirwana S, 1999, GEN PHARMACOL, V32, P621, DOI 10.1016/S0306 3623(98)00277 8
   Jadhav SB, 2006, J PHARM PHARMACOL, V58, P1451, DOI 10.1211/jpp.58.11.0005
   Khosla S, 2009, NEW ENGL J MED, V361, P818, DOI 10.1056/NEJMe0905480
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Macdonald HM, 2004, AM J CLIN NUTR, V79, P155
   Maniam S, 2008, BASIC CLIN PHARMACOL, V103, P55, DOI 10.1111/j.1742 7843.2008.00241.x
   Manolagas SC, ENDOCR REV, V31, P266
   Mehat MZ, 2010, J BONE MINER METAB, V28, P503, DOI 10.1007/s00774 010 0159 2
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Ohnaka K, 2001, BIOCHEM BIOPH RES CO, V287, P337, DOI 10.1006/bbrc.2001.5597
   Pacifici R, 2008, CELL IMMUNOL, V252, P68, DOI 10.1016/j.cellimm.2007.06.008
   PARKER RA, 1993, J BIOL CHEM, V268, P11230
   PEARCE BC, 1994, J MED CHEM, V37, P526, DOI 10.1021/jm00030a012
   PEARCE BC, 1992, J MED CHEM, V35, P3595, DOI 10.1021/jm00098a002
   QURESHI AA, 1986, J BIOL CHEM, V261, P544
   Sen CK, 2006, LIFE SCI, V78, P2088, DOI 10.1016/j.lfs.2005.12.001
   Smith BJ, 2005, CALCIFIED TISSUE INT, V76, P272, DOI 10.1007/s00223 004 0269 8
   Viccica G, 2007, J Endocrinol Invest, V30, P8
   WANG GJ, 1995, J FORMOS MED ASSOC, V94, P589
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Wolf RL, 2005, AM J CLIN NUTR, V82, P581, DOI 10.1093/ajcn/82.3.581
   Yoshida T, 2009, J CELL BIOCHEM, V106, P896, DOI 10.1002/jcb.22059
NR 40
TC 45
Z9 49
U1 0
U2 23
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2014
VL 67
BP 200
EP 207
DI 10.1016/j.bone.2014.07.006
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AO3KJ
UT WOS:000341227800026
PM 25019595
DA 2025 08 17
ER

PT J
AU Voermans, NC
   Dittrich, ATM
   Liguori, S
   Panicucci, C
   Moretti, A
   Weber, DR
   Ward, LM
AF Voermans, Nicol C.
   Dittrich, Anne T. M.
   Liguori, Sara
   Panicucci, Chiara
   Moretti, Antimo
   Weber, David R.
   Ward, Leanne M.
CA 274th ENMC Workshop Studygrp
TI 274th ENMC international workshop: Recommendations for optimizing bone
   strength in neuromuscular disorders. Hoofddorp, The Netherlands, 19 21
   January 2024
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Bone health; Bone strength; Fractures; Prevention; Assessment;
   Management
ID DUCHENNE MUSCULAR DYSTROPHY; INDUCED OSTEOPOROSIS; VERTEBRAL FRACTURES;
   DENOSUMAB TREATMENT; MINERAL DENSITY; MANAGEMENT; HEALTH; DIAGNOSIS;
   RISK; REHABILITATION
AB The 274th ENMC workshop for optimizing bone strength in neuromuscular disorders (NMDs) was held on January 19 21, 2024. The group of participants included experts in the fields of bone health and neuromuscular medicine along with the patient voice. Bone strength represents a crucial aspect of the management of pediatric and adult patients with NMDs. Bone strength may be compromised due to different pathophysiologic mechanisms, including disrupted bone muscle "crosstalk", loss of biomechanical loading, nutritional insufficiency, inadequate weight bearing physical activity, muscle weakness and/or immobility, and drug treatment. While for Duchenne muscular dystrophy recommendations for evaluation and treatment of bone strength have been published, evidence on bone strength in other hereditary and acquired NMDs is scarce. Enhanced knowledge is needed to understand the development and maintenance of bone strength in patients with NMDs. This workshop aimed to develop a strategy to improve bone strength and thus prevent fractures in patients with NMDs.
C1 [Voermans, Nicol C.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Nijmegen, Netherlands.
   [Dittrich, Anne T. M.] Radboud Univ Nijmegen, Radboudumc Amalia Childrens Hosp, Dept Pediat, Med Ctr, Nijmegen, Netherlands.
   [Liguori, Sara; Moretti, Antimo] Univ Campania Luigi Vanvitelli, Dept Med & Surg Specialties & Dent, I 80138 Naples, Italy.
   [Liguori, Sara] Univ Campania Luigi Vanvitelli, Dept Mental & Phys Hlth & Prevent Med, I 80138 Naples, Italy.
   [Panicucci, Chiara] IRCCS Ist Giannina Gaslini, Ctr Translat & Expt Myol, Genoa, Italy.
   [Weber, David R.] Univ Penn, Childrens Hosp Philadelphia, Div Endocrinol, Philadelphia, PA USA.
   [Weber, David R.] Univ Penn, Perelman Sch Med, Philadelphia, PA USA.
   [Ward, Leanne M.] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Universita
   della Campania Vanvitelli; Universita della Campania Vanvitelli;
   University of Genoa; IRCCS Istituto Giannina Gaslini; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania; University of Ottawa; Children's Hospital of
   Eastern Ontario
RP Voermans, NC (通讯作者)，Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Neurol, Med Ctr, Nijmegen, Netherlands.
EM Nicol.Voermans@radboudumc.nl
RI Weber, David/AAU 9831 2020; Panicucci, Chiara/GWM 8241 2022; Moretti,
   Antimo/T 8571 2017; Ward, Leanne/AAF 8482 2020
OI Ward, Leanne M/0000 0003 1557 9185; 
FU MDA USA
FX <STRONG>This workshop was supported by MDA USA. </STRONG>
CR Adaikina A, 2022, NEUROMUSCULAR DISORD, V32, P820, DOI 10.1016/j.nmd.2022.07.398
   Ammann P, 2003, OSTEOPOROSIS INT, V14, pS13, DOI 10.1007/s00198 002 1345 4
   Antoniou G, 2023, MEDICINA LITHUANIA, V59, DOI 10.3390/medicina59020312
   Baranello G, 2019, NEUROMUSCULAR DISORD, V29, P525, DOI 10.1016/j.nmd.2019.06.001
   Bertoldo F, 2015, J CLIN ENDOCR METAB, V100, P401, DOI 10.1210/jc.2014 2763
   Bijlsma JWJ, 2005, RHEUM DIS CLIN N AM, V31, P1, DOI 10.1016/j.rdc.2004.10.003
   Birks S, 2021, BONE, V151, DOI 10.1016/j.bone.2021.116023
   Birnkrant DJ, 2018, LANCET NEUROL, V17, P347, DOI 10.1016/S1474 4422(18)30025 5
   Birnkrant DJ, 2018, LANCET NEUROL, V17, P445, DOI 10.1016/S1474 4422(18)30026 7
   Birnkrant DJ, 2018, LANCET NEUROL, V17, P251, DOI 10.1016/S1474 4422(18)30024 3
   Bouman K, 2024, NEUROMUSCULAR DISORD, V34, P105, DOI 10.1016/j.nmd.2023.11.008
   Bouman K, 2023, J NEUROMUSCULAR DIS, V10, P1, DOI 10.3233/JND 221543
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Broomfield J, 2021, NEUROLOGY, V97, pE2304, DOI 10.1212/WNL.0000000000012910
   Buehring B, 2013, J ALLERGY CLIN IMMUN, V132, P1019, DOI 10.1016/j.jaci.2013.08.040
   Caplliure Llopis J, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.599216
   Chagarlamudi H, 2017, MUSCLE NERVE, V56, P1108, DOI 10.1002/mus.25619
   Compston Juliet, 2006, Arq Bras Endocrinol Metab, V50, P579
   Corrao G, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1137671
   Cosman F, 2018, J BONE MINER RES, V33, P1219, DOI 10.1002/jbmr.3427
   Cosso R., 2018, J Tre Bio Res, V1, P1, DOI [DOI 10.15761/JTBR.1000101, 10.15761/JTBR.1000101]
   Cox M, 2021, AUTOIMMUN REV, V20, DOI 10.1016/j.autrev.2021.102782
   Crabtree NJ, 2022, BONE, V154, DOI 10.1016/j.bone.2021.116248
   Crabtree NJ, 2018, BONE, V116, P181, DOI 10.1016/j.bone.2018.07.019
   Crabtree NJ, 2017, BONE, V97, P168, DOI 10.1016/j.bone.2017.01.006
   Crow Rebecca A, 2018, Trials, V19, P291, DOI 10.1186/s13063 018 2645 0
   Densitometry IISfC, 2023, Bone Mineral Density (BMD) testing
   Dittrich ATM, 2023, APPL SCI BASEL, V13, DOI 10.3390/app13074491
   Elsharkasi HM, 2022, ENDOCR CONNECT, V11, DOI 10.1530/EC 22 0034
   Ferrar L, 2008, J BONE MINER RES, V23, P103, DOI [10.1359/jbmr.070902, 10.1359/JBMR.070902]
   Gao JJ, 2016, ONCOTARGET, V7, P26966, DOI 10.18632/oncotarget.9034
   GENANT HK, 1993, J BONE MINER RES, V8, P1137, DOI 10.1002/jbmr.5650080915
   Guglieri M, 2022, JAMA NEUROL, V79, P1005, DOI 10.1001/jamaneurol.2022.2480
   Guglieri M, 2022, JAMA J AM MED ASSOC, V327, P1456, DOI 10.1001/jama.2022.4315
   Hamoudi D, 2019, HUM MOL GENET, V28, P3101, DOI 10.1093/hmg/ddz124
   Henderson RC, 2010, J BONE MINER RES, V25, P520, DOI 10.1359/jbmr.091007
   Hensel N, 2020, HUM MOL GENET, V29, P2662, DOI 10.1093/hmg/ddaa145
   Jiménez Moreno AC, 2018, NEUROMUSCULAR DISORD, V28, P229, DOI 10.1016/j.nmd.2017.12.010
   Joseph S, 2019, NEUROMUSCULAR DISORD, V29, P59, DOI 10.1016/j.nmd.2018.09.005
   Kalkwarf HJ, 2022, J BONE MINER RES, V37, P776, DOI 10.1002/jbmr.4520
   Karras NA, 2013, J CLIN ONCOL, V31, pE200, DOI 10.1200/JCO.2012.46.4255
   Khatri Ismail A, 2008, J Clin Neuromuscul Dis, V10, P11, DOI 10.1097/CND.0b013e318183e0fa
   Kim SW, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 45591 4
   Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586 013 2715 7
   Lee SLK, 2020, HORM RES PAEDIAT, V93, P108, DOI 10.1159/000508290
   Loscalzo E, 2024, OSTEOPOROSIS INT, V35, P327, DOI 10.1007/s00198 023 06951 z
   Mah JK, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.44178
   Marcadet L, 2023, CELLS BASEL, V12, DOI 10.3390/cells12111538
   McCarthy C, 2021, MICROMACHINES BASEL, V12, DOI 10.3390/mi12121488
   Mercuri E, 2018, NEUROMUSCULAR DISORD, V28, P103, DOI 10.1016/j.nmd.2017.11.005
   Misof BM, 2016, J BONE MINER RES, V31, P1060, DOI 10.1002/jbmr.2756
   Moretti A, 2022, ADV THER, V39, P3308, DOI 10.1007/s12325 022 02179 1
   Papadimas G, 2012, INT J ENDOCRINOL MET, V10, DOI 10.5812/ijem.4967
   Passeri E, 2020, NEUROMUSCULAR DISORD, V30, P28, DOI 10.1016/j.nmd.2019.11.006
   Pedrazzani PS, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 79168 3
   Phung K, 2023, OSTEOPOROSIS INT, V34, P147, DOI 10.1007/s00198 022 06578 6
   Piette AB, 2018, CURR OSTEOPOROS REP, V16, P541, DOI 10.1007/s11914 018 0468 2
   Pouwels S, 2014, MUSCLE NERVE, V50, P919, DOI 10.1002/mus.24240
   Querin G, 2016, J NEUROL NEUROSUR PS, V87, P810, DOI 10.1136/jnnp 2015 311305
   Rutter MM, 2020, MUSCLE NERVE, V61, P623, DOI 10.1002/mus.26846
   Schündeln MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151936
   Semler O, 2012, J MUSCULOSKEL NEURON, V12, P183
   Shanmugarajan S, 2009, J PATHOL, V219, P52, DOI 10.1002/path.2566
   Sheng Bun, 2017, BMC Res Notes, V10, P351, DOI 10.1186/s13104 017 2681 y
   Sherlock SP, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 23072 5
   Shevroja E, 2023, OSTEOPOROSIS INT, V34, P1501, DOI 10.1007/s00198 023 06817 4
   Shuhart CR, 2019, J CLIN DENSITOM, V22, P453, DOI 10.1016/j.jocd.2019.07.001
   Soini V, 2023, J PEDIATR ORTHOPED, V43, P431, DOI 10.1097/BPO.0000000000002422
   Starosta A, 2021, CELL MOL LIFE SCI, V78, P4867, DOI 10.1007/s00018 021 03821 x
   Summer SS, 2021, MUSCLE NERVE, V63, P231, DOI 10.1002/mus.27107
   Swolin Eide D, 2020, CURR OSTEOPOROS REP, V18, P471, DOI 10.1007/s11914 020 00608 0
   Tian C, 2014, NEUROMUSCULAR DISORD, V24, P857, DOI 10.1016/j.nmd.2014.06.213
   Tung Joanna Yuet Ling, 2023, J Bone Metab, V30, P319, DOI 10.11005/jbm.2023.30.4.319
   Tung JYL, 2021, J BONE MINER METAB, V39, P606, DOI 10.1007/s00774 020 01196 w
   Vai S, 2015, BONE, V79, P116, DOI 10.1016/j.bone.2015.05.039
   van den Berg LEM, 2010, BONE, V47, P643, DOI 10.1016/j.bone.2010.06.021
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Vincze A, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03448 2
   Ward LM, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz294
   Ward LM, 2019, CURR OPIN ENDOCRINOL, V26, P39, DOI 10.1097/MED.0000000000000456
   Ward LM, 2018, PEDIATRICS, V142, pS34, DOI 10.1542/peds.2018 0333E
   Wasserman HM, 2017, NEUROMUSCULAR DISORD, V27, P331, DOI 10.1016/j.nmd.2017.01.019
   Weber DR, 2019, J CLIN DENSITOM, V22, P567, DOI 10.1016/j.jocd.2019.07.002
   Weber DR, 2018, PEDIATRICS, V142, pS43, DOI 10.1542/peds.2018 0333F
   Weber DR, 2019, J Clin Densitom
   Wood CL, 2023, ENDOCR CONNECT, V12, DOI 10.1530/EC 23 0245
   Wood CL, 2021, EUR J ENDOCRINOL, V184, P67, DOI 10.1530/EJE 20 0709
   Yeh JH, 2014, NEUROLOGY, V83, P1075, DOI 10.1212/WNL.0000000000000804
NR 88
TC 3
Z9 3
U1 0
U2 0
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960 8966
EI 1873 2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2024
VL 43
BP 1
EP 13
DI 10.1016/j.nmd.2024.07.009
EA AUG 2024
PG 13
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA E1E7L
UT WOS:001300514000001
PM 39173540
DA 2025 08 17
ER

PT J
AU Park, B
AF Park, Byoungduck
TI Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL
   signaling and human cancer cells
SO BIOCHIMIE
LA English
DT Article
DE Triptolide; RANKL; Osteoclastogenesis; NF kappa B; Bone resorption
ID NF KAPPA B; TUMOR NECROSIS FACTOR; FORMATION IN VITRO; RECEPTOR
   ACTIVATOR; BREAST CANCER; MYELOMA CELLS; OSTEOPROTEGERIN LIGAND;
   INFLAMMATORY ARTHRITIS; BONE DISEASE; DIFFERENTIATION
AB Most bone related diseases are characterized by excessive bone resorption by osteoclasts. Receptor activator of nuclear factor kappa B (NF kappa B) ligand (RANKL) has emerged as a major mediator of bone resorption, commonly associated with cancer and chronic inflammatory diseases. Thus inhibitors of RANKL signaling have a potential in preventing bone loss. In the present study, we investigated the ability of triptolide, a diterpenoid isolated from Thunder of God Vine, to inhibit signaling by receptor activator of NF kappa B (RANK) and its ligand (RANKL) and to modulate osteoclastogenesis induced by RANKL and human cancer cells. We found that triptolide suppressed RANKL induced differentiation of precursor cells to osteoclasts, and also inhibited osteoclast formation induced by human breast tumor cells (MDA MB 231), multiple myeloma cells (U266) and prostate tumor cells (PC 3). Triptolide inhibited RANKL induced NF kappa B activation in osteoclast precursor cells by inhibiting I kappa B alpha kinase activation, I kappa B alpha phosphorylation, and I kappa B alpha degradation. Our results suggest that triptolide effectively inhibits RANKL induced NF kappa B activation and RANKL  and tumor cell induced osteoclastogenesis. This warrants further study of triptolide as a potential therapy for osteoporosis and cancer associated bone loss. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 Keimyung Univ, Coll Pharm, Taegu 704701, South Korea.
C3 Keimyung University
RP Park, B (通讯作者)，Keimyung Univ, Coll Pharm, Taegu 704701, South Korea.
EM bdpark@kmu.ac.kr
FU College of Pharmacy specialized Research Fund (from the Institute for
   New Drug Development) of Keimyung University; National Research
   Foundation of Korea (NRF)   Ministry of Science, ICT & Future Planning
   [NRF 2013R1A1A1062064]
FX I thank to Dr. Aggarwal, the Ransom Home, Jr., Professor of Cancer
   Research at MD Anderson Cancer Center, for great supervising. This work
   was supported by College of Pharmacy specialized Research Fund (from the
   Institute for New Drug Development) of Keimyung University and supported
   by Basic Science Research Program through the National Research
   Foundation of Korea (NRF) funded by the Ministry of Science, ICT &
   Future Planning (NRF 2013R1A1A1062064).
CR Abu Amer Y, 2001, J BIOL CHEM, V276, P30499, DOI 10.1074/jbc.M104725200
   Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003
   Bharti AC, 2004, BLOOD, V103, P3175, DOI 10.1182/blood 2003 06 2151
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101
   Boyce BF, 1999, BONE, V25, P137, DOI 10.1016/S8756 3282(99)00105 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200
   Chikatsu N, 2000, BIOCHEM BIOPH RES CO, V267, P632, DOI 10.1006/bbrc.1999.2008
   Clohisy JC, 2003, J IMMUNOL, V171, P5547, DOI 10.4049/jimmunol.171.10.5547
   COLEMAN RE, 1987, BRIT J CANCER, V55, P61, DOI 10.1038/bjc.1987.13
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Giuliani N, 2001, BLOOD, V98, P3527, DOI 10.1182/blood.V98.13.3527
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jimi E, 1999, J IMMUNOL, V163, P434
   Kobayashi Y, 2005, J BIOL CHEM, V280, P11395, DOI 10.1074/jbc.M411189200
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lai FPL, 2004, BRIT J HAEMATOL, V126, P192, DOI 10.1111/j.1365 2141.2004.05018.x
   LOTSOVA V, 1997, NAT MED, V3, P1285
   Mancino AT, 2001, J SURG RES, V100, P18, DOI 10.1006/jsre.2001.6204
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Pajonk F, 1999, J NATL CANCER I, V91, P1956, DOI 10.1093/jnci/91.22.1956
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304 3835(96)04554 5
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang W, 2007, CLIN CANCER RES, V13, P4891, DOI 10.1158/1078 0432.CCR 07 0416
   Wei S, 2001, ENDOCRINOLOGY, V142, P1290, DOI 10.1210/en.142.3.1290
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Yang SM, 2003, MOL CANCER THER, V2, P65
   Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhao GH, 2000, AM J PHYSIOL LUNG C, V279, pL958, DOI 10.1152/ajplung.2000.279.5.L958
   Zhao X., J EXP CLIN CANC RES, V30, P22
   Zhou HF, 2003, NEUROREPORT, V14, P1091, DOI 10.1097/01.wnr.0000073682.00308.47
NR 45
TC 24
Z9 28
U1 1
U2 12
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0300 9084
EI 1638 6183
J9 BIOCHIMIE
JI Biochimie
PD OCT
PY 2014
VL 105
BP 129
EP 136
DI 10.1016/j.biochi.2014.07.003
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA AQ7TP
UT WOS:000343022400015
PM 25047443
DA 2025 08 17
ER

PT J
AU Hu, B
   Chen, YM
   Li, YM
   Deng, CY
   Niu, YT
   Hu, ZW
   Li, Y
   Sun, SY
   Huang, Y
   Deng, XL
   Wei, Y
AF Hu, Bo
   Chen, Yiming
   Li, Yuman
   Deng, Chenyu
   Niu, Yuting
   Hu, Zhewen
   Li, Yao
   Sun, Shiyu
   Huang, Ying
   Deng, Xuliang
   Wei, Yan
TI Substrate Mediated Regulation of Src Expression Drives
   Osteoclastogenesis Divergence
SO GENES
LA English
DT Article
DE osteoclastogenesis; substrate; Src; cytoskeletal remodeling; oxidative
   phosphorylation (OXPHOS)
ID RANKL INDUCED OSTEOCLAST; BONE; DIFFERENTIATION; TOPOGRAPHY; MECHANISM
AB Background/Objectives: Glass, bone, and dentin are commonly applied substrates for osteoclast cultures; however, the impact of these substrates on osteoclastogenesis remains underexplored. This study aimed to address a significant gap in understanding how different substrates influence the process of osteoclastogenesis. Methods: RAW 264.7 cells were cultured and induced with RANKL on glass, bone, and dentin slides. Histological and molecular techniques were used to identify patterns and differences in osteoclast behavior on each substrate. Results: Osteoclasts cultured on glass slides possessed the greatest number of nuclei and the highest expression levels of ACP5 (TRAP) and CTSK, with osteoclasts on bone and dentin slides displaying progressively lower levels. Src expression was also most pronounced in osteoclasts on glass slides, with decreased levels observed on bone and dentin. This variation in Src expression likely contributed to differences in cytoskeletal remodeling and oxidative phosphorylation (OXPHOS), resulting in substrate dependent divergences in osteoclastogenesis. Conclusions: Glass slides were the most favorable substrate for inducing osteoclastogenesis, while bone and dentin slides were less effective. The substrate induced expression of Src played a fundamental role in shaping the phenotypic divergence of osteoclasts. These insights fill important knowledge gaps and have significant implications for the development and selection of in vitro models for bone related diseases and drug screening platforms.
C1 [Hu, Bo; Chen, Yiming; Li, Yuman; Niu, Yuting; Hu, Zhewen; Li, Yao; Huang, Ying; Deng, Xuliang; Wei, Yan] Peking Univ, Sch & Hosp Stomatol, Dept Geriatr Dent, Beijing 100081, Peoples R China.
   [Hu, Bo; Chen, Yiming; Li, Yuman; Deng, Chenyu; Niu, Yuting; Hu, Zhewen; Li, Yao; Sun, Shiyu; Huang, Ying; Deng, Xuliang; Wei, Yan] Natl Ctr Stomatol, Beijing 100081, Peoples R China.
   [Hu, Bo; Chen, Yiming; Li, Yuman; Deng, Chenyu; Niu, Yuting; Hu, Zhewen; Li, Yao; Sun, Shiyu; Huang, Ying; Deng, Xuliang; Wei, Yan] Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.
   [Hu, Bo; Chen, Yiming; Li, Yuman; Deng, Chenyu; Niu, Yuting; Hu, Zhewen; Li, Yao; Sun, Shiyu; Huang, Ying; Deng, Xuliang; Wei, Yan] Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing 100081, Peoples R China.
   [Hu, Bo; Chen, Yiming; Niu, Yuting; Li, Yao] Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, Beijing 100081, Peoples R China.
   [Deng, Chenyu] Peking Univ, Sch & Hosp Stomatol, Dept Orthodont, Beijing 100081, Peoples R China.
   [Sun, Shiyu] Peking Univ, Sch & Hosp Stomatol, Dept Gen Dent, Beijing 100081, Peoples R China.
C3 Peking University; Peking University; Peking University; Peking
   University
RP Wei, Y (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Geriatr Dent, Beijing 100081, Peoples R China.; Wei, Y (通讯作者)，Natl Ctr Stomatol, Beijing 100081, Peoples R China.; Wei, Y (通讯作者)，Natl Clin Res Ctr Oral Dis, Beijing 100081, Peoples R China.; Wei, Y (通讯作者)，Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing 100081, Peoples R China.
EM klluobu@163.com; chenym@pku.edu.cn; kqliyuman@bjmu.edu.cn;
   dengchenyu@pku.edu.cn; niuyt698@163.com; philip0323@163.com;
   liyao2018@126.com; shiyu_yeo@sina.com; hying031129@163.com;
   kqdengxuliang@bjmu.edu.cn; kqweiyan@bjmu.edu.cn
OI Deng, Xuliang/0000 0003 1838 6274; Niu, Yuting/0000 0002 6740 7767
FU National Natural Science Foundation of China;  [U22A20160];  [82221003]
FX This research was supported by the National Natural Science Foundation
   of China (U22A20160, 82221003).
CR Brown MT, 1996, BBA REV CANCER, V1287, P121, DOI 10.1016/0304 419X(96)00003 0
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Condorelli F, 2011, CURR MED CHEM, V18, P2913, DOI 10.2174/092986711796150522
   Costa DO, 2013, BIOMATERIALS, V34, P7215, DOI 10.1016/j.biomaterials.2013.06.014
   Cramer EEA, 2021, CURR OSTEOPOROS REP, V19, P75, DOI 10.1007/s11914 020 00649 5
   Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111
   Das BK, 2022, ELIFE, V11, DOI 10.7554/eLife.73539
   Duong L, 2000, MATRIX BIOL, V19, P97, DOI 10.1016/S0945 053X(00)00051 2
   Geblinger D, 2010, J CELL SCI, V123, P1503, DOI 10.1242/jcs.060954
   Granot Attas S, 2008, EUR J CELL BIOL, V87, P479, DOI 10.1016/j.ejcb.2008.01.006
   Gyori DS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00507
   Harigaya H, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25147651
   He YD, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951 022 01721 1
   Hojjat Farsangi M, 2016, J DRUG TARGET, V24, P192, DOI 10.3109/1061186X.2015.1068319
   Lampiasi N, 2021, BIOLOGY BASEL, V10, DOI 10.3390/biology10020117
   Lau RYC, 2011, J OSTEOPOROS, V2011, DOI 10.4061/2011/293808
   Lemma S, 2016, INT J BIOCHEM CELL B, V79, P168, DOI 10.1016/j.biocel.2016.08.034
   McHugh KP, 2010, ANN RHEUM DIS, V69, P83, DOI 10.1136/ard.2009.120188
   Minetti E, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14050272
   Miyazaki T, 2003, J CELL BIOL, V160, P709, DOI 10.1083/jcb.200209098
   Nakamura I, 2003, J ELECTRON MICROSC, V52, P527, DOI 10.1093/jmicro/52.6.527
   Nakamura I, 2007, J BONE MINER METAB, V25, P337, DOI 10.1007/s00774 007 0773 9
   Park Y, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 44000 9
   Park Min KH, 2019, SEMIN IMMUNOPATHOL, V41, P565, DOI 10.1007/s00281 019 00757 0
   Rashid S, 2023, GENES BASEL, V14, DOI 10.3390/genes14040916
   Reuven Nina, 2024, Methods Mol Biol, V2743, P57, DOI 10.1007/978 1 0716 3569 8_4
   Rody WJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219602
   Rumpler M, 2013, CALCIFIED TISSUE INT, V93, P526, DOI 10.1007/s00223 013 9786 7
   Shalev M, 2019, BBA MOL CELL RES, V1866, P114, DOI 10.1016/j.bbamcr.2018.07.005
   Shemesh M, 2017, J R SOC INTERFACE, V14, DOI 10.1098/rsif.2016.0958
   Soe K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207717
   Solouki S, 2019, PHARMACOL THERAPEUT, V201, P39, DOI 10.1016/j.pharmthera.2019.05.008
   Song CC, 2019, J CELL PHYSIOL, V234, P11969, DOI 10.1002/jcp.27852
   Sun Q, 2020, BIOMECH MODEL MECHAN, V19, P481, DOI 10.1007/s10237 019 01223 4
   Susa Mira, 2004, J Transl Med, V2, P6, DOI 10.1186/1479 5876 2 6
   TEITELBAUM SL, 1993, J BONE MINER RES, V8, pS523
   Wang QX, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13172
   Yang JX, 2019, METHODS MOL BIOL, V1882, P143, DOI 10.1007/978 1 4939 8879 2_12
   Yao ZQ, 2008, J BIOL CHEM, V283, P9917, DOI 10.1074/jbc.M706415200
   Zeng XZ, 2016, ACTA PHARMACOL SIN, V37, P255, DOI 10.1038/aps.2015.85
NR 40
TC 1
Z9 1
U1 10
U2 13
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2073 4425
J9 GENES BASEL
JI Genes
PD SEP
PY 2024
VL 15
IS 9
AR 1217
DI 10.3390/genes15091217
PG 16
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI EXPANDED)
SC Genetics & Heredity
GA H4C9P
UT WOS:001322950200001
PM 39336808
OA gold
DA 2025 08 17
ER

PT J
AU Lorenzo Pouso, AI
   Pérez Sayáns, M
   García, A
   Carballo, J
AF Lorenzo Pouso, Alejandro I.
   Perez Sayans, Mario
   Garcia, Abel
   Carballo, Javier
TI Vitamin D supplementation: Hypothetical effect on medication related
   osteonecrosis of the jaw
SO MEDICAL HYPOTHESES
LA English
DT Article
DE Osteonecrosis; Vitamin; Supplementation; Osteoporosis; Biphosphonates
ID BISPHOSPHONATE RELATED OSTEONECROSIS; BONE MINERAL DENSITY; D BINDING
   PROTEIN; PERIODONTAL DISEASE; DNA METHYLATION; INFLAMMATORY RESPONSE;
   MULTIPLE MYELOMA; D DEFICIENCY; TASK FORCE; CANCER
AB Vitamin D is an important nutrient for bone health and skeleton growth. Few foods are natural sources of this secosteroid; this is the reason why the consumption of vitamin D as a dietary supplement is becoming common in developed countries. For many years vitamin D has been considered crucial in the treatment and prevention of the Global Burden of Disease and in a reduction in mortality among elder people. Many health care providers prescribe these supplements in the management of osteoporosis and metabolic bone diseases; specifically in the primary prevention of fractures. Recently medication related osteonecrosis of the jaw (MRONJ) has been reported as severe late sequelae of antiresorptive therapies (i.e., bisphosphonates and some monoclonal antibodies). Although MRONJ related pathophysiology is not fully understood, there are three fundamental theories to explain it: (1) the inhibition of osteoclasts, (2) the inhibition of angiogenesis and (3) the processes of inflammation infection. Recent advances in Vitamin D research have shown that this secosteroid can play a potential pivotal role in many of the different etiological pathways of MRONJ. Furthermore, there are a large number of co morbidities between the deficit of this vitamin and other MRONJ concomitant outcomes. Our hypothesis argues that the low risk and low cost vitamin D dietary supplementation may prove to be suitable for use as a practical MRONJ prevention strategy. The described framework gives more insight into the study of disease mechanisms, search of potential biomarkers, and therapeutic targets in MRONJ.
C1 [Lorenzo Pouso, Alejandro I.; Perez Sayans, Mario; Garcia, Abel] Univ Santiago de Compostela, Fac Med & Odontol, Sch Dent, Oral Med Oral Surg & Implantol Unit, Santiago De Compostela, Spain.
   [Lorenzo Pouso, Alejandro I.; Perez Sayans, Mario; Garcia, Abel] Hlth Res Inst Santiago De Compostela IDIS, Res Grp GI 1319, Santiago De Compostela, Spain.
   [Carballo, Javier] Univ Vigo, Fac Sci, Dept Food Technol, Ourense Campus, Orense, Spain.
C3 Universidade de Santiago de Compostela; Complexo Hospitalario
   Universitario de Santiago de Compostela; Universidade de Vigo
RP Lorenzo Pouso, AI (通讯作者)，Univ Santiago de Compostela, Fac Med & Odontol, Oral Med Oral Surg & Implantol Unit, Rua Entrerrios S N, Santiago De Compostela 15782, Spain.
EM alexlopo@hotmail.com
RI Garcia Garcia, Abel/L 1815 2014; Perez Sayans, Mario/L 1345 2014; Pouso,
   Alejandro/AAT 2208 2021; Carballo, Javier/AAD 6647 2019; Pérez Sayáns,
   Mario/L 1345 2014
OI Perez Sayans, Mario/0000 0003 2196 9868; Garcia Garcia,
   Abel/0000 0002 5911 5537; Lorenzo Pouso, Alejandro
   Ismael/0000 0002 9180 4703; Carballo, Javier/0000 0002 3737 9830
FU Health Research Institute of Santiago de Compostela (IDIS)
FX Alejandro I. Lorenzo Pouso is recipient of a fellowship from Health
   Research Institute of Santiago de Compostela (IDIS).
CR Abtahi J, 2012, J ORAL PATHOL MED, V41, P494, DOI 10.1111/j.1600 0714.2011.01125.x
   Alvarez Errico D, 2017, FRONT IMMUNOL, V8, DOI [10.3389/fimmu.2017.00318, 10.3389/fpsyg.2017.00904, 10.3389/fmicb.2017.00809]
   [Anonymous], EUR J CLIN NUTR
   Ardine M, 2006, ANN ONCOL, V17, P1336, DOI 10.1093/annonc/mdl045
   Bagan J, 2014, J ORAL PATHOL MED, V43, P371, DOI 10.1111/jop.12151
   Bagan J, 2009, ORAL ONCOL, V45, P551, DOI 10.1016/j.oraloncology.2009.01.002
   Balion C, 2012, NEUROLOGY, V79, P1397, DOI 10.1212/WNL.0b013e31826c197f
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Basi DL, 2011, J ORAL MAXIL SURG, V69, P2698, DOI 10.1016/j.joms.2011.02.065
   Bedogni A, 2012, ONCOLOGIST, V17, P1114, DOI 10.1634/theoncologist.2012 0141
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Bjelakovic G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007470.pub3
   Bolland MJ, 2014, LANCET DIABETES ENDO, V2, P307, DOI 10.1016/S2213 8587(13)70212 2
   Bruggmann D, 2018, NUTR J, V17
   Cackowski FC, 2010, BLOOD, V115, P140, DOI 10.1182/blood 2009 08 237628
   Cannell JJ, 2014, DERM ENDOCRINOL, V6, DOI 10.4161/19381980.2014.983401
   Catalano A, 2012, CALCIFIED TISSUE INT, V90, P279, DOI 10.1007/s00223 012 9577 6
   Chapurlat RD, 2007, J BONE MINER RES, V22, P1502, DOI 10.1359/JBMR.070609
   D'Aiuto F, 2007, J CLIN PERIODONTOL, V34, P124, DOI 10.1111/j.1600 051X.2006.01037.x
   Davis EE, 2007, J NATL MED ASSOC, V99, P658
   De Filippis A, 2017, INT IMMUNOPHARMACOL, V47, P106, DOI 10.1016/j.intimp.2017.03.021
   Dietrich T, 2004, AM J CLIN NUTR, V80, P108
   Diz P, 2012, MED HYPOTHESES, V78, P315, DOI 10.1016/j.mehy.2011.11.011
   English BC, 2010, THER CLIN RISK MANAG, V6, P579, DOI 10.2147/TCRM.S14303
   Fan JX, 2018, CLIN CHIM ACTA, V477, P135, DOI 10.1016/j.cca.2017.12.015
   Fung PPL, 2017, ORAL DIS, V23, P477, DOI 10.1111/odi.12632
   Gil A, 2018, ANN NUTR METAB, V72, P87, DOI 10.1159/000486536
   Hamadeh IS, 2015, CANCER TREAT REV, V41, P455, DOI 10.1016/j.ctrv.2015.04.007
   Hennig BJW, 1999, J PERIODONTOL, V70, P1032, DOI 10.1902/jop.1999.70.9.1032
   Hidalgo AA, 2011, J BIOL CHEM, V286, P36228, DOI 10.1074/jbc.M111.244061
   Hoefert S, 2010, CLIN ORAL INVEST, V14, P271, DOI 10.1007/s00784 009 0300 6
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Holick MF, 2017, ADV EXP MED BIOL, V996, P137, DOI 10.1007/978 3 319 56017 5_12
   Holick MF, 2014, LANCET DIABETES ENDO, V2, P273, DOI 10.1016/S2213 8587(14)70044 0
   Howie RN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132520
   Hujoel PP, 2017, J CLIN PERIODONTOL, V44, pS79, DOI 10.1111/jcpe.12672
   Jamali N., 2017, AM J PHYSL HEART CIR
   Kantor ED, 2016, JAMA J AM MED ASSOC, V316, P1464, DOI 10.1001/jama.2016.14403
   Karras SN, 2014, LANCET, V383, P1292, DOI 10.1016/S0140 6736(14)60640 1
   Khan AA, 2017, J CLIN DENSITOM, V20, P8, DOI 10.1016/j.jocd.2016.09.005
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Kim JW, 2016, CLIN ORAL INVEST, V20, P2251, DOI 10.1007/s00784 016 1718 2
   Kim JW, 2013, BONE, V57, P201, DOI 10.1016/j.bone.2013.08.005
   Laird E, 2014, J CLIN ENDOCR METAB, V99, P1807, DOI 10.1210/jc.2013 3507
   Lappe J, 2017, JAMA J AM MED ASSOC, V317, P1234, DOI 10.1001/jama.2017.2115
   Lee JJ, 2013, HEAD NECK J SCI SPEC, V35, P1787, DOI 10.1002/hed.23235
   Lézot F, 2002, CONNECT TISSUE RES, V43, P509, DOI [10.1080/713713496, 10.1080/03008200290000583]
   Li H, 2014, CHIN J DENT RES, V17, P91, DOI 10.3290/j.cjdr.a33271
   Ma SL, 2017, DNA CELL BIOL, V36, P1134, DOI 10.1089/dna.2017.3817
   Malik S, 2013, CRIT REV CL LAB SCI, V50, P1, DOI 10.3109/10408363.2012.750262
   Manson JE, 2016, NEW ENGL J MED, V375, P1817, DOI 10.1056/NEJMp1608005
   McGowan K., 2017, ORAL DIS
   Meyer V, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01048
   Mondul AM, 2017, EPIDEMIOL REV, V39, P28, DOI 10.1093/epirev/mxx005
   Muscogiuri G, 2017, ARCH TOXICOL, V91, P97, DOI 10.1007/s00204 016 1804 x
   Nahas Neto J, 2018, OSTEOPOROS INT
   Nair R, 2012, J PHARMACOL PHARMACO, V3, P118, DOI 10.4103/0976 500X.95506
   Nakashima A, 2016, WORLD J DIABETES, V7, P89, DOI 10.4239/wjd.v7.i5.89
   Norman AW, 2008, AM J CLIN NUTR, V88, p491S, DOI 10.1093/ajcn/88.2.491S
   Pilz S, 2018, ANTICANCER RES, V38, P1145, DOI 10.21873/anticanres.12333
   Pludowski P, 2018, J STEROID BIOCHEM, V175, P125, DOI 10.1016/j.jsbmb.2017.01.021
   Polidoro S, 2013, MUTAT RES GEN TOX EN, V757, P104, DOI 10.1016/j.mrgentox.2013.07.003
   Powe CE, 2013, NEW ENGL J MED, V369, P1991, DOI 10.1056/NEJMoa1306357
   Quispe D, 2011, BREAST J, V17, P510, DOI 10.1111/j.1524 4741.2011.01119.x
   Ramos Martinez E, 2018, CYTOKINE
   Reid IR, 2017, ENDOCRIN METAB CLIN, V46, P935, DOI 10.1016/j.ecl.2017.07.005
   Reid IR, 2012, NAT REV RHEUMATOL, V8, P90, DOI 10.1038/nrrheum.2011.181
   Reid IR, 2009, BONE, V44, P4, DOI 10.1016/j.bone.2008.09.012
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Saito M, 2015, BONE, V73, P8, DOI 10.1016/j.bone.2014.11.025
   Saito M, 2011, CALCIFIED TISSUE INT, V88, P314, DOI 10.1007/s00223 011 9472 6
   Sánchez A, 2017, OSTEOPOROSIS INT, V28, P1145, DOI 10.1007/s00198 016 3840 z
   Sánchez Diz P, 2009, PHARMACOGENOMICS J, V9, P306, DOI 10.1038/tpj.2009.16
   Sarasquete ME, 2008, BLOOD, V112, P2709, DOI 10.1182/blood 2008 04 147884
   Sulimani RA, 2017, ARCH OSTEOPOROS, V12
   Thaler R, 2013, BIOCHEM PHARMACOL, V85, P173, DOI 10.1016/j.bcp.2012.10.016
   Thumbigere Math V, 2014, J PERIODONTOL, V85, P226, DOI 10.1902/jop.2013.130017
   Timms PM, 2002, QJM INT J MED, V95, P787, DOI 10.1093/qjmed/95.12.787
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   Vermeer JAF, 2016, CURR OSTEOPOROS REP, V14, P219, DOI 10.1007/s11914 016 0318 z
   Vincenzi B, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756 8722 5 56
   Wang SM, 2017, EPIGENETICS US, V12, P187, DOI 10.1080/15592294.2016.1273308
   Won Yougun, 2014, J Bone Metab, V21, P155, DOI 10.11005/jbm.2014.21.2.155
   Yazdi PM, 2015, OR SURG OR MED OR PA, V119, P416, DOI 10.1016/j.oooo.2014.12.024
   Yin GZ, 2011, MED HYPOTHESES, V76, P347, DOI 10.1016/j.mehy.2010.10.036
   Zervas K, 2006, BRIT J HAEMATOL, V134, P620, DOI 10.1111/j.1365 2141.2006.06230.x
   Zhong DN, 2013, ACTA HAEMATOL BASEL, V129, P90, DOI 10.1159/000342120
   Zhou Y, 2014, J STEROID BIOCHEM, V144, P207, DOI 10.1016/j.jsbmb.2013.10.004
NR 89
TC 5
Z9 7
U1 0
U2 16
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0306 9877
EI 1532 2777
J9 MED HYPOTHESES
JI Med. Hypotheses
PD JUL
PY 2018
VL 116
BP 79
EP +
DI 10.1016/j.mehy.2018.04.023
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA GL7HJ
UT WOS:000437368200016
PM 29857915
DA 2025 08 17
ER

PT J
AU Jin, NQ
   Jin, N
   Wang, ZL
   Liu, LL
   Meng, L
   Li, DW
   Li, X
   Zhou, DB
   Liu, J
   Bu, WH
   Sun, HC
   Yang, B
AF Jin, Nianqiang
   Jin, Nuo
   Wang, Zilin
   Liu, Lili
   Meng, Lin
   Li, Daowei
   Li, Xing
   Zhou, Dabo
   Liu, Jie
   Bu, Wenhuan
   Sun, Hongchen
   Yang, Bai
TI Osteopromotive carbon dots promote bone regeneration through the
   PERK eIF2α ATF4 pathway
SO BIOMATERIALS SCIENCE
LA English
DT Article
ID ENDOPLASMIC RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; REGULATES
   OSTEOBLAST DIFFERENTIATION; ER STRESS; QUANTUM DOTS; HYDROTHERMAL
   SYNTHESIS; STEM CELLS; APOPTOSIS; PROLIFERATION; MECHANISM
AB Bone defects are still an unsolved clinical issue that must be overcome. Carbon dots have shown very promising effects in biological therapy. In the current study, we explored their effects on osteogenesis. Furthermore, we revealed the mechanisms in order to develop novel therapeutic approaches to manage the bone defect. For this study, ascorbic acid carbon dots (CDs) were created by a one step microwave assisted method. Results showed that the CDs effectively enhanced matrix mineralization, promoted osteogenic differentiation in vitro, and promoted new bone regeneration in the skull defect model in vivo. Furthermore, our data demonstrated that the ER stress and PERK eIF2 alpha ATF4 pathway were activated by the CD induced increase in intracellular calcium. Taken together, our findings suggest that the PERK pathway plays a critical role in CD induced osteogenic differentiation, and the CDs created herein have the potential to be used to repair bone defects in clinical practice.
C1 [Jin, Nianqiang; Jin, Nuo; Li, Xing; Sun, Hongchen] China Med Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Shenyang 110001, Peoples R China.
   [Wang, Zilin; Liu, Lili; Meng, Lin] Jilin Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Changchun 130000, Peoples R China.
   [Li, Daowei] Jilin Univ, Sch Stomatol, Jilin Prov Key Lab Tooth Dev & Bone Remodeling, Changchun 130021, Peoples R China.
   [Zhou, Dabo] China Med Univ, Sch & Hosp Stornatol, 117 Nanjing North St, Shenyang 130021, Peoples R China.
   [Liu, Jie] Wuhan Univ, Sch Stomatol, Dept Head & Neck Tumor Surg, Wuhan 430000, Peoples R China.
   [Bu, Wenhuan] China Med Univ, Sch Stomatol, Dept Dent Mat, Shenyang 110001, Peoples R China.
   [Bu, Wenhuan] China Med Univ, Dept Ctr Lab, Sch Stomatol, Shenyang 110001, Peoples R China.
   [Yang, Bai] Jilin Univ, State Key Lab Supramol Struct & Mat, Coll Chem, Changchun 130012, Peoples R China.
C3 China Medical University; Jilin University; Jilin University; China
   Medical University; Wuhan University; China Medical University; China
   Medical University; Jilin University
RP Sun, HC (通讯作者)，China Med Univ, Sch & Hosp Stomatol, Dept Oral Pathol, Shenyang 110001, Peoples R China.; Bu, WH (通讯作者)，China Med Univ, Sch Stomatol, Dept Dent Mat, Shenyang 110001, Peoples R China.; Bu, WH (通讯作者)，China Med Univ, Dept Ctr Lab, Sch Stomatol, Shenyang 110001, Peoples R China.
EM nqjin@cmu.edu.cn; 2435841770@qq.com; wangzl17@mails.jlu.edu.cn;
   llliu19@mails.jlu.edu.cn; 1609047433@qq.com; jluldw@jlu.edu.cn;
   lixing15@mails.jlu.edu.cn; dabozhou@126.com; a1991liujie@163.com;
   whbu@cmu.edu.cn; hcsun@jlu.edu.cn
RI Li, Daowei/X 7203 2019; Wang, Zilin/HTT 2378 2023; Liu,
   Lili/HHC 6357 2022; Yang, Bai/F 6483 2012
OI Li, Daowei/0000 0002 4848 9373; 
FU National Key R&D Program of China [2016YFC1102800]; National Natural
   Science Foundation of China [81870741]; China Postdoctoral Science
   Foundation [2019M661177]; Jilin Scientific and Technological Development
   Program [20170101093JC]; Provincial Industrial Innovation Project of
   Jilin Province [2016C044 3]
FX This work was supported by grants from the National Key R&D Program of
   China 2016YFC1102800, the National Natural Science Foundation of China
   (81870741), China Postdoctoral Science Foundation (2019M661177), Jilin
   Scientific and Technological Development Program (20170101093JC), and
   the Provincial Industrial Innovation Project of Jilin Province
   (2016C044 3).
CR [Anonymous], SCI REP
   Balsa E, 2019, MOL CELL, V74, P877, DOI 10.1016/j.molcel.2019.03.031
   Bartok A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 11646 3
   Basso V, 2020, CELL CALCIUM, V87, DOI 10.1016/j.ceca.2020.102186
   Chen FY, 2015, J MOL NEUROSCI, V55, P995, DOI 10.1007/s12031 014 0456 7
   Clarke WR, 2019, INT J CANCER, V144, P1367, DOI 10.1002/ijc.32012
   Dong YQ, 2012, ANAL CHEM, V84, P6220, DOI 10.1021/ac3012126
   Du JJ, 2019, SMALL, V15, DOI 10.1002/smll.201805087
   Feng T, 2016, ACS NANO, V10, P4410, DOI 10.1021/acsnano.6b00043
   Ghosh R, 2014, CELL, V158, P534, DOI 10.1016/j.cell.2014.07.002
   Gonen N., 2019, SCI REP, V9, P1
   Grayson WL, 2015, NAT REV ENDOCRINOL, V11, P140, DOI 10.1038/nrendo.2014.234
   Hammadi M, 2013, FASEB J, V27, P1600, DOI 10.1096/fj.12 218875
   He L, 2013, CELL SIGNAL, V25, P552, DOI 10.1016/j.cellsig.2012.11.015
   Hisanaga S., 2018, SCI REP, V8, P1
   IX Z., 2020, ENDOCRINOLOGY, V161, DOI [10.1210/endocr/bqz028, DOI 10.1210/ENDOCR/BQZ028]
   Jeon WJ, 2017, LIFE SCI, V178, P94, DOI 10.1016/j.lfs.2017.04.012
   Kim SH, 2019, CELLS BASEL, V8, DOI 10.3390/cells8091023
   Kumar V., 2013, FLUORESCENT CARBON N
   Kupsco A, 2015, INT REV CEL MOL BIO, V317, P1, DOI 10.1016/bs.ircmb.2015.02.002
   Laurencin CT, 2014, DRUG DISCOV TODAY, V19, P794, DOI 10.1016/j.drudis.2014.01.012
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Lee H, 2016, BMC CARDIOVASC DISOR, V16, DOI 10.1186/s12872 016 0404 2
   Lee HU, 2014, SCI REP UK, V4, DOI 10.1038/srep04665
   Li J, 2017, BONE, V97, P2, DOI 10.1016/j.bone.2016.12.009
   Li XN, 2014, BIOL TRACE ELEM RES, V158, P113, DOI 10.1007/s12011 014 9897 7
   Lim SY, 2015, CHEM SOC REV, V44, P362, DOI 10.1039/c4cs00269e
   Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778
   Liu F, 2015, DRUG DISCOV THER, V9, P38, DOI 10.5582/ddt.2015.01008
   Liu J, 2020, NANOMATERIALS BASEL, V10, DOI 10.3390/nano10010027
   Liu JJ, 2017, NANOSCALE, V9, P7135, DOI 10.1039/c7nr02128c
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Okubo Y, 2020, BIOCHEM BIOPH RES CO, V522, P1003, DOI 10.1016/j.bbrc.2019.12.006
   Okubo Y, 2019, GLIA, V67, P113, DOI 10.1002/glia.23531
   Peng ZL, 2017, COORDIN CHEM REV, V343, P256, DOI 10.1016/j.ccr.2017.06.001
   Ravichandran R, 2012, BIOMATERIALS, V33, P846, DOI 10.1016/j.biomaterials.2011.10.030
   Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200
   Saito A, 2011, J BIOL CHEM, V286, P4809, DOI 10.1074/jbc.M110.152900
   Sevier CS, 2002, NAT REV MOL CELL BIO, V3, P836, DOI 10.1038/nrm954
   Shao D, 2017, BIOMATER SCI UK, V5, P1820, DOI 10.1039/c7bm00358g
   Sharath Shankar S, 2020, Nanobiomaterial Engineering: Concepts their Appl Biomed Diagnostics, P49, DOI [10.1007/978 981 32 9840 83, DOI 10.1007/978 981 32 9840 83]
   Shi MQ, 2017, ACTA BIOMATER, V54, P175, DOI 10.1016/j.actbio.2017.03.018
   Sicari D, 2020, FEBS J, V287, P27, DOI 10.1111/febs.15107
   Son HE, 2018, LIFE SCI, V193, P34, DOI 10.1016/j.lfs.2017.12.008
   Sun F, 2014, TOXICOLOGY, V325, P52, DOI 10.1016/j.tox.2014.07.006
   Tao HQ, 2012, SMALL, V8, P281, DOI 10.1002/smll.201101706
   Tavasolian F, 2020, IUBMB LIFE, V72, P187, DOI 10.1002/iub.2154
   van Anken E, 2005, CRIT REV BIOCHEM MOL, V40, P191, DOI 10.1080/10409230591008161
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wu F, 2020, ACS APPL MATER INTER, V12, P10142, DOI 10.1021/acsami.0c00170
   Wu ZL, 2013, J MATER CHEM B, V1, P2868, DOI 10.1039/c3tb20418a
   Xia YN, 2008, NAT MATER, V7, P758, DOI 10.1038/nmat2277
   Xiao WC, 2018, J CELL PHYSIOL, V233, P6148, DOI 10.1002/jcp.26463
   Xiong ZY, 2015, INT J MOL SCI, V16, P21153, DOI 10.3390/ijms160921153
   Yang S., 2020, J MOL HISTOL, P1
   Yang SY, 2016, CELL SIGNAL, V28, P880, DOI 10.1016/j.cellsig.2016.04.003
   Yasui H, 2014, CANCER LETT, V347, P151, DOI 10.1016/j.canlet.2014.02.005
   Yoneshima E, 2016, J CELL PHYSIOL, V231, P1321, DOI 10.1002/jcp.25235
   Yu LY, 2018, EXP CELL RES, V362, P51, DOI 10.1016/j.yexcr.2017.11.001
   Zeng QH, 2016, J MATER CHEM B, V4, P5119, DOI 10.1039/c6tb01259k
   Zhang KF, 2019, AM J PHYSIOL ENDOC M, V316, pE590, DOI 10.1152/ajpendo.00371.2018
   Zhu SJ, 2015, NANO RES, V8, P355, DOI 10.1007/s12274 014 0644 3
   Zhu SJ, 2013, ANGEW CHEM INT EDIT, V52, P3953, DOI 10.1002/anie.201300519
NR 63
TC 26
Z9 26
U1 6
U2 125
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2047 4830
EI 2047 4849
J9 BIOMATER SCI UK
JI Biomater. Sci.
PD MAY 21
PY 2020
VL 8
IS 10
BP 2840
EP 2852
DI 10.1039/d0bm00424c
PG 13
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA LU4NP
UT WOS:000537734100007
PM 32307492
DA 2025 08 17
ER

PT J
AU Frieling, JS
   Tordesillas, L
   Bustos, XE
   Ramello, MC
   Bishop, RT
   Cianne, JE
   Snedal, SA
   Li, T
   Lo, CH
   de la Iglesia, J
   Roselli, E
   Benzaid, I
   Wang, XF
   Kim, Y
   Lynch, CC
   Abate Daga, D
AF Frieling, Jeremy S.
   Tordesillas, Leticia
   Bustos, Xiomar E.
   Ramello, Maria Cecilia
   Bishop, Ryan T.
   Cianne, Junior E.
   Snedal, Sebastian A.
   Li, Tao
   Lo, Chen Hao
   de la Iglesia, Janis
   Roselli, Emiliano
   Benzaid, Ismahene
   Wang, Xuefeng
   Kim, Youngchul
   Lynch, Conor C.
   Abate Daga, Daniel
TI γ6 Enriched CAR T cell therapy for bone metastatic castrate resistant
   prostate cancer
SO SCIENCE ADVANCES
LA English
DT Article
ID ZOLEDRONIC ACID; PHOSPHOANTIGEN LEVELS; ANTITUMOR ACTIVITY; GAMMA;
   IMMUNOTHERAPY; BISPHOSPHONATES; CYTOTOXICITY; MECHANISMS; ANTIGEN;
   GROWTH
AB Immune checkpoint blockade has been largely unsuccessful for the treatment of bone metastatic castrate  re sistant prostate cancer (mCRPC). Here, we report a combinatorial strategy to treat mCRPC using gamma 6 enriched chimeric antigen receptor (CAR) T cells and zoledronate (ZOL). In a preclinical murine model of bone mCRPC, gamma 6 CAR T cells targeting prostate stem cell antigen (PSCA) induced a rapid and significant regression of estab lished tumors, combined with increased survival and reduced cancer associated bone disease. Pretreatment with ZOL, a U.S. Food and Drug Administration approved bisphosphonate prescribed to mitigate pathological fracture in mCRPC patients, resulted in CAR independent activation of gamma 6 CAR T cells, increased cytokine secre tion, and enhanced antitumor efficacy. These data show that the activity of the endogenous V gamma 9V62 T cell re ceptor is preserved in CAR T cells, allowing for dual receptor recognition of tumor cells. Collectively, our findings support the use of gamma 6 CAR T cell therapy for mCRPC treatment.
C1 [Frieling, Jeremy S.; Bishop, Ryan T.; Li, Tao; Lo, Chen Hao; Lynch, Conor C.] H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA.
   [Tordesillas, Leticia; Bustos, Xiomar E.; Ramello, Maria Cecilia; Cianne, Junior E.; Snedal, Sebastian A.; Roselli, Emiliano; Benzaid, Ismahene; Abate Daga, Daniel] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA.
   [de la Iglesia, Janis] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol Res, Tampa, FL USA.
   [Wang, Xuefeng; Kim, Youngchul] H Lee Moffitt Canc Ctr & Res Inst, Dept Biosta tist & Bioinformat, Tampa, FL USA.
C3 H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer
   Center & Research Institute; H Lee Moffitt Cancer Center & Research
   Institute; H Lee Moffitt Cancer Center & Research Institute
RP Frieling, JS; Lynch, CC (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Tumor Biol, Tampa, FL 33612 USA.; Tordesillas, L; Abate Daga, D (通讯作者)，H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA.
EM jeremy.frieling@moffitt.org; leticia.tordesil las@moffitt.org;
   conor.lynch@moffitt.org; daniel.abatedaga@moffitt.org
OI Abate Daga, Daniel/0000 0002 2571 0215
FU Team Science Award; Moffitt Cancer Center; NCI [U01 CA244101,
   P30 CA076292]; Analytical Microscopy, Flow Cytometry, Small Animal
   Imaging Laboratory, and Tissue Core Facilities at Moffitt Cancer Center,
   an NCI designated Comprehensive Cancer Center; Department of Defense
   Prostate Cancer Research Program, DOD [W81XWH 18 2 0015,
   W81XWH 18 2 0016, W81XWH 18 2 0017, W81XWH 18 2 0018, W81XWH 18 2 0019,
   R01 CA241169];  [W81XWH 18 2 0013]
FX This work was supported in part by the Team Science Award pilot funds
   provided by Moffitt Cancer Center, by NCI R01 CA241169, by NCI U01
   CA244101, and by the Analytical Microscopy, Flow Cytometry, Small Animal
   Imaging Laboratory, and Tissue Core Facilities at Moffitt Cancer Center,
   an NCI designated Comprehensive Cancer Center (P30 CA076292) . This work
   is supported by the Department of Defense Prostate Cancer Research
   Program, DOD award nos. W81XWH 18 2 0013, W81XWH 18 2 0015,
   W81XWH 18 2 0016, W81XWH 18 2 0017, W81XWH 18 2 0018, and
   W81XWH 18 2 0019 PCRP Prostate Cancer Biorepository Network (PCBN)
CR Abate Daga D., HUM
   Abate Daga D, 2013, BLOOD, V122, P1399, DOI 10.1182/blood 2013 04 495531
   Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Airoldi I, 2015, BLOOD, V125, P2349, DOI 10.1182/blood 2014 09 599423
   Alizadeh D, 2021, CANCER DISCOV, V11, P2248, DOI 10.1158/2159 8290.CD 20 1661
   Amend Sarah R, 2016, J Vis Exp, DOI 10.3791/53936
   Andrea AE, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228620
   Arriaga JM, 2020, NAT CANCER, V1, P1082, DOI 10.1038/s43018 020 00125 0
   Baxevanis CN, 2019, IMMUNOTHERAPY UK, V11, P69, DOI 10.2217/imt 2018 0159
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Benzaïd I, 2012, CLIN CANCER RES, V18, P6249, DOI 10.1158/1078 0432.CCR 12 0918
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   Brown HK, 2009, CURR CANCER DRUG TAR, V9, P807, DOI 10.2174/156800909789760339
   Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698
   Bustos X, 2022, CANCER J, V28, P270, DOI 10.1097/PPO.0000000000000606
   Campbell SC, 2010, UROLOGY, V75, P1138, DOI 10.1016/j.urology.2009.11.083
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Cook LM, 2019, ONCOGENE, V38, P6959, DOI 10.1038/s41388 019 0913 4
   Cook LM, 2016, SCI REP UK, V6, DOI 10.1038/srep29384
   Dannull J, 2000, CANCER RES, V60, P5522
   Deniger DC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00636
   Di Carlo E, 2013, MOL THER, V21, P1034, DOI 10.1038/mt.2013.38
   Duan F, 2012, J IMMUNOL METHODS, V382, P224, DOI 10.1016/j.jim.2012.06.005
   Feldmann A, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1785608
   Fisher JPH, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27572
   Frieling JS, 2015, CANCER CONTROL, V22, P109, DOI 10.1177/107327481502200114
   Gao YF, 2003, J EXP MED, V198, P433, DOI 10.1084/jem.20030584
   Gauthier J, 2021, BLOOD, V137, P323, DOI 10.1182/blood.2020006770
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951
   Greenspan SL, 2005, J CLIN ENDOCR METAB, V90, P6410, DOI 10.1210/jc.2005 0183
   Gu Z, 2000, ONCOGENE, V19, P1288, DOI 10.1038/sj.onc.1203426
   Han X, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045 019 0813 7
   Harly Christelle, 2014, Front Immunol, V5, P657, DOI 10.3389/fimmu.2014.00657
   Junghans R. P., PROSTATE, V76
   Kabelitz D, 2020, CELL MOL IMMUNOL, V17, P925, DOI 10.1038/s41423 020 0504 x
   Kantoff P.W., N ENGL J MED
   Kantoff PW, 2010, J CLIN ONCOL, V28, P1099, DOI 10.1200/JCO.2009.25.0597
   Kondo M, 2011, JOVE J VIS EXP, DOI 10.3791/3182
   Kwon ED, 2014, LANCET ONCOL, V15, P700, DOI 10.1016/S1470 2045(14)70189 5
   Landin AM, 2021, JOVE J VIS EXP, DOI 10.3791/62622
   Larson RC, 2022, NATURE, V604, P563, DOI 10.1038/s41586 022 04585 5
   Lee MV, 2001, CANCER RES, V61, P2602
   Martyniszyn A, 2017, HUM GENE THER, V28, P1147, DOI 10.1089/hum.2017.126
   McGuire JJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 20962 6
   Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673
   Narayan V, 2022, NAT MED, V28, P724, DOI 10.1038/s41591 022 01726 1
   Park TS, 2014, NUCLEIC ACID THER, V24, P356, DOI 10.1089/nat.2014.0486
   Pauza CD, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01305
   Peters C, 2020, METHOD ENZYMOL, V631, P223, DOI 10.1016/bs.mie.2019.07.019
   Phalke Swati P, 2015, Bone Rep, V3, P95, DOI 10.1016/j.bonr.2015.10.004
   Priceman SJ, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1380764
   Ramello M. C., Sci Signal
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.06.053, 10.1016/j.cell.2015.05.001]
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roselli E, 2019, BIODRUGS, V33, P647, DOI 10.1007/s40259 019 00384 z
   Rozenbaum M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01347
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   Santini D, 2009, CANCER IMMUNOL IMMUN, V58, P31, DOI 10.1007/s00262 008 0521 6
   Sebestyen Z, 2020, NAT REV DRUG DISCOV, V19, P169, DOI 10.1038/s41573 019 0038 z
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Vantourout P, 2013, NAT REV IMMUNOL, V13, P88, DOI 10.1038/nri3384
   Vasic D, 2022, SCI IMMUNOL, V7, DOI 10.1126/sciimmunol.abl3642
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Vyborova A, 2020, J CLIN INVEST, V130, P4637, DOI 10.1172/JCI132489
   Wagner J, 2020, MOL THER, V28, P2320, DOI 10.1016/j.ymthe.2020.09.015
NR 67
TC 33
Z9 36
U1 1
U2 14
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
EI 2375 2548
J9 SCI ADV
JI Sci. Adv.
PD MAY 3
PY 2023
VL 9
IS 18
AR eadf0108
DI 10.1126/sciadv.adf0108
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA G3NW2
UT WOS:000988274400013
PM 37134157
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU De Luca, I
   Di Salle, A
   Alessio, N
   Margarucci, S
   Simeone, M
   Galderisi, U
   Calarco, A
   Peluso, G
AF De Luca, Ilenia
   Di Salle, Anna
   Alessio, Nicola
   Margarucci, Sabrina
   Simeone, Michele
   Galderisi, Umberto
   Calarco, Anna
   Peluso, Gianfranco
TI Positively charged polymers modulate the fate of human mesenchymal
   stromal cells via ephrinB2/EphB4 signaling
SO STEM CELL RESEARCH
LA English
DT Article
DE Cationic polymers; MSCs differentiation; Cell cell ephrinB2/EphB4
   signaling; Regenerative medicine
ID STEM CELL; BONE REGENERATION; EPH RECEPTORS; DIFFERENTIATION; MEMBRANES;
   SURFACES; CLUSTERS; BEHAVIOR; EPHRINS
AB Understanding the mechanisms by which mesenchymal stromal cells (MSCs) interact with the physical properties (e.g. topography, charge, zeta potential, and contact angle) of polymeric surfaces is essential to design new bio materials capable of regulating stem cell behavior. The present study investigated the ability of two polymers (pHM1 and pHM3) with different positive surface charge densities to modulate the differentiation of MSCs into osteoblast like phenotype via cell cell ephrinB2/EphB4 signaling. Although pHM1 promoted the phosphorylation of EphB4, leading to cell differentiation, pHM3, characterized by a high positive surface charge density, had no significant effect on EphB4 activation or MSCs differentiation. When the MSCs were cultured on pHM1 in the presence of a forward signaling blocking peptide, the osteoblast differentiation was compromised. Our results demonstrated that the ephrinB2/EphB4 interaction was required for MSCs differentiation into an osteoblast like phenotype and that the presence of a high positive surface charge density altered this interaction. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [De Luca, Ilenia; Di Salle, Anna; Margarucci, Sabrina; Calarco, Anna; Peluso, Gianfranco] CNR, Inst Biosci & BioResources, Naples, Italy.
   [Alessio, Nicola; Galderisi, Umberto] Univ Naples 2, Biotechnol & Mol Biol Sect, Dept Expt Med, Naples, Italy.
   [Simeone, Michele] Med Sch Federico II Naples, Dept Neurosci Reprod & Odontostomatol Sci, Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioscienze e
   Biorisorse (IBBR CNR); Universita della Campania Vanvitelli
RP Calarco, A (通讯作者)，CNR, Inst Biosci & BioResources, Naples, Italy.
EM anna.calarco@ibbr.cnr.it
RI ; Alessio, Nicola/K 2119 2018; Di Salle, A/AAF 5416 2019; de luca,
   ilenia/IWD 5787 2023; Calarco, Anna/P 2568 2019
OI De luca, Ilenia/0000 0003 3776 6627; Di Salle, Anna/0000 0001 6763 3636;
   Calarco, Anna/0000 0002 1441 7662; Alessio, Nicola/0000 0002 5019 2130;
   MARGARUCCI, SABRINA/0000 0001 5361 1241
FU Progetto PON [PON01_01802]; Ricerca e sviluppo di bioregolatori attivi
   suimeccanismi epigenetici dei processi infiammatori nelle malattie
   croniche e degenerative [PON01_02512]
FX This work was supported by Progetto PON   "Ricerca e Competitivita
   2007 2013"   PON01_01802: "Sviluppo di molecole capaci di modulare vie
   metaboliche intracellulari redox sensibili per la prevenzione e la cura
   di patologie infettive, tumorali, neurodegenerative e loro delivery
   mediante piattaforme nano tecnologiche" and PON01_02512: "Ricerca e
   sviluppo di bioregolatori attivi suimeccanismi epigenetici dei processi
   infiammatori nelle malattie croniche e degenerative." The authors
   declare no potential conflicts of interest with respect to the
   authorship and/ or publication of this article.
CR Arthur A, 2009, J DENT RES, V88, P829, DOI 10.1177/0022034509342363
   Arthur A, 2011, BONE, V48, P533, DOI 10.1016/j.bone.2010.10.180
   Chandra P, 2015, BIOMARK INSIGHTS, V10, P105, DOI [10.4137/BMI.S20057, 10.4137/BMIMI.S20057]
   Costa RR, 2014, CHEM SOC REV, V43, P3453, DOI 10.1039/c3cs60393h
   De Rosa M, 2004, J CELL PHYSIOL, V198, P133, DOI 10.1002/jcp.10397
   Di Bernardo G, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt393
   Gucciardo E, 2014, CELL MOL LIFE SCI, V71, P3685, DOI 10.1007/s00018 014 1633 0
   Himanen JP, 2010, P NATL ACAD SCI USA, V107, P10860, DOI 10.1073/pnas.1004148107
   Himanen JP, 2007, CURR OPIN CELL BIOL, V19, P534, DOI 10.1016/j.ceb.2007.08.004
   Iwai R, 2013, BIOMATERIALS, V34, P9096, DOI 10.1016/j.biomaterials.2013.08.027
   Kaivosoja E, 2012, ANN MED, V44, P635, DOI 10.3109/07853890.2011.573805
   Li JH, 2015, ADV HEALTHC MATER, V4, P998, DOI 10.1002/adhm.201500032
   Liao TQ, 2010, BIOTECHNOL PROGR, V26, P1705, DOI 10.1002/btpr.471
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Murphy WL, 2014, NAT MATER, V13, P547, DOI [10.1038/NMAT3937, 10.1038/nmat3937]
   Nguyen T.M., 2015, INT J HEMATOL
   Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662
   Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Petrauskas V, 2015, J PHYS CHEM B, V119, P12164, DOI 10.1021/acs.jpcb.5b05767
   Qu YL, 2014, J BIOMAT SCI POLYM E, V25, P211, DOI 10.1080/09205063.2013.849903
   Rossi G, 2014, J PHYS CONDENS MAT, V26, DOI 10.1088/0953 8984/26/50/503101
   Rosso F, 2003, MAT SCI ENG C BIO S, V23, P371, DOI 10.1016/S0928 4931(02)00290 4
   Samal S., 2015, CATIONIC POLYM REGEN
   Sancho E, 2003, CURR OPIN CELL BIOL, V15, P763, DOI 10.1016/j.ceb.2003.10.012
   Schaupp A, 2014, J CELL BIOL, V204, P409, DOI 10.1083/jcb.201305037
   Schröder K, 2010, J ADHES SCI TECHNOL, V24, P1191, DOI 10.1163/016942409X12619870771501
   Seiradake E, 2010, NAT STRUCT MOL BIOL, V17, P398, DOI 10.1038/nsmb.1782
   Severino V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.445
   Squillaro T., 2015, CELL TRANSPLANT
   Tabujew I, 2015, RSC POLYM CHEM SER, V13, P1
   Tan F, 2012, BIOMED MATER, V7, DOI 10.1088/1748 6041/7/5/055009
   Tiriveedhi V, 2011, BBA BIOMEMBRANES, V1808, P209, DOI 10.1016/j.bbamem.2010.08.017
   Tong ZX, 2015, EMBO J, V34, P987, DOI 10.15252/embj.201490756
   Tonna S, 2014, FASEB J, V28, P4482, DOI 10.1096/fj.14 254300
   Vazin T, 2010, TRENDS BIOTECHNOL, V28, P117, DOI 10.1016/j.tibtech.2009.11.008
   Wang CM, 2015, TRENDS BIOTECHNOL, V33, P10, DOI 10.1016/j.tibtech.2014.11.002
   Wang YY, 2012, J BIOACT COMPAT POL, V27, P122, DOI 10.1177/0883911512436773
   Zhang W., 2015, SCI REP, V5
   Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012
NR 40
TC 34
Z9 36
U1 0
U2 24
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1873 5061
EI 1876 7753
J9 STEM CELL RES
JI Stem Cell Res.
PD SEP
PY 2016
VL 17
IS 2
BP 248
EP 255
DI 10.1016/j.scr.2016.07.005
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology
GA EE3UB
UT WOS:000389523200008
PM 27591481
OA gold
DA 2025 08 17
ER

PT J
AU Kanazawa, I
   Yamaguchi, T
   Yano, S
   Yamauchi, M
   Sugimoto, T
AF Kanazawa, Ippei
   Yamaguchi, Toru
   Yano, Shozo
   Yamauchi, Mika
   Sugimoto, Toshitsugu
TI Metformin enhances the differentiation and mineralization of
   osteoblastic MC3T3 E1 cells via AMP kinase activation as well as eNOS
   and BMP 2 expression
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE metformin; osteoblasts; AMPK; BMP 2; eNOS; AICAR; diabetes mellitus;
   osteoporosis; MC3T3 E1; bone formation
ID NITRIC OXIDE SYNTHASE; PROTEIN KINASE; BONE FORMATION;
   DIABETES MELLITUS; FRACTURE RISK; STIMULATION; APOPTOSIS; STATINS;
   GLUCOSE; INDUCE
AB it is unclear whether metformin, one of the anti hyperglycemic agents commonly used for type 2 diabetes, could affect bone formation through activation of AMP activated Protein kinase (AMPK). In Order to clarify this issue, we investigated the effects of metformin oil the differentiation and mineralization of osteoblastic MC3T3 E1 cells as well as intracellular signal transduction. Metformin (50 mu M) significantly increased collagen I and osteocalcin mRNA expression, stimulated alkaline phosphatase activity, and enhanced cell mineralization. Moreover, metformin significantly activated AMPK in dose  and time dependent manners, and induced endothelial nitric oxide synthase (eNOS) and bone morphogenetic protein 2 (BMP 2) expressions. Supplementation of Ara A (0.1 mM), a specific AMPK inhibitor, significantly reversed the metformin induced eNOS and BMP 2 expressions. Our findings Suggest that metformin can induce the differentiation and mineralization of osteoblasts via activation of the AMPK signaling pathway, and that this drug might be beneficial for not only diabetes but also osteoporosis by promoting bone formation. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Kanazawa, Ippei; Yamaguchi, Toru; Yano, Shozo; Yamauchi, Mika; Sugimoto, Toshitsugu] Shimane Univ, Fac Med, Dept Internal Med 1, Izumo, Shimane 6938501, Japan.
C3 Shimane University
RP Yamaguchi, T (通讯作者)，Shimane Univ, Fac Med, Dept Internal Med 1, 89 1 Enya Cho, Izumo, Shimane 6938501, Japan.
EM ippei.k@med.shimane u.ac.jp; yamaguch@med.shimane u.ac.jp;
   syano@med.shimane u.ac.jp; yamauchi@med.shimane u.ac.jp;
   sugimoto@med.shimane u.ac.jp
RI Yano, Shozo/HJG 6965 2022; Kanazawa, Ippei/F 8609 2010
CR Armour KE, 2001, ENDOCRINOLOGY, V142, P760, DOI 10.1210/en.142.2.760
   BARRETTCONNOR E, 1992, JAMA J AM MED ASSOC, V268, P3333
   BEG ZH, 1973, BIOCHEM BIOPH RES CO, V54, P1362, DOI 10.1016/0006 291X(73)91137 6
   Buse JB, 2004, DIABETES OBES METAB, V6, P133, DOI 10.1111/j.1462 8902.2004.00325.x
   Chen ZP, 1999, FEBS LETT, V443, P285, DOI 10.1016/S0014 5793(98)01705 0
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Fujii N, 2004, P NUTR SOC, V63, P205, DOI 10.1079/PNS2004340
   Garrett IR, 2001, CURR PHARM DESIGN, V7, P715, DOI 10.2174/1381612013397762
   Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432 1033.1997.00259.x
   HARRIS SE, 1994, J BONE MINER RES, V9, P855
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003
   Kanazawa I, 2007, J BONE MINER RES, V22, pS94
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Kefas BA, 2003, DIABETOLOGIA, V46, P250, DOI 10.1007/s00125 002 1030 3
   Kefas BA, 2003, J MOL ENDOCRINOL, V30, P151, DOI 10.1677/jme.0.0300151
   Lai CF, 2001, J BIOL CHEM, V276, P14443, DOI 10.1074/jbc.M010021200
   Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129
   Lipscombe LL, 2007, DIABETES CARE, V30, P835, DOI 10.2337/dc06 1851
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Musi N, 2002, DIABETES, V51, P2074, DOI 10.2337/diabetes.51.7.2074
   Rubin J, 2003, J BIOL CHEM, V278, P34018, DOI 10.1074/jbc.M302822200
   Snehalatha C, 2008, DIABETES VASC DIS RE, V5, P25, DOI 10.3132/dvdr.2008.005
   Strotmeyer ES, 2005, ARCH INTERN MED, V165, P1612, DOI 10.1001/archinte.165.14.1612
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P427, DOI 10.1007/s00198 006 0253 4
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
NR 31
TC 187
Z9 217
U1 1
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 24
PY 2008
VL 375
IS 3
BP 414
EP 419
DI 10.1016/j.bbrc.2008.08.034
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 350MW
UT WOS:000259357700025
PM 18721796
DA 2025 08 17
ER

PT J
AU Matuszewski, L
   Turzanska, K
   Matuszewska, A
   Jablonski, M
   Polkowska, I
   Mazurkiewicz, T
AF Matuszewski, Lukasz
   Turzanska, Karolina
   Matuszewska, Anna
   Jablonski, Miroslaw
   Polkowska, Izabela
   Mazurkiewicz, Tomasz
TI Effect of implanted bisphosphonate enriched cement on the trabecular
   microarchitecture of bone in a rat model using micro computed tomography
SO INTERNATIONAL ORTHOPAEDICS
LA English
DT Article
ID IN VITRO; PAMIDRONATE; FIXATION; HISTOMORPHOMETRY; OSTEOARTHRITIS;
   OSTEOPOROSIS; OSTEOCLASTS; ALLOGRAFT; SURFACE
AB Bisphosphonates (BPs) are antiresorptive drugs typically used to inhibit bone resorption. The latest reports show that BPs play an important role in not only achieving better bone mineral density but also in improving bone microarchitecture. The mechanism of action of the BPs is complex and multifactorial. We tried to determine whether there are any changes in the microarchitectural bone structure during local use of BP (Pamifos 60). The aim of this study was to see if BP enriched cement used in rat models had positive effects on bone formation.
   Research was performed on 40 adult male Wistar rats that were divided into four groups: two control groups and two experimental groups. Rats in the experimental groups were implanted with BP enriched cement into the bone, while the control group rats were implanted with clean bone cement (without BP). Micro computed tomography was applied for the investigation of trabecular microarchitecture of the proximal physis of the tibial bone in all animals three and six weeks after surgery. In all microCT images variables such as bone volume density (BV/TV), trabecular thickness (TbTh), trabecular separation (TbSp) and trabecular number (TbN) were used to describe trabecular bone morphometry.
   The major finding of this study is that using BP enriched cement results in distinct changes in bone microarchitecture. We showed that local use of pamidronate (Pamifos 60) in orthopaedic cement had a positive effect on bone formation. It significantly changed three variables. We noticed increasing bone volume fraction and trabecular thickness together with decreasing trabecular separation.
   In this paper we demonstrate the efficacy of using BP enriched cement in vitro in the tibiae of rats. Our most significant finding based on micro CT picture analysis allows us to start further work on more suitable applications of BP enriched cement in humans. We believe that future successful experiments will facilitate potential use of BP enriched cement in clinical applications.
C1 [Matuszewski, Lukasz] Med Univ Lublin, Paediat Orthoped & Rehabil Clin, Lublin, Poland.
   [Turzanska, Karolina; Jablonski, Miroslaw] Med Univ Lublin, Dept Orthopaed & Rehabil, Lublin, Poland.
   [Matuszewska, Anna] Marie Curie Sklodowska Univ, Dept Biochem, PL 20031 Lublin, Poland.
   [Polkowska, Izabela] Univ Life Sci Lublin, Fac Vet Med, Lublin, Poland.
   [Mazurkiewicz, Tomasz] Med Univ Lublin, Orthopaed & Traumatol Dept, Lublin, Poland.
C3 Medical University of Lublin; Medical University of Lublin; Maria
   Curie Sklodowska University; University of Life Sciences in Lublin;
   Medical University of Lublin
RP Matuszewski, L (通讯作者)，Med Univ Lublin, Paediat Orthoped & Rehabil Clin, Lublin, Poland.
EM lukasz.matuszewski@am.lublin.pl
RI ; Turzanska, Karolina/C 2067 2013; Matuszewski, Łukasz/M 8281 2014;
   turzanska, karolina/C 2067 2013
OI Matuszewska, Anna/0000 0002 5586 5568; turzanska,
   karolina/0000 0001 7359 9622; Matuszewski, Lukasz/0000 0002 7733 0329;
   Polkowska, Izabela/0000 0002 4751 8566
CR Agholme F, 2009, J BONE JOINT SURG BR, V91B, P670, DOI 10.1302/0301 620X.91B5.21867
   Allen MR, 2011, ODONTOLOGY, V99, P8, DOI 10.1007/s10266 010 0153 0
   Aspenberg P, 2002, ACTA ORTHOP SCAND, V73, P20, DOI 10.1080/000164702317281350
   Baas J, 2008, BIOMATERIALS, V29, P2915, DOI 10.1016/j.biomaterials.2008.03.010
   Bock O, 2012, BONE, V50, P317, DOI 10.1016/j.bone.2011.10.027
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   DOUGLAS DL, 1980, LANCET, V1, P1043
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Gao Y, 2009, BIOMATERIALS, V30, P1790, DOI 10.1016/j.biomaterials.2008.12.025
   Geoffroy V, 2011, CALCIFIED TISSUE INT, V88, P464, DOI 10.1007/s00223 011 9480 6
   Giuliani N, 1998, BONE, V22, P455, DOI 10.1016/S8756 3282(98)00033 7
   Glowacki J, 2003, J BONE JOINT SURG AM, V85A, P2371, DOI 10.2106/00004623 200312000 00015
   Jakobsen T, 2007, CLIN ORTHOP RELAT R, P195, DOI 10.1097/BLO.0b013e31813c6696
   Jee JH, 2010, ORAL SURG ORAL MED O, V110, pE47, DOI 10.1016/j.tripleo.2010.03.025
   Jones MD, 2010, ARTHRITIS RHEUM US, V62, P2726, DOI 10.1002/art.27595
   Kajiwara H, 2005, BIOMATERIALS, V26, P581, DOI 10.1016/j.biomaterials.2004.02.072
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Migliorati CA, 2003, J CLIN ONCOL, V21, P4253, DOI 10.1200/JCO.2003.99.132
   Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609
   Peter B, 2006, J BIOMED MATER RES A, V76A, P133, DOI 10.1002/jbm.a.30456
   Plotkin LI, 2006, BONE, V39, P443, DOI 10.1016/j.bone.2006.02.060
   Qi MC, 2012, BONE, V50, P119, DOI 10.1016/j.bone.2011.10.011
   Reinholz GG, 2000, CANCER RES, V60, P6001
   Rodan GA, 1997, BONE, V20, P1, DOI 10.1016/S8756 3282(96)00318 3
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   SAHNI M, 1993, J CLIN INVEST, V91, P2004, DOI 10.1172/JCI116422
   Schindeler A, 2011, J BONE JOINT SURG BR, V93B, P1134, DOI 10.1302/0301 620X.93B8.25940
   Seeman E, 2010, J BONE MINER RES, V25, P1886, DOI 10.1002/jbmr.81
   Tanzer M, 2005, CLIN ORTHOP RELAT R, P30, DOI 10.1097/01.blo.0000194728.62996.2d
   Ward L., 2009, INT J CLIN RHEUMATOL, V4, P657
   WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201
   Wermelin K, 2008, BONE, V42, P365, DOI 10.1016/j.bone.2007.10.013
   Wilkinson JM, 2011, BONE, V49, P95, DOI 10.1016/j.bone.2011.01.009
   Xuenong Z., 2003, ACTA ORTHOP SCAND, V74, P596
   Youshinari M, 2002, BIOMATERIALS, V23, P2870
   Youshinari M, 2001, BIOMATERIALS, V22, P709
NR 37
TC 10
Z9 10
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0341 2695
EI 1432 5195
J9 INT ORTHOP
JI Int. Orthop.
PD JUN
PY 2013
VL 37
IS 6
BP 1187
EP 1193
DI 10.1007/s00264 013 1855 z
PG 7
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 151AB
UT WOS:000319431900029
PM 23503639
OA Green Published
DA 2025 08 17
ER

PT J
AU Thakur, NA
   DeBoyace, SD
   Margulies, BS
AF Thakur, Nikhil A.
   DeBoyace, Sean D.
   Margulies, Bryan S.
TI Antagonism of the Met5 enkephalin opioid growth factor
   receptor signaling axis promotes MSC to differentiate into osteoblasts
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE opioid growth factor receptor; met5 enkephalin; MSC; osteoblast
ID BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL STEM CELLS; DELTA OPIOID
   RECEPTOR; SPINAL ARTHRODESIS; JOINT TISSUES; CANCER RISK; MODEL;
   QUANTIFICATION; PROLIFERATION; EXPRESSION
AB Chronic opioid therapy is associated with bone loss. This led us to hypothesize that the opioid antagonists, that include naloxone, would stimulate bone formation by regulating MSC differentiation. The opioid growth factor receptor (OGFR) is a non canonical opioid receptor that binds naloxone with high affinity whereas the native opioid growth factor, met5 enkephalin (met5), binds both the OGFR and the canonical delta opioid receptor (OPRD). Naloxone and an shRNA OGFR lentivirus were employed to disrupt the OGFR signaling axis in cultured MSC. In parallel, naloxone was administered to bone marrow using a mouse unicortical defect model. OPRD, OGFR, and the met5 ligand were highly expressed in MSC and osteoblasts. A pulse dose of naloxone increased mineral formation in MSC cultures in contrast to MSC treated with continuous naloxone or OGFR deficient MSC. Importantly, SMAD1 and SMAD8/9 expression increased after a pulse dose of naloxone whereas SMAD1, SMAD7, and ID1 were increased in the OGFR deficient MSC. Inhibited OGFR signaling decreased proliferation and increased p21 expression. The addition of naloxone to the unicortical defect resulted in increased bone formation within the defect. Our data suggest that novel mechanism through which signaling through the OGFR regulates osteogenesis via negative regulation of SMAD1 and p21. (c) 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 34:1195 1205, 2016.
C1 [Thakur, Nikhil A.; DeBoyace, Sean D.; Margulies, Bryan S.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University
RP Margulies, BS (通讯作者)，SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
EM bryan.margulies@gmail.com
FU SUNY Upstate Medical University Department of Orthopedic Surgery
FX Grant sponsor: SUNY Upstate Medical University Department of Orthopedic
   Surgery New Faculty Start up Funds.
CR Bergström J, 2003, J ORTHOPAED RES, V21, P465, DOI 10.1016/S0736 0266(02)00162 6
   Carragee EJ, 2013, J BONE JOINT SURG AM, V95A, P1537, DOI 10.2106/JBJS.L.01483
   Carragee EJ, 2011, SPINE J, V11, P471, DOI 10.1016/j.spinee.2011.04.023
   Chang SF, 2009, MOL ENDOCRINOL, V23, P1827, DOI 10.1210/me.2009 0143
   Chen KT, 2011, BONE, V49, P1194, DOI 10.1016/j.bone.2011.08.023
   Cheng F, 2009, MOL BIOL CELL, V20, P319, DOI 10.1091/mbc.E08 07 0681
   CHENG PY, 1995, J NEUROSCI, V15, P5976
   Cooper GS, 2013, SPINE, V38, P1862, DOI 10.1097/BRS.0b013e3182a3d3b4
   COSTA E, 1987, FASEB J, V1, P16, DOI 10.1096/fasebj.1.1.3111927
   Donahue RN, 2011, EXP BIOL MED, V236, P1036, DOI 10.1258/ebm.2011.011121
   Elhassan AM, 1998, J BONE MINER RES, V13, P88, DOI 10.1359/jbmr.1998.13.1.88
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Higuchi S, 2012, CIRC J, V76, P204, DOI 10.1253/circj.CJ 11 0309
   Hoch AI, 2014, STEM CELL TRANSL MED, V3, P643, DOI 10.5966/sctm.2013 0196
   Kelly MP, 2014, J BONE JOINT SURG AM, V96A, P1417, DOI 10.2106/JBJS.M.01190
   Khan SN, 2004, EXPERT OPIN BIOL TH, V4, P741
   King T, 2007, PAIN, V132, P154, DOI 10.1016/j.pain.2007.06.026
   Koski AM, 2010, BMJ CASE REP
   Krajnik M, 2010, HUM PATHOL, V41, P632, DOI 10.1016/j.humpath.2009.08.025
   Liskov AV, 2005, B EXP BIOL MED+, V139, P331, DOI 10.1007/s10517 005 0286 2
   Margulies BS, 2008, J ORTHOP RES, V26, P1512, DOI 10.1002/jor.20679
   Margulies BS, 2015, J ORTHOP RES, V33, P615, DOI 10.1002/jor.22790
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Pérez Castrillón JL, 2000, NEUROENDOCRINOLOGY, V72, P187, DOI 10.1159/000054586
   Petrizzi L, 2007, BMC MUSCULOSKEL DIS, V8, DOI 10.1186/1471 2474 8 43
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304 3940(02)01423 4
   ROSEN H, 1994, J CELL BIOCHEM, V55, P334, DOI 10.1002/jcb.240550310
   ROSEN H, 1991, P NATL ACAD SCI USA, V88, P3705, DOI 10.1073/pnas.88.9.3705
   ROSEN H, 1995, MOL ENDOCRINOL, V9, P1621, DOI 10.1210/me.9.11.1621
   Rosen H, 1998, J BONE MINER RES, V13, P1515, DOI 10.1359/jbmr.1998.13.10.1515
   Seitz S, 2010, CALCIFIED TISSUE INT, V86, P282, DOI 10.1007/s00223 010 9344 5
   Vaccaro AR, 2008, SPINE J, V8, P457, DOI 10.1016/j.spinee.2007.03.012
   Yano M, 2012, ENDOCR J, V59, P653, DOI 10.1507/endocrj.EJ12 0022
   Zagon IS, 2002, BRAIN RES REV, V38, P351, DOI 10.1016/S0165 0173(01)00160 6
   Zagon IS, 2000, MOL BRAIN RES, V84, P106, DOI 10.1016/S0169 328X(00)00232 1
NR 36
TC 15
Z9 17
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0736 0266
EI 1554 527X
J9 J ORTHOP RES
JI J. Orthop. Res.
PD JUL
PY 2016
VL 34
IS 7
BP 1195
EP 1205
DI 10.1002/jor.23135
PG 11
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA DR6OT
UT WOS:000380021900011
PM 26687326
OA Bronze
DA 2025 08 17
ER

PT J
AU Ronghe, R
   Tavares, AAS
AF Ronghe, Rucha
   Tavares, Adriana A. S.
TI The skeleton: an overlooked regulator of systemic glucose metabolism in
   cancer?
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE glucose; bone; metabolism; cancer; systemic
ID RENAL CELL CARCINOMA; BREAST CANCER; THERAPEUTIC TARGET; RECEPTOR
   ACTIVATOR; BONE METASTASES; OVARIAN CANCER; RANK LIGAND; OSTEOBLASTS;
   EXPRESSION; METFORMIN
AB Recent discoveries demonstrated the skeleton's role as an endocrine organ regulating whole body glucose homeostasis. Glucose metabolism is critical for rapid cell proliferation and tumour growth through increasing glucose uptake and fermentation of glucose to lactate despite being in an aerobic environment. This hypothesis paper discusses emerging evidence on how bones can regulate whole body glucose homeostasis with potential to impact on tumour growth and proliferation. Moreover, it proposes a clinical link between bone glucose metabolism and prognosis of cancer based on recent clinical trial data. Targeting metabolic pathways related with classic glucose metabolism and also bone metabolism, novel methods of cancer therapy and treatment could be developed. This paper objective is to highlight the need for future research on this altered metabolism with potential to change future management of cancer patients.
C1 [Ronghe, Rucha] Univ Edinburgh, Edinburgh Med Sch, Edinburgh, Scotland.
   [Tavares, Adriana A. S.] Univ Edinburgh, British Heart Fdn, Queens Med Res Inst, Ctr Cardiovasc Sci, Edinburgh, Scotland.
   [Tavares, Adriana A. S.] Univ Edinburgh, Queens Med Res Inst, Edinburgh Imaging, Edinburgh, Scotland.
C3 University of Edinburgh; University of Edinburgh; University of
   Edinburgh
RP Ronghe, R (通讯作者)，Univ Edinburgh, Edinburgh Med Sch, Edinburgh, Scotland.
EM s1904946@ed.ac.uk
FU BHF [FS/19/34/34354]; Wellcome Trust Technology Development Award
   [221295/Z/20/Z]; Chan Zuckerberg Initiative DAF [2020 225273]; Silicon
   Valley Community Foundation; Wellcome Trust [221295/Z/20/Z] Funding
   Source: Wellcome Trust
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. AT was funded by the BHF
   (FS/19/34/34354), she is a recipient of a Wellcome Trust Technology
   Development Award (221295/Z/20/Z) and a Chan Zuckerberg Initiative DAF
   grant number 2020 225273, an advised fund of Silicon Valley Community
   Foundation (grant DOI https://doi.org/10.37921/690910twdfoo).
CR Abdallah BM, 2015, DIABETES, V64, P3069, DOI 10.2337/db14 1642
   Adekola K, 2012, CURR OPIN ONCOL, V24, P650, DOI 10.1097/CCO.0b013e328356da72
   AGERBAEK MO, 1991, BONE MINER, V12, P101, DOI 10.1016/0169 6009(91)90039 3
   Akram M, 2014, CELL BIOCHEM BIOPHYS, V68, P475, DOI 10.1007/s12013 013 9750 1
   Anderson NM, 2018, PROTEIN CELL, V9, P216, DOI 10.1007/s13238 017 0451 1
   Aparicio LMA, 2010, MOL MED REP, V3, P575, DOI 10.3892/mmr_00000300
   Bardella C, 2011, BBA BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bidard FC, 2008, CLIN CANCER RES, V14, P3306, DOI 10.1158/1078 0432.CCR 07 4749
   Bishayee A, 2009, CANCER PREV RES, V2, P409, DOI 10.1158/1940 6207.CAPR 08 0160
   Bodmer M, 2011, GYNECOL ONCOL, V123, P200, DOI 10.1016/j.ygyno.2011.06.038
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyce BF, 2009, CRIT REV EUKAR GENE, V19, P171, DOI 10.1615/CritRevEukarGeneExpr.v19.i3.10
   Brennan Speranza TC, 2015, CALCIFIED TISSUE INT, V96, P1, DOI 10.1007/s00223 014 9931 y
   Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782
   Bussard KM, 2008, CANCER METAST REV, V27, P41, DOI 10.1007/s10555 007 9109 4
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Canon JR, 2008, CLIN EXP METASTAS, V25, P119, DOI 10.1007/s10585 007 9127 1
   Cantley J, 2015, BMC BIOL, V13, DOI 10.1186/s12915 015 0140 6
   Carbone F, 2016, J MOL CELL CARDIOL, V94, P82, DOI 10.1016/j.yjmcc.2016.03.013
   Carvalho KC, 2011, CLINICS, V66, P965, DOI 10.1590/S1807 59322011000600008
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Chen LQ, 2015, ANNU REV BIOCHEM, V84, P865, DOI 10.1146/annurev biochem 060614 033904
   Chen Y, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.588095
   Cheung EC, 2010, CURR OPIN CELL BIOL, V22, P186, DOI 10.1016/j.ceb.2009.12.006
   Clemens TL, 2011, J BONE MINER RES, V26, P677, DOI 10.1002/jbmr.321
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Crockett JC, 2011, J CELL SCI, V124, P991, DOI 10.1242/jcs.063032
   D'Antonio C, 2014, THER ADV MED ONCOL, V6, P101, DOI 10.1177/1758834014521110
   da Costa AM, 2022, CANCER EPIDEM BIOMAR, V31, P707, DOI 10.1158/1055 9965.EPI 21 0842
   Deng D, 2016, PROTEIN SCI, V25, P546, DOI 10.1002/pro.2858
   Devignes CS, 2018, P NATL ACAD SCI USA, V115, pE992, DOI 10.1073/pnas.1718009115
   Diegel CR, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008361
   Dirckx N, 2018, J CLIN INVEST, V128, P1087, DOI 10.1172/JCI97794
   Donat A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22084120
   Duan P, 2017, INT J ENDOCRINOL, V2017, DOI 10.1155/2017/8724869
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637 013 0047 4
   Dutka M, 2022, CANCERS, V14, DOI 10.3390/cancers14235811
   Eniafe J, 2021, ONCOGENE, V40, P3351, DOI 10.1038/s41388 020 01639 8
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Esser N, 2014, DIABETES RES CLIN PR, V105, P141, DOI 10.1016/j.diabres.2014.04.006
   Evans JMM, 2005, BMJ BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7
   Feng Xu, 2009, Curr Chem Biol, V3, P189
   Feng ZH, 2010, TRENDS CELL BIOL, V20, P427, DOI 10.1016/j.tcb.2010.03.004
   Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Foldager CB, 2009, ACTA ORTHOP, V80, P737, DOI 10.3109/17453670903487040
   Garrido P, 2015, J CELL PHYSIOL, V230, P191, DOI 10.1002/jcp.24698
   Gillespie JR, 2013, ENDOCRINOLOGY, V154, P3702, DOI 10.1210/en.2013 1155
   Gnant M, 2019, LANCET ONCOL, V20, P339, DOI 10.1016/S1470 2045(18)30862 3
   Gonzalez Suarez E, 2010, NATURE, V468, P103, DOI 10.1038/nature09495
   Greenhill C, 2018, NAT REV ENDOCRINOL, V14, DOI 10.1038/nrendo.2018.25
   Guntur AR, 2012, ENDOCR PRACT, V18, P758, DOI 10.4158/EP12141.RA
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Home P, 2013, DIABETES CARE, V36, pS240, DOI 10.2337/dcS13 2002
   Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027
   Hu X, 2018, EBIOMEDICINE, V34, P35, DOI 10.1016/j.ebiom.2018.07.021
   Huang R, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.19
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Jaschke N, 2021, BONE RES, V9, DOI 10.1038/s41413 021 00149 x
   Jeffcoate WJ, 2005, LANCET, V366, P2058, DOI 10.1016/S0140 6736(05)67029 8
   Jehn CF, 2016, ANTICANCER RES, V36, P2631
   Jiang WL, 2020, J ORTHOP SURG HONG K, V28, DOI 10.1177/2309499020915989
   Kaelin WG, 2002, NAT REV CANCER, V2, P673, DOI 10.1038/nrc885
   Karsenty G, 2023, ANNU REV NUTR, V43, P55, DOI 10.1146/annurev nutr 061121 091348
   Kennedy SP, 2020, ONCOGENE, V39, P3028, DOI 10.1038/s41388 020 1202 y
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kim SP, 2017, ENDOCRINOLOGY, V158, P3805, DOI 10.1210/en.2017 00657
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   Kobayashi Y, 2016, J BIOCHEM, V159, P387, DOI 10.1093/jb/mvv124
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038
   Kostenuik PJ, 2005, CURR OPIN PHARMACOL, V5, P618, DOI 10.1016/j.coph.2005.06.005
   Kumar A, 2013, SCI WORLD J, DOI 10.1155/2013/756134
   Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798
   Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293
   Lee NJ, 2018, MOL METAB, V13, P30, DOI 10.1016/j.molmet.2018.05.004
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   Lee NJ, 2015, MOL METAB, V4, P164, DOI 10.1016/j.molmet.2014.12.010
   Leong I, 2018, NAT REV ENDOCRINOL, V14, P379, DOI 10.1038/s41574 018 0036 y
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lidgren A, 2008, BJU INT, V101, P480, DOI 10.1111/j.1464 410X.2007.07238.x
   Liu LS, 2012, J ENDODONT, V38, P943, DOI 10.1016/j.joen.2012.03.010
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535 7163.MCT 12 0131
   Luo XM, 2010, J INT MED RES, V38, P1885, DOI 10.1177/147323001003800601
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Marquez J, 2019, J CLIN MED, V8, DOI 10.3390/jcm8122161
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   McBrayer SK, 2012, BLOOD, V119, P4686, DOI 10.1182/blood 2011 09 377846
   Villaamil VM, 2011, ONCOL REP, V25, P315, DOI 10.3892/or.2010.1096
   Nulali J, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12111674
   Okcu O, 2022, TURK J PATHOL, V38, P114, DOI 10.5146/tjpath.2021.01557
   Opipari AW, 2004, CANCER RES, V64, P696, DOI 10.1158/0008 5472.CAN 03 2404
   Ottewell PD, 2016, J BONE ONCOL, V5, P124, DOI 10.1016/j.jbo.2016.03.007
   Pacheco Soto BT, 2021, J DRUG ASSESS, V10, P97, DOI 10.1080/21556660.2021.1989194
   Paglia DN, 2013, J ORTHOP RES, V31, P783, DOI 10.1002/jor.22288
   Parente P, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756 9966 27 34
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Park HK, 2015, METABOLISM, V64, P24, DOI 10.1016/j.metabol.2014.08.004
   Pereira S, 2021, ENDOCR REV, V42, P1, DOI 10.1210/endrev/bnaa027
   Pliszka M, 2021, CANCERS, V13, DOI 10.3390/cancers13164184
   Pouysségur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871
   Rao S, 2018, TRENDS CELL BIOL, V28, P213, DOI 10.1016/j.tcb.2017.11.001
   Rego DF, 2015, ORAL ONCOL, V51, P416, DOI 10.1016/j.oraloncology.2015.01.007
   Reinicke K, 2012, J CELL BIOCHEM, V113, P553, DOI 10.1002/jcb.23379
   Rodríguez Enríquez S, 2009, J CELL PHYSIOL, V221, P552, DOI 10.1002/jcp.21885
   Röcken M, 2010, J CLIN INVEST, V120, P1800, DOI 10.1172/JCI43424
   Roodman GD, 2008, CANCER TREAT REV, V34, P92, DOI 10.1016/j.ctrv.2007.09.002
   Saraei P, 2019, CANCER MANAG RES, V11, P3295, DOI 10.2147/CMAR.S200059
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shin E, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.728759
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Siddiqui JA, 2016, PHYSIOLOGY, V31, P233, DOI 10.1152/physiol.00061.2014
   Siegel RL, 2023, CA CANCER J CLIN, V73, P17, DOI [10.3322/caac.21763, 10.3322/caac.21820]
   Slavic S, 2018, J MOL MED, V96, P559, DOI 10.1007/s00109 018 1641 x
   Steger Guenther G, 2011, Ther Adv Med Oncol, V3, P233, DOI 10.1177/1758834011412656
   Svensson E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 016022
   Taefehshokr S, 2021, PATHOL RES PRACT, V217, DOI 10.1016/j.prp.2020.153314
   Tanaka K, 2012, J BIOL CHEM, V287, P11616, DOI 10.1074/jbc.M111.292193
   Tarn C, 2006, CANCER RES, V66, P5477, DOI 10.1158/0008 5472.CAN 05 3906
   Tasheva ES, 2002, BBA GENE STRUCT EXPR, V1575, P123, DOI 10.1016/S0167 4781(02)00245 2
   Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451
   Thorens B, 2010, AM J PHYSIOL ENDOC M, V298, pE141, DOI 10.1152/ajpendo.00712.2009
   Valle Tenney R., 2023, Current Opinion in Endocrine and Metabolic Research, V32, DOI [10.1016/j.coemr.2023.100473, DOI 10.1016/J.COEMR.2023.100473]
   van Dam PA, 2020, ADV EXP MED BIOL, V1277, P53, DOI 10.1007/978 3 030 50224 9_3
   Vandamme D, 2013, QJM INT J MED, V106, P891, DOI 10.1093/qjmed/hct163
   Vasseur A, 2021, MOL ONCOL, V15, P1647, DOI 10.1002/1878 0261.12869
   Vera JC, 2001, BIOCHEMISTRY US, V40, P777, DOI 10.1021/bi001660j
   Villani LA, 2016, MOL METAB, V5, P1048, DOI 10.1016/j.molmet.2016.08.014
   Wang YN, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.682947
   Wang YH, 2007, EXP BIOL MED, V232, P1152, DOI 10.3181/0701 RM 8
   Weivoda MM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14003 6
   Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535 7163.MCT 08 0569
   Wu JW, 2017, J CLIN ONCOL, V35, P3647, DOI [10.1200/jco.2017.73.4491, 10.1200/JCO.2017.73.4491]
   Wu JY, 2020, MOL CELL, V77, P213, DOI 10.1016/j.molcel.2019.10.023
   Wu KH, 2018, J FOOD DRUG ANAL, V26, P221, DOI 10.1016/j.jfda.2017.03.009
   Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112
   Xu DY, 2020, INT J ONCOL, V57, P1223, DOI 10.3892/ijo.2020.5120
   Xu T, 2019, ONCOTARGETS THER, V12, P10639, DOI 10.2147/OTT.S222967
   Yao QQ, 2017, BONE, V97, P175, DOI 10.1016/j.bone.2017.01.028
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
   Ylisaukko oja SK, 2006, EUR J HUM GENET, V14, P880, DOI 10.1038/sj.ejhg.5201630
   Zambrano A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133374
   Zhou J, 2020, BIOMED PHARMACOTHER, V132, DOI 10.1016/j.biopha.2020.110821
   Zoch ML, 2016, BONE, V82, P42, DOI 10.1016/j.bone.2015.05.046
NR 150
TC 1
Z9 1
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2234 943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 11
PY 2024
VL 14
AR 1481241
DI 10.3389/fonc.2024.1481241
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA N1L4P
UT WOS:001362028600001
PM 39588310
OA gold
DA 2025 08 17
ER

PT J
AU Dutta, A
   Li, J
   Lu, HM
   Akech, J
   Pratap, J
   Wang, T
   Zerlanko, BJ
   FitzGerald, TJ
   Jiang, Z
   Birbe, R
   Wixted, J
   Violette, SM
   Stein, JL
   Stein, GS
   Lian, JB
   Languino, LR
AF Dutta, Anindita
   Li, Jing
   Lu, Huimin
   Akech, Jacqueline
   Pratap, Jitesh
   Wang, Tao
   Zerlanko, Brad J.
   FitzGerald, Thomas J.
   Jiang, Zhong
   Birbe, Ruth
   Wixted, John
   Violette, Shelia M.
   Stein, Janet L.
   Stein, Gary S.
   Lian, Jane B.
   Languino, Lucia R.
TI Integrin a6 Promotes an Osteolytic Program in Cancer Cells by
   Upregulating MMP2
SO CANCER RESEARCH
LA English
DT Article
ID HUMAN PROSTATE CANCER; BONE METASTASIS; IN VIVO; GROWTH; EXPRESSION;
   PROGRESSION; INVASION; MATRIX METALLOPROTEINASE 9; ADENOCARCINOMA;
   OSTEOBLAST
AB The molecular circuitries controlling osseous prostate metastasis are known to depend on the activity of multiple pathways, including integrin signaling. Here, we demonstrate that the alpha v beta 6 integrin is upregulated in human prostate cancer bone metastasis. In prostate cancer cells, this integrin is a functionally active receptor for fibronectin and latency associated peptide TGF beta 1; it mediates attachment and migration upon ligand binding and is localized in focal contacts. Given the propensity of prostate cancer cells to form bone metastatic lesions, we investigated whether the alpha v beta 6 integrin promotes this type of metastasis. We show for the first time that alpha v beta 6 selectively induces matrix metalloproteinase 2 (MMP2) in vitro in multiple prostate cancer cells and promotes osteolysis in vivo in an immunodeficient mouse model of bone metastasis through upregulation of MMP2, but not MMP9. The effect of alpha v beta 6 on MMP2 expression and activity is independent of androgen receptor in the analyzed prostate cancer cells. Increased levels of parathyroid hormone related protein (PTHrP), known to induce osteoclastogenesis, were also observed in alpha v beta 6 expressing cells. However, by using MMP2 short hairpin RNA, we demonstrate that the alpha v beta 6 effect on bone loss is due to upregulation of soluble MMP2 by the cancer cells, not due to changes in tumor growth rate. Another related av containing integrin, alpha v beta 5, fails to show similar responses, underscoring the significance of alpha v beta 6 activity. Overall, these mechanistic studies establish that expression of a single integrin, alpha v beta 6, contributes to the cancer cell mediated program of osteolysis by inducing matrix degradation through MMP2. Our results open new prospects for molecular therapy for metastatic bone disease.
C1 [Dutta, Anindita; Li, Jing; Lu, Huimin; Akech, Jacqueline; Pratap, Jitesh; Zerlanko, Brad J.; Birbe, Ruth; Wixted, John; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.; Languino, Lucia R.] Thomas Jefferson Univ, Prostate Canc Discovery & Dev Program, Philadelphia, PA 19107 USA.
   [Dutta, Anindita; Lu, Huimin; Zerlanko, Brad J.; Languino, Lucia R.] Thomas Jefferson Univ, Dept Canc Biol, Philadelphia, PA 19107 USA.
   [Birbe, Ruth] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA.
   [Li, Jing; Akech, Jacqueline; Pratap, Jitesh] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA.
   [Wang, Tao; FitzGerald, Thomas J.] Univ Massachusetts, Sch Med, Dept Radiat Oncol, Worcester, MA USA.
   [Jiang, Zhong] Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA.
   [Wixted, John] Univ Massachusetts, Sch Med, Dept Orthoped, Worcester, MA USA.
   [Violette, Shelia M.] Biogen Idec Inc, Cambridge, MA USA.
   [Stein, Janet L.; Stein, Gary S.; Lian, Jane B.] Univ Vermont, Dept Biochem, Burlington, VT 05405 USA.
C3 Thomas Jefferson University; Thomas Jefferson University; Thomas
   Jefferson University; University of Massachusetts System; University of
   Massachusetts Worcester; University of Massachusetts System; University
   of Massachusetts Worcester; University of Massachusetts System;
   University of Massachusetts Worcester; University of Massachusetts
   System; University of Massachusetts Worcester; Biogen; University of
   Vermont
RP Languino, LR (通讯作者)，Thomas Jefferson Univ, 233 S 10th St,BLSB 506, Philadelphia, PA 19107 USA.
EM Lucia.Languino@jefferson.edu
RI ; Birbe, Ruth/NRY 3919 2025; Fuchs, Christiane/AAE 9892 2019; jiang,
   zhongming/NFT 8717 2025
OI FitzGerald, TJ/0000 0002 6256 0615; Birbe, Ruth/0000 0002 0651 2360; Lu,
   Huimin/0009 0006 0442 1226; Languino, Lucia/0000 0001 9011 7031; 
FU NIH [R01 CA89720, PO1 CA140043, S10 RR023540, R37DE012528]; Our Danny
   Cancer Research Foundation [P00010003300000, P60010008300000];
   Commonwealth University Research Enhancement Program; National
   Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK) [DK32520];
   Kimmel Cancer Center Cancer Histology Resources; National Cancer
   Institute (NCI) [P30CA56036]
FX This work was supported by the following grants: NIH R01 CA89720 (L.R.
   Languino); PO1 CA140043 (L.R. Languino, G.S. Stein, and J.B. Lian); Our
   Danny Cancer Research Foundation P00010003300000 (T. Wang) and
   P60010008300000 (J. Li); NIH S10 RR023540 (J.B. Lian) and R37DE012528
   ARRA Merit Award NCI PO1 CA82834 (G.S. Stein and J.B. Lian). This
   project is also funded, in part, under a Commonwealth University
   Research Enhancement Program grant with the Pennsylvania Department of
   Health (H.R.). Histology core resources were supported by National
   Institutes of Diabetes, Digestive and Kidney Diseases (NIDDK) grant
   DK32520 and the Kimmel Cancer Center Cancer Histology Resources
   supported in part by National Cancer Institute (NCI) grant P30CA56036,
   which also supports the Kimmel Cancer Center Cancer Genomics Resource
   used in this study.
CR Ahmed N, 2002, J CELL BIOCHEM, V84, P675, DOI 10.1002/jcb.10080
   Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389
   Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404 06
   Bisanz K, 2005, MOL THER, V12, P634, DOI 10.1016/j.ymthe.2005.05.012
   BREUSS JM, 1995, J CELL SCI, V108, P2241
   Chantrain CF, 2004, CANCER RES, V64, P1675, DOI 10.1158/0008 5472.CAN 03 0160
   Choueiri MB, 2006, CANCER METAST REV, V25, P601, DOI 10.1007/s10555 006 9034 y
   Cicek M, 2006, CANCER METAST REV, V25, P635, DOI 10.1007/s10555 006 9035 x
   Cooper CR, 2002, NEOPLASIA, V4, P191, DOI 10.1038/sj.neo.7900224
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259
   Fornaro M, 1999, J CLIN INVEST, V103, P321, DOI 10.1172/JCI4585
   Franco OE, 2011, CANCER RES, V71, P1272, DOI 10.1158/0008 5472.CAN 10 3142
   Garlick DS, 2012, AM J TRANSL RES, V4, P165
   Goel HL, 2008, ENDOCR RELAT CANCER, V15, P657, DOI 10.1677/ERC 08 0019
   Goel HL, 2004, J CELL BIOL, V166, P407, DOI 10.1083/jcb.200403003
   Hall CL, 2006, CANCER RES, V66, P8648, DOI 10.1158/0008 5472.CAN 06 1544
   Kawamata H, 1997, INT J CANCER, V70, P120, DOI 10.1002/(SICI)1097 0215(19970106)70:1<120::AID IJC18>3.0.CO;2 P
   Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   McCabe NP, 2007, ONCOGENE, V26, P6238, DOI 10.1038/sj.onc.1210429
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200
   Morrissey C, 2010, PROSTATE, V70, P412, DOI 10.1002/pros.21075
   Mosig RA, 2007, HUM MOL GENET, V16, P1113, DOI 10.1093/hmg/ddm060
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nemeth JA, 2002, J NATL CANCER I, V94, P17
   Ports MO, 2009, CANCER RES, V69, P5007, DOI 10.1158/0008 5472.CAN 09 0354
   Pratap J, 2005, MOL CELL BIOL, V25, P8581, DOI 10.1128/MCB.25.19.8581 8591.2005
   Pratap J, 2008, CANCER RES, V68, P7795, DOI 10.1158/0008 5472.CAN 08 1078
   Pratap J, 2010, MOL CANCER THER, V9, P3210, DOI 10.1158/1535 7163.MCT 10 0572
   Roudier MP, 2008, J UROLOGY, V180, P1154, DOI 10.1016/j.juro.2008.04.140
   Sangaletti S, 2008, CANCER RES, V68, P9050, DOI 10.1158/0008 5472.CAN 08 1327
   Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140 6736(10)60172 9
   Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945 053X(00)00065 2
   Sottnik JL, 2012, BONEKEY REP, V1, P1
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   Thiolloy S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029862
   Trerotola M, 2013, CANCER RES, V73, P3155, DOI 10.1158/0008 5472.CAN 12 3266
   Trudel D, 2003, CANCER RES, V63, P8511
   Van Aarsen LAK, 2008, CANCER RES, V68, P561, DOI 10.1158/0008 5472.CAN 07 2307
   Vidal M, 2010, AM J PATHOL, V176, P3007, DOI 10.2353/ajpath.2010.090253
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Weinreb PH, 2004, J BIOL CHEM, V279, P17875, DOI 10.1074/jbc.M312103200
   Yang GY, 2008, CANCER SCI, V99, P879, DOI 10.1111/j.1349 7006.2008.00762.x
   Yin JJ, 2003, P NATL ACAD SCI USA, V100, P10954, DOI 10.1073/pnas.1830978100
   Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970
NR 49
TC 60
Z9 60
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 0008 5472
EI 1538 7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2014
VL 74
IS 5
BP 1598
EP 1608
DI 10.1158/0008 5472.CAN 13 1796
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AC4FG
UT WOS:000332475900031
PM 24385215
OA Green Accepted, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Wei, X
   Huang, XT
   Zhang, LY
   Hu, XY
   Zhang, W
   Zhou, YQ
   Yu, HF
   Ding, CF
   Zhang, LC
   Liu, X
   Zhou, Y
AF Wei, Xin
   Huang, Xiao Teng
   Zhang, Li Yan
   Hu, Xin Yue
   Zhang, Wei
   Zhou, Yong Qiang
   Yu, Hao Fei
   Ding, Cai Feng
   Zhang, Lan Chun
   Liu, Xia
   Zhou, Ying
TI New oxindole alkaloids with selective osteoclast inhibitory activity
   from Gelsemium elegans
SO NATURAL PRODUCT RESEARCH
LA English
DT Article
DE Gelsemium elegans; oxindole alkaloids; osteoclast inhibitory; PCR
   bioassay
ID INDOLE ALKALOIDS; LEAVES
AB A new alkaloid 14 hydroxygelseziridine (1), along with four known oxindoles (2 5), was isolated and characterized from the well known toxic medicine Gelsemium elegans. Their structures were elucidated by means of spectroscopic techniques and quantum chemistry calculations. Structurally, new compound 1 has a three membered oxygen ring at N 4/C 20. All compounds were tested for osteoclast (MOC 1) inhibitory activity in vitro. Compound 2 exhibited the selective osteoclast inhibitory activity. Flow cytometry revealed that the apoptosis of osteoclasts induced by 2. Furthermore, the PCR bioassay suggested that compound 2 may activate the apoptotic pathway of osteoclasts by reducing the expression of IL 6 and c Jun, and increasing caspase 9. This work provided the evidence for the rationality as the traditional treatment for bone related diseases of G. elegans, and shed a new light on its further research.
   [GRAPHICS]
   .
C1 [Wei, Xin; Huang, Xiao Teng; Zhang, Li Yan; Hu, Xin Yue; Zhang, Wei; Zhou, Yong Qiang; Liu, Xia; Zhou, Ying] Guizhou Univ Tradit Chinese Med, Guiyang, Peoples R China.
   [Yu, Hao Fei; Ding, Cai Feng; Zhang, Lan Chun] Kunming Med Univ, Sch Pharmaceut Sci, Dept Zool, Kunming, Yunnan, Peoples R China.
   [Yu, Hao Fei; Ding, Cai Feng; Zhang, Lan Chun] Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming, Yunnan, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine; Kunming Medical
   University; Kunming Medical University
RP Liu, X; Zhou, Y (通讯作者)，Guizhou Univ Tradit Chinese Med, Guiyang, Peoples R China.; Zhang, LC (通讯作者)，Kunming Med Univ, Sch Pharmaceut Sci, Dept Zool, Kunming, Yunnan, Peoples R China.; Zhang, LC (通讯作者)，Kunming Med Univ, Yunnan Key Lab Pharmacol Nat Prod, Kunming, Yunnan, Peoples R China.
EM zhlch_2010@163.com; liuxia0851@126.com; yingzhou71@126.com
RI lanchun, zhang/GQQ 4034 2022; ding, caifeng/KSL 7628 2024
OI Wei, Xin/0000 0001 8361 9877
FU National Natural Science Foundation of China [32000276]; Guizhou Science
   and Technology Project (Xue Shu Xin Miao) [QKHPT RC[2018]5766 12];
   Digitalization, Development and Application of Biotic Resource
   [202002AA100007]
FX This work was supported by the National Natural Science Foundation of
   China (No. 32000276), Guizhou Science and Technology Project (Xue Shu
   Xin Miao) (QKHPT RC[2018]5766 12), Digitalization, Development and
   Application of Biotic Resource (202002AA100007).
CR Hejazizadeh M., 2017, J SHAHREKORD U MED, V18, P35
   Jin GL, 2014, J ETHNOPHARMACOL, V152, P33, DOI 10.1016/j.jep.2014.01.003
   Kitajima M, 2006, J NAT PROD, V69, P715, DOI 10.1021/np060016o
   Kogure N, 2006, ORG LETT, V8, P3085, DOI 10.1021/ol061062i
   LIN LZ, 1991, PHYTOCHEMISTRY, V30, P1311, DOI 10.1016/S0031 9422(00)95223 3
   PONGLUX D, 1988, TETRAHEDRON, V44, P5075, DOI 10.1016/S0040 4020(01)86012 9
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   SCHUN Y, 1985, J NAT PROD, V48, P969, DOI 10.1021/np50042a016
   Takayama H., 1994, NAT PROD LETT, V5, P15, DOI 10.1080/10575639408043929
   Ti Yun Fan, 2014, Zhongguo Gu Shang, V27, P529
   Wei X, 2020, TETRAHEDRON LETT, V61, DOI 10.1016/j.tetlet.2019.151502
   Wei X, 2018, TETRAHEDRON LETT, V59, P2066, DOI 10.1016/j.tetlet.2018.04.041
   Wei X, 2018, BIOORGAN MED CHEM, V26, P1776, DOI 10.1016/j.bmc.2018.02.024
   Wen H., 2020, CHIN J CLIN GASTROEN, V32, P343
   Xu YK, 2015, J NAT PROD, V78, P1511, DOI 10.1021/np5009619
   Zhang W, 2020, CHEM NAT COMPD+, V56, P1140, DOI 10.1007/s10600 020 03248 z
NR 16
TC 9
Z9 9
U1 0
U2 21
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1478 6419
EI 1478 6427
J9 NAT PROD RES
JI Nat. Prod. Res.
PY 2022
VL 36
IS 10
BP 2630
EP 2636
DI 10.1080/14786419.2021.1913589
EA APR 2021
PG 7
WC Chemistry, Applied; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 1S4RD
UT WOS:000668720200001
PM 33908330
DA 2025 08 17
ER

PT J
AU Kondo, H
   Nifuji, A
   Takeda, S
   Ezura, Y
   Rittling, SR
   Denhardt, DT
   Nakashima, K
   Karsenty, G
   Noda, M
AF Kondo, H
   Nifuji, A
   Takeda, S
   Ezura, Y
   Rittling, SR
   Denhardt, DT
   Nakashima, K
   Karsenty, G
   Noda, M
TI Unloading induces osteoblastic cell suppression and osteoclastic cell
   activation to lead to bone loss via sympathetic nervous system
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID OSTEOPOROSIS; RESPONSES; THERAPY
AB Osteoporosis is one of the major health problems in our modern world. Especially, disuse ( unloading) osteoporosis occurs commonly in bedridden patients, a population that is rapidly increasing due to aging associated diseases. However, the mechanisms underlying such unloading induced pathological bone loss have not yet been fully understood. Since sympathetic nervous system could control bone mass, we examined whether unloading induced bone loss is controlled by sympathetic nervous tone. Treatment with beta blocker, propranolol, suppressed the unloading induced reduction in bone mass. Conversely, beta agonist, isoproterenol, reduced bone mass in loaded mice, and under such conditions, unloading no longer further reduced bone mass. Analyses on the cellular bases indicated that unloadinginduced reduction in the levels of osteoblastic cell activities, including mineral apposition rate, mineralizing surface, and bone formation rate, was suppressed by propranolol treatment and that isoproterenol induced reduction in these levels of bone formation parameters was no longer suppressed by unloading. Unloading  induced reduction in the levels of mineralized nodule formation in bone marrow cell cultures was suppressed by propranolol treatment in vivo. In addition, loss of a half dosage in the dopamine beta hydroxylase gene suppressed the unloading induced bone loss and reduction in mineralized nodule formation. Unloading induced increase in the levels of osteoclastic activities such as osteoclast number and surface as well as urinary deoxypyridinoline was all suppressed by the treatment with propranolol. These observations indicated that sympathetic nervous tone mediates unloading induced bone loss through suppression of bone formation by osteoblasts and enhancement of resorption by osteoclasts.
C1 Tokyo Med & Dent Univ, Dept Mol Pharmacol, Inst Med Res, Chiyoda Ku, Tokyo 1010062, Japan.
   Tokyo Med & Dent Univ, 21st Century Ctr Excellence Program Frontier Res, Tokyo 1010062, Japan.
   Tokyo Med & Dent Univ, ABJS Integrated Act Initiat JSPS Core Core Progra, Tokyo 1010062, Japan.
   Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1010062, Japan.
   Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Rutgers State Univ, Piscataway, NJ 08854 USA.
C3 Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Institute of Science Tokyo; Tokyo Medical & Dental University (TMDU);
   Baylor College of Medicine; Rutgers University System; Rutgers
   University New Brunswick
RP Noda, M (通讯作者)，Tokyo Med & Dent Univ, Dept Mol Pharmacol, Inst Med Res, Chiyoda Ku, 3 10 Kanda Surugadai,2 Chome, Tokyo 1010062, Japan.
EM noda.mph@mri.tmd.ac.jp
RI Ezura, Yoichi/L 9485 2016; Nifuji, Akira/AAX 7907 2021; takeda,
   shu/B 5195 2012
OI Nifuji, Akira/0000 0002 8182 4380; Nakashima,
   Kazuhisa/0000 0003 0491 2149; 
CR Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   Bikle Daniel D, 2003, Gravit Space Biol Bull, V16, P45
   BIKLE DD, 1991, J BONE MINER RES, V6, P527
   Commins SP, 2000, J BIOL CHEM, V275, P33059, DOI 10.1074/jbc.M006328200
   Cox JF, 2002, J PHYSIOL LONDON, V538, P309, DOI 10.1113/jphysiol.2001.012574
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Fu Q, 2002, J PHYSIOL LONDON, V544, P653, DOI 10.1113/jphysiol.2002.025098
   Fuller KE, 2004, NEW ENGL J MED, V350, P190
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661
   Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399
   Lanyon L, 2001, J BONE MINER RES, V16, P1937, DOI 10.1359/jbmr.2001.16.11.1937
   Mohamed AM, 2003, NEW ENGL J MED, V349, P1671
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Raisz LG, 2003, ENDOCRIN METAB CLIN, V32, P15, DOI 10.1016/S0889 8529(02)00055 5
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Riggs BL, 2003, J CELL BIOCHEM, V88, P209, DOI 10.1002/jcb.10345
   Serhan CN, 2004, NEW ENGL J MED, V350, P1902, DOI 10.1056/NEJMcibr040318
   Sherman BE, 2000, J BONE MINER RES, V15, P1354, DOI 10.1359/jbmr.2000.15.7.1354
   Strewler GJ, 2004, NEW ENGL J MED, V350, P1172, DOI 10.1056/NEJMp048017
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0
NR 22
TC 156
Z9 174
U1 1
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD AUG 26
PY 2005
VL 280
IS 34
BP 30192
EP 30200
DI 10.1074/jbc.M504179200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 957IC
UT WOS:000231362500027
PM 15961387
OA hybrid
DA 2025 08 17
ER

PT J
AU Serim, TM
   Amasya, G
   Eren Böncü, T
   Sengel Türk, CT
   Özdemir, AN
AF Serim, Tugrul Mert
   Amasya, Gulin
   Eren Boncu, Tugba
   Sengel Turk, Ceyda Tuba
   Ozdemir, Ayse Nurten
TI Electrospun nanofibers: building blocks for the repair of bone tissue
SO BEILSTEIN JOURNAL OF NANOTECHNOLOGY
LA English
DT Article
ID DRUG DELIVERY; IN VITRO; HIERARCHICAL STRUCTURE; SURFACE MORPHOLOGY;
   ULTRAFINE FIBERS; MOLECULAR WEIGHT; RELEASE; SOLVENTS; FABRICATION;
   BEADS
AB Bone, one of the hardest structures of the body, is the basic constituent of the skeletal system, which gives the shape to the body, provides mechanical support for muscles and soft tissues, and provides movement. Even if there is no damage, bone remodeling is a permanent process to preserve and renew the structural, biochemical, and biomechanical integrity of bone tissue. Apart from the remodeling, bone healing is the highly complicated process of repairing deficiencies of bone tissue by the harmonious operation of osteoblasts, osteocytes, osteoclasts, and bone lining cells. Various materials can be used to both trigger the bone healing process and to provide mechanical support to damaged bone. Nanofiber scaffolds are at the forefront of these types of systems because of their extremely large surface area to volume ratio, small pore size, and high porosity. Nanofibers are known to be highly functional systems with the ability to mimic the structure and function of the natural bone matrix, facilitating osteogenesis for cell proliferation and bone regeneration. Electrospinning is an easy and fast method to produce non woven structures consisting of continuous ultrafine fibers with diameters ranging from micrometers down to nanometers. The simplicity and cost effectiveness of the electrospinning technique, its ability to use a wide variety of synthetic, natural, and mixed polymers, and the formation of highly porous and continuous fibers are the remarkable features of this method. The importance of nanofiber based scaffolds in bone tissue regeneration is increasing because of suitable pore size, high porosity, osteoinduction, induction of bone growth with osteoconduction, adaptability to the target area, biodegradation, and appropriate mechanical properties, which are among the main parameters that are important in the design of polymeric bone grafts. The aim of this review is to cast light on the increasing use of nanofiber based scaffolds in bone tissue regeneration and give an insight about bone regeneration, production techniques of the electrospun nanofibers, and varying formulation parameters in order to reach different drug delivery goals. This review also provides an extensive market research of electrospun nanofibers and an overview on scientific research and patents in the field.
C1 [Serim, Tugrul Mert; Amasya, Gulin; Eren Boncu, Tugba; Sengel Turk, Ceyda Tuba] Ankara Univ, Fac Pharm, Dept Pharmaceut Technol, TR 06560 Ankara, Turkiye.
   [Eren Boncu, Tugba] Erciyes Univ, Fac Pharm, Dept Pharmaceut Technol, TR 38280 Kayseri, Turkiye.
   [Ozdemir, Ayse Nurten] Istanbul Aydin Univ, Fac Pharm, Dept Pharmaceut Technol, Istanbul, Turkiye.
C3 Ankara University; Erciyes University; Istanbul Aydin University
RP Eren Böncü, T (通讯作者)，Erciyes Univ, Fac Pharm, Dept Pharmaceut Technol, TR 38280 Kayseri, Turkiye.
RI Sengel Turk, Ceyda Tuba/AAF 7174 2020; Serim, Tugrul/W 2989 2017;
   Amasya, Gülin/AAC 4141 2020; Eren Boncu, Tugba/AAC 2099 2022
CR Agarwal R, 2015, ADV DRUG DELIVER REV, V94, P53, DOI 10.1016/j.addr.2015.03.013
   [Anonymous], PLLA and collagen scaffolds
   [Anonymous], Poly (epsilon caprolactone) nanofibers
   Ansari M, 2019, PROG BIOMATER, V8, P223, DOI 10.1007/s40204 019 00125 z
   Bala Y, 2015, CURR OPIN RHEUMATOL, V27, P406, DOI 10.1097/BOR.0000000000000183
   Battafarano G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041178
   Bayliss L., 2012, Surgery (Oxford), V30, P47, DOI DOI 10.1016/J.MPSUR.2011.12.009
   Beachley V, 2009, MAT SCI ENG C BIO S, V29, P663, DOI 10.1016/j.msec.2008.10.037
   Bhardwaj N, 2010, BIOTECHNOL ADV, V28, P325, DOI 10.1016/j.biotechadv.2010.01.004
   Black J., 2020, Orthopaedics and Trauma, V34, P113, DOI DOI 10.1016/J.MPORTH.2020.03.002
   Buck DW, 2012, PLAST RECONSTR SURG, V129, P1314, DOI 10.1097/PRS.0b013e31824eca94
   Chen ML, 2014, ADV HEALTHC MATER, V3, P1721, DOI 10.1002/adhm.201400166
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Crow BB, 2005, TISSUE ENG, V11, P1077, DOI 10.1089/ten.2005.11.1077
   Cui WG, 2010, SCI TECHNOL ADV MAT, V11, DOI 10.1088/1468 6996/11/1/014108
   De Vrieze S, 2009, J MATER SCI, V44, P1357, DOI 10.1007/s10853 008 3010 6
   Deitzel JM, 2001, POLYMER, V42, P261, DOI 10.1016/S0032 3861(01)00336 6
   Demir MM, 2002, POLYMER, V43, P3303, DOI 10.1016/S0032 3861(02)00136 2
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   DOSHI J, 1995, J ELECTROSTAT, V35, P151, DOI 10.1016/0304 3886(95)00041 8
   Ellison CJ, 2007, POLYMER, V48, P3306, DOI 10.1016/j.polymer.2007.04.005
   Elmarco, Nanospider
   Eren Boncu T, 2019, LAT AM J PHARM, V38, P1552
   Boncu TE, 2020, DRUG DEV IND PHARM, V46, P109, DOI 10.1080/03639045.2019.1706550
   Eren Boncu T, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118758
   European Patent Office, ABOUT US
   Fanavaran Nano Meghyas (FNM Co. Ltd.), INFL8100
   Florencio Silva R, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/421746
   Fratzl P., 2008, P1, DOI 10.1007/978 0 387 73906 9_1
   Garg T, 2015, J DRUG TARGET, V23, P202, DOI 10.3109/1061186X.2014.992899
   Gergin I, 2017, BEILSTEIN J NANOTECH, V8, P1616, DOI 10.3762/bjnano.8.161
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Gilchrist SE, 2013, J CONTROL RELEASE, V170, P64, DOI 10.1016/j.jconrel.2013.04.012
   Gu XH, 2014, INT J ELECTROCHEM SC, V9, P8045
   Guo X. E., 2020, Encyclopedia of Bone Biology, P233, DOI [10.1016/b978 0 12 801238 3.11551 x, DOI 10.1016/B978 0 12 801238 3.11551 X]
   Haider A, 2018, ARAB J CHEM, V11, P1165, DOI 10.1016/j.arabjc.2015.11.015
   He J. H., 2008, Electrospun Nanofibres and Their Applications
   Hrib J, 2015, BEILSTEIN J NANOTECH, V6, P1939, DOI 10.3762/bjnano.6.198
   Hsu YH, 2014, INT J NANOMED, V9, P4347, DOI 10.2147/IJN.S66526
   Huan SQ, 2015, MATERIALS, V8, P2718, DOI 10.3390/ma8052718
   Huang ZM, 2006, J BIOMED MATER RES A, V77A, P169, DOI 10.1002/jbm.a.30564
   Huang ZM, 2003, COMPOS SCI TECHNOL, V63, P2223, DOI 10.1016/S0266 3538(03)00178 7
   Inovenso, Nanospinner 416
   Jabur AR, 2018, J PHYS CONF SER, V1003, DOI 10.1088/1742 6596/1003/1/012069
   Jang JH, 2009, ADV DRUG DELIVER REV, V61, P1065, DOI 10.1016/j.addr.2009.07.008
   Jankovic B, 2013, INT J PHARMACEUT, V455, P338, DOI 10.1016/j.ijpharm.2013.06.083
   Jia L, 2013, J THERM ANAL CALORIM, V112, P595, DOI 10.1007/s10973 012 2607 9
   Jing Z, 2003, J CONTROL RELEASE, V92, P227, DOI 10.1016/S0168 3659(03)00372 9
   Jorgensen L, 2015, RSC ADV, V5, P53644, DOI 10.1039/c5ra10498j
   Kahla R. B., 2021, Bone Remodeling Process, DOI [10.1016/c2020 0 03574 7, DOI 10.1016/C2020 0 03574 7]
   Karuppuswamy P, 2015, MATER LETT, V141, P180, DOI 10.1016/j.matlet.2014.11.044
   Kaynar Ozdemir N., 1987, Bilimler Derg. (1976 2000), V12, P115
   Ki CS, 2005, POLYMER, V46, P5094, DOI 10.1016/j.polymer.2005.04.040
   Kim K, 2004, J CONTROL RELEASE, V98, P47, DOI 10.1016/j.jconrel.2004.04.009
   Lee KH, 2003, POLYMER, V44, P4029, DOI 10.1016/S0032 3861(03)00345 8
   Li NY, 2016, BIOMATER SCI UK, V4, P1554, DOI 10.1039/c6bm00481d
   Li WJ, 2002, J BIOMED MATER RES, V60, P613, DOI 10.1002/jbm.10167
   Lin T, 2004, NANOTECHNOLOGY, V15, P1375, DOI 10.1088/0957 4484/15/9/044
   Lin X, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00757
   Liu KS, 2012, CHEST, V141, P1197, DOI 10.1378/chest.11 1254
   Liu Y, 2008, POLYM INT, V57, P632, DOI 10.1002/pi.2387
   Liu Z, 2016, APPL SURF SCI, V364, P516, DOI 10.1016/j.apsusc.2015.12.176
   Loscertales IG, 2002, SCIENCE, V295, P1695, DOI 10.1126/science.1067595
   Luo CJ, 2010, POLYMER, V51, P1654, DOI 10.1016/j.polymer.2010.01.031
   Luraghi A, 2021, J CONTROL RELEASE, V334, P463, DOI 10.1016/j.jconrel.2021.03.033
   Megelski S, 2002, MACROMOLECULES, V35, P8456, DOI 10.1021/ma020444a
   Morgan E.F., 2021, Marcus and Feldmans Osteoporosis, P15
   Mwiiri FK, 2020, DELIVERY OF DRUGS, VOL. 2, P53, DOI 10.1016/B978 0 12 817776 1.00003 1
   Nayak R, 2012, TEXT RES J, V82, P129, DOI 10.1177/0040517511424524
   Ondarcuhu T, 1998, EUROPHYS LETT, V42, P215, DOI 10.1209/epl/i1998 00233 9
   Ortho Rebirth, ReBOSSIS
   Patterson J, 2010, MATER TODAY, V13, P14, DOI 10.1016/S1369 7021(10)70013 4
   Pillay V, 2013, J NANOMATER, V2013, DOI 10.1155/2013/789289
   Ranganath SH, 2008, BIOMATERIALS, V29, P2996, DOI 10.1016/j.biomaterials.2008.04.002
   Reneker DH, 2008, POLYMER, V49, P2387, DOI 10.1016/j.polymer.2008.02.002
   Reznikov N, 2014, ACTA BIOMATER, V10, P3815, DOI 10.1016/j.actbio.2014.05.024
   Rho JY, 1998, MED ENG PHYS, V20, P92, DOI 10.1016/S1350 4533(98)00007 1
   Sarkar K, 2010, MATER TODAY, V13, P12, DOI 10.1016/S1369 7021(10)70199 1
   Sela JJ, 2012, PRINCIPLES OF BONE REGENERATION, P1, DOI 10.1007/978 1 4614 2059 0_1
   Serim T. M., 2022, Polym. Sci., V2, P1
   Shin SH, 2012, J TISSUE ENG, V3, DOI 10.1177/2041731412443530
   Shin YM, 2001, APPL PHYS LETT, V78, P1149, DOI 10.1063/1.1345798
   Sill TJ, 2008, BIOMATERIALS, V29, P1989, DOI 10.1016/j.biomaterials.2008.01.011
   Srikar R, 2008, LANGMUIR, V24, P965, DOI 10.1021/la702449k
   Su WQ, 2018, MATER LETT, V216, P228, DOI 10.1016/j.matlet.2018.01.087
   Szewczyk PK, 2020, ADV COLLOID INTERFAC, V286, DOI 10.1016/j.cis.2020.102315
   Tan SH, 2005, POLYMER, V46, P6128, DOI 10.1016/j.polymer.2005.05.068
   Vlachou M., 2019, ELECTROSPINNING ELEC, P1, DOI 10.5772/intechopen.86181
   Wagh A, 2013, NANOMED NANOTECHNOL, V9, P449, DOI 10.1016/j.nano.2012.10.009
   Wang C, 2007, MACROMOLECULES, V40, P7973, DOI 10.1021/ma070508n
   Wang L, 2011, WOODHEAD PUBL MATER, P3
   Wang Z, 2016, INT J NANOMED, V11, P1483, DOI 10.2147/IJN.S97445
   Yalcinkaya F, 2016, ELECTROSPINNING   MATERIAL, TECHNIQUES AND BIOMEDICAL APPLICATIONS, P67, DOI 10.5772/65838
   Yang GZ, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671 016 1824 8
   Yang QB, 2004, J POLYM SCI POL PHYS, V42, P3721, DOI 10.1002/polb.20222
   Yu D. G., 2009, Health, V01, P67, DOI DOI 10.4236/HEALTH.2009.12012
   Yuan H, 2017, WOODHEAD PUBL SER TE, V186, P125, DOI 10.1016/B978 0 08 100907 9.00006 4
   Zamani M, 2013, INT J NANOMED, V8, P2997, DOI 10.2147/IJN.S43575
   Zargham S, 2012, J ENG FIBER FABR, V7, P42
   Zhang Q, 2017, DRUG DISCOV TODAY, V22, P1351, DOI 10.1016/j.drudis.2017.05.007
   Zhang XY, 2004, SYNTHETIC MET, V145, P23, DOI 10.1016/j.synthmet.2004.03.012
   Zhang YZ, 2008, BIOMATERIALS, V29, P4314, DOI 10.1016/j.biomaterials.2008.07.038
   Zheng JY, 2014, J NANOMATER, V2014, DOI 10.1155/2014/689298
   Zong XH, 2002, POLYMER, V43, P4403, DOI 10.1016/S0032 3861(02)00275 6
   Zupancic S, 2015, J DRUG DELIV SCI TEC, V30, P408, DOI 10.1016/j.jddst.2015.07.009
NR 105
TC 5
Z9 5
U1 0
U2 9
PU BEILSTEIN INSTITUT
PI FRANKFURT AM MAIN
PA TRAKEHNER STRASSE 7 9, FRANKFURT AM MAIN, 60487, GERMANY
SN 2190 4286
J9 BEILSTEIN J NANOTECH
JI Beilstein J. Nanotechnol.
PD JUL 25
PY 2024
VL 15
BP 941
EP 953
DI 10.3762/bjnano.15.77
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science; Physics
GA ZV8U8
UT WOS:001278161600001
PM 39076689
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Serra, AL
   Braun, SC
   Starke, A
   Savoca, R
   Hersberger, M
   Russmann, S
   Corti, N
   Wüthrich, RP
AF Serra, A. L.
   Braun, S. C.
   Starke, A.
   Savoca, R.
   Hersberger, M.
   Russmann, S.
   Corti, N.
   Wuethrich, R. P.
TI Pharmacokinetics and pharmacodynamics of cinacalcet in patients with
   hyperparathyroidism after renal transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE cinacalcet; hypercalcemia; hyperparathyrodism; renal transplantation
ID CALCIMIMETIC AGENT CINACALCET; NORMALIZES SERUM CALCIUM; PERSISTENT
   HYPERPARATHYROIDISM; SECONDARY HYPERPARATHYROIDISM;
   KIDNEY TRANSPLANTATION; PARATHYROID HORMONE; HEMODIALYSIS PATIENTS;
   SEVERE HYPERCALCEMIA; P GLYCOPROTEIN; RECIPIENTS
AB Cinacalcet is a calcimimetic drug for the treatment of secondary hyperparathyroidism (HPT). In a sequential open label study, ten patients with persistent HPT after renal transplantation received first 30 and then 60 mg oral cinacalcet once daily over 2 weeks each. Cinacalcet steady state oral clearance was 131.1 +/  20.9 l/h and 92.8 +/  9.5 l/h (mean +/  SE) after 30 and 60 mg, respectively. Cinacalcet and parathyroid hormone (PTH) concentrations showed an inverse correlation and were fitted to a simple E max model (E max = 80% reduction vs. baseline, EC50 = 13 ng/mL). A once daily administration of cinacalcet lowered serum calcium over 24 h without fluctuations. The 8 h fractional urinary excretion of calcium was increased after 60 mg cinacalcet (baseline 0.85 +/  0.17%, 30 mg 1.53 +/  0.35%, 60 mg 1.92 +/  0.37%). Renal function remained stable. Cinacalcet pharmacokinetics and pharmacodynamics showed a pronounced interindividual variability. We conclude that the once daily administration of cinacalcet in patients with secondary HPT after renal transplantation effectively reduced iPTH and serum calcium. The transient calciuria could potentially favor nephrocalcinosis and reduce bone mineral density, suggesting that higher doses of cinacalcet need to be used with caution in renal transplant recipients with severe persistent hyperparathyroidism.
C1 [Serra, A. L.; Braun, S. C.; Wuethrich, R. P.] Univ Zurich Hosp, Clin Nephrol, CH 8091 Zurich, Switzerland.
   [Serra, A. L.; Starke, A.; Wuethrich, R. P.] Univ Zurich, Inst Physiol, CH 8006 Zurich, Switzerland.
   [Serra, A. L.; Starke, A.; Wuethrich, R. P.] Univ Zurich, Zurich Ctr Integrat Human Physiol ZIHP, Zurich, Switzerland.
   [Savoca, R.] Reg Hosp Aarau, Ctr Lab Med, Aarau, Switzerland.
   [Hersberger, M.] Univ Zurich Hosp, Inst Clin Chem, CH 8091 Zurich, Switzerland.
   [Russmann, S.; Corti, N.] Univ Zurich Hosp, Div Clin Pharmacol, CH 8091 Zurich, Switzerland.
C3 University of Zurich; University Zurich Hospital; University of Zurich;
   University of Zurich; Zurich Center Integrative Human Physiology (ZIHP);
   University of Zurich; University Zurich Hospital; University of Zurich;
   University Zurich Hospital
RP Serra, AL (通讯作者)，Univ Zurich Hosp, Clin Nephrol, Ramistr 100, CH 8091 Zurich, Switzerland.
EM andreas.serra@usz.ch
OI Hersberger, Martin/0000 0002 4472 329X
CR Apostolou T, 2006, TRANSPL P, V38, P3514, DOI 10.1016/j.transproceed.2006.10.133
   Apostolou T, 2006, CLIN NEPHROL, V65, P374
   BAJPAI M, 2005, DRUG METAB REV S2, V37, P124
   Bushinsky DA, 2006, KIDNEY INT, V69, P1586, DOI 10.1038/sj.ki.5000324
   Chattopadhyay N, 1998, AM J PHYSIOL GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122
   El Amm JM, 2007, TRANSPLANTATION, V83, P546, DOI 10.1097/01.tp.0000253429.33198.2f
   Goodman WG, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341017
   Gwinner W, 2005, AM J TRANSPLANT, V5, P1934, DOI 10.1111/j.1600 6143.2005.00938.x
   HAAS HG, 1971, J CLIN INVEST, V50, P2689, DOI 10.1172/JCI106770
   Harris RZ, 2007, EUR J CLIN PHARMACOL, V63, P159, DOI 10.1007/s00228 006 0129 8
   Harris RZ, 2004, AM J KIDNEY DIS, V44, P1070, DOI 10.1053/j.ajkd.2004.08.029
   HARRIS RZ, 1937, CLIN PHARM, V46, P495
   Hernández D, 2005, KIDNEY INT, V67, P2015, DOI 10.1111/j.1523 1755.2005.00303.x
   HOSKING DJ, 1981, Q J MED, V50, P473
   Jespersen B, 1997, AM J HYPERTENS, V10, P1356, DOI 10.1016/S0895 7061(97)00275 6
   JULIAN BA, 1992, AM J KIDNEY DIS, V19, P99, DOI 10.1016/S0272 6386(12)70118 X
   Kruse AE, 2005, NEPHROL DIAL TRANSPL, V20, P1311, DOI 10.1093/ndt/gfh924
   Kruse AE, 2007, NEPHROL DIAL TRANSPL, V22, P2362, DOI 10.1093/ndt/gfm270
   Leca N, 2006, AM J TRANSPLANT, V6, P2391, DOI 10.1111/j.1600 6143.2006.01475.x
   Lemahieu WPD, 2004, AM J TRANSPLANT, V4, P1514, DOI 10.1111/j.1600 6143.2004.00539.x
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003 4819 130 6 199903160 00002
   Lindberg JS, 2003, KIDNEY INT, V63, P248, DOI 10.1046/j.1523 1755.2003.00720.x
   LOBO PI, 1995, CLIN TRANSPLANT, V9, P277
   Miller WG, 2005, ARCH PATHOL LAB MED, V129, P297
   Moe SM, 2005, KIDNEY INT, V67, P760, DOI 10.1111/j.1523 1755.2005.67139.x
   Nagano N, 2001, NEPHRON, V89, P321, DOI 10.1159/000046093
   Nemeth EF, 2004, J PHARMACOL EXP THER, V308, P627, DOI 10.1124/jpet.103.057273
   Peacock M, 2005, J CLIN ENDOCR METAB, V90, P135, DOI 10.1210/jc.2004 0842
   Pfister MF, 1998, P NATL ACAD SCI USA, V95, P1909, DOI 10.1073/pnas.95.4.1909
   Reinhardt W, 1998, NEPHROL DIAL TRANSPL, V13, P436, DOI 10.1093/oxfordjournals.ndt.a027843
   Schwarz A, 2007, NEPHROL DIAL TRANSPL, V22, P584, DOI 10.1093/ndt/gfl583
   Serra AL, 2005, NEPHROL DIAL TRANSPL, V20, P1315, DOI 10.1093/ndt/gfh925
   Serra AL, 2007, NEPHROL DIAL TRANSPL, V22, P577, DOI 10.1093/ndt/gfl560
   Shoback DM, 2003, J CLIN ENDOCR METAB, V88, P5644, DOI 10.1210/jc.2002 021597
   SONNEVELD P, 1994, J CLIN ONCOL, V12, P1584, DOI 10.1200/JCO.1994.12.8.1584
   Srinivas TR, 2006, CLIN J AM SOC NEPHRO, V1, P323, DOI 10.2215/CJN.00500705
   Szwarc I, 2006, TRANSPLANTATION, V82, P675, DOI 10.1097/01.tp.0000232452.80018.ad
   Treiber A, 2004, J PHARMACOL EXP THER, V308, P1121, DOI 10.1124/jpet.103.061614
   Vezzoli G, 2005, KIDNEY INT, V67, P2006, DOI 10.1111/j.1523 1755.2005.00302.x
   WACHER VJ, 1995, MOL CARCINOGEN, V13, P129, DOI 10.1002/mc.2940130302
NR 40
TC 38
Z9 38
U1 1
U2 2
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 1600 6135
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD APR
PY 2008
VL 8
IS 4
BP 803
EP 810
DI 10.1111/j.1600 6143.2007.02136.x
PG 8
WC Surgery; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery; Transplantation
GA 270YW
UT WOS:000253757100012
PM 18318784
DA 2025 08 17
ER

PT J
AU Kuroki, Y
   Kaji, H
   Kawano, S
   Kanda, F
   Takai, Y
   Kajikawa, M
   Sugimoto, T
AF Kuroki, Yasuo
   Kaji, Hiroshi
   Kawano, Seiji
   Kanda, Fumio
   Takai, Yutaka
   Kajikawa, Michiko
   Sugimoto, Toshitsugu
TI Short term effects of glucocorticoid therapy on biochemical markers of
   bone metabolism in Japanese patients: a prospective study
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE glucocorticoid therapy; biochemical markers of bone metabolism;
   short term effects; prospective study; glucocorticoid induced
   osteoporosis; initial glucocorticoid dose
ID PARATHYROID HORMONE; ALKALINE PHOSPHATASE; RHEUMATIC DISEASES;
   MECHANISMS; TURNOVER; RESORPTION; DEXAMETHASONE; PATHOGENESIS;
   PROMOTION; APOPTOSIS
AB Glucocorticoid (GC) therapy induces rapid bone loss, but the early changes in calcium and bone metabolism in patients treated with GC have not been clarified. To investigate the changes in calcium and bone metabolism during the early stage of GC therapy, we analyzed various biochemical markers of bone metabolism. The serum levels of calcium (Ca), phosphorus, parathyroid hormone (PTH), osteocalcin (OC), bone alkaline phosphatase (BAP), and type I collagen cross linked N telopeptide (NTx), as well as the urinary levels of Ca, creatinine, and NTx, were measured on days 0, 3, 7, and 28 of GC therapy. The subjects were divided into the following four groups: 9 patients receiving pulse therapy (P), 18 patients receiving prednisolone (PSL) at doses >= 40 mg/day (H), 9 patients receiving PSL at doses >= 20 mg/day (M), and 11 patients receiving PSL at doses <= 10 mg/day (S). The serum OC level showed a marked decrease on day 3 of GC therapy ( 41.2% +/  6.6%, P < 0.01), while the BAP level decreased gradually. Both serum and urinary NTx levels significantly increased on day 7 of GC therapy (9.9% +/  4.5%, P < 0.05, and 42.2% +/  10.6%, P < 0.01, respectively). Urinary Ca excretion was increased on day 3 of GC therapy and continued to increase until 4 weeks, while intact PTH showed an increase on day 3 and then remained constant until 4 weeks. In groups P and H, there were significant early changes in OC, BAP, NTx, and intact PTH levels, as well as urinary Ca excretion. Even a PSL dose of < 10 mg/day caused a decrease in the serum OC level. In conclusion, the biochemical markers of Ca and bone metabolism showed different kinetics depending on the dose of GC, and it is important for patients on high dose GC therapy to receive prophylaxis for bone loss from the start of GC treatment.
C1 [Kuroki, Yasuo] Kobe Century Mem Hosp, Hyogo Ku, Kobe, Hyogo 6520855, Japan.
   [Kaji, Hiroshi] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Endocrinol Diabet & Metab, Kobe, Hyogo, Japan.
   [Kawano, Seiji] Kobe Univ Hosp, Clin Lab, Kobe, Hyogo, Japan.
   [Kanda, Fumio] Kobe Univ Hosp, Neurol, Kobe, Hyogo, Japan.
   [Takai, Yutaka] Kobe Rehabil Hosp, Kobe, Hyogo, Japan.
   [Kajikawa, Michiko] Yodogawa Christians Hosp, Osaka, Japan.
   [Sugimoto, Toshitsugu] Shimane Med Univ, Fac Med, Izumo, Shimane 693, Japan.
C3 Kobe University; Kobe University; Kobe University; Shimane University
RP Kuroki, Y (通讯作者)，Kobe Century Mem Hosp, Hyogo Ku, 1 9 1 Misaki Cho, Kobe, Hyogo 6520855, Japan.
EM kuroki@kanebou mh.or.jp
RI Kaji, Hiroshi/AAI 5628 2020
CR BLACKBURN GF, 1991, CLIN CHEM, V37, P1534
   Buttgereit F, 2004, ARTHRITIS RHEUM US, V50, P3408, DOI 10.1002/art.20583
   Buttgereit F, 2002, ANN RHEUM DIS, V61, P718, DOI 10.1136/ard.61.8.718
   Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529 0131(199805)41:5<761::AID ART2>3.0.CO;2 M
   Chaki O, 2000, J BONE MINER RES, V15, P1537, DOI 10.1359/jbmr.2000.15.8.1537
   CHRISTIANSEN C, 1987, LANCET, V1, P1106
   Dovio A, 2004, J CLIN ENDOCR METAB, V89, P4923, DOI 10.1210/jc.2004 0164
   Frediani B, 2004, J RHEUMATOL, V31, P1083
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Garnero P, 1996, J BONE MINER RES, V11, P1531
   GODSCHALK MF, 1988, J BONE MINER RES, V3, P113
   GOMEZ B, 1995, CLIN CHEM, V41, P1560
   HATTERSLEY AT, 1994, CALCIFIED TISSUE INT, V54, P198, DOI 10.1007/BF00301678
   Iki M, 1996, MATURITAS, V25, P59, DOI 10.1016/0378 5122(96)01042 0
   Korakaki E, 2007, J BONE MINER METAB, V25, P172, DOI 10.1007/s00774 006 0742 8
   Kuroki Yasuo, 2004, Mod Rheumatol, V14, P291, DOI 10.3109/s10165 004 0311 8
   Lems WF, 1996, ANN RHEUM DIS, V55, P288, DOI 10.1136/ard.55.5.288
   Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061
   PAZPACHECO E, 1995, J BONE MINER RES, V10, P1713
   Pearce G, 1998, J CLIN ENDOCR METAB, V83, P801, DOI 10.1210/jc.83.3.801
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Rubin MR, 2002, J CLIN ENDOCR METAB, V87, P4033, DOI 10.1210/jc.2002 012101
   SUGIMOTO T, 1989, ENDOCRINOLOGY, V125, P638, DOI 10.1210/endo 125 2 638
   TAPPY L, 1994, J CLIN ENDOCR METAB, V79, P1063, DOI 10.1210/jc.79.4.1063
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   WALTON RJ, 1975, CLIN CHIM ACTA, V63, P227, DOI 10.1016/0009 8981(75)90167 9
   Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043 2760(99)00186 1
   Weinstein RS, 2002, J CLIN INVEST, V109, P1041, DOI 10.1172/JCI200214538
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Woitge HW, 1999, J BONE MINER RES, V14, P792, DOI 10.1359/jbmr.1999.14.5.792
NR 30
TC 24
Z9 25
U1 0
U2 10
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2008
VL 26
IS 3
BP 271
EP 278
DI 10.1007/s00774 007 0821 5
PG 8
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 299HH
UT WOS:000255746200011
PM 18470669
DA 2025 08 17
ER

PT J
AU Lee, GT
   Kang, DI
   Ha, YS
   Jung, YS
   Chung, J
   Min, K
   Kim, TH
   Moon, KH
   Chung, JM
   Lee, DH
   Kim, WJ
   Kim, IY
AF Lee, G. T.
   Kang, D. I.
   Ha, Y S
   Jung, Y. S.
   Chung, J.
   Min, K.
   Kim, T. H.
   Moon, K. H.
   Chung, J. M.
   Lee, D. H.
   Kim, W J
   Kim, I. Y.
TI Prostate cancer bone metastases acquire resistance to androgen
   deprivation via WNT5A mediated BMP 6 induction
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE BMP 6; WNT5A; CRPC; bone metastasis
ID WNT SIGNALING PATHWAY; BETA CATENIN; MORPHOGENETIC PROTEIN 6;
   GROWTH FACTOR; TRANSCRIPTIONAL ACTIVITY; CONTROLLED TRIAL;
   GASTRIC CANCER; II RECEPTOR; EXPRESSION; CELLS
AB Background: Androgen ablation is the first line therapy for patients with metastatic prostate cancer (CaP). However, castration resistance will eventually emerge. In the present study, we have investigated the role of bone morphogenetic protein 6 (BMP 6) in the development of castration resistant prostate cancer (CRPC) in the context of bone metastases.
   Methods: We initially investigated the clinical course of 158 men with advanced CaP who were treated with primary androgen deprivation therapy. To elucidate the underlying mechanism of CRPC in the context of bone metastases, we examined the impact of bone stromal cells on CaP in the absence of androgens using a co culture model.
   Results: In the 158 patients, we found that the median time to prostate specific antigen progression was significantly shorter when bone metastases were present (14 months (95% CI, 10.2 17.8 months) vs 57 months (95% CI, 19.4 94.6 months)). These results suggest that bone tumour interactions may accelerate castration resistance. Consistent with this hypothesis, in vitro co cultures demonstrated that CaP cells proliferated under an androgen depleted condition when incubated with bone stromal cells. Mechanistically, gene expression analysis using quantitative polymerase chain reaction arrays showed a dramatic induction of BMP 6 by CaP cell lines in the presence of bone stromal cells. Further studies revealed that WNT5A derived from bone stromal cells induced the expression of BMP 6 by CaP cells; BMP 6 in turn stimulated cellular proliferation of CaP cells in an androgen deprived media via a physical interaction between Smad5 and beta catenin. Intracellularly, WNT5A increased BMP 6 expression via protein kinase C/NF kappa B pathway in CaP cell lines.
   Conclusions: These observations suggest that bone CaP interaction leads to castration resistance via WNT5A/BMP 6 loop.
C1 [Lee, G. T.; Kang, D. I.; Ha, Y S; Jung, Y. S.; Kim, I. Y.] Rutgers Canc Inst New Jersey, Sect Urol Oncol, New Brunswick, NJ 08901 USA.
   [Lee, G. T.; Kang, D. I.; Ha, Y S; Jung, Y. S.; Kim, I. Y.] Rutgers State Univ, New Brunswick, NJ 08901 USA.
   [Kang, D. I.; Chung, J.; Min, K.] Inje Univ, Coll Med, Dept Urol, Pusan, South Korea.
   [Kim, T. H.] Dong A Univ, Coll Med, Dept Urol, Pusan, South Korea.
   [Moon, K. H.] Univ Ulsan, Coll Med, Dept Urol, Ulsan 680749, South Korea.
   [Chung, J. M.] Kosin Univ, Coll Med, Dept Urol, Pusan, South Korea.
   [Lee, D. H.] Ehwa Womans Univ, Coll Med, Dept Urol, Seoul, South Korea.
   [Kim, W J] Chungbuk Natl Univ, Dept Urol, Coll Med, Cheongju, South Korea.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers Cancer Institute of New
   Jersey; Rutgers University System; Rutgers University New Brunswick;
   Inje University; Dong A University; University of Ulsan; Ewha Womans
   University; Chungbuk National University
RP Kim, IY (通讯作者)，Rutgers Canc Inst New Jersey, Sect Urol Oncol, 195 Little Albany St 4560, New Brunswick, NJ 08901 USA.
EM kimiy@umdnj.edu
OI Chung, Jae Min/0000 0002 7467 5954
FU Tanzman Foundation
FX This work was supported in part by the Tanzman Foundation, Mr John
   Shein, and Mr Mal Wernik.
CR Autzen P, 1998, BRIT J CANCER, V78, P1219, DOI 10.1038/bjc.1998.658
   Barnes J, 1995, WORLD J UROL, V13, P337
   BENTLEY H, 1992, BRIT J CANCER, V66, P1159, DOI 10.1038/bjc.1992.427
   Blaszczyk N, 2004, CLIN CANCER RES, V10, P1860, DOI 10.1158/1078 0432.CCR 0974 3
   Bubley GJ, 1999, J CLIN ONCOL, V17, P3461, DOI 10.1200/JCO.1999.17.11.3461
   Caubet JF, 1997, UROLOGY, V49, P71, DOI 10.1016/S0090 4295(96)00325 1
   Chen GP, 2004, CANCER AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Hamdy FC, 1997, CANCER RES, V57, P4427
   Haudenschild DR, 2004, CANCER RES, V64, P8276, DOI 10.1158/0008 5472.CAN 04 2251
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Huggins C, 1942, ANN SURG, V115, P1192, DOI 10.1097/00000658 194206000 00030
   Ide H, 1997, CANCER RES, V57, P5022
   IOZZO RV, 1995, CANCER RES, V55, P3495
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078 0432.CCR 06 2316
   Kim IY, 2004, ONCOGENE, V23, P7651, DOI 10.1038/sj.onc.1207924
   Kurayoshi M, 2006, CANCER RES, V66, P10439, DOI 10.1158/0008 5472.CAN 06 2359
   Kwon SJ, 2009, IMMUNOLOGY, V128, pe758, DOI 10.1111/j.1365 2567.2009.03079.x
   Lee GT, 2010, J BIOL CHEM, V285, P39401, DOI 10.1074/jbc.M110.103705
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Masiello D, 2004, MOL ENDOCRINOL, V18, P2388, DOI 10.1210/me.2003 0436
   Massagué J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753
   Masuda H, 2003, PROSTATE, V54, P268, DOI 10.1002/pros.10193
   Messing EM, 2006, LANCET ONCOL, V7, P472, DOI 10.1016/S1470 2045(06)70700 8
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0
   Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200
   Morin JP, 2012, ASIAN J ANDROL, V14, P670, DOI 10.1038/aja.2012.70
   Pukrop R, 2005, J PERS DISORD, V19, P563, DOI 10.1521/pedi.2005.19.5.563
   ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632
   Saylor PJ, 2013, J UROLOGY, V189, pS34, DOI 10.1016/j.juro.2012.11.017
   Schellhammer PF, 1996, UROLOGY, V47, P622, DOI 10.1016/S0090 4295(96)00002 7
   Siegel R, 2012, CA CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Smith MR, 2012, LANCET, V379, P39, DOI 10.1016/S0140 6736(11)61226 9
   Song LN, 2003, MOL CELL BIOL, V23, P1674, DOI 10.1128/MCB.23.5.1674 1687.2003
   TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412
   Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078 0432.CCR 05 0525
   Truica CI, 2000, CANCER RES, V60, P4709
   TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092 8674(88)90220 6
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535 6108(02)00045 4
   Yamamoto H, 2010, ONCOGENE, V29, P2036, DOI 10.1038/onc.2009.496
   Yamamoto H, 2009, GASTROENTEROLOGY, V137, P242, DOI 10.1053/j.gastro.2009.02.003
   Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200
   Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366
   YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960 9822(02)70716 1
   Yu PB, 2008, J BIOL CHEM, V283, P3877, DOI 10.1074/jbc.M706797200
NR 49
TC 54
Z9 64
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAR 18
PY 2014
VL 110
IS 6
BP 1634
EP 1644
DI 10.1038/bjc.2014.23
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AD4DB
UT WOS:000333195800028
PM 24518599
OA Green Published
DA 2025 08 17
ER

PT J
AU Ramakrishnan, P
   Maclean, M
   MacGregor, SJ
   Anderson, JG
   Grant, MH
AF Ramakrishnan, Praveen
   Maclean, Michelle
   MacGregor, Scott J.
   Anderson, John G.
   Grant, M. Helen
TI Differential sensitivity of osteoblasts and bacterial pathogens to
   405 nm light highlighting potential for decontamination applications in
   orthopedic surgery
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE healthcare associated infections; arthroplasty surgery; decontamination;
   405 nm light; dose dependent osteoblast cell damage; bacteria
   inactivation
ID INFECTION; CONTAMINATION; INACTIVATION; EXPOSURE; THERAPY; DISINFECTION;
   MECHANISM
AB Healthcare associated infections pose a major threat to patients admitted to hospitals and infection rates following orthopedic arthroplasty surgery are as high as 4%. A 405 nm high intensity narrow spectrum light has been proven to reduce environmental contamination in hospital isolation rooms, and there is potential to develop this technology for application in arthroplasty surgery. Cultured rat osteoblasts were exposed to varying light intensities and it was found that exposures of up to a dose of 36 J/cm(2) had no significant effect on cell viability [3 (4,5 dimethylthiazol 2 yl) 2,5 diphenyltetrazolium bromide assay], function (alkaline phosphatase activity), and proliferation rate (BrdU cell proliferation assay). High irradiance exposures (54 J/cm(2)) significantly affected the cell viability indicating that the effects of 405 nm light on osteoblasts are dose dependent. Additionally, exposure of a variety of clinically related bacteria to a dose of 36 J/cm(2) resulted in up to 100% kill. These results demonstrating the differential sensitivity of osteoblasts and bacteria to 405 nm light are an essential step toward developing the technique for decontamination in orthopedic surgery. (C) 2014 Society of Photo Optical Instrumentation Engineers (SPIE)
C1 [Ramakrishnan, Praveen; Grant, M. Helen] Univ Strathclyde, Dept Biomed Engn, Wolfson Ctr, Glasgow G4 0NW, Lanark, Scotland.
   [Maclean, Michelle; MacGregor, Scott J.; Anderson, John G.] Univ Strathclyde, Robertson Trust Lab Elect Sterilisat Technol, Glasgow G1 1XW, Lanark, Scotland.
C3 University of Strathclyde; University of Strathclyde
RP Grant, MH (通讯作者)，Univ Strathclyde, Dept Biomed Engn, Wolfson Ctr, 106 Rottenrow, Glasgow G4 0NW, Lanark, Scotland.
EM m.h.grant@strath.ac.uk
RI Anderson, John/O 1068 2013; Anderson, John G/O 1068 2013
OI Anderson, John G/0000 0003 4151 1619
FU DTC studentship from the Engineering and Physical Sciences Research
   Council
FX P.R. is supported by a DTC studentship from the Engineering and Physical
   Sciences Research Council. The authors are grateful for the help of Mrs.
   Katie Henderson with mammalian cell culture.
CR Albrecht M, 2009, ORTHOP REV, V1, P85, DOI 10.4081/or.2009.e28
   Bisland SK, 2006, PHOTODIAGN PHOTODYN, V3, P147, DOI 10.1016/S1572 1000(06)00036 6
   Dai TH, 2013, ANTIMICROB AGENTS CH, V57, P1238, DOI 10.1128/AAC.01652 12
   Davis N, 1999, J BONE JOINT SURG BR, V81B, P886, DOI 10.1302/0301 620X.81B5.9545
   Gosden PE, 1998, J HOSP INFECT, V39, P173, DOI 10.1016/S0195 6701(98)90255 9
   HALLIWELL B, 2001, FREE RADICAL BIO MED, P105
   Hamilton H, 2008, CAN J SURG, V51, P111
   Ho G, 2004, PROC SPIE, V5610, P124, DOI 10.1117/12.584384
   Lipovsky A, 2010, LASER SURG MED, V42, P467, DOI 10.1002/lsm.20948
   Loftus RW, 2011, ANESTH ANALG, V112, P98, DOI 10.1213/ANE.0b013e3181e7ce18
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Lubart R., 2011, Laser Therapy, V20, P17
   Maclean M, 2010, J HOSP INFECT, V76, P247, DOI 10.1016/j.jhin.2010.07.010
   Maclean M, 2009, APPL ENVIRON MICROB, V75, P1932, DOI 10.1128/AEM.01892 08
   McDonald RS, 2013, EUR CELLS MATER, V25, P204, DOI 10.22203/eCM.v025a15
   McDonald R, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3561903
   Nitzan Y, 2004, PHOTOCH PHOTOBIO SCI, V3, P430, DOI 10.1039/b315633h
   Nitzan Y, 1999, LASER MED SCI, V14, P269, DOI 10.1007/s101030050094
   Oguma K, 2001, APPL ENVIRON MICROB, V67, P4630, DOI 10.1128/AEM.67.10.4630 4637.2001
   Smith S, 2009, IFMBE PROC, V23, P1352
   Sternberg ED, 1998, TETRAHEDRON, V54, P4151, DOI 10.1016/S0040 4020(98)00015 5
   TAYLOR GJS, 1995, J HOSP INFECT, V30, P85, DOI 10.1016/0195 6701(95)90148 5
   Zhang YS, 2014, J INFECT DIS, V209, P1963, DOI 10.1093/infdis/jit842
NR 23
TC 31
Z9 33
U1 0
U2 6
PU SPIE SOC PHOTO OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083 3668
EI 1560 2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD OCT
PY 2014
VL 19
IS 10
AR 105001
DI 10.1117/1.JBO.19.10.105001
PG 7
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA AU8HM
UT WOS:000345837200008
PM 25277146
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Huang, L
   Jin, P
   Lin, X
   Lin, CW
   Zheng, L
   Zhao, JM
AF Huang, Li
   Jin, Pan
   Lin, Xiao
   Lin, Cuiwu
   Zheng, Li
   Zhao, Jinmin
TI Beneficial effects of sulfonamide based gallates on osteoblasts in
   vitro
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE JEZ C; gallic acid; osteoblast; proliferation; osteoporosis
ID ALKALINE PHOSPHATASE; DIFFERENTIATION; VIVO; OSTEONECROSIS; SINENSIS;
   CULTURES; OSTERIX; RUNX2; CELL; JAW
AB Effective treatments for osteoporosis remain fairly elusive; however, studies have reported that antioxidants may aid in the maintenance of reactive oxygen species at a favorable level, in order to prevent osteoporosis. Gallic acid (GA) and its derivatives are potent antioxidative and anti inflammatory agents that affect several biochemical and pharmacological pathways; however, GA is slightly cytotoxic and suppresses cell proliferation. The present study modified GA by the introduction of sulfonamide, in order to obtain a novel compound known as JEZ C, and investigated its effects on osteoblasts by measuring cell proliferation, viability, morphology, alkaline phosphatase (ALP) activity, and the expression of relevant osteoblast markers. Results indicated that JEZ C may effectively promote osteoblast growth. JEZ C increased ALP activity, upregulated the expression of osteogenic related genes, including runt related transcription factor 2, bone sialoprotein, osteocalcin and alpha 1 type I collagen, thus indicating that JEZ C enhances bone matrix production and mineralization. The recommended range of JEZ C concentration is between 6.25x10( 3) and 6.25x10( 1) mu g/ml, within which cell growth was promoted compared with the control. Specifically, treatment with 6.25x10( 2) mu g/ml JEZ C is ideal. These findings may represent a novel approach to cell based therapy for the treatment of osteoporosis.
C1 [Huang, Li; Jin, Pan; Zheng, Li; Zhao, Jinmin] Guangxi Med Univ, Guangxi Engn Ctr Biomat Tissue & Organ Regenerat, 22 Shuangyong Rd, Nanning 530021, Peoples R China.
   [Huang, Li; Jin, Pan; Zhao, Jinmin] Guangxi Med Univ, Affiliated Hosp 1, Dept Orthoped Trauma & Hand Surg, Nanning, Peoples R China.
   [Lin, Xiao; Lin, Cuiwu] Guangxi Univ, Sch Chem & Chem Engn, Nanning 530004, Peoples R China.
   [Lin, Xiao] Guangxi Inst Tradit Med & Pharmaceut Sci, Guangxi Key Lab Tradit Chinese Med Qual Stand, Nanning 530022, Peoples R China.
   [Zhao, Jinmin] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi
   University; Guangxi Medical University
RP Zheng, L; Zhao, JM (通讯作者)，Guangxi Med Univ, Guangxi Engn Ctr Biomat Tissue & Organ Regenerat, 22 Shuangyong Rd, Nanning 530021, Peoples R China.; Zhao, JM (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Orthoped Trauma & Hand Surg, Nanning, Peoples R China.; Zhao, JM (通讯作者)，Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning 530021, Peoples R China.
EM zheng1i224@l63.com; zhaojinmin@l26.com
RI ; Jin, Pan/W 6434 2019; zhao, jin/LBH 0351 2024
OI Zheng, Li/0000 0002 9666 0024; Zhao, Jinmin/0000 0002 1047 8820
FU National Key Research and Development Program of China [2016YFB0700804];
   Guangxi Scientific Research and Technological Development Foundation
   [1598013 15]; Guangxi Science Fund for Distinguished Young Scholars
   [2014GXNSFGA118006]
FX The present study was financially supported by the National Key Research
   and Development Program of China (grant no. 2016YFB0700804), the Guangxi
   Scientific Research and Technological Development Foundation (grant no.
   Guikegong 1598013 15) and the Guangxi Science Fund for Distinguished
   Young Scholars (grant no. 2014GXNSFGA118006).
CR Adcocks C, 2002, J NUTR, V132, P341, DOI 10.1093/jn/132.3.341
   Baxter BK, 2011, ACS CHEM BIOL, V6, P502, DOI 10.1021/cb100399x
   Blackley S, 2015, J ROY COLL PHYS EDIN, V45, P133, DOI 10.4997/JRCPE.2015.209
   Douglas TEL, 2013, INT J BIOL MACROMOL, V56, P122, DOI 10.1016/j.ijbiomac.2013.02.002
   Enishi T, 2015, J MED INVESTIG, V62, P93, DOI 10.2152/jmi.62.93
   Gavric M, 2014, VOJNOSANIT PREGL, V71, P772, DOI 10.2298/VSP121211025G
   Hsiang CY, 2013, FOOD CHEM, V136, P426, DOI 10.1016/j.foodchem.2012.08.009
   Koromila T, 2014, J CELL BIOCHEM, V115, P27, DOI 10.1002/jcb.24646
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Matsubara T, 2008, J BIOL CHEM, V283, P29119, DOI 10.1074/jbc.M801774200
   Molvik H, 2015, OSTEOPOROSIS INT, V26, P1251, DOI 10.1007/s00198 014 3007 8
   Okamura H, 2013, J CELL PHYSIOL, V228, P1031, DOI 10.1002/jcp.24250
   Ou TT, 2013, CURR MED CHEM, V20, P3944
   PATOUXPIBOUIN M, 1995, TOXICOL IN VITRO, V9, P493, DOI 10.1016/0887 2333(95)00020 9
   Piattelli A, 1996, BIOMATERIALS, V17, P1443, DOI 10.1016/0142 9612(96)87288 7
   Santamaria S, 2012, BIOCHEM PHARMACOL, V84, P813, DOI 10.1016/j.bcp.2012.06.026
   Sapkota K, 2010, BIOSCI BIOTECH BIOCH, V74, P1527, DOI 10.1271/bbb.100058
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Walter MS, 2014, DENT MATER, V30, P200, DOI 10.1016/j.dental.2013.11.006
   Yerram P, 2016, J ONCOL PHARM PRACT
   You TM, 2015, OR SURG OR MED OR PA, V120, P548, DOI 10.1016/j.oooo.2015.07.017
   Zhang W, 2013, BIOMATERIALS, V34, P713, DOI 10.1016/j.biomaterials.2012.10.027
   Zhao SF, 2014, INT J ORAL MAX IMPL, V29, P211, DOI 10.11607/jomi.3147
NR 23
TC 10
Z9 11
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2017
VL 15
IS 3
BP 1149
EP 1156
DI 10.3892/mmr.2017.6142
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EP1VS
UT WOS:000397173000020
PM 28138702
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Yadav, SS
   Li, JY
   Stockert, JA
   Herzog, B
   O'Connor, J
   Garzon Manco, L
   Parsons, R
   Tewari, AK
   Yadav, KK
AF Yadav, Shalini S.
   Li, Jinyi
   Stockert, Jennifer A.
   Herzog, Bryan
   O'Connor, James
   Garzon Manco, Luis
   Parsons, Ramon
   Tewari, Ashutosh K.
   Yadav, Kamlesh K.
TI Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by
   Dovitinib (TKI 258) and its Therapeutic Implications
SO TRANSLATIONAL ONCOLOGY
LA English
DT Article
ID TYROSINE KINASE; INCREASED SURVIVAL; EPH RECEPTORS; CARCINOMA;
   TRANSDIFFERENTIATION; PATHWAY; GROWTH; INTERLEUKIN 6; ACTIVATION; LINE
AB Prostate cancer (PCa) remains the second leading cause of cancer related deaths in American men with an estimated mortality of more than 26,000 in 2016 alone. Aggressive and metastatic tumors are treated with androgen deprivation therapies (ADT); however, the tumors acquire resistance and develop into lethal castration resistant prostate cancer (CRPC). With the advent of better therapeutics, the incidences of a more aggressive neuroendocrine prostate cancer (NEPC) variant continue to emerge. Although de novo occurrences of NEPC are rare, more than 25% of the therapy resistant patients on highly potent new generation anti androgen therapies end up with NEPC. This, along with previous observations of an increase in the number of such NE cells in aggressive tumors, has been suggested as a mechanism of resistance development during prostate cancer progression. Dovitinib (TKI 258/CHIR 258) is a pan receptor tyrosine kinase (RTK) inhibitor that targets VEGFR, FGFR, PDGFR, and KIT. It has shown efficacy in mouse model of PCa bone metastasis, and is presently in clinical trials for several cancers. We observed that both androgen receptor (AR) positive and AR negative PCa cells differentiate into a NE phenotype upon treatment with Dovitinib. The NE differentiation was also observed when mice harboring PC3 xenografted tumors were systemically treated with Dovitinib. The mechanistic underpinnings of this differentiation are unclear, but seem to be supported through MAPK , PI3K , and Wnt signaling pathways. Further elucidation of the differentiation process will enable the identification of alternative salvage or combination therapies to overcome the potential resistance development.
C1 [Yadav, Shalini S.; Li, Jinyi; Stockert, Jennifer A.; Herzog, Bryan; O'Connor, James; Garzon Manco, Luis; Tewari, Ashutosh K.; Yadav, Kamlesh K.] Icahn Sch Med Mt Sinai, Dept Urol, One Gustave L Levy Pl, New York, NY 10029 USA.
   [Parsons, Ramon] Icahn Sch Med Mt Sinai, Dept Oncol Sci, One Gustave L Levy Pl, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai
RP Yadav, KK (通讯作者)，Icahn Sch Med Mt Sinai, Dept Urol, One Gustave L Levy Pl, New York, NY 10029 USA.
EM kamlesh.yadav@mountsinai.org
RI ; Parsons, Ramon/KFT 2922 2024
OI Parsons, Ramon/0000 0002 6656 3514; 
FU Deane Prostate Health
FX We are thankful to the Department of Hematology and Oncology for use of
   their equipment and resources. We also would like to extend our thanks
   to the faculty of the Department of Urology for helpful discussions and
   suggestions. Thanks also to David Mulholland, PhD and Roseanne Wick for
   critical reading of the manuscript. KKY thanks Dr. Nora M Navone, MD
   Anderson Cancer Center for insightful discussions. The research work was
   supported by funds from Deane Prostate Health. Both SSY and KKY are
   Prostate Cancer Foundation Young Investigator Awardees.
CR Abrahamsson PA, 1999, ENDOCR RELAT CANCER, V6, P503, DOI 10.1677/erc.0.0060503
   Cortés MA, 2012, CARCINOGENESIS, V33, P1169, DOI 10.1093/carcin/bgs139
   Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159 8290.CD 11 0259
   BANG YJ, 1994, P NATL ACAD SCI USA, V91, P5330, DOI 10.1073/pnas.91.12.5330
   BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016/0960 0760(94)90131 7
   Blakely BD, 2013, STEM CELLS DEV, V22, P2132, DOI 10.1089/scd.2013.0066
   Burchardt T, 1999, J UROLOGY, V162, P1800, DOI 10.1016/S0022 5347(05)68241 9
   Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972
   Clark CEJ, 2012, NEUROSIGNALS, V20, P202, DOI 10.1159/000332153
   Clifford MA, 2014, P NATL ACAD SCI USA, V111, P4994, DOI 10.1073/pnas.1323793111
   De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618
   Delk NA, 2012, AUTOPHAGY, V8, P650, DOI 10.4161/auto.19226
   Deng XH, 2008, CANCER RES, V68, P9663, DOI 10.1158/0008 5472.CAN 08 2229
   diSantAgnese PA, 1996, CANCER, V78, P357, DOI 10.1002/(SICI)1097 0142(19960715)78:2<357::AID CNCR27>3.0.CO;2 U
   Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004
   El Sheikh SS, 2004, NEOPLASIA, V6, P846, DOI 10.1593/neo.04379
   Galsky MD, 2012, CA CANCER J CLIN, V62, P299, DOI 10.3322/caac.21141
   Gatto G, 2014, CURR BIOL, V24, P2355, DOI 10.1016/j.cub.2014.08.028
   Gutiérrez Cañas I, 2005, PROSTATE, V63, P44, DOI 10.1002/pros.20173
   Ho HYH, 2012, P NATL ACAD SCI USA, V109, P4044, DOI 10.1073/pnas.1200421109
   Hollis ER, 2012, FRONT MOL NEUROSCI, V5, DOI 10.3389/fnmol.2012.00005
   Humphrey PA, 2012, HISTOPATHOLOGY, V60, P59, DOI 10.1111/j.1365 2559.2011.04039.x
   Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849
   Jiborn T, 1998, UROLOGY, V51, P585, DOI 10.1016/S0090 4295(97)00684 5
   Joly S, 2014, EUR J NEUROSCI, V40, P3021, DOI 10.1111/ejn.12677
   Kim J, 2002, CANCER RES, V62, P1549
   Martín Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337
   Miller KD, 2016, CA CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Mori S, 1999, BIOCHEM BIOPH RES CO, V257, P609, DOI 10.1006/bbrc.1999.0515
   Nadal R, 2014, NAT REV UROL, V11, P213, DOI 10.1038/nrurol.2014.21
   O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959 4388(99)80008 7
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Paganoni S, 2005, J CELL SCI, V118, P433, DOI 10.1242/jcs.01622
   Parimi V, 2014, AM J CLIN EXP UROL, V2, P273
   Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806
   Pinski J, 2006, PROSTATE, V66, P1136, DOI 10.1002/pros.20440
   Porta C, 2015, FUTURE ONCOL, V11, P39, DOI 10.2217/fon.14.208
   Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078 0432.CCR 05 1554
   Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506
   Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140 6736(10)60172 9
   Seruga B, 2011, NAT REV CLIN ONCOL, V8, P12, DOI 10.1038/nrclinonc.2010.136
   Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810
   Shen R, 1997, Urol Oncol, V3, P67, DOI 10.1016/S1078 1439(97)00039 2
   Sherwood ER, 1998, BRIT J CANCER, V77, P855, DOI 10.1038/bjc.1998.142
   Small EJ, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.5003
   Spiotto MT, 2000, PROSTATE, V42, P88, DOI 10.1002/(SICI)1097 0045(20000201)42:2<88::AID PROS2>3.0.CO;2 P
   Stankiewicz TR, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00314
   Svensson C, 2014, NUCLEIC ACIDS RES, V42, P999, DOI 10.1093/nar/gkt921
   Tai S, 2011, PROSTATE, V71, P1668, DOI 10.1002/pros.21383
   Terry S, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00060
   Terry S, 2013, NEOPLASIA, V15, P761, DOI 10.1593/neo.122070
   Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175
   Trudel S, 2005, BLOOD, V105, P2941, DOI 10.1182/blood 2004 10 3913
   Uysal Onganer P, 2010, MOL CANCER, V9, DOI 10.1186/1476 4598 9 55
   Wan XH, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009332
   Xie SZ, 2004, PROSTATE, V60, P61, DOI 10.1002/pros.20048
   Yang XZ, 2005, CANCER RES, V65, P5263, DOI 10.1158/0008 5472.CAN 05 0162
   Yap TA, 2012, EPMA J, V3, DOI 10.1007/s13167 011 0138 2
   Yuan TC, 2007, ENDOCR RELAT CANCER, V14, P531, DOI 10.1677/ERC 07 0061
   Zhang XT, 2015, CLIN CANCER RES, V21, P4698, DOI 10.1158/1078 0432.CCR 15 0157
   Zhu YZ, 2014, PROSTATE, V74, P1086, DOI 10.1002/pros.22819
NR 63
TC 31
Z9 38
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936 5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD JUN
PY 2017
VL 10
IS 3
BP 357
EP 366
DI 10.1016/j.tranon.2017.01.011
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FD7LM
UT WOS:000407707600009
PM 28342996
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liou, SF
   Hsu, JH
   Chu, HC
   Lin, HH
   Chen, IJ
   Yeh, JL
AF Liou, Shu Fen
   Hsu, Jong Hau
   Chu, Hsin Chieh
   Lin, Hung Hong
   Chen, Ing Jun
   Yeh, Jwu Lai
TI KMUP 1 Promotes Osteoblast Differentiation Through cAMP and cGMP
   Pathways and Signaling of BMP 2/Smad1/5/8 and Wnt/ Catenin
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID TRANSCRIPTION FACTOR; CYCLIC GMP; KINASE; INVOLVEMENT; RECEPTOR; CELLS;
   PENTOXIFYLLINE; PROLIFERATION; OSTEOGENESIS; INHIBITION
AB Phosphodiesterase (PDE) inhibitors have been suggested as a possible candidate for the treatment of osteopenia, including osteoporosis. KMUP 1 is a novel xanthine derivative with inhibitory activities on the PDE 3, 4, and 5 iso enzymes to suppress the degradation of cAMP and cGMP. This study aimed to investigate the effect of KMUP 1 on osteoblast differentiation and the underlying cellular and molecular mechanisms. Primary osteoblasts and osteoblastic MC3T3 E1 cells were examined. KMUP 1 enhanced alkaline phosphatase (ALP) activity and mineralization compared to untreated controls in primary osteoblasts and MC3T3 E1 cells. KMUP 1 also increased the mRNA expression of the osteoblastic differentiation markers, including collagen type 1a, ALP, osteocalcin, osteoprotegerin, BMP 2, and Runx2, a key transcription regulator for osteoblastic differentiation. The osteogenic effect of KMUP 1 was abolished by BMP signaling inhibitor, noggin. Furthermore, we found that KMUP 1 upregulated Smad1/5/8 phosphorylations with subsequent BRE Luc activation confirmed by transient transfection assay. In addition, KMUP 1 inactivated glycogen synthase kinase 3 (GSK 3), with associated nuclear translocation of  catenin. Co treatment with H89 and KT5823, cAMP and cGMP pathway inhibitors, respectively, reversed the KMUP 1 induced activations of Smad1/5/8,  catenin, and Runx2. The findings demonstrate for the first time that KMUP 1 can promote osteoblast maturation and differentiation in vitro via BMP 2/Smad1/5/8 and Wnt/ catenin pathways. These effects are mediated, in part, by the cAMP and cGMP signaling. Thus, KMUP 1 may be a novel osteoblast activator and a potential new therapy for osteoporosis. J. Cell. Physiol. 230: 2038 2048, 2015. (c) 2014 Wiley Periodicals, Inc.
C1 [Liou, Shu Fen; Lin, Hung Hong] Chia Nan Univ Pharm & Sci, Dept Pharm, Tainan, Taiwan.
   [Hsu, Jong Hau] Kaohsiung Med Univ Hosp, Dept Paediat, Kaohsiung, Taiwan.
   [Hsu, Jong Hau] Kaohsiung Med Univ, Dept Paediat, Coll Med, Fac Med, Kaohsiung 807, Taiwan.
   [Chu, Hsin Chieh; Chen, Ing Jun; Yeh, Jwu Lai] Kaohsiung Med Univ, Dept & Grad Inst Pharmacol, Sch Med, Coll Med, Kaohsiung 807, Taiwan.
C3 Chia Nan University of Pharmacy & Science; Kaohsiung Medical University;
   Kaohsiung Medical University Hospital; Kaohsiung Medical University;
   Kaohsiung Medical University
RP Yeh, JL (通讯作者)，Kaohsiung Med Univ, Dept & Grad Inst Pharmacol, Fac Med, Coll Med, 100 Shih Chuan 1st Rd, Kaohsiung 807, Taiwan.
EM jwulai@kmu.edu.tw
RI ; Yeh, Jwu Lai/A 1535 2010; Chen, Ing Jan/A 1530 2010; Hsu,
   Jong Hau/A 1507 2010
OI Yeh, Jwu Lai/0000 0001 7101 5865; 
FU National Science Council of Taiwan [NSC 99 2320 B 037 015 MY3]
FX Contract grant sponsor: National Science Council of Taiwan;Contract
   grant number: NSC 99 2320 B 037 015 MY3.
CR Armstrong VJ, 2007, J BIOL CHEM, V282, P20715, DOI 10.1074/jbc.M703224200
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Broderick KE, 2007, MOL ENDOCRINOL, V21, P1148, DOI 10.1210/me.2005 0389
   Chen J, 2014, MOL BIOL REP, V41, P2161, DOI 10.1007/s11033 014 3065 1
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671, DOI 10.1067/mai.2001.119555
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Hagiwara H, 1996, AM J PHYSIOL CELL PH, V270, pC1311, DOI 10.1152/ajpcell.1996.270.5.C1311
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hayashi K, 2009, BIOCHEM BIOPH RES CO, V379, P261, DOI 10.1016/j.bbrc.2008.12.035
   Horiuchi H, 2002, BONE, V30, P589, DOI 10.1016/S8756 3282(02)00681 6
   Hsu YY, 2010, TOXICOLOGY, V268, P46, DOI 10.1016/j.tox.2009.11.021
   Itasaki N, 2010, DEV DYNAM, V239, P16, DOI 10.1002/dvdy.22009
   Kim HJ, 2003, J BIOL CHEM, V278, P319, DOI 10.1074/jbc.M203750200
   Kinoshita T, 2000, BONE, V27, P811, DOI 10.1016/S8756 3282(00)00395 1
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Lin RJ, 2002, BRIT J PHARMACOL, V135, P1159, DOI 10.1038/sj.bjp.0704554
   Liou SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069468
   Liu CM, 2007, PROSTATE, V67, P1397, DOI 10.1002/pros.20634
   Liu CM, 2009, PROSTATE, V69, P610, DOI 10.1002/pros.20919
   Lo YC, 2010, J AGR FOOD CHEM, V58, P6643, DOI 10.1021/jf904158k
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Nakagawa K, 2007, BONE, V41, P543, DOI 10.1016/j.bone.2007.06.013
   Nashida T, 1996, BIOCHEM MOL BIOL INT, V40, P1243
   Rangaswami H, 2012, J BIOL CHEM, V287, P21509, DOI 10.1074/jbc.M112.347245
   Schmidt K, 2005, J CELL BIOL, V168, P899, DOI 10.1083/jcb.200408013
   Schwappacher R, 2009, EMBO J, V28, P1537, DOI 10.1038/emboj.2009.103
   Sugama R, 2006, BONE, V38, P206, DOI 10.1016/j.bone.2005.08.006
   Tsutsumimoto T, 2002, BONE, V31, P396, DOI 10.1016/S8756 3282(02)00839 6
   Wakabayashi S, 2002, J BONE MINER RES, V17, P249, DOI 10.1359/jbmr.2002.17.2.249
   Wang DH, 2009, ENDOCRINE, V35, P112, DOI 10.1007/s12020 008 9117 3
   Wu BN, 2006, MOL PHARMACOL, V70, P977, DOI 10.1124/mol.106.024919
   Wu BN, 2004, BRIT J PHARMACOL, V142, P1105, DOI 10.1038/sj.bjp.0705791
   Wu BN, 2001, BRIT J PHARMACOL, V134, P265, DOI 10.1038/sj.bjp.0704231
   Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453
   Yeh JL, 2010, BRIT J PHARMACOL, V159, P1151, DOI 10.1111/j.1476 5381.2009.00587.x
   Zhang JF, 2010, MOL CELL ENDOCRINOL, V314, P70, DOI 10.1016/j.mce.2009.08.012
NR 39
TC 30
Z9 34
U1 0
U2 47
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2015
VL 230
IS 9
BP 2038
EP 2048
DI 10.1002/jcp.24904
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA CJ1HD
UT WOS:000355233700005
PM 25536014
DA 2025 08 17
ER

PT J
AU Cao, YY
   Yang, HQ
   Jin, LY
   Du, J
   Fan, ZP
AF Cao, Yangyang
   Yang, Haoqing
   Jin, Luyuan
   Du, Juan
   Fan, Zhipeng
TI Genome Wide DNA Methylation Analysis during Osteogenic Differentiation
   of Human Bone Marrow Mesenchymal Stem Cells
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID EPIGENETIC REGULATION; GENE; OSTEOBLASTS; EXPRESSION
AB Bone marrow mesenchymal stem cells (BMSCs) nowadays are regarded as promising candidates in cell based therapy for the regeneration of damaged bone tissues that are either incurable or intractable due to the insufficiency of current therapies. Recent studies suggest that BMSCs differentiate into osteoblasts, and that this differentiation is regulated by some specific patterns of epigenetic modifications, such as DNA methylation. However, the potential role of DNA methylation modification in BMSC osteogenic differentiation is unclear. In this study, we performed a genome wide study of DNA methylation between the noninduced and induced osteogenic differentiation of BMSCs at day 7. We found that the majority of cytosines in a CpG context were methylated in induced BMSCs. Our results also revealed that, along with the induced osteogenic differentiation in BMSCs, the average genomic methylation levels and CpG methylation in transcriptional factor regions (TFs) were increased, the CpG methylation level of various genomic elements was mainly in the medium high methylation section, and CpG methylation levels in the repeat element had highly methylated levels. The GO analysis of differentially methylated region  (DMR ) associated genes (DMGs) showed that GO terms, including cytoskeletal protein binding (included in Molecular Function GO terms), skeletal development (included in Biological Process GO terms), mesenchymal cell differentiation (included in Biological Process GO terms), and stem cell differentiation (included in Biological Process), were enriched in the hypermethylated DMGs. Then, the KEGG analysis results showed that the WNT pathway, inositol phosphate metabolism pathway, and cocaine addiction pathway were more correlative with the DMRs during the induced osteogenic differentiation in BMSCs. In conclusion, this study revealed the difference of methylated levels during the noninduced and induced osteogenic differentiation of BMSCs and provided useful information for future works to characterize the important function of epigenetic mechanisms on BMSCs' differentiation.
C1 [Cao, Yangyang; Yang, Haoqing; Du, Juan; Fan, Zhipeng] Capital Med Univ, Lab Mol Signaling & Stem Cells Therapy, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Sch Stomatol, 4 Tiantanxili, Beijing 100050, Peoples R China.
   [Jin, Luyuan] Capital Med Univ, Dept Gen Dent, Sch Stomatol, Beijing 100050, Peoples R China.
   [Jin, Luyuan; Du, Juan] Capital Med Univ, Mol Lab Gene Therapy & Tooth Regenerat, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Sch Stomatol, Beijing 100050, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University
RP Fan, ZP (通讯作者)，Capital Med Univ, Lab Mol Signaling & Stem Cells Therapy, Beijing Key Lab Tooth Regenerat & Funct Reconstru, Sch Stomatol, 4 Tiantanxili, Beijing 100050, Peoples R China.
EM zpfan@ccmu.edu.cn
OI Fan, Zhipeng/0000 0003 0629 3476
FU National Natural Science Foundation of China [81625005]; Beijing Natural
   Science Foundation [7172089]; Discipline Construction Fund from the
   Capital Medical University School of Stomatology [17 09 03]
FX This work was supported by grants from the National Natural Science
   Foundation of China (81625005 to Zhipeng Fan), Beijing Natural Science
   Foundation (7172089 to Zhipeng Fan), and the Discipline Construction
   Fund from the Capital Medical University School of Stomatology (17 09 03
   to Luyuan Jin).
CR Asharani PV, 2012, AM J HUM GENET, V90, P661, DOI 10.1016/j.ajhg.2012.02.026
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bentivegna A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5656701
   Bentivegna A, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/192425
   Bernardo ME, 2012, BONE MARROW TRANSPL, V47, P164, DOI 10.1038/bmt.2011.81
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474 9726.2009.00535.x
   Cui YJ, 2011, NAT MED, V17, P684, DOI 10.1038/nm.2388
   De Haan JR, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471 2105 11 158
   Deng P, 2015, INT J ORAL SCI, V7, P197, DOI 10.1038/ijos.2015.41
   Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913
   Gadkari R, 2014, REGEN MED, V9, P453, DOI [10.2217/rme.14.13, 10.2217/RME.14.13]
   Gori F, 2001, J BIOL CHEM, V276, P46515, DOI 10.1074/jbc.M105757200
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   Guo CJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31318
   Han XF, 2017, AM J TRANSL RES, V9, P4848
   Hoofd C, 2012, CELL SIGNAL, V24, P1461, DOI 10.1016/j.cellsig.2012.03.006
   Huang B, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0018 0
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Lawson KA, 2013, FEBS LETT, V587, P3961, DOI 10.1016/j.febslet.2013.10.028
   Lee JY, 2006, MOL CELLS, V22, P182
   Leskelä HV, 2003, BIOCHEM BIOPH RES CO, V311, P1008, DOI 10.1016/j.bbrc.2003.10.095
   Liu WJ, 2014, BBA GEN SUBJECTS, V1840, P1125, DOI 10.1016/j.bbagen.2013.11.003
   Maeda K, 2013, J MOL MED, V91, P15, DOI 10.1007/s00109 012 0974 0
   Peffers MJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160517
   Pérez Campo FM, 2015, CURR GENOMICS, V16, P368, DOI 10.2174/1389202916666150817202559
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Rinaldi L, 2015, FEBS J, V282, P1589, DOI 10.1111/febs.12946
   Rushton MD, 2014, ARTHRITIS RHEUMATOL, V66, P2450, DOI 10.1002/art.38713
   Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005
   Tan J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006792
   Thorpe AA, 2016, ONCOTARGET, V7, P2189, DOI 10.18632/oncotarget.6782
   Vincent A, 2009, DIFFERENTIATION, V78, P99, DOI 10.1016/j.diff.2009.07.002
   Wang YF, 2017, INT J MOL MED, V40, P1991, DOI 10.3892/ijmm.2017.3155
   Xu XY, 2017, MOL MED REP, V15, P1571, DOI 10.3892/mmr.2017.6178
   Yu WX, 2016, J BIOL CHEM, V291, P10437, DOI 10.1074/jbc.M116.714816
NR 37
TC 19
Z9 23
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PY 2018
VL 2018
AR 8238496
DI 10.1155/2018/8238496
PG 11
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA GU8BY
UT WOS:000445559600001
PM 30275838
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Gong, AGW
   Duan, R
   Wang, HY
   Dong, TNTX
   Tsim, KWK
AF Gong, Amy G. W.
   Duan, Ran
   Wang, Huai Y.
   Dong, Tina T. X.
   Tsim, Karl W. K.
TI Calycosin Orchestrates Osteogenesis of Danggui Buxue Tang in Cultured
   Osteoblasts: Evaluating the Mechanism of Action by Omics and Chemical
   Knock out Methodologies
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE Astragali Radix; Angelicae Sinensis Radix; Danggui Buxue Tang; RNA seq;
   metabolomics; osteoblast
ID CHINESE HERBAL DECOCTION; RADIX ANGELICAE SINENSIS; BIOLOGICAL
   ASSESSMENT; ASTRAGALI RADIX; EXPRESSION; OSTEOCLASTOGENESIS;
   OSTEOPOROSIS; MEDICINE
AB Danggui Buxue Tang (DBT), an ancient Chinese herbal decoction commonly used to mitigate menopausal osteoporosis, contains two herbs: Astragali Radix (AR) and Angelicae Sinensis Radix (ASR). The exact efficacy of individual chemical(s) within DBT, or in any herbal mixture, is hard to be revealed. Calycosin and ferulic acid have been reported to be the predominant chemicals found within DBT, and its roles in regulating osteoblastic differentiation have been proposed here. To probe the roles of calycosin and ferulic acid, these chemicals were specifically depleted from the DBT extracts. Here, calycosin depleted DBT (DBT Delta (cal)) and ferulic acid depleted DBT (DBT Delta (fa)), generated by semi preparative HPLC, were coupled with RNA seq and metabolomics analyses to reveal the synergistic functions of individual chemicals within a complex herbal mixture. The expressions of osteogenic differentiation markers were significantly increased under the treatments of DBT and DBT Delta (fa). The DBT induced genes were markedly reduced in the absent of calycosin, i.e., DBT Delta (cal). In cultured osteoblasts, the DBT activated Wnt/beta catenin and MAPK/Erk and signaling pathways were greatly affected when calycosin was depleted. By metabolomics analysis in DBT treated osteoblasts, the profile of metabolites triggered by DBT Delta (cal) showed distinction to that of DBT and/or DBT Delta (fa). Thus, our findings indicated that calycosin, rather than ferulic acid, could be an indispensable chemical in DBT to orchestrate multi components of DBT in achieving maximal osteogenic properties.
C1 [Gong, Amy G. W.; Duan, Ran; Wang, Huai Y.; Dong, Tina T. X.; Tsim, Karl W. K.] HKUST Shenzhen Res Inst, Shenzhen, Peoples R China.
   [Gong, Amy G. W.; Duan, Ran; Wang, Huai Y.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Gong, Amy G. W.; Duan, Ran; Wang, Huai Y.; Dong, Tina T. X.; Tsim, Karl W. K.] Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China.
C3 Hong Kong University of Science & Technology; Shenzhen Research
   Institute, The Hong Kong University of Science & Technology; Hong Kong
   University of Science & Technology; Hong Kong University of Science &
   Technology
RP Tsim, KWK (通讯作者)，HKUST Shenzhen Res Inst, Shenzhen, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.; Tsim, KWK (通讯作者)，Hong Kong Univ Sci & Technol, Ctr Chinese Med, Hong Kong, Hong Kong, Peoples R China.
EM botsim@ust.hk
RI Duan, Ran/IAO 3140 2023
OI Wang, Huai You/0000 0003 1407 9912
FU Hong Kong Research Grants Council Theme based Research Scheme
   [T13 607/12R]; General Research Funding [663012, 662713, M HKUST604/13,
   TUYF15SC01]; Shenzhen Science and Technology Committee Research Grant
   [JCYJ20160229205726699, JCYJ2016022920581 2004, JCYJ20160229210027564,
   20170326]
FX This study was supported by Hong Kong Research Grants Council
   Theme based Research Scheme (T13 607/12R), General Research Funding
   (663012, 662713, M HKUST604/13), TUYF15SC01, Shenzhen Science and
   Technology Committee Research Grant (JCYJ20160229205726699,
   JCYJ2016022920581 2004, JCYJ20160229210027564, and 20170326).
CR Chandra PP., 2014, J MAT, DOI [10.1155/2014/138163, DOI 10.1155/2014/567893]
   Choi RCY, 2011, EVID BASED COMPL ALT, V2011, P1, DOI 10.1093/ecam/nen085
   Chuffa LGD, 2017, STEROIDS, V118, P93, DOI 10.1016/j.steroids.2016.12.011
   Dong TTX, 2006, J AGR FOOD CHEM, V54, P2767, DOI 10.1021/jf053163l
   Eden JA, 2013, HORM MOL BIOL CLIN I, V14, P57, DOI 10.1515/hmbci 2013 0007
   Ferrer JL, 2008, PLANT PHYSIOL BIOCH, V46, P356, DOI 10.1016/j.plaphy.2007.12.009
   Gao Qiutao, 2007, Chin Med, V2, P12, DOI 10.1186/1749 8546 2 12
   Gong AGW, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165486
   Gong AGW, 2015, J ETHNOPHARMACOL, V168, P150, DOI 10.1016/j.jep.2015.03.033
   Guo AJ, 2012, CHIN MED UK, V7, DOI 10.1186/1749 8546 7 10
   Huang WL, 2009, BIOSYSTEMS, V98, P73, DOI 10.1016/j.biosystems.2009.06.007
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Khan M, 2017, ENDOCRIN METAB CLIN, V46, P181, DOI 10.1016/j.ecl.2016.09.009
   LIM K, 1989, BIOTECHNIQUES, V7, P576
   Lin HQ, 2017, J ETHNOPHARMACOL, V199, P205, DOI 10.1016/j.jep.2017.01.044
   Lisberg A, 2017, CPT PHARMACOMET SYST, V6, P208, DOI 10.1002/psp4.12154
   Ma WG, 2011, ASIAN J ANDROL, V13, P592, DOI 10.1038/aja.2010.127
   Ma XQ, 2002, J AGR FOOD CHEM, V50, P4861, DOI 10.1021/jf0202279
   Na KS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106473
   Orriss IR, 2006, BONE, V39, P300
   Ota T, 2016, CYTOTECHNOLOGY, V68, P2287, DOI 10.1007/s10616 016 0023 x
   Qu Hai bin, 2003, Zhongguo Zhongyao Zazhi, V28, P904
   Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179
   Raisz LG, 2005, NEW ENGL J MED, V353, P164, DOI 10.1056/NEJMcp042092
   Ren GX, 2013, J ETHNOPHARMACOL, V147, P564, DOI 10.1016/j.jep.2013.03.020
   Song ZH, 2004, PLANTA MED, V70, P1222, DOI 10.1055/s 2004 835855
   Spencer GJ, 2006, J CELL SCI, V119, P1283, DOI 10.1242/jcs.02883
   Tan HY, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/2795090
   Tang JY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011822
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Wang JS, 2009, J ETHNOPHARMACOL, V126, P31, DOI 10.1016/j.jep.2009.07.040
   Zhang WDL, 2012, PHYTOMEDICINE, V19, P1042, DOI 10.1016/j.phymed.2012.07.009
   Zhang YQ, 2017, AM J TRANSL RES, V9, P126
   Zhao KJ, 2003, J AGR FOOD CHEM, V51, P2576, DOI 10.1021/jf026178h
   Zheng KYZ, 2011, J AGR FOOD CHEM, V59, P1697, DOI 10.1021/jf104018u
NR 35
TC 22
Z9 26
U1 6
U2 41
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD FEB 1
PY 2018
VL 9
AR 36
DI 10.3389/fphar.2018.00036
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FU4FK
UT WOS:000423808700001
PM 29449812
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Yong, JW
   von Bremen, J
   Ruiz Heiland, G
   Ruf, S
AF Yong, Jiawen
   von Bremen, Julia
   Ruiz Heiland, Gisela
   Ruf, Sabine
TI Adiponectin Interacts In Vitro With Cementoblasts Influencing
   Cell Migration, Proliferation and Cementogenesis Partly Through the MAPK
   Signaling Pathway
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE adiponectin; cementoblasts; migration; proliferation; cementogenesis;
   MAPK
ID ALKALINE PHOSPHATASE ACTIVITY; EXPRESSION LEVELS; DIFFERENTIATION;
   RECEPTORS; KINASE; BONE; PROTEINS; MINERALIZATION; OSTEOBLASTS;
   ACTIVATION
AB Current clinical evidences suggest that circulating Adipokines such as Adiponectin can influence the ratio of orthodontic tooth movement. We aimed to investigate the effect that Adiponectin has on cementoblasts (OCCM 30) and on the intracellular signaling molecules of Mitogen activated protein kinase (MAPK). We demonstrated that OCCM 30 cells express AdipoR1 and AdipoR2. Alizarin Red S staining revealed that Adiponectin increases mineralized nodule formation and quantitative AP activity in a dose dependent manner. Adiponectin up regulates the mRNA levels of AP, BSP, OCN, OPG, Runx 2 as well as F Spondin. Adiponectin also increases the migration and proliferation of OCCM 30 cells. Moreover, Adiponectin induces a transient activation of JNK, P38, ERK1/2 and promotes the phosphorylation of STAT1 and STAT3. The activation of Adiponectin mediated migration and proliferation was attenuated after pharmacological inhibition of P38, ERK1/2 and JNK in different degrees, whereas mineralization was facilitated by MAPK inhibition in varying degrees. Based on our results, Adiponectin favorably affect OCCM 30 cell migration, proliferation as well as cementogenesis. One of the underlying mechanisms is the activation of MAPK signaling pathway.
C1 [Yong, Jiawen; von Bremen, Julia; Ruiz Heiland, Gisela; Ruf, Sabine] Justus Liebig Univ Giessen, Dept Orthodont, Fac Med, Giessen, Germany.
C3 Justus Liebig University Giessen
RP Yong, JW (通讯作者)，Justus Liebig Univ Giessen, Dept Orthodont, Fac Med, Giessen, Germany.
EM Jiawen.Yong@dentist.med.uni giessen.de
RI Yong, Jiawen/AAD 6426 2022; Ruf, Sabine/CAI 6903 2022
OI Yong, Jiawen/0000 0002 3021 075X; 
FU China Scholarship Council (CSC)
FX We sincerely thank J. Deschner and M. Nokhbehsaim, Department of
   Periodontology, University of Bonn, Germany to facilitate the sending of
   OCCM 30 cells. We also thank to the China Scholarship Council (CSC) for
   Ph.D. financial support.
CR Arzate H, 2015, PERIODONTOL 2000, V67, P211, DOI 10.1111/prd.12062
   Benedix F, 2011, OBES SURG, V21, P616, DOI 10.1007/s11695 011 0374 5
   Berner HS, 2004, BONE, V35, P842, DOI 10.1016/j.bone.2004.06.008
   Bosshardt DD, 2005, J DENT RES, V84, P390, DOI 10.1177/154405910508400501
   Buechler C, 2010, FEBS LETT, V584, P4280, DOI 10.1016/j.febslet.2010.09.035
   Cao ZZ, 2015, REPROD BIOL ENDOCRIN, V13, DOI 10.1186/s12958 015 0085 1
   Carbone F, 2012, BIOCHIMIE, V94, P2082, DOI 10.1016/j.biochi.2012.05.018
   Carvalho SM, 2012, J TISSUE ENG REGEN M, V6, P813, DOI 10.1002/term.488
   Caverzasio J, 2007, ENDOCRINOLOGY, V148, P5323, DOI 10.1210/en.2007 0520
   Chen XP, 2013, CYTOKINE GROWTH F R, V24, P83, DOI 10.1016/j.cytogfr.2012.07.004
   D'Errico JA, 2000, J PERIODONTOL, V71, P63, DOI 10.1902/jop.2000.71.1.63
   de Carvalho PM, 2017, ARCH ORAL BIOL, V75, P107, DOI 10.1016/j.archoralbio.2016.10.033
   Ding QR, 2009, CELL RES, V19, P317, DOI 10.1038/cr.2008.299
   Funahashi T, 1999, INTERNAL MED, V38, P202, DOI 10.2169/internalmedicine.38.202
   Hakki SS, 2018, INT J ORAL SCI, V10, P1, DOI 10.1038/s41368 018 0010 5
   Haugen S, 2017, ARCH ORAL BIOL, V83, P304, DOI 10.1016/j.archoralbio.2017.08.009
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Iwayama T, 2012, J PERIODONTAL RES, V47, P563, DOI 10.1111/j.1600 0765.2012.01467.x
   Junker S, 2017, MATRIX BIOL, V62, P75, DOI 10.1016/j.matbio.2016.11.005
   Kadowaki T, 2006, J CLIN INVEST, V116, P1784, DOI 10.1172/JCI29126
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Katsiougiannis S, 2006, ARTHRITIS RHEUM, V54, P2295, DOI 10.1002/art.21944
   Kimura A, 2018, CURR PHARM DESIGN, V24, P3980, DOI 10.2174/1381612824666181116103514
   Kitagawa M, 2012, BIOCHEM BIOPH RES CO, V418, P229, DOI 10.1016/j.bbrc.2011.12.155
   Koh ET, 1997, J BIOMED MATER RES, V37, P432, DOI 10.1002/(SICI)1097 4636(19971205)37:3<432::AID JBM14>3.0.CO;2 D
   Lee HW, 2009, STEM CELLS, V27, P2254, DOI 10.1002/stem.144
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Luo XH, 2005, EXP CELL RES, V309, P99, DOI 10.1016/j.yexcr.2005.05.021
   Luo XH, 2009, J BONE MINER RES, V24, P1461, DOI [10.1359/JBMR.090227, 10.1359/jbmr.090227]
   Mamali I, 2012, PEPTIDES, V33, P120, DOI 10.1016/j.peptides.2011.11.007
   McKee MD, 1996, MICROSC RES TECHNIQ, V33, P141, DOI 10.1002/(SICI)1097 0029(19960201)33:2<141::AID JEMT5>3.0.CO;2 W
   Miyazaki T, 2005, BIOCHEM BIOPH RES CO, V333, P79, DOI 10.1016/j.bbrc.2005.05.076
   Nanci A, 2006, PERIODONTOL 2000, V40, P11, DOI 10.1111/j.1600 0757.2005.00141.x
   Nigro E, 2015, PEPTIDES, V63, P150, DOI 10.1016/j.peptides.2014.11.007
   Oshima K, 2005, BIOCHEM BIOPH RES CO, V331, P520, DOI 10.1016/j.bbrc.2005.03.210
   Park CH, 2017, ACTA BIOMATER, V61, P134, DOI 10.1016/j.actbio.2017.07.039
   Ruiz Heiland G, 2021, CLIN ORAL INVEST, V25, P1933, DOI 10.1007/s00784 020 03501 3
   Saito T, 2008, J DENT RES, V87, P319, DOI 10.1177/154405910808700416
   Saygin NE, 2000, PERIODONTOL 2000, V24, P73, DOI 10.1034/j.1600 0757.2000.2240105.x
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Swarbrick Michael M., 2008, Metabolic Syndrome and Related Disorders, V6, P87, DOI 10.1089/met.2007.0029
   Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309
   Tang J, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/2370438
   Thomson TS, 2003, J ENDODONT, V29, P407, DOI 10.1097/00004770 200306000 00007
   Tokiyasu Y, 2000, J PERIODONTOL, V71, P1829, DOI 10.1902/jop.2000.71.12.1829
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101
   Yamaguchi N, 2010, J PERIODONTAL RES, V45, P296, DOI 10.1111/j.1600 0765.2009.01222.x
   Yamauchi N, 2012, INT J GYNECOL PATHOL, V31, P352, DOI 10.1097/PGP.0b013e3182469583
   Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705
NR 51
TC 18
Z9 19
U1 0
U2 12
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1663 9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD DEC 22
PY 2020
VL 11
AR 585346
DI 10.3389/fphar.2020.585346
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA PN8OP
UT WOS:000604732300001
PM 33414717
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Sharma, AK
   Roberts, RL
   Benson, RD
   Pierce, JL
   Yu, KL
   Hamrick, MW
   McGee Lawrence, ME
AF Sharma, Anuj K.
   Roberts, Rachel L.
   Benson, Reginald D., Jr.
   Pierce, Jessica L.
   Yu, Kanglun
   Hamrick, Mark W.
   McGee Lawrence, Meghan E.
TI The Senolytic Drug Navitoclax (ABT 263) Causes Trabecular Bone Loss and
   Impaired Osteoprogenitor Function in Aged Mice
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE osteoblast; bone marrow stromal cell; skeleton; senescence; senolytic;
   osteoporosis
ID SENESCENT CELLS; DIFFERENTIATION; IDENTIFICATION; DEXAMETHASONE;
   EXPRESSION; CLEARANCE
AB Senescence is a cellular defense mechanism that helps cells prevent acquired damage, but chronic senescence, as in aging, can contribute to the development of age related tissue dysfunction and disease. Previous studies clearly show that removal of senescent cells can help prevent tissue dysfunction and extend healthspan during aging. Senescence increases with age in the skeletal system, and selective depletion of senescent cells or inhibition of their senescence associated secretory phenotype (SASP) has been reported to maintain or improve bone mass in aged mice. This suggests that promoting the selective removal of senescent cells, via the use of senolytic agents, can be beneficial in the treatment of aging related bone loss and osteoporosis. Navitoclax (also known as ABT 263) is a chemotherapeutic drug reported to effectively clear senescent hematopoietic stem cells, muscle stem cells, and mesenchymal stromal cells in previous studies, but its in vivo effects on bone mass had not yet been reported. Therefore, the purpose of this study was to assess the effects of short term navitoclax treatment on bone mass and osteoprogenitor function in old mice. Aged (24 month old) male and female mice were treated with navitoclax (50 mg/kg body mass daily) for 2 weeks. Surprisingly, despite decreasing senescent cell burden, navitoclax treatment decreased trabecular bone volume fraction in aged female and male mice ( 60.1% females,  45.6% males), and BMSC derived osteoblasts from the navitoclax treated mice were impaired in their ability to produce a mineralized matrix ( 88% females,  83% males). Moreover, in vitro administration of navitoclax decreased BMSC colony formation and calcified matrix production by aged BMSC derived osteoblasts, similar to effects seen with the primary BMSC from the animals treated in vivo. Navitoclax also significantly increased metrics of cytotoxicity in both male and female osteogenic cultures (+1.0 to +11.3 fold). Taken together, these results suggest a potentially harmful effect of navitoclax on skeletal lineage cells that should be explored further to definitively assess navitoclax's potential (or risk) as a therapeutic agent for combatting age related musculoskeletal dysfunction and bone loss.
C1 [Sharma, Anuj K.; Roberts, Rachel L.; Benson, Reginald D., Jr.; Pierce, Jessica L.; Yu, Kanglun; Hamrick, Mark W.; McGee Lawrence, Meghan E.] Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.
   [McGee Lawrence, Meghan E.] Augusta Univ, Dept Orthopaed Surg, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; University System of
   Georgia; Augusta University
RP McGee Lawrence, ME (通讯作者)，Augusta Univ, Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA.; McGee Lawrence, ME (通讯作者)，Augusta Univ, Dept Orthopaed Surg, Augusta, GA 30912 USA.
EM mmcgeelawrence@augusta.edu
RI Hamrick, Mark/K 1131 2016; Sharma, Anuj/JTS 4887 2023
OI Sharma, Anuj/0009 0001 5882 709X; 
FU NIH National Institute on Aging [P01 AG036675]
FX This work was supported by the NIH National Institute on Aging
   (P01 AG036675; Project 4).
CR Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   BERESFORD JN, 1994, ARCH ORAL BIOL, V39, P941, DOI 10.1016/0003 9969(94)90077 9
   Blagosklonny MV, 2018, AGING US, V10, P4289, DOI 10.18632/aging.101750
   Calcinotto A, 2019, PHYSIOL REV, V99, P1047, DOI 10.1152/physrev.00020.2018
   Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Deng S, 2019, BIOMED PHARMACOTHER, V110, P602, DOI 10.1016/j.biopha.2018.11.103
   Farr JN, 2017, NAT MED, V23, P1072, DOI 10.1038/nm.4385
   Farr JN, 2016, J BONE MINER RES, V31, P1920, DOI 10.1002/jbmr.2892
   Geng LL, 2019, PROTEIN CELL, V10, P770, DOI 10.1007/s13238 019 0646 8
   Grezella C, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0857 6
   Helman A, 2016, NAT MED, V22, P412, DOI 10.1038/nm.4054
   Hickson LJ, 2019, EBIOMEDICINE, V47, P446, DOI 10.1016/j.ebiom.2019.08.069
   Justice JN, 2019, EBIOMEDICINE, V40, P554, DOI 10.1016/j.ebiom.2018.12.052
   Kaefer A, 2014, CANCER CHEMOTH PHARM, V74, P593, DOI 10.1007/s00280 014 2530 9
   Khosla S, 2018, J CLIN ENDOCR METAB, V103, P1282, DOI 10.1210/jc.2017 02694
   Kim EC, 2019, BMB REP, V52, P47
   Kim HN, 2017, AGING CELL, V16, P693, DOI 10.1111/acel.12597
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lecka Czernik B, 1999, J CELL BIOCHEM, V74, P357, DOI 10.1002/(SICI)1097 4644(19990901)74:3<357::AID JCB5>3.0.CO;2 7
   McGee Lawrence ME, 2018, J CELL PHYSIOL, V233, P2671, DOI 10.1002/jcp.26148
   McGee Lawrence ME, 2016, J BONE MINER RES, V31, P116, DOI 10.1002/jbmr.2602
   McGee Lawrence ME, 2013, BONE, V52, P296, DOI 10.1016/j.bone.2012.10.015
   Moriishi T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086629
   Moriishi T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027487
   Nie ZG, 2018, BIOCHEM BIOPH RES CO, V506, P41, DOI 10.1016/j.bbrc.2018.10.043
   Pang TT, 2018, EXP THER MED, V15, P1293, DOI 10.3892/etm.2017.5513
   Rudin CM, 2012, CLIN CANCER RES, V18, P3163, DOI 10.1158/1078 0432.CCR 11 3090
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   van Deursen JM, 2014, NATURE, V509, P439, DOI 10.1038/nature13193
   Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591 018 0092 9
   Yamanouchi K, 2001, J BONE MINER RES, V16, P857, DOI 10.1359/jbmr.2001.16.5.857
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhu Y, 2016, AGING CELL, V15, P428, DOI 10.1111/acel.12445
   Zhu Y, 2015, AGING CELL, V14, P644, DOI 10.1111/acel.12344
NR 36
TC 78
Z9 84
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD MAY 20
PY 2020
VL 8
AR 354
DI 10.3389/fcell.2020.00354
PG 10
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA LW8RW
UT WOS:000539412100001
PM 32509782
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Bejoy, J
   Bijonowski, B
   Marzano, M
   Jeske, R
   Ma, T
   Li, Y
AF Bejoy, Julie
   Bijonowski, Brent
   Marzano, Mark
   Jeske, Richard
   Ma, Teng
   Li, Yan
TI Wnt Notch Signaling Interactions During Neural and Astroglial Patterning
   of Human Stem Cells
SO TISSUE ENGINEERING PART A
LA English
DT Article
DE pluripotent stem cells; neural patterning; spheroids; Wnt; Notch;
   astroglial
ID FUNCTIONAL CORTICAL NEURONS; SELF ORGANIZATION; DIFFERENTIATION;
   SPECIFICATION; NEUROGENESIS; MODULATION; MECHANISMS; DERIVATION;
   INHIBITION; ASTROCYTES
AB The human brain formation involves complicated processing, which is regulated by a gene regulatory network influenced by different signaling pathways. The cross regulatory interactions between elements of different pathways affect the process of cell fate assignment during neural and astroglial tissue patterning. In this study, the interactions between Wnt and Notch pathways, the two major pathways that influence neural and astroglial differentiation of human induced pluripotent stem cells (hiPSCs) individually, were investigated. In particular, the synergistic effects of Wnt Notch pathway on the neural patterning processes along the anterior posterior or dorsal ventral axis of hiPSC derived cortical spheroids were explored. The human cortical spheroids derived from hiPSCs were treated with Wnt activator CHIR99021 (CHIR), Wnt inhibitor IWP4, and Notch inhibitor (N [N (3,5 difluorophenacetyl) l alanyl] S phenylglycine t butyl ester [DAPT]) individually, or in combinations (CHIR + DAPT, IWP4 + DAPT). The results suggest that CHIR + DAPT can promote Notch signaling, similar or higher than CHIR alone, whereas IWP4 + DAPT reduces Notch activity compared to IWP4 alone. Also, CHIR + DAPT promoted hindbrain marker HOXB4 expression more consistently than CHIR alone, while IWP4 + DAPT promoted Olig2 expression, indicating the synergistic effects distinctly different from that of the individual small molecule. In addition, IWP4 simultaneously promoted dorsal and ventral identity. The patterned neural spheroids can be switched for astroglial differentiation using bone morphogenetic protein 4. This study should advance the derivations of neurons, astroglial cells, and brain region specific organoids from hiPSCs for disease modeling, drug screening, as well as for hiPSC based therapies. Impact Statement Wnt signaling plays a central role in neural patterning of human pluripotent stem cells. It can interact with Notch signaling in defining dorsal ventral and rostral caudal (or anterior posterior) axis of brain organoids. This study investigates novel Wnt and Notch interactions (i.e., Wntch) in neural patterning of dorsal forebrain spheroids or organoids derived from human induced pluripotent stem cells. The synergistic effects of Wnt activator or inhibitor with Notch inhibitor were observed. This study should advance the derivations of neurons, astroglial cells, and brain region specific organoids from human stem cells for disease modeling and drug screening, as well as for stem cell based therapies. The results can be used to establish better in vitro culture methods for efficiently mimicking in vivo structure of central nervous system.
C1 [Bejoy, Julie; Bijonowski, Brent; Marzano, Mark; Jeske, Richard; Ma, Teng; Li, Yan] Florida State Univ, Dept Chem & Biomed Engn, FAMU FSU Coll Engn, 2525 Pottsdamer St, Tallahassee, FL 32310 USA.
   [Bejoy, Julie] Vanderbilt Univ, Coll Med, 221 Kirkland Hall, Nashville, TN 37235 USA.
C3 State University System of Florida; Florida A&M University; Florida
   State University; Vanderbilt University
RP Li, Y (通讯作者)，Florida State Univ, Dept Chem & Biomed Engn, FAMU FSU Coll Engn, 2525 Pottsdamer St, Tallahassee, FL 32310 USA.
EM yli4@fsu.edu
RI Bejoy, Julie/ABE 5371 2021
OI Bejoy, Julie/0000 0002 6406 077X
FU National Science Foundation Career Award [1652992]; Div Of Chem, Bioeng,
   Env, & Transp Sys; Directorate For Engineering [1652992] Funding Source:
   National Science Foundation
FX This work is supported by National Science Foundation Career Award (No.
   1652992 to Y.L.).
CR Azzolin L, 2014, CELL, V158, P157, DOI 10.1016/j.cell.2014.06.013
   Bejoy J, 2018, ACS BIOMATER SCI ENG, V4, P4354, DOI 10.1021/acsbiomaterials.8b01142
   Bejoy J, 2018, ACS BIOMATER SCI ENG, V4, P2922, DOI 10.1021/acsbiomaterials.8b00021
   Bejoy J, 2018, TISSUE ENG PT A, V24, P546, DOI [10.1089/ten.TEA.2017.0153, 10.1089/ten.tea.2017.0153]
   Bejoy J, 2016, ORGANOGENESIS, V12, P1, DOI 10.1080/15476278.2016.1140290
   Borghese L, 2010, STEM CELLS, V28, P955, DOI 10.1002/stem.408
   Bradley RA, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.170910
   Cederquist GY, 2019, NAT BIOTECHNOL, V37, P436, DOI 10.1038/s41587 019 0085 3
   Collu GM, 2014, CELL MOL LIFE SCI, V71, P3553, DOI 10.1007/s00018 014 1644 x
   De Strooper B, 2001, J CELL BIOL, V152, pF17, DOI 10.1083/jcb.152.4.F17
   Dezonne RS, 2017, SCI REP UK, V7, DOI 10.1038/srep45091
   Di Lullo E, 2017, NAT REV NEUROSCI, V18, P573, DOI 10.1038/nrn.2017.107
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   Fiddes IT, 2018, CELL, V173, P1356, DOI 10.1016/j.cell.2018.03.051
   Gross RE, 1996, NEURON, V17, P595, DOI 10.1016/S0896 6273(00)80193 2
   Hayward P, 2008, DEVELOPMENT, V135, P411, DOI 10.1242/dev.000505
   Hirsch C, 2007, EXP CELL RES, V313, P572, DOI 10.1016/j.yexcr.2006.11.002
   Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987 09.2010
   Kamakura S, 2004, NAT CELL BIOL, V6, P547, DOI 10.1038/ncb1138
   Kessler M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9989
   Khakh BS, 2015, NAT NEUROSCI, V18, P942, DOI 10.1038/nn.4043
   Li X, 2018, STEM CELL REP, V11, P998, DOI 10.1016/j.stemcr.2018.08.019
   Lian XJ, 2012, P NATL ACAD SCI USA, V109, pE1848, DOI 10.1073/pnas.1200250109
   Lin F, 2019, ACTA BIOMATER, V86, P125, DOI 10.1016/j.actbio.2019.01.017
   Liu Y, 2011, NAT PROTOC, V6, P640, DOI 10.1038/nprot.2011.310
   Ma L, 2019, STEM CELL REP, V12, P934, DOI 10.1016/j.stemcr.2019.04.007
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Marton RM, 2019, NAT NEUROSCI, V22, P484, DOI 10.1038/s41593 018 0316 9
   Maury Y, 2015, NAT BIOTECHNOL, V33, P89, DOI 10.1038/nbt.3049
   Moya N, 2014, STEM CELL REP, V3, P1015, DOI 10.1016/j.stemcr.2014.10.004
   Muguruma K, 2015, CELL REP, V10, P537, DOI 10.1016/j.celrep.2014.12.051
   Muñoz Descalzo S, 2012, BIOESSAYS, V34, P110, DOI 10.1002/bies.201100102
   Nadadhur AG, 2018, STEM CELL RES, V32, P25, DOI 10.1016/j.scr.2018.08.017
   Namihira M, 2009, DEV CELL, V16, P245, DOI 10.1016/j.devcel.2008.12.014
   Pasca AM, 2015, NAT METHODS, V12, P671, DOI [10.1038/NMETH.3415, 10.1038/nmeth.3415]
   Qi YC, 2017, NAT BIOTECHNOL, V35, P154, DOI 10.1038/nbt.3777
   Sart S, 2016, ACTA BIOMATER, V30, P222, DOI 10.1016/j.actbio.2015.11.016
   Sart S, 2014, TISSUE ENG PT A, V20, P54, DOI [10.1089/ten.tea.2012.0690, 10.1089/ten.TEA.2012.0690]
   Si Tayeb K., 2010, BMC DEV BIOL, V10
   Si Tayeb K, 2010, HEPATOLOGY, V51, P297, DOI 10.1002/hep.23354
   Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017
   Sloan SA, 2017, NEURON, V95, P779, DOI 10.1016/j.neuron.2017.07.035
   Song LQ, 2016, COLLOID SURFACE B, V148, P49, DOI 10.1016/j.colsurfb.2016.08.041
   SONG LQ, 2019, SCI REP UK, V9
   Sonnen KF, 2018, CELL, V172, P1079, DOI 10.1016/j.cell.2018.01.026
   Suzuki IK, 2018, CELL, V173, P1370, DOI 10.1016/j.cell.2018.03.067
   Suzuki IK, 2015, DEVELOPMENT, V142, P3138, DOI 10.1242/dev.120568
   Tao YL, 2016, CELL STEM CELL, V19, P573, DOI 10.1016/j.stem.2016.10.015
   ten Berge D, 2008, CELL STEM CELL, V3, P508, DOI 10.1016/j.stem.2008.09.013
   Tieng V, 2014, STEM CELLS DEV, V23, P1535, DOI 10.1089/scd.2013.0442
   Totaro A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15206
   Trac D, 2019, CIRC RES, V124, P526, DOI 10.1161/CIRCRESAHA.118.313845
   Wilson L, 2005, DEV BIOL, V282, P1, DOI 10.1016/j.ydbio.2005.02.027
   Wimmer RA, 2019, NATURE, V565, P505, DOI 10.1038/s41586 018 0858 8
   Woo SM, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471 2202 10 97
   Xue XF, 2018, NAT MATER, V17, P633, DOI 10.1038/s41563 018 0082 9
   Yan YW, 2018, TISSUE ENG PT A, V24, P418, DOI [10.1089/ten.tea.2016.0400, 10.1089/ten.TEA.2016.0400]
   Yan YW, 2016, ACTA BIOMATER, V42, P114, DOI 10.1016/j.actbio.2016.06.027
   Yan YW, 2015, BIOMATERIALS, V73, P231, DOI 10.1016/j.biomaterials.2015.09.020
   Zhang XX, 2013, STEM CELLS, V31, P2667, DOI 10.1002/stem.1371
   Zhao J, 2017, HUM MOL GENET, V26, P2690, DOI 10.1093/hmg/ddx155
NR 61
TC 24
Z9 27
U1 0
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD APR 1
PY 2020
VL 26
IS 7 8
BP 419
EP 431
DI 10.1089/ten.tea.2019.0202
EA DEC 2019
PG 13
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA LE3HS
UT WOS:000505017200001
PM 31686622
OA Green Published
DA 2025 08 17
ER

PT J
AU Xiong, Y
   Huang, CW
   Shi, C
   Peng, L
   Cheng, YT
   Hong, W
   Liao, J
AF Xiong, Yue
   Huang, Cheng Wei
   Shi, Chao
   Peng, Liang
   Cheng, Yu Ting
   Hong, Wei
   Liao, Jian
TI Quercetin suppresses ovariectomy induced osteoporosis in rat mandibles
   by regulating autophagy and the NLRP3 pathway
SO EXPERIMENTAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Quercetin; alendronate; postmenopausal osteoporosis; autophagy; NLRP3;
   osteoclasts
ID MESENCHYMAL STEM CELLS; BONE LOSS; POSTMENOPAUSAL OSTEOPOROSIS;
   OSTEOGENIC DIFFERENTIATION; GENE EXPRESSION; NANOPARTICLES
AB With the aging population and the popularity of implant prostheses, an increasing number of postmenopausal osteoporosis (PMOP) patients require implant restorations; however, poor bone condition affects the long term stability of implant prostheses. This study aimed to investigate the therapeutic effect of quercetin (QR) compared with alendronate (ALN), the primary treatment for PMOP, on mandibular osteoporosis (OP) induced by ovariectomy (OVX) in female rats. Adult female rats were treated with QR (50 mg/kg/day), ALN (6.25 mg/kg/week) by gavage for 8 weeks, chloroquine (CQ, 10 mg/kg/twice a week), and cytokine release inhibitory drug 3 (MCC950, 10 mg/kg/three times a week) by intraperitoneal injection for 8 weeks after bilateral OVX. Blood samples were collected prior to euthanasia; the mandibles were harvested and subjected to micro computed tomography (micro CT) and pathological analysis. QR administration controlled weight gain and significantly improved the bone microstructure in OVX rats, increasing bone mass, and bone mineral density (BMD), reducing bone trabecular spacing, and decreasing osteoclast numbers. Western blotting, real time quantitative PCR (RT qPCR), and serum markers confirmed that QR inhibited interleukin  1 beta (IL 1 beta) and interleukin 18 (IL 18) on the nucleotide binding oligomerization domain (NOD) like receptor (NLR) protein 3 (NLRP3) pathway thereby inhibiting osteoclast differentiation, immunofluorescence and western blotting also confirmed that QR inhibited autophagy in OVX rats and suppressed the number of tartrate resistant acid phosphatase (TRAP) stained positive osteoclasts. The findings suggest that QR may protect the bone structure and prevent bone loss in osteoporotic rats by inhibiting the NLRP3 pathway and autophagy in osteoclasts with comparable effects to ALN, thus QR may have the potential to be a promising alternative supplement for the preventive and therapeutic treatment of PMOP.
C1 [Xiong, Yue; Cheng, Yu Ting; Liao, Jian] Guizhou Med Univ, Sch Hosp Stomatol, Dept Prosthodont & Implantol, Guiyang 550004, Peoples R China.
   [Huang, Cheng Wei] AOSI CAR Dent, Shantou 515041, Peoples R China.
   [Shi, Chao; Peng, Liang; Hong, Wei] Guizhou Med Univ, Guiyang 550004, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University
RP Xiong, Y; Liao, J (通讯作者)，Guizhou Med Univ, Sch Hosp Stomatol, Dept Prosthodont & Implantol, Guiyang 550004, Peoples R China.
EM 510429863@qq.com; liaojian@gmc.edu.cn
RI XIONG, YUE/HTM 8673 2023; Cheng, Yu Ting/E 6408 2011; Yuan,
   Yahong/KFB 9020 2024; Huang, Cheng Wei/AAG 6276 2020
OI Xiong, Yue/0000 0002 7926 9939; LIAO, JIAN/0000 0003 3519 4485
FU National Natural Science Foundation of China; National Natural Science
   Foundation of China [82060207, 82260198]; Natural Science Foundation
   Project of Guizhou Province: Key Basic Science Project Contract
   [ZK[2023]037]; Guizhou Health and Health Committee Science and
   Technology Fund Program [gzwkj2023 439]
FX The author(s) disclosed receipt of the following financial sup port for
   the research, authorship, and/or publication of this article: This
   research was funded by the National Natural Science Foundation of China
   (grant no. 82060207, 82260198); Natural Science Foundation Project of
   Guizhou Province: Key Basic Science Project Contract (grant no.
   ZK[2023]037); Guizhou Health and Health Committee Science and Technology
   Fund Program (grant no. gzwkj2023 439).
CR Abd El Fattah AI, 2017, CHEM BIOL INTERACT, V271, P30, DOI 10.1016/j.cbi.2017.04.026
   Abdelkarem HM, 2016, TOXICOL MECH METHOD, V26, P692, DOI 10.1080/15376516.2016.1236424
   Abdulkadir A, 2018, PAN AFR MED J, V29, DOI 10.11604/pamj.2018.29.49.12471
   Andres S, 2018, MOL NUTR FOOD RES, V62, DOI 10.1002/mnfr.201700447
   Arai A, 2019, J BONE MINER RES, V34, P1753, DOI 10.1002/jbmr.3756
   Lemos CAA, 2023, CLIN ORAL INVEST, V27, P2483, DOI 10.1007/s00784 023 05005 2
   Black DM., N Engl J Med, V32, DOI [10.1056/NEJMcp1513724, DOI 10.1056/NEJMCP1513724]
   Briot K, 2017, OSTEOPOROSIS INT, V28, P3301, DOI 10.1007/s00198 017 4189 7
   Castelo Branco C, 2013, GYNECOL ENDOCRINOL, V29, P735, DOI 10.3109/09513590.2013.801441
   Cavalier E, 2016, OSTEOPOROSIS INT, V27, P2181, DOI 10.1007/s00198 016 3561 3
   Chen C., 2019, METHODS MOL BIOL, V1952
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Clarke AJ, 2019, NAT REV IMMUNOL, V19, P170, DOI 10.1038/s41577 018 0095 2
   Derakhshanian H, 2013, CAN J PHYSIOL PHARM, V91, P380, DOI 10.1139/cjpp 2012 0190
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580 018 0003 4
   Faienza MF, 2018, EXPERT OPIN BIOL TH, V18, P149, DOI 10.1080/14712598.2018.1401607
   Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697
   He W, 2020, NANOMEDICINE UK, V15, P337, DOI 10.2217/nnm 2019 0026
   Inoue J, 2010, J NUTR SCI VITAMINOL, V56, P326, DOI 10.3177/jnsv.56.326
   Iwasa T, 2018, HORM BEHAV, V97, P25, DOI 10.1016/j.yhbeh.2017.10.005
   Jana N., 2018, KLIN ONKOL, V31
   Jang E, 2020, BIOCHEM PHARMACOL, V178, DOI 10.1016/j.bcp.2020.114098
   Jiang N, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.752546
   Kanis JA., 2019, CALCIF TISSUE INT, V104
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Khairallah P, 2018, CLIN J AM SOC NEPHRO, V13, P962, DOI 10.2215/CJN.11031017
   Khosla S, 2013, J GERONTOL A BIOL, V68, P1226, DOI 10.1093/gerona/gls163
   Kling JM, 2014, J WOMENS HEALTH, V23, P563, DOI 10.1089/jwh.2013.4611
   Li X, 2020, AGEING RES REV, V62, DOI 10.1016/j.arr.2020.101098
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Liang W, 2011, EUR J PHARMACOL, V670, P317, DOI 10.1016/j.ejphar.2011.08.014
   Lorentzon M, 2019, ADV THER, V36, P2811, DOI 10.1007/s12325 019 01063 9
   Ma M, 2016, AGING CLIN EXP RES, V28, P1067, DOI 10.1007/s40520 015 0509 y
   Mbalaviele G, 2017, J CLIN INVEST, V127, P2030, DOI 10.1172/JCI93356
   Minisola S., 2021, JBMR PLUS, V5
   Mousavi S, 2023, MOL BIOL REP, V50, P3693, DOI 10.1007/s11033 023 08311 w
   Niu YB, 2020, ACTA PHARMACOL SIN, V41, P1476, DOI 10.1038/s41401 020 00509 z
   Nogalska A, 2009, ACTA NEUROPATHOL, V118, P407, DOI 10.1007/s00401 009 0564 6
   Qi WD, 2022, MOLECULES, V27, DOI 10.3390/molecules27196545
   Sánchez Martín P, 2019, FEBS J, V286, P8, DOI 10.1111/febs.14712
   Siddiqui JA, 2011, MENOPAUSE, V18, P198, DOI 10.1097/gme.0b013e3181e84e67
   Simon HU, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aag2791
   Srivastava S, 2013, PHYTOMEDICINE, V20, P683, DOI 10.1016/j.phymed.2013.03.001
   Tang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7039802
   Tanida I, 2008, AUTOPHAGY, V4, P131, DOI 10.4161/auto.5233
   Taniyama T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041235
   Tsuji M, 2009, J BONE MINER METAB, V27, P673, DOI 10.1007/s00774 009 0088 0
   Wang N, 2021, PHYTOTHER RES, V35, P2639, DOI 10.1002/ptr.7010
   Wang SM, 2021, CHEMOSPHERE, V268, DOI 10.1016/j.chemosphere.2020.128837
   Wang XC., 2014, MOL MED REP, V10
   Wang Y, 2023, BIOACT MATER, V25, P13, DOI 10.1016/j.bioactmat.2023.01.009
   Wilhelm T, 2018, FEBS J, V285, P2367, DOI 10.1111/febs.14453
   Wong SK, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176448
   Xing LZ, 2017, BIOMED PHARMACOTHER, V89, P1136, DOI 10.1016/j.biopha.2017.02.073
   Yang CG, 2019, MOL MED REP, V19, P1065, DOI 10.3892/mmr.2018.9752
   Yuan YF, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.994995
   Yuan Z., 2018, AM J TRANSL RES, V10
   Zang Y, 2020, J DENT RES, V99, P1287, DOI 10.1177/0022034520933533
   Zhang C, 2022, J NEUROINFLAMM, V19, DOI 10.1186/s12974 022 02445 7
   Zhang Y, 2020, CELL SIGNAL, V67, DOI 10.1016/j.cellsig.2019.109505
   Zhou C, 2014, CELL PROLIFERAT, V47, P124, DOI 10.1111/cpr.12097
NR 62
TC 12
Z9 13
U1 14
U2 28
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1535 3702
EI 1535 3699
J9 EXP BIOL MED
JI Exp. Biol. Med.
PD DEC
PY 2023
VL 248
IS 23
BP 2363
EP 2380
DI 10.1177/15353702231211977
EA JAN 2024
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FQ5R4
UT WOS:001144898300001
PM 38240215
OA Green Published
DA 2025 08 17
ER

PT J
AU Decker, DA
   Higgins, P
   Hayes, K
   Bollinger, C
   Becker, P
   Wright, D
AF Decker, Dima A.
   Higgins, Paul
   Hayes, Kyle
   Bollinger, Chris
   Becker, Patrice
   Wright, Dale
TI Repository corticotropin injection attenuates collagen induced arthritic
   joint structural damage and has enhanced effects in combination with
   etanercept
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Rheumatoid arthritis; Melanocortin receptor agonist; Repository
   corticotropin injection; Bone loss; Etanercept; Osteoclast
ID MELANOCYTE STIMULATING HORMONE; INTERLEUKIN 1 RECEPTOR ANTAGONIST;
   MELANOCORTIN PEPTIDE THERAPY; RHEUMATOID ARTHRITIS; ADRENOCORTICOTROPIC
   HORMONE; ANIMAL MODELS; ACTH; SYSTEM; PROOPIOMELANOCORTIN; INFLAMMATION
AB BackgroundMelanocortin receptor (MCR) agonists have anti inflammatory and immunomodulatory properties mediated by receptors expressed on cells relevant to arthritis. Repository corticotropin injection (RCI; Acthar (R) Gel), an MCR agonist preparation, is approved as adjunctive therapy for rheumatoid arthritis (RA), but its mechanism of action in RA is unclear. This study explored the efficacy of RCI as monotherapy or adjunctive therapy with etanercept (ETN) in an established animal model of collagen induced arthritis (CIA).MethodsAfter induction of CIA, rats (n =10 per group) were randomized to receive subcutaneous RCI (40, 160, or 400U/kg twice daily) alone or in combination with ETN (10mg/kg 3 times daily), ETN alone, or vehicle (on days 13 through 19). Inflammation was assessed via changes in paw edema. Bone damage was determined by microfocal computed tomography histopathology, and immunohistochemistry. Statistical analyses were performed using a 2 way analysis of variance (ANOVA) followed by the Newman Keuls, Dunn's, or Dunnett's multiple comparisons test or a 1 way ANOVA followed by the Dunnett's or Holm Sidak multiple comparisons test.ResultsRCI administration resulted in dose dependent decreases in ankle edema and histopathologic measures of inflammation, pannus formation, cartilage damage, bone resorption, and periosteal bone formation. RCI and ETN showed combined benefits on all parameters measured. Radiographic evidence of bone damage was significantly reduced in rats that received RCI alone or in combination with ETN. This reduction in bone density loss correlated with decreases in the number of CD68 positive macrophages and cathepsin K positive osteoclasts within the lesions.ConclusionsAs monotherapy or adjunctive therapy with ETN, RCI attenuated CIA induced joint structural damage in rats. These data support the clinical efficacy of RCI as adjunctive therapy for patients with RA.
C1 [Decker, Dima A.; Higgins, Paul; Hayes, Kyle; Bollinger, Chris; Becker, Patrice; Wright, Dale] Mallinckrodt Pharmaceut, 675 McDonnell Blvd, Bedminster, NJ 63042 USA.
RP Wright, D (通讯作者)，Mallinckrodt Pharmaceut, 675 McDonnell Blvd, Bedminster, NJ 63042 USA.
EM dale.wright@mnk.com
FU Mallinckrodt Pharmaceuticals
FX These studies were funded by Mallinckrodt Pharmaceuticals. All authors
   are or were employees of Mallinckrodt Pharmaceuticals and were involved
   in the design of the study, the collection, analysis and interpretation
   of the data, and writing the manuscript.
CR Andersen GN, 2005, SCAND J IMMUNOL, V61, P279, DOI 10.1111/j.1365 3083.2005.01565.x
   [Anonymous], 2019, ACTH GEL
   [Anonymous], Guide for the care and use of laboratory animals
   Arnason BG, 2013, MULT SCLER J, V19, P130, DOI 10.1177/1352458512458844
   Gómez SanMiguel AB, 2016, J CACHEXIA SARCOPENI, V7, P79, DOI 10.1002/jcsm.12036
   Bendele A, 1998, PHARM RES DORDR, V15, P1557, DOI 10.1023/A:1011903100188
   Bendele A, 1999, TOXICOL PATHOL, V27, P134, DOI 10.1177/019262339902700125
   Bendele A. M., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P377
   Bendele AM, 2000, ARTHRITIS RHEUM US, V43, P2648, DOI 10.1002/1529 0131(200012)43:12<2648::AID ANR4>3.0.CO;2 M
   Böhm M, 2012, ENDOCR REV, V33, P623, DOI 10.1210/er.2011 1016
   Boston BA, 1999, ANN NY ACAD SCI, V885, P75
   Bugatti S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/681678
   Catania A, 2004, PHARMACOL REV, V56, P1, DOI 10.1124/pr.56.1.1
   Catania A, 2010, THESCIENTIFICWORLDJO, V10, P1840, DOI 10.1100/tsw.2010.173
   Ceriani Giuliana, 1994, Neuroimmunomodulation, V1, P28, DOI 10.1159/000097087
   Chhajlani V, 1996, BIOCHEM MOL BIOL INT, V38, P73
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Choy E, 2012, RHEUMATOLOGY, V51, pV3, DOI 10.1093/rheumatology/kes113
   Choy EH, 2013, NAT REV RHEUMATOL, V9, P154, DOI 10.1038/nrrheum.2013.8
   Decker DA, 2014, LUPUS, V23, P802, DOI 10.1177/0961203314531840
   DONNELLY P, 1982, J RHEUMATOL, V9, P867
   Eriksson C, 2005, ANN RHEUM DIS, V64, P403, DOI 10.1136/ard.2004.024182
   Evans JF, 2004, BONE, V35, P96, DOI 10.1016/j.bone.2004.03.015
   Fischer PA, 2018, OPEN ACCESS RHEUMATO, V10, P13, DOI 10.2147/OARRR.S153307
   Fleischmann R, 2020, RHEUMATOL THER, V7, P327, DOI 10.1007/s40744 020 00199 3
   Gavins FNE, 2006, THESCIENTIFICWORLDJO, V6, P1008, DOI 10.1100/tsw.2006.196
   Getting SJ, 2009, THESCIENTIFICWORLDJO, V9, P1394, DOI 10.1100/tsw.2009.163
   Gillis T, 2017, OPEN ACCESS RHEUMATO, V9, P131, DOI 10.2147/OARRR.S131046
   Grässel S, 2009, ARTHRITIS RHEUM US, V60, P3017, DOI 10.1002/art.24846
   Haringman JJ, 2005, ANN RHEUM DIS, V64, P834, DOI 10.1136/ard.2004.029751
   Jacobs JWG, 2012, RHEUMATOLOGY, V51, piv3, DOI 10.1093/rheumatology/kes083
   Kaneva MK, 2012, BRIT J PHARMACOL, V167, P67, DOI 10.1111/j.1476 5381.2012.01968.x
   Levine YA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104530
   Malaviya Anshuman P., 2012, Inflammopharmacology, V20, P59, DOI 10.1007/s10787 012 0123 y
   McInnes IB, 2011, NEW ENGL J MED, V365, P2205, DOI 10.1056/NEJMra1004965
   Montero Melendez T, 2014, AM J PATHOL, V184, P2333, DOI 10.1016/j.ajpath.2014.04.009
   Montero Melendez T, 2011, AM J PATHOL, V179, P259, DOI 10.1016/j.ajpath.2011.03.042
   Moustafa M, 2002, J INVEST DERMATOL, V119, P1244, DOI 10.1046/j.1523 1747.2002.19602.x
   Olsen NJ, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0823 y
   Pappas DA, 2011, BEST PRACT RES CL RH, V25, P873, DOI 10.1016/j.berh.2011.11.003
   Patel HB, 2010, FASEB J, V24, P4835, DOI 10.1096/fj.10 167759
   Rubbert Roth A, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2666
   SAVAGE O, 1962, LANCET, V1, P232
   SAVAGE O, 1959, ANN RHEUM DIS, V18, P100, DOI 10.1136/ard.18.2.100
   Scarneo SA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 2073 x
   Schioth HB, 1997, J ENDOCRINOL, V155, P73, DOI 10.1677/joe.0.1550073
   Smolen JS, 2007, LANCET, V370, P1861, DOI 10.1016/S0140 6736(07)60784 3
   Sweeney SE, 2004, INT J BIOCHEM CELL B, V36, P372, DOI 10.1016/S1357 2725(03)00259 0
   Taylor Andrew W., 1994, Neuroimmunomodulation, V1, P188, DOI 10.1159/000097167
   TERATO K, 1982, BIOMED RES TOKYO, V3, P495, DOI 10.2220/biomedres.3.495
   TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857
   Via CS, 2001, J IMMUNOL, V167, P6821, DOI 10.4049/jimmunol.167.12.6821
   Wijbrandts CA, 2007, ARTHRITIS RHEUM, V56, P3869, DOI 10.1002/art.22964
   Wright D, 2019, CONS MULT SCLER CTR
   Xia Y, 1996, CELL TISSUE RES, V286, P63, DOI 10.1007/s004410050675
   Yanaba K, 2007, J IMMUNOL, V179, P1369, DOI 10.4049/jimmunol.179.2.1369
   Yang S, 2013, BIOL PROCED ONLINE, V15, DOI 10.1186/1480 9222 15 8
   Yoon SW, 2008, OSTEOARTHR CARTILAGE, V16, P115, DOI 10.1016/j.joca.2007.05.026
   Zaidi M, 2010, P NATL ACAD SCI USA, V107, P8782, DOI 10.1073/pnas.0912176107
   Zhong Q, 2005, BONE, V36, P820, DOI 10.1016/j.bone.2005.01.020
NR 60
TC 0
Z9 0
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD AUG 31
PY 2020
VL 21
IS 1
AR 586
DI 10.1186/s12891 020 03609 3
PG 11
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA NN5WB
UT WOS:000568857500004
PM 32867752
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, DD
   Yi, CQ
   Zhang, DW
   Zhang, JC
   Yang, MS
AF Liu, Dandan
   Yi, Changqing
   Zhang, Dawei
   Zhang, Jinchao
   Yang, Mengsu
TI Inhibition of Proliferation and Differentiation of Mesenchymal Stern
   Cells by Carboxylated Carbon Nanotubes
SO ACS NANO
LA English
DT Article
DE mesenchymal stem cells; carbon nanotubes; adipogenic differentiation;
   osteogenic differentiation; Smad dependent BMP signaling pathway
ID OSTEOGENIC DIFFERENTIATION; PROTEIN; NETWORKS; ADHESION;
   FUNCTIONALIZATION; BIOCOMPATIBILITY; CYTOTOXICITY; SCAFFOLDS; BEHAVIOR;
   MURINE
AB Multipotent mesenchymal stem cells (MSCs) have attracted substantial attention in stem cell therapy and tissue engineering due to their ability to be cultured for successive passages and multilineage differentiation. Carbon nanotubes (CNTs) have been proposed to be used as potential biomedical structures for bone formation. Therefore, it is important to study the mechanisms of interaction between MSCs and CNTs. We demonstrated that carboxylated single walled carbon nanotubes (SWCNTs) and carboxylated multiwalled carbon nanotubes (MWCNTs) inhibited the proliferation, osteogenic differentiation, adipogenic differentiation, and mineralization of MSCs. Oxidative stress assay indicated that reactive oxygen species (ROS) may not be responsible for the observed cytotoxicity of carboxylated CNTs. Quantitative real time polymerase chain reaction (Q PCR) experiments confirmed that the expression of osteoblast specific genes and adipocyte differentiation specific genes was greatly attenuated during the differentiation of MSCs in the presence of carboxylated CNTs. TEM images revealed that CNTs might interact with proteins located on the cell membrane or in the cytoplasm, which have a further impact on subsequent cellular signaling pathways. Q PCR results and Western blot analysis together verified that the inhibition of proliferation and osteogenic differentiation of MSCs may be modulated through a Smad dependent bone morphogenetic protein (BMP) signaling pathway.
C1 [Liu, Dandan; Zhang, Jinchao] Hebei Univ, Coll Chem & Environm Sci, Baoding, Peoples R China.
   [Liu, Dandan; Yi, Changqing; Zhang, Dawei; Yang, Mengsu] City Univ Hong Kong, Shenzhen Res Inst, Biotech & Hlth Ctr, Key Lab Biochip Technol, Shenzhen, Peoples R China.
   [Yi, Changqing; Yang, Mengsu] City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China.
C3 Hebei University; City University of Hong Kong; Shenzhen Research
   Institute, City University of Hong Kong; City University of Hong Kong
RP Zhang, JC (通讯作者)，Hebei Univ, Coll Chem & Environm Sci, Baoding, Peoples R China.
EM jczhang6970@yahoo.com.cn; bhmyang@cityu.edu.hk
RI Zhang, Dawei/IAN 9726 2023; Yang, Mengsu/I 5750 2015; YI,
   Changqing/H 5533 2011
OI Yang, Mengsu/0000 0003 2083 2296; Zhang, Jinchao/0000 0002 5279 0468; 
FU Key Laboratory Funding Scheme of Shenzhen Municipal Government; BTC
   [9683001]
FX C.Q.Y. is responsible for the experiment design, carboxylated CNT
   preparation, and SEM and TEM characterizations. D.D.L. carries out the
   cellular and molecular assays. The financial support from Key Laboratory
   Funding Scheme of Shenzhen Municipal Government, Shenzhen Double 100
   Science and Technology Project, and BTC operation fund (CityU Project
   No. 9683001) is gratefully acknowledged.
CR Abdallah BM, 2004, J BONE MINER RES, V19, P841, DOI 10.1359/JBMR.040118
   Benoit DSW, 2007, ADV FUNCT MATER, V17, P2085, DOI 10.1002/adfm.200700012
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chen RJ, 2001, J AM CHEM SOC, V123, P3838, DOI 10.1021/ja010172b
   Chen W, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1899253
   Correa Duarte MA, 2004, NANO LETT, V4, P2233, DOI 10.1021/nl048574f
   Dumortier H, 2006, NANO LETT, V6, P1522, DOI 10.1021/nl061160x
   FARLEY JR, 1983, SCIENCE, V222, P330
   Fiorito S, 2006, CARBON, V44, P1100, DOI 10.1016/j.carbon.2005.11.009
   Firkowska I, 2008, ADV FUNCT MATER, V18, P3765, DOI 10.1002/adfm.200800760
   Gaillard C, 2009, ADV MATER, V21, P2903, DOI 10.1002/adma.200900050
   Gori F, 2001, J BIOL CHEM, V276, P46515, DOI 10.1074/jbc.M105757200
   Haick H, 2009, ACS NANO, V3, P1258, DOI 10.1021/nn9001775
   Heller DA, 2005, ADV MATER, V17, P2793, DOI 10.1002/adma.200500477
   Hu H, 2004, NANO LETT, V4, P507, DOI 10.1021/nl035193d
   Isobe H, 2006, ANGEW CHEM INT EDIT, V45, P6676, DOI 10.1002/anie.200601718
   Jia G, 2005, ENVIRON SCI TECHNOL, V39, P1378, DOI 10.1021/es048729l
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kagan VE, 2006, TOXICOL LETT, V165, P88, DOI 10.1016/j.toxlet.2006.02.001
   Kam NWS, 2006, ANGEW CHEM INT EDIT, V45, P577, DOI 10.1002/anie.200503389
   Kaur G, 2008, BIOMATERIALS, V29, P4074, DOI 10.1016/j.biomaterials.2008.06.029
   Kelly KA, 1998, ENDOCRINOLOGY, V139, P2622, DOI 10.1210/en.139.5.2622
   KESTON AS, 1965, ANAL BIOCHEM, V11, P1, DOI 10.1016/0003 2697(65)90034 5
   Komori T, 2003, J BONE MINER METAB, V21, P193, DOI 10.1007/s00774 002 0408 0
   Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200
   Kostarelos K, 2007, NAT NANOTECHNOL, V2, P108, DOI 10.1038/nnano.2006.209
   Lovat V, 2005, NANO LETT, V5, P1107, DOI 10.1021/nl050637m
   Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966
   Mooney E, 2008, NANO LETT, V8, P2137, DOI 10.1021/nl073300o
   Mu QX, 2009, ACS NANO, V3, P1139, DOI 10.1021/nn900252j
   Narita N, 2009, NANO LETT, V9, P1406, DOI 10.1021/nl8030746
   Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397
   Nel AE, 2009, NAT MATER, V8, P543, DOI [10.1038/nmat2442, 10.1038/NMAT2442]
   Oreffo ROC, 2005, STEM CELL REV, V1, P169, DOI 10.1385/SCR:1:2:169
   Pantarotto D, 2004, ANGEW CHEM INT EDIT, V43, P5242, DOI 10.1002/anie.200460437
   Park SY, 2007, ADV MATER, V19, P2530, DOI 10.1002/adma.200600875
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Porter AE, 2009, ACS NANO, V3, P1485, DOI 10.1021/nn900416z
   Qi SJ, 2007, CHEMBIOCHEM, V8, P1115, DOI 10.1002/cbic.200700119
   Qi SJ, 2009, ACS APPL MATER INTER, V1, P30, DOI 10.1021/am800027d
   Ryoo HM, 2006, GENE, V366, P51, DOI 10.1016/j.gene.2005.10.011
   Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20 6 530
   Sengupta P, 2005, J BIOL CHEM, V280, P21004, DOI 10.1074/jbc.M413191200
   STEIN GS, 1993, ENDOCR REV, V14, P424, DOI 10.1210/er.14.4.424
   Tay CY, 2010, CARBON, V48, P1095, DOI 10.1016/j.carbon.2009.11.031
   White MA, 2005, ANNU REV PHARMACOL, V45, P587, DOI 10.1146/annurev.pharmtox.45.120403.095807
   Worle Knirsch JM, 2006, NANO LETT, V6, P1261, DOI 10.1021/nl060177c
   Wu P, 2008, ANGEW CHEM INT EDIT, V47, P5022, DOI 10.1002/anie.200705363
   Yi CQ, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/2/025102
   Yi CQ, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957 4484/19/9/095102
   Zhang DW, 2007, NANOTECHNOLOGY, V18, DOI 10.1088/0957 4484/18/47/475102
   Zhang WX, 2008, J BIOL CHEM, V283, P4723, DOI 10.1074/jbc.M704147200
NR 53
TC 179
Z9 193
U1 1
U2 119
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936 0851
EI 1936 086X
J9 ACS NANO
JI ACS Nano
PD APR
PY 2010
VL 4
IS 4
BP 2185
EP 2195
DI 10.1021/nn901479w
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA 586ZX
UT WOS:000276956800052
PM 20218664
DA 2025 08 17
ER

PT J
AU Fan, JJ
   Gao, JY
   Chen, J
   Hou, J
   Liu, MC
   Dang, YM
   Lin, H
AF Fan, Jingjing
   Gao, Jiayu
   Chen, Jie
   Hou, Jia
   Liu, Mengchao
   Dang, Yanmiao
   Lin, Hui
TI Berberine and aspirin prevent traumatic heterotopic ossification by
   inhibition of BMP signalling pathway and osteogenic differentiation
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE AMPK; berberine; aspirin; BMP signalling; heterotopic ossification
ID ACTIVATED PROTEIN KINASE; OSTEOBLAST DIFFERENTIATION; AMPK; GLUCOSE;
   GROWTH
AB Heterotopic ossification (HO) is a pathological process that often occurs in soft tissues following severe trauma. There is no effective therapy for HO. The BMP signalling pathway plays an essential role in the pathogenesis of HO. Our previous study showed that AMPK negatively regulates the BMP signalling pathway and osteogenic differentiation. The present study aims to study the effect of two AMPK activators berberine and aspirin on osteogenic differentiation and HO induced by traumatic injury. The effects of two AMPK activators, berberine and aspirin, on BMP signalling and osteogenic differentiation were measured by western blot, ALP and Alizarin red S staining in C3H10T1/2 cells. A mouse model with Achilles tenotomy was employed to assess the effects of berberine and aspirin on HO using & mu;CT and histological analysis. First, our study showed that berberine and aspirin inhibited phosphorylation of Smad1/5 induced by BMP6 and the inhibition was attributed to the down regulation of ALK2 expression. Second, the combination of berberine and aspirin yielded more potent effects on BMP signalling. Third, we further found that there was an additive effect of berberine and aspirin combination on osteogenic differentiation. Finally, we found that berberine and aspirin blocked trauma induced ectopic bone formation in mice, which may be through suppression of phosphorylation of Smad1/5 in injured tissues. Collectively, these findings indicate that berberine and aspirin inhibit osteogenic differentiation in C3H10T1/2 cells and traumatic HO in mice, possibly through the down regulation of the BMP signalling pathway. Our study sheds a light on prevention and treatment of traumatic HO using AMPK pharmacological activators berberine and aspirin.
C1 [Fan, Jingjing; Gao, Jiayu; Chen, Jie; Hou, Jia; Liu, Mengchao; Dang, Yanmiao; Lin, Hui] Nanchang Univ, Sch Basic Med Sci, Dept Pathophysiol, Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Path, Nanchang, Peoples R China.
   [Lin, Hui] Nanchang Univ, Sch Basic Med Sci, Dept Pathophysiol, Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Path, Nanchang, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Lin, H (通讯作者)，Nanchang Univ, Sch Basic Med Sci, Dept Pathophysiol, Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Path, Nanchang, Jiangxi, Peoples R China.
EM huilin88@ncu.edu.cn
RI Fan, Jingjing/AAS 9918 2021
FU National Natural Science Foundation of China [31900852]; Nature Science
   Foundation of Jiangxi Province of China [20224ACB206024, 20232BAB206081,
   20232BCJ23008]
FX National Natural Science Foundation of China, Grant/Award Number:
   31900852; Nature Science Foundation of Jiangxi Province of China,
   Grant/Award Number: 20224ACB206024, 20232BAB206081 and 20232BCJ23008
CR Agarwal S, 2017, MOL THER, V25, P1974, DOI 10.1016/j.ymthe.2017.01.008
   Amar E, 2015, J HIP PRESERV SURG, V2, P355, DOI 10.1093/jhps/hnv052
   Aykul S, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI153792
   Cappato S, 2016, DIS MODEL MECH, V9, P685, DOI 10.1242/dmm.023929
   Chakkalakal SA, 2016, J BONE MINER RES, V31, P1666, DOI 10.1002/jbmr.2820
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Cholok D, 2018, BONE, V109, P12, DOI 10.1016/j.bone.2017.09.019
   Dey D, 2017, TRANSL RES, V186, P95, DOI 10.1016/j.trsl.2017.06.004
   Evans KN, 2014, CLIN ORTHOP RELAT R, V472, P396, DOI 10.1007/s11999 013 3325 8
   Fukuda T, 2009, J BIOL CHEM, V284, P7149, DOI 10.1074/jbc.M801681200
   González A, 2020, CELL METAB, V31, P472, DOI 10.1016/j.cmet.2020.01.015
   Grenier G, 2013, SKELET MUSCLE, V3, DOI 10.1186/2044 5040 3 29
   Hardie DG, 2016, TRENDS CELL BIOL, V26, P190, DOI 10.1016/j.tcb.2015.10.013
   Hardie DG, 2016, ACTA PHARM SIN B, V6, P1, DOI 10.1016/j.apsb.2015.06.002
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Hou J, 2023, INFLAMMATION, V46, P1414, DOI 10.1007/s10753 023 01817 2
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Huang YF, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00178 4
   Huang YF, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 0509 1
   Hwang CD, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.158996
   Kaplan FS, 2020, BONE, V140, DOI 10.1016/j.bone.2020.115539
   Katagiri T, 2018, BONE, V109, P241, DOI 10.1016/j.bone.2017.07.024
   Langendorf CG, 2015, CELL RES, V25, P5, DOI 10.1038/cr.2014.163
   Lee HW, 2008, J BONE MINER RES, V23, P1227, DOI 10.1359/JBMR.080325
   Lee YS, 2006, DIABETES, V55, P2256, DOI 10.2337/db06 0006
   Li Y, 2018, INT J MOL MED, V41, P2535, DOI 10.3892/ijmm.2018.3498
   Lin H, 2020, J CELL MOL MED, V24, P14491, DOI 10.1111/jcmm.16076
   Lin H, 2017, BBA MOL CELL RES, V1864, P2369, DOI 10.1016/j.bbamcr.2017.08.009
   Lin SC, 2018, CELL METAB, V27, P299, DOI 10.1016/j.cmet.2017.10.009
   Liu XH, 2014, J ORTHOP RES, V32, P183, DOI 10.1002/jor.22500
   Pacifici M, 2018, BONE, V109, P267, DOI 10.1016/j.bone.2017.08.010
   Pavlou G, 2012, EXPERT OPIN PHARMACO, V13, P619, DOI 10.1517/14656566.2012.662342
   Peterson JR, 2015, JOVE J VIS EXP, DOI 10.3791/52880
   Peterson JR, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008810
   Pignolo RJ, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00908
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Van Nest DS, 2021, J ARTHROPLASTY, V36, P1543, DOI 10.1016/j.arth.2020.12.021
   Wang Ye kai, 2011, Zhongguo Gu Shang, V24, P399
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Xi G, 2019, J CELL PHYSIOL, V234, P23232, DOI 10.1002/jcp.28890
   Xie HG, 2018, BIOMED PHARMACOTHER, V108, P280, DOI 10.1016/j.biopha.2018.08.131
   Xu YL, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.770931
   Yamamoto M, 2022, J BONE MINER RES, V37, P2077, DOI 10.1002/jbmr.4617
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhang CS, 2020, CELL METAB, V31, P217, DOI 10.1016/j.cmet.2020.01.005
NR 49
TC 3
Z9 3
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1582 1838
EI 1582 4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD NOV
PY 2023
VL 27
IS 22
BP 3491
EP 3502
DI 10.1111/jcmm.17919
EA AUG 2023
PG 12
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA GP4F2
UT WOS:001052015300001
PM 37605888
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Perelló, J
   Ferrer, MD
   Pérez, MD
   Kaesler, N
   Brandenburg, VM
   Behets, GJ
   D'Haese, PC
   Garg, R
   Isern, B
   Gold, A
   Wolf, M
   Salcedo, C
AF Perello, Joan
   Ferrer, Miquel D.
   del Mar Perez, Maria
   Kaesler, Nadine
   Brandenburg, Vincent M.
   Behets, Geert J.
   D'Haese, Patrick C.
   Garg, Rekha
   Isern, Bernat
   Gold, Alex
   Wolf, Myles
   Salcedo, Carolina
TI Mechanism of action of SNF472, a novel calcification inhibitor to treat
   vascular calcification and calciphylaxis
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE calcific uraemic arteriolopathy; calciphylaxis; inositol hexaphosphate;
   IP6; peripheral arterial calcification; SNF472; vascular calcification
ID PHYTIC ACID; PHYTATE; URINE; THIOSULFATE; PROGRESSION; MORTALITY;
   DISEASE; KIDNEY
AB Background and Purpose No therapy is approved for vascular calcification or calcific uraemic arteriolopathy (calciphylaxis), which increases mortality and morbidity in patients undergoing dialysis. Deposition of hydroxyapatite (HAP) crystals in arterial walls is the common pathophysiologic mechanism. The mechanism of action of SNF472 to reduce HAP deposition in arterial walls was investigated. Experimental Approach We examined SNF472 binding features (affinity, release kinetics and antagonism type) for HAP crystalsin vitro, inhibition of calcification in excised vascular smooth muscle cells from rats and bone parameters in osteoblasts from dogs and rats. Key Results SNF472 bound to HAP with affinity (K D) of 1 10 mu M and saturated HAP at 7.6 mu M. SNF472 binding was fast (80% within 5 min) and insurmountable. SNF472 inhibited HAP crystal formation from 3.8 mu M, with complete inhibition at 30.4 mu M. SNF472 chelated free calcium with an EC(50)of 539 mu M. Chelation of free calcium was imperceptible for SNF472 1 10 mu M in physiological calcium concentrations. The lowest concentration tested in vascular smooth muscle cells, 1 mu M inhibited calcification by 67%. SNF472 showed no deleterious effects on bone mineralization in dogs or in rat osteoblasts. Conclusion and Implications These experiments show that SNF472 binds to HAP and inhibits further HAP crystallization. The EC(50)for chelation of free calcium is 50 fold greater than a maximally effective SNF472 dose, supporting the selectivity of SNF472 for HAP. These findings indicate that SNF472 may have a future role in the treatment of vascular calcification and calcific uraemic arteriolopathy in patients undergoing dialysis.
C1 [Perello, Joan; Ferrer, Miquel D.; del Mar Perez, Maria; Isern, Bernat; Salcedo, Carolina] Sanifit Therapeut, Palma De Mallorca, Spain.
   [Perello, Joan; Ferrer, Miquel D.] Univ Balearic Isl, Palma De Mallorca, Spain.
   [Kaesler, Nadine] Univ Hosp RWTH, Aachen, Germany.
   [Brandenburg, Vincent M.] Rhein Maas Klinikum, Wurselen, Germany.
   [Behets, Geert J.; D'Haese, Patrick C.] Univ Antwerp, Dept Biomed Sci, Lab Pathophysiol, Antwerp, Belgium.
   [Garg, Rekha; Gold, Alex] Sanifit Therapeut, San Diego, CA USA.
   [Wolf, Myles] Duke Univ, Sch Med, Dept Med, Div Nephrol, Durham, NC 27706 USA.
   [Wolf, Myles] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC USA.
C3 Universitat de les Illes Balears; RWTH Aachen University; RWTH Aachen
   University Hospital; University of Antwerp; Duke University; Duke
   University
RP Salcedo, C (通讯作者)，Sanifit Therapeut, Parc Bit,Europa Bldg,2nd Floor, Palma De Mallorca 07121, Spain.
EM carolina.salcedo@sanifit.com
RI ; Isern, Bernat/ABF 3751 2021; Perez, MariadelMar/MFJ 3137 2025;
   Perello, Joan/A 7387 2019; Reynés, Miguel/J 4206 2019
OI Isern, Bernat/0000 0002 3859 4348; Ferrer, Miguel
   D./0000 0003 1924 7727; 
FU Sanifit Therapeutics
FX Sanifit Therapeutics
CR Alexander SPH, 2019, BRIT J PHARMACOL, V176, pS1, DOI 10.1111/bph.14747
   Angelis M, 1997, SURGERY, V122, P1083, DOI 10.1016/S0039 6060(97)90212 9
   [Anonymous], 2018, 2018 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States
   Brandenburg VM, 2019, J NEPHROL, V32, P811, DOI 10.1007/s40620 019 00631 0
   Budisavljevic MN, 1996, J AM SOC NEPHROL, V7, P978
   Budoff MJ, 2010, JACC CARDIOVASC IMAG, V3, P1229, DOI 10.1016/j.jcmg.2010.08.018
   Cao SH, 2011, PHYTOCHEM ANALYSIS, V22, P119, DOI 10.1002/pca.1254
   Chen Y, 2007, ANAL CHIM ACTA, V605, P185, DOI 10.1016/j.aca.2007.10.041
   Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153
   de Jager DJ, 2009, JAMA J AM MED ASSOC, V302, P1782, DOI 10.1001/jama.2009.1488
   Arriero MD, 2012, CELL PHYSIOL BIOCHEM, V30, P974, DOI 10.1159/000341474
   Arriero MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043187
   Ferrer MD, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07203 x
   Ferrer MD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197061
   Grases F, 2004, ANAL CHIM ACTA, V510, P41, DOI 10.1016/j.aca.2003.12.061
   Grases F, 2001, BIOFACTORS, V15, P53, DOI 10.1002/biof.5520150105
   Grases F, 2001, BRIT J NUTR, V86, P225, DOI 10.1079/BJN2001389
   Grases F, 2000, SCAND J UROL NEPHROL, V34, P162, DOI 10.1080/003655900750016526
   Grases F, 2008, CARDIOVASC PATHOL, V17, P139, DOI 10.1016/j.carpath.2007.08.005
   Harding SD, 2018, NUCLEIC ACIDS RES, V46, pD1091, DOI 10.1093/nar/gkx1121
   Jono S, 2000, CIRC RES, V87, pE10, DOI 10.1161/01.RES.87.7.e10
   Joubert P, 2016, MED HYPOTHESES, V94, P89, DOI 10.1016/j.mehy.2016.07.005
   Kapustin AN, 2015, CIRC RES, V116, P1312, DOI 10.1161/CIRCRESAHA.116.305012
   Karamched SR, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 39639 8
   Karwowski W, 2012, MED SCI MONITOR, V18, pRA1, DOI 10.12659/MSM.882181
   Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1038/jcbfm.2010.220, 10.1111/j.1476 5381.2010.00872.x]
   Lanzer P, 2014, EUR HEART J, V35, P1515, DOI 10.1093/eurheartj/ehu163
   Leopold JA, 2015, TRENDS CARDIOVAS MED, V25, P267, DOI 10.1016/j.tcm.2014.10.021
   López González AA, 2013, EUR J NUTR, V52, P717, DOI 10.1007/s00394 012 0377 6
   Mizobuchi M, 2009, J AM SOC NEPHROL, V20, P1453, DOI 10.1681/ASN.2008070692
   Muñoz JA, 2003, ANAL CHEM, V75, P6374, DOI 10.1021/ac0345805
   Muñoz JA, 2010, ANAL CHIM ACTA, V658, P204, DOI 10.1016/j.aca.2009.11.003
   Nigwekar SU, 2018, NEW ENGL J MED, V378, P1704, DOI 10.1056/NEJMra1505292
   Noordzij M, 2011, NEPHROL DIAL TRANSPL, V26, P1662, DOI 10.1093/ndt/gfq582
   O'Neill WC, 2012, NEPHROL DIAL TRANSPL, V27, P521, DOI 10.1093/ndt/gfr375
   O'Neill WC, 2010, KIDNEY INT, V78, P1232, DOI 10.1038/ki.2010.334
   Pasch A, 2008, KIDNEY INT, V74, P1444, DOI 10.1038/ki.2008.455
   Perelló J, 2018, BRIT J CLIN PHARMACO, V84, P2867, DOI 10.1111/bcp.13752
   Raggi P, 2020, CIRCULATION, V141, P728, DOI 10.1161/CIRCULATIONAHA.119.044195
   Salcedo C, 2019, BRIT J CLIN PHARMACO, V85, P796, DOI 10.1111/bcp.13863
   Sarnak MJ, 2003, HYPERTENSION, V42, P1050, DOI 10.1161/01.HYP.0000102971.85504.7c
   Schurgers LJ, 2007, J THROMB HAEMOST, V5, P2503, DOI 10.1111/j.1538 7836.2007.02758.x
   Verberckmoes SC, 2003, KIDNEY INT, V64, P534, DOI 10.1046/j.1523 1755.2003.00123.x
   Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545
   Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523 1755.2004.66015.x
   Yiu AJ, 2015, J CARDIOVASC DEV DIS, V2, P141, DOI 10.3390/jcdd2030141
NR 46
TC 30
Z9 34
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0007 1188
EI 1476 5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD OCT
PY 2020
VL 177
IS 19
BP 4400
EP 4415
DI 10.1111/bph.15163
EA AUG 2020
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NM1XO
UT WOS:000561719800001
PM 32557649
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kalra, SP
   Dube, MG
   Iwaniec, UT
AF Kalra, Satya P.
   Dube, Michael G.
   Iwaniec, Urszula T.
TI Leptin increases osteoblast specific osteocalcin release through a
   hypothalamic relay
SO PEPTIDES
LA English
DT Article; Proceedings Paper
CT 90th Annual Meeting of the Endocrine Society
CY JUN 15 18, 2008
CL San Francisco, CA
SP Endocrine Soc
DE Osteocalcin; Osteoblast; Leptin; Hypothalamus; Bone remodeling;
   Glucose insulin homeostasis
ID BONE FORMATION; METABOLIC SYNDROME; BODY WEIGHT; GENE EXPRESSION;
   FOOD INTAKE; OB/OB MICE; BETA CELL; INSULIN; BRAIN; APPETITE
AB Enhanced long term expression of leptin by gene therapy selectively in the hypothalamus, without leakage to the systemic circulation, abrogated skeletal abnormalities and reinstated weight and insulin glucose homeostasis in leptin deficient ob/ob mice. Whether increases in osteocalcin, a hormone produced by osteoblasts and known to play a role in bone growth and recently in glucose insulin homeostasis, may link these benefits of central leptin was assessed. The effects of a single intraventricular injection of non immunogenic, non pathogenic recombinant adeno associated virus vector encoding leptin gene (rAAV lep) or green fluorescent protein gene (rAAV GFP, control) were studied in three genotypes, wild type (wt), obese diabetic, hyperinsulinemic ob/ob and non obese, diabetic insulinopenic Akita mice. Selective hypothalamic leptin expression with central rAAV lep treatment decreased weight, fat mass, food intake, suppressed insulin levels in oblob and wt mice, and conferred euglycemia by suppressing blood glucose in all three genotypes. Contemporaneously, rAAV lep treatment also augmented blood osteocalcin levels. In wt mice, osteocalcin rose by 51% and, whereas, basal osteocalcin levels in oblob and Akita mice were significantly lower as compared to those in wt mice (26% and 55%, respectively), gene therapy reinstated levels to the control range in oblob mice, and raised 40% above the wt range even in the absence of insulin in Akita mice. These findings demonstrate that the central beneficial effects of leptin on bone growth involve increased hypothalamic relay of signals that augment osteocalcin efflux from osteoblasts into the general circulation, a response that, in turn, may also modulate glucose insulin and weight homeostasis. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Kalra, Satya P.; Dube, Michael G.] Univ Florida, McKnight Brain Inst, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA.
   [Iwaniec, Urszula T.] Oregon State Univ, Dept Nutr & Exercise Sci, Corvallis, OR 97331 USA.
C3 State University System of Florida; University of Florida; Oregon State
   University
RP Kalra, SP (通讯作者)，Univ Florida, McKnight Brain Inst, Coll Med, Dept Neurosci, POB 100244, Gainesville, FL 32610 USA.
EM skalra@mbi.ufl.edu
FU NIDDK NIH HHS [DK37273, R01 DK037273] Funding Source: Medline
CR Bagnasco M, 2002, ENDOCRINOLOGY, V143, P4409, DOI 10.1210/en.2002 220505
   Bagnasco M, 2003, OBES RES, V11, P1463, DOI 10.1038/oby.2003.196
   Baldock PA, 2005, J BONE MINER RES, V20, P1851, DOI 10.1359/JBMR.050523
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Bamshad M, 1999, AM J PHYSIOL REG I, V276, pR1569, DOI 10.1152/ajpregu.1999.276.6.R1569
   Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196 9781(96)00025 3
   Baraille I, 2002, CHEM PHYS, V282, P9, DOI 10.1016/S0301 0104(02)00679 1
   Bartness TJ, 2005, P NUTR SOC, V64, P53, DOI 10.1079/PNS2004409
   Boghossian S, 2005, PEPTIDES, V26, P1512, DOI 10.1016/j.peptides.2005.03.039
   Boghossian S, 2007, NEUROBIOL AGING, V28, P1594, DOI 10.1016/j.neurobiolaging.2006.08.010
   Boghossian S, 2006, PEPTIDES, V27, P3245, DOI 10.1016/j.peptides.2006.07.022
   Buijs RM, 2001, J COMP NEUROL, V431, P405, DOI 10.1002/1096 9861(20010319)431:4<405::AID CNE1079>3.0.CO;2 D
   CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778
   Chan MHM, 2001, J CLIN ENDOCR METAB, V86, P4556
   Chen YY, 2000, REGUL PEPTIDES, V92, P113, DOI 10.1016/S0167 0115(00)00157 9
   Chinookoswong N, 1999, DIABETES, V48, P1487, DOI 10.2337/diabetes.48.7.1487
   Cirmanová V, 2008, PHYSIOL RES, V57, pS143, DOI 10.33549/physiolres.931499
   Della Fera MA, 2005, OBES RES, V13, P1540, DOI 10.1038/oby.2005.189
   Dhillon H, 2001, REGUL PEPTIDES, V99, P69, DOI 10.1016/S0167 0115(01)00237 3
   Dhillon H, 2000, REGUL PEPTIDES, V92, P97, DOI 10.1016/S0167 0115(00)00155 5
   Dube MG, 2008, PEPTIDES, V29, P593, DOI 10.1016/j.peptides.2008.01.001
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ealey KN, 2006, REGUL PEPTIDES, V136, P9, DOI 10.1016/j.regpep.2006.04.013
   Elefteriou F, 2004, P NATL ACAD SCI USA, V101, P3258, DOI 10.1073/pnas.0308744101
   EVANS RM, 2008, ENDOCRINE NEWS, P14
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376
   Guidobono F, 2006, PEPTIDES, V27, P1426, DOI 10.1016/j.peptides.2005.10.014
   Hamrick MW, 2005, J BONE MINER RES, V20, P994, DOI 10.1359/JBMR.050103
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hidaka S, 2002, FASEB J, V16, P509, DOI 10.1096/fj.01 0164com
   Hinoi E, 2008, J CELL BIOL, V183, P1235, DOI 10.1083/jcb.200809113
   Iwaniec UT, 2009, BONE, V44, P404, DOI 10.1016/j.bone.2008.10.058
   Iwaniec UT, 2007, PEPTIDES, V28, P1012, DOI 10.1016/j.peptides.2007.02.001
   Kalra SP, 2008, NUTRITION, V24, P820, DOI 10.1016/j.nut.2008.06.023
   Kalra SP, 2008, PEPTIDES, V29, P127, DOI 10.1016/j.peptides.2007.10.017
   Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68
   Kalra SP, 2004, NEUROPEPTIDES, V38, P201, DOI 10.1016/j.npep.2004.06.003
   Kalra SP, 2005, TRENDS PHARMACOL SCI, V26, P488, DOI 10.1016/j.tips.2005.08.008
   Kastin AJ, 2000, REGUL PEPTIDES, V92, P37, DOI 10.1016/S0167 0115(00)00147 6
   Kastin AJ, 2006, ENDOCRINOLOGY, V147, P2086, DOI 10.1210/en.2006 0208
   Kreier F, 2006, ENDOCRINOLOGY, V147, P1140, DOI 10.1210/en.2005 0667
   Lecklin A, 2005, PEPTIDES, V26, P1176, DOI 10.1016/j.peptides.2005.01.021
   Lee NK, 2008, TRENDS ENDOCRIN MET, V19, P161, DOI 10.1016/j.tem.2008.02.006
   Lord G, 2002, NUTR REV, V60, pS35, DOI 10.1301/002966402320634913
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   Maness LM, 1998, ENDOCRINOLOGY, V139, P4556, DOI 10.1210/en.139.11.4556
   Otukonyong EE, 2005, PEPTIDES, V26, P2559, DOI 10.1016/j.peptides.2005.04.015
   Patel MS, 2007, CALCIFIED TISSUE INT, V80, P337, DOI 10.1007/s00223 007 9015 3
   Ruiz Gaspa S, 2007, J CELL BIOCHEM, V101, P1430, DOI 10.1002/jcb.21259
   Sahu A, 2002, J NEUROENDOCRINOL, V14, P796, DOI 10.1046/j.1365 2826.2002.00840.x
   Seeman E, 2008, RHEUMATOLOGY, V47, P2, DOI 10.1093/rheumatology/ken177
   Shi ZQ, 1998, METABOLISM, V47, P1274, DOI 10.1016/S0026 0495(98)90336 5
   Sierra Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Thomas T, 2004, CURR OPIN PHARMACOL, V4, P295, DOI 10.1016/j.coph.2004.01.009
   Ueno N, 2004, ENDOCRINOLOGY, V145, P4176, DOI 10.1210/en.2004 0262
   Ueno N, 2006, PEPTIDES, V27, P2332, DOI 10.1016/j.peptides.2006.03.006
   Uyama N, 2004, ANAT REC PART A, V280A, P808, DOI 10.1002/ar.a.20086
   Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431
   WHITFIELD JF, 2002, PTH LEPTIN 2 BONE 2
   Wolf G, 2008, NUTR REV, V66, P229, DOI 10.1111/j.1753 4887.2008.00027.x
   Wynne K, 2005, J ENDOCRINOL, V184, P291, DOI 10.1677/joe.1.05866
   Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887
NR 66
TC 35
Z9 38
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0196 9781
EI 1873 5169
J9 PEPTIDES
JI Peptides
PD MAY
PY 2009
VL 30
IS 5
BP 967
EP 973
DI 10.1016/j.peptides.2009.01.020
PG 7
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Pharmacology & Pharmacy
GA 449ZM
UT WOS:000266369900021
PM 19428775
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Li, YX
   Chen, FC
   Liu, T
   Cai, ZP
   Chen, K
   Tang, GX
   Huang, JS
   Liu, XG
   Huang, JJ
   Wang, P
   Liang, YW
   Huang, L
AF Li, Yu Xi
   Chen, Fu Chao
   Liu, Ting
   Cai, Zhao Peng
   Chen, Keng
   Tang, Guo Xue
   Huang, Jun Shen
   Liu, Xiang Ge
   Huang, Jia Jun
   Wang, Peng
   Liang, Yu Wei
   Huang, Lin
TI Pantoprazole (PPZ) Inhibits RANKL Induced Osteoclast Formation and
   Function In Vitro and Prevents Lipopolysaccharide  (LPS ) Induced
   Inflammatory Calvarial Bone Loss In Vivo
SO STEM CELLS INTERNATIONAL
LA English
DT Article
ID PROTON PUMP INHIBITORS; INTRAMUSCULAR ARTESUNATE; SEVERE MALARIA; HEALTH
   WORKER; K+ ATPASE; TNF ALPHA; RISK; OMEPRAZOLE; RESORPTION; FRACTURE
AB Bone remodeling is a process delicately balanced between osteoclastic bone resorption and osteoblastic bone formation. Osteoclasts (OCs) are multinucleated giant cells formed through the fusion of monocytic precursors of the hematopoietic stem cells lineage. OCs are the exclusive cells responsible for the resorption and degradation of the mineralized bone matrix. Pantoprazole (PPZ), a proton pump inhibitor (PPI), is commonly prescribed to reduce excess gastric acid production for conditions such as gastroesophageal reflux disease and peptic ulcer disease. Studies have found contradictory effects of PPI therapy on bone metabolism due to the lack of understanding of the exact underlying mechanism. In this study, we found that PPZ inhibits receptor activator of nuclear factor kappa B (NF kappa B) ligand  (RANKL ) induced osteoclastogenesis from bone marrow monocytic/macrophage (BMMs) precursors and the bone resorbing activity of mature OCs. Correspondingly, the expression of OC marker genes was also attenuated. At the molecular level, PPZ treatment was associated with reduced activation of the ERK MAPK signaling pathways crucial to OC differentiation. Additionally, the in vivo administration of PPZ protected mice against lipopolysaccharide  (LPS ) induced inflammatory calvarial bone erosion, as a result of the reduced number and activity of OCs on the calvarial bone surface. Although PPI use is associated with increased risk of osteoporosis and bone fractures, our study provides evidence for the direct inhibitory effect of PPZ on OC formation and bone resorption in vitro and in vivo, suggesting a potential therapeutic use of PPZ in the treatment of osteolytic disease with localized bone destruction.
C1 [Li, Yu Xi; Chen, Fu Chao; Huang, Jun Shen; Liu, Xiang Ge; Huang, Jia Jun; Liang, Yu Wei; Huang, Lin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou 510120, Peoples R China.
   [Chen, Fu Chao] Soochow Univ, Affiliated Hosp 2, Dept Orthoped, Suzhou 215000, Peoples R China.
   [Liu, Ting] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Anesthesia, Guangzhou 510120, Peoples R China.
   [Cai, Zhao Peng; Chen, Keng; Wang, Peng] Sun Yat Sen Univ, Affiliated Hosp 8, Dept Orthoped, Shenzhen 518033, Peoples R China.
   [Tang, Guo Xue] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, Guangzhou 510120, Peoples R China.
C3 Sun Yat Sen University; Soochow University   China; Sun Yat Sen
   University; Sun Yat Sen University; Sun Yat Sen University
RP Liang, YW; Huang, L (通讯作者)，Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Orthoped, Guangzhou 510120, Peoples R China.
EM liyx73@mail.sysu.edu.cn; 304202166@qq.com; ting.liu.ting@gmail.com;
   caizhp3@mail.sysu.edu.cn; 47948842@qq.com; tanggx5@mail.sysu.edu.cn;
   huangjsh7@mail2.sysu.edu.cn; liu0821a@126.com; huangjjsysu@163.com;
   770858492@qq.com; liangyw36@mail.sysu.edu.cn; huangl5@mail.sysu.edu.cn
RI Huang, Junshen/NZN 4879 2025; Liu, Ting/AHD 4687 2022; Liu,
   Xiangge/HDO 3796 2022; Huang, Jiajun/LBA 9276 2024; Huang,
   Lin/X 5137 2019
OI LI, YUXI/0000 0002 4470 7679; 
FU National Natural Science Foundation of Guangdong Province
   [2017A030310554, 2020A1515011388, 2017A030313652]
FX This study was supported by the National Natural Science Foundation of
   Guangdong Province (grant nos. 2017A030310554, 2020A1515011388, and
   2017A030313652).
CR Abu Amer Y, 2000, J BIOL CHEM, V275, P27307
   Adesoro O, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913 016 1811 x
   Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Costa Rodrigues J, 2013, FEBS J, V280, P5052, DOI 10.1111/febs.12478
   Dou C, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.69
   Duan XH, 2018, THERANOSTICS, V8, P5379, DOI 10.7150/thno.28391
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Hiraga T, 2016, EXPERT OPIN INV DRUG, V25, P319, DOI 10.1517/13543784.2016.1142972
   Histing T, 2012, CALCIFIED TISSUE INT, V90, P507, DOI 10.1007/s00223 012 9601 x
   Hotokezaka H, 2007, J CELL BIOCHEM, V101, P122, DOI 10.1002/jcb.21167
   Hyun JJ, 2010, INT J MOL MED, V26, P877, DOI 10.3892/ijmm_00000537
   Islam S, 2007, BIOCHEM BIOPH RES CO, V360, P346, DOI 10.1016/j.bbrc.2007.06.023
   Jonasson G, 2016, CLIN COSMET INV DENT, V8, P95, DOI 10.2147/CCIDE.S92774
   Joo MK, 2013, MOL MED REP, V7, P1267, DOI 10.3892/mmr.2013.1327
   Jurdic P, 2006, EUR J CELL BIOL, V85, P195, DOI 10.1016/j.ejcb.2005.09.008
   Kefyalew T, 2016, MALARIA J, V15, DOI 10.1186/s12936 016 1561 6
   Kinoshita Y, 2018, J NEUROGASTROENTEROL, V24, P182
   Kocsis I, 2002, CALCIFIED TISSUE INT, V71, P129, DOI 10.1007/s00223 001 2068 9
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010
   Ngamruengphong S, 2011, AM J GASTROENTEROL, V106, P1209, DOI 10.1038/ajg.2011.113
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Park YE, 2017, CURR OPIN PHARMACOL, V34, P21, DOI 10.1016/j.coph.2017.04.001
   PERSSON P, 1993, SCAND J GASTROENTERO, V28, P301, DOI 10.3109/00365529309090245
   Prause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/413097
   Pytlik M, 2012, PHARMACOL REP, V64, P625, DOI 10.1016/S1734 1140(12)70858 7
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Sharara AI, 2013, METABOLISM, V62, P518, DOI 10.1016/j.metabol.2012.09.011
   Sheraly A. R., 2009, Current Drug Delivery, V6, P192
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Song FM, 2018, J CELL PHYSIOL, V233, P1723, DOI 10.1002/jcp.26084
   Suda K, 2002, J CELL PHYSIOL, V190, P101, DOI 10.1002/jcp.10041
   Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330
   Thaler R, 2016, J BIOL CHEM, V291, P6754, DOI 10.1074/jbc.M115.678235
   TUUKKANEN J, 1986, CALCIFIED TISSUE INT, V38, P123, DOI 10.1007/BF02556841
   Vegger JB, 2017, J MUSCULOSKEL NEURON, V17, P162
   Wang LF, 2019, J CELL PHYSIOL, V234, P3207, DOI 10.1002/jcp.27335
   Wei CM, 2018, CELL PHYSIOL BIOCHEM, V48, P644, DOI 10.1159/000491892
   Wu ZX, 2019, J CELL PHYSIOL, V234, P17812, DOI 10.1002/jcp.28408
   Yamasaki Y, 2016, BIOMED REP, V5, P118, DOI 10.3892/br.2016.689
   Yang DQ, 2012, J BONE MINER RES, V27, P1695, DOI 10.1002/jbmr.1623
   Yang HL, 2016, BIOMATERIALS, V80, P1, DOI 10.1016/j.biomaterials.2015.11.046
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Ye XF, 2011, EUR J GASTROEN HEPAT, V23, P794, DOI 10.1097/MEG.0b013e328348a56a
   Yu EW, 2008, CALCIFIED TISSUE INT, V83, P251, DOI 10.1007/s00223 008 9170 1
   Zhu X, 2016, J BONE MINER RES, V31, P560, DOI 10.1002/jbmr.2710
NR 48
TC 11
Z9 11
U1 2
U2 12
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687 966X
EI 1687 9678
J9 STEM CELLS INT
JI Stem Cells Int.
PD NOV 28
PY 2020
VL 2020
AR 8829212
DI 10.1155/2020/8829212
PG 13
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA PE5RT
UT WOS:000598423400001
PM 33354217
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Wu, FF
   Jiang, XS
   Wang, Q
   Lu, Q
   He, FX
   Li, JY
   Li, XF
   Jin, MC
   Xu, JT
AF Wu, Fengfeng
   Jiang, Xuesheng
   Wang, Qun
   Lu, Qian
   He, Fengxiang
   Li, Jianyou
   Li, Xiongfeng
   Jin, Mingchao
   Xu, Juntao
TI The impact of miR 9 in osteosarcoma A study based on meta analysis, TCGA
   data, and bioinformatics analysis
SO MEDICINE
LA English
DT Article
DE microRNA 9; osteosarcoma; meta analysis; the cancer genome atlas;
   bioinformatics
ID NONCODING RNA LINC00968; CELL LUNG CANCER; MIRNA MICROARRAY; MICRORNAS;
   PROGRESSION; SURVIVAL
AB The function of miR 9 in osteosarcoma is not well investigated and controversial. Therefore, we conducted meta analysis to explore the role of miR 9 in osteosarcoma, and collected relevant TCGA data to further testify the result. In addition, bioinformatics analysis was conducted to investigate the mechanism and related pathways of miR 9 3p in osteosarcoma. Literature search was operated on databases up to February 19, 2020, including PubMed, Web of Science, Science Direct, Cochrane Central Register of Controlled Trials, and Wiley Online Library, China National Knowledge Infrastructure, China Biology Medicine disc, Chongqing VIP, and Wan Fang Data. The relation of miR 9 expression with survival outcome was estimated by hazard ratio (HRs) and 95% CIs. Meta analysis was conducted on the Stata 12.0 (Stata Corporation, TX). To further assess the function of miR 9 in osteosarcoma, relevant data from the TCGA database was collected. Three databases, miRDB, miRPathDB 2.0, and Targetscan 7.2, were used for prediction of target genes. Genes present in these 3 databases were considered as predicted target genes of miR 9 3p. Venny 2.1 were used for intersection analysis. Subsequently, GO, KEGG, and PPI network analysis were conducted based on the overlapping target genes of miR 9 3p to explore the possible molecular mechanism in osteosarcoma. Meta analysis shown that overexpression of miR 9 was associated with worse overall survival (OS) (HR = 4.180, 95% CI: 2.880 6.066,P < .001, I 2 = 23.5%). Based on TCGA data, osteosarcoma patients with overexpression of miR 9 3p (HR = 1.603, 95% CI: 1.028 2.499,P = .037) and miR 9 5p (HR = 1.698, 95% CI: 1.133 2.545,P = .01) also suffered poor OS. In bioinformatics analysis, 2 significant and important pathways were enriched: Wnt signaling pathway from gene ontology analysis (gene ontology:0016055,P adjust = .008); hippo signaling pathway from Kyoto Encyclopedia of Genes and Genomes analysis (P adjust = .007). Moreover, network analysis relevant protein protein interaction was visualized, revealing 117 nodes and 161 edges. High miR 9 expression was associated with poor prognosis. Based on bioinformatics analysis, this study enhanced the understanding of the mechanism and related pathways of miR 9 in osteosarcoma.
C1 [Wu, Fengfeng] Huzhou Univ, Huzhou Cent Hosp, Dept Orthoped & Rehabil, Affiliated Cent Hosp,Zhejiang Univ,Huzhou Hosp, Huzhou, Zhejiang, Peoples R China.
   [Jiang, Xuesheng; Lu, Qian; Li, Jianyou; Li, Xiongfeng; Jin, Mingchao] Huzhou Univ, Huzhou Cent Hosp, Dept Orthoped, Affiliated Cent Hosp,Zhejiang Univ,Huzhou Hosp, Huzhou, Zhejiang, Peoples R China.
   [Wang, Qun] Huzhou Wuxing Hosp Integrated Tradit Chinese & We, Dept Internal Med, Huzhou, Zhejiang, Peoples R China.
   [He, Fengxiang] Huzhou Univ, Zhejiang Univ, Huzhou Cent Hosp, Dept Rehabil,Affiliated Cent Hosp,Huzhou Hosp, Huzhou, Zhejiang, Peoples R China.
   [Xu, Juntao] Zhejiang Univ Tradit Chinese Med, Dept Orthoped, Huzhou Tradit Chinese Med Hosp, Huzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Huzhou University; Huzhou University; Zhejiang
   University; Zhejiang University; Huzhou University; Zhejiang Chinese
   Medical University
RP Xu, JT (通讯作者)，Zhejiang Univ Tradit Chinese Med, Dept Orthoped, Huzhou Tradit Chinese Med Hosp, Huzhou, Zhejiang, Peoples R China.
EM xujuntaohz@163.com
RI lu, qian/IUN 7445 2023; Li, Jiazhen/HPF 9994 2023; wu,
   feng/GXH 8764 2022
FU Science and Technology Bureau Program of Huzhou [2018GY29]; Traditional
   Chinese Medicine Scientific Research and Technology Project of Zhejiang
   Province [2016ZA185]; Research on the Application of Public Welfare
   Technology in Zhejiang Province [2017C33222]
FX The authors gratefully acknowledge Science and Technology Bureau Program
   of Huzhou (Grant number: 2018GY29); the Traditional Chinese Medicine
   Scientific Research and Technology Project of Zhejiang Province (Grant
   number: 2016ZA185); Research on the Application of Public Welfare
   Technology in Zhejiang Province (Grant number: 2017C33222).
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Arabi Leila, 2014, Genes Cancer, V5, P56
   Bacci G, 2000, ONCOL REP, V7, P1129
   Backes C, 2017, NUCLEIC ACIDS RES, V45, pD90, DOI 10.1093/nar/gkw926
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Biermann JS, 2013, J NATL COMPR CANC NE, V11, P688, DOI 10.6004/jnccn.2013.0088
   Chai JW, 2017, BIOCHEM BIOPH RES CO, V488, P297, DOI 10.1016/j.bbrc.2017.05.032
   Chen XH, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015774
   Chumbley JR, 2009, NEUROIMAGE, V44, P62, DOI 10.1016/j.neuroimage.2008.05.021
   Du ZG, 2018, MOL MED REP, V18, P1917, DOI 10.3892/mmr.2018.9184
   Fei D, 2014, J INT MED RES, V42, P932, DOI 10.1177/0300060514534643
   Fenger JM, 2016, BMC CANCER, V16, DOI 10.1186/s12885 016 2837 5
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fu CY, 2019, ENVIRON TOXICOL, V34, P902, DOI 10.1002/tox.22761
   Gao S, 2019, INT J ONCOL, V54, P1921, DOI 10.3892/ijo.2019.4783
   Higashi T, 2015, BRIT J CANCER, V113, P252, DOI 10.1038/bjc.2015.170
   Hildebrandt MAT, 2010, ONCOGENE, V29, P5724, DOI 10.1038/onc.2010.305
   Hwang HW, 2006, BRIT J CANCER, V94, P776, DOI 10.1038/sj.bjc.6603023
   Jovanovic M, 2006, ONCOGENE, V25, P6176, DOI 10.1038/sj.onc.1209912
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Li DY, 2018, ONCOL LETT, V15, P9487, DOI 10.3892/ol.2018.8476
   Li DY, 2017, INT J MOL MED, V40, P1895, DOI 10.3892/ijmm.2017.3187
   Liu WJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1629 z
   Llave C, 2002, SCIENCE, V297, P2053, DOI 10.1126/science.1076311
   Luu AK, 2018, BMC VET RES, V14, DOI 10.1186/s12917 018 1651 5
   Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750 3639.2009.00328.x
   Meazza C, 2016, EXPERT REV ANTICANC, V16, P543, DOI 10.1586/14737140.2016.1168697
   Misaghi A, 2018, SICOT J, V4, DOI 10.1051/sicotj/2017028
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097 0258(19981230)17:24<2815::AID SIM110>3.0.CO;2 8
   Qi XJ, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15017318
   Qin FN, 2013, CELL BIOSCI, V3, DOI 10.1186/2045 3701 3 31
   Riley RD, 2015, STAT MED, V34, P2481, DOI 10.1002/sim.6493
   Sarver AL, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750 1172 8 7
   Thomas PD, 2017, METHODS MOL BIOL, V1446, P14, DOI 10.1007/978 1 4939 3743 1_2
   Tsai KW, 2011, EPIGENETICS US, V6, P1189, DOI 10.4161/epi.6.10.16535
   Valencia Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Wang W, 2015, ONCOTARGET, V6, P10297, DOI 10.18632/oncotarget.3305
   Wong KC, 2013, CLIN ORTHOP RELAT R, V471, P814, DOI 10.1007/s11999 012 2590 2
   Wu G, 2020, BOSNIAN J BASIC MED, V20, P218, DOI 10.17305/bjbms.2019.4434
   Xu SH, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477 7819 12 195
   Yang L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174839
   You JN, 2015, CHIN J LAB DIAGN, V19, P27
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang Y, 2018, ONCOL LETT, V16, P6228, DOI 10.3892/ol.2018.9434
   Zhang ZC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007245
   Zhou YF, 2017, ONCOTARGET, V8, P73037, DOI 10.18632/oncotarget.20375
   Zhu L, 2012, MED ONCOL, V29, P1037, DOI 10.1007/s12032 011 9975 z
   Zhu Shao Wen, 2015, Asian Pac J Cancer Prev, V16, P4509
   Zhu XB, 2017, MOL MED REP, V15, P1884, DOI 10.3892/mmr.2017.6203
NR 51
TC 6
Z9 7
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025 7974
EI 1536 5964
J9 MEDICINE
JI Medicine (Baltimore)
PD AUG 28
PY 2020
VL 99
IS 35
AR e21902
DI 10.1097/MD.0000000000021902
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA OC4MP
UT WOS:000579132500065
PM 32871922
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Desai, J
   Wang, Y
   Wang, K
   Malwal, SR
   Oldfield, E
AF Desai, Janish
   Wang, Yang
   Wang, Ke
   Malwal, Satish R.
   Oldfield, Eric
TI Isoprenoid Biosynthesis Inhibitors Targeting Bacterial Cell Growth
SO CHEMMEDCHEM
LA English
DT Article
DE cell wall biosynthesis; drug discovery; Gram negative pathogens;
   membrane proteins; Staphylococcus aureus
ID BONE RESORPTION; BISPHOSPHONATES; FARNESYL; BINDING; PHOSPHATASE;
   MECHANISM; SYNTHASE; PATHWAY; SITE
AB We synthesized potential inhibitors of farnesyl diphosphate synthase (FPPS), undecaprenyl diphosphate synthase (UPPS), or undecaprenyl diphosphate phosphatase (UPPP), and tested them in bacterial cell growth and enzyme inhibition assays. The most active compounds were found to be bisphosphonates with electron withdrawing aryl alkyl side chains which inhibited the growth of Gram negative bacteria (Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa) at approximate to 1 4gmL( 1) levels. They were found to be potent inhibitors of FPPS; cell growth was partially rescued by the addition of farnesol or overexpression of FPPS, and there was synergistic activity with known isoprenoid biosynthesis pathway inhibitors. Lipophilic hydroxyalkyl phosphonic acids inhibited UPPS and UPPP at micromolar levels; they were active (approximate to 2 6gmL( 1)) against Gram positive but not Gram negative organisms, and again exhibited synergistic activity with cell wall biosynthesis inhibitors, but only indifferent effects with other inhibitors. The results are of interest because they describe novel inhibitors of FPPS, UPPS, and UPPP with cell growth inhibitory activities as low as approximate to 1 2gmL( 1).
C1 [Desai, Janish; Oldfield, Eric] Univ Illinois, Ctr Biophys & Quantitat Biol, 1110 West Green St, Urbana, IL 61801 USA.
   [Wang, Yang; Wang, Ke; Malwal, Satish R.; Oldfield, Eric] Univ Illinois, Dept Chem, 600 South Mathews Ave, Urbana, IL 61801 USA.
C3 University of Illinois System; University of Illinois Urbana Champaign;
   University of Illinois System; University of Illinois Urbana Champaign
RP Oldfield, E (通讯作者)，Univ Illinois, Ctr Biophys & Quantitat Biol, 1110 West Green St, Urbana, IL 61801 USA.; Oldfield, E (通讯作者)，Univ Illinois, Dept Chem, 600 South Mathews Ave, Urbana, IL 61801 USA.
EM eo@chad.scs.uiuc.edu
RI Wang, Ke/N 2232 2017
FU United States Public Health Service (NIH) [CA158191, GM065307]; Harriet
   A. Harlin Professorship; University of Illinois Foundation/Oldfield
   Research Fund
FX This work was supported by the United States Public Health Service (NIH
   grants CA158191 and GM065307), a Harriet A. Harlin Professorship, and
   the University of Illinois Foundation/Oldfield Research Fund. The
   authors thank Dr. Robert Schnell and Professor Gunter Schneider for
   providing the P. aeruginosa FPPS expression system and Professor Douglas
   Mitchell for providing the bacteria.
CR [Anonymous], ANT RES THREATS US
   BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003 2697(88)90484 8
   BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
   Brown ED, 2016, NATURE, V529, P336, DOI 10.1038/nature17042
   Cao R, 2008, PROTEINS, V73, P431, DOI 10.1002/prot.22066
   Chang HY, 2014, J BIOL CHEM, V289, P18719, DOI 10.1074/jbc.M114.575076
   Eliopolous G.M., 1998, Antibiotics in Laboratory Medicine, P330
   EUCAST, 2000, CLIN MICROBIOL INFEC, V6, P570
   Farha MA, 2015, P NATL ACAD SCI USA, V112, P11048, DOI 10.1073/pnas.1511751112
   Feng XX, 2015, P NATL ACAD SCI USA, V112, pE7073, DOI 10.1073/pnas.1521988112
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   FLINT DH, 1993, BIOORG CHEM, V21, P367, DOI 10.1006/bioo.1993.1031
   Hartley MD, 2008, BIOORGAN MED CHEM, V16, P5149, DOI 10.1016/j.bmc.2008.03.025
   Hsu MF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056363
   Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573
   Leon A, 2006, J MED CHEM, V49, P7331, DOI 10.1021/jm060492b
   MAIER L, 1992, PHOSPHORUS SULFUR, V70, P39, DOI 10.1080/10426509208049149
   Mukherjee S, 2009, J AM CHEM SOC, V131, P8374, DOI 10.1021/ja902895p
   Oldfield E, 2014, TRENDS PHARMACOL SCI, V35, P664, DOI 10.1016/j.tips.2014.10.007
   Schmidberger JW, 2015, ACTA CRYSTALLOGR D, V71, P721, DOI 10.1107/S1399004715001121
   Singh PK, 2000, AM J PHYSIOL LUNG C, V279, pL799, DOI 10.1152/ajplung.2000.279.5.L799
   Song YC, 2008, BIOORGAN MED CHEM, V16, P8959, DOI 10.1016/j.bmc.2008.08.047
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   WISSNER A, 1979, SYNTHESIS STUTTGART, P27
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Zhu W, 2013, P NATL ACAD SCI USA, V110, P123, DOI 10.1073/pnas.1219899110
   Ziniel PD, 2013, ANTIMICROB AGENTS CH, V57, P5969, DOI 10.1128/AAC.00699 13
NR 29
TC 40
Z9 43
U1 0
U2 25
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860 7179
EI 1860 7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD OCT 6
PY 2016
VL 11
IS 19
BP 2205
EP 2215
DI 10.1002/cmdc.201600343
PG 11
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA DZ2JO
UT WOS:000385668300010
PM 27571880
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Blumsohn, A
   Marin, F
   Nickelsen, T
   Brixen, K
   Sigurdsson, G
   de la Vera, JG
   Boonen, S
   Liu Léage, S
   Barker, C
   Eastell, R
AF Blumsohn, A.
   Marin, F.
   Nickelsen, T.
   Brixen, K.
   Sigurdsson, G.
   Gonzalez de la Vera, J.
   Boonen, S.
   Liu Leage, S.
   Barker, C.
   Eastell, R.
CA EUROFORS Study Grp
TI Early changes in biochemical markers of bone turnover and their
   relationship with bone mineral density changes after 24 months of
   treatment with teriparatide
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE BMD; Bone markers; Bone turnover; Osteoporosis; Postmenopausal women;
   Teriparatide
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; PARATHYROID HORMONE (1 34);
   POSTMENOPAUSAL WOMEN; PROXIMAL FEMUR; ALENDRONATE; THERAPY; BMD;
   EUROFORS; MEN; STANDARDIZATION
AB We report the changes in biochemical markers of bone formation during the first 6 months of teriparatide therapy in postmenopausal women with osteoporosis according to previous antiresorptive treatment. Prior therapy does not adversely affect the response to teriparatide treatment. Similar bone markers levels are reached after 6 months of treatment.
   The response of biochemical markers of bone turnover with teriparatide therapy in subjects who have previously received osteoporosis drugs is not fully elucidated. We examined biochemical markers of bone formation in women with osteoporosis treated with teriparatide and determined: (1) whether the response is associated with prior osteoporosis therapy, (2) which marker shows the best performance for detecting a response to therapy, and (3) the correlations between early changes in bone markers and subsequent bone mineral density (BMD) changes after 24 months of teriparatide.
   We conducted a prospective, open label, 24 month study at 95 centers in 10 countries in 758 postmenopausal women with established osteoporosis (n = 181 treatment na < ve) who had at least one post baseline bone marker determination. Teriparatide (20 mu g/day) was administered for up to 24 months. We measured procollagen type I N terminal propeptide (PINP), bone specific alkaline phosphatase (b ALP), and total alkaline phosphatase (t ALP) at baseline, 1 and 6 months, and change in BMD at the lumbar spine, total hip and femoral neck from baseline to 24 months.
   Significant increases in formation markers occurred after 1 month of teriparatide regardless of prior osteoporosis therapy. The absolute increase at 1 month was lower in previously treated versus treatment na < ve patients, but after 6 months all groups reached similar levels. PINP showed the best signal to noise ratio. Baseline PINP correlated positively and significantly with BMD response at 24 months.
   This study suggests that the long term responsiveness of bone formation markers to teriparatide is not affected in subjects previously treated with antiresorptive drugs.
C1 [Blumsohn, A.] Sheffield Teaching Hosp NHS Fdn Trust, Dept Clin Biochem, Sheffield, S Yorkshire, England.
   [Marin, F.; Nickelsen, T.; Liu Leage, S.; Barker, C.] Lilly Res Ctr, Windlesham, Surrey, England.
   [Brixen, K.] Univ Hosp, Dept Endocrinol, Odense, Denmark.
   [Sigurdsson, G.] Landspitalinn Univ Hosp, Reykjavik, Iceland.
   [Gonzalez de la Vera, J.] Hosp Univ Virgen Macarena, Dept Rheumatol, Seville, Spain.
   [Boonen, S.] Katholieke Univ Leuven, Div Geriatr Med, Leuven, Belgium.
   [Eastell, R.] Univ Sheffield, Sheffield, S Yorkshire, England.
C3 University of Sheffield; Eli Lilly; Lilly Research Laboratories;
   University of Southern Denmark; Odense University Hospital; Landspitali
   National University Hospital; Hospital Universitario Virgen Macarena; KU
   Leuven; University of Sheffield
RP Blumsohn, A (通讯作者)，Sheffield Teaching Hosp NHS Fdn Trust, Dept Clin Biochem, Sheffield, S Yorkshire, England.
EM ablumsohn@googlemail.com
RI MARIN, FERNANDO/HKO 8917 2023; Eastell, Richard/G 5851 2011
OI Cooper, Cyrus/0000 0003 3510 0709; Jensen, Jens Erik
   Beck/0000 0003 4290 0480; Keen, Richard/0009 0001 8216 3828; Selby,
   Peter/0000 0001 9465 9268
FU Lilly Research Center, Europe; Eli Lilly; Medical Research Council
   [MC_UP_A620_1014, U1475000001] Funding Source: researchfish; National
   Institute for Health Research [NF SI 0508 10082] Funding Source:
   researchfish
FX The authors thank Simon Cleall, MSc, for providing statistical advice;
   Deirdre Elmhirst, PhD, Elmhirst Medical Writing Services, for assisting
   in the formatting and language of the manuscript, and the following
   individuals for providing technical assistance in conducting the study:
   Petra Ochs (study coordination), Ruth Alonso, David Lopez, and Laura
   Briones (data management), and Alain Frix (study drug coordination). Dr
   Elmhirst's work on the manuscript was funded by the study sponsor. Steve
   Boonen is senior clinical investigator of the Fund for Scientific
   Research and is holder of the Leuven University Chair in Metabolic Bone
   Diseases. The authors thank the women who participated in this study;
   the doctors, study nurses, and support staff at the local sites; and the
   monitors and study managers in the participating countries. Funding was
   provided by Lilly Research Center, Europe AB received funding from Eli
   Lilly to perform assays of bone turnover for this study. He has no other
   conflicts of interest and has received no personal funding from any
   pharmaceutical or diagnostic company. KB has served as consultant,
   received research grants from and has served on speakers' bureau for Eli
   Lilly. SB has received research funding and consulting fees from Eli
   Lilly. RE has previously consulted and received lecture fees from Eli
   Lilly and received grant support from 1998 to 2005. FM, TN, CB, SL L are
   employees of Eli Lilly. GS, JG have nothing to declare.
CR Bauer DC, 2006, J CLIN ENDOCR METAB, V91, P1370, DOI 10.1210/jc.2005 1712
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Black DM, 2005, NEW ENGL J MED, V353, P555, DOI 10.1056/NEJMoa050336
   Boonen S, 2008, J CLIN ENDOCR METAB, V93, P852, DOI 10.1210/jc.2007 0711
   Borggrefe J, 2010, J BONE MINER RES, V25, P472, DOI 10.1359/jbmr.090820
   Chen PQ, 2005, J BONE MINER RES, V20, P962, DOI 10.1359/JBMR.050105
   Cosman F, 2008, OSTEOPOROSIS INT, V19, P529, DOI 10.1007/s00198 007 0475 0
   Cosman F, 2005, NEW ENGL J MED, V353, P566, DOI 10.1056/NEJMoa050157
   Cosman F, 2009, J CLIN ENDOCR METAB, V94, P3772, DOI 10.1210/jc.2008 2719
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Dobnig H, 2005, J CLIN ENDOCR METAB, V90, P3970, DOI 10.1210/jc.2003 1703
   Dobnig H, 2009, J BONE MINER RES, V24, P1998, DOI [10.1359/JBMR.090527, 10.1359/jbmr.090527]
   Eastell R, 2006, CURR MED RES OPIN, V22, P61, DOI 10.1185/030079905X75096
   Eastell R, 2009, J BONE MINER RES, V24, P726, DOI 10.1359/JBMR.081215
   Ettinger B, 2004, J BONE MINER RES, V19, P745, DOI 10.1359/JBMR.040117
   Finkelstein JS, 2006, J CLIN ENDOCR METAB, V91, P2882, DOI 10.1210/jc.2006 0190
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   GENANT HK, 1994, J BONE MINER RES, V9, P1503
   Graeff C, 2007, J BONE MINER RES, V22, P1426, DOI 10.1359/jbmr.070603
   Graeff C, 2009, J BONE MINER RES, V24, P1672, DOI [10.1359/JBMR.090416, 10.1359/jbmr.090416]
   Greenspan SL, 2007, ANN INTERN MED, V146, P326, DOI 10.7326/0003 4819 146 5 200703060 00005
   Hanson J, 1997, J BONE MINER RES, V12, P1316, DOI 10.1359/jbmr.1997.12.8.1316
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Keaveny TM, 2007, J BONE MINER RES, V22, P149, DOI 10.1359/JBMR.061011
   Lane NE, 2000, OSTEOPOROSIS INT, V11, P434, DOI 10.1007/s001980070111
   Lindsay R, 2007, J BONE MINER RES, V22, pS124
   Lindsay R, 2007, J BONE MINER RES, V22, P495, DOI 10.1359/JBMR.070104
   Ma YFL, 2006, J BONE MINER RES, V21, P855, DOI 10.1359/JBMR.060314
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Miller PD, 2008, J CLIN ENDOCR METAB, V93, P3785, DOI 10.1210/jc.2008 0353
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Obermayer Pietsch BM, 2008, J BONE MINER RES, V23, P1591, DOI 10.1359/JBMR.080506
   Orwoll E, 2003, J BONE MINER RES, V18, P9, DOI 10.1359/jbmr.2003.18.1.9
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   Sato M, 2004, J BONE MINER RES, V19, P623, DOI 10.1359/JBMR.040112
   Seibel Markus J, 2005, Clin Biochem Rev, V26, P97
   Stepan JJ, 2010, OSTEOPOROSIS INT, V21, P2027, DOI 10.1007/s00198 009 1168 7
   Uusi Rasi K, 2005, BONE, V36, P948, DOI 10.1016/j.bone.2005.03.003
   Zanchetta JR, 2003, J BONE MINER RES, V18, P539, DOI 10.1359/jbmr.2003.18.3.539
NR 39
TC 63
Z9 68
U1 0
U2 6
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD JUN
PY 2011
VL 22
IS 6
BP 1935
EP 1946
DI 10.1007/s00198 010 1379 y
PG 12
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 763HA
UT WOS:000290544900032
PM 20938767
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Manning, AT
   O'Brien, N
   Kerin, MJ
AF Manning, A. T.
   O'Brien, N.
   Kerin, M. J.
TI Roles for the calcium sensing receptor in primary and metastatic cancer
SO EJSO
LA English
DT Article
DE calcium sensing receptor (CASR); breast cancer; colorectal cancer;
   parathyroid cancer; parathyroid hormone related peptide (PTHrP); bone
   metastases
ID HORMONE RELATED PROTEIN; EXTRACELLULAR CALCIUM; BREAST CANCER;
   CELL LINE; COLONIC CRYPTS; POTENTIAL ROLE; ACTIVATION; EXPRESSION;
   SECRETION; CARCINOMA
AB Aim: To review the role of the calcium sensing receptor (CASR) in colorectal, breast and parathyroid cancers and related cell lines, and to discuss the effects of CASR in the setting of bone metastases from breast cancer.
   Methods: We performed a literature search of the PubMed database of the National Library of Medicine (NLM) to identify articles concerning the CASR's involvement in different cancers. Further relevant papers were obtained from the references of those identified in the original search.
   Results: Loss of CASR expression is understood to be associated with abnormal differentiation and progression of colorectal carcinoma. It is expressed in both normal and malignant breast tissues and has been implicated in the vicious cycle of bone metastases through its interactions with the parathyroid hormone related peptide (PTHrP). In parathyroid tissue, CASR expression has been linked to proliferation of both parathyroid adenomas and carcinomas.
   Conclusion: Apart from its role in calcium homeostasis, the CASR has many diverse functions in a variety of tissue types throughout the body, and is involved in various signalling pathways relating to cell proliferation and differentiation. CASR has been shown to be involved in the progression and spread of a variety of cancers such as colorectal, breast and parathyroid, and is likely to be the focus of much research to further elucidate its precise role. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Univ Coll Hosp Galway, Dept Surg, Inst Clin Sci, Galway, Ireland.
C3 Ollscoil na Gaillimhe University of Galway
RP Kerin, MJ (通讯作者)，Univ Coll Hosp Galway, Dept Surg, Inst Clin Sci, Galway, Ireland.
EM michael.kerin@nuigalway.ie
RI ; Kerin, Michael/D 6748 2013
OI Kerin, Michael/0000 0003 4164 5561; Manning, Aidan/0000 0001 5438 9080; 
CR Anderson T.J., 1992, Oxford Textbook of Pathology. Pathology of systems, P1643
   Brenner BM, 1998, CANCER LETT, V127, P43, DOI 10.1016/S0304 3835(98)00005 6
   BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0
   BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371
   Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239
   Chakrabarty S, 2003, CANCER RES, V63, P67
   Cheng I, 1998, J CLIN ENDOCR METAB, V83, P703, DOI 10.1210/jc.83.2.703
   Cheng SX, 2004, GASTROENTEROLOGY, V126, P148, DOI 10.1053/j.gastro.2003.10.064
   Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960 0760(99)00055 2
   GARLAND CF, 1991, AM J CLIN NUTR, V54, pS193, DOI 10.1093/ajcn/54.1.193S
   GERDES J, 1991, AM J PATHOL, V138, P867
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Guise TA, 2002, BONE, V30, P670, DOI 10.1016/S8756 3282(02)00685 3
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Haven CJ, 2004, J PATHOL, V202, P86, DOI 10.1002/path.1489
   Hobson SA, 2003, MOL CELL ENDOCRINOL, V200, P189, DOI 10.1016/S0303 7207(01)00749 3
   James JJ, 2003, BRIT J CANCER, V89, P660, DOI 10.1038/sj.bjc.6601198
   Journé F, 2004, BONE, V35, P479, DOI 10.1016/j.bone.2004.03.021
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kanatani N, 1999, BIOCHEM BIOPH RES CO, V261, P144, DOI 10.1006/bbrc.1999.0932
   Lipkin M, 1999, ANN NY ACAD SCI, V889, P120, DOI 10.1111/j.1749 6632.1999.tb08729.x
   Maki DD, 2000, AM J NEURORADIOL, V21, P1064
   MCGRATH CM, 1984, IN VITRO CELL DEV B, V20, P652, DOI 10.1007/BF02619616
   Negri E, 1996, INT J CANCER, V65, P140, DOI 10.1002/(SICI)1097 0215(19960117)65:2<140::AID IJC3>3.0.CO;2 Z
   NOBRELEITAO C, 1995, GASTROENTEROLOGY, V109, P498, DOI 10.1016/0016 5085(95)90338 0
   Peters U, 2004, CANCER EPIDEM BIOMAR, V13, P2181
   Poon Grace, 2005, Proc (Bayl Univ Med Cent), V18, P181
   POWELL GJ, 1991, CANCER RES, V51, P3059
   RUSSO J, 1989, IN VITRO CELL DEV B, V25, P643
   Sanders JL, 2000, ENDOCRINOLOGY, V141, P4357, DOI 10.1210/en.141.12.4357
   Sanders JL, 2000, BIOCHEM BIOPH RES CO, V269, P427, DOI 10.1006/bbrc.2000.2157
   SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014 4827(88)90191 7
   Steddon S, 2005, LANCET, V365, P2237, DOI 10.1016/S0140 6736(05)66782 7
   Strewler GJ, 2000, NEW ENGL J MED, V342, P177, DOI 10.1056/NEJM200001203420306
   VanHouten J, 2004, J CLIN INVEST, V113, P598, DOI 10.1172/JCI200418776
   VANTVEER P, 1991, INT J CANCER, V47, P649, DOI 10.1002/ijc.2910470503
   Wargovich MJ, 2000, CARCINOGENESIS, V21, P1149, DOI 10.1093/carcin/21.6.1149
   Wedin R, 2004, ACTA ONCOL, V43, P460, DOI 10.1080/02841860410033721
   Yamaguchi T, 1998, J BONE MINER RES, V13, P1530, DOI 10.1359/jbmr.1998.13.10.1530
   Yamaguchi T, 1998, ENDOCRINOLOGY, V139, P3561, DOI 10.1210/en.139.8.3561
   Yamaguchi T, 2000, BIOCHEM BIOPH RES CO, V279, P363, DOI 10.1006/bbrc.2000.3955
   Yano S, 2004, BONE, V35, P664, DOI 10.1016/j.bone.2004.04.014
   Yano S, 2003, EUR J ENDOCRINOL, V148, P403, DOI 10.1530/eje.0.1480403
   ZARIDZE D, 1991, INT J CANCER, V48, P493, DOI 10.1002/ijc.2910480404
NR 44
TC 16
Z9 23
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748 7983
EI 1532 2157
J9 EJSO EUR J SURG ONC
JI EJSO
PD SEP
PY 2006
VL 32
IS 7
BP 693
EP 697
DI 10.1016/j.ejso.2006.03.047
PG 5
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Surgery
GA 100MB
UT WOS:000241672100001
PM 16765016
DA 2025 08 17
ER

PT J
AU Rees, JM
   Sleight, VA
   Clark, SJ
   Nakamura, T
   Gillis, JA
   Davey, MG
AF Rees, Jenaid M.
   Sleight, Victoria A.
   Clark, Stephen J.
   Nakamura, Tetsuya
   Gillis, J. Andrew
   Davey, Megan G.
TI Ectodermal Wnt signaling, cell fate determination, and polarity of the
   skate gill arch skeleton
SO ELIFE
LA English
DT Article
DE skate leucoraja erinacea; pharyngeal arch; Wnt; Shh; gill arch;
   skeleton; Other
ID SONIC HEDGEHOG; DISTINCT REQUIREMENTS; LEUCORAJA ERINACEA; FOREGUT
   ENDODERM; PATHWAY GENES; RNA SEQ; EXPRESSION; CATENIN; CHONDROGENESIS;
   PALATE
AB The gill skeleton of cartilaginous fishes (sharks, skates, rays, and holocephalans) exhibits a striking anterior posterior polarity, with a series of fine appendages called branchial rays projecting from the posterior margin of the gill arch cartilages. We previously demonstrated in the skate (Leucoraja erinacea) that branchial rays derive from a posterior domain of pharyngeal arch mesenchyme that is responsive to Sonic hedgehog (Shh) signaling from a distal gill arch epithelial ridge (GAER) signaling centre. However, how branchial ray progenitors are specified exclusively within posterior gill arch mesenchyme is not known. Here, we show that genes encoding several Wnt ligands are expressed in the ectoderm immediately adjacent to the skate GAER, and that these Wnt signals are transduced largely in the anterior arch environment. Using pharmacological manipulation, we show that inhibition of Wnt signalling results in an anterior expansion of Shh signal transduction in developing skate gill arches, and in the formation of ectopic anterior branchial ray cartilages. Our findings demonstrate that ectodermal Wnt signalling contributes to gill arch skeletal polarity in skate by restricting Shh signal transduction and chondrogenesis to the posterior arch environment and highlights the importance of signalling interactions at embryonic tissue boundaries for cell fate determination in vertebrate pharyngeal arches.
C1 [Rees, Jenaid M.; Gillis, J. Andrew] Univ Cambridge, Dept Zool, Cambridge, England.
   [Sleight, Victoria A.] Univ Aberdeen, Sch Biol Sci, Aberdeen, Scotland.
   [Clark, Stephen J.] Babraham Inst, Cambridge, England.
   [Nakamura, Tetsuya] Rutgers State Univ, Dept Genet, Piscataway, NJ USA.
   [Gillis, J. Andrew] Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Marine Biol Lab, Woods Hole, MA 02543 USA.
C3 University of Cambridge; University of Aberdeen; UK Research &
   Innovation (UKRI); Biotechnology and Biological Sciences Research
   Council (BBSRC); Babraham Institute; Rutgers University System; Rutgers
   University New Brunswick; Marine Biological Laboratory   Woods Hole
RP Gillis, JA (通讯作者)，Univ Cambridge, Dept Zool, Cambridge, England.; Gillis, JA (通讯作者)，Josephine Bay Paul Ctr Comparat Mol Biol & Evolut, Marine Biol Lab, Woods Hole, MA 02543 USA.
EM agillis@mbl.edu
RI Davey, Megan/C 7723 2013; Sleight, Victoria/AHE 7337 2022; Clark,
   Stephen/AAC 3324 2020
OI Gillis, Andrew/0000 0003 2062 3777; 
FU Wellcome Trust [214953/Z/18/Z]; Royal Society [UF130182J, URF\R\191007
   J, RG140377J]; Wellcome Trust [214953/Z/18/Z] Funding Source: Wellcome
   Trust
FX Wellcome Trust 214953/Z/18/Z Jenaid M ReesRoyal Society UF130182J Andrew
   GillisRoyal Society URF\R\191007 J Andrew GillisRoyal Society RG140377J
   Andrew Gillis
CR Alexander C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004479
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022 2836(05)80360 2
   Alvarez Medina R, 2008, DEVELOPMENT, V135, P237, DOI 10.1242/dev.012054
   Aronesty E., 2011, Command line tools for processing biological sequencing data. ea utils
   BALLARD WW, 1993, J EXP ZOOL, V267, P318, DOI 10.1002/jez.1402670309
   Brito JM, 2006, P NATL ACAD SCI USA, V103, P11607, DOI 10.1073/pnas.0604751103
   Chen Yunshun., 2023, edgeR: differential analysis of sequence read count data: User's Guide
   Choe CP, 2013, DEV CELL, V24, P296, DOI 10.1016/j.devcel.2012.12.003
   Choi HMT, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.165753
   Church V, 2002, J CELL SCI, V115, P4809, DOI 10.1242/jcs.00152
   Couly G, 2002, DEVELOPMENT, V129, P1061
   COULY G, 1990, DEVELOPMENT, V108, P543
   Criswell KE, 2020, ELIFE, V9, DOI [10.7554/elife.51696, 10.7554/eLife.51696]
   Daniel J.Frank., 1934, The Elasmobranch Fishes, V3d, rev, DOI DOI 10.5962/BHL.TITLE.10180
   Dearden RP, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 10032 3
   Ding M, 2017, ONCOL LETT, V14, P6327, DOI 10.3892/ol.2017.7030
   Dougherty M, 2013, DEVELOPMENT, V140, P76, DOI 10.1242/dev.080473
   Geetha Loganathan P, 2005, DEV BIOL, V288, P221, DOI 10.1016/j.ydbio.2005.09.035
   Geetha Loganathan P, 2009, DEV DYNAM, V238, P1150, DOI 10.1002/dvdy.21934
   Gillis JA, 2017, CURR BIOL, V27, P729, DOI 10.1016/j.cub.2017.01.022
   Gillis JA, 2016, DEVELOPMENT, V143, P1313, DOI 10.1242/dev.133884
   Gillis JA, 2012, DEVELOPMENT, V139, P3142, DOI 10.1242/dev.084046
   Gillis JA, 2011, P NATL ACAD SCI USA, V108, P1507, DOI 10.1073/pnas.1012968108
   Gillis JA, 2009, J MORPHOL, V270, P628, DOI 10.1002/jmor.10710
   Gillis JA, 2009, P NATL ACAD SCI USA, V106, P5720, DOI 10.1073/pnas.0810959106
   Goodnough LH, 2016, DEV DYNAM, V245, P144, DOI [10.1002/DVDY.24367, 10.1002/dvdy.24367]
   Graham A, 2001, BIOESSAYS, V23, P54, DOI 10.1002/1521 1878(200101)23:1<54::AID BIES1007>3.0.CO;2 5
   Graham A, 2008, J EXP ZOOL PART B, V310B, P336, DOI 10.1002/jez.b.21182
   Grevellec A, 2010, SEMIN CELL DEV BIOL, V21, P325, DOI 10.1016/j.semcdb.2010.01.022
   Haas BJ, 2013, NAT PROTOC, V8, P1494, DOI 10.1038/nprot.2013.084
   Hallett SA, 2021, ELIFE, V10, DOI 10.7554/eLife.64513
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Hirschberger C, 2021, MOL BIOL EVOL, V38, P4187, DOI 10.1093/molbev/msab123
   Jezewski PA, 2008, ZEBRAFISH, V5, P169, DOI 10.1089/zeb.2007.0517
   Jiang XB, 2002, DEV BIOL, V241, P106, DOI 10.1006/dbio.2001.0487
   Juriloff DM, 2006, BIRTH DEFECTS RES A, V76, P574, DOI 10.1002/bdra.20302
   Kague E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047394
   Kengaku M, 1998, SCIENCE, V280, P1274, DOI 10.1126/science.280.5367.1274
   Kulak O, 2015, MOL CELL BIOL, V35, P2425, DOI 10.1128/MCB.00392 15
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb 2009 10 3 r25
   Ling ITC, 2017, DEV BIOL, V421, P219, DOI 10.1016/j.ydbio.2016.11.016
   Lu JM, 2009, BIOORG MED CHEM LETT, V19, P3825, DOI 10.1016/j.bmcl.2009.04.040
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184 1193.2002
   Maeda O, 2006, ONCOL REP, V16, P91
   Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756
   Marcais G, 2011, BIOINFORMATICS, V27, P764, DOI 10.1093/bioinformatics/btr011
   Maxwell EE, 2008, ANAT REC, V291, P1079, DOI 10.1002/ar.20719
   Nakamura T, 2015, P NATL ACAD SCI USA, V112, P15940, DOI 10.1073/pnas.1521818112
   Niemann S, 2004, AM J HUM GENET, V74, P558, DOI 10.1086/382196
   Nishimura O, 2017, BIOINFORMATICS, V33, P3635, DOI 10.1093/bioinformatics/btx445
   O'Neill P, 2007, DEV BIOL, V304, P156, DOI 10.1016/j.ydbio.2006.12.029
   PARR BA, 1993, DEVELOPMENT, V119, P247
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Pearse RV, 2001, DEV BIOL, V239, P15, DOI 10.1006/dbio.2001.0430
   Picelli S, 2014, NAT PROTOC, V9, P171, DOI 10.1038/nprot.2014.006
   Raspopovic J, 2014, SCIENCE, V345, P566, DOI 10.1126/science.1252960
   Rees JM, 2022, DEV BIOL, V489, P98, DOI 10.1016/j.ydbio.2022.06.004
   Reid BS, 2011, DEV BIOL, V349, P261, DOI 10.1016/j.ydbio.2010.11.012
   Richardson J, 2012, P ROY SOC B BIOL SCI, V279, P224, DOI 10.1098/rspb.2011.0740
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rochard L, 2016, DEVELOPMENT, V143, P2541, DOI 10.1242/dev.137000
   Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536
   Shimomura Y, 2010, NATURE, V464, P1043, DOI 10.1038/nature08875
   Sleight VA, 2020, ELIFE, V9, DOI 10.7554/eLife.60635
   Summerhurst K, 2008, GENE EXPR PATTERNS, V8, P331, DOI 10.1016/j.gep.2008.01.007
   Sun XD, 2020, THERANOSTICS, V10, P7111, DOI 10.7150/thno.45286
   Takenaka K, 2007, BIOCHEM BIOPH RES CO, V353, P501, DOI 10.1016/j.bbrc.2006.12.058
   ten Berge D, 2008, DEVELOPMENT, V135, P3247, DOI 10.1242/dev.023176
   Thiery AP, 2022, ELIFE, V11, DOI 10.7554/eLife.73173
   Veitch E, 1999, CURR BIOL, V9, P1481, DOI 10.1016/S0960 9822(00)80118 9
   WALL NA, 1995, MECH DEVELOP, V53, P383, DOI 10.1016/0925 4773(95)00453 X
   Witten PE, 2003, J ANAT, V203, P435, DOI 10.1046/j.1469 7580.2003.00239.x
   Zhang XJ, 2015, DEV CELL, V32, P719, DOI 10.1016/j.devcel.2015.02.014
NR 73
TC 3
Z9 3
U1 1
U2 6
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD MAR 20
PY 2023
VL 12
AR e79964
DI 10.7554/eLife.79964
PG 20
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA A7BY8
UT WOS:000956647700001
PM 36940244
OA Green Accepted, Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Goldberg, SR
   Georgiou, J
   Glogauer, M
   Grynpas, MD
AF Goldberg, Stephanie R.
   Georgiou, John
   Glogauer, Michael
   Grynpas, Marc D.
TI A 3D scanning confocal imaging method measures pit volume and captures
   the role of Rac in osteoclast function
SO BONE
LA English
DT Article
DE Confocal; Resorption lacunae; Rac; Osteoclast; Volume imaging
ID BONE RESORPTION; GTPASES; NUCLEI; RHO; MICROSCOPY; DYNAMICS; SURFACE
AB Modulation of Rho GTPases Rac1 and Rac2 impacts bone development, remodeling, and disease. In addition, GTPases are considered treatment targets for dysplastic and erosive bone diseases including Neurofibromatosis type 1. While it is important to understand the effects of Rac modulation on osteoclast function, two dimensional resorption pit area measurements fall short in elucidating the volume aspect of bone resorption activity.
   Bone marrow from wild type. Rac1 and Rac2 null mice was isolated from femora. Osteoclastogenesis was induced by adding M CSF and RANKL in culture plates containing dentin slices and later stained with Picro Sirius Red to image resorption lacunae. Osteoclasts were also plated on glass cover slips and stained with phalloidin and DAPI to measure their surface area and the number of nuclei. Volumetric images were collected on a laser scanning confocal system.
   Sirius Red confocal imaging provided an unambiguous, continuous definition of the pit boundary compared to reflected and transmitted light imaging. Rac1  and Rac2 deficient osteoclasts had fewer nuclei in comparison to wild type counterparts. Rac1 deficient osteoclasts showed reduced resorption pit volume and surface area. Lacunae made by single Rac2 null osteoclasts had reduced volume but surprisingly surface area was unaffected.
   Surface area measures are deceiving since volume changed independently in resorption pits made by individual Rac2 null osteoclasts. Our innovative confocal imaging technique allows us to derive novel conclusions about Rac1 and Rac2 in osteoclast function. The data and method can be applied to study effects of genes and drugs including Rho GTPase modulators on osteoclast function and to develop pharmacotherapeutics to treat bone lytic disorders. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Goldberg, Stephanie R.; Glogauer, Michael] Univ Toronto, Fac Dent, Fac Med, Toronto, ON M5S 3E2, Canada.
   [Goldberg, Stephanie R.; Georgiou, John; Grynpas, Marc D.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5T 3L9, Canada.
   [Goldberg, Stephanie R.; Grynpas, Marc D.] Univ Toronto, Dept Lab Med, Toronto, ON M5S 1A1, Canada.
   [Goldberg, Stephanie R.; Grynpas, Marc D.] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON M5S 1A1, Canada.
C3 University of Toronto; University of Toronto; Sinai Health System
   Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto;
   University of Toronto
RP Glogauer, M (通讯作者)，Univ Toronto, Fac Dent, Fac Med, Room 221 Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.
EM michael.glogauer@utoronto.ca; grynpas@lunenfeld.ca
RI Glogauer, Michael/D 2504 2011; Grynpas, Marc/E 4576 2013; Georgiou,
   John/E 9873 2013
OI Georgiou, John/0000 0003 4503 6384; Glogauer,
   Michael/0000 0002 6248 5977
FU CIHR operating grant
FX The work was supported by a CIHR operating grant to Dr. Michael
   Glogauer. We thank Dr. Kevin Conway of Nikon Canada for assistance on
   confocal analysis and visualization. We would also like to thank Dr.
   Morris Manolson from the Faculty of Dentistry at the University of
   Toronto for providing us with narwhal tusk to use for dentin slice
   production.
CR Athanasou NA, 2011, SKELETAL RADIOL, V40, P1137, DOI 10.1007/s00256 011 1180 9
   Ballanti P, 1997, OSTEOPOROSIS INT, V7, P39, DOI 10.1007/BF01623458
   Blair HC, 2004, HISTOL HISTOPATHOL, V19, P189, DOI 10.14670/HH 19.189
   Boissy P, 2002, ENDOCRINOLOGY, V143, P1913, DOI 10.1210/en.143.5.1913
   BOYDE A, 1992, PHOTOGRAMM REC, V14, P59, DOI 10.1111/j.1477 9730.1992.tb00208.x
   BOYDE A, 1991, CALCIFIED TISSUE INT, V49, P65, DOI 10.1007/BF02565123
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   DOLBER PC, 1993, J HISTOCHEM CYTOCHEM, V41, P465, DOI 10.1177/41.3.7679127
   Fukuda A, 2005, J BONE MINER RES, V20, P2245, DOI 10.1359/JBMR.050816
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Geblinger D, 2009, CHEMBIOCHEM, V10, P158, DOI 10.1002/cbic.200800549
   Gralow JR, 2009, J NATL COMPR CANC NE, V7, pS1, DOI 10.6004/jnccn.2009.0076
   Guo F, 2008, BLOOD, V112, P1767, DOI 10.1182/blood 2008 01 132068
   Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476
   Itokowa T, 2011, CALCIFIED TISSUE INT, V88, P75, DOI 10.1007/s00223 010 9435 3
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   JUNQUEIRA LCU, 1979, HISTOCHEM J, V11, P447, DOI 10.1007/BF01002772
   KAYE M, 1985, KIDNEY INT, V27, P574, DOI 10.1038/ki.1985.49
   Lees RL, 1999, J BONE MINER RES, V14, P937, DOI 10.1359/jbmr.1999.14.6.937
   Magalhaes JKRS, 2011, OSTEOPOROSIS INT, V22, P1481, DOI 10.1007/s00198 010 1355 6
   MAKRIS GP, 1982, ARCH ORAL BIOL, V27, P965, DOI 10.1016/0003 9969(82)90104 2
   Nesbitt SA, 2003, METH MOLEC MED, V80, P259
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Ory S, 2000, J CELL SCI, V113, P1177
   Pai SY, 2010, DIS MARKERS, V29, P177, DOI [10.3233/DMA 2010 0738, 10.1155/2010/380291]
   PIPER K, 1992, ANAT EMBRYOL, V186, P291
   Pradella SDP, 2011, J IMMUNOL METHODS, V372, P162, DOI 10.1016/j.jim.2011.07.010
   Razzouk S, 1999, EUR J CELL BIOL, V78, P249, DOI 10.1016/S0171 9335(99)80058 2
   Soysa Niroshani Surangika, 2009, Journal of Medical and Dental Sciences, V56, P107
   Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403
   Sun CX, 2007, J CELL BIOL, V179, P239, DOI 10.1083/jcb.200705122
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Teti A, 1998, J BONE MINER RES, V13, P50, DOI 10.1359/jbmr.1998.13.1.50
   TRAU H, 1991, AM J DERMATOPATH, V13, P374, DOI 10.1097/00000372 199108000 00008
   Wang YQ, 2008, J BONE MINER RES, V23, P260, DOI 10.1359/JBMR.071013
   Wang YQ, 2009, CALCIFIED TISSUE INT, V85, P257, DOI 10.1007/s00223 009 9274 2
   Wheeler AP, 2006, J CELL SCI, V119, P2749, DOI 10.1242/jcs.03024
   Yan JC, 2008, HUM MOL GENET, V17, P936, DOI 10.1093/hmg/ddm366
NR 39
TC 13
Z9 19
U1 0
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2012
VL 51
IS 1
BP 145
EP 152
DI 10.1016/j.bone.2012.04.018
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 960HS
UT WOS:000305379200019
PM 22561898
DA 2025 08 17
ER

PT J
AU Narsinghani, T
   Sharma, R
AF Narsinghani, Tamanna
   Sharma, Rajesh
TI Synthesis, anti inflammatory activities and docking studies of amide
   derivatives of meclofenamic acid
SO CHEMICAL PAPERS
LA English
DT Article
DE NSAIDs; COX; Meclofenamic acid; Anti inflammatory activity; Docking
ID BIOLOGICAL EVALUATION; CYCLOOXYGENASE 2; INHIBITION; DESIGN; ESTER;
   INDOMETHACIN; BINDING; POTENT; DRUGS; EDEMA
AB NSAIDs constitute a heterogeneous class of pharmacological agents widely prescribed for the treatment of inflammation, pain and edema, as well as osteoarthritis, rheumatoid arthritis and musculoskeletal disorders. This class of drugs has proved efficacious on account of their analgesic, anti pyretic and anti inflammatory activities, but gastrointestinal toxicity exists as the biggest problem associated with their chronic use. Many attempts have been made to structurally modify conventional NSAIDs as selective COX 2 inhibitors based on the old and still prevalent common belief that selective inhibition of COX 2 would provide safer NSAIDs. The present work thus focused on the synthesis of amide derivatives of one of the conventional non selective NSAID, meclofenamic acid utilizing the one pot procedure involving a selective agent, bis (2 oxo 3 oxazolidinyl) phosphonic chloride. The synthesized compounds were tested for their in vivo inflammatory activity using carrageenan rat paw edema assay, and were subsequently docked on COX 2 PDB code 4COX to have better insights into their mechanism of action. The amide derivative with N 4 methoxybenzyl moiety (TSN4) proved to have anti inflammatory potential (72.8%) better than meclofenamic acid (56.75%). This compound also docked with the highest dock score among the synthesized compounds and was found to have both hydrogen bonding with Arg120 and Tyr355 and hydrophobic interactions with Val349, Leu352, Ser353, Tyr385, Trp387, Met522, Val523, Ala527 and Ser530. N 4 methoxybenzyl amide derivative (TSN4) followed by benzyl amide derivative (TSN1) of meclofenamic acid were identified as potential anti inflammatory compounds in both in vivo and in silico studies.
C1 [Narsinghani, Tamanna; Sharma, Rajesh] Devi Ahilya Vishwavidyalaya, Sch Pharm, Takshashila Campus,Khandwa Rd, Indore, Madhya Pradesh, India.
C3 Devi Ahilya University
RP Sharma, R (通讯作者)，Devi Ahilya Vishwavidyalaya, Sch Pharm, Takshashila Campus,Khandwa Rd, Indore, Madhya Pradesh, India.
EM rbsm73@yahoo.co.in
RI narsinghani, Tamanna/AEP 5460 2022; SHARMA, RAJESH/V 1698 2018;
   narsinghani, tamanna/AEP 5460 2022
OI SHARMA, RAJESH/0000 0003 4054 1840; narsinghani,
   tamanna/0000 0002 4917 9879
FU UGC; AICTE
FX The authors are thankful to UGC and AICTE for the financial assistance
   and to the Head, SAIF, CDRI, Lucknow for providing mass, <SUP>1</SUP>H,
   <SUP>13</SUP>C NMR spectral data and elemental analysis data.
CR Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179
   de Miranda AS, 2012, MOLECULES, V17, P14126, DOI 10.3390/molecules171214126
   DIAGOMESEGUER J, 1980, SYNTHESIS STUTTGART, P547
   Halen PKK, 2006, CHEM BIODIVERS, V3, P1238, DOI 10.1002/cbdv.200690125
   Ismail MAH, 2009, MED CHEM RES, V18, P725, DOI 10.1007/s00044 009 9163 2
   Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925
   Kalgutkar AS, 2005, BIOORGAN MED CHEM, V13, P6810, DOI 10.1016/j.bmc.2005.07.073
   Kalgutkar AS, 2002, BIOORG MED CHEM LETT, V12, P521, DOI 10.1016/S0960 894X(01)00792 2
   Kalgutkar AS, 2000, J MED CHEM, V43, P2860, DOI 10.1021/jm000004e
   Khan YS, 2015, BIOCHEMISTRY US, V54, P7283, DOI 10.1021/acs.biochem.5b01024
   Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0
   Malkowski MG, 2000, SCIENCE, V289, P1933, DOI 10.1126/science.289.5486.1933
   Narsinghani T, 2014, CHEM BIOL DRUG DES, V84, P1, DOI 10.1111/cbdd.12292
   Prusakiewicz JJ, 2004, BIOCHEMISTRY US, V43, P15439, DOI 10.1021/bi048534q
   Raghavendra NM, 2012, BIOORG MED CHEM LETT, V22, P820, DOI 10.1016/j.bmcl.2011.12.062
   Rajic Z, 2010, CHEM BIOL DRUG DES, V75, P641, DOI 10.1111/j.1747 0285.2010.00963.x
   Raju T N, 2000, Lancet, V355, P1022, DOI 10.1016/S0140 6736(05)74775 9
   Reddy KS, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001389
   Rowlinson SW, 2003, J BIOL CHEM, V278, P45763, DOI 10.1074/jbc.M305481200
   Sadek B, 2013, J INFLAMM RES, V6, P35, DOI 10.2147/JIR.S39743
   Stoilov R, 2008, J CLIN MED, V1, P15
   VINEGAR R, 1969, J PHARMACOL EXP THER, V166, P96
   WINTER CA, 1962, P SOC EXP BIOL MED, V111, P544
   Zarghi A, 2010, BIOORGAN MED CHEM, V18, P5855, DOI 10.1016/j.bmc.2010.06.094
NR 24
TC 5
Z9 5
U1 0
U2 10
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH 6330, SWITZERLAND
SN 0366 6352
EI 2585 7290
J9 CHEM PAP
JI Chem. Pap.
PD APR
PY 2017
VL 71
IS 4
BP 857
EP 868
DI 10.1007/s11696 016 0102 7
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA ER3TU
UT WOS:000398722600015
DA 2025 08 17
ER

PT J
AU Miceli, TS
   Colson, K
   Faiman, BM
   Miller, K
   Tariman, JD
AF Miceli, Teresa S.
   Colson, Kathleen
   Faiman, Beth M.
   Miller, Kena
   Tariman, Joseph D.
CA Int Myeloma Fdn Nurse Leadership
TI Maintaining Bone Health in Patients With Multiple Myeloma: Survivorship
   Care Plan of the International Myeloma Foundation Nurse Leadership Board
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
ID MARROW TRANSPLANTATION; CLINICAL FEATURES; STAGING SYSTEM; PROTEASOME
   INHIBITOR; CONSENSUS STATEMENT; ZOLEDRONIC ACID; MINERAL DENSITY;
   FRACTURE RISK; DISEASE; MANAGEMENT
AB About 90% of individuals with multiple myeloma will develop osteolytic bone lesions from increased osteoclastic and decreased osteoblastic activity. Severe morbidities from pathologic fractures and other skeletal events can lead to poor circulation, blood clots, muscle wasting, compromised performance status, and overall poor survival. Supportive care targeting bone disease is an essential adjunct to antimyeloma therapy. In addition, the maintenance of bone health in patients with multiple myeloma can significantly improve quality of life. Oncology nurses and other healthcare providers play a central role in the management of bone disease and maintenance throughout the course of treatment. Safe administration of bisphosphonates, promotion of exercise, maintenance of adequate nutrition, vitamin and mineral supplementation, scheduled radiographic examinations, and monitoring of bone complications are among the important functions that oncology nurses and healthcare providers perform in clinical practice.
C1 [Miceli, Teresa S.] Mayo Clin, Bone Marrow Transplant RN Coordinator, Rochester, MN 55905 USA.
   [Colson, Kathleen] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   [Faiman, Beth M.] Cleveland Clin, Hematol & Med Oncol Dept, Cleveland, OH USA.
   [Miller, Kena] Roswell Pk Canc Inst, Dept Med, Lymphoma Myeloma Div, Buffalo, NY 14263 USA.
   [Tariman, Joseph D.] Northwestern Univ, Myeloma Program, Chicago, IL 60611 USA.
C3 Mayo Clinic; Harvard University; Harvard University Medical Affiliates;
   Dana Farber Cancer Institute; Cleveland Clinic Foundation; Roswell Park
   Comprehensive Cancer Center; Northwestern University
RP Miceli, TS (通讯作者)，Mayo Clin, Bone Marrow Transplant RN Coordinator, Rochester, MN 55905 USA.
EM miceli.teresa@mayo.edu
OI Tariman, Joseph D/0000 0002 4986 2627
FU Celgene Corp.; Millennium: Takeda Oncology Company
FX Teresa S. Miceli, RN, BSN, OCN (R), is the bone marrow transplant RN
   coordinator at the Mayo Clinic in Rochester, MN; Kathleen Colson, RN,
   BSN, BS, is a clinical research nurse in the Jerome Lipper Multiple
   Myeloma Center at Dana Farber Cancer Institute in Boston, MA; Beth M.
   Faiman, MSN, APRN BC, AOCN (R), is a nurse practitioner in the
   Hematology and Medical Oncology Department at the Cleveland Clinic in
   Ohio; Kena Miller, RN, MSN, FNP, is a nurse practitioner in the
   Department of Medicine, Lymphoma/Myeloma Division, at Roswell Park
   Cancer Institute in Buffalo, NY; and Joseph D. Tariman, PhD, APRN, BC,
   is an advanced practice nurse in the myeloma program at Northwestern
   University in Chicago, IL. The authors take full responsibility for the
   content of this article. Publication of this supplement was made
   possible through an unrestricted educational grant to the International
   Myeloma Foundation from Celgene Corp. and Millennium: The Takeda
   Oncology Company. Colson is a consultant with Merck & Co., Inc., and
   Millennium: The Takeda Oncology Company; Faiman is a consultant and on
   the speakers bureau at Celgene Corp. and Millennium: The Takeda Oncology
   Company; Miller is on the advisory board and speakers bureau at Celgene
   Corp. and Millennium: The Takeda Oncology Company; and Tariman is a
   consultant with Millennium: The Takeda Oncology Company. The content of
   this article has been reviewed by independent peer reviewers to ensure
   that it is balanced, objective, and free from commercial bias. No
   financial relationships relevant to the content of this article have
   been disclosed by independent peer reviewers or editorial staff. (First
   submission February 2011. Revision submitted March 30, 2011. Accepted
   for publication April 5, 2011.)
CR Adami S, 2009, CURR MED RES OPIN, V25, P1057, DOI [10.1185/03007990902801147, 10.1185/03007990902801147 ]
   Aloia JF, 2008, AM J CLIN NUTR, V88, p545S, DOI 10.1093/ajcn/88.2.545S
   Angtuaco EJC, 2004, RADIOLOGY, V231, P11, DOI 10.1148/radiol.2311020452
   [Anonymous], 2010, CLIN PRACT GUID ONC
   [Anonymous], CANC NURSING PRINCIP
   [Anonymous], WHOS PAIN LADD
   AWAN N, 2002, EUR J ORTHOP SURG TR, V12, P53, DOI DOI 10.1007/S00590 002 0013 X
   Bartel TB, 2009, BLOOD, V114, P2068, DOI 10.1182/blood 2009 03 213280
   Berenson J, 2011, LANCET ONCOL, V12, P225, DOI 10.1016/S1470 2045(11)70008 0
   Berenson JR, 2006, CANCER BIOL THER, V5, P1082, DOI 10.4161/cbt.5.9.3307
   Berkey FJ, 2010, AM FAM PHYSICIAN, V82, P381
   Bischoff Ferrari HA, 2007, J STEROID BIOCHEM, V103, P614, DOI 10.1016/j.jsbmb.2006.12.016
   BOLZONI M, 2010, IMMUNOMODULATORY DRU
   Breitkreutz I, 2008, LEUKEMIA, V22, P1925, DOI 10.1038/leu.2008.174
   Cady B, 2005, J AM COLL SURGEONS, V200, P115, DOI 10.1016/j.jamcollsurg.2004.10.007
   Cafro AM, 2008, CLIN LYMPHOMA MYELOM, V8, P111, DOI 10.3816/CLM.2008.n.013
   Cashman KD, 2007, J NUTR, V137, p2507S, DOI 10.1093/jn/137.11.2507S
   Chau D.L., 2002, CLIN DIABETES, V20, P153
   Coleman R E, 2000, Oncologist, V5, P463, DOI 10.1634/theoncologist.5 6 463
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Dimopoulos MA, 2009, BLOOD, V114, P2007, DOI 10.1182/blood 2009 06 224196
   DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097 0142(197509)36:3<842::AID CNCR2820360303>3.0.CO;2 U
   Durie BGM, 2007, MAYO CLIN PROC, V82, P516, DOI 10.4065/82.4.516
   Durie BGM, 2006, EUR J CANCER, V42, P1539, DOI 10.1016/j.ejca.2005.11.037
   Ebeling PR, 1999, J BONE MINER RES, V14, P342, DOI 10.1359/jbmr.1999.14.3.342
   Epstein Joshua, 2006, Clin Adv Hematol Oncol, V4, P300
   Esteve FR, 2007, BEST PRACT RES CL HA, V20, P613, DOI 10.1016/j.beha.2007.08.003
   Everitt AV, 2006, CLIN INTERV AGING, V1, P11, DOI 10.2147/ciia.2006.1.1.11
   Faiman B, 2008, CLIN J ONCOL NURS, V12, P53, DOI 10.1188/08.CJON.S1.53 62
   Faiman BM, 2011, CLIN J ONCOL NURS, V15, P66, DOI 10.1188/11.CJON.S1.66 76
   Fitch MI, 2008, ONCOL NURS FORUM, V35, P709, DOI 10.1188/08.ONF.709 713
   Golden EB, 2009, BLOOD, V113, P5927, DOI 10.1182/blood 2008 07 171389
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Guise TA, 2006, ONCOLOGIST, V11, P1121, DOI 10.1634/theoncologist.11 10 1121
   Hu K, 2000, ONCOLOGY NY, V14, P101
   Kang MI, 2000, BONE, V26, P275, DOI 10.1016/S8756 3282(99)00265 3
   Kanis John A., 2000, Cancer, V88, P3022, DOI 10.1002/1097 0142(20000615)88:12+<3022::AID CNCR19>3.0.CO;2 R
   Kerschan Schindl K, 2004, BONE MARROW TRANSPL, V34, P491, DOI 10.1038/sj.bmt.1704618
   KIELHOLZ U, 1997, CANCER, V79, P1617
   Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
   Kyle RA, 2003, MAYO CLIN PROC, V78, P21, DOI 10.4065/78.1.21
   KYLE RA, 1985, ARCH INTERN MED, V145, P1451, DOI 10.1001/archinte.145.8.1451
   Kyle RA, 2007, BEST PRACT RES CL HA, V20, P637, DOI 10.1016/j.beha.2007.08.001
   Kyle RA, 2007, J CLIN ONCOL, V25, P2464, DOI 10.1200/JCO.2007.12.1269
   Lee WY, 2002, J KOREAN MED SCI, V17, P749, DOI 10.3346/jkms.2002.17.6.749
   Lee WY, 2002, J CLIN ENDOCR METAB, V87, P329, DOI 10.1210/jc.87.1.329
   Legg V, 2005, AM J NURS, V105, P40, DOI 10.1097/00000446 200506000 00024
   Levy MH, 1996, NEW ENGL J MED, V335, P1124, DOI 10.1056/NEJM199610103351507
   Ludwig H, 2007, BEST PRACT RES CL HA, V20, P817, DOI 10.1016/j.beha.2007.10.001
   Mariette X, 1999, BRIT J HAEMATOL, V104, P723, DOI 10.1046/j.1365 2141.1999.01244.x
   Mauck KF, 2006, MAYO CLIN PROC, V81, P662, DOI 10.4065/81.5.662
   Maxwell Cathy, 2003, Clin J Oncol Nurs, V7, P403, DOI 10.1188/03.CJON.403 408
   Melton LJ, 2005, J BONE MINER RES, V20, P487, DOI 10.1359/JBMR.041131
   Mezuk B, 2008, OSTEOPOROSIS INT, V19, P1, DOI 10.1007/s00198 007 0449 2
   Mezuk B, 2008, J GERONTOL A BIOL, V63, P1410, DOI 10.1093/gerona/63.12.1410
   Montefusco V, 2008, LEUKEMIA LYMPHOMA, V49, P2156, DOI 10.1080/10428190802483778
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   *NAT OST FDN, 2010, FAST FACTS OST 2010
   Pennisi A, 2009, AM J HEMATOL, V84, P6, DOI 10.1002/ajh.21310
   Rome SI, 2011, CLIN J ONCOL NURS, V15, P41, DOI 10.1188/11.S1.CJON.41 52
   Roodman G David, 2008, Hematology Am Soc Hematol Educ Program, P313, DOI 10.1182/asheducation 2008.1.313
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Sezer O, 2009, ONCOLOGIST, V14, P276, DOI 10.1634/theoncologist.2009 0003
   STEINBERG JA, 2009, ALPHA LIPOIC ACID AL
   Szulc P, 2008, J BONE MINER RES, V23, P95, DOI 10.1359/JBMR.070903
   Tariman Joseph D, 2005, Oncol Nurs Forum, V32, pE127, DOI 10.1188/05.ONF.E127 E138
   Terpos E, 2005, ANN ONCOL, V16, P1223, DOI 10.1093/annonc/mdi235
   TERPOS E, 2009, CONSOLIDATION THERAP
   TERPOS E, 2008, EUR HEM ASS 13 C COP
   Tryciecky EW, 1997, SEMIN NUCL MED, V27, P142, DOI 10.1016/S0001 2998(97)80044 X
   Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584
   Weber Donna M, 2005, Hematology Am Soc Hematol Educ Program, P373
   Wick Jeannette Y, 2009, Consult Pharm, V24, P100, DOI 10.4140/TCP.n.2009.100
   Yeh HS, 2006, CLIN CANCER RES, V12, p6279S, DOI 10.1158/1078 0432.CCR 06 0681
   Zou W, 2006, CLIN CANCER RES, V12, P273, DOI 10.1158/1078 0432.CCR 05 0503
NR 76
TC 27
Z9 31
U1 0
U2 9
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092 1095
EI 1538 067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD AUG
PY 2011
VL 15
IS 4
SU S
BP 9
EP 23
DI 10.1188/11.S1.CJON.9 23
PG 15
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA 805KF
UT WOS:000293724600003
PM 21816707
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Karashima, T
   Inoue, K
   Fukata, S
   Iiyama, T
   Kurabayash, A
   Kawada, C
   Shuin, T
AF Karashima, Takashi
   Inoue, Kej
   Fukata, Satoshi
   Iiyama, Tatsuo
   Kurabayash, Atsushi
   Kawada, Chiaki
   Shuin, Taro
TI Blockade of the vascular endothelial growth factor receptor 2 pathway
   inhibits the growth of human renal cell carcinoma, RBM1 IT4, in the
   kidney but not in the bone of nude mice
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE vascular endothelial growth factor receptor 2; TSU 68; osteoclast
   precursor; bone metastasis; renal cell carcinoma
ID TUMOR SUPPRESSOR GENE; HYPOXIA INDUCIBLE FACTOR; HIPPEL LINDAU PROTEIN;
   IN VIVO; MATURE OSTEOCLASTS; ENDOTHELIAL CELLS; SOMATIC MUTATIONS;
   FACTOR VEGF; VHL GENE; RECEPTOR
AB Primary and metastatic RCCs are consistently resistant to radiotherapy, chemotherapy, or immunotherapy. As recurrent or metastatic RCC after surgery is related with poor prognosis and cancer related death, development of therapeutic modalities that can control RCC and improve patient survival is urgently needed. We determined whether blockade of the vascular endothelial growth factor receptor 2 (VEGF R2) signaling pathway inhibits the growth of human renal cell carcinoma cells in the kidney and bone of nude m ice. Male nude mice implanted with 1x10(6) RBM1 IT4 cells in the kidney or in the tibia were treated with oral administrations of TSU 68, anti VEGF R2 tyrosine kinase inhibitor beginning 5 days after implantation. The tumor incidence, tumor weight and bone destruction were determined at twelve weeks after commencing the therapy. VEGF production by RCCs was determined by ELISA and alterations in VEGF production related with genetic instability were also analysed. VEGF R expression of mouse osteoclast precursors (mOCPs) and human umbilical vascular endothelial cell (HUVEC) was determined by RT PCR and Western immunoblotting. In vitro, the effects of TSU 68 on the cellular proliferation of HUVEC, normal human renal proximal tubule epithelial cell (RPTEC) and mOCPs were determined. RBM1 IT4 cells had loss of heterozygosity and frame shift mutation on chromosome 3p, inactivating the von Hippel Lindau (VHL) tumor suppressor gene and resulting in the production of relatively higher levels of VEGF than the RCCs without VHL mutation. TSU 68 significantly inhibited the growth of RBM1 IT4 in the kidney (p < 0.05). In contrast, TSU 68 did not inhibit the growth of RBM1 IT4 in the tibia or bone lysis. Although HUVEC, RPTEC and mOCPs expressed VEGF R2, TSU 68 directly inhibited the VEGF stimulated cell growth of HUVEC and RPTEC but not the mOCPs in vitro. These data indicate that the VEGF VEGF R2 pathway is not required for survival of the osteoclasts and anti VEGF R2 therapy did not contribute to the suppression of metastatic RCC growth in the bone.
C1 Kochi Univ, Dept Urol, Sch Med, Nanko Ku, Kochi 7838505, Japan.
   Kochi Univ, Dept Pathol 2, Sch Med, Nanko Ku, Kochi 7838505, Japan.
C3 Kochi University; Kochi University
RP Karashima, T (通讯作者)，Kochi Univ, Dept Urol, Sch Med, Nanko Ku, Kochi 7838505, Japan.
EM karasima@med.kochi u.ac.jp
CR Althausen P, 1997, CANCER, V80, P1103
   AOKI J, 1988, CANCER AM CANCER SOC, V62, P98, DOI 10.1002/1097 0142(19880701)62:1<98::AID CNCR2820620118>3.0.CO;2 8
   Arora N, 1999, CANCER RES, V59, P183
   Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336
   Brieger J, 1999, J MOL MED JMM, V77, P505, DOI 10.1007/s001099900022
   Chino KJ, 1999, J UROLOGY, V162, P614, DOI 10.1016/S0022 5347(05)68636 3
   Coleman RE, 2004, ONCOLOGIST, V9, P14, DOI 10.1634/theoncologist.9 90004 14
   Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019
   Fong TAT, 1999, CANCER RES, V59, P99
   FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169
   Gallou C, 1999, HUM MUTAT, V13, P464, DOI 10.1002/(SICI)1098 1004(1999)13:6<464::AID HUMU6>3.0.CO;2 A
   Gnarra JR, 1996, BBA REV CANCER, V1242, P201, DOI 10.1016/0304 419X(95)00012 5
   GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594 85
   Gnarra JR, 1996, P NATL ACAD SCI USA, V93, P10589, DOI 10.1073/pnas.93.20.10589
   HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207
   HAUSCHKA PV, 1986, J BIOL CHEM, V261, P2665
   HENRIKSSON C, 1992, SCAND J UROL NEPHROL, V26, P363, DOI 10.3109/00365599209181227
   Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349
   Hoekman K, 2001, CANCER J, V7, pS134
   Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595
   Inoue K, 2000, CLIN CANCER RES, V6, P2635
   Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099
   Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kim SJ, 2003, CLIN CANCER RES, V9, P1200
   Laird AD, 2000, CANCER RES, V60, P4152
   Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01 0700com
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Lipton Allan, 2004, J Support Oncol, V2, P205
   Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732
   Marme D, 1996, WORLD J UROL, V14, P166
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629
   Murray LJ, 2003, CLIN EXP METASTAS, V20, P757, DOI 10.1023/B:CLIN.0000006873.65590.68
   NAITO S, 1989, CLIN EXP METASTAS, V7, P381, DOI 10.1007/BF01753659
   Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014 5793(00)01520 9
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097 2765(00)80096 9
   Pack SD, 1999, CANCER RES, V59, P5560
   Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277
   Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993
   Prewett M, 1999, CANCER RES, V59, P5209
   Ramakrishnan S, 1996, CANCER RES, V56, P1324
   SAITOH H, 1981, CANCER AM CANCER SOC, V48, P1487, DOI 10.1002/1097 0142(19810915)48:6<1487::AID CNCR2820480635>3.0.CO;2 9
   Saleh M, 1996, CANCER RES, V56, P393
   Shaheen RM, 1999, CANCER RES, V59, P5412
   Shaheen RM, 2001, CANCER RES, V61, P1464
   SHUIN T, 1994, CANCER RES, V54, P2852
   Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455
   Sun L, 1999, J MED CHEM, V42, P5120, DOI 10.1021/jm9904295
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Thomas AL, 2003, SEMIN ONCOL, V30, P32, DOI 10.1016/S0093 7754(03)00123 4
   Tombran Tink J, 2004, BIOCHEM BIOPH RES CO, V316, P573, DOI 10.1016/j.bbrc.2004.02.076
   Weber KL, 2002, J UROLOGY, V168, P774, DOI 10.1016/S0022 5347(05)64743 X
   WILNER D, 1982, RADIOLOGY BONE TUMOR, P3678
   Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427
   Xiong HQ, 2004, INVEST NEW DRUG, V22, P459, DOI 10.1023/B:DRUG.0000036688.96453.8d
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Zhu ZP, 1998, CANCER RES, V58, P3209
NR 60
TC 15
Z9 18
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019 6439
EI 1791 2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD APR
PY 2007
VL 30
IS 4
BP 937
EP 945
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 147RP
UT WOS:000245020400020
PM 17332933
DA 2025 08 17
ER

PT J
AU Chang, JY
   Jiang, ZL
   Ma, TY
   Li, J
   Chen, JY
   Ye, PZ
   Feng, L
AF Chang, Jinyuan
   Jiang, Zhenglong
   Ma, Tianyu
   Li, Jie
   Chen, Jiayang
   Ye, Peizhi
   Feng, Li
TI Integrating transcriptomics and network analysis based multiplexed drug
   repurposing to screen drug candidates for M2 macrophage associated
   castration resistant prostate cancer bone metastases
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE drug repurposing; castration resistant prostate cancer; bone metastases;
   network pharmacology; M2 macrophage
ID IN VITRO; THERAPY; TRPM8; COMBINATION; SURVIVAL; DOCKING; BINDING;
   BREAST; CELLS; TRIAL
AB Metastatic castration resistant prostate cancer (CRPC) has long been considered to be associated with patient mortality. Among metastatic organs, bone is the most common metastatic site, with more than 90% of advanced patients developing bone metastases (BMs) before 24 months of death. Although patients were recommended to use bone targeted drugs represented by bisphosphonates to treat BMs of CRPC, there was no significant improvement in patient survival. In addition, the use of immunotherapy and androgen deprivation therapy is limited due to the immunosuppressed state and resistance to antiandrogen agents in patients with bone metastases. Therefore, it is still essential to develop a safe and effective therapeutic schedule for CRPC patients with BMs. To this end, we propose a multiplex drug repurposing scheme targeting differences in patient immune cell composition. The identified drug candidates were ranked from the perspective of M2 macrophages by integrating transcriptome and network based analysis. Meanwhile, computational chemistry and clinical trials were used to generate a comprehensive drug candidate list for the BMs of CRPC by drug redundancy structure filtering. In addition to docetaxel, which has been approved for clinical trials, the list includes norethindrone, testosterone, menthol and foretinib. This study provides a new scheme for BMs of CRPC from the perspective of M2 macrophages. It is undeniable that this multiplex drug repurposing scheme specifically for immune cell related bone metastases can be used for drug screening of any immune related disease, helping clinicians find promising therapeutic schedules more quickly, and providing reference information for drug R&D and clinical trials.
C1 [Chang, Jinyuan; Jiang, Zhenglong; Ma, Tianyu; Li, Jie; Chen, Jiayang; Ye, Peizhi; Feng, Li] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences   Peking Union Medical College;
   Cancer Institute & Hospital   CAMS; Peking Union Medical College
RP Feng, L (通讯作者)，Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, Beijing, Peoples R China.
EM fengli663@126.com
RI CHEN, JIA YANG/M 8413 2014; Chang, Jinyuan/C 4833 2014; ma,
   tianyu/KVB 0680 2024
FU Cancer discipline construction project of integrated traditional Chinese
   and Western medicine of Peking Union Medical College [20192010302];
   Beijing Natural Science Foundation [7222293]; Special subject of
   research and evaluation of China Association of Chinese Medicine
   [CACMRE2021 A 05]
FX This research was supported by the cancer discipline construction
   project of integrated traditional Chinese and Western medicine of Peking
   Union Medical College (20192010302), the Beijing Natural Science
   Foundation (7222293) and the special subject of research and evaluation
   of China Association of Chinese Medicine (CACMRE2021 A 05).
CR Askari A, 2021, IRAN J BASIC MED SCI, V24, P1568, DOI 10.22038/IJBMS.2021.58829.13070
   Bagaev A, 2021, CANCER CELL, V39, P845, DOI 10.1016/j.ccell.2021.04.014
   Beer TM, 2017, J CLIN ONCOL, V35, P40, DOI 10.1200/JCO.2016.69.1584
   Beigoli S, 2019, J BIOMOL STRUCT DYN, V37, P2265, DOI 10.1080/07391102.2018.1491421
   Chamani J, 2006, J COLLOID INTERF SCI, V297, P561, DOI 10.1016/j.jcis.2005.11.035
   Chang JY, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/4931368
   Chang JY, 2020, EVID BASED COMPL ALT, V2020, DOI 10.1155/2020/7617261
   Chen JR, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.789319
   Chen YN, 2020, EUR J PHARMACOL, V877, DOI 10.1016/j.ejphar.2020.173090
   Chen ZQ, 2019, J CHEM INF MODEL, V59, P3353, DOI 10.1021/acs.jcim.9b00332
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978 1 4939 3578 9_5
   Coleman RE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572 020 00216 3
   Dareini M, 2020, SPECTROCHIM ACTA A, V228, DOI 10.1016/j.saa.2019.117528
   Denmeade SR, 2010, PROSTATE, V70, P1600, DOI 10.1002/pros.21196
   Desai K, 2021, ENDOCR REV, V42, P354, DOI 10.1210/endrev/bnab002
   Duan QN, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.15
   Enioutina EY, 2020, EXPERT REV CLIN PHAR, V13, P935, DOI 10.1080/17512433.2020.1803739
   Fang SS, 2021, NUCLEIC ACIDS RES, V49, pD1197, DOI 10.1093/nar/gkaa1063
   Ferreira RS, 2010, J MED CHEM, V53, P4891, DOI 10.1021/jm100488w
   Fu YY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.689727
   Gillessena S, 2020, EUR UROL, V77, P508, DOI 10.1016/j.eururo.2020.01.012
   Gorgulla C, 2020, NATURE, V580, P663, DOI 10.1038/s41586 020 2117 z
   Grant BJ, 2021, PROTEIN SCI, V30, P20, DOI 10.1002/pro.3923
   Hall CL, 2008, NEOPLASIA, V10, P797, DOI 10.1593/neo.08380
   Hofbauer LC, 2021, NAT REV CLIN ONCOL, V18, P488, DOI 10.1038/s41571 021 00499 9
   Hosseinzadeh M, 2019, RES CHEM INTERMEDIAT, V45, P401, DOI 10.1007/s11164 018 3608 5
   Huang QJ, 2021, J PHYS CHEM LETT, V12, P5404, DOI 10.1021/acs.jpclett.1c01253
   Idorn M, 2014, CANCER IMMUNOL IMMUN, V63, P1177, DOI 10.1007/s00262 014 1591 2
   Ihle CL, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0753 3
   Jaaks P, 2022, NATURE, V603, P166, DOI 10.1038/s41586 022 04437 2
   Jiang PL, 2019, THERANOSTICS, V9, P2950, DOI 10.7150/thno.29617
   Kaore SN, 2012, J PHARM PHARMACOL, V64, P1040, DOI 10.1111/j.2042 7158.2012.01464.x
   Kaplan AL, 2016, EUR UROL, V69, P894, DOI 10.1016/j.eururo.2015.12.005
   Karatzas E, 2020, BIOINFORMATICS, V36, P2602, DOI 10.1093/bioinformatics/btz976
   Karatzas E, 2019, COMPUT STRUCT BIOTEC, V17, P939, DOI 10.1016/j.csbj.2019.05.010
   Kfoury Y, 2021, CANCER CELL, V39, P1464, DOI 10.1016/j.ccell.2021.09.005
   Khashkhashi Moghadam S, 2022, J MOL LIQ, V356, DOI 10.1016/j.molliq.2022.119042
   Klement JD, 2018, J CLIN INVEST, V128, P5549, DOI 10.1172/JCI123360
   Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Li P, 2015, BIOINFORMATICS, V31, P2007, DOI 10.1093/bioinformatics/btv080
   Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407
   Loeb S, 2017, J CLIN ONCOL, V35, P1430, DOI 10.1200/JCO.2016.69.5304
   Lokeshwar SD, 2021, NAT REV UROL, V18, P433, DOI 10.1038/s41585 021 00470 4
   Maeser D, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab260
   Marjani N, 2022, LUMINESCENCE, V37, P310, DOI 10.1002/bio.4173
   Moreira DM, 2017, CLIN GENITOURIN CANC, V15, P60, DOI 10.1016/j.clgc.2016.08.018
   Naziroglu M, 2018, REDOX BIOL, V14, P439, DOI 10.1016/j.redox.2017.10.009
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Pang XC, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/5806602
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Paolillo M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194947
   Park D, 2016, BIOMATERIALS, V98, P131, DOI 10.1016/j.biomaterials.2016.05.007
   Pushpakom S, 2019, NAT REV DRUG DISCOV, V18, P41, DOI 10.1038/nrd.2018.168
   Racle J, 2020, METHODS MOL BIOL, V2120, P233, DOI 10.1007/978 1 0716 0327 7_17
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Sadeghzadeh F, 2020, PROTEIN PEPTIDE LETT, V27, P1007, DOI 10.2174/1871530320666200425203636
   Sean D, 2007, BIOINFORMATICS, V23, P1846, DOI 10.1093/bioinformatics/btm254
   Seiwert T, 2013, INVEST NEW DRUG, V31, P417, DOI 10.1007/s10637 012 9861 3
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun W, 2016, DRUG DISCOV TODAY, V21, P1189, DOI 10.1016/j.drudis.2016.05.015
   Tian R, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.843043
   Tomazou M, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbab114
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Vahedian Movahed H, 2011, J BIOMOL STRUCT DYN, V28, P483, DOI 10.1080/07391102.2011.10508590
   Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523
   Wang XY, 2020, GENES BASEL, V11, DOI 10.3390/genes11040435
   Wang ZC, 2018, BIOINFORMATICS, V34, P2150, DOI 10.1093/bioinformatics/bty060
   Wei SH, 2014, PATHOBIOLOGY, V81, P123, DOI 10.1159/000357622
   Wu KY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01731
   Xiong GL, 2021, NUCLEIC ACIDS RES, V49, pW5, DOI 10.1093/nar/gkab255
   Yee NS, 2015, CANCERS, V7, P2134, DOI 10.3390/cancers7040882
   Yu LJ, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12056
   Zare Feizabadi N, 2021, DNA CELL BIOL, V40, P1039, DOI 10.1089/dna.2021.0052
   Zhang L, 2006, ENDOCR RELAT CANCER, V13, P27, DOI 10.1677/erc.1.01093
   Zhang XY, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880 019 0425 1
   Zhang YR, 2021, INT J GEN MED, V14, P2931, DOI 10.2147/IJGM.S321319
NR 78
TC 3
Z9 3
U1 3
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD OCT 26
PY 2022
VL 13
AR 989972
DI 10.3389/fimmu.2022.989972
PG 17
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 6C7HT
UT WOS:000882181100001
PM 36389722
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, JC
   Liang, X
   Tian, XY
   Zhao, MZ
   Mu, YJ
   Yi, HX
   Zhang, Z
   Zhang, LW
AF Zhang, Jincan
   Liang, Xi
   Tian, Xiaoying
   Zhao, Maozhen
   Mu, Yunjuan
   Yi, Huaxi
   Zhang, Zhe
   Zhang, Lanwei
TI Bifidobacterium improves oestrogen deficiency induced
   osteoporosis in mice by modulating intestinal immunity
SO FOOD & FUNCTION
LA English
DT Article
ID BONE LOSS; T CELLS; INFLAMMATION; INCREASES; BARRIER
AB Osteoporosis has become one of the major diseases that threaten the health of middle aged and elderly people, and with the growth of an ageing population, more and more people are affected by osteoporosis these days. In recent years, intestinal flora has been found to affect the host immune system, and an overactive immune system is closely related to bone resorption. Probiotics can effectively improve bone density and strength, reduce bone loss, and improve osteoporosis, but their mechanism of action and relationship with intestinal microbiota are still unclear. In this study, two strains of Bifidobacterium (Bifidobacterium bifidum FL228.1 and Bifidobacterium animalis subsp. Lactis F1 7) that can alleviate intestinal inflammation were screened based on previous experiments. Through the construction of an ovariectomized mouse model, the improvement of osteoporosis by Bifidobacterium was detected, and the influence of Bifidobacterium on intestinal immunity was explored. The results show that Bifidobacterium treatment significantly improved bone mineral density (BMD), bone volume/total volume ratio (BV/TV), and trabecular number (Tb<middle dot>N), and effectively suppressed bone loss. Furthermore, Bifidobacterium treatment could inhibit the expression of inflammatory cytokines in the gut, alleviate gut inflammation, and thus suppress excessive osteoclast generation. Its mechanism of action includes factors that protect the mucosal barrier, including occludin, ZO 1, claudin 2, and MUC2, and the reduction of pro inflammatory M1 macrophages. B. bifidum FL228.1 increased the abundance of beneficial bacteria in the colon, including Lactobacillus and Colidextribacter. B. animalis F1 7 increased the abundance of Bifidobacterium and decreased the abundance of Desulfovibrio and Ruminococcus in the colon. These research findings expand our understanding of the gut bone axis and provide new guidance for the development of probiotic based therapies for osteoporosis in the future.
C1 [Zhang, Jincan; Zhao, Maozhen; Mu, Yunjuan; Yi, Huaxi; Zhang, Zhe; Zhang, Lanwei] Ocean Univ China, Coll Food Sci & Engn, Qingdao 266000, Peoples R China.
   [Liang, Xi] Qingdao Univ, Coll Publ Hlth, Qingdao 266000, Peoples R China.
   [Tian, Xiaoying] Qingdao Univ, Qingdao Med Coll, Qingdao 266000, Peoples R China.
C3 Ocean University of China; Qingdao University; Qingdao University
RP Zhang, Z; Zhang, LW (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao 266000, Peoples R China.
EM zhangzhe1613@ouc.edu.cn; zhanglanwei@ouc.edu.cn
RI Zhang, Jincan/AFN 3025 2022
FU Fundamental Research Funds for the Central Universities [LJNY202101];
   Shandong Taishan Industry Leading Talent Project [202313041];
   Fundamental Research Funds for the Central Universities
   [QDBSH20220202059]; Qingdao Postdoctoral Applied Research Project
   [ZR2023QC031]; Shandong Provincial Natural Science Foundation
FX This work was supported by the Shandong Taishan Industry Leading Talent
   Project (LJNY202101), Fundamental Research Funds for the Central
   Universities (202313041), Qingdao Postdoctoral Applied Research Project
   (QDBSH20220202059), and Shandong Provincial Natural Science Foundation
   (ZR2023QC031).
CR Adamopoulos IE, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2936
   Al Sadi R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158070
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   Burger van Paassen N, 2009, BIOCHEM J, V420, P211, DOI 10.1042/BJ20082222
   Cenci S, 2003, P NATL ACAD SCI USA, V100, P10405, DOI 10.1073/pnas.1533207100
   Cui QY, 2022, FOOD FUNCT, V13, P5115, DOI [10.1039/d1fo04219j, 10.1039/D1FO04219J]
   Cui ZY, 2020, ARCH OSTEOPOROS, V15, DOI 10.1007/s11657 019 0670 6
   de Souza PPC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23063287
   Gao YH, 2007, J CLIN INVEST, V117, P122, DOI 10.1172/JCI30074
   Gu YX, 2022, FOOD BIOSCI, V47, DOI 10.1016/j.fbio.2022.101619
   Guo MY, 2023, GUT MICROBES, V15, DOI 10.1080/19490976.2023.2190304
   Kumar M, 2017, AM J PHYSIOL GASTR L, V312, pG34, DOI 10.1152/ajpgi.00298.2016
   Lan H, 2022, FOOD FUNCT, V13, P1482, DOI [10.1039/d1fo02218k, 10.1039/D1FO02218K]
   Fernández Murga ML, 2020, BONE, V141, DOI 10.1016/j.bone.2020.115580
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Liang X, 2024, FOOD SCI HUM WELL, V13, P813, DOI 10.26599/FSHW.2022.9250069
   Lu YY, 2023, PROBIOTICS ANTIMICRO, V15, P1234, DOI 10.1007/s12602 022 09975 9
   Lv YG, 2016, BIOCHEM BIOPH RES CO, V479, P372, DOI 10.1016/j.bbrc.2016.09.083
   Mccabe LR, 2013, J CELL PHYSIOL, V228, P1793, DOI 10.1002/jcp.24340
   Mei FF, 2021, J AGR FOOD CHEM, V69, P246, DOI 10.1021/acs.jafc.0c06671
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Pacifici R, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2126
   Philippe D, 2011, WORLD J GASTROENTERO, V17, P459, DOI 10.3748/wjg.v17.i4.459
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Rogers NH, 2009, ENDOCRINOLOGY, V150, P2161, DOI 10.1210/en.2008 1405
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Schepper JD, 2020, J BONE MINER RES, V35, P801, DOI 10.1002/jbmr.3947
   Schett G, 2011, EUR J CLIN INVEST, V41, P1361, DOI 10.1111/j.1365 2362.2011.02545.x
   Singh SB, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.882498
   Sinha SR, 2020, CELL HOST MICROBE, V27, P659, DOI 10.1016/j.chom.2020.01.021
   Vancamelbeke M, 2017, EXPERT REV GASTROENT, V11, P821, DOI 10.1080/17474124.2017.1343143
   Wang R, 2023, EUR J NUTR, V62, P1267, DOI 10.1007/s00394 022 03064 x
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Wu F, 2021, J AGR FOOD CHEM, V69, P12753, DOI 10.1021/acs.jafc.1c05793
   Wu YQ, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.01651 22
   Yu J, 2021, J FUNCT FOODS, V87, DOI 10.1016/j.jff.2021.104762
   Yu MC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143137
   Yuan SJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115710
   Zhang YW, 2023, CRIT REV FOOD SCI, V63, P7510, DOI 10.1080/10408398.2022.2047005
   Zhu SY, 2018, J MOL ENDOCRINOL, V60, P185, DOI 10.1530/JME 17 0218
NR 41
TC 26
Z9 27
U1 43
U2 144
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD FEB 19
PY 2024
VL 15
IS 4
DI 10.1039/d3fo05212e
EA JAN 2024
PG 13
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA IC1P1
UT WOS:001151706600001
PM 38273734
DA 2025 08 17
ER

PT J
AU Kusuyama, J
   Kamisono, A
   ChangHwan, S
   Amir, MS
   Bandow, K
   Eiraku, N
   Ohnishi, T
   Matsuguchi, T
AF Kusuyama, Joji
   Kamisono, Ai
   ChangHwan, Seong
   Amir, Muhammad S.
   Bandow, Kenjiro
   Eiraku, Nahoko
   Ohnishi, Tomokazu
   Matsuguchi, Tetsuya
TI Spleen tyrosine kinase influences the early stages of multilineage
   differentiation of bone marrow stromal cell lines by regulating
   phospholipase C gamma activities
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE adipogenesis; bone marrow stromal cell; osteogenesis; PLC; Syk
ID MESENCHYMAL STEM CELLS; OSTEOBLAST DIFFERENTIATION; LINKER REGION; SYK;
   ADIPOGENESIS; BLNK; FAT; PHOSPHORYLATION; TRANSCRIPTION; OSTEOPOROSIS
AB Bone marrow stromal cells (BMSCs) are multipotent cells that can differentiate into adipocytes and osteoblasts. Inadequate BMSC differentiation is occasionally implicated in chronic bone metabolic disorders. However, specific signaling pathways directing BMSC differentiation have not been elucidated. Here, we explored the roles of spleen tyrosine kinase (Syk) in BMSC differentiation into adipocytes and osteoblasts. We found that Syk phosphorylation was increased in the early stage, whereas its protein expression was gradually decreased during the adipogenic and osteogenic differentiation of two mouse mesenchymal stromal cell lines, ST2 and 10T(1/2), and a human BMSC line, UE6E 7 16. Syk inactivation with either a pharmacological inhibitor or Syk specific siRNA suppressed adipogenic differentiation, characterized by decreased lipid droplet appearance and the gene expression of fatty acid protein 4 (Fabp4), peroxisome proliferator activated receptor gamma 2 (Pparg2), CCAAT/enhancer binding proteins a (C/EBPa), and C/EBP beta. In contrast, Syk inhibition promoted osteogenic differentiation, represented by increase in matrix mineralization and alkaline phosphatase (ALP) activity, as well as the expression levels of osteocalcin, runt related transcription factor 2 (Runx2), and distal less homeobox 5 (Dlx5) mRNAs. We also found that Syk induced signals are mediated by phospholipase C gamma 1 (PLC gamma 1) in osteogenesis and PLC gamma 2 in adipogenesis. Notably, Syk activated PLC gamma 2 signaling was partly modulated through B cell linker protein (BLNK) in adipogenic differentiation. On the other hand, growth factor receptor binding protein 2 (Grb2) was involved in Syk PLC gamma 1 axis in osteogenic differentiation. Taken together, these results indicate that Syk PLC. signaling has a dual role in regulating the initial stage of adipogenic and osteogenic differentiation of BMSCs.
C1 [Kusuyama, Joji; Kamisono, Ai; ChangHwan, Seong; Amir, Muhammad S.; Ohnishi, Tomokazu; Matsuguchi, Tetsuya] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Oral Biochem, Field Dev Med, Sakuragaoka 8 35 1, Kagoshima 8908544, Japan.
   [Amir, Muhammad S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Field Oral & Maxillofacial Rehabil, Dept Oral & Maxillofacial Surg, Kagoshima, Japan.
   [Amir, Muhammad S.] Airlangga Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Surabaya, Indonesia.
   [Amir, Muhammad S.] Campus UNAIR, Kota Sby, Jawa Timur, Indonesia.
   [Bandow, Kenjiro] Meikai Univ, Sch Dent, Dept Oral Biol & Tissue Engn, Sakado, Saitama, Japan.
   [Eiraku, Nahoko] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Periodontol, Field Oral & Maxillofacial Rehabil, Kagoshima, Japan.
C3 Kagoshima University; Kagoshima University; Airlangga University; Meikai
   University; Kagoshima University
RP Matsuguchi, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Oral Biochem, Field Dev Med, Sakuragaoka 8 35 1, Kagoshima 8908544, Japan.
EM tmatsugu@dent.kagoshima u.ac.jp
RI Matsuguchi, Tetsuya/HGU 0412 2022; Kusuyama, Joji/AAQ 7547 2020; Amir,
   Muhammad/AAD 3006 2021; Amir, Muhammad Subhan/R 2508 2017
OI Kusuyama, Joji/0000 0003 4054 1939; Bandow, Kenjiro/0000 0002 1362 3034;
   Amir, Muhammad Subhan/0000 0002 0522 9758
FU Ministry of Education, Culture, Sports, Science and Technology, Japan;
   Young Investigator Foundation of Japanese Association of Oral Biology;
   Kanzawa medical research foundation; Nakatomi foundation; Japan
   Foundation for Aging and Health; Grants in Aid for Scientific Research
   [15K20375, 17K11676] Funding Source: KAKEN
FX Ministry of Education, Culture, Sports, Science and Technology, Japan;
   Young Investigator Foundation of Japanese Association of Oral Biology;
   Kanzawa medical research foundation; Nakatomi foundation; The Japan
   Foundation for Aging and Health
CR Almeida M, 2009, J BIOL CHEM, V284, P27438, DOI 10.1074/jbc.M109.023572
   Belov AA, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003576
   Bethel M, 2013, CURR OSTEOPOROS REP, V11, P99, DOI 10.1007/s11914 013 0135 6
   Bielby R, 2007, INJURY, V38, pS26, DOI 10.1016/j.injury.2007.02.007
   Bonilla FA, 2000, P NATL ACAD SCI USA, V97, P1725, DOI 10.1073/pnas.040543597
   Bredella MA, 2011, OBESITY, V19, P49, DOI 10.1038/oby.2010.106
   Caplan AI, 2017, STEM CELL TRANSL MED, V6, P1445, DOI 10.1002/sctm.17 0051
   Carsetti L, 2009, CELL SIGNAL, V21, P1187, DOI 10.1016/j.cellsig.2009.03.007
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0
   Fajas L, 1998, CURR OPIN CELL BIOL, V10, P165, DOI 10.1016/S0955 0674(98)80138 5
   Hinoi E, 2006, J BIOL CHEM, V281, P18015, DOI 10.1074/jbc.M600603200
   Isenmann S, 2009, STEM CELLS, V27, P2457, DOI 10.1002/stem.181
   Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074 7613(00)80012 6
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kajkenova O, 1997, J BONE MINER RES, V12, P1772, DOI 10.1359/jbmr.1997.12.11.1772
   Kusuyama J, 2017, MOL BIOL CELL, V28, P1326, DOI 10.1091/mbc.E16 10 0716
   Kusuyama J, 2016, J LIPID RES, V57, P1806, DOI 10.1194/jlr.M067207
   Kusuyama J, 2014, J BIOL CHEM, V289, P10330, DOI 10.1074/jbc.M113.546382
   Kwon JY, 2012, J BIOL CHEM, V287, P11566, DOI 10.1074/jbc.M111.259721
   Law CL, 1996, MOL CELL BIOL, V16, P1305
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Mócsai A, 2010, NAT REV IMMUNOL, V10, P387, DOI 10.1038/nri2765
   Moerman EJ, 2004, AGING CELL, V3, P379, DOI 10.1111/j.1474 9728.2004.00127.x
   Nakura A, 2011, BONE, V48, P476, DOI 10.1016/j.bone.2010.09.238
   Patsch JM, 2013, J BONE MINER RES, V28, P1721, DOI 10.1002/jbmr.1950
   Pine PR, 2007, CLIN IMMUNOL, V124, P244, DOI 10.1016/j.clim.2007.03.543
   Robey Pamela, 2017, F1000Res, V6, DOI 10.12688/f1000research.10955.1
   Schwartz AV, 2013, J CLIN ENDOCR METAB, V98, P2294, DOI 10.1210/jc.2012 3949
   Simon M, 2005, J BIOL CHEM, V280, P4510, DOI 10.1074/jbc.M410326200
   Sun HJ, 2006, J ORTHOP RES, V24, P2059, DOI 10.1002/jor.20273
   Suzuki A, 2000, J BONE MINER RES, V15, P95, DOI 10.1359/jbmr.2000.15.1.95
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Webb PR, 2003, CELL MOL LIFE SCI, V60, P1504, DOI 10.1007/s00018 003 2337 z
   Wilde JI, 2001, CELL SIGNAL, V13, P691, DOI 10.1016/S0898 6568(01)00191 7
   Xu SL, 2006, J IMMUNOL, V176, P4690, DOI 10.4049/jimmunol.176.8.4690
   Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yoshida K, 2011, BIOCHEM BIOPH RES CO, V411, P774, DOI 10.1016/j.bbrc.2011.07.023
   Yu YH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161993
   Zaidi SK, 2004, EMBO J, V23, P790, DOI 10.1038/sj.emboj.7600073
   Zhang J, 2000, J BIOL CHEM, V275, P35442, DOI 10.1074/jbc.M004549200
   Zhang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076464
   Zhou YR, 2006, INT J BIOCHEM CELL B, V38, P2151, DOI 10.1016/j.biocel.2006.06.009
   Zou W, 2007, J CELL BIOL, V176, P877, DOI 10.1083/jcb.200611083
NR 46
TC 12
Z9 14
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2018
VL 233
IS 3
BP 2549
EP 2559
DI 10.1002/jcp.26130
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA GH5ZZ
UT WOS:000433519300070
PM 28786489
DA 2025 08 17
ER

PT J
AU Wu, ZK
   Yuan, K
   Zhang, Q
   Guo, JJ
   Yang, HL
   Zhou, F
AF Wu, Zhikai
   Yuan, Kai
   Zhang, Qian
   Guo, Jiong Jiong
   Yang, Huilin
   Zhou, Feng
TI Antioxidant PDA PEG nanoparticles alleviate early osteoarthritis by
   inhibiting osteoclastogenesis and angiogenesis in subchondral bone
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE PDA PEG NPs; Osteoarthritis; Osteoclastogenesis; Angiogenesis; ROS;
   PDGF BB
ID SIGNAL TRANSDUCTION; DIFFERENTIATION; CHONDROCYTES; ACTIVATION;
   MANAGEMENT; DOPAMINE; MODELS; NFATC1
AB Accumulating evidence suggests that osteoclastogenesis and angiogenesis in subchondral bone are critical destructive factors in the initiation and progression of osteoarthritis (OA). Herein, methoxypolyethylene glycol amine (mPEG NH2) modified polydopamine nanoparticles (PDA PEG NPs) were synthesized for treating early OA. The cytotoxicity and reactive oxygen species (ROS) scavenging ability of PDA PEG NPs were evaluated. The effects of PDA PEG NPs on osteoclast differentiation and vessel formation were then evaluated. Further, PDA PEG NPs were administrated to anterior cruciate ligament transection (ACLT) induced OA mice. Results demonstrated that PDA PEG NPs had low toxicity both in vitro and in vivo. PDA PEG NPs could inhibit osteoclastogenesis via regulating nuclear factor kappa B (NF kappa B) and mitogen activated protein kinase (MAPK) signaling pathways. Moreover, PDA PEG NPs suppressed osteoclast related angiogenesis via down regulating platelet derived growth factor BB (PDGF BB). In vivo, PDA PEG NPs inhibited subchondral bone resorption and angiogenesis, further rescuing cartilage degradation in OA mice. In conclusion, we demonstrated that PDA PEG NPs deployment could be a potential therapy for OA.
C1 [Wu, Zhikai; Zhang, Qian; Guo, Jiong Jiong; Yang, Huilin; Zhou, Feng] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 899 Ping Hai Rd, Suzhou, Jiangsu, Peoples R China.
   [Wu, Zhikai; Zhou, Feng] Soochow Univ, Orthopaed Inst, Suzhou, Jiangsu, Peoples R China.
   [Yuan, Kai] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med,Dept Orthopaed Surg, Shanghai Key Lab Orthopaed Implants, Shanghai, Peoples R China.
C3 Soochow University   China; Soochow University   China; Shanghai Jiao
   Tong University
RP Guo, JJ; Yang, HL; Zhou, F (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed Surg, 899 Ping Hai Rd, Suzhou, Jiangsu, Peoples R China.; Zhou, F (通讯作者)，Soochow Univ, Orthopaed Inst, Suzhou, Jiangsu, Peoples R China.
EM drjjguo@163.com; suzhouspine@163.com; sdfyyzhoufeng@163.com
OI Zhou, Feng/0009 0002 2010 1450; Guo, Jiong Jiong/0000 0002 3751 5791
FU National Natural Science Foundation of China [82102606]; Natural Science
   Foundation of Jiangsu Province [BK20210093]; Project of Science and
   Technology Development Plan of Suzhou [SKJYD2021081]
FX This work was supported by the National Natural Science Foundation of
   China (82102606), the Natural Science Foundation of Jiangsu Province
   (BK20210093), the Project of Science and Technology Development Plan of
   Suzhou (SKJYD2021081).
CR Abu Amer Y, 2013, OSTEOPOROSIS INT, V24, P2377, DOI 10.1007/s00198 013 2313 x
   Bao XF, 2018, ACS NANO, V12, P8882, DOI 10.1021/acsnano.8b04022
   Bellido M, 2011, OSTEOARTHR CARTILAGE, V19, P1228, DOI 10.1016/j.joca.2011.07.003
   Bijlsma JWJ, 2011, LANCET, V377, P2115, DOI 10.1016/S0140 6736(11)60243 2
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Chen YH, 2018, DALTON T, V47, P2435, DOI 10.1039/c7dt04080f
   Cui Z, 2016, ANN RHEUM DIS, V75, P1714, DOI 10.1136/annrheumdis 2015 207923
   Daugaard R, 2018, J ORTHOP TRANSL, V14, P8, DOI 10.1016/j.jot.2018.03.001
   Dong ZL, 2016, THERANOSTICS, V6, P1031, DOI 10.7150/thno.14431
   Findlay DM, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.28
   Finkel T, 2012, J BIOL CHEM, V287, P4434, DOI 10.1074/jbc.R111.271999
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Gao NS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00270
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Goldring SR, 2016, NAT REV RHEUMATOL, V12, P632, DOI 10.1038/nrrheum.2016.148
   Han JK, 2018, J CELL BIOCHEM, V119, P7310, DOI 10.1002/jcb.27028
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hawker GA, 2011, OSTEOARTHR CARTILAGE, V19, P366, DOI 10.1016/j.joca.2011.01.021
   Hayami T, 2012, BONE, V50, P1250, DOI 10.1016/j.bone.2012.03.025
   Hemlata Gupta S., 2021, ACS OMEGA, V6, P10383, DOI DOI 10.1021/acsomega.1c00755
   Herrero Beaumont G, 2013, NAT REV RHEUMATOL, V9, P448, DOI 10.1038/nrrheum.2013.113
   Hochberg MC, 2012, ARTHRIT CARE RES, V64, P465, DOI 10.1002/acr.21596
   Hu ZA, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00174
   Hügle T, 2017, RHEUMATOLOGY, V56, P1461, DOI 10.1093/rheumatology/kew389
   Jodko Piórecka K, 2015, FREE RADICAL BIO MED, V83, P1, DOI 10.1016/j.freeradbiomed.2015.02.006
   Kapoor M, 2011, NAT REV RHEUMATOL, V7, P33, DOI 10.1038/nrrheum.2010.196
   Kim K, 2010, J IMMUNOL, V185, P7460, DOI 10.4049/jimmunol.1000885
   Kong XY, 2015, INT J BIOL SCI, V11, P1204, DOI 10.7150/ijbs.12296
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lee W, 2018, J NAT PROD, V81, P1343, DOI 10.1021/acs.jnatprod.7b00927
   Lems WF, 2018, ANN RHEUM DIS, V77, P1247, DOI 10.1136/annrheumdis 2017 212364
   Liu MR, 2017, BIOMED PHARMACOTHER, V95, P914, DOI 10.1016/j.biopha.2017.09.011
   Liu YL, 2014, CHEM REV, V114, P5057, DOI 10.1021/cr400407a
   Longo Umile Giuseppe, 2012, Open Orthop J, V6, P558, DOI 10.2174/1874325001206010558
   Lorenz J, 2014, METHODS MOL BIOL, V1194, P401, DOI 10.1007/978 1 4939 1215 5_23
   Luo HY, 2015, RSC ADV, V5, P13470, DOI 10.1039/c4ra16469e
   Madry H, 2010, KNEE SURG SPORT TR A, V18, P419, DOI 10.1007/s00167 010 1054 z
   Mapp PI, 2010, OSTEOARTHR CARTILAGE, V18, P593, DOI 10.1016/j.joca.2009.12.006
   McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003
   Melcarne L, 2016, EXPERT REV GASTROENT, V10, P723, DOI 10.1586/17474124.2016.1142872
   Molfetta L, 2022, CURR RHEUMATOL REV, V18, P2, DOI 10.2174/1573397117666211006094117
   Mu WB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00269
   Munteanu IG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073380
   Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014
   Qiao H, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.11
   Reed KN, 2014, MOL CELL BIOCHEM, V397, P195, DOI 10.1007/s11010 014 2187 z
   Shanmugasundaram S, 2021, INT ORTHOP, V45, P615, DOI 10.1007/s00264 020 04926 x
   Shen C, 2015, OSTEOARTHR CARTILAGE, V23, P2279, DOI 10.1016/j.joca.2015.06.020
   Siebelt M, 2014, BONE, V66, P163, DOI 10.1016/j.bone.2014.06.009
   Sniekers YH, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 20
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Tao HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023199
   Wang TY, 2020, DIABETES RES CLIN PR, V165, DOI 10.1016/j.diabres.2020.108140
   Wang TY, 2021, SMALL, V17, DOI 10.1002/smll.202102485
   Wu D, 2021, CHEM SOC REV, V50, P4432, DOI 10.1039/d0cs00908c
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Yang P, 2021, CHEM SOC REV, V50, P8319, DOI 10.1039/d1cs00374g
   Yang P, 2020, CCS CHEM, V2, P128, DOI 10.31635/ccschem.020.201900077
   Zhao CJ, 2017, BIOMED PHARMACOTHER, V96, P410, DOI 10.1016/j.biopha.2017.10.018
   Zhao DY, 2021, BIOACT MATER, V6, P346, DOI 10.1016/j.bioactmat.2020.08.016
   Zhao H, 2018, NANOSCALE, V10, P6981, DOI 10.1039/c8nr00838h
   Zheng LL, 2021, AGEING RES REV, V66, DOI 10.1016/j.arr.2020.101249
   Zheng ZY, 2021, CELL DEATH DIFFER, V28, P2001, DOI 10.1038/s41418 020 00731 6
   Zhou F, 2019, J CELL MOL MED, V23, P4395, DOI 10.1111/jcmm.14333
   Zhou JJ, 2020, ACCOUNTS CHEM RES, V53, P1269, DOI 10.1021/acs.accounts.0c00150
   Zhu TT, 2022, BIOACT MATER, V9, P446, DOI 10.1016/j.bioactmat.2021.08.005
   Zhu TT, 2020, BIOACT MATER, V5, P584, DOI 10.1016/j.bioactmat.2020.04.008
   Zhu XB, 2019, ANN RHEUM DIS, V78, P1420, DOI 10.1136/annrheumdis 2018 214940
NR 69
TC 41
Z9 42
U1 7
U2 68
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477 3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD NOV 16
PY 2022
VL 20
IS 1
AR 479
DI 10.1186/s12951 022 01697 y
PG 17
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology   Other
   Topics
GA 6H9OQ
UT WOS:000885760200007
PM 36384720
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Deepak, V
   Wang, BL
   Koot, D
   Kasonga, A
   Stander, XX
   Coetzee, M
   Stander, A
AF Deepak, Vishwa
   Wang, Binglin
   Koot, Dwayne
   Kasonga, Abe
   Stander, Xiao Xing
   Coetzee, Magdalena
   Stander, Andre
TI In silico design and bioevaluation of selective benzotriazepine BRD4
   inhibitors with potent antiosteoclastogenic activity
SO CHEMICAL BIOLOGY & DRUG DESIGN
LA English
DT Article
DE mechanism based drug design; molecular modeling; structure based drug
   design
ID CARBONIC ANHYDRASE II; HIGH THROUGHPUT; OSTEOCLAST DIFFERENTIATION;
   MOLECULAR DYNAMICS; BONE RESORPTION; BET; DISCOVERY; OPTIMIZATION;
   REGULATOR; UPDATE
AB The bromodomain (BRD) and extra terminal domain (BET) protein family bind to acetylated histones on lysine residues and act as epigenetic readers. Recently, the role of this protein family in bone loss has been gaining attention. Earlier studies have reported that benzotriazepine (Bzt) derivatives could be effective inhibitors of BET proteins. In this study, using in silico tools we designed three Bzt analogs (W49, W51, and W52). By docking, molecular simulations, and chemiluminescent Alpha Screen binding assay, we show that the studied analogs were selective at inhibiting BRD4 when compared to BRD2. Furthermore, we tested the effectiveness of these analogs on osteoclast formation and function. Among the examined analogs, Bzt W49 and Bzt W52 were found to be the most potent inhibitors of osteoclastogenesis without cytotoxicity in murine RAW264.7 osteoclast progenitors. Both the compounds also inhibited osteoclast formation without affecting cell viability in human CD14+ monocytes. Moreover, owing to attenuated osteoclastogenesis, actin ring formation and bone resorptive function of osteoclasts were severely perturbed. In conclusion, these results suggest that the novel BRD4 selective Bzt analogs designed in this study could be explored further for developing therapeutics against bone loss diseases characterized by excessive osteoclast activity.
C1 [Deepak, Vishwa; Kasonga, Abe; Coetzee, Magdalena; Stander, Andre] Univ Pretoria, Dept Physiol, Fac Hlth Sci, Pretoria, South Africa.
   [Wang, Binglin] WuXi AppTec Wuhan Co Ltd, Wuhan, Peoples R China.
   [Koot, Dwayne] Univ Pretoria, Dept Chem, Fac Nat & Agr Sci, Pretoria, South Africa.
   [Stander, Xiao Xing] Univ Pretoria, Dept Gen Surg, Fac Hlth Sci, Pretoria, South Africa.
   [Coetzee, Magdalena] Univ Pretoria, Inst Food Nutr & Well Being, Pretoria, South Africa.
   [Deepak, Vishwa] Natl Univ Ireland, Coll Engn & Informat, Dept Biomed Engn, Biomech Res Ctr, Galway, Ireland.
C3 University of Pretoria; University of Pretoria; University of Pretoria;
   University of Pretoria; Ollscoil na Gaillimhe University of Galway
RP Stander, A (通讯作者)，Univ Pretoria, Dept Physiol, Pretoria, South Africa.
EM andre.stander@up.ac.za
RI Deepak, Vishwa/I 3416 2014; Kasonga, Abe/I 4548 2019
OI Coetzee, Magdalena/0000 0002 5815 9247; Kasonga,
   Abe/0000 0001 7379 6044; 
FU University of Pretoria [A0X456]; University of Pretoria; Research and
   Development Programme of the University of Pretoria [A0W716]; National
   Research Foundation Thuthuka fund [A0X456, N00521]; Creative Flavors
   International [A0X444]
FX University of Pretoria, Grant/Award Number: A0X456; University of
   Pretoria Vice Chancellor's Postdoctoral Research Fellowship; Research
   and Development Programme of the University of Pretoria, Grant/Award
   Number: A0W716; National Research Foundation Thuthuka fund, Grant/Award
   Number: A0X456 and N00521; Creative Flavors International, Grant/Award
   Number: A0X444.
CR Agrawal A, 2012, METHODS MOL BIOL, V806, P357, DOI 10.1007/978 1 61779 367 7_23
   Archin NM, 2014, CURR OPIN INFECT DIS, V27, P29, DOI 10.1097/QCO.0000000000000026
   Baker NA, 2001, P NATL ACAD SCI USA, V98, P10037, DOI 10.1073/pnas.181342398
   Banerjee C, 2012, J LEUKOCYTE BIOL, V92, P1147, DOI 10.1189/jlb.0312165
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Bickerton GR, 2012, NAT CHEM, V4, P90, DOI [10.1038/NCHEM.1243, 10.1038/nchem.1243]
   Boeyens JCA, 2014, NUTRIENTS, V6, P2584, DOI 10.3390/nu6072584
   Bussi G, 2007, J CHEM PHYS, V126, DOI 10.1063/1.2408420
   Cheng TJ, 2012, AAPS J, V14, P133, DOI 10.1208/s12248 012 9322 0
   Chung CW, 2011, J MED CHEM, V54, P3827, DOI 10.1021/jm200108t
   DARDEN T, 1993, J CHEM PHYS, V98, P10089, DOI 10.1063/1.464397
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Deepak V, 2015, CONNECT TISSUE RES, V56, P195, DOI 10.3109/03008207.2014.989320
   Filippakopoulos P, 2012, BIOORGAN MED CHEM, V20, P1878, DOI 10.1016/j.bmc.2011.10.080
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Gehling VS, 2013, ACS MED CHEM LETT, V4, P835, DOI 10.1021/ml4001485
   Helfrich MH, 2003, MICROSC RES TECHNIQ, V61, P514, DOI 10.1002/jemt.10375
   Hess B, 2008, J CHEM THEORY COMPUT, V4, P116, DOI 10.1021/ct700200b
   Jämbeck JPM, 2014, J PHYS CHEM B, V118, P3793, DOI 10.1021/jp4111234
   Kasonga AE, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125145
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Kumari R, 2014, J CHEM INF MODEL, V54, P1951, DOI 10.1021/ci500020m
   LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817
   Lamoureux F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4511
   Lehenkari P, 1998, EXP CELL RES, V242, P128, DOI 10.1006/excr.1998.4071
   Li CY, 2006, J BONE MINER RES, V21, P865, DOI 10.1359/JBMR.060313
   Li ZC, 2013, NUCLEIC ACIDS RES, V41, P277, DOI 10.1093/nar/gks976
   Lindorff Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Matzuk MM, 2012, CELL, V150, P673, DOI 10.1016/j.cell.2012.06.045
   Meng S, 2014, J DENT RES, V93, P657, DOI 10.1177/0022034514534261
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Mirguet O, 2013, J MED CHEM, V56, P7501, DOI 10.1021/jm401088k
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nickolls John, 2008, ACM Queue, V6, DOI 10.1145/1365490.1365500
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   NOSE S, 1983, MOL PHYS, V50, P1055, DOI 10.1080/00268978300102851
   OBOYLE NM, 2011, J CHEMINFORMATICS, V3, DOI DOI 10.1186/1758 2946 3 33
   Park Min KH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6418
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Puranen JS, 2010, J COMPUT CHEM, V31, P1722, DOI 10.1002/jcc.21460
   Ruiz Carmona S, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003571
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Song I, 2009, FEBS LETT, V583, P2435, DOI 10.1016/j.febslet.2009.06.047
   Figueira Thais Rezende e Silva, 2012, BMC Res Notes, V5, P185, DOI [10.1186/1756 0500 5 367, 10.1186/1756 0500 5 185]
   Soysa NS, 2009, BIOCHEM BIOPH RES CO, V378, P1, DOI 10.1016/j.bbrc.2008.10.146
   Troen BR, 2006, ANN NY ACAD SCI, V1068, P165, DOI 10.1196/annals.1346.018
   Truhlar DG, 2007, J COMPUT CHEM, V28, P73, DOI 10.1002/jcc.20529
   Vainio MJ, 2007, J CHEM INF MODEL, V47, P2462, DOI 10.1021/ci6005646
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Yagi M, 2005, J EXP MED, V202, P345, DOI 10.1084/jem.20050645
NR 52
TC 9
Z9 11
U1 1
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1747 0277
EI 1747 0285
J9 CHEM BIOL DRUG DES
JI Chem. Biol. Drug Des.
PD JUL
PY 2017
VL 90
IS 1
BP 97
EP 111
DI 10.1111/cbdd.12930
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA FA0DX
UT WOS:000405102600008
PM 28032455
DA 2025 08 17
ER

PT J
AU Hinshaw, WB
   Quin, LD
AF Hinshaw, William Banks
   Quin, Louis DuBose
TI RECOGNITION OF THE CAUSATIVE AGENT OF "PHOSSY JAW" AND "FRAGILE FEMUR"
   IN FUMES ARISING FROM WHITE PHOSPHORUS
SO PHOSPHORUS SULFUR AND SILICON AND THE RELATED ELEMENTS
LA English
DT Article; Proceedings Paper
CT IRIS 14th International Symposium on Inorganic Ring Systems
CY JUL 26 31, 2015
CL Univ Regensburg, Regensburg, GERMANY
SP FCI, DFG, RSC, ChemComm, Dalton Transact, MBRAUN, Infineon, Heidolph, SIGMA, Taylor & Francis, Wiley Vch, IRIS
HO Univ Regensburg
DE Phossy jaw; white phosphorus; osteonecrosis of the jaws; atypical femur
   fractures; bisphosphonates; pyrophosphoric acid
ID BONE RESORPTION; PARATHYROID HORMONE; AMERICAN SOCIETY; TISSUE CULTURE;
   TASK FORCE; IN VITRO; PYROPHOSPHATE; DIPHOSPHONATES; FRACTURES;
   HYDROXYAPATITE
AB Exposure to the fumes and smoke from white phosphorus pastes in the strike anywhere match industry was associated, in the latter half of the 19th century, with a low incidence of necrotic lesions of the jaw bones and/or a fragility of the mid femur occasioning fractures after minor trauma. Hundreds of cases were reported in many countries. The plight of these workers was the subject of international social pressure eventually leading to the prohibition of the matches. The reappearance in the early 21st century of two similar maladies associated with bisphosphonic acid (BP) medications led us to investigate the potential connection between these two pairs of debilitating effects. The BP molecules were chosen for development beginning in the early 1970s as pharmacologically satisfactory analogs of a simple inorganic phosphorus compound, pyrophosphoric acid, which had been found to exert an inhibitory effect on bone dissolution in vitro. These BPs inhibited bone loss in vivo. Independently, chemical analyses published in the mid 1980s demonstrated that the original small inorganic phosphorus model molecule was the most prevalent substance in the complex fumes and smoke associated with the pair of legacy diseases, thus persuasively connecting it, mediated by a common biological mechanism, to the modern drug side effects.
C1 [Hinshaw, William Banks] Markle & Hinshaw Gynecol, Franklin, NC 28734 USA.
   [Hinshaw, William Banks] Harris Reg Hosp, Franklin, NC 28734 USA.
   [Quin, Louis DuBose] Duke Univ, Dept Chem, Durham, NC 27706 USA.
C3 Duke University
RP Hinshaw, WB (通讯作者)，Markle & Hinshaw Gynecol, 7190 Ellijay Rd, Franklin, NC 28734 USA.
EM williambh@frontier.com
OI Hinshaw, William/0000 0001 9226 5724
CR [Anonymous], 1982, Great Britain patent, Patent No. [2,118,042, 2118042]
   Ashcroft J, 2006, LANCET ONCOL, V7, P447, DOI 10.1016/S1470 2045(06)70704 5
   Birmingham P, 2008, CLIN ORTHOP RELAT R, V466, P2002, DOI 10.1007/s11999 008 0256 x
   BISAZ S, 1978, CLIN SCI MOL MED, V54, P265, DOI 10.1042/cs0540265
   Brazell R. S., 1984, CHEM PHYS CHARACTERI, P42
   Clarke B. L., ASBMR ANN M
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Dearden W. F., 1899, BMJ BRIT MED J, P270
   Dearden WF, 1901, BMJ BRIT MED J, V2, P408
   DELONG A, 1971, CALC TISS RES, V8, P87, DOI 10.1007/BF02010125
   Diz P, 2012, J AM DENT ASSOC, V143, P981, DOI 10.14219/jada.archive.2012.0323
   Dunford JE, 2008, J MED CHEM, V51, P2187, DOI 10.1021/jm7015733
   Emsley J., 2000, The 13th element
   Eriksen EF, 2007, J BONE MINER RES, V22, P1, DOI 10.1359/JBMR.060910
   Evans K D, 2009, Open Orthop J, V3, P83, DOI 10.2174/1874325000903010083
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH H, 1966, P SOC EXP BIOL MED, V122, P317
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Gotscher J. E., 1981, J PERIODONTAL RES, V16, P331
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Handley D. A., 2012, INT J CLIN PRACT, V66, P1139
   Hinshaw W. B, 2007, ASBMR TOP M DEC
   Hinshaw WB, 2013, ACS MED CHEM LETT, V4, P2, DOI 10.1021/ml300430j
   HUGHES JPW, 1962, BRIT J IND MED, V19, P83
   ISITMAN AT, 1988, J NUCL MED, V29, P1761
   JUNG A, 1970, AM J PHYSIOL, V218, P1757, DOI 10.1152/ajplegacy.1970.218.6.1757
   Kabachnik M. I., 1978, IAN SSSR KH, V2, P433
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   Lewenhak Sheila., 1977, WOMEN TRADE UNIONS O
   Lewis W, 1855, REPORT FRENCH LAWS R, P109
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Marx RE, 2008, J ORAL MAXIL SURG, V66, P2356, DOI 10.1016/j.joms.2007.11.006
   MUHLBAUER RC, 1971, EUR J CLIN INVEST, V1, P336, DOI 10.1111/j.1365 2362.1971.tb00640.x
   Mukherjee S, 2008, J AM CHEM SOC, V130, P1264, DOI 10.1021/ja0759949
   Odvina C. V., 2003, ASBMR ANN M
   REYNOLDS JJ, 1973, CALC TISS RES, V12, P59, DOI 10.1007/BF02013722
   RUSSELL RGG, 1970, CALC TISS RES, V6, P183, DOI 10.1007/BF02196199
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   SCHENK R, 1973, CALC TISS RES, V11, P196, DOI 10.1007/BF02547219
   Schneider JP, 2012, J CLIN ENDOCR METAB, V97, P4324, DOI 10.1210/jc.2012 2590
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Spanggord R. J., ENV FATE WHITE PHOSP, P68
   Thorpe T. E., 1898, REPORTS USE PHOSPHOR
   Von Stubenrauch L., 1899, ARK KLIN CHIRURG, V59, P144
   Ward Emma F., 1928, Journal of Industrial Hygiene, V10, P314
   Whyte MP, 2008, J BONE MINER RES, V23, P1698, DOI 10.1359/JBMR.080511
NR 48
TC 5
Z9 5
U1 0
U2 17
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1042 6507
EI 1563 5325
J9 PHOSPHORUS SULFUR
JI Phosphorus Sulfur Silicon Relat. Elem.
PD DEC 2
PY 2015
VL 190
IS 12
SI SI
BP 2082
EP 2093
DI 10.1080/10426507.2015.1071818
PG 12
WC Chemistry, Inorganic & Nuclear; Chemistry, Organic
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Chemistry
GA CY3OR
UT WOS:000366319600005
DA 2025 08 17
ER

PT J
AU Wang, CF
   Lei, J
   Mao, CY
   Wu, SL
   Zheng, YF
   Liang, CY
   Yang, L
   Zhu, SL
   Li, ZY
   Jiang, H
   Zhang, Y
   Yang, C
   Liu, XM
AF Wang, Chaofeng
   Lei, Jie
   Mao, Congyang
   Wu, Shuilin
   Zheng, Yufeng
   Liang, Chunyong
   Yang, Lei
   Zhu, Shengli
   Li, Zhaoyang
   Jiang, Hui
   Zhang, Yu
   Yang, Cao
   Liu, Xiangmei
TI Defective S TiO2 x/CeO2 Heterojunction for
   Mutual Reinforcing Chemodynamic/Sonocatalytic Antibacterial Therapy and
   Sonoelectric/Ion Activated Bone Regeneration
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bone regeneration; chemodynamic/sonocatalytic antibacterial therapy;
   defective S TiO2 x/CeO2; osteomyelitis; Wnt/beta catenin signaling
   pathway
ID TIO2; PERFORMANCE; IMPLANTS
AB Sonocatalysis and chemodynamics have attracted widespread attention in antibacterial therapy. The transfer efficiency of electrons plays an important role in sonocatalysis and chemodynamics, and how to regulate electron transfer and achieve mutual reinforcement between sonocatalysis and chemodynamic to achieve efficient antibacterial therapy is a difficult problem. Here, this study develops a defective S doped TiO2 and CeO2 heterojunction(S TiO2 x/CeO2)sonosensitizer that can enhance chemodynamic therapy by regulating valence transitions of CeIII/CeIV by sonoelectrons, and enhancing sonocatalytic therapy by creating heterojunctions to accelerate the transfer of interface electron, thereby achieving mutual reinforcement of sonocatalysis and chemodynamic. It could kill 99.3% of S. aureus under ultrasound (US) irradiation . Due to the presence of mixed valence states Ce III/Ce IV in CeO2, S TiO2 x/CeO2 could be as oxy substrates. Ce4+ can deplete glutathione and reacts with H2O2 in bacteria to produce reactive oxygen species (ROS). These activities combines with ROS generated from sonocatalysis, resulting in bacterial death. Meanwhile, the electrical signal generated by S TiO2 x/CeO2 under US stimulation and the cerium ions could activate the Wnt/beta catenin signaling pathway to induce hBMSCs to differentiate into osteoblast. S TiO2 x/CeO2 successfully treats osteomyelitis under US irradiation by effectively clearing infection, suppressing inflammatory, and promoting bone regeneration, and it provides effective treatment for patients with deep infection.
C1 [Wang, Chaofeng; Liang, Chunyong; Yang, Lei; Liu, Xiangmei] Hebei Univ Technol, Sch Hlth Sci & Biomed Engn, Tianjin 300131, Peoples R China.
   [Wang, Chaofeng; Mao, Congyang; Wu, Shuilin; Liu, Xiangmei] Hubei Univ, Biomed Mat Engn Res Ctr, Sch Mat Sci & Engn, Hubei Key Lab Polymer Mat,Minist Educ,Key Lab Gree, Wuhan 430062, Peoples R China.
   [Lei, Jie; Yang, Cao] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.
   [Wu, Shuilin; Zheng, Yufeng] Peking Univ, Sch Mat Sci & Engn, Yiheyuan Rd 5, Beijing 100871, Peoples R China.
   [Wu, Shuilin; Zhu, Shengli; Li, Zhaoyang; Jiang, Hui] Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ China, Yaguan Rd 135, Tianjin 300072, Peoples R China.
   [Zhang, Yu] Guangdong Acad Med Sci, Guangdong Prov Peoples Hosp, Dept Orthoped, Zhongshan 2nd Rd 106, Guangzhou 510080, Peoples R China.
C3 Hebei University of Technology; Hubei University; Huazhong University of
   Science & Technology; Peking University; Tianjin University; Southern
   Medical University   China; Guangdong Academy of Medical Sciences &
   Guangdong General Hospital
RP Liang, CY; Liu, XM (通讯作者)，Hebei Univ Technol, Sch Hlth Sci & Biomed Engn, Tianjin 300131, Peoples R China.; Wu, SL; Liu, XM (通讯作者)，Hubei Univ, Biomed Mat Engn Res Ctr, Sch Mat Sci & Engn, Hubei Key Lab Polymer Mat,Minist Educ,Key Lab Gree, Wuhan 430062, Peoples R China.; Yang, C (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthopaed, Wuhan 430022, Peoples R China.; Wu, SL (通讯作者)，Peking Univ, Sch Mat Sci & Engn, Yiheyuan Rd 5, Beijing 100871, Peoples R China.; Wu, SL (通讯作者)，Tianjin Univ, Sch Mat Sci & Engn, Key Lab Adv Ceram & Machining Technol, Minist Educ China, Yaguan Rd 135, Tianjin 300072, Peoples R China.
EM slwu@pku.edu.cn; liangchunyong@hebut.edu.cn; Caoyangunion@hust.edu.cn;
   liuxiangmei@hebut.edu.cn
RI Wang, Chaofeng/AHD 5201 2022; Zhu, Shengli/D 5281 2009; Li,
   Zhaoyang/JPA 0792 2023; wu, shuilin/GXN 1506 2022; Ray,
   Zit/KUF 2232 2024; Zheng, Yufeng/KLE 9098 2024; Xiangmei,
   Liu/LUZ 0868 2024; wu, shuilin/LUZ 0692 2024
OI liu, xiangmei/0000 0002 6469 2363; Yang, Cao/0000 0002 0058 614X; wu,
   shuilin/0000 0002 1270 1870; Zheng, Y.F./0000 0002 7402 9979
FU C.W. and J.L. contributed equally to this work. This work is jointly
   supported by the national Natural Science Foundation of China (Nos.
   52173251), the China National Funds for Distinguished Young Scientists
   (No.51925104), the Central Guidance on Local Sci [51925104]; national
   Natural Science Foundation of China [52173251]; China National Funds for
   Distinguished Young Scientists [2021A1515220093]; Central Guidance on
   Local Science and Technology Development Fund of Hebei Province
   [2022A1515011536, 82130072]; Guangdong Basic and Applied Basic Research
   Foundation [82072505, U21A2084]; National Natural Science Foundation of
   China; NSFC Guangdong Province Joint Program
FX C.W. and J.L. contributed equally to this work. This work is jointly
   supported by the national Natural Science Foundation of China (Nos.
   52173251), the China National Funds for Distinguished Young Scientists
   (No.51925104), the Central Guidance on Local Science and Technology
   Development Fund of Hebei Province (226Z1303G), Guangdong Basic and
   Applied Basic Research Foundation (2021A1515220093, 2022A1515011536),
   the National Natural Science Foundation of China (82130072, 82072505),
   NSFC Guangdong Province Joint Program (Key program no. U21A2084).
CR Cai PF, 2022, RARE METALS, V41, P4138, DOI 10.1007/s12598 022 02096 w
   Calvo P. J., 2020, Nano Energy, V75
   Cao LJ, 2023, MATER HORIZ, V10, P1342, DOI 10.1039/d2mh01540d
   Cao X., 2023, Adv. Sci, V10
   Cao XS, 2023, SMALL, V19, DOI 10.1002/smll.202303195
   Chen DM, 2022, NANO MICRO LETT, V14, DOI 10.1007/s40820 022 00912 7
   Dong ZL, 2020, CHEM US, V6, P1391, DOI 10.1016/j.chempr.2020.02.020
   Fu JN, 2019, ACS NANO, V13, P13581, DOI 10.1021/acsnano.9b08115
   Fu JN, 2020, ACTA BIOMATER, V101, P152, DOI 10.1016/j.actbio.2019.10.041
   Gong PJ, 2019, CHEM ENG J, V356, P598, DOI 10.1016/j.cej.2018.09.042
   Han ZX, 2021, RARE METALS, V40, P2538, DOI 10.1007/s12598 020 01667 z
   He HN, 2018, ADV MATER, V30, DOI 10.1002/adma.201801013
   He Y, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801254
   Jia GR, 2022, MATTER US, V5, P206, DOI 10.1016/j.matt.2021.10.027
   Jiang ZC, 2023, J MATER SCI TECHNOL, V162, P1, DOI 10.1016/j.jmst.2023.03.045
   Khalid AB, 2016, BONE, V87, P130, DOI 10.1016/j.bone.2016.03.016
   Lei J, 2022, CHEM ENG J, V435, DOI 10.1016/j.cej.2022.134624
   Li J, 2023, ADV MATER, V35, DOI 10.1002/adma.202210342
   Li W, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121063
   Li XL, 2022, ADV FIBER MATER, V4, P1620, DOI 10.1007/s42765 022 00189 w
   Li Y, 2016, BIOMATERIALS, V106, P250, DOI 10.1016/j.biomaterials.2016.08.031
   Li YY, 2022, SMALL, V18, DOI 10.1002/smll.202107594
   Liang S, 2021, ADV MATER, V33, DOI 10.1002/adma.202100333
   Liu QY, 2022, ADV SCI, V9, DOI 10.1002/advs.202200005
   Lu B, 2019, BIOFABRICATION, V11, DOI 10.1088/1758 5090/ab0676
   Luo JC, 2023, BIOL TRACE ELEM RES, V201, P865, DOI 10.1007/s12011 022 03168 9
   Lv R, 2022, RARE METALS, V41, P639, DOI 10.1007/s12598 021 01759 4
   Marcellini S, 2012, BIOESSAYS, V34, P953, DOI 10.1002/bies.201200061
   Massagu e J., 2008, Cell, V134, P215
   Ouyang QL, 2023, SMALL, V19, DOI 10.1002/smll.202205292
   Percival SL, 2012, INT WOUND J, V9, P14, DOI 10.1111/j.1742 481X.2011.00836.x
   Schilling C, 2018, J PHYS CHEM C, V122, P2909, DOI 10.1021/acs.jpcc.8b00027
   Shi LX, 2019, ADV MATER, V31, DOI 10.1002/adma.201804187
   Su K, 2020, ACS NANO, V14, P2077, DOI 10.1021/acsnano.9b08686
   Suryawanshi MP, 2017, ACS CATAL, V7, P8077, DOI 10.1021/acscatal.7b02102
   Troglia A, 2022, ADV SCI, V9, DOI 10.1002/advs.202105114
   Upadhyay RK., 2018, J STEM CELL RES THER, V4, P82
   Wang CF, 2022, BIOACT MATER, V13, P200, DOI 10.1016/j.bioactmat.2021.10.033
   Wang LQ, 2020, ACTA BIOCH BIOPH SIN, V52, P563, DOI 10.1093/abbs/gmaa027
   Wang LB, 2021, CHINESE J CATAL, V42, P1648, DOI 10.1016/S1872 2067(21)63805 6
   Wang M., 2021, Chem. Eng. J, V456
   Wang MF, 2021, SMALL, V17, DOI 10.1002/smll.202005728
   Wang M, 2023, CHEM ENG J, V456, DOI 10.1016/j.cej.2022.140993
   Wang XW, 2020, APPL PHYS REV, V7, DOI 10.1063/5.0027606
   Wang XW, 2020, MATER HORIZ, V7, P2028, DOI 10.1039/d0mh00613k
   Wang YP, 2022, ADV FIBER MATER, V4, P1278, DOI 10.1007/s42765 022 00177 0
   Wang ZY, 2023, ADV FIBER MATER, V5, P484, DOI 10.1007/s42765 022 00234 8
   Wang ZZ, 2023, SMALL, V19, DOI 10.1002/smll.202206987
   Wang ZJ, 2023, ADV FIBER MATER, V5, P107, DOI 10.1007/s42765 022 00223 x
   Pinto MCX, 2015, CELL SIGNAL, V27, P2139, DOI 10.1016/j.cellsig.2015.08.006
   Xia PF, 2020, ANGEW CHEM INT EDIT, V59, P5218, DOI 10.1002/anie.201916012
   Xiang YM, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf0854
   Xu Qianqian, 2021, Adv Mater, V33, pe2008452, DOI 10.1002/adma.202008452
   Xu ZJ, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901502
   Yu Y, 2021, ACS NANO, V15, P10628, DOI 10.1021/acsnano.1c03424
   Zhang JZ, 2023, ADV FIBER MATER, V5, P168, DOI 10.1007/s42765 022 00205 z
   Zhang LZ, 2018, ANAL CHEM, V90, P9821, DOI 10.1021/acs.analchem.8b01768
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhao Z, 2021, ANGEW CHEM INT EDIT, V60, P11910, DOI 10.1002/anie.202100726
   Zhou J, 2018, BIOMATERIALS, V161, P11, DOI 10.1016/j.biomaterials.2018.01.024
   Zhou LQ, 2021, NANO TODAY, V39, DOI 10.1016/j.nantod.2021.101212
   Zhu P, 2020, ADV MATER, V32, DOI 10.1002/adma.202001976
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 63
TC 41
Z9 42
U1 56
U2 219
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD AUG 30
PY 2023
AR 2306493
DI 10.1002/adfm.202306493
PG 17
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA Q5YB6
UT WOS:001058266300001
DA 2025 08 17
ER

PT J
AU Woischnig, AK
   Gonçalves, LM
   Ferreira, M
   Kuehl, R
   Kikhney, J
   Moter, A
   Ribeiro, IAC
   Almeida, AJ
   Khanna, N
   Bettencourt, AF
AF Woischnig, Anne Kathrin
   Goncalves, Lidia M.
   Ferreira, Maxime
   Kuehl, Richard
   Kikhney, Judith
   Moter, Annette
   Ribeiro, Isabel A. C.
   Almeida, Antonio J.
   Khanna, Nina
   Bettencourt, Ana Francisca
TI Acrylic microparticles increase daptomycin intracellular and in
   vivo anti biofilm activity against Staphylococcus aureus
SO INTERNATIONAL JOURNAL OF PHARMACEUTICS
LA English
DT Article
DE PMMA Eudragit; Microparticles; Osteoblast; Orthopedic
   associated infection; Mouse implant associated biofilm infection model
ID FOREIGN BODY INFECTION; DRUG DELIVERY; IMAGE ANALYSIS; BONE CEMENT;
   MODEL; EPIDERMIDIS; NANOPARTICLES; PATHOGENESIS; OSTEOBLASTS;
   COMBINATION
AB Daptomycin (DAP) is a cyclic lipopeptide antibiotic with potential clinical application in orthopedic infections caused by staphylococci. However, it failed to eradicate Staphylococcus aureus in vitro, in intracellular infection studies, as well as in vivo in an experimental model of implant associated biofilm infections. In this study, the antimicrobial effect of DAP encapsulated in poly(methyl methacrylate) Eudragit (PMMA EUD) microparticles (DAP MPs) on intracellular S. aureus was evaluated in human osteoblast cells using fluorescence in situ hybridization (FISH) analysis. Encapsulated DAP was able to reduce the amount of intracellular S. aureus by 73% compared to blank microparticles (MPs). Then, the advantage of treating with DAP MPs versus free DAP was evaluated in a murine model of implant associated biofilm infection. Free DAP showed a > 3 log(10) decrease in planktonic and adherent bacteria but failed to eradicate adherent methicillin resistant S. aureus (MRSA), whereas DAP MPs showed a clearance of planktonic MRSA, significantly reduced adherent MRSA by more than 3 log(10) and cured the infection in 60%. This was linked to the prolonged higher DAP concentration within the tissue cage fluid compared to free DAP. To our knowledge, this study provides the first evidence for the high intracellular and in vivo anti biofilm efficacy of DAP MPs to target staphylococcal infections.
C1 [Woischnig, Anne Kathrin; Kuehl, Richard; Khanna, Nina] Univ & Univ Hosp Basel, Dept Biomed, Lab Infect Biol, Hebelstr 20, CH 4031 Basel, Switzerland.
   [Goncalves, Lidia M.; Ferreira, Maxime; Ribeiro, Isabel A. C.; Almeida, Antonio J.; Bettencourt, Ana Francisca] Univ Lisbon, Fac Pharm, ULisboa, Res Inst Med iMed, Av Prof Gama Pinto, P 1649003 Lisbon, Portugal.
   [Goncalves, Lidia M.] Univ Lisbon, Fac Med, Cardiovasc Ctr, Av Prof Egas Moniz, P 1649028 Lisbon, Portugal.
   [Kuehl, Richard; Khanna, Nina] Univ Hosp Basel, Div Infect Dis, Petersgraben 4, CH 4031 Basel, Switzerland.
   [Kuehl, Richard; Khanna, Nina] Univ Hosp Basel, Hosp Epidemiol, Petersgraben 4, CH 4031 Basel, Switzerland.
   [Kikhney, Judith; Moter, Annette] Charite Univ Med Berlin, Deutsch Herzzentrum Berlin, Biofilmctr, Hindenburgdamm 30, D 12203 Berlin, Germany.
   [Kikhney, Judith; Moter, Annette] Charite Univ Med Berlin, Inst Microbiol, Hindenburgdamm 30, D 12203 Berlin, Germany.
C3 Universidade de Lisboa; Universidade de Lisboa; University of Basel;
   Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; German Heart Center Berlin; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin
RP Bettencourt, AF (通讯作者)，Univ Lisbon, Fac Pharm, ULisboa, Res Inst Med iMed, Av Prof Gama Pinto, P 1649003 Lisbon, Portugal.
EM asimao@ff.ulisoba.pt
RI iMed.ULisboa, NanoBB/B 5393 2014; Goncalves, Lidia/H 6410 2011; Kühl,
   Richard/HNB 5234 2023; Ribeiro, Isabel/JBJ 5802 2023; Khanna,
   Nina/AAL 7648 2021; Kikhney, Judith/HLH 0746 2023; Bettencourt,
   Ana/M 4219 2013; Gonçalves, Lídia/H 6410 2011; Ribeiro,
   Isabel/A 6098 2014; Almeida, Antonio/I 6590 2012; de campos simao
   bettencourt, ana/ABG 2839 2021; Moter, Annette/IAL 9880 2023
OI Goncalves, Lidia/0000 0002 6799 2740; Moter,
   Annette/0000 0003 1318 5780; Khanna, Nina/0000 0002 2642 419X; Kikhney,
   Judith/0000 0002 4849 7947; Bettencourt, Ana/0000 0002 8498 5892;
   Ribeiro, Isabel/0000 0002 7110 6393; Almeida,
   Antonio/0000 0002 7807 4726; Kuehl, Richard/0000 0002 4959 0983; 
FU Portuguese government, Fundacao para a Ciencia e Tecnologia (FCT)
   [EXCL/CTM NAN/0166/2012, Pest UID/DTP/04138/2014]; Fundação para a
   Ciência e a Tecnologia [EXCL/CTM NAN/0166/2012] Funding Source: FCT
FX Portuguese government, Fundacao para a Ciencia e Tecnologia (FCT),
   (Projects: EXCL/CTM NAN/0166/2012; Pest UID/DTP/04138/2014). The paper
   is based upon work from COST TD1305 (Improved Protection of Medical
   Devices against infection).
CR Bettencourt A, 2012, J MICROENCAPSUL, V29, P353, DOI 10.3109/02652048.2011.651500
   BODMEIER R, 1989, J CONTROL RELEASE, V10, P167, DOI 10.1016/0168 3659(89)90059 X
   Daims H, 2006, ENVIRON MICROBIOL, V8, P200, DOI 10.1111/j.1462 2920.2005.00880.x
   Darouiche RO, 2004, NEW ENGL J MED, V350, P1422, DOI 10.1056/NEJMra035415
   Domínguez Herrera J, 2012, ANTIMICROB AGENTS CH, V56, P613, DOI 10.1128/AAC.05606 11
   Donlan RM, 2000, ASAIO J, V46, pS47, DOI 10.1097/00002480 200011000 00037
   Dupieux C, 2017, J ANTIMICROB CHEMOTH, V72, P3353, DOI 10.1093/jac/dkx314
   Dusane D. H., 2017, J ORTHOP RES
   Ferreira IS, 2015, INT J NANOMED, V10, P4351, DOI 10.2147/IJN.S84108
   Ferreira IS, 2015, INT J PHARMACEUT, V485, P171, DOI 10.1016/j.ijpharm.2015.03.016
   Ferreira M, 2017, INT J PHARMACEUT, V532, P241, DOI 10.1016/j.ijpharm.2017.08.089
   Forier K, 2014, J CONTROL RELEASE, V190, P607, DOI 10.1016/j.jconrel.2014.03.055
   Garzoni C, 2009, TRENDS MICROBIOL, V17, P59, DOI 10.1016/j.tim.2008.11.005
   Hudson MC, 1995, MICROB PATHOGENESIS, V19, P409, DOI 10.1006/mpat.1995.0075
   John AK, 2011, ANTIMICROB AGENTS CH, V55, P3510, DOI 10.1128/AAC.00172 11
   John AK, 2009, ANTIMICROB AGENTS CH, V53, P2719, DOI 10.1128/AAC.00047 09
   Josse J, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02433
   Kikhney J., 2018, AAPS PHARMSCITECH
   Kohane DS, 2007, BIOTECHNOL BIOENG, V96, P203, DOI 10.1002/bit.21301
   Kreis CA, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471 2334 13 267
   Kristian SA, 2003, J INFECT DIS, V188, P414, DOI 10.1086/376533
   Mascio CTM, 2007, ANTIMICROB AGENTS CH, V51, P4255, DOI 10.1128/AAC.00824 07
   McLaren AC, 2004, CLIN ORTHOP RELAT R, P101, DOI 10.1097/01.blo.0000143554.56897.26
   Moriarty TF, 2016, EFORT OPEN REV, V1, P89, DOI 10.1302/2058 5241.1.000037
   Moter A, 2000, J MICROBIOL METH, V41, P85, DOI 10.1016/S0167 7012(00)00152 4
   Nowakowska J, 2014, ANTIBIOTICS BASEL, V3, P378, DOI 10.3390/antibiotics3030378
   Rasigade JP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063176
   Riool M, 2014, ACTA BIOMATER, V10, P5202, DOI 10.1016/j.actbio.2014.08.012
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Shi SF, 2012, EXP THER MED, V3, P367, DOI 10.3892/etm.2011.423
   Sjollema J, 2018, ACTA BIOMATER, V70, P12, DOI 10.1016/j.actbio.2018.02.001
   Spaan AN, 2013, ANNU REV MICROBIOL, V67, P629, DOI 10.1146/annurev micro 092412 155746
   Steenbergen JN, 2005, J ANTIMICROB CHEMOTH, V55, P283, DOI 10.1093/jac/dkh546
   Stewart PS, 2009, ANTIMICROB AGENTS CH, V53, P3505, DOI 10.1128/AAC.01728 08
   Thwaites GE, 2011, NAT REV MICROBIOL, V9, P215, DOI 10.1038/nrmicro2508
   Vallet CM, 2011, INT J ANTIMICROB AG, V38, P249, DOI 10.1016/j.ijantimicag.2011.05.011
   Valour F, 2015, ANTIMICROB AGENTS CH, V59, P2029, DOI 10.1128/AAC.04359 14
   Vilhena C, 2012, MINI REV MED CHEM, V12, P202, DOI 10.2174/1389557511209030202
   Vinh Donald C, 2005, J Long Term Eff Med Implants, V15, P467, DOI 10.1615/JLongTermEffMedImplants.v15.i5.20
   ZIMMERLI W, 1984, J CLIN INVEST, V73, P1191, DOI 10.1172/JCI111305
   ZIMMERLI W, 1982, J INFECT DIS, V146, P487, DOI 10.1093/infdis/146.4.487
   Zimmerli W, 2017, APMIS, V125, P353, DOI 10.1111/apm.12687
   Zimmerli W, 2011, SEMIN IMMUNOPATHOL, V33, P295, DOI 10.1007/s00281 011 0275 7
NR 43
TC 7
Z9 8
U1 1
U2 39
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378 5173
EI 1873 3476
J9 INT J PHARMACEUT
JI Int. J. Pharm.
PD OCT 25
PY 2018
VL 550
IS 1 2
BP 372
EP 379
DI 10.1016/j.ijpharm.2018.08.048
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GU3AZ
UT WOS:000445147000036
PM 30153487
DA 2025 08 17
ER

PT J
AU Sidney, LE
   Heathman, TRJ
   Britchford, ER
   Abed, A
   Rahman, CV
   Buttery, LDK
AF Sidney, Laura E.
   Heathman, Thomas R. J.
   Britchford, Emily R.
   Abed, Arif
   Rahman, Cheryl V.
   Buttery, Lee D. K.
TI Investigation of Localized Delivery of Diclofenac Sodium from
   Poly(D,L Lactic Acid co Glycolic Acid)/Poly(Ethylene Glycol)
   Scaffolds Using an In Vitro Osteoblast Inflammation Model
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID NITRIC OXIDE SYNTHASE; NONSTEROIDAL ANTIINFLAMMATORY DRUGS;
   PROSTAGLANDIN PRODUCTION; MACROPHAGE; EXPRESSION; DIFFERENTIATION;
   CYCLOOXYGENASE; PROLIFERATION; MICROSPHERES; CYTOTOXICITY
AB Nonunion fractures and large bone defects are significant targets for osteochondral tissue engineering strategies. A major hurdle in the use of these therapies is the foreign body response of the host. Herein, we report the development of a bone tissue engineering scaffold with the ability to release anti inflammatory drugs, in the hope of evading this response. Porous, sintered scaffolds composed of poly(D,L lactic acid co glycolic acid) (PLGA) and poly(ethylene glycol) (PEG) were prepared with and without the anti inflammatory drug diclofenac sodium. Analysis of drug release over time demonstrated a profile suitable for the treatment of acute inflammation with similar to 80% of drug released over the first 4 days and a subsequent release of around 0.2% per day. Effect of drug release was monitored using an in vitro osteoblast inflammation model, comprised of mouse primary calvarial osteoblasts stimulated with proinflammatory cytokines interleukin 1 beta (IL 1 beta), tumor necrosis factor alpha (TNF alpha), and interferon gamma (IFN gamma). Levels of inflammation were monitored by cell viability and cellular production of nitric oxide (NO) and prostaglandin E 2 (PGE(2)). The osteoblast inflammation model revealed that proinflammatory cytokine addition to the medium reduced cell viability to 33%, but the release of diclofenac sodium from scaffolds inhibited this effect with a final cell viability of similar to 70%. However, releasing diclofenac sodium at high concentrations had a toxic effect on the cells. Proinflammatory cytokine addition led to increased NO and PGE(2) production; diclofenac sodium releasing scaffolds inhibited NO release by similar to 64% and PGE(2) production by similar to 52%, when the scaffold was loaded with the optimal concentration of drug. These observations demonstrate the potential use of PLGA/PEG scaffolds for localized delivery of anti inflammatory drugs in bone tissue engineering applications.
C1 [Sidney, Laura E.; Heathman, Thomas R. J.; Britchford, Emily R.; Abed, Arif; Rahman, Cheryl V.; Buttery, Lee D. K.] Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Div Drug Delivery & Tissue Engn, Nottingham NG7 2RD, England.
   [Heathman, Thomas R. J.; Britchford, Emily R.; Abed, Arif] Univ Nottingham, EPSRC Doctoral Training Ctr Regenerat Med, Nottingham NG7 2RD, England.
C3 University of Nottingham; UK Research & Innovation (UKRI); Engineering &
   Physical Sciences Research Council (EPSRC); University of Nottingham
RP Buttery, LDK (通讯作者)，Univ Nottingham, Sch Pharm, Ctr Biomol Sci, Div Drug Delivery & Tissue Engn, Nottingham NG7 2RD, England.
EM lee.buttery@nottingham.ac.uk
RI Sidney, Laura/J 6254 2019; Buttery, Lee/C 5627 2015
OI Buttery, Lee/0000 0003 3808 6770; Sidney, Laura/0000 0003 1466 7597
FU EPSRC Doctoral Training Centre for Regenerative Medicine
FX The authors would like to acknowledge the staff of the Biomedical
   Services Unit, University of Nottingham, for provision and care of
   animals and Prof. Kevin Shakesheff for provision of the PLGA/PEG
   formulation. Funding for this study was provided by the EPSRC Doctoral
   Training Centre for Regenerative Medicine.
CR AEBERHARD EE, 1995, BIOCHEM BIOPH RES CO, V208, P1053, DOI 10.1006/bbrc.1995.1441
   AKATSU T, 1991, J BONE MINER RES, V6, P183
   AMIN AR, 1995, P NATL ACAD SCI USA, V92, P7926, DOI 10.1073/pnas.92.17.7926
   [Anonymous], PROGR INFLAMMATION R
   [Anonymous], METHODS MOL BIOL
   Attama AA, 2008, INT J PHARM, V355, P307, DOI 10.1016/j.ijpharm.2007.12.007
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   Böstman O, 2000, BIOMATERIALS, V21, P2615, DOI 10.1016/S0142 9612(00)00129 0
   Bruera E, 1998, CANCER INVEST, V16, P538, DOI 10.3109/07357909809011707
   Cantón I, 2010, BIOTECHNOL BIOENG, V105, P396, DOI 10.1002/bit.22530
   Chang JK, 2007, BIOCHEM PHARMACOL, V74, P1371, DOI 10.1016/j.bcp.2007.06.047
   Chang JK, 2009, TOXICOLOGY, V258, P148, DOI 10.1016/j.tox.2009.01.016
   Cho TJ, 2002, J BONE MINER RES, V17, P513, DOI 10.1359/jbmr.2002.17.3.513
   Corry D, 1998, BIOMATERIALS, V19, P1295, DOI 10.1016/S0142 9612(98)00012 X
   Della Porta G, 2010, J PHARM SCI US, V99, P1484, DOI 10.1002/jps.21920
   Dhillon A, 2011, J MATER SCI MATER M, V22, P2599, DOI 10.1007/s10856 011 4443 z
   Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gould TWA, 2013, LARYNGOSCOPE, V123, P3156, DOI 10.1002/lary.24173
   Hickey T, 2002, J BIOMED MATER RES, V61, P180, DOI 10.1002/jbm.10016
   Hughes FJ, 1999, J BIOL CHEM, V274, P1776, DOI 10.1074/jbc.274.3.1776
   Huuskonen J, 2005, J NEUROINFLAMM, V2, DOI 10.1186/1742 2094 2 25
   Ju YM, 2010, J BIOMED MATER RES A, V93A, P200, DOI 10.1002/jbm.a.32512
   Kanematsu M, 1997, J BONE MINER RES, V12, P1789, DOI 10.1359/jbmr.1997.12.11.1789
   Kang YQ, 2008, EUR J PHARM BIOPHARM, V70, P85, DOI 10.1016/j.ejpb.2008.03.011
   KepkaLenhart D, 1996, J LEUKOCYTE BIOL, V59, P840, DOI 10.1002/jlb.59.6.840
   Khaled K, 2010, AAPS PHARMSCITECH, V11, P859, DOI 10.1208/s12249 010 9445 5
   Kolar P, 2010, TISSUE ENG PART B RE, V16, P427, DOI [10.1089/ten.teb.2009.0687, 10.1089/ten.TEB.2009.0687]
   Kon T, 2001, J BONE MINER RES, V16, P1004, DOI 10.1359/jbmr.2001.16.6.1004
   Krischak GD, 2007, ARCH ORTHOP TRAUM SU, V127, P453, DOI 10.1007/s00402 007 0288 9
   Marsolais D, 2003, LAB INVEST, V83, P991, DOI 10.1097/01.LAB.0000078688.07696.AC
   Martin P, 2003, CURR BIOL, V13, P1122, DOI 10.1016/S0960 9822(03)00396 8
   Martinez FO, 2008, FRONT BIOSCI LANDMRK, V13, P453, DOI 10.2741/2692
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693
   Mountziaris PM, 2008, TISSUE ENG PART B RE, V14, P179, DOI 10.1089/ten.teb.2008.0038
   Mouriño V, 2010, J R SOC INTERFACE, V7, P209, DOI 10.1098/rsif.2009.0379
   Na YR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063451
   Nikkola L, 2006, J NANOSCI NANOTECHNO, V6, P3290, DOI 10.1166/jnn.2006.467
   Olinga P, 2001, J HEPATOL, V35, P187, DOI 10.1016/S0168 8278(01)00103 9
   Rahman CV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077435
   Rahman CV, 2014, J TISSUE ENG REGEN M, V8, P59, DOI 10.1002/term.1497
   Rahman CV, 2013, J BIOMED MATER RES B, V101B, P648, DOI 10.1002/jbm.b.32867
   Rainsford K. D., 1999, American Journal of Medicine, V107, p27S
   Rundle CH, 2006, BONE, V38, P521, DOI 10.1016/j.bone.2005.09.015
   SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035
   SALVEMINI D, 1995, BRIT J PHARMACOL, V114, P1171, DOI 10.1111/j.1476 5381.1995.tb13330.x
   Schäffer M, 1998, BJS BRIT J SURG, V85, P444
   Sidney LE, 2014, STEM CELLS DEV, V23, P605, DOI 10.1089/scd.2013.0336
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Smith EL, 2010, TISSUE ENG PART C ME, V16, P1287, DOI [10.1089/ten.tec.2009.0698, 10.1089/ten.TEC.2009.0698]
   TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168
   Toben D, 2011, J BONE MINER RES, V26, P113, DOI 10.1002/jbmr.185
   Tunçay M, 2000, INT J PHARM, V195, P179, DOI 10.1016/S0378 5173(99)00394 4
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 55
TC 32
Z9 33
U1 0
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937 3341
EI 1937 335X
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD JAN 1
PY 2015
VL 21
IS 1 2
BP 362
EP 373
DI 10.1089/ten.tea.2014.0100
PG 12
WC Cell & Tissue Engineering; Cell Biology; Engineering, Biomedical;
   Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science
GA CA1YQ
UT WOS:000348706100017
PM 25104438
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Hattori, H
   Ishihara, M
   Fukuda, T
   Suda, T
   Katagiri, T
AF Hattori, H
   Ishihara, M
   Fukuda, T
   Suda, T
   Katagiri, T
TI Establishment of a novel method for enriching osteoblast progenitors
   from adipose tissues using a difference in cell adhesive properties
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE adipose tissues; osteoblasts; adipocytes; bone formation
ID MUSCLE STEM CELLS; STROMAL CELLS; CALVARIAL DEFECTS; TRANSPLANTATION;
   REGENERATION; POPULATION; EXPRESSION; MOUSE
AB In the clinical field, cell based therapies are used to treat bone defects. Adipose tissues contain many osteoblast progenitors, among other cell types. We separated mouse adipose tissue derived stromal cells (ATSCs) according to their cell adhesive properties. Cells in a fraction adherent to the culture dishes 0.5 h after inoculation (AF 0.5) had a potent ability to differentiate into both osteoblasts and adipocytes in vitro. Their differentiation pathways depended on the culture conditions. In these cells, the expression of marker genes for osteoblast differentiation was induced in osteogenic medium. Moreover, the AF 0.5 cells, which were induced to differentiate into osteoblasts in vitro, formed abundant bone tissues in vivo. These results suggest that the AF 0.5 cells have been enriched with bi potential progenitor cells destined for either osteoblasts or adipocytes. This simple and efficient method for preparing osteoblast progenitor cells from ATSCs may be utilized for bone defect treatment clinically. (c) 2006 Elsevier Inc. All rights reserved.
C1 Saitama Med Sch, Div Pathophysiol, Res Ctr Genom Med, Hidaka, Saitama 3501241, Japan.
   Natl Def Med Coll, Div Biomed Engn, Res Inst, Tokorozawa, Saitama 3598513, Japan.
C3 Saitama Medical University; National Defense Medical College   Japan
RP Saitama Med Sch, Div Pathophysiol, Res Ctr Genom Med, 1397 1 Yamane, Hidaka, Saitama 3501241, Japan.
EM katagiri@saitama med.ac.jp
CR Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Hattori H, 2004, CELLS TISSUES ORGANS, V178, P2, DOI 10.1159/000081088
   Hattori H, 2006, J BIOMED MATER RES B, V76B, P230, DOI 10.1002/jbm.b.30357
   Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085
   Lee MH, 2003, BIOCHEM BIOPH RES CO, V309, P689, DOI 10.1016/j.bbrc.2003.08.058
   Lendeckel S, 2004, J CRANIO MAXILL SURG, V32, P370, DOI 10.1016/j.jcms.2004.06.002
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71
   Qu Petersen ZQ, 2002, J CELL BIOL, V157, P851, DOI 10.1083/jcb.200108150
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Rodriguez AM, 2005, J EXP MED, V201, P1397, DOI 10.1084/jem.20042224
   Satomura K, 2000, J CELL BIOCHEM, V78, P391
   Wada MR, 2002, DEVELOPMENT, V129, P2987
   Warnke PH, 2004, LANCET, V364, P766, DOI 10.1016/S0140 6736(04)16935 3
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 16
TC 21
Z9 26
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAY 19
PY 2006
VL 343
IS 4
BP 1118
EP 1123
DI 10.1016/j.bbrc.2006.03.061
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 038ZQ
UT WOS:000237269000019
PM 16580630
DA 2025 08 17
ER

PT J
AU Minami, K
   Liu, SZ
   Liu, Y
   Chen, AD
   Wan, QQ
   Na, S
   Li, BY
   Matsuura, N
   Koizumi, M
   Yin, YK
   Gan, LY
   Xu, AH
   Li, JL
   Nakshatri, H
   Yokota, H
AF Minami, Kazumasa
   Liu, Shengzhi
   Liu, Yang
   Chen, Andy
   Wan, Qiaoqiao
   Na, Sungsoo
   Li, Bai Yan
   Matsuura, Nariaki
   Koizumi, Masahiko
   Yin, Yukun
   Gan, Liangying
   Xu, Aihua
   Li, Jiliang
   Nakshatri, Harikrishna
   Yokota, Hiroki
TI Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary
   Tumor and Bone Metastasis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BREAST CANCER CELLS; ORTHOTOPIC MODEL; RHO GTPASES; GROWTH; LINES; RAC1;
   OSTEOCLASTOGENESIS; THERAPY
AB Dopaminergic signaling plays a critical role in the nervous system, but little is known about its potential role in breast cancer and bone metabolism. A screening of similar to 1,000 biologically active compounds revealed that a selective agonist of dopamine receptor D1 ( DRD1), A77636, inhibited proliferation of 4T1.2 mammary tumor cells as well as MDA MB 231 breast cancer cells. Herein, we examined the effect of A77636 on bone quality using a mouse model of bone metastasis from mammary tumor. A77636 inhibited migration of cancer cells in a DRD1 dependent fashion and suppressed development of bone resorbing osteoclasts by downregulating NFATc1 through the elevation of phosphorylation of eIF2 alpha. In the mouse model of bone metastasis, A77636 reduced osteolytic lesions and prevented mechanical weakening of the femur and tibia. Collectively, we expect that dopaminergic signaling might provide a novel therapeutic target for breast cancer and bone metastasis.
C1 [Minami, Kazumasa; Liu, Shengzhi; Liu, Yang; Wan, Qiaoqiao; Na, Sungsoo; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Minami, Kazumasa; Koizumi, Masahiko] Osaka Univ, Grad Sch Med, Dept Med Phys & Engn, Suita, Osaka 5650871, Japan.
   [Liu, Shengzhi; Liu, Yang; Li, Bai Yan] Harbin Med Univ, Sch Pharm, Dept Pharmacol, Harbin 150081, Peoples R China.
   [Chen, Andy] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA.
   [Matsuura, Nariaki] Osaka Med Ctr Canc & Cardiovasc Dis, Osaka 5378511, Japan.
   [Yin, Yukun; Gan, Liangying; Xu, Aihua; Li, Jiliang] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA.
   [Nakshatri, Harikrishna] Indiana Univ Sch Med, Simon Canc Res Ctr, Dept Surg, Indianapolis, IN 46202 USA.
C3 Purdue University System; Purdue University; Purdue University in
   Indianapolis; University of Osaka; Harbin Medical University; Purdue
   University System; Purdue University; Osaka Medical Center for Cancer &
   Cardiovascular Diseases; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Indiana University System; Indiana
   University Bloomington
RP Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
EM hyokota@iupui.edu
RI Wan, Qiaoqiao/N 6562 2017; Gan, Liangying/MVV 2480 2025
OI Nakshatri, Harikrishna/0000 0001 8876 0052
FU breast cancer advocacy group; 100 Voices of Hope; Japan Society for the
   Promotion of Science Core to Core Program [23003]
FX The authors appreciate Yu Sun, Shinya Takigawa, ThucNhi TruongVo, and
   Yijia Zhang for technical support. This study was in part supported by
   the funds from the breast cancer advocacy group, 100 Voices of Hope, and
   the Japan Society for the Promotion of Science Core to Core Program,
   23003.
CR Beaulieu JM, 2011, PHARMACOL REV, V63, P182, DOI 10.1124/pr.110.002642
   Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535 7163.MCT 13 0164
   Borcherding DC, 2016, ONCOGENE, V35, P3103, DOI 10.1038/onc.2015.369
   Bunt G, 2004, INT REV CYTOL, V237, P205, DOI 10.1016/S0074 7696(04)37005 1
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Connolly EM, 2002, BRIT J CANCER, V87, P231, DOI 10.1038/sj.bjc.6600462
   Conrad C., 2013, NEUROTHERAPEUTICS, V10, P383
   de Almeida J, 2010, NEUROSCIENCE, V170, P1133, DOI 10.1016/j.neuroscience.2010.08.025
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   FORSTER T, 1948, ANN PHYS BERLIN, V2, P55, DOI 10.1002/andp.19484370105
   Girault JA, 2004, ARCH NEUROL CHICAGO, V61, P641, DOI 10.1001/archneur.61.5.641
   Guise TA, 2013, CELL, V154, P957, DOI 10.1016/j.cell.2013.08.020
   Hamamura K, 2015, CELL SIGNAL, V27, P353, DOI 10.1016/j.cellsig.2014.11.020
   Hamamura K, 2014, INT J ONCOL, V44, P1980, DOI 10.3892/ijo.2014.2366
   Hamamura K, 2013, J BONE MINER METAB, V31, P618, DOI 10.1007/s00774 013 0450 0
   Hanna S, 2013, CELL SIGNAL, V25, P1955, DOI 10.1016/j.cellsig.2013.04.009
   Jandaghi P, 2016, GASTROENTEROLOGY, V151, P1218, DOI 10.1053/j.gastro.2016.08.040
   Kamimura Y, 2005, INT J ONCOL, V26, P337
   KEBABIAN JW, 1992, EUR J PHARMACOL, V229, P203, DOI 10.1016/0014 2999(92)90556 J
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Lidow MS, 1998, SYNAPSE, V28, P10, DOI 10.1002/(SICI)1098 2396(199801)28:1<10::AID SYN2>3.0.CO;2 F
   Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143
   Mabilleau G, 2015, J MUSCULOSKEL NEURON, V15, P42
   Malochet Guinamand S, 2015, JOINT BONE SPINE, V82, P406, DOI 10.1016/j.jbspin.2015.03.009
   Martin YC, 2011, INT J MED CHEM, V2011, DOI 10.1155/2011/424535
   Miller KD, 2016, CA CANCER J CLIN, V66, P271, DOI 10.3322/caac.21349
   Murad H, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935 016 0315 4
   Nash A. I., 2016, J CHEM NEUROANAT, V16, pS0891
   Ott SM, 2008, CLIN J AM SOC NEPHRO, V3, pS151, DOI 10.2215/CJN.04301206
   Ott T, 2014, NEURON, V84, P1317, DOI 10.1016/j.neuron.2014.11.012
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478 811X 8 23
   RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092 8674(78)90101 0
   SASAKI A, 1995, CANCER RES, V55, P3551
   SOULE HD, 1986, IN VITRO CELL DEV B, V22, P6, DOI 10.1007/BF02623435
   Sun WW, 2016, BONE, V85, P1, DOI 10.1016/j.bone.2016.01.013
   Tatem AJ, 2011, LANCET, V377, P30, DOI 10.1016/S0140 6736(11)61226 9
   Teixeira A, 2010, BRIT J OPHTHALMOL, V94, P1226, DOI 10.1136/bjo.2009.166637
   Wang H, 2015, CANCER CELL, V27, P193, DOI 10.1016/j.ccell.2014.11.017
   Xu WX, 2015, CELL SIGNAL, V27, P2332, DOI 10.1016/j.cellsig.2015.08.014
   Zhang MZ, 2015, CURR OPIN NEPHROL HY, V24, P117, DOI 10.1097/MNH.0000000000000104
NR 43
TC 40
Z9 45
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD APR 4
PY 2017
VL 7
AR 45686
DI 10.1038/srep45686
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA EQ5UH
UT WOS:000398147700001
PM 28374823
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ruscitto, A
   Chen, P
   Tosa, I
   Wang, ZY
   Zhou, G
   Safina, I
   Wei, R
   Morel, MM
   Koch, A
   Forman, M
   Reeve, G
   Lecholop, MK
   Wilson, M
   Bonthius, D
   Chen, M
   Ono, M
   Wang, TC
   Yao, H
   Embree, MC
AF Ruscitto, Angela
   Chen, Peng
   Tosa, Ikue
   Wang, Ziyi
   Zhou, Gan
   Safina, Ingrid
   Wei, Ran
   Morel, Mallory M.
   Koch, Alia
   Forman, Michael
   Reeve, Gwendolyn
   Lecholop, Michael K.
   Wilson, Marshall
   Bonthius, Daniel
   Chen, Mo
   Ono, Mitsuaki
   Wang, Timothy C.
   Yao, Hai
   Embree, Mildred C.
TI Lgr5 expressing secretory cells form a Wnt inhibitory niche in cartilage
   critical for chondrocyte identity
SO CELL STEM CELL
LA English
DT Article
ID HISTOLOGICAL ASSESSMENTS; STEM CELL; ARTICULAR CARTILAGE; CONDYLAR
   CARTILAGE; GENE EXPRESSION; INDIAN HEDGEHOG; SMALL INTESTINE;
   OSTEOARTHRITIS; BONE; DIFFERENTIATION
AB Osteoarthritis is a degenerative joint disease that causes pain, degradation, and dysfunction. Excessive canon ical Wnt signaling in osteoarthritis contributes to chondrocyte phenotypic instability and loss of cartilage homeo stasis; however, the regulatory niche is unknown. Using the temporomandibular joint as a model in multiple spe cies, we identify Lgr5 expressing secretory cells as forming a Wnt inhibitory niche that instruct Wnt inactive chondroprogenitors to form the nascent synovial joint and regulate chondrocyte lineage and identity. Lgr5 ablation or suppression during joint development, aging, or osteoarthritis results in depletion of Wnt inactive chondroprogenitors and a surge of Wnt activated, phenotypically unstable chondrocytes with osteoblast like properties. We recapitulate the cartilage niche and create StemJEL, an injectable hydrogel therapy combining hyaluronic acid and sclerostin. Local delivery of StemJEL to post traumatic osteoarthritic jaw and knee joints in rabbit, rat, and mini pig models restores cartilage homeostasis, chondrocyte identity, and joint function. We provide proof of principal that StemJEL preserves the chondrocyte niche and alleviates osteoarthritis.
C1 [Ruscitto, Angela; Tosa, Ikue; Zhou, Gan; Safina, Ingrid; Wei, Ran; Morel, Mallory M.; Embree, Mildred C.] Columbia Univ, Coll Dent Med, Cartilage Biol & Regenerat Med Lab, Irving Med Ctr,Div Orthodont,Sect Growth & Dev, New York, NY 10027 USA.
   [Ruscitto, Angela; Tosa, Ikue; Zhou, Gan; Wang, Timothy C.; Embree, Mildred C.] Columbia Univ, Irving Med Ctr, Columbia Stem Cell Initiat, New York, NY 10032 USA.
   [Chen, Peng; Wilson, Marshall; Bonthius, Daniel; Yao, Hai] Clemson Univ, Med Univ South Carolina, Joint Bioengn Program, Dept Bioengn, Clemson, SC 29634 USA.
   [Chen, Peng; Wilson, Marshall; Bonthius, Daniel; Yao, Hai] Med Univ South Carolina, Coll Dent Med, Dept Oral Hlth Sci, Charleston, SC 29425 USA.
   [Wang, Ziyi; Ono, Mitsuaki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Mol Biol & Biochem, Okayama 7008525, Japan.
   [Koch, Alia; Forman, Michael] Columbia Univ, Coll Dent Med, Sect Hosp Dent, Div Oral & Maxillofacial Surg,Irving Med Ctr, New York, NY 10032 USA.
   [Reeve, Gwendolyn] New York Presbyterian Weill Cornell Med, Div Oral & Maxillofacial Surg, New York, NY 10065 USA.
   [Lecholop, Michael K.] Med Univ South Carolina, Coll Dent Med, Dept Oral & Maxillofacial Surg, Charleston, SC 29425 USA.
   [Chen, Mo] Wnt Sci LLC, Harlem Biospace, New York, NY 10027 USA.
   [Ono, Mitsuaki] Okayama Univ Hosp, Dept Oral Rehabil & Implantol, Okayama 7008525, Japan.
   [Wang, Timothy C.] Columbia Univ, Coll Phys & Surg, Dept Med, Irving Med Ctr,Div Digest & Liver Dis, New York, NY 10032 USA.
C3 Columbia University; NewYork Presbyterian Hospital; Columbia University;
   NewYork Presbyterian Hospital; Medical University of South Carolina;
   Clemson University; Medical University of South Carolina; Okayama
   University; Columbia University; NewYork Presbyterian Hospital; Cornell
   University; Weill Cornell Medicine; Medical University of South
   Carolina; Okayama University; NewYork Presbyterian Hospital; Columbia
   University
RP Embree, MC (通讯作者)，Columbia Univ, Coll Dent Med, Cartilage Biol & Regenerat Med Lab, Irving Med Ctr,Div Orthodont,Sect Growth & Dev, New York, NY 10027 USA.; Embree, MC (通讯作者)，Columbia Univ, Irving Med Ctr, Columbia Stem Cell Initiat, New York, NY 10032 USA.
EM mce2123@cumc.columbia.edu
RI Wang, Ziyi/AAW 6082 2020
OI Wang, Ziyi/0000 0003 1884 8053
FU National Institutes of Health/NIDCR [R00DE022060, 1R01DE029068,
   1R41DE028215, 1R42DE028215]; Columbia University Clinical and
   Translational Sciences Award: Translational Accelerator Program Grant;
   Columbia University Faculty Diversity Award; National Institutes of
   Health [R01DE021134]; National Institutes of Health [P20GM121342,
   T32DE017551]; National Institutes of Dental and Craniofacial Research
   [F31AR076917]; Grants in Aid for Scientific Research [22KF0265] Funding
   Source: KAKEN
FX We thank Dr. Gerard Karsenty (Columbia University Irving Medical Center)
   for critical feedback and advice. We thank Dr. Fred de Sauvage
   (Genentech) for kindly providing the Lgr5DTR EGFP mouse model. We thank
   Thomas Gallien, Dr. Roxanna Swagel, and the vet staff for their support
   on mini pig surgeries at the Medical University of South Carolina. We
   thank Dr. Alex Romanov and the vet staff at Columbia University Irving
   Medical Center for their support on animal surgeries and procedures.
   Funding sources: National Institutes of Health/NIDCR R00DE022060 (to
   M.C.E.), National Institutes of Health/NIDCR 1R01DE029068 (to M.C.E. and
   H.Y.), National Institutes of Health/NIDCR 1R41DE028215 (to M.C.E. and
   M.C.), National Institutes of Health/NIDCR 1R42DE028215 (to M.C.E. and
   M.C.), Columbia University Clinical and Translational Sciences Award:
   Translational Accelerator Program Grant (to M.C.E.), Columbia University
   Faculty Diversity Award (M.C.E.), National Institutes of Health
   R01DE021134 (to H.Y.), National Institutes of Health P20GM121342 (H.Y.),
   National Institutes of Dental and Craniofacial Research T32DE017551 (to
   H.Y.), and National Institutes of Health F31AR076917 (to D.B.).
CR Aigner T, 2007, NAT CLIN PRACT RHEUM, V3, P391, DOI 10.1038/ncprheum0534
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Berenbaum F, 2018, NAT REV RHEUMATOL, V14, P674, DOI 10.1038/s41584 018 0073 x
   Betancourt MCC, 2012, P NATL ACAD SCI USA, V109, P8218, DOI 10.1073/pnas.1119899109
   Boddupally K, 2016, STEM CELLS, V34, P720, DOI 10.1002/stem.2314
   Boettger MK, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3394
   Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965
   Chang JC, 2018, J BONE MINER RES, V33, P1105, DOI 10.1002/jbmr.3397
   Chen CG, 2012, ARTHRITIS RHEUM US, V64, P3278, DOI 10.1002/art.34566
   Chen D, 2020, J ORTHOP TRANSL, V23, P132, DOI 10.1016/j.jot.2019.11.008
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Coles JM, 2010, ARTHRITIS RHEUM US, V62, P1666, DOI 10.1002/art.27436
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Embree MC, 2015, OSTEOARTHR CARTILAGE, V23, P629, DOI 10.1016/j.joca.2014.12.015
   Embree MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13073
   Feng C, 2019, STEM CELL REP, V13, P713, DOI 10.1016/j.stemcr.2019.08.006
   Gerwin N, 2010, OSTEOARTHR CARTILAGE, V18, pS24, DOI 10.1016/j.joca.2010.05.030
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Goldring MB, 2012, THER ADV MUSCULOSKEL, V4, P269, DOI 10.1177/1759720X12448454
   Guo J, 2006, DEV BIOL, V292, P116, DOI 10.1016/j.ydbio.2005.12.044
   Hallett SA, 2021, ELIFE, V10, DOI 10.7554/eLife.64513
   Haseeb A, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2019152118
   Heinemeier KM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8335
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Huey DJ, 2012, SCIENCE, V338, P917, DOI 10.1126/science.1222454
   Hunter DJ, 2020, LANCET, V396, P1711, DOI 10.1016/S0140 6736(20)32230 3
   Hunter DJ, 2019, LANCET, V393, P1745, DOI 10.1016/S0140 6736(19)30417 9
   Ji Q, 2009, SCIENCE, V326, P278, DOI 10.1126/science.1178501
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kovaka S, 2019, GENOME BIOL, V20, DOI 10.1186/s13059 019 1910 1
   Koyama E, 2014, J DENT RES, V93, P663, DOI 10.1177/0022034514535807
   Kronenberg HM, 2007, ANN NY ACAD SCI, V1116, P59, DOI 10.1196/annals.1402.059
   Kronenberg HM, 2006, ANN NY ACAD SCI, V1068, P1, DOI 10.1196/annals.1346.002
   Kubiak M, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4030025
   Kumm J, 2013, OSTEOARTHR CARTILAGE, V21, P815, DOI 10.1016/j.joca.2013.03.008
   Kuroda S, 2009, OSTEOARTHR CARTILAGE, V17, P1408, DOI 10.1016/j.joca.2009.04.025
   Kuwahara ST, 2019, ELIFE, V8, DOI 10.7554/eLife.40715
   Latourte A, 2020, NAT REV RHEUMATOL, V16, P673, DOI 10.1038/s41584 020 00518 6
   Lautenschlager S, 2018, NATURE, V561, P533, DOI 10.1038/s41586 018 0521 4
   Laverty S, 2010, OSTEOARTHR CARTILAGE, V18, pS53, DOI 10.1016/j.joca.2010.05.029
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059 014 0550 8
   Mizuhashi K, 2018, NATURE, V563, P254, DOI 10.1038/s41586 018 0662 5
   Mobasheri A, 2017, NAT REV RHEUMATOL, V13, P302, DOI 10.1038/nrrheum.2017.50
   Monteagudo S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15889
   Murphy MP, 2020, NAT MED, V26, P1583, DOI 10.1038/s41591 020 1013 2
   Muruganandan S, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 30247 1
   Nagata K, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 022 33744 5
   Nathan J, 2018, J DENT RES, V97, P329, DOI 10.1177/0022034517735094
   Ochiai T, 2010, J DENT RES, V89, P349, DOI 10.1177/0022034510363078
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Paul S, 2016, DEVELOPMENT, V143, P2066, DOI 10.1242/dev.131292
   Pesesse L, 2014, OSTEOARTHR CARTILAGE, V22, P547, DOI 10.1016/j.joca.2014.01.010
   Phillips R, 2021, NAT REV RHEUMATOL, V17, P645, DOI 10.1038/s41584 021 00696 x
   Pitsillides AA, 2011, NAT REV RHEUMATOL, V7, P654, DOI 10.1038/nrrheum.2011.129
   Pullig O, 2000, CALCIFIED TISSUE INT, V67, P230, DOI 10.1007/s002230001108
   Purcell P, 2009, P NATL ACAD SCI USA, V106, P18297, DOI 10.1073/pnas.0908836106
   Qin X, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009169
   Risso D, 2014, NAT BIOTECHNOL, V32, P896, DOI 10.1038/nbt.2931
   Ruan MZC, 2013, OSTEOARTHR CARTILAGE, V21, P1355, DOI 10.1016/j.joca.2013.06.016
   Ruscitto A, 2020, FASEB J, V34, P4445, DOI 10.1096/fj.201902287R
   Schmitt M, 2015, CELL DEATH DIFFER, V22, P677, DOI 10.1038/cdd.2014.156
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shibata S, 2008, J ANAT, V213, P274, DOI 10.1111/j.1469 7580.2008.00934.x
   Sigal M, 2019, NAT CELL BIOL, V21, P812, DOI 10.1038/s41556 019 0339 9
   Takahashi K, 1999, OSTEOARTHR CARTILAGE, V7, P182, DOI 10.1053/joca.1998.0207
   Tardaguila M, 2018, GENOME RES, V28, P396, DOI 10.1101/gr.222976.117
   Thakur A, 2016, NANOSCALE, V8, P12362, DOI 10.1039/c6nr02299e
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581
   Vitting Seerup K, 2019, BIOINFORMATICS, V35, P4469, DOI 10.1093/bioinformatics/btz247
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wang CT, 2006, OSTEOARTHR CARTILAGE, V14, P1237, DOI 10.1016/j.joca.2006.05.009
   Wang YD, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0411 x
   Wei JW, 2015, CELL, V161, P1576, DOI 10.1016/j.cell.2015.05.029
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Yang L, 2014, P NATL ACAD SCI USA, V111, P12097, DOI 10.1073/pnas.1302703111
   Yazici Y, 2021, OSTEOARTHR CARTILAGE, V29, P654, DOI 10.1016/j.joca.2021.02.004
   Zhou X, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004820
   Zhou YC, 2017, CURR RHEUMATOL REP, V19, DOI 10.1007/s11926 017 0679 z
NR 81
TC 19
Z9 20
U1 5
U2 31
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1934 5909
EI 1875 9777
J9 CELL STEM CELL
JI Cell Stem Cell
PD SEP 7
PY 2023
VL 30
IS 9
DI 10.1016/j.stem.2023.08.004
EA SEP 2023
PG 28
WC Cell & Tissue Engineering; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA T0KX6
UT WOS:001074973600001
PM 37683603
OA hybrid
DA 2025 08 17
ER

PT J
AU Ishimoto, K
   Tachibana, K
   Hanano, I
   Yamasaki, D
   Nakamura, H
   Kawai, M
   Urano, Y
   Tanaka, T
   Hamakubo, T
   Sakai, J
   Kodama, T
   Doi, T
AF Ishimoto, Kenji
   Tachibana, Keisuke
   Hanano, Ikuko
   Yamasaki, Daisuke
   Nakamura, Hiroki
   Kawai, Megumi
   Urano, Yasuomi
   Tanaka, Toshiya
   Hamakubo, Takao
   Sakai, Juro
   Kodama, Tatsuhiko
   Doi, Takefumi
TI Sterol regulatory element binding protein 2 and nuclear factor Y control
   human farnesyl diphosphate synthase expression and affect cell
   proliferation in hepatoblastoma cells
SO BIOCHEMICAL JOURNAL
LA English
DT Article
DE cell proliferation; farnesyl diphosphate synthase (FDPS); nuclear factor
   Y (NF Y); promoter; sterol regulatory element binding protein (SREBP);
   zoledronic acid
ID DENSITY LIPOPROTEIN RECEPTOR; TRANSCRIPTIONAL REGULATION; PYROPHOSPHATE
   SYNTHASE; GENE; TARGET; IDENTIFICATION; CHOLESTEROL; PATHWAY; BONE; ACID
AB FDPS (farnesyl diphosphate synthase) catalyses the formation of farnesyl diphosphate, a key intermediate in the synthesis of cholesterol and isoprenylated cellular metabolites. FDPS is also the molecular target of nitrogen containing bisphosphonates, which are used as bone antiresorptive drugs in various disorders. In the present study, we characterized the sterol response element and NF Y (nuclear factor Y) binding site in the human FDPS promoter. Using a luciferase assay, electrophoretic mobility shift assay and chromatin immunoprecipitation assay, we demonstrated that these elements are responsible for the transcription of the FDPS gene, and that its transcriptional activation is mediated by SREBP 2 (sterol regulatory element binding protein 2) and NF Y. We also investigated whether sterol mediated FDPS expression is involved in the cell proliferation induced by zoledronic acid, an FDPS inhibitor. We show that the SREBP 2  and NF Y mediated regulation of FDPS gene transcription modulates cell proliferation. These results suggest that SREBP 2 and NF Y are required to trigger cell proliferation through the induction of FDPS expression and that the pharmacological action of zoledronic acid is involved in this pathway.
C1 [Ishimoto, Kenji; Tachibana, Keisuke; Hanano, Ikuko; Yamasaki, Daisuke; Nakamura, Hiroki; Kawai, Megumi; Doi, Takefumi] Osaka Univ, Grad Sch Pharmaceut Sci, Osaka 5650871, Japan.
   [Ishimoto, Kenji; Doi, Takefumi] Osaka Univ, Grad Sch Med, Dept Mol Pharmaceut Sci, Osaka 5650871, Japan.
   [Urano, Yasuomi; Tanaka, Toshiya; Hamakubo, Takao; Sakai, Juro; Kodama, Tatsuhiko] Univ Tokyo, Adv Sci & Technol Res Ctr, Lab Syst Biol & Med, Tokyo 1538904, Japan.
C3 University of Osaka; University of Osaka; University of Tokyo
RP Doi, T (通讯作者)，Osaka Univ, Grad Sch Pharmaceut Sci, 1 6 Yamadaoka, Osaka 5650871, Japan.
EM doi@phs.osaka u.ac.jp
RI Sakai, Juro/KPY 7126 2024; Juro, Sakai/KPY 7126 2024
OI Sakai, Juro/0000 0003 4043 1035; Urano, Yasuomi/0000 0002 4901 1937
FU National Institute of Biomedical Innovation (NIBIO); Grants in Aid for
   Scientific Research [24650442, 24116507, 22229009] Funding Source: KAKEN
FX This study was supported by the Program of Fundamental Studies in Health
   Sciences of the National Institute of Biomedical Innovation (NIBIO).
CR Bhattacharya A, 2003, CANCER RES, V63, P8167
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092 8674(00)80213 5
   Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092 8674(00)80675 3
   Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041
   Brufsky AM, 2008, EXPERT OPIN PHARMACO, V9, P1013, DOI 10.1517/14656566.9.6.1013
   Coxon FP, 2001, J BIOL CHEM, V276, P48213, DOI 10.1074/jbc.M106473200
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097 0142(20000615)88:12+<3080::AID CNCR27>3.0.CO;2 W
   Dooley KA, 1998, J BIOL CHEM, V273, P1349, DOI 10.1074/jbc.273.3.1349
   Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945
   GLOMSET JA, 1992, BIOCHEM SOC T, V20, P479, DOI 10.1042/bst0200479
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Grove JE, 2000, J BONE MINER RES, V15, P971, DOI 10.1359/jbmr.2000.15.5.971
   Guan GM, 1997, J BIOL CHEM, V272, P10295
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Ikeda Y, 2001, J BIOL CHEM, V276, P34259, DOI 10.1074/jbc.M103848200
   Ishimoto K, 2006, FEBS LETT, V580, P4929, DOI 10.1016/j.febslet.2006.08.010
   Ishimoto K, 2009, J BIOL CHEM, V284, P22195, DOI 10.1074/jbc.M109.028753
   Jackson SM, 1998, J LIPID RES, V39, P767
   Jiang F, 2001, J STEROID BIOCHEM, V78, P123, DOI 10.1016/S0960 0760(01)00086 3
   Kavanagh KL, 2006, J BIOL CHEM, V281, P22004, DOI 10.1074/jbc.M602603200
   KRISANS SK, 1994, J BIOL CHEM, V269, P14165
   Levy ME, 2007, MATURITAS, V57, P247, DOI 10.1016/j.maturitas.2007.01.005
   Magaña MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726
   MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808
   Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378 1119(99)00368 6
   MANTOVANI R, 1994, J BIOL CHEM, V269, P20340
   Martín D, 2007, BBA MOL CELL RES, V1773, P419, DOI 10.1016/j.bbamcr.2006.11.015
   Molnár G, 2001, BIOCHEMISTRY US, V40, P10542, DOI 10.1021/bi011158e
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   Romanelli MG, 2009, GENOMICS, V93, P227, DOI 10.1016/j.ygeno.2008.11.002
   Roux C, 1999, DRUGS, V58, P823, DOI 10.2165/00003495 199958050 00005
   Sambrook PN, 2002, CURR PHARM DESIGN, V8, P1877, DOI 10.2174/1381612023393648
   SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161
   Sassano A, 2008, CANCER LETT, V260, P11, DOI 10.1016/j.canlet.2007.11.036
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   SHEARES BT, 1989, BIOCHEMISTRY US, V28, P8129, DOI 10.1021/bi00446a025
   Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163 7827(01)00010 8
   Sugden CJ, 2005, BIOCHEM BIOPH RES CO, V334, P555, DOI 10.1016/j.bbrc.2005.06.117
   Tachibana Keisuke, 2005, Nucl Recept, V3, P3, DOI 10.1186/1478 1336 3 3
   Tassone P, 2000, LEUKEMIA, V14, P841, DOI 10.1038/sj.leu.2401770
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
NR 43
TC 24
Z9 24
U1 0
U2 4
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264 6021
EI 1470 8728
J9 BIOCHEM J
JI Biochem. J.
PD JUL 15
PY 2010
VL 429
BP 347
EP 357
DI 10.1042/BJ20091511
PN 2
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 628AA
UT WOS:000280085000013
PM 20450493
DA 2025 08 17
ER

PT J
AU Marini, F
   Falchetti, A
   Silvestri, S
   Bagger, Y
   Luzi, E
   Tanini, A
   Christiansen, C
   Brandi, ML
AF Marini, Francesca
   Falchetti, Alberto
   Silvestri, Sandra
   Bagger, Yu
   Luzi, Ettore
   Tanini, Annalisa
   Christiansen, Claus
   Brandi, Maria Luisa
TI Modulatory effect of farnesyl pyrophosphate synthase (FDPS)
   rs2297480 polymorphism on the response to long term
   amino bisphosphonate treatment in postmenopausal osteoporosis
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Article; Proceedings Paper
CT 2nd International Meeting on Pharmacogenetics of Osteorticular Disorders
CY APR 19, 2008
CL Florence, ITALY
DE Amino bisphosphonates; Bone Mineral Density (BMD); Bone turnover
   markers; Farnesyl pyrophosphate synthase gene (FDPS); Gene polymorphisms
ID BONE MINERAL DENSITY; FRACTURE RISK; ALENDRONATE; WOMEN; RESORPTION;
   REDUCTION; AMINOBISPHOSPHONATES; ACTIVATION; PREVENTION; PREDICTION
AB Introduction: Polymorphisms of genes encoding enzymes of the mevalonate pathway could modulate the response to amino bisphosphonate treatment in postmenopausal osteoporosis.
   Research design and methods: A characterisation of 234 Danish osteoporotic postmenopausal women (as part of the Prospective Epidemiological Risk Factors study (PERF)), treated for at least 2 years with amino bisphosphonates, with respect to the adenosine/cytosine (A/C) rs2297480 farnesyl pyrophosphate synthase (FDPS) gene polymorphism, was carried out by PCR based enzymatic digestion and quantitative PCR allelic discrimination on genomic DNA extracted from blood leukocytes. The association between these polymorphism genotypes and the response of spine and femur bone mineral density (BMD) and of biochemical bone biomarkers to treatment with amino bisphosphonates was statistically examined.
   Results: FDPS polymorphism did not show any relationship to baseline spinal and femoral BMD in Danish postmenopausal women. BMD response to treatment with amino bisphosphonates was similar in the AA and the AC genotypes, while the CC genotype showed a lower BMD response to 2 year treatment with amino bisphosphonates at all examined skeletal sites (p = 0.60 at the spine and p = 0.59 at the femur). Interestingly, after 2 years of treatment the response of urinary Cross laps to aminobisphosphonates treatment was significantly (p < 0.05) lower in the CC genotype when compared to both the AC and AA genotypes. Even the response of serum osteocalcin was lower in the CC genotype, but without reaching a statistical significance (p = 0.65).
   Conclusions: Danish postmenopausal women with osteoporosis bearing the homozygous CC genotype for rs2297480 FDPS polymorphism showed a decreased response of bone turnover markers to amino bisphosphonate therapy, when compared to the heterozygous AC and to the homozygous AA genotypes. Further investigation on larger and different populations, together with polymorphism functional studies are required to confirm these data.
C1 [Marini, Francesca; Falchetti, Alberto; Silvestri, Sandra; Bagger, Yu; Luzi, Ettore; Tanini, Annalisa; Christiansen, Claus; Brandi, Maria Luisa] Univ Florence, Dept Internal Med, I 50139 Florence, Italy.
   [Bagger, Yu; Christiansen, Claus] Univ Florence, DeGene Spin Off, I 50139 Florence, Italy.
   [Brandi, Maria Luisa] Ctr Clin & Basic Res, Ballerup, Denmark.
C3 University of Florence; University of Florence; Center Clinical & Basic
   Research
RP Brandi, ML (通讯作者)，Univ Florence, Dept Internal Med, Viale Pieraccini 6, I 50139 Florence, Italy.
EM m.brandi@dmi.unifi.it
RI ; L, E/AAG 9596 2019; FALCHETTI, ALBERTO/Q 1787 2016
OI Marini, Francesca/0000 0002 3678 4922; Luzi, Ettore/0000 0002 8896 241X;
   FALCHETTI, ALBERTO/0000 0002 6739 4417
CR Arko B, 2002, J STEROID BIOCHEM, V81, P147, DOI 10.1016/S0960 0760(02)00061 4
   Bagger YZ, 2004, BONE, V34, P728, DOI 10.1016/j.bone.2003.12.021
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Briot K, 2005, BEST PRACT RES CL RH, V19, P951, DOI 10.1016/j.berh.2005.06.004
   Calis KA, 2007, NEW ENGL J MED, V357, P1861, DOI 10.1056/NEJMe078192
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Christgau S, 1998, CLIN CHEM, V44, P2290
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Cummings SR, 2007, NEW ENGL J MED, V356, P1895, DOI 10.1056/NEJMc076132
   Delmas PD, 2002, LANCET, V359, P2018, DOI 10.1016/S0140 6736(02)08827 X
   Delmas PD, 2005, CURR OPIN RHEUMATOL, V17, P462
   Delmas PD, 2004, OSTEOPOROSIS INT, V15, P792, DOI 10.1007/s00198 004 1602 9
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Eastell R, 2007, J BONE MINER RES, V22, P1656, DOI 10.1359/JBMR.07090B
   Farrugia MC, 2006, LARYNGOSCOPE, V116, P115, DOI 10.1097/01.mlg.0000187398.51857.3c
   Ferlazzo V, 2006, INT J IMMUNOPATH PH, V19, P309, DOI 10.1177/039463200601900208
   Garnero P., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P50
   Haga H, 2002, J HUM GENET, V47, P605, DOI 10.1007/s100380200092
   Kanis JA, 2002, LANCET, V359, P1929, DOI 10.1016/S0140 6736(02)08761 5
   Levy ME, 2007, MATURITAS, V57, P247, DOI 10.1016/j.maturitas.2007.01.005
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Marc J, 1999, OSTEOPOROSIS INT, V10, P303, DOI 10.1007/s001980050231
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003 4819 128 4 199802150 00001
   MELTON LJ, 1993, J BONE MINER RES, V8, P1227
   Palomba S, 2003, CLIN ENDOCRINOL, V58, P365, DOI 10.1046/j.1365 2265.2003.01724.x
   Rogers Michael J., 2003, Current Pharmaceutical Design, V9, P2643, DOI 10.2174/1381612033453640
   ROSENQUIST C, 1995, CLIN CHEM, V41, P1439
   Sala SC, 2005, J BONE MINER RES, V20, pS125
   SALA SC, 2005, J ENDOCRINOL INVEST, V28, P2
   Saltman LH, 2005, J CELL PHYSIOL, V204, P871, DOI 10.1002/jcp.20329
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
NR 33
TC 41
Z9 43
U1 0
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2 4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0300 7995
EI 1473 4877
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD SEP
PY 2008
VL 24
IS 9
BP 2609
EP 2615
DI 10.1185/03007990802352894
PG 7
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC General & Internal Medicine; Research & Experimental Medicine
GA 361ZA
UT WOS:000260166300018
PM 18687167
DA 2025 08 17
ER

PT S
AU McManus, MM
   Weiss, KR
   Hughes, DPM
AF McManus, Madonna M.
   Weiss, Kurt R.
   Hughes, Dennis P. M.
BE Kleinerman, ES
TI Understanding the Role of Notch in Osteosarcoma
SO CURRENT ADVANCES IN OSTEOSARCOMA
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Osteosarcoma; Notch; DLL4; Jag1; Angiogenesis; Metastasis; Dormancy;
   Cancer stem cells
ID CANCER STEM CELLS; ENDOTHELIAL GROWTH FACTOR; ALDEHYDE
   DEHYDROGENASE ACTIVITY; BONE MORPHOGENETIC PROTEINS; INHIBITS
   TUMOR GROWTH; BLOOD VESSEL DEVELOPMENT; OSTEOBLAST DIFFERENTIATION;
   EMBRYONIC LETHALITY; GENE EXPRESSION; UP REGULATION
AB The Notch pathway has been described as an oncogene in osteosarcoma, but the myriad functions of all the members of this complex signaling pathway, both in malignant cells and nonmalignant components of tumors, make it more difficult to define Notch as simply an oncogene or a tumor suppressor. The cell autonomous behaviors caused by Notch pathway manipulation may vary between cell lines but can include changes in proliferation, migration, invasiveness, oxidative stress resistance, and expression of markers associated with stemness or tumor initiating cells. Beyond these roles, Notch signaling also plays a vital role in regulating tumor angiogenesis and vasculogenesis, which are vital aspects of osteosarcoma growth and behavior in vivo. Further, osteosarcoma cells themselves express relatively low levels of Notch ligand, making it likely that nonmalignant cells, especially endothelial cells and pericytes, are the major source of Notch activation in osteosarcoma tumors in vivo and in patients. As a result, Notch pathway expression is not expected to be uniform across a tumor but likely to be highest in those areas immediately adjacent to blood vessels. Therapeutic targeting of the Notch pathway is likewise expected to be complicated. Most pharmacologic approaches thus far have focused on inhibition of gamma secretase, a protease of the presenilin complex. This enzyme, however, has numerous other target proteins that would be expected to affect osteosarcoma behavior, including CD44, the WNT/beta catenin pathway, and Her 4. In addition, Notch plays a vital role in tissue and organ homeostasis in numerous systems, and toxicities, especially GI intolerance, have limited the effectiveness of gamma secretase inhibitors. New approaches are in development, and the downstream targets of Notch pathway signaling also may turn out to be good targets for therapy. In summary, a full understanding of the complex functions of Notch in osteosarcoma is only now unfolding, and this deeper knowledge will help position the field to better utilize novel therapies as they are developed.
C1 [McManus, Madonna M.; Hughes, Dennis P. M.] Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX 77030 USA.
   [McManus, Madonna M.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Unit 853, MOD Lab, Houston, TX 77030 USA.
   [Weiss, Kurt R.] Univ Pittsburgh, Med Ctr, Dept Orthoped Surg, Pittsburgh, PA USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Hughes, DPM (通讯作者)，Univ Texas MD Anderson Canc Ctr, Childrens Canc Hosp, Houston, TX 77030 USA.
EM dphughes@mdanderson.org
RI Hughes, Dennis/LPP 7849 2024
CR Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008 5472.CAN 09 3463
   Almog N, 2009, CANCER RES, V69, P836, DOI 10.1158/0008 5472.CAN 08 2590
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Artavanis Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770
   Bai F, 2010, J CHROMATOGR B, V878, P2348, DOI 10.1016/j.jchromb.2010.07.019
   Banerjee C, 1997, J CELL BIOCHEM, V66, P1, DOI 10.1002/(SICI)1097 4644(19970701)66:1<1::AID JCB1>3.0.CO;2 V
   Basu Roy U, 2013, CANCER LETT, V338, P158, DOI 10.1016/j.canlet.2012.05.028
   Benedito R, 2013, EXP CELL RES, V319, P1281, DOI 10.1016/j.yexcr.2013.01.010
   Benedito R, 2012, NATURE, V484, P110, DOI 10.1038/nature10908
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Benjamin LE, 1998, DEVELOPMENT, V125, P1591
   Bigas A, 1998, MOL CELL BIOL, V18, P2324, DOI 10.1128/MCB.18.4.2324
   Blake JA, 2014, NUCLEIC ACIDS RES, V42, pD810, DOI 10.1093/nar/gkt1225
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Capaccione KM, 2013, CARCINOGENESIS, V34, P1420, DOI 10.1093/carcin/bgt127
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011
   Charafe Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078 0432.CCR 09 1630
   Checchin D, 2006, INVEST OPHTH VIS SCI, V47, P3595, DOI 10.1167/iovs.05 1522
   Chen D, 2013, TUMOR BIOL, V34, P1895, DOI 10.1007/s13277 013 0733 z
   Cheng XY, 2009, J CELL MOL MED, V13, P4377, DOI 10.1111/j.1582 4934.2008.00664.x
   Cheung AMS, 2007, LEUKEMIA, V21, P1423, DOI 10.1038/sj.leu.2404721
   Cho HJ, 2007, J BIOCHEM MOL BIOL, V40, P1069
   Claesson Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019
   Crigler L, 2007, FASEB J, V21, P2050, DOI 10.1096/fj.06 5880com
   Crowther M, 2001, J LEUKOCYTE BIOL, V70, P478
   Dailey DD, 2013, BMC VET RES, V9, DOI 10.1186/1746 6148 9 130
   Dallas DJ, 1999, BONE, V25, P9, DOI 10.1016/S8756 3282(99)00099 X
   deAngelis MH, 1997, NATURE, V386, P717, DOI 10.1038/386717a0
   Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004
   del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood 2010 02 270819
   Deng ZL, 2008, FRONT BIOSCI LANDMRK, V13, P2001, DOI 10.2741/2819
   Deregowski V, 2006, J BIOL CHEM, V281, P6203, DOI 10.1074/jbc.M508370200
   Di Fiore R, 2013, J CELL PHYSIOL, V228, P1189, DOI 10.1002/jcp.24272
   Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667
   Domenga V, 2004, GENE DEV, V18, P2730, DOI 10.1101/gad.308904
   Duarte A, 2004, GENE DEV, V18, P2474, DOI 10.1101/gad.1239004
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Dufraine J, 2008, ONCOGENE, V27, P5132, DOI 10.1038/onc.2008.227
   Dumont AG, 2012, CARCINOGENESIS, V33, P1674, DOI 10.1093/carcin/bgs221
   Dunwoodie SL, 2002, DEVELOPMENT, V129, P1795
   Eilken HM, 2010, CURR OPIN CELL BIOL, V22, P617, DOI 10.1016/j.ceb.2010.08.010
   Eilken HM, 2010, NAT MED, V16, P853, DOI 10.1038/nm0810 853
   Engin FZ, 2008, NAT MED, V14, P299, DOI 10.1038/nm1712
   Engin F, 2009, HUM MOL GENET, V18, P1464, DOI 10.1093/hmg/ddp057
   Espinosa L, 2003, J BIOL CHEM, V278, P32227, DOI 10.1074/jbc.M304001200
   Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008 5472.CAN 06 0858
   Fantin A, 2010, BLOOD, V116, P829, DOI 10.1182/blood 2009 12 257832
   Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015 007 0023 5
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603 669
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   Fischer A, 2004, GENE DEV, V18, P901, DOI 10.1101/gad.291004
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Fouladi M, 2011, J CLIN ONCOL, V29, P3529, DOI 10.1200/JCO.2011.35.7806
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Gazzerro E, 2006, REV ENDOCR METAB DIS, V7, P51, DOI 10.1007/s11154 006 9000 6
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gibbs CP, 2011, CURR ORTHOP PRACT, V22, P322, DOI 10.1097/BCO.0b013e318221aee8
   Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200
   Greenwald Iva, 2013, WormBook, P1, DOI 10.1895/wormbook.1.10.2
   Hamada Y, 1999, DEVELOPMENT, V126, P3415
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Harrington LS, 2008, MICROVASC RES, V75, P144, DOI 10.1016/j.mvr.2007.06.006
   Hassan KA, 2013, CLIN CANCER RES, V19, P1972, DOI 10.1158/1078 0432.CCR 12 0370
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   Hellström M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Hellström M, 2007, CELL ADHES MIGR, V1, P133, DOI 10.4161/cam.1.3.4978
   Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872
   Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716
   Hisaki H, 2009, CELL ADHES MIGR, V3, P24
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Honoki K, 2010, ONCOL REP, V24, P501, DOI 10.3892/or_00000885
   Hu PP, 2013, J CANCER RES CLIN, V139, P1157, DOI 10.1007/s00432 013 1425 1
   Hu YY, 2012, ADV EXP MED BIOL, V727, P186, DOI 10.1007/978 1 4614 0899 4_14
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008 5472.CAN 08 4418
   Huang YS, 2012, APOPTOSIS, V17, P749, DOI 10.1007/s10495 012 0734 1
   Hughes DPM, 2009, CANCER TREAT RES, V152, P479, DOI 10.1007/978 1 4419 0284 9_28
   Hughes DPM, 2009, EXPERT OPIN DRUG DEL, V6, P1311, DOI 10.1517/17425240903280422
   Ikeda F, 2006, J IMMUNOL, V177, P2384, DOI 10.4049/jimmunol.177.4.2384
   Indraccolo S, 2006, CELL CYCLE, V5, P1751, DOI 10.4161/cc.5.16.2985
   Indraccolo S, 2013, ADV EXP MED BIOL, V734, P37, DOI 10.1007/978 1 4614 1445 2_3
   Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008 5472.CAN 08 2791
   Iruela Arispe ML, 2009, DEV CELL, V16, P222, DOI 10.1016/j.devcel.2009.01.013
   Iso T, 2003, J CELL PHYSIOL, V194, P237, DOI 10.1002/jcp.10208
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Jiang RL, 1998, GENE DEV, V12, P1046, DOI 10.1101/gad.12.7.1046
   Kageyama R, 1999, CELL RES, V9, P179, DOI 10.1038/sj.cr.7290016
   Kageyama R, 2007, DEV DYNAM, V236, P1403, DOI 10.1002/dvdy.21114
   Kannan S, 2013, J EXP MED, V210, P321, DOI 10.1084/jem.20121527
   Kappas NC, 2008, J CELL BIOL, V181, P847, DOI 10.1083/jcb.200709114
   Khanna C, 2000, CLIN EXP METASTAS, V18, P261, DOI 10.1023/A:1006767007547
   Khanna C, 2001, CANCER RES, V61, P3750
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Kofler Natalie M, 2011, Genes Cancer, V2, P1106, DOI 10.1177/1947601911423030
   Koga T, 2005, NAT MED, V11, P880, DOI 10.1038/nm1270
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kopan R, 2012, COLD SPRING HARB PER, V4
   Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078 0432.CCR 08 3087
   Krebs LT, 2000, GENE DEV, V14, P1343
   Krebs LT, 2004, GENE DEV, V18, P2469, DOI 10.1101/gad.1239204
   Krebs LT, 2010, GENESIS, V48, P146, DOI 10.1002/dvg.20599
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Kume T, 2009, VASC CELL, V1, DOI 10.1186/2040 2384 1 8
   Kunnimalaiyaan M, 2007, ONCOLOGIST, V12, P535, DOI 10.1634/theoncologist.12 5 535
   Lai EC, 2004, DEVELOPMENT, V131, P965, DOI 10.1242/dev.01074
   Lammli J, 2012, INT ORTHOP, V36, P2307, DOI 10.1007/s00264 012 1629 z
   Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Li JL, 2007, CANCER RES, V67, P11244, DOI 10.1158/0008 5472.CAN 07 0969
   Li YG, 2012, FEBS J, V279, P2247, DOI 10.1111/j.1742 4658.2012.08607.x
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Limbourg FP, 2005, CIRCULATION, V111, P1826, DOI 10.1161/01.CIR.0000160870.93058.DD
   Liu B, 2011, ACTA ONCOL, V50, P1142, DOI 10.3109/0284186X.2011.584553
   Liu H, 2009, CIRC RES, V104, P466, DOI 10.1161/CIRCRESAHA.108.184846
   Lobov IB, 2007, P NATL ACAD SCI USA, V104, P3219, DOI 10.1073/pnas.0611206104
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Martins Neves SR, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 139
   Mazumdar J, 2009, J CELL MOL MED, V13, P4319, DOI 10.1111/j.1582 4934.2009.00963.x
   Miyamoto Y, 2003, CANCER CELL, V3, P565, DOI 10.1016/S1535 6108(03)00140 5
   Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362
   Mu XC, 2013, Sarcoma, V2013, P11
   Mu XD, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00143
   Murakami M, 2008, ARTERIOSCL THROM VAS, V28, P658, DOI 10.1161/ATVBAHA.107.150433
   Nakajima M, 2003, MECH DEVELOP, V120, P657, DOI 10.1016/S0925 4773(03)00064 9
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Noguera Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Outtz HH, 2011, BLOOD, V118, P3436, DOI 10.1182/blood 2010 12 327015
   Outtz HH, 2010, J IMMUNOL, V185, P4363, DOI 10.4049/jimmunol.1000720
   Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008 5472.CAN 05 1208
   Phng LK, 2009, DEV CELL, V16, P196, DOI 10.1016/j.devcel.2009.01.015
   Phng LK, 2009, DEV CELL, V16, P70, DOI 10.1016/j.devcel.2008.12.009
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Pregizer S, 2007, J CELL BIOCHEM, V102, P1458, DOI 10.1002/jcb.21366
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008 5472.CAN 06 0793
   Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91
   Rainusso N, 2011, CANCER BIOL THER, V12, P278, DOI 10.4161/cbt.12.4.15951
   Ralston SH, 2006, GENE DEV, V20, P2492, DOI 10.1101/gad.1449506
   Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035
   Rehman AO, 2006, TRENDS CELL BIOL, V16, P293, DOI 10.1016/j.tcb.2006.04.003
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Sabins NC, 2013, MOL THER, V21, P1958, DOI 10.1038/mt.2013.133
   Sainson RCA, 2005, FASEB J, V19, P1027, DOI 10.1096/fj.04 3172fje
   Sato M, 1998, J BONE MINER RES, V13, P1221, DOI 10.1359/jbmr.1998.13.8.1221
   Scehnet JS, 2007, BLOOD, V109, P4753, DOI 10.1182/blood 2006 12 063933
   Schadler KL, 2010, CLIN CANCER RES, V16, P848, DOI 10.1158/1078 0432.CCR 09 1299
   Schmidt T, 2010, NATURE, V465, P697, DOI 10.1038/465697a
   Sciaudone M, 2003, ENDOCRINOLOGY, V144, P5631, DOI 10.1210/en.2003 0463
   Segarra M, 2008, BLOOD, V112, P1904, DOI 10.1182/blood 2007 11 126045
   SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0
   Shawber CJ, 2004, BIOESSAYS, V26, P225, DOI 10.1002/bies.20004
   Shawber CJ, 2003, ANN NY ACAD SCI, V995, P162, DOI 10.1111/j.1749 6632.2003.tb03219.x
   Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092 8674(00)80244 5
   Shibuya M, 2006, J BIOCHEM MOL BIOL, V39, P469
   Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008 5472.CAN 06 3958
   Siclari VA, 2010, J ORTHOP SURG RES, V5, DOI 10.1186/1749 799X 5 78
   Siekmann AF, 2007, NATURE, V445, P781, DOI 10.1038/nature05577
   Siekmann AF, 2013, EXP CELL RES, V319, P1255, DOI 10.1016/j.yexcr.2013.01.019
   Singh N, 2000, EXP HEMATOL, V28, P527, DOI 10.1016/S0301 472X(00)00146 6
   Sörensen I, 2009, BLOOD, V113, P5680, DOI 10.1182/blood 2008 08 174508
   Stewart KS, 2011, BLOOD, V117, P719, DOI 10.1182/blood 2010 05 284869
   Suchting S, 2007, P NATL ACAD SCI USA, V104, P3225, DOI 10.1073/pnas.0611177104
   Sullivan JP, 2010, CANCER RES, V70, P9937, DOI 10.1158/0008 5472.CAN 10 0881
   SWIATEK PJ, 1994, GENE DEV, V8, P707, DOI 10.1101/gad.8.6.707
   Tammela T, 2008, NATURE, V454, P656, DOI 10.1038/nature07083
   Tammela T, 2011, NAT CELL BIOL, V13, P1202, DOI 10.1038/ncb2331
   Tanaka M, 2009, BRIT J CANCER, V100, P1957, DOI 10.1038/sj.bjc.6605060
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016
   Tezuka K, 2002, J BONE MINER RES, V17, P231, DOI 10.1359/jbmr.2002.17.2.231
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Thomas JL, 2013, CELL MOL LIFE SCI, V70, P1779, DOI 10.1007/s00018 013 1312 6
   Trindade A, 2008, BLOOD, V112, P1720, DOI 10.1182/blood 2007 09 112748
   Uyttendaele H, 2001, P NATL ACAD SCI USA, V98, P5643, DOI 10.1073/pnas.091584598
   van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659
   Villa N, 2001, MECH DEVELOP, V108, P161, DOI 10.1016/S0925 4773(01)00469 5
   Wagner ER, 2010, PPAR RES, V2010, DOI 10.1155/2010/956427
   Wang JL, 2012, ADV EXP MED BIOL, V727, P174, DOI 10.1007/978 1 4614 0899 4_13
   Wang L, 2011, CANCER BIOL THER, V11, P457, DOI 10.4161/cbt.11.5.14372
   Wang L, 2011, INT J CANCER, V128, P294, DOI 10.1002/ijc.25331
   Wang L, 2009, CANCER BIOL THER, V8, P543, DOI 10.4161/cbt.8.6.7695
   Wang ZW, 2010, J CELL BIOCHEM, V109, P726, DOI 10.1002/jcb.22451
   Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030
   Weiss KR, 2010, 2010 M MUSC TUM SOC
   Weiss KR, 2006, CLIN ORTHOP RELAT R, P111, DOI 10.1097/01.blo.0000229333.98781.56
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Williams CK, 2006, BLOOD, V107, P931, DOI 10.1182/blood 2005 03 1000
   Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040
   Wilson H, 2008, VET J, V175, P69, DOI 10.1016/j.tvjl.2007.07.025
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097 4644(19990915)74:4<596::AID JCB9>3.0.CO;2 F
   Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yan MH, 2010, NATURE, V463, pE6, DOI 10.1038/nature08751
   Yang M, 2011, CANCER SCI, V102, P1774, DOI 10.1111/j.1349 7006.2011.02028.x
   Yu XW, 2014, TUMOR BIOL, V35, P155, DOI 10.1007/s13277 013 1019 1
   Zage PE, 2012, PEDIATR BLOOD CANCER, V58, P682, DOI 10.1002/pbc.23202
   Zamurovic N, 2004, J BIOL CHEM, V279, P37704, DOI 10.1074/jbc.M403813200
   Zhang JP, 2011, CANCER LETT, V309, P220, DOI 10.1016/j.canlet.2011.06.008
   Zhang P, 2010, ONCOGENE, V29, P2916, DOI 10.1038/onc.2010.62
   Zhao XC, 2013, NEOPLASIA, V15, P815, DOI 10.1593/neo.13550
   Zweidler McKay PA, 2005, BLOOD, V106, P3898, DOI 10.1182/blood 2005 01 0355
   Zweidler McKay PA, 2004, SEMIN CANCER BIOL, V14, P329, DOI 10.1016/j.semcancer.2004.04.012
NR 208
TC 28
Z9 34
U1 0
U2 10
PU SPRINGER VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D 14197 BERLIN, GERMANY
SN 0065 2598
EI 2214 8019
BN 978 3 319 04843 7; 978 3 319 04842 0
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2014
VL 804
BP 67
EP 92
DI 10.1007/978 3 319 04843 7_4
D2 10.1007/978 3 319 04843 7
PG 26
WC Oncology; Cell Biology
WE Book Citation Index– Science (BKCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA BB1YV
UT WOS:000341485500005
DA 2025 08 17
ER

PT J
AU Zhong, JQ
   Hu, XD
   Dong, JY
   Chen, YJ
   Liu, BT
   Hao, MM
   Xie, HJ
   Ke, CH
   Peng, ZX
AF Zhong, Jiaqi
   Hu, Xiaodong
   Dong, Jieyang
   Chen, Yujiong
   Liu, Botao
   Hao, Mingming
   Xie, Haijiao
   Ke, Chunhai
   Peng, Zhaoxiang
TI Bisphosphonates activated keratin assembled nanoparticle targeting bone
   fracture for enhanced immunomodulatory and osteoinductivity
SO CHEMICAL ENGINEERING JOURNAL
LA English
DT Article
DE Self assembly; Protein nanoparticles; Fracture targeting;
   Immunomodulatory; Coagulation promoting
ID SECONDARY STRUCTURE; PROTEIN
AB Bone fractures pose significant clinical challenges and require innovative solutions for effective treatment and rapid recovery. Nanoscale protein based materials are prominent in biotechnology and biomedicine, demonstrating versatility in biological processes and drug delivery. Herein, we designed and fabricated self assembled keratin nanoparticles via a bisphosphonate (BP) activated conformation conservative assembly process. We determined the structural properties of the nanoparticles and explored the immunomodulatory and osteoinductivity functions retained from keratin. In addition, the keratin BP nanoparticles could repair bone fractures. This study on multifunctional self assembled protein drug nanoparticles provides useful baseline data for exploring novel therapeutic options for acute bone fracture and other diseases.
C1 [Zhong, Jiaqi; Hu, Xiaodong; Dong, Jieyang; Chen, Yujiong; Liu, Botao; Hao, Mingming; Ke, Chunhai; Peng, Zhaoxiang] Ningbo Univ, Affiliated Li Huili Hosp, Ningbo 315040, Peoples R China.
   [Zhong, Jiaqi; Hu, Xiaodong; Peng, Zhaoxiang] Ningbo Univ, Hlth Sci Ctr, Ningbo 315211, Peoples R China.
   [Xie, Haijiao] Hangzhou Yanqu Informat Technol Co Ltd, Hangzhou 310003, Peoples R China.
C3 Ningbo University; Ningbo University
RP Ke, CH; Peng, ZX (通讯作者)，Ningbo Univ, Affiliated Li Huili Hosp, Ningbo 315040, Peoples R China.; Peng, ZX (通讯作者)，Ningbo Univ, Hlth Sci Ctr, Ningbo 315211, Peoples R China.
EM k609098003@163.com; pzxao@hotmail.com
RI ; 伯韬, 柳/JBI 8702 2023; Chen, Yujiong/HZH 7454 2023; dong,
   jieyang/JKJ 4136 2023
OI liu, botao/0000 0001 9305 8380; Peng, Zhaoxiang/0000 0001 6508 4100;
   Zhong, Jiaqi/0000 0002 1976 978X; Dong, Jieyang/0000 0002 2798 9491; 
FU Ningbo Natural Science Foundation [2023S030]; Zhejiang Xinmiao Talents
   Program [2023R405050]; Zhejiang Provincial Natural Science Foundation of
   China [LGF21H060003, BY22H181190]; Foundation Project for Medical
   Science and Technology of Zhejiang Province [2022KY1083]; State Key
   Laboratory for Managing Biotic and Chemical Threats to the Quality and
   Safety of Agro products and Core Facility Platform of Ningbo University
FX This work is funded by the Ningbo Natural Science Foundation (2023S030)
   , Zhejiang Xinmiao Talents Program (2023R405050) , the Zhejiang
   Provincial Natural Science Foundation of China under Grant (No.
   LGF21H060003, BY22H181190) , and The Foundation Project for Medical
   Science and Technology of Zhejiang Province (No. 2022KY1083) . The
   authors would like to thank the technical support provided by State Key
   Laboratory for Managing Biotic and Chemical Threats to the Quality and
   Safety of Agro products and Core Facility Platform of Ningbo University,
   we also acknowledge Dr. Tianyu Du, and Dr. Weilai Zhu for providing
   guidance and fruitful discussions.
CR Abbas M, 2017, ADV MATER, V29, DOI 10.1002/adma.201605021
   ASTM, 2017, Standard Practice for Assessment of Hemolytic Properties of Materials
   BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307
   Collins MN, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202010609
   Dias GJ, 2020, INT J BIOL MACROMOL, V165, P100, DOI 10.1016/j.ijbiomac.2020.09.133
   Ding Y, 2020, BIOMATER SCI UK, V8, P1840, DOI 10.1039/c9bm01924c
   Docter D, 2014, NAT PROTOC, V9, P2030, DOI 10.1038/nprot.2014.139
   Dong JY, 2023, J ORTHOP TRANSL, V40, P27, DOI 10.1016/j.jot.2023.05.003
   Feroz S, 2020, BIOACT MATER, V5, P496, DOI 10.1016/j.bioactmat.2020.04.007
   Finkelstein E., 2006, The incidence and economic burden of injuries in the United States, P1
   Gaspar VM, 2020, ADV MATER, V32, DOI 10.1002/adma.201903975
   JACKSON M, 1995, CRIT REV BIOCHEM MOL, V30, P95, DOI 10.3109/10409239509085140
   Jumper J, 2021, NATURE, V596, P583, DOI 10.1038/s41586 021 03819 2
   Kiani A, 2012, ACTA BIOMATER, V8, P333, DOI 10.1016/j.actbio.2011.08.025
   Kim BJ, 2015, ANGEW CHEM INT EDIT, V54, P7318, DOI 10.1002/anie.201501748
   Li JF, 2016, ANGEW CHEM INT EDIT, V55, P2592, DOI 10.1002/anie.201511276
   Li YM, 2017, MAT SCI ENG C MATER, V73, P189, DOI 10.1016/j.msec.2016.12.067
   Lorenz Fonfria VA, 2020, CHEM REV, V120, P3466, DOI 10.1021/acs.chemrev.9b00449
   Lu YP, 2023, ACS APPL MATER INTER, V15, P29841, DOI 10.1021/acsami.3c03237
   Marcandalli J, 2019, CELL, V176, P1420, DOI 10.1016/j.cell.2019.01.046
   Rahmany MB, 2013, BIOMATERIALS, V34, P2492, DOI 10.1016/j.biomaterials.2012.12.008
   Ren ZY, 2022, FOOD CHEM, V375, DOI 10.1016/j.foodchem.2021.131795
   Sequeira I, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 05872 4
   SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079
   Sun Z, 2018, J MATER CHEM B, V6, P6133, DOI 10.1039/c8tb01109e
   Tang JC, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202102465
   Tu J, 2018, PHARMACOL RES, V129, P491, DOI 10.1016/j.phrs.2017.11.025
   Wan XZ, 2020, CHEM ENG J, V400, DOI 10.1016/j.cej.2020.125964
   Wang YM, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202200290
   Wang ZH, 2023, NANO LETT, V23, P6544, DOI 10.1021/acs.nanolett.3c01567
   Waters M, 2018, ACTA BIOMATER, V66, P213, DOI 10.1016/j.actbio.2017.10.042
   Welsh TJ, 2022, NANO LETT, V22, P612, DOI 10.1021/acs.nanolett.1c03138
   Xu F, 2022, SMALL, V18, DOI 10.1002/smll.202201205
   Zhang M, 2024, BIOACT MATER, V31, P368, DOI 10.1016/j.bioactmat.2023.08.016
   Zhang XD, 2021, MATTER US, V4, P2727, DOI 10.1016/j.matt.2021.05.019
   Zhong WJ, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202212870
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 37
TC 4
Z9 4
U1 7
U2 22
PU ELSEVIER SCIENCE SA
PI LAUSANNE
PA PO BOX 564, 1001 LAUSANNE, SWITZERLAND
SN 1385 8947
EI 1873 3212
J9 CHEM ENG J
JI Chem. Eng. J.
PD JUN 1
PY 2024
VL 489
AR 151265
DI 10.1016/j.cej.2024.151265
EA APR 2024
PG 11
WC Engineering, Environmental; Engineering, Chemical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA RX1Y5
UT WOS:001230878200004
DA 2025 08 17
ER

PT J
AU Chotphruethipong, L
   Binlateh, T
   Hutamekalin, P
   Aluko, RE
   Tepaamorndech, S
   Zhang, B
   Benjakul, S
AF Chotphruethipong, Lalita
   Binlateh, Thunwa
   Hutamekalin, Pilaiwanwadee
   Aluko, Rotimi E.
   Tepaamorndech, Surapun
   Zhang, Bin
   Benjakul, Soottawat
TI Impact of Hydrolyzed Collagen from Defatted Sea Bass Skin on
   Proliferation and Differentiation of Preosteoblast MC3T3 E1 Cells
SO FOODS
LA English
DT Article
DE bioactive peptides; sea bass; osteoblast; differentiation; hydrolyzed
   collagen; bone
ID PEPTIDES; PATHWAYS
AB Osteoporosis is a serious problem affecting health of the elderly. Drugs (bisphosphonates) applied for treatment are often accompanied by adverse side effects. Thus, fish byproduct derived peptides, particularly hydrolyzed collagen (HC) from defatted sea bass skin, could be a safe source of anti osteoporosis agents. This study aimed to examine the effects of HC on proliferation and differentiation of preosteoblast cells. HC prepared using papain before Alcalase hydrolysis was determined for molecular weight (MW) distribution. Thereafter, the resulting HC (50 800 mu g/mL) was added to the cell. Proliferation, alkaline phosphatase activity (AP A) and mineralization of cells were investigated. Moreover, the expression of runt related transcription factor 2 (RUNX2) and the p Akt/Akt pathway were also determined using Western blot. The results showed that HC had an MW < 3 kDa. HC (50 200 mu g/mL) could promote cell proliferation. Nevertheless, HC at 100 mu g/mL (HC 100) had enhanced AP A and increased mineralization during the first 7 days of culture. Moreover, HC treated cells had higher calcium depositions than the control (p < 0.05). Additionally, cells treated with HC 100 had higher levels of RUNX2 and p Akt expressions than control (p < 0.05). Therefore, HC could be a promising functional ingredient to promote osteoblast proliferation and differentiation, which could enhance bone strength.
C1 [Chotphruethipong, Lalita; Benjakul, Soottawat] Prince Songkla Univ, Fac Agroind, Int Ctr Excellence Seafood Sci & Innovat, Hat Yai 90110, Songkhla, Thailand.
   [Binlateh, Thunwa] Suranaree Univ Technol, Sch Geriatr Oral Hlth, Inst Dent, Nakhon Ratchasima 30000, Thailand.
   [Hutamekalin, Pilaiwanwadee] Prince Songkla Univ, Fac Sci, Div Hlth & Appl Sci, Hat Yai 90110, Songkhla, Thailand.
   [Aluko, Rotimi E.] Univ Manitoba, Dept Food & Human Nutr Sci, Winnipeg, MB R3T 2N2, Canada.
   [Tepaamorndech, Surapun] Natl Sci & Technol Dev Agcy NSTDA, Natl Ctr Genet Engn & Biotechnol Ctr BIOTEC, 113 Thailand Sci Pk, Pathum Thani 12120, Thailand.
   [Zhang, Bin] Zhejiang Ocean Univ, Coll Food & Pharm, Zhoushan 316022, Peoples R China.
C3 Prince of Songkla University; Suranaree University of Technology; Prince
   of Songkla University; University of Manitoba; National Science &
   Technology Development Agency   Thailand; Zhejiang Ocean University
RP Benjakul, S (通讯作者)，Prince Songkla Univ, Fac Agroind, Int Ctr Excellence Seafood Sci & Innovat, Hat Yai 90110, Songkhla, Thailand.; Aluko, RE (通讯作者)，Univ Manitoba, Dept Food & Human Nutr Sci, Winnipeg, MB R3T 2N2, Canada.
EM lalitac.ch@psu.ac.th; thunwa.bin@gmail.com; pilaiwanwadee.h@psu.ac.th;
   rotimi.aluko@umanitoba.ca; surapun.tep@biotec.or.th;
   zhanbin@zjou.edu.cn; soottawat.b@psu.ac.th
RI Benjakul, Soottawat/C 8927 2009; Aluko, Rotimi/HPG 2631 2023
OI Hutamekalin, Pilaiwanwadee/0000 0003 2892 7003; Benjakul,
   Soottawat/0000 0001 9433 3671; Aluko, Rotimi/0000 0002 9025 2513
FU National Research Council of Thailand (NRCT) under the International
   Research Network (IRN) program; National Science and Technology
   Development Agency [P 20 52297]; Prince of Songkla University
   [AGR6402088N]
FX This research was supported by the National Research Council of Thailand
   (NRCT) under the International Research Network (IRN) program and
   National Science and Technology Development Agency (Grant No.
   P 20 52297). Financial support was provided by Prince of Songkla
   University under the Prachayacharn grant (AGR6402088N).
CR Benjakul S, 2018, INT J FOOD SCI TECH, V53, P1871, DOI 10.1111/ijfs.13772
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Chotphruethipong L, 2021, J FOOD SCI TECH MYS, V58, P541, DOI 10.1007/s13197 020 04566 4
   Chotphruethipong L, 2019, PROCESS BIOCHEM, V86, P58, DOI 10.1016/j.procbio.2019.08.012
   Chotphruethipong L, 2019, J FOOD SCI, V84, P1799, DOI 10.1111/1750 3841.14687
   Chotphruethipong L, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12825
   Chu N, 2018, CELL, V174, P897, DOI 10.1016/j.cell.2018.07.003
   Cohen Solal KA, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0404 3
   Gomathi K, 2020, LIFE SCI, V245, DOI 10.1016/j.lfs.2020.117389
   Gu YX, 2013, J BIOMED MATER RES A, V101, P748, DOI 10.1002/jbm.a.34377
   Heo SY, 2018, CELL BIOCHEM FUNCT, V36, P137, DOI 10.1002/cbf.3325
   Karami Z, 2019, J FOOD SCI TECH MYS, V56, P535, DOI 10.1007/s13197 018 3549 4
   Kimira Y, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658 017 0060 2
   Kimira Y, 2014, BIOCHEM BIOPH RES CO, V453, P498, DOI 10.1016/j.bbrc.2014.09.121
   Li Y, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 40371 6
   Paisrisarn P, 2018, TOXICOL LETT, V299, P172, DOI 10.1016/j.toxlet.2018.10.008
   Sae Leaw T, 2017, J FOOD BIOCHEM, V41, DOI 10.1111/jfbc.12350
   Tao J, 2018, MAR DRUGS, V16, DOI 10.3390/md16040100
   Wang JN, 2020, J AGR FOOD CHEM, V68, P7630, DOI 10.1021/acs.jafc.0c02717
   Wang JN, 2020, MOLECULES, V25, DOI 10.3390/molecules25102305
   Wu CM, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 277
   Wu WM, 2020, J FUNCT FOODS, V64, DOI 10.1016/j.jff.2019.103701
   Ye ML, 2019, RSC ADV, V9, P14627, DOI 10.1039/c9ra00945k
NR 23
TC 18
Z9 19
U1 0
U2 41
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2304 8158
J9 FOODS
JI Foods
PD JUL
PY 2021
VL 10
IS 7
AR 1476
DI 10.3390/foods10071476
PG 13
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA TO0TL
UT WOS:000676635600001
PM 34202207
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wu, MR
   Li, YP
   Zhu, GC
   Lu, Y
   Wang, YP
   Jules, J
   McConnell, M
   Serra, R
   Shao, JZ
   Chen, W
AF Wu, Mengrui
   Li, Yi Ping
   Zhu, Guochun
   Lu, Yun
   Wang, Yiping
   Jules, Joel
   McConnell, Matthew
   Serra, Rosa
   Shao, Jian Zhong
   Chen, Wei
TI Chondrocyte specific Knockout of Cbfβ Reveals the Indispensable Function
   of Cbfβ in Chondrocyte Maturation, Growth Plate Development and
   Trabecular Bone Formation in Mice
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Cbf beta; Runx; Indian hedgehog (Ihh); skeletal development; chondrocyte
   proliferation and hypertrophy; endochondral bone formation
ID BINDING FACTOR BETA; CLEIDOCRANIAL DYSPLASIA; INDIAN HEDGEHOG;
   OSTEOBLAST DIFFERENTIATION; ENDOCHONDRAL SKELETON; IN VITRO; RUNX2;
   EXPRESSION; CARTILAGE; CHONDROGENESIS
AB Despite years of research into bone formation, the mechanisms by which transcription factors specify growth plate development and trabecular bone formation remain unclear and the role of hypertrophic chondrocytes in trabeculae morphogenesis is controversial. To study the role of Core binding factor beta (Cbf beta) in postnatal cartilage development and endochondral bone formation, we generated chondrocyte specific Cbf beta deficient mice (Cbf beta f/fCol2 alpha 1 Cre mice) using floxed alleles of Cbf beta (Cbf beta f/f) and Cre driven by the Collagen 2 alpha 1 promoter (Col2 alpha 1 Cre). Cbf beta f/fCol2 alpha 1 Cre mice evaded developmental and newborn lethality to survive to adulthood and displayed severe skeletal malformation. Cbf alpha f/fCol2 alpha 1 Cre mice had dwarfism, hypoplastic skeletons, defective bone mineralization, shortened limbs, shortened sternum bodies, and un calcified occipital bones and hyoid bones. In the long bone cartilage, the resting zone was elongated, and chondrocyte proliferation and hypertrophy were impaired in Cbf beta f/fCol2 alpha 1 Cre mice, which led to deformation of the growth plates. Primary spongiosa formation was delayed, diaphysis was shortened and trabecular bone formation was almost absent in the mutant mice. In addition, lamellar bone formation in the secondary spongiosa was also impaired. However, osteoclast formation in the trabecular bone was not affected. Cbf beta deficiency led to down regulation of chondrocyte regulating genes [i.e, patched (Ptc1), Cyclin DI and Indian hedgehog (Ihh)] in the cartilage. Interestingly, the expression of Runx2 and Runx3 was not changed in the cartilage of the mutants. Collectively, the results revealed that Cbf beta is crucial for postnatal skeletal development and endochondral bone formation through its function in growth plate development and chondrocyte proliferation and differentiation. This study also revealed that chondrocyte maturation, mediated by Cbf beta, was critical to trabecular bone morphogenesis. Significantly, these findings provide insight into the role of Cbf beta in postnatal skeletogenesis, which may assist in the development of new therapies for osteoporosis.
C1 [Wu, Mengrui; Li, Yi Ping; Wang, Yiping; Shao, Jian Zhong] Zhejiang Univ, Inst Genet, Life Sci Coll, Hangzhou 310058, Zhejiang, Peoples R China.
   [Wu, Mengrui; Li, Yi Ping; Zhu, Guochun; Lu, Yun; Wang, Yiping; Jules, Joel; McConnell, Matthew; Chen, Wei] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Serra, Rosa] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL 35294 USA.
C3 Zhejiang University; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham
RP Chen, W (通讯作者)，Univ Alabama Birmingham, Dept Pathol, SHEL 815,1825 Univ Blvd, Birmingham, AL 35294 USA.
EM ypli@uab.edu; wechen@uab.edu
RI wang, yi/KBB 3614 2024; Shao, Zongze/T 6682 2017; Li,
   Yi Ping/ABF 9245 2020
OI McConnell, Matthew/0000 0003 0194 5287; 
FU National Institutes of Health [AR 44741, AR 055307]
FX We thank Ms. Suzy Newton and Ms. Christie Paulson for their excellent
   assistance with the manuscript. We appreciate the assistance of the
   Center for Metabolic Bone Disease (P30 AR046031), Small Animal
   Phenotyping Core, Metabolism Core, and Neuroscience Molecular Detection
   Core Laboratory (P30 NS0474666) at UAB. This work was supported by the
   National Institutes of Health grants AR 44741 (Y.P.L.) and AR 055307
   (Y.P.L.).
CR Chen W, 2007, J MOL BIOL, V368, P8, DOI 10.1016/j.jmb.2007.01.088
   DeLise AM, 2000, METH MOL B, V137, P359
   Drissi MH, 2003, J CELL BIOCHEM, V90, P1287, DOI 10.1002/jcb.10677
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Enomoto H, 2000, J BIOL CHEM, V275, P8695, DOI 10.1074/jbc.275.12.8695
   Gosset M, 2008, NAT PROTOC, V3, P1253, DOI 10.1038/nprot.2008.95
   Kanatani N, 2006, DEV BIOL, V296, P48, DOI 10.1016/j.ydbio.2006.03.039
   Karp SJ, 2000, DEVELOPMENT, V127, P543
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Khan A, 2006, AM J MED GENET A, V140A, P2349, DOI 10.1002/ajmg.a.31479
   Kimura A, 2010, DEVELOPMENT, V137, P1159, DOI 10.1242/dev.045005
   Kobayashi H, 2000, BIOCHEM BIOPH RES CO, V273, P630, DOI 10.1006/bbrc.2000.2981
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kundu M, 2002, NAT GENET, V32, P639, DOI 10.1038/ng1050
   LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519
   Liakhovitskaia A, 2010, DEV BIOL, V340, P539, DOI 10.1016/j.ydbio.2010.02.005
   Long FX, 2004, DEVELOPMENT, V131, P1309, DOI 10.1242/dev.01006
   Long FX, 2001, DEVELOPMENT, V128, P5099
   Mackie EJ, 2008, INT J BIOCHEM CELL B, V40, P46, DOI 10.1016/j.biocel.2007.06.009
   Maeda Y, 2007, P NATL ACAD SCI USA, V104, P6382, DOI 10.1073/pnas.0608449104
   Mak KK, 2008, DEV CELL, V14, P674, DOI 10.1016/j.devcel.2008.02.003
   MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306
   Miller J, 2002, NAT GENET, V32, P645, DOI 10.1038/ng1049
   Mundlos S, 1999, J MED GENET, V36, P177
   Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092 8674(00)80260 3
   Naoe Y, 2007, J EXP MED, V204, P1749, DOI 10.1084/jem.20062456
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ovchinnikov DA, 2000, GENESIS, V26, P145, DOI 10.1002/(SICI)1526 968X(200002)26:2<145::AID GENE14>3.3.CO;2 3
   Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359
   Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092 8674(00)81389 6
   Wang YJ, 2005, J BONE MINER RES, V20, P1624, DOI 10.1359/JBMR.050516
   Westendorf JJ, 1999, J CELL BIOCHEM, P51
   Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005
   Yoshida CA, 2002, NAT GENET, V32, P633, DOI 10.1038/ng1015
   Yoshida CA, 2004, GENE DEV, V18, P952, DOI 10.1101/gad.1174704
NR 36
TC 29
Z9 31
U1 1
U2 14
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2014
VL 10
IS 8
BP 861
EP 872
DI 10.7150/ijbs.8521
PG 12
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA AT4AZ
UT WOS:000344881300006
PM 25170300
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zhang, L
   Zhang, Y
   Miao, MM
   Hu, SQ
   Wang, XP
   Zhao, LS
   Huang, XW
   Cao, G
   Shou, D
AF Zhang, Li
   Zhang, Yang
   Miao, Maomao
   Hu, Shaoqi
   Wang, Xuping
   Zhao, Lisha
   Huang, Xiaowen
   Cao, Gang
   Shou, Dan
TI Erxian herbal pair enhances bone formation in infected bone nonunion
   models and attenuates lipopolysaccharide induced osteoblastinhibition by
   regulating miRNA 34a 5p
SO BIOENGINEERED
LA English
DT Article
DE Erxian herbal pair; bone repair; LPS induced bone loss; MiRNA 34a 5p;
   osteoblasts
ID ER XIAN DECOCTION; IN VIVO; DIFFERENTIATION; OSTEOGENESIS; FORMULA;
   SMAD2/3; MIR 34A; CANCER; RATS
AB Bacterium induced inflammatory responses cause bone nonunion. Although antibiotics suppress infection, bone loss after antibacterial treatment remains a critical challenge. Erxian herbal pair (EHP) has been proven effective in promoting bone formation. Our study aimed to investigate the effect of EHP on bone repair after anti infection treatment, explore its effect on a lipopolysaccharide (LPS) induced osteoblast. We evaluated effects of EHP on bone repair with Micro CT, and morphology detecting. Chemical constituents of EHP and EHP containing serum (EHP CS) were identified by UHPLC Q/TOF MS. In addition, osteoblast induced by LPS was established and administrated with EHP CS. Cell proliferationwas assessed by MTT. Target prediction identified SMAD2 as a potential target of miRNA 34a 5p. MiRNA mimic, inhibitor and siRNA were transiently transfected into osteoblasts. The mRNA levels and protein expressions of miRNA 34a 5p, BMP2, Runx2, SMAD2 were assessed. The results showed that the main biocactivity ingredients in EHP CS were Baohuoside Iota and Orcinol Glucoside. EHP could promote bone remolding after anti infection therapy and restore the activity of LPS induced osteoblasts. Moreover, miRNA 34a 5p was dramatically downregulated and SMAD2 was upregulated after LPS stimulation, while EHP resisted the inhibition of LPS by promoting miRNA 34a 5p, ALP, and BMP2 expressions. Whereas downregulation of miRNA 34a 5p reversed these effects. Silencing endogenous SMAD2 expression markedly promoted BMP2 and ALP activity and enhanced osteogenesis. Taken together, EHP restored LPS induced bone loss by regulating miRNA 34a 5p levels and repressing its target gene SMAD2. EHP might be a potential adjuvant herbal remedy for the treatment of bone nonunion, and miRNA 34a 5p is a novel target for controlling bone and metabolic diseases.
C1 [Zhang, Li; Miao, Maomao; Hu, Shaoqi; Cao, Gang; Shou, Dan] Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.
   [Zhang, Yang] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Inst Orthopad & Traumatol, Hangzhou 310053, Peoples R China.
   [Wang, Xuping; Zhao, Lisha; Huang, Xiaowen; Shou, Dan] Zhejiang Acad Tradit Chinese Med, Dept Med, Hangzhou 310007, Peoples R China.
   [Zhang, Li] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Zhejiang Prov Hosp Tradit Chinese Med, Dept Pharm, Hangzhou 310006, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical
   University; Zhejiang Chinese Medical University
RP Cao, G; Shou, D (通讯作者)，Zhejiang Chinese Med Univ, Sch Pharmaceut Sci, Hangzhou 310053, Zhejiang, Peoples R China.
EM caogang33@163.com; shoudanok@163.com
RI Cao, Gang/AGQ 9295 2022
OI Shou, Dan/0000 0003 3465 4072
FU National Natural Science Foundation of China [81803808, 81873062];
   Science and technology project of Zhejiang Province [LGF21H28004];
   Zhejiang Provincial Medical and Health Science and Technology Fund
   [2021KY112]; Zhejiang Provincial Traditional Chinese Medicine Science
   and Technology Fund [2021ZA033, 2020ZQ008]
FX This work was supported by the National Natural Science Foundation of
   China (grant nos. 81803808 and 81873062), the Science and technology
   project of Zhejiang Province (grant no. LGF21H28004), the Zhejiang
   Provincial Medical and Health Science and Technology Fund (grant no.
   2021KY112), and the Zhejiang Provincial Traditional Chinese Medicine
   Science and Technology Fund (grant no. 2021ZA033, 2020ZQ008
CR Bian QY, 2013, CHEM PHARM BULL, V61, P802, DOI 10.1248/cpb.c12 01058
   Boyle KK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222034
   Cai PS, 2019, AM J TRANSL RES, V11, P865
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Cheng T, 2016, J CHROMATOGR B, V1033, P353, DOI 10.1016/j.jchromb.2016.09.010
   Choi JY, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122591
   Chou YJ, 2018, J ORTHOP SURG RES, V13, DOI 10.1186/s13018 018 0967 y
   Furman BD, 2015, ARTHRITIS RHEUMATOL, V67, P1234, DOI 10.1002/art.39064
   Hajishengallis G, 2016, SEMIN IMMUNOL, V28, P146, DOI 10.1016/j.smim.2016.02.002
   Inubushi T, 2020, J ORAL BIOSCI, V62, P147, DOI 10.1016/j.job.2020.05.001
   Jiang LC, 2017, CANCER RES, V77, P2746, DOI 10.1158/0008 5472.CAN 16 2183
   Jing YK., 2020, NATURE, V582, P134
   Lan YH, 2019, MOL MED REP, V19, P3291, DOI 10.3892/mmr.2019.9975
   Lee JH, 2018, ARCH ORAL BIOL, V96, P46, DOI 10.1016/j.archoralbio.2018.08.011
   Lee WY, 2016, MOL CELL ENDOCRINOL, V430, P97, DOI 10.1016/j.mce.2016.04.014
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li JY, 2017, CLIN INTERV AGING, V12, P45, DOI 10.2147/CIA.S117597
   Li ZM, 2021, BIOENGINEERED, V12, P1026, DOI 10.1080/21655979.2021.1899533
   Liu H, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1285 y
   Liu SF, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/4079210
   Maagensen H, 2018, J CLIN ENDOCR METAB, V103, P2042, DOI 10.1210/jc.2018 00176
   Marahleh A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02925
   Matsumoto A, 2020, J ORAL BIOSCI, V62, P44, DOI 10.1016/j.job.2020.01.004
   Mei L, 2021, BIOENGINEERED, V12, P11756, DOI 10.1080/21655979.2021.2009618
   Nagao M, 2017, J CELL PHYSIOL, V232, P3337, DOI 10.1002/jcp.25777
   Nazarian A, 2008, CALCIFIED TISSUE INT, V83, P368, DOI 10.1007/s00223 008 9174 x
   Nian H, 2006, J ETHNOPHARMACOL, V108, P96, DOI 10.1016/j.jep.2006.04.020
   Qin ZX, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123984
   Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531
   Ruan LB, 2018, INT J CLIN EXP PATHO, V11, P1135
   Song B, 2009, CYTOKINE GROWTH F R, V20, P379, DOI 10.1016/j.cytogfr.2009.10.010
   Tando T, 2016, J BIOL CHEM, V291, P12184, DOI 10.1074/jbc.M115.680579
   Wang B, 2021, BIOENGINEERED, V12, P12040, DOI 10.1080/21655979.2021.2002498
   Wang GL, 2018, INT J MOL MED, V41, P791, DOI 10.3892/ijmm.2017.3261
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wang NN, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00988
   Wang Q, 2021, BIOENGINEERED, V12, P8173, DOI 10.1080/21655979.2021.1977766
   Winkler H, 2017, EFORT OPEN REV, V2, P110, DOI 10.1302/2058 5241.2.160063
   Wong KC, 2014, AM J CHINESE MED, V42, P409, DOI 10.1142/S0192415X1450027X
   Wu GJ, 2016, ARCH TOXICOL, V90, P905, DOI 10.1007/s00204 015 1491 z
   Wu Y, 2019, RNA BIOL, V16, P1494, DOI 10.1080/15476286.2019.1639311
   Xi YH, 2019, BIOMED PHARMACOTHER, V115, DOI 10.1016/j.biopha.2019.108850
   Zhang K, 2020, ARCH ORAL BIOL, V112, DOI 10.1016/j.archoralbio.2020.104667
   Zhang Y, 2019, JOVE J VIS EXP, DOI 10.3791/57294
   Zhao YW, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/8836599
   Zhou J, 2014, MOLECULES, V19, P177, DOI 10.3390/molecules19010177
   Zhou XY, 2019, DRUG DES DEV THER, V13, P2703, DOI 10.2147/DDDT.S208458
   Zhu Z, 2014, PHARMACOGN MAG, V10, P517, DOI 10.4103/0973 1296.141780
   Zhu Z, 2010, MOLECULES, V15, P4695, DOI 10.3390/molecules15074695
NR 49
TC 6
Z9 6
U1 1
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2165 5979
EI 2165 5987
J9 BIOENGINEERED
JI Bioengineered
PD JUN 1
PY 2022
VL 13
IS 6
BP 14339
EP 14356
DI 10.1080/21655979.2022.2085388
PG 18
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA 8D6BZ
UT WOS:000918377500001
PM 36694425
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Xing, T
   Zhao, YQ
   Zhao, J
   Jiang, ZX
   Zhang, YS
   Li, SH
AF Xing, Tao
   Zhao, Yongqiang
   Zhao, Jun
   Jiang, Zhenxing
   Zhang, Yingshuan
   Li, Shenghua
TI Duhuo Jisheng Decoction inhibits the activity of osteoclasts in
   osteonecrosis of the femoral head via regulation of the RELA/AKT1 axis
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Duhuo Jisheng Decoction; osteonecrosis of the femoral head; osteoclast;
   RELA; AKT1
AB Objective: To investigate the effect of Duhuo Jisheng Decotion (DHJSD) on the activity of osteoclasts in osteonecrosis of the femoral head (ONFH) and its underlying mechanism relating to the RELA/AKT1 axis. Methods: The TCMSP database was used to search for the effective ingredients and the targets of various Chinese medicines in DHJSD. Its targets were intersected with ONFH risk genes in DisGeNET and Malacards databases to obtain the potential target genes. qRT PCR was used to detect the expression of potential target genes in ONFH tissues, and the ChIP experiment was used to verify the relationship between RELA and AKT1 promoter. An ONFH rat model was established and DHJSD was used for the treatment. The expressions of RELA and AKT1 in rats were intervened, and rats were grouped. qRT PCR was applied to detect the expression levels of osteoclast markers ACP5, CTSK, and RANK in the tissues to evaluate the regulation of DHJSD on target genes and the mechanism of osteoclast differentiation. Results: A total of 231 effective targets of DHJSD were screened out in the TCMSP database. Intersection with ONFH risk genes yielded a total of 20 candidate genes. Protein protein interaction analysis showed that AKT1 regulated other genes. KEGG functional enrichment analysis revealed that STAT1, AKT1, PPARG, PPARG, TNF and RELA were enriched in osteoclast differentiation pathway. Compared with normal tissues, the expression of STAT1 was decreased in ONFH tissues, and the expressions of AKT1, PPARG, TNF, and RELA were increased, among which, RELA and AKT1 are the most significantly increased genes (all P<0.05). ChIP experiment found that RELA had a binding relationship with AKT1 promoter. DHJST had the inhibitory effect on the expression of RELA and AKT1 in ONFH tissues, as well as the levels of ACP5, CTSK, and RANK. However, overexpression of RELA or AKT1 attenuated the inhibitory effect of DHJSD on the levels of ACP5, CTSK and RANK. Meanwhile, knocking down RELA partially reversed the effect of AKT1 on the effect of DHJSD. Conclusion: DHJSD inhibits the activity of osteoclasts in ONFH by inhibiting the RELA/AKT1 axis. This study further clarifies the potential specific mechanism of DHJSD to improve ONFH.
C1 [Xing, Tao] Gansu Prov Hosp TCM, Dept Trauma Ctr, Lanzhou 730050, Gansu, Peoples R China.
   [Zhao, Yongqiang] Gansu Prov Hosp TCM, Dept Surg, Lanzhou 730050, Gansu, Peoples R China.
   [Jiang, Zhenxing] Gansu Prov Hosp TCM, Dept Repair & Reconstruct Orthoped, Lanzhou 730050, Gansu, Peoples R China.
   [Li, Shenghua] Gansu Prov Hosp TCM, Clin Med Ctr Orthoped, 418 Guazhou Rd, Lanzhou 730050, Gansu, Peoples R China.
   [Zhao, Jun] Gansu Acad TCM, Ctr Orthoped & Traumatol, Clin Med, Lanzhou, Gansu, Peoples R China.
   [Zhang, Yingshuan] Gansu Univ Chinese Med, Clin Coll TCM, Lanzhou 730000, Gansu, Peoples R China.
C3 Gansu University of Chinese Medicine
RP Li, SH (通讯作者)，Gansu Prov Hosp TCM, Clin Med Ctr Orthoped, 418 Guazhou Rd, Lanzhou 730050, Gansu, Peoples R China.
EM ZYShuan1994@126.com
RI Zhao, Yongqiang/O 7342 2015
CR Balasuriya N, 2018, GENES BASEL, V9, DOI 10.3390/genes9090450
   Balboula AZ, 2020, REPRODUCTION, V159, P757, DOI 10.1530/REP 20 0036
   Bernhardt A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147316
   Brlek P, 2021, CANCERS, V13, DOI 10.3390/cancers13133247
   Chawla M, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024828118
   Chen X, 2021, BONE JOINT RES, V10, P237, DOI 10.1302/2046 3758.104.BJR 2020 0255.R2
   Ghislat G, 2021, SCI IMMUNOL, V6, DOI 10.1126/sciimmunol.abg3570
   Hanada R, 2021, J BONE MINER METAB, V39, P64, DOI 10.1007/s00774 020 01143 9
   He T, 2020, MOL THER NUCL ACIDS, V22, P572, DOI 10.1016/j.omtn.2020.09.024
   Kim I, 2020, MOL BIOL REP, V47, P9511, DOI 10.1007/s11033 020 06021 1
   Lee JY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094717
   Li H, 2019, 2019 CHUTIAN ORTHOPE
   Li JK, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/196702
   Lou PQ, 2021, CHIN TISSUE ENG RES, V32, P5210
   Lu XH., 2020, CLIN RES CHIN MED, V12, P113
   Lu Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12805
   Lv WX, 2021, MOL MED REP, V23, DOI 10.3892/mmr.2021.11984
   Meng L, 2021, FASEB J, V35, DOI 10.1096/fj.202002728R
   Microprosthodontics Group of Orthopedic Branch of Chinese Medical Association, 2012, CHIN J ORTHOPAED, V32, P606
   Quaranta M, 2021, BRIT MED BULL, V137, P98, DOI 10.1093/bmb/ldaa044
   Ren X, 2018, ANTI CANCER AGENT ME, V18, P1082, DOI 10.2174/1871520618666180411123447
   Rezus E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136801
   Shi Qi yun, 2021, Chinese Pharmacological Bulletin, V37, P704, DOI 10.3969/j.issn.1001 1978.2021.05.020
   Su YL, 2020, BLOOD, V135, P167, DOI 10.1182/blood.2019002045
   Yang N, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.447
   Zhang X., 2019, MOD MED HLTH RES, V003, P134
NR 26
TC 4
Z9 4
U1 0
U2 15
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943 8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2022
VL 14
IS 5
BP 3559
EP 3571
PG 13
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA 2A4TG
UT WOS:000809495900019
PM 35702106
DA 2025 08 17
ER

PT J
AU Kane, A
   Rothwell, JG
   Guttentag, A
   Hainsworth, S
   Carter, D
AF Kane, Aidan
   Rothwell, Joanna G.
   Guttentag, Annabel
   Hainsworth, Steven
   Carter, Dee
TI Bisphosphonates synergistically enhance the antifungal activity of
   azoles in dermatophytes and other pathogenic molds
SO MSPHERE
LA English
DT Article
DE dermatophytes; Trichophyton; antifungal agents; antifungal therapy;
   bisphosphonate; azole; ketoconazole; drug synergy; zolendronate
ID IN VITRO; EPIDEMIOLOGIC TRENDS; ASPERGILLUS; MECHANISM
AB Superficial infections of the skin, hair, and nails by fungal dermatophytes are the most prevalent of human mycoses, and many infections are refractory to treatment. As current treatment options are limited, recent research has explored drug synergy with azoles for dermatophytoses. Bisphosphonates, which are approved to treat osteoporosis, can synergistically enhance the activity of azoles in diverse yeast pathogens but their activity has not been explored in dermatophytes or other molds. Market bisphosphonates risedronate, alendronate, and zoledronate (ZOL) were evaluated for antifungal efficacy and synergy with three azole antifungals: fluconazole (FLC), itraconazole (ITR), and ketoconazole (KET). ZOL was the most active bisphosphonate tested, displaying moderate activity against nine dermatophyte species (MIC range 64 256 mu g/mL), and was synergistic with KET in eight of these species. ZOL was also able to synergistically improve the anti biofilm activity of KET and combining KET and ZOL prevented the development of antifungal resistance. Rescue assays in Trichophyton rubrum revealed that the inhibitory effects of ZOL alone and in combination with KET were due to the inhibition of squalene synthesis. Fluorescence microscopy using membrane  and ROS sensitive probes demonstrated that ZOL and KET:ZOL compromised membrane structure and induced oxidative stress. Antifungal activity and synergy between bisphosphonates and azoles were also observed in other clinically relevant molds, including species of Aspergillus and Mucor. These findings indicate that repurposing bisphosphonates as antifungals is a promising strategy for revitalising certain azoles as topical antifungals, and that this combination could be fast tracked for investigation in clinical trials. IMPORTANCE Fungal infections of the skin, hair, and nails, generally grouped together as "tineas" are the most prevalent infectious diseases globally. These infections, caused by fungal species known as dermatophytes, are generally superficial, but can in some cases become aggressive. They are also notoriously difficult to resolve, with few effective treatments and rising levels of drug resistance. Here, we report a potential new treatment that combines azole antifungals with bisphosphonates. Bisphosphonates are approved for the treatment of low bone density diseases, and in fungi they inhibit the biosynthesis of the cell membrane, which is also the target of azoles. Combinations were synergistic across the dermatophyte species and prevented the development of resistance. We extended the study to molds that cause invasive disease, finding synergy in some problematic species. We suggest bisphosphonates could be repurposed as synergents for tinea treatment, and that this combination could be fast tracked for use in clinical therapy.
C1 [Kane, Aidan; Rothwell, Joanna G.; Guttentag, Annabel; Carter, Dee] Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.
   [Hainsworth, Steven] RMIT Univ, Sch Sci, Melbourne, Vic, Australia.
   [Carter, Dee] Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia.
C3 University of Sydney; Royal Melbourne Institute of Technology (RMIT);
   University of Sydney
RP Carter, D (通讯作者)，Univ Sydney, Sch Life & Environm Sci, Sydney, NSW, Australia.; Carter, D (通讯作者)，Univ Sydney, Sydney Inst Infect Dis, Sydney, NSW, Australia.
EM dee.carter@sydney.edu.au
RI ; Carter, Dee/C 1331 2010; Hainsworth, Steven/AAG 8699 2019; Rothwell,
   Joanna/HCI 5693 2022
OI Carter, Dee/0000 0002 4638 0059; Kane, Aidan/0000 0003 4927 0071
FU University of Sydney MBI Seed Funding Grant
FX The authors would like to thank Prof. Ann Lawrie (RMIT, Victoria,
   Australia) for curating and supplying dermatophyte cultures from the
   RMIT fungal culture collection and Dr. Catriona Halliday (Westmead
   Hospital, NSW, Australia) for supplying invasive mold isolates. We thank
   Timothy Newsome, Nicolas Gracie, and Liam Howell (University of Sydney,
   NSW, Australia) for providing resources and expertise in microscopy.
CR Adami S, 1996, DRUG SAFETY, V14, P158, DOI 10.2165/00002018 199614030 00003
   Ashley ESD, 2006, CLIN INFECT DIS, V43, pS28, DOI 10.1086/504492
   Baran R, 2001, BRIT J DERMATOL, V145, P15, DOI 10.1046/j.1365 2133.2001.00045.x
   Bickers DR, 2006, J AM ACAD DERMATOL, V55, P490, DOI 10.1016/j.jaad.2006.05.048
   Brescini L, 2021, J FUNGI, V7, DOI 10.3390/jof7090727
   Clinical and Laboratory Standards Institute, 2018, Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, V3rd
   Costa Orlandi CB, 2014, BIOFOULING, V30, P719, DOI 10.1080/08927014.2014.919282
   de Hoog GS, 2017, MYCOPATHOLOGIA, V182, P5, DOI 10.1007/s11046 016 0073 9
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Enoch DA, 2017, METHODS MOL BIOL, V1508, P17, DOI 10.1007/978 1 4939 6515 1_2
   Gamaletsou MN, 2014, J INFECTION, V68, P478, DOI 10.1016/j.jinf.2013.12.008
   Ghannoum M, 2016, J AM PODIAT MED ASSN, V106, P79, DOI 10.7547/14 109
   Greer DL, 2000, INT J DERMATOL, V39, P302, DOI 10.1046/j.1365 4362.2000.00885.x
   Gupta AK, 2017, MYCOPATHOLOGIA, V182, P127, DOI 10.1007/s11046 016 0045 0
   Gupta AK, 2015, J CUTAN MED SURG, V19, P352, DOI 10.1177/1203475415574970
   Gupta AK, 2014, EXPERT OPIN PHARMACO, V15, P1707, DOI 10.1517/14656566.2014.931373
   Guttentag A, 2021, PATHOGENS, V10, DOI 10.3390/pathogens10020194
   Havlickova B, 2008, MYCOSES, V51, P2, DOI 10.1111/j.1439 0507.2008.01606.x
   Ho FKH, 2020, MYCOPATHOLOGIA, V185, P233, DOI 10.1007/s11046 020 00438 9
   Kane A, 2024, MICROBIOL SPECTR, V12, DOI 10.1128/spectrum.00121 24
   Kane A, 2022, PHARMACEUTICALS BASE, V15, DOI 10.3390/ph15040482
   Kane A, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.01753 20
   Khurana A, 2019, FUNGAL GENET BIOL, V132, DOI 10.1016/j.fgb.2019.103255
   Lewis RE, 2005, ANTIMICROB AGENTS CH, V49, P945, DOI 10.1128/AAC.49.3.945 951.2005
   Markantonatou AM, 2023, J FUNGI, V9, DOI 10.3390/jof9020228
   Maurya VK, 2019, J FAM MED PRIM CARE, V8, P2577, DOI 10.4103/jfmpc.jfmpc_483_19
   Miceli MH, 2011, MYCOSES, V54, pE666, DOI 10.1111/j.1439 0507.2011.02032.x
   Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301
   Perfect JR, 2017, NAT REV DRUG DISCOV, V16, P603, DOI 10.1038/nrd.2017.46
   Pierce CG, 2008, NAT PROTOC, V3, P1494, DOI 10.1038/nprot.2008.141
   Rizzoli R, 2011, CALCIFIED TISSUE INT, V89, P91, DOI 10.1007/s00223 011 9499 8
   Saunte DM, 2008, MED MYCOL, V46, P303, DOI 10.1080/13693780801891732
   Saunte DML, 2021, J EUR ACAD DERMATOL, V35, P1582, DOI 10.1111/jdv.17241
   Sedghizadeh PP, 2017, J MED CHEM, V60, P2326, DOI 10.1021/acs.jmedchem.6b01615
   White TC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a019802
   Yang G, 2015, ANTIMICROB AGENTS CH, V59, P7530, DOI 10.1128/AAC.01873 15
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
NR 37
TC 1
Z9 1
U1 2
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036 2904 USA
EI 2379 5042
J9 MSPHERE
JI mSphere
PD JUN 25
PY 2024
VL 9
IS 6
DI 10.1128/msphere.00248 24
EA JUN 2024
PG 14
WC Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Microbiology
GA WF7T9
UT WOS:001239569500001
PM 38837382
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Yang, DU
   Siddiqi, MH
   Ahn, S
   Kang, S
   Noh, HY
   Yang, DC
AF Yang, Dong Uk
   Siddiqi, Muhammad Hanif
   Ahn, Sungeun
   Kang, Sera
   Noh, Hae Yong
   Yang, Deok Chun
TI In vitro evaluation of the potential therapeutic role of
   Dendropanax morbifera extract in ameliorating osteoporosis
   and resultant bone impairment using MC3T3 E1 cells
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY ANIMAL
LA English
DT Article
DE Dendropanax; Osteoporosis; Osteoblasts; BMP 2; p38; MC3T3 E1 cells
ID ACTIVATED PROTEIN KINASE; OSTEOBLAST DIFFERENTIATION; ANTICOMPLEMENT
   ACTIVITY; ALKALINE PHOSPHATASE; SIGNALING PATHWAY; MAP KINASE;
   EXPRESSION; GENISTEIN; PATHOPHYSIOLOGY; LEVEILLE
AB Osteoporosis is a widespread musculoskeletal deformity that affects thousands of older people every year. leading to bone abnormalities and ultimately increasing the risk of bone fractures in both genders. It is considered a lethal disease causing death in thousands of people at the late stage of life. Dendropanax morbifera Leveille is a subtropical broad leaved prevalent species in Korea. Extracts of the leaves, stems, roots, and seeds of D. morbifera have been used in traditional medicine for the treatment of numerous diseases such as diabetes. atherogenesis, skin disorders, and headaches. However, the anti osteoporosis effects of D. morbifera have not been examined. The primary objectives of this study were to elucidate the anti osteoporosis effect of D. morbifera extract through an in vitro study using pre osteoblastic MC3T3 E1 cells. We found that D. morbifera strongly increased the expression of bone metabolic markers such as alkaline phosphatase (ALP) activity, type I collagen (Col I) level, and mineralization. Additionally, D. morbifera extract also upregulated the mRNA expression levels of osteogenic genes including ALP, osteocalcin (OCN), osterix (Osx), and runt related transcription factor 2 (Runx2) in MC3T3 E1 cells via upregulation of bone morphogenetic protein 2 (BMP 2)/p38 MAPK/JNK and Smad1/5/8 signaling pathways. Moreover, addition of D. morbifera significantly suppressed the inhibitory effect of SB203580 (p38 inhibitor). In conclusion, the current study demonstrated that D. morbifera extract significantly increased osteoblast differentiation and mineralization in MC3T3 E1 cells by regulating BMP 2/p38/JNK and Smad1/5/8. Our study might be helpful in the discovery and development of new anti osteoporosis therapeutic agents.
C1 [Yang, Dong Uk; Ahn, Sungeun; Kang, Sera; Noh, Hae Yong] Kyung Hee Univ, Dept Oriental Med Biotechnol, Coll Life Sci, Yongin, Gyeonggi Do, South Korea.
   [Siddiqi, Muhammad Hanif; Yang, Deok Chun] Kyung Hee Univ, Grad Sch Biotechnol, Coll Life Sci, Yongin 449701, Gyeonggi Do, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Yang, DC (通讯作者)，Kyung Hee Univ, Grad Sch Biotechnol, Coll Life Sci, Yongin 449701, Gyeonggi Do, South Korea.
EM dcyang@khu.ac.kr
FU Korea Institute of Planning & Evaluation for Technology in Food,
   Agriculture, Forestry & Fisheries (KIPET) Republic of Korea [317007 3]
FX This research was supported by the grant from Korea Institute of
   Planning & Evaluation for Technology in Food, Agriculture, Forestry &
   Fisheries (KIPET No. 317007 3) Republic of Korea. The ginseng sample
   used in this study was provided by the Ginseng Bank of Kyung Hee
   University.
CR Chung IM, 2011, PHYTOTHER RES, V25, P784, DOI 10.1002/ptr.3336
   Chung IM, 2009, PHARMAZIE, V64, P547, DOI 10.1691/ph.2009.9555
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   FARLEY JR, 1986, METABOLISM, V35, P563, DOI 10.1016/0026 0495(86)90016 8
   Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756 3282(01)00415 X
   Guicheux J, 2003, J BONE MINER RES, V18, P2060, DOI 10.1359/jbmr.2003.18.11.2060
   Hu YY, 2003, ENDOCRINOLOGY, V144, P2068, DOI 10.1210/en.2002 220863
   Hyun TK, 2015, IND CROP PROD, V74, P263, DOI 10.1016/j.indcrop.2015.05.002
   Hyun TK, 2013, FOOD CHEM, V141, P1947, DOI 10.1016/j.foodchem.2013.05.021
   Jadlowiec J, 2004, J BIOL CHEM, V279, P53323, DOI 10.1074/jbc.M404934200
   Jezek P, 2005, INT J BIOCHEM CELL B, V37, P2478, DOI 10.1016/j.biocel.2005.05.013
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Oka K, 1999, CONTACT DERMATITIS, V40, P209, DOI 10.1111/j.1600 0536.1999.tb06036.x
   Pan W, 2005, J CELL BIOCHEM, V94, P307, DOI 10.1002/jcb.20308
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Park BY, 2004, J ETHNOPHARMACOL, V90, P403, DOI 10.1016/j.jep.2003.11.002
   Prince M, 2001, J CELL BIOCHEM, V80, P424, DOI 10.1002/1097 4644(20010301)80:3<424::AID JCB160>3.0.CO;2 6
   Putnam SE, 2007, PHYTOTHER RES, V21, P99, DOI 10.1002/ptr.2030
   RODAN GA, 1992, BONE, V13, pS3, DOI 10.1016/S8756 3282(09)80003 3
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodríguez JP, 2004, J CELL BIOCHEM, V92, P745, DOI 10.1002/jcb.20119
   Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308
   Saklani A, 2008, DRUG DISCOV TODAY, V13, P161, DOI 10.1016/j.drudis.2007.10.010
   SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191
   Sugimoto E, 2000, INT J MOL MED, V5, P515
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Sykaras Nikitas, 2003, J Oral Sci, V45, P57
   Tullberg Reinert H, 1999, HISTOCHEM CELL BIOL, V112, P271, DOI 10.1007/s004180050447
   Vali B, 2007, J NUTR BIOCHEM, V18, P341, DOI 10.1016/j.jnutbio.2006.06.005
   Yamaguchi M, 2001, MOL CELL BIOCHEM, V223, P131, DOI 10.1023/A:1017930931736
   Yamaguchi M, 1998, MOL CELL BIOCHEM, V178, P377, DOI 10.1023/A:1006809031836
NR 35
TC 4
Z9 5
U1 0
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071 2690
EI 1543 706X
J9 IN VITRO CELL DEV AN
JI In Vitro Cell. Dev. Biol. Anim.
PD MAY
PY 2018
VL 54
IS 5
BP 346
EP 354
DI 10.1007/s11626 018 0242 x
PG 9
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Developmental Biology
GA GE4PZ
UT WOS:000431199600003
PM 29560558
DA 2025 08 17
ER

PT J
AU Ge, GR
   Guo, QP
   Zhou, Y
   Li, WM
   Zhang, W
   Bai, JX
   Wang, Q
   Tao, HQ
   Wang, W
   Wang, Z
   Gan, MF
   Xu, YZ
   Yang, HL
   Li, B
   Geng, DC
AF Ge, Gaoran
   Guo, Qianping
   Zhou, Ying
   Li, Wenming
   Zhang, Wei
   Bai, Jiaxiang
   Wang, Qing
   Tao, Huaqiang
   Wang, Wei
   Wang, Zhen
   Gan, Minfeng
   Xu, Yaozeng
   Yang, Huilin
   Li, Bin
   Geng, Dechun
TI GLI1 facilitates collagen induced arthritis in mice by collaborative
   regulation of DNA methyltransferases
SO ELIFE
LA English
DT Article
DE rheumatoid arthritis; macrophage; osteoclast; GLI1; DNMTs; Mouse
ID HEDGEHOG; DIFFERENTIATION
AB Rheumatoid arthritis (RA) is characterized by joint synovitis and bone destruction, the etiology of which remains to be explored. Many types of cells are involved in the progression of RA joint inflammation, among which the overactivation of M1 macrophages and osteoclasts has been thought to be an essential cause of joint inflammation and bone destruction. Glioma associated oncogene homolog 1 (GLI1) has been revealed to be closely linked to bone metabolism. In this study, GLI1 expression in the synovial tissue of RA patients was positively correlated with RA related scores and was highly expressed in collagen induced arthritis (CIA) mouse articular macrophage like cells. The decreased expression and inhibition of nuclear transfer of GLI1 downregulated macrophage M1 polarization and osteoclast activation, the effect of which was achieved by modulation of DNA methyltransferases (DNMTs) via transcriptional regulation and protein interactions. By pharmacological inhibition of GLI1, the proportion of proinflammatory macrophages and the number of osteoclasts were significantly reduced, and the joint inflammatory response and bone destruction in CIA mice were alleviated. This study clarified the mechanism of GLI1 in macrophage phenotypic changes and activation of osteoclasts, suggesting potential applications of GLI1 inhibitors in the clinical treatment of RA.
C1 [Ge, Gaoran; Guo, Qianping; Li, Wenming; Zhang, Wei; Wang, Qing; Tao, Huaqiang; Wang, Wei; Gan, Minfeng; Xu, Yaozeng; Yang, Huilin; Li, Bin; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Med Coll, Suzhou, Peoples R China.
   [Guo, Qianping; Li, Bin] Soochow Univ, Affiliated Hosp 1, Med Printing Ctr 3D, Sch Biol & Basic Med Sci,Suzhou Med Coll, Suzhou, Peoples R China.
   [Zhou, Ying] Soochow Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Suzhou, Peoples R China.
   [Bai, Jiaxiang] Univ Sci & Technol China, Affiliated Hosp USTC 1, Dept Orthoped, Div Life Sci & Med, Hefei, Anhui, Peoples R China.
   [Wang, Zhen] Shanghai Jiao Tong Univ, Suzhou Kowloon Hosp, Sch Med, Dept Orthopaed, Suzhou, Peoples R China.
   [Li, Bin] Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China.
C3 Soochow University   China; Soochow University   China; Soochow
   University   China; Chinese Academy of Sciences; University of Science &
   Technology of China, CAS; Shanghai Jiao Tong University; Soochow
   University   China
RP Li, B; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Orthoped Inst, Med Coll, Suzhou, Peoples R China.; Li, B (通讯作者)，Soochow Univ, Affiliated Hosp 1, Med Printing Ctr 3D, Sch Biol & Basic Med Sci,Suzhou Med Coll, Suzhou, Peoples R China.; Li, B (通讯作者)，Soochow Univ, Collaborat Innovat Ctr Hematol, Suzhou, Peoples R China.
EM binli@suda.edu.cn; szgengdc@suda.edu.cn
RI ; A, TEST/S 7244 2019; bai, jiaxiang/AAH 3367 2021; Guo,
   Qianping/KIE 7679 2024; Li, Wenming/JTU 5517 2023; Geng,
   Dechun/LMO 1733 2024; Wang, Qing/MCI 8110 2025
OI Ge, Gaoran/0000 0002 5535 7483; Bai, Jiaxiang/0000 0002 3485 5563; Wang,
   Qing/0009 0009 7455 1343
FU National Nature Science Foundation of China; National Nature Science
   Foundation of China; Natural Science Foundation of Jiangsu Province;
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (PAPD); Science and Technology Project of Suzhou; Medical
   Science and Technology Development Foundation; Jiangsu Province
   Department of Health; National and Local Engineering Laboratory of New
   Functional Polymer Materials; Special Project of Diagnosis and Treatment
   for Clinical Diseases of Suzhou; Jiangsu Medical Research Project
FX This work was supported by the National Nature Science Foundation of
   China, the Natural Science Foundation of Jiangsu Province, the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD), the Science and Technology Project of Suzhou, the Key Project
   Supported by the Medical Science and Technology Development Foundation,
   Jiangsu Province Department of Health, the National and Local
   Engineering Laboratory of New Functional Polymer Materials, the Special
   Project of Diagnosis and Treatment for Clinical Diseases of Suzhou and
   the Jiangsu Medical Research Project.
CR Ali SA, 2016, ARTHRITIS RHEUMATOL, V68, P127, DOI 10.1002/art.39337
   Bustamante MF, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075 017 1303 3
   Chen X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0692 9
   Cho DI, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2013.135
   Collins JJP, 2012, AM J PHYSIOL LUNG C, V303, pL778, DOI 10.1152/ajplung.00280.2011
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Fu YA, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392 022 00896 1
   González Rodríguez P, 2022, AUTOPHAGY, V18, P2769, DOI 10.1080/15548627.2022.2039993
   Heller E, 2012, CANCER RES, V72, P897, DOI 10.1158/0008 5472.CAN 11 2681
   Hwang YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072068
   Jemtland R, 2003, BONE, V32, P611, DOI 10.1016/S8756 3282(03)00092 9
   Kim J, 2019, ACS NANO, V13, P3206, DOI 10.1021/acsnano.8b08785
   Kitaura Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109597
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kopinke D, 2021, SEMIN CELL DEV BIOL, V110, P89, DOI 10.1016/j.semcdb.2020.05.029
   Li E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a019133
   Matsumoto T, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1035 9
   Michel NA, 2018, CIRC RES, V122, P693, DOI [10.1161/CIRCRESAHA.117.312055, 10.1161/circresaha.117.312055]
   Murshid NM, 2022, CELL MOL NEUROBIOL, V42, P577, DOI 10.1007/s10571 020 00979 z
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Onodera S, 2020, STEM CELL REP, V15, P125, DOI 10.1016/j.stemcr.2020.05.008
   Tran PT, 2018, INT J MOL MED, V42, P569, DOI 10.3892/ijmm.2018.3627
   Qin SP, 2016, INFLAMMATION, V39, P503, DOI 10.1007/s10753 015 0273 3
   Ramabadran R, 2023, NAT CELL BIOL, V25, P528, DOI 10.1038/s41556 023 01109 9
   Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022
   Sasai N, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01103
   Schneider RK, 2018, CELL STEM CELL, V23, P308, DOI 10.1016/j.stem.2018.07.006
   Shapouri Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Sheng MW, 2021, HEPATOLOGY, V74, P1560, DOI 10.1002/hep.31831
   Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/s41467 017 02171 2
   Sun L, 2010, BRAIN BEHAV IMMUN, V24, P220, DOI 10.1016/j.bbi.2009.09.016
   Tardito S, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102397
   Tóth DM, 2019, ARTHRITIS RHEUMATOL, V71, P1265, DOI 10.1002/art.40877
   Vadell AKE, 2020, AM J CLIN NUTR, V111, P1203, DOI 10.1093/ajcn/nqaa019
   Wang G, 2021, INT IMMUNOPHARMACOL, V96, DOI 10.1016/j.intimp.2021.107744
   Wang XF, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87748
   Wen Q, 2020, J BONE MINER RES, V35, P2252, DOI 10.1002/jbmr.4120
   Wils LJ, 2018, CRIT REV ONCOL HEMAT, V121, P23, DOI 10.1016/j.critrevonc.2017.11.013
   Woo SJ, 2018, EBIOMEDICINE, V38, P228, DOI 10.1016/j.ebiom.2018.11.005
   Wu CL, 2020, OSTEOARTHR CARTILAGE, V28, P544, DOI 10.1016/j.joca.2019.12.007
   Yang P, 2019, J LEUKOCYTE BIOL, V106, P1233, DOI 10.1002/JLB.4RU0619 197R
   Ye L, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0030 y
   Yu J, 2016, SCI REP UK, V6, DOI 10.1038/srep30053
   Zeng X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082279
   Zhang RZ, 2022, INT IMMUNOPHARMACOL, V109, DOI 10.1016/j.intimp.2022.108805
   Zhu SY, 2018, J MOL ENDOCRINOL, V60, P185, DOI 10.1530/JME 17 0218
NR 46
TC 4
Z9 4
U1 4
U2 13
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050 084X
J9 ELIFE
JI eLife
PD NOV 6
PY 2023
VL 12
AR e92142
DI 10.7554/eLife.92142
PG 23
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA DU6M6
UT WOS:001134633500001
PM 37929702
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Yu, Z
   Wang, ZL
   Chen, YT
   Wang, YC
   Tang, LK
   Xi, Y
   Lai, KC
   Zhang, Q
   Li, SY
   Xu, DY
   Tian, AR
   Wu, MJ
   Wang, Y
   Yang, GL
   Gao, CY
   Huang, TB
AF Yu, Zhou
   Wang, Zhaolong
   Chen, Yitong
   Wang, Yuchen
   Tang, Like
   Xi, Yue
   Lai, Kaichen
   Zhang, Qi
   Li, Shuangyang
   Xu, Danyu
   Tian, Anrong
   Wu, Mengjie
   Wang, Ying
   Yang, Guoli
   Gao, Changyou
   Huang, Tingben
TI <hr>Programmed surface platform orchestrates anti bacterial ability and
   time sequential bone healing for implant associated infection
SO BIOMATERIALS
LA English
DT Article
DE Implant associated infection; pH responsive; Antibacterial;
   Time sequential bone healing; Osseointegration
ID MESENCHYMAL STEM CELLS; SILVER NANOPARTICLES; OSTEOGENESIS;
   BIOCOMPATIBILITY; CYTOTOXICITY; MECHANISMS; DEVICES; HEALTH; IONS
AB Implant associated infection (IAI) has become an intractable challenge in clinic. The healing of IAI is a complex physiological process involving a series of spatiotemporal connected events. However, existing titanium based implants in clinic suffer from poor antibacterial effect and single function. Herein, a versatile surface platform based on the presentation of sequential function is developed. Fabrication of titania nanotubes and poly gamma glutamic acid (gamma PGA) achieves the efficient incorporation of silver ions (Ag+) and the pH sensitive release in response to acidic bone infection microenvironment. The optimized PGA/Ag platform exhibits satisfactory biocompatibility and converts macrophages from pro inflammatory M1 to pro healing M2 phenotype during the subsequent healing stage, which creates a beneficial osteoimmune microenvironment and promotes angio/ osteogenesis. Furthermore, the PGA/Ag platform mediates osteoblast/osteoclast coupling through inhibiting CCL3/CCR1 signaling. These biological effects synergistically improve osseointegration under bacterial infection in vivo, matching the healing process of IAI. Overall, the novel integrated PGA/Ag surface platform proposed in this study fulfills function cascades under pathological state and shows great potential in IAI therapy.
C1 [Yu, Zhou; Chen, Yitong; Wang, Yuchen; Tang, Like; Xi, Yue; Lai, Kaichen; Zhang, Qi; Li, Shuangyang; Xu, Danyu; Tian, Anrong; Wu, Mengjie; Wang, Ying; Yang, Guoli; Huang, Tingben] Zhejiang Univ, Engn Res Ctr Oral Biomat & Devices Zhejiang Prov, Zhejiang Prov Clin Res Ctr Oral Dis,Stomatol Hosp, Sch Med,Canc Ctr,Sch Stomatol,Key Lab Oral Biomed, Hangzhou 310006, Zhejiang, Peoples R China.
   [Wang, Zhaolong; Gao, Changyou] Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou 310027, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yang, GL; Huang, TB (通讯作者)，Zhejiang Univ, Engn Res Ctr Oral Biomat & Devices Zhejiang Prov, Zhejiang Prov Clin Res Ctr Oral Dis,Stomatol Hosp, Sch Med,Canc Ctr,Sch Stomatol,Key Lab Oral Biomed, Hangzhou 310006, Zhejiang, Peoples R China.; Gao, CY (通讯作者)，Zhejiang Univ, Dept Polymer Sci & Engn, MOE Key Lab Macromol Synth & Functionalizat, Hangzhou 310027, Zhejiang, Peoples R China.
EM guo_li1977@zju.edu.cn; cygao@zju.edu.cn; htb1990@zju.edu.cn
RI Wang, Yuchen/Q 1354 2018; Gao, Changyou/HDO 7162 2022; Wang,
   Ying/KQU 2949 2024; WANG, ZHAOLONG/JTS 6212 2023
OI xi, yue/0000 0002 8001 8969; 
FU National Natural Science Foundation of China [82201008, 82271001,
   82101061]; Traditional Chinese Medicine Project of Zhejiang Province
   [2021ZB177]; Medical Health Science and Technology Project of Zhejiang
   Provincial Health Commission [2021KY193]
FX This work is supported by the National Natural Science Foundation of
   China (No. 82201008, No. 82271001, No. 82101061) , Traditional Chinese
   Medicine Project of Zhejiang Province (No. 2021ZB177) , and Medical
   Health Science and Technology Project of Zhejiang Provincial Health
   Commission (No. 2021KY193) . We gratefully thank Xiaoli Hong and Chao Bi
   from the Core Facilities, Zhejiang University School of Medicine for
   their technical support.
CR Ahmed W, 2019, MATER TODAY BIO, V2, DOI 10.1016/j.mtbio.2019.100017
   [Anonymous], 2022, Int. J. Nanomed., V17
   [Anonymous], 2022, Bio, V16
   Arciola CR, 2018, NAT REV MICROBIOL, V16, P397, DOI 10.1038/s41579 018 0019 y
   Cao MF, 2018, BIOTECHNOL ADV, V36, P1424, DOI 10.1016/j.biotechadv.2018.05.006
   Chen CY, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba0942
   Chen J, 2023, J MATER CHEM B, V11, P345, DOI 10.1039/d2tb02098j
   Chen K, 2023, ACTA BIOMATER, V157, P683, DOI 10.1016/j.actbio.2022.12.012
   Chernousova S, 2013, ANGEW CHEM INT EDIT, V52, P1636, DOI 10.1002/anie.201205923
   Chopra I, 2007, J ANTIMICROB CHEMOTH, V59, P587, DOI 10.1093/jac/dkm006
   Chu GY, 2024, ADV MATER, V36, DOI 10.1002/adma.202311855
   Ciofu O, 2022, NAT REV MICROBIOL, V20, P621, DOI 10.1038/s41579 022 00682 4
   Connell LS, 2017, POLYM CHEM UK, V8, P1095, DOI 10.1039/c6py01425a
   Derks J, 2015, J CLIN PERIODONTOL, V42, pS158, DOI 10.1111/jcpe.12334
   DeVasConCellos P, 2012, MAT SCI ENG C MATER, V32, P1112, DOI 10.1016/j.msec.2012.02.020
   Diez Escudero A, 2022, ACS APPL MATER INTER, DOI 10.1021/acsami.2c11139
   Gentilini C, 2012, ADV HEALTHC MATER, V1, P308, DOI 10.1002/adhm.201200036
   Guo H, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989 016 0133 9
   Hao ZC, 2023, BIOACT MATER, V23, P206, DOI 10.1016/j.bioactmat.2022.10.018
   Hidalgo E, 1998, TOXICOL LETT, V98, P169, DOI 10.1016/S0378 4274(98)00114 3
   Huang L, 2023, CARBOHYD POLYM, V319, DOI 10.1016/j.carbpol.2023.121186
   Jgs S., 2020, iScience, V24
   Kavanagh N, 2018, CLIN MICROBIOL REV, V31, DOI 10.1128/CMR.00084 17
   Langen UH, 2017, NAT CELL BIOL, V19, P189, DOI 10.1038/ncb3476
   Lao A, 2023, SMALL, V19, DOI 10.1002/smll.202206919
   Li CM, 2020, NAT REV MATER, V5, P61, DOI 10.1038/s41578 019 0150 z
   Li JY, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf8645
   Li M, 2016, ACS APPL MATER INTER, V8, P33972, DOI 10.1021/acsami.6b09457
   Li WR, 2017, INT BIODETER BIODEGR, V123, P304, DOI 10.1016/j.ibiod.2017.07.015
   Li X, 2022, BIOMATERIALS, V287, DOI 10.1016/j.biomaterials.2022.121683
   Li ZY, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg3365
   Magill SS, 2014, NEW ENGL J MED, V370, P1198, DOI 10.1056/NEJMoa1306801
   Mei SL, 2014, BIOMATERIALS, V35, P4255, DOI 10.1016/j.biomaterials.2014.02.005
   Monje A, 2017, J CLIN PERIODONTOL, V44, P636, DOI 10.1111/jcpe.12724
   Monteiro DR, 2009, INT J ANTIMICROB AG, V34, P103, DOI 10.1016/j.ijantimicag.2009.01.017
   Moriarty TF, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572 022 00396 0
   Nguyen AK., 2019, Appl. Vitro Toxicol, V5, P10, DOI [10.1089/aivt.2019.0001, DOI 10.1089/AIVT.2019.0001]
   Ning CY, 2015, CHEM RES TOXICOL, V28, P1815, DOI 10.1021/acs.chemrestox.5b00258
   Pajarinen J, 2019, BIOMATERIALS, V196, P80, DOI 10.1016/j.biomaterials.2017.12.025
   Panácek A, 2009, BIOMATERIALS, V30, P6333, DOI 10.1016/j.biomaterials.2009.07.065
   Park SB, 2021, PROG POLYM SCI, V113, DOI 10.1016/j.progpolymsci.2020.101341
   Pauksch L, 2014, ACTA BIOMATER, V10, P439, DOI 10.1016/j.actbio.2013.09.037
   Qian YZ, 2019, ACS APPL MATER INTER, V11, P37381, DOI 10.1021/acsami.9b07053
   Qiao W, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121038
   Qiu PC, 2020, BIOMATERIALS, V227, DOI 10.1016/j.biomaterials.2019.119552
   Rai M, 2009, BIOTECHNOL ADV, V27, P76, DOI 10.1016/j.biotechadv.2008.09.002
   Rezvani E, 2019, ACTA BIOMATER, V94, P145, DOI 10.1016/j.actbio.2019.05.042
   Rizzello L, 2014, CHEM SOC REV, V43, P1501, DOI 10.1039/c3cs60218d
   Shao HF, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202300932
   Shirazi S, 2022, BIOMATERIALS, V291, DOI 10.1016/j.biomaterials.2022.121903
   Shivaram A, 2017, ACTA BIOMATER, V58, P550, DOI 10.1016/j.actbio.2017.05.048
   Stuart BW, 2022, BIOACT MATER, V8, P325, DOI 10.1016/j.bioactmat.2021.05.055
   Sun L, 2023, NANOSCALE, V15, P2911, DOI 10.1039/d2nr06154f
   Sun W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07626 8
   Takayanagi H, 2015, NAT REV RHEUMATOL, V11, P74, DOI 10.1038/nrrheum.2014.219
   Tang HZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202107300
   Vallet S, 2011, LEUKEMIA, V25, P1174, DOI 10.1038/leu.2011.43
   van Hengel IAJ, 2020, MATER TODAY BIO, V7, DOI 10.1016/j.mtbio.2020.100060
   Wang DA, 2009, CHEM MATER, V21, P1198, DOI 10.1021/cm802384y
   Wang FP, 2023, SMALL, V19, DOI 10.1002/smll.202303591
   Wang LL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 13152 2
   Wang LL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218742
   Wang T, 2022, NAT COMMUN, V13, DOI 10.1038/s41467 021 27816 1
   Wang XL, 2023, ACS NANO, V17, P15568, DOI 10.1021/acsnano.3c02304
   Wang Y, 2020, ADV MATER, V32, DOI [10.1080/1941126X.2019.1709722, 10.1002/adma.201904106]
   Wouthuyzen Bakker M, 2019, J INFECTION, V79, P199, DOI 10.1016/j.jinf.2019.07.003
   Xie K, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201801465
   Xiong Y, 2022, MILITARY MED RES, V9, DOI 10.1186/s40779 022 00426 8
   Xu L, 2021, METABOLISM, V125, DOI 10.1016/j.metabol.2021.154914
   Yan JL, 2020, ACTA BIOMATER, V115, P220, DOI 10.1016/j.actbio.2020.07.062
   Yang FP, 2023, ACTA BIOMATER, V155, P359, DOI 10.1016/j.actbio.2022.11.020
   Yang Q, 2023, ACS NANO, V17, P17131, DOI 10.1021/acsnano.3c04816
   Yang R, 2020, INT J BIOL MACROMOL, V142, P332, DOI 10.1016/j.ijbiomac.2019.09.104
   Yang YH, 2021, BIOMATERIALS, V264, DOI 10.1016/j.biomaterials.2020.120390
   Yu DG, 2023, JCI INSIGHT, V8, DOI 10.1172/jci.insight.159107
   Yuan B, 2023, NANO TODAY, V52, DOI 10.1016/j.nantod.2023.101959
   Zeng JK, 2023, BIOMATERIALS, V297, DOI 10.1016/j.biomaterials.2023.122122
   Zhang CL, 2022, ACS NANO, DOI 10.1021/acsnano.2c06030
   Zhang RZ, 2015, NANOMED NANOTECHNOL, V11, P1949, DOI 10.1016/j.nano.2015.07.016
   Zhang S, 2021, APPL SURF SCI, V535, DOI 10.1016/j.apsusc.2020.147675
   Zhao YB, 2023, BIOMATERIALS, V301, DOI 10.1016/j.biomaterials.2023.122237
   Zhao Y, 2022, ADV SCI, V9, DOI 10.1002/advs.202204535
   Zhou CH, 2021, J ORTHOP TRANSL, V28, P21, DOI 10.1016/j.jot.2020.12.004
   Zhou ZF, 2017, BIOMATERIALS, V121, P1, DOI 10.1016/j.biomaterials.2016.12.031
   Zhu YZ, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf6654
NR 85
TC 9
Z9 9
U1 36
U2 68
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD FEB
PY 2025
VL 313
AR 122772
DI 10.1016/j.biomaterials.2024.122772
EA AUG 2024
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA F0Q4A
UT WOS:001306949500001
PM 39190942
DA 2025 08 17
ER

PT J
AU Katayama, Y
   Battista, M
   Kao, WM
   Hidalgo, A
   Peired, AJ
   Thomas, SA
   Frenette, PS
AF Katayama, Y
   Battista, M
   Kao, WM
   Hidalgo, A
   Peired, AJ
   Thomas, SA
   Frenette, PS
TI Signals from the sympathetic nervous system regulate hematopoietic stem
   cell egress from bone marrow
SO CELL
LA English
DT Article
ID COLONY STIMULATING FACTOR; PROGENITOR CELLS; G CSF; FACTOR I; BLOOD
   STEM; MOBILIZATION; EXPRESSION; INNERVATION; SELECTIN;
   GALACTOCEREBROSIDE
AB Hematopoietic stem and progenitor cells (HSPC), attracted by the chemokine CXCL12, reside in specific niches in the bone marrow (BM). HSPC migration out of the BM is a critical process that underlies modern clinical stem cell transplantation. Here we demonstrate that enforced HSPC egress from BM niches depends critically on the nervous system. UDP galactose ceramide galactosyltransferase deficient (Cgt( / )) mice exhibit aberrant nerve conduction and display virtually no HSPC egress from BM following granulocyte colony stimulating factor (G CSF) or fucoidan administration. Adrenergic tone, osteoblast function, and bone CXCL12 are dysregulated in Cgt( / ) mice. Pharmacological or genetic ablation of adrenergic neurotransmission indicates that norepinephrine (NE) signaling controls G CSF induced osteoblast suppression, bone CXCL12 downregulation, and HSPC mobilization. Further, administration of a beta(2) adrenergic agonist enhances mobilization in both control and NE deficient mice. Thus, these results indicate that the sympathetic nervous system regulates the attraction of stem cells to their niche.
C1 Mt Sinai Sch Med, Immunobiol Ctr, Dept Med, New York, NY 10029 USA.
   Mt Sinai Sch Med, Black Stem Family Cell Inst, Dept Med, New York, NY 10029 USA.
   Okayama Univ Hosp, Dept Hematol Oncol & Resp Med, Okayama 7008558, Japan.
   Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA.
   Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Okayama University; Icahn School of Medicine at Mount
   Sinai; University of Pennsylvania
RP Mt Sinai Sch Med, Immunobiol Ctr, Dept Med, New York, NY 10029 USA.
EM paul.frenette@mssm.edu
RI Peired, Anna/J 9952 2019; Hidalgo, Andrés/L 5643 2014; /R 4916 2019;
   Hidalgo, Andres/L 5643 2014
OI Peired, Anna/0000 0001 9732 1369; Hidalgo, Andres/0000 0001 5513 555X
FU NHLBI NIH HHS [HL69438] Funding Source: Medline; NIDDK NIH HHS [DK56638,
   T32 DK07792] Funding Source: Medline
CR Abkowitz JL, 2003, BLOOD, V102, P1249, DOI 10.1182/blood 2003 01 0318
   [Anonymous], 1984, Myelin
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Bosio A, 1996, P NATL ACAD SCI USA, V93, P13280, DOI 10.1073/pnas.93.23.13280
   Broxmeyer HE, 2005, J EXP MED, V201, P1307, DOI 10.1084/jem.20041385
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   CALVO W, 1968, AM J ANAT, V123, P315, DOI 10.1002/aja.1001230206
   Chien KR, 2005, CELL, V120, P533, DOI 10.1016/j.cell.2005.02.006
   Coetzee T, 1996, CELL, V86, P209, DOI 10.1016/S0092 8674(00)80093 8
   Delezay O, 1997, AIDS, V11, P1311, DOI 10.1097/00002030 199711000 00004
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fedyk ER, 2001, J IMMUNOL, V166, P5749, DOI 10.4049/jimmunol.166.9.5749
   Frenette PS, 2000, BLOOD, V96, P2460, DOI 10.1182/blood.V96.7.2460.h8002460_2460_2468
   Froberg MK, 1999, TRANSFUSION, V39, P410, DOI 10.1046/j.1537 2995.1999.39499235675.x
   HAUSCHKA PV, 1988, CIBA F SYMP, V136, P207
   Heissig B, 2002, CELL, V109, P625, DOI 10.1016/S0092 8674(02)00754 7
   Hidalgo A, 2004, BLOOD, V104, P993, DOI 10.1182/blood 2003 10 3702
   Hinoi E, 2003, FASEB J, V17, P1532, DOI 10.1096/fj.02 0820fje
   HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059
   IVERSEN PO, 1994, ACTA PHYSIOL SCAND, V150, P373, DOI 10.1111/j.1748 1716.1994.tb09701.x
   Katayama Y, 2003, BLOOD, V102, P2060, DOI 10.1182/blood 2003 04 1212
   Katayama Y, 2003, IMMUNITY, V18, P789, DOI 10.1016/S1074 7613(03)00150 X
   Kato Y, 1997, J BONE MINER RES, V12, P2014, DOI 10.1359/jbmr.1997.12.12.2014
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092 8674(00)80453 5
   KORBLING M, 1995, BLOOD, V86, P2842
   Lapidot T, 2002, EXP HEMATOL, V30, P973, DOI 10.1016/S0301 472X(02)00883 4
   Levesque JP, 2004, BLOOD, V104, P65, DOI 10.1182/blood 2003 05 1589
   Lévesque JP, 2002, EXP HEMATOL, V30, P440, DOI 10.1016/S0301 472X(02)00788 9
   Lévesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289
   Lévesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994
   Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031
   LIVNAT S, 1985, J NEUROIMMUNOL, V10, P5, DOI 10.1016/0165 5728(85)90031 1
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Papayannopoulou T, 2004, BLOOD, V103, P1580, DOI 10.1182/blood 2003 05 1595
   Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813
   Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329
   Pui JC, 1999, IMMUNITY, V11, P299, DOI 10.1016/S1074 7613(00)80105 3
   Radtke F, 1999, IMMUNITY, V10, P547, DOI 10.1016/S1074 7613(00)80054 0
   RING PA, 1961, J BONE JOINT SURG BR, V43, P121, DOI 10.1302/0301 620X.43B1.121
   Rix M, 1999, DIABETES CARE, V22, P827, DOI 10.2337/diacare.22.5.827
   ROBERTS DD, 1986, J BIOL CHEM, V261, P6872
   Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559
   Semerad CL, 2005, BLOOD, V106, P3020, DOI 10.1182/blood 2004 01 0272
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   SKINNER MP, 1991, J BIOL CHEM, V266, P5371
   Sprong H, 1998, J BIOL CHEM, V273, P25880, DOI 10.1074/jbc.273.40.25880
   Sun YX, 2005, J BONE MINER RES, V20, P318, DOI 10.1359/JBMR.041109
   Sweeney EA, 2000, P NATL ACAD SCI USA, V97, P6544, DOI 10.1073/pnas.97.12.6544
   Takamatsu Y, 1998, BLOOD, V92, P3465, DOI 10.1182/blood.V92.9.3465.421k35_3465_3473
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092 8674(95)90151 5
   THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Ueda Y, 2004, J EXP MED, V199, P47, DOI 10.1084/jem.20031104
   Visnjic D, 2004, BLOOD, V103, P3258, DOI 10.1182/blood 2003 11 4011
   WADDELL TK, 1995, J BIOL CHEM, V270, P15403, DOI 10.1074/jbc.270.25.15403
   Wright DE, 2002, J EXP MED, V195, P1145, DOI 10.1084/jem.20011284
   Wright DE, 2001, SCIENCE, V294, P1933, DOI 10.1126/science.1064081
   Wright N, 2003, BLOOD, V102, P1978, DOI 10.1182/blood 2002 10 3190
   YAMAZAKI K, 1990, AM J ANAT, V187, P261, DOI 10.1002/aja.1001870306
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
NR 63
TC 1073
Z9 1261
U1 1
U2 62
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0092 8674
EI 1097 4172
J9 CELL
JI Cell
PD JAN 27
PY 2006
VL 124
IS 2
BP 407
EP 421
DI 10.1016/j.cell.2005.10.041
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 008VJ
UT WOS:000235068500027
PM 16439213
OA Bronze
DA 2025 08 17
ER

PT J
AU Pradhan, AK
   Bhoopathi, P
   Talukdar, S
   Shen, XN
   Emdad, L
   Das, SK
   Sarkar, D
   Fisher, PB
AF Pradhan, Anjan K.
   Bhoopathi, Praveen
   Talukdar, Sarmistha
   Shen, Xue Ning
   Emdad, Luni
   Das, Swadesh K.
   Sarkar, Devanand
   Fisher, Paul B.
TI Recombinant MDA 7/IL24 Suppresses Prostate Cancer Bone Metastasis
   through Downregulation of the Akt/Mcl 1 Pathway
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID BCL 2 FAMILY PROTEINS; APOGOSSYPOL DERIVATIVES; TARGETING MCL 1;
   GENE THERAPY; CELLS; APOPTOSIS; MECHANISM; DIFFERENTIATION; CYTOKINE;
   ANGIOGENESIS
AB Prostate cancer is a principal cause of cancer associated morbidity in men. Although 5 year survival of patients with localized prostate cancer approaches 100%, survival decreases precipitously after metastasis. Bone is the preferred site for disseminated prostate cancer cell colonization, altering the equilibrium of bone homeostasis resulting in weak and fragile bones. Currently, no curative options are available for prostate cancer bone metastasis. Melanoma differentiation associated gene 7 (MDA 7)/IL24 is a well studied cytokine established as a therapeutic in a wide array of cancers upon delivery as a gene therapy, In this study, we explored the potential anticancer properties of MDA 7/IL24 delivered as a recombinant protein. Using bone metastasis experimental models, animals treated with recombinant MDA 7/IL24 had significantly less metastatic lesions in their femurs as compared with controls. The inhibitory effects of MDA 7/IL24 on bone metastasis resulted from prostate cancer selective killing and inhibition of osteoclast differentiation, which is necessary for bone resorption. Gain  and loss of function genetic approaches document that prosurvival Akt and Mcl 1 pathways are critically important in the antibone metastatic activity of MDA 7/IL24. Our previous findings showed that MDA 7/IL24 gene therapy plus Mcl 1 inhibitors cooperate synergistically. Similarly, an Mcl 1 small molecule inhibitor synergized with MDA 7/IL24 and induced robust antibone metastatic activity. These results expand the potential applications of MDA 7/IL24 as an anticancer molecule and demonstrate that purified recombinant protein is nontoxic in preclinical animal models and has profound inhibitory effects on bone metastasis, which can be enhanced further when combined with an Mcl 1 inhibitory small molecule. (C) 2018 AACR.
C1 [Pradhan, Anjan K.; Bhoopathi, Praveen; Talukdar, Sarmistha; Shen, Xue Ning; Emdad, Luni; Das, Swadesh K.; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, Dept Human & Mol Genet, Richmond, VA USA.
   [Emdad, Luni; Das, Swadesh K.; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, Inst Mol Med, Richmond, VA USA.
   [Emdad, Luni; Das, Swadesh K.; Sarkar, Devanand; Fisher, Paul B.] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University
RP Fisher, PB (通讯作者)，Virginia Commonwealth Univ, Sch Med, 1101 East Marshall St,Sanger Hall Bldg, Richmond, VA 23298 USA.
EM paul.fisher@vcuhealth.org
RI Pradhan, Anjan/O 2555 2014; bhoopathi, praveen/A 9410 2010; Talukdar,
   Sarmistha/ABH 8480 2020
FU NIH [P50 CA058236]; NCI Cancer Center Support Grant [P30 CA016059];
   National Foundation for Cancer Research (NFCR); Human and Molecular
   Genetics Enhancement Fund; VCU Massey Cancer Center (MCC); VCU Institute
   of Molecular Medicine (VIMM); NIH NCI Cancer Center Support Grant [P30
   CA016059]
FX We thank Drs. Maurizio Pellecchia, Bainan Wu, and Jun Wei for providing
   BI 97D6 and valuable discussions. The present research was supported in
   part by funding from NIH grant P50 CA058236 (to P.B. Fisher and M.G.
   Pomper) and NCI Cancer Center Support Grant to VCU Massey Cancer Center
   P30 CA016059 (to P.B. Fisher and D. Sarkar), the National Foundation for
   Cancer Research (NFCR; to P.B. Fisher), the Human and Molecular Genetics
   Enhancement Fund (to S.K. Das and L. Emdad), VCU Massey Cancer Center
   (MCC) developmental funds (to P.B. Fisher), and VCU Institute of
   Molecular Medicine (VIMM) developmental funds (to P.B. Fisher, S.K. Das,
   and L. Emdad). P.B. Fisher holds the Thelma Newmeyer Corman Chair in
   Cancer Research in the MCC. D. Sarkar is the Harrison Foundation
   Distinguished Professor in Cancer Research in the MCC. Microscopy was
   performed at the VCU Microscopy Facility, supported, in part, by funding
   from NIH NCI Cancer Center Support Grant P30 CA016059.
CR Azab B, 2012, J CELL PHYSIOL, V227, P2145, DOI 10.1002/jcp.22947
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Bhatnagar A, 2014, CANCER RES, V74, P5772, DOI 10.1158/0008 5472.CAN 14 0018
   Bhoopathi P, 2016, CANCER RES, V76, P3572, DOI 10.1158/0008 5472.CAN 15 2959
   Bhutia SK, 2010, CANCER RES, V70, P3667, DOI 10.1158/0008 5472.CAN 09 3647
   Bradley Elizabeth W., 2008, V455, P19, DOI 10.1007/978 1 59745 104 8_2
   Coghlin C, 2010, J PATHOL, V222, P1, DOI 10.1002/path.2727
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Cunningham CC, 2005, MOL THER, V11, P149, DOI 10.1016/j.ymthe.2004.09.019
   Das SK, 2012, ADV CANCER RES, V115, P1, DOI 10.1016/B978 0 12 398342 8.00001 X
   Dash R, 2010, CANCER GENE THER, V17, P447, DOI 10.1038/cgt.2009.91
   Dash R, 2014, CANCER RES, V74, P563, DOI 10.1158/0008 5472.CAN 13 1062
   Dash R, 2011, P NATL ACAD SCI USA, V108, P8785, DOI 10.1073/pnas.1100769108
   Dash R, 2011, DISCOV MED, V11, P46
   Dash R, 2010, CANCER RES, V70, P5034, DOI 10.1158/0008 5472.CAN 10 0563
   Dent P, 2005, J CELL BIOCHEM, V95, P712, DOI 10.1002/jcb.20502
   Fisher PB, 2005, CANCER RES, V65, P10128, DOI 10.1158/0008 5472.CAN 05 3127
   Inoue S, 2005, MOL THER, V12, P707, DOI 10.1016/j.ymthe.2005.05.015
   Jia L, 2008, CANCER CHEMOTH PHARM, V61, P63, DOI 10.1007/s00280 007 0446 3
   Kitada S, 2008, BLOOD, V111, P3211, DOI 10.1182/blood 2007 09 113647
   Leverson JD, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.561
   Liou SF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069468
   Masuda H, 2014, BONE, V58, P1, DOI 10.1016/j.bone.2013.09.020
   Menezes ME, 2014, ADV EXP MED BIOL, V818, P127, DOI 10.1007/978 1 4471 6458 6_6
   Minagawa N, 2005, J BIOL CHEM, V280, P33637, DOI 10.1074/jbc.M503210200
   Moon JB, 2012, J IMMUNOL, V188, P163, DOI 10.4049/jimmunol.1101254
   Nishikawa T, 2004, MOL THER, V9, P818, DOI 10.1016/j.ymthe.2004.03.014
   Pradhan AK, 2017, CANCER RES, V77, P949, DOI 10.1158/0008 5472.CAN 16 1731
   Pradhan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025370
   Quinn BA, 2011, EXPERT OPIN INV DRUG, V20, P1397, DOI 10.1517/13543784.2011.609167
   Ramesh R, 2004, MOL THER, V9, P510, DOI 10.1016/j.ymthe.2004.01.019
   Ramesh R, 2003, CANCER RES, V63, P5105
   Rigaud J, 2002, J UROLOGY, V168, P1423, DOI 10.1016/S0022 5347(05)64465 5
   Riihimäki M, 2011, ONCOLOGIST, V16, P175, DOI 10.1634/theoncologist.2010 0338
   Sarkar S, 2015, ONCOTARGET, V6, P10712, DOI 10.18632/oncotarget.3544
   Sauane M, 2004, ONCOGENE, V23, P7679, DOI 10.1038/sj.onc.1207958
   Sauane M, 2008, P NATL ACAD SCI USA, V105, P9763, DOI 10.1073/pnas.0804089105
   Su ZZ, 2005, ONCOGENE, V24, P7552, DOI 10.1038/sj.onc.1208911
   Sutherland KA, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2681
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Valero V, 2011, CANCER GENE THER, V18, P510, DOI 10.1038/cgt.2011.20
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
   Wei J, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00028
   Wei J, 2010, J MED CHEM, V53, P4166, DOI 10.1021/jm1001265
   Wei J, 2009, J MED CHEM, V52, P4511, DOI 10.1021/jm900472s
   Wei J, 2009, MOL CANCER THER, V8, P904, DOI 10.1158/1535 7163.MCT 08 1050
   Wei J, 2009, CANCER LETT, V273, P107, DOI 10.1016/j.canlet.2008.07.031
   Ye L, 2007, INT J MOL MED, V20, P103
   Yin JJ, 2005, CELL RES, V15, P57, DOI 10.1038/sj.cr.7290266
NR 50
TC 24
Z9 24
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD SEP
PY 2018
VL 17
IS 9
BP 1951
EP 1960
DI 10.1158/1535 7163.MCT 17 1002
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA GS9LX
UT WOS:000444041300014
PM 29934341
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Chen, YW
   Chen, HH
   Huang, WN
   Chen, JP
   Chen, YH
   Chen, YM
AF Chen, Yun Wen
   Chen, Hsin Hua
   Huang, Wen Nan
   Chen, Jun Peng
   Chen, Yi Hsing
   Chen, Yi Ming
TI Potential alleviation of bone mineral density loss with Janus kinase
   inhibitors in rheumatoid arthritis
SO CLINICAL RHEUMATOLOGY
LA English
DT Article
DE Bone loss; Bone mineral density; Janus kinase inhibitor; Non tumour
   necrosis factor inhibitor; Osteoporosis; Rheumatoid arthritis; Tumour
   necrosis factor inhibitor
ID AMERICAN COLLEGE; PROGRESSION; AUTOANTIBODIES; CLASSIFICATION;
   OSTEOPOROSIS; BARICITINIB; CRITERIA
AB ObjectiveRheumatoid arthritis (RA) is characterized by localized bone loss, general osteoporosis and increased fracture risks. Tumour necrosis factor inhibitors (TNFi), non tumour necrosis factor inhibitors (non TNFi) biologic, Janus kinase inhibitors (JAKi) had shown the suppression effects to osteoclast activation and improvement of bone mineral density (BMD). Anti cyclic citrullinated peptide antibody (ACPA) is associated with osteoclast activation and the resultant bone loss. However, few studies have compared BMD changes among patients with RA treated with targeted therapies that have different mechanisms of action.MethodsThis retrospective study recruited patients with RA who had undergone BMD testing twice. Changes in the BMD were compared using the generalized estimating equation (GEE) in treatment groups that received conventional synthetic disease modifying anti rheumatic drugs (csDMARDs), TNFi, non TNFi biologics, and JAKi.ResultsIn total, 362 patients with RA were enrolled (csDMARDs, n = 153, TNFi, n = 71, non TNFi biologics, n = 108, JAKi, n = 30). We observed greater changes in femoral BMD (left, 0.06, 95% CI 0.01 0.12, p = 0.016; right, 0.09, 95% CI 0.04 0.15, p = 0.001 by GEE) following JAKi treatment as compared with other treatments. Compared to the ACPA negative group, patients with ACPA positivity exhibited greater improvement in the femoral BMD (left, 0.09, 95% CI 0.02 0.15, p = 0.008; right, 0.11, 95% CI 0.05 0.18, p = 0.001).ConclusionCompared to other targeted therapies, JAKi might exert a more potent effect to prevent BMD loss, specifically in ACPA positive patients with RA, and could be a potential therapeutic option to mitigate generalized bone loss.Key Points & BULL;JAKi therapy inhibits systemic bone loss in patients with RA.& BULL;ACPA positive RA patients exhibited a greater BMD improvement than ACPA negative RA patients.& BULL;JAKi might more potently prevent BMD decline than conventional synthetic or biological DMARDs.
C1 [Chen, Yun Wen; Chen, Hsin Hua; Huang, Wen Nan; Chen, Yi Hsing; Chen, Yi Ming] Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.
   [Chen, Yun Wen; Chen, Hsin Hua] Taichung Vet Gen Hosp, Div Gen Internal Med, Dept Internal Med, Taichung, Taiwan.
   [Chen, Hsin Hua; Huang, Wen Nan; Chen, Yi Ming] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan.
   [Chen, Hsin Hua; Huang, Wen Nan; Chen, Yi Hsing; Chen, Yi Ming] Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei, Taiwan.
   [Chen, Hsin Hua] Tunghai Univ, Dept Ind Engn & Enterprise Informat, Taichung, Taiwan.
   [Chen, Hsin Hua] Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.
   [Chen, Hsin Hua] Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.
   [Chen, Hsin Hua] Chung Hsing Univ, Big Data Ctr, Taichung, Taiwan.
   [Chen, Hsin Hua] Natl Yang Ming Univ, Inst Publ Hlth & Community Med, Res Ctr, Taipei, Taiwan.
   [Huang, Wen Nan] Ling Tung Univ, Coll Business & Management, Taichung, Taiwan.
   [Chen, Jun Peng] Biostat Task Force Taichung Vet Gen Hosp, Taichung, Taiwan.
   [Chen, Jun Peng; Chen, Yi Ming] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.
   [Chen, Yi Ming] Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.
   [Chen, Yi Ming] Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.
C3 Taichung Veterans General Hospital; Taichung Veterans General Hospital;
   National Chung Hsing University; National Yang Ming Chiao Tung
   University; Tunghai University; National Chung Hsing University;
   National Chung Hsing University; National Chung Hsing University;
   National Yang Ming Chiao Tung University; Taichung Veterans General
   Hospital; National Chung Hsing University; National Chung Hsing
   University
RP Chen, YM (通讯作者)，Taichung Vet Gen Hosp, Div Allergy Immunol & Rheumatol, Taichung, Taiwan.; Chen, YM (通讯作者)，Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung, Taiwan.; Chen, YM (通讯作者)，Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei, Taiwan.; Chen, YM (通讯作者)，Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan.; Chen, YM (通讯作者)，Natl Chung Hsing Univ, Inst Biomed Sci, Taichung, Taiwan.; Chen, YM (通讯作者)，Natl Chung Hsing Univ, Rong Hsing Res Ctr Translat Med, Taichung, Taiwan.
EM ymchen1@vghtc.gov.tw
RI Yi Hsing, Chen/AAQ 6284 2020; Chen, Yi Ming/AAV 3806 2021
OI Chen, Yi Ming/0000 0001 7593 3065
FU The authors appreciate the assistance with statistical analysis that was
   provided by the Biostatistics Task Force of Taichung Veterans General
   Hospital. The authors acknowledge the assistance from the Center for
   Translational Medicine of Taichung Veterans; Biostatistics Task Force of
   Taichung Veterans General Hospital; Center for Translational Medicine of
   Taichung Veterans General Hospital; Osteoporosis Prevention Center of
   Taichung Veterans General Hospital
FX The authors appreciate the assistance with statistical analysis that was
   provided by the Biostatistics Task Force of Taichung Veterans General
   Hospital. The authors acknowledge the assistance from the Center for
   Translational Medicine of Taichung Veterans General Hospital. The
   authors would like to thank the Osteoporosis Prevention Center of
   Taichung Veterans General Hospital for providing the data and assistance
   with statistical analysis.
CR Aletaha D, 2013, ANN RHEUM DIS, V72, P875, DOI 10.1136/annrheumdis 2012 201517
   Amkreutz JAMP, 2021, ARTHRITIS RHEUMATOL, V73, P921, DOI 10.1002/art.41623
   Carbone LD, 1999, CALCIFIED TISSUE INT, V64, P100, DOI 10.1007/s002239900585
   Chen YZ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173410
   Dougados M, 2017, ANN RHEUM DIS, V76, P88, DOI 10.1136/annrheumdis 2016 210094
   Emery P, 2021, ARTHRITIS RES THER, V23, DOI 10.1186/s13075 020 02379 6
   Fautrel B, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091394
   Fleischmann RM, 2019, ANN RHEUM DIS, V78, P1454, DOI 10.1136/annrheumdis 2019 215764
   Fransen J, 2004, RHEUMATOLOGY, V43, P1252, DOI 10.1093/rheumatology/keh297
   Gulyas K, 2020, CLIN RHEUMATOL, V39, P167, DOI 10.1007/s10067 019 04771 3
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Harre U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7651
   Harre U, 2012, J CLIN INVEST, V122, P1791, DOI 10.1172/JCI60975
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Hauser B, 2014, RHEUMATOLOGY, V53, P1759, DOI 10.1093/rheumatology/keu162
   Hecht C, 2015, ANN RHEUM DIS, V74, P2151, DOI 10.1136/annrheumdis 2014 205428
   Hensvold AH, 2015, ARTHRITIS RES THER, V17, DOI 10.1186/s13075 015 0760 9
   HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502
   Ishiguro N, 2019, RHEUMATOLOGY, V58, P997, DOI 10.1093/rheumatology/key416
   Jin S, 2018, OSTEOPOROSIS INT, V29, P1263, DOI 10.1007/s00198 018 4473 1
   Kanis J.A., 2007, ASSESSMENT OSTEOPORO
   KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096
   Katchamart W, 2015, RHEUMATOL INT, V35, P1693, DOI 10.1007/s00296 015 3271 8
   Krieckaert CLM, 2013, RHEUMATOLOGY, V52, P547, DOI 10.1093/rheumatology/kes320
   Laurent L, 2011, ANN RHEUM DIS, V70, P1052, DOI 10.1136/ard.2010.142091
   Raterman HG, 2020, EXPERT OPIN PHARMACO, V21, P1725, DOI 10.1080/14656566.2020.1787381
   Revu S, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4398
   Soós B, 2022, NAT REV RHEUMATOL, V18, P249, DOI 10.1038/s41584 022 00764 w
   Tada M, 2018, RHEUMATOL INT, V38, P777, DOI 10.1007/s00296 017 3922 z
   Thudium CS, 2020, ARTHRITIS RES THER, V22, DOI 10.1186/s13075 020 02340 7
   van der Heijde D, 2022, J RHEUMATOL, V49, P133, DOI 10.3899/jrheum.210346
   van der Heijde D, 2018, CLIN RHEUMATOL, V37, P2381, DOI 10.1007/s10067 018 4221 0
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wheater G, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201527
NR 34
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0770 3198
EI 1434 9949
J9 CLIN RHEUMATOL
JI Clin. Rheumatol.
PD JAN
PY 2024
VL 43
IS 1
BP 117
EP 128
DI 10.1007/s10067 023 06735 0
EA SEP 2023
PG 12
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA IX5N2
UT WOS:001057641100001
PM 37658935
DA 2025 08 17
ER

PT J
AU Hildebrand, S
   Cunningham, J
AF Hildebrand, S.
   Cunningham, J.
TI Is there a role for bisphosphonates in vascular calcification in chronic
   kidney disease?
SO BONE
LA English
DT Article
DE Mineral bone disease; Bisphosphonates; Vascular calcification
ID NITROGEN CONTAINING BISPHOSPHONATE; CORONARY ARTERY CALCIFICATION; STAGE
   RENAL DISEASE; AORTIC CALCIFICATION; BONE DISORDER; CARDIOVASCULAR
   EVENTS; HEMODIALYSIS PATIENTS; CLINICAL DEVELOPMENT; ZOLEDRONIC ACID;
   CKD
AB Theoretically bisphosphonates could accelerate or retard vascular calcification. In subjects with low GFR, the position is further confounded by a combination of uncertain pharmacokinetics (GI absorption is poor and inconsistent at all levels of renal function and the effect of low GFR generally is to increase bioavailability) and a highly variable skeletal substrate with extremes of turnover that increase unpredictably further. Although bisphosphonates reduce bone formation by 70 90% in subjects with normal GFR and reduce the ability of bone to buffer exogenous calcium fluxes, in bisphosphonate treated postmenopausal women accelerated vascular calcification has not been documented. The kidneys assist with this buffering, but the capacity to modulate calcium excretion declines as GFR falls, increasing the risk of hypercalcaemia in the event of high calcium influx. In the ESRD patient, decreased buffering capacity substantially increases the risk of transient hypercalcaemia, especially in the setting of dialysis, and as such may promote vascular calcification which is highly prevalent in the CKD population. Low bone turnover may thus be less of a vascular problem in patients with preserved renal function and a bigger problem when the GFR is low. In patients with stage 4 and 5 CKD, adynamic bone disease associates with the severity and progression of arterial calcification, including coronary artery calcification, and further suppression of bone turnover by a bisphosphonate might exacerbate an already high predisposition to vascular calcification. No convincing signal of harm has emerged from clinical studies thus far. For example 51 individuals with CKD stage 3 4 treated with either alendronate 70 mg per week or placebo for 18 months showed no difference in the rate of vascular calcifications. Conversely an observational study of women with stage 3 4 CKD with pre existing cardiovascular disease found an increased risk of mortality with a hazard ratio of 1.22 (1.04 1.42) in those given bisphosphonates. Direct suppression of vascular calcification by bisphosphonates is probably confined to etidronate   treatment of soft tissue calcification was a recognized indication for this drug and etidronate markedly reduced progression of vascular calcification in CKD patients. Bisphosphonates are analogues of pyrophosphate, a potent calcification inhibitor in bone and soft tissue. Thus the efficacy of etidronate as treatment for soft tissue calcification brought with it a problematic tendency to cause osteomalacia. In contrast, conventional doses of nitrogen containing bisphosphonates fail to yield circulating concentrations sufficient to exert direct anti calcifying effects, at least in patients with good renal function and studies using alendronate and ibandronate have yielded inconsistent vascular outcomes.
C1 [Hildebrand, S.; Cunningham, J.] Royal Free Hosp, Ctr Nephrol, London, England.
C3 University of London; University College London; Royal Free London NHS
   Foundation Trust; UCL Medical School
RP Hildebrand, S (通讯作者)，Royal Free Hosp, Ctr Nephrol, London, England.
EM sarah.hildebrand2@nhs.net
OI Hildebrand, Sarah/0000 0003 0110 1404
CR Ariyoshi T, 2006, CLIN DRUG INVEST, V26, P215, DOI 10.2165/00044011 200626040 00006
   Asci G, 2011, NEPHROL DIAL TRANSPL, V26, P1010, DOI 10.1093/ndt/gfq491
   Barreto DV, 2008, AM J KIDNEY DIS, V52, P1139, DOI 10.1053/j.ajkd.2008.06.024
   BASSETT CAL, 1969, LANCET, V2, P845
   Bellido T, 2011, BONE, V49, P50, DOI 10.1016/j.bone.2010.08.008
   Bergner R, 2013, J NEPHROL, V26, P450, DOI 10.5301/jn.5000188
   Block GA, 2013, CLIN J AM SOC NEPHRO, V8, P2132, DOI 10.2215/CJN.04260413
   Braun J, 1996, AM J KIDNEY DIS, V27, P394, DOI 10.1016/S0272 6386(96)90363 7
   Caffarelli C, 2017, CLIN INTERV AGING, V12, P1819, DOI 10.2147/CIA.S138002
   Cai G, 2020, OSTEOPOROSIS INT, V31, P1741, DOI 10.1007/s00198 020 05430 z
   Cano Megías M, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882 019 1367 1
   Cejka D, 2014, J CLIN ENDOCR METAB, V99, P248, DOI 10.1210/jc.2013 2786
   Cianciolo G, 2014, AM J NEPHROL, V39, P418, DOI 10.1159/000362492
   Cozzolino M, 2018, NEPHROL DIAL TRANSPL, V33, P28, DOI 10.1093/ndt/gfy174
   Cremers S, 2019, BRIT J CLIN PHARMACO, V85, P1052, DOI 10.1111/bcp.13867
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Evenepoel P, 2017, J NEPHROL, V30, P645, DOI 10.1007/s40620 017 0424 8
   Fang YF, 2014, J AM SOC NEPHROL, V25, P1760, DOI 10.1681/ASN.2013080818
   Fang YF, 2014, KIDNEY INT, V85, P142, DOI 10.1038/ki.2013.271
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   FLEISCH HA, 1970, EUR J CLIN INVEST, V1, P12, DOI 10.1111/j.1365 2362.1970.tb00591.x
   Foley RN, 1998, AM J KIDNEY DIS, V32, pS112, DOI 10.1053/ajkd.1998.v32.pm9820470
   Francis M. D., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P2
   Giachelli CM, 2009, KIDNEY INT, V75, P890, DOI 10.1038/ki.2008.644
   Giachelli CM, 2004, SEMIN NEPHROL, V24, P401, DOI 10.1016/j.semnephrol.2004.06.005
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Gonnelli S, 2014, BONE, V61, P27, DOI 10.1016/j.bone.2013.12.017
   Goodman WG, 2000, NEW ENGL J MED, V342, P1478, DOI 10.1056/NEJM200005183422003
   Gutierrez O, 2005, J AM SOC NEPHROL, V16, P2205, DOI 10.1681/ASN.2005010052
   Hartle JE, 2012, AM J KIDNEY DIS, V59, P636, DOI 10.1053/j.ajkd.2011.11.037
   Hashiba H, 2006, THER APHER DIAL, V10, P59, DOI 10.1111/j.1744 9987.2006.00345.x
   Hruska KA, 2017, BONE, V100, P80, DOI 10.1016/j.bone.2017.01.023
   Hruska KA, 2015, CURR OPIN NEPHROL HY, V24, P303, DOI 10.1097/MNH.0000000000000132
   Jamal SA, 2007, J BONE MINER RES, V22, P503, DOI 10.1359/JBMR.070112
   Jobke B, 2014, BONE, V59, P37, DOI 10.1016/j.bone.2013.10.024
   Johnson ML, 2007, CURR OPIN RHEUMATOL, V19, P376, DOI 10.1097/BOR.0b013e32816e06f9
   KASTING GB, 1992, J BONE MINER RES, V7, P513
   Komaba H, 2018, CURR OPIN NEPHROL HY, V27, P298, DOI 10.1097/MNH.0000000000000423
   Kuro o M, 2017, BONE, V100, P4, DOI 10.1016/j.bone.2016.11.013
   Lamarche MC, 2019, NEPHROL DIAL TRANSPL, V34, P1715, DOI 10.1093/ndt/gfy183
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   Lu X, 2017, KIDNEY DIS BASEL, V3, P15, DOI 10.1159/000452880
   Lv W, 2016, INT UROL NEPHROL, V48, P2043, DOI 10.1007/s11255 016 1379 8
   Mäkelä S, 2011, INT J CLIN PHARM TH, V49, P128, DOI 10.5414/CPP49128
   Miller PD, 2013, J BONE MINER RES, V28, P2049, DOI 10.1002/jbmr.2058
   Miller PD, 2011, BONE, V49, P77, DOI 10.1016/j.bone.2010.12.024
   Miller PD, 2005, J BONE MINER RES, V20, P2105, DOI 10.1359/JBMR.050817
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Moe SM, 2004, CIRC RES, V95, P560, DOI 10.1161/01.RES.0000141775.67189.98
   Morena M, 2015, NEPHROL DIAL TRANSPL, V30, P1345, DOI 10.1093/ndt/gfv081
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Nitta K, 2004, AM J KIDNEY DIS, V44, P680, DOI 10.1053/j.ajkd.2004.06.009
   Pan BQ, 2004, J BONE MINER RES, V19, P147, DOI 10.1359/jbmr.2004.19.1.147
   Pavik I, 2013, NEPHROL DIAL TRANSPL, V28, P352, DOI 10.1093/ndt/gfs460
   Plotkin LI, 2008, J BONE MINER RES, V23, P1712, DOI [10.1359/jbmr.080617, 10.1359/JBMR.080617]
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Qureshi AR, 2015, KIDNEY INT, V88, P1356, DOI 10.1038/ki.2015.194
   Rattazzi M, 2013, NEPHROL DIAL TRANSPL, V28, P2968, DOI 10.1093/ndt/gft310
   Reiss AB, 2018, ATHEROSCLEROSIS, V278, P49, DOI 10.1016/j.atherosclerosis.2018.08.046
   Rodríguez García M, 2009, NEPHROL DIAL TRANSPL, V24, P239, DOI 10.1093/ndt/gfn466
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1972, LANCET, V1, P10
   Sabbagh Y, 2012, J BONE MINER RES, V27, P1757, DOI 10.1002/jbmr.1630
   Salam S, 2018, J AM SOC NEPHROL, V29, P1557, DOI 10.1681/ASN.2017050584
   Smit MA, 2019, ENDOCR REV, V40, P1468, DOI 10.1210/er.2018 00220
   SMITH ML, 1983, J NUCL MED, V24, P208
   Tamura K, 2005, J PHARMACOL SCI, V99, P89, DOI 10.1254/jphs.FPJ05019X
   Tamura K, 2007, EUR J PHARMACOL, V558, P159, DOI 10.1016/j.ejphar.2006.12.006
   Toussain ND, 2008, NEPHROL DIAL TRANSPL, V23, P586, DOI 10.1093/ndt/gfm660
   Toussaint ND, 2007, NEPHROLOGY, V12, P500, DOI 10.1111/j.1440 1797.2007.00823.x
   Toussaint ND, 2010, AM J KIDNEY DIS, V56, P57, DOI 10.1053/j.ajkd.2009.12.039
   Umana E, 2003, AM J MED SCI, V325, P237, DOI 10.1097/00000441 200304000 00010
   Vipattawat K, 2014, NEPHROLOGY, V19, P251, DOI 10.1111/nep.12210
   Voelkl L.F., 2019, CELL MOL LIFE SCI, V76
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Yamada S, 2018, KIDNEY INT, V94, P716, DOI 10.1016/j.kint.2018.05.015
   Yamada S, 2017, BONE, V100, P87, DOI 10.1016/j.bone.2016.11.012
   Yang H, 2004, KIDNEY INT, V66, P2293, DOI 10.1111/j.1523 1755.2004.66015.x
   Ylitalo R, 2000, GEN PHARMACOL VASC S, V35, P287, DOI 10.1016/S0306 3623(01)00121 5
NR 83
TC 17
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2021
VL 142
AR 115751
DI 10.1016/j.bone.2020.115751
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA PI8LQ
UT WOS:000601336000005
PM 33188959
DA 2025 08 17
ER

PT J
AU Tseng, SCG
   He, H
   Zhang, SZ
   Chen, SY
AF Tseng, Scheffer C. G.
   He, Hua
   Zhang, Suzhen
   Chen, Szu Yu
TI Niche Regulation of Limbal Epithelial Stem Cells: Relationship between
   Inflammation and Regeneration
SO OCULAR SURFACE
LA English
DT Article
DE amniotic membrane; anti inflammation; anti angiogenesis; antiscarring;
   heavy chain; hyaluronan; inter ainhibitor; limbus; stem cell niche; stem
   cells; umbilical cord
ID AMNIOTIC MEMBRANE TRANSPLANTATION; ALPHA TRYPSIN INHIBITOR;
   OCULAR SURFACE DISORDERS; GROWTH FACTOR BETA; ANTI CD4
   MONOCLONAL ANTIBODY; CORNEAL ALLOGRAFT REJECTION; STIMULATED GENE 6
   TSG 6; ORAL MUCOSAL EPITHELIUM; FETAL WOUND REPAIR; EX VIVO EXPANSION
AB Human limbal palisades of Vogt are the ideal site for studying and practicing regenerative medicine due to their accessibility. Nonresolving inflammation in limbal stroma is common manifestation of limbal stem cell (SC) deficiency and presents as a threat to the success of transplanted limbal epithelial SCs. This pathologic process can be overcome by transplantation of cryopreserved human amniotic membrane (AM), which exerts anti inflammatory, antiscarring and anti angiogenic action to promote wound healing. To determine how AM might exert anti inflammation and promote regeneration, we have purified a novel matrix, HC HA/PTX3, responsible for the efficacy of AM efficacy. HC HA complex is covalently formed by hyaluronan (HA) and heavy chain 1 (HC1) of inter alpha trypsin inhibitor by the catalytic action of tumor necrosis factor stimulated gene 6 (TSG 6) and are tightly associated with pentraxin 3 (PTX3) to form HC HA/PTX3. In vitro reconstitution of the limbal niche can be established by reunion between limbal epithelial progenitors and limbal niche cells on different substrates. In 3 dimensional Matrigel, clonal expansion indicative of SC renewal is correlated with activation of canonical Wnt signaling and suppression of canonical bone morphogenetic protein (BMP) signaling. In contrast, SC quiescence can be achieved in HC HA/PTX3 by activation of canonical BMP signaling and non canonical planar cell polarity (PCP) Wnt signaling, but suppression of canonical Wnt signaling. HC HA/PTX3 is a novel matrix mitigating nonresolving inflammation and restoring SC quiescence in the niche for various applications in regenerative medicine.
C1 TissueTech Inc, R&D Dept, Ocular Surface Ctr, Miami, FL USA.
   Ocular Surface Res & Educ Fdn, Miami, FL USA.
   [Tseng, Scheffer C. G.; He, Hua; Zhang, Suzhen; Chen, Szu Yu] TissueTech Inc, Miami, FL USA.
RP Tseng, SCG (通讯作者)，Ocular Surface Ctr, 7000 SW 97 Ave,Suite 213, Miami, FL 33173 USA.
EM stseng@ocularsurface.com
RI ; Zhang, Suzhen/J 8011 2013; Cheng, Shiyuan/ISU 4685 2023
OI Tseng, Scheffer C.G./0009 0002 7995 9881; 
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland, USA [EY06819, EY017497, EY021045, EY022502]; TissueTech, Inc.;
   Ocular Surface Research & Education Foundation, Miami, FL
FX Supported by Research Grants EY06819, EY017497, EY021045, and EY022502
   from National Eye Institute, National Institutes of Health, Bethesda,
   Maryland, USA, a research grant from TissueTech, Inc., and an
   unrestricted grant from Ocular Surface Research & Education Foundation,
   Miami, FL.
CR Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593
   Akaishi S, 2008, MED HYPOTHESES, V71, P32, DOI 10.1016/j.mehy.2008.01.032
   Amescua G, 2014, AM J OPHTHALMOL, V158, P469, DOI 10.1016/j.ajo.2014.06.002
   AYLIFFE W, 1992, BRIT J OPHTHALMOL, V76, P602, DOI 10.1136/bjo.76.10.602
   Barbaro V, 2007, J CELL BIOL, V177, P1037, DOI 10.1083/jcb.200703003
   Bauer D, 2007, EXP EYE RES, V85, P335, DOI 10.1016/j.exer.2007.05.009
   Bauer D, 2012, INVEST OPHTH VIS SCI, V53, P799, DOI 10.1167/iovs.11 7617
   Bauer D, 2009, INVEST OPHTH VIS SCI, V50, P3188, DOI 10.1167/iovs.08 3041
   Blom AM, 1999, J BIOL CHEM, V274, P298, DOI 10.1074/jbc.274.1.298
   Burillon C, 2012, INVEST OPHTH VIS SCI, V53, P1325, DOI 10.1167/iovs.11 7744
   Campo GM, 2011, BBA MOL BASIS DIS, V1812, P1170, DOI 10.1016/j.bbadis.2011.06.006
   Castagnoli C, 1997, BURNS, V23, P565, DOI 10.1016/S0305 4179(97)00070 3
   CHEN JJY, 1990, INVEST OPHTH VIS SCI, V31, P1301
   CHEN JJY, 1991, INVEST OPHTH VIS SCI, V32, P2219
   Chen SY, 2015, STEM CELLS, V33, P3341, DOI 10.1002/stem.2091
   Chen SY, 2011, TISSUE ENG PART C ME, V17, P537, DOI [10.1089/ten.tec.2010.0609, 10.1089/ten.TEC.2010.0609]
   Choi TH, 2001, CORNEA, V20, P197, DOI 10.1097/00003226 200103000 00019
   Choi YS, 1998, CORNEA, V17, P389, DOI 10.1097/00003226 199807000 00009
   Coulson Thomas VJ, 2014, J BIOL CHEM, V289, P23465, DOI 10.1074/jbc.M114.557447
   Cowin AJ, 2001, EUR J DERMATOL, V11, P424
   Dong C, 2000, ARTHRITIS RES, V2, P179, DOI 10.1186/ar85
   Dua H S, 2000, Indian J Ophthalmol, V48, P83
   DUA HS, 1990, AM J OPHTHALMOL, V110, P646, DOI 10.1016/S0002 9394(14)77062 X
   Duffield JS, 2003, CLIN SCI, V104, P27, DOI 10.1042/CS20020240
   Dziasko MA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094283
   ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975
   Espana EM, 2002, OPHTHALMOLOGY, V109, P2004, DOI 10.1016/S0161 6420(02)01250 2
   Espana EM, 2004, EYE, V18, P406, DOI 10.1038/sj.eye.6700670
   Espana EM, 2003, INVEST OPHTH VIS SCI, V44, P5136, DOI 10.1167/iovs.03 0484
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fülöp C, 2003, DEVELOPMENT, V130, P2253, DOI 10.1242/dev.00422
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Greco V, 2010, DEVELOPMENT, V137, P1585, DOI 10.1242/dev.041103
   Gregory DG, 2011, OPHTHALMOLOGY, V118, P908, DOI 10.1016/j.ophtha.2011.01.046
   Grueterich M, 2003, SURV OPHTHALMOL, V48, P631, DOI 10.1016/j.survophthal.2003.08.003
   Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016
   Han B, 2014, STEM CELL RES, V12, P562, DOI 10.1016/j.scr.2014.01.003
   Haringman JJ, 2005, ANN RHEUM DIS, V64, P834, DOI 10.1136/ard.2004.029751
   He H, 2008, INVEST OPHTH VIS SCI, V49, P4468, DOI 10.1167/iovs.08 1781
   He H, 2014, INVEST OPHTH VIS SCI, V55, P1647, DOI 10.1167/iovs.13 13094
   He H, 2013, J BIOL CHEM, V288, P25792, DOI 10.1074/jbc.M113.479584
   He H, 2009, J BIOL CHEM, V284, P20136, DOI 10.1074/jbc.M109.021881
   HE YG, 1991, INVEST OPHTH VIS SCI, V32, P2723
   Heiligenhaus A, 2001, INVEST OPHTH VIS SCI, V42, P1969
   Hertsenberg AJ, 2015, PROG MOL BIOL TRANSL, V134, P25, DOI 10.1016/bs.pmbts.2015.04.002
   Holland E J, 1996, Trans Am Ophthalmol Soc, V94, P677
   Holland EJ, 2015, CORNEA, V34, pS9, DOI 10.1097/ICO.0000000000000534
   Holland EJ, 1996, CORNEA, V15, P549
   HUANG AJW, 1991, INVEST OPHTH VIS SCI, V32, P96
   Ilari L, 2002, OPHTHALMOLOGY, V109, P1278, DOI 10.1016/S0161 6420(02)01081 3
   Inforzato A, 2011, TISSUE ANTIGENS, V77, P271, DOI 10.1111/j.1399 0039.2011.01645.x
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jessen TE, 2003, REPRODUCTION, V125, P27, DOI 10.1530/rep.0.1250027
   Jiang A, 2006, CORNEA, V25, pS36, DOI 10.1097/01.ico.0000247211.78391.af
   Katikireddy KR, 2014, STEM CELLS, V32, P717, DOI 10.1002/stem.1541
   Kawakita T, 2005, J BIOL CHEM, V280, P27085, DOI 10.1074/jbc.M409567200
   KENYON K., 1995, Ophthalmology, V102, P101
   Kenyon K R, 1989, Dev Ophthalmol, V18, P53
   Khanna S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009539
   Kheirkhah A, 2008, ARCH OPHTHALMOL CHIC, V126, P1059, DOI 10.1001/archopht.126.8.1059
   Kheirkhah A, 2008, CORNEA, V27, P730, DOI 10.1097/QAI.0b013e31815cea8b
   Kheirkhah A, 2008, CORNEA, V27, P56, DOI 10.1097/ICO.0b013e31815873da
   Kim J C, 1995, Korean J Ophthalmol, V9, P32
   Kinoshita S, 2001, PROG RETIN EYE RES, V20, P639, DOI 10.1016/S1350 9462(01)00007 6
   Koh TJ, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001943
   Kolli S, 2014, STEM CELLS, V32, P2135, DOI 10.1002/stem.1694
   Krausgruber T, 2011, NAT IMMUNOL, V12, P231, DOI 10.1038/ni.1990
   KRUSE FE, 1990, INVEST OPHTH VIS SCI, V31, P1903
   Larson BJ, 2010, PLAST RECONSTR SURG, V126, P1172, DOI 10.1097/PRS.0b013e3181eae781
   Lavker RM, 2004, EXP EYE RES, V78, P433, DOI 10.1016/j.exer.2003.09.008
   Lee SB, 2000, CURR EYE RES, V20, P325, DOI 10.1076/0271 3683(200004)20:4;1 5;FT325
   Li GG, 2012, INVEST OPHTH VIS SCI, V53, P5686, DOI 10.1167/iovs.12 10300
   Li GG, 2012, INVEST OPHTH VIS SCI, V53, P3357, DOI 10.1167/iovs.11 9414
   Li LH, 2010, SCIENCE, V327, P542, DOI 10.1126/science.1180794
   Li W, 2006, EXP EYE RES, V82, P282, DOI 10.1016/j.exer.2005.06.022
   Li W, 2008, J CELL PHYSIOL, V215, P657, DOI 10.1002/jcp.21345
   Li W, 2007, CELL RES, V17, P26, DOI 10.1038/sj.cr.7310137
   Liang L, 2009, EYE, V23, P1946, DOI 10.1038/eye.2008.379
   Liang LY, 2009, ARCH OPHTHALMOL CHIC, V127, P1428, DOI 10.1001/archophthalmol.2009.263
   Liechty KW, 1998, J SURG RES, V77, P80, DOI 10.1006/jsre.1998.5345
   Liechty KW, 2000, CYTOKINE, V12, P671, DOI 10.1006/cyto.1999.0598
   LIU CY, 1994, J BIOL CHEM, V269, P24627
   Liu JB, 2011, AM J OPHTHALMOL, V152, P739, DOI 10.1016/j.ajo.2011.03.037
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293
   Meallet MA, 2003, OPHTHALMOLOGY, V110, P1585, DOI 10.1016/S0161 6420(03)00503 7
   Mizushima S, 1998, BIOL PHARM BULL, V21, P167
   Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Müller LJ, 2003, EXP EYE RES, V76, P521, DOI 10.1016/S0014 4835(03)00050 2
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Nathan C, 2010, CELL, V140, P871, DOI 10.1016/j.cell.2010.02.029
   Niederkorn JY, 2007, CURR EYE RES, V32, P1005, DOI 10.1080/02713680701767884
   Niessen FB, 2004, J PATHOL, V202, P121, DOI 10.1002/path.1502
   Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455
   ODUM L, 1990, BIOL CHEM H S, V371, P1153, DOI 10.1515/bchm3.1990.371.2.1153
   Olutoye OO, 1996, J PEDIATR SURG, V31, P91, DOI 10.1016/S0022 3468(96)90326 7
   Ouyang H, 2014, NATURE, V511, P358, DOI 10.1038/nature13465
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Park WC, 2000, INVEST OPHTH VIS SCI, V41, P2906
   Parsonage G, 2005, TRENDS IMMUNOL, V26, P150, DOI 10.1016/j.it.2004.11.014
   PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092 8674(94)90332 8
   Plotkin J, 2003, J IMMUNOL, V171, P4521, DOI 10.4049/jimmunol.171.9.4521
   Prockop SE, 2002, J IMMUNOL, V169, P4354, DOI 10.4049/jimmunol.169.8.4354
   PUANGSRICHARERN V, 1995, OPHTHALMOLOGY, V102, P1476
   Rolfe K J, 2012, ISRN Dermatol, V2012, P698034, DOI 10.5402/2012/698034
   Rugg MS, 2005, J BIOL CHEM, V280, P25674, DOI 10.1074/jbc.M501332200
   Rumman M, 2015, STEM CELLS, V33, P2903, DOI 10.1002/stem.2056
   Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001
   Salustri A, 2004, DEVELOPMENT, V131, P1577, DOI 10.1242/dev.01056
   Sanggaard KW, 2006, BIOCHEMISTRY US, V45, P7661, DOI 10.1021/bi060106s
   Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165
   Sangwan VS, 2012, BRIT J OPHTHALMOL, V96, P931, DOI 10.1136/bjophthalmol 2011 301164
   Scarchilli L, 2007, J BIOL CHEM, V282, P30161, DOI 10.1074/jbc.M703738200
   SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49
   Shammas MC, 2010, AM J OPHTHALMOL, V149, P203, DOI 10.1016/j.ajo.2009.08.040
   Shanmuganathan VA, 2007, BRIT J OPHTHALMOL, V91, P514, DOI 10.1136/bjo.2006.102640
   Shay E, 2011, INVEST OPHTH VIS SCI, V52, P2669, DOI 10.1167/iovs.10 5888
   Shimmura S, 2001, CORNEA, V20, P408, DOI 10.1097/00003226 200105000 00015
   Shortt AJ, 2007, STEM CELLS, V25, P1402, DOI 10.1634/stemcells.2006 0580
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sindrilaru A, 2011, J CLIN INVEST, V121, P985, DOI 10.1172/JCI44490
   SULLIVAN KM, 1995, J PEDIATR SURG, V30, P198, DOI 10.1016/0022 3468(95)90560 X
   Sun T. T., 1999, CORNEAL SURG THEORY, P9
   Tan DTH, 1996, OPHTHALMOLOGY, V103, P29, DOI 10.1016/S0161 6420(96)30737 9
   Thang JTS, 1997, OPHTHALMIC SURG LAS, V28, P765
   Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202
   TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226 199409000 00003
   TSAI RJF, 1988, INVEST OPHTH VIS SCI, V29, P1565
   Tseng SCG, 2010, CURR MOL MED, V10, P841
   Tseng SC, 2016, INVEST OPHT IN PRESS
   Tseng SCG, 1998, ARCH OPHTHALMOL CHIC, V116, P431, DOI 10.1001/archopht.116.4.431
   Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097 4652(199906)179:3<325::AID JCP10>3.0.CO;2 X
   TSENG SCG, 1985, OPHTHALMOLOGY, V92, P728
   Tseng SCG, 1996, MOL BIOL REP, V23, P47, DOI 10.1007/BF00357072
   Tseng SCG., 1998, Hong Kong JOphthalmol, V2, P26
   Tsubota K, 1999, JPN J OPHTHALMOL, V43, P502, DOI 10.1016/S0021 5155(99)00140 9
   TSUBOTA K, 1995, OPHTHALMOLOGY, V102, P1486
   Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201
   Umemoto T, 2005, FEBS LETT, V579, P6569, DOI 10.1016/j.febslet.2005.10.047
   Underhill DM, 2012, NAT REV IMMUNOL, V12, P492, DOI 10.1038/nri3244
   Wang MX, 2001, J CATARACT REFR SURG, V27, P310, DOI 10.1016/S0886 3350(00)00467 3
   Wolosin JM, 2000, PROG RETIN EYE RES, V19, P223, DOI 10.1016/S1350 9462(99)00005 1
   Woo HM, 2001, BRIT J OPHTHALMOL, V85, P345, DOI 10.1136/bjo.85.3.345
   Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228
   Xie HT, 2012, INVEST OPHTH VIS SCI, V53, P279, DOI 10.1167/iovs.11 8441
   Xie HT, 2011, STEM CELLS, V29, P1874, DOI 10.1002/stem.743
   Yamada J, 1999, INVEST OPHTH VIS SCI, V40, P2614
   Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109
   Yeung AMH, 2008, ARCH OPHTHALMOL CHIC, V126, P665, DOI 10.1001/archopht.126.5.665
   Zhang JW, 2006, STEM CELLS, V24, P2826, DOI 10.1634/stemcells.2005 0544
   Zhang SZ, 2014, J BIOL CHEM, V289, P13531, DOI 10.1074/jbc.M113.525287
   Zhang SZ, 2012, J BIOL CHEM, V287, P12433, DOI 10.1074/jbc.M112.342873
   Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200
   Zhuo LS, 2001, J BIOL CHEM, V276, P7693, DOI 10.1074/jbc.C000899200
NR 155
TC 71
Z9 73
U1 2
U2 30
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1542 0124
EI 1937 5913
J9 OCUL SURF
JI Ocul. Surf.
PD APR
PY 2016
VL 14
IS 2
BP 100
EP 112
DI 10.1016/j.jtos.2015.12.002
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Ophthalmology
GA DK9AR
UT WOS:000375222400005
PM 26769483
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Nguyen, KH
   Xu, FH
   Flowers, S
   Williams, EAJ
   Fritton, JC
   Moran, E
AF Kevin Hong Nguyen
   Xu, Fuhua
   Flowers, Stephen
   Williams, Edek A. J.
   Fritton, J. Christopher
   Moran, Elizabeth
TI SWI/SNF Mediated Lineage Determination in Mesenchymal Stem Cells Confers
   Resistance to Osteoporosis
SO STEM CELLS
LA English
DT Article
DE SWI/SNF; mammalian brahma; BRM; Osteoblasts; Adipocytes; Mesenchymal
   stem cells; Osteoporosis
ID CHROMATIN REMODELING COMPLEXES; ADIPOCYTE DIFFERENTIATION; BONE MARROW;
   GENE EXPRESSION; PPAR GAMMA; BRM; BRG1; CANCER; MOUSE; ROLES
AB Redirecting the adipogenic potential of bone marrow derived mesenchymal stem cells to other lineages, particularly osteoblasts, is a key goal in regenerative medicine. Controlling lineage selection through chromatin remodeling complexes such as SWI/SNF, which act coordinately to establish new patterns of gene expression, would be a desirable intervention point, but the requirement for the complex in essentially every lineage pathway has generally precluded selectivity. However, a novel approach now appears possible by targeting the subset of SWI/SNF powered by the alternative ATPase, mammalian brahma (BRM). BRM is not required for development, which has hindered understanding of its contributions, but knockdown genetics here, designed to explore the hypothesis that BRM SWI/SNF has different regulatory roles in different mesenchymal stem cell lineages, shows that depleting BRM from mesenchymal stem cells has a dramatic effect on the balance of lineage selection between osteoblasts and adipocytes. BRM depletion enhances the proportion of cells expressing markers of osteoblast precursors at the expense of cells able to differentiate along the adipocyte lineage. This effect is evident in primary bone marrow stromal cells as well as in established cell culture models. The altered precursor balance has major physiological significance, which becomes apparent as protection against age related osteoporosis and as reduced bone marrow adiposity in adult BRM null mice.
C1 [Kevin Hong Nguyen; Xu, Fuhua; Flowers, Stephen; Williams, Edek A. J.; Fritton, J. Christopher; Moran, Elizabeth] Rutgers State Univ, Dept Orthopaed, New Jersey Med Sch, Newark, NJ 07103 USA.
C3 Rutgers University System; Rutgers University Newark; Rutgers University
   New Brunswick; Rutgers University Biomedical & Health Sciences
RP Moran, E (通讯作者)，Rutgers State Univ, Dept Orthopaed, New Jersey Med Sch, 205 South Orange Ave, Newark, NJ 07103 USA.
EM mor anel@njms.rutgers.edu
OI Fritton, James/0000 0002 6475 7622
FU National Institute of General Medical Sciences; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases; National Cancer
   Institute of the National Institutes of Health [R01GM073257,
   R21 AR063351, T32 CA134268]; NJ Health Foundation
FX We thank the support of Dr. Fred F. Buechel, and also Dr. Karen Knudsen
   for the generous gift of breeding pairs of the BRM knockout mice, and
   the Institut Pasteur for permission to use them. This work was supported
   by the National Institute of General Medical Sciences, the National
   Institute of Arthritis and Musculoskeletal and Skin Diseases, and the
   National Cancer Institute of the National Institutes of Health under
   Grants R01GM073257 (to E.M.), R21 AR063351 (to J.C.F.), and T32 CA134268
   (to S.F.); and a Translational Research Award from the Foundation of
   UMDNJ (now NJ Health Foundation).
CR Akune T, 2004, J CLIN INVEST, V113, P846, DOI 10.1172/JCI200419900
   Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097 2765(00)00127 1
   Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847
   de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882
   Du XL, 2012, J CELL PHYSIOL, V227, P3731, DOI 10.1002/jcp.24083
   Flowers S, 2013, CANCER RES, V73, P2150, DOI 10.1158/0008 5472.CAN 12 1745
   Flowers S, 2011, J BIOL CHEM, V286, P27867, DOI 10.1074/jbc.C111.255091
   Flowers S, 2009, J BIOL CHEM, V284, P10067, DOI 10.1074/jbc.M808782200
   Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514
   Griffin CT, 2008, DEVELOPMENT, V135, P493, DOI 10.1242/dev.010090
   Halliday GM, 2012, EXP DERMATOL, V21, P599, DOI 10.1111/j.1600 0625.2012.01522.x
   Hoffman GR, 2014, P NATL ACAD SCI USA, V111, P3128, DOI 10.1073/pnas.1316793111
   Jilka RL, 2013, J GERONTOL A BIOL, V68, P1209, DOI 10.1093/gerona/glt046
   Kadam S, 2003, MOL CELL, V11, P377, DOI 10.1016/S1097 2765(03)00034 0
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006 291X(05)80208 6
   Katoh M, 2009, J INVEST DERMATOL, V129, P1861, DOI 10.1038/jid.2009.97
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   Kawai M, 2010, AM J PHYSIOL ENDOC M, V299, pE3, DOI 10.1152/ajpendo.00157.2010
   Koga M, 2009, HUM MOL GENET, V18, P2483, DOI 10.1093/hmg/ddp166
   Liu Y, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/895045
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Marie PJ, 2012, GROWTH FACTORS, V30, P117, DOI 10.3109/08977194.2012.656761
   Mehrotra A, 2014, CRIT REV EUKAR GENE, V24, P151, DOI 10.1615/CritRevEukaryotGeneExpr.2014007882
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Narayanan R, 2014, CELL TISSUE RES, V356, P575, DOI 10.1007/s00441 013 1791 7
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Oike T, 2013, CANCER RES, V73, P5508, DOI 10.1158/0008 5472.CAN 12 4593
   Pedersen TÅ, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901
   Perlyn CA, 2006, CLEFT PALATE CRAN J, V43, P740, DOI 10.1597/05 212
   Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4
   Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979
   Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651 4663.2004
   Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008 5472.CAN 08 1794
   Takada I, 2007, ANN NY ACAD SCI, V1116, P182, DOI 10.1196/annals.1402.034
   Tang QQ, 2012, ANNU REV BIOCHEM, V81, P715, DOI 10.1146/annurev biochem 052110 115718
   Van Houdt JKJ, 2012, NAT GENET, V44, P445, DOI 10.1038/ng.1105
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Walsh T, 2008, SCIENCE, V320, P539, DOI 10.1126/science.1155174
   Wilson BG, 2014, MOL CELL BIOL, V34, P1136, DOI 10.1128/MCB.01372 13
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Wolff D, 2011, MOL SYNDROMOL, V2, P237, DOI 10.1159/000337323
   Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099
   Xie YL, 2014, J MOL ENDOCRINOL, V53, pT11, DOI 10.1530/JME 14 0012
   Xu FH, 2012, J BIOL CHEM, V287, P5033, DOI 10.1074/jbc.M111.279968
   Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332
   Zhang M, 2011, MOL CELL BIOL, V31, P2618, DOI 10.1128/MCB.01338 10
NR 50
TC 12
Z9 16
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD OCT
PY 2015
VL 33
IS 10
BP 3028
EP 3038
DI 10.1002/stem.2064
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA CU1FD
UT WOS:000363264500014
PM 26059320
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Rastogi, SK
   Khanka, S
   Kumar, S
   Lakra, A
   Rathur, R
   Sharma, K
   Bisen, AC
   Bhatta, RS
   Kumar, R
   Singh, D
   Sinha, AK
AF Rastogi, Sumit K.
   Khanka, Sonu
   Kumar, Santosh
   Lakra, Amardeep
   Rathur, Rajat
   Sharma, Kriti
   Bisen, Amol Chhatrapati
   Bhatta, Rabi Sankar
   Kumar, Ravindra
   Singh, Divya
   Sinha, Arun K.
TI Design, synthesis and biological evaluation of novel pyrimidine
   derivatives as bone anabolic agents promoting osteogenesis via
   the BMP2/SMAD1 signaling pathway
SO RSC MEDICINAL CHEMISTRY
LA English
DT Article
ID DIFFERENTIATION; REGENERATION; CHALCONES
AB Anti resorptive inhibitors such as bisphosphonates are widely used but they have limited efficacy and serious side effects. Though subcutaneous injection of teriparatide [PTH (1 34)] is an effective anabolic therapy, long term repeated subcutaneous administration is not recommended. Henceforth, orally bio available small molecule based novel therapeutics are unmet medical needs to improve the treatment. In this study, we designed, synthesized, and carried out a biological evaluation of 31 pyrimidine derivatives as potent bone anabolic agents. A series of in vitro experiments confirmed N (5 bromo 4 (4 bromophenyl) 6 (2,4,5 trimethoxyphenyl)pyrimidin 2 yl)hexanamide (18a) as the most efficacious anabolic agent at 1 pM. It promoted osteogenesis by upregulating the expression of osteogenic genes (RUNX2 and type 1 col) via activation of the BMP2/SMAD1 signaling pathway. In vitro osteogenic potential was further validated using an in vivo fracture defect model where compound 18a promoted the bone formation rate at 5 mg kg( 1). We also established the structure activity relationship and pharmacokinetic studies of 18a.
C1 [Rastogi, Sumit K.; Kumar, Santosh; Kumar, Ravindra; Sinha, Arun K.] CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, India.
   [Khanka, Sonu; Lakra, Amardeep; Rathur, Rajat; Sharma, Kriti; Singh, Divya] CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.
   [Rastogi, Sumit K.; Khanka, Sonu; Kumar, Santosh; Rathur, Rajat; Sharma, Kriti; Bisen, Amol Chhatrapati; Bhatta, Rabi Sankar; Kumar, Ravindra; Singh, Divya; Sinha, Arun K.] Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, UP, India.
   [Bisen, Amol Chhatrapati; Bhatta, Rabi Sankar] CSIR Cent Drug Res Inst, Pharmaceut & Pharmacokinet Div, Lucknow 226031, India.
C3 Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Central Drug Research
   Institute (CDRI); Academy of Scientific & Innovative Research (AcSIR);
   Council of Scientific & Industrial Research (CSIR)   India; CSIR  
   Central Drug Research Institute (CDRI)
RP Kumar, R; Sinha, AK (通讯作者)，CSIR Cent Drug Res Inst, Div Med & Proc Chem, Lucknow 226031, India.; Singh, D (通讯作者)，CSIR Cent Drug Res Inst, Div Endocrinol, Lucknow 226031, India.; Kumar, R; Singh, D; Sinha, AK (通讯作者)，Acad Sci & Innovat Res AcSIR, Ghaziabad 201002, UP, India.
EM ravindra.kumar1@cdri.res.in; divya_singh@cdri.res.in;
   aksinha08@rediffmail.com
RI Sinha, Arun/GRS 3222 2022; Bisen, Amol/KVY 8304 2024; Kumar,
   Ravindra/E 6654 2016
OI Bisen, Amol/0000 0003 4841 0140; Bhatta, Rabi
   Sankar/0000 0003 4844 2388; Kumar, Ravindra/0000 0003 0290 679X
FU Science and Engineering Research Board [MLP 2028]; CSIR FBR project;
   CSIR; UGC, DBT [10723]; ICMR
FX The authors acknowledged the CSIR FBR project MLP 2028 for the funding.
   All the authors are thankful to the Director of CSIR CDRI, for providing
   the necessary research facilities. S. K. R. and S. K., are thankful to
   the CSIR for the fellowship. S. K., R. R., K. S., and A. C. B. are
   thankful to UGC, DBT, DST, and ICMR for the fellowship, respectively.
   The authors are thankful to Ayus Dubey for the support in
   pharmacokinetic study and also thankful to in house Sophisticated
   Analytical Instrumentation Facility & Research (SAIF & R) for providing
   the required valuable spectral data. This manuscript has CDRI
   Communication no. 10723.
CR Agarwal K, 2021, BIOORG MED CHEM LETT, V50, DOI 10.1016/j.bmcl.2021.128340
   [Anonymous], 2000, The United State Pharmacopoeia 24
   Bissinger O, 2017, J ORTHOP SURG RES, V12, DOI 10.1186/s13018 017 0609 9
   Cai JZ, 2015, MOLECULES, V20, P10839, DOI 10.3390/molecules200610839
   Cheng M., 2022, FRONT CELL DEV BIOL, V9
   Cosman F, 2014, OSTEOPOROSIS INT, V25, P2359, DOI 10.1007/s00198 014 2794 2
   Dixit M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144541
   Gautam AK, 2011, J NUTR BIOCHEM, V22, P318, DOI 10.1016/j.jnutbio.2010.02.010
   Gilbert AM, 2002, J MED CHEM, V45, P2342, DOI 10.1021/jm010554s
   Goel A, 2015, MOL CELL ENDOCRINOL, V411, P155, DOI 10.1016/j.mce.2015.04.023
   Hu LF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19020360
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Hwang JW, 2021, BIOCHEM BIOPH RES CO, V545, P27, DOI 10.1016/j.bbrc.2021.01.053
   Jang WG, 2012, J BIOL CHEM, V287, P905, DOI 10.1074/jbc.M111.253187
   Kerru N, 2020, MOLECULES, V25, DOI 10.3390/molecules25081909
   Khanka S., 2023, J DRUG DELIVERY THER, V7, P6
   Kumar R, 2010, EUR J MED CHEM, V45, P5292, DOI 10.1016/j.ejmech.2010.08.049
   Leung CY, 2013, J MED CHEM, V56, P7939, DOI 10.1021/jm400946f
   Liu DB, 2018, MED SCI MONITOR, V24, P4363, DOI 10.12659/MSM.905958
   Marotta L, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.988376
   Matsushita Y, 2013, J BIOL CHEM, V288, P19973, DOI 10.1074/jbc.M113.454652
   Oda T., 2009, J MAXILLOFAC SURG, V7, P1478
   Ogra RK, 2009, CURR SCI INDIA, V97, P1644
   Orth R, 2010, CHEM COMMUN, V46, P8475, DOI 10.1039/c0cc02825h
   Pandey AR, 2023, RSC MED CHEM, V14, P1131, DOI 10.1039/d2md00464j
   Pandey AR, 2023, EUR J MED CHEM, V254, DOI 10.1016/j.ejmech.2023.115340
   Pandey AR, 2021, J MED CHEM, V64, P12487, DOI 10.1021/acs.jmedchem.1c00112
   Petek N, 2019, BIOORG CHEM, V84, P226, DOI 10.1016/j.bioorg.2018.11.029
   Rai R, 2022, FREE RADICAL BIO MED, V190, P339, DOI 10.1016/j.freeradbiomed.2022.08.028
   Rai R, 2021, PHYTOMEDICINE, V93, DOI 10.1016/j.phymed.2021.153750
   Rani J, 2016, RES CHEM INTERMEDIAT, V42, P6777, DOI 10.1007/s11164 016 2525 8
   Rankovic Z, 2010, BIOORG MED CHEM LETT, V20, P1524, DOI 10.1016/j.bmcl.2010.01.100
   Robling AG, 2006, ANNU REV BIOMED ENG, V8, P455, DOI 10.1146/annurev.bioeng.8.061505.095721
   Saito K, 2019, BIOORG MED CHEM LETT, V29, P1769, DOI 10.1016/j.bmcl.2019.05.014
   Sharma K, 2023, FREE RADICAL BIO MED, V194, P99, DOI 10.1016/j.freeradbiomed.2022.11.026
   Sharma K, 2022, J CELL BIOCHEM, V123, P1762, DOI 10.1002/jcb.30313
   Sharma N, 2012, J MED CHEM, V55, P297, DOI 10.1021/jm201216y
   Sharma N, 2014, EUR J MED CHEM, V79, P350, DOI 10.1016/j.ejmech.2014.03.079
   Singh KB, 2017, BRIT J NUTR, V117, P1511, DOI 10.1017/S0007114517001556
   Smith NF, 2007, MOL CANCER THER, V6, P428, DOI 10.1158/1535 7163.MCT 06 0324
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Strom O, 2011, Arch Osteoporos, V6, P59, DOI 10.1007/s11657 011 0060 1
   Szulc P., 2021, MARCUS FELDMANS OSTE, Vvol. 2
   Tarver JE, 2016, BIOORG MED CHEM LETT, V26, P1525, DOI 10.1016/j.bmcl.2016.02.021
   Tian H, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.780590
   Tu Kristie N, 2018, P T, V43, P92
   Wong RMY, 2022, OSTEOPOROSIS INT, V33, P2453, DOI 10.1007/s00198 022 06473 0
   Yang W, 2009, J MED CHEM, V52, P1204, DOI 10.1021/jm801178c
   Yoshida M, 2010, BIOORGAN MED CHEM, V18, P8501, DOI 10.1016/j.bmc.2010.10.035
NR 49
TC 6
Z9 6
U1 2
U2 3
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2632 8682
J9 RSC MED CHEM
JI RSC Med. Chem.
PD FEB 21
PY 2024
VL 15
IS 2
BP 677
EP 694
DI 10.1039/d3md00500c
EA JAN 2024
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA IQ2M6
UT WOS:001153938100001
PM 38389884
OA Green Published
DA 2025 08 17
ER

PT J
AU Chen, RX
   Wang, JW
   Chen, L
   Li, ZW
   Feng, QY
   Chen, FQ
   Hao, ZW
   Chen, TH
   Shi, G
   Zhang, Q
   Wang, Y
   Ding, T
   Li, JF
AF Chen, Renxin
   Wang, Junwu
   Chen, Lei
   Li, Zouwei
   Feng, Qinyu
   Chen, Fangqi
   Hao, Zhuowen
   Chen, Tianhong
   Shi, Guang
   Zhang, Qi
   Wang, Yi
   Ding, Tao
   Li, Jingfeng
TI Electrospunned nanofiber membranes of PTH related peptide loaded
   biopolymers for osteoporotic bone defect repair
SO MATERIALS & DESIGN
LA English
DT Article
DE Biopolymer; Nanofiber membrane; PTH related peptide; Sustained release;
   Osteoporotic bone defect
ID DRUG DELIVERY SYSTEMS; OSTEOGENIC DIFFERENTIATION; L LYSINE; CELL;
   SCAFFOLD; MICROSPHERES; EPIDEMIOLOGY
AB Despite the rapid development of the application of tissue engineering techniques in regenerative bone repair, the repair of severe pathologic bone defects, represented by osteoporotic bone defects, is still a huge challenge. Recent studies have identified local delivery of parathyroid hormone relative peptides (PTHrPs) as a novel pathway for bone repair as well, but how to load and locally release PTHrPs for good bone repair is a major obstacle. Here, a biopolymer of PLGA PLL loaded with PTHrP1 is electrospunned into nanofiber membranes for guided bone regeneration. In vitro experiments show that PLGA PLL synergized with PTHrP1 significantly promote osteogenic differentiation and angiogenesis, providing a favorable bone regeneration microenvironment. In vivo experiments show that the membrane recruits endogenous stem cells and promotes their ectopic osteogenic differentiation in an osteoporotic environment. Furthermore, the membrane can promote osteogenic differentiation and angiogenesis in situ and improve the local osteoporotic microenvironment, ultimately promoting the repair of bone defects. Therefore, present study provides a promising strategy for local delivery of PTH, which opens a new pathway for the treatment of osteoporotic bone defects.
C1 [Chen, Renxin; Wang, Junwu; Li, Zouwei; Feng, Qinyu; Hao, Zhuowen; Chen, Tianhong; Shi, Guang; Zhang, Qi; Wang, Yi; Li, Jingfeng] Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Donghu Rd 169, Wuhan 430071, Peoples R China.
   [Chen, Lei] Peoples Liberat Army Gen Hosp, Med Ctr 4, Senior Dept Orthoped, Fucheng Rd 51, Beijing 100048, Peoples R China.
   [Chen, Fangqi; Ding, Tao] Wuhan Univ, Key Lab Artificial Micro & Nanostruct, Minist Educ, Bayi Rd 299, Wuhan 430072, Peoples R China.
   [Chen, Fangqi; Ding, Tao] Wuhan Univ, Sch Phys & Technol, Bayi Rd 299, Wuhan 430072, Peoples R China.
C3 Wuhan University; Chinese People's Liberation Army General Hospital;
   Wuhan University; Wuhan University
RP Wang, Y; Li, JF (通讯作者)，Wuhan Univ, Zhongnan Hosp, Dept Orthoped, Donghu Rd 169, Wuhan 430071, Peoples R China.; Ding, T (通讯作者)，Wuhan Univ, Key Lab Artificial Micro & Nanostruct, Minist Educ, Bayi Rd 299, Wuhan 430072, Peoples R China.; Ding, T (通讯作者)，Wuhan Univ, Sch Phys & Technol, Bayi Rd 299, Wuhan 430072, Peoples R China.
EM wangyi0109@whu.edu.cn; t.ding@whu.edu.cn; jingfengli@whu.edu.cn
RI Wang, Junwu/LUY 2526 2024; Ding, Tao/N 4633 2014; zhang,
   qi/HKO 0879 2023; Hao, Zhuowen/KPY 2988 2024
OI Ding, Tao/0000 0002 1817 3327; junwu, wang/0000 0002 3553 4390
FU Na tional Natural Science Foundation of China [82372405]; Fundamental
   Research Funds for the Central Universities [2042023kf0199,
   2042023kf0211, 2042023kf0233]; Trans lational Medicine and
   Interdisciplinary Research Joint Fund of Zhon gnan Hospital of Wuhan
   University [ZNJC202014]
FX Renxin Chen, Junwu Wang, Lei Chen, Zouwei Li have contributed equally to
   this work. This work was financially supported by the Na tional Natural
   Science Foundation of China (No: 82372405) , the Fundamental Research
   Funds for the Central Universities (No: 2042023kf0199, 2042023kf0211,
   2042023kf0233) , and the Trans lational Medicine and Interdisciplinary
   Research Joint Fund of Zhon gnan Hospital of Wuhan University (No:
   ZNJC202014) . And, we are especially thanks to Dr. Lili Dai and Dr.
   Wenting Fan from the Core Facility of Wuhan University for their
   technical support.
CR Bharadwaz A, 2020, MAT SCI ENG C MATER, V110, DOI 10.1016/j.msec.2020.110698
   Chakraborty S, 2009, ADV DRUG DELIVER REV, V61, P1043, DOI 10.1016/j.addr.2009.07.013
   Chandran M, 2023, OSTEOPOROSIS INT, V34, P1037, DOI 10.1007/s00198 022 06657 8
   Che LB, 2023, BIOACT MATER, V19, P75, DOI 10.1016/j.bioactmat.2022.03.023
   Cotts KG, 2018, JAMA J AM MED ASSOC, V319, P1040, DOI 10.1001/jama.2017.21995
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Davoodi P, 2018, ADV DRUG DELIVER REV, V132, P104, DOI 10.1016/j.addr.2018.07.002
   Fischer D, 2003, BIOMATERIALS, V24, P1121, DOI 10.1016/S0142 9612(02)00445 3
   Foessl I, 2023, NAT REV ENDOCRINOL, V19, P520, DOI 10.1038/s41574 023 00866 9
   Fu R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14076 3
   Garton M, 2020, NEW ENGL J MED, V383, P2189, DOI 10.1056/NEJMc2029828
   Ghosh K, 2007, ADV DRUG DELIVER REV, V59, P1306, DOI 10.1016/j.addr.2007.08.014
   Hao ZW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.790050
   He X, 2021, SMALL, V17, DOI 10.1002/smll.202103521
   Huang JH, 2020, SMALL, V16, DOI 10.1002/smll.201905876
   Huhtamäki T, 2018, NAT PROTOC, V13, P1521, DOI 10.1038/s41596 018 0003 z
   Husain O, 2016, MAT SCI ENG C MATER, V65, P240, DOI 10.1016/j.msec.2016.03.076
   Iaquinta MR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030618
   Infante A, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0995 x
   Javed F, 2016, CLIN ORAL INVEST, V20, P649, DOI 10.1007/s00784 015 1691 1
   Jiang LT, 2018, BIOMATERIALS, V179, P15, DOI 10.1016/j.biomaterials.2018.06.035
   Jin SE, 2021, ACTA BIOMATER, V127, P56, DOI 10.1016/j.actbio.2021.03.067
   Jose MV, 2009, POLYMER, V50, P3778, DOI 10.1016/j.polymer.2009.05.035
   Kang SW, 2008, J BIOMED MATER RES A, V85A, P747, DOI 10.1002/jbm.a.31572
   Kuang LJ, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202105383
   Lane NE, 2006, AM J OBSTET GYNECOL, V194, pS3, DOI 10.1016/j.ajog.2005.08.047
   Liu HF, 2022, MATER DESIGN, V222, DOI 10.1016/j.matdes.2022.111070
   Liu WY, 2012, ADV HEALTHC MATER, V1, P10, DOI 10.1002/adhm.201100021
   MAZIA D, 1975, J CELL BIOL, V66, P198, DOI 10.1083/jcb.66.1.198
   Murphy CM, 2013, EUR CELLS MATER, V26, P120, DOI 10.22203/eCM.v026a09
   Park JH, 2013, TISSUE ENG PART B RE, V19, P172, DOI [10.1089/ten.TEB.2012.0432, 10.1089/ten.teb.2012.0432]
   Peng H, 2009, BIOMACROMOLECULES, V10, P95, DOI 10.1021/bm800937g
   Pérez C, 2002, J PHARM PHARMACOL, V54, P301, DOI 10.1211/0022357021778448
   Richter RF, 2023, BIOACT MATER, V28, P402, DOI 10.1016/j.bioactmat.2023.06.001
   Rotman SG, 2018, J CONTROL RELEASE, V269, P88, DOI 10.1016/j.jconrel.2017.11.009
   Sanhueza C, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111602
   Su PH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082343
   Veldurthy V, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.41
   Wang JW, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202301604
   Wang Y, 2023, ADV SCI, V10, DOI 10.1002/advs.202300516
   Wang Y, 2022, COMPOS PART B ENG, V247, DOI 10.1016/j.compositesb.2022.110289
   Wein MN, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031237
   Wojak Cwik IM, 2013, J BIOMED MATER RES A, V101, P3109, DOI 10.1002/jbm.a.34620
   Wojak Cwik IM, 2019, MAT SCI ENG C MATER, V97, P12, DOI 10.1016/j.msec.2018.12.012
   Xie XJ, 2022, BIOACT MATER, V13, P82, DOI 10.1016/j.bioactmat.2021.11.001
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yuan B, 2020, SCI ADV, V6, DOI 10.1126/sciadv.abc4704
   Yuan Y, 2018, COLLOID SURFACE B, V161, P162, DOI 10.1016/j.colsurfb.2017.10.044
   Zhang CG, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.607017
   Zhang HL, 2019, ACTA BIOMATER, V91, P82, DOI 10.1016/j.actbio.2019.04.024
   Zhao DY, 2021, BIOACT MATER, V6, P346, DOI 10.1016/j.bioactmat.2020.08.016
   Zheng ZH, 2009, J BIOMED MATER RES A, V89A, P453, DOI 10.1002/jbm.a.31979
   Zhu YZ, 2019, ACS APPL MATER INTER, V11, P35513, DOI 10.1021/acsami.9b05521
NR 53
TC 5
Z9 5
U1 10
U2 50
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0264 1275
EI 1873 4197
J9 MATER DESIGN
JI Mater. Des.
PD AUG
PY 2024
VL 244
AR 113179
DI 10.1016/j.matdes.2024.113179
EA JUL 2024
PG 18
WC Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA A0Q1Q
UT WOS:001279662700001
OA gold
DA 2025 08 17
ER

PT J
AU Chaudhari, KR
   Kumar, A
   Khandelwal, VKM
   Mishra, AK
   Monkkonen, J
   Murthy, RSR
AF Chaudhari, Kiran R.
   Kumar, Abhinesh
   Khandelwal, Vinoth Kumar Megraj
   Mishra, Anil K.
   Monkkonen, Jukka
   Murthy, Rayasa S. Ramachandra
TI Targeting Efficiency and Biodistribution of Zoledronate Conjugated
   Docetaxel Loaded Pegylated PBCA Nanoparticles for Bone Metastasis
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE bisphosphonates; zoledronic acid; docetaxel; polybutyl cyanoacrylate
   (PBCA) nanoparticles; bone targeting
ID BREAST CANCER CELLS; CELLULAR UPTAKE; DRUG DELIVERY; IN VITRO;
   BISPHOSPHONATE DRUGS; PLGA NANOPARTICLES; MASS SPECTROMETRY; GENE
   DELIVERY; MECHANISMS; PATHWAYS
AB In an attempt to improve tumor localization of docetaxel (DTX) loaded nanoparticles (NPs), zoledronic acid (ZOL) is used as a ligand to target bone metastasis. DTX loaded ZOL conjugated polyethylene glycol (PEG)ylated polybutyl cyanoacrylate (PBCA) NPs are prepared using an anionic polymerization technique. PBCA PEG ZOL NPs are subjected to cytotoxic assay in both BO2 and MCF 7 cell lines. Cell cycle arrest and apoptosis induced by the PBCA PEG ZOL NPs are studied. Quantitative cellular uptake, NP uptake route characterization, confocal microscopy and IPP/ApppI levels are performed. PBCA PEG ZOL NPs show an enhanced cytotoxic effect in both BO2 as well as MCF 7 cell lines due to higher uptake following ZOL mediated endocytosis. The molecular basis of apoptosis reveals the involvement of a cytoplasmic protein in activating the programmed cell death pathway. Route characterization studies reveal that PBCA PEG ZOL NPs uptake is not completely blocked even by using both inhibitors (genistein and phenyl arsinoxide) simultaneously, conferring that uptake is not entirely based upon clathrin or caveolae. PBCA PEG ZOL NPs showed 7 and 5.3 times increase in IPP and ApppI production, in comparison to ZOL treatment, and 138 times higher than the control group in MCF 7 cell line. In BO2 cell line, after treatment with NPs, IPP was 5.35 times higher than ZOL solution. No ApppI in BO2 cell line after treatment with NPs and ZOL solution was found. NP distribution in tumor infected bone is also significantly high in comparison to the normal bone at any time point. It is concluded that ZOL conjugated NPs provide an efficient and targeted delivery of DTX, with synergistic effects. Thus, these NPs present a promising treatment in the near future, by actively targeting metastatic tumor.
C1 [Chaudhari, Kiran R.; Kumar, Abhinesh] Maharaja Sayajirao Univ Baroda, TIFAC Ctr Relevance & Excellence New Drug Deliver, Dept Pharm, Fatehgunj 390002, Vadodara, India.
   [Chaudhari, Kiran R.; Khandelwal, Vinoth Kumar Megraj; Monkkonen, Jukka] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio 70211, Finland.
   [Chaudhari, Kiran R.; Mishra, Anil K.] Inst Nucl Med & Allied Sci, Dept Radiopharmaceut & Radiat Biol, Delhi 110054, India.
   [Khandelwal, Vinoth Kumar Megraj] Consorzio Mario Negri Sud, Tumor Cell Invas Lab, I 66030 Santa Maria Imbaro, Italy.
   [Murthy, Rayasa S. Ramachandra] ISF Coll Pharm, Moga 142001, Punjab, India.
C3 Maharaja Sayajirao University Baroda; University of Eastern Finland;
   Defence Research & Development Organisation (DRDO); Institute of Nuclear
   Medicine & Allied Sciences (INMAS); Consorzio Mario Negri Sud; ISF
   College of Pharmacy
RP Chaudhari, KR (通讯作者)，Maharaja Sayajirao Univ Baroda, TIFAC Ctr Relevance & Excellence New Drug Deliver, Dept Pharm, Shri GH Patel Pharm Bldg,Donors Plaza, Fatehgunj 390002, Vadodara, India.
EM m_rsr@rediffmail.com
RI Khandelwal, Vinoth/O 8443 2019; Mishra, Anil/J 9502 2013
FU All India Council of Technical Education (AICTE), India
   [(1 10/RID/NDF PG/(39)2008 2009)]
FX This research was supported by National Doctoral Fellowship from All
   India Council of Technical Education (AICTE)
   (1 10/RID/NDF PG/(39)2008 2009), India. The authors are thankful to
   Evobond, Tong Shen Enterprise, Taiwan, for providing the gift sample of
   butylcyanoacrylate monomer. They also thank Mrs. Krishna Chuttani for
   her kind help in conducting animal studies, and Marjo Jauhiainen for her
   help with the estimation of IPP and ApppI.
CR Alila S, 2009, CARBOHYD POLYM, V77, P553, DOI 10.1016/j.carbpol.2009.01.028
   Arulsudar N, 2004, AAPS PHARMSCI, V6, DOI 10.1208/ps060105
   Auriola S, 1997, J CHROMATOGR B, V704, P187, DOI 10.1016/S0378 4347(97)00490 8
   Babbar AK, 2000, NUCL MED BIOL, V27, P419, DOI 10.1016/S0969 8051(00)00092 5
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   BENTZ H, 1992, Patent No. 0512844
   Blau S, 2000, CRIT REV THER DRUG, V17, P425, DOI 10.1615/CritRevTherDrugCarrierSyst.v17.i5.10
   CATIZONE A, 1993, CELL MOL BIOL, V39, P155
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chaudhari KR, 2012, PHARM RES DORDR, V29, P53, DOI 10.1007/s11095 011 0510 x
   Chavanpatil MD, 2006, J NANOSCI NANOTECHNO, V6, P2651, DOI 10.1166/jnn.2006.443
   Chen TL, 2002, J CLIN PHARMACOL, V42, P1228, DOI 10.1177/009127002762491316
   Chirgwin J M., 2003, Science Medicine, V9, P140
   Chithrani BD, 2007, NANO LETT, V7, P1542, DOI 10.1021/nl070363y
   Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451
   Desai MP, 1996, PHARMACEUT RES, V13, P1838, DOI 10.1023/A:1016085108889
   Ebrahimnejad P, 2011, INT J PHARMACEUT, V406, P122, DOI 10.1016/j.ijpharm.2010.12.022
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Jain TK, 2008, BIOMATERIALS, V29, P4012, DOI 10.1016/j.biomaterials.2008.07.004
   Jauhiainen M, 2009, J CHROMATOGR B, V877, P2967, DOI 10.1016/j.jchromb.2009.07.010
   Johannes L, 2002, TRAFFIC, V3, P443, DOI 10.1034/j.1600 0854.2002.30701.x
   Khalil IA, 2006, PHARMACOL REV, V58, P32, DOI 10.1124/pr.58.1.8
   Kim YH, 2001, BIOCONJUGATE CHEM, V12, P932, DOI 10.1021/bc015510c
   Liu XM, 2008, BIOMATERIALS, V29, P1686, DOI 10.1016/j.biomaterials.2007.12.023
   MacLaughlin FC, 1998, J CONTROL RELEASE, V56, P259, DOI 10.1016/S0168 3659(98)00097 2
   Mo Y, 2005, J CONTROL RELEASE, V107, P30, DOI 10.1016/j.jconrel.2004.06.024
   Mondal N, 2010, INT J PHARMACEUT, V397, P194, DOI 10.1016/j.ijpharm.2010.06.049
   Mönkkönen H, 2006, BRIT J PHARMACOL, V147, P437, DOI 10.1038/sj.bjp.0706628
   Mönkkönen H, 2000, J CHROMATOGR B, V738, P395, DOI 10.1016/S0378 4347(99)00559 9
   Morse DL, 2005, MOL CANCER THER, V4, P1495, DOI 10.1158/1535 7163.MCT 05 0130
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022 1759(83)90303 4
   Mundy GR, 1997, CANCER AM CANCER SOC, V80, P1546, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1546::AID CNCR4>3.3.CO;2 R
   Nam HY, 2009, J CONTROL RELEASE, V135, P259, DOI 10.1016/j.jconrel.2009.01.018
   Panyam J, 2002, FASEB J, V16, DOI 10.1096/fj.02 0088com
   Panyam J, 2003, PHARM RES DORDR, V20, P212, DOI 10.1023/A:1022219003551
   Park J, 2009, NANOMED NANOTECHNOL, V5, P410, DOI 10.1016/j.nano.2009.02.002
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Reddy LH, 2004, AAPS J, V6
   ROBERT MJ, 2002, Patent No. 6436386
   Rupper A, 2001, BBA GEN SUBJECTS, V1525, P205, DOI 10.1016/S0304 4165(01)00106 4
   Saha GB., 2005, FUNDAMENTALS NUCL PH, V5th
   Sahoo SK, 2005, MOL PHARMACEUT, V2, P373, DOI 10.1021/mp050032z
   Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168 3659(02)00127 X
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Snehalatha M, 2008, DRUG DELIV, V15, P277, DOI [10.1080/10717540802006500, 10.1080/10717540802006500 ]
   Stolnik S, 2001, J DRUG TARGET, V9, P361, DOI 10.3109/10611860108998772
   Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571
   Torché AM, 2000, J DRUG TARGET, V7, P343
   Vega F, 2006, CANCER RES, V66, P6589, DOI 10.1158/0008 5472.CAN 05 3018
   Williams J, 2003, J CONTROL RELEASE, V91, P167, DOI 10.1016/S0168 3659(03)00241 4
   Woodhouse EC, 1997, CANCER AM CANCER SOC, V80, P1529, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1529::AID CNCR2>3.0.CO;2 F
   Yoshizawa H, 2005, INT J PHARMACEUT, V296, P112, DOI 10.1016/j.ijpharm.2005.02.010
NR 54
TC 27
Z9 31
U1 0
U2 69
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD OCT 10
PY 2012
VL 22
IS 19
BP 4101
EP 4114
DI 10.1002/adfm.201102357
PG 14
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 014VO
UT WOS:000309404000017
OA Bronze
DA 2025 08 17
ER

PT J
AU Sakurai, H
   Sakaguchi, Y
   Shoji, E
   Nishino, T
   Maki, I
   Sakai, H
   Hanaoka, K
   Kakizuka, A
   Sehara Fujisawa, A
AF Sakurai, Hidetoshi
   Sakaguchi, Yasuko
   Shoji, Emi
   Nishino, Tokiko
   Maki, Izumi
   Sakai, Hiroshi
   Hanaoka, Kazunori
   Kakizuka, Akira
   Sehara Fujisawa, Atsuko
TI In Vitro Modeling of Paraxial Mesodermal Progenitors Derived from
   Induced Pluripotent Stem Cells
SO PLOS ONE
LA English
DT Article
ID BONE MORPHOGENETIC PROTEIN 4; PDGF RECEPTOR ALPHA; DIVERGING POINT;
   SKELETAL MUSCLE; PRECURSOR CELLS; MOUSE; GENE; EXPRESSION; GENERATION;
   DIFFERENTIATION
AB Induced pluripotent stem (iPS) cells are generated from adult somatic cells by transduction of defined factors. Given their unlimited proliferation and differentiation potential, iPS cells represent promising sources for cell therapy and tools for research and drug discovery. However, systems for the directional differentiation of iPS cells toward paraxial mesodermal lineages have not been reported. In the present study, we established a protocol for the differentiation of mouse iPS cells into paraxial mesodermal lineages in serum free culture. The protocol was dependent on Activin signaling in addition to BMP and Wnt signaling which were previously shown to be effective for mouse ES cell differentiation. Independently of the cell origin, the number of transgenes, or the type of vectors used to generate iPS cells, the use of serum free monolayer culture stimulated with a combination of BMP4, Activin A, and LiCl enabled preferential promotion of mouse iPS cells to a PDGFR alpha(+)/Flk 1( ) population, which represents a paraxial mesodermal lineage. The mouse iPS cell derived paraxial mesodermal cells exhibited differentiation potential into osteogenic, chondrogenic, and myogenic cells both in vitro and in vivo and contributed to muscle regeneration. Moreover, purification of the PDGFR alpha(+)/KDR  population after differentiation allowed enrichment of human iPS cell populations with paraxial mesodermal characteristics. The resultant PDGFR alpha(+)/KDR  population derived from human iPS cells specifically exhibited osteogenic, chondrogenic, and myogenic differentiation potential in vitro, implying generation of paraxial mesodermal progenitors similar to mouse iPS cell derived progenitors. These findings highlight the potential of protocols based on the serum free, stepwise induction and purification of paraxial mesodermal cell lineages for use in stem cell therapies to treat diseased bone, cartilage, and muscle.
C1 [Sakurai, Hidetoshi; Sakaguchi, Yasuko; Shoji, Emi; Sakai, Hiroshi; Sehara Fujisawa, Atsuko] Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto, Japan.
   [Sakurai, Hidetoshi; Nishino, Tokiko; Maki, Izumi] Kyoto Univ, Ctr iPS Cell Res & Applicat, Dept Clin Applicat, Kyoto, Japan.
   [Sakaguchi, Yasuko; Kakizuka, Akira] Kyoto Univ, Grad Sch Biostudies, Lab Funct Biol, Kyoto, Japan.
   [Hanaoka, Kazunori] Kitasato Univ, Sch Sci, Dept Biosci, Kanagawa, Japan.
C3 Kyoto University; Kyoto University; Kyoto University; Kitasato
   University
RP Sakurai, H (通讯作者)，Kyoto Univ, Inst Frontier Med Sci, Dept Growth Regulat, Kyoto, Japan.
EM hsakurai@cira.kyoto u.ac.jp
RI ; Hiroshi, SAKAI/B 1450 2016; SAKAI, Hiroshi/B 1450 2016
OI Shoji, Emi/0000 0003 2576 5491; SAKAI, Hiroshi/0000 0001 9456 0911
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan (the Leading Project for the Realization of Regenerative
   Medicine), Scientific Research from the JSPS [22790284]; Research Grant
   for Nervous and Mental Disorders from the Ministry of Health, Labor, and
   Welfare; Leading Project of MEXT; Grants in Aid for Scientific Research
   [24657154, 23249016, 22790284] Funding Source: KAKEN
FX This work was funded in part by a Grant in Aid from the Ministry of
   Education, Culture, Sports, Science and Technology (MEXT) of Japan (the
   Leading Project for the Realization of Regenerative Medicine),
   Scientific Research Grant No. 22790284 from the JSPS, and in part by a
   Research Grant for Nervous and Mental Disorders from the Ministry of
   Health, Labor, and Welfare. A.S. is a member of the Global COE Program
   (Center for Frontier Medicine, Field of Regenerative Medicine). This
   research is also supported in by a grant from the Leading Project of
   MEXT (www.mext.go.jp). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Amabile G, 2009, TRENDS MOL MED, V15, P59, DOI 10.1016/j.molmed.2008.12.003
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092 8674(92)90632 M
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092 8674(03)00392 1
   Chapman DL, 1998, NATURE, V391, P695, DOI 10.1038/35624
   Fukada S, 2004, EXP CELL RES, V296, P245, DOI 10.1016/j.yexcr.2004.02.018
   Hart AH, 2002, DEVELOPMENT, V129, P3597
   HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092 8674(87)90579 4
   JOHANSSON BM, 1995, MOL CELL BIOL, V15, P141, DOI 10.1128/MCB.15.1.141
   JONES CM, 1995, DEVELOPMENT, V121, P3651
   Kataoka H, 1997, DEV GROWTH DIFFER, V39, P729
   Kattman SJ, 2011, CELL STEM CELL, V8, P228, DOI 10.1016/j.stem.2010.12.008
   Kudoh H, 2005, BIOCHEM BIOPH RES CO, V328, P507, DOI 10.1016/j.bbrc.2004.12.191
   Labastie MC, 1998, BLOOD, V92, P3624, DOI 10.1182/blood.V92.10.3624.422k17_3624_3635
   Laping NJ, 2002, MOL PHARMACOL, V62, P58, DOI 10.1124/mol.62.1.58
   Maekawa M, 2011, NATURE, V474, P225, DOI 10.1038/nature10106
   Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092 8674(03)00393 3
   Muraglia A, 2003, J CELL SCI, V116, P2949, DOI 10.1242/jcs.00527
   Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374
   Nakagawa M, 2010, P NATL ACAD SCI USA, V107, P14152, DOI 10.1073/pnas.1009374107
   Nakayama N, 2003, J CELL SCI, V116, P2015, DOI 10.1242/jcs.00417
   Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092 8674(00)81769 9
   Nishikawa S, 1998, DEVELOPMENT, V125, P1747
   Nostro MC, 2008, CELL STEM CELL, V2, P60, DOI 10.1016/j.stem.2007.10.011
   Ogawa K, 2007, J CELL SCI, V120, P55, DOI 10.1242/jcs.03296
   Okita K, 2008, SCIENCE, V322, P949, DOI 10.1126/science.1164270
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Okita K, 2010, NAT PROTOC, V5, P418, DOI 10.1038/nprot.2009.231
   OTT MO, 1991, DEVELOPMENT, V111, P1097
   Reshef R, 1998, GENE DEV, V12, P290, DOI 10.1101/gad.12.3.290
   Russ AP, 2000, NATURE, V404, P95, DOI 10.1038/35003601
   Saga Y, 1997, GENE DEV, V11, P1827, DOI 10.1101/gad.11.14.1827
   Sakurai H, 2008, STEM CELLS
   Sakurai H, 2006, STEM CELLS, V24, P575, DOI 10.1634/stemcells.2005 0256
   Sakurai H, 2009, STEM CELL RES, V3, P157, DOI 10.1016/j.scr.2009.08.002
   SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123
   Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092 8674(00)00066 0
   Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005
   TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Wang Y, 2010, STEM CELL RES, V4, P223, DOI 10.1016/j.scr.2010.03.002
   WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0
   WILLIAMS BA, 1994, DEVELOPMENT, V120, P785
   WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105
   Yamamoto H, 1999, J BIOL CHEM, V274, P10681, DOI 10.1074/jbc.274.16.10681
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 47
TC 49
Z9 54
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e47078
DI 10.1371/journal.pone.0047078
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 026VC
UT WOS:000310310200025
PM 23115636
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Li, MZ
   Li, D
   Jiang, YC
   He, P
   Li, YM
   Wu, Y
   Lei, W
   de Bruijn, JD
   Cannon, RD
   Mei, L
   Zhang, H
   Ji, P
   Zhang, HM
   Yuan, HP
AF Li, Mingzheng
   Li, Dan
   Jiang, Yucan
   He, Ping
   Li, Yeming
   Wu, Yan
   Lei, Wei
   de Bruijn, Joost D.
   Cannon, Richard D.
   Mei, Li
   Zhang, Hua
   Ji, Ping
   Zhang, Hongmei
   Yuan, Huipin
TI The genetic background determines material induced bone formation
   through the macrophage osteoclast axis
SO BIOMATERIALS
LA English
DT Article
DE Genetic background; Macrophage polarization; Osteoclastogenesis; Bone
   regeneration; Heterotopic bone formation; Osteoinductive materials
ID FIBRODYSPLASIA OSSIFICANS PROGRESSIVA; CALCIUM PHOSPHATE CERAMICS;
   BETA TRICALCIUM PHOSPHATE; HETEROTOPIC OSSIFICATION; PHASE COMPOSITION;
   OSTEOINDUCTION; MODELS; CHONDROGENESIS; BIOMATERIALS; OSTEOGENESIS
AB Osteoinductive materials are characterized by their ability to induce bone formation in ectopic sites. Thus, osteoinductive materials hold promising potential for repairing bone defects. However, the mechanism of material induced bone formation remains unknown, which limits the design of highly potent osteoinductive materials. Here, we demonstrated a genetic background link among macrophage polarization, osteoclastogenesis and material induced bone formation. The intramuscular implantation of an osteoinductive material in FVB/ NCrl (FVB) mice resulted in more M2 macrophages at week 1, more osteoclasts at week 2 and increased bone formation after week 4 compared with the results obtained in C57BL/6JOlaHsd (C57) mice. Similarly, in vitro, with a greater potential to form M2 macrophages, monocytes derived from FVB mice formed more osteoclasts than those derived from C57 mice. A transcriptomic analysis identified Csf1, Cxcr4 and Tgfbr2 as the main genes controlling macrophage osteoclast coupling, which were further confirmed by related inhibitors. With such coupling, macrophage polarization and osteoclast formation of monocytes in vitro successfully predicted in vivo bone formation in four other mouse strains. Considering material induced bone formation as an example of acquired heterotopic bone formation, the current findings shed a light on precision medicine for both bone regeneration and the treatment of pathological heterotopic bone formation.
C1 [Li, Mingzheng; Li, Dan; Jiang, Yucan; He, Ping; Li, Yeming; Wu, Yan; Lei, Wei; Mei, Li; Ji, Ping; Zhang, Hongmei] Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.
   [de Bruijn, Joost D.; Yuan, Huipin] Kuros Biosci BV, Prof Bronkhorstlaan 10, NL 3723 MB Bilthoven, Netherlands.
   [de Bruijn, Joost D.] Queen Mary Univ London, London, England.
   [Cannon, Richard D.; Mei, Li] Univ Otago, Sir John Walsh Res Inst, Fac Dent, Dept Oral Sci, Dunedin, New Zealand.
   [Zhang, Hua] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing, Peoples R China.
   [Yuan, Huipin] Huipin Yuans Lab, Chengdu, Peoples R China.
C3 Chongqing Medical University; University of London; Queen Mary
   University London; University of Otago; Chongqing Medical University
RP Ji, P; Zhang, HM (通讯作者)，Chongqing Med Univ, Stomatol Hosp, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing Municipal Key Lab Oral Biomed Engn Highe, Chongqing, Peoples R China.; Yuan, HP (通讯作者)，Kuros Biosci BV, Prof Bronkhorstlaan 10, NL 3723 MB Bilthoven, Netherlands.
EM jiping@hospital.cqmu.edu.cn; hmzhang@hospital.cqmu.edu.cn;
   huipin.yuan@kurosbio.com
RI Cannon, Richard/AFP 4563 2022; He, Ping/NYS 5771 2025; Mei,
   Lei/L 4274 2013
OI de Bruijn, Joost/0000 0003 0367 3633; 
FU Program for Youth Innovation in Future Medicine [W0095]
FX <B>Funding</B> This study was supported by the China Postdoctoral
   Science Foun dation (2021MD703929) , the Postdoctoral Science Foundation
   of Chongqing Natural Science Foundation (cstc2021jcy bsh0049) , the
   Basic Research and Frontier Exploration Project of Chongqing (20210131)
   , the National Natural Science Foundation of China (No.82071115 and
   No.31871464 and 82220108019) , and CQMUr Program for Youth Innovation in
   Future Medicine (No. W0095) .
CR Akiyama N, 2011, J BIOMED MATER RES A, V96A, P402, DOI 10.1002/jbm.a.32995
   Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Baird Evan O, 2009, J Orthop Surg Res, V4, P12, DOI 10.1186/1749 799X 4 12
   Barradas AMC, 2012, BIOMATERIALS, V33, P5696, DOI 10.1016/j.biomaterials.2012.04.021
   Barradas AMC, 2011, EUR CELLS MATER, V21, P407, DOI 10.22203/eCM.v021a31
   Baumann D, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc 2020 002319
   Beura LK, 2016, NATURE, V532, P512, DOI 10.1038/nature17655
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brady RD, 2018, BONE, V109, P35, DOI 10.1016/j.bone.2017.05.015
   Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031 10
   Chen XN, 2020, ACTA BIOMATER, V103, P318, DOI 10.1016/j.actbio.2019.12.019
   Convente MR, 2018, J BONE MINER RES, V33, P269, DOI 10.1002/jbmr.3304
   Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102
   Cordova LA, 2014, CLIN SCI, V127, P277, DOI 10.1042/CS20130338
   Davison NL, 2014, BIOMATERIALS, V35, P7441, DOI 10.1016/j.biomaterials.2014.05.048
   Doherty TM, 2002, FASEB J, V16, DOI 10.1096/fj.01 0898hyp
   Du Q, 2021, INT J MED SCI, V18, P2752, DOI 10.7150/ijms.60685
   Edwards DS, 2016, J ORTHOP TRAUMA, V30, pS27, DOI 10.1097/BOT.0000000000000666
   Frost HM, 2001, ANAT RECORD, V262, P398, DOI 10.1002/ar.1049
   Gosain AF, 2002, PLAST RECONSTR SURG, V109, P619, DOI 10.1097/00006534 200202000 00032
   Guo XD, 2021, ACTA BIOMATER, V134, P730, DOI 10.1016/j.actbio.2021.07.037
   Habibovic P, 2005, BIOMATERIALS, V26, P3565, DOI 10.1016/j.biomaterials.2004.09.056
   Huang YF, 2021, NPJ REGEN MED, V6, DOI 10.1038/s41536 021 00178 4
   Hwang CD, 2022, JCI INSIGHT, V7, DOI 10.1172/jci.insight.158996
   Kan C, 2019, BONE RES, V7, DOI 10.1038/s41413 019 0074 7
   Kaplan FS, 2011, ANN NY ACAD SCI, V1237, P5, DOI 10.1111/j.1749 6632.2011.06195.x
   Kawao N, 2016, J BONE MINER METAB, V34, P517, DOI 10.1007/s00774 015 0701 3
   Kelly DJ, 2010, BIRTH DEFECTS RES C, V90, P75, DOI 10.1002/bdrc.20173
   Kim EK, 2010, BBA MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009
   Kini U., 2012, Radionuclide and Hybrid Bone Imaging, P29, DOI [10.1007/978 3 642 02400 92, DOI 10.1007/978 3 642 02400 9_2]
   Kondo N, 2006, BIOMATERIALS, V27, P4419, DOI 10.1016/j.biomaterials.2006.04.016
   Kraft CT, 2016, J TRAUMA ACUTE CARE, V80, P156, DOI 10.1097/TA.0000000000000883
   Lan TT, 2021, BIOMATERIALS, V276, DOI 10.1016/j.biomaterials.2021.121066
   Lee K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103004
   Lehr AM, 2020, SPINE, V45, P944, DOI 10.1097/BRS.0000000000003440
   Li D., 2023, Adv. Sci., V10
   Li L, 2020, J CELL MOL MED, V24, P11046, DOI 10.1111/jcmm.15735
   Li MZ, 2020, J MATER CHEM B, V8, P1863, DOI 10.1039/c9tb02932j
   Liu YN, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.609297
   Loder SJ, 2018, AM J PATHOL, V188, P2464, DOI 10.1016/j.ajpath.2018.07.014
   Louis Ugbo J, 2004, SPINE, V29, P360, DOI 10.1097/01.BRS.0000090823.12652.F9
   Matsuo K, 2019, CURR OSTEOPOROS REP, V17, P387, DOI 10.1007/s11914 019 00541 x
   Meyers C, 2019, JBMR PLUS, V3, DOI 10.1002/jbm4.10172
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Muschler GF, 2010, TISSUE ENG PART B RE, V16, P123, DOI [10.1089/ten.teb.2009.0658, 10.1089/ten.TEB.2009.0658]
   Neamatallah Thikryat, 2019, J Microsc Ultrastruct, V7, P53, DOI 10.4103/JMAU.JMAU_68_18
   Nie ZL, 2023, ACTA BIOMATER, V157, P625, DOI 10.1016/j.actbio.2022.11.005
   Olmsted Davis E, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.686769
   Oryan A, 2014, BIOFACTORS, V40, P459, DOI 10.1002/biof.1177
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Penticuff JC, 2019, NAT REV UROL, V16, P318, DOI 10.1038/s41585 019 0171 9
   Pignolo RJ, 2015, APPL CLIN GENET, V8, P37, DOI 10.2147/TACG.S51064
   Puca AA, 2020, EUR HEART J, V41, P2487, DOI 10.1093/eurheartj/ehz459
   Ripamonti U, 1996, BIOMATERIALS, V17, P31, DOI 10.1016/0142 9612(96)80752 6
   Schmidt AH, 2021, INJURY, V52, pS18, DOI 10.1016/j.injury.2021.01.043
   Schmidt Bleek K, 2016, CYTOKINE GROWTH F R, V27, P141, DOI 10.1016/j.cytogfr.2015.11.006
   Shore EM, 2012, WIRES DEV BIOL, V1, P153, DOI 10.1002/wdev.9
   Sridharan R, 2015, MATER TODAY, V18, P313, DOI 10.1016/j.mattod.2015.01.019
   Standard A., 2013, P ASTM F2529 13
   Stokovic N, 2021, MATERIALS, V14, DOI 10.3390/ma14133513
   URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893
   Walsh MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00511
   Wang J, 2014, J BIOMED MATER RES A, V102, P4234, DOI 10.1002/jbm.a.35102
   Wang J, 2013, J BIOMED MATER RES B, V101B, P1069, DOI 10.1002/jbm.b.32917
   Wang LJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14146 6
   Willems E, 2012, CELL STEM CELL, V11, P242, DOI 10.1016/j.stem.2012.04.025
   Yang ZJ, 1996, BIOMATERIALS, V17, P2131, DOI 10.1016/0142 9612(96)00044 0
   Yao QY, 2018, J BIOL CHEM, V293, P16572, DOI 10.1074/jbc.RA118.003161
   Yao Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.664871
   Yi S, 2020, BMB REP, V53, P646, DOI 10.5483/BMBRep.2020.53.12.199
   Yuan HP, 2006, TISSUE ENG, V12, P1607, DOI 10.1089/ten.2006.12.1607
   Yuan HP, 2010, P NATL ACAD SCI USA, V107, P13614, DOI 10.1073/pnas.1003600107
   Zavaczki E, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/3721383
   Zeiter S, 2020, TISSUE ENG PART C ME, V26, P107, DOI [10.1089/ten.tec.2019.0213, 10.1089/ten.TEC.2019.0213]
   Zhang JL, 2021, J LEUKOCYTE BIOL, V110, P485, DOI 10.1002/JLB.3MA0321 739R
   Zhang JW, 2014, ACTA BIOMATER, V10, P3254, DOI 10.1016/j.actbio.2014.03.021
   Zuscik MJ, 2008, J CLIN INVEST, V118, P429, DOI 10.1172/JCI34174
NR 77
TC 10
Z9 10
U1 5
U2 25
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD NOV
PY 2023
VL 302
AR 122356
DI 10.1016/j.biomaterials.2023.122356
EA OCT 2023
PG 19
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA Y0NY7
UT WOS:001102335100001
PM 37898023
DA 2025 08 17
ER

PT J
AU La Beck, NM
   Liu, XL
   Shmeeda, H
   Shudde, C
   Gabizon, AA
AF La Beck, Ninh M.
   Liu, Xinli
   Shmeeda, Hilary
   Shudde, Claire
   Gabizon, Alberto A.
TI Repurposing amino bisphosphonates by liposome formulation for a new role
   in cancer treatment
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Pegylated liposomal alendronate; PLA; Alendronate; Zoledronate;
   Zoledronic acid; Alendronic acid; Bisphosphonate; Amino bisphosphoonate;
   Immunotherapy; Cancer; Tumor; Metastasis
ID NITROGEN CONTAINING BISPHOSPHONATES; TUMOR ASSOCIATED MACROPHAGES; PLUS
   ZOLEDRONIC ACID; IN VIVO; FOLATE RECEPTOR; DOSE RESPONSE; SOLID TUMOR;
   ALENDRONATE; BONE; THERAPY
AB Amino bisphosphonates (N BPs) have been commercially available for over four decades and are used for the treatment of osteoporosis, Paget's disease, hypercalcemia of malignancy, and bone metastases derived from various cancer types. Zoledronate and alendronate, two of the most potent N BPs, have demonstrated direct tumoricidal activity on tumor cells and immune modulatory effects on myeloid cells and T cells in vitro and in animal models of cancer. However, the rapid renal clearance and sequestration in mineral bone of these drugs in free form severely limit their systemic exposure and applications in cancer patients. Reformulation of N BPs by encapsulation in liposomal nanoparticles addresses these pharmacokinetic barriers, and liposomal zoledronate and alendronate formulations have been found to increase the anticancer efficacy of cytotoxic chemotherapies and adoptive T cell immunotherapies in murine cancer models. Herein, we review the differences in pharmacology between N BPs versus non N  BPs (e.g., clodronate), free versus liposomal N BP formulations, and targeted versus non targeted liposomal N BPs, and the clinical and preclinical evidence supporting a role for liposomal N BPs in the treatment of cancer. We propose that pegylated liposomal alendronate (PLA) has the most potential for clinical translation based on favorable therapeutic index, ability to passively target and accumulate in tumors, proven biocompatibility of the liposome carrier, and preclinical anticancer efficacy.
C1 [La Beck, Ninh M.; Shudde, Claire] Texas Tech Univ, Dept Immunotherapeut & Biotechnol, Hlth Sci Ctr, Jerry H Hodge Sch Pharm, 1718 Pine St, Abilene, TX 79601 USA.
   [La Beck, Ninh M.] Texas Tech Univ, Hlth Sci Ctr, Dept Pharm Practice, Jerry H Hodge Sch Pharm, 1718 Pin St, Abilene, TX 79601 USA.
   [Liu, Xinli] Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, 4849 Calhoun Rd, Houston, TX 77204 USA.
   [Shmeeda, Hilary; Gabizon, Alberto A.] Shaare Zedek Med Ctr, Ctr Nanooncol, Jerusalem, Israel.
   [Gabizon, Alberto A.] Hebrew Univ Jerusalem, Sch Med, POB 3235, IL 91031 Jerusalem, Israel.
C3 Texas Tech University System; Texas Tech University; Texas Tech
   University System; Texas Tech University; University of Houston System;
   University of Houston; Hebrew University of Jerusalem; Shaare Zedek
   Medical Center; Hebrew University of Jerusalem
RP La Beck, NM (通讯作者)，Texas Tech Univ, Hlth Sci Ctr, Jerry H Hodge Sch Pharm, Dept Immunotherapeut & Biotechnol,Dept Pharm Prac, 1718 Pin St, Abilene, TX 79601 USA.
EM irene.la beck@ttuhsc.edu; hilary@szmc.org.il; ces14a@acu.edu;
   agabizon@szmc.org.il
RI ; liu, xinli/MHQ 8850 2025
OI La Beck, Ninh/0000 0002 1956 3263; 
FU National Cancer Institute [NIH R15CA182769]; CPRIT [RP150656]
FX NML acknowledges funding support from the National Cancer Institute
   (R15CA192097). XL acknowledges funding support from the CPRIT (RP150656)
   and National Cancer Institute (NIH R15CA182769).
CR Aderibigbe B, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9010002
   Albert SG, 2017, ENDOCR PRACT, V23, P841, DOI 10.4158/EP161678.RA
   Allavena P, 2012, CLIN EXP IMMUNOL, V167, P195, DOI 10.1111/j.1365 2249.2011.04515.x
   Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037
   Anastasilakis AD, 2012, BONE, V50, P1130, DOI 10.1016/j.bone.2012.02.006
   Au KM, 2016, BIOMATERIALS, V82, P178, DOI 10.1016/j.biomaterials.2015.12.018
   Banai S, 2013, AM HEART J, V165, P234, DOI 10.1016/j.ahj.2012.10.023
   Beauchesne MF, 1999, ANN PHARMACOTHER, V33, P587, DOI 10.1345/aph.18212
   Benzaïd I, 2011, CANCER RES, V71, P4562, DOI 10.1158/0008 5472.CAN 10 3862
   BODY JJ, 1994, ANN ONCOL, V5, P359, DOI 10.1093/oxfordjournals.annonc.a058841
   Body JJ, 1998, J CLIN ONCOL, V16, P3890, DOI 10.1200/JCO.1998.16.12.3890
   BONJOUR JP, 1988, BONE, V9, P123, DOI 10.1016/8756 3282(88)90001 4
   Burwitz BJ, 2014, J LEUKOCYTE BIOL, V96, P491, DOI 10.1189/jlb.5TA0713 373R
   Canna SW, 2012, PEDIATR CLIN N AM, V59, P329, DOI 10.1016/j.pcl.2012.03.002
   Cocquyt V, 1999, J CLIN PHARMACOL, V39, P385, DOI 10.1177/00912709922007958
   Coleman R, 2015, LANCET, V386, P1353, DOI 10.1016/S0140 6736(15)60908 4
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Coxon FP, 2008, BONE, V42, P848, DOI 10.1016/j.bone.2007.12.225
   Silva PGD, 2017, J ORAL PATHOL MED, V46, P1046, DOI 10.1111/jop.12640
   Ding Y, 2017, ORTHOP SURG, V9, P284, DOI 10.1111/os.12338
   Duncan R, 2011, MOL PHARMACEUT, V8, P2101, DOI 10.1021/mp200394t
   Edmonds S, 2016, ACS NANO, V10, P10294, DOI 10.1021/acsnano.6b05935
   Endo Y, 2017, BIOL PHARM BULL, V40, P739, DOI 10.1248/bpb.b16 01020
   Epstein H, 2008, AAPS J, V10, P505, DOI 10.1208/s12248 008 9060 5
   Epstein Barash H, 2010, J CONTROL RELEASE, V146, P182, DOI 10.1016/j.jconrel.2010.03.011
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Gabizon A, 2004, ADV DRUG DELIVER REV, V56, P1177, DOI 10.1016/j.addr.2004.01.011
   Gabizon A, 2003, CLIN PHARMACOKINET, V42, P419, DOI 10.2165/00003088 200342050 00002
   Gabizon A, 1999, BIOCONJUGATE CHEM, V10, P289, DOI 10.1021/bc9801124
   Gabizon A, 2014, LANCET, V384, P2175, DOI 10.1016/S0140 6736(14)61457 4
   Gabizon AA, 2016, DRUG RESIST UPDATE, V29, P90, DOI 10.1016/j.drup.2016.10.003
   Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827
   Genereux P, 2019, TRANSC CARD THER TCT
   GERTZ BJ, 1995, CLIN PHARMACOL THER, V58, P288, DOI 10.1016/0009 9236(95)90245 7
   Gibson JM, 2013, ONCOLOGIST, V18, P1022, DOI 10.1634/theoncologist.2013 0126
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Gober HJ, 2003, J EXP MED, V197, P163, DOI 10.1084/jem.20021500
   Golan T, 2015, CANCER MED US, V4, P1472, DOI 10.1002/cam4.491
   Golombek SK, 2018, ADV DRUG DELIVER REV, V130, P17, DOI 10.1016/j.addr.2018.07.007
   Gür A, 2003, YONSEI MED J, V44, P99
   Gutman D, 2012, J CONTROL RELEASE, V161, P619, DOI 10.1016/j.jconrel.2011.11.037
   Haber E, 2010, J CONTROL RELEASE, V148, P226, DOI 10.1016/j.jconrel.2010.08.030
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hare JI, 2017, ADV DRUG DELIVER REV, V108, P25, DOI 10.1016/j.addr.2016.04.025
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hodgins NO, 2017, J CONTROL RELEASE, V256, P141, DOI 10.1016/j.jconrel.2017.04.025
   Hodgins NO, 2016, J CONTROL RELEASE, V241, P229, DOI 10.1016/j.jconrel.2016.09.023
   Hortobagyi GN, 2017, JAMA ONCOL, V3, P906, DOI 10.1001/jamaoncol.2016.6316
   Keating GM, 2014, DRUGS, V74, P1891, DOI 10.1007/s40265 014 0302 9
   Khan SA, 1997, J BONE MINER RES, V12, P1700, DOI 10.1359/jbmr.1997.12.10.1700
   Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615
   Kunzmann V, 1999, NEW ENGL J MED, V340, P737, DOI 10.1056/NEJM199903043400914
   Kunzmann V, 1997, BOOD, V90, P575
   La Beck NM, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00220
   La Beck NM, 2015, PHARMACOTHERAPY, V35, P963, DOI 10.1002/phar.1643
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   LIN JH, 1991, DRUG METAB DISPOS, V19, P926
   LIN JH, 1992, DRUG METAB DISPOS, V20, P473
   Lin JH, 1999, INT J CLIN PRACT, P18
   Liu H, 2019, BMC CANCER, V19, DOI 10.1186/s12885 019 5379 9
   Livney YD, 2013, ADV DRUG DELIVER REV, V65, P1716, DOI 10.1016/j.addr.2013.08.006
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Ma XQ, 2018, EXP THER MED, V15, P182, DOI 10.3892/etm.2017.5381
   Maeda H, 2003, INT IMMUNOPHARMACOL, V3, P319, DOI 10.1016/S1567 5769(02)00271 0
   Maerten A, 2007, J IMMUNOTHER, V30, P370
   Man F, 2019, MOL THER, V27, P219, DOI 10.1016/j.ymthe.2018.10.006
   MANTOVANI A, 1992, IMMUNOL TODAY, V13, P265, DOI 10.1016/0167 5699(92)90008 U
   Melani C, 2007, CANCER RES, V67, P11438, DOI 10.1158/0008 5472.CAN 07 1882
   Miller PD, 2016, EXPERT OPIN PHARMACO, V17, P473, DOI 10.1517/14656566.2016.1124856
   Moreau MF, 2007, BIOCHEM PHARMACOL, V73, P718, DOI 10.1016/j.bcp.2006.09.031
   National Cancer Institute's Nanotechnology Characterization Laboratory (NCL), 201501A NCL
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   OROURKE NP, 1993, BRIT J CANCER, V67, P560, DOI 10.1038/bjc.1993.102
   Ottewell PD, 2012, BREAST CANCER RES TR, V133, P523, DOI 10.1007/s10549 011 1782 x
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   Parente Pereira AC, 2014, J IMMUNOL, V193, P5557, DOI 10.4049/jimmunol.1402200
   Parker N, 2005, ANAL BIOCHEM, V338, P284, DOI 10.1016/j.ab.2004.12.026
   Petersen GH, 2016, J CONTROL RELEASE, V232, P255, DOI 10.1016/j.jconrel.2016.04.028
   Ponzoni M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071953
   Porras AG, 1999, CLIN PHARMACOKINET, V36, P315, DOI 10.2165/00003088 199936050 00002
   Rajan R, 2018, J CONTROL RELEASE, V271, P139, DOI 10.1016/j.jconrel.2017.12.023
   Ralston SH, 1997, BRIT J CANCER, V75, P295, DOI 10.1038/bjc.1997.48
   Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525
   Reid IR, 1996, AM J MED, V101, P341, DOI 10.1016/S0002 9343(96)00227 6
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roelofs AJ, 2009, BRIT J HAEMATOL, V144, P245, DOI 10.1111/j.1365 2141.2008.07435.x
   Russell RGG, 1999, J BONE MINER RES, V14, P53, DOI 10.1002/jbmr.5650140212
   Santini D, 2007, CLIN CANCER RES, V13, P4482, DOI 10.1158/1078 0432.CCR 07 0551
   SATO M, 1991, J CLIN INVEST, V88, P2095, DOI 10.1172/JCI115539
   Seeliger C, 2015, EUR J MED RES, V20, DOI 10.1186/s40001 014 0074 4
   Shikama Y, 2010, TOXICOL LETT, V199, P123, DOI 10.1016/j.toxlet.2010.08.013
   Shmeeda H., 2016, J DRUG TARGET, P1
   Shmeeda H, 2016, J DRUG TARGET, V24, P878, DOI 10.1080/1061186X.2016.1191081
   Shmeeda H, 2013, J CONTROL RELEASE, V167, P265, DOI 10.1016/j.jconrel.2013.02.003
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Stresing V, 2011, BONE, V48, P259, DOI 10.1016/j.bone.2010.09.035
   Tamai R, 2018, LIFE SCI, V198, P8, DOI 10.1016/j.lfs.2018.02.014
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Thompson K, 2006, MOL PHARMACOL, V69, P1624, DOI 10.1124/mol.105.020776
   van der Velde RY, 2017, BONE, V94, P50, DOI 10.1016/j.bone.2016.10.013
   VANROOIJEN N, 1984, CELL TISSUE RES, V238, P355, DOI 10.1007/BF00217308
   VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022 1759(89)90178 6
   Ventola C Lee, 2017, P T, V42, P742
   Weinberg RA, 2014, BIOLOGY OF CANCER, SECOND EDITION, P1
   Xia W, 2009, BLOOD, V113, P438, DOI 10.1182/blood 2008 04 150789
NR 110
TC 32
Z9 36
U1 2
U2 65
PU ACADEMIC PRESS LTD  ELSEVIER SCIENCE LTD
PI LONDON
PA 24 28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044 579X
EI 1096 3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD JAN
PY 2021
VL 68
SI SI
BP 175
EP 185
DI 10.1016/j.semcancer.2019.12.001
EA FEB 2021
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA QE7DP
UT WOS:000616365300016
PM 31874280
DA 2025 08 17
ER

PT J
AU Checchi, M
   Bertacchini, J
   Grisendi, G
   Smargiassi, A
   Sola, A
   Messori, M
   Palumbo, C
AF Checchi, Marta
   Bertacchini, Jessika
   Grisendi, Giulia
   Smargiassi, Alberto
   Sola, Antonella
   Messori, Massimo
   Palumbo, Carla
TI Proposal of a Novel Natural Biomaterial, the Scleral Ossicle, for the
   Development of Vascularized Bone Tissue In Vitro
SO BIOMEDICINES
LA English
DT Article
DE scleral ossicles; natural scaffold; endothelial cells; osteoblastic
   cells
ID SPONGE LIKE SCAFFOLDS; CRITICAL SIZE DEFECT; STROMAL CELLS;
   ANGIOGENESIS; BMP; OSTEOGENESIS; OSTEOBLASTS; OSTEOCYTE; MECHANISM
AB Recovering of significant skeletal defects could be partially abortive due to the perturbations that affect the regenerative process when defects reach a critical size, thus resulting in a non healed bone. The current standard treatments include allografting, autografting, and other bone implant techniques. However, although they are commonly used in orthopedic surgery, these treatments have some limitations concerning their costs and their side effects such as potential infections or malunions. On this account, the need for suitable constructs to fill the gap in wide fractures is still urgent. As an innovative solution, scleral ossicles (SOs) can be put forward as natural scaffolds for bone repair. SOs are peculiar bony plates forming a ring at the scleral corneal border of the eyeball of lower vertebrates. In the preliminary phases of the study, these ossicles were structurally and functionally characterized. The morphological characterization was performed by SEM analysis, MicroCT analysis and optical profilometry. Then, UV sterilization was carried out to obtain a clean support, without neither contaminations nor modifications of the bone architecture. Subsequently, the SO biocompatibility was tested in culture with different cell lines, focusing the attention to the differentiation capability of endothelial and osteoblastic cells on the SO surface. The results obtained by the above mentioned analysis strongly suggest that SOs can be used as bio scaffolds for functionalization processes, useful in regenerative medicine.
C1 [Checchi, Marta; Bertacchini, Jessika; Smargiassi, Alberto; Palumbo, Carla] Univ Modena & Reggio Emilia, Dept Biomed Metab Sci & Neurosci, Largo del Pozzo 71, I 41125 Modena, Italy.
   [Grisendi, Giulia] Univ Hosp Modena & Reggio Emilia, Div Oncol, Dept Med & Surg Sci Children & Adults, Largo del Pozzo 71, I 41125 Modena, Italy.
   [Sola, Antonella; Messori, Massimo] Univ Modena & Reggio Emilia, Dept Engn Enzo Ferrari, Via Pietro Vivarelli 10 1, I 41125 Modena, Italy.
C3 Universita di Modena e Reggio Emilia; Universita di Modena e Reggio
   Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di
   Modena e Reggio Emilia
RP Checchi, M; Bertacchini, J (通讯作者)，Univ Modena & Reggio Emilia, Dept Biomed Metab Sci & Neurosci, Largo del Pozzo 71, I 41125 Modena, Italy.
EM marta.checchi@unimore.it; jbertacchini@unimore.it;
   giulia.grisendi@unimore.it; alberto.smargiassi@unimore.it;
   antonella.sola@unimore.it; massimo.messori@unimore.it;
   carla.palumbo@unimore.it
RI ; Checchi, Marta/AAJ 3977 2020; Sola, Antonella/I 2393 2012; Messori,
   Massimo/C 9745 2011; Grisendi, Giulia/J 6360 2016; BERTACCHINI,
   JESSIKA/F 4382 2017; Palumbo, Carla/E 5802 2012
OI Checchi, Marta/0000 0002 6399 3172; Messori,
   Massimo/0000 0003 3598 4241; Grisendi, Giulia/0000 0002 0120 6129;
   BERTACCHINI, JESSIKA/0000 0001 9218 9215; Sola,
   Antonella/0000 0002 8649 9388; Palumbo, Carla/0000 0003 0587 0112
CR Barabaschi GDG, 2015, ADV EXP MED BIOL, V881, P79, DOI 10.1007/978 3 319 22345 2_5
   Cellier Eric, 2010, Archives of Physiology and Biochemistry, V116, P50, DOI 10.3109/13813451003610862
   COULOMBRE AJ, 1962, DEV BIOL, V5, P382, DOI 10.1016/0012 1606(62)90020 9
   Cowan CM, 2004, NAT BIOTECHNOL, V22, P560, DOI 10.1038/nbt958
   Dallas SL, 2013, ENDOCR REV, V34, P658, DOI 10.1210/er.2012 1026
   Danti S, 2009, BIOMED MICRODEVICES, V11, P783, DOI 10.1007/s10544 009 9293 9
   Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599
   Duench K, 2012, DEV BIOL, V365, P251, DOI 10.1016/j.ydbio.2012.02.016
   EDINGER TILLY, 1929, ZOOL JAHRB ABT ANAT U ONTOGEN TIERE, V51, P163
   Franz Odendaal TA, 2006, DEV DYNAM, V235, P176, DOI 10.1002/dvdy.20603
   Franz Odendaal TA, 2008, DEV DYNAM, V237, P3240, DOI 10.1002/dvdy.21754
   GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331
   Gonzalvo Feo S, 2014, J IMMUNOL, V192, P2366, DOI 10.4049/jimmunol.1302028
   Guo BL, 2015, REGEN BIOMATER, V2, P47, DOI 10.1093/rb/rbu016
   Harris JS, 2013, BONE, V55, P241, DOI 10.1016/j.bone.2013.02.002
   Jabalee J, 2013, J ANAT, V223, P311, DOI 10.1111/joa.12095
   Jabalee J, 2015, DEV BIOL, V406, P52, DOI 10.1016/j.ydbio.2015.07.014
   Jourdeuil K, 2012, ANAT REC, V295, P691, DOI 10.1002/ar.22429
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Laurencin C, 2006, EXPERT REV MED DEVIC, V3, P49, DOI 10.1586/17434440.3.1.49
   Lazzeri L, 2006, J MATER SCI MATER M, V17, P1211, DOI 10.1007/s10856 006 0594 8
   Lima F.C., 2009, Brazilian Journal of Morphological Sciences, V26, P165
   Liu HB, 2012, J CELL PHYSIOL, V227, P952, DOI 10.1002/jcp.22802
   Mandal CC, 2011, BIOCHEM J, V433, P393, DOI 10.1042/BJ20100357
   Marotti G, 2007, EUR J HISTOCHEM, V51, P15
   Mattii L, 2008, MACROMOL BIOSCI, V8, P819, DOI 10.1002/mabi.200700331
   Mota C, 2015, J TISSUE ENG REGEN M, V9, P174, DOI 10.1002/term.1635
   Palumbo C., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P327
   Palumbo C., 2012, ITAL J ANAT EMBRYOL, V117, P143
   Palumbo C, 2012, CALCIFIED TISSUE INT, V90, P211, DOI 10.1007/s00223 012 9569 6
   Polo Corrales L, 2014, J NANOSCI NANOTECHNO, V14, P15, DOI 10.1166/jnn.2014.9127
   Romer, 2002, provide historical documentation of policymakers support for the idea of a permanent inflation unemployment tradeoff
   SCHMITZ JP, 1986, CLIN ORTHOP RELAT R, P299, DOI 10.1097/00003086 198604000 00036
   SCHMITZ JP, 1990, ACTA ANAT, V138, P185
   Schroeder JE, 2011, INJURY, V42, P609, DOI 10.1016/j.injury.2011.03.029
   Spicer PP, 2012, NAT PROTOC, V7, P1918, DOI 10.1038/nprot.2012.113
   Trombi L, 2008, TRANSFUSION, V48, P2246, DOI 10.1111/j.1537 2995.2008.01829.x
   Trombi L, 2008, J ORTHOP RES, V26, P176, DOI 10.1002/jor.20490
   Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218 7230.2001
   WARHEIT KI, 1989, AUK, V106, P383
   Zhang RR, 2013, BONE, V52, P145, DOI 10.1016/j.bone.2012.09.029
   Zhang SJ, 2017, BIOTECHNOL J, V12, DOI 10.1002/biot.201700008
NR 47
TC 5
Z9 6
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD MAR
PY 2018
VL 6
IS 1
AR 3
DI 10.3390/biomedicines6010003
PG 14
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA GA7GY
UT WOS:000428505300003
PM 29295590
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Zheng, Y
   Zhou, C
   Yu, XX
   Wu, C
   Jia, HL
   Gao, XM
   Yang, JM
   Wang, CQ
   Luo, Q
   Zhu, Y
   Zhang, Y
   Wei, JW
   Sheng, YY
   Dong, QZ
   Qin, LX
AF Zheng, Yan
   Zhou, Chuang
   Yu, Xin Xin
   Wu, Chao
   Jia, Hu Liang
   Gao, Xiao Mei
   Yang, Ji Meng
   Wang, Chao Qun
   Luo, Qin
   Zhu, Ying
   Zhang, Yu
   Wei, Jin Wang
   Sheng, Yuan Yuan
   Dong, Qiong Zhu
   Qin, Lun Xiu
TI Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma
   through recruiting MAPK1 and mediating Ser675 phosphorylation of
   β Catenin
SO CELL DEATH & DISEASE
LA English
DT Article
ID HUMAN HEPATOCELLULAR CARCINOMA; TUMOR GROWTH; ACTIVATION; PATHOGENESIS;
   CANCER; CELLS; EXPRESSION; MANAGEMENT; THERAPIES; PROGNOSIS
AB The incidence and mortality of intrahepatic cholangiocarcinoma (ICC) are increasing worldwide in recent decades. Osteopontin (OPN) plays an important role in cancer metastasis, but its functional mechanism in ICC is not clear yet. In this study, we found that OPN level was elevated both in plasma and tumor tissues of ICC patients, which was closely related to a shorter overall survival (OS) and high probability of tumor relapse after curative resection. The gain and loss of function studies determined that OPN could promote ICC growth and metastasis. OPN selectively interacted with beta Catenin and knockdown of beta Catenin abrogated the effects induced by OPN. OPN recruited MAPK1 and activated MEK MAPK1 pathway to mediate the S675 phosphorylation of beta Catenin and nucleus accumulation, which induced the activation of Wnt signaling. Moreover, a significant correlation between OPN and beta Catenin was found in ICC tissues. OPN, beta Catenin, and their combination were independent prognostic indicator for ICC patients. In conclusion, OPN promotes ICC progression through recruiting MAPK1 and activating the Wnt/beta Catenin pathway and can serve as a novel prognostic marker and therapeutic target for ICC.
C1 [Zheng, Yan; Zhou, Chuang; Yu, Xin Xin; Wu, Chao; Jia, Hu Liang; Gao, Xiao Mei; Yang, Ji Meng; Wang, Chao Qun; Luo, Qin; Zhu, Ying; Zhang, Yu; Wei, Jin Wang; Sheng, Yuan Yuan; Dong, Qiong Zhu; Qin, Lun Xiu] Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
   [Zheng, Yan; Zhou, Chuang; Yu, Xin Xin; Wu, Chao; Jia, Hu Liang; Gao, Xiao Mei; Yang, Ji Meng; Wang, Chao Qun; Luo, Qin; Zhu, Ying; Zhang, Yu; Wei, Jin Wang; Sheng, Yuan Yuan; Dong, Qiong Zhu; Qin, Lun Xiu] Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China.
   [Zheng, Yan; Zhou, Chuang; Yu, Xin Xin; Wu, Chao; Jia, Hu Liang; Gao, Xiao Mei; Yang, Ji Meng; Wang, Chao Qun; Luo, Qin; Zhu, Ying; Zhang, Yu; Wei, Jin Wang; Sheng, Yuan Yuan; Dong, Qiong Zhu; Qin, Lun Xiu] Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Fudan University
RP Dong, QZ; Qin, LX (通讯作者)，Fudan Univ, Huashan Hosp, Dept Gen Surg, Shanghai, Peoples R China.; Dong, QZ; Qin, LX (通讯作者)，Fudan Univ, Canc Metastasis Inst, Shanghai, Peoples R China.; Dong, QZ; Qin, LX (通讯作者)，Fudan Univ, Inst Biomed Sci, Shanghai, Peoples R China.
EM qzhdong@fudan.edu.cn; qinlx@fudan.edu.cn
RI ; Luo, Qin/KDM 6812 2024
OI zheng, yan/0000 0002 9602 1644; Luo, Qin/0000 0003 0255 8430; 
FU National Key Basic Research Program of China [2013CB910500]; National
   Key Research and Development Program of China [2017YFC1308604]; China
   National Natural Science Foundation [81372647, 81672820]; China National
   Key Projects for Infectious Disease [2012ZX10002 012]
FX We thank professor Kun Liang Guan, Yue Xiong, and Xiang huo He in
   Institutes of Biomedical Sciences, Fudan University for providing us ICC
   cell lines. This work is supported by the National Key Basic Research
   Program of China (2013CB910500), the National Key Research and
   Development Program of China (2017YFC1308604), China National Natural
   Science Foundation (81372647 and 81672820), and China National Key
   Projects for Infectious Disease (2012ZX10002 012).
CR Boulter L, 2015, J CLIN INVEST, V125, P1269, DOI 10.1172/JCI76452
   Brembeck FH, 2004, GENE DEV, V18, P2225, DOI 10.1101/gad.317604
   Bridgewater J, 2014, J HEPATOL, V60, P1268, DOI 10.1016/j.jhep.2014.01.021
   Chu QQ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.287
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   de Jong MC, 2011, J CLIN ONCOL, V29, P3140, DOI 10.1200/JCO.2011.35.6519
   Dong QZ, 2013, HEPATOLOGY, V57, P1024, DOI 10.1002/hep.26103
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Hass HG, 2008, WORLD J GASTROENTERO, V14, P2501, DOI 10.3748/wjg.14.2501
   Ilyas SI, 2017, J HEPATOL, V67, P632, DOI 10.1016/j.jhep.2017.03.026
   Ilyas SI, 2013, GASTROENTEROLOGY, V145, P1215, DOI 10.1053/j.gastro.2013.10.013
   Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587
   Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008 5472.CAN 07 2295
   McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045
   Moeini A, 2016, CLIN CANCER RES, V22, P291, DOI 10.1158/1078 0432.CCR 14 3296
   Náger M, 2015, CELL CYCLE, V14, P3644, DOI 10.1080/15384101.2015.1104443
   Njei B, 2014, HEPATOLOGY, V60, P1107, DOI 10.1002/hep.26958
   Piedra J, 2003, MOL CELL BIOL, V23, P2287, DOI 10.1128/MCB.23.7.2287 2297.2003
   Pietras A, 2014, CELL STEM CELL, V14, P357, DOI 10.1016/j.stem.2014.01.005
   Razumilava N, 2014, LANCET, V383, P2168, DOI 10.1016/S0140 6736(13)61903 0
   Sia D, 2013, ONCOGENE, V32, P4861, DOI 10.1038/onc.2012.617
   Sulpice L, 2013, HEPATOLOGY, V58, P1992, DOI 10.1002/hep.26577
   Sun BS, 2008, HEPATOLOGY, V48, P1834, DOI 10.1002/hep.22531
   Tian Q, 2004, P NATL ACAD SCI USA, V101, P15370, DOI 10.1073/pnas.0406499101
   Urtasun R, 2012, HEPATOLOGY, V55, P594, DOI 10.1002/hep.24701
   Wang M, 2017, CANCER RES, V77, P2018, DOI 10.1158/0008 5472.CAN 16 0808
   Wu XM, 2008, CELL, V133, P340, DOI 10.1016/j.cell.2008.01.052
   Xue YH, 2010, HEPATOLOGY, V52, P2012, DOI 10.1002/hep.23942
   Yamada D, 2015, HEPATOLOGY, V61, P1627, DOI 10.1002/hep.27687
   Ye QH, 2003, NAT MED, V9, P416, DOI 10.1038/nm843
   Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017
   Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003
   Zhang J., 2012, GASTROENTEROLOGY, V143
   Zhao SQ, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046 014 0103 8
   Zheng TS, 2014, HEPATOLOGY, V59, P935, DOI 10.1002/hep.26705
   Zhu G, 2012, ONCOGENE, V31, P1001, DOI 10.1038/onc.2011.294
   Zhu XD, 2008, J CLIN ONCOL, V26, P2707, DOI 10.1200/JCO.2007.15.6521
NR 37
TC 46
Z9 52
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041 4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB 7
PY 2018
VL 9
AR 179
DI 10.1038/s41419 017 0226 x
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA FZ2IN
UT WOS:000427401400021
PM 29415992
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, L
   Qu, JK
   Qi, YT
   Duan, YM
   Huang, YW
   Zhou, ZF
   Li, P
   Yao, J
   Huang, BB
   Zhang, SX
   Yu, DH
AF Zhang, Lin
   Qu, Jingkun
   Qi, Yutao
   Duan, Yimin
   Huang, Yu Wen
   Zhou, Zhifen
   Li, Ping
   Yao, Jun
   Huang, Beibei
   Zhang, Shuxing
   Yu, Dihua
TI EZH2 engages TGFβ signaling to promote breast cancer bone metastasis via
   integrin β1 FAK activation
SO NATURE COMMUNICATIONS
LA English
DT Article
ID HISTONE METHYLTRANSFERASE ACTIVITY; E CADHERIN EXPRESSION; ZESTE HOMOLOG
   2; ALPHA 5 BETA 1 INTEGRIN; TUMOR SUPPRESSOR; I RECEPTOR; SMAD;
   INHIBITION; PROTEIN; TGF BETA 1
AB Bone metastases occur in 50 70% of patients with late stage breast cancers and effective therapies are needed. The expression of enhancer of zeste homolog 2 (EZH2) is correlated with breast cancer metastasis, but its function in bone metastasis hasn't been well explored. Here we report that EZH2 promotes osteolytic metastasis of breast cancer through regulating transforming growth factor beta (TGF beta) signaling. EZH2 induces cancer cell proliferation and osteoclast maturation, whereas EZH2 knockdown decreases bone metastasis incidence and outgrowth in vivo. Mechanistically, EZH2 transcriptionally increases ITGB1, which encodes for integrin beta 1. Integrin beta 1 activates focal adhesion kinase (FAK), which phosphorylates TGF beta receptor type I (TGF beta RI) at tyrosine 182 to enhance its binding to TGF beta receptor type II (TGF beta RII), thereby activating TGF beta signaling. Clinically applicable FAK inhibitors but not EZH2 methyltransferase inhibitors effectively inhibit breast cancer bone metastasis in vivo. Overall, we find that the EZH2 integrin beta 1 FAK axis cooperates with the TGF beta signaling pathway to promote bone metastasis of breast cancer.
   Breast cancer cells are known to metastasize to the bone but why the cells should migrate and metastasize to this particular organ is not clearly understood. Here, the authors show that EZH2 activates an integrin B1 and FAK signaling pathway in breast cancer cells, which activates TGFB signaling to drive metastasis in the bone.
C1 [Zhang, Lin; Qu, Jingkun; Qi, Yutao; Duan, Yimin; Huang, Yu Wen; Zhou, Zhifen; Li, Ping; Yao, Jun; Yu, Dihua] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Qi, Yutao; Zhang, Shuxing; Yu, Dihua] Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Huang, Beibei; Zhang, Shuxing] Univ Texas MD Anderson Canc Ctr, Intelligent Mol Discovery Lab, Dept Expt Therapeut, Houston, TX 77030 USA.
   [Qu, Jingkun] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 2, Xian, Shaanxi, Peoples R China.
   [Huang, Yu Wen] China Med Univ, Sch Med, Dept Pharmacol, Taichung, Taiwan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Xi'an Jiaotong University; China Medical
   University Taiwan
RP Yu, DH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.; Yu, DH (通讯作者)，Univ Texas MD Anderson Canc Ctr, UTHlth Grad Sch Biomed Sci, Houston, TX 77030 USA.
EM dyu@mdanderson.org
RI ; Huang, Youju/A 9477 2011; Yao, Jun/JAC 5608 2023; Qu,
   Jingkun/HLG 9227 2023
OI Duan, Yimin/0000 0002 2675 3524; Huang, Yu Wen/0009 0006 5581 8098;
   Huang, Beibei/0000 0003 0555 6924; Qu, Jingkun/0000 0002 5064 2832
FU National Institutes of Health (NIH) [R01CA184836, R01 CA208213,
   R01CA231149]; METAvivor grants [56675, 58284]; NIH Cancer Center Support
   Grant [P30CA016672]; China Scholarship Council [201706280072]; Ministry
   of Education, Taiwan: The International Co cultivation of Talent
   Program; Clinical and Translational Proteomics Service Center at the
   University of Texas Health Science Center; National Cancer Institute
   [R01CA208213] Funding Source: NIH RePORTER
FX We thank members of the Yu's laboratory for insightful discussions. We
   thank D. Norwood, the Department of Scientific Publications of MD
   Anderson Cancer Center for article revision. This work was supported by
   National Institutes of Health (NIH) grants R01CA184836 (D.Y.), R01
   CA208213 (D.Y.), and R01CA231149 (D.Y.), the METAvivor grants 56675 and
   58284 (D.Y.), and NIH Cancer Center Support Grant P30CA016672 to MD
   Anderson Cancer Center (Functional Genomics Core, Flow Cytometry and
   Cellular Imaging resource, Advanced Technology Genomics Core, Research
   Histology Core Laboratory, Cytogenetics and Cell Authentication Core,
   Functional Proteomics Reverse Phase Protein Array Core, and Research
   Animal Support Facility Houston). J.Q. received fellowship from China
   Scholarship Council 201706280072. Y. W.H. received fellowship from the
   Ministry of Education, Taiwan: The International Co cultivation of
   Talent Program. D.Y. is the Hubert L. and Olive Stringer Distinguished
   Chair in Basic Science at MD Anderson. Mass spectrum is performed at and
   supported in part by the Clinical and Translational Proteomics Service
   Center at the University of Texas Health Science Center.
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549 011 1591 2
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Buijs Jeroen T, 2012, Bonekey Rep, V1, P96, DOI 10.1038/bonekey.2012.96
   Cai T, 2000, BIOCHEM BIOPH RES CO, V274, P519, DOI 10.1006/bbrc.2000.3177
   Campbell MG, 2020, CELL, V180, P490, DOI 10.1016/j.cell.2019.12.030
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Chen YR, 2020, HEPATOL COMMUN, V4, P268, DOI 10.1002/hep4.1452
   Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008
   Esposito M, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031252
   Feldkoren B, 2017, EXP CELL RES, V355, P57, DOI 10.1016/j.yexcr.2017.03.051
   Fornetti J, 2018, J BONE MINER RES, V33, P2099, DOI 10.1002/jbmr.3618
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008 5472.CAN 10 1933
   Gulati N, 2018, LEUKEMIA LYMPHOMA, V59, P1574, DOI 10.1080/10428194.2018.1430795
   He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111
   Heldin CH, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a022053
   Hirukawa A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04864 8
   Hu J, 2007, BIOINFORMATICS, V23, P1986, DOI 10.1093/bioinformatics/btm283
   Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470 2045(18)30145 1
   Käkönen SM, 2002, J BIOL CHEM, V277, P24571, DOI 10.1074/jbc.M202561200
   Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102
   Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928
   Khotskaya YB, 2014, AM J TRANSL RES, V6, P361
   Kim J, 2018, CELL REP, V25, P2808, DOI 10.1016/j.celrep.2018.11.035
   Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535 7163.MCT 13 0773
   Kondo Y, 2014, J BIOCHEM, V156, P249, DOI 10.1093/jb/mvu054
   Korpal M, 2010, EUR J CANCER, V46, P1232, DOI 10.1016/j.ejca.2010.02.040
   Kowalski PJ, 2003, BREAST CANCER RES, V5, pR217, DOI 10.1186/bcr651
   Kozakov D, 2017, NAT PROTOC, V12, P255, DOI 10.1038/nprot.2016.169
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004
   LOWE C, 1993, P NATL ACAD SCI USA, V90, P4485, DOI 10.1073/pnas.90.10.4485
   Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010
   Madan R, 2006, HUM PATHOL, V37, P9, DOI 10.1016/j.humpath.2005.09.024
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092 8674(00)80545 0
   Nagae M, 2012, J CELL BIOL, V197, P131, DOI 10.1083/jcb.201111077
   Naik A, 2018, BMC CANCER, V18, DOI 10.1186/s12885 018 4446 y
   Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369
   Quan JJ, 2018, ONCOL REP, V39, P1043, DOI 10.3892/or.2017.6166
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008 5472.CAN 11 3546
   Rossi L, 2020, CHIN CLIN ONCOL, V9, DOI 10.21037/cco.2020.01.07
   Sanulli S, 2015, MOL CELL, V57, P769, DOI 10.1016/j.molcel.2014.12.020
   Siegel RL, 2019, CA CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Soki FN, 2012, FUTURE ONCOL, V8, P803, DOI [10.2217/fon.12.76, 10.2217/FON.12.76]
   SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092 8674(91)90499 O
   Souchelnytskyi S, 1996, EMBO J, V15, P6231, DOI 10.1002/j.1460 2075.1996.tb01013.x
   Stockis J, 2017, P NATL ACAD SCI USA, V114, pE10161, DOI 10.1073/pnas.1710680114
   Sulzmaier FJ, 2014, NAT REV CANCER, V14, P598, DOI 10.1038/nrc3792
   van Dinther M, 2010, J BONE MINER RES, V25, P1208, DOI [10.1002/jbmr.091110, 10.1359/jbmr.091110]
   van Nimwegen MJ, 2007, BIOCHEM PHARMACOL, V73, P597, DOI 10.1016/j.bcp.2006.08.011
   Vasanthakumar A, 2017, EMBO REP, V18, P619, DOI 10.15252/embr.201643237
   Wang H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15045
   Wang J, 2015, MOL MED REP, V11, P3585, DOI 10.3892/mmr.2015.3164
   Warnecke A, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/s12859 014 0370 6
   Wendt MK, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2360
   WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460 2075.1995.tb07214.x
   WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0
   Xu J, 2015, CANCER CELL, V27, P177, DOI 10.1016/j.ccell.2014.11.025
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yomtoubian S, 2020, CELL REP, V30, P755, DOI 10.1016/j.celrep.2019.12.056
   Zhang LB, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay0289
   Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008 5472.CAN 12 1803
   Zhang WJ, 2019, TRENDS CANCER, V5, P95, DOI 10.1016/j.trecan.2018.12.004
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 68
TC 107
Z9 114
U1 4
U2 35
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041 1723
J9 NAT COMMUN
JI Nat. Commun.
PD MAY 10
PY 2022
VL 13
IS 1
AR 2543
DI 10.1038/s41467 022 30105 0
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 1C9UF
UT WOS:000793456800006
PM 35538070
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Joerger, M
   Templeton, A
   Koeberle, D
   Engler, H
   Riesen, WF
   Thürlimann, B
AF Joerger, M.
   Templeton, A.
   Koeberle, D.
   Engler, H.
   Riesen, W. F.
   Thuerlimann, B.
TI Procollagen type I N propeptide is a predictor of skeletal morbidity in
   patients with malignant osteolytic bone disease on bisphosphonates
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE N telopeptide; Malignant bone disease; Pamidronate; Cancer pain; Bone
   turnover marker
ID QUALITY OF LIFE; BREAST CANCER PATIENTS; METASTATIC PROSTATE CANCER;
   RECEIVING ZOLEDRONIC ACID; ORAL IBANDRONATE; PAMIDRONATE DISODIUM;
   TERMINAL PROPEPTIDE; DOUBLE BLIND; BIOCHEMICAL MARKERS; COMPARATIVE
   TRIAL
AB Background There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone targeted therapies is moderate. We assessed the predictive value of the bone formation marker procollagen type I N propeptide (PINP) for skeletal morbidity in patients with MBD receiving pamidronate.
   Methods Seventy patients with advanced MBD were randomized to receive pamidronate 60 mg (n = 35) or 90 mg (n = 35) every 3 weeks for six cycles in a double blind study. PINP was analyzed at baseline and before each administration of pamidronate, using a validated ELISA. Serum PINP concentrations were compared with pain response (visual analog scale VAS, composite pain score) and skeletal morbidity (skeletal related events, SRE) using Student's T test, Wilcoxon rank sum and log rank test, respectively.
   Results Patients with >= 20% pain reduction in the VAS had lower baseline PINP concentrations when compared to patients with < 20% VAS response (P < 0.0001). A high baseline serum PINP concentration (highest tertile versus lower two tertiles) was significantly associated with a shorter duration of pain response (P < 0.0001) and a shorter time interval to first SRE (P < 0.008). Sensitivity of a low baseline PINP serum concentration for freedom from SRE at 1 year from randomization was 75% (15 out of 20 patients), while specificity was 82% (27 out of 33 patients).
   Conclusions Serum PINP has been shown to be a significant predictor for skeletal morbidity in patients with MBD on pamidronate treatment. Prospective validation of PINP in patients with MBD to assess the prognosis or individualize bone targeted treatment is justified.
C1 [Joerger, M.; Templeton, A.; Koeberle, D.] Cantonal Hosp, Dept Hematol & Oncol, CH 9007 St Gallen, Switzerland.
   [Engler, H.; Riesen, W. F.] Cantonal Hosp, Inst Clin Chem & Hematol, CH 9007 St Gallen, Switzerland.
   [Thuerlimann, B.] Cantonal Hosp, Breast Ctr, CH 9007 St Gallen, Switzerland.
C3 Kantonsspital St. Gallen; Kantonsspital St. Gallen; Kantonsspital St.
   Gallen
RP Joerger, M (通讯作者)，Cantonal Hosp, Dept Hematol & Oncol, Rorschacherstr 95, CH 9007 St Gallen, Switzerland.
EM markus.joerger@kssg.ch
RI ; Templeton, Arnoud/AGR 9652 2022; joerger, markus/B 7230 2011
OI Templeton, Arnoud/0000 0002 0847 7087; 
FU AstraZeneca; Novartis; Janssen Cilag; BMS; Sanofi Aventis; Phillips
   Group; Prime Oncology; GSK; EliLilly
FX B. Thurlimann has received reimbursement for Advisory Board activities
   from GSK and Roche, holds stocks of Novartis and Rochen, and received
   honoraria and travel grants related to educational activities from
   AstraZeneca, Novartis, Janssen Cilag, BMS, Sanofi Aventis, Phillips
   Group, Prime Oncology, GSK and EliLilly. No Conflict of interest
   declared by the other authors.
CR Aapro M, 2008, ANN ONCOL, V19, P420, DOI 10.1093/annonc/mdm442
   Agrawal A, 2009, BREAST, V18, P204, DOI 10.1016/j.breast.2009.04.002
   Ahmad AM, 2003, BONE, V32, P170, DOI 10.1016/S8756 3282(02)00952 3
   Body JJ, 2007, ANN ONCOL, V18, P1165, DOI 10.1093/annonc/mdm119
   Body JJ, 2004, BRIT J CANCER, V90, P1133, DOI 10.1038/sj.bjc.6601663
   Body JJ, 2004, PAIN, V111, P306, DOI 10.1016/j.pain.2004.07.011
   Brandt J, 1999, CLIN CHEM, V45, P47
   Brown JE, 2007, CALCIFIED TISSUE INT, V81, P341, DOI 10.1007/s00223 007 9061 x
   Clemons M, 2008, BREAST CANCER RES TR, V108, P79, DOI 10.1007/s10549 007 9583 y
   Coleman RE, 2008, BRIT J CANCER, V98, P1736, DOI 10.1038/sj.bjc.6604382
   Coleman RE, 2005, J CLIN ONCOL, V23, P4925, DOI 10.1200/JCO.2005.06.091
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Cook RJ, 2006, CLIN CANCER RES, V12, P3361, DOI 10.1158/1078 0432.CCR 06 0269
   Díaz Martín MA, 1999, SCAND J CLIN LAB INV, V59, P125, DOI 10.1080/00365519950185850
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Engler H, 1998, CLIN CHEM LAB MED, V36, P879, DOI 10.1515/CCLM.1998.154
   Fizazi K, 2009, J UROLOGY, V182, P509, DOI 10.1016/j.juro.2009.04.023
   Gainford MC, 2005, BMJ BRIT MED J, V330, P769, DOI 10.1136/bmj.330.7494.769
   Garnero P, 2008, CLIN CHEM, V54, P188, DOI 10.1373/clinchem.2007.094953
   Gessner U, 2000, SUPPORT CARE CANCER, V8, P115, DOI 10.1007/s005200050025
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   Heidenreich A, 2001, J UROLOGY, V165, P136, DOI 10.1097/00005392 200101000 00033
   Heidenreich A, 2004, SEMIN ONCOL, V31, P67, DOI 10.1053/j.seminoncol.2004.07.026
   Hong SJ, 2007, YONSEI MED J, V48, P1001, DOI 10.3349/ymj.2007.48.6.1001
   Janjan N, 2001, SEMIN ONCOL, V28, P28, DOI 10.1053/sonc.2001.25444
   Koeberle D, 1999, SUPPORT CARE CANCER, V7, P21, DOI 10.1007/s005200050218
   Kretzschmar Albrecht, 2007, Support Cancer Ther, V4, P203, DOI 10.3816/SCT.2007.n.016
   LEARY ET, 2005, J BONE MINER RES S1, V20, pS227
   Lipton A, 2006, CLIN CANCER RES, V12, p6209S, DOI 10.1158/1078 0432.CCR 06 1213
   Looker AC, 2000, OSTEOPOROSIS INT, V11, P467, DOI 10.1007/s001980070088
   Lüftner D, 2005, ANTICANCER RES, V25, P1491
   Mancini I, 2004, J CLIN ONCOL, V22, P3587, DOI 10.1200/JCO.2004.07.054
   McCaig FM, 2010, BREAST CANCER RES TR, V119, P643, DOI 10.1007/s10549 009 0646 0
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Mystakidou Kyriaki, 2006, Am J Hosp Palliat Care, V23, P41, DOI 10.1177/104990910602300107
   Pollmann D, 2007, ANTICANCER RES, V27, P1853
   PUROHIT OP, 1994, BRIT J CANCER, V70, P554, DOI 10.1038/bjc.1994.344
   Ripamonti C, 2007, SUPPORT CARE CANCER, V15, P1177, DOI 10.1007/s00520 007 0230 2
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2001, CANCER J, V7, P377
   Rosen LS, 2003, CANCER AM CANCER SOC, V98, P1735, DOI 10.1002/cncr.11701
   Saad F, 2004, EUR UROL, V46, P731, DOI 10.1016/j.eururo.2004.08.016
   Sherer JT, 2007, PHARMACOTHERAPY, V27, P207, DOI 10.1592/phco.27.2.207
   Small EJ, 2003, J CLIN ONCOL, V21, P4277, DOI 10.1200/JCO.2003.05.147
   Vinholes J, 1997, J CLIN ONCOL, V15, P131, DOI 10.1200/JCO.1997.15.1.131
   Vinholes J, 1996, CANCER TREAT REV, V22, P289, DOI 10.1016/S0305 7372(96)90021 3
   Wardley A, 2005, BRIT J CANCER, V92, P1869, DOI 10.1038/sj.bjc.6602551
   Weinfurt KP, 2005, ANN ONCOL, V16, P579, DOI 10.1093/annonc/mdi122
   Weinfurt KP, 2004, MED CARE, V42, P164, DOI 10.1097/01.mlr.0000108746.69256.45
NR 49
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344 5704
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD MAY
PY 2011
VL 67
IS 5
BP 1137
EP 1144
DI 10.1007/s00280 010 1420 z
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 754ZX
UT WOS:000289897500017
PM 20683595
DA 2025 08 17
ER

PT J
AU Lee, JH
   Faderl, S
   Pagel, JM
   Jung, CW
   Yoon, SS
   Pardanani, AD
   Becker, PS
   Lee, H
   Choi, J
   Lee, K
   Kim, M
   Cortes, JE
AF Lee, Je Hwan
   Faderl, Stefan
   Pagel, John M.
   Jung, Chul Won
   Yoon, Sung Soo
   Pardanani, Animesh D.
   Becker, Pamela S.
   Lee, Howard
   Choi, Jeongeun
   Lee, Kyoungjune
   Kim, Minkyoung
   Cortes, Jorge E.
TI Phase 1 study of CWP232291 in patients with relapsed or refractory acute
   myeloid leukemia and myelodysplastic syndrome
SO BLOOD ADVANCES
LA English
DT Article
ID INTERNATIONAL WORKING GROUP; CATENIN SIGNALING PATHWAY; BETA CATENIN;
   RESPONSE CRITERIA; INHIBITION; CELLS
AB CWP232291 (CWP291) is a small molecule inhibitor of Wnt signaling that causes degradation of beta catenin via apoptosis induction through endoplasmic reticulum stress activation. This first in human, open label, dose escalation study to evaluate the safety, maximum tolerated dose (MTD), and preliminary efficacy of CWP291 enrolled 69 patients with hematologic malignancies (acute myeloid leukemia [AML], n = 64; myelodysplastic syndrome, n = 5) in 15 dose escalation cohorts of 4 to 334 mg/m(2) using a modified 313 design and 1 dose expansion cohort. CWP291 was administered IV daily for 7 days every 21 days. The most common treatment emergent adverse events (TEAEs) were nausea (n = 44, 64%), vomiting (n = 32, 46%), diarrhea (n = 25, 36%), and infusion related reactions (n = 20, 29%). Grade >= 3 TEAEs in >3 patients (5%) were pneumonia (n = 8, 12%); hypophosphatemia (n = 6, 8%); leukocytosis, nausea, cellulitis, sepsis, and hypokalemia (n 5 5 each, 7% each); and hypertension (n = 4, 6%). Dose limiting toxicities included nausea (n = 3) and abdominal pain, anaphylactic reaction, myalgia, and rash (n = 1, each); theMTD was defined at 257 mg/m(2). CWP232204, the active metabolite of CWP291, showed pharmacokinetic linearity on both days 1 and 7, and a terminal half life of;12 hours. Among 54 response evaluable AML patients, there was one complete response at a dose of 153 mg/m(2) and one partial response at 198 mg/m(2); bone marrow blast percentage reduced from a median of 58.3% to 3.5% and 15.0% to 4.2%, respectively. Future studies will explore CWP291, with a mechanism of action aimed at eradication of earlier progenitors via Wnt pathway blockade, as combination therapy. This trial was registered at www.clinicaltrials.gov as #NCT01398462.
C1 [Lee, Je Hwan] Univ Ulsan, Assn Med Ctr, Coll Med, Seoul, South Korea.
   [Faderl, Stefan] Hackensack Univ, Canc Ctr, Hackensack, NJ USA.
   [Pagel, John M.] Swedish Canc Inst, Seattle, WA USA.
   [Jung, Chul Won] Samsung Med Ctr, Seoul, South Korea.
   [Yoon, Sung Soo; Lee, Howard] Seoul Natl Univ Hosp, Seoul, South Korea.
   [Pardanani, Animesh D.] Mayo Clin, Rochester, MN USA.
   [Becker, Pamela S.] Univ Washington, Seattle, WA 98195 USA.
   [Becker, Pamela S.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.
   [Choi, Jeongeun; Lee, Kyoungjune; Kim, Minkyoung] JW Pharmaceut, Seoul, South Korea.
   [Cortes, Jorge E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
C3 University of Ulsan; Hackensack University Medical Center; Swedish
   Cancer Institute; Swedish Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Seoul National University (SNU); Seoul
   National University Hospital; Mayo Clinic; University of Washington;
   University of Washington Seattle; Fred Hutchinson Cancer Center;
   University of Texas System; UTMD Anderson Cancer Center
RP Cortes, JE (通讯作者)，Georgia Canc Ctr, 1410 Laney Walker Rd,CN2222, Augusta, GA 30912 USA.
EM jorge.cortes@augusta.edu
RI ; Park, Jung Hyun/HJA 3755 2022; Lee, Howard/ABI 7119 2020; Becker,
   Pamela/Q 1222 2019; Yoon, Sung Soo/J 2773 2012; Cortes,
   Jorge/ABA 0627 2022; Lee, Jae Hyun/ABE 3803 2020
OI Yoon, Sung Soo/0000 0003 2591 7459; Lee, Je Hwan/0000 0002 7060 1675;
   Cortes, Jorge/0000 0002 8636 1071; 
FU JW Pharmaceuticals; JW Pharmaceutical Corporation
FX The authors thank the patients and their families for volunteering to be
   part of this clinical trial. CWP291 is being developed by JW
   Pharmaceutical (Seoul, Korea). Writing and editorial support was funded
   by JW Pharmaceuticals and provided by A. Daisy Goodrich. This study was
   funded by JW Pharmaceutical Corporation.
CR [Anonymous], [No title captured]
   Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI [10.1200/JCO.2010.34.4614, 10.1200/JOP.2011.000397]
   Benoit YD, 2017, CELL CHEM BIOL, V24, P833, DOI 10.1016/j.chembiol.2017.05.026
   Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036
   Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood 2005 10 4149
   Cortes JE, 2015, J CLIN ONCOL, V33
   Dandekar S, 2014, BRIT J HAEMATOL, V167, P87, DOI 10.1111/bjh.13011
   Fathi AT, 2019, CLIN CANCER RES, V25, P6015, DOI 10.1158/1078 0432.CCR 19 1986
   Fiskus W, 2015, LEUKEMIA, V29, P1267, DOI 10.1038/leu.2014.340
   Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017
   Guerra VA, 2019, BEST PRACT RES CL HA, V32, P145, DOI 10.1016/j.beha.2019.05.008
   Hsu SK, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102518
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kim SD, 2011, CANCER RES, V71, DOI 10.1158/1538 7445.AM2011 4518
   Le Tourneau C, 2009, JNCI J NATL CANCER I, V101, P708, DOI 10.1093/jnci/djp079
   Lento W, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008011
   Lin HH, 2016, CANCER LETT, V381, P58, DOI 10.1016/j.canlet.2016.07.013
   Masouleh BK, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045 015 0184 7
   Minke KS, 2009, EUR J HAEMATOL, V82, P165, DOI 10.1111/j.1600 0609.2008.01188.x
   Norsworthy KJ, 2019, CLIN CANCER RES, V25, P6021, DOI 10.1158/1078 0432.CCR 19 0365
   Pollyea DA, 2019, CURR OPIN HEMATOL, V26, P71, DOI 10.1097/MOH.0000000000000485
   Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007
   Simon M, 2005, ONCOGENE, V24, P2410, DOI 10.1038/sj.onc.1208431
   Stoddart A, 2017, BLOOD, V129, P2959, DOI 10.1182/blood 2016 08 736454
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Wei AH, 2019, J CLIN ONCOL, V37, P1277, DOI 10.1200/JCO.18.01600
   Xu J, 2008, BRIT J HAEMATOL, V140, P394, DOI 10.1111/j.1365 2141.2007.06914.x
   Yang Y, 2013, CANCER LETT, V333, P9, DOI 10.1016/j.canlet.2012.11.056
   Ysebaert L, 2006, LEUKEMIA, V20, P1211, DOI 10.1038/sj.leu.2404239
   Zheng HC, 2017, ONCOTARGET, V8, P59950, DOI 10.18632/oncotarget.19048
NR 30
TC 49
Z9 51
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2473 9529
EI 2473 9537
J9 BLOOD ADV
JI Blood Adv.
PD MAY 12
PY 2020
VL 4
IS 9
BP 2032
EP 2043
DI 10.1182/bloodadvances.2019000757
PG 12
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA LO2ZM
UT WOS:000533498800024
PM 32396615
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Kern, C
   Quade, M
   Ray, S
   Thomas, J
   Schumacher, M
   Gemming, T
   Gelinsky, M
   Alt, V
   Rohnke, M
AF Kern, Christine
   Quade, Mandy
   Ray, Seemun
   Thomas, Juergen
   Schumacher, Matthias
   Gemming, Thomas
   Gelinsky, Michael
   Alt, Volker
   Rohnke, Marcus
TI Investigation of strontium transport and strontium quantification in
   cortical rat bone by time of flight secondary ion mass spectrometry
SO JOURNAL OF THE ROYAL SOCIETY INTERFACE
LA English
DT Article
DE strontium; osteoporosis; diffusion; time of flight secondary ion mass
   spectrometry; bone nanostructure; quantification
ID CALCIUM PHOSPHATE CEMENTS; OSTEOGENIC DIFFERENTIATION; LOCAL DELIVERY;
   DRUG RELEASE; MARROW; OSTEOPOROSIS; MECHANISMS; RANELATE; COLLAGEN;
   IMPLANT
AB Next generation bone implants will be functionalized with drugs for stimulating bone growth. Modelling of drug release by such functionalized biomaterials and drug dispersion into bone can be used as predicting tool for biomaterials testing in future. Therefore, the determination of experimental parameters to describe and simulate drug release in bone is essential. Here, we focus on Sr2+ transport and quantification in cortical rat bone. Sr2+ dose dependently stimulates bone building osteoblasts and inhibits bone resorbing osteoclasts. It should be preferentially applied in the case of bone fracture in the context of osteoporotic bone status. Transport properties of cortical rat bone were investigated by dipping experiments of bone sections in aqueous Sr2+ solution followed by time of flight secondary ion mass spectrometry (ToF SIMS) depth profiling. Data evaluation was carried out by fitting a suitable mathematical diffusion equation to the experimental data. An average diffusion coefficient of D = (1.68 +/  0.57). 10( 13) cm(2) s( 1) for healthy cortical bone was obtained. This value differed only slightly from the value of D = (4.30 +/  1.43). 10( 13) cm(2) s( 1) for osteoporotic cortical bone. Transmission electron microscopy investigations revealed a comparable nano  and ultrastructure for both types of bone status. Additionally, Sr2+ enriched mineralized collagen standards were prepared for ToF SIMS quantification of Sr2+ content. The obtained calibration curve was used for Sr2+ quantification in cortical and trabecular bone in real bone sections. The results allow important insights regarding the Sr2+ transport properties in healthy and osteoporotic bone and can ultimately be used to perform a simulation of drug release and mobility in bone.
C1 [Kern, Christine; Rohnke, Marcus] Justus Liebig Univ Giessen, Inst Phys Chem, Heinrich Buff Ring 17, D 35392 Giessen, Germany.
   [Quade, Mandy; Schumacher, Matthias; Gelinsky, Michael] Tech Univ Dresden, Ctr Translat Bone Joint & Soft Tissue Res, Fac Med, Fetscherstr 74, D 01307 Dresden, Germany.
   [Quade, Mandy; Schumacher, Matthias; Gelinsky, Michael] Tech Univ Dresden, Univ Hosp, Fetscherstr 74, D 01307 Dresden, Germany.
   [Ray, Seemun; Alt, Volker] Justus Liebig Univ Giessen, Expt Trauma Surg, Aulweg 128, D 35392 Giessen, Germany.
   [Thomas, Juergen; Gemming, Thomas] IFW Dresden, Inst Complex Mat, Helmholtzstr 20, D 01069 Dresden, Germany.
C3 Justus Liebig University Giessen; Technische Universitat Dresden;
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   Justus Liebig University Giessen; Institute for Integrative Nanosciences
   (IIN); Leibniz Association; Leibniz Institute for Solid State &
   Materials Research Dresden
RP Rohnke, M (通讯作者)，Justus Liebig Univ Giessen, Inst Phys Chem, Heinrich Buff Ring 17, D 35392 Giessen, Germany.
EM marcus.rohnke@phys.chemie.uni giessen.de
RI Schumacher, Matthias/I 1530 2013; Gelinsky, Michael/A 9680 2012;
   Gemming, Thomas/D 3920 2015; Rohnke, Marcus/I 2815 2013
OI Schumacher, Matthias/0000 0001 7207 7355; Kern,
   Christine/0000 0003 4480 4003; Gelinsky, Michael/0000 0001 9075 5121;
   Rohnke, Marcus/0000 0002 8867 950X; Gemming, Thomas/0000 0002 7353 595X;
   
FU German Research Foundation (DFG, Collaborative Research Centre
   Transregio) [79]; Interreg [79] Funding Source: Interreg
FX This work was funded by the German Research Foundation (DFG,
   Collaborative Research Centre Transregio 79 subprojects M5, M4, T2 and
   Z2). We gratefully acknowledge the financial support within this
   project.
CR Alt V, 2013, ACTA BIOMATER, V9, P7035, DOI 10.1016/j.actbio.2013.02.002
   Andersen OZ, 2013, BIOMATERIALS, V34, P5883, DOI 10.1016/j.biomaterials.2013.04.031
   Aw MS, 2012, INT J NANOMED, V7, P4883, DOI 10.2147/IJN.S33655
   Belu AM, 2003, BIOMATERIALS, V24, P3635, DOI 10.1016/S0142 9612(03)00159 5
   Bernhardt A, 2008, J MATER SCI MATER M, V19, P269, DOI 10.1007/s10856 006 0059 0
   Boivin G, 2010, OSTEOPOROSIS INT, V21, P667, DOI 10.1007/s00198 009 1005 z
   Boudaoud A, 2014, NAT PROTOC, V9, P457, DOI 10.1038/nprot.2014.024
   Bradt JH, 1999, CHEM MATER, V11, P2694, DOI 10.1021/cm991002p
   Caprioli RM, 2015, J AM SOC MASS SPECTR, V26, P850, DOI 10.1007/s13361 015 1108 z
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Crank John., 1979, The Mathematics of Diffusion
   Fletcher JS, 2013, ANAL CHEM, V85, P610, DOI 10.1021/ac303088m
   Giers MB, 2014, J BIOMED MATER RES B, V102, P806, DOI 10.1002/jbm.b.33062
   Ginebra MP, 2012, ADV DRUG DELIVER REV, V64, P1090, DOI 10.1016/j.addr.2012.01.008
   Ginebra MP, 2006, BIOMATERIALS, V27, P2171, DOI 10.1016/j.biomaterials.2005.11.023
   Heinemann S, 2013, ACTA BIOMATER, V9, P6199, DOI 10.1016/j.actbio.2012.12.017
   Heiss C, 2012, MED SCI MONITOR, V18, pBR199, DOI 10.12659/MSM.882895
   Henss A, 2016, BIOINTERPHASES, V11, DOI 10.1116/1.4928211
   Henss A, 2013, BIOINTERPHASES, V8, DOI 10.1186/1559 4106 8 31
   Henss A, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2013.0332
   Kruppke B, 2018, J BIOMED MATER RES B, V106, P1165, DOI 10.1002/jbm.b.33931
   Li YF, 2012, CLIN ORAL IMPLAN RES, V23, P1038, DOI 10.1111/j.1600 0501.2011.02252.x
   Lode A, 2018, ACTA BIOMATER, V65, P475, DOI 10.1016/j.actbio.2017.10.036
   Maïmoun L, 2010, BONE, V46, P1436, DOI 10.1016/j.bone.2010.01.379
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McKee MD, 2012, PEDIATRIC BONE: BIOLOGY & DISEASES, 2ND EDITION, P9, DOI 10.1016/B978 0 12 382040 2.10002 4
   McLaren A, 2014, CLIN ORTHOP RELAT R, V472, P3324, DOI 10.1007/s11999 014 3493 1
   Muddiman DC, 1995, MASS SPECTROM REV, V14, P383, DOI 10.1002/mas.1280140603
   Noukrati H, 2016, MAT SCI ENG C MATER, V59, P177, DOI 10.1016/j.msec.2015.09.070
   Osterhoff G, 2016, INJURY, V47, pS11, DOI 10.1016/S0020 1383(16)47003 8
   Querido William, 2015, Biomatter, V5, pe1027847, DOI 10.1080/21592535.2015.1027847
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Reznikov N, 2014, ACTA BIOMATER, V10, P3815, DOI 10.1016/j.actbio.2014.05.024
   Rizzoli Rene, 2011, Expert Rev Clin Pharmacol, V4, P593
   Rohnke M, 2017, J CONTROL RELEASE, V262, P159, DOI 10.1016/j.jconrel.2017.07.036
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Schaepe K, 2018, ANAL CHEM, V90, P8856, DOI 10.1021/acs.analchem.8b00892
   Schumacher M, 2013, ACTA BIOMATER, V9, P9547, DOI 10.1016/j.actbio.2013.07.027
   Schumacher M, 2013, ACTA BIOMATER, V9, P7536, DOI 10.1016/j.actbio.2013.03.014
   Schumacher M, 2015, J MATER CHEM B, V3, P4626, DOI 10.1039/c5tb00654f
   Schwarcz HP, 2017, FRONT PHYS, V5, DOI 10.3389/fphy.2017.00039
   SIPS AJAM, 1995, CLIN CHEM, V41, P1446
   Specht AJ, 2017, APPL SPECTROSC, V71, P1962, DOI 10.1177/0003702817694383
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thormann U, 2013, BIOMATERIALS, V34, P8589, DOI 10.1016/j.biomaterials.2013.07.036
   Zebaze RMD, 2010, LANCET, V375, P1729, DOI 10.1016/S0140 6736(10)60320 0
   2016, ACTA BIOMATER, V37, P184, DOI DOI 10.1016/J.ACTBIO.2016.04.016
   2010, J BONE MINER RES, V25, P968, DOI DOI 10.1359/JBMR.091038
   2001, BONE, V28, P446, DOI DOI 10.1016/S8756 3282(01)00419 7
   2018, J BONE MINER METAB, V36, P297, DOI DOI 10.1007/S00774 017 0844 5
   2003, J BONE MINER RES, V18, P1082, DOI DOI 10.1359/JBMR.2003.18.6.1082
   2013, ANAL BIOANAL CHEM, V405, P8769, DOI DOI 10.1007/S00216 013 7329 8
NR 52
TC 19
Z9 19
U1 0
U2 8
PU ROYAL SOC
PI LONDON
PA 6 9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 1742 5689
EI 1742 5662
J9 J R SOC INTERFACE
JI J. R. Soc. Interface
PD FEB
PY 2019
VL 16
IS 151
AR 20180638
DI 10.1098/rsif.2018.0638
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HU6VG
UT WOS:000465418900003
PM 30958183
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Lou, D
   Ye, JF
   Yang, LH
   Wu, Z
   Zheng, W
   Zhang, H
AF Lou, Dan
   Ye, Jifeng
   Yang, Lianhua
   Wu, Zheng
   Zheng, Wei
   Zhang, Hui
TI Icariin stimulates differentiation of bone marrow derived mesenchymal
   stem cells (BM MSCs) through activation of cAMP/PKA/CREB
SO BRAZILIAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Icariin/molecular mechanisms; BM MSCs; cAMP; PKA; CREB
ID OSTEOGENIC DIFFERENTIATION; PROMOTES OSTEOGENESIS; OSTEOBLASTS; PROTEIN;
   PATHWAY
AB Icariin, a prenylated flavonol glycoside isolated from Epimedium, has been considered as a potential alternative therapy for osteoporosis. The present study aimed to clarify the detailed molecular mechanisms of action of icariin on osteoblast function, using bone marrow derived mesenchymal stem cells (BM MSCs). BM MSCs were first stimulated by icariin. Then, gene and protein expression of cAMP/PKA/CREB signaling molecules were analyzed by RT PCR and western blotting (WB), and alkaline phosphatase (ALP) was analyzed in cell lysates by ELISA. MTT assays indicated that icariin did not have significant effects on cell viability up to 1 mu M. Icariin showed a dose dependent effect on the alkaline phosphatase activity of BM MSCs. WB analysis showed that icariin treatment of BM MSCs significantly enhanced the protein expression of protein kinase A (PKA) and cAMP responsive element binding protein (CREB), while RT PCR results showed that icariin dose dependently increased the mRNA levels of PKA and CREB. Icariin induced BM MSC differentiation by BMP2, Smad1, and Runx2. RT PCR and WB results indicated that icariin significantly increased the expression of BMP2, Smad1, and Runx2 in BM MSCs. These results suggest that icariin is an agonist of the cAMP/PKA/CREB pathway in BM MSC differentiation, raising the possibility that it could be used in the treatment of osteoporosis.
C1 [Lou, Dan; Ye, Jifeng; Yang, Lianhua; Zhang, Hui] Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China.
   [Lou, Dan; Ye, Jifeng; Yang, Lianhua; Zhang, Hui] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
   [Wu, Zheng; Zheng, Wei] Harbin Univ Commerce, Harbin, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Harbin
   University of Commerce
RP Zhang, H (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Wenzhou, Peoples R China.; Zhang, H (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
EM zhanghui86577@163.com
FU National Natural Science Foundation of China [31370764]
FX The authors are grateful to the National Natural Science Foundation of
   China (31370764) for their support of this work.
CR Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19 3 180
   Carrington JL, 2005, BIOCHEM BIOPH RES CO, V328, P700, DOI 10.1016/j.bbrc.2004.12.041
   Chen BL, 2016, EXP THER MED, V11, P2399, DOI 10.3892/etm.2016.3177
   Chen KM, 2005, PHARMAZIE, V60, P939
   Dazzi F, 2006, BLOOD REV, V20, P161, DOI 10.1016/j.blre.2005.11.002
   Guo CJ, 2016, SCI REP UK, V6, DOI 10.1038/srep31318
   Hsieh TP, 2010, PHYTOMEDICINE, V17, P414, DOI 10.1016/j.phymed.2009.08.007
   Huang JM, 2017, EVID BASED COMPL ALT, V2017, DOI 10.1155/2017/8085325
   Ivanova Stefka, 2015, Folia Med (Plovdiv), V57, P181, DOI 10.1515/folmed 2015 0037
   Kim JM, 2013, J CELL PHYSIOL, V228, P617, DOI 10.1002/jcp.24171
   Li XY, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/7495135
   Li YP, 2016, J BIOL CHEM, V291, P21584, DOI 10.1074/jbc.M116.730978
   Luo ZQ, 2015, MOL MED REP, V12, P382, DOI 10.3892/mmr.2015.3369
   Ma HP, 2014, CELL PROLIFERAT, V47, P527, DOI 10.1111/cpr.12147
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Wu YQ, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05392 z
   Xu LL, 2015, CELL TISSUE RES, V359, P537, DOI 10.1007/s00441 014 2025 3
   Yang DC, 2008, PLOS ONE, V3, pe1450
   Zhang DW, 2016, CALCIFIED TISSUE INT, V99, P187, DOI 10.1007/s00223 016 0138 2
   Zhang JC, 2011, BIOL TRACE ELEM RES, V143, P1746, DOI 10.1007/s12011 011 8987 z
   Zhao L, 2006, INT J BIOCHEM CELL B, V38, P2064, DOI 10.1016/j.biocel.2006.05.015
   Zhao L, 2009, J BONE MINER RES, V24, P826, DOI [10.1359/JBMR.081236, 10.1359/jbmr.081236]
NR 22
TC 7
Z9 7
U1 2
U2 23
PU UNIV SAO PAULO, CONJUNTO QUIMICAS
PI SAO PAULO
PA SERVICO PUBLICACOES E CIRCULACAO, CAIXA POSTAL 66083, SAO PAULO, 00000,
   BRAZIL
SN 1984 8250
EI 2175 9790
J9 BRAZ J PHARM SCI
JI Braz. J. Pharm. Sci.
PY 2019
VL 55
DI 10.1590/s2175 97902019000218300
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA LA5RY
UT WOS:000524005900001
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zakaria, MF
   Sonoda, S
   Kato, H
   Ma, L
   Uehara, N
   Kyumoto Nakamura, Y
   Sharifa, MM
   Yu, LT
   Dai, LS
   Yamauchi Tomoda, E
   Aijima, R
   Yamaza, H
   Nishimura, F
   Yamaza, T
AF Zakaria, MHD. Fouad
   Sonoda, Soichiro
   Kato, Hiroki
   Ma, Lan
   Uehara, Norihisa
   Kyumoto Nakamura, Yukari
   Sharifa, M. Majd
   Yu, Liting
   Dai, Lisha
   Yamauchi Tomoda, Erika
   Aijima, Reona
   Yamaza, Haruyoshi
   Nishimura, Fusanori
   Yamaza, Takayoshi
TI Erythropoietin receptor signal is crucial for periodontal ligament stem
   cell based tissue reconstruction in periodontal disease
SO SCIENTIFIC REPORTS
LA English
DT Article
ID IN VITRO; SUSCEPTIBILITY; REGENERATION; DISRUPTION; ACTIVATION;
   LEUKEMIA; HEALTHY
AB Alveolar bone loss caused by periodontal disease eventually leads to tooth loss. Periodontal ligament stem cells (PDLSCs) are the tissue specific cells for maintaining and repairing the periodontal ligament, cementum, and alveolar bone. Here, we investigated the role of erythropoietin receptor (EPOR), which regulates the microenvironment modulating function of mesenchymal stem cells, in PDLSC based periodontal therapy. We isolated PDLSCs from patients with chronic periodontal disease and healthy donors, referred to as PD PDLSCs and Cont PDLSCs, respectively. PD PDLSCs exhibited reduced potency of periodontal tissue regeneration and lower expression of EPOR compared to Cont PDLSCs. EPOR silencing suppressed the potency of Cont PDLSCs mimicking PD PDLSCs, whereas EPO mediated EPOR activation rejuvenated the reduced potency of PD PDLSCs. Furthermore, we locally transplanted EPOR silenced and EPOR activated PDLSCs into the gingiva around the teeth of ligament induced periodontitis model mice and demonstrated that EPOR in PDLSCs participated in the regeneration of the periodontal ligament, cementum, and alveolar bone in the ligated teeth. The EPOR mediated paracrine function of PDLSCs maintains periodontal immune suppression and bone metabolic balance via osteoclasts and osteoblasts in the periodontitis model mice. Taken together, these results suggest that EPOR signaling is crucial for PDLSC based periodontal regeneration and paves the way for the development of novel options for periodontal therapy.
C1 [Zakaria, MHD. Fouad; Sonoda, Soichiro; Kato, Hiroki; Ma, Lan; Uehara, Norihisa; Kyumoto Nakamura, Yukari; Sharifa, M. Majd; Yu, Liting; Dai, Lisha; Yamaza, Takayoshi] Kyushu Univ, Grad Sch Dent Sci, Dept Mol Cell Biol & Oral Anat, 3 1 1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan.
   [Zakaria, MHD. Fouad; Nishimura, Fusanori] Kyushu Univ, Grad Sch Dent Sci, Dept Periodontol, Fukuoka, Japan.
   [Ma, Lan] Sun Yat Sen Univ, Guangdong Prov Key Lab Stomatol, South China Ctr Craniofacial Stem Cell Res, Guanghua Sch Stomatol,Hosp Stomatol, Guangzhou, Peoples R China.
   [Yamauchi Tomoda, Erika] Kyushu Univ, Grad Sch Dent Sci, Dept Oral & Maxillofacial Radiol, Fukuoka, Japan.
   [Aijima, Reona] Saga Univ, Fac Med, Dept Oral & Maxillofacial Surg, Saga, Japan.
   [Yamaza, Haruyoshi] Kyushu Univ, Grad Sch Dent Sci, Dept Pediat Dent, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Sun Yat Sen University; Kyushu
   University; Saga University; Kyushu University
RP Yamaza, T (通讯作者)，Kyushu Univ, Grad Sch Dent Sci, Dept Mol Cell Biol & Oral Anat, 3 1 1 Maidashi,Higashi Ku, Fukuoka 8128582, Japan.
EM yamazata@dent.kyushu u.ac.jp
RI Yamaza, Haruyoshi/AAD 4011 2019; Uehara, Norihisa/ABB 8106 2020; Kato,
   Hiroki/N 3495 2019
OI Zakaria, MHD Fouad/0000 0002 7591 5796; Yamaza,
   Haruyoshi/0000 0003 1138 3943; Kato, Hiroki/0000 0002 6529 659X
FU Japan Society for the Promotion of Science [JP22K19565, JP23H03071,
   JP21K16932]; JSPS KAKENHI
FX This work was supported by JSPS KAKENHI, Grant Numbers JP22K19565
   (T.Y.), JP23H03071 (T.Y.), and JP21K16932 (S.S.). We would like to thank
   Editage (https://www.editage.com) for the English language editing.
CR Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002
   Adlung L, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109507
   Akiyama M, 2011, LEUKEMIA RES, V35, P416, DOI 10.1016/j.leukres.2010.11.002
   [Anonymous], 2005, J PERIODONTOL, V76, P1406, DOI 10.1902/jop.2005.76.8.1406
   Atkins GJ, 2005, J CELL PHYSIOL, V203, P573, DOI 10.1002/jcp.20255
   Baker PJ, 2000, INFECT IMMUN, V68, P5864, DOI 10.1128/IAI.68.10.5864 5868.2000
   BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583
   Bulut GB, 2013, BLOOD, V122, P3964, DOI 10.1182/blood 2013 05 506212
   Bulut GB, 2011, J BIOL CHEM, V286, P6449, DOI 10.1074/jbc.M110.186890
   Sczepanik FSC, 2020, PERIODONTOL 2000, V84, P45, DOI 10.1111/prd.12342
   Chen C, 2014, EMBO MOL MED, V6, P322, DOI 10.1002/emmm.201303000
   Chen FM, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0288 1
   Cianci E, 2016, STEM CELL TRANSL MED, V5, P20, DOI 10.5966/sctm.2015 0163
   Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095
   Darveau RP, 2010, NAT REV MICROBIOL, V8, P481, DOI 10.1038/nrmicro2337
   Dey S, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.725734
   Feng F, 2010, ORAL DIS, V16, P20, DOI 10.1111/j.1601 0825.2009.01593.x
   Gillinder KR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180922
   Graziani F, 2017, PERIODONTOL 2000, V75, P152, DOI 10.1111/prd.12201
   Hajishengallis G, 2012, NAT REV MICROBIOL, V10, P717, DOI 10.1038/nrmicro2873
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Iwanaka T, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01630 w
   Jaskelioff M, 2011, NATURE, V469, P102, DOI 10.1038/nature09603
   Jelkmann W, 2016, FRONT HORM RES, V47, P115, DOI 10.1159/000445174
   Krampera M, 2021, CELL STEM CELL, V28, P1708, DOI 10.1016/j.stem.2021.09.006
   Kusuma GD, 2017, STEM CELLS DEV, V26, P617, DOI 10.1089/scd.2016.0349
   Lepelletier Y, 2006, EUR J IMMUNOL, V36, P1782, DOI 10.1002/eji.200535601
   Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154
   Liu DY, 2012, J CLIN PERIODONTOL, V39, P1174, DOI 10.1111/jcpe.12009
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Nagata M, 2017, TISSUE ENG PT A, V23, P367, DOI [10.1089/ten.tea.2016.0274, 10.1089/ten.TEA.2016.0274]
   Orlova A, 2018, EXPERT OPIN THER TAR, V22, P45, DOI 10.1080/14728222.2018.1406924
   Park JC, 2011, J CLIN PERIODONTOL, V38, P721, DOI 10.1111/j.1600 051X.2011.01716.x
   Perreault AA, 2018, CURR OPIN HEMATOL, V25, P189, DOI 10.1097/MOH.0000000000000415
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Polimeni G, 2006, PERIODONTOL 2000, V41, P30, DOI 10.1111/j.1600 0757.2006.00157.x
   Rando TA, 2006, NATURE, V441, P1080, DOI 10.1038/nature04958
   Ren RT, 2017, CELL METAB, V26, P460, DOI 10.1016/j.cmet.2017.07.019
   Rogers H, 2012, J BIOL CHEM, V287, P36720, DOI 10.1074/jbc.M112.378398
   Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036
   Sanchez N, 2020, J CLIN PERIODONTOL, V47, P1391, DOI 10.1111/jcpe.13368
   Schmid Holger, 2010, Cardiovascular & Hematological Agents in Medicinal Chemistry, V8, P164
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shi ST, 2002, NAT BIOTECHNOL, V20, P587, DOI 10.1038/nbt0602 587
   Shusterman A, 2013, J DENT RES, V92, P438, DOI 10.1177/0022034513484039
   Sollinger C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14366 0
   Sonoda S, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02652 8
   Sonoda S, 2021, J IMMUNOL, V206, P3053, DOI 10.4049/jimmunol.2001312
   Sonoda S, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01818 0
   Sonoda S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 21183 6
   Sonoda S, 2016, SCI REP UK, V6, DOI 10.1038/srep19286
   Sun L, 2020, J IMMUNOL, V204, P2177, DOI 10.4049/jimmunol.1900532
   Suresh S, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01534
   Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood 2002 01 0124
   Tsukasaki M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03147 6
   Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395
   Wada N, 2014, STEM CELLS DEV, V23, P2225, DOI 10.1089/scd.2013.0405
   Wada N, 2009, J CELL PHYSIOL, V219, P667, DOI 10.1002/jcp.21710
   Wang LY, 2018, INT J MOL MED, V41, P829, DOI 10.3892/ijmm.2017.3294
   Wesdorp MA, 2023, BIOACT MATER, V20, P627, DOI 10.1016/j.bioactmat.2022.05.036
   Xia Y, 2016, J PERIODONTOL, V87, pE53, DOI 10.1902/jop.2015.150462
   Yamaza H, 2018, ORAL DIS, V24, P809, DOI 10.1111/odi.12827
   Yamaza H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1042 7
   Yamaza T, 2011, J DENT RES, V90, P317, DOI 10.1177/0022034510387796
   Yamaza T, 2022, MOL METAB, V66, DOI 10.1016/j.molmet.2022.101599
   Yamaza T, 2009, BLOOD, V113, P2595, DOI 10.1182/blood 2008 10 182246
   Zheng DH, 2019, DRUG DES DEV THER, V13, P2543, DOI 10.2147/DDDT.S214116
   Zheng DH, 2019, CHEM BIOL INTERACT, V305, P40, DOI 10.1016/j.cbi.2019.03.007
   Zheng W, 2015, INT J MOL MED, V36, P915, DOI 10.3892/ijmm.2015.2314
   ZON LI, 1991, P NATL ACAD SCI USA, V88, P10638, DOI 10.1073/pnas.88.23.10638
NR 70
TC 4
Z9 4
U1 1
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 20
PY 2024
VL 14
IS 1
AR 6719
DI 10.1038/s41598 024 57361 y
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA MG4I1
UT WOS:001192455600067
PM 38509204
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Fu, Y
   Cui, SJ
   Zhou, YH
   Qiu, LX
AF Fu, Yu
   Cui, Shengjie
   Zhou, Yanheng
   Qiu, Lixin
TI Dental Pulp Stem Cell Derived Exosomes Alleviate Mice Knee
   Osteoarthritis by Inhibiting TRPV4 Mediated Osteoclast Activation
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE osteoarthritis; TRPV4; exosome; osteoclast
ID CHANNEL; TRPV4; HIP
AB Osteoarthritis (OA) is a degenerative disease that causes chronic pain and joint swelling and even disables millions of patients. However, current non surgical treatment for OA can only relieve pain without obvious cartilage and subchondral bone repair. Mesenchymal stem cell (MSC) secreted exosomes have promising therapeutic effects on knee OA, but the efficacy of MSC exosome therapy is not well determined, and the mechanisms involved are still unclear. In this study, we isolated dental pulp stem cell (DPSC) derived exosomes by ultracentrifugation and determined the therapeutic effects of a single intra articular injection of DPSC derived exosomes in a mice knee OA model. The results showed that the DPSC derived exosomes effectively improved abnormal subchondral bone remodeling, inhibited the occurrence of bone sclerosis and osteophytes, and alleviated cartilage degradation and synovial inflammation in vivo. Moreover, transient receptor potential vanilloid 4 (TRPV4) was activated during the progression of OA. Enhanced TRPV4 activation facilitated osteoclast differentiation, and TRPV4 inhibition blocked this process in vitro. DPSC derived exosomes repressed osteoclast activation in vivo by inhibiting TRPV4 activation. Our findings demonstrated that a topical, single injection of DPSC derived exosomes is a potential strategy for knee OA treatment, and that the exosomes regulated osteoclast activation by TRPV4 inhibition, which may act as a promising target for clinical OA treatment.
C1 [Fu, Yu; Qiu, Lixin] Peking Univ Sch & Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Clin Div 4, Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing 100081, Peoples R China.
   [Cui, Shengjie; Zhou, Yanheng] Peking Univ Sch & Hosp Stomatol, Hosp Stomatol, Natl Ctr Stomatol,Dept Orthodont, Natl Clin Res Ctr Oral Dis,Natl Engn Res Ctr Oral, Beijing 100081, Peoples R China.
RP Fu, Y (通讯作者)，Peking Univ Sch & Hosp Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Clin Div 4, Natl Engn Res Ctr Oral Biomat & Digital Med Device, Beijing 100081, Peoples R China.
EM fuyu@bjmu.edu.cn
OI Fu, Yu/0000 0002 9792 4749
CR Agarwal P, 2021, NAT BIOMED ENG, V5, P1472, DOI 10.1038/s41551 021 00691 3
   Al Madhoun A, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.717624
   Burchard R, 2019, J ORTHOP SURG RES, V14, DOI 10.1186/s13018 019 1203 0
   Cao BR, 2019, J CELL PHYSIOL, V234, P6831, DOI 10.1002/jcp.27432
   Charlesworth J, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2525 0
   Clark AL, 2010, ARTHRITIS RHEUM US, V62, P2973, DOI 10.1002/art.27624
   Cosenza S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15376 8
   Cui SJ, 2020, J DENT RES, V99, P446, DOI 10.1177/0022034520901710
   Delle Monache S, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10051056
   Delle Monache S, 2019, STEM CELLS DEV, V28, P695, DOI 10.1089/scd.2018.0192
   Denadai Souza A, 2012, ARTHRITIS RHEUM US, V64, P1848, DOI 10.1002/art.34345
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dutta B, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.570195
   Edwards MH, 2017, OSTEOARTHR CARTILAGE, V25, P1478, DOI 10.1016/j.joca.2017.03.011
   Eitan E, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26373
   Freitag J, 2019, REGEN MED, V14, P213, DOI 10.2217/rme 2018 0161
   Fu S, 2021, OSTEOARTHR CARTILAGE, V29, P89, DOI 10.1016/j.joca.2020.08.002
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Gui T, 2022, J BONE MINER RES, V37, P2498, DOI 10.1002/jbmr.4717
   He BH, 2017, OSTEOARTHR CARTILAGE, V25, P2091, DOI 10.1016/j.joca.2017.08.012
   He L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 01781 w
   Hinata M, 2018, PAIN, V159, P939, DOI 10.1097/j.pain.0000000000001169
   Ji LJ, 2019, IMMUNOL RES, V67, P432, DOI 10.1007/s12026 019 09088 6
   Jin SS, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12912
   Jones IA, 2019, NAT REV RHEUMATOL, V15, P77, DOI 10.1038/s41584 018 0123 4
   Kolasinski SL, 2020, ARTHRIT CARE RES, V72, P149, DOI [10.1002/art.41142, 10.1002/acr.24131]
   Kraus VB, 2015, OSTEOARTHR CARTILAGE, V23, P1233, DOI 10.1016/j.joca.2015.03.036
   Lee WS, 2019, STEM CELL TRANSL MED, V8, P504, DOI 10.1002/sctm.18 0122
   Li DH, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.00304
   Makris EA, 2015, NAT REV RHEUMATOL, V11, P21, DOI 10.1038/nrrheum.2014.157
   Masuda K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052269
   Masuyama R, 2012, J BONE MINER RES, V27, P1708, DOI 10.1002/jbmr.1629
   Matas J, 2019, STEM CELL TRANSL MED, V8, P215, DOI 10.1002/sctm.18 0053
   Mattei V, 2021, STEM CELL REV REP, V17, P1635, DOI 10.1007/s12015 021 10162 6
   Pigott JH, 2013, VET COMP ORTHOPAED, V26, P453, DOI 10.3415/VCOT 13 01 0008
   Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318
   Uritani D, 2023, INT J RHEUM DIS, V26, P425, DOI 10.1111/1756 185X.14536
   Xiang XN, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 021 02689 9
   Xie QX, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02011 z
   Xu B, 2019, LIFE SCI, V228, P158, DOI 10.1016/j.lfs.2019.05.003
   Yang RL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04464 6
   Zeng CY, 2021, FRONT PHYSIOL, V12, DOI 10.3389/fphys.2021.794062
   Zhang SP, 2019, BIOMATERIALS, V200, P35, DOI 10.1016/j.biomaterials.2019.02.006
   Zhang SP, 2018, BIOMATERIALS, V156, P16, DOI 10.1016/j.biomaterials.2017.11.028
   Zhao XG, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.575057
   Zhen GH, 2013, NAT MED, V19, P704, DOI 10.1038/nm.3143
NR 46
TC 21
Z9 22
U1 7
U2 49
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2023
VL 24
IS 5
AR 4926
DI 10.3390/ijms24054926
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 9T2NV
UT WOS:000946869300001
PM 36902356
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU López Cuevas, P
   Deane, L
   Yang, YS
   Hammond, CL
   Kague, E
AF Lopez Cuevas, Paco
   Deane, Luke
   Yang, Yushi
   Hammond, Chrissy L.
   Kague, Erika
TI Transformed notochordal cells trigger chronic wounds in zebrafish,
   destabilizing the vertebral column and bone homeostasis
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Chordoma; Notochord; Vertebral column; Zebrafish intervertebral disc;
   Inflammation; Bone homeostasis
ID GENE EXPRESSION; CHORDOMA; MODEL; IMAGE; DIFFERENTIATION; DEGENERATION;
   REGENERATION; THERAPIES; MELANOMA; INVASION
AB Notochordal cells play a pivotal role in vertebral column patterning, contributing to the formation of the inner architecture of intervertebral discs (IVDs). Their disappearance during development has been associated with reduced repair capacity and IVD degeneration. Notochor d cells can give rise to chordomas, a highly invasive bone cancer associated with late diagnosis. Understanding the impact of neoplastic cells during development and on the surrounding vertebral column could open avenues for earlier intervention and therapeutics. We investigated the impact of transformed notochord cells in the zebrafish skeleton using a line expressing RAS in the notochor d under the control of the kita promoter, with the advantage of adulthood endurance. Transformed cells caused damage in the notochord and destabilised the sheath layer, triggering a wound repair mechanism, with enrolment of sheath cells (col9a2(+)) and expression of wt1b, similar to induced notochord wounds. Moreover, increased recruitment of neutrophils and macrophages, displaying abnormal behaviour in proximity to the notochor d sheath and transformed cells, supported parallels between chordomas, wound and inflammation. Cancerous notochordal cells interfere with differentiation of sheath cells to form chordacentra domains, leading to fusions and vertebral clefts during development. Adults displayed IVD irregularities reminiscent of degeneration, including reduced bone mineral density and increased osteoclast activity, along with disorganised osteoblasts and collagen, indicating impaired bone homeostasis. By depleting inflammatory cells, we abrogated chordoma development and rescued the skeletal features of the vertebral column. Therefore, we showed that transformed notochor d cells alter the skeleton during life, causing a wound like phenotype and activating chronic wound response, suggesting parallels between chordoma, wound, IVD degeneration and inflammation, highlighting inflammation as a promising target for future therapeutics. This article has an associated First Person interview with the first author of the paper.
C1 [Lopez Cuevas, Paco; Deane, Luke] Univ Bristol, Sch Biochem, Biomed Sci Bldg, Bristol BS8 1TD, Avon, England.
   [Yang, Yushi] Univ Bristol, Sch Phys, HH Wills Phys Lab, Bristol BS8 1TL, Avon, England.
   [Yang, Yushi] Univ Bristol, Ctr Nanosci & Quantum Informat, Bristol BS8 1FD, Avon, England.
   [Yang, Yushi] Univ Bristol, Bristol Ctr Funct Nanomat, Bristol BS8 1TL, Avon, England.
   [Hammond, Chrissy L.; Kague, Erika] Univ Bristol, Sch Physiol Pharmacol & Neurosci, Biomed Sci, Bristol BS8 1TD, Avon, England.
C3 University of Bristol; University of Bristol; University of Bristol;
   University of Bristol; University of Bristol
RP Kague, E (通讯作者)，Univ Bristol, Sch Physiol Pharmacol & Neurosci, Biomed Sci, Bristol BS8 1TD, Avon, England.
EM erika.kague@bristol.ac.uk
RI ; Yang, Yushi/LTC 9600 2024; Hammond, Chrissy/D 6568 2013
OI Kague, Erika/0000 0002 0266 9424; Hammond, Chrissy/0000 0002 4935 6724;
   Lopez Cuevas, Paco/0000 0002 2963 6438; Deane, Luke/0000 0003 4026 7925
FU Versus Arthritis [21937, 21211]; Fundacion Rafael del Pino; generous
   Bristol Cancer Bequest; China Scholarship Council; Medical Research
   Council (MRC)/UK Research and Innovation [MR/N0137941/1]; Versus
   Arthritis [21937] Funding Source: researchfish; Versus Arthritis; Cancer
   Research UK [21211] Funding Source: researchfish
FX E.K. and C.L.H. were funded by Versus Arthritis (21937, 21211). P.L. C.
   was funded by Fundacion Rafael del Pino, and by a generous Bristol
   Cancer Bequest. Y.Y. was funded by the China Scholarship Council. This
   work was supported by grant MR/N0137941/1 for the GW4 BioMed Doctoral
   Training Partnership, awarded to the Universities of Bath, Bristol,
   Cardiff and Exeter from the Medical Research Council (MRC)/UK Research
   and Innovation.
CR Anelli V, 2009, ZEBRAFISH, V6, P417, DOI 10.1089/zeb.2009.0612
   Bagwell J, 2020, ELIFE, V9, DOI 10.7554/eLife.51221
   Barry JJ, 2011, NEUROSURGERY, V68, P231, DOI 10.1227/NEU.0b013e3181fd2ac5
   Bensimon Brito A, 2016, BMC DEV BIOL, V16, DOI 10.1186/s12861 016 0102 4
   Bergen DJM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00006
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brunt LH, 2017, DEVELOPMENT, V144, P2798, DOI 10.1242/dev.153528
   Burger A, 2014, DIS MODEL MECH, V7, P907, DOI 10.1242/dmm.013128
   Carrington B, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv802
   Chia K, 2018, ELIFE, V7, DOI 10.7554/eLife.31918
   Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805
   Chugh R, 2007, ONCOLOGIST, V12, P1344, DOI 10.1634/theoncologist.12 11 1344
   D'Agati G, 2019, DIS MODEL MECH, V12, DOI 10.1242/dmm.039545
   Dallas SL, 2010, ANN NY ACAD SCI, V1192, P437, DOI 10.1111/j.1749 6632.2009.05246.x
   DEBRUINE FT, 1988, AM J ROENTGENOL, V150, P861, DOI 10.2214/ajr.150.4.861
   Distel M, 2009, P NATL ACAD SCI USA, V106, P13365, DOI 10.1073/pnas.0903060106
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Eming SA, 2017, SCIENCE, V356, P1026, DOI 10.1126/science.aam7928
   Feng Y, 2016, GENES DIS, V3, P178, DOI 10.1016/j.gendis.2016.04.005
   Feng Y, 2012, CURR BIOL, V22, P1253, DOI 10.1016/j.cub.2012.05.010
   Feng Y, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000562
   Fleming A, 2004, DEVELOPMENT, V131, P873, DOI 10.1242/dev.00952
   Forero LL, 2018, ELIFE, V7, DOI 10.7554/eLife.33843
   Freisinger CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112183
   Garcia J, 2017, CURR BIOL, V27, P1982, DOI 10.1016/j.cub.2017.05.035
   GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, 2017, Lancet, V390, P1211, DOI 10.1016/S0140 6736(17)32154 2
   Hall C, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471 213X 7 42
   Hayes AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075787
   Huitema LFA, 2012, P NATL ACAD SCI USA, V109, P21372, DOI 10.1073/pnas.1214231110
   Kague E, 2018, DEV BIOL, V435, P176, DOI 10.1016/j.ydbio.2018.01.021
   Kague E, 2019, FASEB J, V33, P9116, DOI 10.1096/fj.201802654RR
   Katsuura Y, 2019, GLOB SPINE J, V9, P666, DOI 10.1177/2192568218801016
   Liongue C, 2009, BLOOD, V113, P2535, DOI 10.1182/blood 2008 07 171967
   Lopez Baez JC, 2018, ELIFE, V7, DOI 10.7554/eLife.30657
   MacCarthy Morrogh L, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8690
   Mai NC, 2014, DIS MODEL MECH, V7, P871, DOI 10.1242/dmm.014498
   McMaster ML, 2011, J MED GENET, V48, P444, DOI 10.1136/jmg.2010.085092
   Novais EJ, 2020, AGING CELL, V19, DOI 10.1111/acel.13148
   Öner AY, 2006, ACTA RADIOL, V47, P875, DOI 10.1080/02841850600771700
   Pereira M, 2018, J CELL SCI, V131, DOI 10.1242/jcs.216267
   Perner B, 2007, DEV BIOL, V309, P87, DOI 10.1016/j.ydbio.2007.06.022
   Peskin B, 2020, CURR BIOL, V30, P2805, DOI 10.1016/j.cub.2020.05.037
   Pogoda HM, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.159418
   Renshaw SA, 2012, DIS MODEL MECH, V5, P38, DOI 10.1242/dmm.007138
   Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014
   Risbud MV, 2014, NAT REV RHEUMATOL, V10, P44, DOI 10.1038/nrrheum.2013.160
   Rodrigues Pinto R, 2014, EUR SPINE J, V23, P1803, DOI 10.1007/s00586 014 3305 z
   Roh Johnson M, 2017, DEV CELL, V43, P549, DOI 10.1016/j.devcel.2017.11.003
   SALISBURY JR, 1993, J PATHOL, V171, P253, DOI 10.1002/path.1711710404
   Santoriello C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015170
   Schäfer M, 2008, NAT REV MOL CELL BIO, V9, P628, DOI 10.1038/nrm2455
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Singh SP, 2012, DEV CELL, V22, P879, DOI 10.1016/j.devcel.2012.03.006
   Stacchiotti S, 2017, ANN ONCOL, V28, P1230, DOI 10.1093/annonc/mdx054
   Stemple DL, 2005, DEVELOPMENT, V132, P2503, DOI 10.1242/dev.01812
   Sun XD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14169 z
   Terpilowski M., 2019, Journal of Open Source Software, V4, P1169, DOI DOI 10.21105/JOSS.01169
   van den Berg MCW, 2019, CELL REP, V27, P2837, DOI 10.1016/j.celrep.2019.05.029
   van der Walt S, 2014, PEERJ, V2, DOI 10.7717/peerj.453
   Virtanen P, 2020, NAT METHODS, V17, P261, DOI 10.1038/s41592 019 0686 2
   Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969
   Walker MB, 2007, BIOTECH HISTOCHEM, V82, P23, DOI 10.1080/10520290701333558
   Wang F, 2017, ONCOTARGET, V8, P57800, DOI 10.18632/oncotarget.18101
   WESTERFIELD M, 1993, ZEBRAFISH BOOK GUIDE
   White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002
   Wopat S, 2018, CELL REP, V22, P2026, DOI 10.1016/j.celrep.2018.01.084
   Yang LL, 2020, ELIFE, V9, DOI 10.7554/eLife.58191
   Zheng CJ, 2015, THEOR BIOL MED MODEL, V12, DOI 10.1186/s12976 015 0020 3
NR 69
TC 11
Z9 12
U1 0
U2 12
PU COMPANY BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND
SN 1754 8403
EI 1754 8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD MAR
PY 2021
VL 14
IS 3
AR dmm047001
DI 10.1242/dmm.047001
PG 17
WC Cell Biology; Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine; Pathology
GA RH4VS
UT WOS:000636218900001
PM 33579726
OA gold, Green Submitted, Green Published
DA 2025 08 17
ER

PT J
AU Suzuki, A
   Sugiyama, G
   Ohyama, Y
   Kumamaru, W
   Yamada, T
   Mori, Y
AF Suzuki, Azusa
   Sugiyama, Goro
   Ohyama, Yukiko
   Kumamaru, Wataru
   Yamada, Tomohiro
   Mori, Yoshihide
TI Regulation of NF kB Signalling Through the PR55β RelA Interaction in
   Osteoblasts
SO IN VIVO
LA English
DT Article
DE FGF2; NF kB; RelA; osteoblast; PR55 beta; PP2A
ID KAPPA B; TRANSCRIPTION FACTORS; PP2A; PHOSPHORYLATION; ACTIVATION; FGF;
   INHIBITION; P65
AB Background/Aim: Nuclear factor kappa B (NF kB) signalling including the RelA subunit is activated upon fibroblast growth factor (FGF) stimulation. A clear understanding of the mechanisms underlying this action will provide insights into molecular targeting therapy. Furthermore, protein phosphatase 2A (PP2A) is involved in RelA dephosphorylation, but little is known about the underlying mechanism. Materials and Methods: Because the regulatory subunits of PP2A drive NF kB signalling via RelA, we used qRT PCR and immunoblot analysis to investigate the expression of these subunits in MC3T3 E1 cells. We examined weather FGF2 interacts with NF kB using immunocytochemistry (IC), immunoprecipitation (IP), and pull down assay (PD) using recombinant proteins. Results: PR55 beta expression was increased, whereas activated RelA was dephosphorylated upon FGF2 stimulation. Further, the interaction of PR55 beta with RelA was confirmed by IC, IP, and PD. Conclusion: FGF2 induced PR55 beta directly interacts with RelA and regulates NF kB signalling.
C1 [Suzuki, Azusa; Sugiyama, Goro; Ohyama, Yukiko; Kumamaru, Wataru; Yamada, Tomohiro; Mori, Yoshihide] Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Surg, Fukuoka 8128582, Japan.
C3 Kyushu University
RP Sugiyama, G (通讯作者)，Kyushu Univ, Fac Dent Sci, Div Maxillofacial Diagnost & Surg Sci, Sect Oral & Maxillofacial Surg, Fukuoka 8128582, Japan.
EM gs5603@dent.kyushu u.ac.jp
RI Yamada, Tomohiro/JRX 9195 2023
CR AGGARWAL BB, 1995, EXP CELL RES, V218, P381, DOI 10.1006/excr.1995.1169
   Andersen TL, 2010, BRIT J HAEMATOL, V148, P551, DOI 10.1111/j.1365 2141.2009.07980.x
   Barisic S, 2008, CELL DEATH DIFFER, V15, P1681, DOI 10.1038/cdd.2008.98
   Breuer R, 2014, J BIOL CHEM, V289, P14996, DOI 10.1074/jbc.M113.533547
   Byrd VM, 1999, J IMMUNOL, V162, P5853
   Dapunt U, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/728619
   Fujihara C, 2019, J CELL PHYSIOL, V234, P7149, DOI 10.1002/jcp.27469
   Gugasyan R, 2000, IMMUNOL REV, V176, P134
   Hayden MS, 2006, ONCOGENE, V25, P6758, DOI 10.1038/sj.onc.1209943
   Ishibashi K, 2018, CANCER GENOM PROTEOM, V15, P53, DOI 10.21873/cgp.20064
   Jiang X, 2003, J BIOL CHEM, V278, P919, DOI 10.1074/jbc.M208696200
   Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749 6632.2009.05210.x
   Marie PJ, 2003, GENE, V316, P23, DOI 10.1016/S0378 1119(03)00748 0
   Osathanon T, 2011, J CELL BIOCHEM, V112, P1807, DOI 10.1002/jcb.23097
   Reale C, 2018, VITAM HORM, V106, P195, DOI 10.1016/bs.vh.2017.05.003
   REILAND J, 1993, J CELL SCI, V105, P1085
   RETTIG WJ, 1994, J CELL SCI, V107, P487
   Saraf A, 2010, BIOCHEMISTRY US, V49, P986, DOI 10.1021/bi902160t
   Schild A, 2006, INT J DEV NEUROSCI, V24, P437, DOI 10.1016/j.ijdevneu.2006.08.005
   Schmidt K, 2002, EUR J NEUROSCI, V16, P2039, DOI 10.1046/j.1460 9568.2002.02274.x
   SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576
   Tan J, 2010, CANCER CELL, V18, P459, DOI 10.1016/j.ccr.2010.10.021
   Tepper OM, 2004, FASEB J, V18, P1231, DOI 10.1096/fj.03 0847fje
   Wang X, 2000, ONCOGENE, V19, P2346, DOI 10.1038/sj.onc.1203558
   Yoshida K, 2018, MOL CELL ENDOCRINOL, V470, P251, DOI 10.1016/j.mce.2017.11.005
NR 25
TC 7
Z9 10
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258 851X
EI 1791 7549
J9 IN VIVO
JI In Vivo
PD MAR APR
PY 2020
VL 34
IS 2
BP 601
EP 608
DI 10.21873/invivo.11813
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA KS2ML
UT WOS:000518144400016
PM 32111759
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Whitfield, JF
AF Whitfield, JF
TI Parathyroid hormone (PTH) and hematopoiesis: New support for some old
   observations
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE adenylyl cyclase; apoptosis; beta catenin; bone marrow transplants;
   CFU S (colony forming units spleen); cyclic AMP; hematopoiesis; HSC
   (hematopoietic stem cells); Jagged 1; N cadherin; Notch receptors; PTH
   (parathyroid hormone); PTHR1 receptor; stem cell niche; trabecular
   bone lining cells; Wnt; X radiation
ID APOPTOTIC PROTEIN BAD; RAT BONE MARROW; STEM CELL; IN VITRO; SPATIAL
   DISTRIBUTIONS; PHOSPHORYLATION; STIMULATION; RADIATION; PROLIFERATION;
   INDUCTION
AB Forty seven years ago, the parathyroid hormone (PTH) in one injection of Lilly's old bovine parathyroid extract, PTE, was found to greatly increase the 30 day survival of heavily X irradiated rats when given from 18h before to as long as 3 h after irradiation but no later. This was the first indication that PTH might stimulate hematopoiesis. Recent studies have confirmed the relation between PTH and hematopoiesis by showing that hPTH (1 34)OH increases the size of the hematopoietic stem cell pool in mice. The peptide operates through a cyclic AMP mediated burst of jagged I production in osteoblastic cells lining the stem cells' niches on trabecular bone surfaces. The osteoblastic cells' jagged I increases the hematopoietic stem cell pool by activating Notch receptors on attached stem cells. PTH triggered cyclic AMP signals also directly stimulate the proliferation of the hematopoietic stem cells. However, the single PTH injection in the early experiments using PTE probably increased the survival of irradiated rats mainly by preventing the damaged hematopoietic progenitors from irreversibly initiating self destructive apoptogenesis during the first 5 h after irradiation. It has also been shown that several daily injections of hPTH (1 34)OH enable lethally irradiated mice to survive by stimulating the growth of transplanted normal bone marrow cells. If the osteogenic PTHs currently entering or on the verge of entering the market for treating osteoporosis can also drive hematopoiesis in humans as well as rodents, they could be potent tools for reducing the damage inflicted on bone marrow by cytotoxic cancer chemotherapeutic drugs and ionizing radiation.
C1 Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
C3 National Research Council Canada
RP Whitfield, JF (通讯作者)，Natl Res Council Canada, Inst Biol Sci, Montreal Rd Campus, Ottawa, ON K1A 0R6, Canada.
EM pthosteo@rogers.com
CR BECKER AJ, 1965, BLOOD J HEMATOL, V26, P296, DOI 10.1182/blood.V26.3.296.296
   Bellido T, 2001, J BONE MINER RES, V16, pS203
   Bertho JM, 2004, INT J RADIAT BIOL, V80, P73, DOI 10.1080/09553000310001642894
   BYRON JW, 1977, CYCLIC NUCLEOTIDES R, P81
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Chae HJ, 2001, BIOL PHARM BULL, V24, P453, DOI 10.1248/bpb.24.453
   Chen XD, 2004, J BONE MINER RES, V19, pS76
   Drouet M, 1999, STEM CELLS, V17, P273, DOI 10.1002/stem.170273
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   FINDIK D, 1995, J CELL BIOCHEM, V57, P12, DOI 10.1002/jcb.240570103
   GALLIENLARTIGUE O, 1974, CR ACAD SCI D NAT, V278, P1765
   Garcia Bermejo L, 1998, J CELL SCI, V111, P637
   Goud SR, 1999, TOXICOLOGY, V135, P69, DOI 10.1016/S0300 483X(99)00037 2
   Hastings RH, 2004, AM J PHYSIOL CELL PH, V287, pC1616, DOI 10.1152/ajpcell.00300.2004
   KELLER G, 1992, CURR TOP MICROBIOL, V177, P41
   Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356 9363.2000
   LORD BI, 1990, INT J CELL CLONING, V8, P317, DOI 10.1002/stem.5530080501
   LORD BI, 1975, BLOOD, V46, P65
   Marie PJ, 2002, J CELL PHYSIOL, V190, P297, DOI 10.1002/jcp.10073
   Martin MC, 2005, J BIOL CHEM, V280, P15449, DOI 10.1074/jbc.M414325200
   MASON TM, 1989, BRIT J HAEMATOL, V73, P455, DOI 10.1111/j.1365 2141.1989.tb00280.x
   MITHAL A, 2003, ENDOCRIN UPDAT SER, V19, P1
   Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272
   Nemeth EF, 2001, J PHARMACOL EXP THER, V299, P323
   Nilsson SK, 2001, BLOOD, V97, P2293, DOI 10.1182/blood.V97.8.2293
   Peng Ruiyun, 1999, Journal of Environmental Pathology Toxicology and Oncology, V18, P305
   Peng Ruiyun, 1998, Journal of Environmental Pathology Toxicology and Oncology, V17, P129
   PERRIS AD, 1971, AM J PHYSIOL, V220, P773, DOI 10.1152/ajplegacy.1971.220.3.773
   PERRIS AD, 1971, CAN J PHYSIOL PHARM, V49, P22, DOI 10.1139/y71 004
   PERRIS AD, 1966, NATURE, V216, P150
   Plotkin LI, 2002, J BONE MINER RES, V17, pS166
   POTTS JT, 1971, P NATL ACAD SCI USA, V68, P63, DOI 10.1073/pnas.68.1.63
   Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593
   RIXON RH, 1972, J CELL PHYSIOL, V79, P343, DOI 10.1002/jcp.1040790304
   RIXON RH, 1970, EXP CELL RES, V63, P110, DOI 10.1016/0014 4827(70)90337 X
   RIXON RH, 1969, RADIAT RES, V40, P601, DOI 10.2307/3573013
   RIXON RH, 1958, NATURE, V182, P1374, DOI 10.1038/1821374a0
   RIXON RH, 1961, INT J RADIAT BIOL RE, V3, P361, DOI 10.1080/09553006114550421
   SCHOFIELD R, 1979, CLIN HAEMATOL, V8, P221
   SCHOFIELD R, 1978, BLOOD CELLS, V4, P7
   Selye H, 1932, ENDOCRINOLOGY, V16, P547, DOI 10.1210/endo 16 5 547
   Sowa H, 2003, J BIOL CHEM, V278, P52240, DOI 10.1074/jbc.M302566200
   Staal FJT, 2005, NAT REV IMMUNOL, V5, P21, DOI 10.1038/nri1529
   SUVA LJ, 1994, J BONE MINER RES, V9, pS123
   SWIERENGA SHH, 1976, J IMMUNOL, V117, P1608
   Till J., 1961, Radiation Research, V14, P1419
   TREGEAR GW, 1974, H S Z PHYSIOL CHEM, V355, P415, DOI 10.1515/bchm2.1974.355.1.415
   Vávrová J, 2002, FOLIA BIOL PRAGUE, V48, P51
   Virdee K, 2000, CURR BIOL, V10, P1151, DOI 10.1016/S0960 9822(00)00702 8
   Whitfield JF, 2005, EXPERT OPIN INV DRUG, V14, P251, DOI 10.1517/13543784.14.3.251
   Whitfield JF, 2004, J CELL BIOCHEM, V93, P251, DOI 10.1002/jcb.20216
   Whitfield JF, 2005, J CELL BIOCHEM, V95, P437, DOI 10.1002/jcb.20424
   WHITFIELD JF, 1965, 2485E EUR EUR AT EN
   WHITFIELD JF, 2005, GROWING BONE
   Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611
   Zhang JW, 2003, NATURE, V425, P836, DOI 10.1038/nature02041
   Zhu J, 2004, BIOESSAYS, V26, P595, DOI 10.1002/bies.20052
NR 57
TC 13
Z9 18
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0730 2312
EI 1097 4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT 1
PY 2005
VL 96
IS 2
BP 278
EP 284
DI 10.1002/jcb.20526
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 968ND
UT WOS:000232168300005
PM 16088941
DA 2025 08 17
ER

PT J
AU Yao, XW
   Liu, HD
   Ren, MX
   Li, TL
   Jiang, WK
   Zhou, Z
   Liu, ZY
   Yang, M
AF Yao, Xue Wei
   Liu, He Dong
   Ren, Mao Xian
   Li, Tian Lin
   Jiang, Wen Kai
   Zhou, Zhi
   Liu, Zhi Yi
   Yang, Min
TI Aloe polysaccharide promotes osteogenesis potential of adipose derived
   stromal cells via BMP 2/Smads and prevents ovariectomized induced
   osteoporosis
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE BMP 2; Smads signaling pathway; Adipose derived stromal cells; Aloe
   polysaccharide; Osteoporosis
ID POSTMENOPAUSAL OSTEOPOROSIS; OSTEOBLAST; PROTEIN; DIFFERENTIATION;
   FRACTURE; VERA
AB Background Aloe polysaccharide (AP) is a type of an active macromolecule of Aloe vera, which contributes to its function. However, whether AP possesses anti osteoporosis properties is unknown. Methods Adipose derived stromal cells were treated with different concentrations of AP. Early and late osteogenesis were, respectively, evaluated by ALP and Alizarin Red S staining. The effect of AP on the processes of adipogenesis inhibition in ADSCs was analyzed by oil red O staining. Western blot was used to assess the expression of osteogenic and adipogenic related factors. Then, Noggin was administered to further confirm the mechanism by which AP promotes the osteogenesis of ADSCs. Finally, 40 female SD rats were classified into a bilateral laparotomy group (Sham group) and three bilateral ovariectomy groups: OVX group, OVX + AP group, and OVX + AP + Noggin group. The bilateral rat femurs were collected to perform micro CT scanning, HE, Masson trichrome, and Oil red O staining. Results The results indicated that AP could increase ALP expression and calcium deposition. Through molecular mechanisms, AP promotes the protein expression of COL1A1, OPN, and ALP in ADSCs, but downregulates the expression of PPAR gamma. Also, AP directs ADSCs' fate by stimulating the BMP2/Smads signaling pathway. In vivo, the rat AP treated had more trabecular bone than the OVX rat, indicating partial protection from cancellous bone loss after treatment with AP. Conclusion Our results show that AP may promote osteogenesis of ADSCs through BMP 2/Smads signaling pathway and inhibits lipogenic differentiation. Thus, AP might be a promising alternative medicine to treat postmenopausal osteoporosis.
C1 [Yao, Xue Wei; Liu, He Dong; Ren, Mao Xian; Li, Tian Lin; Jiang, Wen Kai; Zhou, Zhi; Liu, Zhi Yi; Yang, Min] Yijishan Hosp, Wannan Med Coll, Dept Trauma Orthoped, Affiliated Hosp 1, 2 Zheshan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
C3 Wannan Medical College
RP Yang, M (通讯作者)，Yijishan Hosp, Wannan Med Coll, Dept Trauma Orthoped, Affiliated Hosp 1, 2 Zheshan Xi Rd, Wuhu 241001, Anhui, Peoples R China.
EM pkuyang@hotmail.com
RI Jiang, Wenkai/A 3148 2016; Yang, Min/HPH 9264 2023
OI Yang, Min/0000 0003 1231 3269
FU National Natural Science Foundation of China [81341054, 81171732];
   Talented Scholars of Wannan Medical College [YR202226]; Technology
   Mountaineering Program of Yijishan Hospital; Wannan Medical College
   [PF2019005]
FX This study was supported by the National Natural Science Foundation of
   China (81341054, 81171732), Talented Scholars of Wannan Medical College
   (YR202226), Technology Mountaineering Program of Yijishan Hospital, and
   Wannan Medical College (PF2019005).
CR An Y, 2019, BIOCHEM BIOPH RES CO, V516, P551, DOI 10.1016/j.bbrc.2019.06.084
   [Anonymous], 2016, N Engl J Med, V374, P1797, DOI 10.1056/NEJMx160008
   Avsian Kretchmer O, 2004, MOL ENDOCRINOL, V18, P1, DOI 10.1210/me.2003 0227
   Balcerzak M, 2003, ACTA BIOCHIM POL, V50, P1019
   Baradaran A, 2014, Clin Ter, V165, P7, DOI 10.7471/CT.2014.1653
   Cano A, 2018, MATURITAS, V107, P7, DOI 10.1016/j.maturitas.2017.10.004
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Chen MJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02154 7
   Choi SW, 2001, BRIT J DERMATOL, V145, P535, DOI 10.1046/j.1365 2133.2001.04410.x
   Das S, 2011, INT J BIOL MACROMOL, V48, P38, DOI 10.1016/j.ijbiomac.2010.09.010
   Hernlund E, 2013, ARCH OSTEOPOROS, V8, DOI 10.1007/s11657 013 0136 1
   James AW, 2010, PLAST RECONSTR SURG, V126, P806, DOI 10.1097/PRS.0b013e3181e5f81a
   Manzano Moreno FJ, 2019, CLIN ORAL INVEST, V23, P813, DOI 10.1007/s00784 018 2505 z
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Khalid S, 2022, OSTEOPOROSIS INT, V33, P1579, DOI 10.1007/s00198 021 06262 1
   Kwack SJ, 2014, J TOXICOL ENV HEAL A, V77, P1319, DOI 10.1080/15287394.2014.951590
   Lee Y, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101660
   Li Y, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e10480
   Liu C, 2021, CARBOHYD POLYM, V261, DOI 10.1016/j.carbpol.2021.117874
   Liu HD, 2022, FREE RADICAL RES, V56, P63, DOI 10.1080/10715762.2022.2037580
   Mazini L, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02006 w
   Miyauchi Y, 2013, P NATL ACAD SCI USA, V110, P16568, DOI 10.1073/pnas.1308755110
   Na K, 2020, SCAND J IMMUNOL, V91, DOI 10.1111/sji.12856
   Peng XM, 2018, REJUV RES, V21, P44, DOI 10.1089/rej.2017.1956
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schilcher J, 2015, ACTA ORTHOP, V86, P100, DOI 10.3109/17453674.2015.1004149
   Shen CL, 2018, OSTEOPOROSIS INT, V29, P881, DOI 10.1007/s00198 017 4356 x
   Vimalraj S, 2015, INT J BIOL MACROMOL, V78, P202, DOI 10.1016/j.ijbiomac.2015.04.008
   Wang KB, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 03125 2
   Xie Yan Ming, 2021, Zhongguo Zhong Yao Za Zhi, V46, P5992, DOI 10.19540/j.cnki.cjcmm.20210709.501
   Xu CJ, 2016, PAK J PHARM SCI, V29, P1123
   Yan CP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.883228
   Yang XM, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 020 02147 x
   Yu B, 2018, CELL STEM CELL, V23, P193, DOI 10.1016/j.stem.2018.06.009
   Yuasa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116462
   Zhang Q, 2022, INT J BIOL MACROMOL, V211, P249, DOI 10.1016/j.ijbiomac.2022.05.072
   Zhang ZD, 2016, BIOMED PHARMACOTHER, V84, P438, DOI 10.1016/j.biopha.2016.09.045
   Zhu W, 2006, BONE, V39, P61, DOI 10.1016/j.bone.2005.12.018
NR 38
TC 8
Z9 11
U1 4
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301 4851
EI 1573 4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD DEC
PY 2022
VL 49
IS 12
BP 11913
EP 11924
DI 10.1007/s11033 022 08003 x
EA OCT 2022
PG 12
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 6S5ZK
UT WOS:000868371000001
PM 36243792
OA hybrid
DA 2025 08 17
ER

PT J
AU Wu, ZY
   Ji, XW
   Shan, C
   Song, J
   Zhao, J
AF Wu, Zeyu
   Ji, Xiaowei
   Shan, Chao
   Song, Jie
   Zhao, Jin
TI Exploring the pharmacological components and effective mechanism of
   Mori Folium against periodontitis using network pharmacology and
   molecular docking
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Mori Folium; Periodontitis; Network pharmacology; Molecular docking;
   Molecular mechanism
ID EXPRESSION; IDENTIFICATION; DISEASES; UPDATE
AB Objectives: To investigate the main active components, potential targets of action and analyze the potential molecular mechanisms of Mori Folium in preventing and treating periodontitis using network pharmacology and molecular docking methods.Materials and methods: The main components and action targets of Mori Folium were obtained in TCMSP and ETCM databases, and then the action targets of Mori Folium components were inversing screening using Swiss Target Prediction and BATMAN TCM databases. Targets associated with periodontitis were retrieved from OMIM, Genecard, DrugBank, NCBI Gene and DisGeNET databases. Intersectional targets of Mori Folium and periodontitis were obtained by Venn analysis. Construction of an "active components targets" network to prevent and treat periodontitis in Mori Folium using Cytoscape 3.8.0. The STRING database was used to construct the protein protein interaction (PPI) network of intersecting targets, and the core network was screened using CytoNCA and MCODE plug ins. Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were performed using the ClusterProfile package of R software, and then the "Mori Folium active components targets signaling pathway" network was constructed using Cytoscape software. Molecular docking was performed using AutoDock Vina software, and Pymol and LigPlus visualized the results.Results: Sixteen active components and 1048 targets were screened from Mori Folium, of which 164 were intersectional with periodontitis targets and were considered potential therapeutic targets. The "Mori Folium active components action targets" network identified Quercetin, Moracin D, Moracin E, Moracin G, Moracin H and Moracin B as the main active ingredients of Mori Folium for the prevention and treatment of periodontitis. PPI network analysis revealed interleukin 6 (IL6), albumin (ALB), tumor necrosis factor (TNF), vascular endothelial growth factor A (VEGFA), RAC alpha serine/threonine protein kinase (AKT1), cellular tumor antigen p53 (TP53), prostaglandin G/H synthase 2 (PTGS2), pro epidermal growth factor (EGF), matrix metalloproteinase 9 (MMP9) and interleukin 6 (IL10) as the top 10 core potential targets. GO and KEGG enrichment analyses showed that the action targets of Mori Folium against periodontitis were mainly related to the response to bacterium and their lipopolysaccharide, angiogenesis and reactive oxygen species metabolic process, as well as through signaling pathways that regulate processes related to the accumulation of advanced glycation end products (AGEs), response to oxidative stress, response to inflammatory, and osteoclast differentiation during the development of the disease. Molecular docking revealed that Quercetin, Moracin D, Moracin E, Moracin G, Moracin H and Moracin B were able to bind stably to AKT1, PTGS2 and ESR1 targets, with Moracin E showing the most stable structure after binding to AKT1.Conclusions: In conclusion, this study revealed the active components, potential targets of action and the potential molecular mechanisms and pharmacological activities involved in the prevention and treatment of periodontitis in Mori Folium, providing a reference for the development of drugs from Mori Folium for the prevention and treatment of periodontitis.
C1 [Wu, Zeyu; Ji, Xiaowei; Shan, Chao; Song, Jie; Zhao, Jin] Xinjiang Med Univ, Affiliated Stomatol Hosp, Affiliated Hosp 1, 137 South Liyushan Rd, Urumqi 830054, Peoples R China.
   [Wu, Zeyu; Ji, Xiaowei; Shan, Chao; Song, Jie; Zhao, Jin] Stomatol Dis Inst Xinjiang Uyghur Autonomous Reg, 137 South Liyushan Rd, Urumqi 830054, Peoples R China.
C3 Xinjiang Medical University
RP Zhao, J (通讯作者)，Xinjiang Med Univ, Affiliated Stomatol Hosp, Affiliated Hosp 1, 137 South Liyushan Rd, Urumqi 830054, Peoples R China.
EM zhaojin@xjmu.edu.cn
OI Zhao, Jin/0000 0002 5207 4680; Wu, Zeyu/0000 0002 4634 0663
FU Special Regional Collaborative Innovation Project of Xinjiang Uygur
   Autonomous Region [2021E01069]; State Key Laboratory of Oral Diseases
   Open Fund [SKLOD2021OF04]
FX Acknowledgements This work was supported by the Special Regional
   Collaborative Innovation Project of Xinjiang Uygur Autonomous Region
   (2021E01069) ; and the State Key Laboratory of Oral Diseases Open Fund
   (SKLOD2021OF04) .
CR [Anonymous], 2010, US Department of Health and Human Services Guidance Regarding Methods for Deidentification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule
   Athanasios A, 2017, CURR DRUG METAB, V18, P5, DOI [10.2174/1389200217666161102150602, 10.2174/138920021801170119204832]
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471 2105 4 2
   Bateman A, 2019, NUCLEIC ACIDS RES, V47, pD506, DOI 10.1093/nar/gky1049
   Beck JD, 2019, J DENT RES, V98, P1053, DOI 10.1177/0022034519846113
   Black RA, 2004, NAT GENET, V36, P934, DOI 10.1038/ng0904 934
   Chandran U, 2017, INNOVATIVE APPROACHES IN DRUG DISCOVERY: ETHNOPHARMACOLOGY, SYSTEMS BIOLOGY, AND HOLISTIC TARGETING, P127, DOI 10.1016/B978 0 12 801814 9.00005 2
   Chen CY, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12071455
   Cheng LS, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070672
   Cheng R, 2015, CELL DEATH DISCOV, V1, DOI 10.1038/cddiscovery.2015.46
   Choi JeongLee Choi JeongLee, 2015, Korean Journal of Pharmacognosy, V46, P309
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   Dominy SS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau3333
   Fong GH, 2008, ANGIOGENESIS, V11, P121, DOI 10.1007/s10456 008 9107 3
   Gu RH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20191673
   Gunjal Shilpa, 2015, Indian J Dent Res, V26, P533, DOI 10.4103/0970 9290.172082
   Halgren TA, 1996, J COMPUT CHEM, V17, P490, DOI [10.1002/(SICI)1096 987X(199604)17:5/6<616::AID JCC5>3.0.CO;2 X, 10.1002/(SICI)1096 987X(199604)17:5/6<490::AID JCC1>3.0.CO;2 P]
   He ZY, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 74977 y
   Herrera Balandrano DD, 2020, WASTE BIOMASS VALORI, V11, P403, DOI 10.1007/s12649 018 0462 z
   Huang HB, 2018, FRONT CHEM, V6, DOI 10.3389/fchem.2018.00138
   Huang Shao Jie, 2020, Natural Product Research and Development, V32, P1087, DOI 10.16333/j.1001 6880.2020.7.001
   Isola G, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020585
   Jian CX, 2014, INFLAMMATION, V37, P1413, DOI 10.1007/s10753 014 9865 6
   Jiménez J, 2017, BIOINFORMATICS, V33, P3036, DOI 10.1093/bioinformatics/btx350
   Jin SE, 2019, MOLECULES, V24, DOI 10.3390/molecules24020265
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kim S, 2021, NUCLEIC ACIDS RES, V49, pD1388, DOI 10.1093/nar/gkaa971
   Könönen E, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081135
   Kubota T, 2008, J PERIODONTOL, V79, P166, DOI 10.1902/jop.2008.070159 
   Lai L.L., 2016, ANHUI MED PHARM J, V20, P2210, DOI 10.3969/j.issn.1009 
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Liu HB, 2014, J CHEM INF MODEL, V54, P1050, DOI 10.1021/ci500004h
   Liu ZY, 2016, SCI REP UK, V6, DOI 10.1038/srep21146
   Moon YM, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4089
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Munoz JE, 2020, Perverse Modernities, P1, DOI 10.1109/imbioc.2019.8777845
   Ng KT, 2011, J PERIODONTOL, V82, P136, DOI 10.1902/jop.2010.100100
   Nonaka K, 2018, J PERIODONTAL RES, V53, P334, DOI 10.1111/jre.12518
   Osta B, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00048
   Pan WY, 2019, J CLIN PERIODONTOL, V46, P286, DOI 10.1111/jcpe.13060
   Papapanou PN, 2018, J PERIODONTOL, V89, pS173, DOI 10.1002/JPER.17 0721
   Park JY, 2011, CELL TRANSPLANT, V20, P271, DOI 10.3727/096368910X519292
   Piñero J, 2017, NUCLEIC ACIDS RES, V45, pD833, DOI 10.1093/nar/gkw943
   Polak D, 2018, J CLIN PERIODONTOL, V45, P150, DOI 10.1111/jcpe.12803
   Rajeshwari HR, 2019, J CONTROL RELEASE, V307, P393, DOI 10.1016/j.jconrel.2019.06.038
   Rayon A, 2009, BIOINFORMATION, V3, P263, DOI 10.6026/97320630003263
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Sun L, 2020, J IMMUNOL, V204, P2177, DOI 10.4049/jimmunol.1900532
   Taherkhani Amir, 2020, J Basic Clin Physiol Pharmacol, V32, P1105, DOI 10.1515/jbcpp 2020 0036
   Taherkhani A, 2021, LETT DRUG DES DISCOV, V18, P16, DOI 10.2174/1570180817999200831094703
   Taskan Mehmet Murat, 2020, Anti Inflammatory & Anti Allergy Agents in Medicinal Chemistry, V19, P436, DOI 10.2174/1871523019666200124114503
   Thaipitakwong T, 2018, PHARM BIOL, V56, P109, DOI 10.1080/13880209.2018.1424210
   The Gene Ontology Consortium, 2017, NUCLEIC ACIDS RES, V45, pD331, DOI DOI 10.1093/NAR/GKW1108
   Vo TTT, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9121211
   Toker H, 2018, J APPL ORAL SCI, V26
   Trott O, 2010, J COMPUT CHEM, V31, P455, DOI 10.1002/jcc.21334
   Wang LM, 2018, J PERIODONTAL RES, V53, P66, DOI 10.1111/jre.12488
   Wang X., 2018, 4 NATL ORAL HLTH EPI, P12
   Wang Y, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.682862
   Wei WX, 2020, DRUG DISCOV TODAY, V25, P1839, DOI 10.1016/j.drudis.2020.07.017
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Wolf J, 2014, CYTOKINE, V70, P11, DOI 10.1016/j.cyto.2014.05.024
   Wu TZ, 2021, INNOVATION AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu HY, 2019, NUCLEIC ACIDS RES, V47, pD976, DOI 10.1093/nar/gky987
   Yan Y, 2020, TRIALS, V21, DOI 10.1186/s13063 019 4031 y
   Yu SJ, 2012, J PERIODONTOL, V83, P119, DOI 10.1902/jop.2011.100754
   Zhang D, 2021, ARCH ORAL BIOL, V122, DOI 10.1016/j.archoralbio.2020.105003
   Zhao BH, 2017, CURR OSTEOPOROS REP, V15, P126, DOI 10.1007/s11914 017 0358 z
   [周文霞 Zhou Wenxia], 2016, [国际药学研究杂志, Journal of International Pharmaceutical Research], V43, P399
   Zizzi A, 2013, J PERIODONTAL RES, V48, P293, DOI 10.1111/jre.12007
NR 72
TC 12
Z9 14
U1 5
U2 49
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD JUL
PY 2022
VL 139
AR 105391
DI 10.1016/j.archoralbio.2022.105391
EA APR 2022
PG 16
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 1C7WB
UT WOS:000793324000001
PM 35430443
DA 2025 08 17
ER

PT J
AU Chen, YY
   Liu, YT
   Xia, H
   Xia, GY
   Xu, JJ
   Lin, S
   Guo, LJ
   Liu, Y
AF Chen, Yingyi
   Liu, Yitong
   Xia, Huan
   Xia, Guiyang
   Xu, Junji
   Lin, Sheng
   Guo, Lijia
   Liu, Yi
TI The effect of the Litcubanine A on the treatment of murine experimental
   periodontitis by inhibiting monocyte macrophage chemotaxis and
   osteoclast differentiation
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE chemotaxis; LA; monocyte macrophage; periodontitis
ID INFLAMMATION; NFATC1; ACTIVATION
AB Background: Periodontal disease is an inflammatory disease of periodontal tissues that is closely connected with systemic diseases. During periodontitis, the inappropriate recruitment and activation of monocytes macrophages causes an increase in osteoclast activity and disrupts bone homeostasis. Therefore, it is a promising therapeutic strategy to treat periodontitis by regulating the functions of monocytes macrophages. Litcubanine A (LA) is an isoquinoline alkaloid extracted from the traditional Chinese medicine Litsea cubeba, which was proven to have reproducible anti inflammatory effects, but its regulatory role on bone homeostasis in periodontitis is still not clear.
   Methods: In this study, zebrafish experiments and a mouse ligature induced periodontitis model were performed, and histological analysis was used to investigate the effect of LA on macrophage chemotaxis under the inflammatory environment. Real time PCR was used to detect the regulatory effect of LA (100 nM similar to 100 mu M) on the chemotaxis function of macrophages induced by LPS. Apoptosis assay and flow cytometry were used to elucidate the influence of LA on macrophage apoptosis and proliferation. To further clarify the regulatory role of LA on macrophage osteoclast differentiation, real time PCR, histological analysis, western blot, and micro computed tomography (micro CT) were performed in vivo and in vitro to verify the impact of LA on bone homeostasis.
   Results: Compared with the control group, the chemotaxis function of macrophage was significantly attenuated by LA in vivo. LA could significantly inhibit the expression of genes encoding the chemokine receptors Ccr1 and Cxcr4, and its ligand chemokine Cxcl12 in macrophages, and suppresses the differentiation of osteoclastic precursors to osteoclasts through the MAPK signaling pathway. There were significantly lower osteoclast differentiation and bone loss in the LA group compared with the control in the ligature induced periodontitis model.
   Conclusion: LA is a promising candidate for the treatment of periodontitis through its reproducible functions of inhibiting monocyte macrophage chemotaxis and osteoclast differentiation.
C1 [Chen, Yingyi; Liu, Yitong; Xu, Junji; Liu, Yi] Capital Med Univ, Sch Stomatol, Dept Periodont, Lab Tissue Regenerat & Immunol, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
   [Chen, Yingyi; Liu, Yitong; Xu, Junji; Liu, Yi] Capital Med Univ, Beijing Friendship Hosp, Immunol Res Ctr Oral & Syst Hlth, Beijing, Peoples R China.
   [Xia, Huan; Xia, Guiyang; Lin, Sheng] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ & Beijing, Beijing, Peoples R China.
   [Guo, Lijia] Capital Med Univ, Sch Stomatol, Dept Orthodont, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University; Beijing
   University of Chinese Medicine; Capital Medical University
RP Liu, Y (通讯作者)，Capital Med Univ, Sch Stomatol, Dept Periodont, Lab Tissue Regenerat & Immunol, Tian Tan Xi Li 4, Beijing 100050, Peoples R China.
EM lililiuyi@163.com
RI ; chen, yingyi/HMO 6773 2023; Xu, Junji/K 5691 2013
OI CHEN, YINGYI/0000 0003 4875 244X; 
FU Beijing Municipal Administration of Hospitals Clinical Medicine
   Development of Special Funding Support; Beijing Municipal Administration
   of Hospitals' Ascent Plan; Beijing Municipal Administration of
   Hospitals' Youth Programme; Beijing Stomatological Hospital, Capital
   Medical University Young Scientist Program; Innovation research team
   project of Beijing Stomatological Hospital, Capital Medical University;
   National Nature Science Foundation; Innovation Foundation of Beijing
   Stomatological Hospital, Capital Medical University
FX Beijing Municipal Administration of Hospitals Clinical Medicine
   Development of Special Funding Support; Beijing Municipal Administration
   of Hospitals' Ascent Plan; Beijing Municipal Administration of
   Hospitals' Youth Programme; Beijing Stomatological Hospital, Capital
   Medical University Young Scientist Program; Innovation research team
   project of Beijing Stomatological Hospital, Capital Medical University;
   National Nature Science Foundation; the Innovation Foundation of Beijing
   Stomatological Hospital, Capital Medical University
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Armitage GC, 2004, PERIODONTOL 2000, V34, P9, DOI 10.1046/j.0906 6713.2002.003421.x
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092 8674(00)00116 1
   Feng HT, 2009, J BIOL CHEM, V284, P14667, DOI 10.1074/jbc.M901670200
   França LFC, 2017, J CLIN PERIODONTOL, V44, P568, DOI 10.1111/jcpe.12729
   Gibaldi D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00306
   Gruber R, 2019, J CLIN PERIODONTOL, V46, P52, DOI 10.1111/jcpe.13056
   Guo JC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03046 z
   Hajishengallis G, 2021, NAT REV IMMUNOL, V21, P426, DOI 10.1038/s41577 020 00488 6
   Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785
   Keestra JAJ, 2015, J PERIODONTAL RES, V50, P689, DOI 10.1111/jre.12252
   Kular J, 2012, CLIN BIOCHEM, V45, P863, DOI 10.1016/j.clinbiochem.2012.03.021
   Kumar RA, 2018, INT IMMUNOPHARMACOL, V65, P348, DOI 10.1016/j.intimp.2018.10.016
   Lee SP, 2001, J BIOL CHEM, V276, P29826, DOI 10.1074/jbc.M101822200
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Liccardo D, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061414
   Liehn EA, 2011, J AM COLL CARDIOL, V58, P2415, DOI 10.1016/j.jacc.2011.08.033
   Lin B, 2013, J ETHNOPHARMACOL, V147, P327, DOI 10.1016/j.jep.2013.03.011
   Liu YT, 2021, J LEUKOCYTE BIOL, V110, P475, DOI 10.1002/JLB.3MA0321 736R
   Nair SP, 1996, INFECT IMMUN, V64, P2371, DOI 10.1128/IAI.64.7.2371 2380.1996
   Pase L, 2012, METHOD ENZYMOL, V506, P135, DOI 10.1016/B978 0 12 391856 7.00032 9
   Pawig L, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00429
   Richards Derek, 2014, Evid Based Dent, V15, P70, DOI 10.1038/sj.ebd.6401037
   Roehl HH, 2018, INT J DEV BIOL, V62, P473, DOI 10.1387/ijdb.170331hr
   Shaath H, 2020, CELLS BASEL, V9, DOI 10.3390/cells9112374
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thouverey C, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.80
   Wu LL, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1500 x
   Xia H, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685556
   Zhang Shui Ying, 2014, Zhongguo Zhong Yao Za Zhi, V39, P769
   Zhao X, 2020, OSTEOARTHR CARTILAGE, V28, P613, DOI 10.1016/j.joca.2020.01.009
   Zhu SP, 2018, BIOL REV, V93, P469, DOI 10.1111/brv.12353
NR 35
TC 6
Z9 7
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD OCT
PY 2023
VL 58
IS 5
BP 948
EP 958
DI 10.1111/jre.13154
EA JUL 2023
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA R4GJ7
UT WOS:001022714500001
PM 37409514
DA 2025 08 17
ER

PT J
AU Kumar, V
   Haldar, S
   Ghosh, S
   Chauhan, S
   Sharma, A
   Dhankhar, P
   Kumar, A
   Jaiswal, S
   Saini, S
   Gupta, S
   Lahiri, D
   Roy, P
AF Kumar, Viney
   Haldar, Swati
   Ghosh, Souvik
   Chauhan, Samrat
   Sharma, Abhishek
   Dhankhar, Poonam
   Kumar, Amit
   Jaiswal, Satish
   Saini, Saakshi
   Gupta, Sumeet
   Lahiri, Debrupa
   Roy, Partha
TI Pterostilbene isothiocyanate impedes RANK/TRAF6 interaction to inhibit
   osteoclastogenesis, promoting osteogenesis in vitro and
   alleviating glucocorticoid induced osteoporosis in rats
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Dexamethasone;
   Pterostilbene isothiocyanate (PTER ITC); Micro computed tomography;
   Scanning electron microscopy; Ultimate compressive strength; Young?s
   modulus
ID OSTEOBLAST DIFFERENTIATION; CORTICAL BONE; MOLECULAR DYNAMICS; SYSTEMS
   BIOLOGY; ALENDRONATE; PROLIFERATION; THERAPY; CALCINEURIN; MECHANISMS;
   ANISOTROPY
AB Prolonged glucocorticoid treatment often leads to glucocorticoid induced osteoporosis (GIOP), a common iat rogenic complication. This study has explored the anti osteoporotic potential of semi synthetic compound, pterostilbene isothiocyanate (PTER ITC) in GIOP rat model and bone formation potential in vitro. Dysregulated bone remodelling leads to osteoporosis. PTER ITC has shown anti osteoclastogenic activity in vitro. However, its molecular target remains unidentified, which has been explored in this study through in silico and experimental approaches. Alizarin Red S and von Kossa staining, and alkaline phosphatase (ALP) activity showed the osteo genic differentiation potential of PTER ITC in pre osteoblastic mouse MC3T3 E1 and human hFOB 1.19 cells, further, confirmed through the expressions of osteogenic markers at transcriptional (RT qPCR) and translational (immunoblotting) levels. The anti osteoclastogenic property of PTER ITC was confirmed through inhibition of actin ring formation in mouse RAW 264.7 and human THP 1 macrophagic cells. Molecular docking and mo lecular dynamic simulation showed that PTER ITC inhibited the crucial osteoclastogenic RANK/TRAF6 inter action, which was further confirmed biochemically through co immunoprecipitation assay. Osteoporotic bone architecture [validated through scanning electron microscopy (SEM), X ray radiography, and micro computed tomography (mu CT)], physiology (confirmed through compression testing, Young's modulus and stress versus strain output) and histology (verified through hematoxylin eosin, Alizarin Red S, von Kossa and Masson trichrome staining) of PTER ITC treated GIOP female Wistar rats were assuaged. Osteoporotic amelioration through PTER ITC treatment was further substantiated through serum biomarkers, like, parathyroid hormone (PTH), ALP, calcium (Ca2+), Procollagen type I N terminal propeptide (P1NP), and 25 hydroxy vitamin D. In conclusion, this study identifies the molecular target of PTER ITC in impeding osteoclastogenesis and facilitating osteogenesis to ameliorate osteoporosis.
C1 [Kumar, Viney; Haldar, Swati; Ghosh, Souvik; Dhankhar, Poonam; Saini, Saakshi; Roy, Partha] Indian Inst Technol Roorkee, Dept Biosci & Bioengn, Roorkee, Uttarakhand, India.
   [Haldar, Swati; Ghosh, Souvik; Lahiri, Debrupa; Roy, Partha] Indian Inst Technol Roorkee, Ctr Nanotechnol, Roorkee, Uttarakhand, India.
   [Chauhan, Samrat; Sharma, Abhishek; Gupta, Sumeet] Maharishi Markandeshwar Deemed Univ, Dept Pharmacol, Mullana, Haryana, India.
   [Kumar, Amit] ICAR Natl Dairy Res Inst, Anim Biotechnol Div, Karnal, Haryana, India.
   [Jaiswal, Satish; Lahiri, Debrupa] Indian Inst Technol, Dept Met & Mat Engn, Roorkee, Uttarakhand, India.
   [Haldar, Swati] Patanjali Res Inst, Drug Discovery & Dev Div, Haridwar, Uttarakhand, India.
   [Chauhan, Samrat] Chitkara Univ, Chitkara Coll Pharm, Rajpura, Punjab, India.
   [Dhankhar, Poonam] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA USA.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT)   Roorkee; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT)   Roorkee; Indian Council
   of Agricultural Research (ICAR); ICAR   National Dairy Research
   Institute; Indian Institute of Technology System (IIT System); Indian
   Institute of Technology (IIT)   Roorkee; Chitkara University, Punjab;
   Virginia Commonwealth University
RP Roy, P (通讯作者)，Indian Inst Technol Roorkee, Dept Biosci & Bioengn, Roorkee, Uttarakhand, India.
EM partha.roy@bt.iitr.ac.in
RI ; KUMAR, VINEY/JFK 1391 2023; Gupta, Sumeet/AAN 1797 2021; CHAUHAN,
   SAMRAT/AAS 7102 2020; DHANKHAR, POONAM/AAG 6297 2021; Dhankhar,
   Poonam/AAG 6297 2021; Haldar, Swati/AAH 5388 2021; Kumar,
   Viney/JFK 1391 2023; Roy, Partha/GNP 6565 2022; Ghosh,
   Souvik/HKM 5114 2023; Sharma, Abhishek/D 6135 2018
OI Sharma, Abhishek Kumar/0000 0001 9480 0049; KUMAR,
   VINEY/0000 0003 3677 3489; DHANKHAR, POONAM/0000 0002 7614 5957; SAINI,
   SAAKSHI/0009 0009 8376 1342; Chauhan, Samrat/0000 0003 4120 6534
FU Department of Biotechnology, Government of India; Council of Scientific
   and Industrial Research, Government of India; 
   [BT/PR12138/MED/97/238/2014];  [9/143 (0897) /2017 EMR I]
FX Funding This work was supported by a research grant from the Department
   of Biotechnology, Government of India (Grant No.
   BT/PR12138/MED/97/238/2014) to PR. VK would like to thank the Council of
   Scientific and Industrial Research, Government of India for fellowship
   to VK [9/143 (0897) /2017 EMR I] .
CR Aki S, 2003, YONSEI MED J, V44, P961, DOI 10.3349/ymj.2003.44.6.961
   Aldo PB, 2013, AM J REPROD IMMUNOL, V70, P80, DOI 10.1111/aji.12129
   [Anonymous], 2012, MENOPAUSE, V19, P257, DOI 10.1097/gme.0b013e31824b970a
   [Anonymous], 1996, Biomolecular Simulation: The Gromos96 Manual and User Guide
   Armstrong AP, 2002, J BIOL CHEM, V277, P44347, DOI 10.1074/jbc.M202009200
   Awadeen MA, 2020, WORLD J STEM CELLS, V12, P55, DOI 10.4252/wjsc.v12.i1.55
   BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092 8674(91)90279 8
   Chellaiah MA, 2020, BONE RES, V8, DOI 10.1038/s41413 019 0079 2
   Chen X, 2018, CONNECT TISSUE RES, V59, P99, DOI 10.1080/03008207.2017.1290085
   Choo MK, 2009, BONE, V45, P579, DOI 10.1016/j.bone.2009.05.009
   Compston J, 2017, ARCH OSTEOPOROS, V12, DOI 10.1007/s11657 017 0324 5
   Coutinho AE, 2011, MOL CELL ENDOCRINOL, V335, P2, DOI 10.1016/j.mce.2010.04.005
   DeLano W. L., 2002, CCP4 Newsletter on protein crystallography, V40, P82
   Dhankhar P, 2022, J BIOMOL STRUCT DYN, V40, P4084, DOI 10.1080/07391102.2020.1852968
   Dias DA, 2012, METABOLITES, V2, DOI 10.3390/metabo2020303
   Feldstein AC, 2009, BONE, V44, P153, DOI 10.1016/j.bone.2008.09.006
   Fouad Elhady EA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e03341
   FULLMER HM, 1964, STAIN TECHNOL, V39, P387, DOI 10.3109/10520296409063311
   Gencel VB, 2012, MINI REV MED CHEM, V12, P149
   Gupta T, 2019, J DIET SUPPL, V16, P699, DOI 10.1080/19390211.2018.1472715
   Hanna H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0942 x
   Heim M, 2004, ENDOCRINOLOGY, V145, P848, DOI 10.1210/en.2003 1014
   Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703
   Hopkins AL, 2008, NAT CHEM BIOL, V4, P682, DOI 10.1038/nchembio.118
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Ioannis SP, 2011, HORM INT J ENDOCRINO, V10, P280, DOI 10.14310/horm.2002.1319
   Karras JC, 2009, AM J ORTHOD DENTOFAC, V136, P843, DOI 10.1016/j.ajodo.2007.11.035
   Kell DB, 2013, FEBS J, V280, P5957, DOI 10.1111/febs.12268
   Khapra Asma P, 2006, Gastrointest Endosc Clin N Am, V16, P99, DOI 10.1016/j.giec.2006.01.002
   Kumar V, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114717
   Lane NE, 1998, ENDOCRIN METAB CLIN, V27, P465, DOI 10.1016/S0889 8529(05)70017 7
   Lems WF, 2014, CURR OPIN RHEUMATOL, V26, P245, DOI 10.1097/BOR.0000000000000057
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Li SM, 2013, J MECH BEHAV BIOMED, V21, P109, DOI 10.1016/j.jmbbm.2013.02.021
   LOCASCIO V, 1990, BONE MINER, V8, P39, DOI 10.1016/0169 6009(91)90139 Q
   Lomovskaya YV, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12020150
   Maciejewski MW, 2017, BIOPHYS J, V112, P1529, DOI 10.1016/j.bpj.2017.03.011
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Margineanu DG, 2014, EPILEPSY BEHAV, V38, P131, DOI 10.1016/j.yebeh.2013.08.029
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   MELOAN S N, 1985, Journal of Histotechnology, V8, P11
   Mithal A, 2012, CURR OSTEOPOROS REP, V10, P245, DOI 10.1007/s11914 012 0114 3
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Nikhil K, 2016, STEROIDS, V108, P17, DOI 10.1016/j.steroids.2016.01.020
   Nikhil K, 2015, PHARMACOL REP, V67, P1264, DOI 10.1016/j.pharep.2015.05.009
   Nikhil K, 2015, INT IMMUNOPHARMACOL, V28, P10, DOI 10.1016/j.intimp.2015.05.003
   Nikhil K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104592
   Nikhil K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093335
   Nikhil K, 2014, EXP CELL RES, V320, P311, DOI 10.1016/j.yexcr.2013.10.015
   Novitskaya E, 2011, ACTA BIOMATER, V7, P3170, DOI 10.1016/j.actbio.2011.04.025
   O'Boyle NM, 2011, J CHEMINFORMATICS, V3, DOI 10.1186/1758 2946 3 33
   PARFITT AM, 1987, CLIN OBSTET GYNECOL, V30, P789, DOI 10.1097/00003081 198712000 00004
   Parfitt AM, 1998, BONE, V23, P491, DOI 10.1016/S8756 3282(98)00140 9
   PARRINELLO M, 1981, J APPL PHYS, V52, P7182, DOI 10.1063/1.328693
   Porter A, 2017, SCI REP UK, V7, DOI 10.1038/srep42505
   Porwal K, 2017, J NUTR BIOCHEM, V44, P22, DOI 10.1016/j.jnutbio.2017.02.011
   PUCHTLER H, 1978, HISTOCHEMISTRY, V56, P177, DOI 10.1007/BF00495978
   PUCHTLER H, 1969, J HISTOCHEM CYTOCHEM, V17, P110, DOI 10.1177/17.2.110
   Schneider MR, 2021, HISTOCHEM CELL BIOL, V156, P523, DOI 10.1007/s00418 021 02051 3
   Schüttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555
   Siller AF, 2018, J BONE MINER RES, V33, P362, DOI 10.1002/jbmr.3225
   Singh N, 2018, INT J BIOL MACROMOL, V108, P214, DOI 10.1016/j.ijbiomac.2017.12.005
   Srivastava S, 2014, J CELL PHYSIOL, V229, P2088, DOI 10.1002/jcp.24668
   Stahn C, 2007, MOL CELL ENDOCRINOL, V275, P71, DOI 10.1016/j.mce.2007.05.019
   Szumilak M, 2021, MOLECULES, V26, DOI 10.3390/molecules26092601
   Takagi T, 2017, BIOCHEM BIOPH RES CO, V483, P718, DOI 10.1016/j.bbrc.2016.12.075
   Talevi A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00205
   Sousa LHT, 2017, ARCH ORAL BIOL, V77, P55, DOI 10.1016/j.archoralbio.2017.01.014
   Trivedi Shilpa, 2020, J Oral Biol Craniofac Res, V10, P158, DOI 10.1016/j.jobcr.2020.04.006
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Weng WD, 2021, J MATER SCI MATER M, V32, DOI 10.1007/s10856 021 06601 y
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Winslow MM, 2006, DEV CELL, V10, P771, DOI 10.1016/j.devcel.2006.04.006
   Yang Y, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00731
   Yanik B, 2007, OSTEOPOROSIS INT, V18, P829, DOI 10.1007/s00198 007 0323 2
   Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888
   Yeo HJ, 2007, J BIOL CHEM, V282, P35318, DOI 10.1074/jbc.M702435200
   Yilmaz M, 2012, OSTEOPOROSIS INT, V23, P2059, DOI 10.1007/s00198 011 1836 2
   Yu LY, 2017, MOL MED REP, V16, P8699, DOI 10.3892/mmr.2017.7720
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057251
   Zhang Y, 2015, SCI REP UK, V5, DOI 10.1038/srep13575
   Zimmermann EA, 2014, BIOMATERIALS, V35, P5472, DOI 10.1016/j.biomaterials.2014.03.066
NR 88
TC 8
Z9 8
U1 1
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD DEC
PY 2022
VL 206
AR 115284
DI 10.1016/j.bcp.2022.115284
EA NOV 2022
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 6G6BP
UT WOS:000884839000001
PM 36209841
DA 2025 08 17
ER

PT J
AU Shim, KS
   Kim, T
   Ha, H
   Cho, CW
   Kim, HS
   Seo, DH
   Ma, JY
AF Shim, Ki Shuk
   Kim, Taesoo
   Ha, Hyunil
   Cho, Chang Won
   Kim, Han Sung
   Seo, Dong Hyun
   Ma, Jin Yeul
TI Hwangryun Haedok Tang Fermented with Lactobacillus casei
   Suppresses Ovariectomy Induced Bone Loss
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID NF KAPPA B; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR;
   NUCLEAR FACTOR; C FOS; RESORPTION; RATS; TRANSACTIVATION; ISOFLAVONES;
   MECHANISMS
AB Hwangryun haedok tang (HRT) is the common recipe in traditional Asian medicine, and microbial fermentation is used for the conventional methods for processing traditional medicine. We investigated the inhibitory effect of the n butanol fraction of HRT (HRT BU) and fHRT (fHRT BU) on the RANKL induced osteoclastogenesis in bone marrow derived macrophages. mRNA expression of osteoclastogenesis related genes were evaluated by real time QPCR. The activation of signaling pathways was determined by western blot analysis. The marker compounds of HRT BU and fHRT BU were analyzed by HPLC. The inhibitory effect of HRT or fHRT on ovariectomy induced bone loss were evaluated using OVX rats with orally administered HRT, fHRT (300, 1000 mg/kg), or its vehicle for 12 weeks. fHRT BU significantly inhibited RANKL induced osteoclastogenesis, and phosphorylation of p38, IKK alpha/beta, and NF kappa Bp65 compared to HRT BU. In addition, fHRT BU also significantly inhibited the mRNA expression of Nf kappa b2, TNF alpha, NFATc1, TRAP, ATPv0d2, and cathepsin K. Furthermore, administration of fHRT had a greater effect on the increase of BMD, and greater improved bone microstructure of the femora than that of HRT in ovariectomy rats. This study demonstrated that bacterial fermentation enhances the inhibitory effect of HRT on osteoclastogenesis and bone loss. These results suggest that fermented HRT might have the beneficial effects on bone disease by inhibiting osteoclastogenesis.
C1 [Shim, Ki Shuk; Kim, Taesoo; Ha, Hyunil; Ma, Jin Yeul] Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
   [Cho, Chang Won] Korea Food Res Inst, Reg Food Ind Res Grp, Songnam 463746, South Korea.
   [Kim, Han Sung; Seo, Dong Hyun] Yonsei Univ, Yonsei Fraunhofer Med Device Lab, Wonju 220710, Gangwon, South Korea.
   [Kim, Han Sung; Seo, Dong Hyun] Yonsei Univ, Inst Med Engn, Dept Biomed Engn, Wonju 220710, Gangwon, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM); Korea Food Research
   Institute (KFRI); Yonsei University; Yonsei University
RP Ma, JY (通讯作者)，Korea Inst Oriental Med, KM Based Herbal Drug Res Grp, Taejon 305811, South Korea.
EM jyma@kiom.re.kr
RI Cho, Chang Won/GPF 4456 2022
FU Korea Institute of Oriental Medicine, Ministry of Education, Science and
   Technology, Republic of Korea [K12050]
FX This work was supported by a grant (K12050) from the Korea Institute of
   Oriental Medicine, Ministry of Education, Science and Technology,
   Republic of Korea.
CR Arakawa K, 2006, PHYTOMEDICINE, V13, P1, DOI 10.1016/j.phymed.2004.02.012
   Asagiri M, 2005, J EXP MED, V202, P1261, DOI 10.1084/jem.20051150
   BAIN SD, 1993, J BONE MINER RES, V8, P219
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Choi H., 2003, Hanyakpoje ya Yimsangeumyoung
   Halleen JM, 1999, J BIOL CHEM, V274, P22907, DOI 10.1074/jbc.274.33.22907
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ishida H, 1998, BIOL PHARM BULL, V21, P62, DOI 10.1248/bpb.21.62
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534 5807(02)00157 0
   Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681
   Lee HS, 2011, J ETHNOPHARMACOL, V133, P710, DOI 10.1016/j.jep.2010.10.047
   Lee SH, 2006, NAT MED, V12, P1403, DOI 10.1038/nm1514
   Lee ZH, 2003, BIOCHEM BIOPH RES CO, V305, P211, DOI 10.1016/S0006 291X(03)00695 8
   Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200
   Mathey J, 2007, OSTEOPOROSIS INT, V18, P671, DOI 10.1007/s00198 007 0351 y
   Matsubara M, 2010, OSTEOPOROSIS INT, V21, P1437, DOI 10.1007/s00198 009 1075 y
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   Ng CC, 2011, J BIOSCI BIOENG, V111, P289, DOI 10.1016/j.jbiosc.2010.11.011
   OMI N, 1995, BONE, V17, pS163, DOI 10.1016/8756 3282(95)00329 C
   Poulsen RC, 2008, NUTR REV, V66, P359, DOI 10.1111/j.1753 4887.2008.00046.x
   Rechner AR, 2002, FREE RADICAL BIO MED, V33, P220, DOI 10.1016/S0891 5849(02)00877 8
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Saftig P, 2000, ADV EXP MED BIOL, V477, P293
   Scheline R R., 1991, Handbook of Mammalian Metabolism of Plant Compounds
   Scholz Ahrens KE, 2007, J NUTR, V137, p838S, DOI 10.1093/jn/137.3.838S
   Sims NA, 2002, BONE, V30, P18, DOI 10.1016/S8756 3282(01)00643 3
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Toda T, 1999, BIOL PHARM BULL, V22, P1193, DOI 10.1248/bpb.22.1193
   Watanabe Fukuda Y, 2009, J GASTROENTEROL, V44, P380, DOI 10.1007/s00535 009 0005 2
   WRONSKI TJ, 1988, ENDOCRINOLOGY, V123, P681, DOI 10.1210/endo 123 2 681
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zeng HW, 2011, J ETHNOPHARMACOL, V135, P561, DOI 10.1016/j.jep.2011.03.055
NR 35
TC 8
Z9 8
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2012
VL 2012
AR 325791
DI 10.1155/2012/325791
PG 12
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 019TF
UT WOS:000309761500001
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Yang, WW
   Wang, YL
   Mo, K
   Chen, WY
   Xie, XT
AF Yang, Weiwei
   Wang, Yulin
   Mo, Ke
   Chen, Wenyang
   Xie, Xiangtao
TI Single cell RNA sequencing reveals multiple immune cell subpopulations
   promote the formation of abnormal bone microenvironment in osteoporosis
SO SCIENTIFIC REPORTS
LA English
DT Article
DE Single cell sequencing; Abnormal bone microenvironment; Immune cells;
   Cell communication; Osteoporosis
ID C MYB; OSTEOCLAST DIFFERENTIATION; T CELLS; OSTEOIMMUNOLOGY; REGULATORS;
   FRACTURES; DIAGNOSIS
AB With the aging of the population, the incidence of osteoporosis (OP) is on the rise, but the ecology of immune cell subpopulations in OP is poorly understood. Therefore, identifying cell subpopulations involved in promoting the development of OP may facilitate the development of new treatments. Based on bioinformatics analysis, we constructed a single cell landscape of the OP microenvironment and identified immune cell subpopulations in OP to further explore the role of different subpopulations in the abnormal bone microenvironment. Among macrophages (Mac), the Mac_OLR1 subpopulation has an M1 like phenotype and significantly activates cytokine and osteoclast differentiation pathways, interacting with osteoclasts via the HBEGF CD9 axis. In neutrophils (Neut), the Neut_RSAD2 subpopulation significantly activated cytokine and osteoclast differentiation pathways and had a high neutrophil extracellular trap (NET) score, and H1FX was identified as its potential regulator. In effector memory T (Tem) cells, the Tem_CCL4 subpopulation significantly activated osteoclast differentiation and immune inflammation related pathways and highly expressed proinflammatory molecules such as CCL4, CCL4L2, CCL5 and IFNG. In B cells, the abundance of the B_ACSM3 subpopulation was significantly increased in the OP group and the osteoclast differentiation pathway was significantly activated, and MYB was identified as its potential regulator. In summary, we identified several immune cell subpopulations that may be involved in promoting the formation of OP, further identified the transcription factors that regulate these subpopulations, and speculated that the development of OP may be accompanied by immune inflammatory responses mediated by these subpopulations. These findings provide candidate molecules and cells for future OP research and may help facilitate the development of new therapies.
C1 [Yang, Weiwei] Guangxi Med Univ, Affiliated Hosp 4, Dept Gynecol, Liuzhou 545005, Guangxi, Peoples R China.
   [Wang, Yulin; Xie, Xiangtao] Guangxi Med Univ, Affiliated Hosp 4, Dept Orthoped, Liuzhou 545005, Guangxi, Peoples R China.
   [Mo, Ke] Guangxi Med Univ, Affiliated Hosp 2, Clin Res Ctr, Nanning 530007, Peoples R China.
   [Chen, Wenyang] Liuzhou Peoples Hosp, Dept Orthoped, Liuzhou 545006, Guangxi, Peoples R China.
   [Xie, Xiangtao] Liuzhou Workers Hosp, Dept Orthoped, Liuzhou 545005, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University
RP Xie, XT (通讯作者)，Guangxi Med Univ, Affiliated Hosp 4, Dept Orthoped, Liuzhou 545005, Guangxi, Peoples R China.; Chen, WY (通讯作者)，Liuzhou Peoples Hosp, Dept Orthoped, Liuzhou 545006, Guangxi, Peoples R China.; Xie, XT (通讯作者)，Liuzhou Workers Hosp, Dept Orthoped, Liuzhou 545005, Guangxi, Peoples R China.
EM chenwenyang295@163.com; xiexiangtao813@163.com
RI Chen, Wenyang/D 1425 2011
FU Project of Guangxi Science and Technology Department [AA24010007];
   Guangxi Natural Science Foundation [2023GXNSFAA026407]; Liuzhou Science
   and Technology Project [2022SB014]
FX This work was supported by grants from the Project of Guangxi Science
   and Technology Department (No.AA24010007), Guangxi Natural Science
   Foundation (2023GXNSFAA026407), Liuzhou Science and Technology Project
   (No.2022SB014).
CR Adachi JD, 2001, OSTEOPOROSIS INT, V12, P903, DOI 10.1007/s001980170017
   Anand S, 2024, CANCER METAST REV, V43, P409, DOI 10.1007/s10555 023 10153 8
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Bai RJ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1012508
   Batoon L, 2021, J BONE MINER RES, V36, P2214, DOI 10.1002/jbmr.4413
   Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314
   Boyce BF, 2008, ARCH BIOCHEM BIOPHYS, V473, P139, DOI 10.1016/j.abb.2008.03.018
   Brown JP, 2021, ENDOCRINOL METAB, V36, P544, DOI 10.3803/EnM.2021.301
   Brown JP, 2017, TOXICOL PATHOL, V45, P859, DOI 10.1177/0192623317737066
   Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096
   Chai RC, 2022, CURR OSTEOPOROS REP, V20, P356, DOI 10.1007/s11914 022 00735 w
   Chang GRL, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1158812
   Chen BY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.711329
   Chen HD, 2019, CELL MOL IMMUNOL, V16, P242, DOI 10.1038/s41423 019 0214 4
   Cheng SJ, 2021, CELL, V184, P792, DOI 10.1016/j.cell.2021.01.010
   Colucci S, 2004, BLOOD, V104, P3722, DOI 10.1182/blood 2004 02 0474
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   Fahl SP, 2009, J IMMUNOL, V183, P5582, DOI 10.4049/jimmunol.0901187
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Franceschi C, 2018, NAT REV ENDOCRINOL, V14, P576, DOI 10.1038/s41574 018 0059 4
   Fujiwara Nagatoshi, 2005, Current Drug Targets   Inflammation and Allergy, V4, P281, DOI 10.2174/1568010054022024
   Gopal R, 2017, CELL ONCOL, V40, P219, DOI 10.1007/s13402 017 0321 0
   Greig KT, 2010, BLOOD, V115, P2796, DOI 10.1182/blood 2009 08 239210
   Hansen MS, 2024, BONE RES, V12, DOI 10.1038/s41413 023 00312 6
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kitano VJF, 2020, J CELL SCI, V133, DOI 10.1242/jcs.243840
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Li X, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.694801
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Liu Z, 2022, ONCOIMMUNOLOGY, V11, DOI 10.1080/2162402X.2022.2085432
   Manabe N, 2001, J IMMUNOL, V167, P2625, DOI 10.4049/jimmunol.167.5.2625
   McClung MR, 2021, AGING CLIN EXP RES, V33, P775, DOI 10.1007/s40520 020 01708 8
   McDonald MM, 2021, CELL, V184, P1940, DOI 10.1016/j.cell.2021.03.010
   Mukaida N, 2020, ADV EXP MED BIOL, V1231, P23, DOI 10.1007/978 3 030 36667 4_3
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Papalexi E, 2018, NAT REV IMMUNOL, V18, P35, DOI 10.1038/nri.2017.76
   Pieters BCH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01901
   Pirraco RP, 2013, J TISSUE ENG REGEN M, V7, P392, DOI 10.1002/term.535
   Qiao ZL, 2022, VIRUSES BASEL, V14, DOI 10.3390/v14112587
   Qiu X, 2021, AGING US, V13, P15595, DOI 10.18632/aging.203124
   Romero JM, 2020, CLIN CANCER RES, V26, P1997, DOI 10.1158/1078 0432.CCR 19 2803
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Sims NA, 2012, CURR OSTEOPOROS REP, V10, P109, DOI 10.1007/s11914 012 0096 1
   Srivastava RK, 2022, J INFLAMM RES, V15, P1667, DOI 10.2147/JIR.S351918
   Srivastava RK, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00657
   Thomas MD, 2005, IMMUNITY, V23, P275, DOI 10.1016/j.immuni.2005.08.005
   Timblin GA, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00437 16
   Trapnell C, 2014, NAT BIOTECHNOL, V32, P381, DOI 10.1038/nbt.2859
   Vaananen HK, 1996, MATURITAS, V23, pS65
   Välimäki E, 2016, J IMMUNOL, V197, P3315, DOI 10.4049/jimmunol.1501840
   van de Sande B, 2020, NAT PROTOC, V15, P2247, DOI 10.1038/s41596 020 0336 2
   von Gunten S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419 020 03250 x
   Wang Y., 2019, bioRxiv, DOI DOI 10.1101/507871
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Xing LP, 2002, J BONE MINER RES, V17, P1200, DOI 10.1359/jbmr.2002.17.7.1200
   Yang Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.756722
   Yang WW, 2022, INT J GEN MED, V15, P749, DOI 10.2147/IJGM.S347416
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang WD, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.965258
   Zhang Y, 2021, OSTEOARTHR CARTILAGE, V29, P1324, DOI 10.1016/j.joca.2021.06.010
   Zheng XC, 2022, ONCOGENE, V41, P3587, DOI 10.1038/s41388 022 02371 1
   Zhou BO, 2014, CELL STEM CELL, V15, P154, DOI 10.1016/j.stem.2014.06.008
   Zupan J, 2013, BIOCHEM MEDICA, V23, P43, DOI 10.11613/BM.2013.007
NR 64
TC 1
Z9 1
U1 4
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 27
PY 2024
VL 14
IS 1
AR 29493
DI 10.1038/s41598 024 80993 z
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA N8O6Z
UT WOS:001366866100009
PM 39604551
OA gold, Green Accepted
DA 2025 08 17
ER

PT J
AU Xia, BJ
   Xu, B
   Sun, Y
   Xiao, LW
   Pan, JF
   Jin, HT
   Tong, PJ
AF Xia, Bingjiang
   Xu, Bing
   Sun, Yan
   Xiao, Luwei
   Pan, Jiafei
   Jin, Hongting
   Tong, Peijian
TI The effects of Liuwei Dihuang on canonical Wnt/β catenin signaling
   pathway in osteoporosis
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Liuwei Dihuang; Wnt; beta catenin; Osteoporosis; Ovariectomized rat;
   Osteoblast
ID POSTMENOPAUSAL OSTEOPOROSIS; CLEIDOCRANIAL DYSPLASIA; BIOCHEMICAL
   MARKERS; BONE TURNOVER; BETA CATENIN; RUNX2 GENE; RAT MODEL; DECOCTION;
   MUTATIONS; FRACTURES
AB Ethnopharrnacological relevance: The Liuwei Dihuang (LWDH), a wellknown classic traditional Chinese medicine formula, consists of six herbs including Rehmannia glutinosa Libosch. (family: Scrophulariaceae), Cornus officinalis Sieb. (family: Comaceae), Dioscorea opposite Thunb. (family: Dioscoreaceae), Alisma orientale (G. Samuelsson) Juz (family: Alismataceae), Poria cocos (Schw.) Wolf (family: Polyporaceae) and Paeonia suffruticosa Andrews (family: Paeoniaceae). It has been used clinically in the treatment of many types of diseases with signs of deficiency of Yin in the kidneys for more than 1000 years in China. The purpose of this study was to observe the effects of LWDH on canonical Wnt/beta catenin signaling pathway in osteoporosis.
   Materials and methods: Osteoporosis model was induced by ovariectomy (OVX) in 8 week old female Sprague Dawley (SD) rats. After 12 weeks of treatment with LWDH by intragastric administration, the rats were put to death in batch. The changes of alkaline phosphatase (ALP), osteocalcin (BGP) and estradiol (E2) in serum were determined, bone mineral density (BMD) and histomorphology of right femur were observed, biomechanics of lumbar vertebra were measured, and the expression of Lrp 5, beta catenin, Runx2, Osx involving the canonical Wnt/beta catenin signaling pathway were detected by RT PCR. In addition, osteoblasts isolated from neonatal rat calvariae were used in this study to investigate the effects of LWDH on the canonical Wnt/beta catenin signaling pathway. Cell proliferation and differentiation were observed by the MTT test, ALP activity and calcified nodules. The expression of Lrp 5, beta catenin, Runx2, Osx mRNA of cells were also detected. All the data were analyzed by SPSS 13.0.
   Results: Twelve weeks of treatment with LWDH could significantly decrease the level of ALP and BGP in serum, increase the BMD of femurs, and improve the biomechanical capabililty of vertebral body in maximum loading and elastic modulus. Concerning histomorphology, we found ordered arrangement of trabeculae, slightly thinning of trabeculae and none obvious slight fractures in femurs after twelve weeks of treatment with LWDH. In osteoblast, serum containing LWDH elicited significantly increase in cell viability (at day 6), alkaline phosphatase activity (at days 2, 4 and 6) and amount of calcified nodules. The expression of Lrp 5, beta catenin, Runx2 and Osx involved in the canonical Wnt/beta catenin signaling pathway were significantly up regulated in the presence of LWDH both in vivo and in vitro experiment.
   Conclusions: Our results suggest that Liuwei Dihuang could alleviate osteoporosis induced by ovariectomy, in part, through up regulation of canonical Wnt/beta catenin signaling pathway of osteoblast. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Xia, Bingjiang; Xu, Bing; Sun, Yan; Xiao, Luwei; Pan, Jiafei; Jin, Hongting; Tong, Peijian] Zhejiang Chinese Med Univ, Hangzhou 310053, Zhejiang, Peoples R China.
   [Xu, Bing; Sun, Yan; Tong, Peijian] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Hangzhou 310006, Zhejiang, Peoples R China.
   [Jin, Hongting; Tong, Peijian] Inst Orthopaed & Traumatol, Hangzhou 310053, Zhejiang, Peoples R China.
   [Xia, Bingjiang] Shaoxing Hosp Tradit Chinese Med, Shaoxing 312000, Zhejiang, Peoples R China.
C3 Zhejiang Chinese Medical University; Zhejiang Chinese Medical University
RP Tong, PJ (通讯作者)，Zhejiang Chinese Med Univ, Affiliated Hosp 1, Youdian Rd, Hangzhou 310006, Zhejiang, Peoples R China.
EM zhongxiyijieheguke@163.com
OI jin, hongting/0000 0001 8795 0874
FU National Natural Science Foundation of China [81202710]; State
   Administration of Tradition Chinese Medicine of Zhejiang province
   [2009YA001]; Zhejiang Provincial Natural Science Foundation of China
   [Y2111184]; Science Technology Department of Zhejiang province
   [2012R10064]
FX This publication was made possible by the National Natural Science
   Foundation of China (Grant no. 81202710), State Administration of
   Tradition Chinese Medicine of Zhejiang province (Grant no. 2009YA001),
   Zhejiang Provincial Natural Science Foundation of China (Grant no.
   Y2111184), and the Science Technology Department of Zhejiang province
   (Grant no. 2012R10064).
CR [Anonymous], CHINA J CHIN MAT MED
   [Anonymous], MOD J INTEGR TRADIT
   Aoyagi M, 1996, BONE, V19, P629, DOI 10.1016/S8756 3282(96)00280 3
   Bakker A, 2003, METH MOLEC MED, V80, P19
   Brunetti G, 2013, AM J PHYSIOL ENDOC M, V304, pE546, DOI 10.1152/ajpendo.00535.2012
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Chen Y, 1994, J Tradit Chin Med, V14, P298
   Clarke B, 2008, CLIN J AM SOC NEPHRO, V3, pS131, DOI 10.2215/CJN.04151206
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Collins GS, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d3651
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Fathilah SN, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472 6882 13 217
   Fei YR, 2012, J CELL PHYSIOL, V227, P3539, DOI 10.1002/jcp.24075
   French DL, 2008, PHYTOMEDICINE, V15, P1069, DOI 10.1016/j.phymed.2008.06.007
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gong YQ, 2001, CELL, V107, P513, DOI 10.1016/S0092 8674(01)00571 2
   Goss PE, 2004, BONE, V34, P384, DOI 10.1016/j.bone.2003.11.006
   Gundberg CM, 2000, CLIN LAB MED, V20, P489
   Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284
   Liu JP, 2013, J ETHNOPHARMACOL, V150, P371, DOI 10.1016/j.jep.2013.09.003
   Max W, 2002, OSTEOPOROSIS INT, V13, P493, DOI 10.1007/s001980200060
   MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902
   Nian H, 2009, PHYTOMEDICINE, V16, P320, DOI 10.1016/j.phymed.2008.12.006
   Nishio Y, 2006, GENE, V372, P62, DOI 10.1016/j.gene.2005.12.022
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Otto F, 2002, HUM MUTAT, V19, P209, DOI 10.1002/humu.10043
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Piscitelli P, 2007, OSTEOPOROSIS INT, V18, P211, DOI 10.1007/s00198 006 0224 9
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   SABOKBAR A, 1994, BONE MINER, V27, P57, DOI 10.1016/S0169 6009(08)80187 0
   SAVILLE PD, 1969, J AM GERIATR SOC, V17, P155, DOI 10.1111/j.1532 5415.1969.tb03169.x
   Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439
   Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   TURNER CH, 1993, BONE, V14, P595, DOI 10.1016/8756 3282(93)90081 K
   Verit Fatma Ferda, 2006, Archives of Gynecology and Obstetrics, V274, P133, DOI 10.1007/s00404 006 0148 9
   Wang P, 2010, J PHARMACEUT BIOMED, V53, P631, DOI 10.1016/j.jpba.2010.04.032
   Wu CR, 2007, J ETHNOPHARMACOL, V113, P79, DOI 10.1016/j.jep.2007.05.003
   Xu XJ, 2013, INT J ENDOCRINOL, V2013, DOI 10.1155/2013/534352
   Yang S, 2006, J ETHNOPHARMACOL, V106, P166, DOI 10.1016/j.jep.2005.12.017
   Yilmaz N, 1999, CLIN CHEM LAB MED, V37, P137, DOI 10.1515/CCLM.1999.025
   Yokozawa T, 2004, AM J CHINESE MED, V32, P829, DOI 10.1142/S0192415X04002442
   Yoshida T, 2003, BLOOD CELL MOL DIS, V30, P184, DOI 10.1016/S1079 9796(03)00020 2
   Zhao XF, 2007, J PHARMACEUT BIOMED, V44, P1183, DOI 10.1016/j.jpba.2007.04.025
   Zhou X, 2010, P NATL ACAD SCI USA, V107, P12919, DOI 10.1073/pnas.0912855107
NR 49
TC 63
Z9 75
U1 1
U2 56
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD APR 11
PY 2014
VL 153
IS 1
BP 133
EP 141
DI 10.1016/j.jep.2014.01.040
PG 9
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA AG4ZI
UT WOS:000335428500011
PM 24530448
DA 2025 08 17
ER

PT J
AU Jeong, C
   Lee, CH
   Lee, YJ
   Seo, J
   Wang, WH
   Park, KH
   Oh, E
   Cho, Y
   Park, C
   Son, YJ
   Park, JHY
   Kang, H
   Lee, KW
AF Jeong, Chanhyeok
   Lee, Chang Hyung
   Lee, Yongjin
   Seo, Jiwon
   Wang, Weihong
   Park, Kyu Hyung
   Oh, Eunseok
   Cho, Youbin
   Park, Chanyoon
   Son, Young Jin
   Park, Jung Han Yoon
   Kang, Heonjoong
   Lee, Ki Won
TI Ulmus macrocarpa Hance trunk bark extracts inhibit
   RANKL induced osteoclast differentiation and prevent ovariectomy induced
   osteoporosis in mice
SO JOURNAL OF ETHNOPHARMACOLOGY
LA English
DT Article
DE Ulmus macrocarpa Han ce; Ovariectomy; Osteoclastogenesis; Natural
   compound; Biological activity
ID C FOS; DAVIDIANA; OSTEOPROTEGERIN; CELLS
AB Ethnopharmacological relevance: Ulmus macrocarpa Hance (UmH) bark has been traditionally utilized for medic inal purposes. The bark extract of this plant has diverse health benefits, and its potential role in enhancing bone health is of distinct interest, particularly when considering the substantial health and economic implications of bone related pathologies, such as osteoporosis. Despite the compelling theoretical implications of UmH bark in fortifying bone health, no definitive evidence at the in vivo level is currently available, thus highlighting the innovative and as yet unexplored potential of this field of study.Aim of the study: Primarily, our study aims to conduct a meticulous analysis of the disparity in the concentration of active compounds in the UmH root bark (Umrb) and trunk bark (Umtb) extracts and confirm UmH bark's efficacy in enhancing bone health in vivo, illuminating the cellular mechanisms involved. Materials and methods: The Umrb and Umtb extracts were subjected to component analysis using high performance liquid chromatography and then assessed for their inhibitory effects on osteoclast differentiation through the TRAP assay. An ovariectomized (OVX) mouse model replicates postmenopausal conditions commonly associated with osteoporosis. Micro CT was used to analyze bone structure parameters, and enzyme linked immunosorbent assay and staining were used to assess bone formation markers and osteoclast activity. Furthermore, this study investigated the impact of the extract on the expression of pivotal proteins and genes involved in bone formation and resorption using mouse bone marrow derived macrophages (BMMs).Results: The findings of our study reveal a significant discrepancy in the concentration of active constituents between Umrb and Umtb, establishing Umtb as a superior source for promoting bone health. I addition, a standardized pilot scale procedure was conducted for credibility. The bone health benefits of Umtb were verified using an OVX model. This validation involved the assessment of various parameters, including BMD, BV/TV, and BS/TV, using micro CT imaging. Additionally, the activation of osteoblasts was evaluated by Umtb by measuring specific factors such as ALP, OCN, OPG in blood samples and through IHC staining. In the same investigations,diminished levels of osteoclast differentiation factors, such as TRAP, NFATc1, were also observed. The observed patterns exhibited consistency in vitro BMM investigations.Conclusions: Through verification at both in vitro levels using BMMs and in vivo levels using the OVX induced mouse model, our research demonstrates that Umtb is a more effective means of improving bone health in comparison to Umrb. These findings pave the way for developing health functional foods or botanical drugs targeting osteoporosis and other bone related disorders and enhance the prospects for future research extensions, including clinical studies, in extract applications.
C1 [Jeong, Chanhyeok; Seo, Jiwon; Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Jeong, Chanhyeok; Seo, Jiwon; Lee, Ki Won] Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
   [Lee, Chang Hyung; Park, Chanyoon; Park, Jung Han Yoon; Kang, Heonjoong; Lee, Ki Won] Seoul Natl Univ, BioMAX Inst, Seoul 08826, South Korea.
   [Lee, Yongjin; Son, Young Jin] Sunchon Natl Univ, Dept Pharm, Sunchon 57922, South Korea.
   [Wang, Weihong; Park, Kyu Hyung; Oh, Eunseok; Cho, Youbin; Park, Chanyoon; Kang, Heonjoong] Seoul Natl Univ, Sch Earth & Environm Sci, Lab Marine Drugs, NS 80, Seoul 08826, South Korea.
   [Wang, Weihong; Oh, Eunseok; Kang, Heonjoong] Seoul Natl Univ, Res Inst Oceanog, NS 80, Seoul 08826, South Korea.
   [Kang, Heonjoong] Seoul Natl Univ, Interdisciplinary Grad Program Genet Engn, NS 80, Seoul 08826, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Adv Inst Convergence Technol, Suwon 16229, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Inst Green Bio Sci & Technol, Pyeongchang 25354, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.
   [Lee, Ki Won] Seoul Natl Univ, Ctr Food & Bio Convergence, Seoul 08826, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Sunchon National University; Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU); Seoul National University (SNU); Seoul National
   University (SNU)
RP Lee, KW (通讯作者)，Seoul Natl Univ, Dept Agr Biotechnol, Seoul 08826, South Korea.; Lee, KW (通讯作者)，Seoul Natl Univ, Res Inst Agr & Life Sci, Seoul 08826, South Korea.
EM cksgur9450@snu.ac.kr; changhyung@snu.ac.kr; yojilee@gmail.com;
   thinkbreaker@snu.ac.kr; pharmacy2007@naver.com; grekhp@snu.ac.kr;
   dmstjr0130@snu.ac.kr; chanyoon0126@snu.ac.kr; chanyoon0126@snu.ac.kr;
   junedong9@snu.ac.kr; sony@sunchon.ac.kr; hjkang@snu.ac.kr;
   kiwon@snu.ac.kr
RI Jin Ho, Seo/B 3621 2014; Lee, Chang Hyung/MTD 8229 2025
OI Lee, Chang Hyung/0000 0002 1907 4400; 
FU BOBSNU Co. Ltd; Bio & Medical Technology Development Program of the
   National Research Foundation (NRF)   Korean government (MSIT)
   [2020M3H1A1073304]; Basic Science Research Program   Ministry of Science
   and ICT [2019R1A2C2005492]; Brain Korea 21 Plus Program of the
   Department of Agricultural Biotechnology, Seoul National University,
   Republic of Korea; Korea Institute of Marine Science & Technology
   Promotion (KIMST)   Ministry of Oceans and Fisheries [20220488]; Korea
   Institute of Planning and Evaluation for Technology in Food, Agriculture
   and Forestry (IPET) through the High Value added Food Technology
   Development Program   Ministry of Agriculture, Food and Rural Affairs
   (MAFRA) [321029 5]
FX This work was supported by BOBSNU Co. Ltd. and the Bio & Medical
   Technology Development Program of the National Research Foundation (NRF)
   funded by the Korean government (MSIT) (No. 2020M3H1A1073304) , the
   Basic Science Research Program funded by the Ministry of Science and ICT
   (2019R1A2C2005492) , Brain Korea 21 Plus Program of the Department of
   Agricultural Biotechnology, Seoul National University, Republic of Korea
   and the Korea Institute of Marine Science & Technology Promotion (KIMST)
   , which is funded by the Ministry of Oceans and Fisheries (20220488) and
   the Korea Institute of Planning and Evaluation for Technology in Food,
   Agriculture and Forestry (IPET) through the High Value added Food
   Technology Development Program, funded by the Ministry of Agriculture,
   Food and Rural Affairs (MAFRA) (321029 5) .
CR Bandow K, 2010, BIOCHEM BIOPH RES CO, V402, P755, DOI 10.1016/j.bbrc.2010.10.103
   Bi HD, 2017, FRONT MED LAUSANNE, V4, DOI 10.3389/fmed.2017.00234
   Blumer MJF, 2012, MECH DEVELOP, V129, P162, DOI 10.1016/j.mod.2012.04.003
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burden AM, 2021, OSTEOPOROSIS INT, V32, P817, DOI 10.1007/s00198 020 05756 8
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Cho AR, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5690816
   Clemens JD, 1997, CLIN CHEM, V43, P2058
   Drake MT, 2017, ENDOCR REV, V38, P325, DOI 10.1210/er.2015 1114
   GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685
   Han HJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217112
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Huang W, 2007, FRONT BIOSCI LANDMRK, V12, P3068, DOI 10.2741/2296
   Jang SA, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/7280342
   Jeong C, 2023, SCI REP UK, V13, DOI 10.1038/s41598 023 38208 4
   Jiang YB, 2005, J BONE MINER METAB, V23, P122, DOI 10.1007/BF03026336
   Jun CD, 1998, J ETHNOPHARMACOL, V62, P129, DOI 10.1016/S0378 8741(98)00063 4
   Kaneshita Y, 2007, ORTHOD WAVES, V66, P122, DOI 10.1016/j.odw.2007.09.003
   Kermanac'h NS, 2002, EUR CYTOKINE NETW, V13, P144
   Kim KJ, 2019, MOLECULES, V24, DOI 10.3390/molecules24203735
   Kim KJ, 2017, J CLIN MED, V6, DOI 10.3390/jcm6030032
   Koyama T., 1991, Obstet. Gynecol. Ther., V63, P203
   Kuo TR, 2017, BIOMARK RES, V5, DOI 10.1186/s40364 017 0097 4
   Kwon JH, 2011, ARCH PHARM RES, V34, P1459, DOI 10.1007/s12272 011 0907 4
   Lamothe B, 2007, BIOCHEM BIOPH RES CO, V359, P1044, DOI 10.1016/j.bbrc.2007.06.017
   Lee SG, 2021, J MICROBIOL BIOTECHN, V31, P1011, DOI 10.4014/jmb.2102.02015
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Nedeva IR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.641162
   Park JH, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0285 4
   Rho J, 2019, J ETHNOPHARMACOL, V233, P115, DOI 10.1016/j.jep.2018.11.042
   Rubinacci A, 1999, CLIN CHEM, V45, P1510
   Sharma C, 2014, INT J PHARM SCI RES, V5, P730, DOI 10.13040/IJPSR.0975 8232.5(3).730 41
   Shi X., 1983, Chinese English terminology of traditional Chinese medicine, P71
   Silva ARA, 2020, FOOD RES INT, V131, DOI 10.1016/j.foodres.2019.108972
   Singaram S, 2019, AFR J PRIM HEALTH CA, V11, DOI 10.4102/phcfm.v11i1.1908
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Suh SJ, 2007, J ETHNOPHARMACOL, V109, P480, DOI 10.1016/j.jep.2006.08.030
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   Wang WH, 2022, ACS OMEGA, V7, DOI 10.1021/acsomega.1c05305
   Wang Y, 2015, AM J PHYSIOL ENDOC M, V308, pE1066, DOI 10.1152/ajpendo.00030.2015
   Yang WK, 2013, MOL MED REP, V8, P726, DOI 10.3892/mmr.2013.1581
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang XZ, 2022, EXP GERONTOL, V164, DOI 10.1016/j.exger.2022.111823
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 44
TC 6
Z9 6
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378 8741
EI 1872 7573
J9 J ETHNOPHARMACOL
JI J. Ethnopharmacol.
PD JAN 30
PY 2024
VL 319
AR 117285
DI 10.1016/j.jep.2023.117285
EA NOV 2023
PN 3
PG 12
WC Plant Sciences; Chemistry, Medicinal; Integrative & Complementary
   Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary
   Medicine
GA Y9FN5
UT WOS:001108245900001
PM 37839769
DA 2025 08 17
ER

PT J
AU Wang, GF
   Luo, JX
   Qiao, YQ
   Zhang, DD
   Liu, YL
   Zhang, WJ
   Liu, XY
   Jiang, XQ
AF Wang, Guifang
   Luo, Jiaxin
   Qiao, Yuqin
   Zhang, Dongdong
   Liu, Yulan
   Zhang, Wenjie
   Liu, Xuanyong
   Jiang, Xinquan
TI AMPK/mTOR Pathway Is Involved in Autophagy Induced by
   Magnesium Incorporated TiO2 Surface to Promote BMSC
   Osteogenic Differentiation
SO JOURNAL OF FUNCTIONAL BIOMATERIALS
LA English
DT Article
DE magnesium; surface modification; titanium; osteogenic activity;
   autophagy
ID OSTEOBLAST DIFFERENTIATION; BONE; MINERALIZATION
AB Magnesium has been extensively utilized to modify titanium implant surfaces based on its important function in promoting osteogenic differentiation. Autophagy has been proven to play a vital role in bone metabolism. Whether there is an association between autophagy and magnesium in promoting osteogenic differentiation remains unclear. In the present study, we focused on investigating the role of magnesium ions in early osteogenic activity and the underlying mechanism related to autophagy. Different concentrations of magnesium were embedded in micro structured titanium surface layers using the micro arc oxidation (MAO) technique. The incorporation of magnesium benefited cell adhesion, spreading, and viability; attenuated intracellular ATP concentrations and p mTOR levels; and upregulated p AMPK levels. This indicates the vital role of the ATP related AMPK/mTOR signaling pathway in the autophagy process associated with osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) induced by magnesium modification on titanium surfaces. The enhanced osteogenic differentiation and improved cellular autophagy activity of BMSCs in their extraction medium further confirmed the function of magnesium ions. The results of the present study advance our understanding of the mechanism by which magnesium regulates BMSC osteogenic differentiation through autophagy regulation. Moreover, endowing implants with the ability to activate autophagy may be a promising strategy for enhancing osseointegration in the translational medicine field in the future.
C1 [Wang, Guifang; Luo, Jiaxin; Liu, Yulan; Zhang, Wenjie; Jiang, Xinquan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prosthodont, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Wang, Guifang; Luo, Jiaxin; Liu, Yulan; Zhang, Wenjie; Jiang, Xinquan] Shanghai Jiao Tong Univ, Coll Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stomat, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Qiao, Yuqin; Zhang, Dongdong; Liu, Xuanyong] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine M, 1295 Dingxi Rd, Shanghai 200050, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Chinese
   Academy of Sciences; Shanghai Institute of Ceramics, CAS
RP Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Prosthodont, Sch Med, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Jiang, XQ (通讯作者)，Shanghai Jiao Tong Univ, Coll Stomatol, Natl Ctr Stomatol, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stomat, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Qiao, YQ (通讯作者)，Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine M, 1295 Dingxi Rd, Shanghai 200050, Peoples R China.
EM qiaoyq@mail.sic.ac.cn; xinquanj@aliyun.com
RI Liu, Xuanyong/J 2609 2018; Zhang, Wenjie/O 5336 2014
OI jiaxin, luo/0000 0002 9069 6317; Zhang, Dongdong/0009 0008 0861 0926;
   Liu, Yulan/0000 0003 4140 3669; 
FU National Natural Science Foundation of China;  [82001011];  [31870944]; 
   [81921002];  [82130027]
FX This work was supported by the National Natural Science Foundation of
   China (82001011, 31870944, 81921002 and 82130027).
CR Bai RJ, 2022, ARTHRITIS RES THER, V24, DOI 10.1186/s13075 022 02848 0
   Becker M, 2020, J MECH BEHAV BIOMED, V109, DOI 10.1016/j.jmbbm.2020.103841
   Belluci MM, 2020, J NUTR BIOCHEM, V77, DOI 10.1016/j.jnutbio.2019.108301
   Bo T, 2016, J BONE MINER RES, V31, P1979, DOI 10.1002/jbmr.2885
   Castiglioni S, 2019, BIOCHEM BIOPH RES CO, V513, P159, DOI 10.1016/j.bbrc.2019.03.178
   Castiglioni S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34324 8
   Chen MW, 2019, J MATER CHEM B, V7, P2657, DOI 10.1039/c9tb00040b
   Chen WR, 2020, EXP CELL RES, V389, DOI 10.1016/j.yexcr.2020.111883
   Cheng Y, 2019, INT J MOL MED, V44, P652, DOI 10.3892/ijmm.2019.4216
   Hénaut L, 2018, ADV CHRONIC KIDNEY D, V25, P281, DOI 10.1053/j.ackd.2017.12.001
   Kaluderovic MR, 2014, CELLS TISSUES ORGANS, V200, P265, DOI 10.1159/000434625
   Kostov K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061724
   Leidi M, 2011, MAGNESIUM RES, V24, P1, DOI 10.1684/mrh.2011.0271
   Li LJ, 2019, ACTA BIOMATER, V96, P674, DOI 10.1016/j.actbio.2019.07.007
   Li SY, 2018, CERAM INT, V44, P16237, DOI 10.1016/j.ceramint.2018.06.009
   Li TY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.589112
   Li YQ, 2018, CELL BIOL INT, V42, P205, DOI 10.1002/cbin.10888
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin SH, 2022, BIOACT MATER, V18, P116, DOI 10.1016/j.bioactmat.2022.03.024
   Lin SH, 2019, ADV SCI, V6, DOI 10.1002/advs.201900209
   López Baltanás R, 2021, EUR J CLIN INVEST, V51, DOI 10.1111/eci.13561
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Nollet M, 2014, AUTOPHAGY, V10, P1965, DOI 10.4161/auto.36182
   Okuzu Y, 2017, ACTA BIOMATER, V63, P383, DOI 10.1016/j.actbio.2017.09.019
   Oost LJ, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.986616
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Park JH, 2012, BIOMATERIALS, V33, P7386, DOI 10.1016/j.biomaterials.2012.06.066
   Rezazadeh H, 2021, EUR J PHARMACOL, V909, DOI 10.1016/j.ejphar.2021.174418
   Sun XW, 2020, J CELL PHYSIOL, V235, P4954, DOI 10.1002/jcp.29374
   Tan L, 2020, J MATER CHEM B, V8, P2286, DOI 10.1039/d0tb00054j
   Tsao YT, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0497 2
   Vidoni C, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0414 7
   Wang GF, 2016, SCI REP UK, V6, DOI 10.1038/srep31769
   Wang GF, 2014, INT J NANOMED, V9, P2387, DOI 10.2147/IJN.S58357
   Wang H, 2022, COLLOID SURFACE B, V210, DOI 10.1016/j.colsurfb.2021.112246
   Wang J, 2010, ELECTROCHIM ACTA, V55, P6897, DOI 10.1016/j.electacta.2010.05.070
   Wang XX, 2020, AUTOPHAGY, V16, P1221, DOI 10.1080/15548627.2019.1659617
   Wei X, 2021, MATER TODAY BIO, V12, DOI 10.1016/j.mtbio.2021.100147
   Yellen G, 2018, J CELL BIOL, V217, P2235, DOI 10.1083/jcb.201803152
   Yue JJ, 2019, J CELL PHYSIOL, V234, P23190, DOI 10.1002/jcp.28885
   Zhang J, 2015, BIOMATERIALS, V53, P251, DOI 10.1016/j.biomaterials.2015.02.097
   Zhang JL, 2019, ADV HEALTHC MATER, V8, DOI 10.1002/adhm.201901030
   Zhang L, 2014, BIOCHEM BIOPH RES CO, V450, P1390, DOI 10.1016/j.bbrc.2014.07.004
   Zhang T, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 98007 7
   Zhang XR, 2021, J MATER CHEM B, V9, P3489, DOI 10.1039/d0tb02991b
   Zhang XF, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/7908205
   Zhao XD, 2020, J TISSUE ENG REGEN M, V14, P1869, DOI 10.1002/term.3142
   Zheng LW, 2017, J INVEST MED, V65, P1014, DOI 10.1136/jim 2017 000426
   Zhu L, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.903432
NR 49
TC 7
Z9 9
U1 2
U2 50
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2079 4983
J9 J FUNCT BIOMATER
JI J. Func. Biomater.
PD DEC
PY 2022
VL 13
IS 4
AR 221
DI 10.3390/jfb13040221
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 7E5SB
UT WOS:000901226400001
PM 36412862
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Iguchi, T
   Miyakawa, Y
   Saito, K
   Nakabayashi, C
   Nakanishi, M
   Saya, H
   Ikeda, Y
   Kizaki, M
AF Iguchi, Toyotaka
   Miyakawa, Yoshitaka
   Saito, Kaori
   Nakabayashi, Chika
   Nakanishi, Makoto
   Saya, Hideyuki
   Ikeda, Yasuo
   Kizaki, Masahiro
TI Zoledronate induced S phase arrest and apoptosis accompanied by DNA
   damage and activation of the ATM/Chkl/cdc25 pathway in human
   osteosarcoma cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE ATM; check point kinase; osteosarcoma; S phase arrest; zoledronate
ID BREAST CANCER CELLS; IN VITRO; BISPHOSPHONATES INHIBIT; PEDIATRIC
   OSTEOSARCOMA; PROSTATE CANCER; MYELOMA; LINES; AMINOBISPHOSPHONATES;
   PHOSPHORYLATION; METASTASES
AB Osteosarcoma is one of the most common primary malignant tumors of the bone in children and adolescents. Some patients continue to have a poor prognosis, as they have metastatic disease and frequent occurrence of drug resistance. Zoledronate is a nitrogen containing bisphosphonate that has been used for the treatment of hypercalcemia and bone metastasis, because it induces apoptosis in osteoclasts and tumor cells by inhibiting the isoprenylation of intracellular small G proteins. Besides inhibiting isoprenylation, little is known about the manner by which bisphosphonates inhibit cellular proliferation and induce apoptosis. This prompted us to investigate the inhibitory effects of zoledronate in human osteosarcoma cell lines, HOS and MG63. HOS cells accumulated in S phase around 6 h after treatment with 10 mu M zoledronate, followed by apoptosis. When HOS cells were treated with zoledronate, ATM kinase and its substrate, check point kinase (Chk)1, were phosphorylated. Zoledronate also induced phosphorylation of cdc25a (Thr506) in HOS cells, which is a substrate of Chk1, and its phosphorylation is known to be critical for S phase arrest. Following treatment with zoledronate, phosphorylated histone H2AX (gamma H2AX) displayed patterns of nuclear foci in HOS cells. As gamma H2AX accumulates at dsDNA breaks, these results demonstrate that zoledronate induced DNA damage and S phase arrest, accompanied by activation of the ATM/Chk1/cdc25 pathway in a human osteosarcoma cell line.
C1 Keio Univ, Sch Med, Dept Internal Med, Div Hematol,Shinjuku Ku, Tokyo 1608582, Japan.
   Keio Univ, Sch Med, Inst Adv Med Res, Shinjuku Ku,Div Gene Regulat, Tokyo 1608582, Japan.
   Nagoya City Univ, Sch Med, Dept Biochem, Nagoya, Aichi 4678601, Japan.
C3 Keio University; Keio University; Nagoya City University
RP Miyakawa, Y (通讯作者)，Keio Univ, Sch Med, Dept Internal Med, Div Hematol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM yoshi@sc.itc.keio.ac.jp
RI Saya, Hideyuki/J 4325 2013
CR Alvarez E, 2003, CLIN CANCER RES, V9, P5705
   Boissier S, 2000, CANCER RES, V60, P2949
   Caudron M, 2005, SCIENCE, V309, P1373, DOI 10.1126/science.1115964
   Clézardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008 5472.CAN 05 0264
   Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200
   Corey E, 2003, CLIN CANCER RES, V9, P295
   Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467
   Das H, 2001, BLOOD, V98, P1616, DOI 10.1182/blood.V98.5.1616
   Fromigue O, 2000, J BONE MINER RES, V15, P2211, DOI 10.1359/jbmr.2000.15.11.2211
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Kunzmann V, 2000, BLOOD, V96, P384
   Lee MV, 2001, CANCER RES, V61, P2602
   Lipton A, 2004, ONCOLOGIST, V9, P38, DOI 10.1634/theoncologist.9 90004 38
   Marina N, 2004, ONCOLOGIST, V9, P422, DOI 10.1634/theoncologist.9 4 422
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439
   Miyakawa Y, 2001, BIOCHEM BIOPH RES CO, V284, P71, DOI 10.1006/bbrc.2001.4950
   Nagarajan Rajaram, 2005, Curr Oncol Rep, V7, P410, DOI 10.1007/s11912 005 0005 1
   Sawafuji K, 2003, LEUKEMIA LYMPHOMA, V44, P1987, DOI 10.1080/1042819031000122033
   Senaratne SG, 2002, BRIT J CANCER, V86, P1479, DOI 10.1038/sj.bjc.6600297
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Tyagi A, 2005, CARCINOGENESIS, V26, P1978, DOI 10.1093/carcin/bgi165
   vanderPluijm G, 1996, J CLIN INVEST, V98, P698, DOI 10.1172/JCI118841
   Zhang HL, 2003, CLIN EXP METASTAS, V20, P153, DOI 10.1023/A:1022621622063
NR 26
TC 44
Z9 54
U1 0
U2 3
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1019 6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD AUG
PY 2007
VL 31
IS 2
BP 285
EP 291
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 193PH
UT WOS:000248286000006
PM 17611684
DA 2025 08 17
ER

PT J
AU Wehrhan, F
   Gross, C
   Creutzburg, K
   Amann, K
   Ries, J
   Kesting, M
   Geppert, CI
   Weber, M
AF Wehrhan, Falk
   Gross, Christian
   Creutzburg, Kay
   Amann, Kerstin
   Ries, Jutta
   Kesting, Marco
   Geppert, Carol Immanuel
   Weber, Manuel
TI Osteoclastic expression of higher level regulators NFATc1 and BCL6 in
   medication related osteonecrosis of the jaw secondary to bisphosphonate
   therapy: a comparison with osteoradionecrosis and osteomyelitis
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Medication related osteonecrosis of the jaw; MRONJ; BRONJ;
   Osteoradionecrosis; ORN; Osteomyelitis; Osteoclasts; NFATc1; BCL6;
   Osteoclastic regulators
ID DIFFERENTIATION; INDUCTION; ACTIVATION; MECHANISM; RANKL
AB BackgroundWith an increasing indication spectrum of antiresorptive drugs, the medication related osteonecrosis of the jaw secondary to bisphosphonate therapy [MRONJ (BP)] is continuously gaining clinical relevance. Impaired osteoclast function, accompanied by altered cell morphology and expression of osteoclastic effector proteins, contributes to the pathogenesis of MRONJ (BP). However, the underlying regulatory mechanisms at a transcriptional level are unaddressed so far. These mechanisms are crucial to the development of disease characteristic osteoclastic anomalies, that contribute to the pathogenesis of MRONJ (BP). NFATc1 is considered a master upstream osteoclastic activator, whereas BCL6 acts as osteoclastic suppressor. The present study aimed to elucidate the NFATc1 and BCL6 mediated osteoclastic regulation and activity in MRONJ (BP) compared to osteoradionecrosis (ORN) and osteomyelitis (OM) and normal jaw bone.MethodsFormalin fixed jaw bone specimens from 70 patients [MRONJ (BP) n=30; OM: n=15, ORN: n=15, control: n=10] were analyzed retrospectively for osteoclast expression of NFATc1 and BCL6. The specimens were processed for H&E staining and immunohistochemistry. The histological sections were digitalized and analyzed by virtual microscopy.ResultsOsteoclastic expression of NFATc1 and BCL6 was significantly higher in MRONJ (BP) specimens compared to OM and control specimens. NFATc1 and BCL6 labeling indices revealed no significant differences between MRONJ (BP) and ORN. The ratio of nuclear BCL6+ osteoclasts to cytoplasmic BCL6+ osteoclasts revealed significantly higher values for MRONJ (BP) specimens compared to OM and controls.ConclusionThis study displays that osteoclasts in MRONJ (BP) tissues feature increased expression of the higher level regulators, paradoxically of both NFATc1 and BCL6. These observations can help to explain the genesis of morphologically altered and resorptive inactive osteoclasts in MRONJ (BP) tissues by outlining the transcriptional regulation of the pathomechanically relevant osteoclastic effector proteins. Furthermore, they strengthen the etiological delineation of MRONJ (BP) from OM and extend the osteoclast profiles of MRONJ (BP), OM and ORN and thus could lead to a better histopathological differentiation that can improve treatment decision and motivate new therapeutic concepts.
C1 [Wehrhan, Falk; Gross, Christian; Creutzburg, Kay; Ries, Jutta; Kesting, Marco; Weber, Manuel] Friedrich Alexander Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, Gluckstr 11, D 91054 Erlangen, Germany.
   [Amann, Kerstin] Friedrich Alexander Univ Erlangen Nurnberg, Dept Nephropathol, Inst Pathol, Erlangen, Germany.
   [Geppert, Carol Immanuel] Friedrich Alexander Univ Erlangen Nurnberg, Inst Pathol, Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg
RP Weber, M (通讯作者)，Friedrich Alexander Univ Erlangen Nurnberg, Dept Oral & Maxillofacial Surg, Gluckstr 11, D 91054 Erlangen, Germany.
EM manuel.weber@uk erlangen.de
OI Gross, Christian/0000 0003 3276 6505; Weber, Manuel/0000 0002 8649 5977
FU Deutsche Gesellschaft fur Zahn , Mund  und Kieferheilkunde (DGZMK)
FX This project was funded by Deutsche Gesellschaft fur Zahn , Mund  und
   Kieferheilkunde (DGZMK).
CR Aghaloo T, 2015, ORAL MAXIL SURG CLIN, V27, P489, DOI 10.1016/j.coms.2015.06.001
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bagan L, 2017, MED ORAL PATOL ORAL, V22, pE542, DOI 10.4317/medoral.22128
   Boquete Castro A, 2016, CLIN ORAL IMPLAN RES, V27, P367, DOI 10.1111/clr.12556
   Cheriex KCAL, 2013, J RECONSTR MICROSURG, V29, P69, DOI 10.1055/s 0032 1329923
   Chronopoulos A, 2018, INT DENT J, V68, P22, DOI 10.1111/idj.12318
   Coxon FP, 2006, CURR OPIN PHARMACOL, V6, P307, DOI 10.1016/j.coph.2006.03.005
   Di Nisio C, 2015, EUR J HISTOCHEM, V59, P45, DOI 10.4081/ejh.2015.2455
   Felsenberg D, 2012, OSTEOLOGIE, V21, P180
   Gross C, 2017, J TRANSL MED, V15, DOI 10.1186/s12967 017 1230 8
   Hansen T, 2006, J ORAL PATHOL MED, V35, P155, DOI 10.1111/j.1600 0714.2006.00391.x
   Khan AA, 2015, J BONE MINER RES, V30, P3, DOI 10.1002/jbmr.2405
   Kim J, 2013, J BONE MINER RES, V28, P2381, DOI 10.1002/jbmr.1973
   Kim Jung Ha, 2014, J Bone Metab, V21, P233, DOI 10.11005/jbm.2014.21.4.233
   Kim K, 2008, MOL ENDOCRINOL, V22, P176, DOI 10.1210/me.2007 0237
   Marx RE, 2012, INT J ORAL MAX SURG, V41, P283, DOI 10.1016/j.ijom.2011.12.016
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   McArdle A, 2015, PLAST RECONSTR SURG, V135, P808, DOI 10.1097/PRS.0000000000000963
   Miyamoto Takeshi, 2011, Keio Journal of Medicine, V60, P101
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Niu HF, 2002, HEMATOL ONCOL, V20, P155, DOI 10.1002/hon.689
   Pingali HV, 2016, J CELL BIOL, V214, P649, DOI 10.1083/jcb.201608075
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Rosenberg A., 2016, DIAGN HISTOPATHOL, V22, P355, DOI [10.1016/j.mpdhp.2016.09.005, DOI 10.1016/J.MPDHP.2016.09.005]
   Ruggiero SL, 2007, J DENT RES, V86, P1013, DOI 10.1177/154405910708601101
   Sena P, 2014, ONCOL REP, V31, P103, DOI 10.3892/or.2013.2846
   Stockmann P, 2010, SUPPORT CARE CANCER, V18, P449, DOI 10.1007/s00520 009 0688 1
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Topazian RG., 1994, ORAL MAXIL LOFACIAL, P51
   Walter C, 2014, CLIN ORAL INVEST, V18, P2221, DOI 10.1007/s00784 014 1205 6
   Yagi M, 2007, J BONE MINER RES, V22, P992, DOI 10.1359/JBMR.070401
   Yang B, 2012, MOL MED REP, V5, P955, DOI 10.3892/mmr.2012.765
   Yang HW, 2015, INT J CLIN EXP PATHO, V8, P5161
   YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 37
TC 26
Z9 27
U1 3
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1479 5876
J9 J TRANSL MED
JI J. Transl. Med.
PD MAR 4
PY 2019
VL 17
AR 69
DI 10.1186/s12967 019 1819 1
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA HN9OK
UT WOS:000460528500001
PM 30832685
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zavrski, I
   Krebbel, H
   Wildemann, B
   Heider, U
   Kaiser, M
   Possinger, K
   Sezer, O
AF Zavrski, I
   Krebbel, H
   Wildemann, B
   Heider, U
   Kaiser, M
   Possinger, K
   Sezer, O
TI Proteasome inhibitors abrogate osteoclast differentiation and osteoclast
   function
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE cancer induced bone disease; NF kappa B; osteoclast; proteasome;
   proteasome inhibitors
ID FACTOR KAPPA B; NECROSIS FACTOR RECEPTOR; BONE DESTRUCTION; RANKL
   EXPRESSION; CELL GROWTH; LIGAND; ACTIVATOR; OSTEOPROTEGERIN; APOPTOSIS;
   PAMIDRONATE
AB Cancer induced bone disease results in bone destruction, pathological fractures, and pain. We hypothesized that the inhibition of the proteasome ubiquitin system in osteoclasts could abolish the receptor activator of NF kappa B ligand (RANKL) mediated osteoclast differentiation and function, since RANKL mediated downstream signaling plays a crucial role in osteoclast life cycle. In this study, we examined the effects of the proteasome inhibitors MG 132 and MG 262 on RANKL induced osteoclast differentiation and function. Osteoclast precursors from peripheral blood mononuclear cells were cultured in the presence of RANKL and M CSF. Osteoclasts were identified as multi nucleated TRAP positive cells. Osteoclast function was quantified with the extent of dentine resorption and TRAP activity in culture supernatants. For the evaluation of the effects of proteasome inhibitors towards osteoclastogenesis, sub apoptotic concentrations of MG 132 and MG 262 were used. Effects on NF kappa B were obtained in treated and untreated osteoclasts. MG 132 and MG 262 inhibit both osteoclast differentiation and osteoclast function. 0.01 mu M MG 132 induced a 3.2 fold (P = 0.004) and 0.001 mu M MG 262 a 3.3 fold (P = 0.004) reduction of osteoclast differentiation, respectively. The resorption capacity was decreased 2.6  and 11.1 fold (P = 0.003) by treatment with 0.01 and 0.1 mu M MG 132, and 14.2  and 16.6 fold (P = 0.003) by 0.001 and 0.01 mu M MG 262, respectively. This decrease correlated with the extent of NF kappa B binding capacity. In conclusion, this study shows for the first time that proteasome inhibitors act on osteoclast development and function at low concentrations and should be considered as potential drugs for the treatment of cancer induced osteolytic bone disease. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Hosp Charite, Dept Oncol & Hematol, Berlin, Germany.
   Univ Hosp Charite, Ctr Musculoskeletal Surg, Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Sezer, O (通讯作者)，Univ Hosp Charite, Dept Oncol & Hematol, Berlin, Germany.
EM sezer@charite.de
RI Wildemann, Britt/G 7732 2012; Kaiser, Martin/LTD 2019 2024
OI Wildemann, Britt/0000 0002 8365 1188; Kaiser, Martin/0000 0002 3677 4804
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Adams J, 1999, CANCER RES, V59, P2615
   Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Ashcroft AJ, 2003, LANCET ONCOL, V4, P284, DOI 10.1016/S1470 2045(03)01076 3
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Farrugia AN, 2003, CANCER RES, V63, P5438
   Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097 4644(19990101)72:1<67::AID JCB8>3.0.CO;2 A
   Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225
   Gori F, 2000, ENDOCRINOLOGY, V141, P4768, DOI 10.1210/en.141.12.4768
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   Heider U, 2004, J CANCER RES CLIN, V130, P469, DOI 10.1007/s00432 004 0578 3
   Heider U, 2003, CLIN CANCER RES, V9, P1436
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hofbauer LC, 2001, CANCER AM CANCER SOC, V92, P460, DOI 10.1002/1097 0142(20010801)92:3<460::AID CNCR1344>3.0.CO;2 D
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Karin M, 2004, NAT REV DRUG DISCOV, V3, P17, DOI 10.1038/nrd1279
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Naujokat C, 2000, EUR J HAEMATOL, V65, P221, DOI 10.1034/j.1600 0609.2000.065004221.x
   Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634
   Orlowski RZ, 2002, J BIOL CHEM, V277, P27864, DOI 10.1074/jbc.M201519200
   Roux S, 2002, BRIT J HAEMATOL, V117, P86, DOI 10.1046/j.1365 2141.2002.03417.x
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood 2002 01 0148
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Teitelbaum SL, 2004, J CLIN INVEST, V114, P463, DOI 10.1172/JCI200422644
   Theriault RL, 1999, J CLIN ONCOL, V17, P846, DOI 10.1200/JCO.1999.17.3.846
   Yamamoto A, 2002, J BONE MINER RES, V17, P612, DOI 10.1359/jbmr.2002.17.4.612
   Zavrski I, 2003, J CANCER RES CLIN, V129, P383, DOI 10.1007/s00432 003 0454 6
NR 33
TC 85
Z9 93
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
EI 1090 2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 22
PY 2005
VL 333
IS 1
BP 200
EP 205
DI 10.1016/j.bbrc.2005.05.098
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 939XE
UT WOS:000230105200029
PM 15936724
DA 2025 08 17
ER

PT J
AU Tian, JW
   Moon, JS
   Nga, H
   Lee, HY
   Nguyen, TL
   Jang, HJ
   Setoyama, D
   Shong, M
   Lee, JH
   Yi, HS
AF Tian, Jingwen
   Moon, Ji Sun
   Nga, Ha Thi
   Lee, Ho Yeop
   Nguyen, Thi Linh
   Jang, Hyo Ju
   Setoyama, Daiki
   Shong, Minho
   Lee, Ju Hee
   Yi, Hyon Seung
TI Brown fat specific mitoribosomal function is crucial for preventing cold
   exposure induced bone loss
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Cold exposure; Bone loss; Brown adipose tissue; Mitochondria
ID ADIPOSE TISSUE; ENERGY; THERMOGENESIS; MOUSE
AB This study examines the interplay between ambient temperature, brown adipose tissue (BAT) function, and bone metabolism, emphasizing the effects of cold exposure and BAT mitochondrial activity on bone health. Utilizing ovariectomized (OVX) mice to model primary osteoporosis and BAT specific mitochondrial dysfunction (BKO) mice, we evaluated the impact of housing temperature on bone density, immune modulation in bone marrow, and the protective role of BAT against bone loss. Cold exposure was found to universally reduce bone mass, enhance osteoclastogenesis, and alter bone marrow T cell populations, implicating the immune system in bone remodeling under cold stress. The thermogenic function of BAT, driven by mitochondrial oxidative phosphorylation, was crucial in protecting against bone loss. Impaired BAT function, through surgical removal or mitochondrial dysfunction, exacerbated bone loss in cold environments, highlighting BAT's metabolic role in maintaining bone health. Furthermore, cold induced changes in BAT function led to systemic metabolic shifts, including elevated long chain fatty acids, which influenced osteoclast differentiation and activity. These findings suggest a systemic mechanism connecting environmental temperature and BAT metabolism with bone physiology, providing new insights into the metabolic and environmental determinants of bone health. Future research could lead to novel bone disease therapies targeting these pathways.
C1 [Tian, Jingwen; Moon, Ji Sun; Nga, Ha Thi; Lee, Ho Yeop; Nguyen, Thi Linh; Jang, Hyo Ju; Yi, Hyon Seung] Chungnam Natl Univ, Sch Med, Lab Endocrinol & Immune Syst, Daejeon 35015, South Korea.
   [Tian, Jingwen; Moon, Ji Sun; Nga, Ha Thi; Lee, Ho Yeop; Nguyen, Thi Linh; Jang, Hyo Ju; Lee, Ju Hee; Yi, Hyon Seung] Chungnam Natl Univ, Dept Internal Med, Sch Med, Daejeon 35015, South Korea.
   [Setoyama, Daiki] Kyushu Univ Hosp, Dept Clin Chem & Lab Med, Fukuoka, Japan.
   [Shong, Minho] Korea Adv Inst Sci & Technol, Grad Sch Med Sci & Engn, Daejeon, South Korea.
C3 Chungnam National University; Chungnam National University; Kyushu
   University; Korea Advanced Institute of Science & Technology (KAIST)
RP Yi, HS (通讯作者)，Chungnam Natl Univ, Sch Med, Lab Endocrinol & Immune Syst, Daejeon 35015, South Korea.; Yi, HS (通讯作者)，Chungnam Natl Univ, Dept Internal Med, Sch Med, Daejeon 35015, South Korea.
EM jmpbooks@cnu.ac.kr
RI Yi, Hyon Seung/ABA 2729 2022; Linh, Nguyen/AAS 5706 2020
FU Korea Health Industry Development Institute
FX Not applicable.
CR Bredella MA, 2014, BONE, V58, P55, DOI 10.1016/j.bone.2013.10.007
   Bredella MA, 2012, J CLIN ENDOCR METAB, V97, pE584, DOI 10.1210/jc.2011 2246
   Cannon B, 2011, J EXP BIOL, V214, P242, DOI 10.1242/jeb.050989
   Chen LP, 2022, INT J BIOL SCI, V18, P6176, DOI 10.7150/ijbs.77051
   Chevalier C, 2020, CELL METAB, V32, P575, DOI 10.1016/j.cmet.2020.08.012
   Choi MJ, 2020, DIABETOLOGIA, V63, P837, DOI 10.1007/s00125 019 05082 7
   Davis SL, 1998, DOMEST ANIM ENDOCRIN, V15, P283, DOI 10.1016/S0739 7240(98)00034 4
   Du JK, 2022, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.778019
   Ginting RP, 2023, CELLS BASEL, V12, DOI 10.3390/cells12060881
   Hoeke G, 2016, CIRC RES, V118, P173, DOI 10.1161/CIRCRESAHA.115.306647
   Hylander BL, 2017, ADV EXP MED BIOL, V1036, P173, DOI 10.1007/978 3 319 67577 0_12
   Iwaniec UT, 2016, OSTEOPOROSIS INT, V27, P3091, DOI 10.1007/s00198 016 3634 3
   Kang SG, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102181
   Kim SJ, 2012, CELL METAB, V16, P274, DOI 10.1016/j.cmet.2012.06.012
   Komatsu N, 2014, NAT MED, V20, P62, DOI 10.1038/nm.3432
   Labbé SM, 2015, FASEB J, V29, P2046, DOI 10.1096/fj.14 266247
   Lau J, 2016, NEUROPEPTIDES, V59, P97, DOI 10.1016/j.npep.2016.03.006
   Lee P, 2013, OSTEOPOROSIS INT, V24, P1513, DOI 10.1007/s00198 012 2110 y
   Li YG, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.826314
   Lidell M E, 2015, Int J Obes Suppl, V5, pS23, DOI 10.1038/ijosup.2015.7
   de Morentin PBM, 2014, CELL METAB, V20, P41, DOI 10.1016/j.cmet.2014.03.031
   Motyl KJ, 2013, J BONE MINER RES, V28, P1885, DOI 10.1002/jbmr.1943
   Nielsen TS, 2014, J MOL ENDOCRINOL, V52, pR199, DOI 10.1530/JME 13 0277
   O'Brien CA, 2010, BONE, V46, P911, DOI 10.1016/j.bone.2009.08.050
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Ricquier D, 2000, J PHYSIOL LONDON, V529, P3, DOI 10.1111/j.1469 7793.2000.00003.x
   Robbins A, 2018, AM J PHYS ANTHROPOL, V167, P557, DOI 10.1002/ajpa.23684
   Serrat MA, 2015, J ORTHOP RES, V33, P692, DOI 10.1002/jor.22812
   Serrat MA, 2008, P NATL ACAD SCI USA, V105, P19348, DOI 10.1073/pnas.0803319105
   Shevchuk NA, 2008, MED HYPOTHESES, V70, P995, DOI 10.1016/j.mehy.2007.04.052
   Sidossis L, 2015, J CLIN INVEST, V125, P478, DOI 10.1172/JCI78362
   Sözen T, 2017, EUR J RHEUMATOL, V4, P46, DOI 10.5152/eurjrheum.2016.048
   Tian JW, 2022, J CACHEXIA SARCOPENI, V13, P1785, DOI 10.1002/jcsm.12975
   Chou TJ, 2022, INT J MED SCI, V19, P499, DOI 10.7150/ijms.66996
   Wee NKY, 2020, CALCIFIED TISSUE INT, V107, P510, DOI 10.1007/s00223 020 00745 9
NR 35
TC 2
Z9 2
U1 1
U2 5
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420 682X
EI 1420 9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2024
VL 81
IS 1
AR 314
DI 10.1007/s00018 024 05347 4
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA A2W7J
UT WOS:001281189700001
PM 39066814
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Chuang, PY
   Shen, SH
   Yang, TY
   Huang, TW
   Huang, KC
AF Chuang, Po Yao
   Shen, Shih Hsun
   Yang, Tien Yu
   Huang, Tsan Wen
   Huang, Kuo Chin
TI Non steroidal anti inflammatory drugs and the risk of a second hip
   fracture: a propensity score matching study
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Non steroidal anti inflammatory drugs; Fragility hip fracture; Second
   hip fracture; Population based study; Propensity score matching
ID BONE MINERAL DENSITY; ELDERLY PEOPLE; PROSTAGLANDINS; OSTEOPOROSIS;
   PREVENTION; ASPIRIN; CAUSAL
AB Background: Non steroidal anti inflammatory drugs (NSAIDs) are frequently prescribed for elderly patients, particularly after a hip fracture. However, we are not clear about the effect of NSAIDs on the risk of a second hip fracture because of confounding factors.
   Methods: This was a Taiwan National Health Insurance Research Database based study using propensity score matching (PSM) to control for confounding. Enrollees were selected from patients with a hip fracture during 1996 2004 and followed longitudinally until December 2009. After PSM for comorbidities and bisphosphonate therapy, 94 patients with a second hip fracture were assigned to the Cases group and 461 without it to the Controls group. The target drugs are NSAIDs; paracetamol and dexamethasone are used for comparison.
   Results: The correlation between the mean daily dose (MDD) ratios of NSAIDs and the probability values of the current statistical tests were highly negative (Pearson's r =  0.920, P = 0.003), which indicated that the higher the MDD ratios, the greater the risks of a second hip fracture. A Kaplan Meier survival analysis showed a time dependent trend of increasing risk of a second hip fracture in patients taking NSAIDs (P < 0.001). Moreover, patients >= 60 years old had a higher risk of a second hip fracture than did those < 60 and taking the NSAIDs diclofenac (P = 0.016) and celecoxib (P = 0.003) and the corticosteroid dexamethasone (P = 0.018), but not those taking analgesic paracetamol (P = 0.074).
   Conclusions: We conclude that taking NSAIDs after a fragility hip fracture dose and time dependently significantly increases the risk of a second hip fracture, especially in elderly patients. To lower the risk of a second hip fracture, any underlying causes for excessively using NSAIDs should be treated and thus fewer NSAIDs prescribed after a first hip fracture.
C1 [Chuang, Po Yao; Shen, Shih Hsun; Yang, Tien Yu; Huang, Tsan Wen; Huang, Kuo Chin] Chang Gung Mem Hosp, Dept Orthopaed Surg, Chiayi, Taiwan.
   [Chuang, Po Yao; Shen, Shih Hsun; Yang, Tien Yu; Huang, Tsan Wen; Huang, Kuo Chin] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University
RP Huang, KC (通讯作者)，Chang Gung Mem Hosp, Dept Orthopaed Surg, Chiayi, Taiwan.; Huang, KC (通讯作者)，Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
EM kc2672@gmail.com
RI Chuang, Po Yao/MVW 9079 2025; HUANG, Kuo Chin/S 7371 2019
CR Bauer DC, 1996, J BONE MINER RES, V11, P29
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087
   Dehejia RH, 2002, REV ECON STAT, V84, P151, DOI 10.1162/003465302317331982
   Ekman EF, 2010, J AM ACAD ORTHOP SUR, V18, P278, DOI 10.5435/00124635 201005000 00004
   FayePetersen OM, 1996, PEDIATR PATHOL LAB M, V16, P489, DOI 10.1080/15513819609168686
   Goodman SN, 1999, ANN INTERN MED, V130, P995, DOI 10.7326/0003 4819 130 12 199906150 00008
   Jee WSS, 1997, BONE, V21, P297, DOI 10.1016/S8756 3282(97)00147 6
   Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198 012 1964 3
   Kannus P, 2000, NEW ENGL J MED, V343, P1506, DOI 10.1056/NEJM200011233432101
   KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066
   KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36
   Khosla S, 2008, ENDOCR REV, V29, P441, DOI 10.1210/er.2008 0002
   Lönnroos E, 2007, OSTEOPOROSIS INT, V18, P1279, DOI 10.1007/s00198 007 0375 3
   Mann B., 2012, The Open Epidemiology Journal, V5, P18, DOI [10.2174/1874297101205010018, DOI 10.2174/1874297101205010018]
   McLellan AR, 2003, OSTEOPOROSIS INT, V14, P1028, DOI 10.1007/s00198 003 1507 z
   Pietschmann P, 2009, GERONTOLOGY, V55, P3, DOI 10.1159/000166209
   Raisz Lawrence G., 2001, American Journal of Medicine, V110, p43S
   Raisz LG, 1999, OSTEOARTHR CARTILAGE, V7, P1
   RASHIQ S, 1986, BMJ BRIT MED J, V292, P861, DOI 10.1136/bmj.292.6524.861
   Rochon PA, 1997, BMJ BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096
   ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41
   Rossini M, 2014, DRUG AGING, V31, P547, DOI 10.1007/s40266 014 0184 2
   Ryg J, 2009, J BONE MINER RES, V24, P1299, DOI [10.1359/jbmr.090207, 10.1359/JBMR.090207]
   Shen SH, 2014, J AM MED DIR ASSOC, V15, P725, DOI 10.1016/j.jamda.2014.05.010
   THOMPSON DD, 1988, J BONE MINER RES, V3, P409
   Van Staa TP, 2000, BONE, V27, P563, DOI 10.1016/S8756 3282(00)00361 6
   Vestergaard P, 2012, OSTEOPOROSIS INT, V23, P1255, DOI 10.1007/s00198 011 1692 0
   Vestergaard P, 2001, PHARMACOECONOMICS, V19, P449, DOI 10.2165/00019053 200119050 00002
   Wilkin T, 2001, BRIT MED J, V323, P795, DOI 10.1136/bmj.323.7316.795
NR 30
TC 8
Z9 8
U1 1
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD MAY 4
PY 2016
VL 17
AR 201
DI 10.1186/s12891 016 1047 2
PG 8
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics; Rheumatology
GA DL5AE
UT WOS:000375648200001
PM 27141945
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, W
   Liu, N
   Shi, HG
   Liu, J
   Shi, LX
   Zhang, B
   Wang, HY
   Ji, JH
   Chu, PK
AF Zhang, Wei
   Liu, Na
   Shi, Haigang
   Liu, Jun
   Shi, Lianxin
   Zhang, Bo
   Wang, Huaiyu
   Ji, Junhui
   Chu, Paul K.
TI Upregulation of BMSCs Osteogenesis by Positively Charged Tertiary Amines
   on Polymeric Implants via Charge/iNOS Signaling Pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; PULSED ELECTROMAGNETIC FIELDS; NITRIC OXIDE;
   BONE REGENERATION; OSTEOBLAST DIFFERENTIATION; PROTONATED AMINES;
   ELECTRON TRANSFER; MEMBRANES; PROLIFERATION; STIMULATION
AB Positively charged surfaces on implants have a similar potential to upregulate osteogenesis of bone marrow derived mesenchymal stem cells (BMSCs) as electromagnetic therapy approved for bone regeneration. Generally, their osteogenesis functions are generally considered to stem from the charge induced adhesion of extracellular matrix (ECM) proteins without exploring the underlying surface charge/cell signaling molecule pathways. Herein, a positively charged surface with controllable tertiary amines is produced on a polymer implant by plasma surface modification. In addition to inhibiting the TNF alpha expression, the positively charged surface with tertiary amines exhibits excellent cytocompatibility as well as remarkably upregulated osteogenesis related gene/protein expressions and calcification of the contacted BMSCs. Stimulated by the charged surface, these BMSCs display high iNOS expressions among the three NOS isoforms. Meanwhile, downregulation of the iNOS by L Can or siRNA inhibit osteogenic differentiation in the BMSCs. These findings suggest that a positively charged surface with tertiary amines induces osteogenesis of BMSCs via the surface charge/iNOS signaling pathway in addition to elevated ECM protein adhesion. Therefore, creating a positively charged surface with tertiary amines is a promising approach to promote osseointegration with bone tissues.
C1 [Zhang, Wei; Shi, Haigang; Liu, Jun; Shi, Lianxin; Ji, Junhui] Chinese Acad Sci, Tech Inst Phys & Chem, Beijing 100190, Peoples R China.
   [Liu, Na; Zhang, Bo] Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Beijing 100853, Peoples R China.
   [Wang, Huaiyu; Chu, Paul K.] City Univ Hong Kong, Dept Phys & Mat Sci, Kowloon, Hong Kong, Peoples R China.
C3 Chinese Academy of Sciences; Technical Institute of Physics & Chemistry,
   CAS; Chinese People's Liberation Army General Hospital; City University
   of Hong Kong
RP Zhang, W (通讯作者)，Chinese Acad Sci, Tech Inst Phys & Chem, Beijing 100190, Peoples R China.
EM weizhang@mail.ipc.ac.cn; jhji@mail.ipc.ac.cn; paul.chu@cityu.edu.hk
RI Chu, Paul/B 5923 2013; Wang, Huaiyu/S 7019 2019; ZHANG,
   BO/JZD 9745 2024; Shi, Lianxin/AAU 2870 2020
OI Chu, Paul/0000 0002 5581 4883; 
FU National Natural Science Foundation of China [NSFC 51473175, 31200741];
   Chinese Academy of Sciences, City University of Hong Kong Strategic
   Research Grant (SRG) [7004188]; Hong Kong Research Grants Council (RGC)
   General Research Funds (GRF) [CityU 112212]
FX Financial support from the National Natural Science Foundation of China
   (NSFC 51473175, 31200741), Chinese Academy of Sciences, City University
   of Hong Kong Strategic Research Grant (SRG) No. 7004188, and Hong Kong
   Research Grants Council (RGC) General Research Funds (GRF) No. CityU
   112212 is acknowledged.
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   Baldik Y, 2005, BONE, V37, P32, DOI 10.1016/j.bone.2004.10.002
   Barrias CC, 2009, BIOMATERIALS, V30, P307, DOI 10.1016/j.biomaterials.2008.09.048
   Brison J, 2013, ANAL CHEM, V85, P10869, DOI 10.1021/ac402288d
   Chang TM, 2013, J AM CHEM SOC, V135, P14821, DOI 10.1021/ja407414d
   Chatakun P, 2014, CELL MOL LIFE SCI, V71, P113, DOI 10.1007/s00018 013 1326 0
   Cheng GZ, 2011, NITRIC OXIDE BIOL CH, V25, P316, DOI 10.1016/j.niox.2011.05.009
   Costa RR, 2014, CHEM SOC REV, V43, P3453, DOI 10.1039/c3cs60393h
   Curran JM, 2013, BIOMATERIALS, V34, P9352, DOI 10.1016/j.biomaterials.2013.08.044
   Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838
   Dubey AK, 2014, J AM CERAM SOC, V97, P481, DOI 10.1111/jace.12647
   Fan ZP, 2009, NAT CELL BIOL, V11, P1002, DOI 10.1038/ncb1913
   Girard Lauriault PL, 2005, PLASMA PROCESS POLYM, V2, P263, DOI 10.1002/ppap.200400092
   Gugala Z, 2006, J BIOMED MATER RES A, V76A, P288, DOI 10.1002/jbm.a.30462
   Hall CJ, 2012, CELL STEM CELL, V10, P198, DOI 10.1016/j.stem.2012.01.007
   Hanus J, 2012, PLASMA PROCESS POLYM, V9, P371, DOI 10.1002/ppap.201100137
   Harding FJ, 2012, ACTA BIOMATER, V8, P1739, DOI 10.1016/j.actbio.2012.01.034
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Kaivosoja E, 2012, ANN MED, V44, P635, DOI 10.3109/07853890.2011.573805
   Klein Nulend J, 2014, OSTEOPOROSIS INT, V25, P1427, DOI 10.1007/s00198 013 2590 4
   Liao TQ, 2010, BIOTECHNOL PROGR, V26, P1705, DOI 10.1002/btpr.471
   Lopez LC, 2007, PLASMA PROCESS POLYM, V4, pS402, DOI 10.1002/ppap.200731008
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744
   Mahadevi AS, 2013, CHEM REV, V113, P2100, DOI 10.1021/cr300222d
   Majumdar A, 2008, J APPL PHYS, V104, DOI 10.1063/1.2990054
   McEvoy N, 2012, CARBON, V50, P1216, DOI 10.1016/j.carbon.2011.10.036
   Nichols SP, 2012, ADV DRUG DELIVER REV, V64, P1177, DOI 10.1016/j.addr.2012.03.002
   Niedbala W, 2011, P NATL ACAD SCI USA, V108, P9220, DOI 10.1073/pnas.1100667108
   Ocarino NM, 2008, NITRIC OXIDE BIOL CH, V19, P320, DOI 10.1016/j.niox.2008.08.004
   Oliveira BL, 2013, J MOL MODEL, V19, P1537, DOI 10.1007/s00894 012 1677 8
   Ostrowski SG, 2004, SCIENCE, V305, P71, DOI 10.1126/science.1099791
   Petit A, 2010, J BIOMED MATER RES A, V94A, P744, DOI 10.1002/jbm.a.32739
   Pevsner Fischer M, 2011, STEM CELL REV REP, V7, P560, DOI 10.1007/s12015 011 9229 7
   Qu YL, 2014, J BIOMAT SCI POLYM E, V25, P211, DOI 10.1080/09205063.2013.849903
   Rashkin MJ, 2004, J AM CHEM SOC, V126, P13320, DOI 10.1021/ja0498538
   Rompolas P, 2013, NATURE, V502, P513, DOI 10.1038/nature12602
   Sabanai K, 2008, J BONE MINER RES, V23, P633, DOI 10.1359/JBMR.080107
   Sabanai Ken, 2009, Clin Calcium, V19, P1133, DOI CliCa090811331141
   Sakai K, 2011, DENT MATER J, V30, P913, DOI 10.4012/dmj.2011 126
   Schröder K, 2010, J ADHES SCI TECHNOL, V24, P1191, DOI 10.1163/016942409X12619870771501
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Setsuhara Y, 2009, THIN SOLID FILMS, V518, P1006, DOI 10.1016/j.tsf.2009.07.161
   Smith BC, 2013, P NATL ACAD SCI USA, V110, pE3577, DOI 10.1073/pnas.1313331110
   Stevens MM, 2005, SCIENCE, V310, P1135, DOI 10.1126/science.1106587
   TABRAH F, 1990, J BONE MINER RES, V5, P437, DOI 10.1002/jbmr.5650050504
   Taylor BC, 2006, BONE, V39, P174, DOI 10.1016/j.bone.2005.12.080
   Teixeira CC, 2005, BONE, V37, P37, DOI 10.1016/j.bone.2005.03.010
   Tejero J, 2010, J BIOL CHEM, V285, P27232, DOI 10.1074/jbc.M110.138842
   Tsai CL, 2011, INVEST OPHTH VIS SCI, V52, P5481, DOI 10.1167/iovs.11 7676
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   Wang CJ, 2009, NITRIC OXIDE BIOL CH, V20, P298, DOI 10.1016/j.niox.2009.02.006
   Wang YY, 2012, J BIOACT COMPAT POL, V27, P122, DOI 10.1177/0883911512436773
   Wang YY, 2010, J BIOACT COMPAT POL, V25, P622, DOI 10.1177/0883911510382765
   Yokota T, 2007, SURF COAT TECH, V201, P8048, DOI 10.1016/j.surfcoat.2006.03.051
   Zhang DX, 1998, J AM SOC MASS SPECTR, V9, P1146, DOI 10.1016/S1044 0305(98)00093 2
NR 56
TC 36
Z9 41
U1 2
U2 51
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAR 20
PY 2015
VL 5
AR 9369
DI 10.1038/srep09369
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CD8OU
UT WOS:000351355700001
PM 25791957
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, YZ
   Zhang, J
   Sun, BY
   Ma, L
   Ma, Y
AF Zhang, Yongzhi
   Zhang, Jin
   Sun, Baiyu
   Ma, Li
   Ma, Yue
TI Catalpol Promotes Osseointegration of Titanium Implants under Conditions
   of Type 2 Diabetes via AKT/GSK3β/FYN Pathway Mediated NRF2 Activation
SO ACS OMEGA
LA English
DT Article
ID OXIDATIVE STRESS; BONE; DYSFUNCTION; INJURY
AB Catalpol (CA), a compound derived from the roots of Rehmannia glutinosa, is recognized for its anti oxidative and anti inflammatory properties. The current study aimed to evaluate the impact of CA on the osseointegration of titanium implants (TIs) in the context of type 2 diabetes and elucidate the underlying pharmacological mechanisms. MC3T3 E1 cells were incubated on the surface of titanium plates and exposed to various media for investigating osteoblast behaviors, as follows: regular medium, medium of high glucose and high lipid (HGHL) that simulates diabetic conditions, HGHL + CA medium, or HGHL + CA + LY294002 (an inhibitor of phosphoinositide 3 kinase or PI3K) medium. TIs were also surgically implanted into the femoral condyle defects in normal mice and mouse models of type 2 diabetes mellitus (T2DM). HGHL induced oxidative stress was found to cause osteoblast dysfunction, accompanied by the inactivation of AKT/GSK3 beta/FYN pathway mediated NRF2 signaling. However, CA administration effectively mitigated HGHL induced oxidative stress and reactivated AKT/GSK3 beta/FYN/NRF2 signaling, resulting in the reversal of HGHL induced dysfunctions in MC3T3 E1 cells, as evidenced by enhanced osteoblast adhesion, proliferation, and differentiation, as well as reduced apoptotic injury. In addition, the positive effects of CA were confirmed in vivo by enhanced osseointegration of TIs observed in mouse models of T2DM using microcomputed tomography and histological analyses. However, the pro osteogenic effects of CA were almost completely nullified by the addition of LY294002. These findings demonstrated for the first time that CA administration ameliorates the impairment in osseointegration of TIs under conditions of T2DM via AKT/GSK3 beta/FYN pathway mediated NRF2 activation. Given its antioxidative and pro osteogenic properties, CA administration holds promise as a reliable therapeutic strategy in the future for implant restoration in patients with T2DM.
C1 [Zhang, Yongzhi; Zhang, Jin] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Yongzhi; Zhang, Jin; Sun, Baiyu; Ma, Li; Ma, Yue] Shandong Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Yongzhi; Zhang, Jin; Sun, Baiyu; Ma, Li; Ma, Yue] Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Jinan 250012, Shandong, Peoples R China.
   [Zhang, Yongzhi; Zhang, Jin; Sun, Baiyu; Ma, Li; Ma, Yue] Shandong Prov Clin Res Ctr Oral Dis, Jinan 250012, Shandong, Peoples R China.
   [Sun, Baiyu] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Prosthodont, Jinan 250012, Shandong, Peoples R China.
   [Ma, Li; Ma, Yue] Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Hlth Care,Dept Gen Dent 2, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Ma, L; Ma, Y (通讯作者)，Shandong Key Lab Oral Tissue Regenerat, Jinan 250012, Shandong, Peoples R China.; Ma, L; Ma, Y (通讯作者)，Shandong Engn Res Ctr Dent Mat & Oral Tissue Regen, Jinan 250012, Shandong, Peoples R China.; Ma, L; Ma, Y (通讯作者)，Shandong Prov Clin Res Ctr Oral Dis, Jinan 250012, Shandong, Peoples R China.; Ma, L; Ma, Y (通讯作者)，Shandong Univ, Sch & Hosp Stomatol, Cheeloo Coll Med, Dept Hlth Care,Dept Gen Dent 2, Jinan 250012, Shandong, Peoples R China.
EM mali@sdu.edu.cn; mayue@sdu.edu.cn
RI Ma, Li/JEP 6982 2023
FU National Natural Science Foundation of China [82071148]; National
   Natural Science Foundation of China [ZR2021MH092]; Natural Science
   Foundation of Shandong Province [BK20210111]; Natural Science Foundation
   of Jiangsu Province
FX The National Natural Science Foundation of China, grant no. 82071148;
   the Natural Science Foundation of Shandong Province, grant no.
   ZR2021MH092; and the Natural Science Foundation of Jiangsu Province,
   grant no. BK20210111.
CR Albrektsson T, 2019, CLIN IMPLANT DENT R, V21, P4, DOI 10.1111/cid.12742
   Arab HH, 2021, ACS CHEM NEUROSCI, V12, P689, DOI 10.1021/acschemneuro.0c00722
   Bhattamisra SK, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11020323
   Bhattamisra SK, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10010032
   Bu TT, 2023, NUTRIENTS, V15, DOI 10.3390/nu15132863
   Chen BH, 2023, LIFE SCI, V312, DOI 10.1016/j.lfs.2022.121092
   Choi EM, 2019, J APPL TOXICOL, V39, P1710, DOI 10.1002/jat.3896
   Dai XZ, 2017, CIRC RES, V120, pE7, DOI 10.1161/CIRCRESAHA.117.310619
   [董鞾 DONG Wei], 2009, [复旦学报. 自然科学版, Journal of Fudan University. Natural Sciences], V48, P409
   Dong Z, 2013, PHYTOMEDICINE, V20, P1023, DOI 10.1016/j.phymed.2013.04.007
   Elbatreek MH, 2019, TRENDS ENDOCRIN MET, V30, P312, DOI 10.1016/j.tem.2019.02.006
   Feng YF, 2013, BIOMATERIALS, V34, P2234, DOI 10.1016/j.biomaterials.2012.12.023
   Feng Z, 2019, TOXICOL IN VITRO, V56, P141, DOI 10.1016/j.tiv.2019.01.016
   Ge HW, 2022, MICROVASC RES, V140, DOI 10.1016/j.mvr.2021.104302
   Hamada Y, 2009, BONE, V45, pS35, DOI 10.1016/j.bone.2009.02.004
   Huang Y, 2015, J NUTR BIOCHEM, V26, P1401, DOI 10.1016/j.jnutbio.2015.08.001
   Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200
   Javed F, 2009, J PERIODONTOL, V80, P1719, DOI 10.1902/jop.2009.090283
   Ji F, 2020, AGING US, V12, P19045, DOI 10.18632/aging.103689
   Jia TT, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109216
   Jiao HL, 2015, CURR OSTEOPOROS REP, V13, P327, DOI 10.1007/s11914 015 0286 8
   Jiao N, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2019.116736
   Klokkevold PR, 2007, INT J ORAL MAX IMPL, V22, P173
   Li MM, 2022, J ETHNOPHARMACOL, V285, DOI 10.1016/j.jep.2021.114820
   Li XM, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00625
   Li Y, 2022, DRUG DES DEV THER, V16, P165, DOI 10.2147/DDDT.S335024
   Ly LD, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2016.157
   Mouthuy PA, 2016, BIOMATERIALS, V109, P55, DOI 10.1016/j.biomaterials.2016.09.010
   Naujokat H, 2016, INT J IMPLANT DENT, V2, DOI 10.1186/s40729 016 0038 2
   Ni HB, 2023, NEUROCHEM RES, V48, P681, DOI 10.1007/s11064 022 03796 6
   Rong H, 2018, FREE RADICAL BIO MED, V120, P114, DOI 10.1016/j.freeradbiomed.2018.03.028
   Tao HQ, 2020, ACTA BIOCH BIOPH SIN, V52, P1055, DOI 10.1093/abbs/gmaa098
   Wang YN, 2021, J DENT RES, V100, P658, DOI 10.1177/0022034520983245
   [武丽南 Wu Linan], 2012, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V17, P126
   Xuan Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.862618
   Yan JT, 2018, PHARMACOL RES, V130, P466, DOI 10.1016/j.phrs.2017.12.026
   Zeng H, 2021, ACTA PHARM SIN B, V11, P71, DOI 10.1016/j.apsb.2020.09.006
   Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974
   Zhang HG, 2018, ONCOTARGET, V9, P3887, DOI 10.18632/oncotarget.23242
   Zhang ZW, 2022, CELLS BASEL, V11, DOI 10.3390/cells11162560
   Zheng LM, 2021, INT J BIOL MACROMOL, V176, P13, DOI 10.1016/j.ijbiomac.2021.01.103
   Zhu HF, 2016, CHIN MED UK, V11, DOI 10.1186/s13020 016 0096 7
   Zhu YH, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118881
NR 44
TC 4
Z9 4
U1 5
U2 15
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2470 1343
J9 ACS OMEGA
JI ACS Omega
PD JAN 25
PY 2024
VL 9
IS 5
BP 5761
EP 5771
DI 10.1021/acsomega.3c08518
PG 11
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry
GA HH4F3
UT WOS:001158581800001
PM 38343941
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Tai, YT
   Fulciniti, M
   Hideshima, T
   Song, WH
   Leiba, M
   Li, XF
   Rumizen, M
   Burger, P
   Morrison, A
   Podar, K
   Chauhan, D
   Tassone, P
   Richardson, P
   Munshi, NC
   Ghobrial, IM
   Anderson, KC
AF Tai, Yu Tzu
   Fulciniti, Mariateresa
   Hideshima, Teru
   Song, Weihua
   Leiba, Merav
   Li, Xian Feng
   Rumizen, Matthew
   Burger, Peter
   Morrison, Aileen
   Podar, Klaus
   Chauhan, Dharminder
   Tassone, Pierfrancesco
   Richardson, Paul
   Munshi, Nikhil C.
   Ghobrial, Irene M.
   Anderson, Kenneth C.
TI Targeting MEK induces myelorna cell cytotoxicity and inhibits
   osteoclastogenesis
SO BLOOD
LA English
DT Article
ID HUMAN MULTIPLE MYELOMA; DEXAMETHASONE INDUCED APOPTOSIS; BONE MARROW
   MICROENVIRONMENT; ACTIVATED PROTEIN KINASE; VEGF SECRETION; GROWTH;
   RESISTANCE; PATHWAY; ERK; SURVIVAL
AB Activation of the extracellular signal regulated kinase1/2 (ERK1/2) signaling cascade mediates human multiple myeloma (MM) growth and survival triggered by cytokines and adhesion to bone marrow stromal cells (BMSCs). Here, we examined the effect of AZD6244 (ARRY 142886), a novel and specific MEK1/2 inhibitor, on human MM cell growth in the bone marrow (BM) milieu. AZD6244 blocks constitutive and cytokine stimulated ERK1/2 phosphorylation and inhibits proliferation and survival of human MM cell lines and patient MM cells, regardless of sensitivity to conventional chemotherapy. Importantly, AZD6244 (200 nM) induces apoptosis in patient MM cells, even in the presence of exogenous interleukin 6 or BMSCs associated with triggering of caspase 3 activity. AZD6244 sensitizes MM cells to both conventional (dexamethasone) and novel (perifosine, lenalidomide, and bortezomib) therapies. AZD6244 down regulates the expression/secretion of osteoclast (OC) activating factors from MM cells and inhibits in vitro differentiation of MM patient PBMCs to OCs induced by ligand for receptor activator of NF kappa B (RANKIL) and macrophage colony stimulating factor (M CSF). Finally, AZD6244 inhibits tumor growth and prolongs survival in vivo in a human plasmacytoma xenograft model. Taken together, these results show that AZD6244 targets both MM cells and OCs in the BM microenvironment, providing the preclinical framework for clinical trials to improve patient outcome in MM.
C1 Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Vet Adm Boston Hlth Care Syst, Boston, MA 02115 USA.
C3 Harvard University; Harvard University Medical Affiliates; Dana Farber
   Cancer Institute; Harvard University; Harvard Medical School
RP Tai, YT (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, M551,44 Binney St, Boston, MA 02115 USA.
EM yu tzu tai@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
RI ; Fonseca, Rafael/K 5371 2019; Munshi, Nikhil/ABE 2338 2021; Tassone,
   Pierfrancesco/AIA 5373 2022; li, xianfeng/GYD 5825 2022; Podar,
   Klaus/ABD 1112 2020; Anderson, Kenneth/ACP 5073 2022
OI Tassone, Pierfrancesco/0000 0002 8298 6787; Podar,
   Klaus/0000 0002 7414 3632; 
FU PHS HHS [R0 1 50947, P0 1 78378] Funding Source: Medline
CR Abe M, 2004, BLOOD, V104, P2484, DOI 10.1182/blood 2003 11 3839
   Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929 7941.2002
   Barlogie B, 2006, J CLIN ONCOL, V24, P929, DOI 10.1200/JCO.2005.04.5807
   Bezieau S, 2001, HUM MUTAT, V18, P212, DOI 10.1002/humu.1177
   Bisping G, 2006, BLOOD, V107, P2079, DOI 10.1182/blood 2004 11 4250
   Burger R, 2001, Hematol J, V2, P42, DOI 10.1038/sj.thj.6200075
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   GeorgiiHemming P, 1996, BLOOD, V88, P2250, DOI 10.1182/blood.V88.6.2250.bloodjournal8862250
   Giuliani N, 2004, LEUKEMIA, V18, P628, DOI 10.1038/sj.leu.2403269
   Grigorieva I, 1998, EXP HEMATOL, V26, P597
   Hideshima T, 2001, CANCER RES, V61, P3071
   Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood 2004 01 0037
   Hideshima T, 2006, BLOOD, V107, P4053, DOI 10.1182/blood 2005 08 3434
   Hu LP, 2003, BLOOD, V101, P3126, DOI 10.1182/blood 2002 08 2640
   Hurt EM, 2004, CANCER CELL, V5, P191, DOI 10.1016/S1535 6108(04)00019 4
   Huynh H, 2007, MOL CANCER THER, V6, P138, DOI 10.1158/1535 7163.MCT 06 0436
   Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037
   Menu E, 2004, BRIT J CANCER, V90, P1076, DOI 10.1038/sj.bjc.6601613
   Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood 2004 11 4512
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood 2003 06 1984
   Ogawa M, 2000, CANCER RES, V60, P4262
   Ottonello L, 2005, INT J IMMUNOPATH PH, V18, P403, DOI 10.1177/039463200501800302
   Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428
   Pollett JB, 2002, BLOOD, V100, P3819, DOI 10.1182/blood 2002 02 0608
   Ribatti D, 2006, ONCOGENE, V25, P4257, DOI 10.1038/sj.onc.1209456
   Richardson P, 2006, J CLIN ONCOL, V24, P334, DOI 10.1200/JCO.2005.03.8851
   Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood 2006 04 015909
   Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304
   Staehler M, 2005, CURR DRUG TARGETS, V6, P835, DOI 10.2174/138945005774574498
   Tai YT, 2005, CANCER RES, V65, P11712, DOI 10.1158/0008 5472.CAN 05 1657
   Tai YT, 2005, CANCER RES, V65, P5898, DOI 10.1158/0008 5472.CAN 04 4125
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008 5472.CAN 06 0190
   Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975
   Vacca A, 1999, BLOOD, V93, P3064
   van de Donk NWCJ, 2006, BLOOD, V107, P3415, DOI 10.1182/blood 2005 11 4449
   Xu FH, 1997, BRIT J HAEMATOL, V97, P429, DOI 10.1046/j.1365 2141.1997.592708.x
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078 0432.CCR 06 1150
NR 38
TC 102
Z9 114
U1 0
U2 4
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006 4971
J9 BLOOD
JI Blood
PD SEP 1
PY 2007
VL 110
IS 5
BP 1656
EP 1663
DI 10.1182/blood 2007 03 081240
PG 8
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA 205YT
UT WOS:000249151800043
PM 17510321
OA Green Published
DA 2025 08 17
ER

PT J
AU Liu, C
   Wang, L
   Zhu, R
   Liu, H
   Ma, R
   Chen, B
   Li, L
   Guo, Y
   Jia, Q
   Shi, S
   Zhao, D
   Mo, F
   Zhao, B
   Niu, J
   Fu, M
   Orekhov, AN
   Brömme, D
   Gao, S
   Zhang, D
AF Liu, C.
   Wang, L.
   Zhu, R.
   Liu, H.
   Ma, R.
   Chen, B.
   Li, L.
   Guo, Y.
   Jia, Q.
   Shi, S.
   Zhao, D.
   Mo, F.
   Zhao, B.
   Niu, J.
   Fu, M.
   Orekhov, A. N.
   Broemme, D.
   Gao, S.
   Zhang, D.
TI Rehmanniae Radix Preparata suppresses bone loss and
   increases bone strength through interfering with canonical Wnt/β catenin
   signaling pathway in OVX rats
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Bone quality; Cathepsin K; OPG/RANKL; Ovariectomized(OVX) rats;
   Rehmanniae Radix Preparata (RRP); Wnt/beta catenin
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; CHINESE HERBAL MEDICINE; LIUWEI
   DIHUANG; OVARIECTOMY; INHIBITION; EXPRESSION; OSTEOBLAST; PREVENTION;
   MANAGEMENT; ECHINACOSIDE
AB A Summary Rehmanniae Radix Preparata (RRP) improves bone quality in OVX rats through the regulation of bone homeostasis via increasing osteoblastogenesis and decreasing osteoclastogenesis, suggesting it has a potential for the development of new anti osteoporotic drugs.
   Introduction Determine the anti osteoporotic effect of RRP in ovariectomized (OVX) rats and identify the signaling pathway involved in this process.
   Methods OVX rats were treated with RRP aqueous extract for 14 weeks. The serum levels of tartrate resistant acid phosphatase (TRAP), receptor activator of nuclear factor kappa B ligand(RANKL), alkaline phosphatase (ALP), and osteoprotegerin (OPG) were determined by ELISA. Bone histopathological alterations were evaluated by H&E, Alizarin red S, and Safranin O staining. Bone mineral density (BMD) and bone microstructure in rat femurs and lumbar bones were determined by dual energy X ray absorptiometry and micro computed tomography. Femoral bone strength was detected by a three point bending assay. The expression of Phospho glycogen synthase kinase 3 beta (p GSK 3), GSK 3, Dickkopf related protein 1 (DKK1), cathepsin K, OPG, RANKL, IGF 1, Runx2, beta catenin, and p beta catenin was determined by western blot and/or immunohistochemical staining.
   Results Treatment of OVX rats with RRP aqueous extract rebuilt bone homeostasis demonstrated by increasing the levels of OPG as well as decreasing the levels of TRAP, RANKL, and ALP in serum. Furthermore, RRP treatment preserved BMD and mechanical strength by increasing cortical bone thickness and epiphyseal thickness as well as improving trabecular distribution in the femurs of OVX rats. In addition, RRP downregulated the expression of DKK1, sclerostin, RANKL, cathepsin K, and the ratio of p beta catenin to beta catenin, along with upregulating the expression of IGF 1, beta catenin, and Runx2 and the ratio of p GSK 3 beta to GSK 3 beta in the tibias and femurs of OVX rats. Echinacoside, jionoside A1/A2, acetoside, isoacetoside, jionoside B1, and jionoside B2 were identified in the RRP aqueous extract.
   Conclusion RRP attenuates bone loss and improves bone quality in OVX rats partly through its regulation of the canonical Wnt/beta catenin signaling pathway, suggesting that RRP has the potential to provide a new source of anti osteoporotic drugs.
C1 [Liu, C.; Wang, L.; Zhu, R.; Liu, H.; Ma, R.; Chen, B.; Li, L.; Guo, Y.; Jia, Q.; Zhao, D.; Mo, F.; Niu, J.; Gao, S.; Zhang, D.] Beijing Univ Chinese Med, Tradit Chinese Med Sch, Diabet Res Ctr, Beijing 100029, Peoples R China.
   [Liu, C.; Wang, L.; Shi, S.; Zhao, B.] Beijing Univ Chinese Med, Chinese Mat Med Sch, Beijing 100029, Peoples R China.
   [Ma, R.] China Acad Chinese Med Sci, Guanganmen Hosp, Beijing 100053, Peoples R China.
   [Guo, Y.] Beijing Univ Chinese Med, Affiliated Clin Hosp 3, Beijing 100029, Peoples R China.
   [Fu, M.] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ H4A 3J1, Canada.
   [Orekhov, A. N.] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Lab Angiopathol, Moscow 125315, Russia.
   [Broemme, D.] Univ British Columbia, Fac Dent, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; China Academy of Chinese Medical Sciences; Guang'anmen
   Hospital, CACMS; Beijing University of Chinese Medicine; McGill
   University; Russian Academy of Medical Sciences; Institute of General
   Pathology & Pathophysiology, RAMS; University of British Columbia
RP Zhang, D (通讯作者)，Beijing Univ Chinese Med, Tradit Chinese Med Sch, Diabet Res Ctr, Beijing 100029, Peoples R China.
EM dongwei1006@gmail.com
RI Zhang, Dongwei/AAS 8384 2020; Mo, Fangfang/LPQ 9010 2024; 史,
   社坡/HPC 0109 2023; Orekhov, Alexander/J 4838 2013; ma,
   rufeng/AAS 6452 2021
FU Beijing Municipal Natural Science Foundation [7172126]; National Natural
   Science Foundation of China [NSFC81273995]
FX Dr. Dongwei Zhang received grants to conduct this study from the Beijing
   Municipal Natural Science Foundation (7172126) and the National Natural
   Science Foundation of China (NSFC81273995). Dr. Sihua Gao received
   grants from the National Natural Science Foundation of China
   (NSFC81274041) and the key drug development program ofMOST
   (20122X09103201 005). Dr. Jianzhao Niu received a grant from the 111
   project of MOE (B07007). Dr. Dieter Br.mme received a grant from the
   Canadian Institute of Health Research (CIHRMOP). All authors declare
   that the results presented in thismanuscript are the true expression of
   findings, and there has been no interference in respondents' free
   communication and dissemination.
CR Amirhosseini M, 2018, J CELL PHYSIOL, V233, P2398, DOI 10.1002/jcp.26111
   Andreollo NA, 2012, ABCD ARQ BRAS CIR DI, V25, P49, DOI 10.1590/S0102 67202012000100011
   [Anonymous], CHINA J CHIN MAT MED
   [Anonymous], CHIN J OSTEOPOROS
   [Anonymous], P 11 END AC C
   [Anonymous], STUDIES CHEM CONSTIT
   [Anonymous], MOD J INTEGR TRADIT
   Appelman Dijkstra NM, 2016, CALCIFIED TISSUE INT, V98, P370, DOI 10.1007/s00223 016 0126 6
   Ardawi MSM, 2013, BONE, V56, P355, DOI 10.1016/j.bone.2013.06.029
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Brömme D, 2016, EXPERT OPIN DRUG DIS, V11, P457, DOI 10.1517/17460441.2016.1160884
   Chen Y, 1994, J Tradit Chin Med, V14, P298
   Chen YY, 2001, AM J PHYSIOL ENDOC M, V280, pE315, DOI 10.1152/ajpendo.2001.280.2.E315
   Fassio A, 2017, CURR PHARM DESIGN, V23, P6241, DOI 10.2174/1381612823666170713104431
   Ge JR, 2018, CHIN J INTEGR MED, V24, P415, DOI 10.1007/s11655 016 2744 2
   Guo YB, 2016, LIFE SCI, V148, P24, DOI 10.1016/j.lfs.2016.02.056
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Hu JH, 2017, BIOCHEM PHARMACOL, V136, P109, DOI 10.1016/j.bcp.2017.04.010
   Ismail B, 2010, FOOD ANALYSIS, FOURTH EDITION, P473, DOI 10.1007/978 1 4419 1478 1_27
   Jain Vardhaman Mulchand, 2017, J Educ Health Promot, V6, P90, DOI 10.4103/jehp.jehp_41_17
   Jiang JMY, 2008, J NUTR, V138, P2106, DOI 10.3945/jn.108.093781
   Jiang ZW, 2017, ACS APPL MATER INTER, V9, P34674, DOI 10.1021/acsami.7b10184
   Kawai M, 2012, ENDOCRIN METAB CLIN, V41, P323, DOI 10.1016/j.ecl.2012.04.013
   Kiem PV, 2008, ARCH PHARM RES, V31, P823, DOI 10.1007/s12272 001 1232 3
   Li F, 2013, PHYTOMEDICINE, V20, P549, DOI 10.1016/j.phymed.2013.01.001
   Li F, 2012, FITOTERAPIA, V83, P1443, DOI 10.1016/j.fitote.2012.08.008
   Li J, 2006, BONE, V39, P754, DOI 10.1016/j.bone.2006.03.017
   Lim DW, 2013, MOLECULES, V18, P5804, DOI 10.3390/molecules18055804
   Lin X, 2015, CLIN INTERV AGING, V10, P1017, DOI 10.2147/CIA.S54613
   Lindberg MK, 2006, BONE, V38, P85, DOI 10.1016/j.bone.2005.07.027
   Liu CY, 2017, J ETHNOPHARMACOL, V198, P351, DOI 10.1016/j.jep.2017.01.021
   Ma RF, 2017, CELL PHYSIOL BIOCHEM, V41, P55, DOI 10.1159/000455936
   Mathews S, 2014, J TISSUE ENG REGEN M, V8, P143, DOI 10.1002/term.1507
   Oh KO, 2003, CLIN CHIM ACTA, V334, P185, DOI 10.1016/S0009 8981(03)00238 9
   Sheng Matilda H C, 2014, J Bone Metab, V21, P41, DOI 10.11005/jbm.2014.21.1.41
   Shu R, 2017, ARCH ORAL BIOL, V74, P82, DOI 10.1016/j.archoralbio.2016.11.012
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Tabatabaei Malazy O, 2017, DARU, V25, DOI 10.1186/s40199 017 0167 z
   Tsentidis C, 2017, OSTEOPOROSIS INT, V28, P945, DOI 10.1007/s00198 016 3802 5
   Ueyama T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065685
   Wang LL, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00266
   Wang LL, 2016, CURR PHARM DESIGN, V22, P328, DOI 10.2174/1381612822666151112145907
   Wu PS, 2011, AM J CHINESE MED, V39, P1173, DOI 10.1142/S0192415X11009482
   Wu TX, 2015, CHEM ENGINEER TRANS, V46, P67, DOI 10.3303/CET1546012
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   Xu X, 2017, BONE RES, V5, DOI 10.1038/boneres.2017.46
   Yan HL, 2017, PHYTOMEDICINE, V26, P45, DOI 10.1016/j.phymed.2017.01.007
   Zhang C, 2017, ACTA CIR BRAS, V32, P418, DOI 10.1590/s0102 865020170060000002
   Zhang XP, 2014, ADV INTELL SYST, V254, P73, DOI 10.1007/978 3 319 03449 2_8
   Zhou J, 2015, J ETHNOPHARMACOL, V164, P229, DOI 10.1016/j.jep.2015.02.026
NR 51
TC 37
Z9 42
U1 0
U2 25
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD FEB
PY 2019
VL 30
IS 2
BP 491
EP 505
DI 10.1007/s00198 018 4670 y
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA HS1BX
UT WOS:000463597000023
PM 30151623
DA 2025 08 17
ER

PT J
AU Sakamoto, S
   Kojima, F
   Igarashi, M
   Sawa, R
   Umekita, M
   Kubota, Y
   Nakae, K
   Yamaguchi, S
   Adachi, H
   Nishimura, Y
   Akamatsu, Y
AF Sakamoto, Shuichi
   Kojima, Fukiko
   Igarashi, Masayuki
   Sawa, Ryuichi
   Umekita, Maya
   Kubota, Yumiko
   Nakae, Koichi
   Yamaguchi, Shoichi
   Adachi, Hayamitsu
   Nishimura, Yoshio
   Akamatsu, Yuzuru
TI Decalpenic acid, a novel small molecule from Penicillium
   verruculosum CR37010, induces early osteoblastic markers in
   pluripotent mesenchymal cells
SO JOURNAL OF ANTIBIOTICS
LA English
DT Article
DE adipocyte; alkaline phosphatase; differentiation; mesenchymal stem cell;
   osteoblast
ID DIFFERENTIATION PATHWAY; BONE FORMATION; OSTEOGENESIS; HEDGEHOG; ROLES;
   CBFA1
AB Osteoblasts are the cells responsible for bone formation during embryonic development and adult life. Small compounds that could induce osteoblast differentiation might be promising sources of therapies for bone diseases such as osteoporosis. During screening for inducers of osteoblast differentiation of mouse pluripotent mesenchymal C3H10T1/2 cells, we isolated a small compound from the fermentation broth of Penicillium verruculosum CR37010. This compound, named decalpenic acid, bears a decalin moiety with a tetraenoic acid side chain. Treatment of C3H10T1/2 cells with decalpenic acid alone induced the expression of early osteoblast markers, such as alkaline phosphatase activity and osteopontin mRNA, but did not induce the late osteoblast marker osteocalcin mRNA or adipocyte markers under our experimental conditions. The Journal of Antibiotics (2010) 63, 703 708; doi:10.1038/ja.2010.114; published online 13 October 2010
C1 [Sakamoto, Shuichi; Kojima, Fukiko; Igarashi, Masayuki; Sawa, Ryuichi; Umekita, Maya; Kubota, Yumiko; Nakae, Koichi; Adachi, Hayamitsu; Nishimura, Yoshio; Akamatsu, Yuzuru] Inst Microbial Chem, Shinagawa Ku, Tokyo 1410021, Japan.
   [Yamaguchi, Shoichi] Meiji Seika Kaisha Ltd, Biosci Labs, Kanagawa, Japan.
C3 Meiji Holdings Co., Ltd.
RP Sakamoto, S (通讯作者)，Inst Microbial Chem, Shinagawa Ku, 3 14 23 Kamiosaki, Tokyo 1410021, Japan.
EM sakamotos@bikaken.or.jp
RI Igarashi, Masayuki/AAG 1628 2020; Sawa, Ryuichi/V 4349 2018
OI Sakamoto, Shuichi/0000 0001 9396 9475; Sawa, Ryuichi/0000 0002 8190 0195
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
FX We thank Dr M Kawada for comments on the manuscript. This work was
   supported in part by a grant in aid from the Ministry of Education,
   Culture, Sports, Science and Technology of Japan (to SS).
CR Breinholt J, 1997, ACTA CHEM SCAND, V51, P1241, DOI 10.3891/acta.chem.scand.51 1241
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Hata K, 2003, MOL BIOL CELL, V14, P545, DOI 10.1091/mbc.E02 06 0356
   Hu HL, 2005, DEVELOPMENT, V132, P49, DOI 10.1242/dev.01564
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee HW, 2006, MOL ENDOCRINOL, V20, P2432, DOI 10.1210/me.2006 0061
   Mitova MI, 2006, J ORG CHEM, V71, P492, DOI 10.1021/jo051883l
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Wu X, 2004, CHEM BIOL, V11, P1229, DOI 10.1016/j.chembiol.2004.06.010
   Wu X, 2002, J AM CHEM SOC, V124, P14520, DOI 10.1021/ja0283908
   YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023
   Yamaguchi A, 2000, ENDOCR REV, V21, P393, DOI 10.1210/er.21.4.393
   Yin T, 2006, J CLIN INVEST, V116, P1195, DOI 10.1172/JCI28568
NR 17
TC 15
Z9 16
U1 0
U2 11
PU JAPAN ANTIBIOTICS RESEARCH ASSOC
PI TOKYO
PA 2 20 8 KAMIOSAKI SHINAGAWA KU, TOKYO, 141, JAPAN
SN 0021 8820
J9 J ANTIBIOT
JI J. Antibiot.
PD DEC
PY 2010
VL 63
IS 12
BP 703
EP 708
DI 10.1038/ja.2010.114
PG 6
WC Biotechnology & Applied Microbiology; Immunology; Microbiology;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Biotechnology & Applied Microbiology; Immunology; Microbiology;
   Pharmacology & Pharmacy
GA 704EF
UT WOS:000286033200004
PM 20940725
OA Bronze
DA 2025 08 17
ER

PT J
AU Berlier, JL
   Kharroubi, I
   Zhang, J
   Dalla Valle, A
   Rigutto, S
   Mathieu, M
   Gangji, V
   Rasschaert, J
AF Berlier, J. L.
   Kharroubi, I.
   Zhang, J.
   Dalla Valle, A.
   Rigutto, S.
   Mathieu, M.
   Gangji, V.
   Rasschaert, J.
TI Glucose Dependent Insulinotropic Peptide Prevents Serum
   Deprivation Induced Apoptosis in Human Bone Marrow Derived Mesenchymal
   Stem Cells and Osteoblastic Cells
SO STEM CELL REVIEWS AND REPORTS
LA English
DT Article
DE Glucose dependent insulinotropic peptide; cAMP accumulation; Apoptosis;
   Human bone marrow derived mesenchymal stem cells; Serum deprivation
ID GASTRIC INHIBITORY POLYPEPTIDE; PROTEIN; SURVIVAL; HYPOXIA; DISEASE;
   MICE; OSTEOGENESIS; REGENERATION; MECHANISMS; EXPRESSION
AB Human bone marrow derived mesenchymal stem cells (hBMSC) are able to differentiate into cells of connective tissue lineages, including bone and cartilage. They are therefore considered as a promising tool for the treatment of bone degenerative diseases. One of the major issues in regenerative cell therapy is the biosafety of fetal bovine serum used for cell culture. Therefore, the development of a culture medium devoid of serum but preserving hBMSC viability will be of clinical value. The glucose dependent insulinotropic peptide (GIP) has an anti apoptotic action in insulin producing cells. Interestingly, GIP also exerts beneficial effects on bone turnover by acting on osteoblasts and osteoclasts. We therefore evaluated the ability of GIP to prevent cell death in osteoblastic cells cultured in serum free conditions. In hBMSC and SaOS 2 cells, activation of the GIP receptor increased intracellular cAMP levels. Serum deprivation induced apoptosis in SaOS 2 and hBMSC that was reduced by 30 and 50 %, respectively, in the presence of GIP. The protective effect of GIP involves activation of the adenylate cyclase pathway and inhibition of caspases 3/7 activation. These findings demonstrate that GIP exerts a protective action against apoptosis in hBMSC and suggest a novel approach to preserve viability of hBMSC cultured in the absence of serum.
C1 [Berlier, J. L.; Kharroubi, I.; Zhang, J.; Dalla Valle, A.; Rigutto, S.; Mathieu, M.; Gangji, V.; Rasschaert, J.] Univ Libre Bruxelles, Fac Med, Lab Bone & Metab Biochem, B 1070 Brussels, Belgium.
   [Gangji, V.] Univ Libre Bruxelles, Dept Rheumatol & Phys Med, Hop Erasme, B 1070 Brussels, Belgium.
C3 Universite Libre de Bruxelles; Universite Libre de Bruxelles
RP Rasschaert, J (通讯作者)，Univ Libre Bruxelles, Fac Med, Lab Bone & Metab Biochem, 808 Route Lennik, B 1070 Brussels, Belgium.
EM jrasscha@ulb.ac.be
OI Rasschaert, Joanne/0000 0002 9388 7995
FU "Region wallonne" (WALEO3, NeurOs) [816882]; David & Alice van Buuren
   Foundation
FX The present study was supported by the "Region wallonne" (WALEO3,
   NeurOs, Convention n degrees 816882) and the David & Alice van Buuren
   Foundation.
CR Baggio LL, 2007, GASTROENTEROLOGY, V132, P2131, DOI 10.1053/j.gastro.2007.03.054
   Bal T, 2017, J TISSUE ENG REGEN M, V11, P694, DOI 10.1002/term.1965
   Bollag RJ, 2000, ENDOCRINOLOGY, V141, P1228, DOI 10.1210/en.141.3.1228
   Brentnall M, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471 2121 14 32
   Chamberlain G, 2007, STEM CELLS, V25, P2739, DOI 10.1634/stemcells.2007 0197
   Chen JH, 2008, STEM CELLS, V26, P135, DOI 10.1634/stemcells.2007 0098
   Chim SM, 2013, CYTOKINE GROWTH F R, V24, P297, DOI 10.1016/j.cytogfr.2013.03.008
   Dicembrini I, 2012, EXP DIABETES RES, DOI 10.1155/2012/519784
   Dimarakis I, 2006, STEM CELLS, V24, P1407, DOI 10.1634/stemcells.2005 0577
   Dimitriou R, 2011, BMC MED, V9, DOI 10.1186/1741 7015 9 66
   Ding KH, 2008, J BONE MINER RES, V23, P536, DOI 10.1359/JBMR.071202
   Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002
   Ehses JA, 2003, ENDOCRINOLOGY, V144, P4433, DOI 10.1210/en.2002 0068
   Follin Arbelet V, 2011, BMC CANCER, V11, DOI 10.1186/1471 2407 11 301
   Fukuda K, 2006, CIRC RES, V98, P1002, DOI 10.1161/01.RES.0000218272.18669.6e
   Gangji Valerie, 2005, J Bone Joint Surg Am, V87 Suppl 1, P106, DOI 10.2106/JBJS.D.02662
   Gaudin Audrain C, 2013, BONE, V53, P221, DOI 10.1016/j.bone.2012.11.039
   Geng YJ, 2003, ANN NY ACAD SCI, V1010, P687, DOI 10.1196/annals.1299.126
   Hauzeur JP, 2010, STEM CELLS INT, V2010, DOI 10.4061/2010/410170
   Holst JJ, 2009, MOL CELL ENDOCRINOL, V297, P127, DOI 10.1016/j.mce.2008.08.012
   Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529
   Insel PA, 2012, ACTA PHYSIOL, V204, P277, DOI 10.1111/j.1748 1716.2011.02273.x
   Jhala US, 2003, GENE DEV, V17, P1575, DOI 10.1101/gad.1097103
   Jung S, 2012, STEM CELLS INT, V2012, DOI 10.1155/2012/123030
   KAPLAN AM, 1994, PEPTIDES, V15, P297, DOI 10.1016/0196 9781(94)90016 7
   Kaushik AP, 2012, WORLD J ORTHOP, V3, P49, DOI 10.5312/wjo.v3.i5.49
   Kim SJ, 2005, J BIOL CHEM, V280, P22297, DOI 10.1074/jbc.M500540200
   Kim SJ, 2008, MOL CELL BIOL, V28, P1644, DOI 10.1128/MCB.00325 07
   Kim W, 2008, PHARMACOL REV, V60, P470, DOI 10.1124/pr.108.000604
   Kon E, 2012, CLIN CASES MINER BON, V9, P24
   Lamkanfi M, 2010, INT J BIOCHEM CELL B, V42, P21, DOI 10.1016/j.biocel.2009.09.013
   Lee HJ, 2010, NEUROSCI LETT, V481, P30, DOI 10.1016/j.neulet.2010.06.045
   Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277
   Li ZW, 2010, J CELL BIOCHEM, V111, P811, DOI 10.1002/jcb.22731
   Liang M, 2008, J BONE MINER RES, V23, P610, DOI 10.1359/JBMR.080106
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Martin MC, 2001, J BIOL CHEM, V276, P45041, DOI 10.1074/jbc.M105197200
   Mathieu M, 2013, BONE, V53, P391, DOI 10.1016/j.bone.2013.01.005
   Mieczkowska A, 2013, BONE, V56, P337, DOI 10.1016/j.bone.2013.07.003
   MINAMIDE LS, 1990, ANAL BIOCHEM, V190, P66, DOI 10.1016/0003 2697(90)90134 U
   Mrak E, 2010, J CELL PHYSIOL, V225, P701, DOI 10.1002/jcp.22266
   Pacheco Pantoja Elda L., 2011, BMC Physiology, V11, P12, DOI 10.1186/1472 6793 11 12
   Potier E, 2007, TISSUE ENG, V13, P1325, DOI 10.1089/ten.2006.0325
   Ra JC, 2011, J TRANSL MED, V9, DOI 10.1186/1479 5876 9 181
   Satija NK, 2007, STEM CELLS DEV, V16, P7, DOI 10.1089/scd.2006.9998
   Schnoke M, 2009, BONE, V45, P590, DOI 10.1016/j.bone.2009.05.006
   Selvaggi TA, 1997, BLOOD, V89, P776, DOI 10.1182/blood.V89.3.776
   Siddappa R, 2008, P NATL ACAD SCI USA, V105, P7281, DOI 10.1073/pnas.0711190105
   Solmesky LJ, 2009, STEM CELLS DEV, V18, P1283, DOI 10.1089/scd.2009.0020
   Sotiropoulou PA, 2006, STEM CELLS, V24, P1409, DOI 10.1634/stemcells.2005 0654
   Tonti GA, 2008, INT J DEV BIOL, V52, P1023, DOI 10.1387/ijdb.082725gt
   Trümper A, 2002, J ENDOCRINOL, V174, DOI 10.1677/joe.0.1740233
   Tsukiyama K, 2006, MOL ENDOCRINOL, V20, P1644, DOI 10.1210/me.2005 0187
   Undale AH, 2009, MAYO CLIN PROC, V84, P893, DOI 10.4065/84.10.893
   Van Sande J, 2006, J CLIN ENDOCR METAB, V91, P1099, DOI 10.1210/jc.2005 1324
   Widenmaier SB, 2009, J BIOL CHEM, V284, P30372, DOI 10.1074/jbc.M109.060178
   Wong WWL, 2008, IUBMB LIFE, V60, P390, DOI 10.1002/iub.51
   Xie D, 2005, BONE, V37, P759, DOI 10.1016/j.bone.2005.06.021
   Xie D, 2007, BONE, V40, P1352, DOI 10.1016/j.bone.2007.01.007
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yin Q, 2011, MOL BIOL REP, V38, P9, DOI 10.1007/s11033 010 0071 9
   Yip RGC, 1998, ENDOCRINOLOGY, V139, P4004, DOI 10.1210/en.139.9.4004
   Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308
   Zhao ZH, 2002, KIDNEY INT, V61, P1276, DOI 10.1046/j.1523 1755.2002.00256.x
   Zhong Q, 2007, AM J PHYSIOL ENDOC M, V292, pE543, DOI 10.1152/ajpendo.00364.2006
   Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005 0121
NR 66
TC 20
Z9 20
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 2629 3269
EI 2629 3277
J9 STEM CELL REV REP
JI Stem Cell Rev. Rep.
PD DEC
PY 2015
VL 11
IS 6
BP 841
EP 851
DI 10.1007/s12015 015 9616 6
PG 11
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA CX1JA
UT WOS:000365451300006
PM 26254594
DA 2025 08 17
ER

PT J
AU Tran, NT
   Trinh, QM
   Lee, GM
   Han, YM
AF Ngoc Tung Tran
   Quynh Mai Trinh
   Lee, Gyun Min
   Han, Yong Mahn
TI Efficient Differentiation of Human Pluripotent Stem Cells into
   Mesenchymal Stem Cells by Modulating Intracellular Signaling Pathways in
   a Feeder/Serum Free System
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID MARROW STROMAL CELLS; BONE MARROW; PROGENITOR CELLS; GROWTH FACTOR;
   DEFINITIVE ENDODERM; WNT/BETA CATENIN; MOUSE; WNT; MESODERM; INDUCTION
AB Mesenchymal stem cells (MSCs) derived from human pluripotent stem cells (hPSC derived MSCs) will be one promising alternative cell source for MSC based therapies. Here, an efficient protocol is demonstrated for generating hPSC derived MSCs under a feeder free culture system by regulating signaling pathways. Simultaneous treatments with Activin A, BIO (6 bromoindirubin 3' oxime), and bone morphogenetic protein 4 (ABB) activated the transcription of mesoderm lineage genes such as T, MIXL1, and WNT3 in hPSCs. The ABB treated hPSCs could develop into CD105(+) cells with a high efficiency of 20% in the MSC induction medium. The properties of the hPSC derived CD105(+) cells were similar to those of adult MSCs in terms of surface antigens. Also, hPSC derived MSCs had the potential to differentiate into adipocytes, osteoblasts, and chondrocytes in vitro. The results demonstrated that functional MSCs could be generated efficiently from hPSCs by the combined modulation of signaling pathways.
C1 [Lee, Gyun Min; Han, Yong Mahn] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
   [Han, Yong Mahn] Korea Adv Inst Sci & Technol, Ctr Stem Cell Differentiat, Taejon 305701, South Korea.
C3 Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced
   Institute of Science & Technology (KAIST)
RP Han, YM (通讯作者)，Korea Adv Inst Sci & Technol, Dept Biol Sci, 335 Gwahangno Yuseong Gu, Taejon 305701, South Korea.
EM gyunminlee@kaist.ac.kr; ymhan@kaist.ac.kr
RI Lee, Gyun/C 2020 2011; Tran, NgocTung/LRU 0710 2024; Han,
   Yong Mahn/C 1652 2011
OI Tran, Ngoc Tung/0000 0003 0896 8641; 
FU Stem Cell Research Center [SC 2210]; NRF [2011 0019509]; MEST; Korea
   Healthcare Technology RD Project [A084697]; MW, Republic of Korea
FX The authors thank Ms. M.J. Jang for maintaining the hESCs. This research
   was supported by a grant (SC 2210) from the Stem Cell Research Center, a
   grant (2011 0019509) from the NRF funded by the MEST, and a grant
   (A084697) from the Korea Healthcare Technology R&D Project funded by the
   MW, Republic of Korea.
CR Amit M, 2004, BIOL REPROD, V70, P837, DOI 10.1095/biolreprod.103.021147
   Baksh D, 2004, J CELL MOL MED, V8, P301, DOI 10.1111/j.1582 4934.2004.tb00320.x
   Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   D'Amour KA, 2005, NAT BIOTECHNOL, V23, P1534, DOI 10.1038/nbt1163
   DiGirolamo CM, 1999, BRIT J HAEMATOL, V107, P275, DOI 10.1046/j.1365 2141.1999.01715.x
   Dreesen O, 2007, STEM CELL REV, V3, P7, DOI 10.1007/s12015 007 0004 8
   Evseenko D, 2010, P NATL ACAD SCI USA, V107, P13742, DOI 10.1073/pnas.1002077107
   Ferreira LS, 2007, CIRC RES, V101, P286, DOI 10.1161/CIRCRESAHA.107.150201
   FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267
   Fukuchi Y, 2004, STEM CELLS, V22, P649, DOI 10.1634/stemcells.22 5 649
   Gadue P, 2006, P NATL ACAD SCI USA, V103, P16806, DOI 10.1073/pnas.0603916103
   Greber B, 2007, STEM CELLS, V25, P455, DOI 10.1634/stemcells.2006 0476
   Hao J, 2006, DEV BIOL, V290, P81, DOI 10.1016/j.ydbio.2005.11.011
   Heasley LE, 2004, EMBO REP, V5, P241, DOI 10.1038/sj.embor.7400098
   Hung SC, 2002, STEM CELLS, V20, P522, DOI 10.1634/stemcells.20 6 522
   James D, 2005, DEVELOPMENT, V132, P1273, DOI 10.1242/dev.01706
   Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004
   Kadivar M, 2006, BIOCHEM BIOPH RES CO, V340, P639, DOI 10.1016/j.bbrc.2005.12.047
   Kang XQ, 2005, WORLD J GASTROENTERO, V11, P7461, DOI 10.3748/wjg.v11.i47.7391
   Kassis I, 2006, BONE MARROW TRANSPL, V37, P967, DOI 10.1038/sj.bmt.1705358
   Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078 0432.CCR 06 2316
   Kattman SJ, 2011, CELL STEM CELL, V8, P228, DOI 10.1016/j.stem.2010.12.008
   Klyushnenkova E, 2005, J BIOMED SCI, V12, P47, DOI 10.1007/s11373 004 8183 7
   Kretlow JD, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471 2121 9 60
   Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140 6736(04)16104 7
   Lee JE, 2010, CELL TRANSPLANT, V19, P1383, DOI 10.3727/096368910X513991
   Lee RH, 2004, CELL PHYSIOL BIOCHEM, V14, P311, DOI 10.1159/000080341
   Lian QZ, 2007, STEM CELLS, V25, P425, DOI 10.1634/stemcells.2006 0420
   Lian QZ, 2010, CIRCULATION, V121, P1113, DOI 10.1161/CIRCULATIONAHA.109.898312
   Lindsley RC, 2006, DEVELOPMENT, V133, P3787, DOI 10.1242/dev.02551
   Madonna R, 2009, ARTERIOSCL THROM VAS, V29, P1723, DOI 10.1161/ATVBAHA.109.187179
   McLean AB, 2007, STEM CELLS, V25, P29, DOI 10.1634/stemcells.2006 0219
   Nusse R, 2008, COLD SH Q B, V73, P59, DOI 10.1101/sqb.2008.73.035
   Okita Keisuke, 2006, Curr Stem Cell Res Ther, V1, P103, DOI 10.2174/157488806775269061
   Oldershaw RA, 2010, NAT BIOTECHNOL, V28, P1221, DOI 10.1038/nbt.1683
   Olivier EN, 2006, STEM CELLS, V24, P1914, DOI 10.1634/stemcells.2005 0648
   Parashurama N, 2008, STEM CELLS, V26, P474, DOI 10.1634/stemcells.2007 0303
   Park SW, 2010, BLOOD, V116, P5762, DOI 10.1182/blood 2010 04 280719
   Pick M, 2007, STEM CELLS, V25, P2206, DOI 10.1634/stemcells.2006 0713
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Reyes M, 2001, BLOOD, V98, P2615, DOI 10.1182/blood.V98.9.2615
   Rho JY, 2006, HUM REPROD, V21, P405, DOI 10.1093/humrep/dei328
   Sanchez Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Stenderup K, 2003, BONE, V33, P919, DOI 10.1016/j.bone.2003.07.005
   Sumi T, 2008, DEVELOPMENT, V135, P2969, DOI 10.1242/dev.021121
   Tada S, 2005, DEVELOPMENT, V132, P4363, DOI 10.1242/dev.02005
   Trivedi P, 2008, EXP HEMATOL, V36, P350, DOI 10.1016/j.exphem.2007.10.007
   Valdimarsdottir G, 2005, APMIS, V113, P773, DOI 10.1111/j.1600 0463.2005.apm_3181.x
   Vallier L, 2004, DEV BIOL, V275, P403, DOI 10.1016/j.ydbio.2004.08.031
   Vodyanik MA, 2010, CELL STEM CELL, V7, P718, DOI 10.1016/j.stem.2010.11.011
   Wagner W, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005846
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001 971
   Xu RH, 2002, NAT BIOTECHNOL, V20, P1261, DOI 10.1038/nbt761
   Zhang PB, 2008, BLOOD, V111, P1933, DOI 10.1182/blood 2007 02 074120
NR 57
TC 22
Z9 30
U1 0
U2 32
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD MAY 1
PY 2012
VL 21
IS 7
BP 1165
EP 1175
DI 10.1089/scd.2011.0346
PG 11
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 932CM
UT WOS:000303268000014
PM 21793661
OA Green Published
DA 2025 08 17
ER

PT J
AU Zhou, L
   Yoon, SJ
   Jang, KY
   Moon, YJ
   Wagle, S
   Lee, KB
   Park, BH
   Kim, JR
AF Zhou, Lu
   Yoon, Sun Jung
   Jang, Kyu Yun
   Moon, Young Jae
   Wagle, Sajeev
   Lee, Kwang Bok
   Park, Byung Hyun
   Kim, Jung Ryul
TI COMP Angiopoietin1 Potentiates the Effects of Bone Morphogenic Protein 2
   on Ischemic Necrosis of the Femoral Head in Rats
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH FACTOR; OSTEOBLAST DIFFERENTIATION; LONG TERM;
   IN VITRO; ANGIOGENESIS; COMP ANG1; BMP 2; ANGIOPOIETIN 1; OSTEONECROSIS;
   REGENERATION
AB Angiogenesis is considered essential for proper bone regeneration. The purpose of this investigation was to determine if a combined therapy of bone morphogenetic protein 2 (BMP 2) and cartilage oligomeric matrix protein angiopoietin 1 (COMP Ang1) can potentiate the therapeutic effect of BMP 2 in a rat model of ischemic necrosis of the femoral head (INFH). INFH was surgically induced in the femoral head of rats, and the animals were divided into the following groups: 1) a sham operated group (sham group), 2) a bovine serum albumin injected group (BSA group), 3) a BMP 2 injected group (BMP 2 group), and 4) a COMP Ang1 and BMP 2 injected group (COMP Ang1 + BMP 2 group) (n = 20/group). Radiologic, histologic, and histomorphometric assessments were performed to assess femoral head morphology, vascular density, and bone resorption activity. Western blots and immunohistochemical staining were performed to evaluate production of BMP related signaling proteins in C3H10T1/2 cells and tissues. Real time RT PCR was performed to investigate expression of the target integrin gene, and the effect of integrin on C3H10T1/2 cells was determined using a cell adhesion assay. Radiographs obtained six weeks after injection revealed better preservation of the architecture of the femoral head in the COMP Ang1 + BMP 2 group compared with the BSA and BMP 2 groups. Histological findings indicated increased trabecular bone and vascularity and decreased osteoclast bone resorption activity in the COMP Ang1 + BMP 2 group compared with those in the BSA and BMP 2 groups. The combination of COMP Ang1 and BMP 2 increased phosphorylation of Smad1/3/5, p38, and Akt. Increased integrin alpha 3 and beta 1 mRNA expression in the COMP Ang1 + BMP 2 group promoted cell adhesion. These results suggest that COMP Ang1 preserved the necrotic femoral head through the potentiation of BMP 2 signaling pathways and angiogenesis. Combination treatment with COMP Ang1 and BMP 2 may be a clinically useful therapeutic application in INFH.
C1 [Zhou, Lu; Yoon, Sun Jung; Wagle, Sajeev; Lee, Kwang Bok; Kim, Jung Ryul] Chonbuk Natl Univ, Dept Orthoped Surg, Sch Med, Res Inst Endocrine Sci, Jeonju, South Korea.
   [Zhou, Lu; Yoon, Sun Jung; Jang, Kyu Yun; Wagle, Sajeev; Lee, Kwang Bok; Kim, Jung Ryul] Res Inst Clin Med, Jeonju, South Korea.
   [Jang, Kyu Yun] Chonbuk Natl Univ, Dept Pathol, Sch Med, Res Inst Endocrine Sci, Jeonju, South Korea.
   [Moon, Young Jae; Park, Byung Hyun] Chonbuk Natl Univ, Dept Biochem, Sch Med, Res Inst Endocrine Sci, Jeonju, South Korea.
   [Zhou, Lu] Taishan Med Univ, Dept Sports Med, Tai An, Shandong, Peoples R China.
C3 Jeonbuk National University; Jeonbuk National University; Jeonbuk
   National University; Shandong First Medical University & Shandong
   Academy of Medical Sciences
RP Kim, JR (通讯作者)，Chonbuk Natl Univ, Dept Orthoped Surg, Sch Med, Res Inst Endocrine Sci, Jeonju, South Korea.
EM jrkeem@jbnu.ac.kr
RI Wagle, Sajeev/N 1524 2013; yoon, su jung/HMO 9552 2023
OI zhou, lu/0000 0001 9014 6350; Yoon, Sun Jung/0000 0003 3487 6863; 
FU National Research Foundation of Korea (NRF)   Korea government
   [2011 0028928]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (No. 2011 0028928). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aya Ay J, 2007, J BONE MINER RES, V22, P93, DOI 10.1359/JBMR.060817
   Bejar J, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742 4682 2 24
   Bostrom MPG, 1998, CLIN ORTHOP RELAT R, pS116, DOI 10.1097/00003086 199810001 00013
   Cho CH, 2005, CIRC RES, V97, P86, DOI 10.1161/01.RES.0000174093.64855.a6
   Cho CH, 2004, P NATL ACAD SCI USA, V101, P5547, DOI 10.1073/pnas.0307574101
   Dallabrida SM, 2005, CIRC RES, V96, DOI 10.1161/01.RES.0000158285.57191.60
   David L, 2009, CYTOKINE GROWTH F R, V20, P203, DOI 10.1016/j.cytogfr.2009.05.001
   Duggirala S S, 1996, Pharm Dev Technol, V1, P165, DOI 10.3109/10837459609029891
   Filvaroff E, 1999, DEVELOPMENT, V126, P4267
   Galeano M, 2003, DIABETOLOGIA, V46, P546, DOI 10.1007/s00125 003 1064 1
   Galiano RD, 2004, AM J PATHOL, V164, P1935, DOI 10.1016/S0002 9440(10)63754 6
   Gerber HP, 2000, TRENDS CARDIOVAS MED, V10, P223, DOI 10.1016/S1050 1738(00)00074 8
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028
   Glowacki J, 1998, CLIN ORTHOP RELAT R, pS82, DOI 10.1097/00003086 199810001 00010
   Itoh K, 2001, ENDOCRINOLOGY, V142, P3656, DOI 10.1210/en.142.8.3656
   Jeong BC, 2010, BONE, V46, P479, DOI 10.1016/j.bone.2009.09.019
   Kakudo N, 2006, LIFE SCI, V79, P1847, DOI 10.1016/j.lfs.2006.06.033
   Kamiya N, 2008, J BONE MINER RES, V23, P2007, DOI 10.1359/JBMR.080809
   Kamoshida G, 2012, FEBS J, V279, P4535, DOI 10.1111/febs.12040
   Kempen DHR, 2009, BIOMATERIALS, V30, P2816, DOI 10.1016/j.biomaterials.2009.01.031
   Kerachian MA, 2006, ENDOTHELIUM J ENDOTH, V13, P237, DOI 10.1080/10623320600904211
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Köppel H, 2011, NEPHROL DIAL TRANSPL, V26, P3852, DOI 10.1093/ndt/gfr324
   Koh GY, 2013, TRENDS MOL MED, V19, P31, DOI 10.1016/j.molmed.2012.10.010
   Lee KB, 2012, J ORTHOP RES, V30, P1985, DOI 10.1002/jor.22160
   Lee KB, 2011, SPINE J, V11, P568, DOI 10.1016/j.spinee.2011.02.001
   MCANDREW MP, 1984, J BONE JOINT SURG AM, V66A, P860, DOI 10.2106/00004623 198466060 00006
   Mohammad KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005275
   Murakami N, 2003, BIOMATERIALS, V24, P2153, DOI 10.1016/S0142 9612(03)00041 3
   Park BH, 2009, BONE, V44, P886, DOI 10.1016/j.bone.2009.01.366
   Patel ZS, 2008, BONE, V43, P931, DOI 10.1016/j.bone.2008.06.019
   Patel ZS, 2008, PHARM RES DORDR, V25, P2370, DOI 10.1007/s11095 008 9685 1
   Puleo DA, 1998, J BIOMED MATER RES, V41, P104, DOI 10.1002/(SICI)1097 4636(199807)41:1<104::AID JBM13>3.0.CO;2 N
   Schmid J, 1997, CLIN ORAL IMPLAN RES, V8, P244, DOI 10.1034/j.1600 0501.1997.080311.x
   Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F
   Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Vandermeer JS, 2011, J BONE JOINT SURG AM, V93A, P905, DOI 10.2106/JBJS.J.00716
   Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756 3282(96)00133 0
   Woo EJ, 2012, SPINE J, V12, P894, DOI 10.1016/j.spinee.2012.09.052
   Youn SW, 2011, BLOOD, V117, P4376, DOI 10.1182/blood 2010 07 295964
   Zimmerman D, 2000, DEV BIOL, V220, P2, DOI 10.1006/dbio.2000.9633
NR 43
TC 4
Z9 6
U1 0
U2 17
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2014
VL 9
IS 10
AR e110593
DI 10.1371/journal.pone.0110593
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AT8TF
UT WOS:000345204100093
PM 25329960
OA Green Published, Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Baranyi, M
   Rittler, D
   Molnár, E
   Shirasawa, S
   Jalsovszky, I
   Varga, IK
   Hegedus, L
   Németh, A
   Dank, M
   Aigner, C
   Tóvári, J
   Tímár, J
   Hegedus, B
   Garay, T
AF Baranyi, Marcell
   Rittler, Dominika
   Molnar, Eszter
   Shirasawa, Senji
   Jalsovszky, Istvan
   Varga, Imre Karoly
   Hegedus, Luca
   Nemeth, Afrodite
   Dank, Magdolna
   Aigner, Clemens
   Tovari, Jozsef
   Timar, Jozsef
   Hegedus, Balazs
   Garay, Tamas
TI Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in
   Colorectal Cancer In Vitro and In Vivo
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Lipophilic bisphosphonate; Zoledronic acid; Colorectal cancer; In vitro;
   In vivo
ID NITROGEN CONTAINING BISPHOSPHONATES; ZOLEDRONIC ACID; HUMAN BREAST; ORAL
   BISPHOSPHONATES; CELL LINES; GROWTH; APOPTOSIS; THERAPY; RISK; KRAS
AB Bisphosphonates, despite proven antitumor effect in vitro in many tumor types, are currently used only for treatment of osteoporosis and bone metastasis. Colorectal cancer is the third most commonly diagnosed type of cancer and lacks targeted therapy for RAS or RAF mutation carrying cases. A new lipophilic bisphosphonate showed promising results in lung cancer models, but their effect on colorectal cancer cells was not investigated excessively. Antitumor effects and impact on RAS related signalization of zoledronic acid (ZA) and a lipophilic bisphosphonate (BPH1222) were investigated on 7 human colorectal cancer cell lines in vitro and in vivo. Furthermore, mutant KRAS dependent effect of prenylation inhibition was investigated using isogeneic cell lines. Both bisphosphonates reduced cell viability in vitro in a dose dependent manner. Both compounds changed cell cycle distribution similarly by increasing the proportion of cells either in the S or in the subG1 phase or both. However, BPH1222 exerted higher inhibitory effect on spheroid growth than ZA. Interestingly, we found profound alterations in phosphorylation level of Erk and S6 proteins upon ZA or BPH1222 treatment. Furthermore, investigation of a mutant KRAS isogeneic model system suggests that the drugs interfere also with the mutant KRAS proteins. In vivo experiments with KRAS mutant xenograft model also revealed growth inhibitory potential of bisphosphonate treatment. Our results show that lipophilic bisphosphonates might extend the therapeutic spectrum of bisphosphonate drugs and could be considered as additional treatment approaches in colorectal cancer.
C1 [Baranyi, Marcell; Rittler, Dominika; Molnar, Eszter; Timar, Jozsef; Hegedus, Balazs; Garay, Tamas] Semmelweis Univ, Dept Pathol 2, H 1091 Budapest, Hungary.
   [Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka, Fukuoka, Japan.
   [Jalsovszky, Istvan; Varga, Imre Karoly] Eotvos Lorand Univ, Fac Sci, Inst Chem, Dept Organ Chem, H 1117 Budapest, Hungary.
   [Hegedus, Luca; Aigner, Clemens; Hegedus, Balazs] Univ Duisburg Essen, Dept Thorac Surg, Ruhrlandklin, D 45239 Essen, Germany.
   [Nemeth, Afrodite; Dank, Magdolna] Semmelweis Univ, Oncol Ctr, H 1091 Budapest, Hungary.
   [Tovari, Jozsef; Garay, Tamas] Natl Inst Oncol, Dept Expt Pharmacol, H 1122 Budapest, Hungary.
   [Garay, Tamas] Pazmany Peter Catholic Univ, Fac Informat Technol, H 1083 Budapest, Hungary.
   [Garay, Tamas] Hungarian Acad Sci, Postdoctoral Fellowship Program, H 1051 Budapest, Hungary.
C3 Semmelweis University; Fukuoka University; Eotvos Lorand University;
   Hungarian Academy of Sciences; Chemical Research Center   HAS;
   University of Duisburg Essen; Semmelweis University; National Institute
   of Oncology Hungary; Pazmany Peter Catholic University; Hungarian
   Academy of Sciences
RP Hegedus, B (通讯作者)，Semmelweis Univ, Dept Pathol 2, H 1091 Budapest, Hungary.
EM baranyi2marci@gmail.com; rittler.dominika@med.semmelweis univ.hu;
   molnar.eszter@med.semmelweis univ.hu; sshirasa@fukuoka u.ac.jp;
   jalso@caesar.elte.hu; vukracs@caesar.elte.hu;
   luca.hegedues@rlk.uk essen.de; afrodite.nemeth@gmail.com;
   dank.magdolna@med.semmelweis univ.hu;
   clemens.aigner@ruhrlandklinik.uk essen.de; jtovari@yahoo.com;
   jtimar@gmail.com; balazs.hegedues@rlk.uk essen.de; garayt@gmail.com
RI Hegedus, Balazs/B 6076 2008; Aigner, Clemens/A 7284 2019; Hegedus,
   Balazs/HKE 7559 2023; Eszter, Molnar/F 1894 2014; Hegedűs,
   Luca/AFL 9911 2022
OI Hegedus, Balazs/0000 0002 4341 4153; Dank, Magdolna/0000 0002 4694 3624;
   Nemeth, Afrodite/0000 0002 8687 5523; Aigner,
   Clemens/0000 0002 7787 991X; 
FU Hungarian National Research, Development and Innovation Office
   [MOB80325, NVKP 16 1 2016 0020]; Hungarian Scientific Research Fund  
   OTKA [K116151]; HAS Postdoctoral Fellowship Program [450,071]
FX This work was supported by the Hungarian National Research, Development
   and Innovation Office (MOB80325 to BH and NVKP 16 1 2016 0020 to
   JTimar), Hungarian Scientific Research Fund   OTKA (K116151 to JTimar)
   and by the HAS Postdoctoral Fellowship Program (450,071 to TG). The
   funding bodies did not play a role in the design of the study, the
   collection, analysis and interpretation of data or in the preparation of
   the manuscript.
CR Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078 0432.CCR 09 2446
   Bonovas S, 2013, BRIT J CLIN PHARMACO, V76, P329, DOI 10.1111/bcp.12135
   Cohen R, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864 017 0453 5
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470 2045(14)70302 X
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470 2045(10)70130 3
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365 2184.2011.00745.x
   Fearon ER, 2011, ANNU REV PATHOL MECH, V6, P479, DOI 10.1146/annurev pathol 011110 130235
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fragni M, 2016, N S ARCH PHARMACOL, V389, P529, DOI 10.1007/s00210 016 1224 8
   Gao X, 2015, TUMOR BIOL, V36, P5315, DOI 10.1007/s13277 015 3192 x
   Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021
   Hack S, 2011, EUR J MED CHEM, V46, P1483, DOI 10.1016/j.ejmech.2011.01.042
   Hegedüs L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00095
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475 2867 12 48
   Ivanov DP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103817
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140 6736(15)01037 5
   Kato J, 2016, INT J CANCER, V138, P1516, DOI 10.1002/ijc.29881
   Kelsey I, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004632
   Kenessey I, 2016, ONCOTARGET, V7, P79489, DOI 10.18632/oncotarget.12806
   Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349 7006.2004.tb03202.x
   Lau KS, 2009, MOL CELLS, V28, P315, DOI 10.1007/s10059 009 0143 7
   Mansouri M, 2014, BIOCHIMIE, V99, P71, DOI 10.1016/j.biochi.2013.11.010
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Michailidou M, 2010, J VASC RES, V47, P481, DOI 10.1159/000313876
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008 5472.CAN 14 0013
   Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013
   Räkel A, 2011, CLIN INTERV AGING, V6, P89, DOI 10.2147/CIA.S7282
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495 008 0211 z
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159 8290.CD 17 0087
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thosani N, 2013, J CLIN ONCOL, V31, P623, DOI 10.1200/JCO.2012.42.9530
   Tímár J, 2010, CURR CANCER DRUG TAR, V10, P813, DOI 10.2174/156800910793357989
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Yang GR, 2013, J CLIN GASTROENTEROL, V47, P741, DOI 10.1097/MCG.0b013e31829e446b
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 50
TC 12
Z9 13
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1219 4956
EI 1532 2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2020
VL 26
IS 3
BP 1957
EP 1969
DI 10.1007/s12253 019 00789 9
EA JAN 2020
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA LY6CR
UT WOS:000505406600002
PM 31902117
DA 2025 08 17
ER

PT J
AU Alsaikhan, F
   Mahmoud, MZ
   Suliman, M
AF Alsaikhan, Fahad
   Mahmoud, Mustafa Z.
   Suliman, Muath
TI Synthesis and characterization of novel denosumab/magnesium based metal
   organic frameworks nanocomposite prepared by ultrasonic route as drug
   delivery system for the treatment of osteoporosis
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE bone; denosumab; drug delivery system; metal organic framework;
   osteoporotic
ID MAGNESIUM; DENOSUMAB; MECHANISM; CO2
AB Introduction: The metal organic frameworks (MOF) have shown fascinating possibilities in biomedical applications, and designing a drug delivery system (DDS) based on the MOF is important. This work aimed at developing a suitable DDS based on Denosumab loaded Metal Organic Framework/ Magnesium (DSB@MOF (Mg)) for attenuating osteoarthritis.
   Materials and Methods: The MOF (Mg) (Mg3(BPT)2(H2O)4) was synthesized using a sonochemical protocol. The efficiency of MOF (Mg) as a DDS was evaluated by loading and releasing DSB as a drug. In addition, the performance of MOF (Mg) was evaluated by releasing Mg ions for bone formation. The MOF (Mg) and DSB@MOF (Mg) cytotoxicity towards the MG63 cells were explored by MTT assay.
   Results: MOF (Mg) characterized by using XRD, SEM, EDX, TGA, and BET. Drug loading, and releasing experiments proved that DSB was loaded on the MOF (Mg) and approximately 72% DSB was released from it after 8 h. The characterization techniques showed that MOF (Mg) was successfully synthesized with good crystal structure and thermal stability. The result of BET showed that MOF (Mg) had high surface areas and pore volume. This is the reason why its 25.73% DSB was loaded in the subsequent drug loading experiment. Drug release and ion release experiments indicated DSB@MOF (Mg) had a good controlled release of DSB and Mg ions in solution. Cytotoxicity assay confirmed that the optimum dose of it had excellent biocompatibility and could stimulate the proliferation of MG63 cells as time went on.
   Conclusion: Due to the high loading amount of DSB and releasing time, DSB@ MOF (Mg) can be promising as a suitable candidate for relieving bone pain caused by osteoporosis, with ossification reinforcing functions.
C1 [Alsaikhan, Fahad] Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Alkharj, Saudi Arabia.
   [Mahmoud, Mustafa Z.] Prince Sattam bin Abdulaziz Univ, Coll Appl Med Sci Al Kharj, Dept Radiol & Med Imaging, Al Kharj, Saudi Arabia.
   [Suliman, Muath] King Khalid Univ, Coll Appl Med Sci, Dept Clin Lab Sci, Abha, Saudi Arabia.
C3 Prince Sattam Bin Abdulaziz University; Prince Sattam Bin Abdulaziz
   University; King Khalid University
RP Alsaikhan, F (通讯作者)，Prince Sattam Bin Abdulaziz Univ, Coll Pharm, Alkharj, Saudi Arabia.
EM fahadsaikhan2000@gmail.com
RI Suliman, Muath/HKN 6580 2023; Mahmoud, Mustafa Z./AAD 4833 2022;
   Al Saikhan, Fahad/H 2265 2016; Al Saikhan, Fahad/H 2265 2016; Mahmoud,
   Prof. Mustafa/AAD 4833 2022
OI Mahmoud, Mustafa Z./0000 0003 2552 9165; Suliman,
   Muath/0009 0005 5549 5164; Al Saikhan, Fahad/0000 0002 4149 3978;
   Al Saikhan, Fahad/0000 0002 4149 3978; 
FU Prince Satam bin Abdulaziz University [PSAU/2023/R/1444]; King Khalid
   University [RGP.02/214/43]
FX This study is supported via funding from Prince Satam bin Abdulaziz
   University project number (PSAU/2023/R/1444). In addition, the authors
   express their gratitude to the Deanship of Scientific Research at King
   Khalid University for funding this work through the Large Research Group
   Project under grant number RGP.02/214/43.
CR Banerjee R, 2008, SCIENCE, V319, P939, DOI 10.1126/science.1152516
   Bao ZB, 2011, J COLLOID INTERF SCI, V353, P549, DOI 10.1016/j.jcis.2010.09.065
   Cao C, 2022, NUCLEIC ACIDS RES, V50, pD1123, DOI 10.1093/nar/gkab957
   Chen TY, 2022, CHINESE CHEM LETT, V33, P2517, DOI 10.1016/j.cclet.2021.11.090
   Cheng Y, 2023, INT J SYST SCI, V54, P1275, DOI 10.1080/00207721.2023.2169845
   Chesi A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09302 x
   Cummings SR, 2009, NEW ENGL J MED, V361, P756, DOI 10.1056/NEJMoa0809493
   Dupont J, 2022, BONE REP, V16, DOI 10.1016/j.bonr.2022.101582
   Ge YM, 2021, MAT SCI ENG C MATER, V129, DOI 10.1016/j.msec.2021.112386
   Geng Z, 2016, J BIOMATER APPL, V31, P140, DOI 10.1177/0885328216633892
   Geng Z, 2015, J MATER CHEM B, V3, P3738, DOI 10.1039/c4tb02148g
   Guo ZY, 2009, INORG CHEM, V48, P8069, DOI 10.1021/ic901056d
   Hanley DA, 2012, INT J CLIN PRACT, V66, P1139, DOI 10.1111/ijcp.12022
   Hassanpouraghdam Y, 2022, INT J BIOL MACROMOL, V221, P256, DOI 10.1016/j.ijbiomac.2022.08.167
   Hinks NJ, 2010, MICROPOR MESOPOR MAT, V129, P330, DOI 10.1016/j.micromeso.2009.04.031
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lei XP, 2022, ACTA PHARM SIN B, V12, P3877, DOI 10.1016/j.apsb.2022.05.024
   Li B, 2023, ACS NANO, V17, P4601, DOI 10.1021/acsnano.2c10694
   Li H, 1999, NATURE, V402, P276, DOI 10.1038/46248
   Li YL, 2022, INT J SYST SCI, V53, P199, DOI 10.1080/00207721.2021.1943562
   Li Z, 2020, MICROPOR MESOPOR MAT, V294, DOI 10.1016/j.micromeso.2019.109835
   Li Z, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 54147 5
   Li Z, 2019, COLLOID SURFACE B, V178, P1, DOI 10.1016/j.colsurfb.2019.02.027
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Ma N, 2015, EUR J CANCER, V51, pS701, DOI 10.1016/S0959 8049(16)31913 X
   Padmanabhan SK, 2013, CERAM INT, V39, P619, DOI 10.1016/j.ceramint.2012.06.073
   Pageau SC, 2009, MABS AUSTIN, V1, P210, DOI 10.4161/mabs.1.3.8592
   Patelli A, 2018, ACS APPL MATER INTER, V10, P39512, DOI 10.1021/acsami.8b15886
   Pooresmaeil M, 2023, EUR POLYM J, V184, DOI 10.1016/j.eurpolymj.2022.111802
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Sanchez Rodriguez D, 2020, MATURITAS, V139, P69, DOI 10.1016/j.maturitas.2020.05.006
   Sugimoto Toshitsugu, 2011, Clin Calcium, V21, P46, DOI CliCa11014651
   Sun KK, 2017, J COLLOID INTERF SCI, V486, P128, DOI 10.1016/j.jcis.2016.09.068
   Sun L, 2020, REGEN BIOMATER, V7, P391, DOI 10.1093/rb/rbaa010
   Terpos E, 2021, LANCET ONCOL, V22, pE119, DOI 10.1016/S1470 2045(20)30559 3
   Venkatraman SK, 2020, J BIOMED MATER RES A, V108, P1546, DOI 10.1002/jbm.a.36925
   Wang JL, 2020, ACTA PHARM SIN B, V10, P313, DOI 10.1016/j.apsb.2019.09.003
   Wang JQ, 2022, J BIONIC ENG, V19, P1359, DOI 10.1007/s42235 022 00230 z
   Wang YX, 2022, CHINESE CHEM LETT, V33, P4605, DOI 10.1016/j.cclet.2022.03.076
   Xu HC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI146832
   Xu YH, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14030566
   Yang LF, 2010, ANGEW CHEM INT EDIT, V49, P5348, DOI 10.1002/anie.201000863
   Zhang HY, 2022, CURR BIOINFORM, V17, P473, DOI 10.2174/1574893617666220404145517
   Zhang LM, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201900772
   Zhang W, 2021, MATER DESIGN, V209, DOI 10.1016/j.matdes.2021.109964
   Zhao DW, 2017, BIOMATERIALS, V112, P287, DOI 10.1016/j.biomaterials.2016.10.017
   Zheng JD, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.940511
   Zhou SQ, 2021, ENGINEERING PRC, V7, P1631, DOI 10.1016/j.eng.2020.10.016
   Zhou WH, 2021, BIOMATER SCI UK, V9, P807, DOI 10.1039/d0bm01584a
NR 49
TC 8
Z9 9
U1 8
U2 59
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 2296 4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD MAY 30
PY 2023
VL 11
AR 1153969
DI 10.3389/fbioe.2023.1153969
PG 8
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA J5CM6
UT WOS:001009796000001
PM 37324440
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhou, Y
   Fyrner, T
   Chen, CH
   Sather, NA
   Hsu, EL
   Stupp, SI
   Snead, ML
AF Zhou, Yan
   Fyrner, Timmy
   Chen, Charlotte H.
   Sather, Nicholas A.
   Hsu, Erin L.
   Stupp, Samuel I.
   Snead, Malcolm L.
TI Optimization of peptide amphiphile lipid raft interaction by changing
   peptide amphiphile lipophilicity
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Peptide amphiphile; Supramolecular nanofiber; Lipid raft; Wnt signaling;
   Caveolin mediated endocytosis; leucine rich amelogenin peptide (LRAP)
ID RICH AMELOGENIN PEPTIDE; BETA CATENIN; PLASMA MEMBRANE; TRANSBILAYER
   ASYMMETRY; BONE MASS; NANOFIBERS; RECEPTOR; CHOLESTEROL; MINERALIZATION;
   ORGANIZATION
AB Various peptide amphiphile (PA) molecules have been developed to promote bone regeneration. Previ ously we discovered that a peptide amphiphile with a palmitic acid tail (C16) attenuates the signaling threshold of leucine rich amelogenin peptide (LRAP) mediated Wnt activation by increasing membrane lipid raft mobility. In the current study, we found that treatment of murine ST2 cells with an inhibitor (Nystatin) or Caveolin 1 specific siRNA abolishes the effect of C16 PA, indicating that Caveolin mediated endocytosis is required. To determine whether hydrophobicity of the PA tail plays a role in its signaling effect, we modified the length of the tail (C12, C16 and C22) or composition (cholesterol). While short ening the tail (C12) decreased the signaling effect, lengthening the tail (C22) had no prominent effect. On the other hand, the cholesterol PA displayed a similar function as the C16 PA at the same concentra tion of 0.001% w/v. Interestingly, a higher concentration of C16 PA (0.0 05%) is cytotoxic while cholesterol PA at the higher concentration (0.0 05%) is well tolerated by cells. Use of the cholesterol PA at 0.005% enabled a further reduction of the signaling threshold of LRAP to 0.20 nM, compared to 0.25 nM at 0.001%. Caveolin mediated endocytosis is also required for cholesterol PA, as evidenced by Caveolin 1 siRNA knockdown experiments. We further demonstrated that the noted effects of cholesterol PA are also observed in human bone marrow mesenchymal stem cells (BMMSCs). Taken together, these results indi cate that the cholesterol PA modulates lipid raft/caveolar dynamics, thereby increasing receptor sensitivity for activation of canonical Wnt signaling. Statement of significance Cell signaling involves not only the binding of growth factors (or other cytokines) and cognate recep tors, but also their clustering on the cell membrane. However, little or no work has been directed thus far toward investigating how biomaterials can serve to enhance growth factor or peptide signaling by increasing diffusion of cell surface receptors within membrane lipid rafts. Therefore, a better understand ing of the cellular and molecular mechanism(s) operating at the material cell membrane interface during cell signaling has the potential to change the paradigm in designing future biomaterials and regenerative medicine therapeutics. In this study, we designed a peptide amphiphile (PA) with a cholesterol tail to enhance canonical Wnt signaling by modulating lipid raft/caveolar dynamics. & COPY; 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Zhou, Yan; Snead, Malcolm L.] Univ Southern Calif, Ctr Craniofacial Mol Biol, Herman Ostrow Sch Dent, 2250 Alcazar St, Los Angeles, CA 90033 USA.
   [Fyrner, Timmy; Chen, Charlotte H.; Sather, Nicholas A.; Hsu, Erin L.; Stupp, Samuel I.] Northwestern Univ, Simpson Querrey Inst BioNanotechnol, Chicago, IL 60611 USA.
   [Stupp, Samuel I.] Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA.
   [Stupp, Samuel I.] Northwestern Univ, Dept Mat Sci & Engn, Evanston, IL 60208 USA.
   [Stupp, Samuel I.] Northwestern Univ, Dept Chem, Evanston, IL 60208 USA.
   [Stupp, Samuel I.] Northwestern Univ, Dept Med, Chicago, IL 60611 USA.
   [Stupp, Samuel I.] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
C3 University of Southern California; Northwestern University; Northwestern
   University; Feinberg School of Medicine; Northwestern University;
   Northwestern University; Northwestern University; Northwestern
   University
RP Zhou, Y (通讯作者)，Univ Southern Calif, Ctr Craniofacial Mol Biol, Herman Ostrow Sch Dent, 2250 Alcazar St, Los Angeles, CA 90033 USA.
EM yzhou@usc.edu
RI ; Fyrner, Timmy/G 5731 2017; Sather, Nicholas/R 4554 2018; Stupp,
   Samuel/B 6737 2009; Hsu, Erin/AAD 6034 2019; Chen,
   Charlotte/AAF 9937 2021
OI Zhou, Yan/0000 0003 0749 5838; Fyrner, Timmy/0000 0003 2119 9883;
   Sather, Nicholas/0000 0001 9135 1882; Chen,
   Charlotte/0000 0002 3119 9919; 
FU NIH, the National Institute of Dental and Craniofacial Research (NIDCR)
   [R01DE15920]; NIH, the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) [R01AR072721]; Northwestern
   University; E.I. DuPont de Nemours amp; Co.; Dow Chemical Company; DOE
   Office of Science [DE AC0206CH11357]; NIH
   [1S10OD01201601/1S10RR01907101A1]; Soft and Hybrid Nanotechnology
   Experimental (SHyNE) Resource [NSF ECCS 1542205]; State of Illinois;
   International Institute for Nanotechnology (IIN); NCI CCSG [P30
   CA060553]
FX This work was supported by NIH, the National Institute of Dental and
   Craniofacial Research (NIDCR) Grant R01DE15920 (S.I.S and M.L.S); and
   the National Institute of Arthritis and Musculoskeletal and Skin
   Diseases (NIAMS) Grant R01AR072721 (S.I.S). X ray scattering was
   performed at the DuPont Northwestern Dow Collaborative Access Team
   (DND CAT) located at Sector 5 of the Advanced Photon Source (APS).
   DND CAT is supported by Northwestern University , E.I. DuPont de Nemours
   & amp; Co., and The Dow Chemical Company. This research used resources
   of the Advanced Photon Source, a U.S. Department of Energy (DOE) Office
   of Science User Facility operated for the DOE Office of Science by
   Argonne National Laboratory under Contract No. DE AC02 06CH11357. This
   work utilized the following facilities at Northwestern University: the
   Peptide Synthesis Core Facility and the Analytical Bio NanoTechnology
   Equipment Core facility (ANTEC) of the Simpson & nbsp;Querrey Institute
   for peptide synthesis and purification and materials characterization.
   NMR and HRMS ESI analyses were performed at the Integrated Molecular
   Structure Education and Research Center (IMSERC) at Northwestern
   University. IMSERC is supported by Northwestern University, the NIH
   (1S10OD012016 01/1S10RR019071 01A1), Soft and Hybrid Nanotechnology
   Experimental (SHyNE) Resource (NSF ECCS 1542205), the State of Illinois,
   and the International Institute for Nanotechnology (IIN). Imaging work
   was performed at the Northwestern University Center for Advanced
   Microscopy generously supported by NCI CCSG P30 CA060553 awarded to the
   Robert H Lurie Comprehensive Cancer Center.
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Ariotti N, 2014, J CELL BIOL, V204, P777, DOI 10.1083/jcb.201307055
   Atsawasuwan P, 2013, J DENT RES, V92, P622, DOI 10.1177/0022034513487906
   Beniash E, 2005, ACTA BIOMATER, V1, P387, DOI 10.1016/j.actbio.2005.04.002
   Bennett CN, 2007, J BONE MINER RES, V22, P1924, DOI 10.1359/JBMR.070810
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cong F, 2004, DEVELOPMENT, V131, P5103, DOI 10.1242/dev.01318
   Courtney KC, 2018, CELL REP, V24, P1037, DOI 10.1016/j.celrep.2018.06.104
   Fedorov VV, 2011, J MOL CELL CARDIOL, V51, P215, DOI 10.1016/j.yjmcc.2011.04.016
   Greenfield MA, 2010, LANGMUIR, V26, P3641, DOI 10.1021/la9030969
   Guler MO, 2006, BIOMACROMOLECULES, V7, P1855, DOI 10.1021/bm060161g
   Hartgerink JD, 2001, SCIENCE, V294, P1684, DOI 10.1126/science.1063187
   Hartgerink JD, 2002, P NATL ACAD SCI USA, V99, P5133, DOI 10.1073/pnas.072699999
   Hermetet F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 018 08228 0
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092 8674(02)00685 2
   Liu SL, 2017, NAT CHEM BIOL, V13, P268, DOI [10.1038/nchembio.2268, 10.1038/NCHEMBIO.2268]
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Mak IWY, 2014, AM J TRANSL RES, V6, P114
   Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108
   Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097 2765(01)00224 6
   Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092 8674(00)80112 9
   Newcomb CJ, 2016, NANO LETT, V16, P3042, DOI 10.1021/acs.nanolett.6b00054
   Ogasawara F, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 39973 x
   Palmer LC, 2008, CHEM REV, V108, P4754, DOI 10.1021/cr8004422
   Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124
   Preslar AT, 2014, ACS NANO, V8, P7325, DOI 10.1021/nn502393u
   Rajangam K, 2006, NANO LETT, V6, P2086, DOI 10.1021/nl0613555
   Rivel T, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 41903 w
   Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023
   Saha AK, 2018, CELL IMMUNOL, V324, P74, DOI 10.1016/j.cellimm.2017.12.005
   Saha AK, 2017, BIOPHYS J, V112, P1481, DOI 10.1016/j.bpj.2017.02.021
   Sakane H, 2010, J CELL SCI, V123, P360, DOI 10.1242/jcs.058008
   Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110
   Silva GA, 2004, SCIENCE, V303, P1352, DOI 10.1126/science.1093783
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Simons K, 2010, NAT REV MOL CELL BIO, V11, P688, DOI 10.1038/nrm2977
   Steck TL, 2018, TRAFFIC, V19, P750, DOI 10.1111/tra.12586
   Stevens JR, 2010, J BONE MINER RES, V25, P2138, DOI 10.1002/jbmr.118
   Storrie H, 2007, BIOMATERIALS, V28, P4608, DOI 10.1016/j.biomaterials.2007.06.026
   Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117
   Tysseling Mattiace VM, 2008, J NEUROSCI, V28, P3814, DOI 10.1523/JNEUROSCI.0143 08.2008
   van Meer G, 2008, NAT REV MOL CELL BIO, V9, P112, DOI 10.1038/nrm2330
   Velázquez Cruz R, 2014, AGE, V36, P1483, DOI 10.1007/s11357 014 9635 2
   Warotayanont R, 2009, BIOCHEM BIOPH RES CO, V387, P558, DOI 10.1016/j.bbrc.2009.07.058
   Wen X, 2011, BIOMATERIALS, V32, P6478, DOI 10.1016/j.biomaterials.2011.05.045
   Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015
NR 48
TC 2
Z9 2
U1 7
U2 26
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JUL 1
PY 2023
VL 164
BP 377
EP 386
DI 10.1016/j.actbio.2023.04.004
EA MAY 2023
PG 10
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA J8XD1
UT WOS:001012390400001
PM 37040812
OA Green Accepted, Green Submitted, Bronze
DA 2025 08 17
ER

PT J
AU Gordon, KE
   Dooley, JM
   Sheppard, KM
   MacSween, J
   Esser, MJ
AF Gordon, Kevin E.
   Dooley, Joseph M.
   Sheppard, Kayla M.
   MacSween, Judith
   Esser, Michael J.
TI Impact of Bisphosphonates on Survival for Patients With Duchenne
   Muscular Dystrophy
SO PEDIATRICS
LA English
DT Article
DE bisphosphonates; Duchenne muscular dystrophy; prognosis; steroids;
   survival
ID APOPTOSIS; PATHWAY; RAS; OSTEOCLASTS; POPULATION; INHIBITION; EXPRESSION
AB OBJECTIVE: In this article we describe the association of bisphosphonate therapy on survival within a regional cohort of patients with Duchenne muscular dystrophy (DMD) who received steroid therapy and were managed in a single center.
   PATIENTS AND METHODS: The records of all patients with confirmed DMD who were born between 1963 and 2006 and who had received at least 1 year of steroid therapy were reviewed from birth until they reached the study end points (death, loss to follow up, or the last follow up was in 2009). A survival analysis was used to account for the variable follow up duration within this cohort.
   RESULTS: Forty four boys from this cohort with DMD were exposed to continuous steroid use. Bisphosphonate therapy was initiated for 16 patients (36%) between 1997 and 2007 at a median age of 12.5 years (range: 7 23 years). At the time of the last follow up in 2009, 13 patients had died (30%) at a median age of 16 years (range: 14 27 years). Survival curves demonstrate that the prescription of bisphosphonates was associated with a significant improvement in survival rate (P = .005, log rank test). Furthermore, a possible therapy duration effect could be shown for bisphosphonate use (P = .007, log rank test).
   CONCLUSIONS: The treatment of patients with DMD with steroids and bisphosphonates seems to be associated with significantly improved survival compared with treatment with steroids alone. Pediatrics 2011;127:e353 e358
C1 [Gordon, Kevin E.; Dooley, Joseph M.; Esser, Michael J.] IWK Hlth Ctr, Div Pediat Neurol, Dept Pediat, Halifax, NS B3K 6R8, Canada.
   [MacSween, Judith] IWK Hlth Ctr, Neuromuscular Clin, Halifax, NS B3K 6R8, Canada.
   [Gordon, Kevin E.; Dooley, Joseph M.; Esser, Michael J.] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada.
   [Esser, Michael J.] Dalhousie Univ, Dept Pharmacol, Halifax, NS B3H 4H7, Canada.
   [Sheppard, Kayla M.] Dalhousie Univ, Fac Med, Halifax, NS, Canada.
C3 Dalhousie University; Dalhousie University Hospital; Dalhousie
   University; Dalhousie University Hospital; Dalhousie University;
   Dalhousie University; Dalhousie University
RP Dooley, JM (通讯作者)，IWK Hlth Ctr, Div Pediat Neurol, Dept Pediat, 5850 5980 Univ Ave, Halifax, NS B3K 6R8, Canada.
EM jdooley@dal.ca
CR Asahi H, 2006, INT J UROL, V13, P593, DOI 10.1111/j.1442 2042.2006.01360.x
   Bifulco M, 2005, LIFE SCI, V77, P1740, DOI 10.1016/j.lfs.2005.05.017
   Bothwell JE, 2003, CLIN PEDIATR, V42, P353, DOI 10.1177/000992280304200408
   Calvert LD, 2006, RESP MED, V100, P1058, DOI 10.1016/j.rmed.2005.09.030
   Claflin DR, 2008, AM J PHYSIOL CELL PH, V294, pC651, DOI 10.1152/ajpcell.00244.2007
   Deconinck N, 2007, PEDIATR NEUROL, V36, P1, DOI 10.1016/j.pediatrneurol.2006.09.016
   Dooley J, 2010, CLIN PEDIATR, V49, P177, DOI 10.1177/0009922809347777
   Dooley JM, 2010, PEDIATR NEUROL, V43, P173, DOI 10.1016/j.pediatrneurol.2010.04.013
   Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960 8966(02)00140 2
   FELIX R, 1976, BIOCHIM BIOPHYS ACTA, V429, P429, DOI 10.1016/0005 2744(76)90291 6
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   HUGHES DE, 1989, J CLIN INVEST, V83, P1930, DOI 10.1172/JCI114100
   Iguchi K, 2007, ANTICANCER RES, V27, P3843
   Jeppesen J, 2003, NEUROMUSCULAR DISORD, V13, P804, DOI 10.1016/S0960 8966(03)00162 7
   Manzur AY, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003725.pub3
   Oades GM, 2003, J UROLOGY, V170, P246, DOI 10.1097/01.ju.0000070685.34760.5f
   Pandha H, 2006, J UROLOGY, V176, P2255, DOI 10.1016/j.juro.2006.07.053
   PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Rodino Klapac LR, 2009, MUSCLE NERVE, V39, P283, DOI 10.1002/mus.21244
   Russell RGG, 2007, ANN NY ACAD SCI, V1117, P209, DOI 10.1196/annals.1402.089
   Santini D, 2003, ANN ONCOL, V14, P1468, DOI 10.1093/annonc/mdg401
   SATO M, 1990, J BONE MINER RES, V5, P31, DOI 10.1002/jbmr.5650050107
   Schmidt A, 1996, P NATL ACAD SCI USA, V93, P3068, DOI 10.1073/pnas.93.7.3068
   *SPSS INC, 1997, SYST SOFTW COMP PROG
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Tatsuda Y, 2010, EUR J PHARMACOL, V627, P348, DOI 10.1016/j.ejphar.2009.10.067
   Vieillard MH, 2008, JOINT BONE SPINE, V75, P34, DOI 10.1016/j.jbspin.2007.05.003
   Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001
   Walter C, 2010, CLIN ORAL INVEST, V14, P35, DOI 10.1007/s00784 009 0266 4
NR 32
TC 41
Z9 47
U1 0
U2 2
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007 1098 USA
SN 0031 4005
EI 1098 4275
J9 PEDIATRICS
JI Pediatrics
PD FEB
PY 2011
VL 127
IS 2
BP E353
EP E358
DI 10.1542/peds.2010 1666
PG 6
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pediatrics
GA 714JF
UT WOS:000286805200013
PM 21242224
DA 2025 08 17
ER

PT J
AU Wang, SH
   Liu, YT
   Lou, CE
   Cai, C
   Ren, WH
   Liu, JY
   Gong, M
   Shang, P
   Zhang, H
AF Wang, Shenghang
   Liu, Yuetong
   Lou, Chenge
   Cai, Chao
   Ren, Weihao
   Liu, Junyu
   Gong, Ming
   Shang, Peng
   Zhang, Hao
TI Moderate static magnetic field promotes fracture healing and regulates
   iron metabolism in mice
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
DE Moderate static magnetic field; Fracture healing; Bone metabolism; Iron
   metabolism
ID INDUCED BONE LOSS; REPAIR; CELLS; INFLAMMATION
AB BackgroundFractures are the most common orthopedic diseases. It is known that static magnetic fields (SMFs) can contribute to the maintenance of bone health. However, the effect and mechanism of SMFs on fracture is still unclear. This study is aim to investigate the effect of moderate static magnetic fields (MMFs) on bone structure and metabolism during fracture healing.MethodsEight week old male C57BL/6J mice were subjected to a unilateral open transverse tibial fracture, and following treatment under geomagnetic field (GMF) or MMF. The micro computed tomography (Micro CT) and three point bending were employed to evaluate the microarchitecture and mechanical properties. Endochondral ossification and bone remodeling were evaluated by bone histomorphometric and serum biochemical assay. In addition, the atomic absorption spectroscopy and ELISA were utilized to examine the influence of MMF exposure on iron metabolism in mice.ResultsMMF exposure increased bone mineral density (BMD), bone volume per tissue volume (BV/TV), mechanical properties, and proportion of mineralized bone matrix of the callus during fracture healing. MMF exposure reduced the proportion of cartilage in the callus area during fracture healing. Meanwhile, MMF exposure increased the number of osteoblasts in callus on the 14th day, and reduced the number of osteoclasts on the 28th day of fracture healing. Furthermore, MMF exposure increased PINP and OCN levels, and reduced the TRAP 5b and beta CTX levels in serum. It was also observed that MMF exposure reduced the iron content in the liver and callus, as well as serum ferritin levels while elevating the serum hepcidin concentration.ConclusionsMMF exposure could accelerate fracture healing via promote the endochondral ossification and bone formation while regulating systemic iron metabolism during fracture healing. This study suggests that MMF may have the potential to become a form of physical therapy for fractures.
C1 [Wang, Shenghang; Gong, Ming; Zhang, Hao] Southern Med Univ, Peoples Hosp Longhua, Affiliated Hosp, Dept Spine Surg, 38 Jinglong Construct Rd, Shenzhen, Peoples R China.
   [Wang, Shenghang; Liu, Yuetong; Lou, Chenge; Cai, Chao; Ren, Weihao; Liu, Junyu] Northwestern Polytech Univ, Sch Life Sci, Xian, Peoples R China.
   [Liu, Yuetong; Lou, Chenge; Cai, Chao; Ren, Weihao; Liu, Junyu; Shang, Peng] Northwestern Polytech Univ Shenzhen, Res & Dev Inst, 45 Gaoxin South 9th Rd, Shenzhen 518057, Peoples R China.
C3 Southern Medical University   China; The People's Hospital of Longhua,
   Shenzhen; Northwestern Polytechnical University; Northwestern
   Polytechnical University
RP Zhang, H (通讯作者)，Southern Med Univ, Peoples Hosp Longhua, Affiliated Hosp, Dept Spine Surg, 38 Jinglong Construct Rd, Shenzhen, Peoples R China.; Shang, P (通讯作者)，Northwestern Polytech Univ Shenzhen, Res & Dev Inst, 45 Gaoxin South 9th Rd, Shenzhen 518057, Peoples R China.
EM shangpeng@nwpu.edu.cn; zhanghaodoctor@hotmail.com
FU We thank Zhouqi Yang at Experimental Center, School of Life Sciences,
   Northwestern Polytechnical University for the help in guidance and
   assistance in experimental ethology.
FX We thank Zhouqi Yang at Experimental Center, School of Life Sciences,
   Northwestern Polytechnical University for the help in guidance and
   assistance in experimental ethology.
CR Adamopoulos IE, 2018, CURR OPIN RHEUMATOL, V30, P59, DOI 10.1097/BOR.0000000000000449
   Adie S, 2011, J BONE JOINT SURG AM, V93A, P1569, DOI 10.2106/JBJS.J.00869
   Aghajanian P, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0021 z
   Amin HD, 2014, TISSUE ENG PT A, V20, P1612, DOI 10.1089/ten.tea.2013.0307
   Aydin N, 2011, INT ORTHOP, V35, P135, DOI 10.1007/s00264 009 0932 9
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Balogh E, 2018, PHARMACEUTICALS BASE, V11, DOI 10.3390/ph11040107
   BASSETT CAL, 1974, ANN NY ACAD SCI, V238, P242, DOI 10.1111/j.1749 6632.1974.tb26794.x
   Bonfanti A, 2022, TRENDS CELL BIOL, V32, P537, DOI 10.1016/j.tcb.2022.01.005
   BRUCE GK, 1987, CLIN ORTHOP RELAT R, P300
   Cao MM, 2022, WORLD J SURG, V46, P2595, DOI 10.1007/s00268 022 06690 y
   Castro IMA, 2023, VET MED SCI, V9, P591, DOI 10.1002/vms3.1071
   Crielaard BJ, 2017, NAT REV DRUG DISCOV, V16, P400, DOI 10.1038/nrd.2016.248
   Del Buono A, 2021, INT ORTHOP, V45, P2945, DOI 10.1007/s00264 021 05125 y
   Djordjevich DM, 2012, ECOTOX ENVIRON SAFE, V81, P98, DOI 10.1016/j.ecoenv.2012.04.025
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   ElHawary H, 2021, SEMIN PLAST SURG, V35, P198, DOI 10.1055/s 0041 1732334
   Goddard AF, 2011, GUT, V60, P1309, DOI 10.1136/gut.2010.228874
   Goodnough LH, 2022, CURR OSTEOPOROS REP, V20, P320, DOI 10.1007/s11914 022 00742 x
   Hoenig T, 2022, NAT REV DIS PRIMERS, V8, DOI 10.1038/s41572 022 00352 y
   Könnecke I, 2014, BONE, V64, P155, DOI 10.1016/j.bone.2014.03.052
   Loi F, 2016, BONE, V86, P119, DOI 10.1016/j.bone.2016.02.020
   Mizoguchi T, 2021, J BONE MINER RES, V36, P1432, DOI 10.1002/jbmr.4410
   Odén A, 2015, OSTEOPOROSIS INT, V26, P2243, DOI 10.1007/s00198 015 3154 6
   Ozaki A, 2000, J Orthop Sci, V5, P64, DOI 10.1007/s007760050010
   Puricelli Edela, 2006, Head Face Med, V2, P43, DOI 10.1186/1746 160X 2 43
   Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004
   Sun YT, 2023, J ORTHOP TRANSL, V39, P43, DOI 10.1016/j.jot.2022.11.007
   Wang SH, 2019, EUR RADIOL, V29, P6029, DOI 10.1007/s00330 019 06256 y
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264 013 2059 2
   Wu AM, 2021, LANCET HEALTH LONGEV, V2, pE580, DOI 10.1016/S2666 7568(21)00172 0
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Xue YR, 2020, J BONE MINER RES, V35, P1163, DOI 10.1002/jbmr.3949
   Yang JC, 2023, PROG BIOPHYS MOL BIO, V177, P168, DOI 10.1016/j.pbiomolbio.2022.11.006
   Yang JC, 2021, INT J RADIAT BIOL, V97, P746, DOI 10.1080/09553002.2021.1900944
   Yang JC, 2021, IEEE T MAGN, V57, DOI 10.1109/TMAG.2021.3072148
   Yang JC, 2018, BIOL TRACE ELEM RES, V184, P214, DOI 10.1007/s12011 017 1161 5
   Yasuda I., 1953, J. Kyoto. Pref .Univ. Med, V4, P395
   Zhang B, 2023, PROG BIOPHYS MOL BIO, V177, P14, DOI 10.1016/j.pbiomolbio.2022.09.002
   Zhang GJ, 2023, J ORTHOP TRANSL, V38, P126, DOI 10.1016/j.jot.2022.10.007
   Zhang H, 2018, BONE, V107, P36, DOI 10.1016/j.bone.2017.10.024
   Zhang J, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111380
   Zhang J, 2018, ELECTROMAGN BIOL MED, V37, P76, DOI 10.1080/15368378.2018.1458626
   Zhang K, 2023, CELLS TISSUES ORGANS, V212, P317, DOI 10.1159/000524291
   Zhang P, 2018, J MOL ENDOCRINOL, V60, P299, DOI 10.1530/JME 17 0301
NR 45
TC 4
Z9 4
U1 1
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475 925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD NOV 15
PY 2023
VL 22
IS 1
AR 107
DI 10.1186/s12938 023 01170 3
PG 16
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering
GA Y0JR0
UT WOS:001102222700001
PM 37968671
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Tanaka, H
   Makita, C
   Manabe, Y
   Kajima, M
   Matsuyama, K
   Matsuo, M
AF Tanaka, Hidekazu
   Makita, Chiyoko
   Manabe, Yuki
   Kajima, Miki
   Matsuyama, Katsuya
   Matsuo, Masayuki
TI Radiation therapy combined with bone modifying agents ameliorates local
   control of osteolytic bone metastases in breast cancer
SO JOURNAL OF RADIATION RESEARCH
LA English
DT Article
DE radiotherapy; bone modifying agents; osteolytic bone metastasis; breast
   cancer
ID SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; DOUBLE BLIND; PALLIATIVE
   RADIOTHERAPY; MULTIPLE MYELOMA; PAMIDRONATE; DENOSUMAB; CARCINOMA
AB Bone modifying agents (BMAs) are frequently used for the treatment of bone metastases. Both BMA and radiation therapy (RT) are effective; however, there are few studies that have evaluated the efficacy of the combination treatment. We evaluated the effectiveness of RT + BMA in breast cancer induced osteolytic bone metastasis as compared to BMA alone. A total of 43 lesions in 25 patients were evaluated. The median follow up period was 18 (range, 2 90) months. None of the lesions was treated with chemotherapy or molecular targeted drugs during the follow up period for evaluating the local response. Patients with complete or partial response were considered as responders, while those with stable or progressive disease were considered as non responders. The rate of response with RT + BMA was significantly higher than that with BMA alone (P = 0.001). The cumulative incidence rate of response at 6 months was 54.4% in the RT + BMA group and 27.5% in the BMA alone group. The median time to response was 4 (range, 2 11) months in the RT + BMA group and 6 (range, 4 16) months in the BMA alone group. The overall survival rate in the responder group (83.1% at 1 year) was significantly higher than that in the non responder group (37.5% at 1 year) (P = 0.029). In conclusion, RT combined with BMA was found to be more effective than BMA alone for the treatment of osteolytic bone metastasis, which thereby improves the prognosis.
C1 [Tanaka, Hidekazu; Makita, Chiyoko; Matsuyama, Katsuya; Matsuo, Masayuki] Gifu Univ Hosp, Dept Radiol, Gifu, Japan.
   [Tanaka, Hidekazu; Manabe, Yuki; Kajima, Miki] Yamaguchi Univ, Dept Radiat Oncol, Grad Sch Med, 1 1 1Minamikogushi, Ube, Yamaguchi 7558505, Japan.
C3 Gifu University; Yamaguchi University
RP Tanaka, H (通讯作者)，Yamaguchi Univ, Dept Radiat Oncol, Grad Sch Med, 1 1 1Minamikogushi, Ube, Yamaguchi 7558505, Japan.
EM h tanaka@yamaguchi u.ac.jp
RI ; Makita, Chiyoko/N 6200 2019; Manabe, Yuki/AAJ 2599 2020
OI Makita, Chiyoko/0000 0003 0178 054X; Tanaka,
   Hidekazu/0000 0002 8673 5707; 
CR Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065
   Arrington SA, 2008, J SURG ONCOL, V97, P284, DOI 10.1002/jso.20949
   Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097 0142(20010401)91:7<1191::AID CNCR1119>3.0.CO;2 0
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Chow E, 2012, CLIN ONCOL UK, V24, P112, DOI 10.1016/j.clon.2011.11.004
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Groenen KHJ, 2016, RADIOTHER ONCOL, V119, P194, DOI 10.1016/j.radonc.2016.03.001
   Harada H, 2010, J RADIAT RES, V51, P131, DOI 10.1269/jrr.09096
   Ibrahim A, 2003, CLIN CANCER RES, V9, P2394
   Imoto S., 2013, KOBETOKIWA DAIGAKU K, V6, P9
   International Agency for Research on Cancer/World Health Organization Lyon, GLOBOCAN 2018
   Japanese Society ofMedical Oncology, 2015, PRACT GUID BON MET
   Kijima T, 2009, BJU INT, V103, P620, DOI 10.1111/j.1464 410X.2008.08124.x
   Klimo P, 2005, NEURO ONCOLOGY, V7, P64, DOI 10.1215/S1152851704000262
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Lutz S, 2011, INT J RADIAT ONCOL, V79, P965, DOI 10.1016/j.ijrobp.2010.11.026
   National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Pichon B, 2016, INT J RADIAT ONCOL, V96, P840, DOI 10.1016/j.ijrobp.2016.07.027
   Roos DE, 2005, RADIOTHER ONCOL, V75, P54, DOI 10.1016/j.radonc.2004.09.017
   Rosen LS, 2004, CANCER, V100, P36, DOI 10.1002/cncr.11892
   Rosen LS, 2001, CANCER J, V7, P377
   Souchon R, 2009, STRAHLENTHER ONKOL, V185, P417, DOI 10.1007/s00066 009 2044 2
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Takeda N, 2012, J ORTHOP SCI, V17, P770, DOI 10.1007/s00776 012 0294 9
   Ural AU, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1543
NR 28
TC 14
Z9 14
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0449 3060
EI 1349 9157
J9 J RADIAT RES
JI J. Radiat. Res.
PD MAY
PY 2020
VL 61
IS 3
BP 494
EP 498
DI 10.1093/jrr/rraa020
PG 5
WC Biology; Oncology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics; Oncology; Radiology, Nuclear
   Medicine & Medical Imaging
GA MD7VK
UT WOS:000544178000018
PM 32266394
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lu, W
   Shi, YX
   Qian, ML
AF Lu, Wei
   Shi, Yuanxin
   Qian, Minglei
TI Notoginsenoside R1 promotes osteogenic differentiation of human bone
   marrow mesenchymal stem cells via ERα/GSK 3β/β catenin signalling
   pathway
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE ER alpha; hBMSCs; Notoginsenoside R1; osteogenic differentiation
ID PROLIFERATION; OSTEOBLASTS; REPAIR
AB Human bone marrow mesenchymal stem cells (hBMSCs) are attractive therapeutic agents for bone tissue regeneration owing to their osteogenic differentiation potential. Notoginsenoside R1 (NGR1) is a novel phytoestrogen with diverse pharmacological activities. Here, we probed whether NGR1 has an effect on the osteogenic differentiation of hBMSCs. EdU, CCK 8 and Transwell assays were used to measure proliferation and migration of hBMSCs after treatment with different doses of NGR1. hBMSCs were treated with osteogenic differentiation induction medium for osteogenesis. Alizarin red S (ARS) and alkaline phosphatase (ALP) staining were used to measure mineralized nodule formation and ALP activity in hBMSCs, respectively. ICI 182780, an antagonist of oestrogen receptor alpha (ER alpha) was used to inhibit ER alpha expression. The results showed that NGR1 enhanced hBMSC proliferation and migration. NGR1 increased ALP activity and mineralized nodule formation as well as promoting ALP, RUNX2 and OCN expression in hBMSCs. NGR1 enhanced ER alpha expression and promoted GSK 3 beta/beta catenin signal transduction in hBMSCs. ICI 182780 reversed NGR1 mediated activation of the GSK 3 beta/beta catenin signalling and promoted an effect on hBMSC behaviour. Thus NGR1 promotes proliferation, migration and osteogenic differentiation of hBMSCs via the ER alpha/GSK 3 beta/beta catenin signalling pathway.
C1 [Lu, Wei; Shi, Yuanxin; Qian, Minglei] Changshu 2 Peoples Hosp, Dept Traumatol, Changshu, Jiangsu, Peoples R China.
   [Qian, Minglei] Changshu 2 Peoples Hosp, Dept Traumatol, 18 Taishan Rd, Changshu, Jiangsu, Peoples R China.
RP Qian, ML (通讯作者)，Changshu 2 Peoples Hosp, Dept Traumatol, 18 Taishan Rd, Changshu, Jiangsu, Peoples R China.
EM allares2022@163.com
CR Arab F, 2023, MOL BIOL REP, V50, P1281, DOI 10.1007/s11033 022 08084 8
   Bian L, 2023, MOL BIOL REP, V50, P1293, DOI 10.1007/s11033 022 08022 8
   Che CT, 2016, MOLECULES, V21, DOI 10.3390/molecules21030239
   Chen L, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951 021 00969 3
   Chen XJ, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108746
   Du FW, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.791643
   Gultekin BA, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/4987437
   Han RQ, 2022, DRUG DES DEV THER, V16, P4399, DOI 10.2147/DDDT.S387004
   He J, 2022, INNATE IMMUN LONDON, V28, P19, DOI 10.1177/17534259211068744
   Huang L, 2020, MOL MED REP, V22, P4754, DOI 10.3892/mmr.2020.11537
   Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303
   Jiang YK, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.577578
   Jin H, 2021, FEBS OPEN BIO, V11, P1223, DOI 10.1002/2211 5463.13082
   Kikuchi A, 2007, CELL SIGNAL, V19, P659, DOI 10.1016/j.cellsig.2006.11.001
   Kim HY, 2018, EUR J PHARMACOL, V834, P84, DOI 10.1016/j.ejphar.2018.07.012
   Kwun IS, 2010, BONE, V46, P732, DOI 10.1016/j.bone.2009.11.003
   Li XF, 2018, BIOMED PHARMACOTHER, V99, P622, DOI 10.1016/j.biopha.2018.01.103
   Li XM, 2021, J CELL MOL MED, V25, P11278, DOI 10.1111/jcmm.17054
   Liu J, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420 022 00902 z
   Liu Y, 2016, INT J MOL MED, V38, P537, DOI 10.3892/ijmm.2016.2652
   Lou Q, 2022, BLOOD, V139, P3204, DOI 10.1182/blood.2021013048
   Maupin KA, 2013, BONE RES, V1, DOI 10.4248/BR201301004
   Nie FJ, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118143
   Niu QN, 2021, REGEN MED, V16, P847, DOI 10.2217/rme 2020 0119
   Sohn HS, 2019, BIOMATER RES, V23
   Tang K, 2021, INT IMMUNOPHARMACOL, V101, DOI 10.1016/j.intimp.2021.107866
   Tian X, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.864326
   Wang MJ, 2022, NEUROIMMUNOMODULAT, V29, P70, DOI 10.1159/000518215
   Wang T, 2015, BIOCHEM BIOPH RES CO, V466, P232, DOI 10.1016/j.bbrc.2015.09.014
   Wang WH, 2017, BIOACT MATER, V2, P224, DOI 10.1016/j.bioactmat.2017.05.007
   Wang X, 2013, INT ORTHOP, V37, P2491, DOI 10.1007/s00264 013 2059 2
   Wang YY, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 03899 z
   Xu H, 2022, BIOENGINEERED, V13, P5653, DOI 10.1080/21655979.2022.2037366
   Ye J, 2020, BIOCHEM BIOPH RES CO, V531, P290, DOI 10.1016/j.bbrc.2020.06.158
   Zhang B, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01227
   Zhang CH, 2023, BIOCHEM BIOPH RES CO, V638, P147, DOI 10.1016/j.bbrc.2022.11.022
   Zhang FX, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.596230
   Zhang L, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 1562 9
   Zhou Y, 2016, EUR J PHARMACOL, V789, P109, DOI 10.1016/j.ejphar.2016.07.027
NR 39
TC 3
Z9 4
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0959 9673
EI 1365 2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD FEB
PY 2024
VL 105
IS 1
BP 4
EP 12
DI 10.1111/iep.12494
EA OCT 2023
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pathology
GA FJ8F9
UT WOS:001094021100001
PM 37899670
DA 2025 08 17
ER

PT J
AU Pan, TH
   Lin, SC
   Yu, KJ
   Yu, GY
   Song, JH
   Lewis, VO
   Bird, JE
   Moon, B
   Lin, PP
   Tannir, N
   Jonasch, E
   Gwood, C
   Gallick, GE
   Yu Lee, LY
   Lin, SH
   Satcher, RL
AF Pan, Tianhong
   Lin, Song Chang
   Yu, Kai Jie
   Yu, Guoyu
   Song, Jian H.
   Lewis, Valerae O.
   Bird, Justin E.
   Moon, Bryan
   Lin, Patrick P.
   Tannir, NizarM.
   Jonasch, Eric
   Gwood, Christopher
   Gallick, Gary E.
   Yu Lee, Li Yuan
   Lin, Sue Hwa
   Satcher, Robert L.
TI BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone
   Metastasis by Inhibiting Osteoblast Differentiation
SO NEOPLASIA
LA English
DT Article
ID PROSTATE CANCER CELLS; GROWTH FACTOR BETA; RANK LIGAND; IN VITRO;
   TGF BETA; BETA IG H3; GENE; ADHESION; EXPRESSION; MIGRATION
AB BACKGROUND: Bone metastasis is common in renal cell carcinoma (RCC), and the lesions are mainly osteolytic. The mechanism of bone destruction in RCC bone metastasis is unknown. METHODS: We used a direct intrafemur injection of mice with bone derived 786 O RCC cells (Bo 786) as an in vivo model to study if inhibition of osteoblast differentiation is involved in osteolytic bone lesions in RCC bone metastasis. RESULTS: We showed that bone derived Bo 786 cells induced osteolytic bone lesions in the femur of mice. We examined the effect of conditioned medium of Bo 786 cells (Bo 786 CM) on both primary mouse osteoblasts and MC3T3 E1 preosteoblasts and found that Bo 786 CM inhibited osteoblast differentiation. Secretome analysis of Bo 786 CM revealed that BIGH3 (Beta ig h3 protein), also known as TGFBI (transforming growth factor beta induced protein), is highly expressed. We generated recombinant BIGH3 and found that BIGH3 inhibited osteoblast differentiation in vitro. In addition, CM from Bo 786 BIGH3 knockdown cells (786 BIGH3 KD) reduced the inhibition of osteoblast differentiation compared to CM from vector control. Intrafemural injection of mice with 786 BIGH3 KD cells showed a reduction in osteolytic bone lesions compared to vector control. Immunohistochemical staining of 18 bone metastasis specimens from human RCC showed strong BIGH3 expression in 11/18 (61%) and moderate BIGH3 expression in 7/18 (39%) of the specimens. CONCLUSIONS: These results suggest that suppression of osteoblast differentiation by BIGH3 is one of the mechanisms that enhance osteolytic lesions in RCC bone metastasis, and raise the possibilty that treatments that increase bone formation may improve therapy outcomes.
C1 [Pan, Tianhong; Lewis, Valerae O.; Bird, Justin E.; Moon, Bryan; Lin, Patrick P.; Satcher, Robert L.] Univ Texas MD Anderson Canc Ctr, Dept Orthoped Oncol, Houston, TX 77030 USA.
   [Lin, Song Chang; Yu, Guoyu; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 89,1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Yu, Kai Jie] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.
   [Song, Jian H.; Tannir, NizarM.; Jonasch, Eric; Gallick, Gary E.; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Yu, Kai Jie] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp Linkou, Div Urol,Dept Surg, Taoyuan, Taiwan.
   [Yu, Kai Jie] Natl Taipei Univ Technol, Dept Chem Engn & Biotechnol, Taipei, Taiwan.
   [Yu, Kai Jie] Natl Taipei Univ Technol, Grad Inst Biochem & Biomed Engn, Taipei, Taiwan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; Baylor College of Medicine; Chang Gung University; Chang
   Gung Memorial Hospital; National Taipei University of Technology;
   National Taipei University of Technology
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 89,1515 Holcombe Blvd, Houston, TX 77030 USA.; Satcher, RL (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM slin@mdanderson.org; rlsatcher@mdanderson.org
RI Yu, Kai Jie/GZA 9147 2022; Satcher, Robert/K 7308 2018
FU National Institutes of Health [CA174798, 5P50 CA140388, P30CA16672];
   Cancer Prevention and Research Institute of Texas [CPRIT RP110327, CPRIT
   RP150179, CPRIT RP150282]; University Cancer Foundation via the Sister
   Institute Network Fund at the MD Anderson Cancer Center; Institutional
   Research Grant (IRG Knowledge Gap Grant) Program at the MD Anderson
   Cancer Center
FX This work was supported by grants from the National Institutes of Health
   [CA174798, 5P50 CA140388, and P30CA16672], by grants from the Cancer
   Prevention and Research Institute of Texas [CPRIT RP110327, CPRIT
   RP150179, CPRIT RP150282], by funds from the University Cancer
   Foundation via the Sister Institute Network Fund at the MD Anderson
   Cancer Center, and by the Institutional Research Grant (IRG Knowledge
   Gap Grant) Program at the MD Anderson Cancer Center.
CR Azim HA, 2012, J EGYPT NATL CANCER, V24, P107, DOI 10.1016/j.jnci.2012.06.002
   Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008 5472.CAN 05 3074
   Brown JM, 2001, UROLOGY, V57, P611, DOI 10.1016/S0090 4295(00)01122 5
   Chen SC, 2016, Int J Mol Sci, V17
   Christoulas D, 2009, EXPERT REV HEMATOL, V2, P385, DOI 10.1586/ehm.09.36
   Chu K, 2008, MOL CANCER RES, V6, P1259, DOI 10.1158/1541 7786.MCR 08 0077
   Dai JL, 2014, CLIN CANCER RES, V20, P617, DOI 10.1158/1078 0432.CCR 13 0839
   Dieudonné SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097 4644(20000201)76:2<231::AID JCB7>3.0.CO;2 X
   Graham TJ, 2014, JNCI J NATL CANCER I, V106, DOI 10.1093/jnci/dju033
   Guise T. A., 2002, Journal of Musculoskeletal & Neuronal Interactions, V2, P570
   Han B, 2014, HUM MOL GENET, V23, P4597, DOI 10.1093/hmg/ddu173
   Heinemann ML, 2014, J CHROMATOGR A, V1371, P125, DOI 10.1016/j.chroma.2014.10.026
   Nguyen HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063219
   Ivanov SV, 2008, BIOCHEM BIOPH RES CO, V370, P536, DOI 10.1016/j.bbrc.2008.03.066
   Jin JK, 2015, ONCOGENE, V34, P1811, DOI 10.1038/onc.2014.116
   Kannabiran C, 2006, HUM MUTAT, V27, P615, DOI 10.1002/humu.20334
   Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097 4644(20000501)77:2<169::AID JCB1>3.0.CO;2 L
   Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200
   Klamer SE, 2013, CELL ADHES MIGR, V7, P434, DOI 10.4161/cam.26596
   LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523 1747.ep12607024
   Lebdai S, 2015, UROL ONCOL, V33, pe11, DOI DOI 10.1016/J.UR0L0NC.2014.06.005
   Lee JM, 2015, CALCIFIED TISSUE INT, V96, P56, DOI 10.1007/s00223 014 9938 4
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Liang AK, 2005, PROTEIN EXPRES PURIF, V44, P58, DOI 10.1016/j.pep.2005.03.025
   Lin SH, 2008, ONCOGENE, V27, P5195, DOI 10.1038/onc.2008.156
   Mikami S, 2009, J PATHOL, V218, P530, DOI 10.1002/path.2567
   Monticone M, 2004, J CELL BIOCHEM, V92, P733, DOI 10.1002/jcb.20120
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Satcher RL, 2015, J CELL SCI, V128, P4629, DOI 10.1242/jcs.176081
   Satcher RL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089880
   SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Thapa N, 2005, BONE, V36, P232, DOI 10.1016/j.bone.2004.08.007
   Thapa N, 2007, INT J BIOCHEM CELL B, V39, P2183, DOI 10.1016/j.biocel.2007.06.004
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Varkaris A, 2016, CLIN CANCER RES, V22, P107, DOI 10.1158/1078 0432.CCR 15 0235
   Wang D, 1999, J BONE MINER RES, V14, P893, DOI 10.1359/jbmr.1999.14.6.893
   WILLIAMS RD, 1978, IN VITRO CELL DEV B, V14, P779, DOI 10.1007/BF02617972
   Yamanaka M, 2008, ONCOL REP, V19, P865
   Young AC, 2009, CLIN CANCER RES, V15, P7582, DOI 10.1158/1078 0432.CCR 09 2131
NR 42
TC 17
Z9 20
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1476 5586
J9 NEOPLASIA
JI Neoplasia
PD JAN
PY 2018
VL 20
IS 1
BP 32
EP 43
DI 10.1016/j.neo.2017.11.002
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA FQ7TQ
UT WOS:000418566000004
PM 29190493
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Sideras, PA
   Stavraka, A
   Gouliamos, A
   Limouris, GS
AF Sideras, Panagiotis A.
   Stavraka, Anastasia
   Gouliamos, Athanasios
   Limouris, Georgios S.
TI Radionuclide Therapy of Painful Bone Metastases A Comparative Study
   Between Consecutive Radionuclide Infusions, Combination With
   Chemotherapy, and Radionuclide Infusions Alone: An In Vivo Comparison of
   Their Effectiveness
SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE
LA English
DT Article
DE consecutive radionuclide treatment; rhenium 186 HEDP;
   (89)strontium chloride; bone metastases; pain palliation; breast and
   prostate cancer
ID ADVANCED PROSTATE CANCER; ZOLEDRONIC ACID; SEEKING RADIONUCLIDES;
   SKELETAL METASTASES; OSSEOUS METASTASES; TARGETED THERAPY;
   CONTROLLED TRIAL; DOUBLE BLIND; PHASE II; MANAGEMENT
AB Radionuclides have been long used for the palliation of skeletal related metastatic pain. They are almost invariably used as the last resource for pain palliation. Their use as single agents with dose escalations, in combination with biphosphonates or chemotherapy is well known in the peer reviewed literature; however, little is known about the combination between different agents. In our study, we used consecutive administration of 2 different radionuclides such as Re 186 1,1 hydroxyethylidenediphosphonate (Re 186 HEDP) and (89)Strontium Chloride (Sr 89 Cl) separated by adequate period of time to allow bone marrow recovery in patients with high chance of bone pain relapse and compared it with Sr 89 Cl and chemotherapy group and Re 186 HEDP with bisphosphonates. The end result was that treatment with consecutive radionuclides was much more effective and safe than the other 2 groups.
C1 [Sideras, Panagiotis A.] Mt Sinai Sch Med, New York, NY 10029 USA.
   [Stavraka, Anastasia; Gouliamos, Athanasios; Limouris, Georgios S.] Aretaieio Univ Hosp, Athens, Greece.
C3 Icahn School of Medicine at Mount Sinai
RP Sideras, PA (通讯作者)，Mt Sinai Sch Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.
EM panagiotis.sideras@mssm.edu
RI Limouris, Georgios/AAI 1471 2019; GOULIAMOS, ATHANASIOS/AAB 2367 2020
CR Amato RJ, 2008, AM J CLIN ONCOL CANC, V31, P532, DOI 10.1097/COC.0b013e318172aa92
   [Anonymous], 1990, World Health Organ Tech Rep Ser, V804, P1
   Arcangeli G, 1998, INT J RADIAT ONCOL, V42, P1119, DOI 10.1016/S0360 3016(98)00264 8
   Auclerc G, 2000, Oncologist, V5, P36, DOI 10.1634/theoncologist.5 1 36
   Berenson JR, 2001, CANCER, V91, P144, DOI 10.1002/1097 0142(20010101)91:1<144::AID CNCR19>3.0.CO;2 Q
   Bishayee A, 2000, J NUCL MED, V41, P2043
   Cipriani C, 1997, EUR J NUCL MED, V24, P1356, DOI 10.1007/s002590050160
   Dafermou A, 2001, EUR J NUCL MED, V28, P788, DOI 10.1007/s002590100533
   Debes JD, 2002, CANCER LETT, V187, P1, DOI 10.1016/S0304 3835(02)00413 5
   DEKLERK JMH, 1994, J NUCL MED, V35, P1423
   Ernst DS, 2003, J CLIN ONCOL, V21, P3335, DOI 10.1200/JCO.2003.03.042
   Finlay OG, 2005, LANCET ONCOL, V6, P392, DOI 10.1016/S1470 2045(05)70206 0
   Fischer M, 2012, BREAST CARE, V7, P100, DOI 10.1159/000337634
   Gilligan T, 2002, UROLOGY, V60, P94, DOI 10.1016/S0090 4295(02)01583 2
   Kudchadkar R, 2005, CA CANCER J CLIN, V55, P145, DOI 10.3322/canjclin.55.3.145
   Lewington VJ, 2005, J NUCL MED, V46, p38S
   LEWINGTON VJ, 1993, EUR J NUCL MED, V20, P66, DOI 10.1007/BF02261248
   Liepe K, 2005, J CANCER RES CLIN, V131, P60, DOI 10.1007/s00432 004 0625 0
   Liepe Knut, 2005, Am J Hosp Palliat Care, V22, P457, DOI 10.1177/104990910502200613
   Limouris GS, 1997, ANTICANCER RES, V17, P1767
   MAXON HR, 1991, J NUCL MED, V32, P1877
   MOR V, 1984, CANCER AM CANCER SOC, V53, P2002, DOI 10.1002/1097 0142(19840501)53:9<2002::AID CNCR2820530933>3.0.CO;2 W
   NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509
   Patchell RA, 2005, LANCET, V366, P643, DOI 10.1016/S0140 6736(05)66954 1
   Payne R, 2000, J PAIN SYMPTOM MANAG, V19, pS12
   Saad F, 2002, SEMIN ONCOL, V29, P19, DOI 10.1053/sonc.2002.37418
   Saad F, 2002, JNCI J NATL CANCER I, V94, P1458, DOI 10.1093/jnci/94.19.1458
   Saarto T, 2002, EUR J PAIN LONDON, V6, P323, DOI 10.1016/S1090 3801(02)00028 9
   Sciuto R, 1998, Clin Ter, V149, P43
   Sciuto R, 2001, BREAST CANCER RES TR, V66, P101, DOI 10.1023/A:1010658522847
   SCOTT J, 1976, PAIN, V2, P175, DOI 10.1016/0304 3959(76)90113 5
   SERAFINI AN, 1994, INT J RADIAT ONCOL, V30, P1187, DOI 10.1016/0360 3016(94)90327 1
   Steenland E, 1999, RADIOTHER ONCOL, V52, P101, DOI 10.1016/S0167 8140(99)00110 3
   Swarm R, 2010, J NATL COMPR CANC NE, V8, P1046, DOI 10.6004/jnccn.2010.0076
   Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720
   Tomblyn M, 2012, CANCER CONTROL, V19, P137, DOI 10.1177/107327481201900208
   Tu SM, 2001, LANCET, V357, P336, DOI 10.1016/S0140 6736(00)03639 4
   Uchiyama M, 1997, CLIN NUCL MED, V22, P605, DOI 10.1097/00003072 199709000 00005
   Zafeirakis A, 2009, CANCER BIOTHER RADIO, V24, P543, DOI 10.1089/cbr.2008.0600
NR 39
TC 3
Z9 3
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1049 9091
EI 1938 2715
J9 AM J HOSP PALLIAT ME
JI Am. J. Hosp. Palliat. Med.
PD DEC
PY 2013
VL 30
IS 8
BP 745
EP 751
DI 10.1177/1049909112469719
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI EXPANDED)
SC Health Care Sciences & Services
GA 255NJ
UT WOS:000327246400001
PM 23264663
DA 2025 08 17
ER

PT J
AU Bashutski, JD
   Eber, RM
   Kinney, JS
   Benavides, E
   Maitra, S
   Braun, TM
   Giannobile, WV
   McCauley, LK
AF Bashutski, Jill D.
   Eber, Robert M.
   Kinney, Janet S.
   Benavides, Erika
   Maitra, Samopriyo
   Braun, Thomas M.
   Giannobile, William V.
   McCauley, Laurie K.
TI Teriparatide and Osseous Regeneration in the Oral Cavity.
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PERIODONTAL WOUND REPAIR; PARATHYROID HORMONE; POSTMENOPAUSAL WOMEN;
   INTRABONY DEFECTS; BONE; MATRIX; OSTEONECROSIS; THERAPY; DISEASE;
   DEBRIDEMENT
AB Background: Intermittent administration of teriparatide, a drug composed of the first 34 amino acids of parathyroid hormone, has anabolic effects on bone. Although teriparatide has been evaluated for the treatment of osteoporosis and for the healing of fractures, clinical trials evaluating it for the treatment of osseous conditions of the oral cavity in humans are lacking.
   Methods: A total of 40 patients with severe, chronic periodontitis underwent periodontal surgery and received daily injections of teriparatide (20 microg) or placebo, along with oral calcium (1000 mg) and vitamin D (800 IU) supplementation, for 6 weeks. The patients were followed for 1 year. The primary outcome was a radiographic linear measurement of alveolar bone level. Secondary outcomes included clinical variables, bone turnover markers in serum and oral fluid, systemic bone mineral density, and quality of life.
   Results: Radiographic linear resolution of osseous defects was significantly greater after teriparatide therapy than after placebo beginning at 6 months, with a mean linear gain in bone at 1 year of 29% as compared with 3% (P<0.001). Clinical improvement was greater in patients taking teriparatide than in those taking placebo, with a reduction in periodontal probing depth of 33% versus 20% (2.42 mm vs. 1.32 mm) and a gain in clinical attachment level of 22% versus 7% (1.58 mm vs. 0.42 mm) in target lesions at 1 year (P=0.02 for both comparisons). No serious adverse events were reported; however, the number of patients in the study was small. No significant differences were noted with respect to the other variables that were assessed.
   Conclusions: Teriparatide, as compared with placebo, was associated with improved clinical outcomes, greater resolution of alveolar bone defects, and accelerated osseous wound healing in the oral cavity. Teriparatide may offer therapeutic potential for localized bone defects in the jaw. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00277706.)
   N Engl J Med 2010;363:2396 405.
C1 [McCauley, Laurie K.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Bashutski, Jill D.; Eber, Robert M.; Kinney, Janet S.; Benavides, Erika; Giannobile, William V.; McCauley, Laurie K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Bashutski, Jill D.; Eber, Robert M.; Kinney, Janet S.; Braun, Thomas M.; Giannobile, William V.; McCauley, Laurie K.] Univ Michigan, Sch Dent, Michigan Ctr Oral Hlth Res, Ann Arbor, MI 48109 USA.
   [Maitra, Samopriyo; Braun, Thomas M.] Univ Michigan, Dept Biostat, Sch Publ Hlth, Ann Arbor, MI 48109 USA.
   [Giannobile, William V.] Univ Michigan, Coll Engn, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan
RP McCauley, LK (通讯作者)，Univ Michigan, Sch Med, Dept Pathol, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.
EM mccauley@umich.edu
RI ; McCauley, Laurie/G 4041 2012
OI Giannobile, William/0000 0002 7102 9746; 
FU Eli Lilly; American Academy of Periodontology Foundation; National
   Center for Research Resources, National Institutes of Health
   [UL1RR024986]
FX Supported in part by Eli Lilly, the American Academy of Periodontology
   Foundation Tarrson Regeneration Scholarship, and a grant (UL1RR024986)
   from the National Center for Research Resources, National Institutes of
   Health, to the University of Michigan Clinical Research Unit.
CR Aspenberg P, 2010, J BONE MINER RES, V25, P404, DOI 10.1359/jbmr.090731
   Barros SP, 2003, J DENT RES, V82, P791, DOI 10.1177/154405910308201006
   Bhongade Manohar L, 2007, J Contemp Dent Pract, V8, P25
   Curtis JW, 2000, NEW ENGL J MED, V342, P895
   Dempster DW, 2001, J BONE MINER RES, V16, pS179
   DUCKWORTH JE, 1983, J PERIODONTOL, V54, P435, DOI 10.1902/jop.1983.54.7.435
   Dybvik T, 2007, J PERIODONTOL, V78, P403, DOI 10.1902/jop.2007.060263
   El Shinnawi Una M, 2003, J Int Acad Periodontol, V5, P5
   Gapski R, 2004, J PERIODONTOL, V75, P441, DOI 10.1902/jop.2004.75.3.441
   Gapski R, 2009, J CLIN PERIODONTOL, V36, P149, DOI 10.1111/j.1600 051X.2008.01351.x
   GIANNOBILE WV, 1995, J CLIN PERIODONTOL, V22, P903, DOI 10.1111/j.1600 051X.1995.tb01793.x
   Graziani F, 2009, J CLIN PERIODONTOL, V36, P419, DOI 10.1111/j.1600 051X.2009.01388.x
   Harper RP, 2007, J ORAL MAXIL SURG, V65, P573, DOI 10.1016/j.joms.2006.10.076
   Heijl L, 1997, J CLIN PERIODONTOL, V24, P705, DOI 10.1111/j.1600 051X.1997.tb00253.x
   Heitz Mayfield LJA, 2002, J CLIN PERIODONTOL, V29, P92, DOI 10.1034/j.1600 051X.29.s3.5.x
   ISIDOR F, 1986, J PERIODONTAL RES, V21, P462, DOI 10.1111/j.1600 0765.1986.tb01482.x
   Jeffcoat Marjorie K, 2007, J Int Acad Periodontol, V9, P70
   Jung RE, 2007, CLIN ORAL IMPLAN RES, V18, P319, DOI 10.1111/j.1600 0501.2007.01342.x
   Jung RE, 2007, INT J ORAL MAX IMPL, V22, P258
   Kitamura M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002611
   Lane N, 2005, J PERIODONTOL, V76, P1113, DOI 10.1902/jop.2005.76.7.1113
   Lau AN, 2009, J RHEUMATOL, V36, P1835, DOI 10.3899/jrheum.081176
   Laurell L, 1998, J PERIODONTOL, V69, P303, DOI 10.1902/jop.1998.69.3.303
   Michalowicz BS, 2006, NEW ENGL J MED, V355, P1885, DOI 10.1056/NEJMoa062249
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Nevins M, 2005, J PERIODONTOL, V76, P2205, DOI 10.1902/jop.2005.76.12.2205
   Offenbacher S, 2009, J PERIODONTOL, V80, P190, DOI [10.1902/jop.2009.080007, 10.1902/jop.2009.080007 ]
   Pettway GJ, 2008, BONE, V42, P806, DOI 10.1016/j.bone.2007.11.017
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   PIHLSTROM BL, 1984, J PERIODONTOL, V55, P499, DOI 10.1902/jop.1984.55.9.499
   Reddy M S, 1993, Dent Clin North Am, V37, P553
   Rocha ML, 2004, J PERIODONTOL, V75, P1579, DOI 10.1902/jop.2004.75.12.1579
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Schneider A, 2003, J ORTHOP RES, V21, P859, DOI 10.1016/S0736 0266(03)00042 1
   Sculean Anton, 2003, Clin Oral Investig, V7, P108, DOI 10.1007/s00784 003 0200 0
   Shirakata Y, 2008, J PERIODONTOL, V79, P25, DOI 10.1902/jop.2008.070141 
   Slade G.D. e., 1994, Counnunity it II Health, V11, P3
   Takaishi Y, 2003, J INT MED RES, V31, P575, DOI 10.1177/147323000303100614
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   Trombelli L, 2002, J CLIN PERIODONTOL, V29, P117, DOI 10.1034/j.1600 051X.29.s3.7.x
   Tsiridis E, 2007, J ORTHOP RES, V25, P1193, DOI 10.1002/jor.20420
NR 41
TC 178
Z9 200
U1 2
U2 40
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451 1413 USA
SN 0028 4793
EI 1533 4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD DEC 16
PY 2010
VL 363
IS 25
BP 2396
EP 2405
DI 10.1056/NEJMoa1005361
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 694ZK
UT WOS:000285340200005
PM 20950166
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Jones, MD
   Tran, CW
   Li, GA
   Maksymowych, WP
   Zernicke, RF
   Doschak, MR
AF Jones, Michael D.
   Tran, Charles W.
   Li, Guang
   Maksymowych, Walter P.
   Zernicke, Ronald F.
   Doschak, Michael R.
TI In Vivo Microfocal Computed Tomography and Micro Magnetic Resonance
   Imaging Evaluation of Antiresorptive and Antiinflammatory Drugs as
   Preventive Treatments of Osteoarthritis in the Rat
SO ARTHRITIS AND RHEUMATISM
LA English
DT Article
ID BONE MARROW EDEMA; CRUCIATE LIGAMENT TRANSECTION; GASTROINTESTINAL
   TOLERABILITY; CYCLOOXYGENASE 2 INHIBITOR; ARTICULAR CARTILAGE; KNEE;
   MELOXICAM; PROGRESSION; BISPHOSPHONATE; RISEDRONATE
AB Objective. To determine whether treatment with an antiresorptive drug in combination with an anti inflammatory drug reduces periarticular bone and soft tissue adaptations associated with the progression of posttraumatic secondary osteoarthritis (OA).
   Methods. We used in vivo microfocal computed tomography (micro CT) to map bony adaptations and in vivo micro magnetic resonance imaging (micro MRI) to examine joint inflammation in a rat model of surgically induced OA secondary to knee triad injury. We examined the arthroprotective effects of the bisphosphonates alendronate and risedronate and the nonsteroidal anti inflammatory drug (NSAID) meloxicam.
   Results. Micro CT revealed reduced levels of periarticular trabecular bone loss in animals with knee triad injury treated with the bisphosphonate drugs alendronate or risedronate, or the NSAID meloxicam, compared with untreated animals. Alendronate treatment reduced bony osteophyte development. While risedronate as a monotherapy did not positively impact osteophytogenesis, combination therapy with risedronate and meloxicam reduced osteophyte severity somewhat. Micro MRI revealed an increased, diffuse water signal in the epiphyses of untreated rats with knee triad injury 8 weeks after surgery, suggestive of a bone marrow lesion like stimulus. In contrast, meloxicam treated rats showed a significant reduction in fluid signal compared with both bisphosphonate treated groups 8 weeks after surgery. Histologic analysis qualitatively confirmed the chondroprotective effect of both bisphosphonate treatments, showing fewer degradative changes compared with untreated rats with knee triad injury.
   Conclusion. Our findings indicate that select combinations of bisphosphonate and NSAID drug therapy in the early stages of secondary OA preserve trabecular bone mass and reduce the impact of osteophytic bony adaptations and bone marrow lesion like stimulus. Bisphosphonate and NSAID therapy may be an effective disease modifying drug regimen if administered early after the initial injury.
C1 [Doschak, Michael R.] Univ Alberta, Dent Pharm Ctr 2121, Edmonton, AB T6G 2N8, Canada.
   [Zernicke, Ronald F.] Univ Michigan, Ann Arbor, MI 48109 USA.
C3 University of Alberta; University of Michigan System; University of
   Michigan
RP Doschak, MR (通讯作者)，Univ Alberta, Dent Pharm Ctr 2121, Edmonton, AB T6G 2N8, Canada.
EM mdoschak@ualberta.ca
RI Li, Guang/C 9539 2011; Tran, Charles/AAL 4841 2021
OI Li, Guang/0000 0002 9097 572X; Maksymowych, Walter/0000 0002 1291 1755;
   Doschak, Michael/0000 0002 0293 6596; 
FU Arthritis Society (Canada); Alberta Heritage Foundation for Medical
   Research
FX Supported by The Arthritis Society (Canada) and the Alberta Heritage
   Foundation for Medical Research (OA Alberta Team Grant).
CR Appleton CTG, 2007, ANN NY ACAD SCI, V1117, P165, DOI 10.1196/annals.1402.022
   Bakker AC, 2001, OSTEOARTHR CARTILAGE, V9, P128, DOI 10.1053/joca.2000.0368
   Blot L, 2000, BRIT J PHARMACOL, V131, P1413, DOI 10.1038/sj.bjp.0703710
   Buckland Wright Christopher, 2004, Osteoarthritis Cartilage, V12 Suppl A, pS10
   Buckland Wright JC, 2007, RHEUMATOLOGY, V46, P257, DOI 10.1093/rheumatology/kel213
   BucklandWright JC, 1996, ANN RHEUM DIS, V55, P749, DOI 10.1136/ard.55.10.749
   Cicuttini FM, 1996, OSTEOARTHR CARTILAGE, V4, P143, DOI 10.1016/S1063 4584(05)80323 1
   Dequeker J, 1998, BRIT J RHEUMATOL, V37, P946
   DIEPPE P, 1993, ANN RHEUM DIS, V52, P557, DOI 10.1136/ard.52.8.557
   Doschak MR, 2005, OSTEOARTHR CARTILAGE, V13, P790, DOI 10.1016/j.joca.2005.04.015
   Doschak MR, 2004, J ORTHOPAED RES, V22, P942, DOI 10.1016/j.orthres.2003.12.018
   Engelhardt G, 1996, BRIT J RHEUMATOL, V35, P4
   Felson DT, 2003, ANN INTERN MED, V139, P330, DOI 10.7326/0003 4819 139 5_Part_1 200309020 00008
   Fujita T, 2008, J INT MED RES, V36, P932, DOI 10.1177/147323000803600509
   Garnero P, 2008, OSTEOARTHR CARTILAGE, V16, P660, DOI 10.1016/j.joca.2007.10.002
   Gurgel Bruno César de Vasconcelos, 2005, Braz. oral res., V19, P312, DOI 10.1590/S1806 83242005000400014
   Harirforoosh S, 2006, CLIN EXP PHARMACOL P, V33, P917, DOI 10.1111/j.1440 1681.2006.04464.x
   Hawkey C, 1998, BRIT J RHEUMATOL, V37, P937
   Hayami T, 2006, BONE, V38, P234, DOI 10.1016/j.bone.2005.08.007
   Hayami T, 2003, J RHEUMATOL, V30, P2207
   Hayami T, 2004, ARTHRITIS RHEUM US, V50, P1193, DOI 10.1002/art.20124
   Jean YH, 2007, OSTEOARTHR CARTILAGE, V15, P638, DOI 10.1016/j.joca.2006.11.008
   Kijowski R, 2006, RADIOLOGY, V238, P943, DOI 10.1148/radiol.2382050122
   Kornaat PR, 2007, EUR RADIOL, V17, P3073, DOI 10.1007/s00330 007 0711 1
   Liu XH, 2006, ANN NY ACAD SCI, V1068, P225, DOI 10.1196/annals.1346.047
   MacNeil JA, 2008, CLIN BIOMECH, V23, P365, DOI 10.1016/j.clinbiomech.2007.10.015
   Myers SL, 1999, J RHEUMATOL, V26, P2645
   POTTENGER LA, 1990, ARTHRITIS RHEUM US, V33, P853, DOI 10.1002/art.1780330612
   Qvist P, 2008, PHARMACOL RES, V58, P1, DOI 10.1016/j.phrs.2008.06.001
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Roemer FW, 2009, OSTEOARTHR CARTILAGE, V17, P1115, DOI 10.1016/j.joca.2009.03.012
   Sengupta S, 2003, CANCER RES, V63, P8351
   Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092 8674(00)81433 6
   van den Berg WB, 1999, Z RHEUMATOL, V58, P136, DOI 10.1007/s003930050163
   van der Kraan PM, 2007, OSTEOARTHR CARTILAGE, V15, P237, DOI 10.1016/j.joca.2006.11.006
   VANDERSLUIJS JA, 1992, J ORTHOPAED RES, V10, P58, DOI 10.1002/jor.1100100107
   Xin B, 2007, CANCER, V110, P791, DOI 10.1002/cncr.22854
   Zanetti M, 2000, RADIOLOGY, V215, P835, DOI 10.1148/radiology.215.3.r00jn05835
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 39
TC 57
Z9 65
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0004 3591
EI 1529 0131
J9 ARTHRITIS RHEUM US
JI Arthritis Rheum.
PD SEP
PY 2010
VL 62
IS 9
BP 2726
EP 2735
DI 10.1002/art.27595
PG 10
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 665TT
UT WOS:000283059100021
PM 20533290
OA Green Published
DA 2025 08 17
ER

PT J
AU Beuselinck, B
   Wolter, P
   Karadimou, A
   Elaidi, R
   Dumez, H
   Rogiers, A
   Van Cann, T
   Willems, L
   Body, JJ
   Berkers, J
   Van Poppel, H
   Lerut, E
   Debruyne, P
   Paridaens, R
   Schöffski, P
AF Beuselinck, B.
   Wolter, P.
   Karadimou, A.
   Elaidi, R.
   Dumez, H.
   Rogiers, A.
   Van Cann, T.
   Willems, L.
   Body, J J
   Berkers, J.
   Van Poppel, H.
   Lerut, E.
   Debruyne, P.
   Paridaens, R.
   Schoffski, P.
TI Concomitant oral tyrosine kinase inhibitors and bisphosphonates in
   advanced renal cell carcinoma with bone metastases
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE bisphosphonates; bone metastases; renal cell carcinoma; osteonecrosis of
   the jaw; outcome; targeted therapy
ID ZOLEDRONIC ACID; DOUBLE BLIND; PHASE III; CANCER STATISTICS;
   INTERFERON ALPHA; PROGRESSION FREE; LUNG CANCER; SURVIVAL;
   OSTEONECROSIS; SUNITINIB
AB BACKGROUND: The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement. Concomitant bisphosphonates could probably improve outcomes but also induce osteonecrosis of the jaw (ONJ).
   METHODS: Retrospective study on all the renal cell carcinoma patients with bone metastases treated with sunitinib or sorafenib between November 2005 and June 2012 at the University Hospitals Leuven and AZ Groeninge in Kortrijk.
   RESULTS: Seventy six patients were included in the outcome analysis: 49 treated with concomitant bisphosphonates, 27 with TKI alone. Both groups were well balanced in terms of prognostic and predictive markers. Response rate (38% vs 16% partial responses, P = 0.028), median progression free survival (7.0 vs 4.0 months, P = 0.0011) and median overall survival (17.0 vs 7.0 months, P = 0.022) were significantly better in patients receiving bisphosphonates. The incidence of ONJ was 10% in patients treated with TKI and bisphosphonates.
   CONCLUSION: Concomitant use of bisphosphonates and TKI in renal cell carcinoma patients with bone involvement probably improves treatment efficacy, to be confirmed by prospective studies, but is associated with a high incidence of ONJ. British Journal of Cancer (2012) 107, 1665 1671. doi:10.1038/bjc.2012.385 www.bjcancer.com (C) 2012 Cancer Research UK
C1 [Beuselinck, B.; Wolter, P.; Dumez, H.; Rogiers, A.; Van Cann, T.; Paridaens, R.; Schoffski, P.] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Dept Gen Med Oncol, B 3000 Louvain, Belgium.
   [Beuselinck, B.; Karadimou, A.] Univ Paris 05, INSERM, Genom Fonct Tumeurs Solides U674, F 75015 Paris, France.
   [Elaidi, R.] Univ Paris 05, Hop Europeen Georges Pompidou, AP HP, Dept Med Oncol, F 75015 Paris, France.
   [Willems, L.] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pharm, B 3000 Louvain, Belgium.
   [Body, J J] Univ Libre Bruxelles, CHU Brugmann, Dept Med, B 1020 Brussels, Belgium.
   [Berkers, J.; Van Poppel, H.] Katholieke Univ Leuven, Dept Urol, Univ Hosp Leuven, B 3000 Louvain, Belgium.
   [Lerut, E.] Katholieke Univ Leuven, Dept Pathol, Univ Hosp Leuven, B 3000 Louvain, Belgium.
   [Debruyne, P.] AZ Groeninge, Dept Med Oncol, B 8500 Kortrijk, Belgium.
C3 KU Leuven; University Hospital Leuven; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Europeen Georges Pompidou   APHP; KU Leuven; University
   Hospital Leuven; Universite Libre de Bruxelles; KU Leuven; University
   Hospital Leuven; KU Leuven; University Hospital Leuven
RP Beuselinck, B (通讯作者)，Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Dept Gen Med Oncol, Herestr 49, B 3000 Louvain, Belgium.
EM benoit.beuselinck@uzleuven.be
RI Rogiers, Aljosja/AHA 0759 2022; Debruyne, Philip/AAU 6685 2021; van
   Cann, Thomas/AAF 3524 2019; Body, Jean Jacques/G 9785 2015
OI Beuselinck, Benoit/0000 0001 7427 9102; Debruyne, Philip
   Robert/0000 0001 5438 9697; 
FU Fonds voor Wetenschappelijk Onderzoek Vlaanderen 'Klinische
   doctoraatsbeurs' (Belgium); Hellenic Society of Medical Oncology
   (Athens, Greece)
FX Benoit Beuselinck received a grant from the Fonds voor Wetenschappelijk
   Onderzoek Vlaanderen 'Klinische doctoraatsbeurs' (Belgium) (2011 2013).
   Alexandra Karadimou received a grant from the Hellenic Society of
   Medical Oncology (Athens, Greece) (2010 2011).
CR Ayllon J, 2009, ANN ONCOL, V20, P600, DOI 10.1093/annonc/mdn788
   Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670
   Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Bozas G, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e15116
   Christodoulou C, 2009, ONCOLOGY BASEL, V76, P209, DOI 10.1159/000201931
   Clezardin P, 2007, CLIN EXP METASTAS, V24, P599, DOI 10.1007/s10585 007 9112 8
   Escudier B, 2007, LANCET, V370, P2103, DOI 10.1016/S0140 6736(07)61904 7
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Guarneri V, 2010, BREAST CANCER RES TR, V122, P181, DOI 10.1007/s10549 010 0866 3
   Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838
   Jemal A, 2006, CA CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Keizman D, 2012, EUR J CANCER, V48, P1031, DOI 10.1016/j.ejca.2012.02.050
   Lam JS, 2005, WORLD J UROL, V23, P202, DOI 10.1007/s00345 004 0466 0
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140 6736(10)62051 X
   Motzer R, 2004, CLIN CANCER RES, V10, p6202S
   Motzer RJ, 1999, J CLIN ONCOL, V17, P2530, DOI 10.1200/JCO.1999.17.8.2530
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140 6736(08)61039 9
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2010, CANCER AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Parkin DM, 2005, CA CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342
   Riechelmann RP, 2008, AM J CLIN ONCOL CANC, V31, P182, DOI 10.1097/COC.0b013e3181574084
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Saad F, 2005, BJU INT, V96, P964, DOI 10.1111/j.1464 410X.2005.05740.x
   Saad F, 2010, SEMIN ONCOL, V37, pS38, DOI 10.1053/j.seminoncol.2010.06.001
   US National Institutes of Health, 2006, KIDN REN PELV CANC 5
   Zaghloul MS, 2010, INT J CLIN ONCOL, V15, P382, DOI 10.1007/s10147 010 0074 5
   Zarogoulidis K, 2009, INT J CANCER, V125, P1705, DOI 10.1002/ijc.24470
   Zekri J, 2001, INT J ONCOL, V19, P379
NR 29
TC 87
Z9 94
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007 0920
EI 1532 1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD NOV 6
PY 2012
VL 107
IS 10
BP 1665
EP 1671
DI 10.1038/bjc.2012.385
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 033JJ
UT WOS:000310790900001
PM 23132391
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Chae, U
   Park, NR
   Kim, ES
   Choi, JY
   Yim, M
   Lee, HS
   Lee, SR
   Lee, S
   Park, JW
   Lee, DS
AF Chae, U.
   Park, N R
   Kim, E. S.
   Choi, J Y
   Yim, M.
   Lee, H S
   Lee, S R
   Lee, S.
   Park, J W
   Lee, D S
TI IDH2 Deficient Mice Develop Spinal Deformities With Aging
SO PHYSIOLOGICAL RESEARCH
LA English
DT Article
DE Isocitrate dehydrogenase 2; Spinal deformity; Osteoclast; Osteoblast;
   Aging; Animal models
ID PROMOTES MITOCHONDRIAL DYSFUNCTION; OXIDATIVE STRESS; IDH2; DEFICIENCY;
   MUTATIONS; SCOLIOSIS; KYPHOSIS; BALANCE
AB Spinal deformities such as scoliosis and kyphosis are incurable, and can lead to decreased physical function, pain, and reduced quality of life. Despite much effort, no clear therapies for the treatment of these conditions have been found. Therefore, the development of an animal model for spinal deformity would be extremely valuable to our understanding of vertebral diseases. In this study, we demonstrate that mice deficient in the mitochondria! enzyme isocitrate dehydrogenase 2 (IDH2) develop spinal deformities with aging. We use morphological analysis as well as radiographic and micro CT imaging of IDH2 deficient mice to characterize these deformities. Histological analysis showed increased abnormalities in IDH2 deficient mice compared to wild type mice. Taken together, the results suggest that IDH2 plays a critical role in maintaining the spinal structure by affecting the homeostatic balance between osteoclasts and osteoblasts. This indicates that IDH2 might be a potent target for the development of therapies for spinal deformities. Our findings also provide a novel animal model for vertebral disease research.
C1 [Chae, U.; Lee, H S; Park, J W; Lee, D S] Kyungpook Natl Univ, Sch Life Sci & Biotechnol, Plus KNU Creat BioRes Grp BK21, Daegu, South Korea.
   [Chae, U.; Lee, H S; Park, J W; Lee, D S] Kyungpook Natl Univ, Coll Nat Sci, Daegu 41566, South Korea.
   [Park, N R; Choi, J Y] Kyungpook Natl Univ, Plus KNU Biomed Convergence Program BK21, Cell & Matrix Res Inst, Dept Biochem & Cell Biol,Sch Med, Daegu, South Korea.
   [Kim, E. S.] Yuseong Sun Gen Hosp, Dept Orthoped Surg, Daejeon, South Korea.
   [Yim, M.] Sookmyung Womens Univ, Coll Pharm, Seoul, South Korea.
   [Lee, S.] Rural Dev Adm, Anim Biotechnol Div, Natl Inst Anim Sci, Seonghwan, Jeollabuk Do, South Korea.
   [Lee, S R] KRIBB, Natl Primate Res Ctr, Cheongju, South Korea.
C3 Kyungpook National University (KNU); Kyungpook National University
   (KNU); Kyungpook National University (KNU); Sookmyung Women's
   University; Rural Development Administration (RDA), Republic of Korea;
   National Institute of Animal Science, Republic of Korea; Korea Research
   Institute of Bioscience & Biotechnology (KRIBB)
RP Park, JW; Lee, DS (通讯作者)，Kyungpook Natl Univ, Coll Nat Sci, Daegu 41566, South Korea.
EM parkjw@knu.ac.kr; lee1@knu.ac.kr
RI ; park, jun yeon/GPX 5293 2022
OI Lee, Dong Seok/0000 0001 6348 8937; Park, NA RAE/0000 0003 3651 7434
FU National Research Foundation of Korea, Republic of Korea
   [NRF 2015R1A4A1042271, NRF 2017R1A2B4008176, NRF 2017R1A5A2015391];
   Korea Research Institute of Bioscience AMP; Biotechnology (KRIBB)
   Research Initiative Program [KGM4611821]; government working for dog
   production technology development, Rural Development Administration,
   Republic of Korea [PJ01179202]
FX This research was supported by grants from the National Research
   Foundation of Korea, Republic of Korea (NRF 2015R1A4A1042271,
   NRF 2017R1A2B4008176, NRF 2017R1A5A2015391), from the Korea Research
   Institute of Bioscience & Biotechnology (KRIBB) Research Initiative
   Program (KGM4611821) and from the government working for dog production
   technology development (Project No. PJ01179202), Rural Development
   Administration, Republic of Korea. We gratefully acknowledge Korea Mouse
   Phenotyping Center (KMPC) for technical support of mouse phenotyping.
CR Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913
   Banfi G, 2008, CLIN CHEM LAB MED, V46, P1550, DOI 10.1515/CCLM.2008.302
   Basu S, 2001, BIOCHEM BIOPH RES CO, V288, P275, DOI 10.1006/bbrc.2001.5747
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Erben RG, 1997, J HISTOCHEM CYTOCHEM, V45, P307, DOI 10.1177/002215549704500215
   Fathi AT, 2014, ONCOLOGIST, V19, P602, DOI 10.1634/theoncologist.2013 0417
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Gao C, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00038
   Ghiam AF, 2012, ONCOGENE, V31, P3826, DOI 10.1038/onc.2011.546
   Hayer S, 2005, J EXP MED, V201, P903, DOI 10.1084/jem.20040852
   Ito K, 2016, EUR SPINE J, V25, P3220, DOI 10.1007/s00586 016 4699 6
   Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200
   Juneja SC, 2014, BONE, V60, P148, DOI 10.1016/j.bone.2013.11.020
   Kaneko MK, 2014, CANCER SCI, V105, P744, DOI 10.1111/cas.12413
   Katzman WB, 2010, J ORTHOP SPORT PHYS, V40, P352, DOI 10.2519/jospt.2010.3099
   Kim HKW, 2013, SPINE, V38, pE1307, DOI 10.1097/BRS.0b013e3182a3d370
   Kim H, 2016, FREE RADICAL RES, V50, P853, DOI 10.1080/10715762.2016.1185519
   Kim S, 2014, BBA MOL BASIS DIS, V1842, P135, DOI 10.1016/j.bbadis.2013.11.008
   Ku HJ, 2015, FREE RADICAL BIO MED, V80, P84, DOI 10.1016/j.freeradbiomed.2014.12.018
   Loeser RF, 2010, CLIN GERIATR MED, V26, P371, DOI 10.1016/j.cger.2010.03.002
   Lutter AH, 2010, J CELL BIOCHEM, V109, P1025, DOI 10.1002/jcb.22485
   McDaniels Davidson Corinne R, 2016, Bone Rep, V5, P57
   Megova M, 2014, J NEUROSCI RES, V92, P1611, DOI 10.1002/jnr.23456
   Mushahary D, 2016, CLIN ORAL IMPLAN RES, V27, pE15, DOI 10.1111/clr.12511
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   Rakheja D, 2012, HUM PATHOL, V43, P1541, DOI 10.1016/j.humpath.2012.05.003
   Reitman ZJ, 2010, CANCER CELL, V17, P215, DOI 10.1016/j.ccr.2010.02.024
   Smolkova Katarina, 2012, Int J Cell Biol, V2012, P273947, DOI 10.1155/2012/273947
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Wauquier F, 2009, TRENDS MOL MED, V15, P468, DOI 10.1016/j.molmed.2009.08.004
   Yu W, 2012, J BIOL CHEM, V287, P14078, DOI 10.1074/jbc.M112.355206
NR 31
TC 7
Z9 7
U1 0
U2 4
PU ACAD SCIENCES CZECH REPUBLIC, INST PHYSIOLOGY
PI PRAGUE 4
PA VIDENSKA 1083, PRAGUE 4 142 20, CZECH REPUBLIC
SN 0862 8408
EI 1802 9973
J9 PHYSIOL RES
JI Physiol. Res.
PY 2018
VL 67
IS 3
BP 487
EP 494
DI 10.33549/physiolres.933711
PG 8
WC Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology
GA GN8ZA
UT WOS:000439466000013
PM 29527922
OA Green Submitted, gold
DA 2025 08 17
ER

PT J
AU Ge, JR
   Xie, LH
   Chen, J
   Li, SQ
   Xu, HJ
   Lai, YL
   Qiu, LL
   Ni, CB
AF Ge, Ji rong
   Xie, Li hua
   Chen, Juan
   Li, Sheng qiang
   Xu, Hui juan
   Lai, Yu lian
   Qiu, Long long
   Ni, Chen bo
TI Liuwei Dihuang Pill () Treats Postmenopausal Osteoporosis with Shen
   (Kidney) Yin Deficiency via Janus Kinase/Signal Transducer and Activator
   of Transcription Signal Pathway by Up regulating Cardiotrophin Like
   Cytokine Factor 1 Expression
SO CHINESE JOURNAL OF INTEGRATIVE MEDICINE
LA English
DT Article
DE postmenopausal osteoporosis; Chinese medicine; Shen (Kidney) yin
   deficiency; cardiotrophin like cytokine factor 1 gene; Liuwei Dihuang
   Pill; Janus kinase/signal transducer and activator of transcription
   signaling pathway
ID CELL STIMULATING FACTOR 3; OSTEOBLAST DIFFERENTIATION; STAT3 ACTIVATION;
   INTERLEUKIN 6; MEDICINE; FAMILY; GROWTH
AB To investigate the mechanism of Liuwei Dihuang Pill (, LDP) in treating postmenopausal osteoporosis (PMOP) with Shen (Kidney) yin deficiency.
   In this study, 205 cases of PMOP were divided into the PMOP Shen yin deficiency group (Group A), PMOP Shen yang deficiency group (Group B), PMOP without Shen deficiency group (Group C), and control group (Group N). Real time polymerase chain reaction (RT PCR) and Western blot techniques were used to observe the effects of LDP treatment on the cardiotrophin like cytokine factor 1 (CLCF1), ankyrin repeat and SOCS box containing 1 (ASB1), and prokineticin 2 (PROK2) genes and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway.
   The mRNA (P < 0.05) and protein (P < 0.01) expression levels of the CLCF1 gene in Group A were significantly lower than the corresponding levels in Group N. After LDP treatment for 3 months, the mRNA expression levels of the CLCF1 gene were obviously up regulated (P < 0.01). After 6 month treatment, the expression levels of CLCF1 mRNA and protein were significantly up regulated (both P < 0.01), and the average bone density of the top femur had significantly increased (P < 0.05). In vitro, CLCF1 overexpression resulted in a significant increase in the total protein and phosphorylated protein levels of JAK2 and STAT3.
   The CLCF1 gene is an important gene associated with PMOP Shen yin deficiency and the therapeutic effects of LDP may be mediated by up regulation of CLCF1 gene expression and activation of the JAK/STAT signaling pathway.
C1 [Ge, Ji rong; Xie, Li hua; Chen, Juan; Li, Sheng qiang; Xu, Hui juan; Lai, Yu lian; Qiu, Long long; Ni, Chen bo] Fujian Acad Tradit Chinese Med, Key Res Lab Osteoporosis Syndrome Genom, Fuzhou 350003, Fujian, Peoples R China.
RP Ge, JR (通讯作者)，Fujian Acad Tradit Chinese Med, Key Res Lab Osteoporosis Syndrome Genom, Fuzhou 350003, Fujian, Peoples R China.
EM jironggecn@163.com
OI Li, Shengqiang/0000 0003 3077 6144
FU National Natural Science Foundation of China [81173280, 81302995,
   81403420]; Fujian Medical Innovation project [2011 CX 30]; Science and
   Technology Department of Fujian Province autonomous non profit research
   institutes topics project [2011R1038 5]; Fujian Academy of Traditional
   Chinese autonomous topics Project [2012fjzyyk 5]
FX Supported by National Natural Science Foundation of China (Nos.
   81173280, 81302995, 81403420), Fujian Medical Innovation project (No.
   2011 CX 30), Science and Technology Department of Fujian Province
   autonomous non profit research institutes topics project (No.
   2011R1038 5), and Fujian Academy of Traditional Chinese autonomous
   topics Project (No. 2012fjzyyk 5)
CR Abraham AK, 2009, BIOCHEM PHARMACOL, V77, P1757, DOI 10.1016/j.bcp.2009.01.007
   Aljabari S, 2013, CASE REP PEDIAT, V2013, DOI 10.1155/2013/173890
   [Anonymous], CHINA J CHIN MAT MED
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Burger R, 2003, BRIT J HAEMATOL, V123, P869, DOI 10.1046/j.1365 2141.2003.04686.x
   Chamorro CI, 2015, TISSUE ENG PT A, V21, P510, DOI [10.1089/ten.TEA.2014.0175, 10.1089/ten.tea.2014.0175]
   Coskun M, 2013, PHARMACOL RES, V76, P1, DOI 10.1016/j.phrs.2013.06.007
   de Bruin AM, 2014, BLOOD, V124, P2479, DOI 10.1182/blood 2014 04 568451
   Elsaeidi F, 2014, J NEUROSCI, V34, P2632, DOI 10.1523/JNEUROSCI.3898 13.2014
   Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765
   Erices A, 2002, EXP CELL RES, V280, P24, DOI 10.1006/excr.2002.5627
   Fu Bing, 2005, J Tradit Chin Med, V25, P186
   Gao Dongu, 2008, Zhong Yao Cai, V31, P251
   González Navajas JM, 2012, NAT REV IMMUNOL, V12, P125, DOI 10.1038/nri3133
   Hahn AF, 2010, J NEUROL SCI, V293, P68, DOI 10.1016/j.jns.2010.02.028
   Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074
   Jiang M, 2012, J ETHNOPHARMACOL, V140, P634, DOI 10.1016/j.jep.2012.01.033
   Joung YH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047477
   Kim Sunhwa, 2005, Nihon Rinsho, V63, P1553
   Laroche M, 2011, AM J MED, V124, P776, DOI 10.1016/j.amjmed.2011.02.038
   Li CH, 2013, BIOCHEM BIOPH RES CO, V435, P533, DOI 10.1016/j.bbrc.2013.04.084
   Li Dong tao, 2011, Zhong Xi Yi Jie He Xue Bao, V9, P1326
   Liu ZH, 1994, OSTEOPOROSIS RES PRE, P226
   Mihara M, 2012, CLIN SCI, V122, P143, DOI 10.1042/CS20110340
   Moortgat S, 2014, EUR J MED GENET, V57, P212, DOI 10.1016/j.ejmg.2014.02.003
   Nakashima T, 2009, J CLIN IMMUNOL, V29, P555, DOI 10.1007/s10875 009 9316 6
   Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777
   Peacock M, 2002, ENDOCR REV, V23, P303, DOI 10.1210/er.23.3.303
   Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301 472X(99)00109 5
   Scott LJ, 2014, DRUG AGING, V31, P555, DOI 10.1007/s40266 014 0191 3
   Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458
   Sugiya N, 2011, OSTEOPOROSIS INT, V22, P1573, DOI 10.1007/s00198 010 1350 y
   Sun GJ, 2013, EUR REV MED PHARMACO, V17, P1
   Tarca AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079217
   Tawara Ken, 2011, Cancer Manag Res, V3, P177, DOI 10.2147/CMR.S18101
   Xia Bing jiang, 2014, Zhongguo Gu Shang, V27, P673
   Xia BJ, 2014, J ETHNOPHARMACOL, V153, P133, DOI 10.1016/j.jep.2014.01.040
   [谢丽华 Xie Lihua], 2011, [中国组织工程研究与临床康复, Journal of Clinical Rehabilitative Tissue Engineering Research], V15, P2833
   Xie YM, 2011, CHIN J INTEGR MED, V17, P52, DOI 10.1007/s11655 011 0613 6
   Zhang HB., 2011, Chinese J Trad Med Traum Ortho, V19, P18
   Zhou P, 2014, SHANXI J TRADIT CHIN, V35, P1191
NR 43
TC 28
Z9 36
U1 1
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1672 0415
EI 1993 0402
J9 CHIN J INTEGR MED
JI Chin. J. Integr. Med.
PD JUN
PY 2018
VL 24
IS 6
BP 415
EP 422
DI 10.1007/s11655 016 2744 2
PG 8
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA GI1YU
UT WOS:000434167400004
PM 28028720
DA 2025 08 17
ER

PT J
AU Yamada, S
   Taniguchi, M
   Tokumoto, M
   Tsuruya, K
   Hirakata, H
   Iida, M
AF Yamada, Shunsuke
   Taniguchi, Masatomo
   Tokumoto, Masanori
   Tsuruya, Kazuhiko
   Hirakata, Hideki
   Iida, Mitsuo
TI Early Intervention With Intravenous or Pulse Oral Vitamin D Therapy Is
   More Effective in the Treatment of Secondary Hyperparathyroidism
SO THERAPEUTIC APHERESIS AND DIALYSIS
LA English
DT Article
DE Early intervention; Hemodialysis; Kidney Disease Outcomes Quality
   Initiative clinical practice guidelines; Parathyroid hormone; Secondary
   hyperparathyroidism; Vitamin D
ID PARATHYROID HORMONE LEVELS; MINERAL METABOLISM; BONE METABOLISM;
   KIDNEY DISEASE; MORTALITY RISK; ASSOCIATION; OUTCOMES; GLAND; PHOSPHATE;
   RECEPTOR
AB The K/DOQI clinical practice guidelines recommend vitamin D therapy should be started when the intact parathyroid hormone (iPTH) exceeds 300 pg/mL in patients with secondary hyperparathyroidism. To examine whether the effect of vitamin D therapy on mineral metabolism and parathyroid gland growth varies according to the stage of secondary hyperparathyroidism and iPTH level, 47 patients with secondary hyperparathyroidism received either intravenous or pulse oral vitamin D therapy. The patients were divided into two groups based on the iPTH level at the start of vitamin D therapy: the P < 300 group (N = 23) with iPTH < 300 pg/mL; and the P >= 300 group (N = 24) with iPTH >= 300 pg/mL. We examined serial changes in several serum mineral parameters and parathyroid gland volume and the cumulative incidence of parathyroidectomy in the first two years. Serum calcium, phosphorus, calcium phosphorus product, and iPTH levels of the P >= 300 group were significantly higher than those of the P < 300 group, and could not be maintained within the target ranges set by the K/DOQI guidelines. In contrast, the serum levels of phosphorus, calcium phosphorus product, and iPTH were maintained within the target ranges and the parathyroid gland did not enlarge in the P < 300 group. The cumulative incidence of parathyroidectomy in the P >= 300 group was significantly higher than in the P < 300 group. Early intervention with intravenous or pulse oral vitamin D therapy at serum iPTH < 300 pg/mL can control serum phosphorus, calcium phosphorus product, and PTH levels to the target ranges and slow the progression of secondary hyperparathyroidism.
C1 [Taniguchi, Masatomo] Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Fukuoka 8128582, Japan.
   [Tsuruya, Kazuhiko] Kyushu Univ, Dept Integrated Therapy Chron Kidney Dis, Grad Sch Med Sci, Fukuoka 8128582, Japan.
   [Hirakata, Hideki] Fukuoka Red Cross Hosp, Div Nephrol, Fukuoka, Japan.
C3 Kyushu University; Kyushu University
RP Taniguchi, M (通讯作者)，Kyushu Univ, Dept Med & Clin Sci, Grad Sch Med Sci, Higashi Ku, Maidashi 3 1 1, Fukuoka 8128582, Japan.
EM masatomo@kcu.med.kyusyu u.ac.jp
RI Yamada, Shunsuke/LVR 6425 2024
CR Arenas MD, 2006, NEPHROL DIAL TRANSPL, V21, P1663, DOI 10.1093/ndt/gfl006
   Block GA, 2004, J AM SOC NEPHROL, V15, P2208, DOI 10.1097/01.ASN.0000133041.27682.A2
   Block GA, 1998, AM J KIDNEY DIS, V31, P607, DOI 10.1053/ajkd.1998.v31.pm9531176
   Eknoyan G, 2003, AM J KIDNEY DIS, V41, pS1, DOI 10.1016/S0272 6386(03)00111 2
   FUKAGAWA M, 1994, NEPHRON, V68, P221, DOI 10.1159/000188261
   Fukagawa M, 2002, NEPHROL DIAL TRANSPL, V17, P1553, DOI 10.1093/ndt/17.9.1553
   FUKUDA N, 1993, J CLIN INVEST, V92, P1436, DOI 10.1172/JCI116720
   Ganesh SK, 2001, J AM SOC NEPHROL, V12, P2131, DOI 10.1681/ASN.V12102131
   Goodman WG, 2000, KIDNEY INT, V58, P436, DOI 10.1046/j.1523 1755.2000.00183.x
   GOODMAN WG, 1994, KIDNEY INT, V46, P1160, DOI 10.1038/ki.1994.380
   Hirata M, 2002, NEPHROL DIAL TRANSPL, V17, P37, DOI 10.1093/ndt/17.suppl_10.37
   Katoh N, 2000, AM J KIDNEY DIS, V35, P465, DOI 10.1016/S0272 6386(00)70199 5
   Kifor O, 1996, J CLIN ENDOCR METAB, V81, P1598, DOI 10.1210/jc.81.4.1598
   London GM, 2004, J AM SOC NEPHROL, V15, P1943, DOI 10.1097/01.asn.0000129337.50739.48
   Marco MP, 2003, KIDNEY INT, V63, pS111, DOI 10.1046/j.1523 1755.63.s85.26.x
   MATSUOKA S, 2003, NEPHROL DIAL TRAN S4, V18, P139
   Moe S, 2006, KIDNEY INT, V69, P1945, DOI 10.1038/sj.ki.5000414
   Noordzij M, 2005, AM J KIDNEY DIS, V46, P925, DOI 10.1053/j.ajkd.2005.08.013
   Okuno S, 2003, NEPHROL DIAL TRANSPL, V18, P2613, DOI 10.1093/ndt/gfg451
   Stevens LA, 2004, J AM SOC NEPHROL, V15, P770, DOI 10.1097/01.ASN.0000113243.24155.2F
   Taniguchi M, 2008, NEPHROL DIAL TRANSPL, V23, P3662, DOI 10.1093/ndt/gfn264
   Tominaga Y, 1997, SEMIN SURG ONCOL, V13, P78, DOI 10.1002/(SICI)1098 2388(199703/04)13:2<78::AID SSU3>3.0.CO;2 Z
   Tominaga Y, 2006, THER APHER DIAL, V10, P198, DOI 10.1111/j.1744 9987.2006.00364.x
   Young EW, 2005, KIDNEY INT, V67, P1179, DOI 10.1111/j.1523 1755.2005.00185.x
NR 24
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1744 9979
EI 1744 9987
J9 THER APHER DIAL
JI Ther. Apher. Dial.
PD AUG
PY 2010
VL 14
IS 4
BP 424
EP 431
DI 10.1111/j.1744 9987.2010.00817.x
PG 8
WC Hematology; Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology; Urology & Nephrology
GA 631NM
UT WOS:000280354300007
PM 20649764
DA 2025 08 17
ER

PT J
AU Ishida, K
   Haudenschild, DR
AF Ishida, Kazunari
   Haudenschild, Dominik R.
TI Interactions between FGF21 and BMP 2 in osteogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Fibroblast growth factor 21; Bone morphogenic protein 2; Osteogenesis;
   Smad pathway
ID FIBROBLAST GROWTH FACTOR; BONE MORPHOGENETIC PROTEIN 2; DIFFERENTIATION;
   CELLS; EXPRESSION; OSTEOBLASTS; INHIBITION; PATHWAY; MAPK
AB Lifestyle related diseases are increasing and the challenge to create innovative drugs to treat such diseases is a main focus in medical science research. Fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism, and is an innovative candidate drug already in clinical trials for type 2 diabetes mellitus and obesity. Bone fragility and impaired fracture healing induced by such lifestyle related conditions are also a growing problem. Bone morphogenic proteins (BMPs) are well known osteogenic growth factors, and BMP 2 is used to augment bone formation in difficult clinical situations. There are many documented interactions between the FGF and BMP family proteins, although the interaction between FGF21 and BMP 2 remains unknown. The aim of this study was to reveal the effect of FGF21 toward BMP 2 dependent osteogenic activity, using C2C12 cells as a model system. We found that FGF21 enhanced BMP 2 dependent transcription and osteogenesis in the C2C12 cell line, which was confirmed by alkaline phosphatase activity, matrix mineralization, and gene expression. Mechanistically, FGF21 enhanced BMP 2 induced intracellular signaling through Smad proteins, but not through p44/ 42MAPK proteins. Furthermore, we identified a negative feedback loop in which BMP 2 decreased endogenous FGF21 mRNA expression. In summary, this study demonstrates interactions between BMP 2 and FGF21 pathways exist in vitro, and that FGF21 enhances the osteogenic activity of BMP 2 by up regulating the BMP 2 dependent Smad signaling pathway. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Ishida, Kazunari; Haudenschild, Dominik R.] Univ Calif Davis, Dept Orthopaed Surg, Lawrence J Ellison Musculoskeletal Res Ctr, Sacramento, CA 95817 USA.
C3 University of California System; University of California Davis
RP Haudenschild, DR (通讯作者)，Univ Calif Davis, Dept Orthopaed Surg, Lawrence J Ellison Musculoskeletal Res Ctr, 4635 2nd Ave,Suite 2000, Sacramento, CA 95817 USA.
EM Dominik.Haudenschild@ucdmc.ucdavis.edu
RI Haudenschild, Dominik/B 2381 2008; Ishida, Kazunari/ABD 9446 2020
OI Haudenschild, Dominik/0000 0001 9947 9864; 
CR Adams AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038438
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846
   Hanada K, 1997, J BONE MINER RES, V12, P1606, DOI 10.1359/jbmr.1997.12.10.1606
   Hayashi H, 2001, J CELL SCI, V114, P1387
   Hernandez RK, 2012, ACTA ORTHOP, V83, P653, DOI 10.3109/17453674.2012.747054
   Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092 8674(00)80562 0
   Huang CY, 2010, J CELL PHYSIOL, V224, P475, DOI 10.1002/jcp.22145
   Huang Z, 2010, CYTOKINE, V51, P305, DOI 10.1016/j.cyto.2010.06.002
   Hulejová H, 2012, PHYSIOL RES, V61, P489, DOI 10.33549/physiolres.932324
   Inagaki T, 2008, CELL METAB, V8, P77, DOI 10.1016/j.cmet.2008.05.006
   Ishida K, 2010, TISSUE ENG PT A, V16, P3271, DOI 10.1089/ten.tea.2009.0268
   Ito Y, 2011, BIOCHEM BIOPH RES CO, V407, P225, DOI 10.1016/j.bbrc.2011.03.003
   Johnson CL, 2009, GASTROENTEROLOGY, V137, P1795, DOI 10.1053/j.gastro.2009.07.064
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606
   Kliewer SA, 2010, AM J CLIN NUTR, V91, p254S, DOI 10.3945/ajcn.2009.28449B
   Kotulák T, 2011, PHYSIOL RES, V60, P757, DOI 10.33549/physiolres.932134
   Kubota K, 2002, BONE, V31, P465, DOI 10.1016/S8756 3282(02)00852 9
   Liu C, 2012, DIFFERENTIATION, V83, P210, DOI 10.1016/j.diff.2011.12.007
   Loeffler I, 2011, J AM SOC NEPHROL, V22, P649, DOI 10.1681/ASN.2010010098
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Maegawa N, 2007, J TISSUE ENG REGEN M, V1, P306, DOI 10.1002/term.41
   Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297
   MAYAHARA H, 1993, GROWTH FACTORS, V9, P73, DOI 10.3109/08977199308991583
   Mckay WF, 2007, INT ORTHOP, V31, P729, DOI 10.1007/s00264 007 0418 6
   Naganawa T, 2008, J CELL BIOCHEM, V103, P1975, DOI 10.1002/jcb.21589
   SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143
   Strotmeyer Elsa S, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P429, DOI 10.1097/MED.0b013e3282f1cba3
   Wei W, 2012, P NATL ACAD SCI USA, V109, P3143, DOI 10.1073/pnas.1200797109
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Wu SF, 2012, J BIOL CHEM, V287, P26060, DOI 10.1074/jbc.M112.343707
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhu W, 2007, J BIOL CHEM, V282, P18676, DOI 10.1074/jbc.M610232200
   Zilberberg L, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 41
NR 35
TC 25
Z9 30
U1 0
U2 30
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0006 291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 22
PY 2013
VL 432
IS 4
BP 677
EP 682
DI 10.1016/j.bbrc.2013.02.019
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 119IJ
UT WOS:000317090700023
PM 23416071
DA 2025 08 17
ER

PT J
AU Zhu, ZS
   Yin, N
   Huang, XY
   Ding, L
   Fang, R
   Xiao, HJ
AF Zhu Zhong Sheng
   Yin Nuo
   Huang Xiao Yan
   Ding Liang
   Fang Rui
   Xiao Hai Jun
TI MMP2 promotes osteoblast differentiation and calcification of
   muscle derived mesenchymal stem cells by interaction with miR 29b 3p
SO TISSUE & CELL
LA English
DT Article
DE MMP2; M MSC; MiRNA 29b 3p; Osteoblast differentiation; Calcification
ID MATRIX METALLOPROTEINASES; BONE REPAIR; MIGRATION; EXPRESSION; THERAPY;
   MSCS
AB Matrix metalloproteinase 2 (MMP2) was previously reported to play important role in the process of stem cell migration and various differentiation behaviors of muscle derived mesenchymal stem cells (M MSCs). However, its role and regulatory mechanism in the osteoblast differentiation and calcification of M MSCs remain unclear. In the current study, we found that MMP2 could facilitate the osteoblast differentiation and calcification of muscle derived mesenchymal stem cells by up regulating the expression of some typical osteogenic differentiation phenotype markers, such as runt related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and osteocalcin (OCN). Besides, we further demonstrated that MMP2 could be directly targeted by miRNA 29b 3p, which was validated by dual luciferase reporter gene and rescue assays. Moreover, increased expression of MMP2 could contribute to forming more calcium nodules representative for osteoblast calcification verified by the alizarin red staining, vice versa. In conclusion, we identified the role of miRNA 29b 3p/MMP2 relationship in regulating osteoblast differentiation and calcification of M MSCs, which may complement the effect of MMPs family on the osteoblast differentiation to some extent, providing some potential clinical application value in the promotion of bone formation in the future.
C1 [Zhu Zhong Sheng; Yin Nuo; Huang Xiao Yan; Ding Liang; Xiao Hai Jun] Shanghai Fengxian Dist Cent Hosp, Dept Orthoped, 6600 Nan Feng Rd, Shanghai 201406, Peoples R China.
   [Fang Rui] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, 222 Huan Hu Xi San Rd, Shanghai 201306, Peoples R China.
C3 Shanghai Jiao Tong University
RP Xiao, HJ (通讯作者)，Shanghai Fengxian Dist Cent Hosp, Dept Orthoped, 6600 Nan Feng Rd, Shanghai 201406, Peoples R China.; Fang, R (通讯作者)，Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Orthoped, 222 Huan Hu Xi San Rd, Shanghai 201306, Peoples R China.
EM zhuzsfr2008@163.com; yn0102067@126.com; hxyhxyhxyhxyhxy9@163.com;
   dl1900@sina.com; fangrui_1984@163.com; xiaohaijun89@163.com
FU Social Science and Technology Development Fund Project of the Science
   and Technology Commission of Shanghai Fengxian District [20181803]
FX This project was supported by Grant from the Social Science and
   Technology Development Fund Project of the Science and Technology
   Commission of Shanghai Fengxian District (No. 20181803).
CR Almalki SG, 2017, STEM CELL TRANSL MED, V6, P1385, DOI 10.1002/sctm.16 0329
   Almalki SG, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0393 1
   Arumugam B, 2018, J CELL PHYSIOL, V233, P1082, DOI 10.1002/jcp.25964
   Beloglazova IB, 2016, B EXP BIOL MED+, V161, P775, DOI 10.1007/s10517 016 3507 y
   Chang CH, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0252163
   Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005
   De Becker A, 2007, HAEMATOLOGICA, V92, P440, DOI 10.3324/haematol.10475
   Gao XQ, 2014, FASEB J, V28, P3792, DOI 10.1096/fj.13 247965
   Hofer HR, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0394 0
   Jackson WM, 2010, EXPERT OPIN BIOL TH, V10, P505, DOI 10.1517/14712591003610606
   Kou LF, 2021, CURR PHARM BIOTECHNO, V22, P451, DOI 10.2174/1389201021666200630140735
   Lemos DR, 2015, BONE, V80, P19, DOI 10.1016/j.bone.2015.06.013
   Lin JL, 2008, FEBS LETT, V582, P2615, DOI 10.1016/j.febslet.2008.06.033
   Mannello F, 2006, STEM CELLS, V24, P475, DOI 10.1634/stemcells.2005 0333
   Najar M, 2016, CYTOTHERAPY, V18, P320, DOI 10.1016/j.jcyt.2015.11.013
   Ould Yahoui A, 2013, CELL TRANSPLANT, V22, P993, DOI 10.3727/096368912X657468
   Owston H, 2016, INJURY, V47, pS3, DOI 10.1016/S0020 1383(16)30834 8
   Rahbarghazi R, 2013, STEM CELLS DEV, V22, P855, DOI 10.1089/scd.2012.0377
   Schneider RK, 2010, BIOMATERIALS, V31, P467, DOI 10.1016/j.biomaterials.2009.09.059
   Shi WZ, 2017, MOL MED REP, V15, P2129, DOI 10.3892/mmr.2017.6275
   Sun JS, 2005, BIOMATERIALS, V26, P3953, DOI 10.1016/j.biomaterials.2004.10.016
   Van Doren SR, 2015, MATRIX BIOL, V44 46, P224, DOI 10.1016/j.matbio.2015.01.005
   Wang C, 2019, J INT MED RES, V47, P3261, DOI 10.1177/0300060519853399
   Winer A, 2018, MOL CANCER THER, V17, P1147, DOI 10.1158/1535 7163.MCT 17 0646
   Xia T, 2020, INT J MOL MED, V46, P709, DOI 10.3892/ijmm.2020.4615
   Yao J, 2012, REJUV RES, V15, P495, DOI 10.1089/rej.2012.1325
   Yin N, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 63496 5
   Zha YH, 2007, CELL BIOL INT, V31, P1089, DOI 10.1016/j.cellbi.2007.03.023
   Zhang C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050525
   Zhang XL, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.581545
   Zhang YZ, 2019, PATHOL RES PRACT, V215, P525, DOI 10.1016/j.prp.2018.12.034
   Zhao W, 2016, SCI REP UK, V6, DOI 10.1038/srep21176
NR 32
TC 3
Z9 3
U1 3
U2 9
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1 3 BAXTERS PLACE,
   LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 0040 8166
J9 TISSUE CELL
JI Tissue Cell
PD JUN
PY 2022
VL 76
AR 101807
DI 10.1016/j.tice.2022.101807
EA MAY 2022
PG 7
WC Anatomy & Morphology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Anatomy & Morphology; Cell Biology
GA 1Q2RC
UT WOS:000802540400001
PM 35594585
DA 2025 08 17
ER

PT J
AU Carpi, M
   Cordella, A
   Placidi, F
   Izzi, F
   Piccirilli, E
   Mercuri, NB
   Tarantino, U
   Liguori, C
AF Carpi, Matteo
   Cordella, Alberto
   Placidi, Fabio
   Izzi, Francesca
   Piccirilli, Eleonora
   Mercuri, Nicola Biagio
   Tarantino, Umberto
   Liguori, Claudio
TI Continuous positive airway pressure treatment improves bone mineral
   density in men affected by severe obstructive sleep apnea syndrome
SO JOURNAL OF CLINICAL SLEEP MEDICINE
LA English
DT Article
DE obstructive sleep apnea; osteoporosis; hypoxia; bone mineral density;
   vitamin D
ID VITAMIN D; OSTEOPOROSIS; HYPOXIA; ASSOCIATION; POPULATION; GUIDELINES;
   THERAPY; DISEASE; CPAP
AB Study Objectives: Obstructive sleep apnea (OSA) and low bone mineral density (BMD) are 2 prevalent conditions with a significant negative impact on patients' well being and quality of life. Recent research has shown low BMD at different bone sites in male patients with OSA. Although the efficacy of continuous positive airway pressure (CPAP) treatment for OSA has been widely demonstrated, the evidence for understanding its impact on BMD and other bone related outcomes is insufficient. The aim of this observational study was to investigate the effect of 12 months of CPAP treatment on lumbar and femur BMD and bone related serum biomarkers in male patients with severe OSA. Methods: Sixty patients (mean age: 55.1 +/  9.9 years) were consecutively included and underwent BMD measurement with dual energy x ray absorptiometry at baseline and after 12 months of CPAP treatment. Vitamin D, parathyroid hormone, and calcium serum levels were examined at the same time points. Results: A significant increase in BMD in the L1 (P < .001, d = 0.27) and L2 (P < .001, d = 0.26) vertebrae was observed after CPAP treatment, along with an increase in vitamin D (P < .001, d = 0.71) and calcium (P < .001, d = 0.73) levels and a decrease in parathyroid hormone levels (P < .001, d = 0.60). The increase in BMD in L1 was significantly correlated with the decrease in parathyroid hormone serum levels (r = 2.50, P < .001). Conclusions: Overall, these findings showed that beneficial OSA treatment might restore bone health and support CPAP treatment as a feasible strategy to improve BMD in male patients with severe OSA. Accordingly, diagnosing and targeting OSA may be warranted in the treatment of male patients with undetermined osteopenia and osteoporosis.
C1 [Carpi, Matteo; Placidi, Fabio; Izzi, Francesca; Mercuri, Nicola Biagio; Liguori, Claudio] Univ Hosp Rome Tor Vergata, Sleep Med Ctr, Neurol Unit, Rome, Italy.
   [Cordella, Alberto] Neuroctr Southern Switzerland, Lugano, Switzerland.
   [Placidi, Fabio; Mercuri, Nicola Biagio; Liguori, Claudio] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
   [Piccirilli, Eleonora; Tarantino, Umberto] Univ Hosp Rome Tor Vergata, Dept Orthoped & Traumatol, Rome, Italy.
   [Liguori, Claudio] Univ Roma Tor Vergata, Sleep Med Ctr, Dept Syst Med, Viale Oxford 81, I 00133 Rome, Italy.
C3 University of Rome Tor Vergata; Policlin Tor Vergata; University of Rome
   Tor Vergata; University of Rome Tor Vergata; Policlin Tor Vergata;
   University of Rome Tor Vergata
RP Liguori, C (通讯作者)，Univ Roma Tor Vergata, Sleep Med Ctr, Dept Syst Med, Viale Oxford 81, I 00133 Rome, Italy.
EM dott.claudioliguori@yahoo.it
RI Carpi, Matteo/ABG 4687 2021; Cordella, Alberto/K 4598 2016; Mercuri,
   Nicola/K 5348 2016; Izzi, Francesca/AAA 1281 2019; Placidi,
   Fabio/J 9620 2018; Piccirilli, Eleonora/AIC 4365 2022
OI Carpi, Matteo/0000 0001 6933 5675; Piccirilli,
   Eleonora/0000 0002 1570 6482
CR Almendros I, 2022, J SLEEP RES, V31, DOI 10.1111/jsr.13418
   [Anonymous], 2021, R LANG ENV STAT COMP
   Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Avlonitou E, 2012, SLEEP BREATH, V16, P563, DOI 10.1007/s11325 011 0543 8
   Batool Anwar S, 2016, J SLEEP RES, V25, P731, DOI 10.1111/jsr.12430
   Berry R.B., 2012, AASM MANUAL SCORING, V176, P2012
   Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172
   Caples SM, 2007, SLEEP, V30, P291, DOI 10.1093/sleep/30.3.291
   Charoenngam N, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1035588
   Chen P, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889 016 3712 7
   Clynes MA, 2020, BRIT MED BULL, V133, P105, DOI 10.1093/bmb/ldaa005
   Cohen J., 2013, Statistical Power Analysis for the Behavioral Sciences, V2nd, DOI DOI 10.4324/9780203771587
   Collop NA, 2007, J CLIN SLEEP MED, V3, P737
   Court Brown CM, 2019, INJURY, V50, P1423, DOI 10.1016/j.injury.2019.06.016
   Daniel S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 10313 w
   Ebeling PR, 2022, ENDOCR REV, V43, P240, DOI 10.1210/endrev/bnab028
   Eimar H, 2017, OSTEOPOROSIS INT, V28, P1835, DOI 10.1007/s00198 017 3912 8
   El Ad B, 2005, INT REV PSYCHIATR, V17, P277, DOI 10.1080/09540260500104508
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Fernandes M, 2021, J ALZHEIMERS DIS REP, V5, P515, DOI 10.3233/ADR 210004
   Gkastaris K, 2020, J MUSCULOSKEL NEURON, V20, P372
   Hair J. F., 2009, Multivariate data analysis, V7th ed.
   Heinzer R, 2015, LANCET RESP MED, V3, P310, DOI 10.1016/S2213 2600(15)00043 0
   HOLM S, 1979, SCAND J STAT, V6, P65
   Kanis JA, 2008, BONE, V42, P467, DOI 10.1016/j.bone.2007.11.001
   Kaufman JM, 2005, OSTEOPOROSIS INT, V16, P510, DOI 10.1007/s00198 004 1713 3
   Kurland ES, 2000, J CLIN ENDOCR METAB, V85, P3069, DOI 10.1210/jc.85.9.3069
   Lakens D., 2013, FRONT PSYCHOL, V4, P863, DOI DOI 10.3389/fpsyg.2013.00863
   Levis S, 2012, CURR OSTEOPOROS REP, V10, P296, DOI 10.1007/s11914 012 0119 y
   Lévy P, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.15
   Liguori C, 2021, SLEEP MED REV, V55, DOI 10.1016/j.smrv.2020.101375
   Liguori C, 2018, J CLIN SLEEP MED, V14, P953, DOI 10.5664/jcsm.7158
   Liguori C, 2017, SLEEP MED, V29, P81, DOI 10.1016/j.sleep.2016.08.022
   Liguori C, 2016, EUR RESPIR J, V47, P987, DOI 10.1183/13993003.01830 2015
   Liguori C, 2015, J CLIN SLEEP MED, V11, P603, DOI 10.5664/jcsm.4766
   Lin JT, 2004, CLIN ORTHOP RELAT R, P126, DOI 10.1097/01.blo.0000132404.30139.f2
   Liu TW, 2017, FRONT NEUROL, V8, DOI 10.3389/fneur.2017.00289
   Mete T, 2013, J ENDOCRINOL INVEST, V36, P681, DOI 10.3275/8923
   Morris SB, 2002, PSYCHOL METHODS, V7, P105, DOI 10.1037//1082 989X.7.1.105
   Neighbors CLP, 2018, SLEEP MED, V43, P100, DOI 10.1016/j.sleep.2017.10.016
   Park JH, 2002, MOL CELL ENDOCRINOL, V192, P197, DOI 10.1016/S0303 7207(02)00036 9
   Patel SR, 2003, ARCH INTERN MED, V163, P565, DOI 10.1001/archinte.163.5.565
   Poole KES, 2006, BMJ BRIT MED J, V333, P1251, DOI 10.1136/bmj.39050.597350.47
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Salari N, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018 021 02772 0
   Senaratna CV, 2017, SLEEP MED REV, V34, P70, DOI 10.1016/j.smrv.2016.07.002
   Sforza E, 2016, SLEEP MED, V22, P25, DOI 10.1016/j.sleep.2016.04.010
   Sheu A, 2016, AUST PRESCR, V39, P85, DOI 10.18773/austprescr.2016.038
   Silverman Stuart L, 2005, Curr Rheumatol Rep, V7, P39, DOI 10.1007/s11926 005 0007 x
   Swanson CM, 2015, J BONE MINER RES, V30, P199, DOI 10.1002/jbmr.2446
   Tomiyama H, 2008, OSTEOPOROSIS INT, V19, P1185, DOI 10.1007/s00198 007 0556 0
   Tu Kristie N, 2018, P T, V43, P92
   Upala S, 2016, INT J ENDOCRINOL MET, V14, DOI 10.5812/ijem.36317
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   Uzkeser H, 2013, SLEEP BREATH, V17, P339, DOI 10.1007/s11325 012 0698 y
   von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.2471/BLT.07.045120
   Wade SW, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 014 0182 3
   Wang CY, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.1013771
   World Health Organization, 2002, ASIA PACIFIC PERSPEC
   Xue SS, 2021, J CLIN ENDOCR METAB, V106, pE2613, DOI 10.1210/clinem/dgab180
   Yüceege M, 2015, SLEEP BIOL RHYTHMS, V13, P189, DOI 10.1111/sbr.12106
NR 61
TC 6
Z9 7
U1 0
U2 7
PU AMER ACAD SLEEP MEDICINE
PI DARIEN
PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA
SN 1550 9389
EI 1550 9397
J9 J CLIN SLEEP MED
JI J. Clin. Sleep Med.
PD JAN 1
PY 2024
VL 20
IS 1
BP 67
EP 73
DI 10.5664/jcsm.10796
PG 7
WC Clinical Neurology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology
GA NI2X2
UT WOS:001199768400015
PM 37677073
DA 2025 08 17
ER

PT J
AU Mandatori, D
   Penolazzi, L
   Pipino, C
   Di Tomo, P
   Di Silvestre, S
   Di Pietro, N
   Trevisani, S
   Angelozzi, M
   Ucci, M
   Piva, R
   Pandolfi, A
AF Mandatori, Domitilla
   Penolazzi, Letizia
   Pipino, Caterina
   Di Tomo, Pamela
   Di Silvestre, Sara
   Di Pietro, Natalia
   Trevisani, Sara
   Angelozzi, Marco
   Ucci, Mariangela
   Piva, Roberta
   Pandolfi, Assunta
TI Menaquinone 4 enhances osteogenic potential of human amniotic fluid
   mesenchymal stem cells cultured in 2D and 3D dynamic culture systems
SO JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE
LA English
DT Article
DE 3D culture; amniotic fluid mesenchymal stem cells; osteogenesis;
   osteoporosis; vitamin K2;  glutamyl carboxylase
ID BONE MINERAL DENSITY; VITAMIN K; POSTMENOPAUSAL WOMEN; IN VITRO;
   REGENERATIVE MEDICINE; EXTRACELLULAR MATRIX; OSTEOPOROSIS; THERAPY;
   DIFFERENTIATION; ACCUMULATION
AB Menaquinones, also known as Vitamin K2 family, regulate calcium homeostasis in a bone vascular cross talk' and recently received particular attention for their positive effect on bone formation. Given that the correlation between menaquinones and bone metabolism to date is still unclear, the objective of our study was to investigate the possible role of menaquinone 4 (MK 4), an isoform of the menaquinones family, in the modulation of osteogenesis. For this reason, we used a model of human amniotic fluid mesenchymal stem cells (hAFMSCs) cultured both in two dimensional (2D) and three dimensional (3D; RCCSbioreactor) in vitro culture systems. Furthermore, to mimic the bone remodelling unit' in vitro, hAFMSCs were co cultured in the 3D system with human monocyte cells (hMCs) as osteoclast precursors. The results showed that in a conventional 2D culture system, hAFMSCs were responsive to the MK 4, which significantly improved the osteogenic process through  glutamyl carboxylase dependent pathway. The same results were obtained in the 3D dynamic system where MK 4 treatment supported the osteoblast like formation promoting the extracellular bone matrix deposition and the expression of the osteogenic related proteins (alkaline phosphatase, osteopontin, collagen type 1 and osteocalcin). Notably, when the hAFMSCs were co cultured in a 3D dynamic system with the hMCs, the presence of MK 4 supported the cellular aggregate formation as well as the osteogenic function of hAFMSCs, but negatively affected the osteoclastogenic process. Taken together, our results demonstrate that MK 4 supported the aggregate formation of hAFMSCs and increased the osteogenic functions. Specifically, our data could help to optimize bone regenerative medicine combining cell based approaches with MK 4 treatment.
C1 [Mandatori, Domitilla; Pipino, Caterina; Di Tomo, Pamela; Di Silvestre, Sara; Ucci, Mariangela; Pandolfi, Assunta] Univ G dAnnunzio, G dAnnunzio Univ Fdn, Ctr Sci Invecchiamento & Med Traslaz, Dept Med Oral & Biotechnol Sci,StemTeCh Grp, Chieti, Italy.
   [Penolazzi, Letizia; Trevisani, Sara; Angelozzi, Marco; Piva, Roberta] Univ Ferrara, Dept Biomed & Specialty Surg Sci, Ferrara, Italy.
   [Di Pietro, Natalia] Univ G dAnnunzio, Dept Med & Aging Sci, Ctr Sci Invecchiamento & Med Traslaz, Chieti, Italy.
C3 G d'Annunzio University of Chieti Pescara; University of Ferrara; G
   d'Annunzio University of Chieti Pescara
RP Pandolfi, A (通讯作者)，Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
EM assunta.pandolfi@unich.it
RI PANDOLFI, Assunta/K 4595 2016; Pipino, Caterina/N 2078 2019; Angelozzi,
   Marco/MZR 4675 2025; Di Pietro, Natalia/K 1604 2016; pandolfi,
   assunta/K 4595 2016
OI PANDOLFI, Assunta/0000 0003 4135 7631; PIPINO,
   CATERINA/0000 0002 4350 8686; Di Pietro, Natalia/0000 0001 9720 2116;
   Piva, Roberta/0000 0003 2663 6210; Penolazzi,
   Letizia/0000 0002 1293 5087
FU Ibersan Santiveri s.r.l. (Italy)
FX This work was partially funded by Ibersan Santiveri s.r.l. (Italy). The
   authors thank Professor Paolo De Coppi for partially providing the
   hAFMSC cultures.
CR Atkins GJ, 2009, AM J PHYSIOL CELL PH, V297, pC1358, DOI 10.1152/ajpcell.00216.2009
   Azuma K, 2014, GERIATR GERONTOL INT, V14, P1, DOI 10.1111/ggi.12060
   Cananzi M, 2009, REPROD BIOMED ONLINE, V18, P17, DOI 10.1016/S1472 6483(10)60111 3
   Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198
   Cauley JA, 2013, J GERONTOL A BIOL, V68, P1243, DOI 10.1093/gerona/glt093
   Chen QA, 2010, ANAL SCI, V26, P1033, DOI 10.2116/analsci.26.1033
   Dalmeijer GW, 2012, ATHEROSCLEROSIS, V225, P397, DOI 10.1016/j.atherosclerosis.2012.09.019
   De Coppi P, 2007, NAT BIOTECHNOL, V25, P100, DOI 10.1038/nbt1274
   Di Tomo P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073816
   El Asmar Margueritta S, 2014, Oman Med J, V29, P172, DOI 10.5001/omj.2014.44
   Flore R, 2013, EUR REV MED PHARMACO, V17, P2433
   Gigante A, 2015, J TISSUE ENG REGEN M, V9, P691, DOI 10.1002/term.1627
   Hamidi MS, 2014, MOL NUTR FOOD RES, V58, P1647, DOI 10.1002/mnfr.201300950
   Huang ZB, 2015, OSTEOPOROSIS INT, V26, P1175, DOI 10.1007/s00198 014 2989 6
   Ichikawa T, 2006, J BIOL CHEM, V281, P16927, DOI 10.1074/jbc.M600896200
   Ito H, 2014, CURR OSTEOPOROS REP, V12, P230, DOI 10.1007/s11914 014 0201 8
   Iwamoto J, 2014, NUTRIENTS, V6, P1971, DOI 10.3390/nu6051971
   Katsuyama H, 2007, INT J MOL MED, V19, P279
   Kiernan J, 2016, STEM CELL TRANSL MED, V5, P683, DOI 10.5966/sctm.2015 0231
   Koitaya N, 2014, J BONE MINER METAB, V32, P142, DOI 10.1007/s00774 013 0472 7
   Koshihara Y, 1997, J BONE MINER RES, V12, P431, DOI 10.1359/jbmr.1997.12.3.431
   Nakamura E, 2014, NUTR J, V13, DOI 10.1186/1475 2891 13 85
   Pantalone A, 2016, EUR REV MED PHARMACO, V20, P2884
   Peister A, 2011, STEM CELL RES, V7, P17, DOI 10.1016/j.scr.2011.03.001
   Penolazzi L, 2016, LIFE SCI, V152, P82, DOI 10.1016/j.lfs.2016.03.035
   Pipino C, 2015, STEM CELLS DEV, V24, P1415, DOI 10.1089/scd.2014.0453
   Pipino C, 2015, WORLD J STEM CELLS, V7, P681, DOI 10.4252/wjsc.v7.i4.681
   Pipino C, 2014, STEM CELLS DEV, V23, P2959, DOI 10.1089/scd.2013.0627
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Ronn SH, 2016, EUR J ENDOCRINOL, V175, pE541, DOI 10.1530/EJE 16 0498
   Roubelakis MG, 2011, J CELL MOL MED, V15, P1896, DOI 10.1111/j.1582 4934.2010.01180.x
   Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515
   Sui BD, 2016, STEM CELL TRANSL MED, V5, P1238, DOI 10.5966/sctm.2015 0347
   SZULC P, 1994, J BONE MINER RES, V9, P1591
   Thijssen HHW, 1996, BRIT J NUTR, V75, P121, DOI 10.1079/BJN19960115
   Tie JK, 2016, J THROMB HAEMOST, V14, P236, DOI 10.1111/jth.13217
   Willems BAG, 2014, MOL NUTR FOOD RES, V58, P1620, DOI 10.1002/mnfr.201300743
   Yamaguchi M, 2011, INT J MOL MED, V27, P3, DOI 10.3892/ijmm.2010.562
   Zhang YL, 2016, INT J BIOL SCI, V12, P347, DOI 10.7150/ijbs.13269
NR 39
TC 17
Z9 17
U1 0
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1932 6254
EI 1932 7005
J9 J TISSUE ENG REGEN M
JI J. Tissue Eng. Regen. Med.
PD FEB
PY 2018
VL 12
IS 2
BP 447
EP 459
PG 13
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
   Biology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Engineering
GA FW3CY
UT WOS:000425184900072
PM 28508565
OA gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Toda, Y
   Kohashi, K
   Yamamoto, H
   Ishihara, S
   Ito, Y
   Susuki, Y
   Kawaguchi, K
   Kiyozawa, D
   Takamatsu, D
   Kinoshita, I
   Yamada, Y
   Maehara, J
   Kimura, A
   Tamiya, S
   Taguchi, K
   Matsunobu, T
   Matsumoto, Y
   Nakashima, Y
   Mawatari, M
   Oda, Y
AF Toda, Yu
   Kohashi, Kenichi
   Yamamoto, Hidetaka
   Ishihara, Shin
   Ito, Yoshihiro
   Susuki, Yosuke
   Kawaguchi, Kengo
   Kiyozawa, Daisuke
   Takamatsu, Dai
   Kinoshita, Izumi
   Yamada, Yuichi
   Maehara, Junki
   Kimura, Atsushi
   Tamiya, Sadafumi
   Taguchi, Kenichi
   Matsunobu, Tomoya
   Matsumoto, Yoshihiro
   Nakashima, Yasuharu
   Mawatari, Masaaki
   Oda, Yoshinao
TI Tumor microenvironment in giant cell tumor of bone: evaluation of PD L1
   expression and SIRPα infiltration after denosumab treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID DEATH LIGAND 1; H3F3A; OSTEOSARCOMA; COEXPRESSION; MULTICENTER;
   ANTIBODIES; MUTATIONS; CARCINOMA; BLOCKADE; IMMUNITY
AB Giant cell tumor of bone (GCTB) is an intermediate malignant bone tumor that is locally aggressive and rarely metastasizes. Denosumab, which is a receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, can be used to treat GCTB. We focused on potential immunotherapy for GCTB and investigated the tumor microenvironment of GCTB. Programmed death ligand 1 (PD L1) and indoleamine 2,3 dioxygenase 1 (IDO1) expression and signal regulatory protein alpha (SIRP alpha), forkhead box P3 (FOXP3), and cluster of differentiation 8 (CD8) infiltration were assessed by immunohistochemical studies of 137 tumor tissues from 96 patients. Of the naive primary specimens, 28% exhibited PD L1 expression and 39% exhibited IDO1 expression. There was significantly more SIRP alpha (+), FOXP3(+), and CD8(+) cell infiltration in PD L1  and IDO1 positive tumors than in PD L1  and IDO1 negative tumors. The frequency of PD L1 expression and SIRP alpha (+) cell infiltration in recurrent lesions treated with denosumab was significantly higher than in primary lesions and recurrent lesions not treated with denosumab. PD L1 expression and higher SIRP alpha (+) cell infiltration were significantly correlated with shorter recurrence free survival. PD L1 and SIRP alpha immune checkpoint inhibitors may provide clinical benefit in GCTB patients with recurrent lesions after denosumab therapy.
C1 [Toda, Yu; Kohashi, Kenichi; Yamamoto, Hidetaka; Ishihara, Shin; Ito, Yoshihiro; Susuki, Yosuke; Kawaguchi, Kengo; Kiyozawa, Daisuke; Takamatsu, Dai; Kinoshita, Izumi; Yamada, Yuichi; Oda, Yoshinao] Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol Pathol Sci, Higashi Ku, Maidashi 3 1 1, Fukuoka 8128582, Japan.
   [Maehara, Junki] Kyushu Univ, Grad Sch Med Sci, Dept Clin Radiol, Fukuoka, Japan.
   [Kimura, Atsushi; Matsumoto, Yoshihiro; Nakashima, Yasuharu] Kyushu Univ, Grad Sch Med Sci, Dept Orthopaed Surg, Fukuoka, Japan.
   [Tamiya, Sadafumi] Kitakyushu Municipal Med Ctr, Dept Pathol, Fukuoka, Japan.
   [Taguchi, Kenichi] Natl Hosp Org Kyushu Canc Ctr, Dept Pathol, Fukuoka, Japan.
   [Matsunobu, Tomoya] Kyushu Rosai Hosp, Dept Orthopaed Surg, Fukuoka, Japan.
   [Mawatari, Masaaki] Saga Univ, Fac Med, Dept Orthopaed Surg, Saga, Japan.
C3 Kyushu University; Kyushu University; Kyushu University; Kyushu Cancer
   Center; Saga University
RP Oda, Y (通讯作者)，Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol Pathol Sci, Higashi Ku, Maidashi 3 1 1, Fukuoka 8128582, Japan.
EM oda@surgpath.med.kyushu u.ac.jp
RI Kawaguchi, Kengo/LFT 9544 2024; TODA, Yoshiaki/U 7601 2019; Yamada,
   Yuichi/ABG 4561 2021
OI Yamada, Yuichi/0000 0002 5516 4737; Takamatsu, Dai/0009 0005 2343 4316;
   KAWAGUCHI, Kengo/0000 0001 9096 6957; Kiyozawa,
   Daisuke/0000 0002 3761 8491
FU Grants in Aid for Scientific Research [21K06887, 21K09325] Funding
   Source: KAKEN
CR Ahern E, 2019, TRIALS, V20, DOI 10.1186/s13063 019 3951 x
   Ahern E, 2017, CLIN CANCER RES, V23, P5789, DOI 10.1158/1078 0432.CCR 17 0606
   Algawahmed H., 2010, Sarcoma, V2010, P586090, DOI 10.1155/2010/586090
   Amary F, 2017, AM J SURG PATHOL, V41, P1059, DOI 10.1097/PAS.0000000000000859
   Balke M, 2008, J CANCER RES CLIN, V134, P969, DOI 10.1007/s00432 008 0370 x
   Behjati S, 2013, NAT GENET, V45, P1479, DOI 10.1038/ng.2814
   Bostwick A Doran, 2015, J Immunother Cancer, V3, P19, DOI 10.1186/s40425 015 0064 2
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Chen X, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03294 2
   Cleven AHG, 2015, AM J SURG PATHOL, V39, P1576, DOI 10.1097/PAS.0000000000000512
   Dancsok AR, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1747340
   Errani C, 2018, J BONE JOINT SURG AM, V100, P496, DOI 10.2106/JBJS.17.00057
   Healey JH, 2019, LANCET ONCOL, V20, P1627, DOI 10.1016/S1470 2045(19)30660 6
   Kato I, 2018, HISTOPATHOLOGY, V72, P914, DOI 10.1111/his.13448
   Kazama R., 2020, CANCER SCI, V2, P17
   Kinoshita F, 2020, ANN SURG ONCOL, V27, P2102, DOI 10.1245/s10434 019 08029 9
   Kivioja AH, 2008, ACTA ORTHOP, V79, P86, DOI 10.1080/17453670710014815
   Kiyozawa D, 2020, HUM PATHOL, V101, P31, DOI 10.1016/j.humpath.2020.04.003
   Koirala P, 2016, SCI REP UK, V6, DOI 10.1038/srep30093
   Kozuma Y, 2018, EUR J CANCER, V101, P20, DOI 10.1016/j.ejca.2018.06.020
   Li ZH, 2016, J CANCER, V7, P784, DOI 10.7150/jca.14549
   Liao YF, 2017, ONCOTARGET, V8, P30276, DOI 10.18632/oncotarget.16326
   Liede A, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1480301
   Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345
   Lussier DM, 2015, J IMMUNOTHER, V38, P96, DOI 10.1097/CJI.0000000000000065
   Metovic J, 2020, CANCER IMMUNOL IMMUN, V69, P1905, DOI 10.1007/s00262 020 02594 9
   Murata Y, 2020, EXPERT OPIN THER TAR, V24, P945, DOI 10.1080/14728222.2020.1811855
   Parra ER, 2018, J THORAC ONCOL, V13, P779, DOI 10.1016/j.jtho.2018.03.002
   Presneau N, 2015, J PATHOL CLIN RES, V1, P113, DOI 10.1002/cjp2.13
   Roitman PD, 2017, HUM PATHOL, V63, P89, DOI 10.1016/j.humpath.2017.02.008
   Rosenbaum MW, 2018, ENDOCR PATHOL, V29, P59, DOI 10.1007/s12022 018 9514 y
   Schalper KA, 2017, CLIN CANCER RES, V23, P370, DOI 10.1158/1078 0432.CCR 16 0150
   Shi R, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 0121 2
   Sikic BI, 2019, J CLIN ONCOL, V37, P946, DOI 10.1200/JCO.18.02018
   Smyth MJ, 2016, J CLIN ONCOL, V34, pE104, DOI 10.1200/JCO.2013.51.3572
   Sundara YT, 2017, CANCER IMMUNOL IMMUN, V66, P119, DOI 10.1007/s00262 016 1925 3
   Takada K, 2020, J CANCER RES CLIN, V146, P2639, DOI 10.1007/s00432 020 03250 6
   Takada K, 2019, LUNG CANCER, V128, P26, DOI 10.1016/j.lungcan.2018.12.008
   Toda Y, 2020, J CANCER RES CLIN, V146, P2607, DOI 10.1007/s00432 020 03242 6
   Torabi A, 2017, PATHOLOGY, V49, P506, DOI 10.1016/j.pathol.2017.05.003
   Ueda T, 2015, ANN ONCOL, V26, P2149, DOI 10.1093/annonc/mdv307
   Urakawa H, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1459 6
   van Dam PA, 2019, CRIT REV ONCOL HEMAT, V133, P85, DOI 10.1016/j.critrevonc.2018.10.011
   WHO Classification of Tumours Editorial Board, 2020, SOFT TISS BON TUM, V3
   Witte HM, 2020, CANCERS, V12, DOI 10.3390/cancers12040873
   Wojcik J, 2016, AM J SURG PATHOL, V40, P72, DOI 10.1097/PAS.0000000000000506
   Yamamoto H, 2020, MED MOL MORPHOL, V53, P1, DOI 10.1007/s00795 019 00238 1
   Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020
   Yanagida E., 2020, HEMATOL ONCOL, V3, P19865
   Yanagita T, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.89140
   Zhang ML, 2019, MODERN PATHOL, V32, P511, DOI 10.1038/s41379 018 0160 1
NR 51
TC 17
Z9 18
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD JUL 20
PY 2021
VL 11
IS 1
AR 14821
DI 10.1038/s41598 021 94022 w
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UK8FY
UT WOS:000692201400038
PM 34285260
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lloyd, AA
   Gludovatz, B
   Riedel, C
   Luengo, EA
   Saiyed, R
   Marty, E
   Lorich, DG
   Lane, JM
   Ritchie, RO
   Busse, B
   Donnelly, E
AF Lloyd, Ashley A.
   Gludovatz, Bernd
   Riedel, Christoph
   Luengo, Emma A.
   Saiyed, Rehan
   Marty, Eric
   Lorich, Dean G.
   Lane, Joseph M.
   Ritchie, Robert O.
   Busse, Bjoern
   Donnelly, Eve
TI Atypical fracture with long term bisphosphonate therapy is associated
   with altered cortical composition and reduced fracture resistance
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE atypical fracture; bisphosphonates; subtrochanteric fracture; fracture
   toughness; FTIR imaging
ID MECHANICAL PROPERTIES; POSTMENOPAUSAL WOMEN; CANCELLOUS BONE; CEMENT
   LINE; ALENDRONATE; HETEROGENEITY; TOUGHNESS; OSTEOPOROSIS; RISEDRONATE;
   POROSITY
AB Bisphosphonates are the most widely prescribed pharmacologic treatment for osteoporosis and reduce fracture risk in postmenopausal women by up to 50%. However, in the past decade these drugs have been associated with atypical femoral fractures (AFFs), rare fractures with a transverse, brittle morphology. The unusual fracture morphology suggests that bisphosphonate treatment may impair toughening mechanisms in cortical bone. The objective of this study was to compare the compositional and mechanical properties of bone biopsies from bisphosphonate treated patients with AFFs to those from patients with typical osteoporotic fractures with and without bisphosphonate treatment. Biopsies of proximal femoral cortical bone adjacent to the fracture site were obtained from postmenopausal women during fracture repair surgery (fracture groups, n = 33) or total hip arthroplasty (nonfracture groups, n = 17). Patients were allocated to five groups based on fracture morphology and history of bisphosphonate treatment [+ BIS Atypical: n = 12, BIS duration: 8.2 (3.0) y; + BIS Typical: n = 10, 7.7 (5.0) y; + BIS Nonfx: n = 5, 6.4 (3.5) y;  BIS Typical: n = 11;  BIS Nonfx: n = 12]. Vibrational spectroscopy and nanoindentation showed that tissue from bisphosphonate treated women with atypical fractures was harder and more mineralized than that from bisphosphonatetreated women with typical osteoporotic fractures. In addition, fracture mechanics measurements showed that tissue from patients treated with bisphosphonates had deficits in fracture toughness, with lower crack initiation toughness and less crack deflection at osteonal boundaries than that of bisphosphonate naive patients. Together, these results suggest a deficit in intrinsic and extrinsic toughening mechanisms, which contribute to AFFs in patients treated with long term bisphosphonates.
C1 [Lloyd, Ashley A.; Luengo, Emma A.; Donnelly, Eve] Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14850 USA.
   [Gludovatz, Bernd] UNSW Sydney, Sch Mech & Mfg Engn, Sydney, NSW 2052, Australia.
   [Riedel, Christoph; Busse, Bjoern] Univ Med Ctr Hamburg, Dept Osteol & Biomech, D 22529 Hamburg, Germany.
   [Saiyed, Rehan; Marty, Eric; Lorich, Dean G.; Lane, Joseph M.] Hosp Special Surg, Dept Orthoped Surg, New York, NY 10021 USA.
   [Lorich, Dean G.; Lane, Joseph M.] Cornell Univ, Weill Med Coll, Orthoped Surg, New York, NY 10065 USA.
   [Lorich, Dean G.; Lane, Joseph M.] NewYork Presbyterian Hosp, Med Orthoped Trauma Serv, Weill Cornell Med Ctr, New York, NY 10065 USA.
   [Ritchie, Robert O.] Lawrence Berkeley Natl Lab, Mat Sci Div, Berkeley, CA 94720 USA.
   [Ritchie, Robert O.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA.
   [Donnelly, Eve] Hosp Special Surg, Res Div, New York, NY 10021 USA.
C3 Cornell University; University of New South Wales Sydney; University of
   Hamburg; University Medical Center Hamburg Eppendorf; Cornell
   University; Weill Cornell Medicine; NewYork Presbyterian Hospital;
   Cornell University; Weill Cornell Medical Center; Weill Cornell
   Medicine; United States Department of Energy (DOE); Lawrence Berkeley
   National Laboratory; University of California System; University of
   California Berkeley
RP Donnelly, E (通讯作者)，Cornell Univ, Dept Mat Sci & Engn, Ithaca, NY 14850 USA.; Donnelly, E (通讯作者)，Hosp Special Surg, Res Div, New York, NY 10021 USA.
EM eve.donnelly@cornell.edu
RI ; Gludovatz, Bernd/O 2121 2014; Ritchie, Robert/A 8066 2008; Busse,
   Björn/AAC 4033 2020; Donnelly, Eve/E 1973 2013
OI Busse, Bjorn/0000 0002 3099 8073; Gludovatz, Bernd/0000 0002 2420 3879;
   Riedel, Christoph/0000 0001 8342 296X; Donnelly, Eve/0000 0001 8165 9568
FU NSF Civil, Mechanical and Manufacturing Innovation Grant [1452852];
   American Society for Bone and Mineral Research Junior Faculty
   Osteoporosis Research Award; German Research Foundation (DFG) [BU
   2562/2 1/3 1]; NSF Graduate Research Fellowship [DGE 1144153]; NSF
   Materials Research Science and Engineering Centers program
   [DMR 1120296]; Directorate For Engineering; Div Of Civil, Mechanical, &
   Manufact Inn [1452852] Funding Source: National Science Foundation
FX We thank Dr. Mathias Bostrom and Dr. Charles Cornell for assistance with
   obtaining biopsies, Dr. Michael Hahn for technical support, and Amy Cao
   and Carmen Ngai for collection and analysis of Raman data. This work was
   supported by NSF Civil, Mechanical and Manufacturing Innovation Grant
   1452852 and an American Society for Bone and Mineral Research Junior
   Faculty Osteoporosis Research Award (to E.D.), and the German Research
   Foundation (DFG) under Grant BU 2562/2 1/3 1 (to B.B.). This material is
   based upon the work supported by an NSF Graduate Research Fellowship (to
   A.A.L.) under Grant DGE 1144153. This work made use of the Cornell
   Center for Materials Research Shared Facilities, which are supported
   through the NSF Materials Research Science and Engineering Centers
   program (Grant DMR 1120296).
CR Abrahamsen B, 2009, J BONE MINER RES, V24, P1095, DOI [10.1359/JBMR.081247, 10.1359/jbmr.081247]
   Acevedo C, 2015, BONE, V81, P352, DOI 10.1016/j.bone.2015.08.002
   Adler RA, 2016, J BONE MINER RES, V31, P16, DOI 10.1002/jbmr.2708
   Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   [Anonymous], 2015, E182015A ASTM INT
   Bajaj D, 2014, BONE, V64, P57, DOI 10.1016/j.bone.2014.03.045
   Black DM, 2010, NEW ENGL J MED, V362, P1761, DOI 10.1056/NEJMoa1001086
   Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140 6736(96)07088 2
   Boskey AL, 2016, J BONE MINER RES, V31, P1070, DOI 10.1002/jbmr.2759
   BURR DB, 1988, J BIOMECH, V21, P939, DOI 10.1016/0021 9290(88)90132 7
   Busse B, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006286
   Clézardin P, 2011, BONE, V49, P66, DOI 10.1016/j.bone.2010.11.017
   Cummings SR, 1998, JAMA J AM MED ASSOC, V280, P2077, DOI 10.1001/jama.280.24.2077
   Currey JD, 2004, P ROY SOC B BIOL SCI, V271, P517, DOI 10.1098/rspb.2003.2634
   Donnelly E, 2006, J BIOMED MATER RES A, V77A, P426, DOI 10.1002/jbm.a.30633
   Donnelly E, 2012, J BONE MINER RES, V27, P672, DOI 10.1002/jbmr.560
   Eastell R, 2011, BONE, V49, P82, DOI 10.1016/j.bone.2011.02.011
   Gourion Arsiquaud S, 2009, J BONE MINER RES, V24, P1565, DOI [10.1359/jbmr.090414, 10.1359/JBMR.090414]
   Harris ST, 1999, JAMA J AM MED ASSOC, V282, P1344, DOI 10.1001/jama.282.14.1344
   Hengsberger S, 2002, BONE, V30, P178, DOI 10.1016/S8756 3282(01)00624 X
   Jha S, 2015, J BONE MINER RES, V30, P2179, DOI 10.1002/jbmr.2565
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Khosla S, 2016, J BONE MINER RES, V31, P1485, DOI 10.1002/jbmr.2888
   Koester KJ, 2008, NAT MATER, V7, P672, DOI 10.1038/nmat2221
   Kolata G., 2016, NY Times
   Launey ME, 2010, ANNU REV MATER RES, V40, P25, DOI [10.1146/annurev matsci 070909 104427, 10.1146/annurev matsci 070909 10442]
   Lenart BA, 2008, NEW ENGL J MED, V358, P1304, DOI 10.1056/NEJMc0707493
   Nalla RK, 2005, J BIOMECH, V38, P1517, DOI 10.1016/j.jbiomech.2004.07.010
   Nalla RK, 2003, NAT MATER, V2, P164, DOI 10.1038/nmat832
   Neviaser AS, 2008, J ORTHOP TRAUMA, V22, P346, DOI 10.1097/BOT.0b013e318172841c
   Odvina CV, 2005, J CLIN ENDOCR METAB, V90, P1294, DOI 10.1210/jc.2004 0952
   OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564
   R Core Team, 2017, R LANG ENV STAT COMP
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Roschger P, 2001, BONE, V29, P185, DOI 10.1016/S8756 3282(01)00485 9
   Sasaki S, 2012, J BONE MINER METAB, V30, P561, DOI 10.1007/s00774 012 0358 0
   Schilcher J, 2011, NEW ENGL J MED, V364, P1728, DOI 10.1056/NEJMoa1010650
   Shane E, 2014, J BONE MINER RES, V29, P1, DOI 10.1002/jbmr.1998
   Shane E, 2010, J BONE MINER RES, V25, P2267, DOI 10.1002/jbmr.253
   Tai K, 2007, NAT MATER, V6, P454, DOI 10.1038/nmat1911
   Tang SY, 2009, OSTEOPOROSIS INT, V20, P887, DOI 10.1007/s00198 008 0754 4
   Vieira RL, 2012, AM J ROENTGENOL, V198, P1144, DOI 10.2214/AJR.11.7442
   Yeni YN, 2000, J BIOMED MATER RES, V51, P504, DOI 10.1002/1097 4636(20000905)51:3<504::AID JBM27>3.0.CO;2 I
   Zimmermann EA, 2016, SCI REP UK, V6, DOI 10.1038/srep21072
NR 44
TC 117
Z9 127
U1 0
U2 23
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
EI 1091 6490
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 15
PY 2017
VL 114
IS 33
BP 8722
EP 8727
DI 10.1073/pnas.1704460114
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA FD6AG
UT WOS:000407610400052
PM 28760963
OA Green Published
DA 2025 08 17
ER

PT J
AU Ratanasereeprasert, N
   Hsu, LF
   Wang, SK
   Chen, YJ
   Chang, JH
   Yao, CCJ
AF Ratanasereeprasert, Nutthakarn
   Hsu, Li Fang
   Wang, Shih Kai
   Chen, Yi Jane
   Chang, Jui Heng
   Yao, Chung Chen Jane
TI Molecular signaling and mechanisms of lowlevel laser induced gene
   expression in cells involved in orthodontic tooth movement
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE Gene regulation; Low level laser therapy; Mitochondrial membrane
   potential; NF kB pathway; Reactive oxygen species
ID CYTOCHROME C OXIDASE; DIRECT CONVERSION; IN VIVO; THERAPY; FIBROBLASTS;
   OSTEOBLASTS; PHOTOBIOMODULATION; INTENSITY; LINE
AB Background: The study aimed to observe molecular signaling, including reactive oxygen species (ROS) and mitochondrial membrane potential (Alirm), to evaluate the alteration of gene expression by low level laser therapy (LLLT) and the correlation between its mechanisms and the NF kB pathway in cells involved in orthodontic tooth movement. Methods: Osteoblast like cells (MG63), immortalized periodontal ligament cells (iPDL), and M1 macrophage like cells were irradiated by 980 nm LLLT with energy densities of 1 and 10 J/cm 2 Alirm and intracellular ROS were monitored using fluorescent probes. The changes of mRNA expression were assessed using reverse transcription polymerase chain reaction (RT PCR). NF kB inhibitor, ROS scavenger, and Alirm suppressor were used to analyze signals associated with the regulation of gene expression. Finally, Western blot analysis was performed to confirm NF kB signaling after LLLT. Results: We found the increases of Alirm and ROS in all three cell types after LLLT, but no significant difference was observed between 1 and 10 J/cm 2 LLLT. Regarding gene expression, some target genes were upregulated in MG63 6 h, 12 h, and 1 day after LLLT and in iPDL cells 12 h and 1 day after LLLT. However, no changes occurred in M1 cells. The inhibitor that significantly reduced most changes in gene expression was NF kB inhibitor. Western blot analysis showed the increase in p IkB a level after LLLT in iPDL and MG63, but not in M1. Conclusion: The 980 nm LLLT increased DJ m and ROS production in all three cell types. However, changes in gene regulation were found only in MG63 and iPDL cells, which related to the NF kB pathway. Copyright <feminine ordinal indicator> 2023, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY  NC  ND license (http://creativecommons.org/licenses/bync nd/4.0/).
C1 [Ratanasereeprasert, Nutthakarn; Chen, Yi Jane; Chang, Jui Heng; Yao, Chung Chen Jane] Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, 1 Chang Te St, Taipei 10048, Taiwan.
   [Hsu, Li Fang] Natl Taiwan Univ Hosp, Dept Dent, Hsin Chu Branch, Hsinchu, Taiwan.
   [Wang, Shih Kai] Natl Taiwan Univ, Childrens Hosp, Sch Dent, Dept Dent,Dept Pediat Dent, Taipei, Taiwan.
   [Chen, Yi Jane; Yao, Chung Chen Jane] Natl Taiwan Univ Hosp, Dent Dept, Div Orthodont & Dentofacial Orthoped, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University; National Taiwan
   University Hospital; National Taiwan University; National Taiwan
   University; National Taiwan University Hospital
RP Yao, CCJ (通讯作者)，Natl Taiwan Univ, Grad Inst Clin Dent, Sch Dent, 1 Chang Te St, Taipei 10048, Taiwan.
EM janeyao@ntu.edu.tw
RI ; Yao, Chung Chen/D 1470 2018; Chen, Yen Yuan/AAF 4335 2020; Wang,
   Shih Kai/P 3644 2019; Wang, Shih Kai/K 5995 2015
OI CHEN, YI JANE/0000 0002 9178 8379; Ratanasereeprasert,
   Nutthakarn/0000 0003 0518 6695; YAO, CHUNG CHEN
   JANE/0000 0002 2293 7000; Wang, Shih Kai/0000 0002 8378 5880
FU National Taiwan University Hospital [109 S004643, 110 S5114]; Min istry
   of Science and Technology [MOST 108 2314 B 002 042, MOST
   111 2314 B 002 112]; National Science and Technology council of Taiwan
   [108 2926 I 002 002 MY4]
FX This work was supported by National Taiwan University Hospital (grant
   number 109 S004643 and 110 S5114) , Min istry of Science and Technology
   (MOST 108 2314 B 002 042 and MOST 111 2314 B 002 112) and the National
   Science and Technology council of Taiwan 108 2926 I 002 002 MY4, the
   Excellence Improvement Program for Doctoral Stu dents, for English
   editing.
CR Abdel Magied N, 2020, BIOL TRACE ELEM RES, V194, P410, DOI 10.1007/s12011 019 01779 3
   Albuquerque Pontes GM, 2015, LASER MED SCI, V30, P59, DOI 10.1007/s10103 014 1616 2
   Behm C, 2022, FRONT ORAL HEALTH, V3, DOI 10.3389/froh.2022.877348
   BILLIAU A, 1977, ANTIMICROB AGENTS CH, V12, P11, DOI 10.1128/AAC.12.1.11
   Callaghan GA, 1996, LASER SURG MED, V19, P201
   Chang HH, 2008, J DENT RES, V87, P692, DOI 10.1177/154405910808700714
   Chang SY, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 55711 9
   Chang Yujung, 2019, Exp Mol Med, V51, P1
   Chen ACH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022453
   Da WCL, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.675385
   de Freitas LF, 2016, IEEE J SEL TOP QUANT, V22, DOI 10.1109/JSTQE.2016.2561201
   De Marchi T, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11091671
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Eid FY, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 14280 0
   Ferraresi C, 2015, PHOTOCHEM PHOTOBIOL, V91, P411, DOI 10.1111/php.12397
   Funes SC, 2018, IMMUNOLOGY, V154, P186, DOI 10.1111/imm.12910
   Hamblin MR, 2022, PHOTOBIOMOD PHOTOMED, V40, P75, DOI 10.1089/photob.2021.0119
   Harorli OT, 2019, PHOTOBIOMODULATION P, V37, P457, DOI 10.1089/photob.2018.4589
   Hayworth CR, 2010, PHOTOCHEM PHOTOBIOL, V86, P673, DOI 10.1111/j.1751 1097.2010.00732.x
   Hsu LF, 2022, J DENT SCI, V17, P331, DOI 10.1016/j.jds.2021.11.015
   Hsu LF, 2018, J PHOTOCH PHOTOBIO B, V186, P41, DOI 10.1016/j.jphotobiol.2018.05.011
   Hung PS, 2010, J DENT RES, V89, P252, DOI 10.1177/0022034509357411
   Kalvelyte AV, 2017, ADV MOLEC TOXICOL, V11, P123, DOI 10.1016/B978 0 12 812522 9.00004 X
   Karu TI, 2010, IUBMB LIFE, V62, P607, DOI 10.1002/iub.359
   Lee JH, 2018, LASER MED SCI, V33, P469, DOI 10.1007/s10103 017 2376 6
   Lekic P, 2001, J PERIODONTAL RES, V36, P71, DOI 10.1034/j.1600 0765.2001.360202.x
   Limpanichkul W, 2006, Orthod Craniofac Res, V9, P38, DOI 10.1111/j.1601 6343.2006.00338.x
   Martirosyan D, 2020, Bioact. Compd. Health Dis., V3, P82
   Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178
   Morganti C, 2019, STEM CELL RES, V40, DOI 10.1016/j.scr.2019.101573
   Niimi H, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00459
   Shimizu S, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 14637 5
   Song JW, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 00553 6
   Tam SY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01255
   Tani A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19071946
   Wang Y, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24043117
   Weiskopf K, 2016, MICROBIOL SPECTR, V4, DOI 10.1128/microbiolspec.MCHD 0031 2016
   Wu Y, 2021, LASER MED SCI, V36, P1535, DOI 10.1007/s10103 021 03278 1
   Xu H, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.835986
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
   Zhang JT, 2008, J CELL PHYSIOL, V217, P518, DOI 10.1002/jcp.21529
   Zheng JY, 2021, BMC ORAL HEALTH, V21, DOI 10.1186/s12903 021 01684 z
NR 42
TC 1
Z9 2
U1 2
U2 8
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N 412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929 6646
EI 1876 0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD APR
PY 2024
VL 123
IS 4
BP 442
EP 451
DI 10.1016/j.jfma.2023.09.011
EA APR 2024
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA RM3T1
UT WOS:001228048000001
PM 37805307
OA gold
DA 2025 08 17
ER

PT J
AU Löfvall, H
   Rothe, M
   Schambach, A
   Henriksen, K
   Richter, J
   Moscatelli, I
AF Loefvall, Henrik
   Rothe, Michael
   Schambach, Axel
   Henriksen, Kim
   Richter, Johan
   Moscatelli, Ilana
TI Hematopoietic Stem Cell Targeted Neonatal Gene Therapy with a Clinically
   Applicable Lentiviral Vector Corrects Osteopetrosis in oc/oc Mice
SO HUMAN GENE THERAPY
LA English
DT Article
DE osteopetrosis; oc; oc; TCIRG1; gene transfer to hematopoietic stem
   cells; lentiviral vectors
ID AUTOSOMAL RECESSIVE OSTEOPETROSIS; TRANSPLANTATION; EXPRESSION; DEFECTS;
   SUBUNIT; MOUSE
AB Infantile malignant osteopetrosis (IMO) is an autosomal recessive disorder characterized by nonfunctional osteoclasts. Approximately 50% of the patients have mutations in the TCIRG1 gene, encoding for a subunit of the osteoclast proton pump. Gene therapy represents a potential alternative treatment to allogeneic stem cell transplantation for IMO. The oc/oc mouse is a model of IMO characterized by a 1,500 bp deletion in the TCIRG1 gene, severe osteopetrosis, and a life span of only 3 weeks. Here we show that the osteopetrotic phenotype in oc/oc mice can be reversed by hematopoietic stem cell targeted gene therapy with a clinically applicable lentiviral vector expressing a wild type form of human TCIRG1 under the mammalian promoter elongation factor 1 alpha short (EFS hT). oc/oc c kit(+) fetal liver cells transduced with EFS hT were transplanted into sublethally irradiated oc/oc mice by temporal vein injection 1 day after birth. A total of 9 of 12 mice survived long term (19 25 weeks) with evidence of tooth eruption, uncharacteristic of oc/oc mice. Splenocytes were harvested 19 25 weeks after transplantation and differentiated into osteoclasts on bone slices to assess resorption and on plastic to assess TCIRG1 protein expression. Vector corrected osteoclasts showed human TCIRG1 expression by Western blot. CTX I release relative to that mediated by oc/oc derived osteoclasts increased 8 239 fold. Resorption pits on bone slices were observed for osteoclasts derived from 7/9 surviving transplanted oc/oc mice. Histopathology of the bones of surviving animals showed varying degrees of rescued phenotype, the majority with almost full correction. The average vector copy number per cell in the bone marrow was 1.8 +/  0.5. Overall, 75% of transplanted mice exhibited long term survival and marked reversal of the osteopetrotic bone phenotype. These findings represent a significant step toward the clinical application of gene therapy for IMO.
C1 [Loefvall, Henrik; Richter, Johan; Moscatelli, Ilana] Lund Univ, Lund Strateg Ctr Stem Cell Biol, Dept Mol Med & Gene Therapy, Lund, Sweden.
   [Loefvall, Henrik; Henriksen, Kim] Nordic Biosci, Dept Endocrinol, Herlev, Denmark.
   [Rothe, Michael; Schambach, Axel] Hannover Med Sch, Inst Expt Hematol, Hannover, Germany.
C3 Lund University; Hannover Medical School
RP Moscatelli, I (通讯作者)，Lund Univ, Dept Mol Med & Gene Therapy, BMC A12, Lund Strateg Ctr Stem Cell Biol, S 22184 Lund, Sweden.
EM ilana.moscatelli@med.lu.se
RI Schambach, Axel/C 5491 2011
OI Lofvall, Henrik/0000 0002 3296 2023
FU Lund University from Rocket Pharmaceuticals (NY, NY); Danish Research
   Foundation (Den Danske Forskningsfond); Lund University Hospital;
   Foundations of Lund University Hospital; European Union
   (FP7Health 2010 CELL PID) [261387]; Marie Curie Initial Training
   Networks (Euroclast, FP7 People 2013 ITN) [607446]; Swedish Foundation
   for Strategic Research
FX This work was supported by a research grant to Lund University from
   Rocket Pharmaceuticals (NY, NY). K.H. is supported by the Danish
   Research Foundation (Den Danske Forskningsfond). J.R. is supported by a
   Clinical Research Award from Lund University Hospital and the
   Foundations of Lund University Hospital. A.S. and M.R. were supported by
   the European Union (FP7Health 2010 CELL PID: no. 261387). H.L. is
   supported by Marie Curie Initial Training Networks (Euroclast,
   FP7 People 2013 ITN: no. 607446). The Lund Stem Cell Center is supported
   by a Center of Excellence grant in life sciences from the Swedish
   Foundation for Strategic Research. The funders had no role in study
   design, data collection and analysis, and decision to publish or
   preparation of the article. Conceptualization: I.M. and J.R.;
   investigation: H.L., M.R., and I.M.; writing original draft: H.L., J.R.,
   and I.M.; writing review and editing: H.L., M.R., A.S., K.H., J.R., and
   I.M.; funding acquisition: J.R.
CR Aiuti A, 2017, EMBO MOL MED, V9, P737, DOI 10.15252/emmm.201707573
   Askmyr M, 2009, CURR GENE THER, V9, P150, DOI 10.2174/156652309788488613
   Blin Wakkach C, 2004, LEUKEMIA, V18, P1505, DOI 10.1038/sj.leu.2403449
   Carbonaro DA, 2014, MOL THER, V22, P607, DOI 10.1038/mt.2013.265
   De Ravin SS, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8856
   De Rijck J, 2013, CELL REP, V5, P886, DOI 10.1016/j.celrep.2013.09.040
   Driessen GJA, 2003, BONE MARROW TRANSPL, V32, P657, DOI 10.1038/sj.bmt.1704194
   Fasth A, 1999, Pediatr Transplant, V3 Suppl 1, P102
   Frattini A, 2000, NAT GENET, V25, P343, DOI 10.1038/77131
   Hacein Bey Abina S, 2003, SCIENCE, V302, P415, DOI 10.1126/science.1088547
   Hacein Bey Abina S, 2003, NEW ENGL J MED, V348, P255, DOI 10.1056/NEJM200301163480314
   Johansson M, 2006, EXP HEMATOL, V34, P242, DOI 10.1016/j.exphem.2005.11.010
   Johansson MK, 2007, BLOOD, V109, P5178, DOI 10.1182/blood 2006 12 061382
   Lorget F, 2000, BIOCHEM BIOPH RES CO, V268, P899, DOI 10.1006/bbrc.2000.2229
   Moscatelli I, 2018, HUM GENE THER, V29, P938, DOI 10.1089/hum.2017.053
   Naldini L, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809958
   Orchard P, 2013, BIOL BLOOD MARROW TR, V19, pS58, DOI 10.1016/j.bbmt.2012.10.026
   Palagano E, 2018, CURR OSTEOPOROS REP, V16, P13, DOI 10.1007/s11914 018 0415 2
   Schulz AS, 2002, BLOOD, V99, P3458, DOI 10.1182/blood.V99.9.3458
   Scimeca JC, 2000, BONE, V26, P207, DOI 10.1016/S8756 3282(99)00278 1
   Segovia Silvestre T, 2009, HUM GENET, V124, P561, DOI 10.1007/s00439 008 0583 8
   Sobacchi C, 2013, NAT REV ENDOCRINOL, V9, P522, DOI 10.1038/nrendo.2013.137
   Taranta A, 2003, AM J PATHOL, V162, P57, DOI 10.1016/S0002 9440(10)63798 4
   Teti A, 2017, BONE, V102, P50, DOI 10.1016/j.bone.2017.02.002
   Thudium CS, 2016, CALCIFIED TISSUE INT, V99, P638, DOI 10.1007/s00223 016 0187 6
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   Wilson CJ, 2000, ARCH DIS CHILD, V83, P449, DOI 10.1136/adc.83.5.449
   Zhou S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062333
   Zhou S, 2010, BLOOD, V116, P900, DOI 10.1182/blood 2009 10 250209
NR 29
TC 18
Z9 21
U1 0
U2 6
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043 0342
EI 1557 7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD NOV 1
PY 2019
VL 30
IS 11
BP 1395
EP 1404
DI 10.1089/hum.2019.047
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
   Experimental Medicine
GA JK9QR
UT WOS:000495173100650
PM 31179768
DA 2025 08 17
ER

PT S
AU Margolis, RN
   Wimalawansa, SI
AF Margolis, Ronald N.
   Wimalawansa, Sunil I.
BE Zaidi, M
TI Novel targets and therapeutics for bone loss
SO SKELETAL DEVELOPMENT AND REMODELING IN HEALTH, DISEASE, AND AGING
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT Conference on Skeletal Development and Remodeling in Health, Disease and
   Aging
CY MAY 18 21, 2005
CL New York, NY
SP NY Acad Sci, Alliance Better Bone Hlth, Procter & Gamble Pharmaceut, Sanofi Aventis, Novartis Pharmaceut Corp, Roche Pharmaceut, Merck & Co
DE osteoporosis; novel therapies; RANKL; OPG; Wnt; leptin; prostaglandins;
   SERMs
ID RANKL; OSTEOBLASTS; PREVENTION; THERAPY
AB Advances in the treatment of osteoporosis over the past decade have resulted in the generation of novel therapeutic agents aimed at providing both anticatabolic and anabolic effects in bone. In depth understanding of the biology of key factors regulating bone metabolism has begun to reveal new approaches to treating this costly and debilitating disease. During the next decade we will observe the development and evolution of several new classes of therapeutic targets and agents to combat this disease.
C1 NIDDKD, Div Diabet Endocrinol & Metab Dis, NIH, Bethesda, MD 20892 USA.
   Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Endocrinol, Dept Med, New Brunswick, NJ 08903 USA.
C3 National Institutes of Health (NIH)   USA; NIH National Institute of
   Diabetes & Digestive & Kidney Diseases (NIDDK); Rutgers University
   System; Rutgers University New Brunswick; Rutgers University Biomedical
   & Health Sciences
RP Margolis, RN (通讯作者)，NIDDKD, Div Diabet Endocrinol & Metab Dis, NIH, 6707 Democracy Blvd,Room 693,Democracy 2, Bethesda, MD 20892 USA.
EM rm76f@nih.gov
RI ; Margolis, Ronald/O 7773 2015
OI Wimalawansa, Prof. Sunil/0000 0003 1096 8595; 
CR AGNUSDEI D, 2000, NEURON INTERACT, V1, P127
   Bennett CN, 2005, P NATL ACAD SCI USA, V102, P3324, DOI 10.1073/pnas.0408742102
   BONNELYE E, 2005, J BIOL CHEM, V280, P3104
   Boyce BF, 2003, KIDNEY INT, V63, pS2, DOI 10.1046/j.1523 1755.63.s85.2.x
   EGHBALIFATOUREC.GZ, N ENGL J MED, V352, P1959
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Ferrari SL, 2005, CURR OPIN LIPIDOL, V16, P207, DOI 10.1097/01.mol.0000162326.62419.e4
   Gallant MA, 2005, J BONE MINER RES, V20, P672, DOI 10.1359/JBMR.041211
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Häusler KD, 2004, J BONE MINER RES, V19, P1873, DOI 10.1359/JBMR.040807
   Holmen SL, 2005, J BIOL CHEM, V280, P21162, DOI 10.1074/jbc.M501900200
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Ito H, 2005, NAT MED, V11, P291, DOI 10.1038/nm1190
   Kennell JA, 2005, J BIOL CHEM, V280, P24004, DOI 10.1074/jbc.M501080200
   Komm BS, 2005, ENDOCRINOLOGY, V146, P3999, DOI 10.1210/en.2005 0030
   Margolis RN, 1996, J CLIN ENDOCR METAB, V81, P872, DOI 10.1210/jc.81.3.872
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   McDonnell DP, 2005, CLIN CANCER RES, V11, p871S
   Nagano N, 2005, J PHARMACOL SCI, V97, P355, DOI 10.1254/jphs.FMJ04007X6
   Qin L, 2004, J BONE MINER RES, V19, pS104
   Reginster JY, 2004, J INTERN MED, V255, P615, DOI 10.1111/j.1365 2796.2004.01292.x
   Rossouw JE, 2002, JAMA J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321
   Wimalawansa SJ, 2000, J BONE MINER RES, V15, P2240, DOI 10.1359/jbmr.2000.15.11.2240
NR 23
TC 7
Z9 8
U1 0
U2 1
PU WILEY BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN STREET, MALDEN 02148, MA USA
SN 0077 8923
BN 1 57331 583 4
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2006
VL 1068
BP 402
EP 409
DI 10.1196/annals.1346.040
PG 8
WC Multidisciplinary Sciences; Orthopedics
WE Conference Proceedings Citation Index   Science (CPCI S); Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Orthopedics
GA BFA92
UT WOS:000240548200040
PM 16831939
DA 2025 08 17
ER

PT J
AU Yang, N
   Sun, HY
   Xue, Y
   Zhang, WC
   Wang, HZ
   Tao, HQ
   Liang, XL
   Li, M
   Xu, YZ
   Chen, L
   Zhang, L
   Huang, LX
   Geng, DC
AF Yang, Ning
   Sun, Houyi
   Xue, Yi
   Zhang, Weicheng
   Wang, Hongzhi
   Tao, Huaqiang
   Liang, Xiaolong
   Li, Meng
   Xu, Yaozeng
   Chen, Liang
   Zhang, Liang
   Huang, Lixin
   Geng, Dechun
TI Inhibition of MAGL activates the Keap1/Nrf2 pathway to attenuate
   glucocorticoid induced osteonecrosis of the femoral head
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Article
DE apoptosis; glucocorticoids; monoacylglycerol lipase; osteonecrosis of
   the femoral head; oxidative stress
ID DEXAMETHASONE INDUCED APOPTOSIS; ENDOCANNABINOID SYSTEM; OSTEOCYTE
   APOPTOSIS; OXIDATIVE STRESS; CELLS; CANNABINOIDS; PROTECTS; TARGETS;
   INJURY; DEATH
AB Glucocorticoids (GCs) are used in treating viral infections, acute spinal cord injury, autoimmune diseases, and shock. Several patients develop GC induced osteonecrosis of the femoral head (ONFH). However, the pathogenic mechanisms underlying GC induced ONFH remain poorly understood. GC directed bone marrow mesenchymal stem cells (BMSCs) fate is an important factor that determines GC induced ONFH. At high concentrations, GCs induce BMSC apoptosis by promoting oxidative stress. In the present study, we aimed to elucidate the molecular mechanisms that relieve GC induced oxidative stress in BMSCs, which would be vital for treating ONFH. The endocannabinoid system regulates oxidative stress in multiple organs. Here, we found that monoacylglycerol lipase (MAGL), a key molecule in the endocannabinoid system, was significantly upregulated during GC treatment in osteoblasts both in vitro and in vivo. MAGL expression was positively correlated with expression of the NADPH oxidase family and apoptosis related proteins. Functional analysis showed that MAGL inhibition markedly reduced oxidative stress and partially rescued BMSC apoptosis. Additionally, in vivo studies indicated that MAGL inhibition effectively attenuated GC induced ONFH. Pathway analysis showed that MAGL inhibition regulated oxidative stress in BMSCs via the Kelch like ECH associated protein 1 (Keap1)/nuclear factor erythroid 2 related factor 2 (Nrf2) pathway. The expression of Nrf2, a major regulator of intracellular antioxidants, was upregulated by inhibiting MAGL. Nrf2 activation can mimic the effect of MAGL inhibition and significantly reduce GC induced oxidative damage in BMSCs. The beneficial effects of MAGL inhibition were attenuated after the blockade of the Keap1/Nrf2 antioxidant signaling pathway. Notably, pharmacological blockade of MAGL conferred femoral head protection in GC induced ONFH, even after oxidative stress responses were initiated. Therefore, MAGL may represent a novel target for the prevention and treatment of GC induced ONFH.
C1 [Yang, Ning; Sun, Houyi; Zhang, Weicheng; Wang, Hongzhi; Tao, Huaqiang; Liang, Xiaolong; Li, Meng; Xu, Yaozeng; Chen, Liang; Huang, Lixin; Geng, Dechun] Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.
   [Xue, Yi] Nanjing Univ Tradit Chinese Med, Changshu Hosp, Dept Orthopaed, Changshu, Jiangsu, Peoples R China.
   [Zhang, Liang] Capital Med Univ, Dept Orthopaed, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
C3 Soochow University   China; Nanjing University of Chinese Medicine;
   Capital Medical University
RP Huang, LX; Geng, DC (通讯作者)，Soochow Univ, Affiliated Hosp 1, Dept Orthopaed, Suzhou 215006, Peoples R China.; Zhang, L (通讯作者)，Capital Med Univ, Dept Orthopaed, Beijing Friendship Hosp, Beijing 100050, Peoples R China.
EM carzl@163.com; bighlx@yeah.net; szgengdc@163.com
RI Xue, Yi/AAN 5026 2021; ning, yang/JDW 5468 2023; Geng,
   Dechun/LMO 1733 2024; Liang, Xiaolong/AAH 3876 2021; Wang,
   Hui/H 2024 2012; Sun, Houyi/HOA 5864 2023
OI GENG, Dechun/0000 0003 4375 2803; Sun, Houyi/0000 0003 0376 368X
FU National Natural Science Foundation of China [82072425, 82072498,
   81873991, 81873990, 81672238]; Research and Development of Biomedical
   Materials and Substitution of Tissue and Organ Repair under the National
   Key RD Program [2016YFC1101505]; Young Medical Talents of Jiangsu
   Province [QNRC2016751]; Natural Science Foundation of Jiangsu Province
   [BK20180001]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (PAPD); Special Project of Diagnosis and
   Treatment for Clinical Diseases of Suzhou [LCZX202003]
FX This research was supported by the National Natural Science Foundation
   of China (82072425, 82072498, 81873991, 81873990 and 81672238), Research
   and Development of Biomedical Materials and Substitution of Tissue and
   Organ Repair under the National Key R&D Program (2016YFC1101505), the
   Young Medical Talents of Jiangsu Province (QNRC2016751), the Natural
   Science Foundation of Jiangsu Province (BK20180001), the Priority
   Academic Program Development of Jiangsu Higher Education Institutions
   (PAPD), and the Special Project of Diagnosis and Treatment for Clinical
   Diseases of Suzhou (LCZX202003).
CR Aymerich MS, 2016, MOL NEUROBIOL, V53, P2312, DOI 10.1007/s12035 015 9213 3
   Bai SC, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9192413
   Barnes NSA, 2016, BRIT J PHARMACOL, V173, P77, DOI 10.1111/bph.13337
   Bellini G, 2017, PHARMACOL RES, V115, P267, DOI 10.1016/j.phrs.2016.11.039
   Bracken MB, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001046.pub2
   Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046
   Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643
   Brewer TF, 2015, ANNU REV BIOCHEM, V84, P765, DOI 10.1146/annurev biochem 060614 034018
   Cao ZX, 2013, GASTROENTEROLOGY, V144, P808, DOI 10.1053/j.gastro.2012.12.028
   Choi SH, 2018, STROKE, V49, P718, DOI 10.1161/STROKEAHA.117.019664
   Cristino L, 2020, NAT REV NEUROL, V16, P9, DOI 10.1038/s41582 019 0284 z
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092 8674(04)00046 7
   DeVuono MV, 2020, PSYCHOPHARMACOLOGY, V237, P2187, DOI 10.1007/s00213 020 05529 5
   Fan JB, 2016, ONCOTARGET, V7, P70613, DOI 10.18632/oncotarget.12138
   Fan Q, 2015, ANN CLIN LAB SCI, V45, P173
   Galán Ganga M, 2020, CELL MOL NEUROBIOL, V40, P167, DOI 10.1007/s10571 019 00719 y
   Gomez O, 2010, GLIA, V58, P1913, DOI 10.1002/glia.21061
   Greenbaum AM, 2012, BLOOD, V120, P295, DOI 10.1182/blood 2011 09 377457
   Guo D, 2012, BIOCHEM BIOPH RES CO, V428, P80, DOI 10.1016/j.bbrc.2012.10.010
   Guo SG, 2017, BIOCHEM BIOPH RES CO, V487, P660, DOI 10.1016/j.bbrc.2017.04.111
   Han DD, 2019, FREE RADICAL BIO MED, V137, P1, DOI 10.1016/j.freeradbiomed.2019.04.014
   Izzo AA, 2010, PHARMACOL THERAPEUT, V126, P21, DOI 10.1016/j.pharmthera.2009.12.005
   Katz PS, 2015, J NEUROTRAUM, V32, P297, DOI 10.1089/neu.2014.3508
   Kim YH, 2012, FREE RADICAL BIO MED, V52, P880, DOI 10.1016/j.freeradbiomed.2011.12.007
   Klahn P, 2020, ANTIBIOTICS BASEL, V9, DOI 10.3390/antibiotics9060297
   Kohnz RA, 2014, CHEM SOC REV, V43, P6859, DOI 10.1039/c4cs00047a
   Kovac S, 2015, BBA GEN SUBJECTS, V1850, P794, DOI 10.1016/j.bbagen.2014.11.021
   Kuang MJ, 2019, INT J BIOL SCI, V15, P1861, DOI 10.7150/ijbs.32262
   Kumar S, 2002, SCIENCE, V297, P1290, DOI 10.1126/science.1076118
   Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312
   Lefaki M, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101317
   Lin C, 2016, SCI REP UK, V6, DOI 10.1038/srep21133
   Liu XY, 2012, MOL CANCER THER, V11, P1421, DOI 10.1158/1535 7163.MCT 12 0026
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Ma L, 2020, FEBS OPEN BIO, V10, P211, DOI 10.1002/2211 5463.12771
   Matono R, 2014, J BIOL CHEM, V289, P24874, DOI 10.1074/jbc.M114.581785
   Matthews AT, 2016, AM J PHYSIOL CELL PH, V311, pC960, DOI 10.1152/ajpcell.00251.2015
   Mishra M, 2014, INVEST OPHTH VIS SCI, V55, P7256, DOI 10.1167/iovs.14 15193
   Mont MA, 2006, J BONE JOINT SURG AM, V88A, P1117, DOI 10.2106/JBJS.E.01041
   Muscarella LA, 2011, EPIGENETICS US, V6, P317, DOI 10.4161/epi.6.3.14408
   Nomura DK, 2011, SCIENCE, V334, P809, DOI 10.1126/science.1209200
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   Oh SY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.114
   Pagano E, 2017, PHARMACOL RES, V119, P227, DOI 10.1016/j.phrs.2017.02.002
   Plotkin LI, 2007, J BIOL CHEM, V282, P24120, DOI 10.1074/jbc.M611435200
   Preet A, 2011, CANCER PREV RES, V4, P65, DOI 10.1158/1940 6207.CAPR 10 0181
   Radhakrishnan R, 2021, DIABETES, V70, P227, DOI 10.2337/db20 0375
   Ren SY, 2020, ACTA PHARMACOL SIN, V41, P1263, DOI 10.1038/s41401 020 0385 7
   Sampaio LS, 2018, BIOCHEM PHARMACOL, V154, P482, DOI 10.1016/j.bcp.2018.06.005
   Serrano A, 2018, NEUROPSYCHOPHARMACOL, V43, P1840, DOI 10.1038/s41386 018 0055 3
   Sharkey KA, 2016, GASTROENTEROLOGY, V151, P252, DOI 10.1053/j.gastro.2016.04.015
   Shen A, 2018, CELL DEATH DIS, V10, DOI 10.1038/s41419 018 1252 z
   Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959
   Shoemaker JL, 2005, J PHARMACOL EXP THER, V315, P828, DOI 10.1124/jpet.105.089474
   Singel KL, 2016, CLIN SCI, V130, P479, DOI 10.1042/CS20150660
   Sticht MA, 2019, BRIT J PHARMACOL, V176, P1524, DOI 10.1111/bph.14453
   Sugishima M, 2020, ANTIOXIDANTS BASEL, V9, DOI 10.3390/antiox9080673
   Tamura R, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 19845 6
   Tao SC, 2017, THERANOSTICS, V7, P733, DOI 10.7150/thno.17450
   Tolba MF, 2017, TOXICOL APPL PHARM, V324, P26, DOI 10.1016/j.taap.2017.03.021
   Wang HY, 2012, CYTOTHERAPY, V14, P423, DOI 10.3109/14653249.2011.652735
   Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006
   Xiong YQ, 2018, BIOCHEM BIOPH RES CO, V506, P578, DOI 10.1016/j.bbrc.2018.10.098
   Xu YX, 2020, STEM CELL RES, V48, DOI 10.1016/j.scr.2020.101954
   Yang Y, 2021, CANCER SCI, V112, P641, DOI 10.1111/cas.14744
   Yin J, 2018, PHARMACOL REP, V70, P270, DOI 10.1016/j.pharep.2017.11.001
   Zamaraev AV, 2017, TRENDS CELL BIOL, V27, P322, DOI 10.1016/j.tcb.2017.01.003
   Zhang MZ, 2019, LIFE SCI, V230, P55, DOI 10.1016/j.lfs.2019.05.056
   Zhao Q, 2005, J BIOL CHEM, V280, P26735, DOI 10.1074/jbc.M412828200
   Zhen YF, 2014, J CELL PHYSIOL, V229, P1475, DOI 10.1002/jcp.24589
   Zheng LZ, 2018, J ORTHOP TRANSL, V13, P13, DOI 10.1016/j.jot.2018.01.003
NR 71
TC 49
Z9 57
U1 2
U2 25
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001 1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD JUN
PY 2021
VL 11
IS 6
AR e447
DI 10.1002/ctm2.447
PG 19
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA TB2YW
UT WOS:000667815600008
PM 34185425
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ahmad, M
   Kroll, T
   Jakob, J
   Rauch, A
   Ploubidou, A
   Tuckermann, J
AF Ahmad, Mubashir
   Kroll, Torsten
   Jakob, Jeanette
   Rauch, Alexander
   Ploubidou, Aspasia
   Tuckermann, Jan
TI Cell based RNAi screening and high content analysis in primary calvarian
   osteoblasts applied to identification of osteoblast differentiation
   regulators
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; BONE FORMATION;
   IN VITRO; GROWTH FACTOR; CULTURE; OSTEOPOROSIS; PHENOTYPE; OSTEOCYTE;
   DISEASE
AB Osteoblasts are responsible for the maintenance of bone homeostasis. Deregulation of their differentiation is etiologically linked to several bone disorders, making this process an important target for therapeutic intervention. Systemic identification of osteoblast regulators has been hampered by the unavailability of physiologically relevant in vitro systems suitable for efficient RNAi and for differentiation read outs compatible with fluorescent microscopy based high content analysis (HCA). Here, we report a new method for identification of osteoblast differentiation regulators by combining siRNA transfection in physiologically relevant cells with high throughput screening (HTS). Primary mouse calvarial osteoblasts were seeded in 384 well format and reverse transfected with siRNAs and their cell number and differentiation was assayed by HCA. Automated image acquisition allowed high throughput analyses and classification of single cell features. The physiological relevance, reproducibility, and sensitivity of the method were validated using known regulators of osteoblast differentiation. The application of HCA to siRNAs against expression of 320 genes led to the identification of five potential suppressors and 60 activators of early osteoblast differentiation. The described method and the associated analysis pipeline are not restricted to RNAi based screening, but can be adapted to large scale drug HTS or to small scale targeted experiments, to identify new critical factors important for early osteoblastogenesis.
C1 [Ahmad, Mubashir; Tuckermann, Jan] Ulm Univ, Inst Comparat Mol Endocrinol CME, Helmholtzstr 8 1, D 89081 Ulm, Germany.
   [Kroll, Torsten; Jakob, Jeanette; Rauch, Alexander; Ploubidou, Aspasia; Tuckermann, Jan] Fritz Lipmann Inst, Leibniz Inst Aging, Beutenbergstr 11, D 07745 Jena, Germany.
C3 Ulm University; Leibniz Association; Leibniz Institut fur
   Alternsforschung   Fritz Lipmann Institut (FLI)
RP Tuckermann, J (通讯作者)，Ulm Univ, Inst Comparat Mol Endocrinol CME, Helmholtzstr 8 1, D 89081 Ulm, Germany.; Tuckermann, J (通讯作者)，Fritz Lipmann Inst, Leibniz Inst Aging, Beutenbergstr 11, D 07745 Jena, Germany.
EM jan.tuckermann@uni ulm.de
RI ; Rauch, Alexander/AAY 5235 2021; Ahmad, Mubashir/HHS 0865 2022
OI Rauch, Alexander/0000 0002 9429 7356; Ahmad,
   Mubashir/0000 0001 9012 4039; Tuckermann, Jan/0000 0003 3691 275X
FU Animal House, Functional Genomics and Imaging Core Facilities of the
   FLI; Federal Government of Germany; State of Thuringia; "PAKT fur
   Forschung und Innovation 2010 (LeibnizAgeNet: signaling pathways in
   age related diseases)", DFG Collaborative research Centre
   [C02/InSt40/492 1]; DFG [tu 220/12 1, Tu 220/14 1, Tu 220/15 1];
   Boehringer Ingelheim Foundation
FX The support of the Animal House, Functional Genomics and Imaging Core
   Facilities of the FLI is gratefully acknowledged, in particular the
   expert assistance of Dominique Galendo and Frank Kaufmann. The FLI is a
   member of the Leibniz Association and is financially supported by the
   Federal Government of Germany and the State of Thuringia. We are
   grateful to Thomas Neidlinger of the Animal Facility at Ulm University.
   We thank Numana Bhat, Dr. Giorgio Caratti and Dr. Ann Kristin Picke for
   critical reading of the manuscript. This work was supported by grants
   from "PAKT fur Forschung und Innovation 2010 (LeibnizAgeNet: signaling
   pathways in age related diseases)", DFG Collaborative research Centre
   1149, C02/InSt40/492 1, DFG trilateral Consortium tu 220/12 1, DFG Tu
   220/14 1, DFG Tu 220/15 1 and from the "Boehringer Ingelheim
   Foundation".
CR Aenlle KK, 2014, MOL ENDOCRINOL, V28, P722, DOI 10.1210/me.2013 1286
   Américo Da Silva L, 2018, FASEB J, V32, P4681, DOI 10.1096/fj.201701229RR
   Birmingham A, 2009, NAT METHODS, V6, P569, DOI 10.1038/nmeth.1351
   Birmingham E, 2012, EUR CELLS MATER, V23, P13, DOI 10.22203/eCM.v023a02
   Boufker HI, 2010, BMC CANCER, V10, DOI 10.1186/1471 2407 10 298
   Boutros M, 2015, CELL, V163, P1314, DOI 10.1016/j.cell.2015.11.007
   CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277
   COUTLEE F, 1989, J CLIN MICROBIOL, V27, P1002, DOI 10.1128/JCM.27.5.1002 1007.1989
   Czekanska EM, 2012, EUR CELLS MATER, V24, P1
   Darcy A, 2012, BONE, V50, P1294, DOI 10.1016/j.bone.2012.03.001
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025
   Giuliani N, 2006, BLOOD, V108, P3992, DOI 10.1182/blood 2006 05 026112
   Glorieux FH, 2001, LANCET, pS45
   Greenfield Edward M, 2012, Curr Mol Pharmacol, V5, P127
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Gresch O, 2012, METHODS MOL BIOL, V801, P65, DOI 10.1007/978 1 61779 352 3_5
   Jaiswal N, 1997, J CELL BIOCHEM, V64, P295, DOI 10.1002/(SICI)1097 4644(199702)64:2<295::AID JCB12>3.3.CO;2 6
   Jonason JH, 2014, METHODS MOL BIOL, V1130, P295, DOI 10.1007/978 1 62703 989 5_22
   Kaabeche K, 2004, J BIOL CHEM, V279, P36259, DOI 10.1074/jbc.M402469200
   Kamentsky L, 2011, BIOINFORMATICS, V27, P1179, DOI 10.1093/bioinformatics/btr095
   Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756 3282(99)00111 8
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kroll Torsten, 2016, Curr Protoc Cytom, V77, DOI 10.1002/cpcy.7
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Li Q, 2016, SCI REP UK, V6, DOI 10.1038/srep27566
   Liu CJ, 2005, J BIOL CHEM, V280, P2788, DOI 10.1074/jbc.M412604200
   Liu P, 2017, CELL DEATH DIFFER, V24, P672, DOI 10.1038/cdd.2016.165
   Liu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11149
   Lyu Q., 2017, Therapeutic potential of nucleic acid aptamers against sclerostin in the treatment of osteoporosis
   MacNabb C, 2016, J OSTEOPOROS, V2016, DOI 10.1155/2016/6217286
   Manjunath N, 2009, ADV DRUG DELIVER REV, V61, P732, DOI 10.1016/j.addr.2009.03.004
   Marie PJ, 2015, CELL MOL LIFE SCI, V72, P1347, DOI 10.1007/s00018 014 1801 2
   Marzia M, 2000, J CELL BIOL, V151, P311, DOI 10.1083/jcb.151.2.311
   McClung MR, 2017, THER ADV MUSCULOSKEL, V9, P263, DOI 10.1177/1759720X17726744
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Osagie Clouard L, 2017, BONE JOINT RES, V6, P14, DOI 10.1302/2046 3758.61.BJR 2016 0085.R1
   Peruzzi B, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1651
   Qiang YW, 2006, BLOOD, V108, p979A, DOI 10.1182/blood.V108.11.3429.3429
   QUARLES LD, 1992, J BONE MINER RES, V7, P683
   Rauch A, 2011, FASEB J, V25, P1323, DOI 10.1096/fj.10 173393
   Rauch A, 2010, CELL METAB, V11, P517, DOI 10.1016/j.cmet.2010.05.005
   Shearer RF, 2015, GENES CELLS, V20, P1, DOI 10.1111/gtc.12183
   Sheehan D., 2013, Physical biochemistry principles and applications
   Siffert R. S., 1951, Journal of Experimental Medicine, V93, P415, DOI 10.1084/jem.93.5.415
   Siggelkow H, 1999, J CELL BIOCHEM, V75, P22, DOI 10.1002/(SICI)1097 4644(19991001)75:1<22::AID JCB3>3.3.CO;2 Y
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Subbiah V, 2010, OSTEOPOROSIS INT, V21, P1041, DOI 10.1007/s00198 009 1004 0
   Takeuchi Y, 2002, J BIOL CHEM, V277, P49011, DOI 10.1074/jbc.M207804200
   Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80
   Westendorf JJ, 2004, GENE, V341, P19, DOI 10.1016/j.gene.2004.06.044
   Zhao LG, 2014, CARBOHYD POLYM, V111, P714, DOI 10.1016/j.carbpol.2014.05.001
   Zhao XK, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 04317 0
   Zou WG, 2013, J EXP MED, V210, P1793, DOI 10.1084/jem.20111790
NR 54
TC 10
Z9 11
U1 1
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 19
PY 2018
VL 8
AR 14045
DI 10.1038/s41598 018 32364 8
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GU1NR
UT WOS:000445031200028
PM 30232406
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Huang, CL
   Xue, M
   Chen, HL
   Jiao, J
   Herschman, HR
   O'Keefe, RJ
   Zhang, XP
AF Huang, Chunlan
   Xue, Ming
   Chen, Hongli
   Jiao, Jing
   Herschman, Harvey R.
   O'Keefe, Regis J.
   Zhang, Xinping
TI The Spatiotemporal Role of COX 2 in Osteogenic and Chondrogenic
   Differentiation of Periosteum Derived Mesenchymal Progenitors in
   Fracture Repair
SO PLOS ONE
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; HYPOXIA INDUCIBLE FACTOR 1 ALPHA;
   CHONDROCYTE DIFFERENTIATION; BONE FORMATION; OSTEOBLAST DIFFERENTIATION;
   PROSTAGLANDIN E 2; STEM CELLS; BMP2 ACTIVITY; PATHWAY; MICE
AB Periosteum provides a major source of mesenchymal progenitor cells for bone fracture repair. Combining cell specific targeted Cox 2 gene deletion approaches with in vitro analyses of the differentiation of periosteum derived mesenchymal progenitor cells (PDMPCs), here we demonstrate a spatial and temporal role for Cox 2 function in the modulation of osteogenic and chondrogenic differentiation of periosteal progenitors in fracture repair. Prx1Cre targeted Cox 2 gene deletion in mesenchyme resulted in marked reduction of intramembraneous and endochondral bone repair, leading to accumulation of poorly differentiated mesenchyme and immature cartilage in periosteal callus. In contrast, Col2Cre targeted Cox 2 gene deletion in cartilage resulted in a deficiency primarily in cartilage conversion into bone. Further cell culture analyses using Cox 2 deficient PDMPCs demonstrated reduced osteogenic differentiation in monolayer cultures, blocked chondrocyte differentiation and hypertrophy in high density micromass cultures. Gene expression microarray analyses demonstrated downregulation of a key set of genes associated with bone/cartilage formation and remodeling, namely Sox9, Runx2, Osx, MMP9, VDR and RANKL. Pathway analyses demonstrated dysregulation of the HIF 1, PI3K AKT and Wnt pathways in Cox 2 deficient cells. Collectively, our data highlight a crucial role for Cox 2 from cells of mesenchymal lineages in modulating key pathways that control periosteal progenitor cell growth, differentiation, and angiogenesis in fracture repair.
C1 [Huang, Chunlan; Xue, Ming; Chen, Hongli; O'Keefe, Regis J.; Zhang, Xinping] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14627 USA.
   [Jiao, Jing; Herschman, Harvey R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
C3 University of Rochester; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Zhang, XP (通讯作者)，Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14627 USA.
EM Xinping_Zhang@URMC.rochester.edu
RI Chen, Hongli/KLY 3077 2024; Jiao, Jing/F 5354 2015
FU Musculoskeletal Transplant Foundation; NYSTEM [N08G 495, N09G346];
   National Institutes of Health [R21 DE021513, RC1 AR058435, AR R01
   AR048681, P50 AR054041]
FX This study is supported by grants from the Musculoskeletal Transplant
   Foundation (XPZ), NYSTEM N08G 495 (XPZ) and N09G346 (XPZ), and the
   National Institutes of Health (R21 DE021513 to XPZ, RC1 AR058435 to XPZ,
   AR R01 AR048681 to XPZ and RJO, P50 AR054041 to RJO). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Agarwal S, 2009, EXPERT REV CLIN IMMU, V5, P145, DOI 10.1586/1744666X.5.2.145
   Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104
   ALLEN HL, 1980, ACTA ORTHOP SCAND, V51, P595, DOI 10.3109/17453678008990848
   ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Barnes GL, 1999, J BONE MINER RES, V14, P1805, DOI 10.1359/jbmr.1999.14.11.1805
   Chappuis V, 2012, BONE, V51, P800, DOI 10.1016/j.bone.2012.07.017
   Chen Y, 2007, PLOS MED, V4, P1216, DOI 10.1371/journal.pmed.0040249
   Chen Y, 2009, J CELL BIOCHEM, V106, P353, DOI 10.1002/jcb.22020
   Colnot C, 2012, J ORTHOP RES, V30, P1869, DOI 10.1002/jor.22181
   Dao DY, 2012, J BONE MINER RES, V27, P1680, DOI 10.1002/jbmr.1639
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002
   EYREBROOK AL, 1984, CLIN ORTHOP RELAT R, P300
   Gaur T, 2009, J CELL PHYSIOL, V220, P174, DOI 10.1002/jcp.21747
   Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435
   Gerstenfeld LC, 2003, J ORTHOP RES, V21, P670, DOI 10.1016/S0736 0266(03)00003 2
   Gerstenfeld Louis C, 2004, Expert Opin Drug Saf, V3, P131, DOI 10.1517/14740338.3.2.131
   Huang C, 2013, MOL THER
   Ishikawa T, 2006, GENESIS, V44, P143, DOI 10.1002/gene.20192
   Ivan M, 2002, P NATL ACAD SCI USA, V99, P13459, DOI 10.1073/pnas.192342099
   Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796
   Kellinsalmi M, 2007, EUR J PHARMACOL, V572, P102, DOI 10.1016/j.ejphar.2007.06.030
   Lau KHW, 2013, BONE, V53, P369, DOI 10.1016/j.bone.2013.01.003
   Lee CM, 2007, J CELL PHYSIOL, V212, P182, DOI 10.1002/jcp.21017
   Lee CM, 2010, J BONE MINER METAB, V28, P8, DOI 10.1007/s00774 009 0096 0
   Li CJ, 2011, BONE, V48, P286, DOI 10.1016/j.bone.2010.09.020
   Li X, 2002, BONE, V30, P567, DOI 10.1016/S8756 3282(02)00683 X
   Malizos KN, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.07.030
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   MCKIBBIN B, 1978, J BONE JOINT SURG BR, V60, P150, DOI 10.1302/0301 620X.60B2.350882
   MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092 8674(95)90125 6
   Mukherjee A, 2010, MOL CELL BIOL, V30, P1018, DOI 10.1128/MCB.01401 09
   Mukherjee A, 2009, J CELL SCI, V122, P716, DOI 10.1242/jcs.042770
   Naik AA, 2009, J BONE MINER RES, V24, P251, DOI [10.1359/jbmr.081002, 10.1359/JBMR.081002]
   Ninomiya T, 2011, EUR J PHARMACOL, V650, P396, DOI 10.1016/j.ejphar.2010.10.021
   Paralkar VM, 2003, P NATL ACAD SCI USA, V100, P6736, DOI 10.1073/pnas.1037343100
   Regard JB., 2012, Cold Spring Harb Perspect Biol, V4
   Riley EH, 1996, CLIN ORTHOP RELAT R, P39, DOI 10.1097/00003086 199603000 00006
   Robertson G, 2006, BONE, V39, P767, DOI 10.1016/j.bone.2006.04.006
   Schipani E, 2001, GENE DEV, V15, P2865
   Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035
   Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105
   Wang JH, 2013, BONE, V57, P311, DOI 10.1016/j.bone.2013.08.015
   Wang Q, 2011, BONE, V48, P524, DOI 10.1016/j.bone.2010.10.178
   Wang Q, 2010, AM J PATHOL, V177, P3100, DOI 10.2353/ajpath.2010.100060
   Wang YJ, 2005, J BONE MINER RES, V20, P1624, DOI 10.1359/JBMR.050516
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yaqub Sheraz, 2008, Critical Reviews in Oncogenesis, V14, P57
   Zhang QZ, 2009, J IMMUNOL, V183, P7787, DOI 10.4049/jimmunol.0902318
   Zhang XP, 2004, BONE, V34, P809, DOI 10.1016/j.bone.2003.12.026
   Zhang XP, 2005, J BONE MINER RES, V20, P2124, DOI 10.1359/JBMR.050806
   Zhao LX, 2012, J CELL MOL MED, V16, P1840, DOI 10.1111/j.1582 4934.2011.01479.x
   Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693
   Zuscik MJ, 2008, J CLIN INVEST, V118, P429, DOI 10.1172/JCI34174
NR 56
TC 25
Z9 30
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2014
VL 9
IS 7
AR e100079
DI 10.1371/journal.pone.0100079
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA AO5BA
UT WOS:000341354100023
PM 24988184
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Penolazzi, L
   Pocaterra, B
   Tavanti, E
   Lambertini, E
   Vesce, F
   Gambari, R
   Piva, R
AF Penolazzi, Letizia
   Pocaterra, Barbara
   Tavanti, Elisa
   Lambertini, Elisabetta
   Vesce, Fortunato
   Gambari, Roberto
   Piva, Roberta
TI Human osteoclasts differentiated from umbilical cord blood precursors
   are less prone to apoptotic stimuli than osteoclasts from peripheral
   blood
SO APOPTOSIS
LA English
DT Article
DE osteoclasts; transcription factor decoy; apoptosis; estrogen receptor
ID ESTROGEN RECEPTOR ALPHA; TRANSCRIPTION FACTORS; CELL PROLIFERATION; RANK
   LIGAND; EXPRESSION; INDUCTION; SURVIVAL; ACTIVATION
AB Osteoclasts (OCs) are specialized bone resorbing cells. For "in vitro" analysis, they may be obtained from the precursors present in peripheral blood (PB) or umbilical cord blood (UCB), but there has been no detailed analysis of how the kind of source and cell culture conditions may affect the behavior of these cells. Here we analyzed the behavior of OCs after transfection with specific transcription factor decoy molecules founding that the OCs from PB undergo apoptosis when nuclear factor kappa B (NF kB) or NFATc1 were removed, or when ER alpha expression was increased. Conversely, OCs from UCB showed a strong resistance to apoptotic stimuli. We found that survival signals including Bcl 2, Bcl XL, and Survivin are present in the OCs/UCB, but not in OCs/PB. The resistance to apoptosis seems to be not correlated with NF kB, NFATc1, or ER alpha expression level, or with the activation of ERK and Akt proteins. One of the mechanisms responsible for bone remodeling is apoptosis, and being susceptible of therapeutic manipulation, the OCs are extensively employed to investigate cell response to therapies for the treatment of bone loss associated with several diseases, including periodontitis, osteoporosis, and metastatic osteolysis. Therefore, our evidences are to be taken in consideration when both the effects of biological modifiers are tested and OCs apoptosis molecular mechanisms are investigated.
C1 [Penolazzi, Letizia; Pocaterra, Barbara; Tavanti, Elisa; Lambertini, Elisabetta; Gambari, Roberto; Piva, Roberta] Univ Ferrara, Mol Biol Sect, Dept Biochem & Mol Biol, I 44100 Ferrara, Italy.
   [Vesce, Fortunato] Univ Ferrara, Sect Obstet & Gynaecol Clin, Dept Biomed Sci & Adv Therapies, I 44100 Ferrara, Italy.
C3 University of Ferrara; University of Ferrara
RP Piva, R (通讯作者)，Univ Ferrara, Mol Biol Sect, Dept Biochem & Mol Biol, Via Fossato Mortara 74, I 44100 Ferrara, Italy.
EM piv@unife.it
RI Vesce, Fortunato/GRO 3320 2022; Gambari, Roberto/F 9555 2015
OI Penolazzi, Letizia/0000 0002 1293 5087; Piva,
   Roberta/0000 0003 2663 6210; Gambari, Roberto/0000 0001 9205 6033
CR Ahn KS, 2007, BLOOD, V110, P2286, DOI 10.1182/blood 2007 04 084996
   Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Atkins GJ, 2006, J BONE MINER RES, V21, P1339, DOI 10.1359/JBMR.060604
   Bharti AC, 2004, J BIOL CHEM, V279, P6065, DOI 10.1074/jbc.M308062200
   Bharti AC, 2004, APOPTOSIS, V9, P677, DOI 10.1023/B:APPT.0000045780.10463.c6
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brandwood CP, 2003, J PATHOL, V201, P504, DOI 10.1002/path.1463
   Bruzzaniti A, 2006, REV ENDOCR METAB DIS, V7, P123, DOI 10.1007/s11154 006 9009 x
   Day CJ, 2005, J CELL BIOCHEM, V95, P17, DOI 10.1002/jcb.20410
   Del Fattore A, 2008, ARCH BIOCHEM BIOPHYS, V473, P147, DOI 10.1016/j.abb.2008.01.011
   Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365 2141.2000.01986.x
   Evans CE, 2006, BMC MUSCULOSKEL DIS, V7, DOI 10.1186/1471 2474 7 21
   FELIX R, 1994, J CELL BIOCHEM, V55, P340, DOI 10.1002/jcb.240550311
   Gao HH, 2006, MOL PHARMACOL, V70, P1621, DOI 10.1124/mol.106.024273
   Gingery A, 2003, J CELL BIOCHEM, V89, P165, DOI 10.1002/jcb.10503
   Glantschnig H, 2003, CELL DEATH DIFFER, V10, P1165, DOI 10.1038/sj.cdd.4401285
   Hentunen TA, 1998, J CLIN INVEST, V102, P88, DOI 10.1172/JCI2004
   Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946
   Hodge JM, 2007, J CELL BIOCHEM, V102, P759, DOI 10.1002/jcb.21331
   Lamoureux F, 2007, CANCER RES, V67, P7308, DOI 10.1158/0008 5472.CAN 06 4130
   Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459
   Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Penolazzi L, 2004, INT J MOL MED, V14, P145
   Penolazzi L, 2007, MOL PHARMACOL, V71, P1457, DOI 10.1124/mol.107.034561
   Piva R, 2005, APOPTOSIS, V10, P1079, DOI 10.1007/s10495 005 0618 8
   Piva R, 2006, ANN NY ACAD SCI, V1091, P509, DOI 10.1196/annals.1378.092
   Quinn JMW, 1998, ENDOCRINOLOGY, V139, P4424, DOI 10.1210/endo.139.10.6331
   Sevilla L, 2001, J BIOL CHEM, V276, P17800, DOI 10.1074/jbc.M008270200
   Shin S, 2001, BIOCHEMISTRY US, V40, P1117, DOI 10.1021/bi001603q
   Stern PH, 2007, J CELL BIOCHEM, V101, P1087, DOI 10.1002/jcb.21311
   Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217
   Sun B, 2007, BIOCHEM BIOPH RES CO, V357, P92, DOI 10.1016/j.bbrc.2007.03.072
   Tamm I, 1998, CANCER RES, V58, P5315
   TANAKA S, 1993, J CLIN INVEST, V91, P257, DOI 10.1172/JCI116179
   Tanaka S, 2007, AM J NEPHROL, V27, P466, DOI 10.1159/000106484
   VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Zaidi M, 2007, NAT MED, V13, P791, DOI 10.1038/nm1593
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 41
TC 6
Z9 7
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360 8185
EI 1573 675X
J9 APOPTOSIS
JI Apoptosis
PD APR
PY 2008
VL 13
IS 4
BP 553
EP 561
DI 10.1007/s10495 008 0188 7
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 278QW
UT WOS:000254302400008
PM 18307044
DA 2025 08 17
ER

PT J
AU Gunaratnam, K
   Vidal, C
   Gimble, JM
   Duque, G
AF Gunaratnam, Krishanthi
   Vidal, Christopher
   Gimble, Jeffrey M.
   Duque, Gustavo
TI Mechanisms of Palmitate Induced Lipotoxicity in Human Osteoblasts
SO ENDOCRINOLOGY
LA English
DT Article
ID PROTEIN PALMITOYLATION; BONE MARROW; ACID; OSTEOPOROSIS; ADIPOCYTE;
   FRACTURE; RISK
AB The interest in the relationship between fat and bone has increased steadily during recent years. Fat could have a lipotoxic effect on bone cells through the secretion of fatty acids. Palmitate is the most prevalent fatty acid secreted by adipocytes in vitro. Considering that palmitate has shown a high lipotoxic effect in other tissues, here we characterized the lipotoxic effect of palmitate on human osteoblasts (Obs). Initially we tested for changes in palmitoylation in this model. Subsequently we compared the capacity of Obs to differentiate and form bone nodules in the presence of palmitate. From a mechanistic approach, we assessed changes in nuclear activity of beta catenin and runt related transcription factor 2 (Runx2)/phosphorylated mothers against decapentaplegic (Smad) complexes using Western blotting and confocal microscopy. Quantitative real time PCR showed negative changes in gene expression of palmitoyltransferase genes. Furthermore, palmitate negatively affected differentiation and bone nodule formation and mineralization by Obs. Although the expression of beta catenin in palmitate treated cells was not affected, there was a significant reduction in the transcriptional activities of both beta catenin and Runx2. Confocal microscopy showed that whereas Runx2 and Smad 4 and  5 complex formation was increased in bone morphogenetic protein 2 treated cells, palmitate had a negative effect on protein expression and colocalization of these factors. In summary, in this study we identified potential mechanisms of palmitate induced lipotoxicity, which include changes in palmitoylation, defective mineralization, and significant alterations in the beta catenin and Runx2/Smad signaling pathways. Our evidence facilitates the understanding of the relationship between fat and bone and could allow the development of new potential therapies for osteoporosis in older persons.
C1 [Gunaratnam, Krishanthi; Vidal, Christopher; Duque, Gustavo] Univ Sydney, Sydney Med Sch Nepean, Ageing Bone Res Program, Penrith, NSW 2750, Australia.
   [Gimble, Jeffrey M.] Tulane Univ, Ctr Stem Cell Res & Regenerat Med, New Orleans, LA 70118 USA.
C3 University of Sydney; Tulane University
RP Duque, G (通讯作者)，Nepean Hosp, Sydney Med Sch Nepean, Level 5,South Block, Penrith, NSW 2750, Australia.
EM gustavo.duque@sydney.edu.au
RI Duque, Gustavo/G 6656 2015; Duque, Gustavo/HDO 1243 2022
OI Duque, Gustavo/0000 0001 8126 0637; 
FU Australian National Health and Medical Research Council [632767]; Nepean
   Medical Research Foundation
FX This work was supported by the Australian National Health and Medical
   Research Council (Grant 632767) and the Nepean Medical Research
   Foundation.
CR Aicart Ramos C, 2011, BBA BIOMEMBRANES, V1808, P2981, DOI 10.1016/j.bbamem.2011.07.009
   Bain G, 2003, BIOCHEM BIOPH RES CO, V301, P84, DOI 10.1016/S0006 291X(02)02951 0
   Comeau JWD, 2006, BIOPHYS J, V91, P4611, DOI 10.1529/biophysj.106.089441
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Farina EK, 2011, J NUTR, V141, P1146, DOI 10.3945/jn.110.133728
   Gasparrini M, 2009, EXP GERONTOL, V44, P613, DOI 10.1016/j.exger.2009.05.009
   Giacca A, 2011, AM J PHYSIOL ENDOC M, V300, pE255, DOI 10.1152/ajpendo.00416.2010
   Gimble JM, 2012, CLIN BIOCHEM, V45, P874, DOI 10.1016/j.clinbiochem.2012.03.006
   Griffith JF, 2009, BONE, V44, P1092, DOI 10.1016/j.bone.2009.02.022
   Khosla S, 2008, J CLIN INVEST, V118, P421, DOI 10.1172/JCI33612
   Kim JE, 2008, BONE, V43, P394, DOI 10.1016/j.bone.2008.03.021
   Kusminski CM, 2009, APOPTOSIS, V14, P1484, DOI 10.1007/s10495 009 0352 8
   Lecka Czernik B, 2002, ENDOCRINOLOGY, V143, P2376, DOI 10.1210/en.143.6.2376
   Leong WF, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004135
   Lian JB, 2006, REV ENDOCR METAB DIS, V7, P1, DOI 10.1007/s11154 006 9001 5
   Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   McCarthy TL, 2010, MOL ENDOCRINOL, V24, P587, DOI 10.1210/me.2009 0379
   Ng A., 2010, BONEKEY OSTEOVISION, V7, P108, DOI [10.1138/20100435, DOI 10.1138/20100435]
   Nguyen ND, 2007, J CLIN ENDOCR METAB, V92, P955, DOI 10.1210/jc.2006 1476
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sepe A, 2011, GERONTOLOGY, V57, P66, DOI 10.1159/000279755
   Unger RH, 2002, ANNU REV MED, V53, P319, DOI 10.1146/annurev.med.53.082901.104057
   Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003 0870
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Xiao Y, 2011, NUTRITION, V27, P214, DOI 10.1016/j.nut.2009.11.012
NR 28
TC 92
Z9 100
U1 1
U2 8
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0013 7227
EI 1945 7170
J9 ENDOCRINOLOGY
JI Endocrinology
PD JAN
PY 2014
VL 155
IS 1
BP 108
EP 116
DI 10.1210/en.2013 1712
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 279NU
UT WOS:000328967500016
PM 24169557
OA Bronze
DA 2025 08 17
ER

PT J
AU Wang, B
   Shao, WK
   Zhao, YB
   Li, ZL
   Wang, P
   Lv, X
   Chen, YJ
   Chen, XD
   Zhu, YX
   Ma, Y
   Han, LZ
   Wu, W
   Feng, Y
AF Wang, Bo
   Shao, Wenkai
   Zhao, Yubai
   Li, Zilin
   Wang, Ping
   Lv, Xiao
   Chen, Yongjin
   Chen, Xiaodong
   Zhu, Yuanxiao
   Ma, Yan
   Han, Lizhi
   Wu, Wen
   Feng, Yong
TI Radial extracorporeal shockwave promotes osteogenesis angiogenesis
   coupling of bone marrow stromal cells from senile osteoporosis via
   activating the Piezo1/CaMKII/CREB axis
SO BONE
LA English
DT Article
DE Senile osteoporosis; Radial extracorporeal shockwave; Bone marrow
   stromal cells; Piezo1
ID WAVE THERAPY; OSTEOBLAST DIFFERENTIATION; STEM CELLS; CALMODULIN
AB Radial extracorporeal shockwave (r ESW) and bone marrow stromal cells (BMSCs) have been reported to alleviate senile osteoporosis (SOP), but its regulatory mechanism remains unclear. In this study, we firstly isolated human BMSCs from bone marrow samples and treated with varying r ESW doses. And we found that r ESW could enhance the proliferation of SOP BMSCs in a dose dependent manner by EdU assay. Subsequently, the impact of r ESW on the proliferation, apoptosis and multipotency of BMSCs was assessed. And the outcomes of flow cytometry, Alizarin red S (ARS), and tube formation test demonstrated that the optimal shockwave obviously boosted SOP BMSCs osteogenesis and angiogenesis but exhibited no significant impact on cell apoptosis. Additionally, the signaling of Piezo1 and CaMKII/CREB was examined by Western blotting, qPCR and immunofluorescence. And the results showed that r ESW promoted the expression of Piezo1, increased intracellular Ca2+ and activated the CaMKII/CREB signaling pathway. Then, the application of Piezo1 siRNA hindered the r ESWinduced enhancement ability of osteogenesis coupling with angiogenesis of SOP BMSCs. The use of the CaMKII/ CREB signaling pathway inhibitor KN93 suppressed the Piezo1 induced increase in osteogenesis and angiogenesis in SOP BMSCs. Finally, we also found that r ESW might alleviate SOP in the senescence accelerated mouse prone 6 (SAMP6) model by activating Piezo1. In conclusion, our research offers experimental evidence and an elucidated underlying molecular mechanism to support the use of r ESW as a credible rehabilitative treatment for senile osteoporosis.
C1 [Wang, Bo; Zhao, Yubai; Wu, Wen] Southern Med Univ, Zhujiang Hosp, Dept Rehabil, Guangzhou 510282, Peoples R China.
   [Wang, Bo; Chen, Yongjin; Zhu, Yuanxiao; Ma, Yan] Huazhong Univ Sci & Technol, Wuhan 1 Hosp, Tongji Med Coll, Dept Rehabil, Wuhan 430030, Peoples R China.
   [Shao, Wenkai; Li, Zilin; Wang, Ping; Lv, Xiao; Feng, Yong] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Peoples R China.
   [Chen, Xiaodong; Han, Lizhi] Bengbu Med Univ, Affiliated Hosp 1, Dept Orthoped, Anhui Key Lab Tissue Transformat, Bengbu 233000, Anhui, Peoples R China.
C3 Southern Medical University   China; Huazhong University of Science &
   Technology; Huazhong University of Science & Technology; Bengbu Medical
   University
RP Wu, W (通讯作者)，Southern Med Univ, Zhujiang Hosp, Dept Rehabil, Guangzhou 510282, Peoples R China.; Feng, Y (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Orthoped, Wuhan 430030, Peoples R China.; Han, LZ (通讯作者)，Bengbu Med Univ, Affiliated Hosp 1, Dept Orthoped, Anhui Key Lab Tissue Transformat, Bengbu 233000, Anhui, Peoples R China.
EM hlz8566@163.com; wuwen66@163.com; fengyong@hust.edu.cn
FU National Natural Science Foundation of China [82270935]; Key Projects of
   Anhui Provincial Education Department [KJ2021A0771]; Wuhan Knowledge
   Innovation Special Basic Research Project [2023020201010159]; Project of
   scientific research plan of Wuhan Municipal Health Commission [WX21Q19]
FX We were very grateful for the language editing services provided by AJE
   (https:// www.aje.cn/) . This work was supported by the National Natural
   Science Foundation of China (82270935) , the Key Projects of Anhui
   Provincial Education Department (KJ2021A0771) , Wuhan Knowledge
   Innovation Special Basic Research Project (2023020201010159) and the
   project of scientific research plan of Wuhan Municipal Health Commission
   (WX21Q19) .
CR Alshihri A, 2020, J TISSUE ENG REGEN M, V14, P1630, DOI 10.1002/term.3126
   Bijlsma AY, 2012, AGEING RES REV, V11, P320, DOI 10.1016/j.arr.2012.01.001
   Catalano MG, 2017, J TISSUE ENG REGEN M, V11, P390, DOI 10.1002/term.1922
   Chandra A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22073553
   Choi YH, 2013, BIOCHEM BIOPH RES CO, V432, P248, DOI 10.1016/j.bbrc.2013.02.005
   Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812
   Gerdesmeyer L, 2008, AM J SPORT MED, V36, P2100, DOI 10.1177/0363546508324176
   Guo Yong, 2016, Chinese Medical Sciences Journal, V31, P100
   Guo YY, 2021, REDOX BIOL, V41, DOI 10.1016/j.redox.2021.101915
   Han K, 2022, REGEN THER, V21, P139, DOI 10.1016/j.reth.2022.06.006
   Han LZ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.606289
   Hsu CC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041217
   Hu J, 2016, SCI REP UK, V6, DOI 10.1038/srep20875
   Hu R, 2022, INT J STEM CELLS, V15, P372, DOI 10.15283/ijsc22024
   Iring A, 2019, J CLIN INVEST, V129, P2775, DOI 10.1172/JCI123825
   Javaheri B, 2019, CURR OSTEOPOROS REP, V17, P560, DOI 10.1007/s11914 019 00553 7
   Jiang YH, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12956
   Kang N, 2020, AM J TRANSL RES, V12, P2093
   Kobayashi M, 2020, BIOCHEM BIOPH RES CO, V530, P632, DOI 10.1016/j.bbrc.2020.07.084
   Li BF, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.627718
   Li CJ, 2021, CELL METAB, V33, P1957, DOI 10.1016/j.cmet.2021.08.009
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu SY, 2022, STEM CELLS INT, V2022, DOI 10.1155/2022/6202842
   Liu ZZ, 2021, AUTOPHAGY, V17, P2766, DOI 10.1080/15548627.2020.1839286
   Ma Y, 2018, AGING CELL, V17, DOI 10.1111/acel.12709
   Mi J, 2022, ADV SCI, V9, DOI 10.1002/advs.202103005
   Motegi S, 2017, J DERMATOL SCI, V86, P83, DOI 10.1016/j.jdermsci.2016.11.005
   Shao JJ, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287 022 02742 1
   Shi L, 2017, OSTEOPOROSIS INT, V28, P2945, DOI 10.1007/s00198 017 4136 7
   Shin MK, 2008, CELL SIGNAL, V20, P613, DOI 10.1016/j.cellsig.2007.11.012
   Song YQ, 2019, NEURON, V102, P373, DOI 10.1016/j.neuron.2019.01.050
   Sugimoto A, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 18089 0
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Wang BJ, 2022, SMALL, V18, DOI 10.1002/smll.202201056
   Wang CG, 2020, EUR J VASC ENDOVASC, V59, P834, DOI 10.1016/j.ejvs.2019.11.003
   Wang Q, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12674
   Wu RW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179476
   Wu XJ, 2022, AGING US, V14, P410, DOI 10.18632/aging.203816
   Xiao JF, 2023, STEM CELL RES THER, V14, DOI 10.1186/s13287 023 03532 z
   Xie H, 2014, NAT MED, V20, P1270, DOI 10.1038/nm.3668
   Xie YH, 2023, J BONE MINER RES, V38, P1015, DOI 10.1002/jbmr.4820
   Zayzafoon M, 2005, J BIOL CHEM, V280, P7049, DOI 10.1074/jbc.M412680200
   Zhang H, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0805 5
   Zhao ZD, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02076 w
NR 44
TC 2
Z9 2
U1 6
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD OCT
PY 2024
VL 187
AR 117196
DI 10.1016/j.bone.2024.117196
EA JUL 2024
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA A2H3Z
UT WOS:001280789600001
PM 39004161
DA 2025 08 17
ER

PT J
AU Yao, J
   Ma, ST
   Feng, WY
   Wei, Y
   Lu, HP
   Zhong, G
   Wu, ZY
   Wang, HT
   Su, W
   Li, J
AF Yao, Jun
   Ma, Shiting
   Feng, Wenyu
   Wei, Yan
   Lu, Huiping
   Zhong, Gang
   Wu, Zhengyuan
   Wang, Hongtao
   Su, Wei
   Li, Jia
TI Tanshinone IIA protects against polyethylene particle induced osteolysis
   response in a mouse calvarial model
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Aseptic loosening; tanshinone IIA; RANKL; osteoclast; osteolysis
ID CROSS LINKED POLYETHYLENE; RECEPTOR ACTIVATOR; JOINT REPLACEMENT; BONE
   LOSS; KAPPA B; HIP; ARTHROPLASTY; DIFFERENTIATION; IRRADIATION;
   EXPRESSION
AB The expression of beta catenin in detectable aseptic loosening after joint replacement and the surrounding osteolysis of the prosthesis is primarily caused by the abrasive particles introduced by the prosthesis, which results in a shortened service life of the prosthesis. Recent studies have shown that debris can induce many cytokines associated with osteolysis. In particular, RANKL directly stimulates osteoclast formation and activity. Thus, we hypothesize that the osteolysis induced by wear particles can be prevented by inhibiting the RANKL signaling pathway. In this study, we established a C57BL/J6 mouse calvarial model of PE granule induced osteolysis, and studied the inhibitory action of tanshinone IIA on osteoclast formation. Eight week old male c57BL/J6 mouse were randomly divided into four groups: Sham group (no PE particle induced + PBS), positive group (PE particle inducted + PBS), low dose group (PE particle induced + 1 ug/g tanshinone IIA), and high dose group (PE granule induced + 2 ug/g tanshinone II). After 21 days, the mice were executed and the calvaria were collected and processed for micro CT scan and histomorphometry analysis. Compared to the positive subgroup, Tanshinone IIA significantly reduced bone absorption induced by PE granules and inhibited the formation and activity of osteoclasts. In addition, ELISA test showed that tanshinone IIA significantly reduced OSCAR and CTX 1 expression. Further, tanshinone IIA enhanced the formation of OPG, thus reducing osteoclast damage to the bone around the implant. Overall, these data indicate that tanshinone IIA represents a promising drug for the treatment of bone absorption by particles and can be a new method of treatment for prophylaxis of aseptic loosening.
C1 [Yao, Jun; Ma, Shiting; Feng, Wenyu; Zhong, Gang; Wu, Zhengyuan; Wang, Hongtao; Su, Wei] Guangxi Med Univ, Dept Orthopaed, Affiliated Hosp 1, Nanning, Guangxi, Peoples R China.
   [Wei, Yan; Lu, Huiping; Li, Jia] Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
   [Yao, Jun; Ma, Shiting; Feng, Wenyu; Wei, Yan; Lu, Huiping; Zhong, Gang; Wu, Zhengyuan; Wang, Hongtao; Su, Wei; Li, Jia] Guangxi Med Univ, Res Ctr Regenerat Med, Nanning, Guangxi, Peoples R China.
   [Yao, Jun; Ma, Shiting; Feng, Wenyu; Wei, Yan; Lu, Huiping; Zhong, Gang; Wu, Zhengyuan; Wang, Hongtao; Su, Wei; Li, Jia] Guangxi Med Univ, Guangxi Key Lab Regenerat Med, Nanning, Guangxi, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Guangxi Medical University
RP Li, J (通讯作者)，Guangxi Med Univ, Dept Pathol, Affiliated Hosp 1, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.; Su, W (通讯作者)，Guangxi Med Univ, Affiliated Hosp 1, Dept Orthoped, 6 Shuangyong Rd, Nanning 530021, Guangxi, Peoples R China.
EM gxsuwei@163.com; jialee2005@126.com
FU Guangxi health and family planning commission Chinese medicine science
   and technology project [GZLC16 32]; Guangxi hygienic technology
   development and promotion application project [S201655]; Guangxi
   scientific research and technology development project [1598012 41]
FX The work was supported by the Guangxi health and family planning
   commission Chinese medicine science and technology project (GZLC16 32),
   Guangxi hygienic technology development and promotion application
   project (S201655) and Guangxi scientific research and technology
   development project (Guangxi research 1598012 41).
CR Al Quhali AM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/802697
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Boyce Brendan F, 2007, Curr Osteoporos Rep, V5, P98
   Boyce BF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2165
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Crotti TN, 2004, BIOMATERIALS, V25, P565, DOI 10.1016/S0142 9612(03)00556 8
   Dorr LD, 2005, J BONE JOINT SURG AM, V87A, P1816, DOI 10.2106/JBJS.D.01915
   Drees P, 2008, BIOMED TECH, V53, P93, DOI 10.1515/BMT.2008.021
   Fulín P, 2014, ACTA CHIR ORTHOP TR, V81, P33
   Granchi D, 2006, J BONE JOINT SURG AM, V88A, P1501, DOI 10.2106/JBJS.E.01038
   Guo YB, 2014, J ETHNOPHARMACOL, V155, P1401, DOI 10.1016/j.jep.2014.07.058
   Holding CA, 2006, BIOMATERIALS, V27, P5212, DOI 10.1016/j.biomaterials.2006.05.054
   Holt G, 2007, CLIN ORTHOP RELAT R, P240, DOI 10.1097/BLO.0b013e31804b4147
   Jia M, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/364604
   Jiang J, 2015, CLIN ORTHOP RELAT R, V473, P2672, DOI 10.1007/s11999 015 4345 3
   Jiang YP, 2013, ACTA ORTHOP BELG, V79, P1
   Johanson PE, 2012, CLIN ORTHOP RELAT R, V470, P3083, DOI 10.1007/s11999 012 2400 x
   Kim HK, 2012, IMMUNOPHARM IMMUNOT, V30, P347
   Kim KJ, 2010, J BIOMED MATER RES, V58, P393
   Kurtz S, 2007, J BONE JOINT SURG AM, V89A, P780, DOI 10.2106/JBJS.F.00222
   Kwak HB, 2006, EXP MOL MED, V38, P256, DOI 10.1038/emm.2006.31
   Learmonth ID, 2007, LANCET, V370, P1508, DOI 10.1016/S0140 6736(07)60457 7
   MacDonald D, 2012, CLIN ORTHOP RELAT R, V470, P1826, DOI 10.1007/s11999 011 2184 4
   Moro T, 2004, NAT MATER, V3, P829, DOI 10.1038/nmat1233
   Muratoglu OK, 2002, BIOMATERIALS, V23, P717, DOI 10.1016/S0142 9612(01)00176 4
   Neuerburg C, 2016, INT J MOL MED, V38, P1652, DOI 10.3892/ijmm.2016.2780
   Noordin S, 2012, CAN J SURG, V55, P408, DOI 10.1503/cjs.003711
   Purdue P Edward, 2006, HSS J, V2, P102, DOI 10.1007/s11420 006 9003 6
   Qiu S, 2015, MOL CELL BIOCHEM, V399, P131, DOI 10.1007/s11010 014 2240 y
   Rao AJ, 2012, ACTA BIOMATER, V8, P2815, DOI 10.1016/j.actbio.2012.03.042
   Ren W, 2010, J ORTHOP RES, V24, P1575
   Shao HG, 2015, BIOMATERIALS, V60, P92, DOI 10.1016/j.biomaterials.2015.04.048
   Shin DK, 2012, ACTA BIOMATER, V8, P3524, DOI 10.1016/j.actbio.2012.05.002
   Urban RM, 2012, J BONE JOINT SURG AM, V94A, P1877, DOI 10.2106/JBJS.J.01507
   von Knoch F, 2005, BIOMATERIALS, V26, P3549, DOI 10.1016/j.biomaterials.2004.09.043
   Wedemeyer C, 2007, CALCIFIED TISSUE INT, V81, P394, DOI 10.1007/s00223 007 9077 2
NR 36
TC 4
Z9 4
U1 0
U2 7
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936 2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2018
VL 11
IS 9
BP 4461
EP 4471
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Pathology
GA GV2NN
UT WOS:000445927500022
PM 31949843
DA 2025 08 17
ER

PT J
AU Wang, X
   Wu, XY
   Zhang, ZL
   Ma, C
   Wu, TT
   Tang, SL
   Zeng, ZY
   Huang, SF
   Gong, C
   Yuan, CF
   Zhang, LH
   Feng, YX
   Huang, B
   Liu, W
   Zhang, B
   Shen, Y
   Luo, WP
   Wang, X
   Liu, B
   Lei, Y
   Ye, ZY
   Zhao, L
   Cao, DG
   Yang, LJ
   Chen, X
   Haydon, RC
   Luu, HH
   Peng, B
   Liu, XB
   He, TC
AF Wang, Xin
   Wu, Xingye
   Zhang, Zhonglin
   Ma, Chao
   Wu, Tingting
   Tang, Shengli
   Zeng, Zongyue
   Huang, Shifeng
   Gong, Cheng
   Yuan, Chengfu
   Zhang, Linghuan
   Feng, Yixiao
   Huang, Bo
   Liu, Wei
   Zhang, Bo
   Shen, Yi
   Luo, Wenping
   Wang, Xi
   Liu, Bo
   Lei, Yan
   Ye, Zhenyu
   Zhao, Ling
   Cao, Daigui
   Yang, Lijuan
   Chen, Xian
   Haydon, Rex C.
   Luu, Hue H.
   Peng, Bing
   Liu, Xubao
   He, Tong Chuan
TI Monensin inhibits cell proliferation and tumor growth of chemo resistant
   pancreatic cancer cells by targeting the EGFR signaling pathway
SO SCIENTIFIC REPORTS
LA English
DT Article
ID HUMAN OSTEOSARCOMA GROWTH; BMP9 INDUCED OSTEOGENIC DIFFERENTIATION;
   PROTEIN 9 BMP9; CYCLE ARREST; OSTEOBLAST DIFFERENTIATION; PROGENITOR
   CELLS; GINSENOSIDE RG3; BONE FORMATION; STEM CELLS; EXPRESSION
AB Pancreatic ductal adenocarcinoma (PDAC) is one of the most deadly malignancies with <5% five year survival rate due to late diagnosis, limited treatment options and chemoresistance. There is thus an urgent unmet clinical need to develop effective anticancer drugs to treat pancreatic cancer. Here, we study the potential of repurposing monensin as an anticancer drug for chemo resistant pancreatic cancer. Using the two commonly used chemo resistant pancreatic cancer cell lines PANC 1 and MiaPaCa 2, we show that monensin suppresses cell proliferation and migration, and cell cycle progression, while solicits apoptosis in pancreatic cancer lines at a low micromole range. Moreover, monensin functions synergistically with gemcitabine or EGFR inhibitor erlotinib in suppressing cell growth and inducing cell death of pancreatic cancer cells. Mechanistically, monensin suppresses numerous cancer associated pathways, such as E2F/DP1, STAT1/2, NFkB, AP 1, Elk 1/SRF, and represses EGFR expression in pancreatic cancer lines. Furthermore, the in vivo study shows that monensin blunts PDAC xenograft tumor growth by suppressing cell proliferation via targeting EGFR pathway. Therefore, our findings demonstrate that monensin can be repurposed as an effective anti pancreatic cancer drug even though more investigations are needed to validate its safety and anticancer efficacy in pre clinical and clinical models.
C1 [Wang, Xin; Peng, Bing; Liu, Xubao] Sichuan Univ, West China Hosp, Dept Pancreat Surg, Chengdu 610041, Sichuan, Peoples R China.
   [Wang, Xin; Wu, Xingye; Zhang, Zhonglin; Ma, Chao; Wu, Tingting; Tang, Shengli; Zeng, Zongyue; Huang, Shifeng; Gong, Cheng; Yuan, Chengfu; Zhang, Linghuan; Feng, Yixiao; Huang, Bo; Liu, Wei; Zhang, Bo; Shen, Yi; Luo, Wenping; Wang, Xi; Liu, Bo; Lei, Yan; Ye, Zhenyu; Zhao, Ling; Cao, Daigui; Yang, Lijuan; Chen, Xian; Haydon, Rex C.; Luu, Hue H.; He, Tong Chuan] Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Orthopaed Surg & Rehabil Med, Chicago, IL 60637 USA.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Surg, Chongqing 400016, Peoples R China.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Clin Lab Med, Chongqing 400016, Peoples R China.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400016, Peoples R China.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Plast Surg & Burn, Chongqing 400016, Peoples R China.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Chongqing 400016, Peoples R China.
   [Wu, Xingye; Huang, Shifeng; Feng, Yixiao; Liu, Wei; Liu, Bo; Lei, Yan; Zhao, Ling] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400016, Peoples R China.
   [Zhang, Zhonglin; Ma, Chao; Wu, Tingting; Tang, Shengli; Gong, Cheng] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Hepatobiliary & Pancreat Surg, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Zhonglin; Ma, Chao; Wu, Tingting; Tang, Shengli; Gong, Cheng] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Neurosurg, Wuhan 430071, Hubei, Peoples R China.
   [Zhang, Zhonglin; Ma, Chao; Wu, Tingting; Tang, Shengli; Gong, Cheng] Wuhan Univ, Affiliated Zhongnan Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan 430071, Hubei, Peoples R China.
   [Zeng, Zongyue; Zhang, Linghuan; Huang, Bo; Wang, Xi; Cao, Daigui] Chongqing Med Univ, Key Lab Diagnost Med, Minist Educ, Chongqing 400016, Peoples R China.
   [Zeng, Zongyue; Zhang, Linghuan; Huang, Bo; Wang, Xi; Cao, Daigui] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China.
   [Zeng, Zongyue; Zhang, Linghuan; Huang, Bo; Wang, Xi; Cao, Daigui] Chongqing Med Univ, Affiliated Hosp, Chongqing 400016, Peoples R China.
   [Yuan, Chengfu] China Three Gorges Univ, Dept Biochem & Mol Biol, Sch Med, Yichang 443002, Peoples R China.
   [Huang, Bo] Nanchang Univ, Dept Clin Lab Med, Affiliated Hosp 2, Nanchang 330031, Jiangxi, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 1, Key Lab Orthopaed Surg Gansu Prov, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 1, Dept Orthopaed Surg, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 1, Dept Obstet & Gynecol, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 2, Key Lab Orthopaed Surg Gansu Prov, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 2, Dept Orthopaed Surg, Lanzhou 730030, Gansu, Peoples R China.
   [Zhang, Bo; Yang, Lijuan] Lanzhou Univ, Hosp 2, Dept Obstet & Gynecol, Lanzhou 730030, Gansu, Peoples R China.
   [Shen, Yi] Cent South Univ, Xiangya Hosp 2, Dept Orthopaed Surg, Changsha 410011, Hunan, Peoples R China.
   [Luo, Wenping] Chongqing Med Univ, Chongqing Key Lab Oral Dis & Biomed Sci, Chongqing, Peoples R China.
   [Luo, Wenping] Chongqing Med Univ, Affiliated Hosp Stomatol, Chongqing, Peoples R China.
   [Ye, Zhenyu] Soochow Univ, Affiliated Hosp 2, Dept Gen Surg, Suzhou 215004, Peoples R China.
   [Chen, Xian] Qingdao Univ, Affiliated Hosp, Dept Clin Lab Med, Qingdao 266061, Peoples R China.
C3 Sichuan University; University of Chicago; University of Chicago Medical
   Center; Chongqing Medical University; Chongqing Medical University;
   Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chongqing Medical University; Wuhan University;
   Wuhan University; Wuhan University; Chongqing Medical University;
   Chongqing Medical University; Chongqing Medical University; China Three
   Gorges University; Nanchang University; Lanzhou University; Lanzhou
   University; Lanzhou University; Lanzhou University; Lanzhou University;
   Lanzhou University; Central South University; Chongqing Medical
   University; Chongqing Medical University; Soochow University   China;
   Qingdao University
RP Liu, XB (通讯作者)，Sichuan Univ, West China Hosp, Dept Pancreat Surg, Chengdu 610041, Sichuan, Peoples R China.; He, TC (通讯作者)，Univ Chicago, Med Ctr, Mol Oncol Lab, Dept Orthopaed Surg & Rehabil Med, Chicago, IL 60637 USA.
EM xbliu@medmail.com.cn; tche@uchicago.edu
RI ; yang, hailong/GXH 9625 2022; wu, tingting/H 8032 2012; Wang,
   Yujie/L 9676 2017; Peng, Bing/NEU 4174 2025; Liu, Wei/L 2099 2019
OI Zeng, Zongyue/0000 0002 4333 5412; 
FU National Key Research and Development Program of China [2016YFC1000803,
   2011CB707906]; National Institutes of Health [CA226303]; National
   Institutes of Health of China [W2017ZWS07]; 135 Research Project of West
   China Hospital of Sichuan University; China Scholarship Council;
   University of Chicago Cancer Center Support Grant [P30CA014599];
   National Center for Advancing Translational Sciences of the National
   Institutes of Health [UL1 TR000430]; Mabel Green Myers Research
   Endowment Fund; University of Chicago Orthopaedic Surgery Alumni Fund
FX A part of the reported work was orally presented at the American College
   of Surgeons Clinical Congress, October 22 26, 2017, San Diego, CA, USA.
   We wish to thank Dr. Keping Xie of the University of Texas MD Anderson
   Cancer Center, Houston, TX for the kind provision of human pancreatic
   cancer lines. The reported study was supported in part by research
   grants from the National Key Research and Development Program of China
   (2016YFC1000803 and 2011CB707906), the National Institutes of Health
   (CA226303 to TCH), the National Institutes of Health of China
   (W2017ZWS07 to XL and XW), and the 135 Research Project of West China
   Hospital of Sichuan University (XL and XW). XW was a recipient of
   pre doctorate scholarship from China Scholarship Council. This project
   was also supported in part by The University of Chicago Cancer Center
   Support Grant (P30CA014599) and the National Center for Advancing
   Translational Sciences of the National Institutes of Health through
   Grant Number UL1 TR000430. TCH was also supported by the Mabel Green
   Myers Research Endowment Fund and The University of Chicago Orthopaedic
   Surgery Alumni Fund.
CR Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965
   Bhattarai D, 2016, CURR TOP MED CHEM, V16, P2156, DOI 10.2174/1568026616666160216153618
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Binenbaum Y, 2015, DRUG RESIST UPDATE, V23, P55, DOI 10.1016/j.drup.2015.10.002
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen WQ, 2016, CA CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen X, 2013, CELL PHYSIOL BIOCHEM, V32, P1083, DOI 10.1159/000354508
   Chen X, 2015, GENES DIS, V2, P96, DOI 10.1016/j.gendis.2014.12.001
   Choi HS, 2013, TUBERC RESPIR DIS, V75, P9, DOI 10.4046/trd.2013.75.1.9
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008 5472.CAN 09 1947
   Chung BM, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471 2121 10 84
   Dayekh K, 2014, MOL CANCER THER, V13, P2559, DOI 10.1158/1535 7163.MCT 13 1086
   Deng YL, 2016, CELL PHYSIOL BIOCHEM, V39, P871, DOI 10.1159/000447797
   Deng YL, 2015, SCI REP UK, V5, DOI 10.1038/srep17523
   Fan JM, 2017, ONCOTARGET, V8, P27105, DOI 10.18632/oncotarget.15637
   Gao JL, 2013, ONCOL REP, V30, P292, DOI 10.3892/or.2013.2438
   Gupta SC, 2013, TRENDS PHARMACOL SCI, V34, P508, DOI 10.1016/j.tips.2013.06.005
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   He BC, 2011, MOL PHARMACOL, V79, P211, DOI 10.1124/mol.110.068668
   He BC, 2011, INT J ONCOL, V38, P437, DOI 10.3892/ijo.2010.858
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557
   Hu N, 2013, J CELL SCI, V126, P532, DOI 10.1242/jcs.114231
   Hu X, 2017, ONCOTARGET, V8, P111847, DOI 10.18632/oncotarget.22915
   Huang EY, 2012, J BONE MINER RES, V27, P1566, DOI 10.1002/jbmr.1622
   Huang EY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032428
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140 6736(16)00141 0
   Ketola K, 2010, MOL CANCER THER, V9, P3175, DOI 10.1158/1535 7163.MCT 10 0368
   Lampot JD, 2015, CELL TRANSPLANT, V24, P1053, DOI 10.3727/096368914X681054
   Li M, 2013, INT J MED SCI, V10, P1035, DOI 10.7150/ijms.6639
   Li RD, 2014, CURR CANCER DRUG TAR, V14, P274, DOI 10.2174/1568009614666140305105805
   Li YS, 2015, CELL PHYSIOL BIOCHEM, V37, P2375, DOI 10.1159/000438591
   Liao J, 2017, GENE THER, V24, P333, DOI 10.1038/gt.2017.24
   Liao JY, 2017, CELL PHYSIOL BIOCHEM, V41, P1905, DOI 10.1159/000471945
   Liao Z, 2015, CURR CANCER DRUG TAR, V15, P726, DOI 10.2174/1568009615666150629132157
   Lu S, 2016, AM J TRANSL RES, V8, P3710
   Luo JY, 2010, J BIOL CHEM, V285, P29588, DOI 10.1074/jbc.M110.130518
   Luo Q, 2004, J BIOL CHEM, V279, P55958, DOI 10.1074/jbc.M407810200
   Luo XJ, 2008, CLIN ORTHOP RELAT R, V466, P2060, DOI 10.1007/s11999 008 0361 x
   Luo XJ, 2008, INT J ONCOL, V32, P975, DOI 10.1007/978 3 540 77385 6
   Luo XJ, 2008, LAB INVEST, V88, P1264, DOI 10.1038/labinvest.2008.98
   Luther GA, 2013, CANCER LETT, V336, P222, DOI 10.1016/j.canlet.2013.05.002
   Luu HH, 2005, CANCER LETT, V229, P135, DOI 10.1016/j.canlet.2005.02.015
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585 005 0365 9
   Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525
   Park WH, 2003, INT J ONCOL, V22, P855
   Park WH, 2003, INT J ONCOL, V22, P377
   Park WH, 2003, INT J ONCOL, V23, P197
   Park WH, 2002, INT J CANCER, V101, P235, DOI 10.1002/ijc.10592
   Park WH, 2002, BRIT J HAEMATOL, V119, P400, DOI 10.1046/j.1365 2141.2002.03834.x
   PRESSMAN BC, 1968, FED PROC, V27, P1283
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008 5472.CAN 14 0155
   Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177
   Rajabpour A, 2017, PANCREATOLOGY, V17, P310, DOI 10.1016/j.pan.2016.12.013
   Rastegar F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014182
   Shui W, 2014, J BIOMED MATER RES A, V102, P3429, DOI 10.1002/jbm.a.35006
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Sleire L, 2017, PHARMACOL RES, V124, P74, DOI 10.1016/j.phrs.2017.07.013
   Song DZ, 2017, J CELL MOL MED, V21, P2782, DOI 10.1111/jcmm.13193
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585 009 9259 6
   Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582 4934.2008.00569.x
   Tumova L, 2014, MOL CANCER THER, V13, P812, DOI 10.1158/1535 7163.MCT 13 0625
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Verbaanderd C, 2017, TRENDS CANCER, V3, P543, DOI 10.1016/j.trecan.2017.06.007
   Wang J, 2017, CELL PHYSIOL BIOCHEM, V41, P484, DOI 10.1159/000456885
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097316
   Wang N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093608
   Wen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094397
   Wolfgang CL, 2013, CA CANCER J CLIN, V63, P318, DOI 10.3322/caac.21190
   Xie DH, 2015, GENES DIS, V2, P133, DOI 10.1016/j.gendis.2015.01.002
   Yang K, 2012, J INVEST DERMATOL, V132, P2479, DOI 10.1038/jid.2012.145
   Ye JX, 2016, BIOMED MATER, V11, DOI 10.1088/1748 6041/11/2/025021
   Yu XY, 2018, CELL PHYSIOL BIOCHEM, V47, P957, DOI 10.1159/000490140
   Zhang FG, 2017, ONCOTARGET, V8, P12968, DOI 10.18632/oncotarget.14673
   Zhang HM, 2015, BIOMATERIALS, V39, P145, DOI 10.1016/j.biomaterials.2014.11.007
   Zhang Q, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132666
   Zhao C, 2017, GENES DIS, V4, P229, DOI 10.1016/j.gendis.2017.10.004
   Zhu GH, 2009, DIFFERENTIATION, V78, P195, DOI 10.1016/j.diff.2009.06.001
   Zou YL, 2017, ACS APPL MATER INTER, V9, P15922, DOI 10.1021/acsami.7b00272
NR 82
TC 66
Z9 67
U1 0
U2 22
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD DEC 17
PY 2018
VL 8
AR 17914
DI 10.1038/s41598 018 36214 5
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA HE5RT
UT WOS:000453444900011
PM 30559409
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ferreira, DD
   Pinto, BLJD
   Kumar, V
   Cardoso, VN
   Fernandes, SO
   Souza, CM
   Cassali, GD
   Moore, A
   Sosnovik, DE
   Farrar, CT
   Leite, EA
   Alves, RJ
   de Oliveira, MC
   Guimaraes, AR
   Caravan, P
AF Ferreira, Diego dos Santos
   Pinto, Bruno Luis Jesus de Oliveira
   Kumar, Vidhya
   Cardoso, Valbert Nascimento
   Fernandes, Simone Odilia
   Souza, Cristina Maria
   Cassali, Geovanni Dantas
   Moore, Anna
   Sosnovik, David E.
   Farrar, Christian T.
   Leite, Elaine Amaral
   Alves, Ricardo Jose
   de Oliveira, Monica Cristina
   Guimaraes, Alexander Ramos
   Caravan, Peter
TI Evaluation of antitumor activity and cardiac toxicity of a bone targeted
   phsensitive liposomal formulation in a bone metastasis tumor model in
   mice
SO NANOMEDICINE NANOTECHNOLOGY BIOLOGY AND MEDICINE
LA English
DT Article
DE Hydroxyapatite targeting; Bisphosphonates; Doxorubicin; Bone tumor;
   Cardiotoxicity
ID DOXORUBICIN; CARDIOTOXICITY; IRON; IDENTIFICATION; CONSEQUENCES;
   CARDIOLIPIN; DELIVERY
AB Chemotherapy for bone tumors is a major challenge because of the inability of therapeutics to penetrate dense bone mineral. We hypothesize that a nanostructured formulation with high affinity for bone could deliver drug to the tumor while minimizing off target toxicity. Here, we evaluated the efficacy and toxicity of a novel bone targeted, pH sensitive liposomal formulation containing doxorubicin in an animal model of bone metastasis. Biodistribution studies with the liposome showed good uptake in tumor, but low accumulation of doxorubicin in the heart. Mice treated with the bone targeted liposome formulation showed a 70% reduction in tumor volume, compared to 35% reduction for free doxorubicin at the same dose. Both cardiac toxicity and overall mortality were significantly lower for animals treated with the bone targeted liposomes compared to free drug. Bone targeted, pH sensitive, doxorubicin containing liposomes represent a promising approach to selectively delivering doxorubicin to bone tumors while minimizing cardiac toxicity. (C) 2017 Elsevier Inc. All rights reserved.
C1 [Ferreira, Diego dos Santos; Pinto, Bruno Luis Jesus de Oliveira; Kumar, Vidhya; Moore, Anna; Sosnovik, David E.; Farrar, Christian T.; Caravan, Peter] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
   [Ferreira, Diego dos Santos; Leite, Elaine Amaral; Alves, Ricardo Jose; de Oliveira, Monica Cristina] Univ Fed Minas Gerais, Dept Pharmaceut Prod, Fac Pharm, BR 31270901 Belo Horizonte, MG, Brazil.
   [Cardoso, Valbert Nascimento; Fernandes, Simone Odilia] Univ Fed Minas Gerais, Dept Clin & Toxicol Anal, Fac Pharm, BR 31270901 Belo Horizonte, MG, Brazil.
   [Souza, Cristina Maria; Cassali, Geovanni Dantas] Univ Fed Minas Gerais, Dept Pathol, Inst Biol Sci, BR 31270901 Belo Horizonte, MG, Brazil.
   [Guimaraes, Alexander Ramos] Oregon Hlth & Sci Univ, Dept Diagnost Radiol, Portland, OR 97239 USA.
C3 Harvard University; Harvard University Medical Affiliates; Massachusetts
   General Hospital; Universidade Federal de Minas Gerais; Universidade
   Federal de Minas Gerais; Universidade Federal de Minas Gerais; Oregon
   Health & Science University
RP Caravan, P (通讯作者)，Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM ferreira@nmr.mgh.harvard.edu; bluis.oliveira@gmail.com;
   vidhya.kumar55@gmail.com; valbertcardoso@yahoo.com.br;
   simoneodilia@yahoo.com.br; cms.souza@yahoo.com.br; cassalig@icb.ufmg.br;
   amoore@helix.mgh.harvard.edu; sosnovik@nmr.mgh.harvard.edu;
   cfarrar@mgh.harvard.edu; leite_elaine@hotmail.com;
   ricardodylan@farmacia.ufmg.br; monica@farmacia.ufmg.br;
   guimaraa@ohsu.edu; caravan@nmr.mgh.harvard.edu
RI Cardoso, Valbert/AAA 7240 2019; Oliveira, Monica/H 2080 2015; Oliveira,
   Bruno/KYR 8757 2024; fernandes, simone/AAU 8611 2020; Cassali,
   Geovanni/A 4535 2008; dos Santos Ferreira, Diego/O 7637 2014; Caravan,
   Peter/M 5663 2017; Alves, Ricardo/I 7978 2015; souza,
   danielle/D 3378 2014; Leite, Elaine/N 9441 2017
OI Farrar, Christian/0000 0001 6623 8220; Oliveira,
   Monica/0000 0003 2594 9581; Oliveira, Bruno/0000 0002 7687 4746;
   Cassali, Geovanni/0000 0002 5650 6743; Cardoso,
   Valbert/0000 0001 7597 9602; Antunes Fernandes, Simone
   Odilia/0000 0002 6139 5187; dos Santos Ferreira,
   Diego/0000 0003 1505 7950; Caravan, Peter/0000 0002 3179 6537; Leite,
   Elaine/0000 0001 8812 3811
FU National Institutes of Health [R01EB009062, S10OD010650]; Fundacao de
   Amparo a Pesquisa do Estado de Minas Gerais, Belo Horizonte, Brazil
   [REDE 40/11]; Fundacao Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior [6188 13 3]
FX This work was supported by the National Institutes of Health [grant
   numbers R01EB009062, S10OD010650]; the Fundacao de Amparo a Pesquisa do
   Estado de Minas Gerais, Belo Horizonte, Brazil [grant number
   REDE 40/11]; and Fundacao Coordenacao de Aperfeicoamento de Pessoal de
   Nivel Superior [grant number: 6188 13 3].
CR Alhareth K, 2012, J CHROMATOGR B, V887, P128, DOI 10.1016/j.jchromb.2012.01.025
   Anada T, 2009, BIOORG MED CHEM LETT, V19, P4148, DOI 10.1016/j.bmcl.2009.05.117
   Bauss F, 1996, CALCIFIED TISSUE INT, V59, P168, DOI 10.1007/s002239900104
   Berthiaume JM, 2007, CELL BIOL TOXICOL, V23, P15, DOI 10.1007/s10565 006 0140 y
   de Barros ALB, 2013, J BIOMED NANOTECHNOL, V9, P1636, DOI 10.1166/jbn.2013.1649
   DeRuiter J., 2002, BISPHOSPHONATES CALC
   Dijkgraaf I, 2007, ANTI CANCER AGENT ME, V7, P543, DOI 10.2174/187152007781668733
   Fernandes RS, 2016, NUCL MED COMMUN, V37, P307, DOI 10.1097/MNM.0000000000000443
   Ferreira DD, 2015, INT J NANOMED, V10, P2441, DOI 10.2147/IJN.S76168
   Ferreira DD, 2013, THER DELIV, V4, P1099, DOI [10.4155/tde.13.80, 10.4155/TDE.13.80]
   Ferreira DS, 2016, INT J NANOMED, V9, P3737
   GOORMAGHTIGH E, 1990, BIOPHYS CHEM, V35, P247, DOI 10.1016/0301 4622(90)80012 V
   Harvey HA, 2007, CLIN BREAST CANCER, V7, pS7, DOI 10.3816/CBC.2007.s.001
   Hengst V, 2007, INT J PHARMACEUT, V331, P224, DOI 10.1016/j.ijpharm.2006.11.024
   Ichikawa Y, 2014, J CLIN INVEST, V124, P617, DOI 10.1172/JCI72931
   JiB J., 2003, DI FIORE HISTOLOGIA
   Júnior ADC, 2007, LIFE SCI, V80, P659, DOI 10.1016/j.lfs.2006.10.011
   KLENNER T, 1990, CANCER TREAT REV, V17, P253, DOI 10.1016/0305 7372(90)90056 L
   Lisic EC, 2001, NUCL MED BIOL, V28, P419, DOI 10.1016/S0969 8051(00)00205 5
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Myers C, 1998, SEMIN ONCOL, V25, P10
   Niu QY, 2016, J PHARMACEUT BIOMED, V118, P338, DOI 10.1016/j.jpba.2015.10.026
   Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163 7827(00)00005 9
   Shea JE, 2005, ADV DRUG DELIVER REV, V57, P945, DOI 10.1016/j.addr.2004.12.017
   Simmons JK, 2015, VET PATHOL, V52, P827, DOI 10.1177/0300985815586223
   Simunek T, 2009, PHARMACOL REP, V61, P154
   Smith MR, 2008, UROL ONCOL SEMIN ORI, V26, P420, DOI 10.1016/j.urolonc.2007.11.004
   Su Z, 2015, SPRINGER THESES RECO, P1, DOI 10.1007/978 3 662 46651 3
   Torchilin VP, 2007, AAPS J, V9, pE128, DOI 10.1208/aapsj0902015
   Ulrich AS, 2002, BIOSCIENCE REP, V22, P129, DOI 10.1023/A:1020178304031
   Wang GL, 2012, J BIOMED MATER RES A, V100A, P684, DOI 10.1002/jbm.a.34002
NR 31
TC 22
Z9 22
U1 1
U2 41
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1549 9634
EI 1549 9642
J9 NANOMED NANOTECHNOL
JI Nanomed. Nanotechnol. Biol. Med.
PD JUL
PY 2017
VL 13
IS 5
BP 1693
EP 1701
DI 10.1016/j.nano.2017.03.005
PG 9
WC Nanoscience & Nanotechnology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Research & Experimental Medicine
GA EY0QG
UT WOS:000403662500012
PM 28343016
OA Green Published, Green Accepted
DA 2025 08 17
ER

PT J
AU Pinto, N
   Klein, Y
   David, E
   Polak, D
   Steinberg, D
   Mizrahi, G
   Khoury, Y
   Barenholz, Y
   Chaushu, S
AF Pinto, Noy
   Klein, Yehuda
   David, Eilon
   Polak, David
   Steinberg, Daniel
   Mizrahi, Gilad
   Khoury, Yasmin
   Barenholz, Yechezkel
   Chaushu, Stella
TI Resolvin D1 improves allograft osteointegration and directly enhances
   osteoblasts differentiation
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE bone; resolvin D1; allograft; regeneration; osteoblasts
ID BONE MORPHOGENETIC PROTEINS; EXPRESSION; OSTEOCLAST; E1
AB IntroductionAllografts are the most common bone grafts for repairing osseous defects. However, their use is associated with an increased risk for infections, donor disease transmission and osteointegration deficiency. Resolvin D1 (RvD1) is an endogenous lipid with a scientifically proven pivotal role in inflammation resolution and osteoclastogenesis inhibition. Yet, its biological relevance as a potential bone regenerative drug has been scarcely studied. Here, we aim to investigate the RvD1 effect on allograft osteointegration in the alveolar bone regeneration (ABR) murine model. MethodsABR model consisted of osseous defects that were generated by the extraction of the maxillary first molar in C57BL/6 mice. The sockets were filled with allograft and analyzed via RNA sequencing. Then they were locally injected with either RvD1 or saline via single or repeated administrations. The mice were sacrificed 2W after the procedure, and regenerated sites were analyzed using mu CT and histology. First, MC3T3 E1 preosteoblasts were plated with IL 17 pro inflammatory medium, and RANKL/OPG ratio was measured. Secondly, the MC3T3 E1 were cultured w/o RvD1, for 3W. Osteoblasts' markers were evaluated in different days, using qRT PCR and Alizarin Red staining for calcified matrix. ResultsIn vivo, neither allograft alone nor single RvD1 administration promote bone regeneration in comparison to the control of spontaneous healing and even triggered an elevation in NR1D1 and IL1RL1 expression, markers associated with inflammation and inhibition of bone cell differentiation. However, repeated RvD1 treatment increased bone content by 135.92% +/  45.98% compared to its specific control, repeated sham, and by 39.12% +/  26.3% when compared to the spontaneous healing control group (n=7/group). Histologically, repeated RvD1 reduced the number of TRAP positive cells, and enhanced allograft osteointegration with new bone formation. In vitro, RvD1 rescued OPG expression and decreased RANKL/OPG ratio in IL 17 pro inflammatory conditions. Furthermore, RvD1 increased the expression of RUNX2, OSX, BSP and OC/BGLAP2 and the mineralized extracellular matrix during MC3T3 E1 osteoblasts differentiation. ConclusionsRepeated administrations of RvD1 promote bone regeneration via a dual mechanism: directly, via enhancement of osteoblasts' differentiation and indirectly, through reduction of osteoclastogenesis and RANKL/OPG ratio. This suggests that RvD1 may be a potential therapeutic bioagent for osseous regeneration following allograft implantation.
C1 [Pinto, Noy; Klein, Yehuda; David, Eilon; Mizrahi, Gilad; Khoury, Yasmin] Hebrew Univ Jerusalem, Inst Dent Sci, Fac Dent Med, Jerusalem, Israel.
   [Pinto, Noy; Klein, Yehuda; David, Eilon; Barenholz, Yechezkel] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Fac Med, Jerusalem, Israel.
   [Klein, Yehuda; Mizrahi, Gilad; Chaushu, Stella] Hebrew Univ Jerusalem, Fac Dent Med, Hadassah Med Ctr, Dept Orthodont, Jerusalem, Israel.
   [Polak, David] Hebrew Univ Jerusalem, Fac Dent Med, Dept Periodont, Jerusalem, Israel.
   [Steinberg, Daniel] Israel Canada IMRIC, Lautenberg Ctr Immunol & Canc Res, Dept Immunol & Canc Res Med Res, Jerusalem, Israel.
   [Steinberg, Daniel] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Fac Med, Dept Dev Biol & Canc Res, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem; Hadassah University Hospital; Hadassah
   University Medical Center; Hebrew University of Jerusalem; Hebrew
   University of Jerusalem
RP Pinto, N; Klein, Y (通讯作者)，Hebrew Univ Jerusalem, Inst Dent Sci, Fac Dent Med, Jerusalem, Israel.; Pinto, N; Klein, Y; Barenholz, Y (通讯作者)，Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Fac Med, Jerusalem, Israel.; Klein, Y; Chaushu, S (通讯作者)，Hebrew Univ Jerusalem, Fac Dent Med, Hadassah Med Ctr, Dept Orthodont, Jerusalem, Israel.
EM noy.pinto@mail.huji.ac.il; yehuda.klein@mail.huji.ac.il;
   chezyb@gmail.com; Drchaushu@gmail.com
FU Kamin grant [6034904]
FX This research was funded and supported by the Kamin grant (6034904).
CR Araújo MG, 2010, CLIN ORAL IMPLAN RES, V21, P55, DOI 10.1111/j.1600 0501.2009.01854.x
   Bach DH, 2018, MOL THER ONCOLYTICS, V8, P1, DOI 10.1016/j.omto.2017.10.002
   Baht GS, 2018, CURR OSTEOPOROS REP, V16, P138, DOI 10.1007/s11914 018 0423 2
   Bajwa NM, 2019, J NEUROSCI RES, V97, P332, DOI 10.1002/jnr.24343
   Bayraktar S, 2018, J TISSUE ENG REGEN M, V12, P114, DOI 10.1002/term.2375
   Benabdoun HA, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075 019 1852 8
   Benabdoune H, 2016, INFLAMM RES, V65, P635, DOI 10.1007/s00011 016 0946 x
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Coetzee M, 2009, CELL BIOCHEM FUNCT, V27, P3, DOI 10.1002/cbf.1526
   Dholakia U, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184911
   Eming SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009337
   Feng YY, 2016, J MOL ENDOCRINOL, V56, P189, DOI 10.1530/JME 15 0264
   Fesseha H., 2020, Osteol, Rheumatol. Open J, V1, P43, DOI [10.17140/ORHOJ 1 113, DOI 10.17140/ORHOJ 1 113]
   Fu C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 12935 x
   Funaki Y, 2018, YONAGO ACTA MED, V61, P8, DOI 10.33160/yam.2018.03.002
   Gao L, 2013, J IMMUNOL, V190, P689, DOI 10.4049/jimmunol.1103688
   Glueck M, 2015, BIORESEARCH OPEN ACC, V4, P121, DOI 10.1089/biores.2015.0002
   Griesenauer B, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00475
   Hashimshony T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059 016 0938 8
   Hirai T, 2015, BIOL OPEN, V4, P1400, DOI 10.1242/bio.012617
   Jiang XF, 2022, J TISSUE ENG REGEN M, V16, P987, DOI 10.1002/term.3345
   Kain V, 2015, J MOL CELL CARDIOL, V84, P24, DOI 10.1016/j.yjmcc.2015.04.003
   Klein Y, 2020, J DENT RES, V99, P820, DOI 10.1177/0022034520911647
   Klein Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.928132
   Klein Y, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 65089 8
   Klein Y, 2020, J PERIODONTOL, V91, P1067, DOI 10.1002/JPER.19 0145
   Klein Y, 2019, J PERIODONTOL, V90, P189, DOI 10.1002/JPER.17 0550
   Kowalczewski CJ, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00513
   Krishnakumar GS, 2017, INT ORTHOP, V41, P1073, DOI 10.1007/s00264 017 3471 9
   Kuroshima S, 2013, J DENT RES, V92, P553, DOI 10.1177/0022034513487558
   Lademann F, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.586031
   Li JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00585
   Liu Q, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.601224
   Martin Leslie R, 2005, Ther Clin Risk Manag, V1, P189
   Marttila E, 2021, ACTA ODONTOL SCAND, V79, P25, DOI 10.1080/00016357.2020.1768285
   Murakami Kosaku, 2016, Nihon Rinsho Meneki Gakkai Kaishi, V39, P155, DOI 10.2177/jsci.39.155
   Murphy GEJ, 2010, ANN RHEUM DIS, V69, P43, DOI 10.1136/ard.2009.120113
   Natto ZS, 2017, J CLIN PERIODONTOL, V44, P649, DOI 10.1111/jcpe.12722
   Norling LV, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.85922
   Peres Juliana Alves, 2011, Braz. Dent. J., V22, P443
   Phan TCA, 2004, HISTOL HISTOPATHOL, V19, P1325, DOI 10.14670/HH 19.1325
   Rath B, 2008, J BIOMECH, V41, P1095, DOI 10.1016/j.jbiomech.2007.11.024
   Saperov V N, 2016, Klin Med (Mosk), V94, P554, DOI 10.18821/0023 2149 2016 94 7 554 559
   Skovrlj B, 2015, SPINE, V40, P1862, DOI 10.1097/BRS.0000000000001126
   Steffens JP, 2014, HORM METAB RES, V46, P193, DOI 10.1055/s 0034 1367031
   Steiner Gregory Gene, 2008, Compend Contin Educ Dent, V29, P114
   Thomas MV, 2011, J DENT RES, V90, P1052, DOI 10.1177/0022034510393967
   Vasconcelos DP, 2018, J BIOMED MATER RES A, V106, P1626, DOI 10.1002/jbm.a.36370
   Wang FF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145677
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb 2014 15 3 r52
   Xu D, 2008, P NATL ACAD SCI USA, V105, P10913, DOI 10.1073/pnas.0801898105
   Yazawa M, 2003, J ORAL MAXIL SURG, V61, P587, DOI 10.1053/joms.2003.50116
   Yellepeddi VK, 2021, CTS CLIN TRANSL SCI, V14, P683, DOI 10.1111/cts.12930
   Zhang M, 2020, J ORTHOP TRANSL, V22, P26, DOI 10.1016/j.jot.2019.09.005
NR 54
TC 8
Z9 9
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
SN 1664 3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD FEB 27
PY 2023
VL 14
AR 1086930
DI 10.3389/fimmu.2023.1086930
PG 12
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA 9T6YE
UT WOS:000947170200001
PM 36923414
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Bojanic, K
   Curcic, IB
   Kuna, L
   Kizivat, T
   Smolic, R
   Lucic, NR
   Kralik, K
   Seric, V
   Ivanac, G
   Tucak Zoric, S
   Vcev, A
   Smolic, M
AF Bojanic, Kristina
   Curcic, Ines Bilic
   Kuna, Lucija
   Kizivat, Tomislav
   Smolic, Robert
   Lucic, Nikola Raguz
   Kralik, Kristina
   Seric, Vatroslav
   Ivanac, Gordana
   Tucak Zoric, Sandra
   Vcev, Aleksandar
   Smolic, Martina
TI Association of Wnt Inhibitors, Bone Mineral Density and Lifestyle
   Parameters in Women with Breast Cancer Treated with Anastrozole Therapy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE aromatase inhibitors; bone density; breast neoplasms; Wnt signaling
   pathway
ID AROMATASE INHIBITORS; SCLEROSTIN LEVELS; AMERICAN SOCIETY; SERUM
   SCLEROSTIN; ADJUVANT TRIALS; DICKKOPF 1; TAMOXIFEN; DKK1; EXPRESSION;
   ESTROGEN
AB Aim: To determine the levels of Wnt inhibitors in patients treated with aromatase inhibitors (AIs) prior to therapy and to investigate their association with bone mineral density (BMD) and lifestyle parameters. Methods: 137 breast cancer patients were divided into a group treated with 1 mg of anastrozole and a group w/o anastrozole therapy. Serum concentrations of sclerostin and dickkopf1 (DKK1) were measured by ELISA. BMD was measured by dual energy X ray absorptiometry (DXA). Lifestyle factors were investigated by a self reported questionnaire. Results: Sclerostin was significantly higher in the AI treated group (31.8 pmol/L vs. 24.1 pmol/L; p < 0.001), whereas DKK1 was significantly lower in the AI treated group (24.3 pmol/L vs. 26.02 pmol/L; p < 0.001). Total hip and femoral neck BMD were significantly lower in the AI treated group. Conclusion: AI treatment was associated with increased levels of sclerostin and decreased levels of DKK1.
C1 [Bojanic, Kristina; Curcic, Ines Bilic; Kizivat, Tomislav; Smolic, Robert; Lucic, Nikola Raguz; Seric, Vatroslav; Tucak Zoric, Sandra; Vcev, Aleksandar; Smolic, Martina] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Mineral Metab, Osijek 31000, Croatia.
   [Bojanic, Kristina] Hlth Ctr Osijek, Dept Radiol, Osijek 31000, Croatia.
   [Curcic, Ines Bilic; Smolic, Robert; Lucic, Nikola Raguz; Smolic, Martina] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Pharmacol, Osijek 31000, Croatia.
   [Curcic, Ines Bilic; Smolic, Robert; Vcev, Aleksandar] Univ Hosp Osijek, Dept Med, Osijek 31000, Croatia.
   [Kuna, Lucija] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Biol, Osijek 31000, Croatia.
   [Kuna, Lucija] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Chem, Osijek 31000, Croatia.
   [Kizivat, Tomislav] Univ Hosp Osijek, Clin Inst Nucl Med & Radiat Safety, Osijek 31000, Croatia.
   [Lucic, Nikola Raguz; Smolic, Martina] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Pharmacol, Osijek 31000, Croatia.
   [Kralik, Kristina] JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Med Stat & Med Informat, Osijek 31000, Croatia.
   [Ivanac, Gordana] Univ Hosp Dubrava, Dept Diagnost & Intervent Radiol, Zagreb 10000, Croatia.
   [Vcev, Aleksandar] JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Pathophysiol, Osijek 31000, Croatia.
C3 University of JJ Strossmayer Osijek; University of JJ Strossmayer
   Osijek; University of JJ Strossmayer Osijek; University of JJ
   Strossmayer Osijek; University of JJ Strossmayer Osijek; University of
   JJ Strossmayer Osijek; University of JJ Strossmayer Osijek
RP Smolic, M (通讯作者)，JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Mineral Metab, Osijek 31000, Croatia.; Smolic, M (通讯作者)，JJ Strossmayer Univ Osijek, Fac Med Osijek, Dept Pharmacol, Osijek 31000, Croatia.; Smolic, M (通讯作者)，JJ Strossmayer Univ Osijek, Fac Dent Med & Hlth Osijek, Dept Pharmacol, Osijek 31000, Croatia.
EM kristina.bojanic@dzo.hr; ibcurcic@mefos.hr; lucija.kuna@fdmz.hr;
   tomislavkizivat@gmail.com; rsmolic@mefos.hr; nikolarlucic@gmail.com;
   kristina.kralik@mefos.hr; vatroslav.seric@mefos.hr;
   gordana.augustan@gmail.com; atucak@mefos.hr; avcev@mefos.hr;
   martina.smolic@mefos.hr
RI Bilic Curcic, Ines/R 6013 2018; Curcic, Ines/R 6013 2018; Kralik,
   Kristina/HCI 4811 2022; Kizivat, Tomislav/L 2024 2017; Smolic,
   Robert/T 6164 2019
OI Bilic Curcic, Ines/0000 0002 8861 5987; Kralik,
   Kristina/0000 0002 4481 6365; Kizivat, Tomislav/0000 0002 2523 6007; 
FU Croatian Ministry of Science, Education and Sports [VIF 2017 MEFOS 5,
   VIF 2017 MEFOS 2]
FX The study was funded by grants from Croatian Ministry of Science,
   Education and Sports dedicated to multi year institutional funding of
   scientific activity at the J.J. Strossmayer University of Osijek,
   Osijek, Croatia grant's numbers: VIF 2017 MEFOS 5 (to M.S.) and
   VIF 2017 MEFOS 2 (to A.V.).
CR Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094
   Atkins GJ, 2011, J BONE MINER RES, V26, P1425, DOI 10.1002/jbmr.345
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Bezooijen RL, 2005, CYTOKINE GROWTH F R, V16, P319, DOI 10.1016/j.cytogfr.2005.02.005
   Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082
   Butler JS, 2011, J ORTHOP RES, V29, P414, DOI 10.1002/jor.21260
   Dawood S, 2014, INDIAN J MED PAEDIAT, V35, P176, DOI 10.4103/0971 5851.138997
   Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274
   Eastell R, 2008, J CLIN ONCOL, V26, P1051, DOI 10.1200/JCO.2007.11.0726
   Eisen A, 2008, CANCER TREAT REV, V34, P157, DOI 10.1016/j.ctrv.2007.11.001
   Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146
   Garnero P, 2013, OSTEOPOROSIS INT, V24, P489, DOI 10.1007/s00198 012 1978 x
   Gatti D, 2012, J BONE MINER RES, V27, P2259, DOI 10.1002/jbmr.1681
   Gavriatopoulou M, 2009, EXPERT OPIN THER TAR, V13, P839, DOI 10.1517/14728220903025770
   Göbel A, 2017, BREAST CANCER RES TR, V164, P737, DOI 10.1007/s10549 017 4296 3
   Hadji P, 2009, CRIT REV ONCOL HEMAT, V69, P73, DOI 10.1016/j.critrevonc.2008.07.013
   Hofbauer LC, 2004, JAMA J AM MED ASSOC, V292, P490, DOI 10.1001/jama.292.4.490
   Ingle JN, 2011, STEROIDS, V76, P765, DOI 10.1016/j.steroids.2011.02.021
   Kalder M, 2014, J CLIN DENSITOM, V17, P66, DOI 10.1016/j.jocd.2013.03.003
   Kim W, 2015, ENDOCRINOL METAB, V30, P58, DOI 10.3803/EnM.2015.30.1.58
   Kyvernitakis I, 2014, J CANCER RES CLIN, V140, P1671, DOI 10.1007/s00432 014 1726 z
   Liakou CG, 2016, ENDOCRINE, V54, P543, DOI 10.1007/s12020 016 1056 9
   Lin CW, 2009, J BONE MINER RES, V24, P1651, DOI [10.1359/JBMR.090411, 10.1359/jbmr.090411]
   Mirza FS, 2010, J CLIN ENDOCR METAB, V95, P1991, DOI 10.1210/jc.2009 2283
   Mödder UI, 2011, J BONE MINER RES, V26, P373, DOI 10.1002/jbmr.217
   Muschitz C, 2015, J CLIN ENDOCR METAB, V100, P891, DOI 10.1210/jc.2014 3367
   Polyzos SA, 2012, OSTEOPOROSIS INT, V23, P1171, DOI 10.1007/s00198 010 1525 6
   Poole KES, 2005, FASEB J, V19, P1842, DOI 10.1096/fj.05 4221fje
   Rabelo FD, 2010, AUTOIMMUN REV, V9, P207, DOI 10.1016/j.autrev.2009.08.003
   Robling AG, 2008, J BIOL CHEM, V283, P5866, DOI 10.1074/jbc.M705092200
   Sankaralingam A, 2014, J OSTEOPOROS, V2014, DOI 10.1155/2014/682763
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Ustun N, 2014, ACTA REUMATOL PORT, V39, P146
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
NR 35
TC 3
Z9 3
U1 0
U2 15
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2077 0383
J9 J CLIN MED
JI J. Clin. Med.
PD SEP
PY 2018
VL 7
IS 9
AR 287
DI 10.3390/jcm7090287
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA GU9AK
UT WOS:000445635800061
PM 30227689
OA gold, Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Arns, S
   Gibe, R
   Moreau, A
   Morshed, MM
   Young, RN
AF Arns, Steve
   Gibe, Romelo
   Moreau, Anne
   Morshed, M. Monzur
   Young, Robert N.
TI Design and synthesis of novel bone targeting dual action pro drugs for
   the treatment and reversal of osteoporosis
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Prostaglandin E 2; EP4 receptor; Agonist; Osteoporosis; Conjugates;
   Bone targeting; Alendronic acid; Dual action; Anabolic; Slow release;
   Radiolabelled
ID SELECTIVE AGONIST; PROSTAGLANDIN E2; BISPHOSPHONATES; DISCOVERY; AGENTS;
   RATS
AB There is an important medical need for effective therapies to redress the general bone loss associated with advanced osteoporosis. Prostaglandin E 2 and related EP4 receptor agonists have been shown to stimulate bone regrowth but their use has been limited by systemic side effects. Herein is described the design and synthesis of novel dual action bone targeting conjugate pro drugs where two classes of active agents, a bone growth stimulating prostaglandin E 2 EP4 receptor subtype agonist (5 or 6) and a bone resorption inhibitor bisphosphonate, alendronic acid (1), are coupled using metabolically labile carbamate or 4 hydroxyphenylacetic acid based linkers. Radiolabelled conjugates 9, 11a/b and 25 were synthesized and evaluated in vivo in rats for uptake of the conjugate into bone and subsequent release of the EP4 agonists over time. While conjugate 11a/b was taken up (9.0% of initial dose) but not released over two weeks, conjugates 9 and 25 were absorbed at 9.4% and 5.9% uptake of the initial dose and slowly released with half lives of approximately 2 weeks and 5 days respectively. These conjugates were well tolerated and offer potential for sustained release and dual synergistic activity through their selective bone targeting and local release of the complimentary active components. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Arns, Steve; Gibe, Romelo; Moreau, Anne; Morshed, M. Monzur; Young, Robert N.] Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.
C3 Simon Fraser University
RP Young, RN (通讯作者)，Simon Fraser Univ, Dept Chem, Burnaby, BC V5A 1S6, Canada.
EM roberty@sfu.ca
OI Young, Robert/0000 0002 8235 6080
FU Canadian Institutes of Health   Institute for Musculoskeletal Health and
   Arthritis; Natural Sciences and Engineering Council of Canada; British
   Columbia Government; Merck Frosst Canada Ltd.
FX The authors acknowledge the support of the Canadian Institutes of Health
     Institute for Musculoskeletal Health and Arthritis and the Natural
   Sciences and Engineering Council of Canada, the British Columbia
   Government Leading Edge Endowment Fund and Merck Frosst Canada Ltd. for
   financial support and for providing radiolabelled tetrazole
   [<SUP>3</SUP>H] 6. The authors are grateful to Dr. Lawrence Amankwa of
   CDRD (Vancouver, Canada) for LC MS MS measurements. The authors also
   acknowledge the technical staff of Animal Care Services in the Animal
   Resources Facility, Simon Fraser University for animal experiments and
   Dr. Nag Kumar for help in preparing the manuscript.
CR Arns S, 2010, J LABELLED COMPD RAD, V53, P205, DOI 10.1002/jlcr.1753
   Billot X, 2003, BIOORG MED CHEM LETT, V13, P1129, DOI 10.1016/S0960 894X(03)00042 8
   Billot X., 2003, Patent No. [WO 03/103772, 03103772]
   Brümmer O, 2001, CHEM COMMUN, P19, DOI 10.1039/b008065i
   Erez R, 2008, BIOORG MED CHEM LETT, V18, P816, DOI 10.1016/j.bmcl.2007.11.029
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gediya LK, 2008, J MED CHEM, V51, P3895, DOI 10.1021/jm8001839
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Heymann D, 2004, TRENDS MOL MED, V10, P337, DOI 10.1016/j.molmed.2004.05.007
   JEE WSS, 1991, BONE MINER, V15, P33, DOI 10.1016/0169 6009(91)90109 D
   Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36
   Maruyama T., 2002, BIOORGAN MED CHEM, V10, P1743
   NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952 3278(90)90081 U
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   UENO K, 1985, BONE, V6, P79, DOI 10.1016/8756 3282(85)90311 4
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Vahle JL, 2004, TOXICOL PATHOL, V32, P426, DOI 10.1080/01926230490462138
   Young RN, 2004, HETEROCYCLES, V64, P437
NR 18
TC 42
Z9 59
U1 0
U2 52
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD MAR 15
PY 2012
VL 20
IS 6
BP 2131
EP 2140
DI 10.1016/j.bmc.2012.01.024
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 904MJ
UT WOS:000301201100034
PM 22341574
DA 2025 08 17
ER

PT J
AU Vanderniet, JA
   Wall, CL
   Mullins, A
   London, K
   Lim, L
   Hibbert, S
   Briody, J
   Padhye, B
   Poon, M
   Biggin, A
   Dalla Pozza, L
   Munns, CF
AF Vanderniet, Joel A.
   Wall, Christie Lee
   Mullins, Anna
   London, Kevin
   Lim, Lydia
   Hibbert, Sally
   Briody, Julie
   Padhye, Bhavna
   Poon, Myra
   Biggin, Andrew
   Dalla Pozza, Luciano
   Munns, Craig F.
TI Denosumab for central giant cell granuloma in an Australian tertiary
   paediatric centre
SO BONE
LA English
DT Article
DE Hypercalcemia; Hypocalcemia; Recurrence; PET CT
ID THERAPY; BONE; MANAGEMENT; LESIONS; TUMOR; JAW
AB Background: Central giant cell granulomas (CGCG) are rare osteolytic, benign but often locally aggressive tumours of bone. Surgical curettage may not be possible in extensive lesions and resection carries high morbidity, especially in growing children, and previous medical therapies have had variable efficacy and high recurrence rates. Interruption of receptor activator of nuclear factor kappa B ligand (RANKL) signalling holds promise as an effective therapeutic strategy for these tumours.
   Aims: To evaluate the efficacy and safety of our protocol for denosumab treatment of CGCG in children.
   Methods: Retrospective review of 4 patients treated with denosumab using a standardised protocol for CGCG in a tertiary paediatric centre. Denosumab 70 mg/m(2) was given 4 weekly, followed by 2 doses of zoledronate 0.025 mg/kg, aimed at preventing rebound hypercalcaemia.
   Results: Treatment of CGCG resulted in metabolic remission in all patients, but recurrence, detected by positron emission tomography (PET), occurred at 6 months in three patients and 12 months in one patient. Three patients developed symptomatic hypercalcaemia 4 5 months and one patient asymptomatic hypercalcaemia 7 months after cessation of denosumab, with 3 requiring additional bisphosphonate treatment.
   Conclusions: Denosumab produced a radiological and metabolic response in our patients, but metabolic recurrence occurred in all patients. PET imaging was effective for monitoring treatment response and early detection of recurrence. Incidence of rebound hypercalcaemia in this paediatric cohort was high. We present proposed changes to our protocol with the aim of producing sustained remission and preventing rebound hypercalcaemia.
C1 [Vanderniet, Joel A.; Wall, Christie Lee; Poon, Myra; Biggin, Andrew] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Sydney, NSW, Australia.
   [Mullins, Anna; Padhye, Bhavna; Dalla Pozza, Luciano] Childrens Hosp Westmead, Canc Ctr Children, Sydney, NSW, Australia.
   [London, Kevin; Briody, Julie] Childrens Hosp Westmead, Dept Nucl Med, Sydney, NSW, Australia.
   [Lim, Lydia] Westmead Hosp, Dept Oral & Maxillofacial Surg, Sydney, NSW, Australia.
   [Lim, Lydia; Hibbert, Sally] Childrens Hosp Westmead, Dept Paediat Dent & Oral & Maxillofacial Surg, Sydney, NSW, Australia.
   [Hibbert, Sally] Westmead Ctr Oral Hlth, Dept Paediat Dent, Sydney, NSW, Australia.
   [Padhye, Bhavna; Biggin, Andrew; Dalla Pozza, Luciano] Univ Sydney, Fac Med & Hlth, Discipline Paediat & Child Hlth, Sydney, NSW, Australia.
   [Munns, Craig F.] Univ Queensland, Fac Med, Brisbane, Qld, Australia.
   [Munns, Craig F.] Univ Queensland, Child Hlth Res Ctr, Brisbane, Qld, Australia.
   [Munns, Craig F.] Queensland Childrens Hosp, Dept Endocrinol & Diabet, Brisbane, Qld, Australia.
C3 University of Sydney; NSW Health; The Children's Hospital at Westmead;
   University of Sydney; NSW Health; The Children's Hospital at Westmead;
   University of Sydney; NSW Health; The Children's Hospital at Westmead;
   University of Sydney; NSW Health; Westmead Hospital; University of
   Sydney; NSW Health; The Children's Hospital at Westmead; University of
   Sydney; University of Queensland; University of Queensland; Childrens
   Health Queensland Hospital & Health Service; Queensland Childrens
   Hospital
RP Vanderniet, JA (通讯作者)，Childrens Hosp Westmead, Inst Endocrinol & Diabet, Locked Bag 4001, Westmead, NSW 2145, Australia.
EM joel.vanderniet@health.nsw.gov.au
RI ; Munns, Craig/A 8719 2015; Vanderniet, Joel/KXR 1401 2024
OI Mullins, Anna/0000 0003 2409 4622; Munns, Craig/0000 0001 5898 5808;
   Vanderniet, Joel/0000 0002 7063 6667; 
CR AUCLAIR PL, 1988, ORAL SURG ORAL MED O, V66, P197, DOI 10.1016/0030 4220(88)90094 1
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Boye K, 2017, ACTA ONCOL, V56, P479, DOI 10.1080/0284186X.2016.1278305
   Bredell M, 2018, J ORAL MAXIL SURG, V76, P775, DOI 10.1016/j.joms.2017.09.013
   Chawla S, 2013, LANCET ONCOL, V14, P901, DOI 10.1016/S1470 2045(13)70277 8
   Chen X, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891 020 03294 2
   Choe M, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28778
   Chrcanovic BR, 2018, J ORAL PATHOL MED, V47, P731, DOI 10.1111/jop.12730
   de Lange J, 2004, HEAD NECK J SCI SPEC, V26, P792, DOI 10.1002/hed.20069
   De Lange J, 2007, ORAL SURG ORAL MED O, V104, P603, DOI 10.1016/j.tripleo.2007.04.003
   Engellau J, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1478 3
   Ferriero K, 2020, FRONT PEDIATR, V8, DOI 10.3389/fped.2020.00515
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   Gupta B, 2015, J CRANIO MAXILL SURG, V43, P1127, DOI 10.1016/j.jcms.2015.04.011
   Hameed M, 2019, BRIT J ORAL MAX SURG, V57, P691, DOI 10.1016/j.bjoms.2019.05.023
   Hao KJ, 2019, J NUCL MED, V60
   Hayashida K, 2022, J ORTHOP SCI, V27, P215, DOI 10.1016/j.jos.2020.11.005
   Kim TS, 2017, JBMR PLUS, V1, P101, DOI 10.1002/jbm4.10010
   Kurucu N, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26926
   Muheremu A, 2017, ONCOL LETT, V14, P1985, DOI 10.3892/ol.2017.6379
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Ooi HL, 2013, HORM RES PAEDIAT, V80, P179, DOI 10.1159/000354303
   Pan KS, 2021, CURR OSTEOPOROS REP, V19, P141, DOI 10.1007/s11914 021 00657 z
   Pogrel MA, 2021, INT J ORAL MAX SURG, V50, P1019, DOI 10.1016/j.ijom.2020.12.013
   Schreuder WH, 2017, J ORAL MAXIL SURG, V75, P105, DOI 10.1016/j.joms.2016.06.007
   Schreuder WH, 2014, J ORAL MAXIL SURG, V72, P1301, DOI 10.1016/j.joms.2014.02.017
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Sydlik C, 2020, WORLD J PEDIATR, V16, P520, DOI 10.1007/s12519 020 00378 w
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   van Langevelde K, 2020, SKELETAL RADIOL, V49, P1345, DOI 10.1007/s00256 020 03449 1
   Wang HD, 2014, J CLIN ENDOCR METAB, V99, P891, DOI 10.1210/jc.2013 3081
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
NR 32
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUN
PY 2022
VL 159
AR 116395
DI 10.1016/j.bone.2022.116395
EA MAR 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0P1IA
UT WOS:000783974800001
PM 35331976
DA 2025 08 17
ER

PT J
AU Guler, E
   Baripoglu, YE
   Alenezi, H
   Arikan, A
   Babazade, R
   Unal, S
   Duruksu, G
   Alfares, FS
   Yazir, Y
   Oktar, FN
   Gunduz, O
   Edirisinghe, M
   Cam, ME
AF Guler, Ece
   Baripoglu, Yaren Ezgi
   Alenezi, Hussain
   Arikan, Ayca
   Babazade, Ravana
   Unal, Semra
   Duruksu, Gokhan
   Alfares, Fawzan S.
   Yazir, Yusufhan
   Oktar, Faik Nuzhet
   Gunduz, Oguzhan
   Edirisinghe, Mohan
   Cam, Muhammet Emin
TI Vitamin D3/vitamin K2/magnesium loaded polylactic
   acid/tricalcium phosphate/polycaprolactone composite nanofibers
   demonstrated osteoinductive effect by increasing Runx2 via
   Wnt/β catenin pathway
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Bone tissue engineering; Composite nanofiber; Osteoblast cell
ID DRUG RELEASE; DIFFERENTIATION; PROLIFERATION; ACTIVATION; OSTEOBLAST;
   HYDROGELS; DELIVERY; FIBERS; PCL
AB Vitamin D3, vitamin K2, and Mg (10%, 1.25%, and 5%, w/w, respectively) loaded PLA (12%, w/v) (TCP (5%, w/ v))/PCL (12%, w/v) 1:1 (v/v) composite nanofibers (DKMF) were produced by electrospinning method (ES) and their osteoinductive effects were investigated in cell culture test. Neither pure nanofibers nor DKMF caused a significant cytotoxic effect in fibroblasts. The induction of the stem cell differentiation into osteogenic cells was observed in the cell culture with both DKMF and pure nanofibers, separately. Vitamin D3, vitamin K2, and magnesium demonstrated to support the osteogenic differentiation of mesenchymal stem cells by expressing Runx2, BMP2, and osteopontin and suppressing PPAR gamma and Sox9. Therefore, the Wnt/beta catenin signaling pathway was activated by DKMF. DKMF promoted large axonal sprouting and needle like elongation of osteoblast cells and enhanced cellular functions such as migration, infiltration, proliferation, and differentiation after seven days of incubation using confocal laser scanning microscopy. The results showed that DKMF demonstrated sustained drug release for 144 h, tougher and stronger structure, higher tensile strength, increased water up take capacity, decreased degradation ratio, and slightly lower Tm and Tg values compared to pure nanofibers. Consequently, DKMF is a promising treatment approach in bone tissue engineering due to its osteoinductive effects.
C1 [Guler, Ece; Babazade, Ravana; Cam, Muhammet Emin] Marmara Univ, Fac Pharm, Dept Pharmacol, TR 34854 Istanbul, Turkey.
   [Guler, Ece; Babazade, Ravana; Unal, Semra; Oktar, Faik Nuzhet; Gunduz, Oguzhan; Edirisinghe, Mohan; Cam, Muhammet Emin] Marmara Univ, Ctr Nanotechnol & Biomat Applicat & Res, TR 34722 Istanbul, Turkey.
   [Baripoglu, Yaren Ezgi; Arikan, Ayca] Marmara Univ, Fac Technol, Dept Bioengn, TR 34722 Istanbul, Turkey.
   [Alenezi, Hussain; Edirisinghe, Mohan] UCL, Dept Mech Engn, Torrington Pl, London WC1E 7JE, England.
   [Alenezi, Hussain; Alfares, Fawzan S.] Coll Technol Studies, Dept Mfg Engn, PAAET, Kuwait 13092, Kuwait.
   [Duruksu, Gokhan; Yazir, Yusufhan] Kocaeli Univ, Med Fac, Stem Cell & Gene Therapies Res & Appl Ctr, TR 41380 Kocaeli, Turkey.
   [Oktar, Faik Nuzhet] Marmara Univ, Fac Engn, Dept Bioengn, TR 34722 Istanbul, Turkey.
   [Gunduz, Oguzhan] Marmara Univ, Fac Technol, Dept Met & Mat Engn, TR 34722 Istanbul, Turkey.
C3 Marmara University; Marmara University; Marmara University; University
   of London; University College London; Public Authority for Applied
   Education & Training (PAAET)   Kuwait; Kocaeli University; Marmara
   University; Marmara University
RP Cam, ME (通讯作者)，Marmara Univ, Fac Pharm, Dept Pharmacol, TR 34854 Istanbul, Turkey.
EM muhammet.cam@marmara.edu.tr
RI Gunduz, Oguzhan/E 5292 2011; GÃ¼ler, Ece/KEJ 1432 2024; Gunduz,
   Oguzhan/AAA 3212 2019; DURUKSU, Gokhan/F 7304 2018; Yazır,
   YUSUFHAN/F 7289 2018; Cam, Muhammet/AAB 4488 2019; Duruksu,
   Gökhan/F 7304 2018
OI Gunduz, Oguzhan/0000 0002 9427 7574; Alenezi, Hussain
   Ali/0000 0003 4563 7868; DURUKSU, Gokhan/0000 0002 3830 2384; Yazir,
   Yusufhan/0000 0002 8472 0261; 
CR Abalymov A, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12030620
   Aguzzi C, 2010, MATER TECHNOL, V25, P205, DOI 10.1179/175355510X12723642365566
   Alakrach A., 2018, J PHYS C SERIES
   Alenezi H, 2019, APPL PHYS REV, V6, DOI 10.1063/1.5110965
   Alexis F, 2005, POLYM INT, V54, P36, DOI 10.1002/pi.1697
   Ansari M, 2019, PROG BIOMATER, V8, P223, DOI 10.1007/s40204 019 00125 z
   Aydin A, 2014, J ORTHOP RES, V32, P151, DOI 10.1002/jor.22484
   Belgheisi G, 2020, APPL CLAY SCI, V185, DOI 10.1016/j.clay.2019.105434
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Bonor JC, 2012, J NANOSCI NANOTECHNO, V12, P2185, DOI 10.1166/jnn.2012.5785
   Bunaciu AA, 2015, CRIT REV ANAL CHEM, V45, P289, DOI 10.1080/10408347.2014.949616
   Cam ME, 2021, MAT SCI ENG C MATER, V119, DOI 10.1016/j.msec.2020.111586
   Cam ME, 2020, INT J PHARMACEUT, V588, DOI 10.1016/j.ijpharm.2020.119782
   Cam ME, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2019.0712
   Cam ME, 2019, EUR POLYM J, V120, DOI 10.1016/j.eurpolymj.2019.109239
   Castiglioni S, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 34324 8
   Castro KC, 2021, INT J BIOL MACROMOL, V173, P251, DOI 10.1016/j.ijbiomac.2021.01.100
   Cesur S, 2020, J AUST CERAM SOC, V56, P533, DOI 10.1007/s41779 019 00363 1
   Chen W., 2005, CROSS LINKED CHITOSA
   Chou SF, 2017, J MECH BEHAV BIOMED, V65, P724, DOI 10.1016/j.jmbbm.2016.09.004
   Day TF, 2005, DEV CELL, V8, P739, DOI 10.1016/j.devcel.2005.03.016
   de Grado GF, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418776819
   di Giacomo V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082789
   Díaz Tocados JM, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 08379 y
   Diba M, 2017, ADV FUNCT MATER, V27, DOI 10.1002/adfm.201703438
   dos Santos VI, 2020, MAT SCI ENG C MATER, V112, DOI 10.1016/j.msec.2020.110849
   Dwivedi Ruby, 2020, J Oral Biol Craniofac Res, V10, P381, DOI 10.1016/j.jobcr.2019.10.003
   Elshishiny F, 2020, ACS OMEGA, V5, P2133, DOI 10.1021/acsomega.9b02832
   Fang R, 2010, J NANOSCI NANOTECHNO, V10, P7747, DOI 10.1166/jnn.2010.2831
   Fu YC, 2013, J MECH BEHAV BIOMED, V27, P64, DOI 10.1016/j.jmbbm.2013.06.009
   Halder M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040896
   Jeon MJ, 2003, J BIOL CHEM, V278, P23270, DOI 10.1074/jbc.M211610200
   Jeong J, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 018 0149 3
   Khan S, 2014, POLYM BULL, V71, P2133, DOI 10.1007/s00289 014 1178 2
   Kim DH, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020575
   Kim L, 2018, FOOD CHEM, V249, P184, DOI 10.1016/j.foodchem.2018.01.006
   Kim YH, 2015, BIOL PHARM BULL, V38, P1033, DOI 10.1248/bpb.b15 00113
   López García J, 2014, J FUNCT BIOMATER, V5, P43, DOI 10.3390/jfb5020043
   Lou YR, 2017, SCI REP UK, V7, DOI 10.1038/srep42816
   Lu Y, 2016, FIBRES TEXT EAST EUR, V24, P17, DOI 10.5604/12303666.1196607
   Mariani E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030636
   McCullen SD, 2009, BIOMED MATER, V4, DOI 10.1088/1748 6041/4/3/035002
   Mehdikhani B., 2014, INT LETT CHEM PHYS A, V17
   de Oca AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089525
   Nep EI, 2012, J THERM ANAL CALORIM, V108, P197, DOI 10.1007/s10973 011 1782 4
   Oliveira JE, 2013, ADV MATER SCI ENG, V2013, DOI 10.1155/2013/409572
   Rambhia KJ, 2015, J CONTROL RELEASE, V219, P119, DOI 10.1016/j.jconrel.2015.08.049
   Ramezanli T, 2017, INT J PHARMACEUT, V516, P196, DOI 10.1016/j.ijpharm.2016.10.072
   Ranganathan S, 2019, INT J BIOL MACROMOL, V133, P354, DOI 10.1016/j.ijbiomac.2019.04.115
   Rijal NP, 2018, MATER SCI ENG B ADV, V228, P18, DOI 10.1016/j.mseb.2017.11.006
   Salih FM, 2004, PHOTODERMATOL PHOTO, V20, P53, DOI 10.1111/j.1600 0781.2004.00068.x
   Sani IS, 2021, INT J BIOL MACROMOL, V182, P1638, DOI 10.1016/j.ijbiomac.2021.05.163
   Shi YC, 2007, BONE, V41, P87, DOI 10.1016/j.bone.2007.04.174
   Tungprapa S, 2007, CELLULOSE, V14, P563, DOI 10.1007/s10570 007 9113 4
   van Driel M, 2017, MOL CELL ENDOCRINOL, V453, P46, DOI 10.1016/j.mce.2017.06.008
   Vieira AC, 2011, J MECH BEHAV BIOMED, V4, P451, DOI 10.1016/j.jmbbm.2010.12.006
   Wasilewski GB, 2019, FRONT CARDIOVASC MED, V6, DOI 10.3389/fcvm.2019.00006
   Wójcik Pastuszka D, 2019, MATERIALS, V12, DOI 10.3390/ma12081202
   Wsoo MA, 2021, INT J BIOL MACROMOL, V181, P82, DOI 10.1016/j.ijbiomac.2021.03.108
   Xu ZY, 2016, RSC ADV, V6, P43626, DOI 10.1039/c6ra03620a
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yonemura K, 2000, CALCIFIED TISSUE INT, V66, P123, DOI 10.1007/PL00005832
   Zhu CX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.660571
NR 63
TC 25
Z9 29
U1 1
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141 8130
EI 1879 0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD NOV 1
PY 2021
VL 190
BP 244
EP 258
DI 10.1016/j.ijbiomac.2021.08.196
EA SEP 2021
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA WL1LY
UT WOS:000710176700008
PM 34492244
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Law, S
   Du, X
   Panwar, P
   Honson, NS
   Pfeifer, T
   Roberge, M
   Brömme, D
AF Law, Simon
   Du, Xin
   Panwar, Preety
   Honson, Nicolette S.
   Pfeifer, Tom
   Roberge, Michel
   Bromme, Dieter
TI Identification of substrate specific inhibitors of cathepsin K through
   high throughput screening
SO BIOCHEMICAL JOURNAL
LA English
DT Article
ID AURINTRICARBOXYLIC ACID; COLLAGENASE ACTIVITY; COLLAGENOLYTIC ACTIVITY;
   BONE RESORPTION; OSTEOPOROSIS; EXPRESSION; DEGRADATION; OSTEOCLASTS;
   MECHANISMS; ODANACATIB
AB Cathepsin K (CatK) is a cysteine protease and drug target for skeletal disorders that is known for its potent collagenase and elastase activity. The formation of oligomeric complexes of CatK in the presence of glycosarninoglycans has been associated with its collagenase activity. Inhibitors that disrupt these complexes can selectively block the collagenase activity without interfering with the other regulatory proteolytic activities of the enzyme. Here, we have developed a fluorescence polarization (FP) assay to screen 4761 compounds for substrate specific ectosteric collagenase inhibitors of CatK. A total of 38 compounds were identified that block the collagenase activity without interfering with the hydrolysis of active site substrates such as the synthetic peptide substrate, benzyloxycarbonyl Phe Arg 7 amido 4 methylcoumarin, and gelatin. The identified inhibitors can be divided into two main classes, negatively charged and polyaromatic compounds which suggest the binding to different ectosteric sites. Two of the inhibitors were highly effective in preventing the bone resorption activity of CatK in osteoclasts. Interestingly, some of the ectosteric inhibitors were capable of differentiating between the collagenase and elastase activity of CatK depending on the ectosteric site utilized by the compound. Owing to their substrate specific selectivity, ectosteric inhibitors represent a viable alternative to side effect prone active site directed inhibitors.
C1 [Law, Simon; Du, Xin; Roberge, Michel; Bromme, Dieter] Univ British Columbia, Dept Biochem & Mol Biol, Fac Med, Vancouver, BC V6T 1Z3, Canada.
   [Law, Simon; Du, Xin; Panwar, Preety; Bromme, Dieter] Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada.
   [Panwar, Preety; Bromme, Dieter] Univ British Columbia, Dept Oral Biol & Med Sci, Fac Dent, Vancouver, BC V6T 1Z3, Canada.
   [Honson, Nicolette S.; Pfeifer, Tom] Univ British Columbia, Ctr Drug Res & Dev, Vancouver, BC V6T 1Z3, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia; University of British Columbia
RP Brömme, D (通讯作者)，Univ British Columbia, Dept Biochem & Mol Biol, Fac Med, Vancouver, BC V6T 1Z3, Canada.; Brömme, D (通讯作者)，Univ British Columbia, Ctr Blood Res, Vancouver, BC V6T 1Z3, Canada.; Brömme, D (通讯作者)，Univ British Columbia, Dept Oral Biol & Med Sci, Fac Dent, Vancouver, BC V6T 1Z3, Canada.
EM dbromme@dentistry.ubc.ca
OI Law, Simon Sau Yin/0000 0002 9650 2958
FU Canadian Institutes of Health Research [MOP 89974, MOP 125866]; Natural
   Sciences & Engineering Research Council of Canada [RGPIN 326803 13];
   Canada Research Chair award
FX This work was supported by the Canadian Institutes of Health Research
   [grant numbers MOP 89974 (D.B.), MOP 125866 (D.B.)], the Natural
   Sciences & Engineering Research Council of Canada [grant number
   RGPIN 326803 13], and a Canada Research Chair award (to D.B.).
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   Baell JB, 2018, ACS CHEM BIOL, V13, P36, DOI 10.1021/acschembio.7b00903
   BINASTEIN M, 1976, MOL PHARMACOL, V12, P191
   Bisaggio DFR, 2008, INT J ANTIMICROB AG, V31, P282, DOI 10.1016/j.ijantimicag.2007.11.001
   Bone HG, 2015, OSTEOPOROSIS INT, V26, P699, DOI 10.1007/s00198 014 2944 6
   Brömme D, 2016, EXPERT OPIN DRUG DIS, V11, P457, DOI 10.1517/17460441.2016.1160884
   Bromme D, 1996, J BIOL CHEM, V271, P2126, DOI 10.1074/jbc.271.4.2126
   CATCHPOOLE DR, 1994, ANTICANCER RES, V14, P853
   Chen CH, 2013, MENOPAUSE, V20, P687, DOI [10.1097/gme.0b013e31828244f0, 10.1097/GME.0b013e31828244f0]
   Cherney MM, 2011, J BIOL CHEM, V286, P8988, DOI 10.1074/jbc.M110.126706
   Costa AG, 2011, NAT REV RHEUMATOL, V7, P447, DOI 10.1038/nrrheum.2011.77
   Du X, 2013, J BIOL CHEM, V288, P34871, DOI 10.1074/jbc.M113.510008
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Garnero P, 2003, J BONE MINER RES, V18, P859, DOI 10.1359/jbmr.2003.18.5.859
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY US, V19, P4299, DOI 10.1021/bi00559a023
   Kafienah W, 1998, BIOCHEM J, V331, P727, DOI 10.1042/bj3310727
   Law S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186869
   Lea WA, 2011, EXPERT OPIN DRUG DIS, V6, P17, DOI 10.1517/17460441.2011.537322
   Lecaille F, 2002, CHEM REV, V102, P4459, DOI 10.1021/cr0101656
   Li ZQ, 2008, J MOL BIOL, V383, P78, DOI 10.1016/j.jmb.2008.07.038
   Li ZQ, 2002, J BIOL CHEM, V277, P28669, DOI 10.1074/jbc.M204004200
   Li ZQ, 2000, BIOCHEMISTRY US, V39, P529, DOI 10.1021/bi992251u
   Lindström E, 2018, J TRANSL MED, V16, DOI 10.1186/s12967 018 1425 7
   Linnevers CJ, 1997, PROTEIN SCI, V6, P919
   McGrath ME, 1997, NAT STRUCT BIOL, V4, P105, DOI 10.1038/nsb0297 105
   Mullard A, 2016, NAT REV DRUG DISCOV, V15, P669, DOI 10.1038/nrd.2016.207
   Panwar P, 2018, BRIT J PHARMACOL, V175, P902, DOI 10.1111/bph.14133
   Panwar P, 2017, J BONE MINER RES, V32, P2415, DOI 10.1002/jbmr.3227
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Rünger TM, 2012, J AM ACAD DERMATOL, V66, pE89, DOI 10.1016/j.jaad.2010.11.033
   Samokhin AO, 2010, J CARDIOVASC PHARM, V56, P98, DOI 10.1097/FJC.0b013e3181e23e10
   SCHULZKEY H, 1985, TROP MED PARASITOL, V36, P244
   Selent J, 2007, J BIOL CHEM, V282, P16492, DOI 10.1074/jbc.M700242200
   Sharma V, 2015, BIOCHEM J, V465, P163, DOI 10.1042/BJ20140809
   SHI GP, 1992, J BIOL CHEM, V267, P7258
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Song DW, 2014, INT J CLIN EXP MED, V7, P4183
   Sun K, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000009034, 10.1097/md.0000000000009034]
   Tabatabaei Malazy O, 2015, J DIABETES METAB DIS, V14, DOI 10.1186/s40200 015 0184 8
   Tanaka M, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891 017 1625 y
   Yasuda Y, 2004, J BIOL CHEM, V279, P36761, DOI 10.1074/jbc.M403986200
   Yasuda Y, 2005, ADV DRUG DELIVER REV, V57, P973, DOI 10.1016/j.addr.2004.12.013
NR 46
TC 4
Z9 4
U1 0
U2 18
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0264 6021
EI 1470 8728
J9 BIOCHEM J
JI Biochem. J.
PD FEB 14
PY 2019
VL 476
BP 499
EP 512
DI 10.1042/BCJ20180851
PN 3
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA HQ4OX
UT WOS:000462392000005
PM 30622151
DA 2025 08 17
ER

PT J
AU Kong, XY
   Yang, Y
   Wu, WB
   Wan, HY
   Li, XM
   Zhong, MC
   Su, XH
   Jia, SW
   Lin, N
AF Kong, Xiangying
   Yang, Yue
   Wu, Wenbin
   Wan, Hongye
   Li, Xiaomin
   Zhong, Michun
   Su, Xiaohui
   Jia, Shiwei
   Lin, Na
TI Triterpenoid Saponin W3 from Anemone flaccida Suppresses
   Osteoclast Differentiation through Inhibiting Activation of MAPKs and
   NF κB Pathways
SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
LA English
DT Article
DE Anemone flaccida; RANKL; Osteoclasts; Bone resorption
ID BONE LOSS; OSTEOPROTEGERIN LIGAND; RHEUMATOID ARTHRITIS; RANKL;
   OSTEOLYSIS; INDUCTION; MODEL
AB Excessive bone resorption by osteoclasts within inflamed joints is the most specific hallmark of rheumatoid arthritis. A. flaccida has long been used for the treatment of arthritis in folk medicine of China; however, the active ingredients responsible for the anti arthritis effects of A. flaccida are still elusive. In this study, W3, a saponin isolated from the extract of A. flaccida was identified as the major active ingredient by using an osteoclast formation model induced by receptor activator of nuclear factor kappa B ligand (RANKL). W3 dose dependently suppressed the actin ring formation and lacunar resorption. Mechanistic investigation revealed that W3 inhibited the RANKL induced TRAF6 expression, decreased phosphorylation of mitogen activated protein kinases (MAPKs) and I kappa B alpha, and suppressed NF kappa B p65 DNA binding activity. Furthermore, W3 almost abrogated the expression of c Fos and nuclear factor of activated T cells (NFATc1). Therefore, our results suggest that W3 is a potential agent for treating lytic bone diseases although further evaluation in vivo and in clinical trials is needed.
C1 [Kong, Xiangying; Yang, Yue; Wu, Wenbin; Wan, Hongye; Li, Xiaomin; Zhong, Michun; Su, Xiaohui; Lin, Na] China Acad Chinese Med Sci, Inst Chinese Mat Med, Beijing 100700, Peoples R China.
   [Jia, Shiwei] Guangzhou Kanghe Pharmaceut Ltd Co, Guangzhou 511440, Guangdong, Peoples R China.
C3 China Academy of Chinese Medical Sciences; Institute of Chinese Materia
   Medica, CACMS
RP Lin, N (通讯作者)，China Acad Chinese Med Sci, Inst Chinese Mat Med, 16 Nanxiaojie, Beijing 100700, Peoples R China.
EM linna888@163.com
RI wan, ye/AAP 9997 2021
OI Wan, Ye/0000 0002 3909 0985
FU major projects of national science and technology [2011ZX09101 006 03,
   2013ZX09301307]; natural science foundation of Beijing [7112096];
   National Natural Science Foundation of China [81274167]
FX This study was supported by the major projects of national science and
   technology (2011ZX09101 006 03, 2013ZX09301307), natural science
   foundation of Beijing (7112096), and the National Natural Science
   Foundation of China (81274167).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bing F.H., 2005, HUBEI J, V27, P48
   Bing FeiHong Bing FeiHong, 2008, Chinese Journal of Immunology, V24, P716
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen DS, 2012, INFLAMMATION, V35, P1798, DOI 10.1007/s10753 012 9500 3
   Cheng BB, 2012, FOOD CHEM TOXICOL, V50, P1610, DOI 10.1016/j.fct.2012.02.019
   Cheng SL, 2008, CARBOHYD RES, V343, P462, DOI 10.1016/j.carres.2007.11.015
   Cully Megan, 2013, Nat Rev Rheumatol, V9, P446, DOI 10.1038/nrrheum.2013.111
   Griese JJ, 2006, J MOL BIOL, V361, P140, DOI 10.1016/j.jmb.2006.06.007
   Han LT, 2013, EVID BASED COMPL ALT, V2013, DOI 10.1155/2013/517931
   Han LT, 2009, J ASIAN NAT PROD RES, V11, P122, DOI 10.1080/10286020802573818
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   Huang Qi Quan, 2009, Curr Rheumatol Rep, V11, P357
   Huh Jeong Eun, 2013, Eur J Pharmacol, V698, P57, DOI 10.1016/j.ejphar.2012.08.013
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Kong XY, 2013, J ETHNOPHARMACOL, V148, P842, DOI 10.1016/j.jep.2013.05.023
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SH, 2008, J BIOL CHEM, V283, P11526, DOI 10.1074/jbc.M708935200
   Leibbrandt A, 2009, ADV EXP MED BIOL, V649, P100
   Li CH, 2011, J BONE MINER RES, V26, P644, DOI 10.1002/jbmr.242
   Liao Y, 2010, APPL CHEM SYNTHESIS
   Medicine SAoTC, 1999, CHIN MAT MED, V7
   Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Takayanagi H, 2007, NAT REV IMMUNOL, V7, P292, DOI 10.1038/nri2062
   Tanaka S, 2001, Mod Rheumatol, V11, P177, DOI 10.3109/s101650170001
   Tanaka Yoshiya, 2005, Current Drug Targets   Inflammation and Allergy, V4, P325, DOI 10.2174/1568010054022015
   Tao HR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023199
   Yamanaka Y, 2013, J ORTHOP RES, V31, P67, DOI 10.1002/jor.22200
   Zhai ZJ, 2014, BRIT J PHARMACOL, V171, P663, DOI 10.1111/bph.12463
NR 32
TC 27
Z9 30
U1 0
U2 12
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1449 2288
J9 INT J BIOL SCI
JI Int. J. Biol. Sci.
PY 2015
VL 11
IS 10
BP 1204
EP 1214
DI 10.7150/ijbs.12296
PG 11
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine   Other
   Topics
GA CP7SE
UT WOS:000360087500008
PM 26327814
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Shimonodan, H
   Nagayama, J
   Nagatoshi, Y
   Hatanaka, M
   Takada, A
   Iguchi, H
   Oda, Y
   Okamura, J
AF Shimonodan, H
   Nagayama, J
   Nagatoshi, Y
   Hatanaka, M
   Takada, A
   Iguchi, H
   Oda, Y
   Okamura, J
TI Acute lymphocytic leukemia in adolescence with multiple osteolytic
   lesions and hypercalcemia mediated by lymphoblast producing parathyroid
   hormone related peptide: A case report and review of the literature
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE acute lymphocytic leukemia; childhood and adolescence; hypercalcemia;
   multiple osteolysis; parathyroid hormone related peptide
ID T CELL LEUKEMIA; HUMORAL HYPERCALCEMIA; PROTEIN; CANCER; MECHANISM;
   CHILDREN
AB Background. Osteopathy is one of the common initial symptoms of acute lymphocytic leukemia (ALL) in children and adolescents, but multiple osteolysis accompanied by hypercalcemia is rarely observed. Procedure. We treated a 14 year old female who had multiple osteolytic lesions and hypercalcemia at initial onset of ALL. In this case we examined some humoral factors, which are known to associate with hypercalcemia in malignancies. Results. Parathyroid hormone related peptide (PTHrP) was elevated in serum, and reverse transcriptasepolymerase chain reaction and immunohistochemistry revealed that the lymphoblasts produced PTHrP directly. Other humoral factors related to hypercalcemia were not detected. ALL relapsed in the bone marrow 3 months after achieving complete remission, and hypercalcemia and elevation of serum PTHrP were also observed. A second remission could not be achieved and hypercalcemia continued. The patient received allogeneic bone marrow transplantation. The serum calcium level became normal after the conditioning therapy. Before engraftment, however, the patient died of infection. Conclusions. The present case suggests that blast producing PTHrP might be associated with multiple osteolytic lesions and hypercalcemia. PTHrP expressed in the lymphoblasts may, in itself, confer a survival advantage to lymphoblasts and contribute to the refractory nature of the disease.
C1 Kyushu Natl Canc Ctr, Sect Pediat, Minami Ku, Fukuoka 8111395, Japan.
   Kyushu Natl Canc Ctr, Inst Clin Res, Fukuoka 8111395, Japan.
   Kyushu Univ, Dept Pathol Anat, Grad Sch Med, Fukuoka 812, Japan.
C3 Kyushu University
RP Nagayama, J (通讯作者)，Kyushu Natl Canc Ctr, Sect Pediat, Minami Ku, 3 1 1 Notame, Fukuoka 8111395, Japan.
EM jnagayama@nk cc.go.jp
CR AKATSU T, 1989, ENDOCRINOLOGY, V125, P20, DOI 10.1210/endo 125 1 20
   AKATSU T, 1989, J BONE MINER RES, V4, P29
   Antunovic P, 1998, MED ONCOL, V15, P58, DOI 10.1007/BF02787346
   BOUDAILLIEZ BR, 1990, PEDIATR NEPHROL, V4, P510, DOI 10.1007/BF00869834
   BROADUS AE, 1988, NEW ENGL J MED, V319, P556
   Choi SJ, 2000, BLOOD, V96, P671
   DAVIES M, 1985, LANCET, V1, P1186
   Dougherty KM, 1999, CANCER RES, V59, P6015
   Firkin F, 1998, LEUKEMIA LYMPHOMA, V29, P499, DOI 10.3109/10428199809050909
   HARUTSUMI M, 1995, MINER ELECTROL METAB, V21, P171
   Hibi S, 1997, INT J HEMATOL, V66, P353
   Hino M, 2001, ANN HEMATOL, V80, P426, DOI 10.1007/s002770100305
   Kai T, 1996, LEUKEMIA LYMPHOMA, V23, P119, DOI 10.3109/10428199609054810
   KIYOKAWA T, 1987, CANCER AM CANCER SOC, V59, P1187, DOI 10.1002/1097 0142(19870315)59:6<1187::AID CNCR2820590626>3.0.CO;2 8
   LEBLANC A, 1984, CANCER AM CANCER SOC, V54, P2132, DOI 10.1002/1097 0142(19841115)54:10<2132::AID CNCR2820541013>3.0.CO;2 V
   Lteif AN, 1998, PEDIATRICS, V102, P990, DOI 10.1542/peds.102.4.990
   Margolin J.F., 2002, Principles and practice of pediatric oncology, V4th, P489
   Matsuzaki K, 1999, ENDOCRINOLOGY, V140, P925, DOI 10.1210/en.140.2.925
   MCKAY C, 1993, CANCER AM CANCER SOC, V72, P256, DOI 10.1002/1097 0142(19930701)72:1<256::AID CNCR2820720145>3.0.CO;2 D
   MUNDY GR, 1984, NEW ENGL J MED, V310, P1718
   Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634
   Oda N, 1998, EUR J ENDOCRINOL, V139, P323, DOI 10.1530/eje.0.1390323
   Okada Y, 2004, J BONE MINER RES, V19, P1105, DOI 10.1359/JBMR.040314
   RAJANTIE J, 1985, PEDIATR RADIOL, V15, P242, DOI 10.1007/BF02388764
   RALSTON SH, 1987, LANCET, V2, P1443
   Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1564::AID CNCR6>3.3.CO;2 H
   Schneider T, 2001, DEUT MED WOCHENSCHR, V126, P7, DOI 10.1055/s 2001 9883
   SONI PN, 1993, POSTGRAD MED J, V69, P483, DOI 10.1136/pgmj.69.812.483
   TAKAHASHI N, 1988, ENDOCRINOLOGY, V123, P2600, DOI 10.1210/endo 123 5 2600
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   TODO S, 1987, JPN J CLIN ONCOL, V17, P357
   Türker M, 2004, J PEDIAT HEMATOL ONC, V26, P116
   VASSILOPOULOUSELLIN R, 1993, CANCER, V71, P1309, DOI 10.1002/1097 0142(19930215)71:4<1309::AID CNCR2820710423>3.0.CO;2 M
   WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759
   Wessels G, 1996, E AFR MED J, V73, P126
   YAMAGUCHI K, 1994, LEUKEMIA, V8, P1708
   Young G, 1998, MED PEDIATR ONCOL, V30, P117, DOI 10.1002/(SICI)1096 911X(199802)30:2<117::AID MPO9>3.0.CO;2 L
NR 37
TC 39
Z9 42
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1545 5009
EI 1545 5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD SEP
PY 2005
VL 45
IS 3
BP 333
EP 339
DI 10.1002/pbc.20357
PG 7
WC Oncology; Hematology; Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology; Pediatrics
GA 948UA
UT WOS:000230740000015
PM 15700250
DA 2025 08 17
ER

PT J
AU Zhou, B
   Lu, XL
   Tang, Z
   Liu, D
   Zhou, YL
   Zeng, P
   Xiong, H
AF Zhou, Biao
   Lu, Xiaolong
   Tang, Zhi
   Liu, Dan
   Zhou, Youliang
   Zeng, Peng
   Xiong, Hui
TI Influence of sinomenine upon mesenchymal stem cells in
   osteoclastogenesis
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Sinomenine; Mesenchymal stem cells; Osteoclastogenesis; RANKL; OPG; PGE2
ID RHEUMATOID ARTHRITIS; BONE RESORPTION; JOINT DAMAGE; OSTEOARTHRITIS;
   TARGETS
AB With the advent of aging, the morbidity rates of such diseases as osteoarthritis, rheumatoid arthritis, and osteoporosis has witnessed a significant increase. As a common rattan drug, sinomenine (SIN) has been widely applied for the treatment of various arthritic diseases in traditional Chinese medicine (TCM) clinics. Given that SIN has been reported to inhibit the expression of Prostaglandin E2 (PGE2) in several types of cells, in this study, the influence of SIN treatment on PGE2 expression in mesenchymal stem cells (MSCs), thereby changing the osteoprotegerin (OPG) receptor/activator for the nuclear factor kappa B ligand (RANKL) ratio, was investigated. Our results showed that, when compared with the untreated cells, treatment with 0.25 mM SIN can down regulate the mRNA and protein expression levels of the Prostaglandin E synthase 3 (PTGES3) or PGE2 and RANKL, while the OPG was up regulated. After being cultured with SIN treated MSC conditioned medium (stMSC CM), the amount of TRAP positive multinucleated osteoclasts differentiated from RAW264.7 cells was reduced. Also, the expression levels of specific markers for active osteoclasts were decreased when incubated with stMSC CM. Moreover, these changes were able to be recovered when the exogenous RANKL was added to the MSC CM culture. This indicates that the increased OPG/RANKL ratio can reduce the osteoclastogenesis of RAW264.7 cells. Our results demonstrated that SIN has an inhibitory effect on osteoclast differentiation through mechanisms involving the inhibition of the PGE2 induced OPG/RANKL ratio. SIN can also serve as a proinflammatory mediator to regulate the MSC immunosuppressive effects. Our findings suggest that SIN can be useful for the treatment of bone diseases associated with over activity of osteoclasts. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Zhou, Biao; Tang, Zhi; Liu, Dan; Zhou, Youliang; Xiong, Hui] Hunan Univ Chinese Med, Changsha, Hunan, Peoples R China.
   [Lu, Xiaolong; Zeng, Peng] Hunan Univ Chinese Med, Affiliated Hosp 2, Changsha, Hunan, Peoples R China.
C3 Hunan University of Chinese Medicine; Hunan University of Chinese
   Medicine
RP Xiong, H (通讯作者)，300 Bachelor Rd, Changsha, Hunan, Peoples R China.
EM xionghuihn@126.com
RI Lu, Xiaolong/Q 5252 2016
FU Natural Science Foundation of Hunan Province, China [2015JJ6083];
   National Natural Science Foundation of China [81574005]
FX This work was funded by the Natural Science Foundation of Hunan
   Province, China (Grant No. 2015JJ6083) and the National Natural Science
   Foundation of China (Grant No. 81574005)
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Castañeda S, 2012, BIOCHEM PHARMACOL, V83, P315, DOI 10.1016/j.bcp.2011.09.018
   Chao CC, 2011, AUTOIMMUNITY, V44, P243, DOI 10.3109/08916934.2010.517815
   Choi Y, 2009, NAT REV RHEUMATOL, V5, P543, DOI 10.1038/nrrheum.2009.175
   Fleischmann RM, 2013, J RHEUMATOL, V40, P113, DOI 10.3899/jrheum.120447
   Gao TL, 2015, SCAND J PAIN, V7, P9, DOI 10.1016/j.sjpain.2014.12.003
   Ghannam S, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt2
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Goldring SR, 2000, CURR OPIN RHEUMATOL, V12, P195, DOI 10.1097/00002281 200005000 00006
   Huang LF, 2015, INT IMMUNOPHARMACOL, V28, P945, DOI 10.1016/j.intimp.2015.04.029
   Iwadate H, 2014, INT J RHEUM DIS, V17, P50, DOI 10.1111/1756 185X.12115
   Jarvinen L, 2008, J IMMUNOL, V181, P4389, DOI 10.4049/jimmunol.181.6.4389
   Keerthi N, 2013, CURR STEM CELL RES T, V8, P444, DOI 10.2174/1574888X1130800062
   Kok T. W., 2005, Angiogenesis, V8, P3, DOI 10.1007/s10456 005 2892 z
   Li X., 2013, PLOS ONE, V8
   LIU L, 1994, ARZNEIMITTEL FORSCH, V44 2, P1223
   Liu LA, 1996, INT J IMMUNOPHARMACO, V18, P529, DOI 10.1016/S0192 0561(96)00025 2
   Ornbjerg LM, 2013, ANN RHEUM DIS, V72, P57, DOI 10.1136/annrheumdis 2012 201319
   Oshita K, 2011, ARTHRITIS RHEUM US, V63, P1658, DOI 10.1002/art.30309
   Ou YQ, 2011, RHEUMATOL INT, V31, P1479, DOI 10.1007/s00296 010 1506 2
   Penfornis P, 2011, METHODS MOL BIOL, V698, P11, DOI 10.1007/978 1 60761 999 4_2
   Prieto Potin I, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891 015 0664 5
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Sharaf Eldin WE, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1908365
   Smolen J.S., 2016, LANCET
   Stoppiello LA, 2014, ARTHRITIS RHEUMATOL, V66, P3018, DOI 10.1002/art.38778
   Sun Y, 2014, INT IMMUNOPHARMACOL, V18, P135, DOI 10.1016/j.intimp.2013.11.014
   Swanson CD, 2009, NAT REV RHEUMATOL, V5, P317, DOI 10.1038/nrrheum.2009.82
   Wilson SR, 2009, J BIOL CHEM, V284, P2584, DOI 10.1074/jbc.M805280200
   Yin CP, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9742034
   Zhao ZJ, 2015, INT IMMUNOPHARMACOL, V29, P354, DOI 10.1016/j.intimp.2015.10.030
   Zhu H, 2009, STEM CELLS DEV, V18, P1473, DOI 10.1089/scd.2009.0021
NR 34
TC 27
Z9 28
U1 3
U2 36
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUN
PY 2017
VL 90
BP 835
EP 841
DI 10.1016/j.biopha.2017.03.084
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EW4KS
UT WOS:000402471000100
PM 28437887
DA 2025 08 17
ER

PT J
AU Hu, R
   Chen, LB
   Chen, XL
   Xie, Z
   Xia, C
   Chen, Y
AF Hu, Rong
   Chen, Libo
   Chen, Xiaolong
   Xie, Zhong
   Xia, Chao
   Chen, Yong
TI Aloperine improves osteoporosis in ovariectomized mice by inhibiting
   RANKL induced NF κB, ERK and JNK approaches
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Aloperine; Osteoclast; RANKL; Postmenopausal osteoporosis; NF kappa B
ID POSTMENOPAUSAL OSTEOPOROSIS; OSTEOCLAST DIFFERENTIATION; BONE;
   INFLAMMATION; APOPTOSIS
AB Presently, postmenopausal osteoporosis mainly caused by excessive activation of in vivo osteoclasts has become a global public health burden. Natural compounds have gradually become the potential drugs for the treatment of postmenopausal osteoporosis. Aloperine is a new alkaloid extracted from the leaves and seeds of sophora bean. The current studies have proved that aloperine has many biological activities, including anti inflammatory, antiviral and anticancer activities. This study shows that aloperine can inhibit activity and formation of osteoclast mediated by RANKL in a dose dependent manner without affecting the activity of bone marrow macrophages (BMM). In addition, it is found that aloperine can inhibit the expression of osteoclast specific marker genes, including nuclear factor of activated T cells cytoplasmic 1 (NFATc1), tartrate resistant acid phosphatase (TRAcP), matrix metallopeptidase 9 (MMP9), cathepsin K (Ctsk), V ATPase d2 and calcitonin receptor. The in vitro experiment of aloperine proved that aloperine can inhibit the degradation of I kappa B alpha and the phosphorylation of P65, ERK and JNK. Additionally, aloperine improves bone loss in ovariectomized (OVX) mice by inhibiting osteoclast activity. This project proved that aloperine can affect the formation of osteoclasts by inhibiting RANKL signaling channel, and it is indicated that aloperine has the potential to be developed as a new drug for the prevention and treatment of postmenopausal osteoporosis.
C1 [Hu, Rong; Chen, Xiaolong] Univ South China, Affiliated Hosp 1, Dept Radiol, Hengyang 421000, Hunan, Peoples R China.
   [Chen, Libo] Univ South China, Affiliated Hosp 1, Dept Urol, Hengyang 421000, Hunan, Peoples R China.
   [Xie, Zhong; Xia, Chao; Chen, Yong] Univ South China, Affiliated Hosp 1, Dept Spinal Surg, Hengyang 421000, Hunan, Peoples R China.
C3 University of South China; University of South China; University of
   South China
RP Chen, Y (通讯作者)，Univ South China, Affiliated Hosp 1, Dept Spinal Surg, Hengyang 421000, Hunan, Peoples R China.
EM yongchen110@sina.com
FU Natural Science Foundation of Hunan Province, China [2019JJ50553]
FX This work was supported by the Natural Science Foundation of Hunan
   Province, China (Grant No. 2019JJ50553).
CR Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593
   Archer DF, 2005, SEMIN REPROD MED, V23, P188, DOI 10.1055/s 2005 869487
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Brosius AD, 1997, ACTA CRYSTALLOGR C, V53, P1510, DOI 10.1107/S0108270197009244
   Chen LR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092213
   Chen S, 2018, BIOMED PHARMACOTHER, V97, P45, DOI 10.1016/j.biopha.2017.09.066
   Choi D, 2020, OSTEOPOROSIS INT, V31, P775, DOI 10.1007/s00198 020 05327 x
   Fu XX, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/5706152
   Gao T, 2015, SCAND J PAIN, V8, P25, DOI 10.1016/j.sjpain.2015.04.025
   Ghayor C, 2011, J BIOL CHEM, V286, P24458, DOI 10.1074/jbc.M111.223297
   Jackson RD, 2014, SEMIN REPROD MED, V32, P454, DOI 10.1055/s 0034 1384629
   Khosla S, 2012, J CLIN ENDOCR METAB, V97, P2272, DOI 10.1210/jc.2012 1027
   Lin TH, 2014, ACTA BIOMATER, V10, P1, DOI 10.1016/j.actbio.2013.09.034
   Liu JS, 2019, PHYTOMEDICINE, V61, DOI 10.1016/j.phymed.2019.152843
   Liu YP, 2019, J CONTROL RELEASE, V304, P39, DOI 10.1016/j.jconrel.2019.04.042
   Manzanero S, 2012, METHODS MOL BIOL, V844, P177, DOI 10.1007/978 1 61779 527 5_12
   Migliorati CA, 2006, LANCET ONCOL, V7, P508, DOI 10.1016/S1470 2045(06)70726 4
   Mo H, 2019, BRAZ J MED BIOL RES, V52, DOI [10.1590/1414 431X20198754, 10.1590/1414 431x20198754]
   Muhammad T, 2020, J CANCER RES CLIN, V146, P861, DOI 10.1007/s00432 020 03157 2
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Ono T, 2020, INFLAMM REGEN, V40, DOI 10.1186/s41232 019 0111 3
   Paschalis EP, 2017, BONE, V95, P41, DOI 10.1016/j.bone.2016.11.002
   Ponnapakkam T, 2014, DRUG DISCOV TODAY, V19, P204, DOI 10.1016/j.drudis.2013.07.015
   Rodan GA, 1998, P NATL ACAD SCI USA, V95, P13361, DOI 10.1073/pnas.95.23.13361
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tao XF, 2018, PHARMACOL RES, V137, P259, DOI 10.1016/j.phrs.2018.09.022
   Wang CY, 2018, INT IMMUNOPHARMACOL, V65, P571, DOI 10.1016/j.intimp.2018.11.003
   Warren JT, 2015, J CELL BIOCHEM, V116, P2476, DOI 10.1002/jcb.25191
   Xu H, 2005, AM J CHINESE MED, V33, P299, DOI 10.1142/S0192415X05002916
   Yu HI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215315
   Yuan F, 2019, INT J SURG, V66, P1, DOI 10.1016/j.ijsu.2019.03.004
   Zhang L, 2014, INT J MOL MED, V33, P1613, DOI 10.3892/ijmm.2014.1718
   Zhang Q, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01028
   Zhang X, 2018, EUR J MED CHEM, V149, P45, DOI 10.1016/j.ejmech.2018.02.061
NR 34
TC 10
Z9 13
U1 1
U2 19
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD AUG
PY 2021
VL 97
AR 107720
DI 10.1016/j.intimp.2021.107720
EA MAY 2021
PG 7
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA TR7TE
UT WOS:000679163200002
PM 33945918
DA 2025 08 17
ER

PT J
AU Nasulewicz Goldeman, A
   Goldeman, W
   Papiernik, D
   Nowak, M
   Mrowczynska, E
   Wietrzyk, J
AF Nasulewicz Goldeman, Anna
   Goldeman, Waldemar
   Papiernik, Diana
   Nowak, Marcin
   Mrowczynska, Ewa
   Wietrzyk, Joanna
TI Anti metastatic activity of aromatic aminomethylidenebisphosphonates in
   a mouse model of 4T1 cell derived breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE bisphosphonates; breast cancer; metastasis; anticancer treatment; mouse
   models
ID BISPHOSPHONATE ZOLEDRONIC ACID; SKELETAL COMPLICATIONS; BONE METASTASES;
   CYCLE ARREST; APOPTOSIS; GROWTH; PATHWAY; PROLIFERATION; DOXORUBICIN;
   ACTIVATION
AB Breast cancer is one of the major causes of cancer related mortality among women worldwide. It metastasizes to distant organs, particularly to bone tissue. Nitrogen containing bisphosphonates are mainly used as an adjuvant therapy to inhibit skeletal related events; however, there is increasing evidence to suggest that these compounds also exert antitumor effects. In previous studies, the authors synthesized two novel aminomethylidenebisphosphonates (BPs), namely benzene 1,4 bis[aminomethylidene(bisphosphonic)] acid (WG12399C) and naphthalene 1,5 bis[aminomethylidene(bisphosphonic)] acid (WG12592A). Both BPs exhibited notable antiresorptive activity in a mouse model of osteoporosis. The present study aimed to assess the in vivo anticancer activity of WG12399C and WG12592A in 4T1 breast adenocarcinoma model. WG12399C exerted an anti metastatic effect by reducing the number of spontaneous lung metastases by similar to 66% in comparison to the control. In the experimental metastasis model of 4T1 luc2 tdTomato cells, this compound reduced the incidence of tumor metastases in the lungs by approximately half in comparison to the control. Both WG12399C and WG12595A also significantly reduced the size and/or number of bone metastatic foci. Their pro apoptotic and anti proliferative activity may, at least in part, explain the observed effects. Incubation with WG12399C induced an almost 6 fold increase in caspase 3 activity in 4T1 cells. Moreover, cells treated with WG12399C or WG12595A exhibited a 2 fold reduction in invasiveness through Matrigel. Furthermore, both the BPs were able to sensitize the 4T1 cells to cytostatics. In summary, the results of the present study indicate that the examined aminomethylidene BPs may be of particular interest in the context of combined treatment in breast cancer therapy.
C1 [Nasulewicz Goldeman, Anna; Papiernik, Diana; Mrowczynska, Ewa; Wietrzyk, Joanna] Polish Acad Sci, Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, PL 53114 Wroclaw, Poland.
   [Goldeman, Waldemar] Wroclaw Univ Sci & Technol, Dept Organ Chem, PL 50370 Wroclaw, Poland.
   [Nowak, Marcin] Wroclaw Univ Environm & Life Sci, Fac Vet Med, PL 50366 Wroclaw, Poland.
   [Nasulewicz Goldeman, Anna] Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, 12 Weigla St, PL 53114 Wroclaw, Poland.
C3 Polish Academy of Sciences; Hirszfeld Institute of Immunology &
   Experimental Therapy of the Polish Academy of Sciences; Wroclaw
   University of Science & Technology; Wroclaw University of Environmental
   & Life Sciences; Polish Academy of Sciences; Hirszfeld Institute of
   Immunology & Experimental Therapy of the Polish Academy of Sciences
RP Nasulewicz Goldeman, A (通讯作者)，Hirszfeld Inst Immunol & Expt Therapy, Dept Expt Oncol, 12 Weigla St, PL 53114 Wroclaw, Poland.
EM zhaodewei2016@163.com
RI ; Wietrzyk, Joanna/O 4392 2018
OI Mrowczynska, Ewa/0000 0002 1204 6108; 
CR [Anonymous], 2015, Breast Cancer
   Balathasan L, 2013, AM J PATHOL, V183, P26, DOI 10.1016/j.ajpath.2013.03.003
   Bellone F, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.748438
   Benassi MS, 2007, CANCER LETT, V250, P194, DOI 10.1016/j.canlet.2006.10.004
   Benford HL, 1999, MOL PHARMACOL, V56, P131, DOI 10.1124/mol.56.1.131
   Blazejczyk A, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046 016 0389 9
   Boissier S, 2000, CANCER RES, V60, P2949
   Buranrat B, 2019, ONCOL LETT, V18, P1246, DOI 10.3892/ol.2019.10438
   Campbell JP, 2012, JOVE J VIS EXP, DOI 10.3791/4260
   Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173
   CHOU TC, 1981, EUR J BIOCHEM, V115, P207, DOI 10.1111/j.1432 1033.1981.tb06218.x
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   D'Oronzo S, 2021, BONE, V147, DOI 10.1016/j.bone.2021.115907
   Denoyelle C, 2003, BRIT J CANCER, V88, P1631, DOI 10.1038/sj.bjc.6600925
   Dhesy Thind S, 2017, J CLIN ONCOL, V35, P2062, DOI 10.1200/JCO.2016.70.7257
   Diel IJ, 1998, NEW ENGL J MED, V339, P357, DOI 10.1056/NEJM199808063390601
   Farhoodi HP, 2020, J BONE ONCOL, V23, DOI 10.1016/j.jbo.2020.100298
   Features T, 2010, BIOWARE ULTRA CELL L
   Gainford MC, 2005, BMJ BRIT MED J, V330, P769, DOI 10.1136/bmj.330.7494.769
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Goldeman W, 2014, BIOORG MED CHEM LETT, V24, P3475, DOI 10.1016/j.bmcl.2014.05.071
   Goldeman W, 2012, TETRAHEDRON LETT, V53, P5290, DOI 10.1016/j.tetlet.2012.07.085
   Goldvaser H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0623 8
   Hiraga T, 2004, CLIN CANCER RES, V10, P4559, DOI 10.1158/1078 0432.CCR 03 0325
   Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401
   Iguchi T, 2003, CELL SIGNAL, V15, P719, DOI 10.1016/S0898 6568(03)00007 X
   Kohno N, 2005, J CLIN ONCOL, V23, P3314, DOI 10.1200/JCO.2005.05.116
   Koto K, 2010, ONCOL REP, V24, P233, DOI 10.3892/or_00000851
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Michigami T, 2002, BREAST CANCER RES TR, V75, P249, DOI 10.1023/A:1019905111666
   Misso G, 2012, CANCER BIOL THER, V13, P1491, DOI 10.4161/cbt.22274
   Miwa A, 2012, AM J HEMATOL, V87, P1084, DOI 10.1002/ajh.23328
   Nasulewicz Goldeman A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179590
   Nasulewicz Goldeman A, 2019, CHEM BIOL DRUG DES, V94, P1835, DOI 10.1111/cbdd.13597
   Okamoto S, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.475
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2008, CLIN CANCER RES, V14, P4658, DOI 10.1158/1078 0432.CCR 07 1545
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Saarto T, 2001, J CLIN ONCOL, V19, P10, DOI 10.1200/JCO.2001.19.1.10
   Santini D, 2003, CLIN CANCER RES, V9, P2893
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Singh SK, 2008, BEILSTEIN J ORG CHEM, V4, DOI 10.3762/bjoc.4.42
   SKEHAN P, 1990, JNCI J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Steinman RA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3223
   Suyama K, 2007, ONCOL REP, V18, P1291
   Tanaka Y, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 05553 0
   van Beek ER, 2009, BREAST CANCER RES TR, V118, P307, DOI 10.1007/s10549 008 0236 6
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Werbeck JL, 2014, VET PATHOL, V51, P868, DOI 10.1177/0300985813505116
   Zhang Z, 2012, CANCER GENE THER, V19, P630, DOI 10.1038/cgt.2012.41
   Zhao ZC, 2018, DRUG DES DEV THER, V12, P3021, DOI 10.2147/DDDT.S168897
   Zhou ZX, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8984
NR 56
TC 0
Z9 0
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021 335X
EI 1791 2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2023
VL 50
IS 1
AR 135
DI 10.3892/or.2023.8572
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA I5EI6
UT WOS:001003006700001
PM 37232374
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Gustafson, CT
   Mamo, T
   Maran, A
   Yaszemski, MJ
AF Gustafson, Carl T.
   Mamo, Tewodros
   Maran, Avudaiappan
   Yaszemski, Michael J.
TI Efflux inhibition by IWR 1 endo confers sensitivity to doxorubicin
   effects in osteosarcoma cells
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Tankyrase inhibitor; Wnt signaling; Multidrug resistance protein 1;
   Efflux transport; Doxorubicin
ID HIGH GRADE OSTEOSARCOMA; LUNG CANCER CELLS; MULTIDRUG RESISTANCE;
   NEOADJUVANT CHEMOTHERAPY; TANKYRASE INHIBITION; OSTEOGENIC SARCOMA;
   P GLYCOPROTEIN; PATHWAY; CHEMORESISTANCE; ACTIVATION
AB Osteosarcoma is the most common bone tumor that affects children and young adults. Despite advances in the use of combination chemotherapy regimens, response to neoadjuvant chemotherapy in osteosarcoma remains a key determinant of patient outcome. Recently, highly potent small molecule inhibitors of canonical Wnt signaling through the poly(ADP ribose) polymerase (PARP) family enzymes, tankyrases 1 & 2 (Tnksl/2), have been considered as possible chemotherapy sensitizing agents. The goal of this study was to determine the ability of the highly specific Tnks1/2 inhibitor IWR 1 endo to sensitize chemotherapy resistant osteosarcoma to doxorubicin. We found that IWR 1 endo significantly inhibited cellular efflux, as measured by cellular retention of Calcein AM and doxorubicin. In a model of doxorubicin resistant osteosarcoma, pre treatment with IWR 1 endo strongly sensitized to doxorubicin. This sensitization reduced the doxorubicin IC50 in doxorubicin resistant cells, but not in chemotherapy na ve cells and caused doxorubicin treated cells to accumulate at the G2/M checkpoint. Further, we found that sensitization with IWR 1 endo produced increased yH2AX foci formation, indicating increased DNA damage by doxorubicin. Taken together, our findings show that IWR 1 endo increases cellular responses to doxorubicin, by blocking efflux transport in a drug resistant model of osteosarcoma.
C1 [Gustafson, Carl T.; Mamo, Tewodros; Yaszemski, Michael J.] Mayo Clin, Coll Med, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA.
   [Maran, Avudaiappan; Yaszemski, Michael J.] Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st SW, Rochester, MN 55905 USA.
   [Maran, Avudaiappan; Yaszemski, Michael J.] Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Maran, A (通讯作者)，Mayo Clin, Dept Orthoped Surg, Coll Med, 200 1st SW, Rochester, MN 55905 USA.
EM maran.avudai@mayo.edu
OI Mamo, Theodros/0000 0002 3474 576X
FU Mayo Clinic Orthopaedic Research Review Committee; Predoctoral Training
   Program in Molecular Pharmacology [NIH T32 GM072474 10]; Predoctoral
   Training Program in Musculoskeletal Research [NIH 5T32 AR56950 7];
   NIH/NCI [1F31CA206388 01A1]; Riviera Foundation; John and Posy Krehbiel
   Endowed Professorship in Orthopedic Surgery and Biomedical Engineering
FX We thank Dr. Martin Fernandez Zapico, Dr. Nicole Murray, and Dr. Joel
   Reid for their thoughtful advice and discussion throughout the
   performance of this work. The Mayo Clinic Microscopy and Cell Analysis
   Core lab is thanked for expert assistance with cell cycle analysis. We
   acknowledge funding support from the Mayo Clinic Orthopaedic Research
   Review Committee (CG), the Predoctoral Training Program in Molecular
   Pharmacology (NIH T32 GM072474 10, CG; Director: Larry Karnitz), the
   Predoctoral Training Program in Musculoskeletal Research (NIH 5T32
   AR56950 7, TM; Director: Jennifer Westendorf), the NIH/NCI Predoctoral
   National Research Service Award (1F31CA206388 01A1, TM), Riviera
   Foundation (AM), and the John and Posy Krehbiel Endowed Professorship in
   Orthopedic Surgery and Biomedical Engineering (MY).
CR Arqués O, 2016, CLIN CANCER RES, V22, P644, DOI 10.1158/1078 0432.CCR 14 3081
   Bao RY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048670
   Busch AM, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 211
   Casás Selves M, 2012, CANCER RES, V72, P4154, DOI 10.1158/0008 5472.CAN 11 2848
   Corrêa S, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 303
   Flahaut M, 2009, ONCOGENE, V28, P2245, DOI 10.1038/onc.2009.80
   Frank NY, 2005, CANCER RES, V65, P4320, DOI 10.1158/0008 5472.CAN 04 3327
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hung TH, 2014, ONCOTARGET, V5, P12273, DOI 10.18632/oncotarget.2631
   Ikeda R, 2011, INT J ONCOL, V38, P513, DOI 10.3892/ijo.2010.866
   Isakoff MS, 2015, J CLIN ONCOL, V33, P3029, DOI 10.1200/JCO.2014.59.4895
   Jun S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10994
   Kulak O, 2015, MOL CELL BIOL, V35, P2425, DOI 10.1128/MCB.00392 15
   Lee SC, 2015, ONCOTARGET, V6, P27146, DOI 10.18632/oncotarget.4354
   Lu JM, 2009, BIOORG MED CHEM LETT, V19, P3825, DOI 10.1016/j.bmcl.2009.04.040
   Meyers PA, 2005, J CLIN ONCOL, V23, P2004, DOI 10.1200/JCO.2005.06.031
   Okada Iwasaki R, 2016, MOL CANCER THER, V15, P1525, DOI 10.1158/1535 7163.MCT 15 0938
   Quackenbush KS, 2016, ONCOTARGET, V7, P28273, DOI 10.18632/oncotarget.8626
   ROSEN G, 1979, CANCER AM CANCER SOC, V43, P2163, DOI 10.1002/1097 0142(197906)43:6<2163::AID CNCR2820430602>3.0.CO;2 S
   Scarborough HA, 2017, CLIN CANCER RES, V23, P1531, DOI 10.1158/1078 0432.CCR 16 1179
   Serra M, 2003, J CLIN ONCOL, V21, P536, DOI 10.1200/JCO.2003.03.144
   Serra M, 2006, INT J ONCOL, V29, P1459
   Steinbach D, 2006, CLIN CANCER RES, V12, P4357, DOI 10.1158/1078 0432.CCR 05 2587
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Turton NJ, 2001, ONCOGENE, V20, P1300, DOI 10.1038/sj.onc.1204235
   Vaidyanathan A, 2016, BRIT J CANCER, V115, P431, DOI 10.1038/bjc.2016.203
   Wang H, 2016, J BIOL CHEM, V291, P15256, DOI 10.1074/jbc.M116.722967
   Wang SY, 2016, INT J DISTRIB SENS N, DOI 10.1155/2016/3159805
   WINKLER K, 1984, J CLIN ONCOL, V2, P617, DOI 10.1200/JCO.1984.2.6.617
   WINKLER K, 1988, J CLIN ONCOL, V6, P329, DOI 10.1200/JCO.1988.6.2.329
   Xia CQ, 2012, MOL PHARMACOL, V82, P1008, DOI 10.1124/mol.112.079129
NR 32
TC 5
Z9 6
U1 0
U2 11
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006 2952
EI 1873 2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD APR
PY 2018
VL 150
BP 141
EP 149
DI 10.1016/j.bcp.2018.01.037
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GE5UH
UT WOS:000431287100014
PM 29412166
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Cheng, L
   Zhu, YR
   Ke, DS
   Xie, DH
AF Cheng, Liang
   Zhu, Yunrong
   Ke, Dianshan
   Xie, Denghui
TI Oestrogen activated autophagy has a negative effect on the
   anti osteoclastogenic function of oestrogen
SO CELL PROLIFERATION
LA English
DT Article
DE autophagy; LC3; oestrogen; osteoclastogenesis; RANKL
ID HORMONE REPLACEMENT THERAPY; TRABECULAR BONE; RANKL; ALPHA; CELLS;
   17 BETA ESTRADIOL; DIFFERENTIATION; OSTEOPOROSIS; EXPRESSION; RATS
AB Objectives Oestrogen is known to inhibit osteoclastogenesis, and numerous studies have identified it as an autophagic activator. To date, the role of oestrogen in the autophagy of osteoclast precursors (OCPs) during osteoclastogenesis remains unclear. This study aimed to determine the effect of autophagy regulated by the biologically active form of oestrogen (17 beta estradiol) on osteoclastogenesis.
   Materials and methods After treatment with 17 beta estradiol in OCPs (from bone marrow derived macrophages, BMMs) and ovariectomy (OVX) mice, we measured the effect of 17 beta estradiol on the autophagy of OCPs in vitro and in vivo. In addition, we studied the role of autophagy in the OCP proliferation, osteoclast differentiation and bone loss regulated by 17 beta estradiol using autophagic inhibitor or knock down of autophagic genes.
   Results The results showed that direct administration of 17 beta estradiol enhanced the autophagic response of OCPs. Interestingly, 17 beta estradiol inhibited the stimulatory effect of receptor activator of nuclear factor kappa B ligand (RANKL) on the autophagy and osteoclastogenesis of OCPs. Moreover, 17 beta estradiol inhibited the downstream signalling of RANKL. Autophagic suppression by pharmacological inhibitors or gene silencing enhanced the inhibitory effect of 17 beta estradiol on osteoclastogenesis. In vivo assays showed that the autophagic inhibitor 3 MA not only inhibited the autophagic activity of the OCPs in the trabecular bone of OVX mice but also enhanced the ability of 17 beta estradiol to ameliorate bone loss.
   Conclusions In conclusion, our study showed that oestrogen directly enhanced the autophagy of OCPs, which inhibited its anti osteoclastogenic effect. Drugs based on autophagic inhibition may enhance the efficacy of oestrogen on osteoporosis.
C1 [Cheng, Liang; Ke, Dianshan; Xie, Denghui] Southern Med Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China.
   [Zhu, Yunrong] Southeast Univ, Coll Med, Affiliated Jiangyin Hosp, Dept Orthoped, Jiangyin, Peoples R China.
C3 Southern Medical University   China; Southeast University   China
RP Ke, DS; Xie, DH (通讯作者)，Southern Med Univ, Affiliated Hosp 3, Guangdong Prov Key Lab Bone & Joint Degenerat Dis, 183 Zhongshan Ave West, Guangzhou 510630, Guangdong, Peoples R China.
EM kds8810@163.com; smuspine@163.com
OI Ke, Dianshan/0000 0003 0260 7191; Zhu, Yunrong/0000 0001 6271 4226
FU National Natural Science Foundation of China [81772315, 81974328]
   Funding Source: Medline; Natural Science Foundation of Guangdong
   Province [2015A030310313] Funding Source: Medline; The Young medical
   talents of Jiangsu Province [QNRC2016132] Funding Source: Medline;
   Jiangmen Medical and Health Science and Technology Project [2019B001]
   Funding Source: Medline
CR Brasseur K, 2013, ENDOCRINOLOGY, V154, P2281, DOI 10.1210/en.2013 1083
   Cao BR, 2019, J CELL PHYSIOL, V234, P6831, DOI 10.1002/jcp.27432
   Cappariello A, 2014, ARCH BIOCHEM BIOPHYS, V558, P70, DOI 10.1016/j.abb.2014.06.017
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chen FJ, 2014, J CELL BIOCHEM, V115, P651, DOI 10.1002/jcb.24700
   Chen KC, 2016, CANCER GENOM PROTEOM, V13, P219
   CHOW J, 1992, J CLIN INVEST, V89, P74, DOI 10.1172/JCI115588
   CHRISTIANSEN C, 1982, J CLIN ENDOCR METAB, V55, P1124, DOI 10.1210/jcem 55 6 1124
   DeSelm CJ, 2011, DEV CELL, V21, P966, DOI 10.1016/j.devcel.2011.08.016
   Freudenberger T, 2010, BASIC RES CARDIOL, V105, P479, DOI 10.1007/s00395 010 0091 6
   Gao YP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 017 0040 5
   Gavali S, 2019, BBA MOL BASIS DIS, V1865, P547, DOI 10.1016/j.bbadis.2018.12.016
   Guido C, 2012, CELL CYCLE, V11, P2911, DOI 10.4161/cc.21336
   Ha J, 2010, J IMMUNOL, V184, P4717, DOI 10.4049/jimmunol.0902444
   Kanis JA., 1994, Osteoporosis
   Karakashev S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 03031 3
   Ke DS, 2019, FASEB J, V33, P11082, DOI 10.1096/fj.201802597RR
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kimura A, 2016, TOXICOLOGY, V339, P9, DOI 10.1016/j.tox.2015.11.005
   Kousteni S, 2002, SCIENCE, V298, P843, DOI 10.1126/science.1074935
   Krum SA, 2008, EMBO J, V27, P535, DOI 10.1038/sj.emboj.7601984
   Lahm T, 2012, AUTOPHAGY, V8, P1146, DOI 10.4161/auto.20520
   Lahm T, 2012, AM J RESP CRIT CARE, V185, P965, DOI 10.1164/rccm.201107 1293OC
   LAW MR, 1991, BMJ BRIT MED J, V303, P453, DOI 10.1136/bmj.303.6800.453
   Li RF, 2014, J HISTOCHEM CYTOCHEM, V62, P879, DOI 10.1369/0022155414551367
   Li XZ, 2016, AM J TRANSL RES, V8, P4134
   Liang L, 2008, J PERIODONTOL, V79, P1745, DOI [10.1902/jop.2008.070437, 10.1902/jop.2008.070437 ]
   Liang XX, 2019, J CELL BIOCHEM, V120, P13121, DOI 10.1002/jcb.28585
   Lin NY, 2016, ANN RHEUM DIS, V75, P1203, DOI 10.1136/annrheumdis 2015 207240
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   LINDSAY R, 1980, LANCET, V2, P1151
   Lu XM, 2009, BIOCHEM BIOPH RES CO, V390, P494, DOI 10.1016/j.bbrc.2009.09.123
   Nelson HD, 2002, JAMA J AM MED ASSOC, V288, P872, DOI 10.1001/jama.288.7.872
   Novack DV, 2007, CELL METAB, V6, P254, DOI 10.1016/j.cmet.2007.09.007
   Palacios VG, 2005, J BIOL CHEM, V280, P13720, DOI 10.1074/jbc.M410995200
   Qi M, 2017, THERANOSTICS, V7, P4498, DOI 10.7150/thno.17949
   REID DM, 1992, LANCET, V339, P370, DOI 10.1016/0140 6736(92)91692 2
   Robinson LJ, 2009, EXP CELL RES, V315, P1287, DOI 10.1016/j.yexcr.2009.01.014
   Rozenberg S, 2013, NAT REV ENDOCRINOL, V9, P216, DOI 10.1038/nrendo.2013.17
   Saiki S, 2011, AUTOPHAGY, V7, P176, DOI 10.4161/auto.7.2.14074
   SHEN V, 1993, J CLIN INVEST, V91, P2479, DOI 10.1172/JCI116483
   Streicher C, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 06614 0
   TAKANOYAMAMOTO T, 1990, P NATL ACAD SCI USA, V87, P2172, DOI 10.1073/pnas.87.6.2172
   Tang N, 2019, J CELL PHYSIOL, V234, P5023, DOI 10.1002/jcp.27304
   Totta P, 2016, SCI REP UK, V6, DOI 10.1038/srep23727
   Tsuda M, 2005, HYPERTENSION, V45, P545, DOI 10.1161/01.HYP.0000157409.88971.fc
   Vickers MR, 2007, BMJ BRIT MED J, V335, P239, DOI 10.1136/bmj.39266.425069.AD
   Villareal DT, 2001, JAMA J AM MED ASSOC, V286, P815, DOI 10.1001/jama.286.7.815
   Wang XF, 2015, AUTOPHAGY, V11, P1998, DOI 10.1080/15548627.2015.1091551
   Wu XJ, 2005, J BONE MINER RES, V20, P107, DOI 10.1359/JBMR.041022
   Xiong QI, 2015, BIOMED RES INT, V2015, P596
   Xiu Y, 2014, J CLIN INVEST, V124, P297, DOI 10.1172/JCI66947
   Zhang L, 2017, J BONE MINER RES, V32, P2466, DOI 10.1002/jbmr.3230
   Zhi X, 2020, J CELL MOL MED, V24, P785, DOI 10.1111/jcmm.14790
NR 55
TC 22
Z9 24
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0960 7722
EI 1365 2184
J9 CELL PROLIFERAT
JI Cell Prolif.
PD APR
PY 2020
VL 53
IS 4
AR e12789
DI 10.1111/cpr.12789
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA LH3EF
UT WOS:000528669500012
PM 32157750
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lu, JS
   Yang, JZ
   Zheng, YS
   Chen, XY
   Fang, SY
AF Lu, Jinsen
   Yang, Jiazhao
   Zheng, Yongshun
   Chen, Xiaoyu
   Fang, Shiyuan
TI Extracellular vesicles from endothelial progenitor cells prevent
   steroid induced osteoporosis by suppressing the ferroptotic pathway in
   mouse osteoblasts based on bioinformatics evidence
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FEMORAL HEAD; INDUCED OSTEONECROSIS; APOPTOSIS; EXOSOMES; ANGIOGENESIS;
   BISPHOSPHONATES; GLUCOCORTICOIDS; DEXAMETHASONE; INCREASE; IRON
AB Abnormal antioxidative capabilities were observed in the pathogenesis of steroid induced osteoporosis (SIOP). Ferroptosis is a recently discovered type of cell death that is characterized by the overproduction of ROS in response to GPX4 and system Xc  downregulation, which is mediated by an Fe2+ fenton reaction. However, investigations focusing on the relationship between ferroptosis and steroid induced bone disease remain limited. In the present study, high dose dexamethasone was used to establish a mouse SIOP model, and extracellular vesicles extracted from bone marrow derived endothelial progenitor cells (EPC EVs) alleviated the pathological changes in SIOP via microtomography (micro CT), with elevations in bone volume (BV), bone surface (BS), trabecular thickness (Tb.Th), and trabecular connectivity density (Conn D) and decreases in trabecular separation (Tb.sp) and the structure model index (SMI). Histopathological analysis, such as haematoxylin and eosin (HE) and Masson staining, showed that EPC EVs treatment increased the volume and density of the trabecular bone and bone marrow. RNA sequencing (RNA seq) and bioinformatics analysis revealed subcellular biological alterations upon steroid and EPC EVs treatment. Compared with the control, high dose dexamethasone downregulated GPX4 and system XC , and the Kyoto Encyclopedia of Genes and Genomes (KEGG) based gene set enrichment analysis suggested that the ferroptotic pathway was activated. In contrast, combination treatment with EPC EVs partly reversed the KEGG mapped changes in the ferroptotic pathway at both the gene and mRNA expression levels. In addition, alterations in ferroptotic marker expression, such as SLC3A2, SLC7A11, and GPX4, were further confirmed by RNA seq. EPC EVs were able to reverse dexamethasone treatment induced alterations in cysteine and several oxidative injury markers, such as malondialdehyde (MDA), glutathione (GSH), and glutathione disulphide (GSSG) (as detected by ELISA). In conclusion, EPC EVs prevented mouse glucocorticoid induced osteoporosis by suppressing the ferroptotic pathway in osteoblasts, which may provide a basis for novel therapies for SIOP in humans.
C1 [Lu, Jinsen; Yang, Jiazhao; Zheng, Yongshun; Fang, Shiyuan] Anhui Med Univ, Anhui Prov Hosp, Dept Orthopaed, Lujiang Rd 17, Hefei 230001, Anhui, Peoples R China.
   [Chen, Xiaoyu] Anhui Med Univ, Dept Histol & Embryol, Meishan Rd 81, Hefei 230032, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University
RP Lu, JS; Fang, SY (通讯作者)，Anhui Med Univ, Anhui Prov Hosp, Dept Orthopaed, Lujiang Rd 17, Hefei 230001, Anhui, Peoples R China.
EM lujinsen@stu.ahmu.edu.cn; fangshiyuan@126.com
RI ; Zheng, Yongshun/AAJ 3120 2021
OI Lu, Jinsen/0000 0002 5239 5361; Zheng, Yongshun/0000 0003 2180 2363
FU National Natural Science Foundation of China [NSFC: 81373421, 81270650]
FX This study was supported by grants from the National Natural Science
   Foundation of China (NSFC: 81373421,81270650). Special thanks to Jiwei
   Li from LIFEGENES Biotechnology (Shanghai, China) for conducting RNA seq
   and bioinformatics analysis. The data discussed in this publication have
   been deposited in the NCBI Gene Expression Omnibus (GEO) database and
   are accessible through the GEO series accession number GSE129228
   (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE129228).Besides,
   use of KEGG imaginary was apporoved by Kanehisa laboratory with official
   permmssion. In addition, thanks to Umibio biotechnology (Shanghai,
   China) for asisting us in extraction and identification of extracellular
   vesicles.
CR Alborzinia N, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003 018 0212 6
   An BC, 2016, MOL CELLS, V39, P631, DOI 10.14348/molcells.2016.0164
   Atanasova S, 2009, STRESS, V12, P215, DOI 10.1080/10253890802305075
   Avecilla ST, 2016, TRANSFUSION, V56, P1008, DOI 10.1111/trf.13534
   Behera Jyotirmaya, 2018, Oncoscience, V5, P181, DOI 10.18632/oncoscience.421
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Burr DB, 2012, NAT REV RHEUMATOL, V8, P665, DOI 10.1038/nrrheum.2012.130
   Caradec J, 2014, CLIN BIOCHEM, V47, P1286, DOI 10.1016/j.clinbiochem.2014.06.011
   Chen XY, 2014, MOL MED REP, V9, P2592, DOI 10.3892/mmr.2014.2070
   Chopra H, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/9847015
   Fleury A, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00370
   Frenkel B, 2015, ADV EXP MED BIOL, V872, P179, DOI 10.1007/978 1 4939 2895 8_8
   Gao MH, 2019, MOL CELL, V73, P354, DOI 10.1016/j.molcel.2018.10.042
   Gray WD, 2015, CIRC RES, V116, P255, DOI 10.1161/CIRCRESAHA.116.304360
   Han YD, 2018, INT J MOL MED, V41, P800, DOI 10.3892/ijmm.2017.3270
   Hao ZC, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12359
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jing H, 2017, FASEB J, V31, P4422, DOI 10.1096/fj.201700118R
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kanehisa M, 2019, PROTEIN SCI, V28, P1947, DOI 10.1002/pro.3715
   Kanehisa M, 2019, NUCLEIC ACIDS RES, V47, pD590, DOI 10.1093/nar/gky962
   Katsimbri P, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12740
   Ke X, 2017, DNA CELL BIOL, V36, P1018, DOI 10.1089/dna.2017.3836
   Kerachian MA, 2009, J STEROID BIOCHEM, V114, P121, DOI 10.1016/j.jsbmb.2009.02.007
   Kohli N, 2018, BONE, V110, P38, DOI 10.1016/j.bone.2018.01.015
   Kubo T, 2016, J ORTHOP SCI, V21, P407, DOI 10.1016/j.jos.2016.03.008
   Kylmäoja E, 2016, CURR STEM CELL RES T, V11, P626, DOI 10.2174/1574888X10666151019115724
   Latunde Dada GO, 2017, BBA GEN SUBJECTS, V1861, P1893, DOI 10.1016/j.bbagen.2017.05.019
   Liu LH, 2017, CHINESE MED J PEKING, V130, P2601, DOI 10.4103/0366 6999.217094
   Luo MY, 2018, CELL DEATH DIFFER, V25, P1457, DOI 10.1038/s41418 017 0053 8
   Luo P, 2018, INT ORTHOP, V42, P1747, DOI 10.1007/s00264 018 3994 8
   Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008 5472.CAN 17 3454
   McIntosh LJ, 1996, EXP NEUROL, V141, P201, DOI 10.1006/exnr.1996.0154
   Medeiros DM, 2016, EXP BIOL MED, V241, P1316, DOI 10.1177/1535370216648805
   Qin YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050712
   Radi E, 2014, J ALZHEIMERS DIS, V42, pS125, DOI 10.3233/JAD 132738
   Rani S, 2016, ADV MATER, V28, P5542, DOI 10.1002/adma.201504009
   Ren K, 2019, ODONTOLOGY, V107, P271, DOI 10.1007/s10266 018 0395 9
   Rossi M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041136
   Samanta S, 2018, ACTA PHARMACOL SIN, V39, P501, DOI 10.1038/aps.2017.162
   Schacht E., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P174
   Seki S, 2017, EUR SPINE J, V26, P2121, DOI 10.1007/s00586 017 4959 0
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sun BC, 2018, REV NEUROSCIENCE, V29, P531, DOI 10.1515/revneuro 2017 0059
   Taghizadieh M, 2016, BRATISL MED J, V117, P47, DOI 10.4149/BLL_2016_010
   Tang YT, 2017, INT J MOL MED, V40, P834, DOI 10.3892/ijmm.2017.3080
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Todorova D, 2017, CIRC RES, V120, P1658, DOI 10.1161/CIRCRESAHA.117.309681
   Vizoso FJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18091852
   Wang M, 2019, CELL DEATH DIFFER, V26, P2329, DOI 10.1038/s41418 019 0304 y
   Xiao FJ, 2019, BIOCHEM BIOPH RES CO, V515, P448, DOI 10.1016/j.bbrc.2019.05.147
   Xie Y, 2016, CELL DEATH DIFFER, V23, P369, DOI 10.1038/cdd.2015.158
   Yin J, 2018, PHARMACOL REP, V70, P270, DOI 10.1016/j.pharep.2017.11.001
   Zeringer Emily, 2013, World J Methodol, V3, P11, DOI 10.5662/wjm.v3.i1.11
   Zhang J, 2015, GENOM PROTEOM BIOINF, V13, P17, DOI 10.1016/j.gpb.2015.02.001
   Zhang JY, 2016, INT J BIOL SCI, V12, P1472, DOI 10.7150/ijbs.15514
   Zhang KX, 2018, MOL CARCINOGEN, V57, P1566, DOI 10.1002/mc.22878
   Zhang ZH, 2018, MOL MED REP, V17, P801, DOI 10.3892/mmr.2017.7963
   Zhao L, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916 018 0700 x
NR 59
TC 72
Z9 87
U1 0
U2 37
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD NOV 6
PY 2019
VL 9
AR 16130
DI 10.1038/s41598 019 52513 x
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA JK1VZ
UT WOS:000494636500019
PM 31695092
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Lee, SJ
   Jang, SA
   Kim, SC
   Ryuk, JA
   Ha, H
AF Lee, Sung Ju
   Jang, Seon A
   Kim, Seong Cheol
   Ryuk, Jin Ah
   Ha, Hyunil
TI Lophatherum gracile Bronghiart Suppresses Receptor Activator of
   Nuclear Factor Kappa B Ligand Stimulated Osteoclastogenesis and Prevents
   Ovariectomy Induced Osteoporosis
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE Lophatherum gracile Bronghiart; osteoporosis; bone loss; ovariectomy
ID C FOS; BONE HOMEOSTASIS; RANKL; DIFFERENTIATION; INDUCTION; NFATC1;
   MINERALIZATION; RESORPTION; FAMILY; LEAVES
AB Lophatherum gracile Bronghiart, used in traditional herbal medicine, has many biological properties including antiviral, antipyretic, antitumor, vasorelaxation, and neutrophilic inflammatory effects. However, its modulatory effects on bone metabolism have not been investigated previously. In this study, we examined the effects of a water extract of the leaves of L. gracile (WELG) on osteoclast differentiation and bone loss, and explored its underlying mechanisms. We found that WELG inhibits osteoclastogenesis by suppressing both receptor activator of nuclear factor kappa B ligand (RANKL) induced early activation of mitogen activated protein kinases (MAPKs) and nuclear factor kappa B (NF kappa B)  and RANKL induced modulation of the positive and negative regulators of osteoclastogenesis in osteoclast precursors. In vivo study demonstrated that WELG protects against bone loss, weight gain, and fat accumulation without affecting uterine atrophy in an ovariectomy induced postmenopausal osteoporosis mice model. In addition, photochemical analysis of WELG identified active constituents known to have bone protective effects. Overall, the results of this study suggest that WELG can be a potential candidate for therapy and prevention of postmenopausal osteoporosis.
C1 [Lee, Sung Ju; Kim, Seong Cheol; Ryuk, Jin Ah; Ha, Hyunil] Korea Inst Oriental Med, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
   [Jang, Seon A] KT&G Corp, Future Technol Res Ctr, 30 Gajeong Ro, Daejeon 34128, South Korea.
C3 Korea Institute of Oriental Medicine (KIOM)
RP Ha, H (通讯作者)，Korea Inst Oriental Med, KM Convergence Res Div, Yuseong Daero 1672, Daejeon 34054, South Korea.
EM hyunil74@kiom.re.kr
FU Korea Institute of Oriental Medicine, Ministry of Science and ICT,
   Republic of Korea [KSN2021330]
FX This study was supported by the Korea Institute of Oriental Medicine,
   Ministry of Science and ICT, Republic of Korea [grant number:
   KSN2021330].
CR Aliprantis AO, 2008, J CLIN INVEST, V118, P3775, DOI 10.1172/JCI35711
   Ambrosi TH, 2017, CELL STEM CELL, V20, P771, DOI 10.1016/j.stem.2017.02.009
   Davis SR, 2012, CLIMACTERIC, V15, P419, DOI 10.3109/13697137.2012.707385
   Fu QR, 2014, J CHROMATOGR A, V1323, P123, DOI 10.1016/j.chroma.2013.11.015
   Gao YG, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158182
   Gohda J, 2005, EMBO J, V24, P790, DOI 10.1038/sj.emboj.7600564
   He QF, 2016, INT J PHARMACOL, V12, P387, DOI 10.3923/ijp.2016.387.393
   Huang H, 2006, BIOCHEM BIOPH RES CO, V351, P99, DOI 10.1016/j.bbrc.2006.10.011
   Hwang YH, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081831
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Kim A, 2016, SCI REP UK, V6, DOI 10.1038/srep36277
   Kim Jung Ha, 2016, Chonnam Med J, V52, P12, DOI 10.4068/cmj.2016.52.1.12
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim K, 2007, BLOOD, V109, P3253, DOI 10.1182/blood 2006 09 048249
   Kwak SC, 2013, BIOL PHARM BULL, V36, P1779
   Lai KH, 2021, J ETHNOPHARMACOL, V264, DOI 10.1016/j.jep.2020.113224
   Li HW, 2021, HORM INT J ENDOCRINO, V20, P49, DOI 10.1007/s42000 020 00216 8
   Liu XK, 2022, FOOD SCI NUTR, V10, P1592, DOI 10.1002/fsn3.2782
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McNamara LM, 2010, J R SOC INTERFACE, V7, P353, DOI 10.1098/rsif.2009.0282
   Muruganandan S, 2018, CURR OSTEOPOROS REP, V16, P434, DOI 10.1007/s11914 018 0451 y
   Nakashima T, 2011, NAT MED, V17, P1231, DOI 10.1038/nm.2452
   Nash LA, 2015, MOL NUTR FOOD RES, V59, P443, DOI 10.1002/mnfr.201400592
   Nishikaw K, 2010, P NATL ACAD SCI USA, V107, P3117, DOI 10.1073/pnas.0912779107
   Pal S, 2021, EUR J PHARMACOL, V913, DOI 10.1016/j.ejphar.2021.174634
   Park JH, 2017, MOL CELLS, V40, P706
   Rozema E, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/983023
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Takayanagi H, 2002, NATURE, V416, P744, DOI 10.1038/416744a
   Tanaka S, 2005, IMMUNOL REV, V208, P30, DOI 10.1111/j.0105 2896.2005.00327.x
   Wada T, 2006, TRENDS MOL MED, V12, P17, DOI 10.1016/j.molmed.2005.11.007
   Wang Y, 2012, PLANTA MED, V78, P46, DOI 10.1055/s 0031 1280128
   Wong BR, 1998, J BIOL CHEM, V273, P28355, DOI 10.1074/jbc.273.43.28355
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Yamaguchi M, 2008, MOL CELL BIOCHEM, V311, P31, DOI 10.1007/s11010 007 9689 x
   Yamaguchi M, 2012, INT J MOL MED, V30, P708, DOI 10.3892/ijmm.2012.1043
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
   Zhang CM, 2015, J CHROMATOGR A, V1381, P160, DOI 10.1016/j.chroma.2015.01.019
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhao S, 2002, J BONE MINER RES, V17, P2068, DOI 10.1359/jbmr.2002.17.11.2068
   Zhou RP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166751
NR 41
TC 3
Z9 3
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2022
VL 23
IS 22
AR 13942
DI 10.3390/ijms232213942
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6K3PB
UT WOS:000887417500001
PM 36430416
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Cheng, MH
   Kim, SJ
AF Cheng, Mi Hyun
   Kim, Sung Jin
TI Inhibitory Effect of Probenecid on Osteoclast Formation via JNK, ROS and
   COX 2
SO BIOMOLECULES & THERAPEUTICS
LA English
DT Article
DE Probenecid; Antiosteoclastogenesis; Oxidative stress; ROS; COX 2; JNK
ID PEROXIDE INDUCED APOPTOSIS; ACTIVATED PROTEIN KINASE; NECROSIS FACTOR
   RECEPTOR; NF KAPPA B; HYDROGEN PEROXIDE; REACTIVE OXYGEN;
   BONE RESORPTION; DIFFERENTIATION; GENERATION; LIPOPOLYSACCHARIDE
AB Probenecid is a representative drug used in the treatment of gout. A recent study showed that probenecid effectively inhibits oxidative stress in neural cells. In the present study, we investigated whether probenecid can affect osteoclast formation through the inhibition of reactive oxygen species (ROS) formation in RAW264.7 cells. Lipopolysaccharide (LPS) induced ROS levels were dose dependently reduced by probenecid. Fluorescence microscopy analysis clearly showed that probenecid inhibits the generation of ROS. Western blot analysis indicated that probenecid affects two downstream signaling molecules of ROS, cyclooxygenase 2 (COX 2) and c Jun N terminal kinase (JNK). These results indicate that probenecid inhibits ROS generation and exerts antiosteoclastogenic activity by inhibiting the COX 2 and JNK pathways. These results suggest that probenecid could potentially be used as a therapeutic agent to prevent bone resorption.
C1 [Cheng, Mi Hyun; Kim, Sung Jin] Kyung Hee Univ, Sch Dent, Grad Sch, Dept Pharmacol & Toxicol, Seoul 02447, South Korea.
C3 Kyung Hee University
RP Kim, SJ (通讯作者)，Kyung Hee Univ, Sch Dent, Grad Sch, Dept Pharmacol & Toxicol, Seoul 02447, South Korea.
EM kimsj@khu.ac.kr
CR Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217
   BEECHWOOD EC, 1964, AM J PHYSIOL, V207, P1265, DOI 10.1152/ajplegacy.1964.207.6.1265
   BISHOP C, 1955, P SOC EXP BIOL MED, V88, P346
   BOGER WP, 1955, ARCH INTERN MED, V95, P83, DOI 10.1001/archinte.1955.00250070099012
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891 5849(00)00302 6
   Chen GP, 2019, BIOCHEM BIOPH RES CO, V509, P329, DOI 10.1016/j.bbrc.2018.12.112
   Chen L, 2009, INT J BIOCHEM CELL B, V41, P1284, DOI 10.1016/j.biocel.2008.10.029
   Darnay BG, 1999, J BIOL CHEM, V274, P7724, DOI 10.1074/jbc.274.12.7724
   Du LN, 2016, J NEUROTRAUM, V33, P1913, DOI 10.1089/neu.2015.4342
   Forman HJ, 2004, AM J PHYSIOL CELL PH, V287, pC246, DOI 10.1152/ajpcell.00516.2003
   Fraser JHE, 1996, BONE, V19, P223, DOI 10.1016/8756 3282(96)00177 9
   GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485
   Geng DC, 2011, J BIOMED MATER RES A, V99A, P516, DOI 10.1002/jbm.a.33197
   Greene EL, 2000, HYPERTENSION, V35, P942, DOI 10.1161/01.HYP.35.4.942
   GUTMAN AB, 1951, B NEW YORK ACAD MED, V27, P144
   HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184
   Hou GQ, 2013, INT J MOL MED, V32, P503, DOI 10.3892/ijmm.2013.1406
   Hwang JS, 2016, PHARMACOL RES, V114, P47, DOI 10.1016/j.phrs.2016.10.014
   Jang HJ, 2013, J RECEPT SIG TRANSD, V33, P387, DOI 10.3109/10799893.2013.839999
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Lin YC, 2009, NEUROCHEM RES, V34, P923, DOI 10.1007/s11064 008 9860 0
   Matsumoto M, 2000, J BIOL CHEM, V275, P31155, DOI 10.1074/jbc.M001229200
   Mizutani H, 2013, J PERIODONTAL RES, V48, P748, DOI 10.1111/jre.12065
   MOLLER JV, 1965, ACTA PHARMACOL TOX, V23, P329
   Oka Y, 2012, J PHARMACOL SCI, V118, P55, DOI 10.1254/jphs.11082FP
   Oldenburg O, 2004, AM J PHYSIOL HEART C, V286, pH468, DOI 10.1152/ajpheart.00360.2003
   Park JB, 2011, PHARMACOL REP, V63, P1145
   Ruffels J, 2004, EUR J PHARMACOL, V483, P163, DOI 10.1016/j.ejphar.2003.10.032
   Schapoval EES, 1998, J ETHNOPHARMACOL, V60, P53, DOI 10.1016/S0378 8741(97)00136 0
   SIROTA JH, 1952, J CLIN INVEST, V31, P692, DOI 10.1172/JCI102651
   STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296
   TALBOTT J H, 1951, Bull Rheum Dis, V2, P1
   Tang T, 2017, SCI REP, V7, P1
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   Vietinghoff G, 2003, PEPTIDES, V24, P931, DOI 10.1016/S0196 9781(03)00157 8
   Wu HB, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0540 y
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang L, 2007, EUR J PHARMACOL, V564, P18, DOI 10.1016/j.ejphar.2007.01.089
   Zhang XJ, 2018, J CELL BIOCHEM, V119, P8981, DOI 10.1002/jcb.27154
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
   Zhuang SG, 2007, AM J PHYSIOL RENAL, V292, pF440, DOI 10.1152/ajprenal.00170.2006
NR 45
TC 14
Z9 16
U1 0
U2 21
PU KOREAN SOC APPLIED PHARMACOLOGY
PI SEOUL
PA RM 805, KOREAN FEDERATION SCIENCE & TECHNOLOGY B/D, 635 4 YEOKSAM DONG,
   KANGNAM GU, SEOUL, 135 703, SOUTH KOREA
SN 1976 9148
EI 2005 4483
J9 BIOMOL THER
JI Biomol. Ther.
PD JAN
PY 2020
VL 28
IS 1
BP 104
EP 109
DI 10.4062/biomolther.2019.047
PG 6
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA JY8LA
UT WOS:000504658700011
PM 31474032
OA Green Published
DA 2025 08 17
ER

PT J
AU Li, X
   Zhou, ZY
   Zhang, YY
   Yang, HL
AF Li, Xiang
   Zhou, Zong yu
   Zhang, Yuan yuan
   Yang, Hui lin
TI IL 6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal
   Cells from the Vertebral Body of the Glucocorticoid Induced Osteoporotic
   Mouse
SO PLOS ONE
LA English
DT Article
ID MESENCHYMAL STEM CELLS; RHEUMATOID ARTHRITIS; INFLAMMATORY MARKERS;
   RECEPTOR INHIBITION; CIRCULATING LEVELS; SIGNALING PATHWAY; MINERAL
   DENSITY; INTERLEUKIN 6; MICE; ADIPOGENESIS
AB Osteoporosis is one of the most prevalent skeletal system diseases. It is characterized by a decrease in bone mass and microarchitectural changes in bone tissue that lead to an attenuation of bone resistance and susceptibility to fracture. Vertebral fracture is by far the most prevalent osteoporotic fracture. In the musculoskeletal system, osteoblasts, originated from bone marrow stromal cells (BMSC), are responsible for osteoid synthesis and mineralization. In osteoporosis, BMSC osteogenic differentiation is defective. However, to date, what leads to the defective BMSC osteogenesis in osteoporosis remains an open question. In the current study, we made attempts to answer this question. A mouse model of glucocorticoid induced osteoporosis (GIO) was established and BMSC were isolated from vertebral body. The impairment of osteogenesis was observed in BMSC of osteoporotic vertebral body. The expression profiles of thirty six factors, which play important roles in bone metabolisms, were compared through antibody array between normal and osteoporotic BMSC. Significantly higher secretion level of IL 6 was observed in osteoporotic BMSCs compared with normal control. We provided evidences that IL 6 over secretion impaired osteogenesis of osteoporotic BMSC. Further, it was observed that beta catenin activity was inhibited in response to IL 6 over secretion. More importantly, in vivo administration of IL 6 neutralizing antibody was found to be helpful to rescue the osteoporotic phenotype of mouse vertebral body. Our study provides a deeper insight into the pathophysiology of osteoporosis and identifies IL 6 as a promising target for osteoporosis therapy.
C1 [Li, Xiang; Yang, Hui lin] Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Peoples R China.
   [Li, Xiang] Huaian First Peoples Hosp, Dept Orthoped, Huaian 223300, Peoples R China.
   [Zhou, Zong yu] Huaiyin Hosp Huaian City, Dept Orthoped, Huaian 223300, Peoples R China.
   [Zhang, Yuan yuan] Huaian First Peoples Hosp, Dept Pediat, Huaian 223300, Peoples R China.
C3 Soochow University   China
RP Yang, HL (通讯作者)，Soochow Univ, Dept Orthoped, Affiliated Hosp 1, Suzhou 215006, Peoples R China.; Zhang, YY (通讯作者)，Huaian First Peoples Hosp, Dept Pediat, Huaian 223300, Peoples R China.
EM hazhangyuanyuan@163.com; hlyang@suda.edu.cn
RI Zhou, Zongyu/LVR 0025 2024
FU Jiangsu Provincial Special Program of Medical Science [BL2012004];
   Jiangsu Provincial Clinical Orthopedic Center; Priority Academic Program
   Development of Jiangsu Higher Education Institutions (PAPD)
FX This study was supported by grants from the Jiangsu Provincial Special
   Program of Medical Science (BL2012004), the Jiangsu Provincial Clinical
   Orthopedic Center, and the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (PAPD).
CR Astudillo P, 2008, J CELL BIOCHEM, V103, P1054, DOI 10.1002/jcb.21516
   Barbour KE, 2012, J BONE MINER RES, V27, P1167, DOI 10.1002/jbmr.1559
   Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666
   Bian ZY, 2010, CANCER SCI, V101, P2554, DOI 10.1111/j.1349 7006.2010.01731.x
   Blanchard F, 2009, CYTOKINE GROWTH F R, V20, P19, DOI 10.1016/j.cytogfr.2008.11.004
   Cushing H, 1994, Obes Res, V2, P486
   De Benedetti F, 2001, J IMMUNOL, V166, P4334, DOI 10.4049/jimmunol.166.7.4334
   De Benedetti F, 2006, ARTHRITIS RHEUM, V54, P3551, DOI 10.1002/art.22175
   De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365 2141.2000.02127.x
   DEMPSTER DW, 1989, J BONE MINER RES, V4, P137
   Ding C, 2008, J CLIN ENDOCR METAB, V93, P1952, DOI 10.1210/jc.2007 2325
   FALLA N, 1993, BLOOD, V82, P3580
   Ferrari SL, 2003, J CLIN ENDOCR METAB, V88, P255, DOI 10.1210/jc.2002 020092
   Fukuyo S, 2014, RHEUMATOLOGY, V53, P1282, DOI 10.1093/rheumatology/ket496
   Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21
   Hattori T, 2010, PHYTOMEDICINE, V17, P170, DOI 10.1016/j.phymed.2009.12.004
   Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747
   HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243
   HOUSSIAU FA, 1988, ARTHRITIS RHEUM US, V31, P784, DOI 10.1002/art.1780310614
   Huh JE, 2013, BBA MOL CELL RES, V1833, P2608, DOI 10.1016/j.bbamcr.2013.06.025
   Kaneshiro S, 2014, J BONE MINER METAB, V32, P378, DOI 10.1007/s00774 013 0514 1
   Karsdal MA, 2012, SEMIN ARTHRITIS RHEU, V42, P131, DOI 10.1016/j.semarthrit.2012.01.004
   Kendler DL, 2016, AM J MED, V129, DOI 10.1016/j.amjmed.2015.09.020
   Khosla S, 2002, J CLIN ENDOCR METAB, V87, P1550, DOI 10.1210/jc.87.4.1550
   KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0
   Koshihara Y, 2002, MECH AGEING DEV, V123, P1321, DOI 10.1016/S0047 6374(02)00071 4
   Lattanzio G, 1997, AM J PATHOL, V151, P689
   Liu XH, 2006, VITAM HORM, V74, P341, DOI 10.1016/S0083 6729(06)74014 6
   Nuttall ME, 2004, CURR OPIN PHARMACOL, V4, P290, DOI 10.1016/j.coph.2004.03.002
   Olmos JM, 1999, METHOD FIND EXP CLIN, V21, P519, DOI 10.1358/mf.1999.21.8.794832
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Park JH, 2013, MENOPAUSE, V20, P747, DOI [10.1097/GME.0b013e31827cabca, 10.1097/gme.0b013e31827cabca]
   POLI V, 1994, EMBO J, V13, P1189, DOI 10.1002/j.1460 2075.1994.tb06368.x
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   REID IR, 1989, CLIN ENDOCRINOL, V30, P83, DOI 10.1111/j.1365 2265.1989.tb03730.x
   Rodríguez JP, 2000, J CELL BIOCHEM, V79, P557, DOI 10.1002/1097 4644(20001215)79:4<557::AID JCB40>3.0.CO;2 H
   Rodríguez JP, 2004, J CELL BIOCHEM, V92, P745, DOI 10.1002/jcb.20119
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   Römer P, 2012, ANN ANAT, V194, P208, DOI 10.1016/j.aanat.2011.09.008
   Sambrook P, 2006, LANCET, V367, P2010, DOI 10.1016/S0140 6736(06)68891 0
   Scheidt Nave C, 2001, J CLIN ENDOCR METAB, V86, P2032, DOI 10.1210/jc.86.5.2032
   Sims NA, 2005, J BONE MINER RES, V20, P1093, DOI 10.1359/JBMR.050209
   TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924
   Terpos E, 2011, CLIN EXP RHEUMATOL, V29, P921
   TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wong PKK, 2003, ARTHRITIS RHEUM US, V48, P1177, DOI 10.1002/art.10943
   Yadav VK, 2010, ANN NY ACAD SCI, V1192, P103, DOI 10.1111/j.1749 6632.2009.05312.x
   Yamaguchi K, 1999, BIOORG MED CHEM LETT, V9, P957, DOI 10.1016/S0960 894X(99)00122 5
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Zhang YX, 2015, J BIOCHEM, V158, P445, DOI 10.1093/jb/mvv059
   Zhang YX, 2015, BBA MOL BASIS DIS, V1852, P2504, DOI 10.1016/j.bbadis.2015.08.020
NR 52
TC 54
Z9 61
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD APR 29
PY 2016
VL 11
IS 4
AR e0154677
DI 10.1371/journal.pone.0154677
PG 19
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DK8XM
UT WOS:000375212600059
PM 27128729
OA Green Submitted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Sieper, J
AF Sieper, Joachim
TI Treatment Challenges in Axial Spondylarthritis and Future Directions
SO CURRENT RHEUMATOLOGY REPORTS
LA English
DT Article
DE Axial spondyloarthritis; Remission; TNF blocker; NSAIDs; Optimizing
   treatment strategies; Non TNF blocker biologics; Radiographic
   progression; Treatment; Treatment challenges; Seronegative arthritis
ID PLACEBO CONTROLLED TRIAL; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ACTIVE
   ANKYLOSING SPONDYLITIS; RANDOMIZED CONTROLLED TRIAL; MAJOR
   CLINICAL RESPONSE; NECROSIS FACTOR THERAPY; WHOLE BODY MRI; RADIOGRAPHIC
   PROGRESSION; RHEUMATOID ARTHRITIS; ESTHER TRIAL
AB Major progress has been made in recent years in the management of axial spondyloarthritis (axSpA), including ankylosing spondylitis (AS) and non radiographic axSpA (nr axSpA). Most predictors of response have been defined for TNF blocker therapy, and new treatment strategies are being discussed about how to best reach remission and how to maintain remission. Other biologics besides TNF blockers have been tested in AS but have so far failed. The IL 17/IL 23 cytokines currently seem to be the most interesting targets. Short term TNF blocker therapy does not inhibit radiographic progression but long term might do so. NSAIDs have been proven to inhibit such progression, even after 2 years of treatment. The effect of a combined therapy of NSAIDs with TNF blockers on the inhibition of new bone formation in AS patients is currently unknown.
C1 Charite, Dept Med 1, Rheumatol, D 12200 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Sieper, J (通讯作者)，Charite, Dept Med 1, Rheumatol, Campus Benjamin Franklin,Hindenburgdamm 30, D 12200 Berlin, Germany.
EM joachim.sieper@charite.de
FU AbbVie; Merck Co.; Pfizer; Janssen Pharmaceutica; Merck Serono
FX Joachim Sieper has served as a consultant for AbbVie, Merck & Co.,
   Pfizer, UCB, Roche, Sanofi, Eli Lilly and Company, and Janssen
   Pharmaceutica; has received grant support from AbbVie, Merck & Co.,
   Pfizer, Janssen Pharmaceutica, and Merck Serono; has received honoraria
   from AbbVie, Merck & Co., Pfizer, and UCB; has received payment for
   development of educational presentations (including service on speakers
   bureaus) from AbbVie, Merck & Co., Pfizer, and UCB; and has had
   travel/accommodations expenses covered/reimbursed by AbbVie, Merck &
   Co., Pfizer, and UCB.
CR [Anonymous], 2024, Ann Rheum Dis
   [Anonymous], ANN RHEUM DIS
   Baeten D, 2013, LANCET IN PRESS
   Baraliakos X, 2007, J RHEUMATOL, V34, P510
   Barkham N, 2009, ANN RHEUM DIS     S3, V68, P72
   Barkhuizen A, 2006, J RHEUMATOL, V33, P1805
   Braun J, 2011, ANN RHEUM DIS, V70, P896, DOI 10.1136/ard.2011.151027
   Breban M, 2008, ARTHRITIS RHEUM US, V58, P88, DOI 10.1002/art.23167
   Dougados M, 2011, ANN RHEUM DIS, V70, P249, DOI 10.1136/ard.2010.133488
   Griffiths CEM, 2010, NEW ENGL J MED, V362, P118, DOI 10.1056/NEJMoa0810652
   Haibel H, 2005, ANN RHEUM DIS, V64, P296, DOI 10.1136/ard.2004.023176
   Haibel H, 2013, ARTHRITIS RHEUM
   Haibel H, 2008, ARTHRITIS RHEUM US, V58, P1981, DOI 10.1002/art.23606
   Heiberg MS, 2008, ARTHRIT RHEUM ARTHR, V59, P234, DOI 10.1002/art.23333
   Jarrett SJ, 2009, ANN RHEUM DIS, V68, P1466, DOI 10.1136/ard.2008.092213
   Kroon F, 2012, ANN RHEUM DIS, V71, P1623, DOI 10.1136/annrheumdis 2012 201370
   Landewé RBM, 2012, ARTHRITIS RHEUM US, V64, pS336
   Li EK, 2008, RHEUMATOLOGY, V47, P1358, DOI 10.1093/rheumatology/ken207
   Lie E, 2011, ANN RHEUM DIS, V70, P157, DOI 10.1136/ard.2010.131797
   Maksymowych WP, 2013, ANN RHEUM DIS, V72, P23, DOI 10.1136/annrheumdis 2011 200859
   Navarro Compán V, 2011, CLIN RHEUMATOL, V30, P993, DOI 10.1007/s10067 011 1722 5
   Poddubnyy D, 2012, ANN RHEUM DIS, V71, P1616, DOI 10.1136/annrheumdis 2011 201252
   Poddubnyy D, 2012, ARTHRITIS RHEUM US, V64, P1388, DOI 10.1002/art.33465
   Poddubnyy D, 2011, ANN RHEUM DIS, V70, P1369, DOI 10.1136/ard.2010.145995
   Rudwaleit M, 2008, ANN RHEUM DIS, V67, P1276, DOI 10.1136/ard.2007.073098
   Rudwaleit M, 2004, ANN RHEUM DIS, V63, P665, DOI 10.1136/ard.2003.016386
   Rudwaleit M, 2009, ANN RHEUM DIS, V68, P777, DOI 10.1136/ard.2009.108233
   Rudwaleit M, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3054
   Schipper LG, 2012, ANN RHEUM DIS, V71, P845, DOI 10.1136/annrheumdis 2011 200274
   Sherlock JP, 2012, NAT MED, V18, P1069, DOI 10.1038/nm.2817
   SIEPER J, 2012, ANN RHEUM DIS     S3, V71, P111, DOI DOI 10.1136/ANNRHEUMDIS 2012 EULAR.1852
   Sieper J, 2008, ARTHRITIS RHEUM US, V58, P649, DOI 10.1002/art.23260
   Sieper J, 2013, ANN RHEUM DIS, V72, P815, DOI 10.1136/annrheumdis 2012 201766
   Sieper J, 2013, ARTHRITIS RHEUM US, V65, P543, DOI 10.1002/art.37803
   Sieper J, 2012, ANN RHEUM DIS, V71, P700, DOI [10.1136/annrheumdis 2011 200358, 10.1136/annrheumdis 2011 201282]
   Smolen JS, 2013, LANCET, V381, P918, DOI 10.1016/S0140 6736(12)61811 X
   Smolen JS., 2013, Ann Rheum Dis
   Song IH, 2010, ARTHRITIS RHEUM US, V62, P1290, DOI 10.1002/art.27383
   Song IH, 2011, ANN RHEUM DIS, V70, P1257, DOI 10.1136/ard.2010.147033
   Song IH, 2011, ANN RHEUM DIS, V70, P590, DOI 10.1136/ard.2010.139667
   Song IH, 2011, ANN RHEUM DIS
   Song IH, 2013, ANN RHEUM DIS, V72, P823, DOI 10.1136/annrheumdis 2012 202389
   Song IH, 2013, ANN RHEUM DIS, V72, P305, DOI 10.1136/annrheumdis 2012 201926
   Song IH, 2012, ANN RHEUM DIS, V71, P1212, DOI 10.1136/annrheumdis 2011 201010
   van der Heijde D, 2005, ARTHRITIS RHEUM US, V52, P582, DOI 10.1002/art.20852
   van der Heijde D, 2008, ARTHRITIS RHEUM US, V58, P3063, DOI 10.1002/art.23901
   van der Heijde D, 2006, ARTHRITIS RHEUM US, V54, P2136, DOI 10.1002/art.21913
   van der Heijde D, 2011, ANN RHEUM DIS, V70, P905, DOI 10.1136/ard.2011.151563
   Vincent FB, 2013, ANN RHEUM DIS, V72, P165, DOI 10.1136/annrheumdis 2012 202545
   Wanders A, 2005, ARTHRITIS RHEUM US, V52, P1756, DOI 10.1002/art.21054
NR 50
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523 3774
EI 1534 6307
J9 CURR RHEUMATOL REP
JI Curr. Rheumatol. Rep.
PD SEP
PY 2013
VL 15
IS 9
AR 356
DI 10.1007/s11926 013 0356 9
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 228HB
UT WOS:000325175500006
PM 23888365
DA 2025 08 17
ER

PT J
AU Kolk, A
   Boskov, M
   Haidari, S
   Tischer, T
   van Griensven, M
   Bissinger, O
   Plank, C
AF Kolk, Andreas
   Boskov, Marko
   Haidari, Selgai
   Tischer, Thomas
   van Griensven, Martijn
   Bissinger, Oliver
   Plank, Christian
TI Comparative analysis of bone regeneration behavior using recombinant
   human BMP 2 versus plasmid DNA of BMP 2
SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
LA English
DT Article
DE BMP 2; gene delivery; bone regeneration; osteoclast; critical size bone
   defect; BMP signaling
ID NONVIRAL GENE VECTORS; MORPHOGENETIC PROTEIN 2; CALCIUM PHOSPHATE;
   IMPLANT SURFACES; SPINE SURGERY; ECTOPIC BONE; IN VIVO; DELIVERY;
   DEFECTS; RELEASE
AB Bone regeneration and the osteoinductive capacity of implants are challenging issues in clinical medicine. Currently, recombinant growth factors and nonviral gene transfer are the most frequently investigated methods for bone growth enhancement, although the more favorable method remains unclear. There is a lack of knowledge in literature about the in vivo comparison of these methods for bone regeneration. BMP 2, which is the most commonly used growth factor for osteogenesis, was applied at its most efficient dose as a recombinant growth factor (rhBMP 2) and as a growth factor encoding copolymer protected gene vector (pBMP 2) in a critical size bone defect (CSD) model to determine the most suitable method for bone regeneration. CSDs were induced bilaterally in 32 Sprague Dawley rats. RhBMP 2 (62.5 mu g) or pBMP 2 (2.5 mu g) was embedded in poly(d,l )lactide coated titanium discs. Survival times were set at 14, 28, 56, and 112 days. After euthanasia, samples were analyzed via micro computed tomography, polychrome sequential fluorescent labeling, and immunohistochemistry. Whereas defects in both groups were bridged with new bone after 56 days, rhBMP 2 initially induced ectopic new bone formation that was later remodeled in an unorganized hypodense manner. In contrast, pBMP 2 led to slower but steady bone regeneration with physiological tissue morphology, as confirmed by high osteoblast activity shown by osteocalcin staining. CD68 and TRAP staining verified high osteoclast activity for the rhBMP 2 group. pBMP 2 successfully induced locally controlled physiological bone regeneration, whereas rhBMP 2 triggered rapid and ectopic but insufficient bone formation. Thus, nonviral gene transfer appears to be more favorable for clinical applications. (c) 2018 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 107A: 163 173, 2019.
C1 [Kolk, Andreas; Boskov, Marko; Haidari, Selgai; Bissinger, Oliver] Tech Univ Munich, Dept Oral & Maxillofacial Surg, Klinikum Rechts Isar, Munich, Germany.
   [Tischer, Thomas] Rostock Univ Med Ctr, Dept Orthopaed, Munich, Germany.
   [van Griensven, Martijn] Tech Univ Munich, Dept Trauma Surg, Expt Trauma Surg, Klinikum Rechts Isar, Munich, Germany.
   [Kolk, Andreas; Plank, Christian] Tech Univ Munich, Inst Mol Immunol & Expt Oncol, Klinikum Rechts Isar, Munich, Germany.
C3 Technical University of Munich; Technical University of Munich;
   Technical University of Munich
RP Kolk, A (通讯作者)，Tech Univ Munich, Dept Oral & Maxillofacial Surg, Klinikum Rechts Isar, Munich, Germany.; Kolk, A (通讯作者)，Tech Univ Munich, Inst Mol Immunol & Expt Oncol, Klinikum Rechts Isar, Munich, Germany.
EM andreas.kolk@tum.de
RI ; van Griensven, Martijn/F 5808 2012; Tischer, Thomas/H 4524 2019
OI Tischer, Thomas/0000 0002 3942 0235; van Griensven,
   Martijn/0000 0001 5104 9881; 
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Bae HW, 2016, J BONE JOINT SURG AM, V98, P2061, DOI 10.2106/JBJS.16.00345
   Bae SE, 2012, J CONTROL RELEASE, V160, P676, DOI 10.1016/j.jconrel.2012.04.021
   Balmayor ER, 2016, BIOMATERIALS, V87, P131, DOI 10.1016/j.biomaterials.2016.02.018
   Balmayor ER, 2015, ADV DRUG DELIVER REV, V94, P13, DOI 10.1016/j.addr.2015.04.022
   Balmayor ER, 2015, FRONT BIOENG BIOTECH, V3, DOI 10.3389/fbioe.2015.00009
   Bansal R, 2015, COLLOID SURFACE B, V135, P661, DOI 10.1016/j.colsurfb.2015.08.025
   Bessho K, 2002, J BIOMED MATER RES, V61, P61, DOI 10.1002/jbm.10169
   Bissinger O, 2017, J CLIN PERIODONTOL, V44, P418, DOI 10.1111/jcpe.12693
   Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473
   Bonnema H, 2003, J BIOMED MATER RES A, V64A, P502, DOI 10.1002/jbm.a.10404
   Cha JK, 2018, CLIN ORAL IMPLAN RES, V29, P300, DOI 10.1111/clr.13117
   Choi JW, 2016, PLAST RECONSTR SURG, V138, p64E, DOI 10.1097/PRS.0000000000002290
   Cunniffe GM, 2017, EUR CELLS MATER, V33, P130, DOI 10.22203/eCM.v033a10
   D'Mello S, 2017, AAPS J, V19, P43, DOI 10.1208/s12248 016 9982 2
   Deppe H, 2004, LASER MED SCI, V18, P190, DOI 10.1007/s10103 003 0279 1
   Deppe H, 2003, INT J ORAL MAX IMPL, V18, P369
   Detsch R, 2015, J TISSUE ENG REGEN M, V9, P1133, DOI 10.1002/term.1851
   DONATH K, 1982, J ORAL PATHOL MED, V11, P318, DOI 10.1111/j.1600 0714.1982.tb00172.x
   Egermann M, 2006, GENE THER, V13, P1290, DOI 10.1038/sj.gt.3302785
   Evans CH, 2015, NAT REV RHEUMATOL, V11, P234, DOI 10.1038/nrrheum.2015.28
   Even J, 2012, J AM ACAD ORTHOP SUR, V20, P547, DOI 10.5435/JAAOS 20 09 547
   Fang YL, 2015, J BIOMED MATER RES B, V103, P1679, DOI 10.1002/jbm.b.33354
   Filgueira L, 2004, J HISTOCHEM CYTOCHEM, V52, P411, DOI 10.1177/002215540405200312
   Finsinger D, 2000, GENE THER, V7, P1183, DOI 10.1038/sj.gt.3301227
   Fu RW, 2013, ANN INTERN MED, V158, P890, DOI 10.7326/0003 4819 158 12 201306180 00006
   Giannoudis PV, 2009, INJURY, V40, P1
   Gruber R, 2009, CLIN ORAL IMPLAN RES, V20, P24, DOI 10.1111/j.1600 0501.2008.01613.x
   Hacobian ARA, 2016, EUR CELLS MATER, V31, P191, DOI 10.22203/eCM.v031a13
   Haidari S, 2017, J BIOMED MATER RES A, V105, P1672, DOI 10.1002/jbm.a.36042
   Hulsart Billström G, 2013, J MATER SCI MATER M, V24, P1201, DOI 10.1007/s10856 013 4877 6
   Kim JS, 2015, CLIN IMPLANT DENT R, V17, P1103, DOI 10.1111/cid.12223
   Kolk A, 2016, J BIOMED MATER RES A, V104, P2441, DOI 10.1002/jbm.a.35773
   Kolk A, 2011, BIOMATERIALS, V32, P6850, DOI 10.1016/j.biomaterials.2011.05.071
   Kopesky P, 2014, BIOL OPEN, V3, P767, DOI 10.1242/bio.20148128
   Liu Y, 2005, BONE, V36, P745, DOI 10.1016/j.bone.2005.02.005
   Liu Y, 2007, BIOMATERIALS, V28, P2677, DOI 10.1016/j.biomaterials.2007.02.003
   Lohse N, 2015, J CONTROL RELEASE, V220, P201, DOI 10.1016/j.jconrel.2015.10.032
   Marsell R, 2009, INJURY, V40, P4
   Molinari Robert W, 2016, J Spine Surg, V2, P9, DOI 10.21037/jss.2016.01.06
   Morgan SM, 2007, BIOMATERIALS, V28, P5332, DOI 10.1016/j.biomaterials.2007.08.029
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Mroz TE, 2010, SPINE, V35, pS86, DOI 10.1097/BRS.0b013e3181d81ef2
   Okubo Y, 2000, CLIN ORTHOP RELAT R, P295
   Parker RM, 2017, EUR SPINE J, V26, P754, DOI 10.1007/s00586 016 4927 0
   Qu XY, 2015, J BIOMED MATER RES A, V103, P2786, DOI 10.1002/jbm.a.35379
   Reckhenrich AK, 2012, EUR CELLS MATER, V23, P441, DOI 10.22203/eCM.v023a34
   Schliephake H, 2008, BIOMATERIALS, V29, P103, DOI 10.1016/j.biomaterials.2007.09.019
   Schmidmaier G, 2002, BONE, V30, P816, DOI 10.1016/S8756 3282(02)00740 8
   Schwabe P, 2012, SCI WORLD J, DOI 10.1100/2012/560142
   Shields LBE, 2006, SPINE, V31, P542, DOI 10.1097/01.brs.0000201424.27509.72
   Skovrlj B, 2015, SPINE, V40, P1862, DOI 10.1097/BRS.0000000000001126
   Smeets R, 2017, J BIOMED MATER RES B, V105, P1216, DOI 10.1002/jbm.b.33660
   Valentin Opran A, 2002, CLIN ORTHOP RELAT R, P110
   Ye ML, 2010, J CONTROL RELEASE, V146, P241, DOI 10.1016/j.jconrel.2010.05.011
NR 55
TC 12
Z9 13
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1549 3296
EI 1552 4965
J9 J BIOMED MATER RES A
JI J. Biomed. Mater. Res. Part A
PD JAN
PY 2019
VL 107
IS 1
BP 163
EP 173
DI 10.1002/jbm.a.36545
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA HC6AD
UT WOS:000451882600017
PM 30358084
DA 2025 08 17
ER

PT J
AU Wang, HC
   Li, CB
   Li, JM
   Zhu, YJ
   Jia, YD
   Zhang, Y
   Zhang, XD
   Li, WL
   Cui, L
   Li, WY
   Liu, YW
AF Wang, Huichao
   Li, Chunbo
   Li, Jianming
   Zhu, Yingjie
   Jia, Yudong
   Zhang, Ying
   Zhang, Xiaodong
   Li, Wenlong
   Cui, Lei
   Li, Wuyin
   Liu, Youwen
TI Naringin enhances osteogenic differentiation through the activation of
   ERK signaling in human bone marrow mesenchymal stem cells
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Bone marrow mesenchymal stem cells; ERK signaling pathway; Naringin;
   Osteogenic differentiation
ID PROMOTES; OSTEOPOROSIS; PROLIFERATION; OSTEOBLAST; THERAPIES
AB Objective(s): Naringin has been reported to regulate bone metabolism. However, its effect on osteogenesis remains unclear. The aim was to investigate the effect of naringin on osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs) through the activation of the ERK signaling pathway in osteogenic differentiation.
   Materials and Methods: Annexin V FITC assay and MTT assay were used to measure the effect of naringin on cytotoxicity and proliferation of hBMSCs, respectively. Alkaline phosphatase activity analysis, Alizarin Red S staining, Western blotting, and real time PCR assay were used to evaluate both the potential effect of naringin on osteogenic differentiation and the role of ERK signaling pathway in osteogenic differentiation.
   Results: Our results showed that naringin had no obvious toxicity on hBMSCs, and could significantly promote the proliferation of hBMSCs. Naringin also enhanced the osteogenic differentiation of hBMSCs and increased the protein and mRNA expression levels of osteogenic markers such as Runx 2, OXS, OCN, and Col1 in a dose dependent manner. In addition, we found that the enhancing effect of naringin on osteogenic differentiation was related to the activation of phosphor ERK, with an increase in duration of activity from 30 min to 120 min. More importantly, both the enhancing effect of naringin on osteogenic differentiation and the activity effect of naringin on ERK signaling pathway were reversed by U0126 addition.
   Conclusion: Our findings demonstrated that naringin promoted proliferation and osteogenesis of hBMSCs by activating the ERK signaling pathway and it might be a potential therapeutic agent for treating or preventing osteoporosis.
C1 [Wang, Huichao; Li, Jianming; Zhu, Yingjie; Jia, Yudong; Zhang, Ying; Zhang, Xiaodong; Li, Wuyin; Liu, Youwen] Luoyang Orthoped Hosp Henan Prov, Orthoped Inst Henan Prov, Luoyang 471002, Peoples R China.
   [Li, Chunbo] Tongji Univ Med, Shanghai Matern & Infant Hosp 1, Shanghai 200126, Peoples R China.
   [Li, Wenlong] Henan Univ Tradit Chinese Med, Zhengzhou 450000, Henan Province, Peoples R China.
   [Cui, Lei] Capital Med Univ, Beijing Shijitan Hosp, Med Sci & Res Ctr, 10 Tieyi Rd, Beijing 100038, Peoples R China.
C3 Tongji University; Henan University of Traditional Chinese Medicine;
   Capital Medical University
RP Liu, YW (通讯作者)，Luoyang Orthoped Hosp Henan Prov, Orthoped Inst Henan Prov, Luoyang 471002, Peoples R China.
EM liuyouwen543@sina.com
RI Cui, Lei/IUM 6033 2023; Li, Wenlong/ABO 3818 2022; Liu,
   Youwen/AAU 5884 2020; LI, JM/AAU 1663 2021
CR Baharara J, 2014, IRAN J BASIC MED SCI, V17, P626
   Bharti S, 2014, PLANTA MED, V80, P437, DOI 10.1055/s 0034 1368351
   Bidwell JP, 2013, CURR OSTEOPOROS REP, V11, P117, DOI 10.1007/s11914 013 0139 2
   Drake MT, 2015, CLIN THER, V37, P1837, DOI 10.1016/j.clinthera.2015.06.006
   Fang B, 2009, TISSUE ENG PT A, V15, P1091, DOI 10.1089/ten.tea.2008.0110
   Gonzalez Andrades M, 2013, J BIOMATER TISS ENG, V3, P245, DOI 10.1166/jbt.2013.1089
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Hou X, 2012, INT J MOL SCI, V13, P7902, DOI 10.3390/ijms13077902
   Jagetia GC, 2004, CLIN CHIM ACTA, V347, P189, DOI 10.1016/j.cccn.2004.04.022
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Li FB, 2014, BIOCHEM BIOPH RES CO, V452, P629, DOI 10.1016/j.bbrc.2014.08.117
   Li LN, 2011, PHYTOMEDICINE, V18, P985, DOI 10.1016/j.phymed.2011.03.002
   Li NH, 2014, DRUG DES DEV THER, V8, P1, DOI 10.2147/DDDT.S52714
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Lim SY, 2015, CURR OPIN RHEUMATOL, V27, P216, DOI 10.1097/BOR.0000000000000169
   Liu MM, 2017, J TISSUE ENG REGEN M, V11, P276, DOI 10.1002/term.1911
   Liu Y, 2012, MOL MED REP, V6, P1343, DOI 10.3892/mmr.2012.1072
   Makras P, 2015, METABOLISM, V64, P1199, DOI 10.1016/j.metabol.2015.07.011
   McArthur GA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00161
   Miraoui H, 2009, J BIOL CHEM, V284, P4897, DOI 10.1074/jbc.M805432200
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Peng Zhang, 2009, EUR J PHARMACOL, V607, P1, DOI 10.1016/j.ejphar.2009.01.035
   Potier E, 2010, J BIOMECH, V43, P807, DOI 10.1016/j.jbiomech.2009.11.019
   Qian WH, 2014, SCI WORLD J, DOI 10.1155/2014/689496
   Xu CX, 2013, MAT SCI ENG C MATER, V33, P1783, DOI 10.1016/j.msec.2013.01.005
   Ying XZ, 2012, INT ORTHOP, V36, P647, DOI 10.1007/s00264 011 1303 x
   Zhou CH, 2014, AMINO ACIDS, V46, P1673, DOI 10.1007/s00726 014 1729 8
NR 28
TC 45
Z9 52
U1 0
U2 26
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944  
   445, MASHHAD, 00000, IRAN
SN 2008 3866
EI 2008 3874
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD APR
PY 2017
VL 20
IS 4
BP 408
EP 414
DI 10.22038/IJBMS.2017.8582
PG 7
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA EX5JG
UT WOS:000403276600009
PM 28804610
DA 2025 08 17
ER

PT J
AU Ivanyi, P
   Winkler, T
   Grossennig, A
   Reuter, C
   Merseburger, AS
   Ganser, A
   Grünwald, V
AF Ivanyi, Philipp
   Winkler, Thomas
   Grossennig, Anika
   Reuter, Christoph
   Merseburger, Axel S.
   Ganser, Arnold
   Gruenwald, Viktor
TI Treatment with tyrosine kinase inhibitors in patients with metastatic
   renal cell carcinoma is associated with drug induced
   hyperparathyroidism: a single center experience in 59 patients
SO WORLD JOURNAL OF UROLOGY
LA English
DT Article
DE Sunitinib; Sorafenib; Secondary hyperparathyroidism; Multi target
   tyrosine kinase inhibitors
ID IMATINIB MESYLATE; ALTERED BONE; CARDIOTOXICITY; SUNITINIB
AB Multi targeted tyrosine kinase inhibitors (MTKIs) are the standard in the treatment of metastatic renal cell carcinoma (mRCC). In spite their clinical activity, interaction with physiological functions has been shown. Here, we report on alterations of the bone mineral metabolism in patients with mRCC treated with MTKIs.
   Fifty nine patients with mRCC treated during April 2005 and September 2009 at our center were evaluated. Demographics, chemistry, parathyroid and renal function, bone metastasis and clinics were assessed, retrospectively. Parathyroid hormone (PTH), calcium and phosphate were either determined prior to, during or after cessation of MTKI therapy.
   From evaluable patients, 90% (N = 53) received at least one MTKI treatment, 10% (N = 8) had evaluations without MTKI exposure. The mean PTH value prior to MTKI treatment was 49.4 (range (r):2.5 115), increased during the therapy to 121.2 (r:5 302) (P = 0.003) and returned to its basic values after MTKI cessation. In parallel, mean phosphate significantly decreased during the treatment from 1.10 (r = 0.66 1.59) to 0.87 (r = 0.48 1.45) (P < 0.001) and calcium showed a slight decrease (P = 0.039). PTH alterations were associated with clinical signs in some patients but not with bone metastasis or renal function. Univariate logistic regression analysis of pathologically elevated PTH levels revealed an association with MTKI treatment duration.
   Even though the mechanism of bone mineral alteration remains elusive, the MTKI treatment is associated with a dysregulated parathyroid axis, which may have clinical implications in a number of patients. Furthermore, prospective trials are mandatory, and PTH monitoring should be considered in selected patients during MTKI treatment.
C1 [Ivanyi, Philipp; Winkler, Thomas; Reuter, Christoph; Ganser, Arnold; Gruenwald, Viktor] Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, D 30625 Hannover, Germany.
   [Grossennig, Anika] Hannover Med Sch, Inst Biometry, D 30625 Hannover, Germany.
   [Merseburger, Axel S.] Hannover Med Sch, Dept Urol & Urol Oncol, D 30625 Hannover, Germany.
C3 Hannover Medical School; Hannover Medical School; Hannover Medical
   School
RP Grünwald, V (通讯作者)，Hannover Med Sch, Clin Hematol Hemostasis Oncol & Stem Cell Transpl, Carl Neuberg Str 1, D 30625 Hannover, Germany.
EM Gruenwald.Viktor@MH Hannover.de
RI ; Winkler, Thomas/S 3787 2017; Ivanyi, Philipp/G 5983 2019; Grünwald,
   Viktor/D 9601 2012; Ivanyi, Philipp/ABE 8130 2020; Ganser,
   Arnold/H 2692 2014
OI Grosshennig, Anika/0000 0003 1455 2474; Ivanyi,
   Philipp/0000 0002 2862 7302; 
FU Novartis; Pfizer; Bayer Health Care and Roche Pharma
FX PI, TW, AGr, CR, ASM, AG, declare no Wnical conXict. VG received honoria
   and travel grants from Novartis, Pfizer, Bayer Health Care and Roche
   Pharma.
CR Berman E, 2006, NEW ENGL J MED, V354, P2006, DOI 10.1056/NEJMoa051140
   Brugarolas J, 2007, NEW ENGL J MED, V356, P185, DOI 10.1056/NEJMe068263
   COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580
   Cohen HT, 2005, NEW ENGL J MED, V353, P2477, DOI 10.1056/NEJMra043172
   Cohen MH, 2005, CLIN CANCER RES, V11, P12
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   Fraser WD, 2009, LANCET, V374, P145, DOI 10.1016/S0140 6736(09)60507 9
   Grey A, 2006, NEW ENGL J MED, V355, P2494, DOI 10.1056/NEJMc062388
   Grünwald V, 2009, ONKOLOGIE, V32, P129, DOI 10.1159/000194949
   Isshiki Ikuko, 2004, Br J Haematol, V125, P420, DOI 10.1111/j.1365 2141.2004.04833.x
   Ivanyi P, 2008, DTSCH ARZTEBL INT, V105, P232, DOI 10.3238/arztebl.2008.0232
   Joensuu H, 2006, NEW ENGL J MED, V355, P628
   Kerkelä R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446
   Lam JS, 2005, WORLD J UROL, V23, P202, DOI 10.1007/s00345 004 0466 0
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   O'Sullivan S, 2007, J BONE MINER RES, V22, P1679, DOI 10.1359/JBMR.070719
   O'Sullivan S, 2009, J CLIN ENDOCR METAB, V94, P1131, DOI 10.1210/jc.2008 2324
   Owen S, 2006, NEW ENGL J MED, V355, P627
   Schmidinger M, 2008, J CLIN ONCOL, V26, P5204, DOI 10.1200/JCO.2007.15.6331
   SEIBEL MJ, 2006, ARQ BRAS ENDOCINOL M, V40, P603
   Stadler WM, 2005, CANCER AM CANCER SOC, V104, P2323, DOI 10.1002/cncr.21453
   Telli ML, 2008, ANN ONCOL, V19, P1613, DOI 10.1093/annonc/mdn168
NR 22
TC 2
Z9 2
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0724 4983
EI 1433 8726
J9 WORLD J UROL
JI World J. Urol.
PD JUN
PY 2010
VL 28
IS 3
BP 311
EP 317
DI 10.1007/s00345 010 0558 y
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Urology & Nephrology
GA 599WC
UT WOS:000277943600011
PM 20443009
DA 2025 08 17
ER

PT J
AU Vijaykumar, A
   Root, SH
   Mina, M
AF Vijaykumar, A.
   Root, S. H.
   Mina, M.
TI Wnt/β Catenin Signaling Promotes the Formation of Preodontoblasts In
   Vitro
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE WNT3a; odontoblast; osteoblasts; pulp biology; dentinogenesis; survival
ID ODONTOBLAST DIFFERENTIATION; BETA CATENIN; DENTIN; DENTINOGENESIS;
   CELLS; LEADS
AB Odontoblast differentiation is a complex and multistep process regulated by signaling pathways, including the Wnt/beta catenin signaling pathway. Both positive and negative effects of Wnt/beta catenin signaling on dentinogenesis have been reported, but the underlying mechanisms of these conflicting results are still unclear. To gain a better insight into the role of Wnt/beta catenin in dentinogenesis, we used dental pulp cells from a panel of transgenic mice, in which fluorescent protein expression identifies cells at different stages of odontoblast and osteoblast differentiation. Our results showed that exposure of pulp cells to WNT3a at various times and durations did not induce premature differentiation of odontoblasts. These treatments supported the survival of undifferentiated cells in dental pulp and promoted the formation of 2.3GFP(+) preodontoblasts and their rapid transition into differentiated odontoblasts expressing DMP1 Cherry and DSPP Cerulean transgenes. WNT3a also promoted osteogenesis in dental pulp cultures. These findings provide critical information for the development of improved treatments for vital pulp therapy and dentin regeneration.
C1 [Vijaykumar, A.; Root, S. H.; Mina, M.] Univ Connecticut Hlth Ctr, Dept Craniofacial Sci, Farmington, CT 06030 USA.
C3 University of Connecticut
RP Mina, M (通讯作者)，Univ Connecticut Hlth Ctr, Sch Dent Med, Dept Craniofacial Sci, Div Pediat Dent, 263 Farmington Ave, Farmington, CT 06030 USA.
EM Mina@uchc.edu
RI Root, Sierra/GNP 7415 2022
OI Vijaykumar, Anushree/0000 0002 9311 8715
FU National Institutes of Health (National Institute of Dental and
   Craniofacial Research) [R01 DE016689, R90 DE022526]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: This work was
   supported by grants R01 DE016689 and R90 DE022526 from the National
   Institutes of Health (National Institute of Dental and Craniofacial
   Research).
CR Amri N, 2016, AM J PATHOL, V186, P2577, DOI 10.1016/j.ajpath.2016.06.013
   Bae CH, 2015, J DENT RES, V94, P439, DOI 10.1177/0022034514567198
   Bae CH, 2013, J PERIODONTAL RES, V48, P405, DOI 10.1111/jre.12018
   Balic A, 2015, CURR TOP DEV BIOL, V115, P157, DOI 10.1016/bs.ctdb.2015.07.006
   Balic A, 2010, BONE, V47, P948, DOI 10.1016/j.bone.2010.08.009
   Balic A, 2010, BONE, V46, P1639, DOI 10.1016/j.bone.2010.02.019
   Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Chen JQ, 2009, DEV BIOL, V334, P174, DOI 10.1016/j.ydbio.2009.07.015
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cruciat CM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a015081
   Ferrer Vaquer A, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 121
   Han NN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088890
   Hunter DJ, 2015, J BONE MINER RES, V30, P1150, DOI 10.1002/jbmr.2444
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172 1183.2002
   Kim JH, 2013, THER ADV MUSCULOSKEL, V5, P13, DOI 10.1177/1759720X12466608
   Kim TH, 2012, ANAT CELL BIOL, V45, P193, DOI 10.5115/acb.2012.45.3.193
   Kim TH, 2011, BIOCHEM BIOPH RES CO, V412, P549, DOI 10.1016/j.bbrc.2011.07.116
   Lim WH, 2014, J BONE MINER RES, V29, P892, DOI 10.1002/jbmr.2088
   Lu XH, 2019, STEM CELL RES THER, V10, DOI 10.1186/s13287 019 1344 4
   Rahman SU, 2018, ACS APPL MATER INTER, V10, P17526, DOI 10.1021/acsami.7b19782
   Sagomonyants K, 2017, J DENT RES, V96, P663, DOI 10.1177/0022034517691732
   Sagomonyants K, 2015, J DENT RES, V94, P1582, DOI 10.1177/0022034515599768
   Sagomonyants K, 2014, CONNECT TISSUE RES, V55, P53, DOI 10.3109/03008207.2014.923867
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Tamura M, 2016, JPN DENT SCI REV, V52, P75, DOI 10.1016/j.jdsr.2016.04.001
   Teufel S, 2019, CURR TOP DEV BIOL, V133, P235, DOI 10.1016/bs.ctdb.2018.11.010
   Vijaykumar A, 2020, J DENT RES, V99, P89, DOI 10.1177/0022034519885089
   Vijaykumar A, 2019, GENESIS, V57, DOI 10.1002/dvg.23324
   Yamashiro T, 2007, DIFFERENTIATION, V75, P452, DOI 10.1111/j.1432 0436.2006.00150.x
   Yokose S, 2010, J BONE MINER METAB, V28, P650, DOI 10.1007/s00774 010 0185 0
   Zhao Y, 2019, J ENDODONT, V45, P1357, DOI 10.1016/j.joen.2019.07.014
NR 32
TC 21
Z9 23
U1 0
U2 19
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
EI 1544 0591
J9 J DENT RES
JI J. Dent. Res.
PD APR
PY 2021
VL 100
IS 4
BP 387
EP 396
DI 10.1177/0022034520967353
PG 10
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA RA6TV
UT WOS:000631550200007
PM 33103548
OA Green Published
DA 2025 08 17
ER

PT J
AU Kim, HY
   Park, SY
   Choung, SY
AF Kim, Hyang Yu
   Park, Sun Young
   Choung, Se Young
TI Enhancing effects of myricetin on the osteogenic differentiation of
   human periodontal ligament stem cells via BMP 2/Smad and ERK/JNK/p38
   mitogen activated protein kinase signaling pathway
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Osteogenesis; Myricetin; Bone morphogenetic protein/Smad;
   Mitogen activated protein kinases; Human periodontal ligament stem cells
ID MARROW STROMAL CELLS; P38 MAP KINASE; OSTEOBLAST DIFFERENTIATION;
   ALKALINE PHOSPHATASE; REGULATED KINASE; BONE FORMATION; TRANSCRIPTION;
   EXPRESSION; REGENERATION; ANTIBIOTICS
AB Myricetin is a flavonoid that found in berries, onions, and red grapes. It has been reported to have various pharmacological effects such as anti inflammation, anti oxidant and anti cancer activities. However, the underlying mechanisms of myricetin on osteogenic differentiation remain unknown in human periodontal ligament stem cells (hPDLSCs). In this study, we investigated the ability of myricetin to increase osteogenic differentiation and its underlying molecular mechanisms. Myricetin significantly increased cell proliferation, alkaline phosphatase (ALP) activity, and alizarin red mineralization activity in hPDLSCs in a dose dependent manner. Furthermore, myricetin dose dependently increased osteogenic related mRNA and protein levels. Interestingly, it enhanced osteogenesis by up regulating bone morphogenetic protein 2 (BMP 2), which induced the expression of BMP receptor type IB, Smad 1/5/9. It also enhanced the phosphorylation of extracellular signal regulated kinases (ERKs), c Jun N terminal kinase (JNK), p38 mitogen activated protein kinases (MAPKs) and Smads. We confirmed that the treatment of myricetin increased phosphorylated GSK 3 beta and beta catenin which is related to osteogenesis. In our studies, myricetin induced increment of ALP activity was decreased by ERK (PD98059), JNK (SP600125), p38 (SB203580), and Smad 1/5/9 (LDN193189) inhibitors. ERK and p38 inhibitors showed the greatest inhibition among the four kinds of inhibitors.
   These results demonstrate that myricetin promoted osteogenic differentiation by the up regulation of ALP activity and expression of osteogenic related factors through BMP 2/Smad and ERK/JNK/p38 MAPK pathways.
C1 [Kim, Hyang Yu; Park, Sun Young; Choung, Se Young] Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
   [Choung, Se Young] Kyung Hee Univ, Coll Pharm, Dept Prevent Pharm & Toxicol, 26 Kyungheedae Ro, Seoul 02447, South Korea.
C3 Kyung Hee University; Kyung Hee University
RP Choung, SY (通讯作者)，Kyung Hee Univ, Grad Sch, Dept Life & Nanopharmaceut Sci, 26 Kyungheedae Ro, Seoul 02447, South Korea.
EM sychoung@khu.ac.kr
RI Choung, Young/HSE 1870 2023; Park, Sun/ABB 2937 2021
CR Abu Ta'a M, 2008, J CLIN PERIODONTOL, V35, P58, DOI 10.1111/j.1600 051X.2007.01162.x
   Albandar JM, 2002, PERIODONTOL 2000, V29, P7, DOI 10.1034/j.1600 0757.2002.290101.x
   [Anonymous], 2004, J PERIODONTOL, V75, P1553
   BERKOVITZ BKB, 1990, EUR J ORTHODONT, V12, P51, DOI 10.1093/ejo/12.1.51
   Bosshardt DD, 2009, PERIODONTOL 2000, V51, P208, DOI 10.1111/j.1600 0757.2009.00317.x
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003 2697(76)90527 3
   Bruderer M, 2014, EUR CELLS MATER, V28, P269, DOI 10.22203/eCM.v028a19
   Chen HB, 2006, GENE DEV, V20, P648, DOI 10.1101/gad.1384706
   DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332
   Dikbas I, 2013, ACTA ODONTOL SCAND, V71, P848, DOI 10.3109/00016357.2012.680908
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eferl R, 2004, EMBO J, V23, P2789, DOI 10.1038/sj.emboj.7600282
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Ge CX, 2009, J BIOL CHEM, V284, P32533, DOI 10.1074/jbc.M109.040980
   Ghosh Choudhury N, 2002, J BIOL CHEM, V277, P33361, DOI 10.1074/jbc.M205053200
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Han J, 2014, J PERIODONTAL RES, V49, P333, DOI 10.1111/jre.12111
   Hsu YL, 2007, BIOCHEM PHARMACOL, V73, P504, DOI 10.1016/j.bcp.2006.10.020
   Hurd TW, 2002, BIOCHEM J, V368, P573, DOI 10.1042/BJ20020579
   Hynes K, 2012, PERIODONTOL 2000, V59, P203, DOI 10.1111/j.1600 0757.2012.00443.x
   Jagodzinski M, 2004, Eur Cell Mater, V7, P35
   Kaps C, 2004, BIOFACTORS, V20, P71, DOI 10.1002/biof.5520200202
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Kärner E, 2009, BBA GEN SUBJECTS, V1790, P110, DOI 10.1016/j.bbagen.2008.10.004
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kirkham G R, 2007, TOPICS TISSUE ENG, V3
   Ko SY, 2012, ARCH ORAL BIOL, V57, P1623, DOI 10.1016/j.archoralbio.2012.06.012
   Lattanzi W., 2011, GENES MOL PATHWAYS O
   Lóotoing L, 2014, MOL NUTR FOOD RES, V58, P1239, DOI 10.1002/mnfr.201300836
   Li Y, 2010, J BONE MINER RES, V25, P154, DOI 10.1359/jbmr.090705
   Liu L, 2009, J ENDODONT, V35, P1368, DOI 10.1016/j.joen.2009.07.005
   MILLER PD, 1988, DENT CLIN N AM, V32, P287
   Nakashima K, 2002, CELL, V108, P17, DOI 10.1016/S0092 8674(01)00622 5
   Ng SKS, 2006, COMMUNITY DENT ORAL, V34, P114, DOI 10.1111/j.1600 0528.2006.00267.x
   Okamoto M, 2006, J BONE MINER RES, V21, P1022, DOI 10.1359/JBMR.060411
   Ong KC, 1997, GEN PHARMACOL VASC S, V29, P121, DOI 10.1016/S0306 3623(96)00421 1
   Park JY, 2011, CELL TRANSPLANT, V20, P271, DOI 10.3727/096368910X519292
   Pietta PG, 2000, J NAT PROD, V63, P1035, DOI 10.1021/np9904509
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Ricardo AC, 2015, BMC NEPHROL, V16, DOI 10.1186/s12882 015 0101 x
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Singhatanadgit W, 2011, IN VITRO CELL DEV AN, V47, P251, DOI 10.1007/s11626 010 9378 z
   Suzuki A, 1999, ENDOCRINOLOGY, V140, P3177, DOI 10.1210/en.140.7.3177
   Suzuki A, 2002, BONE, V30, P91, DOI 10.1016/S8756 3282(01)00660 3
   Wagner DO, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3107mr1
   Walker CB, 2004, PERIODONTOL 2000, V36, P146, DOI 10.1111/j.1600 0757.2004.03677.x
   Wang XY, 2007, ENDOCRINOLOGY, V148, P1629, DOI 10.1210/en.2006 1000
   Yang BY, 2015, PHYTOTHER RES, V29, P1692, DOI 10.1002/ptr.5482
   Yang H, 2012, J ENZYM INHIB MED CH, V27, P261, DOI 10.3109/14756366.2011.587415
   Ying XZ, 2014, EUR J PHARMACOL, V738, P22, DOI 10.1016/j.ejphar.2014.04.049
   Zhou YN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129605
   Ziros PG, 2002, J BIOL CHEM, V277, P23934, DOI 10.1074/jbc.M109881200
   Zou LJ, 2008, J ORTHOP RES, V26, P56, DOI 10.1002/jor.20467
NR 57
TC 68
Z9 72
U1 2
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD SEP 5
PY 2018
VL 834
BP 84
EP 91
DI 10.1016/j.ejphar.2018.07.012
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA GP6FZ
UT WOS:000440974700010
PM 30012495
DA 2025 08 17
ER

PT J
AU Xia, GH
   Zhao, YL
   Yu, Z
   Tian, YY
   Wang, YM
   Wang, SS
   Wang, JF
   Xue, CH
AF Xia, Guanghua
   Zhao, Yanlei
   Yu, Zhe
   Tian, Yingying
   Wang, Yiming
   Wang, Shanshan
   Wang, Jingfeng
   Xue, Changhu
TI Phosphorylated Peptides from Antarctic Krill (Euphausia superba)
   Prevent Estrogen Deficiency Induced Osteoporosis by Inhibiting Bone
   Resorption in Ovariectomized Rats
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article; Proceedings Paper
CT 1st ACS AGFD and ACSThailand Chapter Joint Symposium
CY MAR 04 05, 2014
CL Bangkok, THAILAND
DE phosphoglated peptides; antarctic krill; bone resorption; bone mass;
   receptor activator of nuclear factor kappa B
ID NF KAPPA B; BASIC PROTEIN SUPPLEMENTATION; OSTEOCLAST DIFFERENTIATION;
   MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; REPLACEMENT THERAPY;
   BREAST CANCER; MOUSE MODEL; IN VIVO; RANKL
AB In the current study, we investigated the improvement of phosphorylated peptides from Antarctic krill Euphausia superba (PP AKP) on osteoporosis in ovariectomized rats. PP AKP was supplemented to ovariectomized Sprague Dawley rats for 90 days. The results showed that PP AKP treatment remarkably prevented the reduction of bone mass and improved cancellous bone structure and biochemical properties. PP AKP also significantly decreased serum contents of tartrate resistant acid phosphatase (TRACP), cathepsin K (Cath k), matrix metalloproteinases 9 (MMP 9), deoxypyridinoline (DPD), C terminal telopeptide of collagen I (CTX 1), Ca, and P. Mechanism investigation revealed that PP AKP significantly increased the osteoprotegerin (OPG)/receptor activator of nuclear factor kappa B ligand (RANKL) ratio in mRNA expression, protein expression, and serum content. Further research suggested that NF kappa B signaling pathways were inhibited by suppressing the mRNA and protein expressions of nuclear factor of activated T cells (NFATc1) and tumor necrosis factor receptor associated factor 6 (TRAF6), diminishing the mRNA expression and phosphorylation of nuclear factor kappa B p65 (NF kappa B p65), three key transcription factors in NF kappa B pathways. These results suggest that PP AKP can improve osteoporosis by inhibiting bone resorption via suppressing the activation of osteodastogenesis related NF kappa B pathways.
C1 [Xia, Guanghua; Zhao, Yanlei; Yu, Zhe; Tian, Yingying; Wang, Yiming; Wang, Shanshan; Wang, Jingfeng; Xue, Changhu] Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
C3 Ocean University of China
RP Wang, JF (通讯作者)，Ocean Univ China, Coll Food Sci & Engn, Qingdao 266003, Shandong, Peoples R China.
EM jfwang@ouc.edu.cn
RI Xia, Guanghua/AAN 1812 2021; Tian, Yingying/AHB 8186 2022; yuming,
   wang/K 8179 2012; Wang, Shanshan/D 2283 2014
OI Xia, Guanghua/0000 0001 7269 5751; 
FU National Natural Science Foundation of China [31371876, 31471684,
   U1406402, 31571771]
FX This study is financially supported by National Natural Science
   Foundation of China (No. 31371876, No. 31471684, No. U1406402, and No.
   31571771).
CR Aoe S, 2005, OSTEOPOROSIS INT, V16, P2123, DOI 10.1007/s00198 005 2012 3
   Arron JR, 2000, NATURE, V408, P535, DOI 10.1038/35046196
   Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Britton RA, 2014, J CELL PHYSIOL, V229, P1822, DOI 10.1002/jcp.24636
   BUSH TL, 1991, JAMA J AM MED ASSOC, V266, P1357, DOI 10.1001/jama.266.10.1357
   Cao P. C., 2014, EVID BASED COMPL ALT, V2014, P1, DOI 10.1155/2014/825181
   Chao TY, 2010, CLIN CHIM ACTA, V411, P1553, DOI 10.1016/j.cca.2010.06.027
   Chiang SS, 2011, J AGR FOOD CHEM, V59, P7734, DOI 10.1021/jf2013716
   Crockett JC, 2011, OSTEOPOROSIS INT, V22, P1, DOI 10.1007/s00198 010 1272 8
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Ha J, 2009, INT IMMUNOPHARMACOL, V9, P774, DOI 10.1016/j.intimp.2009.03.001
   Hata I, 1998, J DAIRY RES, V65, P569, DOI 10.1017/S0022029998003136
   Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704
   Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2
   Hong JW, 2010, OSTEOPOROSIS INT, V21, P847, DOI 10.1007/s00198 009 1024 9
   Hu JP, 2008, EUR J PHARMACOL, V580, P70, DOI 10.1016/j.ejphar.2007.11.013
   Kim HK, 2011, MENOPAUSE, V18, P307, DOI 10.1097/gme.0b013e3181f31b1f
   Kim KN, 2010, EUR J PHARMACOL, V649, P369, DOI 10.1016/j.ejphar.2010.09.032
   Kim T, 2013, J ETHNOPHARMACOL, V146, P83, DOI 10.1016/j.jep.2012.11.037
   Kobayashi T, 2015, J VET MED SCI, V77, P503, DOI 10.1292/jvms.13 0421
   Lee DG, 2014, MOL NUTR FOOD RES, V58, P1249, DOI 10.1002/mnfr.201300319
   Lee HY, 2015, J FUNCT FOODS, V13, P192, DOI 10.1016/j.jff.2014.12.039
   Lee JW, 2015, MOL NUTR FOOD RES, V59, P386, DOI 10.1002/mnfr.201400164
   Lucas R, 2014, CLIN BIOCHEM, V47, P1040, DOI 10.1016/j.clinbiochem.2014.04.012
   Ma B, 2012, ACTA PHARMACOL SIN, V33, P479, DOI 10.1038/aps.2011.177
   MATHEIS G, 1991, FOOD CHEM, V39, P13, DOI 10.1016/0308 8146(91)90081 X
   Motyckova G, 2001, P NATL ACAD SCI USA, V98, P5798, DOI 10.1073/pnas.091479298
   Ohlsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092368
   Okamura A, 2004, J BIOMED MATER RES A, V70A, P497, DOI 10.1002/jbm.a.30110
   Pawlowski JW, 2014, J AGR FOOD CHEM, V62, P6108, DOI 10.1021/jf403310q
   Porch JV, 2002, CANCER CAUSE CONTROL, V13, P847, DOI 10.1023/A:1020617415381
   Rizzoli R, 2008, BONE, V42, P841, DOI 10.1016/j.bone.2008.01.003
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Salazar M, 2015, ARCH ORAL BIOL, V60, P776, DOI 10.1016/j.archoralbio.2015.02.003
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Takatsuna H, 2005, J BONE MINER RES, V20, P653, DOI 10.1359/JBMR.041213
   Tan H, 2014, J AGR FOOD CHEM, V62, P836, DOI 10.1021/jf402735u
   Tanaka T, 2011, J AGR FOOD CHEM, V59, P13230, DOI 10.1021/jf2031617
   Uehara K, 2014, NUTRITION, V30, P719, DOI 10.1016/j.nut.2013.11.005
   Wang SW, 2014, J FUNCT FOODS, V6, P215, DOI 10.1016/j.jff.2013.10.009
   Wang YC, 2015, PEPTIDES, V68, P239, DOI 10.1016/j.peptides.2014.10.004
   Wirries A, 2013, INT IMMUNOPHARMACOL, V15, P381, DOI 10.1016/j.intimp.2012.12.033
   Xia GH, 2015, J FUNCT FOODS, V15, P137, DOI 10.1016/j.jff.2015.03.021
   Yoneme H, 2015, NUTRITION, V31, P399, DOI 10.1016/j.nut.2014.08.008
   Zhu SS, 2013, BONE, V53, P340, DOI 10.1016/j.bone.2012.12.044
   Zou ZY, 2009, EUR J NUTR, V48, P301, DOI 10.1007/s00394 009 0014 1
   Zuo T, 2015, J FUNCT FOODS, V12, P530, DOI 10.1016/j.jff.2014.12.015
NR 50
TC 46
Z9 52
U1 3
U2 74
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021 8561
EI 1520 5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD NOV 4
PY 2015
VL 63
IS 43
BP 9550
EP 9557
DI 10.1021/acs.jafc.5b04263
PG 8
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Agriculture; Chemistry; Food Science & Technology
GA CV6BM
UT WOS:000364355700022
PM 26456758
DA 2025 08 17
ER

PT J
AU Liu, XM
   Wiswall, AT
   Rutledge, JE
   Akhter, MR
   Cullen, DM
   Reinhardt, RA
   Wang, D
AF Liu, Xin Ming
   Wiswall, Andrew T.
   Rutledge, John E.
   Akhter, Mohammed R.
   Cullen, Diane M.
   Reinhardt, Richard A.
   Wang, Dong
TI Osteotropic β cyclodextrin for local bone regeneration
SO BIOMATERIALS
LA English
DT Article
DE bone regeneration; osteoporosis; hydroxyapatite; drug delivery
ID ROCURONIUM BROMIDE; BISPHOSPHONATES; RATS; DELIVERY; AGENT;
   PROSTAGLANDIN E2; STIMULATION; STABILITY; REVERSAL; RELEASE
AB An osteotropic alendronate beta cyclodextrin conjugate (ALN beta CD) was developed as a bone targeting delivery system for improved treatment of skeletal diseases. The conjugate shows very strong binding to hydroxyapatite (HA, main component of the skeleton). Its ability in forming molecular inclusion complex with prostaglandin E 1 (PGE(1), a potent bone anabolic agent) was confirmed by phase solubility experiments and differential scanning calorimetry (DSC). In a bilateral rat mandible model, ALN beta CD/PGE(1) molecular complex was shown to stimulate strong local bone anabolic reaction. In the control study, ALN beta CD itself was also found to be bone anabolic. To investigate this finding, other control groups were studied. The histomorphometry data suggest that ALN beta CD itself could generate more new bone at the injection site than its complex with PGE(1). Alendronate (ALN) injection could also cause new bone formation, which locates peripheral to the site of injection. PGE(1), saline or ethanol injections do not have anabolic effect. These findings were also confirmed by micro CT evaluation of mandibular bones. It is clear that the bone anabolic effect of ALN beta CD is independent of mechanical stimuli of the periosteum or ALN injection alone. Further studies are warranted to understand the working mechanism of ALN beta CD as a bone anabolic agent. (c) 2007 Elsevier Ltd. All rights reserved.
C1 [Liu, Xin Ming; Wang, Dong] Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Coll Pharm, Omaha, NE 68198 USA.
   [Wiswall, Andrew T.; Rutledge, John E.; Reinhardt, Richard A.] Univ Nebraska, Med Ctr, Coll Dent, Dept Surg Specialties, Lincoln, NE 68583 USA.
   [Akhter, Mohammed R.; Cullen, Diane M.] Creighton Univ, Osteoporosis Res Ctr, Omaha, NE 68131 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska System; University of Nebraska Medical Center;
   University of Nebraska Lincoln; Creighton University
RP Wang, D (通讯作者)，Univ Nebraska, Med Ctr, Dept Pharmaceut Sci, Coll Pharm, 986025 Nebraska Med Ctr,COP 3026, Omaha, NE 68198 USA.
EM dwang@unmc.edu
FU NIAMS NIH HHS [AR053325, R01 AR053325] Funding Source: Medline
CR Adam JM, 2002, J MED CHEM, V45, P1806, DOI 10.1021/jm011107f
   Davis ME, 2004, NAT REV DRUG DISCOV, V3, P1023, DOI 10.1038/nrd1576
   Duque G, 2007, J BONE MINER RES, V22, P1603, DOI 10.1359/JBMR.070701
   Gijsenbergh F, 2005, ANESTHESIOLOGY, V103, P695, DOI 10.1097/00000542 200510000 00007
   Goldring SR, 2004, ARTHRITIS RHEUM US, V50, P2044, DOI 10.1002/art.20383
   Gu FG, 2005, INT J PHARMACEUT, V290, P101, DOI 10.1016/j.ijpharm.2004.11.021
   HIGUCHI T, 1965, ADV ANAL CHEM INSTRU, V4, P117, DOI DOI 10.1016/S0076 6879(82)87029 8
   HIRAYAMA F, 1984, CHEM PHARM BULL, V32, P4237
   JEE WSS, 1991, BONE MINER, V15, P33, DOI 10.1016/0169 6009(91)90109 D
   Ke HZ, 2006, J BONE MINER RES, V21, P565, DOI 10.1359/JBMR.051110
   Lane JM, 2005, J ORTHOP TRAUMA, V19, pS17, DOI 10.1097/00005131 200511101 00006
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Lin JH, 1999, INT J CLIN PRACT, P18
   Liu XM, 2007, J CONTROL RELEASE, V122, P54, DOI 10.1016/j.jconrel.2007.06.021
   MANN T, 1974, J REPROD FERTIL, V37, P179, DOI 10.1530/jrf.0.0370179
   MILLER SC, 1993, BONE, V14, P143, DOI 10.1016/8756 3282(93)90241 2
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Mussano F, 2007, SPINE, V32, P824, DOI 10.1097/01.brs.0000259227.51180.ca
   Nicholson WT, 2007, PHARMACOTHERAPY, V27, P1181, DOI 10.1592/phco.27.8.1181
   Papapoulos SE, 1997, MEDICINA BUENOS AIRE, V57, P61
   Stein D, 2005, J PERIODONTOL, V76, P1861, DOI 10.1902/jop.2005.76.11.1861
   Stella VJ, 1999, ADV DRUG DELIVER REV, V36, P3, DOI 10.1016/S0169 409X(98)00052 0
   Tanaka M, 2004, BONE, V34, P940, DOI 10.1016/j.bone.2004.01.002
   von Knoch F, 2007, BIOMATERIALS, V28, P3549, DOI 10.1016/j.biomaterials.2007.04.024
   Vrotsos Y, 2003, CRIT REV EUKAR GENE, V13, P255, DOI 10.1615/CritRevEukaryotGeneExpr.v13.i24.170
   Wan Derrick C, 2006, Dent Clin North Am, V50, P175, DOI 10.1016/j.cden.2005.11.003
   YAMAMOTO M, 1992, CHEM PHARM BULL, V40, P747, DOI 10.1248/cpb.40.747
NR 27
TC 47
Z9 50
U1 0
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD APR
PY 2008
VL 29
IS 11
BP 1686
EP 1692
DI 10.1016/j.biomaterials.2007.12.023
PG 7
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 268ZS
UT WOS:000253619900015
PM 18199479
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Zhang, J
   Ding, C
   Shang, P
AF Zhang, Jian
   Ding, Chong
   Shang, Peng
TI Alterations of Mineral Elements in Osteoblast During Differentiation
   Under Hypo, Moderate and High Static Magnetic Fields
SO BIOLOGICAL TRACE ELEMENT RESEARCH
LA English
DT Article
DE Mineral elements; Static magnetic fields; Osteoblast differentiation;
   Bone formation
ID BONE FORMATION; TRACE ELEMENTS; RATS; COPPER; METABOLISM; MANGANESE;
   CELLS; SUPPLEMENTATION; DEFICIENCY; STRENGTH
AB Static magnetic fields (SMFs) can enhance the ability of bone formation by osteoblast and is a potential physical therapy to bone disorders and the maintenance of bone health. But, the mechanism is not clear yet. Certain mineral elements including macro and trace elements are essential for normal bone metabolism. Deficiency of these elements can cause severe bone disorders including osteoporosis. However, there are few reports regarding the role of mineral elements in the regulation of bone formation under SMFs. In this study, hypomagnetic field (HyMF) of 500 nT, moderate SMF (MMF) of 0.2 T, and high SMF (HiMF) of 16 T were used to investigate the effects of SMFs on mineral element (calcium, copper, iron, magnesium, manganese, and zinc) alteration of MC3T3 E1 cells during osteoblast mineralization. The results showed that osteoblasts in differentiation accumulated more mineral elements than non differentiated cell cultures. Furthermore, HyMF reduced osteoblast differentiation but did not affect mineral elements levels compared with control of geomagnetic field. MMF decreased osteoblast differentiation with elevated iron content. HiMF enhanced osteoblast differentiation and increased all the mineral contents except copper. It is suggested that the altered potential of osteoblast differentiation under SMFs may partially due to the involvement of different mineral elements.
C1 [Zhang, Jian; Ding, Chong; Shang, Peng] Northwestern Polytech Univ, Sch Life Sci, Inst Special Environm Biophys, Key Lab Space Biosci & Biotechnol, Xian 710072, Shaanxi, Peoples R China.
C3 Northwestern Polytechnical University
RP Shang, P (通讯作者)，Northwestern Polytech Univ, Sch Life Sci, Inst Special Environm Biophys, Key Lab Space Biosci & Biotechnol, POB 707, Xian 710072, Shaanxi, Peoples R China.
EM shangpeng@nwpu.edu.cn
OI Zhang, Jian/0000 0002 6117 3285
FU National Basic Research Program of China [2011CB710903]; National
   Natural Science Foundation of China [51477141]; Specialized Research
   Fund for the Doctoral Program of Higher Education of China
   [20126102110055]; Fundamental Research Funds for the Central
   Universities of China [3102014KYJD020]
FX This research was supported by the National Basic Research Program of
   China (2011CB710903), National Natural Science Foundation of China
   (51477141), Specialized Research Fund for the Doctoral Program of Higher
   Education of China (20126102110055), and the Fundamental Research Funds
   for the Central Universities of China (3102014KYJD020).
CR Aaseth J, 2012, J TRACE ELEM MED BIO, V26, P149, DOI 10.1016/j.jtemb.2012.03.017
   Aida L, 2014, BIOL TRACE ELEM RES, V160, P67, DOI 10.1007/s12011 014 9987 6
   Amara S, 2007, PHYS MED BIOL, V52, P889, DOI 10.1088/0031 9155/52/4/002
   Amara S, 2009, GEN PHYSIOL BIOPHYS, V28, P260, DOI 10.4149/gpb_2009_03_260
   Angelova M., 2011, Trakia Journal of Sciences, V9, P88
   [Anonymous], 2011, EVID BASED COMPLEMEN
   Bae YJ, 2013, BIOL TRACE ELEM RES, V155, P431, DOI 10.1007/s12011 013 9798 1
   Bae YJ, 2008, BIOL TRACE ELEM RES, V124, P28, DOI 10.1007/s12011 008 8119 6
   BERESFORD JN, 1993, AM J MED GENET, V45, P163, DOI 10.1002/ajmg.1320450205
   Ghodbane S, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/602987
   He YF, 2013, BIOL TRACE ELEM RES, V152, P292, DOI 10.1007/s12011 013 9605 z
   Hong HH, 2004, J CELL PHYSIOL, V200, P53, DOI 10.1002/jcp.10476
   Kim MH, 2011, BIOL TRACE ELEM RES, V144, P109, DOI 10.1007/s12011 011 9044 7
   Li GF, 2012, OSTEOPOROSIS INT, V23, P2403, DOI 10.1007/s00198 012 1982 1
   Medeiros DM, 1997, J TRACE ELEM EXP MED, V10, P197
   Mitchell AL, 2012, NAT REV ENDOCRINOL, V8, P306, DOI [10.1038/nrendo.2012.74, 10.1038/nrendo.2012.186, 10.1038/nrendo.2012.127, 10.1038/nrendo.2012.200, 10.1038/nrendo.2011.245, 10.1038/nrendo.2012.56]
   Nagata M, 2011, BIOL TRACE ELEM RES, V142, P190, DOI 10.1007/s12011 010 8760 8
   Omonkhua AA, 2013, AFR J BIOCH RES, V7, P39
   Puricelli Edela, 2006, Head Face Med, V2, P43, DOI 10.1186/1746 160X 2 43
   Qian AR, 2009, IEEE T APPL SUPERCON, V19, P42, DOI 10.1109/TASC.2009.2012422
   Rico H, 2000, MENOPAUSE, V7, P413, DOI 10.1097/00042192 200011000 00007
   Rico H, 2000, EUR J OBSTET GYN R B, V90, P97, DOI 10.1016/S0301 2115(99)00223 7
   Roughead ZK, 2003, J NUTR, V133, P442, DOI 10.1093/jn/133.2.442
   Rude RK, 2003, CALCIFIED TISSUE INT, V72, P32, DOI 10.1007/s00223 001 1091 1
   Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198 009 1066 z
   Seo HJ, 2010, NUTR RES PRACT, V4, P356, DOI 10.4162/nrp.2010.4.5.356
   Sun JY, 2011, BIOL TRACE ELEM RES, V143, P394, DOI 10.1007/s12011 010 8869 9
   Wang ZJ, 2013, J BONE MINER METAB, V31, P285, DOI 10.1007/s00774 012 0417 6
   Wang Z, 2014, BIOELECTROMAGNETICS, V35, P251, DOI 10.1002/bem.21847
   Yamaguchi M., 2007, Biomed Res Trace Elem, V18, P346
   Yan QC, 1998, MED ENG PHYS, V20, P397, DOI 10.1016/S1350 4533(98)00051 4
   Zhang J, 2014, PROG BIOPHYS MOL BIO, V114, P146, DOI 10.1016/j.pbiomolbio.2014.02.001
   Zofková I, 2013, CLIN CHEM LAB MED, V51, P1555, DOI 10.1515/cclm 2012 0868
NR 33
TC 28
Z9 31
U1 0
U2 46
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0163 4984
EI 1559 0720
J9 BIOL TRACE ELEM RES
JI Biol. Trace Elem. Res.
PD DEC
PY 2014
VL 162
IS 1 3
BP 153
EP 157
DI 10.1007/s12011 014 0157 7
PG 5
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AU4MK
UT WOS:000345585000018
PM 25328139
DA 2025 08 17
ER

PT J
AU Li, S
   Hao, L
   Wang, L
   Lu, Y
   Li, Q
   Zhu, Z
   Shao, JZ
   Chen, W
AF Li, Sheng
   Hao, Liang
   Wang, Lin
   Lu, Yun
   Li, Qian
   Zhu, Zheng
   Shao, Jian Zhong
   Chen, Wei
TI Targeting Atp6v1c1 Prevents Inflammation and Bone Erosion Caused by
   Periodontitis and Reveals Its Critical Function in Osteoimmunology
SO PLOS ONE
LA English
DT Article
ID PORPHYROMONAS GINGIVALIS; GENE THERAPY; CATHEPSIN K; PARKINSONS DISEASE;
   PROTON PUMP; IN VITRO; V ATPASE; MOUSE; EXPRESSION; DIFFERENTIATION
AB Periodontal disease (Periodontitis) is a serious disease that affects a majority of adult Americans and is associated with other systemic diseases, including diabetes, rheumatoid arthritis, and other inflammatory diseases. While great efforts have been devoted toward understanding the pathogenesis of periodontitis, there remains a pressing need for developing potent therapeutic strategies for targeting this pervasive and destructive disease. In this study, we utilized novel adeno associated virus (AAV) mediated Atp6v1c1 knockdown gene therapy to treat bone erosion and inflammatory caused by periodontitis in mouse model. Atp6v1c1 is a subunit of the V ATPase complex and regulator of the assembly of the V0 and V1 domains of the V ATPase complex. We demonstrated previously that Atp6v1c1 has an essential function in osteoclast mediated bone resorption. We hypothesized that Atp6v1c1 may be an ideal target to prevent the bone erosion and inflammation caused by periodontitis. To test the hypothesis, we employed AAV RNAi knockdown of Atp6v1c1 gene expression to prevent bone erosion and gingival inflammation simultaneously. We found that lesion specific injection of AAV shRNA Atp6v1c1 into the periodontal disease lesions protected against bone erosion (>85%) and gingival inflammation caused by P. gingivalis W50 infection. AAV mediated Atp6v1c1 knockdown dramatically reduced osteoclast numbers and inhibited the infiltration of dendritic cells and macrophages in the bacteria induced inflammatory lesions in periodontitis. Silencing of Atp6v1c1 expression also prevented the expressions of osteoclast related genes and pro inflammatory cytokine genes. Our data suggests that AAV shRNA Atp6v1c1 treatment can significantly attenuate the bone erosion and inflammation caused by periodontitis, indicating the dual function of AAV shRNA Atp6v1c1 as an inhibitor of bone erosion mediated by osteoclasts, and as an inhibitor of inflammation through down regulation of pro inflammatory cytokine expression. This study demonstrated that Atp6v1c1 RNAi knockdown gene therapy mediated by AAV shRNA Atp6v1c1 is a promising novel therapeutic approach for the treatment of bone erosion and inflammatory related diseases, such as periodontitis and rheumatoid arthritis.
C1 [Li, Sheng; Hao, Liang; Lu, Yun; Zhu, Zheng; Chen, Wei] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Li, Sheng; Wang, Lin; Zhu, Zheng] Nanjing Med Univ, Coll Stomatol, Nanjing 210029, Jiangsu, Peoples R China.
   [Li, Qian; Shao, Jian Zhong] Zhejiang Univ, Life Sci Coll, Hangzhou 310058, Zhejiang, Peoples R China.
C3 University of Alabama System; University of Alabama Birmingham; Nanjing
   Medical University; Zhejiang University
RP Chen, W (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
EM wechen@uab.edu
RI ; Shao, Zongze/T 6682 2017; Li, Qian/GYJ 2565 2022
OI Hao, Liang/0000 0003 2071 7044; 
FU NIH [R01DE023813]; UAB Department of Pathology
FX This study was supported by NIH grant R01DE023813 (YPL), and the UAB
   Department of Pathology Start Up funding (WC). The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR [Anonymous], J PERIODONTOL
   Carter BJ, 2005, HUM GENE THER, V16, P541, DOI 10.1089/hum.2005.16.541
   Chen W, 2007, HUM MOL GENET, V16, P410, DOI 10.1093/hmg/ddl474
   Chen W, 2014, P NATL ACAD SCI USA, V111, P8482, DOI 10.1073/pnas.1310617111
   Chen W, 2013, P NATL ACAD SCI USA, V110, P7294, DOI 10.1073/pnas.1211383110
   Cipriano DJ, 2008, BBA BIOENERGETICS, V1777, P599, DOI 10.1016/j.bbabio.2008.03.013
   Cirelli JA, 2009, GENE THER, V16, P426, DOI 10.1038/gt.2008.174
   Collins Sara A, 2010, Genet Vaccines Ther, V8, P8, DOI 10.1186/1479 0556 8 8
   Cottard V, 2000, GENE THER, V7, P1930, DOI 10.1038/sj.gt.3301324
   Evans C, 2010, J RHEUMATOL, V37, P683, DOI 10.3899/jrheum.100055
   Feng SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084833
   Feng SM, 2013, INT J BIOL SCI, V9, P853, DOI 10.7150/ijbs.6030
   Feng SM, 2009, BIOCHEM J, V417, P195, DOI 10.1042/BJ20081073
   Fischer CL, 2013, INT J ORAL SCI, V5, P130, DOI 10.1038/ijos.2013.28
   Gao B, 2013, J DENT RES, V92, P180, DOI 10.1177/0022034512468757
   Gasmi M, 2007, MOL THER, V15, P62, DOI 10.1038/sj.mt.6300010
   Hao L, 2015, INFECT IMMUN, V83, P1235, DOI 10.1128/IAI.01713 14
   Hasturk H, 2006, FASEB J, V20, P401, DOI 10.1096/fj.05 4724fje
   Hinton A, 2009, PFLUG ARCH EUR J PHY, V457, P589, DOI 10.1007/s00424 007 0382 4
   Inoue T, 2005, J BIOL CHEM, V280, P27896, DOI 10.1074/jbc.M504890200
   Jiang HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058599
   Kaplitt MG, 2007, LANCET, V369, P2097, DOI 10.1016/S0140 6736(07)60982 9
   Kawai T, 2006, AM J PATHOL, V169, P987, DOI 10.2353/ajpath.2006.060180
   Kim J, 2006, ODONTOLOGY, V94, P10, DOI 10.1007/s10266 006 0060 6
   Li YP, 1996, BIOCHEM BIOPH RES CO, V218, P813, DOI 10.1006/bbrc.1996.0145
   Li YP, 1999, J BONE MINER RES, V14, P487, DOI 10.1359/jbmr.1999.14.4.487
   Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563
   LI YP, 1995, J BONE MINER RES, V10, P1197
   Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121 5130.2001
   Mabbott NA, 2011, IMMUNOLOGY, V133, P482, DOI 10.1111/j.1365 2567.2011.03461.x
   Miyajima S, 2014, SCI REP UK, V4, DOI 10.1038/srep05171
   Musatov S, 2006, P NATL ACAD SCI USA, V103, P10456, DOI 10.1073/pnas.0603045103
   Pérez Sayáns M, 2010, CANCER BIOL THER, V9, P1057, DOI 10.4161/cbt.9.12.11880
   Qi J, 2007, J BIOENERG BIOMEMBR, V39, P423, DOI 10.1007/s10863 007 9116 8
   Qin A, 2012, INT J BIOCHEM CELL B, V44, P1422, DOI 10.1016/j.biocel.2012.05.014
   Sasaki H, 2004, J PERIODONTAL RES, V39, P432, DOI 10.1111/j.1600 0765.2004.00760.x
   Seymour GJ, 2007, CLIN MICROBIOL INFEC, V13, P3, DOI 10.1111/j.1469 0691.2007.01798.x
   Sood S, 2012, MED ORAL PATOL ORAL, V17, pE301, DOI 10.4317/medoral.17472
   Ulrich Vinther M, 2007, ACTA ORTHOP, V78, P5
   Wilensky A, 2009, J CLIN PERIODONTOL, V36, P915, DOI 10.1111/j.1600 051X.2009.01464.x
   Yang S, 2013, BONE RES, V1, P260, DOI 10.4248/BR201303005
   Yang SY, 2007, J CELL SCI, V120, P3362, DOI 10.1242/jcs.008300
   Yang SY, 2007, J BONE MINER RES, V22, P45, DOI 10.1359/JBMR.061007
   Yang SY, 2003, J BONE MINER RES, V18, P705, DOI 10.1359/jbmr.2003.18.4.705
   Yu H, 2011, GENE THER, V18, P344, DOI 10.1038/gt.2010.139
   Zhou Q, 2011, ARTHRITIS RHEUM US, V63, P2318, DOI 10.1002/art.30421
NR 46
TC 9
Z9 13
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD AUG 14
PY 2015
VL 10
IS 8
AR e0134903
DI 10.1371/journal.pone.0134903
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA CO9KD
UT WOS:000359493600045
PM 26274612
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Chen, JR
   Lazarenko, OP
   Zhang, J
   Blackburn, ML
   Ronis, MJJ
   Badger, TM
AF Chen, Jin Ran
   Lazarenko, Oxana P.
   Zhang, Jian
   Blackburn, Michael L.
   Ronis, Martin J. J.
   Badger, Thomas M.
TI Diet  Derived Phenolic Acids Regulate Osteoblast and Adipocyte Lineage
   Commitment and Differentiation in Young Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE p38 MAP KINASE; BONE FORMATION; PPAR; G PROTEIN COUPLED RECEPTOR
ID PROTEIN COUPLED RECEPTORS; BONE GROWTH; INHIBITION; CELLS; FRUIT; MASS
AB A blueberry (BB) supplemented diet has been previously shown to significantly stimulate bone formation in rapidly growing male and female rodents. Phenolic acids (PAs) are metabolites derived from polyphenols found in fruits and vegetables as a result of the actions of gut bacteria, and they were found in the serum of rats fed BB containing diet. We conducted in vitro studies with PAs and demonstrated stimulation of osteoblast differentiation and proliferation. On the other hand, adipogenesis was inhibited. To more fully understand the mechanistic actions of PAs on bone formation, we administered hippuric acid, one of the major metabolites found in animal circulation after BB consumption, to prepubertal female mice for 2 weeks. We found that hippuric acid was able to stimulate bone forming gene expression but suppress PPAR expression, leading to increased bone mass dose dependently. Cellular signaling studies further suggested that the skeletal effects of PAs appeared to be mediated through activation of G protein coupled receptor 109A and downstream p38 MAP kinase and osterix. In conclusion, PAs are capable of altering the mesenchymal stem cell differentiation program and merit investigation as potential dietary therapeutic alternatives to drugs for degenerative bone disorders. (c) 2014 American Society for Bone and Mineral Research.
C1 [Chen, Jin Ran; Lazarenko, Oxana P.; Zhang, Jian; Blackburn, Michael L.; Ronis, Martin J. J.; Badger, Thomas M.] Univ Arkansas Med Sci, Arkansas Childrens Nutr Ctr, Little Rock, AR 72205 USA.
   [Chen, Jin Ran; Zhang, Jian; Ronis, Martin J. J.; Badger, Thomas M.] Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA.
   [Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.] Univ Arkansas Med Sci, Dept Physiol, Little Rock, AR 72205 USA.
   [Lazarenko, Oxana P.; Blackburn, Michael L.; Badger, Thomas M.] Univ Arkansas Med Sci, Dept Biophys, Little Rock, AR 72205 USA.
   [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Pharmacol, Little Rock, AR 72205 USA.
   [Ronis, Martin J. J.] Univ Arkansas Med Sci, Dept Toxicol, Little Rock, AR 72205 USA.
C3 University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences;
   University of Arkansas System; University of Arkansas Medical Sciences
RP Chen, JR (通讯作者)，Arkansas Childrens Nutr Ctr, Slot 512 20B,15 Childrens Way, Little Rock, AR 72202 USA.
EM chenjinran@uams.edu
FU ARS CRIS [6251 51000 005 03S]
FX We thank Matt Ferguson and Trae Pittman for their technical assistance.
   This study was supported by ARS CRIS # 6251 51000 005 03S.
CR Ahmed K, 2009, TRENDS PHARMACOL SCI, V30, P557, DOI 10.1016/j.tips.2009.09.001
   Biasi F, 2011, CURR MED CHEM, V18, P4851, DOI 10.2174/092986711797535263
   Bikkavilli RK, 2008, J CELL SCI, V121, P3598, DOI 10.1242/jcs.032854
   Bonjour Jean Philippe, 2007, Med Sport Sci, V51, P64, DOI 10.1159/000103005
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Brown EM, 1998, ANNU REV MED, V49, P15, DOI 10.1146/annurev.med.49.1.15
   Cao JJ, 2009, BONE, V44, P1097, DOI 10.1016/j.bone.2009.02.017
   Castillo Pichardo L, 2012, NUTR CANCER, V64, P1058, DOI 10.1080/01635581.2012.716898
   Chang J, 2007, J BIOL CHEM, V282, P30938, DOI 10.1074/jbc.M702391200
   Chen JR, 2008, EXP BIOL MED, V233, P1348, DOI 10.3181/0802 RM 63
   Chen JR, 2012, FASEB J, V26, P1131, DOI 10.1096/fj.11 197822
   Chen JR, 2010, J BONE MINER RES, V25, P2399, DOI 10.1002/jbmr.137
   Chen JR, 2010, J BONE MINER RES, V25, P1117, DOI 10.1002/jbmr.7
   Chen JR, 2009, J NUTR, V139, P1839, DOI 10.3945/jn.109.109041
   Davies JH, 2005, ARCH DIS CHILD, V90, P373, DOI 10.1136/adc.2004.053553
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Engler AJ, 2006, CELL, V126, P677, DOI 10.1016/j.cell.2006.06.044
   Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783
   Klibanski A, 2001, JAMA J AM MED ASSOC, V285, P785
   Lanham New SA, 2006, AM J CLIN NUTR, V83, P1254, DOI 10.1093/ajcn/83.6.1254
   Latronico AC, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3143re7
   Mårtensson UEA, 2009, ENDOCRINOLOGY, V150, P687, DOI 10.1210/en.2008 0623
   Martín Blanco E, 2000, BIOESSAYS, V22, P637, DOI 10.1002/1521 1878(200007)22:7<637::AID BIES6>3.0.CO;2 E
   Ogita M, 2008, ENDOCRINOLOGY, V149, P5713, DOI 10.1210/en.2008 0369
   Ren N, 2009, J LIPID RES, V50, P908, DOI 10.1194/jlr.M800625 JLR200
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Rodrigo R, 2012, ADV CLIN CHEM, V58, P225, DOI 10.1016/B978 0 12 394383 5.00014 X
   Sassa S, 2003, IN VIVO, V17, P277
   Setchell KDR, 2003, AM J CLIN NUTR, V78, p593S, DOI 10.1093/ajcn/78.3.593S
   Tang W, 2011, CELL METAB, V14, P116, DOI 10.1016/j.cmet.2011.05.012
   Treiser MD, 2010, P NATL ACAD SCI USA, V107, P610, DOI 10.1073/pnas.0909597107
   Trzeciakiewicz A, 2009, NUTR RES REV, V22, P68, DOI 10.1017/S095442240926402X
   Tylavsky FA, 2004, AM J CLIN NUTR, V79, P311
   Vinolo MAR, 2012, CURR OPIN CLIN NUTR, V15, P112, DOI 10.1097/MCO.0b013e32834f4598
   Zhang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024486
   Zimmerman SG, 2010, DEV BIOL, V340, P54, DOI 10.1016/j.ydbio.2010.01.021
NR 36
TC 39
Z9 43
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2014
VL 29
IS 5
BP 1043
EP 1053
DI 10.1002/jbmr.2034
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA AF4CJ
UT WOS:000334658700003
PM 23832484
DA 2025 08 17
ER

PT J
AU Ye, QY
   Xu, HK
   Liu, SY
   Li, ZH
   Zhou, J
   Ding, F
   Zhang, XG
   Wang, YZ
   Jin, Y
   Wang, QT
AF Ye, Qingyuan
   Xu, Haokun
   Liu, Shiyu
   Li, Zihan
   Zhou, Jun
   Ding, Feng
   Zhang, Xige
   Wang, Yazheng
   Jin, Yan
   Wang, Qintao
TI Apoptotic extracellular vesicles alleviate Pg LPS induced inflammation
   of macrophages via AMPK/SIRT1/NF κB pathway and inhibit adjacent
   osteoclast formation
SO JOURNAL OF PERIODONTOLOGY
LA English
DT Article
DE apoptotic extracellular vesicles; inflammation; macrophages; NF kappa B
   pathway; osteoclasts; periodontitis
ID NF KAPPA B; BONE LOSS; PERIODONTITIS; CELLS
AB Background: Periodontitis is caused by the imbalance of anti bacteria immune response and excessive inflammation whereas macrophages play an important role in inflammation. Thus, it is critical for finding efficient anti inflammatory strategies to alleviate periodontal inflammation and prevent bone destruction. Apoptosis of mesenchymal stem cells (MSCs) exerts immune silencing effects, however, using these effects to develop anti inflammatory strategies remains unknown. In our study, we extracted apoptotic extracellular vesicles (ApoEVs) from bone marrow MSCs (BMMSCs) and found ApoEVs inhibited macrophages polarizing into proinflammatory condition via AMPK/SIRT1/NF kappa B pathway. Besides that, we also found ApoEVs inhibited adjacent osteoclast formation by suppressing the secretion of TNF alpha of proinflammatory macrophages.
   Methods: BMMSCs derived ApoEVs were extracted by gradient centrifugation. Protein expression level and secreted cytokines of ApoEVs treated macrophages were examined by western blot and ELISA, respectively. Besides, the change of NF kappa B pathway and related molecules were examined by immunofluorescence and western blot. The osteoclast formation under the different conditioned mediums from macrophages was measured by TRAP staining, MMP 9 expression, and pit assay.
   Results: ApoEVs were extracted from staurosporine induced apoptotic BMMSCs and were in sphere shapes whose diameters are between 100 and 1000 nm. ApoEVs could be phagocyted by macrophages and in turn reduce the expression of COX2 in proinflammatory macrophages. Besides that, ApoEVs suppressed the secretions of TNF alpha and IL 6 while elevating the secretion of IL 10 in a dose dependent manner. Further studies revealed that ApoEVs inhibited macrophages polarizing into proinflammatory phenotypes via AMPK/SIRT1/NF kappa B pathway. In addition, ApoEVs inhibited osteoclasts differentiation and bone resorption measured by TRAP staining, MMP 9 expression, and pit resorption area by downregulating the secretion of TNF alpha of proinflammatory macrophages.
   Conclusions: The results suggest that ApoEVs inhibited macrophages to skew into proinflammatory phenotypes via AMPK/SIRT1/NF kappa B pathway and suppress adjacent osteoclasts formation by reducing the secretion of TNF alpha. Our findings shed a light on the treatment for periodontitis based on EVs therapy.
C1 [Ye, Qingyuan; Xu, Haokun; Liu, Shiyu; Li, Zihan; Zhou, Jun; Ding, Feng; Zhang, Xige; Wang, Yazheng; Jin, Yan; Wang, Qintao] Air Force Med Univ, State Key Lab Mil Stomatol, Xian, Shaanxi, Peoples R China.
   [Ye, Qingyuan; Xu, Haokun; Liu, Shiyu; Li, Zihan; Zhou, Jun; Ding, Feng; Zhang, Xige; Wang, Yazheng; Jin, Yan; Wang, Qintao] Air Force Med Univ, Natl Clin Res Ctr Oral Dis, Xian, Shaanxi, Peoples R China.
   [Ye, Qingyuan; Zhang, Xige; Wang, Yazheng; Wang, Qintao] Air Force Med Univ, Sch Stomatol, Shaanxi Engn Res Ctr Dent Mat & Adv Manufacture, Dept Periodontol, Xian, Shaanxi, Peoples R China.
   [Ye, Qingyuan; Xu, Haokun; Liu, Shiyu; Li, Zihan; Zhou, Jun; Ding, Feng; Jin, Yan] Air Force Med Univ, Shaanxi Int Joint Res Ctr Oral Dis, Ctr Tissue Engn, Sch Stomatol, Xian, Shaanxi, Peoples R China.
C3 Air Force Medical University; Air Force Medical University; Air Force
   Medical University; Air Force Medical University
RP Wang, QT (通讯作者)，Air Force Med Univ, Sch Stomatol, Dept Periodontol, Xian 710032, Shaanxi, Peoples R China.; Jin, Y (通讯作者)，Air Force Med Univ, Sch Stomatol, Ctr Tissue Engn, Xian 710032, Shaanxi, Peoples R China.
EM yanjin@fmmu.edu.cn; wangqintao@aliyun.com
RI JIN, YAN/HPC 7389 2023; liu, shiyu/HRC 0526 2023
OI Ye, Qingyuan/0000 0001 7804 9726
FU National Natural Science Foundation of China [NNSF81771069,
   NNSF82170955]; open project of State Key Laboratory of Military
   Stomatology [2020KA01]
FX This study is funded by National Natural Science Foundation of China
   (Grant No. NNSF81771069 and NNSF82170955) and the open project of State
   Key Laboratory of Military Stomatology (Grant No. 2020KA01).
CR Arandjelovic S, 2015, NAT IMMUNOL, V16, P907, DOI 10.1038/ni.3253
   Baker RG, 2011, CELL METAB, V13, P11, DOI 10.1016/j.cmet.2010.12.008
   Bandarra D, 2015, DIS MODEL MECH, V8, P169, DOI 10.1242/dmm.017285
   Bartold PM, 2013, PERIODONTOL 2000, V62, P203, DOI 10.1111/j.1600 0757.2012.00450.x
   Battistelli M, 2020, BIOLOGY BASEL, V9, DOI 10.3390/biology9010021
   Bobrie A, 2011, TRAFFIC, V12, P1659, DOI 10.1111/j.1600 0854.2011.01225.x
   Caruso S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01486
   Chen X, 2018, METABOLISM, V83, P256, DOI 10.1016/j.metabol.2018.03.004
   Dismuke WM, 2015, MESENCHYMAL STEM CELL DERIVED EXOSOMES: THE POTENTIAL FOR TRANSLATIONAL NANOMEDICINE, P63
   Dorrington MG, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00705
   Duan XH, 2016, THERANOSTICS, V6, P2183, DOI 10.7150/thno.17140
   Elliott MR, 2016, DEV CELL, V38, P147, DOI 10.1016/j.devcel.2016.06.029
   Funosas Esteban R, 2009, Acta odontol. latinoam., V22, P215
   Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423
   Huang S, 2015, J ORTHOP TRANSL, V3, P26, DOI 10.1016/j.jot.2014.07.005
   Kinane DF., 2017, NAT REV DIS PRIM, V3, P1, DOI DOI 10.1038/NRDP.2017.38
   Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651
   Li Y, 2015, J DENT RES, V94, P362, DOI 10.1177/0022034514561658
   Liu J, 2020, STEM CELL RES THER, V11, DOI 10.1186/s13287 020 02014 w
   McGrath KE, 2015, SEMIN IMMUNOL, V27, P379, DOI 10.1016/j.smim.2016.03.013
   Morioka S, 2019, IMMUNITY, V50, P1149, DOI 10.1016/j.immuni.2019.04.018
   Murphy DE, 2019, EXP MOL MED, V51, DOI 10.1038/s12276 019 0223 5
   Park H, 2015, ANTIOXID REDOX SIGN, V22, P63, DOI 10.1089/ars.2013.5748
   Poon IKH, 2014, NAT REV IMMUNOL, V14, P166, DOI 10.1038/nri3607
   Salminen A, 2019, J MOL MED, V97, P1049, DOI 10.1007/s00109 019 01795 9
   Salminen A, 2011, J MOL MED, V89, P667, DOI 10.1007/s00109 011 0748 0
   Salvi GE, 2005, CURR PHARM DESIGN, V11, P1757, DOI 10.2174/1381612053764878
   Sandra F., 2018, MOLEC CELL BIOMED SC, V2, DOI 10.21705/mcbs.v2i1.16
   Sarko DK, 2017, FRONT NEUROSCI SWITZ, V11, DOI 10.3389/fnins.2017.00082
   Silva MT, 2010, FEBS LETT, V584, P4491, DOI 10.1016/j.febslet.2010.10.046
   Sims NA, 2020, ANNU REV PHYSIOL, V82, P507, DOI 10.1146/annurev physiol 021119 034425
   Slots J, 2017, PERIODONTOL 2000, V75, P7, DOI 10.1111/prd.12221
   Tang B, 2016, INT J NANOMED, V11, P6401, DOI 10.2147/IJN.S101285
   Tang J, 2021, INT IMMUNOPHARMACOL, V91, DOI 10.1016/j.intimp.2020.107272
   Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306
   Wynn TA, 2016, IMMUNITY, V44, P450, DOI 10.1016/j.immuni.2016.02.015
   Xu XB, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20180992
   Yáñez Mó M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066
   Yang JM, 2018, ARCH ORAL BIOL, V96, P234, DOI 10.1016/j.archoralbio.2017.03.006
   Yang SR, 2007, AM J PHYSIOL LUNG C, V292, pL567, DOI 10.1152/ajplung.00308.2006
   Yao HW, 2012, BIOCHEM PHARMACOL, V84, P1332, DOI 10.1016/j.bcp.2012.06.031
   Ying W, 2013, JOVE J VIS EXP, DOI 10.3791/50323
   Zheng CX, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12109
   Zhou CC, 2021, CHIN J DENT RES, V24, P33, DOI 10.3290/j.cjdr.b1105871
   Zhu LF, 2019, ORAL DIS, V25, P1972, DOI 10.1111/odi.13167
   Zhu X, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0027081, 10.1371/journal.pone.0017783]
   Zhuang Z, 2019, J DENT RES, V98, P200, DOI 10.1177/0022034518805984
NR 47
TC 57
Z9 63
U1 7
U2 61
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3492
EI 1943 3670
J9 J PERIODONTOL
JI J. Periodont.
PD NOV
PY 2022
VL 93
IS 11
BP 1738
EP 1751
DI 10.1002/JPER.21 0657
EA AUG 2022
PG 14
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 6P5OY
UT WOS:000835815600001
PM 35499816
DA 2025 08 17
ER

PT J
AU Ottewell, PD
   Wang, N
   Brown, HK
   Reeves, KJ
   Fowles, CA
   Croucher, PI
   Eaton, CL
   Holen, I
AF Ottewell, Penelope D.
   Wang, Ning
   Brown, Hannah K.
   Reeves, Kimberly J.
   Fowles, C. Anne
   Croucher, Peter I.
   Eaton, Colby L.
   Holen, Ingunn
TI Zoledronic Acid Has Differential Antitumor Activity in the Pre  and
   Postmenopausal Bone Microenvironment In Vivo
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID MOUSE MODEL; STEM CELLS; CANCER; THERAPY; OSTEOPROTEGERIN; MOBILIZATION;
   OSTEOCLASTS; EXPRESSION; MATRIX
AB Purpose: Clinical trials in early breast cancer have suggested that benefits of adjuvant bone targeted treatments are restricted to women with established menopause. We developed models that mimic pre and postmenopausal status to investigate effects of altered bone turnover on growth of disseminated breast tumor cells. Here, we report a differential antitumor effect of zoledronic acid (ZOL) in these two settings.
   Experimental design: Twleve week old female Balb/c nude mice with disseminated MDA MB 231 breast tumor cells in bone underwent sham operation or ovariectomy (OVX), mimicking the pre and postmenopausal bone microenvironment, respectively. To determine the effects of bone targeted therapy, sham/OVX animals received saline or 100 mu g/kg ZOL weekly. Tumor growth was assessed by in vivo imaging and effects on bone by real time PCR, micro CT, histomorphometry, and measurements of bone markers. Disseminated tumor cells were detected by two photon microscopy.
   Results: OVX increased bone resorption and induced growth of disseminated tumor cells in bone. Tumors were detected in 83% of animals following OVX (postmenopausal model) compared with 17% following sham operation (premenopausal model). OVX had no effect on tumors outside of bone. OVX induced tumor growth was completely prevented by ZOL, despite the presence of disseminated tumor cells. ZOL did not affect tumor growth in bone in the sham operated animals. ZOL increased bone volume in both groups.
   Conclusions: This is the first demonstration that tumor growth is driven by osteoclast mediated mechanisms in models that mimicpost but not premenopausal bone, providing a biologic rationale for the differential antitumor effects of ZOL reported in these settings.(C) 2014 AACR.
C1 [Ottewell, Penelope D.; Brown, Hannah K.; Holen, Ingunn] Univ Sheffield, Dept Oncol, Acad Unit Clin Oncol, Sheffield S10 2RX, S Yorkshire, England.
   [Wang, Ning; Reeves, Kimberly J.; Fowles, C. Anne; Eaton, Colby L.] Univ Sheffield, Acad Unit Bone Biol, Dept Human Metab, Sheffield S10 2RX, S Yorkshire, England.
   [Croucher, Peter I.] Garvan Inst Med Res, Musculoskeletal Med Div, Sydney, NSW, Australia.
C3 University of Sheffield; University of Sheffield; Garvan Institute of
   Medical Research
RP Ottewell, PD (通讯作者)，Univ Sheffield, Sch Med, Acad Unit Clin Oncol, Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.
EM P.D.Ottewell@sheffield.ac.uk
RI ; Wang, Ning/HKO 8446 2023
OI WANG, NING/0000 0002 2663 7515; Holen, Ingunn/0000 0002 8759 6913;
   Ottewell, Penelope/0000 0002 4826 0771; Croucher,
   Peter/0000 0002 7102 2413
FU Cancer Research UK; Janice Gibson; Ernest Heine Family Foundation;
   Cancer Research UK [11991] Funding Source: researchfish
FX This study was supported by a program grant from Cancer Research UK(to
   C.L. Eaton, P.I. Croucher, and I. Holen). P.I. Croucher is supported by
   Janice Gibson and the Ernest Heine Family Foundation.
CR Aguirre Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Aicher A, 2008, CIRC RES, V103, P796, DOI 10.1161/CIRCRESAHA.107.172718
   Barkan D, 2010, EUR J CANCER, V46, P1181, DOI 10.1016/j.ejca.2010.02.027
   Brown HK, 2009, CURR CANCER DRUG TAR, V9, P807, DOI 10.2174/156800909789760339
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Coleman RE, 2011, NEW ENGL J MED, V365, P1396, DOI 10.1056/NEJMoa1105195
   Driessen RL, 2003, EXP HEMATOL, V31, P1284, DOI 10.1016/j.exphem.2003.08.015
   Ellis SL, 2011, BLOOD, V118, P1516, DOI 10.1182/blood 2010 08 303800
   Gnant M, 2011, LANCET ONCOL, V12, P631, DOI 10.1016/S1470 2045(11)70122 X
   Jodele S, 2006, CANCER METAST REV, V25, P35, DOI 10.1007/s10555 006 7887 8
   Kollet O, 2007, ANNU REV IMMUNOL, V25, P51, DOI 10.1146/annurev.immunol.25.022106.141631
   Kollet O, 2006, NAT MED, V12, P657, DOI 10.1038/nm1417
   Kumar S, 2012, BONE, V50, P1012, DOI 10.1016/j.bone.2012.01.027
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lee SK, 2006, J BONE MINER RES, V21, P1704, DOI 10.1359/JBMR.060726
   Lu CL, 2010, BLOOD, V115, P221, DOI 10.1182/blood 2009 06 228494
   Orlic Iva, 2007, Arhiv za Higijenu Rada i Toksikologiju, V58, P3, DOI 10.2478/v10004 007 0001 y
   Ottewell PD, 2008, JNCI J NATL CANCER I, V100, P1167, DOI 10.1093/jnci/djn240
   Ottewell PD, 2009, MOL CANCER THER, V8, P2821, DOI 10.1158/1535 7163.MCT 09 0462
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Paterson AHG, 2011, CANCER RES, V71, DOI 10.1158/0008 5472.SABCS11 52 3
   Renström J, 2010, CHEM BIOL INTERACT, V184, P7, DOI 10.1016/j.cbi.2009.11.012
   Shiozawa Y, 2011, J CLIN INVEST, V121, P1298, DOI 10.1172/JCI43414
   Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092 8674(00)80209 3
   Steinman RA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3223
   Townson JL, 2006, CELL CYCLE, V5, P1744, DOI 10.4161/cc.5.16.2864
   van der Horst G, 2005, J BONE MINER RES, V20, P1867, DOI 10.1359/JBMR.050614
   van der Pluijm G, 2005, CANCER RES, V65, P7682, DOI 10.1158/0008 5472.CAN 04 4188
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
NR 29
TC 131
Z9 139
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1078 0432
EI 1557 3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2014
VL 20
IS 11
BP 2922
EP 2932
DI 10.1158/1078 0432.CCR 13 1246
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AI8IS
UT WOS:000337157000012
PM 24687923
OA Green Accepted, Green Submitted
DA 2025 08 17
ER

PT J
AU van Schaick, E
   Zheng, J
   Ruixo, JJP
   Gieschke, R
   Jacqmin, P
AF van Schaick, Erno
   Zheng, Jenny
   Ruixo, Juan Jose Perez
   Gieschke, Ronald
   Jacqmin, Philippe
TI A semi mechanistic model of bone mineral density and bone turnover based
   on a circular model of bone remodeling
SO JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
LA English
DT Article
DE Osteoporosis; Pharmacokinetics; Pharmacodynamics; Bone remodeling
ID VITAMIN D SUPPLEMENTATION; POSTMENOPAUSAL WOMEN; THEORETICAL ANALYSIS;
   BIOCHEMICAL MARKERS; PD MODEL; OSTEOPOROSIS; ALENDRONATE; MASS;
   BISPHOSPHONATE; IBANDRONATE
AB Development of novel therapies for bone diseases can benefit from mathematical models that predict drug effect on bone remodeling biomarkers. Therefore, a bone cycle model (BCM) was developed that takes into consideration the concept of the basic multicellular unit and the dynamic equilibrium of bone remodeling. The model is a closed form cyclical model with four compartments representing resorption, formation, primary mineralization, and secondary mineralization. Equations describing the time course of bone turnover biomarkers were developed using the flow rate of bone cycle units (BCU) between the compartments or the amount of BCU in each compartment. A disease progression model representing bone loss in osteoporosis, a vitamin D and calcium supplementation (placebo) model, and a drug model for antiresorptive treatments were added to the model. Initial model parameter values were derived from published bone turnover data. The BCM accurately described biomarker time profiles in postmenopausal women receiving either placebo or bisphosphonate treatment. The slow continual increase in bone mineral density (BMD) observed after 1 year of treatment was accurately described when changes in bone turnover were combined with increases in mineralization. For this purpose, the secondary mineralization compartment was replaced by three catenary chain compartments representing increasing mineral content. The refined BCM satisfactorily predicted biomarker profiles after long term (10 year) bisphosphonate treatment. Furthermore, the model successfully described individual bone turnover markers and BMD results following treatment with denosumab in postmenopausal women. Analyses with this model could be used to optimize dosing regimens and to predict effects of novel osteoporotic treatments.
C1 [van Schaick, Erno; Jacqmin, Philippe] SGS Exprimo NV, B 2800 Mechelen, Belgium.
   [Zheng, Jenny; Ruixo, Juan Jose Perez] Amgen Inc, Pharmacokinet & Drug Metab Div, Thousand Oaks, CA 91320 USA.
   [Gieschke, Ronald] Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, CH 4070 Basel, Switzerland.
C3 Amgen; Roche Holding
RP van Schaick, E (通讯作者)，SGS Exprimo NV, Gen Wittelaan 19A b5, B 2800 Mechelen, Belgium.
EM erno.vanschaick@sgs.com
RI Ruixo, Juan/AAL 2987 2020
OI PEREZ RUIXO, JUAN JOSE/0000 0001 9890 745X
FU Amgen Inc
FX Amgen Inc funded this study. We thank Janet R Wade, PhD, (SGS Exprimo
   NV) for her editorial suggestions. Lisa A Humphries, PhD, of Amgen Inc
   provided editing and formatting support.
CR [Anonymous], S PLUS 6 2 MOD STAT
   [Anonymous], PHARS TRIAL SIM US G
   Bagger YZ, 2003, BONE, V33, P301, DOI 10.1016/S8756 3282(03)00112 1
   Beal S., 1988, NONMEM User Guides
   Berne RM, 1998, PRINCIPLES PHYSL, P850
   Black AJ, 2000, J BONE MINER RES, V15, P557, DOI 10.1359/jbmr.2000.15.3.557
   Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Chesnut CH, 2004, J BONE MINER RES, V19, P1241, DOI 10.1359/JBMR.040325
   Compston Juliet, 2006, Arq Bras Endocrinol Metab, V50, P579
   Cremers S, 2002, EUR J CLIN PHARMACOL, V57, P883, DOI 10.1007/s00228 001 0411 8
   DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003
   Development Core Team, 2007, LANG ENV STAT COMP
   Eastell R, 2003, J BONE MINER RES, V18, P1051, DOI 10.1359/jbmr.2003.18.6.1051
   Eisman JA, 2011, J BONE MINER RES, V26, P242, DOI 10.1002/jbmr.212
   *FOOD DRUG ADM, 1994, GUID PRECL CLIN EV A
   Gabrielsson K, 2000, BIOPHARM DRUG DISPOS, V21, P41
   Gallagher JC, 2002, J CLIN ENDOCR METAB, V87, P4914, DOI 10.1210/jc.2002 020727
   Ganong WilliamF., 1995, REV MED PHYSL, V17th, P352
   Garnero P, 2000, J BONE MINER RES, V15, P1526, DOI 10.1359/jbmr.2000.15.8.1526
   Gieschke R, 2003, 30 EUR S CALC TISS 8
   Hazelwood SJ, 2001, J BIOMECH, V34, P299, DOI 10.1016/S0021 9290(00)00221 9
   HEANEY RP, 1994, J BONE MINER RES, V9, P1515
   Heaney RP, 1997, J BONE MINER RES, V12, P1143, DOI 10.1359/jbmr.1997.12.8.1143
   Hernandez CJ, 2008, BONE, V42, P1014, DOI 10.1016/j.bone.2008.02.001
   Hernandez CJ, 2001, BONE, V29, P74, DOI 10.1016/S8756 3282(01)00467 7
   Hernandez CJ, 2002, J BONE MINER RES, V17, P1662, DOI 10.1359/jbmr.2002.17.9.1662
   Hernandez CJ, 2001, BONE, V29, P511, DOI 10.1016/S8756 3282(01)00613 5
   Hochberg MC, 2002, J CLIN ENDOCR METAB, V87, P1586, DOI 10.1210/jc.87.4.1586
   Holford NHG, 2000, ANNU REV PHARMACOL, V40, P209, DOI 10.1146/annurev.pharmtox.40.1.209
   Hollister S, 2004, BME 456 BIOSOLID MEC
   Jackson RD, 2006, NEW ENGL J MED, V354, P669, DOI 10.1056/NEJMoa055218
   Jacqmin P, 2007, J PHARMACOKINET PHAR, V34, P57, DOI 10.1007/s10928 006 9035 z
   Leeming DJ, 2006, EUR J CLIN PHARMACOL, V62, P781, DOI 10.1007/s00228 006 0174 3
   Lemaire V, 2004, J THEOR BIOL, V229, P293, DOI 10.1016/j.jtbi.2004.03.023
   LIBERMAN UA, 1995, NEW ENGL J MED, V333, P1437, DOI 10.1056/NEJM199511303332201
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Marathe DD, 2011, BIOPHARM DRUG DISPOS, V32, P471, DOI 10.1002/bdd.770
   Martin MJ, 2004, BONE, V35, P918, DOI 10.1016/j.bone.2004.06.010
   MELSEN F, 1980, ACTA PATH MICRO IM A, V88, P83
   Miller PD, 2008, BONE, V43, P222, DOI 10.1016/j.bone.2008.04.007
   Nyman JS, 2004, BONE, V35, P296, DOI 10.1016/j.bone.2004.03.007
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Peacock M, 2000, J CLIN ENDOCR METAB, V85, P3011, DOI 10.1210/jc.85.9.3011
   Pillai G, 2004, BRIT J CLIN PHARMACO, V58, P618, DOI 10.1111/j.1365 2125.2004.02224.x
   Post TM, 2013, J PHARMACOKINET PHAR, V40, P143, DOI 10.1007/s10928 012 9294 9
   Post TM, 2010, CLIN PHARMACOKINET, V49, P89, DOI 10.2165/11318150 000000000 00000
   Ravn P, 1998, BONE, V22, P559, DOI 10.1016/S8756 3282(98)00044 1
   Rosen CJ, 2010, NEW ENGL J MED, V363, P1365, DOI 10.1056/NEJMsb1002227
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Russell RGG, 1999, OSTEOPOROSIS INT, V9, P66, DOI 10.1007/PL00004164
   Schmidt S, 2011, J PHARMACOKINET PHAR, V38, P873, DOI 10.1007/s10928 011 9224 2
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Tayyar S, 1999, BONE, V25, P733, DOI 10.1016/S8756 3282(99)00218 5
   Thiebaud D, 1997, AM J MED, V103, P298, DOI 10.1016/S0002 9343(97)00249 0
   Tonino RP, 2000, J CLIN ENDOCR METAB, V85, P3109, DOI 10.1210/jc.85.9.3109
   Zheng J, 2015, J PHARMACOKINET PHAR
NR 58
TC 10
Z9 11
U1 0
U2 11
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1567 567X
EI 1573 8744
J9 J PHARMACOKINET PHAR
JI J. Pharmacokinet. Pharmacodyn.
PD AUG
PY 2015
VL 42
IS 4
BP 315
EP 332
DI 10.1007/s10928 015 9423 3
PG 18
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA CN1EN
UT WOS:000358160100001
PM 26123920
DA 2025 08 17
ER

PT J
AU Zheng, Y
   Wang, X
   Pan, YJ
   Shi, XF
   Yang, L
   Lou, YL
AF Zheng, Yan
   Wang, Xing
   Pan, Ya Jing
   Shi, Xiao Feng
   Yang, Lei
   Lou, Yong Liang
TI Orientin suppresses osteoclastogenesis and ameliorates
   ovariectomy induced osteoporosis via suppressing ROS production
SO FOOD SCIENCE & NUTRITION
LA English
DT Article
DE NF & kappa;B; Nrf2 pathway; Orientin; osteoclast; osteoporosis; reactive
   oxygen species
ID MODEL
AB The aberrant differentiation of osteoclasts is a key feature of the pathogenesis of osteoporosis, which has a devastating impact on human health. While the effects of Orientin (Ori) on osteoporosis, particularly on RANKL stimulated osteoclast production and activation, remain still unclear, Ori has been found to display several biological activities, including antioxidant and anti inflammatory. In this work, we investigated the possible pathways through which Ori suppressed RANKL induced osteoclast development and showed for the first time that it does so. The macrophages from the bone marrow (BMMs) were cultivated and then treated with Ori after being stimulated with RANKL. Then, TRAP positive multinucleated cells were counted, and F actin ring analysis was used to assess Ori's impact on mature osteoclast development. In addition, dihydroethidium (DHE) staining was used to evaluate the impact of Ori on RANKL induced reactive oxygen species (ROS). In addition, we performed western blotting and quantitative RT PCR analysis to investigate probable causes of these downregulation effects. We discovered that Ori inhibits the creation of osteoclasts, the gene and protein expressions unique to osteoclasts, and the ROS production. By activating Nrf2 and other ROS scavenging enzymes, Ori reduces intracellular ROS levels. The expression of the main transcription factor of osteoclast development, c Fos, was downregulated together with NFATc1, CTSK, and NFATc2, thanks to Ori's inhibition of RANKL induced NF ?B. Consistent with its in vitro antiosteoclastogenic action, Ori therapy in the ovariectomized (OVX) rat model was also able to restore bone mass and improve microarchitecture in the distal femurs. Together, our results demonstrate that Ori is a flavonoid molecule with therapeutic promise for bone illnesses associated with osteoclasts, such as osteoporosis.
C1 [Zheng, Yan; Wang, Xing; Pan, Ya Jing; Shi, Xiao Feng; Lou, Yong Liang] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou Key Lab Sanit Microbiol, Key Lab Lab Med,Minist Educ, Wenzhou, Peoples R China.
   [Zheng, Yan] Affiliated Yueqing Hosp, Dept Endocrinol, Wenzhou, Peoples R China.
   [Yang, Lei] Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.
   [Yang, Lei] Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical
   University
RP Lou, YL (通讯作者)，Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou Key Lab Sanit Microbiol, Key Lab Lab Med,Minist Educ, Wenzhou, Peoples R China.; Yang, L (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 2, Dept Orthoped, Wenzhou, Peoples R China.; Yang, L (通讯作者)，Wenzhou Med Univ, Yuying Childrens Hosp, Wenzhou, Peoples R China.
EM yanglei@wmu.edu.cn; lyl@wmu.edu.cn
RI Shi, Xiao Feng/G 8659 2014
FU Chinese Medicine Research Program of Zhejiang Province [2023010569];
   National Natural Science Foundation of China [82072310]
FX Chinese Medicine Research Program of Zhejiang Province, Grant/Award
   Number: 2023010569; National Natural Science Foundation of China,
   Grant/Award Number: 82072310
CR Cervellati C, 2013, CLIN CHEM LAB MED, V51, P333, DOI 10.1515/cclm 2012 0095
   Choi EM, 2020, CHEM BIOL INTERACT, V318, DOI 10.1016/j.cbi.2020.108978
   Escaffre O, 2015, J GEN VIROL, V96, P2961, DOI 10.1099/jgv.0.000243
   Hadaya D, 2019, J ORAL MAXIL SURG, V77, P71, DOI 10.1016/j.joms.2018.08.010
   Jansen IDC, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176110
   Jin C, 2023, J AGR FOOD CHEM, P2745, DOI 10.1021/acs.jafc.2c05632
   Jing SQ, 2020, NEURAL REGEN RES, V15, P548, DOI 10.4103/1673 5374.266063
   Kim JH, 2019, INT J MOL MED, V44, P913, DOI 10.3892/ijmm.2019.4269
   Kim K, 2020, MOLECULES, V25, DOI 10.3390/molecules25092077
   Kong ZL, 2020, CHEM BIODIVERS, V17, DOI 10.1002/cbdv.201900647
   Lam KY, 2016, ADV PHARMACOL SCI, V2016, DOI 10.1155/2016/4104595
   Lawal AO, 2019, PHYTOMEDICINE, V59, DOI 10.1016/j.phymed.2019.152898
   Li FH, 2022, J AGR FOOD CHEM, DOI 10.1021/acs.jafc.2c02015
   Li YP, 2019, EXP THER MED, V18, P1899, DOI 10.3892/etm.2019.7741
   Marcoline FV, 2016, BONE, V93, P167, DOI 10.1016/j.bone.2016.09.007
   Ruan F, 2012, BIOSCIENCE REP, V32, P511, DOI 10.1042/BSR20110118
   Thangaraj K, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090418
   Vrathasha V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102500
   Wada S, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00740
   Wang XR, 2017, J STROKE CEREBROVASC, V26, P2199, DOI 10.1016/j.jstrokecerebrovasdis.2017.05.002
   Xiao L, 2020, AGING US, V12, P21706, DOI 10.18632/aging.103976
   Xiao QF, 2021, INT IMMUNOPHARMACOL, V90, DOI 10.1016/j.intimp.2020.107189
   Xiong Q, 2016, PROTEOME SCI, V14, DOI 10.1186/s12953 016 0097 6
   Yang CC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1080168
   Yang Y, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190275
   Yi LX, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 020 02112 9
   Yoon DS, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.3
   Yu H, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944 015 0057 7
   Zhang HX, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/8508906
   Zhang W, 2020, J ORTHOP SURG RES, V15, DOI 10.1186/s13018 020 01780 w
   Zhang Z, 2022, APOPTOSIS, V27, P1031, DOI 10.1007/s10495 022 01770 9
   Zhao Y, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/4813140
NR 32
TC 8
Z9 10
U1 2
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 2048 7177
J9 FOOD SCI NUTR
JI Food Sci. Nutr.
PD SEP
PY 2023
VL 11
IS 9
BP 5582
EP 5595
DI 10.1002/fsn3.3516
EA JUN 2023
PG 14
WC Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Food Science & Technology
GA R6IU0
UT WOS:001021412200001
PM 37701239
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Mao, LX
   Xia, LG
   Chang, J
   Liu, JQ
   Jiang, LY
   Wu, CT
   Fang, B
AF Mao, Lixia
   Xia, Lunguo
   Chang, Jiang
   Liu, Jiaqiang
   Jiang, Lingyong
   Wu, Chengtie
   Fang, Bing
TI The synergistic effects of Sr and Si bioactive ions on osteogenesis,
   osteoclastogenesis and angiogenesis for osteoporotic bone regeneration
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Bioceramics; Bioactive ions; Osteoporotic bone; Osteogenesis;
   Osteoclastogenesis; Angiogenesis
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; STRONTIUM RANELATE;
   CALCIUM SILICATE; SIGNALING PATHWAY; IN VITRO; POSTMENOPAUSAL
   OSTEOPOROSIS; OSTEOBLAST DIFFERENTIATION; MORPHOGENETIC PROTEIN 2;
   MOLECULAR MECHANISMS
AB Bioactive ions released from bioceramics play important roles in bone regeneration; however, it is unclear how each ionic composition in complex bioceramics exerts its specific effect on bone regeneration. The aim of this study is to elucidate the functional effects of Sr and Si ions in bioceramics on the regeneration of osteoporotic bone. A model bioceramic with Sr and Si containing components (SMS) was successfully fabricated and the effects of ionic products from SMS bioceramics on the osteogenic, osteoclastic and angiogenic differentiation of rBMSCs OVX and RANKL induced osteoclasts were investigated. The results showed that SMS bioceramics could enhance ALP activity and expression of Col 1, OCN, Runx2, and angiogenic factors including VEGF and Ang 1. SMS bioceramics not only rebalanced the OPGI RANKL ratio of rBMSCs OVX at early stage, but also repressed RANKL induced osteoclast formation and expression of TRAP, DC  STAMP, V ATPase a3, and NFATcl. The synergistic effects of Sr and Si ions were further investigated as compared with those of similar concentrations of Sr and Si ions alone. Sr and Si ions possessed synergistic effects on osteogenesis, osteoclastogenesis, and angiogenesis, attributed to the dominant effects of Sr ions on enhancing angiogenesis and repressing osteoclastogenesis, and the dominant effects of Si ions on stimulating osteogenesis. The in vivo study using critical size mandibular defects of OVX rat models showed that SMS bioceramics could significantly enhance bone formation and mineralization compared with beta TCP bioceramics. Our results are the first to elucidate the specific effect of each ion from bioceramics on osteogenesis, osteoclastogenesis and angiogenesis for osteoporotic bone regeneration, paving the way for the design of functional biomaterials with complex compositions for tissue engineering and regenerative medicine.
   Statement of significance
   Bioactive ions released from bioceramics play important roles for bone regeneration; however, it is unclear how each of ionic compositions in complex bioceramics exerts its specific effect on bone regeneration. The aim of present study is to elucidate the functional effects of Sr and Si ions in complex bioceramics on the regeneration of osteoporotic bone. A model bioceramic with Sr and Si containing components (SMS) was successfully fabricated and the effects of ionic products from SMS bioceramics on the osteogenic, osteoclastic and angiogenic differentiation of rBMSCs OVX and RANKL induced osteoclasts were investigated. The results showed that SMS bioceramics could enhance ALP activity and expression of Col 1, OCN, Runx2 and angiogenic factors including VEGF and Ang 1. SMS bioceramics not only rebalanced the ratio of OPG/RANKL of OVX BMSCs at early stage, but also repressed RANKLinduced osteoclast formation and expression of TRAP, DC STAMP, V ATPase a3, and NFATcl. The synergistic effects of Sr and Si ions were further investigated as compared with the similar concentration of Sr and Si ions alone. It was found that Sr and Si ions possessed synergistic effects on osteogenesis, osteoclastogenesis and angiogenesis, attributed to the dominant effects of Sr ions on enhancing angiogenesis and repressing osteoclastogenesis, and the dominant effects of Si ions on stimulating osteogenesis. The in vivo study using critical size mandibular defects of OVX rat models showed that SMS bioceramics could significantly enhance bone formation and mineralization as compared with beta TCP bioceramics. It is suggested that SMS bioceramics may be a promising biomaterial for osteoporotic bone regeneration.
   To our knowledge, this is the osteogenesis, osteoclastogenesis design functional biomaterials medicine. first time to elucidate the specific effect of each ion from bioceramics on and angiogenesis for osteoporotic bone regeneration, paving the way to with complex compositions for tissue engineering and regenerative (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Mao, Lixia; Xia, Lunguo; Liu, Jiaqiang; Jiang, Lingyong; Fang, Bing] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.
   [Chang, Jiang; Wu, Chengtie] Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai
   Institute of Ceramics, CAS
RP Fang, B (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 9, Ctr Craniofacial Orthodont,Dept Oral & Craniomaxi, Shanghai, Peoples R China.; Wu, CT (通讯作者)，Chinese Acad Sci, Shanghai Inst Ceram, State Key Lab High Performance Ceram & Superfine, Shanghai, Peoples R China.
EM chengtiewu@mail.sic.ac.cn; fangbing@sjtu.edu.cn
FU National Key Research and Development Program of China [2016YFC1100200];
   Key Research Program of Frontier Sciences, CAS [QYZDB SSW SYS027];
   National Natural Science Foundation of China [81671017, 81400554,
   81371178]; Science and Technology Commission of Shanghai Municipality
   [16DZ2260603]; Shanghai Sailing Program [14YF1402400]; Excellent Youth
   Program of Ninth People's Hospital Affiliated to Shanghai Jiao Tong
   University School of Medicine [jyyq08201621]
FX This work was supported by the National Key Research and Development
   Program of China (2016YFC1100200), Key Research Program of Frontier
   Sciences, CAS (QYZDB SSW SYS027), National Natural Science Foundation of
   China (81671017, 81400554, 81371178), Science and Technology Commission
   of Shanghai Municipality (16DZ2260603), Shanghai Sailing Program
   (14YF1402400) and Excellent Youth Program of Ninth People's Hospital
   Affiliated to Shanghai Jiao Tong University School of Medicine
   (jyyq08201621).
CR Aoyama E, 2015, BONE, V73, P242, DOI 10.1016/j.bone.2014.12.058
   Beck GR, 2012, NANOMED NANOTECHNOL, V8, P793, DOI 10.1016/j.nano.2011.11.003
   Bose S, 2013, TRENDS BIOTECHNOL, V31, P594, DOI 10.1016/j.tibtech.2013.06.005
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Chen X., 2017, ONCOTARGET
   Dong YH, 2017, CELL SIGNAL, V34, P55, DOI 10.1016/j.cellsig.2017.03.004
   Ducy P, 1996, NATURE, V382, P448, DOI 10.1038/382448a0
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Fernandes JS, 2016, ACTA BIOMATER, V44, P168, DOI 10.1016/j.actbio.2016.08.042
   Fielding GA, 2014, J BIOMED MATER RES A, V102, P2417, DOI 10.1002/jbm.a.34909
   Gao Y, 2014, TISSUE CELL, V46, P450, DOI 10.1016/j.tice.2014.08.006
   Gentleman E, 2010, BIOMATERIALS, V31, P3949, DOI 10.1016/j.biomaterials.2010.01.121
   Guan M, 2012, NAT MED, V18, P456, DOI 10.1038/nm.2665
   Guo XJ, 2016, INT J BIOL SCI, V12, P1511, DOI 10.7150/ijbs.16499
   Han PP, 2013, BIOMATER SCI UK, V1, P379, DOI 10.1039/c2bm00108j
   He YX, 2011, BONE, V48, P1388, DOI 10.1016/j.bone.2011.03.720
   Jee W. S. S., 2001, Journal of Musculoskeletal & Neuronal Interactions, V1, P193
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Lee MH, 1999, J CELL BIOCHEM, V73, P114, DOI 10.1002/(SICI)1097 4644(19990401)73:1<114::AID JCB13>3.3.CO;2 D
   Lerner UH, 2006, J DENT RES, V85, P584, DOI 10.1177/154405910608500703
   Li H, 2013, ACTA BIOMATER, V9, P6981, DOI 10.1016/j.actbio.2013.02.014
   Lin KL, 2013, BIOMATERIALS, V34, P10028, DOI 10.1016/j.biomaterials.2013.09.056
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Liu XQ, 2014, BIOMATERIALS, V35, P5721, DOI 10.1016/j.biomaterials.2014.04.006
   Liu YQ, 2012, J CLIN INVEST, V122, P3101, DOI 10.1172/JCI61209
   Looney M, 2013, J BIOMATER APPL, V27, P511, DOI 10.1177/0885328211413621
   Ni SY, 2007, J BIOMED MATER RES B, V80B, P174, DOI 10.1002/jbm.b.30582
   O'Donnell MD, 2010, ACTA BIOMATER, V6, P2382, DOI 10.1016/j.actbio.2010.01.006
   Ohara N, 2004, BIOMATERIALS, V25, P1749, DOI 10.1016/j.biomaterials.2003.08.022
   Peng SL, 2011, BONE, V49, P1290, DOI 10.1016/j.bone.2011.08.031
   Peng SL, 2009, CELL PHYSIOL BIOCHEM, V23, P165, DOI 10.1159/000204105
   Rajabi M, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020034
   Ratnayake J T., 2016, J Biomed Mater Res B Appl Biomater
   Roy M, 2012, J BIOMED MATER RES A, V100A, P2450, DOI 10.1002/jbm.a.34181
   Rybchyn MS, 2011, J BIOL CHEM, V286, P23771, DOI 10.1074/jbc.M111.251116
   Saidak Z, 2012, PHARMACOL THERAPEUT, V136, P216, DOI 10.1016/j.pharmthera.2012.07.009
   Saidak Z, 2012, AGING CELL, V11, P467, DOI 10.1111/j.1474 9726.2012.00804.x
   Santocildes Romero ME, 2015, J TISSUE ENG REGEN M, V9, P619, DOI 10.1002/term.2003
   Shen QP, 2013, J PHARM PHARMACOL, V65, P1005, DOI 10.1111/jphp.12054
   Shie MY, 2013, BIOMATERIALS, V34, P6589, DOI 10.1016/j.biomaterials.2013.05.075
   Tat SK, 2011, BONE, V49, P559, DOI 10.1016/j.bone.2011.06.005
   Tella SH, 2014, J STEROID BIOCHEM, V142, P155, DOI 10.1016/j.jsbmb.2013.09.008
   Le TDH, 2016, MAT SCI ENG C MATER, V59, P471, DOI 10.1016/j.msec.2015.10.040
   Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725
   Vahabzadeh S, 2015, J MATER CHEM B, V3, P8973, DOI 10.1039/c5tb01081k
   Wang C, 2013, BIOMATERIALS, V34, P64, DOI 10.1016/j.biomaterials.2012.09.021
   Wang Q, 2014, ASIAN PAC J TROP MED, V7, P358, DOI 10.1016/S1995 7645(14)60055 9
   Wilson A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471 2164 11 229
   Winet H, 1996, BONE, V19, pS39, DOI 10.1016/S8756 3282(96)00133 0
   Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075
   Wu CT, 2014, ACS APPL MATER INTER, V6, P4264, DOI 10.1021/am4060035
   Wu CT, 2012, ACTA BIOMATER, V8, P3805, DOI 10.1016/j.actbio.2012.06.023
   Wu T, 2016, J BIOMED MATER RES A, V104, P3004, DOI 10.1002/jbm.a.35841
   Xia LG, 2016, SCI REP UK, V6, DOI 10.1038/srep22005
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xu S, 2008, BIOMATERIALS, V29, P2588, DOI 10.1016/j.biomaterials.2008.03.013
   Zeng DL, 2012, TISSUE ENG PT A, V18, P871, DOI [10.1089/ten.tea.2011.0379, 10.1089/ten.TEA.2011.0379]
   Zhai ZJ, 2014, BIOMATERIALS, V35, P6299, DOI 10.1016/j.biomaterials.2014.04.044
   Zhang ML, 2012, J BIOMED MATER RES A, V100A, P2979, DOI 10.1002/jbm.a.34246
   Zhang WJ, 2016, ACTA BIOMATER, V33, P290, DOI 10.1016/j.actbio.2016.01.042
   Zhao J, 2012, TISSUE ENG PT A, V18, P185, DOI [10.1089/ten.tea.2011.0297, 10.1089/ten.TEA.2011.0297]
   Zheng H, 2004, CALCIFIED TISSUE INT, V74, P194, DOI 10.1007/s00223 003 0004 x
   Zhou X., 2017, J BIOMED MAT RES A
NR 63
TC 266
Z9 280
U1 7
U2 348
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742 7061
EI 1878 7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD OCT 1
PY 2017
VL 61
BP 217
EP 232
DI 10.1016/j.actbio.2017.08.015
PG 16
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA FI5PD
UT WOS:000412035400018
PM 28807800
DA 2025 08 17
ER

PT J
AU Wang, YQ
   Wang, NX
   Luo, Y
   Yu, CY
   Xiao, JH
AF Wang, Yi Qing
   Wang, Nuo Xin
   Luo, Yi
   Yu, Chang Yin
   Xiao, Jian Hui
TI Ganoderal A effectively induces osteogenic differentiation of human
   amniotic mesenchymal stem cells via cross talk between Wnt/β catenin and
   BMP/SMAD signaling pathways
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Human amniotic mesenchymal stem cell; Ganoderal A; Osteogenic
   differentiation; Wnt/beta catenin signaling; BMP/SMAD signaling
ID PROMOTES; BETA
AB Osteogenic inducers play central roles in effective stem cell based treatment of bone defects/losses. However, the current routine osteogenic inducer is a cocktail comprising three components that must be improved due to low induction efficiency and side effects. Therefore, there is an urgent need to develop safer and more effective osteoinducers. Herein, we demonstrated the osteogenic effect of Ganoderal A (GD A), a tetracyclic triterpenoid compound from Ganoderma lucidum. GD A showed no cytotoxicity toward human amniotic mesenchymal stem cells (hAMSCs) at doses of 0.001 10 mu M; furthermore, 0.01 mu M GD A significantly induced the generation of osteoblast specific markers, such as alkaline phosphatase, and calcium deposition in hAMSCs. At molecular levels, GD A promoted the expression of multiple osteoblast differentiation markers, such as RUNX2, OSX, OPN, ALP, OCN, and COL1 alpha 1. Both Wnt/beta catenin and BMP/SMAD signaling were shown as active during hAMSC osteodifferentiation. Furthermore, specific blocking of both signals by KYA1797K and SB431542 significantly inhibited alkaline phosphatase secretion and RUNX2 and ALP expression when used alone or in combination. Meanwhile, both signals were also blocked. These findings suggest that GD A induces hAMSC differentiation into osteoblasts through signaling cross talk between Wnt/beta catenin and BMP/SMAD. Taken together, GD A is a safe, effective, and novel osteoinducer and might be used for stem cell based therapy for bone defects/losses.
C1 [Wang, Yi Qing; Wang, Nuo Xin; Luo, Yi; Xiao, Jian Hui] Zunyi Med Univ, Zunyi Municiptal Key Lab Med Biotechnol, Affiliated Hosp, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.
   [Wang, Nuo Xin; Luo, Yi; Xiao, Jian Hui] Zunyi Med Univ, Ctr Translat Med, Affiliated Hosp, Zunyi 563003, Guizhou, Peoples R China.
   [Yu, Chang Yin] Zunyi Med Univ, Dept Neurol, Affiliated Hosp, Zunyi 563003, Guizhou, Peoples R China.
C3 Zunyi Medical University; Zunyi Medical University; Zunyi Medical
   University
RP Xiao, JH (通讯作者)，Zunyi Med Univ, Zunyi Municiptal Key Lab Med Biotechnol, Affiliated Hosp, 149 Dalian Rd, Zunyi 563003, Guizhou, Peoples R China.; Yu, CY (通讯作者)，Zunyi Med Univ, Dept Neurol, Affiliated Hosp, Zunyi 563003, Guizhou, Peoples R China.
EM yuchangyin68@163.com; jhxiao@zmu.edu.cn
RI Wang, Yiqing/NCV 5383 2025; Xiao, Jian Hui/JTT 7152 2023
OI Xiao, Jian Hui/0000 0003 2563 9153
FU National Natural Science Foundation of China, P.R.China [81660363,
   81260278, 31960191]; Science and Technology Innovation Leading Academics
   of National High level Personnel of Special Support Program, P.R. China
   [GKFZ 2018 29]; Guizhou High Level Innovative Talent Support Program,
   P.R. China [QKH RC 20154028]; S&T Foundation of Guizhou, P.R. China
   [QKH 2017 1422]
FX The authors are grateful to financial support from National Natural
   Science Foundation of China, P.R.China (Nos. 81660363; 81260278;
   31960191), Science and Technology Innovation Leading Academics of
   National High level Personnel of Special Support Program, P.R. China
   (No. GKFZ 2018 29), Guizhou High Level Innovative Talent Support
   Program, P.R. China (No. QKH RC 20154028), and S&T Foundation of
   Guizhou, P.R. China (No. QKH 2017 1422).
CR Ahmadzadeh A, 2016, CELL TISSUE RES, V363, P321, DOI 10.1007/s00441 015 2300 y
   Bian Q, 2012, MENOPAUSE, V19, P225, DOI 10.1097/gme.0b013e3182272ef1
   Chen Y, 2007, J BIOL CHEM, V282, P526, DOI 10.1074/jbc.M602700200
   Fitri AR, 2018, J PERIODONTOL, V89, P596, DOI 10.1002/JPER.17 0471
   Gaur T, 2005, J BIOL CHEM, V280, P33132, DOI 10.1074/jbc.M500608200
   Gong YS, 2006, J ASIAN NAT PROD RES, V8, P649, DOI 10.1080/10286020500246063
   Gu QH, 2015, PHARMACOL RES, V97, P70, DOI 10.1016/j.phrs.2015.04.004
   Gu YQ, 2016, SCI REP UK, V6, DOI 10.1038/srep25282
   Jakoi A M, 2015, Musculoskelet Surg, V99, P171, DOI 10.1007/s12306 015 0351 6
   Kargozar S, 2019, APPL SCI BASEL, V9, DOI 10.3390/app9010174
   Kmiecik G, 2015, STEM CELL REV REP, V11, P570, DOI 10.1007/s12015 014 9569 1
   Li XD, 2011, J ETHNOPHARMACOL, V134, P268, DOI 10.1016/j.jep.2010.11.075
   Li Y, 2015, EXP THER MED, V9, P2072, DOI 10.3892/etm.2015.2388
   Lindenmair Andrea, 2012, Cells, V1, P1061, DOI 10.3390/cells1041061
   Lindequist U, 2015, PHYTOCHEMISTRY, V114, P102, DOI 10.1016/j.phytochem.2015.02.018
   Liu RM, 2016, EXP CELL RES, V345, P218, DOI 10.1016/j.yexcr.2016.05.019
   Liu RM, 2015, CHEM BIOL INTERACT, V240, P134, DOI 10.1016/j.cbi.2015.08.005
   Lyssiotis CA, 2011, ANGEW CHEM INT EDIT, V50, P200, DOI 10.1002/anie.201004284
   MORIGIWA A, 1986, CHEM PHARM BULL, V34, P3025
   Pantovic A, 2013, BONE, V52, P524, DOI 10.1016/j.bone.2012.10.024
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Shu B, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 07633 7
   Tao K, 2016, TOXICOL LETT, V240, P68, DOI 10.1016/j.toxlet.2015.10.007
   Tsuno H, 2012, MAT SCI ENG C MATER, V32, P2452, DOI 10.1016/j.msec.2012.07.021
   Wang YJ, 2015, BIOTECHNOL ADV, V33, P1626, DOI 10.1016/j.biotechadv.2015.08.005
   Wu CC, 2018, EXP THER MED, V16, P4030, DOI 10.3892/etm.2018.6735
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yang YQ, 2014, PHYTOTHER RES, V28, P1, DOI 10.1002/ptr.4959
   Yu SB, 2018, EVID BASED COMPL ALT, V2018, DOI 10.1155/2018/5892957
   Zhang LT, 2019, LIFE SCI, V232, DOI 10.1016/j.lfs.2019.116669
   Zhang M, 2009, J CELL BIOCHEM, V108, P896, DOI 10.1002/jcb.22319
   Zhao J, 2008, BIOCHEM BIOPH RES CO, V369, P444, DOI 10.1016/j.bbrc.2008.02.054
   Zhao XL, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 10929 3
   Zhong JJ, 2009, ADV BIOCHEM ENG BIOT, V113, P79, DOI 10.1007/10_2008_26
   Zhou HB, 2009, EXP CELL RES, V315, P2953, DOI 10.1016/j.yexcr.2009.07.030
NR 35
TC 29
Z9 31
U1 1
U2 15
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY LES MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY LES MOULINEAUX, FRANCE
SN 0753 3322
EI 1950 6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD MAR
PY 2020
VL 123
AR 109807
DI 10.1016/j.biopha.2019.109807
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA KF8HB
UT WOS:000509476800040
PM 31896066
OA gold
DA 2025 08 17
ER

PT J
AU Kamer, AR
   El Ghorab, N
   Marzec, N
   Margarone, JE
   Dziak, R
AF Kamer, AR
   El Ghorab, N
   Marzec, N
   Margarone, JE
   Dziak, R
TI Nicotine induced proliferation and cytokine release in osteoblastic
   cells
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
ID PERIODONTAL DISEASE; CIGARETTE SMOKING; BONE LOSS; OSTEOPOROSIS;
   SMOKERS; METABOLISM; NONSMOKERS; ESTROGEN; HORMONE; RISK
AB Smoking has deleterious effects on osteoporosis and periodontitis both characterized by bone loss. Smoking also interferes with the protective effect that hormone replacement therapy (HRT) has on bone loss. Our study investigated two mechanisms by which smoking may affect bone metabolism: nicotine induced proliferation and nicotine induced cytokine secretion in osteoblasts. Two osteoblastic cell models were used: mouse osteoblasts derived from mouse calvaria and human osteoblasts. Thymidine incorporation and immunoassays were used to evaluate proliferation, interleukin 6 (IL 6) and tumor necrosis factor alpha (TNF alpha) secretion. Parametric and nonparametric statistical analyses were used for comparisons. The results showed that nicotine induced stimulation and inhibition of proliferation in both osteoblastic cell models. In human osteoblasts, the proliferative and inhibitory effects were also donor dependent. IL 6 secretion showed different patterns in mouse and human osteoblasts. In mouse osteoblasts, nicotine significantly increased IL 6 secretion and estradiol significantly inhibited the nicotine induced IL 6 release. In human osteoblasts, cells derived from one subject did not respond to nicotine. However, in the second sample, nicotine increased secretion of IL 6 but estradiol did not oppose this effect. In human osteoblasts, nicotine also induced an increase in the TNF alpha secretion and estradiol opposed this increase. These results suggest that nicotine affects bone metabolism by modulating proliferation, and IL 6 and TNF alpha secretion. These studies provide a possible explanation for differences in bone loss among subjects who smoke and offer a possible mechanism for the oppositional effect of smoking on HRT in subjects with bone loss.
C1 NYU, Coll Dent, Dept Periodont & Basic Sci, New York, NY 10010 USA.
   SUNY Buffalo, Dept Oral Biol, Buffalo, NY 14260 USA.
   SUNY Buffalo, Dept Oral Surg, Buffalo, NY 14260 USA.
C3 New York University; State University of New York (SUNY) System;
   University at Buffalo, SUNY; State University of New York (SUNY) System;
   University at Buffalo, SUNY
RP Kamer, AR (通讯作者)，NYU, Coll Dent, Dept Periodont, 345 E 24th St, New York, NY 10010 USA.
EM ark5@nyu.edu
OI Kamer, Angela R/0000 0003 4299 8238
CR BERESFORD JN, 1984, METAB BONE DIS RELAT, V5, P229, DOI 10.1016/0221 8747(84)90064 X
   Bergström J, 2000, J PERIODONTOL, V71, P1338, DOI 10.1902/jop.2000.71.8.1338
   BROULIK PD, 1993, HORM METAB RES, V25, P219, DOI 10.1055/s 2007 1002080
   Calsina G, 2002, J CLIN PERIODONTOL, V29, P771
   Carpio LC, 1999, PROSTAG LEUKOTR ESS, V61, P267, DOI 10.1054/plef.1999.0100
   DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298
   DANIELL HW, 1972, J AMER MED ASSOC, V221, P509, DOI 10.1001/jama.1972.03200180051022
   DZIAK R, 1993, J PERIODONTOL, V64, P407
   ELGHORAB N, 1996, J DENT RES, V75, P48
   ERIKSEN ER, 1988, SCIENCE, V244, P84
   FANG MA, 1991, BONE, V12, P283, DOI 10.1016/8756 3282(91)90077 V
   FELDMAN RS, 1983, J PERIODONTOL, V54, P481, DOI 10.1902/jop.1983.54.8.481
   GROSSI SG, 1995, J PERIODONTOL, V66, P23, DOI 10.1902/jop.1995.66.1.23
   Gruber CJ, 2002, NEW ENGL J MED, V346, P340, DOI 10.1056/NEJMra000471
   HOFFMANN D, 1981, CANCER RES, V41, P4305
   HOROWITZ MC, 1993, SCIENCE, V260, P626, DOI 10.1126/science.8480174
   ILL PO, 1993, REV RHUM, V60, P280
   Jansson LE, 2002, J PERIODONTOL, V73, P602, DOI 10.1902/jop.2002.73.6.602
   Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756 3282(98)00077 5
   KRALL EA, 1991, J BONE MINER RES, V6, P331
   LINDEN GJ, 1994, J PERIODONTOL, V65, P718, DOI 10.1902/jop.1994.65.7.718
   MARTINEZCANUT P, 1995, J CLIN PERIODONTOL, V22, P743, DOI 10.1111/j.1600 051X.1995.tb00256.x
   Mueck AO, 2003, ARZNEIMITTELFORSCH, V53, P1
   PELLETIER O, 1970, AM J CLIN NUTR, V23, P520
   PREBER H, 1995, J CLIN PERIODONTOL, V22, P946, DOI 10.1111/j.1600 051X.1995.tb01800.x
   RAMP WK, 1991, P SOC EXP BIOL MED, V197, P36
   Saldanha JB, 2004, J PERIODONTOL, V75, P565, DOI 10.1902/jop.2004.75.4.565
   SHEN V, 1990, J BONE MINER RES, V5, P507, DOI 10.1002/jbmr.5650050513
   Tomar SL, 2000, J PERIODONTOL, V71, P743, DOI 10.1902/jop.2000.71.5.743
   TONETTI MS, 1995, J CLIN PERIODONTOL, V22, P229
   Walker LM, 2001, BONE, V28, P603, DOI 10.1016/S8756 3282(01)00427 6
NR 31
TC 51
Z9 59
U1 0
U2 4
PU PROFESSOR D A SPANDIDOS
PI ATHENS
PA 1, S MERKOURI ST, EDITORIAL OFFICE,, ATHENS 116 35, GREECE
SN 1107 3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD JAN
PY 2006
VL 17
IS 1
BP 121
EP 127
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 996SE
UT WOS:000234194100016
PM 16328020
DA 2025 08 17
ER

PT J
AU Leonard, MB
AF Leonard, Mary B.
TI Glucocorticoid induced osteoporosis in children: Impact of the
   underlying disease
SO PEDIATRICS
LA English
DT Article; Proceedings Paper
CT Workshop on Skeletal Effects of Pharmacologic Agents in Children
CY APR 14, 2005
CL Natl Inst Hlth, Bethesda, MD
SP Amer Soc Bone & Mineral Res, Natl Inst Child Hlth & Human Dev
HO Natl Inst Hlth
DE glucocorticoids; bone mineral density; bone mineral content;
   glucocorticoid induced osteoporosis; growth
ID INFLAMMATORY BOWEL DISEASE; BONE MINERAL DENSITY; CROHNS DISEASE;
   LONG TERM; INFLIXIMAB TREATMENT; OSTEOCLAST FORMATION; BODY COMPOSITION;
   MESSENGER RNA; FRACTURE RISK; YOUNG ADULTS
AB Glucocorticoids inhibit osteoblasts through multiple mechanisms, which results in significant reductions in bone formation. The growing skeleton may be especially vulnerable to adverse glucocorticoid effects on bone formation, which could possibly compromise trabecular and cortical bone accretion. Although decreased bone mineral density has been described in various pediatric disorders that require glucocorticoids, and a population  based study reported increased fracture risk in children who require > 4 courses of glucocorticoids, some of the detrimental bone effects attributed to glucocorticoids may be caused by the underlying inflammatory disease. For example, inflammatory cytokines that are elevated in chronic disease, such as tumor necrosis factor alpha, suppress bone formation and promote bone resorption through mechanisms similar to glucocorticoid  induced osteoporosis. Summarized in this review are changes in bone density and dimensions during growth, the effects of glucocorticoids and cytokines on bone cells, the potential confounding effects of the underlying inflammatory  disease process, and the challenges in interpreting dual  energy x  ray absorptiometry results in children with altered growth and development in the setting of glucocorticoid therapy. Two recent studies of children treated with chronic glucocorticoids highlight the differences in the effect of underlying disease, as well as the importance of associated alterations in growth and development.
C1 Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA.
   Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania
RP Leonard, MB (通讯作者)，Childrens Hosp Philadelphia, Dept Pediat, 34th St & Civ Ctr Blvd,CHOP N,Room 1564, Philadelphia, PA 19104 USA.
EM leonard@email.chop.edu
OI Leonard, Mary/0000 0002 8972 6582
FU NCRR NIH HHS [M01RR00240] Funding Source: Medline; NIDDK NIH HHS
   [K08 DK02523, R01 DK060030, R03 DK058200] Funding Source: Medline
CR [Anonymous], 2000, NIH Consens Statement, V17, P1
   Baldassano RN, 1999, GASTROENTEROL CLIN N, V28, P445, DOI 10.1016/S0889 8553(05)70064 9
   Baron R., 2003, GEN PRINCIPLES BONE, P1
   Bernstein CN, 2000, ANN INTERN MED, V133, P795, DOI 10.7326/0003 4819 133 10 200011210 00012
   Bernstein M, 2005, AM J GASTROENTEROL, V100, P2031, DOI 10.1111/j.1572 0241.2005.50219.x
   Bischoff SC, 1997, AM J GASTROENTEROL, V92, P1157
   Boot AM, 1997, PEDIATR PULM, V24, P379, DOI 10.1002/(SICI)1099 0496(199712)24:6<379::AID PPUL1>3.0.CO;2 C
   Briot K, 2005, ANN RHEUM DIS, V64, P1137, DOI 10.1136/ard.2004.028670
   BRODEHL J, 1991, EUR J PEDIATR, V150, P380, DOI 10.1007/BF02093714
   Burnham JM, 2005, AM J CLIN NUTR, V82, P413, DOI 10.1093/ajcn/82.2.413
   Burnham JM, 2004, J BONE MINER RES, V19, P1961, DOI 10.1359/JBMR.040908
   Burnham Jon M, 2004, Curr Rheumatol Rep, V6, P70, DOI 10.1007/s11926 004 0086 0
   CALKINS BM, 1984, DIGEST DIS SCI, V29, P913, DOI 10.1007/BF01312480
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Crabtree NJ, 2004, BONE, V35, P965, DOI 10.1016/j.bone.2004.06.009
   Daniel V, 1997, CLIN NEPHROL, V47, P289
   Daniels MW, 2003, TRANSPLANTATION, V76, P673, DOI 10.1097/01.TP.0000076627.70050.53
   DELANY AM, 1995, J CELL BIOCHEM, V57, P488, DOI 10.1002/jcb.240570314
   Dempster DW, 1997, J ENDOCRINOL, V154, P397, DOI 10.1677/joe.0.1540397
   Donahue HJ, 2000, BONE, V26, P417, DOI 10.1016/S8756 3282(00)00245 3
   Foster BJ, 2004, AM J CLIN NUTR, V80, P1334, DOI 10.1093/ajcn/80.5.1334
   Franchimont N, 2004, ALIMENT PHARM THER, V20, P607, DOI 10.1111/j.1365 2036.2004.02152.x
   Fries W, 1998, AM J GASTROENTEROL, V93, P2339, DOI 10.1016/S0002 9270(98)00566 8
   Gafni RI, 2004, J PEDIATR US, V144, P253, DOI 10.1016/j.jpeds.2003.08.054
   GARN SM, 1972, AM J PHYS ANTHROPOL, V36, P377, DOI 10.1002/ajpa.1330360308
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Gilsanz V, 1997, J CLIN ENDOCR METAB, V82, P1603, DOI 10.1210/jc.82.5.1603
   GILSANZ V, 1991, NEW ENGL J MED, V325, P1597, DOI 10.1056/NEJM199112053252302
   Gilsanz V, 1998, J CLIN ENDOCR METAB, V83, P1420, DOI 10.1210/jc.83.5.1420
   GIUSTINA A, 1995, J CLIN ENDOCR METAB, V80, P122, DOI 10.1210/jc.80.1.122
   Gokhale R, 1998, GASTROENTEROLOGY, V114, P902, DOI 10.1016/S0016 5085(98)70309 9
   Goulding A, 2000, INT J OBESITY, V24, P627, DOI 10.1038/sj.ijo.0801207
   Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363
   Han YF, 2004, P NATL ACAD SCI USA, V101, P16689, DOI 10.1073/pnas.0407429101
   Han ZH, 1996, J BONE MINER RES, V11, P1967
   HILDEBRAND H, 1994, J PEDIATR GASTR NUTR, V18, P165, DOI 10.1097/00005176 199402000 00008
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Högler W, 2003, BONE, V33, P771, DOI 10.1016/S8756 3282(03)00266 7
   Högler W, 2003, J PEDIATR US, V143, P81, DOI 10.1016/S0022 3476(03)00187 2
   Horlick M, 2004, PEDIATRICS, V114, pE337, DOI 10.1542/peds.2004 0301
   Hyams JS, 1997, J PEDIATR GASTR NUTR, V24, P289, DOI 10.1097/00005176 199703000 00011
   Ikeda S, 2003, BONE, V33, P779, DOI 10.1016/S8756 3282(03)00263 1
   Itonaga I, 2004, BONE, V34, P57, DOI 10.1016/j.bone.2003.08.008
   Klaus J, 2002, GUT, V51, P654, DOI 10.1136/gut.51.5.654
   KLEIN GL, 1995, BONE, V17, P455, DOI 10.1016/8756 3282(95)00279 1
   Kontulainen SA, 2005, J BONE MINER RES, V20, P1202, DOI 10.1359/JBMR.050214
   Kudo O, 2002, J PATHOL, V198, P220, DOI 10.1002/path.1190
   Kudo O, 2003, BONE, V32, P1, DOI 10.1016/S8756 3282(02)00915 8
   Kugathasan S, 2003, J PEDIATR US, V143, P525, DOI 10.1067/S0022 3476(03)00444 X
   LASHNER BA, 1995, GASTROENTEROL CLIN N, V24, P467
   Leonard MB, 2004, AM J CLIN NUTR, V80, P514, DOI 10.1093/ajcn/80.2.514
   Leonard MB, 2002, PEDIATR CLIN N AM, V49, P143, DOI 10.1016/S0031 3955(03)00113 5
   Leonard MB, 2004, NEW ENGL J MED, V351, P868, DOI 10.1056/NEJMoa040367
   Loftus EV, 2002, GASTROENTEROLOGY, V123, P468, DOI 10.1053/gast.2002.34779
   MUNKHOLM P, 1992, SCAND J GASTROENTERO, V27, P609, DOI 10.3109/00365529209000127
   Neu CM, 2001, OSTEOPOROSIS INT, V12, P538, DOI 10.1007/s001980170074
   Ogden CL, 2002, JAMA J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.288.14.1728
   Ortoft G, 1999, J BONE MINER RES, V14, P710, DOI 10.1359/jbmr.1999.14.5.710
   PARFITT AM, 1994, OSTEOPOROSIS INT, V4, P382, DOI 10.1007/BF01622201
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Pereira RC, 2002, BONE, V30, P685, DOI 10.1016/S8756 3282(02)00687 7
   Petit MA, 2005, BONE, V36, P568, DOI 10.1016/j.bone.2004.12.003
   Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647
   Pollak RD, 1998, AM J GASTROENTEROL, V93, P1483
   Rall LC, 2004, RHEUMATOLOGY, V43, P1219, DOI 10.1093/rheumatology/keh321
   Rauch F, 1999, BONE, V25, P69, DOI 10.1016/S8756 3282(99)00104 0
   Rauch F, 2001, PEDIATR RES, V50, P309, DOI 10.1203/00006450 200109000 00003
   RUBIN CT, 1992, CALCIFIED TISSUE INT, V50, P306, DOI 10.1007/BF00301627
   Ryan BM, 2004, ALIMENT PHARM THER, V20, P851, DOI 10.1111/j.1365 2036.2004.02097.x
   Schiessl H, 1998, BONE, V22, P1, DOI 10.1016/S8756 3282(97)00223 8
   Schoenau E, 2002, J BONE MINER RES, V17, P1095, DOI 10.1359/jbmr.2002.17.6.1095
   SEENE T, 1994, J STEROID BIOCHEM, V50, P1, DOI 10.1016/0960 0760(94)90165 1
   Semeao EJ, 1999, INFLAMM BOWEL DIS, V5, P161, DOI 10.1097/00054725 199908000 00003
   Sylvester FA, 2002, J BONE MINER RES, V17, P695, DOI 10.1359/jbmr.2002.17.4.695
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2003, GASTROENTEROLOGY, V125, P1591, DOI 10.1053/j.gastro.2003.09.027
   Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913
   Varghese S, 2002, J PEDIATR GASTR NUTR, V35, P641, DOI 10.1097/00005176 200211000 00010
   Vestergaard P, 2000, GUT, V46, P176, DOI 10.1136/gut.46.2.176
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   Wren TAL, 2005, J PEDIATR US, V146, P776, DOI 10.1016/j.jpeds.2005.01.028
NR 82
TC 101
Z9 109
U1 0
U2 5
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007 1098 USA
SN 0031 4005
EI 1098 4275
J9 PEDIATRICS
JI Pediatrics
PD MAR
PY 2007
VL 119
SU S
BP S166
EP S174
DI 10.1542/peds.2006 2023J
PG 9
WC Pediatrics
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Pediatrics
GA 186DS
UT WOS:000247759900008
PM 17332238
DA 2025 08 17
ER

PT J
AU Dudakovic, A
   Wiemer, AJ
   Lamb, KM
   Vonnahme, LA
   Dietz, SE
   Hohl, RJ
AF Dudakovic, Amel
   Wiemer, Andrew J.
   Lamb, Kimberly M.
   Vonnahme, Laura A.
   Dietz, Sara E.
   Hohl, Raymond J.
TI Inhibition of geranylgeranyl diphosphate synthase induces apoptosis
   through multiple mechanisms and displays synergy with inhibition of
   other isoprenoid biosynthetic enzymes
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID HMG COA REDUCTASE; BONE RESORPTION; IN VITRO; ZOLEDRONIC ACID;
   CANCER CELLS; FARNESYL; BISPHOSPHONATES; PATHWAY; LOVASTATIN; THERAPY
AB Inhibitors of isoprenoid synthesis are widely used for treatment of human diseases, including hypercholesterolemia and osteoporosis, and they have the potential to be useful for treatment of cancer. Statin drugs inhibit the enzyme HMG CoA reductase, whereas nitrogenous bisphosphonates have more recently been shown to inhibit farnesyl disphosphate synthase. In addition, our laboratory has recently developed several potent and specific bisphosphonate inhibitors of geranylgeranyl diphosphate synthase, including digeranyl bisphosphonate. Because all three enzymes fall in the same biosynthetic pathway and many of the biological effects are due to depletion of downstream products, we hypothesized that simultaneous inhibition of these enzymes would result in synergistic growth inhibition. In this study, we show that inhibition of geranylgeranyl diphosphate synthase induces apoptosis in K562 leukemia cells. This induction of apoptosis is in part dependent upon both geranylgeranyl diphosphate depletion and accumulation of farnesyl diphosphate. Combinations of either lovastatin or zoledronate with digeranyl bisphosphonate synergistically inhibited growth and induced apoptosis. These combinations also potently inhibited cellular geranylgeranylation. These results support the potential for combinations of multiple inhibitors of isoprene biosynthesis to inhibit cancer cell growth or metastasis at clinically achievable concentrations.
C1 [Dudakovic, Amel; Hohl, Raymond J.] Univ Iowa, Dept Pharmacol, Iowa City, IA 52242 USA.
   [Wiemer, Andrew J.; Hohl, Raymond J.] Univ Iowa, Interdisciplinary Program Mol & Cellular Biol, Iowa City, IA 52242 USA.
   [Lamb, Kimberly M.; Vonnahme, Laura A.; Dietz, Sara E.; Hohl, Raymond J.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; University of Iowa
RP Hohl, RJ (通讯作者)，Univ Iowa, Dept Pharmacol, SE 313 GH, Iowa City, IA 52242 USA.
EM raymond hohl@uiowa.edu
RI ; Wiemer, Andrew/C 2257 2009
OI Dudakovic, Amel/0000 0002 8850 3977; Wiemer, Andrew/0000 0002 3029 1780;
   Vonnahme, Laura/0000 0001 9781 5748
CR ANDERSEN JM, 1978, J BIOL CHEM, V253, P9024
   Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092 8674(00)80213 5
   BROWN MS, 1980, J LIPID RES, V21, P505
   Burridge K, 2006, NAT CELL BIOL, V8, P781, DOI 10.1038/ncb0806 781
   Caraglia M, 2004, ONCOGENE, V23, P6900, DOI 10.1038/sj.onc.1207814
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065 2571(84)90007 4
   Crick DC, 1997, BIOCHEM BIOPH RES CO, V237, P483, DOI 10.1006/bbrc.1997.7145
   DORSEY JK, 1968, J BIOL CHEM, V243, P4667
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Green JR, 2002, AM J CLIN ONCOL CANC, V25, pS3, DOI 10.1097/00000421 200212001 00002
   GRUNDY SM, 1988, NEW ENGL J MED, V319, P24
   Holstein SA, 2001, MOL CANCER THER, V1, P141
   Holstein SA, 2001, LEUKEMIA RES, V25, P651, DOI 10.1016/S0145 2126(00)00162 4
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Kuroda J, 2003, BLOOD, V102, P2229, DOI 10.1182/blood 2003 01 0305
   Lebowitz PF, 1997, CANCER RES, V57, P708
   LERNER EC, 1995, J BIOL CHEM, V270, P26770, DOI 10.1074/jbc.270.45.26770
   Lewis KA, 2005, LEUKEMIA RES, V29, P527, DOI 10.1016/j.leukres.2004.10.007
   Licata AA, 2005, ANN PHARMACOTHER, V39, P668, DOI 10.1345/aph.1E357
   Maalouf MA, 2007, BIOORGAN MED CHEM, V15, P1959, DOI 10.1016/j.bmc.2007.01.002
   Meigs TE, 1997, ARCH BIOCHEM BIOPHYS, V345, P1, DOI 10.1006/abbi.1997.0200
   Miquel K, 1998, J BIOL CHEM, V273, P26179, DOI 10.1074/jbc.273.40.26179
   PEREZSALA D, 1994, BIOCHEM BIOPH RES CO, V199, P1209, DOI 10.1006/bbrc.1994.1359
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Santini D, 2006, NAT CLIN PRACT ONCOL, V3, P325, DOI 10.1038/ncponc0520
   Schmidmaier R, 2006, ANTI CANCER DRUG, V17, P621, DOI 10.1097/01.cad.0000215058.85813.02
   Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963
   Shipman CM, 1997, BRIT J HAEMATOL, V98, P665, DOI 10.1046/j.1365 2141.1997.2713086.x
   Shull LW, 2006, BIOORGAN MED CHEM, V14, P4130, DOI 10.1016/j.bmc.2006.02.010
   Swanson KM, 2006, CURR CANCER DRUG TAR, V6, P15, DOI 10.2174/156800906775471743
   Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153
   Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312
   Tong HX, 2005, ANAL BIOCHEM, V336, P51, DOI 10.1016/j.ab.2004.09.024
   van Beek E, 1999, J BONE MINER RES, V14, P722, DOI 10.1359/jbmr.1999.14.5.722
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   VOZIYAN PA, 1993, BIOCHEM J, V295, P757, DOI 10.1042/bj2950757
   Wiemer AJ, 2007, BIOCHEM BIOPH RES CO, V353, P921, DOI 10.1016/j.bbrc.2006.12.094
NR 40
TC 41
Z9 47
U1 0
U2 5
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3995 USA
SN 0022 3565
EI 1521 0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD MAR
PY 2008
VL 324
IS 3
BP 1028
EP 1036
DI 10.1124/jpet.107.132217
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 266OH
UT WOS:000253445200017
PM 18083912
DA 2025 08 17
ER

PT J
AU Marycz, K
   Tomaszewski, KA
   Kornicka, K
   Henry, BM
   Wronski, S
   Tarasiuk, J
   Maredziak, M
AF Marycz, Krzysztof
   Tomaszewski, Krzysztof A.
   Kornicka, Katarzyna
   Henry, Brandon Michael
   Wronski, Sebastian
   Tarasiuk, Jacek
   Maredziak, Monika
TI Metformin Decreases Reactive Oxygen Species, Enhances Osteogenic
   Properties of Adipose Derived Multipotent Mesenchymal Stem Cells In
   Vitro, and Increases Bone Density In Vivo
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID ANTIDIABETIC DRUG METFORMIN; INFLAMMATORY RESPONSE; PROTEIN KINASE;
   CANCER; DIFFERENTIATION; INHIBITION; GROWTH; ACTIVATION; OSTEOBLAST;
   PATHWAY
AB Due to its pleiotropic effects, the commonly used drug metformin has gained renewed interest among medical researchers. While metformin is mainly used for the treatment of diabetes, recent studies suggest that it may have further application in anticancer and antiaging therapies. In this study, we investigated the proliferative potential, accumulation of oxidative stress factors, and osteogenic and adipogenic differentiation potential of mouse adipose derived stem cells (MuASCs) isolated from mice treated with metformin for 8 weeks. Moreover, we investigated the influence of metformin supplementation on mice bone density and bone element composition. The ASCs isolated from mice who were treated with metformin for 8 weeks showed highest proliferative potential, generated a robust net of cytoskeletal projections, had reduced expression of markers associated with cellular senescence, and decreased amount of reactive oxygen species in comparison to control group. Furthermore, we demonstrated that these cells possessed greatest osteogenic differentiation potential, while their adipogenic differentiation ability was reduced. We also demonstrated that metformin supplementation increases bone density in vivo. Our result stands as a valuable source of data regarding the in vivo influence of metformin on ASCs and bone density and supports a role for metformin in regenerative medicine.
C1 [Marycz, Krzysztof; Kornicka, Katarzyna] Wroclaw Univ Environm & Life Sci, Electron Microscopy Lab, 5b Kozuchowska St, PL 51631 Wroclaw, Poland.
   [Marycz, Krzysztof; Maredziak, Monika] Wroclaw Res Ctr EIT, 147 Stablowicka St, PL 54066 Wroclaw, Poland.
   [Tomaszewski, Krzysztof A.; Henry, Brandon Michael] Jagiellonian Univ, Coll Med, Dept Anat, 12 Kopernika St, PL 31034 Krakow, Poland.
   [Wronski, Sebastian; Tarasiuk, Jacek] AGH Univ Sci & Technol, Fac Phys & Appl Comp Sci, 30 Mickiewicza St, PL 30059 Krakow, Poland.
   [Maredziak, Monika] Wroclaw Univ Environm & Life Sci, Fac Vet Med, Dept Anim Physiol & Biostruct, 31 Norwida St, PL 50375 Wroclaw, Poland.
C3 Wroclaw University of Environmental & Life Sciences; Jagiellonian
   University; Collegium Medicum Jagiellonian University; AGH University of
   Krakow; Wroclaw University of Environmental & Life Sciences
RP Marycz, K (通讯作者)，Wroclaw Univ Environm & Life Sci, Electron Microscopy Lab, 5b Kozuchowska St, PL 51631 Wroclaw, Poland.; Marycz, K (通讯作者)，Wroclaw Res Ctr EIT, 147 Stablowicka St, PL 54066 Wroclaw, Poland.
EM krzysztofmarycz@interia.pl
RI Henry, MD, Brandon/AFA 8968 2022; Marycz, Krzysztof/A 2249 2017
OI Tomaszewski, Krzysztof/0000 0001 5077 6948
FU Wroclaw Research Centre EIT+ from European Regional Development Fund
   [POIG.01.01.02 02 003/08]; Foundation for Polish Science (FNP)
FX The research was supported by Wroclaw Research Centre EIT+ under the
   project "Biotechnologies and Advanced Medical Technologies," BioMed
   (POIG.01.01.02 02 003/08) financed from the European Regional
   Development Fund (Operational Programmed Innovative Economy, 1.1.2.).
   Krzysztof A. Tomaszewski was supported by the Foundation for Polish
   Science (FNP).
CR Algire C, 2012, CANCER PREV RES, V5, P536, DOI 10.1158/1940 6207.CAPR 11 0536
   Alimova IN, 2009, CELL CYCLE, V8, P909, DOI 10.4161/cc.8.6.7933
   Anisimov VN, 2008, CELL CYCLE, V7, P2769, DOI 10.4161/cc.7.17.6625
   Baer Patrick C, 2014, World J Stem Cells, V6, P256, DOI 10.4252/wjsc.v6.i3.256
   Chen HP, 2013, GUT, V62, P606, DOI 10.1136/gutjnl 2011 301708
   Chen T, 2009, CELL BIOL TOXICOL, V25, P573, DOI 10.1007/s10565 008 9113 7
   Choudhery MS, 2014, J TRANSL MED, V12, DOI 10.1186/1479 5876 12 8
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   FELDKAMP LA, 1984, J OPT SOC AM A, V1, P612, DOI 10.1364/JOSAA.1.000612
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10 0666
   Grzesiak J, 2011, INT J MORPHOL, V29, P1012, DOI 10.4067/S0717 95022011000300059
   Hardie DG, 2008, FEBS LETT, V582, P81, DOI 10.1016/j.febslet.2007.11.018
   Hirsch HA, 2013, P NATL ACAD SCI USA, V110, P972, DOI 10.1073/pnas.1221055110
   Hou XG, 2010, BIOCHEM BIOPH RES CO, V396, P199, DOI 10.1016/j.bbrc.2010.04.017
   Jang WG, 2011, BONE, V48, P885, DOI 10.1016/j.bone.2010.12.003
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Kalra Sanjay, 2012, Indian J Endocrinol Metab, V16, P496, DOI 10.4103/2230 8210.97991
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Karnevi E, 2013, BMC CANCER, V13, DOI 10.1186/1471 2407 13 235
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kim SA, 2012, BIOCHEM BIOPH RES CO, V425, P866, DOI 10.1016/j.bbrc.2012.07.165
   Kornicka K, 2016, RSC ADV, V6, P29524, DOI 10.1039/c6ra00029k
   Kornicka K, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/309169
   Kourelis TV, 2012, MED ONCOL, V29, P1314, DOI 10.1007/s12032 011 9846 7
   Li SN, 2009, HEART VESSELS, V24, P446, DOI 10.1007/s00380 008 1137 7
   Liu BL, 2009, CELL CYCLE, V8, P2031, DOI 10.4161/cc.8.13.8814
   Luo QQ, 2012, BMC CANCER, V12, DOI 10.1186/1471 2407 12 517
   Mahrouf M, 2006, BIOCHEM PHARMACOL, V72, P176, DOI 10.1016/j.bcp.2006.04.027
   Maredziak M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/2152435
   MARYCZ K, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/4710326
   Mattila PK, 2008, NAT REV MOL CELL BIO, V9, P446, DOI 10.1038/nrm2406
   Nicpon J, 2013, POL J VET SCI, V16, P753, DOI 10.2478/pjvs 2013 0107
   Owen MR, 2000, BIOCHEM J, V348, P607, DOI 10.1042/0264 6021:3480607
   Pugeat M, 1999, DRUGS, V58, P41, DOI 10.2165/00003495 199958001 00010
   Ratajczak MZ, 2011, NEPHROL DIAL TRANSPL, V26, P1453, DOI 10.1093/ndt/gfr165
   Schoengraf P, 2013, IMMUNOBIOLOGY, V218, P1, DOI 10.1016/j.imbio.2012.01.020
   Sedlinsky C, 2011, EUR J PHARMACOL, V668, P477, DOI 10.1016/j.ejphar.2011.07.033
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   Smieszek A, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/814896
   Smieszek A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/769402
   SUM CF, 1992, DIABETIC MED, V9, P61, DOI 10.1111/j.1464 5491.1992.tb01716.x
   Teti Anna, 2011, Curr Osteoporos Rep, V9, P264, DOI 10.1007/s11914 011 0078 8
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   van Heemst D, 2010, AGING DIS, V1, P147
   Viollet B, 2012, CLIN SCI, V122, P253, DOI 10.1042/CS20110386
   Volume Graphics GmbH, 2013, REF MAN VGSTUDIO MAX
   Wang C, 2012, J BONE MINER METAB, V30, P630, DOI 10.1007/s00774 012 0374 0
   Wu W, 2011, INT J ARTIF ORGANS, V34, P1128, DOI 10.5301/ijao.5000007
   Zakikhani M, 2006, CANCER RES, V66, P10269, DOI 10.1158/0008 5472.CAN 06 1500
   Zhen DH, 2010, J DIABETES COMPLICAT, V24, P334, DOI 10.1016/j.jdiacomp.2009.05.002
NR 53
TC 59
Z9 66
U1 2
U2 18
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942 0900
EI 1942 0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2016
VL 2016
AR 9785890
DI 10.1155/2016/9785890
PG 19
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA DN4PJ
UT WOS:000377049400001
PM 27195075
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Hatami, E
   Nagesh, PKB
   Chowdhury, P
   Elliot, S
   Shields, D
   Chauhan, SC
   Jaggi, M
   Yallapu, MM
AF Hatami, Elham
   Nagesh, Prashanth Kumar Bhusetty
   Chowdhury, Pallabita
   Elliot, Stacie
   Shields, Deanna
   Chauhan, Subhash Chand
   Jaggi, Meena
   Yallapu, Murali Mohan
TI Development of Zoledronic Acid Based Nanoassemblies for Bone Targeted
   Anticancer Therapy
SO ACS BIOMATERIALS SCIENCE & ENGINEERING
LA English
DT Article
DE nanoparticles; bone metastasis; breast cancer; prostate cancer; lung
   cancer
ID IRON OXIDE NANOPARTICLES; TANNIC ACID; DRUG DELIVERY; BREAST CANCER;
   BISPHOSPHONATES; METASTASIS; INSIGHTS; SYSTEM; AGENTS
AB Bone metastasis occurs in the majority of cancer patients, which hampers quality of life and significantly decreases survival. Aggressive chemotherapy is a traditional treatment regimen that induces severe systemic toxicities. Therefore, bone directed therapies are highly warranted. We report a novel nanoparticle formulation that is composed of poly(vinylpyrrolidone) and tannic acid core nanoparticles (PVT NPs) that forms self assembly with zoledronic acid (ZA@PVT NPs). The construction of ZA@PVT NPs was confirmed by particle size, zeta potential, transmission electron microscopy, and spectral analyses. An optimized bone targeted ZA@PVT NPs formulation showed greater binding and internalization in in vitro with metastasis prostate and breast cancer cells. ZA@PVT NPs were able to deliver ZA more efficiently to tumor cells, which inhibited proliferation of human prostate and breast cancer cells. In addition, ZA@PVT NPs were capable of targeting mouse bones and prostate tumor microarray tissues (ex vivo) while sparing all other vital organs. More importantly, ZA@PVT NPs induce chemo sensitization to docetaxel treatment in cancer cells. Overall, the study results confirm that ZA based, bone targeted NPs have great potential for the treatment of bone metastasis in the near future.
C1 [Hatami, Elham; Nagesh, Prashanth Kumar Bhusetty; Chowdhury, Pallabita; Elliot, Stacie; Shields, Deanna; Chauhan, Subhash Chand; Jaggi, Meena; Yallapu, Murali Mohan] Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Hlth Sci Ctr, 881 Madison Ave, Memphis, TN 38163 USA.
C3 University of Tennessee System; University of Tennessee Health Science
   Center
RP Yallapu, MM (通讯作者)，Univ Tennessee, Coll Pharm, Dept Pharmaceut Sci, Hlth Sci Ctr, 881 Madison Ave, Memphis, TN 38163 USA.
EM myallapu@uthsc.edu
RI ; Bhusetty Nagesh, Prashanth Kumar/ABH 4999 2020; Yallapu,
   Murali/F 5323 2010; Chowdhury, Pallabita/JDW 3910 2023
OI Chowdhury, Pallabita/0000 0003 0561 3204; Bhusetty Nagesh, Prashanth
   Kumar/0000 0003 3518 405X; Hatami, Elham/0000 0001 6776 4003
FU National Institutes of Health [K22 CA174841, R15 CA 213232, R01
   CA210192, R01 CA206069, R01 CA204552]; University of Tennessee Health
   Science Center Funding: CORNET grant by Office of Research; College of
   Pharmacy
FX The authors acknowledge the Core facilities at the College of Pharmacy
   and Center for Cancer Research, The University of Tennessee Health
   Science Center, Memphis, TN. The Department of Chemistry and Nebraska
   Center for Materials and Nanoscience analytical facilities are
   acknowledged for providing the thermal and XRD scans for our samples.
   This work was partially supported by the National Institutes of Health
   (K22 CA174841 and R15 CA 213232), University of Tennessee Health Science
   Center Funding: CORNET grant by Office of Research, and start up & seed
   grant(s) by the College of Pharmacy, to M.M.Y. This work was also
   partially supported by grants obtained by Dr. Subhash C. Chauhan from
   the National Institutes of Health (R01 CA210192, R01 CA206069, and R01
   CA204552).
CR Abouelmagd SA, 2016, ACS BIOMATER SCI ENG, V2, P2294, DOI 10.1021/acsbiomaterials.6b00497
   Adatoz EB, 2018, SOFT MATTER, V14, P3849, DOI 10.1039/c8sm00381e
   Aguilera JR, 2016, RSC ADV, V6, P7279, DOI 10.1039/c5ra19405a
   Ahmed M, 2013, J SURG RES, V185, P27, DOI 10.1016/j.jss.2013.05.108
   [Anonymous], LANGMUIR
   [Anonymous], CALCIF TISSUE RES
   Benedetti CE, 2003, MOL BIOCHEM PARASIT, V128, P157, DOI 10.1016/S0166 6851(03)00057 4
   Berenson JR, 2012, CL LYMPH MYELOM LEUK, V12, P2, DOI 10.1016/j.clml.2011.03.025
   Berenson JR, 2005, ONCOLOGIST, V10, P52, DOI 10.1634/theoncologist.10 1 52
   Brook N, 2018, INT J BIOCHEM CELL B, V96, P63, DOI 10.1016/j.biocel.2018.01.003
   Buenrostro D, 2016, CURR OSTEOPOROS REP, V14, P151, DOI 10.1007/s11914 016 0315 2
   Cao L, 2017, ONCOTARGET, V8, P90308, DOI 10.18632/oncotarget.19856
   Chaudhari KR, 2012, J CONTROL RELEASE, V158, P470, DOI 10.1016/j.jconrel.2011.11.020
   Chen X, 2003, CLIN CANCER RES, V9, P3115
   Choi SW, 2007, J CONTROL RELEASE, V122, P24, DOI 10.1016/j.jconrel.2007.06.003
   Chowdhury P, 2019, J COLLOID INTERF SCI, V535, P133, DOI 10.1016/j.jcis.2018.09.072
   Chowdhury P, 2018, ACTA PHARM SIN B, V8, P602, DOI 10.1016/j.apsb.2017.10.004
   Clyne Melanie, 2012, Nat Rev Urol, V9, P235, DOI 10.1038/nrurol.2012.70
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Darvin P, 2017, J CELL MOL MED, V21, P720, DOI 10.1111/jcmm.13015
   de Castro S, 2010, BIOCONJUGATE CHEM, V21, P1190, DOI 10.1021/bc900569u
   de Miguel L, 2014, INT J PHARMACEUT, V460, P73, DOI 10.1016/j.ijpharm.2013.10.048
   Desai D, 2017, MOL PHARMACEUT, V14, P3218, DOI 10.1021/acs.molpharmaceut.7b00519
   Fan HJ, 2013, BBA MOL CELL BIOL L, V1831, P1260, DOI 10.1016/j.bbalip.2013.04.003
   Ferreira Diego Dos Santos, 2016, Int J Nanomedicine, V11, P3737, DOI 10.2147/IJN.S109966
   Gnant M, 2012, CANCER TREAT REV, V38, P407, DOI 10.1016/j.ctrv.2011.09.003
   Hatami E, 2019, BIOCHEM BIOPHYS REP, V17, P197, DOI 10.1016/j.bbrep.2019.01.007
   Hatami E, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030111
   He YF, 2017, J CONTROL RELEASE, V264, P76, DOI 10.1016/j.jconrel.2017.08.024
   Hernandez RK, 2018, BMC CANCER, V18, DOI 10.1186/s12885 017 3922 0
   Horie N, 2007, BRIT J CANCER, V96, P255, DOI 10.1038/sj.bjc.6603548
   HOWLETT CR, 1984, J ANAT, V139, P115
   Huang H, 2017, RSC ADV, V7, P2829, DOI 10.1039/c6ra26936b
   Jackson JK, 2016, J PHARM SCI US, V105, P3143, DOI 10.1016/j.xphs.2016.06.027
   Jemal A, 2007, CA CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jung SM, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00796
   Katsumi H, 2011, J PHARM SCI US, V100, P3783, DOI 10.1002/jps.22620
   Khan A, 2008, CAN FAM PHYSICIAN, V54, P1019
   Koo H, 2011, ACCOUNTS CHEM RES, V44, P1018, DOI 10.1021/ar2000138
   Koul HK, 2012, PROSTATE CANCER P D, V15, P111, DOI 10.1038/pcan.2011.41
   Kozlovskaya V, 2015, ADV HEALTHC MATER, V4, P686, DOI 10.1002/adhm.201400657
   Lau HH, 2017, J COLLOID INTERF SCI, V505, P332, DOI 10.1016/j.jcis.2017.06.001
   Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 179
   MARTY R, 1975, Critical Reviews in Clinical Radiology and Nuclear Medicine, V6, P403
   Montanari E, 2016, MACROMOL BIOSCI, V16, P1815, DOI 10.1002/mabi.201600311
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nagesh PKB, 2018, CANCERS, V10, DOI 10.3390/cancers10090289
   Nagesh PKB, 2016, COLLOID SURFACE B, V144, P8, DOI 10.1016/j.colsurfb.2016.03.071
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Ossipov DA, 2015, EXPERT OPIN DRUG DEL, V12, P1443, DOI 10.1517/17425247.2015.1021679
   Panahifar A, 2013, ACS APPL MATER INTER, V5, P5219, DOI 10.1021/am4010495
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Richer SM, 2009, ACS CHEM BIOL, V4, P733, DOI 10.1021/cb900121r
   Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   RUSSELL RGG, 1975, CLIN ORTHOP RELAT R, P241
   Saowalak K, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25108 1
   Saracino R, 2016, CURR DRUG TARGETS, V17, P303, DOI 10.2174/1389450116666150427154706
   Shupp AB, 2018, CANCERS, V10, DOI 10.3390/cancers10060182
   Sun WT, 2016, LANGMUIR, V32, P9237, DOI 10.1021/acs.langmuir.6b02228
   Taurin S, 2012, J CONTROL RELEASE, V164, P265, DOI 10.1016/j.jconrel.2012.07.013
   Vinay R, 2016, DRUG DELIV, V23, P21, DOI 10.3109/10717544.2014.913325
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
   Wang GL, 2012, J BIOMED MATER RES A, V100A, P684, DOI 10.1002/jbm.a.34002
   Webb SA, 2007, BIOMACROMOLECULES, V8, P1790, DOI 10.1021/bm061166g
   Yallapu MM, 2010, MACROMOL BIOSCI, V10, P1141, DOI 10.1002/mabi.201000084
   Zaporowska Stachowiak I, 2017, BIOMED PHARMACOTHER, V93, P1277, DOI 10.1016/j.biopha.2017.07.023
NR 70
TC 13
Z9 16
U1 6
U2 41
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2373 9878
J9 ACS BIOMATER SCI ENG
JI ACS Biomater. Sci. Eng.
PD MAY
PY 2019
VL 5
IS 5
BP 2343
EP 2354
DI 10.1021/acsbiomaterials.9b00362
PG 23
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA HY4TE
UT WOS:000468120000026
PM 33405784
DA 2025 08 17
ER

PT J
AU Li, XY
   Guo, YQ
   Yan, WB
   Snyder, MP
   Li, X
AF Li, Xiyan
   Guo, Yuqi
   Yan, Wenbo
   Snyder, Michael P.
   Li, Xin
TI Metformin Improves Diabetic Bone Health by Re Balancing Catabolism and
   Nitrogen Disposal
SO PLOS ONE
LA English
DT Article
ID NF KAPPA B; SUCCINATE RECEPTOR GPR91; ANTIDIABETIC DRUG METFORMIN;
   OSTEOCLAST FORMATION; ACID CYCLE; IN VIVO; DIFFERENTIATION; ACTIVATION;
   GLUTAMATE; CELL
AB Objective
   Metformin, a leading drug used to treat diabetic patients, is reported to benefit bone homeostasis under hyperglycemia in animal models. However, both the molecular targets and the biological pathways affected by metformin in bone are not well identified or characterized. The objective of this study is to investigate the bioengergeric pathways affected by metformin in bone marrow cells of mice.
   Materials and Methods
   Metabolite levels were examined in bone marrow samples extracted from metformin or PBS  treated healthy (Wild type) and hyperglycemic (diabetic) mice using liquid chromatography mass spectrometry (LC MS) based metabolomics. We applied an untargeted high performance LC MS approach which combined multimode chromatography (ion exchange, reversed phase and hydrophilic interaction (HILIC)) and Orbitrap based ultra high accuracy mass spectrometry to achieve a wide coverage. A multivariate clustering was applied to reveal the global trends and major metabolite players.
   Results
   A total of 346 unique metabolites were identified, and they are grouped into distinctive clusters that reflected general and diabetes specific responses to metformin. As evidenced by changes in the TCA and urea cycles, increased catabolism and nitrogen waste that are commonly associated with diabetes were rebalanced upon treatment with metformin. In particular, we found glutamate and succinate whose levels were drastically elevated in diabetic animals were brought back to normal levels by metformin. These two metabolites were further validated as the major targets of metformin in bone marrow stromal cells.
   Conclusion
   Overall using limited sample size, our study revealed the metabolic pathways modulated by metformin in bones which have broad implication in our understanding of bone remodeling under hyperglycemia and in finding therapeutic interventions in mammals.
C1 [Li, Xiyan; Snyder, Michael P.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA.
   [Guo, Yuqi; Li, Xin] NYU, Coll Dent, Basic Sci & Craniofacial Biol, New York, NY 10010 USA.
   [Yan, Wenbo] Nyack Coll, Dept Biol & Chem, New York, NY 10013 USA.
C3 Stanford University; New York University; Nyack College
RP Li, X (通讯作者)，NYU, Coll Dent, Basic Sci & Craniofacial Biol, New York, NY 10010 USA.
EM xl15@nyu.edu
RI ; yan, wenbo/GXV 2795 2022; Maier, Andrea/W 7060 2019; Li,
   Xiyan/B 5495 2011
OI Li, Xin/0000 0002 7414 5734; Li, Xiyan/0000 0002 1959 2160; Snyder,
   Michael/0000 0003 0784 7987; 
FU NIH [R01CA180277, R03 CA172894, 5R01GM06248012 12, 3U54DK10255602S2];
   California Institute for Regenerative Medicine [RB4 06087]
FX This work was supported by NIH grants R01CA180277 and R03 CA172894 to
   Xin Li, 5R01GM06248012 12, 3U54DK10255602S2 grant and California
   Institute for Regenerative Medicine grant (RB4 06087) to MPS. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andrzejewski S, 2014, CANCER METAB, V2, DOI 10.1186/2049 3002 2 12
   Ang ESM, 2007, J CELL PHYSIOL, V212, P787, DOI 10.1002/jcp.21076
   Cheema AK, 2011, J PROTEOME RES, V10, P2651, DOI 10.1021/pr101243j
   Chung YH, 2014, INT J BIOCHEM CELL B, V54, P198, DOI 10.1016/j.biocel.2014.07.018
   Corominas Faja B, 2012, AGING US, V4, P480, DOI 10.18632/aging.100472
   Cowan Robert W, 2012, Front Endocrinol (Lausanne), V3, P89, DOI 10.3389/fendo.2012.00089
   Danaei G, 2011, LANCET, V378, P31, DOI 10.1016/S0140 6736(11)60679 X
   Eriksen EF, 2010, REV ENDOCR METAB DIS, V11, P219, DOI 10.1007/s11154 010 9153 1
   Favret S, 2013, AGING US, V5, P427, DOI 10.18632/aging.100563
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Fernández AM, 2001, GENE DEV, V15, P1926, DOI 10.1101/gad.908001
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gao Y, 2010, EUR J PHARMACOL, V635, P231, DOI 10.1016/j.ejphar.2010.02.051
   Gao Y, 2008, J PHARM PHARMACOL, V60, P1695, DOI 10.1211/jpp.60/12.0017
   Gnana Prakasam JP, 2011, INVEST OPHTH VIS SCI, V52, P3751, DOI 10.1167/iovs.10 6722
   Gore DC, 2005, ANN SURG, V241, P334, DOI 10.1097/01.sla.0000152013.23032.d1
   Gravel SP, 2014, CANCER RES, V74, P7521, DOI 10.1158/0008 5472.CAN 14 2643 T
   Guan SH, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.010728
   Hakak Y, 2009, J LEUKOCYTE BIOL, V85, P837, DOI 10.1189/jlb.1008618
   Hamann C, 2012, NAT REV ENDOCRINOL, V8, P297, DOI 10.1038/nrendo.2011.233
   Hardie DG, 2008, INT J OBESITY, V32, pS7, DOI 10.1038/ijo.2008.116
   Hardie DG, 2011, AM J CLIN NUTR, V93, p891S, DOI 10.3945/ajcn.110.001925
   Hardie DG, 2003, ENDOCRINOLOGY, V144, P5179, DOI 10.1210/en.2003 0982
   HUNDAL HS, 1992, ENDOCRINOLOGY, V131, P1165, DOI 10.1210/en.131.3.1165
   Hundal RS, 2003, DRUGS, V63, P1879, DOI 10.2165/00003495 200363180 00001
   Janzer A, 2014, P NATL ACAD SCI USA, V111, P10574, DOI 10.1073/pnas.1409844111
   Jeyabalan J, 2013, OSTEOPOROSIS INT, V24, P2659, DOI 10.1007/s00198 013 2371 0
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kajiya H, 2012, ADV EXP MED BIOL, V740, P917, DOI 10.1007/978 94 007 2888 2_41
   Kamburov A, 2011, BIOINFORMATICS, V27, P2917, DOI 10.1093/bioinformatics/btr499
   Kawashima Y, 2009, BONE, V44, P648, DOI 10.1016/j.bone.2008.12.012
   Koenig W, 2008, CLIN CHEM, V54, P231, DOI 10.1373/clinchem.2007.099705
   Kos E, 2012, ENDOCR PRACT, V18, P179, DOI 10.4158/EP11009.OR
   KRAKAUER JC, 1995, DIABETES, V44, P775, DOI 10.2337/diabetes.44.7.775
   L Newton Anna, 2013, Bonekey Rep, V2, P315, DOI 10.1038/bonekey.2013.49
   Large V, 1999, DIABETES, V48, P1251, DOI 10.2337/diabetes.48.6.1251
   Levasseur R, 2003, ENDOCRINOLOGY, V144, P2761, DOI 10.1210/en.2002 0071
   Li HW, 2013, BIOCHEM BIOPH RES CO, V430, P951, DOI 10.1016/j.bbrc.2012.12.051
   Li X, 2007, J BIOL CHEM, V282, P33086, DOI 10.1074/jbc.M705194200
   Mai QG, 2011, J CELL BIOCHEM, V112, P2902, DOI 10.1002/jcb.23206
   Mediero A, 2013, BRIT J PHARMACOL, V169, P1372, DOI 10.1111/bph.12227
   Merle B, 2003, J CELL BIOCHEM, V90, P424, DOI 10.1002/jcb.10625
   Miller RA, 2010, J CLIN INVEST, V120, P2267, DOI 10.1172/JCI43661
   Miranda VC, 2014, DRUG TODAY, V50, P623, DOI 10.1358/dot.2014.50.9.2229920
   Miyauchi A, 1996, ENDOCRINOLOGY, V137, P3544, DOI 10.1210/en.137.8.3544
   Newsholme P, 2005, CLIN SCI, V108, P185, DOI 10.1042/CS20040290
   Rubic T, 2008, NAT IMMUNOL, V9, P1261, DOI 10.1038/ni.1657
   Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873
   Shah M, 2010, BONE, V47, P309, DOI 10.1016/j.bone.2010.04.596
   SHAMBAUGH GE, 1977, AM J CLIN NUTR, V30, P2083, DOI 10.1093/ajcn/30.12.2083
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   SULAIMAN WR, 1977, ACTA DIABETOL LAT, V14, P129, DOI 10.1007/BF02581400
   Sundström L, 2013, FEBS LETT, V587, P2399, DOI 10.1016/j.febslet.2013.05.067
   Suzuki K, 2005, DIABETES RES CLIN PR, V68, P117, DOI 10.1016/j.diabres.2004.08.006
   Tagliaferri C, 2015, EUR J NUTR, V54, P1139, DOI 10.1007/s00394 014 0790 0
   Tai ES, 2010, DIABETOLOGIA, V53, P757, DOI 10.1007/s00125 009 1637 8
   Takarada T, 2008, J PHARMACOL SCI, V106, P536, DOI 10.1254/jphs.FM0070243
   Takarada Iemata M, 2011, J CELL PHYSIOL, V226, P652, DOI 10.1002/jcp.22390
   Takizawa M, 2008, DIABETES RES CLIN PR, V82, P119, DOI 10.1016/j.diabres.2008.07.008
   Tsubaki M, 2014, J BIOMED SCI, V21, DOI 10.1186/1423 0127 21 10
   Tsubaki M, 2010, J CELL BIOCHEM, V111, P1661, DOI 10.1002/jcb.22907
   Uno K, 2007, J CELL PHYSIOL, V213, P105, DOI 10.1002/jcp.21095
   Vestergaard P, 2005, DIABETOLOGIA, V48, P1292, DOI 10.1007/s00125 005 1786 3
   Vinaixa M, 2012, METABOLITES, V2, P775, DOI 10.3390/metabo2040775
   Wu CL, 2013, INT J OBESITY, V37, P1079, DOI 10.1038/ijo.2012.171
   Yan WB, 2013, FRONT MED PRC, V7, P81, DOI 10.1007/s11684 013 0243 9
   Zinman B, 2010, J CLIN ENDOCR METAB, V95, P134, DOI 10.1210/jc.2009 0572
NR 67
TC 13
Z9 16
U1 1
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD DEC 30
PY 2015
VL 10
IS 12
AR e0146152
DI 10.1371/journal.pone.0146152
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA DA0TN
UT WOS:000367510500137
PM 26716870
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Rathmann, W
   Kostev, K
AF Rathmann, Wolfgang
   Kostev, Karel
TI Type 2 diabetes incidence in patients initiating denosumab or
   alendronate treatment: a primary care cohort study
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Type 2 diabetes; Bone; Denosumab; Alendronate; bisphosphonate
ID RECEPTOR ACTIVATOR; INSULIN RESISTANCE; INHIBITION; DISEASE; RANKL
AB Denosumab initiation is related to a lower risk of type 2 diabetes than alendronate in anti osteoporotic treatment naive users in primary care practices.
   Purpose Links have been suggested between bone metabolism and glucose tolerance. Downregulation of the receptor activator of nuclear factor kappa B ligand (RANKL) signaling improves glucose metabolism. Denosumab, a human monoclonal antibody against RANKL, may be associated with a lower risk of type 2 diabetes (T2D). The aim was to compare incidence rates of T2DM in primary care patients initiating denosumab or alendronate, which is a first line therapy of osteoporosis. Alendronate as comparator enhances comparability of the two cohorts.
   Method The IQVIA Disease Analyzer comprises a representative panel of general and specialist practices (Germany). A new user comparative study was conducted among patients with denosumab or alendronate treatment (2010 2021) without history of diabetes and age >= 45 years. Incidence rates (per 1,000 person  years) and Cox proportional hazard ratios (HR; 95%CI) for T2DM were estimated.
   Results The cohorts consisted of 3,354 denosumab (age: 75 years; women: 87%) and 27,068 alendronate (76 years; 86%) users. Overall, 1,038 persons developed T2D during 54,916 person years. T2DM incidence rates per 1,000 person years were 11.9 (9.5 14.4) for denosumab and 20.1 (18.8 21.3) for alendronate users, respectively. Denosumab was associated with a reduced risk of T2DM compared to alendronate, adjusting for age, sex, index year, visits, obesity, comorbidities and statins (HR: 0.73; 0.58 0.89).
   Conclusion In this comparative study of older patients seen in routine practices, denosumab was associated with a lower risk of developing T2DM than alendronate.
C1 [Rathmann, Wolfgang] Heinrich Heine Univ, Inst Biometr & Epidemiol, Leibniz Ctr Diabet Res, German Diabet Ctr, Aufm Hennekamp 65, D 40225 Dusseldorf, Germany.
   [Rathmann, Wolfgang] German Ctr Diabet Res, Partner Dusseldorf, Munich, Germany.
   [Kostev, Karel] IQVIA, Epidemiol, Frankfurt, Germany.
C3 Heinrich Heine University Dusseldorf; Leibniz Association; Deutsches
   Diabetes Zentrum (DDZ); German Center for Diabetes Research (DZD); IQVIA
RP Rathmann, W (通讯作者)，Heinrich Heine Univ, Inst Biometr & Epidemiol, Leibniz Ctr Diabet Res, German Diabet Ctr, Aufm Hennekamp 65, D 40225 Dusseldorf, Germany.; Rathmann, W (通讯作者)，German Ctr Diabet Res, Partner Dusseldorf, Munich, Germany.
EM wolfgang.rathmann@ddz.de
RI Qasrawi, Radwan/AAA 6245 2019; Kostev, Karel/S 4755 2019
FU German Federal Ministry of Health (Berlin, Germany); Ministry of Culture
   and Science of the state North Rhine Westphalia (Dusseldorf, Germany);
   German Federal Ministry of Education and Research (BMBF) through the
   German Center for Diabetes Research (DZD e.V.); German Federal Ministry
   of Health (Berlin, Germany); Ministry of Culture and Science of the
   state North Rhine Westphalia (Duesseldorf, Germany); German Federal
   Ministry of Education and Research (BMBF) through the German Center for
   Diabetes Research (DZD e.V.)
FX There was no specific funding related to this study. In general, the
   German Diabetes Center is funded by the German Federal Ministry of
   Health (Berlin, Germany) and the Ministry of Culture and Science of the
   state North Rhine Westphalia (Dusseldorf, Germany) and receives
   additional funding by the German Federal Ministry of Education and
   Research (BMBF) through the German Center for Diabetes Research (DZD
   e.V.).
CR Abe I, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018067
   Chen PW, 2023, OSTEOPOROSIS INT, V34, P387, DOI 10.1007/s00198 022 06616 3
   Dell'Aquila E, 2020, EXPERT OPIN BIOL TH, V20, P1261, DOI 10.1080/14712598.2020.1814731
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Gopaul A, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00971 0
   Kiechl S, 2013, NAT MED, V19, P358, DOI 10.1038/nm.3084
   Kondegowda NG, 2015, CELL METAB, V22, P77, DOI 10.1016/j.cmet.2015.05.021
   Lasco A, 2016, CALCIFIED TISSUE INT, V98, P123, DOI 10.1007/s00223 015 0075 5
   Lyu HC, 2023, BMJ BRIT MED J, V381, DOI 10.1136/bmj 2022 073435
   Marchetti P, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00055
   Napoli N, 2018, DIABETES METAB RES, V34, DOI 10.1002/dmrr.2991
   Pacheco Soto BT, 2021, J DRUG ASSESS, V10, P97, DOI 10.1080/21556660.2021.1989194
   Panagiotakou A, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154264
   Rathmann W, 2022, DIABETOLOGIA, V65, P949, DOI 10.1007/s00125 022 05670 0
   Rathmann W, 2018, INT J CLIN PHARM TH, V56, P459, DOI 10.5414/CP203320
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   Roberts F, 2020, J ENDOCRINOL, V245, pR11, DOI 10.1530/JOE 19 0460
   Schwartz AV, 2013, J BONE MINER RES, V28, P1348, DOI 10.1002/jbmr.1865
   Sun H, 2022, DIABETES RES CLIN PR, V183, DOI 10.1016/j.diabres.2021.109119
   Tilg H, 2017, NAT REV GASTRO HEPAT, V14, P32, DOI 10.1038/nrgastro.2016.147
   Viggers R, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.771426
   Willers C, 2022, ARCH OSTEOPOROS, V17, DOI 10.1007/s11657 021 00969 8
   Yu OHY, 2023, DIABETES CARE, V46, P904, DOI 10.2337/dci22 0047
NR 23
TC 4
Z9 4
U1 1
U2 1
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2024
VL 35
IS 12
BP 2099
EP 2106
DI 10.1007/s00198 024 07182 6
EA JUL 2024
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA M8E3D
UT WOS:001275409600001
PM 39046498
DA 2025 08 17
ER

PT J
AU Mao, HQ
   Zhou, L
   Li, JQ
   Wen, YH
   Chen, Z
   Zhang, L
AF Mao, Han Qing
   Zhou, Lu
   Li, Jia Qi
   Wen, Yuan Hao
   Chen, Zhi
   Zhang, Lu
TI STING inhibition alleviates bone resorption in apical periodontitis
SO INTERNATIONAL ENDODONTIC JOURNAL
LA English
DT Article
DE apical periodontitis; C 176; immunotherapy; osteoclast; STING
ID INNATE IMMUNITY; INFLAMMATION
AB AimThe goal of this study was to investigate the potential effects of an immunotherapeutic drug targeting STING to suppress the overreactive innate immune response and relieve the bone defect in apical periodontitis.MethodologyWe established an apical periodontitis mouse model in Sting /  and WT mice in vivo. The progression of apical periodontitis was analysed by micro CT analysis and H&E staining. The expression level and localization of STING in F4/80+ cells were identified by IHC and immunofluorescence staining. RANKL in periapical tissues was tested by IHC staining. TRAP staining was used to detect osteoclasts. To clarify the effect of STING inhibitor C 176 as an immunotherapeutic drug, mice with apical periodontitis were treated with C 176 and the bone loss was identified by H&E, TRAP, RANKL staining and micro CT. Bone marrow derived macrophages (BMMs) were isolated from Sting /  and WT mice and induced to osteoclasts in a lipopolysaccharide (LPS) induced inflammatory environment in vitro. Moreover, WT BMMs were treated with C 176 to determine the effect on osteoclast differentiation by TRAP staining. The expression levels of osteoclast related genes were tested using qRT PCR.ResultsCompared to WT mice, the bone resorption and inflammatory cell infiltration were reduced in exposed Sting /  mice. In the exposed WT group, STING was activated mainly in F4/80+ macrophages. Histological staining revealed the less osteoclasts and lower expression of osteoclast related factor RANKL in Sting /  mice. The treatment of the STING inhibitor C 176 in an apical periodontitis mice model alleviated inflammation progression and bone loss, similar to the effect observed in Sting /  mice. Expression of RANKL and osteoclast number in periapical tissues were also decreased after C 176 administration. In vitro, TRAP staining showed fewer positive cells and qRT PCR reflected decreased expression of osteoclastic marker, Src and Acp5 were detected during osteoclastic differentiation in Sting /  and C 176 treated BMMs.ConclusionsSTING was activated and was proven to be a positive factor in bone loss and osteoclastogenesis in apical periodontitis. The STING inhibitor C 176 administration could alleviate the bone loss via modulating local immune response, which provided immunotherapy to the treatment of apical periodontitis.
C1 [Mao, Han Qing; Zhou, Lu; Li, Jia Qi; Wen, Yuan Hao; Chen, Zhi; Zhang, Lu] Wuhan Univ, Sch & Hosp Stomatol, Hubei Key Lab Stomatol, Minist Educ,Key Lab Oral Biomed,State Key Lab Oral, Wuhan, Peoples R China.
   [Zhou, Lu; Chen, Zhi; Zhang, Lu] Wuhan Univ, Sch & Hosp Stomatol, Dept Cariol & Endodont, LuoYu Rd 237, Wuhan 430079, Peoples R China.
C3 Wuhan University; Wuhan University
RP Chen, Z; Zhang, L (通讯作者)，Wuhan Univ, Sch & Hosp Stomatol, Dept Cariol & Endodont, LuoYu Rd 237, Wuhan 430079, Peoples R China.
EM zhichen@whu.edu.cn; luzhang2012@whu.edu.cn
RI Chen, Zhi/V 2214 2017; Li, Jason/J 2316 2014
OI Chen, Zhi/0000 0003 2095 1324; 
FU National Natural Science Foundation of China
FX We thank Prof. Bo Zhong for the gift of Sting /  mice.
CR Alvarez C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01664
   Barbalat R, 2011, ANNU REV IMMUNOL, V29, P185, DOI 10.1146/annurev immunol 031210 101340
   Barber GN, 2015, NAT REV IMMUNOL, V15, P760, DOI 10.1038/nri3921
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burdette DL, 2011, NATURE, V478, P515, DOI 10.1038/nature10429
   Chen XJ, 2021, FASEB J, V35, DOI 10.1096/fj.202100069RR
   Colic M, 2009, MOL IMMUNOL, V47, P101, DOI 10.1016/j.molimm.2009.01.011
   Decout A, 2021, NAT REV IMMUNOL, V21, P548, DOI 10.1038/s41577 021 00524 z
   Ding QB, 2023, J CONTROL RELEASE, V363, P221, DOI 10.1016/j.jconrel.2023.09.024
   Du JH, 2023, NAT COMMUN, V14, DOI 10.1038/s41467 023 37116 5
   Gao YH, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 021 00795 x
   Gu QL, 2017, J ORTHOP TRANSL, V10, P86, DOI 10.1016/j.jot.2017.05.002
   Guo Q, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 020 03341 9
   Haag SM, 2018, NATURE, V559, P269, DOI 10.1038/s41586 018 0287 8
   Lacouture M, 2018, AM J CLIN DERMATOL, V19, P31, DOI 10.1007/s40257 018 0384 3
   Li Y, 2022, BRAIN RES BULL, V187, P169, DOI 10.1016/j.brainresbull.2022.07.004
   MacLauchlan S, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2210409120
   Meibers HE, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.113180
   Motwani M, 2019, NAT REV GENET, V20, P657, DOI 10.1038/s41576 019 0151 1
   Nagata S, 2018, ANNU REV IMMUNOL, V36, P489, DOI 10.1146/annurev immunol 042617 053010
   Nair PNR, 2006, INT ENDOD J, V39, P249, DOI 10.1111/j.1365 2591.2006.01099.x
   National Research Council, 2011, Guide for the Care and Use of Laboratory Animals, V8th ed, DOI [DOI 10.17226/12910, 10.17226/12910]
   Ni JJ, 2023, J TRANSL MED, V21, DOI 10.1186/s12967 023 04446 3
   Ordinola Zapata R, 2022, INT ENDOD J, V55, P613, DOI 10.1111/iej.13731
   Ouyang ZJ, 2023, ACS BIOMATER SCI ENG, V9, P3273, DOI 10.1021/acsbiomaterials.2c01509
   Peng YC, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974 020 01830 4
   Qi Y, 2023, INT J OBESITY, DOI 10.1038/s41366 023 01272 x
   Shen HT, 2023, BIOACT MATER, V24, P37, DOI 10.1016/j.bioactmat.2022.12.001
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wu JX, 2013, SCIENCE, V339, P826, DOI 10.1126/science.1229963
   Yang F, 2023, INT ENDOD J, V56, P710, DOI 10.1111/iej.13904
   Yu ZC, 2023, FASEB J, V37, DOI 10.1096/fj.202201600R
   Zhang Q, 2021, ANNU REV IMMUNOL, V39, P279, DOI 10.1146/annurev immunol 093019 123619
   Zhang XW, 2020, IMMUNITY, V53, P43, DOI 10.1016/j.immuni.2020.05.013
   Zhang YF, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420 021 00770 z
   Zhong B, 2009, IMMUNITY, V30, P397, DOI 10.1016/j.immuni.2009.01.008
   Zhou L, 2024, FASEB J, V38, DOI 10.1096/fj.202301648R
   Zhou L, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964 021 00738 7
NR 38
TC 1
Z9 1
U1 5
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0143 2885
EI 1365 2591
J9 INT ENDOD J
JI Int. Endod. J.
PD JUL
PY 2024
VL 57
IS 7
SI SI
BP 951
EP 965
DI 10.1111/iej.14057
EA FEB 2024
PG 15
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA UD5Z7
UT WOS:001173707800001
PM 38411951
DA 2025 08 17
ER

PT J
AU Cheloha, RW
   Chen, BM
   Kumar, NN
   Watanabe, T
   Thorne, RG
   Li, LJ
   Gardella, TJ
   Gellman, SH
AF Cheloha, Ross W.
   Chen, Bingming
   Kumar, Niyanta N.
   Watanabe, Tomoyuki
   Thorne, Robert G.
   Li, Lingjun
   Gardella, Thomas J.
   Gellman, Samuel H.
TI Development of Potent, Protease Resistant Agonists of the Parathyroid
   Hormone Receptor with Broad β Residue Distribution
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID ALPHA HELIX MIMICRY; BONE MINERAL DENSITY; AMINO ACID RESIDUES; CRYO EM
   STRUCTURE; ACTION IN VIVO; CLASS B GPCRS; POSTMENOPAUSAL WOMEN; GLP 1
   RECEPTOR; ORAL DELIVERY; PHARMACOKINETIC PROFILE
AB The parathyroid hormone receptor I (PTHR1) is a member of the B family of GPCRs; these receptors are activated by long polypeptide hormones and constitute targets of drug development efforts. Parathyroid hormone (PTH, 84 residues) and PTH related protein (PTHrP, 141 residues) are natural agonists of PTHR1, and an N terminal fragment of PTH, PTH(1 34), is used clinically to treat osteoporosis. Conventional peptides in the 20 40 mer length range are rapidly degraded by proteases, which may limit their biomedical utility. We have used the PTHR1 ligand system to explore the impact of broadly distributed replacement of alpha amino acid residues with beta amino acid residues on susceptibility to proteolysis and agonist activity. This effort led us to identify new PTHR1 agonists that contain alpha  > beta replacements throughout their sequences, manifest potent agonist activity in cellular assays, and display remarkable resistance to proteolysis, in cases remaining active after extended exposure to simulated gastric fluid. The strategy we have employed suggests a path toward identifying protease resistant agonists of other B family GPCRs.
C1 [Cheloha, Ross W.; Li, Lingjun; Gellman, Samuel H.] Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.
   [Chen, Bingming; Kumar, Niyanta N.; Thorne, Robert G.; Li, Lingjun] Univ Wisconsin, Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.
   [Thorne, Robert G.] Univ Wisconsin Madison Biomed Engn, Clin Neuroengn Training Program, Engn Ctr Bldg,Room 2120,1550 Engn Dr, Madison, WI 53706 USA.
   [Thorne, Robert G.] Wisconsin Inst Med Res II, Neurosci Training Program, Rooms 9531 & 9533,1111 Highland Ave, Madison, WI 53705 USA.
   [Thorne, Robert G.] Wisconsin Inst Med Res II, Ctr Neurosci, Rooms 9531 & 9533,1111 Highland Ave, Madison, WI 53705 USA.
   [Thorne, Robert G.] Univ Wisconsin, UW Dept Pathol & Lab Med, Cellular & Mol Pathol Grad Training Program, 1685 Highland Ave, Madison, WI 53705 USA.
   [Watanabe, Tomoyuki; Gardella, Thomas J.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
   [Watanabe, Tomoyuki; Gardella, Thomas J.] Harvard Med Sch, Boston, MA 02114 USA.
   [Cheloha, Ross W.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
   [Cheloha, Ross W.] Harvard Med Sch, Boston, MA 02115 USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital; Harvard University; Harvard Medical School; Harvard
   University; Harvard University Medical Affiliates; Boston Children's
   Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard
   University; Harvard Medical School
RP Gellman, SH (通讯作者)，Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA.; Gardella, TJ (通讯作者)，Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.; Gardella, TJ (通讯作者)，Harvard Med Sch, Boston, MA 02114 USA.
EM gardella@helix.mgh.harvard.edu; gellman@chem.wisc.edu
RI Kumar, Niyanta/AAT 4140 2020; Thorne, Robert/B 2148 2008
OI Kumar, Niyanta/0000 0003 0302 7850
FU National Institutes of Health [GM 056414, DK11794, AR066261]; NIGMS [T32
   GM008349]; Wisconsin Alumni Research Foundation Discovery Challenge;
   University of Wisconsin Madison Institute for Clinical and Translational
   Research; Clinical and Translational Science Award program [UL1TR000427,
   KL2TR00428]; University of Wisconsin Madison School of Pharmacy; NIH
   [S10 RR029531]; WARF
FX This work was supported by the National Institutes of Health Grants
   GM 056414 (R01, S.H.G.), DK11794 (PO1, T.J.G.), and AR066261 (P30,
   T.J.G.). R.W.C. was supported in part by Biotechnology Training Grant
   T32 GM008349 from NIGMS. Additional support was provided by the
   Wisconsin Alumni Research Foundation Discovery Challenge (R.W.C., B.C.,
   N.N.K.), the University of Wisconsin Madison Institute for Clinical and
   Translational Research and the Clinical and Translational Science Award
   program administered through the NIH National Center for Advancing
   Translational Sciences (NIH Grants UL1TR000427 and KL2TR00428 to R.G.T),
   and the University of Wisconsin Madison School of Pharmacy (N.N.K,
   R.G.T). The LC/MS instrument was purchased through funding support from
   NIH Grant S10 RR029531. L.L. acknowledges a Vilas Distinguished
   Achievement Professorship with funding provided by the WARF and
   University of Wisconsin Madison School of Pharmacy. We thank the
   Analytical Instrumentation Center (School of Pharmacy, University of
   Wisconsin Madison) for instrumentation support. We thank Thomas Dean
   (Massachusetts General Hospital) for excellent technical assistance.
CR Binkowski BF, 2011, ACS CHEM BIOL, V6, P1193, DOI 10.1021/cb200248h
   Bortolato A, 2014, BRIT J PHARMACOL, V171, P3132, DOI 10.1111/bph.12689
   Bray BL, 2003, NAT REV DRUG DISCOV, V2, P587, DOI 10.1038/nrd1133
   Caporale A, 2009, EUR J PHARMACOL, V611, P1, DOI 10.1016/j.ejphar.2009.03.040
   Carter PH, 2015, MOL ENDOCRINOL, V29, P307, DOI 10.1210/me.2014 1129
   Castro M, 2005, P NATL ACAD SCI USA, V102, P16084, DOI 10.1073/pnas.0503942102
   Checco JW, 2016, CURR OPIN STRUC BIOL, V39, P96, DOI 10.1016/j.sbi.2016.06.014
   Checco JW, 2015, J AM CHEM SOC, V137, P11365, DOI 10.1021/jacs.5b05896
   Checco JW, 2015, P NATL ACAD SCI USA, V112, P4552, DOI 10.1073/pnas.1420380112
   Cheloha RW, 2016, ACS CHEM BIOL, V11, P2752, DOI 10.1021/acschembio.6b00404
   Cheloha RW, 2015, NAT REV ENDOCRINOL, V11, P712, DOI 10.1038/nrendo.2015.139
   Cheloha RW, 2015, ACS CHEM BIOL, V10, P844, DOI 10.1021/cb500888q
   Cheloha RW, 2014, NAT BIOTECHNOL, V32, P653, DOI 10.1038/nbt.2920
   Cupp ME, 2013, J PHARMACOL EXP THER, V345, P404, DOI 10.1124/jpet.112.199752
   Czekster CM, 2016, J AM CHEM SOC, V138, P5194, DOI 10.1021/jacs.6b01023
   Dean T, 2006, MOL ENDOCRINOL, V20, P931, DOI 10.1210/me.2005 0349
   Dean T, 2008, MOL ENDOCRINOL, V22, P156, DOI 10.1210/me.2007 0274
   Dedkova LM, 2012, BIOCHEMISTRY US, V51, P401, DOI 10.1021/bi2016124
   Denton EV, 2013, ORG LETT, V15, P5318, DOI 10.1021/ol402568j
   Diao L, 2013, CLIN PHARMACOKINET, V52, P855, DOI 10.1007/s40262 013 0079 0
   DiBonaventura MD, 2010, PATIENT PREFER ADHER, V4, P397, DOI 10.2147/PPA.S14477
   ELLMAN JA, 1992, SCIENCE, V255, P197, DOI 10.1126/science.1553546
   Fallowfield L, 2006, ANN ONCOL, V17, P205, DOI 10.1093/annonc/mdj044
   Feinstein TN, 2013, J BIOL CHEM, V288, P27849, DOI 10.1074/jbc.M112.445098
   Feinstein TN, 2011, NAT CHEM BIOL, V7, P278, DOI 10.1038/nchembio.545
   Ferrandon S, 2009, NAT CHEM BIOL, V5, P734, DOI 10.1038/nchembio.206
   Fosgerau K, 2015, DRUG DISCOV TODAY, V20, P122, DOI 10.1016/j.drudis.2014.10.003
   Fujino T, 2016, J AM CHEM SOC, V138, P1962, DOI 10.1021/jacs.5b12482
   Gardella TJ, 2015, PHARMACOL REV, V67, P310, DOI 10.1124/pr.114.009464
   Gidon A, 2016, METHOD CELL BIOL, V132, P109, DOI 10.1016/bs.mcb.2015.10.007
   Gidon A, 2014, NAT CHEM BIOL, V10, P707, DOI [10.1038/nchembio.1589, 10.1038/NCHEMBIO.1589]
   Guo LT, 2011, INT J PHARMACEUT, V420, P172, DOI 10.1016/j.ijpharm.2011.08.029
   Haase HS, 2012, J AM CHEM SOC, V134, P7652, DOI 10.1021/ja302469a
   Hämmerle SP, 2012, BONE, V50, P965, DOI 10.1016/j.bone.2012.01.009
   Hager MV, 2016, J AM CHEM SOC, V138, P14970, DOI 10.1021/jacs.6b08323
   Hartman MCT, 2006, P NATL ACAD SCI USA, V103, P4356, DOI 10.1073/pnas.0509219103
   Hattersley G, 2016, ENDOCRINOLOGY, V157, P141, DOI 10.1210/en.2015 1726
   Henriksen K, 2013, BONE, V53, P160, DOI 10.1016/j.bone.2012.11.045
   Hoare SRJ, 2001, J BIOL CHEM, V276, P7741, DOI 10.1074/jbc.M009395200
   Hollenstein K, 2014, TRENDS PHARMACOL SCI, V35, P12, DOI 10.1016/j.tips.2013.11.001
   Home W.S., 2009, P NATL ACAD SCI US, V106, P14751, DOI DOI 10.1073/PNAS.0902663106
   Horne WS, 2008, P NATL ACAD SCI USA, V105, P9151, DOI 10.1073/pnas.0801135105
   Horne WS, 2008, ANGEW CHEM INT EDIT, V47, P2853, DOI 10.1002/anie.200705315
   Horwitz MJ, 2013, J BONE MINER RES, V28, P2266, DOI 10.1002/jbmr.1978
   Horwitz MJ, 2010, J CLIN ENDOCR METAB, V95, P1279, DOI 10.1210/jc.2009 0233
   Horwitz MJ, 2003, J CLIN ENDOCR METAB, V88, P569, DOI 10.1210/jc.2002 021122
   Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092 8674(00)81688 8
   Jazayeri A, 2017, NATURE, V546, P254, DOI 10.1038/nature22800
   Johnson LM, 2014, J AM CHEM SOC, V136, P12848, DOI 10.1021/ja507168t
   Johnson LM, 2013, METHOD ENZYMOL, V523, P407, DOI 10.1016/B978 0 12 394292 0.00019 9
   Johnson LM, 2012, J AM CHEM SOC, V134, P7317, DOI 10.1021/ja302428d
   Karsdal MA, 2015, BRIT J CLIN PHARMACO, V79, P720, DOI 10.1111/bcp.12557
   KENT GN, 1985, CLIN SCI, V68, P171, DOI 10.1042/cs0680171
   Kushal S, 2013, P NATL ACAD SCI USA, V110, P15602, DOI 10.1073/pnas.1312473110
   Lao BB, 2014, P NATL ACAD SCI USA, V111, P7531, DOI 10.1073/pnas.1402393111
   Leader B, 2008, NAT REV DRUG DISCOV, V7, P21, DOI 10.1038/nrd2399
   Leder BZ, 2015, J CLIN ENDOCR METAB, V100, P697, DOI 10.1210/jc.2014 3718
   Lee HS, 2001, J ORG CHEM, V66, P3597, DOI 10.1021/jo001534l
   Lelais G, 2004, HELV CHIM ACTA, V87, P3131, DOI 10.1002/hlca.200490280
   Leone Bay A, 2001, PHARMACEUT RES, V18, P964, DOI 10.1023/A:1010936227570
   Leone Bay A, 1998, J MED CHEM, V41, P1163, DOI 10.1021/jm970811m
   LePlae PR, 2001, J ORG CHEM, V66, P5629, DOI 10.1021/jo010279h
   Liang YL, 2017, NATURE, V546, P118, DOI 10.1038/nature22327
   Liao S, 2010, AMINO ACIDS, V38, P1595, DOI 10.1007/s00726 009 0376 y
   Maeda A, 2013, P NATL ACAD SCI USA, V110, P5864, DOI 10.1073/pnas.1301674110
   Maini R, 2013, BIOORGAN MED CHEM, V21, P1088, DOI 10.1016/j.bmc.2013.01.002
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Okazaki M, 2008, P NATL ACAD SCI USA, V105, P16525, DOI 10.1073/pnas.0808750105
   Olson KE, 2015, J NEUROSCI, V35, P16463, DOI 10.1523/JNEUROSCI.2131 15.2015
   Pawar VK, 2014, J CONTROL RELEASE, V196, P168, DOI 10.1016/j.jconrel.2014.09.031
   Peggion E, 2002, BIOCHEMISTRY US, V41, P8162, DOI 10.1021/bi0200155
   Pelay Gimeno M, 2015, ANGEW CHEM INT EDIT, V54, P8896, DOI 10.1002/anie.201412070
   Peterson Kaufman KJ, 2015, ACS CHEM BIOL, V10, P1667, DOI 10.1021/acschembio.5b00109
   Pioszak AA, 2008, P NATL ACAD SCI USA, V105, P5034, DOI 10.1073/pnas.0801027105
   Pioszak AA, 2009, J BIOL CHEM, V284, P28382, DOI 10.1074/jbc.M109.022905
   Plum A, 2013, J PHARM SCI US, V102, P2882, DOI 10.1002/jps.23648
   Qin L, 2004, TRENDS ENDOCRIN MET, V15, P60, DOI 10.1016/j.tem.2004.01.006
   Schievano E, 2003, BIOPOLYMERS, V70, P534, DOI 10.1002/bip.10508
   Serada M, 2012, XENOBIOTICA, V42, P398, DOI 10.3109/00498254.2011.622811
   Shimizu M, 2000, J BIOL CHEM, V275, P21836, DOI 10.1074/jbc.M909861199
   Shimizu M, 2016, J BONE MINER RES, V31, P1405, DOI 10.1002/jbmr.2811
   Shimizu N, 2001, J BIOL CHEM, V276, P49003, DOI 10.1074/jbc.M106827200
   Smart AL, 2014, EXPERT OPIN DRUG DEL, V11, P1323, DOI 10.1517/17425247.2014.917077
   Sturmer A, 2013, CLIN PHARMACOKINET, V52, P995, DOI 10.1007/s40262 013 0083 4
   Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808
   Tan ZP, 2004, J AM CHEM SOC, V126, P12752, DOI 10.1021/ja0472174
   Tsomaia N, 2004, BIOCHEMISTRY US, V43, P690, DOI 10.1021/bi035703i
   Underwood CR, 2010, J BIOL CHEM, V285, P723, DOI 10.1074/jbc.M109.033829
   Uppalapati M, 2016, ACS CHEM BIOL, V11, P1058, DOI 10.1021/acschembio.5b01006
   Varela A, 2017, J BONE MINER RES, V32, P24, DOI 10.1002/jbmr.3003
   Vilardaga JP, 2014, NAT CHEM BIOL, V10, P700, DOI [10.1038/NCHEMBIO.1611, 10.1038/nchembio.1611]
   Vlieghe P, 2010, DRUG DISCOV TODAY, V15, P40, DOI 10.1016/j.drudis.2009.10.009
   Wang J, 2015, MOL PHARMACEUT, V12, P966, DOI 10.1021/mp500809f
   Werner HM, 2016, CHEMBIOCHEM, V17, P712, DOI 10.1002/cbic.201500312
   Zhang Y, 2017, NATURE, V546, P248, DOI 10.1038/nature22394
NR 95
TC 19
Z9 24
U1 0
U2 24
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022 2623
EI 1520 4804
J9 J MED CHEM
JI J. Med. Chem.
PD NOV 9
PY 2017
VL 60
IS 21
BP 8816
EP 8833
DI 10.1021/acs.jmedchem.7b00876
PG 18
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA FM6DV
UT WOS:000415140600011
PM 29064243
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Hruby, M
   Etrych, T
   Kucka, J
   Forsterová, M
   Ulbrich, K
AF Hruby, Martin
   Etrych, Tomas
   Kucka, Jan
   Forsterova, Michaela
   Ulbrich, Karel
TI Hydroxybisphosphonate containing polymeric drug delivery systems
   designed for targeting into bone tissue
SO JOURNAL OF APPLIED POLYMER SCIENCE
LA English
DT Article
DE copolymerization; drug delivery systems; functionalization of polymers;
   radical polymerization; water soluble polymers
ID HPMA COPOLYMERS; IN VITRO; RELEASE; BISPHOSPHONATES; CARRIERS; LINKAGE;
   SPACER; ACIDS
AB The preparation and characterization of a novel polymeric drug delivery system designed for bone targeting of antineoplastics is described. The system was based on biocompatible poly[N (2 hydroxypropyl)methacrylamide] carrier containing hydroxybisphosphonate targeting moieties and the model radiotherapeutics I 125 or In 111 or the anticancer drug doxorubicin. The in vitro binding studies with hydroxyapatite as a bone model proved that the system was efficiently adsorbed on this mineral. The systems contained model drugs bound by stable (amide), hydrolytically cleavable (hydrazone) or enzymatically cleavable (Gly Phe Leu Gly tetrapeptide) spacers. It was proven in vitro that, in the case of cleavable spacers, the drug could be released from the polymer carrier at a rate depending on the pH or enzymatic stimulus. 2006 Wiley Periodicals, Inc.
C1 Acad Sci Czech Republ, Inst Macromol Chem, CR 16206 Prague 6, Czech Republic.
   Charles Univ, Fac Sci, Dept Organ & Nucl Chem, Prague 12843, Czech Republic.
   Acad Sci Czech Republ, Inst Nucl Res, CZ 25068 Rez, Czech Republic.
C3 Czech Academy of Sciences; Institute of Macromolecular Chemistry of the
   Czech Academy of Sciences; Charles University Prague; Czech Academy of
   Sciences
RP Hruby, M (通讯作者)，Acad Sci Czech Republ, Inst Macromol Chem, CR 16206 Prague 6, Czech Republic.
EM hruby@imc.cas.cz
RI Kucka, Jan/G 7884 2014; Hruby, Martin/H 6479 2014; Ulbrich,
   Karel/G 5145 2014; Etrych, Tomas/G 3420 2014
OI Kucka, Jan/0000 0003 2489 5315; Hruby, Martin/0000 0002 5075 261X; 
CR Adams BK, 2003, ARCH DIS CHILD, V88, P631, DOI 10.1136/adc.88.7.631
   Arican A, 1999, MED ONCOL, V16, P204, DOI 10.1007/BF02906133
   Arsos G, 2002, EUR J RADIOL, V43, P66, DOI 10.1016/S0720 048X(01)00427 2
   DROBNIK J, 1976, MAKROMOL CHEM, V177, P2833
   Etrych T, 2002, MACROMOL BIOSCI, V2, P43, DOI 10.1002/1616 5195(20020101)2:1<43::AID MABI43>3.0.CO;2 8
   Etrych T, 2001, J CONTROL RELEASE, V73, P89, DOI 10.1016/S0168 3659(01)00281 4
   Ezra A, 2000, ADV DRUG DELIVER REV, V42, P175, DOI 10.1016/S0169 409X(00)00061 2
   Hirabayashi H, 2003, CLIN PHARMACOKINET, V42, P1319, DOI 10.2165/00003088 200342150 00002
   Jarvis NV, 2002, RADIOCHIM ACTA, V90, P237, DOI 10.1524/ract.2002.90.4_2002.237
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Kissel M, 2001, PDA J PHARM SCI TECH, V55, P191
   REJMANOVA P, 1977, MAKROMOL CHEM, V178, P2159, DOI 10.1002/macp.1977.021780803
   REJMANOVA P, 1983, J MAKROMOL CHEM, V183, P2009
   Stepensky D, 2003, CLIN PHARMACOKINET, V42, P863, DOI 10.2165/00003088 200342100 00001
   SUBR V, 1992, J CONTROL RELEASE, V18, P123, DOI 10.1016/0168 3659(92)90181 P
   SUBR V, 2005, IN PRESS REACT FUNCT
   Torchilin VP, 2005, EXPERT OPIN THER PAT, V15, P63, DOI 10.1517/13543776.15.1.63
   Ulbrich K, 2000, J CONTROL RELEASE, V64, P63, DOI 10.1016/S0168 3659(99)00141 8
   Uludag H, 2000, BIOTECHNOL PROGR, V16, P258, DOI 10.1021/bp990154m
   Uludag H, 2002, CURR PHARM DESIGN, V8, P1929, DOI 10.2174/1381612023393585
   Wang D, 2003, BIOCONJUGATE CHEM, V14, P853, DOI 10.1021/bc034090j
NR 21
TC 32
Z9 42
U1 0
U2 22
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0021 8995
J9 J APPL POLYM SCI
JI J. Appl. Polym. Sci.
PD SEP 5
PY 2006
VL 101
IS 5
BP 3192
EP 3201
DI 10.1002/app.23446
PG 10
WC Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Polymer Science
GA 064ZC
UT WOS:000239128200059
DA 2025 08 17
ER

PT J
AU Wang, YJ
   Tang, H
   He, G
   Shi, YX
   Kang, X
   Lyu, JT
   Zhou, M
   Zhu, M
   Zhang, JQ
   Tang, KL
AF Wang, Yunjiao
   Tang, Hong
   He, Gang
   Shi, Youxing
   Kang, Xia
   Lyu, Jingtong
   Zhou, Mei
   Zhu, Min
   Zhang, Jiqiang
   Tang, Kanglai
TI High Concentration of Aspirin Induces Apoptosis in Rat Tendon Stem Cells
   via Inhibition of the Wnt/ Catenin Pathway
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Tendon stem cells; Aspirin; Wnt;  catenin pathway; Apoptosis
ID OSTEOGENIC DIFFERENTIATION; GROWTH INHIBITION; BETA CATENIN; CANCER;
   PROLIFERATION; TENDINOPATHY; SUPPRESSION; HYPOXIA
AB Background/Aims: Non steroidal anti inflammatory drugs (NSAIDs) are commonly used in clinical practice to relieve fever and pain. Aspirin, as a representative NSAID, has been widely used in the treatment of tendinopathy. Some reports have demonstrated that aspirin can induce apoptosis in cancer cells. However, evidence regarding aspirin treatment for tendinopathy, especially the effect of this treatment on tendon stem cells (TSCs), is lacking. Understanding the effect of aspirin on tendinopathy may provide a basis for the rational use of NSAIDs in clinical practice. The aim of our study was to determine whether aspirin induces apoptosis in rat TSCs via the Wnt/ catenin pathway. Methods: First, we used flow cytometry and fluorescence to detect TSC apoptosis. Protein expression of the apoptosis related caspase 3 pathway was investigated via western blot analysis. Next, we used western blotting to determine the effect of aspirin on the Wnt/ catenin pathway. We used immunostaining to detect the levels of Bcl2, cleaved caspase 3, and P  catenin in the Achilles tendon. Finally, we used flow cytometry, fluorescence, and western blotting to investigate the aspirin induced apoptosis of TSCs via the Wnt/ catenin pathway. Results: Aspirin induced morphological apoptosis in rat TSCs via the mitochondrial/caspase 3 pathway and induced cellular apoptosis in the Achilles tendon. Apoptosis was partly reversed after adding the Wnt signaling activator Wnt3a and lithium chloride (LiCl, a GSK 3 inhibitor). Aspirin administration led to a dose dependent increase in COX 2 expression. Apoptosis was promoted after adding the COX 2 inhibitor NS398. Conclusion: The Wnt/ catenin pathway plays a vital role in aspirin induced apoptosis by regulating mitochondrial/caspase 3 function. Elevating COX 2 levels may protect cells against apoptosis. More importantly, the results remind us to consider the apoptotic effect of aspirin on TSCs and tendon cells when aspirin is administered to treat tendinopathy. The relationship between the positive and negative effects of aspirin remains a subject for future study.
C1 [Wang, Yunjiao; Tang, Hong; He, Gang; Shi, Youxing; Kang, Xia; Lyu, Jingtong; Zhou, Mei; Zhu, Min; Tang, Kanglai] Third Mil Med Univ, Southwest Hosp, Dept Orthopead, Gaotanyan St 30, Chongqing 400038, Peoples R China.
   [Zhang, Jiqiang] Third Mil Med Univ, Dept Neurol, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University
RP Tang, KL (通讯作者)，Third Mil Med Univ, Southwest Hosp, Dept Orthopead, Gaotanyan St 30, Chongqing 400038, Peoples R China.
EM tangkanglai@hotmail.com
RI tang, kang/HNQ 2884 2023; wang, yunjiao/HLP 8098 2023; Zhang,
   Jiqiang/B 4488 2008
OI Zhang, Jiqiang/0000 0002 1905 8750
FU National Natural Science Foundation of China (NSFC) [81230040,
   81572133]; National Key Research and Development of China
   [2016YFC1100500]
FX This study was supported by the National Natural Science Foundation of
   China (NSFC, No. 81230040 and 81572133) and the National Key Research
   and Development of China (No. 2016YFC1100500).
CR Antman EM, 2017, CIRCULATION, V135, P2062, DOI 10.1161/CIRCULATIONAHA.117.027288
   Barker N, 2010, CELL STEM CELL, V7, P656, DOI 10.1016/j.stem.2010.11.016
   Bi Y, 2014, CELL PHYSIOL BIOCHEM, V34, P1318, DOI 10.1159/000366340
   Bi YM, 2007, NAT MED, V13, P1219, DOI 10.1038/nm1630
   Bos CL, 2006, ONCOGENE, V25, P6447, DOI 10.1038/sj.onc.1209658
   Chechik O, 2014, ARCH ORTHOP TRAUM SU, V134, P515, DOI 10.1007/s00402 014 1928 5
   Chen JY, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5030043
   Choi BH, 2013, EXP MOL MED, V45, DOI 10.1038/emm.2013.91
   Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105
   Dakin SG, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4269
   Del Buono Angelo, 2013, Muscles Ligaments Tendons J, V3, P51, DOI 10.11138/mltj/2013.3.1.051
   Ding JH, 2014, EUR J HAEMATOL, V93, P329, DOI 10.1111/ejh.12352
   Farrugia G, 2013, FEMS YEAST RES, V13, P755, DOI 10.1111/1567 1364.12075
   Gillis CT, 2016, J FOOT ANKLE SURG, V55, P235, DOI 10.1053/j.jfas.2015.10.002
   Grancher A, 2018, B CANCER, V105, P171, DOI 10.1016/j.bulcan.2017.09.013
   Hast MW, 2014, BONE JOINT RES, V3, P193, DOI 10.1302/2046 3758.36.2000281
   Henry WS, 2017, CANCER RES, V77, P790, DOI 10.1158/0008 5472.CAN 16 2400
   Huang NX, 2016, MOL NEUROBIOL, V53, P3258, DOI 10.1007/s12035 015 9241 z
   Im SR, 2012, BIOCHEM BIOPH RES CO, V424, P65, DOI 10.1016/j.bbrc.2012.06.067
   Lavagnino M, 2016, MLTJ MUSCLE LIGAMENT, V6, P193, DOI 10.11138/mltj/2016.6.2.193
   Li B, 2016, SCI REP UK, V6, DOI 10.1038/srep26542
   Li LP, 2017, CANCER RES, V77, P4116, DOI 10.1158/0008 5472.CAN 17 0202
   Li T, 2013, CANCER GENE THER, V20, P366, DOI 10.1038/cgt.2013.29
   Ling L, 2009, GENE, V433, P1, DOI 10.1016/j.gene.2008.12.008
   Liu JP, 2013, BIOCHEM BIOPH RES CO, V435, P514, DOI 10.1016/j.bbrc.2012.11.083
   Maffulli Nicola, 2013, Muscles Ligaments Tendons J, V3, P173
   Maffulli N, 2010, J BONE JOINT SURG AM, V92A, P2604, DOI 10.2106/JBJS.I.01744
   Maganaris CN, 2004, SPORTS MED, V34, P1005, DOI 10.2165/00007256 200434140 00005
   Magra M, 2008, J SCI MED SPORT, V11, P243, DOI 10.1016/j.jsams.2007.04.007
   Millar NL, 2017, NAT REV RHEUMATOL, V13, P110, DOI 10.1038/nrrheum.2016.213
   Morris T, 2009, J IMMUNOL, V183, P2089, DOI 10.4049/jimmunol.0900477
   Oliva Francesco, 2014, Muscles Ligaments Tendons J, V4, P273
   Rui YF, 2010, TISSUE ENG PT A, V16, P1549, DOI [10.1089/ten.tea.2009.0529, 10.1089/ten.TEA.2009.0529]
   Tao X, 2015, CELL PHYSIOL BIOCHEM, V35, P699, DOI 10.1159/000369730
   Tsai WC, 2003, J ORTHOPAED RES, V21, P265, DOI 10.1016/S0736 0266(02)00151 1
   Wang WY, 2017, THERANOSTICS, V7, P2134, DOI 10.7150/thno.17665
   Wang Y, 2006, CLIN EXP PHARMACOL P, V33, P696, DOI 10.1111/j.1440 1681.2006.04432.x
   Wong MWN, 2004, CLIN ORTHOP RELAT R, P277, DOI 10.1097/01.blo.0000118184.83983.65
   Zhang JY, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 10
   Zhang JY, 2010, J ORTHOP RES, V28, P198, DOI 10.1002/jor.20962
   Zhu WQ, 2006, STEM CELLS, V24, P416, DOI 10.1634/stemcells.2005 0121
NR 41
TC 19
Z9 22
U1 0
U2 14
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2018
VL 50
IS 6
BP 2046
EP 2059
DI 10.1159/000495050
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA HB4SN
UT WOS:000451046100003
PM 30415260
OA gold
DA 2025 08 17
ER

PT J
AU Weitzmann, MN
   Ofotokun, I
   Titanji, K
   Sharma, A
   Yin, MT
AF Weitzmann, M. Neale
   Ofotokun, Ighovwerha
   Titanji, Kehmia
   Sharma, Anjali
   Yin, Michael T.
TI Bone Loss Among Women Living With HIV
SO CURRENT HIV/AIDS REPORTS
LA English
DT Article
DE Adiposity; Anti retroviral therapy; ART; B cells; Bone loss; cART;
   Falls; Fracture; HAART; HIV; OPG; Osteoclasts; Osteoporosis; RANKL;
   Tcells; TNF
ID ANTIRETROVIRAL THERAPY; MINERAL DENSITY; INFECTED WOMEN; INTERAGENCY
   HIV; POSTMENOPAUSAL WOMEN; PREMENOPAUSAL WOMEN; FRACTURE INCIDENCE; RANK
   LIGAND; TNF ALPHA; RESORPTION
AB Clinical data accumulated over the past two decades attests to a significant decline in bone mineral density (BMD) in patients infected by HIV, which does not remit but may actually intensify with anti retroviral therapy (ART). Long generally perceived as an aberration without clinical consequences in relatively young HIV infected cohorts, recent studies have documented marked increases in fracture incidence in HIV infected men and women over a wide age continuum. Fractures are associated with chronic pain, crippling morbidity, and increased mortality, undermining the gains in quality of life achieved though ART. As bone loss and resulting increases in fracture incidence are a natural consequence of aging, there is now concern regarding the long term consequences of HIV/ART associated premature bone loss, given the transition of the HIV/AIDS population into an older age demographic. The development of guidelines for diagnosis and treatment of bone disease within the context of HIV and ART has been an important recent step in raising awareness of the problem and the implications of bone fracture for patient health. Significant progress has also been made in recent years in dissecting the complex and multifactorial mechanisms driving bone loss in HIV/ART and the role of underlying immunological disruption in skeletal dysmorphogenesis. This review examines recent progress in the field and studies by Women's Interagency HIV Study (WIHS) associated investigators, inside and outside of the WIHS cohort, aimed at identifying skeletal abnormalities, quantifying facture incidence, management, and understanding underlying mechanisms in people living with HIV in the context of chronic ART.
C1 [Weitzmann, M. Neale] Vet Affairs Med Ctr, Atlanta Dept, 1670 Clairmont Rd, Decatur, GA 30033 USA.
   [Weitzmann, M. Neale; Titanji, Kehmia] Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
   [Ofotokun, Ighovwerha] Emory Univ, Div Infect Dis, Dept Med, Sch Med, 49 Jesse Hill Jr Dr, Atlanta, GA 30303 USA.
   [Ofotokun, Ighovwerha] Grady Healthcare Syst, 80 Jesse Hill Jr Dr SE, Atlanta, GA 30303 USA.
   [Sharma, Anjali] Albert Einstein Coll Med, Dept Med, Div Gen Internal Med & Infect Dis, 1300 Morris Pk Ave,Block Bldg 305, Bronx, NY 10461 USA.
   [Yin, Michael T.] Columbia Univ, Div Infect Dis, Med Ctr, 630 West 168th St,PH8 876, New York, NY 10032 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   Emory University; Emory University; Yeshiva University; Montefiore
   Medical Center; Albert Einstein College of Medicine; Columbia University
RP Weitzmann, MN (通讯作者)，Vet Affairs Med Ctr, Atlanta Dept, 1670 Clairmont Rd, Decatur, GA 30033 USA.; Weitzmann, MN (通讯作者)，Emory Univ, Sch Med, Dept Med, Div Endocrinol & Metab & Lipids, 101 Woodruff Circle,1305 WMB, Atlanta, GA 30322 USA.
EM mweitzm@emory.edu; iofotok@emory.edu; ktitanj@emory.edu;
   anjali.sharma@einstein.yu.edu; mty4@columbia.edu
OI Yin, Michael T/0000 0002 9346 9056
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) [R01AR059364, R01AR070091, K23AR061993]; National Institute on
   Aging (NIA) [R01AG040013]; Biomedical Laboratory Research & Development
   Service of the VA Office of Research and Development [5I01BX000105];
   Emory University Research Council; National Heart, Lung, and Blood
   Institute (NHLBI) [K01HL131333]; NIH; National Institute of Allergy and
   Infectious Diseases (NIAID) [R01AI095089]
FX M. Neale Weitzmann is supported by the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (NIAMS) under award numbers
   R01AR059364 and R01AR070091 and by the National Institute on Aging (NIA)
   under award number R01AG040013 and is supported by a grant from the
   Biomedical Laboratory Research & Development Service of the VA Office of
   Research and Development (5I01BX000105).Kehmia Titanji is supported by a
   grant from the Emory University Research Council (URC); has received a
   grant from the National Heart, Lung, and Blood Institute (NHLBI) under
   award number K01HL131333; and has received travel support from
   NIH.Anjali Sharma is supported by the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (NIAMS) under award number
   K23AR061993.Michael T. Yin is supported by a grant from the National
   Institute of Allergy and Infectious Diseases (NIAID) under award number
   R01AI095089 and has received travel support for WIHS meetings.
CR Adeel S, 2013, J INVEST MED, V61, P1178, DOI 10.2310/JIM.0000000000000016
   Anostos K, 2007, ANTIVIR THER, V12, P1049
   Arnsten JH, 2006, CLIN INFECT DIS, V42, P1014, DOI 10.1086/501015
   Bass E, 2007, ANN EPIDEMIOL, V17, P514, DOI 10.1016/j.annepidem.2006.12.004
   Brown TT, 2009, JAIDS J ACQ IMM DEF, V51, P554, DOI 10.1097/QAI.0b013e3181adce44
   Cenci S, 2000, J CLIN INVEST, V106, P1229, DOI 10.1172/JCI11066
   Dolan SE, 2004, AIDS, V18, P475, DOI 10.1097/00002030 200402200 00014
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Eisman JA, 2012, J BONE MINER RES, V27, P2039, DOI 10.1002/jbmr.1698
   Fuller K, 2002, ENDOCRINOLOGY, V143, P1108, DOI 10.1210/en.143.3.1108
   Indridason OS, 2005, OSTEOPOROSIS INT, V16, P417, DOI 10.1007/s00198 004 1699 x
   Khosla S, 2002, OSTEOPOROSIS INT, V13, P394, DOI 10.1007/s001980200045
   Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lencel P, 2011, MED HYPOTHESES, V76, P317, DOI 10.1016/j.mehy.2010.09.023
   Li Y, 2007, BLOOD, V109, P3839, DOI 10.1182/blood 2006 07 037994
   Li Yan, 2014, Open Bone J, V6, P8
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Ofotokun I, 2016, CLIN INFECT DIS, V63, P663, DOI 10.1093/cid/ciw331
   Ofotokun I, 2016, AIDS, V30, P405, DOI 10.1097/QAD.0000000000000918
   Ofotokun I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9282
   Prior J, 2007, OSTEOPOROSIS INT, V18, P1345, DOI 10.1007/s00198 007 0428 7
   Riggs BL, 2002, ENDOCR REV, V23, P279, DOI 10.1210/er.23.3.279
   Sharma A HD, 2016, 23 C RETR OPP INF BO
   Sharma A MY, 2015, 22 C RETR OPP INF SE
   Sharma A, 2015, JAIDS J ACQ IMM DEF, V70, P54, DOI 10.1097/QAI.0000000000000674
   Sharma A, 2012, JAIDS J ACQ IMM DEF, V61, P469, DOI 10.1097/QAI.0b013e31826cba6c
   Teichmann J, 2003, J INFECTION, V46, P221, DOI 10.1053/jinf.2002.1109
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Titanji K, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004497
   Triant VA, 2008, J CLIN ENDOCR METAB, V93, P3499, DOI 10.1210/jc.2008 0828
   Vikulina T, 2010, P NATL ACAD SCI USA, V107, P13848, DOI 10.1073/pnas.1003020107
   Weitzmann MN, 2016, NAT REV END IN PRESS
   Yin M, 2005, OSTEOPOROSIS INT, V16, P1345, DOI 10.1007/s00198 005 1845 0
   Yin MT, 2013, CALCIFIED TISSUE INT, V92, P557, DOI 10.1007/s00223 013 9716 8
   Yin MT, 2012, J CLIN ENDOCR METAB, V97, P554, DOI 10.1210/jc.2011 2197
   Yin MT, 2010, AIDS, V24, P2679, DOI 10.1097/QAD.0b013e32833f6294
   Yin MT, 2010, JAIDS J ACQ IMM DEF, V53, P202, DOI 10.1097/QAI.0b013e3181bf6471
   Yun TJ, 1998, J IMMUNOL, V161, P6113
   Zhang YH, 2001, J BIOL CHEM, V276, P563, DOI 10.1074/jbc.M008198200
NR 40
TC 12
Z9 12
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1548 3568
EI 1548 3576
J9 CURR HIV AIDS REP
JI Curr. Hiv/Aids Rep.
PD DEC
PY 2016
VL 13
IS 6
BP 367
EP 373
DI 10.1007/s11904 016 0336 6
PG 7
WC Infectious Diseases
WE Science Citation Index Expanded (SCI EXPANDED)
SC Infectious Diseases
GA EC4TO
UT WOS:000388127000007
PM 27678124
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Yonezawa, T
   Hasegawa, S
   Asai, M
   Ninomiya, T
   Sasaki, T
   Cha, BY
   Teruya, T
   Ozawa, H
   Yagasaki, K
   Nagai, K
   Woo, JT
AF Yonezawa, Takayuki
   Hasegawa, Shin ichi
   Asai, Midori
   Ninomiya, Tadashi
   Sasaki, Toshinori
   Cha, Byung Yoon
   Teruya, Toshiaki
   Ozawa, Hidehiro
   Yagasaki, Kazumi
   Nagai, Kazuo
   Woo, Je Tae
TI Harmine, a β carboline alkaloid, inhibits osteoclast differentiation and
   bone resorption in vitro and in vivo
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Harmine; Osteoclast; Bone resorption; Osteoporosis
ID NITRIC OXIDE SYNTHASE; PROTEIN KINASE; NATURAL PRODUCTS; DRUG DISCOVERY;
   ACTIVATION; INDUCTION; RECEPTOR; LIPOPOLYSACCHARIDE; MACROPHAGES; LIGAND
AB Bone homeostasis is controlled by the balance between osteoblastic bone formation and osteoclastic bone resorption. Excessive bone resorption is involved in the pathogenesis of bone related disorders such as osteoporosis, arthritis and periodontitis. To obtain new antiresorptive agents, we searched for natural compounds that can inhibit osteoclast differentiation and function. We found that harmine, a beta carboline alkaloid, inhibited multinucleated osteoclast formation induced by receptor activator of nuclear factor kappa B ligand (RANKL) in RAW264.7 cells. Similar results were obtained in cultures of bone marrow macrophages supplemented with macrophage colony stimulating factor and RANKL, as well as in cocultures of bone marrow cells and osteoblastic UAMS 32 cells in the presence of vitamin D(3) and prostaglandin E(2). Furthermore, harmine prevented RANKL induced bone resorption in both cell and bone tissue cultures. Treatment with harmine (10 mg/kg/day) also prevented bone loss in ovariectomized osteoporosis model mice. Structure activity relationship studies showed that the C3 C4 double bond and 7 methoxy group of harmine are important for its inhibitory activity on osteoclast differentiation. In mechanistic studies, we found that harmine inhibited the RANKL induced expression of c Fos and subsequent expression of nuclear factor of activated T cells (NFAT) c1, which is a master regulator of osteoclastogenesis. However, harmine did not affect early signaling molecules such as ERK, p38 MAPK and I kappa B alpha. These results indicate that harmine inhibits osteoclast formation via downregulation of c Fos and NFATc1 induced by RANKL and represses bone resorption. These novel findings may be useful for the treatment of bone destructive diseases. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Hasegawa, Shin ichi; Asai, Midori; Sasaki, Toshinori; Nagai, Kazuo; Woo, Je Tae] Chubu Univ, Dept Biol Chem, Coll Biosci & Biotechnol, Aichi 4878501, Japan.
   [Yonezawa, Takayuki; Yagasaki, Kazumi; Woo, Je Tae] Univ Tokyo, Dept Nutriprote, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Yonezawa, Takayuki; Cha, Byung Yoon; Teruya, Toshiaki; Nagai, Kazuo; Woo, Je Tae] Chubu Univ, Res Inst Biol Funct, Aichi 4878501, Japan.
   [Ninomiya, Tadashi; Ozawa, Hidehiro] Matsumoto Dent Univ, Div Hard Tissue Res, Inst Oral Sci, Nagano 3990781, Japan.
   [Yagasaki, Kazumi] Tokyo Univ Agr & Technol, Div Agrisci & Biosci, Inst Symbiot Sci & Technol, Fuchu, Tokyo 1838509, Japan.
C3 Chubu University; University of Tokyo; Chubu University; Matsumoto
   Dental University; Tokyo University of Agriculture & Technology
RP Woo, JT (通讯作者)，Chubu Univ, Dept Biol Chem, Coll Biosci & Biotechnol, 1200 Matsumoto, Aichi 4878501, Japan.
EM jwoo@isc.chubu.ac.jp
RI ; Yagasaki, Kazumi/AAG 8828 2020; YONEZAWA, Takayuki/O 3047 2019
OI YONEZAWA, Takayuki/0000 0001 8060 0839; 
FU Ministry of Education, Culture, Sports, Science and Technology; Erina
   Co. Inc. (Tokyo, Japan); Grants in Aid for Scientific Research
   [23659883, 21390505] Funding Source: KAKEN
FX The authors are grateful to Dr. Kohji Yamaguchi and Dr. Masamichi Takami
   (Showa University) for technical advice. This work was partly supported
   by a Grant in Aid for Scientific Research (B) from the Ministry of
   Education, Culture, Sports, Science and Technology. This study was
   performed at a laboratory that is supported by an endowment from Erina
   Co. Inc. (Tokyo, Japan).
CR Ajizian SJ, 1999, J INFECT DIS, V179, P939, DOI 10.1086/314659
   ALLEN JRF, 1980, PHYTOCHEMISTRY, V19, P1573, DOI 10.1016/S0031 9422(00)83773 5
   Arron JR, 2006, NATURE, V441, P595, DOI 10.1038/nature04678
   Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797
   Berrougui H, 2006, PHARMACOL RES, V54, P150, DOI 10.1016/j.phrs.2006.04.001
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Cao RH, 2007, CURR MED CHEM, V14, P479, DOI 10.2174/092986707779940998
   Farzin D, 2006, EUR NEUROPSYCHOPHARM, V16, P324, DOI 10.1016/j.euroneuro.2005.08.005
   Feng GJ, 1999, J IMMUNOL, V163, P6403
   Feng X, 2005, IUBMB LIFE, V57, P389, DOI 10.1080/15216540500137669
   Gwack Y, 2006, NATURE, V441, P646, DOI 10.1038/nature04631
   Hämmerle B, 2003, J NEURAL TRANSM SUPP, P129
   Harvey AL, 2008, DRUG DISCOV TODAY, V13, P894, DOI 10.1016/j.drudis.2008.07.004
   Hotokezaka H, 2002, J BIOL CHEM, V277, P47366, DOI 10.1074/jbc.M208284200
   Husbands SM, 2001, DRUG ALCOHOL DEPEN, V64, P203, DOI 10.1016/S0376 8716(01)00123 5
   Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001
   O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Waki H, 2007, CELL METAB, V5, P357, DOI 10.1016/j.cmet.2007.03.010
   Woo JT, 2004, BIOL PHARM BULL, V27, P504, DOI 10.1248/bpb.27.504
   XIE QW, 1994, J BIOL CHEM, V269, P4705
   Yonezawa T, 2007, BIOCHEM BIOPH RES CO, V355, P10, DOI 10.1016/j.bbrc.2006.12.237
   Zhao QX, 2010, INT J BIOCHEM CELL B, V42, P576, DOI 10.1016/j.biocel.2009.12.018
NR 25
TC 46
Z9 52
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 15
PY 2011
VL 650
IS 2 3
BP 511
EP 518
DI 10.1016/j.ejphar.2010.10.048
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 763JW
UT WOS:000290553600004
PM 21047508
DA 2025 08 17
ER

PT J
AU Paniagua, RT
   Chang, A
   Mariano, MM
   Stein, EA
   Wang, Q
   Lindstrom, TM
   Sharpe, O
   Roscow, C
   Ho, PP
   Lee, DM
   Robinson, WH
AF Paniagua, Ricardo T.
   Chang, Anna
   Mariano, Melissa M.
   Stein, Emily A.
   Wang, Qian
   Lindstrom, Tamsin M.
   Sharpe, Orr
   Roscow, Claire
   Ho, Peggy P.
   Lee, David M.
   Robinson, William H.
TI c Fms mediated differentiation and priming of monocyte lineage cells
   play a central role in autoimmune arthritis
SO ARTHRITIS RESEARCH & THERAPY
LA English
DT Article
ID COLLAGEN INDUCED ARTHRITIS; COLONY STIMULATING FACTOR;
   RHEUMATOID ARTHRITIS; IMATINIB MESYLATE; INFLAMMATORY ARTHRITIS;
   MAST CELLS; JOINT DESTRUCTION; BONE MARROW; M CSF; MACROPHAGE
AB Introduction: Tyrosine kinases are key mediators of multiple signaling pathways implicated in rheumatoid arthritis (RA). We previously demonstrated that imatinib mesylate a Food and Drug Administration (FDA) approved, antineoplastic drug that potently inhibits the tyrosine kinases Abl, c Kit, platelet derived growth factor receptor (PDGFR), and c Fms ameliorates murine autoimmune arthritis. However, which of the imatinib targeted kinases is the principal culprit in disease pathogenesis remains unknown. Here we examine the role of c Fms in autoimmune arthritis.
   Methods: We tested the therapeutic efficacy of orally administered imatinib or GW2580, a small molecule that specifically inhibits c Fms, in three mouse models of RA: collagen induced arthritis (CIA), anti collagen antibody induced arthritis (CAIA), and K/BxN serum transfer induced arthritis (K/BxN). Efficacy was evaluated by visual scoring of arthritis severity, paw thickness measurements, and histological analysis. We assessed the in vivo effects of imatinib and GW2580 on macrophage infiltration of synovial joints in CIA, and their in vitro effects on macrophage and osteoclast differentiation, and on osteoclast mediated bone resorption. Further, we determined the effects of imatinib and GW2580 on the ability of macrophage colony stimulating factor (M CSF; the ligand for c Fms) to prime bone marrow derived macrophages to produce tumor necrosis factor (TNF) upon subsequent Fc receptor ligation. Finally, we measured M CSF levels in synovial fluid from patients with RA, osteoarthritis (OA), or psoriatic arthritis (PsA), and levels of total and phosphorylated c Fms in synovial tissue from patients with RA.
   Results: GW2580 was as efficacious as imatinib in reducing arthritis severity in CIA, CAIA, and K/BxN models of RA. Specific inhibition of c Fms abrogated (i) infiltration of macrophages into synovial joints of arthritic mice; (ii) differentiation of monocytes into macrophages and osteoclasts; (iii) osteoclast mediated bone resorption; and (iv) priming of macrophages to produce TNF upon Fc receptor stimulation, an important trigger of synovitis in RA. Expression and activation of c Fms in RA synovium were high, and levels of M CSF were higher in RA synovial fluid than in OA or PsA synovial fluid.
   Conclusions: These results suggest that c Fms plays a central role in the pathogenesis of RA by mediating the differentiation and priming of monocyte lineage cells. Therapeutic targeting of c Fms could provide benefit in RA.
C1 [Paniagua, Ricardo T.; Chang, Anna; Mariano, Melissa M.; Stein, Emily A.; Wang, Qian; Lindstrom, Tamsin M.; Sharpe, Orr; Roscow, Claire; Robinson, William H.] Stanford Univ, Dept Med, Div Rheumatol & Immunol, Sch Med, Stanford, CA 94305 USA.
   [Paniagua, Ricardo T.; Chang, Anna; Mariano, Melissa M.; Stein, Emily A.; Wang, Qian; Lindstrom, Tamsin M.; Sharpe, Orr; Roscow, Claire; Robinson, William H.] Palo Alto VA Hlth Care Syst, GRECC, Palo Alto, CA 94304 USA.
   [Ho, Peggy P.] Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA.
   [Lee, David M.] Harvard Univ, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Dept Med,Sch Med, Boston, MA 02115 USA.
C3 Stanford University; Geriatric Research Education & Clinical Center;
   Stanford University; Harvard University; Harvard Medical School; Harvard
   University Medical Affiliates; Brigham & Women's Hospital
RP Robinson, WH (通讯作者)，Stanford Univ, Dept Med, Div Rheumatol & Immunol, Sch Med, CCSR 4135,269 Campus Dr, Stanford, CA 94305 USA.
EM wrobins@stanford.edu
RI ; Mariano, Mario/L 2557 2015; chang, anna/JXM 8182 2024
OI Robinson, William/0000 0003 4385 704X; /0000 0002 6848 318X; 
FU National Institutes of Health (NIH) National Heart Lung and Blood
   Institute [N01 HV 28183]; NIH National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01 AR 054822]; Veterans Affairs
   Health Care System; NIH [F31]; Stanford University
FX This work was supported by National Institutes of Health (NIH) National
   Heart Lung and Blood Institute contract N01 HV 28183, NIH National
   Institute of Arthritis and Musculoskeletal and Skin Diseases R01
   AR 054822, and Veterans Affairs Health Care System funding awarded to
   WHR as well as an NIH F31 Fellowship Award and Stanford University
   Lieberman Fellowship Award granted to RTP. We thank Darren R Veach
   (Memorial Sloan Kettering Cancer Center) for chemically synthesized
   imatinib, Jessica Hamerman (Benaroya Research Institute, Seattle, WA,
   USA) for insights on Fc receptor activation, and members of the WHR
   laboratory for fruitful discussions. We appreciate GlaxoSmithKline's
   provision of GW2580 for the arthritis prevention studies.
CR Ames PRJ, 2008, J RHEUMATOL, V35, P1682
   Ando W, 2006, J BONE MINER METAB, V24, P274, DOI 10.1007/s00774 006 0684 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Buchdunger E, 2001, BBA REV CANCER, V1551, pM11, DOI 10.1016/S0304 419X(01)00022 1
   Campbell IK, 2000, J LEUKOCYTE BIOL, V68, P144
   Cheon H, 2004, SCAND J IMMUNOL, V60, P455, DOI 10.1111/j.0300 9475.2004.01505.x
   Choy EHS, 2001, NEW ENGL J MED, V344, P907, DOI 10.1056/NEJM200103223441207
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Conway JG, 2008, J PHARMACOL EXP THER, V326, P41, DOI 10.1124/jpet.107.129429
   Conway JG, 2005, P NATL ACAD SCI USA, V102, P16078, DOI 10.1073/pnas.0502000102
   Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461
   Deng GM, 2005, NAT MED, V11, P1066, DOI 10.1038/nm1304
   Dewar AL, 2005, BLOOD, V105, P3127, DOI 10.1182/blood 2004 10 3967
   Druker BJ., 2001, NEW ENGL J MED, V344, P10311037
   Edwards JCW, 2004, NEW ENGL J MED, V350, P2572, DOI 10.1056/NEJMoa032534
   Eklund KK, 2003, ANN MED, V35, P362, DOI 10.1080/07853890310001339
   Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068
   Firestein GS, 2009, NAT CLIN PRACT RHEUM, V5, P1, DOI 10.1038/ncprheum0973
   Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661
   Genovese MC, 2005, NEW ENGL J MED, V353, P1114, DOI 10.1056/NEJMoa050524
   Gredmark S, 2004, J IMMUNOL, V173, P4897, DOI 10.4049/jimmunol.173.8.4897
   Hamerman JA, 2005, NAT IMMUNOL, V6, P579, DOI 10.1038/ni1204
   Irvine KM, 2006, FASEB J, V20, P1921, DOI 10.1096/fj.06 5848fje
   Kim KW, 2007, IMMUNOL LETT, V110, P54, DOI 10.1016/j.imlet.2007.03.004
   Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552
   Koyama Kensuke, 2007, Mod Rheumatol, V17, P306, DOI 10.1007/s10165 007 0592 9
   Lee DM, 2002, SCIENCE, V297, P1689, DOI 10.1126/science.1073176
   Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370
   Miyachi K, 2003, CLIN RHEUMATOL, V22, P329, DOI 10.1007/s10067 003 0716 3
   Monach PA, 2009, P NATL ACAD SCI USA, V106, P15867, DOI 10.1073/pnas.0908032106
   Nakano K, 2007, RHEUMATOLOGY, V46, P597, DOI 10.1093/rheumatology/kel356
   Ohno H, 2008, EUR J IMMUNOL, V38, P283, DOI 10.1002/eji.200737199
   Ohno H, 2006, MOL CANCER THER, V5, P2634, DOI 10.1158/1535 7163.MCT 05 0313
   Paniagua RT, 2006, J CLIN INVEST, V116, P2633, DOI 10.1172/JCI28546
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   ROSLONIEC EF, 1994, CURRENT PROTOCOLS IM
   Serbina NV, 2008, ANNU REV IMMUNOL, V26, P421, DOI 10.1146/annurev.immunol.26.021607.090326
   Shin K, 2006, ARTHRITIS RHEUM US, V54, P2863, DOI 10.1002/art.22058
   Shin K, 2009, J IMMUNOL, V182, P647, DOI 10.4049/jimmunol.182.1.647
   Stanley E R, 1997, Methods Mol Biol, V75, P301
   Tebib J, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2740
   Watanabe N, 2002, BIOCHEM BIOPH RES CO, V294, P1121, DOI 10.1016/S0006 291X(02)00608 3
   Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401
   Xu W, 2007, EUR J IMMUNOL, V37, P1594, DOI 10.1002/eji.200737042
   Yang PT, 2006, ANN RHEUM DIS, V65, P1671, DOI 10.1136/ard.2006.054874
   Yao ZQ, 2006, J BIOL CHEM, V281, P11846, DOI 10.1074/jbc.M512624200
   Zhou JS, 2007, J EXP MED, V204, P2797, DOI 10.1084/jem.20071391
NR 47
TC 62
Z9 86
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1478 6354
EI 1478 6362
J9 ARTHRITIS RES THER
JI Arthritis Res. Ther.
PY 2010
VL 12
IS 1
AR R32
DI 10.1186/ar2940
PG 15
WC Rheumatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Rheumatology
GA 600TV
UT WOS:000278012700045
PM 20181277
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Di Pompo, G
   Kusuzaki, K
   Ponzetti, M
   Leone, VF
   Baldini, N
   Avnet, S
AF Di Pompo, Gemma
   Kusuzaki, Katsuyuki
   Ponzetti, Marco
   Leone, Vito Ferdinando
   Baldini, Nicola
   Avnet, Sofia
TI Radiodynamic Therapy with Acridine Orange Is an Effective Treatment for
   Bone Metastases
SO BIOMEDICINES
LA English
DT Article
DE radiodynamic therapy; acridine orange; tumor acidosis; bone metastases;
   tumor microenvironment
ID PROTON PUMP INHIBITORS; LIMB SALVAGE SURGERY; LOW DOSE RADIATION;
   PHOTODYNAMIC THERAPY; H+ ATPASE; MUSCULOSKELETAL SARCOMAS; FLUORESCENCE
   MICROSCOPY; K+ ATPASE; V ATPASE; PH
AB Current multimodal treatment of bone metastases is partially effective and often associated with side effects, and novel therapeutic options are needed. Acridine orange is a photosensitizing molecule that accumulates in acidic compartments. After photo  or radiodynamic activation (AO PDT or AO RDT), acridine orange can induce lysosomal mediated cell death, and we explored AO RDT as an acid targeted anticancer therapy for bone metastases. We used osteotropic carcinoma cells and human osteoclasts to assess the extracellular acidification and invasiveness of cancer cells, acridine orange uptake and lysosomal pH/stability, and the AO RDT cytotoxicity in vitro. We then used a xenograft model of bone metastasis to compare AO RDT to another antiacid therapeutic strategy (omeprazole). Carcinoma cells showed extracellular acidification activity and tumor derived acidosis enhanced cancer invasiveness. Furthermore, cancer cells accumulated acridine orange more than osteoclasts and were more sensitive to lysosomal death. In vivo, omeprazole did not reduce osteolysis, whereas AO RDT promoted cancer cell necrosis and inhibited tumor induced bone resorption, without affecting osteoclasts. In conclusion, AO RDT was selectively toxic only for carcinoma cells and effective to impair both tumor expansion in bone and tumor associated osteolysis. We therefore suggest the use of AO RDT, in combination with the standard antiresorptive therapies, to reduce disease burden in bone metastasis.
C1 [Di Pompo, Gemma; Baldini, Nicola] IRCCS Ist Ortoped Rizzoli, Biomed Sci & Technol & Nanobiotechnol Lab, I 40136 Bologna, Italy.
   [Kusuzaki, Katsuyuki] Takai Hosp, Dept Musculoskeletal Oncol, Tenri, Nara 6320372, Japan.
   [Ponzetti, Marco] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I 67100 Laquila, Italy.
   [Leone, Vito Ferdinando] Ctr Oncol Vet, I 40037 Bologna, Italy.
   [Baldini, Nicola; Avnet, Sofia] Univ Bologna, Dept Biomed & Neuromotor Sci, I 40126 Bologna, Italy.
C3 University of L'Aquila; University of Bologna
RP Avnet, S (通讯作者)，Univ Bologna, Dept Biomed & Neuromotor Sci, I 40126 Bologna, Italy.
EM sofia.avnet@ior.it
RI Avnet, Sofia/B 3220 2018; Di Pompo, Gemma/J 5317 2018; Baldini,
   Nicola/J 4806 2016; Ponzetti, Marco/AAS 9938 2020
OI Avnet, Sofia/0000 0002 7843 0591; Ponzetti, Marco/0000 0002 7554 1325;
   Di Pompo, Gemma/0000 0001 5121 4330
FU Italian Association for Cancer Research [14191]; Italian Ministry of
   Health; ERANet LAC [PER 2012 ELAC2015/T07 0713]
FX This research was funded by the Italian Association for Cancer Research
   to S.A. (AIRC MFAG n. 14191), Italian Ministry of Health 5 ~ 1000 Anno
   2019, Redditi 2018 "Il microambiente tumorale come bersaglio per terapie
   innovative nei tumori muscoloscheletrici" to N.B., and the ERANet LAC to
   N.B. (PER 2012 ELAC2015/T07 0713).
CR ARNETT TR, 1986, ENDOCRINOLOGY, V119, P119, DOI 10.1210/endo 119 1 119
   Avnet S, 2004, ANTICANCER RES, V24, P1705
   Avnet S, 2019, CANCER METAST REV, V38, P133, DOI 10.1007/s10555 019 09790 9
   Avnet S, 2013, BBA MOL BASIS DIS, V1832, P1105, DOI 10.1016/j.bbadis.2013.04.003
   Ballabio A, 2020, NAT REV MOL CELL BIO, V21, P101, DOI 10.1038/s41580 019 0185 4
   Bernier J, 2004, NAT REV CANCER, V4, P737, DOI 10.1038/nrc1451
   Brunk UT, 1997, FREE RADICAL BIO MED, V23, P616, DOI 10.1016/S0891 5849(97)00007 5
   Byvaltsev VA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00925
   Cahill LC, 2018, LAB INVEST, V98, P150, DOI 10.1038/labinvest.2017.116
   Canitano A, 2016, CANCER LETT, V376, P278, DOI 10.1016/j.canlet.2016.04.015
   Chen R, 2020, CANCERS, V12, DOI 10.3390/cancers12092437
   Ciapetti G, 2017, ACTA BIOMATER, V50, P102, DOI 10.1016/j.actbio.2016.12.013
   Clement S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126425
   Cline B, 2019, WIRES NANOMED NANOBI, V11, DOI 10.1002/wnan.1541
   Clines Gregory A., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000616
   Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Costa Rodrigues J, 2013, FEBS J, V280, P5052, DOI 10.1111/febs.12478
   Cui GL, 2001, SCAND J GASTROENTERO, V36, P1011
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Damaghi M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00370
   De Milito A, 2007, CANCER RES, V67, P5408, DOI 10.1158/0008 5472.CAN 06 4095
   De Milito A, 2012, CURR PHARM DESIGN, V18, P1395, DOI 10.2174/138161212799504911
   DeClerck K, 2010, FRONT BIOSCI LANDMRK, V15, P213, DOI 10.2741/3616
   Di Pompo G, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.678532
   Di Pompo G, 2017, ONCOTARGET, V8, P54478, DOI 10.18632/oncotarget.17091
   Faris P, 2019, CANCERS, V11, DOI 10.3390/cancers11010027
   Fotia C, 2015, CURR PHARM DESIGN, V21, P4088, DOI 10.2174/1381612821666150918144953
   GagnemoPersson R, 1997, CALCIFIED TISSUE INT, V61, P210, DOI 10.1007/s002239900325
   Gareau D, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.066018
   Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008 5472.CAN 05 4193
   Geisslinger F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01156
   Glunde K, 2003, NEOPLASIA, V5, P533, DOI 10.1016/S1476 5586(03)80037 4
   Granchi D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181230
   Hashiguchi S, 2002, ONCOLOGY BASEL, V62, P85, DOI 10.1159/000048251
   Hyun JJ, 2010, INT J MOL MED, V26, P877, DOI 10.3892/ijmm_00000537
   Ito Tetsuhide, 2010, Curr Gastroenterol Rep, V12, P448, DOI 10.1007/s11894 010 0141 0
   Izumi H, 2003, CANCER TREAT REV, V29, P541, DOI 10.1016/S0305 7372(03)00106 3
   Jain M, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.2.024002
   Karsdal MA, 2005, AM J PATHOL, V166, P467, DOI 10.1016/S0002 9440(10)62269 9
   Kato Y, 2005, J BIOL CHEM, V280, P10938, DOI 10.1074/jbc.M411313200
   Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710
   Kolosenko I, 2017, SEMIN CANCER BIOL, V43, P119, DOI 10.1016/j.semcancer.2017.01.008
   Krishnamurthy S, 2018, ARCH PATHOL LAB MED, V142, P396, DOI 10.5858/arpa.2017 0164 OA
   Krolenko SA, 2006, CELL BIOL INT, V30, P933, DOI 10.1016/j.cellbi.2006.06.017
   Kusuzaki K, 2000, ANTICANCER RES, V20, P3019
   Kusuzaki K, 2005, ANTICANCER RES, V25, P1225
   Kusuzaki K, 2000, JPN J CANCER RES, V91, P439, DOI 10.1111/j.1349 7006.2000.tb00964.x
   Kusuzaki K, 2000, ONCOLOGY BASEL, V59, P174, DOI 10.1159/000012156
   Kusuzaki K, 2007, IN VIVO, V21, P205
   Kusuzaki K, 2012, CURR PHARM DESIGN, V18, P1414, DOI 10.2174/138161212799504812
   Lacombe J, 2013, CELL CYCLE, V12, P2744, DOI 10.4161/cc.25825
   Lloyd MC, 2016, CANCER RES, V76, P3136, DOI 10.1158/0008 5472.CAN 15 2962
   Lovejoy DB, 2011, CANCER RES, V71, P5871, DOI 10.1158/0008 5472.CAN 11 1218
   Luciani F, 2004, JNCI J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Martano M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8275935
   Martínez Zaguilán R, 1999, BIOCHEM PHARMACOL, V57, P1037, DOI 10.1016/S0006 2952(99)00022 2
   MartinezZaguilan R, 1996, CLIN EXP METASTAS, V14, P176, DOI 10.1007/BF00121214
   Matsubara T, 2006, ANTICANCER RES, V26, P187
   Matsubara T, 2010, J BONE JOINT SURG BR, V92B, P760, DOI 10.1302/0301 620X.92B6.23788
   Matsubara T, 2010, J SURG ONCOL, V102, P271, DOI 10.1002/jso.21602
   Matsubara T, 2009, ONCOL REP, V21, P89, DOI 10.3892/or_00000193
   MIZUNASHI K, 1993, CALCIFIED TISSUE INT, V53, P21, DOI 10.1007/BF01352010
   Nakamura T, 2008, J SURG ONCOL, V97, P523, DOI 10.1002/jso.21025
   Nakamura T, 2018, PHOTODIAGN PHOTODYN, V23, P165, DOI 10.1016/j.pdpdt.2018.06.001
   Nishi T, 2002, NAT REV MOL CELL BIO, V3, P94, DOI 10.1038/nrm729
   Ouar Z, 2003, BIOCHEM J, V370, P185, DOI 10.1042/BJ20021411
   Paglin S, 2001, CANCER RES, V61, P439
   Perut F, 2014, EXP CELL RES, V320, P21, DOI 10.1016/j.yexcr.2013.10.011
   Petersen NHT, 2013, CANCER CELL, V24, P379, DOI 10.1016/j.ccr.2013.08.003
   Piao SF, 2016, ANN NY ACAD SCI, V1371, P45, DOI 10.1111/nyas.12953
   Pogue BW, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.12.121610
   Prause M, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/413097
   Raghunand N, 1999, BIOCHEM PHARMACOL, V57, P309, DOI 10.1016/S0006 2952(98)00306 2
   ROZHIN J, 1994, CANCER RES, V54, P6517
   Sennoune SR, 2004, AM J PHYSIOL CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   Serrano Puebla A, 2018, BIOCHEM SOC T, V46, P207, DOI 10.1042/BST20170130
   SHIBUTANI T, 1993, J BONE MINER RES, V8, P331
   Sun Wada GH, 2003, J BIOENERG BIOMEMBR, V35, P347, DOI 10.1023/A:1025780932403
   Tsuchie H, 2019, ANTICANCER RES, V39, P6365, DOI 10.21873/anticanres.13849
   TUUKKANEN J, 1986, CALCIFIED TISSUE INT, V38, P123, DOI 10.1007/BF02556841
   Visentin L, 2000, J CLIN INVEST, V106, P309, DOI 10.1172/JCI6145
   Wang FJ, 2018, TRAFFIC, V19, P918, DOI 10.1111/tra.12613
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Yang YX, 2006, JAMA J AM MED ASSOC, V296, P2947, DOI 10.1001/jama.296.24.2947
   Yoneda T, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2015.58
   ZELENIN AV, 1966, NATURE, V212, P425, DOI 10.1038/212425a0
NR 89
TC 3
Z9 3
U1 2
U2 13
PU MDPI
PI BASEL
PA MDPI AG, Grosspeteranlage 5, CH 4052 BASEL, SWITZERLAND
EI 2227 9059
J9 BIOMEDICINES
JI Biomedicines
PD AUG
PY 2022
VL 10
IS 8
AR 1904
DI 10.3390/biomedicines10081904
PG 19
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 4C2SL
UT WOS:000846310000001
PM 36009451
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Liu, AQ
   Lin, D
   Zhao, HJ
   Chen, L
   Cai, BL
   Lin, KL
   Shen, SGF
AF Liu, Anqi
   Lin, Dan
   Zhao, Hanjiang
   Chen, Long
   Cai, Bolei
   Lin, Kaili
   Shen, Steve G. F.
TI Optimized BMSC derived osteoinductive exosomes immobilized in
   hierarchical scaffold via lyophilization for bone repair through
   Bmpr2/Acvr2b competitive receptor activated Smad pathway
SO BIOMATERIALS
LA English
DT Article
DE MSC Derived exosome; miRNA; Hierarchical scaffold; Mesoporous bioactive
   glass; Bone regeneration; Bmpr2; Acvr2b competitive Receptor
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; IN VITRO; ADIPOGENIC
   DIFFERENTIATION; TGF BETA; PROMOTES; PROLIFERATION; ANGIOGENESIS;
   OSTEOBLASTS; MECHANISM
AB Mesenchymal stem cell derived exosomes (MSC exos), with its inherent capacity to modulate cellular behavior, are emerging as a novel cell free therapy for bone regeneration. Herein, focusing on practical applying problems, the osteoinductivity of MSC exos produced by different stem cell sources (rBMSCs/rASCs) and culture conditions (osteoinductive/common) were systematically compared to screen out an optimized osteogenic exosome (BMSCOI exo). Via bioinformatic analyses by miRNA microarray and in vitro pathway verification by gene silencing and miRNA transfection, we first revealed that the osteoinductivity of BMSC OI exo was attributed to multicomponent exosomal miRNAs (let 7a 5p, let 7c 5p, miR 328a 5p and miR 31a 5p). These miRNAs targeted Acvr2b/Acvr1 and regulated the competitive balance of Bmpr2/Acvr2b toward Bmpr elicited Smad1/5/9 phosphorylation. On these bases, lyophilized delivery of BMSC OI exo on hierarchical mesoporous bioactive glass (MBG) scaffold was developed to realize bioactivity maintenance and sustained release by entrapment in the surface microporosity of the scaffold. In a rat cranial defect model, the loading of BMSC OI exo efficiently enhanced the bone forming capacity of the scaffold and induced rapid initiation of bone regeneration. This paper could provide empirical bases of MSC exo based therapy for bone regeneration and theoretical bases of MSC exoinduced osteogenesis mechanism. The BMSC OI exo loaded MBG scaffold developed here represented a promising bone repairing strategy for future clinical application.
C1 [Liu, Anqi; Lin, Dan; Zhao, Hanjiang; Chen, Long; Cai, Bolei; Lin, Kaili; Shen, Steve G. F.] Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp,Sch Med, Coll Stomatol,Dept Oral & Cranio Maxillofacial Su, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.
   [Liu, Anqi; Lin, Dan; Zhao, Hanjiang; Chen, Long; Cai, Bolei; Lin, Kaili; Shen, Steve G. F.] Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
   [Cai, Bolei] Fourth Mil Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, State Key Lab Mil Stomatol, Xian 710032, Peoples R China.
   [Shen, Steve G. F.] Shanghai Univ Med & Hlth Sci, Shanghai 201318, Peoples R China.
C3 Shanghai Jiao Tong University; Air Force Medical University; Shanghai
   University of Medicine & Health Sciences
RP Lin, D; Cai, BL; Lin, KL; Shen, SGF (通讯作者)，Shanghai Jiao Tong Univ, Shanghai Ninth Peoples Hosp,Sch Med, Coll Stomatol,Dept Oral & Cranio Maxillofacial Su, Natl Clin Res Ctr Oral Dis,Shanghai Key Lab Stoma, Shanghai 200011, Peoples R China.; Lin, D; Cai, BL; Lin, KL; Shen, SGF (通讯作者)，Shanghai Res Inst Stomatol, Shanghai 200011, Peoples R China.
EM d.lin@foxmail.com; caibolei1020@126.com; lklecnu@aliyun.com;
   shengf@sumhs.edu.cn
RI Cai, Bo Lei/JTS 5444 2023; Lin, Dan/GQY 4693 2022
OI Anqi, Liu/0009 0003 5617 3912; Lin, Dan/0000 0002 0159 7326; 
FU National Natural Science Foundation of China [81970973, 81771036]; China
   Postdoctoral Science Foundation [2020T130422]; National Key R&D Program
   of China [2017YFB1104100]; Shanghai Sailing Program [19YF1425500]; Three
   Year Action Plan to Promote Clinical Skills and Clinical Creativity in
   Municipal Hospitals [16CR10308B]; Pudong New Area Commission of Health
   and Family Planning [PW2016E 1]
FX The authors gratefully acknowledge the support of the National Natural
   Science Foundation of China (No. 81970973, No. 81771036), China
   Postdoctoral Science Foundation (2020T130422), National Key R&D Program
   of China (No. 2017YFB1104100) and Shanghai Sailing Program
   (19YF1425500), Three Year Action Plan to Promote Clinical Skills and
   Clinical Creativity in Municipal Hospitals (No. 16CR10308B), Pudong New
   Area Commission of Health and Family Planning (PW2016E 1).
CR Baino F, 2016, ACTA BIOMATER, V42, P18, DOI 10.1016/j.actbio.2016.06.033
   Bari E, 2019, NANOMEDICINE UK, V14, P753, DOI 10.2217/nnm 2018 0240
   Bari E, 2018, CELLS BASEL, V7, DOI 10.3390/cells7110190
   Berasi SP, 2011, GROWTH FACTORS, V29, P128, DOI 10.3109/08977194.2011.593178
   Bjorge I.M., 2017, BIOMATERIALS SCI, V6
   Bok TH, 2015, J MED BIOL ENG, V35, P21, DOI 10.1007/s40846 015 0001 3
   Cai ZY, 2016, PHARMAZIE, V71, P625, DOI 10.1691/ph.2016.6734
   Castao I. Mencia, 2018, TISSUE ENG
   Chang ML, 2015, IN VITRO CELL DEV AN, V51, P797, DOI 10.1007/s11626 015 9892 0
   Charoenviriyakul C, 2018, INT J PHARMACEUT, V553, P1, DOI 10.1016/j.ijpharm.2018.10.032
   Chen C., 2016, MOL MED REP
   Chen S, 2014, MOL MED REP, V9, P1820, DOI 10.3892/mmr.2014.2024
   Deng L, 2018, J BONE MINER METAB, V36, P648, DOI 10.1007/s00774 017 0886 8
   Ding H., 2018, CLIN EXPT PHARM PHYS
   Dvorakova J, 2008, CELL BIOL INT, V32, P1116, DOI 10.1016/j.cellbi.2008.04.024
   El Baradie KBY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00181
   Ellur G, 2021, CELL MOL LIFE SCI, V78, P1729, DOI 10.1007/s00018 020 03608 6
   Fen L., 2012, BIOTECHNOL B
   Furuta T, 2016, STEM CELL TRANSL MED, V5, P1620, DOI 10.5966/sctm.2015 0285
   Gan K, 2020, DIABETES RES CLIN PR, V167, DOI 10.1016/j.diabres.2020.108121
   Gibbings D, 2010, TRENDS CELL BIOL, V20, P491, DOI 10.1016/j.tcb.2010.06.001
   Guo Q, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.22
   Hassan M.Q., 2010, Proceedings of the National Academy of Sciences, P1
   Heinecke K, 2009, BMC BIOL, V7, DOI 10.1186/1741 7007 7 59
   Huang CC, 2016, BIOMATERIALS, V111, P103, DOI 10.1016/j.biomaterials.2016.09.029
   Inose H, 2009, P NATL ACAD SCI USA, V106, P20794, DOI 10.1073/pnas.0909311106
   Ji Hong Y., 2015, CHIN J TISSUE ENG RE
   Jones JR, 2006, BIOMATERIALS, V27, P964, DOI 10.1016/j.biomaterials.2005.07.017
   Kabsun, 2015, MOL CELL
   Kargozar S, 2018, ACTA BIOMATER, V81, P1, DOI 10.1016/j.actbio.2018.09.052
   Kawabata M, 1998, CYTOKINE GROWTH F R, V9, P49, DOI 10.1016/S1359 6101(97)00036 1
   Lai RC, 2010, STEM CELL RES, V4, P214, DOI 10.1016/j.scr.2009.12.003
   Li BZ, 2018, ONCOGENE, V37, P5508, DOI 10.1038/s41388 018 0359 0
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li Juntao, 2017, Yichuan, V39, P828, DOI 10.16288/j.yczz.16 403
   Li SS, 2016, CALCIFIED TISSUE INT, V99, P174, DOI 10.1007/s00223 016 0137 3
   Li WY, 2018, ACS APPL MATER INTER, V10, P5240, DOI 10.1021/acsami.7b17620
   Li XF, 2018, BIOMED PHARMACOTHER, V99, P622, DOI 10.1016/j.biopha.2018.01.103
   Li Y, 2015, CURRICULUM WINDOWS: WHAT CURRICULUM THEORISTS OF THE 1970S CAN TEACH US ABOUT SCHOOLS AND SOCIETY TODAY, P1
   Lin D, 2019, BIOMATERIALS, V196, P122, DOI 10.1016/j.biomaterials.2017.11.011
   Liu HZ, 2016, J TOXICOL SCI, V41, P185, DOI 10.2131/jts.41.185
   Liu XL, 2017, NANOSCALE, V9, P4430, DOI 10.1039/c7nr00352h
   Lopatina T, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478 811X 12 26
   Lowery JW, 2011, CRIT REV EUKAR GENE, V21, P177, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.60
   Lu Xihong, 2013, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V38, P341, DOI 10.3969/j.issn.1672 7347.2013.04.002
   Lu ZF, 2017, TISSUE ENG PT A, V23, P1212, DOI 10.1089/ten.tea.2016.0548
   Luo XQ, 2017, 2017 IEEE 7TH INTERNATIONAL CONFERENCE ON POWER AND ENERGY SYSTEMS (ICPES), P1, DOI 10.1109/ICPESYS.2017.8215910
   Luzi E., 2010, J BONE MINER RES, V23
   Martins M, 2016, STEM CELL REP, V6, P284, DOI 10.1016/j.stemcr.2016.01.001
   Minamizaki T., COMMUN BIOL
   Mittelbrunn M, 2012, NAT REV MOL CELL BIO, V13, P328, DOI 10.1038/nrm3335
   NAIR A, 2015, FASEB J S1, V29
   Narayanan R, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/3808674
   Niu HY, 2017, ACS BIOMATER SCI ENG, V3, P3161, DOI 10.1021/acsbiomaterials.7b00315
   Oddrun, 2015, CELL COMMUNICATION S
   Olsen OE, 2015, CELL COMMUN SIGNAL, V13, DOI 10.1186/s12964 015 0104 z
   Pegtel DM, 2010, P NATL ACAD SCI USA, V107, P6328, DOI 10.1073/pnas.0914843107
   Qi, 2017, J BONE MINER METABOL
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Qian, 2019, ARTIFICIAL CELLS NAN
   Qin YW, 2016, SCI REP UK, V6, DOI 10.1038/srep20880
   Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698
   Riazifar M, 2017, ANNU REV PHARMACOL, V57, P125, DOI 10.1146/annurev pharmtox 061616 030146
   Roberts SS, 2014, GOTHIC SUBLECTS: THE TRANSFORMATION OF INDIVIDUALISM IN AMERICAN FICTION, 1790 1861, P28
   Rogler C.E., 2010, HEPATOLOGY, V50, P575
   Shi Y., 2003, CELL
   Shuai Y, 2019, LIFE SCI, V220, P84, DOI 10.1016/j.lfs.2019.01.051
   Shuping S., 2017, STOMATOLOGY
   Silvestro S, 2020, GENES BASEL, V11, DOI 10.3390/genes11020118
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Sun L, 2019, MATER CORROS, V70, P1682, DOI 10.1002/maco.201910801
   Tan Z., 2017, BIOCHEM BIOPH RES CO
   Tang W, 2016, ACTA BIOMATER, V32, P309, DOI 10.1016/j.actbio.2015.12.006
   Tang YF, 2009, OMICS, V13, P331, DOI 10.1089/omi.2009.0017
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Tian F, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/632305
   Trompeter HI, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 111
   Tu X.M., 2016, EXPT THERAPEUTIC MED
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang C, 2016, SCI REP UK, V6, DOI 10.1038/srep30122
   Wei F, 2019, ACTA BIOMATER, V86, P480, DOI 10.1016/j.actbio.2019.01.006
   Weigong, 2015, INT J MOL SCI
   Xiangdong, 2019, VITRO CELLULAR DEV B
   Xu RY, 2018, AGING CELL, V17, DOI 10.1111/acel.12794
   Yan, 2015, MOL THERAPY
   Yan XX, 2006, BIOMATERIALS, V27, P3396, DOI 10.1016/j.biomaterials.2006.01.043
   Yan XX, 2004, ANGEW CHEM INT EDIT, V43, P5980, DOI 10.1002/anie.200460598
   Yan ZX, 2018, EXP THER MED, V15, P2589, DOI 10.3892/etm.2018.5723
   Yang QN, 2019, DRUG DES DEV THER, V13, P2503, DOI 10.2147/DDDT.S211051
   Yang RL, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 04464 6
   Yao, 2016, BIOMEDECINE PHARMACO
   Yeo RWY, 2013, ADV DRUG DELIVER REV, V65, P336, DOI 10.1016/j.addr.2012.07.001
   Ying Z., 2017, PLOS ONE, V12
   Yu, 2018, LIFE SCI
   Zeng HC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15000
   Zhang, 2018, INT J BIOL MACROMOLE
   Zhang HC, 2012, STEM CELLS DEV, V21, P3289, DOI 10.1089/scd.2012.0095
   Zhang J., 2017, MOL MED REP
   Zhang JY, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0391 3
   Zhang S, 2016, OSTEOARTHR CARTILAGE, V24, P2135, DOI 10.1016/j.joca.2016.06.022
   Zhang ZQ, 2015, FEBS LETT, V589, P3671, DOI 10.1016/j.febslet.2015.09.032
   ZHou Yue, 2016, CIRCULATION, V134
   Zhou Z, 2018, SOLID STATE IONICS, V315, P1, DOI 10.1016/j.ssi.2017.11.034
   Zhu SB, 2020, J GENE MED, V22, DOI 10.1002/jgm.3246
NR 104
TC 153
Z9 162
U1 8
U2 200
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD MAY
PY 2021
VL 272
AR 120718
DI 10.1016/j.biomaterials.2021.120718
EA APR 2021
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA RQ5QU
UT WOS:000642474200003
PM 33838528
DA 2025 08 17
ER

PT J
AU Zhang, XH
   Zhou, LM
   Qian, X
AF Zhang, Xuhong
   Zhou, Lamei
   Qian, Xian
TI The Mechanism of "Treating Different Diseases with the Same Treatment"
   by Qiangji Jianpi Decoction in Ankylosing Spondylitis Combined with
   Inflammatory Bowel Disease: A Comprehensive Analysis of Multiple Methods
SO GASTROENTEROLOGY RESEARCH AND PRACTICE
LA English
DT Article
ID CELLS; INFORMATION; PREVALENCE; ARTHRITIS
AB Background. Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are prevalent autoimmune disorders that often co occur, posing significant treatment challenges. This investigation adopts a multidisciplinary strategy, integrating bioinformatics, network pharmacology, molecular docking, and Mendelian randomization, to elucidate the relationship between AS and IBD and to investigate the potential mechanisms of traditional Chinese medicine formulations, represented by Qiangji Jianpi (QJJP) decoction, in treating these comorbid conditions. Methods. We utilized databases to pinpoint common targets among AS, IBD, and QJJP decoction's active compounds through intersection analysis. Through Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses, we mapped a network in Cytoscape, isolating critical targets. Molecular docking with AutoDock validated the affinity between targets and compounds. ROC analysis and dataset validation assessed diagnostic performance, while Gene Set Enrichment Analysis (GSEA) offered pathway insights. Mendelian randomization explored the AS IBD causal relationship. Results. Screening identified 105 targets for QJJP decoction, 414 for AS, and 2420 for IBD, with 85 overlapping. These targets predominantly participate in organismal responses and DNA transcription factor binding, with a significant cellular presence in the endoplasmic reticulum and vesicle lumen. Molecular docking, facilitated by Cytoscape, confirmed IL1A, IFNG, TGFB1, and EDN1 as critical targets, with IFNG demonstrating diagnostic potential through GEO dataset validation. The integration of GSEA with network pharmacology highlighted the therapeutic significance of the relaxin, osteoclast differentiation, HIF 1, and AGE RAGE signaling pathways in QJJP decoction's action. Mendelian randomization analysis indicated a positive causal relationship between IBD and AS, pinpointing rs2193041 as a key SNP influencing IFNG. Conclusion. Based on the principle of "treating different diseases with the same method" in traditional Chinese medicine theory, we explored the intricate mechanisms through which QJJP decoction addresses AS and IBD comorbidity. Our research spotlighted the pivotal role of the IFNG gene. IFNG emerges not only as a key therapeutic target but also assumes significance as a potential diagnostic biomarker through its genetic underpinnings. This investigation establishes a solid base for subsequent experimental inquiries. Our findings introduce novel approaches for incorporating traditional Chinese medicine into the treatment of AS IBD comorbidity, setting the stage for groundbreaking research directions.
C1 [Zhang, Xuhong; Zhou, Lamei] Nanjing Univ Chinese Med, Wuxi Affiliated Hosp, Wuxi, Peoples R China.
   [Qian, Xian] Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine
RP Qian, X (通讯作者)，Nanjing Univ Chinese Med, Affiliated Hosp, Nanjing, Peoples R China.
EM 20215025@njucm.edu.cn; lameizhou@126.com; fsyy00715@njucm.edu.cn
RI Zhang, Xuhong/JXM 0555 2024
OI xian, Qian/0000 0002 9388 2158; Zhang, Xuhong/0000 0002 8519 5649
CR Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkh131, 10.1093/nar/gkw1099]
   Bae JM, 2017, MOD RHEUMATOL, V27, P435, DOI 10.1080/14397595.2016.1211229
   Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
   Boyadjiev SA, 2000, CLIN GENET, V57, P253, DOI 10.1034/j.1399 0004.2000.570403.x
   Brakenhoff LKPM, 2010, J CROHNS COLITIS, V4, P257, DOI 10.1016/j.crohns.2009.11.005
   Brandtzaeg P, 1997, ALIMENT PHARM THER, V11, P24
   Brown MA, 2016, NAT REV RHEUMATOL, V12, P81, DOI 10.1038/nrrheum.2015.133
   Chen L, 2017, ANN RHEUM DIS, V76, P620, DOI 10.1136/annrheumdis 2016 210175
   Chen X, 2022, MOL MED REP, V25, DOI 10.3892/mmr.2022.12680
   Cosconati S, 2010, EXPERT OPIN DRUG DIS, V5, P597, DOI 10.1517/17460441.2010.484460
   Cui ZY, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.587876
   Danoy P, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001195
   Davey Smith G, 2014, HUM MOL GENET, V23, pR89, DOI 10.1093/hmg/ddu328
   De Sousa JFM, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.25006
   de Winter JJ, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1093 z
   Feng XZ, 2020, CELL MOL BIOL, V66, P127, DOI 10.14715/cmb/2020.66.6.23
   Gaudet P, 2017, METHODS MOL BIOL, V1446, P189, DOI 10.1007/978 1 4939 3743 1_14
   Gilis E, 2018, J RHEUMATOL, V45, P36, DOI 10.3899/jrheum.180135
   Gionchetti P, 2015, J RHEUMATOL, V42, P21, DOI 10.3899/jrheum.150628
   Glover LE, 2011, J IMMUNOL, V186, P1790, DOI 10.4049/jimmunol.1001442
   Greenland S, 2018, INT J EPIDEMIOL, V47, P358, DOI 10.1093/ije/dyx275
   HASLOCK I, 1973, ANN RHEUM DIS, V32, P479, DOI 10.1136/ard.32.6.479
   He SM, 2022, PHARMACOLOGY, V107, P495, DOI 10.1159/000525218
   Hedin CRH, 2019, J CROHNS COLITIS, V13, P541, DOI 10.1093/ecco jcc/jjy191
   Hinze Alicia M, 2016, Curr Treatm Opt Rheumatol, V2, P271, DOI 10.1007/s40674 016 0055 6
   Hu LS, 2022, J TISSUE ENG REGEN M, V16, P634, DOI 10.1002/term.3304
   Huo MQ, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 01691 8
   Jia CY, 2020, DRUG DISCOV TODAY, V25, P248, DOI 10.1016/j.drudis.2019.10.014
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kim NY, 2022, CELL SIGNAL, V99, DOI 10.1016/j.cellsig.2022.110433
   Kouranov A, 2006, NUCLEIC ACIDS RES, V34, pD302, DOI 10.1093/nar/gkj120
   Laroche M, 2023, RHEUMATOL INT, V43, P363, DOI 10.1007/s00296 021 05074 0
   Li DF, 2022, INT J NANOMED, V17, P3893, DOI 10.2147/IJN.S370784
   Li JB, 2021, FRONT MED LAUSANNE, V8, DOI 10.3389/fmed.2021.701789
   Li J, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/8348272
   Li NS, 2021, J CELL MOL MED, V25, P4765, DOI 10.1111/jcmm.16445
   Li T, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/4983471
   Li XJ, 2008, TRENDS PHARMACOL SCI, V29, P331, DOI 10.1016/j.tips.2008.04.002
   Lin YQ, 2022, NEUROIMMUNOMODULAT, V29, P486, DOI 10.1159/000525690
   Liu Y, 2022, J ETHNOPHARMACOL, V289, DOI 10.1016/j.jep.2022.115084
   Mauro D, 2021, SEMIN IMMUNOL, V58, DOI 10.1016/j.smim.2022.101607
   Ni J, 2020, IMMUNITY, V52, P1075, DOI 10.1016/j.immuni.2020.05.001
   Ocansey DKW, 2020, BIOL REV, V95, P1287, DOI 10.1111/brv.12608
   Peek CT, 2022, CELL MOL GASTROENTER, V14, P731, DOI 10.1016/j.jcmgh.2022.07.002
   Pinzi L, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184331
   Rehaume LM, 2014, ARTHRITIS RHEUMATOL, V66, P2780, DOI 10.1002/art.38773
   Reveille JD, 2012, ARTHRIT CARE RES, V64, P905, DOI 10.1002/acr.21621
   Ru JL, 2014, J CHEMINFORMATICS, V6, DOI 10.1186/1758 2946 6 13
   Sairenji T, 2017, PRIMARY CARE, V44, P673, DOI 10.1016/j.pop.2017.07.010
   Samuel CS, 2017, BRIT J PHARMACOL, V174, P962, DOI 10.1111/bph.13529
   Seyedian Seyed Saeid, 2019, J Med Life, V12, P113, DOI 10.25122/jml 2018 0075
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Shen Orr SS, 2013, CURR OPIN IMMUNOL, V25, P571, DOI 10.1016/j.coi.2013.09.015
   Smith GD, 2020, EUR J EPIDEMIOL, V35, P99, DOI 10.1007/s10654 020 00622 7
   Stelzer Gil, 2016, Curr Protoc Bioinformatics, V54, DOI 10.1002/cpbi.5
   Stolwijk C, 2015, ANN RHEUM DIS, V74, P65, DOI 10.1136/annrheumdis 2013 203582
   Syrbe U, 2015, GUT, V64, P1011, DOI 10.1136/gutjnl 2014 308436
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Tang GH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00154
   Traini C, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.804623
   Valkovic AL, 2019, MOL CELL ENDOCRINOL, V487, P24, DOI 10.1016/j.mce.2018.12.017
   Waghela BN, 2021, MOL CELL BIOCHEM, V476, P585, DOI 10.1007/s11010 020 03928 y
   Wang GZ, 2022, EVID BASED COMPL ALT, V2022, DOI 10.1155/2022/3997190
   Wang X, 2012, EVID BASED COMPL ALT, V2012, DOI 10.1155/2012/519031
   Wei MQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5217405
   Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD1074, DOI 10.1093/nar/gkx1037
   Xu X, 2012, INT J MOL SCI, V13, P6964, DOI 10.3390/ijms13066964
   Xu ZK, 2019, INT J MOL MED, V43, P1179, DOI 10.3892/ijmm.2018.4038
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056
   Yin JH, 2022, CELL BIOL INT, V46, P46, DOI 10.1002/cbin.11712
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Yuan S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.892790
   Zhang J, 2022, REDOX BIOL, V56, DOI 10.1016/j.redox.2022.102469
   Zhang J, 2021, ANN MED, V53, P1090, DOI 10.1080/07853890.2021.1918345
   Zheng Y, 2021, PEERJ, V9, DOI 10.7717/peerj.12125
   Zhou W, 2016, SCI REP UK, V6, DOI 10.1038/srep36985
NR 76
TC 2
Z9 3
U1 3
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1687 6121
EI 1687 630X
J9 GASTROENT RES PRACT
JI Gastroenterol. Res. Pract.
PD MAY 21
PY 2024
VL 2024
AR 9709260
DI 10.1155/2024/9709260
PG 24
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Gastroenterology & Hepatology
GA ST7T8
UT WOS:001236770800001
PM 38808131
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Böcker, W
   El Khassawna, T
   Bauer, N
   Brodsky, K
   Weisweiler, D
   Govindarajan, P
   Schlewitz, G
   Kampschulte, M
   Dürselen, L
   Thormann, U
   Szalay, G
   Schnettler, R
   Langheinrich, AC
   Heiss, C
AF Boecker, W.
   El Khassawna, T.
   Bauer, N.
   Brodsky, K.
   Weisweiler, D.
   Govindarajan, P.
   Schlewitz, G.
   Kampschulte, M.
   Duerselen, L.
   Thormann, U.
   Szalay, G.
   Schnettler, R.
   Langheinrich, A. C.
   Heiss, C.
TI Short term glucocorticoid treatment causes spinal osteoporosis in
   ovariectomized rats
SO EUROPEAN SPINE JOURNAL
LA English
DT Article
DE Glucocorticoid; Osteoporosis; Postmenopausal; Animal model; Rat; DEXA
ID ANIMAL MODELS; BONE DENSITY; MANAGEMENT; FRACTURE; OSTEOBLASTS;
   DIAGNOSIS; OSTEOPONTIN; INHIBITION; MECHANISMS; OSTEOCYTES
AB In humans, glucocorticoid induced osteoporosis is the most common cause of medication induced osteoporosis. Recent clinical data suggest that glucocorticoid therapy increases the risk of vertebral fractures within a short treatment period. Therefore, this study aimed at investigating vertebral bone in a rat model of glucocorticoid induced postmenopausal osteoporosis.
   Fifty Sprague Dawley rats were randomly assigned into three groups: 1) untreated controls, 2) Sham operated group, and 3) ovariectomized rats treated with glucocorticoid (dexamethasone) for 3 months (3M) after recovery from bilateral ovariectomy. Osteoporotic bone status was determined by means of the gold standard dual energy X ray absorptiometry (DEXA) scan. Vertebral bodies were examined using A mu CT, histological analysis, mRNA expression analysis, and biomechanical compression testing. Further systemic effects were studied biochemically using serum marker analysis.
   Dexamethasone treatment showed at 3M a significantly lower bone mineral density in ovariectomized rats compared to Sham operated control (p < 0.0001) as analyzed in vivo by DEXA. Furthermore, Z scores reached levels of  5.7 in the spine indicating sever osteoporotic bone status. Biomechanical testing of compression stability indicated a lower functional competence (p < 0.0001) in the spine of treated rats. A mu CT analysis showed significant reduction of bone volume density (BV/TV%; p < 0.0001), significantly enhanced trabecular spacing (Tb.Sp; p < 0.0001) with less trabecular number (Tb.N; p < 0.001) and complete loss of trabecular structures in glucocorticoid treated ovariectomized rats. Histological analysis by osteoblast and osteoclast activities reflected a higher bone catabolism reflected by osteoclast counts by TRAP (p < 0.019) and lower bone catabolism indicated by ALP stained area (p < 0.035).Serum analysis showed a significant increase in osteocalcin (p < 0.0001), osteopontin (p < 0.01) and insulin (p < 0.001) at 3M. Expression analysis of molecular markers in the vertebral body revealed lower expression in tenascin C in the OVX steroid animals at 3M.
   Short term glucocorticoid treatment of ovariectomized rats indicates according to DEXA standards a severe osteoporotic bone status in vertebral bone. Nonetheless, dysfunctional bone anabolism and enhanced bone catabolism are observed. Alterations of bone extracellular matrix proteins that correlate to inferior mechanical stability and affected microstructure were noticed and suggest further investigation. Treatment with dexamethasone was also seen to affect insulin and osteopontin levels and thus osteoblast function and maturation. This described animal model presents a recapitulation of clinically obtained data from early phase glucocorticoid induced osteoporosis observed in patients.
C1 [Boecker, W.; El Khassawna, T.; Brodsky, K.; Weisweiler, D.; Govindarajan, P.; Schnettler, R.; Heiss, C.] Univ Giessen, Lab Expt Trauma Surg, D 35390 Giessen, Germany.
   [Boecker, W.; Schlewitz, G.; Thormann, U.; Szalay, G.; Schnettler, R.; Heiss, C.] Univ Hosp Giessen Marburg, Dept Trauma Surg, Giessen, Germany.
   [Bauer, N.] Univ Giessen, Dept Vet Clin Sci Clin Pathol & Clin Pathophysiol, D 35390 Giessen, Germany.
   [Kampschulte, M.] Univ Hosp Giessen Marburg, Dept Radiol, Giessen, Germany.
   [Duerselen, L.] Univ Ulm, Inst Orthoped Res & Biomech, Ctr Musculoskeletal Res, D 89069 Ulm, Germany.
   [Langheinrich, A. C.] BGU Frankfurt, Dept Radiol Frankfurt Main, Giessen, Germany.
C3 Justus Liebig University Giessen; University Hospital of Giessen &
   Marburg; Justus Liebig University Giessen; University Hospital of
   Giessen & Marburg; Ulm University
RP Heiss, C (通讯作者)，Univ Hosp Giessen Marburg, Dept Trauma Surg, Giessen, Germany.
EM wolfgang.boecker@chiru.med.uni giessen.de;
   christian.heiss@chiru.med.uni giessen.de
RI khassawna, Thaqif/J 9748 2013; Thormann, Ulrich/ITU 7557 2023; Dürselen,
   Lutz/B 9447 2012; Durselen, Lutz/B 9447 2012; El khassawna,
   Thaqif/J 9748 2013; Bauer, Natali/LZH 1932 2025; Schlewitz,
   Gudrun/KHU 6818 2024
OI Durselen, Lutz/0000 0002 5470 5423; El khassawna,
   Thaqif/0000 0002 1187 8578; 
FU DFG, German Research Foundation [SFB/TRR 79, T1]; Austrian Science Fund
   (FWF) [T1] Funding Source: Austrian Science Fund (FWF)
FX This study was solely funded by DFG, German Research Foundation (SFB/TRR
   79, T1). The authors sincerely thank Mrs. Stengel A, Ms. Sparer S, Mrs.
   Bergen I and Mrs. Hartmann S (Laboratory of Experimental Trauma Surgery,
   University of Giessen) for their invaluable help.
CR Angeli A, 2006, BONE, V39, P253, DOI 10.1016/j.bone.2006.02.005
   Antonacci MD, 1997, SPINE, V22, P2393, DOI 10.1097/00007632 199710150 00014
   Bouvard B, 2010, CLIN REV BONE MINER, V8, P15, DOI 10.1007/s12018 009 9051 9
   Brunner M, 2011, J CELL BIOL, V194, P307, DOI 10.1083/jcb.201007108
   Caetano Lopes J, 2007, ACTA REUMATOL PORT, V32, P103
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canalis E, 2004, BONE, V34, P593, DOI 10.1016/j.bone.2003.11.026
   Clemens TL, 2011, J BONE MINER RES, V26, P677, DOI 10.1002/jbmr.321
   Cohen A, 2003, OSTEOPOROSIS INT, V14, P617, DOI 10.1007/s00198 003 1426 z
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Cooper C, 2006, OSTEOPOROSIS INT, V17, P337, DOI 10.1007/s00198 005 2039 5
   Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365 2796.1998.00408.x
   Egermann M, 2005, OSTEOPOROSIS INT, V16, pS129, DOI 10.1007/s00198 005 1859 7
   El Khassawna T, 2012, BONE, V51, P651, DOI 10.1016/j.bone.2012.07.011
   FERRETTI JL, 1992, CALCIFIED TISSUE INT, V50, P49, DOI 10.1007/BF00297297
   Govindarajan P, 2013, INT J EXP PATHOL, V94, P387, DOI 10.1111/iep.12038
   GRAVES LLB, 2004, CLIN REV BONE MINER, V2, P79
   GRONOWICZ GA, 1995, ENDOCRINOLOGY, V136, P598, DOI 10.1210/en.136.2.598
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4382, DOI 10.1210/en.140.10.4382
   Huiskes R, 2000, NATURE, V405, P704, DOI 10.1038/35015116
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kanis JA, 2008, OSTEOPOROSIS INT, V19, P385, DOI 10.1007/s00198 007 0543 5
   Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782
   Kanis JA, 2005, OSTEOPOROSIS INT, V16, P229, DOI 10.1007/s00198 004 1811 2
   Kanis JA, 2001, OSTEOPOROSIS INT, V12, P989, DOI 10.1007/s001980170006
   KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802
   Kim David H, 2006, Spine J, V6, P479, DOI 10.1016/j.spinee.2006.04.013
   Kim HJ, 2007, ANN NY ACAD SCI, V1116, P335, DOI 10.1196/annals.1402.057
   Kim HJ, 2006, J CLIN INVEST, V116, P2152, DOI 10.1172/JCI28084
   Kim JB, 2009, CELL, V136, P411, DOI 10.1016/j.cell.2009.01.023
   King CS, 1996, CALCIFIED TISSUE INT, V59, P184, DOI 10.1007/s002239900107
   LAAN RFJM, 1993, CALCIFIED TISSUE INT, V52, P5, DOI 10.1007/BF00675619
   Li W, 2011, OSTEOPOROSIS RESEARCH: ANIMAL MODELS, P123, DOI 10.1007/978 0 85729 293 3_11
   Mazziotti G, 2006, TRENDS ENDOCRIN MET, V17, P144, DOI 10.1016/j.tem.2006.03.009
   Ogoshi T, 2008, MOD RHEUMATOL, V18, P552, DOI 10.1007/s10165 008 0096 2
   ORTOFT G, 1988, CALCIFIED TISSUE INT, V43, P376, DOI 10.1007/BF02553282
   PRUMMEL MF, 1991, J CLIN ENDOCR METAB, V72, P382, DOI 10.1210/jcem 72 2 382
   Reginster JY, 2006, BONE, V38, P4, DOI 10.1016/j.bone.2005.11.024
   RIGGS BL, 1995, BONE, V17, pS505, DOI 10.1016/8756 3282(95)00258 4
   Rubin J, 1998, ENDOCRINOLOGY, V139, P1006, DOI 10.1210/en.139.3.1006
   Shaker JL, 2005, ENDOCRIN METAB CLIN, V34, P341, DOI 10.1016/j.ecl.2005.01.014
   Standal T, 2004, EXP ONCOL, V26, P179
   Steinbuch M, 2004, OSTEOPOROSIS INT, V15, P323, DOI 10.1007/s00198 003 1548 3
   Takuma A, 2003, J BIOL CHEM, V278, P44667, DOI 10.1074/jbc.M300213200
   THOMPSON DD, 1995, BONE, V17, pS125, DOI 10.1016/8756 3282(95)00285 L
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   VILLANUEVA AR, 1986, STAIN TECHNOL, V61, P83, DOI 10.3109/10520298609110713
   Wallach S, 2000, CALCIFIED TISSUE INT, V67, P277, DOI 10.1007/s002230001146
   WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021 9290(94)90010 8
   Weinstein RS, 1998, J CLIN INVEST, V102, P274, DOI 10.1172/JCI2799
   WRONSKI TJ, 1985, CALCIFIED TISSUE INT, V37, P324, DOI 10.1007/BF02554882
   Yamazaki M, 1999, J BONE JOINT SURG BR, V81B, P508, DOI 10.1302/0301 620X.81B3.9398
NR 52
TC 15
Z9 18
U1 0
U2 21
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0940 6719
EI 1432 0932
J9 EUR SPINE J
JI Eur. Spine J.
PD NOV
PY 2014
VL 23
IS 11
BP 2437
EP 2448
DI 10.1007/s00586 014 3463 z
PG 12
WC Clinical Neurology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Orthopedics
GA AS6RC
UT WOS:000344389100024
PM 25077942
DA 2025 08 17
ER

PT J
AU Hsieh, CP
   Chiou, YL
   Lin, CY
AF Hsieh, Cheng Pu
   Chiou, Ya Ling
   Lin, Ching Yuang
TI Hyperbaric oxygen stimulated proliferation and growth of osteoblasts may
   be mediated through the FGF 2/MEK/ERK 1/2/NF κB and PKC/JNK pathways
SO CONNECTIVE TISSUE RESEARCH
LA English
DT Article
DE hyperbaric O 2; osteoblast; FGF 2/MEK/ERK 1/2/NF kappa B pathway;
   PKC/JNK pathway; cell cycle
ID CRITICAL SIZED DEFECTS; ENDOTHELIAL CELLS; FRACTURE REPAIR; BONE;
   THERAPY; RATS; EXPRESSION; DIFFERENTIATION; ANGIOGENESIS; ACTIVATION
AB We investigated whether the hyperbaric oxygen (O 2) could promote the proliferation of growth arrested osteoblasts in vitro and the mechanisms involved in this process. Osteoblasts were exposed to different combinations of saturation and pressure of O 2 and evaluated at 3 and 7 days. Control cells were cultured under ambient O 2 and normal pressure [1 atmosphere (ATA)]; high pressure group cells were treated with high pressure (2.5 ATA) twice daily; high O 2 group cells were treated with a high concentration O 2 (50% O 2) twice daily; and high pressure plus high O 2 group cells were treated with high pressure (2.5 ATA) and a high concentration O 2 (50% O 2) twice daily. Hyperbaric O 2 significantly promoted osteoblast proliferation and cell cycle progression after 3 days of treatment. Hyperbaric O 2 treatment stimulated significantly increased mRNA expression of fibroblast growth factor (FGF) 2 as well as protein expression levels of Akt, p70(S6K), phosphorylated ERK, nuclear factor (NF) kappa B, protein kinase C (PKC)alpha, and phosphorylated c Jun N terminal kinase (JNK). Our findings indicate that high pressure and high O 2 saturation stimulates growth arrested osteoblasts to proliferate. These findings suggest that the proliferative effects of hyperbaric O 2 on osteoblasts may contribute to the recruitment of osteoblasts at the fracture site. The FGF 2/MEK/ERK 1/2/Akt/p70(S6K)/NF kappa B and PKC/JNK pathways may be involved in mediating this process.
C1 [Lin, Ching Yuang] China Med Univ, China Med Univ & Hosp, Div Pediat Nephrol, Childrens Med Ctr, Taichung 40402, Taiwan.
   [Hsieh, Cheng Pu] Changhua Christian Hosp, Dept Orthopaed Surg, Changhua, Taiwan.
   [Hsieh, Cheng Pu] Changhua Christian Hosp, Hyperbar Ctr, Changhua, Taiwan.
   [Hsieh, Cheng Pu] Chang Jung Christian Univ, Coll Hlth Sci, Inst Med Res, Tainan, Taiwan.
   [Chiou, Ya Ling] Hung Kuang Univ, Inst Biomed Nutr, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital  
   Taiwan; Changhua Christian Hospital; Changhua Christian Hospital; Chang
   Jung Christian University; Hungkuang University
RP Lin, CY (通讯作者)，China Med Univ, China Med Univ & Hosp, Div Pediat Nephrol, Childrens Med Ctr, 2 Yuh Der Rd, Taichung 40402, Taiwan.
EM cylin@mail.cmuh.org.tw
FU Academy Cooperation Research Plans of Changhua Christian Hospital;
   Kaohsiung Medical University [92031, 92322]
FX This work was supported by the Academy Cooperation Research Plans of
   Changhua Christian Hospital and Kaohsiung Medical University (plan no.
   92031 and no. 92322). The OB like immortalized cells, MC3T3 E1, were
   supplied by Dr. Chen Chung Hwan of Kaohsiung Medical University.
CR Arnett TR, 2003, J CELL PHYSIOL, V196, P2, DOI 10.1002/jcp.10321
   Barth E, 1990, J Invest Surg, V3, P387, DOI 10.3109/08941939009140365
   Bayati S, 1998, PLAST RECONSTR SURG, V101, P1290, DOI 10.1097/00006534 199804050 00020
   BENNETT MH, 2009, COCHRANE DB SYST REV, V4
   Bilic I, 2005, UNDERSEA HYPERBAR M, V32, P1
   BOLANDER ME, 1992, P SOC EXP BIOL MED, V200, P165
   COLLINOSDOBY P, 1994, J CELL BIOCHEM, V55, P304, DOI 10.1002/jcb.240550306
   Coulson D B, 1966, Surg Forum, V17, P449
   DAHLIN C, 1993, SCAND J PLAST RECONS, V27, P103, DOI 10.3109/02844319309079791
   Dennog C, 1996, MUTAGENESIS, V11, P605, DOI 10.1093/mutage/11.6.605
   Eralp L, 2007, ADV THER, V24, P326, DOI 10.1007/BF02849901
   Fok TCO, 2008, ORAL SURG ORAL MED O, V105, P417, DOI 10.1016/j.tripleo.2007.07.015
   Franceschi RT, 2003, J CELL BIOCHEM, V88, P446, DOI 10.1002/jcb.10369
   Frazier DP, 2007, AM J PHYSIOL HEART C, V292, pH1675, DOI 10.1152/ajpheart.01132.2006
   GLOBUS RK, 1988, ENDOCRINOLOGY, V123, P98, DOI 10.1210/endo 123 1 98
   Gordillo GM, 2003, AM J SURG, V186, P259, DOI 10.1016/S0002 9610(03)00211 3
   Griffin XL, 2008, INJURY, V39, P419, DOI 10.1016/j.injury.2007.12.014
   GRUNDNES O, 1992, ACTA ORTHOP SCAND, V63, P492, DOI 10.3109/17453679209154721
   Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804
   Huang ZM, 2001, J BIOL CHEM, V276, P21351, DOI 10.1074/jbc.M010921200
   Jan A, 2009, ORAL SURG ORAL MED O, V107, P157, DOI 10.1016/j.tripleo.2008.07.010
   Kang Thomas S, 2004, Arch Facial Plast Surg, V6, P31, DOI 10.1001/archfaci.6.1.31
   Karamitros AE, 2006, INJURY, V37, pS63, DOI 10.1016/j.injury.2006.02.042
   Karaplis A C, 2000, Rev Endocr Metab Disord, V1, P331, DOI 10.1023/A:1026526703898
   KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342
   Levin D, 1999, EXP MOL PATHOL, V67, P99, DOI 10.1006/exmp.1999.2273
   Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756 3282(96)00138 X
   Makihara N, 1996, UNDERSEA HYPERBAR M, V23, P1
   Muhonen A, 2004, INT J ORAL MAX SURG, V33, P173, DOI 10.1054/ijom.2003.0489
   NICHOLS JT, 1968, ORAL SURG ORAL MED O, V25, P418, DOI 10.1016/0030 4220(68)90017 0
   NIINIKOSKI J, 1970, CALC TISS RES, V4, P115, DOI 10.1007/BF02152379
   NODA M, 1989, J CELL BIOL, V109, P2529, DOI 10.1083/jcb.109.5.2529
   Saadeh PB, 2000, ENDOCRINOLOGY, V141, P2075, DOI 10.1210/en.141.6.2075
   Salgado CJ, 2009, J PLAST RECONSTR AES, V62, P1568, DOI 10.1016/j.bjps.2008.06.071
   TUNCAY OC, 1994, AM J ORTHOD DENTOFAC, V105, P457, DOI 10.1016/S0889 5406(94)70006 0
   Ueng SWN, 1998, J TRAUMA, V44, P676, DOI 10.1097/00005373 199804000 00020
   Wang DS, 1997, ENDOCRINOLOGY, V138, P2953, DOI 10.1210/en.138.7.2953
   Wang J, 2002, J Postgrad Med, V48, P226
   Wang X, 1998, INT J RADIAT ONCOL, V40, P189
   Wong AK, 2008, J CRANIOFAC SURG, V19, P757, DOI 10.1097/SCS.0b013e31816aac19
   Wu D, 2007, CONNECT TISSUE RES, V48, P206, DOI 10.1080/03008200701458749
   Xiong W, 1997, AM J PHYSIOL LUNG C, V272, pL1205, DOI 10.1152/ajplung.1997.272.6.L1205
   Yamasaki N, 2009, BONE, V44, P71, DOI 10.1016/j.bone.2008.09.015
NR 43
TC 24
Z9 25
U1 0
U2 5
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0300 8207
EI 1607 8438
J9 CONNECT TISSUE RES
JI Connect. Tissue Res.
PD DEC
PY 2010
VL 51
IS 6
BP 497
EP 509
DI 10.3109/03008201003746679
PG 13
WC Cell Biology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Orthopedics
GA 686DQ
UT WOS:000284677400010
PM 20497028
DA 2025 08 17
ER

PT J
AU Yang, M
   Xia, C
   Song, Y
   Zhao, X
   Wong, MS
   Zhang, Y
AF Yang, Min
   Xia, Chao
   Song, Yan
   Zhao, Xi
   Wong, Man Sau
   Zhang, Yan
TI Impairing effects of angiotensin converting enzyme inhibitor Captopril
   on bone of normal mice
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Renin angiotensin system; Angiotensin converting enzyme inhibitor; Bone;
   Captopril; Bradykinin receptor; Angiotensin II
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; MINERAL DENSITY; DIABETES MELLITUS;
   KININ B1; SYSTEM; DIFFERENTIATION; OSTEOCLASTS; ACTIVATION; MECHANISM;
   BLOCKERS
AB There are contradicting results about the effects of angiotensin converting enzyme inhibitors (ACEIs) on bones. This study was aimed to investigate the effect of ACEI, Captopril, on bone metabolism and histology as well as the action of Captopril on skeletal renin angiotensin system (RAS) and bradykinin receptor pathway in normal male mice. The urine, serum, tibias and femurs from normal control mice and Captopril treated (10 mg/kg) mice were collected for biochemical, histological and molecular analyses after drug administration for eight weeks. The mice after the treatment with Captopril had a significant decrease of serum testosterone level. The histological measurements showed the loss of trabecular bone mass and trabecular bone number, and the breakage of trabecular bone network as well as the changes of chondrocyte zone at epiphyseal plate in Captopril treated mice. The defect of Captopril on trabecular bone was reflected by the quantitative bio parameters from micro CT. The expression of renin receptor and bradykinin B2 receptor (B2R) was significantly up regulated in tibia of mice upon to the Captopril treatment, which decreased the ratio of OPG/RANKL and the expression of osteoblastic factor RUNX2. Furthermore, Captopril treatment resulted in the increase of pAkt/Akt and pNE kappa B expression in tibia. The present study revealed the impairing effects of Captopril on bone via interfering with the circulating sex hormone level and B2R pathway, which suggests that the bone metabolism of patients need to be carefully monitored when being prescribed for ACEIs. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Yang, Min; Xia, Chao; Song, Yan; Zhao, Xi; Zhang, Yan] Nantong Univ, Sch Pharm, Nantong 226001, Peoples R China.
   [Wong, Man Sau] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China.
C3 Nantong University; Hong Kong Polytechnic University
RP Zhang, Y (通讯作者)，Qixiu Rd 19, Nantong 226001, Jiangsu, Peoples R China.
EM riceandtiger@163.com
RI Wong, Man Sau/F 2059 2015
OI Wong, Man Sau/0000 0002 0729 8618
FU National Natural Science Foundation of China [81202894]
FX This work was sponsored by National Natural Science Foundation of China
   (No. 81202894).
CR AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095
   Asaba Y, 2009, J BONE MINER RES, V24, P241, DOI [10.1359/jbmr.081006, 10.1359/JBMR.081006]
   Cappuccio FP, 1999, LANCET, V354, P971, DOI 10.1016/S0140 6736(99)01437 3
   Chen Y., 2012, J DIABETES MELLITUS, V2, P353
   Cheng J, 2014, JAMA INTERN MED, V174, P773, DOI 10.1001/jamainternmed.2014.348
   Diao TY, 2014, J BONE MINER METAB, V32, P261, DOI 10.1007/s00774 013 0500 7
   Garcia P, 2010, BRIT J PHARMACOL, V159, P1672, DOI 10.1111/j.1476 5381.2010.00651.x
   García Testal A, 2006, MED CLIN BARCELONA, V127, P692, DOI 10.1157/13095095
   Ghosh M, 2014, ENDOCRINE, V46, P397, DOI 10.1007/s12020 014 0167 4
   Gonçalves Zillo TO, 2013, J CLIN PERIODONTOL, V40, P653, DOI 10.1111/jcpe.12097
   Gu SS, 2012, NEPHROLOGY, V17, P767, DOI 10.1111/j.1440 1797.2012.01656.x
   Gu SS, 2012, BIOSCI BIOTECH BIOCH, V76, P1367, DOI 10.1271/bbb.120123
   HILLSLEY MV, 1994, BIOTECHNOL BIOENG, V43, P573, DOI 10.1002/bit.260430706
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Impellizzeri D, 2014, PHARMACOL RES, V81, P91, DOI 10.1016/j.phrs.2014.02.007
   Inaba S, 2011, J HYPERTENS, V29, P2236, DOI 10.1097/HJH.0b013e32834bbb4d
   Izu Y, 2009, J BIOL CHEM, V284, P4857, DOI 10.1074/jbc.M807610200
   Kawahata H, 2015, HYPERTENS RES, V38, P382, DOI 10.1038/hr.2015.18
   Koïtka A, 2010, DIABETOLOGIA, V53, P584, DOI 10.1007/s00125 009 1619 x
   Koshida H, 1998, HYPERTENS RES CLIN E, V21, P279, DOI 10.1291/hypres.21.279
   Kwok T, 2012, OSTEOPOROSIS INT, V23, P2159, DOI 10.1007/s00198 011 1831 7
   Kwok T, 2010, CLIN CHIM ACTA, V411, P1122, DOI 10.1016/j.cca.2010.04.011
   Lau T, 2004, DIABETOLOGIA, V47, P240, DOI 10.1007/s00125 003 1295 1
   Liu YY, 2011, J BONE MINER METAB, V29, P149, DOI 10.1007/s00774 010 0209 9
   Lynn H, 2006, BONE, V38, P584, DOI 10.1016/j.bone.2005.09.011
   Masunari Naomi, 2008, Hiroshima Journal of Medical Sciences, V57, P17
   Namazi S, 2011, MED HYPOTHESES, V77, P152, DOI 10.1016/j.mehy.2011.04.004
   Rejnmark L, 2006, J HYPERTENS, V24, P581, DOI 10.1097/01.hjh.0000203845.26690.cb
   Shimizu H, 2008, FASEB J, V22, P2465, DOI 10.1096/fj.07 098954
   Shimizu H, 2009, HYPERTENS RES, V32, P786, DOI 10.1038/hr.2009.99
   Shuai B, 2015, OSTEOPOROSIS INT, V26, P1063, DOI 10.1007/s00198 014 2992 y
   Souza PPC, 2013, BRIT J PHARMACOL, V169, P400, DOI 10.1111/bph.12116
   Srivastava S, 2014, J CELL PHYSIOL, V229, P2088, DOI 10.1002/jcp.24668
   Stimpel M, 1995, J HYPERTENS, V13, P1852
   Uchida Y, 2012, CELL CALCIUM, V51, P383, DOI 10.1016/j.ceca.2011.12.014
   Wong WT, 2010, ANTIOXID REDOX SIGN, V13, P757, DOI 10.1089/ars.2009.2831
   Yung LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017437
   Zhang YF, 2012, J BONE MINER METAB, V30, P666, DOI 10.1007/s00774 012 0363 3
   Zhang YT, 2014, ENDOCRINE, V47, P598, DOI 10.1007/s12020 014 0196 z
   Zhang YT, 2014, MOL MED REP, V9, P1128, DOI 10.3892/mmr.2014.1978
NR 40
TC 8
Z9 10
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 15
PY 2016
VL 771
BP 40
EP 47
DI 10.1016/j.ejphar.2015.12.011
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA DA9CO
UT WOS:000368105100005
PM 26683638
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Xie, WC
   Li, F
   Han, Y
   Qin, Y
   Wang, Y
   Chi, XY
   Xiao, J
   Li, ZC
AF Xie, Weixin
   Li, Fan
   Han, Yi
   Qin, Yi
   Wang, Yuan
   Chi, Xiaoying
   Xiao, Jie
   Li, Zhanchun
TI Neuropeptide Y1 receptor antagonist promotes osteoporosis and
   microdamage repair and enhances osteogenic differentiation of bone
   marrow stem cells via cAMP/PKA/CREB pathway
SO AGING US
LA English
DT Article
DE osteoporosis; neuropeptide Y; bone microstructure; bone mcirodamage;
   bone marrow stromal cells
ID POSTMENOPAUSAL WOMEN; SYMPATHETIC ACTIVITY; CANCELLOUS BONE;
   OSTEOARTHRITIS; OSTEOBLASTS; ACTIVATION; EXPRESSION; PROLIFERATION;
   METABOLISM; RESORPTION
AB Osteoporosis is a common metabolic bone disorder in the elderly population. The accumulation of bone microdamage is a critical factor of osteoporotic fracture. Neuropeptide Y (NPY) has been reported to regulated bone metabolism through Y1 receptor (Y1R). In this study the effects and mechanisms of Y1R antagonist on prevention for osteoporosis were characterized. In the clinical experiment, compared with osteoarthritis (OA), osteoporosis (OP) showed significant osteoporotic bone microstructure and accumulation of bone microdamage. NPY and Y1R immunoreactivity in bone were stronger in OP group, and were both correlated with bone volume fraction (BV/TV). In vivo experiment, Y1R antagonist significantly improved osteoporotic microstructure in the ovariectomized (OVX) rats. And Y1R antagonist promoted RUNX2, OPG and inhibit RANKL, MMP9 in bone marrow. In vitro cell culture experiment, NPY inhibited osteogenesis, elevated RANKL/OPG ratio and downregulated the expression of cAMP, p PKAs and p CREB in BMSCs, treated with Y1R antagonist or 8 Bromo cAMP could inhibit the effects of NPY. Together, Y1R antagonist improved the bone microstructure and reduced bone microdamage in OVX rats. NPY Y1R could inhibit osteoblast differentiation of BMSCs via cAMP/PKA/CREB pathway. Our findings highlight the regulation of NPY Y1R in bone metabolism as a potential therapy strategy for the prevention of osteoporosis and osteoporotic fracture.
C1 [Xie, Weixin; Li, Fan; Qin, Yi; Wang, Yuan; Chi, Xiaoying; Xiao, Jie] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Anesthesiol, Shanghai 200127, Peoples R China.
   [Xie, Weixin; Li, Fan; Han, Yi; Li, Zhanchun] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, Shanghai 200127, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Xiao, J (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Anesthesiol, Shanghai 200127, Peoples R China.; Li, ZC (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Orthopaed Surg, Shanghai 200127, Peoples R China.
EM applexiaomz@163.com; lzctgzyyx@163.com
RI ; li, fan/AAY 5915 2020
OI Xie, Weixin/0000 0002 1404 793X; 
FU National Natural Science Foundation of China [81871090, 81400644,
   81400904]; Medical Engineering Joint Fund of Shanghai Jiaotong
   University [YG2016MS53]; Clinical research and cultivation fund of Renji
   Hospital [PY2018 III 07]
FX This work was supported by the National Natural Science Foundation of
   China [grant nos. 81871090, 81400644 and 81400904] and
   Medical Engineering Joint Fund of Shanghai Jiaotong University
   [YG2016MS53], Clinical research and cultivation fund of Renji Hospital
   (PY2018 III 07).
CR Abdallah BM, 2005, CALCIFIED TISSUE INT, V76, P90, DOI 10.1007/s00223 004 0074 4
   Allison SJ, 2007, PEPTIDES, V28, P320, DOI 10.1016/j.peptides.2006.05.029
   Amano S, 2007, BBA GEN SUBJECTS, V1770, P966, DOI 10.1016/j.bbagen.2007.02.009
   Baldock PA, 2007, J BIOL CHEM, V282, P19092, DOI 10.1074/jbc.M700644200
   Bouxsein ML, 2003, OSTEOPOROSIS INT, V14, pS118, DOI 10.1007/s00198 003 1489 x
   BURR DB, 1995, BONE, V17, P431, DOI 10.1016/S8756 3282(95)00241 3
   Burr DB, 1997, J BONE MINER RES, V12, P6, DOI 10.1359/jbmr.1997.12.1.6
   Chesnut CH, 2001, J BONE MINER RES, V16, P2163, DOI 10.1359/jbmr.2001.16.12.2163
   Crespi EJ, 2012, GEN COMP ENDOCR, V177, P348, DOI 10.1016/j.ygcen.2012.04.013
   Dai RC, 2004, J BONE MINER METAB, V22, P215, DOI 10.1007/s00774 003 0472 0
   Danova NA, 2003, BONE, V33, P197, DOI 10.1016/S8756 3282(03)00155 8
   Decressac M, 2009, NEUROBIOL DIS, V34, P441, DOI 10.1016/j.nbd.2009.02.017
   EKBLAD E, 1984, REGUL PEPTIDES, V8, P225, DOI 10.1016/0167 0115(84)90064 8
   Felsenberg D, 2005, CLIN THER, V27, P1, DOI 10.1016/j.clinthera.2004.12.020
   Giner M, 2009, J STEROID BIOCHEM, V113, P46, DOI 10.1016/j.jsbmb.2008.11.005
   He XR, 1998, AM J PHYSIOL REG I, V275, pR1202, DOI 10.1152/ajpregu.1998.275.4.R1202
   Herman BC, 2010, BONE, V47, P766, DOI 10.1016/j.bone.2010.07.006
   Hernandez CJ, 2006, BONE, V39, P1173, DOI 10.1016/j.bone.2006.06.001
   Hofbauer LC, 1999, ENDOCRINOLOGY, V140, P4367, DOI 10.1210/en.140.9.4367
   Igwe JC, 2009, J CELL BIOCHEM, V108, P621, DOI 10.1002/jcb.22294
   Imai S, 2002, MICROSC RES TECHNIQ, V58, P61, DOI 10.1002/jemt.10119
   Jiang LS, 2008, J BONE MINER RES, V23, P475, DOI 10.1359/JBMR.071114
   Jiang X, 2019, MOL MED REP, V20, P2143, DOI 10.3892/mmr.2019.10468
   Kennedy OD, 2012, BONE, V50, P1115, DOI 10.1016/j.bone.2012.01.025
   Khan K, 2015, J NUTR BIOCHEM, V26, P1491, DOI 10.1016/j.jnutbio.2015.07.021
   Kim HJ, 2010, J BONE MINER RES, V25, P1771, DOI 10.1002/jbmr.60
   Lee NJ, 2010, J BONE MINER RES, V25, P1736, DOI 10.1002/jbmr.61
   Li ZC, 2012, ARTHRITIS RHEUM US, V64, P3955, DOI 10.1002/art.34670
   Li ZC, 2011, J NUCL MED, V52, P769, DOI 10.2967/jnumed.110.085456
   Liu W, 2015, MOL MED REP, V11, P3212, DOI 10.3892/mmr.2015.3152
   Liu XG, 2018, BIOMED PHARMACOTHER, V104, P742, DOI 10.1016/j.biopha.2018.04.044
   Logar DB, 2007, J BONE MINER METAB, V25, P219, DOI 10.1007/s00774 007 0753 0
   Loh K, 2015, TRENDS ENDOCRIN MET, V26, P125, DOI 10.1016/j.tem.2015.01.003
   Lundberg P, 2007, J BIOL CHEM, V282, P19082, DOI 10.1074/jbc.M609629200
   Ma J, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 25563 w
   Ma S, 2017, SCI REP UK, V7, DOI 10.1038/srep43399
   Mrak E, 2015, INT J ENDOCRINOL, V2015, DOI 10.1155/2015/547473
   Odvina CV, 2010, CLIN ENDOCRINOL, V72, P161, DOI 10.1111/j.1365 2265.2009.03581.x
   Park KH, 2018, STEM CELLS DEV, V27, P1125, DOI 10.1089/scd.2018.0023
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Tanaka S, 2011, OSTEOPOROSIS INT, V22, P587, DOI 10.1007/s00198 010 1328 9
   Uhl M, 1998, BRIT J RADIOL, V71, P291, DOI 10.1259/bjr.71.843.9616238
   Vongpatanasin W, 2001, CIRCULATION, V103, P2903, DOI 10.1161/01.CIR.103.24.2903
   Wan Y, 2015, PEPTIDES, V63, P126, DOI 10.1016/j.peptides.2014.10.018
   Xiao J, 2016, NEUROPEPTIDES, V56, P97, DOI 10.1016/j.npep.2015.12.006
   Xie WX, 2020, CALCIFIED TISSUE INT, V106, P444, DOI 10.1007/s00223 019 00647 5
   Yang DC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001540
   Yang H, 2018, LAB INVEST, V98, P755, DOI 10.1038/s41374 018 0036 5
   Yokobori E, 2012, J NEUROENDOCRINOL, V24, P766, DOI 10.1111/j.1365 2826.2012.02281.x
   Zhang RR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020780
   Zhang ZM, 2010, OSTEOPOROSIS INT, V21, P1383, DOI 10.1007/s00198 009 1071 2
NR 51
TC 25
Z9 30
U1 1
U2 42
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945 4589
J9 AGING US
JI Aging US
PD MAY 15
PY 2020
VL 12
IS 9
BP 8120
EP 8136
DI 10.18632/aging.103129
PG 17
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA LN7ZB
UT WOS:000533150800033
PM 32381754
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Ruggiu, A
   Ulivi, V
   Sanguineti, F
   Cancedda, R
   Descalzi, F
AF Ruggiu, Alessandra
   Ulivi, Valentina
   Sanguineti, Francesca
   Cancedda, Ranieri
   Descalzi, Fiorella
TI The effect of Platelet Lysate on osteoblast proliferation associated
   with a transient increase of the inflammatory response in bone
   regeneration
SO BIOMATERIALS
LA English
DT Article
DE Osteoblasts; Platelet Lysate; Inflammation; Proliferation; Fracture
   repair
ID MESENCHYMAL STEM CELLS; MARROW STROMAL CELLS; RICH PLASMA; IN VITRO;
   MORPHOGENETIC PROTEINS; TIBIAL OSTEOTOMY; SPORTS MEDICINE;
   DIFFERENTIATION; REPAIR; EXPRESSION
AB Platelet Lysate (PL) contains a cocktail of growth factors and cytokines, which actively participates in tissue repair and its clinical application has been broadly described. The aim of this study was to assess the regenerative potential of PL for bone repair. We demonstrated that PL stimulation induces a transient increase of the inflammatory response in quiescent human osteoblasts, via NF kB activation, COX 2 induction, PGE(2) production and secretion of pro inflammatory cytokines. Furthermore, we showed that long term PL stimulation enhances proliferation of actively replicating osteoblasts, without affecting their differentiation potential, along with changes of cell morphology, resulting in increased cell density at confluence. In confluent resting osteoblasts, PL treatment induced resumption of proliferation, change in cell morphology and increase of cell density at confluence. A burst of PL treatment (24 h) was sufficient to trigger such processes in both conditions. These results correlated with up regulation of the proliferative and survival pathways ERKs and Akt and with cell cycle re activation via induction of CyclinD1 and phosphorylation of Rb, following PL stimulation. Our findings demonstrate that PL treatment results in activation and expansion of resting osteoblasts, without affecting their differentiation potential. Therefore PL represents a good therapeutic candidate in regenerative medicine for bone repair. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Ruggiu, Alessandra; Ulivi, Valentina; Cancedda, Ranieri; Descalzi, Fiorella] Univ Genoa, Dept Expt Med DIMES, I 16132 Genoa, Italy.
   [Ruggiu, Alessandra; Ulivi, Valentina; Sanguineti, Francesca; Cancedda, Ranieri; Descalzi, Fiorella] AOU San Martino IST Natl Canc Res Inst, I 16132 Genoa, Italy.
   [Sanguineti, Francesca] Univ Genoa, Dept Specialized Surg DISC, I 16132 Genoa, Italy.
C3 University of Genoa; University of Genoa
RP Descalzi, F (通讯作者)，Dept Expt Med DIMES, Lgo R Benzi 10, I 16132 Genoa, Italy.
EM fiorella.descalzi@istge.it
FU Regione Liguria (F.E.S.R.)
FX The authors would like to thank Dr. Paolo Strada for providing platelet
   blood fractions, Dr. Maddalena Mastrogiacomo for suggestions and helpful
   discussions and Dr. Paolo Pirani for the help in PL preparation. We also
   acknowledge Prof. Francesco Franchin for providing the biological
   samples. This work was partially supported by funds from Regione Liguria
   (F.E.S.R.). The authors confirm that there are no known conflicts of
   interest associated with this publication and there has been no
   significant financial support for this work that could have influenced
   its outcome. RC is founder and shareholder of the University of Genoa
   spin off company Biorigen s.r.l.
CR Alio JL, 2013, JAMA OPHTHALMOL, V131, P745, DOI 10.1001/jamaophthalmol.2013.2474
   Bastian O, 2011, J LEUKOCYTE BIOL, V89, P669, DOI 10.1189/jlb.0810446
   Borrelli J, 2012, J ORTHOP TRAUMA, V26, P708, DOI 10.1097/BOT.0b013e318274da8b
   Carter M J., 2011, Eplasty
   Chambard JC, 2007, BBA MOL CELL RES, V1773, P1299, DOI 10.1016/j.bbamcr.2006.11.010
   Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603
   Chevallier N, 2010, BIOMATERIALS, V31, P270, DOI 10.1016/j.biomaterials.2009.09.043
   Cho JW, 2012, INT J MOL MED, V29, P32, DOI 10.3892/ijmm.2011.803
   Cho TJ, 2007, CALCIFIED TISSUE INT, V80, P192, DOI 10.1007/s00223 006 0240 y
   Dallari D, 2007, J BONE JOINT SURG AM, V89A, P2413, DOI 10.2106/JBJS.F.01026
   Danesh Meyer M J, 2001, J Int Acad Periodontol, V3, P48
   Doucet C, 2005, J CELL PHYSIOL, V205, P228, DOI 10.1002/jcp.20391
   El Backly R, 2011, TISSUE ENG PT A, V17, P1787, DOI 10.1089/ten.tea.2010.0729
   El Backly RM, 2013, TISSUE ENG PT A, V19, P152, DOI [10.1089/ten.tea.2012.0357, 10.1089/ten.TEA.2012.0357]
   Fennis JPM, 2002, INT J ORAL MAX SURG, V31, P281, DOI 10.1054/ijom.2002.0151
   Foster TE, 2009, AM J SPORT MED, V37, P2259, DOI 10.1177/0363546509349921
   Froum SJ, 2002, INT J PERIODONT REST, V22, P45
   George J, 2006, BIOTECHNOL BIOENG, V95, P404, DOI 10.1002/bit.20939
   Geremicca W, 2010, BLOOD TRANSFUS ITALY, V8, P107, DOI 10.2450/2009.0091 09
   Gómez S, 2013, MAT SCI ENG C MATER, V33, P3329, DOI 10.1016/j.msec.2013.04.013
   Groeneveld EHJ, 2000, EUR J ENDOCRINOL, V142, P9, DOI 10.1530/eje.0.1420009
   GRUNDNES O, 1993, ACTA ORTHOP SCAND, V64, P340, DOI 10.3109/17453679308993640
   Hall MP, 2009, J AM ACAD ORTHOP SUR, V17, P602, DOI 10.5435/00124635 200910000 00002
   HARADA A, 1994, J LEUKOCYTE BIOL, V56, P559, DOI 10.1002/jlb.56.5.559
   Harmon K, 2013, BRIT J SPORT MED, DOI DOI 10.1136/BISP0RTS 2013 092459.31.AVAILABLE
   Heino TJ, 2008, CURR STEM CELL RES T, V3, P131, DOI 10.2174/157488808784223032
   Helmrich U, 2013, BIOMATERIALS, V34, P5025, DOI 10.1016/j.biomaterials.2013.03.040
   Jensen ED, 2010, BIOFACTORS, V36, P25, DOI 10.1002/biof.72
   Kim SA, 2013, MOL MED REP, V7, P476, DOI 10.3892/mmr.2012.1230
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Luu HH, 2007, J ORTHOP RES, V25, P665, DOI 10.1002/jor.20359
   Maggini J, PLOS ONE, DOI DOI 10.1371/I0URNAL.P0NE.0009252.AVAILABLE
   Magnussen RA, 2013, KNEE, V20, P277, DOI 10.1016/j.knee.2012.12.001
   Malik A, 2012, Dent Implantol Update, V23, P89
   MANIATOPOULOS C, 1988, CELL TISSUE RES, V254, P317
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Marx RE, 1998, ORAL SURG ORAL MED O, V85, P638, DOI 10.1016/S1079 2104(98)90029 4
   Mountziaris PM, 2011, TISSUE ENG PART B RE, V17, P393, DOI [10.1089/ten.teb.2011.0182, 10.1089/ten.TEB.2011.0182]
   Nakase T, 2006, J BONE MINER METAB, V24, P425, DOI 10.1007/s00774 006 0718 8
   Nurden AT, 2008, FRONT BIOSCI LANDMRK, V13, DOI 10.2741/2947
   Panda A, 2012, CORNEA, V31, P989, DOI 10.1097/ICO.0b013e3182114661
   Pereira RC, 2013, TISSUE ENG PT A, V19, P1476, DOI [10.1089/ten.tea.2012.0225, 10.1089/ten.TEA.2012.0225]
   Rennekampff HO, 2000, J SURG RES, V93, P41, DOI 10.1006/jsre.2000.5892
   Rozman P, 2007, ACTA DERMATOVEN ALP, V16, P156
   Ruggiu A, 2012, J TISSUE ENG REGEN M, DOI DOI 10.1002/TERM.1559.AVAILABLE
   Sánchez AR, 2003, INT J ORAL MAX IMPL, V18, P93
   Savarino L, 2006, J BIOMED MATER RES B, V76B, P364, DOI 10.1002/jbm.b.30375
   Sclafani AP, 2012, FACIAL PLAST SURG CL, V20, P177, DOI 10.1016/j.fsc.2012.02.004
   Scotti C, 2013, P NATL ACAD SCI USA, V110, P3997, DOI 10.1073/pnas.1220108110
   Shahabipour F, 2013, IN VITRO CELL DEV AN, V49, P440, DOI 10.1007/s11626 013 9591 7
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Soffer E, 2004, CLIN ORAL IMPLAN RES, V15, P581, DOI 10.1111/j.1600 0501.2004.01063.x
   Soffer E, 2003, ORAL SURG ORAL MED O, V95, P521, DOI 10.1067/moe.2003.152
   Tanidir ST, 2010, CORNEA, V29, P664, DOI 10.1097/ICO.0b013e3181c29633
   Tasso R, 2010, BIOMATERIALS, V31, P2121, DOI 10.1016/j.biomaterials.2009.11.064
   Taylor DW, 2011, CLIN J SPORT MED, V21, P344, DOI 10.1097/JSM.0b013e31821d0f65
   Tortelli F, 2009, TISSUE ENG PT A, V15, P2373, DOI 10.1089/ten.tea.2008.0501
   Tortelli F, 2010, BIOMATERIALS, V31, P242, DOI 10.1016/j.biomaterials.2009.09.038
   Tortelli F, 2009, EUR CELLS MATER, V17, P1
   Ulivi V, 2006, J CELL PHYSIOL, V206, P728, DOI 10.1002/jcp.20511
   Villela DL, 2010, GROWTH FACTORS, V28, P111, DOI 10.3109/08977190903468185
   Vogel JP, 2006, PLATELETS, V17, P462, DOI 10.1080/09537100600758867
   Xie C, 2009, AM J PATHOL, V175, P772, DOI 10.2353/ajpath.2009.081099
   Yang X, 2007, BONE, V41, P928, DOI 10.1016/j.bone.2007.07.022
   Zaky SH, 2008, J TISSUE ENG REGEN M, V2, P472, DOI 10.1002/term.119
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
   Zhu W, 2013, INT ENDOD J, DOI DOI 10.1111/IEJ.12087.AVAILABLE
NR 67
TC 34
Z9 34
U1 0
U2 34
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142 9612
EI 1878 5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2013
VL 34
IS 37
BP 9318
EP 9330
DI 10.1016/j.biomaterials.2013.08.018
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA 251AW
UT WOS:000326901200009
PM 24012435
DA 2025 08 17
ER

PT J
AU Zhou, GJ
   Shan, LH
   Tan, R
AF Zhou, Guanjun
   Shan, Lihua
   Tan, Rong
TI Influence of semiconductor laser irradiation on the rate of orthodontic
   tooth movement
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Laser; tooth movement; root resorption; alveolar bone
ID LOW LEVEL LASER; ROOT RESORPTION; THERAPY; VELOCITY
AB Objective: To explore the influence of semiconductor laser on tooth movement and the mechanism. Methods: A total of 10 g of orthodontic force was applied to rat molars to cause experimental tooth movement. A semiconductor laser was used to irradiate the area around the moved tooth, and after 3, 7 and 14 days, the amount of tooth movement and root length were measured. Alveolar bone structure parameters were also measured. The parameters included alveolar bone density (BMD), bone volume fraction (BV/TV) and TbSp. Results: On 14 days after laser irradiation, the distance of tooth movement and root length in irradiation group were much higher than the control group. BMD and BV/TV in the compression side in the irradiation group was significantly lower than the control group, while TbSp was obviously higher. The number of osteoblasts and osteoclasts in irradiation group were observably higher than the control. Conclusion: Semiconductor laser irradiation can accelerate the speed of tooth movement, reduce root resorption during tooth movement and accelerate the reconstruction of alveolar bone.
C1 [Zhou, Guanjun; Shan, Lihua; Tan, Rong] Hebei Med Univ, Hosp 2, Dept Orthodont, Shijiazhuang, Hebei, Peoples R China.
C3 Hebei Medical University
RP Zhou, GJ (通讯作者)，Hebei Med Univ, Hosp 2, Dept Orthodont, Shijiazhuang, Hebei, Peoples R China.
EM guanjunzhou123@sina.com
CR Altan BA, 2012, LASER MED SCI, V27, P131, DOI 10.1007/s10103 010 0853 2
   Bernhardt MK, 2001, AM J ORTHOD DENTOFAC, V120, P20, DOI 10.1067/mod.2001.115616
   BREZNIAK N, 1993, AM J ORTHOD DENTOFAC, V103, P62, DOI 10.1016/0889 5406(93)70106 X
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   BRUDVIK P, 1994, EUR J ORTHODONT, V16, P249, DOI 10.1093/ejo/16.4.249
   Cruz DR, 2004, LASER SURG MED, V35, P117, DOI 10.1002/lsm.20076
   Sousa MVD, 2011, PHOTOMED LASER SURG, V29, P191, DOI 10.1089/pho.2009.2652
   Garcia VG, 2010, LASER MED SCI, V25, P197, DOI 10.1007/s10103 009 0678 z
   Gonzales C, 2008, ANGLE ORTHOD, V78, P502, DOI 10.2319/052007 240.1
   Hasegawa N, 2003, J PERIODONTAL RES, V38, P51, DOI 10.1034/j.1600 0765.2003.01636.x
   Hashimoto F, 2001, EUR J ORTHODONT, V23, P535, DOI 10.1093/ejo/23.5.535
   KALKWARF KL, 1986, J PROSTHET DENT, V56, P317, DOI 10.1016/0022 3913(86)90011 9
   Kawasaki K, 2000, LASER SURG MED, V26, P282, DOI 10.1002/(SICI)1096 9101(2000)26:3<282::AID LSM6>3.0.CO;2 X
   Nakano T, 2014, ANGLE ORTHOD, V84, P1079, DOI 10.2319/121913 929.1
   Saito S, 1997, AM J ORTHOD DENTOFAC, V111, P525, DOI 10.1016/S0889 5406(97)70152 5
   Shirazi M, 2015, LASER MED SCI, V30, P713, DOI 10.1007/s10103 013 1407 1
   Yamaguchi M, 2010, EUR J ORTHODONT, V32, P131, DOI 10.1093/ejo/cjp078
   Yoshida T, 2009, ORTHOD CRANIOFAC RES, V12, P289, DOI 10.1111/j.1601 6343.2009.01464.x
   Youssef M, 2008, LASER MED SCI, V23, P27, DOI 10.1007/s10103 007 0449 7
NR 19
TC 2
Z9 2
U1 0
U2 1
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2019
VL 12
IS 9
BP 11360
EP 11367
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA JB1HH
UT WOS:000488311000038
DA 2025 08 17
ER

PT J
AU Gregory, LS
   Kelly, WL
   Reid, RC
   Fairlie, DP
   Forwood, MR
AF Gregory, LS
   Kelly, WL
   Reid, RC
   Fairlie, DP
   Forwood, MR
TI Inhibitors of cyclo oxygenase 2 and secretory phospholipase A2 preserve
   bone architecture following ovariectomy in adult rats
SO BONE
LA English
DT Article
DE arachidonic acid; bone remodeling; cyclooxygenase isoforms;
   phospholipase A(2); osteoclasts
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; INDUCIBLE CYCLOOXYGENASE COX 2;
   PLATELET ACTIVATING FACTOR; ARACHIDONIC ACID; CANCELLOUS BONE;
   TRABECULAR BONE; PROSTAGLANDIN PRODUCTION; CALVARIAL CELLS; IN VITRO;
   A(2)
AB Epidemiological evidence and in vitro data suggest that COX 2 is a key regulator of accelerated remodeling. Accelerated states of osteoblast and osteoclast activity are regulated by prostaglandins in vitro, but experimental evidence for specific roles of cyclooxygenase 2 (COX 2) and secretory phospholipase A(2) (sPLA(2)) in activated states of remodeling in vivo is lacking. The aim of this study was to determine the effect of specific inhibitors of sPLA(2) IIa and COX 2 on bone remodeling activated by estrogen deficiency in adult female rats. One hundred and twenty four adult female Wistar rats were ovariectomized (OVX) or sham operated. Rats commenced treatment 14 days after surgery with either vehicle, a COX 2 inhibitor (DFU at 0.02 mg/kg/day and 2.0 mg/kg/day) or a sPLA(2) group IIa inhibitor (KH064 at 0.4 mg/kg/day and 4.0 mg/kg/day). Treatment continued daily until rats were sacrificed at 70 days or 98 days post OVX. The right tibiae were harvested, fixed and embedded in methylmethacrylate for structural histomorphometric bone analysis at the proximal tibial metaphysis. The specific COX 2 or sPLA(2) inhibitors prevented ovariectomy induced (OVX induced) decreases in trabecular connectivity (P < 0.05); suppressed the acceleration of bone resorption; and maintained bone turnover at SHAM levels following OVX in the rat. The sPLA2 inhibitor significantly suppressed increases in osteoclast surface induced by OVX (P < 0.05), while the effect of COX 2 inhibition was less marked. These findings demonstrate that inhibitors of COX 2 and sPLA(2) IIa can effectively suppress OVX induced bone loss in the adult rat by conserving trabecular bone mass and architecture through reduced bone remodeling and decreased resorptive activity. Moreover, we report an important role of sPLA(2) IIa in osteoclastogenesis that may be independent of the COX 2 metabolic pathway in the OVX rat in vivo. (c) 2006 Elsevier Inc. All rights reserved.
C1 Univ Queensland, Sch Biomed Sci, Dept Anat & Dev Biol, Brisbane, Qld 4072, Australia.
   Univ Queensland, Inst Mol Biosci, Ctr Drug Design & Dev, Brisbane, Qld 4072, Australia.
C3 University of Queensland; University of Queensland
RP Forwood, MR (通讯作者)，Univ Queensland, Sch Biomed Sci, Dept Anat & Dev Biol, Brisbane, Qld 4072, Australia.
EM l.gregory@qut.edu.au; w.kelly@uq.edu.au; r.reid@imb.uq.edu.au;
   d.fairlie@uq.edu.au; m.forwood@uq.edu.au
RI ; Forwood, Mark/ABA 9040 2021; Fairlie, David/F 8865 2014; Reid,
   Robert/D 8041 2012
OI Forwood, Mark/0000 0002 9963 1616; Fairlie, David/0000 0002 7856 8566;
   Reid, Robert/0000 0002 0829 239X
CR Ajubi NE, 1999, AM J PHYSIOL ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171
   ALTMAN RD, 1995, J ORTHOP TRAUMA, V9, P392, DOI 10.1097/00005131 199505000 00006
   Arumugam TV, 2003, BRIT J PHARMACOL, V140, P71, DOI 10.1038/sj.bjp.0705402
   Baldock PAJ, 1999, J BONE MINER RES, V14, P1442, DOI 10.1359/jbmr.1999.14.8.1442
   BARON R, 1984, ANAT RECORD, V208, P137, DOI 10.1002/ar.1092080114
   Bidgood MJ, 2000, J IMMUNOL, V165, P2790, DOI 10.4049/jimmunol.165.5.2790
   Bonventre JV, 2004, TRENDS IMMUNOL, V25, P116, DOI 10.1016/j.it.2004.01.006
   CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531
   Chen QR, 1997, J BIOL CHEM, V272, P5952, DOI 10.1074/jbc.272.9.5952
   ELLIES LG, 1991, J BONE MINER RES, V6, P843
   Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773
   Fonteh AN, 1998, BBA LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005 2760(98)00079 4
   Forwood MR, 1996, J BONE MINER RES, V11, P1688
   Garcia C, 1996, J BONE MINER RES, V11, P521
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Hansford KA, 2003, CHEMBIOCHEM, V4, P181, DOI 10.1002/cbic.200390029
   Higashi S, 2000, INFLAMM RES, V49, P102, DOI 10.1007/s000110050566
   Hikiji H, 2004, J CLIN INVEST, V114, P85, DOI 10.1172/JC1200420504
   Hirabayashi T, 2004, BIOL PHARM BULL, V27, P1168, DOI 10.1248/bpb.27.1168
   KAWAGUCHI H, 1995, J CLIN INVEST, V96, P539, DOI 10.1172/JCI118066
   Kawaguchi H, 1996, J BONE MINER RES, V11, P358
   KIMMEL DB, 1992, BONE, V13, P167, DOI 10.1016/8756 3282(92)90007 J
   KLEEREKOPER M, 1985, CALCIFIED TISSUE INT, V37, P594, DOI 10.1007/BF02554913
   Kolko M, 2003, NEUROSCI LETT, V338, P164, DOI 10.1016/S0304 3940(02)01385 X
   Kozawa O, 1997, J CELL BIOCHEM, V64, P376
   Kudo I, 2002, PROSTAG OTH LIPID M, V68 9, P3, DOI 10.1016/S0090 6980(02)00020 5
   LANE N, 1990, J BONE MINER RES, V5, P1029
   Li J, 1998, BONE, V23, P459, DOI 10.1016/S8756 3282(98)00123 9
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   LI XJ, 1990, ANAT RECORD, V227, P12, DOI 10.1002/ar.1092270103
   Miyaura C, 2003, J EXP MED, V197, P1303, DOI 10.1084/jem.20030015
   Morton DJ, 1998, J BONE MINER RES, V13, P1924, DOI 10.1359/jbmr.1998.13.12.1924
   Nicoll Griffith DA, 1999, DRUG METAB DISPOS, V27, P403
   Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756 3282(00)00368 9
   Okada Y, 2000, J CLIN INVEST, V105, P823, DOI 10.1172/JCI8195
   Parfitt A.M., 1983, Bone Histomorphometry: Techniques and Interpretation, P143
   PARFITT AM, 1987, AM J MED, V82, P68, DOI 10.1016/0002 9343(87)90274 9
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Parkinson IH, 2003, J BONE MINER RES, V18, P2200, DOI 10.1359/jbmr.2003.18.12.2200
   Peng ZQ, 1997, BONE, V20, P207, DOI 10.1016/S8756 3282(96)00369 9
   PILBEAM CC, 1995, J BONE MINER RES, V10, P406
   PUGH JW, 1973, J BIOMECH, V6, P657, DOI 10.1016/0021 9290(73)90022 5
   PUGH JW, 1973, J BIOMECH, V6, P475, DOI 10.1016/0021 9290(73)90006 7
   Rapuano BE, 1997, PROSTAGLANDINS, V53, P163, DOI 10.1016/S0090 6980(97)00011 7
   Rawlinson SCF, 2000, BONE, V27, P241, DOI 10.1016/S8756 3282(00)00323 9
   REID RC, 2001, Patent No. 200208189
   Riendeau D, 1997, CAN J PHYSIOL PHARM, V75, P1088, DOI 10.1139/cjpp 75 9 1088
   Riggs BL, 2005, J BONE MINER RES, V20, P177, DOI 10.1359/JBMR.041114
   Sato T, 1996, J BONE MINER RES, V11, P392
   SEIBERT K, 1994, RECEPTOR, V4, P17
   Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963
   Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157
   Tai H, 1997, ENDOCRINOLOGY, V138, P2372, DOI 10.1210/en.138.6.2372
   Triggiani M, 2003, J IMMUNOL, V170, P3279, DOI 10.4049/jimmunol.170.6.3279
   WatanabeTomita Y, 1997, PROSTAG LEUKOTR ESS, V57, P335, DOI 10.1016/S0952 3278(97)90553 6
   Westerlind KC, 1997, P NATL ACAD SCI USA, V94, P4199, DOI 10.1073/pnas.94.8.4199
   Woodruff TM, 2005, INT IMMUNOPHARMACOL, V5, P883, DOI 10.1016/j.intimp.2005.01.003
   WRONSKI TJ, 1988, CALCIFIED TISSUE INT, V43, P179, DOI 10.1007/BF02571317
   Zhang XP, 2002, J CLIN INVEST, V109, P1405, DOI 10.1172/JCI200215681
NR 59
TC 38
Z9 46
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
J9 BONE
JI Bone
PD JUL
PY 2006
VL 39
IS 1
BP 134
EP 142
DI 10.1016/j.bone.2005.12.017
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 055DD
UT WOS:000238429300015
PM 16473054
DA 2025 08 17
ER

PT J
AU Gulati, K
   Kant, K
   Findlay, D
   Losic, D
AF Gulati, Karan
   Kant, Krishna
   Findlay, David
   Losic, Dusan
TI Periodically tailored titania nanotubes for enhanced drug loading and
   releasing performances
SO JOURNAL OF MATERIALS CHEMISTRY B
LA English
DT Article
ID TIO2 NANOTUBES; OSTEOBLAST ADHESION; BONE DISEASES; DELIVERY; IMPLANTS;
   PERSPECTIVES; COATINGS; SURFACES; ELUTION; ARRAYS
AB The structural engineering of titania nanotubes (TNTs) using electrochemical anodization was performed to generate periodically modulated (p TNTs) internal structures by applying an oscillatory voltage during the anodization process to demonstrate their improved drug loading and drug releasing properties. Drug loading and in vitro drug release studies compared with conventional TNTs with flat structures suggested considerable improvement with increased drug loading, reduced burst release and extended drug release for over 2 weeks. Furthermore, p TNTs arrays were fractured by ultrasonication into liberated TNTs capsules and their potential applications as drug micro/nano carriers for targeted and localized drug delivery is proposed. The presented electrochemical approach for structural engineering of TNTs provides new prospects in designing TNTs drug releasing implants with advanced drug loading/release characteristics for localized drug delivery. Such implant modifications can further be tailored to cater for various implant challenges and bone therapies like: inflammation, infection and poor implant integration.
C1 [Gulati, Karan; Kant, Krishna; Losic, Dusan] Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia.
   [Findlay, David] Univ Adelaide, Discipline Orthopaed & Trauma, Adelaide, SA 5005, Australia.
C3 University of Adelaide; University of Adelaide
RP Losic, D (通讯作者)，Univ Adelaide, Sch Chem Engn, Adelaide, SA 5005, Australia.
EM dusan.losic@adelaide.edu.au
RI ; Losic, Dusan/B 2436 2009; Kant, Krishna/G 6448 2019
OI Kant, Krishna/0000 0003 2948 9471; Losic, Dusan/0000 0002 1930 072X;
   Gulati, Karan/0000 0002 0927 8362
FU Australian Research Council [FT 110100711, DP 120101680]; University of
   Adelaide
FX The authors acknowledge the financial support of The Australian Research
   Council (FT 110100711 and DP 120101680) and The University of Adelaide
   for this work.
CR Aw M.S., 2011, J BIOMATERIALS NANOB, V2, P477, DOI [10.4236/JBNB.2011.225058, DOI 10.4236/JBNB.2011.225058]
   Aw MS, 2014, BIOMATER SCI UK, V2, P10, DOI 10.1039/c3bm60196j
   Brammer KS, 2009, ACTA BIOMATER, V5, P3215, DOI 10.1016/j.actbio.2009.05.008
   Gao GZ, 2011, BIOMATERIALS, V32, P3899, DOI 10.1016/j.biomaterials.2011.02.013
   Gulati K, 2012, THER DELIV, V3, P857, DOI 10.4155/TDE.12.66
   Gulati K, 2012, ACTA BIOMATER, V8, P449, DOI 10.1016/j.actbio.2011.09.004
   Kazemzadeh Narbat M, 2013, BIOMATERIALS, V34, P5969, DOI 10.1016/j.biomaterials.2013.04.036
   Kodama A, 2009, ACTA BIOMATER, V5, P2322, DOI 10.1016/j.actbio.2009.02.032
   Lin J, 2011, SMALL, V7, P1784, DOI 10.1002/smll.201002098
   Liu Y, 2012, ELECTROCHEM COMMUN, V23, P68, DOI 10.1016/j.elecom.2012.07.007
   Losic D, 2015, EXPERT OPIN DRUG DEL, V12, P103, DOI 10.1517/17425247.2014.945418
   Losic D, 2009, EXPERT OPIN DRUG DEL, V6, P1363, DOI 10.1517/17425240903300857
   Losic D, 2009, SMALL, V5, P1392, DOI 10.1002/smll.200801645
   Mor GK, 2003, J MATER RES, V18, P2588, DOI 10.1557/JMR.2003.0362
   Peng LL, 2009, NANO LETT, V9, P1932, DOI 10.1021/nl9001052
   Popat KC, 2007, SMALL, V3, P1878, DOI 10.1002/smll.200700412
   Popat KC, 2007, BIOMATERIALS, V28, P3188, DOI 10.1016/j.biomaterials.2007.03.020
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Roy P, 2011, ANGEW CHEM INT EDIT, V50, P2904, DOI 10.1002/anie.201001374
   Santos A, 2014, J MATER CHEM B, V2, P6157, DOI 10.1039/c4tb00548a
   Simovic S, 2010, CHEM COMMUN, V46, P1317, DOI 10.1039/b919840g
   Tran PA, 2009, J MATER CHEM, V19, P2653, DOI 10.1039/b814334j
   von Wilmowsky C, 2009, J BIOMED MATER RES B, V89B, P165, DOI 10.1002/jbm.b.31201
   Wang Y, 2014, BIOMATERIALS, V35, P5517, DOI 10.1016/j.biomaterials.2014.03.059
   Webster TJ, 2004, BIOMATERIALS, V25, P4731, DOI 10.1016/j.biomaterials.2003.12.002
   Yang L, 2009, EXPERT OPIN DRUG DEL, V6, P851, DOI 10.1517/17425240903044935
NR 26
TC 44
Z9 44
U1 2
U2 60
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2050 750X
EI 2050 7518
J9 J MATER CHEM B
JI J. Mat. Chem. B
PY 2015
VL 3
IS 12
BP 2553
EP 2559
DI 10.1039/c4tb01882f
PG 7
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Materials Science
GA CD9DJ
UT WOS:000351397300016
PM 32262131
OA Green Published
DA 2025 08 17
ER

PT J
AU Sun, XL
   Xia, TS
   Zhang, SY
   Zhang, JB
   Xu, LCA
   Han, T
   Xin, HL
AF Sun, Xiaolei
   Xia, Tianshuang
   Zhang, Shiyao
   Zhang, Jiabao
   Xu, Lingchuan
   Han, Ting
   Xin, Hailiang
TI Hops extract and xanthohumol ameliorate bone loss induced by iron
   overload via activating Akt/GSK3β/Nrf2 pathway
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE Hops; Xanthohumol; Osteoporosis; Iron overload; Akt/GSK3 beta/Nrf2
   pathway
ID OXIDATIVE STRESS; POSTMENOPAUSAL OSTEOPOROSIS; DIFFERENTIATION; ROLES
AB Introduction Osteoporosis is closely related to iron metabolism. This study aimed to investigate whether hops extract (HLE) and its active component xanthohumol (XAN) could ameliorate bone loss caused by iron overload, and explored its potential mechanism.
   Materials and methods Iron overload mice induced by iron dextran (ID) were used in vivo, and were treated with HLE and XAN for 3 months. Bone micro structure and bone morphology parameters were determined by Micro CT and TRAP staining. Bone metabolism markers and oxidation indexes in serum and bone tissue were evaluated. For in vitro experiment, bone formation indexes were determined. Moreover, the expression of key proteins in protein kinase B (Akt)/glycogen synthetase kinase 3 beta (GSK3 beta)/nuclear factor E2 related (Nrf2) pathway was evaluated by Western blotting.
   Results HLE and XAN effectively improved the bone micro structure of the femur in mice, altered bone metabolism biomarkers, and regulated the expression of proteins related to bone metabolism. Additionally, they significantly promoted cell proliferation, runt related gene 2 (Runx2) expression, and increased ALP activity in ID induced osteoblasts. Moreover, HLE and XAN markedly inhibited the increase of oxidative stress caused by iron overload in vivo and in vitro. Further studies showed that they significantly up regulated the expression of p Akt, p GSK3 beta, nuclear Nrf2, NAD(P)H: quinone oxidoreductase 1 (NQO1), and heme oxygenase 1 (HO 1) in ID induced osteoblasts.
   Conclusion These findings indicated hops and xanthohumol could ameliorate bone loss induced by iron overload via activating Akt/GSK3 beta/Nrf2 pathway, which brought up a novel sight for senile osteoporosis therapy.
C1 [Sun, Xiaolei; Xia, Tianshuang; Zhang, Jiabao; Han, Ting; Xin, Hailiang] Naval Med Univ, Sch Pharm, Dept Pharmacognosy, 325 Guohe Rd, Shanghai 200433, Peoples R China.
   [Sun, Xiaolei; Zhang, Shiyao; Xu, Lingchuan] Shandong Univ Tradit Chinese Med, Sch Pharm, 4655 Daxue Rd, Jinan 250355, Peoples R China.
C3 Naval Medical University; Shandong University of Traditional Chinese
   Medicine
RP Han, T; Xin, HL (通讯作者)，Naval Med Univ, Sch Pharm, Dept Pharmacognosy, 325 Guohe Rd, Shanghai 200433, Peoples R China.; Xu, LCA (通讯作者)，Shandong Univ Tradit Chinese Med, Sch Pharm, 4655 Daxue Rd, Jinan 250355, Peoples R China.
EM xulingchuan518@sina.com; hanting@smmu.edu.cn; hailiangxin@163.com
RI HAN, TINGTING/GQZ 8692 2022; Zhang, Shi yao/GRO 1062 2022
FU Natural Science Foundation of China [82174079, U1603283, 82004015];
   Science and Technology Commission of Shanghai Municipality [21S21902600]
FX This work was supported by the Natural Science Foundation of China (Nos.
   82174079, U1603283, 82004015) and Science and Technology Commission of
   Shanghai Municipality (21S21902600).
CR Abbassy HA, 2019, MEDITERR J HEMATOL I, V11, DOI 10.4084/MJHID.2019.013
   Aghamiri V, 2016, COMPLEMENT THER CLIN, V23, P130, DOI 10.1016/j.ctcp.2015.05.001
   Cheng QA, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/1345193
   Dai PP, 2017, CELL PHYSIOL BIOCHEM, V41, P661, DOI 10.1159/000457945
   Duranti G, 2021, MOLECULES, V26, DOI 10.3390/molecules26165041
   Fao L, 2019, AGEING RES REV, V54, DOI 10.1016/j.arr.2019.100942
   Ge XH, 2018, METAB BRAIN DIS, V33, P1869, DOI 10.1007/s11011 018 0293 4
   Guo Z., 2020, ORTHOPAEDICS, V11, P457
   He Yu qiong, 2018, Yaoxue Xuebao, V53, P1100, DOI 10.16438/j.0513 4870.2018 0024
   Henderson J, 2021, CELLS BASEL, V10, DOI 10.3390/cells10082053
   Jeong HM, 2011, BIOCHEM BIOPH RES CO, V409, P82, DOI 10.1016/j.bbrc.2011.04.113
   Jomova K, 2011, TOXICOLOGY, V283, P65, DOI 10.1016/j.tox.2011.03.001
   Kim MB, 2021, EUR J NUTR, V60, P3315, DOI 10.1007/s00394 021 02509 z
   Li Y, 2014, CHIN J NAT MEDICINES, V12, P204, DOI 10.1016/S1875 5364(14)60034 0
   Lin J, 2017, BIOSCI TRENDS, V11, P496, DOI 10.5582/bst.2017.01216
   Liu G, 2008, HEMOGLOBIN, V32, P181, DOI 10.1080/03630260701726707
   Liu H, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2020.4839
   Loboda A, 2016, CELL MOL LIFE SCI, V73, P3221, DOI 10.1007/s00018 016 2223 0
   Lu W., 2020, CONT MED, V26, P139
   Lv MM., 2021, CHIN GEN PRACT, V24, P3769
   Magtanong L, 2016, CELL DEATH DIFFER, V23, P1099, DOI 10.1038/cdd.2016.25
   Miller Paul D, 2005, Curr Osteoporos Rep, V3, P103, DOI 10.1007/s11914 005 0018 6
   Noh T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005438
   Qi J, 2015, INT J CLIN EXP PATHO, V8, P11995
   Rana AK, 2018, NEUROPHARMACOLOGY, V139, P124, DOI 10.1016/j.neuropharm.2018.07.006
   Rana T, 2012, FREE RADICAL BIO MED, V53, P2298, DOI 10.1016/j.freeradbiomed.2012.10.536
   Sasaoka N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087185
   Sharawy MH, 2021, INT IMMUNOPHARMACOL, V100, DOI 10.1016/j.intimp.2021.108088
   Suh KS, 2018, J APPL TOXICOL, V38, P180, DOI 10.1002/jat.3521
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Wang SP, 2021, ONCOGENE, V40, P4368, DOI 10.1038/s41388 021 01855 w
   [位艳伟 Wei Yanwei], 2018, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V24, P87
   Xia TS, 2021, CHIN J INTEGR MED, V27, P31, DOI 10.1007/s11655 019 2700 z
   Xu GP, 2021, BIOL TRACE ELEM RES, V199, P3781, DOI 10.1007/s12011 020 02508 x
   Xu XX, 2017, MOLECULES, V22, DOI 10.3390/molecules22020197
   Yarjanli Z, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868 017 0369 9
   Zanoli P, 2008, J ETHNOPHARMACOL, V116, P383, DOI 10.1016/j.jep.2008.01.011
   [张萌萌 Zhang Mengmeng], 2014, [中国骨质疏松杂志, Chinese Journal of Osteoporosis], V20, P1263
   Zhao GY, 2015, INFLAMMATION, V38, P718, DOI 10.1007/s10753 014 9982 2
   Zhao L., 2016, ANTIOSTEOPOROSIS MEC
   Zhu YM., 1989, MED FLORA INNER MONG
NR 41
TC 21
Z9 24
U1 1
U2 27
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2022
VL 40
IS 3
BP 375
EP 388
DI 10.1007/s00774 021 01295 2
EA FEB 2022
PG 14
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 1F4QM
UT WOS:000749408600001
PM 35106609
DA 2025 08 17
ER

PT J
AU Cong, Q
   Yang, YZ
AF Cong, Qian
   Yang, Yingzi
TI Hedgehog Signaling Controls Chondrogenesis and Ectopic Bone Formation
   via the Yap Ihh Axis
SO BIOMOLECULES
LA English
DT Article
DE heterotopic bone formation; Hedgehog signaling; Ihh; osteoblast; human
   diseases; FOP
ID INDIAN HEDGEHOG; DIFFERENTIATION; RECEPTOR; GROWTH
AB Fibrodysplasia ossificans progressiva (FOP) is a rare congenital disorder characterized by abnormal bone formation due to ACVR1 gene mutations. The identification of the molecular mechanisms underlying the ectopic bone formation and expansion in FOP is critical for the effective treatment or prevention of HO. Here we find that Hh signaling activation is required for the aberrant ectopic bone formation in FOP. We show that the expression of Indian hedgehog (Ihh), a Hh ligand, as well as downstream Hh signaling, was increased in ectopic bone lesions in Acvr1R206H; ScxCre mice. Pharmacological treatment with an Ihh neutralizing monoclonal antibody dramatically reduced chondrogenesis and ectopic bone formation. Moreover, we find that the activation of Yap in the FOP mouse model and the genetic deletion of Yap halted ectopic bone formation and decreased Ihh expression. Our mechanistic studies showed that Yap and Smad1 directly bind to the Ihh promoter and coordinate to induce chondrogenesis by promoting Ihh expression. Therefore, the Yap activation in FOP lesions promoted ectopic bone formation and expansion in both cell autonomous and non cell autonomous manners. These results uncovered the crucial role of the Yap Ihh axis in FOP pathogenesis, suggesting the inhibition of Ihh or Yap as a potential therapeutic strategy to prevent and reduce HO.
C1 [Cong, Qian; Yang, Yingzi] Harvard Sch Dent Med, Harvard Stem Cell Inst, Dept Dev Biol, Boston, MA 02115 USA.
C3 Harvard University; Harvard School of Dental Medicine
RP Cong, Q (通讯作者)，Harvard Sch Dent Med, Harvard Stem Cell Inst, Dept Dev Biol, Boston, MA 02115 USA.
EM qian_cong@hsdm.harvard.edu; yingzi_yang@hsdm.harvard.edu
RI Yang, Yingzi/J 3501 2012; Cong, Qian/AAZ 4404 2021
FU National Institute of Dental and Craniofacial Research
FX We thank the Yang lab's members for their stimulating discussions. We
   are grateful to Paul B. Yu (Massachusetts General Hospital) and Aris
   Economides (Regeneron Pharmaceuticals, Inc.) for providing the
   Acvr1FlExR206H; ScxCre mice that conditionally express a "knock in"
   allele of Acvr1R206H.
CR Amano K, 2008, J BIOL CHEM, V283, P29513, DOI 10.1074/jbc.M803681200
   Chakkalakal SA, 2016, J BONE MINER RES, V31, P1666, DOI 10.1002/jbmr.2820
   Cimini D, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.934997
   Cong Q, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abb2233
   Culbert AL, 2014, STEM CELLS, V32, P1289, DOI 10.1002/stem.1633
   Deng YJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 07022 2
   Dey D, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf1090
   Giraud J, 2020, INT J CANCER, V146, P2255, DOI 10.1002/ijc.32667
   Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652
   Hatsell SJ, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4358
   Heng BC, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00735
   Hino K, 2015, P NATL ACAD SCI USA, V112, P15438, DOI 10.1073/pnas.1510540112
   Kaplan, 1994, J Am Acad Orthop Surg, V2, P288
   Kaplan FS, 2008, J BONE MINER METAB, V26, P521, DOI 10.1007/s00774 008 0879 8
   Kaplan FS, 2008, BEST PRACT RES CL RH, V22, P191, DOI 10.1016/j.berh.2007.11.007
   Kaplan Frederick S, 2009, Hum Mutat, V30, P379, DOI 10.1002/humu.20868
   La Noce M, 2021, CELLS BASEL, V10, DOI 10.3390/cells10112899
   Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663
   Li Y, 2021, CELL DISCOV, V7, DOI 10.1038/s41421 021 00254 5
   Liu F, 1998, NAT GENET, V20, P325, DOI 10.1038/3793
   Lounev VY, 2009, J BONE JOINT SURG AM, V91A, P652, DOI 10.2106/JBJS.H.01177
   Luzzi AJ, 2023, AM J SPORT MED, V51, P3825, DOI 10.1177/03635465231203210
   Mak KK, 2008, DEVELOPMENT, V135, P1947, DOI 10.1242/dev.018044
   Mckee CM, 2012, J CLIN INVEST, V122, P4025, DOI 10.1172/JCI59348
   Meng XM, 2022, MOL CELL BIOCHEM, V477, P2327, DOI 10.1007/s11010 022 04446 9
   Moya IM, 2019, NAT REV MOL CELL BIO, V20, P211, DOI 10.1038/s41580 018 0086 y
   Pignolo RJ, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750 1172 6 80
   Regard JB, 2013, NAT MED, V19, P1505, DOI 10.1038/nm.3314
   Retting KN, 2009, DEVELOPMENT, V136, P1093, DOI 10.1242/dev.029926
   Seki K, 2004, J BIOL CHEM, V279, P18544, DOI 10.1074/jbc.M311592200
   Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804
   Shen L, 2019, BMC GENET, V20, DOI 10.1186/s12863 018 0697 5
   Shen Q, 2009, J CLIN INVEST, V119, P3462, DOI 10.1172/JCI37412
   Shore EM, 2006, NAT GENET, V38, P525, DOI 10.1038/ng1783
   St Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072
   Stellavato A, 2016, J CELL BIOCHEM, V117, P2158, DOI 10.1002/jcb.25556
   Vanyai HK, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.187187
   Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613
   Wada N, 2005, DEVELOPMENT, V132, P3977, DOI 10.1242/dev.01943
   Wang XB, 2016, CELL METAB, V24, P848, DOI 10.1016/j.cmet.2016.09.016
   Yang YJ, 2021, J ORTHOP TRANSL, V26, P92, DOI 10.1016/j.jot.2020.03.001
   Yoon BS, 2006, DEVELOPMENT, V133, P4667, DOI 10.1242/dev.02680
   Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216
   Zarka M, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.788773
   Zhong LL, 2015, INT J MOL SCI, V16, P19225, DOI 10.3390/ijms160819225
NR 45
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2218 273X
J9 BIOMOLECULES
JI Biomolecules
PD MAR
PY 2024
VL 14
IS 3
AR 347
DI 10.3390/biom14030347
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA MD4F0
UT WOS:001191668000001
PM 38540766
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Jukic, M
   Rozman, K
   Gobec, S
AF Jukic, Marko
   Rozman, Kaja
   Gobec, Stanislav
TI Recent Advances in the Development of Undecaprenyl Pyrophosphate
   Synthase Inhibitors as Potential Antibacterials
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Undecaprenyl pyrophosphate synthase; isoprenoid; peptidoglycan; cell
   wall; UppS inhibitors; antibacterials; antibiotics
ID FARNESYL DIPHOSPHATE SYNTHASE; FLUORESCENT SUBSTRATE ANALOG; ISOPRENOID
   BIOSYNTHESIS; CRYSTAL STRUCTURE; MEVALONATE PATHWAY; MECHANISM;
   BISPHOSPHONATES; EVOLUTION; DISCOVERY; ENZYME
AB Expanding antibiotic use in clinical practice and emergence of bacterial resistance are fueling research efforts for the development of novel antibacterials. Underexploited or completely novel mechanistic approaches and biological targets are of especial interest. Undecaprenyl pyrophosphate synthase (UppS) is an essential enzyme in the biosynthesis of the bacterial cell wall. Although UppS is a validated target, no selective inhibitors occur in materia medica. Nevertheless, several native substrate analogues have been reported and used in enzyme kinetics studies or as pharmacological probes. The majority of small molecule UppS inhibitors belong to the well known class of bisphosphonates that are primarily used for treatment of bone resorption disorders. The most potent compound of this class has an IC50 of 0.59 mu M. Inherently, the selectivity and suitability of such compounds for antimicrobial drug design can be questioned. Therefore, high throughput and virtual screenings for non bisphosphonate inhibitors were performed, and nanomolar inhibitors of UppS were identified, some with antimicrobial activities towards clinically relevant strains. The reported scaffolds belong to tetramic and tetronic acids with IC50 in the 100 nM range, and to dihydropyridines with IC50 down to 40 nM, all with antibacterial activity. Aryl diketo acids are also potent inhibitors with MRSA antimicrobial activity, with the allosteric inhibitor methylisoxazole 4 carboxamide (IC50, 50 nM) active on several pathogenic Streptococcus pneumoniae strains. Clomiphene is a well known oestrogen receptor modulator, and it has been reported to inhibit UppS. Although conclusions on the structure activity relationships cannot be drawn from all these data, these compound series represent an important contribution to the field of antibiotics.
C1 [Jukic, Marko; Rozman, Kaja; Gobec, Stanislav] Univ Ljubljana, Fac Pharm, Dept Pharmaceut Chem, Askerceva 7, Ljubljana 1000, Slovenia.
C3 University of Ljubljana
RP Gobec, S (通讯作者)，Univ Ljubljana, Fac Pharm, Dept Pharmaceut Chem, Askerceva 7, Ljubljana 1000, Slovenia.
EM stanislav.gobec@ffa.uni lj.si
OI Gobec, Stanislav/0000 0002 9678 3083; Jukic, Marko/0000 0001 6083 5024
FU Slovenian research Agency [L1 6745]
FX This work was supported by Slovenian research Agency (research project
   L1 6745; Combating bacterial resistance: optimisation of bacterial cell
   wall biosynthesis inhibitors). We thank Chris Berrie for critical
   reading of the manuscript.
CR Alekshun MN, 2007, CELL, V128, P1037, DOI 10.1016/j.cell.2007.03.004
   Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483 492.1999
   Baell J, 2014, NATURE, V513, P481, DOI 10.1038/513481a
   Boucher Y, 2000, MOL MICROBIOL, V37, P703, DOI 10.1046/j.1365 2958.2000.02004.x
   Buhaescu I, 2007, CLIN BIOCHEM, V40, P575, DOI 10.1016/j.clinbiochem.2007.03.016
   Campbell J, 2011, ACS CHEM BIOL, V6, P106, DOI 10.1021/cb100269f
   Cao R, 2008, PROTEINS, V73, P431, DOI 10.1002/prot.22066
   Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904
   Chang SY, 2003, J BIOL CHEM, V278, P29298, DOI 10.1074/jbc.M302687200
   Chen APC, 2002, J AM CHEM SOC, V124, P15217, DOI 10.1021/ja020937v
   Chen YH, 2002, J BIOL CHEM, V277, P7369, DOI 10.1074/jbc.M110014200
   Danley DE, 2015, PROTEIN SCI, V24, P20, DOI 10.1002/pro.2579
   Durrant JD, 2011, CHEM BIOL DRUG DES, V78, P323, DOI 10.1111/j.1747 0285.2011.01164.x
   Farha MA, 2015, P NATL ACAD SCI USA, V112, P11048, DOI 10.1073/pnas.1511751112
   Fujihashi M, 2001, P NATL ACAD SCI USA, V98, P4337, DOI 10.1073/pnas.071514398
   Fujikura K, 2008, BIOSCI BIOTECH BIOCH, V72, P851, DOI 10.1271/bbb.70723
   Goffinet M, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 60
   Guo RT, 2007, P NATL ACAD SCI USA, V104, P10022, DOI 10.1073/pnas.0702254104
   Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200
   Heuston S, 2012, MICROBIOL SGM, V158, P1389, DOI 10.1099/mic.0.051599 0
   HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878
   Hunter WN, 2007, J BIOL CHEM, V282, P21573, DOI 10.1074/jbc.R700005200
   Inokoshi J, 2013, J ANTIBIOT, V66, P37, DOI 10.1038/ja.2012.83
   Khare Y, 2003, J BIOCHEM, V134, P819, DOI 10.1093/jb/mvg207
   Ko TP, 2001, J BIOL CHEM, V276, P47474, DOI 10.1074/jbc.M106747200
   Kuo CJ, 2008, J BIOMED BIOTECHNOL, DOI 10.1155/2008/841312
   Larsen SD, 2006, BIOORG MED CHEM LETT, V16, P6173, DOI 10.1016/j.bmcl.2006.09.044
   Lee LV, 2010, BIOCHEMISTRY US, V49, P5366, DOI 10.1021/bi100523c
   Lesburg CA, 1997, SCIENCE, V277, P1820, DOI 10.1126/science.277.5333.1820
   Lewis K, 2013, NAT REV DRUG DISCOV, V12, P371, DOI 10.1038/nrd3975
   Li H, 2003, J BIOMOL SCREEN, V8, P712, DOI 10.1177/1087057103258185
   Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432 1033.2002.03014.x
   Lombard J, 2011, MOL BIOL EVOL, V28, P87, DOI 10.1093/molbev/msq177
   Lu YP, 2010, BIOCHEM BIOPH RES CO, V400, P758, DOI 10.1016/j.bbrc.2010.09.001
   Lu YP, 2009, BIOCHEM BIOPH RES CO, V379, P351, DOI 10.1016/j.bbrc.2008.12.061
   Mao JH, 2006, J AM CHEM SOC, V128, P14485, DOI 10.1021/ja061737c
   Martin MB, 2001, J MED CHEM, V44, P909, DOI 10.1021/jm0002578
   Oldfield E, 2012, ANGEW CHEM INT EDIT, V51, P1124, DOI 10.1002/anie.201103110
   Pan JJ, 2000, BIOCHEMISTRY US, V39, P13856, DOI 10.1021/bi001226h
   Peukert S, 2008, BIOORG MED CHEM LETT, V18, P1840, DOI 10.1016/j.bmcl.2008.02.009
   Scholte AA, 2004, BIOORGAN MED CHEM, V12, P763, DOI 10.1016/j.bmc.2003.11.033
   Silver LL, 2013, ANN NY ACAD SCI, V1277, P29, DOI 10.1111/nyas.12006
   Sinko W, 2014, J MED CHEM, V57, P5693, DOI 10.1021/jm5004649
   Sinko W, 2011, CHEM BIOL DRUG DES, V77, P412, DOI 10.1111/j.1747 0285.2011.01101.x
   Steinbüchel A, 2003, CURR OPIN MICROBIOL, V6, P261, DOI 10.1016/S1369 5274(03)00061 4
   TARSHIS LC, 1994, BIOCHEMISTRY US, V33, P10871, DOI 10.1021/bi00202a004
   Teng KH, 2012, MOL MEMBR BIOL, V29, P267, DOI 10.3109/09687688.2012.674162
   Teng KH, 2011, ANAL BIOCHEM, V417, P136, DOI 10.1016/j.ab.2011.05.043
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479 5876 11 276
   Zhang YH, 2012, ACS MED CHEM LETT, V3, P402, DOI 10.1021/ml300038t
   Zhu W, 2015, J MED CHEM, V58, P1215, DOI 10.1021/jm501449u
   Zhu W, 2013, P NATL ACAD SCI USA, V110, P123, DOI 10.1073/pnas.1219899110
NR 52
TC 6
Z9 7
U1 0
U2 35
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y 2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929 8673
EI 1875 533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2016
VL 23
IS 5
BP 464
EP 482
DI 10.2174/0929867323666151231094854
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA DG8JW
UT WOS:000372331100004
PM 26718796
DA 2025 08 17
ER

PT J
AU Mishima, K
   Kitoh, H
   Ohkawara, B
   Okuno, T
   Ito, M
   Masuda, A
   Ishiguro, N
   Ohno, K
AF Mishima, Kenichi
   Kitoh, Hiroshi
   Ohkawara, Bisei
   Okuno, Tatsuya
   Ito, Mikako
   Masuda, Akio
   Ishiguro, Naoki
   Ohno, Kinji
TI Lansoprazole Upregulates Polyubiquitination of the TNF
   Receptor Associated Factor 6 and Facilitates Runx2 mediated
   Osteoblastogenesis
SO EBIOMEDICINE
LA English
DT Article
DE Runx2; Lansoprazole; Osteoblastogenesis; Drug repositioning; TRAF6; CYLD
ID PROTON PUMP INHIBITORS; NF KAPPA B; BONE MINERAL DENSITY; TGF BETA;
   OSTEOCLAST DIFFERENTIATION; DISTRACTION OSTEOGENESIS; MORPHOGENETIC
   PROTEIN 2; DEUBIQUITINATING ENZYME; DEFECTIVE INTERLEUKIN 1; SIGNALING
   PATHWAY
AB The transcription factor, runt related transcription factor 2 (Runx2), plays a pivotal role in the differentiation of the mesenchymal stemcells to the osteochondroblast lineages. Wefound by the drug repositioning strategy that a proton pump inhibitor, lansoprazole, enhances nuclear accumulation of Runx2 and induces osteoblastogenesis of human mesenchymal stromal cells. Systemic administration of lansoprazole to a rat femoral fracture model increased osteoblastogenesis. Dissection of signaling pathways revealed that lansoprazole activates a noncanonical bone morphogenic protein (BMP) transforming growth factor beta (TGF beta) activated kinase 1 (TAK1) p38 mitogen activated protein kinase (MAPK) pathway. We found by in cellulo ubiquitination studies that lansoprazole enhances polyubiquitination of the TNF receptor associated factor 6 (TRAF6) and by in vitro ubiquitination studies that the enhanced polyubiquitination of TRAF6 is attributed to the blocking of a deubiquitination enzyme, cylindromatosis (CYLD). Structural modeling and site directed mutagenesis of CYLD demonstrated that lansoprazole tightly fits in a pocket of CYLD where the C terminal tail of ubiquitin lies. Lansoprazole is a potential therapeutic agent for enhancing osteoblastic differentiation. (C) 2015 The Authors. Published by Elsevier B.V.
C1 [Mishima, Kenichi; Ohkawara, Bisei; Okuno, Tatsuya; Ito, Mikako; Masuda, Akio; Ohno, Kinji] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Neurogenet, Nagoya, Aichi 4668550, Japan.
   [Mishima, Kenichi; Kitoh, Hiroshi; Ishiguro, Naoki] Nagoya Univ, Grad Sch Med, Dept Orthopaed Surg, Nagoya, Aichi 4668550, Japan.
C3 Nagoya University; Nagoya University
RP Ohno, K (通讯作者)，Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Neurogenet, Nagoya, Aichi 4668550, Japan.
EM ohnok@med.nagoya u.ac.jp
RI Ishiguro, Naoki/I 1563 2012; Ohno, Kinji/H 4020 2012; Ito,
   Mikako/I 1941 2012; Masuda, Akio/H 6323 2012; Kitoh,
   Hiroshi/AAC 2093 2021; MISHIMA, Kenichi/E 4406 2015; Okuno,
   Tatsuya/ABD 6927 2020
OI Ohno, Kinji/0000 0002 1529 2750; Masuda, Akio/0000 0002 6437 2853;
   MISHIMA, Kenichi/0000 0003 3350 1664; 
FU Grants in Aid for Scientific Research [26670660] Funding Source: KAKEN
CR Abbott A, 2002, NATURE, V417, P109, DOI 10.1038/417109a
   Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810
   Bian Y, 2009, HUM MOL GENET, V18, P1229, DOI 10.1093/hmg/ddp023
   Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chen J, 2012, J CLIN GASTROENTEROL, V46, P93, DOI 10.1097/MCG.0b013e3182333820
   Chen ZJJ, 2005, NAT CELL BIOL, V7, P758, DOI 10.1038/ncb0805 758
   Costa Rodrigues J, 2013, FEBS J, V280, P5052, DOI 10.1111/febs.12478
   Date T, 2004, J ORTHOP SCI, V9, P503, DOI 10.1007/s00776 004 0815 2
   Dourson ML, 1996, REGUL TOXICOL PHARM, V24, P108, DOI 10.1006/rtph.1996.0116
   Edwards CJ, 2000, LANCET, V355, P2218, DOI 10.1016/S0140 6736(00)02408 9
   Esposito K., 2013, Endocrine
   Foronda NM, 2007, REGUL TOXICOL PHARM, V47, P29, DOI 10.1016/j.yrtph.2006.08.005
   Fossmark R, 2012, J CELL BIOCHEM, V113, P141, DOI 10.1002/jcb.23337
   Greenblatt MB, 2010, J CLIN INVEST, V120, P2457, DOI 10.1172/JCI42285
   Gutierrez GE, 2008, J BONE MINER RES, V23, P1722, DOI 10.1359/JBMR.080603
   Herhaus L, 2014, CELL SIGNAL, V26, P2186, DOI 10.1016/j.cellsig.2014.06.012
   Inoue J, 2000, EXP CELL RES, V254, P14, DOI 10.1006/excr.1999.4733
   Jin W, 2008, J CLIN INVEST, V118, P1858, DOI 10.1172/JCI34257
   Ortuño MJ, 2010, J BIOL CHEM, V285, P31985, DOI 10.1074/jbc.M110.123612
   Katagiri T, 2013, BIOL CHEM, V394, P703, DOI 10.1515/hsz 2012 0310
   Kitoh H, 2004, BONE, V35, P892, DOI 10.1016/j.bone.2004.06.013
   Kobayashi N, 2001, EMBO J, V20, P1271, DOI 10.1093/emboj/20.6.1271
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802
   Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394
   Landström M, 2010, INT J BIOCHEM CELL B, V42, P585, DOI 10.1016/j.biocel.2009.12.023
   Leboy PS, 2006, ANN NY ACAD SCI, V1068, P14, DOI 10.1196/annals.1346.003
   Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783 8792.2000
   Lee KS, 2002, ONCOGENE, V21, P7156, DOI 10.1038/sj.onc.1205937
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Marie PJ, 2008, ARCH BIOCHEM BIOPHYS, V473, P98, DOI 10.1016/j.abb.2008.02.030
   MARINO AA, 1979, CLIN ORTHOP RELAT R, P239
   Matsushita M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081569
   Mills LA, 2012, J BONE JOINT SURG BR, V94B, P865, DOI 10.1302/0301 620X.94B7.27370
   Moayyedi P, 2012, NAT REV GASTRO HEPAT, V9, P132, DOI 10.1038/nrgastro.2011.272
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Ngamruengphong S, 2011, AM J GASTROENTEROL, V106, P1209, DOI 10.1038/ajg.2011.113
   O'Connell MB, 2005, AM J MED, V118, P778, DOI 10.1016/j.amjmed.2005.02.007
   Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491
   Phimphilai M, 2006, J BONE MINER RES, V21, P637, DOI 10.1359/JBMR.060109
   Poblenz AT, 2007, BIOCHEM BIOPH RES CO, V359, P510, DOI 10.1016/j.bbrc.2007.05.151
   Reagan Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07 9574LSF
   Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180
   Schinke T, 2009, NAT MED, V15, P674, DOI 10.1038/nm.1963
   Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   Takamatsu A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092699
   Takamine Y, 2002, CLIN ORTHOP RELAT R, P240
   Tanaka S, 2003, J BONE MINER METAB, V21, P123, DOI 10.1007/s007740300021
   Targownik LE, 2010, GASTROENTEROLOGY, V138, P896, DOI 10.1053/j.gastro.2009.11.014
   Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Ulsamer A, 2008, J BIOL CHEM, V283, P3816, DOI 10.1074/jbc.M704724200
   Xia ZP, 2009, NATURE, V461, P114, DOI 10.1038/nature08247
   Xie Ping, 2013, J Mol Signal, V8, P7, DOI 10.1186/1750 2187 8 7
   Yamamoto R, 2013, J BONE MINER METAB, V31, P26, DOI 10.1007/s00774 012 0380 2
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
NR 59
TC 18
Z9 19
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2352 3964
J9 EBIOMEDICINE
JI EBioMedicine
PD DEC
PY 2015
VL 2
IS 12
BP 2046
EP 2061
DI 10.1016/j.ebiom.2015.11.024
PG 16
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA DA1EC
UT WOS:000367538100039
PM 26844285
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhou, JN
   Mao, YH
   Shi, XT
   Zhang, YD
   Yu, XL
   Liu, X
   Diao, L
   Yang, X
   Liu, CZ
   Liu, D
   Tan, X
   Liu, M
AF Zhou, Junnan
   Mao, Yuhang
   Shi, Xiaotian
   Zhang, Yudie
   Yu, Xiaolu
   Liu, Xuan
   Diao, Li
   Yang, Xue
   Liu, Changze
   Liu, Dan
   Tan, Xin
   Liu, Mei
TI Peimine suppresses collagen induced arthritis, activated fibroblast like
   synoviocytes and TNFα induced MAPK pathways
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Peimine; Rheumatoid arthritis; Collagen  induced arthritis; Fibroblast
    like synoviocytes; MAPKs
ID NF KAPPA B; RHEUMATOID ARTHRITIS; CYTOKINES; CELLS
AB Background and purpose: Peimine (PM), a main isosterol alkaloid component isolated from the bulbs of traditional Chinese herb Fritillaria cirrhosa D. Don, has been demonstrated to exhibit multiple pharmacological properties, including anti inflammation, anti cancer and pain suppression. However, its effect on rheumatoid arthritis (RA) remains unknown. In the present study, we investigated the effect of PM on collagen induced arthritis (CIA) rats in vivo and its inhibition on destructive behaviors of arthritic fibroblast like synoviocytes (FLSs) in vitro.Methods: Arthritis was induced in rats by chicken type II collagen. Arthritis score, radiological evaluation, and histopathological assessment were used to evaluate the therapeutic effects of PM on CIA rats. EdU assay, wound healing assay and real time PCR were used to examine the inhibitory effect of PM on proliferation, migration, and over expression of pro inflammatory cytokines in TNF alpha induced arthritic FLSs. TRAP staining and scanning electron microscopy were used to analyze the effect of PM on osteoclastogensis and bone resorption. Western blot was used to reveal PM's molecular mechanism of action on RA.Results: PM significantly suppressed synovitis and bone destruction in CIA rats. In vitro experiments showed that PM treatment significantly inhibited TNF alpha induced destructive behaviors of arthritic FLSs, including over  proliferation, migration and over expression of pro inflammatory cytokines. Additionally, RANKL induced osteoclast formation and bone resorpting function were also inhibited by PM. Further molecular mechanism studies revealed that PM treatment significantly suppressed TNF alpha induced activations of MAPKs (ERK, JNK and p38) in arthritic FLSs.Conclusion: Our findings provide strong evidence that PM has the potential to be developed as a therapeutic agent for patients with RA.
C1 [Zhou, Junnan; Mao, Yuhang; Shi, Xiaotian; Zhang, Yudie; Yu, Xiaolu; Liu, Xuan; Diao, Li; Yang, Xue; Liu, Changze; Liu, Dan; Tan, Xin; Liu, Mei] Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.
C3 Nanjing Normal University
RP Liu, M (通讯作者)，Nanjing Normal Univ, Coll Life Sci, Jiangsu Key Lab Mol & Med Biotechnol, Nanjing 210023, Peoples R China.
EM meiliunj@163.com
RI , 泽博士/AAV 3782 2020
FU National Natural Science Foundation of China [31870895, 32071165,
   31171135]
FX Funding This work was funded by National Natural Science Foundation of
   China (Grant No. 31870895; 32071165; 31171135) .
CR Abbasi M, 2019, J CELL PHYSIOL, V234, P10018, DOI 10.1002/jcp.27860
   AREND WP, 1990, ARTHRITIS RHEUM US, V33, P305, DOI 10.1002/art.1780330302
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Brennan F, 2007, CURR OPIN RHEUMATOL, V19, P296, DOI 10.1097/BOR.0b013e32805e87f1
   Chen K, 2019, INT J MOL MED, V43, P2241, DOI 10.3892/ijmm.2019.4141
   Choe JY, 2012, JOINT BONE SPINE, V79, P137, DOI 10.1016/j.jbspin.2011.03.018
   Fearon U, 2016, NAT REV RHEUMATOL, V12, P385, DOI 10.1038/nrrheum.2016.69
   Feldmann M, 1999, RHEUMATOLOGY, V38, P3
   Guo JT, 2019, EUR REV MED PHARMACO, V23, P10211, DOI 10.26355/eurrev_201912_19656
   Guo QY, 2018, BAMBOO SILK, V1, P1, DOI [10.1163/24689246 00101001, 10.1038/s41413 018 0016 9]
   Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065
   Lee DM, 2001, LANCET, V358, P903, DOI 10.1016/S0140 6736(01)06075 5
   Lefèvre S, 2009, NAT MED, V15, P1414, DOI 10.1038/nm.2050
   Li J, 2020, INT J RHEUM DIS, V23, P1627, DOI 10.1111/1756 185X.13958
   Li M, 2020, XENOBIOTICA, V50, P1202, DOI 10.1080/00498254.2020.1761572
   Liu CF, 2020, J ETHNOPHARMACOL, V260, DOI 10.1016/j.jep.2020.113039
   Liu M, 2018, J CELL PHYSIOL, V233, P6291, DOI 10.1002/jcp.26517
   Liu ZZ, 2018, J CELL PHYSIOL, V233, P8740, DOI 10.1002/jcp.26754
   May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167 5699(97)01197 3
   McInnes IB, 2017, LANCET, V389, P2328, DOI 10.1016/S0140 6736(17)31472 1
   Park JH, 2017, PHARMACOGN MAG, V13, pS359, DOI 10.4103/0973 1296.210173
   Pezhman L, 2019, ARCH PHYSIOL BIOCHEM, V125, P195, DOI 10.1080/13813455.2018.1446178
   Qiu HW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051514
   [仇海文 Qiu Haiwen], 2017, [南京师大学报. 自然科学版, Journal of Nanjing Normal University. Natural Science], V40, P128
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Tan HL, 2020, J CELL BIOCHEM, V121, P81, DOI 10.1002/jcb.28870
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Vincenti MP, 1998, ARTHRITIS RHEUM, V41, P1987, DOI 10.1002/1529 0131(199811)41:11<1987::AID ART14>3.3.CO;2 #
   Wang J, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01188
   Yi PF, 2013, IMMUNOPHARM IMMUNOT, V35, P567, DOI 10.3109/08923973.2013.822508
   Yip KHM, 2005, J BONE MINER RES, V20, P1462, DOI 10.1359/JBMR.050324
   Zhang LH, 2020, MOLECULES, V25, DOI 10.3390/molecules25051105
   Zhu SL, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01300
NR 34
TC 16
Z9 16
U1 3
U2 22
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD OCT
PY 2022
VL 111
AR 109181
DI 10.1016/j.intimp.2022.109181
EA AUG 2022
PG 11
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 4W9IX
UT WOS:000860469500003
PM 36027853
DA 2025 08 17
ER

PT J
AU Lu, J
   Meng, JM
   Wu, G
   Wei, WL
   Xie, HB
   Liu, YL
AF Lu, Jing
   Meng, Jiaming
   Wu, Gang
   Wei, Wulong
   Xie, Huabao
   Liu, Yanli
TI Th1 cells reduce the osteoblast like phenotype in valvular interstitial
   cells by inhibiting NLRP3 inflammasome activation in macrophages
SO MOLECULAR MEDICINE
LA English
DT Article
DE Th1; IFN gamma; Calcific aortic valve stenosis; NLRP3; Macrophages
ID AORTIC VALVE STENOSIS; INTERFERON GAMMA; IFN GAMMA; ATHEROSCLEROSIS;
   CALCIFICATION; MONOCYTES; MOUSE; MULTIMODALITY; POLARIZATION; SUPPRESSES
AB Background and aimsInflammation is initiates the propagation phase of aortic valve calcification. The activation of NLRP3 signaling in macrophages plays a crucial role in the progression of calcific aortic valve stenosis (CAVS). IFN gamma regulates NLRP3 activity in macrophages. This study aimed to explore the mechanism of IFN gamma regulation and its impact on CAVS progression and valve interstitial cell transdifferentiation.Methods and resultsThe number of Th1 cells and the expression of IFN gamma and STAT1 in the aortic valve, spleen and peripheral blood increased significantly as CAVS progressed. To explore the mechanisms underlying the roles of Th1 cells and IFN gamma, we treated CAVS mice with IFN gamma AAV9 or an anti IFN gamma neutralizing antibody. While IFN gamma promoted aortic valve calcification and dysfunction, it significantly decreased NLRP3 signaling in splenic macrophages and Ly6C+ monocytes. In vitro coculture showed that Th1 cells inhibited NLPR3 activation in ox LDL treated macrophages through the IFN gamma R1/IFN gamma R2 STAT1 pathway. Compared with untreated medium, conditioned medium from Th1 treated bone marrow derived macrophages reduced the osteogenic calcification of valvular interstitial cells.ConclusionInhibition of the NLRP3 inflammasome by Th1 cells protects against valvular interstitial cell calcification as a negative feedback mechanism of adaptive immunity toward innate immunity. This study provides a precision medicine strategy for CAVS based on the targeting of anti inflammatory mechanisms.
C1 [Lu, Jing; Xie, Huabao] Guangxi Med Univ, Clin Med Coll 1, Shuangyong Rd 22, Nanning 530021, Guangxi Zhuang, Peoples R China.
   [Meng, Jiaming; Wu, Gang; Wei, Wulong; Liu, Yanli] Liuzhou Peoples Hosp, Dept Cardiol, Wenchang Rd 8, Liuzhou 545000, Guangxi, Peoples R China.
C3 Guangxi Medical University
RP Xie, HB (通讯作者)，Guangxi Med Univ, Clin Med Coll 1, Shuangyong Rd 22, Nanning 530021, Guangxi Zhuang, Peoples R China.; Liu, YL (通讯作者)，Liuzhou Peoples Hosp, Dept Cardiol, Wenchang Rd 8, Liuzhou 545000, Guangxi, Peoples R China.
EM XieHB20096@163.com; gxlyl@126.com
RI Yanli, Liu/AHB 5152 2022
FU National Natural Science Foundation of China
FX The authors did not use generative AI or AI assisted technologies in the
   development of this manuscript. The Graphical Abstract is supported by
   the Figdraw (www.home for researchers.com).
CR Abplanalp WT, 2020, JAMA CARDIOL, V5, P1170, DOI 10.1001/jamacardio.2020.2468
   Aggarwal SR, 2013, CIRC CARDIOVASC IMAG, V6, P40, DOI 10.1161/CIRCIMAGING.112.980052
   Aikawa E, 2007, CIRCULATION, V115, P377, DOI 10.1161/CIRCULATIONAHA.106.654913
   Auffray C, 2007, SCIENCE, V317, P666, DOI 10.1126/science.1142883
   Awad F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175336
   BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699 0463.1995.tb01092.x
   Bish LT, 2008, HUM GENE THER, V19, P1359, DOI 10.1089/hum.2008.123
   Boshuizen MCS, 2016, ATHEROSCLEROSIS, V246, P325, DOI 10.1016/j.atherosclerosis.2016.01.026
   Buono C, 2005, P NATL ACAD SCI USA, V102, P1596, DOI 10.1073/pnas.0409015102
   Buono C, 2003, ARTERIOSCL THROM VAS, V23, P454, DOI 10.1161/01.ATV.0000059419.11002.6E
   Burke JD, 2019, SEMIN IMMUNOL, V43, DOI 10.1016/j.smim.2019.05.002
   Carlin LM, 2013, CELL, V153, P362, DOI 10.1016/j.cell.2013.03.010
   Christ A, 2018, CELL, V172, P162, DOI 10.1016/j.cell.2017.12.013
   CHRISTEN S, 1994, J CLIN INVEST, V93, P2149, DOI 10.1172/JCI117211
   Cochain C, 2015, CIRC RES, V117, P244, DOI 10.1161/CIRCRESAHA.117.304611
   Decano JL, 2023, CIRCULATION, V148, P1459, DOI 10.1161/CIRCULATIONAHA.123.064794
   Dinh QN, 2017, PHARMACOL RES, V116, P70, DOI 10.1016/j.phrs.2016.12.032
   Dorighello GG, 2022, ANTIOXIDANTS BASEL, V11, DOI 10.3390/antiox11091734
   Eigenbrod T, 2013, J IMMUNOL, V190, P6533, DOI 10.4049/jimmunol.1300324
   Epelman S, 2014, IMMUNITY, V40, P91, DOI 10.1016/j.immuni.2013.11.019
   Goody PR, 2020, ARTERIOSCL THROM VAS, V40, P885, DOI 10.1161/ATVBAHA.119.313067
   Grim JC, 2020, ARTERIOSCL THROM VAS, V40, pE296, DOI 10.1161/ATVBAHA.120.315261
   Hewing B, 2017, THROMB HAEMOSTASIS, V117, P2346, DOI 10.1160/TH17 05 0341
   Hewing B, 2017, J CARDIOVASC TRANSL, V10, P27, DOI 10.1007/s12265 016 9726 9
   Ingersoll MA, 2010, BLOOD, V115, pE10, DOI 10.1182/blood 2009 07 235028
   Jung JJ, 2015, J NUCL MED, V56, P933, DOI 10.2967/jnumed.114.152355
   King VL, 2009, CIRCULATION, V119, P426, DOI 10.1161/CIRCULATIONAHA.108.785949
   Knezevic Tijana, 2016, JACC Basic Transl Sci, V1, P647, DOI 10.1016/j.jacbts.2016.08.008
   Labzin LI, 2016, J ALLERGY CLIN IMMUN, V138, P37, DOI 10.1016/j.jaci.2016.05.010
   Lacey CA, 2019, J LEUKOCYTE BIOL, V106, P27, DOI 10.1002/JLB.4MIA1018 409R
   Lee IF, 2008, EUR J IMMUNOL, V38, P82, DOI 10.1002/eji.200737189
   Lee MS, 2012, J CLIN IMMUNOL, V32, P753, DOI 10.1007/s10875 012 9682 3
   Li G, 2017, J THORAC CARDIOV SUR, V153, P1318, DOI 10.1016/j.jtcvs.2017.01.052
   Lu J, 2022, ATHEROSCLEROSIS, V347, P28, DOI 10.1016/j.atherosclerosis.2022.03.005
   Miller JD, 2011, CIRC RES, V108, P1392, DOI 10.1161/CIRCRESAHA.110.234138
   Mishra BB, 2013, NAT IMMUNOL, V14, P52, DOI 10.1038/ni.2474
   Nagy E, 2017, AM J PATHOL, V187, P1413, DOI 10.1016/j.ajpath.2017.02.012
   Niwa Tamikazu, 2004, J Atheroscler Thromb, V11, P79
   Oikonomou V, 2016, CELL HOST MICROBE, V20, P744, DOI 10.1016/j.chom.2016.10.012
   Parra Izquierdo I, 2021, FEBS J, V288, P6528, DOI 10.1111/febs.16026
   Parra Izquierdo I, 2019, BBA MOL BASIS DIS, V1865, P2168, DOI 10.1016/j.bbadis.2019.04.014
   Raddatz MA, 2020, ARTERIOSCL THROM VAS, V40, pE153, DOI 10.1161/ATVBAHA.120.314360
   Schmidl C, 2014, BLOOD, V123, pE90, DOI 10.1182/blood 2013 02 484188
   Schoenborn JR, 2007, ADV IMMUNOL, V96, P41, DOI 10.1016/S0065 2776(07)96002 2
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Steiner I, 2012, PATHOL RES PRACT, V208, P231, DOI 10.1016/j.prp.2012.02.009
   Swanson KV, 2019, NAT REV IMMUNOL, V19, P477, DOI 10.1038/s41577 019 0165 0
   Taniguchi T, 2015, CIRCULATION, V131, DOI 10.1161/CIRCULATIONAHA.114.014690
   Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005
   Walther T, 2012, HEART, V98, pIV23, DOI 10.1136/heartjnl 2012 302399
   Wasilewski J, 2012, POL J RADIOL, V77, P30, DOI 10.12659/PJR.883626
   Weiss RM, 2006, CIRCULATION, V114, P2065, DOI 10.1161/CIRCULATIONAHA.106.634139
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu XQ, 2018, CELL, V175, P1336, DOI 10.1016/j.cell.2018.09.011
   Youssef A, 2021, TRENDS CARDIOVAS MED, V31, P305, DOI 10.1016/j.tcm.2020.06.001
   Zeng QC, 2017, P NATL ACAD SCI USA, V114, P1631, DOI 10.1073/pnas.1619667114
   Zhou J, 2015, CIRC RES, V117, P943, DOI 10.1161/CIRCRESAHA.115.306932
   Zhu EY, 2019, LIFE SCI, V228, P72, DOI 10.1016/j.lfs.2019.04.050
NR 58
TC 5
Z9 5
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076 1551
EI 1528 3658
J9 MOL MED
JI Mol. Med.
PD JUL 30
PY 2024
VL 30
IS 1
AR 110
DI 10.1186/s10020 024 00882 z
PG 14
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA A1Q0T
UT WOS:001280337500001
PM 39080527
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Ou, ZX
   Cheng, Q
   Chen, YP
   Chen, T
   Rong, XB
   Long, FP
   Zhang, XY
   Liang, QH
   Feng, Z
AF Ou, Zhixue
   Cheng, Qi
   Chen, Yueping
   Chen, Tao
   Rong, Xiangbin
   Long, Feipan
   Zhang, Xiaoyun
   Liang, Qinghua
   Feng, Zhe
TI Chemical characterization of wound ointment (WO) and its effects on
   fracture repair: a rabbit model
SO CHINESE MEDICINE
LA English
DT Article
DE Animals; Osteoclasts; Fracture healing; Wound ointment (WO); Radius
   fracture; VEGF
ID SIGNALING PATHWAY; BONE FORMATION; YUNNAN BAIYAO; ANGIOGENESIS;
   DIFFERENTIATION; WOMEN; VEGF; DOGS
AB Background: Wound ointment (WO), a kind of Chinese medicine, can significantly promote fracture healing. The study aimed at analyzing the chemical composition and the effects of WO on fracture of rabbits and tried to explore the corresponding molecular mechanism in cytokine.& para;& para;Methods: The gualitative and guantitative analysis of WO was conducted by liguid chromatography mass spectrometry (LC MS). Fifty four Zealand mature male rabbits were randomly divided into 3 groups: Control group, Yunnan Baiyao (YB) group and WO group. All the rabbits suffered a fracture of right radius and were then stabilized with an external fixator.Treated with different methods, fracture healing was observed. The bone specimens were subjected to radiograph, immunohistochemistry (IHQ analysis, hematoxylin eosin staining (FIE), western blot and enzyme linked immunosorbent assay (ELISA).& para;& para;Results: A total of 12 active compositions were detected by LC MS. Radiographs showed a considerably better bone healing and remodeling of the fracture in WO group. FIE experiments showed that a large number of osteoclasts appeared in the early stage when treated with WO. In immunohistochemistry (IHC), western blot and ELISA test, significant increases in vascular endothelial growth factor (VEGF) expression were observed in WO group compared with other two groups.& para;& para;Conclusions: Wound ointment contained active compositions which efficiently promoted fracture healing through increasing the expression of VEGF.
C1 [Ou, Zhixue; Chen, Yueping; Chen, Tao; Rong, Xiangbin; Long, Feipan; Zhang, Xiaoyun; Liang, Qinghua; Feng, Zhe] Guangxi Univ Chinese Med, Ruikang Hosp, Dept Traumat Orthoped & Hand Surg, Block B,10 Huadong Rd, Nanning 530011, Guangxi, Peoples R China.
   [Cheng, Qi] Daye Hosp Tradit Chinese Med, Dept Traumat Orthoped, Daye 435100, Hubei, Peoples R China.
C3 Guangxi University of Chinese Medicine
RP Feng, Z (通讯作者)，Guangxi Univ Chinese Med, Ruikang Hosp, Dept Traumat Orthoped & Hand Surg, Block B,10 Huadong Rd, Nanning 530011, Guangxi, Peoples R China.
EM chizf0618@163.com
RI LONG, FEI/NRA 7738 2025; Zhang, Xiao Yun/ADB 7099 2022
FU Guangxi Zhuang Autonomous Region Science and Technology Agency Research
   Project [0816004 37]
FX This study was supported by Guangxi Zhuang Autonomous Region Science and
   Technology Agency Research Project (No. 0816004 37).
CR Arti H, 2016, PAK J MED SCI, V32, P65, DOI 10.12669/pjms.321.8568
   Benetou V, 2016, J BONE MINER RES, V31, P1743, DOI 10.1002/jbmr.2850
   Berendsen AD, 2014, MATRIX BIOL, V35, P223, DOI 10.1016/j.matbio.2013.12.004
   Cunningham TD, 2016, OSTEOPOROSIS INT, V27, P2979, DOI 10.1007/s00198 016 3620 9
   De Kock T, 2015, ENVIRON SCI TECHNOL, V49, P2867, DOI 10.1021/es505738d
   Dombrowski S, 2017, OSTEOPOROSIS INT, V28, P2349, DOI 10.1007/s00198 017 4036 x
   Du B, 2015, INT J NANOMED, V10, P2555, DOI 10.2147/IJN.S78331
   Frederick J, 2017, CAN J VET RES, V81, P41
   Grassmann JP, 2015, J MATER SCI MATER M, V26, DOI 10.1007/s10856 014 5331 0
   Ho Tsung Jung., 2016, Evidence Based Complementary and Alternative Medicine, V2016, DOI DOI 10.1155/2016/1654056
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Karres J, 2015, INJURY, V46, P371, DOI 10.1016/j.injury.2014.11.004
   Katagiri W, 2017, MAX PLAST RECONSTR S, V39, DOI 10.1186/s40902 017 0106 4
   Ke K, 2016, SCI REP UK, V6, DOI 10.1038/srep35233
   Lee JY, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/2136215
   Li R, 2011, INT J CLIN EXP MED, V4, P309
   Issa JPM, 2015, GROWTH FACTORS, V33, P139, DOI 10.3109/08977194.2015.1011270
   Murphy CM, 2015, J BONE MINER RES, V30, P1022, DOI 10.1002/jbmr.2424
   Murphy LA, 2017, J VET EMERG CRIT CAR, V27, P121, DOI 10.1111/vec.12529
   Ogilvie Christian M, 2012, Iowa Orthop J, V32, P90
   Ozturk Burak Yagmur, 2013, Eur J Orthop Surg Traumatol, V23, P767, DOI 10.1007/s00590 012 1070 4
   Song N, 2017, CHEM BIOL INTERACT, V261, P11, DOI 10.1016/j.cbi.2016.10.020
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Sukul M, 2015, TISSUE ENG PT A, V21, P1822, DOI [10.1089/ten.tea.2014.0497, 10.1089/ten.TEA.2014.0497]
   Tang QL, 2014, MOL MED REP, V9, P1277, DOI 10.3892/mmr.2014.1921
   Yang G, 2015, EXP THER MED, V10, P1327, DOI 10.3892/etm.2015.2660
   Zhou J, 2017, MED SCI MONITOR, V23, P555, DOI 10.12659/MSM.902859
NR 27
TC 2
Z9 2
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1749 8546
J9 CHIN MED UK
JI Chin. Med.
PD OCT 30
PY 2017
VL 12
AR 31
DI 10.1186/sl3020 017 0152 y
PG 10
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA FL4NJ
UT WOS:000414206700001
PM 29093746
DA 2025 08 17
ER

PT J
AU Zheng, JW
   Guo, HL
   Qin, Y
   Liu, ZX
   Ding, ZJ
   Zhang, L
   Wang, WQ
AF Zheng, Jiwei
   Guo, Hongliang
   Qin, Ying
   Liu, Zongxiang
   Ding, Zhijiang
   Zhang, Lei
   Wang, Wanqing
TI SNHG5/miR 582 5p/RUNX3 feedback loop regulates osteogenic
   differentiation and apoptosis of bone marrow mesenchymal stem cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE lncRNA; miR 582 5p; osteoporosis; RUNX3; SNHG5
ID NONCODING RNA SNHG5; OSTEOPOROSIS; OSTEOBLAST; WOMEN
AB Osteoporosis is one of the most prevailing orthopedic diseases that causes a heavy burden on public health. Given that bone marrow derived mesenchymal stem cells (BMSCs) are of immense importance in osteoporosis development, it is necessary to expound the mechanisms underlying BMSC osteoblastic differentiation. Although mounting research works have investigated the role of small nucleolar RNA host gene 5 (SNHG5) in various diseases, elucidations on its function in osteoporosis are still scarce. It was observed that SNHG5 and RUNX family transcription factor 3 (RUNX3) were remarkably elevated during osteogenic differentiation of human bone marrow mesenchymal stem cells (hBMSCs). Further, we disclosed that the silencing of SNHG5 suppressed osteogenic differentiation and induced apoptosis of hBMSCs. What's more, SNHG5 acted as a competing endogenous RNA to affect RUNX3 expression via competitively binding with microRNA (miR) 582 5p. RUNX3 was also confirmed to simulate the transcriptional activation of SNHG5. Finally, our findings manifested that the positive feedback loop of SNHG5/miR 582 5p/RUNX3 executed the promoting role in the development of osteoporosis, which shed light on specific molecular mechanism governing SNHG5 in osteogenic differentiation and apoptosis of hBMSCs and indicated that SNHG5 may represent a novel target for the improvement of osteoporosis therapy.
C1 [Zheng, Jiwei; Qin, Ying; Ding, Zhijiang; Wang, Wanqing] Xuzhou Med Univ, Sch Stomatol, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China.
   [Zheng, Jiwei; Qin, Ying; Ding, Zhijiang] Xuzhou Med Univ, Dept Stomatol, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China.
   [Guo, Hongliang] Xuzhou Med Univ, Affiliated Stomatol Hosp, Dept Repair Sect, Xuzhou, Jiangsu, Peoples R China.
   [Liu, Zongxiang; Zhang, Lei] Xuzhou Med Univ, Affiliated Stomatol Hosp, Dept Stomatol, Xuzhou, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University; Xuzhou Medical
   University; Xuzhou Medical University
RP Zheng, JW (通讯作者)，Xuzhou Med Univ, Sch Stomatol, 209 Tongshan Rd, Xuzhou 221004, Jiangsu, Peoples R China.
EM zhengkouqiang@163.com
RI ; Guo, Hongliang/JQV 5537 2023
OI zheng, jiwei/0000 0002 0909 7449; Zheng, Jiwei/0009 0009 2393 0458; 
FU Six Talent Peaks Project in Jiangsu Province; Xuzhou Science and
   Technology Planning Project [KC15SH015]; Jiangsu College Natural Science
   Foundation of China [12KJB320015]; Jiangsu College Students' Innovation
   and Entrepreneurship Training Program [201710313028Z];  [2014 wsw 068]
FX This study was supported by all labs. This article was supported by
   Xuzhou Science and Technology Planning Project (KC15SH015), Six Talent
   Peaks Project in Jiangsu Province (2014 wsw 068), Jiangsu College
   Natural Science Foundation of China (12KJB320015), Jiangsu College
   Students' Innovation and Entrepreneurship Training Program
   (201710313028Z).
CR Brandi ML, 2011, AGING CLIN EXP RES, V23, P3
   Chen S, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0935 9
   Choo SY, 2019, INT J ONCOL, V54, P1327, DOI 10.3892/ijo.2019.4713
   Clarke BL, 2010, RADIOL CLIN N AM, V48, P483, DOI 10.1016/j.rcl.2010.02.014
   Dall TM, 2013, HEALTH AFFAIR, V32, P2013, DOI 10.1377/hlthaff.2013.0714
   Gao J, 2019, ONCOTARGETS THER, V12, P169, DOI 10.2147/OTT.S184078
   Gao XR, 2018, CELL BIOSCI, V8, DOI 10.1186/s13578 018 0216 4
   Gibon E, 2017, J ORTHOP TRANSL, V10, P28, DOI 10.1016/j.jot.2017.04.002
   Hu XH, 2019, J CANCER, V10, P1333, DOI 10.7150/jca.29517
   Huang YP, 2015, STEM CELLS, V33, P3481, DOI 10.1002/stem.2225
   Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   Kim BR, 2019, ONCOGENE, V38, P3903, DOI 10.1038/s41388 019 0693 x
   Li CJ, 2015, J CLIN INVEST, V125, P1509, DOI 10.1172/JCI77716
   Li J, 2018, EUR REV MED PHARMACO, V22, P3342, DOI 10.26355/eurrev_201806_15154
   Li XM, 2019, STEM CELLS DEV, V28, P791, DOI 10.1089/scd.2019.0044
   Li YR, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 0882 5
   Li ZW, 2019, FEBS OPEN BIO, V9, P851, DOI 10.1002/2211 5463.12611
   MacLean C, 2008, ANN INTERN MED, V148, P197, DOI 10.7326/0003 4819 148 3 200802050 00198
   Okazaki R, 2004, ANN RHEUM DIS, V63, P453, DOI 10.1136/ard.2003.011643
   Ouyang SR, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935 019 0784 3
   Ouyang W, 2019, PEERJ, V7, DOI 10.7717/peerj.6683
   Pietschmann P, 2016, GERONTOLOGY, V62, P128, DOI 10.1159/000431091
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Shi XC, 2019, EXP THER MED, V18, P2393, DOI 10.3892/etm.2019.7849
   Sun JK, 2018, J NEURO ONCOL, V140, P15, DOI 10.1007/s11060 018 2927 0
   Thakker Rahul, 2014, Curr Treat Options Cardiovasc Med, V16, P323, DOI 10.1007/s11936 014 0323 4
   Verma S, 2002, J CLIN PATHOL, V55, P693, DOI 10.1136/jcp.55.9.693
   Wang CG, 2019, EXP MOL PATHOL, V107, P77, DOI 10.1016/j.yexmp.2019.01.012
   Wang MH, 2019, AM J TRANSL RES, V11, P1827
   Wang YX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1153 1
   Wang Y, 2018, CELL PHYSIOL BIOCHEM, V47, P2291, DOI 10.1159/000491539
   Wang YF, 2017, INT J MOL MED, V40, P1991, DOI 10.3892/ijmm.2017.3155
   Wang ZX, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180400
   Wang ZW, 2018, BIOMED PHARMACOTHER, V107, P598, DOI 10.1016/j.biopha.2018.08.025
   Watts NB, 2014, NAT REV ENDOCRINOL, V10, P412, DOI 10.1038/nrendo.2014.55
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Wu RY, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1082 z
   Wu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 1014 2
   Xin L, 2019, INT J BIOL MACROMOL, V122, P1046, DOI 10.1016/j.ijbiomac.2018.09.051
   Zhang MB, 2019, CANCER BIOL THER, V20, P524, DOI 10.1080/15384047.2018.1537579
   Zhang QJ, 2019, MOL MED REP, V19, P4927, DOI 10.3892/mmr.2019.10132
   Zhang X, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974 019 1464 x
NR 44
TC 24
Z9 25
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0021 9541
EI 1097 4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD DEC
PY 2024
VL 239
IS 12
AR e29527
DI 10.1002/jcp.29527
EA OCT 2020
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA P7F8X
UT WOS:000583495200001
PM 33111341
DA 2025 08 17
ER

PT J
AU Gu, CY
   Wang, W
   Tang, XZ
   Xu, TT
   Zhang, YX
   Guo, MJ
   Wei, RF
   Wang, YJ
   Jurczyszyn, A
   Janz, S
   Beksac, M
   Zhan, FH
   Seckinger, A
   Hose, D
   Pan, JX
   Yang, Y
AF Gu, Chunyan
   Wang, Wang
   Tang, Xiaozhu
   Xu, Tingting
   Zhang, Yanxin
   Guo, Mengjie
   Wei, Rongfang
   Wang, Yajun
   Jurczyszyn, Artur
   Janz, Siegfried
   Beksac, Meral
   Zhan, Fenghuang
   Seckinger, Anja
   Hose, Dirk
   Pan, Jingxuan
   Yang, Ye
TI CHEK1 and circCHEK1_246aa evoke chromosomal instability and induce bone
   lesion formation in multiple myeloma
SO MOLECULAR CANCER
LA English
DT Article
DE Multiple myeloma; CHEK1; circCHEK1_246aa; Proliferation; Drug
   resistance; Chromosomal instability
ID DRUG RESISTANCE; MOLECULAR CLASSIFICATION; INDUCED APOPTOSIS; KINASE;
   INHIBITOR; CELLS; DYNAMICS; BIOLOGY; CHK1; MK2
AB Background Multiple myeloma (MM) is still incurable and characterized by clonal expansion of plasma cells in the bone marrow (BM). Therefore, effective therapeutic interventions must target both myeloma cells and the BM niche. Methods Cell proliferation, drug resistance, and chromosomal instability (CIN) induced by CHEK1 were confirmed by Giemsa staining, exon sequencing, immunofluorescence and xenograft model in vivo. Bone lesion was evaluated by Tartrate resistant acid phosphatase (TRAP) staining. The existence of circCHEK1_246aa was evaluated by qPCR, Sanger sequencing and Mass Spectrometer. Results We demonstrated that CHEK1 expression was significantly increased in human MM samples relative to normal plasma cells, and that in MM patients, high CHEK1 expression was associated with poor outcomes. Increased CHEK1 expression induced MM cellular proliferation and evoked drug resistance in vitro and in vivo. CHEK1 mediated increases in cell proliferation and drug resistance were due in part to CHEK1 induced CIN. CHEK1 activated CIN, partly by phosphorylating CEP170. Interestingly, CHEK1 promoted osteoclast differentiation by upregulating NFATc1 expression. Intriguingly, we discovered that MM cells expressed circCHEK1_246aa, a circular CHEK1 RNA, which encoded and was translated to the CHEK1 kinase catalytic center. Transfection of circCHEK1_246aa increased MM CIN and osteoclast differentiation similarly to CHEK1 overexpression, suggesting that MM cells could secrete circCHEK1_246aa in the BM niche to increase the invasive potential of MM cells and promote osteoclast differentiation. Conclusions Our findings suggest that targeting the enzymatic catalytic center encoded by CHEK1 mRNA and circCHEK1_246aa is a promising therapeutic modality to target both MM cells and BM niche.
C1 [Gu, Chunyan; Guo, Mengjie; Pan, Jingxuan; Yang, Ye] Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.
   [Gu, Chunyan; Wang, Wang; Tang, Xiaozhu; Xu, Tingting; Zhang, Yanxin; Guo, Mengjie; Wei, Rongfang; Wang, Yajun; Yang, Ye] Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med Nanjing, 138 Xianlin Rd, Nanjing 210023, Peoples R China.
   [Jurczyszyn, Artur] Jagiellonian Univ, Med Coll, Dept Hematol, Krakow, Poland.
   [Janz, Siegfried] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
   [Beksac, Meral] Ankara Univ, Sch Med, Dept Hematol, Ankara, Turkey.
   [Zhan, Fenghuang] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA.
   [Seckinger, Anja; Hose, Dirk] Vrije Univ Brussel VUB, Lab Hematol & Immunol, Jette, Belgium.
   [Seckinger, Anja] Vrije Univ Brussel VUB, Labor Myelomforsch, Jette, Belgium.
   [Pan, Jingxuan] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangdong Prov Key Lab Ophthalmol & Visual Sci, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Peoples R China.
C3 Nanjing University of Chinese Medicine; Nanjing University of Chinese
   Medicine; Jagiellonian University; Collegium Medicum Jagiellonian
   University; Medical College of Wisconsin; Ankara University; University
   of Arkansas System; University of Arkansas Medical Sciences; Vrije
   Universiteit Brussel; Vrije Universiteit Brussel; Sun Yat Sen University
RP Pan, JX; Yang, Y (通讯作者)，Nanjing Univ Chinese Med, Nanjing Hosp Chinese Med, Nanjing, Peoples R China.; Yang, Y (通讯作者)，Nanjing Univ Chinese Med, Sch Med & Holist Integrat Med Nanjing, 138 Xianlin Rd, Nanjing 210023, Peoples R China.; Pan, JX (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, Guangdong Prov Key Lab Ophthalmol & Visual Sci, State Key Lab Ophthalmol, 54 South Xianlie Rd, Guangzhou 510060, Peoples R China.
EM panjx2@mail.sysu.edu.cn; yangye876@sina.com
RI Hose, Dirk/JLM 2482 2023; YANG, YE/B 8740 2014; Beksac,
   Meral/D 6411 2013; YANG, YE/F 4987 2015; ZHOU, YUE/IZE 6277 2023; Zhong,
   Wenzhao/C 3388 2008; Zhang, Yanxin/ABF 2518 2020
OI Hose, Dirk/0000 0003 0806 5223; Beksac, Meral/0000 0003 1797 8657; Janz,
   Siegfried/0000 0002 2229 5511; YANG, YE/0000 0003 0228 5102; Pan,
   Jingxuan/0000 0001 7128 2947; 
FU National Key R&D Program of China [2020YFA0509400]; National Natural
   Science Foundation of China [81970196, 82073885]; Natural Science
   Foundation of Jiangsu Province [BK20200097]; Priority Academic Program
   Development of Jiangsu Higher Education Institutions for Chinese
   Medicine; Priority Academic Program Development of Jiangsu Higher
   Education Institutions (Integration of Chinese and Western Medicine)
FX This work was supported by National Key R&D Program of China (No.
   2020YFA0509400), National Natural Science Foundation of China 81970196
   (to CG) and 82073885 (to YY) and Natural Science Foundation of Jiangsu
   Province BK20200097 (to CG); The Priority Academic Program Development
   of Jiangsu Higher Education Institutions for Chinese Medicine; A Project
   Funded by the Priority Academic Program Development of Jiangsu Higher
   Education Institutions (Integration of Chinese and Western Medicine).
CR Beksac M, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00228
   Bendell JC, 2020, INVEST NEW DRUG, V38, P1145, DOI 10.1007/s10637 019 00873 6
   Bianchi G, 2015, BLOOD, V125, P3049, DOI 10.1182/blood 2014 11 568881
   Bianchi G, 2014, CA CANCER J CLIN, V64, P422, DOI 10.3322/caac.21252
   Broyl A, 2010, BLOOD, V116, P2543, DOI 10.1182/blood 2009 12 261032
   Cánovas B, 2018, CANCER CELL, V33, P1094, DOI 10.1016/j.ccell.2018.04.010
   Cervenka I, 2016, P NATL ACAD SCI USA, V113, P9304, DOI 10.1073/pnas.1608783113
   Chen LJ, 2010, BLOOD, V115, P61, DOI 10.1182/blood 2009 03 210526
   de Boussac H, 2020, HAEMATOLOGICA, V105, P784, DOI 10.3324/haematol.2018.208306
   Dent P, 2019, EXPERT OPIN INV DRUG, V28, P1095, DOI 10.1080/13543784.2019.1694661
   Denu RA, 2018, MOL CANCER RES, V16, P517, DOI 10.1158/1541 7786.MCR 17 0197
   Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053
   Dimopoulos MA, 2015, J CLIN ONCOL, V33, P657, DOI 10.1200/JCO.2014.57.9961
   Dou YC, 2020, CELL, V180, P729, DOI 10.1016/j.cell.2020.01.026
   Feng YS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1071 9
   Ghobrial IM, 2018, NAT REV CLIN ONCOL, V15, P219, DOI 10.1038/nrclinonc.2017.197
   Gu CY, 2021, LEUKEMIA, V35, P1803, DOI 10.1038/s41375 020 01033 z
   Gu CY, 2021, HAEMATOLOGICA, V106, P1774, DOI 10.3324/haematol.2017.182121
   Gu CY, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408 018 0060 0
   Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04 10 0939
   Gulluni F, 2017, CANCER CELL, V32, P444, DOI 10.1016/j.ccell.2017.09.002
   Guo MJ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00722
   Hara Y, 2013, MOL BIOL CELL, V24, P1411, DOI 10.1091/mbc.E12 07 0528
   Huang N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15057
   Landau HJ, 2012, MOL CANCER THER, V11, P1781, DOI 10.1158/1535 7163.MCT 11 0949
   Lawson MA, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9983
   Liu G, 2018, CURR GENOMICS, V19, P200, DOI 10.2174/1389202918666170705150819
   Liu H, 2019, REPROGRAMMED MARROW
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015
   Mulligan G, 2007, BLOOD, V109, P3177, DOI 10.1182/blood 2006 09 044974
   Panic M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005243
   Pawlyn C, 2017, NAT REV CANCER, V17, P543, DOI 10.1038/nrc.2017.63
   Pei XY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089064
   Pei XY, 2011, BLOOD, V118, P5189, DOI 10.1182/blood 2011 02 339432
   Pillai S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10072
   Plummer ER, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3094
   Sankaran DG, 2019, MOL BIOL CELL, V30, P1230, DOI 10.1091/mbc.E18 10 0674
   Sun DD, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392 020 00281 w
   Wang W, 2017, ONCOTARGET, V8, P78234, DOI 10.18632/oncotarget.20829
   Warren NJH, 2020, ONCOGENE, V39, P1389, DOI 10.1038/s41388 019 1079 9
   Yang Y, 2014, ONCOTARGET, V5, P11986, DOI 10.18632/oncotarget.2388
   Yang YB, 2018, JNCI J NATL CANCER I, V110, DOI 10.1093/jnci/djx166
   Zhan F, 2006, BLOOD, V108, P2020, DOI 10.1182/blood 2005 11 013458
   Zheng YH, 2016, JNCI J NATL CANCER I, V108, DOI 10.1093/jnci/djw131
   Zheng YH, 2009, BLOOD, V114, P3625, DOI 10.1182/blood 2009 05 220285
   Zhou F, 2020, BMC CANCER, V20, DOI 10.1186/s12885 020 6515 2
   Zhou W, 2014, LEUKEMIA, V28, P1155, DOI 10.1038/leu.2013.383
   Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001
NR 48
TC 55
Z9 60
U1 5
U2 38
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476 4598
J9 MOL CANCER
JI Mol. Cancer
PD JUN 5
PY 2021
VL 20
IS 1
AR 84
DI 10.1186/s12943 021 01380 0
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA SN3JG
UT WOS:000658188800001
PM 34090465
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Wang, SX
   Xie, X
   Yin, LY
   Li, GQ
   Xie, JY
AF Wang, Shanxi
   Xie, Xing
   Yin, Linyu
   Li, Gaoquan
   Xie, Juying
TI Electroacupuncture stimulation at CV4 sites prevents breast
   cancer induced osteoporosis by activating the Wnt/β catenin signaling
   pathway
SO EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; CV4; Electroacupuncture stimulation; Osteoporosis;
   Wnt/beta catenin
AB Osteoporosis is a common condition among breast cancer patients, characterized by decreased bone density due to chemotherapy and hormone therapy. However, the application of electroacupuncture (EA) stimulation at Guanyuan (CV4) sites has been found to be beneficial in enhancing bone mineral density. In this study, we aimed to investigate the efficacy of EA stimulation at CV4 sites in breast cancer induced osteoporosis and elucidate the potential underlying mechanisms. A breast cancer model in mice was established, EA stimulation at CV4 sites was performed, and hematoxylineosin (HE) stain was conducted to assess the bone mineral density and trabecular bone volume of femur tissues. Additionally, Tartrate resistant acid phosphatase (TRAP) staining was performed to identify and visualize osteoclasts. Furthermore, Western blots were used to evaluate the expression levels of various proteins, including c src, Cathepsin K (CtSK), matrix metalloproteinase 9 (MMP9), Collagen 1A1 (COL1A1), Osteopontin (OPN), Runt related transcription factor 2 (RUNX2), Wnt3a and beta catenin, and Enzyme Linked Immunosorbent Assay (ELISA) to measure the concentration of Alkaline phosphatase (ALP), NO synthase 2 (NOS2), glutathione reductase (GSR), superoxide dismutase (SOD), reactive oxygen species (ROS) and lactate dehydrogenase (LDH) in the serum. The results revealed that EA stimulation in the breast cancer model resulted in higher bone mineral density and trabecular bone volume, along with a reduction in the number of osteoclasts. EA stimulation at CV4 site significantly decreased the protein levels of c src, CtSK and MMP9, while also reducing ROS and LDH production. Conversely, it promoted the expression of COL1A1, OPN, RUNX2, Wnt3a and beta catenin. Additionally, it elevated the concentration of ALP, NOS2, GSR and SOD in the serum. Overall, EA stimulation at the CV4 site may inhibit bone loss and promote bone differentiation by activating the Wnt/beta catenin pathway, indicating its potential use for breast cancer induced osteoporosis treatment.
C1 [Wang, Shanxi; Li, Gaoquan; Xie, Juying] Xiangnan Univ, Coll Med Imaging Lab & Rehabil, Chenzhou 423000, Hunan, Peoples R China.
   [Xie, Xing; Yin, Linyu] Xiangnan Univ, Affiliated Hosp, Chenzhou 423000, Hunan, Peoples R China.
C3 Xiangnan University; Xiangnan University
RP Li, GQ; Xie, JY (通讯作者)，Xiangnan Univ, Coll Med Imaging Lab & Rehabil, Chenzhou 423000, Hunan, Peoples R China.
EM gqli1555@163.com; xiy597189746@163.com
FU Research project of the Health Commission of Hunan Province
   [202216004481]
FX Funding This work was supported by the Research project of the Health
   Commission of Hunan Province (Grant No. 202216004481) .
CR Amorim D, 2022, COMPLEMENT THER CLIN, V46, DOI 10.1016/j.ctcp.2022.101541
   Arellano DL, 2022, J BONE MINER RES, V37, P1446, DOI 10.1002/jbmr.4615
   Fan HL, 2016, MOL MED REP, V13, P2485, DOI 10.3892/mmr.2016.4849
   Feng Y, 2008, AM J CHINESE MED, V36, P889, DOI 10.1142/S0192415X08006326
   Gavrylyak IV, 2022, MED PERSPEKTIVI, V27, P168, DOI 10.26641/2307 0404.2022.4.271217
   He J, 2014, ACUPUNCT MED, V32, P37, DOI 10.1136/acupmed 2012 010271
   Jin XS, 2022, ALLERGOL IMMUNOPATH, V50, P75, DOI 10.15586/aei.v50i5.664
   Kozawa E, 2012, ARTHRITIS RHEUM US, V64, P454, DOI 10.1002/art.33398
   Liu TT, 2022, BIOMED PHARMACOTHER, V151, DOI 10.1016/j.biopha.2022.113140
   Malik JA, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112375
   Pan H, 2018, AM J CHINESE MED, V46, P489, DOI 10.1142/S0192415X18500258
   Qian C, 2022, EUR J GYNAECOL ONCOL, V43, P13, DOI 10.22514/ejgo.2022.053
   Tanjaya J, 2022, BIOMATERIALS, V287, DOI 10.1016/j.biomaterials.2022.121609
   Wang HH, 2021, ACUPUNCT MED, V39, P656, DOI 10.1177/0964528421995494
   Xie G, 2021, BIOCHEM PHARMACOL, V188, DOI 10.1016/j.bcp.2021.114579
   Yu L, 2019, CANCER LETT, V448, P40, DOI 10.1016/j.canlet.2019.01.039
   Zhang Chu Qiong, 2020, Zhen Ci Yan Jiu, V45, P702, DOI 10.13702/j.1000 0607.190957
   Zhang Yuan Yuan, 2019, Zhongguo Zhen Jiu, V39, P1081, DOI 10.13703/j.0255 2930.2019.10.013
NR 18
TC 1
Z9 2
U1 3
U2 9
PU MRE PRESS
PI SINGAPORE
PA 14 ROBINSON RD #08 01A FAR EAST FINANCE, SINGAPORE, SINGAPORE
SN 0392 2936
EI 2709 0086
J9 EUR J GYNAECOL ONCOL
JI Eur. J. Gynaecol. Oncol.
PD JUN 15
PY 2023
VL 44
IS 3
BP 89
EP 95
DI 10.22514/ejgo.2023.043
PG 7
WC Oncology; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Obstetrics & Gynecology
GA K5AL4
UT WOS:001016563600012
OA gold
DA 2025 08 17
ER

PT J
AU Ho, HY
   Wu, JB
   Lin, WC
AF Ho, Hui Ya
   Wu, Jin Bin
   Lin, Wen Chuan
TI Flemingia macrophylla Extract Ameliorates Experimental
   Osteoporosis in Ovariectomized Rats
SO EVIDENCE BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article
ID ESTROGEN RECEPTOR; ER ALPHA; BONE; OSTEOCLAST; ACTIVATION; MECHANISMS;
   MARKERS
AB Flemingia macrophylla (Leguminosae), a native plant of Taiwan, is used as folk medicine. An in vitro study showed that a 75% ethanolic extract of F. macrophylla (FME) inhibited osteoclast differentiation of cultured rat bone marrow cells, and the active component, lespedezaflavanone A (LDF A), was isolated. It was found that oral administration of FME for 13 weeks suppressed bone loss in ovariectomized rats, an experimental model of osteoporosis. In addition, FME decreased urinary deoxypyridinoline concentrations but did not inhibit serum alkaline phosphatase activities, indicating that it ameliorated bone loss via inhibition of bone resorption. These results suggest that FME may represent a useful remedy for the treatment of bone resorption diseases, such as osteoporosis. In addition, LDF A could be used as a marker compound to control the quality of FME.
C1 [Ho, Hui Ya; Wu, Jin Bin] China Med Univ, Grad Inst Pharmaceut Chem, Sch Pharm, Taichung, Taiwan.
   [Lin, Wen Chuan] China Med Univ, Dept Pharmacol, Sch Med, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Lin, Wen Chuan] China Med Univ, Tsuzuki Inst Tradit Med, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Taiwan; China
   Medical University Taiwan
RP Lin, WC (通讯作者)，China Med Univ, Grad Inst Pharmaceut Chem, Sch Pharm, Taichung, Taiwan.
EM wclin@mail.cmu.edu.tw
FU China Medical University (CMU) [96 076]
FX This study was supported by grants from the China Medical University
   (CMU 96 076).
CR Asagiri M, 2007, BONE, V40, P251, DOI 10.1016/j.bone.2006.09.023
   Bohatyrewicz A, 1998, Pol Merkur Lekarski, V5, P192
   COLE AA, 1987, J HISTOCHEM CYTOCHEM, V35, P203, DOI 10.1177/35.2.3540104
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Fontanges E, 2004, JOINT BONE SPINE, V71, P102, DOI 10.1016/j.jbspin.2003.02.001
   Howell A, 2000, CANCER AM CANCER SOC, V89, P817, DOI 10.1002/1097 0142(20000815)89:4<817::AID CNCR14>3.3.CO;2 Y
   JOHNSON CD, EVIDENCE BA IN PRESS
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Kim SW, 2004, J UROLOGY, V172, P1538, DOI 10.1097/01.ju.0000137744.12814.2e
   Koyama T, 1991, SANFUJINKA CHIRYO, V63, P203
   Kuehn BM, 2009, JAMA J AM MED ASSOC, V301, P710, DOI 10.1001/jama.2009.128
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Li ZP, 2006, BIOCHEM BIOPH RES CO, V343, P345, DOI 10.1016/j.bbrc.2006.02.147
   Migliorati CA, 2009, REV RECENT CLIN TRIA, V4, P99, DOI 10.2174/157488709788185978
   Naaz A, 2002, HORM METAB RES, V34, P758, DOI 10.1055/s 2002 38259
   Owens JM, 1997, J CELL PHYSIOL, V172, P79, DOI 10.1002/(SICI)1097 4652(199707)172:1<79::AID JCP9>3.0.CO;2 A
   Santollo J, 2007, AM J PHYSIOL REG I, V293, pR2194, DOI 10.1152/ajpregu.00385.2007
   Schett G, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2110
   SEIBEL MJ, 1993, J BONE MINER RES, V8, P881
   Shih CC, 2001, J ETHNOPHARMACOL, V77, P233, DOI 10.1016/S0378 8741(01)00302 6
   Swaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009 8981(01)00656 8
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   UDAGAWA N, 1990, P NATL ACAD SCI USA, V87, P7260, DOI 10.1073/pnas.87.18.7260
   Usui T, 2006, ENDOCR J, V53, P7, DOI 10.1507/endocrj.53.7
   WANG MS, 1987, PHYTOCHEMISTRY, V26, P1218, DOI 10.1016/S0031 9422(00)82389 4
   Xie F, 2005, EVID BASED COMPL ALT, V2, P353, DOI 10.1093/ecam/neh101
NR 27
TC 7
Z9 9
U1 0
U2 5
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741 427X
EI 1741 4288
J9 EVID BASED COMPL ALT
JI Evid. based Complement Altern. Med.
PY 2011
VL 2011
BP 1
EP 9
DI 10.1093/ecam/nep179
PG 9
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine
GA 802WC
UT WOS:000293540700001
PM 19942664
OA Green Published, Green Submitted, hybrid
DA 2025 08 17
ER

PT J
AU Peng Zhang
   Dai, KR
   Yan, SG
   Yan, WQ
   Chao Zhang
   Chen, DQ
   Bo Xu
   Xu, ZW
AF Peng Zhang
   Dai, Ke rong
   Yan, Shi gui
   Yan, Wei qi
   Chao Zhang
   Chen, De qiang
   Bo Xu
   Xu, Zhan wang
TI Effects of naringin on the proliferation and osteogenic differentiation
   of human bone mesenchymal stem cell
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Naringin; Rhizoma drynariae; Osteogenic differentiation; Human bone
   mesenchymal stem cell
ID DRYNARIAE RHIZOMA EXTRACTS; INHIBITION; MANAGEMENT; TISSUE
AB Rhizoma drynariae is used commonly in the treatment of osteoporosis and bone nonunion in traditional Chinese medicine. Modern pharmacological research indicates that naringin is the main effective component of rhizoma drynariae, which can induce the expression of the osteogenic marker in the osteoblast cell line. However, no former study has described its effect on bone mesenchymal stem cells (BMSCs). In our experiment, we co cultured human BMSCs with different concentrations of naringin solution, then the osteogenic differentiation markers and proliferation ability were analyzed. The results indicated that a certain concentration (1 100 mu g/ml) of the naringin solution may enhance the proliferation and osteogenic differentiation of human BMSCs. Also, our research explains excellently the anti osteoporotic and bone nonunion treatment mechanism of rhizoma drynariae, thus contributing to the exploration of osteogenic differentiation agents from Chinese herbs. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Peng Zhang; Yan, Shi gui; Yan, Wei qi] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, Hangzhou 310009, Zhejiang, Peoples R China.
   [Dai, Ke rong] Shanghai Jiao Tong Univ, Peoples Hosp 9, Dept Orthopaed, Sch Med, Shanghai 200011, Peoples R China.
   [Chen, De qiang; Bo Xu; Xu, Zhan wang] Shandong Univ Tradit Chinese Med, Affiliated Hosp, Dept Orthopaed, Jinan 250014, Shandong, Peoples R China.
   [Chao Zhang] Kun Hua Hosp, Kunming Med Coll, Dept Orthoped, Kunming 650032, Peoples R China.
C3 Zhejiang University; Shanghai Jiao Tong University; Shandong University
   of Traditional Chinese Medicine; Kunming Medical University
RP Peng Zhang (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Orthopaed, 88 JieFang Rd, Hangzhou 310009, Zhejiang, Peoples R China.
EM superzhangpeng@sina.com; xzw6001@163.com
OI Yan, Weiqi/0000 0002 3298 7677
CR Berger I, 2007, HISTOL HISTOPATHOL, V22, P1231, DOI 10.14670/HH 22.1231
   Ding Y, 1995, J Osaka Univ Dent Sch, V35, P21
   Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501
   Hamburger Matthias, 2007, Proc West Pharmacol Soc, V50, P156
   Jeong JC, 2005, J ETHNOPHARMACOL, V96, P489, DOI 10.1016/j.jep.2004.09.038
   Jeong JC, 2003, INT IMMUNOPHARMACOL, V3, P1685, DOI 10.1016/j.intimp.2003.08.003
   Khan AW, 2006, J OBSTET GYNAECOL CA, V28, P136, DOI 10.1016/S1701 2163(16)32063 1
   Kou G, 2008, BIOCHEM BIOPH RES CO, V374, P192, DOI 10.1016/j.bbrc.2008.06.126
   Lane NE, 2003, ARTHRITIS RES THER, V5, P214, DOI 10.1186/ar797
   Liu YR, 2007, J ETHNOPHARMACOL, V111, P573, DOI 10.1016/j.jep.2007.01.005
   Lühe A, 2008, TOXICOL IN VITRO, V22, P899, DOI 10.1016/j.tiv.2008.01.006
   Martin I, 2007, J BIOMECH, V40, P750, DOI 10.1016/j.jbiomech.2006.03.008
   Sun HL, 2006, BIOMATERIALS, V27, P5651, DOI 10.1016/j.biomaterials.2006.07.027
   Wong R., 2007, CHIN MED UK, V2, P13, DOI [10.1186/1749 8546 2 13, DOI 10.1186/1749 8546 2 13]
   Wu JB, 2008, EUR J PHARMACOL, V588, P333, DOI 10.1016/j.ejphar.2008.04.030
   Yamaguchi K, 1999, BIOSCI BIOTECH BIOCH, V63, P731, DOI 10.1271/bbb.63.731
   Yu LJ, 2008, FITOTERAPIA, V79, P529, DOI 10.1016/j.fitote.2008.05.009
   Yun K, 2007, BIOCHEM BIOPH RES CO, V364, P1009, DOI 10.1016/j.bbrc.2007.10.121
   Zheng JW, 2008, CHINESE MED J PEKING, V121, P1037, DOI 10.1097/00029330 200806010 00014
   Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859
NR 20
TC 122
Z9 136
U1 3
U2 52
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0014 2999
EI 1879 0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD APR 1
PY 2009
VL 607
IS 1 3
BP 1
EP 5
DI 10.1016/j.ejphar.2009.01.035
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 432HG
UT WOS:000265123500001
PM 19326565
DA 2025 08 17
ER

PT J
AU Yang, JL
   Zhang, LF
   Wang, Y
   Wang, N
   Wei, HW
   Zhang, S
   Ding, QT
   Sun, SW
   Ding, CB
   Liu, WC
AF Yang, Jiali
   Zhang, Lifeng
   Wang, Yue
   Wang, Ning
   Wei, Hewei
   Zhang, Shuai
   Ding, Qiteng
   Sun, Shuwen
   Ding, Chuanbo
   Liu, Wencong
TI Dihydromyricetin loaded oxidized polysaccharide/L arginine chitosan
   adhesive hydrogel promotes bone regeneration by regulating PI3K/AKT
   signaling pathway and MAPK signaling pathway
SO CARBOHYDRATE POLYMERS
LA English
DT Article
DE Dihydromyricetin; Adhesive hydrogel; Network pharmacology; Bone
   regeneration; Oxidized polysaccharide; Osteogenesis
ID OSTEOBLAST DIFFERENTIATION; OSTEOGENIC DIFFERENTIATION; STEM CELLS;
   EXPRESSION; GROWTH; ANTIBACTERIAL; SCAFFOLD; ACID; VEGF
AB Bone defects caused by trauma, infection and congenital diseases still face great challenges. Dihydromyricetin (DHM) is a kind of flavone extracted from Ampelopsis grossedentata, a traditional Chinese medicine. DHM can enhance the osteogenic differentiation of human bone marrow mesenchymal stem cells with the potential to promote bone regeneration. Hydrogel can be used as a carrier of DHM to promote bone regeneration due to its unique biochemical characteristics and three dimensional structure. In this study, oxidized phellinus igniarius polysaccharides (OP) and L arginine chitosan (CA) are used to develop hydrogel. The pore size and gel strength of the hydrogel can be changed by adjusting the oxidation degree of oxidized phellinus igniarius polysaccharides. The addition of DHM further reduce the pore size of the hydrogel (213 mu m), increase the mechanical properties of the hydrogel, and increase the antioxidant and antibacterial activities of the hydrogel. The scavenging rate of DPPH are 72.30 +/  0.33%, and the inhibition rate of E.coli and S.aureus are 93.12 +/  0.38% and 94.49 +/  1.57%, respectively. In addition, PCAD has good adhesion and biocompatibility, and its extract can effectively promote the osteogenic differentiation of MC3T3 E1 cells. Network pharmacology and molecular docking show that the promoting effect of DHM on osteogenesis may be achieved by activating the PI3K/AKT and MAPK signaling pathways. This is confirmed through in vitro cell experiments and in vivo animal experiments.
C1 [Yang, Jiali; Zhang, Lifeng; Wang, Yue; Wang, Ning; Wei, Hewei; Zhang, Shuai; Ding, Qiteng; Sun, Shuwen; Ding, Chuanbo] Jilin Agr Sci & Technol Coll, Coll Tradit Chinese Med, Jilin 132101, Peoples R China.
   [Yang, Jiali; Zhang, Lifeng; Wang, Yue; Wang, Ning; Wei, Hewei; Zhang, Shuai; Ding, Qiteng; Sun, Shuwen] Jilin Agr Univ, Coll Tradit Chinese Med, Changchun 130118, Peoples R China.
   [Liu, Wencong] Wuzhou Univ, Sch Food & Pharmaceut Engn, Wuzhou 543002, Peoples R China.
C3 Jilin Agricultural Science & Technology University; Jilin Agricultural
   University; Wuzhou University
RP Ding, CB (通讯作者)，Jilin Agr Sci & Technol Coll, Coll Tradit Chinese Med, Jilin 132101, Peoples R China.; Liu, WC (通讯作者)，Wuzhou Univ, Sch Food & Pharmaceut Engn, Wuzhou 543002, Peoples R China.
EM chuanboding0506@163.com; jwlw6803@126.com
RI Zhang, Lifeng/AAY 4917 2021; Wang, Ning/MVZ 6316 2025; Ding,
   Qiteng/KFS 8790 2024; yang, Jiali/AAH 3959 2020; Sun, Shuwen/C 3352 2016
FU Jilin Province Science and Tech nology Development Plan Project
   [20220508062RC]
FX <BOLD>Funding</BOLD> This work was supported by the Jilin Province
   Science and Tech nology Development Plan Project (No. 20220508062RC) .
CR Antunes BP, 2015, CARBOHYD POLYM, V130, P104, DOI 10.1016/j.carbpol.2015.04.072
   Cao FW, 2021, INT J BIOL MACROMOL, V192, P1331, DOI 10.1016/j.ijbiomac.2021.10.055
   Cao ZC, 2023, BIOACT MATER, V20, P221, DOI 10.1016/j.bioactmat.2022.05.025
   Chen HL, 2018, CARBOHYD POLYM, V201, P522, DOI 10.1016/j.carbpol.2018.08.090
   Chen JJ, 2014, ACTA HISTOCHEM, V116, P1337, DOI 10.1016/j.acthis.2014.08.005
   Chen TY, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202400462
   Cho SH, 2017, BIOMATER SCI UK, V5, P285, DOI 10.1039/c6bm00711b
   Cui JM, 2022, MAR DRUGS, V20, DOI 10.3390/md20110688
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   Deng LZ, 2020, COLLOID SURFACE B, V194, DOI 10.1016/j.colsurfb.2020.111159
   Dittmer KE, 2017, J VET DIAGN INVEST, V29, P385, DOI 10.1177/1040638716679861
   Dong JX, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15092296
   Douglas TEL, 2018, J DAIRY SCI, V101, P28, DOI 10.3168/jds.2017 13119
   Eber MR, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100346
   Ghafouri Fard S, 2022, MOL BIOL REP, V49, P9767, DOI 10.1007/s11033 022 07468 0
   Gillman CE, 2021, MAT SCI ENG C MATER, V130, DOI 10.1016/j.msec.2021.112466
   Gui XH, 2018, BIOCHEM BIOPH RES CO, V498, P660, DOI 10.1016/j.bbrc.2018.03.039
   Guntur AR, 2011, J ENDOCRINOL, V211, P123, DOI 10.1530/JOE 11 0175
   He Z, 2016, J PHOTOCH PHOTOBIO B, V161, P40, DOI 10.1016/j.jphotobiol.2016.05.002
   Hou HM, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5370759
   Hou P, 2022, J BIOMED MATER RES B, V110, P1594, DOI 10.1002/jbm.b.35020
   Hou S, 2015, ADV HEALTHC MATER, V4, P1491, DOI 10.1002/adhm.201500093
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Huang DS, 2016, J MOL CELL BIOL, V8, P328, DOI 10.1093/jmcb/mjw036
   Khoobbakht F, 2024, FOOD HYDROCOLLOID, V147, DOI 10.1016/j.foodhyd.2023.109411
   Komori T, 2006, J CELL BIOCHEM, V99, P1233, DOI 10.1002/jcb.20958
   Koons GL, 2020, NAT REV MATER, V5, P584, DOI 10.1038/s41578 020 0204 2
   Kuang J., 2022, Evidence based Complementary and Alternative Medicine, P1
   Lan SY, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000025660
   Laplante P, 2017, J INVEST DERMATOL, V137, P2005, DOI 10.1016/j.jid.2017.04.030
   Lee CS, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202003717
   Leonaviciute G, 2016, CARBOHYD POLYM, V144, P514, DOI 10.1016/j.carbpol.2016.02.075
   Li LQ, 2014, BIOCHIMIE, V104, P100, DOI 10.1016/j.biochi.2014.06.001
   Li T, 2019, INT J BIOL MACROMOL, V137, P382, DOI 10.1016/j.ijbiomac.2019.06.245
   Li WC, 2016, COMPOS SCI TECHNOL, V128, P58, DOI 10.1016/j.compscitech.2016.03.013
   Liang XY, 2018, ACS BIOMATER SCI ENG, V4, P3506, DOI 10.1021/acsbiomaterials.8b00552
   Lin Y, 2023, ISCIENCE, V26, DOI 10.1016/j.isci.2023.107633
   Ling L, 2010, J BIOL CHEM, V285, P26233, DOI 10.1074/jbc.M110.122069
   Ling ZX, 2021, CHEM ENG J, V420, DOI 10.1016/j.cej.2021.130302
   Liu B, 2020, RSC ADV, V10, P25652, DOI 10.1039/d0ra03040f
   Liu HC, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02410 w
   Lou CQ, 2020, FIBER POLYM, V21, P73, DOI 10.1007/s12221 020 9269 1
   Lowery JW, 2011, CRIT REV EUKAR GENE, V21, P177, DOI 10.1615/CritRevEukarGeneExpr.v21.i2.60
   Luo Y, 2022, EXP THER MED, V24, DOI 10.3892/etm.2022.11678
   Macsai CE, 2012, BONE, V50, P1081, DOI 10.1016/j.bone.2012.02.013
   Minoia A, 2023, CELLS BASEL, V12, DOI 10.3390/cells12010051
   Nguyen NTP, 2019, MAT SCI ENG C MATER, V103, DOI 10.1016/j.msec.2019.04.049
   Noori A, 2022, TISSUE CELL, V77, DOI 10.1016/j.tice.2022.101849
   Ong THD, 2017, MAT SCI ENG C MATER, V78, P647, DOI 10.1016/j.msec.2017.04.129
   Pan WH, 2022, INT J BIOL MACROMOL, V195, P190, DOI 10.1016/j.ijbiomac.2021.12.007
   Picone P, 2019, INT J BIOL MACROMOL, V121, P784, DOI 10.1016/j.ijbiomac.2018.10.078
   Pitrolino KA, 2022, CARBOHYD POLYM, V282, DOI 10.1016/j.carbpol.2022.119126
   Ren M, 2023, WEGRZYN G.Oxidative Medicine and Cellular Longevity, V2023, P1
   Shahriari Khalaji M, 2020, POLYMERS BASEL, V12, DOI 10.3390/polym12112683
   Shi XQ, 2019, J ETHNOPHARMACOL, V235, P227, DOI 10.1016/j.jep.2019.01.027
   Sims IM, 2018, CARBOHYD POLYM, V188, P1, DOI 10.1016/j.carbpol.2017.12.075
   Su YL, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100434
   Sun HL, 2010, BIOMATERIALS, V31, P1133, DOI 10.1016/j.biomaterials.2009.10.030
   Tan YY, 2010, ORTHOD CRANIOFAC RES, V13, P223, DOI 10.1111/j.1601 6343.2010.01498.x
   Thomas GP, 2001, J ENDOCRINOL, V170, P451, DOI 10.1677/joe.0.1700451
   Tian HM, 2024, INT J BIOL MACROMOL, V262, DOI 10.1016/j.ijbiomac.2024.129952
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Tu CW, 2022, CLIN ORAL INVEST, V26, P2491, DOI 10.1007/s00784 021 04217 8
   Wang HY, 2016, INT J ONCOL, V48, P1229, DOI 10.3892/ijo.2016.3326
   Wang LL, 2021, INT J BIOL MACROMOL, V192, P350, DOI 10.1016/j.ijbiomac.2021.09.145
   Wang MQ, 2022, ANN PALLIAT MED, V11, P806, DOI 10.21037/apm 21 3286
   Wang S, 2017, ACS BIOMATER SCI ENG, V3, P1092, DOI 10.1021/acsbiomaterials.7b00159
   Wang XY, 2021, CHEM ENG J, V420, DOI 10.1016/j.cej.2020.127589
   Wang YX, 2024, INT J BIOL MACROMOL, V255, DOI 10.1016/j.ijbiomac.2023.128080
   Wasupalli GK, 2020, MAT SCI ENG C MATER, V107, DOI 10.1016/j.msec.2019.110343
   Wickramasinghe ML, 2022, J BIOMED MATER RES B, V110, P1724, DOI 10.1002/jbm.b.35029
   Wu YH, 2018, ADV FUNCT MATER, V28, DOI 10.1002/adfm.201801000
   Xi YM, 2020, EXP CELL RES, V389, DOI 10.1016/j.yexcr.2020.111930
   Xiao XN, 2019, MOLECULES, V24, DOI 10.3390/molecules24152831
   Xu Xiao, 2022, Comput Math Methods Med, V2022, P7895246, DOI 10.1155/2022/7895246
   Xu YW, 2021, BIOMATERIALS, V268, DOI 10.1016/j.biomaterials.2020.120596
   Xue H, 2019, CARBOHYD POLYM, V226, DOI 10.1016/j.carbpol.2019.115302
   Xue HY, 2022, POLYMERS BASEL, V14, DOI 10.3390/polym14091716
   Yang L, 2023, INT J BIOL MACROMOL, V226, P184, DOI 10.1016/j.ijbiomac.2022.12.020
   Yang YY, 2023, CARBOHYD POLYM, V316, DOI 10.1016/j.carbpol.2023.121083
   You BH, 2018, J MATER SCI TECHNOL, V34, P1016, DOI 10.1016/j.jmst.2017.11.016
   Yu M, 2017, J PERIODONTOL, V88, pE159, DOI 10.1902/jop.2017.170016
   Yuan YQ, 2024, BIOSENS BIOELECTRON, V247, DOI 10.1016/j.bios.2023.115930
   Zhang CY, 2023, J ETHNOPHARMACOL, V317, DOI 10.1016/j.jep.2023.116676
   Zhang HY, 2023, INT J BIOL MACROMOL, V253, DOI 10.1016/j.ijbiomac.2023.127189
   Zhang LF, 2023, INT J BIOL MACROMOL, V249, DOI 10.1016/j.ijbiomac.2023.126014
   Zhang SH, 2020, CHEM ENG J, V392, DOI 10.1016/j.cej.2019.123775
   Zhang W, 2016, FUND CLIN PHARMACOL, V30, P596, DOI 10.1111/fcp.12225
   Zhang XJ, 2018, J CELL BIOCHEM, V119, P8981, DOI 10.1002/jcb.27154
   Zhang ZL, 2023, REGEN THER, V24, P201, DOI 10.1016/j.reth.2023.06.015
   Zhang ZQ, 2024, MACROMOL RES, V32, P493, DOI 10.1007/s13233 024 00253 x
   Zhao LB, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00928
   Zhao YC, 2022, INT J BIOL MACROMOL, V216, P475, DOI 10.1016/j.ijbiomac.2022.06.210
   Zhu WQ, 2019, J MOL MED, V97, P1003, DOI 10.1007/s00109 019 01785 x
NR 94
TC 11
Z9 11
U1 18
U2 49
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0144 8617
EI 1879 1344
J9 CARBOHYD POLYM
JI Carbohydr. Polym.
PD DEC 15
PY 2024
VL 346
AR 122614
DI 10.1016/j.carbpol.2024.122614
EA AUG 2024
PG 18
WC Chemistry, Applied; Chemistry, Organic; Polymer Science
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Polymer Science
GA D7O7G
UT WOS:001298045900001
PM 39245525
DA 2025 08 17
ER

PT J
AU Gassner, T
   Chittilappilly, C
   Pirich, T
   Neuditschko, B
   Hackner, K
   Lind, J
   Aksoy, O
   Graichen, U
   Klee, S
   Herzog, F
   Wiesner, C
   Errhalt, P
   Pecherstorfer, M
   Podar, K
   Vallet, S
AF Gassner, Tamara
   Chittilappilly, Christina
   Pirich, Theo
   Neuditschko, Benjamin
   Hackner, Klaus
   Lind, Judith
   Aksoy, Osman
   Graichen, Uwe
   Klee, Sascha
   Herzog, Franz
   Wiesner, Christoph
   Errhalt, Peter
   Pecherstorfer, Martin
   Podar, Klaus
   Vallet, Sonia
TI Favorable impact of PD1/PD L1 antagonists on bone remodeling: an
   exploratory prospective clinical study and ex vivo validation
SO JOURNAL FOR IMMUNOTHERAPY OF CANCER
LA English
DT Article
DE Immune Checkpoint Inhibitor; Treatment related adverse event   trAE;
   Solid tumor; Stem cell; Monocyte
ID CHECKPOINT INHIBITORS; CELLS; DIFFERENTIATION; PLATFORM; HORMONE
AB Background Skeletal morbidity in patients with cancer has a major impact on the quality of life, and preserving bone health while improving outcomes is an important goal of modern antitumor treatment strategies. Despite their widespread use in early disease stages, the effects of immune checkpoint inhibitors (ICIs) on the skeleton are still poorly defined. Here, we initiated a comprehensive investigation of the impact of ICIs on bone health by longitudinal assessment of bone turnover markers in patients with cancer and by validation in a novel bioengineered 3D model of bone remodeling.Methods An exploratory longitudinal study was conducted to assess serum markers of bone resorption (C terminal telopeptide, CTX) and formation (procollagen type I N terminal propeptide, PINP, and osteocalcin, OCN) before each ICI application (programmed cell death 1 (PD1) inhibitor or programmed death ligand 1 (PD L1) inhibitor) for 6 months or until disease progression in patients with advanced cancer and no evidence of bone metastases. To validate the in vivo results, we evaluated osteoclast (OC) and osteoblast (OB) differentiation on treatment with ICIs. In addition, their effect on bone remodeling was assessed by immunohistochemistry, confocal microscopy, and proteomics analysis in a dynamic 3D bone model.Results During the first month of treatment, CTX levels decreased sharply but transiently. In contrast, we observed a delayed increase of serum levels of PINP and OCN after 4 months of therapy. In vitro, ICIs impaired the maturation of preosteoclasts by inhibiting STAT3/NFATc1 signaling but not JNK, ERK, and AKT while lacking any direct effect on osteogenesis. However, using our bioengineered 3D bone model, which enables the simultaneous differentiation of OB and OC precursor cells, we confirmed the uncoupling of the OC/OB activity on exposure to ICIs by demonstrating impaired OC maturation along with increased OB differentiation.Conclusion Our study indicates that the inhibition of the PD1/PD L1 signaling axis interferes with bone turnover and may exert a protective effect on bone by indirectly promoting osteogenesis.
C1 [Gassner, Tamara; Chittilappilly, Christina; Pirich, Theo; Lind, Judith; Aksoy, Osman; Podar, Klaus; Vallet, Sonia] Karl Landsteiner Univ Hlth Sci, Dept Gen & Translat Oncol & Hematol, Div Mol Oncol & Hematol, Krems An Der Donau, Austria.
   [Neuditschko, Benjamin; Herzog, Franz] IMC Univ Appl Sci, Inst Krems Bioanalyt, Krems An Der Donau, Austria.
   [Hackner, Klaus; Errhalt, Peter] Karl Landsteiner Univ Hlth Sci, Krems An Der Donau, Austria.
   [Hackner, Klaus; Errhalt, Peter] Univ Hosp Krems, Div Pneumol, Krems An Der Donau, Austria.
   [Graichen, Uwe; Klee, Sascha] Karl Landsteiner Univ Hlth Sci, Dept Gen Hlth Studies, Div Biostat & Data Sci, Krems An Der Donau, Austria.
   [Wiesner, Christoph] IMC Univ Appl Sci, Dept Med & Pharmaceut Biotechnol, Krems An Der Donau, Austria.
   [Pecherstorfer, Martin; Podar, Klaus; Vallet, Sonia] Univ Hosp Krems, Div Internal Med 2, Krems An Der Donau, Austria.
   [Pecherstorfer, Martin; Vallet, Sonia] Karl Landsteiner Gesell, Karl Landsteiner Inst Support Canc Therapy, St Polten, Austria.
RP Vallet, S (通讯作者)，Karl Landsteiner Univ Hlth Sci, Dept Gen & Translat Oncol & Hematol, Div Mol Oncol & Hematol, Krems An Der Donau, Austria.
EM sonia.vallet@krems.lknoe.at
RI Vallet, Sonia/AHE 3935 2022; Graichen, Uwe/B 8275 2015; Graichen,
   Uwe/GPX 1634 2022
OI Vallet, Sonia/0000 0003 0146 8089; Klee, Sascha/0000 0002 0321 1255;
   Graichen, Uwe/0000 0003 2144 4682; 
FU Open Access Publishing Fund of Karl Landsteiner University of Health
   Sciences, Krems, Austria
FX The authors want to appreciate the contribution of NOE
   Landesgesundheitsagentur, the legal entity of University Hospitals in
   Lower Austria, for providing the organizational framework to conduct
   this research. The authors also would like to acknowledge the support of
   Open Access Publishing Fund of Karl Landsteiner University of Health
   Sciences, Krems, Austria. We are especially grateful to our study nurses
   Mag. Elisabeth Zwickl Traxler and Ms Michaela Scherb for their great
   help and support in organizing and coordinating the clinical study.
CR Afzal MZ, 2018, MELANOMA RES, V28, P341, DOI 10.1097/CMR.0000000000000459
   Bensch F, 2018, NAT MED, V24, P1852, DOI 10.1038/s41591 018 0255 8
   Bolamperti S, 2022, BONE RES, V10, DOI 10.1038/s41413 022 00219 8
   Bongiovanni A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.697298
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Chen CZ, 2020, DIFFERENTIATION, V114, P13, DOI 10.1016/j.diff.2020.05.002
   Cohen J., 2013, Statistical Power Analysis for the Behavioral Sciences, V2nd, DOI DOI 10.4324/9780203771587
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Colleselli K, 2023, CELLS BASEL, V12, DOI 10.3390/cells12101425
   Conforti F, 2018, LANCET ONCOL, V19, P737, DOI 10.1016/S1470 2045(18)30261 4
   Couzin Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432
   Crespo Enriquez I, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.176776
   Davies OG, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00092
   Dieli F, 2007, CANCER RES, V67, P7450, DOI 10.1158/0008 5472.CAN 07 0199
   Dong R, 2020, J TISSUE ENG, V11, DOI 10.1177/2041731420926918
   Dou C, 2018, ADV SCI, V5, DOI 10.1002/advs.201700578
   Fan FJ, 2021, LEUKEMIA, V35, P3509, DOI 10.1038/s41375 021 01271 9
   Ferrarini M, 2017, METHODS MOL BIOL, V1612, P177, DOI 10.1007/978 1 4939 7021 6_13
   Fessas P, 2017, SEMIN ONCOL, V44, P136, DOI 10.1053/j.seminoncol.2017.06.002
   Gómez Aleza C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 20138 8
   Hadji P, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.09.010
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Hurkmans DP, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425 019 0669 y
   Iwasaki M, 2011, EUR J IMMUNOL, V41, P345, DOI 10.1002/eji.201040959
   Kim BJ, 2012, BONE, V51, P431, DOI 10.1016/j.bone.2012.06.015
   Kim JM, 2007, CELL PHYSIOL BIOCHEM, V20, P935, DOI 10.1159/000110454
   Kist de Ruijter Laura, 2021, Clin Cancer Res, V27, P5325, DOI 10.1158/1078 0432.CCR 21 0453
   Klein SL, 2016, NAT REV IMMUNOL, V16, P626, DOI 10.1038/nri.2016.90
   Koh AJ, 2005, ENDOCRINOLOGY, V146, P4584, DOI 10.1210/en.2005 0333
   Kukita T, 1998, CALCIFIED TISSUE INT, V63, P140, DOI 10.1007/s002239900504
   Li XF, 2023, INT IMMUNOPHARMACOL, V120, DOI 10.1016/j.intimp.2023.110404
   Li X, 2020, THORAC CANCER, V11, P2812, DOI 10.1111/1759 7714.13597
   Linhares AD, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 47910 1
   Mangini M, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.966950
   Moseley KF, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425 018 0417 8
   MUNDY GR, 1990, TRENDS ENDOCRIN MET, V1, P307, DOI 10.1016/1043 2760(90)90069 F
   Nagahama K, 2004, BONE, V35, P1059, DOI 10.1016/j.bone.2004.06.018
   Novinec M, 2013, BIOL CHEM, V394, P1163, DOI 10.1515/hsz 2013 0134
   Pantano F, 2022, J BONE ONCOL, V37, DOI 10.1016/j.jbo.2022.100459
   Perez Riverol Y, 2019, NUCLEIC ACIDS RES, V47, pD442, DOI 10.1093/nar/gky1106
   R Core Team, 2023, R LANG ENV STAT COMP, DOI DOI 10.59350/T79XT TF203
   Romeo SG, 2019, NAT CELL BIOL, V21, P430, DOI 10.1038/s41556 019 0304 7
   Rozenblit M, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc 2020 001558
   Samuel JN, 2022, JAMA ONCOL, V8, P879, DOI 10.1001/jamaoncol.2022.0864
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Searle BC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 020 15346 1
   Shah DK, 2013, MABS AUSTIN, V5, P297, DOI 10.4161/mabs.23684
   Siegel RL, 2022, CA CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Stierschneider A, 2023, CELLS BASEL, V12, DOI 10.3390/cells12050697
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tankó LB, 2003, BONE, V32, P687, DOI 10.1016/S8756 3282(03)00091 7
   Tolonen JP, 2022, JBMR PLUS, V6, DOI 10.1002/jbm4.10630
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]
   Vallet S, 2007, BLOOD, V110, P3744, DOI 10.1182/blood 2007 05 093294
   Vallet S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150507
   Velev M, 2023, EUR J CANCER, V182, P66, DOI 10.1016/j.ejca.2022.12.028
   Walsh MC, 2018, NAT REV RHEUMATOL, V14, P146, DOI 10.1038/nrrheum.2017.213
   Wang KY, 2020, J CLIN INVEST, V130, P3603, DOI 10.1172/JCI133334
   Yang YL, 2019, J BIOL CHEM, V294, P15395, DOI 10.1074/jbc.RA119.010139
   Ye CR, 2023, OSTEOPOROSIS INT, V34, P735, DOI 10.1007/s00198 023 06690 1
   Zheng Y, 2022, INT IMMUNOPHARMACOL, V110, DOI 10.1016/j.intimp.2022.109030
   Zhu YJ, 2022, LUNG CANCER, V166, P189, DOI 10.1016/j.lungcan.2022.03.006
   Zuo H, 2022, CANCER GENE THER, V29, P1342, DOI 10.1038/s41417 022 00446 5
NR 63
TC 8
Z9 8
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2051 1426
J9 J IMMUNOTHER CANCER
JI J. Immunother. Cancer
PD MAY
PY 2024
VL 12
IS 5
AR e008669
DI 10.1136/jitc 2023 008669
PG 13
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology
GA QP4B4
UT WOS:001222050100003
PM 38702145
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Zhang, G
   Gong, H
   Xu, HQ
AF Zhang, Gao
   Gong, Hu
   Xu, Hanqiao
TI 被撤回的出版物: Analysis of the Mechanism and Safety of Bisphosphonates in
   Patients with Lung Cancer and Bone Metastases (Retracted Article)
SO COMPUTATIONAL AND MATHEMATICAL METHODS IN MEDICINE
LA English
DT Article; Retracted Publication
AB Objective. To explore the mechanism and safety of bisphosphonates in patients with lung cancer and bone metastases. Method. A total of 104 patients with lung cancer and bone metastases in our hospital were selected and randomly divided into two groups: control group (n=54) and research group (n=50). Chemotherapy was given to the control group, and the research group was treated with bisphosphonate drugs. The quality of life, HAMA, HAMD score, VAS score, treatment effect, serum calcium and KPS score, inflammatory factor levels, and immune function were compared between the two groups. Result. The quality of life in both groups was significantly increased (P < 0.05). The HAMA and HAMD scores of the research group decreased significantly than those of the control group after treatment (P < 0.05). The VAS scores of the two groups were significantly reduced (P < 0.05). The effective rates of treatment in the control group and the research group were 81.5% and 96.0%, respectively. Serum calcium was significantly decreased, and KPS score was significantly increased at weeks 1 and 6 after treatment, and the change was more obvious in the research group (P < 0.05). The levels of inflammatory factors in the two groups were significantly reduced, and the immune indicators were significantly increased. Conclusion. Bisphosphonates have good effect on patients with lung cancer and bone metastases, which can improve anxiety and depression, reduce pain score, improve serum calcium level and immune function, and reduce inflammatory response. Therefore, bisphosphonate drug therapy is worth widely used.
C1 [Zhang, Gao] Gen Hosp Cent Theater Command Chinese Peoples Lib, Dept Oncol, Hubei 430070, Wuhan, Peoples R China.
   [Gong, Hu] Jianghan Univ, Dept Orthoped, Wuhan Sixth Hosp, Affiliated Hosp, Hubei 430015, Wuhan, Peoples R China.
   [Xu, Hanqiao] Jianghan Univ, Dept Thorac Surg, Wuhan Sixth Hosp, Affiliated Hosp, Hubei 430015, Wuhan, Peoples R China.
C3 Jianghan University; Jianghan University
RP Xu, HQ (通讯作者)，Jianghan Univ, Dept Thorac Surg, Wuhan Sixth Hosp, Affiliated Hosp, Hubei 430015, Wuhan, Peoples R China.
EM 382412634@qq.com; 14831362@qq.com; 2009030203@st.btbu.edu.cn
CR Bai SB, 2020, NANOMEDICINE UK, V15, P833, DOI 10.2217/nnm 2020 0024
   Baranyi M, 2020, PATHOL ONCOL RES, V26, P1957, DOI 10.1007/s12253 019 00789 9
   Brown JE, 2019, CANCER INFORM, V18, DOI 10.1177/1176935119866842
   Chen SH, 2020, J MATER CHEM B, V8, P3789, DOI 10.1039/d0tb00046a
   Cheng X, 2021, DRUG DELIV, V28, P37, DOI 10.1080/10717544.2020.1856225
   Cui XX, 2019, ONCOL LETT, V18, P5437, DOI 10.3892/ol.2019.10870
   D'Oronzo S, 2019, J BONE ONCOL, V15, DOI 10.1016/j.jbo.2018.10.004
   Esther Robert, 2020, FP Essent, V493, P27
   Fábián K, 2018, BASIC CLIN PHARMACOL, V122, P126, DOI 10.1111/bcpt.12854
   Goto H, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864 019 0626 5
   Iñiguez Ariza NM, 2020, J BONE ONCOL, V21, DOI 10.1016/j.jbo.2020.100282
   Li X, 2020, THORAC CANCER, V11, P2812, DOI 10.1111/1759 7714.13597
   Link H, 2020, SUPPORT CARE CANCER, V28, P2175, DOI 10.1007/s00520 019 05018 2
   Luo Y, 2020, CANCER SCI, V111, P1840, DOI 10.1111/cas.14361
   Miyashita H, 2021, SUPPORT CARE CANCER, V29, P1629, DOI 10.1007/s00520 020 05665 w
   Ouyang ZX, 2018, CURR DRUG TARGETS, V19, P409, DOI 10.2174/1573399811666150615145409
   Saito G, 2021, SUPPORT CARE CANCER, V29, P4081, DOI 10.1007/s00520 020 05880 5
   Schimmel M, 2018, CLIN ORAL IMPLAN RES, V29, P311, DOI 10.1111/clr.13288
   Tam AH, 2021, ANN PHARMACOTHER, V55, P697, DOI 10.1177/1060028020967629
   Urakawa H, 2020, INT J CANCER, V146, P3504, DOI 10.1002/ijc.32836
   Wood SL, 2020, CANCERS, V12, DOI 10.3390/cancers12082109
   Wu SY, 2021, TRANSL LUNG CANCER R, V10, P439, DOI 10.21037/tlcr 20 835
   Wu XT, 2020, J INT MED RES, V48, DOI 10.1177/0300060520925644
   Xu SQ, 2021, CLIN RESPIR J, V15, P225, DOI 10.1111/crj.13288
   Yamasaki Kana, 2020, Gan To Kagaku Ryoho, V47, P2150
   Yu ZW, 2019, J COMP EFFECT RES, V8, P487, DOI 10.2217/cer 2018 0127
NR 26
TC 2
Z9 2
U1 0
U2 10
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1748 670X
EI 1748 6718
J9 COMPUT MATH METHOD M
JI Comput. Math. Method Med.
PD DEC 13
PY 2021
VL 2021
AR 5343104
DI 10.1155/2021/5343104
PG 6
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Mathematical & Computational Biology
GA YN8HV
UT WOS:000747494600013
PM 34938354
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Dolci, GS
   Portela, LV
   de Souza, DO
   Fossati, ACM
AF Dolci, Gabriel Schmidt
   Portela, Luis Valmor
   de Souza, Diogo Onofre
   Medeiros Fossati, Anna Christina
TI Atorvastatin induced osteoclast inhibition reduces orthodontic relapse
SO AMERICAN JOURNAL OF ORTHODONTICS AND DENTOFACIAL ORTHOPEDICS
LA English
DT Article
ID EXPERIMENTAL TOOTH MOVEMENT; FAMILIAL HYPERCHOLESTEROLEMIA; BONE
   HISTOMORPHOMETRY; RAT MOLARS; SIMVASTATIN; STATINS; CELLS; RESORPTION;
   RANKL; ROSUVASTATIN
AB Introduction: The statin class of drugs enhances osteogenesis and suppresses bone resorption, which could be a plausible biologic mechanism for mitigation of orthodontic relapse. We aimed to determine whether atorvastatin (ATV) might affect orthodontic relapse and osteoclastogenesis by modulating expression of RANKL and osteoprotegerin (OPG), crucial molecules involved in bone turnover. Furthermore, we analyzed the adverse effects of ATV on femur turnover and endochondral ossification. Methods: Wistar rats were subjected to orthodontic tooth movement for 21 days, followed by removal of the appliance and ATV or saline solution administration. Up to 7, 14, and 21 days of ATV administration, tooth relapse was measured, and maxilla and femur sections were obtained and prepared for hematoxylin and eosin, TRAP, and immunohistochemical (RANKL and OPG) staining. Results: ATV decreased tooth relapse (P = 0.03) and osteoclast counts (P = 0.04), which were positively correlated (P=0.006). Statin administration increased periodontal expression of OPG (P=0.008), but not of RANKL protein. ATV administration also enhanced growth plate cartilage thickness. Conclusions: Statin induced OPG overexpression reduces relapse after orthodontic tooth movement, in a phenomenon correlated with decreased osteoclast counts. This phenomenon sheds light on OPG as a molecular target that modulates maxillary bone metabolism and orthodontic relapse.
C1 [Dolci, Gabriel Schmidt] Univ Fed Rio Grande do Sul, Sch Dent, Dept Oral Biol, Porto Alegre, RS, Brazil.
   [Portela, Luis Valmor; de Souza, Diogo Onofre] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Biochem, Porto Alegre, RS, Brazil.
   [Medeiros Fossati, Anna Christina] Univ Fed Rio Grande do Sul, Inst Basic Hlth Sci, Dept Oral Biol, Sch Dent, Porto Alegre, RS, Brazil.
C3 Universidade Federal do Rio Grande do Sul; Universidade Federal do Rio
   Grande do Sul; Universidade Federal do Rio Grande do Sul
RP Fossati, ACM (通讯作者)，Rua Ramiro Barcelos 2492, BR 90035003 Porto Alegre, RS, Brazil.
EM annafo@ufrgs.br
RI Souza, Diogo/J 8894 2014; Portela, Luis/I 3410 2014
OI Dolci, Gabriel/0000 0001 9574 0885; Portela, Luis
   Valmor/0000 0001 6113 8466
CR Avis HJ, 2010, J AM COLL CARDIOL, V55, P1121, DOI 10.1016/j.jacc.2009.10.042
   Odstrcil ADA, 2010, EXP TOXICOL PATHOL, V62, P243, DOI 10.1016/j.etp.2009.04.001
   Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140 6736(05)67394 1
   Dahlberg G., 1940, STAT METHOD MEDICAL
   de Araujo RF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075322
   Egan KP, 2012, HISTOPATHOLOGY, V61, P1168, DOI 10.1111/j.1365 2559.2012.04333.x
   Eiland Lea S, 2010, J Pediatr Pharmacol Ther, V15, P160
   El Khassawna T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071665
   Fan CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046915
   Ferreira LB, 2015, J BIOMATER APPL, V29, P965, DOI 10.1177/0885328214550897
   Franzen TJ, 2013, EUR J ORTHODONT, V35, P152, DOI 10.1093/ejo/cjr127
   Franzen TJ, 2015, EUR J ORTHODONT, V37, P111, DOI 10.1093/ejo/cju053
   Frigotto GCF, 2015, AM J ORTHOD DENTOFAC, V148, P450, DOI 10.1016/j.ajodo.2015.04.031
   Gonzales C, 2009, ANGLE ORTHOD, V79, P703, DOI 10.2319/071308 366.1
   Grasser W. A., 2003, Journal of Musculoskeletal & Neuronal Interactions, V3, P53
   Han GH, 2010, AM J ORTHOD DENTOFAC, V138, P550, DOI 10.1016/j.ajodo.2010.07.006
   Hassan AH, 2010, ANGLE ORTHOD, V80, P1051, DOI 10.2319/112409 665.1
   Hirate Y, 2012, CONNECT TISSUE RES, V53, P207, DOI 10.3109/03008207.2011.628060
   Ho ML, 2009, EUR J CLIN INVEST, V39, P296, DOI 10.1111/j.1365 2362.2009.02092.x
   Hudson JB, 2012, CALCIFIED TISSUE INT, V90, P330, DOI 10.1007/s00223 012 9579 4
   Jin J, 2014, J DENT RES, V93, P294, DOI 10.1177/0022034513516980
   Kang JH, 2014, J DENT RES, V93, P1116, DOI 10.1177/0022034514552677
   Kim JY, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4018
   Kirschneck C, 2014, EUR J PHARMACOL, V744, P67, DOI 10.1016/j.ejphar.2014.09.039
   Leem K, 2002, EUR J PEDIATR, V161, P406, DOI 10.1007/s00431 002 0955 3
   LIPITOR (atorvastatin calcium), 2009, LIPITOR AT CALC HIGH
   Liu ST, 2012, HUM CELL, V25, P29, DOI 10.1007/s13577 011 0028 x
   Macpherson M, 2016, EUR J CLIN PHARMACOL, V72, P19, DOI 10.1007/s00228 015 1946 4
   Maeda T, 2001, BIOCHEM BIOPH RES CO, V280, P874, DOI 10.1006/bbrc.2000.4232
   Miller ML, 2015, J CLIN LIPIDOL, V9, pS67, DOI 10.1016/j.jacl.2015.06.013
   MirHashemi Amir Hossein, 2013, J Dent (Tehran), V10, P532
   Mundy G, 1999, SCIENCE, V286, P1946, DOI 10.1126/science.286.5446.1946
   National Research Council, 1996, GUIDE CARE USE LAB A
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Pedersen TR, 2004, ATHEROSCLEROSIS SUPP, V5, P81, DOI 10.1016/j.atherosclerosissup.2004.08.027
   Perrin S, 2014, NATURE, V507, P423, DOI 10.1038/507423a
   Rattazzi M, 2016, CARDIOVASC THER, V34, P13, DOI 10.1111/1755 5922.12163
   REITAN K, 1967, AMER J ORTHODONTICS, V53, P721, DOI 10.1016/0002 9416(67)90118 2
   Ren YJ, 2005, ARCH ORAL BIOL, V50, P1032, DOI 10.1016/j.archoralbio.2005.04.005
   Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291
   Schneider DA, 2015, ORTHOD CRANIOFAC RES, V18, P187, DOI 10.1111/ocr.12086
   Shirazi M, 2014, IRAN J BASIC MED SCI, V17, P448
   Staal A, 2003, J BONE MINER RES, V18, P88, DOI 10.1359/jbmr.2003.18.1.88
   Stein SH, 2011, J PERIODONTAL RES, V46, P483, DOI 10.1111/j.1600 0765.2011.01364.x
   Verna C, 2000, EUR J ORTHODONT, V22, P343, DOI 10.1093/ejo/22.4.343
   Yamashita A, 2014, NATURE, V513, P507, DOI 10.1038/nature13775
   Yilmaz A, 2006, J LEUKOCYTE BIOL, V79, P529, DOI 10.1189/jlb.0205064
   Yoshida Y, 1999, J ELECTRON MICROSC, V48, P147, DOI 10.1093/oxfordjournals.jmicro.a023661
   Young L, 2013, ORTHOD CRANIOFAC RES, V16, P161, DOI 10.1111/ocr.12014
   Zhao NN, 2012, AM J ORTHOD DENTOFAC, V141, P30, DOI 10.1016/j.ajodo.2011.06.035
NR 50
TC 24
Z9 28
U1 0
U2 7
PU MOSBY ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010 1710 USA
SN 0889 5406
EI 1097 6752
J9 AM J ORTHOD DENTOFAC
JI Am. J. Orthod. Dentofac. Orthop.
PD MAR
PY 2017
VL 151
IS 3
BP 528
EP 538
DI 10.1016/j.ajodo.2016.08.026
PG 11
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA ER7PE
UT WOS:000399004800018
PM 28257738
DA 2025 08 17
ER

PT J
AU Della Rocca, GJ
AF Della Rocca, Gregory J.
TI The science of ultrasound therapy for fracture healing
SO INDIAN JOURNAL OF ORTHOPAEDICS
LA English
DT Article
DE Ultrasound; fracture healing; nonunion
ID INTENSITY PULSED ULTRASOUND; PROTEIN COUPLED RECEPTORS; HUMAN
   OSTEOBLASTS; GENE EXPRESSION; BONE FORMATION; INCREASES; KINASE;
   PATHWAY; CELLS; DIFFERENTIATION
AB Fracture healing involves a complex interplay of cellular processes, culminating in bridging of a fracture gap with bone. Fracture healing can be compromised by numerous exogenous and endogenous patient factors, and intense research is currently going on to identify modalities that can increase the likelihood of successful healing. Low intensity pulsed ultrasound (LIPUS) has been proposed as a modality that may have a benefit for increasing reliable fracture healing as well as perhaps increasing the rate of fracture healing. We conducted a review to establish basic scince evidence of therapeutic role of lipus in fracture healing. An electronic search without language restrictions was accomplished of three databases (PubMed, Embase, Cinahl) for ultrasound related research in osteocyte and chondrocyte cell culture and in animal fracture models, published from inception of the databases through December, 2008. Studies deemed to be most relevant were included in this review. Multiple in vitro and animal in vivo studies were identified. An extensive body of literature exists which delineates the mechanism of action for ultrasound on cellular and tissue signaling systems that may be related to fracture healing. Research on LIPUS in animal fracture models has demonstrated promising results for acceleration of fracture healing and for promotion of fracture healing in compromised tissue beds. A large body of cellular and animal research exists which reveals that LIPUS may be beneficial for accelerating normal fracture healing or for promoting fracture healing in compromised tissue beds. Further investigation of the effects of LIPUS in human fracture healing is warranted for this promising new therapy.
C1 Univ Missouri, Dept Orthopaed Surg, Columbia, MO 65212 USA.
C3 University of Missouri System; University of Missouri Columbia
RP Della Rocca, GJ (通讯作者)，Univ Missouri, Dept Orthopaed Surg, 1 Hosp Dr,MC213,DC053 00, Columbia, MO 65212 USA.
EM dellaroccag@health.missouri.edu
RI Della Rocca, Gregory/AAM 5281 2021
FU NIGMS NIH HHS [T32 GM007171] Funding Source: Medline
CR Anglen Jeff, 2003, J South Orthop Assoc, V12, P46
   ARDAN NI, 1957, J BONE JOINT SURG AM, V39, P394, DOI 10.2106/00004623 195739020 00013
   Azuma Y, 2001, J BONE MINER RES, V16, P671, DOI 10.1359/jbmr.2001.16.4.671
   Busse JW, 2002, CAN MED ASSOC J, V166, P437
   Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   DE NUNNO R, 1952, Ann Ital Chir, V29, P211
   Deckers MML, 2000, ENDOCRINOLOGY, V141, P1667, DOI 10.1210/en.141.5.1667
   DEKEL S, 1981, J BONE JOINT SURG BR, V63, P185, DOI 10.1302/0301 620X.63B2.7217139
   Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978
   Dyson M, 1983, Ultrasound Med Biol, VSuppl 2, P61
   Ebisawa K, 2004, TISSUE ENG, V10, P921, DOI 10.1089/1076327041348437
   EINHORN TA, 1995, J BONE JOINT SURG AM, V77A, P940, DOI 10.2106/00004623 199506000 00016
   Erdogan Ö, 2006, J ORAL MAXIL SURG, V64, P180, DOI 10.1016/j.joms.2005.10.027
   Gebauer GP, 2002, J ORTHOPAED RES, V20, P587, DOI 10.1016/S0736 0266(01)00136 X
   Govender S, 2002, J BONE JOINT SURG AM, V84A, P2123, DOI 10.2106/00004623 200212000 00001
   Hantes ME, 2004, J BONE JOINT SURG AM, V86A, P2275, DOI 10.2106/00004623 200410000 00021
   Heckman J D, 1997, Bull Hosp Jt Dis, V56, P63
   Hsieh YF, 2001, J BONE MINER RES, V16, P918, DOI 10.1359/jbmr.2001.16.5.918
   Kokubu T, 1999, BIOCHEM BIOPH RES CO, V256, P284, DOI 10.1006/bbrc.1999.0318
   Leung KS, 2004, CLIN ORTHOP RELAT R, P253
   Luttrell L M, 1998, Adv Pharmacol, V42, P466
   Mukai S, 2005, ULTRASOUND MED BIOL, V31, P1713, DOI 10.1016/j.ultrasmedbio.2005.07.012
   MUROLO C, 1952, G Ital Chir, V8, P897
   Naruse K, 2003, J BONE MINER RES, V18, P360, DOI 10.1359/jbmr.2003.18.2.360
   Nolte PA, 2001, J ORTHOP RES, V19, P301, DOI 10.1016/S0736 0266(00)00027 9
   Pilla A A, 1990, J Orthop Trauma, V4, P246, DOI 10.1097/00005131 199004030 00002
   Praemer A., 1992, Am. Acad. Orthop. Surg, P85
   RUBIN CT, 1994, CLIN ORTHOP RELAT R, P165
   Ryaby J.T., 1989, Trans Orthop Res, V14, P15
   Ryaby JT, 1998, CLIN ORTHOP RELAT R, pS205
   RYABY JT, 1991, ELECTROMAGNETICS BIO
   Saito M, 2004, CALCIFIED TISSUE INT, V75, P384, DOI 10.1007/s00223 004 0292 9
   Street J, 2002, P NATL ACAD SCI USA, V99, P9656, DOI 10.1073/pnas.152324099
   Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200
   Tang CH, 2006, MOL PHARMACOL, V69, P2047, DOI 10.1124/mol.105.022160
   vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698
   Wadhwa S, 2002, J BONE MINER RES, V17, P266, DOI 10.1359/jbmr.2002.17.2.266
   Wang FS, 2004, BONE, V35, P114, DOI 10.1016/j.bone.2004.02.012
   Warden SJ, 2001, BIOCHEM BIOPH RES CO, V286, P443, DOI 10.1006/bbrc.2001.5412
   Yang KH, 1996, J ORTHOP RES, V14, P802, DOI 10.1002/jor.1100140518
NR 40
TC 25
Z9 31
U1 0
U2 11
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A 202, 2ND FLR, QUBE, C T S  NO 1498A 2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019 5413
EI 1998 3727
J9 INDIAN J ORTHOP
JI Indian J. Orthop.
PD APR JUN
PY 2009
VL 43
IS 2
BP 121
EP 126
DI 10.4103/0019 5413.50845
PG 6
WC Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Orthopedics
GA 505WG
UT WOS:000270729500004
PM 19777126
OA Green Published
DA 2025 08 17
ER

PT J
AU Ciciarello, M
   Zini, R
   Rossi, L
   Salvestrini, V
   Ferrari, D
   Manfredini, R
   Lemoli, RM
AF Ciciarello, Marilena
   Zini, Roberta
   Rossi, Lara
   Salvestrini, Valentina
   Ferrari, Davide
   Manfredini, Rossella
   Lemoli, Roberto M.
TI Extracellular Purines Promote the Differentiation of Human Bone
   Marrow Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic
   Lineages
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID OSTEOBLAST DIFFERENTIATION; ADENOSINE RECEPTORS; STROMAL CELLS;
   INTERNATIONAL UNION; SKELETAL MUSCLE; GENE EXPRESSION; P2Y RECEPTORS;
   PPAR GAMMA; IN VITRO; T CELLS
AB Extracellular nucleotides are potent signaling molecules mediating cell specific biological functions, mostly within the processes of tissue damage and repair and flogosis. We previously demonstrated that adenosine 5' triphosphate (ATP) inhibits the proliferation of human bone marrow derived mesenchymal stem cells (BM hMSCs), while stimulating, in vitro and in vivo, their migration. Here, we investigated the effects of ATP on BM hMSC differentiation capacity. Molecular analysis showed that ATP treatment modulated the expression of several genes governing adipogenic and osteoblastic (ie, WNT pathway related genes) differentiation of MSCs. Functional studies demonstrated that ATP, under specific culture conditions, stimulated adipogenesis by significantly increasing the lipid accumulation and the expression levels of the adipogenic master gene PPAR gamma (peroxisome proliferator activated receptor gamma). In addition, ATP stimulated osteogenic differentiation by promoting mineralization and expression of the osteoblast related gene RUNX2 (runt related transcription factor 2). Furthermore, we demonstrated that ATP stimulated adipogenesis via its triphosphate form, while osteogenic differentiation was induced by the nucleoside adenosine, resulting from ATP degradation induced by CD39 and CD73 ectonucleotidases expressed on the MSC membrane. The pharmacological profile of P2 purinergic receptors (P2Rs) suggests that adipogenic differentiation is mainly mediated by the engagement of P2Y1 and P2Y4 receptors, while stimulation of the P1R adenosine specific subtype A2B is involved in adenosine induced osteogenic differentiation. Thus, we provide new insights into molecular regulation of MSC differentiation.
C1 [Ciciarello, Marilena; Rossi, Lara; Salvestrini, Valentina; Lemoli, Roberto M.] Univ Bologna, Azienda Osped Univ Policlin S Orsola Malpighi, Stem Cell Res Ctr, Inst Hematol,Dept Hematol & Oncol Sci, I 40138 Bologna, Italy.
   [Zini, Roberta; Manfredini, Rossella] Univ Modena & Reggio Emilia, Ctr Regenerat Med, Dept Biomed Sci, Modena, Italy.
   [Ferrari, Davide] Univ Ferrara, Dept Expt & Diagnost Med, I 44100 Ferrara, Italy.
C3 University of Bologna; IRCCS Azienda Ospedaliero Universitaria di
   Bologna; Universita di Modena e Reggio Emilia; University of Ferrara
RP Ciciarello, M (通讯作者)，Univ Bologna, Azienda Osped Univ Policlin S Orsola Malpighi, Stem Cell Res Ctr, Inst Hematol,Dept Hematol & Oncol Sci, Via Massarenti 9, I 40138 Bologna, Italy.
EM marilenaci@hotmail.com
RI Salvestrini, Valentina/KIK 9026 2024; Ciciarello, Marilena/A 4401 2015;
   SALVESTRINI, VALENTINA/KIK 9026 2024; Ferrari, Davide/F 5644 2015;
   LEMOLI, ROBERTO MASSIMO/AAC 2370 2022; LEMOLI, ROBERTO/AAC 2370 2022;
   Manfredini, Rossella/C 5625 2015; Zini, Roberta/I 6734 2012
OI SALVESTRINI, VALENTINA/0000 0003 3192 7151; CICIARELLO,
   MARILENA/0000 0002 4744 507X; Ferrari, Davide/0000 0002 5727 9204;
   LEMOLI, ROBERTO MASSIMO/0000 0001 9000 562X; Manfredini,
   Rossella/0000 0003 0660 6110; Zini, Roberta/0000 0001 6657 0864
FU MIUR; Italian Ministry of Education, University and Scientific Research
   (MIUR); National Research Council of Italy; Italian Association for
   Cancer Research (AIRC); Italian Space Agency (ASI); University of
   Ferrara; AIRC [12055]; Special Program Molecular Clinical Oncology
   [10005]; Regione Emilia Romagna (Progetti di Ricerca Regione Universita)
FX This research was supported by MIUR (PRIN 2008 and FIRB 2011), grants by
   the Italian Ministry of Education, University and Scientific Research
   (MIUR), the National Research Council of Italy, the Italian Association
   for Cancer Research (AIRC), the Italian Space Agency (ASI), and the
   University of Ferrara. Project Tecnopolo of Regione Emilia Romagna and
   AIRC project no. 12055, Special Program Molecular Clinical Oncology 5 x
   1000 to AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative),
   project no. 10005. R.Z. is supported by Regione Emilia Romagna (Progetti
   di Ricerca Regione Universita).
CR Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3
   Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005 0198
   [Anonymous], 2010, CARDIOVASC PSYCHIAT
   Baldridge D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010560
   Billiard J, 2003, J CELL BIOCHEM, V89, P389, DOI 10.1002/jcb.10514
   Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004 0153
   Boland GM, 2004, J CELL BIOCHEM, V93, P1210, DOI 10.1002/jcb.20284
   Borglum JD, 1996, MOL CELL ENDOCRINOL, V117, P17, DOI 10.1016/0303 7207(95)03728 4
   Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013
   Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018 007 6497 0
   Burnstock G, 2006, TRENDS PHARMACOL SCI, V27, P166, DOI 10.1016/j.tips.2006.01.005
   Burnstock G, 2012, J INVEST DERMATOL, V132, P526, DOI 10.1038/jid.2011.344
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Carroll SH, 2012, J BIOL CHEM, V287, P15718, DOI 10.1074/jbc.M112.344994
   Chan TF, 2011, J BONE MINER RES, V26, P1399, DOI 10.1002/jbmr.358
   Chang BHJ, 2006, MOL CELL BIOL, V26, P1063, DOI 10.1128/MCB.26.3.1063 1076.2006
   Cho HY, 2010, BONE, V47, P263, DOI 10.1016/j.bone.2010.05.010
   Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/en.143.3.998
   Cornish J, 2003, ENDOCRINOLOGY, V144, P1194, DOI 10.1210/en.2002 220936
   Di Virgilio F, 2012, CANCER RES, V72, P5441, DOI 10.1158/0008 5472.CAN 12 1600
   Eastman SW, 2009, J CELL BIOL, V184, P881, DOI 10.1083/jcb.200808041
   Eliopoulos N, 2005, BLOOD, V106, P4057, DOI 10.1182/blood 2005 03 1004
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Farmer SR, 2006, CELL METAB, V4, P263, DOI 10.1016/j.cmet.2006.07.001
   Ferrari D, 2011, EXP HEMATOL, V39, P360, DOI 10.1016/j.exphem.2010.12.001
   Fibbe WE, 2007, ANN NY ACAD SCI, V1106, P272, DOI 10.1196/annals.1392.025
   Fortunati D, 2010, MATRIX BIOL, V29, P594, DOI 10.1016/j.matbio.2010.07.001
   Fredholm BB, 2011, PHARMACOL REV, V63, P1, DOI 10.1124/pr.110.003285
   Fredholm BB, 2010, EXP CELL RES, V316, P1284, DOI 10.1016/j.yexcr.2010.02.004
   Gachet C, 2008, THROMB HAEMOSTASIS, V99, P466, DOI 10.1160/TH07 11 0673
   Giustina A, 2008, ENDOCR REV, V29, P535, DOI 10.1210/er.2007 0036
   Gordon JAR, 2011, CELLS TISSUES ORGANS, V194, P146, DOI 10.1159/000324790
   Griffin MD, 2010, HUM GENE THER, V21, P1641, DOI 10.1089/hum.2010.156
   Horwitz EM, 2005, CYTOTHERAPY, V7, P393, DOI 10.1080/14653240500319234
   Isakova IA, 2010, EXP HEMATOL, V38, P957, DOI 10.1016/j.exphem.2010.06.011
   Jacques C, 2007, OSTEOARTHR CARTILAGE, V15, P138, DOI 10.1016/j.joca.2006.07.003
   Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870
   Kim HJ, 2010, J BONE MINER RES, V25, P1771, DOI 10.1002/jbmr.60
   Komori T, 2010, CELL TISSUE RES, V339, P189, DOI 10.1007/s00441 009 0832 8
   Krampera M, 2003, BLOOD, V101, P3722, DOI 10.1182/blood 2002 07 2104
   Krampera M, 2006, BONE, V39, P678, DOI 10.1016/j.bone.2006.04.020
   Lavery K, 2008, J BIOL CHEM, V283, P20948, DOI 10.1074/jbc.M800850200
   Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611
   Lemoli RM, 2004, BLOOD, V104, P1662, DOI 10.1182/blood 2004 03 0834
   Lemoli RM, 2005, HAEMATOLOGICA, V90, P360
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Moldes M, 1997, MOL CELL BIOL, V17, P1796, DOI 10.1128/MCB.17.4.1796
   MURAYAMA T, 1983, ARCH BIOCHEM BIOPHYS, V221, P381, DOI 10.1016/0003 9861(83)90157 1
   Murray SS, 1997, EXP CELL RES, V233, P297, DOI 10.1006/excr.1997.3550
   Nistala H, 2010, J CELL BIOL, V190, P1107, DOI 10.1083/jcb.201003089
   Omatsu Kanbe M, 2006, BIOCHEM J, V393, P171, DOI 10.1042/BJ20051037
   Orriss IR, 2010, CURR OPIN PHARMACOL, V10, P322, DOI 10.1016/j.coph.2010.01.003
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Ouyang X, 2006, J CELL PHYSIOL, V207, P428, DOI 10.1002/jcp.20579
   Park SK, 2004, DIABETES, V53, P2757, DOI 10.2337/diabetes.53.11.2757
   Pellegatti P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002599
   Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143
   Poncelet AJ, 2007, TRANSPLANTATION, V83, P783, DOI 10.1097/01.tp.0000258649.23081.a3
   Rajalin AM, 2011, ARCH BIOCHEM BIOPHYS, V509, P44, DOI 10.1016/j.abb.2011.02.018
   Ralevic V, 1998, PHARMACOL REV, V50, P413
   Rossi L, 2007, BLOOD, V109, P533, DOI 10.1182/blood 2006 01 035634
   Ryten M, 2002, J CELL BIOL, V158, P345, DOI 10.1083/jcb.200202025
   Sak K, 2003, J LEUKOCYTE BIOL, V73, P442, DOI 10.1189/jlb.1102561
   Saldanha Araujo F, 2011, STEM CELL RES, V7, P66, DOI 10.1016/j.scr.2011.04.001
   Salvestrini V, 2012, BLOOD, V119, P217, DOI 10.1182/blood 2011 07 370775
   Sattler C, 2011, CELL TRANSPLANT, V20, P1221, DOI 10.3727/096368910X546553
   Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006 0558
   Sensebé L, 2010, VOX SANG, V98, P93, DOI 10.1111/j.1423 0410.2009.01227.x
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Shryock JC, 1997, AM J CARDIOL, V79, P2, DOI 10.1016/S0002 9149(97)00256 7
   Si WK, 2006, MOL CELL BIOL, V26, P2955, DOI 10.1128/MCB.26.8.2955 2964.2006
   Siqueira MF, 2011, BONE, V48, P1043, DOI 10.1016/j.bone.2011.01.019
   Spiegelman BM, 1997, BIOCHIMIE, V79, P111, DOI 10.1016/S0300 9084(97)81500 3
   Sundin M, 2011, J IMMUNOTHER, V34, P336, DOI 10.1097/CJI.0b013e318217007c
   Takedachi M, 2012, J CELL PHYSIOL, V227, P2622, DOI 10.1002/jcp.23001
   Trabanelli S, 2012, J IMMUNOL, V189, P1303, DOI 10.4049/jimmunol.1103800
   Uccelli A, 2006, EUR J IMMUNOL, V36, P2566, DOI 10.1002/eji.200636416
   VASSAUX G, 1993, BIOCHEM BIOPH RES CO, V193, P1123, DOI 10.1006/bbrc.1993.1742
   Wellner M, 2003, HORM METAB RES, V35, P217
   Yao W, 2010, J BONE MINER RES, V25, P190, DOI 10.1359/jbmr.090719
   Yegutkin GG, 2008, BBA MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024
   Yoshiko Y, 2003, ENDOCRINOLOGY, V144, P4134, DOI 10.1210/en.2003 0130
   ZHANG J, 1995, BIOCHEM J, V306, P205, DOI 10.1042/bj3060205
   Zimmermann H, 2000, N S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309
NR 85
TC 97
Z9 107
U1 0
U2 22
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD APR
PY 2013
VL 22
IS 7
BP 1097
EP 1111
DI 10.1089/scd.2012.0432
PG 15
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA 117IG
UT WOS:000316946200010
PM 23259837
OA Green Published
DA 2025 08 17
ER

PT J
AU Nagashima, T
   Ninomiya, T
   Nakamura, Y
   Nishimura, S
   Ohashi, A
   Aoki, J
   Mizoguchi, T
   Tonogi, M
   Takahashi, T
AF Nagashima, Toshimichi
   Ninomiya, Tadashi
   Nakamura, Yoshiki
   Nishimura, Shirabe
   Ohashi, Akiko
   Aoki, Junya
   Mizoguchi, Toshihide
   Tonogi, Morio
   Takahashi, Tomihisa
TI p53 deficiency promotes bone regeneration by functional regulation of
   mesenchymal stromal cells and osteoblasts
SO JOURNAL OF BONE AND MINERAL METABOLISM
LA English
DT Article
DE p53 deficiency; Mesenchymal stromal cells; Osteoblasts; Drill hole
   healing; Sclerostin
ID SCLEROSTIN; EXPRESSION; THERAPY; GENE; MICE
AB Introduction The detailed mechanism of the process during bone healing of drill hole injury has been elucidated, but a crucial factor in regulating drill hole healing has not been identified. The transcription factor p53 suppresses osteoblast differentiation through inhibition of osterix expression. In present study, we demonstrate the effects of p53 deficiency on the capacity of MSCs and osteoblasts during drill hole healing. Materials and methods Mesenchymal stromal cells (MSCs) and osteoblasts were collected from bone marrow and calvaria of p53 knockout (KO) mice, respectively. The activities of cell mobility, cell proliferation, osteoblast differentiation, and wound healing of MSCs and/or osteoblasts were determined by in vitro experiments. In addition, bone healing of drill hole injury in KO mice was examined by micro CT and immunohistological analysis using anti osterix, Runx2, and sclerostin antibodies. Results KO MSCs stimulated cell mobility, cell proliferation, and osteoblast differentiation. Likewise, KO osteoblasts enhanced cell proliferation and wound healing. KO MSCs and osteoblasts showed high potency in the inflammation and callus formation phases compared to those from wild type (WT) mice. In addition, increased expression of osterix and Runx2 was observed in KO MSCs and osteoblasts that migrated in the drill hole. Conversely, sclerostin expression was inhibited in KO mice. Eventually, KO mice exhibited high repairability of drill hole injury, suggesting a novel role of p53 in MSCs and osteoblasts in improving bone healing. Conclusion p53 Deficiency promotes bone healing of drill hole injury by enhancing the bone regenerative ability of MSCs and osteoblasts.
C1 [Nagashima, Toshimichi; Nakamura, Yoshiki; Nishimura, Shirabe] Nihon Univ, Div Oral Struct & Funct Biol, Grad Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
   [Nagashima, Toshimichi; Aoki, Junya; Tonogi, Morio] Nihon Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
   [Ninomiya, Tadashi; Ohashi, Akiko; Takahashi, Tomihisa] Nihon Univ, Dept Anat, Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
   [Ninomiya, Tadashi; Ohashi, Akiko; Takahashi, Tomihisa] Nihon Univ, Dent Res Ctr, Div Funct Morphol, Sch Dent,Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
   [Nakamura, Yoshiki; Nishimura, Shirabe] Nihon Univ, Dept Orthodont, Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
   [Mizoguchi, Toshihide] Tokyo Dent Coll, Oral Hlth Sci Ctr, Chiyoda Ku, 2 9 18 Kanda Misaki Cho, Tokyo 1010061, Japan.
   [Tonogi, Morio] Nihon Univ, Dent Res Ctr, Div Oral & Craniomaxillofacial Res, Sch Dent,Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
C3 Nihon University; Nihon University; Nihon University; Nihon University;
   Nihon University; Tokyo Dental College; Nihon University
RP Ninomiya, T (通讯作者)，Nihon Univ, Dept Anat, Sch Dent, Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.; Ninomiya, T (通讯作者)，Nihon Univ, Dent Res Ctr, Div Funct Morphol, Sch Dent,Chiyoda Ku, 1 8 13 Kanda Surugadai, Tokyo 1018310, Japan.
EM ninomiya.tadashi@nihon u.ac.jp
OI Ninomiya, Tadashi/0000 0002 6302 2640
FU Sato Fund in Nihon University School of Dentistry; JSPS KAKENHI
   [JP18K09625, JP20K09999, JP20K18682]; Dental Research Center in Nihon
   University School of Dentistry; Grants in Aid for Scientific Research
   [20H03853, 20K18682, 21K09941, 21K19615, 20K09999] Funding Source: KAKEN
FX This work was supported by grants from the Sato Fund in Nihon University
   School of Dentistry, the Dental Research Center in Nihon University
   School of Dentistry, and JSPS KAKENHI (Grant Number JP18K09625,
   JP20K09999, and JP20K18682).
CR Artigas N, 2017, CELL DEATH DIFFER, V24, P2022, DOI 10.1038/cdd.2017.113
   Bertoli C, 2013, NAT REV MOL CELL BIO, V14, P518, DOI 10.1038/nrm3629
   Cascales HS, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000980
   Chen RZ, 2020, THORAC CANCER, V11, P1594, DOI 10.1111/1759 7714.13435
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Einhorn TA, 2015, NAT REV RHEUMATOL, V11, P45, DOI 10.1038/nrrheum.2014.164
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580 019 0110 x
   Hojo H, 2016, DEV CELL, V37, P238, DOI 10.1016/j.devcel.2016.04.002
   Koide M, 2020, SCI REP UK, V10, DOI 10.1038/s41598 020 70817 1
   Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130
   Li GY, 2014, ARCH ORAL BIOL, V59, P513, DOI 10.1016/j.archoralbio.2014.02.015
   Li XD, 2008, J BONE MINER RES, V23, P860, DOI 10.1359/JBMR.080216
   Li XD, 2009, J BONE MINER RES, V24, P578, DOI 10.1359/JBMR.081206
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mehta SA, 2007, ONCOGENE, V26, P3329, DOI 10.1038/sj.onc.1210120
   Nakamura H, 2010, J HISTOCHEM CYTOCHEM, V58, P455, DOI 10.1369/jhc.2010.955393
   Ninomiya T, 2014, CELL TRANSPLANT, V23, P691, DOI 10.3727/096368913X663587
   Ninomiya T, 2011, EUR J PHARMACOL, V650, P396, DOI 10.1016/j.ejphar.2010.10.021
   Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600
   Pérez Campo FM, 2016, CALCIFIED TISSUE INT, V99, P302, DOI 10.1007/s00223 016 0144 4
   Sardh E, 2019, NEW ENGL J MED, V380, P549, DOI 10.1056/NEJMoa1807838
   Shalehin N, 2020, J DENT SCI, V15, P437, DOI 10.1016/j.jds.2019.09.009
   Shapiro F, 2008, EUR CELLS MATER, V15, P53, DOI 10.22203/eCM.v015a05
   Tanaka K, 2010, BONE, V47, P1006, DOI 10.1016/j.bone.2010.08.016
   Tanaka S, 2021, J BONE MINER METAB, V39, P332, DOI 10.1007/s00774 020 01176 0
   TSUKADA T, 1993, ONCOGENE, V8, P3313
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Velletri T, 2021, CELL DEATH DIFFER, V28, P156, DOI 10.1038/s41418 020 0590 4
   Wood DJ, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180112
   Xue YH, 2020, MOL MED REP, V22, P2767, DOI 10.3892/mmr.2020.11361
   Yang Y, 2018, INT J MOL MED, V41, P3366, DOI 10.3892/ijmm.2018.3519
   Yellowley Clare, 2013, Bonekey Rep, V2, P300, DOI 10.1038/bonekey.2013.34
   Zhou X, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419 021 03758 w
NR 34
TC 3
Z9 4
U1 0
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4 3 1 TORANOMON, MINATO KU, TOKYO, 105 6005,
   JAPAN
SN 0914 8779
EI 1435 5604
J9 J BONE MINER METAB
JI J. Bone Miner. Metab.
PD MAY
PY 2022
VL 40
IS 3
BP 434
EP 447
DI 10.1007/s00774 022 01314 w
EA FEB 2022
PG 14
WC Endocrinology & Metabolism; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Research & Experimental Medicine
GA 1F4QM
UT WOS:000760055600001
PM 35195777
DA 2025 08 17
ER

PT J
AU Xia, TS
   Dong, X
   Lin, LY
   Jiang, YP
   Ma, XQ
   Xin, HL
   Zhang, QY
   Qin, LP
AF Xia, Tianshuang
   Dong, Xin
   Lin, Liuyue
   Jiang, Yiping
   Ma, Xueqin
   Xin, Hailiang
   Zhang, Qiaoyan
   Qin, Luping
TI Metabolomics profiling provides valuable insights into the underlying
   mechanisms of Morinda officinalis on protecting
   glucocorticoid induced osteoporosis
SO JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
LA English
DT Article
DE Morinda officinalis; Glucocorticoid induced osteoporosis; Metabolomics;
   Bone metabolism; Osteoblasts; Arachidonic acid metabolism
ID POLYUNSATURATED FATTY ACIDS; BONE LOSS; METABOLISM; TURNOVER; RECEPTOR;
   DENSITY; WOMEN; COX 2; MASS
AB Morinda officinalis (MO) has long been used as a traditional herbal medicine for the treatment of bone fractures and joint diseases in China. Monotropein (Mon) and rubiadin 1 methyl ether (Rub) are major bioactive components in MO. Ample evidence shows that MO and its chemical constituents can prevent osteoporosis induced by estrogen deficiency and ageing. However, there is no study reporting glucocorticoid induced osteoporosis (GIOP). The aim of the present study was to explore the protective effect of MO on GLOP modeled rats and osteoblasts, and elucidate the underlying mechanisms via UHPLC Q TOF/MS based metabolomics profiling. Eight weeks after dexamethasone (DEX) injection and MO treatment in female SD rats aged 12 weeks, bone mineral density (BMD), the micro architecture of the trabecular bone, serum level of bone metabolism markers, and urine metabolomics were assayed in vivo. Cultured osteoblasts were injured with DEX, and the effects of MO, Mon and Rub on osteoblastic proliferation, differentiation and mineralization were examined in vitro. The results showed that MO was able to increase BMD, improve the micro architecture and intervene bone metabolism via regulating alkaline phosphatase (ALP), tartrate resistant acid phosphatase (TRAP) and c terminal telopeptides of type I collagen (CTX I) levels in DEX treated rats. The in vitro experiment showed that MO, Mon and Rub all increased the cell proliferation and ALP activity, and enhanced extracellular matrix mineralization in DEX injured osteoblasts. Metabolomics profiling identified a total of 37 differential metabolites in DEX group vs. the control group, of which 20 were reversed significantly after MO treatment. Further metabolic pathway enrichment and Western blotting analysis showed that MO prevented bone loss mainly by interfering with arachidonic acid metabolism. These results suggested MO had a notable anti GIOP effect, and the underlying mechanisms might be related to arachidonic acid metabolism. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Xia, Tianshuang; Dong, Xin; Lin, Liuyue; Jiang, Yiping; Xin, Hailiang; Zhang, Qiaoyan; Qin, Luping] Second Mil Med Univ, Dept Pharmacognosy, Sch Pharm, Shanghai 200433, Peoples R China.
   [Ma, Xueqin] Ningxia Med Univ, Ningxia Engn & Technol Res Ctr Modernizat Hui Med, Yinchuan 750004, Peoples R China.
   [Zhang, Qiaoyan; Qin, Luping] Zhejiang Chinese Med Univ, Sch Pharm, Hangzhou 310053, Zhejiang, Peoples R China.
C3 Naval Medical University; Ningxia Medical University; Zhejiang Chinese
   Medical University
RP Xin, HL; Zhang, QY; Qin, LP (通讯作者)，Second Mil Med Univ, Dept Pharmacognosy, Sch Pharm, Shanghai 200433, Peoples R China.
EM hailiangxin@163.com; zqy1965@163.com; qinsmmu@126.com
RI ; ma, xueqin/GWR 0125 2022
OI Dong, Xin/0000 0003 3709 0655; 
FU National Natural Science Foundation of China [U1505226]; Shanghai
   Committee of Science and Technology [14401902700]
FX This work was supported by the National Natural Science Foundation of
   China (Grant no. U1505226), and Shanghai Committee of Science and
   Technology (Grant no. 14401902700)
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Casado Díaz A, 2014, GENES NUTR, V9, DOI 10.1007/s12263 013 0375 1
   Chao J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096969
   Chappard D., 2008, Morphologie, V92, P162, DOI 10.1016/j.morpho.2008.10.003
   Chen H, 2016, REDOX BIOL, V10, P168, DOI 10.1016/j.redox.2016.09.014
   Chow LWC, 2011, J STEROID BIOCHEM, V125, P112, DOI 10.1016/j.jsbmb.2010.12.018
   Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138
   GALLWITZ WE, 1993, J BIOL CHEM, V268, P10087
   Garcia C, 1996, J BONE MINER RES, V11, P1619
   Gu G, 2005, APOPTOSIS, V10, P583, DOI 10.1007/s10495 005 1893 0
   He YQ, 2018, BIOCHEM BIOPH RES CO, V506, P927, DOI 10.1016/j.bbrc.2018.10.100
   Hong GJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010203
   Ioannidis G, 2014, ARCH OSTEOPOROS, V9, DOI 10.1007/s11657 013 0169 5
   Järvinen R, 2012, EUR J CLIN NUTR, V66, P496, DOI 10.1038/ejcn.2011.188
   Krieger NS, 2007, J BONE MINER RES, V22, P907, DOI 10.1359/JBMR.070316
   Li P, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287 016 0361 9
   Liu XH, 2010, BIOCHEM BIOPH RES CO, V394, P715, DOI 10.1016/j.bbrc.2010.03.057
   Lv HH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122018
   Ma B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054965
   Millanta F, 2012, J COMP PATHOL, V147, P153, DOI 10.1016/j.jcpa.2012.02.003
   Monroe DG, 2012, GENE, V492, P1, DOI 10.1016/j.gene.2011.10.044
   Moon HJ, 2012, ANN NUTR METAB, V60, P146, DOI 10.1159/000337302
   Peng SL, 2010, J ORTHOP RES, V28, P1208, DOI 10.1002/jor.21127
   Pozzi S, 2007, LEUKEMIA LYMPHOMA, V48, P56, DOI 10.1080/10428190600977690
   Qin LP, 2008, J ETHNOPHARMACOL, V118, P271, DOI 10.1016/j.jep.2008.04.009
   Rahman MM, 2009, J CELL MOL MED, V13, P1833, DOI 10.1111/j.1582 4934.2009.00649.x
   Ribeiro DC, 2017, LIPIDS, V52, P327, DOI 10.1007/s11745 017 4245 2
   Seibel MJ, 2013, LANCET DIABETES ENDO, V1, P59, DOI 10.1016/S2213 8587(13)70045 7
   Seo BI, 2005, PHYTOTHER RES, V19, P231, DOI 10.1002/ptr.1683
   Shi Ji, 2015, Zhong Yao Cai, V38, P245
   Smith CA, 2006, ANAL CHEM, V78, P779, DOI 10.1021/ac051437y
   Smith M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136546
   Szulc P, 2017, OSTEOPOROSIS INT, V28, P2541, DOI 10.1007/s00198 017 4082 4
   Tam J, 2008, FASEB J, V22, P285, DOI 10.1096/fj.06 7957com
   Tolba MF, 2017, TOXICOL APPL PHARM, V324, P26, DOI 10.1016/j.taap.2017.03.021
   Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178
   Treutlein EM, 2018, J BIOL CHEM, V293, P9685, DOI 10.1074/jbc.RA118.002492
   Wang XJ, 2013, MOL CELL PROTEOMICS, V12, P1226, DOI 10.1074/mcp.M112.021683
   Weinstein RS, 2012, ENDOCRIN METAB CLIN, V41, P595, DOI 10.1016/j.ecl.2012.04.004
   Whyte LS, 2012, BRIT J PHARMACOL, V165, P2584, DOI 10.1111/j.1476 5381.2011.01519.x
   Wu YB, 2009, MOLECULES, V14, P573, DOI 10.3390/molecules14010573
   Yang Y, 2017, J ETHNOPHARMACOL, V201, P91, DOI 10.1016/j.jep.2017.02.033
   Zhang J.H., 2017, J. Pharm. Pract., V35, P328, DOI 10.3969/j.issn.1006 0111.2017.04.010
   Zhang ZG, 2016, FITOTERAPIA, V110, P166, DOI 10.1016/j.fitote.2016.03.013
   Zhu MY, 2008, INT J BIOL MACROMOL, V43, P276, DOI 10.1016/j.ijbiomac.2008.06.008
NR 46
TC 32
Z9 41
U1 2
U2 47
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0731 7085
EI 1873 264X
J9 J PHARMACEUT BIOMED
JI J. Pharm. Biomed. Anal.
PD MAR 20
PY 2019
VL 166
BP 336
EP 346
DI 10.1016/j.jpba.2019.01.019
PG 11
WC Chemistry, Analytical; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA HO2AL
UT WOS:000460713700039
PM 30690247
DA 2025 08 17
ER

PT J
AU Li, JR
   Karaplis, AC
   Huang, DC
   Siegel, PM
   Camirand, A
   Yang, XF
   Muller, WJ
   Kremer, R
AF Li, Jiarong
   Karaplis, Andrew C.
   Huang, Dao C.
   Siegel, Peter M.
   Camirand, Anne
   Yang, Xian Fang
   Muller, William J.
   Kremer, Richard
TI PTHrP drives breast tumor initiation, progression, and metastasis in
   mice and is a potential therapy target
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID HORMONE RELATED PROTEIN; MAMMARY GLAND DEVELOPMENT; PARATHYROID HORMONE;
   CANCER METASTASIS; PROSTATE CANCER; TRANSGENIC MICE; BONE METASTASIS;
   LUNG CANCER; MONOCLONAL ANTIBODY; MOUSE MODEL
AB Parathyroid hormone related protein (PTHrP) is a secreted factor expressed in almost all normal fetal and adult tissues. It is involved in a wide range of developmental and physiological processes, including serum calcium regulation. PTHrP is also associated with the progression of skeletal metastases, and its dysregulated expression in advanced cancers causes malignancy associated hypercalcemia. Although PTHrP is frequently expressed by breast tumors and other solid cancers, its effects on tumor progression are unclear. Here, we demonstrate in mice pleiotropic involvement of PTHrP in key steps of breast cancer   it influences the initiation and progression of primary tumors and metastases. Pthrp ablation in the mammary epithelium of the PyMT MMTV breast cancer mouse model caused a delay in primary tumor initiation, inhibited tumor progression, and reduced metastasis to distal sites. Mechanistically, it reduced expression of molecular markets of cell proliferation (Ki67) and angiogenesis (factor VIII), antiapoptotic factor Bcl 2, cell cycle progression regulator cyclin D1, and survival factor AKT1. PTHrP also influenced expression of the adhesion factor CXCR4, and coexpression of PTHrP and CXCR4 was crucial for metastatic spread. Importantly, PTHrP specific neutralizing antibodies slowed the progression and metastasis of human breast cancer xenografts. Our data identify what we believe to be new functions for PTHrP in several key steps of breast cancer and suggest that PTHrP may constitute a novel target for therapeutic intervention.
C1 [Li, Jiarong; Huang, Dao C.; Camirand, Anne; Yang, Xian Fang; Kremer, Richard] McGill Univ, Dept Med, Ctr Hlth, Montreal, PQ H3A 1A1, Canada.
   [Karaplis, Andrew C.; Camirand, Anne] McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Siegel, Peter M.; Muller, William J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A1, Canada.
C3 McGill University; Jewish General Hospital   Montreal; McGill
   University; Lady Davis Institute; McGill University
RP Kremer, R (通讯作者)，McGill Univ, Dept Med, Ctr Hlth, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.
EM richard.kremer@mcgill.ca
OI Kremer, Richard/0000 0002 7053 2139
FU Canadian Institutes for Health Research (CIHR) [MOP 10839, MOP 102555];
   Susan G. Komen Foundation [KG 100766]; US Department of Defense BCRP
   [BC023897]
FX This work was supported by Canadian Institutes for Health Research
   (CIHR) grants MOP 10839 (to R. Kremer) and MOP 102555 (to R. Kremer and
   A. Karaplis); by Susan G. Komen Foundation grant KG 100766 (to R. Kremer
   and A. Karaplis); and by US Department of Defense BCRP Concept Award
   BC023897 (to A. Karaplis). We thank Jing Lian and Bill Papavasiliou for
   technical help.
CR Ackler S, 2002, ONCOGENE, V21, P198, DOI 10.1038/sj.onc.1205052
   Agouni A, 2007, CARCINOGENESIS, V28, P1893, DOI 10.1093/carcin/bgm106
   Alipov GK, 1997, J PATHOL, V182, P174, DOI 10.1002/(SICI)1096 9896(199706)182:2<174::AID PATH840>3.0.CO;2 4
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497
   Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003
   Bohn OL, 2010, INT J CLIN EXP PATHO, V3, P139
   BRANDT DW, 1991, ENDOCRINOLOGY, V129, P2466, DOI 10.1210/endo 129 5 2466
   Bucht E, 1998, CANCER RES, V58, P4113
   Chinni SR, 2006, PROSTATE, V66, P32, DOI 10.1002/pros.20318
   Deftos LJ, 2005, BIOCHEM BIOPH RES CO, V327, P468, DOI 10.1016/j.bbrc.2004.11.162
   Di Cosimo Serena, 2009, Breast Cancer Res, V11 Suppl 3, pS25, DOI 10.1186/bcr2444
   Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120
   Dittmer A, 2006, J BIOL CHEM, V281, P14563, DOI 10.1074/jbc.M510527200
   Dougherty KM, 1999, CANCER RES, V59, P6015
   El Abdaimi K, 2000, AM J PHYSIOL CELL PH, V279, pC1230, DOI 10.1152/ajpcell.2000.279.4.C1230
   Firkin F, 1996, BRIT J HAEMATOL, V94, P486, DOI 10.1046/j.1365 2141.1996.d01 1819.x
   Fleming NI, 2009, CANCER RES, V69, P7473, DOI 10.1158/0008 5472.CAN 09 0194
   Fluck MM, 2009, MICROBIOL MOL BIOL R, V73, P542, DOI 10.1128/MMBR.00009 09
   Gensure RC, 2005, BIOCHEM BIOPH RES CO, V328, P666, DOI 10.1016/j.bbrc.2004.11.069
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Hager JH, 2004, CANCER RES, V64, P2406, DOI 10.1158/0008 5472.CAN 03 3522
   Han Z, 2008, DIGEST DIS SCI, V53, P1801, DOI 10.1007/s10620 007 9824 2
   Hatse S, 2002, FEBS LETT, V527, P255, DOI 10.1016/S0014 5793(02)03143 5
   He B, 2001, ENDOCRINOLOGY, V142, P2070, DOI 10.1210/en.142.5.2070
   HENDERSON J, 1991, CANCER RES, V51, P6521
   Henderson MA, 2001, JNCI J NATL CANCER I, V93, P234, DOI 10.1093/jnci/93.3.234
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hiraki A, 2002, CANCER, V95, P1706, DOI 10.1002/cncr.10828
   IWAMURA M, 1993, CANCER RES, V53, P1724
   Jung Y, 2006, BONE, V38, P497, DOI 10.1016/j.bone.2005.10.003
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277
   Karaplis AC, 2001, CURR PHARM DESIGN, V7, P655, DOI 10.2174/1381612013397753
   Kissin M W, 1993, Eur J Surg Oncol, V19, P134
   KITAZAWA S, 1991, CANCER, V67, P984, DOI 10.1002/1097 0142(19910215)67:4<984::AID CNCR2820670421>3.0.CO;2 0
   KOHNO N, 1994, SURG TODAY, V24, P215, DOI 10.1007/BF02032890
   Kremer R, 1996, AM J MED, V100, P406, DOI 10.1016/S0002 9343(97)89515 0
   Kremer R, 1997, CLIN CANCER RES, V3, P855
   Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027
   Liang ZX, 2005, CANCER RES, V65, P967
   Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602
   Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097 0215(19980812)77:4<640::AID IJC26>3.0.CO;2 8
   Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002 9440(10)63568 7
   Linforth R, 2002, CLIN CANCER RES, V8, P3172
   Luker KE, 2006, CANCER LETT, V238, P30, DOI 10.1016/j.canlet.2005.06.021
   Maioli E, 2004, CELL MOL LIFE SCI, V61, P257, DOI 10.1007/s00018 003 3233 2
   Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008 5472.CAN 06 3782
   Miao DS, 2008, P NATL ACAD SCI USA, V105, P20309, DOI 10.1073/pnas.0805690105
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nishigaki Y, 1999, CLIN CANCER RES, V5, P1473
   Nishihara M, 1999, J PATHOL, V187, P217, DOI 10.1002/(SICI)1096 9896(199901)187:2<217::AID PATH210>3.0.CO;2 0
   Nishihara M, 2007, ANN NY ACAD SCI, V1117, P385, DOI 10.1196/annals.1402.046
   PECHERSTORLER M, 1994, CLIN ENDOCRINOL, V78, P1268
   Philbrick WM, 1998, P NATL ACAD SCI USA, V95, P11846, DOI 10.1073/pnas.95.20.11846
   Rankin W, 1997, CANCER, V80, P1564, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1564::AID CNCR6>3.3.CO;2 H
   Roodman GD, 2004, NEW ENGL J MED, V350, P1655, DOI 10.1056/NEJMra030831
   Saito H, 2005, ANTICANCER RES, V25, P3817
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Truong NU, 2003, AM J MED, V115, P115, DOI 10.1016/S0002 9343(03)00310 3
   Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007
   Wysolmerski JJ, 1998, DEVELOPMENT, V125, P1285
   WYSOLMERSKI JJ, 1995, DEVELOPMENT, V121, P3539
   Zlotnik A, 2008, J PATHOL, V215, P211, DOI 10.1002/path.2350
NR 67
TC 103
Z9 117
U1 0
U2 16
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA
SN 0021 9738
EI 1558 8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD DEC
PY 2011
VL 121
IS 12
BP 4655
EP 4669
DI 10.1172/JCI46134
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 855XL
UT WOS:000297599500017
PM 22056386
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Aprile, A
   Gulino, A
   Storto, M
   Villa, I
   Beretta, S
   Merelli, I
   Rubinacci, A
   Ponzoni, M
   Marktel, S
   Tripodo, C
   Lidonnici, MR
   Ferrari, G
AF Aprile, Annamaria
   Gulino, Alessandro
   Storto, Mariangela
   Villa, Isabella
   Beretta, Stefano
   Merelli, Ivan
   Rubinacci, Alessandro
   Ponzoni, Maurilio
   Marktel, Sarah
   Tripodo, Claudio
   Lidonnici, Maria Rosa
   Ferrari, Giuliana
TI Hematopoietic stem cell function in β thalassemia is impaired and is
   rescued by targeting the bone marrow niche
SO BLOOD
LA English
DT Article
ID LONG TERM; GENE THERAPY; SELF RENEWAL; PROGENITORS; TRANSPLANTATION;
   ERYTHROPOIESIS; OSTEOPONTIN; MAINTENANCE; QUIESCENCE; EXPANSION
AB Hematopoietic stem cells (HSCs) are regulated by signals from the bone marrow (BM) niche that tune hematopoiesis at steady state and in hematologic disorders. To understand HSC niche interactions in altered nonmalignant homeostasis, we selected beta thalassemia, a hemoglobin disorder, as a paradigm. In this severe congenital anemia, alterations sec ondary to the primary hemoglobin defect have a potential impact on HSC niche cross talk. We report that HSCs in thalassemic mice (th3) have an impaired function, caused by the interaction with an altered BM niche. The HSC self renewal defect is rescued after cell transplantation into a normal microenvironment, thus proving the active role of the BM stroma. Consistent with the common finding of osteoporosis in patients, we found reduced bone deposition with decreased levels of parathyroid hormone (PTH), which is a key regulator of bone metabolism but also of HSC activity. In vivo activation of PTH signaling through the reestablished Jagged1 and osteopontin levels correlated with the rescue of the functional pool of th3 HSCs by correcting HSC niche cross talk. Reduced HSC quies cence was confirmed in thalassemic patients, along with altered features of the BM stromal niche. Our findings reveal a defect in HSCs in beta thalassemia induced by an altered BM microenvironment and provide novel and relevant insight for improving transplantation and gene therapy approaches.
C1 [Aprile, Annamaria; Storto, Mariangela; Beretta, Stefano; Merelli, Ivan; Lidonnici, Maria Rosa; Ferrari, Giuliana] Ist Sci San Raffaele, Ist Ricovero & Cura Carattere Sci IRCCS, San Raffaele Telethon Inst Gene Therapy SR TIGET, Milan, Italy.
   [Gulino, Alessandro; Tripodo, Claudio] Univ Palermo, Human Pathol Sect, Dept Hlth Sci, Tumor Immunol Unit, Palermo, Italy.
   [Villa, Isabella; Rubinacci, Alessandro] IRCCS San Raffaele Sci Inst, Div Genet & Cell Biol, Bone Metab Unit, Milan, Italy.
   [Merelli, Ivan] CNR, Inst Biomed Technol, Segrate, Italy.
   [Ponzoni, Maurilio; Ferrari, Giuliana] Univ Vita Salute San Raffaele, Milan, Italy.
   [Ponzoni, Maurilio] IRCCS San Raffaele Sci Inst, Pathol Unit, Unit Lymphoid Malignancies, Milan, Italy.
   [Marktel, Sarah] IRCCS San Raffaele Sci Inst, Hematol & Bone Marrow Transplantat Unit, Milan, Italy.
C3 Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy
   (Sr Tiget); Fondazione IRCCS Istituto Nazionale Tumori Milan; University
   of Palermo; Vita Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di
   Tecnologie Biomediche (ITB CNR); Vita Salute San Raffaele University;
   Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Vita Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Ferrari, G (通讯作者)，Ist Sci San Raffaele, Via Olgettina 58, I 20132 Milan, Italy.
EM ferrari.giuliana@hsr.it
RI ; marktel, sarah/ABH 5549 2020; Beretta, Stefano/AAB 4946 2022; Merelli,
   Ivan/O 2543 2015; Tripodo, Claudio/O 4536 2016; Tripodo,
   Claudio/AAB 6004 2022; Storto, Mariangela/AAO 4741 2020; Lidonnici,
   Maria/AAN 2208 2020; Rubinacci, Alessandro/ABG 5732 2020
OI Aprile, Annamaria/0000 0001 6019 1345; marktel,
   sarah/0000 0002 3768 4288; Rubinacci, Alessandro/0000 0003 1736 0531;
   Beretta, Stefano/0000 0003 4375 004X; Tripodo,
   Claudio/0000 0002 0821 6231; 
FU Telethon SR TIGET Core Grant [A3 2016]; Associazione Italiana per la
   Ricerca sul Cancro (AIRC) [IG15999]; Cooley's Anemia Foundation;
   European Hematology Association
FX This work was supported by Telethon SR TIGET Core Grant A3 2016 (G.F.),
   by Associazione Italiana per la Ricerca sul Cancro (AIRC) grant IG15999
   (C.T.); Cooley's Anemia Foundation 2018 and 2019 Research Fellowships
   (A.A.); and a European Hematology Association 2019 Junior Research Grant
   (A.A.).
CR Abbuehl JP, 2017, CELL STEM CELL, V21, P241, DOI 10.1016/j.stem.2017.07.004
   Adams GB, 2006, NAT IMMUNOL, V7, P333, DOI 10.1038/ni1331
   Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281
   Angelopoulos NG, 2006, J BONE MINER METAB, V24, P138, DOI 10.1007/s00774 005 0660 1
   Angelucci E, 2018, HAEMATOLOGICA, V103, P1094, DOI 10.3324/haematol.2018.196071
   Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004
   Baryawno N, 2017, CELL STEM CELL, V20, P590, DOI 10.1016/j.stem.2017.03.025
   Bowers M, 2015, BLOOD, V125, P2678, DOI 10.1182/blood 2014 06 582924
   Calvi LM, 2012, BLOOD, V119, P2489, DOI 10.1182/blood 2011 06 360933
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cavazzana M, 2017, STEM CELLS DEV, V26, P71, DOI 10.1089/scd.2016.0230
   Centis F, 2000, BLOOD, V96, P3624
   Chambers Stuart M, 2007, Cell Stem Cell, V1, P578, DOI 10.1016/j.stem.2007.10.003
   Christodoulou C, 2020, NATURE, V578, P278, DOI 10.1038/s41586 020 1971 z
   Crane GM, 2017, NAT REV IMMUNOL, V17, P573, DOI 10.1038/nri.2017.53
   Crippa S, 2019, J CLIN INVEST, V129, P1566, DOI 10.1172/JCI123191
   Ding L, 2013, NATURE, V495, P231, DOI 10.1038/nature11885
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Fan Y, 2017, CELL METAB, V25, P661, DOI 10.1016/j.cmet.2017.01.001
   Flach J, 2014, NATURE, V512, P198, DOI 10.1038/nature13619
   Fouzia NA, 2018, BONE MARROW TRANSPL, V53, P169, DOI 10.1038/bmt.2017.231
   Gazit R, 2014, J EXP MED, V211, P1314, DOI 10.1084/jem.20130428
   Guezguez B, 2013, CELL STEM CELL, V13, P175, DOI 10.1016/j.stem.2013.06.015
   Guo PP, 2017, J CLIN INVEST, V127, P4242, DOI 10.1172/JCI92309
   Isidori A, 2018, BLOOD REV, V32, P473, DOI 10.1016/j.blre.2018.04.004
   Kfoury Y, 2015, CELL STEM CELL, V16, P239, DOI 10.1016/j.stem.2015.02.019
   Kiel MJ, 2008, NAT REV IMMUNOL, V8, P290, DOI 10.1038/nri2279
   Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026
   LOCATELLI F, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD 2018 99 112667
   Maillard I, 2008, CELL STEM CELL, V2, P356, DOI 10.1016/j.stem.2008.02.011
   Marktel S, 2019, NAT MED, V25, P234, DOI 10.1038/s41591 018 0301 6
   Mathias LA, 2000, EXP HEMATOL, V28, P1343, DOI 10.1016/S0301 472X(00)00555 5
   Matsumoto A, 2011, CELL STEM CELL, V9, P262, DOI 10.1016/j.stem.2011.06.014
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Mercher T, 2008, CELL STEM CELL, V3, P314, DOI 10.1016/j.stem.2008.07.010
   Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood 2004 11 4422
   Oh P, 2013, CELL STEM CELL, V13, P190, DOI 10.1016/j.stem.2013.05.015
   Pinho S, 2019, NAT REV MOL CELL BIO, V20, P303, DOI 10.1038/s41580 019 0103 9
   Poulos MG, 2013, CELL REP, V4, P1022, DOI 10.1016/j.celrep.2013.07.048
   Rachmilewitz EA, 2011, BLOOD, V118, P3479, DOI 10.1182/blood 2010 08 300335
   Rauner M, 2016, J BONE MINER RES, V31, P1877, DOI 10.1002/jbmr.2857
   Roselli EA, 2010, EMBO MOL MED, V2, P315, DOI 10.1002/emmm.201000083
   Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992
   Taher AT, 2018, LANCET, V391, P155, DOI 10.1016/S0140 6736(17)31822 6
   Terpos E, 2010, ANN NY ACAD SCI, V1202, P237, DOI 10.1111/j.1749 6632.2010.05542.x
   Thompson AA, 2018, NEW ENGL J MED, V378, P1479, DOI 10.1056/NEJMoa1705342
   Tikhonova AN, 2019, NATURE, V569, P222, DOI 10.1038/s41586 019 1104 8
   Tsay J, 2010, BLOOD, V116, P2582, DOI 10.1182/blood 2009 12 260083
   Varnum Finney B, 2011, J CLIN INVEST, V121, P1207, DOI 10.1172/JCI43868
   Vogiatzi MG, 2010, CALCIFIED TISSUE INT, V86, P484, DOI 10.1007/s00223 010 9365 0
   Walkley CR, 2011, INT J HEMATOL, V93, P10, DOI 10.1007/s12185 010 0759 6
   Weber JM, 2006, BONE, V39, P485, DOI 10.1016/j.bone.2006.03.002
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   YANG BL, 1995, P NATL ACAD SCI USA, V92, P11608, DOI 10.1073/pnas.92.25.11608
   Yang MY, 2019, J BONE MINER RES, V34, P1952, DOI 10.1002/jbmr.3811
   Yu VWC, 2015, J EXP MED, V212, P759, DOI 10.1084/jem.20141843
   Zhou BO, 2015, ELIFE, V4, DOI 10.7554/eLife.05521
NR 57
TC 27
Z9 29
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD JUL 30
PY 2020
VL 136
IS 5
BP 610
EP 622
DI 10.1182/blood.2019002721
PG 13
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA NB1YZ
UT WOS:000560311900013
PM 32344432
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Jahejo, AR
   Tian, WX
AF Jahejo, Ali Raza
   Tian, Wen Xia
TI Cellular, molecular and genetical overview of avian tibial
   dyschondroplasia
SO RESEARCH IN VETERINARY SCIENCE
LA English
DT Article
DE Angiogenesis; Biomarkers; Chicken; Pathogenicity; rGSTA3; Treatment
ID GROWTH PLATE CHONDROCYTES; HYPOXIA INDUCIBLE FACTOR; SHOCK PROTEIN 90;
   BROILER CHICKENS; INDIAN HEDGEHOG; BONE FORMATION; EXPRESSION; THIRAM;
   ANGIOGENESIS; IDENTIFICATION
AB Tibial dyschondroplasia (TD) is an intractable avian bone disease that causes severe poultry economic losses. The pathogenicity of TD is unknown. Therefore, TD disease has not been evacuated yet. Based on continuous research findings, we have gone through the molecular and cellular insight into the TD and proposed possible pathogenicity for future studies. Immunity and angiogenesis related genes expressed in the erythrocytes of chicken, influenced the apoptosis of chicken chondrocytes to cause TD. TD could be defined as the irregular, unmineralized and un vascularized mass of cartilage, which is caused by apoptosis, degeneration and insufficient blood supply at the site of the chicken growth plate. The failure of angiogenesis attributed improper nutrients supply to the chondrocytes; ultimately, bone development stopped, poor calcification of cartilage matrix, and apoptosis of chondrocytes occurred. Recent studies explore potential signaling pathways that regulated TD in broiler chickens, including parathyroid hormone related peptide (PTHrP), transforming growth factor 13 (TGF  13)/bone morphogenic proteins (BMPs), and hypoxia inducible factor (HIF). Several studies have reported many medicines to treat TD. However, recently, rGSTA3 protein (50 ?g?kg? 1) is considered the most proper TD treatment. The present review has summarized the molecular and cellular insight into the TD, which will help researchers in medicine development to evacuate TD completely.
C1 [Jahejo, Ali Raza; Tian, Wen Xia] Shanxi Agr Univ, Coll Vet Med, Jinzhong 030801, Peoples R China.
C3 Shanxi Agricultural University
RP Tian, WX (通讯作者)，Shanxi Agr Univ, Coll Vet Med, Jinzhong 030801, Peoples R China.
EM wenxiatian@126.com
RI Jahejo, Ali/AAN 6508 2020; Jahejo, Ali Raza/AAN 6508 2020
OI Jahejo, Ali Raza/0000 0002 4975 1492
FU National Key R D Program [2016YFD0500800]; Shanxi Scholarship Council of
   China [2017073]; Key Scientific and Technological Innovation platform of
   Jinzhong [P1710023]; National Natural Science Foundation of China
   [31072179]; Key Technologies R & D Program of Shanxi Province
   [20130311027 3]; "131" Leading Talent Project for Colleges and
   Universities of Shanxi Province
FX This work was supported by the National Key R & D Program
   (2016YFD0500800) , Research Project Supported by Shanxi Scholarship
   Council of China (2017073) , Key Scientific and Technological Innovation
   platform of Jinzhong (P1710023) , the National Natural Science
   Foundation of China (31072179) , Key Technologies R & D Program of
   Shanxi Province (20130311027 3) and "131" Leading Talent Project for
   Colleges and Universities of Shanxi Province.
CR Barish GD, 2012, CELL METAB, V15, P554, DOI 10.1016/j.cmet.2012.02.012
   Burdan F, 2009, FOLIA HISTOCHEM CYTO, V47, P5, DOI 10.2478/v10042 009 0007 1
   Cancedda FD, 2001, OSTEOARTHR CARTILAGE, V9, pS118, DOI 10.1053/joca.2001.0453
   Cheng KJ, 2016, EUR REV MED PHARMACO, V20, P5067
   Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534 5807(01)00017 X
   Coyle CH, 2009, J ORTHOP RES, V27, P793, DOI 10.1002/jor.20816
   Crowe R, 1999, DEVELOPMENT, V126, P987
   Domowicz MS, 2009, DEV BIOL, V329, P242, DOI 10.1016/j.ydbio.2009.02.024
   Farquharson C, 2000, POULTRY SCI, V79, P994, DOI 10.1093/ps/79.7.994
   Alves MCF, 2016, REV BRAS ZOOTECN, V45, P372, DOI 10.1590/S1806 92902016000700003
   Fong L, 2009, BONE, V44, P1151, DOI 10.1016/j.bone.2009.02.011
   Galas RJ, 2014, J CELL BIOCHEM, V115, P111, DOI 10.1002/jcb.24638
   Genin O, 2008, POULTRY SCI, V87, P1556, DOI 10.3382/ps.2008 00124
   Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467
   Grek CL, 2013, J BIOL CHEM, V288, P26497, DOI 10.1074/jbc.R113.461368
   Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857
   Herzog A, 2011, AM J PHYSIOL REG I, V301, pR140, DOI 10.1152/ajpregu.00134.2011
   Huang SC, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 09664 6
   Huang SC, 2018, J VET SCI, V19, P107, DOI 10.4142/jvs.2018.19.1.107
   Huang SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173698
   Iqbal MK, 2016, AVIAN DIS, V60, P773, DOI 10.1637/11425 041816 Reg
   Iqbal M, 2018, BIOL PROCED ONLINE, V20, DOI 10.1186/s12575 018 0080 y
   Iwasaki M, 1997, MECH DEVELOP, V69, P197, DOI 10.1016/S0925 4773(97)00145 7
   Jacobsen KA, 2008, J BONE MINER RES, V23, P596, DOI 10.1359/JBMR.080103
   Jahejo AR, 2021, DEV COMP IMMUNOL, V114, DOI 10.1016/j.dci.2020.103831
   Jahejo AR, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864 020 6456 9
   Jahejo AR, 2019, RES VET SCI, V127, P65, DOI 10.1016/j.rvsc.2019.10.013
   Jahejo AR, 2019, PAK J ZOOL, V51, P801, DOI 10.17582/journal.pjz/2019.51.3.801.807
   Jia FaJie Jia FaJie, 2018, Acta Veterinaria et Zootechnica Sinica, V49, P811
   Kässmeyer S, 2009, ANAT HISTOL EMBRYOL, V38, P1, DOI 10.1111/j.1439 0264.2008.00894.x
   Koolwijk Pieter, 2001, Angiogenesis, V4, P53, DOI 10.1023/A:1016637700638
   Kronenberg HM, 1998, RECENT PROG HORM RES, V53, P283
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Lee SS, 2012, BIOMATERIALS, V33, P4251, DOI 10.1016/j.biomaterials.2012.03.005
   Lefebvre Veronique, 2005, Birth Defects Research, V75, P200, DOI 10.1002/bdrc.20048
   Li JK, 2008, RES VET SCI, V84, P409, DOI 10.1016/j.rvsc.2007.11.008
   Li QY, 2017, EUR J PHARMACOL, V799, P188, DOI 10.1016/j.ejphar.2017.02.020
   Lilly AJ, 2017, MECH DEVELOP, V146, P31, DOI 10.1016/j.mod.2017.05.004
   Liu R, 2015, VET RES COMMUN, V39, P31, DOI 10.1007/s11259 015 9626 5
   Lopatina T, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478 811X 12 26
   Lu X.X., 2019, J SHANXI AGR U, P95
   Martin TJ, 2005, TRENDS MOL MED, V11, P76, DOI 10.1016/j.molmed.2004.12.004
   Medill NJ, 2001, J CELL BIOCHEM, V80, P504, DOI 10.1002/1097 4644(20010315)80:4<504::AID JCB1004>3.0.CO;2 R
   Mehmood K, 2019, ENVIRON SCI POLLUT R, V26, P16210, DOI 10.1007/s11356 019 05032 1
   Mehmood K, 2019, ECOTOX ENVIRON SAFE, V168, P205, DOI 10.1016/j.ecoenv.2018.10.080
   Mehmood K, 2018, PAK VET J, V38, P76, DOI 10.29261/pakvetj/2018.015
   Mehmood K, 2017, AVIAN DIS, V61, P372, DOI 10.1637/11641 032817 RegR
   Moses HL, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a021865
   Nabi F, 2018, PAK J ZOOL, V50, P1553, DOI 10.17582/journal.pjz/2018.50.4.sc6
   Nabi F, 2018, J VET PHARMACOL THER, V41, P902, DOI 10.1111/jvp.12692
   Nabi F, 2016, AVIAN PATHOL, V45, P187, DOI 10.1080/03079457.2016.1141170
   Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904
   Niu S, 2019, RES VET SCI, V124, P112, DOI 10.1016/j.rvsc.2019.03.004
   Niu S, 2019, PAK J ZOOL, V51, P1475, DOI 10.17582/journal.pjz/2019.51.4.1475.1482
   Nnadi P., 2010, J PARASITOL RES, V2010
   Olsen BR, 2000, ANNU REV CELL DEV BI, V16, P191, DOI 10.1146/annurev.cellbio.16.1.191
   ORTH MW, 1994, VET PATHOL, V31, P403, DOI 10.1177/030098589403100401
   Pelicia K, 2012, BRAZ J POULTRY SCI, V14, P129, DOI 10.1590/S1516 635X2012000200007
   PHILIPPART C, 1993, BONE MINER, V23, P317, DOI 10.1016/S0169 6009(08)80106 7
   Pines M, 2005, WORLD POULTRY SCI J, V61, P285, DOI 10.1079/WPS200454
   Praul CA, 1997, INT J DEV BIOL, V41, P621
   Praul CA, 2000, POULTRY SCI, V79, P1009, DOI 10.1093/ps/79.7.1009
   Provot S, 2005, BIOCHEM BIOPH RES CO, V328, P658, DOI 10.1016/j.bbrc.2004.11.068
   Rajkumar VS, 2006, AM J PATHOL, V169, P2254, DOI 10.2353/ajpath.2006.060196
   Rasaputra KS, 2013, J TOXICOL SCI, V38, P93, DOI 10.2131/jts.38.93
   Rath NC, 2007, POULTRY SCI, V86, P2390, DOI 10.3382/ps.2007 00219
   Rath NC, 2005, J COMP PATHOL, V133, P41, DOI 10.1016/j.jcpa.2005.01.005
   Rath NC, 2004, POULTRY SCI, V83, P266, DOI 10.1093/ps/83.2.266
   Rath NC, 1998, AVIAN DIS, V42, P72, DOI 10.2307/1592578
   Saisawang C, 2012, BIOCHEM J, V442, P181, DOI 10.1042/BJ20111747
   Saito T, 2004, J ENDODONT, V30, P205, DOI 10.1097/00004770 200404000 00005
   Salazar VS, 2016, NAT REV ENDOCRINOL, V12, P203, DOI 10.1038/nrendo.2016.12
   Schipani E, 2005, SEMIN CELL DEV BIOL, V16, P539, DOI 10.1016/j.semcdb.2005.03.003
   Schipani E, 2001, GENE DEV, V15, P2865
   Seo YH, 2015, BIOL PHARM BULL, V38, P389, DOI 10.1248/bpb.b14 00604
   Shahzad M, 2015, AVIAN PATHOL, V44, P13, DOI 10.1080/03079457.2014.987210
   Shahzad M, 2014, AVIAN DIS, V58, P468, DOI 10.1637/10781 012614 ResNote.1
   Shalini S, 2015, CELL DEATH DIFFER, V22, P526, DOI 10.1038/cdd.2014.216
   Shim MY, 2012, POULTRY SCI, V91, P62, DOI 10.3382/ps.2011 01599
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Smolock EM, 2012, CIRCULATION, V126, P2418, DOI 10.1161/CIRCULATIONAHA.112.125971
   Terkhorn SP, 2007, J CELL PHYSIOL, V210, P257, DOI 10.1002/jcp.20873
   Tew KD, 2012, ANTIOXID REDOX SIGN, V17, P1728, DOI 10.1089/ars.2012.4640
   Tian WX, 2009, AVIAN PATHOL, V38, P161, DOI 10.1080/03079450902737789
   Tian WX, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 276
   WALLIS GA, 1993, CURR BIOL, V3, P687, DOI 10.1016/0960 9822(93)90069 Z
   Wang CX, 2018, RES VET SCI, V120, P11, DOI 10.1016/j.rvsc.2018.08.001
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang PZ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148372
   Waqas M, 2020, ECOTOX ENVIRON SAFE, V190, DOI 10.1016/j.ecoenv.2019.110126
   Webster SV, 2003, AVIAN PATHOL, V32, P69, DOI 10.1080/030794502/000070741
   Yan B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11151
   Yang F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156045
   Yang H, 2019, ECOTOX ENVIRON SAFE, V183, DOI 10.1016/j.ecoenv.2019.109575
   Yao WY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01251
   Zanotti S, 2016, ENDOCR REV, V37, P223, DOI 10.1210/er.2016 1002
   Zhang H, 2015, BMC VET RES, V11, DOI 10.1186/s12917 015 0398 5
   Zhang H, 2018, ENVIRON SCI POLLUT R, V25, P28264, DOI 10.1007/s11356 018 2824 2
   Zhang H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00123
   Zhang JP, 2013, POULTRY SCI, V92, P3214, DOI 10.3382/ps.2013 03420
   Zhang JL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133160
   Zhou QB, 2014, MOL THER, V22, P378, DOI 10.1038/mt.2013.243
   Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014
   Zou HY, 1997, GENE DEV, V11, P2191, DOI 10.1101/gad.11.17.2191
NR 105
TC 28
Z9 28
U1 0
U2 17
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0034 5288
EI 1532 2661
J9 RES VET SCI
JI Res. Vet. Sci.
PD MAR
PY 2021
VL 135
BP 569
EP 579
DI 10.1016/j.rvsc.2020.10.002
EA MAR 2021
PG 11
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA RC5SF
UT WOS:000632860100004
PM 33066991
DA 2025 08 17
ER

PT J
AU Wang, QW
   Chen, B
   Ma, F
   Lin, SK
   Cao, M
   Li, Y
   Gu, N
AF Wang, Qiwei
   Chen, Bo
   Ma, Fang
   Lin, Shikang
   Cao, Meng
   Li, Yan
   Gu, Ning
TI Magnetic iron oxide nanoparticles accelerate osteogenic differentiation
   of mesenchymal stem cells via modulation of long noncoding RNA
   INZEB2
SO NANO RESEARCH
LA English
DT Article
DE iron oxide nanoparticle; mesenchymal stem cell; osteogenic
   differentiation; long noncoding RNA; magnetogenetics; nano magnetic
   bioeffects
ID BONE FORMATION; OSTEOBLAST DIFFERENTIATION; MAPK PATHWAY;
   EXTRACELLULAR MATRIX; SKELETAL DEVELOPMENT; DRUG DELIVERY; ZEB PROTEINS;
   IN VIVO; EXPRESSION; GENE
AB Nanomaterials are increasingly used for biomedical applications; thus, it is important to understand their biological effects. Previous studies suggested that magnetic iron oxide nanoparticles (IONPs) have tissue repairing effects. In the present study, we explored cellular effects of IONPs in mesenchymal stem cells (MSCs) and identified the underlying molecular mechanisms. The results showed that our as prepared IONPs were structurally stable in MSCs and promoted osteogenic differentiation of MSCs as whole particles. Moreover, at the molecular level, we compared the gene expression of MSCs with or without IONP exposure and showed that IONPs upregulated long noncoding RNA INZEB2, which is indispensable for maintaining osteogenesis by MSCs. Furthermore, overexpression of INZEB2 downregulated ZEB2, a factor necessary to repress BMP/Smad dependent osteogenic transcription. We also demonstrated that the essential role of INZEB2 in osteogenic differentiation was ZEB2 dependent. In summary, we elucidated the molecular basis of IONPs' effects on MSCs; these findings may serve as a meaningful theoretical foundation for applications of stem cells to regenerative medicine.
C1 [Wang, Qiwei; Chen, Bo; Li, Yan; Gu, Ning] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Key Lab Biomat & Devices, Nanjing 210096, Jiangsu, Peoples R China.
   [Wang, Qiwei; Chen, Bo; Cao, Meng; Gu, Ning] Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.
   [Ma, Fang] Southeast Univ, Inst Life Sci, Key Lab Dev Genes & Human Dis, Minist Educ, Nanjing 210096, Jiangsu, Peoples R China.
   [Lin, Shikang] Signalway Antibody LLC, College Pk, MD 20740 USA.
C3 Southeast University   China; Southeast University   China
RP Gu, N (通讯作者)，Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Jiangsu Key Lab Biomat & Devices, Nanjing 210096, Jiangsu, Peoples R China.; Gu, N (通讯作者)，Collaborat Innovat Ctr Suzhou Nano Sci & Technol, Suzhou 215123, Peoples R China.
EM guning@seu.edu.cn
RI ; Wang, Qiwei/GSO 0564 2022
OI Wang, Qiwei/0000 0001 9197 3163; 
FU National Basic Research Program of China [2013CB733804, 2013CB934400];
   National Natural Science Foundation of China (NSFC) for Key Project of
   International Cooperation [61420106012]; Special Project on Development
   of National Key Scientific Instruments and Equipment of China
   [2011YQ03013403]; Natural Science Foundation of Jiangsu Province
   [BK20130608]; Fundamental Research Funds for the Central Universities;
   Graduate Research and Innovation Program of Jiangsu Province in China
   [KYLX15 0167]
FX This work was supported by grants from the National Basic Research
   Program of China (Nos. 2013CB733804 and 2013CB934400), the National
   Natural Science Foundation of China (NSFC) for Key Project of
   International Cooperation (No. 61420106012), Special Project on
   Development of National Key Scientific Instruments and Equipment of
   China (No. 2011YQ03013403), the Natural Science Foundation of Jiangsu
   Province (No. BK20130608), the Fundamental Research Funds for the
   Central Universities and the Graduate Research and Innovation Program of
   Jiangsu Province in China (No. KYLX15 0167).
CR Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Assa F, 2016, NANO RES, V9, P2203, DOI 10.1007/s12274 016 1131 9
   Bae JS, 2007, J CELL BIOCHEM, V100, P434, DOI 10.1002/jcb.21039
   Bikle DD, 2015, BONE, V80, P79, DOI 10.1016/j.bone.2015.04.036
   Bock N, 2010, ACTA BIOMATER, V6, P786, DOI 10.1016/j.actbio.2009.09.017
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Chen B, 2016, MATER LETT, V170, P93, DOI 10.1016/j.matlet.2016.02.006
   Chen YC, 2010, TOXICOL APPL PHARM, V245, P272, DOI 10.1016/j.taap.2010.03.011
   Cheng K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5880
   Dzamukova MR, 2015, NANO RES, V8, P2515, DOI 10.1007/s12274 015 0759 1
   Eddy SR, 2001, NAT REV GENET, V2, P919, DOI 10.1038/35103511
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Guilak F, 2009, CELL STEM CELL, V5, P17, DOI 10.1016/j.stem.2009.06.016
   Henstock JR, 2014, STEM CELL TRANSL MED, V3, P1363, DOI 10.5966/sctm.2014 0017
   Heymer A, 2008, BIOMATERIALS, V29, P1473, DOI 10.1016/j.biomaterials.2007.12.003
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jaiswal RK, 2000, J BIOL CHEM, V275, P9645, DOI 10.1074/jbc.275.13.9645
   Kanchanawong P, 2010, NATURE, V468, P580, DOI 10.1038/nature09621
   Kirschvink JL, 2001, CURR OPIN NEUROBIOL, V11, P462, DOI 10.1016/S0959 4388(00)00235 X
   Klapperich CM, 2004, BIOMATERIALS, V25, P5631, DOI 10.1016/j.biomaterials.2004.01.025
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Lin XB, 2014, NANO RES, V7, P1195, DOI 10.1007/s12274 014 0482 3
   Liu D, 2016, THERANOSTICS, V6, P1306, DOI 10.7150/thno.14858
   Ma M, 2015, NANO RES, V8, P600, DOI 10.1007/s12274 015 0729 7
   Mahmoudi M, 2011, ACS NANO, V5, P7263, DOI 10.1021/nn2021088
   Marie PJ, 2013, NAT REV ENDOCRINOL, V9, P288, DOI 10.1038/nrendo.2013.4
   MARIE PJ, 1989, IN VITRO CELL DEV B, V25, P373
   Meng J, 2013, SCI REP UK, V3, DOI 10.1038/srep02655
   Nair AV, 2015, ACS NANO, V9, P3641, DOI 10.1021/acsnano.5b00428
   Nikukar H, 2013, ACS NANO, V7, P2758, DOI 10.1021/nn400202j
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Pan YM, 2015, ACS NANO, V9, P6826, DOI 10.1021/nn506782f
   POCKWINSE SM, 1992, J CELL BIOCHEM, V49, P310, DOI 10.1002/jcb.240490315
   Postigo AA, 2003, EMBO J, V22, P2453, DOI 10.1093/emboj/cdg226
   Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   ROBEY PG, 1993, J BONE MINER RES, V8, pS483
   Stanley SA, 2015, NAT MED, V21, P92, DOI 10.1038/nm.3730
   Sun JF, 2014, SCI REP UK, V4, DOI 10.1038/srep05125
   Sun M, 2015, SCI CHINA MATER, V58, P683, DOI 10.1007/s40843 015 0082 x
   Tian F, 2014, BIOMATERIALS, V35, P6412, DOI 10.1016/j.biomaterials.2014.04.052
   van Grunsven LA, 2001, J BONE JOINT SURG AM, V83A, pS40
   Verschueren K, 1999, J BIOL CHEM, V274, P20489, DOI 10.1074/jbc.274.29.20489
   Wang FF, 2016, NANO RES, V9, P1193, DOI 10.1007/s12274 016 1015 z
   Wang N, 2009, NAT REV MOL CELL BIO, V10, P75, DOI 10.1038/nrm2594
   Wang QW, 2016, BIOMATERIALS, V86, P11, DOI 10.1016/j.biomaterials.2016.02.004
   Weightman AP, 2016, NANO RES, V9, P2384, DOI 10.1007/s12274 016 1125 7
   Williams DF, 2008, BIOMATERIALS, V29, P2941, DOI 10.1016/j.biomaterials.2008.04.023
   Winklhofer M, 2010, J R SOC INTERFACE, V7, pS273, DOI 10.1098/rsif.2009.0435.focus
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Yang F, 2015, SCI CHINA MATER, V58, P467, DOI 10.1007/s40843 015 0059 9
   Yang ZZ, 2016, NANO RES, V9, P787, DOI 10.1007/s12274 015 0958 9
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   YOUNG MF, 1992, CLIN ORTHOP RELAT R, P275
   Yun HM, 2016, BIOMATERIALS, V85, P88, DOI 10.1016/j.biomaterials.2016.01.035
   Zahanich I, 2005, J BONE MINER RES, V20, P1637, DOI 10.1359/JBMR.050521
   Zhang S, 2015, NANO RES, V8, P3250, DOI 10.1007/s12274 015 0825 8
NR 61
TC 78
Z9 82
U1 0
U2 96
PU TSINGHUA UNIV PRESS
PI BEIJING
PA TSINGHUA UNIV, RM A703, XUEYAN BLDG, BEIJING, 100084, PEOPLES R CHINA
SN 1998 0124
EI 1998 0000
J9 NANO RES
JI Nano Res.
PD FEB
PY 2017
VL 10
IS 2
BP 626
EP 642
DI 10.1007/s12274 016 1322 4
PG 17
WC Chemistry, Physical; Nanoscience & Nanotechnology; Materials Science,
   Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA EL0OS
UT WOS:000394322300023
DA 2025 08 17
ER

PT J
AU Han, DY
   Zhang, PX
   Jiang, BG
AF Han, Duanyang
   Zhang, Peixun
   Jiang, Baoguo
TI Local administration of IKK small molecule inhibitor may enhance
   fracture healing in osteoporosis patient
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE IKK inhibitor; osteoporosis; fracture healing; NF kappa B signaling
ID FACTOR KAPPA B; MESENCHYMAL STEM CELLS; BONE MARROW; OSTEOGENIC
   DIFFERENTIATION; ESTROGEN DEFICIENCY; IMMUNE SYSTEM; OLDER WOMEN; RATS;
   AGE; DENSITY
AB Osteoporosis is an inflammatory bone disease affecting millions of population worldwide, which often cause increased fracture risks and prolonged fracture healing. Growing evidence suggests that IKK NF kappa B signaling exert inhibitory influence on MSCs osteogenic differentiation and bone formation. Moreover, enhance the fracture healing process in osteoporosis patient. In the current work, IKK NF kappa B differentiated osteoblasts. Thus, manipulating local inflammatory IKK NF kappa B signaling was also found to suppress the anabolic effect of signaling in osteoporotic related fracture emerge as a promising therapy to we hypothesized to use locally delivered IKK small molecule inhibitor to augment the impaired fracture healing ability in osteoporosis patient via enhancing both MSCs osteogenic differentiation and osteoblast function.
C1 [Han, Duanyang; Zhang, Peixun; Jiang, Baoguo] Peking Univ, Peoples Hosp, Dept Orthoped & Trauma, Beijing, Peoples R China.
C3 Peking University
RP Zhang, PX (通讯作者)，Peking Univ, Peoples Hosp, Dept Orthoped & Trauma, Beijing, Peoples R China.
EM zhangpeixun@bjmu.edu.cn
OI Jiang, Baoguo/0000 0001 8436 5266
FU Chinese National Ministry of Science and Technology 973 Project Planning
   [2014CB542200]; ministry of education innovation team [IRT1201];
   Na tional Natural Science Fund [31271284, 31171150, 81171146, 31471144,
   3097 1526, 31100860, 31040043, 31371210, 81372044]; Educational Ministry
   New Century Excellent Talents Support Project [BMU20110270]; Beijing
   Natural Science Foundation [7142164]
FX This work was funded by Chinese National Ministry of Science and
   Technology 973 Project Planning (No. 2014CB542200); The ministry of
   education innovation team (IRT1201); the Na tional Natural Science Fund
   (No. 31271284, 31171150, 81171146, 31471144, 3097 1526, 31100860,
   31040043, 31371210, 81372044), and the Educational Ministry New Century
   Excellent Talents Support Project (No. BMU20110270) and The Beijing
   Natural Science Foundation (7142164).
CR Acharyya S, 2007, J CLIN INVEST, V117, P889, DOI 10.1172/JCI30556
   Allison DF, 2010, MOL CELL, V37, P453, DOI 10.1016/j.molcel.2010.02.004
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   Augat P, 2005, OSTEOPOROSIS INT, V16, pS36, DOI 10.1007/s00198 004 1728 9
   BENAYAHU D, 1992, CALCIFIED TISSUE INT, V51, P195, DOI 10.1007/BF00334547
   BERESFORD JN, 1992, J CELL SCI, V102, P341
   Bergman RJ, 1996, J BONE MINER RES, V11, P568
   BLACK DM, 1992, J BONE MINER RES, V7, P633
   Boivin GY, 2000, BONE, V27, P687, DOI 10.1016/S8756 3282(00)00376 8
   Boskey AL, 2005, OSTEOPOROSIS INT, V16, P2031, DOI 10.1007/s00198 005 1992 3
   Boyce BF, 2010, ANN NY ACAD SCI, V1192, P367, DOI 10.1111/j.1749 6632.2009.05315.x
   BURKHARDT R, 1987, BONE, V8, P157, DOI 10.1016/8756 3282(87)90015 9
   Center JR, 1999, LANCET, V353, P878, DOI 10.1016/S0140 6736(98)09075 8
   Chang J, 2013, P NATL ACAD SCI USA, V110, P9469, DOI 10.1073/pnas.1300532110
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140 6736(93)92555 8
   D'Ippolito G, 1999, J BONE MINER RES, V14, P1115, DOI 10.1359/jbmr.1999.14.7.1115
   FRIEDENSTEIN AJ, 1992, BONE MINER, V18, P199, DOI 10.1016/0169 6009(92)90807 P
   Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092 8674(02)00703 1
   Gilbert L, 2002, J BIOL CHEM, V277, P2695, DOI 10.1074/jbc.M106339200
   Goetz CA, 2008, IMMUNOL RES, V41, P233, DOI 10.1007/s12026 008 8033 1
   Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003 4819 152 6 201003160 00008
   Jimi E, 2005, IMMUNOL REV, V208, P80, DOI 10.1111/j.0105 2896.2005.00329.x
   Krum SA, 2010, NAT REV RHEUMATOL, V6, P607, DOI 10.1038/nrrheum.2010.133
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   LI XH, 1994, J PROSTHET DENT, V72, P324, DOI 10.1016/0022 3913(94)90348 4
   Looker AC, 1997, J BONE MINER RES, V12, P1761, DOI 10.1359/jbmr.1997.12.11.1761
   MANOLAGAS SC, 1995, NEW ENGL J MED, V332, P305, DOI 10.1056/NEJM199502023320506
   McLean Robert R, 2009, Curr Osteoporos Rep, V7, P134
   MELTON LJ, 1993, J BONE MINER RES, V8, P1227
   Meunier P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086 197110000 00021
   Meyer RA, 2001, J ORTHOP RES, V19, P428, DOI 10.1016/S0736 0266(00)90034 2
   Namkung Matthai H, 2001, BONE, V28, P80, DOI 10.1016/S8756 3282(00)00414 2
   Novack DV, 2011, CELL RES, V21, P169, DOI 10.1038/cr.2010.159
   Qiao Lin, 2005, Sichuan Da Xue Xue Bao Yi Xue Ban, V36, P108
   Reikerås O, 2005, ACTA ORTHOP, V76, P749, DOI 10.1080/17453670510045327
   Rodríguez JP, 1999, J CELL BIOCHEM, V75, P414, DOI 10.1002/(SICI)1097 4644(19991201)75:3<414::AID JCB7>3.3.CO;2 3
   ROHOLL PJM, 1994, J BONE MINER RES, V9, P355
   van den Berg WB, 2009, NAT REV RHEUMATOL, V5, P549, DOI 10.1038/nrrheum.2009.179
   Wang Jian wei, 2005, Chin J Traumatol, V8, P111
   Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550
   Weitzmann MN, 2002, J CLIN INVEST, V110, P1643, DOI 10.1172/JCI200215687
   WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
NR 44
TC 2
Z9 2
U1 0
U2 1
PU E CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940 5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2015
VL 8
IS 1
BP 1411
EP 1415
PG 5
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA CB8RA
UT WOS:000349897200180
PM 25785147
DA 2025 08 17
ER

PT J
AU Zhu, YM
   Wu, YP
   Cheng, J
   Wang, Q
   Li, ZW
   Wang, YL
   Wang, DM
   Wang, H
   Zhang, WB
   Ye, JH
   Jiang, HB
   Wang, L
AF Zhu, Yumin
   Wu, Yaping
   Cheng, Jie
   Wang, Qiong
   Li, Zhongwu
   Wang, Yanling
   Wang, Dongmiao
   Wang, Hua
   Zhang, Weibing
   Ye, Jinhai
   Jiang, Hongbing
   Wang, Lin
TI Pharmacological activation of TAZ enhances osteogenic differentiation
   and bone formation of adipose derived stem cells
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Adipose derived stem cells (ADSCs); Hippo; TAZ; Osteogenesis; Bone
   regeneration
ID STIMULATES OSTEOBLAST DIFFERENTIATION; SELF RENEWAL; TRANSCRIPTIONAL
   COACTIVATOR; HIPPO PATHWAY; TISSUE; MODULATOR; TM 25659; RUNX2; FATE;
   THERAPEUTICS
AB Background: Adipose derived stem cells (ADSCs) are an attractive cell source for bone tissue engineering and have great potential for bone regeneration and defect repair. The transcriptional coactivator with PDZ binding motif (TAZ) has been demonstrated to modulate osteogenic and adipogenic differentiation of mesenchymal stem cells. However, its roles during ADSC differentiation and therapeutic potentials for bone regeneration have as yet not been well established.
   Methods: TAZ expression was measured during osteogenic differentiation of ADSCs in vitro. Both loss of function and gain of function approaches by TAZ knockdown or enforced overexpression were utilized to determine its functions during osteogenic differentiation of ADSCs. TM 25659, a chemical activator of TAZ, was used to determine whether pharmacological activation of TAZ in ADSCs enhanced osteogenic differentiation in vitro and bone formation in animal models. The molecular mechanisms underlying TAZ in promoting osteogenesis of ADSCs were also explored.
   Results: Increased TAZ expression was observed during osteogenic differentiation of human ADSCs. TAZ knockdown resulted in compromised osteogenic differentiation and enhanced adipogenic differentiation of ADSCs. In contrast, enforced TAZ overexpression yielded increased osteogenic differentiation and bone regeneration in vivo, and impaired adipogenic differentiation of ADSCs. Pharmacological activation of TAZ by its chemical activator TM 25659 facilitated osteogenic differentiation of ADSCs. Noticeably, transient treatment of ADSCs with TM 25659 or intraperitoneal injection of TM 25659 significantly enhanced bone regeneration of ADSCs loaded with porous beta TCP in vivo. Mechanistically, TM 25659 exposure significantly promoted TAZ phosphorylation and nuclear translocation, and potentiated the assembly of the TAZ Runx2 complex. Subsequently, the TAZ Runx2 complex was further recruited to the promoter of osteocalcin and in turn enhanced its transcription.
   Conclusions: Our findings indicate that TAZ is a key mediator that promotes ADSC commitment to the osteoblast lineage. Pharmacological activation of TAZ in ADSCs might become a feasible and promising approach to enhance bone regeneration and repair.
C1 [Zhu, Yumin; Wu, Yaping; Cheng, Jie; Wang, Qiong; Wang, Yanling; Wang, Lin] Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.
   [Li, Zhongwu; Wang, Dongmiao; Ye, Jinhai; Jiang, Hongbing] Nanjing Med Univ, Sch Stomatol, Dept Oral & Maxillofacial Surg, Nanjing 210029, Jiangsu, Peoples R China.
   [Wang, Hua; Zhang, Weibing; Wang, Lin] Nanjing Med Univ, Sch Stomatol, Dept Oral Orthodont, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Wang, L (通讯作者)，Nanjing Med Univ, Jiangsu Key Lab Oral Dis, Nanjing 210029, Jiangsu, Peoples R China.; Wang, L (通讯作者)，Nanjing Med Univ, Sch Stomatol, Dept Oral Orthodont, Nanjing 210029, Jiangsu, Peoples R China.
EM lw603@njmu.edu.cn
RI Zhu, Yumin/HNR 7046 2023; Wu, Yaping/AAF 8783 2021; Zhang,
   Wei Bing/P 3607 2019; Wang, Hua/MHP 9513 2025; Jiang,
   Hongbing/I 3016 2017
OI Jiang, Hongbing/0000 0002 3748 0381; 
FU National Natural Science Foundation of China [81572669, 81602378,
   8170040997]; Natural Science Foundation of Jiangsu Province [BK20161024,
   BK20161564]; China Postdoctoral Science Foundation [2014 M560436];
   Jiangsu Postdoctoral Science Foundation [1402162C]; Priority Academic
   Program Development of Jiangsu Higher Education Institutions [2014 37];
   Qing Lan Project; Jiangsu Provincial Medical Talent [QNRC2016851];
   Jiangsu Provincial Medical Innovation Team [CXTDA2017036]
FX This work is financially supported by the National Natural Science
   Foundation of China (81572669, 81602378, and 8170040997), the Natural
   Science Foundation of Jiangsu Province (BK20161024 and BK20161564), the
   China Postdoctoral Science Foundation (2014 M560436), the Jiangsu
   Postdoctoral Science Foundation (1402162C), A Project Funded by the
   Priority Academic Program Development of Jiangsu Higher Education
   Institutions (2014 37), the Qing Lan Project, the Jiangsu Provincial
   Medical Talent (QNRC2016851), and the Jiangsu Provincial Medical
   Innovation Team (CXTDA2017036).
CR Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027
   Bhumiratana S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5904
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Byun MR, 2014, CELL DEATH DIFFER, V21, P854, DOI 10.1038/cdd.2014.8
   Byun MR, 2014, J BIOL CHEM, V289, P9926, DOI 10.1074/jbc.M113.522870
   Byun MR, 2014, BONE, V58, P72, DOI 10.1016/j.bone.2013.09.024
   Byun MR, 2012, FEBS LETT, V586, P1086, DOI 10.1016/j.febslet.2012.03.008
   Chen Q, 2016, CELL DEATH DIFFER, V23, P1128, DOI 10.1038/cdd.2015.168
   Choi MK, 2014, BIOPHARM DRUG DISPOS, V35, P183, DOI 10.1002/bdd.1883
   Choi SH, 2012, J PHARMACEUT BIOMED, V63, P47, DOI 10.1016/j.jpba.2012.01.036
   Cui CB, 2003, MOL CELL BIOL, V23, P1004, DOI 10.1128/MCB.23.3.1004 1013.2003
   Daley GQ, 2012, CELL STEM CELL, V10, P740, DOI 10.1016/j.stem.2012.05.010
   Dong WJ, 2015, J CELL PHYSIOL, V230, P680, DOI 10.1002/jcp.24792
   Gao P, 2016, SCI REP UK, V6, DOI 10.1038/srep23367
   Grottkau BE, 2013, BONE RES, V1, DOI 10.4248/BR201302003
   Hong D, 2009, J STEROID BIOCHEM, V116, P86, DOI 10.1016/j.jsbmb.2009.05.007
   Hong JH, 2005, SCIENCE, V309, P1074, DOI 10.1126/science.1110955
   Inagaki T, 2016, NAT REV MOL CELL BIO, V17, P480, DOI 10.1038/nrm.2016.62
   Jang EJ, 2012, BRIT J PHARMACOL, V165, P1584, DOI 10.1111/j.1476 5381.2011.01664.x
   Jung JG, 2015, MOL CELLS, V38, P1037, DOI 10.14348/molcells.2015.0100
   Katz AJ, 2005, STEM CELLS, V23, P412, DOI 10.1634/stemcells.2004 0021
   Kawano S, 2015, J BIOCHEM, V158, P413, DOI 10.1093/jb/mvv051
   Levi B, 2011, STEM CELLS, V29, P576, DOI 10.1002/stem.612
   Li ZW, 2015, MOL ONCOL, V9, P1091, DOI 10.1016/j.molonc.2015.01.007
   Ling LE, 2015, J BIOMED MATER RES A, V103, P1732, DOI 10.1002/jbm.a.35303
   Liu K, 2016, CELL CHEM BIOL, V23, P893, DOI 10.1016/j.chembiol.2016.07.007
   Locke M, 2011, STEM CELLS, V29, P404, DOI 10.1002/stem.593
   Matsumoto Y, 2016, J CLIN INVEST, V126, P4482, DOI 10.1172/JCI87802
   Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115
   Reichert JC, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003720
   Rodriguez AM, 2005, BIOCHIMIE, V87, P125, DOI 10.1016/j.biochi.2004.11.007
   Tang Y, 2017, CELL CYCLE, V16, P399, DOI 10.1080/15384101.2017.1280643
   Tang Y, 2016, NAT CELL BIOL, V18, P917, DOI 10.1038/ncb3394
   Varelas X, 2008, NAT CELL BIOL, V10, P837, DOI 10.1038/ncb1748
   Wang J, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aad3210
   Xia LG, 2014, BIOMATERIALS, V35, P8514, DOI 10.1016/j.biomaterials.2014.06.028
   Xie Q, 2016, BIOMATERIALS, V75, P279, DOI 10.1016/j.biomaterials.2015.10.042
   Xu WL, 2017, TISSUE ENG PT A, V23, P445, DOI [10.1089/ten.tea.2016.0315, 10.1089/ten.TEA.2016.0315]
   Yang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056585
   Yang ZY, 2014, MOL CELL BIOL, V34, P1607, DOI 10.1128/MCB.01346 13
   Ye YP, 2017, BIOMED PHARMACOTHER, V88, P384, DOI 10.1016/j.biopha.2017.01.075
   Zhang WB, 2014, BONE, V58, P59, DOI 10.1016/j.bone.2013.09.015
   Zhang Y, 2016, CELL PHYSIOL BIOCHEM, V38, P283, DOI 10.1159/000438629
   Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02 02 0105
NR 45
TC 50
Z9 60
U1 0
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757 6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD MAR 7
PY 2018
VL 9
AR 53
DI 10.1186/s13287 018 0799 z
PG 16
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA FZ0ME
UT WOS:000427263000001
PM 29514703
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Gyurkovska, V
   Stefanova, T
   Dimitrova, P
   Danova, S
   Tropcheva, R
   Ivanovska, N
AF Gyurkovska, Valeriya
   Stefanova, Tsvetanka
   Dimitrova, Petya
   Danova, Svetla
   Tropcheva, Rositsa
   Ivanovska, Nina
TI Tyrosine Kinase Inhibitor Tyrphostin AG490 Retards Chronic Joint
   Inflammation in Mice
SO INFLAMMATION
LA English
DT Article
DE collagenase induced osteoarthritis (CIOA); osteoclasts; tyrphostin
   AG490; STAT3; TRAIL
ID RHEUMATOID ARTHRITIS; OSTEOCLAST DIFFERENTIATION; BONE RESORPTION;
   LIGAND TRAIL; IN VITRO; RECEPTOR; APOPTOSIS; OSTEOARTHRITIS; CYTOKINE;
   BLOCKING
AB Tyrphostin AG490 is a Janus kinase (JAK) 2 inhibitor that is clinically used as an anticancer agent and is also effective in various models of inflammatory and autoimmune diseases. In this study, we examined the effects of tyrphostin AG490 on the development of collagenase induced osteoarthritis (CIOA). Our results showed that tyrphostin ameliorated cartilage and bone destructions. This effect was associated with decreased expression of signal transducers and activators of transcription 3 (STAT3), phosphorylated JAK2, Dickkopf homolog 1, and receptor activator of nuclear factor kappa B ligand (RANKL) in the joints of arthritic mice. Tyrphostin AG490 suppressed STAT3 phosphorylation and the expression of tumor necrosis factor related apoptosis inducing ligand and RANKL by synovial fluid cells. The drug inhibited RANKL induced osteoclast differentiation in vitro. Molecules, such as tyrphostin AG490 that limit bone erosion and influence osteoclast generation, might have therapeutic utility in joint degenerative disorders.
C1 [Gyurkovska, Valeriya; Stefanova, Tsvetanka; Dimitrova, Petya; Ivanovska, Nina] Bulgarian Acad Sci, Inst Microbiol, Dept Immunol, BU 1113 Sofia, Bulgaria.
   [Danova, Svetla; Tropcheva, Rositsa] Bulgarian Acad Sci, Inst Microbiol, Sect Microbial Genet, BU 1113 Sofia, Bulgaria.
C3 Bulgarian Academy of Sciences; Medical University Sofia; Medical
   University Sofia; Bulgarian Academy of Sciences
RP Ivanovska, N (通讯作者)，Bulgarian Acad Sci, Inst Microbiol, Dept Immunol, BU 1113 Sofia, Bulgaria.
EM nina@microbio.bas.bg
RI ; Dimitrova, Petya/AFW 8031 2022; Danova, Svetla/ABH 7890 2020;
   Tropcheva, Rositsa/AAO 4041 2021
OI Ivanovska, Nina/0000 0002 9878 8208; Dimitrova,
   Albena/0009 0000 6124 607X; Dimitrova, Petya/0000 0003 0920 3712;
   Tropcheva, Rositsa/0000 0001 5408 9002; gyurkovska,
   valeriya/0000 0001 6564 0066
FU National Science Fund, Ministry of Education and Science, Republic of
   Bulgaria [DFNI B01/6]
FX This work was supported by a Grant DFNI B01/6 from the National Science
   Fund, Ministry of Education and Science, Republic of Bulgaria.
CR Blom AB, 2004, OSTEOARTHR CARTILAGE, V12, P627, DOI 10.1016/j.joca.2004.03.003
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Bright JJ, 1999, J IMMUNOL, V162, P6255
   Catrina AI, 2002, ANN RHEUM DIS, V61, P934, DOI 10.1136/ard.61.10.934
   Choy EHS, 2002, ARTHRITIS RHEUM US, V46, P3143, DOI 10.1002/art.10623
   Constantin G, 1998, EUR J IMMUNOL, V28, P3523, DOI 10.1002/(SICI)1521 4141(199811)28:11<3523::AID IMMU3523>3.0.CO;2 X
   Cutolo M, 2013, THER ADV MUSCULOSKEL, V5, P3, DOI 10.1177/1759720X12470753
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Davoodi Semiromi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036079
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dimitrova P, 2008, INT IMMUNOPHARMACOL, V8, P1567, DOI 10.1016/j.intimp.2008.06.013
   Dimitrova P, 2009, J INFLAMM LOND, V6, DOI 10.1186/1476 9255 6 13
   Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365 2567.2009.03058.x
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Goldring SR, 2004, CLIN ORTHOP RELAT R, pS27, DOI 10.1097/01.blo.0000144854.66565.8f
   Heim MH, 1999, J RECEPT SIGNAL TR R, V19, P75, DOI 10.3109/10799899909036638
   Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540
   IGARASHI K, 1994, J BIOL CHEM, V269, P14333
   Ivanovska N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3283
   Jüngel A, 2010, ANN RHEUM DIS, V69, P898, DOI 10.1136/ard.2008.106021
   Koenders MI, 2005, AM J PATHOL, V167, P141, DOI 10.1016/S0002 9440(10)62961 6
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lamhamedi Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894
   Levitzki A, 2006, ANNU REV BIOCHEM, V75, P93, DOI 10.1146/annurev.biochem.75.103004.142657
   Liu H, 2007, SHOCK, V27, P55, DOI 10.1097/01.shk.0000233197.40989.31
   Livshits G, 2009, ARTHRITIS RHEUM US, V60, P2037, DOI 10.1002/art.24598
   Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0
   Miranda Carús ME, 2004, ARTHRITIS RHEUM US, V50, P2786, DOI 10.1002/art.20501
   Morvan F, 2006, J BONE MINER RES, V21, P934, DOI 10.1359/JBMR.060311
   Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151
   Pelletier JP, 2001, ARTHRITIS RHEUM US, V44, P1237, DOI 10.1002/1529 0131(200106)44:6<1237::AID ART214>3.0.CO;2 F
   Peña G, 2010, J MOL MED, V88, P851, DOI 10.1007/s00109 010 0628 z
   Sareila O, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/16161
   Shouda T, 2001, J CLIN INVEST, V108, P1781, DOI 10.1172/JCI13568
   Song KM, 2000, J EXP MED, V191, P1095, DOI 10.1084/jem.191.7.1095
   Takahashi Naoyuki, 2007, V135, P285
   van Bezooijen RL, 2002, ANN RHEUM DIS, V61, P870, DOI 10.1136/ard.61.10.870
   Weir EC, 1996, J BONE MINER RES, V11, P1474
   Wittrant Y, 2004, EXP CELL RES, V293, P292, DOI 10.1016/j.yexcr.2003.10.016
   Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012
   Yoshizaki K, 1998, SPRINGER SEMIN IMMUN, V20, P247, DOI 10.1007/BF00832010
NR 42
TC 17
Z9 20
U1 0
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360 3997
EI 1573 2576
J9 INFLAMMATION
JI Inflammation
PD AUG
PY 2014
VL 37
IS 4
BP 995
EP 1005
DI 10.1007/s10753 014 9820 6
PG 11
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Immunology
GA AK9CR
UT WOS:000338725600001
PM 24473905
DA 2025 08 17
ER

PT J
AU Bighetti Trevisan, RL
   Bueno, NP
   Souza, ATP
   Marques, MM
   Rosa, AL
   Beloti, MM
   Ferraz, EP
AF Bighetti Trevisan, Rayana L. L.
   Bueno, Natalia P.
   Souza, Alann T. P.
   Marques, Marcia M.
   Rosa, Adalberto L. L.
   Beloti, Marcio M. M.
   Ferraz, Emanuela P. P.
TI Disruption of TNF α signaling improves osteoblastic differentiation of
   adipose derived mesenchymal stem cells and bone repair
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE adipose tissue; bone; mesenchymal stem cells; osteoblasts; tumor
   necrosis factor alpha
ID KAPPA B ACTIVATION; OSTEOGENIC DIFFERENTIATION; NECROSIS; TISSUE;
   MECHANISMS; MARROW
AB Adipose tissue is an attractive source of mesenchymal stem cells (at MSCs), but their low osteogenic potential limits their use in bone regeneration. Adipose tissue plays a role in pro inflammatory diseases by releasing cytokines with a catabolic effect on bone, such as tumor necrosis factor alpha (TNF alpha). Thus, we hypothesized that endogenous TNF alpha could have a negative effect on at MSC differentiation into osteoblasts. Short interfering RNAs (siRNAs) targeting TNF alpha receptors (siR1, siR2, and si1R/R2) were transfected into at MSCs, and cell differentiation was assessed by measuring the expression of bone markers, ALP activity, and mineralized matrix. Scrambled was used as Control. Knockout at MSCs (KOR1/R2) was injected in mice calvaria defects, and bone formation was evaluated by microtomography and histological analysis. Data were compared by Kruskal Wallis or analysis of variance (5%). The expression of bone markers confirmed that at MSCs differentiate less than bone marrow MSCs. In silenced cells, the expression of Alp, Runx2, and Opn was generally higher compared to Control. ALP, RUNX2, and OPN were expressed at elevated levels in silenced groups, most notably at MSCs siR1/R2. ALP was detected at high levels in at MSCs siR1/R2 and in MSCs siR1, followed by an increase in mineralized nodules in at MSCs siR1/R2. As the morphometric parameters increased, the groups treated with KOR1/R2 exhibited slight bone formation near the edges of the defects. Endogenous TNF alpha inhibits osteoblast differentiation and activity in at MSCs, and its disruption increases bone formation. While opening a path of investigation, that may lead to the development of new treatments for bone regeneration using at MSC based therapies.
C1 [Bighetti Trevisan, Rayana L. L.; Souza, Alann T. P.; Rosa, Adalberto L. L.; Beloti, Marcio M. M.; Ferraz, Emanuela P. P.] Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
   [Bueno, Natalia P.; Ferraz, Emanuela P. P.] Univ Sao Paulo, Sch Dent, Sao Paulo, SP, Brazil.
   [Marques, Marcia M.] Sigmund Freud Univ, Aachen Dent Laser Ctr, Austria Campus Prater, Vienna, Austria.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Ferraz, EP (通讯作者)，Univ Sao Paulo, Sch Dent Ribeirao Preto, Bone Res Lab, Av Cafe S N, BR 14040904 Ribeirao Preto, SP, Brazil.
EM emanuelaferraz@usp.br
RI Rosa, Adalberto/A 6314 2008; Rosa, Adalberto Luiz/A 6314 2008; Souza,
   Alann/E 4194 2018; Bueno, Natalia/L 4858 2018; Trevisan,
   Rayana/L 9482 2017; Ferraz, Emanuela/J 9441 2012
OI Rosa, Adalberto Luiz/0000 0002 6495 2778; 
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
FX Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
CR Abuna RPF, 2016, J CELL PHYSIOL, V231, P204, DOI 10.1002/jcp.25073
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Chan JK, 2015, EMBO MOL MED, V7, P547, DOI 10.15252/emmm.201404487
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Cho HH, 2010, J CELL PHYSIOL, V223, P168, DOI 10.1002/jcp.22024
   Chong ZX, 2021, PEERJ, V9, DOI 10.7717/peerj.11165
   Freitas GP, 2020, BIO PROTOCOL, V10, DOI 10.21769/BioProtoc.3534
   Freitas GP, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 50067 6
   Glass GE, 2011, P NATL ACAD SCI USA, V108, P1585, DOI 10.1073/pnas.1018501108
   Gregoire C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00619
   Gregory CA, 2004, ANAL BIOCHEM, V329, P77, DOI 10.1016/j.ab.2004.02.002
   Hess K, 2009, BONE, V45, P367, DOI 10.1016/j.bone.2009.04.252
   Horiuchi T, 2010, RHEUMATOLOGY, V49, P1215, DOI 10.1093/rheumatology/keq031
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Killington K, 2018, CURR STEM CELL RES T, V13, P284, DOI 10.2174/1574888X12666170915121137
   Lata M, 2019, ANN NY ACAD SCI, V1442, P5, DOI 10.1111/nyas.13933
   Li CY, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0066 5
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092 8674(01)00237 9
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Merryweather Clarke AT, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 1095 7
   Nanes MS, 2003, GENE, V321, P1, DOI 10.1016/S0378 1119(03)00841 2
   Naudé PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742 4658.2011.08017.x
   Nauth A, 2018, J ORTHOP TRAUMA, V32, pS7, DOI 10.1097/BOT.0000000000001115
   Pachón Peña G, 2011, J CELL PHYSIOL, V226, P843, DOI 10.1002/jcp.22408
   Probert L, 2015, NEUROSCIENCE, V302, P2, DOI 10.1016/j.neuroscience.2015.06.038
   Safarova Y, 2020, REGEN MED, V15, P1579, DOI 10.2217/rme 2019 0081
   Salamon A, 2014, INT J BIOCHEM CELL B, V54, P149, DOI 10.1016/j.biocel.2014.07.014
   Sethi JK, 2021, NAT METAB, V3, P1302, DOI 10.1038/s42255 021 00470 z
   Sethi JK, 2000, FEBS LETT, V469, P77, DOI 10.1016/S0014 5793(00)01250 3
   Si ZZ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108765
   Strioga M, 2012, STEM CELLS DEV, V21, P2724, DOI 10.1089/scd.2011.0722
   Xu LL, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0716 x
   Zhang EH, 2022, COMPUT METH PROG BIO, V213, DOI 10.1016/j.cmpb.2021.106536
   Zuo CJ, 2018, ONCOTARGET, V9, P4833, DOI 10.18632/oncotarget.23373
NR 35
TC 3
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0006 3592
EI 1097 0290
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD OCT
PY 2023
VL 120
IS 10
BP 3067
EP 3078
DI 10.1002/bit.28468
EA JUN 2023
PG 12
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology
GA W9FD4
UT WOS:001005845000001
PM 37317560
DA 2025 08 17
ER

PT J
AU Kuang, HZ
   Ma, J
   Chi, XY
   Fu, QC
   Zhu, QZ
   Cao, WL
   Zhang, P
   Xie, X
AF Kuang, Haizhu
   Ma, Jing
   Chi, Xinyu
   Fu, Qichen
   Zhu, Qianzhe
   Cao, Weiling
   Zhang, Peng
   Xie, Xin
TI Integrated Osteoinductive Factors Exosome@MicroRNA 26a Hydrogel Enhances
   Bone Regeneration
SO ACS APPLIED MATERIALS & INTERFACES
LA English
DT Article
DE miRNA therapeutics; microRNA 26a; exosome; hydrogel; bone regeneration;
   tissue engineering
ID MESENCHYMAL STEM CELLS; CHITOSAN BASED HYDROGELS; INTRAMEMBRANOUS
   OSSIFICATION; DIFFERENTIATION; OSTEOCLAST; EXPRESSION; STRATEGIES;
   FRACTURES; DELIVERY; MIR 26A
AB MicroRNAs (miRNAs) are a new therapeutic tool that can target multiple genes by inducing translation repression and target mRNA degradation. Although miRNAs have gained significant attention in oncology and in work on genetic disorders and autoimmune diseases, their application in tissue regeneration remains hindered by several challenges, such as miRNA degradation. Here, we reported Exosome@MicroRNA 26a (Exo@miR 26a), an osteoinductive factor that can be substituted for routinely used growth factors, which was constructed using bone marrow stem cell (BMSC) derived exosomes and microRNA 26a (miR 26a). Exo@miR 26a integrated hydrogels significantly promoted bone regeneration when implanted into defect sites; as the exosome stimulated angiogenesis, miR 26a promoted osteogenesis while the hydrogel enabled a site directed release. Moreover, BMSC derived exosomes further facilitated healthy bone regeneration by repressing osteoclast differentiationrelated genes rather than damaging osteoclasts. Taken together, our findings demonstrate the promising potential of Exo@miR 26a for bone regeneration and provide a new strategy for the application of miRNA therapy in tissue engineering.
C1 [Kuang, Haizhu; Xie, Xin] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped Surg, Hangzhou 310029, Zhejiang, Peoples R China.
   [Kuang, Haizhu; Chi, Xinyu; Fu, Qichen; Zhu, Qianzhe; Xie, Xin] Zhejiang Univ, Univ Edinburgh Inst, Sch Med, Haining 314400, Peoples R China.
   [Kuang, Haizhu; Cao, Weiling; Zhang, Peng] Shenzhen Univ, Affiliated Hosp 3, Affiliated Luohu Hosp, Dept Pharm, Shenzhen 518001, Peoples R China.
   [Xie, Xin] Zhejiang Univ, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cell & Rege, Hangzhou 310058, Peoples R China.
C3 Zhejiang University; Zhejiang University; Shenzhen University; Zhejiang
   University
RP Xie, X (通讯作者)，Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Orthoped Surg, Hangzhou 310029, Zhejiang, Peoples R China.; Xie, X (通讯作者)，Zhejiang Univ, Univ Edinburgh Inst, Sch Med, Haining 314400, Peoples R China.; Cao, WL; Zhang, P (通讯作者)，Shenzhen Univ, Affiliated Hosp 3, Affiliated Luohu Hosp, Dept Pharm, Shenzhen 518001, Peoples R China.; Xie, X (通讯作者)，Zhejiang Univ, Dr Li Dak Sum & Yip Yio Chin Ctr Stem Cell & Rege, Hangzhou 310058, Peoples R China.
EM 752557163@qq.com; pzhang898018@163.com; xinxie@intl.zju.edu.cn
RI Qianzhe, Zhu/KEH 4636 2024
FU Zhejiang Provincial Natural Science Foundation [LZ19H160001];
   Fundamental Research Funds for the Central Universities [2019QN30006];
   National Natural Science Foundation of China [82003251, 82102118];
   Shenzhen Excellent Scientific and Technological Innovation Talent
   Training Project [RCBS20210706092256079]; Sanming Project of Medicine in
   Shenzhen [SZSM201801060]
FX This work was supported by the Zhejiang Provincial Natural Science
   Foundation (grant no. LZ19H160001) , the Fundamental Research Funds for
   the Central Universities (grant no. 2019QN30006) , the National Natural
   Science Foundation of China (grant nos. 82003251 and 82102118) , the
   Shenzhen Excellent Scientific and Technological Innovation Talent
   Training Project (Doctoral Basic Research Launched,
   RCBS20210706092256079) , and the Sanming Project of Medicine in Shenzhen
   (SZSM201801060) .
CR Abrahamsen B, 2010, CALCIFIED TISSUE INT, V86, P421, DOI 10.1007/s00223 010 9364 1
   Almubarak S, 2016, BONE, V83, P197, DOI 10.1016/j.bone.2015.11.011
   Bannon M, 2011, QJM INT J MED, V104, P279, DOI 10.1093/qjmed/hcr047
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bhattarai N, 2010, ADV DRUG DELIVER REV, V62, P83, DOI 10.1016/j.addr.2009.07.019
   Blair HC, 2017, TISSUE ENG PART B RE, V23, P268, DOI [10.1089/ten.teb.2016.0454, 10.1089/ten.TEB.2016.0454]
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Capeci CM, 2009, J BONE JOINT SURG AM, V91A, P2556, DOI 10.2106/JBJS.H.01774
   Chalbatani GM, 2019, INT J NANOMED, V14, P3111, DOI 10.2147/IJN.S200253
   Charles JF, 2014, TRENDS MOL MED, V20, P449, DOI 10.1016/j.molmed.2014.06.001
   Chehade MJ, 2008, MED J AUSTRALIA, V189, P162, DOI 10.5694/j.1326 5377.2008.tb01952.x
   Cohen MM Jr, 2000, J CRAN GENET DEV BIO, V20, P84
   Crouzier T, 2011, ADV MATER, V23, pH111, DOI 10.1002/adma.201004637
   Dey BK, 2012, GENE DEV, V26, P2180, DOI 10.1101/gad.198085.112
   Ding SY, 2016, NAT REV MATER, V1, DOI [10.1038/natrevmats.2016.71, 10.1038/natrevmats.2016.21]
   Diomede F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093242
   Dreiss CA, 2020, CURR OPIN COLLOID IN, V48, P1, DOI 10.1016/j.cocis.2020.02.001
   Duan L, 2021, NANOSCALE, V13, DOI 10.1039/d0nr07622h
   Fan JB, 2020, ACS NANO, V14, P11973, DOI 10.1021/acsnano.0c05122
   Garimella R, 2008, J HISTOCHEM CYTOCHEM, V56, P569, DOI 10.1369/jhc.2008.950394
   Geiger M, 2003, ADV DRUG DELIVER REV, V55, P1613, DOI 10.1016/j.addr.2003.08.010
   Giusti A, 2011, BONE, V48, P966, DOI 10.1016/j.bone.2010.12.033
   Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568 020 00306 0
   GOTHLIN G, 1976, CLIN ORTHOP RELAT R, P201
   Gu ZY, 2019, AM J TRANSL RES, V11, P2603
   Hamedi H, 2018, CARBOHYD POLYM, V199, P445, DOI 10.1016/j.carbpol.2018.06.114
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Khademhosseini A, 2016, NAT PROTOC, V11, P1775, DOI 10.1038/nprot.2016.123
   Kim HKW, 2013, BONE, V54, P141, DOI 10.1016/j.bone.2013.01.031
   Kim SM, 2017, J CONTROL RELEASE, V266, P8, DOI 10.1016/j.jconrel.2017.09.013
   Koh JSB, 2011, SINGAP MED J, V52, P77
   Lagos Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Li XB, 2018, STEM CELL RES THER, V9, DOI 10.1186/s13287 018 0976 0
   Li XM, 2019, STEM CELLS DEV, V28, P791, DOI 10.1089/scd.2019.0044
   Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101
   Lu GD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.608521
   MALONE RW, 1989, P NATL ACAD SCI USA, V86, P6077, DOI 10.1073/pnas.86.16.6077
   Mao AS, 2015, P NATL ACAD SCI USA, V112, P14452, DOI 10.1073/pnas.1508520112
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Mei W, 2005, BIOCHEM BIOPH RES CO, V328, P651, DOI 10.1016/j.bbrc.2004.11.067
   Moshaverinia A, 2013, BIOMATERIALS, V34, P6572, DOI 10.1016/j.biomaterials.2013.05.048
   Oh CW, 2013, SCI WORLD J, DOI 10.1155/2013/450148
   Paunovska K, 2022, NAT REV GENET, V23, P265, DOI 10.1038/s41576 021 00439 4
   Plotkin LI, 2016, NAT REV ENDOCRINOL, V12, P593, DOI 10.1038/nrendo.2016.71
   Rodriguez Merchan EC, 2004, CLIN ORTHOP RELAT R, P4, DOI 10.1097/00003086 200402000 00003
   Schorey JS, 2008, TRAFFIC, V9, P871, DOI 10.1111/j.1600 0854.2008.00734.x
   Shin H, 2018, ADV THER GERMANY, V1, DOI 10.1002/adtp.201800065
   Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221
   Taraballi F, 2018, ADV HEALTHC MATER, V7, DOI 10.1002/adhm.201800490
   Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504
   Thompson Z, 2002, J ORTHOPAED RES, V20, P1091, DOI 10.1016/S0736 0266(02)00017 7
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Trompeter HI, 2013, BMC GENOMICS, V14, DOI 10.1186/1471 2164 14 111
   Van der Valk D. C., NANOMATERIALS BASEL
   van Griensven M, 2015, ADV DRUG DELIVER REV, V94, P151, DOI 10.1016/j.addr.2015.07.006
   Wu C. C., 2017, J CLIN ENDOCR METAB
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Zhang JW, 2005, DEV BIOL, V284, P1, DOI 10.1016/j.ydbio.2005.05.009
   Zhao X, 2016, ADV HEALTHC MATER, V5, P108, DOI 10.1002/adhm.201500005
   Zheng DK, 2019, BIOCHEM BIOPH RES CO, V511, P826, DOI 10.1016/j.bbrc.2019.02.109
   Zhu LX, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaw6143
NR 62
TC 27
Z9 28
U1 11
U2 119
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1944 8244
EI 1944 8252
J9 ACS APPL MATER INTER
JI ACS Appl. Mater. Interfaces
PD MAY 5
PY 2023
VL 15
IS 19
BP 22805
EP 22816
DI 10.1021/acsami.2c21933
EA MAY 2023
PG 12
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics; Materials Science
GA I8UJ0
UT WOS:000985629300001
PM 37145861
DA 2025 08 17
ER

PT J
AU El Mabhouh, AA
   Nation, PN
   Abele, JT
   Riauka, T
   Postema, E
   McEwan, AJB
   Mercer, JR
AF El Mabhouh, A. A.
   Nation, P. N.
   Abele, J. T.
   Riauka, T.
   Postema, E.
   McEwan, A. J. B.
   Mercer, J. R.
TI A Conjugate of Gemcitabine With Bisphosphonate (Gem/BP) Shows Potential
   as a Targeted Bone Specific Therapeutic Agent in an Animal Model of
   Human Breast Cancer Bone Metastases
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Bone metastases; MDA MB 231; Breast cancer; Gemcitabine; Bisphosphonate
ID IN VIVO; F 18 FLUORIDE; CHEMOTHERAPY; METAANALYSIS; BIOLOGY; CELLS; DRUG
AB Bone metastases in advanced breast cancer patients remains a significant treatment challenge. Bisphosphonates are now a routine first line treatment for prevention and treatment of skeletal damage caused by malignancies and, moreover, have shown an ability to transport therapeutic drugs to the bone. Here, we describe the effect of a conjugate between the potent anticancer drug gemcitabine and a bisphosphonate molecule (Gem/BP) in an animal model of breast cancer metastases. We have previously demonstrated the targeting of this compound to bone in normal mice using an analog labeled with the radionuclide (99m)Tc. Using a bone metastasis model in nude mice produced by intracardiac injection of the human breast cancer cell line MDA MB 23 IBO, we examined the effect of Gem/BP and gemcitabine in reducing the frequency and severity of osteolytic bone lesions. High resolution radiographs and microPET images showed that Gem/BP reduced the number and size of bone metastases relative to the gemcitabine treated and the untreated control groups. Histological examination of the humeri and femurs of the control and gemcitabine groups revealed large metastatic cancer lesions in the outer and inner cortices and the medullary cavities. In contrast, Gem/BP treated mice showed occasional small wedge shaped metastases under the periosteum of the outer cortex and very occasionally in the medulla. These findings suggest that Gem/BP should be further evaluated for use in the treatment of bone metastases in breast cancer.
C1 [Mercer, J. R.] Cross Canc Inst, Div Oncol Imaging, Dept Oncol, Fac Med & Dent, Edmonton, AB T6H 1P6, Canada.
C3 University of Alberta
RP Mercer, JR (通讯作者)，Cross Canc Inst, Div Oncol Imaging, Dept Oncol, Fac Med & Dent, 11560 Univ Ave, Edmonton, AB T6H 1P6, Canada.
EM john.mercer@albertahealthservices.ca
FU Canadian Breast Cancer Foundation; Alberta Cancer Board
FX This work was supported by finding from the Canadian Breast Cancer
   Foundation and the Alberta Cancer Board.
CR Akhtari M, 2008, CANCER BIOL THER, V7, P3, DOI 10.4161/cbt.7.1.5163
   Blackstein M, 2002, ONCOLOGY BASEL, V62, P2, DOI 10.1159/000048240
   Clark JCM, 2008, EXPERT OPIN EMERG DR, V13, P609, DOI 10.1517/14728210802584217 
   Daubiné F, 2007, J NATL CANCER I, V99, P322, DOI 10.1093/jnci/djk054
   El Mabhouh A, 2004, CANCER BIOTHER RADIO, V19, P627, DOI 10.1089/cbr.2004.19.627
   El Mabhouh AA, 2008, EUR J NUCL MED MOL I, V35, P1240, DOI 10.1007/s00259 008 0728 y
   El Mabhouh AA, 2006, NUCL MED BIOL, V33, P715, DOI 10.1016/j.nucmedbio.2006.06.004
   Even Sapir E, 2007, SEMIN NUCL MED, V37, P462, DOI 10.1053/j.semnuclmed.2007.07.002
   Gittens SA, 2005, MOL PHARMACEUT, V2, P392, DOI 10.1021/mp050017u
   Grant FD, 2008, J NUCL MED, V49, P68, DOI 10.2967/jnumed.106.037200
   Green JR, 2003, CANCER, V97, P840, DOI 10.1002/cncr.11128
   Herczegh P, 2002, J MED CHEM, V45, P2338, DOI 10.1021/jm0105326
   Hillner BE, 2000, J CLIN ONCOL, V18, P1378, DOI 10.1200/JCO.2000.18.6.1378
   Hiraga T, 2001, CANCER RES, V61, P4418
   Hirschberg R, 2004, TOXICOLOGY, V196, P165, DOI 10.1016/j.tox.2003.11.012
   Hosain F, 1996, J NUCL MED, V37, P105
   Jones SE, 2008, CLIN BREAST CANCER, V8, P224, DOI 10.3816/CBC.2008.n.025
   Käkönen SM, 2003, CANCER AM CANCER SOC, V97, P834, DOI 10.1002/cncr.11132
   Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535 7163.MCT 07 0234
   KOZLOW W, 2005, REN FAIL, V27, P329
   Liepe K, 2003, BRIT J CANCER, V89, P625, DOI 10.1038/sj.bjc.6601158
   Machado M, 2009, CLIN THER, V31, P962, DOI 10.1016/j.clinthera.2009.05.009
   Mauri D, 2008, JNCI J NATL CANCER I, V100, P1780, DOI 10.1093/jnci/djn414
   Morgan MA, 2008, CLIN CANCER RES, V14, P6744, DOI 10.1158/1078 0432.CCR 08 1032
   Mundy GR, 2001, SEMIN ONCOL, V28, P35, DOI 10.1053/sonc.2001.24158
   Rubens RD, 1998, EUR J CANCER, V34, P210, DOI 10.1016/S0959 8049(97)10128 9
   Serafini AN, 2001, Q J NUCL MED, V45, P91
   Stresing V, 2007, CANCER LETT, V257, P16, DOI 10.1016/j.canlet.2007.07.007
   Veerman G, 1996, CANCER CHEMOTH PHARM, V38, P335, DOI 10.1007/s002800050492
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
NR 30
TC 21
Z9 24
U1 0
U2 16
PU COGNIZANT COMMUNICATION CORP
PI ELMSFORD
PA 3 HARTSDALE ROAD, ELMSFORD, NY 10523 3701 USA
SN 0965 0407
J9 ONCOL RES
JI Oncol. Res.
PY 2011
VL 19
IS 6
BP 287
EP 295
DI 10.3727/096504011X13021877989874
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 777NK
UT WOS:000291628200005
PM 21776824
OA hybrid
DA 2025 08 17
ER

PT J
AU Richette, P
   Roux, C
AF Richette, P.
   Roux, C.
TI Impact of treatments for osteoporosis on cartilage biomarkers in humans
SO OSTEOPOROSIS INTERNATIONAL
LA English
DT Article
DE Biomarkers; Bisphosphonate; Bone; Calcitonin; Estrogens; Osteoarthritis;
   Selective estrogen receptor modulators; Strontium ranelate
ID KNEE OSTEOARTHRITIS; SALMON CALCITONIN; POSTMENOPAUSAL WOMEN;
   SUBCHONDRAL BONE; II DEGRADATION; CTX II; ESTROGEN; CHONDROCYTES;
   SYMPTOMS; TURNOVER
AB The rationale to target bone for treating osteoarthritis (OA) relies on the known cross talk between subchondral bone and cartilage and the demonstration that subchondral bone resorption occurs at an early stage in the development of OA. Therefore, the possible OA disease modifying effects of bone antiresorptive agents are of interest. This paper aims to review the published data on the effect of estrogens, selective estrogen receptor modulators, calcitonin, strontium ranelate, and bisphosphonates on cartilage biomarkers levels used as surrogate endpoints in clinical trials. Except for findings for tibolone, most observations indicated that these antiresorptive therapies decreased the urinary levels of CTX II, a biomarker of type II collagen degradation. These data, which should be cautiously interpreted, suggest that these drugs might favorably affect cartilage homeostasis.
C1 [Richette, P.] Univ Paris Diderot, Hop Lariboisiere, AP HP, Federat Rhumatol, F 75010 Paris, France.
   [Roux, C.] Univ Paris 05, Serv Rhumatol, Hop Cochin, AP HP, F 75014 Paris, France.
   [Richette, P.] Hop Lariboisiere, Federat Rhumatol, F 75475 Paris 10, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Lariboisiere Fernand Widal   APHP; Universite
   Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Cochin   APHP; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Lariboisiere Fernand Widal
     APHP
RP Richette, P (通讯作者)，Hop Lariboisiere, Federat Rhumatol, 2 Rue Ambroise Pare, F 75475 Paris 10, France.
EM pascal.richette@lrb.aphp.fr
OI Richette, Pascal/0000 0003 2132 4074
CR Alexandersen P, 2011, CLIMACTERIC, V14, P236, DOI 10.3109/13697137.2010.507887
   Alexandersen P, 2007, BONE, V40, P218, DOI 10.1016/j.bone.2006.07.028
   Bagger YZ, 2005, BONE, V37, P425, DOI 10.1016/j.bone.2005.04.032
   Bay Jensen AC, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2596
   Bingham CO, 2006, ARTHRITIS RHEUM US, V54, P3494, DOI 10.1002/art.22160
   Christgau S, 2004, MENOPAUSE, V11, P508, DOI 10.1097/01.WCB.0000121484.18437.98
   Funck Brentano T, 2011, CYTOKINE GROWTH F R, V22, P91, DOI 10.1016/j.cytogfr.2011.04.003
   Henrotin Y, 2001, J BONE MINER RES, V16, P299, DOI 10.1359/jbmr.2001.16.2.299
   Kadri A, 2008, ARTHRITIS RHEUM US, V58, P2379, DOI 10.1002/art.23638
   Kadri A, 2010, ANN RHEUM DIS, V69, P1533, DOI 10.1136/ard.2009.124586
   Karsdal MA, 2010, OSTEOARTHR CARTILAGE, V18, P150, DOI 10.1016/j.joca.2009.08.004
   Karsdal MA, 2008, BMC MUSCULOSKEL DIS, V9, DOI 10.1186/1471 2474 9 153
   Karsdal MA, 2007, ANN NY ACAD SCI, V1117, P181, DOI 10.1196/annals.1402.041
   Kraus VB, 2011, OSTEOARTHR CARTILAGE, V19, P515, DOI 10.1016/j.joca.2010.08.019
   Manicourt DH, 2006, ARTHRITIS RHEUM, V54, P3205, DOI 10.1002/art.22075
   Moreau M, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3373
   Mouritzen U, 2003, ANN RHEUM DIS, V62, P332, DOI 10.1136/ard.62.4.332
   Ravn P, 2004, BONE, V35, P1216, DOI 10.1016/j.bone.2004.07.017
   Richette P, 2003, JOINT BONE SPINE, V70, P257, DOI 10.1016/S1297 319X(03)00067 8
   Richette P, 2004, ANN RHEUM DIS, V63, P191, DOI 10.1136/ard.2003.006510
   Richette P, 2007, ANN RHEUM DIS, V66, P345, DOI 10.1136/ard.2006.059550
   Saag KG, 2008, ANN RHEUM DIS, V67, P1358, DOI 10.1136/ard.2008.089912
   Sniekers YH, 2008, OSTEOARTHR CARTILAGE, V16, P533, DOI 10.1016/j.joca.2008.01.002
   Sniekers YH, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3148
   Sondergaard BC, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 62
   Spector TD, 2005, ARTHRITIS RES THER, V7, pR625, DOI 10.1186/ar1716
   Tat SK, 2010, BEST PRACT RES CL RH, V24, P51, DOI 10.1016/j.berh.2009.08.004
NR 27
TC 7
Z9 10
U1 0
U2 10
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0937 941X
EI 1433 2965
J9 OSTEOPOROSIS INT
JI Osteoporosis Int.
PD DEC
PY 2012
VL 23
SU 8
BP S877
EP S880
DI 10.1007/s00198 012 2165 9
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 248TD
UT WOS:000326725200008
PM 23179570
DA 2025 08 17
ER

PT J
AU Norquest, CJ
   Rogic, A
   Gimotty, PA
   Maitz, CA
   Rindt, H
   Ashworth, HL
   Bryan, JN
   Donnelly, LL
   McCleary Wheeler, AL
   Flesner, BK
AF Norquest, Carissa J.
   Rogic, Anita
   Gimotty, Phyllis A.
   Maitz, Charles A.
   Rindt, Hansjorg
   Ashworth, Hayley L.
   Bryan, Jeffrey N.
   Donnelly, Lindsay L.
   McCleary Wheeler, Angela L.
   Flesner, Brian K.
TI Effects of neoadjuvant zoledronate and radiation therapy on cell
   survival, cell cycle distribution, and clinical status in canine
   osteosarcoma
SO FRONTIERS IN VETERINARY SCIENCE
LA English
DT Article
DE osteosarcoma; zoledronate; radiation therapy; pathologic fracture;
   cancer pain
ID APPENDICULAR OSTEOSARCOMA; PALLIATIVE RADIOTHERAPY; BONE METASTASES;
   ACID; CANCER; DOGS; BISPHOSPHONATES; PAMIDRONATE; CRITERIA; TRIAL
AB Introduction Zoledronic acid (ZOL) is a third generation bisphosphonate with a higher affinity for bone resorption areas than earlier bisphosphonates (i.e., pamidronate, PAM). In human medicine, ZOL provides improved bone pain relief and prolonged time to skeletal related events compared to its older generational counterparts. Preclinical studies have investigated its role as an anti neoplastic agent, both independently and synergistically, with radiation therapy (RT). ZOL and RT act synergistically in several neoplastic human cell lines: prostate, breast, osteosarcoma, and fibrosarcoma. However, the exact mechanism of ZOL's radiosensitization has not been fully elucidated.Methods We investigated ZOL's ability to induce apoptosis in canine osteosarcoma cell lines treated with various doses of megavoltage external beam radiotherapy. Second, we evaluated cell cycle arrest in ZOL treated cells to assess several neo adjuvant time points. Finally, we treated 20 dogs with naturally occurring appendicular OS with 0.1 mg/kg ZOL IV 24 h before receiving 8 Gy of RT (once weekly fraction x 4 weeks).Results We found that apoptosis was increased in all ZOL treated cell lines compared to controls, and the combination of ZOL and RT resulted in dissimilar apoptosis between Abrams and D 17 and HMPOS cell lines. Cell cycle arrest (G2/M phase) was minimal and variable between cell lines but perhaps greatest at 48 h post ZOL treatment. Only 10% of dogs treated with ZOL and RT developed pathologic fractures, compared to 44% of dogs historically treated with PAM and RT (p = 0.027).Discussion ZOL and RT appear to be a well tolerated combination treatment scheme for non surgical candidates; future studies must elucidate the ideal timing of ZOL.
C1 [Norquest, Carissa J.; Rogic, Anita; Maitz, Charles A.; Rindt, Hansjorg; Ashworth, Hayley L.; Bryan, Jeffrey N.; Donnelly, Lindsay L.; McCleary Wheeler, Angela L.; Flesner, Brian K.] Univ Missouri, Dept Vet Med & Surg, Coll Vet Med, Columbia, MO 65211 USA.
   [Gimotty, Phyllis A.] Univ Penn, Perelman Sch Med, Dept Biostat Epidemiol & Informat, Philadelphia, PA USA.
   [Flesner, Brian K.] Univ Penn, Dept Clin Sci & Adv Med, Sch Vet Med, Philadelphia, PA 19104 USA.
C3 University of Missouri System; University of Missouri Columbia;
   University of Pennsylvania; University of Pennsylvania
RP Flesner, BK (通讯作者)，Univ Missouri, Dept Vet Med & Surg, Coll Vet Med, Columbia, MO 65211 USA.; Flesner, BK (通讯作者)，Univ Penn, Dept Clin Sci & Adv Med, Sch Vet Med, Philadelphia, PA 19104 USA.
EM bflesner@petdx.com
RI Gimotty, Phyllis/GWZ 4136 2022; Flesner, Brian/GXZ 6439 2022; Maitz,
   Charles/AAE 1841 2021; Fernández Rodríguez, Rubén/S 5380 2018; Bryan,
   Jeffrey/AAB 3182 2022
CR Algur E, 2005, INT J RADIAT ONCOL, V61, P535, DOI 10.1016/j.ijrobp.2004.09.065
   Barger A, 2005, VET PATHOL, V42, P161, DOI 10.1354/vp.42 2 161
   Barroga EF, 1999, J VET MED SCI, V61, P361
   Boerman I, 2012, BMC VET RES, V8, DOI 10.1186/1746 6148 8 56
   Brown DC, 2009, PAIN MED, V10, P133, DOI 10.1111/j.1526 4637.2008.00513.x
   Choi J, 2019, J RADIAT RES, V60, P242, DOI 10.1093/jrr/rry092
   Chu S, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0246443
   Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Denham JW, 2019, LANCET ONCOL, V20, P267, DOI 10.1016/S1470 2045(18)30757 5
   Dhillon S, 2016, DRUGS, V76, P1683, DOI 10.1007/s40265 016 0662 4
   Fan TM, 2008, J VET INTERN MED, V22, P380, DOI 10.1111/j.1939 1676.2008.0046.x
   Fan TM, 2009, J VET INTERN MED, V23, P152, DOI 10.1111/j.1939 1676.2008.0221.x
   Fan TM, 2007, VET CLIN N AM SMALL, V37, P1091, DOI 10.1016/j.cvsm.2007.08.002
   Flesner BK, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.637195
   Garrett L. B. A., 2011, VET CANC SOC ANN M
   Green EM, 2002, J AM ANIM HOSP ASSOC, V38, P445, DOI 10.5326/0380445
   Grosse N, 2014, BMC CANCER, V14, DOI 10.1186/1471 2407 14 203
   Himelstein AL, 2017, JAMA J AM MED ASSOC, V317, P48, DOI 10.1001/jama.2016.19425
   Hoddinott K, 2019, CAN J VET RES, V83, P3
   Hosaka S, 2018, INT J CLIN ONCOL, V23, P1127, DOI 10.1007/s10147 018 1310 7
   Iguchi T, 2007, INT J ONCOL, V31, P285
   Kim EH, 2016, ONCOTARGET, V7, P70869, DOI 10.18632/oncotarget.12281
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   LaDue T, 2001, VET RADIOL ULTRASOUN, V42, P475, DOI 10.1111/j.1740 8261.2001.tb00973.x
   LeBlanc AK, 2021, CLIN CANCER RES, V27, P3005, DOI 10.1158/1078 0432.CCR 21 0315
   Legare ME, 2011, J CANCER, V2, P262, DOI 10.7150/jca.2.262
   Li S, 2019, NEOPLASMA, V66, P766, DOI 10.4149/neo_2018_181128N904
   Lopes MG, 2023, AUST VET J, V101, P58, DOI 10.1111/avj.13218
   Lundberg AP, 2016, J VET INTERN MED, V30, P1235, DOI 10.1111/jvim.13980
   Lundberg AP, 2022, VET COMP ONCOL, V20, P788, DOI 10.1111/vco.12830
   Lutz S, 2017, PRACT RADIAT ONCOL, V7, P4, DOI 10.1016/j.prro.2016.08.001
   Mankin HJ, 1996, J BONE JOINT SURG AM, V78A, P656, DOI 10.2106/00004623 199605000 00004
   Matsumoto S, 2005, LUNG CANCER, V47, P31, DOI 10.1016/j.lungcan.2004.06.003
   Megquier K, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0274383
   Modesto P, 2020, ANIMALS BASEL, V10, DOI 10.3390/ani10111981
   Norquest CJ, 2022, VET MED SCI, V8, P1013, DOI 10.1002/vms3.782
   Poirier V J, 2003, Vet Comp Oncol, V1, P207, DOI 10.1111/j.1476 5810.2003.00026.x
   Reid IR, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115390
   Reinhardt S, 2005, J SMALL ANIM PRACT, V46, P65, DOI 10.1111/j.1748 5827.2005.tb00294.x
   Ryu K, 2010, ANTICANCER RES, V30, P2713
   Sabattini S, 2017, J VET INTERN MED, V31, P864, DOI 10.1111/jvim.14696
   Shannon LM, 2015, P NATL ACAD SCI USA, V112, P13639, DOI 10.1073/pnas.1516215112
   Smith AA, 2023, VET MED SCI, V9, P59, DOI 10.1002/vms3.1000
   Suva LJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115711
   Ural AU, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1543
   Väänänen HK, 2000, J CELL SCI, V113, P377
   Vidal SA, 2021, FRONT VET SCI, V8, DOI 10.3389/fvets.2021.647846
   Vodicka P, 2021, CANCERS, V13, DOI 10.3390/cancers13030479
   Winter MC, 2009, CURR OPIN ONCOL, V21, P499, DOI 10.1097/CCO.0b013e328331c794
   Withers SS, 2015, VET COMP ONCOL, V13, P157, DOI 10.1111/vco.12026
   WITHROW SJ, 1991, CLIN ORTHOP RELAT R, P159
   Yang LQ, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001822
NR 52
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH 1015, SWITZERLAND
EI 2297 1769
J9 FRONT VET SCI
JI Front. Vet. Sci.
PD JAN 31
PY 2024
VL 11
AR 1237084
DI 10.3389/fvets.2024.1237084
PG 10
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Veterinary Sciences
GA HO9L9
UT WOS:001160563700001
PM 38362299
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Fan, Y
   Zha, RR
   Sano, T
   Zhao, XY
   Liu, SZ
   Woollam, MD
   Wu, D
   Sun, X
   Li, KX
   Egi, M
   Li, FJ
   Minami, K
   Siegel, AP
   Horiuchi, T
   Liu, J
   Agarwal, M
   Sudo, A
   Nakshatri, H
   Li, BY
   Yokota, H
AF Fan, Yao
   Zha, Rongrong
   Sano, Tomohiko
   Zhao, Xinyu
   Liu, Shengzhi
   Woollam, Mark D.
   Wu, Di
   Sun, Xun
   Li, Kexin
   Egi, Motoki
   Li, Fangjia
   Minami, Kazumasa
   Siegel, Amanda P.
   Horiuchi, Takashi
   Liu, Jing
   Agarwal, Mangilal
   Sudo, Akihiro
   Nakshatri, Harikrishna
   Li, Bai Yan
   Yokota, Hiroki
TI Mechanical tibial loading remotely suppresses brain tumors by
   dopamine mediated downregulation of CCN4
SO BONE RESEARCH
LA English
DT Article
ID CANCER; METASTASIS; ACTIVATION; EXPRESSION; LRP5; MECHANOTRANSDUCTION;
   MUTATIONS; PATHWAY; MODEL
AB Mechanical loading to the bone is known to be beneficial for bone homeostasis and for suppressing tumor induced osteolysis in the loaded bone. However, whether loading to a weight bearing hind limb can inhibit distant tumor growth in the brain is unknown. We examined the possibility of bone to brain mechanotransduction using a mouse model of a brain tumor by focusing on the response to Lrp5 mediated Wnt signaling and dopamine in tumor cells. The results revealed that loading the tibia with elevated levels of tyrosine hydroxylase, a rate limiting enzyme in dopamine synthesis, markedly reduced the progression of the brain tumors. The simultaneous application of fluphenazine (FP), an antipsychotic dopamine modulator, enhanced tumor suppression. Dopamine and FP exerted antitumor effects through the dopamine receptors DRD1 and DRD2, respectively. Notably, dopamine downregulated Lrp5 via DRD1 in tumor cells. A cytokine array analysis revealed that the reduction in CCN4 was critical for loading driven, dopamine mediated tumor suppression. The silencing of Lrp5 reduced CCN4, and the administration of CCN4 elevated oncogenic genes such as MMP9, Runx2, and Snail. In summary, this study demonstrates that mechanical loading regulates dopaminergic signaling and remotely suppresses brain tumors by inhibiting the Lrp5 CCN4 axis via DRD1, indicating the possibility of developing an adjuvant bone mediated loading therapy.
C1 [Fan, Yao; Zha, Rongrong; Wu, Di; Sun, Xun; Li, Kexin; Li, Bai Yan; Yokota, Hiroki] Harbin Med Univ, Sch Pharm, Dept Phamacol, Harbin, Peoples R China.
   [Fan, Yao; Zha, Rongrong; Sano, Tomohiko; Zhao, Xinyu; Liu, Shengzhi; Wu, Di; Sun, Xun; Li, Kexin; Egi, Motoki; Yokota, Hiroki] Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.
   [Sano, Tomohiko; Sudo, Akihiro] Mie Univ, Dept Orthoped Surg, Tsu, Mie, Japan.
   [Zhao, Xinyu] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China.
   [Woollam, Mark D.; Siegel, Amanda P.] Indiana Univ Purdue Univ, Dept Chem & Chem Biol, Indianapolis, IN 46202 USA.
   [Woollam, Mark D.; Siegel, Amanda P.; Agarwal, Mangilal; Yokota, Hiroki] Indiana Univ Purdue Univ, Integrat Nanosyst Dev Inst, Indianapolis, IN 46202 USA.
   [Egi, Motoki; Horiuchi, Takashi] Mie Univ, Grad Sch Engn, Tsu, Mie, Japan.
   [Li, Fangjia; Liu, Jing] Indiana Univ Purdue Univ, Dept Phys, Indianapolis, IN 46205 USA.
   [Minami, Kazumasa] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, Suita, Osaka, Japan.
   [Liu, Jing; Nakshatri, Harikrishna; Yokota, Hiroki] Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
   [Nakshatri, Harikrishna] Indiana Univ Sch Med, Simon Canc Res Ctr, Dept Surg, Indianapolis, IN 46202 USA.
C3 Harbin Medical University; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Mie University; Chinese Academy of
   Medical Sciences   Peking Union Medical College; Peking Union Medical
   College Hospital; Purdue University System; Purdue University; Purdue
   University in Indianapolis; Purdue University System; Purdue University;
   Purdue University in Indianapolis; Mie University; Purdue University
   System; Purdue University; Purdue University in Indianapolis; University
   of Osaka; Indiana University System; Indiana University Bloomington;
   Indiana University System; Indiana University Bloomington
RP Li, BY; Yokota, H (通讯作者)，Harbin Med Univ, Sch Pharm, Dept Phamacol, Harbin, Peoples R China.; Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Dept Biomed Engn, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Purdue Univ, Integrat Nanosyst Dev Inst, Indianapolis, IN 46202 USA.; Yokota, H (通讯作者)，Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
EM liby@ems.hrbmu.edu.cn; hyokota@iupui.edu
RI ; Siegel, Amanda/AAR 7871 2020; Li, Ke Xin/AAG 5874 2021; Yifan,
   Liu/AHD 1515 2022
OI , Mark Woollam/0009 0008 1577 745X; Liu, Jing/0000 0002 4912 4560; Li,
   Fangjia/0000 0002 7446 9106; 
FU NIH [R01 AR052144, R03 CA238555]
FX The authors thank Stanley Chien for electrostimulation, Rahul Prakash
   for FRET data analysis, and Chuanpeng Dong and Yunlong Liu for
   bioinformatics analysis. This study was supported in part by funds from
   the NIH (R01 AR052144 and R03 CA238555 to H.Y.).
CR Baron R, 2013, NAT MED, V19, P179, DOI 10.1038/nm.3074
   Borcherding DC, 2016, ONCOGENE, V35, P3103, DOI 10.1038/onc.2015.369
   Burnett RM, 2015, ONCOTARGET, V6, P12682, DOI 10.18632/oncotarget.3707
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   Chen A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23833 1
   Crozier Jennifer A, 2016, Breast Dis, V36, P133, DOI 10.3233/BD 160237
   Deng WT, 2019, J BIOL CHEM, V294, P5261, DOI 10.1074/jbc.RA118.006122
   DeSantis CE, 2016, CA CANCER J CLIN, V66, P31, DOI 10.3322/caac.21320
   Ewens A, 2005, ANTICANCER RES, V25, P3905
   Fan Y, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0083 6
   HEYES MP, 1985, LIFE SCI, V36, P671, DOI 10.1016/0024 3205(85)90172 9
   Kang KS, 2015, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00246
   Kotecki N, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918780312
   Lan YL, 2017, ONCOTARGET, V8, P88488, DOI 10.18632/oncotarget.19691
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Li FJ, 2019, SCI REP UK, V9, DOI 10.1038/s41598 019 42132 x
   Lindgren N, 2002, EUR J NEUROSCI, V15, P769, DOI 10.1046/j.1460 9568.2002.01901.x
   Liu SZ, 2018, CANCER RES, V78, P3865, DOI 10.1158/0008 5472.CAN 18 0056
   Minami K, 2017, SCI REP UK, V7, DOI 10.1038/srep45686
   Niziolek PJ, 2012, BONE, V51, P459, DOI 10.1016/j.bone.2012.05.023
   O'Sullivan CC, 2017, SEMIN ONCOL, V44, P85, DOI 10.1053/j.seminoncol.2017.06.006
   Owonikoko TK, 2014, NAT REV CLIN ONCOL, V11, P203, DOI 10.1038/nrclinonc.2014.25
   Phillips GDL, 2017, BREAST CANCER RES TR, V164, P581, DOI 10.1007/s10549 017 4279 4
   Qiu F, 2018, HYPERTENS RES, V41, P718, DOI 10.1038/s41440 018 0066 9
   Rabbani SA, 2013, CANCER MED US, V2, P625, DOI 10.1002/cam4.111
   Sawakami K, 2006, J BIOL CHEM, V281, P23698, DOI 10.1074/jbc.M601000200
   Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311
   Sharif Y, 2018, CLIN ANAT, V31, P812, DOI 10.1002/ca.23083
   Shim JW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085095
   Soto MS, 2016, ADV EXP MED BIOL, V899, P231, DOI 10.1007/978 3 319 26666 4_13
   Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tardy M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009230.pub2
   Tardy M, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009396.pub2
   Tran S, 2017, BEHAV BRAIN RES, V317, P237, DOI 10.1016/j.bbr.2016.09.048
   WARNER RL, 1994, LIFE SCI, V54, P481, DOI 10.1016/0024 3205(94)00407 2
   Wehner T, 2009, CLIN BIOMECH, V24, P299, DOI 10.1016/j.clinbiomech.2008.12.007
   Witzel I, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058 015 0665 1
   Wu D, 2020, FASEB J, V34, P7578, DOI 10.1096/fj.202000096R
   Yan RZ, 2019, P NATL ACAD SCI USA, V116, P13077, DOI 10.1073/pnas.1901902116
   Yang K, 2020, CELL ONCOL, V43, P1175, DOI 10.1007/s13402 020 00550 4
   Yavropoulou MP, 2016, J MUSCULOSKEL NEURON, V16, P221
   Yuan M, 2019, CNS NEUROSCI THER, V25, P123, DOI 10.1111/cns.12993
NR 43
TC 5
Z9 5
U1 1
U2 8
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2095 4700
EI 2095 6231
J9 BONE RES
JI Bone Res.
PD MAY 24
PY 2021
VL 9
IS 1
AR 26
DI 10.1038/s41413 021 00144 2
PG 10
WC Cell & Tissue Engineering
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA SG9OW
UT WOS:000653770400001
PM 34031366
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Chen, HY
   Tan, W
   Tong, TY
   Shi, X
   Ma, SQ
   Zhu, GR
AF Chen, Hongyu
   Tan, Wei
   Tong, Tianyi
   Shi, Xin
   Ma, Shiqing
   Zhu, Guorui
TI A pH Responsive Asymmetric Microfluidic/Chitosan Device for Drug Release
   in Infective Bone Defect Treatment
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE microfluidic device; pH responsive drug release; guided bone
   regeneration
ID GUIDED BONE; TISSUE REGENERATION; MEMBRANE; MECHANISMS; CHITOSAN;
   RESISTANCE
AB Bacterial infection is currently considered to be one of the major reasons that leads to the failure of guided bone regeneration (GBR) therapy. Under the normal condition, the pH is neutral, while the microenvironment will become acid at the sites of infection. Here, we present an asymmetric microfluidic/chitosan device that can achieve pH responsive drug release to treat bacterial infection and promote osteoblast proliferation at the same time. On demand release of minocycline relies on a pH sensitive hydrogel actuator, which swells significantly when exposed to the acid pH of an infected region. The PDMAEMA hydrogel had pronounced pH sensitive properties, and a large volume transition occurred at pH 5 and 6. Over 12 h, the device enabled minocycline solution flowrates of 0.51 1.63 mu g/h and 0.44 1.13 mu g/h at pH 5 and 6, respectively. The asymmetric microfluidic/chitosan device exhibited excellent capabilities for inhibiting Staphylococcus aureus and Streptococcus mutans growth within 24 h. It had no negative effect on proliferation and morphology of L929 fibroblasts and MC3T3 E1 osteoblasts, which indicates good cytocompatibility. Therefore, such a pH responsive drug release asymmetric microfluidic/chitosan device could be a promising therapeutic approach in the treatment of infective bone defects.
C1 [Chen, Hongyu; Tan, Wei; Shi, Xin; Zhu, Guorui] Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
   [Tong, Tianyi] Tianjin Med Univ, Sch & Hosp Stomatol, Tianjin 300070, Peoples R China.
   [Ma, Shiqing] Tianjin Med Univ, Hosp 2, Dept Stomatol, Tianjin 300211, Peoples R China.
C3 Tianjin University; Tianjin Medical University; Tianjin Medical
   University
RP Zhu, GR (通讯作者)，Tianjin Univ, Sch Chem Engn & Technol, Tianjin 300350, Peoples R China.
EM zhuguorui@tju.edu.cn
RI Chen, Hongyu/JGM 9228 2023; tan, wei/HFZ 9071 2022
FU Science and Technology Plan Project of Tianjin [21JCZDJC00420]
FX This research was funded by the Science and Technology Plan Project of
   Tianjin (21JCZDJC00420). The APC was funded by the Science and
   Technology Plan Project of Tianjin (21JCZDJC00420).
CR Asadi A, 2020, J GLOB ANTIMICROB RE, V22, P161, DOI 10.1016/j.jgar.2020.01.022
   Aw MS, 2013, INT J PHARMACEUT, V443, P154, DOI 10.1016/j.ijpharm.2013.01.004
   Boda SK, 2020, BIOMACROMOLECULES, V21, P4945, DOI 10.1021/acs.biomac.0c01163
   Campoccia D, 2010, BIOMATERIALS, V31, P6363, DOI 10.1016/j.biomaterials.2010.05.005
   Carbonell JM, 2014, INT J ORAL MAX SURG, V43, P75, DOI 10.1016/j.ijom.2013.05.017
   Deng Y, 2020, IND ENG CHEM RES, V59, P12123, DOI 10.1021/acs.iecr.0c02107
   Dong YW, 2017, COLLOID SURFACE B, V158, P127, DOI 10.1016/j.colsurfb.2017.06.034
   Elgali I, 2017, EUR J ORAL SCI, V125, P315, DOI 10.1111/eos.12364
   He M, 2017, J COLLOID INTERF SCI, V490, P270, DOI 10.1016/j.jcis.2016.11.062
   He ZQ, 2021, CARBOHYD POLYM, V273, DOI 10.1016/j.carbpol.2021.118525
   Hu JJ, 2019, BIOMATER SCI UK, V7, P581, DOI 10.1039/c8bm01211c
   Hwang C, 2020, MAT SCI ENG C MATER, V115, DOI 10.1016/j.msec.2020.111112
   Iyer MA, 2019, LAB CHIP, V19, P574, DOI 10.1039/c9lc00039a
   Jiang HJ, 2019, LAB CHIP, V19, P2265, DOI 10.1039/c9lc00206e
   Jiang N, 2018, SMALL, V14, DOI 10.1002/smll.201704363
   Jung RE, 2013, CLIN ORAL IMPLAN RES, V24, P1065, DOI 10.1111/j.1600 0501.2012.02522.x
   Kamaly N, 2016, CHEM REV, V116, P2602, DOI 10.1021/acs.chemrev.5b00346
   Kim H, 2016, SCI REP UK, V6, DOI 10.1038/srep36085
   Kuo SM, 2006, J BIOMED MATER RES A, V76A, P408, DOI 10.1002/jbm.a.30534
   Lee JH, 2012, J DRUG DELIV, V2012, DOI 10.1155/2012/527516
   Liu YX, 2021, CHEM REV, V121, P7468, DOI 10.1021/acs.chemrev.0c01289
   Lu ZT, 2017, NEW J CHEM, V41, P432, DOI 10.1039/c6nj03260e
   Ma SQ, 2016, SCI REP UK, V6, DOI 10.1038/srep31822
   Ma SQ, 2014, J DENT, V42, P1603, DOI 10.1016/j.jdent.2014.08.015
   Maiti D, 2018, NANOSCALE, V10, P13976, DOI 10.1039/c8nr03986k
   Meng E, 2012, ADV DRUG DELIVER REV, V64, P1628, DOI 10.1016/j.addr.2012.08.006
   Mirani B, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700718
   Mittal AK, 2020, ACS OMEGA, V5, P24239, DOI 10.1021/acsomega.0c02040
   Nardo T, 2021, BIOMED MATER, V16, DOI 10.1088/1748 605X/abf27e
   Oh SH, 2006, J BIOMAT SCI POLYM E, V17, P1375, DOI 10.1163/156856206778937253
   Ouyang LP, 2018, COLLOID SURFACE B, V163, P175, DOI 10.1016/j.colsurfb.2017.12.045
   Rider P, 2022, BIOACT MATER, V14, P152, DOI 10.1016/j.bioactmat.2021.11.018
   Rompen EH, 1999, J PERIODONTOL, V70, P1144, DOI 10.1902/jop.1999.70.10.1144
   Sasaki Jun Ichi, 2021, Biomater Investig Dent, V8, P54, DOI 10.1080/26415275.2021.1925556
   Schwarz F, 2006, J CLIN PERIODONTOL, V33, P491, DOI 10.1111/j.1600 051X.2006.00936.x
   Shakeri A, 2021, LAB CHIP, V21, P3053, DOI 10.1039/d1lc00288k
   Sirivisoot S, 2015, INT J NANOMED, V10, P4447, DOI 10.2147/IJN.S82830
   Stuart MAC, 2010, NAT MATER, V9, P101, DOI [10.1038/NMAT2614, 10.1038/nmat2614]
   Taktak F., 2016, AFYON KOCATEPE U J S, V16, P68, DOI DOI 10.5578/FMBD.26306
   Wang JL, 2016, POLYMERS BASEL, V8, DOI 10.3390/polym8040115
   Wang Q, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202008906
   Wang Y, 2021, ACS APPL MATER INTER, V13, P33584, DOI 10.1021/acsami.1c09889
   Wei HP, 2022, BONE RES, V10, DOI 10.1038/s41413 021 00180 y
   Wu W, 2011, INT J PHARMACEUT, V416, P104, DOI 10.1016/j.ijpharm.2011.06.015
   Xu C, 2012, J BIOMED MATER RES B, V100B, P1435, DOI 10.1002/jbm.b.32662
   Xue JJ, 2014, BIOMATERIALS, V35, P9395, DOI 10.1016/j.biomaterials.2014.07.060
   Yang Y, 2016, INT J PHARMACEUT, V506, P340, DOI 10.1016/j.ijpharm.2016.04.061
   Zhao DL, 2022, DENT MATER, V38, P431, DOI 10.1016/j.dental.2021.12.026
   Zhu JJ, 2020, J BIOMATER APPL, V34, P1282, DOI 10.1177/0885328220901807
NR 49
TC 7
Z9 7
U1 10
U2 56
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
SN 1661 6596
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2023
VL 24
IS 5
AR 4616
DI 10.3390/ijms24054616
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 9T5WG
UT WOS:000947096300001
PM 36902046
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Uribe Etxebarria, V
   Luzuriaga, J
   García Gallastegui, P
   Agliano, A
   Unda, F
   Ibarretxe, G
AF Uribe Etxebarria, V.
   Luzuriaga, J.
   Garcia Gallastegui, P.
   Agliano, A.
   Unda, F.
   Ibarretxe, G.
TI NOTCH/WNT CROSS SIGNALLING REGULATES STEMNESS OF DENTAL PULP STEM CELLS
   THROUGH EXPRESSION OF NEURAL CREST AND CORE PLURIPOTENCY FACTORS
SO EUROPEAN CELLS & MATERIALS
LA English
DT Article
DE Dental pulp stem cells; multipotency; self renewal; pluripotency core
   factors; neural crest; stemness and differentiation; osteogenesis;
   adipogenesis; Notch; Wnt; BIO; DAPT; Wnt 3a
ID SELF RENEWAL; GENE EXPRESSION; 3RD MOLAR; IN VITRO; WNT; TISSUE;
   DIFFERENTIATION; OCT4; GENERATION; INHIBITION
AB Dental pulp stem cells (DPSCs) from adult teeth express neural crest (NC) markers together with core transcriptional factors associated with stem cell pluripotency, such as Oct4a, Sox2, c Myc, Rex1, Stella/Dppa3, Ssea1/Fut4, Lin28 and Nanog. The possibility to boost the natural stemness features of DPSCs by mild methods, that do not involve gene and/or chromatin modification or gene transfection, is highly desirable for cell therapy. Canonical Wnt and Notch are two highly conserved developmental signalling pathways that are involved in NC emergence and stem cell self renewal. We determined that both pathways coordinate to regulate the expression of core pluripotency and NC factors in DPSCs. Pharmacological inhibition of the Notch pathway for 48 h, by the gamma secretase inhibitor N [N (3,5 Difluorophenacetyl) L alanyl] S phenylglycine t butyl ester (DAPT), abolished the expression of NC and core factors. In addition, it induced a silencing of the canonical Wnt signalling and a clear reduction in the stemness potential of DPSCs, as shown by a reduced ability to generate mature, fully differentiated osteoblasts and adipocytes. Conversely, pharmacological activation of the Wnt pathway for 48 h, by either the glycogen synthase kinase 3 beta (GSK3 beta) inhibitor 6 bromoindirubin 3' oxime (BIO) or the human recombinant protein Wnt 3a, not only largely increased the expression of NC and core factors, but also increased the efficiency of DPSCs to differentiate into mature osteoblasts and adipocytes. These results showed that a short preconditioning activation of Wnt/Notch signalling by small molecules and/or recombinant proteins enhanced the stemness and potency of DPSCs in culture, which could be useful for optimising the therapeutic use of these and other tissue specific stem cells.
C1 [Uribe Etxebarria, V.; Luzuriaga, J.; Garcia Gallastegui, P.; Unda, F.; Ibarretxe, G.] Univ Basque Country, UPV EHU, Fac Med & Nursing, Cell Biol & Histol Dept, Barrio Sarriena S N, Leioa 48940, Spain.
   [Agliano, A.] Canc Res UK Canc Imaging Ctr, Div Radiotherapy & Imaging, Inst Canc Res, 123 Old Brompton Rd, London SW7 3RP, England.
   [Agliano, A.] Royal Marsden NHS Fdn Trust, 123 Old Brompton Rd, London SW7 3RP, England.
C3 University of Basque Country; Royal Marsden NHS Foundation Trust; Cancer
   Research UK; University of London; Institute of Cancer Research   UK;
   Royal Marsden NHS Foundation Trust
RP Ibarretxe, G (通讯作者)，Univ Basque Country, UPV EHU, Fac Med & Nursing, Cell Biol & Histol Dept, Barrio Sarriena S N, Leioa 48940, Spain.
EM gaskon.ibarretxe@ehu.eus
RI ; Garcia Gallastegi, Patricia/AAF 9405 2019; Unda,
   Fernando/AAF 9128 2019; Ibarretxe, Gaskon/AAE 7244 2022
OI Ibarretxe, Gaskon/0000 0002 4961 7402; GARCIA GALLASTEGI,
   PATRICIA/0000 0002 5140 3390; Uribe Etxebarria,
   Veronica/0000 0001 6621 8377; LUZURIAGA GONZALEZ,
   JON/0000 0002 1443 7057; 
FU UPV/EHU [GIU16/66, UFI 11/44]; Basque Government (GV/EJ) [IT831 13];
   Global Training Grant (GV/EJ)
FX Technical and human support provided by the analytical microscopy
   service of SGIKER (UPV/EHU, MINECO, GV/EJ, ERDF and ESF) is gratefully
   acknowledged. This work was funded by the UPV/EHU (GIU16/66, UFI 11/44)
   and the Basque Government (GV/EJ; IT831 13). V.U. received a fellowship
   from The Global Training Grant (GV/EJ) to fund a research stage at The
   Institute of Cancer Research (London, UK).
CR Abe S, 2012, CELL BIOL INT, V36, P927, DOI 10.1042/CBI20110506
   Androutsellis Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940
   [Anonymous], 2012, STEM CELLS INT, DOI DOI 10.1155/2012/103503
   Atari M, 2011, HISTOL HISTOPATHOL, V26, P1057, DOI 10.14670/HH 26.1057
   Atari M, 2012, J CELL SCI, V125, P3343, DOI 10.1242/jcs.096537
   Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008 0530
   Aurrekoetxea M, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00289
   Barker N, 2000, ADV CANCER RES, V77, P1
   Bonnamain V, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00357
   Borggrefe T, 2016, BBA MOL CELL RES, V1863, P303, DOI 10.1016/j.bbamcr.2015.11.020
   Borghese L, 2010, STEM CELLS, V28, P955, DOI 10.1002/stem.408
   Bose B, 2016, STEM CELL REV REP, V12, P73, DOI 10.1007/s12015 015 9620 x
   Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   D'Souza B, 2010, CURR TOP DEV BIOL, V92, P73, DOI 10.1016/S0070 2153(10)92003 6
   Dravid G, 2005, STEM CELLS, V23, P1489, DOI 10.1634/stemcells.2005 0034
   Eubanks EJ, 2014, J ENDODONT, V40, P652, DOI 10.1016/j.joen.2014.01.005
   Famili F, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.326
   Ferro F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041774
   Fox V, 2008, STEM CELLS, V26, P715, DOI 10.1634/stemcells.2007 0368
   Fukunaga Kalabis M, 2015, J INVEST DERMATOL, V135, P1521, DOI 10.1038/jid.2015.59
   Gazarian KG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170321
   Gervois P, 2015, STEM CELLS DEV, V24, P296, DOI 10.1089/scd.2014.0117
   Gronthos S, 2002, J DENT RES, V81, P531, DOI 10.1177/154405910208100806
   Gronthos S, 2000, P NATL ACAD SCI USA, V97, P13625, DOI 10.1073/pnas.240309797
   Hari L, 2012, DEVELOPMENT, V139, P2107, DOI 10.1242/dev.073064
   Huang GTJ, 2009, J DENT RES, V88, P792, DOI 10.1177/0022034509340867
   Ichida JK, 2014, NAT CHEM BIOL, V10, P632, DOI 10.1038/nchembio.1552
   Janebodin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027526
   Jung J., 2016, Stem Cells Int, V2016, P6921097, DOI DOI 10.1155/2016/6921097
   Kaukua N, 2014, NATURE, V513, P551, DOI 10.1038/nature13536
   Kellner M, 2014, ARCH ORAL BIOL, V59, P559, DOI 10.1016/j.archoralbio.2014.02.014
   Kerkis I, 2006, CELLS TISSUES ORGANS, V184, P105, DOI 10.1159/000099617
   Király M, 2009, NEUROCHEM INT, V55, P323, DOI 10.1016/j.neuint.2009.03.017
   Kitajima K, 2016, EXP HEMATOL, V44, P68, DOI 10.1016/j.exphem.2015.09.007
   Kwon C, 2011, NAT CELL BIOL, V13, P1244, DOI 10.1038/ncb2313
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Leung AW, 2016, DEVELOPMENT, V143, P398, DOI 10.1242/dev.130849
   Li J, 2012, MOL CELL BIOCHEM, V362, P233, DOI 10.1007/s11010 011 1148 z
   Liedtke S, 2007, CELL STEM CELL, V1, P364, DOI 10.1016/j.stem.2007.09.003
   Lima RL, 2017, ARCH ORAL BIOL, V73, P121, DOI 10.1016/j.archoralbio.2016.10.003
   Liu JJ, 2015, STEM CELLS, V33, P627, DOI 10.1002/stem.1909
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lluis F, 2008, CELL STEM CELL, V3, P493, DOI 10.1016/j.stem.2008.08.017
   Lowell S, 2006, PLOS BIOL, V4, P805, DOI 10.1371/journal.pbio.0040121
   Marrelli M, 2015, J DENT RES, V94, P843, DOI 10.1177/0022034515570316
   Marrelli M, 2013, INT J BIOL SCI, V9, P1070, DOI 10.7150/ijbs.6662
   Martens W, 2014, FASEB J, V28, P1634, DOI 10.1096/fj.13 243980
   Meijer L, 2003, CHEM BIOL, V10, P1255, DOI 10.1016/j.chembiol.2003.11.010
   Mizutani K, 2007, NATURE, V449, P351, DOI 10.1038/nature06090
   Mokry J, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/673513
   Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099
   Park IH, 2008, NATURE, V451, P141, DOI [10.1038/nature06534, 10.1038/natureO6534]
   Perdigoto CN, 2013, BBA GEN SUBJECTS, V1830, P2307, DOI 10.1016/j.bbagen.2012.08.009
   Petrovic V, 2009, THESCIENTIFICWORLDJO, V9, P1167, DOI 10.1100/tsw.2009.125
   Pierdomenico L, 2005, TRANSPLANTATION, V80, P836, DOI 10.1097/01.tp.0000173794.72151.88
   Pisciotta A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050542
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Rogers CD, 2012, WIRES DEV BIOL, V1, P52, DOI 10.1002/wdev.8
   Rosa V, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5957806
   Saunders A, 2013, STEM CELLS, V31, P1227, DOI 10.1002/stem.1384
   Scheller EL, 2008, J DENT RES, V87, P126, DOI 10.1177/154405910808700206
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schiraldi C, 2012, EUR CELLS MATER, V24, P426, DOI 10.22203/eCM.v024a30
   Shi Y, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0103 4
   Shyamala K, 2015, J Oral Maxillofac Pathol, V19, P221, DOI 10.4103/0973 029X.164536
   Simandi Z, 2016, MOL CELL, V63, P647, DOI 10.1016/j.molcel.2016.06.039
   Stuhlmiller TJ, 2012, CELL MOL LIFE SCI, V69, P3715, DOI 10.1007/s00018 012 0991 8
   Takahashi K, 2007, NAT PROTOC, V2, P3081, DOI 10.1038/nprot.2007.418
   Tatullo M, 2015, J BIOL REG HOMEOS AG, V29, P713
   Thomas S, 2008, HUM MOL GENET, V17, P3411, DOI 10.1093/hmg/ddn235
   Vasanthan P, 2015, J CELL MOL MED, V19, P566, DOI 10.1111/jcmm.12381
   Wang J, 2008, P NATL ACAD SCI USA, V105, P6326, DOI 10.1073/pnas.0802288105
   Wilson R, 2015, STEM CELL TRANSL MED, V4, P905, DOI 10.5966/sctm.2014 0196
   Wu W, 2015, MOL MED REP, V12, P5127, DOI 10.3892/mmr.2015.4106
   Xiao L, 2013, J CELL BIOCHEM, V114, P2624, DOI 10.1002/jcb.24610
   Yan X, 2010, STEM CELLS DEV, V19, P469, DOI 10.1089/scd.2009.0314
   Yiew NKH, 2017, J BIOL CHEM, V292, P6312, DOI 10.1074/jbc.M116.758078
   Yu JH, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471 2121 11 32
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang ZY, 2009, J MOL CELL CARDIOL, V46, P370, DOI 10.1016/j.yjmcc.2008.11.016
NR 83
TC 30
Z9 36
U1 1
U2 16
PU AO RESEARCH INSTITUTE DAVOS ARI
PI DAVOS
PA CLAVADELERSTRASSE 8, DAVOS, CH 7270, SWITZERLAND
SN 1473 2262
J9 EUR CELLS MATER
JI Eur. Cells Mater.
PD JUL DEC
PY 2017
VL 34
BP 249
EP 270
DI 10.22203/eCM.v034a16
PG 22
WC Cell & Tissue Engineering; Engineering, Biomedical; Materials Science,
   Biomaterials; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Engineering; Materials Science; Orthopedics
GA FQ1TU
UT WOS:000418141300016
PM 29092089
OA Bronze, Green Submitted
DA 2025 08 17
ER

PT J
AU Menendez, L
   Yatskievych, TA
   Antin, PB
   Dalton, S
AF Menendez, Laura
   Yatskievych, Tatiana A.
   Antin, Parker B.
   Dalton, Stephen
TI Wnt signaling and a Smad pathway blockade direct the differentiation of
   human pluripotent stem cells to multipotent neural crest cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE developmental biology; embryonic stem cells; human induced pluripotent
   stem cells
ID HUMAN ES; DERIVATION; INDUCTION; MESODERM; XENOPUS
AB Neural crest stem cells can be isolated from differentiated cultures of human pluripotent stem cells, but the process is inefficient and requires cell sorting to obtain a highly enriched population. No specific method for directed differentiation of human pluripotent cells toward neural crest stem cells has yet been reported. This severely restricts the utility of these cells as a model for disease and development and for more applied purposes such as cell therapy and tissue engineering. In this report, we use small molecule compounds in a single step method for the efficient generation of self renewing neural crest like stem cells in chemically defined media. This approach is accomplished directly from human pluripotent cells without the need for coculture on feeder layers or cell sorting to obtain a highly enriched population. Critical to this approach is the activation of canonical Wnt signaling and concurrent suppression of the Activin A/Nodal pathway. Over 12 14 d, pluripotent cells are efficiently specified along the neuroectoderm lineage toward p75(+) Hnk1(+) Ap2(+) neural crest like cells with little or no contamination by Pax6(+) neural progenitors. This cell population can be clonally amplified and maintained for >25 passages (> 100 d) while retaining the capacity to differentiate into peripheral neurons, smooth muscle cells, and mesenchymal precursor cells. Neural crest like stem cell derived mesenchymal precursors have the capacity for differentiation into osteocytes, chondrocytes, and adipocytes. In sum, we have developed methods for the efficient generation of self renewing neural crest stem cells that greatly enhance their potential utility in disease modeling and regenerative medicine.
C1 [Menendez, Laura; Dalton, Stephen] Univ Georgia, Dept Biochem & Mol Biol, Paul D Coverdell Ctr Biomed & Hlth Sci, Athens, GA 30602 USA.
   [Yatskievych, Tatiana A.; Antin, Parker B.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.
C3 University System of Georgia; University of Georgia; University of
   Arizona
RP Dalton, S (通讯作者)，Univ Georgia, Dept Biochem & Mol Biol, Paul D Coverdell Ctr Biomed & Hlth Sci, Athens, GA 30602 USA.
EM sdalton@uga.edu
OI Dalton, Stephen/0000 0002 3450 1263; Antin, Parker/0000 0001 9066 7412
FU National Institute of Child Health and Human Development [HD049647];
   National Institute for General Medical Sciences [GM75334]; National
   Center for Research Resources [P41RR018502]
FX This work was supported by Grant HD049647 from the National Institute of
   Child Health and Human Development (to S.D.), by Grant GM75334 from the
   National Institute for General Medical Sciences (to S. D.), and by Grant
   P41RR018502 from the National Center for Research Resources (to S. D.).
CR Barberi T, 2005, PLOS MED, V2, P554, DOI 10.1371/journal.pmed.0020161
   Barberi T, 2007, NAT MED, V13, P642, DOI 10.1038/nm1533
   Bonstein L, 1998, DEV BIOL, V193, P156, DOI 10.1006/dbio.1997.8795
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Darnell DK, 2000, METH MOL B, V135, P305
   Elkabetz Y, 2008, GENE DEV, V22, P152, DOI 10.1101/gad.1616208
   Garcia Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824
   Jiang XH, 2009, STEM CELLS DEV, V18, P1059, DOI 10.1089/scd.2008.0362
   Koch P, 2009, P NATL ACAD SCI USA, V106, P3225, DOI 10.1073/pnas.0808387106
   LaBonne C, 1998, DEVELOPMENT, V125, P2403
   Lee G, 2007, NAT BIOTECHNOL, V25, P1468, DOI 10.1038/nbt1365
   Lee G, 2010, NAT PROTOC, V5, P688, DOI 10.1038/nprot.2010.35
   Lee G, 2010, NAT METHODS, V7, P25, DOI [10.1038/NMETH.F.283, 10.1038/nmeth.f.283]
   Li XJ, 2005, NAT BIOTECHNOL, V23, P215, DOI 10.1038/nbt1063
   LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092 8674(95)90276 7
   Marchant L, 1998, DEV BIOL, V198, P319, DOI 10.1016/S0012 1606(98)80008 0
   Meijer L, 2004, TRENDS PHARMACOL SCI, V25, P471, DOI 10.1016/j.tips.2004.07.006
   Meulemans D, 2004, DEV CELL, V7, P291, DOI 10.1016/j.devcel.2004.08.007
   Monsoro Burq AH, 2003, DEVELOPMENT, V130, P3111, DOI 10.1242/dev.00531
   Patthey C, 2009, DEVELOPMENT, V136, P73, DOI 10.1242/dev.025890
   Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979
   Selleck MAJ, 1996, P NATL ACAD SCI USA, V93, P9352, DOI 10.1073/pnas.93.18.9352
   Wilson SI, 2001, NATURE, V411, P325, DOI 10.1038/35077115
   Zhou Y, 2008, BIOCHEM BIOPH RES CO, V376, P542, DOI 10.1016/j.bbrc.2008.09.032
NR 24
TC 204
Z9 271
U1 0
U2 28
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027 8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD NOV 29
PY 2011
VL 108
IS 48
BP 19240
EP 19245
DI 10.1073/pnas.1113746108
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA 853ZB
UT WOS:000297463100034
PM 22084120
OA Green Published
DA 2025 08 17
ER

PT J
AU Yu, H
   Venkatesha, SH
   Moudgil, KD
AF Yu, Hua
   Venkatesha, Shivaprasad H.
   Moudgil, Kamal D.
TI Microarray based gene expression profiling reveals the mediators and
   pathways involved in the anti arthritic activity of Celastrus derived
   Celastrol
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Arthritis; Celastrus; Celastrol; Inflammation; Gene expression;
   Microarray
ID RHEUMATOID ARTHRITIS; AUTOIMMUNE ARTHRITIS; TRIPTERYGIUM WILFORDII;
   TERMINAL DETERMINANTS; TRITERPENE CELASTROL; OSTEOCLAST FORMATION;
   LIPID PEROXIDATION; INTERFERON GAMMA; RESPONSES; CELLS
AB Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic inflammation of the joints. The prolonged use of non steroidal anti inflammatory drugs and other newer drugs is associated with severe adverse reactions. Therefore, there is a need for newer anti arthritic agents. Celastrol, a bioactive component of the Chinese herb Celastrus, possesses anti arthritic activity as tested in the adjuvant arthritis (AA) model of rheumatoid arthritis (RA). However, the mechanism of action of Celastrol has not been fully defined. We reasoned that microarray analysis of the lymphoid cells of Celastrol treated arthritic animals might provide vital clues in this regard. We isolated total RNA of the draining lymph node cells (LNCs) of Celastrol treated (Tc) and vehicle treated (Tp) arthritic Lewis rats that were restimulated in vitro with the disease related antigen, mycobacterial heat shock protein 65 (Bhsp65). and tested it using microarray gene chips. Also tested was RNA from LNCs of control arthritic rats just before any treatment (T 0). Seventy six genes involved in various biological functions were differentially regulated by Bhsp65 in LNCs of Tp group, and 19 genes among them were shared by the Tc group. Furthermore, a group of 14 genes was unique to Tc. When Tc and Tp were compared, many of the Bhsp65 induced genes were related to the immune cells, cellular proliferation and inflammatory responses. Our results revealed 10 differentially expressed genes and 14 pathways that constituted the "Celastrol Signature". Our results would help identify novel targets for RA therapy. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Yu, Hua; Venkatesha, Shivaprasad H.; Moudgil, Kamal D.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA.
   [Moudgil, Kamal D.] Univ Maryland, Sch Med, Dept Med, Div Rheumatol, Baltimore, MD 21201 USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore
RP Moudgil, KD (通讯作者)，Univ Maryland, Sch Med, Dept Microbiol & Immunol, 685 W Baltimore St,HSF 1,Suite 380, Baltimore, MD 21201 USA.
EM kmoud001@umaryland.edu
RI Venkatesha, Shivaprasad/S 3141 2016; yu, hua/F 8948 2012
FU National Institutes of Health (Bethesda, MD, USA) [R01AT004321]
FX This work was supported by grant R01AT004321 from the National
   Institutes of Health (Bethesda, MD, USA). We thank Jing Yin and Li Tang
   (Biopolymer Genomics Core) for their help with microarray hybridization
   and signal readout.
CR Allison AC, 2001, PROG NEURO PSYCHOPH, V25, P1341, DOI 10.1016/S0278 5846(01)00192 0
   Bartok B, 2010, IMMUNOL REV, V233, P233, DOI 10.1111/j.0105 2896.2009.00859.x
   Bendele AM, 2000, ARTHRITIS RHEUM US, V43, P2648, DOI 10.1002/1529 0131(200012)43:12<2648::AID ANR4>3.0.CO;2 M
   Braun T, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3380
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201 365
   Cameron M, 2009, PHYTOTHER RES, V23, P1647, DOI 10.1002/ptr.3006
   Canter PH, 2006, PHYTOMEDICINE, V13, P371, DOI 10.1016/j.phymed.2006.01.010
   Cascao R, 2012, AUTOIMMUN REV
   Corrigall VM, 2002, CRIT REV IMMUNOL, V22, P281
   Dia VP, 2011, PEPTIDES, V32, P1979, DOI 10.1016/j.peptides.2011.09.009
   Dostal C, 2007, Vnitr Lek, V53, P1265
   Durai M, 2004, J IMMUNOL, V173, P181, DOI 10.4049/jimmunol.173.1.181
   Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092 8674(00)81109 5
   Firestein GS, 2004, J CLIN INVEST, V114, P471, DOI 10.1172/JCI200422651
   Flammer JR, 2011, MOL ENDOCRINOL, V25, P1075, DOI 10.1210/me.2011 0068
   Fojtíková M, 2010, CLIN EXP RHEUMATOL, V28, P849
   Godkar PB, 2006, PHYTOMEDICINE, V13, P29, DOI 10.1016/j.phymed.2003.11.011
   Gorman CL, 2008, BEST PRACT RES CL RH, V22, P221, DOI 10.1016/j.berh.2008.01.003
   Hansen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026634
   Huang MN, 2010, SEMIN ARTHRITIS RHEU, V40, P164, DOI 10.1016/j.semarthrit.2009.10.002
   Inoue H, 2008, BONE, V42, P1102, DOI 10.1016/j.bone.2008.01.031
   Jaquet V, 2011, BRIT J PHARMACOL, V164, P507, DOI 10.1111/j.1476 5381.2011.01439.x
   Kala CP, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746 4269 2 32
   Kamolmatyakul S, 2001, J DENT RES, V80, P351, DOI 10.1177/00220345010800011001
   Kim DH, 2009, EUR J CLIN INVEST, V39, P819, DOI 10.1111/j.1365 2362.2009.02186.x
   Kim D, 2011, BIOCHEM BIOPH RES CO, V415, P551, DOI 10.1016/j.bbrc.2011.10.087
   Kim EY, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2755
   Li CJ, 2007, FUNCT INTEGR GENOMIC, V7, P193, DOI 10.1007/s10142 006 0043 2
   Li CJ, 2012, GENE REGUL SYST BIO, V6, P1, DOI 10.4137/GRSB.S8303
   Lipsky PE., 2008, HARRISONS PRINCIPLE, V17th, P2083
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MILTENBURG AMM, 1992, SCAND J IMMUNOL, V35, P603, DOI 10.1111/j.1365 3083.1992.tb03260.x
   Moudgil KD, 1997, J EXP MED, V185, P1307, DOI 10.1084/jem.185.7.1307
   Pratt Arthur G, 2009, Best Pract Res Clin Rheumatol, V23, P37, DOI 10.1016/j.berh.2008.08.002
   Roux S, 2009, CURR RHEUMATOL REV, V5, P98, DOI 10.2174/157339709788298428
   SASSA H, 1990, BIOCHEM BIOPH RES CO, V172, P890, DOI 10.1016/0006 291X(90)90759 G
   SASSA H, 1994, FREE RADICAL BIO MED, V17, P201, DOI 10.1016/0891 5849(94)90075 2
   Sato K, 2006, CURR OPIN RHEUMATOL, V18, P419, DOI 10.1097/01.bor.0000231912.24740.a5
   Schopf Lisa R., 2006, P1, DOI 10.1007/978 3 7643 7520 1_1
   Shelly S, 2012, AUTOIMMUN REV, V11, pA465, DOI 10.1016/j.autrev.2011.11.009
   Soeken KL, 2003, RHEUMATOLOGY, V42, P652, DOI 10.1093/rheumatology/keg183
   Tao XL, 2002, ARTHRITIS RHEUM, V46, P1735, DOI 10.1002/art.10411
   Tong L, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2268
   Udagawa N, 1997, J EXP MED, V185, P1005, DOI 10.1084/jem.185.6.1005
   Venkatesha SH, 2011, J BIOL CHEM, V286, P15138, DOI 10.1074/jbc.M111.226365
   Wang WB, 2012, J CELL PHYSIOL, V227, P2196, DOI 10.1002/jcp.22956
   Wang Y, 2012, J IMMUNOL, V188, P222, DOI 10.4049/jimmunol.1002958
   Yu H, 2011, ARTHRITIS RHEUM US, V63, P981, DOI 10.1002/art.30219
   ZIFF M, 1989, RHEUMATOL INT, V9, P97
NR 49
TC 17
Z9 20
U1 0
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD AUG
PY 2012
VL 13
IS 4
BP 499
EP 506
DI 10.1016/j.intimp.2012.05.015
PG 8
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 976KA
UT WOS:000306582200019
PM 22664142
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Liu, YD
   Liu, QF
   Li, ZP
   Acharya, A
   Chen, DY
   Chen, ZT
   Mattheos, N
   Chen, ZF
   Huang, BX
AF Liu, Yudong
   Liu, Qifan
   Li, Zhipeng
   Acharya, Aneesha
   Chen, Danying
   Chen, Zetao
   Mattheos, Nikos
   Chen, Zhuofan
   Huang, Baoxin
TI Long non coding RNA and mRNA expression profiles in peri implantitis vs
   periodontitis
SO JOURNAL OF PERIODONTAL RESEARCH
LA English
DT Article
DE lncRNA; microarray; peri implantitis; periodontitis; transcriptome
ID GENE EXPRESSION; OSTEOCLAST FORMATION; PROSPECTIVE COHORT; PROSTAGLANDIN
   E 2; LESIONS; MELANOCYTES; PARTICLES; LIGAMENT; REVEALS; HEALTH
AB Background and Objective Peri implantitis is a biofilm mediated infectious disease that results in progressive loss of implant supporting bone. As compared to its analogue periodontitis, peri implantitis is generally known to be more aggressive, with comparatively rapid progression and less predictable treatment outcomes, especially when advanced. An understanding of molecular mechanisms underpinning the similarities and differences between peri implantitis and periodontitis is essential to develop novel management strategies. This study aimed to compare long non coding RNAs (lncRNAs) and messenger RNA (mRNA) expression profiles between peri implantitis and periodontitis. Methods Inflamed soft tissue from peri implantitis and periodontitis lesions, and healthy gingival tissue controls were analyzed by microarray. Cluster graphs, gene ontology (GO) analysis, and pathway analysis were performed. Quantitative real time PCR was employed to verify microarray results. The expression levels of RANKL and OPG in the three tissue types were also evaluated, using qRT PCR. Coding non coding (CNC) network analyses were performed. Results Microarray analyses revealed 1079 lncRNAs and 1003 mRNAs as differentially expressed in peri implantitis when compared to periodontitis. The cyclooxygenase 2 pathway was the most up regulated biological process in peri implantitis as compared to periodontitis, whereas hemidesmosome assembly was the most down regulated pathway. Osteoclast differentiation was relatively up regulated, and RANKL/OPG ratio was higher in peri implantitis than in periodontitis. Conclusions The study demonstrated that peri implantitis and periodontitis exhibit significantly different lncRNA and mRNA expression profiles, suggesting that osteoclast differentiation related pathways are comparatively more active in peri implantitis. These data highlight potential molecular targets for periodontitis and peri implantitis therapy development.
C1 [Liu, Yudong; Liu, Qifan; Li, Zhipeng; Chen, Danying; Chen, Zetao; Chen, Zhuofan; Huang, Baoxin] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Liu, Yudong; Liu, Qifan; Li, Zhipeng; Chen, Danying; Chen, Zetao; Chen, Zhuofan; Huang, Baoxin] Guangdong Prov Key Lab Stomatol, Guangzhou, Guangdong, Peoples R China.
   [Acharya, Aneesha; Mattheos, Nikos] Univ Hong Kong, Fac Dent, Hong Kong, Peoples R China.
   [Acharya, Aneesha] Dr DY Patil Vidyapeeth, Dept Periodontol, Pune, Maharashtra, India.
C3 Sun Yat Sen University; University of Hong Kong; Dr DY Patil Vidyapeeth
   Pune
RP Huang, BX (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Dept Oral Implantol, Guanghua Sch Stomatol, 56 Lingyuan West Rd, Guangzhou 510060, Guangdong, Peoples R China.; Chen, ZF (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Zhujiang New Town Dent Clin, 56 Lingyuan West Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM dentistczf@163.com; dentisthbx@163.com
RI Chen, Kuan Hung/LIC 4398 2024; Acharya, Aneesha/H 9940 2019; Mattheos,
   Nikos/C 8614 2011; Li, Zhipeng/JJG 1854 2023; Liu, yudong/MTE 1310 2025;
   Liu, Qifan/LSL 5001 2024
OI Huang, Baoxin/0000 0003 0805 8904; Acharya, Aneesha/0000 0002 9319 6780;
   Mattheos, Nikos/0000 0001 7358 7496; Liu, Yudong/0000 0002 2357 1522; 
FU National Natural Science Foundation of China [81400550, 81600914,
   81970975]; Fundamental Research Funds for the Central Universities
   [19ykpy81]
FX National Natural Science Foundation of China, Grant/Award Number:
   81400550, 81600914 and 81970975; the Fundamental Research Funds for the
   Central Universities, Grant/Award Number: 19ykpy81
CR Anfossi S, 2018, NAT REV CLIN ONCOL, V15, P541, DOI 10.1038/s41571 018 0035 x
   Barwick BG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09555 6
   Becker ST, 2014, CLIN IMPLANT DENT R, V16, P401, DOI 10.1111/cid.12001
   BENJAMINI Y, 1995, J ROY STAT SOC B, V57, P289, DOI 10.1111/j.2517 6161.1995.tb02031.x
   Berglundh T, 2011, J CLIN PERIODONTOL, V38, P188, DOI 10.1111/j.1600 051X.2010.01672.x
   Busam KJ, 1999, ADV ANAT PATHOL, V6, P12, DOI 10.1097/00125480 199901000 00002
   Carcuac O, 2014, J DENT RES, V93, P1083, DOI 10.1177/0022034514551754
   Carter G, 2015, BBA CLIN, V4, P102, DOI 10.1016/j.bbacli.2015.09.001
   Charalampakis G, 2014, CLIN ORAL IMPLAN RES, V25, P1094, DOI 10.1111/clr.12235
   Chen Y, 2017, METAB BRAIN DIS, V32, P281, DOI 10.1007/s11011 017 9965 8
   Daubert D, 2018, CLIN IMPLANT DENT R, V20, P945, DOI 10.1111/cid.12676
   Davanian H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046440
   de Aquino SG, 2017, J CLIN PERIODONTOL, V44, P881, DOI 10.1111/jcpe.12743
   de Magalhaes JP, 2009, BIOINFORMATICS, V25, P875, DOI 10.1093/bioinformatics/btp073
   Derks J, 2015, J CLIN PERIODONTOL, V42, pS158, DOI 10.1111/jcpe.12334
   Dodo Cindy Goes, 2017, Braz. Dent. J., V28, P428, DOI 10.1590/0103 6440201701382
   ERICSSON I, 1993, J CLIN PERIODONTOL, V20, P623, DOI 10.1111/j.1600 051X.1993.tb00706.x
   Gershoni M, 2017, BMC BIOL, V15, DOI 10.1186/s12915 017 0352 z
   Gheshlaghi ZN, 2008, ACTA BIOCH BIOPH SIN, V40, P777, DOI 10.1111/j.1745 7270.2008.00458.x
   Ghighi M, 2018, J PERIODONTAL RES, V53, P29, DOI 10.1111/jre.12483
   Guzeldemir Akcakanat E, 2019, J PERIODONTOL, V90, P663, DOI 10.1002/JPER.18 0477
   Guzeldemir Akcakanat E, 2016, J PERIODONTOL, V87, P58, DOI 10.1902/jop.2015.150175
   Han YK, 2019, J PERIODONTAL RES, V54, P73, DOI 10.1111/jre.12606
   Heitz Mayfield LJA, 2008, J CLIN PERIODONTOL, V35, P292, DOI 10.1111/j.1600 051X.2008.01275.x
   Huang W, 2015, NATURE, V528, P517, DOI 10.1038/nature16193
   Ikeda H, 2000, J PERIODONTOL, V71, P961, DOI 10.1902/jop.2000.71.6.961
   Lafaurie GI, 2017, J PERIODONTOL, V88, P1066, DOI 10.1902/jop.2017.170123
   Irie S, 2014, HANDB EXP PHARMACOL, V222, P387, DOI 10.1007/978 3 642 54215 2_15
   Jing ZL, 2016, BIOCHEM BIOPH RES CO, V472, P360, DOI 10.1016/j.bbrc.2016.02.079
   Karoussis IK, 2003, CLIN ORAL IMPLAN RES, V14, P329, DOI 10.1034/j.1600 0501.000.00934.x
   Karthikeyan B, 2015, J PHARM BIOALLIED SC, V7, P672, DOI 10.4103/0975 7406.163602
   Kikuta J, 2013, J CLIN INVEST, V123, P866, DOI 10.1172/JCI65054
   Kim YG, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246 016 0084 0
   Kitagawa M, 2012, CURR DRUG TARGETS, V13, P1616, DOI 10.2174/138945012803530026
   Klinge Bjorn, 2005, Dent Clin North Am, V49, P661, DOI 10.1016/j.cden.2005.03.007
   Larsen ST, 2010, BASIC CLIN PHARMACOL, V106, P114, DOI 10.1111/j.1742 7843.2009.00473.x
   Liao KL, 2018, MOL IMMUNOL, V101, P182, DOI 10.1016/j.molimm.2018.05.030
   Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110
   Lundmark A, 2015, SCI REP UK, V5, DOI 10.1038/srep18475
   Luo M, 2013, CANCER LETT, V333, P213, DOI 10.1016/j.canlet.2013.01.033
   Mao XH, 2017, IMMUNOLOGY, V150, P379, DOI 10.1111/imm.12698
   MARINELLO CP, 1995, J CLIN PERIODONTOL, V22, P475, DOI 10.1111/j.1600 051X.1995.tb00180.x
   Maruyama N, 2014, SCI REP UK, V4, DOI 10.1038/srep06602
   Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321
   Mattick JS, 2001, EMBO REP, V2, P986, DOI 10.1093/embo reports/kve230
   Mitarai H, 2017, J PERIODONTAL RES, V52, P984, DOI 10.1111/jre.12466
   Montoya MM, 2017, J IMMUNOL, V199, P559, DOI 10.4049/jimmunol.1700170
   Ono K, 2005, J BONE MINER RES, V20, P23, DOI 10.1359/JBMR.041027
   Pettersson M, 2017, J PERIODONTAL RES, V52, P21, DOI 10.1111/jre.12364
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Rao MS, 2019, FRONT GENET, V9, DOI 10.3389/fgene.2018.00636
   Roccuzzo M, 2010, CLIN ORAL IMPLAN RES, V21, P490, DOI 10.1111/j.1600 0501.2009.01886.x
   Rosenbaum M, 2014, GENE DEV, V28, P1165, DOI 10.1101/gad.240762.114
   Sheibanie AF, 2007, J IMMUNOL, V178, P8138, DOI 10.4049/jimmunol.178.12.8138
   Shi J, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.44
   Taiete T, 2018, J PERIODONTOL, V89, P93, DOI 10.1902/jop.2017.170221
   TAKEDA Y, 1993, ARCH HISTOL CYTOL, V56, P417, DOI 10.1679/aohc.56.417
   Tapia CV, 2014, MED MYCOL, V52, P445, DOI 10.1093/mmy/myu026
   Tomczak A, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 23395 2
   Tzach Nahman R, 2017, J CLIN PERIODONTOL, V44, P739, DOI 10.1111/jcpe.12735
   Wang K, 2016, CELL DEATH DIFFER, V23, P1394, DOI 10.1038/cdd.2016.28
   Wutzl A, 2006, J BIOMED MATER RES A, V77A, P75, DOI 10.1002/jbm.a.30615
   Yang KY, 2015, EVID BASED COMPL ALT, V2015, DOI 10.1155/2015/631737
   Zhang XH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15037674
   Zhang Y, 2017, DIS MODEL MECH, V11, pdmm031369
NR 65
TC 51
Z9 53
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 3484
EI 1600 0765
J9 J PERIODONTAL RES
JI J. Periodont. Res.
PD JUN
PY 2020
VL 55
IS 3
BP 342
EP 353
DI 10.1111/jre.12718
EA DEC 2019
PG 12
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA LQ5XB
UT WOS:000503357900001
PM 31853997
DA 2025 08 17
ER

PT J
AU Sun, HH
   Qu, TJ
   Zhang, XH
   Yu, Q
   Chen, FM
AF Sun, Hai Hua
   Qu, Tie Jun
   Zhang, Xian Hua
   Yu, Qing
   Chen, Fa Ming
TI Designing biomaterials for in situ periodontal tissue regeneration
SO BIOTECHNOLOGY PROGRESS
LA English
DT Article
DE cell homing; endogenous regeneration; tissue engineering; controlled
   release; regenerative medicine; biofunctionalized biomaterials
ID GROWTH FACTOR DELIVERY; BONE MORPHOGENETIC PROTEIN 2; MESENCHYMAL
   STEM CELLS; OSTEOBLAST PROGENITOR CELLS; BLOOD VESSEL FORMATION;
   MYOCARDIAL INFARCTION; DRUG DELIVERY; ENGINEERING SCAFFOLDS; ADENOVIRUS
   VECTORS; CONTROLLED RELEASE
AB The regeneration of periodontal tissue poses a significant challenge to biomaterial scientists, tissue engineers and periodontal clinicians. Recent advances in this field have shifted the focus from the attempt to recreate tissue replacements/constructs ex vivo to the development of biofunctionalized biomaterials that incorporate and release regulatory signals in a precise and near physiological fashion to achieve in situ regeneration. The molecular and physical information coded within the biomaterials define a local biochemical and mechanical niche with complex and dynamic regulation that establishes key interactions with host endogenous cells and, hence, may help to unlock latent regenerative pathways in the body by instructing cell homing and regulating cell proliferation/differentiation. In the future, these innovative principles and biomaterial devices promise to have a profound impact on periodontal reconstructive therapy and are also likely to reconcile the clinical and commercial pressures on other tissue engineering endeavors. (c) 2011 American Institute of Chemical Engineers Biotechnol. Prog., 2012
C1 [Sun, Hai Hua; Qu, Tie Jun; Yu, Qing] Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Xian 710032, Shaanxi, Peoples R China.
   [Zhang, Xian Hua] Chinese Peoples Liberat Army Gen Hosp, Periodontol Unit, Dept Stomatol, Beijing 100853, Peoples R China.
   [Chen, Fa Ming] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol & Oral Med, Translat Res Team, Xian 710032, Shaanxi, Peoples R China.
C3 Air Force Medical University; Chinese People's Liberation Army General
   Hospital; Air Force Medical University
RP Yu, Q (通讯作者)，Fourth Mil Med Univ, Sch Stomatol, Dept Operat Dent & Endodont, Xian 710032, Shaanxi, Peoples R China.
EM yuqing@fmmu.edu.cn; cfmsunhh@fmmu.edu.cn
RI ; Yu, Qing/KIG 5023 2024
OI He, Xiaotao/0000 0002 3767 4610; 
FU National Natural Science Foundation of China [81071253/H1818,
   31170912/C1002]
FX Fundings from the National Natural Science Foundation of China
   (81071253/H1818; 31170912/C1002) for some of the work mentioned in the
   review is gratefully appreciated.
CR Al Shammari KF, 2005, J PERIODONTOL, V76, P1910, DOI 10.1902/jop.2005.76.11.1910
   Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004
   Andreadis ST, 2006, TRENDS BIOTECHNOL, V24, P331, DOI 10.1016/j.tibtech.2006.05.001
   Anitua E, 2008, TRENDS PHARMACOL SCI, V29, P37, DOI 10.1016/j.tips.2007.10.010
   Anitua E, 2010, ADV DRUG DELIVER REV, V62, P741, DOI 10.1016/j.addr.2010.01.001
   Annabi N, 2010, TISSUE ENG PART B RE, V16, P371, DOI [10.1089/ten.teb.2009.0639, 10.1089/ten.TEB.2009.0639]
   Badylak SE, 2008, SEMIN IMMUNOL, V20, P109, DOI 10.1016/j.smim.2007.11.003
   Biondi M, 2008, ADV DRUG DELIVER REV, V60, P229, DOI 10.1016/j.addr.2007.08.038
   Blumenthal NM, 2002, J PERIODONTOL, V73, P1494, DOI 10.1902/jop.2002.73.12.1494
   Boccaccio A, 2011, INT J BIOL SCI, V7, P112, DOI 10.7150/ijbs.7.112
   Bohner M, 2010, MATER TODAY, V13, P24, DOI 10.1016/S1369 7021(10)70014 6
   Borselli C, 2010, P NATL ACAD SCI USA, V107, P3287, DOI 10.1073/pnas.0903875106
   Cao Cai fang, 2009, Zhonghua Kou Qiang Yi Xue Za Zhi, V44, P321
   Cao RH, 2003, NAT MED, V9, P604, DOI 10.1038/nm848
   Carr AN, 2006, CARDIOVASC RES, V69, P925, DOI 10.1016/j.cardiores.2005.12.005
   Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075
   Chandler EM, 2011, BIOTECHNOL BIOENG, V108, P1683, DOI 10.1002/bit.23079
   Chang PC, 2010, GENE THER, V17, P95, DOI 10.1038/gt.2009.117
   Chang PC, 2009, HUM GENE THER, V20, P486, DOI 10.1089/hum.2008.114
   Chen FM, 2007, J CONTROL RELEASE, V121, P81, DOI 10.1016/j.jconrel.2007.05.023
   Chen FM, 2007, J CONTROL RELEASE, V118, P65, DOI 10.1016/j.jconrel.2006.11.016
   Chen FM, 2010, TISSUE ENG PART B RE, V16, P219, DOI [10.1089/ten.teb.2009.0562, 10.1089/ten.TEB.2009.0562]
   Chen FM, 2011, BIOMATERIALS, V32, P3189, DOI 10.1016/j.biomaterials.2010.12.032
   Chen FM, 2011, J CONTROL RELEASE, V149, P92, DOI 10.1016/j.jconrel.2010.10.021
   Chen FM, 2010, BIOMATERIALS, V31, P7892, DOI 10.1016/j.biomaterials.2010.07.019
   Chen FM, 2010, BIOMATERIALS, V31, P6279, DOI 10.1016/j.biomaterials.2010.04.053
   Chen FM, 2009, CURR GENE THER, V9, P248, DOI 10.2174/156652309788921071
   Chen FM, 2009, BIOMATERIALS, V30, P5215, DOI 10.1016/j.biomaterials.2009.06.009
   Chen FM, 2009, MED RES REV, V29, P472, DOI 10.1002/med.20144
   Chen RR, 2007, PHARM RES, V24, P258, DOI 10.1007/s11095 006 9173 4
   Chen WH, 2010, CURR PHARM DESIGN, V16, P2388, DOI 10.2174/138161210791920478
   Choi DH, 2010, J CONTROL RELEASE, V147, P193, DOI 10.1016/j.jconrel.2010.07.103
   De Marchis F, 2002, BLOOD, V99, P2045, DOI 10.1182/blood.V99.6.2045
   Dee KC, 1998, J BIOMED MATER RES, V40, P371, DOI 10.1002/(SICI)1097 4636(19980605)40:3<371::AID JBM5>3.0.CO;2 C
   Ding G, 2010, STEM CELLS, V28, P1829, DOI 10.1002/stem.512
   Discher DE, 2005, SCIENCE, V310, P1139, DOI 10.1126/science.1116995
   Discher DE, 2009, SCIENCE, V324, P1673, DOI 10.1126/science.1171643
   Domachuk P, 2010, ADV MATER, V22, P249, DOI 10.1002/adma.200900821
   Duan XJ, 2011, J CELL PHYSIOL, V226, P150, DOI 10.1002/jcp.22316
   Elangovan S, 2010, J BIOMATER APPL, V25, P3, DOI 10.1177/0885328210366490
   Evans CH, 2007, TISSUE ENG, V13, P1987, DOI 10.1089/ten.2006.0302
   Fong ELS, 2011, BIOMATERIALS, V32, P395, DOI 10.1016/j.biomaterials.2010.08.101
   Ghadge SK, 2011, PHARMACOL THERAPEUT, V129, P97, DOI 10.1016/j.pharmthera.2010.09.011
   Giannobile WV, 1996, J PERIODONTAL RES, V31, P301, DOI 10.1111/j.1600 0765.1996.tb00497.x
   Guldberg RE, 2009, J BONE MINER RES, V24, P1507, DOI [10.1359/JBMR.090801, 10.1359/jbmr.090801]
   Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039
   Hakki SS, 2010, J PERIODONTOL, V81, P1663, DOI 10.1902/jop.2010.100074
   Hasegawa N, 2006, J PERIODONTOL, V77, P1003, DOI 10.1902/jop.2006.050341
   He XZ, 2010, INT J PHARMACEUT, V390, P107, DOI 10.1016/j.ijpharm.2009.12.063
   Herberg S, 2008, J CLIN PERIODONTOL, V35, P976, DOI 10.1111/j.1600 051X.2008.01323.x
   Hersel U, 2003, BIOMATERIALS, V24, P4385, DOI 10.1016/S0142 9612(03)00343 0
   Hsiong SX, 2009, TISSUE ENG PT A, V15, P263, DOI 10.1089/ten.tea.2007.0411
   Huang S, 2010, J CONTROL RELEASE, V142, P149, DOI 10.1016/j.jconrel.2009.10.018
   Huebsch N, 2009, NATURE, V462, P426, DOI 10.1038/nature08601
   Hughes Fulford M, 2011, J ORTHOP SURG RES, V6, DOI 10.1186/1749 799X 6 8
   Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400
   Jones KS, 2008, SEMIN IMMUNOL, V20, P130, DOI 10.1016/j.smim.2007.11.005
   Kaigler Darnell, 2006, Expert Opin Drug Deliv, V3, P647, DOI 10.1517/17425247.3.5.647
   Kanczler JM, 2010, BIOMATERIALS, V31, P1242, DOI 10.1016/j.biomaterials.2009.10.059
   Kawaguchi H, 2004, J PERIODONTOL, V75, P1281, DOI 10.1902/jop.2004.75.9.1281
   Kerfoot SM, 2008, AM J PHYSIOL HEART C, V294, pH2524, DOI 10.1152/ajpheart.00984.2007
   Khandwekar AP, 2010, J BIOMED MATER RES A, V95A, P413, DOI 10.1002/jbm.a.32852
   Kim JY, 2010, TISSUE ENG PT A, V16, P3023, DOI [10.1089/ten.tea.2010.0181, 10.1089/ten.TEA.2010.0181]
   Kim K, 2010, J DENT RES, V89, P842, DOI 10.1177/0022034510370803
   Kimura Y, 2010, TISSUE ENG PT A, V16, P1263, DOI [10.1089/ten.tea.2009.0322, 10.1089/ten.TEA.2009.0322]
   Kimura Y, 2010, J BIOMAT SCI POLYM E, V21, P37, DOI 10.1163/156856209X410193
   King GN, 2001, J CLIN PERIODONTOL, V28, P465, DOI 10.1034/j.1600 051x.2001.028005465.x
   Kinoshita A, 1997, J PERIODONTOL, V68, P103, DOI 10.1902/jop.1997.68.2.103
   Kitamura M, 2011, J DENT RES, V90, P35, DOI 10.1177/0022034510384616
   Klopsch C, 2009, J CELL MOL MED, V13, P664, DOI 10.1111/j.1582 4934.2008.00546.x
   Kolambkar YM, 2011, BIOMATERIALS, V32, P65, DOI 10.1016/j.biomaterials.2010.08.074
   Kumagai K, 2008, J ORTHOP RES, V26, P165, DOI 10.1002/jor.20477
   Laird DJ, 2008, CELL, V132, P612, DOI 10.1016/j.cell.2008.01.041
   Lau TT, 2011, EXPERT OPIN BIOL TH, V11, P189, DOI 10.1517/14712598.2011.546338
   Lee CH, 2010, LANCET, V376, P440, DOI 10.1016/S0140 6736(10)60668 X
   Lee DY, 2010, BONE, V46, P673, DOI 10.1016/j.bone.2009.10.018
   Lee Jaebum, 2010, Dent Clin North Am, V54, P93, DOI 10.1016/j.cden.2009.09.001
   Lee JY, CURR PHARM IN PRESS
   Lee K, 2011, J R SOC INTERFACE, V8, P153, DOI 10.1098/rsif.2010.0223
   Lee SH, 2007, ADV DRUG DELIVER REV, V59, P339, DOI 10.1016/j.addr.2007.03.016
   Li HX, 2009, CELLS TISSUES ORGANS, V190, P94, DOI 10.1159/000166547
   Liu Y, 2008, STEM CELLS, V26, P1065, DOI 10.1634/stemcells.2007 0734
   Lutolf MP, 2009, NATURE, V462, P433, DOI 10.1038/nature08602
   Lutolf MP, 2005, NAT BIOTECHNOL, V23, P47, DOI 10.1038/nbt1055
   Lutolf MP, 2003, P NATL ACAD SCI USA, V100, P5413, DOI 10.1073/pnas.0737381100
   Mao JJ, 2010, TISSUE ENG PART B RE, V16, P257, DOI 10.1089/ten.TEB.2009.0496
   Marklein RA, 2010, ADV MATER, V22, P175, DOI 10.1002/adma.200901055
   Mesure L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012949
   Min CK, 2011, J CLIN PERIODONTOL, V38, P261, DOI 10.1111/j.1600 051X.2010.01691.x
   Moioli EK, 2007, ADV DRUG DELIVER REV, V59, P308, DOI 10.1016/j.addr.2007.03.019
   Muzzi L, 2006, J PERIODONTOL, V77, P2084, DOI 10.1902/jop.2006.050227
   Nagaoka M, 2010, ANN BIOMED ENG, V38, P683, DOI 10.1007/s10439 010 9935 3
   Nie T, 2009, ACTA BIOMATER, V5, P865, DOI 10.1016/j.actbio.2008.12.004
   O'Brien FJ, 2011, MATER TODAY, V14, P88, DOI 10.1016/S1369 7021(11)70058 X
   Odörfer KI, 2008, J CELL MOL MED, V12, P2867, DOI 10.1111/j.1582 4934.2008.00511.x
   Otsuki S, 2010, P NATL ACAD SCI USA, V107, P10202, DOI 10.1073/pnas.0913897107
   Otsuru S, 2008, STEM CELLS, V26, P223, DOI 10.1634/stemcells.2007 0515
   Otsuru S, 2007, BIOCHEM BIOPH RES CO, V354, P453, DOI 10.1016/j.bbrc.2006.12.226
   Park YJ, 2000, BIOMATERIALS, V21, P153
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140 6736(05)67728 8
   Pizzo G, 2010, EUR J INTERN MED, V21, P496, DOI 10.1016/j.ejim.2010.07.011
   Place ES, 2009, NAT MATER, V8, P457, DOI [10.1038/nmat2441, 10.1038/NMAT2441]
   Qu D, 2011, J BIOMED MATER RES A, V96A, P543, DOI 10.1002/jbm.a.33009
   Quaglia F, 2008, INT J PHARMACEUT, V364, P281, DOI 10.1016/j.ijpharm.2008.04.030
   Ratanavaraporn J, 2011, BIOMATERIALS, V32, P2797, DOI 10.1016/j.biomaterials.2010.12.052
   Rayment EA, 2010, STEM CELLS, V28, P996, DOI 10.1002/stem.416
   Re'em T, 2010, BIOMATERIALS, V31, P6746, DOI 10.1016/j.biomaterials.2010.05.025
   Reynolds Mark A, 2010, Dent Clin North Am, V54, P55, DOI 10.1016/j.cden.2009.09.003
   Rezania A, 1999, BIOTECHNOL PROGR, V15, P19, DOI 10.1021/bp980083b
   Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101 1029
   Ripamonti U, 2001, EUR J ORAL SCI, V109, P241, DOI 10.1034/j.1600 0722.2001.00041.x
   Schroeder T, 2008, NATURE, V453, P345, DOI 10.1038/nature07043
   Sefton MV, 2008, SEMIN IMMUNOL, V20, P83, DOI 10.1016/j.smim.2007.12.008
   Segers VFM, 2007, CIRCULATION, V116, P1683, DOI 10.1161/CIRCULATIONAHA.107.718718
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Shen WL, 2010, BIOMATERIALS, V31, P7239, DOI 10.1016/j.biomaterials.2010.05.040
   Shimabukuro Y, 2011, J CELL PHYSIOL, V226, P809, DOI 10.1002/jcp.22406
   Sigurdsson TJ, 1996, INT J PERIODONT REST, V16, P525
   Sreejalekshmi KG, 2011, J BIOMED MATER RES A, V96A, P477, DOI 10.1002/jbm.a.32980
   Stevens MM, 2008, MATER TODAY, V11, P18, DOI 10.1016/S1369 7021(08)70086 5
   Sun HH, 2011, J TISSUE ENG REGEN M, V5, pE1, DOI 10.1002/term.369
   Suzuki T, 2011, J DENT RES, V90, P1013, DOI 10.1177/0022034511408426
   Tabata Y, 2005, DRUG DISCOV TODAY, V10, P1639, DOI 10.1016/S1359 6446(05)03639 1
   Tayalia P, 2009, ADV MATER, V21, P3269, DOI 10.1002/adma.200900241
   Thieme S, 2009, TISSUE ENG PART C ME, V15, P687, DOI [10.1089/ten.tec.2008.0556, 10.1089/ten.TEC.2008.0556]
   Tobita M, 2008, TISSUE ENG PT A, V14, P945, DOI 10.1089/ten.tea.2007.0048
   Tsumanuma Y, 2011, BIOMATERIALS, V32, P5819, DOI 10.1016/j.biomaterials.2011.04.071
   Uebersax L, 2009, TISSUE ENG PART B RE, V15, P263, DOI [10.1089/ten.teb.2008.0668, 10.1089/ten.TEB.2008.0668]
   Vasita R, 2006, EXPERT REV MED DEVIC, V3, P29, DOI 10.1586/17434440.3.1.29
   Villar Cristina C, 2010, Dent Clin North Am, V54, P73, DOI 10.1016/j.cden.2009.08.011
   Voog J, 2010, CELL STEM CELL, V6, P103, DOI 10.1016/j.stem.2010.01.011
   Wang XQ, 2009, J CONTROL RELEASE, V134, P81, DOI 10.1016/j.jconrel.2008.10.021
   Wikesjo Ulf M E, 2003, Clin Implant Dent Relat Res, V5, P112, DOI 10.1111/j.1708 8208.2003.tb00192.x
   Yan XZ, 2010, J PERIODONTOL, V81, P1289, DOI 10.1902/jop.2010.090655
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang Y, 2010, BIOMATERIALS, V31, P8574, DOI 10.1016/j.biomaterials.2010.06.026
   Ye Q, 2011, J TISSUE ENG REGEN M, V5, P264, DOI 10.1002/term.311
   Ye QS, 2010, BIOMATERIALS, V31, P9192, DOI 10.1016/j.biomaterials.2010.08.049
   Yilgor P, 2010, J BIOMED MATER RES A, V93A, P528, DOI 10.1002/jbm.a.32520
   Zaruba MM, 2009, CELL STEM CELL, V4, P313, DOI 10.1016/j.stem.2009.02.013
   Zhang G, 2007, TISSUE ENG, V13, P2063, DOI 10.1089/ten.2006.0013
   Zhang YF, 2007, BIOMATERIALS, V28, P4635, DOI 10.1016/j.biomaterials.2007.07.009
   Zhang YF, 2009, J CONTROL RELEASE, V136, P172, DOI 10.1016/j.jconrel.2009.02.016
   Zhu JM, 2010, BIOMATERIALS, V31, P4639, DOI 10.1016/j.biomaterials.2010.02.044
NR 144
TC 45
Z9 50
U1 0
U2 48
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 8756 7938
EI 1520 6033
J9 BIOTECHNOL PROGR
JI Biotechnol. Prog.
PD JAN FEB
PY 2012
VL 28
IS 1
BP 3
EP 20
DI 10.1002/btpr.698
PG 18
WC Biotechnology & Applied Microbiology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Food Science & Technology
GA 885JP
UT WOS:000299775500002
PM 21913341
OA Bronze
DA 2025 08 17
ER

PT J
AU Qiu, SX
   Dan, C
   Ding, LS
   Peng, S
   Chen, SN
   Farnsworth, NR
   Nolta, J
   Gross, ML
   Zhou, P
AF Qiu, Samuel X.
   Dan, Chun
   Ding, Li Sheng
   Peng, Shulin
   Chen, Shao Nong
   Farnsworth, Norman R.
   Nolta, Jan
   Gross, Michael L.
   Zhou, Ping
TI A triterpene glycoside from black cohosh that inhibits
   osteoclastogenesis by modulating RANKL and TNFα signaling pathways
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID NF KAPPA B; CIMICIFUGA RACEMOSA; ISOPROPANOLIC EXTRACT; CYCLOARTANE
   TRITERPENOIDS; BLOCKS OSTEOCLASTOGENESIS; CYTOTOXIC CYCLOARTANES;
   REPLACEMENT THERAPY; BONE DESTRUCTION; JNK ACTIVATION; ESTROGEN
AB Osteoporosis is a major age related source of morbidity and mortality. Increased bone resorption mediated by osteoclasts is central to its pathogenesis. Cytokines, particularly RANKL and TNF alpha, are often increased under pathologic conditions, leading to enhanced osteoclastogenesis. Black cohosh (Actaeal Cimicifuga racemosa L), a popular herbal supplement for the treatment of menopausal symptoms, was recently shown to have the beneficial effect of preventing bone loss. Here, we demonstrate that 25 acetylcimigenol xylopyranoside (ACCX), a triterpenoid glycoside isolated from black cohosh, potently blocks in vitro osteoclastogenesis induced by either RANKL or TNF alpha. This blockage of osteoclastogenesis elicited by ACCX results from abrogation of the NF kappa B and ERK pathways induced by either RANKL or TNF alpha, respectively. Importantly, this compound attenuates TNF alpha induced bone loss in vivo. Therefore, ACCX represents a potential lead for the development of a new class of antiosteoporosis agents.
C1 Washington Univ, Dept Chem, St Louis, MO 63130 USA.
   Chinese Acad Sci, Inst Biol, Chengdu 610041, Peoples R China.
   Univ Illinois, Sch Pharm, Dept Med Chem & Pharmacognosy, PCRPS, Chicago, IL 60612 USA.
   Univ Calif Davis, Davis, CA 95817 USA.
C3 Washington University (WUSTL); Chinese Academy of Sciences; Chengdu
   Institute of Biology, CAS; University of Illinois System; University of
   Illinois Chicago; University of Illinois Chicago Hospital; University of
   California System; University of California Davis
RP Gross, ML (通讯作者)，Washington Univ, Dept Chem, St Louis, MO 63130 USA.
EM mgross@wustl.edu; ping.zhou@ucdmc.ucdavis.edu
RI ; Chen, 6/G 5405 2010
OI Chen, Shao Nong/0000 0003 0748 0863; Nolta, Jan/0000 0003 4576 8542; 
FU NCCIH NIH HHS [P50 AT00155] Funding Source: Medline; NCRR NIH HHS [2P41
   RR00954] Funding Source: Medline; NHLBI NIH HHS [R01 HL073256] Funding
   Source: Medline; NIDDK NIH HHS [2R01 DK6184] Funding Source: Medline
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Burdette JE, 2003, J AGR FOOD CHEM, V51, P5661, DOI 10.1021/jf034264r
   Burdette JE, 2002, J AGR FOOD CHEM, V50, P7022, DOI 10.1021/jf020725h
   Cappuzzo KA, 2004, ANN PHARMACOTHER, V38, P294, DOI 10.1345/aph.1D353
   CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003 4819 122 1 199501010 00002
   Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672
   Cetiner BA, 2002, APPL MICROW WIREL, V14, P20
   Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945
   Chen SN, 2002, PHYTOCHEMISTRY, V61, P409, DOI 10.1016/S0031 9422(02)00209 1
   Chen SN, 2002, J NAT PROD, V65, P1391, DOI 10.1021/np0200818
   Chen SN, 2002, J NAT PROD, V65, P601, DOI 10.1021/np010494t
   Colditz GA, 1997, ANN NY ACAD SCI, V833, P129, DOI 10.1111/j.1749 6632.1997.tb48598.x
   Conte P, 2004, ONCOLOGIST, V9, P28, DOI 10.1634/theoncologist.9 90004 28
   Dai S, 2004, J BIOL CHEM, V279, P37219, DOI 10.1074/jbc.C400258200
   De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560
   Dixon Shanies D, 1999, ONCOL REP, V6, P1383
   Eghbali Fatourechi G, 2003, J CLIN INVEST, V111, P1221, DOI 10.1172/JCI200317215
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Freudenstein J, 2002, CANCER RES, V62, P3448
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Ishida N, 2002, J BIOL CHEM, V277, P41147, DOI 10.1074/jbc.M205063200
   JACQUES E, 2002, J AM MED ASS CHICAGO, V288, P321
   Jimi E, 2004, NAT MED, V10, P617, DOI 10.1038/nm1054
   Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041
   Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132
   Kitaura H, 2004, J IMMUNOL, V173, P4838, DOI 10.4049/jimmunol.173.8.4838
   Kousteni S, 2001, CELL, V104, P719, DOI 10.1016/S0092 8674(02)08100 X
   Kretzschmar G, 2005, J STEROID BIOCHEM, V97, P271, DOI 10.1016/j.jsbmb.2005.05.008
   Lam J, 2000, J CLIN INVEST, V106, P1481, DOI 10.1172/JCI11176
   Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890
   Liske E, 2002, J WOMEN HEALTH GEN B, V11, P163, DOI 10.1089/152460902753645308
   Matsumoto M, 2000, FEBS LETT, V486, P23, DOI 10.1016/S0014 5793(00)02231 6
   Mohamad K, 1997, J NAT PROD, V60, P81, DOI 10.1021/np960594c
   Nisslein T, 2003, J BONE MINER METAB, V21, P370, DOI 10.1007/s00774 003 0431 9
   Novack DV, 2003, J EXP MED, V198, P771, DOI 10.1084/jem.20030116
   Omobuwajo OR, 1996, PHYTOCHEMISTRY, V41, P1325, DOI 10.1016/0031 9422(95)00745 8
   Osmers R, 2005, OBSTET GYNECOL, V105, P1074, DOI 10.1097/01.AOG.0000158865.98070.89
   Pixley FJ, 2004, TRENDS CELL BIOL, V14, P628, DOI 10.1016/j.tcb.2004.09.016
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Ritchlin CT, 2003, J CLIN INVEST, V111, P821, DOI 10.1172/JCI200316069
   Roggia C, 2001, P NATL ACAD SCI USA, V98, P13960, DOI 10.1073/pnas.251534698
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Ruocco MG, 2005, J EXP MED, V201, P1677, DOI 10.1084/jem.20042081
   Seidlová Wuttke D, 2003, MATURITAS, V44, pS39, DOI 10.1016/S0378 5122(02)00347 X
   Shao Y, 2000, J NAT PROD, V63, P905, DOI 10.1021/np000047y
   Takeshita S, 2000, J BONE MINER RES, V15, P1477, DOI 10.1359/jbmr.2000.15.8.1477
   Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tian Z, 2006, FITOTERAPIA, V77, P39, DOI 10.1016/j.fitote.2005.08.001
   Tian Z, 2005, CANCER LETT, V226, P65, DOI 10.1016/j.canlet.2004.11.019
   Viereck V, 2005, J BONE MINER RES, V20, P2036, DOI 10.1359/JBMR.050716
   Watanabe K, 2002, CHEM PHARM BULL, V50, P121, DOI 10.1248/cpb.50.121
   Wei S, 2005, J CLIN INVEST, V115, P282, DOI 10.1172/JCI200523394
   WEITZMANN MN, 2006, NY ACAD SCI, V1068, P256
   Wuttke W, 2003, MATURITAS, V44, pS67, DOI 10.1016/S0378 5122(02)00350 X
   Zheng H, 2006, J BIOL CHEM, V281, P15809, DOI 10.1074/jbc.M513225200
   Zierau O, 2002, J STEROID BIOCHEM, V80, P125, DOI 10.1016/S0960 0760(01)00178 9
NR 58
TC 46
Z9 54
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1074 5521
EI 1879 1301
J9 CHEM BIOL
JI Chem. Biol.
PD JUL
PY 2007
VL 14
IS 7
BP 860
EP 869
DI 10.1016/j.chembiol.2007.06.010
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 195HF
UT WOS:000248402400017
PM 17656322
DA 2025 08 17
ER

PT J
AU Zhang, J
   Zhang, LY
   Yao, G
   Zhao, H
   Wu, SG
AF Zhang, Jian
   Zhang, Lingyan
   Yao, Gang
   Zhao, Hai
   Wu, Shuguang
TI NRF2 is essential for iron overload stimulated osteoclast
   differentiation through regulation of redox and iron homeostasis
SO CELL BIOLOGY AND TOXICOLOGY
LA English
DT Article
DE NRF2; Osteoclast differentiation; Iron homeostasis; Redox balance; Bone
   resorption
ID BONE MINERAL DENSITY; LEVEL; WOMEN
AB Iron overload enhances osteoclastic bone resorption and induces osteoporosis. Excess iron is highly toxic. The modulation of redox and iron homeostasis is critical for osteoclast differentiation under iron overload condition. Nuclear factor erythroid 2 related factor 2 (NRF2) is a transcription factor that regulates the cellular defense against oxidative stress and iron overload through the expression of genes involved in anti oxidative processes and iron metabolism. Our studies demonstrated that NRF2 activation was suppressed during osteoclast differentiation. Under iron overload condition, NRF2 and its mediated antioxidant and iron metabolism genes were activated by reactive oxygen species (ROS), which enhanced antioxidant capability. NRF2 mediated the upregulation of iron exporter ferroportin 1 (FPN1) and iron storage protein ferritin, contributing to decreased levels of intracellular iron. Nfe2l2 knockout induced oxidative stress and promoted osteoclast differentiation under normal condition, but induced ferroptosis under iron overload condition. Nfe2l2 knockout alleviated iron overload induced bone loss by inhibiting osteoclast differentiation. Our results suggest that NRF2 activation is essential for osteoclast differentiation by enhancing antioxidant capability and reducing intracellular iron under iron overload condition. Targeting NRF2 to induce ferroptosis could be a potential therapy for the treatment of iron overload induced osteoporosis.
C1 [Zhang, Jian; Zhang, Lingyan; Yao, Gang; Zhao, Hai; Wu, Shuguang] Guizhou Univ Tradit Chinese Med, Inst Lab Anim Sci, Guiyang 550025, Guizhou, Peoples R China.
C3 Guizhou University of Traditional Chinese Medicine
RP Zhang, J (通讯作者)，Guizhou Univ Tradit Chinese Med, Inst Lab Anim Sci, Guiyang 550025, Guizhou, Peoples R China.
EM zhangjian075@gzy.edu.cn
OI Zhang, Jian/0000 0002 6117 3285
FU Guizhou Provincial Science and Technology Projects [Qian Ke He Ji
   Chu ZK[2021] Yi Ban 398]; National Natural Science Foundation of China
   [82060168, 82360176]; Guizhou Education Department Youth Science and
   Technology Talents Growth Project [Qian Jiao He KY Zi [2021]199]
FX This work was supported by Guizhou Provincial Science and Technology
   Projects (Qian Ke He Ji Chu ZK[2021] Yi Ban 398), the National Natural
   Science Foundation of China (82060168, 82360176), and the Guizhou
   Education Department Youth Science and Technology Talents Growth Project
   (Qian Jiao He KY Zi [2021]199).
CR Babaei M, 2018, CASP J INTERN MED, V9, P232, DOI 10.22088/cjim.9.3.232
   Che JM, 2020, BIOL TRACE ELEM RES, V195, P353, DOI 10.1007/s12011 019 01867 4
   Chen CH, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.798433
   Chen X, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.590226
   Chon SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114972
   Das BK, 2022, ELIFE, V11, DOI 10.7554/eLife.73539
   Dodson M, 2019, REDOX BIOL, V23, DOI 10.1016/j.redox.2019.101107
   Gu ZM, 2015, CANCER RES, V75, P2211, DOI 10.1158/0008 5472.CAN 14 3804
   Hernansanz Agustín P, 2021, ANTIOXIDANTS BASEL, V10, DOI 10.3390/antiox10030415
   Hyeon S, 2013, FREE RADICAL BIO MED, V65, P789, DOI 10.1016/j.freeradbiomed.2013.08.005
   Ishii K, 2009, NAT MED, V15, P259, DOI 10.1038/nm.1910
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580 020 00324 8
   Jung DW, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000009403, 10.1097/md.0000000000009403]
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kanzaki H, 2013, J BIOL CHEM, V288, P23009, DOI 10.1074/jbc.M113.478545
   Ke K, 2015, MOL CELL ENDOCRINOL, V409, P11, DOI 10.1016/j.mce.2015.03.022
   Kerins MJ, 2018, ANTIOXID REDOX SIGN, V29, P1756, DOI 10.1089/ars.2017.7176
   Kim BJ, 2013, OSTEOPOROSIS INT, V24, P2627, DOI 10.1007/s00198 013 2363 0
   Kim BJ, 2012, J BONE MINER RES, V27, P2279, DOI 10.1002/jbmr.1692
   Lee NK, 2005, BLOOD, V106, P852, DOI 10.1182/blood 2004 09 3662
   Park CK, 2014, BONE, V63, P36, DOI 10.1016/j.bone.2014.01.025
   Park JH, 2017, MOL CELLS, V40, P706
   Qin JJ, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964 019 0435 2
   Sun XW, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101309
   Takayanagi H, 2021, J BONE MINER METAB, V39, P13, DOI 10.1007/s00774 020 01191 1
   Udagawa N, 2021, J BONE MINER METAB, V39, P19, DOI 10.1007/s00774 020 01162 6
   Wang L, 2018, J BIOL CHEM, V293, P9248, DOI 10.1074/jbc.RA117.000834
   Xie WJ, 2016, CALCIFIED TISSUE INT, V98, P275, DOI 10.1007/s00223 015 0087 1
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Xue P, 2019, BIOCHEM BIOPH RES CO, V511, P637, DOI 10.1016/j.bbrc.2019.02.095
   Yin YK, 2020, SCI REP UK, V10, DOI 10.1038/s41598 019 57185 1
   Yuan Y, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13194
   Zhang J, 2021, BIOMED PHARMACOTHER, V137, DOI 10.1016/j.biopha.2021.111380
   Zhang J, 2019, TOXICOL LETT, V313, P50, DOI 10.1016/j.toxlet.2019.06.007
   Zhang J, 2019, BONE, V120, P50, DOI 10.1016/j.bone.2018.10.005
   Zhang J, 2017, ELECTROMAGN BIOL MED, V36, P8, DOI 10.3109/15368378.2016.1141362
   Zhang LY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.728172
NR 37
TC 22
Z9 23
U1 2
U2 25
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0742 2091
EI 1573 6822
J9 CELL BIOL TOXICOL
JI Cell Biol. Toxicol.
PD DEC
PY 2023
VL 39
IS 6
BP 3305
EP 3321
DI 10.1007/s10565 023 09834 5
EA OCT 2023
PG 17
WC Cell Biology; Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Toxicology
GA CI0K2
UT WOS:001087565400001
PM 37855941
DA 2025 08 17
ER

PT J
AU Kasoha, M
   Bohle, RM
   Seibold, A
   Gerlinger, C
   Juhasz Böss, I
   Solomayer, EF
AF Kasoha, Mariz
   Bohle, Rainer M.
   Seibold, Anita
   Gerlinger, Christoph
   Juhasz Boess, Ingolf
   Solomayer, Erich Franz
TI Dickkopf 1 (Dkk1) protein expression in breast cancer with special
   reference to bone metastases
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Breast cancer; Dickkopf 1 (Dkk1); Bone metastases;  Catenin; Target
   therapy
ID WNT INHIBITOR DICKKOPF 1; SERUM DICKKOPF 1; CLINICAL SIGNIFICANCE;
   MULTIPLE MYELOMA; PROGNOSTIC VALUE; BETA CATENIN; PROLIFERATION; TARGET;
   CELLS; GENE
AB Dysregulation of the Wnt inhibitor dickkopf 1 protein (Dkk1) has been reported in a variety of cancers. In addition, it has been linked to the progression of malignant bone disease by impairing osteoblast activity. This study investigated serum  and tissue levels of Dkk1 in breast cancer patients with  or without bone metastases. Serum Dkk1 levels were measured by ELISA in 89 breast cancer patients and 86 healthy women. Tissue levels of Dkk1 and  catenin, a major downstream component of Wnt transduction pathway, were tested with immunohistochemical staining in 143 different tissues, including adjacent non tumoral breast tissues, primary breast tumours, lymph nodes metastases, and bone metastases. Serum levels of Dkk1 were significantly increased in breast cancer patients without metastases compared with healthy controls and even more increased in patients with bone metastases. Tissue expression of Dkk1 was positive in 70% of tested primary breast cancer tissues and demonstrated significant correlation with histological type and PR status. Less frequent expression of Dkk1 was found in lymph nodes metastases and bone metastases compared with adjacent non tumoral breast tissues and primary breast tumours. Tissue expression of  catenin was positive in the vast majority of all tested tissue types indicating activated Wnt/ catenin signalling. Our results suggested that Wnt/ catenin signalling in breast tumours and their secondary lymph nodes  and bone metastases is dysregulated and this could be related to aberrant Dkk1 expression levels. Hence, Dkk1 protein might provide insights into the continued development of novel comprehensive and therapeutic strategies for breast cancer and its bone metastases.
C1 [Kasoha, Mariz; Gerlinger, Christoph; Juhasz Boess, Ingolf; Solomayer, Erich Franz] Univ Med Sch Saarland, Dept Gynecol Obstet & Reprod Med, D 66421 Homburg, Germany.
   [Bohle, Rainer M.; Seibold, Anita] Univ Med Sch Saarland, Inst Gen & Special Pathol, D 66421 Homburg, Germany.
C3 Universitatsklinikum des Saarlandes; Universitatsklinikum des Saarlandes
RP Kasoha, M (通讯作者)，Univ Med Sch Saarland, Dept Gynecol Obstet & Reprod Med, D 66421 Homburg, Germany.
EM mariz.kasoha@uks.eu
OI Kasoha, Mariz/0000 0002 5468 4597; Gerlinger,
   Christoph/0000 0003 4538 6413
CR Acar M, 2012, TURK J MED SCI, V42, P1379, DOI 10.3906/sag 1204 30
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Bu GJ, 2008, INT J CANCER, V123, P1034, DOI 10.1002/ijc.23625
   Chen W, 2016, MOL MED REP, V13, P3466, DOI 10.3892/mmr.2016.4986
   Cheng SL, 2008, J BIOL CHEM, V283, P20505, DOI 10.1074/jbc.M800851200
   Christodoulides C, 2006, DIABETOLOGIA, V49, P678, DOI 10.1007/s00125 006 0144 4
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dolled Filhart M, 2006, CANCER RES, V66, P5487, DOI 10.1158/0008 5472.CAN 06 0100
   Durkee BY, 2016, J CLIN ONCOL, V34, P902, DOI 10.1200/JCO.2015.62.9105
   Eads J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw371.90
   Forget MA, 2007, BRIT J CANCER, V96, P646, DOI 10.1038/sj.bjc.6603579
   Fouad YM, 2016, SCAND J GASTROENTERO, V51, P1133, DOI 10.3109/00365521.2016.1172337
   Gao C, 2010, CELL SIGNAL, V22, P717, DOI 10.1016/j.cellsig.2009.11.021
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Göbel A, 2017, BREAST CANCER RES TR, V164, P737, DOI 10.1007/s10549 017 4296 3
   Gonzálex Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303
   Gunn WG, 2006, STEM CELLS, V24, P986, DOI 10.1634/stemcells.2005 0220
   Gyu Beom J, 2015, SCI REP, DOI [10.1038/srep12465, DOI 10.1038/SREP12465]
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104
   Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189
   Iyer SP, 2014, BRIT J HAEMATOL, V167, P366, DOI 10.1111/bjh.13056
   Johnson RW, 2014, CLIN EXP METASTAS, V31, P945, DOI 10.1007/s10585 014 9682 1
   Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008 5472.CAN 10 2993
   Kagey MH, 2017, BRIT J PHARMACOL, V174, P4637, DOI 10.1111/bph.13894
   Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089
   Lipton Allan, 2005, Curr Treat Options Oncol, V6, P161, DOI 10.1007/s11864 005 0023 0
   Liu JT, 2017, MINERVA MED, V108, P334, DOI 10.23736/S0026 4806.17.04807 8
   Liu YQ, 2014, TUMOR BIOL, V35, P3145, DOI 10.1007/s13277 013 1411 x
   Manders K, 2006, BMC CANCER, V6, DOI 10.1186/1471 2407 6 179
   Mariz K, 2015, CLIN EXP METASTAS, V32, P857, DOI 10.1007/s10585 015 9750 1
   Mazon M, 2016, CANCERS, V8, DOI 10.3390/cancers8070062
   Merino VF, 2017, MOL ONCOL, V11, P552, DOI 10.1002/1878 0261.12053
   Mikheev AM, 2008, BREAST CANCER RES TR, V112, P263, DOI 10.1007/s10549 007 9867 2
   Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood 2008 01 132134
   Qiao L, 2008, CANCER LETT, V269, P67, DOI 10.1016/j.canlet.2008.04.032
   Rachner TD, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3616
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Sato N, 2010, CANCER RES, V70, P5326, DOI 10.1158/0008 5472.CAN 09 3879
   Shao YC, 2017, AM J CANCER RES, V7, P1754
   Shen TS, 2016, AM J CLIN PATHOL, V146, P603, DOI 10.1093/ajcp/aqw183
   Sheng SL, 2009, CLIN CHEM, V55, P1656, DOI 10.1373/clinchem.2009.125641
   Siegel RL., 2019, J Clin, V69, P7, DOI DOI 10.3322/CAAC.21772
   Tulac S, 2006, J CLIN ENDOCR METAB, V91, P1453, DOI 10.1210/jc.2005 0769
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Voorzanger Rousselot N, 2007, BRIT J CANCER, V97, P964, DOI 10.1038/sj.bjc.6603959
   Voorzanger Rousselot N, 2009, CALCIFIED TISSUE INT, V84, P348, DOI 10.1007/s00223 009 9225 y
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Xu WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037624
   Zhou SJ, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000 014 0161 4
   Zhou XL, 2010, ACTA PHARMACOL SIN, V31, P202, DOI 10.1038/aps.2009.200
   Zhou Y, 2010, J EXP CLIN CANC RES, V28, P129
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 56
TC 31
Z9 37
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262 0898
EI 1573 7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD DEC
PY 2018
VL 35
IS 8
BP 763
EP 775
DI 10.1007/s10585 018 9937 3
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA HC3TT
UT WOS:000451726300007
PM 30238177
DA 2025 08 17
ER

PT J
AU Bussard, KM
   Mastro, AM
AF Bussard, Karen M.
   Mastro, Andrea M.
TI Ex vivo Analysis of the Bone Microenvironment in Bone Metastatic Breast
   Cancer
SO JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
LA English
DT Article
DE Breast cancer; Bone metastasis; Bone microenvironment; Osteoblast; IL 6;
   MCP 1; VEGF
ID TUMOR CELL LINES; IN VIVO; IMMUNE CELLS; DISEASE; MICE; EXPRESSION;
   INTERLEUKIN 8; PROGRESSION; MECHANISMS; ADHESION
AB In humans, breast cancer has a predilection to metastasize to the skeleton. While the mechanism for preferential metastasis is unknown, the bone microenvironment likely provides a fertile soil for metastatic breast cancer cells. In order to examine the bone microenvironment ex vivo following the formation of breast cancer metastases, several techniques may be employed: fluorescence stereomicroscopy, magnetic resonance imaging (MRI), microCT (mu CT), immunohistochemistry, and cytokine arrays, to name a few. These methods allow for a comprehensive evaluation of the bone microenvironment during bone metastatic breast cancer. By identifying alterations in the bone niche caused by metastatic breast cancer cells, it may be possible to block or disrupt these factors through the use of targeted drugs. Appropriate therapeutic treatment would allow for an improved quality of life and longer survival time for individuals with bone metastatic breast cancer.
C1 [Mastro, Andrea M.] Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA.
   [Bussard, Karen M.] Penn State Univ, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University  
   University Park; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Pennsylvania State University  
   University Park
RP Mastro, AM (通讯作者)，Penn State Univ, Dept Biochem & Mol Biol, 431 S Frear Bldg, University Pk, PA 16802 USA.
EM a36@psu.edu
OI Bussard, Karen/0000 0002 6519 9300; Mastro, Andrea/0000 0003 2710 3360
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bendre M, 2003, CLIN ORTHOP RELAT R, pS39, DOI 10.1097/01.blo.0000093844.72468.f4
   Bendre MS, 2003, BONE, V33, P28, DOI 10.1016/S8756 3282(03)00086 3
   Bendre MS, 2002, CANCER RES, V62, P5571
   Braun S, 2000, GENE THER, V7, P1447, DOI 10.1038/sj.gt.3301261
   CAILLEAU R, 1978, IN VITRO CELL DEV B, V14, P911
   CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661
   Chirgwin J M., 2003, Science Medicine, V9, P140
   de Zoeten EF, 1998, J IMMUNOL, V160, P2915
   DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746
   DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555 007 9100 0
   Fitzgerald KA., 2001, CYTOKINE FACTS BOOK, V2nd
   GALASKO CSB, 1982, CLIN ORTHOP RELAT R, P20
   Guise TA, 1998, ENDOCR REV, V19, P18, DOI 10.1210/er.19.1.18
   Guise Theresa A., 2000, Cancer, V88, P2892, DOI 10.1002/1097 0142(20000615)88:12+<2892::AID CNCR2>3.0.CO;2 Y
   Gupta P., 2004, DRUG DISCOV TODAY, V1, P9, DOI DOI 10.1016/J.DDM0D.2004.05.001
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Harms JF, 2002, BIOTECHNIQUES, V33, P1197, DOI 10.2144/02336bm02
   Jemal A, 2009, CA CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kalikin LM, 2003, CANCER BIOL THER, V2, P656
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535 6108(03)00132 6
   Kinder M, 2008, EXP CELL RES, V314, P173, DOI 10.1016/j.yexcr.2007.09.021
   Kuperwasser C, 2005, CANCER RES, V65, P6130, DOI 10.1158/0008 5472.CAN 04 1408
   Lelekakis M, 1999, CLIN EXP METASTAS, V17, P163, DOI 10.1023/A:1006689719505
   Martin TJ, 2000, ENDOCR RELAT CANCER, V7, P271, DOI 10.1677/erc.0.0070271
   Mastro AM, 2004, J CELL BIOCHEM, V91, P265, DOI 10.1002/jcb.10746
   Mercer RR, 2005, EXP CELL RES, V310, P270, DOI 10.1016/j.yexcr.2005.07.029
   Mercer RR, 2004, CLIN EXP METASTAS, V21, P427, DOI 10.1007/s10585 004 1867 6
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Peyruchaud O, 2001, J BONE MINER RES, V16, P2027, DOI 10.1359/jbmr.2001.16.11.2027
   Phadke PA, 2006, CLIN CANCER RES, V12, P1431, DOI 10.1158/1078 0432.CCR 05 1806
   Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772
   Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081
   Rubens R.D., 2000, CANC SKELETON
   SICILIANO MJ, 1979, CANCER RES, V39, P919
   Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100
   Slettenaar VIF, 2006, ADV DRUG DELIVER REV, V58, P962, DOI 10.1016/j.addr.2006.03.012
   Society A.C., 2009, CANC FACTS FIGURES 2
   Soule H., 1991, U.S. Patent, Patent No. [5,026,637, 5026637]
   Sun SL, 2004, ROBOT CIM INT MANUF, V20, P29, DOI 10.1016/S0736 5845(03)00052 8
   Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929
   Wick M, 1997, J EXP MED, V186, P229, DOI 10.1084/jem.186.2.229
   Yoneda T, 2001, J BONE MINER RES, V16, P1486, DOI 10.1359/jbmr.2001.16.8.1486
   YONEDA T, 1994, BREAST CANCER RES TR, V32, P73, DOI 10.1007/BF00666208
   Yoneda T, 2000, J Orthop Sci, V5, P75, DOI 10.1007/s007760050012
NR 45
TC 8
Z9 9
U1 2
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1083 3021
EI 1573 7039
J9 J MAMMARY GLAND BIOL
JI J. Mammary Gland Biol. Neoplasia
PD DEC
PY 2009
VL 14
IS 4
BP 387
EP 395
DI 10.1007/s10911 009 9159 z
PG 9
WC Oncology; Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Endocrinology & Metabolism; Physiology
GA 528RM
UT WOS:000272464300005
PM 19949843
DA 2025 08 17
ER

PT J
AU Scheller, EL
   Baldwin, CM
   Kuo, S
   D'Silva, NJ
   Feinberg, SE
   Krebsbach, PH
   Edwards, PC
AF Scheller, E. L.
   Baldwin, C. M.
   Kuo, S.
   D'Silva, N. J.
   Feinberg, S. E.
   Krebsbach, P. H.
   Edwards, P. C.
TI Bisphosphonates Inhibit Expression of p63 by Oral Keratinocytes
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE osteonecrosis; oral pathology; gingival; epithelia; keratinocytes;
   zoledronic acid
ID MEVALONATE PATHWAY; BONE RESORPTION; CACO 2 CELLS; STEM CELLS; IN VITRO;
   ALENDRONATE; OSTEONECROSIS; MACROPHAGES; EQUIVALENT; APOPTOSIS
AB Osteonecrosis of the jaw (ONJ), a side effect of bisphosphonate therapy, is characterized by exposed bone that fails to heal within eight weeks. Healing time of oral epithelial wounds is decreased in the presence of amino bisphosphonates; however, the mechanism remains unknown. We examined human tissue from individuals with ONJ and non bisphosphonate treated control individuals to identify changes in oral epithelium and connective tissue. Oral and intravenous bisphosphonate treated ONJ sites had reduced numbers of basal epithelial progenitor cells, as demonstrated by a 13.8 +/  1.1% and 31.9 +/  5.8% reduction of p63 expression, respectively. No significant differences in proliferation rates, vessel density, or macrophage number were noted. In vitro treatment of clonal and primary oral keratinocytes with zoledronic acid (ZA) inhibited p63, and expression was rescued by the addition of mevalonate pathway intermediates. In addition, both ZA treatment and p63 shRNA knock down impaired formation of 3D Ex Vivo Produced Oral Mucosa Equivalents (EVPOME) and closure of an in vitro scratch assay. Analysis of our data suggests that bisphosphonate treatment may delay oral epithelial healing by interfering with p63 positive progenitor cells in the basal layer of the oral epithelium in a mevalonate pathway dependent manner. This delay in healing may increase the likelihood of osteonecrosis developing in already compromised bone.
C1 [Baldwin, C. M.; D'Silva, N. J.; Edwards, P. C.] Univ Michigan, Sch Med, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
   [Scheller, E. L.; Krebsbach, P. H.] Univ Michigan, Sch Med, Dept Biol & Mat Sci, Ann Arbor, MI USA.
   [D'Silva, N. J.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA.
   [Kuo, S.; Feinberg, S. E.] Univ Michigan, Sch Dent, Dept Oral & Maxillofacial Surg, Ann Arbor, MI 48109 USA.
C3 University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Edwards, PC (通讯作者)，Univ Michigan, Sch Med, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA.
EM paulce@umich.edu
RI Krebsbach, Paul/AAC 4765 2021; Scheller, Erica/H 6993 2019; D'Silva,
   Nisha/B 4734 2013; Edwards, Paul/E 1075 2013
OI Edwards, Paul/0000 0001 7884 8480; Scheller, Erica/0000 0002 1551 3816
FU University of Michigan Department of Periodontics and Oral Medicine
   [R01 DE13835, F30 DE019577, R01 DE019431]
FX This work was supported by the University of Michigan Department of
   Periodontics and Oral Medicine (PCE), R01 DE13835 (PHK), F30 DE019577
   (ELS), and R01 DE019431 (SEF). Many thanks to Chris Strayhorn, Nancy
   McAnsh, Tom Lannigan, and Rogerio Castilho for their assistance. The
   authors declare no potential conflicts of interest with respect to the
   authorship and/or publication of this article.
CR Amagase K, 2007, DIGEST DIS SCI, V52, P1879, DOI 10.1007/s10620 007 9769 5
   Bergstrom JD, 2000, ARCH BIOCHEM BIOPHYS, V373, P231, DOI 10.1006/abbi.1999.1502
   Bortoluzzi MC, 2004, ORAL SURG ORAL MED O, V98, P698, DOI 10.1016/j.tripleo.2004.04.001
   Castilho RM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010503
   Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133
   Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087
   Gonzalez Moles MA, 2000, J ORAL PATHOL MED, V29, P514, DOI 10.1034/j.1600 0714.2000.291006.x
   Izumi K, 1999, J ORAL MAXIL SURG, V57, P571, DOI 10.1016/S0278 2391(99)90077 0
   Izumi K, 2003, INT J ORAL MAX SURG, V32, P188, DOI 10.1054/ijom.2002.0365
   Kho Y, 2004, P NATL ACAD SCI USA, V101, P12479, DOI 10.1073/pnas.0403413101
   Kobayashi Y, 2010, J BONE MINER METAB, V28, P165, DOI 10.1007/s00774 009 0128 9
   Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Little NA, 2002, INT J BIOCHEM CELL B, V34, P6, DOI 10.1016/S1357 2725(01)00086 3
   Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531
   Mönkkönen H, 2003, EUR J PHARM SCI, V19, P23, DOI 10.1016/S0928 0987(03)00039 3
   Novince CM, 2009, CELLS TISSUES ORGANS, V189, P275, DOI 10.1159/000152915
   Pellegrini G, 2001, P NATL ACAD SCI USA, V98, P3156, DOI 10.1073/pnas.061032098
   Rubegni P, 2006, NEW ENGL J MED, V355, pE25, DOI 10.1056/NEJMicm054413
   Scheller EL, 2010, STEM CELLS, V28, P1071, DOI 10.1002/stem.432
   Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045
   Stephens P, 2007, ORAL DIS, V13, P1, DOI 10.1111/j.1601 0825.2006.01314.x
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Vaughan MB, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007908
   Warburton G, 2005, WOUND REPAIR REGEN, V13, P19, DOI 10.1111/j.1067 1927.2005.130104.x
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
   Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539
NR 29
TC 23
Z9 25
U1 1
U2 4
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022 0345
J9 J DENT RES
JI J. Dent. Res.
PD JUL
PY 2011
VL 90
IS 7
BP 894
EP 899
DI 10.1177/0022034511407918
PG 6
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 778IH
UT WOS:000291696900012
PM 21551338
OA Green Published, Green Submitted
DA 2025 08 17
ER

PT J
AU Hollenberg, AM
   Huber, A
   Smith, CO
   Eliseev, RA
AF Hollenberg, Alex M.
   Huber, Aric
   Smith, Charles O.
   Eliseev, Roman A.
TI Electromagnetic stimulation increases mitochondrial function in
   osteogenic cells and promotes bone fracture repair
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MESENCHYMAL STEM CELLS; DIFFERENT INTENSITIES; GENE EXPRESSION; FIELD
   PEMF; DIFFERENTIATION; PROLIFERATION; MINERALIZATION; ACCELERATION;
   DYSFUNCTION; ACTIVATION
AB Bone fracture is a growing public health burden and there is a clinical need for non invasive therapies to aid in the fracture healing process. Previous studies have demonstrated the utility of electromagnetic (EM) fields in promoting bone repair; however, its underlying mechanism of action is unclear. Interestingly, there is a growing body of literature describing positive effects of an EM field on mitochondria. In our own work, we have previously demonstrated that differentiation of osteoprogenitors into osteoblasts involves activation of mitochondrial oxidative phosphorylation (OxPhos). Therefore, it was reasonable to propose that EM field therapy exerts bone anabolic effects via stimulation of mitochondrial OxPhos. In this study, we show that application of a low intensity constant EM field source on osteogenic cells in vitro resulted in increased mitochondrial membrane potential and respiratory complex I activity and induced osteogenic differentiation. In the presence of mitochondrial inhibitor antimycin A, the osteoinductive effect was reversed, confirming that this effect was mediated via increased OxPhos activity. Using a mouse tibial bone fracture model in vivo, we show that application of a low intensity constant EM field source enhanced fracture repair via improved biomechanical properties and increased callus bone mineralization. Overall, this study provides supporting evidence that EM field therapy promotes bone fracture repair through mitochondrial OxPhos activation.
C1 [Hollenberg, Alex M.; Huber, Aric; Smith, Charles O.; Eliseev, Roman A.] Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.
   [Eliseev, Roman A.] Univ Rochester, Med Ctr, 601 Elmwood Ave,Rm 1 8541, Rochester, NY 14642 USA.
C3 University of Rochester; University of Rochester
RP Eliseev, RA (通讯作者)，Univ Rochester, Sch Med & Dent, Ctr Musculoskeletal Res, Rochester, NY 14642 USA.; Eliseev, RA (通讯作者)，Univ Rochester, Med Ctr, 601 Elmwood Ave,Rm 1 8541, Rochester, NY 14642 USA.
EM roman_eliseev@urmc.rochester.edu
FU NIH [R01 AR072601, P30 AR069655]; Sanabit Technologies Inc
FX We thank the Center for Musculoskeletal Research and the Mitochondrial
   Interest Group for their fruitful discussions and Histology, Micro CT,
   and Biomechanical cores within the Center for Musculoskeletal Research.
   Financial support was provided by NIH (R01 AR072601 to RAE and P30
   AR069655 to the Center for Musculoskeletal Research) and by Sanabit
   Technologies Inc research contract to RAE.
CR Alberts B., 2002, Molecular Biology of The Cell, V4th
   Almeida M, 2007, J BIOL CHEM, V282, P27285, DOI 10.1074/jbc.M702810200
   Almeida M, 2010, MOL ENDOCRINOL, V24, P2030, DOI 10.1210/me.2010 0189
   [Anonymous], 2004, US Health and Human Services, P437
   BASSETT CAL, 1974, SCIENCE, V184, P575
   BASSETT CAL, 1974, ANN NY ACAD SCI, V238, P242, DOI 10.1111/j.1749 6632.1974.tb26794.x
   BASSETT CAL, 1991, CALCIFIED TISSUE INT, V49, P216, DOI 10.1007/BF02556121
   Beutner G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113330
   Bopassa JC, 2010, AM J PHYSIOL HEART C, V298, pH16, DOI 10.1152/ajpheart.00588.2009
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Chang K, 2003, BIOELECTROMAGNETICS, V24, P431, DOI 10.1002/bem.10118
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007 0509
   Ciombor Deborah McK, 2005, Foot Ankle Clin, V10, P579, DOI 10.1016/j.fcl.2005.06.006
   Colnot C, 2009, J BONE MINER RES, V24, P274, DOI 10.1359/JBMR.081003
   De Mattei M, 2005, BIOELECTROMAGNETICS, V26, P207, DOI 10.1002/bem.20068
   Destefanis M, 2015, INT J RADIAT BIOL, V91, P964, DOI 10.3109/09553002.2015.1101648
   Ehnert S, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 14983 9
   Ehnert Sabrina, 2015, Bone Rep, V3, P48, DOI 10.1016/j.bonr.2015.08.002
   Esen E, 2013, CELL METAB, V17, P745, DOI 10.1016/j.cmet.2013.03.017
   Forni MF, 2016, STEM CELLS, V34, P743, DOI 10.1002/stem.2248
   Ghiasi Mohammad S, 2017, Bone Rep, V6, P87, DOI 10.1016/j.bonr.2017.03.002
   GORCZYNSKA E, 1986, PHYSIOL CHEM PHYS ME, V18, P61
   Griffin XL, 2008, INJURY, V39, P419, DOI 10.1016/j.injury.2007.12.014
   Griffin XL, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008471.pub2
   Gu Q, 2014, CLIN ORTHOP RELAT R, V472, P3536, DOI 10.1007/s11999 014 3820 6
   Hadjiargyrou M, 2014, J BONE MINER RES, V29, P2307, DOI 10.1002/jbmr.2373
   HECKMAN JD, 1981, CLIN ORTHOP RELAT R, P58
   Hollenberg AM, 2020, J BONE MINER RES, V35, P2432, DOI 10.1002/jbmr.4142
   Ishisaka, 2000, Pathophysiology, V7, P149, DOI 10.1016/S0928 4680(00)00043 2
   Jansen JHW, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471 2474 11 188
   Kitaori T, 2009, ARTHRITIS RHEUM US, V60, P813, DOI 10.1002/art.24330
   La Colla A, 2013, J ENDOCRINOL, V216, P331, DOI 10.1530/JOE 12 0486
   Lasalvia M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192894
   Li M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103841
   Lohmann CH, 2000, J ORTHOP RES, V18, P637, DOI 10.1002/jor.1100180417
   Manigrasso MB, 2008, CALCIFIED TISSUE INT, V82, P465, DOI 10.1007/s00223 008 9144 3
   Phetfong J, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658 016 0013 1
   Schwartz Z, 2008, J ORTHOP RES, V26, P1250, DOI 10.1002/jor.20591
   Selvarnurugan N, 2007, J ORTHOP RES, V25, P1213, DOI 10.1002/jor.20409
   Shapovalov Y, 2011, J BIOL CHEM, V286, P22331, DOI 10.1074/jbc.M111.250092
   Shares BH, 2020, BONE, V137, DOI 10.1016/j.bone.2020.115391
   Shares BH, 2018, J BIOL CHEM, V293, P16019, DOI 10.1074/jbc.RA118.004102
   Shum LC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155709
   Shum LC, 2016, STEM CELLS DEV, V25, P114, DOI 10.1089/scd.2015.0193
   Smith CO, 2021, STEM CELLS DEV, V30, P149, DOI 10.1089/scd.2020.0141
   Storch K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167931
   Streit A, 2016, FOOT ANKLE INT, V37, P919, DOI 10.1177/1071100716652621
   Sun LY, 2010, BIOELECTROMAGNETICS, V31, P209, DOI 10.1002/bem.20550
   Tsai MT, 2009, J ORTHOP RES, V27, P1169, DOI 10.1002/jor.20862
   Verdonk R, 2015, ARTHROSCOPY, V31, P715, DOI 10.1016/j.arthro.2014.11.045
   Waldorff EI, 2017, J ORTHOP TRANSL, V9, P60, DOI 10.1016/j.jot.2017.02.006
   Wang DM, 2018, BIOELECTROMAGNETICS, V39, P352, DOI 10.1002/bem.22122
   Yumoto H, 2015, CELL PHYSIOL BIOCHEM, V35, P601, DOI 10.1159/000369722
   Zhou J, 2014, BIOELECTROMAGNETICS, V35, P30, DOI 10.1002/bem.21794
   Zhou J, 2011, BONE, V49, P753, DOI 10.1016/j.bone.2011.06.026
NR 55
TC 25
Z9 27
U1 1
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD SEP 27
PY 2021
VL 11
IS 1
AR 19114
DI 10.1038/s41598 021 98625 1
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA UX1PF
UT WOS:000700619200050
PM 34580378
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Martin, PJ
   Haren, N
   Ghali, O
   Clabaut, A
   Chauveau, C
   Hardouin, P
   Broux, O
AF Martin, Perrine J.
   Haren, Nathalie
   Ghali, Olfa
   Clabaut, Aline
   Chauveau, Christophe
   Hardouin, Pierre
   Broux, Odile
TI Adipogenic RNAs are transferred in osteoblasts via bone marrow
   adipocytes derived extracellular vesicles (EVs)
SO BMC CELL BIOLOGY
LA English
DT Article
DE Extracellular vesicles; RNA transfer; Adipocytes; Osteoblasts;
   Osteoporosis
ID MESENCHYMAL STEM CELLS; REGULATES OSTEOGENIC DIFFERENTIATION; LINEAGE
   PROGRESSION; FAT CONNECTION; IN VITRO; OSTEOPOROSIS; MICRORNAS;
   MECHANISM; PROLIFERATION; PROGRAM
AB Background: In osteoporosis, bone loss is accompanied by increased marrow adiposity. Given their proximity in the bone marrow and their shared origin, a dialogue between adipocytes and osteoblasts could be a factor in the competition between human Mesenchymal Stem Cells (hMSC) differentiation routes, leading to adipocyte differentiation at the expense of osteoblast differentiation. The adipocyte/osteoblast balance is highly regulated at the level of gene transcription. In our work, we focused on PPARgamma, CEBPalpha and CEBPdelta, as these transcription factors are seen as master regulators of adipogenesis and expressed precociously, and on leptin and adiponectin, considered as adipocyte marker genes. In 2010, our group has demonstrated, thanks to a coculture model, that in the presence of hMSC derived adipocytes (hMSC Adi), hMSC derived osteoblasts (hMSC Ost) express lesser amounts of osteogenic markers but exhibit the expression of typical adipogenic genes. Nevertheless, the mechanisms underlying this modulation of gene expression are not clarified. Recently, adipocytes were described as releasing extracellular vesicles (EVs), containing and transferring adipocyte specific transcripts, like PPARgamma, leptin and adiponectin. Here, we investigated whether EVs could be the way in which adipocytes transfer adipogenic RNAs in our coculture model.
   Results: We observed in hMSC Ost incubated in hAdi CM an increase in the adipogenic PPAR., leptin, CEBPa and CEBP delta transcripts as well as the anti osteoblastic miR 138, miR30c, miR125a, miR 125b, miR 31 miRNAs, probably implicated in the observed osteocalcin (OC) and osteopontin (OP) expression decrease. Moreover, EVs were isolated from conditioned media collected from cultures of hMSC at different stages of adipocyte differentiation and these specific adipogenic transcripts were detected inside. Finally, thanks to interspecies conditioned media exposition, we could highlight for the first time a horizontal transfer of adipogenic transcripts from medullary adipocytes to osteoblasts.
   Conclusions: Here, we have shown, for the first time, RNA transfer between hMSC derived adipocytes and osteoblasts through EVs. Additional studies are needed to clarify if this mechanism has a role in the adipocytic switch driven on osteoblasts by adipocytes inside bone marrow and if EVs could be a target component to regulate the competition between osteoblasts and adipocytes in the prevention or in the therapy of osteoporosis and other osteopenia.
C1 [Martin, Perrine J.; Haren, Nathalie; Ghali, Olfa; Clabaut, Aline; Chauveau, Christophe; Hardouin, Pierre; Broux, Odile] Univ Lille Nord France, F 59000 Lille, France.
   [Haren, Nathalie; Ghali, Olfa; Clabaut, Aline; Chauveau, Christophe; Hardouin, Pierre; Broux, Odile] PMOI EA 4490, IFR 114, F 62327 Boulogne Sur Mer, France.
   [Haren, Nathalie; Ghali, Olfa; Clabaut, Aline; Chauveau, Christophe; Hardouin, Pierre; Broux, Odile] PMOI EA 4490, IFR 114, F 59000 Lille, France.
   [Haren, Nathalie; Ghali, Olfa; Clabaut, Aline; Chauveau, Christophe; Hardouin, Pierre; Broux, Odile] Univ Littoral Cote dOpale, F 62327 Boulogne Sur Mer, France.
   [Martin, Perrine J.] UCEIV EA 4492, F 59140 Dunkerque, France.
   [Martin, Perrine J.] Univ Littoral Cote dOpale, Maison Rech Environm Ind 2, UCEIV, F 59140 Dunkerque, France.
C3 Universite de Lille; Universite du Littoral Cote d'Opale; Universite du
   Littoral Cote d'Opale
RP Martin, PJ (通讯作者)，Univ Lille Nord France, F 59000 Lille, France.
EM perrine.martin@univ littoral.fr
OI Hardouin, Pierre/0000 0002 1928 6382; CLABAUT,
   ALINE/0000 0003 1869 3338; Martin, Perrine/0000 0003 4439 5078;
   Chauveau, Christophe/0000 0003 4668 9272
FU ULCO
FX This work was supported by ULCO.
CR Aoki N, 2007, ENDOCRINOLOGY, V148, P3850, DOI 10.1210/en.2006 1479
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Choi D.S., 2014, Mass Spectrom Rev
   Clabaut A, 2010, DIFFERENTIATION, V80, P40, DOI 10.1016/j.diff.2010.04.004
   Duque G, 2008, CURR OPIN RHEUMATOL, V20, P429, DOI 10.1097/BOR.0b013e3283025e9c
   Ecklund K, 2010, J BONE MINER RES, V25, P298, DOI 10.1359/jbmr.090805
   Elbaz A, 2010, J CELL MOL MED, V14, P982, DOI 10.1111/j.1582 4934.2009.00751.x
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Georgiou KR, 2012, AM J STEM CELLS, V1, P205
   Gimble JM, 2006, J CELL BIOCHEM, V98, P251, DOI 10.1002/jcb.20777
   Goettsch C, 2011, AM J PATHOL, V179, P1594, DOI 10.1016/j.ajpath.2011.06.016
   Gong YM, 2014, MOL CELL BIOCHEM, V387, P227, DOI 10.1007/s11010 013 1888 z
   Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099
   Huang K, 2014, BIOCHIMIE, V102, P47, DOI 10.1016/j.biochi.2014.02.005
   Justesen J, 2001, BIOGERONTOLOGY, V2, P165, DOI 10.1023/A:1011513223894
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365 2796.2012.02564.x
   Kollmer Melanie, 2013, J Dev Biol Tissue Eng, V5, P18
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Martin T John, 2014, J Bone Metab, V21, P8, DOI 10.11005/jbm.2014.21.1.8
   Maurin AC, 2002, BONE, V31, P260, DOI 10.1016/S8756 3282(02)00805 0
   Maurin AC, 2000, BONE, V26, P485, DOI 10.1016/S8756 3282(00)00252 0
   Meunier P, 1971, CLIN ORTHOP RELAT R, V80, P147, DOI DOI 10.1097/00003086 197110000 00021
   Müller G, 2011, CELL SIGNAL, V23, P1207, DOI 10.1016/j.cellsig.2011.03.013
   Muruganandan S, 2009, CELL MOL LIFE SCI, V66, P236, DOI 10.1007/s00018 008 8429 z
   Ogawa R, 2010, BIOCHEM BIOPH RES CO, V398, P723, DOI 10.1016/j.bbrc.2010.07.008
   Ponce ML, 2008, J CELL BIOCHEM, V104, P1342, DOI 10.1002/jcb.21711
   Ragni E, 2013, J CELL MOL MED, V17, P168, DOI 10.1111/j.1582 4934.2012.01660.x
   Sadie Van Gijsen H, 2013, CELL MOL LIFE SCI, V70, P2331, DOI 10.1007/s00018 012 1211 2
   Scheideler M, 2008, BMC GENOMICS, V9, DOI 10.1186/1471 2164 9 340
   Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30
   Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wu TT, 2012, J BIOL CHEM, V287, P7503, DOI 10.1074/jbc.M111.292722
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zhang Y, 2012, J BIOL CHEM, V287, P21926, DOI 10.1074/jbc.M112.340398
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhang ZJ, 2012, J CELL BIOCHEM, V113, P888, DOI 10.1002/jcb.23418
   Zhao JW, 2011, AM J MED SCI, V341, P460, DOI 10.1097/MAJ.0b013e31820865d5
NR 40
TC 53
Z9 61
U1 1
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471 2121
J9 BMC CELL BIOL
JI BMC Cell Biol.
PD MAR 18
PY 2015
VL 16
AR 10
DI 10.1186/s12860 015 0057 5
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology
GA CD8OB
UT WOS:000351353700001
PM 25887582
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Xu, Q
   Li, D
   Chen, J
   Yang, J
   Yan, JI
   Xia, YP
   Zhang, F
   Wang, XS
   Cao, H
AF Xu, Qin
   Li, Dan
   Chen, Jing
   Yang, Ju
   Yan, Jiai
   Xia, Yanping
   Zhang, Feng
   Wang, Xuesong
   Cao, Hong
TI Crosstalk between the gut microbiota and postmenopausal osteoporosis:
   Mechanisms and applications
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Postmenopausal osteoporosis; Gut microbiota; Fecal microbiota
   transplantation; Probiotics
ID BONE MINERAL DENSITY; CHAIN FATTY ACIDS; PARATHYROID HORMONE; INTESTINAL
   BARRIER; INDUCED INFLAMMATION; VERTEBRAL FRACTURES; INFANT GUT;
   BILE ACID; T CELLS; WOMEN
AB Postmenopausal osteoporosis (PMO) results from a reduction in bone mass and microarchitectural deterioration in bone tissue due to estrogen deficiency, which may increase the incidence of fragility fractures. The number of people suffering from PMO has increased over the years because of the rapidly aging population worldwide. However, several pharmacological agents for the treatment of PMO have many safety risks and impose a heavy financial burden to patients and society. In recent years, the "gut bone" axis has been proposed as a new approach in the prevention and treatment of PMO. This paper reviews the relationship between the gut microbiota and PMO, which mainly includes the underlying mechanisms between hormones, immunity, nutrient metabolism, metabolites of the gut microbiota and intestinal permeability, and explores the possible role of the gut microbiota in these processes. Finally, we discuss the therapeutic effects of diet, prebiotics, probiotics, and fecal microbiota transplantation on the gut microbiota.
C1 [Xu, Qin; Li, Dan; Yang, Ju; Yan, Jiai; Xia, Yanping; Zhang, Feng; Wang, Xuesong; Cao, Hong] Jiangnan Univ, Affiliated Hosp, Nutr Dept, Wuxi, Jiangsu, Peoples R China.
   [Xu, Qin; Li, Dan; Chen, Jing; Yang, Ju; Yan, Jiai; Zhang, Feng; Wang, Xuesong; Cao, Hong] Jiangnan Univ, Wuxi Sch Med, Wuxi, Jiangsu, Peoples R China.
   [Li, Dan; Yang, Ju; Yan, Jiai; Xia, Yanping; Wang, Xuesong; Cao, Hong] Jiangnan Univ, Affiliated Hosp, Clin Assessment Ctr Funct Food, Wuxi, Jiangsu, Peoples R China.
   [Chen, Jing] Jiangnan Univ, Affiliated Hosp, Nursing Dept, Wuxi, Jiangsu, Peoples R China.
   [Cao, Hong] Jiangnan Univ, Affiliated Hosp, Dept Endocrinol, Wuxi, Jiangsu, Peoples R China.
   [Wang, Xuesong] Jiangnan Univ, Affiliated Hosp, Dept Orthoped, Wuxi, Jiangsu, Peoples R China.
   [Wang, Xuesong; Cao, Hong] 1000 Hefeng Rd, Wuxi, Peoples R China.
C3 Jiangnan University; Jiangnan University; Jiangnan University; Jiangnan
   University; Jiangnan University; Jiangnan University
RP Wang, XS; Cao, H (通讯作者)，1000 Hefeng Rd, Wuxi, Peoples R China.
EM victorwxs@jiangnan.edu.cn; HongCao@jiangnan.edu.cn
FU National Natural Science Foundation of China Projects [32101033];
   Translational Medicine Research Program of Wuxi Translational Medicine
   Center [2021ZHYB05]; Wuxi Health Care Commission Medical Key Discipline
   Construction Project [CXTD2021003]; Wuxi Science and Technology Bureau;
   "Taihu Light" Science and Technology Research [Y20212001]; Wuxi Medical
   and Public Health Technology Innovation Application Project [N20192025]
FX This work was supported by grants from the National Natural Science
   Foundation of China Projects (32101033) , Translational Medicine
   Research Program of Wuxi Translational Medicine Center (2021ZHYB05) ,
   Wuxi Health Care Commission Medical Key Discipline Construction Project
   (CXTD2021003) , Wuxi Science and Technology Bureau, "Taihu Light"
   Science and Technology Research (Y20212001) , and Wuxi Medical and
   Public Health Technology Innovation Application Project (N20192025) .
CR Agusti A, 2018, MOL NEUROBIOL, V55, P5337, DOI 10.1007/s12035 017 0768 z
   Anderson RC, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471 2180 10 316
   Ardita CS, 2014, APPL ENVIRON MICROB, V80, P5068, DOI 10.1128/AEM.01039 14
   Asarat M, 2016, IMMUNOL INVEST, V45, P205, DOI 10.3109/08820139.2015.1122613
   Avenell A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000227.pub4
   Awad WA, 2017, TOXINS, V9, DOI 10.3390/toxins9020060
   Bartell SM, 2011, J BONE MINER RES, V26, P1710, DOI 10.1002/jbmr.406
   Bellerba F, 2021, NUTRIENTS, V13, DOI 10.3390/nu13103378
   Bhukhai K, 2012, J BIOL CHEM, V287, P36168, DOI 10.1074/jbc.M112.344747
   Blake J, 2021, MENOPAUSE, V28, P973, DOI 10.1097/GME.0000000000001831
   Bosco N, 2021, GENES IMMUN, V22, P289, DOI 10.1038/s41435 021 00126 8
   Boufker HI, 2011, BONE, V49, P1219, DOI 10.1016/j.bone.2011.08.013
   Bowyer RCE, 2022, SCI TOTAL ENVIRON, V813, DOI 10.1016/j.scitotenv.2021.152321
   Boyce EG, 2018, ANN PHARMACOTHER, V52, P462, DOI 10.1177/1060028017748649
   Brent MB, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.588773
   Bryk G, 2016, EUR J NUTR, V55, P2445, DOI 10.1007/s00394 015 1052 5
   Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07 1403
   Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06 1491
   Chen KLA, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 26506 1
   Chen X, 2020, AGING DIS, V11, P629, DOI 10.14336/AD.2019.0613
   Chen ZQ, 2022, J GERONTOL A BIOL, V77, P1494, DOI 10.1093/gerona/glab172
   Cheng CH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031376
   Cheung AM, 2008, PLOS MED, V5, P1461, DOI 10.1371/journal.pmed.0050196
   Cheung Ching Lung, 2018, Osteoporos Sarcopenia, V4, P16, DOI 10.1016/j.afos.2018.03.003
   Chevalier C, 2020, CELL METAB, V32, P575, DOI 10.1016/j.cmet.2020.08.012
   Cho SW, 2013, J BONE MINER RES, V28, P2109, DOI 10.1002/jbmr.1961
   Cosman F, 2017, OSTEOPOROSIS INT, V28, P2021, DOI 10.1007/s00198 017 3959 6
   Cosman F, 2016, NEW ENGL J MED, V375, P1532, DOI 10.1056/NEJMoa1607948
   Crothers JW, 2021, BMC GASTROENTEROL, V21, DOI 10.1186/s12876 021 01856 9
   Cui LJ, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00958 x
   Dar HY, 2018, NUTRITION, V54, P118, DOI 10.1016/j.nut.2018.02.013
   Dar Hamid Y, 2018, Bone Rep, V8, P46, DOI 10.1016/j.bonr.2018.02.001
   De Vadder F, 2021, J MOL ENDOCRINOL, V66, pR67, DOI 10.1530/JME 20 0288
   Delgado Calle J, 2017, BONE, V96, P29, DOI 10.1016/j.bone.2016.10.007
   Dempster DW, 2001, J BONE MINER RES, V16, P1846, DOI 10.1359/jbmr.2001.16.10.1846
   Diab DL, 2014, EXPERT OPIN DRUG SAF, V13, P247, DOI 10.1517/14740338.2014.860133
   Dixit M, 2021, MOL CELL ENDOCRINOL, V519, DOI 10.1016/j.mce.2020.111052
   Dorgan JF, 2002, JNCI J NATL CANCER I, V94, P606
   Ebetino FH, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116289
   Erjavec I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150102
   Ervin SM, 2019, J BIOL CHEM, V294, P18586, DOI 10.1074/jbc.RA119.010950
   Fehily SR, 2021, J GASTROEN HEPATOL, V36, P2672, DOI 10.1111/jgh.15598
   Fischer V, 2022, SEMIN CELL DEV BIOL, V123, P14, DOI 10.1016/j.semcdb.2021.05.014
   Formoso G, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008536.pub3
   Fusaro M, 2017, CLIN CASES MINER BON, V14, P200, DOI 10.11138/ccmbm/2017.14.1.200
   Gebrayel P, 2022, J TRANSL MED, V20, DOI 10.1186/s12967 022 03296 9
   Ghosh S, 2021, ARCH MICROBIOL, V203, P5281, DOI 10.1007/s00203 021 02516 y
   Gilsenan A, 2018, OSTEOPOROSIS INT, V29, P2335, DOI 10.1007/s00198 018 4604 8
   Gilsenan A, 2021, J BONE MINER RES, V36, P244, DOI 10.1002/jbmr.4188
   Glogowska Szelag J, 2019, ENDOKRYNOL POL, V70, P478, DOI 10.5603/EP.a2019.0043
   Goldstein SR, 2022, CLIMACTERIC, V25, P56, DOI 10.1080/13697137.2021.1936485
   Gravenstein KS, 2011, J CLIN ENDOCR METAB, V96, pE884, DOI 10.1210/jc.2010 2589
   Green JE, 2020, GUT MICROBES, V12, P1, DOI 10.1080/19490976.2020.1854640
   Guss JD, 2019, BONE, V127, P146, DOI 10.1016/j.bone.2019.06.010
   Hameed ASS, 2020, BIOTECHNOL ADV, V43, DOI 10.1016/j.biotechadv.2020.107576
   Han CQ, 2016, CELL PHYSIOL BIOCHEM, V38, P2464, DOI 10.1159/000445597
   Han YJ, 2018, BONE RES, V6, DOI 10.1038/s41413 018 0019 6
   Hansen MS, 2022, SEMIN CELL DEV BIOL, V123, P74, DOI 10.1016/j.semcdb.2021.06.024
   He JQ, 2020, AGING US, V12, P8583, DOI 10.18632/aging.103168
   He QT, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02623 z
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Inose H, 2011, J BONE MINER RES, V26, P2002, DOI 10.1002/jbmr.439
   García Vieyra MI, 2014, J MED FOOD, V17, P1247, DOI 10.1089/jmf.2013.0137
   Queipo Ortuño MI, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065465
   Ishizu T, 2021, SPORTS, V9, DOI 10.3390/sports9060082
   Jafarnejad S, 2017, J AM COLL NUTR, V36, P497, DOI 10.1080/07315724.2017.1318724
   Jennings A, 2020, NUTRIENTS, V12, DOI 10.3390/nu12041154
   Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932
   Jones ML, 2013, J CLIN ENDOCR METAB, V98, P2944, DOI 10.1210/jc.2012 4262
   Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213
   Khosla S, 2020, J CLIN INVEST, V130, P1615, DOI 10.1172/JCI135712
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Kibbie JJ, 2021, IMMUNOBIOLOGY, V226, DOI 10.1016/j.imbio.2021.152126
   Kim DS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01525
   Kim D, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041149
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kloosterboer HJ, 2004, MATURITAS, V48, pS30, DOI 10.1016/j.maturitas.2004.02.012
   Knight R, 2017, ANNU REV GENOM HUM G, V18, P65, DOI 10.1146/annurev genom 083115 022438
   Kraenzlin ME, 2011, NAT REV ENDOCRINOL, V7, P647, DOI 10.1038/nrendo.2011.108
   Kvaerner AS, 2021, BMC CANCER, V21, DOI 10.1186/s12885 021 08640 8
   Lawenius L, 2020, AM J PHYSIOL ENDOC M, V318, pE480, DOI 10.1152/ajpendo.00425.2019
   Lee CS, 2021, J APPL MICROBIOL, V130, P2041, DOI 10.1111/jam.14852
   Lerner UH, 2015, J INTERN MED, V277, P630, DOI 10.1111/joim.12368
   Lewiecki EM, 2018, THER ADV MUSCULOSKEL, V10, P209, DOI 10.1177/1759720X18805759
   Li JY, 2020, J CLIN INVEST, V130, P1767, DOI 10.1172/JCI133473
   Li JY, 2016, J CLIN INVEST, V126, P2049, DOI 10.1172/JCI86062
   Li L, 2019, AGING US, V11, P9348, DOI 10.18632/aging.102376
   Lian WS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179135
   Liao HJ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1353 3
   Lin H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm 20 5307
   Lin NY, 2013, ANN RHEUM DIS, V72, P761, DOI 10.1136/annrheumdis 2012 201671
   Liu CX, 2020, FOOD FUNCT, V11, P10817, DOI [10.1039/d0fo00787k, 10.1039/D0FO00787K]
   Liu JH, 2021, ADV SCI, V8, DOI 10.1002/advs.202004831
   Liu QQ, 2021, J NUTR BIOCHEM, V98, DOI 10.1016/j.jnutbio.2021.108863
   Liu YK, 2020, AGING US, V12, P10633, DOI 10.18632/aging.103283
   Locklin RM, 2003, J CELL BIOCHEM, V89, P180, DOI 10.1002/jcb.10490
   Lu LJW, 2000, CANCER RES, V60, P4112
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Mao JD, 2020, J NUTR, V150, P1313, DOI 10.1093/jn/nxaa009
   Marzullo P, 2021, INT J OBESITY, V45, P2291, DOI 10.1038/s41366 021 00866 7
   McCloskey E, 2021, OSTEOPOROSIS INT, V32, P251, DOI 10.1007/s00198 020 05557 z
   Mei L, 2021, BIOENGINEERED, V12, P11756, DOI 10.1080/21655979.2021.2009618
   Meijer K, 2010, CURR OPIN CLIN NUTR, V13, P715, DOI 10.1097/MCO.0b013e32833eebe5
   Merlotti D, 2019, EXPERT OPIN PHARMACO, V20, P805, DOI 10.1080/14656566.2019.1583208
   Milani C, 2017, MICROBIOL MOL BIOL R, V81, DOI 10.1128/MMBR.00036 17
   Miller PD, 2016, JAMA J AM MED ASSOC, V316, P722, DOI 10.1001/jama.2016.11136
   Mizokami A, 2017, BIOCHEM PHARMACOL, V132, P1, DOI 10.1016/j.bcp.2017.02.001
   Molinaro A, 2018, TRENDS ENDOCRIN MET, V29, P31, DOI 10.1016/j.tem.2017.11.002
   Mousavi SE, 2022, SCI TOTAL ENVIRON, V816, DOI 10.1016/j.scitotenv.2021.151654
   National Institute for Health and Care Excellence, 2017, GUID OST ASS RISK FR
   Nishikawa A, 2016, CLIN INTERV AGING, V11, P913, DOI 10.2147/CIA.S107285
   Noel SE, 2020, AM J CLIN NUTR, V111, P1267, DOI 10.1093/ajcn/nqaa090
   Nowinski A, 2018, NUTRITION, V46, P7, DOI 10.1016/j.nut.2017.08.001
   Oh S, 2010, IMMUNOL REV, V233, P97, DOI 10.1111/j.0105 2896.2009.00848.x
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Ono T, 2017, CURR OSTEOPOROS REP, V15, P367, DOI 10.1007/s11914 017 0381 0
   Ozaki D, 2021, OSTEOPOROSIS INT, V32, P145, DOI 10.1007/s00198 020 05728 y
   Patrick David M, 2006, BMC Physiol, V6, P2, DOI 10.1186/1472 6793 6 2
   Peng LY, 2009, J NUTR, V139, P1619, DOI 10.3945/jn.109.104638
   Quattrini S, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020531
   Rajilic Stojanovic M, 2014, FEMS MICROBIOL REV, V38, P996, DOI 10.1111/1574 6976.12075
   Raphael I, 2015, CYTOKINE, V74, P5, DOI 10.1016/j.cyto.2014.09.011
   Reid IR, 2022, LANCET, V399, P1080, DOI 10.1016/S0140 6736(21)02646 5
   Reigstad CS, 2015, FASEB J, V29, P1395, DOI 10.1096/fj.14 259598
   Rivas A, 2013, INT J FOOD SCI NUTR, V64, P155, DOI 10.3109/09637486.2012.718743
   Rivera Huerta M, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/9758982
   Ronn SH, 2021, OSTEOPOROSIS INT, V32, P185, DOI 10.1007/s00198 020 05638 z
   Saag KG, 2017, NEW ENGL J MED, V377, P1417, DOI 10.1056/NEJMoa1708322
   Sandoval DA, 2015, PHYSIOL REV, V95, P513, DOI 10.1152/physrev.00013.2014
   Sapra L, 2021, SCI REP UK, V11, DOI 10.1038/s41598 020 80536 2
   Sayin SI, 2013, CELL METAB, V17, P225, DOI 10.1016/j.cmet.2013.01.003
   Schwarzer M, 2016, SCIENCE, V351, P854, DOI 10.1126/science.aad8588
   Seely KD, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179452
   Shah SA, 2017, CNS NEUROSCI THER, V23, P33, DOI 10.1111/cns.12588
   Shahriarpour Z, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 021 00886 w
   Shoback D, 2020, J CLIN ENDOCR METAB, V105, P587, DOI 10.1210/clinem/dgaa048
   Singh S, 2022, OSTEOPOROSIS INT, V33, P1, DOI 10.1007/s00198 021 06095 y
   Siu A, 2019, ANN INTERN MED, V171, P51, DOI 10.7326/M19 0961
   Sjögren K, 2012, J BONE MINER RES, V27, P1357, DOI 10.1002/jbmr.1588
   Takahashi N, 1999, BIOCHEM BIOPH RES CO, V256, P449, DOI 10.1006/bbrc.1999.0252
   Takayanagi H, 2010, ADV EXP MED BIOL, V658, P61, DOI 10.1007/978 1 4419 1050 9_7
   Tarracchini C, 2021, MICROB GENOMICS, V7, DOI 10.1099/mgen.0.000609
   Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365 2567.2006.02321.x
   Teoh L, 2021, BRIT J CLIN PHARMACO, V87, P2767, DOI 10.1111/bcp.14681
   Tsourdi E, 2017, BONE, V105, P11, DOI 10.1016/j.bone.2017.08.003
   Tsujikawa Y, 2021, BIOSCI MICROB FOOD H, V40, P186, DOI 10.12938/bmfh.2020 083
   Turroni F, 2020, ITAL J PEDIATR, V46, DOI 10.1186/s13052 020 0781 0
   Turroni F, 2018, CELL MOL LIFE SCI, V75, P103, DOI 10.1007/s00018 017 2672 0
   Tyagi AM, 2018, IMMUNITY, V49, P1116, DOI 10.1016/j.immuni.2018.10.013
   Uccello M, 2012, BMC SURG, V12, DOI 10.1186/1471 2482 12 S1 S35
   Vacca M, 2022, EUR J NUTR, V61, P2517, DOI 10.1007/s00394 022 02822 1
   Vinogradova Y, 2020, BMJ BRIT MED J, V371, DOI 10.1136/bmj.m3873
   Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858
   Wan Y, 2013, BONE, V55, P258, DOI 10.1016/j.bone.2012.12.052
   Wang ZX, 2021, AM J CLIN NUTR, V114, P1304, DOI 10.1093/ajcn/nqab194
   Wei ZT, 2021, FASEB J, V35, DOI 10.1096/fj.202100887RR
   Wen KC, 2020, FRONT CELL INFECT MI, V10, DOI 10.3389/fcimb.2020.535310
   Weng SJ, 2019, CHEM BIOL INTERACT, V300, P101, DOI 10.1016/j.cbi.2019.01.012
   Williamson S, 2017, OSTEOPOROSIS INT, V28, P2791, DOI 10.1007/s00198 017 4153 6
   Wu Q, 2020, J CLIN MED, V9, DOI 10.3390/jcm9020499
   Wu Q, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010285
   Wu SP, 2015, AM J PHYSIOL GASTR L, V309, pG341, DOI 10.1152/ajpgi.00105.2015
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yadav VK, 2010, NAT MED, V16, P308, DOI 10.1038/nm.2098
   Yamauchi M, 2001, CLIN ENDOCRINOL, V55, P341, DOI 10.1046/j.1365 2265.2001.01361.x
   Yan H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179586
   Yan J, 2016, P NATL ACAD SCI USA, V113, pE7554, DOI 10.1073/pnas.1607235113
   Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047
   Ye L, 2003, J CELL PHYSIOL, V196, P362, DOI 10.1002/jcp.10315
   Yoo JE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2020.30405
   Yu JW, 2021, BMJ OPEN, V11, DOI 10.1136/bmjopen 2020 041393
   Yu MC, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI143137
   Yu MC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467 019 14148 4
   Yuan SJ, 2021, BONE, V142, DOI 10.1016/j.bone.2020.115710
   Zeng LT, 2021, EVID BASED COMPL ALT, V2021, DOI 10.1155/2021/9924410
   Zhang YL, 2022, J INFLAMM RES, V15, P533, DOI 10.2147/JIR.S344009
   Zhao LM, 2010, TISSUE ENG PT A, V16, P725, DOI 10.1089/ten.TEA.2009.0495
   Zheng L, 2017, J IMMUNOL, V199, P2976, DOI 10.4049/jimmunol.1700105
   Zhong ZD, 2012, P NATL ACAD SCI USA, V109, pE2197, DOI 10.1073/pnas.1120407109
   Zhong ZDA, 2015, DEV DYNAM, V244, P1347, DOI 10.1002/dvdy.24316
   Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1
NR 181
TC 49
Z9 58
U1 5
U2 51
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567 5769
EI 1878 1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD SEP
PY 2022
VL 110
AR 108998
DI 10.1016/j.intimp.2022.108998
EA JUL 2022
PG 13
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 3B0AK
UT WOS:000827612600004
PM 35785728
DA 2025 08 17
ER

PT J
AU Lin, XX
   Yang, Y
   Huang, YH
   Li, E
   Zhuang, XM
   Zhang, ZC
   Xu, RG
   Yu, XL
   Deng, FL
AF Lin, Xiaoxuan
   Yang, Yang
   Huang, Yaohong
   Li, E.
   Zhuang, Xiumei
   Zhang, Zhengchuan
   Xu, Ruogu
   Yu, Xiaolin
   Deng, Feilong
TI Mettl3 mediated m<SUP>6</SUP>A RNA methylation regulates osteolysis
   induced by titanium particles
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE osteolysis; aseptic loosening; titanium particles;
   methyltransferase like 3; N6 methyladenosine RNA methylation; epigenetic
   regulation
ID INDUCED OSTEOGENIC INHIBITION; WEAR DEBRIS; PERIPROSTHETIC OSTEOLYSIS;
   METAL CONCENTRATIONS; IN VITRO; N 6 METHYLADENOSINE; INDUCTION;
   OSTEOBLASTS; CORROSION; WRITERS
AB Peri prosthetic osteolysis (PPO) induced by wear particles is considered the primary cause of titanium prosthesis failure and revision surgery. The specific molecular mechanisms involve titanium particles inducing multiple intracellular pathways, which impact disease prevention and the targeted therapy of PPO. Notably, N6 methyladenosine (m6A) serves critical roles in epigenetic regulation, particularly in bone metabolism and inflammatory responses. Thus, the present study aimed to determine the role of RNA methylation in titanium particle induced osteolysis. Results of reverse transcription quantitative PCR (RT qPCR), western blotting, ELISA and RNA dot blot assays revealed that titanium particles induced osteogenic inhibition and proinflammatory responses, accompanied by the reduced expression of methyltransferase like (Mettl) 3, a key component of m6A methyltransferase. Specific lentiviruses vectors were employed for Mettl3 knockdown and overexpression experiments. RT qPCR, western blotting and ELISA revealed that the knockdown of Mettl3 induced osteogenic inhibition and proinflammatory responses comparable with that induced by titanium particle, while Mettl3 overexpression attenuated titanium particle induced cellular reactions. Methylated RNA immunoprecipitation qPCR results revealed that titanium particles mediated the methylation of two inhibitory molecules, namely Smad7 and SMAD specific E3 ubiquitin protein ligase 1, via Mettl3 in bone morphogenetic protein signaling, leading to osteogenic inhibition. Furthermore, titanium particles induced activation of the nucleotide binding oligomerization domain 1 signaling pathway through methylation regulation, and the subsequent activation of the MAPK and NF kappa B pathways. Collectively, the results of the present study indicated that titanium particles utilized Mettl3 as an upstream regulatory molecule to induce osteogenic inhibition and inflammatory responses. Thus, the present study may provide novel insights into potential therapeutic targets for aseptic loosening in titanium prostheses.
C1 [Lin, Xiaoxuan; Yang, Yang; Huang, Yaohong; Zhang, Zhengchuan; Xu, Ruogu; Yu, Xiaolin; Deng, Feilong] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Oral Implantol, Guangzhou 510055, Guangdong, Peoples R China.
   [Li, E.] Zhuhai Women & Childrens Hosp, Zhuhai Ctr Maternal & Child Healthcare, Dept Stomatol, Zhuhai 519000, Guangdong, Peoples R China.
   [Zhuang, Xiumei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Stomatol, Guangzhou 510000, Guangdong, Peoples R China.
   [Yu, Xiaolin; Deng, Feilong] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Oral Implantol, 56 Lingyuanxilu St, Guangzhou 510055, Guangdong, Peoples R China.
C3 Sun Yat Sen University; South China University of Technology; Sun Yat
   Sen University; Sun Yat Sen University
RP Yu, XL; Deng, FL (通讯作者)，Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Oral Implantol, 56 Lingyuanxilu St, Guangzhou 510055, Guangdong, Peoples R China.
EM dengfl@mail.sysu.edu.cn; dengfl@mail.sysu.edu.cn
RI Zhang, Zhengchuan/GRX 0978 2022
OI Zhang, Zhengchuan/0000 0002 8132 9427
FU The Science and Technology Bureau of Nansha, Guangzhou
FX Not applicable.
CR Afzal F, 2005, J CELL PHYSIOL, V204, P63, DOI 10.1002/jcp.20258
   Agarwal S, 2004, CURR ORTHOPAED, V18, P220, DOI 10.1016/j.cuor.2004.03.002
   Batista PJ, 2017, GENOM PROTEOM BIOINF, V15, P154, DOI 10.1016/j.gpb.2017.03.002
   Bauer TW, 2002, CLIN ORTHOP RELAT R, P138, DOI 10.1097/01.blo.00000038467.05771.90
   Cai YJ, 2022, CELL SIGNAL, V93, DOI 10.1016/j.cellsig.2022.110283
   Caruso R, 2014, IMMUNITY, V41, P898, DOI 10.1016/j.immuni.2014.12.010
   Chassot E, 2004, MED ENG PHYS, V26, P193, DOI 10.1016/j.medengphy.2003.10.008
   Chen D, 2015, GENET MOL RES, V14, P40, DOI 10.4238/2015.January.15.6
   Choi MG, 2005, P NATL ACAD SCI USA, V102, P4578, DOI 10.1073/pnas.0500693102
   Dattani R, 2007, POSTGRAD MED J, V83, P312, DOI 10.1136/pgmj.2006.053215
   Day JS, 2013, J SHOULDER ELB SURG, V22, P924, DOI 10.1016/j.jse.2013.02.001
   Delanois RE, 2017, J ARTHROPLASTY, V32, P2663, DOI 10.1016/j.arth.2017.03.066
   Deng ZT, 2021, BIOMATER SCI UK, V9, P1291, DOI 10.1039/d0bm01256d
   Derks J, 2015, J CLIN PERIODONTOL, V42, pS158, DOI 10.1111/jcpe.12334
   Du H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12626
   Eger M, 2017, SCI REP UK, V7, DOI 10.1038/srep39612
   Eliaz N, 2019, MATERIALS, V12, DOI 10.3390/ma12030407
   Fang CH, 2021, CELL SIGNAL, V85, DOI 10.1016/j.cellsig.2021.110060
   Fritz EA, 2005, J ORTHOP RES, V23, P1249, DOI 10.1016/j.orthres.2005.03.013
   Geng DC, 2015, BIOMATERIALS, V69, P12, DOI 10.1016/j.biomaterials.2015.07.061
   Geng TX, 2018, MOL MED REP, V17, P3829, DOI 10.3892/mmr.2017.8292
   Goodman SB, 2007, BIOMATERIALS, V28, P5044, DOI 10.1016/j.biomaterials.2007.06.035
   Gornet MF, 2017, SPINE, V42, P366, DOI 10.1097/BRS.0000000000001745
   Gu Y, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.275
   Guglielmotti MB, 2019, PERIODONTOL 2000, V79, P178, DOI 10.1111/prd.12254
   Hodges NA, 2021, BIOMATERIALS, V278, DOI 10.1016/j.biomaterials.2021.121127
   Hsu PJ, 2017, CELL RES, V27, P1115, DOI 10.1038/cr.2017.99
   Huang M, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.783322
   Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]
   Jiang XL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392 020 00450 x
   Jiang YP, 2013, ACTA BIOMATER, V9, P7564, DOI 10.1016/j.actbio.2013.03.010
   Keegan GM, 2007, J BONE JOINT SURG BR, V89B, P567, DOI 10.1302/0301 620X.89B5.18903
   Kersse K, 2011, CYTOKINE GROWTH F R, V22, P257, DOI 10.1016/j.cytogfr.2011.09.003
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kotsakis GA, 2021, PERIODONTOL 2000, V86, P231, DOI 10.1111/prd.12372
   Li D, 2022, NUCLEIC ACIDS RES, V50, P12462, DOI 10.1093/nar/gkac1084
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691013
   Lin Z, 2017, CELL RES, V27, P1216, DOI 10.1038/cr.2017.117
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lukina E, 2016, SPINE J, V16, P380, DOI 10.1016/j.spinee.2015.11.040
   Luo JH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.670711
   Luo SH, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.112259
   Magone K, 2015, ARCH ORTHOP TRAUM SU, V135, P683, DOI 10.1007/s00402 015 2196 8
   Man K, 2017, J FUNCT BIOMATER, V8, DOI 10.3390/jfb8030033
   Mapperley C, 2021, J EXP MED, V218, DOI 10.1084/jem.20200829
   McArthur BA, 2019, HSS J, V15, P286, DOI 10.1007/s11420 018 9641 5
   Mombelli A, 2018, CLIN ORAL IMPLAN RES, V29, P37, DOI 10.1111/clr.13305
   Mouhyi J, 2012, CLIN IMPLANT DENT R, V14, P170, DOI 10.1111/j.1708 8208.2009.00244.x
   Nachbur U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7442
   Nguyen TTT, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25501 x
   Ollivere B, 2012, J BONE JOINT SURG BR, V94B, P10, DOI 10.1302/0301 620X.94B1.28047
   Pei G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136714
   Prestat M, 2021, ACTA BIOMATER, V136, P72, DOI 10.1016/j.actbio.2021.10.002
   Ratnadiwakara M, 2018, BIO PROTOCOL, V8, DOI 10.21769/BioProtoc.3072
   Redlich K, 2012, NAT REV DRUG DISCOV, V11, P234, DOI 10.1038/nrd3669
   Safioti LM, 2017, J PERIODONTOL, V88, P436, DOI 10.1902/jop.2016.160524
   Schwartz S, 2014, CELL REP, V8, P284, DOI 10.1016/j.celrep.2014.05.048
   Shah R, 2016, EUR J PROSTHODONT RE, V24, P171, DOI 10.1922/EJPRD_1531Shah10
   Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025
   Song H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467 021 25803 0
   Tan X, 2015, VET IMMUNOL IMMUNOP, V168, P68, DOI 10.1016/j.vetimm.2015.08.010
   Tay ML, 2022, J ISAKOS, V7, P132, DOI 10.1016/j.jisako.2022.06.001
   Tian C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030551
   Tsuchiya K, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1962656
   Urban RM, 2000, J BONE JOINT SURG AM, V82A, P457, DOI 10.2106/00004623 200004000 00002
   Voggenreiter G, 2003, BIOMATERIALS, V24, P247, DOI 10.1016/S0142 9612(02)00312 5
   Wang JH, 2016, SCI REP UK, V6, DOI 10.1038/srep23827
   Wang LL, 2020, INT J BIOL MACROMOL, V142, P142, DOI 10.1016/j.ijbiomac.2019.09.084
   Wang P, 2016, MOL CELL, V63, P306, DOI 10.1016/j.molcel.2016.05.041
   Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014
   Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730
   Winkler R, 2019, NAT IMMUNOL, V20, P173, DOI 10.1038/s41590 018 0275 z
   Wu MR, 2016, BONE RES, V4, DOI 10.1038/boneres.2016.9
   Wu RF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419 019 1417 4
   Wu YS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467 018 06898 4
   Xiong LB, 2019, THERANOSTICS, V9, P7140, DOI 10.7150/thno.35988
   Xu K, 2017, CELL RES, V27, P1100, DOI 10.1038/cr.2017.100
   Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018
   Yang Y, 2018, CELL RES, V28, P616, DOI 10.1038/s41422 018 0040 8
   Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045 020 00951 w
   Zhang YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010199
   Zheng GQ, 2013, MOL CELL, V49, P18, DOI 10.1016/j.molcel.2012.10.015
   Zheng K, 2021, BIOACT MATER, V6, P3343, DOI 10.1016/j.bioactmat.2021.02.039
   Zhou J, 2015, NATURE, V526, P591, DOI 10.1038/nature15377
   Zhou ZY, 2023, EPIGENETICS US, V18, DOI 10.1080/15592294.2023.2217033
   Zhu ZG, 2018, MOL MED REP, V18, P2561, DOI 10.3892/mmr.2018.9286
NR 86
TC 1
Z9 1
U1 2
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791 2997
EI 1791 3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2024
VL 29
IS 3
AR 36
DI 10.3892/mmr.2024.13160
PG 16
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Research & Experimental Medicine
GA KB1B4
UT WOS:001177398700001
PM 38214327
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Qiao, JT
   Liu, AY
   Liu, JY
   Guan, DH
   Chen, TX
AF Qiao, Jiutao
   Liu, Aiyun
   Liu, Jianyu
   Guan, Dehong
   Chen, Tianxin
TI Salvianolic acid B (Sal B) alleviates the decreased activity induced by
   prednisolone acetate on osteoblasts by up regulation of bone formation
   and differentiation genes
SO FOOD & FUNCTION
LA English
DT Article
ID GLUCOCORTICOID INDUCED OSTEOPOROSIS; ALKALINE PHOSPHATASE; I COLLAGEN;
   EXPRESSION; GROWTH; CELLS; FRACTURES; STRAIN; NRF2
AB Glucocorticoids (GCs) are widely used to treat a variety of autoimmune diseases, but long term use can lead to osteoporosis. To elucidate the mechanism of osteoporosis caused by glucocorticoids and to find effective protective drugs/foods, osteoblasts treated by prednisolone acetate were studied and salvianolic acid B (Sal B) was added to osteoblasts. The results showed that Sal B increased the activity of ALP and stimulated the expression of ALP that had been suppressed by prednisolone acetate. To further study the mechanisms of the protective effect of Sal B on osteoblasts treated with prednisolone acetate, the effects of gene expression involved with bone formation and differentiation were studied. The results show that the mRNA and protein expression of Runx2, Osx, OCN, IGF I, Col I and HO I was up regulated by Sal B. In conclusion, by stimulating the osteoblast activity and the expression of genes related to bone formation and differentiation, Sal B had a protective effect on osteoblasts that had been treated with prednisolone acetate.
C1 [Qiao, Jiutao; Liu, Aiyun; Liu, Jianyu; Guan, Dehong; Chen, Tianxin] Harbin Med Univ, Affiliated Hosp 2, 246 Xuefu Rd, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Qiao, JT (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, 246 Xuefu Rd, Harbin, Heilongjiang, Peoples R China.
EM JiutaoQ1111@126.com
RI Li, Yifan/AAN 2776 2021
CR ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   BIEWENER AA, 1986, CALCIFIED TISSUE INT, V39, P390, DOI 10.1007/BF02555177
   BOUILLON R, 1991, HORM RES, V36, P49, DOI 10.1159/000182189
   Buttgereit F, 2015, CLIN EXP RHEUMATOL, V33, pS29
   Canalis E, 2007, OSTEOPOROSIS INT, V18, P1319, DOI 10.1007/s00198 007 0394 0
   Canchen M., 2017, ARCH OSTEOPOROS, V12, P33, DOI [10.1007/s11657 017 0329 0, DOI 10.1007/S11657 017 0329 0]
   Chenhui Y., 2009, BRAIN RES, V1282, P133, DOI [10.1016/j.brainres.2009.05.009, DOI 10.1016/J.BRAINRES.2009.05.009]
   Cutrim DMSL, 2007, BRAZ J MED BIOL RES, V40, P221, DOI 10.1590/S0100 879X2006005000054
   Defang L., 2016, NAT COMMUN, V7, P10872, DOI [10.1038/ncomms10872, DOI 10.1038/NCOMMS10872]
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Ferron M, 2008, P NATL ACAD SCI USA, V105, P5266, DOI 10.1073/pnas.0711119105
   Gonzalez Fernandez D., 2012, THESIS
   HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo 122 1 254
   Hu K, 2016, J CLIN INVEST, V126, P509, DOI 10.1172/JCI82585
   Ignatius A, 2005, BIOMATERIALS, V26, P311, DOI 10.1016/j.biomaterials.2004.02.045
   Jeon WJ, 2017, LIFE SCI, V178, P94, DOI 10.1016/j.lfs.2017.04.012
   Kim IS, 1999, MECH DEVELOP, V80, P159, DOI 10.1016/S0925 4773(98)00210 X
   Liao CC, 2012, PLOS ONE, V7, DOI DOI 10.1371/journal.pone.0034647
   Lili W., 2017, CHIN J OSTEOPOROSIS, V23, P281
   LUKERT BP, 1990, ANN INTERN MED, V112, P352, DOI 10.7326/0003 4819 112 5 352
   Maeda T, 2004, J CELL BIOCHEM, V92, P458, DOI 10.1002/jcb.20074
   Manelli F, 2000, TRENDS ENDOCRIN MET, V11, P79, DOI 10.1016/S1043 2760(00)00234 4
   Mazziotti G, 2010, OSTEOPOROSIS IN MEN: THE EFFECTS OF GENDER ON SKELETAL HEALTH, 2ND EDITION, P415, DOI 10.1016/B978 0 12 374602 3.00034 1
   Melville KM, 2015, J BONE MINER RES, V30, P1468, DOI 10.1002/jbmr.2488
   MICHEL BA, 1991, J RHEUMATOL, V18, P804
   Pavlin D, 2000, CALCIFIED TISSUE INT, V67, P163, DOI 10.1007/s00223001105
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Rui Wang, 2018, Journal of Functional Foods, V46, P288, DOI 10.1016/j.jff.2018.04.047
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Sims Natalie A, 2014, Bonekey Rep, V3, P481, DOI 10.1038/bonekey.2013.215
   Velichkova M, 2005, MOL CELL BIOL, V25, P4501, DOI 10.1128/MCB.25.11.4501 4513.2005
   Xi H., 2004, DEVELOPMENT, V131, P1663, DOI [10.1242/dev.01117, DOI 10.1242/DEV.01117]
   Yagi K, 2003, J CELL BIOCHEM, V88, P1077, DOI 10.1002/jcb.10467
   Yamada T, 1999, HISTOCHEM J, V31, P687, DOI 10.1023/A:1003855922395
   Yamamoto K, 2015, P NATL ACAD SCI USA, V112, P6152, DOI 10.1073/pnas.1420713112
   Yu JH, 2015, INT J CLIN EXP MED, V8, P14793
   Yubo G., 2014, J ETHNOPHARMACOL, V155, P1401, DOI [10.1016/j.jep.2014.07.058, DOI 10.1016/J.JEP.2014.07.058]
NR 39
TC 16
Z9 19
U1 0
U2 14
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2042 6496
EI 2042 650X
J9 FOOD FUNCT
JI Food Funct.
PD SEP 1
PY 2019
VL 10
IS 9
BP 6184
EP 6192
DI 10.1039/c9fo01246j
PG 9
WC Biochemistry & Molecular Biology; Food Science & Technology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Food Science & Technology
GA IZ3ZP
UT WOS:000487024400077
PM 31501830
DA 2025 08 17
ER

PT J
AU Feng, RT
   Rios, JA
   Onishi, T
   Lokshin, A
   Gorelik, E
   Lentzsch, S
AF Feng, Rentian
   Rios, Jorge A.
   Onishi, Tomifumi
   Lokshin, Anna
   Gorelik, Elieser
   Lentzsch, Suzanne
TI Cell based and cytokine directed chemical screen to identify potential
   anti multiple myeloma agents
SO LEUKEMIA RESEARCH
LA English
DT Article
DE Drug screening; Cytokine; Anti myeloma; Luminex
ID HISTONE DEACETYLASE INHIBITOR; DNA DAMAGE; GROWTH; CANCER; APOPTOSIS;
   PATHOPHYSIOLOGY; OSTEOCLAST; PATHWAYS; SURVIVAL; THERAPY
AB We used a novel high throughput drug screening assay, based on Luminex technology, to identify anti myeloma agents capable of inhibiting cytokines and growth factors essential for multiple myeloma (MM) from a chemical library of 1120 compounds provided by MMRF. Tetracycline derivatives inhibited MM cell proliferation and osteoclast activating factors without obvious effect on cell viability. Steroid compounds specifically decreased angiogenesis related factors, but stimulated osteoclast activating factors. Antihelmintic drugs potently inhibited cytokines and were cytotoxic. The screen identified potential candidates with potent anti MM properties that need further investigation. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Feng, Rentian; Rios, Jorge A.; Onishi, Tomifumi; Lentzsch, Suzanne] Univ Pittsburgh, Dept Med, Div Hematol & Oncol, Inst Canc, Pittsburgh, PA 15232 USA.
   [Lokshin, Anna; Gorelik, Elieser] Univ Pittsburgh, Dept Pathol, Med Ctr, Pittsburgh, PA 15232 USA.
   [Lokshin, Anna; Gorelik, Elieser] Univ Pittsburgh, Dept Immunol, Med Ctr, Pittsburgh, PA 15232 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Lentzsch, S (通讯作者)，Univ Pittsburgh, Dept Med, Div Hematol & Oncol, Inst Canc, 5150 Ctr Ave,568, Pittsburgh, PA 15232 USA.
EM lentzschs@upmc.edu
RI Rios, Jorge/KIJ 8801 2024
FU Multiple Myeloma Research Foundation (MMRF)
FX This study was supported by Multiple Myeloma Research Foundation (MMRF)
   to S. L. We thank Ms. Rita Bhuta for excellent assistance in the
   preparation of the manuscript.
CR Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Aggarwal R, 2006, EXP HEMATOL, V34, P1289, DOI 10.1016/j.exphem.2006.06.017
   Bommert K, 2006, EUR J CANCER, V42, P1574, DOI 10.1016/j.ejca.2005.12.026
   Broek IV, 2008, CLIN EXP METASTAS, V25, P325, DOI 10.1007/s10585 007 9108 4
   Chen JQ, 2006, BREAST CANCER RES TR, V96, P1, DOI 10.1007/s10549 005 9053 3
   Doudican N, 2008, MOL CANCER RES, V6, P1308, DOI 10.1158/1541 7786.MCR 07 2159
   Feng RT, 2008, MOL CANCER THER, V7, P1494, DOI 10.1158/1535 7163.MCT 08 0183
   Feng R, 2007, BRIT J HAEMATOL, V139, P385, DOI 10.1111/j.1365 2141.2007.06772.x
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Gatto B, 1996, CANCER RES, V56, P2795
   Gorelik E, 2005, CANCER EPIDEM BIOMAR, V14, P981, DOI 10.1158/1055 9965.EPI 04 0404
   HELIGE C, 1993, EUR J CANCER, V29A, P124, DOI 10.1016/0959 8049(93)90589 8
   Ihenetu K, 2007, CLIN CHEM, V53, P1315, DOI 10.1373/clinchem.2006.082081
   Kim HJ, 2007, ADV EXP MED BIOL, V602, P43
   Kulikov A, 2007, BBA BIOMEMBRANES, V1768, P1691, DOI 10.1016/j.bbamem.2007.04.012
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Lentzsch S, 2007, HEMATOL ONCOL CLIN N, V21, P1035, DOI 10.1016/j.hoc.2007.08.009
   *LEUK LYMPH SOC, FACTS 2008 2009 LEUK
   Levina V, 2008, INT J CANCER, V123, P2031, DOI 10.1002/ijc.23732
   Mitsiades CS, 2006, EUR J CANCER, V42, P1564, DOI 10.1016/j.ejca.2005.12.025
   Mukhopadhyay T, 2002, CLIN CANCER RES, V8, P2963
   Niesvizky R, 2008, BLOOD, V111, P1101, DOI 10.1182/blood 2007 05 090258
   Pourgholami MH, 2006, CLIN CANCER RES, V12, P1928, DOI 10.1158/1078 0432.CCR 05 1181
   REPKE KRH, 1995, ANTI CANCER DRUG DES, V10, P177
   Roodman G David, 2004, Cancer Treat Res, V118, P83
   Sambrook PN, 2007, NEW ENGL J MED, V357, P2084, DOI 10.1056/NEJMe0706770
   Silver RF, 1998, J IMMUNOL, V160, P2408
   Sirohi B, 2004, LANCET, V363, P875, DOI 10.1016/S0140 6736(04)15736 X
   Urashima M, 1997, BLOOD, V90, P754, DOI 10.1182/blood.V90.2.754.754_754_765
   Yano A, 2006, CLIN CANCER RES, V12, P6012, DOI 10.1158/1078 0432.CCR 06 0749
   Yip KW, 2006, MOL CANCER THER, V5, P2234, DOI 10.1158/1535 7163.MCT 06 0134
NR 31
TC 8
Z9 8
U1 1
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0145 2126
EI 1873 5835
J9 LEUKEMIA RES
JI Leuk. Res.
PD JUL
PY 2010
VL 34
IS 7
BP 917
EP 924
DI 10.1016/j.leukres.2009.12.002
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 598KS
UT WOS:000277836300018
PM 20116850
DA 2025 08 17
ER

PT J
AU Mishra, S
   Tai, Q
   Gu, X
   Schmitz, J
   Poullard, A
   Fajardo, RJ
   Mahalingam, D
   Chen, XD
   Zhu, XQ
   Sun, LZ
AF Mishra, Sweta
   Tai, Qin
   Gu, Xiang
   Schmitz, James
   Poullard, Ashley
   Fajardo, Roberto J.
   Mahalingam, Devalingam
   Chen, Xiaodong
   Zhu, Xueqiong
   Sun, Lu Zhe
TI Estrogen and estrogen receptor alpha promotes malignancy and
   osteoblastic tumorigenesis in prostate cancer
SO ONCOTARGET
LA English
DT Article
DE prostate cancer; estrogen receptor; bone; osteoblastic; metastasis
ID ANDROGEN RECEPTOR; ER BETA; OSTEOMIMETIC PROPERTIES; BONE METASTASIS;
   GROWTH; PROLIFERATION; EXPRESSION; PATHWAY; PROTEIN; CARCINOGENESIS
AB The role of estrogen signaling in regulating prostate tumorigenesis is relatively underexplored. Although, an increasing body of evidence has linked estrogen receptor beta (ER beta) to prostate cancer, the function of estrogen receptor alpha (ER alpha) in prostate cancer is not very well studied. We have discovered a novel role of ER alpha in the pathogenesis of prostate tumors. Here, we show that prostate cancer cells express ER alpha and estrogen induces oncogenic properties in prostate cancer cells through ER alpha. Importantly, ER alpha knockdown in the human prostate cancer PacMetUT1 cells as well as pharmacological inhibition of ER alpha with ICI 182,780 inhibited osteoblastic lesion formation and lung metastasis in vivo. Co culture of pre osteoblasts with cancer cells showed a significant induction of osteogenic markers in the pre osteoblasts, which was attenuated by knockdown of ER alpha in cancer cells suggesting that estrogen/ER alpha signaling promotes crosstalk between cancer and osteoblastic progenitors to stimulate osteoblastic tumorigenesis. These results suggest that ER alpha expression in prostate cancer cells is essential for osteoblastic lesion formation and lung metastasis. Thus, inhibition of ER alpha signaling in prostate cancer cells may be a novel therapeutic strategy to inhibit the osteoblastic lesion development as well as lung metastasis in patients with advanced prostate cancer.
C1 [Mishra, Sweta; Tai, Qin; Gu, Xiang; Sun, Lu Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Schmitz, James; Fajardo, Roberto J.] Univ Texas Hlth Sci Ctr San Antonio, Dept Orthoped Surg, San Antonio, TX 78229 USA.
   [Mahalingam, Devalingam; Sun, Lu Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Chen, Xiaodong] Univ Texas Hlth Sci Ctr San Antonio, Dent Sch, San Antonio, TX 78229 USA.
   [Zhu, Xueqiong] Wenzhou Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Wenzhou, Peoples R China.
   [Poullard, Ashley] Brown Univ, Dept Med, Providence, RI 02912 USA.
   [Tai, Qin] Cent South Univ, Xiangya Hosp 2, Dept Vasc Surg, Changsha, Hunan, Peoples R China.
   [Tai, Qin] Cent South Univ, Xiangya Sch Med, Changsha, Hunan, Peoples R China.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; Cancer Therapy & Research Center;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; Wenzhou Medical University; Brown
   University; Central South University; Central South University
RP Sun, LZ (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
EM SUNL@UTHSCSA.EDU
RI Chen, Xiao Dong/ADG 8612 2022; zhu, xueqiong/U 1320 2019; ,
   LuZhe/AAW 4095 2021
OI Chen, Xiao Dong/0000 0003 1602 806X
FU Cancer Prevention and Research Institute of Texas (CPRIT)
   [RP120290 IIRA]; NIH [R01CA172886]; Cancer Therapy and Research Center
   at the University of Texas Health Science Center at San Antonio
   (UTHSCSA) through the NCI Cancer Center [2 P30 CA054174]
FX This study was in part supported by RP120290 IIRA from Cancer Prevention
   and Research Institute of Texas (CPRIT), and R01CA172886 from NIH, and
   the Cancer Therapy and Research Center at the University of Texas Health
   Science Center at San Antonio (UTHSCSA) through the NCI Cancer Center
   Support Grant 2 P30 CA054174.
CR Bonkhoff H, 1999, AM J PATHOL, V155, P641, DOI 10.1016/S0002 9440(10)65160 7
   Bosland M C, 2000, J Natl Cancer Inst Monogr, P39
   Bossard C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044787
   CITRIN DL, 1991, PROSTATE, V18, P139, DOI 10.1002/pros.2990180206
   Dai JL, 2008, CANCER RES, V68, P5785, DOI 10.1158/0008 5472.CAN 07 6541
   Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008 5472.CAN 05 1891
   Dey P, 2012, MOL ENDOCRINOL, V26, P1991, DOI 10.1210/me.2012.1227
   Fradet A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075092
   Guise TA, 1996, J CLIN INVEST, V98, P1544, DOI 10.1172/JCI118947
   Härkönen PL, 2004, J STEROID BIOCHEM, V92, P297, DOI 10.1016/j.jsbmb.2004.10.016
   Ho SM, 2004, J CELL BIOCHEM, V91, P491, DOI 10.1002/jcb.10759
   Hussain S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040732
   Khosla S, 2012, TRENDS ENDOCRIN MET, V23, P576, DOI 10.1016/j.tem.2012.03.008
   Koeneman KS, 1999, PROSTATE, V39, P246
   Kunath F, 2012, BMC MED, V10, DOI 10.1186/1741 7015 10 96
   LEAV I, 1989, PROSTATE, V15, P23, DOI 10.1002/pros.2990150104
   Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002 9440(10)61676 8
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471 2105 12 323
   Lin DL, 2001, PROSTATE, V47, P212, DOI 10.1002/pros.1065
   Liu XY, 2010, INDIAN J PHARMACOL, V42, P312, DOI 10.4103/0253 7613.70397
   Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030
   MARTIKAINEN P, 1987, ENDOCRINOLOGY, V121, P604, DOI 10.1210/endo 121 2 604
   McPherson SJ, 2010, P NATL ACAD SCI USA, V107, P3123, DOI 10.1073/pnas.0905524107
   Mishra S, 2014, ONCOGENE, V33, P4097, DOI 10.1038/onc.2013.374
   Mishra S, 2014, MOL CANCER, V13, DOI 10.1186/1476 4598 13 212
   Mishra S, 2011, PROSTATE, V71, P1441, DOI 10.1002/pros.21361
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Muthusamy S, 2011, P NATL ACAD SCI USA, V108, P20090, DOI 10.1073/pnas.1117772108
   Nakajima Y, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001551
   NELSON JB, 1995, NAT MED, V1, P944, DOI 10.1038/nm0995 944
   NEVALAINEN MT, 1991, ENDOCRINOLOGY, V129, P612, DOI 10.1210/endo 129 2 612
   Paruthiyil S, 2004, CANCER RES, V64, P423, DOI 10.1158/0008 5472.CAN 03 2446
   Prins GS, 2008, STEROIDS, V73, P233, DOI 10.1016/j.steroids.2007.10.013
   Ricke WA, 2008, FASEB J, V22, P1512, DOI 10.1096/fj.07 9526com
   Risbridger GP, 2001, ENDOCRINOLOGY, V142, P2443, DOI 10.1210/en.142.6.2443
   Rucci Nadia, 2010, Front Biosci (Schol Ed), V2, P907
   Saltzstein D, 2005, PROSTATE CANCER P D, V8, P75, DOI 10.1038/sj.pcan.4500782
   Siegel R, 2014, CA CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Singh AS, 2005, J UROLOGY, V174, P820, DOI 10.1097/01.ju.0000169133.82167.aa
   Slusarz A, 2012, ENDOCRINOLOGY, V153, P4160, DOI 10.1210/en.2012 1030
   Smith MR, 2013, J UROLOGY, V189, pS45, DOI 10.1016/j.juro.2012.11.016
   Smith MR, 2004, J CLIN ENDOCR METAB, V89, P3841, DOI 10.1210/jc.2003 032058
   Steiner MS, 2003, WORLD J UROL, V21, P31, DOI 10.1007/s00345 002 0316 x
   Tohfe Moustapha, 2008, Cases J, V1, P316, DOI 10.1186/1757 1626 1 316
   Troyer DA, 2008, PROSTATE, V68, P883, DOI 10.1002/pros.20758
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Virk MS, 2009, BONE, V44, P160, DOI 10.1016/j.bone.2008.09.009
   Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535 6108(03)00215 0
   Windahl SH, 2013, P NATL ACAD SCI USA, V110, P2294, DOI 10.1073/pnas.1220811110
   Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097 0215(19980911)77:6<887::AID IJC15>3.0.CO;2 Z
   Zayzafoon M, 2004, J BIOL CHEM, V279, P3662, DOI 10.1074/jbc.M308158200
   Zellweger T, 2013, ENDOCR RELAT CANCER, V20, P403, DOI 10.1530/ERC 12 0402
   Zhau HYE, 2011, CLIN CANCER RES, V17, P2159, DOI 10.1158/1078 0432.CCR 10 2523
NR 54
TC 52
Z9 56
U1 1
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949 2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 29
PY 2015
VL 6
IS 42
BP 44388
EP 44402
DI 10.18632/oncotarget.6317
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA DD4QX
UT WOS:000369908800026
PM 26575018
OA Green Submitted, gold, Green Published
DA 2025 08 17
ER

PT J
AU Zhang, P
   Wang, S
   Wang, L
   Shan, BC
   Zhang, H
   Yang, F
   Zhou, ZQ
   Wang, X
   Yuan, Y
   Xu, YJ
AF Zhang, Peng
   Wang, Sheng
   Wang, Liang
   Shan, Bing Chen
   Zhang, Hui
   Yang, Fan
   Zhou, Zhi Qiang
   Wang, Xiao
   Yuan, Ye
   Xu, You Jia
TI Hepcidin is an endogenous protective factor for osteoporosis by reducing
   iron levels
SO JOURNAL OF MOLECULAR ENDOCRINOLOGY
LA English
DT Article
DE hepcidin; osteoporosis; oxidative stress; bone metabolism; iron
   metabolism
ID BONE MINERAL DENSITY; POSTMENOPAUSAL OSTEOPOROSIS; BETA CATENIN;
   MENOPAUSE; CHELATION; WOMEN; AGE; ACCUMULATION; OSTEOGENESIS;
   CONTRIBUTES
AB Postmenopausal osteoporosis is a global health issue. Although a lack of estrogen is considered the major reason for postmenopausal osteoporosis, other factors might also contribute the etiology of the disease. In previous reports, we and others proposed that iron accumulation after menopause accelerates osteoporosis, and here, we genetically modified the expression of an endogenous hormone, hepcidin, to modulate iron status in a mouse model. Our results show that hepcidin levels negatively correlate with bone loss in both knockout and overexpression (with ovariectomy) murine models. In addition, iron overload enhances reactive oxygen species (ROS) activity and attenuates the functions of primary osteoblasts, while iron depletion could reverse this phenomenon through inhibiting the functions of primary osteoclasts. Therefore, our results provide more evidence of the 'iron accumulation' hypothesis, which suggests that high iron levels are risk factors for osteoporosis, and the 'Huang's hypothesis' that hepcidin is a potential drug target for the prevention of postmenopausal osteoporosis.
C1 [Zhang, Peng; Shan, Bing Chen; Zhou, Zhi Qiang; Xu, You Jia] Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou, Peoples R China.
   [Wang, Sheng] Fudan Univ, Zhongshan Hosp, Emergency Dept, Shanghai, Peoples R China.
   [Wang, Liang] Soochow Univ, Childrens Hosp, Dept Radiol, Suzhou, Jiangsu, Peoples R China.
   [Zhang, Hui; Yang, Fan; Wang, Xiao; Yuan, Ye; Xu, You Jia] Soochow Univ, Osteoprosis Inst, Suzhou, Peoples R China.
C3 Soochow University   China; Fudan University; Soochow University  
   China; Soochow University   China
RP Xu, YJ (通讯作者)，Soochow Univ, Affiliated Hosp 2, Dept Orthopaed, Suzhou, Peoples R China.; Xu, YJ (通讯作者)，Soochow Univ, Osteoprosis Inst, Suzhou, Peoples R China.
EM xuyoujia@suda.edu.cn
RI Zhou, Zhiqiang/HIR 4954 2022
FU National Natural Science Foundation of China [81502812, 81572179,
   81773439]; Clinical Special Program of Jiangsu Province [BL2014044];
   Minsheng Science and Technology Project of Suzhou [SS201634]; Clinical
   Medical Center Project of Suzhou [Szzx201504]; Advantage Discipline
   Groups of the Second Affiliated Hospital of Soochow University
   [XKQ2015001]
FX This study was supported by the National Natural Science Foundation of
   China (grant nos. 81502812, 81572179 and 81773439), the Clinical Special
   Program of Jiangsu Province (grant no. BL2014044), Minsheng Science and
   Technology Project of Suzhou (grant no. SS201634), Clinical Medical
   Center Project of Suzhou (grant no. Szzx201504), Advantage Discipline
   Groups of the Second Affiliated Hospital of Soochow University (grant
   no. XKQ2015001).
CR Almeida M, 2007, J BIOL CHEM, V282, P27298, DOI 10.1074/jbc.M702811200
   Baschant U, 2016, HAEMATOLOGICA, V101, P1499, DOI 10.3324/haematol.2016.144808
   Cauley JA, 2015, CURR OPIN ENDOCRINOL, V22, P490, DOI 10.1097/MED.0000000000000204
   Chen B, 2015, EXP THER MED, V10, P7, DOI 10.3892/etm.2015.2484
   Cutler W, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128895
   Fucharoen S, 2015, ANN TRANSL MED, V3, DOI [10.3978/j.issn.2305 5839.2015.AB044, DOI 10.3978/J.ISSN.2305 5839.2015.AB044]
   Gong DD, 2016, INT J CARDIOL, V203, P115, DOI 10.1016/j.ijcard.2015.10.092
   Honour JW, 2018, ANN CLIN BIOCHEM, V55, P18, DOI 10.1177/0004563217739930
   Huang X, 2013, BONE, V55, P458, DOI 10.1016/j.bone.2013.03.008
   Huang XI, 2015, U. S. Patent Application, DOI 10.1093/nar/27.22.4324, Patent No. [12/704.187, 12704187]
   Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324
   Jeney V, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00077
   Jia P, 2012, J ORTHOP RES, V30, P1843, DOI 10.1002/jor.22133
   Jiang Y, 2016, BIOCHEM BIOPH RES CO, V476, P1, DOI 10.1016/j.bbrc.2016.05.118
   Kodama K, 2014, PEDIATR INT, V56, pE41, DOI 10.1111/ped.12395
   Li GF, 2012, MOL CELL BIOCHEM, V366, P169, DOI 10.1007/s11010 012 1294 y
   Liu G, 2006, BIOMETALS, V19, P245, DOI 10.1007/s10534 005 6666 2
   Liu J, 2018, MOL MED REP, V17, P350, DOI 10.3892/mmr.2017.7876
   Lu HD, 2015, MOL MED REP, V11, P143, DOI 10.3892/mmr.2014.2769
   Ma Y, 2010, BONE, V47, pS424, DOI 10.1016/j.bone.2010.09.247
   Messa E, 2010, HAEMATOL HEMATOL J, V95, P1308, DOI 10.3324/haematol.2009.016824
   Messner DJ, 2009, LIVER INT, V29, P63, DOI 10.1111/j.1478 3231.2008.01793.x
   Miller PD, 2016, J CLIN ENDOCR METAB, V101, P3163, DOI 10.1210/jc.2016 1801
   Pluchino N, 2011, WOMENS HEALTH, V7, P71, DOI 10.2217/WHE.10.80
   Poggi M, 2016, ANN HEMATOL, V95, P757, DOI 10.1007/s00277 016 2633 y
   Qian Y, 2015, CELL SIGNAL, V27, P934, DOI 10.1016/j.cellsig.2015.01.017
   Qu ZH, 2008, BIOCHEM BIOPH RES CO, V370, P332, DOI 10.1016/j.bbrc.2008.03.092
   Shen GS, 2014, CALCIFIED TISSUE INT, V94, P632, DOI 10.1007/s00223 014 9845 8
   Sirichakwal PP, 2015, J NUTR, V145, P990, DOI 10.3945/jn.114.207290
   Song JF, 2014, MED SCI MONITOR, V20, P2624, DOI 10.12659/MSM.892581
   Sullivan SD, 2015, MENOPAUSE, V22, P1035, DOI 10.1097/GME.0000000000000451
   Sun L, 2014, GENE, V543, P161, DOI 10.1016/j.gene.2014.02.023
   Wang X, 2015, J ENDOCRINOL, V226, P121, DOI 10.1530/JOE 14 0657
   Weinberg ED, 2006, BIOMETALS, V19, P633, DOI 10.1007/s10534 006 9000 8
   Xu You jia, 2013, Zhonghua Yi Xue Za Zhi, V93, P3809
   Xu YJ, 2011, REGUL PEPTIDES, V172, P58, DOI 10.1016/j.regpep.2011.08.009
   Xu Z, 2017, BONE, V94, P152, DOI 10.1016/j.bone.2016.09.023
   Zhao NN, 2013, J CLIN INVEST, V123, P2337, DOI 10.1172/JCI67225
NR 38
TC 31
Z9 35
U1 1
U2 29
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
   ENGLAND
SN 0952 5041
EI 1479 6813
J9 J MOL ENDOCRINOL
JI J. Mol. Endocrinol.
PD MAY
PY 2018
VL 60
IS 4
BP 299
EP 308
DI 10.1530/JME 17 0301
PG 10
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA GM5NB
UT WOS:000438183900006
PM 29563156
OA Bronze
DA 2025 08 17
ER

PT J
AU Shi, WG
   Zhang, YN
   Chen, KM
   He, JP
   Feng, X
   Wei, WJ
   Hua, JR
   Wang, JF
AF Shi, Wengui
   Zhang, Yanan
   Chen, Keming
   He, Jinpeng
   Feng, Xiu
   Wei, Wenjun
   Hua, Junrui
   Wang, Jufang
TI Primary cilia act as microgravity sensors by depolymerizing microtubules
   to inhibit osteoblastic differentiation and mineralization
SO BONE
LA English
DT Article
DE Microgravity; Osteoblasts; Primary cilium; Microtubule
ID MESENCHYMAL STEM CELLS; OSTEOGENIC DIFFERENTIATION; CYTOSKELETON
AB Microgravity induced bone deterioration is a major challenge in long term spaceflights since the underlying mechanisms remain elusive. Previously, we reported that primary cilia of osteoblasts gradually disappeared in microgravity conditions, and cilia abrogation was necessary for the inhibition of osteogenesis induced by microgravity. However, the precise roles of primary cilia have not been fully elucidated. Here, we report that microgravity depolymerizes the microtubule network of rat calvarial osteoblasts (ROBs) reversibly but has no effect on the architecture of actin filaments. Preventing primary ciliogenesis by chloral hydrate or a small interfering RNA sequence (siRNA) targeting intraflagellar transport protein 88 (IFT88) effectively relieves microgravity induced microtubule depolymerization, whereas the stabilization of microtubules using pharmacological approaches cannot prevent the disappearance of primary cilia in microgravity conditions. Furthermore, quantification of the number of microtubules emerging from the ciliary base body shows that microgravity significantly decreases the number of basal microtubules, which is dependent on the existence of primary cilia. Finally, microgravity induced repression of the differentiation, maturation, and mineralization of ROBs is abrogated by the stabilization of cytoplasmic microtubules. Taken together, these data suggest that primary cilia dependent depolymerization of microtubules is responsible for the inhibition of osteogenesis induced by microgravity. Our study provides a new perspective regarding the mechanism of microgravity induced bone loss, supporting the previously established role of primary cilia as a sensor in bone metabolism.
C1 [Shi, Wengui; Zhang, Yanan; He, Jinpeng; Feng, Xiu; Wei, Wenjun; Hua, Junrui; Wang, Jufang] Chinese Acad Sci, Inst Modern Phys, Key Lab Space Radiobiol Gansu Prov, Lanzhou 730000, Peoples R China.
   [Shi, Wengui; Zhang, Yanan; He, Jinpeng; Feng, Xiu; Wei, Wenjun; Hua, Junrui; Wang, Jufang] Chinese Acad Sci, Inst Modern Phys, CAS Key Lab Heavy Ion Radiat Biol & Med, Lanzhou 730000, Peoples R China.
   [Shi, Wengui] Lanzhou Univ, Cuiying Biomed Res Ctr, Hosp 2, Lanzhou 730030, Peoples R China.
   [Chen, Keming] Joint Logist Support 940 Hosp CPLA, Inst Orthopaed, Lanzhou 730050, Peoples R China.
   [Feng, Xiu; Wang, Jufang] Univ Chinese Acad Sci, Beijing 100049, Peoples R China.
C3 Chinese Academy of Sciences; Institute of Modern Physics, CAS; Chinese
   Academy of Sciences; Institute of Modern Physics, CAS; Lanzhou
   University; Chinese Academy of Sciences; University of Chinese Academy
   of Sciences, CAS
RP Wang, JF (通讯作者)，Chinese Acad Sci, Inst Modern Phys, Lanzhou 730000, Peoples R China.
EM jufangwang@impcas.ac.cn
RI He, Jinpeng/L 7106 2019; Wei, Wenjun/AAE 7575 2021
OI Shi, Wengui/0000 0003 1039 3576; He, Jinpeng/0000 0003 0651 2659
FU National Natural Sciences Foundation of China [31870851, 81770879];
   Science and Technology Research Project of Gansu Province [145RTSA012,
   17JR5RA307]; International Science & Technology Cooperation Program of
   China [2015DFR30940]
FX This work was supported by the National Natural Sciences Foundation of
   China (Nos. 31870851 and 81770879), the Science and Technology Research
   Project of Gansu Province (Nos. 145RTSA012 and 17JR5RA307) and the
   International Science & Technology Cooperation Program of China (No.
   2015DFR30940).
CR Aleshcheva G, 2015, FASEB J, V29, P2303, DOI 10.1096/fj.14 268151
   Anderson CT, 2008, ANAT REC, V291, P1074, DOI 10.1002/ar.20754
   Arganda Carreras I, 2010, MICROSC RES TECHNIQ, V73, P1019, DOI 10.1002/jemt.20829
   Buey RM, 2004, CHEM BIOL, V11, P225, DOI 10.1016/j.chembiol.2004.01.014
   Chen Z, 2016, SCI REP UK, V6, DOI 10.1038/srep25771
   Clement CA, 2009, METHOD CELL BIOL, V94, P181, DOI 10.1016/S0091 679X(08)94009 7
   Corrigan MA, 2019, CELL MOL BIOENG, V12, P53, DOI 10.1007/s12195 018 00561 0
   Crawford Young SJ, 2006, INT J DEV BIOL, V50, P183, DOI 10.1387/ijdb.052077sc
   Delaine Smith RM, 2014, FASEB J, V28, P430, DOI 10.1096/fj.13 231894
   Doube M, 2010, BONE, V47, P1076, DOI 10.1016/j.bone.2010.08.023
   Espinha LC, 2014, CYTOSKELETON, V71, P435, DOI 10.1002/cm.21183
   Frangi AF, 1998, LECT NOTES COMPUT SC, V1496, P130, DOI 10.1007/BFb0056195
   He JP, 2018, ACTA PHARMACOL SIN, V39, P1760, DOI 10.1038/s41401 018 0040 8
   Hoey David A, 2012, Front Endocrinol (Lausanne), V3, P75, DOI 10.3389/fendo.2012.00075
   Hu LF, 2015, CELL BIOL INT, V39, P364, DOI 10.1002/cbin.10391
   Jeffries EP, 2019, FASEB J, V33, P4866, DOI 10.1096/fj.201801382R
   Lewis ML, 1998, FASEB J, V12, P1007, DOI 10.1096/fasebj.12.11.1007
   Lloyd SA, 2012, J BONE MINER RES, V27, P2359, DOI 10.1002/jbmr.1687
   Malone AMD, 2007, P NATL ACAD SCI USA, V104, P13325, DOI 10.1073/pnas.0700636104
   Meloni MA, 2011, CYTOSKELETON, V68, P125, DOI 10.1002/cm.20499
   Meyers VE, 2005, J BONE MINER RES, V20, P1858, DOI 10.1359/JBMR.050611
   Nabavi N, 2011, BONE, V49, P965, DOI 10.1016/j.bone.2011.07.036
   Nguyen AM, 2015, BIOL OPEN, V4, P1733, DOI 10.1242/bio.014787
   Noda K, 2016, P NATL ACAD SCI USA, V113, pE2589, DOI 10.1073/pnas.1519458113
   Ontiveros C, 2003, J CELL BIOCHEM, V88, P427, DOI 10.1002/jcb.10410
   Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232 002 1042 4
   Prasad RM, 2014, BIOSENSORS BASEL, V4, P47, DOI 10.3390/bios4010047
   RIJKEN PJ, 1992, ADV SPACE RES SERIES, V12, P145, DOI 10.1016/0273 1177(92)90277 5
   Rittweger J, 2005, BONE, V36, P1019, DOI 10.1016/j.bone.2004.11.014
   Satir P, 2010, J CELL SCI, V123, P499, DOI 10.1242/jcs.050377
   Sciola L, 1999, ADV SPACE RES, V24, P801, DOI 10.1016/S0273 1177(99)00078 2
   Sharma N, 2011, MOL BIOL CELL, V22, P806, DOI 10.1091/mbc.E10 03 0269
   Shen TD, 2019, J BIOMED NANOTECHNOL, V15, P196, DOI 10.1166/jbn.2019.2664
   Shi WG, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 02049 9
   Sibonga J, 2019, BONE, V128, DOI 10.1016/j.bone.2019.07.013
   Temiyasathit S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033368
   Vassy J., 2001, FASEB Journal, V15, P1104
   Villalobos E, 2019, CIRCULATION, V139, P2342, DOI 10.1161/CIRCULATIONAHA.117.028752
   Vorselen D, 2014, FASEB J, V28, P536, DOI 10.1096/fj.13 236356
   White RJ, 2001, NATURE, V409, P1115, DOI 10.1038/35059243
   Wuest SL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/971474
   Xie YF, 2016, BONE, V93, P22, DOI 10.1016/j.bone.2016.09.008
   Yang F, 2008, CHINESE SCI BULL, V53, P1185, DOI 10.1007/s11434 008 0167 y
   Zayzafoon M, 2004, ENDOCRINOLOGY, V145, P2421, DOI 10.1210/en.2003 1156
   Zhang J, 2018, BIOMED ENVIRON SCI, V31, P1, DOI 10.3967/bes2018.001
   Ziambaras Konstantinos, 2005, Hormones (Athens), V4, P18
NR 46
TC 20
Z9 28
U1 2
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JUL
PY 2020
VL 136
AR 115346
DI 10.1016/j.bone.2020.115346
PG 13
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA LQ6SP
UT WOS:000535131500008
PM 32240849
DA 2025 08 17
ER

PT J
AU Busto, F
   Sepúlveda, H
   Prieto, CP
   Carrasco, M
   Díaz, L
   Palma, J
   Lattus, J
   Montecino, M
   Palma, V
AF Busto, Francisco
   Sepulveda, Hugo
   Prieto, Catalina P.
   Carrasco, Margarita
   Diaz, Lorena
   Palma, Jose
   Lattus, Jose
   Montecino, Martin
   Palma, Veronica
TI Runt Related Transcription Factor 2 Induction During Differentiation of
   Wharton's Jelly Mesenchymal Stem Cells to Osteoblasts Is Regulated by
   Jumonji AT Rich Interactive Domain 1B Histone Demethylase
SO STEM CELLS
LA English
DT Article
DE Epigenetics; Mesenchymal stem cells (MSCs); Umbilical cord; Osteoblasts
ID BONE MORPHOGENETIC PROTEIN 2; FREE CULTURE CONDITIONS; HUMAN
   UMBILICAL CORD; OSTEOGENIC DIFFERENTIATION; STROMAL CELLS;
   GENE EXPRESSION; IN VITRO; OSTEOCALCIN GENE; SELF RENEWAL; JARID1B
AB Novel bone regeneration approaches aim to obtain immature osteoblasts from somatic stem cells. Umbilical cord Wharton's jelly mesenchymal stem cells (WJ MSCs) are an ideal source for cell therapy. Hence, the study of mechanisms involved in WJ MSC osteoblastic differentiation is crucial to exploit their developmental capacity. Here, we have assessed epigenetic control of the Runt related transcription factor 2 (RUNX2) osteogenic master regulator gene in WJ MSC. We present evidence indicating that modulation of RUNX2 expression through preventing Jumonji AT rich interactive domain 1B (JARID1B) histone demethylase activity is relevant to enhance WJ MSC osteoblastic potential. Hence, JARID1B loss of function in WJ MSC results in increased RUNX2/p57 expression. Our data highlight JARID1B activity as a novel target to modulate WJ MSC osteoblastic differentiation with potential applications in bone tissue engineering. Stem Cells2017;35:2430 2441
C1 [Busto, Francisco; Prieto, Catalina P.; Diaz, Lorena; Palma, Jose; Palma, Veronica] Univ Chile, Fac Sci, Lab Stem Cells & Dev, Santiago 3425, Chile.
   [Busto, Francisco; Sepulveda, Hugo; Prieto, Catalina P.; Carrasco, Margarita; Montecino, Martin; Palma, Veronica] FONDAP Ctr Genome Regulat, Santiago, Chile.
   [Busto, Francisco] Univ Dundee, Sch Life Sci, Sir James Black Ctr, Dundee, Scotland.
   [Sepulveda, Hugo; Carrasco, Margarita; Montecino, Martin] Univ Andres Bello, Ctr Biomed Res, Fac Biol Sci, Santiago, Chile.
   [Sepulveda, Hugo; Carrasco, Margarita; Montecino, Martin] Univ Andres Bello, Fac Med, Santiago, Chile.
   [Lattus, Jose] Univ Chile, Dept Obstet & Gynecol, Dr Luis Tisne Brousse Hosp, Campus Oriente, Santiago, Chile.
C3 Universidad de Chile; University of Dundee; Universidad Andres Bello;
   Universidad Andres Bello; Universidad de Chile
RP Palma, V (通讯作者)，Univ Chile, Fac Sci, Lab Stem Cells & Dev, Santiago 3425, Chile.; Montecino, M (通讯作者)，Univ Andres Bello, Gene Regulat Lab, Ctr Invest Biomed, Ave Republ 239, Santiago, Chile.
EM mmontecino@unab.cl; vpalma@uchile.cl
RI Prieto, Catalina/MSZ 1936 2025
OI Palma, Veronica/0000 0002 4320 7525; BUSTOS,
   FRANCISCO/0000 0001 5457 4956; Palma Liberona, Jose
   Antonio/0000 0002 5049 7276; Montecino, Martin/0000 0002 6025 0023
FU FONDAP CRG (Center for Genome Regulation) [15090007]; FONDECYT
   [1130706]; FONDECYT(P) [3140368]; FONDEF [D09E1047]; CONICYT
FX We thank Dr. Maria Rosa Bono for flow citometry expertise and MD fellows
   and personnel of Hospital Luis Tisne Brousse for umbilical cord
   collection, especially Drs. S. Aedo, A. Sepulveda, C. Berrios, F.
   Galvez, and M. Acevedo. This work was supported by FONDAP CRG (Center
   for Genome Regulation) (15090007, to M. M. and V.P.), FONDECYT (1130706,
   to M. M.), FONDECYT(P) (3140368, to C. P.), and FONDEF (D09E1047, to
   V.P.), and CONICYT doctoral fellowship (to H.S.). F.B. is currently
   affiliated with the Medical Research Council, Protein Phosphorylation
   and Ubiquitylation Unit, University of Dundee, Dundee, U.K.
CR Amini Ami R., 2012, Critical Reviews in Biomedical Engineering, V40, P363
   Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006 0709
   Banerjee C, 2001, ENDOCRINOLOGY, V142, P4026, DOI 10.1210/en.142.9.4026
   Brydone AS, 2010, P I MECH ENG H, V224, P1329, DOI 10.1243/09544119JEIM770
   Canha Gouveia A, 2015, BIOFABRICATION, V7, DOI 10.1088/1758 5090/7/3/035009
   Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200
   Carbonare LD, 2012, STEM CELL REV REP, V8, P891, DOI 10.1007/s12015 011 9337 4
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Cellot S, 2013, BLOOD, V122, P1545, DOI 10.1182/blood 2013 04 496281
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Corotchi MC, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt232
   Dey BK, 2008, MOL CELL BIOL, V28, P5312, DOI 10.1128/MCB.00128 08
   DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475
   Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905
   Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463 8471.1998
   Edwards SS, 2014, ANGIOGENESIS, V17, P851, DOI 10.1007/s10456 014 9432 7
   Fong CY, 2011, STEM CELL REV REP, V7, P1, DOI 10.1007/s12015 010 9166 x
   Frausin S, 2015, ACTA HISTOCHEM, V117, P329, DOI 10.1016/j.acthis.2015.02.005
   Gauthaman K, 2011, TISSUE ENG PT A, V17, P71, DOI [10.1089/ten.tea.2010.0224, 10.1089/ten.TEA.2010.0224]
   Geraerts M, 2006, BMC BIOTECHNOL, V6, DOI 10.1186/1472 6750 6 34
   Grandy R, 2011, MOL CELL BIOL, V31, P2997, DOI 10.1128/MCB.05096 11
   Hassan MQ, 2004, MOL CELL BIOL, V24, P9248, DOI 10.1128/MCB.24.20.9248 9261.2004
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang B, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0018 0
   Hubble Matthew J W, 2002, Surg Technol Int, V10, P261
   Hung BP, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt158
   Ji XN, 2015, BMC CANCER, V15, DOI 10.1186/s12885 015 1798 4
   Joerger Messerli MS, 2016, BEST PRACT RES CL OB, V31, P30, DOI 10.1016/j.bpobgyn.2015.07.006
   Kalaszczynska I, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/430847
   Karsenty G, 2008, ANNU REV GENOM HUM G, V9, P183, DOI 10.1146/annurev.genom.9.081307.164437
   Kidder BL, 2013, MOL CELL BIOL, V33, P4793, DOI 10.1128/MCB.00692 13
   Kim DW, 2013, INT J MOL SCI, V14, P11692, DOI 10.3390/ijms140611692
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   La Rocca G, 2013, CURR STEM CELL RES T, V8, P100, DOI 10.2174/1574888X11308010012
   Langenbach F, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt328
   Lee JS, 2011, BIOMATERIALS, V32, P760, DOI 10.1016/j.biomaterials.2010.09.042
   Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200
   Lee SJ, 2010, BIOMATERIALS, V31, P5652, DOI 10.1016/j.biomaterials.2010.03.019
   Lian J. B., 2003, Current Pharmaceutical Design, V9, P2677, DOI 10.2174/1381612033453659
   Liu TM, 2013, TISSUE ENG PART B RE, V19, P254, DOI [10.1089/ten.TEB.2012.0527, 10.1089/ten.teb.2012.0527]
   Liu WG, 2001, J CELL BIOL, V155, P157, DOI 10.1083/jcb.200105052
   Marolt D, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt10
   Marupanthorn K, 2017, INT J MOL MED, V39, P654, DOI 10.3892/ijmm.2017.2872
   Maruyama Z, 2007, DEV DYNAM, V236, P1876, DOI 10.1002/dvdy.21187
   Mosna F, 2010, STEM CELLS DEV, V19, P1449, DOI 10.1089/scd.2010.0140
   Nekanti U, 2010, INT J BIOL SCI, V6, P499
   Pittenger MF, 2011, SCIENCE, V143, P143
   Prieto CP, 2017, STEM CELL RES THER, V8, DOI 10.1186/s13287 017 0494 5
   Reppel L, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0263 2
   Rojas A, 2015, J BIOL CHEM, V290, P28329, DOI 10.1074/jbc.M115.657825
   Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681
   Sarugaser R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006498
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Sepulveda H, 2017, J CELL PHYSIOL, V232, P2519, DOI 10.1002/jcp.25627
   Shibuya N, 2015, CLIN PODIATR MED SUR, V32, P21, DOI 10.1016/j.cpm.2014.09.011
   Si JW, 2015, WORLD J STEM CELLS, V7, P149, DOI 10.4252/wjsc.v7.i1.149
   Soutoglou E, 2002, SCIENCE, V295, P1901, DOI 10.1126/science.1068356
   STANFORD CM, 1995, J BIOL CHEM, V270, P9420, DOI 10.1074/jbc.270.16.9420
   Stein GS, 2004, ONCOGENE, V23, P4315, DOI 10.1038/sj.onc.1207676
   Tumber A, 2017, CELL CHEM BIOL, V24, P371, DOI 10.1016/j.chembiol.2017.02.006
   Van Damme A, 2006, STEM CELLS, V24, P896, DOI 10.1634/stemcells.2003 0106
   Venugopal P, 2011, STEM CELLS CLONING, V4, P39, DOI 10.2147/SCCAA.S17548
   Wang CD, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.238
   Wang HS, 2004, STEM CELLS, V22, P1330, DOI 10.1634/stemcells.2004 0013
   Wang LM, 2010, TISSUE ENG PT A, V16, P1937, DOI [10.1089/ten.tea.2009.0706, 10.1089/ten.TEA.2009.0706]
   Xie LQ, 2011, EMBO J, V30, P1473, DOI 10.1038/emboj.2011.91
   Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009
NR 68
TC 22
Z9 23
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1066 5099
EI 1549 4918
J9 STEM CELLS
JI Stem Cells
PD DEC
PY 2017
VL 35
IS 12
BP 2430
EP 2441
DI 10.1002/stem.2704
PG 12
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA FO9YQ
UT WOS:000417255100010
PM 28895234
OA Bronze, Green Accepted
DA 2025 08 17
ER

PT J
AU Renò, F
   Migliario, M
   Rizzi, M
   Invernizzi, M
   Cisari, C
   Cannas, M
AF Reno, Filippo
   Migliario, Mario
   Rizzi, Manuela
   Invernizzi, Marco
   Cisari, Carlo
   Cannas, Mario
TI Low concentration amino bisphosphonates stimulate human keratinocyte
   proliferation and in vitro wound healing
SO INTERNATIONAL WOUND JOURNAL
LA English
DT Article
DE amino bisphosphonates; human keratinocytes; wound healing
ID CELL; MECHANISMS; MIGRATION; SUPPRESSION; ADHESION; MODEL
AB Amino bisphosphonates (N BPs) are widely used to treat a great variety of clinical conditions involving altered calcium metabolism, as well as to prevent bone metastases. The use of N BPs, however, display well known side effects, including cellular toxicity, mainly at soft tissue and mucosal level, that arise from N BPs ability to induce cell apoptosis when administered at clinically relevant concentrations. The aim of this study was to evaluate, in an in vitro wound healing model, the effect of N BPs low concentration (10 nM10 mu M) stimulation on keratinocyte cellular behaviour. Human keratinocytes were treated with neridronate and zoledronate, two N BPs with different chemical structure and clinical potency, but sharing a common pharmacological target: farnesyl pyrophosphate (FPP) synthase. Surprisingly, at the tested concentrations, both drugs stimulated keratinocytes proliferation, upregulating cytokeratin 5 while downregulating filaggrin expression, and wound healing ability, without any significant effect on matrix metalloproteinase (MMP) 9 activity. The lack of N BPs effect on MMP 9 activity indicates that wound closure, in our experimental model, is mainly due to an increase in cell proliferation rather than to an increase in cell migration. Therefore, it can be hypothesised that the observed wound healing results could be ascribed to an N BPs mediated reduction of FPP endogenous levels, thus suggesting new possible clinical applications for these compounds.
C1 [Reno, Filippo; Rizzi, Manuela; Cannas, Mario] Univ Piemonte Orientale, Expt & Clin Med Dept, Human Anat Lab, I 28100 Novara, Italy.
   [Migliario, Mario] Univ Piemonte Orientale, Dent Clin, Expt & Clin Med Dept, I 28100 Novara, Italy.
   [Invernizzi, Marco; Cisari, Carlo] Azienda Osped Univ Maggiore della Carita, I 28100 Novara, Italy.
C3 University of Eastern Piedmont Amedeo Avogadro; University of Eastern
   Piedmont Amedeo Avogadro; University of Eastern Piedmont Amedeo Avogadro
RP Renò, F (通讯作者)，Univ Piemonte Orientale, Expt & Clin Med Dept, Human Anat Lab, Via Solaroli 17, I 28100 Novara, Italy.
EM filippo.reno@med.unipmn.it
RI Migliario, Mario/AAB 3945 2019; Renò, Filippo/AAA 5591 2019; Rizzi,
   Manuela/AAE 9202 2021; Invernizzi, Marco/I 9635 2019
OI RIZZI, Manuela/0000 0002 6174 7111; Invernizzi,
   Marco/0000 0001 5141 0681; Migliario, Mario/0000 0003 1627 4164
CR Bensadoun RJ, 2008, B CANCER, V95, P413, DOI [10.1068/bdc.2008.0617, 10.1684/bdc.2008.0617]
   Bezzi M, 2003, J BIOL CHEM, V278, P43603, DOI 10.1074/jbc.M308114200
   Blank MA, 1997, DIGEST DIS SCI, V42, P281, DOI 10.1023/A:1018849415297
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   Coleman R, 2011, ANN NY ACAD SCI, V1218, P3, DOI 10.1111/j.1749 6632.2010.05766.x
   Drake MT, 2008, MAYO CLIN PROC, V83, P1032, DOI 10.4065/83.9.1032
   Fleisch H, 1998, ENDOCR REV, V19, P80, DOI 10.1210/er.19.1.80
   Fleisch H, 2002, BREAST CANCER RES, V4, P30, DOI 10.1186/bcr414
   Green JR, 2011, CRIT REV ONCOL HEMAT, V77, pS3, DOI 10.1016/S1040 8428(11)70003 8
   Guise TA, 2008, CANCER TREAT REV, V34, pS19, DOI 10.1016/j.ctrv.2008.03.006
   Hasmim M, 2007, J THROMB HAEMOST, V5, P166, DOI 10.1111/j.1538 7836.2006.02259.x
   Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Lichtenberger LM, 2000, DIGEST DIS SCI, V45, P1792, DOI 10.1023/A:1005574009856
   Magremanne M, 2008, Rev Med Brux, V29, P262
   Pabst AP, CLIN ORAL I IN PRESS
   Presland RB, 2000, CRIT REV ORAL BIOL M, V11, P383, DOI 10.1177/10454411000110040101
   Reszka AA, 2001, MOL PHARMACOL, V59, P193, DOI 10.1124/mol.59.2.193
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Rogers MJ, 1997, CANCER, V80, P1652, DOI 10.1002/(SICI)1097 0142(19971015)80:8+<1652::AID CNCR15>3.0.CO;2 Z
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Vukelic S, 2010, J BIOL CHEM, V285, P1980, DOI 10.1074/jbc.M109.016741
   Wallace JL, 1999, ALIMENT PHARM THER, V13, P1675
   Walter C, 2011, ORAL DIS, V17, P194, DOI 10.1111/j.1601 0825.2010.01720.x
NR 25
TC 4
Z9 4
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 1742 4801
EI 1742 481X
J9 INT WOUND J
JI Int. Wound J.
PD AUG
PY 2012
VL 9
IS 4
BP 442
EP 450
DI 10.1111/j.1742 481X.2011.00905.x
PG 9
WC Dermatology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dermatology; Surgery
GA 974BY
UT WOS:000306406000014
PM 22182245
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Ish Shalom, S
   Caraco, Y
   Khazen, NS
   Gershinsky, M
   Szalat, A
   Schwartz, P
   Arbit, E
   Galitzer, H
   Tang, JCY
   Burshtein, G
   Rothner, A
   Raskin, A
   Blum, M
   Fraser, WD
AF Ish Shalom, Sofia
   Caraco, Yoseph
   Khazen, Nariman Saba
   Gershinsky, Michal
   Szalat, Auryan
   Schwartz, Phillip
   Arbit, Ehud
   Galitzer, Hillel
   Tang, Jonathan C. Y.
   Burshtein, Gregory
   Rothner, Ariel
   Raskin, Arthur
   Blum, Miriam
   Fraser, William D.
TI Safety and Efficacy of Oral Human Parathyroid Hormone (1 34) in
   Hypoparathyroidism: An Open Label Study
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE HYPOPARATHYROIDISM; ORAL PARATHYROID HORMONE; PARATHYROID&#8208; RELATED
   DISORDERS; CALCIUM; PHOSPHATE DISORDERS; PARATHYROID HORMONE
ID LONG TERM TREATMENT; QUALITY OF LIFE; REPLACEMENT THERAPY; PTH(1 84);
   CALCITRIOL; CHILDREN; TRIAL; PARATHYROID HORMONE 1 34; EPIDEMIOLOGY;
   CHALLENGES
AB The standard treatment of primary hypoparathyroidism (hypoPT) with oral calcium supplementation and calcitriol (or an analog), intended to control hypocalcemia and hyperphosphatemia and avoid hypercalciuria, remains challenging for both patients and clinicians. In 2015, human parathyroid hormone (hPTH) (1 84) administered as a daily subcutaneous injection was approved as an adjunctive treatment in patients who cannot be well controlled on the standard treatments alone. This open label study aimed to assess the safety and efficacy of an oral hPTH(1 34) formulation as an adjunct to standard treatment in adult subjects with hypoparathyroidism. Oral hPTH(1 34) tablets (0.75 mg human hPTH(1 34) acetate) were administered four times daily for 16 consecutive weeks, and changes in calcium supplementation and alfacalcidol use, albumin adjusted serum calcium (ACa), serum phosphate, urinary calcium excretion, and quality of life throughout the study were monitored. Of the 19 enrolled subjects, 15 completed the trial per protocol. A median 42% reduction from baseline in exogenous calcium dose was recorded (p = .001), whereas median serum ACa levels remained above the lower target ACa levels for hypoPT patients (>7.5 mg/dL) throughout the study. Median serum phosphate levels rapidly decreased (23%, p = .0003) 2 hours after the first dose and were maintained within the normal range for the duration of the study. A notable, but not statistically significant, median decrease (21%, p = .07) in 24 hour urine calcium excretion was observed between the first and last treatment days. Only four possible drug related, non serious adverse events were reported over the 16 week study, all by the same patient. A small but statistically significant increase from baseline quality of life (5%, p = .03) was reported by the end of the treatment period. Oral hPTH(1 34) treatment was generally safe and well tolerated and allowed for a reduction in exogenous calcium supplementation, while maintaining normocalcemia in adult patients with hypoparathyroidism. (c) 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).
C1 [Ish Shalom, Sofia; Khazen, Nariman Saba; Gershinsky, Michal] Lin Med Ctr, Clalit Hlth Serv, Endocrine Res Ctr, IL 3498206 Haifa, Israel.
   [Caraco, Yoseph; Szalat, Auryan] Hebrew Univ Jerusalem, Hadassah Med Ctr, Sch Med, Jerusalem, Israel.
   [Schwartz, Phillip; Arbit, Ehud; Galitzer, Hillel; Burshtein, Gregory; Rothner, Ariel; Raskin, Arthur; Blum, Miriam] Entera Bio Ltd, Jerusalem Bio Pk, Jerusalem, Israel.
   [Tang, Jonathan C. Y.; Fraser, William D.] Univ East Anglia, Fac Med & Hlth Sci, Bioanalyt Facil, Biomed Res Ctr,Norwich Med Sch, Norwich, Norfolk, England.
   [Fraser, William D.] Norfolk & Norwich Univ Hosp, Dept Endocrinol, Norwich, Norfolk, England.
   [Fraser, William D.] Norfolk & Norwich Univ Hosp, Dept Clin Biochem, Norwich, Norfolk, England.
C3 Clalit Health Services; Hebrew University of Jerusalem; Hadassah
   University Hospital; Hadassah University Medical Center; University of
   East Anglia; Norfolk & Norwich University Hospitals NHS Foundation
   Trust; Norfolk & Norwich University Hospital; Norfolk & Norwich
   University Hospitals NHS Foundation Trust; Norfolk & Norwich University
   Hospital
RP Ish Shalom, S (通讯作者)，Lin Med Ctr, Clalit Hlth Serv, Endocrine Res Ctr, IL 3498206 Haifa, Israel.
EM sishshalom@gmail.com
RI szalat, auryan/JNR 7010 2023; Caraco, Yoseph/CAI 4768 2022; Tang,
   Jonathan/G 3090 2011
OI Rothner, Ariel/0000 0003 0247 742X; Saba Khazen,
   Nariman/0009 0006 0231 8321; Tang, Jonathan/0000 0001 6305 6333
FU Entera Bio Ltd
FX This work was supported by Entera Bio Ltd, which provided both financial
   support and supplied the study drug. We are grateful to the patients who
   participated in this study and made it possible. The authors acknowledge
   the dedicated staff at the study centers, Linn Medical Center, Haifa,
   Israel, and Hadassah Clinical Research Center, Jerusalem, Israel, as
   well as Lital Friedman and Arthur Santora, MD, for their critical review
   and assistance with the manuscript.
CR Bergwitz C, 2010, ANNU REV MED, V61, P91, DOI 10.1146/annurev.med.051308.111339
   Bilezikian JP, 2016, J CLIN ENDOCR METAB, V101, P2313, DOI 10.1210/jc.2015 3910
   Bilezikian JP, 2011, J BONE MINER RES, V26, P2317, DOI 10.1002/jbmr.483
   Brandi ML, 2016, J CLIN ENDOCR METAB, V101, P2273, DOI 10.1210/jc.2015 3907
   Büttner M, 2017, ENDOCRINE, V58, P14, DOI 10.1007/s12020 017 1377 3
   Chen K., 2019, ENDOCR ABSTRACTS, V63, pGP25
   Clarke BL, 2016, J CLIN ENDOCR METAB, V101, P2284, DOI 10.1210/jc.2015 3908
   Clarke BL, 2014, CLIN THER, V36, P722, DOI 10.1016/j.clinthera.2014.04.001
   Cusano NE, 2014, J CLIN ENDOCR METAB, V99, P3694, DOI 10.1210/jc.2014 2267
   Cusano NE, 2013, J CLIN ENDOCR METAB, V98, P137, DOI 10.1210/jc.2012 2984
   Gafni RI, 2012, J BONE MINER RES, V27, P1811, DOI 10.1002/jbmr.1627
   JUSKO WJ, 1994, CLIN PHARMACOL THER, V56, P406, DOI 10.1038/clpt.1994.155
   Lewis JR, 2012, J BONE MINER RES, V27, P719, DOI 10.1002/jbmr.1484
   Mannstadt M, 2013, LANCET DIABETES ENDO, V1, P275, DOI 10.1016/S2213 8587(13)70106 2
   Mitragotri S, 2014, NAT REV DRUG DISCOV, V13, P655, DOI 10.1038/nrd4363
   Parker, 2005, GOODMAN GILMANS PHAR
   Powers J, 2013, J BONE MINER RES, V28, P2570, DOI 10.1002/jbmr.2004
   Rothner, 2017, 2017 ASBMR ANN M SEP
   Rubin MR, 2010, OSTEOPOROSIS INT, V21, P1927, DOI 10.1007/s00198 009 1149 x
   Rubin MR, 2016, J CLIN ENDOCR METAB, V101, P2742, DOI 10.1210/jc.2015 4135
   Rubin MR, 2008, J BONE MINER RES, V23, P2018, DOI 10.1359/JBMR.080803
   Santonati A, 2015, J CLIN ENDOCR METAB, V100, P3590, DOI 10.1210/jc.2015 1855
   Satterwhite J, 2010, CALCIFIED TISSUE INT, V87, P485, DOI 10.1007/s00223 010 9424 6
   Shoback DM, 2016, J CLIN ENDOCR METAB, V101, P2300, DOI 10.1210/jc.2015 3909
   Sikjaer T, 2011, J BONE MINER RES, V26, P2358, DOI 10.1002/jbmr.470
   Washbourne, 2014, 2014 ASBMR ANN M SEP
   Winer KK, 2008, J CLIN ENDOCR METAB, V93, P3389, DOI 10.1210/jc.2007 2552
   Winer KK, 2014, J PEDIATR US, V165, P556, DOI 10.1016/j.jpeds.2014.04.060
   Winer KK, 2012, J CLIN ENDOCR METAB, V97, P391, DOI 10.1210/jc.2011 1908
   Winer KK, 2010, J CLIN ENDOCR METAB, V95, P2680, DOI 10.1210/jc.2009 2464
   Winer KK, 2003, J CLIN ENDOCR METAB, V88, P4214, DOI 10.1210/jc.2002 021736
   Winer KK, 1998, J CLIN ENDOCR METAB, V83, P3480, DOI 10.1210/jc.83.10.3480
   Winer KK, 1996, JAMA J AM MED ASSOC, V276, P631, DOI 10.1001/jama.276.8.631
NR 33
TC 11
Z9 12
U1 5
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2021
VL 36
IS 6
BP 1060
EP 1068
DI 10.1002/jbmr.4274
EA MAR 2021
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA SS7DH
UT WOS:000625466800001
PM 33666947
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Cheung, LC
   Tickner, J
   Hughes, AM
   Skut, P
   Howlett, M
   Foley, B
   Oommen, J
   Wells, JE
   He, B
   Singh, S
   Chua, GA
   Ford, J
   Mullighan, CG
   Kotecha, RS
   Kees, UR
AF Cheung, Laurence C.
   Tickner, Jennifer
   Hughes, Anastasia M.
   Skut, Patrycja
   Howlett, Meegan
   Foley, Bree
   Oommen, Joyce
   Wells, Julia E.
   He, Bo
   Singh, Sajla
   Chua, Grace Alyssa
   Ford, Jette
   Mullighan, Charles G.
   Kotecha, Rishi S.
   Kees, Ursula R.
TI New therapeutic opportunities from dissecting the pre B leukemia bone
   marrow microenvironment
SO LEUKEMIA
LA English
DT Article
ID ACUTE LYMPHOBLASTIC LEUKEMIA; HEMATOPOIETIC STEM CELLS; STROMAL CELLS;
   TUMOR MICROENVIRONMENT; OSTEOBLASTIC CELLS; COLLAGEN SYNTHESIS;
   MYELOID LEUKEMIA; NICHE; CHILDREN; CANCER
AB The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations to the bone marrow microenvironment during leukemogenesis. Therefore, in this study, we focused on the development of precursor B cell ALL (pre B ALL) in an immunocompetent BCR ABL1(+) model. Here we show that hematopoiesis was perturbed, B lymphopoiesis was impaired, collagen production was reduced, and the number of osteoblastic cells was decreased in the bone marrow microenvironment. As previously found in children with ALL, the leukemia bearing mice exhibited severe bone loss during leukemogenesis. Leukemia cells produced high levels of receptor activator of nuclear factor kappa B ligand (RANKL), sufficient to cause osteoclast mediated bone resorption. In vivo administration of zoledronic acid rescued leukemia induced bone loss, reduced disease burden and prolonged survival in leukemia bearing mice. Taken together, we provide evidence that targeting leukemia induced bone loss is a therapeutic strategy for pre B ALL.
C1 [Cheung, Laurence C.; Hughes, Anastasia M.; Skut, Patrycja; Howlett, Meegan; Foley, Bree; Oommen, Joyce; Wells, Julia E.; Singh, Sajla; Chua, Grace Alyssa; Ford, Jette; Kotecha, Rishi S.; Kees, Ursula R.] Univ Western Australia, Telethon Kids Canc Ctr, Telethon Kids Inst, Perth, WA, Australia.
   [Cheung, Laurence C.] Curtin Univ, Sch Pharm & Biomed Sci, Perth, WA, Australia.
   [Tickner, Jennifer] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA, Australia.
   [He, Bo] Univ Western Australia, Ctr Med Res, Harry Perkins Inst Med Res, Perth, WA, Australia.
   [Mullighan, Charles G.] St Jude Childrens Res Hosp, Dept Pathol, 332 N Lauderdale St, Memphis, TN 38105 USA.
   [Kotecha, Rishi S.] Princess Margaret Hosp Children, Dept Haematol & Oncol, Perth, WA, Australia.
   [Kotecha, Rishi S.] Univ Western Australia, Sch Med, Perth, WA, Australia.
C3 The Kids Research Institute Australia; University of Western Australia;
   Curtin University; University of Western Australia; University of
   Western Australia; Harry Perkins Institute of Medical Research; St Jude
   Children's Research Hospital; Princess Margaret Hospital for Children;
   University of Western Australia; University of Western Australia
RP Cheung, LC (通讯作者)，Univ Western Australia, Telethon Kids Canc Ctr, Telethon Kids Inst, Perth, WA, Australia.; Cheung, LC (通讯作者)，Curtin Univ, Sch Pharm & Biomed Sci, Perth, WA, Australia.
EM Laurence.cheung@telethonkids.org.au
RI ; Tickner, Jennifer/H 5965 2014; Cheung, Laurence C/R 9932 2017;
   Howlett, Michael/W 7544 2019; Kotecha, Rishi/JAO 0855 2023; Cheung,
   Laurence/R 9932 2017; Mullighan, Charles/H 3253 2011
OI Foley, Bree/0000 0003 3826 2682; Tickner, Jennifer/0000 0002 5020 0671;
   Cheung, Laurence C/0000 0001 6298 5288; Kotecha,
   Rishi/0000 0003 1836 4075; Howlett, Meegan/0000 0003 4332 6572
FU Children's Leukaemia and Cancer Research Foundation, Western Australia;
   Cancer Council Western Australia, Western Australia; National Health and
   Medical Research Council of Australia (NHMRC) [APP1142627]; Kids' Cancer
   Project, New South Wales, Australia
FX This work was supported by the Children's Leukaemia and Cancer Research
   Foundation, Western Australia, and Cancer Council Western Australia,
   Western Australia. Rishi S. Kotecha is supported by a Fellowship from
   the National Health and Medical Research Council of Australia (NHMRC
   APP1142627). Sajla Singh is supported by The Kids' Cancer Project, New
   South Wales, Australia.
CR Arranz L, 2014, NATURE, V512, P78, DOI 10.1038/nature13383
   Ayala F, 2009, LEUKEMIA, V23, P2233, DOI 10.1038/leu.2009.175
   Balderman SR, 2016, BLOOD, V127, P616, DOI 10.1182/blood 2015 06 653113
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040
   Cazzaniga G, 2018, HAEMATOLOGICA, V103, P107, DOI 10.3324/haematol.2017.176917
   Ceppi F, 2017, EUR J PEDIATR, V176, P1163, DOI 10.1007/s00431 017 2982 0
   Collin Osdoby P, 2012, METHODS MOL BIOL, V816, P187, DOI 10.1007/978 1 61779 415 5_13
   Cui P, 2018, LEUKEMIA RES, V65, P49, DOI 10.1016/j.leukres.2018.01.002
   Delogu A, 2006, IMMUNITY, V24, P269, DOI 10.1016/j.immuni.2006.01.012
   Doan PL, 2012, LEUKEMIA, V26, P54, DOI 10.1038/leu.2011.236
   Ebihara Y, 2006, EXP HEMATOL, V34, P219, DOI 10.1016/j.exphem.2005.10.008
   FERNANDEZ M, 1987, EXPERIENTIA, V43, P1223, DOI 10.1007/BF01945534
   Frisch BJ, 2012, BLOOD, V119, P540, DOI 10.1182/blood 2011 04 348151
   Giustacchini A, 2017, NAT MED, V23, P692, DOI 10.1038/nm.4336
   HALTON JM, 1995, J PEDIATR US, V126, P557, DOI 10.1016/S0022 3476(95)70349 7
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hawkins ED, 2016, NATURE, V538, P518, DOI 10.1038/nature19801
   Heltemes Harris LM, 2011, J EXP MED, V208, P1135, DOI 10.1084/jem.20101947
   Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972
   Jain MD, 2018, STEM CELLS, V36, P36, DOI 10.1002/stem.2715
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kotecha RS, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.17
   Krause DS, 2013, NAT MED, V19, P1513, DOI 10.1038/nm.3364
   Krevvata M, 2014, BLOOD, V124, P2834, DOI 10.1182/blood 2013 07 517219
   Lee DW, 2015, LANCET, V385, P517, DOI 10.1016/S0140 6736(14)61403 3
   Leeuw JA, 2003, PEDIATR RES, V54, P814, DOI 10.1203/01.PDR.0000090929.16450.DE
   Lim M, 2016, LEUKEMIA, V30, P154, DOI 10.1038/leu.2015.210
   Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909
   Mansour A, 2011, CELL RES, V21, P1102, DOI 10.1038/cr.2011.21
   Medyouf H, 2014, CELL STEM CELL, V14, P824, DOI 10.1016/j.stem.2014.02.014
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Morrison SJ, 2014, NATURE, V505, P327, DOI 10.1038/nature12984
   Mullighan CG, 2007, NATURE, V446, P758, DOI 10.1038/nature05690
   Nguyen TV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126233
   Padhye B, 2016, CANCER MED US, V5, P960, DOI 10.1002/cam4.645
   Passaro D, 2015, CANCER CELL, V27, P769, DOI 10.1016/j.ccell.2015.05.003
   Pitt LA, 2015, CANCER CELL, V27, P755, DOI 10.1016/j.ccell.2015.05.002
   Polak R, 2015, BLOOD, V126, P2404, DOI 10.1182/blood 2015 03 634238
   Rajakumar SA, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.908.908
   Reshmi SC, 2017, BLOOD, V129, P3352, DOI 10.1182/blood 2016 12 758979
   Rosen LS, 2003, J CLIN ONCOL, V21, P3150, DOI 10.1200/JCO.2003.04.105
   Schepers K, 2013, CELL STEM CELL, V13, P285, DOI 10.1016/j.stem.2013.06.009
   Schewe DM, 2017, BLOOD, V130, P1543, DOI 10.1182/blood 2017 01 764316
   Schrappe M, 2018, J CLIN ONCOL, V36, P244, DOI 10.1200/JCO.2017.74.4946
   Shafat MS, 2017, BLOOD, V129, P1320, DOI 10.1182/blood 2016 08 734798
   Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703
   Smith MA, 2010, J CLIN ONCOL, V28, P2625, DOI 10.1200/JCO.2009.27.0421
   Sorva R, 1997, BONE, V20, P139, DOI 10.1016/S8756 3282(96)00343 2
   Tasian SK, 2017, BLOOD, V130, P2064, DOI 10.1182/blood 2017 06 743252
   Tavor S, 2008, LEUKEMIA, V22, P2151, DOI 10.1038/leu.2008.238
   Tesfai Y, 2012, LEUKEMIA RES, V36, P299, DOI 10.1016/j.leukres.2011.08.001
   Tokoyoda K, 2004, IMMUNITY, V20, P707, DOI 10.1016/j.immuni.2004.05.001
   Vijayakrishnan J, 2017, LEUKEMIA, V31, P573, DOI 10.1038/leu.2016.271
   von Stackelberg A, 2016, J CLIN ONCOL, V34, P4381, DOI 10.1200/JCO.2016.67.3301
   Vora A, 2016, J CLIN ONCOL, V34, P919, DOI 10.1200/JCO.2015.64.2850
   Wang WH, 2016, CANCER RES, V76, P1641, DOI 10.1158/0008 5472.CAN 15 2092
   Wayne AS, 2017, BLOOD, V130, P1620, DOI [10.1182/blood 2017 02749101, 10.1182/blood 2017 02 749101]
   Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055
   Wells JE, 2015, INT J CANCER, V137, P504, DOI 10.1002/ijc.28972
   Williams RT, 2006, P NATL ACAD SCI USA, V103, P6688, DOI 10.1073/pnas.0602030103
   Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood 2009 07 233437
   Wu JY, 2008, P NATL ACAD SCI USA, V105, P16976, DOI 10.1073/pnas.0802898105
   Zhu J, 2007, BLOOD, V109, P3706, DOI 10.1182/blood 2006 08 041384
NR 65
TC 35
Z9 35
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD NOV
PY 2018
VL 32
IS 11
BP 2326
EP 2338
DI 10.1038/s41375 018 0144 7
PG 13
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA GZ6PI
UT WOS:000449561300003
PM 29740160
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Thorup, AS
   Strachan, D
   Caxaria, S
   Poulet, B
   Thomas, BL
   Eldridge, SE
   Nalesso, G
   Whiteford, JR
   Pitzalis, C
   Aigner, T
   Corder, R
   Bertrand, J
   Dell'Accio, F
AF Thorup, Anne Sophie
   Strachan, Danielle
   Caxaria, Sara
   Poulet, Blandine
   Thomas, Bethan L.
   Eldridge, Suzanne E.
   Nalesso, Giovanna
   Whiteford, James R.
   Pitzalis, Costantino
   Aigner, Thomas
   Corder, Roger
   Bertrand, Jessica
   Dell'Accio, Francesco
TI ROR2 blockade as a therapy for osteoarthritis
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HUMAN ARTICULAR CHONDROCYTES; PLANAR CELL POLARITY; GENE EXPRESSION;
   TYROSINE KINASE; IN VIVO; CARTILAGE DEGRADATION; PHENOTYPIC STABILITY;
   HIP OSTEOARTHRITIS; GROWTH; MOUSE
AB Osteoarthritis is characterized by the loss of the articular cartilage, bone remodeling, pain, and disability. No pharmacological intervention can currently halt progression of osteoarthritis. Here, we show that blocking receptor tyrosine kinase like orphan receptor 2 (ROR2) improves cartilage integrity and pain in osteoarthritis models by inhibiting yes associated protein (YAP) signaling. ROR2 was up regulated in the cartilage in response to inflammatory cytokines and mechanical stress. The main ligand for ROR2, WNT5A, and the targets YAP and connective tissue growth factor were up regulated in osteoarthritis in humans. In vitro, ROR2 overexpression inhibited chondrocytic differentiation. Conversely, ROR2 blockade triggered chondrogenic differentiation of C3H10T1/2 cells and suppressed the expression of the cartilage degrading enzymes a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) 4 and ADAMTS 5. The chondrogenic effect of ROR2 blockade in the cartilage was independent of WNT signaling and was mediated by down regulation of YAP signaling. ROR2 signaling induced G protein and Rho dependent nuclear accumulation of YAP, and YAP inhibition was required but not sufficient for ROR2 blockade induced chondrogenesis. ROR2 silencing protected mice from instability induced osteoarthritis with improved structural outcomes, sustained pain relief, and without apparent side effects or organ toxicity. Last, ROR2 silencing in human articular chondrocytes transplanted in nude mice led to the formation of cartilage organoids with more and better differentiated extracellular matrix, suggesting that the anabolic effect of ROR2 blockade is conserved in humans. Thus, ROR2 blockade is efficacious and well tolerated in preclinical animal models of osteoarthritis.
C1 [Thorup, Anne Sophie; Strachan, Danielle; Caxaria, Sara; Thomas, Bethan L.; Eldridge, Suzanne E.; Whiteford, James R.; Pitzalis, Costantino; Corder, Roger; Dell'Accio, Francesco] Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
   [Poulet, Blandine] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool L7 8TX, Merseyside, England.
   [Nalesso, Giovanna] Univ Surrey, Fac Hlth & Med Sci, Sch Vet Med, Dept Vet Preclin Sci, Guildford GU2 7AL, Surrey, England.
   [Aigner, Thomas] Med Ctr Coburg, Inst Pathol, Ketschendorferstr 33, D 96450 Coburg, Germany.
   [Bertrand, Jessica] Otto von Guericke Univ, Dept Orthopaed Surg, D 39120 Magdeburg, Germany.
C3 University of London; Queen Mary University London; University of
   Liverpool; University of Surrey; Klinikum Coburg; Otto von Guericke
   University
RP Thorup, AS; Dell'Accio, F (通讯作者)，Queen Mary Univ London, Barts & London Sch Med & Dent, William Harvey Res Inst, London EC1M 6BQ, England.
EM asthorup@gmail.com; fdellaccio@gmail.com
RI ; Bertrand, Jessica/MAH 6604 2025; Corder, Roger/H 2588 2012
OI Pitzalis, Costantino/0000 0003 1326 5051; Eldridge,
   Suzanne/0000 0002 1630 6261; Strachan, Danielle/0000 0002 9544 6341;
   Thorup, Anne Sophie/0000 0002 0435 4071; Caxaria,
   Sara/0000 0002 8434 8332; Nalesso, Giovanna/0000 0002 9424 3075;
   Whiteford, James/0000 0002 8967 7389
FU Medical College of St. Bartholomew's Hospital Trust; William Harvey
   Research Foundation; FOREUM foundation for research in rheumatology
   [1016807]; MRC [MR/L022893/1, MR/N010973/1, MR/P026362/1, MR/K013076/1];
   DFG Emmy Noether program [BE4328/5 1]; Versus Arthritis [21515, 20886,
   21621, 20859]; Barts Charity [MGU0313] Funding Source: researchfish;
   Medical Research Council [MR/L022893/1, 1095739, MR/N010973/1,
   MR/P020941/1, MR/K013076/1, MR/P026362/1] Funding Source: researchfish;
   Rosetrees [M380 F1] Funding Source: researchfish; Versus Arthritis
   [20886, 20859, 19654] Funding Source: researchfish; MRC [MR/K013076/1,
   MR/P026362/1, MR/P020941/1, MR/N010973/1, MR/L022893/1, MR/R000956/1]
   Funding Source: UKRI
FX We acknowledge funding support of this work by the Medical College of
   St. Bartholomew's Hospital Trust, the William Harvey Research
   Foundation, the FOREUM foundation for research in rheumatology
   (1016807), the MRC (MR/L022893/1, MR/N010973/1, MR/P026362/1, and
   MR/K013076/1), Versus Arthritis (21515, 20886, 21621, and 20859), and
   the DFG Emmy Noether program (BE4328/5 1).
CR Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107
   Al Shawi R, 2001, DEV GENES EVOL, V211, P161, DOI 10.1007/s004270100140
   Betancourt MCC, 2012, P NATL ACAD SCI USA, V109, P8218, DOI 10.1073/pnas.1119899109
   Buckwalter JA, 2004, CLIN ORTHOP RELAT R, pS6, DOI 10.1097/01.blo.0000143938.30681.9d
   Byun S, 2013, ARCH BIOCHEM BIOPHYS, V532, P15, DOI 10.1016/j.abb.2012.12.020
   Caramés B, 2012, ANN RHEUM DIS, V71, P575, DOI 10.1136/annrheumdis 2011 200557
   Chong KW, 2013, ARTHRITIS RHEUM US, V65, P2346, DOI 10.1002/art.38039
   Comblain F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156902
   Corder Roger, 2002, Methods Mol Biol, V206, P147
   Davidson ENB, 2006, ANN RHEUM DIS, V65, P1414, DOI 10.1136/ard.2005.045971
   Davidson ENB, 2015, ANN RHEUM DIS, V74, P1257, DOI 10.1136/annrheumdis 2013 204528
   De Bari C, 2001, ARTHRITIS RHEUM, V44, P85, DOI 10.1002/1529 0131(200101)44:1<85::AID ANR12>3.0.CO;2 6
   De Bari C, 2001, ARTHRITIS RHEUM US, V44, P1928, DOI 10.1002/1529 0131(200108)44:8<1928::AID ART331>3.0.CO;2 P
   DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488
   Dell'Accio F, 2003, EXP CELL RES, V287, P16, DOI 10.1016/S0014 4827(03)00036 3
   Dell'Accio F, 2001, ARTHRITIS RHEUM US, V44, P1608, DOI 10.1002/1529 0131(200107)44:7<1608::AID ART284>3.0.CO;2 T
   Denker AE, 1999, DIFFERENTIATION, V64, P67, DOI 10.1046/j.1432 0436.1999.6420067.x
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   DiDomenico CD, 2017, J BIOMECH ENG T ASME, V139, DOI 10.1115/1.4035265
   Distler A, 2014, ANN RHEUM DIS, V73, P624, DOI 10.1136/annrheumdis 2013 203995
   Eldridge S, 2016, ANN RHEUM DIS, V75, P1228, DOI 10.1136/annrheumdis 2015 207316
   Enomoto Iwamoto M, 2002, DEV BIOL, V251, P142, DOI 10.1006/dbio.2002.0802
   Fitzgerald K, 2017, NEW ENGL J MED, V376, P41, DOI 10.1056/NEJMoa1609243
   Gao B, 2011, DEV CELL, V20, P163, DOI 10.1016/j.devcel.2011.01.001
   Glasson SS, 2007, OSTEOARTHR CARTILAGE, V15, P1061, DOI 10.1016/j.joca.2007.03.006
   Glasson SS, 2010, OSTEOARTHR CARTILAGE, V18, pS17, DOI 10.1016/j.joca.2010.05.025
   Glasson SS, 2005, NATURE, V434, P644, DOI 10.1038/nature03369
   GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595
   GRUBBS FE, 1950, ANN MATH STAT, V21, P27, DOI 10.1214/aoms/1177729885
   GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761
   Gruber J, 2004, ARTHRITIS RHEUM US, V50, P2539, DOI 10.1002/art.20369
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Hamada D, 2014, METHODS MOL BIOL, V1130, P61, DOI 10.1007/978 1 62703 989 5_5
   Hartmann C, 2000, DEVELOPMENT, V127, P3141
   He FL, 2008, DEVELOPMENT, V135, P3871, DOI 10.1242/dev.025767
   Hiligsmann M, 2013, SEMIN ARTHRITIS RHEU, V43, P303, DOI 10.1016/j.semarthrit.2013.07.003
   Hoyles RK, 2008, ARTHRITIS RHEUM US, V58, P1175, DOI 10.1002/art.23379
   Hubertsson J, 2013, ANN RHEUM DIS, V72, P401, DOI 10.1136/annrheumdis 2012 201472
   Ijiri K, 2008, ARTHRITIS RHEUM US, V58, P2075, DOI 10.1002/art.23504
   Johnson K, 2012, SCIENCE, V336, P717, DOI 10.1126/science.1215157
   Kamekura S, 2005, OSTEOARTHR CARTILAGE, V13, P632, DOI 10.1016/j.joca.2005.03.004
   Kerkhof JM, 2008, OSTEOARTHR CARTILAGE, V16, P1141, DOI 10.1016/j.joca.2008.02.007
   Kotlarz H, 2009, ARTHRITIS RHEUM US, V60, P3546, DOI 10.1002/art.24984
   Loeser RF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054633
   Lories RJU, 2009, OSTEOARTHR CARTILAGE, V17, P390, DOI 10.1016/j.joca.2008.07.018
   Lories RJU, 2007, ARTHRITIS RHEUM US, V56, P4095, DOI 10.1002/art.23137
   Lories RJ, 2006, RHEUMATOLOGY, V45, P113, DOI 10.1093/rheumatology/kei148
   Loughlin J, 2004, P NATL ACAD SCI USA, V101, P9757, DOI 10.1073/pnas.0403456101
   Ma B, 2013, OSTEOARTHR CARTILAGE, V21, P599, DOI 10.1016/j.joca.2013.01.014
   MANKIN HJ, 1971, J BONE JOINT SURG AM, VA 53, P523, DOI 10.2106/00004623 197153030 00009
   MAROUDAS A, 1976, J ANAT, V122, P335
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mikels A, 2009, J BIOL CHEM, V284, P30167, DOI 10.1074/jbc.M109.041715
   Mo JS, 2014, EMBO REP, V15, P642, DOI 10.15252/embr.201438638
   Monteleone G, 2015, NEW ENGL J MED, V372, P1104, DOI [10.1056/NEJMc1504845, 10.1056/NEJMoa1407250]
   Nagase H, 2003, ARTHRITIS RES THER, V5, P94, DOI 10.1186/ar630
   Nalesso G, 2017, ANN RHEUM DIS, V76, P218, DOI 10.1136/annrheumdis 2015 208577
   Nalesso G, 2011, J CELL BIOL, V193, P551, DOI 10.1083/jcb.201011051
   Neogi T, 2013, OSTEOARTHR CARTILAGE, V21, P1145, DOI 10.1016/j.joca.2013.03.018
   Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365 2443.2003.00662.x
   Park HW, 2015, CELL, V162, P780, DOI 10.1016/j.cell.2015.07.013
   Pasi KJ, 2017, NEW ENGL J MED, V377, P819, DOI [10.1056/NEJMoa1616569, 10.1056/NEJMoa1708483]
   Poulet B, 2015, OSTEOARTHR CARTILAGE, V23, P940, DOI 10.1016/j.joca.2015.01.012
   Rudnicki JA, 1997, DEV BIOL, V185, P104, DOI 10.1006/dbio.1997.8536
   Saito T, 2010, NAT MED, V16, P678, DOI 10.1038/nm.2146
   Sampson ER, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002214
   Schambony A, 2007, DEV CELL, V12, P779, DOI 10.1016/j.devcel.2007.02.016
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Schwabe GC, 2004, DEV DYNAM, V229, P400, DOI 10.1002/dvdy.10466
   Sherwood J, 2015, ANN RHEUM DIS, V74, P2207, DOI 10.1136/annrheumdis 2014 205546
   Sherwood JC, 2014, DRUG DISCOV TODAY, V19, P1172, DOI 10.1016/j.drudis.2014.05.014
   Stanton H, 2005, NATURE, V434, P648, DOI 10.1038/nature03417
   Turkiewicz A, 2014, OSTEOARTHR CARTILAGE, V22, P1826, DOI 10.1016/j.joca.2014.07.015
   Valverde Franco G, 2015, AM J PATHOL, V185, P335, DOI 10.1016/j.ajpath.2014.10.004
   van der Kraan PM, 2010, OSTEOARTHR CARTILAGE, V18, P735, DOI 10.1016/j.joca.2010.03.001
   Verzijl N, 2000, J BIOL CHEM, V275, P39027, DOI 10.1074/jbc.M006700200
   Wallkamm V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109428
   Yamamoto S, 2008, DEV CELL, V15, P23, DOI 10.1016/j.devcel.2008.05.007
   Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153
   Yu J, 2016, J CLIN INVEST, V126, P585, DOI 10.1172/JCI83535
   Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907
NR 81
TC 42
Z9 47
U1 2
U2 25
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946 6234
EI 1946 6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD SEP 16
PY 2020
VL 12
IS 561
AR eaax3063
DI 10.1126/scitranslmed.aax3063
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA NQ6HM
UT WOS:000570971200001
PM 32938794
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Anwar, MJ
   Radhakrishna, KV
   Sharma, A
   Vohora, D
AF Anwar, Md Jamir
   Radhakrishna, K. V.
   Sharma, Abhay
   Vohora, Divya
TI Raloxifene preserves phenytoin and sodium valproate induced bone loss by
   modulating serum estradiol and TGF β3 content in bone of female mice
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Phenytoin; Sodium valproate; Raloxifene; Estradiol; TGF beta 3; Bone
   turnover markers
ID GROWTH FACTOR BETA; VITAMIN D; ANTIEPILEPTIC DRUGS; RAT BONE;
   POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; OSTEOCLAST DIFFERENTIATION;
   HUMAN OSTEOBLASTS; MINERAL DENSITY; GENE EXPRESSION
AB Antiepileptic drugs (AEDs) induced adverse consequences on bone are now well recognized. Despite this, there is limited data on the effect of anti osteoporotic therapies on AEDs induced bone loss. We hypothesize that estrogen deprivation following phenytoin (PHT) and sodium valproate (SVP) therapy could lead to adverse bony effects. Both PHT and SVP inhibit human aromatase enzyme and stimulate microsomal catabolism of oestrogens. Estrogen deficiency states are known to reduce the deposition of transforming growth factor beta (TGF beta 3), a bone matrix protein, having anti osteoclastic property. Thus, an attempt was made to investigate the effect of raloxifene, a selective oestrogen receptor modulator, in comparison with calcium and vitamin D3 (CVD) supplementation, on PHT and SVP induced alterations in bone in mice and to unravel the role of estradiol and TGF beta 3 in mediation of bony effects by either AEDs or raloxifene. Further, the effect of raloxifene on seizures and on the antiepileptic efficacy of PHT and SW was investigated. Swiss strains of female mice were treated with PHT (35 mg/kg, p.o.) and SVP (300 mg/kg, p.o.) for 120 days to induce bone loss as evidenced by reduced bone mineral density (BMD) and altered bone turnover markers (BTMs) in lumbar bones (alkaline phosphatase, tartarate resistant acid phosphatase, hydroxyproline) and urine (calcium). The bone loss was accompanied by reduced serum estradiol levels and bone TGF beta 3 content. Preventive and therapeutic treatment with raloxifene ameliorated bony alterations and was more effective than CVD. It also significantly restored estradiol and TGF beta 3 levels. Deprived estrogen levels (that in turn reduced lumbar TGF beta 3 content) following PHT and SVP, thus, might represent one of the various mechanisms of AEDs induced bone loss. Raloxifene preserved the bony changes without interfering with antiepileptic efficacy of these drugs, and hence raloxifene could be a potential therapeutic option in the management of PHT and SVP induced bone disease if clinically approved. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Anwar, Md Jamir; Vohora, Divya] Hamdard Univ, Jamia Hamdard, Fac Pharm, Dept Pharmacol,Neurobehav Pharmacol Lab, New Delhi 110062, India.
   [Radhakrishna, K. V.] NIN, Dept Clin Res, Hyderabad 500007, Andhra Pradesh, India.
   [Sharma, Abhay] Inst Genom & Integrat Biol, New Delhi 110025, India.
C3 Jamia Hamdard University; Indian Council of Medical Research (ICMR);
   ICMR   National Institute of Nutrition (NIN); Council of Scientific &
   Industrial Research (CSIR)   India; CSIR   Institute of Genomics &
   Integrative Biology (IGIB)
RP Vohora, D (通讯作者)，Hamdard Univ, Jamia Hamdard, Fac Pharm, Dept Pharmacol,Neurobehav Pharmacol Lab, New Delhi 110062, India.
EM dvohra@jamiahamdard.ac.in
RI ; Sharma, Abhay/IVU 8563 2023; Vohora, Divya/H 4245 2019
OI Vohora, Divya/0000 0003 1852 9191; Sharma, Abhay/0000 0003 1306 1497;
   Anwar, Md Jamir/0000 0002 9895 8166
FU Indian Council of Medical Research (ICMR), New Delhi, India; CSIR as
   SRF, New Delhi
FX This study was supported by a research project funded by Indian Council
   of Medical Research (ICMR), New Delhi, India. Financial assistance from
   CSIR as SRF, New Delhi to Md. Jamir Anwar is also gratefully
   acknowledged. We are also thankful to Mrs. Usha Rani, DEXA incharge,
   clinical research department, National Institute of Nutrition (NIN),
   Hyderabad, India for extending necessary facilities.
CR [Anonymous], COCHRANE DATABASE SY
   Boluk A, 2004, PHARMACOL RES, V50, P93, DOI 10.1016/j.phrs.2003.11.011
   Borowicz KK, 2002, POL J PHARMACOL, V54, P103
   Brown JP, 2009, CLIN BIOCHEM, V42, P929, DOI 10.1016/j.clinbiochem.2009.04.001
   CHENU C, 1988, P NATL ACAD SCI USA, V85, P5683, DOI 10.1073/pnas.85.15.5683
   Christenson RH, 1997, CLIN BIOCHEM, V30, P573, DOI 10.1016/S0009 9120(97)00113 6
   COX DA, 1995, CELL BIOL INT, V19, P357, DOI 10.1006/cbir.1995.1082
   Das S, 2013, DRUG DES DEV THER, V7, P435, DOI 10.2147/DDDT.S31504
   Delmas R.D., 1993, OSTEOPOROSIS INT, V3, P81
   Dhillon N, 2011, NEUROPEDIATRICS, V42, P119, DOI 10.1055/s 0031 1279783
   Dijke P.T., 1990, MOL CELL BIOL, V10, P4473
   Enjuanes A, 2003, EUR J ENDOCRINOL, V148, P519, DOI 10.1530/eje.0.1480519
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   FINKELMAN RD, 1992, P NATL ACAD SCI USA, V89, P12190, DOI 10.1073/pnas.89.24.12190
   FINKELMAN RD, 1991, P NATL ACAD SCI USA, V88, P3657, DOI 10.1073/pnas.88.9.3657
   Fitzpatrick LA, 2004, EPILEPSY BEHAV, V5, pS3, DOI 10.1016/j.yebeh.2003.11.026
   Grainger DJ, 1999, OSTEOPOROSIS INT, V9, P398, DOI 10.1007/s001980050163
   HEINICKE RJ, 1984, GEN PHARMACOL VASC S, V15, P85, DOI 10.1016/0306 3623(84)90088 0
   Hu XW, 2011, EPILEPSY RES, V97, P73, DOI 10.1016/j.eplepsyres.2011.07.006
   Jacobsen NW, 2008, TOXICOL IN VITRO, V22, P146, DOI 10.1016/j.tiv.2007.09.004
   Johnell O, 2002, J CLIN ENDOCR METAB, V87, P985, DOI 10.1210/jc.87.3.985
   Khanna S, 2011, BONE, V48, P597, DOI 10.1016/j.bone.2010.10.172
   Khanna S, 2009, DRUG DISCOV TODAY, V14, P428, DOI 10.1016/j.drudis.2009.01.004
   Kinuta K, 2000, ENDOCRINOLOGY, V141, P1317, DOI 10.1210/en.141.4.1317
   Kruse R, 1968, Monatsschr Kinderheilkd, V116, P378
   Lazzari AA, 2013, EPILEPSIA, V54, P1997, DOI 10.1111/epi.12351
   Lee RH, 2010, AM J GERIATR PHARMAC, V8, P34, DOI 10.1016/j.amjopharm.2010.02.003
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luvizuto ER, 2011, ARCH ORAL BIOL, V56, P984, DOI 10.1016/j.archoralbio.2011.03.015
   Maclay E, 1978, Ulster Med J, V47, P63
   MARCUS R, 1991, Journal of Bone and Mineral Research, V6, pS125
   Miki Y, 2009, J STEROID BIOCHEM, V113, P281, DOI 10.1016/j.jsbmb.2009.01.010
   MINKIN C, 1982, CALCIFIED TISSUE INT, V34, P285, DOI 10.1007/BF02411252
   Murthy PSN, 2006, J STEROID BIOCHEM, V100, P117, DOI 10.1016/j.jsbmb.2006.03.009
   Nissen Meyer LSH, 2007, EPILEPSIA, V48, P1850, DOI 10.1111/j.1528 1167.2007.01176.x
   OREFFO ROC, 1989, BIOCHEM BIOPH RES CO, V158, P817, DOI 10.1016/0006 291X(89)92795 2
   Pack AM, 2008, NEUROLOGY, V70, P1586, DOI 10.1212/01.wnl.0000310981.44676.de
   Pack AM, 2011, EPILEPSY BEHAV, V21, P453, DOI 10.1016/j.yebeh.2011.05.001
   POLLARD FH, 1956, ANALYST, V81, P348, DOI 10.1039/an9568100348
   Quinn JMW, 2001, J BONE MINER RES, V16, P1787, DOI 10.1359/jbmr.2001.16.10.1787
   Robinson JA, 1996, ENDOCRINOLOGY, V137, P615, DOI 10.1210/en.137.2.615
   Roste LS, 2002, REPROD TOXICOL, V16, P767
   Sachdeva A, 2005, INDIAN J CLIN BIOCHE, V20, P131, DOI 10.1007/BF02893058
   Sanders S, 2013, SOUTH MED J, V106, P698, DOI 10.1097/SMJ.0b013e3182a0df8b
   Scharfman H.E., 2009, ENDOCRINOLOGY, V44, P37
   Seeman E, 2006, OSTEOPOROSIS INT, V17, P313, DOI 10.1007/s00198 005 2030 1
   Sheth RD, 2007, EPILEPSIA, V48, P39, DOI 10.1111/j.1528 1167.2007.01401.x
   STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009 8981(67)90167 2
   Swaminathan R, 2001, CLIN CHIM ACTA, V313, P95, DOI 10.1016/S0009 8981(01)00656 8
   Taranta A, 2002, BONE, V30, P368, DOI 10.1016/S8756 3282(01)00685 8
   Tauboll E, 2003, EPILEPSIA, V44, P1014, DOI 10.1046/j.1528 1157.2003.60702.x
   TENNISWOOD M, 1976, CAN J BIOCHEM CELL B, V54, P350, DOI 10.1139/o76 051
   Uebelhart B, 2004, J BONE MINER RES, V19, P1518, DOI 10.1359/JBMR.040503
   Vaananen H.K., 1996, MATURITAS S, V23, P65
   Valsamis HA, 2006, NUTR METABOLISM, V3, DOI 10.1186/1743 7075 3 36
   Vasikaran Samuel D, 2006, Clin Biochem Rev, V27, P119
   Viguet Carrin S, 2006, OSTEOPOROSIS INT, V17, P319, DOI 10.1007/s00198 005 2035 9
   Yague JG, 2009, ENDOCRINE, V35, P252, DOI 10.1007/s12020 008 9134 2
   Yang NN, 1996, ENDOCRINOLOGY, V137, P2075, DOI 10.1210/en.137.5.2075
NR 59
TC 11
Z9 12
U1 0
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0928 0987
EI 1879 0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD OCT 1
PY 2014
VL 62
BP 219
EP 226
DI 10.1016/j.ejps.2014.05.018
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA AN0VG
UT WOS:000340301500026
PM 24880111
DA 2025 08 17
ER

PT J
AU Li, C
   Liu, HY
   Liao, YX
   Zhu, Y
   Tian, JY
   Wang, X
   Hu, ZQ
   Zhan, YX
   Li, XB
   Liang, XT
   He, J
   Li, YM
   Shang, DW
   Zheng, QS
   Wang, TH
   Song, HF
   Fang, Y
AF Li, Chen
   Liu, Haiyan
   Liao, Yixiang
   Zhu, Yu
   Tian, Jingyuan
   Wang, Xuan
   Hu, Zhiqin
   Zhan, Yaoxuan
   Li, Xianbo
   Liang, Xintong
   He, Jin
   Li, Yongmei
   Shang, Dewei
   Zheng, Qingshan
   Wang, Tenghua
   Song, Haifeng
   Fang, Yi
TI Phase I, Randomized, Placebo Controlled, Dose Escalation Study of GB223,
   a Fully Humanized Monoclonal Antibody to RANKL, in Healthy Chinese
   Adults
SO BIODRUGS
LA English
DT Article
ID OSTEOCLAST DIFFERENTIATION; LIGAND; DENOSUMAB; OSTEOPOROSIS;
   PERFORMANCE; RECEPTOR
AB BackgroundGB223 is a novel, fully humanized monoclonal antibody against the receptor activator of nuclear factor kappa B ligand (RANKL). In this phase I study, the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of GB223 were investigated.Patients and MethodsThis was a randomized, double blinded, placebo controlled, single dose escalation study conducted in 44 healthy Chinese adults. Participants were randomly assigned to receive a single subcutaneous injection dose of 7, 21, 63, 119, or 140 mg of GB223 (n = 34) or placebo (n = 10) and were followed up for 140 252 days.ResultsThe results of noncompartmental analysis showed that GB223 was slowly absorbed after dosing, with a time to reach maximum concentration (T max) ranging from 5 to 11 days. Serum GB223 concentrations decreased slowly, with a long half life ranging from 7.91 to 19.60 days. A two compartment Michaelis Menten model was found to best describe the pharmacokinetics of GB223, and the absorption rate of GB223 differed between males (0.0146 h( 1)) and females (0.0081 h( 1)). Serum C terminal telopeptide of type I collagen decreased significantly postdose, and the inhibition lasted 42 168 days. No deaths or drug related serious adverse events occurred. The most frequent adverse events were blood parathyroid hormone increased (94.1%), blood phosphorus decreased (67.6%) and blood calcium decreased (58.8%). In the GB223 group, 44.1% (15/34) of subjects were antidrug antibody positive after dosing.ConclusionIn this study, we demonstrated for the first time that a single subcutaneous injection of GB223, from 7 to 140 mg, is safe and well tolerated in healthy Chinese subjects. GB223 has a nonlinear pharmacokinetic profile, and sex was a potential covariate that may affect the absorption rate of GB223.
C1 [Li, Chen; Zhu, Yu; Tian, Jingyuan; Hu, Zhiqin; Liang, Xintong; He, Jin; Li, Yongmei; Wang, Tenghua] Guangzhou Med Univ, Dept Pharm, Key Lab Biol Targeting Diag Therapy & Rehabil Guan, Affiliated Hosp 5, Guangzhou, Peoples R China.
   [Li, Chen; Liu, Haiyan; Liao, Yixiang; Wang, Xuan; Zhan, Yaoxuan; Li, Xianbo] Guangzhou Med Univ, Key Lab Biol Targeting Diag Therapy & Rehabil Guan, Phase I Clin Res Ctr, Affiliated Hosp 5, Guangzhou, Peoples R China.
   [Shang, Dewei] Guangzhou Med Univ, Dept Pharm, Affiliated Brain Hosp, Guangzhou, Peoples R China.
   [Zheng, Qingshan] Shanghai Univ Tradit Chinese Med, Ctr Drug Clin Res, Shanghai, Peoples R China.
   [Song, Haifeng] Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing, Peoples R China.
   [Fang, Yi] Peking Univ Peoples Hosp, Clin Trial Inst Res Ward, Beijing, Peoples R China.
C3 Guangzhou Medical University; Guangzhou Medical University; Guangzhou
   Medical University; Shanghai University of Traditional Chinese Medicine;
   Academy of Military Medical Sciences   China
RP Wang, TH (通讯作者)，Guangzhou Med Univ, Dept Pharm, Key Lab Biol Targeting Diag Therapy & Rehabil Guan, Affiliated Hosp 5, Guangzhou, Peoples R China.; Song, HF (通讯作者)，Beijing Inst Radiat Med, Dept Pharmacol & Toxicol, Beijing, Peoples R China.; Fang, Y (通讯作者)，Peking Univ Peoples Hosp, Clin Trial Inst Res Ward, Beijing, Peoples R China.
EM wangtenghua88@126.com; songhf@nic.bmi.ac.cn; phaseistudy@163.com
RI Li, Chen/HTO 9578 2023; Shang, Dewei/AAI 8415 2020; Liu,
   Haiyan/ABD 8689 2021; Li, Yongmei/AAR 9646 2021
CR [Anonymous], 2020, XGEV FULL PRESCR INF
   [Anonymous], 2022, PROL FULL PRESCR INF
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Chen HJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.821944
   Chen Q, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197984
   Dempster DW, 2016, J CLIN ENDOCR METAB, V101, P1353, DOI 10.1210/jc.2015 4181
   Dempster DW, 2012, CLIN THER, V34, P521, DOI 10.1016/j.clinthera.2012.02.002
   Diker Cohen T, 2020, J CLIN ENDOCR METAB, V105, DOI 10.1210/clinem/dgz322
   Ebina K, 2017, J BONE MINER METAB, V35, P571, DOI 10.1007/s00774 016 0792 5
   Ette EI, 1997, J CLIN PHARMACOL, V37, P486, DOI 10.1002/j.1552 4604.1997.tb04326.x
   Ferrari Lacraz S, 2011, OSTEOPOROSIS INT, V22, P435, DOI 10.1007/s00198 010 1326 y
   Goltzman D, 2018, ENDOCRIN METAB CLIN, V47, P743, DOI 10.1016/j.ecl.2018.07.003
   Hooker AC, 2007, PHARM RES, V24, P2187, DOI 10.1007/s11095 007 9361 x
   Hou J, 2022, INT IMMUNOPHARMACOL, V107, DOI 10.1016/j.intimp.2022.108666
   Kim JM, 2020, CELLS BASEL, V9, DOI 10.3390/cells9092073
   Kim NS, 2006, MOL CELL BIOL, V26, P1002, DOI 10.1128/MCB.26.3.1002 1013.2006
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Niu SP, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.893166
   Post TM, 2008, J PHARMACOKINET PHAR, V35, P185, DOI 10.1007/s10928 007 9081 1
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Richter WF, 2012, AAPS J, V14, P559, DOI 10.1208/s12248 012 9367 0
   Suda T, 1999, ENDOCR REV, V20, P345, DOI 10.1210/er.20.3.345
   Sutjandra L, 2011, CLIN PHARMACOKINET, V50, P793, DOI 10.2165/11594240 000000000 00000
   Suzuki T, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080871
   Tabrizi MA, 2006, DRUG DISCOV TODAY, V11, P81, DOI 10.1016/S1359 6446(05)03638 X
   van der Spoel E, 2019, BONE, V120, P61, DOI 10.1016/j.bone.2018.10.002
   Zhang H, 2021, EXPERT OPIN INV DRUG, V30, P185, DOI 10.1080/13543784.2021.1863371
   Zhang H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.01329
NR 28
TC 1
Z9 2
U1 2
U2 13
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1173 8804
EI 1179 190X
J9 BIODRUGS
JI Biodrugs
PD SEP
PY 2023
VL 37
IS 5
BP 721
EP 735
DI 10.1007/s40259 023 00604 7
EA JUN 2023
PG 15
WC Oncology; Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Immunology; Pharmacology & Pharmacy
GA P0EG0
UT WOS:001002582200002
PM 37278972
DA 2025 08 17
ER

PT J
AU Tamechika, S
   Sasaki, K
   Hayami, Y
   Ohmura, S
   Maeda, S
   Iwagaitsu, S
   Naniwa, T
AF Tamechika, Shin ya
   Sasaki, Kaneshige
   Hayami, Yoshihito
   Ohmura, Shin ichiro
   Maeda, Shinji
   Iwagaitsu, Shiho
   Naniwa, Taio
TI Patient satisfaction and efficacy of switching from weekly
   bisphosphonates to monthly minodronate for treatment and prevention of
   glucocorticoid induced osteoporosis in Japanese patients with systemic
   rheumatic diseases: a randomized, clinical trial
SO ARCHIVES OF OSTEOPOROSIS
LA English
DT Article
DE Glucocorticoid induced osteoporosis; Glucocorticoid; Bisphosphonate;
   Minodronate; Alendronate; Risedronate
ID CORTICOSTEROID INDUCED OSTEOPOROSIS; BONE RESORPTION;
   MOLECULAR MECHANISMS; OSTEOCLAST APOPTOSIS; WEEKLY ALENDRONATE;
   DOUBLE BLIND; OPEN LABEL; IN VIVO; MANAGEMENT; PREFERENCE
AB aSummary The randomized, clinical trial demonstrated that switching to monthly minodronate from weekly alendronate and risedronate provides greater increases in patients' satisfaction and bone mineral density and more substantial decreases in a bone resorption marker than continuing weekly alendronate and risedronate in patients with systemic rheumatic diseases on glucocorticoid therapy.
   Purpose Osteoporosis and associated fractures are major concerns for patients with systemic rheumatic diseases on long term glucocorticoid therapy. Bisphosphonates increase bone mineral density (BMD) and reduce the frequency of vertebral fractures, but they are associated with poor adherence. The effects of monthly oral minodronate on patients' satisfaction, BMD, and bone turnover markers were investigated in patients with systemic rheumatic diseases on glucocorticoids and weekly oral alendronate or risedronate.
   Methods Study patients with systemic rheumatic diseases on oral glucocorticoids and weekly alendronate 35 mg or risedronate 17.5 mg were randomly assigned either to switch to minodronate 50 mg every 4 weeks or to continue the currently taking weekly bisphosphonate for 52 weeks after a 24 week run in period. Patients were stratified by hospital site, sex, and menopausal status in women at enrollment. The primary endpoint was the difference between the proportions of patients who responded very satisfactory or satisfactory for the current bisphosphonate therapy at weeks 48 and 76 between the two groups. Secondary endpoints included percentage changes in lumbar spine BMD and bone turnover markers from the time of starting allocated treatment.
   Results Monthly minodronate was superior to weekly alendronate or risedronate for patients' satisfaction, the increase of lumbar spine BMD, and suppression of serum tartrate resistant acid phosphatase 5b at week 76.
   Conclusions Monthly minodronate is more acceptable and may be more effective than weekly alendronate or risedronate for prevention and treatment of bone loss in patients with systemic rheumatic diseases on glucocorticoid therapy.
C1 [Tamechika, Shin ya; Ohmura, Shin ichiro; Maeda, Shinji; Iwagaitsu, Shiho; Naniwa, Taio] Nagoya City Univ, Nagoya City Univ Hosp, Div Rheumatol, Dept Internal Med,Grad Sch Med Sci,Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   [Tamechika, Shin ya; Ohmura, Shin ichiro; Maeda, Shinji; Iwagaitsu, Shiho; Naniwa, Taio] Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
   [Sasaki, Kaneshige] Aichi Prefectural Federat Agr Cooperat Hlth & Wel, Dept Rheumatol, Yalomi, Aichi, Japan.
   [Hayami, Yoshihito] Nagoya City West Med Ctr, Dept Rheumatol, Nagoya, Aichi, Japan.
C3 Nagoya City University; Nagoya City University
RP Naniwa, T (通讯作者)，Nagoya City Univ, Nagoya City Univ Hosp, Div Rheumatol, Dept Internal Med,Grad Sch Med Sci,Mizuho Ku, Nagoya, Aichi 4678601, Japan.; Naniwa, T (通讯作者)，Nagoya City Univ, Dept Resp Med Allergy & Clin Immunol, Grad Sch Med Sci, Mizuho Ku, Nagoya, Aichi 4678601, Japan.
EM tnaniwa@med.nagoya cu.ac.jp
RI ; Naniwa, Taio/IYJ 2605 2023
OI Naniwa, Taio/0000 0002 0489 2611; Iwagaitsu, Shiho/0000 0002 7187 0463
FU Department of Respiratory Medicine, Allergy and Clinical Immunology,
   Nagoya City University Graduate School of Medical Sciences
FX The authors would like to thank Drs. Jun ichi Wada (Division of
   Rheumatology, Department of Internal Medicine, Nagoya City University
   Hospital), who collected the samples of the patients, and Prof. Akio
   Niimi (Department of Respiratory Medicine, Allergy and Clinical
   Immunology, Nagoya City University Graduate School of Medical Sciences),
   who provided general support as a department chair.
CR Adachi JD, 2001, ARTHRITIS RHEUM US, V44, P202, DOI 10.1002/1529 0131(200101)44:1<202::AID ANR27>3.0.CO;2 W
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Brown JP, 2009, J BONE MINER RES, V24, P153, DOI [10.1359/JBMR.0809010, 10.1359/jbmr.080901]
   Buckley L, 2017, ARTHRIT CARE RES, V69, P1095, DOI 10.1002/acr.23279
   Cohen S, 1999, ARTHRITIS RHEUM, V42, P2309, DOI 10.1002/1529 0131(199911)42:11<2309::AID ANR8>3.0.CO;2 K
   Curtis Jeffrey R, 2007, Curr Osteoporos Rep, V5, P14, DOI 10.1007/BF02938618
   Díez Pérez A, 2011, BONE, V49, P493, DOI 10.1016/j.bone.2011.05.007
   Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235
   Ebina K, 2016, OSTEOPOROSIS INT, V27, P351, DOI 10.1007/s00198 015 3369 6
   Emkey R, 2005, CURR MED RES OPIN, V21, P1895, DOI 10.1185/030079905X74862
   Fardet L, 2011, RHEUMATOLOGY, V50, P1982, DOI 10.1093/rheumatology/ker017
   Furuta Kenji, 2008, Nihon Shokakibyo Gakkai Zasshi, V105, P817
   Gennari L, 2009, LANCET, V373, P1225, DOI 10.1016/S0140 6736(09)60704 2
   Hagino H, 2009, BONE, V44, P1078, DOI 10.1016/j.bone.2009.02.016
   Hongo H, 2016, J HISTOCHEM CYTOCHEM, V64, P601, DOI 10.1369/0022155416665577
   Hosoi Takayuki, 2015, Clin Calcium, V25, P1279, DOI CliCa150912791283
   Iwamoto J, 2016, J BONE MINER METAB, V34, P201, DOI 10.1007/s00774 015 0653 7
   Kamimura Mikio, 2016, Osteoporos Sarcopenia, V2, P170, DOI 10.1016/j.afos.2016.07.002
   Kim YH, 2002, EXP MOL MED, V34, P145, DOI 10.1038/emm.2002.21
   Lekamwasam S, 2012, OSTEOPOROSIS INT, V23, P2257, DOI 10.1007/s00198 012 1958 1
   Lems WF, 2007, ARTHRITIS RHEUM US, V56, P3518, DOI 10.1002/art.22975
   Matsumoto T, 2009, OSTEOPOROSIS INT, V20, P1429, DOI 10.1007/s00198 008 0816 7
   Nancollas GH, 2006, BONE, V38, P617, DOI 10.1016/j.bone.2005.05.003
   Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796
   Raggatt LJ, 2010, J BIOL CHEM, V285, P25103, DOI 10.1074/jbc.R109.041087
   Reginster JY, 2006, CLIN INTERV AGING, V1, P415, DOI 10.2147/ciia.2006.1.4.415
   Roelofs AJ, 2006, CLIN CANCER RES, V12, p6222S, DOI 10.1158/1078 0432.CCR 06 0843
   Roux S, 2009, CURR RHEUMATOL REV, V5, P98, DOI 10.2174/157339709788298428
   Saag KG, 1998, NEW ENGL J MED, V339, P292, DOI 10.1056/NEJM199807303390502
   Saag KG, 2003, ENDOCRIN METAB CLIN, V32, P135, DOI 10.1016/S0889 8529(02)00064 6
   Sekiguchi M, 2012, J NEW REM CLIN, V61, P1683
   Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170
   Silverman S, 2015, OSTEOPOROSIS INT, V26, P419, DOI 10.1007/s00198 014 2883 2
   Soucy E, 2000, J RHEUMATOL, V27, P1506
   Suzuki Y, 2014, J BONE MINER METAB, V32, P337, DOI 10.1007/s00774 014 0586 6
   Tanishima Shinji, 2007, Mod Rheumatol, V17, P198, DOI 10.1007/s10165 007 0566 y
   van Staa TP, 2006, CALCIFIED TISSUE INT, V79, P129, DOI 10.1007/s00223 006 0019 1
   van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777, DOI 10.1007/s001980200108
   Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993
   Vestergaard P, 2003, J INTERN MED, V254, P486, DOI 10.1046/j.1365 2796.2003.01219.x
   Wells GA, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001155.pub2
   Widler L, 2002, J MED CHEM, V45, P3721, DOI 10.1021/jm020819i
   Zhang Q, 2005, ARTHRITIS RHEUM US, V52, P2708, DOI 10.1002/art.21236
NR 43
TC 8
Z9 10
U1 0
U2 4
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 1862 3522
EI 1862 3514
J9 ARCH OSTEOPOROS
JI Arch. Osteoporos.
PD JUN 13
PY 2018
VL 13
IS 1
AR 67
DI 10.1007/s11657 018 0451 7
PG 12
WC Endocrinology & Metabolism; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism; Orthopedics
GA GJ6MA
UT WOS:000435497100001
PM 29904824
DA 2025 08 17
ER

PT J
AU Leow, PC
   Bahety, P
   Boon, CP
   Lee, CY
   Tan, KL
   Yang, TM
   Ee, PLR
AF Leow, Pay Chin
   Bahety, Priti
   Boon, Choon Pei
   Lee, Chong Yew
   Tan, Kheng Lin
   Yang, Tianming
   Ee, Pui Lai Rachel
TI Functionalized curcumin analogs as potent modulators of the
   Wnt/β catenin signaling pathway
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Curcumin analog; Osteosarcoma; Wnt signaling; Invasion; Drug discovery
ID NF KAPPA B; MONO CARBONYL ANALOGS; I CLINICAL TRIAL; CANCER CELLS;
   CHEMOPREVENTIVE AGENT; HUMAN OSTEOSARCOMA; PANCREATIC CANCER;
   DOWN REGULATION; GROWTH ARREST; STAT PATHWAY
AB Osteosarcoma is a primary bone malignancy with aggressive metastatic potential and poor prognosis rates. In our earlier work we have investigated the therapeutic potential of curcumin as an anti invasive agent in osteosarcoma by its ability to regulate the Wnt/beta catenin signaling pathway. However, the clinical use of curcumin is limited owing to its low potency and poor pharmacokinetic profile. In this study, an attempt was made to achieve more potent Wnt inhibitory activity in osteosarcoma cells by carrying out synthetic chemical modifications of curcumin. We synthesized a total of five series consisting of 43 curcumin analogs and screened in HEK293T cells for inhibition of beta catenin transcriptional activity. Six promising analogs, which were 6.5  to 60 fold more potent than curcumin in inhibiting Wnt activity, were further assessed for their anti invasive activity and Wnt inhibitory mechanisms. Western blot analysis showed disruption of beta catenin protein nuclear translocation following treatment with analogs 2f, 3c and 4f. Using transwell assays, we also found that these compounds were more potent than la (curcumin) in impeding the invasion of osteosarcoma cells, possibly through suppressing MMP 9 activity. Structure activity relationship studies revealed that Wnt inhibitory effects could be enhanced by shortening and restraining the flexibility of the 7 carbon linker moiety connecting the terminal aromatic rings of curcumin and substituting both rings with appropriate substituents. Our results demonstrate that the synthesized curcumin analogs are more potent Wnt inhibitors in osteosarcoma cell lines as compared to parental curcumin and are good lead compounds for further development. Future in vivo tests with these compounds will define their therapeutic potentials as promising drug candidates for clinical treatment of osteosarcoma. (C) 2013 Elsevier Masson SAS. All rights reserved.
C1 [Leow, Pay Chin; Bahety, Priti; Boon, Choon Pei; Lee, Chong Yew; Tan, Kheng Lin; Yang, Tianming; Ee, Pui Lai Rachel] Natl Univ Singapore, Dept Pharm, Fac Sci, Singapore 117543, Singapore.
C3 National University of Singapore
RP Ee, PLR (通讯作者)，Natl Univ Singapore, Dept Pharm, Fac Sci, 18 Sci Dr 4, Singapore 117543, Singapore.
EM phaeplr@nus.edu.sg
RI EE, P.L./C 7538 2014; Lee, Chong Yew/E 2367 2012
OI Bahety, Priti/0000 0002 5556 970X; Ee, Pui Lai
   Rachel/0000 0002 7277 6233; Bahety, Priti/0000 0002 9793 5288; Lee,
   Chong Yew/0000 0003 0632 3794
FU Ministry of Education Academic Research Fund (AcRF) [R148000150112];
   National University of Singapore
FX We thank Dr Yi Yan Yang and Professor Victor Nurcombe for providing the
   HEK293T cells and L Wnt 3A cells respectively. We also thank A/Prof Mei
   Lin Go for her helpful comments and suggestions. This work was made
   possible by the Ministry of Education Academic Research Fund (AcRF)
   R148000150112 to PLRE and National University of Singapore Graduate
   Scholarships to PCL, KLT and PB.
CR Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r
   Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507
   Balasubramanian S, 2007, J BIOL CHEM, V282, P6707, DOI 10.1074/jbc.M606003200
   Bharti AC, 2003, J IMMUNOL, V171, P3863, DOI 10.4049/jimmunol.171.7.3863
   Bhattacharyya S, 2007, J BIOL CHEM, V282, P15954, DOI 10.1074/jbc.M608189200
   Blasius R, 2006, BIOCHEM PHARMACOL, V72, P1547, DOI 10.1016/j.bcp.2006.07.029
   Chen K, 2008, PEDIATR BLOOD CANCER, V51, P349, DOI 10.1002/pbc.21595
   Chen Y, 2007, BASIC CLIN PHARMACOL, V101, P427, DOI 10.1111/j.1742 7843.2007.00142.x
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627
   Dass CR, 2006, CLIN EXP METASTAS, V23, P367, DOI 10.1007/s10585 006 9046 6
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078 0432.CCR 08 0024
   Fuchs JR, 2009, BIOORG MED CHEM LETT, V19, P2065, DOI 10.1016/j.bmcl.2009.01.104
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Guo Y, 2008, CLIN ORTHOP RELAT R, V466, P2039, DOI 10.1007/s11999 008 0344 y
   Guo Y, 2007, J ORTHOP RES, V25, P964, DOI 10.1002/jor.20356
   Haydon RC, 2002, INT J CANCER, V102, P338, DOI 10.1002/ijc.10719
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Hoang BH, 2004, INT J CANCER, V109, P106, DOI 10.1002/ijc.11677
   Iwao K, 1999, JPN J CANCER RES, V90, P205, DOI 10.1111/j.1349 7006.1999.tb00734.x
   Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947
   Kakarala M, 2010, BREAST CANCER RES TR, V122, P777, DOI 10.1007/s10549 009 0612 x
   Kim HY, 2003, J IMMUNOL, V171, P6072, DOI 10.4049/jimmunol.171.11.6072
   Kirk KL, 2006, CURR TOP MED CHEM, V6, P1447, DOI 10.2174/156802606777951073
   Leow PC, 2010, INVEST NEW DRUG, V28, P766, DOI 10.1007/s10637 009 9311 z
   Li XF, 2009, CHEM ASIAN J, V4, P540, DOI 10.1002/asia.200800354
   Liang G, 2008, CHEM PHARM BULL, V56, P162, DOI 10.1248/cpb.56.162
   Liang GA, 2009, BIOORGAN MED CHEM, V17, P2623, DOI 10.1016/j.bmc.2008.10.044
   MEYERS PA, 1993, J CLIN ONCOL, V11, P449, DOI 10.1200/JCO.1993.11.3.449
   Natarajan C, 2002, J IMMUNOL, V168, P6506, DOI 10.4049/jimmunol.168.12.6506
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Ohtsu H, 2002, J MED CHEM, V45, P5037, DOI 10.1021/jm020200g
   Park CH, 2005, FEBS LETT, V579, P2965, DOI 10.1016/j.febslet.2005.04.013
   Polakis P, 2000, GENE DEV, V14, P1837
   Qiu X, 2008, BIOORGAN MED CHEM, V16, P8035, DOI 10.1016/j.bmc.2008.07.054
   Rajasingh J, 2006, BIOCHEM BIOPH RES CO, V340, P359, DOI 10.1016/j.bbrc.2005.12.014
   Ryu MJ, 2008, BIOCHEM BIOPH RES CO, V377, P1304, DOI 10.1016/j.bbrc.2008.10.171
   Saydmohammed M, 2010, J CELL BIOCHEM, V110, P447, DOI 10.1002/jcb.22558
   Sharma C, 2006, TOXICOLOGY, V228, P1, DOI 10.1016/j.tox.2006.07.027
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078 0432.CCR 04 0744
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Surh YJ, 2003, NAT REV CANCER, V3, P768, DOI 10.1038/nrc1189
   Surh YJ, 2000, BIOFACTORS, V12, P107, DOI 10.1002/biof.5520120117
   Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884
   Vyas A, 2013, CURR PHARM DESIGN, V19, P2047
   Wang ZW, 2006, CANCER AM CANCER SOC, V106, P2503, DOI 10.1002/cncr.21904
   Yallapu MM, 2012, DRUG DISCOV TODAY, V17, P71, DOI 10.1016/j.drudis.2011.09.009
   Zambre AP, 2006, BIOORGAN MED CHEM, V14, P7196, DOI 10.1016/j.bmc.2006.06.056
   Zhao CG, 2013, CURR PHARM DESIGN, V19, P2114
NR 49
TC 50
Z9 53
U1 2
U2 29
PU ELSEVIER FRANCE EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0223 5234
EI 1768 3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD JAN
PY 2014
VL 71
BP 67
EP 80
DI 10.1016/j.ejmech.2013.10.073
PG 14
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA AB0QB
UT WOS:000331496100008
PM 24275249
DA 2025 08 17
ER

PT J
AU Tang, CH
   Yang, RS
   Fu, WM
AF Tang, CH
   Yang, RS
   Fu, WM
TI Prostaglandin E2 stimulates fibronectin expression through
   EP1 receptor, phospholipase C, protein kinase Cα, and c Src
   pathway in primary cultured rat osteoblasts
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TYROSINE KINASE; BONE RESORPTION; GROWTH FACTOR; E 2 PGE(2); TGF BETA;
   CLONING; FIBRILLOGENESIS; MECHANISM; SUBTYPES; CAMP
AB Fibronectin (Fn) is involved in the early stages of bone formation, and prostaglandin E (PGE) is an important factor regulating osteogenesis. Here we found that PGE(2) enhanced extracellular Fn assembly in rat primary osteoblasts, as shown by immunofluorescence staining and enzyme linked immunosorbent assay. PGE(2) also increased the protein levels of Fn by using Western blotting analysis. By using pharmacological inhibitors or activators or genetic inhibition by the EP receptor, antisense oligonucleotides revealed that the EP1 receptor but not other PGE receptors is involved in PGE(2) mediated up regulation of Fn. At the mechanistic level, Ca2+ chelator (1,2 bis(2 aminophenoxy) ethane N,N,N ',N ' tetraacetic acid tetrakis(acetoxymethyl ester)), phosphatidylinositol phospholipase C inhibitor (U73122), or Src inhibitor (PP2) attenuated the PGE2 induced Fn expression. Protein kinaseC(PKC) inhibitor (GF109203X) also inhibited the potentiating action of PGE(2). Furthermore, treatment with antisense oligonucleotides of various PKC isoforms, including alpha, beta, epsilon, and delta, demonstrated that alpha isozyme plays an important role in the enhancement action of PGE(2) on Fn assembly. Flow cytometry and reverse transcription PCR showed that PGE(2) and 17 phenyl trinor PGE(2) (EP1/EP3 agonist) increased the surface expression and mRNA level of alpha 5 or beta 1 integrins. Fn promoter activity was enhanced by PGE(2) and 17 phenyl trinor PGE2 in cells transfected with pGL2F1900 Luc. Cotransfection with dominant negative mutants of PKC alpha or c Src inhibited the potentiating action of PGE(2) on Fn promoter activity. Local administration of PGE(2) or 17 phenyl trinor PGE2 into the metaphysis of the tibia via the implantation of a needle cannula significantly increased the Fn and alpha 5 beta 1 integrin immunostaining and bone volume of secondary spongiosa in tibia. Taken together, our results provided evidence that PGE(2) increased Fn and promoted bone formation in rat osteoblasts via the EP1/phospholipase C/PKC alpha/c Src signaling pathway.
C1 Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei, Taiwan.
   Natl Taiwan Univ, Coll Med, Dept Orthopaed, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University
RP Natl Taiwan Univ, Coll Med, Dept Pharmacol, 1,Sect 1,Jen Ai Rd, Taipei, Taiwan.
EM yang@ha.mc.ntu.edu.tw
OI FU, WEN MEI/0000 0003 4157 8987; Yang, Rong Sen/0000 0002 0553 4779
CR AKATSU T, 1989, J BONE MINER RES, V4, P29
   Boie Y, 1997, EUR J PHARMACOL, V340, P227, DOI 10.1016/S0014 2999(97)01383 6
   Burke A, 2002, PROSTAG LEUKOTR ESS, V67, P229, DOI 10.1054/plef.2002.0424
   Canalis Ernesto, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P155
   CLOVER J, 1992, J CELL SCI, V103, P267
   ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092 8674(95)90487 5
   EXTON JH, 1994, BBA LIPID LIPID MET, V1212, P26, DOI 10.1016/0005 2760(94)90186 4
   GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092 8674(90)90098 Y
   Globus RK, 1998, J CELL SCI, V111, P1385
   GRZESIK WJ, 1994, J BONE MINER RES, V9, P487, DOI 10.1002/jbmr.5650090408
   HEINO J, 1993, ANN MED, V25, P335, DOI 10.3109/07853899309147294
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092 8674(92)90115 S
   Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955 0674(93)90030 T
   Kaiser E, 2001, J CELL BIOCHEM, V83, P617, DOI 10.1002/jcb.1256
   Kaneki H, 1999, J CELL BIOCHEM, V73, P36, DOI 10.1002/(SICI)1097 4644(19990401)73:1<36::AID JCB5>3.3.CO;2 6
   KATSUYAMA M, 1995, FEBS LETT, V372, P151, DOI 10.1016/0014 5793(95)00966 D
   Lu WY, 1999, NAT NEUROSCI, V2, P331, DOI 10.1038/7243
   Mo A, 2002, BONE, V31, P402, DOI 10.1016/S8756 3282(02)00835 9
   Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955 0674(92)90104 K
   Moursi AM, 1997, J CELL SCI, V110, P2187
   NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456
   Park YG, 2004, INT J BIOCHEM CELL B, V36, P2270, DOI 10.1016/j.biocel.2004.04.019
   Ping PP, 1999, CIRC RES, V85, P542, DOI 10.1161/01.RES.85.6.542
   POTTS JR, 1994, CURR OPIN CELL BIOL, V6, P648, DOI 10.1016/0955 0674(94)90090 6
   Samoto H, 2003, J BIOL CHEM, V278, P28659, DOI 10.1074/jbc.M300671200
   Southall MD, 2001, J BIOL CHEM, V276, P16083, DOI 10.1074/jbc.M011408200
   Su JL, 2004, CANCER RES, V64, P554, DOI 10.1158/0008 5472.CAN 03 1301
   Suda M, 1996, ENDOCRINOLOGY, V137, P1698, DOI 10.1210/en.137.5.1698
   SUGIMOTO Y, 1992, J BIOL CHEM, V267, P6463
   Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470
   Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554
   Tang CH, 2004, MOL PHARMACOL, V66, P440
   Tang CH, 2003, J BONE MINER RES, V18, P502, DOI 10.1359/jbmr.2003.18.3.502
   WATABE A, 1993, J BIOL CHEM, V268, P20175
   Weinreb M, 2001, BONE, V28, P275, DOI 10.1016/S8756 3282(00)00447 6
   Wierzbicka Patynowski I, 2003, J CELL SCI, V116, P3269, DOI 10.1242/jcs.00670
   WU CY, 1993, J BIOL CHEM, V268, P21883
   YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008
   Yamaguchi T, 2004, J NEUROCHEM, V88, P148, DOI 10.1046/j.1471 4159.2003.02151.x
   Yang RS, 2002, MOL PHARMACOL, V61, P1163, DOI 10.1124/mol.61.5.1163
   Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391
NR 41
TC 90
Z9 105
U1 0
U2 5
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI ROCKVILLE
PA 11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES
SN 0021 9258
EI 1083 351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUN 17
PY 2005
VL 280
IS 24
BP 22907
EP 22916
DI 10.1074/jbc.M500130200
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA 934XB
UT WOS:000229741800044
PM 15833739
OA hybrid
DA 2025 08 17
ER

PT J
AU Iyer, S
   Viernes, DR
   Chisholm, JD
   Margulies, BS
   Kerr, WG
AF Iyer, Sonia
   Viernes, Dennis R.
   Chisholm, John D.
   Margulies, Bryan S.
   Kerr, William G.
TI SHIP1 Regulates MSC Numbers and Their Osteolineage Commitment by
   Limiting Induction of the PI3K/Akt/β Catenin/Id2 Axis
SO STEM CELLS AND DEVELOPMENT
LA English
DT Article
ID HEMATOPOIETIC STEM CELLS; LOOP HELIX PROTEINS; ID PROTEINS; BONE MARROW;
   SELF RENEWAL; RADIATION THERAPY; GROWTH; PROLIFERATION; EXPRESSION;
   DIFFERENTIATION
AB Here, we show that Src homology 2 domain containing inositol 5' phosphatase 1 (SHIP1) is required for the efficient development of osteoblasts from mesenchymal stem cells (MSCs) such that bone growth and density are reduced in mice that lack SHIP1 expression in MSCs. We find that SHIP1 promotes the osteogenic output of MSCs by limiting activation of the PI3K/Akt/beta catenin pathway required for induction of the MSC stemness factor Id2. In parallel, we demonstrate that mice with myeloid restricted ablation of SHIP1, including osteoclasts (OCs), show no reduction in bone mass or density. Hence, diminished bone mass and density in the SHIP1 deficient mice results from SHIP deficiency in MSC and osteolineage progenitors. Intriguingly, mice with a SHIP deficient MSC compartment also exhibit decreased OC numbers. In agreement with our genetic findings we also show that treatment of mice with an SHIP1 inhibitor (SHIPi) significantly reduces bone mass. These findings demonstrate a novel role for SHIP1 in MSC fate determination and bone growth. Further, SHIPi may represent a novel therapeutic approach to limit bone development in osteopetrotic and sclerotic bone diseases.
C1 [Iyer, Sonia; Kerr, William G.] SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA.
   [Viernes, Dennis R.; Chisholm, John D.] Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.
   [Margulies, Bryan S.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA.
   [Kerr, William G.] SUNY Upstate Med Univ, Dept Pediat, Syracuse, NY 13210 USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University; Syracuse University; State University of New York (SUNY)
   System; SUNY Upstate Medical University; State University of New York
   (SUNY) System; SUNY Upstate Medical University
RP Kerr, WG (通讯作者)，SUNY Upstate Med Univ, Dept Microbiol & Immunol, Syracuse, NY 13210 USA.
EM kerrw@upstate.edu
RI Kerr, William/B 8616 2015
OI Kerr, William/0000 0002 4720 7135; Chisholm, John/0000 0001 9518 2393;
   Iyer, Sonia/0000 0003 3840 5583
FU NIH [RO1 HL72523, R01 HL085580, R01 HL107127]; Paige Arnold Butterfly
   Run
FX This work was supported in part by grants from the NIH (RO1 HL72523, R01
   HL085580, and R01 HL107127) and the Paige Arnold Butterfly Run. W.G.K.
   is the Murphy Family Professor of Children's Oncology Research, an
   Empire Scholar of the State University of NY, and a Senior Scholar of
   the Crohn's and Colitis Foundation of America.
CR [Anonymous], PRIMER METABOLIC BON
   [Anonymous], CIBA F SYMP
   Bechard M, 2012, MOL CELL BIOL, V32, P288, DOI 10.1128/MCB.05372 11
   BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092 8674(90)90214 Y
   Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002
   Brooks R, 2010, J IMMUNOL, V184, P3582, DOI 10.4049/jimmunol.0902844
   CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504
   Chell JM, 2010, CELL, V143, P1161, DOI 10.1016/j.cell.2010.12.007
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chung UI, 2001, J CLIN INVEST, V107, P295, DOI 10.1172/JCI11706
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Collazo MM, 2012, EUR J IMMUNOL, V42, P1785, DOI 10.1002/eji.201142092
   CRUZORIVE LM, 1990, AM J PHYSIOL, V258, pL148, DOI 10.1152/ajplung.1990.258.4.L148
   Dacquin R, 2002, DEV DYNAM, V224, P245, DOI 10.1002/dvdy.10100
   Damron TA, 2003, J BONE JOINT SURG AM, V85A, P1302, DOI 10.2106/00004623 200307000 00017
   Desponts C, 2006, BLOOD, V107, P4338, DOI 10.1182/blood 2005 12 5021
   Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008 5472.CAN 10 1028
   Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665
   FRIEDENSTEIN AJ, 1974, EXP HEMATOL, V2, P83
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Fuhler GM, 2012, MOL MED, V18, P65, DOI 10.2119/molmed.2011.00178
   Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518
   Hadjidakis DJ, 2006, ANN NY ACAD SCI, V1092, P385, DOI 10.1196/annals.1365.035
   Hazen AL, 2009, BLOOD, V113, P2924, DOI 10.1182/blood 2008 02 138008
   Helgason CD, 2003, BLOOD, V102, P3541, DOI 10.1182/blood 2002 12 3939
   Hocking LJ, 2001, AM J HUM GENET, V69, P1055, DOI 10.1086/323798
   Houlihan DD, 2012, NAT PROTOC, V7, P2103, DOI 10.1038/nprot.2012.125
   Jögi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200
   Jung S, 2010, STEM CELLS DEV, V19, P831, DOI 10.1089/scd.2009.0093
   Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121
   Kröger N, 2006, BONE MARROW TRANSPL, V37, P183, DOI 10.1038/sj.bmt.1705226
   Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657
   Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093
   Le Belle JE, 2011, CELL STEM CELL, V8, P59, DOI 10.1016/j.stem.2010.11.028
   Li HJ, 2010, BLOOD, V116, P1060, DOI 10.1182/blood 2009 11 255075
   Ma K, 2008, CELL SIGNAL, V20, P684, DOI 10.1016/j.cellsig.2007.12.004
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535 7163.MCT 08 0017
   MARCUS R., 2009, Fundamentals of Osteoporosis
   Margulies BS, 2006, CALCIFIED TISSUE INT, V78, P302, DOI 10.1007/s00223 005 0135 3
   Margulies Bryan, 2003, Am J Clin Oncol, V26, pe106, DOI 10.1097/00000421 200308000 00032
   Margulies BS, 2008, J ORTHOP RES, V26, P1512, DOI 10.1002/jor.20679
   MARTIN TJ, 1994, J CELL BIOCHEM, V56, P357, DOI 10.1002/jcb.240560312
   Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429 440.2000
   Méndez Ferrer S, 2010, NATURE, V466, P829, DOI 10.1038/nature09262
   Morikawa S, 2009, J EXP MED, V206, P2483, DOI 10.1084/jem.20091046
   Norton JD, 2000, J CELL SCI, V113, P3897
   Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962 8924(97)01183 5
   O'Toole PJ, 2003, J BIOL CHEM, V278, P45770, DOI 10.1074/jbc.M306056200
   Ojeda L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023414
   Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013
   Pan HJ, 2010, J IMMUNOL, V184, P5502, DOI 10.4049/jimmunol.0901601
   Paolella BR, 2011, STEM CELLS, V29, P1090, DOI 10.1002/stem.660
   Park KW, 2008, MOL ENDOCRINOL, V22, P2038, DOI 10.1210/me.2007 0454
   Pateder DB, 2000, EXP CELL RES, V256, P555, DOI 10.1006/excr.2000.4860
   Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500
   Peng Y, 2004, J BIOL CHEM, V279, P32941, DOI 10.1074/jbc.M403344200
   Perry JM, 2011, GENE DEV, V25, P1928, DOI 10.1101/gad.17421911
   Pinho S, 2013, J EXP MED, V210, P1351, DOI 10.1084/jem.20122252
   Rodda SJ, 2006, DEVELOPMENT, V133, P3231, DOI 10.1242/dev.02480
   Schepers K, 2012, BLOOD, V120, P3425, DOI 10.1182/blood 2011 11 395418
   Sewell GW, 2009, CURR OPIN IMMUNOL, V21, P506, DOI 10.1016/j.coi.2009.06.003
   Takeshita S, 2002, NAT MED, V8, P943, DOI 10.1038/nm752
   Tan XH, 2007, J CELL SCI, V120, P2162, DOI 10.1242/jcs.03466
   Teitelbaum SL, 2003, NAT REV GENET, V4, P638, DOI 10.1038/nrg1122
   Tu Z, 2001, BLOOD, V98, P2028, DOI 10.1182/blood.V98.7.2028
   Wall JE, 1996, ORTHOPEDICS, V19, P657
   Wang HX, 2013, CRIT REV ONCOL HEMAT, V85, P1, DOI 10.1016/j.critrevonc.2012.05.004
   Wang JW, 2002, SCIENCE, V295, P2094, DOI 10.1126/science.1068438
   Welham MJ, 2007, BIOCHEM SOC T, V35, P225, DOI 10.1042/BST0350225
   Williams SA, 2011, CELL, V146, P917, DOI 10.1016/j.cell.2011.07.040
   Wilsman NJ, 1996, J ORTHOP RES, V14, P927, DOI 10.1002/jor.1100140613
   Winkler IG, 2010, BLOOD, V116, P375, DOI 10.1182/blood 2009 07 233437
   Yamashita T, 2012, WORLD J ORTHOP, V3, P175, DOI 10.5312/wjo.v3.i11.175
   Yilmaz ÖH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703
   Yoon KA, 2012, STEM CELLS DEV, V21, P3391, DOI 10.1089/scd.2012.0128
   Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092
   Zhang JW, 2006, NATURE, V441, P518, DOI 10.1038/nature04747
   Zhang Q, 2011, MOLECULES, V16, P10146, DOI 10.3390/molecules161210146
   Zhu H, 2010, NAT PROTOC, V5, P550, DOI 10.1038/nprot.2009.238
NR 79
TC 23
Z9 26
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1547 3287
EI 1557 8534
J9 STEM CELLS DEV
JI Stem Cells Dev.
PD OCT 1
PY 2014
VL 23
IS 19
BP 2336
EP 2351
DI 10.1089/scd.2014.0122
PG 16
WC Cell & Tissue Engineering; Hematology; Medicine, Research &
   Experimental; Transplantation
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Hematology; Research & Experimental Medicine;
   Transplantation
GA AP5XJ
UT WOS:000342151700007
PM 24857423
OA Green Published
DA 2025 08 17
ER

PT J
AU Buenning, ME
   Bielfeldt, M
   Nebe, B
   Staehlke, S
AF Buenning, Maren E.
   Bielfeldt, Meike
   Nebe, Barbara
   Staehlke, Susanne
TI Short Time Alternating Current Electrical Stimulation and Cell
   Membrane Related Components
SO APPLIED SCIENCES BASEL
LA English
DT Article
DE electrical stimulation; alternating current; IonOptix system; confocal
   microscopy; Litesizer; zeta potential; particle size; osteoblasts;
   aquaporins; hyaluronan
ID MATRIX ADHESION; TITANIUM; PROLIFERATION; ORGANIZATION; PROTEINS
AB Featured Application Physical factors such as light, mechanical forces, physical plasma, but especially the electric field derived from a direct or alternating current, are potent stimuli for cells finally being able to regenerate human tissues. The demand for effective regenerative therapies is increasing due to aging populations. Electrical stimulation is operated, i.e., in bones (medical implants), the brain (movement disorders), muscles (rehabilitation), and connective tissue (skin wounds). Although this has been successfully carried out, the mechanism of action still needs to be fully understood.Abstract Electrical stimulation (ES) and its effects on biological systems is an area of research in regenerative medicine. The focus here is on the mechanism of action of ES on cell membrane related components. A short alternating current (AC) stimulation (10 min) was applied on suspended human MG 63 osteoblasts via a commercially available multi channel system (IonOptix). The pulsed ES with 1 V or 5 V and frequencies of 20 Hz on cells was performed immediately after cell seeding. The in vitro investigations were conducted by microscopy, flow cytometry, and particle analysis via a Litesizer within 24 h. The short time ES with the parameter 1 V and 20 Hz was beneficial for the process of cell attachment, which could be related to an enhanced deposition of fibronectin on the glass bottom from the protein containing medium (10% FBS). The MG 63 cells' spherical coat hyaluronan remained constant and did not contribute to this AC triggered adhesion. In this context, the cells' zeta potential also did not play a role. The membrane potential analyzed via DiBAC4(3) was unchanged. Only the aquaporin channel AQP 8 in the cell membrane was significantly enhanced. Suspended cells in an AC electric field were activated during their settlement, and the fibronectin adsorption on the bottom contributed to this effect but not the membrane related components.
C1 [Buenning, Maren E.; Bielfeldt, Meike; Nebe, Barbara; Staehlke, Susanne] Rostock Univ Med Ctr, Inst Cell Biol, D 18057 Rostock, Germany.
   [Nebe, Barbara] Univ Rostock, Dept Life Light & Matter, D 18051 Rostock, Germany.
C3 University of Rostock
RP Staehlke, S (通讯作者)，Rostock Univ Med Ctr, Inst Cell Biol, D 18057 Rostock, Germany.
EM meike.bielfeldt@med.uni rostock.de; barbara.nebe@med.uni rostock.de;
   susanne.staehlke@med.uni rostock.de
OI Bunning, Maren Elisabeth/0009 0001 9033 1801; Stahlke,
   Susanne/0000 0002 0251 8263; Bielfeldt, Meike/0000 0003 4200 4934
FU Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)
FX We are grateful for the support of Julius Zimmermann (Institute of
   General Electrical Engineering, University of Rostock, Germany, now:
   University of Pavia, Italy). We acknowledge Christian Fettkenhauer
   (Anton Paar Germany GmbH) concerning his excellent support for Litesizer
   measurements. Furthermore, we would also like to thank Thomas Freitag
   (Bachelor thesis, Institute for Cell Biology, Rostock University Medical
   Center) for his work on cell vitality under ES.
CR Adan A, 2017, CRIT REV BIOTECHNOL, V37, P163, DOI 10.3109/07388551.2015.1128876
   Benavidez TE, 2015, LANGMUIR, V31, P2455, DOI 10.1021/la504890v
   Budde K, 2019, IEEE ENG MED BIO, P1082, DOI [10.1109/EMBC.2019.8856863, 10.1109/embc.2019.8856863]
   Busse JW, 2008, ACTA ORTHOP, V79, P689, DOI 10.1080/17453670810016722
   Chen C, 2019, BIOMATER RES, V23, DOI 10.1186/s40824 019 0176 8
   Chidawanyika Tamutenda, 2021, J Cell Signal, V2, P206, DOI 10.33696/signaling.2.052
   Cifuentes M, 2011, J CELL PHYSIOL, V226, P1425, DOI 10.1002/jcp.22668
   Cohen M, 2006, EMBO J, V25, P302, DOI 10.1038/sj.emboj.7600960
   DEAN DD, 1994, CALCIFIED TISSUE INT, V54, P399, DOI 10.1007/BF00305527
   Demais V., 2014, Morphologie, V98, P53, DOI 10.1016/j.morpho.2014.02.003
   Edamana S, 2021, AM J PHYSIOL CELL PH, V320, pC771, DOI 10.1152/ajpcell.00608.2020
   Eischen Loges M, 2018, PEERJ, V6, DOI 10.7717/peerj.4959
   Ercan B, 2010, BIOMATERIALS, V31, P3684, DOI 10.1016/j.biomaterials.2010.01.078
   Ercan B, 2008, INT J NANOMED, V3, P477
   Finke B, 2007, BIOMATERIALS, V28, P4521, DOI 10.1016/j.biomaterials.2007.06.028
   Freshney RI., 2010, Culture of Animal Cells: A Manual of Basic Technique and Specialized Applications, V6th, P1, DOI [10.1002/9780470649367, DOI 10.1002/9780470649367]
   FUKADA E, 1957, J PHYS SOC JPN, V12, P1158, DOI 10.1143/JPSJ.12.1158
   Gera N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125269
   Giladi M, 2015, SCI REP UK, V5, DOI 10.1038/srep18046
   Giladi M, 2014, PANCREATOLOGY, V14, P54, DOI 10.1016/j.pan.2013.11.009
   Griffin Michelle, 2011, Eplasty, V11, pe34
   GRINNELL F, 1979, CELL, V17, P117, DOI 10.1016/0092 8674(79)90300 3
   Gruening M, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.01016
   Haglin JM, 2017, JBJS REV, V5, DOI 10.2106/JBJS.RVW.16.00117
   Hoentsch M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104559
   Hynes RO, 1999, P NATL ACAD SCI USA, V96, P2588, DOI 10.1073/pnas.96.6.2588
   Jin G, 2015, J BIOMED MATER RES B, V103, P935, DOI 10.1002/jbm.b.33268
   Khitrin AK, 2014, CHEM PHYS LIPIDS, V184, P76, DOI 10.1016/j.chemphyslip.2014.10.005
   Leif Robert C., 1986, Cytometry, V7, P111, DOI DOI 10.1002/CYTO.990070119
   Leppik L, 2020, EUR J TRAUMA EMERG S, V46, P231, DOI 10.1007/s00068 020 01324 1
   Love MR, 2018, J CELL PHYSIOL, V233, P1860, DOI 10.1002/jcp.25975
   Lüthen F, 2005, BIOMATERIALS, V26, P2423, DOI 10.1016/j.biomaterials.2004.07.054
   Mobasheri A, 2005, J MOL HISTOL, V36, P1, DOI 10.1007/s10735 004 2633 4
   Mobini S, 2017, PEERJ, V5, DOI 10.7717/peerj.2821
   Mobini S, 2016, BIOTECHNIQUES, V60, P95, DOI 10.2144/000114382
   Nebe B, 2007, BIOMOL ENG, V24, P447, DOI 10.1016/j.bioeng.2007.07.004
   Nicksic PJ, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.793945
   O'Hearn Sean F, 2016, Biochem Biophys Rep, V8, P249, DOI 10.1016/j.bbrep.2016.09.004
   Pettersen E, 2022, J NEUROENG REHABIL, V19, DOI 10.1186/s12984 022 01005 7
   Pettersen E, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 01901 3
   Rodrigues C, 2019, CANCERS, V11, DOI 10.3390/cancers11070932
   Sahm F, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.965181
   Saldaña L, 2011, ACTA BIOMATER, V7, P4210, DOI 10.1016/j.actbio.2011.07.019
   Shteingauz A, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419 018 1085 9
   Snuggs JW, 2021, SCI REP UK, V11, DOI 10.1038/s41598 021 81838 9
   Snuggs JW, 2019, JOR SPINE, V2, DOI 10.1002/jsp2.1049
   Staehlke S, 2022, CELLS BASEL, V11, DOI 10.3390/cells11172650
   Staehlke S, 2019, CELL BIOL INT, V43, P22, DOI 10.1002/cbin.11073
   Sun S, 2007, FASEB J, V21, P1472, DOI 10.1096/fj.06 7153com
   Thannickal VJ, 2000, AM J PHYSIOL LUNG C, V279, pL1005
   Vasquez Sancho F, 2018, ADV MATER, V30, DOI 10.1002/adma.201705316
   Vohra S, 2008, J MATER SCI MATER M, V19, P3567, DOI 10.1007/s10856 008 3525 z
   Xian MY, 2022, COLLOID SURFACE B, V209, DOI 10.1016/j.colsurfb.2021.112158
   Zannetti A, 2020, CELLS BASEL, V9, DOI 10.3390/cells9122678
   Zimmerman E, 2002, BIOPHYS J, V82, P1848, DOI 10.1016/S0006 3495(02)75535 5
NR 55
TC 1
Z9 1
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2076 3417
J9 APPL SCI BASEL
JI Appl. Sci. Basel
PD JAN
PY 2024
VL 14
IS 2
AR 812
DI 10.3390/app14020812
PG 14
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA FY2Z1
UT WOS:001149360300001
OA gold
DA 2025 08 17
ER

PT J
AU Toyama, T
   Todoki, K
   Takahashi, Y
   Watanabe, K
   Takahashi, S
   Sugiyama, S
   Lee, MCI
   Hamada, N
AF Toyama, Toshizo
   Todoki, Kazuo
   Takahashi, Yusuke
   Watanabe, Kiyoko
   Takahashi, Shun suke
   Sugiyama, Shuta
   Lee, Masaichi Chang il
   Hamada, Nobushiro
TI Inhibitory effects of Jixueteng on P.
   gingivalis induced bone loss and osteoclast differentiation
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE Jixueteng; Bone resorption; P. gingivalis; Periodontitis
ID ( ) EPIGALLOCATECHIN GALLATE; PERIODONTITIS; INDUCTION; BACTERIUM;
   EXTRACTS; GROWTH
AB Objective: The aim of this study was to investigate the possibility of Jixueteng as a preventive and therapeutic drug for the periodontitis. We investigated the inhibitory effects of Jixueteng on Porphyromonas gingivalis induced bone loss in mice, antibacterial activity against P. gingivalis and differentiation of osteoclast and viability of cells.
   Materials and methods: Fifty four male, 4 week old C57BL/6N mice, were randomly divided into the following three groups of 18 mice each; group A served as the P. gingivalis noninfected control (sham group), group B was infected orally with P. gingivalis and group C was administered Jixueteng extract in drinking water and was then infected with P. gingivalis. In order to evaluate the effect of Jixueteng, the distance from the alveolar bone crest to the cemento enamel junction was determined. P. gingivalis suspension was exposed for 1, 15 and 60 min to 5 ml of the Jixueteng extract. Furthermore, to clarify the mechanism of the inhibitory effects of Jixueteng on osteoclast formation, Jixueteng extract was added to the culture of mouse bone marrow cells, osteoclast precursor.
   Results: Administration of Jixueteng along with P. gingivalis infection significantly reduced alveolar bone loss compared to P. gingivalis infection. Jixueteng treatment at the concentration of 0.01% significantly inhibited osteoclast formation. The addition of Jixueteng extract (0.1%, 0.01%, and 0.001%) to the culture showed a significant inhibition of the number of surviving osteoclasts in a dose dependent manner.
   Conclusion: Jixueteng has an antibacterial activity against P. gingivalis and inhibitory effects on osteoclastogenesis, it may be useful as a therapeutic drug in the treatment of P. gingivalis induced periodontitis. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Toyama, Toshizo; Takahashi, Yusuke; Watanabe, Kiyoko; Hamada, Nobushiro] Kanagawa Dent Coll, Dept Infect Control, Div Microbiol, Yokosuka, Kanagawa 2388580, Japan.
   [Todoki, Kazuo] Shonan Coll, Dept Nursing, Yokosuka, Kanagawa 2388580, Japan.
   [Takahashi, Shun suke; Sugiyama, Shuta; Lee, Masaichi Chang il] Kanagawa Dent Coll, Dept Clin Care Med, Div Pharmacol, Yokosuka, Kanagawa 2388580, Japan.
   [Takahashi, Shun suke; Sugiyama, Shuta; Lee, Masaichi Chang il] Kanagawa Dent Coll, Dept Clin Care Med, ESR Lab, Yokosuka, Kanagawa 2388580, Japan.
C3 Kanagawa Dental College; Kanagawa Dental College; Kanagawa Dental
   College
RP Hamada, N (通讯作者)，Kanagawa Dent Coll, Dept Infect Control, Div Microbiol, 82 Inaoka Cho, Yokosuka, Kanagawa 2388580, Japan.
EM hamadano@kdcnet.ac.jp
FU Grants in Aid for Scientific Research [23593073] Funding Source: KAKEN
CR Amano A, 2000, J DENT RES, V79, P1664, DOI 10.1177/00220345000790090501
   Ashimoto A, 1996, ORAL MICROBIOL IMMUN, V11, P266, DOI 10.1111/j.1399 302X.1996.tb00180.x
   Baker PJ, 1999, INFECT IMMUN, V67, P2804, DOI 10.1128/IAI.67.6.2804 2809.1999
   Cheng XL, 2011, J CHROMATOGR A, V1218, P5774, DOI 10.1016/j.chroma.2011.06.091
   Corbet EF, 2011, PERIODONTOL 2000, V56, P25, DOI 10.1111/j.1600 0757.2010.00362.x
   Cui Yan jun, 2002, Yaoxue Xuebao, V37, P784
   Darveau RP, 1997, PERIODONTOL 2000, V14, P12, DOI 10.1111/j.1600 0757.1997.tb00190.x
   Hamada N, 2007, J PERIODONTOL, V78, P933, DOI 10.1902/jop.2007.060245
   HAMADA S, 1980, MICROBIOL REV, V44, P331, DOI 10.1128/MMBR.44.2.331 384.1980
   Hamilton Miller JMT, 2001, J MED MICROBIOL, V50, P299, DOI 10.1099/0022 1317 50 4 299
   Hietala EL, 1998, J DENT RES, V77, P1384, DOI 10.1177/00220345980770060201
   HOLT SC, 1988, SCIENCE, V239, P55, DOI 10.1126/science.3336774
   Huang KC, 1993, PHARM CHINESE HERBS, P146
   Jimi E, 1999, EXP CELL RES, V247, P84, DOI 10.1006/excr.1998.4320
   Lam TL, 2000, LIFE SCI, V67, P2889, DOI 10.1016/S0024 3205(00)00864 X
   Lee JH, 2007, VACCINE, V25, P3834, DOI 10.1016/j.vaccine.2007.01.108
   Li MY, 2008, ARCH PHARM RES, V31, P640, DOI 10.1007/s12272 001 1206 5
   Li RW, 2003, J ETHNOPHARMACOL, V85, P61, DOI 10.1016/S0378 8741(02)00339 2
   Liao H, 2008, EVID BASED COMPL ALT, V5, P429, DOI 10.1093/ecam/nem054
   Lin M, 1989, CHIN TRADIT HERBAL D, V20, P53
   Liu XT, 2007, PLANTA MED, V73, P84, DOI 10.1055/s 2006 951773
   Maeda Yamamoto M, 2003, J AGR FOOD CHEM, V51, P1858, DOI 10.1021/jf021039l
   Matsunaga T, 2010, BIOSCI BIOTECH BIOCH, V74, P2445, DOI 10.1271/bbb.100499
   Morgan TD, 2001, J APPL MICROBIOL, V90, P53, DOI 10.1046/j.1365 2672.2001.01217.x
   Nakamura T, 2007, CELL, V130, P811, DOI 10.1016/j.cell.2007.07.025
   Offenbacher S, 1996, Ann Periodontol, V1, P821, DOI 10.1902/annals.1996.1.1.821
   Pederson L, 1997, J BONE MINER RES, V12, P742, DOI 10.1359/jbmr.1997.12.5.742
   Potterat Olivier, 2008, V65
   Rose LF, 2000, PERIODONTAL MED, P172
   Sakanaka S, 1996, BIOSCI BIOTECH BIOCH, V60, P745, DOI 10.1271/bbb.60.745
   SOCRANSKY SS, 1970, J DENT RES, V49, P203, DOI 10.1177/00220345700490020401
   STOUFI ED, 1987, J CLIN IMMUNOL, V7, P235, DOI 10.1007/BF00915729
   Su E Y, 1997, Zhongguo Zhong Xi Yi Jie He Za Zhi, V17, P213
   Tang Y, 2007, CHINESE J EXPT TRADI, V13, P51
   Taubman MA, 2001, CRIT REV ORAL BIOL M, V12, P125, DOI 10.1177/10454411010120020301
   Teng YTA, 2000, J CLIN INVEST, V106, pR59, DOI 10.1172/JCI10763
   Wang DX, 2008, CHINESE MED J PEKING, V121, P752, DOI 10.1097/00029330 200804020 00018
   Wang KH, 2006, J ETHNOPHARMACOL, V106, P353, DOI 10.1016/j.jep.2006.01.010
   Yun JH, 2007, J PERIODONTAL RES, V42, P212, DOI 10.1111/j.1600 0765.2006.00935.x
   Yun JH, 2004, J PERIODONTAL RES, V39, P300, DOI 10.1111/j.1600 0765.2004.00743.x
NR 40
TC 12
Z9 12
U1 0
U2 17
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003 9969
EI 1879 1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD NOV
PY 2012
VL 57
IS 11
BP 1529
EP 1536
DI 10.1016/j.archoralbio.2012.05.011
PG 8
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA 050IO
UT WOS:000312047200010
PM 22749496
DA 2025 08 17
ER

PT J
AU Yoshida, S
   Ikedo, A
   Yanagihara, Y
   Sakaue, T
   Saeki, N
   Imai, Y
AF Yoshida, Shuhei
   Ikedo, Aoi
   Yanagihara, Yuta
   Sakaue, Tomohisa
   Saeki, Noritaka
   Imai, Yuuki
TI Bub1 suppresses inflammatory arthritis associated bone loss in mice
   through inhibition of TNFα mediated osteoclastogenesis
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE rheumatoid arthritis; bone metabolism; osteoclasts; Bub1; NF kappa B
ID RHEUMATOID ARTHRITIS; GENE THERAPY; DIFFERENTIATION; PHOSPHORYLATION;
   ACTIVATION; INCREASES; PROVIDES; RECEPTOR; DENSITY; EROSION
AB Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovitis, bone and cartilage destruction, and increased fracture risk with bone loss. Although disease modifying antirheumatic drugs have dramatically improved clinical outcomes, these therapies are not universally effective in all patients because of the heterogeneity of RA pathogenesis. Therefore, it is necessary to elucidate the molecular mechanisms underlying RA pathogenesis, including associated bone loss, in order to identify novel therapeutic targets. In this study, we found that Budding uninhibited by benzimidazoles 1 (BUB1) was highly expressed in RA patients' synovium and murine ankle tissue with arthritis. As CD45(+)CD11b(+) myeloid cells are a Bub1 highly expressing population among synovial cells in mice, myeloid cell specific Bub1 conditional knockout (Bub1(Delta LysM)) mice were generated. Bub1(Delta LysM) mice exhibited reduced femoral bone mineral density when compared with control (Ctrl) mice under K/BxN serum transfer arthritis, with no significant differences in joint inflammation or bone erosion based on a semi quantitative erosion score and histological analysis. Bone histomorphometry revealed that femoral bone mass of Bub1(Delta LysM) under arthritis was reduced by increased osteoclastic bone resorption. RNA seq and subsequent Gene Set Enrichment Analysis demonstrated a significantly enriched nuclear factor kappa B pathway among upregulated genes in receptor activator of nuclear factor kappa B ligand (RANKL) stimulated bone marrow derived macrophages (BMMs) obtained from Bub1(Delta LysM) mice. Indeed, osteoclastogenesis using BMMs derived from Bub1(Delta LysM) was enhanced by RANKL and tumor necrosis factor alpha or RANKL and IL 1 beta treatment compared with Ctrl. Finally, osteoclastogenesis was increased by Bub1 inhibitor BAY1816032 treatment in BMMs derived from wildtype mice. These data suggest that Bub1 expressed in macrophages plays a protective role against inflammatory arthritis associated bone loss through inhibition of inflammation mediated osteoclastogenesis.
C1 [Yoshida, Shuhei; Imai, Yuuki] Ehime Univ, Grad Sch Med, Dept Pathophysiol, Toon, Ehime 7910295, Japan.
   [Ikedo, Aoi; Yanagihara, Yuta; Saeki, Noritaka; Imai, Yuuki] Ehime Univ, Div Integrat Pathophysiol, Toon, Ehime 7910295, Japan.
   [Sakaue, Tomohisa] Ehime Univ, Grad Sch Med, Dept Cardiovasc & Thorac Surg, Toon, Ehime 7910295, Japan.
   [Sakaue, Tomohisa] Ehime Univ, Proteo Sci Ctr PROS, Div Cell Growth & Tumor Regulat, Toon, Ehime 7910295, Japan.
   [Saeki, Noritaka] Ehime Univ, Div Med Res Support, Toon, Ehime 7910295, Japan.
C3 Ehime University; Ehime University; Ehime University; Ehime University;
   Ehime University
RP Imai, Y (通讯作者)，Ehime Univ, Grad Sch Med, Dept Pathophysiol, Toon, Ehime 7910295, Japan.; Imai, Y (通讯作者)，Ehime Univ, Div Integrat Pathophysiol, Toon, Ehime 7910295, Japan.
EM h447031z@mails.cc.ehime u.ac.jp; aikedo@m.ehime u.ac.jp;
   yanagihara.yuta.mu@ehime u.ac.jp; sakaue@m.ehime u.ac.jp;
   nsaeki@m.ehime u.ac.jp; y imai@m.ehime u.ac.jp
RI Imai, Yuuki/ABC 4687 2020; Saeki, Noritaka/AAK 8797 2021
OI Ikedo, Aoi/0009 0006 2927 6520
FU Japan Society for the Promotion of Science (JSPS) KAKENHI; Center
   (ADRES); Grants in Aid for Scientific Research [21K05974] Funding
   Source: KAKEN
FX We gratefully thank the members of the Advanced Research Support Center
   (ADRES) and the members of the Division of Integrative Pathophysiology,
   Proteo Science Center (PROS) of Ehime University for their technical
   assistance and helpful support.
CR Arai F, 1999, J EXP MED, V190, P1741, DOI 10.1084/jem.190.12.1741
   Bécède M, 2019, SEMIN ARTHRITIS RHEU, V49, P211, DOI 10.1016/j.semarthrit.2019.02.004
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Broeren MGA, 2016, HUM GENE THER, V27, P244, DOI 10.1089/hum.2015.127
   BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466
   Christensen AD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00213
   Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805
   Geurts J, 2009, MOL THER, V17, P1877, DOI 10.1038/mt.2009.182
   Godina Gonzalez S, 2010, INFLAMM RES, V59, P1041, DOI 10.1007/s00011 010 0224 2
   Hasegawa T, 2019, NAT IMMUNOL, V20, P1631, DOI 10.1038/s41590 019 0526 7
   Haugeberg G, 2000, ARTHRITIS RHEUM, V43, P522, DOI 10.1002/1529 0131(200003)43:3<522::AID ANR7>3.0.CO;2 Y
   Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008 5472.CAN 06 3326
   Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015
   Juhász B, 2017, OSTEOPOROSIS INT, V28, P1271, DOI 10.1007/s00198 016 3850 x
   Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500
   Kawashima SA, 2010, SCIENCE, V327, P172, DOI 10.1126/science.1180189
   Kim T, 2021, ANIM CELLS SYST, V25, P1, DOI 10.1080/19768354.2021.1884599
   Kocijan R, 2014, J BONE MINER RES, V29, P1005, DOI 10.1002/jbmr.2109
   Komatsu N, 2022, NAT REV RHEUMATOL, V18, P415, DOI 10.1038/s41584 022 00793 5
   Kondo N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010922
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Maeda Y, 2017, J BONE MINER RES, V32, P461, DOI 10.1002/jbmr.3005
   Miyauchi Y, 2010, J EXP MED, V207, P751, DOI 10.1084/jem.20091957
   Nyati S, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005379
   O'Brien W, 2016, ARTHRITIS RHEUMATOL, V68, P2889, DOI 10.1002/art.39837
   Okamoto K, 2017, PHYSIOL REV, V97, P1295, DOI 10.1152/physrev.00036.2016
   Pandolfi F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155238
   Perera D, 2007, DEV CELL, V13, P566, DOI 10.1016/j.devcel.2007.08.008
   Prieto C, 2020, BIOINFORMATICS, V36, P1955, DOI 10.1093/bioinformatics/btz854
   Saeki N, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI150533
   Saeki N, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964 020 00678 8
   Schett G, 2012, NAT REV RHEUMATOL, V8, P656, DOI 10.1038/nrrheum.2012.153
   Siemeister G, 2019, CLIN CANCER RES, V25, P1404, DOI 10.1158/1078 0432.CCR 18 0628
   Smolen JS, 2016, LANCET, V388, P2023, DOI 10.1016/S0140 6736(16)30173 8
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031
   Tilston Valerie, 2009, BMC Res Notes, V2, P190, DOI 10.1186/1756 0500 2 190
   Tsukasaki M, 2019, NAT REV IMMUNOL, V19, P626, DOI 10.1038/s41577 019 0178 8
   Walsh AM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183928
   Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood 2003 06 2158
   Weissmann G, 2006, BULL HOSP JT DIS, V64, P12
   Williams GL, 2007, CELL CYCLE, V6, P1699, DOI 10.4161/cc.6.14.4493
   Wright NC, 2011, J RHEUMATOL, V38, P1680, DOI 10.3899/jrheum.101196
   Yamamoto Y, 2013, ENDOCRINOLOGY, V154, P1008, DOI 10.1210/en.2012 1542
   Yamanaka H, 2020, MOD RHEUMATOL, V30, P1, DOI 10.1080/14397595.2019.1660028
   Yao ZQ, 2022, CELLS BASEL, V11, DOI 10.3390/cells11010132
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Yokota K, 2014, ARTHRITIS RHEUMATOL, V66, P121, DOI 10.1002/art.38218
   Zhao BH, 2009, NAT MED, V15, P1066, DOI 10.1038/nm.2007
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467 019 09234 6
   Zhu LJ, 2020, ONCOL LETT, V19, P3506, DOI 10.3892/ol.2020.11445
NR 52
TC 5
Z9 5
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD APR 19
PY 2024
VL 39
IS 3
DI 10.1093/jbmr/zjae015
EA MAR 2024
PG 15
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA OF0X3
UT WOS:001205744400001
PM 38477771
OA hybrid
DA 2025 08 17
ER

PT J
AU Brown, TJ
   Barrett, N
   Meng, H
   Ricciotti, E
   McDonnell, C
   Dancis, A
   Qualtieri, J
   FitzGerald, GA
   Cotter, M
   Babushok, DV
AF Brown, Timothy J.
   Barrett, Neil
   Meng, Hu
   Ricciotti, Emanuela
   McDonnell, Ciara
   Dancis, Andrew
   Qualtieri, Julianne
   FitzGerald, Garret A.
   Cotter, Melanie
   V. Babushok, Daria
TI Nonsteroidal anti inflammatory drugs as a targeted therapy for bone
   marrow failure in Ghosal hematodiaphyseal dysplasia
SO BLOOD
LA English
DT Article
ID THROMBOXANE SYNTHASE INHIBITION; PROSTAGLANDIN ENDOPEROXIDES; DIAPHYSEAL
   DYSPLASIA; ANEMIA; CELLS
AB Advances in genomic diagnostics hold promise for improved care of rare hematologic diseases. Here, we describe a novel targeted therapeutic approach for Ghosal hema todiaphyseal dysplasia, an autosomal recessive disease characterized by severe normo cytic anemia and bone abnormalities due to loss of function mutations in thromboxane A synthase 1 (TBXAS1). TBXAS1 metabolizes prostaglandin H2 (PGH2), a cyclooxygenase (COX) product of arachidonic acid, into thromboxane A2. Loss of function mutations in TBXAS result in an increase in PGH2 availability for other PG synthases. The current treatment for Ghosal hematodiaphyseal dysplasia syndrome consists of corticosteroids. We hypothesize that nonsteroidal anti inflammatory drugs (NSAIDs), which inhibit COX 1 and COX 2, could ameliorate the effects of TBXAS1 loss and improve hematologic func tion by reducing prostaglandin formation. We treated 2 patients with Ghosal hema todiaphyseal dysplasia syndrome, an adult and a child, with standard doses of NSAIDs (aspirin or ibuprofen). Both patients had rapid improvements concerning hematologic parameters and inflammatory markers without adverse events. Mass spectrometry analysis demonstrated that urinary PG metabolites were increased along with proin flammatory lipoxygenase (LOX) products 5 hydroxyeicosatetraenoic acid and leukotriene E4. Our data show that NSAIDs at standard doses surprisingly reduced both COX and LOX products, leading to the resolution of cytopenia, and should be considered for first line treatment for Ghosal hematodiaphyseal dysplasia syndrome.
C1 [Brown, Timothy J.; Dancis, Andrew; V. Babushok, Daria] Hosp Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA USA.
   [Barrett, Neil; Cotter, Melanie] Childrens Hlth Ireland Temple St Crumlin, Paediat Haematol, Dublin, Ireland.
   [Meng, Hu; Ricciotti, Emanuela; FitzGerald, Garret A.] Univ Penn, Inst Translat Med & Therapeut, Perelman Sch Med, Philadelphia, PA USA.
   [Ricciotti, Emanuela] Univ Penn, Perelman Sch Med, Dept Syst Pharmacol & Translat Therapeut, Philadelphia, PA USA.
   [McDonnell, Ciara] Childrens Hlth Ireland Temple St Crumlin, Dublin, Ireland.
   [McDonnell, Ciara] Univ Dublin, Trinity Coll Dublin, Discipline Paediat, Dublin, Ireland.
   [Qualtieri, Julianne] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA.
   [V. Babushok, Daria] Childrens Hosp Philadelphia, Comprehens Bone Marrow Failure Ctr, Philadelphia, PA USA.
   [Cotter, Melanie] Childrens Hlth Ireland Temple St Crumlin, Dublin, Ireland.
   [V. Babushok, Daria] Biomed Res Bldg,Room 808,421 Curie Blvd, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; University of Pennsylvania; University of
   Pennsylvania; Trinity College Dublin; University of Pennsylvania;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia
RP Cotter, M (通讯作者)，Childrens Hlth Ireland Temple St Crumlin, Dublin, Ireland.; Babushok, DV (通讯作者)，Biomed Res Bldg,Room 808,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM melanie.cotter@cuh.ie; daria.babushok@pennmedicine.upenn.edu
RI Ricciotti, Emanuela/AAH 2729 2019; Brown, Timothy/AAA 3151 2022
OI McDonnell, Ciara/0000 0001 9414 5873; Babushok,
   Daria/0000 0002 1745 0353; 
FU National Institutes of Health [T32CA009679, L30CA274783,
   R03HL160678 01]; American Society of Hematology Scholar Awards
FX This work was supported by the National Institutes of Health (grant
   T32CA009679 and L30CA274783) (T.J.B.) , (grant R03HL160678 01) , and
   (American Society of Hematology Scholar Awards) (D.V.B.) . G.A.F. is the
   McNeil Professor of Translational Medicine and Therapeutics.
CR Arora R, 2015, SKELETAL RADIOL, V44, P447, DOI 10.1007/s00256 014 1989 0
   Ciftciler R, 2019, TRANSFUS APHER SCI, V58, P449, DOI 10.1016/j.transci.2019.04.027
   Datta K, 2013, INDIAN J PEDIATR, V80, P1050, DOI 10.1007/s12098 012 0872 z
   FITZGERALD DJ, 1988, J CLIN INVEST, V82, P1708, DOI 10.1172/JCI113784
   FITZGERALD GA, 1985, CIRCULATION, V72, P1194, DOI 10.1161/01.CIR.72.6.1194
   FITZGERALD GA, 1983, CIRCULATION, V67, P1174, DOI 10.1161/01.CIR.67.6.1174
   Geneviève D, 2008, NAT GENET, V40, P284, DOI 10.1038/ng.2007.66
   GHOSAL S P, 1957, Indian J Pediatr, V24, P359, DOI 10.1007/BF02902979
   GHOSAL SP, 1988, J PEDIATR US, V113, P49, DOI 10.1016/S0022 3476(88)80527 4
   Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015
   Hagedorn EJ, 2014, EXP CELL RES, V329, P220, DOI 10.1016/j.yexcr.2014.07.030
   Jeevan A, 2016, INDIAN PEDIATR, V53, P347, DOI 10.1007/s13312 016 0851 y
   Joy P, 2021, AM J MED GENET A, V185, P596, DOI 10.1002/ajmg.a.61961
   Kim SY, 2021, MOL GENET GENOM MED, V9, DOI 10.1002/mgg3.1494
   Kini PG, 2018, INDIAN J HEMATOL BLO, V34, P181, DOI 10.1007/s12288 017 0818 8
   LORENZ RL, 1986, BIOCHEM PHARMACOL, V35, P761, DOI 10.1016/0006 2952(86)90243 1
   Mazaheri P, 2010, PEDIATR BLOOD CANCER, V55, P1187, DOI 10.1002/pbc.22662
   OZSOYLU S, 1989, J PEDIATR US, V114, P904, DOI 10.1016/S0022 3476(89)80170 2
   PELUS LM, 1988, BLOOD, V71, P1633
   Pullarkat V, 2003, AM J HEMATOL, V72, P8, DOI 10.1002/ajh.10258
   Shakiba M, 2020, IJHOSCR
   Sharma R, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26777
   TANIGUCHI S, 1989, KIDNEY INT, V36, P712, DOI 10.1038/ki.1989.251
   Vezza R, 2002, THROMB HAEMOSTASIS, V87, P114, DOI 10.1055/s 0037 1612953
NR 24
TC 5
Z9 5
U1 0
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0006 4971
EI 1528 0020
J9 BLOOD
JI Blood
PD MAR 30
PY 2023
VL 141
IS 13
BP 1553
EP 1559
DI 10.1182/blood.2022018667
EA MAR 2023
PG 7
WC Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Hematology
GA E9AI2
UT WOS:000978380200001
PM 36574346
OA Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Kohrt, WM
   Barry, DW
   Van Pelt, RE
   Jankowski, CM
   Wolfe, P
   Schwartz, RS
AF Kohrt, Wendy M.
   Barry, Daniel W.
   Van Pelt, Rachael E.
   Jankowski, Catherine M.
   Wolfe, Pamela
   Schwartz, Robert S.
TI Timing of Ibuprofen Use and Bone Mineral Density Adaptations to Exercise
   Training
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE EXERCISE TRAINING; BONE MINERAL DENSITY; NONSTEROIDAL ANTI INFLAMMATORY
   DRUGS; CYCLOOXYGENASE; PROSTAGLANDINS
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; SELECTIVE CYCLOOXYGENASE 2
   INHIBITOR; OVARIECTOMIZED RATS; OLDER WOMEN; CYTOKINE RESPONSE;
   CANCELLOUS BONE; PROSTAGLANDINS; NAPROXEN; ASPIRIN; COX 2
AB Prostaglandins (PGs) are essential signaling factors in bone mechanotransduction. In animals, inhibition of the enzyme responsible for PG synthesis (cyclooxygenase) by nonsteroidal anti inflammatory drugs (NSAIDs) blocks the bone formation response to loading when administered before, but not immediately after, loading. The aim of this proof of concept study was to determine whether the timing of NSAID use influences bone mineral density (BMD) adaptations to exercise in humans. Healthy premenopausal women (n = 73) aged 21 to 40 years completed a supervised 9 month weight bearing exercise training program. They were randomized to take (1) ibuprofen (400 mg) before exercise, placebo after (IBUP/PLAC), (2) placebo before, ibuprofen after (PLAC/IBUP), or (3) placebo before and after (PLAC/PLAC) exercise. Relative changes in hip and lumbar spine BMD from before to after exercise training were assessed using a Hologic Delphi W dual energy X ray absorptiometry (DXA) instrument. Because this was the first study to evaluate whether ibuprofen use affects skeletal adaptations to exercise, only women who were compliant with exercise were included in the primary analyses (IBUP/PLAC, n = 17; PLAC/PLAC, n = 23; and PLAC/IBUP, n = 14). There was a significant effect of drug treatment, adjusted for baseline BMD, on the BMD response to exercise for regions of the hip (total, p<.001; neck, p = .026; trochanter, p = .040; shaft, p = .019) but not the spine (p = .242). The largest increases in BMD occurred in the group that took ibuprofen after exercise. Total hip BMD changes averaged 0.2% +/  1.3%, 0.4% +/  1.8%, and 2.1% +/  1.7% in the IBUP/PLAC, PLAC/PLAC, and PLAC/IBUP groups, respectively. This preliminary study suggests that taking NSAIDs after exercise enhances the adaptive response of BMD to exercise, whereas taking NSAIDs before may impair the adaptive response. (C) 2010 American Society for Bone and Mineral Research.
C1 [Kohrt, Wendy M.; Van Pelt, Rachael E.; Jankowski, Catherine M.; Schwartz, Robert S.] Univ Colorado, Dept Med, Div Geriatr Med, Denver, CO USA.
   [Barry, Daniel W.] Univ Colorado, Dept Med, Div Gen Internal Med, Denver, CO USA.
   [Wolfe, Pamela] Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80202 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado Denver; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   Denver; University of Colorado System; University of Colorado Denver
RP Kohrt, WM (通讯作者)，Mail Stop B179,12631 E 17th Ave,Room 8111, Aurora, CO 80045 USA.
EM wendy.kohrt@ucdenver.edu
OI Van Pelt, Rachael/0000 0003 4187 7063
FU Department of Defense [DAMD 17 01 1 0805]; National Institutes of Health
   (General Clinical Research Center) [R01 AG018857, M01 RR000051];
   National Institutes of Health (Clinical Nutrition Research Unit) [P30
   DK048520]
FX This research was supported by Department of Defense Award
   DAMD 17 01 1 0805 and National Institutes of Health Awards R01 AG018857,
   M01 RR000051 (General Clinical Research Center) and P30 DK048520
   (Clinical Nutrition Research Unit).
CR Alam I, 2005, J BONE MINER RES, V20, P438, DOI 10.1359/JBMR.041124
   Bakker AD, 2003, BIOCHEM BIOPH RES CO, V305, P677, DOI 10.1016/S0006 291X(03)00831 3
   Bauer DC, 1996, J BONE MINER RES, V11, P29
   Carbone LD, 2003, J BONE MINER RES, V18, P1795, DOI 10.1359/jbmr.2003.18.10.1795
   Cheng MZ, 1997, J BONE MINER RES, V12, P1424, DOI 10.1359/jbmr.1997.12.9.1424
   Chow J W, 2000, Exerc Sport Sci Rev, V28, P185
   Chow JWM, 1998, J BONE MINER RES, V13, P1039, DOI 10.1359/jbmr.1998.13.6.1039
   CHOW JWM, 1994, AM J PHYSIOL, V267, P287
   FORWOOD MR, 1996, J BONE MINER RES, V11, P168
   Gregory LS, 2006, BONE, V39, P134, DOI 10.1016/j.bone.2005.12.017
   Hinz B, 2008, FASEB J, V22, P383, DOI 10.1096/fj.07 8506com
   Jiang Y, 1998, BONE, V22, P509, DOI 10.1016/S8756 3282(98)00027 1
   Kasukawa Y, 2007, TOHOKU J EXP MED, V211, P275, DOI 10.1620/tjem.211.275
   KIMMEL DB, 1992, BONE, V13, P167, DOI 10.1016/8756 3282(92)90007 J
   Kis B, 2005, J PHARMACOL EXP THER, V315, P1, DOI 10.1124/jpet.105.085431
   Kohrt WM, 1998, J APPL PHYSIOL, V84, P1506, DOI 10.1152/jappl.1998.84.5.1506
   Kohrt WM, 1997, J BONE MINER RES, V12, P1253, DOI 10.1359/jbmr.1997.12.8.1253
   LANE N, 1990, J BONE MINER RES, V5, P1029
   Lane NE, 1997, J RHEUMATOL, V24, P1132
   Li J, 2002, CALCIFIED TISSUE INT, V70, P320, DOI 10.1007/s00223 001 1025 y
   Li M, 2007, INT ORTHOP, V31, P767, DOI 10.1007/s00264 007 0406 x
   Moldoveanu AI, 2001, SPORTS MED, V31, P115, DOI 10.2165/00007256 200131020 00004
   Morton DJ, 1998, J BONE MINER RES, V13, P1924, DOI 10.1359/jbmr.1998.13.12.1924
   Mundy GR, 2007, NUTR REV, V65, pS147, DOI [10.1111/j.1753 4887.2007.tb00353.x, 10.1301/nr.2007.dec.S147 S151]
   Nieman DC, 2004, J APPL PHYSIOL, V96, P1292, DOI 10.1152/japplphysiol.01064.2003
   Paulsen G, 2005, MED SCI SPORT EXER, V37, P1877, DOI 10.1249/01.mss.0000177064.65927.98
   PEAD MJ, 1989, CALCIFIED TISSUE INT, V45, P34, DOI 10.1007/BF02556658
   Raisz LG., 2001, AM J MED, V110, P43, DOI DOI 10.1016/S0002 9343(00)00684 7
   Richards JB, 2006, OSTEOPOROSIS INT, V17, P1410, DOI 10.1007/s00198 006 0142 x
   Saino H, 1997, J BONE MINER RES, V12, P1844, DOI 10.1359/jbmr.1997.12.11.1844
   Shen CL, 2006, J BONE MINER METAB, V24, P461, DOI 10.1007/s00774 006 0709 9
   Sibonga JD, 1998, J BONE MINER RES, V13, P863, DOI 10.1359/jbmr.1998.13.5.863
   SOMJEN D, 1980, BIOCHIM BIOPHYS ACTA, V627, P91, DOI 10.1016/0304 4165(80)90126 9
   Thorsen K, 1996, J CLIN INVEST, V98, P2446, DOI 10.1172/JCI119061
   Van Staa TP, 2000, BONE, V27, P563, DOI 10.1016/S8756 3282(00)00361 6
   Zaman G, 1997, J BONE MINER RES, V12, P769, DOI 10.1359/jbmr.1997.12.5.769
NR 36
TC 25
Z9 30
U1 0
U2 15
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0884 0431
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD JUN
PY 2010
VL 25
IS 6
BP 1415
EP 1422
DI 10.1002/jbmr.24
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 619PE
UT WOS:000279441300023
PM 20200939
OA Green Accepted, Green Published, Bronze
DA 2025 08 17
ER

PT J
AU Jategaonkar, AA
   Badhey, AK
   Sokoya, M
   Kadakia, S
   Mudrovich, S
   Ducic, Y
AF Jategaonkar, Ameya A.
   Badhey, Arvind K.
   Sokoya, Mofiyinfolu
   Kadakia, Sameep
   Mudrovich, Steven
   Ducic, Yadranko
TI Total mandibulectomy defect in the setting of chronic bisphosphonate use
SO AMERICAN JOURNAL OF OTOLARYNGOLOGY
LA English
DT Article
ID SURGEONS POSITION PAPER; AMERICAN ASSOCIATION; OSTEONECROSIS; JAWS;
   UPDATE
AB Bisphosphonates are among several drugs known in modern medicine to have a potentially deleterious effect on the mandible with chronic use. While purportedly causing a necrotic reaction in the bone, the complete mechanism is not fully elucidated yet as cases are quite rare in the general public. Despite the esoteric nature of this entity, patients suffering from bisphosphonate induced necrosis have a complicated and prolonged course often involving varying degrees of mandibular debridement with severe cases requiring reconstruction. In this report, we present the unique case of a patient with a progressive mandibular osteonecrosis requiring complete mandibulectomy and fibula flap reconstruction.
C1 [Jategaonkar, Ameya A.; Badhey, Arvind K.] New York Eye & Ear Infirm Mt Sinai, New York, NY USA.
   [Sokoya, Mofiyinfolu] Univ Colorado, Denver, CO 80202 USA.
   [Kadakia, Sameep] Otolaryngol & Facial Plast Surg Associates, 923 Penn Ave, Ft Worth, TX 76104 USA.
   [Mudrovich, Steven] Baylor All St Med Ctr, Ft Worth, TX USA.
   [Ducic, Yadranko] Otolaryngol & Facial Plast Surg Associates, Ft Worth, TX USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; University of Colorado
   System; University of Colorado Denver
RP Kadakia, S (通讯作者)，Otolaryngol & Facial Plast Surg Associates, 923 Penn Ave, Ft Worth, TX 76104 USA.
EM sameep8779@gmail.com
OI Badhey, Arvind/0000 0003 0730 0500
CR Clezardin Philippe, 2013, Bonekey Rep, V2, P267, DOI 10.1038/bonekey.2013.1
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Lopes RN, 2015, J ORAL MAXIL SURG, V73, P1288, DOI 10.1016/j.joms.2015.01.008
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Ruggiero SL, 2014, J ORAL MAXIL SURG, V72, P1938, DOI 10.1016/j.joms.2014.04.031
   Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Rupel K, 2014, ORAL ONCOL, V50, P1049, DOI 10.1016/j.oraloncology.2014.08.016
   Seth R, 2010, LARYNGOSCOPE, V120, P2165, DOI 10.1002/lary.21062
NR 9
TC 2
Z9 2
U1 0
U2 2
PU W B SAUNDERS CO ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103 2899 USA
SN 0196 0709
EI 1532 818X
J9 AM J OTOLARYNG
JI Am. J. Otolaryngol.
PD SEP OCT
PY 2018
VL 39
IS 5
BP 649
EP 651
DI 10.1016/j.amjoto.2018.05.004
PG 3
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Otorhinolaryngology
GA GS8AV
UT WOS:000443929600042
PM 29778637
DA 2025 08 17
ER

PT J
AU Watts, NB
   Marciani, RD
AF Watts, Nelson B.
   Marciani, Robert D.
TI Osteonecrosis of the jaw
SO SOUTHERN MEDICAL JOURNAL
LA English
DT Article
DE bisphosphonate; jaw; osteonecrosis; osteoporosis
ID BISPHOSPHONATE ASSOCIATED OSTEONECROSIS; AVASCULAR NECROSIS;
   POSTMENOPAUSAL WOMEN; ZOLEDRONIC ACID; ALENDRONATE; OSTEOPOROSIS
AB The first bisphosphonate (etidronate) was approved by the FDA in 1977; alendronate was approved in 1995 for the prevention and treatment of osteoporosis. Bisphosphonates have emerged as the agents of choice for the treatment of osteoporosis and have proved useful in the treatment of skeletal complications of malignancy (hypercalcemia, bone metastases) and have been used long term in millions of patients. Osteonecrosis of the jaw (ONJ) is a newly described condition (2003) defined as exposed bone in the maxillofacial area, not associated with radiation or any other known cause and not healing for 8 weeks. Most cases have followed dental extraction, another invasive dental procedure, or poorly fitting dentures. Although most cases are painful and it can be progressive, approximately one third of cases are painless and some do resolve. Although ONJ occurs exclusively or almost exclusively in patients receiving bisphosphonate therapy, a causal association has not been shown, and the mechanism is not clear. In patients receiving high dose IV bisphosphonates for malignant diseases, ONJ may occur in 5 to 10% over 3 years. It does occur in patients receiving oral or IV bisphosphonates for osteoporosis, but is rare in that setting; about I case per 100,000. Treatment is conservative (antimicrobial mouthwash, antibiotics for secondary infection, limited debridement). Preventive strategies should include good dental hygiene for all patients and completion of elective invasive dental procedures before initiating high dose IV bisphosphonate therapy for cancer. Patients with osteoporosis receiving lower dose bisphosphonate therapy do not require special precautions, but should be informed of the low risk of this complication.
C1 [Watts, Nelson B.; Marciani, Robert D.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Endocrinol Metab & Diabet, Cincinnati, OH USA.
   [Watts, Nelson B.; Marciani, Robert D.] Univ Cincinnati, Coll Med, Dept Oral & Maxillofacial Surg, Cincinnati, OH USA.
C3 University System of Ohio; University of Cincinnati; University System
   of Ohio; University of Cincinnati
RP Watts, NB (通讯作者)，Univ Cincinnati, Bone Hlth & Osteoporosis Ctr, 222 Piedmont Ave,Suite 4300, Cincinnati, OH 45221 USA.
EM nelson.watts@uc.edu
CR AAOMS, 2007, J ORAL MAXIL SURG, V65, P369, DOI 10.1016/j.joms.2006.11.003
   Agarwala S, 2002, RHEUMATOLOGY, V41, P346, DOI 10.1093/rheumatology/41.3.346 a
   BASSETT CAL, 1969, LANCET, V2, P845
   Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157
   Black DM, 2006, J BONE MINER RES, V21, pS16
   Black DM, 2006, JAMA J AM MED ASSOC, V296, P2927, DOI 10.1001/jama.296.24.2927
   Bone HG, 2004, NEW ENGL J MED, V350, P1189, DOI 10.1056/NEJMoa030897
   Capsoni F, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2050
   Corso A, 2007, LEUKEMIA, V21, P1545, DOI 10.1038/sj.leu.2404682
   Demerjian N, 1999, CLIN RHEUMATOL, V18, P349, DOI 10.1007/s100670050116
   Desai MM, 2005, RHEUMATOLOGY, V44, P1331, DOI 10.1093/rheumatology/kei003
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Gonzalez Moles MA, 2000, J ORAL PATHOL MED, V29, P514, DOI 10.1034/j.1600 0714.2000.291006.x
   Harper RP, 2007, J ORAL MAXIL SURG, V65, P573, DOI 10.1016/j.joms.2006.10.076
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hoffman RM, 2005, J GEN INTERN MED, V20, P55
   *IMS HLTH, 2006, NPA PLUS
   Jeffcoat MK, 2006, INT J ORAL MAX IMPL, V21, P349
   Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ
   KNOX R, 2006, SIDE EFFECTS NOTED B
   KOLATA G, 2006, DRUG BONES NEWLY LIN
   MARX RE, 1983, J ORAL MAXIL SURG, V41, P351, DOI 10.1016/S0278 2391(83)80005 6
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   *MERCK PHARM, 2007, DAT FIL
   Palomo L, 2005, MENOPAUSE, V12, P685, DOI 10.1097/01.gme.0000184421.50696.34
   *PROCT GAMBL PHARM, 2007, DAT FIL
   *ROCH PHARM, 2007, DAT FIL
   Rubegni P, 2006, NEW ENGL J MED, V355, pE25, DOI 10.1056/NEJMicm054413
   RUBIN R, 2005, DRUG LINKED DEATH JA
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   Russell RGG, 1999, BONE, V25, P97, DOI 10.1016/S8756 3282(99)00116 7
   Treister N, 2006, NEW ENGL J MED, V355, P2348, DOI 10.1056/NEJMicm055784
   Vescovi P, 2006, J ORAL MAXIL SURG, V64, P1460, DOI 10.1016/j.joms.2006.05.042
   Watts N.B., 2000, The Osteoporotic Syndrome, P121
   WATTS NB, 2007, COMMUNICATION
   Woo SB, 2006, ANN INTERN MED, V144, P753, DOI 10.7326/0003 4819 144 10 200605160 00009
NR 36
TC 13
Z9 15
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0038 4348
EI 1541 8243
J9 SOUTH MED J
JI South.Med.J.
PD FEB
PY 2008
VL 101
IS 2
BP 160
EP 165
DI 10.1097/SMJ.0b013e31816127d9
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC General & Internal Medicine
GA 262LP
UT WOS:000253150300018
PM 18364618
DA 2025 08 17
ER

PT J
AU Panek, M
   Marijanovic, I
   Ivkovic, A
AF Panek, Marina
   Marijanovic, Inga
   Ivkovic, Alan
TI Stem cells in bone regeneration
SO PERIODICUM BIOLOGORUM
LA English
DT Article
DE stem cells; bone regeneration; orthopaedics; tissue engineering;
   regenerative medicine
ID MARROW; TISSUE; CULTURE; BLOOD; FRACTURES; THERAPY
AB Bone defects, including normal fracture healing as well as healing problems represent a global health problem. The need for better treatment of bone defects is one of the central issues of tissue engineering and regenerative medicine. Regenerative orthopedics has several approaches   activation of endogenous stem cells, stem cell therapy and tissue engineering. Development of new treatments is mainly focused on the tissue engineering strategies that include stem cells, bioactive signals and appropriate scaffold support.
   The aim of this review is to describe a variety of stem cells that have an ability to become bone cells and therefore are of central importance for bone tissue engineering. Several cell types have been proposed as starting material   embryonic stem cells, induced pluripotent stem cells and adult stem cells. Due to ethical and safety issues, embryonic and induced pluripotent stem cells may be more suitable for studying human development and tissue formation under diverse experimental conditions, and represent an excellent base for understanding human diseases and development of innovative therapeutic solutions. Among adult stem cells, mesenchymal stem cells are the most suitable for bone tissue engineering. They can be isolated from variety of mesenchymal tissues and can differentiate into osteoblasts when given appropriate mechanical support and osteoinductive signal.
   The near future of bone healing and regeneration is closely related to advances in tissue engineering. The optimization of protocols of bone graft production using autologous mesenchymal stem cells loaded on appropriate scaffolds, exposed to osteogenic inducers and mechanical force in bioreactor, should be able to solve the current limitations in managing bone injuries.
C1 [Panek, Marina] Univ Zagreb, Sch Med, Ctr Translat & Clin Res, Dept Intercellular Commun, Zagreb 10000, Croatia.
   [Marijanovic, Inga] Univ Zagreb, Fac Sci, Dept Mol Biol, Zagreb 10000, Croatia.
   [Ivkovic, Alan] Univ Hosp Sveti Duh, Dept Orthoped Surg, Zagreb 10000, Croatia.
   [Ivkovic, Alan] Univ Rijeka, Dept Biotechnol, Rijeka 51000, Croatia.
C3 University of Zagreb; University of Zagreb; University of Rijeka
RP Ivkovic, A (通讯作者)，Univ Hosp Sveti Duh, Dept Orthoped Surg, Sveti Duh 64, HR 10000 Zagreb, Croatia.
EM alan.ivkovic@gmail.com
RI ; Ivkovic, Alan/V 8656 2019
OI Ivkovic, Alan/0000 0003 0236 6244; 
FU Croatian Science Foundation
FX Marina Panek is supported for the PhD studies by the Croatian Science
   Foundation Young Investigators Grant.
CR Arvidson K, 2011, J CELL MOL MED, V15, P718, DOI 10.1111/j.1582 4934.2010.01224.x
   Bianco P, 2013, NAT MED, V19, P35, DOI 10.1038/nm.3028
   Borgström F, 2013, OSTEOPOROSIS INT, V24, P811, DOI 10.1007/s00198 012 2240 2
   Chen P, 2005, COLLOID SURFACE A, V261, P3, DOI 10.1016/j.colsurfa.2004.12.048
   Dalal J, 2012, PEDIATR RES, V71, P445, DOI 10.1038/pr.2011.56
   de Peppo Giuseppe Maria, 2012, J Blood Transfus, V2012, P317632, DOI 10.1155/2012/317632
   Dogaki Y, 2014, INT ORTHOP, V38, P1779, DOI 10.1007/s00264 014 2440 9
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   FAGHIHI M B E, 2011, REGENERATIVE MED TIS
   Fiorentini E, 2011, INT J ARTIF ORGANS, V34, P998, DOI 10.5301/ijao.5000001
   FRIEDENSTEIN AJ, 1968, TRANSPLANTATION, V6, P230, DOI 10.1097/00007890 196803000 00009
   Friess W, 1999, INT J PHARM, V187, P91, DOI 10.1016/S0378 5173(99)00174 X
   Fröhlich M, 2008, CURR STEM CELL RES T, V3, P254, DOI 10.2174/157488808786733962
   Gamblin AL, 2014, BIOMATERIALS, V35, P9660, DOI 10.1016/j.biomaterials.2014.08.018
   Glatt V, 2012, J BONE JOINT SURG AM, V94A, P2063, DOI 10.2106/JBJS.K.01604
   Gusic N, 2014, INT ORTHOP, V38, P1877, DOI 10.1007/s00264 014 2412 0
   Hamada K, 2008, J BIOMED MATER RES A, V84A, P128, DOI 10.1002/jbm.a.31439
   HAYNESWORTH SE, 1992, BONE, V13, P81, DOI 10.1016/8756 3282(92)90364 3
   Hollinger JO, 1998, J BIOMED MATER RES, V43, P356, DOI 10.1002/(SICI)1097 4636(199824)43:4<356::AID JBM3>3.0.CO;2 7
   Ivkovic A, 2010, GENE THER, V17, P779, DOI 10.1038/gt.2010.16
   Ivkovic Alan, 2011, Front Biosci (Elite Ed), V3, P923
   Johnstone B, 1998, EXP CELL RES, V238, P265, DOI 10.1006/excr.1997.3858
   Kadiyala S, 1997, CELL TRANSPLANT, V6, P125, DOI 10.1016/S0963 6897(96)00279 5
   Kalfas I H, 2001, Neurosurg Focus, V10, pE1
   Kishk NA, 2010, NEUROREHAB NEURAL RE, V24, P702, DOI 10.1177/1545968310369801
   Krylova T A, 2014, Tsitologiia, V56, P562
   Lengner CJ, 2010, ANN NY ACAD SCI, V1192, P38, DOI 10.1111/j.1749 6632.2009.05213.x
   Lin KL, 2014, ACTA BIOMATER, V10, P4071, DOI 10.1016/j.actbio.2014.06.017
   Linero I, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107001
   Manganas LN, 2007, SCIENCE, V318, P980, DOI 10.1126/science.1147851
   Marino JT, 2010, ORTHOP CLIN N AM, V41, P15, DOI 10.1016/j.ocl.2009.08.003
   Marolt D, 2012, P NATL ACAD SCI USA, V109, P8705, DOI 10.1073/pnas.1201830109
   Marolt D, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt10
   Miller MA, 2011, INT ORTHOP, V35, P599, DOI 10.1007/s00264 010 1013 9
   Mundra V, 2013, MOL PHARMACEUT, V10, P77, DOI 10.1021/mp3005148
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Oryan A, 2014, J ORTHOP SURG RES, V9, DOI 10.1186/1749 799X 9 18
   PARTAP NAP S., 2010, TISSUE ENG
   Prosecká E, 2015, J BIOMED MATER RES A, V103, P671, DOI 10.1002/jbm.a.35216
   Qin YH, 2014, POSTGRAD MED J, V90, P643, DOI 10.1136/postgradmedj 2013 132387
   Rivron NC, 2012, P NATL ACAD SCI USA, V109, P4413, DOI 10.1073/pnas.1117627109
   Ryu HH, 2012, J VET MED SCI, V74, P1617, DOI 10.1292/jvms.12 0065
   Scadden DT, 2006, NATURE, V441, P1075, DOI 10.1038/nature04957
   Shore EM, 2011, J BONE MINER RES, V26, P1163, DOI 10.1002/jbmr.404
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tang MH, 2014, TISSUE ENG PT A, V20, P1295, DOI [10.1089/ten.tea.2013.0211, 10.1089/ten.TEA.2013.0211]
   Teng SS, 2014, TISSUE ENG PART B RE, V20, P328, DOI [10.1089/ten.teb.2013.0301, 10.1089/ten.TEB.2013.0301]
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Trivanovic D, 2013, SRP ARK CELOK LEK, V141, P178, DOI 10.2298/SARH1304178T
   Ullah I, 2015, BIOSCIENCE REP, V35, DOI 10.1042/BSR20150025
   Wang P, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.17
   Wei X, 2013, ACTA PHARMACOL SIN, V34, P747, DOI 10.1038/aps.2013.50
   Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092 8674(00)81692 X
   Yeatts AB, 2013, BBA GEN SUBJECTS, V1830, P2470, DOI 10.1016/j.bbagen.2012.06.007
   YOSHIKAWA T, 2010, SPINE, V35, P1
NR 55
TC 7
Z9 7
U1 1
U2 26
PU PERIODICUM BIOLOGORUM
PI ZAGREB
PA HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA
SN 0031 5362
J9 PERIOD BIOL
JI Period. Biol.
PD MAR
PY 2015
VL 117
IS 1
BP 177
EP 184
PG 8
WC Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Life Sciences & Biomedicine   Other Topics
GA CJ5XQ
UT WOS:000355567400023
DA 2025 08 17
ER

PT J
AU Adami, G
AF Adami, Giovanni
TI Regulation of bone mass in inflammatory diseases
SO BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
DE inflammation; wnt system; osteoporosis; bone metabolism; disease
   modifying drugs; glucocorticoids
ID TNF ALPHA THERAPY; MINERAL DENSITY; RHEUMATOID ARTHRITIS; VERTEBRAL
   FRACTURES; LUMBAR SPINE; METABOLISM; INFLIXIMAB; RISK; OSTEOPOROSIS;
   BISPHOSPHONATES
AB Inflammation is among the major determinants of bone loss in chronic disease and aging. Bone metabolism is radically affected by inflammation with consequent bone loss and increased fracture risk. Various cytokines and mediators are involved in the pathogenesis of bone loss in inflammatory conditions. The present review has the aim of discussing the main pathways involved in the pathogenesis of bone loss in inflammatory diseases, focusing in particular on the Wnt system and its regulators. Literature review of studies published between inception to 2021 on osteoporosis and inflammation was conducted. I will discuss the epidemiology of osteoporosis and fractures in common inflammatory diseases. The molecular basis of bone loss related to inflammation will be discussed as well. Finally, the effects of various anti inflammatory medications on bone metabolism will be reviewed.(c) 2021 Elsevier Ltd. All rights reserved.
C1 [Adami, Giovanni] Univ Verona, Rheumatol Unit, Pz Scuro 10, I 37134 Verona, Italy.
C3 University of Verona
RP Adami, G (通讯作者)，Univ Verona, Rheumatol Unit, Pz Scuro 10, I 37134 Verona, Italy.
EM giovanni.adami@univr.it
RI Adami, Giovanni/AAQ 2160 2021
OI Adami, Giovanni/0000 0002 8915 0755
CR Adam S, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay4447
   Adami G, 2021, OSTEOPOROSIS INT, V32, pS153, DOI 10.1007/s00198 021 06060 9
   Adami G, 2019, OSTEOPOROSIS INT, V30, P1145, DOI 10.1007/s00198 019 04906 x
   Adami G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235867
   Adami G, 2019, CURR RHEUMATOL REP, V21, DOI 10.1007/s11926 019 0836 7
   Adami G, 2018, CLIN CASES MINER BON, V15, P177, DOI 10.11138/ccmbm/2018.15.2.177
   Adami G, 2016, CALCIFIED TISSUE INT, V99, P360, DOI 10.1007/s00223 016 0161 3
   Adas Okuma MG, 2020, OSTEOPOROSIS INT, V31, P687, DOI 10.1007/s00198 019 05235 9
   Barreira SC, 2016, CLIN REV ALLERG IMMU, V51, P100, DOI 10.1007/s12016 016 8547 6
   Bedi B, 2010, ANN NY ACAD SCI, V1192, P215, DOI 10.1111/j.1749 6632.2009.05216.x
   Bertoldo E, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.620920
   Black DM, 2022, J BONE MINER RES, V37, P21, DOI 10.1002/jbmr.4434
   Black DM, 2016, NEW ENGL J MED, V374, P254, DOI 10.1056/NEJMcp1513724
   Bon J, 2020, J BONE MINER RES, V35, P1952, DOI 10.1002/jbmr.4103
   Brabnikova Maresova K, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075 014 0460 x
   Briot K, 2013, ANN RHEUM DIS, V72, P1914, DOI 10.1136/annrheumdis 2012 201845
   Bugatti S, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 1116 9
   Chalitsios CV, 2021, THORAX, V76, P21, DOI 10.1136/thoraxjnl 2020 215664
   Chapurlat RD, 2016, RHEUMATOLOGY, V55, P1714, DOI 10.1093/rheumatology/kev410
   Chopin F, 2008, ANN RHEUM DIS, V67, P353, DOI 10.1136/ard.2007.076604
   D'Amelio P, 2010, OSTEOPOROSIS INT, V21, P1741, DOI 10.1007/s00198 009 1129 1
   Dischereit G, 2013, CLIN RHEUMATOL, V32, P377, DOI 10.1007/s10067 012 2128 8
   Eekman DA, 2011, ANN RHEUM DIS, V70, P389, DOI 10.1136/ard.2009.127787
   Franceschi C, 2000, ANN NY ACAD SCI, V908, P244
   Gatti D, 2011, J CLIN ENDOCR METAB, V96, P1555, DOI 10.1210/jc.2010 2552
   Geusens P, 2007, CURR OPIN RHEUMATOL, V19, P335, DOI 10.1097/BOR.0b013e328133f5b3
   Glass DA, 2005, DEV CELL, V8, P751, DOI 10.1016/j.devcel.2005.02.017
   Güler Yüksel M, 2008, ANN RHEUM DIS, V67, P823, DOI 10.1136/ard.2007.073817
   Hamar A, 2021, OSTEOPOROSIS INT, V32, P1621, DOI 10.1007/s00198 021 05871 0
   Janson C, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00515 2020
   Jin S, 2018, OSTEOPOROSIS INT, V29, P1263, DOI 10.1007/s00198 018 4473 1
   Kanis JA, 2021, ARCH OSTEOPOROS, V16, DOI 10.1007/s11657 020 00871 9
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018 016 2425 5
   Keller JJ, 2013, OSTEOPOROSIS INT, V24, P1835, DOI 10.1007/s00198 012 2185 5
   Kim SY, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3107
   Kocijan R, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926 013 0366 7
   Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551
   Lange U, 2005, RHEUMATOLOGY, V44, P1546, DOI 10.1093/rheumatology/kei082
   Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581
   Ludvigsson JF, 2019, AM J GASTROENTEROL, V114, P291, DOI 10.14309/ajg.0000000000000062
   Ma YB, 2018, INT IMMUNOPHARMACOL, V59, P227, DOI 10.1016/j.intimp.2018.04.019
   Maeda S, 2012, INT J RHEUMATOL, V2012, DOI 10.1155/2012/539683
   Manara M, 2015, RMD OPEN, V1, DOI 10.1136/rmdopen 2015 000065
   Marotte H, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2219
   Mazzucchelli R, 2018, OSTEOPOROSIS INT, V29, P2231, DOI 10.1007/s00198 018 4605 7
   Mazzucchelli R, 2018, RMD OPEN, V4, DOI 10.1136/rmdopen 2018 000671
   MICHEL BA, 1993, J RHEUMATOL, V20, P1666
   Montala N, 2011, J RHEUMATOL, V38, P893, DOI 10.3899/jrheum.100851
   Murakami K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181126
   Nicol AJ, 2011, BRIT J CANCER, V105, P778, DOI 10.1038/bjc.2011.293
   Ogdie A, 2017, ANN RHEUM DIS, V76, DOI 10.1136/annrheumdis 2016 210441
   Okano T, 2014, J BONE MINER METAB, V32, P593, DOI 10.1007/s00774 013 0535 9
   Orsolini G, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104354
   Orsolini G, 2018, CLIN RHEUMATOL, V37, P3093, DOI 10.1007/s10067 018 4205 0
   Orsolini G, 2017, CALCIFIED TISSUE INT, V101, P17, DOI 10.1007/s00223 017 0253 8
   Orsolini G, 2016, CALCIFIED TISSUE INT, V98, P580, DOI 10.1007/s00223 016 0114 x
   Orstavik RE, 2004, ANN RHEUM DIS, V63, P177, DOI 10.1136/ard.2003.005850
   Reid IR, 2020, J BONE MINER RES, V35, P20, DOI 10.1002/jbmr.3860
   Rossini M, 2016, RHEUMATOL INT, V36, P469, DOI 10.1007/s00296 015 3387 x
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P249, DOI 10.1007/s00223 013 9750 6
   Rossini M, 2013, CALCIFIED TISSUE INT, V93, P121, DOI 10.1007/s00223 013 9749 z
   Rossini M, 2012, CALCIFIED TISSUE INT, V91, P395, DOI 10.1007/s00223 012 9647 9
   Rotta D, 2020, FRONT MED LAUSANNE, V7, DOI 10.3389/fmed.2020.613720
   Sapey E, 2019, AM J RESP CRIT CARE, V200, P1282, DOI 10.1164/rccm.201812 2328OC
   Seriolo B, 2006, ANN NY ACAD SCI, V1069, P420, DOI 10.1196/annals.1351.040
   Shaw AT, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075 016 0998 x
   Sing CW, 2020, J BONE MINER RES, V35, P1676, DOI 10.1002/jbmr.4030
   Sing CW, 2018, J BONE MINER RES, V33, P1422, DOI 10.1002/jbmr.3448
   Tada M, 2018, RHEUMATOL INT, V38, P777, DOI 10.1007/s00296 017 3922 z
   Tedeschi SK, 2019, ARTHRITIS RHEUMATOL, V71, P1141, DOI 10.1002/art.40818
   Thompson K, 2010, ADV EXP MED BIOL, V658, P11, DOI 10.1007/978 1 4419 1050 9_2
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Toussirot E, 2017, EUR J RHEUMATOL, V4, P189, DOI 10.5152/eurjrheum.2017.17006
   Uderhardt S, 2010, ANN RHEUM DIS, V69, P592, DOI 10.1136/ard.2008.102046
   Viapiana O, 2013, CALCIFIED TISSUE INT, V92, P324, DOI 10.1007/s00223 012 9665 7
   Vis M, 2006, ANN RHEUM DIS, V65, P1495, DOI 10.1136/ard.2005.044198
   Vis M, 2003, ARTHRITIS RHEUM, V48, P2996, DOI 10.1002/art.11292
   Wang H, 2011, J IMMUNOL, V187, P5099, DOI 10.4049/jimmunol.1002697
   Wang X, 2016, OSTEOPOROSIS INT, V27, P1413, DOI 10.1007/s00198 015 3449 7
   Weivoda MM, 2016, J BONE MINER RES, V31, P65, DOI 10.1002/jbmr.2599
   Wendling D, 2004, EXPERT OPIN PHARMACO, V5, P1497, DOI 10.1517/14656566.5.7.1497
NR 81
TC 24
Z9 28
U1 2
U2 23
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1521 690X
EI 1532 1908
J9 BEST PRACT RES CL EN
JI Best Pract. Res. Clin. Endoc. Metab.
PD MAR
PY 2022
VL 36
IS 2
SI SI
AR 101611
DI 10.1016/j.beem.2021.101611
EA MAR 2022
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 0I0FM
UT WOS:000779104100003
PM 35120799
DA 2025 08 17
ER

PT J
AU Wang, XH
   Guo, YW
   Tolba, E
   Kokkinopoulou, M
   Wiens, M
   Schröder, HC
   Müller, WEG
AF Wang, Xiao Hong
   Guo, Yue Wei
   Tolba, Emad
   Kokkinopoulou, Maria
   Wiens, Matthias
   Schroeder, Heinz C.
   Mueller, Werner E. G.
TI Two Armed Activation of Bone Mineral Deposition by the Flavones Baicalin
   and Baicalein, Encapsulated in Polyphosphate Microparticles
SO AMERICAN JOURNAL OF CHINESE MEDICINE
LA English
DT Article
DE Baicalin; Baicalein; Polyphosphate Microparticles; Bone Mineralization;
   Primary Human Osteoblasts; Calcium Efflux/Transport; Phospholipase C;
   Alkaline Phosphatase
ID OSTEOBLAST LIKE CELLS; SCUTELLARIA BAICALENSIS; WNT/BETA CATENIN; SAOS 2
   CELLS; CULTURED OSTEOBLASTS; SIGNALING PATHWAYS; NA+/CA2+ EXCHANGE;
   CALCIUM PHOSPHATE; PLASMA MEMBRANE; METABOLIC FUEL
AB In this study, we investigated the effect of the two flavonoids, baicalin (baicalein 7 O beta D glucuronic acid) and its aglycone, baicalein (5,6,7 trihydroxyflavone), after encapsulation into amorphous calcium polyphosphate (Ca polyP) microparticles on mineralization of primary human osteoblasts (phOSB). Both flavonoids, which come from root extracts of Scutellaria baicalensis Georgi, are used in Traditional Chinese Medicine, and are nontoxic in cells up to a concentration of 3 mu g/ml. The morphogenetically active, energy rich Ca polyP particles with a stoichiometric P: Ca ratio of 1: 2 are degraded by cellular alkaline phosphatase (ALP) to ortho phosphate used for bone hydroxyapatite formation. Here we show that the flavone loaded Ca polyP microparticles are readily taken up by phOSB, resulting in the accumulation of polyP around the nuclei and the formation of intracellular vesicles containing the ALP. In addition, we demonstrate that baicalin/baicalein causes a rise of the intracellular calcium [Ca2+](i) a level which markedly is augmented after encapsulation into Ca polyP, through activation of the phospholipase C. Moreover, both flavones, either alone or associated with Ca polyP microparticles, upregulate the expression of the osteoblast calcium efflux channel, the plasma membrane Ca2+ ATPase (PMCA), while the expression of ALP, which promotes bone mineralization, is induced by Ca polyP and by the flavones only if present in the Ca polyP microparticle associated form. As a result, the extent of bone mineralization is markedly enhanced. Based on the two armed activating function, new applications of baicalin/baicalein as a component of nutriceuticals for osteoporosis prevention or bone implants can be envisaged.
C1 [Wang, Xiao Hong; Tolba, Emad; Wiens, Matthias; Schroeder, Heinz C.; Mueller, Werner E. G.] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, Duesbergweg 6, D 55128 Mainz, Germany.
   [Guo, Yue Wei] Chinese Acad Sci, Shanghai Inst Materia Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China.
   [Kokkinopoulou, Maria] Max Planck Inst Polymer Res, D 55128 Mainz, Germany.
C3 Johannes Gutenberg University of Mainz; Chinese Academy of Sciences;
   Shanghai Institute of Materia Medica, CAS; Max Planck Society
RP Wang, XH; Müller, WEG (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Physiol Chem, ERC Adv Investigator Grant Res Grp, Duesbergweg 6, D 55128 Mainz, Germany.
EM wang013@uni mainz.de; wmueller@uni mainz.de
RI ; Tolba, Emad/E 1049 2016; Müller, W./AAR 8651 2020
OI Schroder, Heinz C./0000 0003 0992 6427; Wiens,
   Matthias/0000 0001 9219 0478; Tolba, Emad/0000 0002 3422 2344; Muller,
   Werner E.G./0000 0002 8223 3689
FU ERC [268476]; Deutsche Forschungsgemeinschaft [Schr 277/10 3]; European
   Commission [268476, 604036, 311848]; International Human Frontier
   Science Program; BiomaTiCS research initiative of the University Medical
   Center, Mainz
FX W.E.G. M. is a holder of an ERC Advanced Investigator Grant (No. 268476
   "BIOSI LICA"). This work was supported by grants from the Deutsche
   Forschungsgemeinschaft (Schr 277/10 3), the European Commission
   ("Bio Scaffolds: Customized Rapid Proto typing of Bioactive Scaffolds",
   No. 604036; "MarBioTec*EU CN*", No. 268476; and "BlueGenics", No.
   311848), the International Human Frontier Science Program and the
   BiomaTiCS research initiative of the University Medical Center, Mainz.
CR Abramowitz J, 1996, MINER ELECTROL METAB, V22, P336
   ABRAMOWITZ J, 1995, MINER ELECTROL METAB, V21, P367
   ANDERSON RE, 1984, IN VITRO CELL DEV B, V20, P837, DOI 10.1007/BF02619629
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Boonrungsiman S, 2012, P NATL ACAD SCI USA, V109, P14170, DOI 10.1073/pnas.1208916109
   Burg Golani T, 2013, J BACTERIOL, V195, P5262, DOI 10.1128/JB.00697 13
   CARAFOLI E, 1991, PHYSIOL REV, V71, P129, DOI 10.1152/physrev.1991.71.1.129
   Chan E, 2010, CURR OPIN DRUG DISC, V13, P50
   Chang J, 2009, NAT MED, V15, P682, DOI 10.1038/nm.1954
   Chen JC, 2013, INT J MOL SCI, V14, P6012, DOI 10.3390/ijms14036012
   Chen M, 2014, J NEUROINTERV SURG, V6, P329, DOI 10.1136/neurintsurg 2014 011239
   DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   Godwin SL, 2002, BONE, V30, P559, DOI 10.1016/S8756 3282(01)00700 1
   Guo AJY, 2011, J BIOL CHEM, V286, P27882, DOI 10.1074/jbc.M111.236281
   ISHIMARU K, 1995, PHYTOCHEMISTRY, V40, P279, DOI 10.1016/0031 9422(95)00200 Q
   Kang MJ, 2014, ARCH PHARM RES, V37, P371, DOI 10.1007/s12272 013 0179 2
   Kim YH, 2007, ARCH PHARM RES, V30, P260, DOI 10.1007/BF02977703
   Kokkinopoulou M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101078
   Kyo R, 1998, J PHARM PHARMACOL, V50, P1179, DOI 10.1111/j.2042 7158.1998.tb03331.x
   Li HF, 2015, DRUG DES DEV THER, V9, P5169, DOI 10.2147/DDDT.S81578
   Liu Z.Y., 2009, SCI RES, V1, P134
   Lo Vasco V.R., 2016, AVICENNA J MED BIOCH, V4, DOI 10.17795/ajmb 34104
   Lorenz B, 2001, BBA PROTEIN STRUCT M, V1547, P254, DOI 10.1016/S0167 4838(01)00193 5
   Lu WY, 2014, J CELL BIOCHEM, V115, P1799, DOI 10.1002/jcb.24850
   Mansuri ML, 2014, GENES NUTR, V9, DOI 10.1007/s12263 014 0400 z
   Moghaddam E, 2014, SCI REP UK, V4, DOI 10.1038/srep05452
   Müller WEG, 2015, MACROMOL BIOSCI, V15, P1182, DOI 10.1002/mabi.201500100
   Müller WEG, 2015, EUR J PHARM BIOPHARM, V93, P214, DOI 10.1016/j.ejpb.2015.04.005
   Müller WEG, 2015, MATER LETT, V148, P163, DOI 10.1016/j.matlet.2015.02.070
   Müller WEG, 2011, ACTA BIOMATER, V7, P2661, DOI 10.1016/j.actbio.2011.03.007
   Müller WEG, 2015, J CELL SCI, V128, P2202, DOI 10.1242/jcs.170605
   Mukherjee C., 2015, PROTOC EXCH, DOI [10.1038/protex.2015.066, DOI 10.1038/PRO TEX.2015.066]
   Müller CI, 2006, LEUKEMIA RES, V30, P841, DOI 10.1016/j.leukres.2005.12.004
   Muller Werner E G, 2004, Keio J Med, V53, P159, DOI 10.2302/kjm.53.159
   Nakano Y, 2007, BONE, V41, P549, DOI 10.1016/j.bone.2007.06.011
   Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055
   Perovic S, 2001, BMC CELL BIOL, V2, DOI 10.1186/1471 2121 2 7
   Petrie A., 2013, STAT VET ANIMAL SCI, P85, DOI ISBN: 978 0 470 67075 0
   Pines M, 1996, BONE, V18, P381, DOI 10.1016/8756 3282(96)00008 7
   Raynaud S, 2002, BIOMATERIALS, V23, P1065, DOI 10.1016/S0142 9612(01)00218 6
   Robubi A, 2014, BONE JOINT RES, V3, P236, DOI 10.1302/2046 3758.37.2000231
   Schröder HC, 2005, J BIOMED MATER RES B, V75B, P387, DOI 10.1002/jbm.b.30322
   Schröder HC, 2012, J CELL BIOCHEM, V113, P3197, DOI 10.1002/jcb.24196
   SHEN V, 1983, BIOCHIM BIOPHYS ACTA, V727, P230, DOI 10.1016/0005 2736(83)90408 X
   Shen YC, 2003, EUR J PHARMACOL, V465, P171, DOI 10.1016/S0014 2999(03)01378 5
   Spencer JPE, 2007, GENES NUTR, V2, P257, DOI 10.1007/s12263 007 0056 z
   Stains JP, 2001, J BONE MINER RES, V16, P1434, DOI 10.1359/jbmr.2001.16.8.1434
   Tarayre C, 2016, SENSORS BASEL, V16, DOI 10.3390/s16060797
   Uchimura T, 2015, J CELL BIOCHEM, V116, P2858, DOI 10.1002/jcb.25232
   Verheyen EM, 2010, DEV DYNAM, V239, P34, DOI 10.1002/dvdy.22019
   von Pfolspeundt H., 1868, BUCH B UNDTH ERTZNEI
   Wang XH, 2016, BIOTECHNOL J, V11, P11, DOI 10.1002/biot.201500168
   Wang XH, 2014, BIOCHEM PHARMACOL, V89, P413, DOI 10.1016/j.bcp.2014.03.020
   WATSON LP, 1989, J HISTOCHEM CYTOCHEM, V37, P1235, DOI 10.1177/37.8.2526836
   Wei ZF, 2015, IND CROP PROD, V63, P175, DOI 10.1016/j.indcrop.2014.10.013
   White KE, 1996, J BONE MINER RES, V11, P1666
   Wiens M, 2010, CALCIFIED TISSUE INT, V87, P513, DOI 10.1007/s00223 010 9408 6
   Wiens M, 2010, BIOMATERIALS, V31, P7716, DOI 10.1016/j.biomaterials.2010.07.002
   Winder WW, 1999, AM J PHYSIOL ENDOC M, V277, pE1, DOI 10.1152/ajpendo.1999.277.1.E1
   Xu F, 2013, J PHARM SCI US, V102, P4205, DOI 10.1002/jps.23727
   Zhang XW, 2011, PHARM BIOL, V49, P256, DOI 10.3109/13880209.2010.501803
   Zhao Q, 2016, SCI BULL, V61, P1391, DOI 10.1007/s11434 016 1136 5
NR 63
TC 10
Z9 10
U1 0
U2 26
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 0192 415X
EI 1793 6853
J9 AM J CHINESE MED
JI Am. J. Chin. Med.
PY 2017
VL 45
IS 3
BP 533
EP 555
DI 10.1142/S0192415X1750032X
PG 23
WC Integrative & Complementary Medicine; Medicine, General & Internal
WE Science Citation Index Expanded (SCI EXPANDED)
SC Integrative & Complementary Medicine; General & Internal Medicine
GA EW2GL
UT WOS:000402314500008
PM 28367715
DA 2025 08 17
ER

PT J
AU Lee, YC
   Gajdosik, MS
   Josic, D
   Clifton, JG
   Logothetis, C
   Yu Lee, LY
   Gallick, GE
   Maity, SN
   Lin, SH
AF Lee, Yu Chen
   Gajdosik, Martina Srajer
   Josic, Djuro
   Clifton, James G.
   Logothetis, Christopher
   Yu Lee, Li Yuan
   Gallick, Gary E.
   Maity, Sankar N.
   Lin, Sue Hwa
TI Secretome Analysis of an Osteogenic Prostate Tumor Identifies Complex
   Signaling Networks Mediating Cross talk of Cancer and Stromal Cells
   Within the Tumor Microenvironment
SO MOLECULAR & CELLULAR PROTEOMICS
LA English
DT Article
ID MACROPHAGE INHIBITORY CYTOKINE 1; BETA TYPE I; PLASMA MEMBRANE PROTEOME;
   HIGH THROUGHPUT ANALYSIS; MASS SPECTROMETRY; BONE METASTASES; RAT LIVER;
   GROWTH; MOUSE; PROGRESSION
AB A distinct feature of human prostate cancer (PCa) is the development of osteoblastic (bone forming) bone metastases. Metastatic growth in the bone is supported by factors secreted by PCa cells that activate signaling networks in the tumor microenvironment that augment tumor growth. To better understand these signaling networks and identify potential targets for therapy of bone metastases, we characterized the secretome of a patient derived xenograft, MDA PCa 118b (PCa 118b), generated from osteoblastic bone lesion. PCa 118b induces osteoblastic tumors when implanted either in mouse femurs or subcutaneously. To study signaling molecules critical to these unique tumor/microenvironment mediated events, we performed mass spectrometry on conditioned media of isolated PCa 118b tumor cells, and identified 26 secretory proteins, such as TGF beta 2, GDF15, FGF3, FGF19, CXCL1, galectins, and beta 2 microglobulin, which represent both novel and previously published secreted proteins. RT PCR using human versus mouse specific primers showed that TGF beta 2, GDF15, FGF3, FGF19, and CXCL1 were secreted from PCa 118b cells. TGF beta 2, GDF15, FGF3, and FGF19 function as both autocrine and paracrine factors on tumor cells and stromal cells, that is, endothelial cells and osteoblasts. In contrast, CXCL1 functions as a paracrine factor through the CXCR2 receptor expressed on endothelial cells and osteoblasts. Thus, our study reveals a complex PCa bone metastasis secretome with paracrine and autocrine signaling functions that mediate cross talk among multiple cell types within the tumor microenvironment.
C1 [Lee, Yu Chen; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA.
   [Logothetis, Christopher; Gallick, Gary E.; Maity, Sankar N.; Lin, Sue Hwa] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Yu Lee, Li Yuan] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
   [Gajdosik, Martina Srajer] Josip Juraj Strossmayer Univ, Dept Chem, Osijek 31000, Croatia.
   [Josic, Djuro] Univ Rijeka, Dept Biotechnol, Rijeka 51000, Croatia.
   [Clifton, James G.] Brown Univ, Dept Mol Pharmacol Physiol & Biotechnol, Providence, RI 02903 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine;
   University of JJ Strossmayer Osijek; University of Rijeka; Brown
   University
RP Lin, SH (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Unit 89, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM slin@mdanderson.org
RI ; Šrajer Gajdošik, Martina/I 1436 2019
OI Srajer Gajdosik, Martina/0000 0002 8790 9465; Maity,
   Sankar/0000 0002 2387 6545; 
FU Cancer Prevention and Research Institute of Texas [CPRIT RP110327];
   National Institutes of Health [RO1 174798, P50 CA140388, 1S10RR020923];
   US Department of Defense [PC093132]; Prostate Cancer Foundation; Cancer
   Center Support grant from the National Cancer Institute [2P30CA016647];
   European Union FP7 PEOPLE IAPP  [324400   GlycoMet]; National Science
   Foundation EPSCoR [1004057]; Rhode Island Science and Technology
   Advisory Council grant; Division of Biology and Medicine, Brown
   University
FX This work was supported by Cancer Prevention and Research Institute of
   Texas (CPRIT RP110327), National Institutes of Health Grant RO1 174798,
   P50 CA140388, US Department of Defense Grant PC093132, and an award from
   the Prostate Cancer Foundation, a Cancer Center Support grant
   2P30CA016647 from the National Cancer Institute, and the European Union
   FP7 PEOPLE 2012 IAPP  proposal No. 324400   GlycoMet. This research is
   also in part conducted using the Rhode Island NSF/EPSCoR Proteomics
   Shared Resource Facility, which is supported in part by the National
   Science Foundation EPSCoR Grant No. 1004057, National Institutes of
   Health Grant No. 1S10RR020923, a Rhode Island Science and Technology
   Advisory Council grant, and the Division of Biology and Medicine, Brown
   University.
CR Bischoff DS, 2011, BONE, V48, P267, DOI 10.1016/j.bone.2010.09.026
   CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519
   Cao LL, 2013, ANAL CHEM, V85, P8112, DOI 10.1021/ac400774g
   Cao R, 2008, J PROTEOME RES, V7, P535, DOI 10.1021/pr070411f
   Carstens JL, 2014, CANCER RES, V74, P609, DOI 10.1158/0008 5472.CAN 13 1093
   Cuny GD, 2008, BIOORG MED CHEM LETT, V18, P4388, DOI 10.1016/j.bmcl.2008.06.052
   Dallas SL, 2005, J CELL PHYSIOL, V202, P361, DOI 10.1002/jcp.20147
   Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019
   Feng S, 2013, CANCER RES, V73, P2551, DOI 10.1158/0008 5472.CAN 12 4108
   Feng S, 2012, CLIN CANCER RES, V18, P3880, DOI 10.1158/1078 0432.CCR 11 3214
   Ge RR, 2006, CLIN CANCER RES, V12, P4315, DOI 10.1158/1078 0432.CCR 06 0162
   Gellibert F, 2006, J MED CHEM, V49, P2210, DOI 10.1021/jm0509905
   Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008 5472.CAN 05 1317
   Husaini Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043833
   Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754
   Itoh N, 2011, J BIOCHEM, V149, P121, DOI 10.1093/jb/mvq121
   Lee SH, 2007, CANCER RES, V67, P11045, DOI 10.1158/0008 5472.CAN 07 0986
   Lee YC, 2010, ONCOGENE, V29, P3196, DOI 10.1038/onc.2010.73
   Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008 5472.CAN 10 4374
   Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093
   Lin SH, 2008, ONCOGENE, V27, P5195, DOI 10.1038/onc.2008.156
   Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528
   Lu XN, 2005, MOL CELL PROTEOMICS, V4, P1948, DOI 10.1074/mcp.M500138 MCP200
   Mimeault M, 2010, J CELL PHYSIOL, V224, P626, DOI 10.1002/jcp.22196
   Moore BB, 1999, AM J PATHOL, V154, P1503, DOI 10.1016/S0002 9440(10)65404 1
   Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760
   Petersen M, 2008, KIDNEY INT, V73, P705, DOI 10.1038/sj.ki.5002717
   Selander KS, 2007, CANCER EPIDEM BIOMAR, V16, P532, DOI 10.1158/1055 9965.EPI 06 0841
   Senapati S, 2010, ONCOGENE, V29, P1293, DOI 10.1038/onc.2009.420
   Speers AE, 2007, CHEM REV, V107, P3687, DOI 10.1021/cr068286z
   Uhl M, 2004, CANCER RES, V64, P7954, DOI 10.1158/0008 5472.CAN 04 1013
   Vanhara P, 2012, PROSTATE CANCER P D, V15, P320, DOI 10.1038/pcan.2012.6
   Wakchoure S, 2009, PROSTATE, V69, P652, DOI 10.1002/pros.20913
   Yang F, 2013, CANCER RES, V73, P3716, DOI 10.1158/0008 5472.CAN 12 3274
   Yu PB, 2008, NAT MED, V14, P1363, DOI 10.1038/nm.1888
   Zhou L, 2008, BLOOD, V112, P3434, DOI 10.1182/blood 2008 02 139824
NR 36
TC 45
Z9 45
U1 1
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 3996 USA
SN 1535 9476
EI 1535 9484
J9 MOL CELL PROTEOMICS
JI Mol. Cell. Proteomics
PD MAR
PY 2015
VL 14
IS 3
BP 471
EP 483
DI 10.1074/mcp.M114.039909
PG 13
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology
GA CC9EP
UT WOS:000350671300003
PM 25527621
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Feng, GY
   Liu, W
   Yu, Y
   Tian, BB
   Zhang, YK
   Yang, FH
   Huang, J
   Zhang, PX
   Wang, W
   Li, DY
   Sun, S
   Niu, XF
   Chai, LM
   Li, JY
AF Feng, Guiyu
   Liu, Wei
   Yu, Yao
   Tian, Bingbing
   Zhang, Yingkai
   Yang, Fenghe
   Huang, Jian
   Zhang, Pingxin
   Wang, Wei
   Li, Dongyang
   Sun, Song
   Niu, Xufeng
   Chai, Limin
   Li, Jinyu
TI Angiogenesis coupled with osteogenesis in a bone tissue engineering
   scaffold enhances bone repair in osteoporotic bone defects
SO BIOMEDICAL MATERIALS
LA English
DT Article
DE osteoporosis; angiogenesis; osteogenesis; poly ((L) lactic acid);
   nano hydroxyapatite; collagen; magnesium
ID MECHANICAL PROPERTIES; VASCULAR CONTRIBUTION; POLY(L LACTIC ACID);
   RHIZOMA DRYNARIAE; PANAX NOTOGINSENG; RELEASE; MICROSPHERES;
   REGENERATION; COMPOSITES; DELIVERY
AB Increased life expectancy has resulted in an increase in osteoporosis incidence worldwide. The coupling of angiogenesis and osteogenesis is indispensable for bone repair. Although traditional Chinese medicine (TCM) exerts therapeutic effects on osteoporosis, TCM related scaffolds, which focus on the coupling of angiogenesis and osteogenesis, have not yet been used for the treatment of osteoporotic bone defects. Panax notoginseng saponin (PNS), the active ingredient of Panax notoginseng, was added to a poly ((L) lactic acid) (PLLA) matrix. Osteopractic total flavone (OTF), the active ingredient of Rhizoma Drynariae, was encapsulated in nano hydroxyapatite/collagen (nHAC) and added to the PLLA matrix. Magnesium (Mg) particles were added to the PLLA matrix to overcome the bioinert character of PLLA and neutralize the acidic byproducts generated by PLLA. In this OTF PNS/nHAC/Mg/PLLA scaffold, PNS was released faster than OTF. The control group had an empty bone tunnel; scaffolds containing OTF:PNS = 100:0, 50:50, and 0:100 were used as the treatment groups. Scaffold groups promoted new vessel and bone formation, increased the osteoid tissue, and suppressed the osteoclast activity around osteoporotic bone defects. Scaffold groups upregulated the expression levels of angiogenic and osteogenic proteins. Among these scaffolds, the OTF PNS (50:50) scaffold exhibited a better capacity for osteogenesis than the OTF PNS (100:0 and 0:100) scaffolds. Activation of the bone morphogenic protein (BMP) 2/BMP receptor (BMPR) 1A/runt related transcription factor (RUNX) 2 signaling pathway may be a possible mechanism for the promotion of osteogenesis. Our study demonstrated that the OTF PNS/nHAC/Mg/PLLA scaffold could promote osteogenesis via the coupling of angiogenesis and osteogenesis in osteoporotic rats with bone defects, and activating the BMP 2/BMPR1A/RUNX2 signaling pathway may be an osteogenesis related mechanism. However, further experiments are necessary to facilitate its practical application in the treatment of osteoporotic bone defects.
C1 [Feng, Guiyu; Liu, Wei; Zhang, Yingkai; Zhang, Pingxin; Wang, Wei; Li, Dongyang; Sun, Song; Chai, Limin] Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ & Beijing, Key Lab Chinese Internal Med, Beijing 100700, Peoples R China.
   [Huang, Jian; Li, Jinyu] Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, Beijing 100700, Peoples R China.
   [Yu, Yao; Yang, Fenghe; Niu, Xufeng] Beihang Univ, Sch Biol Sci & Med Engn, Beijing Adv Innovat Ctr Biomed Engn, Minist Educ,Key Lab Biomech & Mechanobiol, Beijing 100083, Peoples R China.
   [Tian, Bingbing] Beijing Univ Chinese Med, Dongzhimen Hosp, Operating Room, Beijing 100700, Peoples R China.
C3 Beijing University of Chinese Medicine; Beijing University of Chinese
   Medicine; Beihang University; Beijing University of Chinese Medicine
RP Chai, LM (通讯作者)，Beijing Univ Chinese Med, Dongzhimen Hosp, Minist Educ & Beijing, Key Lab Chinese Internal Med, Beijing 100700, Peoples R China.; Li, JY (通讯作者)，Beijing Univ Chinese Med, Dongzhimen Hosp, Dept Orthoped, Beijing 100700, Peoples R China.; Niu, XF (通讯作者)，Beihang Univ, Sch Biol Sci & Med Engn, Beijing Adv Innovat Ctr Biomed Engn, Minist Educ,Key Lab Biomech & Mechanobiol, Beijing 100083, Peoples R China.
EM nxf@buaa.edu.cn; liminchai@hotmail.com; leery_5566@163.com
RI Tian, Bingbing/AAC 1357 2021; Feng, Guiyu/KOD 6115 2024
FU National Natural Science Foundation of China [82074463, 82222076]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 82074463 and 82222076).
CR Ayoubi M, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202100113
   Behera J, 2021, THERANOSTICS, V11, P7715, DOI 10.7150/thno.58410
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Ding L, 2012, NATURE, V481, P457, DOI 10.1038/nature10783
   Farah S, 2016, ADV DRUG DELIVER REV, V107, P367, DOI 10.1016/j.addr.2016.06.012
   Feng GY, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14010031
   Gosset A, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101551
   Gu JC, 2017, ACS APPL MATER INTER, V9, P5968, DOI 10.1021/acsami.6b13547
   Guan XM, 2014, ACS APPL MATER INTER, V6, P21525, DOI 10.1021/am506543a
   Hayashi M, 2012, NATURE, V485, P69, DOI 10.1038/nature11000
   Hong SJ, 2009, PHYTOTHER RES, V23, P677, DOI 10.1002/ptr.2705
   Hu H, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/8412468
   Huang J, 2020, POULTRY SCI, V99, P5047, DOI 10.1016/j.psj.2020.06.057
   Huang J, 2018, THERANOSTICS, V8, P2435, DOI 10.7150/thno.22144
   Ji G, 2019, BONE JOINT J, V101B, P108, DOI 10.1302/0301 620X.101B7.BJJ 2018 1473.R1
   Kellermair J, 2013, BLOOD, V122, P3376, DOI 10.1182/blood 2013 04 499558
   Komori T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21207513
   Kum CH, 2014, SMALL, V10, P3783, DOI 10.1002/smll.201302880
   Kum CH, 2013, J MATER CHEM B, V1, P2764, DOI [10.1039/C3TB00490B, 10.1039/c3tb00490b]
   Kusumbe AP, 2014, NATURE, V507, P323, DOI 10.1038/nature13145
   Liao SS, 2004, J BIOMED MATER RES B, V69B, P158, DOI 10.1002/jbm.b.20035
   Liu LT, 2016, CURR OSTEOPOROS REP, V14, P386, DOI 10.1007/s11914 016 0339 7
   Liu XY, 2012, J ETHNOPHARMACOL, V139, P311, DOI 10.1016/j.jep.2011.11.017
   Lyndon JA, 2014, J CONTROL RELEASE, V179, P63, DOI 10.1016/j.jconrel.2014.01.026
   Melton LJ, 2001, CALCIFIED TISSUE INT, V69, P179, DOI 10.1007/s00223 001 1043 9
   Nan K, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02390 x
   Ng TB, 2006, J PHARM PHARMACOL, V58, P1007, DOI 10.1211/jpp.58.8.0001
   Niu XF, 2017, SCI REP UK, V7, DOI 10.1038/srep45655
   Niu XF, 2016, MACROMOL BIOSCI, V16, P1039, DOI 10.1002/mabi.201600020
   Niu XF, 2015, J BIOMED MATER RES A, V103, P2635, DOI 10.1002/jbm.a.35408
   Niu XF, 2011, ARTIF ORGANS, V35, pE119, DOI 10.1111/j.1525 1594.2011.01274.x
   Niu XF, 2009, J CONTROL RELEASE, V134, P111, DOI 10.1016/j.jconrel.2008.11.020
   Nizet A, 2020, CLIN CHIM ACTA, V501, P198, DOI 10.1016/j.cca.2019.11.012
   Oliveira FC, 2019, INT J NANOMED, V14, P865, DOI 10.2147/IJN.S192456
   Qi X, 2016, INT J BIOL SCI, V12, P836, DOI 10.7150/ijbs.14809
   Qin X, 2021, J BONE MINER RES, V36, P2081, DOI 10.1002/jbmr.4386
   Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5
   Ramasamy SK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13601
   Ramasamy SK, 2016, ANNU REV CELL DEV BI, V32, P649, DOI 10.1146/annurev cellbio 111315 124936
   Randi AM, 2018, BLOOD, V132, P132, DOI 10.1182/blood 2018 01 769018
   Red Horse K, 2007, DEV CELL, V12, P181, DOI 10.1016/j.devcel.2007.01.013
   Rodrigues SC, 2013, J BIOMED MATER RES A, V101, P1080, DOI 10.1002/jbm.a.34394
   Shen JJ, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287 021 02487 3
   Stegen S, 2015, BONE, V70, P19, DOI 10.1016/j.bone.2014.09.017
   Tashiro Y, 2012, BLOOD, V119, P6382, DOI 10.1182/blood 2011 12 399659
   Theis V, 2018, CURR PROTEIN PEPT SC, V19, P589, DOI 10.2174/1389203719666180104113937
   Tomlinson RE, 2013, BONE RES, V1, P311, DOI 10.4248/BR201304002
   TRUETA J, 1963, J BONE JOINT SURG BR, V45, P572, DOI 10.1302/0301 620X.45B3.572
   TRUETA J, 1960, J BONE JOINT SURG BR, V42, P97, DOI 10.1302/0301 620X.42B1.97
   Tuckermann J, 2021, NAT REV RHEUMATOL, V17, P608, DOI 10.1038/s41584 021 00682 3
   Valo H, 2009, SMALL, V5, P1791, DOI 10.1002/smll.200801907
   Wang XL, 2011, PHYTOMEDICINE, V18, P868, DOI 10.1016/j.phymed.2011.01.022
   Wu D, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.687551
   Xu T, 2019, BONE, V122, P218, DOI 10.1016/j.bone.2019.03.006
   Yang FH, 2019, ACS APPL MATER INTER, V11, P23546, DOI 10.1021/acsami.9b03766
   Yang M, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12784
   Yang W J., 2020, BIOMED RES INT, V2020, P501
   Yuan ZY, 2019, ACTA BIOMATER, V85, P294, DOI 10.1016/j.actbio.2018.12.017
   Zhang KY, 2012, ACS APPL MATER INTER, V4, P3091, DOI 10.1021/am3004522
   Zhang XN, 2016, CHEM BIOL INTERACT, V256, P188, DOI 10.1016/j.cbi.2016.07.003
NR 60
TC 1
Z9 3
U1 5
U2 46
PU IOP Publishing Ltd
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 1748 6041
EI 1748 605X
J9 BIOMED MATER
JI Biomed. Mater.
PD JUL 1
PY 2023
VL 18
IS 4
AR 045002
DI 10.1088/1748 605X/accf55
PG 20
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Engineering; Materials Science
GA F4AS8
UT WOS:000981794600001
PM 37144422
DA 2025 08 17
ER

PT J
AU Korn, MA
   Schmitt, H
   Angermüller, S
   Chambers, D
   Seeling, M
   Lux, UT
   Brey, S
   Royzman, D
   Brückner, C
   Popp, V
   Percivalle, E
   Bäuerle, T
   Zinser, E
   Winkler, TH
   Steinkasserer, A
   Nimmerjahn, F
   Nitschke, L
AF Korn, Marina A.
   Schmitt, Heike
   Angermuller, Sieglinde
   Chambers, David
   Seeling, Michaela
   Lux, Uwe T.
   Brey, Stefanie
   Royzman, Dmytro
   Bruckner, Christin
   Popp, Vanessa
   Percivalle, Elena
   Bauerle, Tobias
   Zinser, Elisabeth
   Winkler, Thomas H.
   Steinkasserer, Alexander
   Nimmerjahn, Falk
   Nitschke, Lars
TI Siglec 15 on Osteoclasts Is Crucial for Bone Erosion in Serum Transfer
   Arthritis
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID FUNCTIONAL OSTEOCLASTS; RECEPTOR ACTIVATOR; DIFFERENTIATION; LIGAND;
   OSTEOPROTEGERIN; DESTRUCTION; CYTOKINES; DISEASE; LECTIN; ALPHA
AB Siglec 15 is a conserved sialic acid binding Ig like lectin, which is expressed on osteoclasts. Deficiency of Siglec 15 leads to an impaired osteoclast development, resulting in a mild osteopetrotic phenotype. The role of Siglec 15 in arthritis is still largely unclear. To address this, we generated Siglec 15 knockout mice and analyzed them in a mouse arthritis model. We could show that Siglec 15 is directly involved in pathologic bone erosion in the K/BxN serum transfer arthritis model. Histological analyses of joint destruction provided evidence for a significant reduction in bone erosion area and osteoclast numbers in Sigler 15( / ) mice, whereas the inflammation area and cartilage destruction was comparable to wild type mice. Thus, Siglec 15 on osteoclasts has a crucial function for bone erosion during arthritis. In addition, we generated a new monoclonal anti Siglec 15 Ab to clarify its expression pattern on immune cells. Whereas this Ab demonstrated an almost exclusive Siglec 15 expression on murine osteoclasts and hardly any other expression on various other immune cell types, human Siglec 15 was more broadly expressed on human myeloid cells, including human osteoclasts. Taken together, our findings show a role of Siglec 15 as a regulator of pathologic bone resorption in arthritis and highlight its potential as a target for future therapies, as Siglec 15 blocking Abs are available.
C1 [Korn, Marina A.; Schmitt, Heike; Angermuller, Sieglinde; Chambers, David; Seeling, Michaela; Brey, Stefanie; Bruckner, Christin; Winkler, Thomas H.; Nimmerjahn, Falk; Nitschke, Lars] Univ Erlangen Nurnberg, Dept Biol, Div Genet, Staudtstr 5, D 91058 Erlangen, Germany.
   [Lux, Uwe T.] Univ Erlangen Nurnberg, Dept Biol, Div Anim Physiol, D 91058 Erlangen, Germany.
   [Royzman, Dmytro; Zinser, Elisabeth; Steinkasserer, Alexander] Univ Hosp Erlangen, Dept Immune Modulat, D 91054 Erlangen, Germany.
   [Popp, Vanessa; Percivalle, Elena; Bauerle, Tobias] Univ Hosp Erlangen, Preclin Imaging Ctr Erlangen, Inst Radiol, D 91054 Erlangen, Germany.
   [Seeling, Michaela] Tech Univ Munich, Sch Med, Inst Clin Chem & Pathobiochem, Munich, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   Technical University of Munich
RP Nitschke, L (通讯作者)，Univ Erlangen Nurnberg, Dept Biol, Div Genet, Staudtstr 5, D 91058 Erlangen, Germany.
EM lars.nitschke@fau.de
RI ; percivalle, elena/K 7994 2016; Baeuerle, Tobias/LSL 3005 2024
OI Brey, Stefanie/0000 0001 6384 4938; Lux, Uwe
   Thorsten/0000 0002 9652 4778; Chambers, David/0000 0003 3716 3172;
   Knott, Heike/0000 0001 5638 9471; Seeling, Michaela/0000 0002 4788 4021;
   
FU Deutsche Forschungsgemeinschaft (DFG) via Collaborative Research Centre
   (CRC) 1181; DFG [CRC1181, 2084]
FX This work was supported by the Deutsche Forschungsgemeinschaft (DFG) via
   Collaborative Research Centre (CRC) 1181 Projects B06 (to L.N.), A07 (to
   F.N.), and B03 (to A.S.). T.B. was funded by DFG CRC1181 (project Z01)
   and Schwerpunktprogramm 2084: mBONE (Project 03).
CR Angata T, 2007, GLYCOBIOLOGY, V17, P838, DOI 10.1093/glycob/cwm049
   Angata T, 2020, J BIOMED SCI, V27, DOI 10.1186/s12929 019 0610 1
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   BROMLEY M, 1984, ARTHRITIS RHEUM US, V27, P968, DOI 10.1002/art.1780270902
   Christensen AD, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00213
   Cohen SB, 2008, ARTHRITIS RHEUM, V58, P1299, DOI 10.1002/art.23417
   Crotti TN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4088
   Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397
   Gravallese EM, 1998, AM J PATHOL, V152, P943
   Haynes DR, 2001, RHEUMATOLOGY, V40, P623, DOI 10.1093/rheumatology/40.6.623
   Hiruma Y, 2013, BONE, V53, P87, DOI 10.1016/j.bone.2012.11.036
   Hiruma Y, 2011, BIOCHEM BIOPH RES CO, V409, P424, DOI 10.1016/j.bbrc.2011.05.015
   Ishida Kitagawa N, 2012, J BIOL CHEM, V287, P17493, DOI 10.1074/jbc.M111.324194
   Ji H, 2002, IMMUNITY, V16, P157, DOI 10.1016/S1074 7613(02)00275 3
   Kameda Y, 2015, BONE, V71, P217, DOI 10.1016/j.bone.2014.10.027
   Kameda Y, 2013, J BONE MINER RES, V28, P2463, DOI 10.1002/jbmr.1989
   Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074 7613(00)80045 X
   Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092 8674(00)81989 3
   McInnes IB, 2007, NAT REV IMMUNOL, V7, P429, DOI 10.1038/nri2094
   Mócsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101
   Murugesan G, 2021, GLYCOBIOLOGY, V31, P44, DOI 10.1093/glycob/cwaa048
   Nam J, 2010, MOD RHEUMATOL, V20, P325, DOI 10.1007/s10165 010 0277 7
   Pettit AR, 2001, AM J PATHOL, V159, P1689, DOI 10.1016/S0002 9440(10)63016 7
   Pettitt SJ, 2009, NAT METHODS, V6, P493, DOI 10.1038/nmeth.1342
   Redlich K, 2002, J CLIN INVEST, V110, P1419, DOI 10.1172/JCI200215582
   Romas E, 2002, BONE, V30, P340, DOI 10.1016/S8756 3282(01)00682 2
   Sato D, 2018, BONE, V116, P172, DOI 10.1016/j.bone.2018.07.026
   Schett G, 2009, J BONE MINER RES, V24, P1142, DOI 10.1359/jbmr.090533
   Scott DL, 2010, LANCET, V376, P1094, DOI 10.1016/S0140 6736(10)60826 4
   Seeling M, 2015, P NATL ACAD SCI USA, V112, pE4337, DOI 10.1073/pnas.1512310112
   Shimizu T, 2015, BONE, V79, P65, DOI 10.1016/j.bone.2015.05.029
   Sinigaglia L, 2006, RHEUM DIS CLIN N AM, V32, P631, DOI 10.1016/j.rdc.2006.07.002
   Smolen JS, 2016, LANCET, V388, P1984
   Smolen JS, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2018.1
   Steffen Ulrike, 2019, Curr Protoc Immunol, V125, pe74, DOI 10.1002/cpim.74
   Stuible M, 2014, J BIOL CHEM, V289, P6498, DOI 10.1074/jbc.M113.494542
   Takamiya R, 2013, GLYCOBIOLOGY, V23, P178, DOI 10.1093/glycob/cws139
   Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105 2896.2005.00338.x
   Wang J, 2019, NAT MED, V25, P656, DOI 10.1038/s41591 019 0374 x
   Wipke BT, 2001, J IMMUNOL, V167, P1601, DOI 10.4049/jimmunol.167.3.1601
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
NR 41
TC 10
Z9 12
U1 0
U2 6
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022 1767
EI 1550 6606
J9 J IMMUNOL
JI J. Immunol.
PD NOV 15
PY 2020
VL 205
IS 10
BP 2595
EP 2605
DI 10.4049/jimmunol.2000472
PG 11
WC Immunology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Immunology
GA OS6DI
UT WOS:000590251700005
PM 33020147
DA 2025 08 17
ER

PT J
AU Feng, R
   Lentzsch, S
AF Feng, Rentian
   Lentzsch, Suzanne
TI Treatment of multiple myeloma with SDX 308
SO DRUG NEWS & PERSPECTIVES
LA English
DT Article
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; CHRONIC LYMPHOCYTIC LEUKEMIA;
   INDOLE PYRAN ANALOGS; R ETODOLAC SDX 101; INHIBITION; CANCER;
   CYTOTOXICITY; ENANTIOMER; CELECOXIB
AB Multiple myeloma (MM) is a hematologic malignancy characterized by dysregulated proliferation of plasma cells and increased osteoclast activity that results in bone destruction and lytic lesions. Therefore, novel treatment modalities targeting both myeloma cell and osteoclast function may dramatically improve MM patient outcome. As an R enantiomer of the cyclooxygenase (COX) inhibitor etodolac, SDX 101 has shown favorable antimyeloma effects. More recently, another structural analogue of etodolac, SDX 308, has displayed in vitro cytotoxic activity on tumor lines and in vivo antitumor efficacy in mice. SDX 308 has high antimyeloma activity and shows synergism in combination with other drugs for the treatment of chronic lymphocytic leukemia (CLL). In addition SDX 308 inhibits osteoclast (OCL) formation resulting in complete abrogation of bone resorption. Therefore, SDX 308 might be an attractive drug for the treatment of diseases with increased OCL activity, such as osteolytic lesions in multiple myeloma and metastatic carcinomas as well as osteoporosis. In the present review, we discuss SDX 308 as a new therapeutic candidate for the treatment of MM and diseases with increased osteoclast activity. (c) 2007 Prous Science. All rights reserved.
C1 Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Dept Med, Pittsburgh, PA 15232 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Lentzsch, S (通讯作者)，Univ Pittsburgh, Inst Canc, Div Hematol Oncol, Dept Med, UPMC Cancer Pavil,5th Floor,5150 Ctr Ave, Pittsburgh, PA 15232 USA.
EM lentzschs@upmc.edu
FU NCATS NIH HHS [UL1 TR000005] Funding Source: Medline
CR Adachi S, 2003, ACTA HAEMATOL BASEL, V111, P107, DOI 10.1159/000074490
   Behari J, 2007, J HEPATOL, V46, P849, DOI 10.1016/j.jhep.2006.11.017
   DEMERSON CA, 1983, J MED CHEM, V26, P1778, DOI 10.1021/jm00366a025
   Feng RT, 2007, BLOOD, V109, P2130, DOI 10.1182/blood 2006 07 027458
   Grösch S, 2006, JNCI J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206
   Huls G, 2003, LANCET, V362, P230, DOI 10.1016/S0140 6736(03)13915 3
   HUMBER LG, 1986, J MED CHEM, V29, P871, DOI 10.1021/jm00155a047
   Kardosh A, 2005, BLOOD, V106, P4330, DOI 10.1182/blood 2005 07 2819
   Kolluri SK, 2005, P NATL ACAD SCI USA, V102, P2525, DOI 10.1073/pnas.0409721102
   Kulp SK, 2004, CANCER RES, V64, P1444, DOI 10.1158/0008 5472.CAN 03 2396
   Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875
   Latif T, 2005, CLIN LYMPHOMA MYELOM, V6, P228, DOI 10.3816/CLM.2005.n.050
   LEONI LM, 2004, P AM ASS CANC RES AA, V45
   LEONI LM, 2004, BLOOD, V104
   Lindhagen E, 2007, CANCER CHEMOTH PHARM, V60, P545, DOI 10.1007/s00280 006 0400 9
   Lindhagen E, 2007, INVEST NEW DRUG, V25, P297, DOI 10.1007/s10637 007 9049 4
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Nardella FA, 2002, BLOOD, V99, P2625, DOI 10.1182/blood.V99.7.2625
   Plumb JA, 2003, MOL CANCER THER, V2, P721
   Ries LAG., 1973, SEER CANC STAT REV
   Robak P, 2006, LEUKEMIA LYMPHOMA, V47, P2625, DOI 10.1080/10428190600948147
   SKEITH KJ, 1994, CLIN PHARMACOKINET, V26, P233, DOI 10.2165/00003088 199426030 00006
   Ulrich CM, 2006, NAT REV CANCER, V6, P130, DOI 10.1038/nrc1801
   Wang WH, 2003, JNCI J NATL CANCER I, V95, P1784, DOI 10.1093/jnci/djg106
   Yasui H, 2007, LEUKEMIA, V21, P535, DOI 10.1038/sj.leu.2404561
   Yasui H, 2005, BLOOD, V106, P706, DOI 10.1182/blood 2005 02 0838
   Zhang L, 2000, SCIENCE, V290, P989, DOI 10.1126/science.290.5493.989
   Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451
NR 28
TC 7
Z9 8
U1 0
U2 0
PU PROUS SCIENCE, SAU THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0214 0934
EI 2013 0139
J9 DRUG NEWS PERSPECT
JI Drug News Perspect.
PD SEP
PY 2007
VL 20
IS 7
BP 431
EP 435
DI 10.1358/dnp.2007.20.7.1149631
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA 236KN
UT WOS:000251302000002
PM 17992265
DA 2025 08 17
ER

PT J
AU Kim, EH
   Kim, MS
   Takahashi, A
   Suzuki, M
   Vares, G
   Uzawa, A
   Fujimori, A
   Ohno, T
   Sai, S
AF Kim, Eun Ho
   Kim, Mi Sook
   Takahashi, Akihisa
   Suzuki, Masao
   Vares, Guillaume
   Uzawa, Akiko
   Fujimori, Akira
   Ohno, Tatsuya
   Sai, Sei
TI Carbon Ion Beam Irradiation Alone or in Combination with Zoledronic acid
   Effectively Kills Osteosarcoma Cells
SO CANCERS
LA English
DT Article
DE zoledronic acid; osteosarcoma cells; bone cancer; carbon ion; miR 29b
ID SIGNALING PATHWAY; BREAST CANCER; RADIOTHERAPY; BONE; METASTASES;
   DENOSUMAB; SURVIVAL; THERAPY
AB Osteosarcoma (OSA) is the most common malignant bone tumor in children and adolescents. The overall five year survival rate for all bone cancers is below 70%; however, when the cancer has spread beyond the bone, it is about 15 30%. Herein, we evaluated the effects of carbon ion beam irradiation alone or in combination with zoledronic acid (ZOL) on OSA cells. Carbon ion beam irradiation in combination with ZOL significantly inhibited OSA cell proliferation by arresting cell cycle progression and initiating KHOS and U2OS cell apoptosis, compared to treatments with carbon ion beam irradiation, X ray irradiation, and ZOL alone. Moreover, we observed that this combination greatly inhibited OSA cell motility and invasion, accompanied by the suppression of the Pi3K/Akt and MAPK signaling pathways, which are related to cell proliferation and survival, compared to individual treatments with carbon ion beam or X ray irradiation, or ZOL. Furthermore, ZOL treatment upregulated microRNA (miR) 29b expression; the combination with a miR 29b mimic further decreased OSA cell viability via activation of the caspase 3 pathway. Thus, ZOL mediated enhancement of carbon ion beam radiosensitivity may occur via miR 29b upregulation; co treatment with the miR 29b mimic further decreased OSA cell survival. These findings suggest that the carbon ion beam irradiation in combination with ZOL has high potential to increase OSA cell death.
C1 [Kim, Eun Ho] Daegu Catholic Univ, Sch Med, Dept Biochem, Daegu 42472, South Korea.
   [Kim, Mi Sook] Korea Inst Radiol & Med Sci, Dept Radiat Oncol, Seoul 139706, South Korea.
   [Takahashi, Akihisa] Gunma Univ, Heavy Ion Med Ctr, 3 39 22 Showa Machi, Maebashi, Gunma 3718511, Japan.
   [Suzuki, Masao; Uzawa, Akiko; Fujimori, Akira; Sai, Sei] Natl Inst Radiol Sci, Natl Inst Quantum & Radiol Sci & Technol, Dept Basic Med Sci Radiat Damages, Chiba 2638555, Japan.
   [Vares, Guillaume] Okinawa Inst Sci & Technol Grad Univ OIST, Cell Signal Unit, Okinawa 9040495, Japan.
   [Ohno, Tatsuya] Gunma Univ, Dept Radiat Oncol, Grad Sch Med, 3 39 22 Showa Machi, Maebashi, Gunma 3718511, Japan.
C3 Catholic University of Daegu; Korea Institute of Radiological & Medical
   Sciences; Gunma University; National Institutes for Quantum Science &
   Technology; Okinawa Institute of Science & Technology Graduate
   University; Gunma University
RP Kim, EH (通讯作者)，Daegu Catholic Univ, Sch Med, Dept Biochem, Daegu 42472, South Korea.; Sai, S (通讯作者)，Natl Inst Radiol Sci, Natl Inst Quantum & Radiol Sci & Technol, Dept Basic Med Sci Radiat Damages, Chiba 2638555, Japan.
EM eh140149@cu.ac.kr; mskim@kirams.re.kr; a takahashi@gunma u.ac.jp;
   suzuki.masao@qst.go.jp; guillaume.vares@oist.jp; uzawa.akiko@qst.go.jp;
   fujimori.akira@qst.go.jp; tohno@gunma u.ac.jp; sai.sei@qst.go.jp
RI ; Vares, Guillaume/S 6530 2019; Vares, Guillaume/A 9257 2011
OI Takahashi, Akihisa/0000 0002 9960 2153; Vares,
   Guillaume/0000 0002 6191 9032
FU National Research Foundation of Korea (NRF) [NRF 2019M2A2B4095150,
   NRF 2017R1D1A1B03028923]
FX This work was supported by a National Research Foundation of Korea (NRF)
   grant (No. NRF 2019M2A2B4095150, NRF 2017R1D1A1B03028923).
CR Anderson ME, 2016, ORTHOP CLIN N AM, V47, P283, DOI 10.1016/j.ocl.2015.08.022
   Bühler H, 2016, IN VIVO, V30, P761, DOI 10.21873/invivo.10992
   Cheng D, 2017, ONCOTARGET, V8, P81062, DOI 10.18632/oncotarget.19009
   Cui X, 2011, CANCER RES, V71, P3676, DOI 10.1158/0008 5472.CAN 10 2926
   DeLaney TF, 2005, INT J RADIAT ONCOL, V61, P492, DOI 10.1016/j.ijrobp.2004.05.051
   Demizu Y, 2017, INT J RADIAT ONCOL, V98, P367, DOI 10.1016/j.ijrobp.2017.02.030
   Denham JW, 2019, LANCET ONCOL, V20, P267, DOI 10.1016/S1470 2045(18)30757 5
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   Du C, 2017, ONCOL LETT, V14, P4237, DOI 10.3892/ol.2017.6710
   Feng CJ, 2016, ONCOL REP, V35, P3460, DOI 10.3892/or.2016.4741
   Fragni M, 2016, N S ARCH PHARMACOL, V389, P529, DOI 10.1007/s00210 016 1224 8
   Geller David S, 2010, Clin Adv Hematol Oncol, V8, P705
   Gill J, 2013, PHARMACOL THERAPEUT, V137, P89, DOI 10.1016/j.pharmthera.2012.09.003
   Groenen KHJ, 2016, RADIOTHER ONCOL, V119, P194, DOI 10.1016/j.radonc.2016.03.001
   HE L, 2012, BIOCHEM BIOPH RES CO, V17, P547, DOI DOI 10.1016/J.EGYPRO.2012.02.134
   Heng M, 2020, EUR J CANCER, V125, P130, DOI 10.1016/j.ejca.2019.07.029
   Imai R, 2006, LANCET ONCOL, V7, P1034, DOI 10.1016/S1470 2045(06)70978 0
   Jia LF, 2014, ORAL ONCOL, V50, P1062, DOI 10.1016/j.oraloncology.2014.07.010
   Kamada T, 2015, LANCET ONCOL, V16, pE93, DOI 10.1016/S1470 2045(14)70412 7
   Kijima T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064615
   Kim EH, 2016, ONCOTARGET, V7, P70869, DOI 10.18632/oncotarget.12281
   Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470 2045(12)70073 6
   Koto K, 2013, INT J ONCOL, V42, P525, DOI 10.3892/ijo.2012.1735
   Lindsey BA, 2017, RHEUMATOL THER, V4, P25, DOI 10.1007/s40744 016 0050 2
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Matsunobu A, 2012, CANCER AM CANCER SOC, V118, P4555, DOI 10.1002/cncr.27451
   Mohamad Osama, 2018, Oncotarget, V9, P22976, DOI 10.18632/oncotarget.25165
   Oh JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111812
   Oonishi K, 2012, RADIOTHER ONCOL, V105, P258, DOI 10.1016/j.radonc.2012.08.009
   Orita Y, 2015, ANN SURG ONCOL, V22, P4008, DOI 10.1245/s10434 015 4497 0
   Pichon B, 2016, INT J RADIAT ONCOL, V96, P840, DOI 10.1016/j.ijrobp.2016.07.027
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Polascik Thomas J, 2008, Ther Clin Risk Manag, V4, P261
   Rouhrazi H, 2018, BIOTECH HISTOCHEM, V93, P77, DOI 10.1080/10520295.2017.1387286
   Sai Sei, 2018, Oncotarget, V9, P14849, DOI 10.18632/oncotarget.23756
   Sai S, 2015, MOL CANCER, V14, DOI 10.1186/s12943 015 0429 7
   Sai S, 2015, ONCOTARGET, V6, P5517, DOI 10.18632/oncotarget.3584
   Schwarz R, 2009, CANCER TREAT RES, V152, P147, DOI 10.1007/978 1 4419 0284 9_7
   Shapiro CL, 2017, J CLIN ONCOL, V35, P3949, DOI 10.1200/JCO.2017.73.7437
   Shin J, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935 017 0476 9
   Sugahara S, 2012, RADIOTHER ONCOL, V105, P226, DOI 10.1016/j.radonc.2012.09.010
   Vadhan Raj S, 2012, ANN ONCOL, V23, P3045, DOI 10.1093/annonc/mds175
   Wang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046 019 1109 z
   Wolfe TD, 2011, CLIN EXP METASTAS, V28, P377, DOI 10.1007/s10585 011 9377 9
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943 019 0954 x
   You YJ, 2019, ONCOTARGETS THER, V12, P4323, DOI 10.2147/OTT.S202516
   Yuan F, 2019, INT J SURG, V66, P1, DOI 10.1016/j.ijsu.2019.03.004
   Zhang TT, 2019, MOL THER, V27, P1183, DOI 10.1016/j.ymthe.2019.03.020
NR 48
TC 10
Z9 10
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 2072 6694
J9 CANCERS
JI Cancers
PD MAR
PY 2020
VL 12
IS 3
AR 698
DI 10.3390/cancers12030698
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA LJ5VG
UT WOS:000530232300174
PM 32187978
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Park, HS
   Lee, A
   Chae, BJ
   Bae, JS
   Song, BJ
   Jung, SS
AF Park, Hyung Seok
   Lee, Ahwon
   Chae, Byung Joo
   Bae, Ja Seong
   Song, Byung Joo
   Jung, Sang Seol
TI Expression of Receptor Activator of Nuclear Factor Kappa B as a Poor
   Prognostic Marker in Breast Cancer
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE breast neoplasms; osteoprotegerin; prognosis; RANK ligand; receptor
   activator of nuclear factor kappa B; survival
ID OSTEOCLAST DIFFERENTIATION FACTOR; INTERNATIONAL EXPERT CONSENSUS;
   OSTEOPROTEGERIN LIGAND; ZOLEDRONIC ACID; BONE METASTASES;
   PROSTATE CANCER; PRIMARY THERAPY; PHASE II; RANKL; DENOSUMAB
AB PurposeReceptor activator of nuclear factor kappa B and its ligand (RANK/RANKL) and Osteoprotegerin (OPG) are key molecules for regulating osteoclastic activity in bone. However, little is known about the role of RANK related molecules in breast cancer prognosis. We aimed to evaluate RANK, RANKL, and OPG expression and the associated clinical impact in breast cancer.
   MethodsTissue microarray (TMA) from 185 patients with primary breast cancer was established. Immunohistochemistry for RANK, RANKL, and OPG was performed. Clinicopathologic features and survival outcomes associated with expression of RANK, RANKL, and OPG were analyzed.
   ResultsRANK, RANKL, and OPG were expressed in 74.1%, 78.4%, and 45.9% of patients, respectively. RANKL expression was associated with lower Ki 67 level. OPG expression was related to small tumor size, node negativity, and low Ki 67. There was no significant difference in clinicopathologic features between tumors with RANK and those without RANK. RANK expression was significantly associated with poor disease free survival in univariate analysis (P=0.04) and multivariate analysis (P=0.02). RANKL expression was associated with improved skeletal disease free survival in multivariate analysis (P=0.03).
   ConclusionsThe RANK/RANKL pathway regulated by OPG may have a role in predicting progression and prognosis of breast cancer. J. Surg. Oncol. 2014 110:807 812. (c) 2014 Wiley Periodicals, Inc.
C1 [Park, Hyung Seok] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea.
   [Lee, Ahwon] Catholic Univ, Coll Med, Seoul St Marys Hosp, Dept Hosp Pathol, Seoul, South Korea.
   [Chae, Byung Joo; Bae, Ja Seong; Song, Byung Joo; Jung, Sang Seol] Catholic Univ Korea, Dept Surg, Coll Med, Seoul 137701, South Korea.
C3 Yonsei University; Yonsei University Health System; Seoul St. Mary's
   Hospital; Catholic University of Korea; Catholic University of Korea
RP Song, BJ (通讯作者)，Catholic Univ Korea, Dept Surg, Coll Med, Seoul 137701, South Korea.
EM bjsong@catholic.ac.kr
RI Park, Joohyun/KAL 8175 2024; Park, Hong Gyu/C 6000 2008
OI Park, Hyung Seok/0000 0001 5322 6036; 
FU Korea Breast Cancer Foundation
FX A major part of this study was presented at the poster session of the
   2nd International Breast Cancer Symposium and 29th Annual Meeting of
   KBCS, 26 27 April 2013, Jeju, Korea Republic. The present research has
   been supported by Korea Breast Cancer Foundation.
CR Azim H, 2013, EXPERT REV ANTICANC, V13, P195, DOI [10.1586/era.12.177, 10.1586/ERA.12.177]
   Bekker PJ, 2004, J BONE MINER RES, V19, P1059, DOI 10.1359/JBMR.040305
   Bhatia P, 2005, CLIN CANCER RES, V11, P162
   Chae BJ, 2011, J SURG ONCOL, V103, P768, DOI 10.1002/jso.21861
   Chae BJ, 2009, JPN J CLIN ONCOL, V39, P217, DOI 10.1093/jjco/hyp007
   Chuang FH, 2009, J ORAL PATHOL MED, V38, P753, DOI 10.1111/j.1600 0714.2009.00793.x
   Coleman R, 2012, JNCI J NATL CANCER I, V104, P1059, DOI 10.1093/jnci/djs263
   Dougall WC, 2006, CANCER METAST REV, V25, P541, DOI 10.1007/s10555 006 9021 3
   Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092 8674(00)00103 3
   Fizazi K, 2009, J CLIN ONCOL, V27, P1564, DOI 10.1200/JCO.2008.19.2146
   Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091
   Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852
   Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092 8674(00)81569 X
   Lipton A, 2007, J CLIN ONCOL, V25, P4431, DOI 10.1200/JCO.2007.11.8604
   Nakagawa N, 1998, BIOCHEM BIOPH RES CO, V253, P395, DOI 10.1006/bbrc.1998.9788
   Owen S, 2013, ANTICANCER RES, V33, P199
   Recknor C, 2013, OBSTET GYNECOL, V121, P1291, DOI 10.1097/AOG.0b013e318291718c
   Santini D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019234
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Sottnik JL, 2013, CURR MOL MED, V13, P626
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Van Poznak C, 2006, J CLIN PATHOL, V59, P56, DOI 10.1136/jcp.2005.026534
   Wolff AC, 2007, ARCH PATHOL LAB MED, V131, P18, DOI 10.1043/1543 2165(2007)131[18:ASOCCO]2.0.CO;2
   Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597
   Zhang XY, 2013, ORAL ONCOL, V49, P119, DOI 10.1016/j.oraloncology.2012.08.004
NR 28
TC 37
Z9 39
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0022 4790
EI 1096 9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD DEC 1
PY 2014
VL 110
IS 7
BP 807
EP 812
DI 10.1002/jso.23737
PG 6
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Surgery
GA AS9GW
UT WOS:000344552200007
PM 25111682
DA 2025 08 17
ER

PT J
AU Boran, G
   Tavakoli, S
   Dierking, I
   Kamali, AR
   Ege, D
AF Boran, Gokcen
   Tavakoli, Sepideh
   Dierking, Ingo
   Kamali, Ali Reza
   Ege, Duygu
TI Synergistic effect of graphene oxide and zoledronic acid for
   osteoporosis and cancer treatment
SO SCIENTIFIC REPORTS
LA English
DT Article
ID ALKALINE PHOSPHATASE ACTIVITY; DRUG DELIVERY; IN VITRO; OSTEOBLAST
   DIFFERENTIATION; MEVALONATE PATHWAY; CARBON NANOTUBES; STEM CELLS;
   BISPHOSPHONATES; HYDROXYAPATITE; MINERALIZATION
AB Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treatment of osteoporosis and metastasis. In this study, graphene oxide (GO) is conjugated with ZOL, and the nanostructured material is evaluated in terms viability, proliferation and differentiation. Furthermore, the associated morphological changes of bone marrow derived mesenchymal stem cells (BM MSC), and Michigan Cancer Foundation 7 (MCF 7) breast cancer cells, as well as the effect of the drugs on mineralization of BM MSCs are investigated using a variety of characterization techniques including Fourier Transform Infrared Spectroscopy (FTIR), scanning electron microscopy (SEM) as well as alamar blue, acridine orange, and alizarin red assays. Nanostructured ZOL GO with an optimum performance is synthesized using ZOL and GO suspensions with the concentration of 50 mu M and 2.91ng/ml, respectively. ZOL GO nanostructures can facilitate the mineralization of BM MSC cells, demonstrated by the formation of clusters around the cells. The results obtained confirm the performance of ZOL GO nanostructures as promising drug complexes for the treatment of osteoporosis and metastasis.
C1 [Boran, Gokcen; Tavakoli, Sepideh; Ege, Duygu] Bogazici Univ, Inst Biomed Engn, TR 34368 Istanbul, Turkey.
   [Tavakoli, Sepideh] Northeastern Univ, Coll Engn, Boston, MA 02115 USA.
   [Dierking, Ingo] Univ Manchester, Dept Phys & Astron, Manchester M13 9PL, Lancs, England.
   [Kamali, Ali Reza] Northeastern Univ, Energy & Environm Mat Res Ctr E2MC, Sch Met, Shenyang 110819, Peoples R China.
C3 Bogazici University; Northeastern University; University of Manchester;
   Northeastern University   China
RP Ege, D (通讯作者)，Bogazici Univ, Inst Biomed Engn, TR 34368 Istanbul, Turkey.
EM duygu.ege@boun.edu.tr
RI Ege, Duygu/A 6423 2016; Kamali, Ali/AAY 9567 2021; Ege,
   Duygu/JAO 0714 2023; Kamali, Ali Reza/AAY 9567 2021
OI Ege, Duygu/0000 0002 9922 6995; BORAN, GOKCEN/0000 0001 5744 7098;
   Kamali, Ali Reza/0000 0002 2849 8547
FU Bogazici University Research fund [13601]; Scientific and Technological
   Research Council of Turkey (TUBITAK) [117M231]
FX This work was supported by Bogazici University Research fund (No. 13601)
   and the Scientific and Technological Research Council of Turkey
   (TUBITAK) (No. 117M231).
CR Agabiti SS, 2016, MOL MEMBR BIOL, V33, P1, DOI 10.1080/09687688.2016.1213432
   Allan C, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418784098
   Bagri A, 2010, NAT CHEM, V2, P581, DOI [10.1038/nchem.686, 10.1038/NCHEM.686]
   Banks CE, 2006, ANGEW CHEM INT EDIT, V45, P2533, DOI 10.1002/anie.200600033
   Basso Fernanda Gonçalves, 2013, J. Bras. Patol. Med. Lab., V49, P368, DOI 10.1590/S1676 24442013000500011
   Basso FG, 2016, BRAZ ORAL RES, V30, DOI [10.1590/1807 3107bor 2016.vol30.0122, 10.1590/1807 3107BOR 2016.vol30.0122]
   Boccaccini AR, 2017, ADV ENG MATER, P16
   Brennan MA, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045019
   Chen S., 2019, J ORTHOP TRANSL
   Çiplak Z, 2015, FULLER NANOTUB CAR N, V23, P361, DOI 10.1080/1536383X.2014.894025
   Ebert R, 2009, BONE, V44, P858, DOI 10.1016/j.bone.2009.01.009
   Ege D., 2017, ADV ENG MATER, V19, P16, DOI 10.1002/adem.201700627
   Elsayed M, 2016, BIOL PHARM BULL, V39, P1238, DOI 10.1248/bpb.b15 00746
   Fournier PG, 2010, NEOPLASIA, V12, P571, DOI 10.1593/neo.10282
   Frandsen CJ, 2013, INT J BIOMATER, V2013, DOI 10.1155/2013/513680
   Gao F, 2018, INT J CLIN EXP MED, V11, P4585
   Gautam S, 2018, RES REV A, V8, P20
   Göbel A, 2016, CANCER LETT, V375, P162, DOI 10.1016/j.canlet.2016.03.004
   Gou W, 2014, PLOS ONE, V9, P1
   He DN, 2015, RSC ADV, V5, P11966, DOI 10.1039/c4ra14511a
   Hu L, 2017, STEM CELLS DEV, V26, P123, DOI 10.1089/scd.2016.0173
   Hussien NA, 2018, ARTIF CELL NANOMED B, V46, pS264, DOI 10.1080/21691401.2017.1421211
   Igarashi K, 1997, PROSTAG LEUKOTR ESS, V56, P121, DOI 10.1016/S0952 3278(97)90508 1
   Jagdev SP, 2001, BRIT J CANCER, V84, P1126, DOI 10.1054/bjoc.2001.1727
   Junankar S, 2015, BONE CANCER: PRIMARY BONE CANCER AND BONE METASTASES, 2ND EDITION, P615, DOI 10.1016/B978 0 12 416721 6.00051 0
   Kadow Romacker A, 2013, J BIOMATER APPL, V27, P577, DOI 10.1177/0885328211415722
   Kang ES, 2018, COLLOID SURFACE B, V169, P20, DOI 10.1016/j.colsurfb.2018.04.053
   Kellinsalmi M, 2005, BASIC CLIN PHARMACOL, V97, P382, DOI 10.1111/j.1742 7843.2005.pto_176.x
   Khajuria DK, 2017, MAT SCI ENG C MATER, V71, P698, DOI 10.1016/j.msec.2016.10.066
   Khajuria DK, 2015, EUR J PHARM SCI, V66, P173, DOI 10.1016/j.ejps.2014.10.015
   Kolanthai E, 2018, ACS APPL MATER INTER, V10, P12441, DOI 10.1021/acsami.8b00699
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Lim DJ, 2014, ARCH PHARM RES, V37, P43, DOI 10.1007/s12272 013 0277 1
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Liu Z, 2011, MATER TODAY, V14, P316, DOI 10.1016/S1369 7021(11)70161 4
   Logan N, 2013, STEM CELLS INT, V2013, DOI 10.1155/2013/361637
   Macedo F, 2017, ONCOL REV, V11, P43, DOI 10.4081/oncol.2017.321
   Manoratne C., 2017, Mater Sci Res India, V14, P19, DOI [DOI 10.13005/MSRI/140104, 10.13005/msri/140104]
   Mohajeri M, 2019, J CELL PHYSIOL, V234, P298, DOI 10.1002/jcp.26899
   Murtey M., 2016, MODERN ELECT MICROSC, P161, DOI DOI 10.5772/61720
   Nadar RA, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201601119
   Ou LL, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989 016 0168 y
   Pan BQ, 2004, BONE, V34, P112, DOI 10.1016/j.bone.2003.08.013
   Pan YZ, 2012, EXPERT OPIN DRUG DEL, V9, P1365, DOI 10.1517/17425247.2012.729575
   Paredes JI, 2008, LANGMUIR, V24, P10560, DOI 10.1021/la801744a
   Park J, 2014, FRONT CHEM, V2, DOI [10.3389/fchem.2014.00050, 10.3389/fchem.2014.00077]
   Park YE, 2019, CALCIFIED TISSUE INT, V105, P497, DOI 10.1007/s00223 019 00590 5
   Patntirapong S, 2012, J ORAL PATHOL MED, V41, P713, DOI 10.1111/j.1600 0714.2012.01154.x
   Peter B, 2005, BONE, V36, P52, DOI 10.1016/j.bone.2004.10.004
   Polascik TJ, 2008, DRUG DES DEV THER, V3, P27
   Pozzi S, 2009, CLIN CANCER RES, V15, P5829, DOI 10.1158/1078 0432.CCR 09 0426
   Prasanthi MM., 2017, INT RES J PHARM, V8, P50, DOI [10.7897/2230 8407.080224, DOI 10.7897/2230 8407.080224]
   Räikkönen J, 2010, BIOCHEM PHARMACOL, V79, P777, DOI 10.1016/j.bcp.2009.10.003
   Raina DB, 2018, J CONTROL RELEASE, V272, P83, DOI 10.1016/j.jconrel.2018.01.006
   Raina DB, 2016, SCI REP UK, V6, DOI 10.1038/srep26033
   Rampersad SN, 2012, SENSORS BASEL, V12, P12347, DOI 10.3390/s120912347
   Recker RR, 2008, J BONE MINER RES, V23, P6, DOI 10.1359/JBMR.070906
   Sahoo NG, 2011, CHEM COMMUN, V47, P5235, DOI 10.1039/c1cc00075f
   Schech AJ, 2012, J STEROID BIOCHEM, V132, P195, DOI 10.1016/j.jsbmb.2012.05.008
   Schindeler A, 2005, BIOCHEM BIOPH RES CO, V338, P710, DOI 10.1016/j.bbrc.2005.09.198
   Schmid Alliana A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010148
   Shane E., 2013, OSTEOPOROSIS, P1873
   Shmeeda H, 2010, J CONTROL RELEASE, V146, P76, DOI 10.1016/j.jconrel.2010.04.028
   Svensson E, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen 2017 016022
   Talukdar Y, 2014, BIOMATERIALS, V35, P4863, DOI 10.1016/j.biomaterials.2014.02.054
   Tanvetyanon T, 2006, ANN ONCOL, V17, P897, DOI 10.1093/annonc/mdj105
   Tavakoli S, 2019, MRS ADV, V4, P1231, DOI 10.1557/adv.2019.117
   Tiwari G, 2012, INT J PHARM INVESTIG, V2, P2, DOI 10.4103/2230 973X.96920
   Torger B, 2013, BIOINTERPHASES, V8, DOI 10.1186/1559 4106 8 25
   Ural AU, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1543
   Vaisman DN, 2005, BIOL TRACE ELEM RES, V104, P131, DOI 10.1385/BTER:104:2:131
   Valenti MT, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010041
   Waller DD, 2019, CRIT REV BIOCHEM MOL, V54, P41, DOI 10.1080/10409238.2019.1568964
   Wu J, 2012, NANOTECHNOLOGY, V23, DOI 10.1088/0957 4484/23/35/355101
   Yang LJ, 2015, COLLOID SURFACE B, V129, P21, DOI 10.1016/j.colsurfb.2015.03.022
   Yang XY, 2008, J PHYS CHEM C, V112, P17554, DOI 10.1021/jp806751k
   Yang X, 2019, ARTIF CELL NANOMED B, V47, P822, DOI 10.1080/21691401.2019.1576706
   Zhang RY, 2012, MAT SCI ENG C MATER, V32, P1247, DOI 10.1016/j.msec.2012.03.016
   Zhang XY, 2012, TOXICOL RES UK, V1, P62, DOI 10.1039/c2tx20006f
   Zlatev HP, 2016, EUR J PHARM SCI, V86, P58, DOI 10.1016/j.ejps.2016.02.016
NR 80
TC 37
Z9 37
U1 0
U2 32
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045 2322
J9 SCI REP UK
JI Sci Rep
PD MAY 8
PY 2020
VL 10
IS 1
AR 7827
DI 10.1038/s41598 020 64760 4
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA NB2PG
UT WOS:000560354300016
PM 32385391
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Borggaard, XG
   Pirapaharan, DC
   Delaissé, JM
   Soe, K
AF Borggaard, Xenia G.
   Pirapaharan, Dinisha C.
   Delaisse, Jean Marie
   Soe, Kent
TI Osteoclasts' Ability to Generate Trenches Rather Than Pits Depends on
   High Levels of Active Cathepsin K and Efficient Clearance of Resorption
   Products
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE cathepsin K; osteoclast; bone resorption; pit; trench; lysosome;
   transcytosis; clathrin; chloroquine; functional secretory domain
ID SCANNING ELECTRON MICROSCOPY; BASAL PLASMA MEMBRANE; BONE RESORPTION;
   ENDOCYTIC TRAFFICKING; RUFFLED BORDER; CELL; DEGRADATION; CHLOROQUINE;
   INHIBITOR; DYNAMICS
AB Until recently, it was well accepted that osteoclasts resorb bone according to the resorption cycle model. This model is based on the assumption that osteoclasts are immobile during bone erosion, allowing the actin ring to be firmly attached and thereby provide an effective seal encircling the resorptive compartment. However, through time lapse, it was recently documented that osteoclasts making elongated resorption cavities and trenches move across the bone surface while efficiently resorbing bone. However, it was also shown that osteoclasts making rounded cavities and pits indeed resorb bone while they are immobile. Only little is known about what distinguishes these two different resorption modes. This is of both basic and clinical interest because these resorption modes are differently sensitive to drugs and are affected by the gender as well as age of the donor. In the present manuscript we show that: 1. levels of active cathepsin K determine the switch from pit to trench mode; 2. pit and trench mode depend on clathrin mediated endocytosis; and 3. a mechanism integrating release of resorption products and membrane/integrin recycling is required for prolongation of trench mode. Our study therefore contributes to an improved understanding of the molecular and cellular determinants for the two osteoclastic bone resorption modes.
C1 [Borggaard, Xenia G.; Pirapaharan, Dinisha C.; Delaisse, Jean Marie; Soe, Kent] Vejle Hosp, Dept Clin Cell Biol, Lillebaelt Hosp, DK 7100 Vejle, Denmark.
   [Borggaard, Xenia G.; Pirapaharan, Dinisha C.; Delaisse, Jean Marie; Soe, Kent] Univ Southern Denmark, Dept Reg Hlth Res, DK 7100 Vejle, Denmark.
   [Borggaard, Xenia G.; Delaisse, Jean Marie; Soe, Kent] Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.
   [Borggaard, Xenia G.; Delaisse, Jean Marie; Soe, Kent] Univ Southern Denmark, Dept Clin Res, Pathol Res Unit, Clin Cell Biol, DK 5000 Odense C, Denmark.
   [Borggaard, Xenia G.; Delaisse, Jean Marie; Soe, Kent] Univ Southern Denmark, Dept Mol Med, Clin Cell Biol, DK 5000 Odense C, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark; University of Southern Denmark; Odense University
   Hospital; University of Southern Denmark; University of Southern Denmark
RP Borggaard, XG (通讯作者)，Vejle Hosp, Dept Clin Cell Biol, Lillebaelt Hosp, DK 7100 Vejle, Denmark.; Borggaard, XG (通讯作者)，Univ Southern Denmark, Dept Reg Hlth Res, DK 7100 Vejle, Denmark.; Borggaard, XG (通讯作者)，Odense Univ Hosp, Dept Pathol, Clin Cell Biol, DK 5000 Odense C, Denmark.; Borggaard, XG (通讯作者)，Univ Southern Denmark, Dept Clin Res, Pathol Res Unit, Clin Cell Biol, DK 5000 Odense C, Denmark.; Borggaard, XG (通讯作者)，Univ Southern Denmark, Dept Mol Med, Clin Cell Biol, DK 5000 Odense C, Denmark.
EM Xenia.Goldberg.Borggaard@rsyd.dk; dinisha2@hotmail.com;
   Jean Marie.Delaisse@rsyd.dk; kent.soee@rsyd.dk
RI Soe, Kent/N 3618 2017; Borggaard, Xenia/AAX 2722 2020
OI Soe, Kent/0000 0001 7402 314X; Delaisse, Jean Marie/0000 0001 7370 1500;
   Goldberg Borggaard, Xenia/0000 0002 4922 2478
CR Aguda AH, 2014, P NATL ACAD SCI USA, V111, P17474, DOI 10.1073/pnas.1414126111
   BOYDE A, 1986, SCAN ELECTRON MICROS, V1986, P1537
   Bretscher MS, 1996, CELL, V85, P465, DOI 10.1016/S0092 8674(00)81246 5
   Brunet S, 2004, MOL BIOL CELL, V15, P5318, DOI 10.1091/mbc.E04 05 0385
   CHAMBERS TJ, 1985, CELL TISSUE RES, V241, P671
   Coxon FP, 2008, SEMIN CELL DEV BIOL, V19, P424, DOI 10.1016/j.semcdb.2008.08.004
   DEDUVE C, 1974, BIOCHEM PHARMACOL, V23, P2495, DOI 10.1016/0006 2952(74)90174 9
   DEMPSTER DW, 1986, J BONE MINER RES, V1, P15
   Everts V, 2002, J BONE MINER RES, V17, P77, DOI 10.1359/jbmr.2002.17.1.77
   Feng X, 2013, BONE RES, V1, DOI 10.4248/BR201301003
   Florey O, 2015, AUTOPHAGY, V11, P88, DOI 10.4161/15548627.2014.984277
   Garnero P, 1998, J BIOL CHEM, V273, P32347, DOI 10.1074/jbc.273.48.32347
   Gauthier JY, 2008, BIOORG MED CHEM LETT, V18, P923, DOI 10.1016/j.bmcl.2007.12.047
   Gentzsch C, 2003, CALCIFIED TISSUE INT, V72, P698, DOI 10.1007/s00223 002 2020 7
   Georgess D, 2014, CELL ADHES MIGR, V8, P192, DOI 10.4161/cam.27840
   Hirvonen Mirkka J, 2013, Bonekey Rep, V2, P306, DOI 10.1038/bonekey.2013.40
   JONES SJ, 1985, SCANNING, V7, P5, DOI 10.1002/sca.4950070101
   LAKKAKORPI PT, 1991, J BONE MINER RES, V6, P817
   LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0
   Lee J, 1999, NATURE, V400, P382, DOI 10.1038/22578
   Leung P, 2011, BONE, V49, P623, DOI 10.1016/j.bone.2011.06.014
   Lu SY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173771
   Luxenburg C, 2012, J CELL SCI, V125, P1666, DOI 10.1242/jcs.075903
   Mauthe M, 2018, AUTOPHAGY, V14, P1435, DOI 10.1080/15548627.2018.1474314
   Merrild DMH, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.32
   MOller A.M.J., 2018, J BONE ONCOL, V13, P41
   Moller AMJ, 2018, SCI REP UK, V8, DOI 10.1038/s41598 018 31159 1
   Moller AMJ, 2020, BONE RES, V8, DOI 10.1038/s41413 020 0102 7
   Mulari MTK, 2008, EXP CELL RES, V314, P1641, DOI 10.1016/j.yexcr.2008.02.011
   Mulari MTK, 2003, TRAFFIC, V4, P113, DOI 10.1034/j.1600 0854.2003.40206.x
   Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266
   Ng PY, 2019, BIOCHEM SOC T, V47, P639, DOI 10.1042/BST20180445
   Novack DV, 2011, AGEING RES REV, V10, P54, DOI 10.1016/j.arr.2009.09.005
   Palokangas H, 1997, J CELL SCI, V110, P1767
   Panwar P, 2018, BRIT J PHARMACOL, V175, P902, DOI 10.1111/bph.14133
   Panwar P, 2017, J BONE MINER RES, V32, P2415, DOI 10.1002/jbmr.3227
   Panwar P, 2016, BRIT J PHARMACOL, V173, P396, DOI 10.1111/bph.13383
   Panwar P, 2013, J BIOL CHEM, V288, P5940, DOI 10.1074/jbc.M112.419689
   Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049
   Saftig P, 1998, P NATL ACAD SCI USA, V95, P13453, DOI 10.1073/pnas.95.23.13453
   Salo J, 1996, J CELL SCI, V109, P301
   Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270
   Saltel F, 2004, MOL BIOL CELL, V15, P5231, DOI 10.1091/mbc.E04 06 0522
   Soe K, 2021, SEMIN CELL DEV BIOL, V112, P8, DOI 10.1016/j.semcdb.2020.05.016
   Soe K, 2017, J CELL SCI, V130, P2026, DOI 10.1242/jcs.202036
   Soe K, 2013, BONE, V56, P191, DOI 10.1016/j.bone.2013.06.007
   Soe K, 2011, BONE, V48, P837, DOI 10.1016/j.bone.2010.11.011
   Soe K, 2010, J BONE MINER RES, V25, P2184, DOI 10.1002/jbmr.113
   Stenbeck G, 2004, J CELL SCI, V117, P827, DOI 10.1242/jcs.00935
   Stenbeck G, 2000, J CELL SCI, V113, P1577
   Sun XY, 2015, P NATL ACAD SCI USA, V112, P12557, DOI 10.1073/pnas.1502970112
   Takahashi N, 2007, ODONTOLOGY, V95, P1, DOI 10.1007/s10266 007 0071 y
   Vääräniemi J, 2004, J BONE MINER RES, V19, P1432, DOI 10.1359/JBMR.040603
   van den Dries K, 2019, J CELL SCI, V132, DOI 10.1242/jcs.236828
   Vives V, 2011, J BONE MINER RES, V26, P1099, DOI 10.1002/jbmr.282
   von Kleist L, 2012, TRAFFIC, V13, P495, DOI 10.1111/j.1600 0854.2011.01292.x
   von Kleist L, 2011, CELL, V146, P471, DOI 10.1016/j.cell.2011.06.025
   Wheal BD, 2014, J BONE MINER RES, V29, P725, DOI 10.1002/jbmr.2068
   WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430
   YAYON A, 1983, CELL BIOL INT REP, V7, P895, DOI 10.1016/0309 1651(83)90207 2
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10 5278
NR 61
TC 23
Z9 26
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN ANLAGE 66, CH 4052 BASEL, SWITZERLAND
EI 1422 0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2020
VL 21
IS 16
AR 5924
DI 10.3390/ijms21165924
PG 18
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NI8HD
UT WOS:000565587200001
PM 32824687
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Vanderniet, JA
   Tsinas, D
   Wall, CL
   Girgis, CM
   London, K
   Keane, C
   Briody, J
   Hibbert, S
   Poon, M
   Padhye, B
   Biggin, A
   Dalla Pozza, L
   Gray, RJ
   Munns, CF
AF Vanderniet, Joel A.
   Tsinas, Dionysios
   Wall, Christie Lee
   Girgis, Christian M.
   London, Kevin
   Keane, Corinne
   Briody, Julie
   Hibbert, Sally
   Poon, Myra
   Padhye, Bhavna
   Biggin, Andrew
   Dalla Pozza, Luciano
   Gray, Randolph J.
   Munns, Craig F.
TI Surgical Management and Denosumab for Aneurysmal Bone Cysts of the Spine
   in an Australian Tertiary Paediatric Centre
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Embolisation; Sclerotherapy; PET; CT; Hypercalcemia; Hypocalcemia
ID GIANT CELL TUMOR; HYPERCALCEMIA; THERAPY; LESIONS; LIGAND
AB Aneurysmal bone cysts (ABC) are rare osteolytic, benign but often locally aggressive tumours of the long bones or vertebrae. For spinal ABC, surgical management, embolisation or sclerotherapy alone often carry high morbidity and/or high recurrence rates. Interruption of receptor activator of nuclear factor kappa B ligand (RANKL) signalling holds promise as an effective therapeutic strategy for these tumours. We aimed to review the approach to surgical management and evaluate the efficacy and safety of denosumab for ABC of the spine in children. Retrospective review of 7 patients treated with denosumab using a standardised protocol for ABC of the spine in a tertiary paediatric centre. Surgical intervention was only conducted if there was spinal instability or significant neurological impairment. Denosumab 70 mg/m(2) was given 4 weekly for at least 6 months, followed by 2 doses of zoledronate 0.025 mg/kg, aiming to prevent rebound hypercalcaemia. All patients achieved stability of the spine and resolution of neurological impairment, if present. Six patients achieved metabolic remission and have ceased denosumab without recurrence to date; the other showed clinical and radiological improvement without complete metabolic remission. Three patients developed symptomatic hypercalcaemia 5 7 months after cessation of denosumab, requiring additional bisphosphonate treatment. We present our algorithm for the surgical and medical management of paediatric spinal ABC. Denosumab produced a radiological and metabolic response in all patients, with complete remission in most. Follow up time was not long enough to evaluate the endurance of response after cessation in some patients. Incidence of rebound hypercalcaemia in this paediatric cohort was high, prompting a change to our protocol.
C1 [Vanderniet, Joel A.; Wall, Christie Lee; Poon, Myra; Biggin, Andrew] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Locked Bag 4001, Sydney, NSW 2145, Australia.
   [Tsinas, Dionysios; Keane, Corinne; Gray, Randolph J.] Childrens Hosp Westmead, Dept Orthopaed, Sydney, NSW, Australia.
   [Girgis, Christian M.; Padhye, Bhavna; Biggin, Andrew; Dalla Pozza, Luciano] Univ Sydney, Fac Med & Hlth, Sydney, NSW, Australia.
   [Girgis, Christian M.] Royal North Shore Hosp, Dept Endocrinol, Sydney, NSW, Australia.
   [Girgis, Christian M.] Westmead Hosp, Dept Diabet & Endocrinol, Sydney, NSW, Australia.
   [London, Kevin; Briody, Julie] Childrens Hosp Westmead, Dept Nucl Med, Sydney, NSW, Australia.
   [Hibbert, Sally] Childrens Hosp Westmead, Dept Dent, Sydney, NSW, Australia.
   [Hibbert, Sally] Westmead Ctr Oral Hlth, Dept Paediat Dent, Sydney, NSW, Australia.
   [Padhye, Bhavna; Dalla Pozza, Luciano] Childrens Hosp Westmead, Canc Ctr Children, Sydney, NSW, Australia.
   [Munns, Craig F.] Univ Queensland, Child Hlth Res Ctr, Brisbane, Qld, Australia.
   [Munns, Craig F.] Univ Queensland, Mayne Acad Paediat, Brisbane, Qld, Australia.
C3 NSW Health; The Children's Hospital at Westmead; University of Sydney;
   NSW Health; The Children's Hospital at Westmead; University of Sydney;
   University of Sydney; Royal North Shore Hospital; University of Sydney;
   NSW Health; Westmead Hospital; University of Sydney; NSW Health; The
   Children's Hospital at Westmead; NSW Health; The Children's Hospital at
   Westmead; University of Sydney; NSW Health; The Children's Hospital at
   Westmead; University of Sydney; University of Queensland; University of
   Queensland
RP Vanderniet, JA (通讯作者)，Childrens Hosp Westmead, Inst Endocrinol & Diabet, Locked Bag 4001, Sydney, NSW 2145, Australia.
EM joel.vanderniet@health.nsw.gov.au
RI Vanderniet, Joel/KXR 1401 2024; Munns, Craig/A 8719 2015
OI Munns, Craig/0000 0001 5898 5808; Vanderniet, Joel/0000 0002 7063 6667
CR Alhumaid I, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.3989
   Boyce AM, 2017, CURR OSTEOPOROS REP, V15, P283, DOI 10.1007/s11914 017 0380 1
   Boyce AM, 2012, J BONE MINER RES, V27, P1462, DOI 10.1002/jbmr.1603
   Boye K, 2017, ACTA ONCOL, V56, P479, DOI 10.1080/0284186X.2016.1278305
   Chawla S, 2019, LANCET ONCOL, V20, P1719, DOI 10.1016/S1470 2045(19)30663 1
   Choe M, 2021, PEDIATR BLOOD CANCER, V68, DOI 10.1002/pbc.28778
   Cornelis F, 2014, BONE, V58, P11, DOI 10.1016/j.bone.2013.10.004
   Del Sindaco G, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.698963
   Dürr HR, 2019, BMC MUSCULOSKEL DIS, V20, DOI 10.1186/s12891 019 2855 y
   Engellau J, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957 018 1478 3
   Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037
   Fisher CG, 2010, SPINE, V35, pE1221, DOI 10.1097/BRS.0b013e3181e16ae2
   Gossai N, 2015, PEDIATR BLOOD CANCER, V62, P1078, DOI 10.1002/pbc.25393
   Grasemann C, 2013, J CLIN ENDOCR METAB, V98, P3121, DOI 10.1210/jc.2013 1143
   Hao KJ, 2019, J NUCL MED, V60
   Horiuchi K, 2021, BONE REP, V15, DOI 10.1016/j.bonr.2021.101148
   Kieser DC, 2018, EUR SPINE J, V27, P851, DOI 10.1007/s00586 018 5470 y
   Kurucu N, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26926
   Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007
   Lange T, 2013, EUR SPINE J, V22, P1417, DOI 10.1007/s00586 013 2715 7
   Maximen J, 2022, JOINT BONE SPINE, V89, DOI 10.1016/j.jbspin.2021.105260
   Muheremu A, 2017, ONCOL LETT, V14, P1985, DOI 10.3892/ol.2017.6379
   Oliveira AM, 2014, HUM PATHOL, V45, P1, DOI 10.1016/j.humpath.2013.03.005
   Ooi HL, 2013, HORM RES PAEDIAT, V80, P179, DOI 10.1159/000354303
   Palmerini E, 2018, TUMORI J, V104, P344, DOI 10.1177/0300891618784808
   Pan KS, 2021, CURR OSTEOPOROS REP, V19, P141, DOI 10.1007/s11914 021 00657 z
   Papagelopoulos PJ, 2001, J BONE JOINT SURG AM, V83A, P1674, DOI 10.2106/00004623 200111000 00009
   Park HY, 2016, CURR REV MUSCULOSKE, V9, P435, DOI 10.1007/s12178 016 9371 6
   Pelle DW, 2014, TRANSL RES, V164, P139, DOI 10.1016/j.trsl.2014.03.005
   Rapp TB, 2012, J AM ACAD ORTHOP SUR, V20, P233, DOI 10.5435/JAAOS 20 04 233
   Sciot R, 2000, MODERN PATHOL, V13, P1206, DOI 10.1038/modpathol.3880224
   Setsu N, 2016, J BONE MINER METAB, V34, P118, DOI 10.1007/s00774 015 0677 z
   Simm PJ, 2013, J PEDIATR ORTHOPED, V33, pE61, DOI 10.1097/BPO.0b013e318285c3a7
   Sydlik C, 2020, WORLD J PEDIATR, V16, P520, DOI 10.1007/s12519 020 00378 w
   Thomas D, 2010, LANCET ONCOL, V11, P275, DOI 10.1016/S1470 2045(10)70010 3
   Uday S, 2018, J CLIN ENDOCR METAB, V103, P596, DOI 10.1210/jc.2017 02025
   Vanderniet JA, 2022, BONE, V159, DOI 10.1016/j.bone.2022.116395
   Wang HD, 2014, J CLIN ENDOCR METAB, V99, P891, DOI 10.1210/jc.2013 3081
   Wilson JR, 2012, SPINAL CORD, V50, P840, DOI 10.1038/sc.2012.59
   Won KY, 2011, PATHOLOGY, V43, P318, DOI 10.1097/PAT.0b013e3283463536
NR 40
TC 6
Z9 6
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD MAY
PY 2023
VL 112
IS 5
BP 592
EP 602
DI 10.1007/s00223 023 01068 1
EA FEB 2023
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA E3OL5
UT WOS:000934192800001
PM 36810677
DA 2025 08 17
ER

PT J
AU Alvi, MN
   Ansari, MT
   Siddiqi, FA
   Ishaque, A
   Abbas, M
   Saeed Ul Hassan
AF Alvi, Muhammad Nadeem
   Ansari, Muhammad Tayyab
   Siddiqi, Faheem Ahmed
   Ishaque, Ambreen
   Abbas, Muhammad
   Saeed Ul Hassan
TI Hematopoietic effects of Azadirachta indica methanolic extract in
   cyclophosphamide mediated myelosuppressed albino rat
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Azadirachta indica; B19 virus; cyclophosphamide; filgrastim;
   myelosuppression; myelotoxicity
ID CHEMOTHERAPY
AB Myelosuppression or bone marrow suppression is one of the most common side effects caused by anti cancer drugs. Certain nonsteroidal anti inflammatory drugs (NSAIDs), antibiotics and viruses like B19 virus can also cause bone marrow suppression resulting in serious consequences like leukopenia, anemia and thrombocytopenia. Currently, it is mainly treated by Filgrastim, use of which is not without side effects. Certain natural drugs can be a safer alternative to treat myelosuppression. Azadirachta indica, commonly known as Neem, is an important medicinal plant of subcontinent. Keeping in view the traditional uses of Neem, present study aims to investigate its potential role in reversing myelosuppression. Albino rats were used to determine hematopoietic activity of Neem leaves after inducing myelosuppression by cyclophosphamide given subcutaneously. Filgrastim was used as reference standard to compare the antimyelosuppressant activity of the drug. The drug was evaluated in three doses i.e. 50mg/kg, 100mg/kg and 200mg/kg body weight, while blood samples were drawn on 0, 1st, 7th, 14th and 21st day. The drug was found to be effective in reversing bone marrow suppression in all three doses based on the hematological parameters (mean WBC, RBC, platelets, Hb, Hct etc.) which improved significantly. The results suggest that the drug can be used as antimyelosuppressant after establishing its safety and identifying its active constituents with their mechanism of action.
C1 [Alvi, Muhammad Nadeem; Ansari, Muhammad Tayyab; Abbas, Muhammad] Bahauddin Zakariya Univ, Fac Pharm, Dept Pharmaceut Chem, Multan, Pakistan.
   [Alvi, Muhammad Nadeem; Siddiqi, Faheem Ahmed; Ishaque, Ambreen] Univ Cent Punjab, Fac Pharm, Lahore, Pakistan.
   [Saeed Ul Hassan] Imran Adrees Coll Pharm, 3Km Daska Rd, Sialkot, Pakistan.
C3 Bahauddin Zakariya University; University of Central Punjab
RP Alvi, MN (通讯作者)，Bahauddin Zakariya Univ, Fac Pharm, Dept Pharmaceut Chem, Multan, Pakistan.; Alvi, MN (通讯作者)，Univ Cent Punjab, Fac Pharm, Lahore, Pakistan.
EM nadeem.alvi@ucp.edu.pk
RI Alvi, Nadeem/KLZ 1561 2024; Khan, Muhammad Amir/JEZ 6363 2023; Ansari,
   Muhammad/GQI 1517 2022
CR Adebayo JO., 2005, Biokemistri, V17, P45, DOI [10.4314/biokem.v17i1.32588, DOI 10.4314/BIOKEM.V17I1.32588]
   Ajagbonna O. P., 1999, Sokoto Journal of Veterinary Sciences, V1, P36
   El Radhi AS, 2018, CLIN MANUAL FEVER CH, P141
   Gurib Fakim Ameenah, 2006, Molecular Aspects of Medicine, V27, P1, DOI 10.1016/j.mam.2005.07.008
   Iranloye B.O., 2002, African Journal of Biomedical Research, V5
   Larson SB, 2002, CLIN RES STUDY INVOL, P1
   Lopes FCM, 2005, BIOL PHARM BULL, V28, P1726, DOI 10.1248/bpb.28.1726
   Moore JO, 1997, BLOOD, V89, P780, DOI 10.1182/blood.V89.3.780
   Neboh Emeka E, 2015, Adv Biomed Res, V4, P5, DOI 10.4103/2277 9175.148285
   Ohlsson A, 2010, EVIDENCE BASED CHILD, V5, P151
   OKPANYI SN, 1981, PLANTA MED, V41, P34, DOI 10.1055/s 2007 971670
   Owoyele B. V., 2011, Journal of Applied Pharmaceutical Science, V1, P176
   Oyagbemi AA, 2008, AFR J BIOTECHNOL, V7, P1721
   Padayachee B., 2012, Journal of Medicinal Plants Research, V6, P5831
   Patil S., 2013, J. Pharmacogn. Phytochem, V1, P57
   PAULOSE CS, 1987, J NEUROSCI METH, V22, P141, DOI 10.1016/0165 0270(87)90008 2
   Phillipson JD, 2001, PHYTOCHEMISTRY, V56, P237, DOI 10.1016/S0031 9422(00)00456 8
   Pimple B.P., 2013, BIOACTIVE DIETARY FA, P459
   Rajasekaran C., 2008, ETHNOBOTANICAL LEAFL, V1, P161
   Sarah R, 2019, NATURAL BIO ACTIVE COMPOUNDS, VOL 1: PRODUCTION AND APPLICATIONS, P509, DOI 10.1007/978 981 13 7154 7_17
   Sheng Y, 2000, PHYTOMEDICINE, V7, P137, DOI 10.1016/S0944 7113(00)80086 0
   Subbalakshmi Lokanadhan Subbalakshmi Lokanadhan, 2012, Journal of Biopesticides, V5, P72
   Subenthiran S, 2013, EVID BASED COMPL ALT, V7
   Tahir N., 2014, Biomedica, V17, P21
   VANHERCK H, 1991, LAB ANIM, V25, P325, DOI 10.1258/002367791780809931
   YOBURN BC, 1984, PHYSIOL BEHAV, V33, P89, DOI 10.1016/0031 9384(84)90018 0
NR 26
TC 0
Z9 0
U1 1
U2 3
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011 601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD SEP
PY 2020
VL 33
IS 5
SU S
BP 2269
EP 2273
DI 10.36721/PJPS.2020.33.5.SUP.2269 2273.1
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Pharmacology & Pharmacy
GA NZ0QS
UT WOS:000576798000008
PM 33832900
DA 2025 08 17
ER

PT J
AU Jakob, A
   Zahn, MO
   Nusch, A
   Werner, T
   Schnell, R
   Frank, M
   Hamm, N
   Dässler, KU
   Losem, C
   Welslau, M
   Hoevel, P
   Potthoff, K
AF Jakob, Andreas
   Zahn, Mark Oliver
   Nusch, Arnd
   Werner, Thorsten
   Schnell, Roland
   Frank, Melanie
   Hamm, Nicole
   Daessler, Klaus Ulrich
   Losem, Christoph
   Welslau, Manfred
   Hoevel, Petra
   Potthoff, Karin
TI Real world patient reported outcomes of breast cancer or prostate cancer
   patients receiving antiresorptive therapy for bone metastases: Final
   results of the PROBone registry study
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Bone metastases; Bone pain; Antiresorptive treatment; Bone targeted
   agents; Quality of life
ID QUALITY OF LIFE; SKELETAL RELATED EVENTS; ZOLEDRONIC ACID; FUNCTIONAL
   ASSESSMENT; DOUBLE BLIND; PAIN; BISPHOSPHONATES; COMPLICATIONS; DISEASE;
   PAMIDRONATE
AB Background: In breast cancer and prostate cancer patients, bone metastases (BM) present the main cause of morbidity and often cause debilitating pain, impaired functioning and subsequent deterioration of quality of life (QoL). The management of BM is still challenging. Maintenance or improvement in QoL is the main goal of treatment. Antiresorptive treatment, such as denosumab and bisphosphonates, can help to reduce the frequency of skeletal complications, to control bone pain and potentially to improve QoL. The optimal time point for initiation of antiresorptive therapy is still discussed controversially. In patients with BM, bone pain can be used as a surrogate measure of QoL. However, limited data exist on health related QoL in patients with BM under antiresorptive treatment. The PROBone registry study evaluated complaints and limitations caused by BM of breast and prostate cancer patients using patient reported outcomes (PROs) in real world in Germany.
   Methods: Between 2014 and 2019, 500 patients with histological confirmation of advanced breast or prostate cancer, diagnosed with BM at start of their first antiresorptive therapy were prospectively enrolled in 65 outpatient centers specialized in medical oncology across Germany. Changes of QoL were assessed monthly from baseline until a maximum of 12 months using the validated pain score Functional Assessment of Cancer Therapy Quality of Life Measurement in patients with bone pain (FACT BP) supplemented by questions on general pain and on the impact of time spent for treatment of illness on patients' daily activities. Statistical analysis was performed descriptively by relative and absolute frequencies.
   Results: In total, 486 patients were eligible for final analysis, of these 310 were diagnosed with breast cancer and 176 with prostate cancer. Median age was 67 years for breast cancer and 76 years for prostate cancer patients. 79.7% of breast cancer and 59.7% of prostate patients started antiresorptive treatment within 3 months after diagnosis of BM. More than 75% of patients suffered from bone pain at study inclusion. In total 52% of breast cancer patients and 47.9% of prostate cancer patients reported to take pain medication during the observation period. In breast and prostate cancer patients an initial pain reduction after start of BTA was observed: General pain and bone pain levels as well as the median FACT BP score showed a constant improvement over the first months and maintained stable at a constant level afterwards. Subgroup analysis showed that patients without pain at baseline reported distinctly better FACT BP scores throughout the whole observation period than patients with pain at baseline. Looking at time stress (M) scores, younger breast cancer patients (<65 years) showed highest burden especially during the first months of treatment.
   Conclusions: Our results indicate overall good adherence to current guideline recommendation, with most breast and prostate cancer patients starting antiresorptive therapy within the first 3 months after diagnosis of BM. This point gains even more importance as our data support current recommendations by ESMO guidelines as well as by German evidence based S3 guidelines for diagnosis and treatment of breast and prostate cancer to initiate bone targeted agents (BTA) as soon as BM are diagnosed, to keep pain levels at the lowest level possible, to minimize the debilitating effects of metastatic bone pain and maintain a good QoL. Bone pain management by an early use of BTA following BM diagnosis might improve patient care. (C) 2022 iOMEDICO AG. Published by Elsevier GmbH.
C1 [Jakob, Andreas] Hirslanden Med Ctr, Tumor Ctr Aarau, Aarau, Switzerland.
   [Zahn, Mark Oliver] Oncol Practice Goslar, Goslar, Germany.
   [Nusch, Arnd] Practice Hematol & Internal Oncol, Ratingen, Germany.
   [Werner, Thorsten] Urol Praxis Herzberg, Herzberg, Germany.
   [Schnell, Roland] Practice Internal Oncol & Hematol, Frechen, Germany.
   [Frank, Melanie; Hamm, Nicole; Potthoff, Karin] iOMEDICO, Freiburg, Germany.
   [Daessler, Klaus Ulrich] Oncol Practice, Freital, Germany.
   [Losem, Christoph] Med Care Ctr Oncol & Hematol, Neuss, Germany.
   [Welslau, Manfred] Med Care Ctr Hosp Aschaffenburg GmbH, Aschaffenburg, Germany.
   [Hoevel, Petra] Gen Hosp Celle, Med Care Ctr, Celle, Germany.
C3 iOMEDICO AG
RP Potthoff, K (通讯作者)，iOMEDICO, Freiburg, Germany.
EM manuscript@iomedico.com
RI Jakob, Andreas/K 6278 2018
FU Amgen GmbH (Germany)
FX The study was financially supported by Amgen GmbH (Germany). AMGEN GmbH
   had no role in study design, data collection and analysis,
   interpretation of results, decision to publish, or preparation of the
   manuscript.
CR AlZahrani M, 2021, J BONE ONCOL, V26, DOI 10.1016/j.jbo.2020.100339
   [Anonymous], 2021, 043022OL AWMF
   [Anonymous], GUIDELINES PROGRAM O
   Apolone G, 2009, BRIT J CANCER, V100, P1566, DOI 10.1038/sj.bjc.6605053
   Body JJ, 2019, J BONE ONCOL, V14, DOI 10.1016/j.jbo.2018.100212
   Body JJ, 2017, CRIT REV ONCOL HEMAT, V115, P67, DOI 10.1016/j.critrevonc.2017.04.008
   Body JJ, 2003, ANN ONCOL, V14, P1399, DOI 10.1093/annonc/mdg367
   Broom R, 2009, J PAIN SYMPTOM MANAG, V38, P244, DOI 10.1016/j.jpainsymman.2008.08.005
   Coleman R, 2020, ANN ONCOL, V31, P1650, DOI 10.1016/j.annonc.2020.07.019
   Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078 0432.CCR 06 0931
   Costa L, 2009, NAT CLIN PRACT ONCOL, V6, P163, DOI 10.1038/ncponc1323
   Deandrea S, 2008, ANN ONCOL, V19, P1985, DOI 10.1093/annonc/mdn419
   Delgado DA, 2018, JAAOS GLOB RES REV, V2, DOI 10.5435/JAAOSGlobal D 17 00088
   Diel IJ, 2004, EUR J CANCER, V40, P1704, DOI 10.1016/j.ejca.2004.03.025
   Diel IJ, 2007, SUPPORT CARE CANCER, V15, P1243, DOI 10.1007/s00520 007 0244 9
   FACT BP FACIT Group, US
   Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016/S0140 6736(10)62344 6
   Galvano A, 2019, J BONE ONCOL, V18, DOI 10.1016/j.jbo.2019.100252
   Gonzalez Rodriguez E., 2019, GALVANO J BONE ONCOL, V22, DOI [10.1016/j.jbo, DOI 10.1016/J.JBO]
   Gralow J, 2007, J PAIN SYMPTOM MANAG, V33, P462, DOI 10.1016/j.jpainsymman.2007.01.001
   Kuchuk I, 2013, J BONE ONCOL, V2, P154, DOI 10.1016/j.jbo.2013.07.004
   Lebret T, 2017, EUR J CANCER CARE, V26, DOI 10.1111/ecc.12490
   Lipton A, 2000, CANCER, V88, P1082, DOI 10.1002/(SICI)1097 0142(20000301)88:5<1082::AID CNCR20>3.0.CO;2 Z
   Lipton A, 2012, EUR J CANCER, V48, P3082, DOI 10.1016/j.ejca.2012.08.002
   Middlemiss T, 2011, CLIN ONCOL UK, V23, P387, DOI 10.1016/j.clon.2011.03.003
   Mukaka MM, 2012, MALAWI MED J, V24, P69
   Parker C, 2013, NEW ENGL J MED, V369, P213, DOI 10.1056/NEJMoa1213755
   Patrick DL, 2015, SUPPORT CARE CANCER, V23, P1157, DOI 10.1007/s00520 014 2525 4
   Pereira J, 2016, J MED ECON, V19, P611, DOI 10.3111/13696998.2016.1150852
   Rosen LS, 2001, CANCER J, V7, P377
   Saad F, 2004, J NATL CANCER I, V96, P879, DOI 10.1093/jnci/djh141
   SCHIEGNITZ E, 2018, S3 LEITLINIEANTIRESO
   Schröder J, 2017, EUR J CANCER, V79, P139, DOI 10.1016/j.ejca.2017.03.031
   Selvaggi G, 2005, CRIT REV ONCOL HEMAT, V56, P365, DOI 10.1016/j.critrevonc.2005.03.011
   Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101
   Svendsen Marie Louise, 2013, Clin Epidemiol, V5, P97, DOI 10.2147/CLEP.S42325
   Trinkaus M, 2010, SUPPORT CARE CANCER, V18, P197, DOI 10.1007/s00520 009 0645 z
   Van Poznak C, 2017, J CLIN ONCOL, V35, P3978, DOI 10.1200/JCO.2017.75.4614
   von Moos R, 2018, J BONE ONCOL, V11, P1, DOI 10.1016/j.jbo.2017.11.004
   von Moos R, 2016, SUPPORT CARE CANCER, V24, P1327, DOI 10.1007/s00520 015 2908 1
   Wen DT, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00495
   Wong MHF, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub3
   Yarom N, 2019, J CLIN ONCOL, V37, P2270, DOI 10.1200/JCO.19.01186
   Zajaczkowska R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236047
NR 44
TC 7
Z9 7
U1 1
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2212 1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD APR
PY 2022
VL 33
AR 100420
DI 10.1016/j.jbo.2022.100420
EA MAR 2022
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA 2P7TZ
UT WOS:000819939700009
PM 35340302
OA gold, Green Published
DA 2025 08 17
ER

PT J
AU Shah, M
   Kola, B
   Bataveljic, A
   Arnett, TR
   Viollet, B
   Saxon, L
   Korbonits, M
   Chenu, C
AF Shah, M.
   Kola, B.
   Bataveljic, A.
   Arnett, T. R.
   Viollet, B.
   Saxon, L.
   Korbonits, M.
   Chenu, C.
TI AMP activated protein kinase (AMPK) activation regulates in vitro
   bone formation and bone mass
SO BONE
LA English
DT Article
DE AMP kinase; Osteoblasts; Knockout mice; Energy metabolism; Bone;
   Metformin
ID OSTEOBLASTIC MC3T3 E1 CELLS; INSULIN SENSITIVITY; ENERGY HOMEOSTASIS;
   ANTIDIABETIC DRUGS; BMP 2 EXPRESSION; FOOD INTAKE; DIFFERENTIATION;
   PROLIFERATION; METFORMIN; ROSIGLITAZONE
AB Adenosine 5' monophosphate activated protein kinase (AMPK), a regulator of energy homeostasis, has a central role in mediating the appetite modulating and metabolic effects of many hormones and antidiabetic drugs metformin and glitazones. The objective of this study was to determine if AMPK can be activated in osteoblasts by known AMPK modulators and if AMPK activity is involved in osteoblast function in vitro and regulation of bone mass in vivo. ROS 17/2.8 rat osteoblast like cells were cultured in the presence of AMPK activators (AICAR and metformin), AMPK inhibitor (compound C), the gastric peptide hormone ghrelin and the beta adrenergic blocker propranolol. AMPK activity was measured in cell lysates by a functional kinase assay and AMPK protein phosphorylation was studied by Western Blotting using an antibody recognizing AMPK Thr 172 residue. We demonstrated that treatment of ROS 17/2.8 cells with AICAR and metformin stimulates Thr 172 phosphorylation of AMPK and dose dependently increases its activity. In contrast, treatment of ROS 17/2.8 cells with compound C inhibited AMPK phosphorylation. Ghrelin and propranolol dose dependently increased AMPK phosphorylation and activity. Cell proliferation and alkaline phosphatase activity were not affected by metformin treatment while AICAR significantly inhibited ROS 17/2.8 cell proliferation and alkaline phosphatase activity at high concentrations. To study the effect of AMPK activation on bone formation in vitro, primary osteoblasts obtained from rat calvaria were cultured for 14 17 days in the presence of AICAR, metformin and compound C. Formation of 'trabecular shaped' bone nodules was evaluated following alizarin red staining. We demonstrated that both AICAR and metformin dose dependently increase trabecular bone nodule formation, while compound C inhibits bone formation. When primary osteoblasts were co treated with AICAR and compound C, compound C suppressed the stimulatory effect of AICAR on bone nodule formation. AMPK is a alpha beta gamma heterotrimer, where alpha is the catalytic subunit. RTPCR analysis of AMPK subunits in ROS17/2.8 osteoblastic cells and in mouse tibia showed that the AMPK alpha 1 subunit is the dominant isoform expressed in bone. We analysed the bone phenotype of 4 month old male wild type (WT) and AMPK alpha 1 /  KO mice using micro CT. Both cortical and trabecular bone compartments were smaller in the AMPK alpha 1 deficient mice compared to the WT mice. Altogether, our data support a role for AMPK signalling in skeletal physiology. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Shah, M.; Bataveljic, A.; Saxon, L.; Chenu, C.] Univ London Royal Vet Coll, Dept Vet Basic Sci, London NW1 OTU, England.
   [Kola, B.; Korbonits, M.] Barts & London Med Sch, Dept Endocrinol, London, England.
   [Arnett, T. R.] UCL, Dept Cell & Dev Biol, London, England.
   [Viollet, B.] Univ Paris 05, U567, UMR 8104, Dept Endocrinol Metab & Canc,CNRS,INSERM, Paris, France.
C3 University of London; University of London Royal Veterinary College;
   University of London; Queen Mary University London; University of
   London; University College London; Universite Paris Cite; Centre
   National de la Recherche Scientifique (CNRS); CNRS   National Institute
   for Biology (INSB); Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Chenu, C (通讯作者)，Univ London Royal Vet Coll, Dept Vet Basic Sci, Royal Coll St, London NW1 OTU, England.
EM cchenu@rvc.ac.uk
RI Korbonits, Marta/AFV 9501 2022; Viollet, Benoit/O 6927 2017; Arnett,
   Tim/AAW 4445 2021
OI Korbonits, Marta/0000 0002 4101 9432; Viollet,
   Benoit/0000 0002 0121 0224; 
FU Wellcome Trust
FX This work was funded by the Wellcome Trust. The authors are very
   grateful to Dr Andy Sunters for helpful discussions.
CR Ahn JD, 2006, ENDOCRINOLOGY, V147, P3196, DOI 10.1210/en.2006 0281
   Andersson U, 2004, J BIOL CHEM, V279, P12005, DOI 10.1074/jbc.C300557200
   Baldock PA, 2002, J CLIN INVEST, V109, P915, DOI 10.1172/JCI200214588
   Benvenuti S, 2007, J ENDOCRINOL INVEST, V30, pRC26, DOI 10.1007/BF03350807
   Bright NJ, 2009, ACTA PHYSIOL, V196, P15, DOI 10.1111/j.1748 1716.2009.01971.x
   Confavreux CB, 2009, MOL CELL ENDOCRINOL, V310, P21, DOI 10.1016/j.mce.2009.04.004
   Cornish J, 2002, J ENDOCRINOL, V175, P405, DOI 10.1677/joe.0.1750405
   Cortizo AM, 2006, EUR J PHARMACOL, V536, P38, DOI 10.1016/j.ejphar.2006.02.030
   Costanzo Garvey DL, 2009, CELL METAB, V10, P366, DOI 10.1016/j.cmet.2009.09.010
   Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Dzamko NL, 2009, ACTA PHYSIOL, V196, P115, DOI 10.1111/j.1748 1716.2009.01969.x
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   Fryer LGD, 2002, J BIOL CHEM, V277, P25226, DOI 10.1074/jbc.M202489200
   Fu L, 2007, EUR J PHARMACOL, V569, P155, DOI 10.1016/j.ejphar.2007.05.005
   Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200
   Grey A, 2007, J CLIN ENDOCR METAB, V92, P1305, DOI 10.1210/jc.2006 2646
   Hamrick MW, 2008, J BONE MINER RES, V23, P870, DOI 10.1359/JBMR.080213
   Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304
   Hardie DG, 2006, J PHYSIOL LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944
   Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540
   Hou CH, 2008, CELL SIGNAL, V20, P978, DOI 10.1016/j.cellsig.2008.01.013
   Hwang JT, 2005, BIOCHEM BIOPH RES CO, V338, P694, DOI 10.1016/j.bbrc.2005.09.195
   Idris AI, 2005, NAT MED, V11, P774, DOI 10.1038/nm1255
   Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027
   Jorgensen SB, 2004, J BIOL CHEM, V279, P1070, DOI 10.1074/jbc.M306205200
   Kanazawa I, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471 2121 8 51
   Kanazawa I, 2008, BIOCHEM BIOPH RES CO, V375, P414, DOI 10.1016/j.bbrc.2008.08.034
   Kanazawa I, 2009, AM J PHYSIOL ENDOC M, V296, pE139, DOI 10.1152/ajpendo.90677.2008
   Kasai T, 2009, J CELL PHYSIOL, V221, P740, DOI 10.1002/jcp.21917
   Kim JE, 2008, BONE, V43, P394, DOI 10.1016/j.bone.2008.03.021
   Kola B, 2005, J BIOL CHEM, V280, P25196, DOI 10.1074/jbc.C500175200
   Kola B, 2006, TRENDS ENDOCRIN MET, V17, P205, DOI 10.1016/j.tem.2006.05.006
   KOMORAVA SV, 2000, AM J PHYSIOL CELL PH, V279, pC1220
   Lage R, 2008, TRENDS MOL MED, V14, P539, DOI 10.1016/j.molmed.2008.09.007
   Lazarenko OP, 2007, ENDOCRINOLOGY, V148, P2669, DOI 10.1210/en.2006 1587
   LeBrasseur NK, 2006, AM J PHYSIOL ENDOC M, V291, pE175, DOI 10.1152/ajpendo.00453.2005
   Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047
   LOWRY OH, 1954, J BIOL CHEM, V207, P19
   Ma L, 2009, ARCH ORAL BIOL, V54, P951, DOI 10.1016/j.archoralbio.2009.07.010
   Maccarinelli G, 2005, J ENDOCRINOL, V184, P249, DOI 10.1677/joe.1.05837
   Marenzana M, 2007, BONE, V41, P206, DOI 10.1016/j.bone.2007.04.184
   McBride A, 2009, CELL METAB, V9, P23, DOI 10.1016/j.cmet.2008.11.008
   Mcgee SL, 2008, FRONT BIOSCI LANDMRK, V13, P3022, DOI 10.2741/2907
   Minokoshi Y, 2004, NATURE, V428, P569, DOI 10.1038/nature02440
   Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a
   Motoshima H, 2006, J PHYSIOL LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324
   Oakhill JS, 2009, ACTA PHYSIOL, V196, P3, DOI 10.1111/j.1748 1716.2009.01977.x
   OEI L, 2004, J CLIN INVEST, V113, P805
   Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200
   PETTY RG, 1992, DIABETIC MED, V9, P30, DOI 10.1111/j.1464 5491.1992.tb01710.x
   Peuler JD, 1996, AM J HYPERTENS, V9, P188, DOI 10.1016/0895 7061(95)00393 2
   Qi JZ, 2008, EMBO J, V27, P1537, DOI 10.1038/emboj.2008.92
   QUINN JMW, 2009, FASEB J, V2010, P275
   Rattan R, 2005, J BIOL CHEM, V280, P39582, DOI 10.1074/jbc.M507443200
   Reihill JA, 2007, BIOCHEM BIOPH RES CO, V354, P1084, DOI 10.1016/j.bbrc.2007.01.110
   Rosen CJ, 2006, NAT CLIN PRACT RHEUM, V2, P35, DOI 10.1038/ncprheum0070
   Sato S, 2007, NAT MED, V13, P1234, DOI 10.1038/nm1640
   Molinuevo MS, 2010, J BONE MINER RES, V25, P211, DOI 10.1359/jbmr.090732
   Steinberg GR, 2009, PHYSIOL REV, V89, P1025, DOI [10.1152/physrev.00011.2008, 10.15252/embj.201488104]
   Thorens B, 2004, CURR OPIN CLIN NUTR, V7, P471, DOI 10.1097/01.mco.0000134368.91900.84
   Um JH, 2010, DIABETES, V59, P554, DOI 10.2337/db09 0482
   Utting JC, 2006, EXP CELL RES, V312, P1693, DOI 10.1016/j.yexcr.2006.02.007
   van der Velde M, 2008, VITAM HORM, V77, P239, DOI 10.1016/S0083 6729(06)77010 8
   Viollet B, 2003, BIOCHEM SOC T, V31, P216, DOI 10.1042/bst0310216
   Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567
   Viollet B, 2009, FRONT BIOSCI LANDMRK, V14, P3380, DOI 10.2741/3460
   ZHEN D, 2009, J DIABETES COMP 0721
   Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073
   Zhou G, 2009, ACTA PHYSIOL, V196, P175, DOI 10.1111/j.1748 1716.2009.01967.x
   Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505
   Zhuang Yongxian, 2008, J Mol Signal, V3, P18, DOI 10.1186/1750 2187 3 18
NR 72
TC 166
Z9 185
U1 0
U2 31
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD AUG
PY 2010
VL 47
IS 2
BP 309
EP 319
DI 10.1016/j.bone.2010.04.596
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 632SW
UT WOS:000280449300018
PM 20399918
OA Green Accepted, Green Published
DA 2025 08 17
ER

PT J
AU Otsuka, M
   Hirano, R
AF Otsuka, Makoto
   Hirano, Ryuhei
TI Bone cell activity responsive drug release from biodegradable
   apatite/collagen nano composite cements In vitro dissolution
   medium responsive vitamin K2 release
SO COLLOIDS AND SURFACES B BIOINTERFACES
LA English
DT Article
DE Self setting apatite/collagen composite; Menatetrenone; Dissolution
   medium responsive drug release; Drug delivery system
ID CALCIUM PHOSPHATE CEMENT; HYDROXYAPATITE; MECHANISM; VIVO; RATS
AB A biodegradable drug delivery system with perforated macro pores was established using an apatite/collagen composite cement containing menatetrenone (VK2). The drug release capabilities of the device were investigated in vitro under osteoblast and osteoclast like conditions (SOB and SOC). A bulk powder of apatite cement containing 2.5% VK2 and 20% bovine collagen was obtained by grinding, kneaded with phosphoric acid, and poured into molds, producing fixed blocks with 0 60 perforated macro pores. The characteristics of these samples were measured by X ray powder diffraction analysis and Fourier transformed and infrared spectroscopy, and found to be very similar to those of natural bone. Drug release tests were performed under SOB in simulated body fluid (pH 7.8), and then under SOC in acetate buffer (pH 4.5) at 37.0 +/  0.1 degrees C, and the process repeated twice. The device released almost no drug in SOB, but a significant amount in SOC. The drug release in SOC was not proportional to the number of macro pores in the first test, but was in the second. The device showed dissolution medium responsive drug release. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Otsuka, Makoto] Musashino Univ, Pharmaceut Sci Res Inst, Grad Sch Pharmaceut Sci, Nishi Tokyo 2028585, Japan.
   [Hirano, Ryuhei] Kobe Pharmaceut Univ, Kobe, Hyogo 6588558, Japan.
C3 Kobe Pharmaceutical University
RP Otsuka, M (通讯作者)，Musashino Univ, Pharmaceut Sci Res Inst, Grad Sch Pharmaceut Sci, Shinmachi 1 1 20, Nishi Tokyo 2028585, Japan.
EM motsuka@musashino u.ac.jp
FU MEXT; Ministry of Education, Culture, Sports, Sciences and Technology,
   Japan; Musashino Jyosigakuin
FX The authors thank Dr. Atsuo Ito, National Institute of Advanced
   Industrial Science and Technology for his scientific advice to prepare
   cement block. Part of this study was supported by a Grant from MEXT.
   HAITEKU (2004 2008) from the Ministry of Education, Culture, Sports,
   Sciences and Technology, Japan, and Research Funds from Musashino
   Jyosigakuin (2009).
CR BARON R, 1987, LYMPHOCYTES MACROPHA, P209
   CORLTZ BR, 1995, SCIENCE, V267, P1796
   Du C, 1999, J BIOMED MATER RES, V44, P407, DOI 10.1002/(SICI)1097 4636(19990315)44:4<407::AID JBM6>3.0.CO;2 T
   ERIKSEN EF, 1990, BONE MINERAL RES, V7, P273
   Hamada H, 2010, BIOL PHARM BULL, V33, P1228, DOI 10.1248/bpb.33.1228
   Itoh S, 2002, BIOMATERIALS, V23, P3919, DOI 10.1016/S0142 9612(02)00126 6
   Kikuchi M, 2001, BIOMATERIALS, V22, P1705, DOI 10.1016/S0142 9612(00)00305 7
   KOKUBO T, 1991, J AM CERAM SOC, V74, P1739, DOI 10.1111/j.1151 2916.1991.tb07176.x
   Martins VCA, 1998, ARTIF ORGANS, V22, P215, DOI 10.1046/j.1525 1594.1998.06004.x
   MCLEAN F, 1968, FUNDAMENTALS PHYSL S, P119
   MEHLISCH DR, 1990, ORAL SURG ORAL MED O, V70, P685, DOI 10.1016/0030 4220(90)90001 9
   Miyamoto Y, 1998, BIOMATERIALS, V19, P707, DOI 10.1016/S0142 9612(97)00186 5
   Otsuka M, 1997, J CONTROL RELEASE, V43, P115, DOI 10.1016/S0168 3659(96)01493 9
   Otsuka M, 1997, J PHARM PHARMACOL, V49, P1182, DOI 10.1111/j.2042 7158.1997.tb06067.x
   Otsuka M, 2006, J BIOMED MATER RES B, V79B, P176, DOI 10.1002/jbm.b.30528
   Otsuka M, 2010, J PHARM SCI US, V99, P286, DOI 10.1002/jps.21835
   Rehman I, 1997, J MATER SCI MATER M, V8, P1, DOI 10.1023/A:1018570213546
   Väänänen HK, 2000, J CELL SCI, V113, P377
NR 18
TC 15
Z9 17
U1 0
U2 17
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0927 7765
J9 COLLOID SURFACE B
JI Colloid Surf. B Biointerfaces
PD JUL 1
PY 2011
VL 85
IS 2
BP 338
EP 342
DI 10.1016/j.colsurfb.2011.03.006
PG 5
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA 767FZ
UT WOS:000290842000031
PM 21458964
DA 2025 08 17
ER

PT J
AU Oest, ME
   Gong, B
   Esmonde White, K
   Mann, KA
   Zimmerman, ND
   Damron, TA
   Morris, MD
AF Oest, Megan E.
   Gong, Bo
   Esmonde White, Karen
   Mann, Kenneth A.
   Zimmerman, Nicholas D.
   Damron, Timothy A.
   Morris, Michael D.
TI Parathyroid hormone attenuates radiation induced increases in collagen
   crosslink ratio at periosteal surfaces of mouse tibia
SO BONE
LA English
DT Article
DE Radiation therapy; Bone; Parathyroid hormone; Raman spectroscopy;
   Collagen crosslinking; Extracellular matrix
ID RAMAN SPECTROSCOPY; BIOMECHANICAL PROPERTIES; BONE ARCHITECTURE; PELVIC
   FRACTURES; AMIFOSTINE; IRRADIATION; GROWTH; RADIOTHERAPY; WOMEN;
   GLYCATION
AB As part of our ongoing efforts to understand underlying mechanisms contributing to radiation associated bone fragility and to identify possible treatments, we evaluated the longitudinal effects of parathyroid hormone (PTH) treatment on bone quality in a murine model of limited field irradiation. We hypothesized PTH would mitigate radiation induced changes in the chemical composition and structure of bone, as measured by microscope based Raman spectroscopy. We further hypothesized that collagen crosslinking would be especially responsive to PTH treatment. Raman spectroscopy was performed on retrieved tibiae (6 7/group/time point) to quantify metrics associated with bone quality, including: mineral to matrix ratio, carbonate to phosphate ratio, mineral crystallinity, collagen crosslink (trivalent:divalent) ratio, and the mineral and matrix depolarization ratios. Irradiation disrupted the molecular structure and orientation of bone collagen, as evidenced by a higher collagen crosslink ratio and lower matrix depolarization ratio (vs. non  irradiated control bones), persisting until 12 weeks post  irradiation. Radiation transiently affected the mineral phase, as evidenced by increased mineral crystallinity and mineral to matrix ratio at 4 weeks compared to controls. Radiation decreased bone mineral depolarization ratios through 12 weeks, indicating increased mineral alignment. PTH treatment partially attenuated radiation  induced increases in collagen crosslink ratio, but did not restore collagen or mineral alignment. These post radiation matrix changes are consistent with our previous studies of radiation damage to bone, and suggest that the initial radiation damage to bone matrix has extensive effects on the quality of tissue deposited thereafter. In addition to maintaining bone quality, preventing initial radiation damage to the bone matrix (i.e. crosslink ratio, matrix orientation) may be critical to preventing late  onset fragility fractures. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Oest, Megan E.; Mann, Kenneth A.; Zimmerman, Nicholas D.; Damron, Timothy A.] SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA.
   [Gong, Bo; Morris, Michael D.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA.
   [Esmonde White, Karen] Univ Michigan, Sch Med, Dept Internal Med Rheumatol, Ann Arbor, MI 48109 USA.
C3 State University of New York (SUNY) System; SUNY Upstate Medical
   University; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan
RP Oest, ME (通讯作者)，SUNY Upstate Med Univ, Dept Orthoped Surg, 750 E Adams St, Syracuse, NY 13210 USA.
EM oestm@upstate.edu
RI Damron, Timothy/AAE 5816 2020
FU National Institute of Arthritis and Musculoskeletal and Skin Diseases
   (NIAMS) of the National Institutes of Health [AR065419]; David G. Murray
   Endowment (SUNY Upstate Medical University); Michigan Diabetes Research
   and Training Center; NIH/NIDDK [2P30 DK020572]; NIH [R01 AR052010];
   National Institute of Diabetes and Digestive and Kidney Diseases
   [P30DK020572] Funding Source: NIH RePORTER
FX This study was funded by the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of
   Health under award number AR065419 (to TAD), and by the David G. Murray
   Endowment (SUNY Upstate Medical University, to TAD). Funding is
   gratefully acknowledged from a Pilot and Feasibility Grant from the
   Michigan Diabetes Research and Training Center, subgrant of NIH/NIDDK
   2P30 DK020572 (KEW) and NIH R01 AR052010 (to MDM). The content is solely
   the responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health. The authors have no
   financial or professional conflicts of interest to disclose.
CR Akkus O, 2004, BONE, V34, P443, DOI 10.1016/j.bone.2003.11.003
   Allen MR, 2006, CLIN REV BONE MINER, V4, P259, DOI 10.1385/BMM:4:4:259
   Baxter NN, 2005, JAMA J AM MED ASSOC, V294, P2587, DOI 10.1001/jama.294.20.2587
   Chalidis B, 2007, EXPERT OPIN INV DRUG, V16, P441, DOI 10.1517/13543784.16.4.441
   Chandra A, 2014, BONE, V67, P33, DOI 10.1016/j.bone.2014.06.030
   Chandra A, 2013, BONE, V55, P449, DOI 10.1016/j.bone.2013.02.023
   Chen WY, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748 717X 8 245
   Damron TA, 2001, INT J RADIAT ONCOL, V50, P479, DOI 10.1016/S0360 3016(01)01532 2
   Damron TA, 2000, INT J CANCER, V90, P73, DOI 10.1002/(SICI)1097 0215(20000420)90:2<73::AID IJC3>3.3.CO;2 5
   Damron TA, 2000, INT J RADIAT ONCOL, V47, P1067, DOI 10.1016/S0360 3016(00)00511 3
   Damron TA, 2008, RADIAT RES, V170, P284, DOI 10.1667/RR1254.1
   Damron TA, 2009, INT J RADIAT ONCOL, V74, P949, DOI 10.1016/j.ijrobp.2008.10.009
   Demers JLH, 2015, BIOMED OPT EXPRESS, V6, P793, DOI 10.1364/BOE.6.000793
   Dhakal S, 2011, INT J RADIAT ONCOL, V80, P1158, DOI 10.1016/j.ijrobp.2010.04.012
   Felice PA, 2015, J BONE MINER METAB, V33, P279, DOI 10.1007/s00774 014 0599 1
   Gallagher KK, 2013, HEAD NECK J SCI SPEC, V35, P1732, DOI 10.1002/hed.23216
   Gong B, 2013, BONE, V57, P252, DOI 10.1016/j.bone.2013.08.014
   GUNNESS M, 1993, BONE, V14, P277, DOI 10.1016/8756 3282(93)90152 Z
   Kelly J, 2005, J PEDIAT HEMATOL ONC, V27, P248, DOI 10.1097/01.mph.0000162526.77400.78
   Li ZQ, 2016, AM J PHYSIOL ENDOC M, V310, pE355, DOI 10.1152/ajpendo.00309.2015
   Lieber CA, 2003, APPL SPECTROSC, V57, P1363, DOI 10.1366/000370203322554518
   Mandair GS, 2015, BONEKEY REP, V4, DOI 10.1038/bonekey.2014.115
   Margulies BS, 2008, J ORTHOP RES, V26, P1512, DOI 10.1002/jor.20679
   McCreadie BR, 2006, BONE, V39, P1190, DOI 10.1016/j.bone.2006.06.008
   Misof BM, 2012, J BONE MINER RES, V27, P2551, DOI 10.1002/jbmr.1699
   Oest M., 2013, ANN M ORTH RES SOC S
   Oest ME, 2015, J ORTHOP RES, V33, P334, DOI 10.1002/jor.22761
   Oest ME, 2014, RADIAT RES, V181, P439, DOI 10.1667/RR13451.1
   Panwar P, 2015, J BIOL CHEM, V290, P23291, DOI 10.1074/jbc.M115.644310
   Sato M, 2002, ENDOCRINOLOGY, V143, P3230, DOI 10.1210/en.2002 220149
   Small W, 2005, JAMA J AM MED ASSOC, V294, P2635, DOI 10.1001/jama.294.20.2635
   Song Y., 2006, C P IEEE ENG MED BIO, P95
   Stewart AF, 2000, J BONE MINER RES, V15, P1517, DOI 10.1359/jbmr.2000.15.8.1517
   Tchanque Fossuo CN, 2013, BONE, V52, P712, DOI 10.1016/j.bone.2012.07.029
   Valcourt U, 2007, J BIOL CHEM, V282, P5691, DOI 10.1074/jbc.M610536200
   Wernle JD, 2010, J BIOMECH, V43, P2738, DOI 10.1016/j.jbiomech.2010.06.017
   Willey JS, 2008, RADIAT RES, V170, P388, DOI 10.1667/RR1388.1
   Willey JS, 2010, BONE, V46, P101, DOI 10.1016/j.bone.2009.09.002
NR 38
TC 32
Z9 34
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD MAY
PY 2016
VL 86
BP 91
EP 97
DI 10.1016/j.bone.2016.03.003
PG 7
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA DJ9CX
UT WOS:000374512700012
PM 26960578
OA Green Accepted
DA 2025 08 17
ER

PT J
AU Geng, S
   Sun, B
   Lu, R
   Wang, JZ
AF Geng, Shuo
   Sun, Bo
   Lu, Ran
   Wang, Jingze
TI Coleusin Factor, a Novel Anticancer Diterpenoid, Inhibits Osteosarcoma
   Growth by Inducing Bone Morphogenetic Protein 2 Dependent
   Differentiation
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID OSTEOBLASTIC DIFFERENTIATION; TGF BETA; EXPRESSION; CELLS;
   MINERALIZATION; PROMOTES; PROTEIN; REGULATORS; THERAPY; NUCLEUS
AB Coleusin factor is a diterpenoid compound isolated from the root of a tropical plant, Coleus forskohlii. Although Coleusin factor has been reported to suppress proliferation of and induce apoptosis in several types of cancer cells, the effects of Coleusin factor on osteosarcoma and the underlying mechanism are still not fully understood. In this study, we show that Coleusin factor treatment potently inhibits the growth of osteosarcoma cells associated with G(1) cell cycle arrest. Interestingly, apoptosis and cell death are not induced. Instead, Coleusin factor causes osteosarcoma cells to exhibit typical properties of differentiated osteoblasts, including a morphologic alteration resembling osteoblasts, the expression of osteoblast differentiation markers, elevated alkaline phosphatase activity, and increased cellular mineralization. Coleusin factor treatment significantly increases the expression of bone morphogenetic protein 2 (BMP 2), a crucial osteogenic regulator, and runt related transcription factor 2 (RUNX2), one of the key transcription factors of the BMP pathway. When BMP 2 signaling is blocked, Coleusin factor fails to inhibit cell proliferation and to induce osteoblast differentiation. Thus, upregulation of BMP 2 autocrine is critical for Coleusin factor to induce osteoblast differentiation and exert its anticancer effects on osteosarcoma. Importantly, administration of Coleusin factor inhibits the growth of osteosarcoma xenografted in nude mice without systemic or immunologic toxicity. Osteosarcoma is a highly aggressive cancer marked by the loss of normal differentiation. Coleusin factor represents a new type of BMP 2 inducer that restores differentiation in osteosarcoma cells. It may provide a promising therapeutic strategy against osteosarcoma with minimal side effects. (c) 2014 AACR.
C1 [Geng, Shuo; Sun, Bo; Wang, Jingze] Inst Zool, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China.
   [Geng, Shuo; Sun, Bo] Chinese Acad Sci, Grad Univ, Beijing 100101, Peoples R China.
   [Lu, Ran] Capital Normal Univ, Dept Biol, Beijing, Peoples R China.
   [Geng, Shuo] Virginia Tech, Dept Biol Sci, Blacksburg, VA USA.
C3 Chinese Academy of Sciences; Institute of Zoology, CAS; Chinese Academy
   of Sciences; University of Chinese Academy of Sciences, CAS; Capital
   Normal University; Virginia Polytechnic Institute & State University
RP Wang, JZ (通讯作者)，Chinese Acad Sci, Inst Zool, State Key Lab Biomembrane & Membrane Biotechnol, 1 Beichen West Rd, Beijing 100101, Peoples R China.
EM jzwang.ioz@gmail.com
RI Geng, Shuo/J 3735 2013; lu, ran/HHC 8613 2022
FU National Natural Sciences Foundation of China [30171071]
FX This work was supported by funding from National Natural Sciences
   Foundation of China (#30171071; J. Wang).
CR [Anonymous], 1973, Cancer
   Bais MV, 2009, BONE, V45, P254, DOI 10.1016/j.bone.2009.04.239
   Cain Jason E., 2013, Sarcoma, V2013, P608964, DOI 10.1155/2013/608964
   Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537
   Chen GQ, 2012, INT J BIOL SCI, V8, P272, DOI 10.7150/ijbs.2929
   Chou AJ, 2006, EXPERT REV ANTICANC, V6, P1075, DOI 10.1586/14737140.6.7.1075
   Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432 007 0330 x
   Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9
   Diamantino TC, 2001, CHEMOSPHERE, V45, P553, DOI 10.1016/S0045 6535(01)00029 7
   DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097 0142(19950101)75:1+<203::AID CNCR2820751308>3.0.CO;2 V
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Endo Munoz L, 2010, BRIT J CANCER, V103, P73, DOI 10.1038/sj.bjc.6605723
   Geng S, 2007, CELL BIOL INT, V31, P1420, DOI 10.1016/j.cellbi.2007.06.008
   Ghosh Choudhury N, 2000, BBA MOL CELL RES, V1497, P186, DOI 10.1016/S0167 4889(00)00060 4
   Gordon JAR, 2007, BONE, V41, P462, DOI 10.1016/j.bone.2007.04.191
   Haydon RC, 2002, CLIN CANCER RES, V8, P1288
   Haydon RC, 2007, CLIN ORTHOP RELAT R, P237, DOI 10.1097/BLO.0b013e31802b683c
   He BC, 2010, CLIN CANCER RES, V16, P2235, DOI 10.1158/1078 0432.CCR 09 2499
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168
   Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785
   Hopyan S, 1999, J ORTHOPAED RES, V17, P633, DOI 10.1002/jor.1100170503
   Huang WB, 2002, EXP CELL RES, V274, P226, DOI 10.1006/excr.2002.5483
   Ide H, 1997, CANCER RES, V57, P5022
   Janeway KA, 2010, LANCET ONCOL, V11, P670, DOI 10.1016/S1470 2045(10)70062 0
   KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755
   Kawamura C, 2000, BLOOD, V96, P2005, DOI 10.1182/blood.V96.6.2005.h8002005a_2005_2011
   Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092 8674(00)80258 5
   Lee CH, 2011, EUR J PHARMACOL, V668, P383, DOI 10.1016/j.ejphar.2011.06.059
   Luo P, 2010, ONCOGENE, V29, P2772, DOI 10.1038/onc.2010.50
   Mintz MB, 2005, CANCER RES, V65, P1748, DOI 10.1158/0008 5472.CAN 04 2463
   Mizuno M, 2000, J CELL PHYSIOL, V184, P207, DOI 10.1002/1097 4652(200008)184:2<207::AID JCP8>3.3.CO;2 L
   REN J, 1990, JPN J CANCER RES, V81, P920, DOI 10.1111/j.1349 7006.1990.tb02668.x
   Rosen V, 2009, CYTOKINE GROWTH F R, V20, P475, DOI 10.1016/j.cytogfr.2009.10.018
   Salvatori L, 2009, J CELL PHYSIOL, V220, P35, DOI 10.1002/jcp.21724
   Shi SL, 2009, J CELL BIOCHEM, V108, P926, DOI 10.1002/jcb.22324
   Sun B, 2011, CANCER LETT, V301, P95, DOI 10.1016/j.canlet.2010.10.010
   Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999 008 0335 z
   Thomas D, 2006, J CELL BIOCHEM, V98, P757, DOI 10.1002/jcb.20850
   Thomas DM, 2004, J CELL BIOL, V167, P925, DOI 10.1083/jcb.200409187
   Tsuji K, 2006, NAT GENET, V38, P1424, DOI 10.1038/ng1916
   Wagner Eric R., 2011, Sarcoma, V2011, P325238, DOI 10.1155/2011/325238
   Wang L, 2012, INT J CANCER, V131, P1941, DOI 10.1002/ijc.27444
   Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404 200507000 00005
   Wennberg C, 2000, J BONE MINER RES, V15, P1879, DOI 10.1359/jbmr.2000.15.10.1879
   WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241
   Yan FG, 2011, EUR J PHARMACOL, V652, P23, DOI 10.1016/j.ejphar.2010.11.018
   Ye J, 2006, HEPATOL RES, V35, P88, DOI 10.1016/j.hepres.2006.02.007
   Ye L, 2011, FRONT BIOSCI LANDMRK, V16, P865, DOI 10.2741/3725
   Zhao M, 2009, MOL CELL BIOL, V29, P1291, DOI 10.1128/MCB.01566 08
NR 50
TC 15
Z9 17
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106 4404 USA
SN 1535 7163
EI 1538 8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUN
PY 2014
VL 13
IS 6
BP 1431
EP 1441
DI 10.1158/1535 7163.MCT 13 0934
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology
GA AI8LX
UT WOS:000337168600005
PM 24723453
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Zhao, YF
   Zeng, DL
   Xia, LG
   Zhang, SM
   Xu, LY
   Jiang, XQ
   Zhang, FQ
AF Zhao, Yan Fang
   Zeng, De Liang
   Xia, Lun Guo
   Zhang, Song Mei
   Xu, Lian Yi
   Jiang, Xin Quan
   Zhang, Fu Qiang
TI Osteogenic potential of bone marrow stromal cells derived from
   streptozotocin induced diabetic rats
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Article
DE diabetes mellitus; bone marrow stromal cells; osteogenesis; tissue
   engineering; insulin; insulin like growth factor 1
ID MESENCHYMAL STEM CELLS; TISSUE ENGINEERED BONE; OSTEOBLAST
   PROLIFERATION; PHOSPHATE CEMENT; INSULIN; MELLITUS; DIFFERENTIATION;
   ACTIVATION; TYPE 1; SCAFFOLDS
AB Type 1 diabetes mellitus (T1DM) is associated with a series of bone complications, which are still a great challenge in the clinic. Bone marrow stromal cells (BMSCs) are crucial to bone remodeling and are attractive candidates for tissue engineering. Hence, we aimed to investigate whether impaired functions of BMSCs play a role in the pathogenesis of bone complications associated with T1DM. BMSCs were isolated from normal and streptozotocin induced diabetic rats, and their proliferation and osteogenic differentiation ability were analyzed. Diabetic BMSCs demonstrated reduced proliferation ability, osteoblast gene expression, alkaline phosphatase activity and mineralization. Nude mice transplanted with diabetic BMSCs in a calcium phosphate cement scaffold exhibited reduced new bone formation, as detected by hematoxylin and eosin staining and immunohistochemistry. These changes may be partially related to impaired insulin and insulin like growth factor 1 (IGF 1) signaling. Weak gene expression of insulin receptor (IR), IGF 1, insulin like growth factor 1 receptor (IGF 1R), and insulin receptor substrate 1 (IRS 1) was observed in the diabetic BMSCs compared with normal BMSCs, together with decreased protein level of IGF 1, IGF 1R, IRS 1 and phosphorylated extracellular signal regulated kinase. Therefore, impaired proliferation and osteogenic potential of BMSCs may be responsible for bone complications related to T1DM, mediated partially by impaired insulin and IGF 1 signaling. These findings may provide a new target with which to devise strategies for therapy.
C1 [Zhao, Yan Fang; Zeng, De Liang; Zhang, Song Mei; Xu, Lian Yi; Jiang, Xin Quan; Zhang, Fu Qiang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Prosthodont, Shanghai 200011, Peoples R China.
   [Xia, Lun Guo] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Oral & Maxillofacial Surg, Shanghai 200011, Peoples R China.
   [Jiang, Xin Quan] Shanghai Jiao Tong Univ, Peoples Hosp 9, Shanghai Res Inst Stomatol,Shanghai Key Lab Stoma, Oral Bioengn Lab,Regenerat Med Lab,Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Zhang, FQ (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Prosthodont, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM fredzc@online.sh.cn; xinquanj@yahoo.cn
RI Zhang, Songmei/N 5079 2018; Zhao, Yanfang/AAV 6783 2021; Xu,
   Lianyi/KBB 9332 2024
OI Zhao, Yanfang/0000 0003 4126 1955; 
FU National Basic Research Program of China (973 Program) [2012CB933604];
   National Science Fund for Distinguished Young Scholars of China
   [81225006]; National Natural Science Foundation of China [81170939]
FX This study was jointly supported by the National Basic Research Program
   of China (973 Program, No. 2012CB933604), the National Science Fund for
   Distinguished Young Scholars of China (No. 81225006) and the National
   Natural Science Foundation of China (No. 81170939).
CR AboElAsrar MA, 2012, CYTOKINE, V59, P86, DOI 10.1016/j.cyto.2012.03.019
   Breitbart EA, 2010, J ORTHOP RES, V28, P942, DOI 10.1002/jor.21065
   Cramer C, 2010, STEM CELLS DEV, V19, P1875, DOI 10.1089/scd.2010.0009
   Fulzele K, 2012, BONE, V50, P452, DOI 10.1016/j.bone.2011.06.018
   Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002
   Gandhi A, 2005, BONE, V37, P482, DOI 10.1016/j.bone.2005.04.039
   Ge CX, 2012, J BONE MINER RES, V27, P538, DOI 10.1002/jbmr.561
   Hie M, 2011, INT J MOL MED, V28, P455, DOI 10.3892/ijmm.2011.697
   Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510
   Janghorbani M, 2007, AM J EPIDEMIOL, V166, P495, DOI 10.1093/aje/kwm106
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Jin P, 2010, TRANSPL P, V42, P2745, DOI 10.1016/j.transproceed.2010.05.145
   Khan M, 2011, STEM CELLS DEV, V20, P67, DOI 10.1089/scd.2009.0397
   Khosla S, 2010, STEM CELLS, V28, P2124, DOI 10.1002/stem.546
   Lü KG, 2011, ANN BIOMED ENG, V39, P1829, DOI 10.1007/s10439 011 0276 7
   Mauney JR, 2005, TISSUE ENG, V11, P787, DOI 10.1089/ten.2005.11.787
   McCabe LR, 2007, J CELL BIOCHEM, V102, P1343, DOI 10.1002/jcb.21573
   Ogata N, 2000, J CLIN INVEST, V105, P935, DOI 10.1172/JCI9017
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P673, DOI 10.1111/j.1600 0501.2010.01923.x
   Retzepi M, 2010, CLIN ORAL IMPLAN RES, V21, P71, DOI 10.1111/j.1600 0501.2009.01805.x
   STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320
   Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   THALLER SR, 1995, J CRANIOFAC SURG, V6, P218, DOI 10.1097/00001665 199505000 00007
   Wang XJ, 2011, CELL PROLIFERAT, V44, P274, DOI 10.1111/j.1365 2184.2011.00750.x
   Xia LG, 2011, CALCIFIED TISSUE INT, V89, P53, DOI 10.1007/s00223 011 9493 1
   Xian LL, 2012, NAT MED, V18, P1095, DOI 10.1038/nm.2793
   Yang JH, 2010, CELL BIOCHEM FUNCT, V28, P334, DOI 10.1002/cbf.1668
   Yaturu S, 2009, J DIABETES, V1, P246, DOI 10.1111/j.1753 0407.2009.00049.x
   Zeng DL, 2012, TISSUE ENG PT A, V18, P871, DOI [10.1089/ten.tea.2011.0379, 10.1089/ten.TEA.2011.0379]
   Zhang M, 2002, J BIOL CHEM, V277, P44005, DOI 10.1074/jbc.M208265200
   Zhang W, 2012, CELL BIOCHEM FUNCT, V30, P297, DOI 10.1002/cbf.2801
NR 32
TC 45
Z9 51
U1 0
U2 17
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107 3756
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD MAR
PY 2013
VL 31
IS 3
BP 614
EP 620
DI 10.3892/ijmm.2013.1227
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA 089IZ
UT WOS:000314905500016
PM 23292283
OA Bronze
DA 2025 08 17
ER

PT J
AU Ozyurtseven, BT
   Serin, I
   Nursal, AF
   Pehlivan, S
   Pehlivan, M
AF Tas Ozyurtseven, Betul
   Serin, Istemi
   Nursal, Ayse Feyda
   Pehlivan, Sacide
   Pehlivan, Mustafa
TI Medication related osteonecrosis of the jaw (MRONJ) and eNOS
   Polymorphisms in multiple myeloma patients: a single center experience
SO BMC ORAL HEALTH
LA English
DT Article
DE Medication related osteonecrosis of the jaws (MRONJ); Bisphosphonate;
   Multiple myeloma; Endothelial nitric oxide synthase
ID NITRIC OXIDE SYNTHASE; NITROGEN CONTAINING BISPHOSPHONATES; GENE
   POLYMORPHISMS; IN VITRO; ELECTRON TRANSFER; ISCHEMIC STROKE; CACO 2
   CELLS; ASSOCIATION; GLU298ASP; G894T
AB Background Multiple myeloma (MM) constitutes approximately 10% of hematological malignancies. Bisphosphonates have established themselves in solid organ metastasis and multiple myeloma lytic bone lesions by inhibiting osteoclast activation. Medication related osteonecrosis of the jaw (MRONJ) emerges as an important complication. Investigating host based factors, and developing personal risk factors gain importance in the development mechanism of MRONJ. We aimed to reveal the different genotype polymorphisms, and clinical effects of eNOS in patients with a diagnosis of MRONJ in MM patients. Methods Medical records and blood samples were collected from 60 MRONJ patients with MM and 60 healthy controls. Inclusion criteria was having an exposed maxillofacial bone for more than eight weeks, a history of bisphosphonates, and no history of radiation therapy for the jaws. eNOS G894T and intron 4 VNTR were calculated by polymerase chain reaction and/or restriction fragment length polymorphism. Results eNOS G894T and VNTR genotypes and alleles were compared statistically with the healthy control group. There was no significant difference between the two groups. In comparison between G894T and clinical parameters, aphthous stomatitis was more common in TT genotype, while DMFT > 3 was more common in TG GG genotype (p = 0.035, 0.023). Conclusions eNOS induces osteogenesis in bone metabolism, with its regulatory effects on bone remodeling and also NO induced angiogenesis takes place indirectly with its protective effect on endothelial functions. We see that these polymorphisms affecting the entire process of bone remodeling and angiogenesis, especially mucosal damage, which is the triggering factor of MRONJ pathology, have been revealed in the MM patient group. Considering the MRONJ initiating factors, it is necessary to emphasize the importance of our study results. It should be seen as an important step for new studies towards MRONJ and its treatment.
C1 [Tas Ozyurtseven, Betul] Gaziantep Univ, Fac Dent, Dept Oral & Maxillofacial Surg, Gaziantep, Turkey.
   [Nursal, Ayse Feyda] Hitit Univ, Fac Med, Dept Med Genet, Corum, Turkey.
   [Pehlivan, Mustafa] Gaziantep Univ, Fac Med, Dept Hematol, Gaziantep, Turkey.
   [Pehlivan, Sacide] Istanbul Univ, Istanbul Fac Med, Dept Med Biol, Istanbul, Turkey.
   [Serin, Istemi] Univ Hlth Sci, Istanbul Training & Res Hosp, Dept Hematol, TR 34098 Istanbul, Turkey.
C3 Gaziantep University; Hitit University; Gaziantep University; Istanbul
   University; Istanbul Training & Research Hospital
RP Serin, I (通讯作者)，Univ Hlth Sci, Istanbul Training & Res Hosp, Dept Hematol, TR 34098 Istanbul, Turkey.
EM serinistemi@hotmail.com
RI Pehlivan, Mustafa/N 3210 2015; Pehlivan, Sacide/AAC 6755 2020; PEHLIVAN,
   MUSTAFA/N 3210 2015; Nursal, Ayse/ABG 7404 2021; SERIN,
   Istemi/GRX 7028 2022; Taş, Betül/AAG 8174 2020
OI PEHLIVAN, MUSTAFA/0000 0002 6692 085X; SERIN, Istemi/0000 0003 1855 774X
CR Almazrooa SA, 2009, J AM DENT ASSOC, V140, P864, DOI 10.14219/jada.archive.2009.0280
   Antoniades C, 2006, INT J CARDIOL, V107, P95, DOI 10.1016/j.ijcard.2005.02.039
   Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465
   Baur DA, 2012, J ORAL MAXIL SURG, V70, P2802, DOI 10.1016/j.joms.2012.02.019
   Bauss F, 2008, J BONE MINER METAB, V26, P406, DOI 10.1007/s00774 007 0837 x
   Berger K, 2007, HUM GENET, V121, P169, DOI 10.1007/s00439 006 0302 2
   Collin Osdoby P, 2000, J BONE MINER RES, V15, P474, DOI 10.1359/jbmr.2000.15.3.474
   DeSesa CR, 2016, J ORAL MAXIL SURG, V74, P292, DOI 10.1016/j.joms.2015.07.019
   Diakite B, 2014, META GENE, V2, P349, DOI 10.1016/j.mgene.2014.04.003
   Durie BGM, 2005, NEW ENGL J MED, V353, P99
   Erciyas K, 2010, AFR J BIOTECHNOL, V9, P3042
   Glass DA, 2003, NEW ENGL J MED, V349, P2479, DOI 10.1056/NEJMp038176
   Guyatt GH, 2002, ENDOCRIN METAB CLIN, V31, P659, DOI 10.1016/S0889 8529(02)00024 5
   Hoff AO, 2006, J CLIN ONCOL, V24, p475S
   Karasneh JA, 2011, J ORAL PATHOL MED, V40, P715, DOI 10.1111/j.1600 0714.2011.01039.x
   Karasneh JA, 2009, ARCH ORAL BIOL, V54, P583, DOI 10.1016/j.archoralbio.2009.03.008
   Katsarelis H, 2015, J DENT RES, V94, P534, DOI 10.1177/0022034515572021
   Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004
   Kuroshima S, 2019, J ORAL BIOSCI, V61, P99, DOI 10.1016/j.job.2019.03.005
   Landesberg R, 2008, J ORAL MAXIL SURG, V66, P839, DOI 10.1016/j.joms.2008.01.026
   Lee YC, 2009, J SEX MED, V6, P3158, DOI 10.1111/j.1743 6109.2009.01353.x
   Leeson CPM, 2002, CIRC RES, V90, P1153, DOI 10.1161/01.RES.0000020562.07492.D4
   Limones A, 2020, MED ORAL PATOL ORAL, V25, pE326, DOI 10.4317/medoral.23324
   Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Morris PG, 2011, J ORAL MAXIL SURG, V69, P114, DOI 10.1016/j.joms.2010.06.210
   Otto S, 2010, J ORAL MAXIL SURG, V68, P2837, DOI 10.1016/j.joms.2010.07.017
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470 2045(14)70442 5
   Ruggiero SL, 2011, ANN NY ACAD SCI, V1218, P38, DOI 10.1111/j.1749 6632.2010.05768.x
   Saidi S, 2010, ACTA NEUROL SCAND, V121, P114, DOI 10.1111/j.1600 0404.2009.01192.x
   Santini D, 2002, CLIN CANCER RES, V8, P1080
   Siegel RL, 2020, CA CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Smith BC, 2013, P NATL ACAD SCI USA, V110, pE3577, DOI 10.1073/pnas.1313331110
   Soni Y, 2020, AM J MENS HEALTH, V14, DOI 10.1177/1557988320903191
   Suri S, 2001, BONE, V29, P336, DOI 10.1016/S8756 3282(01)00589 0
   Tejero J, 2010, J BIOL CHEM, V285, P27232, DOI 10.1074/jbc.M110.138842
   Tsurushima H, 2013, INT J ORAL MAX SURG, V42, P1481, DOI 10.1016/j.ijom.2013.06.011
   Twiss IM, 1999, J BONE MINER RES, V14, P784, DOI 10.1359/jbmr.1999.14.5.784
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
   Zhang W, 2016, COLLOID SURFACE B, V148, P354, DOI 10.1016/j.colsurfb.2016.08.049
NR 41
TC 3
Z9 3
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1472 6831
J9 BMC ORAL HEALTH
JI BMC Oral Health
PD MAY 18
PY 2021
VL 21
IS 1
AR 272
DI 10.1186/s12903 021 01634 9
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA SM5YV
UT WOS:000657681500002
PM 34006261
OA Green Published, gold
DA 2025 08 17
ER

PT J
AU Lath, DL
   Buckle, CH
   Evans, HR
   Fisher, M
   Down, JM
   Lawson, MA
   Chantry, AD
AF Lath, Darren L.
   Buckle, Clive H.
   Evans, Holly R.
   Fisher, Matthew
   Down, Jenny M.
   Lawson, Michelle A.
   Chantry, Andrew D.
TI ARQ 197, a small molecule inhibitor of c Met, reduces tumour burden and
   prevents myeloma induced bone disease in vivo
SO PLOS ONE
LA English
DT Article
ID HEPATOCYTE GROWTH FACTOR; MULTIPLE MYELOMA; ARQ 197; ENDOTHELIAL CELLS;
   TYROSINE KINASES; GENE EXPRESSION; CANCER THERAPY; DEXAMETHASONE;
   LENALIDOMIDE; COMBINATION
AB The receptor tyrosine kinase c Met, its ligand HGF, and components of the downstream signalling pathway, have all been implicated in the pathogenesis of myeloma, both as modulators of plasma cell proliferation and as agents driving osteoclast differentiation and osteoblast inhibition thus, all these contribute substantially to the bone destruction typically caused by myeloma. Patients with elevated levels of HGF have a poor prognosis, therefore, targeting these entities in such patients may be of substantial benefit. We hypothesized that ARQ 197 (Tivantinib), a small molecule c Met inhibitor, would reduce myeloma cell growth and prevent myeloma associated bone disease in a murine model. In vitro we assessed the effects of ARQ 197 on myeloma cell proliferation, cytotoxicity and c Met protein expression in human myeloma cell lines. In vivo we injected NOD/SCID gamma mice with PBS (non tumour bearing) or JJN3 cells and treated them with either ARQ 197 or vehicle. In vitro exposure of JJN3, U266 or NCI H929 cells to ARQ 197 resulted in a significant inhibition of cell proliferation and an induction of cell death by necrosis, probably caused by significantly reduced levels of phosphorylated c Met. In vivo ARQ 197 treatment of JJN3 tumour bearing mice resulted in a significant reduction in tumour burden, tumour cell proliferation, bone lesion number, trabecular bone loss and prevented significant decreases in the bone formation rate on the cortico endosteal bone surface compared to the vehicle group. However, no significant differences on bone parameters were observed in non tumour mice treated with ARQ 197 compared to vehicle, implying that in tumour bearing mice the effects of ARQ 197 on bone cells was indirect. In summary, these res ults suggest that ARQ 197 could be a promising therapeutic in myeloma patients, leading to both a reduction in tumour burden and an inhibition of myeloma induced bone disease.
C1 [Lath, Darren L.; Buckle, Clive H.; Evans, Holly R.; Fisher, Matthew; Down, Jenny M.; Lawson, Michelle A.; Chantry, Andrew D.] Univ Sheffield, Med Sch, Dept Oncol & Metab, Sheffield, S Yorkshire, England.
   [Lath, Darren L.; Buckle, Clive H.; Evans, Holly R.; Down, Jenny M.; Lawson, Michelle A.; Chantry, Andrew D.] Univ Sheffield, Med Sch, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
   [Chantry, Andrew D.] Sheffield Teaching Hosp NHS Fdn Trust, Royal Hallamshire Hosp, Dept Haematol, Sheffield, S Yorkshire, England.
C3 University of Sheffield; University of Sheffield; University of
   Sheffield
RP Lath, DL (通讯作者)，Univ Sheffield, Med Sch, Dept Oncol & Metab, Sheffield, S Yorkshire, England.; Lath, DL (通讯作者)，Univ Sheffield, Med Sch, Mellanby Ctr Bone Res, Sheffield, S Yorkshire, England.
EM d.lath@shef.ac.uk
RI ; Chantry, Andrew/B 3065 2009; Lawson, Michelle/M 6095 2019
OI Lawson, Michelle/0000 0002 5446 923X; Down, Jenny/0009 0006 5378 8999;
   Chantry, Andrew/0000 0002 2797 7626; 
FU Bloodwise [12053]
FX This work was supported by a Bloodwise (https://bloodwise.org.uk/)
   Specialist Programme Grant (no. 12053) awarded to Dr A.D Chantry. The
   funders had no role in study design, data collection and analysis,
   decision to publish or preparation of the manuscript.
CR Abildgaard N, 2000, EUR J HAEMATOL, V64, P121, DOI 10.1034/j.1600 0609.2000.90074.x
   Adjei AA, 2011, ONCOLOGIST, V16, P788, DOI 10.1634/theoncologist.2010 0380
   Agrawal A, METHODS MOL BIOL MET, V806
   An G, 2016, BLOOD, V128, P1590, DOI 10.1182/blood 2016 03 707547
   Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141
   Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751
   Dimopoulos MA, 2001, ANN ONCOL, V12, P991, DOI 10.1023/A:1011132808904
   Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470 2045(15)00464 7
   Dimopoulos MA, 2009, J CLIN ONCOL, V27, P6086, DOI 10.1200/JCO.2009.22.2232
   Eathiraj S, 2011, J BIOL CHEM, V286, P20666, DOI 10.1074/jbc.M110.213801
   Evans HR, 2016, BONE, V83, P9, DOI 10.1016/j.bone.2015.10.004
   Ferrucci A, 2014, CLIN CANCER RES, V20, P5796, DOI 10.1158/1078 0432.CCR 14 0847
   Grano M, 1996, P NATL ACAD SCI USA, V93, P7644, DOI 10.1073/pnas.93.15.7644
   Hamid R, 2004, TOXICOL IN VITRO, V18, P703, DOI 10.1016/j.tiv.2004.03.012
   Hov H, 2004, CLIN CANCER RES, V10, P6686, DOI 10.1158/1078 0432.CCR 04 0874
   Jagannath S, 2006, HAEMATOL HEMATOL J, V91, P929
   Jiang WG, 2005, CRIT REV ONCOL HEMAT, V53, P35, DOI 10.1016/j.critrevonc.2004.09.004
   Kassen D, 2016, BRIT J HAEMATOL, V172, P64, DOI 10.1111/bjh.13790
   Katayama R, 2013, CANCER RES, V73, P3087, DOI 10.1158/0008 5472.CAN 12 3256
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood 2007 10 116129
   Lacy MQ, 2010, LEUKEMIA, V24, P1934, DOI 10.1038/leu.2010.190
   Lawson MA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119546
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654
   Ludek P, 2010, EUR J HAEMATOL, V84, P332, DOI 10.1111/j.1600 0609.2009.01396.x
   Mahmood T, 2012, N AM J MED SCI, V4, P429, DOI 10.4103/1947 2714.100998
   Mahtouk K, 2010, BBA REV CANCER, V1806, P208, DOI 10.1016/j.bbcan.2010.07.006
   Moreau P, 2015, BLOOD, V125, P3076, DOI 10.1182/blood 2014 09 568915
   Moschetta M, 2013, CLIN CANCER RES, V19, P4371, DOI 10.1158/1078 0432.CCR 13 0039
   Munshi N, 2010, MOL CANCER THER, V9, P1544, DOI 10.1158/1535 7163.MCT 09 1173
   Orlowski RZ, 2008, CLIN CANCER RES, V14, P1649, DOI 10.1158/1078 0432.CCR 07 2218
   Orlowski RZ, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.1953.1953
   Palumbo A, 2001, HAEMATOLOGICA, V86, P399
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Phillip CJ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045 016 0335 5
   Podar K, 2004, BLOOD, V103, P3474, DOI 10.1182/blood 2003 10 3527
   Podar K, 2006, P NATL ACAD SCI USA, V103, P19478, DOI 10.1073/pnas.0609329103
   Puzanov I, 2015, INVEST NEW DRUG, V33, P159, DOI 10.1007/s10637 014 0167 5
   Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood 2006 04 015909
   Seidel C, 1998, BLOOD, V91, P806, DOI 10.1182/blood.V91.3.806.806_806_812
   Seidel C, 2002, BRIT J HAEMATOL, V119, P672, DOI 10.1046/j.1365 2141.2002.03898.x
   Stadtmauer EA, 2009, EUR J HAEMATOL, V82, P426, DOI 10.1111/j.1600 0609.2009.01257.x
   Standal T, 2007, BLOOD, V109, P3024, DOI 10.1182/blood 2006 07 034884
   Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321
   Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111
   Traxler P, 2003, EXPERT OPIN THER TAR, V7, P215, DOI 10.1517/eott.7.2.215.23784
   Underiner TL, 2010, ANTI CANCER AGENT ME, V10, P7, DOI 10.2174/1871520611009010007
   Wader KF, 2012, HISTOPATHOLOGY, V60, P443, DOI 10.1111/j.1365 2559.2011.04112.x
   Zaman S, 2015, NEOPLASIA, V17, P289, DOI 10.1016/j.neo.2015.01.006
NR 53
TC 10
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932 6203
J9 PLOS ONE
JI PLoS One
PD JUN 20
PY 2018
VL 13
IS 6
AR e0199517
DI 10.1371/journal.pone.0199517
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Science & Technology   Other Topics
GA GJ8QS
UT WOS:000435655600073
PM 29924867
OA Green Accepted, Green Published, gold
DA 2025 08 17
ER

PT J
AU Goetschel, F
   Kern, C
   Lang, S
   Sparna, T
   Markmann, C
   Schwager, J
   McNelly, S
   Weizsäcker, F
   Laufer, S
   Hecht, A
   Merfort, I
AF Goetschel, Frank
   Kern, Claudia
   Lang, Simona
   Sparna, Titus
   Markmann, Cordula
   Schwager, Joseph
   McNelly, Sabine
   von Weizsacker, Fritz
   Laufer, Stefan
   Hecht, Andreas
   Merfort, Irmgard
TI Inhibition of GSK3 differentially modulates NF κB, CREB, AP 1 and
   β catenin signaling in hepatocytes, but fails to promote TNF α induced
   apoptosis
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE TNF alpha; Wnt; NF kappa B; AP 1; CREB; beta catenin; glycogen synthase
   kinase 3; hepatocyte; liver; apoptosis
ID GLYCOGEN SYNTHASE KINASE 3; C JUN; PROTEIN KINASE; EMBRYONIC LETHALITY;
   INTERLEUKIN 6 PROTECTS; MOLECULAR MECHANISM; LIVER DEGENERATION; MOUSE
   HEPATOCYTES; SKELETAL MUSCLE; DEATH RECEPTOR
AB Glycogen synthase kinase 3 (GSK 3) is known to modulate cell survival and apoptosis through multiple intracellular signaling pathways. However, its hepatoprotective function and its role in activation of NF kappa B and anti apoptotic factors are poorly understood and remain controversial. Here we investigated whether inhibition of GSK 3 could induce apoptosis in the presence of TNF alpha in primary mouse hepatocytes. We show that pharmacological inhibition of GSK 3 in primary mouse hepatocytes does not lead to TNF alpha induced apoptosis despite reduced NF kappa B activity. Enhanced stability of IKB alpha appears to be responsible for lower levels of nuclear NF kappa B and hence reduced transactivation. Additionally, inhibition of GSK 3 was accompanied by marked upregulation of beta catenin, AP 1, and CREB transcription factors. Stimulation of canonical Wnt signaling and CREB activity led to elevated levels of anti apoptotic factors. Hence, survival of primary mouse hepatocytes may be caused by the activation and/or upregulation of other key regulators of liver homeostasis and regeneration. These signaling molecules may compensate for the compromised anti apoptotic function of NF kappa B and allow survival of hepatocytes in the presence of TNF alpha and GSK 3 inhibition. (C) 2008 Elsevier Inc. All rights reserved.
C1 [Goetschel, Frank; Hecht, Andreas] Univ Freiburg, Inst Mol Med & Cell Res, D 7800 Freiburg, Germany.
   [Kern, Claudia; Lang, Simona; Sparna, Titus; Markmann, Cordula; Merfort, Irmgard] Univ Freiburg, Dept Pharmaceut Biol & Biotechnol, D 7800 Freiburg, Germany.
   [Schwager, Joseph] DSM Nutrit Prod, CH 4303 Kaiseraugst, Switzerland.
   [McNelly, Sabine; von Weizsacker, Fritz] Univ Hosp Freiburg, Dept Med, Freiburg, Germany.
   [Laufer, Stefan] Univ Tubingen, Dept Pharmaceut & Med Chem, D 72074 Tubingen, Germany.
C3 University of Freiburg; University of Freiburg; DSM NV; University of
   Freiburg; Eberhard Karls University of Tubingen
RP Hecht, A (通讯作者)，Stefan Meier St 17, D 79104 Freiburg, Germany.
EM andreas.hecht@mol med.uni freiburg.de;
   irmgard.merfort@pharmazie.uni freiburg.de
OI Hecht, Andreas/0000 0003 2262 2575; Laufer, Stefan/0000 0001 6952 1486
CR Aberle H, 1996, J BIOL CHEM, V271, P1520, DOI 10.1074/jbc.271.3.1520
   Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Almeida M, 2005, J BIOL CHEM, V280, P41342, DOI 10.1074/jbc.M502168200
   ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092 8674(88)90143 2
   Bansal MB, 2005, J HEPATOL, V42, P548, DOI 10.1016/j.jhep.2004.11.043
   BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0
   Beurel E, 2006, PROG NEUROBIOL, V79, P173, DOI 10.1016/j.pneurobio.2006.07.006
   BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092 8674(91)90241 P
   Cao SJ, 2006, J BIOL CHEM, V281, P26041, DOI 10.1074/jbc.M602222200
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074 5521(00)00025 9
   CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0
   Deng J, 2004, MOL CARCINOGEN, V39, P139, DOI 10.1002/mc.10169
   Deng JO, 2002, CANCER CELL, V2, P323, DOI 10.1016/S1535 6108(02)00154 X
   Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001
   Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384
   Dunn C, 2002, CELL SIGNAL, V14, P585, DOI 10.1016/S0898 6568(01)00275 3
   Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049
   Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092 8674(03)00042 4
   Ekert PG, 2006, BLOOD, V108, P1461, DOI 10.1182/blood 2006 03 014209
   EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432 1033.1980.tb06059.x
   García Piñeres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200
   Geisler F, 2007, GASTROENTEROLOGY, V132, P2489, DOI 10.1053/j.gastro.2007.03.033
   Grimes CA, 2001, J NEUROCHEM, V78, P1219, DOI 10.1046/j.1471 4159.2001.00495.x
   Gujral JS, 2004, AM J PHYSIOL GASTR L, V286, pG499, DOI 10.1152/ajpgi.00318.2003
   Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017
   Hedgepeth CM, 1997, DEV BIOL, V185, P82, DOI 10.1006/dbio.1997.8552
   HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0
   Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574
   Hoffmann A, 2006, ONCOGENE, V25, P6706, DOI 10.1038/sj.onc.1209933
   JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309
   Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
   Jové M, 2006, ENDOCRINOLOGY, V147, P552, DOI 10.1210/en.2005 0440
   Klingmüller U, 2006, IEE P SYST BIOL, V153, P433, DOI 10.1049/ip syb:20050067
   Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200
   Laufer SA, 2003, J MED CHEM, V46, P3230, DOI 10.1021/jm030766k
   Li XH, 2002, BIPOLAR DISORD, V4, P137, DOI 10.1034/j.1399 5618.2002.40201.x
   Liang MH, 2006, J BIOL CHEM, V281, P30479, DOI 10.1074/jbc.M607468200
   Liao XB, 2003, MOL CANCER THER, V2, P1215
   Liu LZ, 2004, SER INF MANAGE SCI, V3, P279
   Liu XX, 2005, CURR BIOL, V15, P1989, DOI 10.1016/j.cub.2005.10.050
   Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005
   Martin M, 2005, NAT IMMUNOL, V6, P777, DOI 10.1038/ni1221
   Mezhybovska M, 2006, J BIOL CHEM, V281, P6776, DOI 10.1074/jbc.M509999200
   Monga SPS, 2003, GASTROENTEROLOGY, V124, P202, DOI 10.1053/gast.2003.50000
   Monga SPS, 2001, HEPATOLOGY, V33, P1098, DOI 10.1053/jhep.2001.23786
   Mori N, 1997, EUR J HAEMATOL, V59, P162
   Morton S, 2003, EMBO J, V22, P3876, DOI 10.1093/emboj/cdg388
   Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914
   Neubauer K, 1998, LAB INVEST, V78, P185
   Park JM, 2005, IMMUNITY, V23, P319, DOI 10.1016/j.immuni.2005.08.010
   Phiel CJ, 2001, ANNU REV PHARMACOL, V41, P789, DOI 10.1146/annurev.pharmtox.41.1.789
   Porath D, 2005, J PHARMACOL EXP THER, V315, P1172, DOI 10.1124/jpet.105.090167
   Safadi R, 2004, GASTROENTEROLOGY, V127, P870, DOI 10.1053/j.gastro.2004.04.062
   Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934
   Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200
   Schwabe RF, 2002, AM J PHYSIOL GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002
   Sekine S, 2006, HEPATOLOGY, V43, P817, DOI 10.1002/hep.21131
   Sethi G, 2006, J BIOL CHEM, V281, P23425, DOI 10.1074/jbc.M602627200
   Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444 8455.2005
   TAKADA Y, 2004, J BIOL CHEM, V279, P37528
   Tan XP, 2006, GASTROENTEROLOGY, V131, P1561, DOI 10.1053/j.gastro.2006.08.042
   Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074 7613(00)80042 4
   Taub R, 2003, J CLIN INVEST, V112, P978, DOI 10.1172/JCI20031200319974
   Taub R, 2004, NAT REV MOL CELL BIO, V5, P836, DOI 10.1038/nrm1489
   Thompson K, 1998, HEPATOLOGY, V28, P1597, DOI 10.1002/hep.510280620
   Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907
   Vines A, 2006, J BIOL CHEM, V281, P16985, DOI 10.1074/jbc.M602446200
   Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189
   Wang Q, 2006, ONCOGENE, V25, P43, DOI 10.1038/sj.onc.1209004
   Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005
   WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460 2075.1990.tb07419.x
   Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003
   Xie HM, 2005, J IMMUNOL, V175, P7981, DOI 10.4049/jimmunol.175.12.7981
   Yin XM, 2000, CELL RES, V10, P161, DOI 10.1038/sj.cr.7290045
   Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185
   Zhao YG, 2003, GASTROENTEROLOGY, V125, P854, DOI 10.1016/S0016 5085(03)01066 7
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 78
TC 63
Z9 78
U1 0
U2 4
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 0014 4827
EI 1090 2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD APR 1
PY 2008
VL 314
IS 6
BP 1351
EP 1366
DI 10.1016/j.yexcr.2007.12.015
PG 16
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Cell Biology
GA 283BX
UT WOS:000254612700014
PM 18261723
DA 2025 08 17
ER

PT J
AU Huang, ZP
   Sun, HY
   Lu, Y
   Zhao, FN
   Liu, C
   Wang, QL
   Zheng, CM
   Lu, RP
   Song, KG
AF Huang, Zhipeng
   Sun, Haoyuan
   Lu, Yang
   Zhao, Fengnian
   Liu, Chang
   Wang, Qinglong
   Zheng, Changming
   Lu, Renpei
   Song, Keguan
TI 被撤回的出版物: Strontium/Chitosan/Hydroxyapatite/Norcantharidin Composite That
   Inhibits Osteosarcoma and Promotes Osteogenesis In Vitro (Retracted
   Article)
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article; Retracted Publication
ID BONE; APOPTOSIS; STRONTIUM; MECHANISMS; SCAFFOLDS; CELLS; PRODUCTS;
   REPAIR; ACID
AB Hydroxyapatite can deliver drugs, and its composite material is capable of repairing bone defects in tumors. This study was conducted to evaluate the effect of composite materials on tumor growth inhibition and bone growth induction. Composites containing drug delivery compounds were synthesized by coprecipitation and freeze drying and then characterized by scanning electron microscopy (SEM), X ray diffraction (XRD), and Fourier transform infrared spectroscopy (FTIR). In addition, the effect of hydroxyapatite nanoparticles (nano SHAP) on proliferation of an osteosarcoma cell line (MG 63) and an osteoblast cell line (MC3T3 E1) was evaluated, and its mechanism was studied. The use of nano SHAP alone did not affect the proliferation of normal cell lines. However, nanoparticles containing different amounts of norcantharidin in the composite materials and had different inhibitory effects on osteosarcoma and different effects on osteoblasts. And, with the increase of the content of norcantharidin, the antitumor performance of the composite has been enhanced. In summary, the nano SHAP system developed in this study is a drug delivery material that can inhibit the growth of tumors and induce the proliferation of osteoblasts.
C1 [Huang, Zhipeng; Sun, Haoyuan; Lu, Yang; Zhao, Fengnian; Liu, Chang; Wang, Qinglong; Zheng, Changming; Lu, Renpei; Song, Keguan] Harbin Med Univ, Affiliated Hosp 1, 23 Post St, Harbin, Heilongjiang, Peoples R China.
C3 Harbin Medical University
RP Song, KG (通讯作者)，Harbin Med Univ, Affiliated Hosp 1, 23 Post St, Harbin, Heilongjiang, Peoples R China.
EM doctorhuang106@163.com; 1374501387@qq.com; 369089223@qq.com;
   454185074@qq.com; liuchang515@qq.com; 924507070@qq.com;
   2938684566@qq.com; 304831715@qq.com; songkeguan@sohu.com
RI Huang, Zhipeng/HKF 8317 2023
FU China National Key Research and Development Program [2017YFB0702604];
   Rheumatology and Immunology Laboratory of the First Affiliated Hospital
   of Harbin Medical University
FX This work was supported by the China National Key Research and
   Development Program (2017YFB0702604). The authors thank the Rheumatology
   and Immunology Laboratory of the First Affiliated Hospital of Harbin
   Medical University for its support.
CR An J, 2016, LIFE SCI, V147, P46, DOI 10.1016/j.lfs.2016.01.024
   Chen YN, 2002, INT J CANCER, V100, P158, DOI 10.1002/ijc.10479
   Deng LP, 2013, CURR MED CHEM, V20, P159, DOI 10.2174/092986713804806711
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fonseca García A, 2014, J BIOMED MATER RES A, V102, P3341, DOI 10.1002/jbm.a.34893
   Gharedaghi M, 2016, ARCH BONE JT SURG AB, V4, P236
   Govindaraj D, 2017, MAT SCI ENG C MATER, V79, P875, DOI 10.1016/j.msec.2017.05.095
   Grimer RJ, 2005, LANCET ONCOL, V6, P85, DOI 10.1016/S1470 2045(05)01734 1
   Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939
   He Q, 2019, CANCER LETT, V448, P94, DOI 10.1016/j.canlet.2019.02.004
   Hongju P., 2012, NANOTECHNOLOGY, V23
   Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027
   Kim IY, 2008, BIOTECHNOL ADV, V26, P1, DOI 10.1016/j.biotechadv.2007.07.009
   Kok SH, 2003, ORAL ONCOL, V39, P19, DOI 10.1016/S1368 8375(01)00129 4
   Kuo JH, 2010, INT J ONCOL, V37, P1243, DOI 10.3892/ijo_00000775
   Lei Y, 2017, MAT SCI ENG C MATER, V72, P134, DOI 10.1016/j.msec.2016.11.063
   Li M, 2016, SCI REP UK, V6, DOI 10.1038/srep32323
   Li ST, 2011, BIOCHEM BIOPH RES CO, V410, P698, DOI 10.1016/j.bbrc.2011.06.065
   Li XQ, 2010, CHIN J INTEGR MED, V16, P448, DOI 10.1007/s11655 010 0538 5
   Lopez Beltran A, 2007, ANAL QUANT CYTOL, V29, P71
   Lu Y, 2018, MAT SCI ENG C MATER, V82, P225, DOI 10.1016/j.msec.2017.08.043
   Lukasiewicz S, 2015, LANGMUIR, V31, P6415, DOI 10.1021/acs.langmuir.5b01226
   Marie PJ, 2011, OSTEOPOROSIS INT, V22, P1659, DOI 10.1007/s00198 010 1369 0
   Marie PJ, 2001, CALCIFIED TISSUE INT, V69, P121, DOI 10.1007/s002230010055
   Martínez Vázquez FJ, 2015, ACTA BIOMATER, V15, P200, DOI 10.1016/j.actbio.2014.12.021
   Mei LW, 2019, CANCER SCI, V110, P582, DOI 10.1111/cas.13900
   Mi Y, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819876918
   Mitra D, 2017, ACS APPL MATER INTER, V9, P29515, DOI 10.1021/acsami.7b07700
   Qiu K, 2006, BIOMATERIALS, V27, P1277, DOI 10.1016/j.biomaterials.2005.08.006
   Saint Jean SJ, 2005, J MATER SCI MATER M, V16, P993, DOI 10.1007/s10856 005 4754 z
   Saraf AJ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00004
   Shanmugam S, 2014, APPL SURF SCI, V303, P277, DOI 10.1016/j.apsusc.2014.02.166
   Simon JL, 2003, J BIOMED MATER RES A, V66A, P275, DOI 10.1002/jbm.a.10569
   Takarada T, 2013, J BONE MINER RES, V28, P2064, DOI 10.1002/jbmr.1945
   Venkatesan J, 2014, J BIOMED NANOTECHNOL, V10, P3124, DOI 10.1166/jbn.2014.1893
   Wu F, 2016, ACS APPL MATER INTER, V8, P109, DOI 10.1021/acsami.5b07427
   Xiao WJ, 2016, TUMOR BIOL, V37, P15643, DOI 10.1007/s13277 015 4488 6
   Xuan MJ, 2016, J AM CHEM SOC, V138, P6492, DOI 10.1021/jacs.6b00902
   Yang F, 2011, STEM CELLS, V29, P981, DOI 10.1002/stem.646
   Yuan HP, 1999, BIOMATERIALS, V20, P1799, DOI 10.1016/S0142 9612(99)00075 7
   Zhang XB, 2012, J MATER SCI MATER M, V23, P1941, DOI 10.1007/s10856 012 4662 y
   Zhi DF, 2018, ADV COLLOID INTERFAC, V253, P117, DOI 10.1016/j.cis.2017.12.006
   Zhou JH, 2013, ACS APPL MATER INTER, V5, P5358, DOI 10.1021/am401339n
   Zhou T, 2015, BIOMED MATER, V10, DOI 10.1088/1748 6041/10/4/045013
   Zhu YC, 2019, ONCOL LETT, V17, P456, DOI 10.3892/ol.2018.9615
NR 45
TC 16
Z9 17
U1 1
U2 16
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314 6133
EI 2314 6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD JAN 31
PY 2020
VL 2020
AR 9825073
DI 10.1155/2020/9825073
PG 9
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA KM8JE
UT WOS:000514386900011
PM 32076624
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU De Luca, L
   Chiminazzo, A
   Sperni, L
   Strukul, G
   Scarso, A
AF De Luca, Lorena
   Chiminazzo, Andrea
   Sperni, Laura
   Strukul, Giorgio
   Scarso, Alessandro
TI Pyrrolidine Containing Bisphosphonates as Potential Anti Resorption Bone
   Drugs
SO CHEMISTRY A EUROPEAN JOURNAL
LA English
DT Article
ID GERANYLGERANYL DIPHOSPHATE SYNTHASE; 1,3 DIPOLAR CYCLOADDITION;
   AZOMETHINE YLIDES; INHIBITORS; ACIDS; VINYLIDENEBISPHOSPHONATE; DESIGN;
   ESTERS; AGENTS
AB Bisphosphonates, particularly those with N substituted groups, are currently the most popular drugs for the treatment of osteoporosis. However, their chemical structures are still rather simple and new synthetic methods are needed to expand their molecular complexity and also improve their specificity of action towards other targets as anticancer, antibacterial, and antimalarial drugs. Herein, we report a new class of potential antiresorption bisphosphonate drugs that have a pyrrolidine unit with different substituents, obtained through a simple dipolar cycloaddition reaction between azomethine ylides and vinylidenebisphosphonate derivatives as precursors. The methodology led to the efficient preparation of a wide range of (1 methylpyrrolidine  3,3 diyl)bis(phosphonic esters) derivatives with different substituents in position 4.
C1 [De Luca, Lorena; Chiminazzo, Andrea; Sperni, Laura; Strukul, Giorgio; Scarso, Alessandro] Univ Ca Foscari Venezia, Dipartimento Sci Mol Nanosistemi, Via Torino 155, I 30170 Venice, Italy.
C3 Universita Ca Foscari Venezia
RP Scarso, A (通讯作者)，Univ Ca Foscari Venezia, Dipartimento Sci Mol Nanosistemi, Via Torino 155, I 30170 Venice, Italy.
EM alesca@unive.it
RI Scarso, Alessandro/B 8197 2014; Strukul, Giorgio/C 3024 2014
OI Scarso, Alessandro/0000 0001 6114 9181; Strukul,
   Giorgio/0000 0001 8942 8254; 
FU Italian MIUR; Universita Ca' Foscari
FX We thank the Italian MIUR and Universita Ca' Foscari for financial
   support.
CR Adrio J, 2014, CHEM COMMUN, V50, P12434, DOI 10.1039/c4cc04381b
   Bianchini G, 2013, GREEN CHEM, V15, P656, DOI 10.1039/c2gc36800e
   Bortolini O, 2011, TETRAHEDRON, V67, P5635, DOI 10.1016/j.tet.2011.05.098
   Chiminazzo A, 2014, CHEMCATCHEM, V6, P2712, DOI 10.1002/cctc.201402346
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Egorov M, 2011, EUR J ORG CHEM, V2011, P7148, DOI 10.1002/ejoc.201101094
   Ferrer Casal M, 2013, SYNTHESIS STUTTGART, V45, P2397, DOI 10.1055/s 0033 1338498
   Flores M, 2013, CURR ORG CHEM, V17, P1957, DOI 10.2174/13852728113179990092
   Foust BJ, 2016, BIOORGAN MED CHEM, V24, P3734, DOI 10.1016/j.bmc.2016.06.019
   Granchi D, 2013, EUR J MED CHEM, V65, P448, DOI 10.1016/j.ejmech.2013.04.032
   Katritzky A. R., 2010, HDB HETEROCYCLIC CHE
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Li GZ, 2014, NEW J CHEM, V38, P3350, DOI 10.1039/c4nj00558a
   MCCONNELL RL, 1956, J AM CHEM SOC, V78, P4450, DOI 10.1021/ja01598a069
   No JH, 2012, P NATL ACAD SCI USA, V109, P4058, DOI 10.1073/pnas.1118215109
   NUGENT RA, 1993, J MED CHEM, V36, P134, DOI 10.1021/jm00053a017
   Page PCB, 2001, J ORG CHEM, V66, P3704, DOI 10.1021/jo001489h
   Rogers MJ, 2011, BONE, V49, P34, DOI 10.1016/j.bone.2010.11.008
   Roth A. G., 2009, ANGEW CHEM, V121, P7697
   Roth AG, 2009, ANGEW CHEM INT EDIT, V48, P7560, DOI 10.1002/anie.200903288
   Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022
   Ruzziconi R, 2003, J ORG CHEM, V68, P736, DOI 10.1021/jo0205154
   Santos MMM, 2014, TETRAHEDRON, V70, P9735, DOI 10.1016/j.tet.2014.08.005
   Simoni D, 2008, J MED CHEM, V51, P6800, DOI 10.1021/jm801003y
   Tsuge O., 1989, Adv. Heterocycl. Chem, V45, P231, DOI [DOI 10.1016/S0065 2725(08)60590 2, DOI 10.1016/S0065 2725(08)60332 3]
   Wiemer AJ, 2008, BIOORGAN MED CHEM, V16, P3652, DOI 10.1016/j.bmc.2008.02.016
   YUAN CG, 1990, PHOSPHORUS SULFUR, V53, P21
   Zhang SF, 2007, CHEM SOC REV, V36, P507, DOI 10.1039/b512310k
   Zhang Y., 2010, ANGEW CHEM, V122, P1154
   Zhang YH, 2010, ANGEW CHEM INT EDIT, V49, P1136, DOI 10.1002/anie.200905933
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
   Zhou X, 2014, BEILSTEIN J ORG CHEM, V10, P1645, DOI 10.3762/bjoc.10.171
   Zhu RY, 2014, TETRAHEDRON ASYMMETR, V25, P617, DOI 10.1016/j.tetasy.2014.03.008
NR 33
TC 14
Z9 14
U1 0
U2 12
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0947 6539
EI 1521 3765
J9 CHEM EUR J
JI Chem. Eur. J.
PD MAR
PY 2017
VL 23
IS 14
BP 3474
EP 3478
DI 10.1002/chem.201605878
PG 5
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA EN1MZ
UT WOS:000395775700030
PM 28181705
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Heo, SY
   Ko, SC
   Nam, SY
   Oh, J
   Kim, YM
   Kim, JI
   Kim, N
   Yi, M
   Jung, WK
AF Heo, Seong Yeong
   Ko, Seok Chun
   Nam, Seung Yun
   Oh, Junghwan
   Kim, Young Mog
   Kim, Jae Il
   Kim, Namwon
   Yi, Myunggi
   Jung, Won Kyo
TI Fish bone peptide promotes osteogenic differentiation of MC3T3 E1
   pre osteoblasts through upregulation of MAPKs and Smad pathways
   activated BMP 2 receptor
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Article
DE alkaline phosphatase (ALP); Johnius belengerii; mitogen activated
   protein kinases (MAPKs); osteoblast differentiation; Smad 1/5/8
ID PROCESSING BY PRODUCTS; PROTEIN KINASE; STEM CELLS; FRAME;
   MINERALIZATION; ADIPOGENESIS; PURIFICATION; EXTRACTION; EXPRESSION;
   INTESTINE
AB Fish bone, a by product of fishery processing, is composed of protein, calcium, and other minerals. The objective of this study was to investigate the effects of a bioactive peptide isolated from the bone of the marine fish, Johnius belengerii, on the osteoblastic differentiation of MC3T3 E1 pre osteoblasts. Post consecutive purification by liquid chromatography, a potent osteogenic peptide, composed of 3 amino acids, Lys Ser Ala (KSA, MW: 304.17Da), was identified. The purified peptide promoted cell proliferation, alkaline phosphatase activity, mineral deposition, and expression levels of phenotypic markers of osteoblastic differentiation in MC3T3 E1 pre osteoblast. The purified peptide induced phosphorylation of mitogen activated protein kinases, including p38 mitogen activated protein kinase, extracellular regulated kinase, and c Jun N terminal kinase as well as Smads. As attested by molecular modelling study, the purified peptide interacted with the core interface residues in bone morphogenetic protein receptors with high affinity. Thus, the purified peptide could serve as a potential pharmacological substance for controlling bone metabolism.
C1 [Heo, Seong Yeong; Nam, Seung Yun; Oh, Junghwan; Yi, Myunggi; Jung, Won Kyo] Pukyong Natl Univ, Dept Biomed Engn, Busan 48513, South Korea.
   [Heo, Seong Yeong; Nam, Seung Yun; Oh, Junghwan; Yi, Myunggi; Jung, Won Kyo] Pukyong Natl Univ, Ctr Marine Integrated Biomed Technol Plus BK21, Busan 48513, South Korea.
   [Heo, Seong Yeong; Ko, Seok Chun; Nam, Seung Yun; Oh, Junghwan; Kim, Young Mog; Jung, Won Kyo] Pukyong Natl Univ, Marine Integrated Bion Res Ctr, Busan, South Korea.
   [Kim, Young Mog] Pukyong Natl Univ, Dept Food Sci & Technol, Busan, South Korea.
   [Kim, Jae Il] Pukyong Natl Univ, Dept Food Sci & Nutr, Busan, South Korea.
   [Kim, Namwon] Texas State Univ, Ingram Sch Engn, San Marcos, TX USA.
C3 Pukyong National University; Pukyong National University; Pukyong
   National University; Pukyong National University; Pukyong National
   University; Texas State University System; Texas State University San
   Marcos
RP Yi, M; Jung, WK (通讯作者)，Pukyong Natl Univ, Dept Biomed Engn, Busan 48513, South Korea.; Yi, M; Jung, WK (通讯作者)，Pukyong Natl Univ, Ctr Marine Integrated Biomed Technol Plus BK21, Busan 48513, South Korea.
EM myunggi@pknu.ac.kr; wkjung@pknu.ac.kr
RI Kim, Young Mog/ISR 9870 2023; Nam, Seung Yun/AGO 0393 2022; Jung,
   Won Kyo/D 6824 2016; Oh, Junghwan/G 1473 2015; Heo,
   Seong Yeong/AAA 8554 2022
OI Kim, Namwon/0000 0001 7738 9593; Jung, Won Kyo/0000 0002 1615 750X; Oh,
   Junghwan/0000 0002 5837 0958; 
FU Ministry of Oceans and Fisheries [20150220]
FX Ministry of Oceans and Fisheries, Grant/Award Number: 20150220
CR Ahn CB, 2014, FOOD CHEM, V147, P78, DOI 10.1016/j.foodchem.2013.09.136
   Allendorph GP, 2006, P NATL ACAD SCI USA, V103, P7643, DOI 10.1073/pnas.0602558103
   Vázquez JA, 2013, MAR DRUGS, V11, P747, DOI 10.3390/md11030747
   Aubin Jane E., 1993, P1
   Beck GR, 1998, J CELL BIOCHEM, V68, P269, DOI 10.1002/(SICI)1097 4644(19980201)68:2<269::AID JCB13>3.0.CO;2 A
   BERWEGER CD, 1995, CHEM PHYS LETT, V232, P429, DOI 10.1016/0009 2614(94)01391 8
   Bose S, 2012, ACTA BIOMATER, V8, P1401, DOI 10.1016/j.actbio.2011.11.017
   Boutinguiza M, 2012, MAT SCI ENG C MATER, V32, P478, DOI 10.1016/j.msec.2011.11.021
   Chen Q, 2014, STEM CELLS, V32, P327, DOI 10.1002/stem.1567
   Cho Suengmok, 2014, Fisheries and Aquatic Sciences, V17, P175, DOI 10.5657/FAS.2014.0175
   Ngo DH, 2016, PROCESS BIOCHEM, V51, P1622, DOI 10.1016/j.procbio.2016.07.006
   Duplomb L, 2007, STEM CELLS, V25, P544, DOI 10.1634/stemcells.2006 0395
   Fang YW, 2015, BRAZ ARCH BIOL TECHN, V58, P343, DOI 10.1590/S1516 8913201500297
   Feng X, 2011, ANNU REV PATHOL MECH, V6, P121, DOI 10.1146/annurev pathol 011110 130203
   Ge CX, 2007, J CELL BIOL, V176, P709, DOI 10.1083/jcb.200610046
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Heining E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025163
   Huang RL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.101
   Jung WK, 2006, BRIT J NUTR, V95, P124, DOI 10.1079/BJN20051615
   Jung WK, 2006, FOOD CHEM, V94, P26, DOI 10.1016/j.foodchem.2004.09.048
   Jung WK, 2007, EUR FOOD RES TECHNOL, V224, P763, DOI 10.1007/s00217 006 0371 4
   Kanazawa I, 2009, J CLIN ENDOCR METAB, V94, P45, DOI 10.1210/jc.2008 1455
   Kapinas K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3325
   Katagiri T, 2002, ORAL DIS, V8, P147, DOI 10.1034/j.1601 0825.2002.01829.x
   Keller S, 2004, NAT STRUCT MOL BIOL, V11, P481, DOI 10.1038/nsmb756
   Kim D. Y, 2015, J FISH ERIES MARINE, V27, P566
   Kim M, 2013, BIOPROC BIOSYST ENG, V36, P1725, DOI 10.1007/s00449 013 0947 x
   Kim SK, 2006, FOOD RES INT, V39, P383, DOI 10.1016/j.foodres.2005.10.010
   Kim SK, 2003, J FOOD BIOCHEM, V27, P255, DOI 10.1111/j.1745 4514.2003.tb00280.x
   Ko SC, 2016, RSC ADV, V6, P54169, DOI 10.1039/c6ra06308j
   Ko SC, 2016, EUR FOOD RES TECHNOL, V242, P163, DOI 10.1007/s00217 015 2526 7
   Ko SC, 2016, INT J MOL MED, V37, P243, DOI 10.3892/ijmm.2015.2420
   Krichen F, 2015, INT J BIOL MACROMOL, V75, P283, DOI 10.1016/j.ijbiomac.2015.01.044
   Lehane DB, 1999, GEN COMP ENDOCR, V114, P80, DOI 10.1006/gcen.1998.7237
   Li YA, 2011, J MATER SCI, V46, P1396, DOI 10.1007/s10853 010 4933 2
   Mezquita Raya P, 2001, J BONE MINER RES, V16, P1408, DOI 10.1359/jbmr.2001.16.8.1408
   Nguyen MHT, 2013, PROCESS BIOCHEM, V48, P1387, DOI 10.1016/j.procbio.2013.06.031
   Muralidharan N, 2013, J FOOD SCI TECH MYS, V50, P1106, DOI 10.1007/s13197 011 0440 y
   Novitskaya E, 2011, ACTA BIOMATER, V7, P3170, DOI 10.1016/j.actbio.2011.04.025
   Patel JJ, 2014, CELL BIOCHEM FUNCT, V32, P368, DOI 10.1002/cbf.3025
   Cervera MAR, 2015, EUR J LIPID SCI TECH, V117, P724, DOI 10.1002/ejlt.201400356
   Schmid N, 2011, EUR BIOPHYS J BIOPHY, V40, P843, DOI 10.1007/s00249 011 0700 9
   Shore EM, 2010, NAT REV RHEUMATOL, V6, P518, DOI 10.1038/nrrheum.2010.122
   Song LG, 2013, EUR J PHARMACOL, V714, P15, DOI 10.1016/j.ejphar.2013.05.039
   Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156
   Van der Spoel D, 2005, J COMPUT CHEM, V26, P1701, DOI 10.1002/jcc.20291
   Weber D, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472 6807 7 6
   Wei YB, 2017, ARCH ORAL BIOL, V74, P114, DOI 10.1016/j.archoralbio.2016.11.014
   WEISS RE, 1979, CALCIFIED TISSUE INT, V28, P43, DOI 10.1007/BF02441217
   Yagi M, 2011, SPINE, V36, P1652, DOI 10.1097/BRS.0b013e31820110b4
   You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200
NR 51
TC 56
Z9 63
U1 6
U2 95
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0263 6484
EI 1099 0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD APR
PY 2018
VL 36
IS 3
BP 137
EP 146
DI 10.1002/cbf.3325
PG 10
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GB9RY
UT WOS:000429412700003
PM 29392739
DA 2025 08 17
ER

PT J
AU Aloysius, A
   DasGupta, R
   Dhawan, J
AF Aloysius, Ajoy
   DasGupta, Ramanuj
   Dhawan, Jyotsna
TI The transcription factor Lef1 switches partners from β catenin to Smad3
   during muscle stem cell quiescence
SO SCIENCE SIGNALING
LA English
DT Article
ID GROWTH FACTOR BETA; SATELLITE CELL; SELF RENEWAL; TGF BETA;
   SKELETAL MUSCLE; MYOGENIC DIFFERENTIATION; CROSS TALK; WNT; ACTIVATION;
   PROLIFERATION
AB Skeletal muscle stem cells (MuSCs), also known as satellite cells, persist in adult mammals by entering a state of quiescence (G(0)) during the early postnatal period. Quiescence is reversed during damage induced regeneration and re established after regeneration. Entry of cultured myoblasts into G(0) is associated with a specific, reversible induction of Wnt target genes, thus implicating members of the Tcf and Lef1 (Tcf/Lef) transcription factor family, which mediate transcriptional responses to Wnt signaling, in the initiation of quiescence. We found that the canonical Wnt effector beta catenin, which cooperates with Tcf/Lef, was dispensable for myoblasts to enter quiescence. Using pharmacological and genetic approaches in cultured C2C12 myoblasts and in MuSCs, we demonstrated that Tcf/Lef activity during quiescence depended not on beta catenin but on the transforming growth factor beta (TGF beta) effector and transcriptional coactivator Smad3, which colocalized with Lef1 at canonical Wnt responsive elements and directly interacted with Lef1 specifically in G(0). Depletion of Smad3, but not beta catenin, reduced Lef1 occupancy at target promoters, Tcf/Lef target gene expression, and self renewal of myoblasts. In vivo, MuSCs underwent a switch from beta catenin Lef1 to Smad3 Lef1 interactions during the postnatal switch from proliferation to quiescence, with beta catenin Lef1 interactions recurring during damage induced reactivation. Our findings suggest that the interplay of Wnt Tcf/Lef and TGF beta Smad3 signaling activates canonical Wnt target promoters in a manner that depends on beta catenin during myoblast proliferation but is independent of beta catenin during MuSC quiescence.
C1 [Aloysius, Ajoy] Tata Inst Fundamental Res, Natl Ctr Biol Sci, Bangalore 560065, Karnataka, India.
   [Aloysius, Ajoy; Dhawan, Jyotsna] Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.
   [Aloysius, Ajoy; Dhawan, Jyotsna] Inst Stem Cell Biol & Regenerat Med, Bangalore 560065, Karnataka, India.
   [DasGupta, Ramanuj] Genome Inst Singapore, Singapore, Singapore.
C3 Tata Institute of Fundamental Research (TIFR); National Centre for
   Biological Sciences (NCBS); Council of Scientific & Industrial Research
   (CSIR)   India; CSIR   Centre for Cellular & Molecular Biology (CCMB);
   Department of Biotechnology (DBT) India; Institute for Stem Cell Biology
   & Regenerative Medicine   inStem; Agency for Science Technology &
   Research (A*STAR); A*STAR   Genome Institute of Singapore (GIS)
RP Dhawan, J (通讯作者)，Ctr Cellular & Mol Biol, Hyderabad 500007, Andhra Pradesh, India.; Dhawan, J (通讯作者)，Inst Stem Cell Biol & Regenerat Med, Bangalore 560065, Karnataka, India.
EM jdhawan@ccmb.res.in
OI ALOYSIUS, AJOY/0000 0001 6705 4810
FU National Mouse Research Resourc grante from Department of Biotechnology
   (DBT) [BT/PR5981/MED/31/181/2012]; Tata Institute of Fundamental
   Research NCBS; California Institute of Regenerative Medicine InStem
   grant; DBT; InStem; CSIR CCMB
FX Animal work was partially supported by National Mouse Research Resource
   grant (BT/PR5981/MED/31/181/2012; 2013 2016) from Department of
   Biotechnology (DBT). This work was supported by a doctoral fellowship
   from Tata Institute of Fundamental Research NCBS to A.A., a California
   Institute of Regenerative Medicine InStem grant to R.D., Indo Denmark
   and Indo Australia grants from DBT to J.D., and core funds from InStem
   and CSIR CCMB.
CR Arce L, 2006, ONCOGENE, V25, P7492, DOI 10.1038/sj.onc.1210056
   Attisano L, 2004, CANCER METAST REV, V23, P53, DOI 10.1023/A:1025811012690
   Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5 17
   Bendall AJ, 1999, DEVELOPMENT, V126, P4965
   BISCHOFF R, 1990, J CELL BIOL, V111, P201, DOI 10.1083/jcb.111.1.201
   Bjornson CRR, 2012, STEM CELLS, V30, P232, DOI 10.1002/stem.773
   BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092 8674(83)90300 8
   Brack AS, 2008, CELL STEM CELL, V2, P50, DOI 10.1016/j.stem.2007.10.006
   Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Chatterjee SS, 2015, J CELL BIOL, V211, P39, DOI 10.1083/jcb.201503017
   Cheedipudi S, 2015, NUCLEIC ACIDS RES, V43, P6236, DOI 10.1093/nar/gkv567
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Chu GC, 2004, DEVELOPMENT, V131, P3501, DOI 10.1242/dev.01248
   Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615
   Cole MF, 2008, GENE DEV, V22, P746, DOI 10.1101/gad.1642408
   Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010
   Conboy IM, 2002, DEV CELL, V3, P397, DOI 10.1016/S1534 5807(02)00254 X
   DasGupta R, 1999, DEVELOPMENT, V126, P4557
   Davidson KC, 2012, P NATL ACAD SCI USA, V109, P4485, DOI 10.1073/pnas.1118777109
   Dhawan J, 2015, J CELL SCI, V128, P4467, DOI 10.1242/jcs.177758
   Dorsky RI, 2002, DEV BIOL, V241, P229, DOI 10.1006/dbio.2001.0515
   Duan CM, 2010, GEN COMP ENDOCR, V167, P344, DOI 10.1016/j.ygcen.2010.04.009
   Faunes F, 2013, DEVELOPMENT, V140, P1171, DOI 10.1242/dev.085654
   Fink SP, 2001, CANCER RES, V61, P256
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Ge XJ, 2011, CELL RES, V21, P1591, DOI 10.1038/cr.2011.72
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Grumolato L, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003603
   Guo X, 2008, GENE DEV, V22, P106, DOI 10.1101/gad.1590908
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Hausburg MA, 2015, ELIFE, V4, DOI 10.7554/eLife.03390
   Hikasa H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.185280
   Hikasa H, 2010, DEV CELL, V19, P521, DOI 10.1016/j.devcel.2010.09.005
   Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222
   Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65
   Jinnin M, 2006, MOL PHARMACOL, V69, P597, DOI 10.1124/mol.105.017483
   Kadauke S, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756 8935 6 6
   Kandasamy M, 2014, J CELL MOL MED, V18, P1444, DOI 10.1111/jcmm.12298
   Kim CH, 2000, NATURE, V407, P913, DOI 10.1038/35038097
   Kollias HD, 2008, J APPL PHYSIOL, V104, P579, DOI 10.1152/japplphysiol.01091.2007
   Kordes C, 2008, BIOCHEM BIOPH RES CO, V367, P116, DOI 10.1016/j.bbrc.2007.12.085
   Kratochwil K, 2002, GENE DEV, V16, P3173, DOI 10.1101/gad.1035602
   Kretschmer A, 2003, ONCOGENE, V22, P6748, DOI 10.1038/sj.onc.1206791
   Labbé E, 2000, P NATL ACAD SCI USA, V97, P8358, DOI 10.1073/pnas.150152697
   Lee KY, 2002, J BIOCHEM MOL BIOL, V35, P47
   Li X, 2008, POULTRY SCI, V87, P1823, DOI 10.3382/ps.2008 00133
   Liu F, 2005, DEVELOPMENT, V132, P5375, DOI 10.1242/dev.02152
   Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905
   Lyashenko N, 2011, NAT CELL BIOL, V13, P753, DOI 10.1038/ncb2260
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   McCroskery S, 2003, J CELL BIOL, V162, P1135, DOI 10.1083/jcb.200207056
   Melnikova IN, 1999, EXP CELL RES, V247, P94, DOI 10.1006/excr.1998.4330
   Milasincic DJ, 1996, IN VITRO CELL DEV AN, V32, P90
   Montarras D, 2013, FEBS J, V280, P4036, DOI 10.1111/febs.12372
   Morris SAL, 2016, GENES DIS, V3, P41, DOI 10.1016/j.gendis.2015.12.003
   Mourikis P, 2012, STEM CELLS, V30, P243, DOI 10.1002/stem.775
   Mullen AC, 2011, CELL, V147, P565, DOI 10.1016/j.cell.2011.08.050
   Murphy MM, 2014, STEM CELL REP, V3, P475, DOI 10.1016/j.stemcr.2014.06.019
   Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353
   Nawshad A, 2003, J CELL BIOL, V163, P1291, DOI 10.1083/jcb.200306024
   Nishita M., 2000, INTERACTION WNT TGF, V357, P781
   Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47
   Otto A, 2008, J CELL SCI, V121, P2939, DOI 10.1242/jcs.026534
   Paris ND, 2016, ELIFE, V5, DOI 10.7554/eLife.19484
   Parisi A, 2015, J CELL BIOL, V210, P717, DOI 10.1083/jcb.201501053
   Pasut A, 2013, JOVE J VIS EXP, DOI 10.3791/50074
   Rathbone CR, 2011, J MUSCLE RES CELL M, V32, P99, DOI 10.1007/s10974 011 9255 8
   Reya T, 2000, IMMUNITY, V13, P15, DOI 10.1016/S1074 7613(00)00004 2
   Rockman SP, 2001, J BIOL CHEM, V276, P45113, DOI 10.1074/jbc.M107742200
   Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734
   Rudolf A, 2016, CELL REP, V15, P1277, DOI 10.1016/j.celrep.2016.04.022
   Sachidanandan C, 2002, J CELL SCI, V115, P2701
   Sambasivan R, 2009, DEV CELL, V16, P810, DOI 10.1016/j.devcel.2009.05.008
   Schuijers J, 2012, EMBO J, V31, P2685, DOI 10.1038/emboj.2012.149
   Sebastian S, 2009, P NATL ACAD SCI USA, V106, P4719, DOI 10.1073/pnas.0807136106
   SNOW MH, 1977, ANAT RECORD, V188, P201, DOI 10.1002/ar.1091880206
   Solberg N, 2012, MOL CELL BIOCHEM, V365, P53, DOI 10.1007/s11010 012 1243 9
   Subramaniam S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065097
   Tamai K, 2004, MOL CELL, V13, P149, DOI 10.1016/S1097 2765(03)00484 2
   Troy A, 2012, CELL STEM CELL, V11, P541, DOI 10.1016/j.stem.2012.05.025
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   van Veelen W, 2011, GUT, V60, P1204, DOI 10.1136/gut.2010.233460
   Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960 9822(03)00240 9
   VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0
   von Maltzahn J, 2012, TRENDS CELL BIOL, V22, P602, DOI 10.1016/j.tcb.2012.07.008
   Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323
   White RB, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471 213X 10 21
   Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471 213X 2 8
   YAFFE D, 1977, DIFFERENTIATION, V7, P159, DOI 10.1111/j.1432 0436.1977.tb01507.x
   Yi F, 2011, NAT CELL BIOL, V13, P762, DOI 10.1038/ncb2283
   Yilmaz A, 2015, STEM CELL RES, V15, P542, DOI 10.1016/j.scr.2015.09.012
   Zammit PS, 2004, J CELL BIOL, V166, P347, DOI 10.1083/jcb.200312007
NR 94
TC 24
Z9 25
U1 0
U2 3
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945 0877
EI 1937 9145
J9 SCI SIGNAL
JI Sci. Signal.
PD JUL 24
PY 2018
VL 11
IS 540
AR eaan3000
DI 10.1126/scisignal.aan3000
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GO0AN
UT WOS:000439579100002
PM 30042129
OA Bronze
DA 2025 08 17
ER

PT J
AU Guedeney, N
   Deschamp, J
   Legigan, T
   Monteil, M
   Migianu Griffoni, E
   Lecouvey, M
AF Guedeney, Nicolas
   Deschamp, Julia
   Legigan, Thibaut
   Monteil, Maelle
   Migianu Griffoni, Evelyne
   Lecouvey, Marc
TI Synthesis of new alendronate analogs for bone targeted drug delivery
   strategies
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID BISPHOSPHONATE PRODRUGS; IN VITRO; ACID; HYDROXYAPATITE; BINDING;
   FARNESYL; SODIUM; ESTERS; AGENTS; ALKYL
AB 1 Hydroxymethylene 1,1 bisphosphonate (HMBP) derivatives are widely used for the treatment of bone disorders and for bone imagery. Through their high affinity for bone matrix hydroxyapatite, they have shown promising development as powerful bone vectors for many bioactive compounds. To improve the toolbox of conjugatable bisphosphonates, we reported here a convenient synthesis of alendronate derivatives bearing tunable functions on their side chain. The developed straightforward synthetic strategy provides substituted 1 aminoalkyl 1 hydroxymethylene 1,1 bisphosphonates (N HMBPs) for conjugation strategies.
   1 Hydroxymethylene 1,1 bisphosphonate (HMBP) derivatives bearing a tunable side chain function (azide, amine or maleimide) were developed to be used as bone vectors for imagery and bioactive compounds.
C1 [Guedeney, Nicolas; Deschamp, Julia; Legigan, Thibaut; Monteil, Maelle; Migianu Griffoni, Evelyne; Lecouvey, Marc] Univ Sorbonne Paris Nord, Dept Chem, UMR CNRS 7244, 1 Rue Chablis, F 93000 Bobigny, France.
RP Guedeney, N (通讯作者)，Univ Sorbonne Paris Nord, Dept Chem, UMR CNRS 7244, 1 Rue Chablis, F 93000 Bobigny, France.
EM nicolas.guedeney@gmail.com
RI ; Lecouvey, Marc/ADO 6272 2022
OI Deschamp, Julia/0000 0002 1979 6913; Migianu Griffoni,
   Evelyne/0000 0002 4029 9874; Guedeney, Nicolas/0000 0003 4029 6777
FU Universite Sorbonne Paris Nord (USPN); Centre National de la Recherche
   Scientifique (CNRS); Ministere de l'Enseignement Superieur et de la
   Recherche (MESR); GDR Phosphore 2008 (CNRS)
FX The authors strongly acknowledge Universite Sorbonne Paris Nord (USPN),
   Centre National de la Recherche Scientifique (CNRS), Ministere de
   l'Enseignement Superieur et de la Recherche (MESR) and GDR Phosphore
   2008 (CNRS) for Financial Support. The authors thank the NMR PF facility
   (Universite Sorbonne Paris Nord USPN) and Cyril Colas from the
   "Federation de Recherche" ICOA/CBM (FR2708) for HRMS analysis.
CR Alanne AL, 2012, MOLECULES, V17, P10928, DOI 10.3390/molecules170910928
   Bala JLF, 2010, SYNTHETIC COMMUN, V40, P3577, DOI 10.1080/00397910903531706
   Bao K, 2015, THERANOSTICS, V5, P609, DOI 10.7150/thno.11222
   Bird RE, 2021, BIOCONJUGATE CHEM, V32, P2457, DOI 10.1021/acs.bioconjchem.1c00461
   Camper N, 2010, NEW J CHEM, V34, P949, DOI 10.1039/b9nj00597h
   Chmielewska E., 2016, Open Pharm. Sci. J, P56, DOI DOI 10.2174/1874844901603010056
   Clézardin P, 2011, BONE, V48, P71, DOI 10.1016/j.bone.2010.07.016
   Cole LE, 2016, ADV DRUG DELIVER REV, V99, P12, DOI 10.1016/j.addr.2015.10.005
   Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014
   David E, 2019, BIOCONJUGATE CHEM, V30, P1665, DOI 10.1021/acs.bioconjchem.9b00210
   Dussart J, 2020, ORG PROCESS RES DEV, V24, P637, DOI 10.1021/acs.oprd.9b00490
   Dussart J, 2018, ORG BIOMOL CHEM, V16, P6969, DOI 10.1039/c8ob01878b
   Dussart Gautheret J, 2021, MOLECULES, V26, DOI 10.3390/molecules26247609
   Ebetino FH, 2022, BONE, V156, DOI 10.1016/j.bone.2021.116289
   Ebetino FH, 2011, BONE, V49, P20, DOI 10.1016/j.bone.2011.03.774
   Farrell Kristen B, 2018, Bone Rep, V9, P47, DOI 10.1016/j.bonr.2018.06.007
   FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262
   Gil L, 1999, BIOORGAN MED CHEM, V7, P901, DOI 10.1016/S0968 0896(99)00045 0
   Guedeney N., 2018, SULFUR SILICON RELAT, P1
   Guénin E, 2007, EUR J ORG CHEM, V2007, P3380, DOI 10.1002/ejoc.200601067
   Ha P, 2023, NPJ MICROGRAVITY, V9, DOI 10.1038/s41526 023 00319 7
   Hochdörffer K, 2012, J MED CHEM, V55, P7502, DOI 10.1021/jm300493m
   Hsiao CHC, 2018, BIOCHEM PHARMACOL, V158, P298, DOI 10.1016/j.bcp.2018.10.035
   Itzstein Cecile, 2011, Small GTPases, V2, P117
   Kachbi Khelfallah S, 2016, BEILSTEIN J ORG CHEM, V12, P1366, DOI 10.3762/bjoc.12.130
   Kashemirov BA, 2008, BIOCONJUGATE CHEM, V19, P2308, DOI 10.1021/bc800369c
   Katsumi H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135966
   Khelfallah SK, 2015, ORG BIOMOL CHEM, V13, P11382, DOI 10.1039/c5ob01967b
   Kieczykowski GR, 1995, J ORG CHEM, V60, P8310, DOI 10.1021/jo00130a036
   Lawson MA, 2010, J BIOMED MATER RES B, V92B, P149, DOI 10.1002/jbm.b.31500
   Lecouvey M, 2001, TETRAHEDRON LETT, V42, P8475, DOI 10.1016/S0040 4039(01)01844 5
   LIN JH, 1992, DRUG METAB DISPOS, V20, P608
   Lin JH, 1996, BONE, V18, P75, DOI 10.1016/8756 3282(95)00445 9
   Manaswiyoungkul P, 2020, RSC MED CHEM, V11, P51, DOI 10.1039/c9md00442d
   Massarenti C, 2017, ORG BIOMOL CHEM, V15, P4907, DOI 10.1039/c7ob00774d
   MCKENNA CE, 1977, TETRAHEDRON LETT, P155
   Meloun M, 2011, J CHEM ENG DATA, V56, P3848, DOI 10.1021/je200512e
   Merino P, 2017, RSC ADV, V7, P10947, DOI 10.1039/c6ra28316k
   Nair DP, 2014, CHEM MATER, V26, P724, DOI 10.1021/cm402180t
   NICHOLSON DA, 1971, J ORG CHEM, V36, P3843, DOI 10.1021/jo00823a621
   Niemi R, 2000, EUR J PHARM SCI, V11, P173, DOI 10.1016/S0928 0987(00)00099 3
   Pardasani D, 2018, CHEMISTRYSELECT, V3, P253, DOI 10.1002/slct.201702149
   Puljula E, 2015, ACS MED CHEM LETT, V6, P397, DOI 10.1021/ml5004603
   Ren YL, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.910970
   Rogers MJ, 2020, BONE, V139, DOI 10.1016/j.bone.2020.115493
   Russell RGG, 2008, OSTEOPOROSIS INT, V19, P733, DOI 10.1007/s00198 007 0540 8
   Stapleton M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071345
   Sun ST, 2021, BRIT J PHARMACOL, V178, P2008, DOI 10.1111/bph.15251
   Tian ZR, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2051
   Turhanen PA, 2001, SYNTHESIS STUTTGART, P633
   Turhanen PA, 2008, BEILSTEIN J ORG CHEM, V4, DOI 10.1186/1860 5397 4 7
   Vachal P, 2006, J MED CHEM, V49, P3060, DOI 10.1021/jm060398v
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V255, P491, DOI 10.1006/bbrc.1999.0224
   Wilkening I, 2008, CHEM COMMUN, P2932, DOI 10.1039/b802030b
   Wilkening I, 2011, CHEM COMMUN, V47, P349, DOI 10.1039/c0cc02472d
   Xing LP, 2020, BONE, V138, DOI 10.1016/j.bone.2020.115492
   YOKOMATSU T, 1994, J ORG CHEM, V59, P7930, DOI 10.1021/jo00104a064
   Young RN, 2018, CURR OPIN PHARMACOL, V40, P87, DOI 10.1016/j.coph.2018.03.010
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
NR 59
TC 2
Z9 2
U1 4
U2 11
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144 0546
EI 1369 9261
J9 NEW J CHEM
JI New J. Chem.
PD JAN 15
PY 2024
VL 48
IS 3
BP 1436
EP 1442
DI 10.1039/d3nj04980a
EA DEC 2023
PG 7
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED); Index Chemicus (IC)
SC Chemistry
GA ET3A8
UT WOS:001134585300001
DA 2025 08 17
ER

PT J
AU Wang, FD
   Wang, EJ
   Han, J
   Li, Y
   Jin, Y
   Lv, FF
   Ren, C
   Liu, HF
   Zhou, GQ
AF Wang, Fudan
   Wang, Enjun
   Han, Jing
   Li, Yang
   Jin, Yi
   Lv, Fangfang
   Ren, Cui
   Liu, Huifang
   Zhou, Guoqiang
TI Cerium oxide nanoparticles promote proliferation of primary osteoblasts
   via cell cycle machinery in vitro
SO JOURNAL OF NANOPARTICLE RESEARCH
LA English
DT Article
DE Cerium oxide; Nanoparticles; Primary osteoblasts; Proliferation; Cell
   cycle; Biomedicine; Health effects
ID OXIDATIVE STRESS; ADIPOGENIC DIFFERENTIATION; APOPTOSIS; CEO2; TOXICITY
AB Nano cerium oxide, as a kind of rare earth oxide of the lanthanide series, had many potential applications in biomedical fields, such as drug carrier, antitumor, anti oxidative damage, and biological imaging. Furthermore, cerium dioxide (CeO2) had anti apoptotic effects on macrophages, cardiomyocytes, and pancreatic islets cells and relieved the symptom of autoimmune encephalomyelitis. CeO2 could also protect endothelial cells from oxidative injury. Previous research showed that CeO2 nanoparticles tended to accumulate in the bone (20% of the total intake) after intravenous administration. Moreover, our previous studies also showed that CeO2 nanoparticles could promote the proliferation, differentiation, and mineralization of osteoblasts (OBs). However, the mechanisms of it were still unclear. In the current study, we studied the effect and mechanisms of CeO2 nanoparticles on OBs. The cell proliferation, cellular uptake, endocytosis mechanism, cell cycle, BrdU incorporation, and cell adhesion forces were analyzed. The results showed that CeO2 nanoparticles entered the cell through caveolae and clathrin pathways and promoted the proliferation of primary OBs. The mechanism was that CeO2 nanoparticles pushed more OBs through the G1/S checkpoint and into S phase. Moreover, they also increased cell adhesion force. All in all, the results should be significant for the applications of nano CeO2 in biomedical fields and bone metabolism disease.
C1 [Wang, Fudan; Han, Jing; Li, Yang; Jin, Yi; Liu, Huifang; Zhou, Guoqiang] Hebei Univ, Minist Educ, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag, Baoding 071002, Peoples R China.
   [Wang, Fudan; Han, Jing; Li, Yang; Jin, Yi; Zhou, Guoqiang] Hebei Univ, Coll Chem & Environm, Baoding 071002, Peoples R China.
   [Wang, Enjun] Hebei Univ, Coll Nursing, Baoding 071002, Peoples R China.
   [Jin, Yi; Zhou, Guoqiang] Hebei Univ, Coll Basic Med Sci, Key Lab Pathogenesis Mech & Control Inflammatory, Baoding 071000, Peoples R China.
   [Lv, Fangfang; Ren, Cui; Liu, Huifang] Hebei Univ, Key Lab Pharmaceut Qual Control Hebei Prov, Coll Pharmaceut Sci, Baoding 071002, Peoples R China.
C3 Hebei University; Hebei University; Hebei University; Hebei University;
   Hebei University
RP Liu, HF; Zhou, GQ (通讯作者)，Hebei Univ, Minist Educ, Key Lab Chem Biol Hebei Prov, Key Lab Med Chem & Mol Diag, Baoding 071002, Peoples R China.; Wang, EJ (通讯作者)，Hebei Univ, Coll Nursing, Baoding 071002, Peoples R China.
EM wangenjun2009@163.com; liu huifang@163.com; zhougq1982@163.com
OI Liu, hiufang/0000 0001 5170 8381
FU National Natural Science Foundation of China [21001038, 21471044];
   Natural Science Foundation of Hebei Province [B2018201185, B2018201157,
   B2020201020]; Third Batch of Top Youth Talent Support Program of Hebei
   Province; Priority Strategy Project of Key Laboratory of Medicinal
   Chemistry and Molecular Diagnosis of Ministry of Education [ts2019006];
   Post graduate's Innovation Fund Project of Hebei University
   [hbu2019ss015]; Science and Technology Project of Hebei Education
   Department [ZD2018036, ZD2020150]; Medical Science Foundation of Hebei
   University [2020A03, 2020A04]; Advanced Talents Incubation Program of
   the Hebei University [801260201020]; Talent Training Program of Hebei
   University [521000981169, 521000981196]
FX This work was supported by the National Natural Science Foundation of
   China (21001038, 21471044), the Natural Science Foundation of Hebei
   Province (B2018201185, B2018201157, B2020201020), the Third Batch of Top
   Youth Talent Support Program of Hebei Province, the Priority Strategy
   Project of Key Laboratory of Medicinal Chemistry and Molecular Diagnosis
   of Ministry of Education (ts2019006), the Post graduate's Innovation
   Fund Project of Hebei University (hbu2019ss015), Science and Technology
   Project of Hebei Education Department (ZD2018036, ZD2020150), Medical
   Science Foundation of Hebei University (2020A03, 2020A04), Advanced
   Talents Incubation Program of the Hebei University (801260201020), and
   Talent Training Program of Hebei University (521000981169,
   521000981196).
CR Chen SZ, 2014, MAT SCI ENG C MATER, V43, P330, DOI 10.1016/j.msec.2014.07.029
   Chen SZ, 2013, BIOL TRACE ELEM RES, V154, P156, DOI 10.1007/s12011 013 9678 8
   Dai CY, 2014, BIOL TRACE ELEM RES, V162, P158, DOI 10.1007/s12011 014 0151 0
   DAMMER U, 1995, SCIENCE, V267, P1173, DOI 10.1126/science.7855599
   De Falco M, 2010, CURR PHARM DESIGN, V16, P1417, DOI 10.2174/138161210791033914
   Estevez AY, 2011, ACS SYM SER, V1083, P255
   Ferlini C, 1996, CYTOMETRY, V24, P106
   Gong QH, 2018, INORG CHEM FRONT, V5, P3197, DOI 10.1039/c8qi01068d
   Humphries MJ, 2018, J CELL BIOL
   Jones MC, 2019, PHILOS T R SOC B, V374, DOI 10.1098/rstb.2018.0227
   Kailasa SK, 2019, MAT SCI ENG C MATER, V98, P834, DOI 10.1016/j.msec.2019.01.002
   Kitchin KT, 2014, ENVIRON SCI NANO, V1, P466, DOI 10.1039/c4en00096j
   Phan LMT, 2019, BIOMATER SCI UK, V7, P5187, DOI 10.1039/c9bm01228a
   Li WL, 2020, ELECTROCHIM ACTA, V337, DOI 10.1016/j.electacta.2020.135684
   Lin WS, 2006, INT J TOXICOL, V25, P451, DOI 10.1080/10915810600959543
   Liu HF, 2017, ACS APPL MATER INTER, V9, P5784, DOI 10.1021/acsami.6b14682
   Luo LJ, 2020, BIOMATERIALS, V243, DOI 10.1016/j.biomaterials.2020.119961
   Niu JL, 2011, J PHARMACOL EXP THER, V338, P53, DOI 10.1124/jpet.111.179978
   [Pan Xin 潘鑫], 2013, [Journal of Chinese Pharmaceutical Sciences, 中国药学], V22, P64
   Pourkhalili N, 2012, TOXICOL MECH METHOD, V22, P476, DOI 10.3109/15376516.2012.673093
   Rafique R, 2019, TRAC TREND ANAL CHEM, V120, DOI 10.1016/j.trac.2019.115646
   Shen WH, 2005, MICROPOR MESOPOR MAT, V85, P157, DOI 10.1016/j.micromeso.2005.06.006
   Singh S, 2010, MOL BIOSYST, V6, P1813, DOI 10.1039/c0mb00014k
   Taguchi M, 2016, CATAL COMMUN, V84, P93, DOI 10.1016/j.catcom.2016.06.009
   Xia T, 2008, ACS NANO, V2, P2121, DOI 10.1021/nn800511k
   Xu C, 2013, ADV HEALTHC MATER, V2, P1591, DOI 10.1002/adhm.201200464
   Xu KQ, 2019, NANO RES, V12, P2947, DOI 10.1007/s12274 019 2532 3
   Yokel RA, 2012, TOXICOL SCI, V127, P256, DOI 10.1093/toxsci/kfs067
   Yu SW, 2005, J CELL BIOCHEM, V94, P508, DOI 10.1002/jcb.20303
   Zhang JC, 2011, J RARE EARTH, V29, P507, DOI 10.1016/S1002 0721(10)60487 5
   Zhang JC, 2012, J RARE EARTH, V30, P90, DOI 10.1016/S1002 0721(10)60645 X
   Zhang JC, 2010, CHINESE SCI BULL, V55, P2505, DOI 10.1007/s11434 010 3153 0
   Zhang JC, 2009, CHINESE SCI BULL, V54, P66, DOI 10.1007/s11434 008 0503 2
   Zhou GQ, 2014, MICRO NANO LETT, V9, P91, DOI 10.1049/mnl.2013.0586
NR 34
TC 7
Z9 7
U1 2
U2 40
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1388 0764
EI 1572 896X
J9 J NANOPART RES
JI J. Nanopart. Res.
PD JAN
PY 2021
VL 23
IS 1
AR 30
DI 10.1007/s11051 020 05115 y
PG 11
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science
GA QE7UR
UT WOS:000616413500025
DA 2025 08 17
ER

PT J
AU Pin, F
   Jones, AJ
   Huot, JR
   Narasimhan, A
   Zimmers, TA
   Bonewald, LF
   Bonetto, A
AF Pin, Fabrizio
   Jones, Alexander J.
   Huot, Joshua R.
   Narasimhan, Ashok
   Zimmers, Teresa A.
   Bonewald, Lynda F.
   Bonetto, Andrea
TI RANKL Blockade Reduces Cachexia and Bone Loss Induced by Non Metastatic
   Ovarian Cancer in Mice
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article
DE MUSCLE; BONE; CACHEXIA; CANCER; RANKL; ANTIRESORPTIVE TREATMENTS
ID NF KAPPA B; RECEPTOR ACTIVATOR; MUSCLE WEAKNESS; MINERAL DENSITY;
   GENE EXPRESSION; BODY COMPOSITION; PROSTATE CANCER; BREAST CANCER;
   OSTEOCYTE; OSTEOPOROSIS
AB Tumor  and bone derived soluble factors have been proposed to participate in the alterations of skeletal muscle size and function in cachexia. We previously showed that mice bearing ovarian cancer (OvCa) exhibit cachexia associated with marked bone loss, whereas bone targeting agents, such as bisphosphonates, are able to preserve muscle mass in animals exposed to anticancer drugs. De identified CT images and plasma samples from female patients affected with OvCa were used for body composition assessment and quantification of circulating cross linked C telopeptide type I (CTX I) and receptor activator of NF kB ligand (RANKL), respectively. Female mice bearing ES 2 tumors were used to characterize cancer  and RANKL associated effects on muscle and bone. Murine C2C12 and human HSMM myotube cultures were used to determine the OvCa  and RANKL dependent effects on myofiber size. To the extent of isolating new regulators of bone and muscle in cachexia, here we demonstrate that subjects affected with OvCa display evidence of cachexia and increased bone turnover. Similarly, mice carrying OvCa present high RANKL levels. By using in vitro and in vivo experimental models, we found that elevated circulating RANKL is sufficient to cause skeletal muscle atrophy and bone resorption, whereas bone preservation by means of antiresorptive and anti RANKL treatments concurrently benefit muscle mass and function in cancer cachexia. Altogether, our data contribute to identifying RANKL as a novel therapeutic target for the treatment of musculoskeletal complications associated with RANKL expressing non metastatic cancers. (c) 2021 American Society for Bone and Mineral Research (ASBMR).
C1 [Pin, Fabrizio; Zimmers, Teresa A.; Bonewald, Lynda F.; Bonetto, Andrea] Indiana Univ Sch Med, Dept Anat Cell Biol & Physiol, Indianapolis, IN 46202 USA.
   [Jones, Alexander J.; Zimmers, Teresa A.; Bonetto, Andrea] Indiana Univ Sch Med, Dept Otolaryngol Head & Neck Surg, Indianapolis, IN 46202 USA.
   [Huot, Joshua R.; Narasimhan, Ashok; Zimmers, Teresa A.; Bonetto, Andrea] Indiana Univ Sch Med, Dept Surg, 980 West Walnut St,R3 0522, Indianapolis, IN 46202 USA.
   [Zimmers, Teresa A.; Bonewald, Lynda F.; Bonetto, Andrea] Indiana Univ Sch Med, Simon Comprehens Canc Ctr, Indianapolis, IN 46202 USA.
   [Zimmers, Teresa A.; Bonewald, Lynda F.; Bonetto, Andrea] Indiana Univ Sch Med, Indiana Ctr Musculoskeletal Hlth, Indianapolis, IN 46202 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; Indiana University System; Indiana
   University Bloomington
RP Bonetto, A (通讯作者)，Indiana Univ Sch Med, Dept Surg, 980 West Walnut St,R3 0522, Indianapolis, IN 46202 USA.
EM abonetto@iu.edu
RI ; Jones, Alexander/AAP 2978 2020; Zimmers, Teresa/AAD 5461 2019;
   Bonewald, Lynda/Q 3638 2019; Bonetto, Andrea/MTA 9318 2025
OI Jones, Alexander/0000 0002 9219 285X; Bonetto,
   Andrea/0000 0002 3235 1871; Narasimhan, Ashok/0000 0003 2065 0580; 
FU Department of Surgery; Department of Otolaryngology   Head & Neck
   Surgery at Indiana University; National Cancer Institute [R01CA122596,
   R01CA194593]; Veterans Administration [1I01 BX004177 01]; Lustgarten
   Foundation; IU Simon Cancer Center [NIH P30CA082709]; National Institute
   of Aging [PO1AG039355]; Showalter Research Trust; V Foundation for
   Cancer Research [V2017 021]; American Cancer Society
   [132013 RSG 18 010 01 CCG]; National Institute of Arthritis and
   Musculoskeletal and Skin Diseases [R01AR079379]; IU Simon Cancer Center
   Support Grant [P30 CA082709]; Indiana Genomic Initiative at Indiana
   University (INGEN); Lilly Endowment, Inc.; National Institute on Aging
   [P01AG039355] Funding Source: NIH RePORTER
FX This study was supported by the Department of Surgery and the Department
   of Otolaryngology   Head & Neck Surgery at Indiana University, by grants
   from the National Cancer Institute (R01CA122596, R01CA194593), the
   Veterans Administration (1I01 BX004177 01), the Lustgarten Foundation,
   the IU Simon Cancer Center (NIH P30CA082709) to TAZ, by grants from the
   National Institute of Aging (PO1AG039355) to LFB, and by grants from the
   Showalter Research Trust, the V Foundation for Cancer Research
   (V2017 021), the American Cancer Society (Research Scholar Grant
   132013 RSG 18 010 01 CCG), and the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases (R01AR079379) to AB. The #MF 20
   anti Myosin Heavy Chain monoclonal antibody (developed by Fischman DA at
   Cornell University) and the #MANDRA1(7A10) anti Dystrophin monoclonal
   antibody (developed by Morris GE at NE Wales Institute) were obtained
   from the Developmental Studies Hybridoma Bank, created by the NICHD of
   the NIH and maintained at The University of Iowa, Department of Biology,
   Iowa City, IA, USA. We thank the Simon Comprehensive Cancer Center at
   Indiana University School of Medicine, funded by the IU Simon Cancer
   Center Support Grant P30 CA082709, for the use of the In Vivo
   Therapeutic Core, which provided the NSG mice, and the Tissue
   Procurement and Distribution Core, which provided the plasma samples
   from OvCa patients. The RNA sequencing was carried out in the Center for
   Medical Genomics at Indiana University School of Medicine, which is
   partially supported by the Indiana Genomic Initiative at Indiana
   University (INGEN); INGEN is supported in part by the Lilly Endowment,
   Inc. The survival data in the OvCa patients were generated thanks to the
   Human Protein Atlas database, available from . Authors' roles: FP, LFB,
   and AB conceived and designed the experiments. FP and JRH performed the
   in vitro and in vivo experiments and molecular characterization of
   cachexia in OvCa patients and in mice. AJJ performed the body
   composition analysis in the CT scans from OvCa patients. FP, AN, TAZ,
   and AB analyzed the RNA sequencing data. FP, TAZ, LFB, and AB wrote and
   edited the manuscript.
CR Agarwala S, 2019, ANN REHABIL MED ARM, V43, P314, DOI 10.5535/arm.2019.43.3.314
   Amin MB, 2017, CA CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   Anglesio MS, 2013, PLOS ONE, V8, DOI [10.1371/annotation/ffcaf179 872f 470b 8bb6 f06d8ba6d03a, 10.1371/journal.pone.0072162]
   Barreto R, 2017, SCI REP UK, V7, DOI 10.1038/s41598 017 15040 1
   Berruti A, 2002, J UROLOGY, V167, P2361, DOI 10.1016/S0022 5347(05)64985 3
   Bonetto A, 2016, JOVE J VIS EXP, DOI 10.3791/54893
   Bonetto A, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00679
   Bonnet N, 2019, J CLIN INVEST, V129, P3214, DOI 10.1172/JCI125915
   Borsheim E, 2014, J BONE MINER RES, V29, P1369, DOI 10.1002/jbmr.2162
   Breese MR, 2013, BIOINFORMATICS, V29, P494, DOI 10.1093/bioinformatics/bts731
   Bronger H, 2017, INT J GYNECOL CANCER, V27, P223, DOI 10.1097/IGC.0000000000000867
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen JL, 2014, FASEB J, V28, P1711, DOI 10.1096/fj.13 245894
   Cheung WY, 2012, BONE, V50, P104, DOI 10.1016/j.bone.2011.09.052
   Collin Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200
   Fontes Oliveira CC, 2013, BBA GEN SUBJECTS, V1830, P2770, DOI 10.1016/j.bbagen.2012.11.009
   de Paula NS, 2018, INT J GYNECOL CANCER, V28, P412, DOI 10.1097/IGC.0000000000001157
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Dufresne SS, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478 018 0533 1
   Dufresne SS, 2016, AM J PHYSIOL CELL PH, V310, pC663, DOI 10.1152/ajpcell.00285.2015
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Essex AL, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00809
   Evans WJ, 2008, CLIN NUTR, V27, P793, DOI 10.1016/j.clnu.2008.06.013
   Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354
   Fearon KC, 2006, AM J CLIN NUTR, V83, P1345, DOI 10.1093/ajcn/83.6.1345
   Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470 2045(10)70218 7
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Fuller K, 1998, J EXP MED, V188, P997, DOI 10.1084/jem.188.5.997
   Gadducci A, 2001, ANTICANCER RES, V21, P2941
   Guntur AR, 2012, ENDOCR PRACT, V18, P758, DOI 10.4158/EP12141.RA
   HAMILTON TC, 1983, CANCER RES, V43, P5379
   Hamoudi D, 2020, HUM MOL GENET, V29, P483, DOI 10.1093/hmg/ddz312
   Hamoudi D, 2019, HUM MOL GENET, V28, P3101, DOI 10.1093/hmg/ddz124
   Hayes S, 2005, BREAST CANCER RES TR, V94, P1, DOI 10.1007/s10549 005 5991 z
   Huang CY, 2020, J CACHEXIA SARCOPENI, V11, P534, DOI 10.1002/jcsm.12524
   Hung YC, 2002, JPN J CLIN ONCOL, V32, P422, DOI 10.1093/jjco/hyf082
   Huot JR, 2020, J CACHEXIA SARCOPENI, V11, P1779, DOI 10.1002/jcsm.12642
   Huot JR, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.136687
   Jemal A., 2010, CA CANCER J CLIN, V60, P277, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kanematsu M, 2000, J BONE MINER RES, V15, P1321, DOI 10.1359/jbmr.2000.15.7.1321
   Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI 10.1359/JBMR.081112
   Lee JE, 2020, OBSTET GYNECOL SCI, V63, P470, DOI 10.5468/ogs.20012
   Leibbrandt A, 2008, ANN NY ACAD SCI, V1143, P123, DOI 10.1196/annals.1443.016
   Li JB, 2020, J BONE MINER RES, V35, P1535, DOI 10.1002/jbmr.4021
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   LIPTON A, 2012, CLIN MED INSIGHTS ON, V6
   Luan XD, 2012, J IMMUNOL, V189, P245, DOI 10.4049/jimmunol.1103387
   McClung Michael R, 2006, Curr Osteoporos Rep, V4, P28, DOI 10.1007/s11914 006 0012 7
   Meeske K, 2007, QUAL LIFE RES, V16, P947, DOI 10.1007/s11136 007 9215 3
   Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040
   Mourtzakis M, 2008, APPL PHYSIOL NUTR ME, V33, P997, DOI 10.1139/H08 075
   O'Carrigan B, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub4
   OKEN MM, 1982, AM J CLIN ONCOL CANC, V5, P649, DOI 10.1097/00000421 198212000 00014
   Paul PK, 2010, J CELL BIOL, V191, P1395, DOI 10.1083/jcb.201006098
   Pin F, 2021, CANCER LETT, V520, P80, DOI 10.1016/j.canlet.2021.06.030
   Pin F, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00543
   Pin F, 2018, J CACHEXIA SARCOPENI, V9, P685, DOI 10.1002/jcsm.12311
   Plotkin LI, 1999, J CLIN INVEST, V104, P1363, DOI 10.1172/JCI6800
   Plotkin LI, 2015, J BIOL CHEM, V290, P18934, DOI 10.1074/jbc.M115.642090
   Renema N, 2016, BIOSCIENCE REP, V36, DOI 10.1042/BSR20160150
   Rinotas V, 2014, J BONE MINER RES, V29, P1158, DOI 10.1002/jbmr.2112
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roby KF, 2000, CARCINOGENESIS, V21, P585, DOI 10.1093/carcin/21.4.585
   Rupert JE, 2021, J EXP MED, V218, DOI 10.1084/jem.20190450
   Rutten IJG, 2017, EJSO EUR J SURG ONC, V43, P717, DOI 10.1016/j.ejso.2016.12.016
   Santini D, 2011, J CELL PHYSIOL, V226, P780, DOI 10.1002/jcp.22402
   Severinsen MCK, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa016
   SEYBERTH HW, 1975, NEW ENGL J MED, V293, P1278, DOI 10.1056/NEJM197512182932502
   SHERWIN SA, 1983, CANCER RES, V43, P403
   SUVA LJ, 1987, SCIENCE, V237, P893, DOI 10.1126/science.3616618
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Torres ML, 2013, GYNECOL ONCOL, V129, P548, DOI 10.1016/j.ygyno.2013.03.003
   von Moos R, 2019, CANCER TREAT REV, V76, P57, DOI 10.1016/j.ctrv.2019.05.003
   Waning DL, 2015, NAT MED, V21, P1262, DOI 10.1038/nm.3961
   Wei JT, 1999, UROLOGY, V54, P607, DOI 10.1016/S0090 4295(99)00301 5
   Wieser V, 2019, CANCERS, V11, DOI 10.3390/cancers11060791
   Wright LE, 2017, ONCOTARGET, V8, P8406, DOI 10.18632/oncotarget.14139
   Xiong JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138189
   Zhang N, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00325
   Zhang X, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414 431X20176265, 10.1590/1414 431x20176265]
NR 82
TC 21
Z9 23
U1 1
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAR
PY 2022
VL 37
IS 3
BP 381
EP 396
DI 10.1002/jbmr.4480
EA DEC 2021
PG 16
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA ZW0AY
UT WOS:000729624000001
PM 34904285
OA Green Accepted, Bronze
DA 2025 08 17
ER

PT J
AU Park, SB
   Kim, CH
   Hong, M
   Yang, HJ
   Chung, CK
AF Park, Sung Bae
   Kim, Chi Heon
   Hong, Minyoung
   Yang, Hee Jin
   Chung, Chun Kee
TI Effect of a selective estrogen receptor modulator on bone formation in
   osteoporotic spine fusion using an ovariectomized rat model
SO SPINE JOURNAL
LA English
DT Article
DE Fusion; Osteoporosis; Rat; Selective estrogen receptor modulator; Spine;
   Trabecular
ID PARATHYROID HORMONE; ARTHRODESIS MODEL; RALOXIFENE; BISPHOSPHONATES;
   PREVALENCE; MECHANISMS; FRACTURES; APOPTOSIS; CELLS; WOMEN
AB BACKGROUND CONTEXT: Selective estrogen receptor modulators (SERMs) are drugs used to treat osteoporosis. Selective estrogen receptor modulators improve bone mineral density and bone mechanical strength. However, there is a lack of data on the effect of SERMs on osteoporotic spinal fusion.
   PURPOSE: This study aimed to investigate whether treatment with a SERM enhances spinal fusion in an ovariectomized (OVX) rat model.
   STUDY DESIGN: An in vivo animal study was carried out.
   METHODS: Female Sprague Dawley rats (n=90) were OVX or sham operated, and randomized into three groups: control (sham operated+fusion procedure+saline administration), OVX (OVX+fusion procedure+saline administration), and SERM (OVX+fusion procedure+administration of SERM). Eight weeks after OVX, a bilateral lumbar spinal fusion procedure was performed using autologous iliac bone. In each group, gene expression was evaluated at 2, 4, and 8 weeks after the fusion procedure, histologic analysis was performed at 4 and 8 weeks after the procedure, and bone parameters were measured by micro computed tomography at 2 days, 4 weeks, and 8 weeks after the procedure.
   RESULTS: Bone mineral density and trabecular quality of the vertebral body were significantly higher in the SERM group compared with the OVX group 16 weeks after OVX. The fusion rate and bone volume ratio were higher in the fusion bed of the SERM group compared with the OVX group 8 weeks after the fusion procedure. Real time reverse transcription polymerase chain reaction at 4 and 8 weeks after the fusion procedure showed increased expression of the genes for osteoblast related markers (alkaline phosphatase, osteocalcin, runt related transcription factor 2, and transforming growth factor) in the SERM group compared with the OVX group. The OVX group showed sparse bone mass between transverse processes. By contrast, the SERM group exhibited a compact bridging fusion mass within the fusion bed at 8 weeks after the fusion procedure.
   CONCLUSIONS: Selective estrogen receptor modulator treatment improved the trabecular quality of the vertebral body, enhanced spinal fusion, and increased the amount of compact bone mass within the fusion bed in rats that had received an ovariectomy. Therapeutic SERM treatment may be recommended to improve the fusion rate in osteoporotic patients who undergo spinal fusion. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Park, Sung Bae; Yang, Hee Jin] Seoul Natl Univ, Boramae Med Ctr, Dept Neurosurg, Seoul, South Korea.
   [Kim, Chi Heon; Hong, Minyoung; Chung, Chun Kee] Seoul Natl Univ, Coll Med, Dept Neurosurg, Seoul, South Korea.
   [Chung, Chun Kee] Seoul Natl Univ, Coll Nat Sci, Dept Brain & Cognit Sci, Seoul 151742, South Korea.
   [Chung, Chun Kee] Seoul Natl Univ Hosp, Clin Res Inst, Seoul 110744, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital
RP Chung, CK (通讯作者)，Seoul Natl Univ Hosp, Dept Neurosurg, 101 Daehak No, Seoul 110744, South Korea.
EM chungc@snu.ac.kr
RI Chung, Chun/J 5650 2012; Chung, Chun Kee/J 5650 2012; Kim,
   Chi/J 6536 2019
OI Chung, Chun Kee/0000 0003 3485 2327; 
FU Seoul National University Hospital Research Fund [04 2014 0550];
   National Research Foundation of Korea (NRF)   Korean government (MSIP)
   [2010 0028631]
FX This research was jointly supported by grant no. 04 2014 0550 from The
   Seoul National University Hospital Research Fund. This work was
   supported by the National Research Foundation of Korea (NRF) grant
   funded by the Korean government (MSIP) (no. 2010 0028631).
CR Ahmet Camcioglu N, 2009, EUR J OBSTET GYN R B, V147, P192, DOI 10.1016/j.ejogrb.2009.09.001
   [Anonymous], BONE
   BODEN SD, 1995, SPINE, V20, P412, DOI 10.1097/00007632 199502001 00003
   Burge R, 2007, J BONE MINER RES, V22, P465, DOI [10.1359/jbmr.061113, 10.1359/JBMR.061113]
   Cao YP, 2002, J BONE MINER RES, V17, P2237, DOI 10.1359/jbmr.2002.17.12.2237
   Chin DK, 2007, OSTEOPOROSIS INT, V18, P1219, DOI 10.1007/s00198 007 0370 8
   Cummings SR, 2002, LANCET, V359, P1761, DOI 10.1016/S0140 6736(02)08657 9
   Ettinger B, 1999, JAMA J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637
   Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007
   Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004 0006
   Huang RC, 2005, SPINE, V30, P2516, DOI 10.1097/01.brs.0000186470.28070.7b
   HUGHES DE, 1995, J BONE MINER RES, V10, P1478
   Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610
   KALU DN, 1991, BONE MINER, V15, P175, DOI 10.1016/0169 6009(91)90124 I
   Kim David H, 2006, Spine J, V6, P479, DOI 10.1016/j.spinee.2006.04.013
   Kim KH, 2012, BONE, V50, P1039, DOI 10.1016/j.bone.2012.02.007
   Lee YK, 2012, OSTEOPOROSIS INT, V23, P1859, DOI 10.1007/s00198 011 1833 5
   Lehman Ronald A Jr, 2004, Spine J, V4, P36, DOI 10.1016/S1529 9430(03)00427 3
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   Messalli EM, 2010, INT J WOMENS HLTH, V9, P11
   Omi Naomi, 2011, Clin Calcium, V21, P173, DOI CliCa1102173180
   Parfitt AM, 1996, J BONE MINER RES, V11, P150
   Park SB, 2014, SPINE J, V14, P1748, DOI 10.1016/j.spinee.2014.01.042
   Park SB, 2011, J KOREAN NEUROSURG S, V49, P317, DOI 10.3340/jkns.2011.49.6.317
   Rachner TD, 2011, LANCET, V377, P1276, DOI 10.1016/S0140 6736(10)62349 5
   Riggs BL, 2003, NEW ENGL J MED, V348, P618, DOI 10.1056/NEJMra022219
   Schuiling KD, 2011, J MIDWIFERY WOM HEAL, V56, P615, DOI 10.1111/j.1542 2011.2011.00135.x
   Spiro AS, 2013, J BONE MINER METAB, V31, P629, DOI 10.1007/s00774 013 0461 x
   Stuermer EK, 2010, LANGENBECK ARCH SURG, V395, P163, DOI 10.1007/s00423 008 0436 x
   Takada J, 2010, J BONE MINER METAB, V28, P561, DOI 10.1007/s00774 010 0164 5
   Takahata M, 2008, BONE, V43, P1057, DOI 10.1016/j.bone.2008.08.124
   Tu ZZ, 2012, J CANCER RES CLIN, V138, P1091, DOI 10.1007/s00432 011 1145 3
   WILTSE LL, 1988, SPINE, V13, P696
NR 33
TC 16
Z9 18
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 1529 9430
EI 1878 1632
J9 SPINE J
JI Spine Journal
PD JAN 1
PY 2016
VL 16
IS 1
BP 72
EP 81
DI 10.1016/j.spinee.2015.08.061
PG 10
WC Clinical Neurology; Orthopedics
WE Science Citation Index Expanded (SCI EXPANDED)
SC Neurosciences & Neurology; Orthopedics
GA CY8KA
UT WOS:000366656100036
PM 26343247
DA 2025 08 17
ER

PT J
AU Chen, R
   Wang, MT
   Qi, QL
   Tang, YL
   Guo, ZZ
   Wu, S
   Li, QY
AF Chen, Rui
   Wang, Mengting
   Qi, Qiaoling
   Tang, Yanli
   Guo, Zhenzhao
   Wu, Shuai
   Li, Qiyan
TI Sequential anti inflammatory and osteogenic effects of a dual drug
   delivery scaffold loaded with parthenolide and naringin in periodontitis
SO JOURNAL OF PERIODONTAL AND IMPLANT SCIENCE
LA English
DT Article
DE Drug delivery systems; Naringin; Parthenolide; Periodontitis
ID WEB SERVER; KAPPA B; BONE; IDENTIFICATION; REGENERATION; PREDICTION;
   GENE; MICE
AB Purpose: Our pilot study showed that a 3 dimensional dual drug delivery scaffold (DDDS) loaded with Chinese herbs significantly increased the regenerated bone volume fraction. This study aimed to confirm the synergistic anti inflammatory and osteogenic preclinical effects of this system.Methods: The targets and pathways of parthenolide and naringin were predicted. Three cell models were used to assess the anti inflammatory effects of parthenolide and the osteogenic effects of naringin. First, the distance between the cementoenamel junction and alveolar bone crest (CEJ ABC) and the bone mineral density (BMD) of surgical defects were measured in a rat model of periodontitis with periodontal fenestration defects. Additionally, the mRNA expression levels of matrix metallopeptidase 9 (MMP9) and alkaline phosphatase (ALP) were measured. Furthermore, the number of inflammatory cells and osteoclasts, as well as the protein expression levels of tumor necrosis factor alpha (TNF a) and levels of ALP were determined. Results: Target prediction suggested prostaglandin peroxidase synthase (PTGS2) as a potential target of parthenolide, while cytochrome P450 family 19 subfamily A1 (CYP19A1) and taste 2 receptor member 31 (TAS2R31) were potential targets of naringin. Parthenolide mainly targeted inflammation related pathways, while naringin participated in steroid hormone synthesis and taste transduction. In vitro experiments revealed significant anti inflammatory effects of parthenolide on RAW264.7 cells, and significant osteogenic effects of naringin on bone marrow mesenchymal stem cells and MC3T3 E1 cells. DDDS loaded with parthenolide and naringin decreased the CEJ ABC distance and increased BMD and ALP levels in a time dependent manner. Inflammation was significantly alleviated after 14 days of DDDS treatment. Additionally, after 56 days, the DDDS group exhibited the highest BMD and ALP levels.Conclusions: DDDS loaded with parthenolide and naringin in a rat model achieved significant synergistic anti inflammatory and osteogenic effects, providing powerful preclinical evidence.
C1 [Chen, Rui; Wang, Mengting; Tang, Yanli; Li, Qiyan] First Peoples Hosp Yunnan Prov, Dept Stomatol, Kunming, Peoples R China.
   [Chen, Rui; Wang, Mengting; Tang, Yanli; Li, Qiyan] Kunming Univ Sci & Technol, Affiliated Hosp, Kunming, Peoples R China.
   [Qi, Qiaoling] Dali Univ, Yunnan Prov Key Lab Entomol Biopharmaceut R&D, Dali, Peoples R China.
   [Guo, Zhenzhao; Wu, Shuai] Jinan Univ, Guangzhou, Peoples R China.
   [Li, Qiyan] First Peoples Hosp Yunnan Prov, Dept Stomatol, 157 Jinbi St, Kunming 650032, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology; Kunming University of
   Science & Technology; Dali University; Jinan University; Kunming
   University of Science & Technology
RP Li, QY (通讯作者)，First Peoples Hosp Yunnan Prov, Dept Stomatol, 157 Jinbi St, Kunming 650032, Yunnan, Peoples R China.
EM ynliqiyan@aliyun.com
RI ; Tang, Yanli/IXW 8378 2023
OI , guo/0000 0003 4262 130X; Chen, Rui/0000 0003 3396 7827; Shuai,
   Wu/0000 0003 4343 5103; 
CR Carda C, 2005, TISSUE CELL, V37, P247, DOI 10.1016/j.tice.2005.03.002
   Chen LL, 2011, ARCH ORAL BIOL, V56, P1655, DOI 10.1016/j.archoralbio.2011.06.008
   Cho YD, 2017, ADV MATER SCI ENG, V2017, DOI 10.1155/2017/1948241
   da Silva IA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00010
   Daina A, 2019, NUCLEIC ACIDS RES, V47, pW357, DOI 10.1093/nar/gkz382
   de Oliveira RR, 2007, J PERIODONTOL, V78, P965, DOI 10.1902/jop.2007.060494
   Di Nardo G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22020631
   Feng D, 2010, INFLAMM RES, V59, P115, DOI 10.1007/s00011 009 0077 8
   Greene CS, 2015, NAT GENET, V47, P569, DOI 10.1038/ng.3259
   Guo ZZ, 2017, J MATER CHEM B, V5, P7701, DOI 10.1039/c7tb00909g
   Ji Y, 2014, DENT MATER, V30, P1263, DOI 10.1016/j.dental.2014.08.381
   Jo S, 2019, INT J RHEUM DIS, V22, P252, DOI 10.1111/1756 185X.13419
   Keiser MJ, 2007, NAT BIOTECHNOL, V25, P197, DOI 10.1038/nbt1284
   Killoy WJ, 2002, J CLIN PERIODONTOL, V29, P22
   Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074 5521(01)00049 7
   Li NH, 2013, J ORTHOP SCI, V18, P478, DOI 10.1007/s00776 013 0362 9
   Li Q., 2012, Journal of signal transduction, V2012, P308943, DOI [DOI 10.1155/2012/308943, 10.1155/2012/308943]
   Li SS, 2015, ACTA BIOCH BIOPH SIN, V47, P368, DOI 10.1093/abbs/gmv019
   Liu XP, 2013, BIOINFORMATICS, V29, P1910, DOI 10.1093/bioinformatics/btt303
   Ma Zhi wei, 2008, Hua Xi Kou Qiang Yi Xue Za Zhi, V26, P23
   McAllister BS, 2007, J PERIODONTOL, V78, P377, DOI 10.1902/jop.2007.060048
   Pang WY, 2010, BRIT J PHARMACOL, V159, P1693, DOI 10.1111/j.1476 5381.2010.00664.x
   Parsa A, 2015, CLIN ORAL IMPLAN RES, V26, pE1, DOI 10.1111/clr.12315
   Seol YJ, 2010, METHODS MOL BIOL, V666, P285, DOI 10.1007/978 1 60761 820 1_18
   Shi FD, 2001, J IMMUNOL, V167, P3000, DOI 10.4049/jimmunol.167.5.3000
   Smallie T, 2015, J IMMUNOL, V195, P277, DOI 10.4049/jimmunol.1402830
   Snel B, 2000, NUCLEIC ACIDS RES, V28, P3442, DOI 10.1093/nar/28.18.3442
   Straka M, 2015, NEUROENDOCRINOL LETT, V36, P401
   Wang D, 2016, INT IMMUNOPHARMACOL, V38, P132, DOI 10.1016/j.intimp.2016.05.024
   Wang MT, 2015, NAT PROD RES, V29, P1092, DOI 10.1080/14786419.2014.981541
   Warde Farley D, 2010, NUCLEIC ACIDS RES, V38, pW214, DOI 10.1093/nar/gkq537
   Yang X, 2015, J PERIODONTAL RES, V50, P748, DOI 10.1111/jre.12261
   Yin LH, 2015, STEM CELLS INT, V2015, DOI 10.1155/2015/758706
   Yin P, 2015, HUM MOL GENET, V24, P1350, DOI 10.1093/hmg/ddu544
   Zhang J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/9749751
   Zhou YQ, 2021, FREE RADICAL BIO MED, V171, P55, DOI 10.1016/j.freeradbiomed.2021.05.009
NR 36
TC 5
Z9 5
U1 2
U2 14
PU KOREAN ACAD PERIODONTOLOGY
PI SEOUL
PA OFFICIAL B D 2212, 163 SINMUNRO 1 GA, JONGNO GU, SEOUL, 110 990, SOUTH
   KOREA
SN 2093 2278
EI 2093 2286
J9 J PERIODONTAL IMPLAN
JI J. Periodontal Implant Sci.
PD FEB
PY 2023
VL 53
IS 1
BP 20
EP 37
DI 10.5051/jpis.2105700285
PG 18
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA E6KM2
UT WOS:000976608600003
PM 36468470
OA Green Published
DA 2025 08 17
ER

PT J
AU Sabanai, K
   Tsutsui, M
   Sakai, A
   Hirasawa, H
   Tanaka, S
   Nakamura, E
   Tanimoto, A
   Sasaguri, Y
   Ito, M
   Shimokawa, H
   Nakamura, T
   Yanagihara, N
AF Sabanai, Ken
   Tsutsui, Masato
   Sakai, Akinori
   Hirasawa, Hideyuki
   Tanaka, Shinya
   Nakamura, Eiichiro
   Tanimoto, Akihide
   Sasaguri, Yasuyuki
   Ito, Masako
   Shimokawa, Hiroaki
   Nakamura, Toshitaka
   Yanagihara, Nobuyuki
TI Genetic disruption of all NO synthase isoforms enhances BMD and bone
   turnover in mice in vivo: Involvement of the renin angiotensin system
SO JOURNAL OF BONE AND MINERAL RESEARCH
LA English
DT Article; Proceedings Paper
CT 28th Annual Meeting of the
   American Society for Bone and Mineral Research
CY SEP 15 19, 2006
CL Philadelphia, PA
SP Amer Soc Bone & Mineral Res
DE NO synthase; bone formation; bone resorption; bone metabolism;
   angiotensin II
ID NITRIC OXIDE SYNTHASE; VASCULAR SMOOTH MUSCLE; OSTEOBLAST LIKE CELLS;
   HIGH FAT DIET; DEFICIENT MICE; OXIDATIVE STRESS; FUNCTIONAL ROLE;
   EXPRESSION; POTENTIATION; ENDOTHELIUM
AB Introduction: NO is synthesized by three different NO synthase (NOS) isoforms, including neuronal (nNOS), inducible (iNOS) and endothelial NOS (eNOS). The roles of NO in bone metabolism have been extensively investigated in pharmacological studies and in studies with NOS isoform deficient mice. However, because of the nonspecificity of agents and compensation among the NOS isoforms, the ultimate roles of endogenous NO are still poorly understood. To address this point, we successfully generated mice in which all three NOS genes are completely disrupted. In this study, we examined whether bone metabolism is abnormal in those mice.
   Materials and Methods: Experiments were performed in 12 wk old male wildtype, singly nNOS( / ), iNOS( / ), and eNOS( / ) and triply n/i/eNOS( / ) mice. BMD was assessed by DXA. The kinetics of osteoblastic bone formation and those of osteoclastic bone resorption were evaluated by measurements of morphological and biochemical markers.
   Results: BMD was significantly higher only in the triply NOS /  mice but not in any singly NOS /  mice compared with the wildtype mice. Markers of osteoblastic bone formation, including bone formation rate, mineral apposition rate, and serum alkaline phosphatase concentration, were also significantly larger only in the triply NOS /  mice compared with wildtype mice. Furthermore, markers of osteoclastic bone resorption, including osteoclast number, osteoclast surface, and urinary deoxypyridinoline excretion, were again significantly greater only in the triply NOS /  mice. Importantly, the renin angiotensin system in bone was significantly activated in the triply NOS /  mice, and long term oral treatment with an angiotensin II type I (AT,) receptor blocker normalized this pathological bone remodeling in those mice.
   Conclusions: These results provide the first direct evidence that genetic disruption of the whole NOS system enhances BMD and bone turnover in mice in vivo through the AT, receptor pathway, showing the critical role of the endogenous NO/NOS system in maintaining bone homeostasis.
C1 [Sabanai, Ken; Sakai, Akinori; Hirasawa, Hideyuki; Tanaka, Shinya; Nakamura, Eiichiro; Nakamura, Toshitaka] Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed Surg, Kitakyushu, Fukuoka 807, Japan.
   [Sabanai, Ken; Tsutsui, Masato; Yanagihara, Nobuyuki] Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Kitakyushu, Fukuoka 807, Japan.
   [Tanimoto, Akihide; Sasaguri, Yasuyuki] Univ Occupat & Environm Hlth, Sch Med, Dept Pathol, Kitakyushu, Fukuoka 807, Japan.
   [Ito, Masako] Nagasaki Univ, Dept Radiol, Grad Sch Biomed Sci, Nagasaki 852, Japan.
   [Shimokawa, Hiroaki] Tohoku Univ, Dept Cardiovasc Med, Grad Sch Med, Sendai, Miyagi 980, Japan.
C3 University of Occupational & Environmental Health   Japan; University of
   Occupational & Environmental Health   Japan; University of Occupational
   & Environmental Health   Japan; Nagasaki University; Tohoku University
RP Sabanai, K (通讯作者)，Univ Occupat & Environm Hlth, Sch Med, Dept Orthopaed Surg, Kitakyushu, Fukuoka 807, Japan.
RI ; Tanaka, Shinya/LYO 5987 2024
OI Shimokawa, Hiroaki/0000 0001 7534 4826; 
CR Aguirre J, 2001, AM J PATHOL, V158, P247, DOI 10.1016/S0002 9440(10)63963 6
   BAB IA, 1994, J CELL BIOCHEM, V55, P358, DOI 10.1002/jcb.240550313
   Bowler Wayne B., 1998, Frontiers in Bioscience, V3, pD769
   BRANDI ML, 1995, P NATL ACAD SCI USA, V92, P2954, DOI 10.1073/pnas.92.7.2954
   BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135
   Caballero Alias AM, 2004, CALCIFIED TISSUE INT, V75, P78, DOI 10.1007/s00223 003 0161 y
   FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135
   Gotoh M, 2005, HYPERTENS RES, V28, P565, DOI 10.1291/hypres.28.565
   Gyurko R, 2005, BONE, V36, P472, DOI 10.1016/j.bone.2004.12.002
   Hamada Y, 2007, BONE, V40, P1408, DOI 10.1016/j.bone.2006.12.057
   Hatton R, 1997, J ENDOCRINOL, V152, P5, DOI 10.1677/joe.0.1520005
   Helfrich MH, 1997, J BONE MINER RES, V12, P1108, DOI 10.1359/jbmr.1997.12.7.1108
   Hirasawa H, 2007, J BONE MINER RES, V22, P1020, DOI 10.1359/JBMR.070330
   Hiruma Y, 1997, BIOCHEM BIOPH RES CO, V230, P176, DOI 10.1006/bbrc.1996.5914
   IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535
   KASTEN TP, 1994, P NATL ACAD SCI USA, V91, P3569, DOI 10.1073/pnas.91.9.3569
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MacPherson H, 1999, BONE, V24, P179, DOI 10.1016/S8756 3282(98)00173 2
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Morishita T, 2005, P NATL ACAD SCI USA, V102, P10616, DOI 10.1073/pnas.0502236102
   Murad F, 1997, CIRCULATION, V95, P1101
   Nakamura H, 2005, EUR J PHARMACOL, V512, P239, DOI 10.1016/j.ejphar.2005.02.047
   PARFITT AM, 1994, J CELL BIOCHEM, V55, P273, DOI 10.1002/jcb.240550303
   Parhami F, 2001, J BONE MINER RES, V16, P182, DOI 10.1359/jbmr.2001.16.1.182
   RIANCHO JA, 1995, J BONE MINER RES, V10, P439
   Son H, 1996, CELL, V87, P1015, DOI 10.1016/S0092 8674(00)81796 1
   Suda O, 2004, ARTERIOSCL THROM VAS, V24, P1682, DOI 10.1161/01.ATV.0000136656.26019.6e
   Suda O, 2002, CIRCULATION, V106, P1729, DOI 10.1161/01.CIR.0000029749.16101.44
   Tsukahara H, 1996, AM J PHYSIOL ENDOC M, V270, pE840, DOI 10.1152/ajpendo.1996.270.5.E840
   Tsutsui M, 2006, J PHARMACOL SCI, V102, P147, DOI 10.1254/jphs.CPJ06015X
   Turner CH, 1997, BONE, V21, P487, DOI 10.1016/S8756 3282(97)00202 0
   van't Hof RJ, 2004, ENDOCRINOLOGY, V145, P5068, DOI 10.1210/en.2004 0205
   van't Hof RJ, 2001, IMMUNOLOGY, V103, P255, DOI 10.1046/j.1365 2567.2001.01261.x
   Watanuki M, 2002, J BONE MINER RES, V17, P1015, DOI 10.1359/jbmr.2002.17.6.1015
NR 34
TC 22
Z9 23
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030 5774, NJ USA
SN 0884 0431
EI 1523 4681
J9 J BONE MINER RES
JI J. Bone Miner. Res.
PD MAY
PY 2008
VL 23
IS 5
BP 633
EP 643
DI 10.1359/JBMR.080107
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Endocrinology & Metabolism
GA 291NC
UT WOS:000255203100006
PM 18433298
OA Bronze
DA 2025 08 17
ER

PT J
AU Villani, C
   Chen, YH
   George, A
AF Villani, Cassandra
   Chen, Yinghua
   George, Anne
TI Role of DMP1 mediated GRP78 activation in osteoimmunomodulation of
   periodontal ligament stem cells
SO JOURNAL OF STRUCTURAL BIOLOGY
LA English
DT Article
ID DIFFERENTIAL EXPRESSION ANALYSIS
AB The oral microbiome dysbiosis that causes periodontal disease leads to disruption of various signaling pathways that can result in alveolar bone degradation and subsequent tooth loss. Previous studies have demonstrated the potential of stem cell based therapies in regeneration of the lost periodontium for the preservation of natural dentition. Periodontal ligament stem cells (PDLSCs) have osteoblast differentiation potential and their proximity to bone makes them an ideal candidate for regenerative therapies. Dentin matrix protein 1 (DMP1), a non collagenous extracellular matrix protein, is integral to mineralized tissue formation due to its dual roles as an extracellular mediator of hydroxyapatite deposition and intracellular regulator of osteoblastogenesis. Heat shock protein 5A (GRP78) is a master regulator of the endoplasmic reticulum stress response and previous studies in our laboratory have also demonstrated its function as a membrane receptor for DMP1. Bulk RNA sequencing analysis of PDLSCs and PDLSCs overexpressing GRP78 (PDLSCs GRP78) ) with or without treatment with DMP1 was conducted to evaluate alterations to the differentially expressed gene profiles. This study aims to elucidate pathways in PDLSCs that are altered upon treatment with DMP1 to further characterize its relationship with GRP78 and cell stress signaling cascades. Pathway enrichment analysis of each transcriptomic profile demonstrated enrichment of osteogenic and immune response pathways upon DMP1 stimulation. Results from this study indicate a novel role for DMP1 and GRP78 in modulating immune signaling cascades in PDLSCs.
C1 [Villani, Cassandra; Chen, Yinghua; George, Anne] Univ Illinois, Dept Oral Biol, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP George, A (通讯作者)，Univ Illinois, Coll Dent, Dept Oral Biol, 801 S Paulina St, Chicago, IL 60612 USA.
EM anneg@uic.edu
FU NIH NIDCR [DE031737, DE028531]; Brodie Endowment Fund
FX We kindly acknowledge funding from NIH NIDCR DE031737 & DE028531 and the
   Brodie Endowment Fund.
CR Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020
   Cekici A, 2014, PERIODONTOL 2000, V64, P57, DOI 10.1111/prd.12002
   De Almeida J, 2015, J PERIODONTOL, V86, P1166, DOI 10.1902/jop.2015.150166
   Duran I, 2017, J BONE MINER RES, V32, P1309, DOI 10.1002/jbmr.3095
   Eke PI, 2012, J DENT RES, V91, P914, DOI 10.1177/0022034512457373
   Greene AC, 2022, SCI REP UK, V12, DOI 10.1038/s41598 022 09150 8
   Hathaway Schrader JD, 2021, PERIODONTOL 2000, V86, P157, DOI 10.1111/prd.12368
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Krämer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Merkel A, 2023, EUR CELLS MATER, V45, P14, DOI 10.22203/eCM.v045a02
   Merkel A, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01175
   Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200
   R Core Team, 2023, R LANG ENV STAT COMP
   Ravindran S, 2012, HISTOCHEM CELL BIOL, V138, P113, DOI 10.1007/s00418 012 0952 1
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Seo BM, 2004, LANCET, V364, P149, DOI 10.1016/S0140 6736(04)16627 0
   Sherman BT, 2022, NUCLEIC ACIDS RES, V50, pW216, DOI 10.1093/nar/gkac194
   Wang JY, 2024, INT J ORAL SCI, V16, DOI 10.1038/s41368 023 00274 9
NR 19
TC 0
Z9 0
U1 2
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101 4495 USA
SN 1047 8477
EI 1095 8657
J9 J STRUCT BIOL
JI J. Struct. Biol.
PD DEC
PY 2024
VL 216
IS 4
AR 108133
DI 10.1016/j.jsb.2024.108133
EA OCT 2024
PG 8
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA J4Z8Z
UT WOS:001337172600001
PM 39389243
DA 2025 08 17
ER

PT J
AU Shen, W
   Prisk, V
   Li, Y
   Foster, W
   Huard, J
AF Shen, Wei
   Prisk, Victor
   Li, Yong
   Foster, William
   Huard, Johnny
TI Inhibited skeletal muscle healing in cyclooxygenase 2 gene deficient
   mice:: the role of PGE2 and PGF2β
SO JOURNAL OF APPLIED PHYSIOLOGY
LA English
DT Article
DE muscle injury; inflammation; nonsteroidal anti inflammatory drugs;
   prostaglandin F 2 alpha; prostaglandin E 2; fusion
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN E 2; SATELLITE CELLS;
   REGENERATION; DIFFERENTIATION; MACROPHAGES; GROWTH; INJURY;
   PROLIFERATION; MEDICATION
AB Inhibited skeletal muscle healing in cyclooxygenase 2 gene deficient mice: the role of PGE(2) and PGF(2 alpha). J Appl Physiol 101: 1215 1221, 2006. First published June 15, 2006; doi:10.1152/japplphysiol.01331.2005. Non steroidal anti inflammatory drugs (NSAIDs) are commonly used to treat skeletal muscle injury. However, studies have shown that NSAIDs may be detrimental to the healing process. Mediated by prostaglandin F 2 alpha (PGF(2 alpha)) and prostaglandin E 2 (PGE(2)), the cycloxy genase 2 (COX 2) pathway plays an important role in muscle healing. We hypothesize that the COX 2 pathway is important for the fusion of muscle cells and the regeneration of injured muscle. For the in vitro experiments, we isolated myogenic precursor cells from wild type (Wt) and COX 2 gene deficient (COX 2( / )) mice and examined the effect of PGE(2) and PGF(2 alpha) on cell fusion. For the in vivo experiments, we created laceration injury on the tibialis anterior (TA) muscles of Wt and COX 2( / ) mice. Five and 14 days after injury, we examined the TA muscles histologically and functionally. We found that the secondary fusion between nascent myotubes and myogenic precursor cells isolated from COX 2( / ) mice was severely compromised compared with that of Wt controls but was restored by the addition of PGF(2 alpha) or, to a lesser extent, PGE(2) to the culture. Histological and functional assessments of the TA muscles in COX 2( / ) mice revealed decreased regeneration relative to that observed in the Wt mice. The findings reported here demonstrate that the COX 2 pathway plays an important role in muscle healing and that prostaglandins are key mediators of the COX 2 pathway. It suggests that the decision to use NSAIDs to treat muscle injuries warrants critical evaluation because NSAIDs might impair muscle healing by inhibiting the fusion of myogenic precursor cells.
C1 Childrens Hosp Pittsburgh, Growth & Dev Lab, Pittsburgh, PA 15213 USA.
   Univ Pittsburgh, Sch Med, Dept Orthopaed Surg, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh
RP Huard, J (通讯作者)，Childrens Hosp Pittsburgh, Growth & Dev Lab, 4100 Rangos Res Ctr,3460 5th Ave, Pittsburgh, PA 15213 USA.
EM jhuard@pitt.edu
RI ; Li, Yong/AAM 2367 2021
OI Li, Yong/0000 0001 7956 9600; 
FU NCRR NIH HHS [C06 RR 14489] Funding Source: Medline; NIAMS NIH HHS [1R01
   AR 47973 01] Funding Source: Medline
CR ALMEKINDERS LC, 1986, AM J SPORT MED, V14, P303, DOI 10.1177/036354658601400411
   Bondesen BA, 2004, AM J PHYSIOL CELL PH, V287, pC475, DOI 10.1152/ajpcell.00088.2004
   CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129
   Chazaud B, 2003, J CELL BIOL, V163, P1133, DOI 10.1083/jcb.200212046
   Fukushima K, 2001, AM J SPORT MED, V29, P394, DOI 10.1177/03635465010290040201
   HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620
   Harris RC, 2001, AM J PHYSIOL RENAL, V281, pF1, DOI 10.1152/ajprenal.2001.281.1.F1
   Hedenberg Magnusson B, 2002, ACTA ODONTOL SCAND, V60, P29, DOI 10.1080/000163502753471970
   Hersh EV, 2000, CLIN THER, V22, P500, DOI 10.1016/S0149 2918(00)80043 0
   Horsley V, 2004, CELLS TISSUES ORGANS, V176, P67, DOI 10.1159/000075028
   Horsley V, 2003, J CELL BIOL, V161, P111, DOI 10.1083/jcb.200208085
   Huard J, 2002, J BONE JOINT SURG AM, V84A, P822, DOI 10.2106/00004623 200205000 00022
   Jankowski RJ, 2002, GENE THER, V9, P642, DOI 10.1038/sj.gt.3301719
   KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036
   LANDAY A, 1983, J IMMUNOL, V131, P2757
   Lee JY, 2000, J CELL BIOL, V150, P1085, DOI 10.1083/jcb.150.5.1085
   Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960 8966(98)00111 4
   Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002 9440(10)63188 4
   Li Y., 2001, Current Opinion in Orthopaedics, V12, P409, DOI DOI 10.1097/00001433 200110000 00008
   Massimino ML, 1997, BIOCHEM BIOPH RES CO, V235, P754, DOI 10.1006/bbrc.1997.6823
   MCARDLE A, 1994, J APPL PHYSIOL, V76, P1274, DOI 10.1152/jappl.1994.76.3.1274
   McCormack K, 1998, J RHEUMATOL, V25, P2279
   Menetrey J, 2000, J BONE JOINT SURG BR, V82B, P131, DOI 10.1302/0301 620X.82B1.8954
   MENSE S, 1981, BRAIN RES, V225, P95, DOI 10.1016/0006 8993(81)90320 6
   MISHRA DK, 1995, J BONE JOINT SURG AM, V77, P1510, DOI 10.2106/00004623 199510000 00005
   Musarò A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839
   Natsu K, 2004, TISSUE ENG, V10, P1093, DOI 10.1089/1076327041887754
   OBREMSKY WT, 1994, AM J SPORT MED, V22, P558, DOI 10.1177/036354659402200420
   PALMER RM, 1990, PROSTAG LEUKOTR ESS, V39, P95, DOI 10.1016/0952 3278(90)90017 F
   Prisk V, 2003, HISTOL HISTOPATHOL, V18, P1243, DOI 10.14670/HH 18.1243
   Qu ZQ, 1998, J CELL BIOL, V142, P1257, DOI 10.1083/jcb.142.5.1257
   Rahusen FTG, 2004, AM J SPORT MED, V32, P1856, DOI 10.1177/0363546504266069
   RODEMANN HP, 1982, J BIOL CHEM, V257, P1632
   Sakamoto A, 2004, SHOCK, V22, P76, DOI 10.1097/01.shk.0000129338.99410.5d
   Shen W, 2005, AM J PATHOL, V167, P1105, DOI 10.1016/S0002 9440(10)61199 6
   STENSON WF, 1986, PROSTAG OTH LIPID M, V32, P5, DOI 10.1016/0090 6980(86)90137 1
   TETSUKA T, 1994, P NATL ACAD SCI USA, V91, P12168, DOI 10.1073/pnas.91.25.12168
   Trappe TA, 2001, J CLIN ENDOCR METAB, V86, P5067, DOI 10.1210/jc.86.10.5067
   van Eeden SF, 1999, J IMMUNOL METHODS, V232, P23, DOI 10.1016/S0022 1759(99)00148 9
   VANDENBURGH HH, 1995, J CELL PHYSIOL, V163, P285, DOI 10.1002/jcp.1041630209
   Wani MR, 1999, ENDOCRINOLOGY, V140, P1927, DOI 10.1210/en.140.4.1927
   Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099
   Watchko J, 2002, HUM GENE THER, V13, P1451, DOI 10.1089/10430340260185085
   WEILER JM, 1992, CLIN SPORT MED, V11, P625
   WHITE S, 1991, PROSTAG LEUKOTR ESS, V43, P209, DOI 10.1016/0952 3278(91)90033 2
NR 45
TC 82
Z9 102
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 8750 7587
J9 J APPL PHYSIOL
JI J. Appl. Physiol.
PD OCT
PY 2006
VL 101
IS 4
BP 1215
EP 1221
DI 10.1152/japplphysiol.01331.2005
PG 7
WC Physiology; Sport Sciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Physiology; Sport Sciences
GA 084CS
UT WOS:000240510000028
PM 16778000
OA Green Submitted
DA 2025 08 17
ER

PT J
AU Breitkreutz, I
   Raab, MS
   Vallet, S
   Hideshima, T
   Raje, N
   Mitsiades, C
   Chauhan, D
   Okawa, Y
   Munshi, NC
   Richardson, PG
   Anderson, KC
AF Breitkreutz, I.
   Raab, M. S.
   Vallet, S.
   Hideshima, T.
   Raje, N.
   Mitsiades, C.
   Chauhan, D.
   Okawa, Y.
   Munshi, N. C.
   Richardson, P. G.
   Anderson, K. C.
TI Lenalidomide inhibits osteoclastogenesis, survival factors and
   bone remodeling markers in multiple myeloma
SO LEUKEMIA
LA English
DT Article
DE multiple myeloma; osteoclastogenesis; bone disease; lenalidomide;
   bortezomib
ID MACROPHAGE INFLAMMATORY PROTEIN 1 ALPHA; NECROSIS FACTOR FAMILY;
   RECEPTOR ACTIVATOR; PLUS DEXAMETHASONE; OSTEOLYTIC LESIONS; TUMOR
   BURDEN; CELLS; BORTEZOMIB; LIGAND; EXPRESSION
AB Osteolytic bone disease in multiple myeloma (MM) is caused by enhanced osteoclast (OCL) activation and inhibition of osteoblast function. Lenalidomide and bortezomib have shown promising response rates in relapsed and newly diagnosed MM, and bortezomib has recently been reported to inhibit OCLs. We here investigated the effect of lenalidomide on OCL formation and osteoclastogenesis in comparison with bortezomib. Both drugs decreased alpha Vb3 integrin, tartrate resistant acid phosphatase positive cells and bone resorption on dentin disks. In addition, both agents decreased receptor activator of nuclear factor kappa B ligand (RANKL) secretion of bone marrow stromal cells (BMSCs) derived from MM patients. We identified PU.1 and pERK as major targets of lenalidomide, and nuclear factor of activated T cells of bortezomib, resulting in inhibition of osteoclastogenesis. Furthermore, downregulation of cathepsin K, essential for resorption of the bone collagen matrix, was observed. We demonstrated a significant decrease of growth and survival factors including macrophage inflammatory protein alpha, B cell activating factor and a proliferation inducing ligand. Importantly, in serum from MM patients treated with lenalidomide, the essential bone remodeling factor RANKL, as well as the RANKL/OPG ratio, were significantly reduced, whereas osteoprotegerin (OPG) was increased. We conclude that both agents specifically target key factors in osteoclastogenesis, and could directly affect the MM OCL BMSCs activation loop in osteolytic bone disease.
C1 [Breitkreutz, I.; Raab, M. S.; Vallet, S.; Hideshima, T.; Raje, N.; Mitsiades, C.; Chauhan, D.; Okawa, Y.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr,LeBow Inst Mye, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Harvard University Medical
   Affiliates; Dana Farber Cancer Institute
RP Anderson, KC (通讯作者)，Harvard Univ, Sch Med, Dana Farber Canc Inst,Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr,LeBow Inst Mye, 44 Binney St, Boston, MA 02115 USA.
EM Iris_Breitkreutz@dfci.harvard.edu; Kenneth_Anderson@dfci.harvard.edu
RI Anderson, Kenneth/ACP 5073 2022; Vallet, Sonia/AHE 3935 2022; Munshi,
   Nikhil/ABE 2338 2021
OI Vallet, Sonia/0000 0003 0146 8089; 
FU Multiple Myeloma Research Foundation; National Foundation of Cancer
   Research; NIH [CA50947, CA78373, CA10070]
FX We thank the patients, nursing staff as well as the clinical research
   coordinators of the Jerome Lipper Multiple Myeloma Center/Dana Farber
   Cancer Institute, for their help in providing serum specimens for this
   study. This work was supported by the Multiple Myeloma Research
   Foundation, LeBow Fund to Cure Myeloma (KCA); National Foundation of
   Cancer Research and NIH grants CA50947, CA78373 and CA10070.
CR Abe M, 2006, LEUKEMIA, V20, P1313, DOI 10.1038/sj.leu.2404228
   Abe M, 2002, BLOOD, V100, P2195, DOI 10.1182/blood.V100.6.2195.h81802002195_2195_2202
   Anderson G, 2006, BLOOD, V107, P3098, DOI 10.1182/blood 2005 08 3450
   Berenson JR, 1996, NEW ENGL J MED, V334, P488, DOI 10.1056/NEJM199602223340802
   Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   Callander NS, 2001, SEMIN HEMATOL, V38, P276, DOI 10.1053/shem.2001.26007
   Choi SJ, 2000, BLOOD, V96, P671
   Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594
   Faccio R, 2002, J CELL SCI, V115, P2919
   Farrugia AN, 2003, CANCER RES, V63, P5438
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185
   Han JH, 2001, BLOOD, V97, P3349, DOI 10.1182/blood.V97.11.3349
   Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952
   Hideshima T, 2001, SEMIN ONCOL, V28, P607, DOI 10.1053/sonc.2001.28608
   Jagannath S, 2004, BRIT J HAEMATOL, V127, P165, DOI 10.1111/j.1365 2141.2004.05188.x
   Lee JW, 2004, BLOOD, V103, P2308, DOI 10.1182/blood 2003 06 1992
   Lee SE, 2002, BONE, V30, P71, DOI 10.1016/S8756 3282(01)00657 3
   Lentzsch S, 2003, BLOOD, V101, P3568, DOI 10.1182/blood 2002 08 2383
   Moore PA, 1999, SCIENCE, V285, P260, DOI 10.1126/science.285.5425.260
   Moreaux J, 2005, BLOOD, V106, P1021, DOI 10.1182/blood 2004 11 4512
   Moreaux J, 2004, BLOOD, V103, P3148, DOI 10.1182/blood 2003 06 1984
   Oyajobi BO, 2003, BLOOD, V102, P311, DOI 10.1182/blood 2002 12 3905
   Richardson PG, 2006, BLOOD, V108, P3458, DOI 10.1182/blood 2006 04 015909
   Richardson PG, 2005, NEW ENGL J MED, V352, P2487, DOI 10.1056/NEJMoa043445
   Rieman DJ, 2001, BONE, V28, P282, DOI 10.1016/S8756 3282(00)00445 2
   Sezer O, 2003, BLOOD, V101, P2094, DOI 10.1182/blood 2002 09 2684
   Sezer O, 2002, BLOOD, V99, P4646, DOI 10.1182/blood 2002 01 0148
   Tai YT, 2006, CANCER RES, V66, P6675, DOI 10.1158/0008 5472.CAN 06 0190
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Terpos E, 2005, LEUKEMIA, V19, P1969, DOI 10.1038/sj.leu.2403890
   Terpos E, 2003, BLOOD, V102, P1064, DOI 10.1182/blood 2003 02 0380
   Terpos E, 2006, BRIT J HAEMATOL, V135, P688, DOI 10.1111/j.1365 2141.2006.06356.x
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0
   Vanderkerken K, 2003, CANCER RES, V63, P287
   von Metzler I, 2007, LEUKEMIA, V21, P2025, DOI 10.1038/sj.leu.2404806
   WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0
   Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596
   Yaccoby S, 2008, LEUKEMIA, V22, P406, DOI 10.1038/sj.leu.2405048
   Zangari M, 2005, BRIT J HAEMATOL, V131, P71, DOI 10.1111/j.1365 2141.2005.05733.x
NR 41
TC 176
Z9 187
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887 6924
EI 1476 5551
J9 LEUKEMIA
JI Leukemia
PD OCT
PY 2008
VL 22
IS 10
BP 1925
EP 1932
DI 10.1038/leu.2008.174
PG 8
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Oncology; Hematology
GA 359SA
UT WOS:000260007200014
PM 18596740
DA 2025 08 17
ER

PT J
AU Kondo, M
   Kondo, H
   Miyazawa, K
   Goto, S
   Togari, A
AF Kondo, Mayo
   Kondo, Hisataka
   Miyazawa, Ken
   Goto, Shigemi
   Togari, Akifumi
TI Experimental tooth movement induced osteoclast activation is regulated
   by sympathetic signaling
SO BONE
LA English
DT Article
DE Experimental tooth movement; Mechano adaptive response; Sympathetic
   nervous system
ID GENE RELATED PEPTIDE; BONE MARROW CELLS; NERVOUS SYSTEM; PERIODONTIUM
   INCIDENT; ADAPTIVE RESPONSE; PRESSURE ZONES; RAT MOLAR; FIBERS; CGRP;
   INNERVATION
AB Experimental tooth movement (ETM) changes the distribution of sensory nerve fibers in periodontal ligament and the bone architecture through the stimulation of bone remodeling. As the sympathetic nervous system is involved in bone remodeling, we examined whether ETM is controlled by sympathetic signaling or not. In male mice, elastic rubber was inserted between upper left first molar (M1) and second molar (M2) for 3 or 5 days. Nerve fibers immunoreactive for not only sensory neuromarkers, such as calcitonin gene related peptide (CGRP), but also sympathetic neuromarkers, such as tyrosine hydroxylase (TH) and neuropeptide V (NPY) were increased in the periodontal ligament during ETM. To elucidate the effect of the sympathetic signal mediated by ETM, mice were intraperitoneally injected with a beta antagonist, propranolol (PRO: 20 mu g/g/day), or a beta agonist, isoproterenol (ISO: 5 mu g/g/day) from 7 days before ETM. PRO treatment suppressed the amount of tooth movement by 12.9% in 3 day ETM and by 32.2% in 5 day ETM compared with vehicle treatment. On the other hand, ISO treatment increased it. Furthermore, ETM remarkably increased the osteoclast number on the bone surface (alveolar socket) (Oc.N/BS) in all drug treatments. PRO treatment suppressed Oc.N/BS by 39.4% in 3 day ETM, while ISO treatment increased it by 32.1% in 3 day ETM compared with vehicle treatment. Chemical sympathectomy using 6 hydroxydopamine (6 OHDA: 250 mu g/g) showed results similar to those for PRO treatment in terms of both the amount of tooth movement and osteoclast parameters. Our data showed that blockade of sympathetic signaling inhibited the tooth movement and osteoclast increase induced by ETM, and stimulation of sympathetic signaling accelerated these responses. These data suggest that the mechano adaptive response induced by ETM is controlled by sympathetic signaling through osteoclast activation. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Togari, Akifumi] Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Chikusa Ku, Nagoya, Aichi 4648650, Japan.
   [Kondo, Mayo; Miyazawa, Ken; Goto, Shigemi] Aichi Gakuin Univ, Sch Dent, Dept Orthodont, Nagoya, Aichi 4648650, Japan.
C3 Aichi Gakuin University; Aichi Gakuin University
RP Togari, A (通讯作者)，Aichi Gakuin Univ, Sch Dent, Dept Pharmacol, Chikusa Ku, 1 100 Kusumoto Cho, Nagoya, Aichi 4648650, Japan.
EM togariaf@dpc.aichi gakuin.ac.jp
CR Amano S, 2007, BBA GEN SUBJECTS, V1770, P966, DOI 10.1016/j.bbagen.2007.02.009
   Arai M, 2003, BBA MOL CELL RES, V1640, P137, DOI 10.1016/S0167 4889(03)00042 9
   Bataille C, 2012, BONE, V50, P1162, DOI 10.1016/j.bone.2012.01.023
   Bikle DD, 2003, BIOL BULL, V16, P45
   BJURHOLM A, 1991, INT ORTHOP, V15, P325
   Bonnet N, 2005, BONE, V37, P622, DOI 10.1016/j.bone.2005.07.012
   Bonnet N, 2005, MED SCI SPORT EXER, V37, P1493, DOI 10.1249/01.mss.0000177592.82507.95
   BROWN DF, 1991, AM J ORTHOD DENTOFAC, V100, P349, DOI 10.1016/0889 5406(91)70073 6
   CRIDLAND RA, 1988, NEUROPEPTIDES, V11, P23, DOI 10.1016/0143 4179(88)90024 8
   de Souza RL, 2005, J BONE MINER RES, V20, P2159, DOI 10.1359/JBMR.050812
   DECHAMPLAIN J, 1971, CAN J PHYSIOL PHARM, V49, P345, DOI 10.1139/y71 038
   Deguchi T, 2006, J DENT RES, V85, P658, DOI 10.1177/154405910608500715
   DIETRICH JW, 1979, ENDOCRINOLOGY, V104, P1644, DOI 10.1210/endo 104 6 1644
   Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092 8674(00)81558 5
   Ehrlich PJ, 2002, OSTEOPOROSIS INT, V13, P688, DOI 10.1007/s001980200095
   Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398
   FLACH AJ, 1983, INVEST OPHTH VIS SCI, V24, P766
   Hino K, 2006, J CELL BIOCHEM, V99, P845, DOI 10.1002/jcb.20935
   Ishijima M, 2002, J BONE MINER RES, V17, P661, DOI 10.1359/jbmr.2002.17.4.661
   Ishizuka K, 2005, NEUROSCI LETT, V379, P47, DOI 10.1016/j.neulet.2004.12.046
   Kato J, 1996, ACTA ANAT, V157, P53
   Kondo A, 2003, AM J PHYSIOL ENDOC M, V285, pE661, DOI 10.1152/ajpendo.00026.2003
   Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200
   Kondo H, 2011, J CELL BIOCHEM, V112, P3525, DOI 10.1002/jcb.23327
   Kondo H, 2011, CALCIFIED TISSUE INT, V88, P23, DOI 10.1007/s00223 010 9421 9
   KVINNSLAND I, 1990, EUR J ORTHODONT, V12, P320, DOI 10.1093/ejo/12.3.320
   Lanyon L, 2001, J BONE MINER RES, V16, P1937, DOI 10.1359/jbmr.2001.16.11.1937
   Levasseur R, 2003, JOINT BONE SPINE, V70, P515, DOI 10.1016/j.jbspin.2003.07.006
   Marenzana M., 2008, Journal of Musculoskeletal & Neuronal Interactions, V8, P111
   Marenzana M, 2007, BONE, V41, P206, DOI 10.1016/j.bone.2007.04.184
   Nagao M, 2011, P NATL ACAD SCI USA, V108, P17767, DOI 10.1073/pnas.1109402108
   Noda Masaki, 2010, Clin Calcium, V20, P1801, DOI CliCa101218011805
   NOREVALL LI, 1995, EUR J ORTHODONT, V17, P311, DOI 10.1093/ejo/17.4.311
   PARFITT AM, 1987, J BONE MINER RES, V2, P595, DOI 10.1002/jbmr.5650020617
   Purpura P, 1996, CANCER RES, V56, P2336
   RYGH P, 1972, ACTA ODONTOL SCAND, V30, P575, DOI 10.3109/00016357209019790
   RYGH P, 1973, ACTA ODONTOL SCAND, V31, P109, DOI 10.3109/00016357309004617
   RYU PD, 1988, PHYSIOL BOHEMOSLOV, V37, P259
   SAITO I, 1991, ARCH ORAL BIOL, V36, P689, DOI 10.1016/0003 9969(91)90023 N
   Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756 3282(99)00215 X
   TAKANOYAMAMOTO T, 1992, J DENT RES, V71, P53, DOI 10.1177/00220345920710010901
   Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092 8674(02)01049 8
   Takeda S, 2001, J BONE MINER METAB, V19, P195, DOI 10.1007/s007740170042
   Takeuchi T, 2001, BIOCHEM PHARMACOL, V61, P579, DOI 10.1016/S0006 2952(00)00591 8
   Togari A, 1997, NEUROSCI LETT, V233, P125, DOI 10.1016/S0304 3940(97)00649 6
   Togari A, 2002, MICROSC RES TECHNIQ, V58, P77, DOI 10.1002/jemt.10121
   VAN PT, 1982, ANAT RECORD, V202, P445, DOI 10.1002/ar.1092020403
   VandevskaRadunovic V, 1997, EUR J ORTHODONT, V19, P517, DOI 10.1093/ejo/19.5.517
   Wada S, 2001, CLIN ORAL IMPLAN RES, V12, P219, DOI 10.1034/j.1600 0501.2001.012003219.x
   WALDO CM, 1954, J DENT RES, V33, P481, DOI 10.1177/00220345540330040701
   WILLIAMS JM, 1981, BRAIN RES BULL, V6, P83, DOI 10.1016/S0361 9230(81)80072 X
   Yamashiro T, 2000, BONE, V26, P663, DOI 10.1016/S8756 3282(00)00282 9
   Yokoya K, 1997, J DENT RES, V76, P580, DOI 10.1177/00220345970760010901
   Zhang P, 2006, J APPL PHYSIOL, V100, P1452, DOI 10.1152/japplphysiol.00997.2005
NR 54
TC 34
Z9 38
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010 1710 USA
SN 8756 3282
EI 1873 2763
J9 BONE
JI Bone
PD JAN
PY 2013
VL 52
IS 1
BP 39
EP 47
DI 10.1016/j.bone.2012.09.007
PG 9
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 060BK
UT WOS:000312750700005
PM 23000507
DA 2025 08 17
ER

PT J
AU Rendina, D
   De Filippo, G
   Tauchmanovà, L
   Insabato, L
   Muscariello, R
   Gianfrancesco, F
   Esposito, T
   Cioffi, M
   Colao, A
   Strazzullo, P
   Mossetti, G
AF Rendina, Domenico
   De Filippo, Gianpaolo
   Tauchmanova, Libuse
   Insabato, Luigi
   Muscariello, Riccardo
   Gianfrancesco, Fernando
   Esposito, Teresa
   Cioffi, Michele
   Colao, Annamaria
   Strazzullo, Pasquale
   Mossetti, Giuseppe
TI Bone Turnover and the Osteoprotegerin RANKL Pathway in Tumor Induced
   Osteomalacia: A Longitudinal Study of Five Cases
SO CALCIFIED TISSUE INTERNATIONAL
LA English
DT Article
DE Oncogenic osteomalacia; Osteoprotegerin system; Bone turnover; Bone
   mineral density; Longitudinal study
ID OSTEOCLAST DIFFERENTIATION; PHOSPHATE; FIBROBLAST GROWTH FACTOR 23;
   HOMEOSTASIS; FGF23; HYPOPHOSPHATEMIA; ACTIVATION
AB To evaluate serum levels of osteoprotegerin (OPG), soluble receptor activator of the nuclear factor kappa B (RANKL), and their relationship with FGF 23, lumbar bone mineral density (BMD), and bone turnover markers, five patients with tumor induced osteomalacia (TIO) and 40 healthy controls were studied. TIO patients were followed for 360 days after surgical removal of underlying tumor (n = 2) or beginning of therapy with phosphate and calcitriol when surgical treatment was impossible (n = 3). At diagnosis, TIO patients had higher levels of FGF 23 and bone specific alkaline phosphatase (bALP) and lower levels of cathepsin K (CathK), RANKL, and RANKL/OPG ratio compared to controls. During the follow up, FGF 23 decreased significantly only in patients who underwent a surgical excision, while phosphate and BMD increased in all patients. The increases in BMD, phosphate, and renal phosphate reabsorption rate were directly related. In the first 60 days of follow up, we observed a prolonged inhibition of RANKL, CathK, and bone resorption markers associated with a persistence of TIO symptoms and an increase in bALP. From day 60, levels of bone turnover markers returned progressively within the normal range and a clinical remission was observed. The inhibition of the RANKL/OPG pathway and the uncoupling of bone formation and resorption observed in patients with active TIO may be a compensatory mechanism, attempting to reduce worsening of osteomalacia. The BMD increase during TIO treatment is related to the improvement of phosphate rather than FGF 23 levels. A "hungry bone" like syndrome was observed after surgical or pharmacological treatment.
C1 [Rendina, Domenico; Muscariello, Riccardo; Strazzullo, Pasquale; Mossetti, Giuseppe] Univ Naples Federico II, Dept Clin & Expt Med, I 80131 Naples, Italy.
   [De Filippo, Gianpaolo] Gaetano Rummo Hosp, Pediat Endocrinol Unit, Benevento, Italy.
   [Tauchmanova, Libuse; Colao, Annamaria] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I 80131 Naples, Italy.
   [Insabato, Luigi] Univ Naples Federico II, Dept Funct & Morphol Sci, Sect Pathol, I 80131 Naples, Italy.
   [Gianfrancesco, Fernando; Esposito, Teresa] Italian Natl Res Council, Inst Genet & Biophys Adriano Buzzati Traverso, Naples, Italy.
   [Cioffi, Michele] Univ Naples 2, Dept Clin Pathol, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II;
   University of Naples Federico II; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati Traverso"
   (IGB CNR); Universita della Campania Vanvitelli
RP Mossetti, G (通讯作者)，Univ Naples Federico II, Dept Clin & Expt Med, Via Sergio Pansini 5, I 80131 Naples, Italy.
EM giumosse@unina.it
RI ; De+Filippo, Gianpaolo/AAE 5584 2019; Gianfrancesco,
   Fernando/P 6853 2014; Colao, Annamaria/A 7671 2011; Muscariello,
   Riccardo/AAW 1394 2020; Esposito, Teresa/AAA 5488 2019
OI CIOFFI, Michele/0000 0003 3883 111X; Gianfrancesco,
   Fernando/0000 0002 3812 2471; Esposito, Teresa/0000 0002 7879 8441;
   Rendina, Domenico/0000 0002 0331 0392
CR Boyle WJ, 2003, NATURE, V423, P337, DOI 10.1038/nature01658
   CUMMINGS SR, 1995, J BONE MINER RES, V10, P518
   de Beur SMJ, 2005, JAMA J AM MED ASSOC, V294, P1260
   DEBEUR SMJ, 2006, PRIMER METABOLIC BON, P345
   Drezner M K, 2001, Rev Endocr Metab Disord, V2, P175, DOI 10.1023/A:1010006811394
   Fitzpatrick LA, 2002, DISORDERS BONE MINER, P568
   Folpe AL, 2004, AM J SURG PATHOL, V28, P1, DOI 10.1097/00000478 200401000 00001
   Fukumoto S, 2007, BONE, V40, P1190, DOI 10.1016/j.bone.2006.12.062
   Harada S, 2003, NATURE, V423, P349, DOI 10.1038/nature01660
   Hayashibara T, 2007, J BONE MINER RES, V22, P1743, DOI 10.1359/JBMR.070709
   Henriksen K, 2007, OSTEOPOROSIS INT, V18, P681, DOI 10.1007/s00198 006 0286 8
   Imel EA, 2006, J CLIN ENDOCR METAB, V91, P2055, DOI 10.1210/jc.2005 2105
   Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881
   Kendall F., 2005, Muscles: Testing and Function with Posture and Pain
   Mossetti G, 2005, BONE, V36, P549, DOI 10.1016/j.bone.2004.11.004
   MOZAR A, 2008, J CELL PHYSL, V275, P41
   Nawrot Wawrzyniak K, 2009, CALCIFIED TISSUE INT, V84, P313, DOI 10.1007/s00223 009 9216 z
   Rendina D, 2006, J CLIN ENDOCR METAB, V91, P959, DOI 10.1210/jc.2005 1606
   Reyes Múgica M, 2000, PEDIATR DEVEL PATHOL, V3, P61, DOI 10.1007/s100240050008
   SEIBEL M, 1996, CLIN BIOMECHANICS LO, P207
   Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198
   Siener R, 2002, EUR UROL, V42, P289, DOI 10.1016/S0302 2838(02)00316 0
   Sitara D, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000154
   Theoleyre S, 2004, CYTOKINE GROWTH F R, V15, P457, DOI 10.1016/j.cytogfr.2004.06.004
   Tiselius HG, 2001, EUR UROL, V40, P362, DOI 10.1159/000049803
   TONG D, 1982, CANCER AM CANCER SOC, V50, P893, DOI 10.1002/1097 0142(19820901)50:5<893::AID CNCR2820500515>3.0.CO;2 Y
   Ueland T, 2001, EUR J ENDOCRINOL, V145, P685, DOI 10.1530/eje.0.1450685
   Umphrey Lisa G, 2007, Endocr Pract, V13, P458
   WALTON RJ, 1975, LANCET, V2, P309, DOI 10.1016/S0140 6736(75)92736 1
   Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227
   White KE, 2006, ENDOCR REV, V27, P221, DOI 10.1210/er.2005 0019
   YATES AJ, 1991, J BONE MINER RES, V6, P473
NR 32
TC 25
Z9 25
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171 967X
EI 1432 0827
J9 CALCIFIED TISSUE INT
JI Calcif. Tissue Int.
PD OCT
PY 2009
VL 85
IS 4
BP 293
EP 300
DI 10.1007/s00223 009 9275 1
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI EXPANDED)
SC Endocrinology & Metabolism
GA 504WA
UT WOS:000270647400003
PM 19763378
DA 2025 08 17
ER

PT J
AU Shan, ZM
   Cheng, N
   Huang, R
   Zhao, B
   Zhou, YL
AF Shan, Zimei
   Cheng, Na
   Huang, Rong
   Zhao, Bin
   Zhou, Yali
TI Puerarin promotes the proliferation and differentiation of MC3T3 E1
   cells via microRNA 106b by targeting receptor activator of nuclear
   factor κB ligand
SO EXPERIMENTAL AND THERAPEUTIC MEDICINE
LA English
DT Article
DE puerarin; microRNA 106b; MC3T3 E1 cell; receptor activator of nuclear
   factor kappa B ligand; osteoporosis
ID EPITHELIAL MESENCHYMAL TRANSITION; OSTEOBLAST DIFFERENTIATION;
   ENDOMETRIAL CANCER; BONE; EXPRESSION; BREAST; ESTROGEN; MIRNAS; RANKL;
   GENE
AB Puerarin, an isoflavone C glucoside extracted from the root of Pueraria Labata (Willd.) Ohwi, is one of the most important crude herbs used in Chinese medicine for various medicinal purposes. Accumulating evidence has indicated that puerarin suppresses bone resorption and promotes bone formation. However, the molecular mechanism involved in puerarin associated bone formation is unclear. The present study aimed to investigate the molecular mechanism of puerarin induced osteoblast proliferation and differentiation. The study showed that puerarin treatment differentially affected cell proliferation in a time dependent manner. Notably, at a concentration of 20 mu M, puerarin significantly promoted cell proliferation in comparison with the control (P<0.01). Furthermore, puerarin promoted MC3T3 E1 cell differentiation at an appropriate concentration. In addition, miR 106b was significantly upregulated in MC3T3 E1 cells following treatment with 20 mu M puerarin (P<0.01),and a known target for miR 106b, receptor activator of nuclear factor kappa B ligand (RANKL) was demonstrated using the luciferase reporter assay. Furthermore, inhibition of miR 106b significantly reversed the promotion of cell differentiation induced by puerarin in MC3T3 E1 cells (P<0.01). In conclusion, the present study demonstrated that puerarin exerts its role in MC3T3 E1 osteogenesis through miR 106b by targeting RANKL. The findings suggest that puerarin may be considered a promising anti osteoporotic agent for the treatment of osteoporosis.
C1 [Shan, Zimei; Cheng, Na; Huang, Rong; Zhao, Bin; Zhou, Yali] Peoples Hosp Xinjiang Uyger Autonomous Reg, Dept Hlth Care Cadres, 28 Chenggong Rd, Urumqi 830001, Xinjiang, Peoples R China.
RP Zhou, YL (通讯作者)，Peoples Hosp Xinjiang Uyger Autonomous Reg, Dept Hlth Care Cadres, 28 Chenggong Rd, Urumqi 830001, Xinjiang, Peoples R China.
EM zhou__yali@163.com
CR [Anonymous], 2008, PLOS ONE, DOI DOI 10.1371/JOURNAL.PONE.0002557
   Arfat Y, 2015, CURR MED CHEM, V22, P748, DOI 10.2174/0929867321999141106121227
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092 8674(04)00045 5
   Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035
   Chuang TD, 2012, MOL ENDOCRINOL, V26, P1028, DOI 10.1210/me.2012 1075
   Collison Joanna, 2017, Nat Rev Rheumatol, V13, P130, DOI 10.1038/nrrheum.2017.11
   Dong PX, 2014, MOL CARCINOGEN, V53, P349, DOI 10.1002/mc.21983
   Erson AE, 2008, CLIN GENET, V74, P296, DOI 10.1111/j.1399 0004.2008.01076.x
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   HORIGUCHI Y, 1991, INFECT IMMUN, V59, P1112, DOI 10.1128/IAI.59.3.1112 1116.1991
   Itoh T, 2009, J BIOL CHEM, V284, P19272, DOI 10.1074/jbc.M109.014001
   James AW, 2013, SCIENTIFICA, V2013, DOI 10.1155/2013/684736
   Johnell O, 2006, OSTEOPOROSIS INT, V17, P1726, DOI 10.1007/s00198 006 0172 4
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kawasaki H, 2003, NATURE, V426, P100, DOI 10.1038/nature02141
   Keung WM, 1996, P NATL ACAD SCI USA, V93, P4284, DOI 10.1073/pnas.93.9.4284
   Laneve P, 2007, P NATL ACAD SCI USA, V104, P7957, DOI 10.1073/pnas.0700071104
   Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Liu K, 2017, BONE, V97, P130, DOI 10.1016/j.bone.2017.01.014
   Liu YX, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005467.pub2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv HH, 2015, MOL MED REP, V12, P2283, DOI 10.3892/mmr.2015.3647
   Maji AK, 2014, NAT PROD RES, V28, P2111, DOI 10.1080/14786419.2014.928291
   Ni XJ, 2014, CANCER SCI, V105, P18, DOI 10.1111/cas.12309
   Orija IB, 2003, CLIN ENDOCRINOL, V59, P657, DOI 10.1046/j.1365 2265.2003.01833.x
   Papaioannou G, 2014, CELL MOL LIFE SCI, V71, P4747, DOI 10.1007/s00018 014 1700 6
   Persson I, 1999, CANCER CAUSE CONTROL, V10, P253, DOI 10.1023/A:1008909128110
   Pi CX, 2015, FRONT BIOSCI LANDMRK, V20, P119, DOI 10.2741/4301
   Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508
   Sheu SY, 2012, CHINESE MED J PEKING, V125, P3646, DOI 10.3760/cma.j.issn.0366 6999.2012.20.009
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Song GS, 2009, J BIOL CHEM, V284, P31921, DOI 10.1074/jbc.M109.046862
   Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330
   Tang XL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179860
   Thompson BJ, 2006, CELL, V126, P767, DOI 10.1016/j.cell.2006.07.013
   Urasopon N, 2008, MATURITAS, V59, P137, DOI 10.1016/j.maturitas.2008.01.001
   Wang C, 2014, CHIN J NAT MEDICINES, V12, P436, DOI 10.1016/S1875 5364(14)60068 6
   Wang T, 2015, ONCOTARGET, V6, P18980, DOI 10.18632/oncotarget.4223
   Wang Y, 2014, PHYTOMEDICINE, V21, P1032, DOI 10.1016/j.phymed.2014.04.012
   Wirries A, 2013, INT IMMUNOPHARMACOL, V15, P381, DOI 10.1016/j.intimp.2012.12.033
   Wong R, 2007, OSTEOARTHR CARTILAGE, V15, P894, DOI 10.1016/j.joca.2007.02.009
   Zheng L, 2015, INT J CLIN EXP PATHO, V8, P10534
NR 43
TC 17
Z9 21
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792 0981
EI 1792 1015
J9 EXP THER MED
JI Exp. Ther. Med.
PD JAN
PY 2018
VL 15
IS 1
BP 55
EP 60
DI 10.3892/etm.2017.5405
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA FV0WL
UT WOS:000424281600007
PM 29375675
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Kelly, SP
   Ramkumar, DB
   Lozano Calderon, SA
   Newman, ET
   Raskin, KA
   Chebib, I
   Schwab, JH
   Peacock, ZS
AF Kelly, Sean P.
   Ramkumar, Dipak B.
   Lozano Calderon, Santiago A.
   Newman, Erik T.
   Raskin, Kevin A.
   Chebib, Ivan
   Schwab, Joseph H.
   Peacock, Zachary S.
TI Sclerostin Immunohistochemical Staining in Aggressive Maxillofacial
   Giant Cell Lesions: Initial Results and Potential Therapeutic Target
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Bone tumor; central giant cell granulomatous lesion; craniofacial; giant
   cell lesion
ID REPARATIVE GRANULOMA; POSTMENOPAUSAL WOMEN; BONE; TUMORS; JAWS;
   EXPRESSION; MANAGEMENT; OSTEOPROTEGERIN; DENOSUMAB; DISEASE
AB Introduction: Maxillofacial (MF) giant cell lesions (GCLs) are benign, often locally aggressive lesions with potential for recurrence. Systemic treatments have included interferon alpha, calcitonin, bisphosphonates, and denosumab. Sclerostin (SOST) is typically thought to be a negative regulator of bone metabolism and anti SOST agents have been used to treat osteoporosis; however, its role in central giant cell granuloma is unknown. The purpose of this study was to evaluate the expression of SOST in MF GCLs. Materials and Methods: This was a retrospective study of patients with MF GCLs treated at a single institution between 1993 and 2008 with a minimum follow up of 6 months. Representative tissue was used to create a tissue microarray and SOST immunohistochemical (IHC) staining and grading was performed. The primary outcomes were IHC staining of the stromal cells and giant cells. The secondary outcomes included correlation of IHC staining and patient predictor variables including clinically benign and aggressive lesions. All analyses were completed using univariate statistical tests. Results: A total of 37 subjects were included (29 clinically aggressive and 8 clinically benign). Sclerostin staining was present in 30 of 37 subjects (81%). Of these, 22 (60%) had stromal cell staining and 28 (76%) had giant cell staining. The presence or absence of staining, of either cell type, was not associated with aggressiveness, presence of clinical symptoms, tumor size, previous interferon therapy, previous surgery, or the race or age of the patient. Discussion: Maxillofacial GCLs have an overall high level of SOST staining; however, the role of SOST in treatment and prognosis is unknown and warrants further study.
C1 [Kelly, Sean P.] Tripler Army Med Ctr, Dept Orthopaed Surg, 1 Jarrett White Rd, Honolulu, HI 96859 USA.
   [Ramkumar, Dipak B.] Beth Israel Leahy Hosp & Med Ctr, Dept Orthopaed Surg, Burlington, MA USA.
   [Lozano Calderon, Santiago A.; Newman, Erik T.; Raskin, Kevin A.; Schwab, Joseph H.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
   [Chebib, Ivan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
   [Peacock, Zachary S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA.
C3 Tripler Army Medical Center; United States Department of Defense; United
   States Army; Harvard University; Harvard University Medical Affiliates;
   Massachusetts General Hospital; Harvard University; Harvard University
   Medical Affiliates; Massachusetts General Hospital; Harvard University;
   Harvard University Medical Affiliates; Massachusetts General Hospital
RP Kelly, SP (通讯作者)，Tripler Army Med Ctr, Dept Orthopaed Surg, 1 Jarrett White Rd, Honolulu, HI 96859 USA.
EM spk2117@gmail.com
RI ; Peacock, Zachary/AAF 9942 2019
OI HUITRON, EFREN/0009 0008 2046 3359; 
CR Abdo EN, 2005, BRIT J ORAL MAX SURG, V43, P74, DOI 10.1016/j.bjoms.2004.08.015
   Al Sukaini A, 2017, CLIN ORTHOP RELAT R, V475, P3071, DOI 10.1007/s11999 017 5451 1
   Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756 3282(01)00404 5
   AUCLAIR PL, 1988, ORAL SURG ORAL MED O, V66, P197, DOI 10.1016/0030 4220(88)90094 1
   AUSTIN L T Jr, 1959, Oral Surg Oral Med Oral Pathol, V12, P1285, DOI 10.1016/0030 4220(59)90215 4
   CHUONG R, 1986, J ORAL MAXIL SURG, V44, P708, DOI 10.1016/0278 2391(86)90040 6
   CHUONG R, 1985, J ORAL MAXIL SURG, V43, P323, DOI 10.1016/0278 2391(85)90251 4
   de Lange J, 2006, INT J ORAL MAX SURG, V35, P865, DOI 10.1016/j.ijom.2006.02.011
   de Lange J, 1999, INT J ORAL MAX SURG, V28, P372, DOI 10.1016/S0901 5027(99)80086 1
   EISENBUD L, 1988, J ORAL MAXIL SURG, V46, P376, DOI 10.1016/0278 2391(88)90221 2
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   Evenepoel P, 2015, J CLIN ENDOCR METAB, V100, P4669, DOI 10.1210/jc.2015 3056
   FICARRA G, 1987, ORAL SURG ORAL MED O, V64, P44, DOI 10.1016/0030 4220(87)90115 0
   Gomes CC, 2014, OR SURG OR MED OR PA, V118, P583, DOI 10.1016/j.oooo.2014.07.011
   Guañabens N, 2016, J BONE MINER RES, V31, P1725, DOI 10.1002/jbmr.2845
   Gupta B, 2015, J CRANIO MAXILL SURG, V43, P1127, DOI 10.1016/j.jcms.2015.04.011
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Inagaki Y, 2016, HISTOPATHOLOGY, V69, P470, DOI 10.1111/his.12953
   Kaban LB, 2007, J ORAL MAXIL SURG, V65, P2018, DOI 10.1016/j.joms.2007.03.030
   Kauzman A, 2004, J ORAL PATHOL MED, V33, P170, DOI 10.1111/j.0904 2512.2004.00101.x
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kruse Lösler B, 2006, ORAL SURG ORAL MED O, V101, P346, DOI 10.1016/j.tripleo.2005.02.060
   Kurtz M, 2001, ORAL SURG ORAL MED O, V91, P636, DOI 10.1067/moe.2001.115721
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Peacock ZS, 2017, J ORAL MAXIL SURG, V75, P298, DOI 10.1016/j.joms.2016.07.014
   Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P2573, DOI 10.1016/j.joms.2011.12.005
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Resnick CM, 2010, J ORAL MAXIL SURG, V68, P130, DOI 10.1016/j.joms.2009.04.106
   Salerno M, 2008, CLIN ORTHOP RELAT R, V466, P2081, DOI 10.1007/s11999 008 0327 z
   Schreuder WH, 2017, J ORAL MAXIL SURG, V75, P105, DOI 10.1016/j.joms.2016.06.007
   Schreuder WH, 2014, J ORAL MAXIL SURG, V72, P1301, DOI 10.1016/j.joms.2014.02.017
   Shen J, 2016, HUM PATHOL, V58, P24, DOI 10.1016/j.humpath.2016.07.016
   SIDHU MS, 1995, BRIT J ORAL MAX SURG, V33, P43, DOI 10.1016/0266 4356(95)90086 1
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   WALDRON CA, 1966, AM J CLIN PATHOL, V45, P437
   Wang CN, 2006, ONCOL REP, V15, P589
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wu L, 2016, INT J MOL MED, V38, P1395, DOI 10.3892/ijmm.2016.2741
   Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020
NR 43
TC 0
Z9 0
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2022
VL 33
IS 3
BP 790
EP 793
DI 10.1097/SCS.0000000000008344
PG 4
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 1I3MR
UT WOS:000797136800068
DA 2025 08 17
ER

PT J
AU Kelly, SP
   Ramkumar, DB
   Lozano Calderon, SA
   Newman, ET
   Raskin, KA
   Chebib, I
   Schwab, JH
   Peacock, ZS
AF Kelly, Sean P.
   Ramkumar, Dipak B.
   Lozano Calderon, Santiago A.
   Newman, Erik T.
   Raskin, Kevin A.
   Chebib, Ivan
   Schwab, Joseph H.
   Peacock, Zachary S.
TI Sclerostin Immunohistochemical Staining in Aggressive Maxillofacial
   Giant Cell Lesions: Initial Results and Potential Therapeutic Target
SO JOURNAL OF CRANIOFACIAL SURGERY
LA English
DT Article
DE Bone tumor; central giant cell granulomatous lesion; craniofacial; giant
   cell lesion
ID REPARATIVE GRANULOMA; POSTMENOPAUSAL WOMEN; BONE; TUMORS; JAWS;
   EXPRESSION; MANAGEMENT; OSTEOPROTEGERIN; DENOSUMAB; DISEASE
AB Introduction:Maxillofacial (MF) giant cell lesions (GCLs) are benign, often locally aggressive lesions with potential for recurrence. Systemic treatments have included interferon alpha, calcitonin, bisphosphonates, and denosumab. Sclerostin (SOST) is typically thought to be a negative regulator of bone metabolism and anti SOST agents have been used to treat osteoporosis; however, its role in central giant cell granuloma is unknown. The purpose of this study was to evaluate the expression of SOST in MF GCLs.Materials and Methods:This was a retrospective study of patients with MF GCLs treated at a single institution between 1993 and 2008 with a minimum follow up of 6 months. Representative tissue was used to create a tissue microarray and SOST immunohistochemical (IHC) staining and grading was performed. The primary outcomes were IHC staining of the stromal cells and giant cells. The secondary outcomes included correlation of IHC staining and patient predictor variables including clinically benign and aggressive lesions. All analyses were completed using univariate statistical tests.Results:A total of 37 subjects were included (29 clinically aggressive and 8 clinically benign). Sclerostin staining was present in 30 of 37 subjects (81%). Of these, 22 (60%) had stromal cell staining and 28 (76%) had giant cell staining. The presence or absence of staining, of either cell type, was not associated with aggressiveness, presence of clinical symptoms, tumor size, previous interferon therapy, previous surgery, or the race or age of the patient.Discussion:Maxillofacial GCLs have an overall high level of SOST staining; however, the role of SOST in treatment and prognosis is unknown and warrants further study.
C1 [Kelly, Sean P.] Tripler Army Med Ctr, Dept Orthopaed Surg, 1 JarrettWhite Rd, Honolulu, HI 96859 USA.
   [Ramkumar, Dipak B.] Beth Israel Leahy Hosp, Burlington, MA USA.
   [Ramkumar, Dipak B.] Med Ctr, Dept Orthopaed Surg, Burlington, MA USA.
   [Lozano Calderon, Santiago A.; Newman, Erik T.; Raskin, Kevin A.; Schwab, Joseph H.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA USA.
   [Chebib, Ivan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA.
   [Peacock, Zachary S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA USA.
C3 United States Department of Defense; United States Army; Tripler Army
   Medical Center; Harvard University; Harvard University Medical
   Affiliates; Massachusetts General Hospital; Harvard University; Harvard
   University Medical Affiliates; Massachusetts General Hospital; Harvard
   University; Harvard University Medical Affiliates; Massachusetts General
   Hospital
RP Kelly, SP (通讯作者)，Tripler Army Med Ctr, Dept Orthopaed Surg, 1 JarrettWhite Rd, Honolulu, HI 96859 USA.
EM spk2117@gmail.com
CR Abdo EN, 2005, BRIT J ORAL MAX SURG, V43, P74, DOI 10.1016/j.bjoms.2004.08.015
   Al Sukaini A, 2017, CLIN ORTHOP RELAT R, V475, P3071, DOI 10.1007/s11999 017 5451 1
   Atkins GJ, 2001, BONE, V28, P370, DOI 10.1016/S8756 3282(01)00404 5
   AUCLAIR PL, 1988, ORAL SURG ORAL MED O, V66, P197, DOI 10.1016/0030 4220(88)90094 1
   AUSTIN L T Jr, 1959, Oral Surg Oral Med Oral Pathol, V12, P1285, DOI 10.1016/0030 4220(59)90215 4
   CHUONG R, 1986, J ORAL MAXIL SURG, V44, P708, DOI 10.1016/0278 2391(86)90040 6
   CHUONG R, 1985, J ORAL MAXIL SURG, V43, P323, DOI 10.1016/0278 2391(85)90251 4
   de Lange J, 2006, INT J ORAL MAX SURG, V35, P865, DOI 10.1016/j.ijom.2006.02.011
   de Lange J, 1999, INT J ORAL MAX SURG, V28, P372, DOI 10.1016/S0901 5027(99)80086 1
   EISENBUD L, 1988, J ORAL MAXIL SURG, V46, P376, DOI 10.1016/0278 2391(88)90221 2
   ENNEKING WF, 1986, CLIN ORTHOP RELAT R, P9
   Evenepoel P, 2015, J CLIN ENDOCR METAB, V100, P4669, DOI 10.1210/jc.2015 3056
   FICARRA G, 1987, ORAL SURG ORAL MED O, V64, P44, DOI 10.1016/0030 4220(87)90115 0
   Gomes CC, 2014, OR SURG OR MED OR PA, V118, P583, DOI 10.1016/j.oooo.2014.07.011
   Guañabens N, 2016, J BONE MINER RES, V31, P1725, DOI 10.1002/jbmr.2845
   Gupta B, 2015, J CRANIO MAXILL SURG, V43, P1127, DOI 10.1016/j.jcms.2015.04.011
   Huang L, 2000, AM J PATHOL, V156, P761, DOI 10.1016/S0002 9440(10)64942 5
   Inagaki Y, 2016, HISTOPATHOLOGY, V69, P470, DOI 10.1111/his.12953
   Kaban LB, 2007, J ORAL MAXIL SURG, V65, P2018, DOI 10.1016/j.joms.2007.03.030
   Kauzman A, 2004, J ORAL PATHOL MED, V33, P170, DOI 10.1111/j.0904 2512.2004.00101.x
   Kendler DL, 2019, OSTEOPOROSIS INT, V30, P2437, DOI 10.1007/s00198 019 05146 9
   Kruse Lösler B, 2006, ORAL SURG ORAL MED O, V101, P346, DOI 10.1016/j.tripleo.2005.02.060
   Kurtz M, 2001, ORAL SURG ORAL MED O, V91, P636, DOI 10.1067/moe.2001.115721
   Langdahl BL, 2017, LANCET, V390, P1585, DOI 10.1016/S0140 6736(17)31613 6
   Mak IWY, 2014, J BONE JOINT SURG AM, V96A, DOI 10.2106/JBJS.M.01332
   McClung MR, 2014, NEW ENGL J MED, V370, P412, DOI 10.1056/NEJMoa1305224
   Murphey MD, 2001, RADIOGRAPHICS, V21, P1283, DOI 10.1148/radiographics.21.5.g01se251283
   Naidu A, 2014, J ORAL MAXIL SURG, V72, P2469, DOI 10.1016/j.joms.2014.06.456
   Peacock ZS, 2017, J ORAL MAXIL SURG, V75, P298, DOI 10.1016/j.joms.2016.07.014
   Peacock ZS, 2012, J ORAL MAXIL SURG, V70, P2573, DOI 10.1016/j.joms.2011.12.005
   Recker RR, 2015, J BONE MINER RES, V30, P216, DOI 10.1002/jbmr.2351
   Resnick CM, 2010, J ORAL MAXIL SURG, V68, P130, DOI 10.1016/j.joms.2009.04.106
   Salerno M, 2008, CLIN ORTHOP RELAT R, V466, P2081, DOI 10.1007/s11999 008 0327 z
   Schreuder WH, 2017, J ORAL MAXIL SURG, V75, P105, DOI 10.1016/j.joms.2016.06.007
   Schreuder WH, 2014, J ORAL MAXIL SURG, V72, P1301, DOI 10.1016/j.joms.2014.02.017
   Shen J, 2016, HUM PATHOL, V58, P24, DOI 10.1016/j.humpath.2016.07.016
   SIDHU MS, 1995, BRIT J ORAL MAX SURG, V33, P43, DOI 10.1016/0266 4356(95)90086 1
   van Bezooijen RL, 2004, J EXP MED, V199, P805, DOI 10.1084/jem.20031454
   WALDRON CA, 1966, AM J CLIN PATHOL, V45, P437
   Wang CN, 2006, ONCOL REP, V15, P589
   Wijenayaka AR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025900
   Wu L, 2016, INT J MOL MED, V38, P1395, DOI 10.3892/ijmm.2016.2741
   Yamamoto H, 2018, HUM PATHOL, V73, P41, DOI 10.1016/j.humpath.2017.11.020
NR 43
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1049 2275
EI 1536 3732
J9 J CRANIOFAC SURG
JI J. Craniofac. Surg.
PD MAY
PY 2022
VL 33
IS 3
BP 790
EP 793
DI 10.1097/SCS.0000000000008344
PG 4
WC Surgery
WE Science Citation Index Expanded (SCI EXPANDED)
SC Surgery
GA 5WZ6B
UT WOS:001546336400010
DA 2025 08 17
ER

PT J
AU Gleizal, A
   Li, SL
   Pialat, JB
   Beziat, JL
AF Gleizal, Arnaud
   Li, Shuli
   Pialat, Jean Baptiste
   Beziat, Jean Luc
TI Transcriptional expression of calvarial bone after treatment with
   low intensity ultrasound:: An in vitro study
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE physiotherapy; ultrasound; osteoblast; gene expression
ID DENTIN MATRIX PROTEIN 1; OSTEOBLAST DIFFERENTIATION; GENE; CBFA1;
   STIMULATION; PROMOTER; CELLS
AB The capacity to reossify a calvarial bone defect is very small in mature animals and in humans greater than 2 y of age. The clinical treatment of injured tissue sites of bones by low intensity pulsed ultrasound is widespread, but little is known about the precise effects of ultrasound on the fundamental processes that promote repair and regeneration. In this study, we used real time polymerase chain reaction (RT PCR) to investigate the expression of osteogenesis associated genes after stimulation by low intensity ultrasound in adult mouse osteoblast from the parietal calvaria. The gene associated with the Runx2 pathway had notably higher levels after 1, 2 and 3 days of stimulation. Therefore, low intensity ultrasound seems to have an effect on the transcriptional gene expression of the calvarial bone in vitro. (E mail: jean luc.beziat@chu lyon.fr) (c) 2006 World Federation for Ultrasound in Medicine & Biology.
C1 Hop Nord, Serv Chirurg Maxillo Faciale, Dept Oral & Maxillofacial Surg, F 69317 Lyon 04, France.
   Stanford Univ, Dept Surg, Palo Alto, CA 94304 USA.
   Hop Nord, Dept Radiol, Lyon, France.
C3 Stanford University
RP Beziat, JL (通讯作者)，Hop Nord, Serv Chirurg Maxillo Faciale, Dept Oral & Maxillofacial Surg, 93 Grande Rue Croix Rousse, F 69317 Lyon 04, France.
EM jean luc.beziat@chu lyon.fr
RI Pialat, Jean Baptiste/ACD 7897 2022
CR Chen YJ, 2003, FEBS LETT, V554, P154, DOI 10.1016/S0014 5793(03)01157 8
   Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092 8674(00)80257 3
   Eberson CP, 2003, J PEDIATR ORTHOPED, V23, P46, DOI 10.1097/00004694 200301000 00009
   Feng JQ, 2003, J DENT RES, V82, P776, DOI 10.1177/154405910308201003
   Feng JQ, 2002, J BONE MINER RES, V17, P1822, DOI 10.1359/jbmr.2002.17.10.1822
   Fisher LW, 2003, CONNECT TISSUE RES, V44, P33, DOI 10.1080/03008200390152061
   Hanai J, 1999, J BIOL CHEM, V274, P31577, DOI 10.1074/jbc.274.44.31577
   Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972
   Harle J, 2001, J MATER SCI MATER M, V12, P1001, DOI 10.1023/A:1012825519114
   Hatta M, 2002, INT J MOL MED, V9, P147
   Karsenty G, 1999, BONE, V25, P107, DOI 10.1016/S8756 3282(99)00111 8
   Narayanan K, 2004, J BIOL CHEM, V279, P44294, DOI 10.1074/jbc.M403511200
   Narayanan K, 2003, J BIOL CHEM, V278, P17500, DOI 10.1074/jbc.M212700200
   Naruse K, 2000, BIOCHEM BIOPH RES CO, V268, P216, DOI 10.1006/bbrc.2000.2094
   Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092 8674(00)80259 7
   Reher P, 1997, ULTRASOUND MED BIOL, V23, P1251, DOI 10.1016/S0301 5629(97)00031 8
   Reher P, 1999, CYTOKINE, V11, P416, DOI 10.1006/cyto.1998.0444
   Spector JA, 2002, PLAST RECONSTR SURG, V109, P631, DOI 10.1097/00006534 200202000 00033
   Takikawa S, 2001, J ULTRAS MED, V20, P197, DOI 10.7863/jum.2001.20.3.197
   Tou LQ, 2003, MOL CELL ENDOCRINOL, V205, P121, DOI 10.1016/S0303 7207(03)00151 5
NR 20
TC 28
Z9 31
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301 5629
EI 1879 291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD OCT
PY 2006
VL 32
IS 10
BP 1569
EP 1574
DI 10.1016/j.ultrasmedbio.2006.05.014
PG 6
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA 099KF
UT WOS:000241592500016
PM 17045878
DA 2025 08 17
ER

PT J
AU Phal, PM
   Myall, RWT
   Assael, LA
   Weissman, JL
AF Phal, P. M.
   Myall, R. W. T.
   Assael, L. A.
   Weissman, J. L.
TI Imaging findings of bisphosphonate associated osteonecrosis of the jaws
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Article; Proceedings Paper
CT 44th Annual Meeting of the American Society of Neuroradiology
CY APR 29 MAY 05, 2006
CL San Diego, CA
SP Amer Soc Neuroradiol
ID PHOSSY JAW; SCLEROSING OSTEOMYELITIS; OSTEOPETROSIS; BONE; MECHANISMS;
   NECROSIS; DISEASE
AB BACKGROUND AND PURPOSE: Bisphosphonates are drugs that decrease bone turnover by inhibiting osteoclast activity. An association between the use of bisphosphonates and osteonecrosis of the maxilla and mandible has recently been described. This study describes the imaging findings of bisphosphonate associated osteonecrosis of the jaws.
   MATERIALS AND METHODS: This is a retrospective series of 15 clinically diagnosed patients, identified at 3 centers. Eleven patients were women, of whom 6 had breast cancer, 3 had osteoporosis, and 2 had multiple myeloma. Of the 4 male patients, 2 had prostate cancer, 1 had multiple myeloma, and 1 had osteoporosis. The age range of the patients was 52 85 years (average, 68 years). The mandible was the clinical site of involvement in 11 patients, and the maxilla was involved in 4 patients. Imaging consisted of orthopantomograms in 14 patients, CT scans in 5 patients, and radionuclide bone scan in 1 patient. Nine patients had sequential imaging. Two radiologists reviewed the images.
   RESULTS: All of the patients had a degree of osseous sclerosis, most commonly involving the alveolar margin, but lamina dura thickening and full thickness sclerosis were also observed. The sclerotic change encroached on the mandibular canal in 3 patients. Less commonly encountered findings included poorly healing or nonhealing extraction sockets, periapical lucencies, widening of the perioclontal ligament space, osteolysis, sequestra, oroantral fistula, soft tissue thickening, and periosteal new bone formation.
   CONCLUSIONS: The most common finding in bisphosphonate associated osteonecrosis was osseous sclerosis. This varied from subtle thickening of the lamina dura and alveolar crest to attenuated osteopetrosis like sclerosis.
C1 Oregon Hlth & Sci Univ, Div Neuroradiol, Sch Dent, Portland, OR 97201 USA.
   Oregon Hlth & Sci Univ, Dept Oral & Maxillofacial Surg, Sch Dent, Portland, OR 97201 USA.
   Oregon Hlth & Sci Univ, Dept Otolaryngol, Portland, OR 97201 USA.
   Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University; Oregon Health & Science University
RP Phal, PM (通讯作者)，Royal Melbourne Hosp, Dept Radiol, CO Post Off, Parkville, Vic 3050, Australia.
EM pphal@iprimus.com.au
CR Bagan JV, 2005, J ORAL PATHOL MED, V34, P120, DOI 10.1111/j.1600 0714.2004.00269.x
   Batra P, 2004, INT DENT J, V54, P418, DOI 10.1111/j.1875 595X.2004.tb00298.x
   Carneiro E, 2006, AM J NEURORADIOL, V27, P1096
   Chiandussi S, 2006, DENTOMAXILLOFAC RAD, V35, P236, DOI 10.1259/dmfr/27458726
   Donoghue AM, 2005, MED J AUSTRALIA, V183, P163, DOI 10.5694/j.1326 5377.2005.tb06970.x
   Fournier P, 2002, CANCER RES, V62, P6538
   Hellstein JW, 2005, J ORAL MAXIL SURG, V63, P682, DOI 10.1016/j.joms.2005.01.010
   Hino S, 2005, INT J ORAL MAX SURG, V34, P576, DOI 10.1016/j.ijom.2005.01.003
   Junquera L, 2005, AM J OTOLARYNG, V26, P275, DOI 10.1016/j.amjoto.2005.01.007
   KOLATA G, 2003, NY TIMES        0602
   Marx RE, 2005, J ORAL MAXIL SURG, V63, P1567, DOI 10.1016/j.joms.2005.07.010
   Marx RE, 2003, J ORAL MAXIL SURG, V61, P1115, DOI 10.1016/S0278 2391(03)00720 1
   Miesse AM, 2004, TECH PAPERS ISA, V449, P266
   Migliorati CA, 2005, CANCER, V104, P83, DOI 10.1002/cncr.21130
   MILES AEW, 1972, BRIT DENT J, V133, P203, DOI 10.1038/sj.bdj.4802906
   *NOV, 2005, EXP PAN REC PREV DIA
   Orpe EC, 1996, DENTOMAXILLOFAC RAD, V25, P125, DOI 10.1259/dmfr.25.3.9084260
   Polizzotto MN, 2006, BRIT J HAEMATOL, V132, P114, DOI 10.1111/j.1365 2141.2005.05833.x
   Resnick D., 2005, Bone and joint imaging, V3rd
   Reszka AA, 2004, MINI REV MED CHEM, V4, P711
   Reszka Alfred A, 2003, Curr Osteoporos Rep, V1, P45, DOI 10.1007/s11914 003 0008 5
   Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004
   RUGGIERO SL, 2005, M AM ASS OR MAX SURG
   Seeman E, 2006, NEW ENGL J MED, V354, P2250, DOI 10.1056/NEJMra053077
   Sparidans RW, 1998, PHARM WORLD SCI, V20, P206, DOI 10.1023/A:1008626026484
   Tolar J, 2004, NEW ENGL J MED, V351, P2839, DOI 10.1056/NEJMra040952
   van der Waal RIF, 2003, BRIT J ORAL MAX SURG, V41, P3, DOI 10.1016/S0266 4356(02)00301 7
   White S., 2000, ORAL RADIOLOGY PRINC, VFourth
   Whyte MP, 2003, NEW ENGL J MED, V349, P457, DOI 10.1056/NEJMoa023110
   Wood J, 2002, J PHARMACOL EXP THER, V302, P1055, DOI 10.1124/jpet.102.035295
NR 30
TC 107
Z9 117
U1 0
U2 3
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834 9349 USA
SN 0195 6108
EI 1936 959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD JUN JUL
PY 2007
VL 28
IS 6
BP 1139
EP 1145
DI 10.3174/ajnr.A0518
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI EXPANDED); Conference Proceedings Citation Index   Science (CPCI S)
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 180VZ
UT WOS:000247395800032
PM 17569974
OA Green Published, hybrid
DA 2025 08 17
ER

PT J
AU Unnithan, AR
   Sasikala, ARK
   Shrestha, BK
   Lincoln, A
   Thomson, T
   El Haj, AJ
AF Unnithan, Afeesh Rajan
   Sasikala, Arathyram Ramachandra Kurup
   Shrestha, Bishnu Kumar
   Lincoln, Alex
   Thomson, Thomas
   El Haj, Alicia J.
TI Remotely Actuated Magnetic Nanocarpets for Bone Tissue Engineering:
   Non Invasive Modulation of Mechanosensitive Ion Channels for Enhanced
   Osteogenesis
SO ADVANCED FUNCTIONAL MATERIALS
LA English
DT Article
DE magnetic nanoparticles; mechanosensitive ion channels;
   mechanotransduction; osteogenesis; Piezo1 ion channels
ID MESENCHYMAL STEM CELLS; GRAPHENE BASED MATERIALS; CARBON NANOTUBES;
   DRUG DELIVERY; DIFFERENTIATION; NANOPARTICLES; NANOCOMPOSITES;
   ACTIVATION; OXIDE; BIOCOMPATIBILITY
AB Non invasive approaches using remotely controllable nanomaterials have demonstrated their potential ability to enhance treatment efficacy in regenerative medicine and tissue repair. Although magnetic nanoparticles (MNPs) have been used for multiple healthcare applications where their remote control properties can show significant advances, enhanced surface functional groups, and electrical properties would expand their capabilities. To address this, in this study, MNPs incorporated Graphene Oxide (GO) based nanocomposites (GOMNPs) are developed and functionalized with TREK1 and Piezo1 antibodies to specifically target the respective mechanosensitive ion channels. Magnetic ion channel activation (MICA) technology is used to remotely activate MG63 osteoblast like cells tagged with these functionalized GOMNPs. Remote activation of mechanotransduction pathways shows significant upregulation in osteogenic gene expression as well as enhanced alkaline phosphate activity and calcium mineralization with enhanced bone formation. The development of a GOMNP composite has extensive applicability for future clinical translation.
C1 [Unnithan, Afeesh Rajan; El Haj, Alicia J.] Univ Birmingham, Sch Chem Engn, Inst Translat Med, Healthcare Technol Inst, Birmingham B15 2TT, W Midlands, England.
   [Sasikala, Arathyram Ramachandra Kurup] Univ Birmingham, Coll Med & Dent Sci, Sch Pharm, Birmingham B15 2TT, W Midlands, England.
   [Shrestha, Bishnu Kumar] Jeonbuk Natl Univ, Grad Sch, Dept Bionanosyst Engn, Jeonju 561756, South Korea.
   [Lincoln, Alex; Thomson, Thomas] Univ Manchester, Dept Comp Sci, Manchester M13 9PL, Lancs, England.
C3 University of Birmingham; University of Birmingham; Jeonbuk National
   University; University of Manchester
RP Unnithan, AR; El Haj, AJ (通讯作者)，Univ Birmingham, Sch Chem Engn, Inst Translat Med, Healthcare Technol Inst, Birmingham B15 2TT, W Midlands, England.
EM a.rajanunnithan@bham.ac.uk; a.elhaj@bham.ac.uk
RI Rajan Unnithan, Afeesh/I 2338 2013; Sasikala, Arathyram/X 7079 2019;
   Unnithan, Afeesh/I 2338 2013; Haj, Alicia/B 3315 2012
OI Rajan Unnithan, Afeesh/0000 0002 0795 1613; El Haj,
   Alicia/0000 0003 3544 5678; Lincoln, Alexander/0009 0001 7681 3716; 
FU European Union's Horizon2020 ERC Advanced Grant [789119]; European
   Research Council (ERC) [789119] Funding Source: European Research
   Council (ERC)
FX This research has been funded by the European Union's Horizon2020 ERC
   Advanced Grant. Grant agreement ID: 789119.
CR Fattah ARA, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00240
   Achawi S, 2021, NANOMATERIALS BASEL, V11, DOI 10.3390/nano11112963
   Adabi M, 2017, ARTIF CELL NANOMED B, V45, P833, DOI 10.1080/21691401.2016.1178134
   Ali A, 2021, FRONT CHEM, V9, DOI 10.3389/fchem.2021.629054
   Chen GY, 2012, BIOMATERIALS, V33, P418, DOI 10.1016/j.biomaterials.2011.09.071
   Cole AJ, 2011, TRENDS BIOTECHNOL, V29, P323, DOI 10.1016/j.tibtech.2011.03.001
   Coste B, 2012, NATURE, V483, P176, DOI 10.1038/nature10812
   Coste B, 2010, SCIENCE, V330, P55, DOI 10.1126/science.1193270
   Cox CD, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10366
   Crowder SW, 2013, NANOSCALE, V5, P4171, DOI 10.1039/c3nr00803g
   Djillani A, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00379
   Dobson J, 2006, GENE THER, V13, P283, DOI 10.1038/sj.gt.3302720
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Fathi Achachelouei M, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00113
   Gahl TJ, 2018, FRONT NEUROSCI SWITZ, V12, DOI 10.3389/fnins.2018.00299
   Gonzalez Rodriguez R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217072
   Gothard D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145080
   Henstock JR, 2018, J TISSUE ENG, V9, DOI 10.1177/2041731418808695
   Henstock JR, 2014, STEM CELL TRANSL MED, V3, P1363, DOI 10.5966/sctm.2014 0017
   Hu KH, 2016, J CELL BIOL, V213, P535, DOI 10.1083/jcb.201511053
   Huang YH, 2016, RSC ADV, V6, P5718, DOI 10.1039/c5ra22013k
   Hughes S, 2005, MED ENG PHYS, V27, P754, DOI 10.1016/j.medengphy.2005.04.006
   Hughes S, 2008, J R SOC INTERFACE, V5, P855, DOI 10.1098/rsif.2007.1274
   Hughes S, 2007, J BIOMECH, V40, pS96, DOI 10.1016/j.jbiomech.2007.03.002
   Jin RX, 2021, ENVIRON SCI POLLUT R, V28, P5126, DOI 10.1007/s11356 020 10886 x
   Johnsen S, 2008, PHYS TODAY, V61, P29, DOI 10.1063/1.2897947
   Kenry, 2018, BIOMATERIALS, V155, P236, DOI 10.1016/j.biomaterials.2017.10.004
   Kommireddy DS, 2006, BIOMATERIALS, V27, P4296, DOI 10.1016/j.biomaterials.2006.03.042
   Lee WC, 2011, ACS NANO, V5, P7334, DOI 10.1021/nn202190c
   Li N, 2013, SCI REP UK, V3, DOI 10.1038/srep01604
   Li XH, 2019, ELIFE, V8, DOI 10.7554/eLife.49631
   Liu JQ, 2013, ACTA BIOMATER, V9, P9243, DOI 10.1016/j.actbio.2013.08.016
   Liu L, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00228
   Manolagas SC, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1008714
   Markides H, 2018, NPJ REGEN MED, V3, DOI 10.1038/s41536 018 0048 1
   Marshall KL, 2012, ADV EXP MED BIOL, V739, P142, DOI 10.1007/978 1 4614 1704 0_9
   McCarthy JR, 2008, ADV DRUG DELIVER REV, V60, P1241, DOI 10.1016/j.addr.2008.03.014
   Mooney E, 2008, NANO LETT, V8, P2137, DOI 10.1021/nl073300o
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Park SY, 2011, ADV MATER, V23, pH263, DOI 10.1002/adma.201101503
   Peyronnet R, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00558
   Qin W, 2020, DENT MATER, V36, P1289, DOI 10.1016/j.dental.2020.06.004
   Ranade SS, 2014, P NATL ACAD SCI USA, V111, P10347, DOI 10.1073/pnas.1409233111
   Safari J, 2014, J MOL STRUCT, V1072, P53, DOI 10.1016/j.molstruc.2014.04.023
   Saito N, 2009, CHEM SOC REV, V38, P1897, DOI 10.1039/b804822n
   Saravanakumar B, 2013, MATER RES BULL, V48, P878, DOI 10.1016/j.materresbull.2012.11.048
   Sasikala ARK, 2016, SCI REP UK, V6, DOI 10.1038/srep20543
   Sasikala ARK, 2015, NANOSCALE, V7, P18119, DOI 10.1039/c5nr05844a
   Schneider Futschik EK, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081157
   Stewart L, 2021, CELLS BASEL, V10, DOI 10.3390/cells10050990
   Stout DA, 2012, MATER TODAY, V15, P312, DOI 10.1016/S1369 7021(12)70136 0
   Sun WJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47454
   Tsimbouri PM, 2013, BIOMATERIALS, V34, P2177, DOI 10.1016/j.biomaterials.2012.12.019
   Varanda L.C., 2011, BIOMEDICAL ENG TREND, DOI [10.5772/992397, DOI 10.5772/992397]
   Xie GQ, 2012, J MATER CHEM, V22, P25485
   Xu W, 2018, J MATER CHEM B, V6, P5234, DOI 10.1039/c8tb01352g
   Yang YQ, 2013, MATER TODAY, V16, P365, DOI 10.1016/j.mattod.2013.09.004
   Yi CQ, 2010, ACS NANO, V4, P6439, DOI 10.1021/nn101373r
   Zhang H, 2020, BIOMATER SCI UK, V8, P5984, DOI 10.1039/d0bm00906g
   Zhang YX, 2021, NATURE, V590, P509, DOI 10.1038/s41586 021 03196 w
   Zhao QC, 2018, NATURE, V563, pE19, DOI 10.1038/s41586 018 0513 4
NR 61
TC 15
Z9 15
U1 5
U2 46
PU WILEY V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1616 301X
EI 1616 3028
J9 ADV FUNCT MATER
JI Adv. Funct. Mater.
PD DEC
PY 2022
VL 32
IS 50
SI SI
AR 2201311
DI 10.1002/adfm.202201311
EA JUL 2022
PG 13
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Science & Technology   Other Topics; Materials Science;
   Physics
GA 6Y5AT
UT WOS:000822316700001
OA hybrid, Green Published
DA 2025 08 17
ER

PT J
AU Panwar, P
   Singh, S
   Kumar, N
   Rawat, H
   Mishra, AK
AF Panwar, Puja
   Singh, Sweta
   Kumar, Nitin
   Rawat, Harish
   Mishra, Anil K.
TI Synthesis, characterization, and in vivo skeletal localization of a new
   <SUP>99m</SUP>Tc based multidentate phosphonate chelate::
   5 Amino 1,3 bis(ethylamine (N,N dimethyl diphosphonic acid)
   acetamido) benzene
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE IPTMP; 5 aminoisophthalate tetramethylene phosphonic acid; chelating
   agent; Tc 99m; bone seeking agent
ID BONE METASTASES; TC 99M MDP; BISPHOSPHONATES; PYROPHOSPHATE;
   DERIVATIVES; EFFICACY; BINDING; AGENTS
AB The tetraphosphonate ligand, 5 amino 1,3 bis(ethylamine (NN dimethyl diphosphonic acid) acetamido) benzene (IPTMP) used in the present study was prepared from 5 nitroisophthalate dimethylester to label with radionuclide for targeted diagnosis and therapy. The synthesized multidentate phosphonate ligand was characterized on the basis of spectroscopic techniques, which exhibited good metal ion control properties when complexed to 99mTe with high in vitro and in vivo stability. Excellent quality bone images of rabbit were imaged showing rapid clearance of background activity and visualization of skeleton at 1h. (c) 2006 Elsevier Ltd. All rights reserved.
C1 Inst Nucl Med & Allied Sci, Div Cyclotron & Radiopharmaceut Sci, Delhi 110054, India.
C3 Defence Research & Development Organisation (DRDO); Institute of Nuclear
   Medicine & Allied Sciences (INMAS)
RP Mishra, AK (通讯作者)，Inst Nucl Med & Allied Sci, Div Cyclotron & Radiopharmaceut Sci, Brig SK Mazumdar Rd, Delhi 110054, India.
EM akmishra@inmas.org
RI Mishra, Anil/J 9502 2013
CR Ali MS, 1996, BIOCONJUGATE CHEM, V7, P576, DOI 10.1021/bc960051e
   Bailly T, 1995, PHOSPHORUS SULFUR, V101, P131, DOI 10.1080/10426509508042509
   BISAZ S, 1978, CLIN SCI MOL MED, V54, P265, DOI 10.1042/cs0540265
   DAVIS M A, 1976, Seminars in Nuclear Medicine, V6, P19, DOI 10.1016/S0001 2998(76)80033 5
   deMurphy CA, 1997, NUCL MED BIOL, V24, P27, DOI 10.1016/S0969 8051(96)00151 5
   Dufau C, 1995, PHOSPHORUS SULFUR, V107, P145, DOI 10.1080/10426509508027930
   Even P, 2004, LETT ORG CHEM, V1, P75, DOI 10.2174/1570178043488563
   FITTON A, 1991, DRUGS, V41, P289, DOI 10.2165/00003495 199141020 00009
   FRANCIS MD, 1980, J NUCL MED, V21, P1185
   Franz RD, 2001, AAPS PHARMSCI, V3
   GOECKELER WF, 1987, J NUCL MED, V28, P495
   Hamdy NAT, 2001, SEMIN NUCL MED, V31, P62, DOI 10.1053/snuc.2001.18767
   JONES A G, 1976, Seminars in Nuclear Medicine, V6, P3, DOI 10.1016/S0001 2998(76)80032 3
   JUNG A, 1973, CALC TISS RES, V11, P269, DOI 10.1007/BF02547227
   Kubícek V, 2003, DALTON T, P3927, DOI 10.1039/b305844a
   Kunzmann V, 2000, BLOOD, V96, P384
   Lin WY, 1997, EUR J NUCL MED, V24, P590, DOI 10.1007/s002590050091
   MAXON HR, 1988, RADIOLOGY, V166, P501, DOI 10.1148/radiology.166.2.3122267
   Mishra AK, 2005, CHEM LETT, V34, P1098, DOI 10.1246/cl.2005.1098
   MOEDRITZ.K, 1966, J ORG CHEM, V31, P1603, DOI 10.1021/jo01343a067
   Muhlbauer Roman C., 1995, P171
   PAUWELS EKJ, 1983, EUR J NUCL MED, V8, P118
   PRENEN JAC, 1991, J NUCL MED, V32, P2057
   RICHARDS AG, 1974, J NUCL MED, V15, P1057
   Rodan GA, 1996, J CLIN INVEST, V97, P2692, DOI 10.1172/JCI118722
   SCHOMACKER K, 1988, APPL RADIAT ISOTOPES, V39, P261, DOI 10.1016/0883 2889(88)90182 7
   SUNDBERG MW, 1974, J MED CHEM, V17, P1304, DOI 10.1021/jm00258a015
   TURNER JH, 1987, EUR J NUCL MED, V13, P432
   Vegt E, 2006, J NUCL MED, V47, P432
   Volkert W A, 1986, Int J Rad Appl Instrum B, V13, P31, DOI 10.1016/0883 2897(86)90248 5
   VORNE M, 1983, EUR J NUCL MED, V8, P395
NR 31
TC 16
Z9 17
U1 0
U2 4
PU PERGAMON ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968 0896
EI 1464 3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JAN 15
PY 2007
VL 15
IS 2
BP 1138
EP 1145
DI 10.1016/j.bmc.2006.10.005
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA 123SG
UT WOS:000243315300051
PM 17088066
DA 2025 08 17
ER

PT J
AU He, W
   Cronstein, BN
AF He, W.
   Cronstein, B. N.
TI Adenosine A1 receptor regulates osteoclast formation by
   altering TRAF6/TAK1 signaling
SO PURINERGIC SIGNALLING
LA English
DT Article
DE Adenosine A(1) receptor; Osteoclastogenesis; TAK1; TRAF6; NF kappa B
ID NF KAPPA B; NUCLEAR FACTOR; DEFECTIVE INTERLEUKIN 1; BONE DESTRUCTION;
   TERMINAL KINASE; PAGETS DISEASE; LIGAND RANKL; C FOS; TAK1; ACTIVATION
AB Adenosine is an endogenous nucleoside that modulates many physiological processes through four receptor subtypes (A(1), A(2a), A(2b), A(3)). Previous work from our laboratory has uncovered a critical role for adenosine A(1) receptor (A(1) R) in osteoclastogenesis both in vivo and in vitro. Our current work focuses on understanding the details of how A(1) R modulates the receptor activator of NF kappa B ligand (RANKL) induced signaling in osteoclastogenesis. Osteoclasts were generated from mouse bone marrow precursors in the presence of RANKL and macrophage colony stimulating factor. A pharmacological antagonist of A(1) R (DPCPX) inhibited RANKL induced osteoclast differentiation, including osteoclast specific genes (Acp5, MMP9, beta(3) Integrin, alpha(v) Integrin, and CTSK) and osteoclast specific transcription factors such as c fos and nuclear factor of activated T cells cytoplasmic 1 (NFATc1) expression in a dose dependent manner. DPCPX also inhibited RANKL induced activation of NF kappa B and JNK/c Jun but had little effect on other mitogen activated protein kinases (p38 and Erk). Finally, immunoprecipitation analysis showed that blockade of A(1)R resulted in disruption of the association of tumor necrosis factor receptor associated factor 6 (TRAF6) and transforming growth factor beta activated kinase 1 (TAK1), a signaling event that is important for activation of NF kappa B and JNK, suggesting the participation of adenosine/A(1)R in early signaling of RANKL. Collectively, these data demonstrated an important role of adenosine, through A(1)R in RANKL induced osteoclastogenesis.
C1 [He, W.; Cronstein, B. N.] NYU, Sch Med, New York, NY 10016 USA.
C3 New York University
RP Cronstein, BN (通讯作者)，NYU, Sch Med, 550 1st Ave, New York, NY 10016 USA.
EM cronsb01@med.nyu.edu
RI Cronstein, Bruce/D 4678 2011
OI Cronstein, Bruce/0000 0002 4295 7383
FU National Institutes of Health [AR56672, AR56672S1, AR54897]; NYU HHC
   Clinical and Translational Science Institute [UL1RR029893]; Vilcek
   Foundation; King Pharmaceuticals; NIH; OSI Pharmaceuticals; URL
   Pharmaceuticals, Inc.
FX This work was supported by grants from the National Institutes of Health
   (AR56672, AR56672S1 and AR54897), the NYU HHC Clinical and Translational
   Science Institute (UL1RR029893) and the Vilcek Foundation. Bruce
   Cronstein, MD. Consultant (within the past 2 years), all <$10,000:
   Bristol Myers Squibb, Novartis, CanFite Biopharmaceuticals, Cypress
   Laboratories, Regeneron (Westat, DSMB), Endocyte, Protalex, Allos, Inc.,
   Savient,. Equity: CanFite Biopharmaceuticals received for membership in
   Scientific Advisory Board. Grants: King Pharmaceuticals, NIH, Vilcek
   Foundation, OSI Pharmaceuticals, URL Pharmaceuticals, Inc. Board Member:
   Vilcek Foundation. Intellectual Property: Patents on use of adenosine
   A<INF>2A</INF> receptor agonists to promote wound healing and use of
   A<INF>2A</INF> receptor antagonists to inhibit fibrosis. Patent on use
   of adenosine A<INF>1</INF> receptor antagonists to treat osteoporosis
   and other diseases of bone. Patent on the use of adenosine A<INF>1</INF>
   and A<INF>2B</INF> Receptor antagonists to treat fatty liver. Patent on
   the use of adenosine A<INF>2A</INF> receptor agonists to prevent
   prosthesis loosening.
CR Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413
   Besse A, 2007, J BIOL CHEM, V282, P3918, DOI 10.1074/jbc.M608867200
   Brust TB, 2007, NEUROPHARMACOLOGY, V53, P906, DOI 10.1016/j.neuropharm.2007.09.001
   CAO X, 1993, J BIOL CHEM, V268, P27371
   Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5
   David JP, 2002, J CELL SCI, V115, P4317, DOI 10.1242/jcs.00082
   David JP, 2001, J CELL PHYSIOL, V188, P89, DOI 10.1002/jcp.1099
   Evans BAJ, 2006, J BONE MINER RES, V21, P228, DOI 10.1359/JBMR.051021
   Faccio R, 2003, J CELL BIOL, V162, P499, DOI 10.1083/jcb.200212082
   Faccio R, 2003, J CLIN INVEST, V111, P749, DOI 10.1172/JCI200316924
   Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482
   Gharibi B, 2012, INT J OBESITY, V36, P397, DOI 10.1038/ijo.2011.129
   Gravallese EM, 2002, ANN RHEUM DIS, V61, P84, DOI 10.1136/ard.61.suppl_2.ii84
   GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685
   GRUBER HE, 1986, MINER ELECTROL METAB, V12, P246
   Hirayama T, 2002, RHEUMATOLOGY, V41, P1232, DOI 10.1093/rheumatology/41.11.1232
   Huang H, 2006, CELL DEATH DIFFER, V13, P1879, DOI 10.1038/sj.cdd.4401882
   Ikeda F, 2004, J CLIN INVEST, V114, P475, DOI 10.1172/JCI200419657
   Ikeda F, 2008, J BONE MINER RES, V23, P907, DOI 10.1359/JBMR.080211
   Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197 1285
   Kara FM, 2010, FASEB J, V24, P2325, DOI 10.1096/fj.09 147447
   Kara FM, 2010, ARTHRITIS RHEUM US, V62, P534, DOI 10.1002/art.27219
   Kim N, 2005, J EXP MED, V202, P589, DOI 10.1084/jem.20050978
   Lee SW, 2002, J BIOCHEM MOL BIOL, V35, P371
   Liu AMF, 2004, J BIOL CHEM, V279, P53196, DOI 10.1074/jbc.M410196200
   Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015
   Lozo P., 2004, Acta Medica Croatica, V58, P5
   Matsuo K, 2004, J BIOL CHEM, V279, P26475, DOI 10.1074/jbc.M313973200
   McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905
   Mediero A, 2012, AM J PATHOL, V180, P775, DOI 10.1016/j.ajpath.2011.10.017
   Merrill J T, 1997, J Clin Rheumatol, V3, P328, DOI 10.1097/00124743 199712000 00005
   Merrill JT, 1997, ARTHRITIS RHEUM, V40, P1308, DOI 10.1002/1529 0131(199707)40:7<1308::AID ART16>3.0.CO;2 M
   Mizukami J, 2002, MOL CELL BIOL, V22, P992, DOI 10.1128/MCB.22.4.992 1000.2002
   Montesinos MC, 2000, ARTHRITIS RHEUM, V43, P656, DOI 10.1002/1529 0131(200003)43:3<656::AID ANR23>3.0.CO;2 H
   Morlon A, 2005, HUM MOL GENET, V14, P3751, DOI 10.1093/hmg/ddi405
   Naito A, 1999, GENES CELLS, V4, P353, DOI 10.1046/j.1365 2443.1999.00265.x
   Nakamura I, 1996, CELL TISSUE RES, V286, P507, DOI 10.1007/s004410050720
   Neale SD, 2000, BONE, V27, P409, DOI 10.1016/S8756 3282(00)00345 8
   Ninomiya Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465
   Reddy SV, 2004, J CELL BIOCHEM, V93, P688, DOI 10.1002/jcb.20256
   REDDY SV, 1995, J BONE MINER RES, V10, P601
   Roato I, 2004, FASEB J, V18, P228, DOI 10.1096/fj.04 1823fje
   Roato I, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003627
   Russell JM, 2007, CALCIFIED TISSUE INT, V81, P316, DOI 10.1007/s00223 007 9060 y
   Sakellari D, 2008, J CLIN PERIODONTOL, V35, P938, DOI 10.1111/j.1600 051X.2008.01314.x
   Shryock JC, 1998, MOL PHARMACOL, V53, P886
   Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780
   Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475 2484.2001
   Takayanagi H, 2002, DEV CELL, V3, P889, DOI 10.1016/S1534 5807(02)00369 6
   Teramachi J, 2011, LAB INVEST, V91, P719, DOI 10.1038/labinvest.2011.9
   Tjoa STS, 2008, J CLIN PERIODONTOL, V35, P568, DOI 10.1111/j.1600 051X.2008.01241.x
   Verzijl D, 2011, PURINERG SIGNAL, V7, P171, DOI 10.1007/s11302 011 9232 0
   Yamashita T, 2007, J BIOL CHEM, V282, P18245, DOI 10.1074/jbc.M610701200
NR 53
TC 45
Z9 52
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1573 9538
EI 1573 9546
J9 PURINERG SIGNAL
JI Purinergic Signal.
PD JUN
PY 2012
VL 8
IS 2
BP 327
EP 337
DI 10.1007/s11302 012 9292 9
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 949QZ
UT WOS:000304592200017
PM 22311477
OA Green Published
DA 2025 08 17
ER

PT J
AU Shamapari, R
   Nagaraj, K
AF Shamapari, R.
   Nagaraj, K.
TI Upregulation of ACSL, ND75, Vha26 and sesB genes by antiepileptic drugs
   resulted in genotoxicity in drosophila
SO TOXICOLOGY RESEARCH
LA English
DT Article
DE antiepileptic drugs; clobazam; vigabatrin; oxidative stress;
   genotoxicity
ID OXIDATIVE STRESS; NITRIC OXIDE; LIPID PEROXIDATION; DNA DAMAGE;
   MITOCHONDRIAL DYSFUNCTION; SIGNAL TRANSDUCTION; PROTEIN OXIDATION; ACID;
   ASSAY; BRAIN
AB Clobazam (CLB) and Vigabatrin (VGB) are commonly used antiepileptic drugs (AEDs) in the treatment of epilepsy. Here, we have investigated the potential genotoxic effects of these AEDs in Drosophila melanogaster. The Drosophila larvae were exposed to different concentrations of CLB and VGB containing food media. The assessment encompassed oxidative stress, DNA damage, protein levels, and gene expression profiles. In the CLB treated group, a reduction in reactive oxygen species (ROS) and lipid peroxidation (LPO) levels was observed, alongside increased levels of superoxide dismutase (SOD), catalase (CAT), and nitric oxide (NO). Conversely, the VGB treated group displayed contrasting results, with increased ROS and LPO and decreased SOD, CAT, and NO levels. However, both CLB and VGB induced DNA damage in Drosophila. Proteomic analysis (SDS PAGE and OHRLCMS) in the CLB and VGB groups identified numerous proteins, including Acyl CoA synthetase long chain, NADH ubiquinone oxidoreductase 75 kDa subunit, V type proton ATPase subunit E, ADP/ATP carrier protein, malic enzyme, and DNA binding protein modulo. These proteins were found to be associated with pathways like growth promotion, notch signaling, Wnt signaling, neuromuscular junction (NMJ) signaling, bone morphogenetic protein (BMP) signaling, and other GABAergic mechanisms. Furthermore, mRNA levels of ACSL, ND75, Vha26, sesB, and Men genes were upregulated in both CLB and VGB treated groups. These findings suggest that CLB and VGB could have the potential to induce genotoxicity and post transcriptional modifications in humans, highlighting the importance of monitoring their effects when used as AEDs.
C1 [Shamapari, R.; Nagaraj, K.] Kuvempu Univ, Dept PG Studies & Res Appl Zool, Mol Genet Lab, Shivamogga 577451, Karnataka, India.
C3 Kuvempu University
RP Nagaraj, K (通讯作者)，Kuvempu Univ, Dept PG Studies & Res Appl Zool, Mol Genet Lab, Shivamogga 577451, Karnataka, India.
EM shamapari.r@gmail.com; knagarajv@gmail.com
FU Laboratory of molecular virology and immunology, Dept. of Microbiology
FX The authors are thankful to Prof. N.B. Thippeswamy, Laboratory of
   molecular virology and immunology, Dept. of Microbiology, Kuvempu
   University, for allowing us to use his laboratory facilities to carry
   out some of the experiments. We are thankful to Dr H.M. Kumaraswamy,
   Laboratory of experimental medicine, Dept. of Biotechnology, Kuvempu
   University, for permitting us to use a fluorescent microscope facility.
   We are thankful to Prof. Rajeshwara Achur, Department of Biochemistry,
   Kuvempu University, for permitting us to use the fluorescence
   spectrophotometer facility. The authors also acknowledge the Proteomics
   facility, Indian Institute of Technology, Bombay for conducting the
   OHRLCMS analysis.
CR Abou eisha A., 2018, Asian J Pharm Clin Res, V11, P372
   Ademowo OS, 2017, BIOGERONTOLOGY, V18, P859, DOI 10.1007/s10522 017 9710 z
   Adonaylo VN, 1999, TOXICOLOGY, V132, P19, DOI 10.1016/S0300 483X(98)00134 6
   Akbar H, 2018, DRUG CHEM TOXICOL, V41, P135, DOI 10.1080/01480545.2017.1321011
   Amkiss S, 2021, ARAB J CHEM, V14, DOI 10.1016/j.arabjc.2020.102976
   Anet A, 2019, J HAZARD MATER, V370, P42, DOI 10.1016/j.jhazmat.2018.07.050
   [Anonymous], US
   [Anonymous], U.S
   Arhan E, 2011, SEIZURE EUR J EPILEP, V20, P138, DOI 10.1016/j.seizure.2010.11.003
   Ashraf NU, 2015, FREE RADICAL RES, V49, P1405, DOI 10.3109/10715762.2015.1078461
   Aykaç A, 2020, CLIN PSYCHOPHARM NEU, V18, P174, DOI 10.9758/cpn.2020.18.2.174
   Bak LK, 2006, J NEUROCHEM, V98, P641, DOI 10.1111/j.1471 4159.2006.03913.x
   Beg T, 2018, CNS NEUROL DISORD DR, V17, P421, DOI 10.2174/1871527317666180508123050
   Bertin G, 2006, BIOCHIMIE, V88, P1549, DOI 10.1016/j.biochi.2006.10.001
   Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025
   Bikjdaouene L, 2003, J PINEAL RES, V35, P54, DOI 10.1034/j.1600 079X.2003.00055.x
   Bott LC, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab245
   BRAMBILLA G, 1986, MUTAT RES, V171, P169, DOI 10.1016/0165 1218(86)90051 0
   Broderick KE, 2003, AM J PHYSIOL CELL PH, V285, pC1207, DOI 10.1152/ajpcell.00123.2003
   Bruxel EM, 2022, EPILEPSIA OPEN, V7, pS94, DOI 10.1002/epi4.12536
   Casida JE, 2015, PESTIC BIOCHEM PHYS, V121, P22, DOI 10.1016/j.pestbp.2014.11.006
   Casida JE, 2013, ANNU REV ENTOMOL, V58, P99, DOI 10.1146/annurev ento 120811 153645
   Celotto AM, 2012, BRAIN BEHAV, V2, P424, DOI 10.1002/brb3.73
   Chen KJ, 2008, ANTIOXID REDOX SIGN, V10, P1185, DOI 10.1089/ars.2007.1959
   Coelho VR, 2016, HUM EXP TOXICOL, V35, P958, DOI 10.1177/0960327115611970
   Collins MP, 2020, BBA BIOMEMBRANES, V1862, DOI 10.1016/j.bbamem.2020.183341
   Curcio R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176052
   De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382 199901000 00001
   Driver AS, 2000, NEUROTOXICOL TERATOL, V22, P175, DOI 10.1016/S0892 0362(99)00069 0
   Dulac A, 2021, ENEURO, V8, P1, DOI 10.1523/ENEURO.0193 21.2021
   Dundaroz R, 2001, KOCATEPE TIP DERGISI, V2, P153
   Dunkov BC, 1997, DNA CELL BIOL, V16, P1345, DOI 10.1089/dna.1997.16.1345
   EL Shorbagy M.H., 2016, INT J PHARM SCI, V8, P82
   Eleftherianos I, 2014, INFECT IMMUN, V82, P4169, DOI 10.1128/IAI.02318 14
   Elkholi R, 2019, MOL CELL, V74, P452, DOI 10.1016/j.molcel.2019.02.012
   Elustondo P, 2017, BBA MOL CELL BIOL L, V1862, P90, DOI 10.1016/j.bbalip.2016.08.012
   Engel JJ., 2007, EPILEPSY COMPREHENSI, V2nd
   Fantel AG, 1996, TERATOLOGY, V53, P196, DOI 10.1002/(SICI)1096 9926(199603)53:3<196::AID TERA7>3.0.CO;2 2
   Fassio A, 2018, BRAIN, V141, P1703, DOI 10.1093/brain/awy092
   Ffrench Constant RH, 2016, J NEUROGENET, V30, P163, DOI 10.1080/01677063.2016.1229781
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955 0674(03)00002 4
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   flybase, ABOUT US
   Friedberg EC, 2004, CURR OPIN GENET DEV, V14, P5, DOI 10.1016/j.gde.2003.11.001
   GEER BW, 1980, COMP BIOCHEM PHYS B, V65, P25, DOI 10.1016/0305 0491(80)90109 1
   Goldstein JA, 2001, BRIT J CLIN PHARMACO, V52, P349, DOI 10.1046/j.0306 5251.2001.01499.x
   Greenberg DA, 2005, AM J HUM GENET, V76, P139, DOI 10.1086/426735
   Guedes RNC, 2006, PHYSIOL ENTOMOL, V31, P30, DOI 10.1111/j.1365 3032.2005.00479.x
   Hacke ACM, 2021, J ETHNOPHARMACOL, V275, DOI 10.1016/j.jep.2021.114142
   Hadwan MH, 2018, ANAL BIOCHEM, V542, P29, DOI 10.1016/j.ab.2017.11.013
   Halliwell B, 2000, AM J CLIN NUTR, V72, P1082
   Huang Y, 2016, J CELL SCI, V129, P4034, DOI 10.1242/jcs.195032
   Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166 2236(96)10074 6
   Ikonomidou C, 2001, BIOCHEM PHARMACOL, V62, P401, DOI 10.1016/S0006 2952(01)00696 7
   Ikonomidou C, 2011, ANTIOXID REDOX SIGN, V14, P1535, DOI 10.1089/ars.2010.3581
   Jahromi SR., 2018, Int J Basic Sci Med, V3, P63
   Kim GH, 2015, BIOCHEM BIOPH RES CO, V456, P676, DOI 10.1016/j.bbrc.2014.12.020
   Kirkby RD, 1996, EPILEPSY RES, V24, P91, DOI 10.1016/0920 1211(96)00005 8
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Knabl J, 2008, NATURE, V451, P330, DOI 10.1038/nature06493
   Kovac S, 2016, REACT OXYGEN SPECIES, V1, P38, DOI DOI 10.20455/ROS.2016.807
   Kwak HB, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16071157
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   Layton ME, 1999, J MOL NEUROSCI, V13, P63, DOI 10.1385/JMN:13:1 2:63
   LEVENBOOK L, 1984, INSECT BIOCHEM, V14, P77, DOI 10.1016/0020 1790(84)90086 6
   Liu ZH, 2014, J NEUROSCI, V34, P2785, DOI 10.1523/JNEUROSCI.3547 13.2014
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Löw K, 2000, SCIENCE, V290, P131, DOI 10.1126/science.290.5489.131
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAERTENS P, 1995, AM J MED GENET, V57, P225, DOI 10.1002/ajmg.1320570222
   Matés JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009 9120(99)00075 2
   Mitchell LE, 2004, LANCET, V364, P1885, DOI 10.1016/S0140 6736(04)17445 X
   Mo DQ, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00723
   Mota SI, 2015, BBA MOL BASIS DIS, V1852, P1428, DOI 10.1016/j.bbadis.2015.03.015
   Nakamura F, 1996, EPILEPSIA, V37, P728, DOI 10.1111/j.1528 1157.1996.tb00643.x
   Ni Y, 2019, CELLS BASEL, V8, DOI 10.3390/cells8101149
   OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003 2697(79)90738 3
   Oliveira AA, 2007, CELL MOL NEUROBIOL, V27, P395, DOI 10.1007/s10571 006 9132 y
   Palmieri F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040655
   Papa S, 2012, FEBS LETT, V586, P568, DOI 10.1016/j.febslet.2011.09.019
   Patel M, 2004, FREE RADICAL BIO MED, V37, P1951, DOI 10.1016/j.freeradbiomed.2004.08.021
   Patel M, 2016, TRENDS PHARMACOL SCI, V37, P768, DOI 10.1016/j.tips.2016.06.007
   Pearson JN, 2016, ANN NY ACAD SCI, V1378, P17, DOI 10.1111/nyas.13115
   Poolsup N, 2000, J CLIN PHARM THER, V25, P197
   Powell CL, 2005, CANCER LETT, V229, P1, DOI 10.1016/j.canlet.2004.12.002
   Raza M., 2002, SCI PHARM, V7, P135, DOI DOI 10.3797/SCIPHARM.AUT 02 16
   Rudolph U, 1999, NATURE, V401, P796, DOI 10.1038/44579
   RUNSWICK MJ, 1989, BIOCHEMISTRY US, V28, P9452, DOI 10.1021/bi00450a031
   Selvaraj Vasuki Selvaraj Vasuki, 2016, Free Radicals and Antioxidants, V6, P167, DOI 10.5530/fra.2016.2.6
   Shacter E, 2000, METHOD ENZYMOL, V319, P428
   Shacter E, 2000, DRUG METAB REV, V32, P307, DOI 10.1081/DMR 100102336
   Shamapari R, 2023, NEUROTOXICOL TERATOL, V100, DOI 10.1016/j.ntt.2023.107305
   Shih JJ, 2013, THER CLIN RISK MANAG, V9, P285, DOI 10.2147/TCRM.S37317
   Shin EJ, 2011, NEUROCHEM INT, V59, P122, DOI 10.1016/j.neuint.2011.03.025
   Shishmanova Doseva M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052264
   Shiva S, 2017, NITRIC OXIDE: BIOLOGY AND PATHOBIOLOGY, 3RD EDITION, P137, DOI 10.1016/B978 0 12 804273 1.00011 9
   Siddique HR, 2005, MUTAGENESIS, V20, P285, DOI 10.1093/mutage/gei032
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014 4827(88)90265 0
   SINHA AK, 1972, ANAL BIOCHEM, V47, P389, DOI 10.1016/0003 2697(72)90132 7
   Sobaniec W, 2006, J CHILD NEUROL, V21, P558, DOI 10.2310/7010.2006.00115
   STADTMAN ER, 1992, SCIENCE, V257, P1220, DOI 10.1126/science.1355616
   Streit AK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148461
   Sun W, 2006, INSECT MOL BIOL, V15, P455, DOI 10.1111/j.1365 2583.2006.00662.x
   Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361 9230(96)00159 1
   Tabatabaei AR, 1999, CHEM RES TOXICOL, V12, P323, DOI 10.1021/tx9801864
   Taghdiri MM, 2013, IRAN J PEDIATR, V23, P653
   Tripathi A., 2022, Ion transportersfrom basic properties to medical treatment, DOI [10.5772/intechopen.106848, DOI 10.5772/INTECHOPEN.106848]
   Tung EWY, 2011, MOL PHARMACOL, V80, P979, DOI 10.1124/mol.111.072314
   Uzunhan TA, 2020, MED B SISLI ETFAL HO, V54, P236, DOI 10.14744/SEMB.2020.60252
   VanderHorst DJ, 1997, COMP BIOCHEM PHYS B, V117, P463, DOI 10.1016/S0305 0491(97)00184 3
   Vijg J., 2007, Aging of the genome: the dual role of DNA in life and death, V1st, P138
   von Renesse Anja, 2019, JIMD Rep, V43, P27, DOI 10.1007/8904_2018_93
   Wang MC, 2005, CELL, V121, P115, DOI 10.1016/j.cell.2005.02.030
   Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532
   Webb SJ, 2001, DEV NEUROPSYCHOL, V19, P147, DOI 10.1207/S15326942DN1902_2
   Wheless JW, 2013, J CHILD NEUROL, V28, P219, DOI 10.1177/0883073812463609
   Xie NC, 2016, NEUROCHEM RES, V41, P1335, DOI 10.1007/s11064 016 1835 y
   Yan J, 2006, J PHARMACOL EXP THER, V319, P613, DOI 10.1124/jpet.106.109850
   Yan Y, 2009, DEV CELL, V17, P387, DOI 10.1016/j.devcel.2009.07.001
   Yoon DH, 2011, BIOCHEM BIOPH RES CO, V414, P49, DOI 10.1016/j.bbrc.2011.09.019
   Yoshida T, 2022, BIOCHEMISTRY US, V61, P1548, DOI 10.1021/acs.biochem.2c00123
   Zhang B, 2010, CELL MOL NEUROBIOL, V30, P137, DOI 10.1007/s10571 009 9438 7
   Zhang Y, 2009, HUM MOL GENET, V18, P3894, DOI 10.1093/hmg/ddp332
   Zhang YQ, 1999, GENETICS, V153, P891
   Zoghbi HY, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a009886
NR 125
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2045 452X
EI 2045 4538
J9 TOXICOL RES UK
JI Toxicol. Res.
PD NOV 5
PY 2024
VL 13
IS 6
AR tfae180
DI 10.1093/toxres/tfae180
PG 16
WC Toxicology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Toxicology
GA L0S8B
UT WOS:001347914500001
PM 39507589
DA 2025 08 17
ER

PT J
AU Ou, LL
   Lan, Y
   Feng, ZA
   Feng, LB
   Yang, JJ
   Liu, Y
   Bian, LM
   Tan, JL
   Lai, RF
   Guo, R
AF Ou, Lingling
   Lan, Yong
   Feng, Zhigiang
   Feng, Longbao
   Yang, Junjie
   Liu, Yu
   Bian, Liming
   Tan, Jiali
   Lai, Renfa
   Guo, Rui
TI Functionalization of SF/HAP Scaffold with GO PEI miRNA inhibitor
   Complexes to Enhance Bone Regeneration through Activating Transcription
   Factor 4
SO THERANOSTICS
LA English
DT Article
DE miRNA 214 inhibitor; GO PEI; SF/HAP scaffold; activating transcription
   factor 4 (ATF4); bone regeneration
ID MESENCHYMAL STEM CELLS; GRAPHENE OXIDE; OSTEOGENIC DIFFERENTIATION;
   OSTEOBLASTIC DIFFERENTIATION; COMPOSITE SCAFFOLDS; NONVIRAL VECTORS;
   INTERFERING RNA; GENE THERAPY; ATF4; HYDROXYAPATITE
AB Evidence indicates that microRNAs (miRNAs) play vital roles in regulating osteogenic differentiation and bone formation.
   Methods: Here, we show that a polyethyleneimine (PEI) functionalized graphene oxide (GO) complex efficiently loaded with the miR 214 inhibitor is assembled into silk fibroin/hydroxyapatite (SF/HAP) scaffolds that spatially control the release of the miR 214 inhibitor.
   Results: SF/HAP/GO scaffolds with nanosized GO show high mechanical strength, and their hierarchical microporous structures promote cell adhesion and growth. The SF/HAP/GO PEI scaffolds loaded with mir 214 inhibitor (SF/HAP/GPM) were tested for their ability to enhance osteogenic differentiation by inhibiting the expression of miR 214 while inversely increasing the expression of activating transcription factor 4 (ATF4) and activating the Akt and ERK1/2 signaling pathways in mouse osteoblastic cells (MC3T3 E1) in vitro. Similarly, the scaffolds activated the osteoblastic activity of endogenous osteoblast cells to repair critical sized bone defects in rats without the need for loading osteoblast cells.
   Conclusion: This technology is used to increase osteogenic differentiation and mineralized bone formation in bone defects, which helps to achieve cell free scaffold based miRNA inhibitor therapy for bone tissue engineering.
C1 [Ou, Lingling; Feng, Zhigiang; Yang, Junjie; Lai, Renfa] Jinan Univ, Affiliated Hosp 1, 613 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.
   [Lan, Yong; Feng, Longbao] Beogene Biotech Guangzhou CO LTD, Guangzhou 510663, Guangdong, Peoples R China.
   [Liu, Yu] Guangzhou Chuangseed Biomed Mat CO LTD, Guangzhou 510663, Guangdong, Peoples R China.
   [Bian, Liming] Chinese Univ Hong Kong, Dept Biomed Engn, Hong Kong, Peoples R China.
   [Tan, Jiali] Sun Yat Sen Univ, Hosp Stomatol, Guanghua Sch Stomatol, Dept Orthodont, Guangzhou 510055, Guangdong, Peoples R China.
   [Tan, Jiali] Guangdong Prov Key Lab Stomatol, Guangzhou 510055, Guangdong, Peoples R China.
   [Guo, Rui] Jinan Univ, Guangdong Prov Engn & Technol Res Ctr Drug Carrie, Key Lab Biomat Guangdong Higher Educ Inst, Dept Biomed Engn, Guangzhou 510632, Guangdong, Peoples R China.
C3 Jinan University; Chinese University of Hong Kong; Sun Yat Sen
   University; Jinan University
RP Lai, RF (通讯作者)，Jinan Univ, Affiliated Hosp 1, 613 West Huangpu Ave, Guangzhou 510632, Guangdong, Peoples R China.; Guo, R (通讯作者)，Jinan Univ, Guangdong Prov Engn & Technol Res Ctr Drug Carrie, Key Lab Biomat Guangdong Higher Educ Inst, Dept Biomed Engn, Guangzhou 510632, Guangdong, Peoples R China.
EM Prof.Dr.Lai@163.com; guorui@jnu.edu.cn
RI Bian, Liming/A 7183 2011; Yang, Junjie/ABA 4361 2021; 敬亮,
   许/AHA 5467 2022
FU National Natural Science Foundation of China [81703120, 31271019];
   Science and Technology Program of Guangzhou [201508020115, 201601010270,
   2017010160489, 201704030083]; Natural Science Foundation of Guangdong
   Province [2017A030310365]; Guangdong Provincial Medical Research
   Foundation [A2016360]; Pearl River S&T Nova Program of Guangzhou
   [201710010155, 201806010072]; Science and Technology Project of
   Guangdong Province [2015A010101313, 2017A050506011, 2017B090911012,
   2018A050506040, 2018A050506019, 2018A050506021]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81703120, 31271019), the Science and Technology Program of
   Guangzhou (201508020115, 201601010270, 2017010160489, 201704030083),
   Natural Science Foundation of Guangdong Province (2017A030310365), and
   Guangdong Provincial Medical Research Foundation (A2016360), the Pearl
   River S&T Nova Program of Guangzhou (201710010155, 201806010072), and
   the Science and Technology Project of Guangdong Province
   (2015A010101313, 2017A050506011, 2017B090911012, 2018A050506040,
   2018A050506019, 2018A050506021).
CR Baker N, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287 015 0225 8
   Bez M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3128
   Bi LX, 2013, ACTA BIOMATER, V9, P8015, DOI 10.1016/j.actbio.2013.04.043
   Burnett JC, 2012, CHEM BIOL, V19, P60, DOI 10.1016/j.chembiol.2011.12.008
   Chen L, 2014, STEM CELLS, V32, P902, DOI 10.1002/stem.1615
   Choi HY, 2016, J CONTROL RELEASE, V235, P222, DOI 10.1016/j.jconrel.2016.06.007
   Chung C, 2013, ACCOUNTS CHEM RES, V46, P2211, DOI 10.1021/ar300159f
   Dalby B, 2004, METHODS, V33, P95, DOI 10.1016/j.ymeth.2003.11.023
   Davis NE, 2012, BIOMATERIALS, V33, P6691, DOI 10.1016/j.biomaterials.2012.06.015
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Duan S, 2015, J BIOMED MATER RES A, V103, P1424, DOI 10.1002/jbm.a.35283
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Farokhi M, 2018, BIOTECHNOL ADV, V36, P68, DOI 10.1016/j.biotechadv.2017.10.001
   Feng LZ, 2011, NANOSCALE, V3, P1252, DOI 10.1039/c0nr00680g
   Fu HL, 2013, ACTA BIOMATER, V9, P5718, DOI 10.1016/j.actbio.2012.11.017
   Giatsidis G, 2013, PLAST RECONSTR SURG, V131, P1425, DOI 10.1097/PRS.0b013e31828bd153
   Guzman Villanueva D, 2012, J PHARM SCI US, V101, P4046, DOI 10.1002/jps.23300
   Halim A, 2018, NANOMATERIALS BASEL, V8, DOI 10.3390/nano8090736
   Hasan A, 2018, INT J NANOMED, V13, P5637, DOI 10.2147/IJN.S153758
   Höbel S, 2010, J GENE MED, V12, P287, DOI 10.1002/jgm.1431
   Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008 5472.CAN 10 4645
   Jiang XQ, 2009, BIOMATERIALS, V30, P4522, DOI 10.1016/j.biomaterials.2009.05.021
   Kim HD, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700612
   Kim HH, 2014, INT J BIOL MACROMOL, V70, P516, DOI 10.1016/j.ijbiomac.2014.06.052
   Kirtane AR, 2013, NAT NANOTECHNOL, V8, P805, DOI 10.1038/nnano.2013.234
   Kundu J, 2008, J MATER SCI MATER M, V19, P2679, DOI 10.1007/s10856 008 3398 1
   Lai GJ, 2015, INT J NANOMED, V10, P567, DOI 10.2147/IJN.S73780
   Li DF, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10872
   Li JB, 2014, CHEM SOC REV, V43, P506, DOI 10.1039/c3cs60312a
   Li MJ, 2014, CARBON, V66, P302, DOI 10.1016/j.carbon.2013.09.004
   Liao KH, 2011, ACS APPL MATER INTER, V3, P2607, DOI 10.1021/am200428v
   Lin KL, 2010, J BONE MINER RES, V25, P2489, DOI 10.1002/jbmr.159
   Liu H, 2015, BIOMATERIALS, V49, P103, DOI 10.1016/j.biomaterials.2015.01.017
   Liu ZB, 2014, ANAL BIOANAL CHEM, V406, P6885, DOI 10.1007/s00216 014 7888 3
   Mintzer MA, 2009, CHEM REV, V109, P259, DOI 10.1021/cr800409e
   Miyazaki Y, 2012, NAT MED, V18, P1136, DOI 10.1038/nm.2791
   Mu QX, 2012, ACS APPL MATER INTER, V4, P2259, DOI 10.1021/am300253c
   Nayak S, 2010, GENE THER, V17, P295, DOI 10.1038/gt.2009.148
   Nayak TR, 2011, ACS NANO, V5, P4670, DOI 10.1021/nn200500h
   Neffe AT, 2015, ADV MATER, V27, P1738, DOI 10.1002/adma.201404787
   Pang YX, 2003, J EUR CERAM SOC, V23, P1697, DOI 10.1016/S0955 2219(02)00413 2
   Parayath NN, 2018, NANO LETT, V18, P3571, DOI 10.1021/acs.nanolett.8b00689
   Ren DP, 2015, J CELL PHYSIOL, V230, P2426, DOI 10.1002/jcp.24972
   Shen XF, 2016, BIOMATERIALS, V106, P205, DOI 10.1016/j.biomaterials.2016.08.023
   Shi KK, 2013, BONE, V55, P487, DOI 10.1016/j.bone.2013.04.002
   Shin SR, 2016, ADV DRUG DELIVER REV, V105, P255, DOI 10.1016/j.addr.2016.03.007
   Sun YQ, 2019, J CELL PHYSIOL, V234, P231, DOI 10.1002/jcp.26856
   Sun YP, 2018, CHEM SCI, V9, P6516, DOI 10.1039/c8sc02100g
   Tang LAL, 2010, J AM CHEM SOC, V132, P10976, DOI 10.1021/ja104017y
   Tang ZW, 2010, SMALL, V6, P1205, DOI 10.1002/smll.201000024
   Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181
   van Rooij E, 2012, CIRC RES, V110, P496, DOI 10.1161/CIRCRESAHA.111.247916
   Verma IM, 2013, SCIENCE, V341, P853, DOI 10.1126/science.1242551
   Wang C, 2013, BIOMATERIALS, V34, P64, DOI 10.1016/j.biomaterials.2012.09.021
   Wang WG, 2012, DEVELOPMENT, V139, P601, DOI 10.1242/dev.069575
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Weaver CL, 2015, ADV HEALTHC MATER, V4, P1408, DOI 10.1002/adhm.201500056
   Wei GB, 2007, BIOMATERIALS, V28, P2087, DOI 10.1016/j.biomaterials.2006.12.028
   Whitehead KA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5277
   Wongpanit P, 2010, J BIOMAT SCI POLYM E, V21, P1403, DOI 10.1163/092050609X12517858243706
   Wubneh A, 2018, ACTA BIOMATER, V80, P1, DOI 10.1016/j.actbio.2018.09.031
   Xiang SN, 2012, J CONTROL RELEASE, V158, P371, DOI 10.1016/j.jconrel.2011.09.093
   Xie CM, 2016, ACS APPL MATER INTER, V8, P1707, DOI 10.1021/acsami.5b09232
   Yang XG, 2004, CELL, V117, P387, DOI 10.1016/S0092 8674(04)00344 7
   Yao SQ, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3028647
   Yin D, 2013, NANOTECHNOLOGY, V24, DOI 10.1088/0957 4484/24/10/105102
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yin LC, 2013, ADV MATER, V25, P3063, DOI 10.1002/adma.201205088
   Yu SB, 2013, INT J BIOL SCI, V9, P256, DOI 10.7150/ijbs.5898
   Yue H, 2012, BIOMATERIALS, V33, P4013, DOI 10.1016/j.biomaterials.2012.02.021
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang XJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10376
   Zhao CY, 2015, RNA BIOL, V12, P343, DOI 10.1080/15476286.2015.1017205
   Zou DH, 2011, STEM CELLS, V29, P1380, DOI 10.1002/stem.693
NR 74
TC 52
Z9 57
U1 2
U2 62
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838 7640
J9 THERANOSTICS
JI Theranostics
PY 2019
VL 9
IS 15
BP 4525
EP 4541
DI 10.7150/thno.34676
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI EXPANDED)
SC Research & Experimental Medicine
GA IE6JN
UT WOS:000472482600018
PM 31285777
OA Green Published, gold, Green Submitted
DA 2025 08 17
ER

PT J
AU Ameri, M
   Daddona, PE
   Maa, YF
AF Ameri, Mahmoud
   Daddona, Peter E.
   Maa, Yuh Fun
TI Demonstrated Solid State Stability of Parathyroid Hormone PTH(1 34)
   Coated on a Novel Transdermal Microprojection Delivery System
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE aggregation; drug coating; formulation compatibility; internal vapor
   analysis; oxidation; parathyroid hormone; PTH(1 34); transdermal
   microprojection delivery system
ID ALENDRONATE; TERIPARATIDE; RESIDUES
AB This study assessed conditions necessary for at least a 2 year, ambient temperature storage stability of the peptide parathyroid hormone 1 34, or PTH(1 34), coated on a novel transdermal microprojection delivery system, or ZP PTH.
   Liquid coating characterization of high concentration PTH(1 34) formulations (> 20% w/w) was assessed by viscosity and contact angle measurements along with RP HPLC and SEC HPLC. Solid state coating morphology of PTH(1 34) on microprojection arrays was determined by SEM, and stability on storage was assessed after dissolution and testing with stability indicating assays. Internal vapor analysis was performed to detect and quantify volatile organics released by patch components into the headspace inside the final package.
   Aggregation and oxidation were the primary degradation mechanisms for solid state PTH(1 34) in this transdermal delivery system. Although these two degradation pathways can be retarded by appropriate stabilizers and use of foil pouch packaging (nitrogen purged and desiccant), the solid state drug formulation's compatibility with patch components, particularly the plastic retainer ring, surprisingly dictated PTH(1 34) stability. Internal vapor analysis demonstrated that PTH(1 34) was particularly vulnerable to vapors such as moisture, oxygen, and outgassed formaldehyde, and each of these volatiles played a unique and significant role in PTH(1 34)'s degradation mechanism.
   Identifying degradation mechanisms of volatile compounds on solid state PTH(1 34) peptide stability allowed for the rationale for selection of final formulation, system components and packaging conditions. A > 2 yr, ambient temperature storage stability was demonstrated for solid state drug coated on a novel transdermal microprojection delivery system. This system was successfully tested in a Phase 2 clinical trial for the treatment of post menopausal women with osteoporosis.
C1 [Ameri, Mahmoud; Daddona, Peter E.; Maa, Yuh Fun] Zosano Pharma Inc, Fremont, CA 94555 USA.
RP Maa, YF (通讯作者)，Zosano Pharma Inc, 34790 Ardentech Court, Fremont, CA 94555 USA.
EM ymaa@zosanopharma.com
RI Ameri, Mahmoud/T 2202 2018
CR Cormier M, 2004, J CONTROL RELEASE, V97, P503, DOI 10.1016/j.jconrel.2004.04.003
   CORMIER M, 2003, Patent No. 0914178
   Finkelstein JS, 2003, NEW ENGL J MED, V349, P1216, DOI 10.1056/NEJMoa035725
   Fraenkel L, 2007, PATIENT EDUC COUNS, V65, P237, DOI 10.1016/j.pec.2006.08.004
   Fraenkel L, 2006, ARTHRIT RHEUM ARTHR, V55, P729, DOI 10.1002/art.22229
   FRELINGER AL, 1984, J BIOL CHEM, V259, P5507
   FRELINGER AL, 1986, ARCH BIOCHEM BIOPHYS, V244, P641, DOI 10.1016/0003 9861(86)90632 6
   Govalakrishnan V, 2004, J BONE MINER RES, V19, pS460
   Keaveny TM, 2007, J BONE MINER RES, V22, pS26
   Keaveny TM, 2008, J BONE MINER RES, V23, P1974, DOI [10.1359/jbmr.080805, 10.1359/JBMR.080805]
   LANE LE, 2008, ARTHRITIS RHEUM S, V58, P1
   Lin WQ, 2001, PHARMACEUT RES, V18, P1789, DOI 10.1023/A:1013395102049
   MANNING MC, 1989, PHARM RES DORDR, V6, P903, DOI 10.1023/A:1015929109894
   Matriano JA, 2002, PHARMACEUT RES, V19, P63, DOI 10.1023/A:1013607400040
   McClung MR, 2005, ARCH INTERN MED, V165, P1762, DOI 10.1001/archinte.165.15.1762
   Nabuchi Y, 1997, PHARMACEUT RES, V14, P1685, DOI 10.1023/A:1012115426306
   Proos ER, 2008, PHARM RES, V25, P1387, DOI 10.1007/s11095 008 9544 0
   Saag KG, 2007, NEW ENGL J MED, V357, P2028, DOI 10.1056/NEJMoa071408
   TRAUTMAN JC, 2002, Patent No. 7435299
   TRAUTMAN JC, 2002, Patent No. 6855372
   Widera G, 2006, VACCINE, V24, P1653, DOI 10.1016/j.vaccine.2005.09.049
   ZULL JE, 1990, J BIOL CHEM, V265, P5671
NR 22
TC 40
Z9 54
U1 2
U2 35
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724 8741
EI 1573 904X
J9 PHARM RES DORDR
JI Pharm. Res.
PD NOV
PY 2009
VL 26
IS 11
BP 2454
EP 2463
DI 10.1007/s11095 009 9960 9
PG 10
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 507ZP
UT WOS:000270896000007
PM 20183917
DA 2025 08 17
ER

PT J
AU Wu, JH
   Wang, C
   Miao, X
   Wu, YG
   Yuan, JB
   Ding, MC
   Li, JF
   Shi, ZC
AF Wu, Jinhui
   Wang, Chao
   Miao, Xiong
   Wu, Yungang
   Yuan, Jiabin
   Ding, Muchen
   Li, Jingfeng
   Shi, Zhicai
TI Age Related Insulin Like Growth Factor Binding Protein 4 Overexpression
   Inhibits Osteogenic Differentiation of Rat Mesenchymal Stem Cells
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Aging; Insulin like growth factor binding protein 4; Bone marrow derived
   mesenchymal stem cells; Osteogenic differentiation
ID BONE MARROW; OSTEOBLAST DIFFERENTIATION; SENESCENCE; PATHWAYS;
   ACTIVATION; INDUCTION; CARTILAGE; ERK
AB Background/Aims: Insulin like growth factor binding proteins (IGFBP) play important roles in bone metabolism. IGFBP4 is involved in senescent associated phenomena in mesenchymal stem cells (MSCs). The goal of the present study was to determine whether age related IGFBP4 overexpression is associated with the impaired osteogenic differentiation potential of aged bone marrow derived MSCs. Methods: MSCs were isolated from Sprague Dawley rats aged 3 26 months. The bone morphogenetic protein (BMP) 2 induced osteogenic differentiation of rat MSCs was assessed by analyzing the expression levels of osteoblast marker genes [runtrelated transcription factor 2 (RUNX2), alkaline phosphatase (ALP), and osteocalcin (OC)], ALP activity and calcification. Results: Our study showed that IGFBP4 mRNA and protein expression increased with age in parallel with impaired osteogenic differentiation of MSCs cultured in BMP2 containing osteogenic medium, as evidenced by the downregulation of osteoblast marker genes, and decreased ALP activity and calcium deposits. IGFBP4 overexpression impaired BMP2 induced osteogenic differentiation potential of young MSCs, whereas IGFBP4 knockdown restored the osteogenic potency of aged MSCs. Moreover, IGFBP4 knockdown stimulated the activation of Erk and Smad by increasing phosphorylation. Conclusion: Collectively, our results demonstrate that IGFBP4 overexpression plays a role in the impairment of MSC differentiation potential via the Erk and Smad pathways, suggesting potential targets to improve MSC function for cell therapy applications. (C) 2017 The Author(s) Published by S. Karger AG, Basel.
C1 [Wu, Jinhui; Wang, Chao; Miao, Xiong; Wu, Yungang; Yuan, Jiabin; Ding, Muchen; Li, Jingfeng; Shi, Zhicai] Changhai Hosp, Orthoped Dept, 168 Changhai Rd, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Li, JF; Shi, ZC (通讯作者)，Changhai Hosp, Orthoped Dept, 168 Changhai Rd, Shanghai 200433, Peoples R China.
EM lijingfeng75@163.com; zhicaishi@vip.sina.com
RI Yuan, Jia/KWU 8157 2024; 李, 景峰/ISB 3492 2023; Wang, Chao/JJE 1212 2023
FU National Natural Science Foundation of China [81672204, 81372019]
FX This work is supported by grants nos. 81672204 and 81372019 from the
   National Natural Science Foundation of China.
CR Auh QS, 2016, ONCOTARGET
   Chen LA, 2010, J BONE MINER RES, V25, P2447, DOI 10.1002/jbmr.133
   Choi H, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929 016 0260 5
   Chung PL, 2014, J CELL BIOCHEM, V115, P1412, DOI 10.1002/jcb.24792
   Cui Y, 2016, CELL PHYSIOL BIOCHEM, V39, P1347, DOI 10.1159/000447839
   Eskildsen T, 2011, P NATL ACAD SCI USA, V108, P6139, DOI 10.1073/pnas.1016758108
   Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001 0033
   Greenblatt MB, 2013, ANNU REV CELL DEV BI, V29, P63, DOI 10.1146/annurev cellbio 101512 122347
   Guang LG, 2013, INT J BIOCHEM CELL B, V45, P1813, DOI 10.1016/j.biocel.2013.05.034
   Izal I, 2013, KNEE SURG SPORT TR A, V21, P1737, DOI 10.1007/s00167 012 2148 6
   Joiner DM, 2012, BIOGERONTOLOGY, V13, P467, DOI 10.1007/s10522 012 9391 6
   Kang IH, 2015, J CELL PHYSIOL, V230, P911, DOI 10.1002/jcp.24822
   Kim BS, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2014.95
   Kim KS, 2007, MOL BIOL CELL, V18, P4543, DOI 10.1091/mbc.E07 03 0280
   Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149
   Li HX, 2011, CYTOTHERAPY, V13, P1057, DOI 10.3109/14653249.2011.597380
   Lin YM, 2016, BIOCHEM BIOPH RES CO, V469, P903, DOI 10.1016/j.bbrc.2015.12.003
   Liu Y, 2014, CLIN EXP MED, V14, P13, DOI 10.1007/s10238 012 0218 1
   Minato A, 2012, BIOMATERIALS, V33, P515, DOI 10.1016/j.biomaterials.2011.09.070
   Mukherjee A, 2008, MOL ENDOCRINOL, V22, P1238, DOI 10.1210/me.2008 0001
   Nohe A, 2004, CELL SIGNAL, V16, P291, DOI 10.1016/j.cellsig.2003.08.011
   Odabas S, 2014, METHODS MOL BIOL, V1109, P47, DOI 10.1007/978 1 4614 9437 9_3
   Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423
   Severino V, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.445
   Shang J, 2016, BBA MOL CELL RES, V1863, P520, DOI 10.1016/j.bbamcr.2016.01.005
   Sittadjody S, 2012, CLIN CHIM ACTA, V414, P281, DOI 10.1016/j.cca.2012.09.030
   Tanaka Y, 2004, INT J CANCER, V109, P336, DOI 10.1002/ijc.11700
   Tokalov SV, 2007, STEM CELLS DEV, V16, P439, DOI 10.1089/scd.2006.0078
   Wang JY, 2015, ONCOTARGET, V6, P20636, DOI 10.18632/oncotarget.4114
   Wu XH, 2014, FEBS LETT, V588, P143, DOI 10.1016/j.febslet.2013.11.022
   Xue YY, 2014, J CELL BIOCHEM, V115, P1495, DOI 10.1002/jcb.24804
   You L, 2016, CELL PHYSIOL BIOCHEM, V39, P253, DOI 10.1159/000445621
   Zhang HY, 2015, CELL PHYSIOL BIOCHEM, V37, P548, DOI 10.1159/000430376
   Zhang W, 2013, BIOMATERIALS, V34, P713, DOI 10.1016/j.biomaterials.2012.10.027
   Zhong YB, 2011, J CELL SCI, V124, P1925, DOI 10.1242/jcs.082644
NR 35
TC 21
Z9 22
U1 0
U2 8
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH 4009 BASEL, SWITZERLAND
SN 1015 8987
EI 1421 9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2017
VL 42
IS 2
BP 640
EP 650
DI 10.1159/000477873
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI EXPANDED)
SC Cell Biology; Physiology
GA FA8YU
UT WOS:000405733400018
PM 28595186
OA gold
DA 2025 08 17
ER

EF